PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Guo, X; Liu, W; Pan, Y; Ni, P; Ji, J; Guo, L; Zhang, J; Wu, J; Jiang, J; Chen, X; Cai, Q; Li, J; Zhang, J; Gu, Q; Liu, B; Zhu, Z; Yu, Y				Guo, X.; Liu, W.; Pan, Y.; Ni, P.; Ji, J.; Guo, L.; Zhang, J.; Wu, J.; Jiang, J.; Chen, X.; Cai, Q.; Li, J.; Zhang, J.; Gu, Q.; Liu, B.; Zhu, Z.; Yu, Y.			Homeobox gene IRX1 is a tumor suppressor gene in gastric carcinoma	ONCOGENE			English	Article						epigenetic; gastric carcinoma; homeobox genes; IRX1; tumor suppressor	SQUAMOUS-CELL CARCINOMA; PROTEOMICS TECHNOLOGY; EPIGENETIC THERAPY; ENDOTHELIAL-CELLS; LUNG DEVELOPMENT; DNA METHYLATION; IROQUOIS GENES; BREAST-CANCER; EXPRESSION; IDENTIFICATION	The IRX1 tumor suppressor gene is located on 5p15.33, a cancer susceptibility locus. Loss of heterozygosity of 5p15.33 in gastric cancer was identified in our previous work. In this study, we analyzed the molecular features and function of IRX1. We found that IRX1 expression was lost or reduced in gastric cancer. However, no mutations were identified in IRX1-encoding regions. IRX1 transcription was suppressed by hypermethylation, and the expression of IRX1 mRNA was partially restored in gastric cancer cells after 5-Aza-dC treatment. Restoring IRX1 expression in SGC-7901 and NCI-N87 gastric cancer cells inhibited growth, invasion and tumorigenesis in vitro and in vivo. We identified a number of target genes by global microarray analysis after IRX1 transfection combined with real-time PCR and chromatin immunoprecipitation assay. BDKRB2, an angiogenesis-related gene, HIST2H2BE and FGF7, cell proliferation and invasion-related genes, were identified as direct IRX1 target genes. The hypermethylation of IRX1 was not only detected in primary gastric cancer tissues but also in the peripheral blood of gastric cancer patients, suggesting IRX1 could potentially serve as a biomarker for gastric cancer. Oncogene (2010) 29, 3908-3920; doi:10.1038/onc.2010.143; published online 3 May 2010	[Guo, X.; Liu, W.; Pan, Y.; Ji, J.; Guo, L.; Zhang, J.; Wu, J.; Jiang, J.; Chen, X.; Cai, Q.; Li, J.; Zhang, J.; Gu, Q.; Liu, B.; Zhu, Z.; Yu, Y.] Shanghai Ruijin Hosp, Dept Surg, Shanghai, Peoples R China; [Guo, X.; Liu, W.; Pan, Y.; Ji, J.; Guo, L.; Zhang, J.; Wu, J.; Jiang, J.; Chen, X.; Cai, Q.; Li, J.; Zhang, J.; Gu, Q.; Liu, B.; Zhu, Z.; Yu, Y.] Shanghai Inst Digest Surg, Shanghai, Peoples R China; [Ni, P.] Shanghai Jiao Tong Univ, Sch Med, Dept Clin Biochem, Shanghai 200025, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University	Yu, Y (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Surg, Ruijin Er Rd 197, Shanghai 200025, Peoples R China.	surgeryzhu@yahoo.com.cn; yingyan3y@yahoo.com.cn	Liu, Bingya/GMW-5655-2022		National Natural Science Foundation of China [30572127, 30770961, 30973486]; Chinese National High Tech Program [863-2006AA02A402, 2006AA02A301]; Shanghai Pu Jiang Project [PJ200700367]; Shanghai Science and Technology Commission [09DZ1950101, 09JC1409600]; Shanghai Charity Foundation for Cancer Research	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chinese National High Tech Program(National High Technology Research and Development Program of China); Shanghai Pu Jiang Project(Shanghai Pujiang Program); Shanghai Science and Technology Commission(Shanghai Science & Technology CommitteeScience & Technology Commission of Shanghai Municipality (STCSM)); Shanghai Charity Foundation for Cancer Research	This work was supported, in part by grants from the National Natural Science Foundation of China (30572127, 30770961 and 30973486), the Chinese National High Tech Program (863-2006AA02A402, 2006AA02A301), the Shanghai Pu Jiang Project (PJ200700367), Key Research Project from Shanghai Science and Technology Commission (09DZ1950101 and 09JC1409600), and Shanghai Charity Foundation for Cancer Research.	Alarcon P, 2008, DEVELOPMENT, V135, P3197, DOI 10.1242/dev.023697; Asaka SI, 2006, SURG TODAY, V36, P793, DOI 10.1007/s00595-006-3261-2; Becker MB, 2001, MECH DEVELOP, V106, P155, DOI 10.1016/S0925-4773(01)00412-9; Bennett KL, 2008, CANCER RES, V68, P4494, DOI 10.1158/0008-5472.CAN-07-6509; Bergman Y, 1998, BIOL CHEM, V379, P401; Cairns Paul, 2009, V507, P165, DOI 10.1007/978-1-59745-522-0_13; Choi IS, 2005, CELL RES, V15, P247, DOI 10.1038/sj.cr.7290293; Do Jee C, 2009, EUR J CANCER, V45, P1282, DOI 10.1016/j.ejca.2008.12.027; Duffy MJ, 2009, EUR J CANCER, V45, P335, DOI 10.1016/j.ejca.2008.12.008; Duggan DJ, 1999, NAT GENET, V21, P10, DOI 10.1038/4434; Esteller M, 2007, HUM MOL GENET, V16, pR50, DOI 10.1093/hmg/ddm018; Ferguson CA, 1998, GENE DEV, V12, P2636, DOI 10.1101/gad.12.16.2636; Garinis GA, 2002, HUM GENET, V111, P115, DOI 10.1007/s00439-002-0783-6; Hao Y, 2008, J PROTEOME RES, V7, P3668, DOI 10.1021/pr700638k; Hellebrekers DMEI, 2007, CANCER RES, V67, P4138, DOI 10.1158/0008-5472.CAN-06-3032; Huang QJ, 2008, J CANCER RES CLIN, V134, P1219, DOI 10.1007/s00432-008-0398-y; Hurtubise A, 2008, CANCER CELL INT, V8, DOI 10.1186/1475-2867-8-16; Ikeda Y, 2004, CANCER RES, V64, P5178, DOI 10.1158/0008-5472.CAN-03-3589; Iorns E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005120; Ishihara K, 2002, INT IMMUNOPHARMACOL, V2, P499, DOI 10.1016/S1567-5769(01)00193-X; Ishihara K, 2001, JPN J PHARMACOL, V87, P318, DOI 10.1254/jjp.87.318; Jin GF, 2009, CARCINOGENESIS, V30, P987, DOI 10.1093/carcin/bgp090; KAMEI M, 1992, BIOTHERAPY, V4, P17, DOI 10.1007/BF02171705; Kawakami K, 2000, J NATL CANCER I, V92, P1805, DOI 10.1093/jnci/92.22.1805; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; Knudson AG, 1996, J CANCER RES CLIN, V122, P135, DOI 10.1007/BF01366952; Kuga D, 2008, NEURO-ONCOLOGY, V10, P995, DOI 10.1215/15228517-2008-064; Lai IR, 2002, HEPATO-GASTROENTEROL, V49, P1157; Lemaire M, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-128; Lewis MT, 1999, CELL TISSUE RES, V296, P549, DOI 10.1007/s004410051316; Lu Y, 2005, CANCER LETT, V224, P329, DOI 10.1016/j.canlet.2004.11.057; McKay JD, 2008, NAT GENET, V40, P1404, DOI 10.1038/ng.254; Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774; Perez-Diez A, 2007, ADV EXP MED BIOL, V593, P74; Plendl J, 2000, BIOL CHEM, V381, P1103, DOI 10.1515/BC.2000.135; Quackenbush J, 2006, NEW ENGL J MED, V354, P2463, DOI 10.1056/NEJMra042342; Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461; Ropiquet F, 1999, INT J CANCER, V82, P237, DOI 10.1002/(SICI)1097-0215(19990719)82:2<237::AID-IJC14>3.0.CO;2-Q; Schneider-Stock R, 2007, IDRUGS, V10, P557; Shaker S, 2004, ONCOL REP, V11, P1253; Shaoul R, 2006, BIOCHEM BIOPH RES CO, V350, P825, DOI 10.1016/j.bbrc.2006.08.198; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tamura M, 1999, CANCER RES, V59, P442; TELFORD JL, 1994, TRENDS BIOTECHNOL, V12, P420, DOI 10.1016/0167-7799(94)90031-0; Tocchi A, 1998, J CANCER RES CLIN, V124, P450, DOI 10.1007/s004320050198; Tommasi S, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2233; Toyota M, 2005, SEMIN ONCOL, V32, P521, DOI 10.1053/j.seminoncol.2005.07.003; Tycko B, 2000, J CLIN INVEST, V105, P401, DOI 10.1172/JCI9462; Ushijima T, 2006, J GASTROENTEROL, V41, P401, DOI 10.1007/s00535-006-1846-6; van Tuyl M, 2006, AM J PHYSIOL-LUNG C, V290, pL777, DOI 10.1152/ajplung.00293.2005; Yamashita K, 2002, CANCER CELL, V2, P485, DOI 10.1016/S1535-6108(02)00215-5; Ychou M, 2000, DIS MARKERS, V16, P105, DOI 10.1155/2000/595492; Yu Ying-yan, 2006, Zhonghua Zhongliu Zazhi, V28, P84; Zhao HJ, 2005, PROSTATE, V63, P187, DOI 10.1002/pros.20158	54	70	80	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2010	29	27					3908	3920		10.1038/onc.2010.143	http://dx.doi.org/10.1038/onc.2010.143			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	621SL	20440264				2022-12-17	WOS:000279603200004
J	Rachakonda, G; Sekhar, KR; Jowhar, D; Samson, PC; Wikswo, JP; Beauchamp, RD; Datta, PK; Freeman, ML				Rachakonda, G.; Sekhar, K. R.; Jowhar, D.; Samson, P. C.; Wikswo, J. P.; Beauchamp, R. D.; Datta, P. K.; Freeman, M. L.			Increased cell migration and plasticity in Nrf2-deficient cancer cell lines	ONCOGENE			English	Article						Nrf2; TGF-beta; Smad; Cadherin; motility; oncogenesis	EPITHELIAL-MESENCHYMAL TRANSITION; TRANSCRIPTION FACTOR NRF2; ACTIVATOR INHIBITOR-1 PROMOTER; GENE-EXPRESSION PROFILES; UBIQUITIN LIGASE COMPLEX; FACTOR-DEFICIENT MICE; TGF-BETA; OXIDATIVE STRESS; LUNG-CANCER; BREAST-CANCER	Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) expression is deregulated in many cancers. Genetic and biochemical approaches coupled with functional assays in cultured cells were used to explore the consequences of Nrf2 repression. Nrf2 suppression by Keap1-directed ubiquitylation or the expression of independent short hairpin RNA (shRNA)/siRNA sequences enhanced cellular levels of reactive oxygen species, Smad-dependent tumor cell motility and growth in soft agar. Loss of Nrf2 was accompanied by concomitant Smad linker region/C-terminus phosphorylation, induction of the E-cadherin transcriptional repressor Slug and suppression of the cell-cell adhesion protein E-cadherin. Ectopic expression of the wildtype but not dominant-negative Nrf2 suppressed the activity of a synthetic transforming growth factor-beta 1-responsive CAGA-directed luciferase reporter. shRNA knock-down of Nrf2 enhanced the activity of the synthetic CAGA reporter, as well as the expression of the endogenous Smad target gene plasminogen activator inhibitor-1. Finally, we found that Nrf2/Smad3/Smad4 formed an immunoprecipitable nuclear complex. Thus, loss of Nrf2 increased R-Smad phosphorylation and R-Smad signaling, supporting the hypothesis that loss of Nrf2 in an oncogenic context-dependent manner can enhance cellular plasticity and motility, in part by using transforming growth factor-beta/Smad signaling. Oncogene (2010) 29, 3703-3714; doi: 10.1038/onc.2010.118; published online 3 May 2010	[Freeman, M. L.] Vanderbilt Univ, Sch Med, Dept Radiat Oncol, Nashville, TN 37232 USA; [Jowhar, D.; Samson, P. C.; Wikswo, J. P.] Vanderbilt Univ, Dept Phys & Astron, Nashville, TN 37232 USA; [Jowhar, D.; Samson, P. C.; Wikswo, J. P.] Vanderbilt Univ, Vanderbilt Inst Integrat Biosyst Res & Educ, Nashville, TN 37232 USA; [Wikswo, J. P.] Vanderbilt Univ, Dept Biomed Engn, Nashville, TN 37232 USA; [Wikswo, J. P.] Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; [Beauchamp, R. D.; Datta, P. K.] Vanderbilt Univ, Dept Surg, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Freeman, ML (corresponding author), Vanderbilt Univ, Sch Med, Dept Radiat Oncol, B 902 TVC, Nashville, TN 37232 USA.	michael.freeman@vanderbilt.edu		Konjeti, Sekhar/0000-0003-2930-0739; Freeman, Michael/0000-0003-1881-366X; Beauchamp, Robert Daniel/0000-0002-8446-4114	NIH [RO1CA104590, RO1CA115556, RO1CA069457, R01DK052334, RO1CA095195, RO1CA113519, P50CA090949, U01AI061223]; Vanderbilt-Ingram Cancer Center [P30CA68485]; Vanderbilt Institute for Integrative Biosystems Research and Education; NATIONAL CANCER INSTITUTE [P50CA090949, R01CA104590, R01CA069457, R01CA115556, R01CA095195, P30CA068485, R01CA113519] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI061223] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052334] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Vanderbilt-Ingram Cancer Center; Vanderbilt Institute for Integrative Biosystems Research and Education; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We are grateful for the assistance provided by Dr Swati Biswas. This research was supported in part by NIH Grants RO1CA104590, RO1CA115556, RO1CA069457, R01DK052334, RO1CA095195, RO1CA113519, P50CA090949 (Project# 4), U01AI061223, the Vanderbilt-Ingram Cancer Center grant P30CA68485, and the Vanderbilt Institute for Integrative Biosystems Research and Education.	Barve A, 2009, INT J CANCER, V124, P1693, DOI 10.1002/ijc.24106; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Biswas S, 2007, J CLIN INVEST, V117, P1305, DOI 10.1172/JCI30740; Brown SL, 2008, CANCER RES, V68, P364, DOI 10.1158/0008-5472.CAN-07-2170; Calonge MJ, 1999, J BIOL CHEM, V274, P33637, DOI 10.1074/jbc.274.47.33637; Cao JX, 2009, EMBO J, V28, P1505, DOI 10.1038/emboj.2009.101; CHAKRABORTY AK, 1992, MELANOMA RES, V2, P315, DOI 10.1097/00008390-199212000-00004; Chan KM, 1996, P NATL ACAD SCI USA, V93, P13943, DOI 10.1073/pnas.93.24.13943; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; Chung CH, 2004, CANCER CELL, V5, P489, DOI 10.1016/S1535-6108(04)00112-6; Coulouarn C, 2008, HEPATOLOGY, V47, P2059, DOI 10.1002/hep.22283; Frohlich DA, 2008, ONCOGENE, V27, P4353, DOI 10.1038/onc.2008.79; GREENBURG G, 1982, J CELL BIOL, V95, P333, DOI 10.1083/jcb.95.1.333; Grinberg AV, 2003, J BIOL CHEM, V278, P11227, DOI 10.1074/jbc.M211734200; Hayashi A, 2003, BIOCHEM BIOPH RES CO, V310, P824, DOI 10.1016/j.bbrc.2003.09.086; Hendrix ND, 2006, CANCER RES, V66, P1354, DOI 10.1158/0008-5472.CAN-05-3694; Hirayama A, 2003, FREE RADICAL BIO MED, V34, P1236, DOI 10.1016/S0891-5849(03)00073-X; Homma S, 2009, CLIN CANCER RES, V15, P3423, DOI 10.1158/1078-0432.CCR-08-2822; Hong F, 2005, J BIOL CHEM, V280, P31768, DOI 10.1074/jbc.M503346200; HUBER BE, 1987, CANCER RES, V47, P3414; Inoue Y, 2007, ONCOGENE, V26, P500, DOI 10.1038/sj.onc.1209826; Jinnin M, 2006, MOL PHARMACOL, V69, P597, DOI 10.1124/mol.105.017483; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Katoh Y, 2001, GENES CELLS, V6, P857, DOI 10.1046/j.1365-2443.2001.00469.x; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021; Kusano Y, 2008, BIOCHEMISTRY-US, V47, P6169, DOI 10.1021/bi800199z; Kwak MK, 2001, MOL MED, V7, P135, DOI 10.1007/BF03401947; Lee DF, 2009, MOL CELL, V36, P131, DOI 10.1016/j.molcel.2009.07.025; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Liu JR, 2004, HUM GENE THER, V15, P239, DOI 10.1089/104303404322886093; Lo SC, 2006, J BIOL CHEM, V281, P37893, DOI 10.1074/jbc.M606539200; Loignon M, 2009, MOL CANCER THER, V8, P2432, DOI 10.1158/1535-7163.MCT-08-1186; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Mates JM, 2008, ARCH TOXICOL, V82, P273, DOI 10.1007/s00204-008-0304-z; Matsuzaki K, 2009, CANCER RES, V69, P5321, DOI 10.1158/0008-5472.CAN-08-4203; Matsuzawa A, 2008, BBA-GEN SUBJECTS, V1780, P1325, DOI 10.1016/j.bbagen.2007.12.011; Mithani SK, 2004, J SURG RES, V117, P296, DOI 10.1016/S0022-4804(03)00335-4; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Muller N, 2002, ONCOGENE, V21, P6049, DOI 10.1038/sj.onc.1205766; Nioi P, 2007, BIOCHEM BIOPH RES CO, V362, P816, DOI 10.1016/j.bbrc.2007.08.051; Nogueira V, 2008, CANCER CELL, V14, P458, DOI 10.1016/j.ccr.2008.11.003; Ohta T, 2008, CANCER RES, V68, P1303, DOI 10.1158/0008-5472.CAN-07-5003; Padmanabhan B, 2006, MOL CELL, V21, P689, DOI 10.1016/j.molcel.2006.01.013; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; Safina AF, 2009, CELL CYCLE, V8, P284, DOI 10.4161/cc.8.2.7590; Sarsour EH, 2008, AGING CELL, V7, P405, DOI 10.1111/j.1474-9726.2008.00384.x; Sekhar KR, 2003, CANCER RES, V63, P5636; Shibata T, 2008, P NATL ACAD SCI USA, V105, P13568, DOI 10.1073/pnas.0806268105; Shiou SR, 2007, CANCER RES, V67, P1571, DOI 10.1158/0008-5472.CAN-06-1680; Singh A, 2008, CANCER RES, V68, P7975, DOI 10.1158/0008-5472.CAN-08-1401; Singh A, 2006, PLOS MED, V3, P1865, DOI 10.1371/journal.pmed.0030420; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; Stacy DR, 2006, HEAD NECK-J SCI SPEC, V28, P813, DOI 10.1002/hed.20430; Strachan GD, 2005, BIOCHEM BIOPH RES CO, V336, P490, DOI 10.1016/j.bbrc.2005.08.127; SUN Y, 1989, INT J CANCER, V44, P1028, DOI 10.1002/ijc.2910440615; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Thuault S, 2006, J CELL BIOL, V174, P175, DOI 10.1083/jcb.200512110; Tonks NK, 2005, CELL, V121, P667, DOI 10.1016/j.cell.2005.05.016; VALENZUELA DM, 1986, NUCLEIC ACIDS RES, V14, P843, DOI 10.1093/nar/14.2.843; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Verrecchia F, 2001, ONCOGENE, V20, P3332, DOI 10.1038/sj.onc.1204448; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Weydert CJ, 2006, FREE RADICAL BIO MED, V41, P226, DOI 10.1016/j.freeradbiomed.2006.03.015; Whitesides GM, 2001, ANNU REV BIOMED ENG, V3, P335, DOI 10.1146/annurev.bioeng.3.1.335; Wurmbach E, 2007, HEPATOLOGY, V45, P938, DOI 10.1002/hep.21622; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yano T, 2001, CARCINOGENESIS, V22, P1593, DOI 10.1093/carcin/22.10.1593; Ye QH, 2003, NAT MED, V9, P416, DOI 10.1038/nm843; Yu R, 2000, J BIOL CHEM, V275, P39907, DOI 10.1074/jbc.M004037200; Yu SW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008579; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zhang DD, 2004, MOL CELL BIOL, V24, P10941, DOI 10.1128/MCB.24.24.10941-10953.2004; Zhang Y, 2002, CANCER RES, V62, P1205	78	70	71	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 24	2010	29	25					3703	3714		10.1038/onc.2010.118	http://dx.doi.org/10.1038/onc.2010.118			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615CG	20440267	Green Accepted			2022-12-17	WOS:000279108600010
J	Liu, Y; Karaca, M; Zhang, Z; Gioeli, D; Earp, HS; Whang, YE				Liu, Y.; Karaca, M.; Zhang, Z.; Gioeli, D.; Earp, H. S.; Whang, Y. E.			Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases	ONCOGENE			English	Article						androgen receptor; phosphorylation; Ack1 kinase; dasatinib; prostate cancer	RECURRENT PROSTATE-CANCER; ACTIVATION; RESISTANT; GROWTH; INTERLEUKIN-6; INDEPENDENCE; PROGRESSION; EXPRESSION; PATHWAY	Activation of androgen receptor (AR) may have a role in the development of castration-resistant prostate cancer. Two intracellular tyrosine kinases, Ack1 (activated cdc42-associated kinase) and Src, phosphorylate and enhance AR activity and promote prostate xenograft tumor growth in castrated animals. However, the upstream signals that activate these kinases and lead to AR activation are incompletely characterized. In this study, we investigated AR phosphorylation in response to non-androgen ligand stimulation using phospho-specific antibodies. Treatment of LNCaP and LAPC-4 cells with epidermal growth factor (EGF), heregulin, Gas6 (ligand binding to the Mer receptor tyrosine kinase and activating Ack1 downstream), interleukin (IL)-6 or bombesin stimulated cell proliferation in the absence of androgen. Treatment of LNCaP and LAPC-4 cells with EGF, heregulin or Gas6 induced AR phosphorylation at Tyr-267, whereas IL-6 or bombesin treatment did not. AR phosphorylation at Tyr-534 was induced by treatment with EGF, IL-6 or bombesin, but not by heregulin or Gas6. Small interfering RNA-mediated knockdown of Ack1 or Src showed that Ack1 mediates heregulin- and Gas6-induced AR Tyr-267 phosphorylation, whereas Src mediates Tyr-534 phosphorylation induced by EGF, IL-6 and bombesin. Dasatinib, a Src inhibitor, blocked EGF-induced Tyr-534 phosphorylation. In addition, we showed that dasatinib also inhibited Ack1 kinase. Dasatinib inhibited heregulin-induced Ack1 kinase activity and AR Tyr-267 phosphorylation. In addition, dasatinib inhibited heregulin-induced AR-dependent reporter activity. Dasatinib also inhibited heregulin-induced expression of endogenous AR target genes. Dasatinib inhibited Ack1-dependent colony formation and prostate xenograft tumor growth in castrated mice. Interestingly, Ack1 or Src knockdown or dasatinib did not inhibit EGF-induced AR Tyr-267 phosphorylation or EGF-stimulated AR activity, suggesting the existence of an additional tyrosine kinase that phosphorylates AR at Tyr-267. These data suggest that specific tyrosine kinases phosphorylate AR at distinct sites and that dasatinib may exert antitumor activity in prostate cancer through inhibition of Ack1. Oncogene (2010) 29, 3208-3216; doi: 10.1038/onc.2010.103; published online 12 April 2010	[Liu, Y.; Zhang, Z.; Earp, H. S.; Whang, Y. E.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Karaca, M.; Whang, Y. E.] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; [Gioeli, D.] Univ Virginia Hlth Syst, Dept Microbiol, Charlottesville, VA USA; [Earp, H. S.; Whang, Y. E.] Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; [Earp, H. S.] Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Virginia; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Whang, YE (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Campus Box 7295, Chapel Hill, NC 27599 USA.	ywhang@med.unc.edu	, Animal Studies Core/AAF-4432-2022; , Animal Studies Core/ADK-4234-2022; Whang, Young/AAK-7435-2021	Whang, Young/0000-0002-1621-6661	NIH [R01CA120921, R01CA120304, T32ES007017]; NATIONAL CANCER INSTITUTE [R01CA120921, R01CA120304, R01CA124706] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007017] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Francis Lee of Bristol-Myers-Squibb for providing dasatinib, Charlene Ross and staff of the UNC Lineberger Animal Studies Facility for assistance in xenograft tumor experiments, Dominic Moore for statistical analysis and Nupam Mahajan for discussions and sharing unpublished papers. This study was supported by grants from NIH R01CA120921 (YEW), NIH R01CA120304 (HSE) and NIH T32ES007017 (MK).	Araujo J, 2009, J CLIN ONCOL, V27; Araujo J, 2009, INT J CANCER, V124, P1, DOI 10.1002/ijc.23998; Brave M, 2008, CLIN CANCER RES, V14, P352, DOI 10.1158/1078-0432.CCR-07-4175; Carter TA, 2005, P NATL ACAD SCI USA, V102, P11011, DOI 10.1073/pnas.0504952102; Chen L, 2004, NEW ASTRON, V10, P39, DOI 10.1016/j.newast.2004.04.008; DaSilva J, 2009, CANCER RES, V69, P7402, DOI 10.1158/0008-5472.CAN-08-4687; Desai SJ, 2006, CANCER RES, V66, P10449, DOI 10.1158/0008-5472.CAN-06-2582; Forbes S, 2006, BRIT J CANCER, V94, P318, DOI 10.1038/sj.bjc.6602928; Galisteo ML, 2006, P NATL ACAD SCI USA, V103, P9796, DOI 10.1073/pnas.0603714103; Gioeli D, 2006, MOL ENDOCRINOL, V20, P503, DOI 10.1210/me.2005-0351; Gioeli D, 2002, J BIOL CHEM, V277, P29304, DOI 10.1074/jbc.M204131200; Gong J, 2006, ONCOGENE, V25, P2011, DOI 10.1038/sj.onc.1209231; Gregory CW, 2005, CLIN CANCER RES, V11, P1704, DOI 10.1158/1078-0432.CCR-04-1158; Gregory CW, 2004, J BIOL CHEM, V279, P7119, DOI 10.1074/jbc.M307649200; Gregory CW, 1998, CANCER RES, V58, P5718; Gregory CW, 2001, CANCER RES, V61, P2892; Guo ZY, 2006, CANCER CELL, V10, P309, DOI 10.1016/j.ccr.2006.08.021; Klein KA, 1997, NAT MED, V3, P402, DOI 10.1038/nm0497-402; Kraus S, 2006, CANCER RES, V66, P11047, DOI 10.1158/0008-5472.CAN-06-0596; Lee LF, 2001, MOL CELL BIOL, V21, P8385, DOI 10.1128/MCB.21.24.8385-8397.2001; Liu YB, 2005, CANCER RES, V65, P3404, DOI 10.1158/0008-5472.CAN-04-4292; Mahajan NP, 2005, CANCER RES, V65, P10514, DOI 10.1158/0008-5472.CAN-05-1127; Mahajan NP, 2007, P NATL ACAD SCI USA, V104, P8438, DOI 10.1073/pnas.0700420104; Mellinghoff IK, 2004, CANCER CELL, V6, P517, DOI 10.1016/j.ccr.2004.09.031; Pao-Chun L, 2009, J BIOL CHEM, V284, P34954, DOI 10.1074/jbc.M109.072660; Park SI, 2008, CANCER RES, V68, P3323, DOI 10.1158/0008-5472.CAN-07-2997; Ponguta LA, 2008, J BIOL CHEM, V283, P20989, DOI 10.1074/jbc.M802392200; Scher HI, 2005, J CLIN ONCOL, V23, P8253, DOI 10.1200/JCO.2005.03.4777; Ueda T, 2002, J BIOL CHEM, V277, P38087, DOI 10.1074/jbc.M203313200; Ueda T, 2002, J BIOL CHEM, V277, P7076, DOI 10.1074/jbc.M108255200; van der Horst EH, 2005, P NATL ACAD SCI USA, V102, P15901, DOI 10.1073/pnas.0508014102; Wang Y, 2007, CURR CANCER DRUG TAR, V7, P591, DOI 10.2174/156800907781662248; Yang JC, 2009, CANCER RES, V69, P151, DOI 10.1158/0008-5472.CAN-08-0442; Yu EY, 2009, CLIN CANCER RES, V15, P7421, DOI 10.1158/1078-0432.CCR-09-1691; Zhang JF, 2000, ENDOCRINOLOGY, V141, P4698, DOI 10.1210/en.141.12.4698	35	70	77	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2010	29	22					3208	3216		10.1038/onc.2010.103	http://dx.doi.org/10.1038/onc.2010.103			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	605BA	20383201	Green Accepted, Green Submitted			2022-12-17	WOS:000278321100004
J	Matrone, MA; Whipple, RA; Thompson, K; Cho, EH; Vitolo, MI; Balzer, EM; Yoon, JR; Ioffe, OB; Tuttle, KC; Tan, M; Martin, SS				Matrone, M. A.; Whipple, R. A.; Thompson, K.; Cho, E. H.; Vitolo, M. I.; Balzer, E. M.; Yoon, J. R.; Ioffe, O. B.; Tuttle, K. C.; Tan, M.; Martin, S. S.			Metastatic breast tumors express increased tau, which promotes microtentacle formation and the reattachment of detached breast tumor cells	ONCOGENE			English	Article						microtentacles; tau; microtubule-associated proteins; microtubules; circulating tumor cells	MICROTUBULE-ASSOCIATED PROTEINS; PACLITAXEL SENSITIVITY; CANCER; NEURODEGENERATION; 3-REPEAT-TAU; CHEMOTHERAPY; 4-REPEAT-TAU; DYNAMICS; ADHESION; DISEASE	The cytoskeletal organization of detached and circulating tumor cells (CTCs) is currently not well defined and may provide potential targets for new therapies to limit metastatic tumor spread. In vivo, CTCs reattach in distant tissues by a mechanism that is tubulin-dependent and suppressed by polymerized actin. The cytoskeletal mechanisms that promote reattachment of CTCs match exactly with the mechanisms supporting tubulin microtentacles (McTN), which we have recently identified in detached breast tumor cells. In this study, we aimed to investigate how McTN formation is affected by the microtubule-associated protein, tau, which is expressed in a subset of chemotherapy-resistant breast cancers. We demonstrate that endogenous tau protein localizes to McTNs and is both necessary and sufficient to promote McTN extension in detached breast tumor cells. Tau-induced McTNs increase reattachment of suspended cells and retention of CTCs in lung capillaries. Analysis of patient-matched primary and metastatic tumors reveals that 52% possess tau expression in metastases and 26% display significantly increased tau expression over disease progression. Tau enrichment in metastatic tumors and the ability of tau to promote tumor cell reattachment through McTN formation support a model in which tau-induced microtubule stabilization provides a selective advantage during tumor metastasis. Oncogene (2010) 29, 3217-3227; doi: 10.1038/onc.2010.68; published online 15 March 2010	[Martin, S. S.] Univ Maryland, Greenebaum Canc Ctr, Sch Med, Program Mol Med, Baltimore, MD 21201 USA; [Whipple, R. A.; Thompson, K.; Vitolo, M. I.; Tuttle, K. C.; Tan, M.; Martin, S. S.] Univ Maryland, Marlene & Stewart Greenebaum NCI Canc Ctr, Sch Med, Baltimore, MD 21201 USA; [Yoon, J. R.; Martin, S. S.] Univ Maryland, Dept Physiol, Sch Med, Baltimore, MD 21201 USA; [Ioffe, O. B.] Univ Maryland, Dept Pathol, Sch Med, Baltimore, MD 21201 USA; [Tan, M.] Univ Maryland, Dept Epidemiol & Prevent Med, Sch Med, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Martin, SS (corresponding author), Univ Maryland, Greenebaum Canc Ctr, Sch Med, Program Mol Med, 655 W Baltimore St,Rm 10-029, Baltimore, MD 21201 USA.	ssmartin@som.umaryland.edu	Cho, Edward/B-3727-2012	Cho, Edward/0000-0002-0278-334X; Vitolo, Michele/0000-0001-8055-9645	National Cancer Institute [R01-CA124704]; USA Medical Research and Materiel Command [BC061047]; Flight Attendants Medical Research Institute [CIA-062497]; NATIONAL CANCER INSTITUTE [K01CA096555, P30CA134274, R01CA124704] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); USA Medical Research and Materiel Command(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC)); Flight Attendants Medical Research Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by Grant R01-CA124704 from National Cancer Institute, Breast Cancer Idea Award from USA Medical Research and Materiel Command (BC061047) and a Clinical Innovator Award from Flight Attendants Medical Research Institute (CIA-062497). We thank Dr I-Chu Tseng and the Dr Chen-Yong Lin laboratory for immunohistochemistry assistance, Dr Larry Changwan Lu for his assistance with the statistical analyses, Aric Colunga and the Dr Laure Aurelian laboratory for imaging assistance, Dr William Twaddell for assistance with pathological scoring of vimentin staining, and Dr Michele Weiss for Figure 6 assistance.	Atienza JM, 2006, ASSAY DRUG DEV TECHN, V4, P597, DOI 10.1089/adt.2006.4.597; BALZER EM, 2009, BREAST CANC RES TREA; Bhat KMR, 2007, CLIN CANCER RES, V13, P2849, DOI 10.1158/1078-0432.CCR-06-3040; Bulic B, 2009, ANGEW CHEM INT EDIT, V48, P1741, DOI 10.1002/anie.200802621; Camara O, 2007, ANN ONCOL, V18, P1484, DOI 10.1093/annonc/mdm206; Cassimeris L, 2001, INT REV CYTOL, V210, P163; CHEN J, 1992, NATURE, V360, P674, DOI 10.1038/360674a0; Dickey CA, 2006, MOL NEURODEGENER, V1, DOI 10.1186/1750-1326-1-6; DRUBIN DG, 1985, J CELL BIOL, V101, P1799, DOI 10.1083/jcb.101.5.1799; ENGEL LW, 1978, CANCER RES, V38, P3352; Gazdar AF, 1998, INT J CANCER, V78, P766, DOI 10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L; Goedert M, 2004, SEMIN CELL DEV BIOL, V15, P45, DOI 10.1016/j.semcdb.2003.12.015; Haier J, 2001, APMIS, V109, P241, DOI 10.1034/j.1600-0463.2001.d01-118.x; Hall A, 2009, CANCER METAST REV, V28, P5, DOI 10.1007/s10555-008-9166-3; Husemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003; Ingber DE, 2003, J CELL SCI, V116, P1157, DOI 10.1242/jcs.00359; JANMEY PA, 1991, J CELL BIOL, V113, P155, DOI 10.1083/jcb.113.1.155; Janni W, 2005, CANCER-AM CANCER SOC, V103, P884, DOI 10.1002/cncr.20834; KNOPS J, 1991, J CELL BIOL, V114, P725, DOI 10.1083/jcb.114.4.725; Korb T, 2004, EXP CELL RES, V299, P236, DOI 10.1016/j.yexcr.2004.06.001; LEE G, 1992, J CELL SCI, V102, P227; Levy SF, 2005, J BIOL CHEM, V280, P13520, DOI 10.1074/jbc.M413490200; McGrogan BT, 2008, BBA-REV CANCER, V1785, P96, DOI 10.1016/j.bbcan.2007.10.004; Mialhe A, 2001, CANCER RES, V61, P5024; Panda D, 2003, P NATL ACAD SCI USA, V100, P9548, DOI 10.1073/pnas.1633508100; Pusztai L, 2009, J CLIN ONCOL, V27, P4287, DOI 10.1200/JCO.2008.21.6887; Remmerbach TW, 2009, CANCER RES, V69, P1728, DOI 10.1158/0008-5472.CAN-08-4073; Rosenberg KJ, 2008, P NATL ACAD SCI USA, V105, P7445, DOI 10.1073/pnas.0802036105; Rouzier R, 2005, P NATL ACAD SCI USA, V102, P8315, DOI 10.1073/pnas.0408974102; Schaap IAT, 2007, J STRUCT BIOL, V158, P282, DOI 10.1016/j.jsb.2006.11.010; Sharma VM, 2007, J CELL SCI, V120, P748, DOI 10.1242/jcs.03378; Steeg PS, 2008, NAT CLIN PRACT ONCOL, V5, P206, DOI 10.1038/ncponc1066; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Wagner P, 2005, CELL CYCLE, V4, P1149, DOI 10.4161/cc.4.9.2038; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WEISS L, 1991, CELL BIOPHYS, V18, P73, DOI 10.1007/BF02989807; Whipple RA, 2008, CANCER RES, V68, P5678, DOI 10.1158/0008-5472.CAN-07-6589; Whipple RA, 2007, EXP CELL RES, V313, P1326, DOI 10.1016/j.yexcr.2007.02.001; Willipinski-Stapelfeldt B, 2005, CLIN CANCER RES, V11, P8006, DOI 10.1158/1078-0432.CCR-05-0632; Yamauchi K, 2006, CANCER RES, V66, P4208, DOI 10.1158/0008-5472.CAN-05-3927	41	70	71	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 3	2010	29	22					3217	3227		10.1038/onc.2010.68	http://dx.doi.org/10.1038/onc.2010.68			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	605BA	20228842	Green Accepted			2022-12-17	WOS:000278321100005
J	Shah, KM; Stewart, SE; Wei, W; Woodman, CBJ; O'Neil, JD; Dawson, CW; Young, LS				Shah, K. M.; Stewart, S. E.; Wei, W.; Woodman, C. B. J.; O'Neil, J. D.; Dawson, C. W.; Young, L. S.			The EBV-encoded latent membrane proteins, LMP2A and LMP2B, limit the actions of interferon by targeting interferon receptors for degradation	ONCOGENE			English	Article						EBV; NPC; interferon; endosomes; lysosomes	EPSTEIN-BARR-VIRUS; DOWN-REGULATION; CELL-RECEPTOR; 2A; ACTIVATION; CARCINOMA; SUSCEPTIBILITY; PATHOGENESIS; TRAFFICKING; ASSOCIATION	Although frequently expressed in Epstein-Barr virus (EBV)-positive malignancies, the role that latent membrane protein 2A and 2B (LMP2A and LMP2B) have in the oncogenic process remains obscure. Here we show a novel function for these proteins in epithelial cells, namely, their ability to modulate signalling from type I/II interferon receptors (IFNRs). We show that LMP2A- and LMP2B-expressing epithelial cells show decreased responsiveness to interferon (IFN)alpha and IFN gamma, as assessed by STAT1 phosphorylation, ISGF3 and GAF-mediated binding to IFN-stimulated response element and IFN gamma-activated factor sequence elements and luciferase reporter activation. Transcriptional pro. ling highlighted the extent of this modulation, with both viral proteins impacting 'globally' on IFN-stimulated gene expression. Although not affecting the levels of cell-surface IFNRs, LMP2A and LMP2B accelerated the turnover of IFNRs through processes requiring endosome acidification. This function may form part of EBV's strategy to limit anti-viral responses and de. ne a novel function for LMP2A and LMP2B in modulating signalling from receptors that participate in innate immune responses. Oncogene (2009) 28, 3903-3914; doi:10.1038/onc.2009.249; published online 31 August 2009	[Shah, K. M.; Wei, W.; Woodman, C. B. J.; O'Neil, J. D.; Dawson, C. W.; Young, L. S.] Univ Birmingham, Canc Res UK Inst Canc Studies, Sch Med, Birmingham B15 2TT, W Midlands, England; [Stewart, S. E.] Univ Edinburgh, Sch Med, Div Pathway Med, Edinburgh, Midlothian, Scotland	Cancer Research UK; University of Birmingham; University of Edinburgh	Young, LS (corresponding author), Univ Birmingham, Canc Res UK Inst Canc Studies, Sch Canc Sci, Birmingham B15 2TT, W Midlands, England.	L.S.Young@bham.ac.uk	Young, Lawrence S/B-7213-2009	Young, Lawrence S/0000-0003-3919-4298; Wei, Wenbin/0000-0003-1288-6999	Cancer Research UK; European Commission's FP6 Life Sciences Health Programme [LSHC-CT-.2005-018704]	Cancer Research UK(Cancer Research UK); European Commission's FP6 Life Sciences Health Programme	This work was supported by programme funding from Cancer Research UK and the European Commission's FP6 Life Sciences Health Programme (INCA project LSHC-CT-.2005-018704).	Adachi K, 2007, ARCH VIROL, V152, P2217, DOI 10.1007/s00705-007-1061-7; Allen MD, 2005, J VIROL, V79, P1789, DOI 10.1128/JVI.79.3.1789-1802.2005; Anderson LJ, 2008, VIROLOGY, V371, P257, DOI 10.1016/j.virol.2007.10.009; Beadling C, 1996, EMBO J, V15, P1902, DOI 10.1002/j.1460-2075.1996.tb00541.x; Cassady KA, 2002, J VIROL, V76, P2029, DOI 10.1128/jvi.76.5.2029-2035.2002; Cho NH, 2006, J VIROL, V80, P108, DOI 10.1128/JVI.80.1.108-118.2006; Claudinon J, 2007, BIOCHIMIE, V89, P735, DOI 10.1016/j.biochi.2007.03.014; CONRAD M, 1993, J VIROL, V67, P6170, DOI 10.1128/JVI.67.10.6170-6178.1993; Dawson CW, 2000, VIROLOGY, V272, P204, DOI 10.1006/viro.2000.0344; Dawson CW, 2001, VIROLOGY, V289, P192, DOI 10.1006/viro.2001.1142; Dykstra ML, 2001, IMMUNITY, V14, P57, DOI 10.1016/S1074-7613(01)00089-9; Feys HB, 2008, BLOOD, V112, P102; Ikeda M, 2007, VIROLOGY, V360, P461, DOI 10.1016/j.virol.2006.10.046; Katze MG, 2002, J INTERF CYTOK RES, V22, P283, DOI 10.1089/107999002753675695; Li QL, 2007, J VIROL, V81, P2117, DOI 10.1128/JVI.01961-06; Liu J, 2008, BIOCHEM BIOPH RES CO, V367, P388, DOI 10.1016/j.bbrc.2007.12.137; Longan L, 2000, J GEN VIROL, V81, P2245, DOI 10.1099/0022-1317-81-9-2245; Longnecker R, 2000, ADV CANCER RES, V79, P175, DOI 10.1016/S0065-230X(00)79006-3; Mancao C, 2007, BLOOD, V110, P3715, DOI 10.1182/blood-2007-05-090142; Morrison JA, 2003, J VIROL, V77, P12276, DOI 10.1128/JVI.77.22.12276-12284.2003; Morrison TE, 2001, IMMUNITY, V15, P787, DOI 10.1016/S1074-7613(01)00226-6; Nanbo A, 2002, REV MED VIROL, V12, P321, DOI 10.1002/rmv.363; Offermann MK, 2007, CURR TOP MICROBIOL, V312, P185; Ogino T, 2007, INT J CANCER, V120, P2401, DOI 10.1002/ijc.22334; Raab-Traub N, 2002, SEMIN CANCER BIOL, V12, P431, DOI 10.1016/S1044579X0200086X; Ragimbeau J, 2003, EMBO J, V22, P537, DOI 10.1093/emboj/cdg038; Randall RE, 2008, J GEN VIROL, V89, P1, DOI 10.1099/vir.0.83391-0; Rechsteiner MP, 2008, J VIROL, V82, P1739, DOI 10.1128/JVI.01723-07; Rechsteiner MP, 2007, J GEN VIROL, V88, P1454, DOI 10.1099/vir.0.82790-0; Rezaee SAR, 2006, J GEN VIROL, V87, P1781, DOI 10.1099/vir.0.81919-0; Rovedo M, 2007, J VIROL, V81, P84, DOI 10.1128/JVI.01302-06; Scholle F, 2000, J VIROL, V74, P10681, DOI 10.1128/JVI.74.22.10681-10689.2000; Stewart S, 2004, P NATL ACAD SCI USA, V101, P15730, DOI 10.1073/pnas.0402135101; Tao Qian, 2007, Expert Reviews in Molecular Medicine, V9, P1, DOI 10.1017/S1462399407000312; Uozaki H, 2008, INT J CLIN EXP PATHO, V1, P198; Young LS, 2004, NAT REV CANCER, V4, P757, DOI 10.1038/nrc1452	36	70	72	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2009	28	44					3903	3914		10.1038/onc.2009.249	http://dx.doi.org/10.1038/onc.2009.249			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	515LJ	19718044	Green Accepted			2022-12-17	WOS:000271471900005
J	Finkbeiner, MR; Astanehe, A; To, K; Fotovati, A; Davies, AH; Zhao, Y; Jiang, H; Stratford, AL; Shadeo, A; Boccaccio, C; Comoglio, P; Mertens, PR; Eirew, P; Raouf, A; Eaves, CJ; Dunn, SE				Finkbeiner, M. R.; Astanehe, A.; To, K.; Fotovati, A.; Davies, A. H.; Zhao, Y.; Jiang, H.; Stratford, A. L.; Shadeo, A.; Boccaccio, C.; Comoglio, P.; Mertens, P. R.; Eirew, P.; Raouf, A.; Eaves, C. J.; Dunn, S. E.			Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells	ONCOGENE			English	Article						YB-1; MET receptor; ChIP-on-chip; basal-like breast cancer; mammary progenitors	GROWTH-FACTOR RECEPTOR; BOX BINDING PROTEIN-1; BREAST-CANCER CELLS; EPITHELIAL STEM-CELLS; INVASIVE GROWTH; IN-VIVO; C-MET; EXPRESSION; HER-2; BINDING-PROTEIN-1	Basal-like breast cancers (BLBCs) are aggressive tumors with high relapse rates and poor survival. We recently reported that > 70% of primary BLBCs express the oncogenic transcription/translation factor Y-box binding protein-1 (YB-1) and silencing it with small interfering RNAs (siRNAs) attenuates the growth of BLBC cell lines. To understand the basis of these earlier findings, we profiled YB-1: DNA complexes by chromatin immunoprecipitation (ChIP)-on-chip. Several tumor growth-promoting genes such as MET, CD44, CD49f, WNT and NOTCH family members were identified. In addition, YB-1 and MET are coordinately expressed in BLBC cell lines, as well as in normal human mammary progenitor cells. MET was confirmed to be a YB-1 target through traditional ChIP and gel-shift assays. More specifically, YB-1 binds to -1018 bp on the MET promoter. Silencing YB-1 with siRNA decreased MET promoter activity, transcripts, as well as protein levels and signaling. Conversely, expressing wild-type YB-1 or a constitutively active mutant YB-1 (D102) increased MET expression. Finally, silencing YB-1 or MET attenuated anchorage-independent growth of BLBC cell lines. Together, these findings implicate MET as a target of YB-1 that work in concert to promote BLBC growth.	[Finkbeiner, M. R.; Astanehe, A.; To, K.; Fotovati, A.; Davies, A. H.; Zhao, Y.; Jiang, H.; Stratford, A. L.; Dunn, S. E.] Univ British Columbia, Dept Pediat, Lab Oncogen Res, Vancouver, BC V5Z 4H4, Canada; [Finkbeiner, M. R.; Astanehe, A.; To, K.; Fotovati, A.; Davies, A. H.; Zhao, Y.; Jiang, H.; Stratford, A. L.; Dunn, S. E.] Univ British Columbia, Dept Expt Med, Child & Family Res Inst, Vancouver, BC V5Z 4H4, Canada; [Shadeo, A.] British Columbia Canc Agcy, Canc Genet & Dev Biol, Vancouver, BC V5Z 4E6, Canada; [Boccaccio, C.; Comoglio, P.] Univ Turin, Sch Med, Inst Canc Res & Treatment IRCC, Candiolo, Italy; [Mertens, P. R.] Univ Hosp Aachen, Div Nephrol & Clin Immunol, Aachen, Germany; [Eirew, P.; Raouf, A.; Eaves, C. J.] British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada	University of British Columbia; Child & Family Research Institute; University of British Columbia; British Columbia Cancer Agency; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; RWTH Aachen University; RWTH Aachen University Hospital; British Columbia Cancer Agency	Dunn, SE (corresponding author), Univ British Columbia, Dept Pediat, Lab Oncogen Res, 950 W 28th Ave, Vancouver, BC V5Z 4H4, Canada.	sedunn@interchange.ubc.ca	Boccaccio, Carla/AHE-7875-2022; Mertens, Peter/AAI-7310-2020	Boccaccio, Carla/0000-0003-2620-9083; Eaves, Connie/0000-0002-3452-1926; Comoglio, Paolo/0000-0002-7056-5328; Shadeo, Ashleen/0000-0002-0866-0519	Canadian Breast Cancer Research Alliance; National Institute of Health; Michael Smith Foundation; Canadian Institute for Health; Canadian Breast Cancer Foundation; US Department of Defense Breast Cancer Research; Terry Fox Foundation; National Cancer Institute of Canada; Canadian Imperial Bank of Commerce; Canadian Stem Cell Network Studentship	Canadian Breast Cancer Research Alliance; National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Michael Smith Foundation(Michael Smith Foundation for Health Research); Canadian Institute for Health(Canadian Institutes of Health Research (CIHR)); Canadian Breast Cancer Foundation(Canadian Cancer Society (CCS)); US Department of Defense Breast Cancer Research(United States Department of Defense); Terry Fox Foundation; National Cancer Institute of Canada(Canadian Cancer Society (CCS)); Canadian Imperial Bank of Commerce; Canadian Stem Cell Network Studentship	This project was funded by the Canadian Breast Cancer Research Alliance (awarded to SED) and the National Institute of Health (RO1 awarded to SED). A Astanehe, K To and A Davies are recipients of Michael Smith Foundation for Health Research Graduate Studentships. A Astanehe and K To are recipients of Canadian Institute for Health Graduate Studentships. A Stratford holds a Canadian Breast Cancer Foundation Postdoctoral Fellowship. P Eirew is the recipient of the US Department of Defense Breast Cancer Research Program Studentship, the Terry Fox Foundation Research Studentship from the National Cancer Institute of Canada, the Canadian Imperial Bank of Commerce Interdisciplinary Award and the Canadian Stem Cell Network Studentship.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Boccaccio C, 2006, NAT REV CANCER, V6, P637, DOI 10.1038/nrc1912; Boon EMJ, 2002, CANCER RES, V62, P5126; Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254; Colozza M, 2007, ONCOLOGIST, V12, P253, DOI 10.1634/theoncologist.12-3-253; Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530; Dontu G, 2004, BREAST CANCER RES, V6, pR605, DOI 10.1186/bcr920; Dunn BK, 2007, EUR J CANCER PREV, V16, P232, DOI 10.1097/CEJ.0b013e328011ed2d; Eirew P, 2008, NAT MED, V14, P1384, DOI 10.1038/nm.1791; Farnie G, 2007, JNCI-J NATL CANCER I, V99, P616, DOI 10.1093/jnci/djk133; Gambarotta G, 1996, ONCOGENE, V13, P1911; Habibi G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2156; Kuwano M, 2004, MOL CANCER THER, V3, P1485; Lee C, 2008, CANCER RES, V68, P8661, DOI 10.1158/0008-5472.CAN-08-1082; Leo C, 2007, GYNECOL ONCOL, V104, P181, DOI 10.1016/j.ygyno.2006.07.040; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Okamoto T, 2000, ONCOGENE, V19, P6194, DOI 10.1038/sj.onc.1204029; Orian-Rousseau V, 2002, GENE DEV, V16, P3074, DOI 10.1101/gad.242602; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Raouf A, 2008, CELL STEM CELL, V3, P109, DOI 10.1016/j.stem.2008.05.018; Sachs M, 2000, J CELL BIOL, V150, P1375, DOI 10.1083/jcb.150.6.1375; Shadeo A, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1370; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Stratford AL, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1767; Stratford AL, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2202; Sutherland BW, 2005, ONCOGENE, V24, P4281, DOI 10.1038/sj.onc.1208590; To K, 2007, MOL PHARMACOL, V72, P641, DOI 10.1124/mol.107.036111; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; van Roeyen CRC, 2005, J AM SOC NEPHROL, V16, P2985, DOI 10.1681/ASN.2004111009; Welm AL, 2005, P NATL ACAD SCI USA, V102, P4324, DOI 10.1073/pnas.0500470102; Wu J, 2006, CANCER RES, V66, P4872, DOI 10.1158/0008-5472.CAN-05-3561; Yoshida S, 2004, J CLIN ENDOCR METAB, V89, P823, DOI 10.1210/jc.2003-030874; Zhao Y, 2007, STEM CELLS, V25, P1681, DOI 10.1634/stemcells.2006-0794	37	70	70	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	11					1421	1431		10.1038/onc.2008.485	http://dx.doi.org/10.1038/onc.2008.485			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421JE	19151767				2022-12-17	WOS:000264354400003
J	Hamanaka, RB; Bobrovnikova-Marjon, E; Ji, X; Liebhaber, SA; Diehl, JA				Hamanaka, R. B.; Bobrovnikova-Marjon, E.; Ji, X.; Liebhaber, S. A.; Diehl, J. A.			PERK-dependent regulation of IAP translation during ER stress	ONCOGENE			English	Article						PERK; ER stress; apoptosis; IAP	ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; NF-KAPPA-B; INDUCED CELL-DEATH; MESSENGER-RNA TRANSLATION; RIBOSOME ENTRY SITE; INDUCED APOPTOSIS; MITOCHONDRIAL APOPTOSIS; MAMMALIAN-CELLS; TUMOR-GROWTH	Exposure of cells to endoplasmic reticulum (ER) stress leads to activation of phosphatidylinositol 3-kinase (PI3K)-Akt signaling pathway and transcriptional induction of the inhibitor of apoptosis family of proteins. One of the proximal effectors of the ER stress response, the PKR-like ER kinase (PERK), leads to cellular adaptation to stress by multiple mechanisms, including attenuation of protein synthesis and transcriptional induction of prosurvival genes. Although PERK activity leads to cellular adaptation to ER stress, we now demonstrate that PERK activity also inhibits the ER stress-induced apoptotic program through the induction of cellular inhibitor of apoptosis (cIAP1 and cIAP2) proteins. This induction of IAPs occurs through both transcriptional and translational responses that are PERK dependent. Reintroduction of cIAP1 or cIAP2 expression into PERK-/- murine embryonic fibroblasts during ER stress delays the early onset of ER stress-induced caspase activation and apoptosis observed in these cells. Furthermore, we demonstrate that the activation of the PI3K-Akt pathway by ER stress is dependent on PERK, suggesting additional ways in which PERK activity protects cells from ER stress-induced apoptosis.	[Hamanaka, R. B.; Bobrovnikova-Marjon, E.; Diehl, J. A.] Univ Penn, Leonard & Madlyn Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; [Hamanaka, R. B.; Bobrovnikova-Marjon, E.; Diehl, J. A.] Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA; [Hamanaka, R. B.; Bobrovnikova-Marjon, E.] Univ Penn, Dept Canc Biol, Philadelphia, PA 19104 USA; [Ji, X.; Liebhaber, S. A.] Univ Penn, Dept Genet, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Diehl, JA (corresponding author), Abramson Family Canc Res Inst, 454 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	adiehl@mail.med.upenn.edu			National Institutes of Health [F32CA1238252, P01 CA104838]; Leukemia & Lymphoma Scholar award; Abramson Family Cancer Research Institute; NATIONAL CANCER INSTITUTE [P01CA104838] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Leukemia & Lymphoma Scholar award(Leukemia and Lymphoma Society); Abramson Family Cancer Research Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank M Romero for technical assistance and X Yang for providing IAP expression vectors. This study was supported by a grant from the National Institutes of Health F32CA1238252 (EBM); P01 CA104838, a Leukemia & Lymphoma Scholar award and the Abramson Family Cancer Research Institute (JAD).	Bellacosa A, 2004, CANCER BIOL THER, V3, P268, DOI 10.4161/cbt.3.3.703; Bertrand MJM, 2008, MOL CELL, V30, P689, DOI 10.1016/j.molcel.2008.05.014; Bi MX, 2005, EMBO J, V24, P3470, DOI 10.1038/sj.emboj.7600777; Brewer JW, 2000, P NATL ACAD SCI USA, V97, P12625, DOI 10.1073/pnas.220247197; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Clem RJ, 2001, J BIOL CHEM, V276, P7602, DOI 10.1074/jbc.M010259200; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Cullinan SB, 2003, MOL CELL BIOL, V23, P7198, DOI 10.1128/MCB.23.20.7198-7209.2003; Dan HC, 2004, J BIOL CHEM, V279, P5405, DOI 10.1074/jbc.M312044200; Debatin KM, 2004, ONCOGENE, V23, P2950, DOI 10.1038/sj.onc.1207558; Deng J, 2004, MOL CELL BIOL, V24, P10161, DOI 10.1128/MCB.24.23.10161-10168.2004; Deniaud A, 2008, ONCOGENE, V27, P285, DOI 10.1038/sj.onc.1210638; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Di Sano F, 2006, J BIOL CHEM, V281, P2693, DOI 10.1074/jbc.M509110200; Eckelman BP, 2006, J BIOL CHEM, V281, P3254, DOI 10.1074/jbc.M510863200; Fels DR, 2006, CANCER BIOL THER, V5, P723, DOI 10.4161/cbt.5.7.2967; Fernandez J, 2002, J BIOL CHEM, V277, P19198, DOI 10.1074/jbc.M201052200; Fernandez J, 2002, J BIOL CHEM, V277, P11780, DOI 10.1074/jbc.M110778200; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Hitomi J, 2004, J CELL BIOL, V165, P347, DOI 10.1083/jcb.200310015; Hosoi T, 2007, BRAIN RES, V1152, P27, DOI 10.1016/j.brainres.2007.03.052; Hu P, 2006, MOL CELL BIOL, V26, P3071, DOI 10.1128/MCB.26.8.3071-3084.2006; Hu P, 2004, J BIOL CHEM, V279, P49420, DOI 10.1074/jbc.M407700200; Jamora C, 1996, P NATL ACAD SCI USA, V93, P7690, DOI 10.1073/pnas.93.15.7690; Ji XJ, 2003, MOL CELL BIOL, V23, P899, DOI 10.1128/MCB.23.3.899-907.2003; Jiang HY, 2003, MOL CELL BIOL, V23, P5651, DOI 10.1128/MCB.23.16.5651-5663.2003; Katayama T, 2004, J CHEM NEUROANAT, V28, P67, DOI 10.1016/j.jchemneu.2003.12.004; Kaufman RJ, 2004, TRENDS BIOCHEM SCI, V29, P152, DOI 10.1016/j.tibs.2004.01.004; Kazemi S, 2007, MOL BIOL CELL, V18, P3635, DOI 10.1091/mbc.E07-01-0053; Li JZ, 2006, J BIOL CHEM, V281, P7260, DOI 10.1074/jbc.M509868200; Liston P, 2003, ONCOGENE, V22, P8568, DOI 10.1038/sj.onc.1207101; Mathai JP, 2005, J BIOL CHEM, V280, P23829, DOI 10.1074/jbc.M500800200; Morishima N, 2004, J BIOL CHEM, V279, P50375, DOI 10.1074/jbc.M408493200; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Orth R, 1997, J BIOL CHEM, V272, P8841; Petersen SL, 2007, CANCER CELL, V12, P445, DOI 10.1016/j.ccr.2007.08.029; Puthalakath H, 2007, CELL, V129, P1337, DOI 10.1016/j.cell.2007.04.027; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; Romero-Ramirez L, 2004, CANCER RES, V64, P5943, DOI 10.1158/0008-5472.CAN-04-1606; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Scott FL, 2005, EMBO J, V24, P645, DOI 10.1038/sj.emboj.7600544; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Shiozaki EN, 2003, MOL CELL, V11, P519, DOI 10.1016/S1097-2765(03)00054-6; Shiraishi H, 2006, J CELL SCI, V119, P3958, DOI 10.1242/jcs.03160; Simons M, 1999, J NEUROCHEM, V72, P292, DOI 10.1046/j.1471-4159.1999.0720292.x; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Varfolomeev E, 2007, CELL, V131, P669, DOI 10.1016/j.cell.2007.10.030; Vattem KM, 2004, P NATL ACAD SCI USA, V101, P11269, DOI 10.1073/pnas.0400541101; Vince JE, 2007, CELL, V131, P682, DOI 10.1016/j.cell.2007.10.037; Vucic D, 2007, CLIN CANCER RES, V13, P5995, DOI 10.1158/1078-0432.CCR-07-0729; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Warnakulasuriyarachchi D, 2004, J BIOL CHEM, V279, P17148, DOI 10.1074/jbc.M308737200	63	70	74	4	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	6					910	920		10.1038/onc.2008.428	http://dx.doi.org/10.1038/onc.2008.428			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406UI	19029953	Green Accepted			2022-12-17	WOS:000263320000013
J	Frederick, LA; Matthews, JA; Jamieson, L; Justilien, V; Thompson, EA; Radisky, DC; Fields, AP				Frederick, L. A.; Matthews, J. A.; Jamieson, L.; Justilien, V.; Thompson, E. A.; Radisky, D. C.; Fields, A. P.			Matrix metalloproteinase-10 is a critical effector of protein kinase C iota-Par6 alpha-mediated lung cancer	ONCOGENE			English	Article						non-small cell lung cancer; Rac1; PB1 domain; cellular invasion; anchorage-independent growth	SQUAMOUS-CELL CARCINOMA; C-IOTA; TRANSFORMED GROWTH; EXPRESSION; INVASION; TARGET; CDC42; LINKS; HEAD; NECK	Protein kinase C iota (PKC iota) drives transformed growth of non-small cell lung cancer (NSCLC) cells through the Rho family GTPase Rac1. We show here that PKC iota activates Rac1 in NSCLC cells by formation of a PKC iota-Par6 alpha complex that drives anchorage-independent growth and invasion through activation of matrix metalloproteinase-10 (MMP-10) expression. RNAi-mediated knockdown of PKC iota, Par6 alpha or Rac1 expression inhibits NSCLC transformation and MMP-10 expression in vitro. Expression of wild-type Par6 alpha in Par6 alpha-deficient cells restores transformation and MMP-10 expression, whereas expression of Par6 alpha mutants that either cannot bind PKC iota (Par6 alpha-K19A) or couple to Rac1 (Par6 alpha-Delta CRIB) do not. Knockdown of MMP-10 expression blocks anchorage-independent growth and invasion of NSCLC cells and addition of catalytically active MMP-10 to PKC iota- or Par6 alpha-deficient cells restores anchorage-independent growth and invasion. Dominant-negative PKC iota inhibits tumorigenicity and MMP-10 expression in subcutaneous NSCLC tumors. MMP-10 and PKC iota are coordinately overexpressed in primary NSCLC tumors, and tumor MMP-10 expression predicts poor survival in NSCLC patients. Our data define a PKC iota-Par6 alpha-Rac1 signaling axis that drives anchorage-independent growth and invasion of NSCLC cells through induction of MMP-10 expression.	[Frederick, L. A.; Matthews, J. A.; Jamieson, L.; Justilien, V.; Thompson, E. A.; Radisky, D. C.; Fields, A. P.] Mayo Clin, Coll Med, Dept Canc Biol, Jacksonville, FL 32224 USA	Mayo Clinic	Fields, AP (corresponding author), Mayo Clin, Coll Med, Dept Canc Biol, Griffin Canc Res Bldg,Rm 212,4500 San Pablo Rd, Jacksonville, FL 32224 USA.	fields.alan@mayo.edu	Radisky, Derek/B-6569-2018	Radisky, Derek/0000-0002-1962-8784	NATIONAL CANCER INSTITUTE [R01CA081436] Funding Source: NIH RePORTER; NCI NIH HHS [CA081436, R01 CA081436, R01 CA081436-11] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bodey B, 2001, IN VIVO, V15, P175; Cho NH, 2004, ONCOGENE, V23, P845, DOI 10.1038/sj.onc.1207140; Delebecq TJ, 2000, CLIN CANCER RES, V6, P1086; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Erdogan E, 2006, J BIOL CHEM, V281, P28450, DOI 10.1074/jbc.M606054200; Fields AP, 2007, PHARMACOL RES, V55, P487, DOI 10.1016/j.phrs.2007.04.015; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Gill JH, 2004, NEOPLASIA, V6, P777, DOI 10.1593/neo.04283; Imoto I, 2001, BIOCHEM BIOPH RES CO, V286, P559, DOI 10.1006/bbrc.2001.5428; Impola U, 2004, J PATHOL, V202, P14, DOI 10.1002/path.1479; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Kleinman HK, 2005, SEMIN CANCER BIOL, V15, P378, DOI 10.1016/j.semcancer.2005.05.004; Kren L, 2006, Cesk Patol, V42, P16; Mathew R, 2002, CANCER DETECT PREV, V26, P222, DOI 10.1016/S0361-090X(02)00035-1; MULLER D, 1991, INT J CANCER, V48, P550, DOI 10.1002/ijc.2910480412; Noda Y, 2001, GENES CELLS, V6, P107, DOI 10.1046/j.1365-2443.2001.00404.x; O-charoenrat P, 2001, ARCH OTOLARYNGOL, V127, P813; Osada H, 2002, ONCOGENE, V21, P7421, DOI 10.1038/sj.onc.1205802; Pimkhaokham A, 2000, JPN J CANCER RES, V91, P1126, DOI 10.1111/j.1349-7006.2000.tb00895.x; Qiu RG, 2000, CURR BIOL, V10, P697, DOI 10.1016/S0960-9822(00)00535-2; Regala RP, 2005, CANCER RES, V65, P8905, DOI 10.1158/0008-5472.CAN-05-2372; Regala RP, 2005, J BIOL CHEM, V280, P31109, DOI 10.1074/jbc.M505402200; Snaddon J, 2001, BRIT J CANCER, V84, P1630, DOI 10.1054/bjoc.2001.1848; Stallings-Mann M, 2006, CANCER RES, V66, P1767, DOI 10.1158/0008-5472.CAN-05-3405; Van Themsche C, 2004, J IMMUNOL, V173, P3605, DOI 10.4049/jimmunol.173.6.3605; Zhang J, 2004, J BIOL CHEM, V279, P22118, DOI 10.1074/jbc.M400774200	26	70	78	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 14	2008	27	35					4841	4853		10.1038/onc.2008.119	http://dx.doi.org/10.1038/onc.2008.119			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337OJ	18427549	Green Accepted			2022-12-17	WOS:000258445100009
J	Lewis, SM; Holcik, M				Lewis, S. M.; Holcik, M.			For IRES trans-acting factors, it is all about location	ONCOGENE			English	Editorial Material						translation regulation; RNA binding protein; subcellular localization; vincristine	TRANSLATION; STRESS	The translation of many proteins involved in transcription, cell cycle progression, apoptosis and cell survival is mediated by internal ribosome entry sites ( IRESs) present within the 5'-untranslated regions ( 5'-UTRs) of their messenger RNA molecules ( mRNAs). Several recent reports now demonstrate that the proteins controlling IRES-dependent translation initiation are regulated by their subcellular localization.	[Lewis, S. M.; Holcik, M.] Childrens Hosp Eastern Ontario, Res Inst, Apoptosis Res Ctr, Ottawa, ON K1H 8L1, Canada	University of Ottawa; Children's Hospital of Eastern Ontario	Holcik, M (corresponding author), Childrens Hosp Eastern Ontario, Res Inst, Apoptosis Res Ctr, 401 Smyth Rd, Ottawa, ON K1H 8L1, Canada.	martin@mgcheo.med.uottawa.ca	Lewis, Stephen/E-5533-2010; Holcik, Martin/A-9768-2008; Holcik, Martin/E-5372-2011; Holcik, Martin/AAC-6660-2019	Lewis, Stephen/0000-0001-9537-5822; Holcik, Martin/0000-0002-1922-5299				Baird SD, 2006, RNA, V12, P1755, DOI 10.1261/rna.157806; Dobbyn HC, 2008, ONCOGENE, V27, P1167, DOI 10.1038/sj.onc.1210723; Holcik M, 2005, NAT REV MOL CELL BIO, V6, P318, DOI 10.1038/nrm1618; Lewis SM, 2007, MOL BIOL CELL, V18, P1302, DOI 10.1091/mbc.E06-06-0515; Lin JC, 2007, P NATL ACAD SCI USA, V104, P2235, DOI 10.1073/pnas.0611015104; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; Spriggs KA, 2005, CELL DEATH DIFFER, V12, P585, DOI 10.1038/sj.cdd.4401642	9	70	76	2	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2008	27	8					1033	1035		10.1038/sj.onc.1210777	http://dx.doi.org/10.1038/sj.onc.1210777			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17767196				2022-12-17	WOS:000253136700001
J	Di Maira, G; Brustolon, F; Bertacchini, J; Tosoni, K; Marmiroli, S; Pinna, LA; Ruzzene, M				Di Maira, G.; Brustolon, F.; Bertacchini, J.; Tosoni, K.; Marmiroli, S.; Pinna, L. A.; Ruzzene, M.			Pharmacological inhibition of protein kinase CK2 reverts the multidrug resistance phenotype of a CEM cell line characterized by high CK2 level	ONCOGENE			English	Article						CK2; MDR; CEM cells; inhibitors; casein kinase 2; CKII	INDUCED APOPTOSIS; CASEIN KINASE-2; P-GLYCOPROTEIN; CANCER-CELLS; II-ALPHA; IN-VIVO; 4,5,6,7-TETRABROMOBENZOTRIAZOLE; PHOSPHORYLATES; EXPRESSION; AKT/PKB	Protein kinase CK2 is an ubiquitous and constitutively active kinase, which phosphorylates many cellular proteins and is implicated in the regulation of cell survival, proliferation and transformation. We investigated its possible involvement in the multidrug resistance phenotype (MDR) by analysing its level in two variants of CEM cells, namely S-CEM and R.-CEM, normally sensitive or resistant to chemical apoptosis, respectively. We found that, while the CK2 regulatory subunit beta was equally expressed in the two cell variants, CK2 alpha catalytic subunit was higher in R-CEM and this was accompanied by a higher phosphorylation of endogenous protein substrates. Pharmacological downregulation of CK2 activity by a panel of specific inhibitors, or knockdown of CK2 alpha expression by RNA interference, were able to induce cell death in R-CEM. CK2 inhibitors could promote an increased uptake of chemotherapeutic drugs inside the cells and sensitize them to drug-induced apoptosis in a co-operative manner. CK2 blockade was also effective in inducing cell death of a different MDR line (U2OS). We therefore conclude that inhibition of CK2 can be considered as a promising tool to revert the MDR phenotype.	Univ Padua, Dept Biol Chem, I-35121 Padua, Italy; Univ Padua, Inst Neurosci, CNR, Padua, Italy; VIMM, Padua, Italy; Univ Modena & Reggio Emilia, Dept Anat & Histol, Modena, Italy	University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua; Veneto Institute Molecular Medicine; Universita di Modena e Reggio Emilia	Ruzzene, M (corresponding author), Univ Padua, Dept Biol Chem, Viale G Colombo 3, I-35121 Padua, Italy.	maria.ruzzene@unipd.it	Marmiroli, Sandra/J-5242-2016; BERTACCHINI, JESSIKA/F-4382-2017	Marmiroli, Sandra/0000-0001-5545-9319; BERTACCHINI, JESSIKA/0000-0001-9218-9215; Ruzzene, Maria/0000-0001-8712-8151; Pinna, Lorenzo A./0000-0002-8856-4956; Di Maira, Giovanni/0000-0003-2041-6022				Ahmad KA, 2005, ANTI-CANCER DRUG, V16, P1037, DOI 10.1097/00001813-200511000-00001; Ahmad KA, 2007, MOL CANCER THER, V6, P1006, DOI 10.1158/1535-7163.MCT-06-0491; Ahmed K, 2002, TRENDS CELL BIOL, V12, P226, DOI 10.1016/S0962-8924(02)02279-1; Allende CC, 1998, J CELL BIOCHEM, P129; Borst P, 1997, SEMIN CANCER BIOL, V8, P131, DOI 10.1006/scbi.1997.0072; Cenni V, 2004, INT J ONCOL, V25, P1599; De Moliner E, 2003, J BIOL CHEM, V278, P1831, DOI 10.1074/jbc.M209367200; Di Maira G, 2005, CELL DEATH DIFFER, V12, P668, DOI 10.1038/sj.cdd.4401604; Dupuis ML, 2003, CHEMOTHERAPY, V49, P8, DOI 10.1159/000069782; Filhol O, 2004, EMBO REP, V5, P351, DOI 10.1038/sj.embor.7400115; Giovannetti E, 2004, CLIN CANCER RES, V10, P2936, DOI 10.1158/1078-0432.CCR-03-0520; Glavy JS, 1997, J BIOL CHEM, V272, P5909, DOI 10.1074/jbc.272.9.5909; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; Guo CH, 2001, J BIOL CHEM, V276, P5992, DOI 10.1074/jbc.M004862200; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; Klumpp S, 2004, NEUROCHEM INT, V45, P747, DOI 10.1016/j.neuint.2004.02.006; Landesman-Bollag E, 1998, ONCOGENE, V16, P2965, DOI 10.1038/sj.onc.1201854; Ling V, 1997, CANCER CHEMOTH PHARM, V40, pS3, DOI 10.1007/s002800051053; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Matsumoto Y, 2001, JPN J CANCER RES, V92, P778, DOI 10.1111/j.1349-7006.2001.tb01161.x; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; Meggio F, 2004, BIOCHEMISTRY-US, V43, P12931, DOI 10.1021/bi048999g; Orlandini M, 1998, J BIOL CHEM, V273, P21291, DOI 10.1074/jbc.273.33.21291; Pagano MA, 2004, J MED CHEM, V47, P6239, DOI 10.1021/jm049854a; Pinna LA, 2002, J CELL SCI, V115, P3873, DOI 10.1242/jcs.00074; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; Ruzzene M, 2002, BIOCHEM J, V364, P41, DOI 10.1042/bj3640041; Salvi M, 2006, FEBS LETT, V580, P3948, DOI 10.1016/j.febslet.2006.06.031; Sarno S, 2005, BBA-PROTEINS PROTEOM, V1754, P263, DOI 10.1016/j.bbapap.2005.07.043; Sarno S, 2005, MOL CELL BIOCHEM, V274, P69, DOI 10.1007/s11010-005-3079-z; Sarno S, 2003, BIOCHEM J, V374, P639, DOI 10.1042/BJ20030674; Sarno S, 2001, FEBS LETT, V496, P44, DOI 10.1016/S0014-5793(01)02404-8; Sawicka M, 2004, J PHARM PHARMACOL, V56, P1067, DOI 10.1211/0022357044265; Seeber S, 2005, APOPTOSIS, V10, P875, DOI 10.1007/s10495-005-0380-y; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SZYSZKA R, 1995, BIOCHEM BIOPH RES CO, V208, P418, DOI 10.1006/bbrc.1995.1354; Tapia JC, 2006, P NATL ACAD SCI USA, V103, P15079, DOI 10.1073/pnas.0606845103	37	70	71	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2007	26	48					6915	6926		10.1038/sj.onc.1210495	http://dx.doi.org/10.1038/sj.onc.1210495			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220WQ	17486073				2022-12-17	WOS:000250188400007
J	Iwasaki, H; Akashi, K				Iwasaki, H.; Akashi, K.			Hematopoietic developmental pathways: on cellular basis	ONCOGENE			English	Review						hematopoietic stem cell; lineage commitment; transcription factor; leukemic stem cell	ACUTE MYELOGENOUS LEUKEMIA; MYELOID LINEAGE COMMITMENT; STEM-CELLS; BONE-MARROW; LONG-TERM; DENDRITIC CELLS; INTERLEUKIN-7 RECEPTOR; COMMITTED PROGENITOR; FLT3 LIGAND; CORD BLOOD	To elucidate the molecular mechanisms underlying normal and malignant hematopoietic development, it is critical to identify developmental intermediates for each lineage downstream of hematopoietic stem cells. Recent advances in prospective isolation of hematopoietic stem and progenitor cells, and effficient xenogeneic transplantation systems have provided a detailed developmental map in both mouse and human hematopoiesis, demonstrating that surface phenotypes of mouse stem - progenitor cells and their human counterparts are considerably different. Here, we summarize the phenotype and functional properties and their differences of hematopoietic stem and progenitor cell populations between mouse and human.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Kyushu Univ Hosp, Ctr Cellular & Mol Med, Fukuoka 812, Japan	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Kyushu University	Akashi, K (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.	Koichi_akashi@dfci.harvard.edu						Adolfsson J, 2001, IMMUNITY, V15, P659, DOI 10.1016/S1074-7613(01)00220-5; Adolfsson J, 2005, CELL, V121, P295, DOI 10.1016/j.cell.2005.02.013; Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Akashi K, 2005, CELL, V121, P160, DOI 10.1016/j.cell.2005.04.005; Akashi K, 1997, CELL, V89, P1033, DOI 10.1016/S0092-8674(00)80291-3; Allman D, 2003, NAT IMMUNOL, V4, P168, DOI 10.1038/ni878; Arinobu Y, 2005, P NATL ACAD SCI USA, V102, P18105, DOI 10.1073/pnas.0509148102; ARINOBU Y, 2007, IN PRESS CELL STEM C; Back J, 2005, EXP HEMATOL, V33, P395, DOI 10.1016/j.exphem.2004.12.010; Barabe F, 2007, SCIENCE, V316, P600, DOI 10.1126/science.1139851; BAUM CM, 1992, P NATL ACAD SCI USA, V89, P2804, DOI 10.1073/pnas.89.7.2804; Bhandoola A, 2006, NAT REV IMMUNOL, V6, P117, DOI 10.1038/nri1778; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; Carow CE, 1996, BLOOD, V87, P1089, DOI 10.1182/blood.V87.3.1089.bloodjournal8731089; Castor A, 2005, NAT MED, V11, P630, DOI 10.1038/nm1253; Christensen JL, 2001, P NATL ACAD SCI USA, V98, P14541, DOI 10.1073/pnas.261562798; Corcoran AE, 1998, NATURE, V391, P904, DOI 10.1038/36122; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; D'Amico A, 2003, J EXP MED, V198, P293, DOI 10.1084/jem.20030107; DeKoter RP, 2002, IMMUNITY, V16, P297, DOI 10.1016/S1074-7613(02)00269-8; DeKoter RP, 1998, EMBO J, V17, P4456, DOI 10.1093/emboj/17.15.4456; Forsberg EC, 2006, CELL, V126, P415, DOI 10.1016/j.cell.2006.06.037; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; GALY A, 1995, IMMUNITY, V3, P459, DOI 10.1016/1074-7613(95)90175-2; Gilliland DG, 2002, SEMIN HEMATOL, V39, P6, DOI 10.1053/shem.2002.36921; Goodell MA, 1997, NAT MED, V3, P1337, DOI 10.1038/nm1297-1337; Gotze KS, 1998, BLOOD, V91, P1947, DOI 10.1182/blood.V91.6.1947.1947_1947_1958; Gounari F, 2002, NAT IMMUNOL, V3, P489, DOI 10.1038/ni778; Graf T, 2002, BLOOD, V99, P3089, DOI 10.1182/blood.V99.9.3089; Hao QL, 2001, BLOOD, V97, P3683, DOI 10.1182/blood.V97.12.3683; Heyworth C, 2002, EMBO J, V21, P3770, DOI 10.1093/emboj/cdf368; Huntly BJP, 2005, NAT REV CANCER, V5, P311, DOI 10.1038/nrc1592; Huntly BJP, 2004, CANCER CELL, V6, P587, DOI 10.1016/j.ccr.2004.10.015; Igarashi H, 2001, BLOOD, V97, P2680, DOI 10.1182/blood.V97.9.2680; Igarashi H, 2002, IMMUNITY, V17, P117, DOI 10.1016/S1074-7613(02)00366-7; IKUTA K, 1992, P NATL ACAD SCI USA, V89, P1502, DOI 10.1073/pnas.89.4.1502; Ishikawa F, 2005, BLOOD, V106, P1565, DOI 10.1182/blood-2005-02-0516; Ishikawa F, 2003, LEUKEMIA, V17, P960, DOI 10.1038/sj.leu.2402878; ISHIKAWA F, 2007, IN PRESS BLOOD; Iwama A, 1998, NUCLEIC ACIDS RES, V26, P3034, DOI 10.1093/nar/26.12.3034; Iwasaki H, 2005, BLOOD, V106, P1590, DOI 10.1182/blood-2005-03-0860; Iwasaki H, 2003, IMMUNITY, V19, P451, DOI 10.1016/S1074-7613(03)00242-5; Iwasaki H, 2005, J EXP MED, V201, P1891, DOI 10.1084/jem.20050548; Iwasaki H, 2006, GENE DEV, V20, P3010, DOI 10.1101/gad.1493506; Iwasaki H, 2007, IMMUNITY, V26, P726, DOI 10.1016/j.immuni.2007.06.004; Jaiswal S, 2003, P NATL ACAD SCI USA, V100, P10002, DOI 10.1073/pnas.1633833100; Jordan CT, 2000, LEUKEMIA, V14, P1777, DOI 10.1038/sj.leu.2401903; Jordan CT, 2002, LEUKEMIA, V16, P559, DOI 10.1038/sj.leu.2402446; Karsunky H, 2003, J EXP MED, V198, P305, DOI 10.1084/jem.20030323; Kiyoi H, 1999, BLOOD, V93, P3074; Kogan SC, 2001, J EXP MED, V193, P531, DOI 10.1084/jem.193.4.531; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; Krivtsov AV, 2006, NATURE, V442, P818, DOI 10.1038/nature04980; Krueger A, 2007, IMMUNITY, V26, P105, DOI 10.1016/j.immuni.2006.12.004; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; Kuwata N, 1999, J IMMUNOL, V163, P6355; Lai AY, 2006, J EXP MED, V203, P1867, DOI 10.1084/jem.20060697; MACKAREHTSCHIAN K, 1995, IMMUNITY, V3, P147, DOI 10.1016/1074-7613(95)90167-1; Manz MG, 2002, P NATL ACAD SCI USA, V99, P11872, DOI 10.1073/pnas.172384399; Martin CH, 2003, NAT IMMUNOL, V4, P866, DOI 10.1038/ni965; McKenna HJ, 2000, BLOOD, V95, P3489, DOI 10.1182/blood.V95.11.3489; Miyamoto T, 2002, DEV CELL, V3, P137, DOI 10.1016/S1534-5807(02)00201-0; Miyamoto T, 2000, P NATL ACAD SCI USA, V97, P7521, DOI 10.1073/pnas.97.13.7521; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; Morrison SJ, 1997, DEVELOPMENT, V124, P1929; Nakorn TN, 2002, J CLIN INVEST, V109, P1579, DOI 10.1172/JCI200215272; Nerlov C, 2000, BLOOD, V95, P2543, DOI 10.1182/blood.V95.8.2543.008k19_2543_2551; Nerlov C, 1998, GENE DEV, V12, P2403, DOI 10.1101/gad.12.15.2403; Okuno Y, 2002, P NATL ACAD SCI USA, V99, P6246, DOI 10.1073/pnas.092027799; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; Passegue E, 2003, P NATL ACAD SCI USA, V100, P11842, DOI 10.1073/pnas.2034201100; Perry SS, 2006, J IMMUNOL, V177, P2880, DOI 10.4049/jimmunol.177.5.2880; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; Puel A, 1998, NAT GENET, V20, P394, DOI 10.1038/3877; Randall TD, 1996, BLOOD, V87, P4057, DOI 10.1182/blood.V87.10.4057.bloodjournal87104057; Rappold I, 1997, BLOOD, V90, P111; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; Rosnet O, 1996, LEUKEMIA, V10, P238; Schnittger S, 2002, BLOOD, V100, P59, DOI 10.1182/blood.V100.1.59; Schwarz BA, 2004, NAT IMMUNOL, V5, P953, DOI 10.1038/ni1101; Seshasayee D, 1998, MOL CELL BIOL, V18, P3278, DOI 10.1128/MCB.18.6.3278; Sitnicka E, 2002, IMMUNITY, V17, P463, DOI 10.1016/S1074-7613(02)00419-3; Sitnicka E, 2003, BLOOD, V102, P881, DOI 10.1182/blood-2002-06-1694; So CW, 2003, CANCER CELL, V3, P161, DOI 10.1016/S1535-6108(03)00019-9; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; Stirewalt DL, 2003, NAT REV CANCER, V3, P650, DOI 10.1038/nrc1169; TERSTAPPEN LWMM, 1991, BLOOD, V77, P1218; Thiede C, 2002, BLOOD, V99, P4326, DOI 10.1182/blood.V99.12.4326; Traggiai E, 2004, SCIENCE, V304, P104, DOI 10.1126/science.1093933; Umland O, 2007, J IMMUNOL, V178, P4147, DOI 10.4049/jimmunol.178.7.4147; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807; Walsh JC, 2002, IMMUNITY, V17, P665, DOI 10.1016/S1074-7613(02)00452-1; Wang J, 2005, EMBO J, V24, P368, DOI 10.1038/sj.emboj.7600521; Ye M, 2003, IMMUNITY, V19, P689, DOI 10.1016/S1074-7613(03)00299-1; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298; Zhang DE, 1996, CURR TOP MICROBIOL, V211, P137; Zhang P, 2000, BLOOD, V96, P2641; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705	100	70	74	3	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	47					6687	6696		10.1038/sj.onc.1210754	http://dx.doi.org/10.1038/sj.onc.1210754			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220HE	17934478				2022-12-17	WOS:000250147000002
J	Pulukuri, SM; Patibandla, S; Patel, J; Estes, N; Rao, JS				Pulukuri, S. M.; Patibandla, S.; Patel, J.; Estes, N.; Rao, J. S.			Epigenetic inactivation of the tissue inhibitor of metalloproteinase-2 (TIMP-2) gene in human prostate tumors	ONCOGENE			English	Article						CpG methylation; TIMP-2; MeCP2; prostate cancer	IN-VIVO; TRANSCRIPTIONAL REPRESSION; CANCER STATISTICS; DNA METHYLATION; GELATINASE-A; EXPRESSION; INVASION; CELLS; HYPERMETHYLATION; ANGIOGENESIS	Gene silencing via CpG island methylation in the promoter region is one of the mechanisms by which tumor suppressor genes are inactivated in human cancers. Previous studies have shown that the tissue inhibitors of metalloproteinases (TIMP)-2 gene, which is an endogenous inhibitor of matrix metalloproteinases involved in cell invasion and tumorigenesis, is downregulated or silenced in a variety of human cancer cell lines. Here, we investigated the mechanism underlying TIMP-2 expression in prostate cancer cell lines and primary prostate tumor samples. We observed a strong correlation between promoter hypermethylation and lost expression of TIMP-2 gene, which was supported by other results demonstrating that promoter demethylation by 5-aza-2'-deoxycytidine and trichostatin A reactivated TIMP-2 and restored its expression in TIMP-2-silenced metastatic prostate cell lines. These results were further substantiated by a chromatin immunoprecipitation assay, showing the preferential binding of MeCP2 to methylated CpG island in TIMP-2-silenced metastatic prostate cell lines. In vitro Matrigel invasion assays showed that re-expression of TIMP- 2 after a combined treatment with 5-aza and trichostatin-A in metastatic prostate cells resulted in a significant reduction of tumor cell invasion. Furthermore, CpG methylation of TIMP- 2 promoter was also shown in primary prostate tumors that expressed decreased TIMP-2 protein levels. These results suggest that the downregulation of the TIMP- 2 gene is associated with promoter methylation and that this may play an important role in prostate cancer progression during the invasive and metastatic stages of the disease.	Univ Illinois, Coll Med, Dept Canc Biol & Pharmacol, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Pathol, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Surg, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Neurosurg, Peoria, IL 61656 USA	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria	Rao, JS (corresponding author), Univ Illinois, Coll Med, Dept Canc Biol & Pharmacol, Box-1649, Peoria, IL 61656 USA.	jsrao@uic.edu			NCI NIH HHS [R01 CA075557, CA75557, CA116708, CA95058, R01 CA116708, CA92393, R01 CA092393, R01 CA095058] Funding Source: Medline; NINDS NIH HHS [R01 NS047699, NS57529, NS47699, R01 NS057529] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075557, R01CA092393, R01CA095058, R01CA116708] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS057529, R01NS047699] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bachman KE, 1999, CANCER RES, V59, P798; Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151; DECLERCK YA, 1992, CANCER RES, V52, P701; Esteller M, 2001, CANCER RES, V61, P3225; Galm O, 2005, ONCOGENE, V24, P4799, DOI 10.1038/sj.onc.1208599; Gokaslan ZL, 1998, CLIN EXP METASTAS, V16, P721, DOI 10.1023/A:1006580728338; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; Hajitou A, 2001, CANCER RES, V61, P3450; Hegeman Robert B, 2004, Clin Prostate Cancer, V3, P150, DOI 10.3816/CGC.2004.n.025; Imren S, 1996, CANCER RES, V56, P2891; Ivanova T, 2004, INT J CANCER, V108, P882, DOI 10.1002/ijc.11652; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Kasamon KM, 2004, CURR OPIN UROL, V14, P185, DOI 10.1097/00042307-200405000-00008; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; MOHANAM S, 1995, CLIN EXP METASTAS, V13, P57, DOI 10.1007/BF00144019; Nagase H, 1998, Cell Res, V8, P179; Oliver GW, 1997, ANAL BIOCHEM, V244, P161, DOI 10.1006/abio.1996.9895; Pennie WD, 1999, CELL GROWTH DIFFER, V10, P279; Pulukuri SM, 2006, ONCOGENE, V25, P4559, DOI 10.1038/sj.onc.1209462; Rao JS, 2003, NAT REV CANCER, V3, P489, DOI 10.1038/nrc1121; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Valente P, 1998, INT J CANCER, V75, P246, DOI 10.1002/(SICI)1097-0215(19980119)75:2<246::AID-IJC13>3.0.CO;2-B; Wajed SA, 2001, ANN SURG, V234, P10, DOI 10.1097/00000658-200107000-00003; Yamamoto M, 1996, CANCER RES, V56, P384; Yoon SO, 2001, J BIOL CHEM, V276, P20085, DOI 10.1074/jbc.M101143200; Yu F, 2000, NUCLEIC ACIDS RES, V28, P2201, DOI 10.1093/nar/28.10.2201	27	70	71	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2007	26	36					5229	5237		10.1038/sj.onc.1210329	http://dx.doi.org/10.1038/sj.onc.1210329			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CQ	17325663	Green Accepted			2022-12-17	WOS:000248674200006
J	Liu, J; Kumar, KGS; Yu, D; Molton, SA; McMahon, M; Herlyn, M; Thomas-Tikhonenko, A; Fuchs, SY				Liu, J.; Kumar, K. G. Suresh; Yu, D.; Molton, S. A.; McMahon, M.; Herlyn, M.; Thomas-Tikhonenko, A.; Fuchs, S. Y.			Oncogenic BRAF regulates beta-Trcp expression and NF-kappa B activity in human melanoma cells	ONCOGENE			English	Article						BRAF; melanoma; beta-Trcp; NF-kappa B; I kappa B kinase	MALIGNANT-MELANOMA; SIGNALING PATHWAYS; COLORECTAL TUMORS; KINASE ACTIVATION; RAF; TRANSFORMATION; MUTATIONS; APOPTOSIS; PHOSPHORYLATION; INHIBITION	Mutational activation of BRAF is a frequent event in human malignant melanomas suggesting that BRAF-dependent signaling is conducive to melanoma cell growth and survival. Previously published work reported that melanoma cells exhibit constitutive anti-apoptotic nuclear factor kappa B (NF-kappa B) transcription factor activation triggered by proteolysis of its inhibitor I kappa B. I kappa B degradation is dependent upon its phosphorylation by the I kappa B kinase (IKK) complex and subsequent ubiquitination facilitated by beta-Trcp E3 ubiquitin ligase. Here, we report that melanocytes expressing a conditionally oncogenic form of BRAF(V600E) exhibit enhanced beta-Trcp expression, increased IKK activity and a concomitant increase in the rate of I kappa B alpha degradation. Conversely, inhibition of BRAF signaling using either a broad-spectrum Raf inhibitor (BAY 43-9006) or by selective knock-down of BRAF(V600E) expression by RNA interference in human melanoma cells leads to decreased IKK activity and beta-Trcp expression, stabilization of I kappa B, inhibition of NF-kappa B transcriptional activity and sensitization of these cells to apoptosis. Taken together, these data support a model in which mutational activation of BRAF in human melanomas contributes to constitutive induction of NF-kappa B activity and to increased survival of melanoma cells.	Univ Penn, Sch Vet Med, Dept Biol Anim, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathobiol, Philadelphia, PA 19104 USA; Univ Calif San Francisco, Inst Canc Res, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of California System; University of California San Francisco; University of California System; University of California San Francisco; The Wistar Institute	Fuchs, SY (corresponding author), Univ Penn, Sch Vet Med, Dept Biol Anim, 3800 Spruce St,Room 161E VET, Philadelphia, PA 19104 USA.	syfuchs@vet.upenn.edu	Thomas-Tikhonenko, Andrei/E-5329-2011	Thomas-Tikhonenko, Andrei/0000-0002-2739-2206; Liu, Jianghuai/0000-0002-2382-9140	NCI NIH HHS [R01 CA102709, CA25874, P50 CA093372, CA93372, R01 CA092900, P01 CA025874, CA092900, CA108972, CA102709, R01 CA108972] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA093372, R01CA102709, R01CA092900, P01CA025874, R01CA108972] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amiri KI, 2005, CANCER METAST REV, V24, P301, DOI 10.1007/s10555-005-1579-7; Baumann B, 2000, P NATL ACAD SCI USA, V97, P4615, DOI 10.1073/pnas.080583397; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Fuchs SY, 2004, ONCOGENE, V23, P2028, DOI 10.1038/sj.onc.1207389; Hingorani SR, 2003, CANCER RES, V63, P5198; Hoeflich MP, 2006, CANCER RES, V66, P999, DOI 10.1158/0008-5472.CAN-05-2720; Ikenoue T, 2004, CANCER RES, V64, P3428, DOI 10.1158/0008-5472.CAN-03-3591; Ikenoue T, 2003, CANCER RES, V63, P8132; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Norris JL, 1999, J BIOL CHEM, V274, P13841, DOI 10.1074/jbc.274.20.13841; Panka DJ, 2006, CANCER RES, V66, P1611, DOI 10.1158/0008-5472.CAN-05-0808; Satyamoorthy K, 2003, CANCER RES, V63, P756; Sharma A, 2005, CANCER RES, V65, P2412, DOI 10.1158/0008-5472.CAN-04-2423; Smalley KSM, 2003, INT J CANCER, V104, P527, DOI 10.1002/ijc.10978; Smalley KSM, 2005, ANN NY ACAD SCI, V1059, P16, DOI 10.1196/annals.1339.005; Soldatenkov VA, 1999, CANCER RES, V59, P5085; Spiegelman V, 2002, ONCOGENE, V21, P856, DOI 10.1038/sj.onc.1205132; Spiegelman VS, 2002, J BIOL CHEM, V277, P36624, DOI 10.1074/jbc.M204524200; Ueda Y, 2006, PIGM CELL RES, V19, P112, DOI 10.1111/j.1600-0749.2006.00304.x; Yang JM, 2006, CLIN CANCER RES, V12, P950, DOI 10.1158/1078-0432.CCR-05-1220; Yang JM, 2001, CANCER RES, V61, P4901; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	22	70	71	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 22	2007	26	13					1954	1958		10.1038/sj.onc.1209994	http://dx.doi.org/10.1038/sj.onc.1209994			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	149AE	17001349	Green Accepted			2022-12-17	WOS:000245117700013
J	Weber, RG; Hoischen, A; Ehrler, M; Zipper, P; Kaulich, K; Blaschke, B; Becker, AJ; Weber-Mangal, S; Jauch, A; Radlwimmer, B; Schramm, J; Wiestler, OD; Lichter, P; Reifenberger, G				Weber, R. G.; Hoischen, A.; Ehrler, M.; Zipper, P.; Kaulich, K.; Blaschke, B.; Becker, A. J.; Weber-Mangal, S.; Jauch, A.; Radlwimmer, B.; Schramm, J.; Wiestler, O. D.; Lichter, P.; Reifenberger, G.			Frequent loss of chromosome 9, homozygous CDKN2A/p14ARF/CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytomas	ONCOGENE			English	Article						pleomorphic xanthoastrocytomas; comparative genomic hybridization; molecular genetics; tumor-suppressor gene; DNA-microarray	COMPARATIVE GENOMIC HYBRIDIZATION; SCLEROSIS GENE TSC1; GLIOMA PROGRESSION; CELL CARCINOMA; P53 MUTATION; IMBALANCES; GROWTH; TUMORS; 9Q34	The molecular pathogenesis of pleomorphic xanthoastrocytoma (PXA), a rare astrocytic brain tumor with a relatively favorable prognosis, is still poorly understood. We characterized 50 PXAs by comparative genomic hybridization (CGH) and found the most common imbalance to be loss on chromosome 9 in 50% of tumors. Other recurrent losses affected chromosomes 17 (10%), 8, 18, 22 (4% each). Recurrent gains were identified on chromosomes X (16%), 7, 9q, 20 (8% each), 4, 5, 19 ( 4% each). Two tumors demonstrated amplifications mapping to 2p23-p25, 4p15, 12q13, 12q21, 21q21 and 21q22. Analysis of 10 PXAs with available high molecular weight DNA by high-resolution array-based CGH indicated homozygous 9p21.3 deletions involving the CDKN2A/p14(ARF)/CDKN2B loci in six tumors (60%). Interphase fluorescence in situ hybridization to tissue sections confirmed the presence of tumor cells with homozygous 9p21.3 deletions. Mutational analysis of candidate genes on 9q, PTCH and TSC1, revealed no mutations in PXAs with 9q loss and no evidence of TSC1 promoter methylation. However, PXAs consistently showed low TSC1 transcript levels. Taken together, our study identifies loss of chromosome 9 as the most common chromosomal imbalance in PXAs and suggests important roles for homozygous CDKN2A/p14ARF/CDKN2B deletion as well as low TSC1 mRNA expression in these tumors.	Univ Bonn, Dept Human Genet, D-53111 Bonn, Germany; Otto Von Guericke Univ, Dept Human Genet, Magdeburg, Germany; Univ Dusseldorf, Dept Neuropathol, D-4000 Dusseldorf, Germany; Univ Bonn, Dept Neuropathol, D-5300 Bonn, Germany; Univ Heidelberg, Dept Human Genet, D-6900 Heidelberg, Germany; German Canc Res Ctr, D-6900 Heidelberg, Germany; Univ Bonn, Dept Neurosurg, D-5300 Bonn, Germany	University of Bonn; Otto von Guericke University; Heinrich Heine University Dusseldorf; University of Bonn; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); University of Bonn	Weber, RG (corresponding author), Univ Bonn, Dept Human Genet, Wilhelmstr 31, D-53111 Bonn, Germany.	ruthild.weber@ukb.uni-bonn.de	Hoischen, Alexander/AGF-7293-2022; Becker, Albert J/F-6248-2012; Radlwimmer, Bernhard F/I-3229-2013; Hoischen, Alexander/D-1282-2013; Reifenberger, Guido/AAE-3599-2019; Weber, Ruthild/E-2906-2015	Hoischen, Alexander/0000-0002-8072-4476; Radlwimmer, Bernhard F/0000-0002-4553-7800; Hoischen, Alexander/0000-0002-8072-4476; Weber, Ruthild/0000-0001-6610-1080				Becker AJ, 2001, NEUROPATH APPL NEURO, V27, P105, DOI 10.1046/j.0305-1846.2001.00302.x; DUMANOIR S, 1993, HUM GENET, V90, P590, DOI 10.1007/BF00202476; Giannini C, 2001, NEUROGENETICS, V3, P159, DOI 10.1007/s100480100116; Giannini C, 1999, CANCER, V85, P2033, DOI 10.1002/(SICI)1097-0142(19990501)85:9<2033::AID-CNCR22>3.3.CO;2-Q; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Jiang WG, 2005, EUR J CANCER, V41, P1628, DOI 10.1016/j.ejca.2005.03.023; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Kaulich K, 2002, J NEUROPATH EXP NEUR, V61, P1092, DOI 10.1093/jnen/61.12.1092; Kepes JJ, 2000, WHO CLASSIFICATION T, P52; Knowles MA, 2003, CANCER RES, V63, P7652; Li YS, 1995, CANCER GENET CYTOGEN, V84, P46, DOI 10.1016/0165-4608(95)00065-8; LICHTER P, 1995, METHOD ENZYMOL, V254, P334; Long X, 2005, CURR BIOL, V15, P702, DOI 10.1016/j.cub.2005.02.053; Mollemann M, 2005, INT J CANCER, V113, P379, DOI 10.1002/ijc.20575; Paulus W, 1996, ACTA NEUROPATHOL, V91, P293, DOI 10.1007/s004010050428; Pei XH, 2005, ONCOGENE, V24, P2787, DOI 10.1038/sj.onc.1208611; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Reifenberger G, 2004, J MOL MED, V82, P656, DOI 10.1007/s00109-004-0564-x; Reifenberger G, 2003, ACTA NEUROPATHOL, V105, P358, DOI 10.1007/s00401-002-0652-3; Reifenberger J, 2005, BRIT J DERMATOL, V152, P43, DOI 10.1111/J.1365-2133.2005.06353.X; Reifenberger J, 1996, J NEUROPATH EXP NEUR, V55, P822, DOI 10.1097/00005072-199607000-00007; Sambrook J, 1989, MOL CLONING LAB MANU; SAWYER JR, 1991, CANCER GENET CYTOGEN, V55, P225, DOI 10.1016/0165-4608(91)90081-5; SAWYER JR, 1992, CANCER GENET CYTOGEN, V60, P152, DOI 10.1016/0165-4608(92)90008-V; Schwaenen C, 2004, P NATL ACAD SCI USA, V101, P1039, DOI 10.1073/pnas.0304717101; SolinasToldo S, 1997, GENE CHROMOSOME CANC, V20, P399, DOI 10.1002/(SICI)1098-2264(199712)20:4<399::AID-GCC12>3.0.CO;2-I; van den Boom J, 2003, AM J PATHOL, V163, P1033, DOI 10.1016/S0002-9440(10)63463-3; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Weber RG, 1996, ONCOGENE, V13, P983; Yin XL, 2002, CANCER GENET CYTOGEN, V132, P14, DOI 10.1016/S0165-4608(01)00512-X; Zielinski B, 2005, GENE CHROMOSOME CANC, V43, P294, DOI 10.1002/gcc.20186	32	70	72	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2007	26	7					1088	1097		10.1038/sj.onc.1209851	http://dx.doi.org/10.1038/sj.onc.1209851			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	136SW	16909113				2022-12-17	WOS:000244245400015
J	Wu, X; Shell, SM; Liu, Y; Zou, Y				Wu, X.; Shell, S. M.; Liu, Y.; Zou, Y.			ATR-dependent checkpoint modulates XPA nuclear import in response to UV irradiation	ONCOGENE			English	Article						XPA; ATR; nuclear accumulation; DNA damage response; nucleotide excision repair	NUCLEOTIDE EXCISION-REPAIR; PIGMENTOSUM GROUP-A; CYCLOBUTANE PYRIMIDINE DIMERS; CELL-CYCLE CHECKPOINTS; DNA-DAMAGE; S-PHASE; RADIOSENSITIZING AGENT; ATAXIA-TELANGIECTASIA; IONIZING IRRADIATION; KINASE-ACTIVITY	In response to DNA damage, mammalian cells activate various DNA repair pathways to remove DNA lesions and, meanwhile, halt cell cycle progressions to allow sufficient time for repair. The nucleotide excision repair (NER) and the ATR-dependent cell cycle checkpoint activation are two major cellular responses to DNA damage induced by UV irradiation. However, how these two processes are coordinated in the response is poorly understood. Here we showed that the essential NER factor XPA (xeroderma pigmentosum group A) underwent nuclear accumulation upon UV irradiation, and strikingly, such an event occurred in an ATR (Ataxia-Telangiectasia mutated and RAD3-related)-dependent manner. Either treatment of cells with ATR kinase inhibitors or transfection of cells with small interfering RNA targeting ATR compromised the UV-induced XPA nuclear translocation. Consistently, the ATR-deficient cells displayed no substantial XPA nuclear translocation while the translocation remained intact in ATM (AtaxiaTelangiectasia mutated)-deficient cells in response to UV irradiation. Moreover, we found that ATR is required for the UV-induced nuclear focus formation of XPA. Taken together, our results suggested that the ATR checkpoint pathway may modulate NER activity through the regulation of XPA redistribution in human cells upon UV irradiation.	E Tennessee State Univ, James H Quillen Coll Med, Dept Biochem & Mol Biol, Johnson City, TN 37614 USA	East Tennessee State University	Zou, Y (corresponding author), E Tennessee State Univ, James H Quillen Coll Med, Dept Biochem & Mol Biol, 100 CR Rd,Box 70581, Johnson City, TN 37614 USA.	zouy@etsu.edu	Zou, Yue/ABA-8429-2020		NCI NIH HHS [CA86927, R56 CA086927, R01 CA086927-04, R56 CA086927-06A1, R01 CA086927, R01 CA086927-05] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R56CA086927, R01CA086927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Adimoolam S, 2002, P NATL ACAD SCI USA, V99, P12985, DOI 10.1073/pnas.202485699; Barr SM, 2003, CURR BIOL, V13, P1047, DOI 10.1016/S0960-9822(03)00376-2; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Costa RMA, 2003, BIOCHIMIE, V85, P1083, DOI 10.1016/j.biochi.2003.10.017; Dart DA, 2004, J BIOL CHEM, V279, P16433, DOI 10.1074/jbc.M314212200; Feng ZH, 2004, J BIOL CHEM, V279, P28574, DOI 10.1074/jbc.M404137200; Ford JM, 2005, MUTAT RES-FUND MOL M, V577, P195, DOI 10.1016/j.mrfmmm.2005.04.005; Garinis GA, 2005, EMBO J, V24, P3952, DOI 10.1038/sj.emboj.7600849; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Giannattasio M, 2004, EMBO J, V23, P429, DOI 10.1038/sj.emboj.7600051; Guzder SN, 2006, MOL CELL BIOL, V26, P1135, DOI 10.1128/MCB.26.3.1135-1141.2006; Iakoucheva LM, 2001, PROTEIN SCI, V10, P1353, DOI 10.1110/ps.40101; Jiang H, 1999, CANCER RES, V59, P4529; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Koberle B, 2006, DNA REPAIR, V5, P641, DOI 10.1016/j.dnarep.2005.12.001; Liu Y, 2005, BIOCHEMISTRY-US, V44, P7361, DOI 10.1021/bi047598y; MIURA N, 1991, J BIOL CHEM, V266, P19786; MIYAMOTO I, 1992, J BIOL CHEM, V267, P12182; Neecke H, 1999, EMBO J, V18, P4485, DOI 10.1093/emboj/18.16.4485; Nghiem P, 2002, J BIOL CHEM, V277, P4428, DOI 10.1074/jbc.M106113200; Nitta M, 2000, NUCLEIC ACIDS RES, V28, P4212, DOI 10.1093/nar/28.21.4212; O'Driscoll M, 2003, NAT GENET, V33, P497, DOI 10.1038/ng1129; O'Neill T, 2000, J BIOL CHEM, V275, P22719, DOI 10.1074/jbc.M001002200; Rademakers S, 2003, MOL CELL BIOL, V23, P5755, DOI 10.1128/MCB.23.16.5755-5767.2003; Riedl T, 2003, EMBO J, V22, P5293, DOI 10.1093/emboj/cdg489; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sarkaria JN, 1998, CANCER RES, V58, P4375; Thomas RK, 2003, MARK HEALTH SERV, V23, P38; Volker M, 2001, MOL CELL, V8, P213, DOI 10.1016/S1097-2765(01)00281-7; Wang J, 2006, CANCER RES, V66, P1906, DOI 10.1158/0008-5472.CAN-05-3444; Wright JA, 1998, P NATL ACAD SCI USA, V95, P7445, DOI 10.1073/pnas.95.13.7445; Wu XM, 2006, CANCER RES, V66, P2997, DOI 10.1158/0008-5472.CAN-05-3403; Wu XM, 2005, ONCOGENE, V24, P4728, DOI 10.1038/sj.onc.1208674; Wu YM, 2005, J CELL BIOCHEM, V96, P751, DOI 10.1002/jcb.20577; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Yu SR, 2001, MUTAT RES-DNA REPAIR, V485, P229, DOI 10.1016/S0921-8777(01)00061-1; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302	44	70	73	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2007	26	5					757	764		10.1038/sj.onc.1209828	http://dx.doi.org/10.1038/sj.onc.1209828			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	131WM	16862173	Green Accepted			2022-12-17	WOS:000243902200012
J	Hagerstrand, D; Hesselager, G; Achterberg, S; Bolin, UW; Kowanetz, M; Kastemar, M; Heldin, CH; Isaksson, A; Nister, M; Ostman, A				Hagerstrand, D.; Hesselager, G.; Achterberg, S.; Bolin, U. Wickenberg; Kowanetz, M.; Kastemar, M.; Heldin, C-H; Isaksson, A.; Nister, M.; Ostman, A.			Characterization of an imatinib-sensitive subset of high-grade human glioma cultures	ONCOGENE			English	Article						PDGF receptor; imatinib; CXCL12; glioblastoma multiforme; microarray	GROWTH-FACTOR-RECEPTOR; TYROSINE KINASE; BRAIN-TUMORS; CELL-GROWTH; PDGF RECEPTORS; MESSENGER-RNA; PHASE-II; B-CHAIN; GLIOBLASTOMA; EXPRESSION	High-grade gliomas, including glioblastomas, are malignant brain tumors for which improved treatment is urgently needed. Genetic studies have demonstrated the existence of biologically distinct subsets. Preliminary studies have indicated that platelet-derived growth factor (PDGF) receptor signaling contributes to the growth of some of these tumors. In this study, human high-grade glioma primary cultures were analysed for sensitivity to treatment with the PDGF receptor inhibitor imatinib/Glivec/Gleevec/STI571. Six out of 15 cultures displayed more than 40% growth inhibition after imatinib treatment, whereas seven cultures showed less than 20% growth inhibition. In the sensitive cultures, apoptosis contributed to growth inhibition. Platelet-derived growth factor receptor status correlated with imatinib sensitivity. Supervised analyses of gene expression profiles and real-time PCR analyses identified expression of the chemokine CXCL12/SDF-1 (stromal cell-derived factor 1) as a predictor of imatinib sensitivity. Exogenous addition of CXCL12 to imatinib-insensitive cultures conferred some imatinib sensitivity. Finally, coregulation of CXCL12 and PDGF alpha-receptor was observed in glioblastoma biopsies. We have thus defined the characteristics of a novel imatinib-sensitive subset of glioma cultures, and provided evidence for a functional relationship between imatinib sensitivity and chemokine signaling. These findings will assist in the design and evaluation of clinical trials exploring therapeutic effects of imatinib on malignant brain tumors.	Canc Ctr Karolinska, Dept Oncol Pathol, Karolinska Inst, S-17176 Stockholm, Sweden; Uppsala Univ, Dept Genet & Pathol, Rudbeck Lab, Uppsala, Sweden; Uppsala Univ, Ludwig Inst Canc Res, Uppsala, Sweden	Karolinska Institutet; Uppsala University; Ludwig Institute for Cancer Research; Uppsala University	Ostman, A (corresponding author), Canc Ctr Karolinska, Dept Oncol Pathol, Karolinska Inst, R8-03, S-17176 Stockholm, Sweden.	arne.ostman@ki.se	Hägerstrand, Daniel/AAH-3009-2019; Hägerstrand, Daniel C/D-1584-2014	Hägerstrand, Daniel/0000-0001-7270-0776; Hägerstrand, Daniel C/0000-0001-7270-0776; Isaksson, Anders/0000-0001-6576-7825	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Backlund LM, 2003, CLIN CANCER RES, V9, P4151; Cabioglu N, 2005, CANCER RES, V65, P6493, DOI 10.1158/0008-5472.CAN-04-1303; Capdeville R, 2002, NAT REV DRUG DISCOV, V1, P493, DOI 10.1038/nrd839; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Dresemann G, 2005, ANN ONCOL, V16, P1702, DOI 10.1093/annonc/mdi317; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Freije WA, 2004, CANCER RES, V64, P6503, DOI 10.1158/0008-5472.CAN-04-0452; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Haas-Kogan DA, 2005, JNCI-J NATL CANCER I, V97, P880, DOI 10.1093/jnci/dji161; Heimberger AB, 2002, CLIN CANCER RES, V8, P3496; HERMANSON M, 1992, CANCER RES, V52, P3213; HERMANSSON M, 1988, P NATL ACAD SCI USA, V85, P7748, DOI 10.1073/pnas.85.20.7748; Johnson BE, 2005, CANCER RES, V65, P7525, DOI 10.1158/0008-5472.CAN-05-1257; Kilic T, 2000, CANCER RES, V60, P5143; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215; KOVALENKO M, 1994, CANCER RES, V54, P6106; Liang Y, 2005, P NATL ACAD SCI USA, V102, P5814, DOI 10.1073/pnas.0402870102; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; Mellinghoff IK, 2005, NEW ENGL J MED, V353, P2012, DOI 10.1056/NEJMoa051918; Mischel PS, 2003, ONCOGENE, V22, P2361, DOI 10.1038/sj.onc.1206344; Nutt CL, 2003, CANCER RES, V63, P1602; Ohgaki H, 2004, CANCER RES, V64, P6892, DOI 10.1158/0008-5472.CAN-04-1337; Ostman A, 2004, CYTOKINE GROWTH F R, V15, P275, DOI 10.1016/j.cytogfr.2004.03.002; Pietras K, 2003, CANCER CELL, V3, P439, DOI 10.1016/S1535-6108(03)00089-8; Pietras K, 2001, CANCER RES, V61, P2929; PONTEN J, 1978, MED BIOL, V56, P184; Porcile C, 2005, EXP CELL RES, V308, P241, DOI 10.1016/j.yexcr.2005.04.024; Reardon DA, 2005, J CLIN ONCOL, V23, P9359, DOI 10.1200/JCO.2005.03.2185; Rempel SA, 2000, CLIN CANCER RES, V6, P102; Rich JN, 2004, J CLIN ONCOL, V22, P133, DOI 10.1200/JCO.2004.08.110; Sawyers C, 2004, NATURE, V432, P294, DOI 10.1038/nature03095; SHAMAH SM, 1993, MOL CELL BIOL, V13, P7203, DOI 10.1128/MCB.13.12.7203; Sihto H, 2005, J CLIN ONCOL, V23, P49, DOI 10.1200/JCO.2005.02.093; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Sjoblom T, 2001, CANCER RES, V61, P5778; STRAWN LM, 1994, J BIOL CHEM, V269, P21215; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Uhrbom L, 1998, CANCER RES, V58, P5275; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; WESTERMARK B, 1995, GLIA, V15, P257, DOI 10.1002/glia.440150307; Yuan XP, 2004, ONCOGENE, V23, P9392, DOI 10.1038/sj.onc.1208311	44	70	70	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2006	25	35					4913	4922		10.1038/sj.onc.1209497	http://dx.doi.org/10.1038/sj.onc.1209497			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QE	16547494	Bronze			2022-12-17	WOS:000239687100009
J	La, P; Desmond, A; Hou, Z; Silva, AC; Schepp, RW; Hua, X				La, P.; Desmond, A.; Hou, Z.; Silva, A. C.; Schepp, R. W.; Hua, X.			Tumor suppressor menin: the essential role of nuclear localization signal domains in coordinating gene expression	ONCOGENE			English	Article						menin; MEN1; nuclear localization signals; gene transcription; tumorigenesis; tumor suppressor	ENDOCRINE NEOPLASIA TYPE-1; HISTONE METHYLTRANSFERASE COMPLEX; JUND-ACTIVATED TRANSCRIPTION; BETA-INDUCED TRANSCRIPTION; INHIBITOR-1 GENE; EPITHELIAL-CELLS; SMAD PROTEINS; DNA-DAMAGE; INSULINOMA; CHROMATIN	Menin is encoded by the tumor suppressor gene MEN1 that is mutated in patients with an inherited tumor syndrome, multiple endocrine neoplasia type 1 ( MEN1). Although menin is a nuclear protein and directly binds to DNA through its nuclear localization signals (NLSs), the precise role for each of the NLSs in nuclear translocation and gene expression remains to be elucidated. Here, we show that point mutations in three individual NLSs, NLS1, NLS2, and a novel accessory NLS, NLSa, do not block nuclear translocation, but compromise the ability of menin to repress expression of the endogenous insulin-like growth factor binding protein-2 (IGFBP-2) gene. This repression is not released by an inhibitor of histone deacetylases. Although subtle mutations in menin NLSs do not affect menin association with chromatin, they abolish menin binding to the IGFBP-2 promoter in vivo. Furthermore, each of the NLSs is also crucial for menin-mediated induction of caspase 8 expression. Together, these results suggest that menin may act as a scaffold protein in coordinating activation and repression of gene transcription and that its NLSs play a more important role in controlling gene transcription than merely targeting menin into the nucleus.	Univ Penn, Dept Canc Biol, Abramson Family Canc Res Inst, Abramson Canc Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Hua, X (corresponding author), Univ Penn, Dept Canc Biol, Abramson Family Canc Res Inst, Abramson Canc Ctr, 412 BRB2-3,421 Curied Blvd, Philadelphia, PA 19104 USA.	huax@mail.med.upenn.edu	Desmond, Angela/GZG-5470-2022	Desmond, Angela/0000-0002-8325-713X	NCI NIH HHS [R01 CA113962, R01 CA100912] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100912, R01CA113962] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal SK, 1999, CELL, V96, P143, DOI 10.1016/S0092-8674(00)80967-8; Busygina V, 2004, HUM MOL GENET, V13, P2399, DOI 10.1093/hmg/ddh271; Chandrasekharappa SC, 2003, J INTERN MED, V253, P606, DOI 10.1046/j.1365-2796.2003.01165.x; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Gobl AE, 1999, BBA-GENE STRUCT EXPR, V1447, P51, DOI 10.1016/S0167-4781(99)00132-3; Guru SC, 1998, P NATL ACAD SCI USA, V95, P1630, DOI 10.1073/pnas.95.4.1630; Hua XX, 1999, P NATL ACAD SCI USA, V96, P13130, DOI 10.1073/pnas.96.23.13130; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Hughes CM, 2004, MOL CELL, V13, P587, DOI 10.1016/S1097-2765(04)00081-4; Jin SH, 2003, CANCER RES, V63, P4204; Kaji H, 2001, P NATL ACAD SCI USA, V98, P3837, DOI 10.1073/pnas.061358098; Kim H, 2003, CANCER RES, V63, P6135; Kim YS, 1999, ONCOGENE, V18, P5936, DOI 10.1038/sj.onc.1203005; Komeili A, 2001, ANNU REV GENET, V35, P341, DOI 10.1146/annurev.genet.35.102401.090720; La P, 2004, J BIOL CHEM, V279, P49045, DOI 10.1074/jbc.M409358200; La P, 2004, ENDOCRINOLOGY, V145, P3443, DOI 10.1210/en.2004-0124; La P, 2003, ONCOGENE, V22, P198, DOI 10.1038/sj.onc.1206100; Lin SY, 2003, CELL, V113, P881, DOI 10.1016/S0092-8674(03)00430-6; Makkerh JPS, 1996, CURR BIOL, V6, P1025, DOI 10.1016/S0960-9822(02)00648-6; Moroianu J, 1999, J CELL BIOCHEM, P76; Pannett AAJ, 1999, ENDOCR-RELAT CANCER, V6, P449, DOI 10.1677/erc.0.0060449; Poisson A, 2003, CANCER LETT, V189, P1, DOI 10.1016/S0304-3835(02)00509-8; Qiao FY, 2001, J BIOL CHEM, V276, P23391, DOI 10.1074/jbc.M101855200; Ratineau C, 2004, J BIOL CHEM, V279, P24477, DOI 10.1074/jbc.M401835200; Sayo Y, 2002, ENDOCRINOLOGY, V143, P2437, DOI 10.1210/en.143.6.2437; SCAPPATICCI S, 1992, CANCER GENET CYTOGEN, V63, P17, DOI 10.1016/0165-4608(92)90057-F; Schnepp RW, 2004, CANCER RES, V64, P6791, DOI 10.1158/0008-5472.CAN-04-0724; Schnepp RW, 2004, J BIOL CHEM, V279, P10685, DOI 10.1074/jbc.M308073200; Wu JS, 2000, TRENDS BIOCHEM SCI, V25, P619, DOI 10.1016/S0968-0004(00)01718-7; Yokoyama A, 2004, MOL CELL BIOL, V24, P5639, DOI 10.1128/MCB.24.13.5639-5649.2004; Zaidi SK, 2001, J CELL SCI, V114, P3093	31	70	75	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2006	25	25					3537	3546		10.1038/sj.onc.1209400	http://dx.doi.org/10.1038/sj.onc.1209400			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KC	16449969				2022-12-17	WOS:000238448200006
J	Su, ZZ; Lebedeva, IV; Sarkar, D; Emdad, L; Gupta, P; Kitada, S; Dent, P; Reed, JC; Fisher, PB				Su, ZZ; Lebedeva, IV; Sarkar, D; Emdad, L; Gupta, P; Kitada, S; Dent, P; Reed, JC; Fisher, PB			Ionizing radiation enhances therapeutic activity of mda-7/IL-24: overcoming radiation- and mda-7/IL-24-resistance in prostate cancer cells overexpressing the antiapoptotic proteins bcl-x(L) or bcl-2	ONCOGENE			English	Article						mda-7/1L-24; prostate cancer; ionizing radiation; apoptosis; bcl-family	DIFFERENTIATION-ASSOCIATED GENE-7; IN-VITRO; IMMUNOHISTOCHEMICAL ANALYSIS; INHIBITS GROWTH; GAMMA-RADIATION; APOPTOSIS; DEATH; RADIOSENSITIVITY; ACTIVATION; EXPRESSION	Subtraction hybridization applied to terminally differentiating human melanoma cells identified mda-7/IL-24, a cytokine belonging to the IL-10 gene superfamily. Adenoviral-mediated delivery of mda-7/IL-24 (Ad. mda7) provokes apoptosis selectively in a wide spectrum of cancers in vitro in cell culture, in vivo in human tumor xenograft animal models and in patients with advanced carcinomas and melanomas. In human prostate cancer cells, a role for mitochondrial dysfunction and induction of reactive oxygen species in the apoptotic process has been established. Ectopic overexpression of bcl-x(L) and bcl-2 prevents these changes including apoptosis induction in prostate tumor cells by Ad.mda-7. We now document that this resistance to apoptosis can be reversed by treating bcl-2 family overexpressing prostate tumor cells with ionizing radiation in combination with Ad.mda-7 or purified GSTMDA-7 protein. Additionally, radiation augments apoptosis induction by mda-7/IL-24 in parental and neomycin-resistant prostate tumor cells. Radiosensitization to mda7/IL-24 is dependent on JNK signaling, as treatment with the JNK 1/2/3 inhibitor SP600125 abolishes this effect. Considering that elevated expression of bcl-x(L) and bcl-2 are frequent events in prostate cancer development and progression, the present studies support the use of ionizing radiation in combination with mda-7/IL-24 as a means of augmenting the therapeutic benefit of this gene in prostate cancer, particularly in the context of tumors displaying resistance to radiation therapy owing to bcl-2family member overexpression.	Columbia Univ Coll Phys & Surg, Dept Pathol, Herbert Irving Comprehens Canc Ctr, Med Ctr, New York, NY 10032 USA; Burnham Inst, La Jolla, CA 92037 USA; Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA USA; Columbia Univ Coll Phys & Surg, Dept Urol, Herbert Irving Comprehens Canc Ctr, Med Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Neurosurg, Herbert Irving Comprehens Canc Ctr, Med Ctr, New York, NY 10032 USA	Columbia University; Sanford Burnham Prebys Medical Discovery Institute; Virginia Commonwealth University; Columbia University; Columbia University	Fisher, PB (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pathol, Herbert Irving Comprehens Canc Ctr, Med Ctr, 630 W 168th St, New York, NY 10032 USA.	pbf1@columbia.edu	Lebedeva, Irina V/A-3156-2008	Lebedeva, Irina V/0000-0002-1693-9392	NATIONAL CANCER INSTITUTE [R01CA098712, R01CA097318, R01CA088906, P01CA104177] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060554] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA88906, R01 CA72955, P01 CA104177, R01 CA097318, R01 CA098712] Funding Source: Medline; NIDDK NIH HHS [DK52585] Funding Source: Medline; NIGMS NIH HHS [GM60554] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAE VL, 1994, INT J CANCER, V58, P721, DOI 10.1002/ijc.2910580517; Bai XZ, 1999, INT J ONCOL, V14, P785; Bauer JJ, 1996, J UROLOGY, V156, P1511, DOI 10.1016/S0022-5347(01)65641-6; Catz SD, 2003, APOPTOSIS, V8, P29, DOI 10.1023/A:1021692801278; Chada S, 2004, MOL THER, V10, P1085, DOI 10.1016/j.ymthe.2004.08.020; Chaudhary KS, 1999, ENVIRON HEALTH PERSP, V107, P49, DOI 10.2307/3434471; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; COLOMBEL M, 1993, AM J PATHOL, V143, P390; Cooperberg MR, 2004, ONCOLOGY-NY, V18, P1239; Dent P, 2003, ONCOGENE, V22, P5885, DOI 10.1038/sj.onc.1206701; Dent P, 2003, RADIAT RES, V159, P283, DOI 10.1667/0033-7587(2003)159[0283:SARIAO]2.0.CO;2; Fisher PB, 2003, CANCER BIOL THER, V2, pS23; FISHER PB, 2005, IN PRESS CANC RES; Gopalkrishnan RV, 2001, J CELL PHYSIOL, V189, P245, DOI 10.1002/jcp.10023; GUPTA P, 2005, IN PRESS PHARM THER; Kajiwara T, 1999, INT J UROL, V6, P520, DOI 10.1046/j.1442-2042.1999.00102.x; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; Kawabe S, 2002, MOL THER, V6, P637, DOI 10.1006/mthe.2002.0714; Keshgegian AA, 1998, AM J CLIN PATHOL, V110, P443; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Krajewska M, 1996, AM J PATHOL, V148, P1567; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; Lebedeva I, 2000, CANCER RES, V60, P6052; Lebedeva IV, 2003, ONCOGENE, V22, P8758, DOI 10.1038/sj.onc.1206891; Lebedeva IV, 2005, MOL THER, V11, P4, DOI 10.1016/j.ymthe.2004.08.012; Lebedeva IV, 2002, ONCOGENE, V21, P708, DOI 10.1038/sj.onc.1205116; Li XY, 2001, CANCER RES, V61, P1699; Liu QY, 1997, CLIN CANCER RES, V3, P2039; Mabjeesh NJ, 2002, ENDOCR-RELAT CANCER, V9, DOI 10.1677/erc.0.0090115; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; Reed JC, 1996, J CELL BIOCHEM, V60, P23, DOI 10.1002/(SICI)1097-4644(19960101)60:1<23::AID-JCB5>3.3.CO;2-3; Saito Y, 2005, CANCER GENE THER, V12, P238, DOI 10.1038/sj.cgt.7700780; Sarkar D, 2005, P NATL ACAD SCI USA, V102, P14034, DOI 10.1073/pnas.0506837102; Sauane M, 2004, ONCOGENE, V23, P7679, DOI 10.1038/sj.onc.1207958; Srivastava RK, 1999, MOL CELL BIOL, V19, P5659; Su ZZ, 2001, P NATL ACAD SCI USA, V98, P10332, DOI 10.1073/pnas.171315198; Su ZZ, 2003, ONCOGENE, V22, P1164, DOI 10.1038/sj.onc.1206062; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; SU ZZ, 2005, ONCOGENE, V24; Yacoub A, 2004, CANCER BIOL THER, V3, P739, DOI 10.4161/cbt.3.8.968; Yacoub A, 2003, CANCER BIOL THER, V2, P347, DOI 10.4161/cbt.2.4.422; Yacoub A, 2003, CLIN CANCER RES, V9, P3272; Yacoub A, 2003, MOL CANCER THER, V2, P623	44	70	80	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2006	25	16					2339	2348		10.1038/sj.onc.1209271	http://dx.doi.org/10.1038/sj.onc.1209271			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032HC	16331261				2022-12-17	WOS:000236764300006
J	Kawaguchi, T; Kato, S; Otsuka, K; Watanabe, G; Kumabe, T; Tominaga, T; Yoshimoto, T; Ishioka, C				Kawaguchi, T; Kato, S; Otsuka, K; Watanabe, G; Kumabe, T; Tominaga, T; Yoshimoto, T; Ishioka, C			The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library	ONCOGENE			English	Article						p53; oligomerization; transactivation	PROLYL ISOMERASE PIN1; TUMOR-SUPPRESSOR P53; LI-FRAUMENI SYNDROME; TETRAMERIZATION DOMAIN; DNA-BINDING; WILD-TYPE; P53-INDUCED APOPTOSIS; TRANSFORMING DOMAIN; CRYSTAL-STRUCTURE; MUTANTS	Tumor suppressor p53 forms a homo-tetramer through its COOH-terminal oligomerization domain and acts as a sequence-specific transcription factor. We have analysed the interrelation among the transcriptional activities, the structure and the cancer-related mutations in the oligomerization domain by using a comprehensive missense mutation library. Here, we examined the ability of 184 mutant p53s in the domain to form an oligomer by expressing these mutant p53s in yeast, and compared the data with the previous information. We showed that specific residues in the alpha-helix and the beta-strand of the oligomerization domain were critical for both oligomer formation and sequence-specific transactivation, and the activities were closely related. In particular, the alpha-helix was more sensitive to amino-acid substitutions than the beta-strand. We found identity in the interrelation between the two activities, that is, monomer mutants were transcriptionally inactive whereas dimer and tetramer mutants retained their transcriptional activities. In TP53 mutation databases, a small number of mutations have been reported in this domain. Surprisingly, most do not encode p53s defective in functional properties. These results indicate that, although oligomer formation is essential for p53 transactivation function, the inactivation of oligomer formation and therefore the inactivation of transactivation may not be essential for tumor suppression by p53 because they do not lead to oncogenic proteins.	Inst Dev Aging & Canc, Dept Clin Oncol, Aoba Ku, Sendai, Miyagi 9808575, Japan; Tohoku Univ Hosp, Aoba Ku, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Grad Sch Med, Dept Neurosurg, Sendai, Miyagi 8908574, Japan	Tohoku University; Tohoku University	Ishioka, C (corresponding author), Inst Dev Aging & Canc, Dept Clin Oncol, Aoba Ku, 4-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.	chikashi@idac.tohoku.ac.jp	Kato, Shunsuke/F-7607-2014	Ishioka, Chikashi/0000-0002-3023-1227				Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Brachmann RK, 1996, P NATL ACAD SCI USA, V93, P4091, DOI 10.1073/pnas.93.9.4091; Chene P, 1999, J MOL BIOL, V288, P891, DOI 10.1006/jmbi.1999.2738; Chene P, 1997, J MOL BIOL, V273, P873, DOI 10.1006/jmbi.1997.1360; CLORE GM, 1995, SCIENCE, V267, P1515, DOI 10.1126/science.7878474; Davison TS, 1998, ONCOGENE, V17, P651, DOI 10.1038/sj.onc.1202062; DiGiammarino EL, 2002, NAT STRUCT BIOL, V9, P12, DOI 10.1038/nsb730; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; ISHIOKA C, 1995, ONCOGENE, V10, P1485; Ishioka C, 1997, BIOCHEM BIOPH RES CO, V232, P54, DOI 10.1006/bbrc.1997.6216; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; Kakudo Y, 2005, CANCER RES, V65, P2108, DOI 10.1158/0008-5472.CAN-04-2935; Kato S, 2003, P NATL ACAD SCI USA, V100, P8424, DOI 10.1073/pnas.1431692100; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; Lomax ME, 1998, ONCOGENE, V17, P643, DOI 10.1038/sj.onc.1201974; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Mateu MG, 1998, EMBO J, V17, P2748, DOI 10.1093/emboj/17.10.2748; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Miller M, 1996, FEBS LETT, V399, P166, DOI 10.1016/S0014-5793(96)01231-8; Mittl PRE, 1998, ACTA CRYSTALLOGR D, V54, P86, DOI 10.1107/S0907444997006550; MIYASHITA T, 1995, CELL, V80, P293; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SLINGERLAND JM, 1991, J CELL PHYSIOL, V148, P391, DOI 10.1002/jcp.1041480309; Soussi T, 2005, HUM MUTAT, V25, P6, DOI 10.1002/humu.20114; SRIVASTAVA S, 1993, ONCOGENE, V8, P2449; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; Varley JM, 1996, ONCOGENE, V12, P2437; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zheng HW, 2002, NATURE, V419, P849, DOI 10.1038/nature01116	41	70	71	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2005	24	46					6976	6981		10.1038/sj.onc.1208839	http://dx.doi.org/10.1038/sj.onc.1208839			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	975ZD	16007150				2022-12-17	WOS:000232701700012
J	Wang, F; Zhu, Y; Huang, Y; McAvoy, S; Johnson, WB; Cheung, TH; Chung, TKH; Lo, KWK; Yim, SF; Yu, MMY; Ngan, HYS; Wong, YF; Smith, DI				Wang, F; Zhu, Y; Huang, Y; McAvoy, S; Johnson, WB; Cheung, TH; Chung, TKH; Lo, KWK; Yim, SF; Yu, MMY; Ngan, HYS; Wong, YF; Smith, DI			Transcriptional repression of WEE1 by Kruppel-like factor 2 is involved in DNA damage-induced apoptosis	ONCOGENE			English	Article						transcriptional regulation; KLF2; WEE1	TUMOR-SUPPRESSOR GENE; COLORECTAL-CANCER; KINASE INHIBITOR; TYROSINE KINASES; PROSTATE-CANCER; PROTEIN-KINASE; CELL-GROWTH; FACTOR KLF2; G2 ARREST; CHECKPOINT	Human Kruppel-like factor 2 (KLF2) is a Cys(2)/His(2) zinc-finger-containing transcriptional factor, which is involved in multiple cellular pathways. Utilizing gene expression profiling to identify aberrantly expressed genes in ovarian cancer, we found that KLF2 was significantly and specifically downregulated in ovarian tumors. After reintroducing KLF2 into ovarian cancer cell lines, we observed decreased cell growth and increased sensitivity to DNA damage-induced apoptosis. Analysis of genes that could be potential targets of KLF2 revealed that KLF2 negatively regulated WEE1 expression. WEE1 encodes a tyrosine kinase that regulates the G2/M cell cycle transition. Expression of KLF2 markedly repressed the transcription of WEE1 by directly binding to an SPI/CPBP motif located between -252 bp and the start codon of the WEE1 promoter. Both activation and zinc-finger domains of KLF2 were required for this suppression of Wee1 expression. In addition, we demonstrated that Wee1 expression prevents cancer cells from undergoing apoptosis in response to DNA damage; however, this resistance was abolished by coexpression of KLF2, which inhibits WEE1 transcription. Thus, the level of WEE1 is regulated by KLF2 and enhanced KLF2 expression sensitizes cells to DNA damage-induced apoptosis.	Mayo Clin, Coll Med, Dept Lab Med & Pathol, Div Expt Pathol, Rochester, MN USA; Mayo Clin, Coll Med, Dept Mol Pharmacol, Rochester, MN USA; Mayo Clin, Coll Med, Dept Expt Therapeut, Rochester, MN USA; Chinese Univ Hong Kong, Prince Wales Hosp, Dept Obstet & Gynecol, Hong Kong, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China	Mayo Clinic; Mayo Clinic; Mayo Clinic; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong	Smith, DI (corresponding author), Mayo Fdn, Mayo Clin, Ctr Canc, Div Expt Pathol, 200 1st St SW, Rochester, MN 55905 USA.	smith.david@mayo.edu		Ngan, Hextan Y S/0000-0003-3945-159X; CHUNG, Tony/0000-0002-6362-8546				Banerjee SS, 2003, J BIOL CHEM, V278, P2581, DOI 10.1074/jbc.M210859200; Benzeno S, 2004, CANCER RES, V64, P3885, DOI 10.1158/0008-5472.CAN-03-2818; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Buckley AF, 2001, NAT IMMUNOL, V2, P698, DOI 10.1038/90633; Chen CS, 2003, AM J PATHOL, V162, P1349, DOI 10.1016/S0002-9440(10)63930-2; Chen XM, 2003, J MOL BIOL, V326, P665, DOI 10.1016/S0022-2836(02)01449-3; Dekker RJ, 2002, BLOOD, V100, P1689, DOI 10.1182/blood-2002-01-0046; Denkinger DJ, 2001, GENE, V281, P133, DOI 10.1016/S0378-1119(01)00792-2; Dent P, 2001, CLIN CANCER RES, V7, P775; Elder RT, 2001, VIROLOGY, V287, P359, DOI 10.1006/viro.2001.1007; Huddleson JP, 2004, BIOL CHEM, V385, P723, DOI 10.1515/BC.2004.088; Ito G, 2004, CANCER RES, V64, P3838, DOI 10.1158/0008-5472.CAN-04-0185; Kimmelman AC, 2004, ONCOGENE, V23, P5077, DOI 10.1038/sj.onc.1207662; Kremer-Tal S, 2004, HEPATOLOGY, V40, P1047, DOI 10.1002/hep.20460; Kuo CT, 1997, GENE DEV, V11, P2996, DOI 10.1101/gad.11.22.2996; Lai JP, 2003, J BIOL CHEM, V278, P23107, DOI 10.1074/jbc.M302203200; Li J, 2002, RADIAT RES, V157, P322, DOI 10.1667/0033-7587(2002)157[0322:WTTIGP]2.0.CO;2; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; Pandya AY, 2004, CLIN CANCER RES, V10, P2709, DOI 10.1158/1078-0432.CCR-03-0484; Pendergast AM, 1996, CURR OPIN CELL BIOL, V8, P174, DOI 10.1016/S0955-0674(96)80063-9; Reeves HL, 2004, GASTROENTEROLOGY, V126, P1090, DOI 10.1053/j.gastro.2004.01.005; ROWLEY R, 1992, NATURE, V356, P353, DOI 10.1038/356353a0; SenBanerjee S, 2004, J EXP MED, V199, P1305, DOI 10.1084/jem.20031132; Tourret J, 1996, Prog Cell Cycle Res, V2, P91; Vax VV, 2003, ENDOCR-RELAT CANCER, V10, P397, DOI 10.1677/erc.0.0100397; Wang YL, 2004, CANCER BIOL THER, V3, P305, DOI 10.4161/cbt.3.3.697; Wu JH, 2004, ONCOGENE, V23, P8088, DOI 10.1038/sj.onc.1207996; Yoon HS, 2003, J BIOL CHEM, V278, P2101, DOI 10.1074/jbc.M211027200; Yuan HD, 2004, J VIROL, V78, P8183, DOI 10.1128/JVI.78.15.8183-8190.2004; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200; Zhao WD, 2004, ONCOGENE, V23, P395, DOI 10.1038/sj.onc.1207067	32	70	71	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3875	3885		10.1038/sj.onc.1208546	http://dx.doi.org/10.1038/sj.onc.1208546			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15735666				2022-12-17	WOS:000229435300003
J	Taki, M; Kagawa, S; Nishizaki, M; Mizuguchi, H; Hayakawa, T; Kyo, S; Nagai, K; Urata, Y; Tanaka, N; Fujiwara, T				Taki, M; Kagawa, S; Nishizaki, M; Mizuguchi, H; Hayakawa, T; Kyo, S; Nagai, K; Urata, Y; Tanaka, N; Fujiwara, T			Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD)	ONCOGENE			English	Article						RGD; adenovirus; telomerase; replication; gene therapy	GENE-THERAPY; TRANSGENE EXPRESSION; CANCER-CELLS; RECEPTOR EXPRESSION; GLIOMA-CELLS; FIBER KNOB; BAX GENE; IN-VITRO; VECTOR; PROMOTER	Replication-competent oncolytic viruses are being developed for human cancer therapy. We previously reported that an attenuated adenovirus (OBP-301, 'Telomelysin'), in which the hTERT promoter element drives expression of E1A and E1B genes linked with an IRES, could replicate in cancer cells, and causes selective lysis of cancer cells. We further constructed OBP-405 ('Telomelysin-RGD') that contains an RGD motif in the HI loop of the fiber knob. We examined whether OBP-405 could be effective in overcoming the limitations of OBP-301, specifically their inefficient infection into cells lacking the primary receptor, the coxsackievirus and adenovirus receptor ( CAR). By flow cytometric analysis, H1299 ( lung) and SW620 ( colorectal) tumor cells showed high levels of CAR expression, whereas LN444 ( glioblastoma), LNZ308 ( glioblastoma), and H1299-R5 ( lung) tumor cells were negative for CAR expression. A quantitative realtime PCR analysis demonstrated that fiber-modified OBP-405 infected more efficiently than OBP-301, although the intracellular replication rate of both viruses was consistent. The comparative antitumor effect of fiber-modified OBP-405 and unmodified OBP-301 for human cancer cells was evaluated in vitro by XTT assay as well as in vivo by using athymic mice carrying xenografts. OBP-405 had a profound oncolytic effect on human cancer cell lines compared to OBP-301, in particular on cells with low CAR expression. Intratumoral injection of 107 plaque-forming units of OBP-405 into CAR-negative H1299-R5 lung tumor xenografts in nu/nu mice resulted in a significant inhibition of tumor growth and long-term survival in all treated mice. Moreover, selective replication of OBP-405 in the distant, uninjected H1299-R5 tumors was demonstrated. Our results suggest that fiber-modified replication-competent adenovirus OBP-405 exhibits a broad target range by increasing infection efficiency, an outcome that has important implications for the treatment of human cancers.	Okayama Univ Hosp, Ctr Gene & Cell Therapy, Okayama 7008558, Japan; Okayama Univ, Sch Med & Dent, Dept Surg, Div Surg Oncol, Okayama 7008558, Japan; Natl Inst Hlth Sci, Div Cellular & Gene Therapy Prod, Tokyo 1588501, Japan; Kanazawa Univ, Sch Med, Dept Obstet & Gynecol, Kanazawa, Ishikawa 9208641, Japan; Oncolys Biopharma Inc, Tokyo 1060031, Japan	Okayama University; Okayama University; National Institute of Health Sciences - Japan; Kanazawa University; Oncolys BioPharma	Fujiwara, T (corresponding author), Okayama Univ Hosp, Ctr Gene & Cell Therapy, 2-5-1 Shikata Cho, Okayama 7008558, Japan.	toshi_f@md.okayama-u.ac.jp	Kagawa, Shunsuke/B-2189-2011	Mizuguchi, Hiroyuki/0000-0003-0594-8178; Kagawa, Shunsuke/0000-0002-3610-8211				Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Collins K, 2002, ONCOGENE, V21, P564, DOI 10.1038/sj.onc.1205083; Davydova J, 2004, CANCER RES, V64, P4319, DOI 10.1158/0008-5472.CAN-04-0064; DeWeese TL, 2001, CANCER RES, V61, P7464; Dmitriev I, 1998, J VIROL, V72, P9706, DOI 10.1128/JVI.72.12.9706-9713.1998; Fang BL, 2003, CURR OPIN MOL THER, V5, P475; Fechner H, 2000, GENE THER, V7, P1954, DOI 10.1038/sj.gt.3301321; GINSBERG HS, 1991, P NATL ACAD SCI USA, V88, P1651, DOI 10.1073/pnas.88.5.1651; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Gu J, 2000, CANCER RES, V60, P5359; Gu J, 2002, ONCOGENE, V21, P4757, DOI 10.1038/sj.onc.1205582; Hemminki A, 2003, CANCER RES, V63, P847; HUARD J, 1995, GENE THER, V2, P107; KANEGAE Y, 1994, JPN J MED SCI BIOL, V47, P157, DOI 10.7883/yoken1952.47.157; Kawashima T, 2004, CLIN CANCER RES, V10, P285, DOI 10.1158/1078-0432.CCR-1075-3; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kirn D, 2001, NAT MED, V7, P781, DOI 10.1038/89901; Koga S, 2000, HUM GENE THER, V11, P1397, DOI 10.1089/10430340050057477; Kohn EC, 2004, SEMIN ONCOL, V31, P39, DOI 10.1053/j.seminoncol.2004.01.009; Komata T, 2001, CANCER RES, V61, P5796; Krasnykh V, 1998, J VIROL, V72, P1844, DOI 10.1128/JVI.72.3.1844-1852.1998; Lamfers MLM, 2002, CANCER RES, V62, P5736; Li YM, 1999, CANCER RES, V59, P325; MAIZEL JV, 1968, VIROLOGY, V36, P115, DOI 10.1016/0042-6822(68)90121-9; McCormick F, 2001, NAT REV CANCER, V1, P130, DOI 10.1038/35101008; Miller CR, 1998, CANCER RES, V58, P5738; Mizuguchi H, 2001, GENE THER, V8, P730, DOI 10.1038/sj.gt.3301453; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; PRINCE GA, 1993, J VIROL, V67, P101, DOI 10.1128/JVI.67.1.101-111.1993; Shay Jerry W., 1996, Current Opinion in Oncology, V8, P66, DOI 10.1097/00001622-199601000-00012; Tango Y, 2004, CANCER SCI, V95, P459, DOI 10.1111/j.1349-7006.2004.tb03232.x; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; Umeoka T, 2004, CANCER RES, V64, P6259, DOI 10.1158/0008-5472.CAN-04-1335; Wickham TJ, 1997, J VIROL, V71, P8221, DOI 10.1128/JVI.71.11.8221-8229.1997; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; Wood M, 1999, CANCER GENE THER, V6, P367, DOI 10.1038/sj.cgt.7700090	36	70	74	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2005	24	19					3130	3140		10.1038/sj.onc.1208460	http://dx.doi.org/10.1038/sj.onc.1208460			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735729				2022-12-17	WOS:000228728100007
J	Izeradjene, K; Douglas, L; Delaney, A; Houghton, JA				Izeradjene, K; Douglas, L; Delaney, A; Houghton, JA			Casein kinase II (CK2) enhances death-inducing signaling complex (DISC) activity in TRAIL-induced apoptosis in human colon carcinoma cell lines	ONCOGENE			English	Article						TRAIL; apoptosis; DISC; CK2	KAPPA-B-ALPHA; MEDIATED APOPTOSIS; CANCER-CELLS; ACTIVATION; CD95; PHOSPHORYLATION; TRANSCRIPTION; EXPRESSION; CLEAVAGE; LIGAND	Protein kinase casein kinase II (CK2) is increased in response to diverse growth stimuli, as well as being elevated in many human cancers examined. We have demonstrated that CK2 is a key survival factor that protects human colon carcinoma cells from TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. We determined that inhibition of CK2 phosphorylation events by DRB (5,6- dichlorobenzimidazole) resulted in dramatic sensitization of tumor cells to TRAIL-induced apoptosis, in the absence of effects in normal cells. Sensitization was caspase dependent, and independent of regulation via NF-kappa B. Further, inhibition of phosphorylation by CK2 did not modify the expression level of antiapoptotic proteins. Analysis of TRAIL-induced death-inducing signaling complex ( DISC) formation demonstrated enhanced formation of the DISC, enhanced cleavage of caspase-8 and cleavage of Bid in the presence of DRB, thereby facilitating the release of proapoptotic factors from the mitochondria with subsequent down-regulation of the expression of XIAP and c-IAP1. Further, silencing of CK2 alpha in HT29 cells following transfection of CK2 alpha shRNA abrogated CK2 kinase activity while simultaneously increasing TRAIL sensitivity. These findings demonstrate that CK2 plays a critical antiapoptotic role by conferring resistance to TRAIL at the level of the DISC.	St Jude Childrens Res Hosp, Div Mol Therapeut, Dept Hematol Oncol, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Izeradjene, K (corresponding author), St Jude Childrens Res Hosp, Div Mol Therapeut, Dept Hematol Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA.	izeradjene@stjude.org			NCI NIH HHS [CA 32613, CA 21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA032613, R37CA032613, P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Almasan A, 2003, CYTOKINE GROWTH F R, V14, P337, DOI 10.1016/S1359-6101(03)00029-7; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; Bernard D, 2001, J BIOL CHEM, V276, P27322, DOI 10.1074/jbc.M011183200; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; Ehrhardt H, 2003, ONCOGENE, V22, P3842, DOI 10.1038/sj.onc.1206520; Faust RA, 1999, INT J BIOCHEM CELL B, V31, P941, DOI 10.1016/S1357-2725(99)00050-3; Griffith TS, 1998, J IMMUNOL, V161, P2833; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Guo CH, 2001, J BIOL CHEM, V276, P5992, DOI 10.1074/jbc.M004862200; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Holmstrom TH, 2000, CRIT REV IMMUNOL, V20, P121; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; Jeremias I, 1998, EUR CYTOKINE NETW, V9, P687; Keane MM, 2000, BREAST CANCER RES TR, V64, P211, DOI 10.1023/A:1006458407515; KIKKAWA U, 1992, MOL CELL BIOL, V12, P5711, DOI 10.1128/MCB.12.12.5711; Krippner-Heidenreich A, 2001, BIOCHEM J, V358, P705, DOI 10.1042/0264-6021:3580705; Lacour S, 2003, ONCOGENE, V22, P1807, DOI 10.1038/sj.onc.1206127; Landesman-Bollag E, 2001, ONCOGENE, V20, P3247, DOI 10.1038/sj.onc.1204411; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; Marsters SA, 1996, CURR BIOL, V6, P750, DOI 10.1016/S0960-9822(09)00456-4; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; Persons DA, 1999, BLOOD, V93, P488, DOI 10.1182/blood.V93.2.488.402k17_488_499; Petak I, 2003, CELL DEATH DIFFER, V10, P729, DOI 10.1038/sj.cdd.4401232; Ravi R, 2002, CANCER RES, V62, P4180; Romieu-Mourez R, 2002, CANCER RES, V62, P6770; Ruzzene M, 2002, BIOCHEM J, V364, P41, DOI 10.1042/bj3640041; Sarker M, 2002, ONCOGENE, V21, P4323, DOI 10.1038/sj.onc.1205523; Sarker M, 2001, CELL DEATH DIFFER, V8, P172, DOI 10.1038/sj.cdd.4400791; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Sun XM, 2002, J BIOL CHEM, V277, P11345, DOI 10.1074/jbc.M109893200; Tillman DM, 1998, CELL DEATH DIFFER, V5, P450, DOI 10.1038/sj.cdd.4400369; Trauzold A, 2001, ONCOGENE, V20, P4258, DOI 10.1038/sj.onc.1204559; Varadhachary AS, 2001, J IMMUNOL, V166, P6564, DOI 10.4049/jimmunol.166.11.6564; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Wang HM, 2001, MOL CELL BIOCHEM, V227, P167, DOI 10.1023/A:1013112908734; Xu X, 1999, NAT GENET, V23, P118, DOI 10.1038/12729	43	70	78	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2005	24	12					2050	2058		10.1038/sj.onc.1208397	http://dx.doi.org/10.1038/sj.onc.1208397			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15688023				2022-12-17	WOS:000227681900009
J	Nasr, R; El-Sabban, ME; Karam, JA; Dbaibo, G; Kfoury, Y; Arnulf, B; Lepelletier, Y; Bex, F; de The, H; Hermine, O; Bazarbachi, A				Nasr, R; El-Sabban, ME; Karam, JA; Dbaibo, G; Kfoury, Y; Arnulf, B; Lepelletier, Y; Bex, F; de The, H; Hermine, O; Bazarbachi, A			Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma	ONCOGENE			English	Article						HTLV-I; leukemia; lymphoma; treatment; proteasome inhibitors; PS-341	VIRUS TYPE-I; NF-KAPPA-B; INTERFERON-ALPHA; LEUKEMIA-LYMPHOMA; INDUCED APOPTOSIS; CYCLE ARREST; TAX PROTEIN; ACTIVATION; GROWTH; INDUCTION	HTLV-I associated adult T-cell leukemia (ATL) and HTLV-I-negative peripheral T-cell lymphomas are associated with poor prognosis. Using pharmacological concentrations of the proteasome inhibitor PS-341, we demonstrate inhibition of cell proliferation and induction of apoptosis in fresh ATL cells, HTLV-I transformed and HTLV-I-negative malignant T cells, while normal resting or activated T lymphocytes were resistant. Combination of PS-341 and doxorubicin or etoposide resulted in an additive growth inhibition. In HTLV-I-negative malignant cells, PS-341 treatment significantly downregulated the antiapoptotic protein X-IAP and to a lesser extent c-IAP-1 and bcl-XL and resulted in caspase-dependent apoptosis. In HTLV-I transformed cells, the inhibition of the proteasomal degradation of Tax by PS-341 likely explains the relative protection of HTLV-I infected cells against caspase-dependent apoptosis. PS-341 treatment of these cells stabilized IkappaBalpha, IkappaBbeta, IkappaBepsilon, p21, p27 and p53 proteins and selectively inhibited Rel-A DNA binding NF-kappaB complexes. In both HTLV-I-positive and -negative cells, PS-341 treatment induced ceramide accumulation that correlated with apoptosis. We conclude that PS-341 affects multiple pathways critical for the survival of HTLV-I-positive and -negative malignant T cells supporting a potential therapeutic role for PS-341 in both ATL and HTLV-I-negative T-cell lymphomas, whether alone or in combination with chemotherapy.	Amer Univ Beirut, Fac Med, Dept Internal Med, Beirut, Lebanon; Amer Univ Beirut, Fac Med, Dept Human Morphol, Beirut, Lebanon; Amer Univ Beirut, Fac Med, Dept Pediat, Beirut, Lebanon; Hop Necker Enfants Malad, CNRS, UMR 8603, F-75743 Paris 15, France; Hop Necker Enfants Malad, Dept Hematol, F-75743 Paris 15, France; Free Univ Brussels, Dept Mol Biol, Brussels, Belgium; Com Paris Ligue Canc, Lab Associe, CNRS, UPR 9051, Paris, France	American University of Beirut; American University of Beirut; American University of Beirut; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Hermine, O (corresponding author), Amer Univ Beirut, Fac Med, Dept Internal Med, POB 113-6044, Beirut, Lebanon.	hermine@necker.fr; bazarbac@aub.edu.lb	Dbaibo, Ghassan S./X-2978-2019; lepelletier, yves/AAF-1546-2020; Nasr, Rihab/AAF-1606-2020; Hermine, Olivier/Q-7072-2018; Karam, Jose A/A-9006-2009	lepelletier, yves/0000-0001-7746-5170; Nasr, Rihab/0000-0003-1166-4999; Hermine, Olivier/0000-0003-2574-3874; Bazarbachi, Ali/0000-0002-7171-4997				Adams J, 1999, CANCER RES, V59, P2615; Adams J, 2003, CANCER TREAT REV, V29, P3, DOI 10.1016/S0305-7372(03)00081-1; Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; An WG, 2000, LEUKEMIA, V14, P1276, DOI 10.1038/sj.leu.2401812; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Bangham CRM, 2000, CURR OPIN IMMUNOL, V12, P397, DOI 10.1016/S0952-7915(00)00107-2; Bazarbachi A, 1999, BLOOD, V93, P278, DOI 10.1182/blood.V93.1.278.401k22_278_283; Bazarbachi A, 1996, J ACQ IMMUN DEF SYND, V13, pS186, DOI 10.1097/00042560-199600001-00028; Bazarbachi A, 2001, VIRUS RES, V78, P79, DOI 10.1016/S0168-1702(01)00286-6; Bielawska A, 2001, ANAL BIOCHEM, V298, P141, DOI 10.1006/abio.2001.5342; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; DBAIBO GS, 1995, P NATL ACAD SCI USA, V92, P1347, DOI 10.1073/pnas.92.5.1347; De La Fuente C, 2000, J VIROL, V74, P7270, DOI 10.1128/JVI.74.16.7270-7283.2000; El-Sabban ME, 2000, BLOOD, V96, P2849; Gatto S, 2003, HAEMATOLOGICA, V88, P853; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GILL PS, 1995, NEW ENGL J MED, V332, P1744, DOI 10.1056/NEJM199506293322603; Gisselbrecht C, 1998, BLOOD, V92, P76; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HERMINE O, 1995, NEW ENGL J MED, V332, P1749, DOI 10.1056/NEJM199506293322604; Hermine Olivier, 2002, Hematol J, V3, P276, DOI 10.1038/sj.thj.6200195; Hideshima T, 2003, BLOOD, V101, P1530, DOI 10.1182/blood-2002-08-2543; Huang Y, 2000, CANCER RES, V60, P4426; Ikeda K, 1999, INT J CANCER, V82, P599, DOI 10.1002/(SICI)1097-0215(19990812)82:4<599::AID-IJC21>3.0.CO;2-R; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; KANNO T, 1994, MOL CELL BIOL, V14, P6443, DOI 10.1128/MCB.14.10.6443; Kawakami A, 1999, BLOOD, V94, P3847, DOI 10.1182/blood.V94.11.3847.423a24_3847_3854; Kawata S, 2003, J VIROL, V77, P7291, DOI 10.1128/JVI.77.13.7291-7299.2003; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; Lau A, 1998, BLOOD, V91, P2467, DOI 10.1182/blood.V91.7.2467.2467_2467_2474; Ling YH, 2003, CLIN CANCER RES, V9, P1145; Lomas M, 2002, J GEN VIROL, V83, P641, DOI 10.1099/0022-1317-83-3-641; Ma MH, 2003, CLIN CANCER RES, V9, P1136; Mahieux R, 2000, J VIROL, V74, P6866, DOI 10.1128/JVI.74.15.6866-6874.2000; Mitra-Kaushik S, 2004, BLOOD, V104, P802, DOI 10.1182/blood-2003-11-3967; Nasr R, 2003, BLOOD, V101, P4576, DOI 10.1182/blood-2002-09-2986; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Olson NE, 2003, J IMMUNOL, V170, P6065, DOI 10.4049/jimmunol.170.12.6065; Pham LV, 2003, J IMMUNOL, V171, P88, DOI 10.4049/jimmunol.171.1.88; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; Satou Y, 2004, LEUKEMIA, V18, P1357, DOI 10.1038/sj.leu.2403400; Sayers TJ, 2003, BLOOD, V102, P303, DOI 10.1182/blood-2002-09-2975; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; Sun SC, 2000, AIDS RES HUM RETROV, V16, P1591, DOI 10.1089/08892220050193001; Tamiya S, 1998, BLOOD, V91, P3935; Tan C, 2002, CANCER RES, V62, P1083; WATTEL E, 1995, J VIROL, V69, P2863, DOI 10.1128/JVI.69.5.2863-2868.1995; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Zar JH., 1999, BIOSTATISTICAL ANAL	51	70	73	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					419	430		10.1038/sj.onc.1208212	http://dx.doi.org/10.1038/sj.onc.1208212			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15543232				2022-12-17	WOS:000226279700013
J	Yoon, T; Chakrabortty, A; Franks, R; Valli, T; Kiyokawa, H; Raychaudhuri, P				Yoon, T; Chakrabortty, A; Franks, R; Valli, T; Kiyokawa, H; Raychaudhuri, P			Tumor-prone phenotype of the DDB2-deficient mice	ONCOGENE			English	Article						DDB2; DNA repair; XP-E; UV-induced tumor; DDB2 knockout mice	DNA-BINDING-PROTEIN; PIGMENTOSUM GROUP-E; NUCLEOTIDE EXCISION-REPAIR; GLOBAL GENOMIC REPAIR; GROUP-E CELLS; XERODERMA-PIGMENTOSUM; DAMAGED-DNA; UBIQUITIN LIGASE; UV-IRRADIATION; ULTRAVIOLET-B	DDB2 is an essential subunit of the damaged-DNA recognition factor DDB, which is involved in global genomic repair in human cells. Moreover, DDB2 is mutated in the repair-deficiency disease xeroderma pigmentosum ( Group E). Expression of DDB2 in human cells is induced by P53, BRCA1 and by ionizing radiation. The DDB2 protein associates with transcriptional activator and coactivator proteins. In addition, DDB2 in conjunction with DDB1 associates with cullin 4A and the Cop9/signalosome. We generated a mouse strain deficient for DDB2 (DDB2-/-). Consistent with the human disease (XP-E), the DDB2-/- mice were susceptible to UV-induced skin carcinogenesis. We observed a significant difference in the initial rate of cyclobutane pyrimidine dimer (CPD)-removal from the skin following UV irradiation. Also, the DDB2-deficient mice exhibited a significantly reduced life span compared to their wild-type littermates. Moreover, unlike other XP-deficient mice, the DDB2-deficient mice developed spontaneous malignant tumors at a high rate between the ages of 20 and 25 months. The observations suggest that, in addition to DNA repair, the other interactions of DDB2 are significant in its tumor suppression function.	Univ Illinois, Dept Biochem & Mol Genet MC 669, Chicago, IL 60607 USA; Univ Illinois, Coll Vet Med, Urbana, IL 61802 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Urbana-Champaign	Raychaudhuri, P (corresponding author), Univ Illinois, Dept Biochem & Mol Genet MC 669, 900 S Ashland Ave, Chicago, IL 60607 USA.	pradip@uic.edu		Kiyokawa, Hiroaki/0000-0002-7942-6455	NATIONAL CANCER INSTITUTE [R01CA077637, R01CA100204, R01CA088863] Funding Source: NIH RePORTER; NCI NIH HHS [CA 88863, R01 CA088863, 1R01CA100204, R01 CA100204, R01 CA088863-05, R01 CA077637, CA 77637, R01 CA077637-06A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMIC M, 1991, J BIOL CHEM, V266, P22439; Chen XA, 2001, J BIOL CHEM, V276, P48175, DOI 10.1074/jbc.M106808200; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; Cleaver JE, 1999, HUM MUTAT, V14, P9, DOI 10.1002/(SICI)1098-1004(1999)14:1<9::AID-HUMU2>3.3.CO;2-Y; Datta A, 2001, MUTAT RES-DNA REPAIR, V486, P89, DOI 10.1016/S0921-8777(01)00082-9; DEVRIES A, 1995, NATURE, V377, P169, DOI 10.1038/377169a0; Friedberg E.C., 2016, DNA REPAIR MUTAGENES, V33, P35; Fujiwara Y, 1999, J BIOL CHEM, V274, P20027, DOI 10.1074/jbc.274.28.20027; Groisman R, 2003, CELL, V113, P357, DOI 10.1016/S0092-8674(03)00316-7; Hartman AR, 2002, NAT GENET, V32, P180, DOI 10.1038/ng953; Hayes S, 1998, MOL CELL BIOL, V18, P240, DOI 10.1128/MCB.18.1.240; HWANG BJ, 1993, BIOCHEMISTRY-US, V32, P1657, DOI 10.1021/bi00057a033; Hwang BJ, 1998, MOL CELL BIOL, V18, P4391, DOI 10.1128/MCB.18.7.4391; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Inoki T, 2004, BIOCHEM BIOPH RES CO, V314, P1036, DOI 10.1016/j.bbrc.2004.01.003; Itoh T, 2004, P NATL ACAD SCI USA, V101, P2052, DOI 10.1073/pnas.0306551101; Itoh T, 2003, MOL CELL BIOL, V23, P7540, DOI 10.1128/MCB.23.21.7540-7553.2003; Itoh T, 2000, J INVEST DERMATOL, V114, P1022, DOI 10.1046/j.1523-1747.2000.00952.x; IWAO K, 1999, NUCL ACIDS S SER, V42, P207; Kazantsev A, 1996, P NATL ACAD SCI USA, V93, P5014, DOI 10.1073/pnas.93.10.5014; KEENEY S, 1993, J BIOL CHEM, V268, P21293; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Lin GY, 2000, J VIROL, V74, P9152, DOI 10.1128/JVI.74.19.9152-9166.2000; Lu YP, 1999, CANCER RES, V59, P4591; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; Nag A, 2001, J VIROL, V75, P10383, DOI 10.1128/JVI.75.21.10383-10392.2001; Nag A, 2001, MOL CELL BIOL, V21, P6738, DOI 10.1128/MCB.21.20.6738-6747.2001; NAKANE H, 1995, NATURE, V377, P165, DOI 10.1038/377165a0; Nichols AF, 2000, J BIOL CHEM, V275, P21422, DOI 10.1074/jbc.M000960200; Nichols AF, 1996, J BIOL CHEM, V271, P24317, DOI 10.1074/jbc.271.40.24317; REARDON JT, 1993, J BIOL CHEM, V268, P21301; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SANDS AT, 1995, NATURE, V377, P162, DOI 10.1038/377162a0; Shiyanov P, 1999, J BIOL CHEM, V274, P35309, DOI 10.1074/jbc.274.50.35309; Takimoto R, 2002, CANCER BIOL THER, V1, P177, DOI 10.4161/cbt.65; Tang JY, 2000, MOL CELL, V5, P737, DOI 10.1016/S1097-2765(00)80252-X; Tini M, 2002, MOL CELL, V9, P265, DOI 10.1016/S1097-2765(02)00453-7; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Ulane CM, 2002, VIROLOGY, V304, P160, DOI 10.1006/viro.2002.1773; Wakasugi M, 2002, J BIOL CHEM, V277, P1637, DOI 10.1074/jbc.C100610200; Wertz IE, 2004, SCIENCE, V303, P1371, DOI 10.1126/science.1093549; Wijnhoven SWP, 2000, ONCOGENE, V19, P5034, DOI 10.1038/sj.onc.1203844; Zolezzi F, 2000, GENE, V245, P151, DOI 10.1016/S0378-1119(00)00022-6	43	70	73	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					469	478		10.1038/sj.onc.1208211	http://dx.doi.org/10.1038/sj.onc.1208211			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15558025	Green Accepted			2022-12-17	WOS:000226279700017
J	Rodriguez-Gonzalez, A; de Molina, AR; Fernandez, F; Lacal, JC				Rodriguez-Gonzalez, A; de Molina, AR; Fernandez, F; Lacal, JC			Choline kinase inhibition induces the increase in ceramides resulting in a highly specific and selective cytotoxic antitumoral strategy as a potential mechanism of action	ONCOGENE			English	Article						choline kinase; drug design; MN58b; apoptosis; cell cycle arrest; phospholipid metabolism	HAMSTER OVARY CELLS; CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; EPIDERMAL-GROWTH-FACTOR; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; SIGNAL-TRANSDUCTION; CDP-CHOLINE; GLUTATHIONE-PEROXIDASE; INDUCED APOPTOSIS; IN-VIVO; PHOSPHATIDYLETHANOLAMINE	Choline kinase (ChoK, E. C. 2.7.1.32) is involved in the synthesis of phosphatidylcholine ( PC), and has been found to be increased in human tumors and tumor-derived cell lines. Furthermore, ChoK inhibitors have been reported to show a potent and selective antitumoral activity both in vitro and in vivo. Here, we provide the basis for a rational understanding of the antitumoral activity of ChoK inhibitors. In normal cells, blockage of de novo phosphorylcholine (PCho) synthesis by inhibition of ChoK promotes the dephosphorylation of pRb, resulting in a reversible cell cycle arrest at G0/G1 phase. In contrast, ChoK inhibition in tumor cells renders cells unable to arrest in G0/G1 as manifested by a lack of pRb dephosphorylation. Furthermore, tumor cells specifically suffer a drastic wobble in the metabolism of main membrane lipids PC and sphingomyelin (SM). This lipid disruption results in the enlargement of the intracellular levels of ceramides. As a consequence, normal cells remain unaffected, but tumor cells are promoted to apoptosis. Thus, we provide in this study the rationale for the potential clinical use of ChoK inhibitors.	CSIC, Inst Invest Biomed, Dept Mol & Cellular Biol Canc, Translat Oncol Unit, E-28029 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Lacal, JC (corresponding author), CSIC, Inst Invest Biomed, Dept Mol & Cellular Biol Canc, Translat Oncol Unit, Arturo Duperier 4, E-28029 Madrid, Spain.	jclacal@iib.uam.es	Lacal, Juan Carlos/AAL-2235-2020; de Molina, Ana Ramirez/AAA-3848-2019; Lacal, Juan Carlos/N-9064-2015	Lacal, Juan Carlos/0000-0002-1908-2777				BIELAWSKA A, 1992, FEBS LETT, V307, P211, DOI 10.1016/0014-5793(92)80769-D; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; Brennan P, 1999, MOL CELL BIOL, V19, P4729; Brindley DN, 1996, BIOCHEM CELL BIOL, V74, P469, DOI 10.1139/o96-051; Cui Z, 1996, J BIOL CHEM, V271, P14668, DOI 10.1074/jbc.271.25.14668; Cui Z, 2002, BBA-MOL CELL BIOL L, V1585, P87, DOI 10.1016/S1388-1981(02)00328-1; Davies SMA, 2001, BIOCHEMISTRY-US, V40, P10522, DOI 10.1021/bi010904c; DBAIBO GS, 1995, P NATL ACAD SCI USA, V92, P1347, DOI 10.1073/pnas.92.5.1347; DeLong CJ, 1999, J BIOL CHEM, V274, P29683, DOI 10.1074/jbc.274.42.29683; DEMOLINA AR, IN PRESS CANC RES; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; ESKO JD, 1982, P NATL ACAD SCI-BIOL, V79, P1698, DOI 10.1073/pnas.79.6.1698; ESKO JD, 1981, J BIOL CHEM, V256, P7388; Fernandez-Tome MD, 2002, BBA-MOL CELL BIOL L, V1583, P185, DOI 10.1016/S1388-1981(02)00208-1; Finney RE, 2000, CANCER RES, V60, P5204; Flores I, 1999, J IMMUNOL, V163, P708; Flores I, 1998, J IMMUNOL, V160, P3528; Foster DA, 2003, MOL CANCER RES, V1, P789; Golfman LS, 2001, J BIOL CHEM, V276, P43688, DOI 10.1074/jbc.M108170200; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Henneberry AL, 1999, BIOCHEM J, V339, P291, DOI 10.1042/0264-6021:3390291; Hernandez-Alcoceba R, 1999, CANCER RES, V59, P3112; HernandezAlcoceba R, 1997, ONCOGENE, V15, P2289, DOI 10.1038/sj.onc.1201414; HolmesMcNary MQ, 1997, DEV BRAIN RES, V101, P9, DOI 10.1016/S0165-3806(97)00044-8; HOUWELING M, 1995, J BIOL CHEM, V270, P16277, DOI 10.1074/jbc.270.27.16277; HUDSON JM, 1995, DNA CELL BIOL, V14, P759, DOI 10.1089/dna.1995.14.759; Hundertmark S, 1999, HORM METAB RES, V31, P8, DOI 10.1055/s-2007-978688; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; JARVIS WD, 1994, J BIOL CHEM, V269, P31685; JIMENEZ B, 1995, J CELL BIOCHEM, V57, P141, DOI 10.1002/jcb.240570114; Kim KH, 1999, J BIOL CHEM, V274, P9531, DOI 10.1074/jbc.274.14.9531; Kolesnick R, 2002, J CLIN INVEST, V110, P3, DOI 10.1172/JCI200216127; KUGE O, 1986, J BIOL CHEM, V261, P5795; Lacal J C, 2001, IDrugs, V4, P419; Lacal JC, 1997, FEBS LETT, V410, P73, DOI 10.1016/S0014-5793(97)00444-4; Lykidis A, 2001, PROG NUCLEIC ACID RE, V65, P361; MAN AS, 1994, LIPIDS, V29, P15, DOI 10.1007/BF02537085; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Ostrander DB, 2001, J BIOL CHEM, V276, P38061; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V779, P217, DOI 10.1016/0304-4157(84)90010-8; Rodriguez-Gonzalez A, 2003, ONCOGENE, V22, P8803, DOI 10.1038/sj.onc.1207062; RUIZRUIZ CAL, 2002, BIOCHEM J, P825; Ruvolo PP, 2003, PHARMACOL RES, V47, P383, DOI 10.1016/S1043-6618(03)00050-1; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sillence DJ, 1998, BIOCHEM J, V331, P251, DOI 10.1042/bj3310251; Spiegel S, 2002, LEUKEMIA, V16, P1596, DOI 10.1038/sj.leu.2402611; TAKAHASHI K, 1987, ARCH BIOCHEM BIOPHYS, V256, P677, DOI 10.1016/0003-9861(87)90624-2; Tsukiyama T, 2001, J IMMUNOL, V166, P304, DOI 10.4049/jimmunol.166.1.304; UCHIDA T, 1994, J BIOCHEM-TOKYO, V116, P508, DOI 10.1093/oxfordjournals.jbchem.a124554; Uchida T, 1996, BBA-LIPID LIPID MET, V1304, P89, DOI 10.1016/S0005-2760(96)00109-9; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; Vance DE, 1997, BBA-LIPID LIPID MET, V1348, P142, DOI 10.1016/S0005-2760(97)00108-2; Wang XD, 2001, GENE DEV, V15, P2922; WARDEN CH, 1985, J BIOL CHEM, V260, P6006; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINHOLD PA, 1989, BIOCHIM BIOPHYS ACTA, V1006, P299, DOI 10.1016/0005-2760(89)90017-9; Wieder T, 1998, J BIOL CHEM, V273, P11025, DOI 10.1074/jbc.273.18.11025; WIEPRECHT M, 1994, BIOCHEM J, V297, P241, DOI 10.1042/bj2970241; WITTENBERG J, 1953, J BIOL CHEM, V202, P431; Yen CLE, 1999, FASEB J, V13, P135, DOI 10.1096/fasebj.13.1.135; Yen CLE, 2001, FASEB J, V15, P1704, DOI 10.1096/fj.00-0800com; ZEISEL SH, 1993, FASEB J, V7, P551, DOI 10.1096/fasebj.7.6.8472893; ZEISEL SH, 1991, FASEB J, V5, P2093, DOI 10.1096/fasebj.5.7.2010061	66	70	75	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2004	23	50					8247	8259		10.1038/sj.onc.1208045	http://dx.doi.org/10.1038/sj.onc.1208045			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	866CC	15378008				2022-12-17	WOS:000224749500007
J	Poole, AJ; Heap, D; Carroll, RE; Tyner, AL				Poole, AJ; Heap, D; Carroll, RE; Tyner, AL			Tumor suppressor functions for the Cdk inhibitor p21 in the mouse colon	ONCOGENE			English	Article						p21; Waf1; azoxymethane; aberrant crypt foci; colon	ABERRANT CRYPT FOCI; CELL-CYCLE; COLORECTAL-CANCER; INDUCED APOPTOSIS; GENE-TRANSFER; LARGE-BOWEL; DNA-DAMAGE; P21(WAF1/CIP1); CARCINOMA; MICE	The Cdk inhibitor p21 regulates p53-mediated growth arrest following DNA damage. It is expressed during epithelial differentiation in a variety of organs including colon. We investigated susceptibility of p21-deficient mice to the colon carcinogen azoxymethane (AOM). After AOM injections, rodents develop putative premalignant lesions called aberrant crypt foci (ACF) that are localized to the distal three centimeters of the colon. p21-deficient mice developed significantly higher numbers of ACF than wild-type mice in response to AOM, and these were not restricted to distal colon. After AOM treatment, increased numbers of lymphoid aggregates were detected in p21-deficient colon. Proliferation was similar in wild type and p21-deficient colon before and after AOM injection, but AOM-induced apoptosis was detected only in wild-type crypt epithelial cells, and not in the p21-deficient colon. The proapoptotic function uncovered for p21 was unexpected, because p21 acts as an inhibitor of apoptosis in many systems, and is not required for p53-dependent apoptosis. Enhanced formation of ACF in p21-deficient mice supports a tumor suppressor function for p21 in the colon. Reduced apoptosis of colon epithelial cells with deleterious mutations may be an initiating event in the formation of ACF, with inflammatory cell cytokine expression contributing to their further expansion.	Univ Illinois, Coll Med, Dept Biochem & Mol Genet, Chicago, IL 60607 USA; Univ Illinois, Dept Med, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Tyner, AL (corresponding author), Univ Illinois, Coll Med, Dept Biochem & Mol Genet, M-C 669,900 S Ashland Ave, Chicago, IL 60607 USA.	atyner@uic.edu		Tyner, Angela/0000-0001-7448-8625	NATIONAL CANCER INSTITUTE [K08CA080360] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056283] Funding Source: NIH RePORTER; NCI NIH HHS [CA-80360] Funding Source: Medline; NIDDK NIH HHS [R01 DK056283, DK56283, R01 DK056283-05, DK07788] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Balomenos D, 2000, NAT MED, V6, P171, DOI 10.1038/72272; BIRD RP, 1989, CANCER SURV, V8, P189; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CARTER JW, 1994, CANCER RES, V54, P4304; Cheng JD, 1999, CLIN CANCER RES, V5, P1057; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; FEINBERG A, 1980, CANCER RES, V40, P4446; Gartel AL, 2002, MOL CANCER THER, V1, P639; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gartel AL, 1996, EXP CELL RES, V227, P171, DOI 10.1006/excr.1996.0264; Goke R, 2001, DIGESTION, V64, P75, DOI 10.1159/000048843; Hingorani R, 2000, J IMMUNOL, V164, P4032, DOI 10.4049/jimmunol.164.8.4032; Hirose Y, 1996, JPN J CANCER RES, V87, P575, DOI 10.1111/j.1349-7006.1996.tb00262.x; Jackson RJ, 2003, CANCER RES, V63, P3021; Kadowaki Y, 1999, CLIN CANCER RES, V5, P4233; Kang KH, 1999, EXP CELL RES, V253, P403, DOI 10.1006/excr.1999.4644; Kwon YH, 2003, J BIOL CHEM, V278, P30348, DOI 10.1074/jbc.M300996200; Kwon YH, 2002, J BIOL CHEM, V277, P41417, DOI 10.1074/jbc.M203388200; Lincet H, 2000, CANCER LETT, V161, P17, DOI 10.1016/S0304-3835(00)00586-3; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Martin-Caballero J, 2001, CANCER RES, V61, P6234; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Paulsen JE, 2001, CANCER RES, V61, P5010; Philipp J, 1999, ONCOGENE, V18, P4689, DOI 10.1038/sj.onc.1202840; POTTEN CS, 1992, CARCINOGENESIS, V13, P2305, DOI 10.1093/carcin/13.12.2305; Rhodes JM, 2002, TRENDS MOL MED, V8, P10, DOI 10.1016/S1471-4914(01)02194-3; Rothenberg ME, 2001, IMMUNOL REV, V179, P139, DOI 10.1034/j.1600-065X.2001.790114.x; SHEIKH MS, 1995, ONCOGENE, V11, P1899; Takayama T, 1998, NEW ENGL J MED, V339, P1277, DOI 10.1056/NEJM199810293391803; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; Tsao YP, 1999, J VIROL, V73, P4983, DOI 10.1128/JVI.73.6.4983-4990.1999; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Wataru AA, 2003, TOXICOL LETT, V144, P213, DOI 10.1016/S0378-4274(03)00221-2; Yang JM, 2001, J BIOL CHEM, V276, P47828, DOI 10.1074/jbc.M106103200	39	70	73	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2004	23	49					8128	8134		10.1038/sj.onc.1207994	http://dx.doi.org/10.1038/sj.onc.1207994			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865HE	15377995				2022-12-17	WOS:000224692500010
J	Bell, DR; Van Zant, G				Bell, DR; Van Zant, G			Stem cells, aging, and cancer: inevitabilities and outcomes	ONCOGENE			English	Review						stem cell; aging; leukemia; self-renewal; AML	ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; GENETIC-CONTROL; IN-VIVO; SERIAL TRANSPLANTATION; HEMATOPOIETIC-CELLS; FLT3 MUTATIONS; BLAST CRISIS; FUSION GENE	Given the unique abilities of a stem cell to self-renew, differentiate, and proliferate, it is no wonder that they are critically important to an organism during development and to maintain homeostasis. Likewise, when something goes awry within a stem cell, it is likely to have far-reaching effects, since stem cells persist throughout the lifetime of the individual. Two significant biological phenomena that involve stem cells are the inevitable process of aging and a major health issue whose incidence increases with aging: cancer. In this review, we summarize evidence and theories concerning these two stem cell processes. The inability of stem cells to be passaged indefinitely in mice and the data supporting regular replication of the quiescent stem cell pool are discussed. Further, the current evidence indicating a stem cell origin of acute myeloid leukemia, including examples from both experimental mouse models and human clinical samples, is evaluated. Finally, we propose a model in which aging of the stem cell population of the hematopoietic system in particular can create conditions that are permissive to leukemia development; in fact, we suggest that aging is a secondary event in leukemogenesis.	Univ Kentucky, Dept Internal Med, Markey Canc Ctr, Lexington, KY 40536 USA; Univ Kentucky, Markey Canc Ctr, Dept Physiol, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Van Zant, G (corresponding author), Univ Kentucky, Dept Internal Med, Markey Canc Ctr, 800 Rose St,Rm CC 414, Lexington, KY 40536 USA.	gvzant1@uky.edu			NATIONAL INSTITUTE ON AGING [R01AG022859, R01AG016653, R01AG020917] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG016653, R01 AG20917, R01 AG022859] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Allsopp RC, 2003, BLOOD, V102, P517, DOI 10.1182/blood-2002-07-2334; Allsopp RC, 2001, J EXP MED, V193, P917, DOI 10.1084/jem.193.8.917; Antonchuk J, 2002, CELL, V109, P39, DOI 10.1016/S0092-8674(02)00697-9; Balducci L, 2003, J AM GERIATR SOC, V51, pS2; BIOLA O, 2003, NAT REV GENET, V4, P911; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; BOTNICK LE, 1982, BLOOD, V60, P268; Bradford GB, 1997, EXP HEMATOL, V25, P445; Brendel C, 2000, LEUKEMIA, V14, P1711, DOI 10.1038/sj.leu.2401907; Care RS, 2003, BRIT J HAEMATOL, V121, P775, DOI 10.1046/j.1365-2141.2003.04362.x; Cesari M, 2004, J GERONTOL A-BIOL, V59, P249; Chen JC, 2000, EXP HEMATOL, V28, P442, DOI 10.1016/S0301-472X(99)00157-5; Chen JC, 2000, BLOOD, V96, P4124; Cheshier SP, 1999, P NATL ACAD SCI USA, V96, P3120, DOI 10.1073/pnas.96.6.3120; Clarke DL, 2000, SCIENCE, V288, P1660, DOI 10.1126/science.288.5471.1660; CLAXTON DF, 1994, BLOOD, V83, P1750; Counter CM, 1996, MUTAT RES-REV GENET, V366, P45, DOI 10.1016/S0165-1110(96)90006-8; Dash A, 2001, BEST PRACT RES CL HA, V14, P49, DOI 10.1053/beha.2000.0115; Dash AB, 2002, P NATL ACAD SCI USA, V99, P7622, DOI 10.1073/pnas.102583199; de Haan G, 2000, BLOOD, V96, P1374, DOI 10.1182/blood.V96.4.1374.h8001374_1374_1379; De Haan G, 1999, FASEB J, V13, P707, DOI 10.1096/fasebj.13.6.707; de Haan G, 1999, BLOOD, V93, P3294, DOI 10.1182/blood.V93.10.3294.410k07_3294_3301; Deguchi K, 2002, LEUKEMIA, V16, P740, DOI 10.1038/sj.leu.2402500; deHaan G, 1997, BLOOD, V89, P1543, DOI 10.1182/blood.V89.5.1543.1543_1543_1550; deHaan G, 1997, J EXP MED, V186, P529, DOI 10.1084/jem.186.4.529; DePinho RA, 2000, NATURE, V408, P248, DOI 10.1038/35041694; Ershler WB, 2003, J AM GERIATR SOC, V51, pS18; Ford AM, 1998, P NATL ACAD SCI USA, V95, P4584, DOI 10.1073/pnas.95.8.4584; Geiger H, 2004, EXP HEMATOL, V32, P60, DOI 10.1016/j.exphem.2003.09.015; Geiger H, 2002, NAT IMMUNOL, V3, P329, DOI 10.1038/ni0402-329; Geiger H, 2001, BLOOD, V98, P2966, DOI 10.1182/blood.V98.10.2966; Giles RH, 1997, LEUKEMIA, V11, P2087, DOI 10.1038/sj.leu.2400882; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Guzman Monica L, 2004, Cancer Control, V11, P97; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARRISON DE, 1973, P NATL ACAD SCI USA, V70, P3184, DOI 10.1073/pnas.70.11.3184; HARRISON DE, 1987, BLOOD, V69, P773; Hawke TJ, 2001, J APPL PHYSIOL, V91, P534, DOI 10.1152/jappl.2001.91.2.534; Iscove NN, 1997, CURR BIOL, V7, P805, DOI 10.1016/S0960-9822(06)00341-1; Jordan CT, 2002, LEUKEMIA, V16, P559, DOI 10.1038/sj.leu.2402446; KAY HEM, 1965, LANCET, V2, P418; Kim M, 2003, ANN NY ACAD SCI, V996, P195, DOI 10.1111/j.1749-6632.2003.tb03247.x; KROSL J, 2003, BLOOD, V102, P130; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Liang Y, 2003, CURR OPIN HEMATOL, V10, P195, DOI 10.1097/00062752-200305000-00001; LIPSCHITZ DA, 1981, AM J HEMATOL, V11, P47, DOI 10.1002/ajh.2830110106; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Liu Y, 2000, CURR BIOL, V10, P1459, DOI 10.1016/S0960-9822(00)00805-8; Lowenberg B, 1999, NEW ENGL J MED, V341, P1051, DOI 10.1056/NEJM199909303411407; Marley SB, 1999, BRIT J HAEMATOL, V106, P162; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; MIRRO J, 1992, LEUKEMIA, V6, P13; Miyamoto T, 2000, P NATL ACAD SCI USA, V97, P7521, DOI 10.1073/pnas.97.13.7521; Mizuki M, 2000, BLOOD, V96, P3907, DOI 10.1182/blood.V96.12.3907; Morrison SJ, 2002, J IMMUNOL, V168, P635, DOI 10.4049/jimmunol.168.2.635; MullerSieburg CE, 1996, J EXP MED, V183, P1141, DOI 10.1084/jem.183.3.1141; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; *NCI, 2000, SEER CANC STAT REV, P1975; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Penninx BWJH, 2003, AM J MED, V115, P104, DOI 10.1016/S0002-9343(03)00263-8; PIETRZYK ME, 1985, BLOOD, V66, P1460; Pineault N, 2003, BLOOD, V101, P4529, DOI 10.1182/blood-2002-08-2484; Raza-Egilmez SZ, 1998, CANCER RES, V58, P4269; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Rothstein G, 2003, J AM GERIATR SOC, V51, pS22; Rowley JD, 1997, BLOOD, V90, P535; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; SIMINOVITCH L, 1964, J CELL COMPAR PHYSL, V64, P23, DOI 10.1002/jcp.1030640104; Taki T, 1997, BLOOD, V89, P3945, DOI 10.1182/blood.V89.11.3945; THIRMAN MJ, 1993, NEW ENGL J MED, V329, P909, DOI 10.1056/NEJM199309233291302; THIRMAN MJ, 1994, P NATL ACAD SCI USA, V91, P12110, DOI 10.1073/pnas.91.25.12110; Thorsteinsdottir U, 2002, BLOOD, V99, P121, DOI 10.1182/blood.V99.1.121; Toma JG, 2001, NAT CELL BIOL, V3, P778, DOI 10.1038/ncb0901-778; Tse KF, 2000, LEUKEMIA, V14, P1766, DOI 10.1038/sj.leu.2401905; Van Zant G, 2003, EXP HEMATOL, V31, P659, DOI 10.1016/S0301-472X(03)00088-2; Van Zant G, 2003, INT J HEMATOL, V77, P29, DOI 10.1007/BF02982600; VANZANT G, 1983, CELL, V35, P639, DOI 10.1016/0092-8674(83)90096-X; VANZANT G, 1990, J EXP MED, V171, P1547, DOI 10.1084/jem.171.5.1547; VAZIRI H, 1994, P NATL ACAD SCI USA, V91, P9857, DOI 10.1073/pnas.91.21.9857; Vessey CJ, 2001, PATHOLOGY, V33, P130; Vicario-Abejon C, 2000, EUR J NEUROSCI, V12, P677, DOI 10.1046/j.1460-9568.2000.00953.x; Wang JCY, 1998, BLOOD, V91, P2406, DOI 10.1182/blood.V91.7.2406.2406_2406_2414; Weissman IL, 2000, CELL, V100, P157, DOI 10.1016/S0092-8674(00)81692-X; Wiemels JL, 1999, BLOOD, V94, P1057, DOI 10.1182/blood.V94.3.1057.415k10_1057_1062; Wiemels JL, 1999, LANCET, V354, P1499, DOI 10.1016/S0140-6736(99)09403-9; Yamamoto K, 2000, BRIT J HAEMATOL, V109, P423, DOI 10.1046/j.1365-2141.2000.02003.x	89	70	79	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2004	23	43					7290	7296		10.1038/sj.onc.1207949	http://dx.doi.org/10.1038/sj.onc.1207949			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	855TZ	15378089				2022-12-17	WOS:000223998800015
J	Davies, GC; Ettenberg, SA; Coats, AO; Mussante, M; Ravichandran, S; Collins, J; Nau, MM; Lipkowitz, S				Davies, GC; Ettenberg, SA; Coats, AO; Mussante, M; Ravichandran, S; Collins, J; Nau, MM; Lipkowitz, S			Cbl-b interacts with ubiquitinated proteins; differential functions of the UBA domains of c-Cbl and Cbl-b	ONCOGENE			English	Article						Cbl proteins; ubiquitin associated (UBA) domain; ubiquitin	GROWTH-FACTOR RECEPTOR; DAMAGE-INDUCIBLE PROTEINS; T-CELL-ACTIVATION; CUE DOMAIN; TYROSINE PHOSPHORYLATION; BINDING-PROTEIN; RING FINGER; HIV-1 VPR; V-CBL; PROTEASOME	Cbl proteins are ubiquitin protein ligases, which ubiquitinate activated tyrosine kinases and target them for degradation. Both c-Cbl and Cbl-b have an ubiquitin associated (UBA) domain at their C-terminal end. We observed that high molecular weight ubiquitinated proteins constitutively coimmunoprecipitated with transfected and endogenous Cbl-b, but not c-Cbl. The binding site for these ubiquitinated proteins was mapped to the UBA domain of Cbl-b (UBAb). GST-fusion proteins containing the UBAb interacted with ubiquitinated proteins and polyubiquitin chains in vitro, whereas those containing the UBA domain of c-Cbl (UBA(c)) did not. The UBAb had a much greater affinity for polyubiquitin chains than for monoubiquitin. Analysis of the UBA(b) and UBA(c) demonstrate that the affinity for ubiquitin is determined by multiple amino-acid differences between the two domains. Overexpression of the UBA(b), but not overexpression of the UBA(c), inhibited a variety of ubiquitin-mediated processes such as degradation of ubiquitinated proteins (i.e. EGFR, Mdm-2, and Siah-1). This in vivo result is consistent with the differences in ubiquitin binding observed in vitro between the UBA(b) and UBA(c). This difference in ubiquitin-binding may reflect distinct regulatory functions of c-Cbl and Cbl-b.	NCI, Cellular & Mol Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; NCI, Adv Biomed Comp Ctr, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lipkowitz, S (corresponding author), NCI, Cellular & Mol Biol Lab, Ctr Canc Res, NIH, Bldg 37,Rm 2066, Bethesda, MD 20892 USA.	lipkowitz@nih.gov			NATIONAL CANCER INSTITUTE [ZIASC007263, Z01SC007263] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguilar RC, 2003, J BIOL CHEM, V278, P10737, DOI 10.1074/jbc.M211622200; Bachmaier K, 2000, NATURE, V403, P211, DOI 10.1038/35003228; Bartkiewicz M, 1999, J BIOL CHEM, V274, P30887, DOI 10.1074/jbc.274.43.30887; Bertolaet BL, 2001, NAT STRUCT BIOL, V8, P417, DOI 10.1038/87575; Bertolaet BL, 2001, J MOL BIOL, V313, P955, DOI 10.1006/jmbi.2001.5105; BLAKE TJ, 1992, ONCOGENE, V7, P757; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Chen L, 2001, EMBO REP, V2, P933, DOI 10.1093/embo-reports/kve203; Chen L, 2002, MOL CELL BIOL, V22, P4902, DOI 10.1128/MCB.22.13.4902-4913.2002; Chiang YPJ, 2000, NATURE, V403, P216, DOI 10.1038/35003235; Chim N, 2004, PROTEINS, V54, P784, DOI 10.1002/prot.10636; Ciani B, 2003, J BIOL CHEM, V278, P37409, DOI 10.1074/jbc.M307416200; Davies BA, 2003, J BIOL CHEM, V278, P19826, DOI 10.1074/jbc.M301059200; Dieckmann T, 1998, NAT STRUCT BIOL, V5, P1042, DOI 10.1038/4220; Ettenberg S A, 1999, Mol Cell Biol Res Commun, V2, P111, DOI 10.1006/mcbr.1999.0157; Ettenberg SA, 1999, ONCOGENE, V18, P1855, DOI 10.1038/sj.onc.1202499; Ettenberg SA, 2001, J BIOL CHEM, V276, P27677, DOI 10.1074/jbc.M102641200; Funakoshi M, 2002, P NATL ACAD SCI USA, V99, P745, DOI 10.1073/pnas.012585199; Hofmann K, 1996, TRENDS BIOCHEM SCI, V21, P172, DOI 10.1016/S0968-0004(96)30015-7; HOU D, 1994, J BIOL CHEM, V269, P14244; Hu G, 1999, MOL CELL BIOL, V19, P724; Jaroszewski L, 1998, PROTEIN SCI, V7, P1431; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kang RS, 2003, CELL, V113, P621, DOI 10.1016/S0092-8674(03)00362-3; Keane MM, 1999, ONCOGENE, V18, P3365, DOI 10.1038/sj.onc.1202753; KEANE MM, 1995, ONCOGENE, V10, P2367; Kim M, 2004, ONCOGENE, V23, P1645, DOI 10.1038/sj.onc.1207298; Kleijnen MF, 2003, MOL BIOL CELL, V14, P3868, DOI 10.1091/mbc.E02-11-0766; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lill NL, 2000, J BIOL CHEM, V275, P367, DOI 10.1074/jbc.275.1.367; Liu J, 2003, J BIOL CHEM, V278, P36754, DOI 10.1074/jbc.M300664200; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; Madura K, 2002, CELL CYCLE, V1, P233, DOI 10.4161/cc.1.4.130; Magnifico A, 2003, J BIOL CHEM, V278, P43169, DOI 10.1074/jbc.M308009200; Meyer HH, 2002, EMBO J, V21, P5645, DOI 10.1093/emboj/cdf579; Mueller TD, 2004, J BIOL CHEM, V279, P11926, DOI 10.1074/jbc.M312865200; Mueller TD, 2002, J MOL BIOL, V319, P1243, DOI 10.1016/S0022-2836(02)00302-9; Naramura M, 1998, P NATL ACAD SCI USA, V95, P15547, DOI 10.1073/pnas.95.26.15547; Nau MM, 2003, GENE, V308, P103, DOI 10.1016/S0378-1119(03)00471-2; Prag G, 2003, CELL, V113, P609, DOI 10.1016/S0092-8674(03)00364-7; Raasi S, 2003, J BIOL CHEM, V278, P8951, DOI 10.1074/jbc.M212841200; Rao H, 2002, J BIOL CHEM, V277, P11691, DOI 10.1074/jbc.M200245200; Ryu KS, 2003, J BIOL CHEM, V278, P36621, DOI 10.1074/jbc.M304628200; Saito T, 2002, J BIOL CHEM, V277, P33624, DOI 10.1074/jbc.M201909200; Schnell JD, 2003, J BIOL CHEM, V278, P35857, DOI 10.1074/jbc.R300018200; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Shih SC, 2003, EMBO J, V22, P1273, DOI 10.1093/emboj/cdg140; Tanaka T, 2003, J BIOL CHEM, V278, P32905, DOI 10.1074/jbc.M212057200; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Wang QH, 2003, BIOCHEMISTRY-US, V42, P13529, DOI 10.1021/bi035391j; Waterman H, 1999, EMBO J, V18, P3348, DOI 10.1093/emboj/18.12.3348; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939; Withers-Ward ES, 2000, BIOCHEMISTRY-US, V39, P14103, DOI 10.1021/bi0017071; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Yokouchi M, 2001, J BIOL CHEM, V276, P35185, DOI 10.1074/jbc.M102219200; Yuan XM, 2004, EMBO J, V23, P1463, DOI 10.1038/sj.emboj.7600152; Zhang J, 2002, J IMMUNOL, V169, P2236, DOI 10.4049/jimmunol.169.5.2236	60	70	73	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2004	23	42					7104	7115		10.1038/sj.onc.1207952	http://dx.doi.org/10.1038/sj.onc.1207952			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	854EX	15273720				2022-12-17	WOS:000223885100011
J	Iida, S; Hirota, T; Morisaki, T; Marumoto, T; Hara, T; Kuninaka, S; Honda, S; Kosai, K; Kawasuji, M; Pallas, DC; Saya, H				Iida, S; Hirota, T; Morisaki, T; Marumoto, T; Hara, T; Kuninaka, S; Honda, S; Kosai, K; Kawasuji, M; Pallas, DC; Saya, H			Tumor suppressor WARTS ensures genomic integrity by regulating both mitotic progression and G(1) tetraploidy checkpoint function	ONCOGENE			English	Article						cell cycle; mitotic kinase; spindle checkpoint; p53; polyploid	HUMAN HOMOLOG; SPINDLE; KINASE; CELLS; TRANSITION; ANAPHASE; MITOSIS; LATS1; CENTROSOME; METAPHASE	Defects in chromosomes or mitotic spindles activate the spindle checkpoint, resulting in cell cycle arrest at prometaphase. The prolonged activation of spindle checkpoint generally leads to mitotic exit without segregation after a transient mitotic arrest and the consequent formation of tetraploid G(1) cells. These tetraploid cells are usually blocked to enter the subsequent S phase by the activation of p53/pRb pathway, which is referred to as the G(1) tetraploidy checkpoint. A human homologue of the Drosophila warts tumor suppressor, WARTS, is an evolutionarily conserved serine-threonine kinase and implicated in development of human tumors. We previously showed that WARTS plays a crucial role in controlling mitotic progression by forming a regulatory complex with zyxin, a regulator of actin. lament assembly, on mitotic apparatus. However, when WARTS is activated during cell cycle and how the loss of WARTS function leads to tumorigenesis have not been elucidated. Here we show that WARTS is activated during mitosis in mammalian cells, and that overexpression of a kinase-inactive WARTS in Rat1 fibroblasts significantly induced mitotic delay. This delay resulted from prolonged activation of the spindle assembly checkpoint and was frequently followed by mitotic slippage and the development of tetraploidy. The resulting tetraploid cells then abrogated the G(1) tetraploidy checkpoint and entered S phase to achieve a DNA content of 8N. This impairment of G(1) tetraploidy checkpoint was caused as a consequence of failure to induce p53 expression by expressing a kinase-inactive WARTS. WARTS thus plays a critical role in maintenance of ploidy through its actions in both mitotic progression and the G(1) tetraploidy checkpoint.	Kumamoto Univ, Grad Sch Med Sci, Dept Tumor Genet & Biol, Kumamoto 8608556, Japan; Kumamoto Univ, Grad Sch Med Sci, Dept Cardiovasc Surg, Kumamoto 8608556, Japan; Kurume Univ, Cognit & Mol Res Inst Brain Dis, Div Gene Therapy & Regenerat Med, Kurume, Fukuoka 8300011, Japan; Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Ctr, Atlanta, GA 30322 USA	Kumamoto University; Kumamoto University; Kurume University; Emory University; Emory University	Saya, H (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Tumor Genet & Biol, 1-1-1 Honjo, Kumamoto 8608556, Japan.	hsaya@gpo.kumamoto-u.ac.jp	Saya, Hideyuki/J-4325-2013; Kuninaka, Shinji/J-7158-2013		NCI NIH HHS [R01 CA057327] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057327] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hirota T, 2000, J CELL BIOL, V149, P1073, DOI 10.1083/jcb.149.5.1073; Hisaoka M, 2002, LAB INVEST, V82, P1427, DOI 10.1097/01.LAB.0000032381.68634.CA; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Margolis RL, 2003, J CELL BIOCHEM, V88, P673, DOI 10.1002/jcb.10411; Marumoto T, 2003, J BIOL CHEM, V278, P51786, DOI 10.1074/jbc.M306275200; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; Nishiyama Y, 1999, FEBS LETT, V459, P159, DOI 10.1016/S0014-5793(99)01224-7; SHACKNEY SE, 1989, CANCER RES, V49, P3344; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; TOYN JH, 1994, EMBO J, V13, P1103, DOI 10.1002/j.1460-2075.1994.tb06359.x; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; Xia H, 2002, ONCOGENE, V21, P1233, DOI 10.1038/sj.onc.1205174; Yang XL, 2001, ONCOGENE, V20, P6516, DOI 10.1038/sj.onc.1204817; Yasui Y, 1998, J CELL BIOL, V143, P1249, DOI 10.1083/jcb.143.5.1249	24	70	72	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2004	23	31					5266	5274		10.1038/sj.onc.1207623	http://dx.doi.org/10.1038/sj.onc.1207623			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15122335				2022-12-17	WOS:000222491600002
J	Zhu, HB; Zhang, LD; Wu, SH; Teraishi, F; Davis, JJ; Jacob, D; Fang, BL				Zhu, HB; Zhang, LD; Wu, SH; Teraishi, F; Davis, JJ; Jacob, D; Fang, BL			Induction of S-phase arrest and p21 overexpression by a small molecule 2[[3-(2,3-dichlorophenoxy)propyl] amino]ethanol in correlation with activation of ERK	ONCOGENE			English	Article						S-phase arrest; p21; ATM; p53; ERK; small molecule	CYCLIN-DEPENDENT KINASES; TAXOL-INDUCED APOPTOSIS; CELL-CYCLE; CANCER-CELLS; DNA-DAMAGE; PROTEIN-KINASES; INHIBITOR P21; GENE-THERAPY; ADENOVIRUS; P53	We recently found that a small molecule 2[[3-(2,3-dichlorophenoxy)propyl]amino]ethanol (2,3-DCPE) could induce apoptosis and downregulate Bcl-XL expression in various cancer cells. Here, we found that 2,3- DCPE suppressed the proliferation of Bcl-XL-overexpressing cancer cells without inducing apoptosis. Subsequently, we found that 2,3-DCPE could induce S-phase arrest and upregulate p21 but not p27 at a time- and dose-dependent but p53-dispensable manner in DLD-1 human colon cancer cells. Activation of ERK was also detected after treatment with 2,3-DCPE. Moreover, p21 induction was dramatically attenuated by ERK inhibitors PD98059 and U0126. Induction of p21 and S-phase arrest and corresponding activation of ERK were also observed in ATM-defective cells, suggesting that 2,3-DCPE-induced these events were ATM-dispensable. Furthermore, ERK inhibitors dramatically attenuated 2,3-DCPE-induced S-phase arrest. Together, our data indicate that ERK activation correlated with the 2,3-DCPE-mediated induction of p21 expression and S-phase arrest. This finding may have implication for cancer therapy.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Unit 445, Houston, TX 77030 USA; Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Surg Oncol, Hangzhou 310016, Peoples R China; Univ Texas, Grad Sch Biomed Sci, Program Gene Therapy & Virol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Zhejiang University; University of Texas System	Fang, BL (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Unit 445, 1515 Holcombe Blvd, Houston, TX 77030 USA.	Bfang@mdanderson.org			NATIONAL CANCER INSTITUTE [R01CA098582, R01CA092487, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, R01 CA 098582-01A1, R01 CA 092487-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bacus SS, 2001, ONCOGENE, V20, P147, DOI 10.1038/sj.onc.1204062; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Beier F, 1999, J BIOL CHEM, V274, P30273, DOI 10.1074/jbc.274.42.30273; Borel F, 2002, J CELL SCI, V115, P2829; Chen G, 1997, ONCOGENE, V15, P1643, DOI 10.1038/sj.onc.1201347; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EASTHAM JA, 1995, CANCER RES, V55, P5151; EL DW, 1993, CELL, V75, P817; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Gartel AL, 2002, MOL CANCER THER, V1, P639; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Hall MC, 2000, J UROLOGY, V163, P1033, DOI 10.1016/S0022-5347(05)67877-9; HARPER JW, 1993, CELL, V75, P805; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kagawa S, 2001, CANCER RES, V61, P3330; Katayose Y, 1997, CANCER RES, V57, P5441; Kim GY, 2002, J BIOL CHEM, V277, P29792, DOI 10.1074/jbc.M201299200; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; Kornmann M, 1998, J CLIN INVEST, V101, P344, DOI 10.1172/JCI1323; Lodygin D, 2002, J CLIN INVEST, V110, P1717, DOI 10.1172/JCI200216588; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Ogryzko VV, 1997, MOL CELL BIOL, V17, P4877, DOI 10.1128/MCB.17.8.4877; Park KS, 2002, BRIT J PHARMACOL, V137, P597, DOI 10.1038/sj.bjp.0704909; Pedeux R, 1998, J INVEST DERMATOL, V111, P472, DOI 10.1046/j.1523-1747.1998.00324.x; Schreiber M, 1999, ONCOGENE, V18, P1663, DOI 10.1038/sj.onc.1202466; Seidman R, 2001, EXP CELL RES, V268, P84, DOI 10.1006/excr.2001.5262; Senderowicz AM, 2000, ONCOGENE, V19, P6600, DOI 10.1038/sj.onc.1204085; Shapiro GI, 1999, J CLIN INVEST, V104, P1645, DOI 10.1172/JCI9054; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Toogood PL, 2002, CURR OPIN CHEM BIOL, V6, P472, DOI 10.1016/S1367-5931(02)00342-3; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wu SH, 2004, CANCER RES, V64, P1110, DOI 10.1158/0008-5472.CAN-03-2790; Zhang L, 2002, GENE THER, V9, P1262, DOI 10.1038/sj.gt.3301797; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	38	70	76	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					4984	4992		10.1038/sj.onc.1207645	http://dx.doi.org/10.1038/sj.onc.1207645			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15122344				2022-12-17	WOS:000222237300004
J	Powell, JG; Wang, XY; Allard, BL; Sahin, M; Wang, XL; Hay, ID; Hiddinga, HJ; Deshpande, SS; Kroll, TG; Grebe, SKG; Eberhardt, NL; McIver, B				Powell, JG; Wang, XY; Allard, BL; Sahin, M; Wang, XL; Hay, ID; Hiddinga, HJ; Deshpande, SS; Kroll, TG; Grebe, SKG; Eberhardt, NL; McIver, B			The PAX8/PPARc fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARc inhibition	ONCOGENE			English	Article						PAX8/PPAR gamma; fusion oncogene; follicular thyroid carcinoma; adenoma-to-carcinoma progression; PPAR gamma inhibition	ACTIVATED-RECEPTOR-GAMMA; THYROID EPITHELIAL-CELLS; HUMAN PROSTATE-CANCER; PAX8-PPAR-GAMMA REARRANGEMENT; TRANSGENIC MICE; COLON-CANCER; RAS ONCOGENE; FACTOR PAX8; CARCINOMAS; GENE	Follicular thyroid carcinoma (FTC) frequently harbors the PAX8/PPARgamma fusion gene (PPFP); however, its oncogenic role and mechanism(s) of action remain undefined. We investigated PPFP's effects on cell growth, apoptosis, cell-cell, and cell-matrix interactions in immortalized human thyroid cells (Nthy-ori 3-1) and NIH 3T3 cells. PPFP expression increased the growth of transient and stable Nthy-ori transfectants (similar to threefold by 72 h). There was an 8.4% increase of cells in the S + G2/M phase, a 7.8% decrease in cells in the G0 + G1 phase and a 66% decline in apoptosis at 72 h. Stable Nthy-ori PPFP transfectants grew in soft agar, and PPFP-transfected NIH 3T3 cells exhibited efficient focus formation, suggesting loss of anchorage-dependent growth and contact inhibition, respectively. Overexpression of PPARgamma in Nthy-ori cells did not recapitulate PPFP's growth effects. Treatment of Nthy-ori cells with an irreversible PPARgamma inhibitor mimicked the growth-promoting effects of PPFP and co-expression of PPFP and PPARgamma blocked PPARgamma transactivation activity. Our data provide functional evidence that PPFP acts as an oncoprotein, whose transforming properties depend in part on inhibition of PPARgamma. Our data suggest that PPFP contributes to malignant transformation during FTC oncogenesis by acting on several cellular pathways, at least some of which are normally regulated by PPARgamma.	Mayo Clin, Dept Med, Div Endocrinol, Rochester, MN 55906 USA; Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55906 USA; Ankara Univ, Sch Med, Dept Endocrinol, TR-06100 Ankara, Turkey; Mayo Clin, Dept Med, Div Cardiovasc Dis, Rochester, MN 55906 USA; Emory Univ, Sch Med, Winship Canc Ctr, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Ctr, Dept Hematol & Oncol, Atlanta, GA 30322 USA; Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55906 USA	Mayo Clinic; Mayo Clinic; Ankara University; Mayo Clinic; Emory University; Emory University; Mayo Clinic	Eberhardt, NL (corresponding author), Mayo Clin, Endocrine Res Unit, 200 1st St SW, Rochester, MN 55905 USA.	eberhardt@mayo.edu	Hay, Ian/AAH-8508-2019; Sahin, Mustafa/AAH-3394-2019	Hay, Ian/0000-0002-5527-3909; Sahin, Mustafa/0000-0002-4718-0083				Aldred MA, 2003, ONCOGENE, V22, P3412, DOI 10.1038/sj.onc.1206400; Allen TD, 2000, LEUKEMIA LYMPHOMA, V39, P241, DOI 10.3109/10428190009065824; BONGARZONE I, 1989, ONCOGENE, V4, P1457; BURNS JS, 1989, BRIT J CANCER, V59, P755, DOI 10.1038/bjc.1989.158; Cimini A, 2000, BBA-GEN SUBJECTS, V1474, P397, DOI 10.1016/S0304-4165(00)00036-2; Espinoza CR, 2001, J MOL ENDOCRINOL, V27, P59, DOI 10.1677/jme.0.0270059; Fagin JA, 2002, MOL ENDOCRINOL, V16, P903, DOI 10.1210/me.16.5.903; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; French CA, 2003, AM J PATHOL, V162, P1053, DOI 10.1016/S0002-9440(10)63902-8; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hiddinga HJ, 1999, AM J PATHOL, V154, P1077, DOI 10.1016/S0002-9440(10)65360-6; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Ijpenberg A, 1997, J BIOL CHEM, V272, P20108, DOI 10.1074/jbc.272.32.20108; Jhiang SM, 1998, RECENT RES CANCER, V154, P265; Jiang SW, 2001, J BIOL CHEM, V276, P23464, DOI 10.1074/jbc.M010934200; Jones CJ, 2000, MOL CELL BIOL, V20, P5690, DOI 10.1128/MCB.20.15.5690-5699.2000; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; Kroll TG, 2000, SCIENCE, V289, P1357, DOI 10.1126/science.289.5483.1357; Kubota T, 1998, CANCER RES, V58, P3344; LEMOINE NR, 1989, BRIT J CANCER, V60, P897, DOI 10.1038/bjc.1989.387; Marques AR, 2002, J CLIN ENDOCR METAB, V87, P3947, DOI 10.1210/jc.87.8.3947; Martelli ML, 2002, J CLIN ENDOCR METAB, V87, P4728, DOI 10.1210/jc.2001-012054; Mascia A, 2002, J ENDOCRINOL, V172, P163, DOI 10.1677/joe.0.1720163; Meriane M, 2002, ONCOGENE, V21, P2901, DOI 10.1038/sj.onc.1205396; Mueller E, 2000, P NATL ACAD SCI USA, V97, P10990, DOI 10.1073/pnas.180329197; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Nikiforova MN, 2003, J CLIN ENDOCR METAB, V88, P2318, DOI 10.1210/jc.2002-021907; Nikiforova MN, 2002, AM J SURG PATHOL, V26, P1016, DOI 10.1097/00000478-200208000-00006; Ohno M, 1999, MOL CELL BIOL, V19, P2051; Ohta T, 2002, INT J ONCOL, V21, P37; POLEEV A, 1995, EUR J BIOCHEM, V228, P899, DOI 10.1111/j.1432-1033.1995.tb20338.x; SANTELLI G, 1993, CANCER RES, V53, P5523; SANTORO M, 1995, EUR J ENDOCRINOL, V133, P513, DOI 10.1530/eje.0.1330513; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; Satoh T, 2002, ONCOGENE, V21, P2171, DOI 10.1038/sj.onc.1205279; Takashima T, 2001, INT J ONCOL, V19, P465; Vilain C, 2001, J CLIN ENDOCR METAB, V86, P234, DOI 10.1210/jc.86.1.234	38	70	74	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3634	3641		10.1038/sj.onc.1207399	http://dx.doi.org/10.1038/sj.onc.1207399			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT					2022-12-17	WOS:000221101700015
J	Todd, DE; Densham, RM; Molton, SA; Balmanno, K; Newson, C; Weston, CR; Garner, AP; Scott, L; Cook, SJ				Todd, DE; Densham, RM; Molton, SA; Balmanno, K; Newson, C; Weston, CR; Garner, AP; Scott, L; Cook, SJ			ERK1/2 and p38 cooperate to induce a p21(CIP1)-dependent G(1) cell cycle arrest	ONCOGENE			English	Article						ERK; JNK; MEKK; p21(CIP)1; p38; Raf	MESSENGER-RNA STABILIZATION; SIGNAL-REGULATED KINASE; KAPPA-B ACTIVATION; DEPENDENT KINASES; CDK INHIBITORS; RETINOBLASTOMA PROTEIN; DNA-DAMAGE; TRANSCRIPTION FACTORS; UV-RADIATION; HUMAN CANCER	To study the mechanisms by which mitogen- and stress-activated protein kinases regulate cell cycle re-entry, we have used a panel of conditional kinases that stimulate defined MAPK or SAPK cascades. Activation of DeltaMEKK3:ER* during serum restimulation of quiescent cells causes a strong activation of JNK1 and p38alpha but only a modest potentiation of serum-stimulated ERK1/2 activity. In CCl39 cells this promoted a sustained G(1) arrest that correlated with decreased expression of cyclin D1 and Cdc25A, increased expression of p21(CIP1) and inhibition of CDK2 activity. In Rat-1 cells, in which p21(CIP1) expression is silenced by methylation, DeltaMEKK3:ER* activation caused only a transient delay in the S phase entry rather than a sustained G(1) arrest. Furthermore, p21(CIP1-/-) 3T3 cells were defective for the DeltaMEKK3:ER*- induced G(1) cell cycle arrest compared to their wild-type counterparts. These results suggest that activated DeltaMEKK3: ER* inhibits the G(1)-->S progression by two kinetically distinct mechanisms, with expression of p21(CIP1) being required to ensure a sustained G(1) cell cycle arrest. The ERK1/2 and p38alphabeta pathways cooperated to induce p21(CIP1) expression and inhibition of p38alphabeta caused a partial reversal of the cell cycle arrest. In contrast, selective activation of ERK1/2 by DeltaRaf-1:ER* did not inhibit serum stimulated cell cycle re-entry. Finally, selective activation of JNK by DeltaMEKK1: ER* failed to inhibit cell cycle re-entry, even in cells that retained wild-type p53, arguing against a major role for JNK alone in antagonizing the G(1)-->S transition.	Babraham Inst, Signalling Programme, Cambridge CB2 4AT, England; Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Beatson Institute	Cook, SJ (corresponding author), Babraham Inst, Signalling Programme, Babraham Hall, Cambridge CB2 4AT, England.	simon.cook@bbsrc.ac.uk	Densham, Ruth/AAO-1971-2020	Densham, Ruth/0000-0003-4490-2842; Balmanno, Kathryn/0000-0002-6417-3889	Biotechnology and Biological Sciences Research Council [BBS/E/B/0000H457, BBS/E/B/0000C199] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; Allan LA, 2000, MOL CELL BIOL, V20, P1291, DOI 10.1128/MCB.20.4.1291-1298.2000; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; Casanovas O, 2000, J BIOL CHEM, V275, P35091, DOI 10.1074/jbc.M006324200; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; CLARKE PR, 1995, CURR BIOL, V5, P40, DOI 10.1016/S0960-9822(95)00013-3; Cook SJ, 1999, MOL CELL BIOL, V19, P330; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Deacon K, 1999, J BIOL CHEM, V274, P16604, DOI 10.1074/jbc.274.23.16604; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ellinger-Ziegelbauer H, 1999, MOL CELL BIOL, V19, P3857; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Garner AP, 2002, ONCOGENE, V21, P8089, DOI 10.1038/sj.onc.1206000; Geng Y, 1996, ONCOGENE, V12, P1173; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; KASTAN MB, 1991, CANCER RES, V51, P6304; Kim GY, 2002, J BIOL CHEM, V277, P29792, DOI 10.1074/jbc.M201299200; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McMahon M, 2001, BBA-REV CANCER, V1471, pM63, DOI 10.1016/S0304-419X(00)00027-5; Molnar A, 1997, J BIOL CHEM, V272, P13229, DOI 10.1074/jbc.272.20.13229; Molton SA, 2003, ONCOGENE, V22, P4690, DOI 10.1038/sj.onc.1206692; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Park JS, 2000, MOL BIOL CELL, V11, P2915, DOI 10.1091/mbc.11.9.2915; Persons DL, 2000, J BIOL CHEM, V275, P35778, DOI 10.1074/jbc.M004267200; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Sanchez-Prieto R, 2000, CANCER RES, V60, P2464; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shirane M, 1999, J BIOL CHEM, V274, P13886, DOI 10.1074/jbc.274.20.13886; Squires MS, 2002, BIOCHEM J, V366, P673, DOI 10.1042/BJ20020372; TISHLER RB, 1993, CANCER RES, V53, P2212; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Ussat S, 2002, BIOCHEM BIOPH RES CO, V294, P672, DOI 10.1016/S0006-291X(02)00532-6; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang S, 1999, EMBO J, V18, P1559, DOI 10.1093/emboj/18.6.1559; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Weston CR, 2003, ONCOGENE, V22, P1281, DOI 10.1038/sj.onc.1206261; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	70	70	75	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3284	3295		10.1038/sj.onc.1207467	http://dx.doi.org/10.1038/sj.onc.1207467			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	14981547				2022-12-17	WOS:000220975000003
J	Oliveira, C; de Bruin, J; Nabais, S; Ligtenberg, M; Moutinho, C; Nagengast, FM; Seruca, R; van Krieken, H; Carneiro, F				Oliveira, C; de Bruin, J; Nabais, S; Ligtenberg, M; Moutinho, C; Nagengast, FM; Seruca, R; van Krieken, H; Carneiro, F			Intragenic deletion of CDH1 as the inactivating mechanism of the wild-type allele in an HDGC tumour	ONCOGENE			English	Article						E-cadherin; hereditary diffuse gastric cancer; HDGC; mutation; intragenic deletion; second hit	FAMILIAL GASTRIC-CANCER; E-CADHERIN GENE; GERMLINE MUTATIONS; BETA-CATENIN; CARCINOMA; METHYLATION; EXPRESSION; PATTERNS; CELLS	Mutations in CDH1, encoding E- cadherin, are the underlying genetic defect in approximately one- third of the hereditary diffuse gastric cancer ( HDGC) families described so far. Tumours arising in these families show abnormal or absence of E- cadherin expression, following the model of tumour suppressor gene inactivation. A single study has been reported showing inactivation of the CDH1 wild- type allele in tumour cells from HDGC families either by promoter methylation or by somatic mutation. In order to find the genetic alteration responsible for the presence of diffuse gastric cancers in four members of a Caucasian family, we have screened the coding sequence of CDH1 for germline mutations and searched for the second inactivating hit in the tumour samples. In this family, we have found a germline splice- site mutation in all members affected by gastric cancer and, in one tumour, a somatic deletion affecting at least exon 8 of CDH1. Our results show that a CDH1 intragenic deletion is the second hit inactivating the wild- type allele, in one of the tumours in this family.	Univ Porto IPATIMUP, Inst Mol Pathol & Immunol, P-4200465 Oporto, Portugal; Univ Med Ctr Nijmegen, Dept Pathol, NL-6500 HB Nijmegen, Netherlands; Univ Med Ctr Nijmegen, Dept Human Genet, NL-6500 HB Nijmegen, Netherlands; Univ Med Ctr Nijmegen, Dept Gastroenterol, NL-6500 HB Nijmegen, Netherlands; Univ Porto, Fac Med, P-4200465 Oporto, Portugal	Universidade do Porto; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Universidade do Porto	Oliveira, C (corresponding author), Univ Porto IPATIMUP, Inst Mol Pathol & Immunol, P-4200465 Oporto, Portugal.	carlaol@ipatimup.pt	seruca, raquel/F-8187-2011; Ligtenberg, Marjolijn/N-9666-2013; Oliveira, Carla/F-8188-2011; Carneiro, Fatima/J-6432-2013; Nabais, Sérgio/AAQ-5859-2020; van Krieken, Joannes H J M/D-4138-2009; Carneiro, Fatima/AAV-8677-2021	Ligtenberg, Marjolijn/0000-0003-1290-1474; Oliveira, Carla/0000-0001-8340-2264; Carneiro, Fatima/0000-0002-1964-1006; van Krieken, Joannes H J M/0000-0001-6544-1040; Carneiro, Fatima/0000-0002-1964-1006; Seruca, Raquel/0000-0002-8851-4166				Avizienyte E, 2001, J MED GENET, V38, P49, DOI 10.1136/jmg.38.1.49; Caldas C, 1999, J MED GENET, V36, P873; Chen YT, 1999, J CELL BIOL, V144, P687, DOI 10.1083/jcb.144.4.687; Dussaulx-Garin L, 2001, EUR J GASTROEN HEPAT, V13, P711, DOI 10.1097/00042737-200106000-00016; Gayther SA, 1998, CANCER RES, V58, P4086; Grady WM, 2000, NAT GENET, V26, P16, DOI 10.1038/79120; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Guilford PJ, 1999, HUM MUTAT, V14, P249, DOI 10.1002/(SICI)1098-1004(1999)14:3<249::AID-HUMU8>3.0.CO;2-9; Handschuh G, 1999, ONCOGENE, V18, P4301, DOI 10.1038/sj.onc.1202790; Huber AH, 2001, J BIOL CHEM, V276, P12301, DOI 10.1074/jbc.M010377200; Humar B, 2002, HUM MUTAT, V19, P518, DOI 10.1002/humu.10067; Iida S, 1999, CLIN CANCER RES, V5, P1445; Jonsson BA, 2002, INT J CANCER, V98, P838, DOI 10.1002/ijc.10258; Keller G, 1999, AM J PATHOL, V155, P337, DOI 10.1016/S0002-9440(10)65129-2; Machado JC, 2000, J PATHOL, V190, P437; Machado JC, 1998, INT J SURG PATHOL, V6, P135, DOI 10.1177/106689699800600302; Nabais S, 2003, INT J SURG PATHOL, V11, P1, DOI 10.1177/106689690301100102; Oliveira C, 2003, EXPERT REV MOL DIAGN, V3, P201; Oliveira C, 2002, HUM MUTAT, V19, P510, DOI 10.1002/humu.10068; Richards FM, 1999, HUM MOL GENET, V8, P607, DOI 10.1093/hmg/8.4.607; Shinmura K, 1999, CARCINOGENESIS, V20, P1127, DOI 10.1093/carcin/20.6.1127; Wang Y, 2003, JPN J CLIN ONCOL, V33, P17, DOI 10.1093/jjco/hyg002; Yabuta T, 2002, INT J CANCER, V101, P434, DOI 10.1002/ijc.10633; Yoon KA, 1999, J HUM GENET, V44, P177, DOI 10.1007/s100380050137	25	70	73	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2004	23	12					2236	2240		10.1038/sj.onc.1207335	http://dx.doi.org/10.1038/sj.onc.1207335			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	804EB	14661064				2022-12-17	WOS:000220280900014
J	Regl, G; Kasper, M; Schnidar, H; Eichberger, T; Neill, GW; Ikram, MS; Quinn, AG; Philpott, MP; Frischauf, AM; Aberger, F				Regl, G; Kasper, M; Schnidar, H; Eichberger, T; Neill, GW; Ikram, MS; Quinn, AG; Philpott, MP; Frischauf, AM; Aberger, F			The zinc-finger transcription factor GLI2 antagonizes contact inhibition and differentiation of human epidermal cells	ONCOGENE			English	Article						hedgehog signalling; GLI proteins; keratinocytes; basal cell carcinoma; epidermal differentiation; cell cycle	SONIC HEDGEHOG; KERATINOCYTE DIFFERENTIATION; GENE-EXPRESSION; CYCLE PROGRESSION; UP-REGULATION; TARGET GENES; FLOOR PLATE; BASAL; PROLIFERATION; CARCINOMA	In stratified epidermis, activation of the Hh/Gli signal transduction pathway has been implicated in the control of cell proliferation and tumorigenesis. The zinc-finger transcription factor Gli2 has been identified as critical mediator of the Hh signal at the distal end of the pathway, but the molecular mechanisms by which Gli2 regulates cell proliferation or induces epidermal malignancies such as basal cell carcinoma are still unclear. Here, we provide evidence for a role of human GLI2 in antagonizing contact inhibition and epidermal differentiation. We show by gene expression pro. ling that activation of the GLI2 oncogene in human keratinocytes activates the transcription of a number of genes involved in cell cycle progression such as E2F1, CCND1, CDC2 and CDC45L, while it represses genes associated with epidermal differentiation. Analysis of the proliferative effect of GLI2 revealed that GLI2 is able to induce G1-S phase progression in contact-inhibited keratinocytes. Detailed time-course experiments identified E2F1 as early transcriptional target of GLI2. Further, we show that GLI2 expression in human keratinocytes results in a marked downregulation of epidermal differentiation markers. The data suggest a role for GLI2 in Hh-induced epidermal neoplasia by opposing epithelial cell cycle arrest signals and epidermal differentiation.	Salzburg Univ, Inst Genet, A-5020 Salzburg, Austria; Univ London, Barts & London Queen Mary Sch Med & Dent, Ctr Cutaneaous Res, London WC1E 7HU, England; AstraZeneca R&D Charnwood, Expt Med, Loughborough, Leics, England	Salzburg University; University of London; Queen Mary University London; AstraZeneca	Aberger, F (corresponding author), Salzburg Univ, Inst Genet, Hellbrunner Str 34, A-5020 Salzburg, Austria.	fritz.aberger@sbg.ac.at	Kasper, Maria/Q-6318-2016; Schnidar, Harald/C-7049-2009; Neill, Graham/C-9008-2012; Aberger, Fritz/B-6357-2012	Aberger, Fritz/0000-0003-2009-6305; Philpott, Michael/0000-0002-1255-4612; Kasper, Maria/0000-0002-6117-2717				Aberger F, 2001, GENOMICS, V77, P50, DOI 10.1006/geno.2001.6623; Arata Y, 2000, J BIOL CHEM, V275, P6337, DOI 10.1074/jbc.275.9.6337; AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; Bai CB, 2002, DEVELOPMENT, V129, P4753; Bikle DD, 2001, MOL CELL ENDOCRINOL, V177, P161, DOI 10.1016/S0303-7207(01)00452-X; Bonifas JM, 2001, J INVEST DERMATOL, V116, P739, DOI 10.1046/j.1523-1747.2001.01315.x; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Chopra A, 1998, J INVEST DERMATOL, V110, P52, DOI 10.1046/j.1523-1747.1998.00089.x; Deng H, 1997, NAT BIOTECHNOL, V15, P1388, DOI 10.1038/nbt1297-1388; Ding Q, 1998, DEVELOPMENT, V125, P2533; Duman-Scheel M, 2002, NATURE, V417, P299, DOI 10.1038/417299a; Fan HR, 1999, J CELL BIOL, V147, P71, DOI 10.1083/jcb.147.1.71; Garach-Jehoshua O, 1998, BRIT J DERMATOL, V139, P950; Goodrich LV, 1998, NEURON, V21, P1243, DOI 10.1016/S0896-6273(00)80645-5; Grachtchouk M, 2000, NAT GENET, V24, P216, DOI 10.1038/73417; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jee SH, 2001, ONCOGENE, V20, P198, DOI 10.1038/sj.onc.1204076; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; JONES PH, 1995, CELL, V80, P83, DOI 10.1016/0092-8674(95)90453-0; Kenney AM, 2000, MOL CELL BIOL, V20, P9055, DOI 10.1128/MCB.20.23.9055-9067.2000; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Martin KJ, 2001, P NATL ACAD SCI USA, V98, P2646, DOI 10.1073/pnas.041622398; Matise MP, 1998, DEVELOPMENT, V125, P2759; Medvedev A, 1999, J BIOL CHEM, V274, P3887, DOI 10.1074/jbc.274.6.3887; Mill P, 2003, GENE DEV, V17, P282, DOI 10.1101/gad.1038103; Morasso MI, 1996, J CELL BIOL, V135, P1879, DOI 10.1083/jcb.135.6.1879; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Mullor JL, 2002, TRENDS CELL BIOL, V12, P562, DOI 10.1016/S0962-8924(02)02405-4; Nickoloff BJ, 2002, CELL DEATH DIFFER, V9, P842, DOI 10.1038/sj.cdd.4401036; Nilsson M, 2000, P NATL ACAD SCI USA, V97, P3438, DOI 10.1073/pnas.050467397; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Park HL, 2000, DEVELOPMENT, V127, P1593; Regl G, 2002, ONCOGENE, V21, P5529, DOI 10.1038/sj.onc.1205748; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; Rutberg SE, 1996, ONCOGENE, V13, P167; Sasaki H, 1999, DEVELOPMENT, V126, P3915; SAVOIA P, 1993, J INVEST DERMATOL, V101, P352, DOI 10.1111/1523-1747.ep12365531; Schoop VM, 1999, J INVEST DERMATOL, V112, P343, DOI 10.1046/j.1523-1747.1999.00524.x; Sheng H, 2002, CANCER RES, V62, P5308; Sherr CJ, 2000, CANCER RES, V60, P3689; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Takahashi H, 1997, J INVEST DERMATOL, V108, P843, DOI 10.1111/1523-1747.ep12292575; Toftgard R, 2000, CELL MOL LIFE SCI, V57, P1720, DOI 10.1007/PL00000654; Tuominen H, 1997, J CUTAN PATHOL, V24, P590, DOI 10.1111/j.1600-0560.1997.tb01089.x; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Varani J, 2000, BRIT J CANCER, V82, P657, DOI 10.1054/bjoc.1999.0978; Watanabe R, 1998, J BIOL CHEM, V273, P9651, DOI 10.1074/jbc.273.16.9651; Weiner HL, 2002, CANCER RES, V62, P6385; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; Werner S, 2001, TRENDS CELL BIOL, V11, P143, DOI 10.1016/S0962-8924(01)01955-9; Wetmore C, 2003, CURR OPIN GENET DEV, V13, P34, DOI 10.1016/S0959-437X(03)00002-9; Xie JW, 2001, P NATL ACAD SCI USA, V98, P9255, DOI 10.1073/pnas.151173398; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Yoon JW, 2002, J BIOL CHEM, V277, P5548, DOI 10.1074/jbc.M105708200; ZETTERGREN JG, 1984, P NATL ACAD SCI-BIOL, V81, P238, DOI 10.1073/pnas.81.1.238	60	70	73	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1263	1274		10.1038/sj.onc.1207240	http://dx.doi.org/10.1038/sj.onc.1207240			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14691458				2022-12-17	WOS:000188892200011
J	Harmes, DC; Bresnick, E; Lubin, EA; Watson, JK; Heim, KE; Curtin, JC; Suskind, AM; Lamb, J; DiRenzo, J				Harmes, DC; Bresnick, E; Lubin, EA; Watson, JK; Heim, KE; Curtin, JC; Suskind, AM; Lamb, J; DiRenzo, J			Positive and negative regulation of Delta N-p63 promoter activity by p53 and Delta N-p63-alpha contributes to differential regulation of p53 target genes	ONCOGENE			English	Article						p53; p63; mammary epithelia; gene regulation	MAMMARY-GLAND; STEM-CELLS; NEOPLASTIC-CELLS; DNA-DAMAGE; P63; P73; EXPRESSION; APOPTOSIS; HOMOLOG; FAMILY	Mammary epithelial regeneration implies the existence of cellular progenitors with retained replicative capacity, prolonged lifespan and developmental potency. Evidence exists that DeltaN-p63 isoforms preserve these features by modulating p53 activity in basal epithelia. DeltaN-p63 mRNA levels decline at the onset of differentiation suggesting that its transcriptional regulation may contribute to the initiation of differentiation. To study transcriptional regulation of DeltaN-p63, a 10.3 kbp fragment containing the DeltaN-p63 promoter was isolated. We report here that DeltaN-p63 is a positive and negative transcriptional target of p53 and DeltaN-p63-alpha, respectively. Disruption of p53 activity or expression abolishes the expression of DeltaN-p63-alpha. This regulation is mediated by a p53-binding element sufficient to confer these activities to a heterologous promoter. Chromatin immune-precipitation indicates that, in asynchronously growing cells, p53 occupies this element. In response to DNA damage, DeltaN-p63-alpha is recruited to this element as transcription of DeltaN-p63 declines. Disruption of DeltaN-p63-alpha expression had differential effects on the transcriptional regulation of several p53-target genes. These findings indicate that p53 contributes to the preservation of basal epithelia by driving the expression of DeltaN-p63 isoforms. These studies also suggest that in response to genotoxic stress, DeltaN-p63-alpha mediates the silencing of its own promoter thereby altering the pattern of p53-target gene expression.	Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA; Dartmouth Coll, Hanover, NH 03755 USA; Dana Farber Canc Inst, Boston, MA 02115 USA	Dartmouth College; Dartmouth College; Dartmouth College; Harvard University; Dana-Farber Cancer Institute	DiRenzo, J (corresponding author), Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, 7650 Remsen, Hanover, NH 03755 USA.			/0000-0002-1702-6085				Barker N, 1999, AM J PATHOL, V154, P29, DOI 10.1016/S0002-9440(10)65247-9; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; DiRenzo J, 2002, CANCER RES, V62, P89; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Hall PA, 2000, CARCINOGENESIS, V21, P153, DOI 10.1093/carcin/21.2.153; Hennighausen L, 1998, GENE DEV, V12, P449, DOI 10.1101/gad.12.4.449; Hovey RC, 2002, J MAMMARY GLAND BIOL, V7, P17, DOI 10.1023/A:1015766322258; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Jerry DJ, 1999, J MAMMARY GLAND BIOL, V4, P177, DOI 10.1023/A:1018777224808; Jerry DJ, 2002, J DAIRY SCI, V85, P1103, DOI 10.3168/jds.S0022-0302(02)74171-4; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Li P, 1998, INT J EXP PATHOL, V79, P193, DOI 10.1046/j.1365-2613.1998.00068.x; Liefer KM, 2000, CANCER RES, V60, P4016; Marin MC, 2000, BBA-REV CANCER, V1470, pM93, DOI 10.1016/S0304-419X(00)00010-X; Masso-Welch PA, 2000, J MAMMARY GLAND BIOL, V5, P165, DOI 10.1023/A:1026491221687; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; Nylander K, 2002, J PATHOL, V198, P417, DOI 10.1002/path.1231; Parsa R, 1999, J INVEST DERMATOL, V113, P1099, DOI 10.1046/j.1523-1747.1999.00780.x; Patturajan M, 2002, CANCER CELL, V1, P369, DOI 10.1016/S1535-6108(02)00057-0; Pellegrini G, 2001, P NATL ACAD SCI USA, V98, P3156, DOI 10.1073/pnas.061032098; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Sasaki Y, 2002, J BIOL CHEM, V277, P719, DOI 10.1074/jbc.M108080200; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Signoretti S, 2000, AM J PATHOL, V157, P1769, DOI 10.1016/S0002-9440(10)64814-6; Smith GH, 2001, MICROSC RES TECHNIQ, V52, P190, DOI 10.1002/1097-0029(20010115)52:2<190::AID-JEMT1005>3.0.CO;2-O; Suliman Y, 2001, CANCER RES, V61, P6467; van Bokhoven H, 2002, AM J HUM GENET, V71, P1, DOI 10.1086/341450; van Bokhoven H, 2002, TRENDS MOL MED, V8, P133, DOI 10.1016/S1471-4914(01)02260-2; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0	37	70	71	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 23	2003	22	48					7607	7616		10.1038/sj.onc.1207129	http://dx.doi.org/10.1038/sj.onc.1207129			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KQ	14576823				2022-12-17	WOS:000186113000008
J	Sharpless, NE; Kannan, K; Xu, J; Bosenberg, MW; Chin, LD				Sharpless, NE; Kannan, K; Xu, J; Bosenberg, MW; Chin, LD			Both products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo	ONCOGENE			English	Article						melanoma; RAS	GERMLINE MUTATION; TUMOR SUPPRESSION; RAS; P16(INK4A); P53; P19(ARF); GENE; SUSCEPTIBILITY; INACTIVATION; FIBROBLASTS	Deletion of the INK4a/ARF locus at 9p21 is detected with high frequency in human melanoma. Within a short genomic distance, this locus encodes several proteins with established tumor-suppressor roles in a broad spectrum of cancer types. Several lines of evidence support the view that p10(INKa4) and p19(ARF) exert the tumor-suppressor activities of this locus, although their relative importance in specific cancer types such as melanoma has been less rigorously documented on the genetic level. Here, we exploit a well-defined mouse model of RAS-induced melanomas to examine the impact of germline p16(INK4a) or p19(ARF) nullizygosity on melanoma formation. We demonstrate that loss of either Ink4a/Arf product can cooperate with RAS activation to produce clinically indistinguishable melanomas. In line with the common phenotypic end point, we further show that RAS+ p16(INK4a)-/- melanomas sustain somatic inactivation of p19(ARF)-p53 and, correspondingly, that RAS+ p19(ARF)-/- melanomas experience high-frequency loss of p16(INK4a). These genetic studies provide definitive proof that p16(INK4a), and p19(ARF) cooperate to suppress the development of melanoma in vivo.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Dept Pathol, Sch Med, Boston, MA 02115 USA; Harvard Univ, Dept Dermatol, Sch Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	Chin, LD (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St,M413, Boston, MA 02115 USA.	Lynda_Chin@dfci.harvard.edu		Sharpless, Norman/0000-0001-7078-9455				Bardeesy N, 2001, MOL CELL BIOL, V21, P2144, DOI 10.1128/MCB.21.6.2144-2153.2001; Brookes S, 2002, EMBO J, V21, P2936, DOI 10.1093/emboj/cdf289; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Flores JF, 1996, CANCER RES, V56, P5023; GLENDENING JM, 1995, CANCER RES, V55, P5531; Gonzalgo ML, 1997, CANCER RES, V57, P5336; Groth A, 2000, J BIOL CHEM, V275, P27473; Herlyn M, 1996, AM J PATHOL, V149, P739; HERMAN JG, 1995, CANCER RES, V55, P4525; Hewitt C, 2002, HUM MOL GENET, V11, P1273, DOI 10.1093/hmg/11.11.1273; Huot TJ, 2002, MOL CELL BIOL, V22, P8135, DOI 10.1128/MCB.22.23.8135-8143.2002; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Patel AC, 2000, CARCINOGENESIS, V21, P1691, DOI 10.1093/carcin/21.9.1691; Randerson-Moor JA, 2001, HUM MOL GENET, V10, P55, DOI 10.1093/hmg/10.1.55; Rizos H, 2001, ONCOGENE, V20, P5543, DOI 10.1038/sj.onc.1204728; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Schmid M, 1998, ONCOGENE, V17, P2669, DOI 10.1038/sj.onc.1202205; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sharpless NE, 2002, CANCER RES, V62, P2761; Sotillo R, 2001, P NATL ACAD SCI USA, V98, P13312, DOI 10.1073/pnas.241338598; Walker GJ, 1998, GENE CHROMOSOME CANC, V22, P157, DOI 10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N	29	70	83	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	2003	22	32					5055	5059		10.1038/sj.onc.1206809	http://dx.doi.org/10.1038/sj.onc.1206809			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902988				2022-12-17	WOS:000184578900013
J	Span, PN; Tjan-Heijnen, VCG; Manders, P; Beex, LVAM; Sweep, CGJ				Span, PN; Tjan-Heijnen, VCG; Manders, P; Beex, LVAM; Sweep, CGJ			Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer	ONCOGENE			English	Article						cell cycle; prognosis; multivariate study; treatment interaction; tamoxifen	PROGNOSTIC FACTORS; E OVEREXPRESSION; CELL-CYCLE; EXPRESSION; DEREGULATION; SURVIVAL; PROTEIN; KINASE; PROLIFERATION; RISK	Recently, cyclin-E was reported to be the most prominent prognostic factor for breast cancer outcome described so far, even surpassing axillary nodal involvement. Earlier studies on the prognostic value of cyclin-E in breast cancer, however, yielded heterogeneous results. Therefore, we set out to confirm and extend these results by quantitative Taqman RT-PCR of cyclin-E levels in 277 resectable breast cancers. Cyclin-E levels were not associated with relapse-free survival (RFS) or overall survival (OS) in the total cohort of patients, or in the subset of patients without involved lymph nodes that were not treated with adjuvant systemic therapy. Besides several classical clinicopathological factors, the interaction between cyclin-E and adjuvant endocrine therapy (P = 0.01, HR = 3.04, 95% CI: 1.30-7.09) was found to contribute significantly in multivariate analyses. Cyclin-E levels were associated with poor RFS specifically in patients treated with adjuvant endocrine therapy (n = 108, P = 0.001, HR = 4.01, 95% CI: 1.76-9.12), independent of estrogen receptor status. In conclusion, cyclin-E is not a pure prognostic factor in breast cancer, but rather a predictor of failure of endocrine therapy. Differences in literature on the presumed prognostic value of cyclin-E may be due to differences in treatment. Assessment of cyclin-E levels can aid in improving adjuvant treatment selection.	Univ Med Ctr Nijmegen, Dept Chem Endocrinol 530, NL-6500 HB Nijmegen, Netherlands; Univ Med Ctr Nijmegen, Dept Med Oncol, Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen	Span, PN (corresponding author), Univ Med Ctr Nijmegen, Dept Chem Endocrinol 530, POB 9101, NL-6500 HB Nijmegen, Netherlands.		Span, Paul N./A-3143-2009; Manders, P./L-4501-2015; Span, Paul/G-4710-2012; Sweep, C.G.J./H-8096-2014	Span, Paul/0000-0002-1930-6638; Sweep, C.G.J./0000-0003-1103-3070				ALTMAN DG, 1994, J NATL CANCER I, V86, P829, DOI 10.1093/jnci/86.11.829; Altman DG, 1998, BREAST CANCER RES TR, V52, P289, DOI 10.1023/A:1006193704132; Bindels EMJ, 2002, ONCOGENE, V21, P8158, DOI 10.1038/sj.onc.1206012; COX DR, 1972, J R STAT SOC B, V34, P187; Dhillon NK, 2002, ONCOGENE, V21, P4626, DOI 10.1038/sj.onc.1205576; Donnellan R, 2001, HUM PATHOL, V32, P89, DOI 10.1053/hupa.2001.21141; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Foekens JA, 2003, CANCER RES, V63, P337; Harbeck N, 2002, CANCER RES, V62, P4617; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Keyomarsi K, 2002, NEW ENGL J MED, V347, P1566, DOI 10.1056/NEJMoa021153; Keyomarsi K, 1997, Prog Cell Cycle Res, V3, P171; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KEYOMARSI K, 1995, ONCOGENE, V11, P941; Kim HK, 2001, EUR J SURG ONCOL, V27, P464, DOI 10.1053/ejso.2001.1137; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Kuhling H, 2003, J PATHOL, V199, P424, DOI 10.1002/path.1322; Muller-Tidow C, 2001, CANCER RES, V61, P647; Nielsen NH, 1996, BRIT J CANCER, V74, P874, DOI 10.1038/bjc.1996.451; Nielsen NH, 1997, ONCOGENE, V14, P295, DOI 10.1038/sj.onc.1200833; Payton M, 2002, ONCOGENE, V21, P8529, DOI 10.1038/sj.onc.1206035; Porter DC, 2001, MOL CELL BIOL, V21, P6254, DOI 10.1128/MCB.21.18.6254-6269.2001; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076	25	70	71	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 31	2003	22	31					4898	4904		10.1038/sj.onc.1206818	http://dx.doi.org/10.1038/sj.onc.1206818			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894232				2022-12-17	WOS:000184344600014
J	Matushansky, I; Radparvar, F; Skoultchi, AI				Matushansky, I; Radparvar, F; Skoultchi, AI			CDK6 blocks differentiation: coupling cell proliferation to the block to differentiation in leukemic cells	ONCOGENE			English	Article						cyclin-dependent kinase 6; PU. 1; erythroleukemia; proliferation; differentiation	CYCLIN-DEPENDENT KINASE-6; PU.1 TRANSCRIPTION FACTOR; ERYTHROLEUKEMIA-CELLS; ERYTHROID-DIFFERENTIATION; TERMINAL DIFFERENTIATION; FRIEND-ERYTHROLEUKEMIA; EXPRESSION; GENE; DISRUPTION; REGULATORS	Cell proliferation and differentiation are highly coordinated during normal development. Many tumor cells exhibit both uncontrolled proliferation and a block to terminal differentiation. To understand the mechanisms coordinating these two processes, we have investigated the relation between cyclin-dependent kinase (CDK) activities and the block to differentiation in murine erythroleukemia (MEL) cells. We found that CDK6 (but not CDK4) is rapidly downregulated as MEL cells are induced to re-enter erythroid differentiation and that maintenance of CDK6 (but not CDK4) activity by transfection blocks differentiation. Moreover, we found that PU.1, an Ets transcription factor that is oncogenic in erythroid cells and also can block their differentiation, controls the synthesis of CDK6 mRNA. These results suggest a mechanism for coupling proliferation and the block to differentiation in these leukemic cells through the action of an oncogenic transcription factor (PU.1) on a key cell cycle regulator (CDK6). Our findings suggest that studying the relative roles of CDK6 and CDK4 in other types of malignant cells will be important in designing approaches for cell cycle inhibition and differentiation therapy in cancer.	Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Skoultchi, AI (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	skoultch@aecom.yu.edu			NATIONAL CANCER INSTITUTE [R37CA016368, P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000194] Funding Source: NIH RePORTER; NCI NIH HHS [5R37CA16368, 2P30CA13330] Funding Source: Medline; NIA NIH HHS [5T32AG00194] Funding Source: Medline; NIGMS NIH HHS [5T32GM07288-25] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chilosi M, 1998, AM J PATHOL, V152, P209; Corcoran MM, 1999, ONCOGENE, V18, P6271, DOI 10.1038/sj.onc.1203033; Costello JF, 1997, CANCER RES, V57, P1250; DellaRagione F, 1997, BIOCHEM BIOPH RES CO, V231, P73, DOI 10.1006/bbrc.1997.5938; Easton J, 1998, CANCER RES, V58, P2624; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; Gossen Manfred, 1994, Current Opinion in Biotechnology, V5, P516, DOI 10.1016/0958-1669(94)90067-1; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Grossel MJ, 1999, J BIOL CHEM, V274, P29960, DOI 10.1074/jbc.274.42.29960; GUSELLA J, 1976, CELL, V9, P221, DOI 10.1016/0092-8674(76)90113-6; Hsieh FF, 2000, BLOOD, V96, P2746, DOI 10.1182/blood.V96.8.2746.h8002746_2746_2754; KIYOKAWA H, 1994, MOL CELL BIOL, V14, P7195, DOI 10.1128/MCB.14.11.7195; LEVENSON R, 1979, J CELL BIOL, V82, P715, DOI 10.1083/jcb.82.3.715; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; MARKS PA, 1987, ANN NY ACAD SCI, V511, P246, DOI 10.1111/j.1749-6632.1987.tb36252.x; Matushansky I, 2000, BLOOD, V96, P2755, DOI 10.1182/blood.V96.8.2755.h8002755_2755_2764; Matushansky I, 2000, P NATL ACAD SCI USA, V97, P14317, DOI 10.1073/pnas.250488697; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; Nerlov C, 2000, BLOOD, V95, P2543, DOI 10.1182/blood.V95.8.2543.008k19_2543_2551; Nerlov C, 1998, GENE DEV, V12, P2403, DOI 10.1101/gad.12.15.2403; PAUL R, 1989, J VIROL, V63, P4958, DOI 10.1128/JVI.63.11.4958-4961.1989; Rao G, 1997, ONCOGENE, V14, P123, DOI 10.1038/sj.onc.1200807; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; Rifkind RA, 1996, PHARMACOL THERAPEUT, V69, P97, DOI 10.1016/0163-7258(95)02044-6; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Senderowicz AM, 2000, J NATL CANCER I, V92, P1185, DOI 10.1093/jnci/92.14.1185; Steinman RA, 2002, ONCOGENE, V21, P3403, DOI 10.1038/sj.onc.1205325; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Timmermann S, 1997, CELL GROWTH DIFFER, V8, P361; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705; Zhu L, 2001, CURR OPIN GENET DEV, V11, P91, DOI 10.1016/S0959-437X(00)00162-3	34	70	73	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2003	22	27					4143	4149		10.1038/sj.onc.1206484	http://dx.doi.org/10.1038/sj.onc.1206484			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698CJ	12833137				2022-12-17	WOS:000183979800001
J	Lang, SE; Hearing, P				Lang, SE; Hearing, P			The adenovirus E1A oncoprotein recruits the cellular TRRAP/GCN5 histone acetyltransferase complex	ONCOGENE			English	Article						E1A; GCN5; TRRAP; HAT	C-MYC; TRANSCRIPTIONAL ACTIVATION; ESSENTIAL COFACTOR; CBP; TRANSFORMATION; P300; PROTEINS; PROMOTER; PCAF; E2F1	The adenovirus E1A oncoprotein stimulates cell growth and inhibits differentiation by deregulating the normal transcription program via interaction with positive and negative cellular effectors. E1A associates with transcriptional regulatory complexes containing p400 and TRRAP involved in chromatin remodeling and decondensation. TRRAP is a component of three distinct human histone acetyltransferase (HAT) complexes: the TIP60 complex and complexes containing GCN5 or PCAF. We demonstrate here that E1A binds a TRRAP complex that contains the GCN5 acetyltransferase during a normal adenovirus infection. E1A binds GCN5 and TRRAP in vivo early after virus infection. E1A is associated with significant HAT activity in vitro that is partly attributable to GCN5. E1A represses c-Myc- and E2F-1-directed transcriptional activation in vivo by sequestering GCN5 and/or TRRAP. Our results demonstrate that E1A distinctly binds TRRAP/GCN5, p300/CBP and PCAF HAT complexes. Through interactions with multiple HAT complexes, E1A may deregulate cellular transcription programs and facilitate infection by recruiting functional HAT coactivators to viral and cellular promoter regions.	SUNY Stony Brook, Sch Med, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Hearing, P (corresponding author), SUNY Stony Brook, Sch Med, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.				NATIONAL CANCER INSTITUTE [T32CA009176, P01CA028146] Funding Source: NIH RePORTER; NCI NIH HHS [CA09176, CA28146] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chan HM, 2001, J CELL SCI, V114, P2363; Deleu L, 2001, ONCOGENE, V20, P8270, DOI 10.1038/sj.onc.1205159; Fax P, 2000, J BIOL CHEM, V275, P40554, DOI 10.1074/jbc.M004626200; Fax P, 2000, J BIOL CHEM, V275, P8911, DOI 10.1074/jbc.275.12.8911; Flinn EM, 2002, J BIOL CHEM, V277, P23399, DOI 10.1074/jbc.M201704200; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; Kulesza CA, 2002, ONCOGENE, V21, P1411, DOI 10.1038/sj.onc.1205201; Lang SE, 2001, J BIOL CHEM, V276, P32627, DOI 10.1074/jbc.M102067200; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5054, DOI 10.1128/MCB.22.14.5054-5063.2002; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Park J, 2001, GENE DEV, V15, P1619, DOI 10.1101/gad.900101; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Reid JL, 1998, EMBO J, V17, P4469, DOI 10.1093/emboj/17.15.4469; Shuen M, 2002, J BIOL CHEM, V277, P30844, DOI 10.1074/jbc.M201877200; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Trouche D, 1996, P NATL ACAD SCI USA, V93, P1439, DOI 10.1073/pnas.93.4.1439; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WONG HK, 1994, J VIROL, V68, P4910, DOI 10.1128/JVI.68.8.4910-4920.1994	29	70	73	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2003	22	18					2836	2841		10.1038/sj.onc.1206376	http://dx.doi.org/10.1038/sj.onc.1206376			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ	12743606				2022-12-17	WOS:000182569300014
J	Holsinger, LJ; Ward, K; Duffield, B; Zachwieja, J; Jallal, B				Holsinger, LJ; Ward, K; Duffield, B; Zachwieja, J; Jallal, B			The transmembrane receptor protein tyrosine phosphatase DEP1 interacts with p120(ctn)	ONCOGENE			English	Article						DEP1; adherens junction; p120(ctn); protein tyrosine phosphatase	CELL-CELL-ADHESION; E-CADHERIN; SIGNAL-TRANSDUCTION; BETA-CATENIN; ALPHA-CATENIN; PHOSPHORYLATION; SUBSTRATE; COMPLEX; ASSOCIATION; DIFFERENTIATION	The receptor-like protein tyrosine phosphatase DEPI, also known as CD148, is expressed predominantly in epithelial cells, in a variety of tumor cell lines, and in lymphocytes. Expression of DEP1 is enhanced at high cell density, and this observation suggests that DEP1 may function in the regulation of cell adhesion and possibly contact inhibition of cell growth. In order to investigate the function of DEPI, substrate-trapping mutants of the phosphatase were used to identify potential substrates. GST-fusion proteins containing the DEPI catalytic domain with a substrate-trapping D/A mutation were found to interact with p120(ctn), a component of adherens junctions. DEPI also interacted with other members of the catenin gene family including beta-catenin and gamma-catenin. The interaction with p120(ctn) is likely to be direct, as the interaction occurs in K562 cells lacking functional adherens junctions and E-cadherin expression. Catalytic domains of the tyrosine phosphatases PTP-PEST, CD45, and PTPbeta did not interact with proteins of the catenin family to detectable levels, suggesting that the interaction of DEN with these proteins is specific. DEN expression was concentrated at sites of cell-cell contact in A549 cells. p120(ctn) was found to colocalize with these structures. Together these data suggest an important rote for DEP-1 in the function of cell-cell contacts and adherens junctions.	SUGEN Inc, San Francisco, CA 94080 USA	Pfizer	Holsinger, LJ (corresponding author), SUGEN Inc, 230 E Grand Ave, San Francisco, CA 94080 USA.	leslie-holsinger@sugen.com						AGHIB DF, 1995, EXP CELL RES, V218, P359, DOI 10.1006/excr.1995.1167; Aicher B, 1997, J CELL BIOL, V138, P681, DOI 10.1083/jcb.138.3.681; Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Baker JE, 2001, MOL CELL BIOL, V21, P2393, DOI 10.1128/MCB.21.7.2393-2403.2001; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Brady-Kalnay SM, 1998, J CELL BIOL, V141, P287, DOI 10.1083/jcb.141.1.287; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; Calautti E, 1998, J CELL BIOL, V141, P1449, DOI 10.1083/jcb.141.6.1449; DANIEL JM, 1995, MOL CELL BIOL, V15, P4819; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; de la Fuente-Garcia MA, 1998, BLOOD, V91, P2800, DOI 10.1182/blood.V91.8.2800.2800_2800_2809; Fachinger G, 1999, ONCOGENE, V18, P5948, DOI 10.1038/sj.onc.1202992; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Fuchs M, 1996, J BIOL CHEM, V271, P16712, DOI 10.1074/jbc.271.28.16712; Gaya A, 1999, LEUKEMIA LYMPHOMA, V35, P237, DOI 10.3109/10428199909145726; GUMBINER BM, 1995, CURR OPIN CELL BIOL, V7, P634, DOI 10.1016/0955-0674(95)80104-9; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; Jallal B, 1997, J BIOL CHEM, V272, P12158, DOI 10.1074/jbc.272.18.12158; Keane MM, 1996, CANCER RES, V56, P4236; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; Kovalenko M, 2000, J BIOL CHEM, V275, P16219, DOI 10.1074/jbc.275.21.16219; Kypta RM, 1996, J CELL BIOL, V134, P1519, DOI 10.1083/jcb.134.6.1519; Lampugnani MG, 1997, J CELL SCI, V110, P2065; LAMPUGNANI MG, 1995, J CELL BIOL, V129, P203, DOI 10.1083/jcb.129.1.203; Mariner DJ, 2001, J BIOL CHEM, V276, P28006, DOI 10.1074/jbc.M102443200; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; Osborne JM, 1998, J LEUKOCYTE BIOL, V64, P692, DOI 10.1002/jlb.64.5.692; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; Ozawa M, 1998, J BIOL CHEM, V273, P6166, DOI 10.1074/jbc.273.11.6166; Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Shiozaki H, 1996, CANCER, V77, P1605, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1605::AID-CNCR4>3.3.CO;2-R; Sorby M, 2001, ONCOGENE, V20, P5219, DOI 10.1038/sj.onc.1204581; STADDON JM, 1995, J CELL BIOL, V130, P369, DOI 10.1083/jcb.130.2.369; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; Takahashi T, 1999, J AM SOC NEPHROL, V10, P2135; Tangye SG, 1998, J IMMUNOL, V161, P3249; Tangye SG, 1998, J IMMUNOL, V161, P3803; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624; Zondag GCM, 2000, J BIOL CHEM, V275, P11264, DOI 10.1074/jbc.275.15.11264	49	70	80	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2002	21	46					7067	7076		10.1038/sj.onc.1205858	http://dx.doi.org/10.1038/sj.onc.1205858			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370829				2022-12-17	WOS:000178424900010
J	Gallo, A; Cuozzo, C; Esposito, I; Maggiolini, M; Bonofiglio, D; Vivacqua, A; Garramone, M; Weiss, C; Bohmann, D; Musti, AM				Gallo, A; Cuozzo, C; Esposito, I; Maggiolini, M; Bonofiglio, D; Vivacqua, A; Garramone, M; Weiss, C; Bohmann, D; Musti, AM			Menin uncouples Elk-1, JunD and c-Jun phosphorylation from MAP kinase activation	ONCOGENE			English	Article						AP-1; menin; Elk-1; MAPK; JunD	MULTIPLE ENDOCRINE NEOPLASIA; SIGNAL-REGULATED KINASE; CELL-PROLIFERATION; SOMATIC MUTATION; GROWTH-FACTORS; FOS PROMOTER; HA-RAS; PROTEIN; TRANSFORMATION; TRANSCRIPTION	Menin, a nuclear protein encoded by the tumor suppressor gene MEN1, interacts with the AP-1 transcription factor JunD and inhibits its transcriptional activity. In addition, overexpression of Menin counteracts Ras-induced tumorigenesis. We show that Menin inhibits ERK-dependent phosphorylation and activation of both JunD and the Ets-domain transcription factor Elk-1. We also show that Menin represses the inducible activity of the c-fos promoter. Furthermore, Menin expression inhibits Jun N-terminal kinase (JNK)mediated phosphorylation of both JunD and c-Jun. Kinase assays show that Menin overexpression does not interfere with activation of either ERK2 or JNK1, suggesting that Menin acts at a level downstream of MAPK activation. An N-terminal deletion mutant of Menin that cannot inhibit JunD phosphorylation by JNK, can still repress JunD phosphorylation by ERK2, suggesting that Menin interferes with ERK and JNK pathways through two distinct inhibitory mechanisms. Taken together, our data suggest that Menin uncouples ERK and JNK activation from phosphorylation of their nuclear targets Elk-1, JunD and c-Jun, hence inhibiting accumulation of active Fos/Jun heterodimers. This study provides new molecular insights into the tumor suppressor function of Menin and suggests a mechanism by which Menin may interfere with Ras-dependent cell transformation and oncogenesis.	Univ Naples Federico II, CNR, Dipartimento Biol & Patol Cellulare & Mol, Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Univ Calabria, Dipartimento Farmacobiol, I-87036 Arcavacata Di Rende, CS, Italy; Univ Rochester, Med Ctr, Dept Biomed Genet, Rochester, NY 14642 USA	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; University of Calabria; University of Rochester	Musti, AM (corresponding author), Univ Naples Federico II, CNR, Dipartimento Biol & Patol Cellulare & Mol, Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy.		vivacqua, adele/I-2771-2015; Musti, Anna Maria/M-2520-2019; Maggiolini, Marcello/Z-4729-2019; Bonofiglio, Daniela/AAV-8371-2020; Weiss, Carsten/I-1811-2013	vivacqua, adele/0000-0001-5333-8396; Weiss, Carsten/0000-0002-5380-3208; BONOFIGLIO, Daniela/0000-0002-4142-0496; MUSTI, Anna Maria/0000-0003-1443-2739; Maggiolini, Marcello/0000-0002-7485-854X				Agarwal SK, 1999, CELL, V96, P143, DOI 10.1016/S0092-8674(00)80967-8; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Crabtree JS, 2001, P NATL ACAD SCI USA, V98, P1118, DOI 10.1073/pnas.98.3.1118; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Gobl AE, 1999, BBA-GENE STRUCT EXPR, V1447, P51, DOI 10.1016/S0167-4781(99)00132-3; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Guru SC, 1998, P NATL ACAD SCI USA, V95, P1630, DOI 10.1073/pnas.95.4.1630; Heppner C, 1997, NAT GENET, V16, P375, DOI 10.1038/ng0897-375; Heppner C, 2001, ONCOGENE, V20, P4917, DOI 10.1038/sj.onc.1204529; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Houslay MD, 2000, MOL PHARMACOL, V58, P659, DOI 10.1124/mol.58.4.659; JANKNECHT R, 1995, CARCINOGENESIS, V16, P443, DOI 10.1093/carcin/16.3.443; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JANKNECHT R, 1994, ONCOGENE, V9, P1273; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Kaji H, 2001, P NATL ACAD SCI USA, V98, P3837, DOI 10.1073/pnas.061358098; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kim YS, 1999, ONCOGENE, V18, P5936, DOI 10.1038/sj.onc.1203005; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Marx SJ, 1999, RECENT PROG HORM RES, V54, P397; Marx SJ, 1998, J INTERN MED, V243, P447; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; Musti AM, 1996, BIOL CHEM, V377, P619, DOI 10.1515/bchm3.1996.377.10.619; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; Qiu WS, 2000, J BIOL CHEM, V275, P31921, DOI 10.1074/jbc.M003327200; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Rosenberger SF, 1999, J BIOL CHEM, V274, P1124, DOI 10.1074/jbc.274.2.1124; Sambrook J., 1989, MOL CLONING LAB MANU; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Wang HL, 1996, ONCOGENE, V13, P2639; Watanabe S, 1996, J BIOL CHEM, V271, P12681, DOI 10.1074/jbc.271.21.12681; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710	52	70	75	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 19	2002	21	42					6434	6445		10.1038/sj.onc.1205822	http://dx.doi.org/10.1038/sj.onc.1205822			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592FD	12226747				2022-12-17	WOS:000177925300004
J	Olsen, CL; Gardie, GB; Yaswen, P; Stampfer, MR				Olsen, CL; Gardie, GB; Yaswen, P; Stampfer, MR			Raf-1-induced growth arrest in human mammary epithelial cells is p16-independent and is overcome in immortal cells during conversion	ONCOGENE			English	Article						conversion; senescence; immortalizatiom; Raf-1; p16(INK4a); human mammary epithelial cells	RAF-1 PROTEIN-KINASE; CYCLE ARREST; ONCOGENIC RAS; CANCER CELLS; SENESCENCE; TRANSFORMATION; FIBROBLASTS; EXPRESSION; ACTIVATION; INDUCTION	Using an estrogen-inducible retroviral system, we demonstrate that oncogenie Raf-1 induces growth arrest and morphological changes in finite lifespan human mammary epithelia] cells (HMEC). This arrest does not rely on expression of the cyclin-dependent kinase inhibitor (CKI) p16(INK4a), nor on changes in expression of the CKIs p21(Cip1), p14(ARF), p27(Kip1) or p57(Kip2). The Raf-induced arrest is independent of viral oncogene mediated inactivation of p53 and pRB, or e-myc overexpression. Flow cytometric analysis demonstrates that cells arrest in both G1 and G2. The Raf-induced arrest is mitigated or eliminated in some immortally transformed HMEC. Immortal HMEC that have both overcome replicative senescence and undergone the recently described conversion process maintain growth in the presence of transduced oncogenic Raf-1; they also gain EGF-independent growth and a low frequency of anchorage-independent growth. However, HMEC that have overcome replicative senescence but have not undergone conversion and HMEC immortalized by transduction with the catalytic subunit of telomerase, hTERT, remain severely growth arrested. These results indicate that the molecular mechanisms responsible for the Raf-1-induced growth arrest may Nary among different finite lifespan cell types, and that in HMEC, this mechanism is altered during the conversion process, rather than as a direct consequence of overcoming senescence or expressing hTERT.	Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Stampfer, MR (corresponding author), Lawrence Berkeley Natl Lab, Div Life Sci, 1 Cyclotron Rd,Bldg 70A-1118, Berkeley, CA 94720 USA.				NCI NIH HHS [CA-24822] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEY MC, 1988, CANCER RES, V48, P589; Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; ElAshry D, 1997, ONCOGENE, V15, P423, DOI 10.1038/sj.onc.1201198; Fanton CP, 2001, J BIOL CHEM, V276, P18871, DOI 10.1074/jbc.M011514200; FINER MH, 1994, BLOOD, V83, P43; Garbe J, 1999, ONCOGENE, V18, P2169, DOI 10.1038/sj.onc.1202523; Gardie B, 1998, BLOOD, V91, P1016, DOI 10.1182/blood.V91.3.1016.1016_1016_1020; HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; Krtolica A, 1996, CANCER RES, V56, P1168; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; Malumbres M, 2000, MOL CELL BIOL, V20, P2915, DOI 10.1128/MCB.20.8.2915-2925.2000; MCMAHON M, 2000, BIOCHIM BIOPHYS ACTA, P1; Nijjar T, 1999, CANCER RES, V59, P5112; Ravi RK, 1999, J CELL BIOCHEM, V72, P458, DOI 10.1002/(SICI)1097-4644(19990315)72:4<458::AID-JCB2>3.0.CO;2-C; Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579; Roper E, 2001, EMBO REP, V2, P145, DOI 10.1093/embo-reports/kve020; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Stampfer M, 1985, J TISSUE CULTURE MET, V9, P107; Stampfer MR, 1997, MOL BIOL CELL, V8, P2391, DOI 10.1091/mbc.8.12.2391; STAMPFER MR, 1993, EXP CELL RES, V208, P175, DOI 10.1006/excr.1993.1236; Stampfer MR, 2000, J MAMMARY GLAND BIOL, V5, P365, DOI 10.1023/A:1009525827514; Stampfer MR, 2001, P NATL ACAD SCI USA, V98, P4498, DOI 10.1073/pnas.071483998; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; Tlsty TD, 2001, J MAMMARY GLAND BIOL, V6, P235, DOI 10.1023/A:1011369026168; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	35	70	72	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 12	2002	21	41					6328	6339		10.1038/sj.onc.1205780	http://dx.doi.org/10.1038/sj.onc.1205780			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214273	Green Submitted			2022-12-17	WOS:000177829000009
J	Ueda, K; Murata-Hori, M; Tatsuka, M; Hosoya, H				Ueda, K; Murata-Hori, M; Tatsuka, M; Hosoya, H			Rho-kinase contributes to diphosphorylation of myosin II regulatory light chain in nonmuscle cells	ONCOGENE			English	Article						myosin II regulatory light chain; diphosphorylation; Rho-kinase; reorganization of actin filaments; nonmuscle cells	SMOOTH-MUSCLE MYOSIN; GTP-BINDING PROTEIN; ACTIN STRESS FIBERS; FOCAL ADHESIONS; SERINE/THREONINE KINASE; PLATELET MYOSIN; CLEAVAGE FURROW; TUMOR-CELLS; HELA-CELLS; 2ND SITE	Phosphorylation of myosin 11 regulatory light chain (MRLC) is important for cell motility and cytokinesis in nonmuscle cells. Although the regulation of monophosphorylated MRLC at serine 19 throughout the cell cycle was examined in detail, MRLC diphosphorylation at both threonine 18 and serine 19 is still unclear. Here we found that Rho-kinase has an activity for MRLC diphosphorylation in nonmuscle cells using sequential column chromatographies. Transfection of Rho-kinase-EGFP induced the excess diphosphorylated MRLC and the bundling of the actin filaments. Conversely, the treatment of cells with a specific inhibitor of Rho-kinase, Y-27632, resulted in the decrease of endogenous diphosphorylated MRLC and actin stress fibers. Immunolocatization studies showed that both diphosphorylated MRLC and Rho-kinase accumulated and colocalized at the contractile ring and the midbody in dividing cells. Taken together, it is suggested that Rho-kinase contributes to MRLC diphosphorylation and reorganization of actin filaments in nonmuscle cells.	Hiroshima Univ, Dept Biol Sci, Grad Sch Sci, Higashihiroshima 7398526, Japan; Hiroshima Univ, Dept Mol Radiobiol, Res Inst Radiat Biol & Med, Hiroshima 7348553, Japan	Hiroshima University; Hiroshima University	Hosoya, H (corresponding author), Hiroshima Univ, Dept Biol Sci, Grad Sch Sci, Higashihiroshima 7398526, Japan.			Hamao, Kozue/0000-0002-9594-1940				Ai S, 2001, ATHEROSCLEROSIS, V155, P321, DOI 10.1016/S0021-9150(00)00585-2; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; APPLEGATE D, 1992, J CELL BIOL, V117, P1223, DOI 10.1083/jcb.117.6.1223; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; Feng JH, 1999, J BIOL CHEM, V274, P37385, DOI 10.1074/jbc.274.52.37385; GOECKELER ZM, 1995, J CELL BIOL, V130, P613, DOI 10.1083/jcb.130.3.613; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; Helige C, 1997, INVAS METAST, V17, P26; Hino M, 2000, BIOCHEM BIOPH RES CO, V271, P164, DOI 10.1006/bbrc.2000.2553; IKEBE M, 1989, BIOCHEMISTRY-US, V28, P8750, DOI 10.1021/bi00448a011; IKEBE M, 1986, J BIOL CHEM, V261, P36; IKEBE M, 1985, J BIOL CHEM, V260, P27; Ishikawa K, 1998, DNA Res, V5, P169, DOI 10.1093/dnares/5.3.169; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; ITOH K, 1992, BIOCHIM BIOPHYS ACTA, V1136, P52, DOI 10.1016/0167-4889(92)90084-O; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Kaneko K, 2002, PANCREAS, V24, P34, DOI 10.1097/00006676-200201000-00005; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; Kolega J, 1999, CELL MOTIL CYTOSKEL, V43, P255, DOI 10.1002/(SICI)1097-0169(1999)43:3<255::AID-CM8>3.0.CO;2-T; Kosako H, 2000, ONCOGENE, V19, P6059, DOI 10.1038/sj.onc.1203987; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Matsumura F, 1998, J CELL BIOL, V140, P119, DOI 10.1083/jcb.140.1.119; Murata-Hori M, 1998, BIOMED RES-TOKYO, V19, P111, DOI 10.2220/biomedres.19.111; Murata-Hori M, 2001, ONCOGENE, V20, P8175, DOI 10.1038/sj.onc.1205055; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sakurada K, 1998, AM J PHYSIOL-CELL PH, V274, pC1563, DOI 10.1152/ajpcell.1998.274.6.C1563; Somlyo AV, 2000, BIOCHEM BIOPH RES CO, V269, P652, DOI 10.1006/bbrc.2000.2343; Suizu F, 2000, J BIOCHEM-TOKYO, V128, P435, DOI 10.1093/oxfordjournals.jbchem.a022771; TAKAISHI K, 1994, ONCOGENE, V9, P273; Totsukawa G, 2000, J CELL BIOL, V150, P797, DOI 10.1083/jcb.150.4.797; TRYBUS KM, 1989, J CELL BIOL, V109, P2887, DOI 10.1083/jcb.109.6.2887; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Yasui Y, 1998, J CELL BIOL, V143, P1249, DOI 10.1083/jcb.143.5.1249; Yoshioka K, 1998, J BIOL CHEM, V273, P5146, DOI 10.1074/jbc.273.9.5146	42	70	70	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2002	21	38					5852	5860		10.1038/sj.onc.1205747	http://dx.doi.org/10.1038/sj.onc.1205747			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185584				2022-12-17	WOS:000177520900004
J	Blaker, H; von Herbay, A; Penzel, R; Gross, S; Otto, HF				Blaker, H; von Herbay, A; Penzel, R; Gross, S; Otto, HF			Genetics of adenocarcinomas of the small intestine: frequent deletions at chromosome 18q and mutations of the SMAD4 gene	ONCOGENE			English	Article						small intestine; adenocarcinoma; LOH; CGH; SMAD4	COMPARATIVE GENOMIC HYBRIDIZATION; INTERNATIONAL COLLABORATIVE GROUP; NONPOLYPOSIS COLORECTAL-CANCER; K-RAS MUTATIONS; MICROSATELLITE INSTABILITY; CARCINOMAS; POLYPOSIS; LOSSES; GAINS; DPC4	The small intestinal mucosa makes up about 90% of the total surface of the gastrointestinal tract. However, adenocarcinomas arise rarely in this location. To elucidate genetic alterations underlying tumour development in the small intestine we investigated 17 sporadic adenocarcinomas. By comparative genomic hybridization recurrent gains of chromosomal material were found at chromosomes 7, 8, 13q, and 20 (5/17, each), while non-random losses were seen at 8p, 17p (4/17, each), and 18 (8/17 cases). Deletions at 5q, the location of the APC tumour suppressor gene, were seen in three cases. Microsatellite analysis with markers on chromosomal arms 1p, 5q, 8p, 17p, 18q, 19p, and 22q revealed a microsatellite instable phenotype in two cases and a high frequency of loss at 18q21-q22 (80%). Given the high incidence of 18q21-q22 deletions, we performed sequencing analysis of SMAD4, a downstream component of the TGF beta -pathway, located at 18q21. Four tumours displayed mutations in highly conserved domains of the gene indicating disruption of TGF beta -signalling. Our data reveal complex genetic alterations in sporadic small intestinal carcinomas. However, most tumours share deletions of 18q21-q22, which frequently target SMAD4. This indicates that disruption of TGF beta -signalling plays a critical role in small intestinal tumorigenesis.	Heidelberg Univ, Dept Pathol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Blaker, H (corresponding author), Heidelberg Univ, Dept Pathol, Neuenheimer Feld 220-221, D-69120 Heidelberg, Germany.	hendrik.blaeker@med.uni-heidelberg.de						Arai M, 1997, INT J CANCER, V70, P390, DOI 10.1002/(SICI)1097-0215(19970207)70:4<390::AID-IJC3>3.0.CO;2-R; Arber N, 2000, GASTROENTEROLOGY, V118, P1045, DOI 10.1016/S0016-5085(00)70357-X; Blaker H, 1999, GENE CHROMOSOME CANC, V25, P399; De Angelis PM, 1999, BRIT J CANCER, V80, P526; EMI M, 1992, CANCER RES, V52, P5368; Houlston R, 1998, HUM MOL GENET, V7, P1907, DOI 10.1093/hmg/7.12.1907; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; ISOLA J, 1994, AM J PATHOL, V145, P1301; Jones JB, 2000, NUCLEIC ACIDS RES, V28, P2363, DOI 10.1093/nar/28.12.2363; KIM HG, 1994, AM J PATHOL, V145, P148; LENNARDJONES JE, 1977, GASTROENTEROLOGY, V73, P1280; Lerebours F, 1999, GENE CHROMOSOME CANC, V25, P147, DOI 10.1002/(SICI)1098-2264(199906)25:2<147::AID-GCC10>3.0.CO;2-Z; LIGHTDALE CJ, 1994, BOCKUS GASTROENTEROL, P1274; LOGAN RFA, 1989, GASTROENTEROLOGY, V97, P265, DOI 10.1016/0016-5085(89)90060-7; Mahlamaki EH, 1997, GENE CHROMOSOME CANC, V20, P383, DOI 10.1002/(SICI)1098-2264(199712)20:4<383::AID-GCC10>3.0.CO;2-O; Messerini L, 1997, J PATHOL, V182, P380; MING SC, 1992, PATHOLOGY GASTROINTE, P816; Moore PS, 2000, HUM MUTAT, V15; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Moskaluk CA, 1997, DIAGN MOL PATHOL, V6, P85, DOI 10.1097/00019606-199704000-00003; Murata M, 2000, AM J GASTROENTEROL, V95, P1576; Negri E, 1999, INT J CANCER, V82, P171, DOI 10.1002/(SICI)1097-0215(19990719)82:2&lt;171::AID-IJC3&gt;3.0.CO;2-T; Neugut AI, 1998, CANCER EPIDEM BIOMAR, V7, P243; Park JG, 1999, DIS COLON RECTUM, V42, P710, DOI 10.1007/BF02236922; Pohl C, 2000, HEPATO-GASTROENTEROL, V47, P57; Rashid A, 1997, GASTROENTEROLOGY, V113, P127, DOI 10.1016/S0016-5085(97)70087-8; Roth S, 1999, GENE CHROMOSOME CANC, V26, P54, DOI 10.1002/(SICI)1098-2264(199909)26:1<54::AID-GCC8>3.0.CO;2-D; Sakakura C, 1999, GENE CHROMOSOME CANC, V24, P299, DOI 10.1002/(SICI)1098-2264(199904)24:4<299::AID-GCC2>3.0.CO;2-U; Schutte M, 1996, CANCER RES, V56, P2527; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; SPIGELMAN AD, 1989, LANCET, V2, P783, DOI 10.1016/s0140-6736(89)90840-4; Sutter T, 1996, DIGEST DIS SCI, V41, P115, DOI 10.1007/BF02208591; Tarapore P, 2000, CANCER INVEST, V18, P148, DOI 10.3109/07357900009038246; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; Thibodeau SN, 1998, CANCER RES, V58, P1713; Vasen HFA, 1999, GASTROENTEROLOGY, V116, P1453, DOI 10.1016/S0016-5085(99)70510-X; VISAKORPI T, 1995, CANCER RES, V55, P342; Whitelaw SC, 1997, GASTROENTEROLOGY, V112, P327, DOI 10.1053/gast.1997.v112.pm9024286; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504; Yustein AS, 1999, CANCER RES, V59, P1437	40	70	70	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2002	21	1					158	164		10.1038/sj.onc.1205041	http://dx.doi.org/10.1038/sj.onc.1205041			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	505AD	11791187				2022-12-17	WOS:000172887800017
J	Dorey, K; Engen, JR; Kretzschmar, J; Wilm, M; Neubauer, G; Schindler, T; Superti-Furga, G				Dorey, K; Engen, JR; Kretzschmar, J; Wilm, M; Neubauer, G; Schindler, T; Superti-Furga, G			Phosphorylation and structure-based functional studies reveal a positive and a negative role for the activation loop of the c-Abl tyrosine kinase	ONCOGENE			English	Article						activation loop; crystal structure; phosphorylation; tyrosine kinase	PROTEIN-KINASE; CRYSTAL-STRUCTURE; ONCOGENIC FORMS; BCR-ABL; SRC; DOMAIN; FAMILY; AUTOPHOSPHORYLATION; MUTATION; RESIDUES	c-Abl is a nuclear and cytoplasmic tyrosine kinase involved in a variety of cellular growth and differentiation processes. In contrast to its oncogenic counterparts, like BCR-Abl, c-Abl is not constitutively tyrosine phosphorylated and its catalytic activity is very low. Here we report tyrosine phosphorylation of endogenous c-Abl and a concomitant increase in catalytic activity. Using Abl -/- cells reconstituted with mutated c-Abl forms, we show that phosphorylation and activity depend on Tyr412 in the activation loop. Tyr412 is also required for stimulation by PDGF or by cotransfection of active Src. Phosphorylation of Tyr412 can occur autocatalytically by a trans-mechanism and cause activation of otherwise inactive c-Abl, suggesting a positive feedback loop on c-Abl activity. In the recent structure of the Abl catalytic domain bound to the STI-571 inhibitor, unphosphorylated Tyr412 in the activation loop points inward and appears to interfere with catalysis. We mutated residues involved in stabilizing this inhibited form of the activation loop and in positioning Tyr412. These mutations resulted in tyrosine phosphorylation and activation of c-Abl, as if relieving c-Abl from inhibition. Tyr412 is therefore necessary both for activity and for regulation of c-Abl, by stabilizing the inactive or the active conformation of the enzyme in a phosphorylation-dependent manner.	European Mol Biol Lab, Dev Biol Programme, D-69117 Heidelberg, Germany; European Mol Biol Lab, Biochem Instrumentat Programme, D-69117 Heidelberg, Germany; Rockefeller Univ, Labs Mol Biophys, New York, NY 10021 USA	European Molecular Biology Laboratory (EMBL); European Molecular Biology Laboratory (EMBL); Rockefeller University	Superti-Furga, G (corresponding author), European Mol Biol Lab, Dev Biol Programme, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Superti-Furga, Giulio/F-4755-2015; Superti-Furga, Giulio/AAE-5681-2019	Superti-Furga, Giulio/0000-0002-0570-1768; Wilm, Matthias/0000-0002-5461-6834; Dorey, Karel/0000-0003-0846-5286; Engen, John R./0000-0002-6918-9476				Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Allen PB, 1996, J BIOL CHEM, V271, P19585, DOI 10.1074/jbc.271.32.19585; Ausubel F., 1992, MOL REPROD DEV, DOI DOI 10.1002/MRD.1080010210; Barila D, 2000, EMBO J, V19, P273, DOI 10.1093/emboj/19.2.273; Barila D, 1998, NAT GENET, V18, P280, DOI 10.1038/ng0398-280; Brasher BB, 2000, J BIOL CHEM, V275, P35631, DOI 10.1074/jbc.M005401200; Cong F, 1999, MOL CELL BIOL, V19, P8314; Cong F, 2000, MOL CELL, V6, P1413, DOI 10.1016/S1097-2765(00)00138-6; Dikstein R, 1996, P NATL ACAD SCI USA, V93, P2387, DOI 10.1073/pnas.93.6.2387; Dorey K, 1999, BIOL CHEM, V380, P223; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; Gonfloni S, 2000, NAT STRUCT BIOL, V7, P281; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hubbard SR, 1999, PROG BIOPHYS MOL BIO, V71, P343, DOI 10.1016/S0079-6107(98)00047-9; Hubbard SR, 1999, NAT STRUCT BIOL, V6, P711, DOI 10.1038/11468; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Juang JL, 1999, ONCOGENE, V18, P5138, DOI 10.1038/sj.onc.1202911; KINGHTON DR, 1991, SCIENCE, V253, P415; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Neet K, 1996, GENES CELLS, V1, P147, DOI 10.1046/j.1365-2443.1996.d01-234.x; PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Raitano A. B., 1997, BIOCHIM BIOPHYS ACTA, V1333, P201, DOI 10.1016/S0304-419X(97)00023-1; SAWYERS CL, 1994, CELL, V77, P1; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; SEFTON BM, 1981, P NATL ACAD SCI-BIOL, V78, P1552, DOI 10.1073/pnas.78.3.1552; Smith CM, 1999, PROG BIOPHYS MOL BIO, V71, P313, DOI 10.1016/S0079-6107(98)00059-5; Smith JM, 1999, J BIOL CHEM, V274, P27956, DOI 10.1074/jbc.274.39.27956; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WITTE ON, 1981, J VIROL, V39, P870, DOI 10.1128/JVI.39.3.870-878.1981; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; Zou XM, 1999, J BIOL CHEM, V274, P18141, DOI 10.1074/jbc.274.26.18141	39	70	71	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 6	2001	20	56					8075	8084		10.1038/sj.onc.1205017	http://dx.doi.org/10.1038/sj.onc.1205017			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	496LJ	11781820				2022-12-17	WOS:000172396800004
J	Ichaso, N; Dilworth, SM				Ichaso, N; Dilworth, SM			Cell transformation by the middle T-antigen of polyoma virus	ONCOGENE			English	Review						middle T-antigen; cell transformation; signalling pathways; tyrosine kinases; PP2A	PROTEIN PHOSPHATASE 2A; PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; MEDIUM TUMOR-ANTIGEN; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; COMPLEX-FORMATION; NEOPLASTIC TRANSFORMATION; ONCOGENIC TRANSFORMATION; MONOCLONAL-ANTIBODIES; SH2 DOMAINS	The polyoma virus region expressed early in the lytic cycle encodes three proteins, or T-antigens, that together cause the infected cell to enter the cell cycle and so provide a suitable cellular environment for replication of the viral genome. Under some circumstances infection does not kill the cell, but the T-antigens are still produced, resulting in the cell becoming transformed and tumorigenic. Most of this transforming action is exerted by the middle T-antigen, which has the ability to convert established cell lines to an oncogenic state. Middle T is a membrane bound polypeptide that interacts with a number of the proteins used by tyrosine kinase associated receptors to stimulate mitogenesis, so MT can be considered as a permanently active analogue of a receptor. Through a defined series of interactions, MT assembles a large multi-protein complex at the cell membrane, consisting of MT, the core dimer of protein phosphatase 2A, an si-c-family tyrosine kinase, and via phosphotyrosines, ShcA, phosphatidylinositol (3') kinase, and phospholipase C gamma -1. Tyrosine phosphorylation stimulates PI3K and PLC gamma -1 enzymatic activity, and on ShcA creates binding sites for Grb2 with its associated Sos1 and Gab1. This activates p21(ras), and hence, the MAP kinase cascade. Consequently, MT can be used as a model for studying cell transformation and growth factor receptor signalling pathways.	Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Metab Med, London W12 0NN, England	Imperial College London	Dilworth, SM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Metab Med, Du Cane Rd, London W12 0NN, England.	s.dilworth@ic.ac.uk						Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Blaikie PA, 1997, J BIOL CHEM, V272, P20671, DOI 10.1074/jbc.272.33.20671; Brewster CEP, 1997, J VIROL, V71, P5512, DOI 10.1128/JVI.71.7.5512-5520.1997; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CAMPBELL KS, 1995, J VIROL, V69, P3721, DOI 10.1128/JVI.69.6.3721-3728.1995; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; Chen YC, 1999, ONCOGENE, V18, P139, DOI 10.1038/sj.onc.1202272; CHENG SH, 1988, MOL CELL BIOL, V8, P1736, DOI 10.1128/MCB.8.4.1736; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; COHEN B, 1990, MOL CELL BIOL, V10, P2909, DOI 10.1128/MCB.10.6.2909; COHEN B, 1990, P NATL ACAD SCI USA, V87, P4458, DOI 10.1073/pnas.87.12.4458; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; COURTNEIDGE SA, 1991, J VIROL, V65, P3301, DOI 10.1128/JVI.65.6.3301-3308.1991; Cullere X, 1998, J VIROL, V72, P558; DAHL J, 1992, MOL CELL BIOL, V12, P5050, DOI 10.1128/MCB.12.11.5050; Dankort DL, 2000, ONCOGENE, V19, P1038, DOI 10.1038/sj.onc.1203272; DILWORTH SM, 1982, P NATL ACAD SCI-BIOL, V79, P1059, DOI 10.1073/pnas.79.4.1059; DILWORTH SM, 1993, J VIROL, V67, P2235, DOI 10.1128/JVI.67.4.2235-2244.1993; DILWORTH SM, 1986, EMBO J, V5, P491, DOI 10.1002/j.1460-2075.1986.tb04238.x; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; Dilworth Stephen M., 1995, Trends in Microbiology, V3, P31, DOI 10.1016/S0966-842X(00)88866-6; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; DRUKER BJ, 1992, J VIROL, V66, P5770, DOI 10.1128/JVI.66.10.5770-5776.1992; Dunant N, 1997, CELL SIGNAL, V9, P385, DOI 10.1016/S0898-6568(97)00040-5; Dunant NM, 1996, J VIROL, V70, P1323, DOI 10.1128/JVI.70.3.1323-1330.1996; Dunant NM, 1997, J VIROL, V71, P199, DOI 10.1128/JVI.71.1.199-206.1997; EDDY BE, 1958, P SOC EXP BIOL MED, V98, P848; Elliott J, 1998, ONCOGENE, V17, P1797, DOI 10.1038/sj.onc.1202083; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; GLENN GM, 1995, J VIROL, V69, P3729, DOI 10.1128/JVI.69.6.3729-3736.1995; Glover HR, 1999, ONCOGENE, V18, P4364, DOI 10.1038/sj.onc.1202816; GORGA FR, 1990, J VIROL, V64, P105, DOI 10.1128/JVI.64.1.105-112.1990; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Goutebroze L, 1997, J VIROL, V71, P1436, DOI 10.1128/JVI.71.2.1436-1442.1997; GROSS L, 1953, P SOC EXP BIOL MED, V83, P414; Helmbrecht K, 2000, CELL PROLIFERAT, V33, P341, DOI 10.1046/j.1365-2184.2000.00189.x; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; Kennedy AP, 1998, J BIOL CHEM, V273, P11505, DOI 10.1074/jbc.273.19.11505; KIEFER F, 1994, ADV CANCER RES, V64, P125, DOI 10.1016/S0065-230X(08)60837-4; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LING LE, 1992, J VIROL, V66, P1702, DOI 10.1128/JVI.66.3.1702-1708.1992; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; MAGNUSSON G, 1981, J VIROL, V39, P673, DOI 10.1128/JVI.39.3.673-683.1981; MARCELLUS R, 1991, ONCOGENE, V6, P1037; MARKLAND W, 1986, J VIROL, V59, P384, DOI 10.1128/JVI.59.2.384-391.1986; MARKLAND W, 1987, BIOCHIM BIOPHYS ACTA, V907, P299, DOI 10.1016/0304-419X(87)90011-4; MATTHEWS JT, 1986, J VIROL, V58, P239, DOI 10.1128/JVI.58.2.239-246.1986; Meier R, 1999, J RECEPT SIGNAL TR R, V19, P121, DOI 10.3109/10799899909036639; Meili R, 1998, ONCOGENE, V16, P903, DOI 10.1038/sj.onc.1201605; Messerschmitt AS, 1997, VIROLOGY, V227, P271, DOI 10.1006/viro.1996.8316; METCALF D, 1987, EMBO J, V6, P3703, DOI 10.1002/j.1460-2075.1987.tb02704.x; MUMBY M, 1995, SEMIN CANCER BIOL, V6, P229, DOI 10.1006/scbi.1995.0030; MUSER J, 1989, ONCOGENE, V4, P1433; NICHOLSON PR, 2001, VIRUSES CELL TRANSFO, P85; Ogris E, 1999, J VIROL, V73, P7390, DOI 10.1128/JVI.73.9.7390-7398.1999; PALLAS DC, 1989, J VIROL, V63, P4533, DOI 10.1128/JVI.63.11.4533-4539.1989; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Platko JD, 1998, EXP CELL RES, V238, P42, DOI 10.1006/excr.1997.3782; RASSOULZADEGAN M, 1983, P NATL ACAD SCI-BIOL, V80, P4354, DOI 10.1073/pnas.80.14.4354; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; RUEDIGER R, 1992, MOL CELL BIOL, V12, P4872, DOI 10.1128/MCB.12.11.4872; SALCINI AE, 1994, ONCOGENE, V9, P2827; SCHERNECK S, 1990, Archiv fuer Geschwulstforschung, V60, P271; Senften M, 1997, J VIROL, V71, P6990, DOI 10.1128/JVI.71.9.6990-6995.1997; SERUNIAN LA, 1990, J VIROL, V64, P4718, DOI 10.1128/JVI.64.10.4718-4725.1990; SU W, 1995, J BIOL CHEM, V270, P12331, DOI 10.1074/jbc.270.21.12331; Summers SA, 1998, BIOCHEM BIOPH RES CO, V246, P76, DOI 10.1006/bbrc.1998.8575; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TEMPLETON D, 1984, MOL CELL BIOL, V4, P282, DOI 10.1128/MCB.4.2.282; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; ULUG ET, 1992, J VIROL, V66, P1458, DOI 10.1128/JVI.66.3.1458-1467.1992; ULUG ET, 1990, J VIROL, V64, P3895, DOI 10.1128/JVI.64.8.3895-3904.1990; Urich M, 1997, ONCOGENE, V14, P1235, DOI 10.1038/sj.onc.1200982; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; VICIANA PR, 1994, NATURE, V370, P527; WALTER G, 1987, J VIROL, V61, P405, DOI 10.1128/JVI.61.2.405-410.1987; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; YOAKIM M, 1992, J VIROL, V66, P5485, DOI 10.1128/JVI.66.9.5485-5491.1992; YONEMOTO W, 1987, MOL CELL BIOL, V7, P905, DOI 10.1128/MCB.7.2.905; Zhu WJ, 1998, ONCOGENE, V17, P565, DOI 10.1038/sj.onc.1201979	89	70	72	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	2001	20	54					7908	7916		10.1038/sj.onc.1204859	http://dx.doi.org/10.1038/sj.onc.1204859			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	495JF	11753673				2022-12-17	WOS:000172336500010
J	Hoover, RR; Gerlach, MJ; Koh, EY; Daley, GQ				Hoover, RR; Gerlach, MJ; Koh, EY; Daley, GQ			Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells	ONCOGENE			English	Article						BCR/ABL; signal transduction; STAT5; Ras; apoptosis; DNA damage	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; ABL TYROSINE KINASE; BCR-ABL; INHIBITS APOPTOSIS; ACTIVATION; RECEPTOR; P210; SURVIVAL; GROWTH	The Akt, Ras and STAT5 signaling pathways have each been linked to transformation of hematopoietic cells by BCR/ABL. However the relative contributions of these signaling pathways to BCR/ABL mediated cytokine-independent survival, proliferation and resistance to DNA damage-induced apoptosis have not been systematically defined. Here we report that activation of either Akt, Ras or STAT5 confers cytokine-independent survival to IL-3 dependent BaF3 cells. Ras or STAT5, but not Akt, also drives cytokine-independent proliferation and imparts sustained resistance to DNA damage-induced apoptosis. We also show that dominant negative (DN) inhibition of STAT5, but not Ras or Akt, significantly reduces resistance to DNA damage-induced apoptosis in BCR/ABL transformed BaF3 cells. Whereas inhibition of STAT5 or Ras alone does not compromise cytokine-independent proliferation of BaF3-BCR/ABL cells, simultaneous blockade of both STAT5 and Ras reduces proliferation and maximally sensitizes BaF3-BCR/ABL cells to DNA damage induced by gamma -irradiation, suggesting a cooperative role for these two signaling pathways in BCR/ABL transformation. The anti-apoptotic properties of BCR/ABL can be partly explained by an increase in the expression of Pim-1 and Bcl-XL, as ectopic expression of these STAT5 target genes imparts both cytokine-independent survival and partial gamma -radiation resistance. These data illustrate both cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed cells, with STAT5 playing a dominant role in resistance to DNA damage-induced apoptosis.	Whitehead Inst, Cambridge Ctr 9, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute	Daley, GQ (corresponding author), Whitehead Inst, Cambridge Ctr 9, Cambridge, MA 02142 USA.	daley@wi.mit.edu			NCI NIH HHS [CA 76418, CA 86991] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA076418, R01CA086991] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Amarante-Mendes GP, 1998, ONCOGENE, V16, P1383, DOI 10.1038/sj.onc.1201664; AMOS TAS, 1995, BRIT J HAEMATOL, V91, P387, DOI 10.1111/j.1365-2141.1995.tb05308.x; BEDI A, 1994, BLOOD, V83, P2038; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; Cambier N, 1998, ONCOGENE, V16, P335, DOI 10.1038/sj.onc.1201490; Cortez D, 1996, ONCOGENE, V13, P2589; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Dubrez L, 1998, BLOOD, V91, P2415, DOI 10.1182/blood.V91.7.2415.2415_2415_2422; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Ihle JN, 1998, ANN NY ACAD SCI, V865, P1, DOI 10.1111/j.1749-6632.1998.tb11157.x; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; JANSSEN JWG, 1987, P NATL ACAD SCI USA, V84, P9228, DOI 10.1073/pnas.84.24.9228; Jiang XY, 1999, P NATL ACAD SCI USA, V96, P12804, DOI 10.1073/pnas.96.22.12804; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Lilly M, 1997, CANCER RES, V57, P5348; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MANDANAS RA, 1993, BLOOD, V82, P1838; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; Peters DG, 2001, BLOOD, V97, P1404, DOI 10.1182/blood.V97.5.1404; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; Rebollo A, 1999, BLOOD, V94, P2971, DOI 10.1182/blood.V94.9.2971.421k43_2971_2980; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; Santos SCR, 2000, ONCOGENE, V19, P1164, DOI 10.1038/sj.onc.1203418; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; Schwaller J, 2000, MOL CELL, V6, P693, DOI 10.1016/S1097-2765(00)00067-8; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; SKORSKI T, 1995, CANCER RES, V55, P2275; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; Wang DM, 1996, MOL CELL BIOL, V16, P6141; Wang QH, 1999, MOL CELL BIOL, V19, P4008; WilsonRawls J, 1996, CANCER RES, V56, P3426	47	70	74	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2001	20	41					5826	5835		10.1038/sj.onc.1204549	http://dx.doi.org/10.1038/sj.onc.1204549			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593388				2022-12-17	WOS:000171037200006
J	Pekarsky, Y; Hallas, C; Croce, CM				Pekarsky, Y; Hallas, C; Croce, CM			The role of TCL1 in human T-cell leukemia	ONCOGENE			English	Article						14q32.1; TCLI; TCLIb; Akt; T-cell leukemia	CHROMOSOME-TRANSLOCATION; TRANSGENIC MICE; GENE; EXPRESSION; RECEPTOR; PHOSPHORYLATION; ACTIVATION; ONCOGENE; LYMPHOMA; REGION	The TCL1 locus on human chromosome 14q32.1 is activated in T-cell leukemias by translocations and inversions that juxtapose it to regulatory elements of T-cell receptor genes. We isolated and characterized four genes at this locus, TCL1 and TCL1b (T-cell leukemia/lymphoma 1 and 1b), and TNG1 and TNG2 (TCL neighboring genes 1 and 2) all of which are overexpressed following rearrangements involving 14q32.1. TCL1 and TCL1b show 60% similarity and are represented in the mouse by a cluster of six homologous genes. In humans TCL1 and TCL1b show similar expression patterns: They are expressed mainly in CD4-/CD8- immature T-cells, pre B-cells and virgin B-cells. Expression decreases significantly at more mature stages of B-cell development. Activation of TCL1 and/or TCL1b in mature T-cells causes T-cell leukemia in humans. The oncogenic nature of TCL1 was confirmed by the analysis of a transgenic mouse model. Functional analysis of Tcl1 revealed its involvement in a P13-kinase dependent Akt (PKB) pro-survival pathway through its interaction with the Akt kinase which increases Akt's enzymatic activity and promotes translocation of Akt to the nucleus.	Thomas Jefferson Univ, Kimmerl Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University	Croce, CM (corresponding author), Thomas Jefferson Univ, Kimmerl Canc Ctr, 233 S 10th St,BLSB Room 1050, Philadelphia, PA 19107 USA.	Carlo.Croce@mail.tju.edu	Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; Hallas, Cora/0000-0002-5732-4810	NATIONAL CANCER INSTITUTE [P01CA081534, P20CA081534] Funding Source: NIH RePORTER; NCI NIH HHS [CA 81534] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ariyama Y, 1999, J HUM GENET, V44, P357, DOI 10.1007/s100380050178; ARRUSHDI A, 1983, SCIENCE, V222, P390, DOI 10.1126/science.6414084; BRITOBABAPULLE V, 1991, CANCER GENET CYTOGEN, V55, P1, DOI 10.1016/0165-4608(91)90228-M; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Cheng LEC, 1997, EMBO J, V16, P1865, DOI 10.1093/emboj/16.8.1865; CIMINO G, 1991, CANCER RES, V51, P6712; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; Croce CM, 1999, CANCER RES, V59, p1778S; CROCE CM, 1985, SCIENCE, V227, P1044, DOI 10.1126/science.3919442; CROCE CM, 1987, CELL, V49, P155, DOI 10.1016/0092-8674(87)90552-6; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DAVIS IJ, 1993, MOL ENDOCRINOL, V7, P953, DOI 10.1210/me.7.8.953; ERICSON J, 1985, P NATL ACAD SCI USA, V79, P5611; Gritti C, 1998, BLOOD, V92, P368, DOI 10.1182/blood.V92.2.368.414k39_368_373; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Hallas C, 1999, P NATL ACAD SCI USA, V96, P14418, DOI 10.1073/pnas.96.25.14418; HIRATA Y, 1993, J BIOL CHEM, V268, P24808; Katagiri Y, 1997, J BIOL CHEM, V272, P31278, DOI 10.1074/jbc.272.50.31278; Laine J, 2000, MOL CELL, V6, P395, DOI 10.1016/S1097-2765(00)00039-3; Madani A, 1996, BLOOD, V87, P1923; Mok CL, 1999, J EXP MED, V189, P575, DOI 10.1084/jem.189.3.575; NARDUCCI MG, 1995, BLOOD, V86, P2358, DOI 10.1182/blood.V86.6.2358.bloodjournal8662358; Narducci MG, 1997, CANCER RES, V57, P5452; Narducci MG, 2000, CANCER RES, V60, P2095; Ozes ON, 1999, NATURE, V401, P82; PEGORARO L, 1984, P NATL ACAD SCI-BIOL, V81, P7166, DOI 10.1073/pnas.81.22.7166; Pekarsky Y, 2000, P NATL ACAD SCI USA, V97, P3028, DOI 10.1073/pnas.040557697; Pekarsky Y, 1999, P NATL ACAD SCI USA, V96, P2949, DOI 10.1073/pnas.96.6.2949; Pekarsky Y, 2001, P NATL ACAD SCI USA, V98, P3690, DOI 10.1073/pnas.051003198; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RUSSO G, 1989, P NATL ACAD SCI USA, V86, P602, DOI 10.1073/pnas.86.2.602; Sakashita A, 1998, LEUKEMIA, V12, P970, DOI 10.1038/sj.leu.2401023; SCHICHMAN SA, 1994, P NATL ACAD SCI USA, V91, P6236, DOI 10.1073/pnas.91.13.6236; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; STAAL SP, 1977, P NATL ACAD SCI USA, V74, P3065, DOI 10.1073/pnas.74.7.3065; STERN MH, 1993, ONCOGENE, V8, P2475; Takizawa J, 1998, JPN J CANCER RES, V89, P712, DOI 10.1111/j.1349-7006.1998.tb03275.x; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; Thick J, 1996, ONCOGENE, V12, P379; VIRGILIO L, 1994, P NATL ACAD SCI USA, V91, P12530, DOI 10.1073/pnas.91.26.12530; VIRGILIO L, 1993, P NATL ACAD SCI USA, V90, P9275, DOI 10.1073/pnas.90.20.9275; Virgilio L, 1998, P NATL ACAD SCI USA, V95, P3885, DOI 10.1073/pnas.95.7.3885; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	43	70	73	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2001	20	40					5638	5643		10.1038/sj.onc.1204596	http://dx.doi.org/10.1038/sj.onc.1204596			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	470TP	11607815				2022-12-17	WOS:000170887500006
J	Ning, ZQ; Li, J; McGuinness, M; Arceci, RJ				Ning, ZQ; Li, J; McGuinness, M; Arceci, RJ			STAT3 activation is required for Asp(816) mutant c-Kit induced tumorigenicity	ONCOGENE			English	Article						STAT3; c-Kit mutation; tumorigenicity	RECEPTOR TYROSINE KINASE; LIGAND-INDEPENDENT ACTIVATION; ACUTE MYELOID-LEUKEMIA; STEM-CELL FACTOR; CONSTITUTIVE ACTIVATION; SIGNALING PATHWAYS; NIH3T3 FIBROBLASTS; CATALYTIC DOMAIN; GENE-REGULATION; POINT MUTATION	Activating mutations of c-kit at codon 816 (Asp(816)) have been identified in variety of malignancies, including acute myeloid leukemia (AML), mastocytosis and germ cell tumors. The mutant c-Kit receptor confers cytokine independence and induces tumorigenicity. However, the molecular mechanisms, particularly the changes in the signal transduction pathways, responsible for these biological effects induced by mutant c-Kit are largely undefined. Using the human embryonic kidney cell line, 293, we show in the current report that constitutive activation of STAT3 and STAT1 is associated with D816H mutant c-Kit. Transfection of dominant negative STAT3, but not STAT1 inhibits mutant c-Kit mediated anchorage-independent growth in vitro and tumor formation in vivo. Expression of constitutively activated STAT3 restores the mutant c-Kit receptor's transforming ability in 293 cells. These results demonstrate that activation of STAT3 by Asp(816) mutant c-Kit is required for the anchorage-independent growth and tumorigenicity induced by Asp(816) mutant c-Kit.	Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Div Pediat Oncol, Baltimore, MD 21231 USA; Childrens Hosp, Med Ctr, Div Hematol Oncol, Cincinnati, OH 45229 USA	Johns Hopkins University; Johns Hopkins Medicine; Cincinnati Children's Hospital Medical Center	Arceci, RJ (corresponding author), Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Div Pediat Oncol, Baltimore, MD 21231 USA.							ALEXANDER WS, 1991, EMBO J, V10, P3683, DOI 10.1002/j.1460-2075.1991.tb04936.x; ARRICK BA, 1992, J CELL BIOL, V118, P715, DOI 10.1083/jcb.118.3.715; Ashman LK, 1999, LEUKEMIA LYMPHOMA, V34, P451, DOI 10.3109/10428199909058472; Beghini A, 2000, BLOOD, V95, P726, DOI 10.1182/blood.V95.2.726; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Caruana G, 1998, ONCOGENE, V16, P179, DOI 10.1038/sj.onc.1201494; Caruana G, 1999, ONCOGENE, V18, P5573, DOI 10.1038/sj.onc.1202939; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; CROSIER PS, 1993, BLOOD, V82, P1151; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; de Groot RP, 1999, BLOOD, V94, P1108, DOI 10.1182/blood.V94.3.1108.415k07_1108_1112; Ferrao P, 1997, BLOOD, V90, P4539; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; Fukada T, 1998, EMBO J, V17, P6670, DOI 10.1093/emboj/17.22.6670; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Hashimoto K, 1996, AM J PATHOL, V148, P189; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; Hunter MG, 2000, BLOOD, V95, P2132, DOI 10.1182/blood.V95.6.2132; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; KANAKURA Y, 1994, LEUKEMIA, V8, pS18; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Leslie NR, 1998, BLOOD, V92, P4798, DOI 10.1182/blood.V92.12.4798.424k12_4798_4807; Linnekin D, 1999, INT J BIOCHEM CELL B, V31, P1053, DOI 10.1016/S1357-2725(99)00078-3; Longley BJ, 1999, P NATL ACAD SCI USA, V96, P1609, DOI 10.1073/pnas.96.4.1609; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; MACAULEY A, 1988, J VIROL, V62, P4712, DOI 10.1128/JVI.62.12.4712-4721.1988; Moriyama Y, 1996, J BIOL CHEM, V271, P3347; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Ning ZQ, 2001, BLOOD, V97, P3559, DOI 10.1182/blood.V97.11.3559; NING ZQ, 2001, IN PRESS LEUK LYMPHO; Piao XH, 1996, BLOOD, V87, P3117, DOI 10.1182/blood.V87.8.3117.bloodjournal8783117; PIETRA D, 1998, GENE, V213, P119; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; Tian QS, 1999, AM J PATHOL, V154, P1643, DOI 10.1016/S0002-9440(10)65419-3; Tsai YT, 2000, MOL CELL BIOL, V20, P2043, DOI 10.1128/MCB.20.6.2043-2054.2000; TSUJIMURA T, 1995, INT ARCH ALLERGY IMM, V106, P377, DOI 10.1159/000236870; TSUJIMURA T, 1994, BLOOD, V83, P2619; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; Wooten DK, 2000, J BIOL CHEM, V275, P26566, DOI 10.1074/jbc.M003495200; Yajima T, 1998, HUM GENE THER, V9, P779, DOI 10.1089/hum.1998.9.6-779; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; Yokota S, 1997, LEUKEMIA, V11, P1605, DOI 10.1038/sj.leu.2400812; Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	56	70	73	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2001	20	33					4528	4536		10.1038/sj.onc.1204590	http://dx.doi.org/10.1038/sj.onc.1204590			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494148				2022-12-17	WOS:000170074900010
J	Signori, E; Bagni, C; Papa, S; Primerano, B; Rinaldi, M; Amaldi, F; Fazio, VM				Signori, E; Bagni, C; Papa, S; Primerano, B; Rinaldi, M; Amaldi, F; Fazio, VM			A somatic mutation in the 5 ' UTR of BRCA1 gene in sporadic breast cancer causes down-modulation of translation efficiency	ONCOGENE			English	Article						BRCA1; translational regulation; somatic mutation; sporadic breast cancer	OVARIAN-CANCER; MESSENGER-RNA; ALPHA-THALASSEMIA; PROMOTER REGION; AUG CODON; PROTEIN; CARCINOMAS; EXPRESSION; METHYLATION; NUCLEOTIDES	Mutations in the 5' UTR which cause increment/ decrement of translation efficiency have been recently described as a novel molecular mechanism of disease. Alterations in the consensus sequence for the translation initiation may promote context-dependent leaky scanning of ribosomes and/or initiation from a downstream AUG codon. Initiation of translation from a downstream in-frame AUG codon in BRCA1 gene was recently identified in normal cells and possibly in breast cancer. Here we present further insight into BRCA1 translational pathophysiology investigating the role of the canonical structure of the initiation consensus sequence of BRCA1. We have analysed the effect of a somatic point mutation (117 G > C) in position -3 with respect to the AUG of the BRCA1 gene, identified in a highly, aggressive sporadic breast cancer. We constructed chimeric genes encoding the luciferase reporter sequence downstream of the wild type or the mutated BRCA1 5'UTR. These transcripts were tested for their activity in in vitro and in vivo systems. In in vitro transcription/ translation assays the estimated translation efficiency of the construct with the mutated BRCA1 5'UTR was 30-50% lower than that with the wild type BRCA1 5'UTR. The same chimeric genes were analysed for their expression in vivo by transient transfection in human cells. While the two constructs were equally transcribed, the plasmid carrying the mutated sequence produced 70% less luciferase activity compared to the wild type sequence. Finally, to obtain a direct evaluation on translational efficiency in vivo, we analysed mRNA translation on translationally active and non-active ribosomes separated from transfected cells. Mutant mRNA was partially localized in subpolysomal particles analytically confirming a polysome recruitment defect. Thus, characterization of BRCA1 5'UTR and translation efficiency seems to provide new insight into BRCA1 role in breast and ovarian cancer pathogenesis.	IRCCS H Casa Solliveo Sofferenza, Lab Mol Pathol & Gene Therapy, I-71013 San Giovanni Rotondo, FG, Italy; CNR, Ist Neurobiol & Med Mol, Area Ric Tor Vergata, I-00133 Rome, Italy; Univ Roma Tor Vergata, Dipartimento Biol, I-00133 Rome, Italy; Sch Med, Lab Mol Med & Biotechnol, I-00155 Rome, Italy	IRCCS Casa Sollievo Della Sofferenza; Consiglio Nazionale delle Ricerche (CNR); University of Rome Tor Vergata; University of Rome Tor Vergata	Fazio, VM (corresponding author), IRCCS H Casa Solliveo Sofferenza, Lab Mol Pathol & Gene Therapy, I-71013 San Giovanni Rotondo, FG, Italy.	VitoM.Fazio@ims.rm.cnr.it	Signori, Emanuela/H-5134-2019; rinaldi, monica/D-2221-2016; Fazio, Vito Michele VMF/H-3007-2016	Signori, Emanuela/0000-0003-0286-7401; rinaldi, monica/0000-0002-6889-9388; Fazio, Vito Michele VMF/0000-0002-7751-1867; Bagni, Claudia/0000-0002-4419-210X				Bernard-Gallon D, 1998, ONCOL REP, V5, P995; Brown MA, 1996, ONCOGENE, V12, P2507; Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509; Cazzola M, 2000, BLOOD, V95, P3280, DOI 10.1182/blood.V95.11.3280.011k41_3280_3288; Choong CS, 1996, J CLIN INVEST, V98, P1423, DOI 10.1172/JCI118930; Conne B, 2000, NAT MED, V6, P637, DOI 10.1038/76211; ESTELLER M, 2000, JNCI, V92, P565; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Gorman C., 1985, DNA CLONING, V2; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Jarvis EM, 1998, CANCER GENET CYTOGEN, V101, P109, DOI 10.1016/S0165-4608(97)00267-7; Khoo US, 1999, ONCOGENE, V18, P4643, DOI 10.1038/sj.onc.1202847; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1990, NUCLEIC ACIDS RES, V18, P2828, DOI 10.1093/nar/18.9.2828; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Lee WY, 1999, HISTOPATHOLOGY, V34, P106; Lida Y, 1996, NUCLEIC ACIDS RES, V24, P3313, DOI 10.1093/nar/24.17.3313; Liu JS, 2000, ONCOGENE, V19, P2767, DOI 10.1038/sj.onc.1203599; LORENI F, 1992, EUR J BIOCHEM, V205, P1027, DOI 10.1111/j.1432-1033.1992.tb16870.x; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MORLE F, 1986, NUCLEIC ACIDS RES, V14, P3279, DOI 10.1093/nar/14.8.3279; MORLE F, 1985, EMBO J, V4, P1245, DOI 10.1002/j.1460-2075.1985.tb03767.x; Papa S, 1998, JNCI-J NATL CANCER I, V90, P1011, DOI 10.1093/jnci/90.13.1011; Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086; Rio PG, 1999, INT J CANCER, V80, P823, DOI 10.1002/(SICI)1097-0215(19990315)80:6<823::AID-IJC5>3.0.CO;2-3; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Seery LT, 1999, INT J CANCER, V84, P258, DOI 10.1002/(SICI)1097-0215(19990621)84:3<258::AID-IJC10>3.3.CO;2-8; SZABO CI, 1995, HUM MOL GENET, V4, P1811, DOI 10.1093/hmg/4.suppl_1.1811; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Wang Q, 2000, ONCOGENE, V19, P6152, DOI 10.1038/sj.onc.1203974; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Yoshikawa K, 1999, CLIN CANCER RES, V5, P1249; Zheng L, 2000, ONCOGENE, V19, P6159, DOI 10.1038/sj.onc.1203968	37	70	73	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2001	20	33					4596	4600		10.1038/sj.onc.1204620	http://dx.doi.org/10.1038/sj.onc.1204620			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494157	Green Published			2022-12-17	WOS:000170074900019
J	Shao, RG; Cao, CX; Nieves-Neira, W; Dimanche-Boitrel, MT; Solary, E; Pommier, Y				Shao, RG; Cao, CX; Nieves-Neira, W; Dimanche-Boitrel, MT; Solary, E; Pommier, Y			Activation of the Fas pathway independently of Fas ligand during apoptosis induced by camptothecin in p53 mutant human colon carcinoma cells	ONCOGENE			English	Article						Bar; caspase; FADD; z-VAD; nuclease; programmed cell death	DRUG-INDUCED APOPTOSIS; CANCER-CELLS; TOPOISOMERASE-I; CUTTING EDGE; DNA-DAMAGE; WILD-TYPE; DEATH; CD95; CYTOTOXICITY; EXPRESSION	The present study explored the role of the cell surface receptor Fas (CD95/APO-1) in apoptosis induced by camptothecin (CPT) in the HT29 colon carcinoma cell line. CPT-induced apoptosis was associated with high molecular weight DNA fragmentation as measured by filter elution, This fragmentation was inhibited by the caspase inhibitor, z-VAD-fmk and by cycloheximide, which also prevented proteolytic activation of caspase-3 and poly(ADP-ribose)polymerase cleavage. Under such conditions, Fas, Fas ligand, Bar, and p21 expression were increased and Fas recruited the FADD adaptor. Fas expression increase was blocked by cycloheximide but not by z-VAD-fmk, consistent with caspase activation downstream from Fas, Treatment of HT29 cells with Fast or with the CH-11 agonistic anti-Fas antibody potentiated the apoptotic response of cells treated with CPT, The anti-Fas blocking antibody ZB4 and the Fas-ligand inhibitor failed to protect HT29 cells from CPT-induced apoptosis, Such a protection was obtained by transient expression of constructs encoding a dominant-negative mutant of FADD, FADD in an antisense orientation and E8 or MC159 viral proteins that inhibit Fas-induced apoptosis at the level of FADD and procaspase-8, respectively. Together, these data show that topoisomerase I-mediated DNA damage-induced apoptosis involves activation of the Fas pathway without detectable Fas-ligand requirement in CPT-treated cells.	NCI, Mol Pharmacol Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA; Fac Med & Pharm Dijon, INSERM U517, Dept Biol & Therapy Canc, Dijon, France	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne	Pommier, Y (corresponding author), NCI, Mol Pharmacol Lab, Div Basic Sci, NIH, Bldg 37,Rm 4E28, Bethesda, MD 20892 USA.		Dimanche-Boitrel, Marie-Therese M/I-4642-2015	Solary, Eric/0000-0002-8629-1341; Dimanche-Boitrel, Marie-Therese/0000-0002-8038-7780				Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; BERTRAND R, 1995, DRUG DEVELOP RES, V34, P138, DOI 10.1002/ddr.430340206; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; CHEN AY, 1994, ANN REV PHARM TOXICO, V94, P194; DUBREZ L, 1995, LEUKEMIA, V9, P1013; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; Favre-Felix N, 2000, J IMMUNOL, V164, P5023, DOI 10.4049/jimmunol.164.10.5023; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; GOLDWASSER F, 1995, CANCER RES, V55, P2116; Goldwasser F, 1996, CANCER RES, V56, P4430; Gunthert AR, 1996, J CELL BIOL, V134, P1089, DOI 10.1083/jcb.134.4.1089; Houghton JA, 1997, P NATL ACAD SCI USA, V94, P8144, DOI 10.1073/pnas.94.15.8144; Khodarev NN, 1998, INT J RADIAT BIOL, V73, P455; KRAMMER PH, 1994, IMMUNOL REV, V142, P175, DOI 10.1111/j.1600-065X.1994.tb00889.x; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Memon SA, 1998, J IMMUNOL, V160, P2046; Micheau O, 1997, J NATL CANCER I, V89, P783, DOI 10.1093/jnci/89.11.783; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; MIYASHITA T, 1995, CELL, V80, P293; MOLLER P, 1994, INT J CANCER, V57, P371, DOI 10.1002/ijc.2910570314; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; OConnor PM, 1997, CANCER RES, V57, P4285; OCONNOR PM, 1991, CANCER COMMUN, V3, P233, DOI 10.3727/095535491820873083; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Pommier Y, 1998, BBA-GENE STRUCT EXPR, V1400, P83, DOI 10.1016/S0167-4781(98)00129-8; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; Rusnak JM, 1996, MOL PHARMACOL, V49, P244; Shao RG, 1996, EXP CELL RES, V227, P190, DOI 10.1006/excr.1996.0266; Shao RG, 1997, CANCER RES, V57, P4029; Shao RG, 1997, EXP CELL RES, V234, P388, DOI 10.1006/excr.1997.3650; Shao RG, 1999, EMBO J, V18, P1397, DOI 10.1093/emboj/18.5.1397; SHIMIZU T, 1995, CANCER RES, V55, P228; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Strumberg D, 2000, MOL CELL BIOL, V20, P3977, DOI 10.1128/MCB.20.11.3977-3987.2000; Tanaka M, 1996, NAT MED, V2, P317, DOI 10.1038/nm0396-317; Tillman DM, 1998, CELL DEATH DIFFER, V5, P450, DOI 10.1038/sj.cdd.4400369; Villunger A, 1997, CANCER RES, V57, P3331; ZHAN QM, 1995, INT J ONCOL, V6, P937	44	70	78	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2001	20	15					1852	1859		10.1038/sj.onc.1204264	http://dx.doi.org/10.1038/sj.onc.1204264			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	418TX	11313933				2022-12-17	WOS:000167908400006
J	Reiss, K; Wang, JY; Romano, G; Tu, X; Peruzzi, F; Baserga, R				Reiss, K; Wang, JY; Romano, G; Tu, X; Peruzzi, F; Baserga, R			Mechanisms of regulation of cell adhesion and motility by insulin receptor substrate-1 in prostate cancer cells	ONCOGENE			English	Article						prostate cancer; cell adhesion; cell motility; signal transduction	GROWTH-FACTOR-I; SERINE KINASE PHOSPHORYLATES; DOMINANT-NEGATIVE MUTANT; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; PLECKSTRIN HOMOLOGY; SIGNALING PATHWAYS; RETROVIRAL VECTORS; LIGAND OCCUPANCY; BINDING-PROTEINS	LNCaP cells are human prostatic cancer cells that have a frame-shift mutation of the tumor suppressor gene PTEN and do not express the insulin receptor substrate-1 (IRS-I), a major substrate of the type 1 insulin-like growth factor receptor (IGF-IR). Ectopic expression of IRS-1 in LNCaP cells increases cell adhesion and decreases cell motility by an IGF-I-independent mechanism. We show nom that these effects of IRS-1 are accompanied by serine phosphorylation of IRS-1 and are inhibited by inhibitors of phosphatidylinositol 3-kinase (PI3K), We have confirmed the requirement for PI3K activity and serine phosphorylation by the use of IRS-1 mutants, expressed in LNCaP cells. Serine phosphorylation inhibits IGF-I-induced tyrosyl phosphorylation of IRS-1, which is restored by the expression of wild-type PTEN or by inhibition of PI3K activity. Finally, IRS-1 in LNCaP cells co-immunoprecipitates with integrin alpha 5 beta 1, and the association is again IGF-I-independent. We conclude that in LNCaP cells, IRS-1 is serine phosphorylated by PI3K, generating effects that are different, and even opposite, from those generated by IGF-I.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University	Baserga, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, 624 Biol Life Sci Bldg,233 S 10th St, Philadelphia, PA 19107 USA.		Peruzzi, Francesca/M-9804-2014		NATIONAL CANCER INSTITUTE [P01CA056309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS036466] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016291] Funding Source: NIH RePORTER; NCI NIH HHS [CA 56309] Funding Source: Medline; NIA NIH HHS [AG 16291] Funding Source: Medline; NINDS NIH HHS [P0-1 NS 36466] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baserga R, 1999, CONT ENDOCRINOL, V17, P329; Blakesley VA, 1999, CONT ENDOCRINOL, V17, P143; Brooks PC, 1997, J CLIN INVEST, V99, P1390, DOI 10.1172/JCI119298; Carson JP, 1999, CANCER RES, V59, P1449; Cengel KA, 1999, J BIOL CHEM, V274, P27969, DOI 10.1074/jbc.274.39.27969; Ceresa BP, 1996, J BIOL CHEM, V271, P12121, DOI 10.1074/jbc.271.21.12121; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Clemmons DR, 1999, ENDOCRINOLOGY, V140, P4616, DOI 10.1210/en.140.10.4616; DAmbrosio C, 1997, CANCER RES, V57, P3264; DAMBROSIO C, 1995, CELL GROWTH DIFFER, V6, P557; Davies MA, 1999, CANCER RES, V59, P2551; Delahaye L, 1998, ENDOCRINOLOGY, V139, P4911, DOI 10.1210/en.139.12.4911; Doerr ME, 1996, J BIOL CHEM, V271, P2443, DOI 10.1074/jbc.271.5.2443; Dunn SE, 1998, CANCER RES, V58, P3353; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; FREUND GG, 1995, BIOCHEM BIOPH RES CO, V206, P272, DOI 10.1006/bbrc.1995.1038; Furnari FB, 1998, CANCER RES, V58, P5002; Grimberg A, 2000, J CELL PHYSIOL, V183, P1, DOI 10.1002/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO;2-J; Guilherme A, 1998, J BIOL CHEM, V273, P22899, DOI 10.1074/jbc.273.36.22899; Guilherme A, 1998, J BIOL CHEM, V273, P33119, DOI 10.1074/jbc.273.50.33119; Guvakova MA, 1997, EXP CELL RES, V231, P149, DOI 10.1006/excr.1996.3457; HAWLEY RG, 1994, GENE THER, V1, P136; Jones JI, 1996, P NATL ACAD SCI USA, V93, P2482, DOI 10.1073/pnas.93.6.2482; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; LAM K, 1994, J BIOL CHEM, V269, P20648; Lebrun P, 1998, J BIOL CHEM, V273, P32244, DOI 10.1074/jbc.273.48.32244; Lee AV, 2000, MOL CELL BIOL, V20, P1489, DOI 10.1128/MCB.20.5.1489-1496.2000; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li J, 1998, CANCER RES, V58, P5667; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; Mothe I, 1996, J BIOL CHEM, V271, P11222, DOI 10.1074/jbc.271.19.11222; MYERS MG, 1994, J BIOL CHEM, V269, P28783; Ogawa W, 1998, MOL CELL BIOCHEM, V182, P13, DOI 10.1023/A:1006862807598; Paz K, 1999, J BIOL CHEM, V274, P28816, DOI 10.1074/jbc.274.40.28816; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; PIETRZKOWSKI Z, 1993, CANCER RES, V53, P1102; Raucher D, 2000, CELL, V100, P221, DOI 10.1016/S0092-8674(00)81560-3; Reiss K, 2000, ONCOGENE, V19, P2687, DOI 10.1038/sj.onc.1203587; Reiss K, 1998, CLIN CANCER RES, V4, P2647; Renshaw MW, 1999, J CELL BIOL, V147, P611, DOI 10.1083/jcb.147.3.611; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Romano G, 1999, J CELL BIOCHEM, V72, P294, DOI 10.1002/(SICI)1097-4644(19990201)72:2<294::AID-JCB14>3.0.CO;2-0; Rubini M, 1997, EXP CELL RES, V230, P284, DOI 10.1006/excr.1996.3430; Sarbassov DD, 1998, MOL ENDOCRINOL, V12, P1870, DOI 10.1210/me.12.12.1870; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; Shakibaei M, 1999, BIOCHEM J, V342, P615, DOI 10.1042/0264-6021:3420615; Staubs PA, 1998, J BIOL CHEM, V273, P25139, DOI 10.1074/jbc.273.39.25139; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Tanaka S, 1996, J BIOL CHEM, V271, P14610, DOI 10.1074/jbc.271.24.14610; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423; Valentinis B, 1998, J CELL PHYSIOL, V176, P648, DOI 10.1002/(SICI)1097-4652(199809)176:3<648::AID-JCP22>3.3.CO;2-6; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; WITKOWSKI CM, 1993, J CANCER RES CLIN, V119, P637, DOI 10.1007/BF01215981; Yenush L, 1998, MOL CELL BIOL, V18, P6784, DOI 10.1128/MCB.18.11.6784; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; YU SF, 1986, P NATL ACAD SCI USA, V83, P3194, DOI 10.1073/pnas.83.10.3194; Zheng B, 1998, P NATL ACAD SCI USA, V95, P11217, DOI 10.1073/pnas.95.19.11217; Zheng DQ, 1999, CANCER RES, V59, P1655	61	70	71	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2001	20	4					490	500		10.1038/sj.onc.1204112	http://dx.doi.org/10.1038/sj.onc.1204112			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395DB	11313980				2022-12-17	WOS:000166562500009
J	Chen, YR; Shrivastava, A; Tan, TH				Chen, YR; Shrivastava, A; Tan, TH			Down-regulation of the c-Jun N-terminal kinase (JNK) phosphatase M3/6 and activation of JNK by hydrogen peroxide and pyrrolidine dithiocarbamate	ONCOGENE			English	Article						JNK; phosphatase; oxidation; metal ions	TUMOR-NECROSIS-FACTOR; PROTEIN-KINASES; SIGNAL-TRANSDUCTION; INTRACELLULAR LEVEL; GAMMA-RADIATION; CELL-DEATH; METAL-IONS; APOPTOSIS; PATHWAY; STRESS	Oxidative stress activates the c-Jun N-terminal kinase (JNK) pathway. However, the exact mechanisms by which reactive oxygen species (ROS) activate JNK are unclear. We found that the ability of hydrogen peroxide (H2O2) to induce JNK activation varied in different cell types. Pyrrolidine dithiocarbamate (PDTC), a presumed antioxidant, induced JNK activation on its own and enhanced JNK activation by H2O2 in many cell types, including Jurkat, HEK293, and LNCaP and Tsu-Prl prostate cancer cells. The activation of JNK by PDTC, in the presence or absence of exogenous H2O2, was dependent on its chelating ability to metal ions, most likely copper ions, Despite the strong JNK-activating ability, H2O2 plus PDTC did not induce significant activation of the upstream kinases, SEK1/MKK4 and MKK7. However, the JNK inactivation rate was slower in cells treated with H2O2 pins PDTC compared with the rate in cells treated with ultraviolet C CUV-C), Treatment of H2O2 pins PDTC significantly decreased the expression levels of a JNK phosphatase, M3/6 (also named hVH-5), but not the levels of other phosphatases (PP2A and PP4), In contrast, UV-C irradiation did not cause the down-regulation of M3/6, These results suggest that JNK activation by H2O2 plus PDTC resulted from the down-regulation of JNK phosphatases. Our data also reveal a necessity to carefully evaluate the pharmacological and biochemical properties of PDTC.	Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA	Baylor College of Medicine	Tan, TH (corresponding author), Baylor Coll Med, Dept Immunol, M929,1 Baylor Plaza, Houston, TX 77030 USA.		Chen, Yi-Rong/CAF-2186-2022; Chen, Yi-Rong/CAH-7991-2022; Tan, Tse-Hua/E-3983-2010; Chen, Yi-Rong/E-3991-2010; Tan, Tse-Hua/ABD-7080-2021	Chen, Yi-Rong/0000-0002-4307-3002; Chen, Yi-Rong/0000-0002-4307-3002; Tan, Tse-Hua/0000-0003-4969-3170; Chen, Yi-Rong/0000-0002-4307-3002; Tan, Tse-Hua/0000-0003-4969-3170	NCI NIH HHS [P50-CA58204] Funding Source: Medline; NIAID NIH HHS [R01-AI38649, R01-AI42532] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058204] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042532, R01AI038649] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Chen J, 1998, BIOCHEM BIOPH RES CO, V247, P827, DOI 10.1006/bbrc.1998.8792; Chen Y. R., 1999, GENE THER MOL BIOL, V4, P83; Chen YR, 1998, J BIOL CHEM, V273, P1769, DOI 10.1074/jbc.273.3.1769; Chen YR, 2000, INT J ONCOL, V16, P651; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chen YR, 1998, ONCOGENE, V17, P173, DOI 10.1038/sj.onc.1201941; delArco PG, 1996, J BIOL CHEM, V271, P26335; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Fuchs D, 1997, OXIDATIVE STRESS MOL, P139; GILMAN AG, 1990, GOODMAN GILMANS PHAR, P1635; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HAUPTMANN N, 1997, OXIDATIVE STRESS MOL, P1; Hu MCT, 1998, J BIOL CHEM, V273, P33561, DOI 10.1074/jbc.273.50.33561; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kim CH, 1999, FEBS LETT, V449, P28, DOI 10.1016/S0014-5793(99)00390-7; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LENTNER C, 1984, GEIGY SCI TABLES, V3, P85; Luo YQ, 1998, J BIOL CHEM, V273, P3756, DOI 10.1074/jbc.273.6.3756; MARTELL KJ, 1995, J NEUROCHEM, V65, P1823; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; NOBEL CSI, 1995, J BIOL CHEM, V270, P26202, DOI 10.1074/jbc.270.44.26202; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; Smith A, 1997, CURR BIOL, V7, P893, DOI 10.1016/S0960-9822(06)00380-0; Theodosiou AM, 1996, HUM MOL GENET, V5, P675, DOI 10.1093/hmg/5.5.675; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Verhaegh GW, 1997, MOL CELL BIOL, V17, P5699, DOI 10.1128/MCB.17.10.5699; Wilhelm D, 1997, MOL CELL BIOL, V17, P4792, DOI 10.1128/MCB.17.8.4792; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378	41	70	78	2	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					367	374		10.1038/sj.onc.1204105	http://dx.doi.org/10.1038/sj.onc.1204105			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313966				2022-12-17	WOS:000166411000011
J	Gartel, AL; Goufman, E; Najmabadi, F; Tyner, AL				Gartel, AL; Goufman, E; Najmabadi, F; Tyner, AL			Sp1 and Sp3 activate p21 (WAF1/CIP1) gene transcription in the Caco-2 colon adenocarcinoma cell line	ONCOGENE			English	Article						p21; Caco-2; promoter; Sp1; Sp3	MEDIATED NEURONAL DIFFERENTIATION; HISTONE DEACETYLASE INHIBITOR; REPRESS TRANSCRIPTION; BINDING-SITES; DNA-BINDING; CHLORAMPHENICOL ACETYLTRANSFERASE; PROMOTER ACTIVITY; CYCLE REGULATION; FAMILY MEMBERS; PC12 CELLS	The CDK inhibitor p21(WAF1/CIP1) is a negative regulator of the cell cycle, and its expression is induced during terminal differentiation in vitro and in vivo. Expression of p21 is controlled at the transcriptional level by both p53-dependent and -independent mechanisms. Our previous studies established that p21 is expressed in the Caco-2 adenocarcinoma cell line, and its expression is induced by a p53-independent mechanism during differentiation of these cells, Here we have found that transcription of p21 in Caco-2 cells is controlled primarily by the transcription factors Sp1 and Sp3 through two Spl binding sites, Sp1-1 and Sp1-2 located between -119 and -114 bp and between -109 and -104 bp of the p21 promoter, respectively, Spl and Sp3 binding to the p21 promoter increased during Caco-2 cell differentiation, while the absolute level of Spl did not change and the absolute level of Sp3 increased approximately twofold. Transfection experiments in the SL2 Drosophila cell line that lacks endogenous Sp3 activity demonstrated that Spl transactivates the p21 promoter primarily through the Sp1-2 site, while Sp3 acts through the Spl-l site, In these cells Sp3 is a stronger transactivator of the p21 promoter than Spl, Our data suggest that induction of p21 transcription during Caco-2 differentiation is modulated by Sp1/Sp3 interactions with the p21 promoter.	Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gartel, AL (corresponding author), Univ Illinois, Dept Mol Genet, 900 S Ashland Ave, Chicago, IL 60607 USA.		Goufman, Eugene/AAG-6882-2019	Tyner, Angela/0000-0001-7448-8625	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048836, R01DK056283] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK056283, R01 DK056283-05, DK48836] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham C, 1998, GASTROENTEROLOGY, V114, P503, DOI 10.1016/S0016-5085(98)70533-5; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Bigger CB, 1997, J BIOL CHEM, V272, P25976, DOI 10.1074/jbc.272.41.25976; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Billon N, 1999, ONCOGENE, V18, P2872, DOI 10.1038/sj.onc.1202712; Billon N, 1996, ONCOGENE, V13, P2047; Black AR, 1999, J BIOL CHEM, V274, P1207, DOI 10.1074/jbc.274.3.1207; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; Djelloul S, 1997, FEBS LETT, V406, P234, DOI 10.1016/S0014-5793(97)00208-1; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Evers BM, 1996, AM J PHYSIOL-GASTR L, V271, pG722, DOI 10.1152/ajpgi.1996.271.4.G722; Gartel A L, 1998, Prog Mol Subcell Biol, V20, P43; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; Gartel AL, 1998, ONCOGENE, V17, P3463, DOI 10.1038/sj.onc.1202240; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gartel AL, 1996, EXP CELL RES, V227, P171, DOI 10.1006/excr.1996.0264; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; Hata Y, 1998, J BIOL CHEM, V273, P19294, DOI 10.1074/jbc.273.30.19294; JIANG HP, 1994, ONCOGENE, V9, P3397; Karantzoulis-Fegaras F, 1999, J BIOL CHEM, V274, P3076, DOI 10.1074/jbc.274.5.3076; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Kwon HS, 1999, J BIOL CHEM, V274, P20, DOI 10.1074/jbc.274.1.20; Lee SJ, 1998, J BIOL CHEM, V273, P10618, DOI 10.1074/jbc.273.17.10618; Li JM, 1998, NUCLEIC ACIDS RES, V26, P2449, DOI 10.1093/nar/26.10.2449; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MAJELLO B, 1995, ONCOGENE, V10, P1841; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; MURRAY IA, 1991, NUCLEIC ACIDS RES, V19, P6648; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Nielsen SJ, 1998, BIOCHEM J, V333, P511, DOI 10.1042/bj3330511; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; Pagliuca A, 1998, J BIOL CHEM, V273, P7668, DOI 10.1074/jbc.273.13.7668; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PINTO M, 1983, BIOL CELL, V47, P323; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; Rajakumar RA, 1998, J BIOL CHEM, V273, P27474, DOI 10.1074/jbc.273.42.27474; Ray A, 1999, J BIOL CHEM, V274, P4300, DOI 10.1074/jbc.274.7.4300; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Scaglione-Sewell B, 1998, CANCER RES, V58, P1074; Schafer D, 1997, FEBS LETT, V417, P325, DOI 10.1016/S0014-5793(97)01314-8; Sowa Y, 1999, CANCER RES, V59, P4266; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Wildhage I, 1999, ENDOCRINOLOGY, V140, P624, DOI 10.1210/en.140.2.624; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yan GZ, 1997, J NEUROSCI, V17, P6122; Zhang YG, 1999, J BIOL CHEM, V274, P12367, DOI 10.1074/jbc.274.18.12367; Zhao LY, 1997, J BIOL CHEM, V272, P4869, DOI 10.1074/jbc.272.8.4869	62	70	70	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 26	2000	19	45					5182	5188		10.1038/sj.onc.1203900	http://dx.doi.org/10.1038/sj.onc.1203900			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368NP	11064455				2022-12-17	WOS:000090124100007
J	Giehl, K; Seidel, B; Gierschik, P; Adler, G; Menke, A				Giehl, K; Seidel, B; Gierschik, P; Adler, G; Menke, A			TGF beta(1) represses proliferation of pancreatic carcinoma cells which correlates with Smad4-independent inhibition of ERK activation	ONCOGENE			English	Article						TGF beta; EGF; ERK2; proliferation control	GROWTH-FACTOR-BETA; RAS-BINDING DOMAIN; TGF-BETA; PROTEIN-KINASE; EPITHELIAL-CELLS; CANCER-CELLS; MAP KINASE; I RECEPTOR; NUCLEAR TRANSLOCATION; SIGNALING PATHWAYS	Transforming growth factor beta (TGF beta) is a tumor suppressor acting as inhibitor of cell cycle progression of epithelial cells. We show that treatment of the pancreatic carcinoma cell lines PANC-1 and BxPC-3 with TGF beta(1) inhibits both growth factor-induced activation of the extracellular signal-regulated kinase 2 (ERK2) and translocation of the kinase to the nucleus. TGF beta(1) causes a concentration-dependent reduction of cell proliferation in both cell lines, By measuring ERK activation, we can show that TGF beta(1) is able to repress ERK activation induced by mitogenic stimuli such as EGF, This inhibitory effect of TGF beta(1) is not mediated by suppression of Ras or c-Raf-1 activation, but mediated by TGF beta(1)-induced activation of a serine-threonine phosphatase, as demonstrated by inhibition of phosphatases by treatment with okadaic acid. Results obtained in the Smad4-deficient pancreatic carcinoma cell line BxPC-3, demonstrate that TGF beta(1)-induced growth inhibition is mediated by a Smad4-independent prevention of ERK2 activation. In contrast to the effects of TGF beta(1) on epithelial cells, mesenchymal NIH3T3 fibroblasts exhibit elevated ERK2 activation and increased cell proliferation in response to TGF beta(1) treatment, Smad4-independent phosphatase-mediated inhibition of mitogen-activated ERK2 represents a novel effector pathway contributing to suppression of epithelial pancreatic carcinoma cell proliferation by TGF beta(1), in addition to the well-known Smad-induced tumor suppressor activity of TGF beta.	Univ Ulm, Dept Internal Med 1, D-89070 Ulm, Germany; Univ Ulm, Dept Pharmacol & Toxicol, D-89070 Ulm, Germany	Ulm University; Ulm University	Menke, A (corresponding author), Univ Ulm, Dept Internal Med 1, D-89070 Ulm, Germany.							ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; Axmann A, 1998, BIOCHEM BIOPH RES CO, V249, P456, DOI 10.1006/bbrc.1998.9188; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Calonge MJ, 1999, J BIOL CHEM, V274, P33637, DOI 10.1074/jbc.274.47.33637; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Chen YG, 1997, EMBO J, V16, P3866, DOI 10.1093/emboj/16.13.3866; Dai JL, 1999, MOL CARCINOGEN, V26, P37, DOI 10.1002/(SICI)1098-2744(199909)26:1<37::AID-MC5>3.0.CO;2-6; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Dixon M, 1999, HEPATOLOGY, V29, P1418, DOI 10.1002/hep.510290516; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; FREEMAN JW, 1995, J CELL PHYSIOL, V165, P155, DOI 10.1002/jcp.1041650118; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; Giehl K, 2000, ONCOGENE, V19, P2930, DOI 10.1038/sj.onc.1203612; Griswold-Prenner I, 1998, MOL CELL BIOL, V18, P6595, DOI 10.1128/MCB.18.11.6595; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Heldin Carl-Henrik, 1996, Cytokine and Growth Factor Reviews, V7, P3, DOI 10.1016/1359-6101(96)00002-0; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; KAWABATA M, 1995, J BIOL CHEM, V270, P29628; Ko TC, 1998, ONCOGENE, V16, P3445, DOI 10.1038/sj.onc.1201902; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Liu JH, 1999, ONCOGENE, V18, P269, DOI 10.1038/sj.onc.1202263; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Menke A, 1999, BBA-MOL CELL RES, V1449, P178, DOI 10.1016/S0167-4889(99)00011-7; Menke A, 1997, GASTROENTEROLOGY, V113, P295, DOI 10.1016/S0016-5085(97)70107-0; MULDER KM, 1992, J BIOL CHEM, V267, P5029; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Polyak K, 1996, BBA-REV CANCER, V1242, P185, DOI 10.1016/0304-419X(95)00009-5; Reimann T, 1997, FEBS LETT, V403, P57, DOI 10.1016/S0014-5793(97)00024-0; Roberts AB, 1990, GROWTH FACTORS, V2, P135, DOI 10.3109/08977199009071500; Rodeck U, 1999, CANCER RES, V59, P547; Schutte M, 1996, CANCER RES, V56, P2527; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; Villanueva A, 1998, ONCOGENE, V17, P1969, DOI 10.1038/sj.onc.1202118; Wang TW, 1996, SCIENCE, V271, P1120, DOI 10.1126/science.271.5252.1120; ZHENG CF, 1994, J BIOL CHEM, V269, P19947	50	70	73	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 14	2000	19	39					4531	4541		10.1038/sj.onc.1203806	http://dx.doi.org/10.1038/sj.onc.1203806			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352UT	11002426				2022-12-17	WOS:000089236800010
J	Maul, RS; Chang, DD				Maul, RS; Chang, DD			EPLIN, Epithelial protein lost in neoplasm	ONCOGENE			English	Article						breast; prostate; cancer; EPLIN	CANCER-CELLS; LIM DOMAINS; ADHESION; BINDING	We have identified a novel cytoskeletal protein, EPLIN (Epithelial Protein Lost In Neoplasm), that is preferentially er;pressed in human epithelial cells. Two EPLIN isoforms, a 600 amino acid EPLIN-alpha and a 759 amino acid EPLIN-beta, are detected in primary epithelial cells of oral mucosa, prostate and mammary glands. The expression of EPLIN-alpha is either down-regulated or lost in the majority of oral cancer cell lines (8/8), prostate cancer cell lines (4/4) and xenograft tumors (3/3), and breast cancer cell lines (5/6), The amino acid sequence of EPLIN is characterized by the presence of a single centrally located LIM domain. Both EPLIN isoforms localize to filamentous actin and suppress cell proliferation when overexpressed. These findings indicate that the loss of EPLIN seen in cancer cells may play a role in cancer progression.	Univ Calif Los Angeles, Sch Med, Div Hemeonc,Jonnson Comprehens Canc Ctr, Dept Med & Microbiol Immunol & Mol Mol Genet, Los Angeles, CA 90095 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Chang, DD (corresponding author), Univ Calif Los Angeles, Sch Med, Div Hemeonc,Jonnson Comprehens Canc Ctr, Dept Med & Microbiol Immunol & Mol Mol Genet, Factor 10-240,10833 Le Conte Ave, Los Angeles, CA 90095 USA.				NATIONAL CANCER INSTITUTE [T32CA075956] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM058215] Funding Source: NIH RePORTER; NCI NIH HHS [TF32CA75956] Funding Source: Medline; NIGMS NIH HHS [GM58215] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARBER S, 1994, CELL, V79, P221, DOI 10.1016/0092-8674(94)90192-9; BALTZ R, 1992, PLANT J, V2, P713, DOI 10.1046/j.1365-313X.1992.t01-13-00999.x; Beckerle MC, 1997, BIOESSAYS, V19, P949, DOI 10.1002/bies.950191104; Brown MC, 1996, J CELL BIOL, V135, P1109, DOI 10.1083/jcb.135.4.1109; Chang DD, 1998, ONCOGENE, V16, P1921, DOI 10.1038/sj.onc.1201715; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; Jurata LW, 1998, CURR TOP MICROBIOL, V228, P75; Klein KA, 1997, NAT MED, V3, P402, DOI 10.1038/nm0497-402; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LIANG P, 1995, CURR OPIN IMMUNOL, V7, P274, DOI 10.1016/0952-7915(95)80015-8; Nagase T, 1998, DNA Res, V5, P277, DOI 10.1093/dnares/5.5.277; PEREZALVARADO GC, 1994, NAT STRUCT BIOL, V1, P388, DOI 10.1038/nsb0694-388; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; YANG JX, 1995, J BIOL CHEM, V270, P12152, DOI 10.1074/jbc.270.20.12152; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	16	70	73	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 16	1999	18	54					7838	7841		10.1038/sj.onc.1203206	http://dx.doi.org/10.1038/sj.onc.1203206			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	265RJ	10618726				2022-12-17	WOS:000084256900015
J	Yap, DBS; Hsieh, JK; Chan, FSG; Lu, X				Yap, DBS; Hsieh, JK; Chan, FSG; Lu, X			mdm2: a bridge over the two tumour suppressors, p53 and Rb	ONCOGENE			English	Review						regulation of mdm2; transactivation; transrepression; apoptosis; p53 stability; E2F1	WILD-TYPE P53; RETINOBLASTOMA GENE-PRODUCT; ABL TYROSINE KINASE; S-PHASE ENTRY; P53-MEDIATED TRANSCRIPTIONAL REPRESSION; UBIQUITIN-PROTEASOME PATHWAY; CELL-CYCLE ARREST; P53-DEPENDENT APOPTOSIS; DNA-DAMAGE; SV40-TRANSFORMED CELLS	The inactivation of the p53 and Rb pathways would account for the majority of human tumours. There are many levels of cross talk between p53 and Rb that have been identified. However, the identification of the mdm2-Rb interaction established a closer link between the two most well studied tumour suppressors, p53 and Rb. Recent studies of the novel trimeric complex Rb-mdm2-p53 provided us with a functional insight of how the two tumour suppressors can act together in regulating p53 induced apoptosis. Beginning with the properties of the Rb-mdm2-p53 trimeric complex, we shall review the propounding evidence suggesting that the apoptotic function of p53 is linked to its transrepression function. The uncoupling of the apoptotic function and transactivation function of p53 will also be discussed.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Ludwig Inst Canc Res, London W2 1PG, England	Imperial College London; Ludwig Institute for Cancer Research	Lu, X (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Ludwig Inst Canc Res, St Marys Campus,Norfolk Pl, London W2 1PG, England.			Yap, Damian/0000-0002-5370-4592; Lu, Xin/0000-0002-6587-1152				Amellem O, 1996, EXP CELL RES, V227, P106, DOI 10.1006/excr.1996.0255; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Bremner R, 1997, AM J HUM GENET, V61, P556, DOI 10.1086/515499; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chen JD, 1996, MOL CELL BIOL, V16, P2445; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CordonCardo C, 1997, CANCER RES, V57, P1217; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GOGA A, 1995, ONCOGENE, V11, P791; Harbour JW, 1998, OPHTHALMOLOGY, V105, P1442, DOI 10.1016/S0161-6420(98)98025-3; HARPER JW, 1993, CELL, V75, P805; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Holmberg C, 1998, ONCOGENE, V17, P143, DOI 10.1038/sj.onc.1201915; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Krtolica A, 1998, ONCOGENE, V17, P2295, DOI 10.1038/sj.onc.1202159; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1990, BIOESSAYS, V12, P62; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Lohmann DR, 1996, AM J HUM GENET, V58, P940; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lu X, 1996, ONCOGENE, V13, P413; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; LUNA RMD, 1995, NATURE, V378, P203; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Matsumoto R, 1998, CANCER RES, V58, P609; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; NEVINS JR, 1992, SCIENCE, V258, P424; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Pan HC, 1998, MOL CELL, V2, P283, DOI 10.1016/S1097-2765(00)80273-7; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sabbatini P, 1997, CELL GROWTH DIFFER, V8, P643; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHAULIAN E, 1995, ONCOGENE, V10, P671; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; SUBLER MA, 1994, ONCOGENE, V9, P1351; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; WADAYAMA B, 1994, CANCER RES, V54, P3042; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WELCH PJ, 1995, GENE DEV, V9, P31, DOI 10.1101/gad.9.1.31; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Xu HJ, 1996, CLIN CANCER RES, V2, P1169; XU HJ, 1994, JNCI-J NATL CANCER I, V86, P695, DOI 10.1093/jnci/86.9.695; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	105	70	74	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 13	1999	18	53					7681	7689		10.1038/sj.onc.1202954	http://dx.doi.org/10.1038/sj.onc.1202954			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DD	10618708				2022-12-17	WOS:000084634500007
J	Soldatenkov, VA; Albor, A; Patel, BKR; Dreszer, R; Dritschilo, A; Notario, V				Soldatenkov, VA; Albor, A; Patel, BKR; Dreszer, R; Dritschilo, A; Notario, V			Regulation of the human poly(ADP-ribose) polymerase promoter by the ETS transcription factor	ONCOGENE			English	Article						ETS transcription factors; poly(ADP-ribose) polymerase; gene regulation; Ewing's sarcoma	EWINGS-SARCOMA CELLS; DNA-BINDING; GENE-EXPRESSION; MESSENGER-RNA; BETA-GENE; EWS GENE; TRANSLOCATION; PROTEIN; APOPTOSIS; INHIBITION	Ewing's sarcoma (EWS) cells accumulate elevated steady-state levels of poly (ADP-ribose) polymerase (PARP) mRNA and protein, To understand the molecular mechanisms underlying PARP upregulation, we cloned and analysed the 5'-flanking region of the PARP gene from EWS cells. Nucleotide sequence analysis demonstrated no variations in the PARP promoter region in EWS cells. The PARP promoter encompasses multiple binding motifs for the ETS transcription factor. We have also observed that there is a coordinated up-regulation of the expression of both PARP and ETS1, relative to cells of other human tumor types expressing lower levels of PARP, Transient coexpression of ETS1 in EWS cells resulted in a strong enhancement of PARP-promoter activity. The participation of ETS in the regulation of PARP gene expression was further demonstrated in EWS cells stably transfected with Ets1 antisense cDNA constructs. Antisense-mediated down-regulation of endogenous ETS1 resulted in the inhibition of PARP expression in EWS cells, and sensitized these cells to ionizing radiation. These data provide support for ETS regulation of PARP expression levels, and implicate ETS transcription factors in the radiation response of EWS cells.	Georgetown Univ, Med Ctr, Dept Radiat Med, Lombardi Canc Ctr, Washington, DC 20007 USA	Georgetown University	Notario, V (corresponding author), Georgetown Univ, Med Ctr, Dept Radiat Med, Lombardi Canc Ctr, Room E215A,3970 Reservoir Rd NW, Washington, DC 20007 USA.		/AAB-6461-2022; /AFP-0764-2022		NCI NIH HHS [P01-CA74175] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA074175] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERMAN SL, 1993, P NATL ACAD SCI USA, V90, P11865, DOI 10.1073/pnas.90.24.11865; ALBOR A, 1994, CANCER RES, V54, P4502; AVILA MA, 1994, YEAST, V10, P1003, DOI 10.1002/yea.320100803; Bassuk AG, 1997, ADV IMMUNOL, V64, P65, DOI 10.1016/S0065-2776(08)60887-1; BHATIA K, 1990, J CELL PHYSIOL, V144, P345, DOI 10.1002/jcp.1041440221; BHATIA K, 1989, ADP RIBOSE TRANSFER, P494; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CESARONE CF, 1990, BIOCHIM BIOPHYS ACTA, V1087, P241, DOI 10.1016/0167-4781(90)90211-J; CHERNEY BW, 1987, P NATL ACAD SCI USA, V84, P8370, DOI 10.1073/pnas.84.23.8370; CLEAVER JE, 1991, MUTAT RES, V257, P1, DOI 10.1016/0165-1110(91)90016-O; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DEMURCIA G, 1991, BIOESSAYS, V13, P455, DOI 10.1002/bies.950130905; DING RC, 1992, J BIOL CHEM, V267, P12804; Hodge D R, 1995, Methods Mol Biol, V37, P409; Huang CC, 1997, ONCOGENE, V15, P851, DOI 10.1038/sj.onc.1201408; INGOLIA DE, 1986, MOL CELL BIOL, V6, P4458, DOI 10.1128/MCB.6.12.4458; JEON IS, 1995, ONCOGENE, V10, P1229; JOLLIFF K, 1991, NUCLEIC ACIDS RES, V19, P2267, DOI 10.1093/nar/19.9.2267; JORGENSEN TJ, 1993, RADIAT ONCOL INVEST, V1, P189; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; KUPPER JH, 1995, MOL CELL BIOL, V15, P3154; MAVROTHALASSITIS GJ, 1990, P NATL ACAD SCI USA, V87, P1047, DOI 10.1073/pnas.87.3.1047; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; NEGRONI M, 1993, BIOCHIM BIOPHYS ACTA, V1173, P133, DOI 10.1016/0167-4781(93)90173-B; Oei SL, 1997, BIOCHEM BIOPH RES CO, V240, P108, DOI 10.1006/bbrc.1997.7621; OEI SL, 1994, MOL CELL BIOCHEM, V138, P99, DOI 10.1007/BF00928449; OGURA T, 1990, BIOCHEM BIOPH RES CO, V167, P701, DOI 10.1016/0006-291X(90)92082-B; OHNO T, 1993, CANCER RES, V53, P5859; Papas Takis S., 1997, Leukemia (Basingstoke), V11, P557; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; PRASAD SC, 1990, CANCER RES, V50, P38; ROBERTSON M, 1988, NATURE, V336, P522, DOI 10.1038/336522a0; ROMANOSPICA V, 1995, J IMMUNOL, V154, P2724; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SCHREIBER V, 1995, P NATL ACAD SCI USA, V92, P4753, DOI 10.1073/pnas.92.11.4753; Schwachtgen JL, 1997, ONCOGENE, V15, P3091, DOI 10.1038/sj.onc.1201502; SETH A, 1990, ONCOGENE, V5, P1761; Soldatenkov VA, 1997, CANCER J SCI AM, V3, P13; SOLDATENKOV VA, 1995, CANCER RES, V55, P4240; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; THRAVES PJ, 1989, ADP RIBOSE TRANSFER, P520; VELASCO JA, 1995, ONCOGENE, V10, P2253; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WEIN KH, 1993, BIOCHIM BIOPHYS ACTA, V1176, P69, DOI 10.1016/0167-4889(93)90179-S; YAMAGUCHI M, 1988, NUCLEIC ACIDS RES, V16, P8773, DOI 10.1093/nar/16.18.8773; YEE D, 1990, J CLIN INVEST, V86, P1806, DOI 10.1172/JCI114910; YOKOYAMA Y, 1990, EUR J BIOCHEM, V194, P521, DOI 10.1111/j.1432-1033.1990.tb15647.x; Zhang M, 1997, CELL GROWTH DIFFER, V8, P179	54	70	70	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	1999	18	27					3954	3962		10.1038/sj.onc.1202778	http://dx.doi.org/10.1038/sj.onc.1202778			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435618				2022-12-17	WOS:000081327800005
J	Bergametti, F; Prigent, S; Luber, B; Benoit, A; Tiollais, P; Sarasin, A; Transy, C				Bergametti, F; Prigent, S; Luber, B; Benoit, A; Tiollais, P; Sarasin, A; Transy, C			The proapoptotic effect of hepatitis B virus HBx protein correlates with its transactivation activity in stably transfected cell lines	ONCOGENE			English	Article						hepatitis B virus; X gene; apoptosis; transactivation	NUCLEOTIDE EXCISION-REPAIR; DNA-BINDING PROTEIN; X-GENE PRODUCT; HUMAN FIBROBLASTS; HELA-CELLS; APOPTOSIS; TRANSCRIPTION; ACTIVATION; EXPRESSION; INTERACTS	The role of hepatitis B virus carcinogenesis associated with chronic, viral infection remains ill-defined. Indeed, pleiotropic effects have been ascribed to HBx: in addition to its well-documented ability to indirectly stimulate transcription, the protein has been reported to affect cell growth, signal transduction, DNA repair and apoptosis, In this work, we generated Chang (CCL-13)-derived cell lines constitutively expressing wild type or mutant HBx, as a model of HBx-host cell interaction closer to the chronic infection setting, than the classically used transient expression systems, We document the potentiation by HBx of the apoptotic cell death pathway in the recipient cells. This effect is unlikely to rely on p53 activity since the protein is functionally inactivated in CCL-13, In addition, antioxidants and cyclosporin A failed to reduce the apoptotic response back to the normal level, suggesting that production of reactive oxygen species and calcineurin activation are not directly involved in the proapoptotic effect of HBx. In contrast, our data show that transactivation and stimulation of apoptosis are tightly linked HBx activities. Finally, expression of transactivation-active protein did not result in detectable change in the pattern of MAP kinases phosphorylation nor did it affect the ability of the host cell to repair in vitro irradiated plasmid DNA.	Inst Pasteur, INSERM, U163, Unite Recombinaison & Express Genet, F-75724 Paris, France; Hop Necker Enfants Malad, INSERM, U370, Paris, France; Inst Rech Canc, Mol Genet Lab, UPR42 CNRS IFC1, Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Transy, C (corresponding author), Inst Pasteur, INSERM, U163, Unite Recombinaison & Express Genet, F-75724 Paris, France.							ABRAMIC M, 1991, J BIOL CHEM, V266, P22493; BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; Bender K, 1997, J PHOTOCH PHOTOBIO B, V37, P1, DOI 10.1016/S1011-1344(96)07459-3; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; Buendia M A, 1992, Semin Cancer Biol, V3, P309; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; CROSS JC, 1993, P NATL ACAD SCI USA, V90, P8078, DOI 10.1073/pnas.90.17.8078; Dandri M, 1996, J VIROL, V70, P5246, DOI 10.1128/JVI.70.8.5246-5254.1996; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FAKTOR O, 1990, ONCOGENE, V5, P867; FISCHER M, 1995, VIRUS GENES, V10, P99, DOI 10.1007/BF01724303; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; Ford JM, 1998, CANCER RES, V58, P599; FOUREL G, 1992, MOL CELL BIOL, V12, P5336, DOI 10.1128/MCB.12.12.5336; FRITSCH A, 1978, CR ACAD SCI D NAT, V287, P1453; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; Haviv I, 1996, EMBO J, V15, P3413, DOI 10.1002/j.1460-2075.1996.tb00707.x; Huang JK, 1996, J VIROL, V70, P5582, DOI 10.1128/JVI.70.8.5582-5591.1996; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KEENEY S, 1992, MUTAT RES, V273, P49, DOI 10.1016/0921-8777(92)90049-9; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; LAVAPPA KS, 1976, NATURE, V259, P211, DOI 10.1038/259211a0; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Lee Y, 1998, GENE, V207, P111, DOI 10.1016/S0378-1119(97)00603-3; Lin Y, 1997, J BIOL CHEM, V272, P7132, DOI 10.1074/jbc.272.11.7132; LOCK RB, 1994, CANCER RES, V54, P4933; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MASON WS, 1981, VIRAL HEPATITIS, P107; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; Miossec C, 1997, J BIOL CHEM, V272, P13459, DOI 10.1074/jbc.272.21.13459; Miranda EI, 1996, MUTAT RES-FUND MOL M, V349, P173, DOI 10.1016/0027-5107(95)00164-6; Nassal M, 1996, J VIRAL HEPATITIS, V3, P217, DOI 10.1111/j.1365-2893.1996.tb00047.x; NATOLI G, 1994, ONCOGENE, V9, P2837; Oguey D, 1996, HEPATOLOGY, V24, P1024, DOI 10.1002/hep.510240508; QADRI I, 1995, P NATL ACAD SCI USA, V92, P1003, DOI 10.1073/pnas.92.4.1003; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; RUNKEL L, 1993, VIROLOGY, V197, P529, DOI 10.1006/viro.1993.1626; Sitterlin D, 1997, J VIROL, V71, P6194, DOI 10.1128/JVI.71.8.6194-6199.1997; SMITH ML, 1995, ONCOGENE, V10, P1053; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; WANG XW, 1995, CANCER RES, V55, P6012; Weeda G, 1997, AM J HUM GENET, V60, P320; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yen T. S. Benedict, 1996, Journal of Biomedical Science, V3, P20; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	51	70	73	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	1999	18	18					2860	2871		10.1038/sj.onc.1202643	http://dx.doi.org/10.1038/sj.onc.1202643			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FK	10362257				2022-12-17	WOS:000080125100009
J	Matsubara, K; Kishida, S; Matsuura, Y; Kitayama, H; Noda, M; Kikuchi, A				Matsubara, K; Kishida, S; Matsuura, Y; Kitayama, H; Noda, M; Kikuchi, A			Plasma membrane recruitment of RalGDS is critical for Ras-dependent Ral activation	ONCOGENE			English	Article						intracellular localization; post-translational modification; RalGDS; Ras; Rap	NUCLEOTIDE DISSOCIATION STIMULATOR; GTP-BINDING PROTEINS; C-FOS PROMOTER; SIGNAL-TRANSDUCTION; EUKARYOTIC CELLS; EXCHANGE FACTOR; GOLGI-COMPLEX; H-RAS; R-RAS; TRANSFORMATION	In COS cells, Ral GDP dissociation stimulator (RalGDS)-induced Ral activation was stimulated by Ras(G12V) or a Rap1/Ras chimera in which the IV-terminal region of Rap1 was ligated to the C-terminal region of Ras but not by Rap1(G12V) or a Ras/Rap1 chimera in which the IV-terminal region of Ras was ligated to the C-terminal region of Rap1, although RalGDS interacted with these small GTP-binding proteins, When Ras(G12V), Ral and the Rap1/Ras chimera were individually expressed in NIH3T3 cells, they localized to the plasma membrane. Rap1(Q63E) and the Ras/Rap1 chimera were detected in the perinuclear region, When RalGDS was expressed alone, it was abundant in the cytoplasm, When coexpressed with Ras(G12V) or the Rap1/Ras chimera, RalGDS was detected at the plasma membrane, whereas when coexpressed with Rap1(Q63E) or the Ras/Rap1 chimera, RalGDS was observed in the perinuclear region. RalGDS which was targeted to the plasma membrane by the addition of Ras farnesylation site (RaLGDS-CAAX) activated Ral in the absence of Ras(G12V). Although RalGDS did not stimulate the dissociation of GDP from Ral in the absence of the GTP-bound form of Ras in a reconstitution assay using the liposomes, RalGDS-CAAX could stimulate it without Pas, Ras(G12V) activated Raf-1 when they were coexpressed in Sf9 cells, whereas Ras(G12V) did not affect the RalGDS activity, These results indicate that Pas recruits RalGDS to the plasma membrane and that the translocated RalGDS induces the activation of Ral, but that Rap1 does not activate Pal due to distinct subcellular localization.	Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, Hiroshima 7348551, Japan; Natl Inst Infect Dis, Dept Virol 2, Shinjyuku Ku, Tokyo 1628640, Japan; Kyoto Univ, Grad Sch Med, Dept Mol Oncol, Sakyo Ku, Kyoto 6068501, Japan	Hiroshima University; National Institute of Infectious Diseases (NIID); Kyoto University	Kikuchi, A (corresponding author), Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.			kishida, shosei/0000-0003-0405-851X				ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; BERGER G, 1994, BRIT J HAEMATOL, V88, P372, DOI 10.1111/j.1365-2141.1994.tb05033.x; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Hinoi T, 1996, J BIOL CHEM, V271, P19710, DOI 10.1074/jbc.271.33.19710; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Hu CD, 1995, J BIOL CHEM, V270, P30274, DOI 10.1074/jbc.270.51.30274; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KIKUCHI A, 1994, J BIOL CHEM, V269, P20054; Kikuchi A, 1996, J BIOL CHEM, V271, P588, DOI 10.1074/jbc.271.1.588; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Kishida S, 1997, ONCOGENE, V15, P2899, DOI 10.1038/sj.onc.1201473; KITAYAMA H, 1990, JPN J CANCER RES, V81, P445, DOI 10.1111/j.1349-7006.1990.tb02589.x; KITAYAMA H, 1993, KREV 1 RELATED GENES; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LopezBarahona M, 1996, ONCOGENE, V12, P463; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARIDONNEAUPARINI I, 1992, J BIOL CHEM, V267, P6396; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; Murai H, 1997, J BIOL CHEM, V272, P10483; NODA M, 1993, BIOCHIM BIOPHYS ACTA, V1155, P97, DOI 10.1016/0304-419X(93)90024-7; Okazaki M, 1997, ONCOGENE, V14, P515, DOI 10.1038/sj.onc.1200860; PIZON V, 1994, J CELL SCI, V107, P1661; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Summers MD, 1987, MANUAL METHODS BACUL; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; YAMAGUCHI M, 1995, J BIOL CHEM, V270, P1; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	43	70	72	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	1999	18	6					1303	1312		10.1038/sj.onc.1202425	http://dx.doi.org/10.1038/sj.onc.1202425			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FW	10022812				2022-12-17	WOS:000078510900006
J	Bafico, A; Gazit, A; Wu-Morgan, SS; Yaniv, A; Aaronson, SA				Bafico, A; Gazit, A; Wu-Morgan, SS; Yaniv, A; Aaronson, SA			Characterization of Wnt-1 and Wnt-2 induced growth alterations and signaling pathways in NIH3T3 fibroblasts	ONCOGENE			English	Article						Wnt; oncogene; NIH3T3; cell adhesion; beta-catenin; MAPK	MAMMARY EPITHELIAL-CELLS; GLYCOGEN-SYNTHASE KINASE-3; TRANSCRIPTION FACTOR LEF-1; CADHERIN-CATENIN COMPLEX; BETA-CATENIN; TYROSINE PHOSPHORYLATION; MAP KINASE; PROTEIN; TRANSFORMATION; EXPRESSION	Members of the Wnt family induce mouse mammary tumors and partially transform mammary epithelial cells in culture. However, their mechanism of transformation remains to be elucidated. In NIH3T3 mouse embryo fibroblasts, a standard transformation model, Wnt-1 and Wnt-2 were shown to induce altered properties including increased saturation density and growth in soft agar, Such cells also exhibited increased cell-cell adhesiveness. However, unlike oncogenes such as PDGFB or ras, Wnt-1 and -2 failed to induce detectable transformed foci following transfection, and stable NIH3T3 transfectants lacked tumor forming capacity. Wnt-1 and -2 transfectants exhibited increased uncomplexed, cytosolic beta-catenin, which was not observed with PDGFB, ras or erbB2 transfectants. In transient transfection, Wnt-1 and -2 induced a rapid increase in cytosolic beta-catenin but no detectable increase in the phosphorylated activated forms of MAP kinase, In contrast, ras was a potent activator of MAP kinase but had no effect on free beta-catenin levels. These findings establish that both Wnt signaling and pattern of growth alterations differ from those of oncogenes which activate proliferative signaling pathways in NIH3T3 cells.	CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; Tel Aviv Univ, Sackler Sch Med, Dept Human Microbiol, IL-69978 Tel Aviv, Israel	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Tel Aviv University; Sackler Faculty of Medicine	Aaronson, SA (corresponding author), CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA.				NATIONAL CANCER INSTITUTE [R01CA071672, R01CA066654] Funding Source: NIH RePORTER; NCI NIH HHS [1-R01-CA71672, 1-R01-CA66654] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BLASBAND A, 1992, ONCOGENE, V7, P153; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BRADBURY JM, 1994, ONCOGENE, V9, P2597; BRADLEY RS, 1995, MOL CELL BIOL, V15, P4616; BRADLEY RS, 1993, J CELL BIOL, V123, P1857, DOI 10.1083/jcb.123.6.1857; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; BURRUS LW, 1995, EXP CELL RES, V220, P363, DOI 10.1006/excr.1995.1327; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; Christiansen JH, 1996, ONCOGENE, V12, P2705; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; ECHELARD Y, 1994, DEVELOPMENT, V120, P2213; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; FALCO JP, 1988, ONCOGENE, V2, P573; GUMBINER BM, 1995, CURR OPIN CELL BIOL, V7, P634, DOI 10.1016/0955-0674(95)80104-9; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; JUE SF, 1992, MOL CELL BIOL, V12, P321, DOI 10.1128/MCB.12.1.321; LAROCHELLE WJ, 1995, J CELL BIOL, V129, P357, DOI 10.1083/jcb.129.2.357; LIN TP, 1992, CANCER RES, V52, P4413; MASON JO, 1992, MOL BIOL CELL, V3, P521, DOI 10.1091/mbc.3.5.521; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; MIKI T, 1995, METHOD ENZYMOL, V254, P196; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; OLSON DJ, 1994, CELL GROWTH DIFFER, V5, P197; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; PARKIN NT, 1993, GENE DEV, V7, P2181, DOI 10.1101/gad.7.11.2181; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Perrimon N, 1996, CELL, V86, P513, DOI 10.1016/S0092-8674(00)80124-5; RIJSEWIJK F, 1987, EMBO J, V6, P127, DOI 10.1002/j.1460-2075.1987.tb04729.x; ROELINK H, 1992, ONCOGENE, V7, P487; ROTHBACHER U, 1995, DEV BIOL, V170, P717, DOI 10.1006/dbio.1995.1249; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; SOKOL SY, 1995, DEVELOPMENT, V121, P1637; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278	46	70	74	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	1998	16	21					2819	2825		10.1038/sj.onc.1201797	http://dx.doi.org/10.1038/sj.onc.1201797			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ013	9652750				2022-12-17	WOS:000073812200015
J	Miller, WE; Cheshire, JL; Baldwin, AS; Raab-Traub, N				Miller, WE; Cheshire, JL; Baldwin, AS; Raab-Traub, N			The NPC derived C15 LMP1 protein confers enhanced activation of NF-kappa B and induction of the EGFR in epithelial cells	ONCOGENE			English	Article						Epstein-Barr Virus; LMP1; NPC; sequence variation; EGFR; NF-kappa B; TRAF	EPSTEIN-BARR-VIRUS; HUMAN PAPILLOMAVIRUS TYPE-16; TERMINAL CYTOPLASMIC DOMAIN; LATENT MEMBRANE-PROTEIN; NASOPHARYNGEAL CARCINOMA; FACTOR RECEPTOR; TRANSFORMING PROTEIN; REGULATORY SEQUENCE; NUCLEAR FACTOR; EXPRESSION	The Epstein-Barr Virus (EBV) LMP1 protein is frequently expressed in nasopharyngeal carcinoma and is essential for the transforming effects of EBV. Analysis of LMP1 genes isolated from tumor biopsies has revealed considerable sequence variation including deletion of amino acids 343-352. Several studies have suggested that this sequence variation could enhance the transforming potential of LMP1. LMP1 has profound effects on cellular gene expression mediated in part through activation of the NF-kappa B transcription factor. In addition, LMP1 engages the TRAF signaling pathway resulting in the induction of EGFR expression, In this study, the LMP1 proteins derived from the laboratory strain B95-8 and the NPC strain C15 were analysed for their ability to activate NF-kappa B and also to induce expression of the EGFR. The data suggest that the C15-LMP1 protein activates NF-kappa B more efficiently and induces higher levels of the EGFR. Analysis of chimeric LMP1 proteins indicates that the amino terminal 181 amino acids of C15-LMP1 confer this increased signaling capability, and that deletion of amino acids 343-352 does not affect these properties. Finally, these data provide evidence that five amino acid changes within the transmembrane domain in the C15-LMP1 protein lead to enhanced NF-kappa B activation and EGFR induction.	Univ N Carolina, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Curriculum Genet, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Raab-Traub, N (corresponding author), Univ N Carolina, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA.			Miller, William/0000-0001-6900-4884	NATIONAL CANCER INSTITUTE [P01CA019014, R01CA032979] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011644] Funding Source: NIH RePORTER; NCI NIH HHS [CA19014, CA32979] Funding Source: Medline; NIDCR NIH HHS [DE11644] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ABDELHAMID M, 1992, VIROLOGY, V190, P168, DOI 10.1016/0042-6822(92)91202-6; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BALDWIN AS, 1987, MOL CELL BIOL, V7, P305, DOI 10.1128/MCB.7.1.305; BUSSON P, 1992, INT J CANCER, V50, P863, DOI 10.1002/ijc.2910500605; BUSSON P, 1988, INT J CANCER, V42, P599, DOI 10.1002/ijc.2910420422; BUSSON P, 1992, J VIROL, V66, P3257, DOI 10.1128/JVI.66.5.3257-3262.1992; CHEN ML, 1992, ONCOGENE, V7, P2130; Cheshire JL, 1997, MOL CELL BIOL, V17, P6746, DOI 10.1128/MCB.17.11.6746; Devergne O, 1996, MOL CELL BIOL, V16, P7098; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; Fries KL, 1996, J VIROL, V70, P8653, DOI 10.1128/JVI.70.12.8653-8659.1996; GILLIGAN K, 1990, J VIROL, V64, P4948, DOI 10.1128/JVI.64.10.4948-4956.1990; GILLIGAN KJ, 1991, J VIROL, V65, P6252, DOI 10.1128/JVI.65.11.6252-6259.1991; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HOWLEY PM, 1996, PAPILLOMAVIRINAE VIR, P2045; HU LF, 1991, J GEN VIROL, V72, P2399, DOI 10.1099/0022-1317-72-10-2399; HU LF, 1993, ONCOGENE, V8, P1575; HUEN DS, 1995, ONCOGENE, V10, P549; IZUMI KM, 1994, J VIROL, V68, P4369, DOI 10.1128/JVI.68.7.4369-4376.1994; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; Kieff E, 1996, VIROLOGY, P2343; KNECHT H, 1995, ONCOGENE, V10, P523; KNECHT H, 1993, BLOOD, V82, P2937; Knecht H, 1996, BLOOD, V87, P876, DOI 10.1182/blood.V87.3.876.bloodjournal873876; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Li SN, 1996, ONCOGENE, V12, P2129; LIEBOWITZ D, 1986, J VIROL, V58, P233, DOI 10.1128/JVI.58.1.233-237.1986; LIEBOWITZ D, 1992, J VIROL, V66, P4612, DOI 10.1128/JVI.66.7.4612-4616.1992; MILLER WE, 1994, J GEN VIROL, V75, P2729, DOI 10.1099/0022-1317-75-10-2729; MILLER WE, 1995, J VIROL, V69, P4390, DOI 10.1128/JVI.69.7.4390-4398.1995; Miller WE, 1997, J VIROL, V71, P586, DOI 10.1128/JVI.71.1.586-594.1997; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; PAINE E, 1995, J VIROL, V69, P4572, DOI 10.1128/JVI.69.7.4572-4576.1995; Raab-Traub N, 1992, Semin Cancer Biol, V3, P297; RAABTRAUB N, 1987, INT J CANCER, V39, P25, DOI 10.1002/ijc.2910390106; RAABTRAUB N, 1986, CELL, V47, P883, DOI 10.1016/0092-8674(86)90803-2; RAJADURAI P, 1995, NEW ENGL J MED, V333, P693; RICKINSON AB, 1987, J VIROL, V61, P1310, DOI 10.1128/JVI.61.5.1310-1317.1987; Rickinson AB, 1996, VIROLOGY, P2397; Rothenberger S, 1997, ONCOGENE, V14, P2123, DOI 10.1038/sj.onc.1201032; ROWE M, 1989, J VIROL, V63, P1031, DOI 10.1128/JVI.63.3.1031-1039.1989; SAMPLE J, 1994, J GEN VIROL, V75, P2741, DOI 10.1099/0022-1317-75-10-2741; SAMPLE J, 1990, J VIROL, V64, P4084, DOI 10.1128/JVI.64.9.4084-4092.1990; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEINMAN RI, 1993, MOL CELL BIOL, V13, P6089, DOI 10.1128/MCB.13.10.6089; SCHORPP M, 1988, J MOL BIOL, V202, P307, DOI 10.1016/0022-2836(88)90460-3; SMITH PR, 1991, NUCLEIC ACIDS RES, V19, P2435, DOI 10.1093/nar/19.9.2435; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; TRIVEDI P, 1994, EUR J CANCER, V30A, P84, DOI 10.1016/S0959-8049(05)80024-3; WANG D, 1988, J VIROL, V62, P2337, DOI 10.1128/JVI.62.7.2337-2346.1988; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604; YOUNG LS, 1988, J GEN VIROL, V69, P1051, DOI 10.1099/0022-1317-69-5-1051	57	70	76	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 9	1998	16	14					1869	1877		10.1038/sj.onc.1201696	http://dx.doi.org/10.1038/sj.onc.1201696			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZG368	9583684				2022-12-17	WOS:000072994600010
J	Ueffing, M; Lovric, J; Philipp, A; Mischak, H; Kolch, W				Ueffing, M; Lovric, J; Philipp, A; Mischak, H; Kolch, W			Protein kinase C-epsilon associates with the Raf-1 kinase and induces the production of growth factors that stimulate Raf-1 activity	ONCOGENE			English	Article						PKC epsilon; Raf-1 kinase; growth factors; autocrine loops	ACTIVATES RAF-1; PLASMA-MEMBRANE; SIGNAL-TRANSDUCTION; RAT FIBROBLASTS; TYROSINE KINASE; CELLS; PHOSPHORYLATION; ISOZYMES; OVEREXPRESSION; MECHANISMS	Several observations indicate that the Raf-1 kinase is a downstream effector of protein kinase C-epsilon (PKC epsilon). We recently have shown that Raf-1 is constitutively activated in PKC epsilon transformed Rat6 fibroblasts, and transformation can be reverted by expression of a dominant negative Raf-1, but not a dominant negative Ras mutant (Cacace et al., 1996), Cai et al, (1997) demonstrated that PKC epsilon induced proliferation of NIH3T3 cells is independent of Ras or Src, but depends on Raf-1. These authors further suggested that PKC epsilon activates Raf-1 by direct phosphorylation. Here we have investigated the functional interaction between PKC epsilon and Raf-1, PKCE, but not PKC alpha, was found to bind to the Raf-1 kinase domain, The association appeared to be direct, as it could be reconstituted in vitro with purified proteins, Raf-1 and PKC epsilon could be co-precipitated from Sf-9 insect cells and PKC epsilon transformed NIH313 cells (NIH/epsilon). The association was negatively regulated by ATP in vitro and by TPA treatment in NIH/epsilon cells, but not in Sf-9 insect cells, Raf-1 was constitutively activated in NIH/epsilon cells, How ever, using coexpression experiments in Sf-9 cells and transiently transfected A293 cells we did not obtain any evidence for a direct activation of Raf-1 by PKC epsilon. PKCE did not induce translocation of Raf-1 to the membrane, Furthermore, PKCE did not activate Raf-1 nor enhance the kinase activity of Raf-1 that had been pre-activated by coexpression of Ras or the Lck tyrosine kinase, In contrast, conditioned media from PKC epsilon transformed cells induced a robust activation of Raf-1. This activation could be partially reproduced by recombinant TGF beta, a growth factors secreted by PKC epsilon transformed Rat6 cells. In conclusion, our results suggest that PKC epsilon stimulates Raf-1 indirectly by inducing the production of autocrine growth factors.			Ueffing, M (corresponding author), GSF FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT,INST KLIN MOL BIOL & TUMORGENET,MARCHIONINSTR 25,D-81377 MUNICH,GERMANY.		Mischak, Harald/E-8685-2011; Admin, SBI/HGB-2738-2022; Kolch, Walter/ABF-2102-2021	Kolch, Walter/0000-0001-5777-5016; Lovric, Josip/0000-0002-0338-6581; Mischak, Harald/0000-0003-0323-0306				ARITA Y, 1992, CANCER RES, V52, P4514; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; BORNER C, 1995, J BIOL CHEM, V270, P78, DOI 10.1074/jbc.270.1.78; CACACE AM, 1993, ONCOGENE, V8, P2095; Cacace AM, 1996, ONCOGENE, V13, P2517; CACACE AM, UNPUB; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DEKKER LV, 1995, CURR OPIN STRUC BIOL, V5, P396, DOI 10.1016/0959-440X(95)80103-0; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; GOODNIGHT J, 1994, PROTEIN KINASE C DIF, P160; HA KS, 1993, J BIOL CHEM, V268, P10534; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; Janosch P, 1996, J BIOL CHEM, V271, P13868, DOI 10.1074/jbc.271.23.13868; KIESER A, 1994, ONCOGENE, V9, P963; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI PM, 1993, ONCOGENE, V8, P1731; Malarkey K, 1996, CELL SIGNAL, V8, P123, DOI 10.1016/0898-6568(95)02036-5; Marais R, 1996, CANCER SURV, V27, P101; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Marshall CJ, 1996, NATURE, V383, P127, DOI 10.1038/383127a0; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MISCHAK H, 1993, J BIOL CHEM, V268, P60090; MORRISON DK, 1995, MOL REPROD DEV, V42, P507, DOI 10.1002/mrd.1080420420; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Perletti GP, 1996, ONCOGENE, V12, P847; SOZERI O, 1992, ONCOGENE, V7, P2259; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; THOMPSON PA, 1991, CELL GROWTH DIFFER, V2, P609; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; Xia K, 1996, P NATL ACAD SCI USA, V93, P11681, DOI 10.1073/pnas.93.21.11681	37	70	70	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 11	1997	15	24					2921	2927		10.1038/sj.onc.1201477	http://dx.doi.org/10.1038/sj.onc.1201477			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK377	9416835				2022-12-17	WOS:A1997YK37700004
J	Chung, YJ; Park, SW; Song, JM; Lee, KY; Seo, EJ; Choi, SW; Rhyu, MG				Chung, YJ; Park, SW; Song, JM; Lee, KY; Seo, EJ; Choi, SW; Rhyu, MG			Evidence of genetic progression in human gastric carcinomas with microsatellite instability	ONCOGENE			English	Article						gastric carcinoma; mutator phenotype; transforming growth factor beta receptor type II; BAX; insulin-like growth factor II receptor	NONPOLYPOSIS COLON-CANCER; CELL LUNG-CANCER; II RECEPTOR GENE; COLORECTAL-CANCER; MISMATCH REPAIR; MUTATOR PHENOTYPE; BETA RECEPTOR; MUTATIONS; HOMOLOG; CARCINOGENESIS	Mutator phenotype tumors provide unique opportunities to unravel malignant progression because of various gene alterations acquired during clonal tumor evolution, Gastric carcinomas, which have been known to show frequent genetic instability, would be composed of initial gene alterations shared by most tumor areas and subsequent alterations restricted to particular tumor sites, To analyse the timing of genetic events, we examined separate sites of tumor tissue obtained from a given gastric carcinoma patient with microsatellite instability (MSI), Our study included 95 normal/tumor area pairs from 25 patients, Six of the 25 patients (24%) demonstrated various levels of MSI ranging from 7% (two of 30) to 97% (28 of 29) of markers tested in multiple tumor sites. Of the six patients, five manifested frameshift mutations in a tract of ten deoxyadenosines within transforming growth factor beta receptor type II and four demonstrated frameshift mutations in a tract of eight deoxyguanosines within BAX. These mutations were common to all tumor sites regardless of the various level of MSI phenotype, indicating initial events, Two of the six patients exhibited frameshift mutations in mononucleotide repeats of mismatch repair genes, hMSH3 and hMSH6, and the insulin-like growth factor II receptor in restricted tumor areas, indicating additional alterations. Insulin-like growth factor II receptor mutations appear to be caused by hMSH3 and hMSH6 mutations because the former mutations were confined to tumor portions with the latter two mismatch repair lesions, These results provide genetic progression evidence for gastric carcinomas of the mutator pathway, In this pathway, mismatch repair insufficiency initially targets mononucleotide tracts of transforming growth factor beta receptor type II and BAX. During tumorigenesis, primary mismatch repair failure may give rise to the secondary mismatch repair lesions, frameshift mutations of hMSH3 and hMSH6, which result in another tumorigenic mutation in the insulin-like growth factor II receptor.	CATHOLIC UNIV,COLL MED,DEPT MICROBIOL,SOCHO GU,SEOUL 137701,SOUTH KOREA; CATHOLIC UNIV,COLL MED,DEPT CLIN PATHOL,SEOUL 137701,SOUTH KOREA; CATHOLIC UNIV,COLL MED,DEPT INTERNAL MED,SEOUL 137701,SOUTH KOREA	Catholic University of Korea; Catholic University of Korea; Catholic University of Korea								AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Akiyama Y, 1996, JPN J CANCER RES, V87, P595, DOI 10.1111/j.1349-7006.1996.tb00265.x; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CHONG JM, 1994, CANCER RES, V54, P4595; Chung YJ, 1996, CANCER RES, V56, P4662; CORREA P, 1994, CANCER RES, V54, pS1941; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; EYFJORD JE, 1995, CANCER RES, V55, P646; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FONG KM, 1995, CANCER RES, V55, P28; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; HAN HJ, 1993, CANCER RES, V53, P5087; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KARRAN P, 1990, MUTAT RES, V236, P269, DOI 10.1016/0921-8777(90)90010-3; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; Larson AA, 1996, CANCER RES, V56, P1426; LAU MMH, 1994, GENE DEV, V8, P2953, DOI 10.1101/gad.8.24.2953; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LOEB LA, 1991, CANCER RES, V51, P3075; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MERLO A, 1994, CANCER RES, V54, P2098; MYEROFF LL, 1995, CANCER RES, V55, P5545; OKA Y, 1985, J BIOL CHEM, V260, P9435; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OOTA K, 1977, INT HIST CLASSIFICAT, V18; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; PARSONS R, 1995, CANCER RES, V55, P5548; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Reitmair AH, 1996, CANCER RES, V56, P2922; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; RHYU MG, 1994, ONCOGENE, V9, P29; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Zhu JG, 1996, ONCOGENE, V12, P1417	39	70	77	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 2	1997	15	14					1719	1726		10.1038/sj.onc.1201343	http://dx.doi.org/10.1038/sj.onc.1201343			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349506				2022-12-17	WOS:A1997XY63100012
J	Leung, HY; Mehta, P; Gray, LB; Collins, AT; Robson, CN; Neal, DE				Leung, HY; Mehta, P; Gray, LB; Collins, AT; Robson, CN; Neal, DE			Keratinocyte growth factor expression in hormone insensitive prostate cancer	ONCOGENE			English	Article						kGF; FGF; FGFR isoform; alternative splicing; prostate cancer; paracrine loop	FACTOR RECEPTOR-1; FGF-RECEPTOR; CELLS; BINDING; ACTIVATION; ANDROGEN; CLONING	Cellular interactions between stroma and epithelium are important in the growth and proliferation of prostate cancer, Peptide growth factors may facilitate the progression of prostate cancer as autocrine and/or paracrine factors, Keratinocyte Growth Factor (KGF or FGF7) has a differentiative and proliferative effect on the epithelium of the developing rat prostate, We investigated if KGF may act as a paracrine agent in human prostate cancer and examined the expression of KGF and Fibroblast Growth Factor Receptors (FGFRs) (IIIb and IIIc isoforms of the FGFR1 and FGFR2 genes), Sixty-five percent (11 out of 17 informative cases) of prostate cancers (CaP) expressed KGF mRNA by RT-PCR, while KGF expression was not detected in benign prostatic hyperplasia (BPH) (n = 6), Upregulation of KGF expression was related to hormone insensitive tumours (P<0.05), Tumour grade and stage were not associated with KGF expression, The source of KGF expression was further characterised using an in vitro primary culture model, showing its restriction to the prostatic stroma, The FGFR1IIIb isoform was expressed in all cases of prostate cancer (n = 17), and FGFR1IIIc mRNA was not detected, In the BPH group, FGFR1IIIb transcripts were detected in four out of six cases, FGFR2IIIb expression was detected in five of six cases of BPH and twelve out of seventeen (71%) cases of prostate cancer, In CaP, though not reaching statistical significance, the persistence of FGFR2IIIb expression appeared to be associated with hormone insensitive tumours (P=0.052), FGFR2IIIc expression was present in eleven of seventeen tumours but was absent in all six cases of BPH. Functional assessment of recombinant KGF in a proliferation assay demonstrated a mitogenic effect of up to 100% on cultured prostatic epithelial cells.			Leung, HY (corresponding author), UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT SURG,FRAMLINGTON PL,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND.		Collins, Anne/A-8243-2008	Leung, Hing Y./0000-0002-3933-3975; Neal, David/0000-0002-6033-5086; Collins, Anne/0000-0002-2991-2703				Byrne RL, 1996, BRIT J UROL, V77, P627, DOI 10.1046/j.1464-410X.1996.09721.x; COLLINS AT, 1994, J ENDOCRINOL, V143, P269, DOI 10.1677/joe.0.1430269; CRUMLEY G, 1991, ONCOGENE, V6, P2255; CUNHA GR, 1983, RECENT PROG HORM RES, V39, P559; EISEMANN A, 1991, ONCOGENE, V6, P2379; EISEMANN A, 1991, ONCOGENE, V6, P1195; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; HAMAGUCHI A, 1995, PROSTATE, V27, P141, DOI 10.1002/pros.2990270304; Ittman M, 1997, J UROLOGY, V157, P351, DOI 10.1016/S0022-5347(01)65376-X; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; LEUNG HY, 1994, INT J ONCOL, V4, P1219; McGarvey TW, 1995, EXP MOL PATHOL, V63, P52, DOI 10.1006/exmp.1995.1030; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; PARTANEN J, 1992, Progress in Growth Factor Research, V4, P69, DOI 10.1016/0955-2235(92)90005-3; Peehl DM, 1996, GROWTH REGULAT, V6, P22; Smallwood PM, 1996, P NATL ACAD SCI USA, V93, P9850, DOI 10.1073/pnas.93.18.9850; STORY MT, 1994, GROWTH FACTORS, V10, P269, DOI 10.3109/08977199409010993; Sugimura Y, 1996, INT J DEV BIOL, V40, P941; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918; YAN GC, 1992, BIOCHEM BIOPH RES CO, V183, P423, DOI 10.1016/0006-291X(92)90498-A; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513	26	70	72	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 28	1997	15	9					1115	1120		10.1038/sj.onc.1201256	http://dx.doi.org/10.1038/sj.onc.1201256			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XT161	9285567				2022-12-17	WOS:A1997XT16100014
J	Lane, S; Farlie, P; Watson, R				Lane, S; Farlie, P; Watson, R			B-Myb function can be markedly enhanced by cyclin A-dependent kinase and protein truncation	ONCOGENE			English	Article						B-Myb; cyclin A; transactivation; cell cycle	DNA-BINDING ACTIVITY; C-MYB; TRANSCRIPTIONAL ACTIVATION; CELL-CYCLE; GENE-PRODUCT; ONCOGENE; TRANSACTIVATION; EXPRESSION; DOMAINS; TRANSFORMATION	Transcription of the B-Myb gene is cell cycle regulated by an E2F-dependent mechanism and its product, B-Myb, is itself a transcription factor required for S-phase entry. Previously, rye have shown that B-Myb is specifically phosphorylated during S-phase and that similar modification to a less electrophoretically mobile form could be induced by baculovirus-expressed cyclin A/Cdk2 kinase. We report here that cyclin A-mediated phosphorylation of B-Myb is associated with a marked increase in transactivation function in U-2 OS cells. In contrast to previous studies, transactivation of the luciferase reporter was dependent upon Myb binding sites located upstream of the promoter. Enhancement of B-Myb activation function was also obtained by truncation of the C-terminus just downstream of a domain conserved in evolution. Potentiation of B-Myb activity by phosphorylation was not simply a consequence of overcoming the negative effect of the C-terminus, however, as the truncated protein was to a lesser extent also activated by cyclin A/Cdk2. Whereas wild-type B-Myb transactivation activity could not be potentiated by cyclin A/Cdk2 in NIH3T3 cells, the truncated protein was hyperactive. Finally, we showed that B-Myb synergises with cyclin A to promote U-2 OS cells into S-phase.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,SCH MED,ST MARYS HOSP,LUDWIG INST CANC RES,LONDON W2 1PG,ENGLAND; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,SCH MED,ST MARYS HOSP,DEPT MED MICROBIOL,LONDON W2 1PG,ENGLAND	Imperial College London; Ludwig Institute for Cancer Research; Imperial College London								ARSURA M, 1992, BLOOD, V79, P2708; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; Bies J, 1996, ONCOGENE, V12, P355; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; FOOS G, 1994, ONCOGENE, V9, P2481; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOLAY J, 1994, ONCOGENE, V9, P2469; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HU YL, 1991, ONCOGENE, V6, P1549; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; MA XP, 1994, CANCER RES, V54, P6512; Marhamati DJ, 1996, J BIOL CHEM, V271, P3359; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OEHLER T, 1990, NUCLEIC ACIDS RES, V18, P1703, DOI 10.1093/nar/18.7.1703; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Robinson C, 1996, ONCOGENE, V12, P1855; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sala A, 1996, J BIOL CHEM, V271, P9363, DOI 10.1074/jbc.271.16.9363; Sitzmann J, 1996, ONCOGENE, V12, P1889; TAKAHASHI T, 1995, FEBS LETT, V358, P89, DOI 10.1016/0014-5793(94)01402-M; TASHIRO S, 1995, ONCOGENE, V10, P1699; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	37	70	70	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 22	1997	14	20					2445	2453		10.1038/sj.onc.1201086	http://dx.doi.org/10.1038/sj.onc.1201086			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WZ680	9188859				2022-12-17	WOS:A1997WZ68000008
J	Malumbres, M; Perez de Castro, I; Santos, J; Melendez, B; Mangues, R; Serrano, M; Pellicer, A; FernandezPiqueras, J				Malumbres, M; Perez de Castro, I; Santos, J; Melendez, B; Mangues, R; Serrano, M; Pellicer, A; FernandezPiqueras, J			Inactivation of the cyclin-dependent kinase inhibitor p15(INK4b) by deletion and de novo methylation with independence of p16(INK4 alpha) alterations in murine primary T-cell lymphomas	ONCOGENE			English	Article						p15(INK4b); p16(INK4a); CDK inhibitors; T-cell lymphomas; DNA methylation	TUMOR-SUPPRESSOR GENE; ACUTE LYMPHOBLASTIC-LEUKEMIA; GROWTH-FACTOR-BETA; MOUSE SKIN TUMORS; K-RAS; HUMAN CANCERS; ALLELOTYPE ANALYSIS; MTS1 P16(INK4A); GAMMA-RADIATION; DNA METHYLATION	A wide panel of murine induced T-cell lymphomas have been analysed for p16(INK4a) Or p15(INK4b) alterations, Only one gamma-radiation-induced lymphoma showed p16(INK4a) homozygous deletion and no other intragenic mutations were found in these INK4 genes, However, de novo methylation of the 5' CpG islands of the murine p15(INK4b) and p16(INK4a) genes was found to be highly frequent, While p16(INK4a) hypermethylation was found in 36% of the neutron-radiation-induced lymphomas and 15% of the gamma-radiation-induced lymphomas, de novo methylation of p15(INK4b) occurs in 88% and 42% of these tumors respectively, correlating with deficient expression of the corresponding mRNA and allelic losses in the p15(INK4b) and p16(INK4a) chromosome location, These data represent, to our knowledge, the first report on the significant involvement of hypermethylation of these INK4 genes in murine primary tumors, Moreover, they show the importance of allelic losses and CpG island methylation of p15(INK4b) gene inactivation and support a tumor suppressor role for p15(INK4b) in T-cell lymphomas independent of p16(INK4a).	NYU, MED CTR, DEPT PATHOL, NEW YORK, NY 10016 USA; NYU, MED CTR, KAPLAN COMPREHENS CANC CTR, NEW YORK, NY 10016 USA; UNIV AUTONOMA MADRID, FAC CIENCIAS, DEPT BIOL, LAB GENET MOL HUMANA, E-28049 MADRID, SPAIN; COLD SPRING HARBOR LAB, HOWARD HUGHES MED INST, COLD SPRING HARBOR, NY 11724 USA	New York University; New York University; Autonomous University of Madrid; Cold Spring Harbor Laboratory; Howard Hughes Medical Institute			de Castro, Ignacio Pérez/A-6260-2012; Mangues, Ramon/J-6396-2014; Malumbres, Marcos/E-8834-2011; Serrano, Manuel/H-2634-2015; Holt, Janet E/B-2415-2013; Santos, Javier/ABF-5755-2021; MARTINEZ, ANTONIO PELLICER/C-4832-2015; Melendez, Barbara/E-1216-2017	de Castro, Ignacio Pérez/0000-0002-8822-8274; Mangues, Ramon/0000-0003-2661-9525; Malumbres, Marcos/0000-0002-0829-6315; Serrano, Manuel/0000-0001-7177-9312; Santos, Javier/0000-0002-4168-6251; Melendez, Barbara/0000-0001-5004-8895; Pellicer, Angel/0000-0002-5062-0692	NCI NIH HHS [CA50434, 5T32 CA09161, CA36327] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009161, R37CA036327, R01CA050434, R01CA036327] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; ANTEQUERA F, 1993, DNA METHYLATION MOL, P169; Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; BIRD AP, 1995, TRENDS GENET, V11, P94, DOI 10.1016/S0168-9525(00)89009-5; CAYUELA JM, 1995, BLOOD, V85, P854, DOI 10.1182/blood.V85.3.854a.bloodjournal853854a; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; DEBUSTROS A, 1988, P NATL ACAD SCI USA, V85, P5693; DIAMOND LE, 1988, MOL CELL BIOL, V8, P2233, DOI 10.1128/MCB.8.5.2233; DIAZ MO, 1990, NEW ENGL J MED, V322, P77, DOI 10.1056/NEJM199001113220202; Duro D, 1996, CANCER RES, V56, P848; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GLENDENING JM, 1995, CANCER RES, V55, P5531; GOMBART AF, 1995, BLOOD, V86, P1534, DOI 10.1182/blood.V86.4.1534.bloodjournal8641534; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GRANA X, 1995, ONCOGENE, V11, P211; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; GUERRERO I, 1984, SCIENCE, V225, P1159, DOI 10.1126/science.6474169; GUERRERO I, 1984, P NATL ACAD SCI-BIOL, V81, P202, DOI 10.1073/pnas.81.1.202; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HEBERT J, 1994, BLOOD, V84, P4038, DOI 10.1182/blood.V84.12.4038.bloodjournal84124038; HEGI ME, 1994, CANCER RES, V54, P6257; Herman JG, 1996, CANCER RES, V56, P722; HERMAN JG, 1995, CANCER RES, V55, P4525; HERZOG CR, 1994, CANCER RES, V54, P4007; Heyman M, 1996, BLOOD, V87, P1657, DOI 10.1182/blood.V87.4.1657.bloodjournal8741657; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HIRAMA T, 1995, BLOOD, V86, P841; HOOPER WC, 1991, LEUKEMIA RES, V15, P179, DOI 10.1016/0145-2126(91)90118-D; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HUTCHINSON F, 1985, PROG NUCLEIC ACID RE, V32, P115, DOI 10.1016/S0079-6603(08)60347-5; ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235; JEN J, 1994, CANCER RES, V54, P6353; Jiang P, 1995, J MOL EVOL, V41, P795; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KEMP CJ, 1993, CANCER RES, V53, P6022; Khleif SN, 1996, P NATL ACAD SCI USA, V93, P4350, DOI 10.1073/pnas.93.9.4350; KODURU PRK, 1995, BLOOD, V86, P2900; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Larsen CJ, 1996, ONCOGENE, V12, P2041; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; LINARDOPOULOS S, 1995, CANCER RES, V55, P5168; LOIS AF, 1995, CANCER RES, V55, P4010; MACLEOD AR, 1995, J BIOL CHEM, V270, P11327, DOI 10.1074/jbc.270.19.11327; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; NEWCOMB EW, 1988, CANCER RES, V48, P5514; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OGAWA S, 1995, BLOOD, V86, P1548, DOI 10.1182/blood.V86.4.1548.bloodjournal8641548; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OKUDA T, 1995, BLOOD, V85, P2013; OTSUKI T, 1995, CANCER RES, V55, P1436; OTTERSON GA, 1995, ONCOGENE, V11, P1211; POLLOCK PM, 1996, CANCER, V15, P77; QUELLE DE, 1995, CELL, V83, P993; QUELLE DE, 1995, ONCOGENE, V11, P635; RASOOL O, 1995, BLOOD, V85, P3431, DOI 10.1182/blood.V85.12.3431.bloodjournal85123431; RICHARDSON KK, 1987, P NATL ACAD SCI USA, V84, P344, DOI 10.1073/pnas.84.2.344; Santos J, 1996, ONCOGENE, V12, P669; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SIEBERT R, 1995, BRIT J HAEMATOL, V91, P350, DOI 10.1111/j.1365-2141.1995.tb05302.x; SLOAN SR, 1990, MOL CELL BIOL, V10, P405, DOI 10.1128/MCB.10.1.405; STONE S, 1995, ONCOGENE, V11, P987; STRANKS G, 1995, BLOOD, V85, P893, DOI 10.1182/blood.V85.4.893.bloodjournal854893; TAKEUCHI S, 1995, BLOOD, V86, P755, DOI 10.1182/blood.V86.2.755.bloodjournal862755; TAM SW, 1994, CANCER RES, V54, P5816; Winston JT, 1996, ONCOGENE, V12, P127; WISEMAN RW, 1994, P NATL ACAD SCI USA, V91, P3759, DOI 10.1073/pnas.91.9.3759; Wu JJ, 1996, CANCER RES, V56, P616; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891	71	70	74	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 20	1997	14	11					1361	1370		10.1038/sj.onc.1200969	http://dx.doi.org/10.1038/sj.onc.1200969			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WP109	9178896				2022-12-17	WOS:A1997WP10900011
J	Bui, TD; Rankin, J; Smith, K; Huguet, EL; Ruben, S; Strachan, T; Harris, AL; Lindsay, S				Bui, TD; Rankin, J; Smith, K; Huguet, EL; Ruben, S; Strachan, T; Harris, AL; Lindsay, S			A novel human Wnt gene, WNT10B, maps to 12q13 and is expressed in human breast carcinomas	ONCOGENE			English	Article						WNT10B; cloning; breast carcinoma	MAMMARY EPITHELIUM; MOLECULAR-CLONING; TRANSGENIC MICE; TUMORS; ONCOGENE; FAMILY; INT-1; HYPERPLASIA; MULTIPLE; SEQUENCE	Several members of the Wnt gene family have been shown to cause mammary tumors in mouse. Using degenerate primer polymerase chain reaction (PCR) on human genomic DNA, and specific PCR of cDNA libraries, we have isolated a WNT gene which has not previously been described in human. The gene is the human homologue of mouse Wnt10b, recently shown to be one of the oncogenes cooperating with FGF3 in the development of mouse mammary tumour virus (MMTV) induced mouse mammary carcinomas. The human WNT10B sequence was 88% and 95% identical to the murine gene at nucleotide and amino acid levels, respectively, YAC FISH mapping localises the gene to 12q13, a chromosomal region frequently rearranged in human tumours and also containing the WNT1 gene. In normal and benign proliferations of human breast tissue, WNT10B expression was not detected by ribonuclease protection assays but was found at low levels in RT-PCR experiments. In contrast, using both methods, WNT10B expression was found to be elevated in 3 of 50 primary breast carcinomas. Southern blot analysis of the carcinoma expressing the highest levels of WNT10B showed no amplification or rearrangement of the gene. The WNT10B gene was also expressed in some cancer and non cancerous breast cell lines. These findings suggest that the WNT10B gene may be involved in human breast cancer, and show that there is differential expression of the WNT10B gene in benign and malignant disease.	UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOL MED,IMPERIAL CANC RES FUND,GROWTH FACTORS GRP,OXFORD OX3 9DU,ENGLAND; UNIV NEWCASTLE UPON TYNE,DEPT HUMAN GENET,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND; HUMAN GENOME SCI INC,ROCKVILLE,MD 20850	University of Oxford; Newcastle University - UK; GlaxoSmithKline; Human Genome Sciences Inc			Harris, Adrian L/ABA-3343-2020	Harris, Adrian L/0000-0003-1376-8409; Lindsay, Susan/0000-0003-2980-4582				ADAMSON MC, 1994, GENOMICS, V24, P9, DOI 10.1006/geno.1994.1575; ANAND R, 1990, NUCLEIC ACIDS RES, V18, P1951, DOI 10.1093/nar/18.8.1951; Ausubel F, 1990, CURRENT PROTOCOLS MO, V1; BUHLER TA, 1993, DEV BIOL, V155, P87, DOI 10.1006/dbio.1993.1009; CLARK CC, 1993, GENOMICS, V18, P249, DOI 10.1006/geno.1993.1463; EDWARDS PAW, 1992, ONCOGENE, V7, P2041; FANTES JA, 1992, AM J HUM GENET, V51, P1286; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GAVIN BJ, 1992, MOL CELL BIOL, V12, P2418, DOI 10.1128/MCB.12.5.2418; HUGUET EL, 1994, CANCER RES, V54, P2615; Lako M, 1996, GENOMICS, V35, P386, DOI 10.1006/geno.1996.0374; LAZO PA, 1992, FEBS LETT, V300, P109, DOI 10.1016/0014-5793(92)80175-G; LEE FS, 1995, P NATL ACAD SCI USA, V92, P2268, DOI 10.1073/pnas.92.6.2268; LEJEUNE S, 1995, CLIN CANCER RES, V1, P215; LIN TP, 1992, CANCER RES, V52, P4413; MCCARTHY SA, 1992, J BIOL CHEM, V267, P21617; MCMAHON AP, 1992, TIG, V8, P237; MOCK BA, 1993, ENCY MOUSE GENOME, V3; NILBERT M, 1995, CANCER GENET CYTOGEN, V83, P32, DOI 10.1016/S0165-4608(95)00016-X; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; ROELINK H, 1993, GENOMICS, V17, P790, DOI 10.1006/geno.1993.1412; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; TAYLORPAPADIMITRIOU J, 1993, CANCER SURV, V16, P59; VANDEVEN WJM, 1995, GENE CHROMOSOME CANC, V12, P296; VANOOYEN A, 1985, EMBO J, V4, P2905, DOI 10.1002/j.1460-2075.1985.tb04021.x; WAINWRIGHT BJ, 1988, EMBO J, V7, P1743, DOI 10.1002/j.1460-2075.1988.tb03003.x; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278	28	70	80	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 13	1997	14	10					1249	1253		10.1038/sj.onc.1200936	http://dx.doi.org/10.1038/sj.onc.1200936			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121776				2022-12-17	WOS:A1997WM78200016
J	Kashanchi, F; Araujo, J; Doniger, J; Muralidhar, S; Hoch, R; Khleif, S; Mendelson, E; Thompson, J; Azumi, N; Brady, JN; Luppi, M; Torelli, G; Rosenthal, LJ				Kashanchi, F; Araujo, J; Doniger, J; Muralidhar, S; Hoch, R; Khleif, S; Mendelson, E; Thompson, J; Azumi, N; Brady, JN; Luppi, M; Torelli, G; Rosenthal, LJ			Human herpesvirus 6 (HHV-6) ORF-1 transactivating gene exhibits malignant transforming activity and its protein binds to p53	ONCOGENE			English	Article						p53 binding; p53-activated transcription; HHV-6 transformation gene	POLYMERASE CHAIN-REACTION; VIRUS HUMAN HERPESVIRUS-6; EXANTHEM-SUBITUM; TRANSCRIPTIONAL ACTIVATION; NEOPLASTIC TRANSFORMATION; HUMAN CYTOMEGALOVIRUS; TRANSGENIC MICE; HUMAN LYMPHOMAS; LYMPHOCYTES-T; CELL-LINES	The 357 amino acid open reading frame 1 (OFF-1), also designated DR7, within the SalI-L fragment of human herpesvirus 6 (HHV-6) exhibited transactivation of the human immunodeficiency virus type 1 (HIV-1) long terminal repeat (LTR) promoter and increased HIV-1 replication (Kashanchi et al., Virology, 201, 95-106, 1994). Tn the current study, the SalI-L transforming region was localized to the SalI-L-SH subfragment, Several ORFs identified in SalI-L-SH by sequence analysis were cloned into a selectable mammalian expression vector, pBK-CMV, Only pBK/ORF1 transformed NIH3T3 cells. Furthermore, cells expressing ORF-1 protein produced fibrosarcomas when injected into nude mice, whereas control cells, expressing either no ORF-1 protein or C-terminal truncated (after residue 172) ORF-1 protein, were not tumorigenic, Western blot analysis of proteins extracted from the tumors revealed ORF-1 protein. Additional studies indicated that ORF-1 was expressed in HHV-6-infected human T-cells by 18 h. Co-immunoprecipitation experiments showed that ORF-1 protein bound to tumor suppressor protein p53, and the OFF-1 binding domain on p53 was located between residues 28 and 187 of p53, overlapping with the specific DNA binding domain. Functional studies showed that p53-activated transcription was inhibited in ORF-1, but not in truncated OFF-1, expressing cells. Importantly, the truncated ORF-1 mutant also failed to cause transformation. Analysis of several human tumors by PCR revealed OFF-1 DNA sequences in some angioimmunoblastic lymphadenopathies, Hodgkin's and non-Hodgkin's lymphomas and glioblastomas. The detection of OFF-1 sequences in human tumors, while not proof per se, is a prerequisite for establishing its role in tumor development. Taken together, the results demonstrate that OFF-1 is an HHV-6 oncogene that binds to and affects p53. The identification of both transforming and transactivating activities within ORF-1 is a characteristic of other viral oncogenes and is the first reported for HHV-6.	GEORGETOWN UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,WASHINGTON,DC 20007; GEORGETOWN UNIV,MED CTR,VINCENT T LOMBARDI CANC RES CTR,WASHINGTON,DC 20007; GEORGETOWN UNIV,MED CTR,DEPT PATHOL,WASHINGTON,DC 20007; NCI,MOL VIROL LAB,NIH,BETHESDA,MD 20892; NCI,NAVY MED ONCOL BRANCH,BETHESDA,MD 20892; UNIV MODENA,CTR EXPT HEMATOL,I-41100 MODENA,ITALY	Georgetown University; Georgetown University; Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Universita di Modena e Reggio Emilia			Luppi, Mario/J-3668-2016	Luppi, Mario/0000-0002-0373-1154; Hoch, Renee/0000-0003-0042-3751	NATIONAL CANCER INSTITUTE [R55CA060577, R01CA060577] Funding Source: NIH RePORTER; NCI NIH HHS [CA 60577] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABLASHI DV, 1987, NATURE, V329, P207, DOI 10.1038/329207a0; ABLASHI DV, 1988, INT J CANCER, V42, P787, DOI 10.1002/ijc.2910420526; ABLASHI DV, 1995, TRENDS MICROBIOL, V3, P324, DOI 10.1016/S0966-842X(00)88964-7; ASANO Y, 1990, LANCET, V335, P862, DOI 10.1016/0140-6736(90)90983-C; BERTRAM G, 1991, In Vivo (Attiki), V5, P271; BLAZQUEZ MV, 1995, J ACQ IMMUN DEF SYND, V9, P389; BOVENZI P, 1993, LANCET, V341, P1288, DOI 10.1016/0140-6736(93)91198-U; BUCHWALD D, 1992, ANN INTERN MED, V116, P103, DOI 10.7326/0003-4819-116-2-103; CARRIGAN DR, 1991, LANCET, V338, P147, DOI 10.1016/0140-6736(91)90137-E; CHALLONER PB, 1995, P NATL ACAD SCI USA, V92, P7440, DOI 10.1073/pnas.92.16.7440; CHEN M, 1994, J VIROL, V68, P1173, DOI 10.1128/JVI.68.2.1173-1178.1994; CLANTON DJ, 1983, P NATL ACAD SCI-BIOL, V80, P3826, DOI 10.1073/pnas.80.12.3826; CONE RW, 1993, J CLIN MICROBIOL, V31, P1262, DOI 10.1128/JCM.31.5.1262-1267.1993; Dalal S, 1996, J VIROL, V70, P683, DOI 10.1128/JVI.70.2.683-688.1996; FUJITA M, 1995, ONCOGENE, V11, P15; GOMPELS UA, 1995, VIROLOGY, V209, P29, DOI 10.1006/viro.1995.1228; Hansen R, 1995, ONCOGENE, V11, P2535; HORVAT RT, 1991, J VIROL, V65, P2895, DOI 10.1128/JVI.65.6.2895-2902.1991; HUIBREGTSE JM, 1994, COLD SPRING HARB SYM, V59, P237, DOI 10.1101/SQB.1994.059.01.028; ISHIGURO N, 1990, ACTA PAEDIATR SCAND, V79, P987, DOI 10.1111/j.1651-2227.1990.tb11369.x; JOSEPHS SF, 1988, LEUKEMIA, V2, P132; KASHANCHI F, 1994, VIROLOGY, V201, P95, DOI 10.1006/viro.1994.1269; KASHANCHI F, 1993, J VIROL, V67, P2894, DOI 10.1128/JVI.67.5.2894-2902.1993; Kikuchi M, 1992, HUMAN HERPESVIRUS, VDV, P175; KIM SH, 1994, P NATL ACAD SCI USA, V91, P6914, DOI 10.1073/pnas.91.15.6914; KO Y, 1995, MOL CELL PROBE, V9, P215, DOI 10.1016/S0890-8508(95)90070-5; Krueger G R, 1991, In Vivo, V5, P217; Krueger G R, 1994, In Vivo, V8, P501; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LEVINE PH, 1992, J INFECT DIS, V166, P291, DOI 10.1093/infdis/166.2.291; LI QT, 1995, J BIOL CHEM, V270, P15777, DOI 10.1074/jbc.270.26.15777; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LUDLOW JW, 1995, VIRUS RES, V35, P113, DOI 10.1016/0168-1702(94)00094-S; LUPPI M, 1993, J INFECT DIS, V168, P1074, DOI 10.1093/infdis/168.4.1074; LUPPI M, 1995, J MED VIROL, V47, P105, DOI 10.1002/jmv.1890470119; LUPPI M, 1993, LEUKEMIA RES, V17, P1003, DOI 10.1016/0145-2126(93)90049-Q; LUSSO P, 1995, J EXP MED, V181, P1303, DOI 10.1084/jem.181.4.1303; LUSSO P, 1989, NATURE, V337, P370, DOI 10.1038/337370a0; LUSSO P, 1988, J EXP MED, V167, P1659, DOI 10.1084/jem.167.5.1659; MANSUR CP, 1995, ONCOGENE, V10, P457; MARTIN MED, 1991, J VIROL, V65, P5381, DOI 10.1128/JVI.65.10.5381-5390.1991; MIDGLEY CA, 1992, J CELL SCI, V101, P183; Nicholas J, 1996, J VIROL, V70, P5975, DOI 10.1128/JVI.70.9.5975-5989.1996; NIEDERMAN JC, 1988, LANCET, V2, P817; NISSIM A, 1994, EMBO J, V13, P692, DOI 10.1002/j.1460-2075.1994.tb06308.x; PELLETT PE, 1996, FIELDS VIROLOGY, P2587; QAVI HB, 1995, INVEST OPHTH VIS SCI, V36, P2040; RAZZAQUE A, 1993, VIROLOGY, V195, P113, DOI 10.1006/viro.1993.1351; RAZZAQUE A, 1990, ONCOGENE, V5, P1365; RUPPERT JM, 1993, MOL CELL BIOL, V13, P3811, DOI 10.1128/MCB.13.6.3811; SAITO Y, 1995, J NEUROVIROL, V1, P30, DOI 10.3109/13550289509111008; SIECZKOWSKI L, 1995, VIROLOGY, V211, P544, DOI 10.1006/viro.1995.1436; SOUSSI T, 1990, ONCOGENE, V5, P945; STEEPER TA, 1990, AM J CLIN PATHOL, V93, P776, DOI 10.1093/ajcp/93.6.776; TAKAHASHI K, 1988, LANCET, V1, P1463; TAKAHASHI K, 1989, J VIROL, V63, P3161, DOI 10.1128/JVI.63.7.3161-3163.1989; Target Lusso P, 1992, HUMAN HERPESVIRUS, P25; THOMPSON J, 1994, ONCOGENE, V9, P1167; TLSTY TD, 1994, COLD SPRING HARB SYM, V59, P265, DOI 10.1101/SQB.1994.059.01.031; TORELLI G, 1995, J MED VIROL, V46, P178, DOI 10.1002/jmv.1890460303; TORELLI G, 1991, BLOOD, V77, P2251, DOI 10.1182/blood.V77.10.2251.2251; UITTENBOGAARD MN, 1995, J BIOL CHEM, V270, P28503, DOI 10.1074/jbc.270.48.28503; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; White E, 1995, Curr Top Microbiol Immunol, V199 ( Pt 3), P34; YAMANISHI K, 1988, LANCET, V1, P1065	68	70	77	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 23	1997	14	3					359	367		10.1038/sj.onc.1200840	http://dx.doi.org/10.1038/sj.onc.1200840			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD516	9018122				2022-12-17	WOS:A1997WD51600012
J	Lei, JY; Zou, TT; Shi, YQ; Zhou, XL; Smolinski, KN; Yin, J; Souza, RF; Appel, R; Wang, S; Cymes, K; Chan, O; Abraham, JM; Harpaz, N; Meltzer, SJ				Lei, JY; Zou, TT; Shi, YQ; Zhou, XL; Smolinski, KN; Yin, J; Souza, RF; Appel, R; Wang, S; Cymes, K; Chan, O; Abraham, JM; Harpaz, N; Meltzer, SJ			Infrequent DPC4 gene mutation in esophageal cancer, gastric cancer and ulcerative colitis-associated neoplasms	ONCOGENE			English	Article						DPC4; mutation; tumor suppressor gene; esophageal cancer; gastric cancer; DNA sequencing	TUMOR-SUPPRESSOR GENE; ADENOMATOUS POLYPOSIS; DROSOPHILA; DYSPLASIAS; ALLELOTYPE; DELETIONS; CARCINOMA; BETA; P53	Homozygously Deleted in Pancreatic Cancer 4 (DPC4), a recently identified candidate tumor suppressor gene, was previously shown to be altered in human pancreatic cancers, We examined DPC4 mutation in 30 examples of three other types of gastrointestinal malignancy: 10 esophageal cancers, 10 gastric cancers and 10 colorectal cancers occurring in the preneoplastic condition, ulcerative colitis, The entire coding region of DPC4 (including all 11 exons) was analysed by either direct sequencing of PCR product or the in vitro synthesized protein assay. No coding region mutations of DPC4 were found in any of the samples examined, Our results suggest that inactivation of DPC4 may not be important in the majority of these types of gastrointestinal cancer.	UNIV MARYLAND,SCH MED,DEPT MED,DIV GASTROENTEROL,BALTIMORE,MD 21201; VET AFFAIRS HOSP,BALTIMORE,MD 21201; MT SINAI UNIV,SCH MED,DEPT PATHOL,NEW YORK,NY	University System of Maryland; University of Maryland Baltimore; Icahn School of Medicine at Mount Sinai			Harpaz, Noam/L-3411-2017	Harpaz, Noam/0000-0003-4923-2200				ALEXANDROW MG, 1995, CANCER RES, V55, P1452; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HURSH DA, 1993, DEVELOPMENT, V117, P1211; Kim SK, 1996, CANCER RES, V56, P2519; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MELTZER SJ, 1990, CANCER RES, V50, P3627; Nagatake M, 1996, CANCER RES, V56, P2718; POWELL SM, 1994, GASTROENTEROLOGY, V107, P1759, DOI 10.1016/0016-5085(94)90818-4; RHYU MG, 1994, GASTROENTEROLOGY, V106, P1584, DOI 10.1016/0016-5085(94)90414-6; SEKELSKY JJ, 1995, GENETICS, V139, P1347; SHIBAGAKI I, 1994, CANCER RES, V54, P2996; SHUTTE M, 1996, CANCER RES, V56, P2527; TARMIN L, 1995, CANCER RES, V55, P2035; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; TOYOOKA M, 1995, CANCER RES, V55, P3165; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; XIAO S, 1995, CANCER RES, V55, P2968	20	70	75	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2459	2462						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957088				2022-12-17	WOS:A1996VX10800019
J	Marra, G; Chang, CL; Laghi, LA; Chauhan, DP; Young, D; Boland, CR				Marra, G; Chang, CL; Laghi, LA; Chauhan, DP; Young, D; Boland, CR			Expression of human MutS homolog 2 (hMSH2) protein in resting and proliferating cells	ONCOGENE			English	Article						hMSH2; protein expression; cell cycle; DNA mismatch repair	NONPOLYPOSIS COLON-CANCER; DNA MISMATCH REPAIR; SACCHAROMYCES-CEREVISIAE; MICROSATELLITE INSTABILITY; COLORECTAL-CANCER; MUTATIONS; GENE; YEAST; MSH2; RECOMBINATION	The hMSH2 protein plays an important role in the DNA mismatch repair system. Since this system is involved in the correction of errors that occur during DNA replication, we studied the expression of hMSH2 protein in resting and DNA-replicating cells, as well as through the cell cycle in cell types with different growth characteristics. Using Western blot analysis, we showed that hMSH2 protein was detectable in resting peripheral blood lymphocytes and thymocytes. However, when these cells were induced to proliferate, the protein level increased at least 12-fold. In cell-cycle dependent expression studies we chose two DNA mismatch repair proficient cell lines (HEL and HeLa-S3), and flow cytometry was used to monitor cell-cycle progression. At every phase in the cell cycle, the steady-state level of hMSH2 was higher than in resting lymphocytes or thymocytes, and only minor variations of expression level were observed through the cell cycle. In particular, a two to fourfold decrease in hMSH2 expression occurred at G(1) in HEL and at early S phase in HeLa-S3, but higher expression levels resumed during the replicative and postreplicative phases of the cell cycle. Interestingly, hMSH2 protein expression decreased fourfold when HEL cells were induced to differentiate along the megakaryocyte lineage, when continuous DNA replication occurs without mitosis. These results suggest that a basal level of hMSH2 protein expression is necessary for resting and differentiated cells, and that increased hMSH2 protein expression is required when DNA replication is activated and followed by mitosis.	UNIV CALIF SAN DIEGO, DEPT MED, DIV GASTROENTEROL, LA JOLLA, CA 92093 USA; UNIV MICHIGAN, DEPT PEDIAT, ANN ARBOR, MI 48109 USA; UNIV CALIF SAN DIEGO, CTR CANC, CORE FLOW CYTOMETRY FACIL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of Michigan System; University of Michigan; University of California System; University of California San Diego			Laghi, Luigi/GZM-5831-2022; Chang, Christina/B-9650-2009	Laghi, Luigi/0000-0003-4187-1059				ALANI E, 1994, GENETICS, V137, P19; BICKNELL DC, 1994, P NATL ACAD SCI USA, V91, P4751, DOI 10.1073/pnas.91.11.4751; BISHOP DK, 1989, P NATL ACAD SCI USA, V86, P3713, DOI 10.1073/pnas.86.10.3713; BISHOP DK, 1987, NATURE, V328, P362, DOI 10.1038/328362a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; Carethers JM, 1996, J CLIN INVEST, V98, P199, DOI 10.1172/JCI118767; CHANG CL, 1988, J BACTERIOL, V170, P4015, DOI 10.1128/jb.170.9.4015-4022.1988; CHI NW, 1994, J BIOL CHEM, V269, P29984; FISHEL R, 1994, CANCER RES, V54, P5539; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; HAWN MT, 1995, CANCER RES, V55, P3721; HOLLINGSWORTH NM, 1995, GENE DEV, V9, P1728, DOI 10.1101/gad.9.14.1728; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; KOLODNER RD, 1994, GENOMICS, V24, P516, DOI 10.1006/geno.1994.1661; KRAMER B, 1989, MOL CELL BIOL, V9, P4432, DOI 10.1128/MCB.9.10.4432; KRAMER W, 1989, J BACTERIOL, V171, P5339, DOI 10.1128/jb.171.10.5339-5346.1989; LAZAR V, 1994, HUM MOL GENET, V3, P2257, DOI 10.1093/hmg/3.12.2257; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Leach FS, 1996, CANCER RES, V56, P235; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; LIU B, 1994, CANCER RES, V54, P4590; LIU B, 1995, NAT MED, V1, P348, DOI 10.1038/nm0495-348; LOEB LA, 1994, CANCER RES, V54, P5059; LONG MW, 1990, J CLIN INVEST, V85, P1072, DOI 10.1172/JCI114538; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCE MC, 1995, GASTROENTEROLOGY, V109, P1368, DOI 10.1016/0016-5085(95)90600-2; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MARRA G, 1995, J NATL CANCER I, V87, P1114, DOI 10.1093/jnci/87.15.1114; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; Mellon I, 1996, P NATL ACAD SCI USA, V93, P1292, DOI 10.1073/pnas.93.3.1292; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; NAN HJ, 1995, HUM MOL GENET, V4, P237, DOI 10.1093/hmg/4.2.237; NEW L, 1993, MOL GEN GENET, V239, P97, DOI 10.1007/BF00281607; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; NYSTROMLAHTI M, 1995, NAT MED, V1, P1203, DOI 10.1038/nm1195-1203; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; REENAN RAG, 1992, GENETICS, V132, P963; ROSSMACDONALD P, 1994, CELL, V79, P1069, DOI 10.1016/0092-8674(94)90037-X; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SELVA EM, 1995, GENETICS, V139, P1175; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; TABILIO A, 1984, EMBO J, V3, P453, DOI 10.1002/j.1460-2075.1984.tb01827.x; TANNERGARD P, 1995, CANCER RES, V55, P6092; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; TURKA LA, 1991, J IMMUNOL, V146, P1428; WIJNEN J, 1995, AM J HUM GENET, V56, P1060; WILSON TM, 1995, CANCER RES, V55, P5146	52	70	70	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	1996	13	10					2189	2196						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950986				2022-12-17	WOS:A1996VV14500016
J	Sjoblom, T; Lahdetie, J				Sjoblom, T; Lahdetie, J			Expression of p53 in normal and gamma-irradiated rat testis suggests a role for p53 in meiotic recombination and repair	ONCOGENE			English	Article						p53; testis; spermatocytes; meiosis; rat; gamma-irradiation	TUMOR-SUPPRESSOR PROTEIN; DNA-DAMAGING AGENTS; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; GERM-CELLS; X-RAYS; MOUSE; SPERMATOGENESIS; SPERMATOCYTES; CHROMOSOMES	In testis, the expression of tumor suppressor protein p53 is stronger than in other tissues suggesting a role for it in spermatogenesis. We have studied the expression of p53 in both unirradiated and gamma-irradiated rat testis using the stage-specific model of rat seminiferous epithelium, Our results show that p53 is expressed during meiosis in normal rat spermatogenesis and its expression is localized to the preleptotene-early pachytene spermatocytes. The most prominent expression is in zygotene - early pachytene spermatocytes (stages XIII-I of seminiferous epithelium). After irradiation p53 levels increased in a time and a dose-dependent manner being highest with the doses of 6.0 and 12.0 Gy and 4 h after irradiation, This increase occurs in the same cells that normally express elevated levels of p53. These results support the view that p53 is involved in meiosis of the male rat and we suggest that p53 has a role in recombinational processes and/or formation of the synaptonemal complex. We also demonstrate that p53 takes part in the response of primary spermatocytes to gamma-irradiation induced DNA damage.	UNIV TURKU,CTR REPROD & DEV MED,FIN-20520 TURKU,FINLAND	University of Turku	Sjoblom, T (corresponding author), UNIV TURKU,DEPT MED GENET,KIINAMYLLYNKATU 10,FIN-20520 TURKU,FINLAND.							ALMON E, 1993, DEV BIOL, V156, P107, DOI 10.1006/dbio.1993.1062; BACKER LC, 1991, RADIAT RES, V125, P187, DOI 10.2307/3577887; BAE IS, 1995, CANCER RES, V55, P2387; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; COOGAN TP, 1988, MUTAT RES, V194, P183, DOI 10.1016/0167-8817(88)90020-X; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRITSCHE M, 1993, ONCOGENE, V8, P307; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; HAAPAJARVI T, 1995, ONCOGENE, V11, P151; HAN KA, 1992, NUCLEIC ACIDS RES, V20, P1979, DOI 10.1093/nar/20.8.1979; HARPER JW, 1993, CELL, V75, P805; JONES DJ, 1995, TRENDS GENET, V11, P165; KASTAN MB, 1991, CANCER RES, V51, P6304; KIERSZENBAUM AL, 1994, ENDOCR REV, V15, P116, DOI 10.1210/er.15.1.116; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEBLOND CP, 1952, ANN NY ACAD SCI, V55, P548, DOI 10.1111/j.1749-6632.1952.tb26576.x; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MORITA T, 1993, P NATL ACAD SCI USA, V90, P6577, DOI 10.1073/pnas.90.14.6577; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; PARVINEN M, 1993, METHODS TOXICOLOGY A, V3, P142; PERRY ME, 1993, CURR OPIN GENET DEV, V3, P50, DOI 10.1016/S0959-437X(05)80340-5; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; RASMUSSEN SW, 1978, CARLSBERG RES COMMUN, V43, P275, DOI 10.1007/BF02906106; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; ROTTER V, 1994, SEMIN CANCER BIOL, V5, P229; ROTTER V, 1993, P NATL ACAD SCI USA, V90, P9075, DOI 10.1073/pnas.90.19.9075; SCHMID P, 1991, DEVELOPMENT, V113, P857; SCHWARTZ D, 1993, ONCOGENE, V8, P1487; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHI SR, 1991, J HISTOCHEM CYTOCHEM, V39, P741, DOI 10.1177/39.6.1709656; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SJOBLOM T, 1995, MUTAT RES-FUND MOL M, V331, P181, DOI 10.1016/0027-5107(95)00067-S; SMITH ML, 1995, ONCOGENE, V10, P1053; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STEWART N, 1995, ONCOGENE, V10, P109; TATES AD, 1983, MUTAT RES, V121, P131, DOI 10.1016/0165-7992(83)90111-2; TISHLER RB, 1993, CANCER RES, V53, P2212; VANDERMEER Y, 1992, RADIAT RES, V130, P296, DOI 10.2307/3578374; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WOLFES H, 1989, SCIENCE, V245, P740, DOI 10.1126/science.2475907; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZENVIRTH D, 1992, EMBO J, V11, P3441, DOI 10.1002/j.1460-2075.1992.tb05423.x; ZHAN QM, 1994, ONCOGENE, V9, P3743	56	70	73	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2499	2505						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700508				2022-12-17	WOS:A1996UW48700003
J	Nguyen, HQ; Danilenko, DM; Bucay, N; DeRose, ML; Van, GY; Thomason, A; Simonet, WS				Nguyen, HQ; Danilenko, DM; Bucay, N; DeRose, ML; Van, GY; Thomason, A; Simonet, WS			Expression of keratinocyte growth factor in embryonic liver of transgenic mice causes changes in epithelial growth and differentiation resulting in polycystic kidneys and other organ malformations	ONCOGENE			English	Article						keratinocyte growth factor; transgenic mice; mesenchymal-epithelial interactions; polycystic kidney	FETAL-RAT LUNG; MESENCHYMAL INTERACTIONS; CELLS; RECEPTOR; ORGANOGENESIS; AUTOCRINE; PATHWAYS; GENES; KGF	Expression of human keratinocyte growth factor (KGF/FGF-7) was directed to hepatocytes during the later period of mouse gestation using a human apolipoprotein E (ApoE) gene promoter and its associated liver-specific enhancer, Human KGF was detectable in liver extracts and serum prepared from e(17.5)-e(19.5) embryos, concomitant with the appearance of morphological abnormalities in several organs which express KGF receptor, The most striking phenotypic aberration in the ApoE-hKGF transgenic embryos was marked hyperplasia and cystic dilation of the cortical and medullary kidney collecting duct system, a phenotype resembling infantile polycystic kidney disease in humans, Transgenic embryos had enlarged livers, with prominent biliary epithelial hyperplasia, and also exhibited enhanced bronchiolar epithelial and type II pneumocyte proliferation, There was variable hyperplasia of intestinal epithelia, and urothelium of the urinary bladder and ureters, When compared to age-matched littermate controls, marked epidermal papillomatous acanthosis and hyperkeratosis in the skin, with a notable decrease in the slumber of developing hair follicles was seen in transgenic embryos, The pancreas exhibited significant ductal hyperplasia, with an increase in the number of ductal epithelial cells staining positive for insulin expression, High systemic levels of KGF during the latter stages of embryogenesis causes abnormalities in epithelial growth and differentiation within multiple organ systems and results in perinatal lethality, Correct temporal and spatial expression of KGF during the latter stages of organ development is likely to play a critical role in mesenchymal-epithelial signaling required for normal embryonic growth and development.	AMGEN INC, AMGEN CTR, DEPT DEV BIOL, THOUSAND OAKS, CA 91320 USA; AMGEN INC, AMGEN CTR, DEPT EXPTL PATHOL, THOUSAND OAKS, CA 91320 USA; AMGEN INC, AMGEN CTR, DEPT BIOL MOLEC, THOUSAND OAKS, CA 91320 USA	Amgen; Amgen; Amgen				Danilenko, Dimitry/0000-0002-8326-1921; De Rose, Margaret/0000-0001-9481-7334				AARONSON SA, 1989, ANN NY ACAD SCI, V567, P122, DOI 10.1111/j.1749-6632.1989.tb16464.x; AARONSON SA, 1991, ANN NY ACAD SCI, V638, P62, DOI 10.1111/j.1749-6632.1991.tb49018.x; AARONSON SA, 1990, AM REV RESPIR DIS, V142, pS7, DOI 10.1164/ajrccm/142.6_Pt_2.S7; ADAMSON IYR, 1986, LAB INVEST, V55, P145; ADAMSON IYR, 1984, LAB INVEST, V50, P461; ALARID ET, 1994, P NATL ACAD SCI USA, V91, P1074, DOI 10.1073/pnas.91.3.1074; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; BRODY AR, 1981, EXP LUNG RES, V2, P207, DOI 10.3109/01902148109052316; BRODY AR, 1976, VIRCHOWS ARCH A, V372, P39, DOI 10.1007/BF00429715; CHUNG LWK, 1991, CANCER SURV, V11, P91; DANILENKO DM, 1995, AM J PATHOL, V147, P145; FINCH PW, 1995, DEV DYNAM, V203, P223, DOI 10.1002/aja.1002030210; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; GUO LF, 1993, EMBO J, V12, P973, DOI 10.1002/j.1460-2075.1993.tb05738.x; HOUSLEY RM, 1994, J CLIN INVEST, V94, P1764, DOI 10.1172/JCI117524; MASON IJ, 1994, MECH DEVELOP, V45, P15, DOI 10.1016/0925-4773(94)90050-7; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; PANOS RJ, 1993, J CLIN INVEST, V92, P969, DOI 10.1172/JCI116673; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; PETERS KG, 1992, DEVELOPMENT, V114, P233; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; SAXEN L, 1987, PEDIATR NEPHROL, V1, P385, DOI 10.1007/BF00849241; SHOJI S, 1990, AM REV RESPIR DIS, V141, P433, DOI 10.1164/ajrccm/141.2.433; Simonet WS, 1995, P NATL ACAD SCI USA, V92, P12461, DOI 10.1073/pnas.92.26.12461; SIMONET WS, 1994, J CLIN INVEST, V94, P1310, DOI 10.1172/JCI117450; SIMONET WS, 1993, J BIOL CHEM, V268, P8221; SPARGO BH, 1988, PATHOLOGY, P839; STILES AD, 1986, EXP LUNG RES, V11, P165, DOI 10.3109/01902148609064294; THESLEFF I, 1991, J CRAN GENET DEV BIO, V11, P229; ULICH TR, 1994, J CLIN INVEST, V93, P1298, DOI 10.1172/JCI117086; URTREGER AO, 1991, DEVELOPMENT, V113, P1419; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; YI ES, 1994, AM J PATHOL, V145, P80; YI ES, 1994, AM J PATHOL, V145, P1015; YI ES, 1995, IN PRESS J UROLOGY	36	70	80	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	1996	12	10					2109	2119						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668336				2022-12-17	WOS:A1996UP28300009
J	KUZMIN, I; DUH, FM; LATIF, F; GEIL, L; ZBAR, B; LERMAN, MI				KUZMIN, I; DUH, FM; LATIF, F; GEIL, L; ZBAR, B; LERMAN, MI			IDENTIFICATION OF THE PROMOTER OF THE HUMAN VON HIPPEL-LINDAU DISEASE TUMOR-SUPPRESSOR GENE	ONCOGENE			English	Article						VON HIPPEL-LINDAU DISEASE; PROMOTER; TUMOR SUPPRESSOR	HUMAN RETINOBLASTOMA GENE; TRANSCRIPTION FACTOR; SMALL REGION; CHROMOSOME-3; CARCINOMA; NRF-1; LOCUS; DNA	The von Hippel-Lindau (VHL) disease gene is a novel multiple tumor suppressor gene which plays a causal role in the origin of some common cancers including clear cell renal carcinomas and hemangioblastomas of the central nervous system. Here we report the identification of transcription start sites and the promoter of the human VHL gene. The promoter sequence does not contain TATA and CCAAT boxes. Transcription is initiated around a putative SP1 binding site about 60 bp upstream from the first AUG codon in the VHL mRNA. Several putative transcription factor binding sites, notably for nuclear respiratory factor 1 and PAX, were found upstream of the transcription start sites, Promoter-luciferase expression constructs demonstrate, that the promoter is functional when transfected into 293 cells (transformed primary human embryonal kidney cells) and UMRC 6 renal carcinoma cells. Activity is dependent on correct orientation of the promoter. A minimal promoter region of 106 bp was delineated, A set of VHL minigenes, containing the 5' flanking VHL genomic region, was constructed and transfected into UMRC 6 cells. In these cells the level of transcription from the minigenes driven by VHL promoter was comparable with endogenous VHL expression.	NCI, FREDERICK CANC RES & DEV CTR, PROGRAM RESOURCES INC DYNCORP, BIOL CARCINOGENESIS & DEV PROGRAM, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	KUZMIN, I (corresponding author), NCI, FREDERICK CANC RES & DEV CTR, IMMUNOBIOL LAB, FREDERICK, MD 21702 USA.							BERGER SL, 1987, ANAL BIOCHEM, V161, P272, DOI 10.1016/0003-2697(87)90451-9; BIENZTADMOR B, 1985, EMBO J, V4, P3209, DOI 10.1002/j.1460-2075.1985.tb04067.x; BRAUCH H, 1995, IN PRESS HUM GENET; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; CHANG ACY, 1988, FOCUS, V10, P66; CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FRAIZER GC, 1994, J BIOL CHEM, V269, P8892; GILL RM, 1994, CELL GROWTH DIFFER, V5, P467; GLENN GM, 1991, HUM GENET, V87, P207, DOI 10.1007/BF00204184; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GROSSMAN HB, 1985, J SURG ONCOL, V28, P237; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HOFMANN W, 1993, ONCOGENE, V8, P3123; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; HOSOE S, 1990, GENOMICS, V8, P634, DOI 10.1016/0888-7543(90)90249-T; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KANNO H, 1994, CANCER RES, V54, P4845; KUZMIN I, 1994, CANCER RES, V54, P2486; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LATIF F, 1993, CANCER RES, V53, P861; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MAHER ER, 1991, J MED GENET, V28, P443, DOI 10.1136/jmg.28.7.443; MAHER ER, 1991, GENOMICS, V10, P957, DOI 10.1016/0888-7543(91)90185-H; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MCKUSICK VA, 1992, MENDELIAN INHERITANC, P1145; PLACHOV D, 1990, DEVELOPMENT, V110, P643; RICHARDS FM, 1994, HUM MOL GENET, V3, P595, DOI 10.1093/hmg/3.4.595; ROTHENPIELER UW, 1993, DEVELOPMENT, V119, P711; SEIZINGER BR, 1991, P NATL ACAD SCI USA, V88, P2864, DOI 10.1073/pnas.88.7.2864; SEIZINGER BR, 1988, NATURE, V332, P268, DOI 10.1038/332268a0; SHUIN T, 1994, CANCER RES, V54, P2852; TANG A, 1989, ONCOGENE, V4, P401; TORY K, 1992, GENOMICS, V13, P275, DOI 10.1016/0888-7543(92)90243-L; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309; WADA KN, 1992, NUCLEIC ACIDS RES, V20, P2111, DOI 10.1093/nar/20.suppl.2111; YAO M, 1993, HUM GENET, V92, P605, DOI 10.1007/BF00420947	43	70	73	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	1995	10	11					2185	2194						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784063				2022-12-17	WOS:A1995RB70300014
J	SAITOH, S; CUNNINGHAM, J; DEVRIES, EMG; MCGOVERN, RM; SCHROEDER, JJ; HARTMANN, A; BLASZYK, H; WOLD, LE; SCHAID, D; SOMMER, SS; KOVACH, JS				SAITOH, S; CUNNINGHAM, J; DEVRIES, EMG; MCGOVERN, RM; SCHROEDER, JJ; HARTMANN, A; BLASZYK, H; WOLD, LE; SCHAID, D; SOMMER, SS; KOVACH, JS			P53 GENE-MUTATIONS IN BREAST CANCERS IN MIDWESTERN US WOMEN - NULL AS WELL AS MISSENSE-TYPE MUTATIONS ARE ASSOCIATED WITH POOR-PROGNOSIS	ONCOGENE			English	Article							TUMOR-SUPPRESSOR GENE; HEPATOCELLULAR CARCINOMAS; MOLECULAR EPIDEMIOLOGY; SKIN; OCCUR; AMPLIFICATION; PATTERN	We determined the pattern of mutations in exons 2-11 and adjacent intronic regions in breast cancers from Midwestern US white women. Twenty-one mutations were detected in 53 tumors (39.6%). Comparisons of the pattern of mutations within exons 5-9 showed that the frequency of missense mutations (44%) was lower in breast cancers of US Midwestern women than in most tumor types including breast cancers in other populations. Compared to breast cancers reported in a Scottish population, US women had a high frequency of microdeletion mutations (P = 0.006) and a low frequency of G:C-->T:A transversions (P = 0.046). These findings suggest that environmental or endogenous factors contribute to p53 mutagenesis in mammary tissue to different extents among different populations. With a median follow-up of 19 months, the presence of a mutation was associated with shorter time to disease recurrence (P = 0.05) and shorter survival (P = 0.003). Putative dominant negative missense-type mutations (missense and in-frame microdeletions; P = 0.001) and null mutations (hemizygous nonsense and frameshift mutations; P = 0.007) were equally ominous. Thus, tumors with missense p53 mutations resulting in overexpression of a dysfunctional but otherwise intact protein have a clinical outcome similar to tumors with null mutations resulting in a truncated or garbled protein.	MAYO CLIN & MAYO FDN,DEPT ONCOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT LAB MED & PATHOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT HLTH SCI RES,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic					NATIONAL CANCER INSTITUTE [R01CA056881] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA56881, CA15086] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, CANCER RES, V50, P7717; BLASZYK H, 1994, IN PRESS HUMAN MUT; BORING CC, 1994, CA-CANCER J CLIN, V43, P7; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CHIBA I, 1990, ONCOGENE, V5, P1603; COLEMAN MP, 1993, IARC SCI PUBLICATION, V121; COLES C, 1992, CANCER RES, V52, P5291; COURSAGET P, 1993, BRIT J CANCER, V67, P1395, DOI 10.1038/bjc.1993.258; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; ELLEDGE RM, 1993, BREAST CANCER RES TR, V27, P95, DOI 10.1007/BF00683196; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; JONES PA, 1991, CANCER RES, V51, P3617; KANJILAL S, 1993, CANCER RES, V53, P2961; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOVACH JS, 1991, JNCI-J NATL CANCER I, V83, P1004, DOI 10.1093/jnci/83.14.1004; KRESS S, 1992, CANCER RES, V52, P6400; MAZARS R, 1992, CANCER RES, V52, P3918; MOLES JP, 1993, ONCOGENE, V8, P583; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OLSON DC, 1994, CELL GROWTH DIFFER, V5, P61; Osborne CK, 1991, BREAST DIS, P301; SARKAR G, 1992, GENOMICS, V13, P441, DOI 10.1016/0888-7543(92)90266-U; SHIELDS PG, 1991, JAMA-J AM MED ASSOC, V266, P681, DOI 10.1001/jama.266.5.681; SOMMER SS, 1990, NATURE, V346, P22, DOI 10.1038/346022b0; SOMMER SS, 1992, J NATL CANCER I, V84, P246, DOI 10.1093/jnci/84.4.246; Sommer Steve S., 1994, P214; STOFLET ES, 1988, SCIENCE, V239, P491, DOI 10.1126/science.3340835; THORLACIUS S, 1993, CANCER RES, V53, P1637; TSUDA H, 1993, JPN J CANCER RES, V84, P394, DOI 10.1111/j.1349-7006.1993.tb00149.x; 1991, STAT XACT VER 2 0	33	70	70	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2869	2875						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084591				2022-12-17	WOS:A1994PG82200012
J	MARVEL, J; PERKINS, GR; RIVAS, AL; COLLINS, MKL				MARVEL, J; PERKINS, GR; RIVAS, AL; COLLINS, MKL			GROWTH-FACTOR STARVATION OF BCL-2 OVEREXPRESSING MURINE BONE-MARROW CELLS INDUCED REFRACTORINESS TO IL-3 STIMULATION OF PROLIFERATION	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION; C-MYC; HEMATOPOIETIC-CELLS; CALCIUM IONOPHORES; GENE-EXPRESSION; GERMINAL CENTER; APOPTOSIS; DEATH; SURVIVAL	Murine bone-marrow derived BAF3 cells, overexpressing the human Bcl-2 gene product, showed considerably delayed onset of apoptosis when deprived of IL-3. Such Bcl-2-BAF3 cells arrested rapidly in the G1 phase of the cell cycle upon IL-3 removal, then became refractory to IL-3 re-stimulation. The delay in IL-3 induced proliferation of Bcl-2 over-expressing cells was due to down-regulation of a specific signalling pathway. In the refractory cells, IL-3 was able to stimulate protein tyrosine phosphorylation and c-myc mRNA accumulation, but not rapid Erk2 activation or cdc2 mRNA accumulation.	INST CANC RES,CHESTER BEATTY LABS,237 FULHAM RD,LONDON SW3 6JB,ENGLAND; CSIC,INST LOPEZ NEYRA PARASITOL,GRANADA,SPAIN	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN)			marvel, jacqueline/H-8638-2014; Lopez-Rivas, Abelardo/E-5115-2015	marvel, jacqueline/0000-0001-6241-459X; Lopez-Rivas, Abelardo/0000-0002-9351-9690				ALNEMRI ES, 1992, P NATL ACAD SCI USA, V89, P7295, DOI 10.1073/pnas.89.16.7295; BARDON S, 1987, CANCER RES, V47, P1441; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COLLINS M, 1991, Current Biology, V1, P140, DOI 10.1016/0960-9822(91)90212-F; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KAWAKAMI M, 1991, EXP CELL RES, V193, P120, DOI 10.1016/0014-4827(91)90545-6; LEEVERS S, 1992, EMBO J, V11, P568; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LIU YJ, 1991, EUR J IMMUNOL, V21, P1905, DOI 10.1002/eji.1830210819; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; NAKAMURA Y, 1992, SCIENCE, V257, P1138, DOI 10.1126/science.257.5073.1138; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PEZZELLA F, 1990, AM J PATHOL, V137, P225; POPPEMA S, 1992, IMMUNOL REV, V126, P163, DOI 10.1111/j.1600-065X.1992.tb00636.x; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V149, P535; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V148, P1416; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; Sambrook J., 1989, MOL CLONING LAB MANU; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SHIGII SM, 1980, SELECTED METHODS CEL; STERN M, 1992, J IMMUNOL, V148, P3543; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TAGA T, 1992, FASEB J, V6, P3387, DOI 10.1096/fasebj.6.15.1334470; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VONBOEHMER H, 1992, IMMUNOL TODAY, V13, P454, DOI 10.1016/0167-5699(92)90075-I; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	44	70	71	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1117	1122						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134114				2022-12-17	WOS:A1994NC04800014
J	LOFTS, FJ; HURST, HC; STERNBERG, MJE; GULLICK, WJ				LOFTS, FJ; HURST, HC; STERNBERG, MJE; GULLICK, WJ			SPECIFIC SHORT TRANSMEMBRANE SEQUENCES CAN INHIBIT TRANSFORMATION BY THE MUTANT NEU GROWTH-FACTOR RECEPTOR IN-VITRO AND IN-VIVO	ONCOGENE			English	Article							TYROSINE KINASE-ACTIVITY; ONCOGENIC ACTIVATION; SIGNAL TRANSDUCTION; TRUNCATED RECEPTOR; POINT MUTATION; EGF RECEPTOR; PROTEIN; DOMAIN; DIMERIZATION; EXPRESSION	The neu oncogene is activated by a point mutation within its transmembrane domain that results in the substitution of glutamic acid for valine at position 664, and is associated with constitutive activation of the tyrosine kinase. It has been proposed that the mutation allows for stabilization of homodimers of the receptor that are necessary for transduction of the mitogenic signal. To investigate the role of the alpha-helical transmembrane sequence in the function of neu, we constructed an expression vector to produce a variety of short transmembrane neu proteins, lacking ligand binding or intracellular kinase domains. Such sequences should interact with full-length receptors and prevent receptor dimerization and thus act as specific inhibitors of function. These small proteins all included a pentapeptide from position 661-665, which has been proposed to be necessary for packing. We show that the short transmembrane molecules are expressed at the cell surface and can retard the growth of neu-transformed cells in monolayers, as colonies in soft agar and as tumours in animals. As predicted by molecular modelling, the magnitude of inhibition depended on the nature of the packing surface, suggesting that the neu transmembrane domain is directly involved in neu protein dimerization.	HAMMERSMITH HOSP,ICRF,ONCOL GRP,MOLEC ONCOL LAB,DU CANE RD,LONDON W12 0HS,ENGLAND; HAMMERSMITH HOSP,ICRF,ONCOL GRP,GENE TRANSCRIPT LAB,LONDON W12 0HS,ENGLAND; ICRF,BIOMOLEC MODELLING LAB,LONDON WC2A 3PX,ENGLAND	Imperial College London; Imperial College London				Sternberg, Michael/0000-0002-1884-5445				AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BARGMANN CI, 1986, CELL, V45, P469; BASU A, 1989, MOL CELL BIOL, V9, P671, DOI 10.1128/MCB.9.2.671; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2921; BORMANN BJ, 1989, J BIOL CHEM, V264, P4033; BRANDTRAUF PW, 1990, P NATL ACAD SCI USA, V87, P8660, DOI 10.1073/pnas.87.21.8660; CAO H, 1992, EMBO J, V11, P923, DOI 10.1002/j.1460-2075.1992.tb05131.x; CAO HN, 1992, J BIOL CHEM, V267, P20489; CARPENTER CD, 1991, J BIOL CHEM, V266, P5750; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DOBASHI K, 1991, P NATL ACAD SCI USA, V88, P8582, DOI 10.1073/pnas.88.19.8582; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; DUAN DSR, 1991, J BIOL CHEM, V266, P413; Gullick W J, 1988, Methods Mol Biol, V3, P341, DOI 10.1385/0-89603-126-8:341; GULLICK WJ, 1992, EMBO J, V11, P43, DOI 10.1002/j.1460-2075.1992.tb05025.x; GULLICK WJ, 1987, INT J CANCER, V40, P246, DOI 10.1002/ijc.2910400221; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LI W, 1991, EMBO J, V10, P277, DOI 10.1002/j.1460-2075.1991.tb07948.x; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; STERNBERG MJE, 1990, PROTEIN ENG, V3, P245, DOI 10.1093/protein/3.4.245; STERNBERG MJE, 1989, NATURE, V339, P587, DOI 10.1038/339587a0; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; UENO H, 1992, J BIOL CHEM, V267, P1470; WEINER DB, 1989, ONCOGENE, V4, P1175; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WIDES RJ, 1990, EUR J BIOCHEM, V189, P637, DOI 10.1111/j.1432-1033.1990.tb15532.x; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034	43	70	74	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2813	2820						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8104327				2022-12-17	WOS:A1993LX34300023
J	HASSAPOGLIDOU, S; DIAMANDIS, EP; SUTHERLAND, DJA				HASSAPOGLIDOU, S; DIAMANDIS, EP; SUTHERLAND, DJA			QUANTIFICATION OF P53 PROTEIN IN TUMOR-CELL LINES, BREAST-TISSUE EXTRACTS AND SERUM WITH TIME-RESOLVED IMMUNOFLUOROMETRY	ONCOGENE			English	Article							CONFORMATION POLYMORPHISM ANALYSIS; PROGNOSTIC FACTORS; SUPPRESSOR GENE; CANCER; MUTATIONS; FREQUENT; EXPRESSION; ANTIBODIES	We have developed a highly sensitive time-resolved immunofluorometric procedure for quantifying mutant or wild-type, human or murine, p53 protein. The method uses monoclonal PAb240 or PAb421 antibodies for capture and a polyclonal rabbit antibody for detection. The final immunocomplex is quantified with an alkaline phosphatase substrate which, when hydrolyzed by the enzyme, forms highly fluorescent long-lived complexes with Tb3+-EDTA. The detection limit is approximately 1 pg of protein per assay. The assay was applied for the quantification of p53 protein in lysates from 23 cell lines and overproducers of mutant protein were identified. Eight hundred cancer patients sera tested negative for the presence of p53. We have also applied the quantitative immunofluorometric procedure for measuring mutant p53 protein in breast tumor extracts specifically prepared for steroid hormone receptor analysis. Sixty-four out of the 264 extracts (24%) were positive for p53. Significant negative correlations between levels of p53 and steroid hormone receptors were found. The proposed analytical methodology simplifies the assessment of p53 status in tumor extracts, has many advantages over immunohistochemical techniques and is proposed as a method of choice for routine clinical use and other investigations involving p53.	TORONTO HOSP,TORONTO WESTERN DIV,DIV CLIN BIOCHEM,399 BATHURST ST,TORONTO M5T 258,ON,CANADA; UNIV TORONTO,DEPT CLIN BIOCHEM,TORONTO M5G 1L5,ONTARIO,CANADA; UNIV TORONTO,SUNNYBROOK MED CTR,TORONTO BAYVIEW REG CANC CTR,TORONTO M4N 3M5,ON,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center				Diamandis, Eleftherios/0000-0002-1589-820X				BARTEK J, 1991, ONCOGENE, V6, P1699; BARTEK J, 1990, ONCOGENE, V5, P893; BARTON CM, 1991, BRIT J CANCER, V64, P1076, DOI 10.1038/bjc.1991.467; BORRESEN AL, 1991, P NATL ACAD SCI USA, V88, P8405, DOI 10.1073/pnas.88.19.8405; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALLAHAN R, 1992, J NATL CANCER I, V84, P826, DOI 10.1093/jnci/84.11.826; CATTORETTI G, 1988, INT J CANCER, V41, P178, DOI 10.1002/ijc.2910410204; CHANG K, 1991, J HISTOCHEM CYTOCHEM, V39, P1281, DOI 10.1177/39.9.1680897; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHIBA I, 1990, ONCOGENE, V5, P1603; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; CHRISTOPOULOS TK, 1992, ANAL CHEM, V64, P342, DOI 10.1021/ac00028a004; CRAWFORD LV, 1982, INT J CANCER, V30, P403, DOI 10.1002/ijc.2910300404; DAVIDOFF AM, 1991, SURGERY, V110, P259; DAVIDOFF AM, 1992, ONCOGENE, V7, P127; DIAMANDIS EP, 1988, CLIN BIOCHEM, V21, P139, DOI 10.1016/S0009-9120(88)80104-8; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GRAVES RF, 1988, THESIS U LONDON; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HENDERSON IC, 1991, BREAST DISEASES, P332; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KOENDERS PG, 1991, CANCER RES, V51, P4544; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEHMAN TA, 1991, CANCER RES, V51, P4090; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; MALKIN D, 1990, SCIENCE, V250, P233; MIDGLEY CA, 1992, IN PRESS J CELL SCI; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MURAKAMI Y, 1991, CANCER RES, V51, P3356; OSTROWSKI JL, 1991, J PATHOL, V164, P75, DOI 10.1002/path.1711640113; PROSSER J, 1992, BRIT J CANCER, V65, P527, DOI 10.1038/bjc.1992.109; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; ROMANO JW, 1989, ONCOGENE, V4, P1483; SINGERLAND J M, 1991, Blood, V77, P1500; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TAMURA G, 1991, CANCER RES, V51, P3056; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; VISAKORPI T, 1992, J NATL CANCER I, V84, P883, DOI 10.1093/jnci/84.11.883; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WINFORDTHOMAS D, 1992, J PATHOL, V166, P329; WINTER SF, 1992, CANCER RES, V52, P4168	49	70	71	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1501	1509						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502476				2022-12-17	WOS:A1993LE06400013
J	ROSNET, O; STEPHENSON, D; MATTEI, MG; MARCHETTO, S; SHIBUYA, M; CHAPMAN, VM; BIRNBAUM, D				ROSNET, O; STEPHENSON, D; MATTEI, MG; MARCHETTO, S; SHIBUYA, M; CHAPMAN, VM; BIRNBAUM, D			CLOSE PHYSICAL LINKAGE OF THE FLT1 AND FLT3 GENES ON CHROMOSOME-13 IN MAN AND CHROMOSOME-5 IN MOUSE	ONCOGENE			English	Article							RECEPTOR TYROSINE KINASE; ENDOTHELIAL-CELL MITOGEN; ONCOGENE C-KIT; GROWTH-FACTOR; W-LOCUS; LOCALIZATION; FMS; EXPRESSION; REGION; MICE	Receptor-type tyrosine kinases (RTK) with five or seven immunoglobulin-like domains in their extracellular region are encoded by genes grouped in clusters. In human, two such clusters have been individualized, in chromosomal regions 4q11-q12 and 5q33-qter respectively. We define here a third cluster located on chromosome 13q and containing two contiguous RTK genes, FLT1 and FLT3. The former has recently been shown to encode a RTK of a new class while the latter codes for a hematopoietic receptor closely related to the products of the FMS and KIT genes. The physical linkage is also evidenced in mouse, where the two genes appear to lie within a 350 kb Mlu I fragment, on mouse chromosome 5.	ROSWELL PK CANC INST,DEPT MOLEC & CELLULAR BIOL,BUFFALO,NY 14263; UNIV TOKYO,INST MED SCI,DEPT GENET,MINATO KU,TOKYO 108,JAPAN; HOP LA TIMONE,INSERM,U242,F-13385 MARSEILLE 4,FRANCE	Roswell Park Cancer Institute; University of Tokyo; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	ROSNET, O (corresponding author), INSERM,U119,MOLEC ONCOL LAB,27 BLVD LEI ROURE,F-13009 MARSEILLE,FRANCE.		Rosnet, Olivier/G-3536-2013	Rosnet, Olivier/0000-0002-3020-910X	NHGRI NIH HHS [HG00170] Funding Source: Medline	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		AKAM M, 1989, CELL, V57, P347, DOI 10.1016/0092-8674(89)90909-4; ANDRE C, 1992, ONCOGENE, V7, P685; ANDRE C, 1992, THESIS U PARIS 7; APRELIKOVA O, 1992, CANCER RES, V52, P746; ARMSTRONG E, 1992, GENE CHROMOSOME CANC, V4, P94, DOI 10.1002/gcc.2870040116; BIRG F, 1992, IN PRESS BLOOD; BOWES C, 1990, NATURE, V347, P677, DOI 10.1038/347677a0; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHAPMAN VM, 1986, CURR TOP MICROBIOL, V127, P114; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; DAURIOL L, 1988, HUM GENET, V78, P374, DOI 10.1007/BF00291740; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; GALLAND F, 1992, GENOMICS, V13, P475, DOI 10.1016/0888-7543(92)90277-Y; GEISSLER E, 1988, CELL, V5, P185; GEISSLER EN, 1981, GENETICS, V97, P337; GOKKEL E, 1992, ONCOGENE, V7, P1423; GRUNEBERG H, 1960, GENET RES, V1, P69, DOI 10.1017/S0016672300000094; HAMMER RE, 1987, SCIENCE, V235, P53, DOI 10.1126/science.2432657; HAMPE A, 1989, ONCOGENE RES, V7, P9; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HSIEH CL, 1991, CYTOGENET CELL GENET, V56, P160, DOI 10.1159/000133076; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KOZAK C, 1992, IN PRESS MAMMALIAN G, V3; KOZAK C, 1991, MAMM GENOME, V1, P579; LACOMBE C, 1988, BLOOD, V72, P1440; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LI WH, 1991, FUNDAMENTALS MOL EVO, P136; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MCDONALD JD, 1986, MOL CELL BIOL, V6, P842, DOI 10.1128/MCB.6.3.842; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; NGUYEN C, 1987, EMBO J, V6, P3285, DOI 10.1002/j.1460-2075.1987.tb02647.x; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OELRICHS RB, 1993, ONCOGENE, V8, P15; PANTAZIS P, 1991, P NATL ACAD SCI USA, V88, P2481, DOI 10.1073/pnas.88.6.2481; PFISTER K, 1982, BIOCHEM GENET, V20, P519, DOI 10.1007/BF00484702; ROBERTS WM, 1988, CELL, V55, P655, DOI 10.1016/0092-8674(88)90224-3; ROSNET O, 1991, ONCOGENE, V6, P1641; ROSNET O, 1991, GENOMICS, V9, P380, DOI 10.1016/0888-7543(91)90270-O; Sambrook J., 1989, MOL CLONING; SARZANI R, 1992, BIOCHEM BIOPH RES CO, V186, P706, DOI 10.1016/0006-291X(92)90804-T; SATOH H, 1987, JPN J CANCER RES, V78, P772; SHIBUYA M, 1990, ONCOGENE, V5, P519; SINGH G, 1991, P NATL ACAD SCI USA, V88, P10706, DOI 10.1073/pnas.88.23.10706; SMITH EA, 1991, P NATL ACAD SCI USA, V88, P4811, DOI 10.1073/pnas.88.11.4811; STENMAN G, 1989, GENE CHROMOSOME CANC, V1, P155, DOI 10.1002/gcc.2870010208; STEPHENSON DA, 1991, P NATL ACAD SCI USA, V88, P6, DOI 10.1073/pnas.88.1.6; TERMAN BI, 1991, ONCOGENE, V6, P1677; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDENBARK GR, 1992, ONCOGENE, V7, P1259; VISVADER J, 1989, MOL CELL BIOL, V9, P1336, DOI 10.1128/MCB.9.3.1336; WARRINGTON JA, 1992, GENOMICS, V13, P803, DOI 10.1016/0888-7543(92)90156-M; WILKIE TM, 1992, NAT GENET, V1, P85, DOI 10.1038/ng0592-85; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x	56	70	74	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					173	179						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8380915				2022-12-17	WOS:A1993KN00500021
J	TORMANEN, VT; PFEIFER, GP				TORMANEN, VT; PFEIFER, GP			MAPPING OF UV PHOTOPRODUCTS WITHIN RAS PROTOONCOGENES IN UV-IRRADIATED CELLS - CORRELATION WITH MUTATIONS IN HUMAN SKIN-CANCER	ONCOGENE			English	Article							LIGATION-MEDIATED PCR; N-RAS; PYRIMIDINE DIMERS; METHYLATION ANALYSIS; ESCHERICHIA-COLI; XERODERMA PIGMENTOSUM; 6-4 PHOTOPRODUCTS; POINT MUTATIONS; MAMMALIAN-CELLS; DNA DAMAGE	Mutations in ras proto-oncogenes have been found in human skin cancers. Since ultraviolet light is implicated in the development of skin cancers, we have investigated the formation of UV-induced photoproducts along exons 1 and 2 of the three ras proto-oncogenes, H-ras, K-ras, and N-ras, in UV-irradiated human cells. The two major types of DNA photoproducts, cyclobutane pyrimidine dimers and pyrimidine (6-4) pyrimidone photoproducts [(6-4) photoproducts], were mapped at the DNA sequence level by ligation-mediated polymerase chain reaction (LMPCR). No significant differences were seen between irradiated purified DNA and irradiated cells, implying that local chromatin structure does not influence the distribution of photoproducts along exons 1 and 2 of the three ras genes. We find that the transcribed strand near codon 61 in H-ras, K-ras and N-ras shows a high frequency of potentially mutagenic cyclobutane dimers and (6-4) photoproducts. Codon 12 of H-ras, K-ras and N-ras displays only barely detectable photoproducts at a CpC dinucleotide. In human skin cancers, mutations were most frequently detected at codon 12 of H-ras and K-ras. These results imply that the initial frequency distribution of a mutagenic DNA adduct may not correlate with mutation spectra in human tumors.	CITY HOPE NATL MED CTR,BECKMAN RES INT,DEPT BIOL,DUARTE,CA 91010	City of Hope; Beckman Research Institute of City of Hope								ALBINO AP, 1989, ONCOGENE, V4, P1363; ANANTHASWAMY HN, 1990, PHOTOCHEM PHOTOBIOL, V52, P1119, DOI 10.1111/j.1751-1097.1990.tb08452.x; ARMSTRONG JD, 1990, P NATL ACAD SCI USA, V87, P9005, DOI 10.1073/pnas.87.22.9005; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARBACID M, 1990, EUR J CLIN INVEST, V20, P225, DOI 10.1111/j.1365-2362.1990.tb01848.x; BECKER MM, 1984, NATURE, V309, P682, DOI 10.1038/309682a0; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOURRE F, 1987, NUCLEIC ACIDS RES, V15, P8861, DOI 10.1093/nar/15.21.8861; BRASH DE, 1982, NATURE, V298, P189, DOI 10.1038/298189a0; BRASH DE, 1988, PHOTOCHEM PHOTOBIOL, V48, P59; BRASH DE, 1987, P NATL ACAD SCI USA, V84, P3782, DOI 10.1073/pnas.84.11.3782; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BROWN R, 1984, EMBO J, V3, P1321, DOI 10.1002/j.1460-2075.1984.tb01970.x; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; COLLINS SJ, 1988, ONCOGENE RES, V3, P117; COROMINAS M, 1989, P NATL ACAD SCI USA, V86, P6372, DOI 10.1073/pnas.86.16.6372; DROBETSKY EA, 1987, P NATL ACAD SCI USA, V84, P9103, DOI 10.1073/pnas.84.24.9103; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GALE JM, 1987, P NATL ACAD SCI USA, V84, P6644, DOI 10.1073/pnas.84.19.6644; GROSSMAN L, 1988, FASEB J, V2, P2696, DOI 10.1096/fasebj.2.11.3294078; HASELTINE WA, 1980, NATURE, V285, P634, DOI 10.1038/285634a0; KEIJZER W, 1989, CANCER RES, V49, P1229; KOEHLER DR, 1991, J BIOL CHEM, V266, P11766; LEON J, 1988, MOL CELL BIOL, V8, P786, DOI 10.1128/MCB.8.2.786; LIPPKE JA, 1981, P NATL ACAD SCI-BIOL, V78, P3388, DOI 10.1073/pnas.78.6.3388; LIU E, 1987, NATURE, V330, P186, DOI 10.1038/330186a0; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MEULLER PR, 1989, SCIENCE, V246, P780; MILLER JH, 1985, J MOL BIOL, V182, P45, DOI 10.1016/0022-2836(85)90026-9; MITCHELL DL, 1990, NUCLEIC ACIDS RES, V18, P963, DOI 10.1093/nar/18.4.963; MITCHELL DL, 1992, NUCLEIC ACIDS RES, V20, P225, DOI 10.1093/nar/20.2.225; MITCHELL DL, 1988, PHOTOCHEM PHOTOBIOL, V48, P51; MITCHELL DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P805, DOI 10.1111/j.1751-1097.1989.tb05578.x; PADUA RA, 1985, MOL CELL BIOL, V5, P582, DOI 10.1128/MCB.5.3.582; PFEIFER GP, 1992, MOL CELL BIOL, V12, P1798, DOI 10.1128/MCB.12.4.1798; PFEIFER GP, 1991, P NATL ACAD SCI USA, V88, P1374, DOI 10.1073/pnas.88.4.1374; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; PFEIFER GP, 1991, GENE DEV, V5, P1102, DOI 10.1101/gad.5.6.1102; PFEIFER GP, 1992, METHODS MOL BIOL PCR; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P196, DOI 10.1002/mc.2940040306; PIERCEALL WE, 1991, ONCOGENE, V6, P2085; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P445, DOI 10.1002/mc.2940040606; RYCHLIK W, 1989, NUCLEIC ACIDS RES, V17, P8543, DOI 10.1093/nar/17.21.8543; SANCAR A, 1984, J BIOL CHEM, V259, P6028; SARASIN A, 1991, 9TH P INT C RAD RES, P42; SCOTTO J, 1983, NIH832433 PUBL; SHUKLA VK, 1989, ONCOGENE RES, V5, P121; STEIGERWALD SD, 1990, NUCLEIC ACIDS RES, V18, P1435, DOI 10.1093/nar/18.6.1435; SUAREZ HG, 1989, CANCER RES, V49, P1223; THOMAS DC, 1989, J BIOL CHEM, V264, P18005; VANDERLUBBE JLM, 1988, ONCOGENE RES, V3, P9; VANDERSCHROEFF JG, 1990, J INVEST DERMATOL, V94, P423, DOI 10.1111/1523-1747.ep12874504; VANTVEER LJ, 1989, MOL CELL BIOL, V9, P3114, DOI 10.1128/MCB.9.7.3114; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	58	70	70	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1729	1736						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1501884				2022-12-17	WOS:A1992JJ37600008
J	KUMABE, T; SOHMA, Y; KAYAMA, T; YOSHIMOTO, T; YAMAMOTO, T				KUMABE, T; SOHMA, Y; KAYAMA, T; YOSHIMOTO, T; YAMAMOTO, T			AMPLIFICATION OF ALPHA-PLATELET-DERIVED GROWTH-FACTOR RECEPTOR GENE LACKING AN EXON CODING FOR A PORTION OF THE EXTRACELLULAR REGION IN A PRIMARY BRAIN-TUMOR OF GLIAL ORIGIN	ONCOGENE			English	Article							TYROSINE KINASE-ACTIVITY; SIMIAN SARCOMA-VIRUS; FMS PROTO-ONCOGENE; PDGF RECEPTOR; GLIOBLASTOMA-MULTIFORME; NUCLEOTIDE-SEQUENCE; SIGNAL TRANSDUCTION; CDNA CLONING; EXPRESSION; FAMILY	In a primary brain tumor of glial origin, we found overexpression of the alpha-platelet-derived growth factor (alpha-PDGF) receptor mRNA. Southern blot analysis of the gene revealed amplification of the rearranged alpha-PDGF receptor gene in the glioma. A cDNA coding for an aberrant transcript from the amplified receptor gene was obtained and characterized. Partial nucleotide sequence analysis of the cDNA revealed a deletion of 243 nucleotides coding for 81 amino acids in a portion of the immunoglobulin-like domains of the extracellular region of the receptor. cDNA polymerase chain reaction (PCR) of the total cellular RNA in the glioma indicated that more than 80% of the transcripts have a deletion of 243 nucleotides. Analysis of a PCR-amplified DNA fragment derived from the amplified alpha-PDGF receptor gene in the glioma revealed that an exon coding for the 81 amino acids was removed by a 2.1 kb gene deletion. We also found amplification of the alpha-PDGF receptor gene in macroscopically normal cortex adjacent to the glioma from the same patient. The amplified gene in the macroscopically normal cortex has no major gene deletion, suggesting that gene amplification is not sufficient for the development of malignant gliomas.	TOHOKU UNIV,GENE RES CTR,1-1 TSUTSUMIDORI AMAMIYA,AOBA KU,SENDAI 981,JAPAN; TOHOKU UNIV,SCH MED,INST BRAIN DIS,DIV NEUROSURG,AOBA KU,SENDAI,MIYAGI 980,JAPAN	Tohoku University; Tohoku University								BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BURGER PC, 1985, CANCER, V56, P1106, DOI 10.1002/1097-0142(19850901)56:5<1106::AID-CNCR2820560525>3.0.CO;2-2; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FELDMAN RA, 1982, J VIROL, V42, P228, DOI 10.1128/JVI.42.1.228-236.1982; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HELDIN CH, 1985, MOL CELL ENDOCRINOL, V39, P169, DOI 10.1016/0303-7207(85)90061-9; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN CH, 1989, TRENDS GENET, V5, P108, DOI 10.1016/0168-9525(89)90040-1; LEE KH, 1990, MOL CELL BIOL, V10, P2237, DOI 10.1128/MCB.10.5.2237; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; MALDEN LT, 1988, CANCER RES, V48, P2711; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATSUSHIME H, 1986, MOL CELL BIOL, V6, P3000, DOI 10.1128/MCB.6.8.3000; NECKAMEYER WS, 1985, J VIROL, V53, P879, DOI 10.1128/JVI.53.3.879-884.1985; NECKAMEYER WS, 1986, MOL CELL BIOL, V6, P1478, DOI 10.1128/MCB.6.5.1478; NISTER M, 1988, CELL, V52, P791, DOI 10.1016/0092-8674(88)90421-7; RETTENMIER CW, 1985, SCIENCE, V228, P320, DOI 10.1126/science.2580348; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMID CW, 1982, SCIENCE, V216, P1065, DOI 10.1126/science.6281889; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHIBUYA M, 1990, ONCOGENE, V5, P519; STECK PA, 1988, CANCER RES, V48, P5433; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAHLS WP, 1990, MOL CELL BIOL, V10, P785, DOI 10.1128/MCB.10.2.785; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WESTERMARK B, 1983, GROWTH MATURATION FA, P73; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YAMAMOTO T, 1983, CELL, V35, P71, DOI 10.1016/0092-8674(83)90209-X; YAMAZAKI H, 1988, MOL CELL BIOL, V8, P1816, DOI 10.1128/MCB.8.4.1816; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZULCH KJ, 1979, INT HISTOLOGICAL CLA, V21	42	70	91	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					627	633						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1314366				2022-12-17	WOS:A1992HQ68200003
J	MOBERG, KH; LOGAN, TJ; TYNDALL, WA; HALL, DJ				MOBERG, KH; LOGAN, TJ; TYNDALL, WA; HALL, DJ			3 DISTINCT ELEMENTS WITHIN THE MURINE C-MYC PROMOTER ARE REQUIRED FOR TRANSCRIPTION	ONCOGENE			English	Article							RNA POLYMERASE-II; ADENOVIRUS E1A PROTEINS; TRANS-ACTIVATION; UPSTREAM ELEMENT; GROWTH-FACTOR; GENE; INITIATION; BINDING; STIMULATION; ONCOGENE	We have undertaken a detailed analysis of the cis-acting elements that are required for optimal transcription initiation from P2, the major promoter of the murine c-myc gene. We find that three elements contribute to promoter strength, termed ME1a2, E2F and ME1a1 at positions -85, -64 and -46 respectively (relative to P2). Individually the elements are weak, but combined they contribute to full promoter activity, all acting in a positive fashion. The E2F element is the site at which the SV40 large T antigen transactivates the c-myc promoter. However, transactivation requires the presence of the ME1a2 or ME1a1 elements in addition to E2F. By a number of criteria it appears that the ME1a2 and ME1a1 elements bind the same or a very closely related protein (monomer M(r) 94000). It was found that Hela cells contain a novel factor that is capable of binding to the ME1a1 and ME1a2 elements but only in the presence of the protein-dissociating agents deoxycholate or formamide. Finally, the E2F factor binds DNA both as a monomer and as a multiprotein complex; the latter is cell type specific. Both types of bound E2F factor form less stable protein-DNA complexes than the ME1a2/ME1a1 factor.	THOMAS JEFFERSON UNIV,DEPT BIOCHEM & MOLEC BIOL,233 S 10TH ST,PHILADELPHIA,PA 19107	Jefferson University			Moberg, Ken/J-4849-2017	Moberg, Ken/0000-0002-9820-5543	NATIONAL CANCER INSTITUTE [R29CA051170] Funding Source: NIH RePORTER; NCI NIH HHS [CA51170-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASSELIN C, 1989, ONCOGENE, V4, P549; Ausubel F., 1992, MOL REPROD DEV, DOI DOI 10.1002/MRD.1080010210; AVIGAN MI, 1990, J BIOL CHEM, V265, P18538; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAUERLE PA, 1988, CELL, V53, P211; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DEAN M, 1986, J BIOL CHEM, V261, P9161; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HALL DJ, 1987, J BIOL CHEM, V262, P15302; HALL DJ, 1990, ONCOGENE, V5, P47; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; HEIBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; IGUCHIARIGA SMM, 1988, EMBO J, V7, P3135, DOI 10.1002/j.1460-2075.1988.tb03180.x; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; LIPP M, 1989, ONCOGENE, V4, P535; LOEKEN MR, 1986, MOL CELL BIOL, V6, P2020, DOI 10.1128/MCB.6.6.2020; LOEKEN MR, 1989, J BIOL CHEM, V264, P6572; MOBERG KH, 1991, J CELL PHYSIOL, V148, P75, DOI 10.1002/jcp.1041480110; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; NISHIKURA K, 1986, MOL CELL BIOL, V6, P4093, DOI 10.1128/MCB.6.11.4093; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; WEISINGER G, 1988, ONCOGENE, V3, P635	32	70	71	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					411	421						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1549358				2022-12-17	WOS:A1992HK00500003
J	TAHIRA, T; ISHIZAKA, Y; ITOH, F; NAKAYASU, M; SUGIMURA, T; NAGAO, M				TAHIRA, T; ISHIZAKA, Y; ITOH, F; NAKAYASU, M; SUGIMURA, T; NAGAO, M			EXPRESSION OF THE RET PROTOONCOGENE IN HUMAN NEUROBLASTOMA CELL-LINES AND ITS INCREASE DURING NEURONAL DIFFERENTIATION INDUCED BY RETINOIC ACID	ONCOGENE			English	Article							BLASTOMA CELLS; MESSENGER-RNA; PROTOONCOGENE; SEQUENCE; MORPHOLOGY; INVITRO; TISSUES; FAMILY; GENE	Previously we observed specific expression of the ret proto-oncogene (proto-ret) in human neuroblastoma cell lines. A neuronal subline and non-neuronal sublines were isolated from the SK-N-SH cell line, which is composed of a heterogeneous cell population. Expression of proto-ret was defected in the neuronal subline, named SH-4305, but not in three non-neuronal sublines. Expression of proto-ret in the SH-4305 cells increased markedly after treatment with retinoic acid for 1 day, with concomitant morphological change, namely neurite outgrowth, and induction of neurofilament mRNA expression. Induction of proto-ret mRNA was observed in all seven neuroblastoma cell lines tested, being highest in the line with the lowest basal level of proto-ret expression. The induction of proto-ret expression seemed to be correlated with neurite outgrowth and increase of neurofilament mRNA expression. These data suggest that the proto-ret product plays a role in neuronal differentiation.	NATL CANC CTR,RES INST,DIV CARCINOGENESIS,1-1 TSUKIJI 5 CHOME,CHUO KU,TOKYO 104,JAPAN	National Cancer Center - Japan								ABEMAYOR E, 1989, ENVIRON HEALTH PERSP, V80, P3, DOI 10.2307/3430727; BIEDLER JL, 1973, CANCER RES, V33, P2643; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CICCARONE V, 1989, CANCER RES, V49, P219; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; HALL BK, 1988, NEURAL CREST, P96; IKEDA I, 1990, ONCOGENE, V5, P1291; ISHIKAWA S, 1977, ACTA PATHOL JAPON, V27, P697; ISHIZAKA Y, 1989, ONCOGENE, V4, P789; ITOH F, 1989, Tumor Research, V24, P1; MYERS MW, 1987, EMBO J, V6, P1617, DOI 10.1002/j.1460-2075.1987.tb02409.x; NAGAO M, 1990, JPN J CANCER RES, V81, P309, DOI 10.1111/j.1349-7006.1990.tb02566.x; PAHLMAN S, 1984, CELL DIFFER DEV, V14, P135, DOI 10.1016/0045-6039(84)90038-1; RETTIG WJ, 1987, CANCER RES, V47, P1383; REYNOLDS CP, 1988, ADV NEUROBLASTOMA RE, V2, P291; ROSS RA, 1983, J NATL CANCER I, V71, P741; ROSS RA, 1980, ADV NEUROBLASTOMA RE, P151; SANTORO M, 1990, ONCOGENE, V5, P1595; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SIDELL N, 1986, EXP CELL BIOL, V54, P287; SZENTIRMAY Z, 1990, ONCOGENE, V5, P701; TAHIRA T, 1988, BIOCHEM BIOPH RES CO, V153, P1290, DOI 10.1016/S0006-291X(88)81368-8; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; THIELE CJ, 1988, ONCOGENE, V3, P281; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; TSOKOS M, 1987, AM J PATHOL, V128, P484; TUMILOWICZ JJ, 1970, CANCER RES, V30, P2110	30	70	70	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2333	2338						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766678				2022-12-17	WOS:A1991GX73500023
J	FUKUI, Y; SALTIEL, AR; HANAFUSA, H				FUKUI, Y; SALTIEL, AR; HANAFUSA, H			PHOSPHATIDYLINOSITOL-3 KINASE IS ACTIVATED IN V-SRC, V-YES, AND V-FPS TRANSFORMED CHICKEN-EMBRYO FIBROBLASTS	ONCOGENE			English	Article							MIDDLE T-ANTIGEN; INOSITOL TRISPHOSPHATE; SIGNAL TRANSDUCTION; TYROSINE KINASE; SARCOMA-VIRUS; BOVINE BRAIN; ASSOCIATION; PP60C-SRC; 3-KINASE; PROTEIN	PI-3 kinase activity has been shown to associate with p60v-src. We found that immunoprecipitates of p60v-src exhibit an activity that catalyzes the formation of PI-3-P, PI-3,4-P2 and PIP3 from PI, PI-4-P, and PI-4,5-P2, respectively. Transformation of chicken embryo fibroblasts (CEF) by p60v-src of Rous sarcoma virus (RSV) caused elevation of PI-3-P, PI-3,4-P2, and PIP3, suggesting that the PI-3 kinase may be activated in these cells. Similar elevations were seen in cells transformed with the v-yes or v-fps oncogenes, but not with v-ros or v-ras. We have established also a system that allows the binding of PI-3 kinase to purified p60v-src in vitro, reproducing the binding seen in vivo. This assay indicated that more PI-3 kinase activity binds to purified p60v-src in cell lysates from CEF transformed with v-yes or v-fps, suggesting that some modification or overexpression of PI-3 kinase takes place in these cells.	ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021	Rockefeller University			Saltiel, Alan/L-3632-2019; Fukui, Yasuhisa/E-8806-2010	Saltiel, Alan/0000-0002-9726-9828	NCI NIH HHS [CA44356] Funding Source: Medline; NIDDK NIH HHS [DK33804] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R23DK033804, R01DK033804] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; CHAN TO, 1990, MOL CELL BIOL, V10, P3280, DOI 10.1128/MCB.10.6.3280; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; FELDMAN RA, 1985, J VIROL, V42, P228; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; FUKUI Y, 1989, ONCOGENE RES, V4, P283; GHYSDAEL J, 1981, P NATL ACAD SCI-BIOL, V78, P2611, DOI 10.1073/pnas.78.4.2611; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; HANAFUSA H, 1969, P NATL ACAD SCI USA, V63, P318, DOI 10.1073/pnas.63.2.318; HANAFUSA T, 1980, P NATL ACAD SCI-BIOL, V77, P3009, DOI 10.1073/pnas.77.5.3009; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SALTIEL AR, 1987, BIOCHEM J, V241, P759, DOI 10.1042/bj2410759; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SUMMERS MD, 1985, BANBURY REPORT, V22, P319; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; ULUG ET, 1990, J VIROL, V64, P3895, DOI 10.1128/JVI.64.8.3895-3904.1990; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0	29	70	71	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1991	6	3					407	411						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	1849246				2022-12-17	WOS:A1991FT34400009
J	GANDINO, L; DIRENZO, MF; GIORDANO, S; BUSSOLINO, F; COMOGLIO, PM				GANDINO, L; DIRENZO, MF; GIORDANO, S; BUSSOLINO, F; COMOGLIO, PM			PROTEIN KINASE-C ACTIVATION INHIBITS TYROSINE PHOSPHORYLATION OF THE C-MET PROTEIN	ONCOGENE			English	Article									UNIV TURIN,DEPT BIOMED SCI & ONCOL,C SO M DAZEGLIO 52,I-10126 TURIN,ITALY; UNIV TURIN,DEPT GENET BIOL & CHEM MED,I-10126 TURIN,ITALY	University of Turin; University of Turin			Bussolino, Federico/AES-3951-2022; Giordano, Silvia/J-9858-2018; DI RENZO, Maria Flavia/B-6091-2012; Bussolino, Federico/K-2500-2016	Giordano, Silvia/0000-0003-1854-1086; DI RENZO, Maria Flavia/0000-0002-5093-3373; Bussolino, Federico/0000-0002-5348-1341				BLACKSHEAR PJ, 1988, FASEB J, V2, P2957, DOI 10.1096/fasebj.2.14.2972578; BROWN KD, 1979, BIOCHEM BIOPH RES CO, V86, P1037, DOI 10.1016/0006-291X(79)90221-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; COCHET C, 1984, J BIOL CHEM, V259, P2553; COMOGLIO PM, 1984, EMBO J, V3, P483, DOI 10.1002/j.1460-2075.1984.tb01834.x; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAVIS RJ, 1984, J BIOL CHEM, V259, P8545; DIRENZO MF, 1986, EUR J BIOCHEM, V158, P383; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; DOWNWARD J, 1985, J BIOL CHEM, V260, P4538; FRIEDMAN BA, 1984, P NATL ACAD SCI-BIOL, V81, P3034, DOI 10.1073/pnas.81.10.3034; GIORDANO S, 1988, MOL CELL BIOL, V8, P3510, DOI 10.1128/MCB.8.8.3510; GIORDANO S, 1988, J CELL BIOCHEM, V38, P229, DOI 10.1002/jcb.240380402; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GOULD KL, 1985, CELL, V42, P849, DOI 10.1016/0092-8674(85)90281-8; HEPLER JR, 1988, J BIOL CHEM, V263, P7610; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; JACOBS S, 1983, P NATL ACAD SCI-BIOL, V80, P6211, DOI 10.1073/pnas.80.20.6211; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; KING CS, 1986, J BIOL CHEM, V261, P73; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN MF, 1988, MOL CELL BIOL, V8, P5477, DOI 10.1128/MCB.8.12.5477; LIVNEH E, 1988, MOL CELL BIOL, V8, P2302, DOI 10.1128/MCB.8.6.2302; MOTOYAMA T, 1984, ACTA MED BIOL, V27, P49; NESTLER EJ, 1983, NATURE, V305, P583, DOI 10.1038/305583a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; RANDO RR, 1988, FASEB J, V2, P2348, DOI 10.1096/fasebj.2.8.3282960; ROOME J, 1988, BIOCHEM J, V256, P493, DOI 10.1042/bj2560493; SHACKELFORD DA, 1984, J BIOL CHEM, V259, P1706; SHOYAB M, 1979, NATURE, V279, P387, DOI 10.1038/279387a0; STURANI E, 1988, MOL CELL BIOL, V8, P1345, DOI 10.1128/MCB.8.3.1345; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3440; TEMPEST PR, 1988, BRIT J CANCER, V58, P3, DOI 10.1038/bjc.1988.150; TEMPEST PR, 1986, FEBS LETT, V209, P357, DOI 10.1016/0014-5793(86)81142-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WHITELEY B, 1986, J CELL BIOL, V103, P1355, DOI 10.1083/jcb.103.4.1355	40	70	72	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1990	5	5					721	725						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG374	2111905				2022-12-17	WOS:A1990DG37400013
J	NGUYEN, C; ROUX, D; MATTEI, MG; DELAPEYRIERE, O; GOLDFARB, M; BIRNBAUM, D; JORDAN, BR				NGUYEN, C; ROUX, D; MATTEI, MG; DELAPEYRIERE, O; GOLDFARB, M; BIRNBAUM, D; JORDAN, BR			THE FGF-RELATED ONCOGENES HST AND INT 2, AND THE BCL 1 LOCUS ARE CONTAINED WITHIN ONE MEGABASE IN BAND Q13 OF CHROMOSOME-11, WHILE THE FGF 5 ONCOGENE MAPS TO 4Q21	ONCOGENE			English	Article									CNRS, INSERM, CTR IMMUNOL, CASE 906, F-13288 MARSEILLE 9, FRANCE; HOP ENFANTS TIMONE, INSERM U242, F-13385 MARSEILLE 5, FRANCE; INSERM, U119, F-13009 MARSEILLE, FRANCE; COLUMBIA UNIV COLL PHYS & SURG, NEW YORK, NY 10032 USA	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Institut National de la Sante et de la Recherche Medicale (Inserm); Columbia University			Nguyen, Catherine/M-4119-2016	Nguyen, Catherine/0000-0001-9376-6360				ADELAIDE J, 1988, ONCOGENE, V2, P413; BERENSON J, 1988, P AACR, V29, P1754; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOVI PD, 1987, P NATL ACAD SCI USA, V84, P5660, DOI 10.1073/pnas.84.16.5660; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; DEBRAEKELEER M, 1986, CANCER GENET CYTOGEN, V23, P333, DOI 10.1016/0165-4608(86)90017-8; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GOSPODAROWICZ D, 1986, CELL DIFFER DEV, V19, P1, DOI 10.1016/0045-6039(86)90021-7; HAYMAN MJ, 1985, P NATL ACAD SCI USA, V82, P8237, DOI 10.1073/pnas.82.23.8237; JAKOBOVITS A, 1986, P NATL ACAD SCI USA, V83, P7806, DOI 10.1073/pnas.83.20.7806; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; LIDEREAU R, 1988, IN PRESS ONCOGENE RE; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; MERGIA A, 1986, BIOCHEM BIOPH RES CO, V138, P644, DOI 10.1016/S0006-291X(86)80545-9; NAKAGAMA H, 1987, JPN J CANCER RES, V78, P651; NGUYEN C, 1987, EMBO J, V6, P3285, DOI 10.1002/j.1460-2075.1987.tb02647.x; PETERS G, 1983, CELL, V33, P369, DOI 10.1016/0092-8674(83)90418-X; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; YOSHIDA MC, 1988, P NATL ACAD SCI USA, V85, P4861, DOI 10.1073/pnas.85.13.4861; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310; ZEHNBAUER BA, 1988, MOL CELL BIOL, V8, P522, DOI 10.1128/MCB.8.2.522; ZHAN X, 1987, ONCOGENE, V1, P369; ZHAN X, 1988, IN PRESS MOL CELL BI; ZHOU DJ, 1988, ONCOGENE, V2, P279	30	70	70	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1988	3	6					703	708						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R6460	2577873				2022-12-17	WOS:A1988R646000013
J	ZHAN, X; CULPEPPER, A; REDDY, M; LOVELESS, J; GOLDFARB, M				ZHAN, X; CULPEPPER, A; REDDY, M; LOVELESS, J; GOLDFARB, M			HUMAN ONCOGENES DETECTED BY A DEFINED MEDIUM CULTURE ASSAY	ONCOGENE			English	Article									COLUMBIA UNIV COLL PHYS & SURG, DEPT BIOCHEM & MOLEC BIOPHYS, 630 W 168TH ST, NEW YORK, NY 10032 USA; MEM SLOAN KETTERING INST CANC RES, HUMAN TUMOR CELL LAB, RYE, NY 10580 USA	Columbia University; Memorial Sloan Kettering Cancer Center								ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; FASANO O, 1983, Journal of Molecular and Applied Genetics, V2, P173; FOGH J, 1977, JNCI-J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221; FOGH J, 1977, J NATL CANCER I, V58, P209, DOI 10.1093/jnci/58.2.209; Fogh J, 1978, Natl Cancer Inst Monogr, P5; FUKUI M, 1985, P NATL ACAD SCI USA, V82, P5954, DOI 10.1073/pnas.82.17.5954; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HALL A, 1983, NATURE, V303, P396, DOI 10.1038/303396a0; HOHN B, 1977, P NATL ACAD SCI USA, V74, P3259, DOI 10.1073/pnas.74.8.3259; JELINEK WR, 1980, P NATL ACAD SCI-BIOL, V77, P1398, DOI 10.1073/pnas.77.3.1398; KRONTIRIS TG, 1981, P NATL ACAD SCI-BIOL, V78, P1181, DOI 10.1073/pnas.78.2.1181; MANIATIS T, 1975, P NATL ACAD SCI USA, V72, P1184, DOI 10.1073/pnas.72.3.1184; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MULLER R, 1984, EMBO J, V3, P1121, DOI 10.1002/j.1460-2075.1984.tb01939.x; MURRAY MJ, 1981, CELL, V25, P355, DOI 10.1016/0092-8674(81)90054-4; OCHIYA T, 1986, P NATL ACAD SCI USA, V83, P4993, DOI 10.1073/pnas.83.14.4993; PARADA LF, 1982, NATURE, V297, P474, DOI 10.1038/297474a0; PERUCHO M, 1981, CELL, V27, P467, DOI 10.1016/0092-8674(81)90388-3; PULCIANI S, 1982, NATURE, V300, P539, DOI 10.1038/300539a0; RASHEED S, 1977, J NATL CANCER I, V58, P881, DOI 10.1093/jnci/58.4.881; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SCHER CD, 1978, J CELL PHYSIOL, V97, P371, DOI 10.1002/jcp.1040970312; SHARP PA, 1974, COLD SPRING HARB SYM, V39, P457, DOI 10.1101/SQB.1974.039.01.058; SHIH C, 1979, P NATL ACAD SCI USA, V76, P5714, DOI 10.1073/pnas.76.11.5714; SHIMIZU K, 1983, P NATL ACAD SCI-BIOL, V80, P2112, DOI 10.1073/pnas.80.8.2112; SHIMIZU K, 1985, P NATL ACAD SCI USA, V82, P5641, DOI 10.1073/pnas.82.17.5641; SMITH HS, 1971, VIROLOGY, V44, P359, DOI 10.1016/0042-6822(71)90267-4; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAKAKI T, 1980, J CANCER RES CLIN, V96, P27, DOI 10.1007/BF00412894; TANAKA T, 1975, J BACTERIOL, V121, P354, DOI 10.1128/JB.121.1.354-362.1975; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; YAMAMOTO KR, 1970, VIROLOGY, V40, P734, DOI 10.1016/0042-6822(70)90218-7; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3; YUASA Y, 1983, NATURE, V303, P775, DOI 10.1038/303775a0; ZHAN X, 1986, MOL CELL BIOL, V6, P3541, DOI 10.1128/MCB.6.10.3541	44	70	73	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene		1987	1	4					369	376						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	K7483	3330780				2022-12-17	WOS:A1987K748300005
J	Li, BB; Hong, JX; Hong, M; Wang, YJ; Yu, TT; Zang, SB; Wu, QL				Li, Beibei; Hong, Jiaxin; Hong, Mei; Wang, Yajun; Yu, Tingting; Zang, Sibin; Wu, Qiuling			piRNA-823 delivered by multiple myeloma-derived extracellular vesicles promoted tumorigenesis through re-educating endothelial cells in the tumor environment	ONCOGENE			English	Article							NOVO DNA METHYLATION; BONE-MARROW MICROENVIRONMENT; LEUKEMIA-CELLS; SMALL RNA; EXOSOMES; MICROVESICLES; ANGIOGENESIS; CONTRIBUTES; PROTEINS; MIRNAS	Extracellular vesicles (EVs) can carry a wide array of RNAs in the tumor microenvironment, and are crucial for communication between tumor and surrounding stromal cells, including endothelial cells. Piwi-interacting RNAs (piRNAs) are important regulators implicated in the pathogenesis of multiple myeloma (MM). However, little is understood about the role of piRNA-823 in intercellular communication between MM and endothelial cells. In this study, we found that piRNA-823 mainly accumulated in EVs from peripheral blood of MM patients and EVs derived from MM cells (MM-derived-EVs). Increased piRNA-823 expression was associated with late stages and poor prognosis of MM. The MM-derived-EVs effectively transferred piRNA-823 to EA.hy926 endothelial cells. The piRNA-823 mimic and inhibitor were designed to upregulate or to suppress the endogenous function of piRNA-823. Transfection with piRNA-823 mimic or treatment with MM-derived-EVs significantly promoted the proliferation, tube formation, and invasion of EA.hy926 cells by enhancing the expression of VEGF, IL-6, and ICAM-1 and attenuating apoptosis. EA.hy926 cells transfected with piRNA-823 mimic or pre-treated with MM-derived-EVs promoted the growth of xenograft MM in mice. In contrast, the transfection with piRNA-823 inhibitor or treatment with EVs from piRNA-823 inhibitor-transfected-MM cells had diametrically opposite effects. Our findings demonstrated that piRNA-823 carried by MM-derived-EVs is essential for the re-education of ECs toward a unique environment amenable to the growth of MM cells by altering its biological characteristics. Our findings may pave the way for the development of new piRNA-mediated prognostic stratification and therapeutic strategies for MM.	[Li, Beibei; Hong, Jiaxin; Hong, Mei; Wang, Yajun; Yu, Tingting; Zang, Sibin; Wu, Qiuling] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Inst Hematol, Wuhan, Hubei, Peoples R China; [Hong, Jiaxin] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan, Hubei, Peoples R China; [Hong, Mei] Soochow Univ, Collaborat Innovat Ctr Hematol, Suzhou, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Soochow University - China	Wu, QL (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Inst Hematol, Wuhan, Hubei, Peoples R China.	wuqiuling927@qq.com	yu, tingting/HGA-4783-2022	Wu, Qiuling/0000-0001-6488-5731	National Natural Science Foundation of P.R China [30500686, 81770219]	National Natural Science Foundation of P.R China(National Natural Science Foundation of China (NSFC))	The authors would like to thank all the participants for their kind cooperation. The research was supported by the National Natural Science Foundation of P.R China (no. 30500686, for Q-LW) and (no. 81770219, for Q-LW).	Abdi J, 2014, BIOMARK RES, V2, DOI 10.1186/2050-7771-2-10; Aravin A, 2006, NATURE, V442, P203, DOI 10.1038/nature04916; Aravin AA, 2008, MOL CELL, V31, P785, DOI 10.1016/j.molcel.2008.09.003; Aravin AA, 2008, GENE DEV, V22, P970, DOI 10.1101/gad.1669408; Becker A, 2016, CANCER CELL, V30, P836, DOI 10.1016/j.ccell.2016.10.009; Canella A, 2016, EXPERT REV MOL DIAGN, V16, P277, DOI 10.1586/14737159.2016.1132627; Chantrain CF, 2008, CANCER MICROENVIRON, V1, P23, DOI 10.1007/s12307-008-0010-7; Cheng J, 2012, CANCER LETT, V315, P12, DOI 10.1016/j.canlet.2011.10.004; Cheng J, 2011, CLIN CHIM ACTA, V412, P1621, DOI 10.1016/j.cca.2011.05.015; Cui L, 2011, CLIN BIOCHEM, V44, P1050, DOI 10.1016/j.clinbiochem.2011.06.004; Girard A, 2006, NATURE, V442, P199, DOI 10.1038/nature04917; Grange C, 2006, ONCOL REP, V15, P381; Hida K, 2004, CANCER RES, V64, P8249, DOI 10.1158/0008-5472.CAN-04-1567; Jinek M, 2009, NATURE, V457, P405, DOI 10.1038/nature07755; Korn C, 2017, BLOOD, V129, P811, DOI 10.1182/blood-2016-09-670224; Ku HY, 2014, NATL SCI REV, V1, P205, DOI 10.1093/nsr/nwu014; Kuramochi-Miyagawa S, 2008, GENE DEV, V22, P908, DOI 10.1101/gad.1640708; Kyle RA, 2004, NEW ENGL J MED, V351, P1860, DOI 10.1056/NEJMra041875; Laffont B, 2013, BLOOD, V122, P253, DOI 10.1182/blood-2013-03-492801; Li J, 2013, J BIOL CHEM, V288, P23586, DOI 10.1074/jbc.M113.489302; Li LM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046957; Manier S, 2017, BLOOD, V129, P2429, DOI 10.1182/blood-2016-09-742296; Meister G, 2004, MOL CELL, V15, P185, DOI 10.1016/j.molcel.2004.07.007; Mineo M, 2012, ANGIOGENESIS, V15, P33, DOI 10.1007/s10456-011-9241-1; Morgan GJ, 2012, NAT REV CANCER, V12, P335, DOI 10.1038/nrc3257; Nazarenko I, 2010, CANCER RES, V70, P1668, DOI 10.1158/0008-5472.CAN-09-2470; Ogata-Kawata H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092921; Paggetti J, 2015, BLOOD, V126, P1106, DOI 10.1182/blood-2014-12-618025; Pezzolo A, 2007, J CLIN ONCOL, V25, P376, DOI 10.1200/JCO.2006.09.0696; Raaijmakers MHGP, 2010, NATURE, V464, P852, DOI 10.1038/nature08851; Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138; Ricci-Vitiani L, 2010, NATURE, V468, P824, DOI 10.1038/nature09557; Rigolin GM, 2006, BLOOD, V107, P2531, DOI 10.1182/blood-2005-04-1768; Sarkar A, 2017, FASEB J, V31, P436, DOI 10.1096/fj.201600637RR; Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800; St Croix B, 2000, SCIENCE, V289, P1197; Streubel B, 2004, NEW ENGL J MED, V351, P250, DOI 10.1056/NEJMoa033153; Svensson KJ, 2013, BIOCHEM SOC T, V41, P273, DOI 10.1042/BST20120248; Tadokoro H, 2013, J BIOL CHEM, V288, P34343, DOI 10.1074/jbc.M113.480822; Taverna S, 2012, INT J CANCER, V130, P2033, DOI 10.1002/ijc.26217; Umezu T, 2013, ONCOGENE, V32, P2747, DOI 10.1038/onc.2012.295; Umezu T, 2014, BLOOD, V124, P3748, DOI 10.1182/blood-2014-05-576116; Wang JH, 2016, ONCOTARGET, V7, P38927, DOI 10.18632/oncotarget.7792; Wang R, 2010, NATURE, V468, P829, DOI 10.1038/nature09624; Wu QL, 2010, BIOCHEM BIOPH RES CO, V396, P915, DOI 10.1016/j.bbrc.2010.05.022; Yan H, 2015, LEUKEMIA, V29, P196, DOI 10.1038/leu.2014.135	46	69	69	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2019	38	26					5227	5238		10.1038/s41388-019-0788-4	http://dx.doi.org/10.1038/s41388-019-0788-4			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IF4AX	30890754				2022-12-17	WOS:000473025300008
J	Bian, X; Gao, J; Luo, F; Rui, C; Zheng, T; Wang, D; Wang, Y; Roberts, TM; Liu, P; Zhao, JJ; Cheng, H				Bian, X.; Gao, J.; Luo, F.; Rui, C.; Zheng, T.; Wang, D.; Wang, Y.; Roberts, T. M.; Liu, P.; Zhao, J. J.; Cheng, H.			PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy	ONCOGENE			English	Article							NEGATIVE BREAST-CANCER; HOMOLOGOUS RECOMBINATION REPAIR; OVARIAN-CANCER; DNA-REPAIR; POLY(ADP-RIBOSE) POLYMERASE; PROSTATE-CANCER; PI3K INHIBITOR; NUCLEAR PTEN; MUTANT-CELLS; OLAPARIB	Poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as promising cancer therapeutics especially for tumors with deficient homologous recombination (HR) repair. However, as HR-deficient tumors represent only a small fraction of endometrial cancers, the therapeutic utility of PARP inhibitors is limited in this disease. Somatic loss of phosphatase and tensin homolog (PTEN), a tumor suppressor that counteracts phosphoinositide 3-kinase (PI3K) activity, is one of the most common genetic aberrations in endometrioid endometrial cancer. While previous works have identified the role of PTEN in DNA double-strand break repair, vulnerabilities of PTEN-deficient endometrioid endometrial cancers to PARP inhibition remain controversial. Here we find that PTENdeficient endometrioid endometrial cancer cells are not responsive to PARP inhibitor Olaparib alone, but instead show superior sensitivity to compound inhibition with PI3K inhibitor BKM120, as evidenced by reduced clonogenic cell growth and threedimensional (3D) spheroid disintegration. Mechanistically, PI3K blockade by BKM120 attenuated HR competency with.H2AX accumulation and reduced RAD51 and BRCA1 expression in Ishikawa, AN3CA and Nou-1 cells, but the same combination treatment led to enhanced phosphorylation of DNA-PK, a non-homologous end joining repair protein, in Hec-108 cells. Furthermore, we show that CRISPR/Cas9-mediated PTEN depletion rendered PTEN wild-type Hec-1A endometrioid endometrial cancer cells responsive to combined inhibition of PARP/PI3K, with concomitantly induced DNA damage accumulation and repair defects. The combination of BKM120 and Olaparib cooperated to inhibit tumor growth in a genetic mouse model of Pten-deficient endometrioid endometrial cancer. Together, these results suggest PI3K inhibition may be a plausible approach to expand the utility of PARP inhibitors to endometrioid endometrial cancers in a PTEN-deficient setting.	[Bian, X.; Gao, J.; Rui, C.; Wang, D.; Liu, P.; Cheng, H.] Dalian Med Univ, Inst Canc Stem Cell, Hosp 2, Canc Inst, Dalian, Peoples R China; [Luo, F.] Dalian Med Univ, Hosp 2, Dept Acute Abdomen Surg, Dalian, Peoples R China; [Zheng, T.] Dalian Med Univ, Coll Basic Med Sci, Dalian, Peoples R China; [Wang, Y.] Dalian Med Univ, Dept Obstet & Gynecol, Hosp 2, Dalian, Peoples R China; [Roberts, T. M.; Zhao, J. J.] Dana Farber Canc Inst, Dept Canc Biol, 450 Brookline Ave Smith 936, Boston, MA 02215 USA; [Liu, P.] Dalian Med Univ, Coll Pharm, Dalian, Peoples R China	Dalian Medical University; Dalian Medical University; Dalian Medical University; Dalian Medical University; Harvard University; Dana-Farber Cancer Institute; Dalian Medical University	Zhao, JJ (corresponding author), Dana Farber Canc Inst, Dept Canc Biol, 450 Brookline Ave Smith 936, Boston, MA 02215 USA.; Cheng, H (corresponding author), Dalian Med Univ, Inst Canc, Hosp 2, Dalian 116023, Peoples R China.; Liu, P (corresponding author), Dalian Med Univ, Inst Canc Stem Cell, Dalian 116044, Peoples R China.	pixu_liu@dmu.edu.cn; jean_zhao@dfci.harvard.edu; hailingcheng_dmu@163.com			National Natural Science Foundation of China [81472447, 81672575, 81372853, 81572586, 81602274]; Liaoning Provincial Climbing Scholars Supporting Program of China; Liaoning Provincial Science and Technology Program for Oversea Talents; Provincial Natural Science Foundation of Liaoning [2014023002]; National Institutes of Health/National Cancer Institute (NIH/NCI) [P50 CA168504, CA187918, P50 CA165962, CA210057-01, CA172461-04]; Breast Cancer Research Foundation; DFCI SSCWC Program Project Grant; NATIONAL CANCER INSTITUTE [R01CA187918, P50CA165962, P50CA168504, R01CA172461, R35CA210057] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Liaoning Provincial Climbing Scholars Supporting Program of China; Liaoning Provincial Science and Technology Program for Oversea Talents; Provincial Natural Science Foundation of Liaoning; National Institutes of Health/National Cancer Institute (NIH/NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Breast Cancer Research Foundation; DFCI SSCWC Program Project Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by National Natural Science Foundation of China (No. 81472447 and No. 81672575 to H Cheng; No. 81372853 and No. 81572586 to P Liu; No. 81602274 to J Gao), Liaoning Provincial Climbing Scholars Supporting Program of China (H Cheng, P Liu), Liaoning Provincial Science and Technology Program for Oversea Talents (H Cheng), Provincial Natural Science Foundation of Liaoning (No. 2014023002 to P Liu), National Institutes of Health/National Cancer Institute (NIH/NCI) (P50 CA168504, CA187918, P50 CA165962, CA210057-01 and CA172461-04 to JJZ), and Breast Cancer Research Foundation and DFCI SSCWC Program Project Grant.	Amant F, 2005, LANCET, V366, P491, DOI 10.1016/S0140-6736(05)67063-8; Bassi C, 2013, SCIENCE, V341, P395, DOI 10.1126/science.1236188; Bunney TD, 2010, NAT REV CANCER, V10, P342, DOI 10.1038/nrc2842; Cardillo TM, 2017, CLIN CANCER RES, V23, P3405, DOI 10.1158/1078-0432.CCR-16-2401; Cardnell RJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152584; Chan SL, 2010, LANCET, V376, P211, DOI 10.1016/S0140-6736(10)61119-1; Cheng HL, 2014, CANCER RES, V74, P15, DOI 10.1158/0008-5472.CAN-13-0544; Cheung LWT, 2011, CANCER DISCOV, V1, P170, DOI 10.1158/2159-8290.CD-11-0039; Dedes KJ, 2011, NAT REV CLIN ONCOL, V8, P261, DOI 10.1038/nrclinonc.2010.216; Dedes KJ, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001538; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Forster MD, 2011, NAT REV CLIN ONCOL, V8, P302, DOI 10.1038/nrclinonc.2011.42; Fraser M, 2012, CLIN CANCER RES, V18, P1015, DOI 10.1158/1078-0432.CCR-11-2189; Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Gonzalez-Billalabeitia E, 2014, CANCER DISCOV, V4, P896, DOI 10.1158/2159-8290.CD-13-0230; Ibrahim YH, 2012, CANCER DISCOV, V2, P1036, DOI 10.1158/2159-8290.CD-11-0348; Janzen DM, 2013, MOL CANCER THER, V12, P2917, DOI 10.1158/1535-7163.MCT-13-0572; JOHNSON CV, 1991, METHOD CELL BIOL, V35, P73; Johnson N, 2011, NAT MED, V17, P875, DOI 10.1038/nm.2377; Juvekar A, 2012, CANCER DISCOV, V2, P1048, DOI 10.1158/2159-8290.CD-11-0336; Kim G, 2015, CLIN CANCER RES, V21, P4257, DOI 10.1158/1078-0432.CCR-15-0887; Konstantinopoulos PA, 2015, CANCER DISCOV, V5, P1137, DOI 10.1158/2159-8290.CD-15-0714; Li L, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12235; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926; Martins FC, 2012, CANCER DISCOV, V2, P503, DOI 10.1158/2159-8290.CD-11-0325; Mateo J, 2015, NEW ENGL J MED, V373, P1697, DOI 10.1056/NEJMoa1506859; McEllin B, 2010, CANCER RES, V70, P5457, DOI 10.1158/0008-5472.CAN-09-4295; Mendes-Pereira AM, 2009, EMBO MOL MED, V1, P315, DOI 10.1002/emmm.200900041; Mirza MR, 2016, NEW ENGL J MED, V375, P2154, DOI 10.1056/NEJMoa1611310; Miyasaka A, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-179; Mo W, 2016, CLIN CANCER RES, V22, P1699, DOI 10.1158/1078-0432.CCR-15-1772; Muranen T, 2012, CANCER CELL, V21, P227, DOI 10.1016/j.ccr.2011.12.024; Okkenhaug K, 2016, CANCER DISCOV, V6, P1090, DOI 10.1158/2159-8290.CD-16-0716; Puc J, 2005, CANCER CELL, V7, P193, DOI 10.1016/j.ccr.2005.01.009; Rodon J, 2013, NAT REV CLIN ONCOL, V10, P143, DOI 10.1038/nrclinonc.2013.10; Roy R, 2012, NAT REV CANCER, V12, P68, DOI 10.1038/nrc3181; Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042; Swisher EM, 2017, LANCET ONCOL, V18, P75, DOI [10.1016/s1470-2045(16)30559-9, 10.1016/S1470-2045(16)30559-9]; Thorpe LM, 2015, NAT REV CANCER, V15, P7, DOI 10.1038/nrc3860; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Wang D, 2016, GYNECOL ONCOL, V142, P548, DOI 10.1016/j.ygyno.2016.07.092; Wang D, 2016, ONCOTARGET, V7, P13153, DOI 10.18632/oncotarget.7549; Weigelt B, 2013, CLIN CANCER RES, V19, P3533, DOI 10.1158/1078-0432.CCR-12-3815	47	69	71	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2018	37	3					341	351		10.1038/onc.2017.326	http://dx.doi.org/10.1038/onc.2017.326			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS9QS	28945226	Green Published, hybrid			2022-12-17	WOS:000422753900007
J	Ahmad, R; Kumar, B; Chen, Z; Chen, X; Muller, D; Lele, SM; Washington, MK; Batra, SK; Dhawan, P; Singh, AB				Ahmad, R.; Kumar, B.; Chen, Z.; Chen, X.; Mueller, D.; Lele, S. M.; Washington, M. K.; Batra, S. K.; Dhawan, P.; Singh, A. B.			Loss of claudin-3 expression induces IL6/gp130/Stat3 signaling to promote colon cancer malignancy by hyperactivating Wnt/beta-catenin signaling	ONCOGENE			English	Article							BETA-CATENIN; EPITHELIAL-CELLS; TIGHT JUNCTION; GROWTH; TRANSDUCER; PATHWAY; CLDN3; GENE; ACTIVATION; RESISTANCE	The hyperactivated Wnt/beta-catenin signaling acts as a switch to induce epithelial to mesenchymal transition and promote colorectal cancer. However, due to its essential role in gut homeostasis, therapeutic targeting of this pathway has proven challenging. Additionally, IL-6/Stat-3 signaling, activated by microbial translocation through the dysregulated mucosal barrier in colon adenomas, facilitates the adenoma to adenocarcinomas transition. However, inter-dependence between these signaling pathways and key mucosal barrier components in regulating colon tumorigenesis and cancer progression remains unclear. In current study, we have discovered, using a comprehensive investigative regimen, a novel and tissue-specific role of claudin-3, a tight junction integral protein, in inhibiting colon cancer progression by serving as the common rheostat of Stat-3 and Wnt-signaling activation. Loss of claudin-3 also predicted poor patient survival. These findings however contrasted an upregulated claudin-3 expression in other cancer types and implicated role of the epigenetic regulation. Claudin-3 -/- mice revealed dedifferentiated and leaky colonic epithelium, and developed invasive adenocarcinoma when subjected to colon cancer. Wnt-signaling hyperactivation, albeit in GSK-3 beta independent manner, differentiated colon cancer in claudin-3 -/- mice versus WT-mice. Claudin-3 loss also upregulated the gp130/IL6/Stat3 signaling in colonic epithelium potentially assisted by infiltrating immune components. Genetic and pharmacological studies confirmed that claudin-3 loss induces Wnt/beta-catenin activation, which is further exacerbated by Stat-3-activation and help promote colon cancer. Overall, these novel findings identify claudin-3 as a therapeutic target for inhibiting overactivation of Wnt-signaling to prevent CRC malignancy.	[Ahmad, R.; Kumar, B.; Batra, S. K.; Dhawan, P.; Singh, A. B.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Chen, Z.] Zhengzhou Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Zhengzhou, Henan, Peoples R China; [Chen, X.] Univ Miami, Miller Sch Med, Div Biostat, Miami, FL 33136 USA; [Mueller, D.] Charite, Dept Pediat Nephrol, Berlin, Germany; [Mueller, D.] Berlin Inst Hlth, Berlin, Germany; [Lele, S. M.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA; [Washington, M. K.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN USA; [Dhawan, P.; Singh, A. B.] VA Nebraska Western Iowa Hlth Care Syst, Omaha, NE USA	University of Nebraska System; University of Nebraska Medical Center; Zhengzhou University; University of Miami; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Berlin Institute of Health; University of Nebraska System; University of Nebraska Medical Center; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Nebraska-Western Iowa Health Care System	Singh, AB (corresponding author), Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.	amar.singh@unmc.edu	kumar, Balawant/ABB-2847-2021; Kumar, Balawant/AAW-9616-2021	kumar, Balawant/0000-0002-8187-3078; 	 [BX002086];  [DK088902];  [BX002761]; NATIONAL CANCER INSTITUTE [P50CA095103] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK088902] Funding Source: NIH RePORTER; Veterans Affairs [I01BX002086, I01BX002761] Funding Source: NIH RePORTER	; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Veterans Affairs(US Department of Veterans Affairs)	This work was supported by BX002086 (PD), DK088902 and BX002761 (ABS).	Ahmad R, 2014, MUCOSAL IMMUNOL, V7, P1340, DOI 10.1038/mi.2014.21; Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419; Bartholow TL, 2011, DIAGN PATHOL, V6, DOI 10.1186/1746-1596-6-12; Bhat AA, 2015, ONCOGENE, V34, P4570, DOI 10.1038/onc.2014.385; Cereijido M, 2008, BBA-BIOMEMBRANES, V1778, P770, DOI 10.1016/j.bbamem.2007.09.001; Clark JA, 2006, AM J PHYSIOL-GASTR L, V291, pG938, DOI 10.1152/ajpgi.00090.2006; de Araujo WM, 2010, J CANCER RES CLIN, V136, P1773, DOI 10.1007/s00432-010-0836-5; de Souza WF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074994; Deschenes C, 2001, GASTROENTEROLOGY, V120, P423, DOI 10.1053/gast.2001.21199; Dhawan P, 2005, J CLIN INVEST, V115, P1765, DOI 10.1172/JCI24543; Dhawan P, 2011, ONCOGENE, V30, P3234, DOI 10.1038/onc.2011.43; Dube PE, 2012, J CLIN INVEST, V122, P2780, DOI 10.1172/JCI62888; Dzierzewicz Z, 2002, ACTA BIOCHIM POL, V49, P211; Gavert N, 2007, J CELL BIOCHEM, V102, P820, DOI 10.1002/jcb.21505; Gibson DL, 2008, CELL MICROBIOL, V10, P388, DOI 10.1111/j.1462-5822.2007.01052.x; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Grivennikov SI, 2012, NATURE, V491, P254, DOI 10.1038/nature11465; Hbibi AT, 2009, FEBS J, V276, P2505, DOI 10.1111/j.1742-4658.2009.06975.x; Heinzelmann-Schwarz VA, 2004, CLIN CANCER RES, V10, P4427, DOI 10.1158/1078-0432.CCR-04-0073; HENTTINEN T, 1995, J IMMUNOL, V155, P4582; Hinoi T, 2000, J BIOL CHEM, V275, P34399, DOI 10.1074/jbc.M003997200; Holmes JL, 2006, GENE EXPR PATTERNS, V6, P581, DOI 10.1016/j.modgep.2005.12.001; Honda H, 2007, CANCER BIOL THER, V6, P1733, DOI 10.4161/cbt.6.11.4832; Jiang L, 2014, ONCOTARGET, V5, P7663, DOI 10.18632/oncotarget.2288; KEDINGER M, 1990, DIFFERENTIATION, V43, P87, DOI 10.1111/j.1432-0436.1990.tb00434.x; Kooij G, 2014, ACTA NEUROPATHOL, V128, P267, DOI 10.1007/s00401-013-1227-1; Krishnan M, 2010, ONCOGENE, V29, P305, DOI 10.1038/onc.2009.324; Kwon MJ, 2010, CARCINOGENESIS, V31, P974, DOI 10.1093/carcin/bgp336; Lee J, 2012, J BIOL CHEM, V287, P18182, DOI 10.1074/jbc.M111.328831; Long HY, 2001, CANCER RES, V61, P7878; MATSUMOTO H, 1990, GASTROENTEROLOGY, V98, P1199, DOI 10.1016/0016-5085(90)90334-W; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MOSER AR, 1995, EUR J CANCER, V31A, P1061, DOI 10.1016/0959-8049(95)00181-H; Mullin J M, 2004, Sci STKE, V2004, ppe2, DOI 10.1126/stke.2162004pe2; MULLIN JM, 1988, J CELL PHYSIOL, V134, P357, DOI 10.1002/jcp.1041340306; MULLIN JM, 1988, CANCER RES, V48, P4886; Nagaraja GM, 2006, ONCOGENE, V25, P2328, DOI 10.1038/sj.onc.1209265; Ngan CY, 2007, BRIT J CANCER, V96, P986, DOI 10.1038/sj.bjc.6603651; Patel RM, 2012, AM J PATHOL, V180, P626, DOI 10.1016/j.ajpath.2011.10.025; Pramanik KC, 2015, ONCOTARGET, V6, P11561, DOI 10.18632/oncotarget.3427; Rajput A, 2008, J SURG RES, V147, P276, DOI 10.1016/j.jss.2007.04.021; Ramalingam A, 2010, AM J PHYSIOL-CELL PH, V299, pC1028, DOI 10.1152/ajpcell.00482.2009; Ray S, 2013, J INVEST DERMATOL, V133, P1212, DOI 10.1038/jid.2012.499; Royer C, 2011, CELL DEATH DIFFER, V18, P1470, DOI 10.1038/cdd.2011.60; Singh AB, 2015, SEMIN CELL DEV BIOL, V42, P58, DOI 10.1016/j.semcdb.2015.05.001; Soler AP, 1999, CARCINOGENESIS, V20, P1425, DOI 10.1093/carcin/20.8.1425; Tenbaum SP, 2012, NAT MED, V18, P892, DOI 10.1038/nm.2772; Thaker AI, 2012, JOVE-J VIS EXP, DOI 10.3791/4100; Turgeon N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073785; Vucic EA, 2008, PHARMACOGENOMICS, V9, P215, DOI 10.2217/14622416.9.2.215; Wu JQ, 2016, CELL REP, V14, P1979, DOI 10.1016/j.celrep.2016.01.074; Yaqinuddin A, 2009, J UROLOGY, V182, P756, DOI 10.1016/j.juro.2009.03.082; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734	54	69	75	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2017	36	47					6592	6604		10.1038/onc.2017.259	http://dx.doi.org/10.1038/onc.2017.259			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FN5LN	28783170	Green Accepted			2022-12-17	WOS:000416049200008
J	Liu, CC; Cai, DL; Sun, F; Wu, ZH; Yue, B; Zhao, SL; Wu, XS; Zhang, M; Zhu, XW; Peng, ZH; Yan, DW				Liu, C-C; Cai, D-L; Sun, F.; Wu, Z-H; Yue, B.; Zhao, S-L; Wu, X-S; Zhang, M.; Zhu, X-W; Peng, Z-H; Yan, D-W			FERMT1 mediates epithelial-mesenchymal transition to promote colon cancer metastasis via modulation of beta-catenin transcriptional activity	ONCOGENE			English	Article							COLORECTAL-CANCER; KINDLIN-1; WNT; EXPRESSION; INHIBITION; CARCINOMA; ADHESION; COMPLEX; PROLIFERATION; KERATINOCYTES	We previously demonstrated that fermitin family member 1 (FERMT1) was significantly overexpressed in colon cancer (CC) and associated with poor metastasis-free survival. This study aimed to investigate the precise role of FERMT1 in CC metastasis and the mechanism by which FERMT1 is involved in the epithelial-mesenchymal transition (EMT). Correlations between FERMT1 and EMT markers (E-cadherin, Slug, N-cadherin and beta-catenin) were examined via immunohistochemistry in a cohort of CC tissues and adjacent normal colon mucosae. A series of in vitro and in vivo assays were performed to elucidate the function of FERMT1 in CC metastasis and underlying mechanisms. The upregulated expression of FERMT1 in CC tissues correlated positively with that of Slug, N-cadherin and beta-catenin, but correlated inversely with E-cadherin expression. Altered FERMT1 expression led to marked changes in the proliferation, migration, invasion and EMT markers of CC cells both in vitro and in vivo. Investigations of underlying mechanisms found that FERMT1 interacted directly with beta-catenin and activated the Wnt/beta-catenin signaling pathway by decreasing the phosphorylation level of beta-catenin, enhancing beta-catenin nuclear translocation and increasing the transcriptional activity of beta-catenin/TCF/LEF. Activation of the Wnt/beta-catenin pathway by CHIR99021 reversed the effect of FERMT1 knockdown, whereas inhibition of the Wnt/beta-catenin pathway by XAV939 impaired the effect of FERMT1 overexpression on EMT and cell motility. In conclusion, findings of this study suggest that FERMT1 activates the beta-catenin transcriptional activity to promote EMT in CC metastasis.	[Liu, C-C; Yue, B.; Zhao, S-L; Zhu, X-W; Peng, Z-H; Yan, D-W] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Dept Gen Surg, Sch Med, 85 Wujin Rd, Shanghai 200080, Peoples R China; [Cai, D-L] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Dept Drug Allocat Ctr, Sch Med, Shanghai, Peoples R China; [Sun, F.; Wu, X-S] Kunming Med Univ, Dept Gastrointestinal Surg, Affiliated Hosp 2, Kunming, Peoples R China; [Wu, Z-H] Qingdao Univ, Dept Hapatobiliary Surg, Affiliated Hosp, Qingdao, Peoples R China; [Zhang, M.] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Dept Pathol, Sch Med, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Kunming Medical University; Qingdao University; Shanghai Jiao Tong University	Yan, DW (corresponding author), Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Dept Gen Surg, Sch Med, 85 Wujin Rd, Shanghai 200080, Peoples R China.	yandw70@163.com			National Natural Science Foundation of China [81172328]; Medical Guidance Project of Shanghai Science and Technology Commission [114119a4600, 124119a1700]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Medical Guidance Project of Shanghai Science and Technology Commission	This work was supported by National Natural Science Foundation of China (no. 81172328) and Medical Guidance Project of Shanghai Science and Technology Commission (114119a4600) (124119a1700). We thank Jiachen Nan for her generous help.	Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Eccles SA, 2007, LANCET, V369, P1742, DOI 10.1016/S0140-6736(07)60781-8; Fagotto F, 2013, EMBO REP, V14, P422, DOI 10.1038/embor.2013.45; Fan JW, 2011, CLIN CANCER RES, V17, P2908, DOI 10.1158/1078-0432.CCR-10-2552; Fodde R, 2007, CURR OPIN CELL BIOL, V19, P150, DOI 10.1016/j.ceb.2007.02.007; Gonzalez DM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005189; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Has C, 2008, BRIT J DERMATOL, V159, P1192, DOI 10.1111/j.1365-2133.2008.08760.x; Herz C, 2006, J BIOL CHEM, V281, P36082, DOI 10.1074/jbc.M606259200; Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kern J S, 2007, J Pathol, V213, P462, DOI 10.1002/path.2253; Kiriyama K, 2013, ANTICANCER RES, V33, P167; Lai-Cheong JE, 2009, AM J PATHOL, V175, P1431, DOI 10.2353/ajpath.2009.081154; Larjava H, 2008, EMBO REP, V9, P1203, DOI 10.1038/embor.2008.202; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Li VSW, 2012, CELL, V149, P1245, DOI 10.1016/j.cell.2012.05.002; Loboda A, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-9; Ma HX, 2015, TUMOR BIOL, V36, P4235, DOI 10.1007/s13277-015-3060-8; Mahawithitwong P, 2013, INT J ONCOL, V42, P1360, DOI 10.3892/ijo.2013.1838; Malanchi I, 2008, NATURE, V452, P650, DOI 10.1038/nature06835; Nawshad A, 2005, CELLS TISSUES ORGANS, V179, P11, DOI 10.1159/000084505; Niehrs C, 2012, NAT REV MOL CELL BIO, V13, P767, DOI 10.1038/nrm3470; Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976; Rognoni E, 2014, NAT MED, V20, P350, DOI 10.1038/nm.3490; Siegel DH, 2003, AM J HUM GENET, V73, P174, DOI 10.1086/376609; Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220; Sin S, 2011, J NATL CANCER I, V103, P1323, DOI 10.1093/jnci/djr290; Sleeman JP, 2011, CELL, V145, DOI 10.1016/j.cell.2011.03.029; Thaker PH, 2004, CLIN CANCER RES, V10, P5145, DOI 10.1158/1078-0432.CCR-03-0589; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Ussar S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000289; Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150; Walther A, 2009, NAT REV CANCER, V9, P489, DOI 10.1038/nrc2645; Weng WH, 2015, INT J CANCER, V136, P493, DOI 10.1002/ijc.28722; White BD, 2012, GASTROENTEROLOGY, V142, P219, DOI 10.1053/j.gastro.2011.12.001; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Wu DQ, 2010, TRENDS BIOCHEM SCI, V35, P161, DOI 10.1016/j.tibs.2009.10.002; Yan DW, 2010, BRIT J CANCER, V103, P961, DOI 10.1038/sj.bjc.6605870; Yu HY, 2014, CLIN CANCER RES, V20, P3434, DOI 10.1158/1078-0432.CCR-13-2952	43	69	70	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 30	2017	36	13					1779	1792		10.1038/onc.2016.339	http://dx.doi.org/10.1038/onc.2016.339			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EQ5NF	27641329				2022-12-17	WOS:000398128900004
J	Jiang, YX; Yang, SW; Li, PA; Luo, X; Li, ZY; Hao, YX; Yu, PW				Jiang, Y-X; Yang, S-W; Li, P-A; Luo, X.; Li, Z-Y; Hao, Y-X; Yu, P-W			The promotion of the transformation of quiescent gastric cancer stem cells by IL-17 and the underlying mechanisms	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; TUMOR-GROWTH; T-CELLS; ASSOCIATION; EXPRESSION; STAT3; CD26; HETEROGENEITY; INFLAMMATION; PREVENTION	Postoperative recurrence and metastasis have crucial roles in the poor prognosis of gastric cancer patients. Previous studies have indicated that gastric cancer originates from cancer stem cells (CSCs), and some investigators have found that a particular subset of CSCs possesses higher metastatic capacity. However, the specific mechanism remains uncertain. In the present study, we aimed to explore the biological functions of the inflammatory cytokine interleukin-17 (IL-17) in gastric cancer metastasis and the distinct IL-17-induced transformation of quiescent gastric CSCs. Our results showed that invasive gastric CSCs were CD26+ and CXCR4+ and were closely associated with increased metastatic ability. The quiescent gastric CSCs, which were CD26- and CXCR4-, were exposed to appropriate concentrations of IL-17; this resulted in the decreased expression of E-cadherin and the increased expression of vimentin and N-cadherin. In addition, the upregulation of IL-17 both in vitro and in vivo resulted in a significant induction of invasion, migration and tumor formation ability in gastric CSCs compared with the control group, which was not treated with IL-17. Further experiments indicated that the activation of the downstream phosphorylated signal transducer and activator of transcription 3 (STAT3) transcription factor pathway was facilitated by IL-17. On the contrary, the downregulation of STAT3 by the specific inhibitor Stattic significantly reversed the IL-17-induced epithelial-mesenchymal transition (EMT)-associated properties of quiescent gastric CSCs. Moreover, tumorigenesis and metastasis were suppressed. Taken together, we suggest that IL-17 is positively correlated with the transformation of quiescent gastric CSCs into invasive gastric CSCs and that targeting IL-17 may emerge as a possible novel therapeutic strategy for gastric cancer.	[Jiang, Y-X; Yang, S-W; Li, P-A; Luo, X.; Li, Z-Y; Hao, Y-X; Yu, P-W] Third Mil Med Univ, Southwest Hosp, Ctr Minimal Invas Gastrointestinal Surg, Dept Gen Surg, 30 Gaotanyan St, Chongqing 400038, Peoples R China	Army Medical University	Hao, YX; Yu, PW (corresponding author), Third Mil Med Univ, Southwest Hosp, Ctr Minimal Invas Gastrointestinal Surg, Dept Gen Surg, 30 Gaotanyan St, Chongqing 400038, Peoples R China.	haoyingxue@hotmail.com; yupeiwu01@sina.com			National Natural Science Foundation of China [81372559]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This project was supported by grants from the National Natural Science Foundation of China (81372559).	Bleau AM, 2014, HISTOL HISTOPATHOL, V29, P1499, DOI 10.14670/HH-29.1499; Botelho FM, 2013, J IMMUNOL, V191, P1453, DOI 10.4049/jimmunol.1203318; Das UN, 2011, CANCER METAST REV, V30, P311, DOI 10.1007/s10555-011-9316-x; Davies S, 2015, BIOMED PHARMACOTHER, V71, P135, DOI 10.1016/j.biopha.2015.02.031; Fagoonee S, 2014, PANMINERVA MED, V56, P289; Guo D, 2012, ONCOL REP, V28, P241, DOI 10.3892/or.2012.1781; Guo HQ, 2003, WORLD J GASTROENTERO, V9, P432, DOI 10.3748/wjg.v9.i3.432; Hamada S, 2016, DIGEST DIS SCI, V61, P1561, DOI 10.1007/s10620-015-4001-5; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Herrero R, 2014, JAMA-J AM MED ASSOC, V312, P1197, DOI 10.1001/jama.2014.10498; Huang XC, 2015, ONCOTARGETS THER, V8, P2989, DOI 10.2147/OTT.S91511; Iacopino F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105166; Jinushi M, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.28862; Jung A, 2007, ERNST SCHERING FOUND, V5, P109, DOI 10.1007/2789_2007_047; Lam CSC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098582; Liao WT, 2014, AM J STEM CELLS, V3, P46; Lin L, 2012, INT J CANCER, V130, P1459, DOI 10.1002/ijc.26152; Liu S, 2016, ONCOTARGET, V7, P13651, DOI 10.18632/oncotarget.7296; Liu XS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106834; Long ZW, 2015, WORLD J GASTROENTERO, V21, P5707, DOI 10.3748/wjg.v21.i18.5707; Lu Z, 2013, J RES MED SCI, V18, P647; Ma SB, 2014, CANCER RES, V74, P1969, DOI 10.1158/0008-5472.CAN-13-2534; Magee JA, 2012, CANCER CELL, V21, P283, DOI 10.1016/j.ccr.2012.03.003; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mannello F, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-169; Oliveras-Ferraros C, 2014, CELL CYCLE, V13, P1132, DOI 10.4161/cc.27982; Paganessi LA, 2011, EXP HEMATOL, V39, P384, DOI 10.1016/j.exphem.2010.12.003; Pang R, 2010, CELL STEM CELL, V6, P603, DOI 10.1016/j.stem.2010.04.001; Prabhash K, 2010, ANN ONCOL, V21, P582, DOI 10.1093/annonc/mdp342; Qiao B, 2012, BIOL CELL, V104, P476, DOI 10.1111/boc.201100077; Santisteban M, 2009, CANCER RES, V69, P2887, DOI 10.1158/0008-5472.CAN-08-3343; Wang L, 2009, J EXP MED, V206, P1457, DOI 10.1084/jem.20090207; Wang T, 2015, ONCOTARGET, V6, P30975, DOI 10.18632/oncotarget.5199; Wright MH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1855; Wu X, 2015, TUMOR BIOL, V37, P5493; Yang L, 2011, CANCER LETT, V310, P46, DOI 10.1016/j.canlet.2011.06.003; Zhang X, 2016, ONCOTARGET, V7, P9851; Zhou JB, 2007, P NATL ACAD SCI USA, V104, P16158, DOI 10.1073/pnas.0702596104; Zhu YT, 2014, STEM CELL RES, V13, P111, DOI 10.1016/j.scr.2014.04.006; Zhuang Y, 2012, GASTROENTEROLOGY, V143, P951, DOI 10.1053/j.gastro.2012.06.010	40	69	73	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	9					1256	1264		10.1038/onc.2016.291	http://dx.doi.org/10.1038/onc.2016.291			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2SV	27524415	hybrid, Green Published			2022-12-17	WOS:000395861300009
J	Debruyne, DN; Bhatnagar, N; Sharma, B; Luther, W; Moore, NF; Cheung, K; Gray, NS; George, RE				Debruyne, D. N.; Bhatnagar, N.; Sharma, B.; Luther, W.; Moore, N. F.; Cheung, K.; Gray, N. S.; George, R. E.			ALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma is associated with AXL activation and induction of EMT	ONCOGENE			English	Article							GENE-EXPRESSION SIGNATURE; CANCER-CELLS; THERAPEUTIC TARGET; KINASE INHIBITOR; LUNG-CANCER; RECEPTOR; MUTATIONS; GROWTH; EGFR; MYCN	The crizotinib-resistant ALK(F1174L) mutation arises de novo in neuroblastoma (NB) and is acquired in ALK translocation-driven cancers, lending impetus to the development of novel anaplastic lymphoma kinase (ALK) inhibitors with different modes of action. The diaminopyrimidine TAE684 and its derivative ceritinib (LDK378), which are structurally distinct from crizotinib, are active against NB cells expressing ALK(F1174L). Here we demonstrate acquired resistance to TAE684 and LDK378 in ALK(F1174L)-driven human NB cells that is linked to overexpression and activation of the AXL tyrosine kinase and epithelial-to-mesenchymal transition (EMT). AXL phosphorylation conferred TAE684 resistance to NB cells through upregulated extracellular signal-regulated kinase (ERK) signaling. Inhibition of AXL partly rescued TAE684 resistance, resensitizing these cells to this compound. AXL activation in resistant cells was mediated through increased expression of the active form of its ligand, GAS6, that also served to stabilize the AXL protein. Although ectopic expression of AXL and TWIST2 individually in TAE684-sensitive parental cells led to the elevated expression of mesenchymal markers and invasive capacity, only AXL overexpression induced resistance to TAE684 as well. TAE684-resistant cells showed greater sensitivity to HSP90 inhibition than did their parental counterparts, with downregulation of AXL and AXL-mediated ERK signaling. Our studies indicate that aberrant AXL signaling and development of an EMT phenotype underlie resistance of ALK(F1174L)-driven NB cells to TAE684 and its derivatives. We suggest that the combination of ALK and AXL or HSP90 inhibitors be considered to delay the emergence of such resistance.	[Debruyne, D. N.; Bhatnagar, N.; Sharma, B.; Luther, W.; Moore, N. F.; George, R. E.] Dana Farber Canc Inst, Dept Pediat Hematol Oncol, Boston, MA 02115 USA; [Debruyne, D. N.; Bhatnagar, N.; Sharma, B.; Luther, W.; Moore, N. F.; George, R. E.] Boston Childrens Hosp, Boston, MA USA; [Cheung, K.] Mem Sloan Kettering Canc Ctr, Dept Pediat Oncol, 1275 York Ave, New York, NY 10021 USA; [Gray, N. S.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; [Gray, N. S.] Harvard Med Sch, Dept Biol Chem & Mol Pharmacol, Boston, MA USA; [George, R. E.] Harvard Med Sch, Dept Pediat, Boston, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Memorial Sloan Kettering Cancer Center; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	George, RE (corresponding author), Dana Farber Canc Inst, Dept Pediat Oncol, Dana 640E,450 Brookline Ave, Boston, MA 02215 USA.	rani_george@dfci.harvard.edu	George, Rani/AAG-7635-2019		NIH/NCI [R01 CA148688]; Friends for Life Neuroblastoma Fellowship; Ruth L Kirschstein NRSA [F32CA183566]; NATIONAL CANCER INSTITUTE [R01CA148688, P30CA008748] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Friends for Life Neuroblastoma Fellowship; Ruth L Kirschstein NRSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by NIH/NCI R01 CA148688 (to REG), Friends for Life Neuroblastoma Fellowship (to DND) and a Ruth L Kirschstein NRSA F32CA183566 (to NFM).	Anastassiou D, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-529; Berry T, 2012, CANCER CELL, V22, P117, DOI 10.1016/j.ccr.2012.06.001; Blick T, 2010, J MAMMARY GLAND BIOL, V15, P235, DOI 10.1007/s10911-010-9175-z; Bresler SC, 2014, CANCER CELL, V26, P682, DOI 10.1016/j.ccell.2014.09.019; Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558; Chen JY, 2013, J MED CHEM, V56, P5673, DOI 10.1021/jm401005u; Chen YY, 2008, NATURE, V455, P971, DOI 10.1038/nature07399; De Brouwer S, 2010, CLIN CANCER RES, V16, P4353, DOI 10.1158/1078-0432.CCR-09-2660; Duijkers FAM, 2013, GENE, V521, P62, DOI 10.1016/j.gene.2013.03.029; Eleveld TF, 2015, NAT GENET, V47, P864, DOI 10.1038/ng.3333; Fridell YWC, 1996, MOL CELL BIOL, V16, P135; Gainor JF, 2013, J CLIN ONCOL, V31, P3987, DOI 10.1200/JCO.2012.45.2029; Galkin AV, 2007, P NATL ACAD SCI USA, V104, P270, DOI 10.1073/pnas.0609412103; George RE, 2008, NATURE, V455, P975, DOI 10.1038/nature07397; Giles KM, 2013, MOL CANCER THER, V12, P2541, DOI 10.1158/1535-7163.MCT-13-0170; Gjerdrum C, 2010, P NATL ACAD SCI USA, V107, P1124, DOI 10.1073/pnas.0909333107; Goruppi S, 1997, FEBS LETT, V415, P59, DOI 10.1016/S0014-5793(97)01093-4; GRECO WR, 1995, PHARMACOL REV, V47, P331; Heuckmann JM, 2011, CLIN CANCER RES, V17, P7394, DOI 10.1158/1078-0432.CCR-11-1648; Holland SJ, 2010, CANCER RES, V70, P1544, DOI 10.1158/0008-5472.CAN-09-2997; Hong J, 2013, CANCER RES, V73, P331, DOI 10.1158/0008-5472.CAN-12-3151; Janoueix-Lerosey I, 2008, NATURE, V455, P967, DOI 10.1038/nature07398; Kim HR, 2013, MOL ONCOL, V7, P1093, DOI 10.1016/j.molonc.2013.08.001; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Korshunov VA, 2012, CLIN SCI, V122, P361, DOI 10.1042/CS20110411; Krishnamoorthy GP, 2013, J BIOL CHEM, V288, P17481, DOI 10.1074/jbc.M112.439422; Lemke G, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a009076; Liu L, 2009, CANCER RES, V69, P6871, DOI 10.1158/0008-5472.CAN-08-4490; Mahon FX, 2000, BLOOD, V96, P1070, DOI 10.1182/blood.V96.3.1070.015k17_1070_1079; Mark MR, 1996, J BIOL CHEM, V271, P9785, DOI 10.1074/jbc.271.16.9785; Mosse YP, 2008, NATURE, V455, P930, DOI 10.1038/nature07261; Mudduluru G, 2011, ONCOGENE, V30, P2888, DOI 10.1038/onc.2011.13; Mudduluru G, 2008, BIOSCIENCE REP, V28, P161, DOI 10.1042/BSR20080046; Normant E, 2011, ONCOGENE, V30, P2581, DOI 10.1038/onc.2010.625; Reich M, 2006, NAT GENET, V38, P500, DOI 10.1038/ng0506-500; Sakamoto H, 2011, CANCER CELL, V19, P679, DOI 10.1016/j.ccr.2011.04.004; Sasaki T, 2010, CANCER RES, V70, P10038, DOI 10.1158/0008-5472.CAN-10-2956; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Stenhoff J, 2004, BIOCHEM BIOPH RES CO, V319, P871, DOI 10.1016/j.bbrc.2004.05.070; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Vajkoczy P, 2006, P NATL ACAD SCI USA, V103, P5799, DOI 10.1073/pnas.0510923103; Vuoriluoto K, 2011, ONCOGENE, V30, P1436, DOI 10.1038/onc.2010.509; Wilson C, 2014, CANCER RES, V74, P5878, DOI 10.1158/0008-5472.CAN-14-1009; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Wu ZX, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.016675; Zhang ZF, 2012, NAT GENET, V44, P852, DOI 10.1038/ng.2330	47	69	73	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2016	35	28					3681	3691		10.1038/onc.2015.434	http://dx.doi.org/10.1038/onc.2015.434			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UQ	26616860	Green Accepted, Green Published, hybrid			2022-12-17	WOS:000379622800007
J	Blanco, FF; Jimbo, M; Wulfkuhle, J; Gallagher, I; Deng, J; Enyenihi, L; Meisner-Kober, N; Londin, E; Rigoutsos, I; Sawicki, JA; Risbud, MV; Witkiewicz, AK; Mccue, PA; Jiang, W; Rui, H; Yeo, CJ; Petricoin, E; Winter, JM; Brody, JR				Blanco, F. F.; Jimbo, M.; Wulfkuhle, J.; Gallagher, I.; Deng, J.; Enyenihi, L.; Meisner-Kober, N.; Londin, E.; Rigoutsos, I.; Sawicki, J. A.; Risbud, M. V.; Witkiewicz, A. K.; Mccue, P. A.; Jiang, W.; Rui, H.; Yeo, C. J.; Petricoin, E.; Winter, J. M.; Brody, J. R.			The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells	ONCOGENE			English	Article							PATHWAY ACTIVATION; STABILITY FACTOR; GENE-EXPRESSION; TUMOR HYPOXIA; KINASE PIM-1; C-MYC; GROWTH; GEMCITABINE; LEUKEMIA; TARGET	Previously, it has been shown that pancreatic ductal adenocarcinoma (PDA) tumors exhibit high levels of hypoxia, characterized by low oxygen pressure (pO(2)) and decreased O-2 intracellular perfusion. Chronic hypoxia is strongly associated with resistance to cytotoxic chemotherapy and chemoradiation in an understudied phenomenon known as hypoxia-induced chemoresistance. The hypoxia-inducible, pro-oncogenic, serine-threonine kinase PIM1 (Proviral Integration site for Moloney murine leukemia virus 1) has emerged as a key regulator of hypoxia-induced chemoresistance in PDA and other cancers. Although its role in therapeutic resistance has been described previously, the molecular mechanism behind PIM1 overexpression in PDA is unknown. Here, we demonstrate that cis-acting AU-rich elements (ARE) present within a 38-base pair region of the PIM1 mRNA 3'-untranslated region mediate a regulatory interaction with the mRNA stability factor HuR (Hu antigen R) in the context of tumor hypoxia. Predominantly expressed in the nucleus in PDA cells, HuR translocates to the cytoplasm in response to hypoxic stress and stabilizes the PIM1 mRNA transcript, resulting in PIM1 protein overexpression. A reverse-phase protein array revealed that HuR-mediated regulation of PIM1 protects cells from hypoxic stress through phosphorylation and inactivation of the apoptotic effector BAD and activation of MEK1/2. Importantly, pharmacological inhibition of HuR by MS-444 inhibits HuR homodimerization and its cytoplasmic translocation, abrogates hypoxia-induced PIM1 overexpression and markedly enhances PDA cell sensitivity to oxaliplatin and 5-fluorouracil under physiologic low oxygen conditions. Taken together, these results support the notion that HuR has prosurvival properties in PDA cells by enabling them with growth advantages in stressful tumor microenvironment niches. Accordingly, these studies provide evidence that therapeutic disruption of HuR's regulation of PIM1 may be a key strategy in breaking an elusive chemotherapeutic resistance mechanism acquired by PDA cells that reside in hypoxic PDA microenvironments.	[Blanco, F. F.] Thomas Jefferson Univ, Div Clin Pharmacol, Dept Pharmacol & Expt Therapeut, Philadelphia, PA 19107 USA; [Blanco, F. F.; Jimbo, M.; Enyenihi, L.; Yeo, C. J.; Winter, J. M.; Brody, J. R.] Thomas Jefferson Univ, Dept Surg, 1015 Walnut St,Suite 618,Curtis Bldg, Philadelphia, PA 19107 USA; [Wulfkuhle, J.; Gallagher, I.; Deng, J.; Petricoin, E.] George Mason Univ, Ctr Appl Prote & Mol Med, Sch Syst Biol, Manassas, VA USA; [Meisner-Kober, N.] Novartis, Novartis Inst Biomed Res, Basel, Switzerland; [Londin, E.; Rigoutsos, I.] Thomas Jefferson Univ, Ctr Computat Med, Philadelphia, PA 19107 USA; [Sawicki, J. A.] Lankenau Inst Med Res, Philadelphia, PA USA; [Risbud, M. V.] Thomas Jefferson Univ, Dept Orthoped Surg, Philadelphia, PA 19107 USA; [Witkiewicz, A. K.] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA; [Mccue, P. A.; Jiang, W.] Thomas Jefferson Univ, Dept Pathol, Philadelphia, PA 19107 USA; [Rui, H.] Thomas Jefferson Univ, Dept Canc Biol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University; George Mason University; Novartis; Jefferson University; Lankenau Medical Center; Lankenau Institute for Medical Research; Jefferson University; University of Texas System; University of Texas Southwestern Medical Center Dallas; Jefferson University; Jefferson University	Brody, JR (corresponding author), Thomas Jefferson Univ, Dept Surg, 1015 Walnut St,Suite 618,Curtis Bldg, Philadelphia, PA 19107 USA.	jonathan.brody@jefferson.edu	Rigoutsos, Isidore/C-5381-2012; Meisner-Kober, Nicole/AFL-9351-2022; Meisner-Kober, Nicole/AAH-1412-2022	Meisner-Kober, Nicole/0000-0003-0912-5902; Enyenihi, Liz/0000-0001-6952-1515; Rigoutsos, Isidore/0000-0003-1529-8631; Londin, Eric/0000-0003-4331-6366	NIH-NIGMS [T32 GM008562 20]; NIH-NCI [R21 CA182692 01A1]; American Cancer Society [MRSG-14-019-01-CDD]; Mary Halinski Pancreatic Cancer Research Fund; Hirshberg Foundation; NATIONAL CANCER INSTITUTE [R21CA182692] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008562] Funding Source: NIH RePORTER	NIH-NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIH-NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); Mary Halinski Pancreatic Cancer Research Fund; Hirshberg Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We acknowledge the TJU's Bioimaging core for their assistance with confocal image acquisition and analysis. We also acknowledge Zachary Schoepflin at the TJU Department of Orthopedic Surgery for his assistance with hypoxia chambers. This work was supported by NIH-NIGMS T32 GM008562 20 (to FFB), NIH-NCI R21 CA182692 01A1 (to JRB), American Cancer Society MRSG-14-019-01-CDD (to JMW), the Mary Halinski Pancreatic Cancer Research Fund (to JRB) and the Hirshberg Foundation (to JRB, JW).	ACS, 2014, CANC FACTS FIG 2013; Aho TLT, 2004, FEBS LETT, V571, P43, DOI 10.1016/j.febslet.2004.06.050; Anderson ARA, 2006, CELL, V127, P905, DOI 10.1016/j.cell.2006.09.042; Ayala GE, 2004, CANCER RES, V64, P6082, DOI 10.1158/0008-5472.CAN-04-0838; Bachmann M, 2004, J BIOL CHEM, V279, P48319, DOI 10.1074/jbc.M404440200; Bermudez O, 2011, J CELL PHYSIOL, V226, P276, DOI 10.1002/jcp.22339; Blanco FF, 2014, MOL CELL BIOL, V34, P180, DOI 10.1128/MCB.01020-13; Block KM, 2012, PANCREAS, V41, P773, DOI 10.1097/MPA.0b013e31823cdd10; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Brody JR, 2011, WIRES RNA, V2, P435, DOI 10.1002/wrna.62; Buchler P, 2004, J SURG RES, V120, P295, DOI 10.1016/j.jss.2004.02.014; Burkhart RA, 2013, RNA BIOL, V10, P1312, DOI 10.4161/rna.25274; Calaluce R, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-126; Chang Q, 2011, CANCER RES, V71, P3110, DOI 10.1158/0008-5472.CAN-10-4049; Chen J, 2009, ONCOGENE, V28, P2581, DOI 10.1038/onc.2009.124; Chen J, 2009, AM J PATHOL, V175, P400, DOI 10.2353/ajpath.2009.080972; Chen LS, 2009, BLOOD, V114, P4150, DOI 10.1182/blood-2009-03-212852; Chou CW, 2012, NEURO-ONCOLOGY, V14, P1227, DOI 10.1093/neuonc/nos195; Cohen AM, 2004, LEUKEMIA LYMPHOMA, V45, P951, DOI 10.1080/10428190310001641251; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Costantino CL, 2009, CANCER RES, V69, P4567, DOI 10.1158/0008-5472.CAN-09-0371; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI12973; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Federici G, 2013, MOL CANCER RES, V11, P676, DOI 10.1158/1541-7786.MCR-12-0690; Flamant L, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-391; Ghosh M, 2009, J CLIN INVEST, V119, P3530, DOI 10.1172/JCI38263; Harrison LB, 2002, ONCOLOGIST, V7, P492, DOI 10.1634/theoncologist.7-6-492; Hsi ED, 2008, LEUKEMIA LYMPHOMA, V49, P2081, DOI 10.1080/10428190802419640; Humar R, 2002, FASEB J, V16, DOI 10.1096/fj.01-0658com; Improta G, 2011, J PROTEOME RES, V10, P3089, DOI 10.1021/pr200065t; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Kishore S, 2011, NAT METHODS, V8, P559, DOI [10.1038/nmeth.1608, 10.1038/NMETH.1608]; Koong AC, 2000, INT J RADIAT ONCOL, V48, P919, DOI 10.1016/S0360-3016(00)00803-8; Kurosu T, 2011, BRIT J CANCER, V104, P819, DOI 10.1038/bjc.2011.20; Lal S, 2014, CANCER RES, V74, P1128, DOI 10.1158/0008-5472.CAN-13-1915; Lara PC, 2009, RADIAT ONCOL, V4, DOI 10.1186/1748-717X-4-29; Liao WL, 2011, J BIOL CHEM, V286, P35499, DOI 10.1074/jbc.M111.263582; Liu L, 2014, MOL BIOL CELL, V25, P3308, DOI 10.1091/mbc.E14-03-0853; Magnuson NS, 2010, FUTURE ONCOL, V6, P1461, DOI 10.2217/FON.10.106; Martelli M, 2008, CRIT REV ONCOL HEMAT, V68, P256, DOI 10.1016/j.critrevonc.2008.07.020; Meisner NC, 2007, NAT CHEM BIOL, V3, P508, DOI 10.1038/nchembio.2007.14; Miyata Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059095; Mochizuki T, 1999, J BIOL CHEM, V274, P18659, DOI 10.1074/jbc.274.26.18659; Mukherjee N, 2011, MOL CELL, V43, P327, DOI 10.1016/j.molcel.2011.06.007; Nabors LB, 2001, CANCER RES, V61, P2154; Pineda DM, 2012, CANCER BIOL THER, V13, P946, DOI 10.4161/cbt.20952; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Reiser-Erkan C, 2008, CANCER BIOL THER, V7, P1352, DOI 10.4161/cbt.7.9.6418; Richards NG, 2010, ANN SURG, V252, P499, DOI 10.1097/SLA.0b013e3181f1fd44; Selvendiran K, 2009, INT J CANCER, V125, P2198, DOI 10.1002/ijc.24601; Shay KP, 2005, MOL CANCER RES, V3, P170; Sullivan R, 2008, MOL CANCER THER, V7, P1961, DOI 10.1158/1535-7163.MCT-08-0198; Tamburini J, 2009, BLOOD, V114, P1618, DOI 10.1182/blood-2008-10-184515; Tholey RM, 2015, MOL CANCER RES, V13, P439, DOI 10.1158/1541-7786.MCR-14-0199; Tu ML, 2011, LIFE SCI, V88, P233, DOI 10.1016/j.lfs.2010.12.001; Vineis P, 2010, CARCINOGENESIS, V31, P1703, DOI 10.1093/carcin/bgq087; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369; Wang J, 2010, ONCOGENE, V29, P2477, DOI 10.1038/onc.2010.10; Wang PY, 2010, BIOCHEM J, V426, P293, DOI 10.1042/BJ20091459; Wu XQ, 2015, ACS CHEM BIOL, V10, P1476, DOI 10.1021/cb500851u; Xu DP, 2011, CARCINOGENESIS, V32, P488, DOI 10.1093/carcin/bgr007; Yiakouvaki A, 2012, J CLIN INVEST, V122, P48, DOI 10.1172/JCI45021; Young LE, 2012, MOL CANCER RES, V10, P167, DOI 10.1158/1541-7786.MCR-11-0337; Young LE, 2010, CURR COLORECT CANC R, V6, P60, DOI 10.1007/s11888-010-0044-3; Young LE, 2009, GASTROENTEROLOGY, V136, P1669, DOI 10.1053/j.gastro.2009.01.010; Zhu HF, 2015, MOL CANCER RES, V13, P809, DOI 10.1158/1541-7786.MCR-14-0241; Zhu Y, 2002, BRIT J HAEMATOL, V119, P905, DOI 10.1046/j.1365-2141.2002.03931.x; Zou J, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-3	69	69	73	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2016	35	19					2529	2541		10.1038/onc.2015.325	http://dx.doi.org/10.1038/onc.2015.325			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GQ	26387536	Green Accepted			2022-12-17	WOS:000376165500011
J	Poria, DK; Guha, A; Nandi, I; Ray, PS				Poria, D. K.; Guha, A.; Nandi, I.; Ray, P. S.			RNA-binding protein HuR sequesters microRNA-21 to prevent translation repression of proinflammatory tumor suppressor gene programmed cell death 4	ONCOGENE			English	Article							MESSENGER-RNA; EXPRESSION; PDCD4; MECHANISMS; STRESS; MIR-21; TARGET; SWITCH; VEGFA; DECOY	Translation control of proinflammatory genes has a crucial role in regulating the inflammatory response and preventing chronic inflammation, including a transition to cancer. The proinflammatory tumor suppressor protein programmed cell death 4 (PDCD4) is important for maintaining the balance between inflammation and tumorigenesis. PDCD4 messenger RNA translation is inhibited by the oncogenic microRNA, miR-21. AU-rich element-binding protein HuR was found to interact with the PDCD4 3'-untranslated region (UTR) and prevent miR-21-mediated repression of PDCD4 translation. Cells stably expressing miR-21 showed higher proliferation and reduced apoptosis, which was reversed by HuR expression. Inflammatory stimulus caused nuclear-cytoplasmic relocalization of HuR, reversing the translation repression of PDCD4. Unprecedentedly, HuR was also found to bind to miR-21 directly, preventing its interaction with the PDCD4 3'-UTR, thereby preventing the translation repression of PDCD4. This suggests that HuR might act as a 'miRNA sponge' to regulate miRNA-mediated translation regulation under conditions of stress-induced nuclear-cytoplasmic translocation of HuR, which would allow fine-tuned gene expression in complex regulatory environments.	[Poria, D. K.; Guha, A.; Nandi, I.; Ray, P. S.] Indian Inst Sci Educ & Res, Dept Biol Sci, Kolkata, India	Indian Institute of Science Education & Research (IISER) - Kolkata	Ray, PS (corresponding author), Indian Inst Sci Educ & Res, Dept Biol Sci, Mohanpur Campus, Nadia 741246, W Bengal, India.	psray@iiserkol.ac.in	Poria, Dipak Kumar/AAM-2084-2021; Ray, Partho Sarothi/H-3020-2019	Poria, Dipak Kumar/0000-0002-6935-4160; Ray, Partho Sarothi/0000-0002-8795-3060; Guha, Abhishek/0000-0003-2767-9941; Nandi, Ipsita/0000-0002-4502-2559	Wellcome Trust-DBT India Alliance intermediate fellowship [WT500139/Z/09/Z]; CSIR senior research fellowship; IISER PBIP fellowship	Wellcome Trust-DBT India Alliance intermediate fellowship(Wellcome Trust DBT India Alliance); CSIR senior research fellowship(Council of Scientific & Industrial Research (CSIR) - India); IISER PBIP fellowship	We acknowledge P L Fox (Cleveland Clinic), S Das (IISc Bangalore), S N Bhattacharyya (IICB, Kolkata), D Chattopadhyay (University of Calcutta) and S Sengupta (University of Calcutta) for providing reagents and laboratory facilities. We are thankful to LRI Molecular Biotechnology Core for services provided. This work was supported by a Wellcome Trust-DBT India Alliance intermediate fellowship (WT500139/Z/09/Z) to PSR, a CSIR senior research fellowship to DKP and IISER PBIP fellowship to AG.	Abdelmohsen K, 2008, BIOL CHEM, V389, P243, DOI 10.1515/BC.2008.022; Abdelmohsen K, 2009, EMBO J, V28, P1271, DOI 10.1038/emboj.2009.67; Anderson P, 2010, NAT REV IMMUNOL, V10, P24, DOI 10.1038/nri2685; Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; Balkhi MY, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004177; Bhattacharyya SN, 2006, CELL, V125, P1111, DOI 10.1016/j.cell.2006.04.031; Biyanee A, 2015, ONCOGENE, V34, P1384, DOI 10.1038/onc.2014.83; Dormoy-Raclet V, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3388; Ebert MS, 2010, CURR BIOL, V20, pR858, DOI 10.1016/j.cub.2010.08.052; Eiring AM, 2010, CELL, V140, P652, DOI 10.1016/j.cell.2010.01.007; Epis MR, 2011, J BIOL CHEM, V286, P41442, DOI 10.1074/jbc.M111.301481; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Frankel LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200; Gebauer F, 2004, NAT REV MOL CELL BIO, V5, P827, DOI 10.1038/nrm1488; Hilliard A, 2006, J IMMUNOL, V177, P8095, DOI 10.4049/jimmunol.177.11.8095; Hinman MN, 2008, CELL MOL LIFE SCI, V65, P3168, DOI 10.1007/s00018-008-8252-6; Jafarifar F, 2011, EMBO J, V30, P1324, DOI 10.1038/emboj.2011.38; Kedde M, 2010, NAT CELL BIOL, V12, P1014, DOI 10.1038/ncb2105; Lankat-Buttgereit B, 2009, BIOL CELL, V101, P309, DOI 10.1042/BC20080191; Lebedeva S, 2011, MOL CELL, V43, P340, DOI 10.1016/j.molcel.2011.06.008; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lu Z, 2008, ONCOGENE, V27, P4373, DOI 10.1038/onc.2008.72; Mukherjee N, 2011, MOL CELL, V43, P327, DOI 10.1016/j.molcel.2011.06.007; Ray PS, 2009, NATURE, V457, P915, DOI 10.1038/nature07598; Ray PS, 2002, NUCLEIC ACIDS RES, V30, P4500, DOI 10.1093/nar/gkf583; Sheedy FJ, 2010, NAT IMMUNOL, V11, P141, DOI 10.1038/ni.1828; Si ML, 2007, ONCOGENE, V26, P2799, DOI 10.1038/sj.onc.1210083; Srikantan S, 2012, CURR PROTEIN PEPT SC, V13, P372, DOI 10.2174/138920312801619394; Srikantan S, 2011, MOL CELL BIOL, V31, P3790, DOI 10.1128/MCB.05639-11; Tominaga K, 2011, MOL CELL BIOL, V31, P4219, DOI 10.1128/MCB.05955-11; Uren PJ, 2011, J BIOL CHEM, V286, P37063, DOI 10.1074/jbc.C111.266882; van Kouwenhove M, 2011, NAT REV CANCER, V11, P644, DOI 10.1038/nrc3107; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Yao P, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001635; Young LE, 2012, MOL CANCER RES, V10, P167, DOI 10.1158/1541-7786.MCR-11-0337	35	69	73	3	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2016	35	13					1703	1715		10.1038/onc.2015.235	http://dx.doi.org/10.1038/onc.2015.235			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RP	26189797	Green Published, hybrid			2022-12-17	WOS:000373064200009
J	Xu, Q; Liu, LZ; Yin, Y; He, J; Li, Q; Qian, X; You, Y; Lu, Z; Peiper, SC; Shu, Y; Jiang, BH				Xu, Q.; Liu, L-Z; Yin, Y.; He, J.; Li, Q.; Qian, X.; You, Y.; Lu, Z.; Peiper, S. C.; Shu, Y.; Jiang, B-H			Regulatory circuit of PKM2/NF-kappa B/miR-148a/152-modulated tumor angiogenesis and cancer progression	ONCOGENE			English	Article							PYRUVATE-KINASE M2; GENE-TRANSCRIPTION; GLUCOSE-METABOLISM; GROWTH; PROMOTES; CELLS; PKM2; APOPTOSIS; INSULIN; TRANSFORMATION	Upregulation of the embryonic M2 isoform of pyruvate kinase (PKM2) emerges as a critical player in the cancer development and metabolism, yet the underlying mechanism of PKM2 overexpression remains to be elucidated. Here we demonstrate that IGF-1/IGF-IR regulates PKM2 expression by enhancing HIF-1 alpha-p65 complex binding to PKM2 promoter. PKM2 expression is regulated by miR-148a/152 suppression. PKM2 directly interacts with NF-kappa B p65 subunit to promote EGR1 expression for regulating miR-148a/152 feedback circuit in normal cells, but not in cancer cells because of the DNA hypermethylation of miR-148a and miR-152 gene promoters. The silencing of miR-148a/152 contributes to the overexpression of PKM2, NF-kappa B or/and IGF-IR in some cancer cells. We show that disruption of PKM2/NF-kappa B/miR-148a/152 feedback loop can regulate cancer cell growth and angiogenesis, and is also associated with triple-negative breast cancer (TNBC) phenotype, which may have clinical implication for providing novel biomarker(s) of TNBC and potential therapeutic target(s) in the future.	[Xu, Q.; Li, Q.; Qian, X.; Jiang, B-H] Nanjing Med Univ, Collaborat Innovat Ctr Canc Personalized Med, State Key Lab Reprod Med, Dept Pathol,Canc Ctr, Nanjing, Jiangsu, Peoples R China; [Liu, L-Z; He, J.; Peiper, S. C.; Jiang, B-H] Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; [Shu, Y.] Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, Collaborat Innovat Ctr Canc Personalized Med,Canc, Nanjing, Jiangsu, Peoples R China; [You, Y.] Nanjing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China; [Lu, Z.] Univ Texas MD Anderson Canc Ctr, Brain Tumor Ctr, Houston, TX 77030 USA; [Lu, Z.] Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; [Yin, Y.] Anhui Med Univ, Dept Pathol, Hefei, Peoples R China	Nanjing Medical University; Jefferson University; Nanjing Medical University; Nanjing Medical University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Anhui Medical University	Shu, Y (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, Nanjing, Jiangsu, Peoples R China.	shuyongqian@csco.org.cn; binghjiang@yahoo.com	Shu, Yongqian/ABD-5698-2021	Liu, Ling-Zhi/0000-0001-9234-457X; Jiang, Bing-Hua/0000-0003-4526-2031; He, Jun/0000-0002-5162-6041; Hartl, Carla/0000-0001-9769-7462	National Natural Science Foundation of China [81320108019, 81270736, 81071642]; Jiangsu Province Clinical Science and Technology Project [BL2012008]; Priority Academic Program Development of Jiangsu Higher Education Institutions [JX10231801]; Jiangsu Province's Key Discipline of Medicine [XK201117]; National Institutes of Health [R01ES020868, R21CA175975]; NATIONAL CANCER INSTITUTE [R21CA175975] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES020868] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Jiangsu Province Clinical Science and Technology Project; Priority Academic Program Development of Jiangsu Higher Education Institutions; Jiangsu Province's Key Discipline of Medicine; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported in part by National Natural Science Foundation of China (81320108019, 81270736, 81071642), by Jiangsu Province Clinical Science and Technology Project (BL2012008), the Priority Academic Program Development of Jiangsu Higher Education Institutions (JX10231801), Jiangsu Province's Key Discipline of Medicine (XK201117), and by National Institutes of Health grants R01ES020868 and R21CA175975.	Badve S, 2011, MODERN PATHOL, V24, P157, DOI 10.1038/modpathol.2010.200; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Christofk HR, 2008, NATURE, V452, P181, DOI 10.1038/nature06667; Ferguson EC, 2008, TRENDS BIOCHEM SCI, V33, P359, DOI 10.1016/j.tibs.2008.05.006; Gao XL, 2012, MOL CELL, V45, P598, DOI 10.1016/j.molcel.2012.01.001; GULER HP, 1987, NEW ENGL J MED, V317, P137, DOI 10.1056/NEJM198707163170303; Hitosugi T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000431; Iqbal MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036764; Jung CJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027740; Kefas B, 2010, NEURO-ONCOLOGY, V12, P1102, DOI 10.1093/neuonc/noq080; Kitamura K, 2011, J HEPATOL, V55, P846, DOI 10.1016/j.jhep.2011.01.038; Kosugi M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028234; Kwon OH, 2012, BIOCHEM BIOPH RES CO, V423, P38, DOI 10.1016/j.bbrc.2012.05.063; Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251; Liu CT, 1998, CANCER GENE THER, V5, P3; Liu XG, 2010, J IMMUNOL, V185, P7244, DOI 10.4049/jimmunol.1001573; Luo WB, 2011, CELL, V145, P732, DOI 10.1016/j.cell.2011.03.054; Lv L, 2011, MOL CELL, V42, P719, DOI 10.1016/j.molcel.2011.04.025; Macintyre AN, 2011, MOL CELL, V42, P713, DOI 10.1016/j.molcel.2011.06.003; Mazurek S, 2003, ANTICANCER RES, V23, P1149; Mitsiades CS, 2004, CANCER CELL, V5, P221, DOI 10.1016/S1535-6108(04)00050-9; Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536; Portales-Casamar E, 2010, NUCLEIC ACIDS RES, V38, pD105, DOI 10.1093/nar/gkp950; Schmidt M, 2010, J CANCER RES CLIN, V136, P219, DOI 10.1007/s00432-009-0652-y; Schultz NA, 2012, WORLD J SURG, V36, P2699, DOI 10.1007/s00268-012-1705-y; Sun QA, 2011, P NATL ACAD SCI USA, V108, P4129, DOI 10.1073/pnas.1014769108; Takahashi M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046684; Tamada M, 2012, CANCER RES, V72, P1438, DOI 10.1158/0008-5472.CAN-11-3024; Thyss R, 2005, EMBO J, V24, P128, DOI 10.1038/sj.emboj.7600501; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Xu Q, 2013, J MOL CELL BIOL, V5, P3, DOI 10.1093/jmcb/mjs049; Yang WW, 2012, MOL CELL, V48, P771, DOI 10.1016/j.molcel.2012.09.028; Yang WW, 2012, CELL, V150, P685, DOI 10.1016/j.cell.2012.07.018; Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598; Zhang H, 2011, CELL DEATH DIFFER, V18, P1702, DOI 10.1038/cdd.2011.28; Zhang R, 2014, TUMOR BIOL, V35, P837, DOI 10.1007/s13277-013-1115-2	36	69	72	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2015	34	43					5482	5493		10.1038/onc.2015.6	http://dx.doi.org/10.1038/onc.2015.6			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU4EM	25703326				2022-12-17	WOS:000363479700008
J	Althoff, K; Beckers, A; Bell, E; Nortmeyer, M; Thor, T; Sprussel, A; Lindner, S; De Preter, K; Florin, A; Heukamp, LC; Klein-Hitpass, L; Astrahantseff, K; Kumps, C; Speleman, F; Eggert, A; Westermann, F; Schramm, A; Schulte, JH				Althoff, K.; Beckers, A.; Bell, E.; Nortmeyer, M.; Thor, T.; Spruessel, A.; Lindner, S.; De Preter, K.; Florin, A.; Heukamp, L. C.; Klein-Hitpass, L.; Astrahantseff, K.; Kumps, C.; Speleman, F.; Eggert, A.; Westermann, F.; Schramm, A.; Schulte, J. H.			A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies	ONCOGENE			English	Article							RISK STRATIFICATION; MIRNA EXPRESSION; GENE-EXPRESSION; P-TEFB; DIFFERENTIATION; PROGRESSION; PHENOTYPE; BIOLOGY; GAINS	Neuroblastoma, a childhood cancer that originates from neural crest-derived cells, is the most common deadly solid tumor of infancy. Amplification of the MYCN oncogene, which occurs in approximately 20-25% of human neuroblastomas, is the most prominent genetic marker of high-stage disease. The availability of valid preclinical in vivo models is a prerequisite to develop novel targeted therapies. We here report on the generation of transgenic mice with Cre-conditional induction of MYCN in dopamine a-hydroxylase-expressing cells, termed LSL-MYCN; Dbh-iCre. These mice develop neuroblastic tumors with an incidence of 475%, regardless of strain background. Molecular profiling of tumors revealed upregulation of the MYCN-dependent miR-17-92 cluster as well as expression of neuroblastoma marker genes, including tyrosine hydroxylase and the neural cell adhesion molecule 1. Gene set enrichment analyses demonstrated significant correlation with MYC-associated expression patterns. Array comparative genome hybridization showed that chromosomal aberrations in LSL-MYCN; Dbh-iCre tumors were syntenic to those observed in human neuroblastomas. Treatment of a cell line established from a tumor derived from a LSL-MYCN; Dbh-iCre mouse with JQ1 or MLN8237 reduced cell viability and demonstrated oncogene addiction to MYCN. Here we report establishment of the first Cre-conditional human MYCN-driven mouse model for neuroblastoma that closely recapitulates the human disease with respect to tumor localization, histology, marker expression and genomic make up. This mouse model is a valuable tool for further functional studies and to assess the effect of targeted therapies.	[Althoff, K.; Thor, T.; Spruessel, A.; Lindner, S.; Schramm, A.; Schulte, J. H.] Univ Childrens Hosp Essen, Dept Pediat Oncol & Haematol, D-45122 Essen, Germany; [Althoff, K.; Thor, T.; Spruessel, A.; Lindner, S.; Schulte, J. H.] German Canc Consortium DKTK, Hufelandstr, Germany; [Beckers, A.; De Preter, K.; Kumps, C.; Speleman, F.; Schulte, J. H.] Ghent Univ Hosp, Ctr Med Genet Ghent, Ghent, Belgium; [Bell, E.; Nortmeyer, M.; Thor, T.; Spruessel, A.; Lindner, S.; Westermann, F.; Schulte, J. H.] German Canc Res Ctr, Heidelberg, Germany; [Thor, T.; Spruessel, A.; Lindner, S.; Schulte, J. H.] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Translat Neurooncol, Essen, Germany; [Florin, A.; Heukamp, L. C.] Univ Hosp Cologne, Inst Pathol, Cologne, Germany; [Heukamp, L. C.] Blackfield AG, New Oncol, Cologne, Germany; [Klein-Hitpass, L.] Univ Duisburg Essen, Fac Med, Inst Cell Biol Canc Res, Essen, Germany; [Astrahantseff, K.; Eggert, A.] Charite, Dept Pediat Oncol Hematol & BMT, D-13353 Berlin, Germany	University of Duisburg Essen; Helmholtz Association; German Cancer Research Center (DKFZ); Ghent University; Ghent University Hospital; Helmholtz Association; German Cancer Research Center (DKFZ); University of Duisburg Essen; University of Cologne; University of Duisburg Essen; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Schulte, JH (corresponding author), Univ Childrens Hosp Essen, Dept Pediat Oncol & Haematol, Hufeland St 55, D-45122 Essen, Germany.	Johannes.schulte@uni-due.de	Eggert, Angelika/AAE-6907-2022; speleman, frank/AAR-5184-2020; Schulte, Johannes H./V-2474-2018; De Preter, Katleen/I-7135-2013; Schramm, Alexander/G-5688-2010; Westermann, Frank/F-7509-2013; Heukamp, Lukas/G-9967-2012	Eggert, Angelika/0000-0003-3476-8184; speleman, frank/0000-0002-6628-8559; De Preter, Katleen/0000-0002-7726-5096; Schramm, Alexander/0000-0001-7670-7529; Heukamp, Lukas/0000-0002-3388-3482; Schulte, Johannes Hubertus/0000-0003-0671-1201	National Genome Research Network of the German Ministry for Education and Research (NGFNplus) [PKN-01GS0894-6]; European Union [259348-2]; German research council [SFB 832]; German Cancer Aid [111301]; Agency for Innovation by Science and Technology (IWT); Fund for Scientific Research Flanders (FWO)	National Genome Research Network of the German Ministry for Education and Research (NGFNplus); European Union(European Commission); German research council(German Research Foundation (DFG)); German Cancer Aid(Deutsche Krebshilfe); Agency for Innovation by Science and Technology (IWT)(Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT)); Fund for Scientific Research Flanders (FWO)(FWO)	We thank S Dreesmann, A Odersky, S Schafers and N Solomentsew for excellent technical assistance and A Henssen for helpful discussions. This work was supported by the National Genome Research Network of the German Ministry for Education and Research (NGFNplus grant #PKN-01GS0894-6 to JHS, AE and AS), the 7th framework European Union project, ASSET (contract #259348-2 to AE, FS and JHS), the German research council (SFB 832, A5 and Z1 to LCH), by the German Cancer Aid (Grant No 111301 to JHS), by the Agency for Innovation by Science and Technology (IWT PhD grant to AB and CK) and the Fund for Scientific Research Flanders (FWO post-doc grant to KDP).	Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Brockmann M, 2013, CANCER CELL, V24, P75, DOI 10.1016/j.ccr.2013.05.005; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Casola S, 2010, METHODS MOL BIOL, V667, P145, DOI 10.1007/978-1-60761-811-9_10; Cimmino F, 2009, ONCOGENE, V28, P2015, DOI 10.1038/onc.2009.70; De Preter K, 2011, CLIN CANCER RES, V17, P7684, DOI 10.1158/1078-0432.CCR-11-0610; Eberhardy SR, 2002, J BIOL CHEM, V277, P40156, DOI 10.1074/jbc.M207441200; Fredlund E, 2008, P NATL ACAD SCI USA, V105, P14094, DOI 10.1073/pnas.0804455105; Gargano B, 2007, CELL CYCLE, V6, P2031, DOI 10.4161/cc.6.16.4554; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Hackett CS, 2003, CANCER RES, V63, P5266; Hansford LM, 2004, P NATL ACAD SCI USA, V101, P12664, DOI 10.1073/pnas.0401083101; Heukamp LC, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003967; Hong F, 2011, R PACKAGE VERSION; Jiang MR, 2011, CURR TOP DEV BIOL, V94, P77, DOI 10.1016/B978-0-12-380916-2.00004-8; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Maris JM, 2010, NEW ENGL J MED, V362, P2202, DOI 10.1056/NEJMra0804577; Menten B, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-124; Mestdagh P, 2010, ONCOGENE, V29, P1394, DOI 10.1038/onc.2009.429; Mestdagh P, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-6-r64; Molenaar JJ, 2012, NAT GENET, V44, P1199, DOI 10.1038/ng.2436; Mootha VK, 2003, CELL, V115, P629, DOI 10.1016/S0092-8674(03)00926-7; Olshen AB, 2004, BIOSTATISTICS, V5, P557, DOI 10.1093/biostatistics/kxh008; Ora I, 2011, SEMIN CANCER BIOL, V21, P217, DOI 10.1016/j.semcancer.2011.07.002; Park JR, 2010, HEMATOL ONCOL CLIN N, V24, P65, DOI 10.1016/j.hoc.2009.11.011; Puissant A, 2013, CANCER DISCOV, V3, P308, DOI 10.1158/2159-8290.CD-12-0418; Rasmuson A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051297; Schleiermacher G, 2010, J CLIN ONCOL, V28, P3122, DOI 10.1200/JCO.2009.26.7955; Schramm A, 2007, CLIN CANCER RES, V13, P1459, DOI 10.1158/1078-0432.CCR-06-2032; Schulte JH, 2013, ONCOGENE, V32, P1059, DOI 10.1038/onc.2012.106; Schulte JH, 2011, CLIN CANCER RES, V17, P5082, DOI 10.1158/1078-0432.CCR-10-2809; Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735; Simon T, 2011, PEDIATR BLOOD CANCER, V56, P578, DOI 10.1002/pbc.22693; Stallings RL, 2003, CANCER GENET CYTOGEN, V140, P133, DOI 10.1016/S0165-4608(02)00681-7; Stanke M, 2006, DEVELOPMENT, V133, P141, DOI 10.1242/dev.02189; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tchorz JS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030011; Vandesompele J, 2005, J CLIN ONCOL, V23, P2280, DOI 10.1200/JCO.2005.06.104; Vandesompele J, 2001, MED PEDIATR ONCOL, V36, P5, DOI 10.1002/1096-911X(20010101)36:1<5::AID-MPO1003>3.0.CO;2-E; Weiss WA, 2000, CANCER RES, V60, P2483; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Westermann F, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-10-r150; Whiteford CC, 2007, CANCER RES, V67, P32, DOI 10.1158/0008-5472.CAN-06-0610; Yang ZY, 2008, MOL CELL BIOL, V28, P967, DOI 10.1128/MCB.01020-07	44	69	69	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	26					3357	3368		10.1038/onc.2014.269	http://dx.doi.org/10.1038/onc.2014.269			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CL3SU	25174395	hybrid, Green Published			2022-12-17	WOS:000356871700002
J	Chou, SD; Murshid, A; Eguchi, T; Gong, J; Calderwood, SK				Chou, S-D; Murshid, A.; Eguchi, T.; Gong, J.; Calderwood, S. K.			HSF1 regulation of beta-catenin in mammary cancer cells through control of HuR/elavL1 expression	ONCOGENE			English	Article							HEAT-SHOCK FACTOR-1; TRANSCRIPTION FACTOR HSF1; RNA STABILITY FACTOR; RICH ELEMENTS; STEM-CELLS; PHOSPHORYLATION; BINDING; HUR; ACTIVATION; PROTEINS	There is now compelling evidence to indicate a place for heat shock factor 1 (HSF1) in mammary carcinogenesis, tumour progression and metastasis. Here we have investigated a role for HSF1 in regulating the expression of the stem cell renewal factor beta-catenin in immortalized human mammary epithelial and carcinoma cells. We found HSF1 to be involved in regulating the translation of beta-catenin, by investigating effects of gain and loss of HSF1 on this protein. Interestingly, although HSF1 is a potent transcription factor, it was not directly involved in regulating levels of beta-catenin mRNA. Instead, our data suggest a complex role in translational regulation. HSF1 was shown to regulate levels of the RNA-binding protein HuR that controlled beta-catenin translation. An extra complexity was added to this scenario when it was shown that the long non-coding RNA molecule lincRNA-p21, known to be involved in beta-catenin mRNA (CTNNB1) translational regulation, was controlled by HSF1 repression. We have shown previously that HSF1 was positively regulated through phosphorylation by mammalian target of rapamycin (mTOR) kinase on a key residue, serine 326, essential for transcriptional activity. In this study, we found that mTOR knockdown not only decreased HSF1-S326 phosphorylation in mammary cells, but also decreased beta-catenin expression through a mechanism requiring HuR. Our data point to a complex role for HSF1 in the regulation of HuR and beta-catenin expression that may be significant in mammary carcinogenesis.	[Chou, S-D; Murshid, A.; Eguchi, T.; Calderwood, S. K.] Harvard Univ, Sch Med, Dept Radiat Oncol, BIDMC, Boston, MA 02215 USA; [Gong, J.] Boston Univ, Med Ctr, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Boston University	Calderwood, SK (corresponding author), Harvard Univ, Sch Med, Dept Radiat Oncol, BIDMC, 21-27 Burlington Ave,99 Brookline Ave, Boston, MA 02215 USA.	scalderw@bidmc.harvard.edu		Eguchi, Takanori/0000-0002-3297-6126	NIH [RO-1CA047407, R01CA119045, RO-1CA094397]; NATIONAL CANCER INSTITUTE [R01CA094397, R01CA176326, R01CA119045, R01CA047407] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the Department of Radiation Oncology, Beth Israel Deaconess Medical Center for support and encouragement. We are very grateful for help with construct preparation from Dr Tom Prince. This work was supported by NIH research grants RO-1CA047407, R01CA119045 and RO-1CA094397.	Barreau C, 2005, NUCLEIC ACIDS RES, V33, P7138, DOI 10.1093/nar/gki1012; Calderwood SK, 2012, CURR MOL MED, V12, P1102, DOI 10.2174/156652412803306675; Calderwood SK, 2012, J CELL BIOCHEM, V113, P1096, DOI 10.1002/jcb.23461; Charafe-Jauffret E, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-202; Chou SD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039679; Chu BY, 1998, J BIOL CHEM, V273, P18640, DOI 10.1074/jbc.273.29.18640; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; Ciocca DR, 2013, ARCH TOXICOL, V87, P19, DOI 10.1007/s00204-012-0918-z; Ciocca DR, 2005, CELL STRESS CHAPERON, V10, P86, DOI 10.1379/CSC-99r.1; Dai C, 2007, CELL, V130, P1005, DOI 10.1016/j.cell.2007.07.020; de Silanes IL, 2003, ONCOGENE, V22, P7146, DOI 10.1038/sj.onc.1206862; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI12973; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Gabai VL, 2012, MOL CELL BIOL, V32, P929, DOI 10.1128/MCB.05921-11; Gotoh J, 2003, CARCINOGENESIS, V24, P435, DOI 10.1093/carcin/24.3.435; Hietakangas V, 2003, MOL CELL BIOL, V23, P2953, DOI 10.1128/MCB.23.8.2953-2968.2003; Jin XJ, 2011, CELL METAB, V14, P91, DOI 10.1016/j.cmet.2011.03.025; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Khaleque M, 2008, ONCOGENE, V27, P1886, DOI 10.1038/sj.onc.1210834; Khaleque MA, 2005, ONCOGENE, V24, P6564, DOI 10.1038/sj.onc.1208798; Kim G, 2012, AGING CELL, V11, P617, DOI 10.1111/j.1474-9726.2012.00827.x; Kline MP, 1997, MOL CELL BIOL, V17, P2107, DOI 10.1128/MCB.17.4.2107; Knauf U, 1996, GENE DEV, V10, P2782, DOI 10.1101/gad.10.21.2782; Lebedeva S, 2011, MOL CELL, V43, P340, DOI 10.1016/j.molcel.2011.06.008; Lindvall C, 2007, STEM CELL REV, V3, P157, DOI 10.1007/s12015-007-0025-3; Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Mendillo ML, 2012, CELL, V150, P549, DOI 10.1016/j.cell.2012.06.031; Metcalfe C, 2011, J CELL SCI, V124, P3537, DOI 10.1242/jcs.091991; Min JN, 2007, ONCOGENE, V26, P5086, DOI 10.1038/sj.onc.1210317; Murshid A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013830; Nabors LB, 2001, CANCER RES, V61, P2154; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Santagata S, 2013, SCIENCE, V341, P250, DOI 10.1126/science.1238303; Santagata S, 2011, P NATL ACAD SCI USA, V108, P18378, DOI 10.1073/pnas.1115031108; Saydam O, 2009, MOL CELL BIOL, V29, P5923, DOI 10.1128/MCB.00332-09; Srikantan S, 2012, FRONT BIOSCI-LANDMRK, V17, P189, DOI 10.2741/3921; Su J, 2012, INT J ONCOL, V40, P1162, DOI 10.3892/ijo.2011.1322; Veronese A, 2011, P NATL ACAD SCI USA, V108, P4840, DOI 10.1073/pnas.1101734108; Vleminckx K, 1999, MECH DEVELOP, V81, P65, DOI 10.1016/S0925-4773(98)00225-1; Wang XZ, 2004, J BIOL CHEM, V279, P49460, DOI 10.1074/jbc.M406059200; Wang XZ, 2003, MOL CELL BIOL, V23, P6013, DOI 10.1128/MCB.23.17.6013-6026.2003; Weng DS, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3102; Yecies JL, 2011, J MOL MED, V89, P221, DOI 10.1007/s00109-011-0726-6; Yoon JH, 2012, MOL CELL, V47, P648, DOI 10.1016/j.molcel.2012.06.027; Zhang Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028950	47	69	70	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 23	2015	34	17					2178	2188		10.1038/onc.2014.177	http://dx.doi.org/10.1038/onc.2014.177			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG7HG	24954509	Green Accepted, Green Submitted			2022-12-17	WOS:000353473000004
J	Zhou, JZ; Riquelme, MA; Gao, X; Ellies, LG; Sun, LZ; Jiang, JX				Zhou, J. Z.; Riquelme, M. A.; Gao, X.; Ellies, L. G.; Sun, L. Z.; Jiang, J. X.			Differential impact of adenosine nucleotides released by osteocytes on breast cancer growth and bone metastasis	ONCOGENE			English	Article							HUMAN-TUMOR-CELLS; RECEPTORS; SURVIVAL; ATP; 5'-TRIPHOSPHATE; HEMICHANNELS; ACTIVATION; MECHANISMS; MIGRATION; MODELS	Extracellular ATP has been shown to either inhibit or promote cancer growth and migration; however, the mechanism underlying this discrepancy remained elusive. Here we demonstrate the divergent roles of ATP and adenosine released by bone osteocytes on breast cancers. We showed that conditioned media (CM) collected from osteocytes treated with alendronate (AD), a bisphosphonate drug, inhibited the migration of human breast cancer MDA-MB-231 cells. Removal of the extracellular ATP by apyrase in CM abolished this effect, suggesting the involvement of ATP. ATP exerted its inhibitory effect through the activation of purinergic P2X receptor signaling in breast cancer cells evidenced by the attenuation of the inhibition by an antagonist, oxidized ATP, as well as knocking down P2X7 with small interfering RNA (siRNA), and the inhibition of migration by an agonist, BzATP. Intriguingly, ATP had a biphasic effect on breast cancer cells-lower dosage inhibited but higher dosage promoted its migration. The stimulatory effect on migration was blocked by an adenosine receptor antagonist, MRS1754, ARL67156, an ecto-ATPase inhibitor, and A(2A) receptor siRNA, suggesting that in contrast to ATP, adenosine, a metabolic product of ATP, promoted migration of breast cancer cells. Consistently, non-hydrolyzable ATP, ATP gamma S, only inhibited but did not promote cancer cell migration. ATP also had a similar inhibitory effect on the Py8119 mouse mammary carcinoma cells; however, adenosine had no effect owing to the absence of the A(2A) receptor. Consistently, ATP.S inhibited, whereas adenosine promoted anchorage-independent growth of MDA-MB-231 cells. Our in vivo xenograft study showed a significant delay of tumor growth with the treatment of ATP gamma S. Moreover, the extent of bone metastasis in a mouse intratibial model was significantly reduced with the treatment of ATP gamma S. Together, our results suggest the distinct roles of ATP and adenosine released by osteocytes and the activation of corresponding receptors P2X7 and A(2A) signaling on breast cancer cell growth, migration and bone metastasis.	[Zhou, J. Z.; Riquelme, M. A.; Gao, X.; Jiang, J. X.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA; [Ellies, L. G.] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; [Sun, L. Z.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; [Sun, L. Z.] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of California System; University of California San Diego; University of Texas System; University of Texas Health San Antonio; Cancer Therapy & Research Center; University of Texas System; University of Texas Health San Antonio	Jiang, JX (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	jiangj@uthscsa.edu	Riquelme, Manuel/B-1082-2015; , LuZhe/AAW-4095-2021	Riquelme, Manuel/0000-0002-1915-0434; Jiang, Jean/0000-0002-2185-5716	Welch Foundation [AQ-1507]; National Institutes of Health [EY012085, ES022057, CA118182]; NCI Cancer Center Support grant [2 P30 CA054174-17]; NATIONAL CANCER INSTITUTE [P30CA054174, K22CA118182] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R29EY012085, R01EY012085] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES022057] Funding Source: NIH RePORTER	Welch Foundation(The Welch Foundation); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI Cancer Center Support grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Dr Sumin Gu, Dr Sweta Mishra and Dr Tanuka Biswas for technical assistance. The work was supported by the Welch Foundation grant AQ-1507 and National Institutes of Health grant EY012085 to JXJ, ES022057 to L-ZS, CA118182 to LGE and the NCI Cancer Center Support grant 2 P30 CA054174-17 to Cancer Therapy and Research Center.	Abbracchio MP, 2006, PHARMACOL REV, V58, P281, DOI 10.1124/pr.58.3.3; Agteresch HJ, 2003, ANTI-CANCER DRUG, V14, P639, DOI 10.1097/00001813-200309000-00009; Agteresch HJ, 2000, EUR J CLIN PHARMACOL, V56, P49, DOI 10.1007/s002280050719; Batra N, 2012, BBA-BIOMEMBRANES, V1818, P1909, DOI 10.1016/j.bbamem.2011.09.018; Beijer S, 2009, ANTI-CANCER DRUG, V20, P625, DOI 10.1097/CAD.0b013e32832d4f22; Bonewald LF, 2007, ANN NY ACAD SCI, V1116, P281, DOI 10.1196/annals.1402.018; Brown Sue A, 2007, Curr Osteoporos Rep, V5, P120; Burnstock G, 2008, J PHYSIOL-LONDON, V586, P3307, DOI 10.1113/jphysiol.2008.155903; Campbell JP, 2012, JOVE-J VIS EXP, DOI 10.3791/4260; Deli T, 2008, PATHOL ONCOL RES, V14, P219, DOI 10.1007/s12253-008-9071-7; Falzoni S, 2013, INTERFACE FOCUS, V3, DOI 10.1098/rsfs.2012.0101; Genetos DC, 2007, J CELL PHYSIOL, V212, P207, DOI 10.1002/jcp.21021; Gessi S, 2011, BBA-BIOMEMBRANES, V1808, P1400, DOI 10.1016/j.bbamem.2010.09.020; Jelassi B, 2011, ONCOGENE, V30, P2108, DOI 10.1038/onc.2010.593; Jin JK, 2011, INT J CANCER, V128, P2545, DOI 10.1002/ijc.26024; Kohno N, 2008, INT J CLIN ONCOL, V13, P18, DOI 10.1007/s10147-007-0726-2; Kretschmann KL, 2012, CANCER METAST REV, V31, P579, DOI 10.1007/s10555-012-9378-4; Leth-Larsen R, 2009, MOL CELL PROTEOMICS, V8, P1436, DOI 10.1074/mcp.M800061-MCP200; Matsuo K, 2009, CURR OPIN NEPHROL HY, V18, P292, DOI 10.1097/MNH.0b013e32832b75f1; Mishra S, 2011, PROSTATE, V71, P1441, DOI 10.1002/pros.21361; Ohta A, 2006, P NATL ACAD SCI USA, V103, P13132, DOI 10.1073/pnas.0605251103; Plotkin LI, 2002, J BIOL CHEM, V277, P8648, DOI 10.1074/jbc.M108625200; RAPAPORT E, 1983, CANCER RES, V43, P4402; RAPAPORT E, 1988, EUR J CANCER CLIN ON, V24, P1491, DOI 10.1016/0277-5379(88)90340-9; Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831; Salvestrini V, 2012, BLOOD, V119, P217, DOI 10.1182/blood-2011-07-370775; Savariar EN, 2013, CANCER RES, V73, P855, DOI 10.1158/0008-5472.CAN-12-2969; Shabbir M, 2009, INT J UROL, V16, P143, DOI 10.1111/j.1442-2042.2008.02207.x; Van der Pluijm G, 2001, J BONE MINER RES, V16, P1077, DOI 10.1359/jbmr.2001.16.6.1077; Wang L, 2008, J CANCER RES CLIN, V134, P365, DOI 10.1007/s00432-007-0292-z; Welch D. R., 2003, Journal of Musculoskeletal & Neuronal Interactions, V3, P30; White N, 2006, TRENDS PHARMACOL SCI, V27, P211, DOI 10.1016/j.tips.2006.02.004; Woodhouse EC, 1998, BIOCHEM BIOPH RES CO, V246, P888, DOI 10.1006/bbrc.1998.8714; Zhang W, 2011, BIOCHEM PHARMACOL, V82, P411, DOI 10.1016/j.bcp.2011.05.009; Zhi XL, 2007, CLIN EXP METASTAS, V24, P439, DOI 10.1007/s10585-007-9081-y	35	69	73	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	2015	34	14					1831	1842		10.1038/onc.2014.113	http://dx.doi.org/10.1038/onc.2014.113			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE9IQ	24837364	Green Accepted			2022-12-17	WOS:000352158000010
J	Li, X; Liu, Y; Granberg, KJ; Wang, Q; Moore, LM; Ji, P; Gumin, J; Sulman, EP; Calin, GA; Haapasalo, H; Nykter, M; Shmulevich, I; Fuller, GN; Lang, FF; Zhang, W				Li, X.; Liu, Y.; Granberg, K. J.; Wang, Q.; Moore, L. M.; Ji, P.; Gumin, J.; Sulman, E. P.; Calin, G. A.; Haapasalo, H.; Nykter, M.; Shmulevich, I.; Fuller, G. N.; Lang, F. F.; Zhang, W.			Two mature products of MIR-491 coordinate to suppress key cancer hallmarks in glioblastoma	ONCOGENE			English	Article							CHROMOSOME 9P21 DELETIONS; TUMOR STEM-CELLS; MOLECULAR PROCESSES; GROWTH; IDENTIFICATION; EXPRESSION; MICRORNA; IGFBP2; GENE; PATHWAY	MIR-491 is commonly co-deleted with its adjacent CDKN2A on chromosome 9p21.3 in glioblastoma multiforme (GBM). However, it is not known whether deletion of MIR-491 is only a passenger event or has an important role. Small-RNA sequencing of samples from GBM patients demonstrated that both mature products of MIR-491 (miR-491-5p and -3p) are downregulated in tumors compared with the normal brain. The integration of GBM data from The Cancer Genome Atlas (TCGA), miRNA target prediction and reporter assays showed that miR-491-5p directly targets EGFR, CDK6 and Bcl-xL, whereas miR-491-3p targets IGFBP2 and CDK6. Functionally, miR-491-3p inhibited glioma cell invasion; overexpression of both miR-491-5p and -3p inhibited proliferation of glioma cell lines and impaired the propagation of glioma stem cells (GSCs), thereby prolonging survival of xenograft mice. Moreover, knockdown of miR-491-5p in primary Ink4a-Arf-null mouse glial progenitor cells exacerbated cell proliferation and invasion. Therefore, MIR-491 is a tumor suppressor gene that, by utilizing both mature forms, coordinately controls the key cancer hallmarks: proliferation, invasion and stem cell propagation.	[Li, X.; Liu, Y.; Granberg, K. J.; Moore, L. M.; Ji, P.; Fuller, G. N.; Zhang, W.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Li, X.; Wang, Q.] Fourth Mil Med Univ, Dept Biochem & Mol Biol, State Key Lab Canc Biol, Xian 710032, Peoples R China; [Granberg, K. J.; Nykter, M.] Tampere Univ Technol, Dept Signal Proc, FIN-33101 Tampere, Finland; [Granberg, K. J.; Haapasalo, H.] Fimlab Labs, Dept Pathol, Tampere, Finland; [Granberg, K. J.; Haapasalo, H.] Univ Tampere, FIN-33101 Tampere, Finland; [Gumin, J.; Lang, F. F.] Univ Texas MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; [Sulman, E. P.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA; [Calin, G. A.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Calin, G. A.; Zhang, W.] Univ Texas MD Anderson Canc Ctr, Noncoding RNA Ctr, Houston, TX 77030 USA; [Nykter, M.] Univ Tampere, Inst Biomed Technol, FIN-33101 Tampere, Finland; [Shmulevich, I.] Inst Syst Biol, Seattle, WA USA	University of Texas System; UTMD Anderson Cancer Center; Air Force Military Medical University; Tampere University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Tampere University; Institute for Systems Biology (ISB)	Zhang, W (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Pathol, 1515 Holcombe Blvd Unit 85, Houston, TX 77030 USA.	wzhang@mdanderson.org	Calin, George/E-9390-2011	Sulman, Erik/0000-0003-4933-9120; Rautajoki, Kirsi Johanna/0000-0001-6549-7810; Calin, George/0000-0002-7427-0578; Calin, George/0000-0001-6704-5615; Fuller, Gregory/0000-0001-9447-2647; Nykter, Matti/0000-0001-6956-2843	National Institutes of Health [CA098503, CA141432, CA143835, CA115729, CA127001]; Broach Foundation; Gene Pennebaker Brain Cancer Fund; Academy of Finland [259038]; Fourth Military Medical University [4138C4IA1Z]; American Cancer Society; IVY Foundation; Elias Foundation; NATIONAL CANCER INSTITUTE [R56CA098503, R01CA141432, R01CA098503, U24CA143835, P30CA016672, R01CA115729, P50CA127001] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Broach Foundation; Gene Pennebaker Brain Cancer Fund; Academy of Finland(Academy of Finland); Fourth Military Medical University; American Cancer Society(American Cancer Society); IVY Foundation; Elias Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We appreciate Xinna Zhang at the MicroRNA Core Facility for help with miRNA hybridization experiments, Zhimin Lu at the Department of Neuro-Oncology-Research for helpful comments, and Kathryn L Hale at the Department of Scientific Publications at MD Anderson Cancer Center for manuscript editing. This work was supported by grants from the National Institutes of Health (CA098503 to WZ and IS, CA141432 and CA143835 to WZ and CA115729 and CA127001 to FFL), IVY, Elias and Broach Foundations, the Gene Pennebaker Brain Cancer Fund, and the Academy of Finland (grant 259038 to KG); Xia Li was supported by a fellowship from The Fourth Military Medical University (4138C4IA1Z). Lynette Moore was supported by a fellowship from the American Cancer Society.	Ayuso-Sacido A, 2010, J NEURO-ONCOL, V97, P323, DOI 10.1007/s11060-009-0035-x; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Beukelaers P, 2011, STEM CELLS, V29, P713, DOI 10.1002/stem.616; Bexell D, 2013, CANCER TREAT REV, V39, P358, DOI 10.1016/j.ctrv.2012.06.006; Brockschmidt A, 2012, BRAIN, V135, P1027, DOI 10.1093/brain/aws045; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; CHAO DT, 1995, J EXP MED, V182, P821, DOI 10.1084/jem.182.3.821; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Das S, 2008, NAT CLIN PRACT NEURO, V4, P427, DOI 10.1038/ncpneuro0862; Dong JT, 2001, CANCER METAST REV, V20, P173, DOI 10.1023/A:1015575125780; Dunlap SM, 2007, P NATL ACAD SCI USA, V104, P11736, DOI 10.1073/pnas.0703145104; Feng JJ, 2012, CANCER-AM CANCER SOC, V118, P232, DOI 10.1002/cncr.26250; Fukushima T, 2007, J BIOL CHEM, V282, P18634, DOI 10.1074/jbc.M609567200; Fuxe J, 2000, CELL GROWTH DIFFER, V11, P373; Griffero F, 2009, J BIOL CHEM, V284, P7138, DOI 10.1074/jbc.M807111200; Guessous F, 2010, CELL CYCLE, V9, P1031, DOI 10.4161/cc.9.6.10987; Gursky S, 2001, CANCER GENET CYTOGEN, V129, P93, DOI 10.1016/S0165-4608(01)00444-7; Hai C, 2012, CHIN J CANCER, V31, P233, DOI 10.5732/cjc.011.10367; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He H, 2010, J PROTEOME RES, V9, P2098, DOI 10.1021/pr900793a; Hegi ME, 2011, MOL CANCER THER, V10, P1102, DOI 10.1158/1535-7163.MCT-11-0048; Holmes KM, 2012, P NATL ACAD SCI USA, V109, P3475, DOI 10.1073/pnas.1120375109; Hsieh D, 2010, BIOCHEM BIOPH RES CO, V397, P367, DOI 10.1016/j.bbrc.2010.05.145; Hwang DW, 2011, BIOMATERIALS, V32, P4968, DOI 10.1016/j.biomaterials.2011.03.047; Jiang H, 2007, J NATL CANCER I, V99, P1410, DOI 10.1093/jnci/djm102; Jin X, 2011, CANCER RES, V71, P7125, DOI 10.1158/0008-5472.CAN-11-1330; Kefas B, 2008, CANCER RES, V68, P3566, DOI 10.1158/0008-5472.CAN-07-6639; Kim BN, 2005, INT J ONCOL, V26, P1217; Kohno T, 2006, DNA REPAIR, V5, P1273, DOI 10.1016/j.dnarep.2006.05.021; Lee EJ, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-7; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Mirimanoff RO, 2014, CHIN J CANCER, V33, P1, DOI 10.5732/cjc.013.10215; Moore LM, 2013, J PATHOL, V229, P449, DOI 10.1002/path.4109; Moore LM, 2009, P NATL ACAD SCI USA, V106, P16675, DOI 10.1073/pnas.0900807106; Nakano H, 2010, INT J CANCER, V127, P1072, DOI 10.1002/ijc.25143; Papagiannakopoulos T, 2012, ONCOGENE, V31, P1884, DOI 10.1038/onc.2011.380; Parker BC, 2013, J CLIN INVEST, V123, P855, DOI 10.1172/JCI67144; Png KJ, 2012, NATURE, V481, P190, DOI 10.1038/nature10661; Rich JN, 2004, J CLIN ONCOL, V22, P133, DOI 10.1200/JCO.2004.08.110; Sasaki S, 2003, ONCOGENE, V22, P3792, DOI 10.1038/sj.onc.1206589; Sato M, 2005, GENE CHROMOSOME CANC, V44, P405, DOI 10.1002/gcc.20253; Sempere LF, 2007, CANCER RES, V67, P11612, DOI 10.1158/0008-5472.CAN-07-5019; Silber J, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-14; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Soeda A, 2008, J BIOL CHEM, V283, P10958, DOI 10.1074/jbc.M704205200; Testa JR, 1997, CANCER GENET CYTOGEN, V95, P20, DOI 10.1016/S0165-4608(96)00337-8; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wang GK, 2006, J BIOL CHEM, V281, P14085, DOI 10.1074/jbc.M513686200; Wang H, 2003, CANCER RES, V63, P4315; Yan W, 2011, BRAIN RES, V1411, P108, DOI 10.1016/j.brainres.2011.07.002; Yin J, 2011, MOL THER, V19, P1161, DOI 10.1038/mt.2011.28; Zhang W, 2007, CANCER BIOL THER, V6, P995; Zhou ZM, 2011, CANCER BIOTHER RADIO, V26, P77, DOI 10.1089/cbr.2010.0857	55	69	72	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2015	34	13					1619	1628		10.1038/onc.2014.98	http://dx.doi.org/10.1038/onc.2014.98			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE5CS	24747968	Green Accepted			2022-12-17	WOS:000351848400002
J	Leanza, L; Zoratti, M; Gulbins, E; Szabo, I				Leanza, L.; Zoratti, M.; Gulbins, E.; Szabo, I.			Mitochondrial ion channels as oncological targets	ONCOGENE			English	Review						mitochondria; ion channels; direct targeting; pharmacology	PERMEABILITY TRANSITION PORE; DEPENDENT ANION CHANNEL; POTASSIUM CHANNEL; CELL-DEATH; CANCER-CELLS; CALCIUM UNIPORTER; INDUCED APOPTOSIS; OXIDATIVE STRESS; INNER MEMBRANE; MUTATIONAL INACTIVATION	Mitochondria, the key bioenergetic intracellular organelles, harbor a number of proteins with proven or hypothetical ion channel functions. Growing evidence points to the important contribution of these channels to the regulation of mitochondrial function, such as ion homeostasis imbalances profoundly affecting energy transducing processes, reactive oxygen species production and mitochondrial integrity. Given the central role of mitochondria in apoptosis, their ion channels with the potential to compromise mitochondrial function have become promising targets for the treatment of malignancies. Importantly, in vivo evidence demonstrates the involvement of the proton-transporting uncoupling protein, a mitochondrial potassium channel, the outer membrane located porin and the permeability transition pore in tumor progression/control. In this review, we focus on mitochondrial channels that have been assigned a definite role in cell death regulation and possess clear oncological relevance. Overall, based on in vivo and in vitro genetic and pharmacological evidence, mitochondrial ion channels are emerging as promising targets for cancer treatment.	[Leanza, L.; Szabo, I.] Univ Padua, Dept Biol, I-35138 Padua, PD, Italy; [Zoratti, M.] Univ Padua, CNR, Inst Neurosci, I-35138 Padua, PD, Italy; [Zoratti, M.] Univ Padua, Dept Biomed Sci, I-35138 Padua, PD, Italy; [Gulbins, E.] Univ Duisburg Essen, Dept Mol Biol, Essen, Germany	University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Padua; University of Duisburg Essen	Szabo, I (corresponding author), Univ Padua, Dept Biol, Viale G Colombo 3, I-35138 Padua, PD, Italy.	ildi@civ.bio.unipd.it; ildiko.szabo@unipd.it	Szabo, Ildiko/AAW-5972-2021; Leanza, Luigi/K-3060-2016; Padova, Ildiko/K-5344-2016; Gulbins, Erich/L-6989-2014	Szabo, Ildiko/0000-0002-3637-3947; Leanza, Luigi/0000-0002-5919-7114; Gulbins, Erich/0000-0002-3117-1342	Italian Association for Cancer Research (AIRC) [11814]; EMBO Young Investigator Program grant; Progetti di Rilevante Interesse Nazionale (PRIN) program [2010CSJX4F, 20107Z8XBW_004]; Fondazione Cassa di Risparmio di Padova e Rovigo; CNR Project of Special Interest on Aging; DFG [Gu 335/13-3]; International Association for Cancer Research; Progetto Giovani Studiosi	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); EMBO Young Investigator Program grant; Progetti di Rilevante Interesse Nazionale (PRIN) program(Ministry of Education, Universities and Research (MIUR)); Fondazione Cassa di Risparmio di Padova e Rovigo(Fondazione Cariparo); CNR Project of Special Interest on Aging(Consiglio Nazionale delle Ricerche (CNR)); DFG(German Research Foundation (DFG)); International Association for Cancer Research; Progetto Giovani Studiosi	We are grateful to all co-authors for their important contributions to the work carried out in their laboratories and reported in this review. We apologize for not citing all publications that have been published on this topic. The work carried out in the authors' laboratories was supported in part by grants from the Italian Association for Cancer Research (AIRC; Grant 11814 to IS), the EMBO Young Investigator Program grant (to IS), the Progetti di Rilevante Interesse Nazionale (PRIN) program (2010CSJX4F to IS and 20107Z8XBW_004 to MZ), the Fondazione Cassa di Risparmio di Padova e Rovigo (to MZ), the CNR Project of Special Interest on Aging (to MZ), the DFG Grant Gu 335/13-3 (to EG), the International Association for Cancer Research (to EG) and the Progetto Giovani Studiosi 2012 (to LL).	Anastasiou D, 2011, SCIENCE, V334, P1278, DOI 10.1126/science.1211485; Annis MG, 2005, EMBO J, V24, P2096, DOI 10.1038/sj.emboj.7600675; Aon MA, 2010, BBA-BIOENERGETICS, V1797, P71, DOI 10.1016/j.bbabio.2009.08.002; Arbel N, 2012, J BIOL CHEM, V287, P23152, DOI 10.1074/jbc.M112.345918; Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Arvizo RR, 2013, J BIOL CHEM, V288, P17610, DOI 10.1074/jbc.M112.435206; Ayyasamy V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024792; Azoulay-Zohar H, 2004, BIOCHEM J, V377, P347, DOI 10.1042/BJ20031465; Baffy G, 2011, BRIT J CANCER, V105, P469, DOI 10.1038/bjc.2011.245; Baffy G, 2010, MITOCHONDRION, V10, P243, DOI 10.1016/j.mito.2009.12.143; Baines CP, 2007, NAT CELL BIOL, V9, P550, DOI 10.1038/ncb1575; Baughman JM, 2011, NATURE, V476, P341, DOI 10.1038/nature10234; Bednarczyk P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068125; Bender T, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a011106; Bernardi P, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00095; Bialik S, 2006, ANNU REV BIOCHEM, V75, P189, DOI 10.1146/annurev.biochem.75.103004.142615; Biasutto L, 2011, ANTIOXID REDOX SIGN, V15, P3039, DOI 10.1089/ars.2011.4021; Brenner C, 2006, ONCOGENE, V25, P4744, DOI 10.1038/sj.onc.1209609; Brenner C, 2012, CIRC RES, V111, P1237, DOI 10.1161/CIRCRESAHA.112.265942; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; Cannon B, 2006, BBA-BIOENERGETICS, V1757, P449, DOI 10.1016/j.bbabio.2006.05.016; Cardaci S, 2012, J BIOENERG BIOMEMBR, V44, P17, DOI 10.1007/s10863-012-9422-7; Cavalieri E, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-45; Cavalieri E, 2009, FEBS J, V276, P3990, DOI 10.1111/j.1742-4658.2009.07108.x; Chaudhuri D, 2013, ELIFE, V2, DOI 10.7554/eLife.00704; Chiara F, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.184; Chiara F, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001852; Chiara F, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00016; Circu ML, 2010, FREE RADICAL BIO MED, V48, P749, DOI 10.1016/j.freeradbiomed.2009.12.022; Cogliati S, 2013, CELL, V155, P160, DOI 10.1016/j.cell.2013.08.032; CROMPTON M, 1988, BIOCHEM J, V255, P357; Curry MC, 2013, BIOCHEM BIOPH RES CO, V434, P695, DOI 10.1016/j.bbrc.2013.04.015; Davies NJ, 2009, CANCER RES, V69, P4769, DOI 10.1158/0008-5472.CAN-08-4533; Davis FM, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-76; De Marchi U, 2009, CELL CALCIUM, V45, P509, DOI 10.1016/j.ceca.2009.03.014; De Stefani D, 2011, NATURE, V476, P336, DOI 10.1038/nature10230; Debska-Vielhaber G, 2009, J PHYSIOL PHARMACOL, V60, P27; Dejean LM, 2010, BBA-BIOENERGETICS, V1797, P1231, DOI 10.1016/j.bbabio.2010.01.007; Demin OV, 1998, MOL CELL BIOCHEM, V184, P21, DOI 10.1023/A:1006849920918; Denton RM, 2009, BBA-BIOENERGETICS, V1787, P1309, DOI 10.1016/j.bbabio.2009.01.005; Derdak Z, 2008, CANCER RES, V68, P2813, DOI 10.1158/0008-5472.CAN-08-0053; Dolga AM, 2013, J BIOL CHEM, V288, P10792, DOI 10.1074/jbc.M113.453522; Dong JX, 2013, J MEMBRANE BIOL, V246, P375, DOI 10.1007/s00232-013-9543-x; Drago I, 2011, EMBO J, V30, P4119, DOI 10.1038/emboj.2011.337; el Dein OS, 2012, BIOCHEM PHARMACOL, V83, P1172, DOI 10.1016/j.bcp.2012.01.017; Elliott MA, 2012, INT J PHARMACEUT, V426, P67, DOI 10.1016/j.ijpharm.2012.01.024; Fedorenko A, 2012, CELL, V151, P400, DOI 10.1016/j.cell.2012.09.010; Felipe A, 2012, CURR MED CHEM, V19, P661, DOI 10.2174/092986712798992048; Fiaschi Tania, 2012, Int J Cell Biol, V2012, P762825, DOI 10.1155/2012/762825; Fingrut O, 2002, LEUKEMIA, V16, P608, DOI 10.1038/sj.leu.2402419; Flescher E, 2005, ANTI-CANCER DRUG, V16, P911, DOI 10.1097/01.cad.0000176501.63680.80; Flescher E, 2007, CANCER LETT, V245, P1, DOI 10.1016/j.canlet.2006.03.001; FOURNIER N, 1987, J BIOENERG BIOMEMBR, V19, P297, DOI 10.1007/BF00762419; Friese MA, 2007, NAT MED, V13, P1483, DOI 10.1038/nm1668; Fulda S, 1998, J BIOL CHEM, V273, P33942, DOI 10.1074/jbc.273.51.33942; Fulda S, 2010, NAT REV DRUG DISCOV, V9, P447, DOI 10.1038/nrd3137; Gall JM, 2011, KIDNEY INT, V79, P1207, DOI 10.1038/ki.2010.532; Galluzzi L, 2008, CELL CYCLE, V7, P1949, DOI 10.4161/cc.7.13.6222; Galluzzi L, 2013, NAT REV DRUG DISCOV, V12, P829, DOI 10.1038/nrd4145; Galluzzi L, 2012, NAT REV MOL CELL BIO, V13, P780, DOI 10.1038/nrm3479; GELB BD, 1992, P NATL ACAD SCI USA, V89, P202, DOI 10.1073/pnas.89.1.202; Ghibelli L, 2010, MITOCHONDRION, V10, P604, DOI 10.1016/j.mito.2010.08.003; Giorgio V, 2013, P NATL ACAD SCI USA, V110, P5887, DOI 10.1073/pnas.1217823110; Grills C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014635; Gulbins E, 2010, BBA-BIOENERGETICS, V1797, P1251, DOI 10.1016/j.bbabio.2010.01.018; Gunter TE, 2000, CELL CALCIUM, V28, P285, DOI 10.1054/ceca.2000.0168; Guo X P, 1991, Zhong Xi Yi Jie He Za Zhi, V11, P598; HALESTRAP AP, 1987, BIOCHEM J, V244, P159, DOI 10.1042/bj2440159; Han WD, 2007, MOL CANCER THER, V6, P1641, DOI 10.1158/1535-7163.MCT-06-0511; Hoang T, 2012, BIOCHEMISTRY-US, V51, P4004, DOI 10.1021/bi3003378; Horton KL, 2012, CHEMBIOCHEM, V13, P476, DOI 10.1002/cbic.201100415; Innamaa A, 2013, ANTICANCER RES, V33, P1401; Ionov Y, 2000, P NATL ACAD SCI USA, V97, P10872, DOI 10.1073/pnas.190210897; Javadov S, 2011, CELL PHYSIOL BIOCHEM, V27, P179, DOI 10.1159/000327943; Ji Q, 2003, PROSTATE, V54, P275, DOI 10.1002/pros.10192; Jones S, 2008, BBA-MOL CELL RES, V1783, P849, DOI 10.1016/j.bbamcr.2008.01.009; Kadenbach B, 2003, BBA-BIOENERGETICS, V1604, P77, DOI 10.1016/S0005-2728(03)00027-6; Kim JH, 2004, ONCOL REP, V12, P1233; Kinnally KW, 2011, BBA-MOL CELL RES, V1813, P616, DOI 10.1016/j.bbamcr.2010.09.013; Kirichok Y, 2004, NATURE, V427, P360, DOI 10.1038/nature02246; Klippel S, 2012, BRIT J HAEMATOL, V159, P340, DOI 10.1111/j.1365-2141.2012.09253.x; Ko JH, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-106; Ko YH, 2012, J BIOENERG BIOMEMBR, V44, P163, DOI 10.1007/s10863-012-9417-4; Ko YH, 2004, BIOCHEM BIOPH RES CO, V324, P269, DOI 10.1016/j.bbrc.2004.09.047; Koren I, 2010, CANCER BIOL THER, V9, P1046, DOI 10.4161/cbt.9.12.11879; Kosztka L, 2011, MELANOMA RES, V21, P308, DOI 10.1097/CMR.0b013e3283462713; Kovacs I, 2005, VIRCHOWS ARCH, V446, P402, DOI 10.1007/s00428-005-1205-7; Kowaltowski AJ, 2009, FREE RADICAL BIO MED, V47, P333, DOI 10.1016/j.freeradbiomed.2009.05.004; Landes T, 2011, BBA-MOL CELL RES, V1813, P540, DOI 10.1016/j.bbamcr.2011.01.021; Lau E, 2012, CELL, V148, P543, DOI 10.1016/j.cell.2012.01.016; Leanza L, 2013, LEUKEMIA, V27, P1782, DOI 10.1038/leu.2013.56; Leanza L, 2012, CURR MED CHEM, V19, P5394, DOI 10.2174/092986712803833281; Leanza L, 2013, CURR PHARM DES; Leanza L, 2012, EMBO MOL MED, V4, P577, DOI 10.1002/emmm.201200235; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Lee GW, 2012, ACTA PHYSIOL, V204, P513, DOI 10.1111/j.1748-1716.2011.02359.x; Lei XB, 2006, FASEB J, V20, P2147, DOI 10.1096/fj.05-5665fje; Lemasters JJ, 2006, BBA-MOL BASIS DIS, V1762, P181, DOI 10.1016/j.bbadis.2005.10.006; Lena A, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-13; Li L, 2007, CANCER RES, V67, P4894, DOI 10.1158/0008-5472.CAN-06-3818; Liu JH, 2013, FREE RADICAL BIO MED, V63, P485, DOI 10.1016/j.freeradbiomed.2013.05.038; Maack C, 2006, CIRC RES, V99, P172, DOI 10.1161/01.RES.0000232546.92777.05; Mader A, 2010, BIOCHEM J, V429, P147, DOI 10.1042/BJ20091338; Majewski N, 2004, MOL CELL, V16, P819, DOI 10.1016/j.molcel.2004.11.014; Malinska D, 2010, FEBS LETT, V584, P2043, DOI 10.1016/j.febslet.2010.01.013; Mallilankaraman K, 2012, CELL, V151, P630, DOI 10.1016/j.cell.2012.10.011; Marchi S, 2013, CURR BIOL, V23, P58, DOI 10.1016/j.cub.2012.11.026; Martinez-Caballero S, 2009, J BIOL CHEM, V284, P12235, DOI 10.1074/jbc.M806610200; Matassa DS, 2012, AM J CANCER RES, V2, P235; McCommis KS, 2012, BBA-BIOMEMBRANES, V1818, P1444, DOI 10.1016/j.bbamem.2011.10.025; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; Meijerink JPP, 1998, BLOOD, V91, P2991, DOI 10.1182/blood.V91.8.2991.2991_2991_2997; Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386; Neuzil J, 2013, MITOCHONDRION, V13, P199, DOI 10.1016/j.mito.2012.07.112; Ni BY, 2012, CLIN CANCER RES, V18, P140, DOI 10.1158/1078-0432.CCR-10-3450; NICHOLS BJ, 1995, MOL CELL BIOCHEM, V149, P203, DOI 10.1007/BF01076578; Norman KG, 2010, MITOCHONDRION, V10, P94, DOI 10.1016/j.mito.2009.10.001; O-Uchi J, 2013, ANTIOXID REDOX SIGNA; Orr AL, 2012, J BIOL CHEM, V287, P42921, DOI 10.1074/jbc.M112.397828; Palmieri B, 2011, EUR REV MED PHARMACO, V15, P333; Pan X, 2013, NAT CELL BIOL, V15, P1464, DOI 10.1038/ncb2868; Panieri E, 2013, FREE RADICAL BIO MED, V57, P176, DOI 10.1016/j.freeradbiomed.2012.12.024; Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200; Pedersen PL, 2007, J BIOENERG BIOMEMBR, V39, P1, DOI 10.1007/s10863-007-9070-5; Pedersen PL, 2012, J BIOENERG BIOMEMBR, V44, P1, DOI 10.1007/s10863-012-9425-4; Pelicano H, 2003, J BIOL CHEM, V278, P37832, DOI 10.1074/jbc.M301546200; Peng TI, 2010, ANN NY ACAD SCI, V1201, P183, DOI 10.1111/j.1749-6632.2010.05634.x; Pereira CV, 2008, TOXICOL SCI, V105, P408, DOI 10.1093/toxsci/kfn131; Pereira GC, 2007, J PHARMACOL EXP THER, V323, P636, DOI 10.1124/jpet.107.128017; Perevoshchikova IV, 2010, FEBS LETT, V584, P2397, DOI 10.1016/j.febslet.2010.04.033; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Plovanich M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055785; Prezma T, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.316; Quast SA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039290; Quinlan CL, 2013, REDOX BIOL, V1, P304, DOI 10.1016/j.redox.2013.04.005; Raffaello A, 2013, EMBO J, V32, P2362, DOI 10.1038/emboj.2013.157; Ralph SJ, 2011, PHARM RES-DORDR, V28, P2695, DOI 10.1007/s11095-011-0566-7; Ralph SJ, 2010, MOL ASPECTS MED, V31, P145, DOI 10.1016/j.mam.2010.02.008; Rasola A, 2011, CELL CALCIUM, V50, P222, DOI 10.1016/j.ceca.2011.04.007; Rasola A, 2010, FEBS LETT, V584, P1989, DOI 10.1016/j.febslet.2010.02.022; Rasola A, 2010, P NATL ACAD SCI USA, V107, P726, DOI 10.1073/pnas.0912742107; Raviv Z, 2013, CANCER CHEMOTH PHARM, V71, P275, DOI 10.1007/s00280-012-2039-z; Ren YZR, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004009; Risso A, 2002, MOL CELL BIOL, V22, P1926, DOI 10.1128/MCB.22.6.1926-1935.2002; Rizzuto R, 2012, NAT REV MOL CELL BIO, V13, P566, DOI 10.1038/nrm3412; Rodrigues-Ferreira C, 2012, J BIOENERG BIOMEMBR, V44, P39, DOI 10.1007/s10863-012-9413-8; Rusznak Z, 2008, VIRCHOWS ARCH, V452, P415, DOI 10.1007/s00428-007-0545-x; Samudio I, 2008, CANCER RES, V68, P5198, DOI 10.1158/0008-5472.CAN-08-0555; Sancak Y, 2013, SCIENCE, V342, P1379, DOI 10.1126/science.1242993; Sanchez-Alvarez R, 2013, CELL CYCLE, V12, P172, DOI 10.4161/cc.23058; Sassi N, 2010, BBA-BIOENERGETICS, V1797, P1260, DOI 10.1016/j.bbabio.2009.12.015; Schonherr R, 2005, J MEMBRANE BIOL, V205, P175, DOI 10.1007/s00232-005-0782-3; Scorrano L, 2009, INT J BIOCHEM CELL B, V41, P1875, DOI 10.1016/j.biocel.2009.04.016; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; Shoshan MC, 2012, J BIOENERG BIOMEMBR, V44, P7, DOI 10.1007/s10863-012-9419-2; Shoshan-Barmatz V, 2012, CURR MED CHEM, V19, P714, DOI 10.2174/092986712798992110; Shoshan-Barmatz V, 2010, MOL ASPECTS MED, V31, P227, DOI 10.1016/j.mam.2010.03.002; Shoshan-Barmatzt V, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00164; Simamura E, 2008, J BIOENERG BIOMEMBR, V40, P213, DOI 10.1007/s10863-008-9158-6; Singh H, 2012, J PHYSIOL-LONDON, V590, P5937, DOI 10.1113/jphysiol.2011.215533; Smith RAJ, 2012, TRENDS PHARMACOL SCI, V33, P341, DOI 10.1016/j.tips.2012.03.010; Smith RAJ, 2011, ANTIOXID REDOX SIGN, V15, P3021, DOI 10.1089/ars.2011.3969; Starkov AA, 2008, ANN NY ACAD SCI, V1147, P37, DOI 10.1196/annals.1427.015; Stowe DF, 2013, BBA-BIOMEMBRANES, V1828, P427, DOI 10.1016/j.bbamem.2012.08.031; Szabo I, 2005, J BIOL CHEM, V280, P12790, DOI 10.1074/jbc.M413548200; Szabo I, 2011, CELL DEATH DIFFER, V18, P427, DOI 10.1038/cdd.2010.112; SZABO I, 1991, J BIOL CHEM, V266, P3376; Szabo I, 2012, PFLUG ARCH EUR J PHY, V463, P231, DOI 10.1007/s00424-011-1058-7; Szabo I, 2008, P NATL ACAD SCI USA, V105, P14861, DOI 10.1073/pnas.0804236T05; Tajeddine N, 2008, ONCOGENE, V27, P4221, DOI 10.1038/onc.2008.63; Takeda K, 2008, ANNU REV PHARMACOL, V48, P199, DOI 10.1146/annurev.pharmtox.48.113006.094606; Tan WZ, 2012, BBA-BIOMEMBRANES, V1818, P1555, DOI 10.1016/j.bbamem.2011.12.032; Tang ZJ, 2012, J BIOENERG BIOMEMBR, V44, P117, DOI 10.1007/s10863-012-9420-9; Tikunov A, 2010, ARCH BIOCHEM BIOPHYS, V495, P174, DOI 10.1016/j.abb.2010.01.008; Toczylowska-Maminska R, 2014, J INVEST DERMATOL, V134, P764, DOI 10.1038/jid.2013.422; Tomasello F, 2009, CELL RES, V19, P1363, DOI 10.1038/cr.2009.98; Tong OS, 2008, ANTI-CANCER DRUG, V19, P573, DOI 10.1097/CAD.0b013e3282fc46b0; Traba J, 2012, CELL DEATH DIFFER, V19, P650, DOI 10.1038/cdd.2011.139; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Tsujimoto Y, 2000, CELL DEATH DIFFER, V7, P1174, DOI 10.1038/sj.cdd.4400780; Ueda S, 2002, ANTIOXID REDOX SIGN, V4, P405, DOI 10.1089/15230860260196209; Venediktova N, 2013, MOL CELL BIOCHEM, V383, P261, DOI 10.1007/s11010-013-1774-8; Vihko P, 2005, J STEROID BIOCHEM, V93, P277, DOI 10.1016/j.jsbmb.2005.01.002; Wallace DC, 2012, NAT REV CANCER, V12, P685, DOI 10.1038/nrc3365; Wang J, 2008, CANCER BIOL THER, V7, P1875, DOI 10.4161/cbt.7.12.7067; Wang YZ, 2013, CELL DEATH DIFFER, V20, P1359, DOI 10.1038/cdd.2013.90; Wolf A, 2011, J EXP MED, V208, P313, DOI 10.1084/jem.20101470; Wrzosek A, 2012, EUR J PHARMACOL, V690, P60, DOI 10.1016/j.ejphar.2012.06.029; Wulff H, 2000, P NATL ACAD SCI USA, V97, P8151, DOI 10.1073/pnas.97.14.8151; Yagoda N, 2007, NATURE, V447, P864, DOI 10.1038/nature05859; Zaid H, 2005, CELL DEATH DIFFER, V12, P751, DOI 10.1038/sj.cdd.4401599; Zoratti M, 2009, BBA-BIOENERGETICS, V1787, P351, DOI 10.1016/j.bbabio.2008.11.015	193	69	71	1	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2014	33	49					5569	5581		10.1038/onc.2013.578	http://dx.doi.org/10.1038/onc.2013.578			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW1ZW	24469031				2022-12-17	WOS:000346088700001
J	Leconet, W; Larbouret, C; Chardes, T; Thomas, G; Neiveyans, M; Busson, M; Jarlier, M; Radosevic-Robin, N; Pugniere, M; Bernex, F; Penault-Llorca, F; Pasquet, JM; Pelegrin, A; Robert, B				Leconet, W.; Larbouret, C.; Chardes, T.; Thomas, G.; Neiveyans, M.; Busson, M.; Jarlier, M.; Radosevic-Robin, N.; Pugniere, M.; Bernex, F.; Penault-Llorca, F.; Pasquet, J-M; Pelegrin, A.; Robert, B.			Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy	ONCOGENE			English	Article						RTK; monoclonal antibodies; pancreatic cancer; targeted therapy	TO-MESENCHYMAL TRANSITION; TYROSINE KINASE AXL; THERAPEUTIC TARGET; DRUG-RESISTANCE; MONOCLONAL-ANTIBODY; CELL INVASION; TUMOR-GROWTH; ACTIVATION; EGFR; OVEREXPRESSION	AXL receptor tyrosine kinase (RTK) is implicated in proliferation and invasion of many cancers, particularly in pancreatic ductal adenocarcinoma (PDAC), for which new therapeutic options are urgently required. We investigated whether inhibition of AXL activity by specific monoclonal antibodies (mAbs) is efficient in limiting proliferation and migration of pancreatic cancer cells. Expression of AXL was evaluated by immunohistochemistry in 42 PDAC. The AXL role in oncogenesis was studied using the short hairpin RNA approach in a pancreatic carcinoma cell line. We further generated antihuman AXL mAbs and evaluated their inhibitory effects and the AXL downstream signaling pathways first in vitro, in a panel of pancreatic cancer cell lines and then in vivo, using subcutaneous or orthotopic pancreatic tumor xenografts. AXL receptor was found expressed in 76% (32/ 42) of PDAC and was predominantly present in invasive cells. The AXL-knockdown Panc-1 cells decreased in vitro cell migration, survival and proliferation, and reduced in vivo tumor growth. Two selected anti-AXL mAbs (D9 and E8), which inhibited phosphorylation of AXL and of its downstream target AKT without affecting growth arrest-specific factor 6 (GAS6) binding, induced downexpression of AXL by internalization, leading to an inhibition of proliferation and migration in the four pancreatic cancer cell lines studied. In vivo, treatment by anti-AXL mAbs significantly reduced growth of both subcutaneous and orthotopic pancreatic tumor xenografts independently of their KRAS mutation status. Our in vitro and preclinical in vivo data demonstrate that anti-human AXL mAbs could represent a new approach to the pancreatic cancer immunotherapy.	[Leconet, W.; Larbouret, C.; Chardes, T.; Thomas, G.; Neiveyans, M.; Busson, M.; Pugniere, M.; Bernex, F.; Pelegrin, A.; Robert, B.] Univ Montpellier I, INSERM U896, IRCM, CRLC Val dAurelle Paul Lamarque, Montpellier 5, France; [Jarlier, M.] CRLC Val dAurelle Paul Lamarque, Unite Biostat, F-34298 Montpellier 5, Languedoc Rouss, France; [Radosevic-Robin, N.; Penault-Llorca, F.] Ctr Jean Perrin, Dept Biopathol, F-63011 Clermont Ferrand 1, France; [Radosevic-Robin, N.; Penault-Llorca, F.] Univ Auvergne, ERTICa EA4677, Clermont Ferrand, France; [Pasquet, J-M] Univ Victor Segalen, Hematol Lab, CHU Bordeaux, INSERM U876, Bordeaux, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; UNICANCER; Centre Jean Perrin; Universite Clermont Auvergne (UCA); CHU Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	Robert, B (corresponding author), CRLC Val dAurelle Paul Lamarque, IRCM INSERM U896, 208 Rue Apothicaires, F-34298 Montpellier 5, Languedoc Rouss, France.	bruno.robert@inserm.fr	Chardès, Thierry/B-5420-2019; Pèlegrin, André/J-3167-2016; Pugniere, Martine/T-1355-2017; ROBERT, Bruno/AAB-7581-2020; PUGNIERE, Martine/AAD-4315-2020; Leconet, Wilhem/AAH-5681-2020; PASQUET, JEAN-MAX/I-9702-2014; PASQUET, JEAN-MAX/T-4906-2019	Chardès, Thierry/0000-0002-1836-7439; Pugniere, Martine/0000-0002-2049-2909; ROBERT, Bruno/0000-0001-5573-6945; PUGNIERE, Martine/0000-0002-2049-2909; PASQUET, JEAN-MAX/0000-0002-1345-3776; Pelegrin, Andre/0000-0001-9254-2648	INSERM; Oribase Pharma	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Oribase Pharma	We thank Florence Frayssinoux, Sabine Bousquie and Genevieve Heintz for their technical help. We also thank the ICRM animal facility staff and the 'Reseau d'Histologie Experimentale de Montpellier' histology facility for processing our animal tissues and RIO Imaging facilities. This work was supported by INSERM and Oribase Pharma.	Beck A, 2010, NAT REV IMMUNOL, V10, P345, DOI 10.1038/nri2747; Bibeau F, 2009, J CLIN ONCOL, V27, P1122, DOI 10.1200/JCO.2008.18.0463; Bossard C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044787; Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558; Cartron G, 2002, BLOOD, V99, P754, DOI 10.1182/blood.V99.3.754; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Gaborit N, 2011, J BIOL CHEM, V286, P11337, DOI 10.1074/jbc.M111.223503; Gioia R, 2011, BLOOD, V118, P2211, DOI 10.1182/blood-2010-10-313692; Gjerdrum C, 2010, P NATL ACAD SCI USA, V107, P1124, DOI 10.1073/pnas.0909333107; Hong CC, 2008, CANCER LETT, V268, P314, DOI 10.1016/j.canlet.2008.04.017; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Kim EJ, 2011, CURR OPIN GASTROEN, V27, P460, DOI 10.1097/MOG.0b013e328349e31f; Koorstra JBM, 2009, CANCER BIOL THER, V8, P618, DOI 10.4161/cbt.8.7.7923; Krantz SB, 2012, J SURG RES, V173, P105, DOI 10.1016/j.jss.2011.09.020; Larbouret C, 2007, CLIN CANCER RES, V13, P3356, DOI 10.1158/1078-0432.CCR-06-2302; Lay JD, 2007, CANCER RES, V67, P3878, DOI 10.1158/0008-5472.CAN-06-3191; Li Y, 2009, ONCOGENE, V28, P3442, DOI 10.1038/onc.2009.212; Linger RMA, 2013, ONCOGENE, V32, P3420, DOI 10.1038/onc.2012.355; Linger RMA, 2008, ADV CANCER RES, V100, P35, DOI 10.1016/S0065-230X(08)00002-X; Linger RM, 2010, EXPERT OPIN THER TAR, V14, P1073, DOI 10.1517/14728222.2010.515980; LIU E, 1988, P NATL ACAD SCI USA, V85, P1952, DOI 10.1073/pnas.85.6.1952; Liu L, 2009, CANCER RES, V69, P6871, DOI 10.1158/0008-5472.CAN-08-4490; Macleod K, 2005, CANCER RES, V65, P6789, DOI 10.1158/0008-5472.CAN-04-2684; Mahadevan D, 2007, ONCOGENE, V26, P3909, DOI 10.1038/sj.onc.1210173; Mishra A, 2012, MOL CANCER RES, V10, P703, DOI 10.1158/1541-7786.MCR-11-0569; Musolino A, 2008, J CLIN ONCOL, V26, P1789, DOI 10.1200/JCO.2007.14.8957; Nelson NJ, 2007, J NATL CANCER I, V99, P1432, DOI 10.1093/jnci/djm180; Rankin EB, 2010, CANCER RES, V70, P7570, DOI 10.1158/0008-5472.CAN-10-1267; Robert B, 1996, CANCER RES, V56, P4758; Song XZ, 2011, CANCER-AM CANCER SOC, V117, P734, DOI 10.1002/cncr.25483; Tai KY, 2008, ONCOGENE, V27, P4044, DOI 10.1038/onc.2008.57; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tredan O, 2007, J NATL CANCER I, V99, P1441, DOI 10.1093/jnci/djm135; Troiani T, 2012, CURR DRUG TARGETS, V13, P802, DOI 10.2174/138945012800564158; Vanneman M, 2012, NAT REV CANCER, V12, P237, DOI 10.1038/nrc3237; Verma A, 2011, MOL CANCER THER, V10, P1763, DOI 10.1158/1535-7163.MCT-11-0116; Vuoriluoto K, 2011, ONCOGENE, V30, P1436, DOI 10.1038/onc.2010.509; Wong HH, 2009, NAT REV GASTRO HEPAT, V6, P412, DOI 10.1038/nrgastro.2009.89; Ye X, 2010, ONCOGENE, V29, P5254, DOI 10.1038/onc.2010.268; Zhang ZF, 2012, NAT GENET, V44, P852, DOI 10.1038/ng.2330	40	69	78	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2014	33	47					5405	5414		10.1038/onc.2013.487	http://dx.doi.org/10.1038/onc.2013.487			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MG	24240689	Green Submitted, Green Published, Green Accepted			2022-12-17	WOS:000345120700002
J	Benson, EK; Mungamuri, SK; Attie, O; Kracikova, M; Sachidanandam, R; Manfredi, JJ; Aaronson, SA				Benson, E. K.; Mungamuri, S. K.; Attie, O.; Kracikova, M.; Sachidanandam, R.; Manfredi, J. J.; Aaronson, S. A.			p53-dependent gene repression through p21 is mediated by recruitment of E2F4 repression complexes	ONCOGENE			English	Article						p53; p21; E2F4; RB; p130; transcriptional repression	ARF TUMOR-SUPPRESSOR; WILD-TYPE P53; CELL-CYCLE; TRANSCRIPTIONAL REPRESSION; NEGATIVE REGULATION; DOWN-REGULATION; POCKET PROTEIN; DIRECT BINDING; SURVIVIN GENE; TARGET GENES	The p53 tumor suppressor protein is a major sensor of cellular stresses, and upon stabilization, activates or represses many genes that control cell fate decisions. While the mechanism of p53-mediated transactivation is well established, several mechanisms have been proposed for p53-mediated repression. Here, we demonstrate that the cyclin-dependent kinase inhibitor p21 is both necessary and sufficient for the downregulation of known p53-repression targets, including survivin, CDC25C, and CDC25B in response to p53 induction. These same targets are similarly repressed in response to p16 overexpression, implicating the involvement of the shared downstream retinoblastoma (RB)-E2F pathway. We further show that in response to either p53 or p21 induction, E2F4 complexes are specifically recruited onto the promoters of these p53-repression targets. Moreover, abrogation of E2F4 recruitment via the inactivation of RB pocket proteins, but not by RB loss of function alone, prevents the repression of these genes. Finally, our results indicate that E2F4 promoter occupancy is globally associated with p53-repression targets, but not with p53 activation targets, implicating E2F4 complexes as effectors of p21-dependent p53-mediated repression.	[Benson, E. K.; Mungamuri, S. K.; Kracikova, M.; Manfredi, J. J.; Aaronson, S. A.] Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA; [Attie, O.; Sachidanandam, R.] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Aaronson, SA (corresponding author), Mt Sinai Sch Med, Dept Oncol Sci, 1 Gustave L Levy Pl,Box 1130, New York, NY 10029 USA.	stuart.aaronson@mssm.edu	sachidanandam, ravi/Q-6916-2019	sachidanandam, ravi/0000-0001-9844-4459; Mungamuri, Sathish Kumar/0000-0002-0012-5298	Breast Cancer Research Foundation; National Cancer Institute [P01CA080058]; NCI [T32CA078207]; NATIONAL CANCER INSTITUTE [T32CA078207, P01CA080058] Funding Source: NIH RePORTER	Breast Cancer Research Foundation; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by grants from the Breast Cancer Research Foundation and by Award Number P01CA080058 from the National Cancer Institute. EB was supported by the NCI Training Program in Cancer Biology (T32CA078207). We thank S Lee, Cutaneous Biology Research, MGH Harvard Medical School for helpful discussions.	Akiri G, 2009, ONCOGENE, V28, P2163, DOI 10.1038/onc.2009.82; Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; Aslanian A, 2004, GENE DEV, V18, P1413, DOI 10.1101/gad.1196704; Banerjee T, 2009, NUCLEIC ACIDS RES, V37, P2688, DOI 10.1093/nar/gkp110; Benson EK, 2010, J CELL SCI, V123, P2605, DOI 10.1242/jcs.067306; Bindra RS, 2006, CANCER BIOL THER, V5, P1400, DOI 10.4161/cbt.5.10.3454; Bohlig L, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/464916; Brooks CL, 2010, CELL RES, V20, P614, DOI 10.1038/cr.2010.53; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Burger A, 2010, P NATL ACAD SCI USA, V107, P4016, DOI 10.1073/pnas.0915138107; Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473; Chen HZ, 2009, NAT REV CANCER, V9, P785, DOI 10.1038/nrc2696; Chicas A, 2010, CANCER CELL, V17, P376, DOI 10.1016/j.ccr.2010.01.023; Crosby ME, 2004, CANCER BIOL THER, V3, P1208, DOI 10.4161/cbt.3.12.1494; Dalvai M, 2011, ONCOGENE, V30, P2282, DOI 10.1038/onc.2010.588; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; El-Deiry WS, 2003, ONCOGENE, V22, P7486, DOI 10.1038/sj.onc.1206949; Esteve PO, 2007, J BIOL CHEM, V282, P2615, DOI 10.1074/jbc.M606203200; Fang L, 1999, ONCOGENE, V18, P2789, DOI 10.1038/sj.onc.1202615; Godefroy N, 2004, NUCLEIC ACIDS RES, V32, P4480, DOI 10.1093/nar/gkh773; Gottifredi V, 2001, MOL CELL BIOL, V21, P1066, DOI 10.1128/MCB.21.4.1066-1076.2001; Hammond EM, 2006, MOL CELL BIOL, V26, P3492, DOI 10.1128/MCB.26.9.3492-3504.2006; Helmbold H, 2009, ONCOGENE, V28, P3456, DOI 10.1038/onc.2009.222; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Imbriano C, 2005, MOL CELL BIOL, V25, P3737, DOI 10.1128/MCB.25.9.3737-3751.2005; Innocente SA, 2005, FEBS LETT, V579, P1001, DOI 10.1016/j.febslet.2004.12.073; Jung YS, 2010, CELL SIGNAL, V22, P1003, DOI 10.1016/j.cellsig.2010.01.013; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Kho PS, 2004, J BIOL CHEM, V279, P21183, DOI 10.1074/jbc.M311912200; Kitayner M, 2006, MOL CELL, V22, P741, DOI 10.1016/j.molcel.2006.05.015; Komori H, 2005, EMBO J, V24, P3724, DOI 10.1038/sj.emboj.7600836; Kracikova M, 2013, CELL DEATH DIFFER, V20, P576, DOI 10.1038/cdd.2012.155; Lammens T, 2009, TRENDS CELL BIOL, V19, P111, DOI 10.1016/j.tcb.2009.01.002; Laptenko O, 2006, CELL DEATH DIFFER, V13, P951, DOI 10.1038/sj.cdd.4401916; Lee BK, 2011, NUCLEIC ACIDS RES, V39, P3558, DOI 10.1093/nar/gkq1313; Li BQ, 2001, J BIOL CHEM, V276, P29729, DOI 10.1074/jbc.M101167200; Litovchick L, 2007, MOL CELL, V26, P539, DOI 10.1016/j.molcel.2007.04.015; Litovchick L, 2011, GENE DEV, V25, P801, DOI 10.1101/gad.2034211; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Macip S, 2002, EMBO J, V21, P2180, DOI 10.1093/emboj/21.9.2180; Mandinova A, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001366; Matsui T, 2004, J BIOL CHEM, V279, P25093, DOI 10.1074/jbc.M403232200; Mirza A, 2003, ONCOGENE, V22, P3645, DOI 10.1038/sj.onc.1206477; Mungamuri SK, 2012, NAT STRUCT MOL BIOL, V19, P478, DOI 10.1038/nsmb.2271; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Rashid NN, 2011, J GEN VIROL, V92, P2620, DOI 10.1099/vir.0.035352-0; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Roperch JP, 1998, NAT MED, V4, P835, DOI 10.1038/nm0798-835; Rother K, 2007, CELL CYCLE, V6, P853, DOI 10.4161/cc.6.7.4017; Roy S, 2008, MOL CANCER THER, V7, P1931, DOI 10.1158/1535-7163.MCT-07-2353; Sengupta S, 2005, ONCOGENE, V24, P1738, DOI 10.1038/sj.onc.1208380; Shats I, 2004, J BIOL CHEM, V279, P50976, DOI 10.1074/jbc.M402502200; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Spurgers KB, 2006, J BIOL CHEM, V281, P25134, DOI 10.1074/jbc.M513901200; St Clair S, 2004, MOL CELL, V16, P725; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; Takahashi Y, 2000, GENE DEV, V14, P804; Tang XH, 2004, ONCOGENE, V23, P5759, DOI 10.1038/sj.onc.1207706; TEWEY KM, 1984, SCIENCE, V226, P466, DOI 10.1126/science.6093249; TSANG NM, 1994, RADIAT RES, V140, P172, DOI 10.2307/3578900; Ucar D, 2009, BIOINFORMATICS, V25, pI137, DOI 10.1093/bioinformatics/btp213; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang B, 2010, CELL CYCLE, V9, P870, DOI 10.4161/cc.9.5.10825; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Zeng YX, 2011, CANCER RES, V71, P2781, DOI 10.1158/0008-5472.CAN-10-3483; Zhu WC, 2004, EMBO J, V23, P4615, DOI 10.1038/sj.emboj.7600459	69	69	69	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2014	33	30					3959	3969		10.1038/onc.2013.378	http://dx.doi.org/10.1038/onc.2013.378			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8NA	24096481	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000339394700008
J	West, NR; Murray, JI; Watson, PH				West, N. R.; Murray, J. I.; Watson, P. H.			Oncostatin-M promotes phenotypic changes associated with mesenchymal and stem cell-like differentiation in breast cancer	ONCOGENE			English	Article						oncostatin-M; breast cancer; cancer stem cell; cytokine; epithelial-to-mesenchymal transition; inflammation	PATHOLOGICAL COMPLETE RESPONSE; STEROID-HORMONE RECEPTORS; IN-VITRO PROPAGATION; SIGNAL TRANSDUCER; TRANSITION; EXPRESSION; CARCINOMA; PATHWAY; ALPHA; CHEMOTHERAPY	Cancer stem cell (CSC) biology and the epithelial-to-mesenchymal transition (EMT) are thought to be mechanistically linked and may be key components of cancer development and progression. However, stimuli that induce EMT and CSC-like features ('stemness') are poorly defined. We and others have shown that the inflammatory cytokine oncostatin-M (OSM) mediates phenotypic changes in breast cancer that are consistent with EMT and dedifferentiation, including enhanced migration and loss of hormone receptors. In this study, we have expanded on these prior observations to determine whether OSM is a cell-extrinsic driver of EMT and/or stemness. OSM stimulation of the luminal breast cancer cell lines MCF7 and T47D induced EMT features including loss of membranous E-cadherin and induction of snail and slug expression. OSM treatment markedly enhanced the formation of mammospheres (up to 20-fold, P < 0.001), which displayed high expression of the pluripotency factor SOX2. The proportion of cells with a CD44(high)CD24(-/low) phenotype was similarly increased by OSM (P < 0.001). OSM-induced mammosphere formation and CD44(high)CD24(-/low) induction was dependent on PI3K signalling. In silico analysis of human breast tumours (from a publicly available data set, n = 322) confirmed that co-expression of a PI3K transcriptional signature, but not MAPK or STAT3 signatures, was necessary to detect an association between OSMR and poor prognosis. Assessment of a second in silico data set (n = 241 breast tumours) confirmed a significant relationship between OSMR, markers of EMT and CSCs, and chemotherapy resistance. Direct analysis of mRNA expression by RT-PCR in a third cohort (n = 72 breast tumours) demonstrated that high expression of OSM is associated positively with indicators of EMT (SNAI1, P < 0.001) and stemness (SOX2, P < 0.05). Our data suggest for the first time that OSM may promote a clinically relevant EMT/CSC-like phenotype in human breast cancer via a PI3K-dependent mechanism.	[West, N. R.; Murray, J. I.; Watson, P. H.] British Columbia Canc Agcy, Deeley Res Ctr, Victoria, BC, Canada; [West, N. R.; Watson, P. H.] Univ Victoria, Dept Biochem & Microbiol, Victoria, BC, Canada; [Watson, P. H.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada	British Columbia Cancer Agency; University of Victoria; University of British Columbia	Watson, PH (corresponding author), Deeley Res Ctr, 2410 Lee Ave,3rd Floor Res, Victoria, BC V8R 6V5, Canada.	pwatson@bccancer.bc.ca		West, Nathaniel/0000-0001-9991-0503; Watson, Peter/0000-0002-1642-0638	Canadian Breast Cancer Foundation (CBCF); BC/Yukon chapter; US DOD Breast Cancer Research Program Predoctoral award [W81XWH-08-1-0781]; CBCF BC/Yukon Region postdoctoral fellowship; BC Cancer Foundation	Canadian Breast Cancer Foundation (CBCF); BC/Yukon chapter; US DOD Breast Cancer Research Program Predoctoral award; CBCF BC/Yukon Region postdoctoral fellowship; BC Cancer Foundation	We are grateful to members of the Deeley Research Centre for helpful discussion. We thank the Manitoba Breast Tumour Bank (a member of the Canadian Tumour Repository Network) for providing breast cancer tissue specimens and the authors of the UNC and MAQC cohorts for making their data freely available. Financial support was from the Canadian Breast Cancer Foundation (CBCF), BC/Yukon chapter and the BC Cancer Foundation. NRW was supported by a US DOD Breast Cancer Research Program Predoctoral award (W81XWH-08-1-0781). JIM is supported by a CBCF BC/Yukon Region postdoctoral fellowship.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Alvarez JV, 2005, CANCER RES, V65, P5054, DOI 10.1158/0008-5472.CAN-04-4281; Asiedu MK, 2011, CANCER RES, V71, P4707, DOI 10.1158/0008-5472.CAN-10-4554; Balic M, 2006, CLIN CANCER RES, V12, P5615, DOI 10.1158/1078-0432.CCR-06-0169; Bhat-Nakshatri P, 2004, BRIT J CANCER, V90, P853, DOI 10.1038/sj.bjc.6601541; Blanchard F, 2001, J BIOL CHEM, V276, P47038, DOI 10.1074/jbc.M107971200; Chavey C, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1648; Christiansen JJ, 2006, CANCER RES, V66, P8319, DOI 10.1158/0008-5472.CAN-06-0410; Clarkson RWE, 2006, MOL ENDOCRINOL, V20, P675, DOI 10.1210/me.2005-0392; Colleoni M, 2004, CLIN CANCER RES, V10, P6622, DOI 10.1158/1078-0432.CCR-04-0380; Colleoni M, 2009, BREAST CANCER RES TR, V116, P359, DOI 10.1007/s10549-008-0223-y; Creighton CJ, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2594; Dangi-Garimella S, 2009, EMBO J, V28, P347, DOI 10.1038/emboj.2008.294; Dhasarathy A, 2007, MOL ENDOCRINOL, V21, P2907, DOI 10.1210/me.2007-0293; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Douglas AM, 1997, ONCOGENE, V14, P661, DOI 10.1038/sj.onc.1200882; Dubois-Marshall S, 2011, CLIN EXP METASTAS, V28, P811, DOI 10.1007/s10585-011-9412-x; Emberley ED, 2005, CANCER RES, V65, P5696, DOI 10.1158/0008-5472.CAN-04-3927; Emberley ED, 2004, BREAST CANCER RES, V6, P153, DOI 10.1186/bcr816; Fulford LG, 2006, HISTOPATHOLOGY, V49, P22, DOI 10.1111/j.1365-2559.2006.02453.x; de Herreros AG, 2010, J MAMMARY GLAND BIOL, V15, P135, DOI 10.1007/s10911-010-9179-8; Ginestier C, 2010, J CLIN INVEST, V120, P485, DOI 10.1172/JCI39397; Grant SL, 2002, ONCOGENE, V21, P460, DOI 10.1038/sj.onc.1205100; Guarneri V, 2006, J CLIN ONCOL, V24, P1037, DOI 10.1200/JCO.2005.02.6914; Guo L, 2013, ONCOGENE, V32, P5272, DOI 10.1038/onc.2012.573; Hardt O, 2012, CANCER LETT, V325, P165, DOI 10.1016/j.canlet.2012.06.010; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Holzer RG, 2004, CLIN EXP METASTAS, V21, P167, DOI 10.1023/B:CLIN.0000024760.02667.db; Iliopoulos D, 2011, P NATL ACAD SCI USA, V108, P1397, DOI 10.1073/pnas.1018898108; Jorcyk CL, 2006, CYTOKINE, V33, P323, DOI 10.1016/j.cyto.2006.03.004; Klymkowsky MW, 2009, AM J PATHOL, V174, P1588, DOI 10.2353/ajpath.2009.080545; Korkaya H, 2011, J CLIN INVEST, V121, P3804, DOI 10.1172/JCI57099; Korkaya H, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000121; Lawson JC, 2009, BREAST CANCER RES TR, V118, P241, DOI 10.1007/s10549-009-0524-9; Leis O, 2012, ONCOGENE, V31, P1354, DOI 10.1038/onc.2011.338; Liu JW, 1997, CELL GROWTH DIFFER, V8, P667; Loboda A, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-26; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; May CD, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2789; Mego M, 2010, NAT REV CLIN ONCOL, V7, P693, DOI 10.1038/nrclinonc.2010.171; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Plath K, 2011, NAT REV GENET, V12, P253, DOI 10.1038/nrg2955; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Popovici V, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2468; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Rakha EA, 2008, HISTOPATHOLOGY, V52, P67, DOI 10.1111/j.1365-2559.2007.02894.x; Ring AE, 2004, BRIT J CANCER, V91, P2012, DOI 10.1038/sj.bjc.6602235; Rodriguez-Pinilla SM, 2007, MODERN PATHOL, V20, P474, DOI 10.1038/modpathol.3800760; Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533; Sullivan NJ, 2009, ONCOGENE, V28, P2940, DOI 10.1038/onc.2009.180; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tanaka M, 2004, REV PHYSIOL BIOCH P, V149, P39, DOI 10.1007/s10254-003-0013-1; Teschendorff AE, 2007, PLOS COMPUT BIOL, V3, P1539, DOI 10.1371/journal.pcbi.0030161; West NR, 2010, ONCOGENE, V29, P2083, DOI 10.1038/onc.2009.488; West NR, 2012, ENDOCR-RELAT CANCER, V19, P181, DOI 10.1530/ERC-11-0326; Ye Y, 2010, ONCOGENE, V29, P1451, DOI 10.1038/onc.2009.433; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183; Zhang F, 2003, ONCOGENE, V22, P894, DOI 10.1038/sj.onc.1206158; Zhou JB, 2007, P NATL ACAD SCI USA, V104, P16158, DOI 10.1073/pnas.0702596104	61	69	70	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	2014	33	12					1485	1494		10.1038/onc.2013.105	http://dx.doi.org/10.1038/onc.2013.105			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD4TS	23584474				2022-12-17	WOS:000333244200002
J	Sarkar, S; Brautigan, DL; Parsons, SJ; Larner, JM				Sarkar, S.; Brautigan, D. L.; Parsons, S. J.; Larner, J. M.			Androgen receptor degradation by the E3 ligase CHIP modulates mitotic arrest in prostate cancer cells	ONCOGENE			English	Article						prostate cancer; androgen receptor; 2-methoxyestradiol; CHIP; mitotic arrest	ENDOGENOUS MAMMALIAN METABOLITE; ACTIVATED PROTEIN-KINASE; INHIBITS ANGIOGENESIS; ESTROGEN METABOLITE; CDC6 TRANSCRIPTION; ENDOTHELIAL-CELLS; CYCLE PROGRESSION; 2-METHOXYESTRADIOL; EXPRESSION; APOPTOSIS	The androgen receptor (AR) has a vital role in the onset and progression of prostate cancer by promoting G1-S progression, possibly by functioning as a licensing factor for DNA replication. We here report that low dose 2-methoxyestradiol (2-ME), an endogenous estrogen metabolite, induces mitotic arrest in prostate cancer cells involving activation of the E3 ligase CHIP (C-terminus of Hsp70-interacting protein) and degradation of the AR. Depletion of the AR by small interfering RNA (siRNA) eliminates 2-ME-induced arrest and introducing AR into PC3-M cells confers 2-ME-induced mitotic arrest. Knockdown of CHIP or MDM2 (mouse homolog of double minute 2 protein) individually or in combination reduced AR degradation and abrogated M phase arrest induced by 2-ME. Our data link AR degradation via ubiquitination to mitotic arrest. Targeting the AR by activating E3 ligases such as CHIP represents a novel strategy for the treatment of prostate cancer.	[Sarkar, S.; Larner, J. M.] Univ Virginia, Sch Med, Hlth Sci Ctr, Dept Radiat Oncol, Charlottesville, VA 22908 USA; [Brautigan, D. L.] Univ Virginia, Ctr Cell Signaling, Charlottesville, VA 22908 USA; [Brautigan, D. L.; Parsons, S. J.] Univ Virginia, Sch Med, Dept Microbiol Immunol & Canc Biol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Larner, JM (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Radiat Oncol, 1300 Jefferson Pk Ave, Charlottesville, VA 22908 USA.	jml2p@virginia.edu			National Institutes of Health [5R01CA142823-02]; Charles R. Burnett Jr and W. Griffin Burnett Fund; NATIONAL CANCER INSTITUTE [R01CA120413, R01CA142823] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Charles R. Burnett Jr and W. Griffin Burnett Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported, in whole or in part, by the National Institutes of Health grant 5R01CA142823-02 (to J. M. L.) as well as the Charles R. Burnett Jr and W. Griffin Burnett Fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Cardozo CP, 2003, ARCH BIOCHEM BIOPHYS, V410, P134, DOI 10.1016/S0003-9861(02)00680-X; Casarez EV, 2007, CANCER RES, V67, P8316, DOI 10.1158/0008-5472.CAN-07-1755; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chymkowitch P, 2011, EMBO J, V30, P468, DOI 10.1038/emboj.2010.337; CUSHMAN M, 1995, J MED CHEM, V38, P2041, DOI 10.1021/jm00012a003; D'Antonio JM, 2009, ENDOCR-RELAT CANCER, V16, P325, DOI 10.1677/ERC-08-0205; Day JM, 2003, J STEROID BIOCHEM, V84, P317, DOI 10.1016/S0960-0760(03)00045-1; FOTSIS T, 1994, NATURE, V368, P237, DOI 10.1038/368237a0; Gao XH, 2005, ENDOCRINOLOGY, V146, P1707, DOI 10.1210/en.2004-1198; Gaughan L, 2005, NUCLEIC ACIDS RES, V33, P13, DOI 10.1093/nar/gki141; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; Hamel E, 1996, BIOCHEMISTRY-US, V35, P1304, DOI 10.1021/bi951559s; He B, 2004, J BIOL CHEM, V279, P30643, DOI 10.1074/jbc.M403117200; Huang CY, 2005, MOL ENDOCRINOL, V19, P2915, DOI 10.1210/me.2005-0097; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Jin F, 2009, NUCLEIC ACIDS RES, V37, P4826, DOI 10.1093/nar/gkp510; Kumar AP, 2001, MOL CARCINOGEN, V31, P111, DOI 10.1002/mc.1046; Lara PN, 1999, CANCER INVEST, V17, P137; Lee DK, 2003, J CLIN ENDOCR METAB, V88, P4043, DOI 10.1210/jc.2003-030261; Lee HJ, 2003, CELL MOL LIFE SCI, V60, P1613, DOI 10.1007/s00018-003-2309-3; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Litvinov IV, 2006, P NATL ACAD SCI USA, V103, P15085, DOI 10.1073/pnas.0603057103; Mallik I, 2008, BBA-MOL CELL RES, V1783, P1737, DOI 10.1016/j.bbamcr.2008.05.006; Morishima Y, 2008, HUM MOL GENET, V17, P3942, DOI 10.1093/hmg/ddn296; PERTSCHUK LP, 1994, ANN SURG ONCOL, V1, P495, DOI 10.1007/BF02303615; Prins GS, 1998, J UROLOGY, V159, P641, DOI 10.1016/S0022-5347(01)63692-9; Qadan LR, 2001, BIOCHEM BIOPH RES CO, V285, P1259, DOI 10.1006/bbrc.2001.5320; Schiewer MJ, 2012, MOL CELL ENDOCRINOL, V352, P34, DOI 10.1016/j.mce.2011.06.033; Sharifi Nima, 2006, Am J Ther, V13, P166, DOI 10.1097/00045391-200603000-00013; Sharma MJ, 2003, EMBO J, V22, P6101, DOI 10.1093/emboj/cdg585; Szostak MJ, 2000, ONCOL REP, V7, P699; Tsukamoto A, 1998, BIOCHEM BIOPH RES CO, V248, P9, DOI 10.1006/bbrc.1998.8902; Wang AM, 2010, J BIOL CHEM, V285, P15714, DOI 10.1074/jbc.M109.098806; Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056; Yue TL, 1997, MOL PHARMACOL, V51, P951, DOI 10.1124/mol.51.6.951	36	69	71	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2014	33	1					26	33		10.1038/onc.2012.561	http://dx.doi.org/10.1038/onc.2012.561			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	282YU	23246967	Green Accepted			2022-12-17	WOS:000329212000004
J	Orre, LM; Panizza, E; Kaminskyy, VO; Vernet, E; Graslund, T; Zhivotovsky, B; Lehtio, J				Orre, L. M.; Panizza, E.; Kaminskyy, V. O.; Vernet, E.; Graslund, T.; Zhivotovsky, B.; Lehtio, J.			S100A4 interacts with p53 in the nucleus and promotes p53 degradation	ONCOGENE			English	Article						S100A4; p53; interaction study; proximity ligation assay; immunoprecipitation	METASTASIS-INDUCING PROTEIN; HUMAN BREAST-CANCER; CALCIUM-BINDING PROTEIN; TUMOR-SUPPRESSOR P53; N-TERMINAL DOMAIN; CELL LUNG-CANCER; COLORECTAL-CANCER; E-CADHERIN; DIFFERENTIAL EXPRESSION; PROGNOSTIC-SIGNIFICANCE	S100A4 is a small calcium-binding protein that is commonly overexpressed in a range of different tumor types, and it is widely accepted that S100A4 has an important role in the process of cancer metastasis. In vitro binding assays has shown that S100A4 interacts with the tumor suppressor protein p53, indicating that S100A4 may have additional roles in tumor development. In the present study, we show that endogenous S100A4 and p53 interact in complex samples, and that the interaction increases after inhibition of MDM2-dependent p53 degradation using Nutlin-3A. Further, using proximity ligation assay, we show that the interaction takes place in the cell nucleus. S100A4 knockdown experiments in two p53 wild-type cell lines, A549 and HeLa, resulted in stabilization of p53 protein, indicating that S100A4 is promoting p53 degradation. Finally, we demonstrate that S100A4 knockdown leads to p53-dependent cell cycle arrest and increased cisplatin-induced apoptosis. Thus, our data add a new layer to the oncogenic properties of S100A4 through its inhibition of p53-dependent processes.	[Orre, L. M.; Panizza, E.; Lehtio, J.] Karolinska Inst, Sci Life Lab, Dept Pathol & Oncol, S-17121 Stockholm, Sweden; [Kaminskyy, V. O.; Zhivotovsky, B.] Karolinska Inst, Inst Environm Med, Div Toxicol, S-17121 Stockholm, Sweden; [Vernet, E.; Graslund, T.] AlbaNova Univ Ctr, Royal Inst Technol, KTH, Div Mol Biotechnol,Sch Biotechnol, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Royal Institute of Technology	Orre, LM (corresponding author), Karolinska Inst, Sci Life Lab, Dept Pathol & Oncol, POB 1031, S-17121 Stockholm, Sweden.	lukas.orre@ki.se	Vernet, Erik/G-8520-2011; Vernet, Erik/O-1880-2019; Zhivotovsky, Boris/A-4346-2014	Vernet, Erik/0000-0002-4175-1244; Vernet, Erik/0000-0002-4175-1244; Zhivotovsky, Boris/0000-0002-2238-3482; Kaminskyy, Vitaliy/0000-0002-8151-5270; Panizza, Elena/0000-0003-3490-4107; Orre, Lukas/0000-0002-0384-1003; Lehtio, Janne/0000-0002-8100-9562	Swedish Cancer Society; Swedish Research Foundation; Swedish Research council; Swedish Childhood Cancer Society; European Union; Swedish Institute; Karolinska Institutet; Karolinska Institutet KID funding; Stockholm Cancer Society	Swedish Cancer Society(Swedish Cancer Society); Swedish Research Foundation; Swedish Research council(Swedish Research CouncilEuropean Commission); Swedish Childhood Cancer Society; European Union(European Commission); Swedish Institute; Karolinska Institutet(Karolinska Institutet); Karolinska Institutet KID funding(Karolinska Institutet); Stockholm Cancer Society	We thank Professor Didier Trono at the School of Life Sciences, EPFL, Lausanne, Switzerland for providing the helper plasmids for viral vector production, pG32231 and pMD2.G. We also thank the group of Professor Hjalmar Brismar for assistance in the use of confocal microscopy. This study was supported by grants from the Swedish and Stockholm Cancer Societies, the Swedish Research Foundation, the Swedish Research council, the Swedish Childhood Cancer Society, the European Union (Chemores and Apo-Sys). VOK was supported by a fellowship from the Swedish Institute and Karolinska Institutet. EP was supported by Karolinska Institutet KID funding.	Ambartsumian NS, 1996, ONCOGENE, V13, P1621; Berge G, 2011, AMINO ACIDS, V41, P875, DOI 10.1007/s00726-010-0514-6; Berge G, 2011, AMINO ACIDS, V41, P863, DOI 10.1007/s00726-010-0497-3; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Chen HL, 2001, BIOCHEM BIOPH RES CO, V286, P1212, DOI 10.1006/bbrc.2001.5517; Cho YG, 2003, APMIS, V111, P539, DOI 10.1034/j.1600-0463.2003.1110502.x; Cho YG, 2005, WORLD J GASTROENTERO, V11, P4852, DOI 10.3748/wjg.v11.i31.4852; DAVIES BR, 1993, ONCOGENE, V8, P999; Davies BR, 2002, J PATHOL, V196, P292, DOI 10.1002/path.1051; De Petris L, 2009, LUNG CANCER, V63, P410, DOI 10.1016/j.lungcan.2008.06.003; Deshaies RJ, 2009, ANNU REV BIOCHEM, V78, P399, DOI 10.1146/annurev.biochem.78.101807.093809; Fernandez-Fernandez MR, 2005, P NATL ACAD SCI USA, V102, P4735, DOI 10.1073/pnas.0501459102; Flatmark K, 2003, J PATHOL, V200, P589, DOI 10.1002/path.1381; Gongoll S, 2002, GASTROENTEROLOGY, V123, P1478, DOI 10.1053/gast.2002.36606; Grigorian M, 1996, INT J CANCER, V67, P831, DOI 10.1002/(SICI)1097-0215(19960917)67:6<831::AID-IJC13>3.0.CO;2-4; Grigorian M, 2001, J BIOL CHEM, V276, P22699, DOI 10.1074/jbc.M010231200; Gupta S, 2003, J CLIN ONCOL, V21, P106, DOI 10.1200/JCO.2003.03.024; Heizmann Claus W, 2002, Methods Mol Biol, V172, P69; Hemandas AK, 2006, J SURG ONCOL, V93, P498, DOI 10.1002/jso.20460; Hjerpe R, 2010, INT J BIOCHEM CELL B, V42, P725, DOI 10.1016/j.biocel.2010.01.010; Ismail TM, 2010, J BIOL CHEM, V285, P914, DOI 10.1074/jbc.M109.010892; Itahana Y, 2009, J BIOL CHEM, V284, P5158, DOI 10.1074/jbc.M805696200; Kaminskyy VO, 2012, AUTOPHAGY, V8, P1032, DOI 10.4161/auto.20123; Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279; Kim JH, 2009, ONCOL REP, V22, P41, DOI 10.3892/or_00000404; Kimura K, 2000, INT J ONCOL, V16, P1125; Kriajevska M, 2000, BBA-MOL CELL RES, V1498, P252, DOI 10.1016/S0167-4889(00)00100-2; Lee WY, 2004, ONCOLOGY-BASEL, V66, P429, DOI 10.1159/000079496; Li ZH, 2006, CANCER RES, V66, P5173, DOI 10.1158/0008-5472.CAN-05-3087; Matsubara D, 2005, CANCER SCI, V96, P844, DOI 10.1111/j.1349-7006.2005.00121.x; Matsumoto K, 2007, UROLOGY, V70, P602, DOI 10.1016/j.urology.2007.04.007; Oida Y, 2006, ONCOL REP, V16, P457; Orre LM, 2007, MOL CELL PROTEOMICS, V6, P2122, DOI 10.1074/mcp.M700202-MCP200; Pedersen KB, 2002, BRIT J CANCER, V87, P1281, DOI 10.1038/sj.bjc.6600624; Platt-Higgins AM, 2000, INT J CANCER, V89, P198, DOI 10.1002/(SICI)1097-0215(20000320)89:2<198::AID-IJC16>3.0.CO;2-L; Poyurovsky MV, 2010, NAT STRUCT MOL BIOL, V17, P982, DOI 10.1038/nsmb.1872; Rosty C, 2002, AM J PATHOL, V160, P45, DOI 10.1016/S0002-9440(10)64347-7; Rudland PS, 2000, CANCER RES, V60, P1595; Sali A, 2003, NATURE, V422, P216, DOI 10.1038/nature01513; Santamaria-Kisiel L, 2006, BIOCHEM J, V396, P201, DOI 10.1042/BJ20060195; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Soderberg O, 2008, METHODS, V45, P227, DOI 10.1016/j.ymeth.2008.06.014; Tang Y, 2008, CELL, V133, P612, DOI 10.1016/j.cell.2008.03.025; van Dieck J, 2010, ONCOGENE, V29, P2024, DOI 10.1038/onc.2009.490; van Dieck J, 2010, FEBS LETT, V584, P3269, DOI 10.1016/j.febslet.2010.06.024; van Dieck J, 2009, J MOL BIOL, V394, P922, DOI 10.1016/j.jmb.2009.10.002; van Dieck J, 2009, J BIOL CHEM, V284, P13804, DOI 10.1074/jbc.M901351200; Vasilescu J, 2004, PROTEOMICS, V4, P3845, DOI 10.1002/pmic.200400856; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Xie R, 2007, MODERN PATHOL, V20, P1045, DOI 10.1038/modpathol.3800940; Zou M, 2005, BRIT J CANCER, V93, P1277, DOI 10.1038/sj.bjc.6602856	52	69	71	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	2013	32	49					5531	5540		10.1038/onc.2013.213	http://dx.doi.org/10.1038/onc.2013.213			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	269XF	23752197	hybrid			2022-12-17	WOS:000328276400004
J	Janssen, A; Medema, RH				Janssen, A.; Medema, R. H.			Genetic instability: tipping the balance	ONCOGENE			English	Review						chromosome instability; cancer; mitosis; DNA damage; translocations; aneuploidy	SPINDLE-ASSEMBLY CHECKPOINT; MEROTELIC KINETOCHORE ORIENTATION; TUMOR-SUPPRESSOR GENE; CANCER CELL-LINES; COMPARATIVE GENOMIC HYBRIDIZATION; PREMATURE CHROMATID SEPARATION; MOSAIC VARIEGATED ANEUPLOIDY; WHOLE CHROMOSOME INSTABILITY; AGING-ASSOCIATED PHENOTYPES; MAMMALIAN TISSUE-CELLS	Tumor cells typically contain a genome that is highly divergent from the genome of normal, non-transformed cells. This genetic divergence is caused by a number of distinct changes that the tumor cell acquires during its transformation from a normal cell into a tumorigenic counterpart. Changes to the genome include mutations, deletions, insertions, and also gross chromosomal aberrations, such as chromosome translocations and whole chromosome gains or losses. This genetic disorder of the tumor cell has complicated the identification of crucial driver mutations that cause cancer. Moreover, the large genetic divergence between different tumors causes them to behave very differently, and makes it difficult to predict response to therapy. In addition, tumor cells are genetically unstable and frequently acquire new mutations and/or gross chromosomal aberrations as they divide. This is beneficial for the overall capacity of a tumor to adapt to changes in its environment, but newly acquired genetic alterations can also compromise the genetic dominance of the tumor cell and thus affect tumor cell viability. Here, we review the mechanisms that can cause gross chromosomal aberrations, and discuss how these affect tumor cell viability.	[Janssen, A.; Medema, R. H.] Netherlands Canc Inst, Div Cell Biol, NL-1066 CX Amsterdam, Holland, Netherlands; [Janssen, A.] Univ Med Ctr Utrecht, Dept Med Oncol, Utrecht, Netherlands; [Janssen, A.] Univ Med Ctr Utrecht, Canc Genom Ctr, Utrecht, Netherlands	Netherlands Cancer Institute; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Medema, RH (corresponding author), Netherlands Canc Inst, Div Cell Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Holland, Netherlands.	r.medema@nki.nl	Medema, Rene H/E-2981-2013	Medema, Rene/0000-0002-6754-0381; Janssen, Aniek/0000-0001-6731-6657				Abdel-Rahman WM, 2001, P NATL ACAD SCI USA, V98, P2538, DOI 10.1073/pnas.041603298; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Allshire RC, 2008, NAT REV GENET, V9, P923, DOI 10.1038/nrg2466; Guerrero AA, 2010, P NATL ACAD SCI USA, V107, P4159, DOI 10.1073/pnas.0912143106; Aoki K, 2007, ONCOGENE, V26, P3511, DOI 10.1038/sj.onc.1210141; Aoki K, 2007, J CELL SCI, V120, P3327, DOI 10.1242/jcs.03485; Babu JR, 2003, J CELL BIOL, V160, P341, DOI 10.1083/jcb.200211048; Baker DJ, 2008, NAT CELL BIOL, V10, P825, DOI 10.1038/ncb1744; Baker DJ, 2009, CANCER CELL, V16, P475, DOI 10.1016/j.ccr.2009.10.023; Baker DJ, 2004, NAT GENET, V36, P744, DOI 10.1038/ng1382; Baker DJ, 2006, J CELL BIOL, V172, P529, DOI 10.1083/jcb.200507081; Bakhoum SF, 2011, CLIN CANCER RES, V17, P7704, DOI 10.1158/1078-0432.CCR-11-2049; Bakhoum SF, 2009, CURR BIOL, V19, P1937, DOI 10.1016/j.cub.2009.09.055; Bakhoum SF, 2009, NAT CELL BIOL, V11, P27, DOI 10.1038/ncb1809; Barber TD, 2008, P NATL ACAD SCI USA, V105, P3443, DOI 10.1073/pnas.0712384105; Barnhart MC, 2011, J CELL BIOL, V194, P229, DOI 10.1083/jcb.201012017; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Baudis M, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-226; BENDER MA, 1974, MUTAT RES, V23, P197, DOI 10.1016/0027-5107(74)90140-7; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bin OY, 2002, CLIN ENDOCRINOL, V56, P341, DOI 10.1046/j.1365-2265.2002.01475.x; Birkbak NJ, 2011, CANCER RES, V71, P3447, DOI 10.1158/0008-5472.CAN-10-3667; Boveri T, 1914, FRAGE ENTSTEHUNG MAL, V1; Burds AA, 2005, P NATL ACAD SCI USA, V102, P11296, DOI 10.1073/pnas.0505053102; Cahill DP, 1999, GENOMICS, V58, P181, DOI 10.1006/geno.1999.5831; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861; Castro MAA, 2006, MUTAT RES-FUND MOL M, V600, P150, DOI 10.1016/j.mrfmmm.2006.04.003; Chan KL, 2009, NAT CELL BIOL, V11, P753, DOI 10.1038/ncb1882; Chan KL, 2007, EMBO J, V26, P3397, DOI 10.1038/sj.emboj.7601777; Chesnokova V, 2005, MOL ENDOCRINOL, V19, P2371, DOI 10.1210/me.2005-0137; Chi YH, 2009, INT J CANCER, V124, P1483, DOI 10.1002/ijc.24094; Choi CM, 2009, LUNG CANCER, V64, P66, DOI 10.1016/j.lungcan.2008.07.016; Cimini D, 2004, CURR BIOL, V14, P2149, DOI 10.1016/j.cub.2004.11.029; Cimini D, 2003, J CELL SCI, V116, P4213, DOI 10.1242/jcs.00716; Cimini D, 2002, J CELL SCI, V115, P507; Cimini D, 2001, J CELL BIOL, V153, P517, DOI 10.1083/jcb.153.3.517; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Crasta K, 2012, NATURE, V482, P53, DOI 10.1038/nature10802; Dai W, 2004, CANCER RES, V64, P440, DOI 10.1158/0008-5472.CAN-03-3119; Daniel J, 2011, P NATL ACAD SCI USA, V108, P5384, DOI 10.1073/pnas.1007645108; Davidson JM, 2000, BRIT J CANCER, V83, P1309, DOI 10.1054/bjoc.2000.1458; Davoli T, 2012, CANCER CELL, V21, P765, DOI 10.1016/j.ccr.2012.03.044; Diaz-Rodriguez E, 2008, P NATL ACAD SCI USA, V105, P16719, DOI 10.1073/pnas.0803504105; Dikovskaya D, 2007, J CELL BIOL, V176, P183, DOI 10.1083/jcb.200610099; Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2; Draviam VM, 2006, EMBO J, V25, P2814, DOI 10.1038/sj.emboj.7601168; Duesberg P, 2004, IUBMB LIFE, V56, P65, DOI 10.1080/15216540410001667902; Duesberg P, 1998, P NATL ACAD SCI USA, V95, P13692, DOI 10.1073/pnas.95.23.13692; Duesberg P, 2000, P NATL ACAD SCI USA, V97, P14295, DOI 10.1073/pnas.97.26.14295; Duesberg P, 2007, DRUG RESIST UPDATE, V10, P51, DOI 10.1016/j.drup.2007.02.003; Duker NJ, 2002, AM J MED GENET, V115, P125, DOI 10.1002/ajmg.10688; Duncan AW, 2010, NATURE, V467, P707, DOI 10.1038/nature09414; Fabarius A, 2003, CANCER GENET CYTOGEN, V143, P59, DOI 10.1016/S0165-4608(03)00003-7; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Gao CF, 2007, P NATL ACAD SCI USA, V104, P8995, DOI 10.1073/pnas.0700631104; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Garcia-Higuera I, 2008, NAT CELL BIOL, V10, P802, DOI 10.1038/ncb1742; Gascoigne KE, 2008, CANCER CELL, V14, P111, DOI 10.1016/j.ccr.2008.07.002; Ghadimi BM, 2000, GENE CHROMOSOME CANC, V27, P183, DOI 10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P; Gisselsson D, 2001, AM J PATHOL, V158, P199, DOI 10.1016/S0002-9440(10)63958-2; Gisselsson D, 2001, P NATL ACAD SCI USA, V98, P12683, DOI 10.1073/pnas.211357798; Gisselsson D, 2000, P NATL ACAD SCI USA, V97, P5357, DOI 10.1073/pnas.090013497; Grabsch H, 2003, J PATHOL, V200, P16, DOI 10.1002/path.1324; Hanks S, 2004, NAT GENET, V36, P1159, DOI 10.1038/ng1449; Hansemann D., 1890, ARCH PATHOL ANAT PH, V119, P299, DOI DOI 10.1007/BF01882039; Harrigan JA, 2011, J CELL BIOL, V193, P97, DOI 10.1083/jcb.201011083; Haruki N, 2001, CANCER LETT, V162, P201, DOI 10.1016/S0304-3835(00)00675-3; HASTIE ND, 1989, TRENDS GENET, V5, P326, DOI 10.1016/0168-9525(89)90137-6; HEIM S, 1986, CANCER GENET CYTOGEN, V22, P99, DOI 10.1016/0165-4608(86)90169-X; Hempen PM, 2003, HUM MUTAT, V21, DOI 10.1002/humu.9120; HENEEN WK, 1975, EXP CELL RES, V91, P57, DOI 10.1016/0014-4827(75)90140-8; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Heun P, 2006, DEV CELL, V10, P303, DOI 10.1016/j.devcel.2006.01.014; Holland AJ, 2012, EMBO REP, V13, P501, DOI 10.1038/embor.2012.55; Hu Z, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2487; Ichijima Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008821; Iwaizumi M, 2009, GUT, V58, P249, DOI 10.1136/gut.2008.149468; Iwanaga Y, 2007, CANCER RES, V67, P160, DOI 10.1158/0008-5472.CAN-06-3326; Jallepalli PV, 2001, CELL, V105, P445, DOI 10.1016/S0092-8674(01)00340-3; Janssen A, 2011, ONCOGENE, V30, P2799, DOI 10.1038/onc.2011.30; Janssen A, 2011, SCIENCE, V333, P1895, DOI 10.1126/science.1210214; Janssen A, 2011, NAT CELL BIOL, V13, P199, DOI 10.1038/ncb0311-199; Janssen A, 2009, P NATL ACAD SCI USA, V106, P19108, DOI 10.1073/pnas.0904343106; Jeganathan K, 2007, J CELL BIOL, V179, P255, DOI 10.1083/jcb.200706015; Kabeche L, 2012, CURR BIOL, V22, P638, DOI 10.1016/j.cub.2012.02.030; Kalitsis P, 2000, GENE DEV, V14, P2277, DOI 10.1101/gad.827500; Kalitsis P, 2005, GENE CHROMOSOME CANC, V44, P29, DOI 10.1002/gcc.20215; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; Kasai T, 2002, J BIOL CHEM, V277, P5187, DOI 10.1074/jbc.M110295200; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kolodner RD, 2011, SCIENCE, V333, P942, DOI 10.1126/science.1211154; Kops GJPL, 2004, P NATL ACAD SCI USA, V101, P8699, DOI 10.1073/pnas.0401142101; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Kracjovic M, 2010, NATURE CELL BIOL; Kuukasjarvi T, 1997, CANCER RES, V57, P1597; Lee AJX, 2011, CANCER RES, V71, P1858, DOI 10.1158/0008-5472.CAN-10-3604; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li M, 2010, P NATL ACAD SCI USA, V107, P14188, DOI 10.1073/pnas.1005960107; Li M, 2009, J CELL BIOL, V185, P983, DOI 10.1083/jcb.200904020; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Lukas C, 2011, NAT CELL BIOL, V13, P243, DOI 10.1038/ncb2201; LUONGO C, 1994, CANCER RES, V54, P5947; Malureanu L, 2010, J CELL BIOL, V191, P313, DOI 10.1083/jcb.201003090; Manning AL, 2011, TRENDS CELL BIOL, V21, P433, DOI 10.1016/j.tcb.2011.05.003; Manning AL, 2010, GENE DEV, V24, P1364, DOI 10.1101/gad.1917310; Matsuura S, 2000, AM J HUM GENET, V67, P483, DOI 10.1086/303022; Matsuura S, 2006, AM J MED GENET A, V140A, P358, DOI 10.1002/ajmg.a.31069; McClelland SE, 2009, CELL CYCLE, V8, P3262, DOI 10.4161/cc.8.20.9690; McClintock B, 1938, GENETICS, V23, P315; McClintock B, 1941, GENETICS, V26, P234; McGranahan N, 2012, EMBO REP, V13, P528, DOI 10.1038/embor.2012.61; Michel L, 2004, P NATL ACAD SCI USA, V101, P4459, DOI 10.1073/pnas.0306069101; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Minhas KM, 2003, INT J CANCER, V107, P46, DOI 10.1002/ijc.11341; Mitelman F, 1997, CANCER GENET CYTOGEN, V95, P1, DOI 10.1016/S0165-4608(96)00252-X; Mitelman F, 2012, MITELMAN DATABASE CH; Mitelman F, 2007, NAT REV CANCER, V7, P233, DOI 10.1038/nrc2091; Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163; Myrie KA, 2000, CANCER LETT, V152, P193, DOI 10.1016/S0304-3835(00)00340-2; Nambiar M, 2008, BBA-REV CANCER, V1786, P139, DOI 10.1016/j.bbcan.2008.07.005; Nasmyth K, 2009, ANNU REV GENET, V43, P525, DOI 10.1146/annurev-genet-102108-134233; Natarajan AT, 2008, MUTAT RES-GEN TOX EN, V657, P3, DOI 10.1016/j.mrgentox.2008.08.017; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Nishizaki T, 1997, INT J CANCER, V74, P513, DOI 10.1002/(SICI)1097-0215(19971021)74:5<513::AID-IJC6>3.0.CO;2-6; Nishizaki T, 1997, GENE CHROMOSOME CANC, V19, P267, DOI 10.1002/(SICI)1098-2264(199708)19:4<267::AID-GCC9>3.0.CO;2-V; Nowak MA, 2002, P NATL ACAD SCI USA, V99, P16226, DOI 10.1073/pnas.202617399; NOWELL P C, 1962, Blut, V8, P65; Obe G, 2010, CYTOGENET GENOME RES, V128, P8, DOI 10.1159/000303328; Obe G, 2002, MUTAT RES-FUND MOL M, V504, P17, DOI 10.1016/S0027-5107(02)00076-3; Olszak AM, 2011, NAT CELL BIOL, V13, P799, DOI 10.1038/ncb2272; Overholtzer M, 2008, NAT REV MOL CELL BIO, V9, P796, DOI 10.1038/nrm2504; Overholtzer M, 2007, CELL, V131, P966, DOI 10.1016/j.cell.2007.10.040; Pampalona J, 2010, GENE CHROMOSOME CANC, V49, P368, DOI 10.1002/gcc.20749; Pavelka N, 2010, NATURE, V468, P321, DOI 10.1038/nature09529; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; Pfau SJ, 2012, EMBO REP, V13, P515, DOI 10.1038/embor.2012.65; Pihan GA, 2001, CANCER RES, V61, P2212; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; Rajagopalan H, 2003, NAT REV CANCER, V3, P695, DOI 10.1038/nrc1165; Rancati G, 2008, CELL, V135, P879, DOI 10.1016/j.cell.2008.09.039; Rao CV, 2005, P NATL ACAD SCI USA, V102, P4365, DOI 10.1073/pnas.0407822102; Rehen SK, 2005, J NEUROSCI, V25, P2176, DOI 10.1523/JNEUROSCI.4560-04.2005; Remeseiro S, 2012, EMBO J, V31, P2076, DOI 10.1038/emboj.2012.11; Ricke RM, 2008, TRENDS GENET, V24, P457, DOI 10.1016/j.tig.2008.07.002; Ricke RM, 2011, J CELL BIOL, V193, P1049, DOI 10.1083/jcb.201012035; Roschke AV, 2003, CANCER RES, V63, P8634; Roylance R, 2011, CANCER EPIDEM BIOMAR, V20, P2183, DOI 10.1158/1055-9965.EPI-11-0343; Rusan NM, 2008, J CELL BIOL, V181, P719, DOI 10.1083/jcb.200802107; Ryan SD, 2012, P NATL ACAD SCI USA, V109, pE2205, DOI 10.1073/pnas.1201911109; Saeki A, 2002, CANCER-AM CANCER SOC, V94, P2047, DOI 10.1002/cncr.10448; Salimian KJ, 2011, CURR BIOL, V21, P1158, DOI 10.1016/j.cub.2011.06.015; Sato N, 2001, CANCER GENET CYTOGEN, V126, P13, DOI 10.1016/S0165-4608(00)00384-8; Schliekelman M, 2009, CANCER RES, V69, P45, DOI 10.1158/0008-5472.CAN-07-6330; Schvartzman JM, 2011, CANCER CELL, V19, P701, DOI 10.1016/j.ccr.2011.04.017; Sheffer M, 2009, P NATL ACAD SCI USA, V106, P7131, DOI 10.1073/pnas.0902232106; Sheltzer JM, 2011, SCIENCE, V333, P1026, DOI 10.1126/science.1206412; Shi QH, 2005, NATURE, V437, P1038, DOI 10.1038/nature03958; Silkworth WT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006564; Sluder G, 1997, J CELL SCI, V110, P421; Solomon DA, 2011, SCIENCE, V333, P1039, DOI 10.1126/science.1203619; Sotillo R, 2007, CANCER CELL, V11, P9, DOI 10.1016/j.ccr.2006.10.019; Sotillo R, 2010, NATURE, V464, P436, DOI 10.1038/nature08803; Stewenius Y, 2007, CLIN CANCER RES, V13, P6593, DOI 10.1158/1078-0432.CCR-07-1081; Stolz A, 2010, NAT CELL BIOL, V12, P492, DOI 10.1038/ncb2051; Suijkerbuijk SJE, 2010, CANCER RES, V70, P4891, DOI 10.1158/0008-5472.CAN-09-4319; Swanton C, 2009, P NATL ACAD SCI USA, V106, P8671, DOI 10.1073/pnas.0811835106; Sze KMF, 2004, J BIOMED SCI, V11, P920, DOI 10.1159/000081839; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; Tanaka K, 2001, JPN J CANCER RES, V92, P952, DOI 10.1111/j.1349-7006.2001.tb01186.x; Thompson SL, 2008, J CELL BIOL, V180, P665, DOI 10.1083/jcb.200712029; Thompson SL, 2011, P NATL ACAD SCI USA, V108, P17974, DOI 10.1073/pnas.1109720108; Thompson SL, 2010, J CELL BIOL, V188, P369, DOI 10.1083/jcb.200905057; Tighe A, 2001, EMBO REP, V2, P609, DOI 10.1093/embo-reports/kve127; Tomonaga T, 2003, CANCER RES, V63, P3511; Torres EM, 2007, SCIENCE, V317, P916, DOI 10.1126/science.1142210; Torres EM, 2010, CELL, V143, P71, DOI 10.1016/j.cell.2010.08.038; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7; van der Waal MS, 2012, EXP CELL RES, V318, P1407, DOI 10.1016/j.yexcr.2012.03.015; Van Hooser AA, 2001, J CELL SCI, V114, P3529; van Ree JH, 2010, J CELL BIOL, V188, P83, DOI 10.1083/jcb.200906147; Walther A, 2008, GUT, V57, P941, DOI 10.1136/gut.2007.135004; Wang Q, 2004, BLOOD, V103, P1278, DOI 10.1182/blood-2003-06-2158; Wang XH, 2002, CANCER RES, V62, P1662; Wang XH, 2000, CARCINOGENESIS, V21, P2293, DOI 10.1093/carcin/21.12.2293; Wang ZH, 2004, CANCER RES, V64, P2998, DOI 10.1158/0008-5472.CAN-04-0587; Wang ZY, 2001, MOL ENDOCRINOL, V15, P1870, DOI 10.1210/me.15.11.1870; Weaver BAA, 2003, J CELL BIOL, V162, P551, DOI 10.1083/jcb.200303167; Weaver BAA, 2007, CANCER CELL, V11, P25, DOI 10.1016/j.ccr.2006.12.003; Weaver BAA, 2006, CURR OPIN CELL BIOL, V18, P658, DOI 10.1016/j.ceb.2006.10.002; Weitzel DH, 2000, CELL TISSUE RES, V300, P57, DOI 10.1007/s004410000189; Williams BR, 2008, SCIENCE, V322, P703, DOI 10.1126/science.1160058; Yoon DS, 2002, AM J PATHOL, V161, P391, DOI 10.1016/S0002-9440(10)64194-6; Yuan BB, 2006, CLIN CANCER RES, V12, P405, DOI 10.1158/1078-0432.CCR-05-0903; Zhang DW, 2004, ONCOGENE, V23, P8720, DOI 10.1038/sj.onc.1208153; Zhang JY, 2007, J CELL BIOL, V178, P773, DOI 10.1083/jcb.200702138; Zhang NG, 2008, P NATL ACAD SCI USA, V105, P13033, DOI 10.1073/pnas.0801610105	202	69	72	1	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2013	32	38					4459	4470		10.1038/onc.2012.576	http://dx.doi.org/10.1038/onc.2012.576			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223SW	23246960				2022-12-17	WOS:000324831300001
J	Sundqvist, A; Zieba, A; Vasilaki, E; Hidalgo, CH; Soderberg, O; Koinuma, D; Miyazono, K; Heldin, CH; Landegren, U; ten Dijke, P; van Dam, H				Sundqvist, A.; Zieba, A.; Vasilaki, E.; Hidalgo, C. Herrera; Soderberg, O.; Koinuma, D.; Miyazono, K.; Heldin, C-H; Landegren, U.; ten Dijke, P.; van Dam, H.			Specific interactions between Smad proteins and AP-1 components determine TGF beta-induced breast cancer cell invasion	ONCOGENE			English	Article						invasion; spheroids; TGF beta; AP-1; Smad; PLA	GROWTH-FACTOR-BETA; MAMMARY-GLAND DEVELOPMENT; MESENCHYMAL TRANSITION; COLORECTAL CANCERS; PROXIMITY LIGATION; TUMOR-SUPPRESSOR; IN-SITU; TUMORIGENESIS; TRANSCRIPTION; PATHWAYS	Deregulation of the transforming growth factor beta (TGF beta) signal transduction cascade is functionally linked to cancer. In early phases, TGFb acts as a tumor suppressor by inhibiting tumor cell proliferation, whereas in late phases, it can act as a tumor promoter by stimulating tumor cell invasion and metastasis. Smad transcriptional effectors mediate TGF beta responses, but relatively little is known about the Smad-containing complexes that are important for epithelial-mesenchymal transition and invasion. In this study, we have tested the hypothesis that specific members of the AP-1 transcription factor family determine TGF beta signaling specificity in breast cancer cell invasion. Using a 3D model of collagen-embedded spheroids of MCF10A-MII premalignant human breast cancer cells, we identified the AP-1 transcription factor components c-Jun, JunB, c-Fos and Fra1 as essential factors for TGF beta-induced invasion and found that various mesenchymal and invasion-associated TGF beta-induced genes are co-regulated by these proteins. In situ proximity ligation assays showed that TGF beta signaling not only induces complexes between Smad3 and Smad4 in the nucleus but also complexes between Smad2/3 and Fra1, whereas complexes between Smad3, c-Jun and JunB could already be detected before TGF beta stimulation. Finally, chromatin immunoprecipitations showed that c-Jun, JunB and Fra1, but not c-Fos, are required for TGF beta-induced binding of Smad2/3 to the mmp-10 and pai-1 promoters. Together these results suggest that in particular formation of Smad2/3-Fra1 complexes may reflect activation of the Smad/AP-1-dependent TGF beta-induced invasion program.	[Sundqvist, A.; Vasilaki, E.; Hidalgo, C. Herrera; Miyazono, K.; Heldin, C-H; ten Dijke, P.; van Dam, H.] Uppsala Univ, Sci Life Lab, Ludwig Inst Canc Res, Uppsala, Sweden; [Zieba, A.; Soderberg, O.; Landegren, U.] Uppsala Univ, Rudbeck Lab, Sci Life Lab, Dept Immunol Genet & Pathol, Uppsala, Sweden; [Koinuma, D.; Miyazono, K.] Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Tokyo, Japan; [ten Dijke, P.; van Dam, H.] Leiden Univ, Med Ctr, Ctr Biomed Genet, Dept Mol Cell Biol, NL-2300 RC Leiden, Netherlands	Ludwig Institute for Cancer Research; Uppsala University; Uppsala University; University of Tokyo; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	van Dam, H (corresponding author), Leiden Univ, Med Ctr, Ctr Biomed Genet, Dept Mol Cell Biol, POB 9600, NL-2300 RC Leiden, Netherlands.	vdam@lumc.nl	Koinuma, Daizo/Y-8716-2018; Landegren, Ulf D/A-8197-2019; Söderberg, Ola/O-5130-2017; Vasilaki, Eleftheria/AAY-6392-2020; Dijke, Peter ten/AAG-4660-2021	Koinuma, Daizo/0000-0001-5611-2122; Söderberg, Ola/0000-0003-2883-1925; Dijke, Peter ten/0000-0002-7234-342X; van Dam, Hans/0000-0002-8307-4325	Swedish Cancerfonden [090773]; Netherlands Centre for Biomedical Genetics	Swedish Cancerfonden; Netherlands Centre for Biomedical Genetics	We thank our colleagues, in particular Aris Moustakas and Masato Morikawa, for their valuable discussion and help with experiments. This work was supported by the Swedish Cancerfonden (090773) and the Netherlands Centre for Biomedical Genetics.	Baan B, 2010, MOL CELL PROTEOMICS, V9, P1982, DOI 10.1074/mcp.M110.000943; Belguise K, 2005, ONCOGENE, V24, P1434, DOI 10.1038/sj.onc.1208312; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Deckers M, 2006, CANCER RES, V66, P2202, DOI 10.1158/0008-5472.CAN-05-3560; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dumont N, 2000, BREAST CANCER RES, V2, P125, DOI 10.1186/bcr44; Dzwonek J, 2009, MOL CANCER RES, V7, P1342, DOI 10.1158/1541-7786.MCR-08-0558; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Gomis RR, 2006, CANCER CELL, V10, P203, DOI 10.1016/j.ccr.2006.07.019; Heldin CH, 2012, CELL TISSUE RES, V347, P21, DOI 10.1007/s00441-011-1190-x; Hess J, 2004, J CELL SCI, V117, P5965, DOI 10.1242/jcs.01589; Javelaud D, 2005, ONCOGENE, V24, P5742, DOI 10.1038/sj.onc.1208928; Koinuma D, 2009, MOL CELL BIOL, V29, P172, DOI 10.1128/MCB.01038-08; Laverty HG, 2009, CYTOKINE GROWTH F R, V20, P305, DOI 10.1016/j.cytogfr.2009.07.002; Leary RJ, 2008, P NATL ACAD SCI USA, V105, P16224, DOI 10.1073/pnas.0808041105; Levy L, 2006, CYTOKINE GROWTH F R, V17, P41, DOI 10.1016/j.cytogfr.2005.09.009; Lopez-Bergami P, 2010, NAT REV CANCER, V10, P65, DOI 10.1038/nrc2681; Luo YP, 2010, ONCOGENE, V29, P662, DOI 10.1038/onc.2009.308; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Mu YB, 2012, CELL TISSUE RES, V347, P11, DOI 10.1007/s00441-011-1201-y; Ozanne BW, 2007, ONCOGENE, V26, P1, DOI 10.1038/sj.onc.1209759; Parvani JG, 2011, J MAMMARY GLAND BIOL, V16, P127, DOI 10.1007/s10911-011-9207-3; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; Ross S, 2008, INT J BIOCHEM CELL B, V40, P383, DOI 10.1016/j.biocel.2007.09.006; Schmierer B, 2007, NAT REV MOL CELL BIO, V8, P970, DOI 10.1038/nrm2297; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; Sundqvist A, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3066; Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899; ten Dijke P, 2007, NAT REV MOL CELL BIO, V8, P857, DOI 10.1038/nrm2262; Thuault S, 2008, J BIOL CHEM, V283, P33437, DOI 10.1074/jbc.M802016200; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Verde P, 2007, CELL CYCLE, V6, P2633, DOI 10.4161/cc.6.21.4850; Verrecchia F, 2001, ONCOGENE, V20, P2205, DOI 10.1038/sj.onc.1204347; Wagner EF, 2010, ANN RHEUM DIS, V69, P86, DOI 10.1136/ard.2009.119396; Wakefield LM, 2001, J MAMMARY GLAND BIOL, V6, P67, DOI 10.1023/A:1009568532177; Wiercinska E, 2011, BREAST CANCER RES TR, V128, P657, DOI 10.1007/s10549-010-1147-x; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Zavadil J, 2001, P NATL ACAD SCI USA, V98, P6686, DOI 10.1073/pnas.111614398; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	41	69	70	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 1	2013	32	31					3606	3615		10.1038/onc.2012.370	http://dx.doi.org/10.1038/onc.2012.370			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194MW	22926518				2022-12-17	WOS:000322638400005
J	Gebeshuber, CA; Martinez, J				Gebeshuber, C. A.; Martinez, J.			miR-100 suppresses IGF2 and inhibits breast tumorigenesis by interfering with proliferation and survival signaling	ONCOGENE			English	Article						breast cancer; IGF2; miR-100	II MESSENGER-RNA; GENE-EXPRESSION; CANCER; INSULIN; MICRORNAS; CELLS; TUMOR	Dysregulation of micro RNAs is crucially implicated in tumorigenesis. We detected downregulation of miR-100 in breast cancer cells, leading to an upregulation of the proliferation- and survival-promoting oncogene insulin-like growth factor (IGF) 2. Stable overexpression of miR-100 strongly reduced IGF2 expression and inhibited tumor growth. In invasive human breast tumors, miR-100 was reduced about fourfold as compared with benign patient samples, whereas IGF2 was strongly enhanced. MiR-100 has also been shown to suppress other proteins of the IGF/mammalian target of rapamycin (mTOR) signaling cascade in different human tumors. Our results reveal miR-100 as a context-dependent master regulator of the IGF/mTOR pathway and a potential target for therapeutic approaches.	[Gebeshuber, C. A.; Martinez, J.] Austrian Acad Sci, Inst Mol Biotechnol, A-1010 Vienna, Austria	Austrian Academy of Sciences; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA)	Gebeshuber, CA (corresponding author), Med Univ Vienna, Dept Pathol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	christoph.gebeshuber@meduniwien.ac.at; javier.martinez@imba.oeaw.ac.at		Gebeshuber, Christoph A/0000-0003-3293-4572; Martinez, Javier/0000-0001-9152-7323	FWF; Austrian Government's GENAU program; IMBA	FWF(Austrian Science Fund (FWF)); Austrian Government's GENAU program; IMBA	We thank Albin Rudisch and Marlies Schlauf for technical assistance and Florian Grebien and Wolfgang Sommergruber for critical comments on the manuscript. CG was funded from the FWF and the Austrian Government's GENAU program. JM was funded by the IMBA.	ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bazzini AA, SCIENCE, V336, P233; Burns JL, 2001, DEVELOPMENT, V128, P3819; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Cui HM, 1998, NAT MED, V4, P1276, DOI 10.1038/3260; Doghman M, 2010, CANCER RES, V70, P4666, DOI 10.1158/0008-5472.CAN-09-3970; Dupont J, 2001, ENDOCRINOLOGY, V142, P4969, DOI 10.1210/en.142.11.4969; Fan C, 2006, NEW ENGL J MED, V355, P560, DOI 10.1056/NEJMoa052933; Garzon R, 2010, NAT REV DRUG DISCOV, V9, P775, DOI 10.1038/nrd3179; Giani C, 1996, BREAST CANCER RES TR, V41, P43, DOI 10.1007/BF01807035; Hausser J, 2009, NUCLEIC ACIDS RES, V37, pW266, DOI 10.1093/nar/gkp412; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Jones RA, 2007, ONCOGENE, V26, P1636, DOI 10.1038/sj.onc.1209955; Kauppinen S, 2006, HANDB EXP PHARM, V173, P405; McCann AH, 1996, HUM MOL GENET, V5, P1123, DOI 10.1093/hmg/5.8.1123; Nagaraja AK, 2010, MOL ENDOCRINOL, V24, P447, DOI 10.1210/me.2009-0295; NIELSEN FC, 1995, NATURE, V377, P358, DOI 10.1038/377358a0; Pacher M, 2007, CARCINOGENESIS, V28, P49, DOI 10.1093/carcin/bgl091; Pollak M, 2008, BEST PRACT RES CL EN, V22, P625, DOI 10.1016/j.beem.2008.08.004; Pravtcheva DD, 1998, J EXP ZOOL, V281, P43, DOI 10.1002/(SICI)1097-010X(19980501)281:1<43::AID-JEZ7>3.3.CO;2-3; Romero-Cordoba S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031904; SASAKI H, 1992, GENE DEV, V6, P1843, DOI 10.1101/gad.6.10.1843; Shi W, 2010, INT J CANCER, V126, P2036, DOI 10.1002/ijc.24880; Tovar V, 2010, J HEPATOL, V52, P550, DOI 10.1016/j.jhep.2010.01.015; WILLISON K, 1991, TRENDS GENET, V7, P107, DOI 10.1016/0168-9525(91)90441-R	26	69	75	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 4	2013	32	27					3306	3310		10.1038/onc.2012.372	http://dx.doi.org/10.1038/onc.2012.372			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	176JZ	22926517				2022-12-17	WOS:000321301600010
J	Schulte, JH; Lindner, S; Bohrer, A; Maurer, J; De Preter, K; Lefever, S; Heukamp, L; Schulte, S; Molenaar, J; Versteeg, R; Thor, T; Kunkele, A; Vandesompele, J; Speleman, F; Schorle, H; Eggert, A; Schramm, A				Schulte, J. H.; Lindner, S.; Bohrer, A.; Maurer, J.; De Preter, K.; Lefever, S.; Heukamp, L.; Schulte, S.; Molenaar, J.; Versteeg, R.; Thor, T.; Kuenkele, A.; Vandesompele, J.; Speleman, F.; Schorle, H.; Eggert, A.; Schramm, A.			MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells	ONCOGENE			English	Article						neuroblastoma; MYCN; neural crest progenitor cell	EXPRESSION; MEDULLOBLASTOMA; ORIGIN	Neuroblastonna is an embryonal tumor with a heterogeneous clinical course. The tumor is presumed to be derived from the neural crest, but the cells of origin remain to be determined. To date, few recurrent genetic changes contributing to neuroblastoma formation, such as amplification of the MYCN oncogene and activating mutations of the ALK oncogene, have been identified. The possibility to model neuroblastoma in mice allows investigation of the cell of origin hypothesis in further detail. Here we present the evidence that murine neural crest progenitor cells can give rise to neuroblastonna upon transformation with MYCN or ALK(F1174L). For this purpose we used JoMa1, a multipotent neural crest progenitor cell line, which is kept in a viable and undifferentiated state by a tamoxifen-activated c-Myc transgene (c-MycER(T)). Expression of MYCN or ALK(F1174L), one of the oncogenic ALK variants identified in primary neuroblastomas, enabled these cells to grow independently of c-MycER(T) activity in vitro and caused formation of neuroblastoma-like tumors in vivo in contrast to parental JoMa1 cells and JoMa1 cells-expressing TrkA or GFP. Tumorigenicity was enhanced upon serial transplantation of tumor-derived cells, and tumor cells remained susceptible to the MYC-inhibitor, NBT-272, indicating that cell growth depended on functional MYCN. Our findings support neural crest progenitor cells as the precursor cells of neuroblastoma, and indicate that neuroblastomas arise as their malignant progeny. Oncogene (2013) 32, 1059-1065; doi:10.1038/onc.2012.106; published online 9 April 2012	[Schulte, J. H.; Lindner, S.; Bohrer, A.; Schulte, S.; Thor, T.; Kuenkele, A.; Eggert, A.; Schramm, A.] Univ Childrens Hosp Essen, Dept Pediat Oncol & Haematol, D-45122 Essen, Germany; [Maurer, J.; Schorle, H.] Univ Bonn, Inst Pathol, Dept Dev Pathol, Bonn, Germany; [De Preter, K.; Lefever, S.; Vandesompele, J.; Speleman, F.] Ghent Univ Hosp, CMGG, Ghent, Belgium; [Heukamp, L.] Univ Bonn, Dept Pathol, Bonn, Germany; [Molenaar, J.; Versteeg, R.] Univ Amsterdam, Acad Med Ctr, Dept Human Genet, NL-1105 AZ Amsterdam, Netherlands	University of Duisburg Essen; University of Bonn; Ghent University; Ghent University Hospital; University of Bonn; University of Amsterdam; Academic Medical Center Amsterdam	Schulte, JH (corresponding author), Univ Childrens Hosp Essen, Dept Pediat Oncol & Haematol, Hufelandstr 55, D-45122 Essen, Germany.	Johannes.schulte@uni-due.de	Heukamp, Lukas C/A-8338-2013; Maurer, Jochen/G-4832-2018; speleman, frank/AAR-5184-2020; Schramm, Alexander/G-5688-2010; Vandesompele, Jo/W-3411-2018; Schulte, Johannes H./V-2474-2018; Eggert, Angelika/AAE-6907-2022; Versteeg, Rogier/AAQ-1765-2020; Schulte, Johannes H/G-3981-2010; De Preter, Katleen/I-7135-2013; Schorle, Hubert/S-1713-2019; Schorle, Hubert/M-5001-2016; Heukamp, Lukas/G-9967-2012	Maurer, Jochen/0000-0003-3962-3128; speleman, frank/0000-0002-6628-8559; Schramm, Alexander/0000-0001-7670-7529; Vandesompele, Jo/0000-0001-6274-0184; Eggert, Angelika/0000-0003-3476-8184; De Preter, Katleen/0000-0002-7726-5096; Schorle, Hubert/0000-0001-8272-0076; Kunkele, Annette/0000-0002-8406-5412; Heukamp, Lukas/0000-0002-3388-3482; Schulte, Johannes Hubertus/0000-0003-0671-1201; Versteeg, Rogier/0000-0001-7172-0388	German National Genome Research Network (NGFN) [PKN-01GS0894-6]; German Cancer Aid [108941]	German National Genome Research Network (NGFN); German Cancer Aid(Deutsche Krebshilfe)	We thank E Mahlow, 5 Dreesmann, A Odersky and M Baumann for their excellent technical assistance and K Astrahantseff for proof reading the manuscript. This work was supported by the German National Genome Research Network (NGFN plus grant no. PKN-01GS0894-6 to JHS, AE and AS) and by the German Cancer Aid (grant no. 108941 to JHS and AE).	Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; BECKWITH JB, 1963, AM J PATHOL, V43, P1089; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; De Preter K, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-9-r84; Gibson P, 2010, NATURE, V468, P1095, DOI 10.1038/nature09587; Hata K, 2007, LIVER TRANSPLANT, V13, P114, DOI 10.1002/lt.20957; Jager R, 2004, GENESIS, V38, P145, DOI 10.1002/gene.20014; Johnson RA, 2010, NATURE, V466, P632, DOI 10.1038/nature09173; Maris JM, 2010, NEW ENGL J MED, V362, P2202, DOI 10.1056/NEJMra0804577; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; Maurer J, 2007, DIFFERENTIATION, V75, P580, DOI 10.1111/j.1432-0436.2007.00164.x; Pajtler K, 2010, J VIS EXP; Riggi N, 2008, CANCER RES, V68, P2176, DOI 10.1158/0008-5472.CAN-07-1761; Schulte JH, 2005, ONCOGENE, V24, P165, DOI 10.1038/sj.onc.1208000; Schulte JH, 2010, INT J CANCER, V127, P2374, DOI 10.1002/ijc.25436; Schulte JH, 2009, INT J CANCER, V124, P2488, DOI 10.1002/ijc.24204; Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735; Soucek L, 2008, NATURE, V455, P679, DOI 10.1038/nature07260; Swartling FJ, 2010, GENE DEV, V24, P1059, DOI 10.1101/gad.1907510; von Bueren AO, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-19; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Zender L, 2008, CELL, V135, P852, DOI 10.1016/j.cell.2008.09.061	22	69	71	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2013	32	8					1059	1065		10.1038/onc.2012.106	http://dx.doi.org/10.1038/onc.2012.106			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111LQ	22484425				2022-12-17	WOS:000316523200013
J	Stresing, V; Baltziskueta, E; Rubio, N; Blanco, J; Arriba, MC; Valls, J; Janier, M; Clezardin, P; Sanz-Pamplona, R; Nieva, C; Marro, M; Dmitri, P; Sierra, A				Stresing, V.; Baltziskueta, E.; Rubio, N.; Blanco, J.; Arriba, Ma C.; Valls, J.; Janier, M.; Clezardin, P.; Sanz-Pamplona, R.; Nieva, C.; Marro, M.; Dmitri, P.; Sierra, A.			Peroxiredoxin 2 specifically regulates the oxidative and metabolic stress response of human metastatic breast cancer cells in lungs	ONCOGENE			English	Article						angiogenesis; lung metastasis; metabolic stress; oxidative stress; peroxiredoxins	TRANSFORMED-CELLS; HYDROGEN-PEROXIDE; BONE METASTASES; LOW-LEVEL; KAPPA-B; PROTEIN; GENES; LINES; ACID; CARCINOMA	Little is known about metastatic pathways that are specific to the lung rather than other organs. We previously showed that antioxidant proteins such as peroxiredoxins were specifically upregulated in lung metastatic breast cancer cells. We hypothesize that cancer cells that live under aerobic conditions, as might be the case in lungs, protect themselves against the damage caused by reactive oxygen species (ROS). To examine this hypothesis, we studied the role of peroxiredoxin-2 (PRDX2) in lung vs bone metastasis formation. A metastatic variant of MDA-MB-435 breast cancer cells that specifically metastasize to lungs (435-L3) was transduced with short hairpin RNAs to specifically silence PRDX2. Conversely, a bone metastatic variant of MDA-MB-231 cells (BO2) was stably transfected to overexpress PRDX2. The 435-L3 cells silenced for PRDX2 were significantly more sensitive to H2O2-induced oxidative stress than the parental and scrambled transfected cells. BO2/PRDX2 cells produced less ROS than BO2/green fluorescent protein control cells under oxidative stress. Moreover, PRDX2 knockdown inhibited the growth of 435-L3 cells in the lungs, whereas lymph node metastasis remained unaffected. In contrast, PRDX2 overexpression in bone metastatic BO2 breast cancer cells led to drastic inhibition of the skeletal tumor burden and reduction of bone destruction. Furthermore, PRDX2 expression in breast cancer cells was associated with a glucose-dependent phenotype, different from bone metastatic cells. Overall, our results strongly suggest that PRDX2 is a targetable 'metabolic adaptor' driver protein implicated in the selective growth of metastatic cells in the lungs by protecting them against oxidative stress. Oncogene (2013) 32, 724-735; doi:10.1038/onc.2012.93; published online 19 March 2012	[Stresing, V.; Baltziskueta, E.; Arriba, Ma C.; Nieva, C.; Sierra, A.] Bellvitge Biomed Res Inst IDIBELL, Biol Clues Invas & Metastat Phenotype Grp, E-08908 Barcelona, Spain; [Stresing, V.; Clezardin, P.] Laennec Sch Med, INSERM, UMR 664, IFR62, Lyon, France; [Rubio, N.; Blanco, J.] Hosp Santa Creu & Sant Pau, CIBER Bioingn Biomat & Nanomed CIBER BBN, Cardiovasc Res Ctr CSIC ICCC, Barcelona, Spain; [Valls, J.] Inst Recerca Biomed Lleida IRBLLEIDA, Lleida, Spain; [Valls, J.] IDIBELL Inst Catala Oncol, Serv Epidemiol, Barcelona, Spain; [Janier, M.] Hop Edouard Herriot, Lyon, France; [Sanz-Pamplona, R.] IDIBELL Inst Catala Oncol, Unit Biomarkers & Susceptibil, Barcelona, Spain; [Sanz-Pamplona, R.] IDIBELL Inst Catala Oncol, CIBERESP, Barcelona, Spain; [Marro, M.; Dmitri, P.] ICFO Inst Ciencies Foton, Castelldefels, E Barcelona, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Institut National de la Sante et de la Recherche Medicale (Inserm); CIBER - Centro de Investigacion Biomedica en Red; CIBERBBN; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Institut Catala de Ciencies Cardiovasculars (ICCC); Hospital of Santa Creu i Sant Pau; Institut de Recerca Biomedica - IRB Lleida; Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); CHU Lyon; Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Catalan Institute of Oncology; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Barcelona Institute of Science & Technology; Universitat Politecnica de Catalunya; Institut de Ciencies Fotoniques (ICFO)	Sierra, A (corresponding author), Bellvitge Biomed Res Inst IDIBELL, Biol Clues Invas & Metastat Phenotype Grp, Avda Gran Via Hosp Llobregat,199, E-08908 Barcelona, Spain.	asierra@idibell.cat	Marro, Monica/AAV-1362-2021; del Carmen Arriba Pérez, María/I-2112-2015; Rubio, Nuria/H-3156-2015; Valls, Joan/GXM-6532-2022; Clezardin, Philippe/M-8071-2014; Blanco, Jeronimo/H-2764-2015; Marro, Monica/E-4159-2016	Marro, Monica/0000-0003-4031-4605; del Carmen Arriba Pérez, María/0000-0001-8033-7444; Rubio, Nuria/0000-0003-2471-4684; Clezardin, Philippe/0000-0003-0149-4463; Blanco, Jeronimo/0000-0003-3765-0640; Marro, Monica/0000-0003-4031-4605; Valls, Joan/0000-0002-4806-7568; Papkovsky, Dmitri/0000-0003-1556-1145; Janier, Marc/0000-0001-5937-9180; Sierra, Angels/0000-0003-1023-3492; Sanz-Pamplona, Rebeca/0000-0002-2187-3527	Spanish Ministry of Health and Consumer Affairs [FIS/PI071245, FIS/PI10/00057]; EC MetaBre [LSHC-CT-2004-506049]; INCA (ONCOIMAGE) [07/3D1316/PF-108-01/NG-LC]; Ministry of Education and Science [SAF2004-0188-E]; AECC Scientific Foundation; Private Foundation Cellex Barcelona	Spanish Ministry of Health and Consumer Affairs(Spanish Government); EC MetaBre; INCA (ONCOIMAGE); Ministry of Education and Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); AECC Scientific Foundation; Private Foundation Cellex Barcelona	We would like to thank Oriol Casanovas (Angiogenesis Laboratory, IDIBELL) for scientific discussions and his expert advice on angiogenesis. We would also like to thank Berta Martin, Vanessa Hernandez and Mac Dominguez for his expert technical assistance. We are grateful to Mr R Rycroft for expert language advice and Victor Moreno for expert statistical advice (Barcelona University). We thanks Jose Carlos Perales and Andy Mendez for the advice and support the metabolic analysis (Barcelona University). We acknowledge all the partners of the MetaBre consortium for their collaboration and stimulating criticism. This study was supported by grants from the Spanish Ministry of Health and Consumer Affairs (FIS/PI071245 and FIS/PI10/00057), EC MetaBre (contract no. LSHC-CT-2004-506049), INCA (ONCOIMAGE, no 07/3D1316/PF-108-01/NG-LC), the Ministry of Education and Science (SAF2004-0188-E), AECC Scientific Foundation and Private Foundation Cellex Barcelona.	[Anonymous], 2009, LANG ENV STAT COMP; Archer SL, 2008, AM J PHYSIOL-HEART C, V294, pH570, DOI 10.1152/ajpheart.01324.2007; Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020; Boucharaba A, 2004, J CLIN INVEST, V114, P1714, DOI 10.1172/JCI200422123; Bubici C, 2006, ONCOGENE, V25, P6731, DOI 10.1038/sj.onc.1209936; Budihardjo II, 1998, CLIN CANCER RES, V4, P117; Buzzai M, 2005, ONCOGENE, V24, P4165, DOI 10.1038/sj.onc.1208622; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Chambers AF, 2009, CANCER RES, V69, P5292, DOI 10.1158/0008-5472.CAN-09-1528; Chevallet M, 2003, J BIOL CHEM, V278, P37146, DOI 10.1074/jbc.M305161200; Dong F, 2009, CLIN CANCER RES, V15, P2588, DOI 10.1158/1078-0432.CCR-08-2356; El Hilali N, 2005, CLIN CANCER RES, V11, P1253; Espana L, 2005, AM J PATHOL, V167, P1125, DOI 10.1016/S0002-9440(10)61201-1; Fidler IJ, 2002, DIFFERENTIATION, V70, P498, DOI 10.1046/j.1432-0436.2002.700904.x; Fujii J, 2002, REDOX REP, V7, P123, DOI 10.1179/135100002125000352; Ganong WF, 2005, LANGE BASIC SCI, P631; Graves JA, 2009, J BIOL CHEM, V284, P6520, DOI 10.1074/jbc.M807564200; Gupta GP, 2007, P NATL ACAD SCI USA, V104, P19506, DOI 10.1073/pnas.0709185104; Han YH, 2006, FREE RADICAL RES, V40, P1182, DOI 10.1080/10715760600868552; Haraldsen JD, 2009, ORG BIOMOL CHEM, V7, P3040, DOI 10.1039/b901735f; Husemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003; Iles KE, 2002, IMMUNOL RES, V26, P95, DOI 10.1385/IR:26:1-3:095; Jang YY, 2007, BLOOD, V110, P3056, DOI 10.1182/blood-2007-05-087759; Karihtala P, 2003, CLIN CANCER RES, V9, P3418; Kim H, 2000, J BIOL CHEM, V275, P18266, DOI 10.1074/jbc.275.24.18266; Lee KW, 2011, J BIOL CHEM, V286, P8394, DOI 10.1074/jbc.M110.179416; Lehtonen ST, 2004, INT J CANCER, V111, P514, DOI 10.1002/ijc.20294; Low FM, 2007, BLOOD, V109, P2611, DOI 10.1182/blood-2006-09-048728; Martin B, 2008, J PROTEOME RES, V7, P3242, DOI 10.1021/pr800137w; Mendez O, 2005, CLIN EXP METASTAS, V22, P297, DOI 10.1007/s10585-005-8751-x; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Minn AJ, 2007, P NATL ACAD SCI USA, V104, P6740, DOI 10.1073/pnas.0701138104; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Neumann CA, 2007, CURR OPIN PHARMACOL, V7, P375, DOI 10.1016/j.coph.2007.04.007; Nguyen DX, 2007, NAT REV GENET, V8, P341, DOI 10.1038/nrg2101; Olahova M, 2008, P NATL ACAD SCI USA, V105, P19839, DOI 10.1073/pnas.0805507105; Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046; Pecheur I, 2002, FASEB J, V16, P1266, DOI 10.1096/fj.01-0911fje; Peyruchaud O, 2003, J BIOL CHEM, V278, P45826, DOI 10.1074/jbc.M309024200; Peyruchaud O, 2001, J BONE MINER RES, V16, P2027, DOI 10.1359/jbmr.2001.16.11.2027; Pinheiro J., 2006, MIXED EFFECT MODELS; Rabilloud T, 2002, J BIOL CHEM, V277, P19396, DOI 10.1074/jbc.M106585200; Ralser M, 2009, NAT BIOTECHNOL, V27, P604, DOI 10.1038/nbt0709-604; Roman I, 2007, BIOMATERIALS, V28, P2718, DOI 10.1016/j.biomaterials.2007.02.011; Semenza GL, 2008, J CLIN INVEST, V118, P3835, DOI 10.1172/JCI37373; Seo JH, 2009, J BIOL CHEM, V284, P13455, DOI 10.1074/jbc.M900641200; Tao MF, 2007, MOL BIOSYST, V3, P60, DOI 10.1039/b615284h; Ueda S, 2002, ANTIOXID REDOX SIGN, V4, P405, DOI 10.1089/15230860260196209; Ungerstedt JS, 2005, P NATL ACAD SCI USA, V102, P673, DOI 10.1073/pnas.0408732102; VandenHoek TL, 1997, J MOL CELL CARDIOL, V29, P2571, DOI 10.1006/jmcc.1997.0497; Wang W, 2010, J PROTEOME RES, V9, P3812, DOI 10.1021/pr901180w; Weigelt B, 2005, CANCER RES, V65, P9155, DOI 10.1158/0008-5472.CAN-05-2553; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; ZHANG RD, 1991, INVAS METAST, V11, P204	54	69	70	1	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2013	32	6					724	735		10.1038/onc.2012.93	http://dx.doi.org/10.1038/onc.2012.93			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101AF	22430214				2022-12-17	WOS:000315746700006
J	Liu, W; Lindberg, J; Sui, G; Luo, J; Egevad, L; Li, T; Xie, C; Wan, M; Kim, ST; Wang, Z; Turner, AR; Zhang, Z; Feng, J; Yan, Y; Sun, J; Bova, GS; Ewing, CM; Yan, G; Gielzak, M; Cramer, SD; Vessella, RL; Zheng, SL; Gronberg, H; Isaacs, WB; Xu, J				Liu, W.; Lindberg, J.; Sui, G.; Luo, J.; Egevad, L.; Li, T.; Xie, C.; Wan, M.; Kim, S-T; Wang, Z.; Turner, A. R.; Zhang, Z.; Feng, J.; Yan, Y.; Sun, J.; Bova, G. S.; Ewing, C. M.; Yan, G.; Gielzak, M.; Cramer, S. D.; Vessella, R. L.; Zheng, S. L.; Gronberg, H.; Isaacs, W. B.; Xu, J.			Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer	ONCOGENE			English	Article						CHD1; homozygous deletion; prostate cancer	COPY NUMBER ANALYSIS; HUMAN LUNG-CANCER; ANDROGEN RECEPTOR; RNAI TECHNOLOGY; STEM-CELLS; CHROMATIN; GENE; EXPRESSION; MUTATIONS; PATHWAY	A clearer definition of the molecular determinants that drive the development and progression of prostate cancer (PCa) is urgently needed. Efforts to map recurrent somatic deletions in the tumor genome, especially homozygous deletions (HODs), have provided important positional information in the search for cancer-causing genes. Analyzing HODs in the tumors of 244 patients from two independent cohorts and 22 PCa xenografts using high-resolution single-nucleotide polymorphism arrays, herein we report the identification of CHD1, a chromatin remodeler, as one of the most frequently homozygously deleted genes in PCa, second only to PTEN in this regard. The HODs observed in CHD1, including deletions affecting only internal exons of CHD1, were found to completely extinguish the expression of mRNA of this gene in PCa xenografts. Loss of this chromatin remodeler in clinical specimens is significantly associated with an increased number of additional chromosomal deletions, both hemi- and homozygous, especially on 2q, 5q and 6q. Together with the deletions observed in HEK293 cells stably transfected with CHD1 small hairpin RNA, these data suggest a causal relationship. Downregulation of Chd1 in mouse prostate epithelial cells caused dramatic morphological changes indicative of increased invasiveness, but did not result in transformation. Indicating a new role of CHD1, these findings collectively suggest that distinct CHD1 associated alterations of genomic structure evolve during and are required for the development of PCa. Oncogene (2012) 31, 3939-3948; doi:10.1038/onc.2011.554; published online 5 December 2011	[Luo, J.; Ewing, C. M.; Yan, G.; Gielzak, M.; Isaacs, W. B.] Johns Hopkins Med Inst, Brady Urol Inst, Baltimore, MD 21287 USA; [Liu, W.; Li, T.; Xie, C.; Kim, S-T; Wang, Z.; Turner, A. R.; Zhang, Z.; Feng, J.; Sun, J.; Zheng, S. L.; Xu, J.] Wake Forest Univ, Bowman Gray Sch Med, Ctr Canc Genom, Winston Salem, NC 27157 USA; [Liu, W.; Li, T.; Xie, C.; Kim, S-T; Wang, Z.; Turner, A. R.; Zhang, Z.; Feng, J.; Sun, J.; Zheng, S. L.; Xu, J.] Wake Forest Univ, Bowman Gray Sch Med, Ctr Human Genom & Personalized Med Res, Winston Salem, NC USA; [Lindberg, J.; Gronberg, H.] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden; [Sui, G.; Wan, M.; Cramer, S. D.] Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Winston Salem, NC USA; [Egevad, L.] Karolinska Univ Hosp, Dept Pathol & Cytol, Stockholm, Sweden; [Yan, Y.; Xu, J.] Van Andel Res Inst, Ctr Genet Epidemiol & Prevent, Grand Rapids, MI USA; [Bova, G. S.] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; [Vessella, R. L.] Univ Washington, Dept Urol, Seattle, WA 98195 USA	Johns Hopkins University; Johns Hopkins Medicine; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Karolinska Institutet; Wake Forest University; Wake Forest Baptist Medical Center; Karolinska Institutet; Karolinska University Hospital; Van Andel Institute; Johns Hopkins University; Johns Hopkins Medicine; University of Washington; University of Washington Seattle	Isaacs, WB (corresponding author), Johns Hopkins Med Inst, Brady Urol Inst, Marburg 115,600 N Wolfe St, Baltimore, MD 21287 USA.	wisaacs@jhmi.edu; jxu@wfubmc.edu	Kim, Seong-Tae/E-4474-2017; Lindberg, Johan/F-4104-2011; LI, TAO/AAL-5932-2020	Kim, Seong-Tae/0000-0001-7436-1405; LI, TAO/0000-0001-7343-9688; Lindberg, Johan/0000-0003-3610-6774; Egevad, Lars/0000-0001-8531-222X; Bova, George/0000-0003-1639-3104	National Institutes of Health [CA135008, CA133066, CA119069, CA131338, 133009]; NATIONAL CANCER INSTITUTE [R01CA131338, R01CA129418, R01CA133009, R01CA133066, R01CA112517, R01CA135008, R01CA119069] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The study is partially supported by the National Institutes of Health Grants CA135008 and CA133066 (to W Liu and WB Isaacs), CA119069 (to J Xu), CA131338 and 133009 (to SL Zheng and WB Isaacs). We thank Tamara Adams for editing the manuscript. The support of William T Gerrard, Mario Duhon, Jennifer and John Chalsty and P Kevin Jaffe (to WBI) is gratefully acknowledged.	Anderson K, 2011, NATURE, V469, P356, DOI 10.1038/nature09650; Avvakumov N, 2011, MOL CELL, V41, P502, DOI 10.1016/j.molcel.2011.02.013; Barclay WW, 2008, STEM CELLS, V26, P600, DOI 10.1634/stemcells.2007-0309; Barclay WW, 2005, PROSTATE, V63, P291, DOI 10.1002/pros.20193; Berger MF, 2011, NATURE, V470, P214, DOI 10.1038/nature09744; Beroukhim R, 2007, P NATL ACAD SCI USA, V104, P20007, DOI 10.1073/pnas.0710052104; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bettermann K, 2010, CANCER CELL, V17, P481, DOI 10.1016/j.ccr.2010.03.021; Bignell GR, 2010, NATURE, V463, P893, DOI 10.1038/nature08768; Cao P, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-108; Carver BS, 2009, NAT GENET, V41, P619, DOI 10.1038/ng.370; Cengiz B, 2007, ORAL ONCOL, V43, P241, DOI 10.1016/j.oraloncology.2006.03.004; Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672; Deng Z, 2009, ONCOGENE, V28, P3746, DOI 10.1038/onc.2009.231; Deng ZY, 2007, MOL CELL BIOL, V27, P3780, DOI 10.1128/MCB.01761-06; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Ding Z, 2011, NATURE, V466, P869; Gaspar-Maia A, 2009, NATURE, V460, P863, DOI 10.1038/nature08212; Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333; Kan ZY, 2010, NATURE, V466, P869, DOI 10.1038/nature09208; King JC, 2009, NAT GENET, V41, P524, DOI 10.1038/ng.371; Kohno T, 2010, GENE CHROMOSOME CANC, V49, P342, DOI 10.1002/gcc.20746; Konev AY, 2007, SCIENCE, V317, P1087, DOI 10.1126/science.1145339; Liu W, 2007, CLIN CANCER RES, V13, P5028, DOI 10.1158/1078-0432.CCR-07-0300; Liu WN, 2009, NAT MED, V15, P559, DOI 10.1038/nm.1944; Lu YJ, 2010, GENE CHROMOSOME CANC, V49, P412, DOI 10.1002/gcc.20752; McDaniel IE, 2008, GENETICS, V178, P583, DOI 10.1534/genetics.107.079038; Medina PP, 2008, HUM MUTAT, V29, P617, DOI 10.1002/humu.20730; Nancarrow DJ, 2008, CANCER RES, V68, P4163, DOI 10.1158/0008-5472.CAN-07-6710; Rahrmann EP, 2009, CANCER RES, V69, P4388, DOI 10.1158/0008-5472.CAN-08-3901; Robbins CM, 2011, GENOME RES, V21, P47, DOI 10.1101/gr.107961.110; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Sims RJ, 2007, MOL CELL, V28, P665, DOI 10.1016/j.molcel.2007.11.010; Sims RJ, 2009, NATURE, V460, P802, DOI 10.1038/460802a; Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055; STOKES DG, 1995, MOL CELL BIOL, V15, P2745; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Sui G, 2005, METH MOL B, V309, P205; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Weissman B, 2009, CANCER RES, V69, P8223, DOI 10.1158/0008-5472.CAN-09-2166; Yin D, 2009, MOL CANCER RES, V7, P665, DOI 10.1158/1541-7786.MCR-08-0270	41	69	69	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2012	31	35					3939	3948		10.1038/onc.2011.554	http://dx.doi.org/10.1038/onc.2011.554			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999VJ	22139082	Green Accepted			2022-12-17	WOS:000308342800003
J	Sevenich, L; Werner, F; Gajda, M; Schurigt, U; Sieber, C; Muller, S; Follo, M; Peters, C; Reinheckel, T				Sevenich, L.; Werner, F.; Gajda, M.; Schurigt, U.; Sieber, C.; Mueller, S.; Follo, M.; Peters, C.; Reinheckel, T.			Transgenic expression of human cathepsin B promotes progression and metastasis of polyoma-middle-T-induced breast cancer in mice	ONCOGENE			English	Article						protease; tumor microenvironment; tumor-associated inflammation; lysosome	CYSTEINE CATHEPSINS; TUMOR-GROWTH; MAST-CELLS; DEGRADING PROTEASES; VEGF-A; ANGIOGENESIS; INVASION; DEGRADATION; MACROPHAGES; CARCINOMAS	Elevated expression of the cysteine protease cathepsin B (CTSB) has been correlated with a poor prognosis for cancer patients. In order to model high CTSB expression in mammary cancer, transgenic mice expressing human CTSB were crossed with transgenic polyoma virus middle T oncogene breast cancer mice (mouse mammary tumor virus-PymT), resulting in a 20-fold increase in cathepsin B activity in the tumors of double-transgenic animals. CTSB expression did not affect tumor onset, but CTSB transgenic mice showed accelerated tumor growth with significant increase in weight for end-stage tumors, as well as an overall worsening in their histopathological grades. Notably, the lung metastases in the CTSB transgenic animals were found to be both significantly larger and to occur at a significantly higher frequency. Ex vivo analysis of primary PymT tumor cells revealed no significant effects from elevated CTSB levels on tumor cell characteristics, that is, the formation of tumor cell colonies and the sprouting of invasive strands from PymT cell spheroids. However, tumors from CTSB-overexpressing mice showed increased numbers of tumor-associated B cells and mast cells. In addition, more CD31+ endothelial cells were detected in these tumors, correlating with higher levels of vascular endothelial growth factor (VEGF) being present in the tumor and serum. We conclude that elevated proteolytic CTSB activity facilitates progression and metastasis of PymT-induced mammary carcinomas, and is associated with increased immune cell infiltration, enhanced VEGF levels and the promotion of tumor angiogenesis. Oncogene (2011) 30, 54-64; doi: 10.1038/onc.2010.387; published online 6 September 2010	[Sevenich, L.; Werner, F.; Schurigt, U.; Sieber, C.; Mueller, S.; Reinheckel, T.] Univ Freiburg, Inst Mol Med & Cell Res, D-79104 Freiburg, Germany; [Sevenich, L.; Werner, F.] Univ Freiburg, Fac Biol, D-79104 Freiburg, Germany; [Werner, F.] Univ Freiburg, Spemann Grad Sch Biol & Med SGBM, D-79104 Freiburg, Germany; [Gajda, M.] Univ Jena, Inst Pathol, Jena, Germany; [Follo, M.] Univ Med Ctr, Core Facil, Dept Hematol & Oncol, Freiburg, Germany; [Peters, C.; Reinheckel, T.] Univ Freiburg, Ludwig Heilmeyer Comprehens Canc Ctr, D-79104 Freiburg, Germany; [Peters, C.; Reinheckel, T.] Univ Freiburg, Ctr Biol Signalling Studies Bioss, D-79104 Freiburg, Germany	University of Freiburg; University of Freiburg; University of Freiburg; Friedrich Schiller University of Jena; University of Freiburg; University of Freiburg; University of Freiburg	Reinheckel, T (corresponding author), Univ Freiburg, Inst Mol Med & Cell Res, Stefan Meier Str 17, D-79104 Freiburg, Germany.	thomas.reinheckel@uniklinik-freiburg.de	Reinheckel, Thomas/AAL-9761-2021	Reinheckel, Thomas/0000-0001-9866-9105; Schurigt, Uta/0000-0003-4423-5955; Muller, Sebastian/0000-0001-8071-8853; Follo, Marie/0000-0002-3090-7442	European Commission [201279]; Deutsche Forschungsgemeinschaft [SFB 850, B7]; Excellence Initiative of the German Federal and State Governments [EXC 294, GSC-4]	European Commission(European CommissionEuropean Commission Joint Research Centre); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Excellence Initiative of the German Federal and State Governments	The Tg(CTSB)<SUP>+/0</SUP> mice were kindly provided by Dr L Pennacchio, Genomics Division, Lawrence Berkeley Laboratory. We thank Anne Schwinde, Ulrike Reif, Lisa Christiansson and Anna Heisswolf for excellent technical assistance. This work was supported by European Commission FP7 Grant 201279 (Microenvimet), Deutsche Forschungsgemeinschaft SFB 850 Project B7, and by the Excellence Initiative of the German Federal and State Governments (EXC 294 and GSC-4, Spemann Graduate School).	Allavena P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI 10.1016/j.critrevonc.2007.07.004; Andreu P, 2010, CANCER CELL, V17, P121, DOI 10.1016/j.ccr.2009.12.019; BARRETT AJ, 1992, ANN NY ACAD SCI, V674, P1; Berdowska I, 2004, CLIN CHIM ACTA, V342, P41, DOI 10.1016/j.cccn.2003.12.016; Brix K, 2008, BIOCHIMIE, V90, P194, DOI 10.1016/j.biochi.2007.07.024; BUCK MR, 1992, BIOCHEM J, V282, P273, DOI 10.1042/bj2820273; Caglic D, 2009, BIOL CHEM, V390, P175, DOI 10.1515/BC.2009.021; Chang SH, 2009, CANCER RES, V69, P4537, DOI 10.1158/0008-5472.CAN-08-4539; Coulibaly S, 1999, INT J CANCER, V83, P526, DOI 10.1002/(SICI)1097-0215(19991112)83:4<526::AID-IJC15>3.3.CO;2-D; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Crivellato E, 2008, CANCER LETT, V269, P1, DOI 10.1016/j.canlet.2008.03.031; de Visser KE, 2005, CANCER CELL, V7, P411, DOI 10.1016/j.ccr.2005.04.014; Del Rosso M, 2002, CLIN EXP METASTAS, V19, P193, DOI 10.1023/A:1015531321445; DeNardo DG, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1746; Dennemarker J, 2010, ONCOGENE, V29, P1611, DOI 10.1038/onc.2009.466; Du R, 2008, CANCER CELL, V13, P206, DOI 10.1016/j.ccr.2008.01.034; Duewell P, 2010, NATURE, V464, P1357, DOI 10.1038/nature08938; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Gocheva V, 2006, GENE DEV, V20, P543, DOI 10.1101/gad.1407406; Gocheva V, 2010, GENE DEV, V24, P241, DOI 10.1101/gad.1874010; Gondi CS, 2004, CANCER RES, V64, P4069, DOI 10.1158/0008-5472.CAN-04-1243; Green KA, 2005, BIOESSAYS, V27, P894, DOI 10.1002/bies.20281; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hawinkels LJAC, 2008, EUR J CANCER, V44, P1904, DOI 10.1016/j.ejca.2008.06.031; Houseweart MK, 2003, J NEUROBIOL, V56, P315, DOI 10.1002/neu.10253; Jedeszko C, 2004, BIOL CHEM, V385, P1017, DOI 10.1515/BC.2004.132; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; KATZ HR, 1995, INT ARCH ALLERGY IMM, V107, P76, DOI 10.1159/000236936; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Ma JX, 2000, J BIOL CHEM, V275, P12806, DOI 10.1074/jbc.275.17.12806; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Mohamed MM, 2006, NAT REV CANCER, V6, P764, DOI 10.1038/nrc1949; Nagy JA, 2007, ANNU REV PATHOL-MECH, V2, P251, DOI 10.1146/annurev.pathol.2.010506.134925; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Premzl A, 2003, EXP CELL RES, V283, P206, DOI 10.1016/S0014-4827(02)00055-1; Rawlings ND, 2010, NUCLEIC ACIDS RES, V38, pD227, DOI 10.1093/nar/gkp971; Ribatti D, 2001, BRIT J HAEMATOL, V115, P514, DOI 10.1046/j.1365-2141.2001.03202.x; ROZHIN J, 1994, CANCER RES, V54, P6517; Sevenich L, 2010, P NATL ACAD SCI USA, V107, P2497, DOI 10.1073/pnas.0907240107; Shin M, 2007, BIOL CHEM, V388, P1173, DOI 10.1515/BC.2007.154; Takai T, 2005, J CLIN IMMUNOL, V25, P1, DOI 10.1007/s10875-005-0353-8; Tummalapalli P, 2007, INT J ONCOL, V31, P1039; Turk V, 2004, CANCER CELL, V5, P409, DOI 10.1016/S1535-6108(04)00117-5; Van Damme J, 2004, SEMIN CANCER BIOL, V14, P201, DOI 10.1016/j.semcancer.2003.10.007; Vasiljeva O, 2008, ONCOGENE, V27, P4191, DOI 10.1038/onc.2008.59; Vasiljeva O, 2007, CURR PHARM DESIGN, V13, P387, DOI 10.2174/138161207780162962; Vasiljeva O, 2006, CANCER RES, V66, P5242, DOI 10.1158/0008-5472.CAN-05-4463; Werb Z, 1999, APMIS, V107, P11, DOI 10.1111/j.1699-0463.1999.tb01521.x	53	69	69	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	1					54	64		10.1038/onc.2010.387	http://dx.doi.org/10.1038/onc.2010.387			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	703EQ	20818432				2022-12-17	WOS:000285959300005
J	Arias-Romero, LE; Villamar-Cruz, O; Pacheco, A; Kosoff, R; Huang, M; Muthuswamy, SK; Chernoff, J				Arias-Romero, L. E.; Villamar-Cruz, O.; Pacheco, A.; Kosoff, R.; Huang, M.; Muthuswamy, S. K.; Chernoff, J.			A Rac-Pak signaling pathway is essential for ErbB2-mediated transformation of human breast epithelial cancer cells	ONCOGENE			English	Article						transformation; small GTPase; protein kinase; ErbB2; signal transduction; breast cancer	REGULATED KINASE; P21-ACTIVATED KINASES; TAMOXIFEN RESISTANCE; ACTIVATION; PROGRESSION; VECTORS; ISOFORM; TARGETS; ERBB2	The activation of receptor tyrosine kinases, particularly ErbB2, has an important role in the genesis of breast cancer. ErbB2 kinase activity promotes Ras-mediated stimulation of downstream protein kinase cascades, including the Ras/Raf-1/MAPK/ERK kinase (Mek)/extra-cellular signal-regulated kinase (Erk) pathway, leading to tumor cell growth and migration. Signaling through the Ras-Erk pathway can be influenced by p21-activated kinase-1 (Pak1), an effector of the Rho family GTPases Rac and Cdc42. In this study, we asked if ErbB2 expression correlates with Pak1 and Erk activity in human breast cancer specimens, and if Pak1 signaling is required for ErbB2 transformation in a three-dimensional (3D) in vitro setting and in xenografts. We found a correlation between ErbB2 expression and activation of Pak in estrogen receptor-positive human breast tumor samples and observed that in 3D cultures, activation of Rac-Pak1 pathway by ErbB2 homodimers induced growth factor-independent proliferation and promoted disruption of 3D mammary acinar-like structures through activation of the Erk and Akt pathways. Further, we found that inhibition of Pak1 by small molecules compromised activation of Erk and Akt, resulting in reversion of the malignant phenotype and restoration of normal acinar architecture. Finally, ErbB2-amplified breast cancer cells expressing a specific Pak inhibitor showed delayed tumor formation and downregulation of Erk and Akt signaling in vivo. These data imply that the Rac-Pak pathway is vital to ErbB2-mediated transformation and that Pak inhibitors represent plausible drug targets in breast cancers in which ErbB2 signaling is activated. Oncogene (2010) 29, 5839-5849; doi: 10.1038/onc.2010.318; published online 16 August 2010	[Arias-Romero, L. E.; Villamar-Cruz, O.; Pacheco, A.; Huang, M.; Chernoff, J.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; [Kosoff, R.] Univ Penn, Canc Biol Program, Philadelphia, PA 19104 USA; [Muthuswamy, S. K.] Univ Toronto, Ontario Canc Inst, Toronto, ON, Canada	Fox Chase Cancer Center; University of Pennsylvania; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Chernoff, J (corresponding author), Fox Chase Canc Ctr, 333 Cottman Ave, Philadelphia, PA 19111 USA.	Jonathan.Chernoff@fccc.edu	Chernoff, Jonathan/I-7631-2014; Muthuswamy, Senthil K/AGY-2834-2022	Chernoff, Jonathan/0000-0002-4803-7836; Muthuswamy, Senthil K/0000-0001-6564-9634; Villamar-Cruz, Olga/0000-0003-4265-9367; Arias-Romero, Luis E./0000-0001-5676-2483	NIH [R01 CA58836, R01 CA098830, P30 CA006927]; NATIONAL CANCER INSTITUTE [R01CA058836, R01CA098830, P30CA006927, R56CA098830] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dan Kalman (Emory University School of Medicine) and Ariad Pharmaceuticals, for their gifts of pAdlox vectors and AP1510, respectively, and Fang Zhu, of the FCCC Biostatistics Facility, for statistical analysis of TMA and xengraft data. This work was supported by grants from the NIH to JC (R01 CA58836) and SM (R01 CA098830) and to the Fox Chase Cancer Center (P30 CA006927), as well as by an appropriation from the state of Pennsylvania.	Amundadottir LT, 1998, ONCOGENE, V16, P737, DOI 10.1038/sj.onc.1201829; Arias-Romero LE, 2008, BIOL CELL, V100, P97, DOI 10.1042/BC20070109; Beeser A, 2005, J BIOL CHEM, V280, P36609, DOI 10.1074/jbc.M502306200; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Deacon SW, 2008, CHEM BIOL, V15, P322, DOI 10.1016/j.chembiol.2008.03.005; Dummler B, 2009, CANCER METAST REV, V28, P51, DOI 10.1007/s10555-008-9168-1; Eblen ST, 2002, MOL CELL BIOL, V22, P6023, DOI 10.1128/MCB.22.17.6023-6033.2002; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Higuchi M, 2008, NAT CELL BIOL, V10, P1356, DOI 10.1038/ncb1795; Hofmann C, 2004, J CELL SCI, V117, P4343, DOI 10.1242/jcs.01392; Holm C, 2006, JNCI-J NATL CANCER I, V98, P671, DOI 10.1093/jnci/djj185; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Jaffer ZM, 2002, INT J BIOCHEM CELL B, V34, P713, DOI 10.1016/S1357-2725(01)00158-3; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Li QW, 2008, NEOPLASIA, V10, P314, DOI 10.1593/neo.07970; Lightcap CM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006025; Maksimoska J, 2008, J AM CHEM SOC, V130, P15764, DOI 10.1021/ja805555a; Mao K, 2008, J MOL CELL CARDIOL, V44, P429, DOI 10.1016/j.yjmcc.2007.10.016; Menard RE, 2003, CELL SIGNAL, V15, P1099, DOI 10.1016/S0898-6568(03)00087-1; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Porchia LM, 2007, MOL PHARMACOL, V72, P1124, DOI 10.1124/mol.107.037556; Rayala SK, 2006, CANCER RES, V66, P5985, DOI 10.1158/0008-5472.CAN-06-0978; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; SHALABY MR, 1992, J EXP MED, V175, P217, DOI 10.1084/jem.175.1.217; Shou J, 2004, JNCI-J NATL CANCER I, V96, P926, DOI 10.1093/jnci/djh166; SOULE HD, 1990, CANCER RES, V50, P6075; Srinivasan S, 2003, J CELL BIOL, V160, P375, DOI 10.1083/jcb.200208179; Treeck O, 2003, EUR J CANCER, V39, P1302, DOI 10.1016/S0959-8049(02)00777-3; Viaud J, 2009, MOL CANCER THER, V8, P2559, DOI 10.1158/1535-7163.MCT-09-0102; Wang RA, 2006, ONCOGENE, V25, P2931, DOI 10.1038/sj.onc.1209309; Wang SZE, 2006, CANCER RES, V66, P9591, DOI 10.1158/0008-5472.CAN-06-2071; Weigelt B, 2010, BREAST CANCER RES TR, V122, P35, DOI 10.1007/s10549-009-0502-2; Zhan LX, 2006, CANCER RES, V66, P5201, DOI 10.1158/0008-5472.CAN-05-4081	36	69	71	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	43					5839	5849		10.1038/onc.2010.318	http://dx.doi.org/10.1038/onc.2010.318			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	672LY	20711231	Green Accepted			2022-12-17	WOS:000283586200009
J	Xu, L; Nilsson, MB; Saintigny, P; Cascone, T; Herynk, MH; Du, Z; Nikolinakos, PG; Yang, Y; Prudkin, L; Liu, D; Lee, JJ; Johnson, FM; Wong, KK; Girard, L; Gazdar, AF; Minna, JD; Kurie, JM; Wistuba, II; Heymach, JV				Xu, L.; Nilsson, M. B.; Saintigny, P.; Cascone, T.; Herynk, M. H.; Du, Z.; Nikolinakos, P. G.; Yang, Y.; Prudkin, L.; Liu, D.; Lee, J. J.; Johnson, F. M.; Wong, K-K; Girard, L.; Gazdar, A. F.; Minna, J. D.; Kurie, J. M.; Wistuba, I. I.; Heymach, J. V.			Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1 alpha in non-small cell lung cancer cells	ONCOGENE			English	Article						EGFR; MET; non-small cell lung cancer; HIF-1 alpha; invasiveness	PREVIOUSLY TREATED PATIENTS; KINASE DOMAIN MUTATIONS; FACTOR SCATTER FACTOR; IN-VITRO INVASION; C-MET; TYROSINE KINASE; FACTOR-ALPHA; CROSS-TALK; SIGNALING PATHWAY; EGF RECEPTOR	Recent studies have established that amplification of the MET proto-oncogene can cause resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) cell lines with EGFR-activating mutations. The role of non-amplified MET in EGFR-dependent signaling before TKI resistance, however, is not well understood. Using NSCLC cell lines and transgenic models, we demonstrate here that EGFR activation by either mutation or ligand binding increases MET gene expression and protein levels. Our analysis of 202 NSCLC patient specimens was consistent with these observations: levels of MET were significantly higher in NSCLC with EGFR mutations than in NSCLC with wild-type EGFR. EGFR regulation of MET levels in cell lines occurred through the hypoxia-inducible factor (HIF)-1 alpha pathway in a hypoxia-independent manner. This regulation was lost, however, after MET gene amplification or overexpression of a constitutively active form of HIF-1 alpha. EGFR- and hypoxia-induced invasiveness of NSCLC cells, but not cell survival, were found to be MET dependent. These findings establish that, absent MET amplification, EGFR signaling can regulate MET levels through HIF-1 alpha and that MET is a key downstream mediator of EGFR- induced invasiveness in EGFR- dependent NSCLC cells. Oncogene (2010) 29, 2616-2627; doi:10.1038/onc.2010.16; published online 15 February 2010	[Xu, L.; Nilsson, M. B.; Saintigny, P.; Cascone, T.; Herynk, M. H.; Nikolinakos, P. G.; Yang, Y.; Johnson, F. M.; Kurie, J. M.; Heymach, J. V.] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; [Du, Z.; Wistuba, I. I.; Heymach, J. V.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; [Prudkin, L.; Wistuba, I. I.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Liu, D.; Lee, J. J.] Univ Texas MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA; [Wong, K-K] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Girard, L.; Gazdar, A. F.; Minna, J. D.] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Hamon Ctr Therapeut Oncol Res, Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA; [Minna, J. D.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Harvard University; Dana-Farber Cancer Institute; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Heymach, JV (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, 1515 Holcombe Blvd,Unit 432, Houston, TX 77030 USA.	jheymach@mdanderson.org	Center, Univ of Texas-M D Anderson Cancer/AAE-8182-2019; Lee, Jack/P-7331-2019; Heymach, John/AAG-2361-2019; Yang, Yanan/F-1592-2010	Center, Univ of Texas-M D Anderson Cancer/0000-0001-5469-9214; Lee, Jack/0000-0002-4584-929X; Heymach, John/0000-0001-9068-8942; Saintigny, Pierre/0000-0002-8090-9323	NIH [P50 CA70907, P01 CA06294]; Department of Defense [W81XWH-07-1-0306 01]; Metastasis Foundation; Physician-Scientist Program; American Society for Clinical Oncology Career Development Award; Damon Runyon Cancer Research Foundation [CI 24-04]; NATIONAL CANCER INSTITUTE [P50CA070907, P01CA006294] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); Metastasis Foundation; Physician-Scientist Program; American Society for Clinical Oncology Career Development Award; Damon Runyon Cancer Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Mien-Chie Hung, Scott Lippman, and Kian Ang for their critical review, Dr Jeffrey Engelman for the EGFR-transfected NIH 3T3 cell lines, and Joseph Munch for editorial assistance. Supported in part by the NIH Lung Cancer SPORE grant P50 CA70907, NIH Grant P01 CA06294, Department of Defense Grant W81XWH-07-1-0306 01, awards from the Metastasis Foundation, the Physician-Scientist Program, and the American Society for Clinical Oncology Career Development Award (JVH). JVH is a Damon Runyon-Lilly Clinical Investigator supported in part by the Damon Runyon Cancer Research Foundation (CI 24-04).	Beadsmoore CJ, 2003, EUR J RADIOL, V45, P8, DOI 10.1016/S0720-048X(02)00287-5; Bergstrom JD, 2000, EXP CELL RES, V259, P293, DOI 10.1006/excr.2000.4967; Bredin CG, 2003, ANTICANCER RES, V23, P4877; Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704; COOPER CS, 1986, EMBO J, V5, P2623, DOI 10.1002/j.1460-2075.1986.tb04543.x; Cuvier C, 1997, CLIN EXP METASTAS, V15, P19; Damstrup L, 1998, BRIT J CANCER, V78, P631, DOI 10.1038/bjc.1998.553; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Fukuoka M, 2003, J CLIN ONCOL, V21, P2237, DOI 10.1200/JCO.2003.10.038; Guo A, 2008, P NATL ACAD SCI USA, V105, P692, DOI 10.1073/pnas.0707270105; HAMADA J, 1995, CANCER LETT, V89, P161, DOI 10.1016/0304-3835(95)03686-Q; Hirami Y, 2004, CANCER LETT, V214, P157, DOI 10.1016/j.canlet.2004.04.028; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Huang PH, 2007, P NATL ACAD SCI USA, V104, P12867, DOI 10.1073/pnas.0705158104; Ichimura E, 1996, JPN J CANCER RES, V87, P1063, DOI 10.1111/j.1349-7006.1996.tb03111.x; Ide T, 2006, INT J CANCER, V119, P2750, DOI 10.1002/ijc.22178; Janne PA, 2005, J CLIN ONCOL, V23, P3227, DOI 10.1200/JCO.2005.09.985; Ji HB, 2006, CANCER CELL, V9, P485, DOI 10.1016/j.ccr.2006.04.022; Jo MJ, 2000, J BIOL CHEM, V275, P8806, DOI 10.1074/jbc.275.12.8806; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Kim WY, 2006, EMBO J, V25, P4650, DOI 10.1038/sj.emboj.7601300; Kris MG, 2003, JAMA-J AM MED ASSOC, V290, P2149, DOI 10.1001/jama.290.16.2149; Lin M, 2004, BIOINFORMATICS, V20, P1233, DOI 10.1093/bioinformatics/bth069; LIU C, 1993, AM J PATHOL, V142, P1155; Lutterbach B, 2007, CANCER RES, V67, P2081, DOI 10.1158/0008-5472.CAN-06-3495; Luwor RB, 2005, ONCOGENE, V24, P4433, DOI 10.1038/sj.onc.1208625; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Nakamura Y, 2007, CANCER SCI, V98, P1006, DOI 10.1111/j.1349-7006.2007.00493.x; Olivero M, 1996, BRIT J CANCER, V74, P1862, DOI 10.1038/bjc.1996.646; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pai R, 2003, FASEB J, V17, P1640, DOI 10.1096/fj.02-1011com; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Pao W, 2005, J CLIN ONCOL, V23, P2556, DOI 10.1200/JCO.2005.07.799; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; Peng XH, 2006, J BIOL CHEM, V281, P25903, DOI 10.1074/jbc.M603414200; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Peruzzi B, 2006, CLIN CANCER RES, V12, P3657, DOI 10.1158/1078-0432.CCR-06-0818; Phillips RJ, 2005, J BIOL CHEM, V280, P22473, DOI 10.1074/jbc.M500963200; Pore N, 2006, CANCER RES, V66, P3197, DOI 10.1158/0008-5472.CAN-05-3090; Qiao H, 2002, J CELL BIOCHEM, V86, P665, DOI 10.1002/jcb.10239; Rosario M, 2003, TRENDS CELL BIOL, V13, P328, DOI 10.1016/S0962-8924(03)00104-1; Ross J, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2001-2-2-reviews3004; Scheving LA, 2002, BIOCHEM BIOPH RES CO, V290, P197, DOI 10.1006/bbrc.2001.6157; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Shimamura T, 2005, CANCER RES, V65, P6401, DOI 10.1158/0008-5472.CAN-05-0933; Shimazaki K, 2003, BRAIN RES, V962, P105, DOI 10.1016/S0006-8993(02)03975-6; Siegfried JM, 1998, ANN THORAC SURG, V66, P1915, DOI 10.1016/S0003-4975(98)01165-5; Smolen GA, 2006, P NATL ACAD SCI USA, V103, P2316, DOI 10.1073/pnas.0508776103; Stabile LP, 2004, GENE THER, V11, P325, DOI 10.1038/sj.gt.3302169; Swinson DEB, 2006, CLIN LUNG CANCER, V7, P250, DOI 10.3816/CLC.2006.n.002; Swinson DEB, 2004, INT J CANCER, V111, P43, DOI 10.1002/ijc.20052; Thatcher N, 2005, LANCET, V366, P1527, DOI 10.1016/S0140-6736(05)67625-8; Weinberger PM, 2005, ARCH OTOLARYNGOL, V131, P707, DOI 10.1001/archotol.131.8.707; Yang Y, 2008, MOL CANCER THER, V7, P952, DOI 10.1158/1535-7163.MCT-07-2045; Yi S, 1998, BRIT J CANCER, V77, P2162, DOI 10.1038/bjc.1998.361; Zhao XJ, 2005, CANCER RES, V65, P5561, DOI 10.1158/0008-5472.CAN-04-4603; Zhong H, 2000, CANCER RES, V60, P1541; Zhou QC, 2006, ZEBRAFISH, V3, P39, DOI 10.1089/zeb.2006.3.39	60	69	71	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2010	29	18					2616	2627		10.1038/onc.2010.16	http://dx.doi.org/10.1038/onc.2010.16			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592DC	20154724	Green Accepted			2022-12-17	WOS:000277354600002
J	El Hour, M; Moncada-Pazos, A; Blacher, S; Masset, A; Cal, S; Berndt, S; Detilleux, J; Host, L; Obaya, AJ; Maillard, C; Foidart, JM; Ectors, F; Noel, A; Lopez-Otin, C				El Hour, M.; Moncada-Pazos, A.; Blacher, S.; Masset, A.; Cal, S.; Berndt, S.; Detilleux, J.; Host, L.; Obaya, A. J.; Maillard, C.; Foidart, J. M.; Ectors, F.; Noel, A.; Lopez-Otin, C.			Higher sensitivity of Adamts12-deficient mice to tumor growth and angiogenesis	ONCOGENE			English	Article						ADAMTS-12; angiogenesis; tumor suppression	MATRIX METALLOPROTEINASES; ADAMTS METALLOPROTEINASES; EMERGING ROLES; CANCER; VASCULARIZATION; SUSCEPTIBILITY; PROGRESSION; EXPRESSION; PROTEASES; STROMA	ADAMTS (a disintegrin and metalloproteinase domain with thrombospondin motifs) constitute a family of endopeptidases related to matrix metalloproteinases. These proteases have been largely implicated in tissue remodeling and angiogenesis associated with physiological and pathological processes. To elucidate the in vivo functions of ADAMTS-12, we have generated a knockout mouse strain (Adamts12(-/-)) in which Adamts12 gene was deleted. The mutant mice had normal gestations and no apparent defects in growth, life span and fertility. By applying three different in vivo models of angiogenesis (malignant keratinocyte transplantation, Matrigel plug and aortic ring assays) to Adamts12(-/-) mice, we provide evidence for a protective effect of this host enzyme toward angiogenesis and cancer progression. In the absence of Adamts-12, both the angiogenic response and tumor invasion into host tissue were increased. Complementing results were obtained by using medium conditioned by cells overexpressing human ADAMTS-12, which inhibited vessel outgrowth in the aortic ring assay. This angioinhibitory effect of ADAMTS-12 was independent of its enzymatic activity as a mutated inactive form of the enzyme was similarly efficient in inhibiting endothelial cell sprouting in the aortic ring assay than the wild-type form. Altogether, our results show that ADAMTS-12 displays antiangiogenic properties and protect the host toward tumor progression. Oncogene (2010) 29, 3025-3032; doi:10.1038/onc.2010.49; published online 8 March 2010	[Noel, A.] Univ Liege, Lab Tumor & Dev Biol, GIGA Canc, CHU Sart Tilman, B-4000 Liege, Belgium; [Moncada-Pazos, A.; Cal, S.; Obaya, A. J.; Lopez-Otin, C.] Univ Oviedo, Inst Univ Oncol, Dept Bioquim & Biol Mol, Asturias, Spain; [Ectors, F.] Univ Liege, GIGA Transgenesis, B-4000 Liege, Belgium	University of Liege; University of Oviedo; Instituto Universitario de Oncologia de Asturias; University of Liege	Noel, A (corresponding author), Univ Liege, Lab Tumor & Dev Biol, GIGA Canc, CHU Sart Tilman, Tour Pathol B23, B-4000 Liege, Belgium.	agnes.noel@ulg.ac.be	López-Otín, Carlos/AAB-2106-2020; Obaya, Alvaro J./AAQ-6115-2021	López-Otín, Carlos/0000-0001-6964-1904; Obaya, Alvaro J./0000-0002-4163-2173; Noel, Agnes/0000-0002-7670-6179; MONCADA PAZOS, ANGELA/0000-0002-3871-2965	Ministerio de Ciencia e Innovacion, Fundacion M. Botin (Spain) [201279]; FP7-HEALTH-2007-A [201279]; Fonds de la Recherche Scientifique-FNRS (FRS-FNRS, Belgium); Foundation against Cancer; DGTRE from the SPW (Region Wallonne, Belgium); Interuniversity Attraction Poles Programme-Belgian Science Policy (Brussels, Belgium)	Ministerio de Ciencia e Innovacion, Fundacion M. Botin (Spain)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); FP7-HEALTH-2007-A; Fonds de la Recherche Scientifique-FNRS (FRS-FNRS, Belgium)(Fonds de la Recherche Scientifique - FNRS); Foundation against Cancer; DGTRE from the SPW (Region Wallonne, Belgium); Interuniversity Attraction Poles Programme-Belgian Science Policy (Brussels, Belgium)(Belgian Federal Science Policy Office)	The authors acknowledge F Olivier, G Roland and L Volders for their excellent technical assistance. This work was supported by grants from Ministerio de Ciencia e Innovacion, Fundacion M. Botin (Spain), the FP7-HEALTH-2007-A-Project No. 201279 'MICROENVIMET', the Fonds de la Recherche Scientifique-FNRS (FRS-FNRS, Belgium), the Foundation against Cancer (foundation of public interest, Belgium), the DGTRE from the SPW (Region Wallonne, Belgium), the Interuniversity Attraction Poles Programme-Belgian Science Policy (Brussels, Belgium). MEH, AM, JD, LH and FE are recipients of grants from the Fonds de la Recherche Scientifique (FRS-FNRS, Belgium).	Bai XH, 2009, CELL MOL LIFE SCI, V66, P667, DOI 10.1007/s00018-008-8633-x; Balbin M, 2003, NAT GENET, V35, P252, DOI 10.1038/ng1249; Berndt S, 2006, FASEB J, V20, P2630, DOI 10.1096/fj.06-5885fje; Berndt Sarah, 2008, P305, DOI 10.1007/978-0-387-69057-5_16; Blacher S, 2008, MICROVASC RES, V75, P169, DOI 10.1016/j.mvr.2007.09.002; Cal S, 2001, J BIOL CHEM, V276, P17932, DOI 10.1074/jbc.M100534200; Cauwe B, 2007, CRIT REV BIOCHEM MOL, V42, P113, DOI 10.1080/10409230701340019; Dunn JR, 2006, BRIT J CANCER, V94, P1186, DOI 10.1038/sj.bjc.6603006; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; FUSENIG NE, 1983, J INVEST DERMATOL, V81, P168; Iruela-Arispe ML, 2003, ANN NY ACAD SCI, V995, P183, DOI 10.1111/j.1749-6632.2003.tb03221.x; Jost M, 2007, AM J PATHOL, V171, P1369, DOI 10.2353/ajpath.2007.070074; Jost M, 2006, CANCER RES, V66, P5234, DOI 10.1158/0008-5472.CAN-05-4315; Jost Maud, 2008, P327, DOI 10.1007/978-0-387-69057-5_17; Kurz T, 2006, J ALLERGY CLIN IMMUN, V118, P396, DOI 10.1016/j.jaci.2006.04.036; Lambert V, 2003, FASEB J, V17, P2290, DOI 10.1096/fj.03-0113fje; Liu YJ, 2006, ONCOGENE, V25, P2452, DOI 10.1038/sj.onc.1209287; Llamazares M, 2007, J CELL SCI, V120, P3544, DOI 10.1242/jcs.005751; Lopez-Otin C, 2007, NAT REV CANCER, V7, P800, DOI 10.1038/nrc2228; Luque A, 2003, J BIOL CHEM, V278, P23656, DOI 10.1074/jbc.M212964200; Masson Veronique, 2002, Biological Procedures Online, V4, P24, DOI 10.1251/bpo30; Moncada-Pazos A, 2009, J CELL SCI, V122, P2906, DOI 10.1242/jcs.050468; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Noel A, 2008, SEMIN CELL DEV BIOL, V19, P52, DOI 10.1016/j.semcdb.2007.05.011; Nyberg P, 2008, FRONT BIOSCI, V13, P6537, DOI 10.2741/3173; Overall CM, 2007, NAT REV MOL CELL BIO, V8, P245, DOI 10.1038/nrm2120; Porter S, 2004, CLIN CANCER RES, V10, P2429, DOI 10.1158/1078-0432.CCR-0398-3; Porter S, 2005, BIOCHEM J, V386, P15, DOI 10.1042/BJ20040424; Rocks N, 2008, BIOCHIMIE, V90, P369, DOI 10.1016/j.biochi.2007.08.008; Vazquez F, 1999, J BIOL CHEM, V274, P23349, DOI 10.1074/jbc.274.33.23349	30	69	69	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2010	29	20					3025	3032		10.1038/onc.2010.49	http://dx.doi.org/10.1038/onc.2010.49			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599DM	20208563	Green Submitted, Green Published			2022-12-17	WOS:000277890400013
J	Taniguchi, E; Nishijo, K; McCleish, AT; Michalek, JE; Grayson, MH; Infante, AJ; Abboud, HE; Legallo, RD; Qualman, SJ; Rubin, BP; Keller, C				Taniguchi, E.; Nishijo, K.; McCleish, A. T.; Michalek, J. E.; Grayson, M. H.; Infante, A. J.; Abboud, H. E.; Legallo, R. D.; Qualman, S. J.; Rubin, B. P.; Keller, C.			PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma	ONCOGENE			English	Article						PDGFR-A; therapeutic target; alveolar rhabdomyosarcoma	GROWTH-FACTOR; IN-VIVO; ALPHA; KINASE; ACTIVATION; EXPRESSION; IMATINIB; RECEPTOR; DISEASE; CELLS	Alveolar rhabdomyosarcoma is an aggressive skeletal muscle cancer of childhood. Our initial studies of rhabdomyosarcoma gene expression for patients enrolled in a national clinical trial suggested that platelet-derived growth factor receptor A (PDGFR-A) may be a mediator of disease progression and metastasis. Using our conditional mouse tumor models that authentically recapitulate the primary mutations and metastatic progression of alveolar rhabdomyosarcomas in humans, we found by immunoblotting and immunokinase assays that PDGFR-A and its downstream effectors, mitogen-activated protein kinase and Akt, were highly activated in both primary and metastatic tumors. Inhibition of PDGFR-A by RNA interference, small molecule inhibitor or neutralizing antibody had a dramatic effect on tumor cell growth both in vitro and in vivo, although resistance evolved in one-third of tumors. These results establish proof-of-principal for PDGFR-A as a therapeutic target in alveolar rhabdomyosarcoma.	[Taniguchi, E.; Nishijo, K.; McCleish, A. T.; Keller, C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, Greehey Childrens Canc Res Inst, San Antonio, TX 78229 USA; [Michalek, J. E.; Grayson, M. H.; Infante, A. J.; Keller, C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pediat, San Antonio, TX 78229 USA; [Michalek, J. E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA; [Abboud, H. E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA; [Legallo, R. D.] Univ Virginia Hlth Syst, Dept Pathol, Charlottesville, VA USA; [Qualman, S. J.] Ohio State Univ, Dept Pediat, Columbus Childrens Res Inst, Ctr Childhood Canc, Columbus, OH 43210 USA; [Rubin, B. P.] Cleveland Clin, Taussig Canc Ctr, Dept Anat Pathol, Cleveland, OH 44106 USA; [Rubin, B. P.] Cleveland Clin, Lerner Res Inst, Cleveland, OH 44106 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Virginia; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Keller, C (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, Greehey Childrens Canc Res Inst, 8403 Floyd Curl Dr,MC7784, San Antonio, TX 78229 USA.	kellerc2@uthscsa.edu		Keller, Charles/0000-0003-2505-7487	NIH [RO1CA 133229]; University Research Council (UTHSCSA); Sarcoma Foundation of America; Amschwand Sarcoma Cancer Foundation; National Cancer Institute Center; San Antonio Cancer Center [P30 CA54174]; NATIONAL CANCER INSTITUTE [R01CA133229, P30CA054174] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University Research Council (UTHSCSA); Sarcoma Foundation of America; Amschwand Sarcoma Cancer Foundation; National Cancer Institute Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); San Antonio Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Frederic G Barr ( The University of Pennsylvania School of Medicine) for providing Pax3: Fkhr cDNA and Pax7: Fkhr cDNA, and Dr Guillermina Lozano ( University of Texas M. D. Anderson Cancer Center) for providing p53 cDNA. This work was funded in part by grants from NIH RO1CA 133229, the University Research Council (UTHSCSA), the Sarcoma Foundation of America, and the Amschwand Sarcoma Cancer Foundation. Animal care costs for this study were in part defrayed by a National Cancer Institute Center grant to the San Antonio Cancer Center ( Grant number P30 CA54174), of which CK is a member. We thank Dr Sharon B Murphy for critical reading of this article, and Gary Chisholm for statistical support.	Armistead PM, 2007, CANCER, V110, P2293, DOI 10.1002/cncr.23038; Arndt CAS, 1999, NEW ENGL J MED, V341, P342, DOI 10.1056/NEJM199907293410507; Blandford MC, 2006, PEDIATR BLOOD CANCER, V46, P329, DOI 10.1002/pbc.20466; Capdeville R, 2002, NAT REV DRUG DISCOV, V1, P493, DOI 10.1038/nrd839; Choudhury GG, 2000, KIDNEY INT, V57, P908, DOI 10.1046/j.1523-1755.2000.00907.x; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; Crist WM, 2001, J CLIN ONCOL, V19, P3091, DOI 10.1200/JCO.2001.19.12.3091; DEVARE SG, 1983, P NATL ACAD SCI-BIOL, V80, P731, DOI 10.1073/pnas.80.3.731; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Epstein JA, 1998, MOL CELL BIOL, V18, P4118, DOI 10.1128/MCB.18.7.4118; Heinrich MC, 2003, J CLIN ONCOL, V21, P4342, DOI 10.1200/JCO.2003.04.190; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Keller C, 2004, GENE DEV, V18, P2614, DOI 10.1101/gad.1244004; Keller C, 2004, GENE DEV, V18, P2608, DOI 10.1101/gad.1243904; MacDonald TJ, 2001, NAT GENET, V29, P143, DOI 10.1038/ng731; Matei D, 2006, ONCOGENE, V25, P2060, DOI 10.1038/sj.onc.1209232; Mehrotra M, 2004, J CELL BIOCHEM, V93, P741, DOI 10.1002/jcb.20138; Meijerink J, 2001, J MOL DIAGN, V3, P55, DOI 10.1016/S1525-1578(10)60652-6; Pani L, 2002, GENE DEV, V16, P676, DOI 10.1101/gad.969302; Ricono JM, 2002, AM J PHYSIOL-RENAL, V282, pF211, DOI 10.1152/ajprenal.0323.2000; Schneider L, 2005, CURR BIOL, V15, P1861, DOI 10.1016/j.cub.2005.09.012; Stover EH, 2005, BLOOD, V106, P3206, DOI 10.1182/blood-2005-05-1932; Stover EH, 2006, P NATL ACAD SCI USA, V103, P8078, DOI 10.1073/pnas.0601192103; Takahashi Y, 2004, MODERN PATHOL, V17, P660, DOI 10.1038/modpathol.3800101; Underwood TJ, 2007, FEBS LETT, V581, P5831, DOI 10.1016/j.febslet.2007.11.056	25	69	74	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 30	2008	27	51					6550	6560		10.1038/onc.2008.255	http://dx.doi.org/10.1038/onc.2008.255			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	366RS	18679424	Green Accepted			2022-12-17	WOS:000260501700002
J	Ueki, T; Nishidate, T; Park, JH; Lin, ML; Shimo, A; Hirata, K; Nakamura, Y; Katagiri, T				Ueki, T.; Nishidate, T.; Park, J. H.; Lin, M. L.; Shimo, A.; Hirata, K.; Nakamura, Y.; Katagiri, T.			Involvement of elevated expression of multiple cell-cycle regulator, DTL/RAMP (denticleless/RA-regulated nuclear matrix associated protein), in the growth of breast cancer cells	ONCOGENE			English	Article						cDNA microarray; molecular target; AURKB; multiple cell-cycle regulator; cytokinesis	SYNOVIAL SARCOMAS; MOLECULAR TARGETS; KINASE; GENE; IDENTIFICATION; THERAPY; COMPLEX; PHOSPHORYLATION; CARCINOGENESIS; CYTOKINESIS	To investigate the detailed molecular mechanism of mammary carcinogenesis and discover novel therapeutic targets, we previously analysed gene expression profiles of breast cancers. We here report characterization of a significant role of DTL/RAMP (denticleless/RA-regulated nuclear matrix associated protein) in mammary carcinogenesis. Semiquantitative RT-PCR and northern blot analyses confirmed upregulation of DTL/RAMP in the majority of breast cancer cases and all of breast cancer cell lines examined. Immunocytochemical and western blot analyses using anti-DTL/RAMP polyclonal antibody revealed cell-cycle-dependent localization of endogenous DTL/RAMP protein in breast cancer cells; nuclear localization was observed in cells at interphase and the protein was concentrated at the contractile ring in cytokinesis process. The expression level of DTL/RAMP protein became highest at G(1)/S phases, whereas its phosphorylation level was enhanced during mitotic phase. Treatment of breast cancer cells, T47D and HBC4, with small-interfering RNAs against DTL/RAMP effectively suppressed its expression and caused accumulation of G(2)/M cells, resulting in growth inhibition of cancer cells. We further demonstrate the in vitro phosphorylation of DTL/RAMP through an interaction with the mitotic kinase, Aurora kinase-B (AURKB). Interestingly, depletion of AURKB expression with siRNA in breast cancer cells reduced the phosphorylation of DTL/RAMP and decreased the stability of DTL/RAMP protein. These findings imply important roles of DTL/RAMP in growth of breast cancer cells and suggest that DTL/RAMP might be a promising molecular target for treatment of breast cancer.	[Ueki, T.; Nishidate, T.; Park, J. H.; Lin, M. L.; Shimo, A.; Nakamura, Y.; Katagiri, T.] Univ Tokyo, Mol Med Lab, Ctr Human Genome, Inst Med Sci,Minato Ku, Tokyo 1088639, Japan; [Ueki, T.; Hirata, K.] Sapporo Med Univ, Dept Surg, Chuo Ku, Sapporo, Hokkaido, Japan	University of Tokyo; Sapporo Medical University	Katagiri, T (corresponding author), Univ Tokyo, Mol Med Lab, Ctr Human Genome, Inst Med Sci,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	tkatagi@ims.u-tokyo.ac.jp	Katagiri, Toyomasa/I-7344-2012					Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Bange J, 2001, NAT MED, V7, P548, DOI 10.1038/87872; Banks D, 2006, CELL CYCLE, V5, P1719, DOI 10.4161/cc.5.15.3150; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Cheeseman LM, 2002, CELL, V111, P163, DOI 10.1016/S0092-8674(02)00973-X; Cheung WMW, 2001, J BIOL CHEM, V276, P17083, DOI 10.1074/jbc.M010802200; Dechat T, 1998, EMBO J, V17, P4887, DOI 10.1093/emboj/17.16.4887; Goto H, 2003, J BIOL CHEM, V278, P8526, DOI 10.1074/jbc.M210892200; Higa LA, 2006, NAT CELL BIOL, V8, P1277, DOI 10.1038/ncb1490; Higa LA, 2006, CELL CYCLE, V5, P1675, DOI 10.4161/cc.5.15.3149; Hirota E, 2006, INT J ONCOL, V29, P799; Lin ML, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1650; Nagayama S, 2004, ONCOGENE, V23, P5551, DOI 10.1038/sj.onc.1207710; Nagayama S, 2005, ONCOGENE, V24, P6201, DOI 10.1038/sj.onc.1208780; Navolanic PM, 2005, INT J ONCOL, V27, P1341; Nishidate T, 2004, INT J ONCOL, V25, P797; Ohashi S, 2006, ONCOGENE, V25, P7691, DOI 10.1038/sj.onc.1209754; Park JH, 2006, CANCER RES, V66, P9186, DOI 10.1158/0008-5472.CAN-06-1601; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Petricoin EF, 2002, NAT GENET, V32, P474, DOI 10.1038/ng1029; Sansam CL, 2006, GENE DEV, V20, P3117, DOI 10.1101/gad.1482106; Severson AF, 2000, CURR BIOL, V10, P1162, DOI 10.1016/S0960-9822(00)00715-6; Shimo A, 2007, CANCER SCI, V98, P174, DOI 10.1111/j.1349-7006.2006.00381.x; Shimokawa T, 2003, CANCER RES, V63, P6116; Terada Y, 2001, CELL STRUCT FUNCT, V26, P653, DOI 10.1247/csf.26.653; Togashi A, 2005, CANCER RES, V65, P4817, DOI 10.1158/0008-5472.CAN-05-0120	26	69	72	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2008	27	43					5672	5683		10.1038/onc.2008.186	http://dx.doi.org/10.1038/onc.2008.186			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352HM	18542055				2022-12-17	WOS:000259487100003
J	Wilson, JB; Yamamoto, K; Marriott, AS; Hussain, S; Sung, P; Hoatlin, ME; Mathew, CG; Takata, M; Thompson, LH; Kupfer, GM; Jones, NJ				Wilson, J. B.; Yamamoto, K.; Marriott, A. S.; Hussain, S.; Sung, P.; Hoatlin, M. E.; Mathew, C. G.; Takata, M.; Thompson, L. H.; Kupfer, G. M.; Jones, N. J.			FANCG promotes formation of a newly identified protein complex containing BRCA2, FANCD2 and XRCC3	ONCOGENE			English	Article						fanconi anemia; ATR; interstrand crosslinks; DNA repair; RAD51 paralog; replication restart; epistasis	DOUBLE-STRAND BREAKS; HAMSTER CELL MUTANTS; ANEMIA PATHWAY; HOMOLOGOUS RECOMBINATION; COMPLEMENTATION GROUP; ATAXIA-TELANGIECTASIA; MONOUBIQUITINATED FANCD2; CROSS-LINKS; REPAIR; GENE	Fanconi anemia (FA) is a human disorder characterized by cancer susceptibility and cellular sensitivity to DNA crosslinks and other damages. Thirteen complementation groups and genes are identified, including BRCA2, which is defective in the FA-D1 group. Eight of the FA proteins, including FANCG, participate in a nuclear core complex that is required for the monoubiquitylation of FANCD2 and FANCI. FANCD2, like FANCD1/BRCA2, is not part of the core complex, and we previously showed direct BRCA2-FANCD2 interaction using yeast two-hybrid analysis. We now show in human and hamster cells that expression of FANCG protein, but not the other core complex proteins, is required for co-precipitation of BRCA2 and FANCD2. We also show that phosphorylation of FANCG serine 7 is required for its co-precipitation with BRCA2, XRCC3 and FANCD2, as well as the direct interaction of BRCA2-FANCD2. These results argue that FANCG has a role independent of the FA core complex, and we propose that phosphorylation of serine 7 is the signalling event required for forming a discrete complex comprising FANCD1/BRCA2-FANCD2-FANCG- XRCC3 (D1-D2-G-X3). Cells that fail to express either phospho-Ser7-FANCG, or full length BRCA2 protein, lack the interactions amongst the four component proteins. A role for D1-D2-G-X3 in homologous recombination repair (HRR) is supported by our finding that FANCG and the RAD51-paralog XRCC3 are epistatic for sensitivity to DNA crosslinking compounds in DT40 chicken cells. Our findings further define the intricate interface between FANC and HRR proteins in maintaining chromosome stability.	[Wilson, J. B.; Marriott, A. S.; Jones, N. J.] Univ Liverpool, Sch Biol Sci, Mol Oncol & Stem Cell Res Grp, Liverpool L69 7ZB, Merseyside, England; [Yamamoto, K.; Takata, M.] Kawasaki Med Sch, Dept Immunol & Med Genet, Okayama, Japan; [Hussain, S.] Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; [Sung, P.] Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06510 USA; [Hoatlin, M. E.] Oregon Hlth & Sci Univ, Div Biochem & Mol Biol, Portland, OR USA; [Mathew, C. G.] Oregon Hlth & Sci Univ, Div Biochem & Mol Biol, Portland, OR USA; [Thompson, L. H.] Lawrence Livermore Natl Lab, Biosci & Biotechnol Div, Livermore, CA USA; [Kupfer, G. M.] Yale Univ, Sch Med, Div Hematol Oncol, Dept Pediat, New Haven, CT USA	University of Liverpool; Kawasaki Medical School; University of Cambridge; Yale University; Oregon Health & Science University; Oregon Health & Science University; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; Yale University	Jones, NJ (corresponding author), Univ Liverpool, Sch Biol Sci, Mol Oncol & Stem Cell Res Grp, Biosci Bldg,Crown St, Liverpool L69 7ZB, Merseyside, England.	njjones@liv.ac.uk	Jones, Nigel J/D-1997-2010; Mathew, Christopher G/G-3434-2015	Mathew, Christopher G/0000-0003-4178-1838; Takata, Minoru/0000-0002-4926-3675				Alderton GK, 2004, HUM MOL GENET, V13, P3127, DOI 10.1093/hmg/ddh335; Alter BP, 1996, AM J HEMATOL, V53, P99, DOI 10.1002/(SICI)1096-8652(199610)53:2<99::AID-AJH7>3.3.CO;2-M; Blom E, 2004, DNA REPAIR, V3, P77, DOI 10.1016/j.dnarep.2003.09.007; Bogliolo M, 2007, EMBO J, V26, P1340, DOI 10.1038/sj.emboj.7601574; Bridge WL, 2005, NAT GENET, V37, P953, DOI 10.1038/ng1627; Busch DB, 1996, MUTAT RES-DNA REPAIR, V363, P209, DOI 10.1016/0921-8777(96)00014-6; Carreau M, 1999, MUTAT RES-DNA REPAIR, V435, P103, DOI 10.1016/S0921-8777(99)00041-5; Ciccia A, 2007, MOL CELL, V25, P331, DOI 10.1016/j.molcel.2007.01.003; Collins N, 2005, INT J HEMATOL, V82, P176, DOI 10.1532/IJH97.05108; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; de Winter JP, 1998, NAT GENET, V20, P281, DOI 10.1038/3093; de Winter JP, 2000, HUM MOL GENET, V9, P2665, DOI 10.1093/hmg/9.18.2665; Dronkert MLG, 2001, MUTAT RES-DNA REPAIR, V486, P217, DOI 10.1016/S0921-8777(01)00092-1; Esashi F, 2005, NATURE, V434, P598, DOI 10.1038/nature03404; Garcia-Higuera I, 1999, MOL CELL BIOL, V19, P4866; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Goggins M, 1996, CANCER RES, V56, P5360; Gordon SM, 2003, BLOOD, V102, P136, DOI 10.1182/blood-2002-11-3517; Gregory RC, 2003, SEMIN CANCER BIOL, V13, P77, DOI 10.1016/S1044-579X(02)00102-5; Groves MR, 1999, CURR OPIN STRUC BIOL, V9, P383, DOI 10.1016/S0959-440X(99)80052-9; Gudmundsdottir K, 2006, ONCOGENE, V25, P5864, DOI 10.1038/sj.onc.1209874; Henry-Mowatt J, 2003, MOL CELL, V11, P1109, DOI 10.1016/S1097-2765(03)00132-1; Hinz JM, 2007, NUCLEIC ACIDS RES, V35, P3733, DOI 10.1093/nar/gkm315; Hinz JM, 2006, DNA REPAIR, V5, P875, DOI 10.1016/j.dnarep.2006.05.039; Hirano S, 2005, EMBO J, V24, P418, DOI 10.1038/sj.emboj.7600534; Ho GPH, 2006, MOL CELL BIOL, V26, P7005, DOI 10.1128/MCB.02018-05; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Hussain S, 2004, HUM MOL GENET, V13, P1241, DOI 10.1093/hmg/ddh135; Hussain S, 2003, HUM MOL GENET, V12, P2503, DOI 10.1093/hmg/ddg266; Hussain S, 2006, DNA REPAIR, V5, P629, DOI 10.1016/j.dnarep.2006.02.007; Johnson MA, 2000, MUTAGENESIS, V15, P367, DOI 10.1093/mutage/15.4.367; Johnson MA, 1999, MUTAT RES-DNA REPAIR, V435, P271, DOI 10.1016/S0921-8777(99)00055-5; Kennedy RD, 2005, GENE DEV, V19, P2925, DOI 10.1101/gad.1370505; Kupfer GM, 1997, NAT GENET, V17, P487, DOI 10.1038/ng1297-487; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; Lamerdin JE, 2004, MUTAGENESIS, V19, P237, DOI 10.1093/mutage/geh019; Levitus M, 2006, CELL ONCOL, V28, P3; Ling C, 2007, EMBO J, V26, P2104, DOI 10.1038/sj.emboj.7601666; Liu N, 2002, NUCLEIC ACIDS RES, V30, P1009, DOI 10.1093/nar/30.4.1009; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; Lyakhovich A, 2007, CELL CYCLE, V6, P1019, DOI 10.4161/cc.6.9.4223; Masson JY, 2001, GENE DEV, V15, P3296, DOI 10.1101/gad.947001; Mathew CG, 2006, ONCOGENE, V25, P5875, DOI 10.1038/sj.onc.1209878; Meetei AR, 2005, NAT GENET, V37, P958, DOI 10.1038/ng1626; Mi J, 2004, MOL CELL BIOL, V24, P8576, DOI 10.1128/MCB.24.19.8576-8585.2004; Mirchandani KD, 2006, EXP CELL RES, V312, P2647, DOI 10.1016/j.yexcr.2006.06.014; Nakanishi K, 2005, P NATL ACAD SCI USA, V102, P1110, DOI 10.1073/pnas.0407796102; Niedernhofer LJ, 2007, MOL CELL, V25, P487, DOI 10.1016/j.molcel.2007.02.002; Niedzwiedz W, 2004, MOL CELL, V15, P607, DOI 10.1016/j.molcel.2004.08.009; O'Driscoll M, 2003, NAT GENET, V33, P497, DOI 10.1038/ng1129; Ohashi A, 2005, J BIOL CHEM, V280, P14877, DOI 10.1074/jbc.M414669200; Pace P, 2002, EMBO J, V21, P3414, DOI 10.1093/emboj/cdf355; Patel KJ, 2007, DNA REPAIR, V6, P885, DOI 10.1016/j.dnarep.2007.02.002; Qiao FY, 2004, J BIOL CHEM, V279, P46035, DOI 10.1074/jbc.M408323200; Reid S, 2007, NAT GENET, V39, P162, DOI 10.1038/ng1947; Sarkaria JN, 1998, CANCER RES, V58, P4375; Smogorzewska A, 2007, CELL, V129, P289, DOI 10.1016/j.cell.2007.03.009; Takata M, 2001, MOL CELL BIOL, V21, P2858, DOI 10.1128/MCB.21.8.2858-2866.2001; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Taniguchi T, 2002, CELL, V109, P459, DOI 10.1016/S0092-8674(02)00747-X; Taniguchi T, 2006, BLOOD, V107, P4223, DOI 10.1182/blood-2005-10-4240; Tebbs RS, 2005, DNA REPAIR, V4, P11, DOI 10.1016/j.dnarep.2004.06.013; Thacker J, 2005, CANCER LETT, V219, P125, DOI 10.1016/j.canlet.2004.08.018; Thompson LH, 2005, NAT GENET, V37, P921, DOI 10.1038/ng0905-921; Thompson LH, 2005, ENVIRON MOL MUTAGEN, V45, P128, DOI 10.1002/em.20109; Waisfisz Q, 1999, P NATL ACAD SCI USA, V96, P10320, DOI 10.1073/pnas.96.18.10320; Wang WD, 2007, NAT REV GENET, V8, P735, DOI 10.1038/nrg2159; Wang XZ, 2004, MOL CELL BIOL, V24, P5850, DOI 10.1128/MCB.24.13.5850-5862.2004; WHITNEY M, 1995, NAT GENET, V11, P341, DOI 10.1038/ng1195-341; Wiegant WW, 2006, MUTAT RES-FUND MOL M, V600, P79, DOI 10.1016/j.mrfmmm.2006.03.001; Wilson JB, 2001, CARCINOGENESIS, V22, P1939, DOI 10.1093/carcin/22.12.1939; Xia B, 2007, NAT GENET, V39, P159, DOI 10.1038/ng1942; Xia B, 2006, MOL CELL, V22, P719, DOI 10.1016/j.molcel.2006.05.022; Yamada NA, 2004, J BIOL CHEM, V279, P23250, DOI 10.1074/jbc.M402247200; Yamamoto K, 2003, MOL CELL BIOL, V23, P5421, DOI 10.1128/MCB.23.15.5421-5430.2003; Yamashita T, 1998, P NATL ACAD SCI USA, V95, P13085, DOI 10.1073/pnas.95.22.13085; Yamashita YM, 2002, EMBO J, V21, P5558, DOI 10.1093/emboj/cdf534; Yang YG, 2005, CARCINOGENESIS, V26, P1731, DOI 10.1093/carcin/bgi134; Zhang NX, 2007, DNA REPAIR, V6, P1670, DOI 10.1016/j.dnarep.2007.06.002; Zhang Y, 1998, EMBO J, V17, P7304, DOI 10.1093/emboj/17.24.7304	80	69	75	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2008	27	26					3641	3652		10.1038/sj.onc.1211034	http://dx.doi.org/10.1038/sj.onc.1211034			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312HH	18212739				2022-12-17	WOS:000256659300001
J	Hurst, CD; Tomlinson, DC; Williams, SV; Platt, FM; Knowles, MA				Hurst, C. D.; Tomlinson, D. C.; Williams, S. V.; Platt, F. M.; Knowles, M. A.			Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification	ONCOGENE			English	Article						E2F3; Rb; bladder cancer; 6p22 amplification	GENOME-WIDE ASSOCIATION; RETINOBLASTOMA PROTEIN; CELL-CYCLE; ALTERED EXPRESSION; COPY NUMBER; IN-VITRO; CANCER; PRB; PROLIFERATION; CARCINOMA	E2F3 and CDKAL1 are candidate genes from the 6p22 region frequently amplified in bladder cancer. Expression of E2F3 isoforms (E2F3a and b) and CDKAL1 were examined and modulated in 6p22-amplified bladder cell lines. Eight lines with amplification showed overexpression of both E2F3 isoforms and CDKAL1. shRNA-mediated knockdown of CDKAL1 had no effect on proliferation. Knockdown of E2F3a or E2F3b alone induced antiproliferative effects, with the most significant effect on proliferation being observed when both isoforms were knocked down together. As E2Fs interact with the Rb tumour suppressor protein, Rb expression was analysed. There was a striking relationship between 6p22.3 amplification, E2F3 overexpression and lack of Rb expression. This was also examined in primary bladder tumours. Array-CGH detected 6p22.3 amplification in 8/91 invasive tumours. Five were studied in more detail. Four showed 13q14.2 loss (including RB1) and expressed no Rb protein. In the fifth, 13q was unaltered but the CDKN2A locus was deleted. This tumour was negative for p16 and positive for Rb protein. As p16 is a negative regulator of the Rb pathway, its loss represents an alternative mechanism for inactivation. Indeed, a phospho-specific Rb antibody showed much Rb protein in a hyperphosphorylated (inactive) form. We conclude that inactivation of the Rb pathway is required in addition to E2F3 overexpression in this subset of bladder tumours.	[Hurst, C. D.; Tomlinson, D. C.; Williams, S. V.; Platt, F. M.; Knowles, M. A.] St James Univ Hosp, Sect Oncol, Canc Res UK Clin Ctr, Leeds Insts Mol Med, Leeds LS9 7TF, W Yorkshire, England	Cancer Research UK; Saint James's University Hospital; University of Leeds	Knowles, MA (corresponding author), St James Univ Hosp, Sect Oncol, Canc Res UK Clin Ctr, Leeds Insts Mol Med, Beckett St, Leeds LS9 7TF, W Yorkshire, England.	m.a.knowles@leeds.ac.uk		Knowles, Margaret/0000-0002-9363-8657; Tomlinson, Darren/0000-0003-4134-7484	Cancer Research UK [C6228/A5433, A5433] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Aaboe M, 2006, CANCER RES, V66, P3434, DOI 10.1158/0008-5472.CAN-05-3456; Aslanian A, 2004, GENE DEV, V18, P1413, DOI 10.1101/gad.1196704; Benedict WF, 1999, ONCOGENE, V18, P1197, DOI 10.1038/sj.onc.1202452; Blais A, 2004, CURR OPIN GENET DEV, V14, P527, DOI 10.1016/j.gde.2004.07.003; Blaveri E, 2005, CLIN CANCER RES, V11, P7012, DOI 10.1158/1078-0432.CCR-05-0177; Bruch J, 1998, GENE CHROMOSOME CANC, V23, P167, DOI 10.1002/(SICI)1098-2264(199810)23:2<167::AID-GCC10>3.0.CO;2-L; Bruch J, 2000, CANCER RES, V60, P4526; Chapman EJ, 2006, ONCOGENE, V25, P5037, DOI 10.1038/sj.onc.1209513; Chapman EJ, 2005, CLIN CANCER RES, V11, P5740, DOI 10.1158/1078-0432.CCR-05-0411; Chatterjee SJ, 2004, J PATHOL, V203, P762, DOI 10.1002/path.1567; CHRISTIAN BJ, 1987, CANCER RES, V47, P6066; Cooper CS, 2006, LUNG CANCER, V54, P155, DOI 10.1016/j.lungcan.2006.07.005; CORDONCARDO C, 1992, J NATL CANCER I, V84, P1251, DOI 10.1093/jnci/84.16.1251; Cote RJ, 1998, CANCER RES, V58, P1090; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Denchi EL, 2005, MOL CELL BIOL, V25, P2660, DOI 10.1128/MCB.25.7.2660-2672.2005; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Evans AJ, 2004, AM J PATHOL, V164, P285, DOI 10.1016/S0002-9440(10)63118-5; Feber A, 2004, ONCOGENE, V23, P1627, DOI 10.1038/sj.onc.1207274; Fiegler H, 2003, GENE CHROMOSOME CANC, V36, P361, DOI 10.1002/gcc.10155; Frolov MV, 2001, GENE DEV, V15, P2146, DOI 10.1101/gad.903901; He YW, 2000, ONCOGENE, V19, P3422, DOI 10.1038/sj.onc.1203682; Humbert PO, 2000, GENE DEV, V14, P690; Hurst CD, 2004, ONCOGENE, V23, P2250, DOI 10.1038/sj.onc.1207260; KALLIONIEMI A, 1995, GENE CHROMOSOME CANC, V12, P213, DOI 10.1002/gcc.2870120309; Le Frere-Belda MA, 2004, HUM PATHOL, V35, P817, DOI 10.1016/j.humpath.2004.01.019; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; LOGOTHETIS CJ, 1992, J NATL CANCER I, V84, P1256, DOI 10.1093/jnci/84.16.1256; Oeggerli M, 2006, ONCOGENE, V25, P6538, DOI 10.1038/sj.onc.1209946; Oeggerli M, 2004, ONCOGENE, V23, P5616, DOI 10.1038/sj.onc.1207749; Olsson AY, 2007, ONCOGENE, V26, P1028, DOI 10.1038/sj.onc.1209854; Orlic M, 2006, GENE CHROMOSOME CANC, V45, P72, DOI 10.1002/gcc.20263; PAULIE S, 1983, INT J CANCER, V31, P297, DOI 10.1002/ijc.2910310308; Paulson QX, 2006, CELL CYCLE, V5, P184, DOI 10.4161/cc.5.2.2307; Prat E, 2001, UROLOGY, V57, P986, DOI 10.1016/S0090-4295(01)00909-8; Saxena R, 2007, SCIENCE, V316, P1331, DOI 10.1126/science.1142358; Scott LJ, 2007, SCIENCE, V316, P1341, DOI 10.1126/science.1142382; Steinthorsdottir V, 2007, NAT GENET, V39, P770, DOI 10.1038/ng2043; Stevens C, 2004, DNA REPAIR, V3, P1071, DOI 10.1016/j.dnarep.2004.03.034; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tomlinson D, 2007, ONCOGENE, V26, P5889, DOI 10.1038/sj.onc.1210399; Tomovska S, 2001, INT J ONCOL, V18, P1239; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Veltman JA, 2003, CANCER RES, V63, P2872; Wu QO, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-16; XU HJ, 1993, INT J CANCER, V53, P781, DOI 10.1002/ijc.2910530513; YEAGER T, 1995, CANCER RES, V55, P493; Zeggini E, 2007, SCIENCE, V316, P1336, DOI 10.1126/science.1142364; Ziebold U, 2003, MOL CELL BIOL, V23, P6542, DOI 10.1128/MCB.23.18.6542-6552.2003; Ziebold U, 2001, GENE DEV, V15, P386, DOI 10.1101/gad.858801	53	69	71	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2008	27	19					2716	2727		10.1038/sj.onc.1210934	http://dx.doi.org/10.1038/sj.onc.1210934			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292IK	18037967	Green Accepted			2022-12-17	WOS:000255259500006
J	Massimi, P; Shai, A; Lambert, P; Banks, L				Massimi, P.; Shai, A.; Lambert, P.; Banks, L.			HPV E6 degradation of p53 and PDZ containing substrates in an E6AP null background	ONCOGENE			English	Article						HPV E6; p53; PDZ; E6AP; proteasome	HUMAN-PAPILLOMAVIRUS E6; UBIQUITIN-PROTEIN LIGASE; LARGE TUMOR-SUPPRESSOR; MEDIATED DEGRADATION; ADENOVIRUS E4-ORF1; EPITHELIAL-CELLS; IN-VIVO; ONCOPROTEIN; TARGET; TYPE-16	Human papillomavirus(HPV) type 16 and 18 E6 proteins target many of their cellular substrates for proteasome-mediated degradation. In the case of p53, this is mediated by the E6AP ubiquitin ligase. However it is still unclear whether other E6 substrates, in particular those containing PDZ domains, are also degraded in a similar manner. To investigate this, we established an epithelial cell line from E6AP-null mice and used these cells as a background to perform E6-mediated in vivo degradation assays. We show that the PDZ domain-containing substrates of E6, including Scribble, MAGI-1 and MAGI-3, are all subject to E6-mediated degradation in these cells. Strikingly, we also found that p53 could be degraded by E6 within these cells in a proteasome-dependent manner. These results demonstrate that HPV-16 and -18 E6 can target substrates for degradation in a manner independent of the E6AP ubiquitin ligase.	[Massimi, P.; Banks, L.] Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, TS, Italy; [Shai, A.; Lambert, P.] Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Madison, WI 53706 USA	International Center for Genetic Engineering & Biotechnology (ICGEB); University of Wisconsin System; University of Wisconsin Madison	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Area Sci Pk,Padriciano 99, I-34012 Trieste, TS, Italy.	banks@icgeb.org			NCI NIH HHS [CA022443, CA098428] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA022443, R01CA098428] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Camus S, 2007, ONCOGENE, V26, P4059, DOI 10.1038/sj.onc.1210188; Cooper B, 2003, VIROLOGY, V306, P87, DOI 10.1016/S0042-6822(02)00012-0; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Gardiol D, 1998, J GEN VIROL, V79, P1963, DOI 10.1099/0022-1317-79-8-1963; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; Grm HS, 2004, J GEN VIROL, V85, P2815, DOI 10.1099/vir.0.80035-0; Hengstermann A, 2005, J VIROL, V79, P9296, DOI 10.1128/JVI.79.14.9296-9300.2005; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; Jiang YH, 1998, NEURON, V21, P799, DOI 10.1016/S0896-6273(00)80596-6; Kelley ML, 2005, J VIROL, V79, P3737, DOI 10.1128/JVI.79.6.3737-3747.2005; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Latorre IJ, 2005, J CELL SCI, V118, P4283, DOI 10.1242/jcs.02560; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee CH, 2004, J VIROL, V78, P12366, DOI 10.1128/JVI.78.22.12366-12377.2004; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; Liu Y, 1999, J VIROL, V73, P7297, DOI 10.1128/JVI.73.9.7297-7307.1999; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Nguyen ML, 2003, J VIROL, V77, P6957, DOI 10.1128/JVI.77.12.6957-6964.2003; Pim D, 2000, ONCOGENE, V19, P719, DOI 10.1038/sj.onc.1203374; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Shai A, 2007, CANCER RES, V67, P1626, DOI 10.1158/0008-5472.CAN-06-3344; Storrs CH, 2007, J VIROL, V81, P4080, DOI 10.1128/JVI.02545-06; Thomas M, 2005, ONCOGENE, V24, P6222, DOI 10.1038/sj.onc.1208757; Thomas M, 1999, MOL CELL BIOL, V19, P1092; Thomas M, 2002, ONCOGENE, V21, P5088, DOI 10.1038/sj.onc.1205668; Thomas M, 1999, ONCOGENE, V18, P7690, DOI 10.1038/sj.onc.1202953; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	29	69	75	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2008	27	12					1800	1804		10.1038/sj.onc.1210810	http://dx.doi.org/10.1038/sj.onc.1210810			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	273WF	17934525				2022-12-17	WOS:000253962100016
J	Gast, D; Riedle, S; Issa, Y; Pfeifer, M; Beckhove, P; Sanderson, MP; Arlt, M; Moldenhauer, G; Fogel, M; Kruger, A; Altevogt, P				Gast, D.; Riedle, S.; Issa, Y.; Pfeifer, M.; Beckhove, P.; Sanderson, M. P.; Arlt, M.; Moldenhauer, G.; Fogel, M.; Krueger, A.; Altevogt, P.			The cytoplasmic part of L1-CAM controls growth and gene expression in human tumors that is reversed by therapeutic antibodies	ONCOGENE			English	Article						cell migration; tumor growth; signaling; therapeutic antibodies	CELL-ADHESION MOLECULE; ACTIVATED PROTEIN-KINASES; MELANOMA PROGRESSION; MALIGNANT-MELANOMA; OVARIAN CARCINOMAS; NEURITE OUTGROWTH; L1 CD171; MIGRATION; METASTASIS; BINDING	L1 cell adhesion molecule (L1-CAM) is a transmembrane cell adhesion molecule involved in cell migration and axon guidance in the developing nervous system. L1 is also overexpressed in ovarian and endometrial carcinomas and is associated with a bad prognosis. In carcinoma cell lines, L1 overexpression augments cell motility, tumor growth in mice and induces expression of Erk-dependent genes. Here, we show that a mutation in the cytoplasmic portion of L1 (T1247A, S1248A) abrogates Erk activation, blocks cell migration on extracellular matrix proteins and did not augment tumor growth in non-obese diabetic/severe combined immuno-deficient mice. In cells expressing mutant L1, the induction of Erk-dependent genes such as beta 3-integrin, cathepsin-B and several transcription factors is eliminated and the invasive phenotype is abrogated. L1 antibodies showed similar effects. They prevented Erk activation and interfered with the Erk-dependent gene expression pattern. These findings provide a rationale for the mode of action of L1 antibodies and suggest that interference with L1 function could become a valuable target for therapy.	[Gast, D.; Riedle, S.; Issa, Y.; Pfeifer, M.; Beckhove, P.; Sanderson, M. P.; Moldenhauer, G.; Altevogt, P.] German Canc Res Ctr, Tumor Immunol Programme, D-69120 Heidelberg, Germany; [Arlt, M.; Krueger, A.] Tech Univ Munich, Inst Expt Oncol & Therapy, Munich, Germany; [Fogel, M.] Kaplan Med Ctr, Dept Pathol, Rehovot, Israel	Helmholtz Association; German Cancer Research Center (DKFZ); Technical University of Munich; Hebrew University of Jerusalem; Kaplan Medical Center	Altevogt, P (corresponding author), German Canc Res Ctr, Tumor Immunol Programme, D010,Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	P.Altevogt@dkfz.de	Sanderson, Michael/I-1674-2017	Sanderson, Michael/0000-0001-5362-486X				Allory Y, 2005, CLIN CANCER RES, V11, P1190; Arlt MJE, 2006, CANCER RES, V66, P936, DOI 10.1158/0008-5472.CAN-05-1818; Bar-Eli M, 2001, PIGM CELL RES, V14, P78, DOI 10.1034/j.1600-0749.2001.140202.x; Brunner G, 1998, EXP CELL RES, V239, P301, DOI 10.1006/excr.1997.3877; Cheng L, 2005, J NEUROCHEM, V94, P1102, DOI 10.1111/j.1471-4159.2005.03254.x; Cheng L, 2005, J NEUROSCI, V25, P395, DOI 10.1523/JNEUROSCI.4097-04.2005; Colucci-D'Amato L, 2003, BIOESSAYS, V25, P1085, DOI 10.1002/bies.10355; Fogel M, 2003, LANCET, V362, P869, DOI 10.1016/S0140-6736(03)14342-5; Fogel M, 2003, CANCER LETT, V189, P237, DOI 10.1016/S0304-3835(02)00513-X; Gast D, 2005, INT J CANCER, V115, P658, DOI 10.1002/ijc.20869; Gavert N, 2005, J CELL BIOL, V168, P633, DOI 10.1083/jcb.200408051; Gutwein P, 2000, J BIOL CHEM, V275, P15490, DOI 10.1074/jbc.275.20.15490; Gutwein P, 2002, FASEB J, V16, P292, DOI 10.1096/fj.02-0430fje; Huszar M, 2006, HUM PATHOL, V37, P1000, DOI 10.1016/j.humpath.2006.03.014; IGNELZI MA, 1994, NEURON, V12, P873, DOI 10.1016/0896-6273(94)90339-5; Knogler K, 2007, CLIN CANCER RES, V13, P603, DOI 10.1158/1078-0432.CCR-06-1486; Lotan R, 1996, FASEB J, V10, P1031, DOI 10.1096/fasebj.10.9.8801164; Mechtersheimer S, 2001, J CELL BIOL, V155, P661, DOI 10.1083/jcb.200101099; Meier F, 2006, INT J CANCER, V119, P549, DOI 10.1002/ijc.21880; MOLDENHAUER G, 1987, BRIT J CANCER, V56, P714, DOI 10.1038/bjc.1987.276; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; Primiano T, 2003, CANCER CELL, V4, P41, DOI 10.1016/S1535-6108(03)00169-7; Schaefer AW, 1999, J BIOL CHEM, V274, P37965, DOI 10.1074/jbc.274.53.37965; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schmid RS, 2000, J NEUROSCI, V20, P4177; Senner V, 2002, GLIA, V38, P146, DOI 10.1002/glia.10058; Shtutman M, 2006, CANCER RES, V66, P11370, DOI 10.1158/0008-5472.CAN-06-2106; Silletti S, 2004, J BIOL CHEM, V279, P28880, DOI 10.1074/jbc.M404075200; Tang NF, 2006, J NEUROCHEM, V96, P1480, DOI 10.1111/j.1471-4159.2006.03649.x; Thelen K, 2002, J NEUROSCI, V22, P4918, DOI 10.1523/JNEUROSCI.22-12-04918.2002; Thies A, 2002, EUR J CANCER, V38, P1708, DOI 10.1016/S0959-8049(02)00105-3	31	69	71	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2008	27	9					1281	1289		10.1038/sj.onc.1210747	http://dx.doi.org/10.1038/sj.onc.1210747			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	266BT	17952127				2022-12-17	WOS:000253407000010
J	Okawa, ER; Gotoh, T; Manne, J; Igarashi, J; Fujita, T; Silverman, KA; Xhao, H; Mosse, YP; White, PS; Brodeur, GM				Okawa, E. R.; Gotoh, T.; Manne, J.; Igarashi, J.; Fujita, T.; Silverman, K. A.; Xhao, H.; Mosse, Y. P.; White, P. S.; Brodeur, G. M.			Expression and sequence analysis of candidates for the 1p36.31 tumor suppressor gene deleted in neuroblastomas	ONCOGENE			English	Article						neuroblastoma; 1p36; tumor suppressor gene; gene expression; CHD5; mutation	N-MYC AMPLIFICATION; HOMOZYGOUS DELETION; NERVOUS-SYSTEM; CHROMOSOME 1P; CELL-LINES; REGION; LOCI; IDENTIFICATION; CAMTA1; RIBOSOMAL-PROTEIN-L22	Neuroblastomas are characterized by 1p deletions, suggesting that a tumor suppressor gene (TSG) resides in this region. We have mapped the smallest region of deletion (SRD) to a 2Mb region of 1p36.31 using microsatellite and single nucleotide polymorphisms. We have identified 23 genes in this region, and we have analysed these genes for mutations and RNA expression patterns to identify candidate TSGs. W e sequenced the coding exons of these genes in 30 neuroblastoma cell lines. Although rare mutations were found in 10 of the 23 genes, none showed a pattern of genetic change consistent with homozygous inactivation. We examined the expression of these 23 genes in 20 neuroblastoma cell lines, and most showed readily detectable expression, and no correlation with 1p deletion. How ever, 7 genes showed uniformly low expression in the lines, and 2 genes (CHD5, RNF207) had virtually absent expression, consistent with the expected pattern for a TSG. Our mutation and expression analysis in neuroblastoma cell lines, combined with expression analysis in normal tissues, putative function and prior implication in neuroblastoma pathogenesis, suggests that the most promising TSG deleted from the 1p36 SRD is CHD5, but TNFRSF25, CAMTA1 and AJAP1 are also viable candidates.	[Okawa, E. R.; Gotoh, T.; Manne, J.; Igarashi, J.; Fujita, T.; Silverman, K. A.; Mosse, Y. P.; White, P. S.; Brodeur, G. M.] Univ Penn, Childrens Hosp Philadelphia, Div Oncol, Dept Pediat, Philadelphia, PA 19104 USA; [Xhao, H.] Childrens Hosp Philadelphia, Dept Pediat, Div Biostat & Data Management Core, Philadelphia, PA 19104 USA; [Xhao, H.] Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Brodeur, GM (corresponding author), Childrens Hosp Philadelphia, Div Oncol, 3615 Civic Ctr Blvd,ARC Rm 902D, Philadelphia, PA 19104 USA.	brodeur@email.chop.edu			NCI NIH HHS [R01-CA039771] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039771] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attiyeh EF, 2005, NEW ENGL J MED, V353, P2243, DOI 10.1056/NEJMoa052399; BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; Bagchi A, 2007, CELL, V128, P459, DOI 10.1016/j.cell.2006.11.052; Bauer A, 2001, GENE CHROMOSOME CANC, V31, P228, DOI 10.1002/gcc.1139; Bergo MO, 2004, J CLIN INVEST, V113, P539, DOI 10.1172/JCI200418829; BRODEUR GM, 1981, CANCER RES, V41, P4678; BRODEUR GM, 1977, CANCER-AM CANCER SOC, V40, P2256, DOI 10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Brodeur GM, 2006, PRINCIPLES PRACTICE, P933; Buetow KH, 1999, NAT GENET, V21, P323, DOI 10.1038/6851; CARON H, 1995, HUM MOL GENET, V4, P535, DOI 10.1093/hmg/4.4.535; Caron H, 2001, GENE CHROMOSOME CANC, V30, P168, DOI 10.1002/1098-2264(200102)30:2<168::AID-GCC1072>3.0.CO;2-E; Chen YZ, 2001, GENE CHROMOSOME CANC, V31, P326, DOI 10.1002/gcc.1151; CHENG NC, 1995, ONCOGENE, V10, P291; Eggert A, 2002, EUR J CANCER, V38, P92, DOI 10.1016/S0959-8049(01)00347-1; Elia A, 2004, EUR J BIOCHEM, V271, P1895, DOI 10.1111/j.1432-1033.2004.04099.x; Fok V, 2006, RNA, V12, P872, DOI 10.1261/rna.2339606; GEHRING M, 1995, CANCER RES, V55, P5366; Grenet J, 1998, GENOMICS, V49, P385, DOI 10.1006/geno.1998.5300; Gunderson KL, 2005, NAT GENET, V37, P549, DOI 10.1038/ng1547; Henrich KO, 2007, EUR J CANCER, V43, P607, DOI 10.1016/j.ejca.2006.09.023; Henrich KO, 2006, CLIN CANCER RES, V12, P131, DOI 10.1158/1078-0432.CCR-05-1431; Ho R, 2005, CANCER RES, V65, P9868, DOI 10.1158/0008-5472.CAN-04-2426; Katoh M, 2003, INT J ONCOL, V23, P1219; Maris JM, 1997, EUR J CANCER, V33, P1991, DOI 10.1016/S0959-8049(97)00279-7; Martinsson T, 1997, EUR J CANCER, V33, P1997, DOI 10.1016/S0959-8049(97)00278-5; MARTINSSON T, 1995, CANCER RES, V55, P5681; McDonald JM, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-35; Ohira M, 2000, ONCOGENE, V19, P4302, DOI 10.1038/sj.onc.1203786; OLIPHANT A, 2002, BIOTECHNIQUES S, V56, P60; Rozen S, 2000, Methods Mol Biol, V132, P365; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; Steemers FJ, 2006, NAT METHODS, V3, P31, DOI 10.1038/NMETH842; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; Thompson PM, 2003, ONCOGENE, V22, P1002, DOI 10.1038/sj.onc.1206211; Thompson PM, 2001, CANCER RES, V61, P679; Wang Q, 2006, CANCER RES, V66, P6050, DOI 10.1158/0008-5472.CAN-05-4618; White PS, 2005, ONCOGENE, V24, P2684, DOI 10.1038/sj.onc.1208306; WHITE PS, 1995, P NATL ACAD SCI USA, V92, P5520, DOI 10.1073/pnas.92.12.5520; Winter-Vann AM, 2005, P NATL ACAD SCI USA, V102, P4336, DOI 10.1073/pnas.0408107102	40	69	71	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 31	2008	27	6					803	810		10.1038/sj.onc.1210675	http://dx.doi.org/10.1038/sj.onc.1210675			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17667943				2022-12-17	WOS:000252884500009
J	Van Etten, RA				Van Etten, R. A.			Aberrant cytokine signaling in leukemia	ONCOGENE			English	Review						tyrosine kinase; kinase inhibitor; leukemia stem cell	ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; HEMATOPOIETIC STEM-CELLS; ABL TYROSINE KINASE; IDIOPATHIC HYPEREOSINOPHILIC SYNDROME; INTERNAL TANDEM DUPLICATION; MARROW TRANSPLANT MODEL; DNA-BINDING ACTIVITY; BCR-ABL	Abnormalities of cytokine and growth factor signaling pathways are characteristic of all forms of leukemia: lymphoid and myeloid, acute and chronic. In normal hematopoietic cells, cytokines provide the stimulus for proliferation, survival, self- renewal, differentiation and functional activation. In leukemic cells, these pathways are usurped to subserve critical parts of the malignant program. In this review, our current knowledge of leukemic cell cytokine signaling will be summarized, and some speculations on the significance and implications of these insights will be advanced. A better understanding of aberrant cytokine signaling in leukemia should provide additional targets for the rational therapy of these diseases.	Tufts Univ New England Med Ctr, Mol Oncol Res Inst, Boston, MA 02111 USA; Tufts Univ New England Med Ctr, Div Hematol Oncol, Boston, MA 02111 USA	Tufts Medical Center; Tufts Medical Center	Van Etten, RA (corresponding author), Tufts Univ New England Med Ctr, Mol Oncol Res Inst, Boston, MA 02111 USA.	rvanetten@tufts-nemc.org			NATIONAL CANCER INSTITUTE [R01CA105043, R01CA090576] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA105043, R01 CA090576, CA105043, CA090576] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antonchuk J, 2002, CELL, V109, P39, DOI 10.1016/S0092-8674(02)00697-9; Apperley JF, 2002, NEW ENGL J MED, V347, P481, DOI 10.1056/NEJMoa020150; Araki T, 2004, NAT MED, V10, P849, DOI 10.1038/nm1084; Baxter EJ, 2002, HUM MOL GENET, V11, P1391, DOI 10.1093/hmg/11.12.1391; Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9; Benekli M, 2002, BLOOD, V99, P252, DOI 10.1182/blood.V99.1.252; Bhardwaj G, 2001, NAT IMMUNOL, V2, P172, DOI 10.1038/84282; Braun BS, 2004, P NATL ACAD SCI USA, V101, P597, DOI 10.1073/pnas.0307203101; Bunting KD, 2002, BLOOD, V99, P479, DOI 10.1182/blood.V99.2.479; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Castor A, 2005, NAT MED, V11, P630, DOI 10.1038/nm1253; Chan IT, 2004, J CLIN INVEST, V113, P528, DOI 10.1172/JCI200420476; Chen J, 2004, P NATL ACAD SCI USA, V101, P14479, DOI 10.1073/pnas.0404438101; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Cobaleda C, 2000, BLOOD, V95, P1007, DOI 10.1182/blood.V95.3.1007.003k35_1007_1013; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; Cui Y, 2004, MOL CELL BIOL, V24, P8037, DOI 10.1128/MCB.24.18.8037-8047.2004; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; De Keersmaecker K, 2005, BLOOD, V105, P4849, DOI 10.1182/blood-2004-12-4897; Deininger M, 2005, BLOOD, V105, P2640, DOI 10.1182/blood-2004-08-3097; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Eisterer W, 2005, LEUKEMIA, V19, P435, DOI 10.1038/sj.leu.2403649; Emanuel PD, 2000, BLOOD, V95, P639, DOI 10.1182/blood.V95.2.639; Fiedler W, 2003, BLOOD, V102, P2763, DOI 10.1182/blood-2002-10-2998; Giles FJ, 2005, CURR MOL MED, V5, P653, DOI 10.2174/156652405774641034; Gilliland DG, 2002, CANCER CELL, V1, P417, DOI 10.1016/S1535-6108(02)00081-8; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GouilleuxGruart V, 1996, BLOOD, V87, P1692; Grandage VL, 2005, LEUKEMIA, V19, P586, DOI 10.1038/sj.leu.2403653; Graux C, 2004, NAT GENET, V36, P1084, DOI 10.1038/ng1425; Griffith J, 2004, MOL CELL, V13, P169, DOI 10.1016/S1097-2765(03)00505-7; Gu HH, 2001, NATURE, V412, P186, DOI 10.1038/35084076; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Gururajan M, 2007, J IMMUNOL, V178, P111, DOI 10.4049/jimmunol.178.1.111; Guzman ML, 2005, BLOOD, V105, P4163, DOI 10.1182/blood-2004-10-4135; Guzman ML, 2001, BLOOD, V98, P2301, DOI 10.1182/blood.V98.8.2301; Guzman ML, 2002, P NATL ACAD SCI USA, V99, P16220, DOI 10.1073/pnas.252462599; Haferlach T, 1997, BRIT J HAEMATOL, V97, P99, DOI 10.1046/j.1365-2141.1997.9662656.x; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hoelbl A, 2006, BLOOD, V107, P4898, DOI 10.1182/blood-2005-09-3596; Huntly BJP, 2004, CANCER CELL, V6, P587, DOI 10.1016/j.ccr.2004.10.015; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Irish JM, 2004, CELL, V118, P217, DOI 10.1016/j.cell.2004.06.028; Jaiswal S, 2003, P NATL ACAD SCI USA, V100, P10002, DOI 10.1073/pnas.1633833100; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Jones AV, 2004, CELL MOL LIFE SCI, V61, P2912, DOI 10.1007/s00018-004-4272-z; Jones AV, 2005, BLOOD, V106, P2162, DOI 10.1182/blood-2005-03-1320; Karanu FN, 2000, J EXP MED, V192, P1365, DOI 10.1084/jem.192.9.1365; Kelly LM, 2002, BLOOD, V99, P310, DOI 10.1182/blood.V99.1.310; Kelly LM, 2002, P NATL ACAD SCI USA, V99, P8283, DOI 10.1073/pnas.122233699; Klion AD, 2003, BLOOD, V101, P4660, DOI 10.1182/blood-2003-01-0006; Kottaridis PD, 2002, BLOOD, V100, P2393, DOI 10.1182/blood-2002-02-0420; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Kralovics R, 2006, BLOOD, V108, P1377, DOI 10.1182/blood-2005-11-009605; Krivtsov AV, 2006, NATURE, V442, P818, DOI 10.1038/nature04980; Lacout C, 2006, BLOOD, V108, P1652, DOI 10.1182/blood-2006-02-002030; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Le DT, 2004, BLOOD, V103, P4243, DOI 10.1182/blood-2003-08-2650; Lee JW, 2004, LEUKEMIA, V18, P170, DOI 10.1038/sj.leu.2403201; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Lu XH, 2005, P NATL ACAD SCI USA, V102, P18962, DOI 10.1073/pnas.0509714102; Lunghi P, 2003, LEUKEMIA, V17, P1783, DOI 10.1038/sj.leu.2403032; Macdonald D, 2002, ACTA HAEMATOL-BASEL, V107, P101, DOI 10.1159/000046639; Martelli AM, 2006, LEUKEMIA, V20, P911, DOI 10.1038/sj.leu.2404245; Milella M, 2002, BLOOD, V99, P3461, DOI 10.1182/blood.V99.9.3461; Million RP, 2002, BLOOD, V99, P4568, DOI 10.1182/blood-2001-12-0244; Million RP, 2000, BLOOD, V96, P664; Nakao M, 1996, LEUKEMIA, V10, P1911; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; Pardanani A, 2003, BLOOD, V102, P3093, DOI 10.1182/blood-2003-05-1627; Pardanani AD, 2006, BLOOD, V108, P3472, DOI 10.1182/blood-2006-04-018879; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; Pendergast AM, 2002, ADV CANCER RES, V85, P51, DOI 10.1016/S0065-230X(02)85003-5; Pikman Y, 2006, PLOS MED, V3, P1140, DOI 10.1371/journal.pmed.0030270; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; Pulford K, 2004, CELL MOL LIFE SCI, V61, P2939, DOI 10.1007/s00018-004-4275-9; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Roumiantsev S, 2004, CANCER CELL, V5, P287, DOI 10.1016/S1535-6108(04)00053-4; Samanta AK, 2006, CANCER RES, V66, P6468, DOI 10.1158/0008-5472.CAN-06-0025; Sattler M, 2002, CANCER CELL, V1, P479, DOI 10.1016/S1535-6108(02)00074-0; Scherr M, 2006, BLOOD, V107, P3279, DOI 10.1182/blood-2005-08-3087; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Scott LM, 2007, NEW ENGL J MED, V356, P459, DOI 10.1056/NEJMoa065202; Scott LM, 2005, BLOOD, V106, P2920, DOI 10.1182/blood-2005-05-2087; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; Shannon K, 1995, Curr Opin Hematol, V2, P305; Side L, 1997, NEW ENGL J MED, V336, P1713, DOI 10.1056/NEJM199706123362404; Smith BD, 2004, BLOOD, V103, P3669, DOI 10.1182/blood-2003-11-3775; Smith KM, 2003, MOL CELL, V12, P27, DOI 10.1016/S1097-2765(03)00274-0; Somervaille TCP, 2006, CANCER CELL, V10, P257, DOI 10.1016/j.ccr.2006.08.020; Steensma DP, 2006, LEUKEMIA, V20, P971, DOI 10.1038/sj.leu.2404206; Steensma DP, 2005, BLOOD, V106, P1207, DOI 10.1182/blood-2005-03-1183; Stone RM, 2005, BLOOD, V105, P54, DOI 10.1182/blood-2004-03-0891; Stover EH, 2006, P NATL ACAD SCI USA, V103, P8078, DOI 10.1073/pnas.0601192103; Sujobert P, 2005, BLOOD, V106, P1063, DOI 10.1182/blood-2004-08-3225; Tartaglia M, 2004, CURR OPIN HEMATOL, V11, P44, DOI 10.1097/00062752-200401000-00007; Tartaglia M, 2001, NAT GENET, V29, P465, DOI 10.1038/ng772; Thorington Richard W. Jr., 2002, Journal of Mammalian Evolution, V9, P99; Trowbridge JJ, 2006, P NATL ACAD SCI USA, V103, P14134, DOI 10.1073/pnas.0604568103; Ugo V, 2004, EXP HEMATOL, V32, P179, DOI 10.1016/j.exphem.2003.11.003; Van Etten R A, 2001, Curr Oncol Rep, V3, P228; Van Etten RA, 2004, CANCER CELL, V6, P547, DOI 10.1016/j.ccr.2004.12.004; Van Etten RA, 2004, LEUKEMIA RES, V28, pS21, DOI 10.1016/j.leukres.2003.10.005; Van Etten RA, 2003, CURR BIOL, V13, pR608, DOI 10.1016/S0960-9822(03)00528-1; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; Wadleigh M, 2005, BLOOD, V105, P22, DOI 10.1182/blood-2003-11-3896; Walters DK, 2006, CANCER CELL, V10, P65, DOI 10.1016/j.ccr.2006.06.002; Walz C, 2006, GENE CHROMOSOME CANC, V45, P950, DOI 10.1002/gcc.20359; Wang JCY, 2005, TRENDS CELL BIOL, V15, P494, DOI 10.1016/j.tcb.2005.07.004; Wang JCY, 1998, BLOOD, V91, P2406, DOI 10.1182/blood.V91.7.2406.2406_2406_2414; Wang L, 2007, BLOOD; WeberNordt RM, 1996, BLOOD, V88, P809; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Weisberg E, 2002, CANCER CELL, V1, P433, DOI 10.1016/S1535-6108(02)00069-7; Wernig G, 2006, BLOOD, V107, P4274, DOI 10.1182/blood-2005-12-4824; Wossning T, 2006, J EXP MED, V203, P2829, DOI 10.1084/jem.20060967; Wu JH, 2004, CANCER RES, V64, P6461, DOI 10.1158/0008-5472.CAN-04-0866; Xia Z, 1998, CANCER RES, V58, P3173; Xiao S, 1998, NAT GENET, V18, P84, DOI 10.1038/ng0198-84; Xu Q, 2005, BLOOD, V106, P4261, DOI 10.1182/blood-2004-11-4468; Xu Q, 2003, BLOOD, V102, P972, DOI 10.1182/blood-2002-11-3429; Yamamoto Y, 2001, BLOOD, V97, P2434, DOI 10.1182/blood.V97.8.2434; Ye D, 2006, BLOOD, V107, P4917, DOI 10.1182/blood-2005-10-4110; Yu CR, 2002, CANCER RES, V62, P188; Zaleskas VM, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000018; Zhang XW, 2001, MOL CELL BIOL, V21, P840, DOI 10.1128/MCB.21.3.840-853.2001; Zhao S, 2004, LEUKEMIA, V18, P267, DOI 10.1038/sj.leu.2403220; Zheng R, 2004, BLOOD, V103, P267, DOI 10.1182/blood-2003-06-1969	139	69	69	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2007	26	47					6738	6749		10.1038/sj.onc.1210758	http://dx.doi.org/10.1038/sj.onc.1210758			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220HE	17934482	Green Accepted, Green Published			2022-12-17	WOS:000250147000006
J	Yuen, JSP; Cockman, ME; Sullivan, M; Protheroe, A; Turner, GDH; Roberts, IS; Pugh, CW; Werner, H; Macaulay, VM				Yuen, J. S. P.; Cockman, M. E.; Sullivan, M.; Protheroe, A.; Turner, G. D. H.; Roberts, I. S.; Pugh, C. W.; Werner, H.; Macaulay, V. M.			The VHL tumor suppressor inhibits expression of the IGF1R and its loss induces IGF1R upregulation in human clear cell renal carcinoma	ONCOGENE			English	Article						type IIGF receptor; renal cancer; VHL; Sp1; HuR	GROWTH-FACTOR-I; MESSENGER-RNA TURNOVER; LINDAU GENE-PRODUCT; FACTOR RECEPTOR; COLORECTAL-CANCER; PROSTATE-CANCER; HIF-ALPHA; HYPOXIA; BINDING; PROTEIN	Clear cell renal cell cancer (CC-RCC) is a highly chemoresistant tumor characterized by frequent inactivation of the von Hippel-Lindau (VHL) gene. The prognosis is reportedly worse in patients whose tumors express immunoreactive type I insulin-like growth factor receptor (IGF1R), a key mediator of tumor cell survival. We aimed to investigate how IGF1R expression is regulated, and found that IGF1R protein levels were unaffected by hypoxia, but were higher in CC-RCC cells harboring mutant inactive VHL than in isogenic cells expressing wild-type (WT) VHL. IGF1R mRNA and promoter activities were significantly lower in CC-RCC cells expressing WT VHL, consistent with a transcriptional effect. In Sp1-null Drosophila Schneider cells, IGF1R promoter activity was dependent on exogenous Sp1, and was suppressed by full-length VHL protein (pVHL) but only partially by truncated VHL lacking the Sp1-binding motif. pVHL also reduced the stability of IGF1R mRNA via sequestration of HuR protein. Finally, IGF1R mRNA levels were significantly higher in CC-RCC biopsies than benign kidney, confirming the clinical relevance of these findings. Thus, we have identified a new hypoxia-independent role for VHL in suppressing IGF1R transcription and mRNA stability. VHL inactivation leads to IGF1R upregulation, contributing to renal tumorigenesis and potentially also to chemoresistance.	Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Canc Res UK Lab, Oxford OX3 9DS, England; Henry Wellcome Bldg Mol Pathol, Oxford, England; Churchill Hosp, Dept Urol, Oxford OX3 7LJ, England; Churchill Hosp, Dept Med Oncol, Oxford OX3 7LJ, England; John Radcliffe Hosp, Dept Cell Pathol, Oxford OX3 9DU, England; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel	Cancer Research UK; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; Tel Aviv University; Sackler Faculty of Medicine	Macaulay, VM (corresponding author), Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Canc Res UK Lab, Headley Way, Oxford OX3 9DS, England.	macaulay@cancer.org.uk	Cockman, Matthew/V-9619-2019	Cockman, Matthew/0000-0002-3310-4821; Pugh, Chris/0000-0002-5170-1662	MRC [G0601061] Funding Source: UKRI; Medical Research Council [G0601061] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abramovitch S, 2003, FEBS LETT, V541, P149, DOI 10.1016/S0014-5793(03)00315-6; Ahmad N, 2004, HUM PATHOL, V35, P1132, DOI 10.1016/j.humpath.2004.05.012; Banks RE, 2006, CANCER RES, V66, P2000, DOI 10.1158/0008-5472.CAN-05-3074; Bohula EA, 2003, J BIOL CHEM, V278, P15991, DOI 10.1074/jbc.M300714200; Chen CYA, 2002, MOL CELL BIOL, V22, P7268, DOI 10.1128/MCB.22.20.7268-7278.2002; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Cohen HT, 1999, BIOCHEM BIOPH RES CO, V266, P43, DOI 10.1006/bbrc.1999.1767; Conaway RC, 2002, ADV CANCER RES, V85, P1, DOI 10.1016/S0065-230X(02)85001-1; COOKE DW, 1991, BIOCHEM BIOPH RES CO, V177, P1113, DOI 10.1016/0006-291X(91)90654-P; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Datta K, 2000, J BIOL CHEM, V275, P20700, DOI 10.1074/jbc.M909970199; Datta K, 2005, ONCOGENE, V24, P7850, DOI 10.1038/sj.onc.1208912; Dunn SE, 1997, CANCER RES, V57, P2687; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; Gherzi R, 2004, MOL CELL, V14, P571, DOI 10.1016/j.molcel.2004.05.002; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Hakam A, 1999, HUM PATHOL, V30, P1128, DOI 10.1016/S0046-8177(99)90027-8; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hellawell GO, 2002, CANCER RES, V62, P2942; Iliopoulos O, 1997, MOL MED, V3, P289, DOI 10.1007/BF03401807; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kim KW, 1998, CANCER RES, V58, P348; Kruhoffer M, 2005, BRIT J CANCER, V92, P2240, DOI 10.1038/sj.bjc.6602621; Lee S, 2005, CANCER CELL, V8, P155, DOI 10.1016/j.ccr.2005.06.015; Macaulay VM, 2001, ONCOGENE, V20, P4029, DOI 10.1038/sj.onc.1204565; MAMULA PW, 1992, DNA CELL BIOL, V11, P43, DOI 10.1089/dna.1992.11.43; Mandriota SJ, 2002, CANCER CELL, V1, P459, DOI 10.1016/S1535-6108(02)00071-5; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Meng Z, 2005, NUCLEIC ACIDS RES, V33, P2962, DOI 10.1093/nar/gki603; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ohlsson C, 1998, ENDOCRINOLOGY, V139, P1101, DOI 10.1210/en.139.3.1101; Ord JJ, 2005, BRIT J CANCER, V93, P346, DOI 10.1038/sj.bjc.6602666; Parker AS, 2004, CANCER-AM CANCER SOC, V100, P2577, DOI 10.1002/cncr.20322; Parker AS, 2003, J UROLOGY, V170, P420, DOI 10.1097/01.ju.0000071474.70103.92; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rafty LA, 2002, J CELL BIOCHEM, V85, P490, DOI 10.1002/jcb.10152; Raineri I, 2004, NUCLEIC ACIDS RES, V32, P1279, DOI 10.1093/nar/gkh282; Riedemann J, 2007, BIOCHEM BIOPH RES CO, V355, P707, DOI 10.1016/j.bbrc.2007.02.012; Rochester MA, 2005, CANCER GENE THER, V12, P90, DOI 10.1038/sj.cgt.7700775; SELL C, 1995, CANCER RES, V55, P303; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Steinbrech DS, 2000, ANN PLAS SURG, V44, P529, DOI 10.1097/00000637-200044050-00012; Treins C, 2005, MOL ENDOCRINOL, V19, P1304, DOI 10.1210/me.2004-0239; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Werner H, 2000, CELL MOL LIFE SCI, V57, P932, DOI 10.1007/PL00000735; WERNER H, 1994, J BIOL CHEM, V269, P12577; WERNER H, 1992, MOL ENDOCRINOL, V6, P1545, DOI 10.1210/me.6.10.1545; Wykoff CC, 2004, BRIT J CANCER, V90, P1235, DOI 10.1038/sj.bjc.6601657; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085	55	69	70	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	45					6499	6508		10.1038/sj.onc.1210474	http://dx.doi.org/10.1038/sj.onc.1210474			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	217AF	17486080				2022-12-17	WOS:000249919800003
J	Ke, Y; Wu, D; Princen, F; Nguyen, T; Pang, Y; Lesperance, J; Muller, WJ; Oshima, RG; Feng, GS				Ke, Y.; Wu, D.; Princen, F.; Nguyen, T.; Pang, Y.; Lesperance, J.; Muller, W. J.; Oshima, R. G.; Feng, G-S			Role of Gab2 in mammary tumorigenesis and metastasis	ONCOGENE			English	Article						Gab2; mammary tumor; metastasis; signal transduction; cell migration; scaffolding protein	HUMAN BREAST-CANCER; DOCKING PROTEIN GAB2; SIGNAL-TRANSDUCTION; TRANSGENIC MICE; GROWTH-FACTOR; INDUCTION; KINASE; ACTIVATION; EXPRESSION; MIGRATION	Overexpression of the adaptor/scaffolding protein Gab2 has been detected in primary human breast cancer cells and cell lines, although its functional signifi. cance in breast carcinogenesis is not fully understood. Here, we show a requirement for Gab2 in promoting mammary tumor metastasis. Although Gab2 expression levels were elevated in mammary tumors induced by the Neu (ErbB-2) oncogene, homozygous deletion of Gab2 in mice had only a modest effect on the initiation of Neu-induced mammary tumors. Notably, ablation of Gab2 severely suppressed lung metastasis. Gab2-deficient cancer cells displayed normal Akt activities, and their proliferative rate in vitro was similar to control cells. However, Gab2(-/-) cancer cells exhibited decreased migration and impaired Erk activation, and the defects were rescued by re-introduction of Gab2 into Gab2(-/-) cells. These. ndings suggest that although Gab2 overexpression may confer growth advantage to tumor cells, the functional requirement for Gab2 in mammary tumor initiation/growth may be dispensable, and that Gab2 may have a prominent role in promoting mammary tumor metastasis.	Burnham Inst Med Res, Ctr Canc, La Jolla, CA 92037 USA; Royal Victoria Hosp, Mol Oncol Grp, Montreal, PQ, Canada	Sanford Burnham Prebys Medical Discovery Institute; McGill University; Royal Victoria Hospital	Feng, GS (corresponding author), Burnham Inst Med Res, Ctr Canc, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	gfeng@burnham.org			NCI NIH HHS [CA78606, CA102583] Funding Source: Medline; NHLBI NIH HHS [HL66208] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA102583, R01CA078606] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066208] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abassi YA, 2004, J IMMUNOL METHODS, V292, P195, DOI 10.1016/j.jim.2004.06.022; Amundadottir LT, 1998, ONCOGENE, V16, P737, DOI 10.1038/sj.onc.1201829; Bentires-Alj M, 2006, NAT MED, V12, P114, DOI 10.1038/nm1341; Bourguignon LYW, 1998, J CELL PHYSIOL, V176, P206, DOI 10.1002/(SICI)1097-4652(199807)176:1<206::AID-JCP22>3.0.CO;2-3; Brummer T, 2006, J BIOL CHEM, V281, P626, DOI 10.1074/jbc.M509567200; Daly RJ, 2002, ONCOGENE, V21, P5175, DOI 10.1038/sj.onc.1205522; Dankort D, 2001, MOL CELL BIOL, V21, P1540, DOI 10.1128/MCB.21.5.1540-1551.2001; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; Huang E, 2003, LANCET, V361, P1590, DOI 10.1016/S0140-6736(03)13308-9; Liu Y, 2002, FEBS LETT, V515, P1, DOI 10.1016/S0014-5793(02)02425-0; Meng SS, 2005, BIOCHEM J, V391, P143, DOI 10.1042/BJ20050229; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Reddy KB, 2003, CANCER METAST REV, V22, P395, DOI 10.1023/A:1023781114568; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Slamon D, 2001, SEMIN ONCOL, V28, P13, DOI 10.1053/sonc.2001.22812; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; White DE, 2004, CANCER CELL, V6, P159, DOI 10.1016/j.ccr.2004.06.025; Xing JZ, 2005, CHEM RES TOXICOL, V18, P154, DOI 10.1021/tx049721s; Yamada K, 2001, CYTOGENET CELL GENET, V94, P39, DOI 10.1159/000048780; Yu WM, 2002, BLOOD, V99, P2351, DOI 10.1182/blood.V99.7.2351; Zhang EE, 2004, P NATL ACAD SCI USA, V101, P16064, DOI 10.1073/pnas.0405041101; Zhao MS, 1999, INTERNET J CHEM, V2	24	69	71	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2007	26	34					4951	4960		10.1038/sj.onc.1210315	http://dx.doi.org/10.1038/sj.onc.1210315			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194CV	17310989				2022-12-17	WOS:000248322500007
J	Kong, LJ; Chang, JT; Bild, AH; Nevins, JR				Kong, L-J; Chang, J. T.; Bild, A. H.; Nevins, J. R.			Compensation and specificity of function within the E2F family	ONCOGENE			English	Article						E2F; cell cycle; expression signatures	TRANSCRIPTION FACTOR; DNA-REPLICATION; CELL-CYCLE; S-PHASE; EXPRESSION; PROLIFERATION; INDUCTION; PATHWAY; CANCER; LEADS	Functions encoded by single genes in lower organisms are often represented by multiple related genes in the mammalian genome. An example is the retinoblastoma and E2F families of proteins that regulate transcription during the cell cycle. Analysis of gene function using germline mutations is often confounded by overlapping function resulting in compensation. Indeed, in cells deleted of the E2F1 or E2F3 genes, there is an increase in the expression of the other family member. To avoid complications of compensatory effects, we have used small-interfering RNAs that target individual E2F proteins to generate a temporary loss of E2F function. We find that both E2F1 and E2F3 are required for cells to enter the S phase from a quiescent state, whereas only E2F3 is necessary for the S phase in growing cells. We also find that the acute loss of E2F3 activity affects the expression of genes encoding DNA replication and mitotic activities, whereas loss of E2F1 affects a limited number of genes that are distinct from those regulated by E2F3. We conclude that the long-term loss of E2F activity does lead to compensation by other family members and that the analysis of acute loss of function reveals specific and distinct roles for these proteins.	Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Inst Genome Sci & Policy, Durham, NC 27710 USA	Duke University	Nevins, JR (corresponding author), Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Inst Genome Sci & Policy, Durham, NC 27710 USA.	j.nevins@duke.edu			NATIONAL CANCER INSTITUTE [R01CA106520, R01CA104663] Funding Source: NIH RePORTER; NCI NIH HHS [CA112952, CA104663, CA106520] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attwooll C, 2004, EMBO J, V23, P4709, DOI 10.1038/sj.emboj.7600481; Cook JG, 2002, P NATL ACAD SCI USA, V99, P1347, DOI 10.1073/pnas.032677499; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Giangrande PH, 2003, MOL CELL BIOL, V23, P3707, DOI 10.1128/MCB.23.11.3707-3720.2003; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Humbert PO, 2000, GENE DEV, V14, P690; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; JOHNSON AF, 1993, ECOSYSTEMS WORLD, V2, P365; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muller M J, 2001, Obes Rev, V2, P15; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Nevins JR, 1997, METHOD ENZYMOL, V283, P205; Polager S, 2002, ONCOGENE, V21, P437, DOI 10.1038/sj.onc.1205102; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Rempel RE, 2000, MOL CELL, V6, P293, DOI 10.1016/S1097-2765(00)00030-7; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Schlisio S, 2002, EMBO J, V21, P5775, DOI 10.1093/emboj/cdf577; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Smith DS, 2000, CELL GROWTH DIFFER, V11, P625; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499; Zhu WC, 2004, EMBO J, V23, P4615, DOI 10.1038/sj.emboj.7600459	28	69	72	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	3					321	327		10.1038/sj.onc.1209817	http://dx.doi.org/10.1038/sj.onc.1209817			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16909124				2022-12-17	WOS:000243544000001
J	Ma, Z; Izumi, H; Kanai, M; Kabuyama, Y; Ahn, NG; Fukasawa, K				Ma, Z.; Izumi, H.; Kanai, M.; Kabuyama, Y.; Ahn, N. G.; Fukasawa, K.			Mortalin controls centrosome duplication via modulating centrosomal localization of p53	ONCOGENE			English	Article						mortalin; p53; centrosome; centrosome duplication	CHROMOSOME INSTABILITY; FAMILY; CELLS; CYCLE; PHOSPHORYLATION; AMPLIFICATION; INDUCTION; ARREST; MEMBER; BINDS	Abnormal amplification of centrosomes, commonly found in human cancer, is the major cause of mitotic defects and chromosome instability in cancer cells. Like DNA, centrosomes duplicate once in each cell cycle, hence the defect in the mechanism that ensures centrosome duplication to occur once and only once in each cell cycle results in abnormal amplification of centrosomes and mitotic defects. Centrosomes are non-membranous organelles, and undergo dynamic changes in its constituents during the centrosome duplication cycle. Through a comparative mass spectrometric analysis of unduplicated and duplicated centrosomes, we identified mortalin, a member of heat shock protein family, as a protein that associates preferentially with duplicated centrosomes. Further analysis revealed that mortalin localized to centrosomes in late G1 before centrosome duplication, remained at centrosomes during S and G2, and dissociated from centrosomes during mitosis. Overexpression of mortalin overrides the p53-dependent suppression of centrosome duplication, and mortalin-driven centrosome duplication requires physical interaction between mortalin and p53. Moreover, mortalin promotes dissociation of p53 from centrosomes through physical interaction. The p53 mutant that lacks the ability to bind to mortalin remains at centrosomes, and suppresses centrosome duplication in a transactivation function-independent manner. Thus, our present findings not only identify mortalin as an upstream molecule of p53 but also provide evidence for the involvement of centrosomally localized p53 in the regulation of centrosome duplication.	Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA; Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA	University System of Ohio; University of Cincinnati; University of Colorado System; University of Colorado Boulder	Fukasawa, K (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol, POB 670521, Cincinnati, OH 45267 USA.	kenji.fukasawa@uc.edu			NCI NIH HHS [CA90522, CA95925] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090522, R01CA095925] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; BROWN CR, 1994, J CELL PHYSIOL, V160, P47, DOI 10.1002/jcp.1041600107; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Ciciarello M, 2001, J BIOL CHEM, V276, P19205, DOI 10.1074/jbc.M009528200; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; Hadari YR, 1997, J BIOL CHEM, V272, P657; Hinchcliffe EH, 2002, ONCOGENE, V21, P6154, DOI 10.1038/sj.onc.1205826; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Kaul SC, 2002, EXP GERONTOL, V37, P1157, DOI 10.1016/S0531-5565(02)00135-3; Kaul SC, 2001, NEOPLASIA, V3, P110, DOI 10.1038/sj.neo.7900139; Kawamura K, 2004, CANCER RES, V64, P4800, DOI 10.1158/0008-5472.CAN-03-3908; Lange BMH, 1996, TRENDS CELL BIOL, V6, P348, DOI 10.1016/0962-8924(96)10033-7; Morris VB, 2000, EXP CELL RES, V256, P122, DOI 10.1006/excr.2000.4800; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; Oakley BR, 2000, CURR TOP DEV BIOL, V49, P27; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Ran QT, 2000, BIOCHEM BIOPH RES CO, V275, P174, DOI 10.1006/bbrc.2000.3237; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; STEWART N, 1995, ONCOGENE, V10, P109; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Tarapore P, 2001, ONCOGENE, V20, P6851, DOI 10.1038/sj.onc.1204848; TIMSON J, 1975, MUTAT RES, V32, P115, DOI 10.1016/0165-1110(75)90002-0; Tsujimoto Y, 1998, GENES CELLS, V3, P697, DOI 10.1046/j.1365-2443.1998.00223.x; WADHWA R, 1995, EXP CELL RES, V216, P101, DOI 10.1006/excr.1995.1013; WADHWA R, 1993, EXP CELL RES, V207, P442, DOI 10.1006/excr.1993.1213; Wadhwa R, 1998, J BIOL CHEM, V273, P29586, DOI 10.1074/jbc.273.45.29586; Wadhwa R, 2002, EXP CELL RES, V274, P246, DOI 10.1006/excr.2002.5468; ZAJDEL MEB, 1988, ONCOGENE, V2, P579	31	69	75	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2006	25	39					5377	5390		10.1038/sj.onc.1209543	http://dx.doi.org/10.1038/sj.onc.1209543			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078ZI	16619038				2022-12-17	WOS:000240144900003
J	Liu, L; Andrews, L; Tollefsbol, TO				Liu, L.; Andrews, L. G.; Tollefsbol, T. O.			Loss of the human polycomb group protein BMI1promotes cancer-specific cell death	ONCOGENE			English	Article						BMI1; cancer stem cells; telomerase; INK4A-ARF; PcG proteins	LIFE-SPAN; SELF-RENEWAL; BMI-1 ONCOPROTEIN; LEUKEMIA-CELLS; MYC; IDENTIFICATION; TRANSFORMATION; PROLIFERATION; TUMORIGENESIS; SENESCENCE	The polycomb group protein BMI1 has been shown to support normal stem cell proliferation via its putative stem cell factor function, but it is not known if BMI1 may also act as a cancer stem cell factor to promote cancer development. To determine the role of human BMI1 in cancer growth and survival, we performed a loss-of-function analysis of BMI1 by RNA interference (RNAi) in both normal and malignant human cells. Our results indicate that BMI1 is crucial for the short-term survival of cancer cells but not of normal cells. We also demonstrated that loss of BMI1 was more effective in suppressing cancer cell growth than retinoid-treatment, and surviving cancer cells showed significantly reduced tumorigenicity. The cancer-specific growth retardation was mediated by an increased level of apoptosis and a delayed cell cycle progression due to the loss of BMI1. By comparison, BMI1 deficiency caused only a moderate inhibition of the cell cycle progression in normal lung cells. In both normal and cancer cells, the loss of BMI1 led to an upregulation of INK4A-ARF, but with no significant effect on the level of telomerase gene expression, suggesting that other BMI1-cooperative factors in addition to INK4A-ARF activation may be involved in the BMI1-dependent cancer-specific growth retardation. Thus, human BMI1 is critical for the short-term survival of cancer cells, and inhibition of BMI1 has minimal effect on the survival of normal cells. These findings provide a foundation for developing a cancer-specific therapy targeting BMI1.	Univ Alabama Birmingham, Dept Biol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Ctr Aging, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Liu, L (corresponding author), Univ Alabama Birmingham, Dept Biol, 175 Campbell Hall,1300 Univ Blvd, Birmingham, AL 35294 USA.	liangliu@uab.edu		Tollefsbol, Trygve/0000-0002-0284-1511	NATIONAL CANCER INSTITUTE [R21CA114019] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R03AG020375] Funding Source: NIH RePORTER; NCI NIH HHS [R21 CA114019, R21 CA114019-02] Funding Source: Medline; NIA NIH HHS [R03 AG020375-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bea S, 2001, CANCER RES, V61, P2409; Blair A, 1997, BLOOD, V89, P3104, DOI 10.1182/blood.V89.9.3104; Bruggeman SWM, 2005, GENE DEV, V19, P1438, DOI 10.1101/gad.1299305; Casillas MA, 2003, GENE, V316, P57, DOI 10.1016/S0378-1119(03)00739-X; Cohen KJ, 1996, MOL CELL BIOL, V16, P5527; Dimri GP, 2002, CANCER RES, V62, P4736; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; Itahana K, 2003, MOL CELL BIOL, V23, P389, DOI 10.1128/MCB.23.1.389-401.2003; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; KAKUNAGA T, 1985, TRANSFORMATION ASSAY; Leung C, 2004, NATURE, V428, P337, DOI 10.1038/nature02385; Liu L, 2004, MOL CANCER THER, V3, P1003; Mihara K, 2006, BLOOD, V107, P305, DOI 10.1182/blood-2005-06-2393; Molofsky AV, 2005, GENE DEV, V19, P1432, DOI 10.1101/gad.1299505; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Mori T, 2005, MOL CELL BIOL, V25, P5183, DOI 10.1128/MCB.25.12.5183-5195.2005; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Shakhova O, 2005, J MOL MED, V83, P596, DOI 10.1007/s00109-005-0682-0; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Takeda Y, 2004, J GENE MED, V6, P833, DOI 10.1002/jgm.583; Terai M, 2005, MOL BIOL CELL, V16, P1491, DOI 10.1091/mbc.e04-07-0652; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; Vonlanthen S, 2001, BRIT J CANCER, V84, P1372, DOI 10.1054/bjoc.2001.1791	28	69	84	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2006	25	31					4370	4375		10.1038/sj.onc.1209454	http://dx.doi.org/10.1038/sj.onc.1209454			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	066OU	16501599	Green Accepted			2022-12-17	WOS:000239240100012
J	Sun, Q; Matta, H; Lu, G; Chaudhary, PM				Sun, Q; Matta, H; Lu, G; Chaudhary, PM			Induction of IL-8 expression by human herpesvirus 8 encoded vFLIP K13 via NF-kappa B activation	ONCOGENE			English	Article						vFLIP; KSHV; HHV-8; IL-8; K13; NF-kappa B	SARCOMA-ASSOCIATED HERPESVIRUS; ECTODERMAL DYSPLASIA RECEPTOR; PROTEIN-COUPLED RECEPTOR; KAPOSIS-SARCOMA; INTERLEUKIN-8 GENE; SIGNAL-TRANSDUCTION; SPINDLE CELLS; KINASE; APOPTOSIS; TRANSCRIPTION	Human herpesvirus 8 (HHV-8) encodes a viral FLICE inhibitory protein (vFLIP), called K13, with homology to the prodomain of caspase 8. K13 has been postulated to protect virally infected cells against death receptor-induced apoptosis. We report that K13 leads to constitutive upregulation of IL-8 secretion by transcriptional upregulation of its promoter. K13-induced IL-8 promoter activation is dependent on an intact NF-kappa B-binding site and is associated with increased binding of classical NF-kappa B pathway subunits p65, c-Rel and p50, respectively. IL-8 production is defective in K13 mutants defective in classical NF-kappa B activation and is blocked by genetic and pharmacological inhibitors of this pathway. In contrast, K13 failed to activate the JNK/AP-1 pathway and deletion of AP-1-binding site in the IL-8 promoter or use of a specific JNK inhibitor had only a partial effect on K13-induced IL-8 promoter activation. Collectively, above results demonstrate that K13 is a major mediator of IL-8 production and therapeutic agents targeting K13-induced NF-kappa B pathway may have a role in the treatment of conditions in which HHV-8-induced IL-8 production plays a pathogenic role.	Univ Pittsburgh, Dept Med, Div Hematol Oncol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Med, Hillman Canc Ctr, Pittsburgh, PA USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chaudhary, PM (corresponding author), Univ Pittsburgh, Dept Med, Div Hematol Oncol, 5117 Ctr Ave,Suite 1-19A, Pittsburgh, PA 15213 USA.	chaudharypm@upmc.edu	Chaudhary, Preet/E-1970-2018		NATIONAL CANCER INSTITUTE [R01CA085177] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA85177] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams J, 2000, ONCOGENE, V19, P6687, DOI 10.1038/sj.onc.1204088; An JB, 2003, ONCOGENE, V22, P3371, DOI 10.1038/sj.onc.1206407; Bais C, 2003, CANCER CELL, V3, P131, DOI 10.1016/S1535-6108(03)00024-2; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Chaudhary PM, 1999, ONCOGENE, V18, P5738, DOI 10.1038/sj.onc.1202976; Chaudhary PM, 1999, J BIOL CHEM, V274, P19211, DOI 10.1074/jbc.274.27.19211; Dourmishev LA, 2003, MICROBIOL MOL BIOL R, V67, P175, DOI 10.1128/MMBR.67.2.175-212.2003; ENSOLI B, 1995, P ASSOC AM PHYSICIAN, V107, P8; Falvo JV, 2000, MOL CELL BIOL, V20, P4814, DOI 10.1128/MCB.20.13.4814-4825.2000; Gershengorn MC, 1998, J CLIN INVEST, V102, P1469, DOI 10.1172/JCI4461; Hoffmann E, 2002, J LEUKOCYTE BIOL, V72, P847; Holtmann H, 1999, MOL CELL BIOL, V19, P6742; Hu SM, 1997, J BIOL CHEM, V272, P9621; Jiang GQ, 2003, J BIOL CHEM, V278, P180, DOI 10.1074/jbc.M205565200; Kapahi P, 2000, J BIOL CHEM, V275, P36062, DOI 10.1074/jbc.M007204200; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Lane BR, 2002, J VIROL, V76, P11570, DOI 10.1128/JVI.76.22.11570-11583.2002; Lane BR, 2001, J VIROL, V75, P8195, DOI 10.1128/JVI.75.17.8195-8202.2001; Le XD, 2000, J INTERF CYTOK RES, V20, P935, DOI 10.1089/10799900050198372; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Liu L, 2002, J BIOL CHEM, V277, P13745, DOI 10.1074/jbc.M110480200; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Masood R, 2001, CLIN CANCER RES, V7, P2693; Masood Rizwan, 1993, Current Opinion in Oncology, V5, P831, DOI 10.1097/00001622-199309000-00010; Matta H, 2004, P NATL ACAD SCI USA, V101, P9399, DOI 10.1073/pnas.0308016101; Matta H, 2003, J BIOL CHEM, V278, P52406, DOI 10.1074/jbc.M307308200; Moore PS, 2003, ANNU REV MICROBIOL, V57, P609, DOI 10.1146/annurev.micro.57.030502.090824; Mori N, 1998, CANCER RES, V58, P3993; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; Nurnberg W, 1999, J PATHOL, V189, P546, DOI 10.1002/(SICI)1096-9896(199912)189:4<546::AID-PATH487>3.0.CO;2-L; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Pomerantz JL, 2002, MOL CELL, V10, P693, DOI 10.1016/S1097-2765(02)00697-4; Roussel RR, 2000, ARCH BIOCHEM BIOPHYS, V377, P204, DOI 10.1006/abbi.2000.1770; Sarid R, 1998, J VIROL, V72, P1005, DOI 10.1128/JVI.72.2.1005-1012.1998; Schulz TF, 1998, J GEN VIROL, V79, P1573, DOI 10.1099/0022-1317-79-7-1573; Singh RK, 1999, MELANOMA RES, V9, P383, DOI 10.1097/00008390-199908000-00007; Sinha SK, 2002, J BIOL CHEM, V277, P44953, DOI 10.1074/jbc.M207923200; Sinha SK, 2004, J BIOL CHEM, V279, P41873, DOI 10.1074/jbc.M407363200; SMITH DR, 1994, J EXP MED, V179, P1409, DOI 10.1084/jem.179.5.1409; Sparmann A, 2004, CANCER CELL, V6, P447, DOI 10.1016/j.ccr.2004.09.028; Sturzl M, 1999, J NATL CANCER I, V91, P1725, DOI 10.1093/jnci/91.20.1725; Sun QM, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-9; Sun QM, 2003, J BIOL CHEM, V278, P52437, DOI 10.1074/jbc.M304199200; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; UEDA T, 1994, J GASTROENTEROL, V29, P423, DOI 10.1007/BF02361238; Verma SC, 2003, FEMS MICROBIOL LETT, V222, P155, DOI 10.1016/S0378-1097(03)00261-1; Wang JF, 2004, BBA-MOL CELL RES, V1691, P129, DOI 10.1016/j.bbamcr.2004.01.002; WATANABE K, 1989, BIOCHEM BIOPH RES CO, V161, P1093, DOI 10.1016/0006-291X(89)91355-7; Wu GD, 1997, J BIOL CHEM, V272, P2396; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445; Yokoe T, 1997, ANTICANCER RES, V17, P695	53	69	71	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2006	25	19					2717	2726		10.1038/sj.onc.1209298	http://dx.doi.org/10.1038/sj.onc.1209298			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	039AW	16418726				2022-12-17	WOS:000237272900003
J	Yin, D; Xie, D; Sakajiri, S; Miller, CW; Zhu, H; Popoviciu, ML; Said, JW; Black, KL; Koeffler, HP				Yin, D; Xie, D; Sakajiri, S; Miller, CW; Zhu, H; Popoviciu, ML; Said, JW; Black, KL; Koeffler, HP			DLK1: increased expression in gliomas and associated with oncogenic activities	ONCOGENE			English	Article						DLK1; expression; oncogenic activities; glioma	EPIDERMAL-GROWTH-FACTOR; EGF-LIKE REPEATS; PROTEIN DLK; DELTA-LIKE; CELL-LINE; ADIPOCYTE DIFFERENTIATION; FETAL ANTIGEN-1; HUMAN HOMOLOG; GENE; PREF-1	DLK1 ( delta-like) is a transmembrane and secreted protein in the epidermal growth factor- like homeotic family. Although expressed widely during embryonic development, only a few tissues retain the expression in adults. Neuroendocrine tumors often highly express this protein; therefore, we hypothesized that brain tumors might also express it. This study found that the expression of DLK1 in gliomas was higher than that in normal brain (P < 0.05). After stable transfection of a DLK1 cDNA expression vector into GBM cell lines, their proliferation was increased. Furthermore, they lost contact inhibition, had enhanced anchorage-independent growth in soft agar, and had significantly greater capacity to migrate. Western blot studies showed that expression of cyclin D1, CDK2, and E2F4 were increased, and Rb levels were decreased in these cells. DLK1 was found on the cell surface and secreted in the medium from the transfected GBM cells. DLK1-enriched condition medium stimulated the growth of glioblastoma multiforme cell lines and explants. DLK1 antibody blocked cell growth stimulated by DLK1. In summary, these results suggest that DLK1 may play a role in the formation or progression of gliomas.	Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Div Hematol & Oncol, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Maxine Dunitz Neurosurg Inst, Los Angeles, CA 90048 USA; Chinese Acad Sci, Inst Nutr Sci, SIBS, Shanghai, Peoples R China	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Yin, D (corresponding author), Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Div Hematol & Oncol, 8700 Beverly Blvd,Davis Bldg 5022 Room, Los Angeles, CA 90048 USA.	Dong.Yin@cshs.org		Black, Keith/0000-0002-0546-4934; Xie, Dong/0000-0002-1150-8657				Abdallah BM, 2004, J BONE MINER RES, V19, P841, DOI 10.1359/JBMR.040118; Baladron V, 2005, EXP CELL RES, V303, P343, DOI 10.1016/j.yexcr.2004.10.001; Baladron V, 2002, BIOCHEM BIOPH RES CO, V291, P193, DOI 10.1006/bbrc.2002.6431; Bauer SR, 1998, MOL CELL BIOL, V18, P5247, DOI 10.1128/MCB.18.9.5247; Boney CM, 1996, ENDOCRINOLOGY, V137, P2923, DOI 10.1210/en.137.7.2923; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; CARPENTER G, 1986, EXP CELL RES, V164, P1, DOI 10.1016/0014-4827(86)90449-0; COOPER MJ, 1990, CELL GROWTH DIFFER, V1, P149; Edwards PAW, 1999, CANCER METAST REV, V18, P175, DOI 10.1023/A:1006304821464; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; ENGEL J, 1989, FEBS LETT, V251, P1, DOI 10.1016/0014-5793(89)81417-6; Fan X, 2004, CANCER RES, V64, P7787, DOI 10.1158/0008-5472.CAN-04-1446; Floridon C, 2000, DIFFERENTIATION, V66, P49, DOI 10.1046/j.1432-0436.2000.066001049.x; GAETANO C, 1992, CANCER RES, V52, P4402; Garces C, 1999, DIFFERENTIATION, V64, P103, DOI 10.1007/s002580050265; Halder SK, 1998, ENDOCRINOLOGY, V139, P3316, DOI 10.1210/en.139.7.3316; Hartman J, 2004, ONCOGENE, V23, P8826, DOI 10.1038/sj.onc.1208139; HELMAN LJ, 1987, P NATL ACAD SCI USA, V84, P2336, DOI 10.1073/pnas.84.8.2336; JENSEN CH, 1993, HUM REPROD, V8, P635, DOI 10.1093/oxfordjournals.humrep.a138110; Kaneta M, 2000, J IMMUNOL, V164, P256, DOI 10.4049/jimmunol.164.1.256; Laborda J, 2000, HISTOL HISTOPATHOL, V15, P119, DOI 10.14670/HH-15.119; LABORDA J, 1993, J BIOL CHEM, V268, P3817; LEE YL, 1995, BBA-GENE STRUCT EXPR, V1261, P223; Mark M, 1997, PEDIATR RES, V42, P421, DOI 10.1203/00006450-199710000-00001; Moon YS, 2002, MOL CELL BIOL, V22, P5585, DOI 10.1128/MCB.22.15.5585-5592.2002; Moore KA, 1997, P NATL ACAD SCI USA, V94, P4011, DOI 10.1073/pnas.94.8.4011; Muller P, 2002, J BIOL CHEM, V277, P28376, DOI 10.1074/jbc.C200340200; MUNKER R, 1986, J CLIN INVEST, V78, P424, DOI 10.1172/JCI112593; Muskavitch M.A.T., 1990, Current Topics in Developmental Biology, V24, P289, DOI 10.1016/S0070-2153(08)60091-5; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Samulewicz SJ, 2002, WOUND REPAIR REGEN, V10, P215, DOI 10.1046/j.1524-475X.2002.10404.x; Schmidt JV, 2000, GENE DEV, V14, P1997; SIMPSON P, 1995, NATURE, V375, P736, DOI 10.1038/375736a0; SMAS CM, 1994, BIOCHEMISTRY-US, V33, P9257, DOI 10.1021/bi00197a029; SMAS CM, 1993, CELL, V73, P725, DOI 10.1016/0092-8674(93)90252-L; Sriuranpong V, 2001, CANCER RES, V61, P3200; Stockhausen MT, 2005, BRIT J CANCER, V92, P751, DOI 10.1038/sj.bjc.6602309; Takada S, 2002, HUM MOL GENET, V11, P77, DOI 10.1093/hmg/11.1.77; Takada S, 2000, CURR BIOL, V10, P1135, DOI 10.1016/S0960-9822(00)00704-1; Tornehave D, 1996, HISTOCHEM CELL BIOL, V106, P535; TORNEHAVE D, 1993, ANAT EMBRYOL, V187, P335; van Limpt V, 2000, MED PEDIATR ONCOL, V35, P554, DOI 10.1002/1096-911X(20001201)35:6<554::AID-MPO13>3.0.CO;2-R; Wylie AA, 2000, GENOME RES, V10, P1711, DOI 10.1101/gr.161600; Yin D, 2002, ONCOGENE, V21, P8372, DOI 10.1038/sj.onc.1206031	44	69	77	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 23	2006	25	13					1852	1861		10.1038/sj.onc.1209219	http://dx.doi.org/10.1038/sj.onc.1209219			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16288219				2022-12-17	WOS:000236224800002
J	Shmulevitz, M; Marcato, P; Lee, PWK				Shmulevitz, M; Marcato, P; Lee, PWK			Unshackling the links between reovirus oncolysis, Ras signaling, translational control and cancer	ONCOGENE			English	Review						cancer; oncolytic virus; oncolysis; reovirus; translation; Ras	DEPENDENT PROTEIN-KINASE; VIRAL ATTACHMENT PROTEIN; HOST-CELL PERMISSIVENESS; HUMAN BREAST-CANCER; MESSENGER-RNA; MALIGNANT-TRANSFORMATION; PERSISTENT INFECTION; ADAPTER PROTEINS; EXCHANGE FACTORS; MEASLES-VIRUS	Reovirus has an inherent preference for replicating in cells with dysregulated growth factor signaling cascades that comprise Ras activation. Precisely how reovirus exploits the host cell Ras pathway is unclear, but there is evidence suggesting that activated Ras signaling is important for efficient viral protein synthesis. De. ning the molecular mechanism of reovirus oncolysis will shed light on reovirus replication and important aspects of cellular transformation, Ras signaling cascades and regulation of protein translation.	Dalhousie Univ, Dept Microbiol, Halifax, NS B3K 1X5, Canada; Dalhousie Univ, Dept Immunol, Halifax, NS B3K 1X5, Canada	Dalhousie University; Dalhousie University	Lee, PWK (corresponding author), Dalhousie Univ, Dept Microbiol, 7P Sir Charles Tupper Med Bldg,5850 Coll St, Halifax, NS B3K 1X5, Canada.	patrick.lee@dal.ca		Marcato, Paola/0000-0001-8619-283X				AHMED R, 1981, CELL, V25, P325, DOI 10.1016/0092-8674(81)90050-7; Anderson BD, 2004, CANCER RES, V64, P4919, DOI 10.1158/0008-5472.CAN-04-0884; ARMSTRONG GD, 1984, VIROLOGY, V138, P37, DOI 10.1016/0042-6822(84)90145-4; Balachandran S, 2004, CANCER CELL, V5, P51, DOI 10.1016/S1535-6108(03)00330-1; BARBER GN, 1995, J BIOL CHEM, V270, P17423, DOI 10.1074/jbc.270.29.17423; BEATTIE E, 1995, J VIROL, V69, P499, DOI 10.1128/JVI.69.1.499-505.1995; Bergmann M, 2001, CANCER RES, V61, P8188; Biederer C, 2002, J MOL MED-JMM, V80, P163, DOI 10.1007/s00109-001-0295-1; BISCHOFF JR, 1989, VIROLOGY, V172, P106, DOI 10.1016/0042-6822(89)90112-8; BOS JL, 1989, CANCER RES, V49, P4682; Brostrom CO, 1998, PROG NUCLEIC ACID RE, V58, P79; Buday L, 1999, BBA-REV BIOMEMBRANES, V1422, P187, DOI 10.1016/S0304-4157(99)00005-2; Campbell PM, 2004, SEMIN CANCER BIOL, V14, P105, DOI 10.1016/j.semcancer.2003.09.015; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chappell JD, 1997, J VIROL, V71, P1834, DOI 10.1128/JVI.71.3.1834-1841.1997; Chappell JD, 2000, J VIROL, V74, P8472, DOI 10.1128/JVI.74.18.8472-8479.2000; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; Clemens MJ, 2004, ONCOGENE, V23, P3180, DOI 10.1038/sj.onc.1207544; Clemens MJ, 1999, INT J BIOCHEM CELL B, V31, P1, DOI 10.1016/S1357-2725(98)00127-7; Coffey MC, 1998, SCIENCE, V282, P1332, DOI 10.1126/science.282.5392.1332; COHEN JA, 1988, MICROBIOL SCI, V5, P265; Cuddihy AR, 1999, MOL CELL BIOL, V19, P2475; deHaro C, 1996, FASEB J, V10, P1378, DOI 10.1096/fasebj.10.12.8903508; DERMODY TS, 1993, J VIROL, V67, P2055, DOI 10.1128/JVI.67.4.2055-2063.1993; DERMODY TS, 1990, J VIROL, V64, P5173, DOI 10.1128/JVI.64.10.5173-5176.1990; Dobbelstein M, 2004, CURR TOP MICROBIOL, V273, P291; Donze O, 1999, VIROLOGY, V256, P322, DOI 10.1006/viro.1999.9618; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; DUNCAN MR, 1978, J VIROL, V28, P444, DOI 10.1128/JVI.28.2.444-449.1978; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; Farassati F, 2001, NAT CELL BIOL, V3, P745, DOI 10.1038/35087061; Feig LA, 2003, TRENDS CELL BIOL, V13, P419, DOI 10.1016/S0962-8924(03)00152-1; Feig LA, 2002, CURR BIOL, V12, pR259, DOI 10.1016/S0960-9822(02)00787-X; Grote D, 2001, BLOOD, V97, P3746, DOI 10.1182/blood.V97.12.3746; HASHIRO G, 1977, ARCH VIROL, V54, P307, DOI 10.1007/BF01314776; Heise C, 2000, NAT MED, V6, P1134, DOI 10.1038/80474; Hirasawa K, 2002, CANCER RES, V62, P1696; Hirasawa K, 2003, CANCER RES, V63, P348; Jagus R, 1999, INT J BIOCHEM CELL B, V31, P123, DOI 10.1016/S1357-2725(98)00136-8; JANES PW, 1994, ONCOGENE, V9, P3601; KAUFFMAN RS, 1983, VIROLOGY, V131, P79, DOI 10.1016/0042-6822(83)90535-4; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Martin-Blanco E, 2000, BIOESSAYS, V22, P637, DOI 10.1002/1521-1878(200007)22:7<637::AID-BIES6>3.0.CO;2-E; Martuza RL, 2000, J CLIN INVEST, V105, P841, DOI 10.1172/JCI9744; Matsumoto K, 1998, EMBO J, V17, P2107, DOI 10.1093/emboj/17.7.2107; Mazumder B, 2001, MOL CELL BIOL, V21, P6440, DOI 10.1128/MCB.21.19.6440-6449.2001; McCormick F, 2000, SEMIN CANCER BIOL, V10, P453, DOI 10.1006/scbi.2000.0336; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MINICH WB, 1992, BIOCHIMIE, V74, P477, DOI 10.1016/0300-9084(92)90088-V; MUNDSCHAU LJ, 1994, BIOCHIMIE, V76, P792, DOI 10.1016/0300-9084(94)90083-3; Muster T, 2004, INT J CANCER, V110, P15, DOI 10.1002/ijc.20078; Norman KL, 2002, HUM GENE THER, V13, P641, DOI 10.1089/10430340252837233; Norman KL, 2000, J CLIN INVEST, V105, P1035, DOI 10.1172/JCI9871; Norman KL, 2004, P NATL ACAD SCI USA, V101, P11099, DOI 10.1073/pnas.0404310101; Nussbaum JM, 2003, CANCER LETT, V196, P207, DOI 10.1016/S0304-3835(03)00276-3; O'Shea CC, 2004, CANCER CELL, V6, P611, DOI 10.1016/j.ccr.2004.11.012; Ouwens DM, 2002, EMBO J, V21, P3782, DOI 10.1093/emboj/cdf361; OVERBECK AF, 1995, MOL REPROD DEV, V42, P468, DOI 10.1002/mrd.1080420415; PACITTI AF, 1987, J VIROL, V61, P1407, DOI 10.1128/JVI.61.5.1407-1415.1987; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PAWSON T, 1994, ADV CANCER RES, V64, P87, DOI 10.1016/S0065-230X(08)60835-0; Pecora AL, 2002, J CLIN ONCOL, V20, P2251, DOI 10.1200/JCO.2002.08.042; Pickering BM, 2005, SEMIN CELL DEV BIOL, V16, P39, DOI 10.1016/j.semcdb.2004.11.006; Repasky GA, 2004, TRENDS CELL BIOL, V14, P639, DOI 10.1016/j.tcb.2004.09.014; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; RODRIGUEZVICIAN.P, 1997, CELL, V89, P47; RUBIN DH, 1985, J VIROL, V53, P391, DOI 10.1128/JVI.53.2.391-398.1985; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Schneider-Schaulies J, 2000, J GEN VIROL, V81, P1413, DOI 10.1099/0022-1317-81-6-1413; Sieczkarski SB, 2005, CURR TOP MICROBIOL, V285, P1; Sinkovics JG, 2000, J CLIN VIROL, V16, P1, DOI 10.1016/S1386-6532(99)00072-4; Skabkin MA, 2004, NUCLEIC ACIDS RES, V32, P5621, DOI 10.1093/nar/gkh889; SPIRIN AS, 1994, MOL REPROD DEV, V38, P107, DOI 10.1002/mrd.1080380117; Stojdl DF, 2000, NAT MED, V6, P821, DOI 10.1038/77558; Strong JE, 1996, J VIROL, V70, P612, DOI 10.1128/JVI.70.1.612-616.1996; Strong JE, 1998, EMBO J, V17, P3351, DOI 10.1093/emboj/17.12.3351; STRONG JE, 1993, VIROLOGY, V197, P405, DOI 10.1006/viro.1993.1602; Tyler K.L., 2001, FIELDS VIROLOGY, P1729; TZAHAR E, 1998, BIOCHIM BIOPHYS ACTA, V1377, P25; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; WEK RC, 1994, TRENDS BIOCHEM SCI, V19, P491, DOI 10.1016/0968-0004(94)90136-8; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Willis AE, 1999, INT J BIOCHEM CELL B, V31, P73, DOI 10.1016/S1357-2725(98)00133-2; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1; Yang WQ, 2004, CLIN CANCER RES, V10, P8561, DOI 10.1158/1078-0432.CCR-04-0940; Yang WQ, 2003, CANCER RES, V63, P3162	94	69	74	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2005	24	52					7720	7728		10.1038/sj.onc.1209041	http://dx.doi.org/10.1038/sj.onc.1209041			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985JD	16299532				2022-12-17	WOS:000233372600008
J	Golestaneh, N; Mishra, B				Golestaneh, N; Mishra, B			TGF-beta, neuronal stem cells and glioblastoma	ONCOGENE			English	Review						TGF-beta; CNS cancer; glioblastoma; ELF; Smad	TRANSFORMING-GROWTH-FACTOR; PROTEASOME INHIBITOR PS-341; RECEPTOR-TYPE-II; FACTOR-KAPPA-B; CANCER-CELLS; MICROSATELLITE INSTABILITY; PROGENITOR CELLS; BRAIN SPECTRIN; GLIOMA-CELLS; AUTOCRINE HYPOTHESIS	Transforming growth factor beta (TGF-beta) signaling leads to a number of biological end points involving cell growth, differentiation, and morphogenesis. Typically, the cellular effect accompanies an induction of mesodermal cell fate and inhibition of neural cell differentiation. However, during pathological conditions, these defined effects of TGF-beta can be reversed; for example, the growth-inhibitory effect is replaced with its tumor promoting ability. A multitude of factors and cross-signaling pathways have been reported to be involved in modulating the dual effects of TGF-beta. In this review, we focus on the potential role of TGF-beta signal transduction during development of neural progenitor cells and its relation to glioblastoma development from neural stem cells.	Georgetown Univ, Sch Med, Dev Neurobiol Lab, Washington, DC 20007 USA	Georgetown University	Mishra, B (corresponding author), Georgetown Univ, Sch Med, Dev Neurobiol Lab, Med Dent Bldg NW,Room 211-213,3900 Reservoir Rd N, Washington, DC 20007 USA.	bm72@georgetown.edu			NIDDK NIH HHS [R01 DK58637] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Altaba AR, 2002, NAT REV CANCER, V2, P361, DOI 10.1038/nrc796; Anderson DJ, 2001, NEURON, V30, P19, DOI 10.1016/S0896-6273(01)00260-4; Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5; Barcellos-Hoff MH, 2000, BREAST CANCER RES, V2, P92, DOI 10.1186/bcr40; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; BENNETT V, 1982, NATURE, V299, P126, DOI 10.1038/299126a0; BIRKENMEIER CS, 1988, P NATL ACAD SCI USA, V85, P8121, DOI 10.1073/pnas.85.21.8121; BODMER S, 1989, J IMMUNOL, V143, P3222; Bottner M, 2000, J NEUROCHEM, V75, P2227, DOI 10.1046/j.1471-4159.2000.0752227.x; Brionne TC, 2003, NEURON, V40, P1133, DOI 10.1016/S0896-6273(03)00766-9; Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890; Chesnutt C, 2004, DEV BIOL, V274, P334, DOI 10.1016/j.ydbio.2004.07.019; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; DACUNHA A, 1993, J NEUROIMMUNOL, V42, P71, DOI 10.1016/0165-5728(93)90214-J; DAHLSTRAND J, 1995, DEV BRAIN RES, V84, P109, DOI 10.1016/0165-3806(94)00162-S; Dahmane N, 2001, DEVELOPMENT, V128, P5201; DAVIS J, 1983, J BIOL CHEM, V258, P7757; DE M, 2000, J CELL SCI, V113, P2331; Deng MJ, 2004, TISSUE ENG, V10, P1597, DOI 10.1089/1076327042500409; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; Dubreuil RR, 2000, J CELL BIOL, V149, P647, DOI 10.1083/jcb.149.3.647; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; Friese MA, 2004, CANCER RES, V64, P7596, DOI 10.1158/0008-5472.CAN-04-1627; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gage FH, 2002, J NEUROSCI, V22, P612, DOI 10.1523/JNEUROSCI.22-03-00612.2002; GALLAGHER PG, 1993, SEMIN HEMATOL, V30, P4; Galter D, 1999, J NEUROSCI RES, V56, P531, DOI 10.1002/(SICI)1097-4547(19990601)56:5<531::AID-JNR8>3.0.CO;2-O; Goggins M, 1998, CANCER RES, V58, P5329; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; GOODMAN SR, 1995, BRAIN RES BULL, V36, P593, DOI 10.1016/0361-9230(94)00264-2; Grady WM, 1999, CANCER RES, V59, P320; Gross CG, 2000, NAT REV NEUROSCI, V1, P67, DOI 10.1038/35036235; Halatsch ME, 2003, ANTICANCER RES, V23, P2315; Hammarlund M, 2000, J CELL BIOL, V149, P931, DOI 10.1083/jcb.149.4.931; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hayashi S, 2001, NEUROL MED-CHIR, V41, P187, DOI 10.2176/nmc.41.187; Hayes NVL, 2000, J CELL SCI, V113, P2023; Held-Feindt J, 2000, J PHYSIOLOGY-PARIS, V94, P251, DOI 10.1016/S0928-4257(00)00213-8; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; Hideshima T, 2003, BLOOD, V101, P1530, DOI 10.1182/blood-2002-08-2543; Hitoshi S, 2002, DEVELOPMENT, V129, P233; HORST HA, 1992, HUM PATHOL, V23, P1284, DOI 10.1016/0046-8177(92)90297-G; Hu XT, 2001, J HEMATOTH STEM CELL, V10, P67, DOI 10.1089/152581601750098255; HUMPHREY PA, 1991, BIOCHEM BIOPH RES CO, V178, P1413, DOI 10.1016/0006-291X(91)91051-D; Isoe S, 1998, J NEUROSURG, V88, P529, DOI 10.3171/jns.1998.88.3.0529; Izumoto S, 1997, CANCER LETT, V112, P251, DOI 10.1016/S0304-3835(96)04583-1; JENNINGS MT, 1991, INT J CANCER, V49, P129, DOI 10.1002/ijc.2910490124; JENNINGS MT, 1994, HUM PATHOL, V25, P464, DOI 10.1016/0046-8177(94)90118-X; Jennings MT, 1997, J NEURO-ONCOL, V31, P233, DOI 10.1023/A:1005767616500; JOHNSON MD, 1993, HUM PATHOL, V24, P457, DOI 10.1016/0046-8177(93)90156-B; Kawase Y, 2004, EXP CELL RES, V295, P194, DOI 10.1016/j.yexcr.2003.12.027; Kawauchi S, 2004, DEV NEUROSCI-BASEL, V26, P166, DOI 10.1159/000082135; Kim J, 2003, NEURON, V38, P17, DOI 10.1016/S0896-6273(03)00163-6; Kuan CT, 2001, ENDOCR-RELAT CANCER, V8, P83, DOI 10.1677/erc.0.0080083; Kumada T, 2004, DEV NEUROSCI-BASEL, V26, P68, DOI 10.1159/000080714; LEVINE J, 1981, J CELL BIOL, V90, P631, DOI 10.1083/jcb.90.3.631; LINDHOLM D, 1992, J CELL BIOL, V117, P395, DOI 10.1083/jcb.117.2.395; Lo LC, 2002, DEVELOPMENT, V129, P1553; Lopez-Coviella I, 2002, J PHYSIOLOGY-PARIS, V96, P53, DOI 10.1016/S0928-4257(01)00080-8; Mann KM, 2004, J CELL BIOL, V165, P483, DOI 10.1083/jcb.200402105; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MASSAGUE J, 1992, MOL REPROD DEV, V32, P99, DOI 10.1002/mrd.1080320204; Massague J, 1996, CANCER SURV, V27, P41; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Matsuura I, 2004, NATURE, V430, P226, DOI 10.1038/nature02650; Mentlein R, 2001, INT J CANCER, V92, P545, DOI 10.1002/ijc.1223; MERZAK A, 1994, BRIT J CANCER, V70, P199, DOI 10.1038/bjc.1994.280; Mishra L, 1999, ONCOGENE, V18, P353, DOI 10.1038/sj.onc.1202313; Mishra L, 1998, INT J DEV BIOL, V42, P221; MOON RT, 1987, BIOESSAYS, V7, P159, DOI 10.1002/bies.950070405; Moorthy S, 2000, J CELL BIOL, V149, P915, DOI 10.1083/jcb.149.4.915; Morrison SJ, 1997, CELL, V88, P287, DOI 10.1016/S0092-8674(00)81867-X; Moses HL, 1996, CURR OPIN GENET DEV, V6, P581, DOI 10.1016/S0959-437X(96)80087-6; Munoz-Sanjuan I, 2002, NAT REV NEUROSCI, V3, P271, DOI 10.1038/nrn786; MYEROFF LL, 1995, CANCER RES, V55, P5545; Nagai S, 2002, J NEUROSURG, V96, P909, DOI 10.3171/jns.2002.96.5.0909; NAKAGAWA T, 1987, P NATL ACAD SCI USA, V84, P5923, DOI 10.1073/pnas.84.16.5923; NELSON WJ, 1986, J CELL BIOL, V103, P1751, DOI 10.1083/jcb.103.5.1751; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; Okano-Uchida T, 2004, P NATL ACAD SCI USA, V101, P1211, DOI 10.1073/pnas.0307972100; Panchision DM, 2002, CURR OPIN GENET DEV, V12, P478, DOI 10.1016/S0959-437X(02)00329-5; Panchision DM, 2001, GENE DEV, V15, P2094, DOI 10.1101/gad.894701; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; PAULUS W, 1995, J NEUROPATH EXP NEUR, V54, P236, DOI 10.1097/00005072-199503000-00010; Peng Y, 2002, NEUROSCIENCE, V109, P657, DOI 10.1016/S0306-4522(01)00526-7; Pera MF, 2004, J CELL SCI, V117, P1269, DOI 10.1242/jcs.00970; PLATE KH, 1992, LAB INVEST, V67, P529; Rajan P, 2003, J CELL BIOL, V161, P911, DOI 10.1083/jcb.200211021; Reiss M, 1999, MICROBES INFECT, V1, P1327, DOI 10.1016/S1286-4579(99)00251-8; Reiss M, 1997, ONCOL RES, V9, P447; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; RIEDERER BM, 1986, J CELL BIOL, V102, P2088, DOI 10.1083/jcb.102.6.2088; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; SAMUELS V, 1989, AM J PATHOL, V134, P895; Schier AF, 2001, INT J DEV BIOL, V45, P289; Setoguchi T, 2004, EXP NEUROL, V189, P33, DOI 10.1016/j.expneurol.2003.12.007; Sieber-Blum M, 1997, J ANAT, V191, P493, DOI 10.1046/j.1469-7580.1997.19140493.x; Sihag RK, 1996, J NEUROSCI RES, V44, P430, DOI 10.1002/(SICI)1097-4547(19960601)44:5<430::AID-JNR3>3.0.CO;2-G; SIKORSKI AF, 1991, BRAIN RES BULL, V27, P195, DOI 10.1016/0361-9230(91)90067-T; Sikorski AF, 2000, BRAIN RES, V852, P161, DOI 10.1016/S0006-8993(99)02253-2; Sonntag KC, 2005, MOL CELL NEUROSCI, V28, P417, DOI 10.1016/j.mcn.2004.06.003; Sporn MB, 1999, MICROBES INFECT, V1, P1251, DOI 10.1016/S1286-4579(99)00260-9; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; Tang Y, 2003, SCIENCE, V299, P574, DOI 10.1126/science.1075994; Tang Y, 2002, ONCOGENE, V21, P5255, DOI 10.1038/sj.onc.1205548; Temple S, 2001, NAT REV NEUROSCI, V2, P513, DOI 10.1038/35081577; Tsai RYL, 2000, J NEUROSCI, V20, P3725, DOI 10.1523/JNEUROSCI.20-10-03725.2000; Tsai RYL, 2002, GENE DEV, V16, P2991, DOI 10.1101/gad.55671; Tsai RYL, 2002, DEV CELL, V2, P707, DOI 10.1016/S1534-5807(02)00195-8; Villanueva A, 1998, ONCOGENE, V17, P1969, DOI 10.1038/sj.onc.1202118; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Weissman IL, 2001, ANNU REV CELL DEV BI, V17, P387, DOI 10.1146/annurev.cellbio.17.1.387; Weller M, 1995, BRAIN RES REV, V21, P128, DOI 10.1016/0165-0173(95)00010-0; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Wurdak H, 2005, GENE DEV, V19, P530, DOI 10.1101/gad.317405; YAMADA N, 1995, INT J CANCER, V62, P386, DOI 10.1002/ijc.2910620405; Yang Y, 2004, CANCER SCI, V95, P176, DOI 10.1111/j.1349-7006.2004.tb03200.x; Yin D, 2005, ONCOGENE, V24, P344, DOI 10.1038/sj.onc.1208225; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523; Yung SY, 2002, P NATL ACAD SCI USA, V99, P16273, DOI 10.1073/pnas.232586699; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhou YX, 2003, J BIOL CHEM, V278, P42313, DOI 10.1074/jbc.M308287200; Ziemnicka-Kotula D, 1998, J BIOL CHEM, V273, P13681, DOI 10.1074/jbc.273.22.13681	129	69	73	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2005	24	37					5722	5730		10.1038/sj.onc.1208925	http://dx.doi.org/10.1038/sj.onc.1208925			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	958MQ	16123805				2022-12-17	WOS:000231452800007
J	Spinola, M; Galvan, A; Pignatiello, C; Conti, B; Pastorino, U; Nicander, B; Paroni, R; Dragani, TA				Spinola, M; Galvan, A; Pignatiello, C; Conti, B; Pastorino, U; Nicander, B; Paroni, R; Dragani, TA			Identification and functional characterization of the candidate tumor suppressor gene TRIT1 in human lung cancer	ONCOGENE			English	Article						lung cancer; disease models; tumor suppressor genes; nonsense suppressor	TRANSFER-RNA MODIFICATION; ESCHERICHIA-COLI K-12; SELENOCYSTEINE INCORPORATION; SELENOPROTEIN SYNTHESIS; MIAA GENE; ISOPENTENYLADENOSINE; TRANSLATION; ENZYME; MITOCHONDRIAL; ARABIDOPSIS	tRNA-isopentenyltransferase (tRNA-IPT) catalyses the addition of N-6-isopentenyladenosine (i(6)A) on residue 37 of tRNA molecules that bind codons starting with uridine. Post-transcriptional modifications of tRNA molecules have been demonstrated to be essential in maintaining the correct reading frame of the translational machinery, thus improving fidelity and efficiency of protein synthesis. We show here that the human tRNA-isopentenyltransferase (TRIT1) gene encodes a complex pattern of mRNA variants through alternative splicing in both normal and tumor lung tissue and that the nonsense suppressor activity of tRNA-IPT is maintained only in the full-length mRNA isoform, as revealed by gene complementation in yeast. Expression of the full-length transcript was down-regulated 6-14-fold in lung adenocarcinomas as compared to normal lung tissue. A549 lung cancer cells transfected to express the functional TRIT1 gene formed significantly smaller colonies with reduced scattering on the edges and had only limited ability to induce tumors in nude mice. Our findings raise the possibility of TRIT1 as a candidate lung tumor suppressor.	Ist Nazl Tumori, Dept Expt Oncol & Labs, I-20133 Milan, Italy; Ist Nazl Tumori, Dept Thorac Surg, I-20133 Milan, Italy; Swedish Univ Agr Sci, Dept Plant Biol, Uppsala, Sweden; Univ Milan, San Paolo Hosp, Dept Med Surg & Dent Sci, Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Swedish University of Agricultural Sciences; San Paolo-Polo Universitaria Hospital; University of Milan	Dragani, TA (corresponding author), Ist Nazl Tumori, Dept Expt Oncol & Labs, Via G Venezian 1, I-20133 Milan, Italy.	dragani@istitutotumori.mi.it	PARONI, RITA/C-2955-2012; Dragani, Tommaso A./K-4493-2016; Pastorino, Ugo/C-2712-2017; PARONI, RITA/AAC-6265-2020	PARONI, RITA/0000-0002-3186-8860; Dragani, Tommaso A./0000-0001-5915-4598; Pastorino, Ugo/0000-0001-9974-7902; PARONI, RITA/0000-0002-3186-8860				Berry MJ, 2001, BIOFACTORS, V14, P17, DOI 10.1002/biof.5520140104; Bjork GR, 1999, FEBS LETT, V452, P47, DOI 10.1016/S0014-5793(99)00528-1; Bjornsti MA, 2004, CANCER CELL, V5, P519, DOI 10.1016/j.ccr.2004.05.027; CAILLET J, 1988, J BACTERIOL, V170, P4147, DOI 10.1128/jb.170.9.4147-4152.1988; CONNOLLY DM, 1989, J BACTERIOL, V171, P3233, DOI 10.1128/jb.171.6.3233-3246.1989; DIAZ I, 1987, MOL GEN GENET, V208, P373, DOI 10.1007/BF00328126; DIHANICH ME, 1987, MOL CELL BIOL, V7, P177, DOI 10.1128/MCB.7.1.177; DIRHEIMER G, 1995, BIOCHIMIE, V77, P99, DOI 10.1016/0300-9084(96)88111-9; GEHRKE CW, 1982, J CHROMATOGR, V230, P297, DOI 10.1016/S0378-4347(00)80479-X; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; GILLMAN EC, 1991, MOL CELL BIOL, V11, P2382, DOI 10.1128/MCB.11.5.2382; Golovko A, 2000, GENE, V258, P85, DOI 10.1016/S0378-1119(00)00421-2; Lemieux J, 2001, GENETICS, V159, P147; Leung HCE, 1997, J BIOL CHEM, V272, P13073, DOI 10.1074/jbc.272.20.13073; Low SC, 1996, TRENDS BIOCHEM SCI, V21, P203, DOI 10.1016/S0968-0004(96)80016-8; MILLER CO, 1955, J AM CHEM SOC, V77, P1392, DOI 10.1021/ja01610a105; Mok MC., 1994, CYTOKININS CHEM ACTI, P155, DOI DOI 10.1201/9781351071284; Moustafa ME, 2001, MOL CELL BIOL, V21, P3840, DOI 10.1128/MCB.21.11.3840-3852.2001; PERSSON BC, 1993, MOL MICROBIOL, V8, P1011, DOI 10.1111/j.1365-2958.1993.tb01645.x; PERSSON BC, 1994, BIOCHIMIE, V76, P1152, DOI 10.1016/0300-9084(94)90044-2; Rozenski J, 1999, NUCLEIC ACIDS RES, V27, P196, DOI 10.1093/nar/27.1.196; Sakakibara H, 2002, J PLANT GROWTH REGUL, V21, P17, DOI 10.1007/s003440010043; Takei K, 2001, J BIOL CHEM, V276, P26405, DOI 10.1074/jbc.M102130200; Urbonavicius J, 2001, EMBO J, V20, P4863, DOI 10.1093/emboj/20.17.4863; Warner GJ, 2000, J BIOL CHEM, V275, P28110	25	69	73	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 18	2005	24	35					5502	5509		10.1038/sj.onc.1208687	http://dx.doi.org/10.1038/sj.onc.1208687			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	955JN	15870694				2022-12-17	WOS:000231222300010
J	Mambo, E; Chatterjee, A; de Souza-Pinto, NC; Mayard, S; Hogue, BA; Joque, MO; Dizdaroglu, M; Bohr, VA; Sidransky, D				Mambo, E; Chatterjee, A; de Souza-Pinto, NC; Mayard, S; Hogue, BA; Joque, MO; Dizdaroglu, M; Bohr, VA; Sidransky, D			Oxidized guanine lesions and hOgg1 activity in lung cancer	ONCOGENE			English	Article						hOGG1; lung cancer; 8-oxoG; mitochondria; DNA repair	OXIDATIVE DNA-DAMAGE; TRANSCRIPTION-COUPLED REPAIR; BASE EXCISION-REPAIR; ESCHERICHIA-COLI; MAMMALIAN-CELLS; NUCLEAR-DNA; P53 GENE; OGG1; MITOCHONDRIAL; 8-OXOGUANINE	In humans, the oxidatively induced DNA lesion 8-hydroxyguanine (8-oxoG) is removed from DNA by hOgg1, a DNA glycosylase/AP lyase that specifically incises 8-oxoG opposite cytosine. We analysed the expression of hOGG1 mRNA in 18 lung cancer and three normal cell lines. Although hOGG1 was overexpressed in most cell lines, 2/18 (11.1%) showed a lower hOGG1 mRNA and protein expression (similar to 80% decrease) relative to normal cell lines. Liquid chromatography/mass spectrometry analysis showed increased levels of 8-oxoG in the two cell lines with the lowest hOGG1 mRNA expression. We examined the ability of nuclear and mitochondrial extracts to incise 8-oxoG lesion in cell lines H1650 and H226 expressing lower hOGG1 mRNA and H1915 and H1975 with higher than normal hOGG1 mRNA expression. Both nuclear and mitochondrial extracts from H1915 and H1975 cells were proficient in 8-oxoG removal. However, both cell lines with the lowest hOGG1 mRNA expression exhibited a severe reduction in 8-oxoG incision in both nuclear and mitochondrial extracts. Under-expression of hOGG1 mRNA and hOgg1 protein was associated with a decrease in mitochondrial DNA repair in response to oxidative damaging agents. These results provide evidence for defective incision of 8-oxoG in both nuclear and mitochondria of H1650 and H226 lung cancer cell lines. These results may implicate 8-oxoG repair defects in certain lung cancers.	Johns Hopkins Univ, Sch Med, Head & Neck Canc Res Div, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA; NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; Natl Inst Stand & Technol, Chem Sci & Technol Lab, Gaithersburg, MD 20899 USA	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institute of Standards & Technology (NIST) - USA	Sidransky, D (corresponding author), Johns Hopkins Univ, Sch Med, Head & Neck Canc Res Div, Dept Otolaryngol Head & Neck Surg, 720 Rutland Ave,818 Ross Res Bldg, Baltimore, MD 21205 USA.	dsidrans@jhmi.edu	Souza-Pinto, Nadja C./C-3462-2013; Souza-Pinto, Nadja/T-3050-2019; Bohr, Vilhelm/AAP-5931-2020	Souza-Pinto, Nadja C./0000-0003-4206-964X; Souza-Pinto, Nadja/0000-0003-4206-964X; Hoque, Mohammad Obaidul/0000-0001-6701-9978	NCI NIH HHS [5 U01 CA084986-04, 5P50CA096784-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA084986, P50CA096784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000727, Z01AG000733, ZIAAG000727, ZIAAG000733] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Arai T, 2002, CARCINOGENESIS, V23, P2005, DOI 10.1093/carcin/23.12.2005; Audebert M, 2002, DNA REPAIR, V1, P497, DOI 10.1016/S1568-7864(02)00034-4; Audebert M, 2000, CANCER RES, V60, P4740; Ayala-Torres S, 2000, METHODS, V22, P135, DOI 10.1006/meth.2000.1054; Blons H, 1999, MOL CARCINOGEN, V26, P254; Bohr VA, 2002, GENE, V286, P127, DOI 10.1016/S0378-1119(01)00813-7; Boiteux S, 1999, BIOCHIMIE, V81, P59, DOI 10.1016/S0300-9084(99)80039-X; Cherng SH, 2002, J TOXICOL ENV HEAL A, V65, P265, DOI 10.1080/15287390252800855; Chevillard S, 1998, ONCOGENE, V16, P3083, DOI 10.1038/sj.onc.1202096; Croteau DL, 1997, J BIOL CHEM, V272, P27338, DOI 10.1074/jbc.272.43.27338; Dhenaut A, 2000, MUTAT RES-DNA REPAIR, V461, P109, DOI 10.1016/S0921-8777(00)00042-2; Dhenaut A, 2001, ADV EXP MED BIOL, V500, P613; Dherin C, 1999, NUCLEIC ACIDS RES, V27, P4001, DOI 10.1093/nar/27.20.4001; Dizdaroglu M, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.3.e12; Dobson AW, 2000, J BIOL CHEM, V275, P37518, DOI 10.1074/jbc.M000831200; Gunther T, 1997, J CANCER RES CLIN, V123, P388, DOI 10.1007/s004320050076; Hashiguchi K, 2004, NUCLEIC ACIDS RES, V32, P5596, DOI 10.1093/nar/gkh863; Hodges NJ, 2002, CARCINOGENESIS, V23, P55, DOI 10.1093/carcin/23.1.55; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; Hu YC, 2005, INT J CANCER, V114, P387, DOI 10.1002/ijc.20730; Hyun JW, 2000, ONCOGENE, V19, P4476, DOI 10.1038/sj.onc.1203787; JARUGA P, 1994, FEBS LETT, V341, P59, DOI 10.1016/0014-5793(94)80240-8; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; Kohno T, 1998, ONCOGENE, V16, P3219, DOI 10.1038/sj.onc.1201872; Kuraoka I, 2003, J BIOL CHEM, V278, P7294, DOI 10.1074/jbc.M208102200; Larsen E, 2004, DNA REPAIR, V3, P1457, DOI 10.1016/j.dnarep.2004.06.008; Le Page F, 2000, P NATL ACAD SCI USA, V97, P8397, DOI 10.1073/pnas.140137297; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; Lightowlers RN, 1997, TRENDS GENET, V13, P450, DOI 10.1016/S0168-9525(97)01266-3; Mambo E, 2003, P NATL ACAD SCI USA, V100, P1838, DOI 10.1073/pnas.0437910100; Mambo E, 2002, CANCER RES, V62, P1349; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; MICHAELS ML, 1991, NUCLEIC ACIDS RES, V19, P3629, DOI 10.1093/nar/19.13.3629; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Monden Y, 1999, BIOCHEM BIOPH RES CO, V258, P605, DOI 10.1006/bbrc.1999.0649; Nishioka K, 1999, MOL BIOL CELL, V10, P1637, DOI 10.1091/mbc.10.5.1637; OLINSKI R, 1992, FEBS LETT, V309, P193, DOI 10.1016/0014-5793(92)81093-2; Paz-Elizur T, 2003, J NATL CANCER I, V95, P1312, DOI 10.1093/jnci/djg033; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; Sakumi K, 2003, CANCER RES, V63, P902; Sava V, 2004, FREE RADICAL BIO MED, V36, P1144, DOI 10.1016/j.freeradbiomed.2004.01.019; Shinmura K, 2001, ANTIOXID REDOX SIGN, V3, P597, DOI 10.1089/15230860152542952; TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B; Takao M, 1998, NUCLEIC ACIDS RES, V26, P2917, DOI 10.1093/nar/26.12.2917; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; Thomas D, 1997, MOL GEN GENET, V254, P171, DOI 10.1007/s004380050405; Viswanathan A, 1998, J BIOL CHEM, V273, P21276, DOI 10.1074/jbc.273.33.21276; Vogel U, 2004, BIOCHEM GENET, V42, P453, DOI 10.1023/B:BIGI.0000043957.03420.7e; Wikman H, 2000, INT J CANCER, V88, P932, DOI 10.1002/1097-0215(20001215)88:6<932::AID-IJC15>3.0.CO;2-P; Xie YL, 2004, CANCER RES, V64, P3096, DOI 10.1158/0008-5472.CAN-03-3834; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514	51	69	72	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2005	24	28					4496	4508		10.1038/sj.onc.1208669	http://dx.doi.org/10.1038/sj.onc.1208669			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	940PT	15856018				2022-12-17	WOS:000230157100003
J	Guo, Y; Yang, K; Harwalkar, J; Nye, JM; Mason, DR; Garrett, MD; Hitomi, M; Stacey, DW				Guo, Y; Yang, K; Harwalkar, J; Nye, JM; Mason, DR; Garrett, MD; Hitomi, M; Stacey, DW			Phosphorylation of cyclin D1 at Thr 286 during S phase leads to its proteasomal degradation and allows efficient DNA synthesis	ONCOGENE			English	Article						cyclin D1; proliferative signaling; cell cycle; S phase; proliferation	CELL-CYCLE PROGRESSION; SYNTHASE KINASE 3-BETA; NUCLEAR-PROTEIN; D1; BINDING; RAS; EXPRESSION; GROWTH; PROLIFERATION; P27(KIP1)	Continuing proliferation requires regulation of cyclin D1 levels in each cell cycle phase. Growth factors stimulate high levels during G2 phase, which commits the cell to continue through G1 phase with sufficient cyclin D1 to initiate DNA synthesis. Upon entry into S phase, however, cyclin D1 levels rapidly decline. Our goal is to understand the mechanism and importance of this S-phase suppression. Here, we demonstrate that cyclin D1 levels decline during S phase due to reduced protein stability, without alterations in the rate of protein synthesis. This decline depends upon Thr 286, since mutation of this site eliminates the normal pattern of cyclin D1 suppression during S phase. As evidence that phosphorylation of Thr 286 is responsible for this decline, Thr 286 is shown to be more efficiently phosphorylated during S phase than in other cell cycle periods. Finally, high cyclin D1 levels during S phase are shown to inhibit DNA synthesis. This inhibitory activity presumably blocks the growth of cells with altered cyclin D1 expression characteristics. Abnormal stimulation of cyclin D1 might result in levels high enough to promote G1/S phase transition even in the absence of appropriate growth stimuli. In such cells, however, the levels of cyclin D1 would presumably be too high to be suppressed during S phase, resulting in the inhibition of DNA synthesis.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Genet, Cleveland, OH 44195 USA; Inst Canc Res, Haddow Labs, Canc Res UK, Ctr Canc Therapeut, Sutton SM2 5NG, Surrey, England	Cleveland Clinic Foundation; Cancer Research UK; University of London; Institute of Cancer Research - UK	Stacey, DW (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Genet, NC2-151,9500 Euclid Ave, Cleveland, OH 44195 USA.	Staceyd@ccf.org		Mason, David/0000-0001-5122-0538	NCI NIH HHS [CA9219] Funding Source: Medline; NIGMS NIH HHS [GM52271] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; ATADJA P, 1995, EXP CELL RES, V217, P205, DOI 10.1006/excr.1995.1080; Bagui TK, 2003, MOL CELL BIOL, V23, P7285, DOI 10.1128/MCB.23.20.7285-7290.2003; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Fukami-Kobayashi J, 1999, EXP CELL RES, V246, P338, DOI 10.1006/excr.1998.4306; Guo Y, 2002, ONCOGENE, V21, P7545, DOI 10.1038/sj.onc.1205907; Han EKH, 1996, CELL GROWTH DIFFER, V7, P699; Hitomi M, 1999, MOL CELL BIOL, V19, P4623; Hitomi M, 1999, CURR BIOL, V9, P1075, DOI 10.1016/S0960-9822(99)80476-X; Kelly BL, 1998, P NATL ACAD SCI USA, V95, P2535, DOI 10.1073/pnas.95.5.2535; LUKAS J, 1994, ONCOGENE, V9, P707; MATSUOKA S, 1994, J BIOL CHEM, V269, P11030; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; Sa G, 2004, EXP CELL RES, V300, P427, DOI 10.1016/j.yexcr.2004.07.032; Sa G, 2002, CELL CYCLE, V1, P50, DOI 10.4161/cc.1.1.100; Scovassi AI, 1997, EXP CELL RES, V237, P127, DOI 10.1006/excr.1997.3770; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Solomon DA, 2003, J BIOL CHEM, V278, P30339, DOI 10.1074/jbc.M303969200; Stacey DW, 2003, CURR OPIN CELL BIOL, V15, P158, DOI 10.1016/S0955-0674(03)00008-5; WOODGETT JR, 2001, SCI STKE, pRE12; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	27	69	69	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2005	24	16					2599	2612		10.1038/sj.onc.1208326	http://dx.doi.org/10.1038/sj.onc.1208326			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15735756				2022-12-17	WOS:000228356700002
J	Ji, P; Agrawal, S; Diederichs, S; Baumer, N; Becker, A; Cauvet, T; Kowski, S; Beger, C; Welte, K; Berdel, WE; Serve, H; Muller-Tidow, C				Ji, P; Agrawal, S; Diederichs, S; Baumer, N; Becker, A; Cauvet, T; Kowski, S; Beger, C; Welte, K; Berdel, WE; Serve, H; Muller-Tidow, C			Cyclin A1, the alternative A-type cyclin, contributes to G1/S cell cycle progression in somatic cells	ONCOGENE			English	Article						cyclin A1; leukemia; cell cycle; siRNA	ACUTE MYELOID-LEUKEMIA; HEMATOPOIETIC-CELLS; MICE; PROTEINS; MOUSE; EXPRESSION; MEIOSIS; FAMILY; E2F	Cyclin A1 is an alternative A-type cyclin that is essential for spermatogenesis, but it is also expressed in hematopoietic progenitor cells and in acute myeloid leukemia. Its functions during cell cycle progression of somatic cells are incompletely understood. Here, we have analysed the cell cycle functions of cyclin A1 in transformed and non-transformed cells. Murine embryonic fibroblasts derived from cyclin A1-deficient mice were significantly impaired in their proliferative capacity. In accordance, cyclin A1(-/-) cells accumulated in G1 and G2/M phase while the percentage of S phase cells decreased. Also, lectin stimulated splenic lymphocytes from cyclin A1(-/-) mice proliferated slower than their wild-type counterparts. Forced cyclin A1 overexpression in NIH3T3 cells and in U937 leukemic cells either by transient transfection or by retroviral infection enhanced S phase entry. Consequently, siRNA mediated silencing of cyclin A1 in highly cyclin A1 expressing ML1 leukemic cells significantly slowed S phase entry, decreased proliferation and inhibited colony formation. Taken together, these analyses demonstrate that cyclin A1 contributes to G1 to S cell cycle progression in somatic cells. Cyclin A1 overexpression enhances S phase entry consistent with an oncogenic function. Finally, cyclin A1 might be a therapeutic target since its silencing inhibited leukemia cell growth.	Univ Munster, Dept Med, D-48149 Munster, Germany; MHH Hannover, Dept Pediat Hematol & Oncol, D-30625 Hannover, Germany	University of Munster; Hannover Medical School	Muller-Tidow, C (corresponding author), Univ Munster, Dept Med, Domagkstr 3, D-48149 Munster, Germany.	muellerc@uni-muenster.de	Müller-Tidow, Carsten CMT/B-5257-2014; Müller-Tidow, Carsten/O-7207-2018; Diederichs, Sven/J-6237-2012	Müller-Tidow, Carsten/0000-0002-7166-5232; Diederichs, Sven/0000-0001-7901-4752				Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Coletta RD, 2004, P NATL ACAD SCI USA, V101, P6478, DOI 10.1073/pnas.0401139101; Diederichs S, 2004, J BIOL CHEM, V279, P33727, DOI 10.1074/jbc.M401708200; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Knudson AG, 2002, AM J MED GENET, V111, P96, DOI 10.1002/ajmg.10320; Lania L, 1999, J CELL PHYSIOL, V179, P134, DOI 10.1002/(SICI)1097-4652(199905)179:2<134::AID-JCP3>3.0.CO;2-O; Liao C, 2001, P NATL ACAD SCI USA, V98, P6853, DOI 10.1073/pnas.121540098; Liu D, 1998, NAT GENET, V20, P377, DOI 10.1038/3855; Muller C, 2000, BLOOD, V96, P3894, DOI 10.1182/blood.V96.12.3894.h8003894_3894_3899; Muller-Tidow C, 2004, MOL CELL BIOL, V24, P2890, DOI 10.1128/MCB.24.7.2890-2904.2004; Muller-Tidow C, 2001, BLOOD, V97, P2091, DOI 10.1182/blood.V97.7.2091; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Parisi T, 2003, EMBO J, V22, P4794, DOI 10.1093/emboj/cdg482; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Sweeney C, 1996, DEVELOPMENT, V122, P53; van der Meer T, 2004, REPRODUCTION, V127, P503, DOI 10.1530/rep.1.00131; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Yang R, 1999, MOL CELL BIOL, V19, P2400; Yang R, 1997, CANCER RES, V57, P913; Yang R, 1999, BLOOD, V93, P2067	22	69	74	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2005	24	16					2739	2744		10.1038/sj.onc.1208356	http://dx.doi.org/10.1038/sj.onc.1208356			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15829981				2022-12-17	WOS:000228356700016
J	Scholz, C; Wieder, T; Starck, L; Essmann, F; Schulze-Osthoff, K; Dorken, B; Daniel, PT				Scholz, C; Wieder, T; Starck, L; Essmann, F; Schulze-Osthoff, K; Dorken, B; Daniel, PT			Arsenic trioxide triggers a regulated form of caspase-independent necrotic cell death via the mitochondrial death pathway	ONCOGENE			English	Article						arsenic trioxide; caspase-independence; ATP; mitochondria; necrosis	ACUTE PROMYELOCYTIC LEUKEMIA; DRUG-INDUCED APOPTOSIS; DAMAGE-INDUCED APOPTOSIS; HUMAN CARCINOMA-CELLS; CYTOCHROME-C; IDENTIFIES PATIENTS; AMPLIFICATION LOOP; GROWTH-INHIBITION; DEPENDENT PATHWAY; MALIGNANT-CELLS	Cell death is generally believed to occur either by accidental, lytic necrosis or by programmed cell death, that is, apoptosis. The initiation and execution of cell death, however, is far more complex and includes pathways like caspase-independent apoptosis or actively triggered necrosis. In this study, we investigated the mechanisms of cell death induced by arsenic trioxide ( arsenite, As2O3), a clinically efficient agent in anticancer therapy. As2O3-induced cell death coincides with cytochrome c release, facilitates mitochondrial permeability transition and is sensitive to inhibition by Bcl-x(L), indicating that cell demise is regulated through the mitochondrial apoptosis pathway. Nevertheless, only little caspase-3 activation was observed and As2O3-induced cell death was only weakly obstructed by the broad spectrum caspase inhibitor z-VAD-fmk. Moreover, disruption of caspase-9 or -2 failed to decrease the amount of As2O3-mediated cell death. Interestingly, As2O3-induced cell death had a predominantly necrosis-like phenotype as assessed by Annexin-V/propidium iodide staining and LDH release. Finally, blocking glutathione synthetase by buthionine sulfoximine enhanced the As2O3-mediated necrosis-like cell death without increasing caspase-3 cleavage. As2O3 does, however, not directly inhibit caspases, but appears to interfere with caspase activation. Altogether, our data clearly delineate a mode of As2O3-triggered cell death that differs considerably from that induced by conventional anticancer drugs. These findings may explain the capability of As2O3 to efficiently kill even chemoresistant tumor cells with disturbed apoptosis signaling and caspase activation, a frequent finding in malignancy.	Humboldt Univ, Charite, Dept Hematol Oncol & Tumor Immunol, Robert Rossle Klin, D-13353 Berlin, Germany; Univ Dusseldorf, Inst Mol Med, D-4000 Dusseldorf, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Heinrich Heine University Dusseldorf	Daniel, PT (corresponding author), Humboldt Univ, Charite, Dept Hematol Oncol & Tumor Immunol, Robert Rossle Klin, Campus Virchow Klinikum,Augustenburger Pl 1, D-13353 Berlin, Germany.	pdaniel@mdc-berlin.de	Essmann, Frank/ABG-7409-2020; Schulze-Osthoff, Klaus/N-9025-2013; Scholz, Christian W/Q-2778-2017	Essmann, Frank/0000-0003-4369-8456; Schulze-Osthoff, Klaus/0000-0003-1443-2720; Scholz, Christian W/0000-0001-6260-4086				Akao Y, 1998, BRIT J HAEMATOL, V102, P1055, DOI 10.1046/j.1365-2141.1998.00869.x; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Blagosklonny MV, 2000, LEUKEMIA, V14, P1502, DOI 10.1038/sj.leu.2401864; Bosanquet AG, 2002, LEUKEMIA, V16, P1035, DOI 10.1038/sj.leu.2402539; Chen YC, 1998, J CELL PHYSIOL, V177, P324, DOI 10.1002/(SICI)1097-4652(199811)177:2<324::AID-JCP14>3.0.CO;2-9; Dai J, 1999, BLOOD, V93, P268, DOI 10.1182/blood.V93.1.268.401a21_268_277; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; Daniel PT, 1998, BLOOD, V92, P4750, DOI 10.1182/blood.V92.12.4750.424k34_4750_4757; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; DHEIN J, 1992, J IMMUNOL, V149, P3166; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; FERNANDES RS, 1994, BIOCHEM PHARMACOL, V48, P675, DOI 10.1016/0006-2952(94)90044-2; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; Friedrich K, 2001, ONCOGENE, V20, P2749, DOI 10.1038/sj.onc.1204342; Fulda S, 2001, ONCOGENE, V20, P1063, DOI 10.1038/sj.onc.1204141; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Gottlieb E, 2000, MOL CELL BIOL, V20, P5680, DOI 10.1128/MCB.20.15.5680-5689.2000; Guner D, 2003, INT J CANCER, V103, P445, DOI 10.1002/ijc.10850; Hasenjager A, 2004, ONCOGENE, V23, P4523, DOI 10.1038/sj.onc.1207594; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Hu YM, 1999, EMBO J, V18, P3586, DOI 10.1093/emboj/18.13.3586; Jing YK, 1999, BLOOD, V94, P2102, DOI 10.1182/blood.V94.6.2102; Kitamura K, 2000, LEUKEMIA, V14, P1743, DOI 10.1038/sj.leu.2401900; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; LANOTTE M, 1991, BLOOD, V77, P1080; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Mrozek A, 2003, CELL DEATH DIFFER, V10, P461, DOI 10.1038/sj.cdd.4401193; Niu C, 1999, BLOOD, V94, P3315, DOI 10.1182/blood.V94.10.3315.422k16_3315_3324; Norbury CJ, 2004, ONCOGENE, V23, P2797, DOI 10.1038/sj.onc.1207532; Perkins C, 2000, BLOOD, V95, P1014, DOI 10.1182/blood.V95.3.1014.003k04_1014_1022; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Prokop A, 2003, ONCOGENE, V22, P9107, DOI 10.1038/sj.onc.1207196; Prokop A, 2000, LEUKEMIA, V14, P1606, DOI 10.1038/sj.leu.2401866; Radetzki S, 2002, ONCOGENE, V21, P227, DOI 10.1038/sj/onc/1205010; Reers M, 1995, METHOD ENZYMOL, V260, P406, DOI 10.1016/0076-6879(95)60154-6; Robertson JD, 2004, EMBO REP, V5, P643, DOI 10.1038/sj.embor.7400153; Rudner J, 2001, J CELL SCI, V114, P4161; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Schelwies K, 2002, INT J CANCER, V99, P589, DOI 10.1002/ijc.10380; Schmelz K, 2004, ONCOGENE, V23, P6743, DOI 10.1038/sj.onc.1207848; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Sturm I, 2001, J CLIN ONCOL, V19, P2272, DOI 10.1200/JCO.2001.19.8.2272; Troy CM, 2003, CELL DEATH DIFFER, V10, P101, DOI 10.1038/sj.cdd.4401175; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; Vander Heiden MG, 2000, P NATL ACAD SCI USA, V97, P4666, DOI 10.1073/pnas.090082297; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Wang TS, 1996, J CELL PHYSIOL, V169, P256, DOI 10.1002/(SICI)1097-4652(199611)169:2<256::AID-JCP5>3.0.CO;2-N; Wang ZG, 1998, BLOOD, V92, P1497, DOI 10.1182/blood.V92.5.1497.417k41_1497_1504; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yang CH, 1999, BRIT J CANCER, V81, P796, DOI 10.1038/sj.bjc.6690766; Zhang W, 1998, LEUKEMIA, V12, P1383, DOI 10.1038/sj.leu.2401112; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978; Zhu XH, 1999, J NATL CANCER I, V91, P772, DOI 10.1093/jnci/91.9.772; Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	62	69	73	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2005	24	11					1904	1913		10.1038/sj.onc.1208233	http://dx.doi.org/10.1038/sj.onc.1208233			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	905BH	15674346				2022-12-17	WOS:000227542000009
J	Abdel-Rahman, WM; Ollikainen, M; Kariola, R; Jarvinen, HJ; Mecklin, JP; Nystrom-Lahti, M; Knuutila, S; Peltomaki, P				Abdel-Rahman, WM; Ollikainen, M; Kariola, R; Jarvinen, HJ; Mecklin, JP; Nystrom-Lahti, M; Knuutila, S; Peltomaki, P			Comprehensive characterization of HNPCC-related colorectal cancers reveals striking molecular features in families with no germline mismatch repair gene mutations	ONCOGENE			English	Article						HNPCC; colorectal cancer; mismatch repair; beta-catenin; CGH; p53; KRAS; CDX2; LOH	NONPOLYPOSIS COLON-CANCER; BETA-CATENIN; MICROSATELLITE INSTABILITY; INSTITUTE WORKSHOP; CDX2 EXPRESSION; APC MUTATIONS; ALLELIC LOSS; CARCINOMAS; TUMORS; DNA	A considerable fraction of families with HNPCC shows no germline mismatch repair (MMR) gene mutations. We previously detected 'hidden' MMR gene defects in 42% of such families, leaving the remaining 58% 'truly' mutation negative. Here, we characterized 50 colorectal carcinomas and five adenomas arising in HNPCC families; 24 truly MMR gene mutation negative and 31 MMR gene mutation positive. Among 31 tumors from MMR gene mutation positive families, 25 (81%) had active Wnt signaling as indicated by aberrant beta-catenin localization with or without CTNNB1 mutations, compared to only 7/18 tumors from MMR gene mutation negative families (39%; P = 0.005). CGH studies revealed stable profiles in 9/16 (56%) of MMR gene mutation negative tumors, which was significantly associated with membranous beta-catenin (P = 0.005). Tumors with membranous beta-catenin from the MMR gene mutation negative group also showed low frequency of TP53 mutations compared to those with nuclear beta-catenin. Thus, a majority of the MMR gene mutation negative cases exhibited a novel molecular pattern characterized by the paucity of changes in common pathways to colorectal carcinogenesis. This feature distinguishes the MMR gene mutation negative families from both HNPCC families linked to MMR defects and sporadic cases, suggesting the involvement of novel predisposition genes and pathways in such families.	Univ Helsinki, Dept Med Genet, Biomed Helsinki, Helsinki 00014, Finland; Zagazig Univ, Dept Pathol, Fac Med, Zagazig, Egypt; Univ Helsinki, Dept Biol & Environm Sci, Helsinki, Finland; Helsinki Univ Hosp, Dept Clin Genet, Helsinki, Finland; Helsinki Univ Hosp, Dept Surg 2, Helsinki, Finland; Jyvaskyla Cent Hosp, Dept Surg, Jyvaskyla, Finland; Haartman Inst, Dept Pathol, Lab Cytomol Genet, Helsinki, Finland; Univ Helsinki, HUSLAB, Helsinki, Finland; Univ Helsinki, Cent Hosp, Helsinki, Finland	University of Helsinki; Egyptian Knowledge Bank (EKB); Zagazig University; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; Central Finland Central Hospital; University of Helsinki; University of Helsinki; Helsinki University Central Hospital	Abdel-Rahman, WM (corresponding author), Univ Helsinki, Dept Med Genet, Biomed Helsinki, POB 63 Haartmaninkatu 8, Helsinki 00014, Finland.	Wael.Abdel-Rahman@helsinki.fi	Mecklin, Jukka-Pekka/AAB-5378-2020; Mecklin, Jukka-Pekka/AAC-9650-2019; Ollikainen, Miina E/K-7464-2012	Mecklin, Jukka-Pekka/0000-0003-4895-2249; Ollikainen, Miina E/0000-0003-3661-7400; Abdel-Rahman, Wael/0000-0002-2149-1043; Peltomaki, Paivi/0000-0001-8819-2980; Nystrom, Minna/0000-0003-0827-0243				Abdel-Rahman WM, 2001, P NATL ACAD SCI USA, V98, P2538, DOI 10.1073/pnas.041603298; Boland CR, 1998, CANCER RES, V58, P5248; Chan TL, 2001, ONCOGENE, V20, P4871, DOI 10.1038/sj.onc.1204653; COSTA A, 1995, J PATHOL, V176, P45, DOI 10.1002/path.1711760108; Curtis LJ, 2000, J PATHOL, V192, P440; da Costa LT, 1999, ONCOGENE, V18, P5010, DOI 10.1038/sj.onc.1202872; Deng GR, 2004, CLIN CANCER RES, V10, P191, DOI 10.1158/1078-0432.CCR-1118-3; El-Rifai W, 1997, LAB INVEST, V77, P699; Fujiwara T, 1998, AM J PATHOL, V153, P1063, DOI 10.1016/S0002-9440(10)65651-9; Hao XP, 2002, VIRCHOWS ARCH, V440, P362, DOI 10.1007/s00428-001-0570-0; Hinoi T, 2001, AM J PATHOL, V159, P2239, DOI 10.1016/S0002-9440(10)63074-X; Hinoi T, 2003, J BIOL CHEM, V278, P44608, DOI 10.1074/jbc.M307435200; Holmberg M, 1998, Hum Mutat, V11, P482; Huang J, 1996, P NATL ACAD SCI USA, V93, P9049, DOI 10.1073/pnas.93.17.9049; Huang JQ, 2001, CANCER RES, V61, P1619; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Iwamoto M, 2000, CARCINOGENESIS, V21, P1935, DOI 10.1093/carcin/21.11.1935; KARIOLA R, IN PRESS FAM CANC; KIM HG, 1994, AM J PATHOL, V145, P148; Kitaeva MN, 1997, CANCER RES, V57, P4478; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; Kuismanen SA, 2002, AM J PATHOL, V160, P1953, DOI 10.1016/S0002-9440(10)61144-3; Kumar R, 2003, ONCOGENE, V22, P9217, DOI 10.1038/sj.onc.1206909; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Leslie A, 2003, CANCER RES, V63, P4656; Liu T, 2001, CANCER RES, V61, P7798; Lovig T, 2002, SCAND J GASTROENTERO, V37, P1184, DOI 10.1080/003655202760373407; Mirabelli-Primdahl L, 1999, CANCER RES, V59, P3346; Miyaki M, 1999, CANCER RES, V59, P4506; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MULERIS M, 1995, GENE CHROMOSOME CANC, V14, P223, DOI 10.1002/gcc.2870140312; NYSTROMLAHTI M, 1995, NAT MED, V1, P1203, DOI 10.1038/nm1195-1203; NystromLahti M, 1996, HUM MOL GENET, V5, P763, DOI 10.1093/hmg/5.6.763; Oliveira C, 2003, ONCOGENE, V22, P9192, DOI 10.1038/sj.onc.1207061; Peltomaki P, 2003, J CLIN ONCOL, V21, P1174, DOI 10.1200/JCO.2003.04.060; Qualtrough D, 2002, GUT, V51, P184, DOI 10.1136/gut.51.2.184; Renkonen E, 2003, J CLIN ONCOL, V21, P3629, DOI 10.1200/JCO.2003.03.181; RodriguezBigas MA, 1997, J NATL CANCER I, V89, P1758, DOI 10.1093/jnci/89.23.1758; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Salahshor S, 1999, GENE CHROMOSOME CANC, V26, P247, DOI 10.1002/(SICI)1098-2264(199911)26:3<247::AID-GCC9>3.3.CO;2-8; SCHLEGEL J, 1995, CANCER RES, V55, P6002; Schweizer P, 2001, CANCER RES, V61, P2813; Sparks AB, 1998, CANCER RES, V58, P1130; Vasen HFA, 1999, GASTROENTEROLOGY, V116, P1453, DOI 10.1016/S0016-5085(99)70510-X; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wicking C, 1998, ONCOGENE, V17, P657, DOI 10.1038/sj.onc.1201971; Wijnen J, 1997, AM J HUM GENET, V61, P329, DOI 10.1086/514847; Yagi OK, 1999, BRIT J CANCER, V79, P440, DOI 10.1038/sj.bjc.6690068	49	69	77	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2005	24	9					1542	1551		10.1038/sj.onc.1208387	http://dx.doi.org/10.1038/sj.onc.1208387			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15674332				2022-12-17	WOS:000227218200007
J	Tanami, H; Imoto, I; Hirasawa, A; Yuki, Y; Sonoda, I; Inoue, J; Yasui, K; Misawa-Furihata, A; Kawakami, Y; Inazawa, J				Tanami, H; Imoto, I; Hirasawa, A; Yuki, Y; Sonoda, I; Inoue, J; Yasui, K; Misawa-Furihata, A; Kawakami, Y; Inazawa, J			Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines	ONCOGENE			English	Article						malignant melanoma; BRAF; mutation; gene amplification; comparative genomic hybridization	COMPARATIVE GENOMIC HYBRIDIZATION; B-RAF; CUTANEOUS MELANOMAS; POTENTIAL TARGET; MUTATIONS; AMPLIFICATION; CANCER; IDENTIFICATION; ACTIVATION; PATHWAY	Comparative genomic hybridization (CGH) using 40 cell lines derived from malignant melanomas (MMs) revealed frequent amplification at 7q33-q34 containing BRAF gene, which often is mutated in MM. We found this gene to be amplified to a remarkable degree in the MM cell lines that exhibited high-level gains at 7q33-q34 in CGH. Among 40 cell lines, the eight lines that revealed neither BRAF nor NRAS mutations showed even higher levels of BRAF mRNA expression than the 32 mutated lines, although DNA amplification at 7q33-q34 was not detected in every lines overexpressing BRAF. MM cells that carried wild-type BRAF and NRAS showed constitutive overexpression of B-Raf protein and phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2), even after serum starvation. Not only downregulation of the endogenously overexpressed wild-type B-Raf by antisense oligonucleotide but also a treatment with an inhibitor of mitogen-activated protein kinase kinase (MAPKK, MEK) reduced phosphorylated ERK1/2 and cell growth, whereas the exogenously expressed wild-type B-Raf promoted cell growth in MM cells. Our results provide the evidence that overexpression of wild-type B-Raf, in part but not always as a result of gene amplification, is one of the mechanisms underlying constitutive activation of the MAPK pathway that stimulates growth of MM cells.	Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Bunkyo Ku, Tokyo 1138510, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Saitama, Japan; Keio Univ, Sch Med, Inst Adv Med Res, Div Cellular Signaling, Tokyo, Japan	Tokyo Medical & Dental University (TMDU); Japan Science & Technology Agency (JST); Keio University	Inazawa, J (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	johinaz.cgen@mri.tmd.ac.jp	imoto, Issei/D-8065-2012; Imoto, Issei/AAD-5799-2020; Kawakami, Yutaka/E-7429-2013	Kawakami, Yutaka/0000-0003-4836-2855; Imoto, Issei/0000-0002-4150-7938				Ariyama Y, 1998, J HUM GENET, V43, P187, DOI 10.1007/s100380050067; Balazs M, 2001, CYTOMETRY, V46, P222, DOI 10.1002/cyto.1131; Bastian BC, 1998, CANCER RES, V58, P2170; Brose MS, 2002, CANCER RES, V62, P6997; Calipel A, 2003, J BIOL CHEM, V278, P42409, DOI 10.1074/jbc.M308709200; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Chong H, 2003, CELL SIGNAL, V15, P463, DOI 10.1016/S0898-6568(02)00139-0; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Edmunds SC, 2003, BRIT J CANCER, V88, P1403, DOI 10.1038/sj.bjc.6600919; Fukuda Y, 2000, GENE CHROMOSOME CANC, V29, P315, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1047>3.0.CO;2-E; Herlyn M, 2000, MELANOMA RES, V10, P303, DOI 10.1097/00008390-200008000-00001; Hoa M, 2002, CANCER RES, V62, P7154; Imoto I, 2003, CANCER RES, V63, P5691; Imoto I, 2001, CANCER RES, V61, P6629; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; KUKITA A, 1989, Journal of Investigative Dermatology, V92, p210S, DOI 10.1111/1523-1747.ep13075564; Kumar R, 2003, ONCOGENE, V22, P9217, DOI 10.1038/sj.onc.1206909; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Metzelaar-Blok JAW, 1999, HUM IMMUNOL, V60, P962, DOI 10.1016/S0198-8859(99)00067-1; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Roelofs H, 2000, AM J PATHOL, V157, P1155, DOI 10.1016/S0002-9440(10)64631-7; Saito-Ohara F, 2003, CANCER RES, V63, P1876; Satyamoorthy K, 2003, CANCER RES, V63, P756; Sauter ER, 1998, MOL CARCINOGEN, V23, P132, DOI 10.1002/(SICI)1098-2744(199811)23:3<132::AID-MC2>3.0.CO;2-1; Sauter ER, 2002, CANCER RES, V62, P3200; Smalley KSM, 2003, INT J CANCER, V104, P527, DOI 10.1002/ijc.10978; Sonoda I, 2004, CANCER RES, V64, P3741, DOI 10.1158/0008-5472.CAN-04-0172; Tuveson DA, 2003, CANCER CELL, V4, P95, DOI 10.1016/S1535-6108(03)00189-2; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Yasui K, 2002, HEPATOLOGY, V35, P1476, DOI 10.1053/jhep.2002.33683	32	69	72	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2004	23	54					8796	8804		10.1038/sj.onc.1208152	http://dx.doi.org/10.1038/sj.onc.1208152			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ	15467732				2022-12-17	WOS:000225165100009
J	von Haefen, C; Gillissen, B; Hemmati, PG; Wendt, J; Guner, D; Mrozek, A; Belka, C; Dorken, B; Daniel, PT				von Haefen, C; Gillissen, B; Hemmati, PG; Wendt, J; Guner, D; Mrozek, A; Belka, C; Dorken, B; Daniel, PT			Multidomain Bcl-2 homolog Bax but not Bak mediates synergistic induction of apoptosis by TRAIL and 5-FU through the mitochondrial apoptosis pathway	ONCOGENE			English	Article						TRAIL; Bax; Bak; apoptosis; mitochondrial pathway; synergy	NEGATIVE PROGNOSTIC-FACTOR; DEATH LIGAND; CELL-DEATH; PROTEIN EXPRESSION; ANTITUMOR-ACTIVITY; OLIGOMERIZES BAK; BREAST-CANCER; ACTIVATION; RESISTANCE; CARCINOMA	The death ligand TRAIL synergizes with DNA-damaging therapies such as chemotherapeutic drugs or ionizing irradiation. Here, we show that the synergism of TRAIL and 5-fluorouracil (5-FU) and cross-sensitization between TRAIL and 5-FU for induction of apoptosis, entirely depend on Bax proficiency in human DU145 and HCT116 carcinoma cells. DU145 prostate carcinoma cells that have lost Bax protein expression due to mutation fail to release cytochrome c and to activate caspase-3 and -9 when exposed to TRAIL and 5-FU. In contrast, TRAIL sensitized for 5-FU-induced apoptosis and vice versa upon reconstitution of Bax expression. Isobolographic analyses of ED50 doses for 5-FU at increasing TRAIL concentrations showed a clear synergism of TRAIL and 5-FU in Bax-expressing cells. In contrast, the effect was merely additive in DU145 cells lacking Bax. Notably, both DU145 and HCT116 Bax-deficient cells still express Bak. This indicates that Bak is not sufficient to mediate cross-sensitization and synergism between 5-FU and TRAIL. Stable overexpression of Bak in DU145 sensitized for epirubicin-induced apoptosis but failed to confer synergy between TRAIL and 5-FU. Moreover, we show by the use of EGFP-tagged Bax and Bak that TRAIL and 5-FU synergistically trigger oligomerization and clustering of Bax but not Bak. These data clearly establish distinct roles for Bax and Bak in linking the TRAIL death receptor pathway to the mitochondrial apoptosis signaling cascade and delineate a higher degree of specificity in signaling for cell death by multidomain Bcl-2 homologs.	Humboldt Univ, Univ Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, Berlin, Germany; Univ Tubingen, Fac Med, Dept Radiat Oncol, Tubingen, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Daniel, PT (corresponding author), Charite Campus Berlin Buch,Lindenberger Weg 80, D-13125 Berlin, Germany.	pdaniel@mdc-berlin.de		Gillissen, Bernhard/0000-0002-1815-2091				Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Bonavida B, 1999, INT J ONCOL, V15, P793; Bosanquet AG, 2002, LEUKEMIA, V16, P1035, DOI 10.1038/sj.leu.2402539; Cartron PF, 2003, MOL CELL BIOL, V23, P4701, DOI 10.1128/MCB.23.13.4701-4712.2003; Chandra D, 2004, MOL CELL BIOL, V24, P6592, DOI 10.1128/mcb.24.15.6592-6607.2004; CONEY LR, 1994, INT J CANCER, V58, P562, DOI 10.1002/ijc.2910580419; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; DHEIN J, 1992, J IMMUNOL, V149, P3166; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Gessner PK, 1995, TOXICOLOGY, V105, P161, DOI 10.1016/0300-483X(95)03210-7; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Gliniak B, 1999, CANCER RES, V59, P6153; Guner D, 2003, INT J CANCER, V103, P445, DOI 10.1002/ijc.10850; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Johnson TR, 2003, ONCOGENE, V22, P4953, DOI 10.1038/sj.onc.1206656; JSCHMELZ K, 2004, ONCOGENE, DOI DOI 10.1038/SJ.ONC1207848; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Leverkus M, 2000, CANCER RES, V60, P553; LUCKINGFAMIRA KM, 1994, LEUKEMIA, V8, P1825; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mrozek A, 2003, CELL DEATH DIFFER, V10, P461, DOI 10.1038/sj.cdd.4401193; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; Nutt LK, 2002, J BIOL CHEM, V277, P9219, DOI 10.1074/jbc.M106817200; Prokop A, 2000, LEUKEMIA, V14, P1606, DOI 10.1038/sj.leu.2401866; Radetzki S, 2002, ONCOGENE, V21, P227, DOI 10.1038/sj/onc/1205010; Raisova M, 2000, FEBS LETT, V473, P27, DOI 10.1016/S0014-5793(00)01491-5; Raisova M, 2001, J INVEST DERMATOL, V117, P333, DOI 10.1046/j.0022-202x.2001.01409.x; Rudner J, 2001, J CELL SCI, V114, P4161; Schelwies K, 2002, INT J CANCER, V99, P589, DOI 10.1002/ijc.10380; Sturm I, 2000, INT J CANCER, V87, P517, DOI 10.1002/1097-0215(20000815)87:4<517::AID-IJC9>3.0.CO;2-B; Sturm I, 2003, CELL DEATH DIFFER, V10, P477, DOI 10.1038/sj.cdd.4401194; Sturm I, 2001, J CLIN ONCOL, V19, P2272, DOI 10.1200/JCO.2001.19.8.2272; Sturm I, 1999, J CLIN ONCOL, V17, P1364, DOI 10.1200/JCO.1999.17.5.1364; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang SL, 2003, P NATL ACAD SCI USA, V100, P15095, DOI 10.1073/pnas.2435285100; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Wen JH, 2000, BLOOD, V96, P3900, DOI 10.1182/blood.V96.12.3900.h8003900_3900_3906; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; WIEDER T, 1995, BIOCHEM J, V311, P873, DOI 10.1042/bj3110873; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	50	69	71	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2004	23	50					8320	8332		10.1038/sj.onc.1207971	http://dx.doi.org/10.1038/sj.onc.1207971			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	866CC	15467752				2022-12-17	WOS:000224749500014
J	Wang, ZX; Fukuda, S; Pelus, LM				Wang, ZX; Fukuda, S; Pelus, LM			Survivin regulates the p53 tumor suppressor gene family	ONCOGENE			English	Article						survivin; apoptosis; p53; p63; p73	CELL-CYCLE ENTRY; MDM2 ONCOPROTEIN; APOPTOSIS; P73; P21(CIP1/WAF1); EXPRESSION; PROTEIN; CANCER; P63; CLEAVAGE	Survivin regulates cell division and inhibits apoptosis by blocking caspase activation. The tumor suppressor p53 inhibits cell cycle progression and induces apoptosis. Since Survivin overexpression and loss of wild-type p53 expression/function occur in most cancers, we investigated whether Survivin regulates p53. Stable overexpression of Survivin protects BaF3 cells from Adriamycin-induced apoptosis, while dominant-negative (T34A) and antisense (AS) Survivin accelerate apoptosis. In BaF3 cells and transiently transfected MCF7 breast cancer cells, elevation of total and phospho-Ser(15)-p53 in response to Adriamycin is blocked by Survivin and enhanced by Survivin disruption. Furthermore, in Adriamycin-treated MCF7 cells, ectopic Survivin decreased p53 mRNA and increased mRNA and protein of the p53 homologues DeltaNp63 and TAp73 and mRNA for DeltaNp73, suggesting that Survivin may differentially regulate p53 family transcription. Concomitant with decreasing p53 mRNA, Survivin decreased Mdm2 mRNA. Survivin disruption by T34A or AS Survivin resulted in reduced Mdm2 protein. The caspase inhibitor, Z-VAD-FMK, blocked the decrease in Mdm2 as well as the increase in p53 resulting from Survivin disruption, indicating that Survivin regulates Mdm2 at the post-translational level. Proteosome inhibition confirmed that reduced p53 protein observed in cells overexpressing Survivin is due to enhanced p53 degradation resulting from Survivin-mediated inhibition of Mdm2 cleavage by caspases. In summary, our results identify regulatory interactions between Survivin and p53 at the mRNA and protein levels, and suggest that the p53 homologues DeltaNp63, TAp73 and DeltaNp73 may also be regulated by Survivin.	Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Pelus, LM (corresponding author), Indiana Univ, Sch Med, Walther Oncol Ctr, 950 W Walnut St, Indianapolis, IN 46202 USA.	lpelus@iupui.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079654] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL079654] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adida C, 2000, BRIT J HAEMATOL, V111, P196, DOI 10.1046/j.1365-2141.2000.02328.x; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Beltrami E, 2004, J BIOL CHEM, V279, P2077, DOI 10.1074/jbc.M309479200; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; Chen J, 2000, NEOPLASIA, V2, P235, DOI 10.1038/sj.neo.7900091; Chen LH, 1997, J BIOL CHEM, V272, P22966, DOI 10.1074/jbc.272.36.22966; Chumakov PM, 2000, BIOCHEMISTRY-MOSCOW+, V65, P28; Erhardt P, 1997, J BIOL CHEM, V272, P15049, DOI 10.1074/jbc.272.24.15049; Freebern WJ, 2003, J BIOL CHEM, V278, P2249, DOI 10.1074/jbc.M208517200; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Fukuda S, 2004, BLOOD, V103, P120, DOI 10.1182/blood-2003-05-1756; Fukuda S, 2002, BLOOD, V100, P2463, DOI 10.1182/blood.V100.7.2463; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; Goetz AW, 2001, CANCER RES, V61, P7635; Grossman D, 2001, P NATL ACAD SCI USA, V98, P635, DOI 10.1073/pnas.230450097; Hall PA, 2000, CARCINOGENESIS, V21, P153, DOI 10.1093/carcin/21.2.153; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hayashibara T, 2002, NUTR CANCER, V44, P192, DOI 10.1207/S15327914NC4402_12; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kostrouchova M, 2003, P NATL ACAD SCI USA, V100, P5240, DOI 10.1073/pnas.0730770100; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Li Y, 2002, J BIOL CHEM, V277, P11352, DOI 10.1074/jbc.M109062200; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; McKay TR, 2003, ONCOGENE, V22, P3539, DOI 10.1038/sj.onc.1206417; Mesri M, 2001, J CLIN INVEST, V108, P981, DOI 10.1172/JCI12983; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; Novak U, 2001, ANN ONCOL, V12, P981, DOI 10.1023/A:1011153206003; NYLANDER K, 2003, J PATHOL, V198, P5686; Okada H, 2004, J EXP MED, V199, P399, DOI 10.1084/jem.20032092; Olie RA, 2000, CANCER RES, V60, P2805; Pennati M, 2004, ONCOGENE, V23, P386, DOI 10.1038/sj.onc.1207071; PERRY ME, 1993, CURR OPIN GENET DEV, V3, P50, DOI 10.1016/S0959-437X(05)80340-5; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; Suzuki A, 2000, ONCOGENE, V19, P3225, DOI 10.1038/sj.onc.1203665; Waltermann A, 2003, ONCOGENE, V22, P5686, DOI 10.1038/sj.onc.1206859; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zhou MX, 2002, J PHARMACOL EXP THER, V303, P124, DOI 10.1124/jpet.102.037192	48	69	80	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2004	23	49					8146	8153		10.1038/sj.onc.1207992	http://dx.doi.org/10.1038/sj.onc.1207992			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865HE	15361831				2022-12-17	WOS:000224692500012
J	Suzuki, A; Kusakai, G; Kishimoto, A; Shimojo, Y; Miyamoto, S; Ogura, T; Ochiai, A; Esumi, H				Suzuki, A; Kusakai, G; Kishimoto, A; Shimojo, Y; Miyamoto, S; Ogura, T; Ochiai, A; Esumi, H			Regulation of caspase-6 and FLIP by the AMPK family member ARK5	ONCOGENE			English	Article						ARK5; caspase-6; FLIP; Fas ligand/Fas system; colorectal cancer	ACTIVATED PROTEIN-KINASE; TRAIL-INDUCED APOPTOSIS; HUMAN COLON-CANCER; FAS LIGAND; CELL-DEATH; NUTRIENT DEPRIVATION; GLUCOSE STARVATION; LIVER METASTASES; TUMOR-CELLS; EXPRESSION	Colorectal cancer cells are unique in that they escape Fas-mediated cell death in the presence of Fas ligand, and we recently reported that AMP-activated protein kinase-related kinase 5 (ARK5) suppresses cell death signaling mediated by cell death receptor in Akt-dependent manner. In the current study, therefore, we examined whether ARK5 is involved in the escape from Fas-mediated cell death of colorectal cancer cells. Among 10 cell lines, ARK5 mRNA expression was observed in LoVo, SW480, and SW1116 cell lines. Interestingly, SW480 and SW1116 cell lines, but not LoVo cell line, showed expressions of both Fas ligand ( FasL) and Fas mRNAs. SW620 cell line also showed FasL mRNA; however, Fas and ARK5 mRNAs were not detected. Furthermore, well-coincided expression among ARK5, FasL, and Fas mRNAs was observed in tumor tissues from patients with colorectal cancer, suggesting the suppression of FasL/Fas system-induced cell death by ARK5 in colorectal cancer cell lines. Intensive cell death, which was dependent on the FasL/Fas system was encountered when ARK5 antisense RNA (ARK5/AS) was introduced into SW480 cells. FLIP was expressed in only ARK5 mRNA-expressing cell lines, and ARK5/AS induced FLIP cleavage in a caspase-6-dependent manner. Amino-acid sequence analysis of caspase-6 revealed two putative sites of phosphorylation by ARK5 at Ser(80) and Ser(257). Although active caspase-6 overexpression induced cell death in SW480 and DLD-1 cell lines, SW480 cells, but not DLD-1 cells, exhibited strong resistance to procaspase-6 overexpression. Moreover, mutant caspase-6, in which the Ser257 was substituted by Ala ( caspase-6/SA), induced cell death and FLIP degradation, even in SW480 cells. Active ARK5 was found to phosphorylate wild-type caspase-6 in vitro, but not caspase-6/SA, and the prevented activation of caspase-6 was promoted due to its phosphorylation by active ARK5 in vitro. On the basis of the results of this study, we propose that ARK5 negatively regulates procaspase-6 by phosphorylation at Ser(257), leading to resistance to the FasL/Fas system.	Natl Canc Ctr, Res Inst E, Invest Treatment Div, Chiba 2778577, Japan; Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Chiba 2778562, Japan; Natl Canc Ctr, Res Inst E, Div Pathol, Chiba 2778577, Japan	National Cancer Center - Japan; University of Tokyo; National Cancer Center - Japan	Esumi, H (corresponding author), Natl Canc Ctr, Res Inst E, Canc Physiol Project, 6-5-1 Kashiwanoha, Chiba 2778577, Japan.	hesumi@east.ncc.go.jp						Bennett MW, 2001, J CLIN PATHOL, V54, P598, DOI 10.1136/jcp.54.8.598; Berman R S, 2001, Cancer Treat Res, V109, P183; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Ding EX, 1998, RES COMMUN MOL PATH, V101, P13; Esumi H, 2002, J BIOL CHEM, V277, P32791, DOI 10.1074/jbc.M112270200; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hashimoto K, 2002, BIOCHEM BIOPH RES CO, V290, P263, DOI 10.1006/bbrc.2001.6193; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Izuishi K, 2000, CANCER RES, V60, P6201; Kato K, 2002, ONCOGENE, V21, P6082, DOI 10.1038/sj.onc.1205737; Kelly MM, 2002, CANCER BIOL THER, V1, P520, DOI 10.4161/cbt.1.5.169; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Kusakai G, 2004, AM J PATHOL, V164, P987, DOI 10.1016/S0002-9440(10)63186-0; LEITHAUSER F, 1993, LAB INVEST, V69, P415; Liu KB, 2003, J IMMUNOL, V170, P6329, DOI 10.4049/jimmunol.170.12.6329; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nakanishi K, 2002, CANCER RES, V62, P2971; O'Connell J, 1998, J PATHOL, V186, P240; PESO LD, 1997, SCIENCE, V278, P687; PEUDOEBERL L, 1999, INT J CANCER, V81, P772; Shiraki K, 1997, P NATL ACAD SCI USA, V94, P6420, DOI 10.1073/pnas.94.12.6420; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Suzuki A, 2004, MOL CELL BIOL, V24, P3526, DOI 10.1128/MCB.24.8.3526-3535.2004; Suzuki A, 2003, ONCOGENE, V22, P6177, DOI 10.1038/sj.onc.1206899; Suzuki A, 2003, J BIOL CHEM, V278, P48, DOI 10.1074/jbc.M206025200; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; Wyllie A H, 1980, Int Rev Cytol, V68, P251	36	69	75	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2004	23	42					7067	7075		10.1038/sj.onc.1207963	http://dx.doi.org/10.1038/sj.onc.1207963			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	854EX	15273717				2022-12-17	WOS:000223885100007
J	Guo, FK; Zheng, Y				Guo, FK; Zheng, Y			Rho family GTPases cooperate with p53 deletion to promote primary mouse embryonic fibroblast cell invasion	ONCOGENE			English	Article						Rho GTPases; p53; cell migration; invasion	TUMOR-SUPPRESSOR PROTEIN; GENE-EXPRESSION; BREAST-CANCER; RAS; TRANSFORMATION; MOTILITY; GROWTH; RAC1; OVEREXPRESSION; PROLIFERATION	The Rho family GTPases Rac1, RhoA and Cdc42 function as molecular switches that transduce intracellular signals regulating multiple cell functions including gene expression, adhesion, migration and invasion. p53 and its regulator p19(Arf) on the other hand, are tumor suppressors that are critical in regulating cell cycle progression and apoptosis. Previously, we have demonstrated that the Rho proteins contribute to the cell proliferation, gene transcription and migration phenotypes unleashed by p19Arf or p53 deletion in primary mouse embryo fibroblasts (MEFs). To further investigate their functional interaction in the present study, we have examined the involvement of Rho signaling pathways in p53-mediated cell invasion. We found that in primary MEFs (1) p53 or p19(Arf) deficiency led to a marked increase in the number of focal adhesion plaques and fibronectin production, and RhoA, Rac1 and Cdc42 contribute to the p53- and p19(Arf)-mediated focal adhesion regulation, but not fibronectin synthesis; (2) although endogenous Rac1 activity was required for the p19(Arf) or p53 deficiency-induced migration phenotype, hyperactive Rho GTPases could not further enhance cell migration, rather they suppressed cell-cell adhesion of p53(-/-) MEFs; (3) expression of the active mutant of RhoA, Rac1 or Cdc42, but not Ras, promoted an invasion phenotype of p53(-/-), not p19Arf(-/-), cells; (4) although ROCK activation can partially recapitulate Rho-induced invasion phenotype, multiple pathways regulated by RhoA, in addition to ROCK, are required to fully cooperate with p53 deficiency to promote cell invasion; and (5) extracellular proteases produced by the active RhoA-transduced cells are also required for the invasion phenotype of p53(-/-) cells. Combined with our previous observations, these results strongly suggest that mitogenic activation of Rho family GTPases can cooperate with p53 deficiency to promote primary cell invasion as well as transformation and that multiple signaling components regulated by the Rho proteins are involved in these processes.	Univ Cincinnati, Childrens Hosp Res Fdn, Div Expt Hematol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati	Zheng, Y (corresponding author), Univ Cincinnati, Childrens Hosp Res Fdn, Div Expt Hematol, Cincinnati, OH 45229 USA.	yi.zheng@chmcc.org	Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074	NCI NIH HHS [CA105117] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA105117] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexandrova A, 2000, ONCOGENE, V19, P5826, DOI 10.1038/sj.onc.1203944; Aznar S, 2001, CANCER LETT, V165, P1, DOI 10.1016/S0304-3835(01)00412-8; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Boettner B, 2002, GENE, V286, P155, DOI 10.1016/S0378-1119(02)00426-2; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Comer KA, 1998, ONCOGENE, V16, P1299, DOI 10.1038/sj.onc.1201645; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Fujisawa K, 1998, J BIOL CHEM, V273, P18943, DOI 10.1074/jbc.273.30.18943; Gadea G, 2002, EMBO J, V21, P2373, DOI 10.1093/emboj/21.10.2373; Gloushankova N, 1997, ONCOGENE, V15, P2985, DOI 10.1038/sj.onc.1201483; Guo FK, 2004, MOL CELL BIOL, V24, P1426, DOI 10.1128/MCB.24.3.1426-1438.2004; Guo FK, 2003, J BIOL CHEM, V278, P14414, DOI 10.1074/jbc.M300341200; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Iotsova V, 1996, CELL GROWTH DIFFER, V7, P629; Kaibuchi K, 1999, CURR OPIN CELL BIOL, V11, P591, DOI 10.1016/S0955-0674(99)00014-9; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Mira JP, 2000, P NATL ACAD SCI USA, V97, P185, DOI 10.1073/pnas.97.1.185; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Preudhomme C, 2000, ONCOGENE, V19, P2023, DOI 10.1038/sj.onc.1203521; Ridley AJ, 2001, J CELL SCI, V114, P2713; Sablina AA, 2003, J BIOL CHEM, V278, P27362, DOI 10.1074/jbc.M300547200; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; Schwartz MA, 2000, TRENDS BIOCHEM SCI, V25, P388, DOI 10.1016/S0968-0004(00)01605-4; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Sun YB, 1999, J BIOL CHEM, V274, P11535, DOI 10.1074/jbc.274.17.11535; Suwa H, 1998, BRIT J CANCER, V77, P147, DOI 10.1038/bjc.1998.23; VAN AL, 1997, GENE DEV, V11, P2295; Zhao RB, 2000, GENE DEV, V14, P981; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	43	69	70	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5577	5585		10.1038/sj.onc.1207752	http://dx.doi.org/10.1038/sj.onc.1207752			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15122327				2022-12-17	WOS:000222629500002
J	Kimmelman, AC; Qiao, RF; Narla, G; Banno, A; Lau, N; Bos, PD; Rodriguez, NN; Liang, BC; Guha, A; Martignetti, JA; Friedman, SL; Chan, AM				Kimmelman, AC; Qiao, RF; Narla, G; Banno, A; Lau, N; Bos, PD; Rodriguez, NN; Liang, BC; Guha, A; Martignetti, JA; Friedman, SL; Chan, AM			Suppression of glioblastoma tumorigenicity by the Kruppel-like transcription factor KLF6	ONCOGENE			English	Article						glioblastoma; tumor suppressor; KLF6; Kruppel; transcription factor	EPIDERMAL-GROWTH-FACTOR; HUMAN GLIOMAS; GENE; EXPRESSION; P53; OVEREXPRESSION; HETEROZYGOSITY; ACTIVATION; ONCOGENE; REGION	The Kruppel-like transcription factor KLF6 is a novel tumor-suppressor gene mutated in a significant fraction of human prostate cancer. It is localized to human chromosome 10p14-15, a region that displays frequent loss of heterozygosity in glioblastoma multiforme (GBM). Indeed, mutations of the KLF6 gene have recently been reported in this tumor type. In this study, we report that the expression of KLF6 is attenuated in human GBM when compared with primary astrocytes. Expression of KLF6 in GBM cells reverts their tumorigenicity both in vitro and in vivo, which is correlated with its transactivation of the p21/CIP1/WAF1 promoter. Additionally, KLF6 inhibits cellular transformation induced by several oncogenes (c-sis/PDGF-B, nu-src, H-Ras, and EGFR) that are components of signaling cascades implicated in GBM. Our results provide the first evidence of functional tumor suppression by KFL6, and its loss may contribute to glial tumor progression.	Mt Sinai Sch Med, Derald H Ruttenberg Ctr Canc, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Med, Div Liver Dis, New York, NY 10029 USA; Toronto Western Hosp, Div Neurosurg, Toronto, ON M5T 2S8, Canada; Biogen Idec, San Diego, CA 92121 USA; Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Biogen; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Chan, AM (corresponding author), Mt Sinai Sch Med, Derald H Ruttenberg Ctr Canc, 1 Gustave Levy Pl,Box 1130, New York, NY 10029 USA.	Andrew.Chan@mssm.edu	Chan, Andrew/AAC-1145-2020; Narla, Goutham/AAZ-5710-2020; Chan, Andrew Man-Lok/J-9497-2013	Chan, Andrew/0000-0001-9923-5464; Narla, Goutham/0000-0003-4098-4203; Chan, Andrew Man-Lok/0000-0001-9923-5464	NATIONAL CANCER INSTITUTE [R29CA078509, T32CA078207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037340] Funding Source: NIH RePORTER; NCI NIH HHS [CA78509, CA78207] Funding Source: Medline; NIDDK NIH HHS [DK37340] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Banker G., 1998, CULTURING NERVE CELL; Botella LM, 2002, BLOOD, V100, P4001, DOI 10.1182/blood.V100.12.4001; Broome MA, 1996, J BIOL CHEM, V271, P16798, DOI 10.1074/jbc.271.28.16798; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; Ding H, 2001, CANCER RES, V61, P3826; Givol I, 1995, ONCOGENE, V11, P2609; Harada K, 2000, GENOMICS, V67, P268, DOI 10.1006/geno.2000.6257; Holland EC, 2000, P NATL ACAD SCI USA, V97, P6242, DOI 10.1073/pnas.97.12.6242; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Jeng YM, 2003, INT J CANCER, V105, P625, DOI 10.1002/ijc.11123; Kato H, 2000, CLIN CANCER RES, V6, P3937; Kimmelman AC, 1996, GENOMICS, V34, P250, DOI 10.1006/geno.1996.0277; KLEIHUES P, 2000, WHO; Kojima S, 2000, BLOOD, V95, P1309; Kon H, 1998, ONCOGENE, V16, P257, DOI 10.1038/sj.onc.1201488; KRUSE CA, 1992, IN VITRO CELL DEV-AN, V28A, P609; LAROCHELLE WJ, 1990, SCIENCE, V248, P1541, DOI 10.1126/science.2163109; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; Osada M, 1999, MOL CELL BIOL, V19, P6333; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; RADANY EH, 1992, P NATL ACAD SCI USA, V89, P6467, DOI 10.1073/pnas.89.14.6467; Ratziu V, 1998, P NATL ACAD SCI USA, V95, P9500, DOI 10.1073/pnas.95.16.9500; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Theurillat JP, 1999, AM J PATHOL, V154, P581, DOI 10.1016/S0002-9440(10)65303-5; Turner J, 1999, TRENDS BIOCHEM SCI, V24, P236, DOI 10.1016/S0968-0004(99)01406-1; Voesten AMJ, 1997, GENE CHROMOSOME CANC, V20, P167, DOI 10.1002/(SICI)1098-2264(199710)20:2<167::AID-GCC7>3.0.CO;2-1; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200	30	69	71	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					5077	5083		10.1038/sj.onc.1207662	http://dx.doi.org/10.1038/sj.onc.1207662			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15064720				2022-12-17	WOS:000222237300014
J	Dai, Q; Liu, JH; Chen, J; Durrant, D; McIntyre, TM; Lee, RM				Dai, Q; Liu, JH; Chen, J; Durrant, D; McIntyre, TM; Lee, RM			Mitochondrial ceramide increases in UV-irradiated HeLa cells and is mainly derived from hydrolysis of sphingomyelin	ONCOGENE			English	Article						apoptosis; mitochondria; sphingomyelin; ceramide; D609; myriocin; fumonicin B	KINASE-C-DELTA; NOVO SPHINGOLIPID BIOSYNTHESIS; NF-KAPPA-B; CYTOCHROME-C; SERINE PALMITOYLTRANSFERASE; INDUCED APOPTOSIS; CASPASE ACTIVATION; ENDONUCLEASE-G; DISTINCT POOL; P53 PROTEIN	Sphingolipids are important signaling molecules in many biologic processes, but little is known about their organelle-specific roles. Using HeLa cells, we investigated the effects of UV and etoposide-induced apoptosis on the contents of sphingomyelin (SM) and ceramide in subcellular compartments. UV irradiation of HeLa cells increased the levels of SM in all subcellular fractions, but the change was most dramatic in mitochondria. Using diacylglycerol kinase assays to quantify ceramide, we found that the levels of ceramide in mitochondria increased as early as 2 h after UV irradiation and remained elevated at 6 h. The increase in mitochondrial SM and ceramide was inhibited by D609, an inhibitor of sphingomyelinase and SM synthase. The inhibition of sphingolipid production correlated with protection of the mitochondrial transmembrane potential and prevention of cytochrome c release following UV irradiation. In contrast, myriocin, an inhibitor of the de novo ceramide synthesis pathway, only partially suppressed the production of ceramides in mitochondria and cannot suppress UV-induced apoptosis. Fumonicin B1, an inhibitor of ceramide synthase, can only prevent mitochondrial ceramide synthesis and UV-induced apoptosis in a small degree. These results indicate that mitochondrial ceramide production in UV-irradiated HeLa cells is not mediated by the de novo synthesis pathway, but mainly through SM hydrolysis.	Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; Univ Utah, Sect Oncol, Salt Lake City, UT 84112 USA; Univ Utah, Sch Med, Dept Internal Med, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Lee, RM (corresponding author), Univ Utah, Huntsman Canc Inst, 2000 Circle Hope,Suite 5244, Salt Lake City, UT 84112 USA.	ray.lee@hci.utah.edu			NCI NIH HHS [K08CA795093] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Bejaoui K, 2002, J CLIN INVEST, V110, P1301, DOI 10.1172/JCI200216450; Bielawska A, 2001, ANAL BIOCHEM, V298, P141, DOI 10.1006/abio.2001.5342; Birbes H, 2002, ADV ENZYME REGUL, V42, P113, DOI 10.1016/S0065-2571(01)00026-7; Birbes H, 2001, FASEB J, V15, P2669, DOI 10.1096/fj.01-0539com; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brenner C, 2000, SCIENCE, V289, P1150, DOI 10.1126/science.289.5482.1150; Cory S, 1998, BBA-REV CANCER, V1377, pR25, DOI 10.1016/S0304-419X(98)00003-1; Cowen DS, 1996, J BIOL CHEM, V271, P22297, DOI 10.1074/jbc.271.37.22297; Dawkins JL, 2001, NAT GENET, V27, P309, DOI 10.1038/85879; Deng J, 2002, ONCOGENE, V21, P44, DOI 10.1038/sj.onc.1204900; Denning MF, 2002, CELL DEATH DIFFER, V9, P40, DOI 10.1038/sj.cdd.4400929; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; El Bawab S, 2000, J BIOL CHEM, V275, P21508, DOI 10.1074/jbc.M002522200; El Bawab S, 2001, J BIOL CHEM, V276, P16758, DOI 10.1074/jbc.M009331200; FINE JB, 1982, J LIPID RES, V23, P660; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; Garcia-Ruiz C, 2003, J CLIN INVEST, V111, P197, DOI 10.1172/JCI200316010; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; Grether-Beck S, 2000, EMBO J, V19, P5793, DOI 10.1093/emboj/19.21.5793; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Hodgkin MN, 1998, TRENDS BIOCHEM SCI, V23, P200, DOI 10.1016/S0968-0004(98)01200-6; Ito Y, 2001, CELL DEATH DIFFER, V8, P794, DOI 10.1038/sj.cdd.4400886; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Kirschnek S, 2000, J BIOL CHEM, V275, P27316; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Li LW, 1999, MOL CELL BIOL, V19, P8547; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LINARDIC CM, 1994, J BIOL CHEM, V269, P23530; Linn SC, 2001, BIOCHEM SOC T, V29, P831, DOI 10.1042/BST0290831; Liu JH, 2003, CANCER RES, V63, P1153; Luberto C, 1998, J BIOL CHEM, V273, P14550, DOI 10.1074/jbc.273.23.14550; Luberto C, 2000, J BIOL CHEM, V275, P14760, DOI 10.1074/jbc.275.19.14760; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Merrill AH, 2002, J BIOL CHEM, V277, P25843, DOI 10.1074/jbc.R200009200; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Parrish J, 2001, NATURE, V412, P90, DOI 10.1038/35083608; Perry DK, 2000, J BIOL CHEM, V275, P9078, DOI 10.1074/jbc.275.12.9078; Perry DK, 2000, METHOD ENZYMOL, V312, P22; Perry DK, 2000, ANN NY ACAD SCI, V905, P91; Pettus BJ, 2002, BBA-MOL CELL BIOL L, V1585, P114, DOI 10.1016/S1388-1981(02)00331-1; Richter C, 1999, BIOCHEM SOC SYMP, V66, P27, DOI 10.1042/bss0660027; Sansome C, 2001, FEBS LETT, V488, P110, DOI 10.1016/S0014-5793(00)02368-1; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Schmelz EM, 2000, J NUTR, V130, P522, DOI 10.1093/jn/130.3.522; Schmelz EM, 2001, CANCER RES, V61, P6723; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; Shimeno H, 1998, LIPIDS, V33, P601, DOI 10.1007/s11745-998-0246-2; Sumitomo M, 2002, J CLIN INVEST, V109, P827, DOI 10.1172/JCI200214146; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Uchida Y, 2003, J INVEST DERMATOL, V120, P662, DOI 10.1046/j.1523-1747.2003.12098.x; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang XD, 2001, GENE DEV, V15, P2922; Zhang P, 1997, J BIOL CHEM, V272, P9609	61	69	69	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3650	3658		10.1038/sj.onc.1207430	http://dx.doi.org/10.1038/sj.onc.1207430			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15077187				2022-12-17	WOS:000221101700017
J	Nieto, M; Samper, E; Fraga, MF; de Buitrago, GG; Esteller, M; Serrano, M				Nieto, M; Samper, E; Fraga, MF; de Buitrago, GG; Esteller, M; Serrano, M			The absence of p53 is critical for the induction of apoptosis by 5-aza-2 '-deoxycytidine	ONCOGENE			English	Article						p53; apoptosis; demethylation; 5-aza-2 '-deoxycytidine	DNA METHYLATION; MYELODYSPLASTIC SYNDROME; P53-DEPENDENT APOPTOSIS; MITOTIC CATASTROPHE; TUMOR SUPPRESSION; ONCOGENIC RAS; INK4A LOCUS; CELLS; MICE; METHYLTRANSFERASE	The absence of functional p53 has complex consequences on the cellular responses to cytotoxic drugs. Here, we have examined the role of p53 in the response to 5-aza-2'-deoxycytidine (5-aza-dC or decitabine). Primary mouse embryonic fibroblasts deficient for p53 undergo apoptosis after treatment with 5-aza-dC. When compared with other demethylating drugs or chemotherapeutic treatments, 5-aza-dC showed the highest selectivity ratio for triggering apoptosis in p53-deficient cells relative to wild-type cells. Moreover, the apoptotic efficacy of 5-aza-dC is proprietary of p53-deficient cells, not being observed in cells lacking other cell-cycle regulators, such as p19(ARF), p16(INK4a), p21(CIP1/WAF1), E2F-1, or E2F-2. Interestingly, treatment with 5-aza-dC results in the same degree of global genomic hypomethylation in wild-type and p53-null cells. However, wild-type cells activate p53 and arrest at G2/M, whereas p53-null cells accumulate severe chromosomal aberrations and undergo apoptosis. Significantly, the impact of p53-deficiency on the response to 5-aza-dC is not exclusive of primary non-neoplastic cells, but it is also present in neoplastically transformed cells. Finally, treatment of mice bearing genetically defined tumors with nontoxic doses of 5-aza-dC results in therapeutical responses only on tumors lacking p53, but not on tumors lacking p19(ARF). Together, our results put forward the hypothesis that the absence of p53 may determine a higher chemotherapeutic index for 5-aza-dC.	Spanish Natl Canc Ctr CNIO, Madrid 28029, Spain; Spanish Natl Ctr Biotechnol CNB, Dept Immunol & Oncol, Madrid, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Serrano, M (corresponding author), Spanish Natl Canc Ctr CNIO, 3 Melchor Fernandez Almagro St, Madrid 28029, Spain.	mserrano@cnio.es	Fraga, Mario F/H-7824-2017; Esteller, Manel/L-5956-2014; Serrano, Manuel/H-2634-2015	Fraga, Mario F/0000-0001-8450-2603; Esteller, Manel/0000-0003-4490-6093; Serrano, Manuel/0000-0001-7177-9312				Abad JL, 2002, J GENE MED, V4, P27, DOI 10.1002/jgm.242; Bernstein C, 2002, MUTAT RES-REV MUTAT, V511, P145, DOI 10.1016/S1383-5742(02)00009-1; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Cheng JC, 2003, J NATL CANCER I, V95, P399, DOI 10.1093/jnci/95.5.399; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; DECABO SF, 1994, EXPERIENTIA, V50, P658; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Fraga MF, 2002, ELECTROPHORESIS, V23, P1677, DOI 10.1002/1522-2683(200206)23:11&lt;1677::AID-ELPS1677&gt;3.0.CO;2-Z; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Gudkov AV, 2003, NAT REV CANCER, V3, P117, DOI 10.1038/nrc992; HAAF T, 1995, PHARMACOL THERAPEUT, V65, P19, DOI 10.1016/0163-7258(94)00053-6; HARVEY M, 1993, ONCOGENE, V8, P2457; Hawkins DS, 1996, CANCER RES, V56, P892; Hendry JH, 1997, INT J RADIAT BIOL, V71, P709, DOI 10.1080/095530097143716; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Ianzini F, 1998, MUTAGENESIS, V13, P337, DOI 10.1093/mutage/13.4.337; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Karpf AR, 2001, MOL PHARMACOL, V59, P751, DOI 10.1124/mol.59.4.751; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Lackinger D, 2000, MUTAT RES-FUND MOL M, V457, P113, DOI 10.1016/S0027-5107(00)00133-0; LANZA F, 1995, STEM CELLS, V13, P445, DOI 10.1002/stem.5530130416; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; Lin XH, 2001, CANCER RES, V61, P8611; Lin YF, 2003, DNA REPAIR, V2, P1, DOI 10.1016/S1568-7864(02)00183-0; Lips J, 2001, CARCINOGENESIS, V22, P579, DOI 10.1093/carcin/22.4.579; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; McKay BC, 2001, ONCOGENE, V20, P6805, DOI 10.1038/sj.onc.1204901; Mori N, 1995, LEUKEMIA RES, V19, P869, DOI 10.1016/0145-2126(95)00058-5; Murga M, 2001, IMMUNITY, V15, P959, DOI 10.1016/S1074-7613(01)00254-0; Palmero I, 2001, METHOD ENZYMOL, V333, P247; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Paz MF, 2003, CANCER RES, V63, P1114; Peller S, 1998, SEMIN CANCER BIOL, V8, P379, DOI 10.1006/scbi.1998.0100; Plumb JA, 2000, CANCER RES, V60, P6039; PURDIE CA, 1994, ONCOGENE, V9, P603; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Ruiz-Vela A, 2002, FEBS LETT, V517, P133, DOI 10.1016/S0014-5793(02)02607-8; Santini V, 2001, ANN INTERN MED, V134, P573, DOI 10.7326/0003-4819-134-7-200104030-00011; SCHEINBART LS, 1991, J RHEUMATOL, V18, P530; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Stancheva I, 2001, EMBO J, V20, P1963, DOI 10.1093/emboj/20.8.1963; Stuppia L, 1997, CANCER GENET CYTOGEN, V98, P28, DOI 10.1016/S0165-4608(96)00413-X; Tang JL, 1998, ANTICANCER RES, V18, P3757; UELAND PM, 1982, PHARMACOL REV, V34, P223; VANGROENINGEN CJ, 1986, CANCER RES, V46, P4831; Weller M, 1998, CELL TISSUE RES, V292, P435, DOI 10.1007/s004410051072; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	55	69	72	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					735	743		10.1038/sj.onc.1207175	http://dx.doi.org/10.1038/sj.onc.1207175			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14737108				2022-12-17	WOS:000188304900012
J	Kim, B; van Golen, CM; Feldman, EL				Kim, B; van Golen, CM; Feldman, EL			Insulin-like growth factor-I signaling in human neuroblastoma cells	ONCOGENE			English	Article						insulin-like growth factor I; neuroblastoma; Shc; insulin receptor substrate; FAK; paxillin	FOCAL ADHESION KINASE; TYROSINE PHOSPHORYLATION; RECEPTOR SUBSTRATE-1; PHOSPHATIDYLINOSITOL 3-KINASE; NEURAL CREST; DIFFERENTIAL REGULATION; HEMATOPOIETIC-CELLS; PREVENTS APOPTOSIS; MEDIATED SURVIVAL; BREAST-CANCER	Neuroblastoma is a heterogeneous tumor consisting of N (neuronal) and S (stromal) cells. We report that more tumorigenic and motile N cells express higher levels of IGF-I receptor (IGF-IR) than less tumorigenic, more adherent S cells. Shc, one of the two major docking partners of IGF-IR, is equally expressed in N and S cell lines. IGF-I treatment phosphorylates Shc in N cells, but only weakly activates Shc in S cells. Expression of the second partner, insulin receptor substrate (IRS), is cell type specific. S cells exclusively express IRS-1 that undergoes sustained phosphorylation by IGF-I. In contrast, N cells express IRS-2 that is transiently phosphorylated by IGF-I. Downstream of IRS-2 and Shc, IGF-I treatment results in strong activation of Akt and MAPK in N cells and activation of both pathways is required for IGF-I-mediated differentiation. Only IGF-IR activation of phosphatidylinositol-3 kinase is required for tumor edge ruffling in N and S cells, with stimulation of focal adhesion kinase (FAK) and paxillin. This detailed understanding of the 'biochemical signature' of N and S cells provides the background needed to target and disrupt specific IGF signaling pathways in an attempt to develop more effective therapies.	Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Kim, B (corresponding author), Univ Michigan, Dept Neurol, 4414 Kresge III,200 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	bhumsoo@umich.edu		Feldman, Eva/0000-0002-9162-2694	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038849, R01NS036778] Funding Source: NIH RePORTER; NINDS NIH HHS [NS36778, NS38849] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON DJ, 1993, ANNU REV NEUROSCI, V16, P129, DOI 10.1146/annurev.ne.16.030193.001021; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BASERGA R, 1995, CANCER RES, V55, P249; BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; BIEDLER JL, 1973, CANCER RES, V33, P2643; BIEDLER JL, 1988, ADV NEUROBLASTOMA RE, V2, P265; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Cheng HL, 2000, MOL CELL ENDOCRINOL, V170, P211, DOI 10.1016/S0303-7207(00)00324-5; CICCARONE V, 1989, CANCER RES, V49, P219; Corvi R, 1997, J NEURO-ONCOL, V31, P25, DOI 10.1023/A:1005721027709; DECLERCK YA, 1987, CANCER RES, V47, P6505; DEMEYTS P, 1994, HORM RES, V42, P152, DOI 10.1159/000184188; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Encinas M, 1999, J NEUROCHEM, V73, P1409, DOI 10.1046/j.1471-4159.1999.0731409.x; FAVROT MC, 1991, INT J CANCER, V49, P347, DOI 10.1002/ijc.2910490306; Feldman EL, 1997, NEUROBIOL DIS, V4, P201, DOI 10.1006/nbdi.1997.0156; FLICKINGER KS, 1994, EXP CELL RES, V213, P156, DOI 10.1006/excr.1994.1185; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Frappaz D, 2000, J CLIN ONCOL, V18, P468, DOI 10.1200/JCO.2000.18.3.468; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; Greene MW, 2003, J BIOL CHEM, V278, P8199, DOI 10.1074/jbc.M209153200; Guo HB, 2002, CANCER RES, V62, P6837; Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1; Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Ivankovic-Dikic I, 2000, NAT CELL BIOL, V2, P574, DOI 10.1038/35023515; Judware R, 1995, ONCOGENE, V11, P2599; Kim B, 1997, J BIOL CHEM, V272, P21268, DOI 10.1074/jbc.272.34.21268; Kim B, 2002, J BIOL CHEM, V277, P27393, DOI 10.1074/jbc.M201963200; Kim B, 1998, ENDOCRINOLOGY, V139, P4881, DOI 10.1210/en.139.12.4881; Kim BS, 1998, J NEUROCHEM, V71, P1333; Kim BS, 1998, J BIOL CHEM, V273, P34543, DOI 10.1074/jbc.273.51.34543; Kurihara S, 2000, ENDOCR J, V47, P739, DOI 10.1507/endocrj.47.739; Lebrun P, 1998, J BIOL CHEM, V273, P32244, DOI 10.1074/jbc.273.48.32244; Leventhal PS, 1997, TRENDS ENDOCRIN MET, V8, P1, DOI 10.1016/S1043-2760(96)00202-0; Leventhal PS, 1997, J BIOL CHEM, V272, P5214, DOI 10.1074/jbc.272.8.5214; Liu XD, 1998, CANCER RES, V58, P5432; Meyer G, 2002, J NEUROCHEM, V83, P490, DOI 10.1046/j.1471-4159.2002.01185.x; Meyer GE, 2001, ONCOGENE, V20, P7542, DOI 10.1038/sj.onc.1204927; Miller TM, 1997, J BIOL CHEM, V272, P9847; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; Ogihara T, 1997, J BIOL CHEM, V272, P12868, DOI 10.1074/jbc.272.19.12868; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Pederson TM, 2001, DIABETES, V50, P24, DOI 10.2337/diabetes.50.1.24; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; Reiss K, 2000, ONCOGENE, V19, P2687, DOI 10.1038/sj.onc.1203587; Reiss K, 1998, CLIN CANCER RES, V4, P2647; RETTIG WJ, 1987, CANCER RES, V47, P1383; ROSS RA, 1985, CANCER RES, V45, P1628; ROSS RA, 1995, CELL GROWTH DIFFER, V6, P449; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; Rui LY, 2001, J BIOL CHEM, V276, P40362, DOI 10.1074/jbc.M105332200; Russell JW, 1998, J NEUROBIOL, V36, P455, DOI 10.1002/(SICI)1097-4695(19980915)36:4<455::AID-NEU1>3.0.CO;2-V; Salgia R, 1999, ONCOGENE, V18, P67, DOI 10.1038/sj.onc.1202273; Sarbassov DD, 1998, MOL ENDOCRINOL, V12, P1870, DOI 10.1210/me.12.12.1870; SASAOKA T, 1994, J BIOL CHEM, V269, P32621; Schaller MD, 2001, ONCOGENE, V20, P6459, DOI 10.1038/sj.onc.1204786; Schmidt ML, 2000, J CLIN ONCOL, V18, P1260, DOI 10.1200/JCO.2000.18.6.1260; Scibelli A, 2003, VET RES, V34, P193, DOI 10.1051/vetres:2002066; Seiler AEM, 2001, J NEUROCHEM, V76, P573, DOI 10.1046/j.1471-4159.2001.00025.x; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Singleton JR, 1996, CANCER RES, V56, P4522; Thomas JW, 1999, J BIOL CHEM, V274, P36684, DOI 10.1074/jbc.274.51.36684; TUMILOWICZ JJ, 1970, CANCER RES, V30, P2110; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423; Valentinis B, 2000, J BIOL CHEM, V275, P25451, DOI 10.1074/jbc.M002271200; van Golen CM, 2001, CELL GROWTH DIFFER, V12, P371; Van Golen CM, 2000, J CELL PHYSIOL, V182, P24, DOI 10.1002/(SICI)1097-4652(200001)182:1<24::AID-JCP3>3.0.CO;2-6; Vincent AM, 2002, GROWTH HORM IGF RES, V12, P193, DOI 10.1016/S1096-6374(02)00017-5; Waters SB, 1996, TRENDS CELL BIOL, V6, P1, DOI 10.1016/0962-8924(96)81024-5; Yee D, 2002, SEMIN ONCOL, V29, P86, DOI 10.1053/sonc.2002.34060; YOSHIHARA T, 1992, INT J CANCER, V51, P620, DOI 10.1002/ijc.2910510419; Yu H, 1999, JNCI-J NATL CANCER I, V91, P151, DOI 10.1093/jnci/91.2.151; Zumkeller W, 1999, HORM METAB RES, V31, P138, DOI 10.1055/s-2007-978711	77	69	69	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					130	141		10.1038/sj.onc.1206924	http://dx.doi.org/10.1038/sj.onc.1206924			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712218				2022-12-17	WOS:000187895300014
J	Panaretakis, T; Pokrovskaja, K; Shoshan, MC; Grander, D				Panaretakis, T; Pokrovskaja, K; Shoshan, MC; Grander, D			Interferon-alpha-induced apoptosis in U266 cells is associated with activation of the proapoptotic Bcl-2 family members Bak and Bax	ONCOGENE			English	Article						apoptosis; IFN alpha; Bak; Bax; Bcl-2	CHRONIC LYMPHOCYTIC-LEUKEMIA; DRUG-INDUCED APOPTOSIS; MULTIPLE-MYELOMA; CYTOCHROME-C; CONFORMATIONAL-CHANGES; BH3-ONLY PROTEINS; OLIGOMERIZES BAK; UP-REGULATION; DEATH; MITOCHONDRIA	We have recently reported that the cytokine interferon-alpha (IFNalpha), commonly used in the treatment of cancer, induced a caspase-dependent apoptosis in tumor cell lines. The signaling mechanisms involved have not been defined. Here, we show that both proapoptotic Bcl-2 family members Bak and Bax were activated by IFNalpha, strictly in correlation with the induction of apoptosis. Using double stainings, we demonstrated that Bak was activated prior to cytochrome c (cyt c) release and caspase-3 activation, whereas activated Bax was only found in cells with released cyt c, mitochondrial depolarization, as well as activated caspase-3. Furthermore, IFNalpha-induced activation of Bak, and to a large extent also of Bax, was dependent on caspase activity. With the use of a panel of specific caspase inhibitors we found, however, that none of caspases-1 to -10 were responsible for this activation. Neither was the Ca2+-dependent protease calpain nor the stress-activated p38 SAPK pathway significantly involved. Overexpression of Bcl-2 blocked apoptosis induced by IFNalpha totally abolished Bak activation, as well as decreased the amount of activated Bax. We conclude that IFNalpha induces Bak and Bax activation via distinct mechanisms involving an unknown protease, and that their activation is regulated by Bcl-2.	Karolinska Hosp & Inst, Dept Pathol & Oncol, CCK, S-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital	Grander, D (corresponding author), Karolinska Hosp & Inst, Dept Pathol & Oncol, CCK, R8-03, S-17176 Stockholm, Sweden.			Panaretakis, Theocharis/0000-0001-5754-6950; Pokrovskaja Tamm, Katja/0000-0001-6359-1256				Bellosillo B, 2002, BLOOD, V100, P1810, DOI 10.1182/blood-2001-12-0327; Bradbury DA, 1997, LEUKEMIA LYMPHOMA, V24, P221, DOI 10.3109/10428199709039010; Cai JY, 1999, J BIOENERG BIOMEMBR, V31, P327, DOI 10.1023/A:1005423818280; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Consoli U, 2002, BRIT J HAEMATOL, V116, P774, DOI 10.1046/j.0007-1048.2002.03344.x; Dai CH, 1999, BLOOD, V93, P3309, DOI 10.1182/blood.V93.10.3309.410k04_3309_3316; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Grander D, 2000, ACTA ONCOL, V39, P801, DOI 10.1080/028418600750063532; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Loeffler M, 2000, EXP CELL RES, V256, P19, DOI 10.1006/excr.2000.4833; Los M, 1997, BLOOD, V90, P3118, DOI 10.1182/blood.V90.8.3118; Ludwig H, 2000, ACTA ONCOL, V39, P815; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lutz RJ, 2000, BIOCHEM SOC T, V28, P51, DOI 10.1042/bst0280051; Mandic A, 2002, MOL CELL BIOL, V22, P3003, DOI 10.1128/MCB.22.9.3003-3013.2002; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Ogilvy S, 1999, P NATL ACAD SCI USA, V96, P14943, DOI 10.1073/pnas.96.26.14943; Panaretakis T, 2002, J BIOL CHEM, V277, P44317, DOI 10.1074/jbc.M205273200; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj/cdd/4400998; Puthier D, 2001, BRIT J HAEMATOL, V112, P358, DOI 10.1046/j.1365-2141.2001.02575.x; Raza A, 2000, LEUKEMIA RES, V24, P63, DOI 10.1016/S0145-2126(99)00152-6; Sangfelt O, 1997, CELL GROWTH DIFFER, V8, P343; SANGFELT O, 1995, INT J CANCER, V63, P190, DOI 10.1002/ijc.2910630207; Smalley RV, 2001, LEUKEMIA, V15, P1118, DOI 10.1038/sj.leu.2402161; Strander H, 1996, BIOTHERAPY, V8, P213, DOI 10.1007/BF01877207; Thyrell L, 2002, ONCOGENE, V21, P1251, DOI 10.1038/sj.onc.1205179; Wang GQ, 2001, J BIOL CHEM, V276, P34307, DOI 10.1074/jbc.M103526200; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060	37	69	72	4	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 17	2003	22	29					4543	4556		10.1038/sj.onc.1206503	http://dx.doi.org/10.1038/sj.onc.1206503			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881711				2022-12-17	WOS:000184054700010
J	Kool, J; Hamdi, M; Cornelissen-Steijger, P; van der Eb, AJ; Terleth, C; van Dam, H				Kool, J; Hamdi, M; Cornelissen-Steijger, P; van der Eb, AJ; Terleth, C; van Dam, H			Induction of ATF3 by ionizing radiation is mediated via a signaling pathway that includes ATM, Nibrin1, stress-induced MAPkinases and ATF-2	ONCOGENE			English	Article						ionizing radiation; ATM; NBS; ATF3; ATF-2	NIJMEGEN BREAKAGE SYNDROME; CELL-CYCLE CHECKPOINT; MAMMALIAN UV RESPONSE; DNA-DAMAGE RESPONSE; S-PHASE CHECKPOINT; C-JUN INDUCTION; NF-KAPPA-B; ATAXIA-TELANGIECTASIA; GENOTOXIC STRESS; GROWTH-FACTOR	Exposure of human cells to genotoxic agents induces various signaling pathways involved in the execution of stress- and DNA-damage responses. Inappropriate functioning of the DNA-damage response to ionizing radiation (IR) is associated with the human diseases ataxia-telangiectasia (A-T) and Nijmegen Breakage syndrome (NBS). Here, we show that IR efficiently induces Jun/ATF transcription factor activity in normal human diploid fibroblasts, but not in fibroblasts derived from A-T and NBS patients. IR was found to enhance the expression of c-Jun and, in particular, ATF3, but, in contrast to various other stress stimuli, did not induce the expression of c-Fos. Using specific inhibitors, we found that the ATM- and Nibrin1-dependent activation of ATF3 does neither require p53 nor reactive oxygen species, but is dependent on the p38 and JNK MAPkinases. Via these kinases, IR activates ATF-2, one of the transcription factors acting on the atf3 promoter. The activation of ATF-2 by IR resembles ATF-2 activation by certain growth factors, since IR mainly induced the second step of ATF-2 phosphorylation via the stress-inducible MAPkinases, phosphorylation of Thr69. As IR does not enhance ATF-2 phosphorylation in ATM and Nibrin1-deficient cells, both ATF-2 and ATF3 seem to play an important role in the protective response of human cells to IR.	Leiden Univ, Ctr Biomed Genet, Dept Mol Cell Biol, Sect Gene Regulat,Med Ctr, NL-2333 AL Leiden, Netherlands; Leiden Univ, Dept Radiat Genet & Chem Mutagenesis, Med Ctr, NL-2333 AL Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	van Dam, H (corresponding author), Leiden Univ, Ctr Biomed Genet, Dept Mol Cell Biol, Sect Gene Regulat,Med Ctr, Wassenaarseweg 72, NL-2333 AL Leiden, Netherlands.	vdam@lumc.nl		van Dam, Hans/0000-0002-8307-4325				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Allan AL, 2001, J BIOL CHEM, V276, P27272, DOI 10.1074/jbc.M103196200; Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676; Bar-Shira A, 2002, ONCOGENE, V21, P849, DOI 10.1038/sj.onc.1205127; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Buscemi G, 2001, MOL CELL BIOL, V21, P5214, DOI 10.1128/MCB.21.15.5214-5222.2001; Cai Y, 2000, BLOOD, V96, P2140, DOI 10.1182/blood.V96.6.2140.h8002140_2140_2148; COFFER PJ, 1995, ONCOGENE, V11, P561; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Girard PM, 2002, ONCOGENE, V21, P4191, DOI 10.1038/sj.onc.1205596; Gross S, 1999, J BIOL CHEM, V274, P26378, DOI 10.1074/jbc.274.37.26378; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAAS S, 1995, CARCINOGENESIS, V16, P985, DOI 10.1093/carcin/16.5.985; Hai T, 1999, GENE EXPRESSION, V7, P321; HSU JC, 1992, MOL CELL BIOL, V12, P4654, DOI 10.1128/MCB.12.10.4654; JASPERS NGJ, 1988, CYTOGENET CELL GENET, V49, P259, DOI 10.1159/000132673; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kawasaki H, 2000, NATURE, V405, P195, DOI 10.1038/35012097; KHANNA KK, 1995, ONCOGENE, V11, P609; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; KLEIN B, 1990, EXP CELL RES, V191, P256, DOI 10.1016/0014-4827(90)90012-Y; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Mashima T, 2001, J CELL PHYSIOL, V188, P352, DOI 10.1002/jcp.1130; Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174; Ouwens DM, 2002, EMBO J, V21, P3782, DOI 10.1093/emboj/cdf361; Perez S, 2001, ONCOGENE, V20, P1135, DOI 10.1038/sj.onc.1204200; Pfeiffer P, 1996, MUTAT RES-REV GENET, V366, P69, DOI 10.1016/S0165-1110(96)90029-9; Ronai Z, 1998, ONCOGENE, V16, P523, DOI 10.1038/sj.onc.1201566; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; Shaulian E, 1999, J BIOL CHEM, V274, P29595, DOI 10.1074/jbc.274.42.29595; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; TAMM I, 1976, J CELL BIOL, V69, P229, DOI 10.1083/jcb.69.2.229; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; vanLaar T, 1995, BIOCHEM BIOPH RES CO, V217, P769, DOI 10.1006/bbrc.1995.2839; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Wilhelm D, 1997, MOL CELL BIOL, V17, P4792, DOI 10.1128/MCB.17.8.4792; Wim JM, 1997, MOL CELL BIOL, V17, P5016, DOI 10.1128/MCB.17.9.5016; Wolfgang CD, 2000, J BIOL CHEM, V275, P16865, DOI 10.1074/jbc.M909637199; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Yamazaki V, 1998, CANCER RES, V58, P2316; Yan CH, 2002, J BIOL CHEM, V277, P10804, DOI 10.1074/jbc.M112069200; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; ZANDOMENI R, 1982, P NATL ACAD SCI-BIOL, V79, P3167, DOI 10.1073/pnas.79.10.3167; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	57	69	69	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2003	22	27					4235	4242		10.1038/sj.onc.1206611	http://dx.doi.org/10.1038/sj.onc.1206611			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698CJ	12833146				2022-12-17	WOS:000183979800010
J	Ramirez-Montagut, T; Turk, MJ; Wolchok, JD; Guevara-Patino, JA; Houghton, AN				Ramirez-Montagut, T; Turk, MJ; Wolchok, JD; Guevara-Patino, JA; Houghton, AN			Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity	ONCOGENE			English	Article						cancer; differentiation; germ cell	CYTOLYTIC T-LYMPHOCYTES; PHASE-I TRIAL; INFILTRATING LYMPHOCYTES; MALIGNANT-MELANOMA; FC-RECEPTORS; DIFFERENTIATION ANTIGEN; SURFACE-ANTIGENS; GD3 GANGLIOSIDE; BETA-CATENIN; CELL	Cancer cells express self-antigens that are weakly recognized by the immune system. Even though responses against autologous cells are difficult to induce, the immune system is still able to mount a response against cancer. The discovery of the molecular identity of antigens that are recognized by the immune system of melanoma patients has led to the elucidation of tumor immunity at a cellular and molecular level. Multiple pathways in both the priming and effector phases of melanoma rejection have been described. Animal models' active immunotherapies for melanoma show a requirement for the cellular compartment of the immune system in the priming phase, primarily CD4 + T cells. More diverse elements are required for the effector phase, including components from the innate immune system (macrophages, complement and/or natural killer cells) and from the adaptive immune system (CD8 + T cells and B cells). Minor differences in amino-acid sequences of antigens must determine the particular mechanisms involved in tumor rejection. Since the immune system contains T and B cells that recognize and reject autologous cells, a consequence of tumor immunity is potential autoimmunity. There are distinct pathways for tumor immunity and autoimmunity. The requirements for autoimmunity at the priming phase seem to be CD4 + /IFN-gamma dependent while the effector mechanisms are alternative and redundant. Vitiligo (autoimmune hypopigmentation) can be mediated by T cells, FcgammaR + macrophages and/or complement.	Cornell Univ, Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Cornell Univ, Weill Grad Sch Med Sci, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University	Houghton, AN (corresponding author), Cornell Univ, Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.		Guevara, Jose/AAD-6707-2020					ALBINO AP, 1992, ONCOGENE, V7, P2315; BAKKER ABH, 1994, J EXP MED, V179, P1005, DOI 10.1084/jem.179.3.1005; Barker PA, 2002, J NEUROSCI RES, V67, P705, DOI 10.1002/jnr.10160; Bowne WB, 1999, J EXP MED, V190, P1717, DOI 10.1084/jem.190.11.1717; BOYSE EA, 1969, ANNU REV GENET, V3, P269, DOI 10.1146/annurev.ge.03.120169.001413; Castelli C, 1998, EUR J IMMUNOL, V28, P1143; Chen YT, 1997, P NATL ACAD SCI USA, V94, P1914, DOI 10.1073/pnas.94.5.1914; Chiari R, 2000, CANCER RES, V60, P4855; Clynes R, 1998, P NATL ACAD SCI USA, V95, P652, DOI 10.1073/pnas.95.2.652; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Colella TA, 2000, J EXP MED, V191, P1221, DOI 10.1084/jem.191.7.1221; Demunter A, 2002, MODERN PATHOL, V15, P454, DOI 10.1038/modpathol.3880546; DISIS ML, 1994, CANCER RES, V54, P16; Dyall R, 1998, J EXP MED, V188, P1553, DOI 10.1084/jem.188.9.1553; HAMILTON WB, 1993, INT J CANCER, V53, P566, DOI 10.1002/ijc.2910530407; HARA I, 1995, J EXP MED, V182, P1609, DOI 10.1084/jem.182.5.1609; Hawkins WG, 2000, SURGERY, V128, P273, DOI 10.1067/msy.2000.107421; HOUGHTON AN, 1985, P NATL ACAD SCI USA, V82, P1242, DOI 10.1073/pnas.82.4.1242; HOUGHTON AN, 1982, J EXP MED, V156, P1755, DOI 10.1084/jem.156.6.1755; HOUGHTON AN, 1994, J EXP MED, V180, P1, DOI 10.1084/jem.180.1.1; HOUGHTON AN, 1980, P NATL ACAD SCI-BIOL, V77, P4260, DOI 10.1073/pnas.77.7.4260; HOUGHTON AN, 1987, J EXP MED, V165, P812, DOI 10.1084/jem.165.3.812; Jager E, 1999, INT J CANCER, V84, P506, DOI 10.1002/(SICI)1097-0215(19991022)84:5<506::AID-IJC10>3.0.CO;2-6; Jager E, 2000, J EXP MED, V191, P625, DOI 10.1084/jem.191.4.625; KAWAKAMI Y, 1994, P NATL ACAD SCI USA, V91, P6458, DOI 10.1073/pnas.91.14.6458; KAWAKAMI Y, 1994, J EXP MED, V180, P347, DOI 10.1084/jem.180.1.347; Kurnick JT, 2001, J IMMUNOL, V167, P1204, DOI 10.4049/jimmunol.167.3.1204; Lewis JJ, 2000, INT J CANCER, V87, P391, DOI 10.1002/1097-0215(20000801)87:3<391::AID-IJC13>3.0.CO;2-K; Li K, 1998, CANCER IMMUNOL IMMUN, V47, P32, DOI 10.1007/s002620050501; LIVINGSTON PO, 1994, J CLIN ONCOL, V12, P1036, DOI 10.1200/JCO.1994.12.5.1036; Lloyd K. O., 1991, CANCER BIOL, V2, P421; Loftus DJ, 1996, J EXP MED, V184, P647, DOI 10.1084/jem.184.2.647; Lucas S, 2000, INT J CANCER, V87, P55, DOI 10.1002/1097-0215(20000701)87:1<55::AID-IJC8>3.3.CO;2-A; LURQUIN C, 1989, CELL, V58, P293, DOI 10.1016/0092-8674(89)90844-1; MATTES MJ, 1983, INT J CANCER, V32, P717, DOI 10.1002/ijc.2910320610; Moreau-Aubry A, 2000, J EXP MED, V191, P1617, DOI 10.1084/jem.191.9.1617; Naftzger C, 1996, P NATL ACAD SCI USA, V93, P14809, DOI 10.1073/pnas.93.25.14809; Pieper R, 1999, J EXP MED, V189, P757, DOI 10.1084/jem.189.5.757; Ramirez-Montagut T, 2000, CLIN EXP IMMUNOL, V119, P11, DOI 10.1046/j.1365-2249.2000.01089.x; RITTER G, 1991, INT J CANCER, V48, P379, DOI 10.1002/ijc.2910480312; Robbins PF, 1996, J EXP MED, V183, P1185, DOI 10.1084/jem.183.3.1185; Skipper JCA, 1996, J EXP MED, V183, P527, DOI 10.1084/jem.183.2.527; Takechi Y, 1996, CLIN CANCER RES, V2, P1837; THOMSON TM, 1988, J INVEST DERMATOL, V90, P459, DOI 10.1111/1523-1747.ep12460906; Trcka J, 2002, IMMUNITY, V16, P861, DOI 10.1016/S1074-7613(02)00327-8; VADHANRAJ S, 1988, J CLIN ONCOL, V6, P1636, DOI 10.1200/JCO.1988.6.10.1636; Van den Eynde B, 1999, J EXP MED, V190, P1793, DOI 10.1084/jem.190.12.1793; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; VIJAYASARADHI S, 1990, J EXP MED, V171, P1375, DOI 10.1084/jem.171.4.1375; Wang RF, 1999, SCIENCE, V284, P1351, DOI 10.1126/science.284.5418.1351; Weber LW, 1998, J CLIN INVEST, V102, P1258, DOI 10.1172/JCI4004; Wolchok J D, 2001, Cancer Immun, V1, P9; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Yamshchikov G, 2001, CLIN CANCER RES, V7, p909S; Zeng G, 2000, J IMMUNOL, V165, P1153, DOI 10.4049/jimmunol.165.2.1153	55	69	89	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 19	2003	22	20					3180	3187		10.1038/sj.onc.1206462	http://dx.doi.org/10.1038/sj.onc.1206462			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	682MV	12789294				2022-12-17	WOS:000183096600020
J	Djavaheri-Mergny, M; Wietzerbin, J; Besancon, F				Djavaheri-Mergny, M; Wietzerbin, J; Besancon, F			2-methoxyestradiol induces apoptosis in Ewing sarcoma cells through mitochondrial hydrogen peroxide production	ONCOGENE			English	Article						Ewing tumor; apoptosis; 2-methoxyestradiol; reactive oxygen species; mitochondria	N-TERMINAL KINASE; ENDOGENOUS ESTROGEN METABOLITE; CANCER-CELLS; GLUTATHIONE-PEROXIDASE; SIGNALING PATHWAY; INHIBITS ANGIOGENESIS; ENDOTHELIAL-CELLS; OXIDATIVE STRESS; PROSTATE-CANCER; TUMOR-GROWTH	The Ewing sarcoma is the second most common bone tumor in children and young adults. Despite the advances in therapy, the 5-year survival rate for patients with metastatic disease is poor, indicating the need for alternative treatments. Here, we report that 2-methoxy-estradiol (2-Me), a natural estrogen metabolite, induced a caspase-dependent apoptosis of Ewing sarcoma-derived cells independently of their p53 status. 2-Me-induced apoptosis occurred through the mitochondrial death pathway as evidenced by reduction of the mitochondrial transmembrane potential, cytochrome c release and caspase-9 activation. Treatment of cells with 2-Me resulted in generation of intracellular H2O2, which occurred earlier than caspase-9 activation. The H2O2-reducing agent Ebselen and the lipid peroxidation inhibitor vitamin E decreased both 2-Me-induced caspase-9 activation and cell death, thus providing evidence for a role of H2O2 and lipid peroxides in the initiation of this process. Rotenone, an inhibitor of the mitochondrial respiratory chain, abolished both apoptosis and H2O2 production, thereby identifying mitochondria as the source of H2O2. Moreover, we observed that treatment of cells with 2-Me or H2O2 induced activation of the c-Jun N-terminal kinase (JNK). Overexpression of a dominant-negative mutant of JNK1 reduced 2-Me-induced apoptosis indicating that JNK participates in this process. Altogether, our results provide evidence that 2-Me triggers apoptosis of Ewing sarcoma cells through induction of a mitochondria redox-dependent mechanism and suggest that this compound or other agents that selectively increase the level of reactive oxygen species may prove useful to the development of novel strategies for treatment of Ewing tumors.	Inst Curie, Sect Rech, INSERM, U365, F-75248 Paris 05, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Djavaheri-Mergny, M (corresponding author), Inst Curie, Sect Rech, INSERM, U365, 26 Rue Ulm, F-75248 Paris 05, France.		Djavaheri-Mergny, Mojgan/L-3890-2019; Djavaheri-Mergny, Mojgan/N-6315-2017	Djavaheri-Mergny, Mojgan/0000-0003-4893-6505; Djavaheri-Mergny, Mojgan/0000-0003-4893-6505				Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; Aoki H, 2002, J BIOL CHEM, V277, P10244, DOI 10.1074/jbc.M112355200; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Attalla H, 1998, BIOCHEM BIOPH RES CO, V247, P616, DOI 10.1006/bbrc.1998.8870; Benhar M, 2002, EMBO REP, V3, P420, DOI 10.1093/embo-reports/kvf094; Cai JY, 1999, J BIOENERG BIOMEMBR, V31, P327, DOI 10.1023/A:1005423818280; Castedo M, 2002, J IMMUNOL METHODS, V265, P39, DOI 10.1016/S0022-1759(02)00069-8; Curtin JF, 2002, J IMMUNOL METHODS, V265, P49, DOI 10.1016/S0022-1759(02)00070-4; Dauphinot L, 2001, ONCOGENE, V20, P3258, DOI 10.1038/sj.onc.1204437; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200; DeSilva DR, 1998, J IMMUNOL, V160, P4175; Djavaheri-Mergny M, 2001, FREE RADICAL RES, V34, P583, DOI 10.1080/10715760100300481; Ekert PG, 2001, J CELL BIOL, V152, P483, DOI 10.1083/jcb.152.3.483; Ferri KF, 2001, BIOESSAYS, V23, P111, DOI 10.1002/1521-1878(200102)23:2<111::AID-BIES1016>3.0.CO;2-Y; Fleury C, 2002, BIOCHIMIE, V84, P131, DOI 10.1016/S0300-9084(02)01369-X; FOTSIS T, 1994, NATURE, V368, P237, DOI 10.1038/368237a0; Gupta S, 2001, LIFE SCI, V69, P2957, DOI 10.1016/S0024-3205(01)01404-7; HALLIWELL B, 1984, LANCET, V2, P1095; Hamel E, 1996, BIOCHEMISTRY-US, V35, P1304, DOI 10.1021/bi951559s; Hashimoto M, 2002, J BIOL CHEM, V277, P11465, DOI 10.1074/jbc.M111428200; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Javelaud D, 2001, ONCOGENE, V20, P4365, DOI 10.1038/sj.onc.1204570; Kotamraju S, 2000, J BIOL CHEM, V275, P33585, DOI 10.1074/jbc.M003890200; KOVAR H, 1993, ONCOGENE, V8, P2683; Kovar Heinrich, 1998, Current Opinion in Oncology, V10, P334, DOI 10.1097/00001622-199807000-00010; Kumar AP, 2001, MOL CARCINOGEN, V31, P111, DOI 10.1002/mc.1046; Kushner BH, 2001, J CLIN ONCOL, V19, P870, DOI 10.1200/JCO.2001.19.3.870; LEDENEV AN, 1986, BIOCHEM INT, V13, P391; Lin HL, 2000, CANCER-AM CANCER SOC, V89, P983, DOI 10.1002/1097-0142(20000901)89:5<983::AID-CNCR7>3.3.CO;2-7; Mukhopadhyay T, 1997, ONCOGENE, V14, P379, DOI 10.1038/sj.onc.1200835; Nakamura Y, 2002, J BIOL CHEM, V277, P2687, DOI 10.1074/jbc.M109641200; Nomura K, 2001, BIOL SIGNAL RECEPT, V10, P81; Oberlin O, 2001, BRIT J CANCER, V85, P1646, DOI 10.1054/bjoc.2001.2150; Ollinger Karin, 2002, Subcell Biochem, V36, P151; Petrosillo G, 2001, FEBS LETT, V509, P435, DOI 10.1016/S0014-5793(01)03206-9; Pinkerton CR, 2001, EUR J CANCER, V37, P1338, DOI 10.1016/S0959-8049(01)00131-9; Pribluda VS, 2000, CANCER METAST REV, V19, P173, DOI 10.1023/A:1026543018478; Qadan LR, 2001, BIOCHEM BIOPH RES CO, V285, P1259, DOI 10.1006/bbrc.2001.5320; Qanungo S, 2002, ONCOGENE, V21, P4149, DOI 10.1038/sj.onc.1205508; Ramachandran A, 2002, BIOL CHEM, V383, P693, DOI 10.1515/BC.2002.071; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; Reed JC, 2002, MOL CELL, V9, P1, DOI 10.1016/S1097-2765(02)00437-9; Sartorius U, 2001, CHEMBIOCHEM, V2, P20, DOI 10.1002/1439-7633(20010105)2:1<20::AID-CBIC20>3.3.CO;2-O; Schumacher G, 2001, J CANCER RES CLIN, V127, P405, DOI 10.1007/s004320000233; SIES H, 1994, METHOD ENZYMOL, V234, P476; Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304; Sitailo LA, 2002, J BIOL CHEM, V277, P19346, DOI 10.1074/jbc.M200401200; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Szibor M, 2001, ANTIOXID REDOX SIGN, V3, P515, DOI 10.1089/15230860152409149; Tang DG, 2002, BIOL CHEM, V383, P425, DOI 10.1515/BC.2002.046; YAGI K, 1987, CHEM PHYS LIPIDS, V45, P337, DOI 10.1016/0009-3084(87)90071-5; Yue TL, 1997, MOL PHARMACOL, V51, P951, DOI 10.1124/mol.51.6.951; Zhao R, 2002, P NATL ACAD SCI USA, V99, P8579, DOI 10.1073/pnas.122061399; Zhao YF, 2001, ANTIOXID REDOX SIGN, V3, P375, DOI 10.1089/15230860152409022	56	69	73	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2003	22	17					2558	2567		10.1038/sj.onc.1206356	http://dx.doi.org/10.1038/sj.onc.1206356			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730670				2022-12-17	WOS:000182569000003
J	Kanaya, T; Kyo, S; Maida, Y; Yatabe, N; Tanaka, M; Nakamura, M; Inoue, M				Kanaya, T; Kyo, S; Maida, Y; Yatabe, N; Tanaka, M; Nakamura, M; Inoue, M			Frequent hypermethylation of MLH1 promoter in normal endometrium of patients with endometrial cancers	ONCOGENE			English	Article						MLH1; methylation; promoter; endometrial cancer; microsatellite instability	NONPOLYPOSIS COLON-CANCER; ISLAND METHYLATOR PHENOTYPE; MICROSATELLITE INSTABILITY; COLORECTAL-CANCER; CARCINOMA; MUTATIONS; HMLH1; PTEN; CARCINOGENESIS; CONSEQUENCES	Silencing of the MLH1 gene by promoter hypermethylation is the mechanism underlying the microsatellite instability (MSI) phenotype in endometrial cancers. However, the profile of CpG methylation in a wide range of MLH1 promoters in endometrial cancers and in the normal endometrium is largely unknown. The present study investigates the region 700 bp upstream of MLH1 covering 48 CpG sites using bisulfite sequencing. Methylation status was classified as full (over 80% of CpGs are methylated), partial (10-80%) or nonmethylation (less than 10%). Of 56 endometrioid endometrial cancers, 16 (29%) were fully methylated, 14 (25%) were partially methylated and 26 (46%) were not methylated. Analyses of MLH1 by immunohistochemical means and of MSI revealed that the degree, rather than region-specific methylation of CpG islands is critical for decreased MLH1 expression and the MSI phenotype. Among 12 patients with methylated cancers, five (42%) patients contained methylated promoters in their normal endometria with profiles similar to those of cancer lesions, and these were associated with the MSI phenotype. In contrast, only one of 31 (3%) normal endometria from patients without endometrial malignancies harbored methylated promoters. These findings suggest that hypermethylation of the MLH1 promoter is frequent in the histologically normal endometrium adjacent to cancers, supporting the notion that hypermethylation of mismatch repair genes is the initial step that triggers various genetic events in endometrial carcinogenesis.	Kanazawa Univ, Sch Med, Dept Obstet & Gynecol, Kanazawa, Ishikawa 9208641, Japan	Kanazawa University	Kyo, S (corresponding author), Kanazawa Univ, Sch Med, Dept Obstet & Gynecol, 13-1 Takaramachi, Kanazawa, Ishikawa 9208641, Japan.							BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BURKS RT, 1994, ONCOGENE, V9, P1163; Deng GR, 1999, CANCER RES, V59, P2029; Deng GR, 2001, ONCOGENE, V20, P7120, DOI 10.1038/sj.onc.1204891; DUGGAN BD, 1994, J NATL CANCER I, V86, P1216, DOI 10.1093/jnci/86.16.1216; Esteller M, 1998, ONCOGENE, V17, P2413, DOI 10.1038/sj.onc.1202178; Esteller M, 2001, CANCER RES, V61, P3225; Esteller M, 1999, AM J PATHOL, V155, P1767, DOI 10.1016/S0002-9440(10)65492-2; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Gurin CC, 1999, CANCER RES, V59, P462; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Inoue M, 2001, INT J GYNECOL CANCER, V11, P339, DOI 10.1046/j.1525-1438.2001.01046.x; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KATABUCHI H, 1995, CANCER RES, V55, P5556; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Mutter GL, 2001, CANCER RES, V61, P4311; Mutter GL, 2000, JNCI-J NATL CANCER I, V92, P924, DOI 10.1093/jnci/92.11.924; Nakagawa H, 2001, CANCER RES, V61, P6991; Papadopoulos N, 1997, HUM MUTAT, V10, P89, DOI 10.1002/(SICI)1098-1004(1997)10:2<89::AID-HUMU1>3.3.CO;2-K; Peltomaki P, 1997, ADV CANCER RES, V71, P93, DOI 10.1016/S0065-230X(08)60097-4; Simpkins SB, 1999, HUM MOL GENET, V8, P661, DOI 10.1093/hmg/8.4.661; Tashiro H, 1997, CANCER RES, V57, P3935; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Toyota M, 1999, CANCER RES, V59, P5438; Zhou XP, 2002, HUM MOL GENET, V11, P445, DOI 10.1093/hmg/11.4.445	27	69	72	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 17	2003	22	15					2352	2360		10.1038/sj.onc.1206365	http://dx.doi.org/10.1038/sj.onc.1206365			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	667KV	12700670	Green Submitted			2022-12-17	WOS:000182231500013
J	Zhang, SL; Qian, XL; Redman, C; Bliskovski, V; Ramsay, ES; Lowy, DR; Mock, BA				Zhang, SL; Qian, XL; Redman, C; Bliskovski, V; Ramsay, ES; Lowy, DR; Mock, BA			p16(INK4a) gene promoter variation and differential binding of a repressor, the ras-responsive zinc-finger transcription factor, RREB	ONCOGENE			English	Article						p16 promoter; RREB; plasmacytoma; NIH 3T3	SUSCEPTIBILITY; PROTEIN; INDUCTION; P19(ARF); REGION; CDKN2A; PROLIFERATION; PLASMACYTOMAS; INTERLEUKIN-6; METHYLATION	BALB/c mice are susceptible to the development of pristane-induced plasma cell tumors, and have a rare allelic variant in the coding region of the p16(INK4a) (p16) tumor suppressor gene that produces a protein with impaired activity. We have now found that the BALB/c p16 promoter has an allelic variant that may also compromise p16 activity. Following pristane treatment, BALB/c p16 mRNA levels in B cells were lower than that in DBA/2 or C.D2-Petr1, a resistant BALB/c congenic strain that harbors DBA/2 chromatin surrounding the p16 locus. Four sequence variants were found between BALB/c and DBA/2 in the p16 promoter region. In reporter assays, the DBA promoter was at least four times more active in driving luciferase expression than the BALB/c promoter. Most of the difference in activity was localized to a single nucleotide deletion in BALB/c. This deletion created a consensus binding site for RREB, a ras-responsive transcriptional element with zinc-finger binding motifs. Transient transfections with RREB confirmed that the p16 promoter can be downregulated by RREB, in a Ras- or Mek-dependent manner, and that the BALB/c promoter is more sensitive than DBA/2 to regulation by RREB. BALB/c mice have both regulatory and coding region defects that may contribute to the impairment of p16 gene function.	NCI, Ctr Canc Res, Genet Lab, NIH, Bethesda, MD 20892 USA; NCI, Ctr Canc Res, Cellular Oncol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Mock, BA (corresponding author), NCI, Ctr Canc Res, Genet Lab, NIH, 37 COnvent Dr,MSC 4255,Bldg 37,Rm 2B-08, Bethesda, MD 20892 USA.	bev@helix.nih.gov	Mock, Beverly A/B-3110-2015	Mock, Beverly A/0000-0003-2479-4549	NATIONAL CANCER INSTITUTE [Z01BC008905, Z01BC010008, ZIABC008905, ZIABC010008] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398; Anborgh PH, 1999, MOL CELL BIOL, V19, P4611; Baylin S, 2002, CANCER CELL, V1, P299, DOI 10.1016/S1535-6108(02)00061-2; BOTTORFF D, 1995, MOL CELL BIOL, V15, P5113; Brown RT, 1995, J BIOL CHEM, V270, P31129, DOI 10.1074/jbc.270.52.31129; Dilworth D, 2000, BLOOD, V95, P1869, DOI 10.1182/blood.V95.5.1869.005k09_1869_1871; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; Herzog CR, 1999, MOL CARCINOGEN, V25, P92, DOI 10.1002/(SICI)1098-2744(199906)25:2<92::AID-MC3>3.0.CO;2-2; HILBERT DM, 1995, J EXP MED, V182, P243, DOI 10.1084/jem.182.1.243; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kaneko S, 1999, BIOCHEM MOL BIOL INT, V47, P205; KATO J, 1993, GENE DEV, V7, P331; Klangby U, 1998, BLOOD, V91, P1680, DOI 10.1182/blood.V91.5.1680.1680_1680_1687; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Mock BA, 1997, BLOOD, V90, P4092, DOI 10.1182/blood.V90.10.4092; MOCK BA, 1993, P NATL ACAD SCI USA, V90, P9499, DOI 10.1073/pnas.90.20.9499; Morse HC, 1980, PROGR MYELOMA, P263; Myohanen S, 2001, J BIOL CHEM, V276, P1634, DOI 10.1074/jbc.M004481200; NORDAN RP, 1986, SCIENCE, V233, P566, DOI 10.1126/science.3726549; Ogata A, 1997, J IMMUNOL, V159, P2212; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; POTTER M, 1994, J NATL CANCER I, V86, P1058, DOI 10.1093/jnci/86.14.1058; POTTER M, 1962, NATURE, V193, P1086, DOI 10.1038/1931086a0; POTTER M, 1994, CANCER RES, V54, P969; POTTER M, 1984, CANCER SURV, V3, P247; Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Soloff EV, 1996, GENE, V180, P213, DOI 10.1016/S0378-1119(96)00410-6; Taniai M, 2002, GASTROENTEROLOGY, V123, P1090, DOI 10.1053/gast.2002.36021; Thiagalingam A, 1996, MOL CELL BIOL, V16, P5335; Wang W, 2001, J BIOL CHEM, V276, P48655, DOI 10.1074/jbc.M108278200; Zhang SL, 1999, CURR TOP MICROBIOL, V246, P363; Zhang SL, 1998, P NATL ACAD SCI USA, V95, P2429, DOI 10.1073/pnas.95.5.2429; Zhang SL, 2001, MOL CELL BIOL, V21, P310, DOI 10.1128/MCB.21.1.310-318.2001	39	69	71	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2003	22	15					2285	2295		10.1038/sj.onc.1206257	http://dx.doi.org/10.1038/sj.onc.1206257			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	667KV	12700664				2022-12-17	WOS:000182231500007
J	Moorehead, RA; Sanchez, OH; Baldwin, RM; Khokha, R				Moorehead, RA; Sanchez, OH; Baldwin, RM; Khokha, R			Transgenic overexpression of IGF-II induces spontaneous lung tumors: a model for human lung adenocarcinoma	ONCOGENE			English	Article						IGF-II; lung cancer; CREB; transgenic model	GROWTH-FACTOR-I; CANCER CELL-LINES; ELEMENT-BINDING PROTEIN; TRANSCRIPTION FACTOR-I; NF-KAPPA-B; PULMONARY ADENOCARCINOMA; GENE-EXPRESSION; MOUSE; PROLIFERATION; ENDOTOXEMIA	Elevated levels of insulin-like growth factor (IGF)-II are associated with a poor prognosis in human pulmonary adenocarcinoma; however, a causal role for IGF-II in pulmonary adenocarcinoma has not been demonstrated. Here, we show that transgenic overexpression of IGF-II in lung epithelium induces lung tumors in 69% of mice older than 18 months of age. These tumors displayed morphological characteristics of human pulmonary adenocarcinoma such as their epithelial origin, tubulo-acinar architecture and expression of TTF-1, SP-B and proSP-C. Examination of signaling molecules downstream of the IGF-IR showed the activation of either the Erk1/Erk2 or p38 MAPK pathways, but not both, within the lung tumors. Notably, all lung tumors contained high levels of phosphorylated CREB, suggesting that both the Erk1/ Erk2 and p38 MAPK pathways converged on this transcription factor. Moreover, IGF-II induced proliferation and CREB phosphorylation in human lung cancer cell lines, suggesting that IGF-II and CREB also contribute to the growth of human lung tumors. Thus, IGF-II is an important genetic factor in the development of lung tumorigenesis, in which activation of CREB is a ubiquitous event. The MMTV-IGF-II transgenic mice provide a critical model for elucidating the role of IGF-II in this fatal human disease.	Univ Toronto, Dept Med Biophys, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto	Khokha, R (corresponding author), Univ Toronto, Dept Med Biophys, Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	rkhokha@oci.utoronto.ca		, Roger/0000-0001-9539-6295; Khokha, Rama/0000-0002-6028-1524				Abraham E, 2001, J IMMUNOL, V166, P522, DOI 10.4049/jimmunol.166.1.522; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Chailley-Heu B, 2001, J PATHOL, V195, P482, DOI 10.1002/path.960; Clark JC, 2001, AM J PHYSIOL-LUNG C, V280, pL705, DOI 10.1152/ajplung.2001.280.4.L705; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DiLoreto C, 1997, J CLIN PATHOL, V50, P30, DOI 10.1136/jcp.50.1.30; Fata JE, 1999, DEV BIOL, V211, P238, DOI 10.1006/dbio.1999.9313; George CLS, 1999, AM J PHYSIOL-LUNG C, V276, pL776, DOI 10.1152/ajplung.1999.276.5.L776; Grimberg A, 2000, J CELL PHYSIOL, V183, P1, DOI 10.1002/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO;2-J; HARVEY MB, 1995, DEVELOPMENT, V121, P1005; Inderdeo DS, 1996, BIOL REPROD, V55, P498, DOI 10.1095/biolreprod55.3.498; JAQUES G, 1988, EXP CELL RES, V176, P336, DOI 10.1016/0014-4827(88)90335-7; KAISER U, 1993, J CANCER RES CLIN, V119, P665, DOI 10.1007/BF01215985; Kaufmann O, 2000, HISTOPATHOLOGY, V36, P8; Lawlor MA, 2001, J CELL SCI, V114, P2903; Lee CT, 1996, CANCER RES, V56, P3038; London SJ, 2002, JNCI-J NATL CANCER I, V94, P749, DOI 10.1093/jnci/94.10.749; Lukanova A, 2001, INT J CANCER, V92, P888, DOI 10.1002/ijc.1265; Mendelson CR, 2000, ANNU REV PHYSIOL, V62, P875, DOI 10.1146/annurev.physiol.62.1.875; MINUTO F, 1988, CANCER RES, V48, P3716; MINUTO F, 1986, CANCER RES, V46, P985; Moorehead RA, 2001, CELL DEATH DIFFER, V8, P16, DOI 10.1038/sj.cdd.4400762; NAKANISHI Y, 1988, J CLIN INVEST, V82, P354, DOI 10.1172/JCI113594; Nguyen LQ, 2000, MOL ENDOCRINOL, V14, P1448, DOI 10.1210/me.14.9.1448; Ordonez NG, 2000, AM J SURG PATHOL, V24, P1217, DOI 10.1097/00000478-200009000-00004; REHM S, 1994, TUMOURS MOUSE, V2, P325; ROTSCH M, 1992, J CANCER RES CLIN, V118, P502, DOI 10.1007/BF01225264; Rudolph D, 1998, P NATL ACAD SCI USA, V95, P4481, DOI 10.1073/pnas.95.8.4481; Samet JM, 1998, AM J PHYSIOL-LUNG C, V275, pL551, DOI 10.1152/ajplung.1998.275.3.L551; SCHARDT C, 1993, EXP CELL RES, V204, P22, DOI 10.1006/excr.1993.1004; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Schneider MR, 2000, FASEB J, V14, P629, DOI 10.1096/fasebj.14.5.629; Shenkar R, 1999, J IMMUNOL, V163, P954; Shenkar R, 2001, AM J PHYSIOL-LUNG C, V281, pL418, DOI 10.1152/ajplung.2001.281.2.L418; Takanami I, 1996, J SURG ONCOL, V61, P205, DOI 10.1002/(SICI)1096-9098(199603)61:3<205::AID-JSO8>3.0.CO;2-F; Toretsky JA, 1996, J ENDOCRINOL, V149, P367, DOI 10.1677/joe.0.1490367; Wetterau LA, 1999, MOL GENET METAB, V68, P161, DOI 10.1006/mgme.1999.2920; Yan C, 1997, J BIOL CHEM, V272, P17327, DOI 10.1074/jbc.272.28.17327; Yu H, 1999, JNCI-J NATL CANCER I, V91, P151, DOI 10.1093/jnci/91.2.151; Zia F, 1996, J CELL BIOCHEM, P269	40	69	86	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2003	22	6					853	857		10.1038/sj.onc.1206188	http://dx.doi.org/10.1038/sj.onc.1206188			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584565				2022-12-17	WOS:000180864300008
J	Debruyne, PR; Bruyneel, EA; Karaguni, IM; Li, X; Flatau, G; Muller, O; Zimber, A; Gespach, C; Mareel, MM				Debruyne, PR; Bruyneel, EA; Karaguni, IM; Li, X; Flatau, G; Muller, O; Zimber, A; Gespach, C; Mareel, MM			Bile acids stimulate invasion and haptotaxis in human colorectal cancer cells through activation of multiple oncogenic signaling pathways	ONCOGENE			English	Article						bile acids; invasion; colorectal cancer	PROTEIN-KINASE-C; COLONIC EPITHELIAL-CELLS; DOWN-REGULATION; ADENOCARCINOMA CELLS; LITHOCHOLIC ACID; NUCLEAR RECEPTOR; CADHERIN/CATENIN COMPLEX; URSODEOXYCHOLIC ACID; CELLULAR INVASION; INDUCED APOPTOSIS	Bile acids are implicated in colorectal carcinogenesis as evidenced by epidemiological and experimental studies. We examined whether bile acids stimulate cellular invasion of human colorectal and dog kidney epithelial cells at different stages of tumor progression. Colon PC/AA/C1, PCmsrc, and HCT-8/E11 cells and kidney MDCKT23 cells were seeded on top of collagen type I gels and invasive cells were counted after 24 h incubation. Activation of the Rac1 and RhoA small GTPases was investigated by pull-down assays. Haptotaxis was analysed with modified Boyden chambers. Lithocholic acid, chenodeoxycholic acid, cholic acid and deoxycholic acid stimulated cellular invasion of SRC-and RhoA-transformed PCmsrc and MDCKT23-RhoAV14 cells, and of HCT-8/E11 cells originating from a sporadic tumor, but were ineffective in premalignant PC/AA/C1 and MDCKT23 cells. Bile acid-stimulated invasion occurred through stimulation of haptotaxis and was dependent on the RhoA/Rho-kinase pathway and signaling cascades using protein kinase C, mitogen-activated protein kinase, and cyclooxygenase-2. Accordingly, BA-induced invasion was associated with activation of the Rac1 and RhoA GTPases and expression of the farnesoid X receptor. We conclude that bile acids stimulate invasion and haptotaxis in colorectal cancer cells via several cancer invasion signaling pathways.	Ghent Univ Hosp, Dept Radiotherapy & Nucl Med, Expt Cancerol Lab, B-9000 Ghent, Belgium; Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany; INSERM, U 452, UFR Med, F-06107 Nice, France; Hop St Antoine, INSERM, U482, F-75571 Paris 12, France	Ghent University; Ghent University Hospital; Max Planck Society; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Mareel, MM (corresponding author), Ghent Univ Hosp, Dept Radiotherapy & Nucl Med, Expt Cancerol Lab, 1P7,Pintelaan 185, B-9000 Ghent, Belgium.	marc.mareel@rug.ac.be	Debruyne, Philip/AAU-6685-2021	Debruyne, Philip/0000-0001-5438-9697				Andre F, 1999, INT J CANCER, V83, P497, DOI 10.1002/(SICI)1097-0215(19991112)83:4<497::AID-IJC11>3.3.CO;2-4; Attoub S, 2000, FASEB J, V14, P2329, DOI 10.1096/fj.00-0162; AZNAVOORIAN S, 1990, J NATL CANCER I, V82, P1485, DOI 10.1093/jnci/82.18.1485; Batlle E, 1998, J BIOL CHEM, V273, P15091, DOI 10.1074/jbc.273.24.15091; Batta AK, 1998, CANCER RES, V58, P1684; BAYERDORFFER E, 1993, GASTROENTEROLOGY, V104, P145, DOI 10.1016/0016-5085(93)90846-5; Bracke ME, 1997, EUR J CELL BIOL, V74, P342; BRACKE ME, 1993, BRIT J CANCER, V68, P282, DOI 10.1038/bjc.1993.329; Chang JH, 1998, MOL CELL BIOL, V18, P4986, DOI 10.1128/MCB.18.9.4986; Dannenberg AJ, 1999, SEMIN ONCOL, V26, P499; EARNEST DL, 1994, CANCER RES, V54, P5071; Emami S, 2001, FASEB J, V15, P351, DOI 10.1096/fj.00-0355com; Empereur S, 1997, BRIT J CANCER, V75, P241, DOI 10.1038/bjc.1997.40; Fujita T, 1998, CANCER RES, V58, P4823; Glinghammar B, 2001, GASTROENTEROLOGY, V120, P401, DOI 10.1053/gast.2001.21188; Gupta S, 2001, J BIOL CHEM, V276, P15816, DOI 10.1074/jbc.M010878200; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Halvorsen B, 2000, BIOCHEM J, V349, P189, DOI 10.1042/0264-6021:3490189; HENNIGAN RF, 1994, ONCOGENE, V9, P3591; HILL MJ, 1971, LANCET, V1, P95; Hirano F, 1996, CARCINOGENESIS, V17, P427, DOI 10.1093/carcin/17.3.427; Hofmann J, 1997, FASEB J, V11, P649, DOI 10.1096/fasebj.11.8.9240967; HUANG XP, 1992, INT J CANCER, V52, P444, DOI 10.1002/ijc.2910520319; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Kamano T, 1999, DIS COLON RECTUM, V42, P668, DOI 10.1007/BF02234147; Kotelevets L, 1998, J BIOL CHEM, V273, P14138, DOI 10.1074/jbc.273.23.14138; Kozoni V, 2000, CARCINOGENESIS, V21, P999, DOI 10.1093/carcin/21.5.999; Kurtz W., 1992, Verdauungskrankheiten, V10, P153; Kurz AK, 2000, BIOCHEM J, V350, P207, DOI 10.1042/0264-6021:3500207; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; LATTA RK, 1993, CANCER LETT, V70, P167, DOI 10.1016/0304-3835(93)90227-Z; LEHMANN M, 1994, CANCER RES, V54, P2102; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Mareel M, 1996, J CELL BIOCHEM, V61, P524; MCMICHAEL AJ, 1985, JNCI-J NATL CANCER I, V75, P185; McMillan L, 2000, BIOCHEM BIOPH RES CO, V273, P45, DOI 10.1006/bbrc.2000.2899; Moseley R, 1999, TXB GASTROENTEROLOGY, P380; NAGENGAST FM, 1995, EUR J CANCER, V31A, P1067, DOI 10.1016/0959-8049(95)00216-6; NARISAWA T, 1974, JNCI-J NATL CANCER I, V53, P1093, DOI 10.1093/jnci/53.4.1093; Owen RW, 1997, SCAND J GASTROENTERO, V32, P76, DOI 10.1080/00365521.1997.11720725; Ozanne BW, 2000, EUR J CANCER, V36, P1640, DOI 10.1016/S0959-8049(00)00175-1; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; PONGRACZ J, 1995, INT J CANCER, V61, P35, DOI 10.1002/ijc.2910610107; Qiao D, 2001, CARCINOGENESIS, V22, P35, DOI 10.1093/carcin/22.1.35; Qiao DH, 2000, J BIOL CHEM, V275, P15090, DOI 10.1074/jbc.M908890199; Rao YP, 1997, J LIPID RES, V38, P2446; REDDY BS, 1981, CANCER RES, V41, P3766; REDDY BS, 1977, CANCER RES, V37, P3228; Rodrigues S, 2001, FASEB J, V15, P1517, DOI 10.1096/fj.00-0802com; Rust C, 2000, J BIOL CHEM, V275, P20210, DOI 10.1074/jbc.M909992199; Sander EE, 1999, EUR J CANCER, V35, P1302, DOI 10.1016/S0959-8049(99)00145-8; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Schlottmann K, 2000, CANCER RES, V60, P4270; Shimao Y, 1999, CLIN EXP METASTAS, V17, P351; Slice LW, 2000, BIOCHEM BIOPH RES CO, V276, P406, DOI 10.1006/bbrc.2000.3487; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; SUMMERTON J, 1983, BRIT J SURG, V70, P549, DOI 10.1002/bjs.1800700914; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; VAKAET L, 1991, INVAS METAST, V11, P249; VERMEULEN SJ, 1995, CANCER RES, V55, P4722; Vermeulen SJ, 1999, ONCOGENE, V18, P905, DOI 10.1038/sj.onc.1202348; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404; WILLIAMS AC, 1990, CANCER RES, V50, P4724; Xie W, 2001, P NATL ACAD SCI USA, V98, P3375, DOI 10.1073/pnas.051014398; Zhang F, 1998, J BIOL CHEM, V273, P2424, DOI 10.1074/jbc.273.4.2424; Zimber A, 2000, CANCER RES, V60, P672; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775	70	69	72	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2002	21	44					6740	6750		10.1038/sj.onc.1205729	http://dx.doi.org/10.1038/sj.onc.1205729			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360401				2022-12-17	WOS:000178315800004
J	Bandyopadhyay, A; Zhu, Y; Malik, SN; Kreisberg, J; Brattain, MG; Sprague, EA; Luo, J; Lopez-Casillas, F; Sun, LZ				Bandyopadhyay, A; Zhu, Y; Malik, SN; Kreisberg, J; Brattain, MG; Sprague, EA; Luo, J; Lopez-Casillas, F; Sun, LZ			Extracellular domain of TGF beta type III receptor inhibits angiogenesis and tumor growth in human cancer cells	ONCOGENE			English	Article						TGF beta type III receptor; angiogenesis; metastasis; tumor growth	TRANSFORMING GROWTH-FACTOR-BETA-1; SUPPRESSES TUMORIGENICITY; IN-VIVO; BETAGLYCAN; EXPRESSION; PROTEOGLYCAN; METASTASIS; ANTIBODIES; MEMBRANE; STIMULATION	TGFbeta overexpression in human cancer cells has been shown to promote tumor progression. In the present study, we sought to determine whether sequestration of endogenous TGFbeta by the expression of a soluble TGFbeta type III receptor (sRIII), can reduce malignancy in human carcinoma cells and whether the tumor-suppressive activity of sRIII is associated with the inhibition of angiogenesis. Ectopic expression of sRIII significantly inhibited the growth of tumors formed by human colon carcinoma HCT116 and breast carcinoma MDA-MB-435 cells in nude mice. It also reduced the metastatic potential of the MDA-MB-435 cells. Thus, endogenous TGFbeta appears to be necessary for the progression of these two carcinomas. Furthermore, when the tumor cells were mixed with Matrigel and embedded subcutaneously in nude mice, the blood volume in Matrigel plugs containing sRIII-expressing cells as indicated by hemoglobin levels was significantly lower than that in Matrigel plugs containing the respective control cells. Blood vessel counts in paraffin sections of the Matrigel plugs containing sRIII-expressing cells were also significantly lower than those in paraffin sections of the Matrigel plugs containing control cells. Treatment of human endothelial cells with a recombinant sRIII significantly inhibited their ability to form a capillary web structure on Matrigel. These results for the first time indicate that the sRIII-induced tumor suppression appears to be in part due to the inhibition of angiogenesis.	Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Surg, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Radiol, San Antonio, TX 78229 USA; Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Biol Celular, Mexico City 04510, DF, Mexico	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Universidad Nacional Autonoma de Mexico	Sun, LZ (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	SUNL@UTHSCSA.EDU	, LuZhe/AAW-4095-2021		NATIONAL CANCER INSTITUTE [R01CA079683, R01CA075253, R01CA072001, R01CA050457] Funding Source: NIH RePORTER; NCI NIH HHS [CA79683, CA75253, CA72001, CA50457] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; ARTEAGA CL, 1990, CELL GROWTH DIFFER, V1, P367; ARTEAGA CL, 1993, CELL GROWTH DIFFER, V4, P193; ARTEAGA CL, 1993, J CLIN INVEST, V92, P2569, DOI 10.1172/JCI116871; Bandyopadhyay A, 1999, CANCER RES, V59, P5041; BOYD DD, 1988, CANCER RES, V48, P2469; BRATTAIN MG, 1984, CANCER METAST REV, V3, P177, DOI 10.1007/BF00048384; CARMICHAEL J, 1987, CANCER RES, V47, P936; Chen CG, 1997, J BIOL CHEM, V272, P12862, DOI 10.1074/jbc.272.19.12862; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Chishima T, 1997, CANCER RES, V57, P2042; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Esparza-Lopez J, 2001, J BIOL CHEM, V276, P14588, DOI 10.1074/jbc.M008866200; Fajardo LF, 1996, LAB INVEST, V74, P600; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOLKMAN J, 1972, ANN SURG, V175, P409, DOI 10.1097/00000658-197203000-00014; FRIDMAN R, 1991, JNCI-J NATL CANCER I, V83, P769, DOI 10.1093/jnci/83.11.769; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Harlow E LD, 1988, ANTIBODIES LAB MANUA; HERBST TJ, 1988, J CELL BIOL, V106, P1365, DOI 10.1083/jcb.106.4.1365; JOSEPH A, 1995, J NATL CANCER I, V87, P372, DOI 10.1093/jnci/87.5.372; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; MADRI JA, 1988, J CELL BIOL, V106, P1375, DOI 10.1083/jcb.106.4.1375; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; NORGAARD P, 1995, CANCER TREAT REV, V21, P367, DOI 10.1016/0305-7372(95)90038-1; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; PASSANITI A, 1992, LAB INVEST, V67, P519; PRICE JE, 1990, CANCER RES, V50, P717; Price JE, 1996, BREAST CANCER RES TR, V39, P93, DOI 10.1007/BF01806081; Reiss M, 1999, MICROBES INFECT, V1, P1327, DOI 10.1016/S1286-4579(99)00251-8; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; Sun LZ, 1997, J BIOL CHEM, V272, P25367, DOI 10.1074/jbc.272.40.25367; UEKI N, 1992, BIOCHIM BIOPHYS ACTA, V1137, P189; UEKI N, 1993, JPN J CANCER RES, V84, P589, DOI 10.1111/j.1349-7006.1993.tb02017.x; Vilchis-Landeros MM, 2001, BIOCHEM J, V355, P215, DOI 10.1042/0264-6021:3550215; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; WELCH DR, 1990, P NATL ACAD SCI USA, V87, P7678, DOI 10.1073/pnas.87.19.7678; YANG EY, 1990, J CELL BIOL, V111, P731, DOI 10.1083/jcb.111.2.731; Ye SC, 1999, CANCER RES, V59, P4725; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523	43	69	78	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3541	3551		10.1038/sj.onc.1205439	http://dx.doi.org/10.1038/sj.onc.1205439			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032856				2022-12-17	WOS:000175793700005
J	Sim, EUH; Smith, A; Szilagi, E; Rae, F; Ioannou, P; Lindsay, MH; Little, MH				Sim, EUH; Smith, A; Szilagi, E; Rae, F; Ioannou, P; Lindsay, MH; Little, MH			Wnt-4 regulation by the Wilms' tumour suppressor gene, WT1	ONCOGENE			English	Article						Wnt-4; WT1; Denys-Drash syndrome; kidney development; expression profiling	DNA-BINDING; ORNITHINE-DECARBOXYLASE; REPRESSES TRANSCRIPTION; SUSCEPTIBILITY GENE; GROWTH-FACTOR; PROTEIN; EXPRESSION; TARGET; TRANSFORMATION; ASSOCIATION	The Wilms' tumour suppressor gene, WT1, encodes multiple nuclear protein isoforms, all containing four C-terminal zinc finger motifs. WT1 proteins can both activate and repress putative target genes in vitro, although the in vivo relevance of these putative target genes is often unverified. WT1 mutations can result in Wilms' tumour and the Denys-Drash Syndrome (DDS) of infantile nephropathy, XY pseudohermaphroditism and predisposition to Wilms' tumour. We have established stable transfectants of the mouse mesonephric cell line, M15, which express WT1 harbouring a common DDS point mutation (R394W). A comparison of the expression profiles of M15 and transfectant C2A was performed using Nylon-based arrays. Very few genes showed differential expression. However Wnt-4, a member of the Wnt gene family of secreted glycoproteins, was downregulated in C2A and other similar clones. Doxycycline induction of WT1-A or WT1-D expression in HEK293 stable transfectants also elicited an elevation in Wnt4 expression. Wnt4 is critical for the mesenchyme-to-epithetial transition during kidney development, making it an attractive putative WT1 target. We have mapped human Wnt-4 gene to chromosome 1p35-36, a region of frequent LOH in WT, have characterized the genomic structure of the human Wnt4 gene and isolated 9 kb of immediate promoter. While several potential WT1 binding sites exist within this promoter, reporter analysis does not strongly support the direct regulation of Wnt4 by WT1. We propose that Wnt-4 regulation by WT1 occurs at a more distant promoter or enhancer site, or is indirect.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Dept Biochem, Brisbane, Qld 4072, Australia; Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia	University of Queensland; University of Queensland; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne	Little, MH (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	M.Little@imb.uq.edu.au	Smith, Aaron/A-8329-2010; Sim, Edmund Ui-Hang/J-2863-2019; Little, Melissa Helen/A-6170-2010	Sim, Edmund Ui-Hang/0000-0001-8652-8495; Little, Melissa Helen/0000-0003-0380-2263				Bergstein I, 1997, GENOMICS, V46, P450, DOI 10.1006/geno.1997.5041; Borel F, 1996, BIOCHEMISTRY-US, V35, P12070, DOI 10.1021/bi960758o; Bruening W, 1996, J BIOL CHEM, V271, P8646, DOI 10.1074/jbc.271.15.8646; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Christiansen JH, 1996, ONCOGENE, V12, P2705; Dejong V, 1999, ONCOGENE, V18, P3143, DOI 10.1038/sj.onc.1202654; Englert C, 1997, CANCER RES, V57, P1429; EVERS R, 1995, EMBO J, V14, P1248, DOI 10.1002/j.1460-2075.1995.tb07108.x; FRAIZER GC, 1994, J BIOL CHEM, V269, P8892; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; GAVIN BJ, 1990, DEVELOPMENT, V3, P2319; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HAMILTON TB, 1995, NUCLEIC ACIDS RES, V23, P277, DOI 10.1093/nar/23.2.277; HEWITT SM, 1995, CANCER RES, V55, P5386; Holmes G, 1997, BIOCHEM BIOPH RES CO, V233, P723, DOI 10.1006/bbrc.1997.6545; Hosono S, 1999, ONCOGENE, V18, P417, DOI 10.1038/sj.onc.1202311; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; Kim J, 1999, MOL CELL BIOL, V19, P2289; Koesters R, 1999, CANCER RES, V59, P3880; KU M, 1993, DEVELOPMENT, V119, P1161; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; Li RS, 1999, EXP CELL RES, V247, P257, DOI 10.1006/excr.1998.4361; Little M, 1999, BIOESSAYS, V21, P191, DOI 10.1002/(SICI)1521-1878(199903)21:3<191::AID-BIES3>3.3.CO;2-#; Little M, 1997, HUM MUTAT, V9, P209, DOI 10.1002/(SICI)1098-1004(1997)9:3<209::AID-HUMU2>3.0.CO;2-2; LITTLE M, 1995, HUM MOL GENET, V4, P351, DOI 10.1093/hmg/4.3.351; Little MH, 1996, ONCOGENE, V13, P1461; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MATSUNAGA E, 1981, HUM GENET, V57, P231; MILLER RW, 1964, NEW ENGL J MED, V270, P922, DOI 10.1056/NEJM196404302701802; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Moshier JA, 1996, NUCLEIC ACIDS RES, V24, P1149, DOI 10.1093/nar/24.6.1149; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; Nusse R, 1999, TRENDS GENET, V15, P1, DOI 10.1016/S0168-9525(98)01634-5; Oh S, 1999, J BIOL CHEM, V274, P37473, DOI 10.1074/jbc.274.52.37473; Patek CE, 1999, P NATL ACAD SCI USA, V96, P2931, DOI 10.1073/pnas.96.6.2931; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rahman N, 1998, HUM GENET, V103, P547, DOI 10.1007/PL00008708; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; Scharnhorst V, 1999, J BIOL CHEM, V274, P23456, DOI 10.1074/jbc.274.33.23456; SHARMA PM, 1994, GENE DEV, V8, P720, DOI 10.1101/gad.8.6.720; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; SHOYAB M, 1988, P NATL ACAD SCI USA, V85, P6528, DOI 10.1073/pnas.85.17.6528; SINGER RH, 1992, CURR OPIN CELL BIOL, V4, P1; SLATER RM, 1992, CANCER GENET CYTOGEN, V61, P111, DOI 10.1016/0165-4608(92)90071-F; Stanhope-Baker P, 2000, J BIOL CHEM, V275, P38139, DOI 10.1074/jbc.M004901200; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; Thate C, 1998, ONCOGENE, V17, P1287, DOI 10.1038/sj.onc.1202055; Vainio S, 1999, NATURE, V397, P405, DOI 10.1038/17068; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278	58	69	71	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2002	21	19					2948	2960		10.1038/sj.onc.1205373	http://dx.doi.org/10.1038/sj.onc.1205373			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082525	Green Accepted			2022-12-17	WOS:000175262700002
J	Griffiths, GJ; Corfe, BM; Savory, P; Leech, S; Esposti, MD; Hickman, JA; Dive, C				Griffiths, GJ; Corfe, BM; Savory, P; Leech, S; Esposti, MD; Hickman, JA; Dive, C			Cellular damage signals promote sequential changes at the N-terminus and BH-1 domain of the pro-apoptotic protein Bak	ONCOGENE			English	Article						apoptosis; chemotherapy; Bak; Bcl-x(L); cytochrome c	INDUCED CONFORMATIONAL CHANGE; CYTOCHROME-C RELEASE; BCL-X-L; SURVIVAL SIGNALS; DEATH; MITOCHONDRIA; BCL-X(L); MEMBRANE; LOCALIZATION; DIMERIZATION	The pro-apoptotic protein Bak is converted from a latent to an active form by damage-induced signals. This process involves an early exposure of an occluded N-terminal epitope of Bak in intact cells. Here we report a subsequent damage-induced change in Bak, detected using an antibody to the central BH-1 domain. Bak coimmunoprecipitated with Bcl-x(L) both in undamaged cells and early after damage, when the N-terminal epitope was exposed but the BH-1 epitope remained occluded. A subsequent decrease in binding of Bak to Bcl-x(L) correlated with exposure of an epitope in the Bak BH-1 domain. Overexpression of Bcl-x(L) did not affect the kinetics of exposure of the Bak N-terminal epitope but delayed exposure of the BH-1 domain. Cytochrome c release from mitochondria facilitates the activation of apoptotic caspases. The majority of cells with exposed Bak BH-1 domains contained cytosolic cytochrome c. However, a small proportion of cells exhibited exposed Bak BH-1 domains that co-localized with mitochondrial cytochrome c. The data are consistent with a two-step model for the activation of Bak by drug-induced damage signals where dissociation of Bcl-x(L) from the BH-1 domain of Bak occurs immediately prior to or concomitantly with cytochrome c release.	Univ Manchester, Sch Biol Sci, CRC, Mol Pharmacol Grp, Manchester M13 9PT, Lancs, England; Inst Rech Servier, F-92150 Suresnes, France	University of Manchester; Servier; Institut de Recherches Internationales Servier	Dive, C (corresponding author), Univ Manchester, Sch Biol Sci, G38 Stopford Bldg,Oxford Rd, Manchester B13 9PT, Lancs, England.		Degli Esposti, Mauro/C-3270-2012	Dive, Caroline/0000-0002-1726-8850; Corfe, Bernard/0000-0003-0449-2228; Degli Esposti, Mauro/0000-0002-0977-119X				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; MIYASHITA T, 1995, CELL, V80, P293; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Murphy KM, 2000, J BIOL CHEM, V275, P17225, DOI 10.1074/jbc.C900590199; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Taylor ST, 2000, J NATL CANCER I, V92, P18, DOI 10.1093/jnci/92.1.18; Wang K, 1998, MOL CELL BIOL, V18, P6083, DOI 10.1128/MCB.18.10.6083; Wei MC, 2000, GENE DEV, V14, P2060; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	30	69	72	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 15	2001	20	52					7668	7676		10.1038/sj.onc.1204995	http://dx.doi.org/10.1038/sj.onc.1204995			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	491TC	11753644				2022-12-17	WOS:000172124100009
J	Kastner, P; Chan, S				Kastner, P; Chan, S			Function of RAR alpha during the maturation of neutrophils	ONCOGENE			English	Article						retinoids; granulocyte; differentiation	RETINOIC ACID RECEPTOR; THYROID-HORMONE RECEPTOR; BINDING-PROTEIN EPSILON; MYC ANTAGONIST MAD1; RXR-ALPHA; ERYTHROID-DIFFERENTIATION; TRANSCRIPTIONAL ACTIVATION; MYELOID PROGENITORS; HISTONE DEACETYLASE; HEMATOPOIETIC-CELLS	The retinoic acid receptor alpha gene is the target of chromosomal rearrangements in all cases of acute promyelocytic leukemia (APL). This recurrent involvement of RAR alpha in the pathogenesis of APL is likely to reflect an important role played by this receptor during the differentiation of immature myeloid cells to neutrophils. RAR alpha is a negative regulator of promyelocyte differentiation when not complexed with RA, and stimulates this differentiation when bound to RA. Since RARs are dispensable for the generation of mature neutrophils, their role thus appears to be to modulatory, rather than obligatory, for the control of neutrophil differentiation. In vitro, retinoic acid is also a potent inducer of neutrophil cell fate, suggesting that it might play a role in the commitment of pluripotent hematopoietic progenitors to the neutrophil lineage. Thus, the APL translocations target an important regulator of myeloid cell differentiation.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Chan, S (corresponding author), ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries,BP163, F-67404 Illkirch Graffenstaden, France.	scpk@igbmc.u-strasbg.fr						Altucci L, 2001, NAT MED, V7, P680, DOI 10.1038/89050; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; Bauer A, 1998, EMBO J, V17, P4291, DOI 10.1093/emboj/17.15.4291; BOEHM MF, 1995, J MED CHEM, V38, P3146, DOI 10.1021/jm00016a018; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chiba H, 1997, MOL CELL BIOL, V17, P3013, DOI 10.1128/MCB.17.6.3013; Chih DY, 1997, BLOOD, V90, P2987, DOI 10.1182/blood.V90.8.2987; Cultraro CM, 1997, MOL CELL BIOL, V17, P2353, DOI 10.1128/MCB.17.5.2353; Dilworth FJ, 2000, MOL CELL, V6, P1049, DOI 10.1016/S1097-2765(00)00103-9; DINNEN RD, 1994, CELL GROWTH DIFFER, V5, P855; DRACH J, 1994, CANCER RES, V54, P1746; Du CC, 1999, BLOOD, V94, P793, DOI 10.1182/blood.V94.2.793.414k43_793_802; Fajas L, 1998, CURR OPIN CELL BIOL, V10, P165, DOI 10.1016/S0955-0674(98)80138-5; Foley KP, 1998, EMBO J, V17, P774, DOI 10.1093/emboj/17.3.774; Fraichard A, 1997, EMBO J, V16, P4412, DOI 10.1093/emboj/16.14.4412; Ghyselinck NB, 1997, INT J DEV BIOL, V41, P425; Glass CK, 2000, GENE DEV, V14, P121; GRATAS C, 1993, LEUKEMIA, V7, P1156; GRIEP AE, 1988, P NATL ACAD SCI USA, V85, P6806, DOI 10.1073/pnas.85.18.6806; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; Hashimoto K, 2001, P NATL ACAD SCI USA, V98, P3998, DOI 10.1073/pnas.051454698; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Imai T, 2001, P NATL ACAD SCI USA, V98, P4581, DOI 10.1073/pnas.071056098; Imai T, 2001, P NATL ACAD SCI USA, V98, P224, DOI 10.1073/pnas.011528898; JIANG HP, 1994, ONCOGENE, V9, P3397; Kastner P, 1997, DEVELOPMENT, V124, P313; Kastner P, 1996, GENE DEV, V10, P80, DOI 10.1101/gad.10.1.80; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; Kastner P, 2001, BLOOD, V97, P1314, DOI 10.1182/blood.V97.5.1314; KASTNER P, 1994, CELL, V78, P987, DOI 10.1016/0092-8674(94)90274-7; Krezel W, 1998, SCIENCE, V279, P863, DOI 10.1126/science.279.5352.863; Krezel W, 1996, P NATL ACAD SCI USA, V93, P9010, DOI 10.1073/pnas.93.17.9010; Kuwata T, 2000, BLOOD, V95, P3349, DOI 10.1182/blood.V95.11.3349; LABBAYE C, 1994, BLOOD, V83, P651; Labrecque J, 1998, BLOOD, V92, P607, DOI 10.1182/blood.V92.2.607.414k06_607_615; Lane MD, 1999, BIOCHEM BIOPH RES CO, V266, P677, DOI 10.1006/bbrc.1999.1885; Lawson ND, 1999, EXP HEMATOL, V27, P1682, DOI 10.1016/S0301-472X(99)00108-3; Lawson ND, 1999, EXP HEMATOL, V27, P1355, DOI 10.1016/S0301-472X(99)00085-5; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; Li M, 2000, NATURE, V407, P633, DOI 10.1038/35036595; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; Liu TX, 2000, BLOOD, V96, P1496, DOI 10.1182/blood.V96.4.1496.h8001496_1496_1504; LOHNES D, 1994, DEVELOPMENT, V120, P2723; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; Mascrez B, 1998, DEVELOPMENT, V125, P4691; Mascrez B, 2001, DEVELOPMENT, V128, P2049; Matikainen S, 1996, BLOOD, V88, P114; Mehta K, 1996, CELL GROWTH DIFFER, V7, P179; Mehta K, 1997, BLOOD, V89, P3607, DOI 10.1182/blood.V89.10.3607.3607_3607_3614; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; MENDELSOHN C, 1994, DEVELOPMENT, V120, P2749; METZ T, 1992, ONCOGENE, V7, P597; Minucci S, 1999, SEMIN CELL DEV BIOL, V10, P215, DOI 10.1006/scdb.1999.0303; Monczak Y, 1997, BLOOD, V90, P3345, DOI 10.1182/blood.V90.9.3345; NAGPAL S, 1992, P NATL ACAD SCI USA, V89, P2718, DOI 10.1073/pnas.89.7.2718; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Niederreither K, 1999, NAT GENET, V21, P444, DOI 10.1038/7788; ONODERA M, 1995, ONCOGENE, V11, P1291; PANDOLFI PP, 1992, EMBO J, V11, P1397, DOI 10.1002/j.1460-2075.1992.tb05185.x; Park DJ, 1999, J CLIN INVEST, V103, P1399, DOI 10.1172/JCI2887; PAUL CC, 1995, BLOOD, V86, P3737, DOI 10.1182/blood.V86.10.3737.bloodjournal86103737; Pulverer B, 2000, J CELL PHYSIOL, V183, P399, DOI 10.1002/(SICI)1097-4652(200006)183:3<399::AID-JCP13>3.3.CO;2-Z; Purton LE, 2000, BLOOD, V95, P470, DOI 10.1182/blood.V95.2.470; Purton LE, 1999, BLOOD, V94, P483, DOI 10.1182/blood.V94.2.483.414k12_483_495; Rochette-Egly C, 2001, HISTOL HISTOPATHOL, V16, P909, DOI 10.14670/HH-16.909; Rodriguez-Pena A, 1999, J NEUROBIOL, V40, P497, DOI 10.1002/(SICI)1097-4695(19990915)40:4<497::AID-NEU7>3.0.CO;2-#; Subbarayan V, 1997, MECH DEVELOP, V66, P131, DOI 10.1016/S0925-4773(97)00098-1; SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007; Taneja R, 1997, EMBO J, V16, P6452, DOI 10.1093/emboj/16.21.6452; Tocci A, 1996, BLOOD, V88, P2878, DOI 10.1182/blood.V88.8.2878.bloodjournal8882878; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831; TSAI S, 1993, P NATL ACAD SCI USA, V90, P7153, DOI 10.1073/pnas.90.15.7153; Ueno H, 1998, LEUKEMIA RES, V22, P517, DOI 10.1016/S0145-2126(98)00026-5; VANBOCKSTAELE DR, 1993, ANN HEMATOL, V66, P61, DOI 10.1007/BF01695885; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P13187, DOI 10.1073/pnas.94.24.13187; ZAULI G, 1995, BRIT J HAEMATOL, V90, P274, DOI 10.1111/j.1365-2141.1995.tb05147.x	85	69	73	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2001	20	49					7178	7185		10.1038/sj.onc.1204757	http://dx.doi.org/10.1038/sj.onc.1204757			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487TM	11704846				2022-12-17	WOS:000171891900006
J	Janicke, RU; Engels, IH; Dunkern, T; Kaina, B; Schulze-Osthoff, K; Porter, AG				Janicke, RU; Engels, IH; Dunkern, T; Kaina, B; Schulze-Osthoff, K; Porter, AG			Ionizing radiation but not anticancer drugs causes cell cycle arrest and failure to activate the mitochondrial death pathway in MCF-7 breast carcinoma cells	ONCOGENE			English	Article						apoptosis; intrinsic death pathway; DNA; damage; cell cycle arrest	CYTOCHROME-C RELEASE; ETOPOSIDE-INDUCED APOPTOSIS; HUMAN LYMPHOMA-CELLS; CASPASE ACTIVATION; TUMOR-CELLS; DNA-DAMAGE; P53-DEPENDENT APOPTOSIS; THYMOCYTE APOPTOSIS; DEPENDENT APOPTOSIS; SIGNALING COMPLEX	There is considerable evidence that ionizing radiation (IR) and chemotherapeutic drugs mediate apoptosis through the intrinsic death pathway via the release of mitochondrial cytochrome c and activation of caspases-9 and -3. Here we show that MCF-7 cells that lack caspase-3 undergo a caspase-dependent apoptotic cell death in the absence of DNA fragmentation and x-fodrin cleavage following treatment with etoposide or doxorubicin, but not after exposure to IR. Re-expression of caspase-3 restored DNA fragmentation and a-fodrin cleavage following drug treatment, but it did not alter the radiation-resistant phenotype of these cells. In contrast to the anticancer drugs, IR failed to induce the intrinsic death pathway in MCF-7/casp-3 cells, an event readily observed in IR-induced apoptosis of HeLa cells. Although IR-induced DNA double-strand breaks were repaired with similar efficiencies in all cell lines, cell cycle analyses revealed a persistent G2/M arrest in the two MCF-7 cell lines, but not in HeLa cells. Together, our data demonstrate that caspase-3 is required for DNA fragmentation and a-fodrin cleavage in drug-induced apoptosis and that the intrinsic death pathway is fully functional in MCF-7 cells. Furthermore, they show that the radiation-resistant phenotype of MCF-7 cells is not due to the lack of caspase-3, but is caused by the failure of IR to activate the intrinsic death pathway. We propose (1) different signaling pathways are induced by anticancer drugs and IR, and (2) IR-induced G2/M arrest prevents the generation of an apoptotic signal required for the activation of the intrinsic death pathway.	Univ Munster, Dept Immunol & Cell Biol, D-48149 Munster, Germany; Univ Mainz, Inst Toxicol, D-55131 Mainz, Germany; Inst Mol & Cell Biol, Singapore 117609, Singapore	University of Munster; Johannes Gutenberg University of Mainz; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Janicke, RU (corresponding author), Univ Munster, Dept Immunol & Cell Biol, Rontgenstr 21, D-48149 Munster, Germany.		Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chen Q, 2000, CELL DEATH DIFFER, V7, P227, DOI 10.1038/sj.cdd.4400629; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; Droin N, 1998, ONCOGENE, V16, P2885, DOI 10.1038/sj.onc.1201821; Dubrez L, 1996, EMBO J, V15, P5504, DOI 10.1002/j.1460-2075.1996.tb00935.x; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; FAN SJ, 1995, CANCER RES, V55, P1649; FAN SJ, 1994, CANCER RES, V54, P5824; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Fuchs EJ, 1997, CANCER RES, V57, P2550; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hannun YA, 1997, BLOOD, V89, P1845, DOI 10.1182/blood.V89.6.1845; Heenan M, 1996, CYTOTECHNOLOGY, V19, P237, DOI 10.1007/BF00744218; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Janicke RU, 1996, MOL CELL BIOL, V16, P5245; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Klaude M, 1996, MUTAT RES-DNA REPAIR, V363, P89, DOI 10.1016/0921-8777(95)00063-1; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Lee Y, 1999, J BIOL CHEM, V274, P19792, DOI 10.1074/jbc.274.28.19792; LEHNERT S, 1989, RADIAT RES, V118, P568, DOI 10.2307/3577414; Levenson AS, 1997, CANCER RES, V57, P3071; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Martins LM, 1997, J BIOL CHEM, V272, P7421, DOI 10.1074/jbc.272.11.7421; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OSHITA F, 1992, J CANCER RES CLIN, V119, P28, DOI 10.1007/BF01209484; Porter AG, 1997, BIOESSAYS, V19, P501, DOI 10.1002/bies.950190609; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; Sabbatini P, 1997, CELL GROWTH DIFFER, V8, P643; Schmitt CA, 1999, J PATHOL, V187, P127; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Simizu S, 1998, J BIOL CHEM, V273, P26900, DOI 10.1074/jbc.273.41.26900; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Van de Craen M, 1998, CELL DEATH DIFFER, V5, P838, DOI 10.1038/sj.cdd.4400444; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Vassault A, 1984, METHODS ENZYM ANAL, V3, P118; Wang JYJ, 1998, CURR OPIN CELL BIOL, V10, P240, DOI 10.1016/S0955-0674(98)80146-4; Wertz IE, 1996, TRENDS BIOCHEM SCI, V21, P359, DOI 10.1016/0968-0004(96)40002-0; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yu YJ, 1998, CANCER RES, V58, P4277; ZHAN QM, 1994, ONCOGENE, V9, P3743; Zheng TS, 1998, P NATL ACAD SCI USA, V95, P13618, DOI 10.1073/pnas.95.23.13618	64	69	72	1	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 16	2001	20	36					5043	5053		10.1038/sj.onc.1204659	http://dx.doi.org/10.1038/sj.onc.1204659			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526489				2022-12-17	WOS:000170439800014
J	Jia, L; Patwari, Y; Srinivasula, SM; Newland, AC; Fernandes-Alnemri, T; Alnemri, ES; Kelsey, SM				Jia, L; Patwari, Y; Srinivasula, SM; Newland, AC; Fernandes-Alnemri, T; Alnemri, ES; Kelsey, SM			Bax translocation is crucial for the sensitivity of leukaemic cells to etoposide-induced apoptosis	ONCOGENE			English	Article						apoptosis; Bax expression and translocation; caspases; chemotherapy; etoposide; leukaemia	CYTOCHROME-C; BCR-ABL; DEPENDENT APOPTOSIS; CASPASE ACTIVATION; BCL-2; P53; RELEASE; MITOCHONDRIA; INDUCTION; RESISTANT	Bax translocation from cytosol to mitochondria is believed to be a crucial step for triggering cytochrome c release from mitochondria. However, it is unclear whether Bax translocation is associated with Bax induction by DNA damaging agents. The induction of Bax in response to DNA damaging agents has been considered to be linked with p53. In this study, we used the p53 negative human chronic myeloid leukaemia K562 cell line. Bax up-regulation occurred at the whole cell level after DNA damage induced by etoposide. However, after incubation with etoposide, Bax failed to translocate to mitochondria and as a result, the apoptotic process was blocked. A Bax stable transfectant, the K/Bax cell line, expressed more Bax protein in the cytosol, mitochondria and nuclei. This Bax overexpression induced cytochrome c release, a reduction of cytochrome c oxidase activity and mitochondrial membrane potential (Delta Psim). However, Bax-induced apoptosis was blocked downstream of mitochondria in K562 cells. The increased levels of mitochondrial Bax sensitized cells to etoposide-induced activation of caspases-2, -3 and -9 and apoptosis. However, after transient transfection with the Apaf-1 gene, K/Bax cells were sensitized to etoposide-induced caspase activation and apoptosis to a larger extent compared with Bax or Apaf-1 transfection alone. We therefore conclude that two mechanisms contribute to the resistance of K562 cells to etoposide-induced apoptosis; firstly failure of Bax targeting to mitochondria and, secondly, deficiency of Apaf-1. Uncoupling of Bax translocation from Bax induction can occur in response to etoposide-induced DNA damage.	St Bartholomews & Royal London Sch Med & Dent, Dept Haematol, London E1 2AD, England; Thomas Jefferson Univ, Dept Microbiol & Immunol, Kimmel Canc Inst, Philadelphia, PA 19107 USA	University of London; Queen Mary University London; Jefferson University	Jia, L (corresponding author), St Bartholomews & Royal London Sch Med & Dent, Dept Haematol, Turner St, London E1 2AD, England.	L.Jia@mds.qmw.ac.uk	Alnemri, Emad S/B-4526-2010	Jia, Li/0000-0002-6076-8455				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Deng YB, 2000, P NATL ACAD SCI USA, V97, P12050, DOI 10.1073/pnas.97.22.12050; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Fang GF, 2000, BLOOD, V96, P2246, DOI 10.1182/blood.V96.6.2246.h8002246_2246_2253; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Fu WN, 2001, BIOCHEM BIOPH RES CO, V282, P268, DOI 10.1006/bbrc.2001.4575; Fukumi S, 2000, MOL CELL BIOCHEM, V206, P43, DOI 10.1023/A:1007056727876; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Jia L, 1996, BLOOD, V87, P2401, DOI 10.1182/blood.V87.6.2401.bloodjournal8762401; Jia L, 1997, BRIT J HAEMATOL, V98, P686, DOI 10.1046/j.1365-2141.1997.2683085.x; Jia L, 2001, BLOOD, V98, P414, DOI 10.1182/blood.V98.2.414; Jia L, 1999, BLOOD, V93, P2353, DOI 10.1182/blood.V93.7.2353.407k20_2353_2359; KANTER PM, 1982, MOL PHARMACOL, V22, P145; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Landowski TH, 1999, BLOOD, V94, P265, DOI 10.1182/blood.V94.1.265.413k37_265_274; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LUBBERT M, 1988, J EXP MED, V167, P873, DOI 10.1084/jem.167.3.873; Martins LM, 1997, BLOOD, V90, P4283, DOI 10.1182/blood.V90.11.4283.4283_4283_4296; MIYASHITA T, 1995, CELL, V80, P293; Perkins C, 2000, BLOOD, V95, P1014, DOI 10.1182/blood.V95.3.1014.003k04_1014_1022; PROKOCIMER M, 1986, BLOOD, V68, P113; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Svingen PA, 2000, BLOOD, V96, P3922, DOI 10.1182/blood.V96.12.3922.h8003922_3922_3931; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZHAN QM, 1994, ONCOGENE, V9, P3743	31	69	73	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2001	20	35					4817	4826		10.1038/sj.onc.1204628	http://dx.doi.org/10.1038/sj.onc.1204628			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521193				2022-12-17	WOS:000170271800006
J	Gershenwald, JE; Sumner, W; Calderone, T; Wang, Z; Huang, SY; Bar-Eli, M				Gershenwald, JE; Sumner, W; Calderone, T; Wang, Z; Huang, SY; Bar-Eli, M			Dominant-negative transcription factor AP-2 augments SB-2 melanoma tumor growth in vivo	ONCOGENE			English	Article						melanoma; angiogenesis; metastasis; matrix metallaproteinase-2; transcriptional regulation	HUMAN-MALIGNANT MELANOMA; MMP-2 IMMUNOREACTIVE PROTEIN; PRIMARY CUTANEOUS MELANOMA; IV COLLAGENASE GENE; C-KIT EXPRESSION; DNA-BINDING; E-CADHERIN; MATRIX METALLOPROTEINASES; SIGNAL-TRANSDUCTION; RELATIVE EXPRESSION	We have previously demonstrated that the transition of melanoma to the metastatic phenotype is associated with a loss of expression of the transcription factor AP-2. To further investigate the role of AP-2 in the progression of human melanoma, we attempted to inactivate AP-2 in primary cutaneous SB-2 melanoma cells by using a dominant-negative AP-2, or AP-2B, gene, AP-2B is an alternatively spliced AP-2 variant capable of inhibiting AP-2 trans-activator function, Stable transfection of primary cutaneous melanoma SB-2 cells with the dominant-negative AP-2B gene was confirmed by RT-PCR and Northern blot analyses, Electromobility shift assay using nuclear extracts from these cell lines demonstrated decreased functional binding of AP-2B-transfected cells to the AP-2 consensus binding sequence compared with neo-transfected controls. In addition, CAT activity driven by a construct containing the AP-2 consensus binding sequence was downregulated in the AP-2B transfected cells, indicating AP-2 activity was quenched in the transfected cells, Orthotopic (subcutaneous) injection of the dominant-negative (AP-2B)-transfected cell lines into nude mice increased their tumorigenicity compared to control neo-transfected cells, The AP-2B-transfected cells displayed an increase in MMP-2 expression (by Northern blot) and MMP-2 activity (by zymography), which resulted in an increase in invasiveness through Matrigel-coated filters. The AP-2B-transfected tumors also displayed an increase in MMP-2 expression, microvessel density, and angiogenesis in vivo. These results demonstrate that inactivation of AP-2 contributes to the progression of melanoma, at least partially via deregulation of the MMP-2 gene.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Bar-Eli, M (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Gershenwald, Jeff/AAX-4367-2020	Gershenwald, Jeff/0000-0003-4519-5369	NATIONAL CANCER INSTITUTE [T32CA009599, R01CA076098] Funding Source: NIH RePORTER; NCI NIH HHS [CA76098, T-32 CA09599] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ariizumi K, 1996, J DERMATOL SCI, V12, P147, DOI 10.1016/0923-1811(95)00474-2; Bar-Eli M, 1999, CANCER METAST REV, V18, P377, DOI 10.1023/A:1006377309524; BarEli M, 1997, J CELL PHYSIOL, V173, P275, DOI 10.1002/(SICI)1097-4652(199711)173:2<275::AID-JCP35>3.0.CO;2-C; BAUER R, 1994, NUCLEIC ACIDS RES, V22, P1413, DOI 10.1093/nar/22.8.1413; BLOOD CH, 1990, BIOCHIM BIOPHYS ACTA, V1032, P89, DOI 10.1016/0304-419X(90)90014-R; BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; COPEMAN MC, 1992, PATHOLOGY, V24, P307, DOI 10.3109/00313029209068886; DESCHEEMAEKER KA, 1992, J BIOL CHEM, V267, P15086; DUAN CM, 1995, J BIOL CHEM, V270, P24844, DOI 10.1074/jbc.270.42.24844; Fang D, 1999, BIOCHEM BIOPH RES CO, V256, P657, DOI 10.1006/bbrc.1999.0400; FIDLER IJ, 1990, CANCER RES, V50, P6130; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRISCH SM, 1990, MOL CELL BIOL, V10, P6524, DOI 10.1128/MCB.10.12.6524; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; GAYNOR RB, 1991, GENOMICS, V10, P1100, DOI 10.1016/0888-7543(91)90209-W; Goding CR, 2000, GENE DEV, V14, P1712; GretherBeck S, 1996, P NATL ACAD SCI USA, V93, P14586, DOI 10.1073/pnas.93.25.14586; HASLINGER A, 1985, P NATL ACAD SCI USA, V82, P8572, DOI 10.1073/pnas.82.24.8572; HEALY E, 1995, GENE CHROMOSOME CANC, V12, P152, DOI 10.1002/gcc.2870120211; Herbst RS, 2000, CLIN CANCER RES, V6, P790; Hofmann UB, 1999, BRIT J CANCER, V81, P774, DOI 10.1038/sj.bjc.6690763; HOLMAN CDJ, 1980, INT J CANCER, V25, P317, DOI 10.1002/ijc.2910250303; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; Huang S, 2000, CLIN CANCER RES, V6, P2573; Huang SY, 1996, ONCOGENE, V13, P2339; HUHTALA P, 1990, J BIOL CHEM, V265, P11077; HYMAN SE, 1989, MOL CELL BIOL, V9, P321, DOI 10.1128/MCB.9.1.321; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Jean D, 2000, MOL CELL BIOCHEM, V212, P19, DOI 10.1023/A:1007128101751; Jean D, 1998, J BIOL CHEM, V273, P24884, DOI 10.1074/jbc.273.38.24884; Jean D, 1998, J BIOL CHEM, V273, P16501, DOI 10.1074/jbc.273.26.16501; Jean D, 2000, ONCOGENE, V19, P2721, DOI 10.1038/sj.onc.1203569; KANNAN F, 1994, GENE DEV, V8, P1258, DOI 10.1101/gad.8.11.1258; Kannan P, 1999, NUCLEIC ACIDS RES, V27, P866, DOI 10.1093/nar/27.3.866; KANNO M, 1989, EMBO J, V8, P4205, DOI 10.1002/j.1460-2075.1989.tb08606.x; KARELINA TV, 1995, J INVEST DERMATOL, V105, P411, DOI 10.1111/1523-1747.ep12321097; Karjalainen JM, 1998, J CLIN ONCOL, V16, P3584, DOI 10.1200/JCO.1998.16.11.3584; Karjalainen JM, 2000, BRIT J CANCER, V82, P2015; King R, 1999, AM J PATHOL, V155, P731, DOI 10.1016/S0002-9440(10)65172-3; Kuniyasu H, 1999, CLIN CANCER RES, V5, P25; Kuniyasu H, 2000, CLIN CANCER RES, V6, P2295; LASSAM N, 1992, ONCOGENE, V7, P51; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; LI LM, 1989, JNCI-J NATL CANCER I, V81, P1406, DOI 10.1093/jnci/81.18.1406; Liotta L A, 1990, Semin Cancer Biol, V1, P99; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; LIOTTA LA, 1986, CANCER RES, V46, P1; LUCA M, 1993, MELANOMA RES, V3, P35, DOI 10.1097/00008390-199304000-00006; Luca M, 1997, AM J PATHOL, V151, P1105; LUCA M, 1995, ONCOGENE, V11, P1399; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; Maytin EV, 1999, DEV BIOL, V216, P164, DOI 10.1006/dbio.1999.9460; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; NYBORG JK, 1990, J BIOL CHEM, V265, P8230; PATHAK S, 1983, CYTOGENET CELL GENET, V36, P573, DOI 10.1159/000131975; Qin HW, 1999, J BIOL CHEM, V274, P29130, DOI 10.1074/jbc.274.41.29130; Real LM, 1998, INT J CANCER, V75, P317, DOI 10.1002/(SICI)1097-0215(19980119)75:2<317::AID-IJC23>3.0.CO;2-8; ROMERDAHL CA, 1988, CANCER RES, V48, P4007; Ropponen KM, 1999, BRIT J CANCER, V81, P133, DOI 10.1038/sj.bjc.6690662; RUTBERG SE, 1994, MOL CARCINOGEN, V10, P82, DOI 10.1002/mc.2940100205; Schmidt VA, 1996, J BIOL CHEM, V271, P9307, DOI 10.1074/jbc.271.16.9307; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; SHIH IM, 1994, CANCER RES, V54, P2514; SINGH RK, 1995, CANCER RES, V55, P3669; Somasundaram K, 1996, P NATL ACAD SCI USA, V93, P3088, DOI 10.1073/pnas.93.7.3088; TRENT JM, 1989, CANCER RES, V49, P420; Vaisanen A, 1999, J PATHOL, V188, P56; Vaisanen A, 1998, J PATHOL, V186, P51; VERSCHRAEGEN CF, 1991, ANTICANCER RES, V11, P529; WELCH DR, 1994, ONCOGENE, V9, P255; WILLIAMS T, 1991, SCIENCE, V251, P1067, DOI 10.1126/science.1998122; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Xie SH, 1997, CANCER RES, V57, P2295; Xie SH, 1997, ONCOGENE, V15, P2069, DOI 10.1038/sj.onc.1201358; ZAKUT R, 1993, ONCOGENE, V8, P2221; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; ZHANG J, 1995, CANCER RES, V55, P4640; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0	85	69	71	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2001	20	26					3363	3375		10.1038/sj.onc.1204450	http://dx.doi.org/10.1038/sj.onc.1204450			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	441UW	11423987				2022-12-17	WOS:000169248800007
J	Deroo, BJ; Archer, TK				Deroo, BJ; Archer, TK			Glucocorticoid receptor-mediated chromatin remodeling in vivo	ONCOGENE			English	Review						glucocorticoid receptor; chromatin; mouse mammary tumor virus; BRG1; Swi/Snf; histone	HUMAN BREAST-CANCER; TUMOR VIRUS PROMOTER; LINKER HISTONE H1; TRANSCRIPTION IN-VIVO; YEAST SWI/SNF COMPLEX; SWI-SNF COMPLEX; GENE-EXPRESSION; MMTV PROMOTER; RAPID EXCHANGE; LIVING CELLS	The compaction of DNA into chromatin provides an additional level of gene regulation in eukaryotes that may not be available to prokaryotes. When packaged as chromatin, most promoters are transcriptionally repressed, and transcription factors have reduced access to their binding sites. The glucocorticoid receptor (GR) is a ligand-activated transcription factor that regulates the activity of genes involved in many physiological processes. To regulate eukaryotic genes, the GR binds to target sites within promoter regions of genes assembled as chromatin, This interaction alters the nucleosomal architecture to allow binding of other transcription factors, and formation of the preinitiation complex. The mouse mammary tumor virus (MMTV) promoter has been used extensively as a model to explore the processes by which the GR remodels chromatin and activates transcription. Significant progress has been made in our understanding of the mechanisms used by the GR to modify chromatin structure, and the limits placed on the GR by post-translational modifications of histones, We will describe recent developments in the processes used by the GR to activate transcription in vivo via chromatin remodeling complexes, histone H1 phosphorylation, and recruitment of diverse coactivators.	NIEHS, Chromatin & Gene Express Sect, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Archer, TK (corresponding author), NIEHS, Chromatin & Gene Express Sect, Reprod & Dev Toxicol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.		Archer, Trevor K/E-5191-2019	Archer, Trevor K/0000-0001-7651-3644	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES071007] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARCHER TK, 1994, MOL ENDOCRINOL, V8, P1154, DOI 10.1210/me.8.9.1154; Archer TK, 1997, TRENDS ENDOCRIN MET, V8, P384, DOI 10.1016/S1043-2760(97)00159-8; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; ARCHER TK, 1989, STEROID THYROID HORM, P221; Armstrong JA, 1998, CELL, V95, P93, DOI 10.1016/S0092-8674(00)81785-7; Bartsch J, 1996, P NATL ACAD SCI USA, V93, P10741, DOI 10.1073/pnas.93.20.10741; BOUVET P, 1994, GENE DEV, V8, P1147, DOI 10.1101/gad.8.10.1147; BRESNICK EH, 1990, P NATL ACAD SCI USA, V87, P3977, DOI 10.1073/pnas.87.10.3977; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P273, DOI 10.1093/nar/20.2.273; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Collingwood TN, 1999, J MOL ENDOCRINOL, V23, P255, DOI 10.1677/jme.0.0230255; Crane-Robinson C, 1999, BIOESSAYS, V21, P367, DOI 10.1002/(SICI)1521-1878(199905)21:5<367::AID-BIES2>3.0.CO;2-4; Dou YL, 1999, MOL CELL, V4, P641, DOI 10.1016/S1097-2765(00)80215-4; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Farrants AKO, 1997, MOL CELL BIOL, V17, P895, DOI 10.1128/MCB.17.2.895; Fletcher TM, 2000, MOL CELL BIOL, V20, P6466, DOI 10.1128/MCB.20.17.6466-6475.2000; Fletcher TM, 1996, CRIT REV EUKAR GENE, V6, P149, DOI 10.1615/CritRevEukarGeneExpr.v6.i2-3.40; Fryer CJ, 1998, J BIOL CHEM, V273, P1175, DOI 10.1074/jbc.273.2.1175; Fryer CJ, 2000, J BIOL CHEM, V275, P17771, DOI 10.1074/jbc.M908729199; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HAGER GL, 1991, NUCLEAR HORMONE RECE, P217; Havas K, 2000, CELL, V103, P1133, DOI 10.1016/S0092-8674(00)00215-4; Hill DA, 2000, BIOCHEMISTRY-US, V39, P11649, DOI 10.1021/bi001330z; Kadam S, 2000, GENE DEV, V14, P2441, DOI 10.1101/gad.828000; Karin M, 1998, CELL, V93, P487, DOI 10.1016/S0092-8674(00)81177-0; Kinyamu HK, 2000, J BIOL CHEM, V275, P20061, DOI 10.1074/jbc.M001142200; LEE HL, 1994, MOL CELL BIOL, V14, P32, DOI 10.1128/MCB.14.1.32; Lee HL, 1998, EMBO J, V17, P1454, DOI 10.1093/emboj/17.5.1454; Lever MA, 2000, NATURE, V408, P873, DOI 10.1038/35048603; Logie C, 1997, EMBO J, V16, P6772, DOI 10.1093/emboj/16.22.6772; Lorch Y, 1999, CELL, V96, P389, DOI 10.1016/S0092-8674(00)80551-6; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; Misteli T, 2000, NATURE, V408, P877, DOI 10.1038/35048610; Mizzen CA, 1999, J BIOL CHEM, V274, P14533, DOI 10.1074/jbc.274.21.14533; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; MYMRYK JS, 1995, GENE DEV, V9, P1366, DOI 10.1101/gad.9.11.1366; MYMRYK JS, 1995, MOL CELL BIOL, V15, P26, DOI 10.1128/MCB.15.1.26; Nie ZQ, 2000, MOL CELL BIOL, V20, P8879, DOI 10.1128/MCB.20.23.8879-8888.2000; Orphanides G, 2000, NATURE, V407, P471, DOI 10.1038/35035000; OwenHughes T, 1996, SCIENCE, V273, P513, DOI 10.1126/science.273.5274.513; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; Schnitzler G, 1998, CELL, V94, P17, DOI 10.1016/S0092-8674(00)81217-9; Shen XT, 1996, CELL, V86, P475, DOI 10.1016/S0092-8674(00)80120-8; Steinbach OC, 1997, NATURE, V389, P395, DOI 10.1038/38755; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Wallberg AE, 2000, MOL CELL BIOL, V20, P2004, DOI 10.1128/MCB.20.6.2004-2013.2000; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; WEINBERGER C, 1985, SCIENCE, V228, P740, DOI 10.1126/science.2581314; Whitehouse I, 1999, NATURE, V400, P784, DOI 10.1038/23506; Windahl SH, 1999, J STEROID BIOCHEM, V71, P93, DOI 10.1016/S0960-0760(99)00128-4; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711; Wong AKC, 2000, CANCER RES, V60, P6171; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; Zhang L, 2000, J BIOL CHEM, V275, P33850, DOI 10.1074/jbc.M005341200	60	69	71	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	2001	20	24					3039	3046		10.1038/sj.onc.1204328	http://dx.doi.org/10.1038/sj.onc.1204328			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442WT	11420719				2022-12-17	WOS:000169308500007
J	Argentini, M; Barboule, N; Wasylyk, B				Argentini, M; Barboule, N; Wasylyk, B			The contribution of the acidic domain of MDM2 to p53 and MDM2 stability	ONCOGENE			English	Article						ring finger domain; ubiquitylation; nuclear export; p300; NES	RING-FINGER DOMAIN; NUCLEAR EXPORT; IN-VIVO; NUCLEOLAR-LOCALIZATION; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; UBIQUITIN LIGASE; ONCOPROTEIN MDM2; DNA-DAMAGE; CELL-LINE	p53 and MDM2 are both degraded by the ubiquitin-proteasome pathway, MDM2 binds p53 and promotes its rapid degradation, MDM2 is an E3 ligase that activates self and p53 ubiquitylation, Moreover, MDM2 nuclear-cytoplasmic shuttling contributes to p53 degradation in the cytoplasm, We have identified a new region of MDM2 which regulates the stability of both p53 and MDM2, The first 50 amino-acids of the MDM2 acidic domain (222-272) contribute to MDM2 and MDM2-mediated p53 degradation by a mechanism which is independent of either MDM2 E3-ligase activity or MDM2 nucleo-cytoplasmic shuttling, The transcriptional coactivator p300 could have been involved, since it binds to the MDM2 acidic domain, Howe, er, we found that p300 stabilises MDM2, even in absence of an intact acidic domain, indicating that the MDM2 acidic region contributes to proteolysis independently of p300, We propose that the MDM2 acidic domain is required for unbiquitylated MDM2 and p53 to be degraded by cytoplasmic proteasomes.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Wasylyk, B (corresponding author), ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries,BP 163, F-67404 Illkirch, France.		Wasylyk, Bohdan/ABG-6778-2020	Wasylyk, Bohdan/0000-0002-1718-1237				Argentini M, 2000, ONCOGENE, V19, P3849, DOI 10.1038/sj.onc.1203737; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Blaydes JP, 1998, ONCOGENE, V16, P3317, DOI 10.1038/sj.onc.1201880; Boyd MT, 2000, J BIOL CHEM, V275, P31883, DOI 10.1074/jbc.M004252200; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Chang YC, 1998, CELL GROWTH DIFFER, V9, P79; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Elenbaas B, 1996, MOL MED, V2, P439, DOI 10.1007/BF03401903; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Ganguli G, 2000, EMBO J, V19, P5135, DOI 10.1093/emboj/19.19.5135; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Gu JJ, 2000, MOL CELL BIOL, V20, P1243, DOI 10.1128/MCB.20.4.1243-1253.2000; Haas AL, 1997, FASEB J, V11, P1257; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hay TJ, 2000, FEBS LETT, V478, P183, DOI 10.1016/S0014-5793(00)01850-0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Juven-Gershon T, 1999, MOL MED, V5, P71, DOI 10.1007/BF03402141; KASTAN MB, 1991, CANCER RES, V51, P6304; Kleijnen MF, 2000, MOL CELL, V6, P409, DOI 10.1016/S1097-2765(00)00040-X; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kobet E, 2000, P NATL ACAD SCI USA, V97, P12547, DOI 10.1073/pnas.97.23.12547; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kubbutat MHG, 1999, CELL GROWTH DIFFER, V10, P87; Leveillard T, 1997, J BIOL CHEM, V272, P30651, DOI 10.1074/jbc.272.49.30651; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lohrum MAE, 2000, NAT CELL BIOL, V2, P179, DOI 10.1038/35004057; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; LUNA RMD, 1995, NATURE, V378, P203; Maki CG, 1996, CANCER RES, V56, P2649; Maki CG, 1999, J BIOL CHEM, V274, P16531, DOI 10.1074/jbc.274.23.16531; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOSER FG, 1975, J CELL BIOL, V66, P676, DOI 10.1083/jcb.66.3.676; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Palmer A, 1996, BIOCHEM J, V316, P401, DOI 10.1042/bj3160401; Pickart CM, 2000, NAT CELL BIOL, V2, pE139, DOI 10.1038/35019610; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Rivett AJ, 1998, CURR OPIN IMMUNOL, V10, P110, DOI 10.1016/S0952-7915(98)80040-X; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; STRACK PR, 1992, INT J BIOCHEM, V24, P887, DOI 10.1016/0020-711X(92)90093-G; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Wasylyk C, 1999, ONCOGENE, V18, P1921, DOI 10.1038/sj.onc.1202528; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Xie YM, 2000, P NATL ACAD SCI USA, V97, P2497, DOI 10.1073/pnas.060025497; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhao RB, 2000, GENE DEV, V14, P981; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	65	69	69	1	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 15	2001	20	11					1267	1275		10.1038/sj.onc.1204241	http://dx.doi.org/10.1038/sj.onc.1204241			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	411JM	11313871				2022-12-17	WOS:000167495000001
J	Kim, YC; Song, KS; Yoon, G; Nam, MJ; Ryu, WS				Kim, YC; Song, KS; Yoon, G; Nam, MJ; Ryu, WS			Activated ras oncogene collaborates with HBx gene of hepatitis B virus to transform cells by suppressing HBx-mediated apoptosis	ONCOGENE			English	Article						hepatitis B virus; X gene; apoptosis; H-ras oncogene	NF-KAPPA-B; X-PROTEIN; TRANSGENIC MICE; HEPATOCELLULAR-CARCINOMA; IN-VIVO; C-MYC; EMBRYO FIBROBLASTS; TRANSCRIPTION; DEATH; EXPRESSION	The hepatitis B virus HBx protein is a promiscuous transactivator implicated in the development of hepatocellular carcinoma. The ectopic expression of HBx fails to transform both primary and immortalized rodent cells, but rather induces apoptosis, Furthermore, most transgenic mice harboring HBx do not develop liver tumors. Thus, it remains unclear whether and how HBx contributes to oncogenesis, Here, we show that HBx collaborates with activated H-ras to transform immortalized rodent cells. Indeed, REF52 cells transfected by both HBx and activated H-uas were morphologically transformed and were able to grow in soft agar, Remarkably, nude mice injected with REF52 cells transfected by both HBx and activated H-ras developed tumors, whereas the mice injected with REF52 cells transfected by either gene alone did not. Thus, we concluded that HBx could contribute to neoplastic transformation of cells in collaboration with other oncogenes, such as H-ras, that renders cells to overcome the HBx-mediated apoptosis, Further, we found that HBx mediated apoptosis was suppressed by activated H-ras through activation of the phosphatidylinositol-3 kinase and Akt pathway. Data presented here firmly established the oncogenic potential of HBx during multistage carcinogenesis.	Yonsei Univ, Dept Biochem, Seoul 120749, South Korea; Natl Inst Hlth, Div Canc Res, Seoul 122701, South Korea	Yonsei University; Korea Centers for Disease Control & Prevention (KCDC); Korea National Institute of Health (KNIH)	Ryu, WS (corresponding author), Yonsei Univ, Dept Biochem, 134 Shinchondong, Seoul 120749, South Korea.			Kim, Young Chul/0000-0002-6782-2186; Ryu, Wang-Shick/0000-0002-0383-5666				BEASLEY RP, 1981, LANCET, V2, P1129; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; BILLET O, 1995, J VIROL, V69, P5912, DOI 10.1128/JVI.69.9.5912-5916.1995; BLUM HE, 1992, J VIROL, V66, P1223, DOI 10.1128/JVI.66.2.1223-1227.1992; BUENDIA MA, 1992, ADV CANCER RES, V59, P167, DOI 10.1016/S0065-230X(08)60306-1; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; Chirillo P, 1996, J VIROL, V70, P641, DOI 10.1128/JVI.70.1.641-646.1996; Dandri M, 1996, J VIROL, V70, P5246, DOI 10.1128/JVI.70.8.5246-5254.1996; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GUIDOTTI LG, 1995, J VIROL, V69, P6158, DOI 10.1128/JVI.69.10.6158-6169.1995; Haviv I, 1998, MOL CELL BIOL, V18, P1562, DOI 10.1128/MCB.18.3.1562; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; KOHL NE, 1987, ONCOGENE, V2, P41; KOIKE K, 1994, HEPATOLOGY, V19, P810, DOI 10.1002/hep.1840190403; KOIKE K, 1994, J CLIN INVEST, V94, P44, DOI 10.1172/JCI117343; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE TH, 1990, J VIROL, V64, P5939, DOI 10.1128/JVI.64.12.5939-5947.1990; Lee YH, 1998, J BIOL CHEM, V273, P25510, DOI 10.1074/jbc.273.39.25510; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; LUCITO R, 1992, J VIROL, V66, P983, DOI 10.1128/JVI.66.2.983-991.1992; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NATOLI G, 1994, ONCOGENE, V9, P2837; Oguey D, 1996, HEPATOLOGY, V24, P1024, DOI 10.1002/hep.510240508; PATERLINI P, 1995, HEPATOLOGY, V21, P313, DOI 10.1002/hep.1840210208; Qadri I, 1996, P NATL ACAD SCI USA, V93, P10578, DOI 10.1073/pnas.93.20.10578; Schuster R, 2000, ONCOGENE, V19, P1173, DOI 10.1038/sj.onc.1203417; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Su Q, 1998, HEPATOLOGY, V27, P1109, DOI 10.1002/hep.510270428; Tarn C, 1999, J BIOL CHEM, V274, P2327, DOI 10.1074/jbc.274.4.2327; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; Terradillos O, 1998, ONCOGENE, V17, P2115, DOI 10.1038/sj.onc.1202432; WILLIAMS JS, 1995, P NATL ACAD SCI USA, V92, P3819, DOI 10.1073/pnas.92.9.3819; Yen T. S. Benedict, 1996, Journal of Biomedical Science, V3, P20; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	53	69	84	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2001	20	1					16	23		10.1038/sj.onc.1203840	http://dx.doi.org/10.1038/sj.onc.1203840			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	391NE	11244501				2022-12-17	WOS:000166361400003
J	Ardini, E; Agresti, R; Tagliabue, E; Greco, M; Aiello, P; Yang, LT; Menard, S; Sap, J				Ardini, E; Agresti, R; Tagliabue, E; Greco, M; Aiello, P; Yang, LT; Menard, S; Sap, J			Expression of protein tyrosine phosphatase alpha (RPTP alpha) in human breast cancer correlates with low tumor grade, and inhibits tumor cell growth in vitro and in vivo	ONCOGENE			English	Article						tyrosine phosphatase; c-Src; PTP; breast cancer; tumor marker	DOWN-REGULATION; MAMMARY-TUMORS; C-SRC; SIGNAL-TRANSDUCTION; PROGNOSTIC FACTOR; TRANSGENIC MICE; FACTOR RECEPTOR; NEU ONCOGENE; PTP-ALPHA; IN-VIVO	Tyrosine phosphorylation is controlled by a balance of tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs), Whereas the contribution of PTKs to breast tumorigenesis is the subject of intense scrutiny, the potential role of PTPs is poorly known. RPTP alpha is implicated in the activation of Src family kinases, and regulation of integrin signaling, cell adhesion, and growth factor responsiveness. To explore its potential contribution to human neoplasia, we surveyed RPTPa protein levels in primary human breast cancer. We found RPTPa levels to vary widely among tumors, with 29% of cases manifesting significant overexpression, High RPTP alpha protein levels correlated significantly with low tumor grade and positive estrogen receptor status. Expression of RPTP alpha in breast carcinoma cells led to growth inhibition, associated with increased accumulation in G(0) and G(1), and delayed tumor growth and metastasis. To our knowledge, this is the first example of a study correlating expression level of a specific bona fide PTP with neoplastic disease status in humans.	Ist Nazl Tumori, Mol Targeting Unit, Div Expt Oncol, I-20133 Milan, Italy; Ist Nazl Tumori, Gen Surg Breast Unit B, I-20133 Milan, Italy; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; NYU, Sch Med, Kaplan Canc Ctr, New York, NY 10016 USA	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; New York University; New York University	Menard, S (corresponding author), Ist Nazl Tumori, Mol Targeting Unit, Div Expt Oncol, Via Venezian 1, I-20133 Milan, Italy.		menard, sylvie mm/C-7940-2011; Agresti, Roberto/AAB-6062-2019; Tagliabue, Elda/B-9377-2017	Agresti, Roberto/0000-0003-4700-1951; Tagliabue, Elda/0000-0001-9877-2903	NATIONAL CANCER INSTITUTE [R21CA066229, P30CA016087, R29CA068365] Funding Source: NIH RePORTER; NCI NIH HHS [R29 CA68365, P30CA16087, 5R21 CA66229-04] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aicher B, 1997, J CELL BIOL, V138, P681, DOI 10.1083/jcb.138.3.681; BARKER KT, 1995, ONCOGENE, V10, P569; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Carraway KL, 1999, J BIOL CHEM, V274, P5263, DOI 10.1074/jbc.274.9.5263; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; Cong LN, 1999, BIOCHEM BIOPH RES CO, V255, P200, DOI 10.1006/bbrc.1999.0183; DAUM G, 1994, J BIOL CHEM, V269, P10524; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; denHertog J, 1996, EMBO J, V15, P3016, DOI 10.1002/j.1460-2075.1996.tb00665.x; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Egan C, 1999, ONCOGENE, V18, P1227, DOI 10.1038/sj.onc.1202233; Ellis MJ, 1998, BREAST CANCER RES TR, V52, P175, DOI 10.1023/A:1006127621512; Elson A, 1999, ONCOGENE, V18, P7535, DOI 10.1038/sj.onc.1203098; ELSON A, 1995, J BIOL CHEM, V270, P26116, DOI 10.1074/jbc.270.44.26116; ELSON A, 1995, P NATL ACAD SCI USA, V92, P12335; ELSTON CW, 1984, AUST NZ J SURG, V54, P11, DOI 10.1111/j.1445-2197.1984.tb06677.x; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FREISS G, 1994, MOL ENDOCRINOL, V8, P1389, DOI 10.1210/me.8.10.1389; Ghoussoub RAD, 1998, CANCER, V82, P1513, DOI 10.1002/(SICI)1097-0142(19980415)82:8<1513::AID-CNCR13>3.0.CO;2-7; Giani C, 1998, ONCOGENE, V17, P425, DOI 10.1038/sj.onc.1201954; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Jacob KK, 1998, J BIOL CHEM, V273, P4800, DOI 10.1074/jbc.273.8.4800; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; Keane MM, 1996, CANCER RES, V56, P4236; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; Lollini PL, 1998, INT J CANCER, V77, P937, DOI 10.1002/(SICI)1097-0215(19980911)77:6<937::AID-IJC24>3.0.CO;2-X; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; MCCARTY KS, 1985, ARCH PATHOL LAB MED, V109, P716; MOLLER NPH, 1995, J BIOL CHEM, V270, P23126, DOI 10.1074/jbc.270.39.23126; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Neel BG, 1997, CURR OPIN IMMUNOL, V9, P405, DOI 10.1016/S0952-7915(97)80088-X; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; OTTENHOFFKALFF AE, 1995, BREAST CANCER RES TR, V33, P245, DOI 10.1007/BF00665949; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PEREIRA H, 1995, HISTOPATHOLOGY, V27, P219, DOI 10.1111/j.1365-2559.1995.tb00213.x; Petrone A, 2000, J CELL SCI, V113, P2345; PIZAO PE, 1992, BRIT J CANCER, V66, P660, DOI 10.1038/bjc.1992.333; Ponniah S, 1999, CURR BIOL, V9, P535, DOI 10.1016/S0960-9822(99)80238-3; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; Rosenkranz S, 2000, J BIOL CHEM, V275, P9620, DOI 10.1074/jbc.275.13.9620; Ross JS, 1999, SEMIN CANCER BIOL, V9, P125, DOI 10.1006/scbi.1998.0083; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SILVESTRINI R, 1985, CANCER, V56, P1982, DOI 10.1002/1097-0142(19851015)56:8<1982::AID-CNCR2820560816>3.0.CO;2-I; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; SU J, 1996, J BIOL CHEM, V271, P28026; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TABITI K, 1995, CANCER LETT, V93, P239, DOI 10.1016/0304-3835(95)03816-F; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Tzahar E, 1998, BBA-REV CANCER, V1377, pM25, DOI 10.1016/S0304-419X(97)00032-2; *UICC, 1997, ILL GUID TNM PTNM CL; Werner H, 1997, CRIT REV ONCOGENESIS, V8, P71, DOI 10.1615/CritRevOncog.v8.i1.40; ZHAI YF, 1995, MOL CARCINOGEN, V14, P103, DOI 10.1002/mc.2940140206; ZHAI YF, 1993, CANCER RES, V53, P2272; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	63	69	72	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 12	2000	19	43					4979	4987		10.1038/sj.onc.1203869	http://dx.doi.org/10.1038/sj.onc.1203869			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363KF	11042685				2022-12-17	WOS:000089834300005
J	Mitchell, PJ; Sara, EA; Crompton, MR				Mitchell, PJ; Sara, EA; Crompton, MR			A novel adaptor-like protein which is a substrate for the non-receptor tyrosine kinase, BRK	ONCOGENE			English	Article						BKS; BRK; PH domain; tyrosine kinase; SH2 domain	BREAST-CANCER; SIGNALING PROTEINS; CRYSTAL-STRUCTURE; PH DOMAIN; SRC; PHOSPHORYLATION; MUTATION; ACTIVATION; PP60C-SRC; HOMOLOGY	The brk gene encodes a non-receptor tyrosine kinase that has been found to be overexpressed in approximately two thirds of breast tumours. Using a yeast two-hybrid based screen, we have cloned cDNAs encoding a novel protein, BKS, that is a substrate for the kinase activity of BRK and has the characteristics of an adaptor protein. BKS possesses an N-terminal PH-like domain followed by an SH2-like domain. In co-transfection experiments, high levels of phosphotyrosine were observed on BKS and BRK was found to be associated with BKS, both of which were dependent on the catalytic activity of BRK. The phosphorylation of and association with BKS by BRK was also dependent on the SH2-like domain present within BKS, In addition, BKS recruited an unidentified 100 kDa protein that was also phosphorylated on tyrosine residues in the presence of BRK. We have determined that the BKS protein is expressed in most adult human tissues.	Inst Canc Res, Breakthrough Toby Robinson Canc Res Ctr, Sect Cell Biol & Expt Pathol, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Mitchell, PJ (corresponding author), UCL, Mol Cell Biol Lab, MRC, Gower St, London WC1E 6BT, England.		Mitchell, Philip J/F-6393-2013; Fraser, Elizabeth/M-7049-2015	Fraser, Elizabeth/0000-0001-8420-3208				ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; Barker KT, 1997, ONCOGENE, V15, P799, DOI 10.1038/sj.onc.1201241; Baron V, 1998, ENDOCRINOLOGY, V139, P3034, DOI 10.1210/en.139.6.3034; BarPeled M, 1996, ANAL BIOCHEM, V241, P140, DOI 10.1006/abio.1996.0390; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; Blomberg N, 1999, TRENDS BIOCHEM SCI, V24, P441, DOI 10.1016/S0968-0004(99)01472-3; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Coffer PJ, 1998, BIOCHEM J, V335, P1; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; DAVIDSON D, 1994, J BIOL CHEM, V269, P10956; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; FUKADA M, 1996, J BIOL CHEM, V271, P30303; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; GIOANNI J, 1990, BRIT J CANCER, V62, P8, DOI 10.1038/bjc.1990.219; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Kamalati T, 1996, J BIOL CHEM, V271, P30956, DOI 10.1074/jbc.271.48.30956; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; Kolibaba KS, 1997, BIOCHIM BIOPHYS ACTA, V1333, P217; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; Mitchell PJ, 1997, ONCOGENE, V15, P1497, DOI 10.1038/sj.onc.1201292; MITCHELL PJ, 1994, ONCOGENE, V9, P2383; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NIRANJAN B, 1995, DEVELOPMENT, V121, P2897; Ohya K, 1999, P NATL ACAD SCI USA, V96, P11976, DOI 10.1073/pnas.96.21.11976; OKADA M, 1991, J BIOL CHEM, V266, P24249; PATERSON MC, 1991, CANCER RES, V51, P556; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; SCHAFFHAUSEN B, 1995, BIOCHIM BIOPHYS ACTA, V28, P61; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STAMPS AC, 1994, INT J CANCER, V57, P865, DOI 10.1002/ijc.2910570616; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; VANHEYNINGEN V, 1994, NATURE, V367, P319, DOI 10.1038/367319a0; VASIOUKHIN V, 1995, ONCOGENE, V10, P349; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; ZIEGLER SF, 1989, MOL CELL BIOL, V9, P2724, DOI 10.1128/MCB.9.6.2724	51	69	71	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 31	2000	19	37					4273	4282		10.1038/sj.onc.1203775	http://dx.doi.org/10.1038/sj.onc.1203775			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349FL	10980601				2022-12-17	WOS:000089032900010
J	Lelievre, E; Mattot, V; Huber, P; Vandenbunder, B; Soncin, F				Lelievre, E; Mattot, V; Huber, P; Vandenbunder, B; Soncin, F			ETS1 lowers capillary endothelial cell density at confluence and induces the expression of VE-cadherin	ONCOGENE			English	Article						angiogenesis; endothelium; adhesion; transcription	BINDING-SITES; PLASMINOGEN-ACTIVATOR; TRANSGENIC MICE; GENE PROMOTER; CHICK-EMBRYO; DNA-BINDING; TRANSCRIPTION; C-ETS-1; GROWTH; PROTEIN	Ets1 is a transcription factor expressed in endothelial cells during angiogenesis but its target genes and function in blood vessel formation are still unknown. We have over-expressed Ets1 as a tagged protein in brain capillary endothelial cells and in 3T3 fibroblasts using a retroviral vector. Over-expression of Ets1 reduced by nearly half cell density at confluence of endothelials but not of fibroblasts, As density at confluence is controlled in part by cadherins, this growth arrest could be due to the up-regulation of these cell contact molecules. Indeed, Ets1 increased the expression of the endothelial-specific VE-cadherin without affecting N-cadherin expression levels. In parallel, both dominant negative mutant of Ets members and an Ets1 anti-sense oligonucleotide inhibited VE-cadherin expression in endothelial cells, Ets1 bound to two Ets-binding sites located in the proximal region of the VE-cadherin promoter. Mutation of these sites abolished Ets1-induced transactivation of the promoter. The present work is the first demonstration of a function of Ets1 in the regulation of a specific endothelial marker based on its endogenous gene and protein expression.	Inst Pasteur Lille, Inst Biol Lille, CNRS, EP560, F-59021 Lille, France; CEA, Lab Transgenese & Differenciat Cellulaire, Grenoble, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; CEA	Soncin, F (corresponding author), Inst Pasteur Lille, Inst Biol Lille, CNRS, EP560, 1 Rue Calmette, F-59021 Lille, France.		SONCIN, Fabrice/A-1475-2009; Huber, Philippe/C-7971-2019	SONCIN, Fabrice/0000-0001-6312-0673; Huber, Philippe/0000-0002-4153-7694; Lelievre, Etienne/0000-0003-0452-1578				AUERBACH R, 1991, INT J RADIAT BIOL, V60, P1, DOI 10.1080/09553009114551401; Bach TL, 1998, EXP CELL RES, V238, P324, DOI 10.1006/excr.1997.3844; Breier G, 1996, BLOOD, V87, P630, DOI 10.1182/blood.V87.2.630.bloodjournal872630; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Caveda L, 1996, J CLIN INVEST, V98, P886, DOI 10.1172/JCI118870; COFFER P, 1994, ONCOGENE, V9, P911; Corada M, 1999, P NATL ACAD SCI USA, V96, P9815, DOI 10.1073/pnas.96.17.9815; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; FISHER RJ, 1991, ONCOGENE, V6, P2249; GARLANDA C, 1994, P NATL ACAD SCI USA, V91, P7291, DOI 10.1073/pnas.91.15.7291; GHYSDAEL J, 1997, ONCOGENES TRANSCRIPT, V1, P29; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Gory S, 1998, J BIOL CHEM, V273, P6750, DOI 10.1074/jbc.273.12.6750; Gory S, 1999, BLOOD, V93, P184, DOI 10.1182/blood.V93.1.184.401a20_184_192; Gory-Faure S, 1999, DEVELOPMENT, V126, P2093; GREVIN D, 1993, INT J DEV BIOL, V37, P519; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; Huber P, 1996, GENOMICS, V32, P21, DOI 10.1006/geno.1996.0072; Iljin K, 1999, FASEB J, V13, P377, DOI 10.1096/fasebj.13.2.377; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; Kanda S, 1996, CELL GROWTH DIFFER, V7, P383; KHACHIGIAN LM, 1994, J BIOL CHEM, V269, P22647; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511; Macias D, 1998, ANAT EMBRYOL, V198, P307, DOI 10.1007/s004290050186; Mager AM, 1998, INT J DEV BIOL, V42, P561; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; Mattot V, 2000, ONCOGENE, V19, P762, DOI 10.1038/sj.onc.1203248; Navarro P, 1995, J BIOL CHEM, V270, P30965, DOI 10.1074/jbc.270.52.30965; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; Oda N, 1999, J CELL PHYSIOL, V178, P121, DOI 10.1002/(SICI)1097-4652(199902)178:2<121::AID-JCP1>3.3.CO;2-6; OKA T, 1991, ONCOGENE, V6, P2077; PARDANAUD L, 1993, CELL ADHES COMMUN, V1, P151, DOI 10.3109/15419069309095691; QUEVA C, 1993, ONCOGENE, V8, P2511; Rahimi N, 1999, MOL BIOL CELL, V10, P3401, DOI 10.1091/mbc.10.10.3401; Robinson L, 1997, P NATL ACAD SCI USA, V94, P7170, DOI 10.1073/pnas.94.14.7170; ROSEN GD, 1994, J BIOL CHEM, V269, P15652; SETH A, 1993, ONCOGENE, V8, P1783; SETH A, 1990, ONCOGENE, V5, P1761; SUZUKI H, 1995, P NATL ACAD SCI USA, V92, P4442, DOI 10.1073/pnas.92.10.4442; Tanaka K, 1998, J CELL PHYSIOL, V176, P235, DOI 10.1002/(SICI)1097-4652(199808)176:2<235::AID-JCP2>3.0.CO;2-P; Telo P, 1998, J BIOL CHEM, V273, P17565, DOI 10.1074/jbc.273.28.17565; VANDENBUNDER B, 1994, INVAS METAST, V14, P198; VANDENBUNDER B, 1989, DEVELOPMENT, V106, P265; Vittet D, 1997, P NATL ACAD SCI USA, V94, P6273, DOI 10.1073/pnas.94.12.6273; Wakiya K, 1996, J BIOL CHEM, V271, P30823, DOI 10.1074/jbc.271.48.30823; WERNERT N, 1994, CANCER RES, V54, P5683; WERNERT N, 1992, AM J PATHOL, V140, P119; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699	51	69	71	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 11	2000	19	20					2438	2446		10.1038/sj.onc.1203563	http://dx.doi.org/10.1038/sj.onc.1203563			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	313UV	10828886				2022-12-17	WOS:000087018400009
J	Schulze-Garg, C; Lohler, J; Gocht, A; Deppert, W				Schulze-Garg, C; Lohler, J; Gocht, A; Deppert, W			A transgenic mouse model for the ductal carcinoma in situ (DCIS) of the mammary gland	ONCOGENE			English	Article						DCIS; ductal carcinoma in situ; mouse model; SV40 large T-antigen	LARGE T-ANTIGEN; BREAST-CONSERVING SURGERY; PROTEIN GENE PROMOTER; IN-SITU; INTRADUCTAL CARCINOMA; RESTRICTION ELEMENT; BALB/C MICE; HYBRID GENE; HA-RAS; EXPRESSION	The ductal carcinoma in situ (DCIS) of the mammary gland represents an early, pre-invasive stage in the development of invasive breast carcinoma and is increasingly diagnosed since the introduction of high-quality mammography screening. Uncertainties in the prognosis for patients with DCIS have caused a controversial discussion about adequate treatment, and it is suspected that most patients undergoing mastectomy may be overtreated, In order to improve treatment and treatment decision, it therefore is highly desirable to identify prognostic markers and therapeutic targets for DCIS. We here introduce a set of transgenic mice (WAP-T and WAP-T-NP lines) presenting with various morphological forms of DCLS-like lesions. In these mite the SV40 large tumor antigen is specifically induced in epithelial cells of the terminal duct lobular units (TDLU), As a consequence of continuous expression of the oncogene, the animals develop multifocal DCIS and consequently invasive carcinoma within strain specific periods of latency. DCIS lesions in transgenic mire exhibit distinct architectural and cytological features which closely resemble those commonly present in humans, We therefore propose these transgenic lines as an experimental model to study the underlying molecular events leading to DCIS and its progression to invasive disease.	Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany; Mice & More, D-20251 Hamburg, Germany; Marienkrankenhaus, Inst Pathol, D-22087 Hamburg, Germany	Heinrich Pette Institute; University of Hamburg; St. Marien Hospital	Schulze-Garg, C (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.							ANDRES AC, 1987, P NATL ACAD SCI USA, V84, P1299, DOI 10.1073/pnas.84.5.1299; Bartek J, 1999, J PATHOL, V187, P95, DOI 10.1002/(SICI)1096-9896(199901)187:1<95::AID-PATH249>3.0.CO;2-#; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; BELLAMY COC, 1993, HUM PATHOL, V24, P16, DOI 10.1016/0046-8177(93)90057-N; BRIGHT RK, 1994, J IMMUNOL, V153, P2064; BURDON T, 1991, J BIOL CHEM, V266, P6909; Butel JS, 1999, JNCI-J NATL CANCER I, V91, P119, DOI 10.1093/jnci/91.2.119; CHOI YW, 1988, MOL CELL BIOL, V8, P3382, DOI 10.1128/MCB.8.8.3382; Daphna-Iken D, 1998, ONCOGENE, V17, P2711, DOI 10.1038/sj.onc.1202212; DEPPERT W, 1979, NATURE, V277, P322, DOI 10.1038/277322a0; Ernster V L, 1997, J Natl Cancer Inst Monogr, P151; Ernster VL, 1996, JAMA-J AM MED ASSOC, V275, P913, DOI 10.1001/jama.275.12.913; Fanning E, 1998, DEV BIOL STAND, V94, P3; FRELINGER JA, 1983, TRANSPLANT P, V15, P2024; GURNEY EG, 1986, J VIROL, V57, P1168, DOI 10.1128/JVI.57.3.1168-1172.1986; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hogan B., 1986, MANIPULATING MOUSE E; HOLLAND R, 1994, SEMIN DIAGN PATHOL, V11, P167; Husler MR, 1998, TRANSGENIC RES, V7, P253, DOI 10.1023/A:1008865911660; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; Macleod KF, 1999, J PATHOL, V187, P43, DOI 10.1002/(SICI)1096-9896(199901)187:1<43::AID-PATH246>3.0.CO;2-P; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; ORN A, 1982, NATURE, V297, P415, DOI 10.1038/297415a0; PFIZENMAIER K, 1980, J IMMUNOL, V124, P1888; PITTIUS CW, 1988, MOL ENDOCRINOL, V2, P1027, DOI 10.1210/mend-2-11-1027; RAVDIN PM, 1997, DUCTAL CARCINOMA IN; ROBLES MTS, 1994, MOL CELL BIOL, V14, P2686, DOI 10.1128/MCB.14.4.2686; SANDGREN EP, 1995, CANCER RES, V55, P3915; SCHIRMBECK R, 1993, EUR J IMMUNOL, V23, P1528, DOI 10.1002/eji.1830230720; SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x; SCHULZ M, 1989, EUR J IMMUNOL, V19, P1657, DOI 10.1002/eji.1830190921; Scott MA, 1997, HUM PATHOL, V28, P967, DOI 10.1016/S0046-8177(97)90013-7; SILVERSTEIN MJ, 1995, LANCET, V345, P1154; SILVERSTEIN MJ, 1990, CANCER, V66, P102, DOI 10.1002/1097-0142(19900701)66:1<102::AID-CNCR2820660119>3.0.CO;2-5; SILVERSTEIN MJ, 1995, EUR J CANCER, V31A, P1425, DOI 10.1016/0959-8049(95)00283-O; SILVERSTEIN MJ, 1997, DUCTAL CARCINOMA IN; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; Solin LJ, 1996, J CLIN ONCOL, V14, P754, DOI 10.1200/JCO.1996.14.3.754; SOLIN LJ, 1993, CANCER-AM CANCER SOC, V71, P2532, DOI 10.1002/1097-0142(19930415)71:8<2532::AID-CNCR2820710817>3.0.CO;2-0; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Talamonti MS, 1996, SEMIN SURG ONCOL, V12, P300; Tzeng YJ, 1998, ONCOGENE, V16, P2103, DOI 10.1038/sj.onc.1201733; TZENG YJ, 1993, ONCOGENE, V8, P1965; WEBSTER MA, 1995, P NATL ACAD SCI USA, V92, P7849, DOI 10.1073/pnas.92.17.7849; Zerrahn J, 1996, J IMMUNOL, V156, P3919	45	69	72	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2000	19	8			SI		1028	1037		10.1038/sj.onc.1203281	http://dx.doi.org/10.1038/sj.onc.1203281			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292LT	10713686				2022-12-17	WOS:000085796400008
J	Rubbi, CP; Milner, J				Rubbi, CP; Milner, J			Non-activated p53 co-localizes with sites of transcription within both the nucleoplasm and the nucleolus	ONCOGENE			English	Article						latent p53; transcription sites; nucleolus; confocal microscopy; hdm-2	RNA-POLYMERASE-II; WILD-TYPE P53; NASCENT RNA; INDUCED APOPTOSIS; CONFOCAL IMAGES; NUCLEAR MATRIX; DNA-DAMAGE; CELL-CYCLE; PROTEIN; MICROSCOPY	The p53 tumour suppressor functions as a sensor of genotoxic stress and, once activated, induces cell growth arrest or apoptosis, The precise intranuclear localization of latent p53 protein in non-stressed cells is unknown, Such information is essential in order to understand how relatively few molecules of p53 can detect and respond to DNA damage. Here we present the first detailed supramolecular localization of p53 in the nuclei of cells under normal conditions of growth, We show that soluble, non-bound p53 is released by permeabilization, leaving structurally bound p53 in both the nucleus and nucleolus. ln situ biochemical studies reveal (i) that nuclear-bound p53 is tethered by RNA (directly or indirectly) and (ii) that a sub-population of nuclear-bound p53 co-localizes with sites of RNA synthesis. Transcriptional co-localization appeared to be independent of p53 conformation but dependent upon its quaternary structure. In the nucleolus p53 was observed at sites of rRNA synthesis and also adjacent to such sites. In contrast, nucleolar hdm-2 (shown by others to complex p53 and 5S RNA) was excluded from sites of rRNA synthesis. Our discovery that p53 is physically linked with sites of transcription may explain how relatively few p53 protein molecules can monitor genetic stress and respond preferentially to damage of actively transcribed genes.	Univ York, Dept Biol, YCR P53 Res Grp, York YO1 5DD, N Yorkshire, England	University of York - UK	Milner, J (corresponding author), Univ York, Dept Biol, YCR P53 Res Grp, York YO1 5DD, N Yorkshire, England.							ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; Andera L, 1997, MOL MED, V3, P852, DOI 10.1007/BF03401721; BARBARESE E, 1995, J CELL SCI, V108, P2781; Bonsing BA, 1997, CYTOMETRY, V28, P11, DOI 10.1002/(SICI)1097-0320(19970501)28:1<11::AID-CYTO2>3.3.CO;2-H; Budde A, 1999, ONCOGENE, V18, P1119, DOI 10.1038/sj.onc.1202402; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CONCHELLO JA, 1994, APPL OPTICS, V33, P3740, DOI 10.1364/AO.33.003740; Fay FS, 1997, EXP CELL RES, V231, P27, DOI 10.1006/excr.1996.3460; FONTOURA BMA, 1992, MOL CELL BIOL, V12, P5145, DOI 10.1128/MCB.12.11.5145; GIBSON SF, 1991, J OPT SOC AM A, V8, P1601, DOI 10.1364/JOSAA.8.001601; Gobert C, 1996, BIOCHEMISTRY-US, V35, P5778, DOI 10.1021/bi952327w; Gonzalez R.C., 1993, DIGITAL IMAGE PROCES, P583; Grande MA, 1997, J CELL SCI, V110, P1781; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; Katsumoto T, 1995, BIOL CELL, V84, P167, DOI 10.1016/0248-4900(96)89426-3; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lane DP, 1996, ONCOGENE, V12, P2461; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Ljungman M, 1996, ONCOGENE, V13, P823; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; MANDERS EMM, 1993, J MICROSC-OXFORD, V169, P375, DOI 10.1111/j.1365-2818.1993.tb03313.x; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; Michael WM, 1996, J BIOL CHEM, V271, P11571, DOI 10.1074/jbc.271.19.11571; MILNER J, 1993, ONCOGENE, V8, P2001; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Pederson T, 1998, J MOL BIOL, V277, P147, DOI 10.1006/jmbi.1997.1618; Pombo A, 1996, EXP CELL RES, V229, P201, DOI 10.1006/excr.1996.0360; Pritchard DM, 1997, P NATL ACAD SCI USA, V94, P1795, DOI 10.1073/pnas.94.5.1795; Scheer U, 1999, CURR OPIN CELL BIOL, V11, P385, DOI 10.1016/S0955-0674(99)80054-4; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cb.11.110195.000521; Stenoien D, 1998, J CELL BIOCHEM, V70, P213, DOI 10.1002/(SICI)1097-4644(19980801)70:2<213::AID-JCB7>3.0.CO;2-R; TANEJA KL, 1992, J CELL BIOL, V119, P1245, DOI 10.1083/jcb.119.5.1245; TEPOELE RH, 1999, IN PRESS ONCOGENE; vanGool AJ, 1997, EMBO J, V16, P4155, DOI 10.1093/emboj/16.14.4155; WANSINK DG, 1993, J CELL BIOL, V122, P283, DOI 10.1083/jcb.122.2.283; WEBER J, 1977, CELL, V10, P611, DOI 10.1016/0092-8674(77)90093-9; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; ZERRAHN J, 1992, ONCOGENE, V7, P1371	43	69	70	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					85	96		10.1038/sj.onc.1203378	http://dx.doi.org/10.1038/sj.onc.1203378			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644983				2022-12-17	WOS:000084844300010
J	Li, H; Cao, Y; Berndt, MC; Funder, JW; Liu, JP				Li, H; Cao, Y; Berndt, MC; Funder, JW; Liu, JP			Molecular interactions between telomerase and the tumor suppressor protein p53 in vitro	ONCOGENE			English	Article						telomerase reverse transcriptase (TERT); telomerase-associated protein 1 (TEP1); p53; telomerase inhibitory polypeptide 1 (TEIPP1); breast cancer cells	CATALYTIC SUBUNIT GENE; BREAST-CANCER CELLS; RNA COMPONENT; SPONTANEOUS IMMORTALIZATION; TETRAHYMENA TELOMERASE; REVERSE-TRANSCRIPTASE; MAMMALIAN TELOMERASE; MOUSE TELOMERASE; MUTANT P53; LIFE-SPAN	The telomere DNA polymerase (telomerase) and the tumor suppressor protein p53 are frequently associated with human cancers, and activation of telomerase and inactivation of p53 involved in cancer cell immortalization. In this report, we demonstrate a direct interaction of telomerase with p53 in the nuclear lysates of human breast cancer cells, and with recombinant human p53, by affinity chromatography and immunoprecipitation. On activity criteria, the interaction is between the carboxyl-terminal region of p53 and a region close to the amino-terminus of human telomerase-associated protein 1 (hTEP1). Incubation of recombinant p53 with nuclear telomerase extracts results in inhibition of telomerase activity, with the C-terminal region of p53 being essential for inhibition. This effect is not mediated by binding to telomerase substrate DNA, but requires the region near the N-terminus of hTEP1, in that a synthetic peptide derived from this region of hTEP1 similarly inhibits telomerase activity. Together, these in vitro interactions between telomerase and p53 suggest that the activity of telomerase may be regulated by p53, downregulation of which in turn would favor up-regulation of telomerase activity in cancer cell development.	Baker Med Res Inst, Mol Signalling Lab, Prahran, Vic 3181, Australia	Baker Heart and Diabetes Institute	Liu, JP (corresponding author), Baker Med Res Inst, Mol Signalling Lab, POB 6492,St Kilda Rd Cent, Melbourne, Vic 8008, Australia.		Berndt, Michael C/D-5580-2012; Liu, Jun-Ping/AAA-5521-2020	Liu, Jun-Ping/0000-0001-7442-2116				ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; Beattie TL, 1998, CURR BIOL, V8, P177, DOI 10.1016/S0960-9822(98)70067-3; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BOND JA, 1994, ONCOGENE, V9, P1885; Broccoli D, 1996, MOL CELL BIOL, V16, P3765; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; Counter CM, 1997, P NATL ACAD SCI USA, V94, P9202, DOI 10.1073/pnas.94.17.9202; de Lange T, 1998, NATURE, V392, P753, DOI 10.1038/33790; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Fujimoto K, 1997, BIOCHEM BIOPH RES CO, V241, P775, DOI 10.1006/bbrc.1997.7806; Gollahon LS, 1998, ONCOGENE, V17, P709, DOI 10.1038/sj.onc.1201987; Gollahon LS, 1996, ONCOGENE, V12, P715; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; Greider CW, 1998, CURR BIOL, V8, pR178, DOI 10.1016/S0960-9822(98)70105-8; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kondo S, 1998, FASEB J, V12, P801, DOI 10.1096/fasebj.12.10.801; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li H, 1998, J BIOL CHEM, V273, P33436, DOI 10.1074/jbc.273.50.33436; Li H, 1997, J BIOL CHEM, V272, P16729, DOI 10.1074/jbc.272.27.16729; Lingner J, 1996, P NATL ACAD SCI USA, V93, P10712, DOI 10.1073/pnas.93.20.10712; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; Niida H, 1998, NAT GENET, V19, P203, DOI 10.1038/580; Oren M, 1998, NATURE, V391, P233, DOI 10.1038/34551; Ouellette MM, 1999, BIOCHEM BIOPH RES CO, V254, P795, DOI 10.1006/bbrc.1998.0114; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Roos G, 1998, INT J CANCER, V79, P343, DOI 10.1002/(SICI)1097-0215(19980821)79:4<343::AID-IJC6>3.0.CO;2-V; RUPPERT JM, 1993, MOL CELL BIOL, V13, P3811, DOI 10.1128/MCB.13.6.3811; Sedivy JM, 1998, P NATL ACAD SCI USA, V95, P9078, DOI 10.1073/pnas.95.16.9078; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; Takakura M, 1999, CANCER RES, V59, P551; Tsao DA, 1998, GENE, V221, P51, DOI 10.1016/S0378-1119(98)00432-6; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wen JP, 1998, HUM MOL GENET, V7, P1137, DOI 10.1093/hmg/7.7.1137; WHITEHEAD RH, 1984, JNCI-J NATL CANCER I, V73, P643; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; WynfordThomas D, 1996, J PATHOL, V180, P118, DOI 10.1002/(SICI)1096-9896(199610)180:2<118::AID-PATH673>3.0.CO;2-I; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601	58	69	89	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6785	6794		10.1038/sj.onc.1203061	http://dx.doi.org/10.1038/sj.onc.1203061			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597287				2022-12-17	WOS:000083792000021
J	Izzi, L; Turbide, C; Houde, C; Kunath, T; Beauchemin, N				Izzi, L; Turbide, C; Houde, C; Kunath, T; Beauchemin, N			cis-Determinants in the cytoplasmic domain of CEACAM1 responsible for its tumor inhibitory function	ONCOGENE			English	Article						CEA; BGP; CD66a; C-CAM; tumor suppressor; colon cancer; SHP-1; SHP-2; Tyr phosphorylation	CELL-ADHESION MOLECULE; CARCINOEMBRYONIC ANTIGEN FAMILY; MOUSE BILIARY GLYCOPROTEIN; C-CAM; GENE FAMILY; EPITHELIAL-CELLS; TYROSINE KINASE; ECTO-ATPASE; HEPATOCELLULAR CARCINOMAS; INTERCELLULAR-ADHESION	CEACAM1, also known as C-CAM, BGP and CD66a, is a member of the carcinoembryonic antigen (CEA) family which is itself part of the immunoglobulin supergene family, CEACAM1 is involved in intercellular adhesion, signal transduction and tumor cell growth regulation, CEACAM1 is down-regulated in colon and prostate carcinomas, as well as in endometrial, bladder and hepatic tumors, and 30% of breast cancers, We have shown in a mouse colon tumor model that CEACAM1 with a long cytoplasmic domain inhibited the development of tumors whereas a splice variant lacking the cytoplasmic domain did not, In this study, we define the subregions of the long cytoplasmic domain participating in the tumor inhibition phenotype of CEACAM1, We show that a single point mutation of Tyr488, conforming to an Immune-receptor Tyrosine Inhibition Motif (ITIM), was sufficient to reverse the in vivo tumor cell growth inhibition, Substitution or deletion of residues in the C-terminal region of the CEACAM1 cytoplasmic domain also led to reversal of tumor cell growth inhibition. This result is in agreement with our previous studies demonstrating the C-terminal region of the cytoplasmic domain influences the levels of CEACAM1 Tyr phosphorylation and its association with the protein Tyr phosphatases SHP-1 and SHP-2, Furthermore, removal of the N-terminal domain of CEACAM1, essential for intercellular adhesion, did not impair the tumor inhibitory effect. These results suggest that Tyr phosphorylation or dephosphorylation of the CEACAM1 cytoplasmic domain represents a crucial step in the control of epithelial cell proliferation.	McGill Univ, McGill Canc Ctr, Dept Biochem, Montreal, PQ, Canada; McGill Univ, McGill Canc Ctr, Dept Med & Oncol, Montreal, PQ, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	McGill University; McGill University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Beauchemin, N (corresponding author), McGill Univ, McGill Canc Ctr, Dept Biochem, McIntyre Med Sci Bldg,Room 716,3655 Drummond St, Montreal, PQ, Canada.			Kunath, Tilo/0000-0002-8805-7356				Bamberger AM, 1998, AM J PATHOL, V152, P1401; BARNETT TR, 1989, J CELL BIOL, V108, P267, DOI 10.1083/jcb.108.2.267; Beauchemin N, 1998, CELL ADHES COMMUN S, V5, P155; Beauchemin N, 1997, ONCOGENE, V14, P783, DOI 10.1038/sj.onc.1200888; BEAUCHEMIN N, 1999, UNPUB CANC RES; BRATTAIN MG, 1980, CANCER RES, V40, P2142; BRUMMER J, 1995, ONCOGENE, V11, P1649; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; CHEUNG PH, 1993, J BIOL CHEM, V268, P24303; Daniels E, 1996, DEV DYNAM, V206, P272, DOI 10.1002/(SICI)1097-0177(199607)206:3<272::AID-AJA5>3.3.CO;2-U; DVEKSLER GS, 1993, P NATL ACAD SCI USA, V90, P1716, DOI 10.1073/pnas.90.5.1716; Edlund M, 1996, J BIOL CHEM, V271, P1393, DOI 10.1074/jbc.271.3.1393; FORMISANO P, 1995, J BIOL CHEM, V270, P24073, DOI 10.1074/jbc.270.41.24073; FRANGSMYR L, 1995, CANCER RES, V55, P2963; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HANSSON M, 1989, EXP CELL RES, V181, P63, DOI 10.1016/0014-4827(89)90182-1; Hauck CR, 1998, EMBO J, V17, P443, DOI 10.1093/emboj/17.2.443; HINODA Y, 1988, P NATL ACAD SCI USA, V85, P6959, DOI 10.1073/pnas.85.18.6959; HIXSON DC, 1985, CANCER RES, V45, P3742; HSIEH JT, 1995, CANCER RES, V55, P190; Huber M, 1999, J BIOL CHEM, V274, P335, DOI 10.1074/jbc.274.1.335; Ilantzis C, 1997, LAB INVEST, V76, P703; Kinugasa T, 1998, INT J CANCER, V76, P148, DOI 10.1002/(SICI)1097-0215(19980330)76:1<148::AID-IJC23>3.3.CO;2-J; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KLEINERMAN DI, 1995, CANCER RES, V55, P2831; Kleinerman DI, 1996, CANCER RES, V56, P3431; KLEINERMAN DI, 1995, CANCER RES, V55, P1215; Kunath T, 1995, ONCOGENE, V11, P2375; LIN SH, 1989, J BIOL CHEM, V264, P14408; Luo WP, 1998, ONCOGENE, V16, P1141, DOI 10.1038/sj.onc.1201619; Luo WP, 1997, ONCOGENE, V14, P1697, DOI 10.1038/sj.onc.1200999; MCCUAIG K, 1992, CELL GROWTH DIFFER, V3, P165; Moskaluk CA, 1996, BBA-REV CANCER, V1288, pM31, DOI 10.1016/S0304-419X(96)00033-9; NAJJAR SM, 1993, J BIOL CHEM, V268, P1201; NEDELLEC P, 1995, EUR J BIOCHEM, V231, P104, DOI 10.1111/j.1432-1033.1995.tb20676.x; NEDELLEC P, 1994, J VIROL, V68, P4525; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; Nollau P, 1997, CANCER RES, V57, P2354; OCKLIND C, 1982, J BIOL CHEM, V257, P6788; OHWADA A, 1994, AM J RESP CELL MOL, V11, P214, DOI 10.1165/ajrcmb.11.2.8049082; OIKAWA S, 1992, BIOCHEM BIOPH RES CO, V186, P881, DOI 10.1016/0006-291X(92)90828-9; Pennisi E, 1998, SCIENCE, V281, P1438, DOI 10.1126/science.281.5382.1438; PENSIERO MN, 1992, J VIROL, V66, P4028, DOI 10.1128/JVI.66.7.4028-4039.1992; REESJONES RW, 1985, J BIOL CHEM, V260, P4461; Riethdorf L, 1997, J HISTOCHEM CYTOCHEM, V45, P957, DOI 10.1177/002215549704500705; ROBBINS J, 1991, GENOMICS, V10, P583, DOI 10.1016/0888-7543(91)90439-L; ROJAS M, 1990, CELL GROWTH DIFFER, V1, P527; ROSENBERG M, 1993, CANCER RES, V53, P4938; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; SIPPEL CJ, 1994, J BIOL CHEM, V269, P19539; SKUBITZ KM, 1995, J IMMUNOL, V155, P5382; SOUTHERN PJ, 1982, J MOL APPL GENET, V1, P314; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tanaka K, 1997, INT J CANCER, V74, P15, DOI 10.1002/(SICI)1097-0215(19970220)74:1<15::AID-IJC3>3.0.CO;2-3; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; THOMPSON JA, 1991, J CLIN LAB ANAL, V5, P344, DOI 10.1002/jcla.1860050510; Turbide C, 1997, CANCER RES, V57, P2781; VALLEJO AN, 1994, PCR METH APPL, V4, pS123; WATT SM, 1994, BLOOD, V84, P200; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	62	69	70	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	1999	18	40					5563	5572		10.1038/sj.onc.1202935	http://dx.doi.org/10.1038/sj.onc.1202935			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	241QU	10523833				2022-12-17	WOS:000082894700009
J	Yao, Y; Slosberg, ED; Wang, L; Hibshoosh, H; Zhang, YJ; Xing, WQ; Santella, RM; Weinstein, IB				Yao, Y; Slosberg, ED; Wang, L; Hibshoosh, H; Zhang, YJ; Xing, WQ; Santella, RM; Weinstein, IB			Increased susceptibility to carcinogen-induced mammary tumors in MMTV-Cdc25B transgenic mice	ONCOGENE			English	Article						Cdc25B; transgenic mice; DMBA; synergy; mammary tumor; MMTV-LTR	PHOSPHORYLATES HUMAN CDC25C; XENOPUS EGG EXTRACTS; GROWTH-FACTOR-ALPHA; MOUSE MAMMARY; CELL-CYCLE; FISSION YEAST; MITOTIC INDUCER; SYNERGISTIC INTERACTION; TRANSCRIPTIONAL CONTROL; TYROSINE PHOSPHATASE	Cdc25 phosphatases activate cyclin-dependent kinases (Cdks) by dephosphorylating critical phospho-tyrosine and phospho-threonine residues on these proteins. Several types of studies indicate that Cdc25s can enhance cell proliferation and oncogenesis, Furthermore, overexpression of Cdc25A and/or B have been detected in several types of primary human cancers, including breast cancers. To further assess the oncogenic capacity of Cdc25B in vivo, we have generated transgenic mice that overexpress Cdc25B in the mammary epithelium, driven by the MMTV-LTR promoter. Although these mice are grossly normal for up to 18 months, the ectopic expression of Cdc25B in their mammary glands increases the susceptibility of these mice to induction of mammary tumors by the carcinogen 9,10-dimethyl-1,2-benzanthracene (DMBA).	Columbia Univ Coll Phys & Surg, Dept Med, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Integrated Program CMBS, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Genet, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Sch Publ Hlth, Div Environm Hlth Sci, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University	Weinstein, IB (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, Herbert Irving Comprehens Canc Ctr, 701 W 168th St, New York, NY 10032 USA.				NCI NIH HHS [R01 CA/ES63467, T32CA09503] Funding Source: Medline; NIGMS NIH HHS [T32GM07088] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063467, T32CA009503] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007088] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aldaz CM, 1996, CARCINOGENESIS, V17, P2069, DOI 10.1093/carcin/17.9.2069; AMUNDADOTTIR LT, 1995, CELL GROWTH DIFFER, V6, P737; ARCHULETA MM, 1992, TOXICOL APPL PHARM, V113, P133, DOI 10.1016/0041-008X(92)90017-M; Baldin V, 1997, J BIOL CHEM, V272, P32731, DOI 10.1074/jbc.272.52.32731; Baldin V, 1997, ONCOGENE, V14, P2485, DOI 10.1038/sj.onc.1201063; BEATO M, 1991, FASEB J, V5, P2044, DOI 10.1096/fasebj.5.7.2010057; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; BORTNER DM, 1995, CELL GROWTH DIFFER, V6, P1579; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; CARDIFF RD, 1993, CANCER SURV, V16, P97; CLARKE PR, 1993, MOL BIOL CELL, V4, P397, DOI 10.1091/mbc.4.4.397; DANDEKAR S, 1986, MOL CELL BIOL, V6, P4104, DOI 10.1128/MCB.6.11.4104; Draetta G, 1997, BBA-REV CANCER, V1332, pM53, DOI 10.1016/S0304-419X(96)00049-2; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Gabrielli BG, 1997, J BIOL CHEM, V272, P28607, DOI 10.1074/jbc.272.45.28607; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Gasparotto D, 1997, CANCER RES, V57, P2366; GRIECO D, 1994, P NATL ACAD SCI USA, V91, P9896, DOI 10.1073/pnas.91.21.9896; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HALTER SA, 1992, AM J PATHOL, V140, P1131; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hennighausen L, 1995, J CELL BIOCHEM, V59, P463, DOI 10.1002/jcb.240590407; HENRARD D, 1988, J VIROL, V62, P3046, DOI 10.1128/JVI.62.8.3046-3049.1988; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HOFFMANN I, 1994, J CELL SCI, P75; HOGAN B, 1994, ANIPULATING MOUSE EM; Iavarone A, 1997, NATURE, V387, P417; JIANG W, 1993, ONCOGENE, V8, P3447; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Klein MG, 1998, EXP CELL RES, V244, P26, DOI 10.1006/excr.1998.4153; Kudo Y, 1997, JPN J CANCER RES, V88, P947, DOI 10.1111/j.1349-7006.1997.tb00313.x; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; LI BL, 1995, MOL CARCINOGEN, V14, P75, DOI 10.1002/mc.2940140203; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; MEDINA D, 1980, CANCER RES, V40, P368; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; NAGATA A, 1991, NEW BIOL, V3, P959; NIELSEN LL, 1991, CANCER RES, V51, P3762; OGG S, 1994, J BIOL CHEM, V269, P30461; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PIERCE DF, 1995, P NATL ACAD SCI USA, V92, P4254, DOI 10.1073/pnas.92.10.4254; Quezado MM, 1998, HUM PATHOL, V29, P604, DOI 10.1016/S0046-8177(98)80010-5; ROLLINI P, 1992, J VIROL, V66, P4580, DOI 10.1128/JVI.66.7.4580-4586.1992; ROSS SR, 1990, MOL CELL BIOL, V10, P5822, DOI 10.1128/MCB.10.11.5822; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Santarelli R, 1996, ONCOGENE, V12, P495; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Spitkovsky D, 1996, ONCOGENE, V12, P2549; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; Stutman O, 1975, Adv Cancer Res, V22, P261; TRUSS M, 1992, J STEROID BIOCHEM, V41, P241, DOI 10.1016/0960-0760(92)90350-R; TURUSOV VS, 1994, TUMORS MOUSE PATHOLO, V2, P776; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WEINBERG RA, 1989, CANCER RES, V49, P3713; WITTY JP, 1995, CANCER RES, V55, P1401; Wu W., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P544	65	69	71	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	1999	18	37					5159	5166		10.1038/sj.onc.1202908	http://dx.doi.org/10.1038/sj.onc.1202908			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235RE	10498865				2022-12-17	WOS:000082555700004
J	Aguirre-Ghiso, JA; Frankel, P; Farias, EF; Lu, ZM; Jiang, H; Olsen, A; Feig, LA; Joffe, EB; Foster, DA				Aguirre-Ghiso, JA; Frankel, P; Farias, EF; Lu, ZM; Jiang, H; Olsen, A; Feig, LA; Joffe, EB; Foster, DA			RalA requirement for v-Src- and v-Ras-induced tumorigenicity and overproduction of urokinase-type plasminogen activator: involvement of metalloproteases	ONCOGENE			English	Article						GTPase; metalloproteases; Ral; Ras; Src; tumorigenicity; uPA	PROTEIN-TYROSINE KINASES; PHOSPHOLIPASE-D; SIGNALING PATHWAY; GENE-EXPRESSION; CELL-LINE; COLLAGENASE; RECEPTOR; METASTASIS; TRANSFORMATION; MECHANISM	Overproduction of urokinase-type plasminogen activator (uPA) and metalloproteases (MMPs) is strongly correlated with tumorigenicity and with invasive and metastatic phenotypes of human and experimental tumors. We demonstrated previously that overproduction of uPA in turner cells is mediated by a phospholipase D (PLD)and protein kinase C-dependent mechanism. The oncogenic stimulus of v-Src and v-Ras results in the activation of PLD, which is dependent upon the monomeric GTPase RalA, We have therefore investigated whether RaLA plays a role in uPA and MNP overproduction that is observed in response to oncogenic signals, We report here that NIH3T3 cells transformed by both v-Src and v-Ras, constitutively overproduce uPA and that expression of a dominant negative RalA mutant (S28N) blocks overproduction of uPA in both the v-Src-and v-Ras-transformed cells. v-Src and v-Ras also induced an upregulation of the activity of MMP-2 and MMP-9 as detected by zymograms, however only the v-Src induction correlated with MMP protein levels detected by Western blot analysis, The dominant negative RalA mutant blocked increased MMP-2 and 9 overproduction induced by v-Src, but not the increased activity of MMP-2 and 9 induced by v-Ras. And, consistent with a role for the RalA/PLD pathway in mitogenesis and tumor development, the dominant negative RaLA mutant completely blocked tumor formation by v-Src- and v-Ras-transformed NIH3T3 cells injected subcutaneously in syngeneic mice, The data presented here implicate RalA and PLD as signaling mediators for tumor formation and protease production by transformed cells.	Univ Buenos Aires, Inst Oncol Angel H Roffo, Dept Cell Biol, Res Area, RA-1417 Buenos Aires, DF, Argentina; CUNY Hunter Coll, Dept Biol Sci, New York, NY 10021 USA; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA	University of Buenos Aires; City University of New York (CUNY) System; Hunter College (CUNY); Tufts University	Aguirre-Ghiso, JA (corresponding author), CUNY Mt Sinai Sch Med, Dept Med, Div Neoplast Dis, New York, NY 10029 USA.			Aguirre-Ghiso, Julio/0000-0002-6694-6507; BAL de KIER JOFFE, ELISA DORA/0000-0001-6952-0029	NCRR NIH HHS [RR-03037] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALONSO DF, 1993, CANCER LETT, V70, P181, DOI 10.1016/0304-3835(93)90229-3; BELL SM, 1993, MOL CELL BIOL, V13, P5888, DOI 10.1128/MCB.13.9.5888; Bi K, 1997, CURR BIOL, V7, P301, DOI 10.1016/S0960-9822(06)00153-9; BLOBE GC, 1994, CANCER METAST REV, V13, P411, DOI 10.1007/BF00666107; Boyd D, 1996, CANCER METAST REV, V15, P77, DOI 10.1007/BF00049488; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; Carmeliet P, 1997, NAT GENET, V17, P439, DOI 10.1038/ng1297-439; CARPENTER CL, 1996, BIOCH BIOPHYS ACTA R, V1288, P11; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; Exton JH, 1998, BBA-MOL CELL BIOL L, V1436, P105, DOI 10.1016/S0005-2760(98)00124-6; FOSTER DA, 1993, CELL SIGNAL, V5, P389, DOI 10.1016/0898-6568(93)90078-Z; Ghiso JAA, 1997, BBA-MOL CELL RES, V1356, P171, DOI 10.1016/S0167-4889(96)00173-5; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; HART IR, 1989, BIOCHIM BIOPHYS ACTA, V989, P65, DOI 10.1016/0304-419X(89)90035-8; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; JIANG H, 1995, J BIOL CHEM, V270, P6006, DOI 10.1074/jbc.270.11.6006; Lengyel E, 1997, ONCOGENE, V14, P2563, DOI 10.1038/sj.onc.1201098; Lengyel E, 1996, J CELL BIOCHEM, V61, P430, DOI 10.1002/(SICI)1097-4644(19960601)61:3<430::AID-JCB10>3.0.CO;2-N; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1991, CANCER RES, V51, pS5054; Luo JQ, 1997, BIOCHEM BIOPH RES CO, V235, P854, DOI 10.1006/bbrc.1997.6793; Luo JQ, 1998, P NATL ACAD SCI USA, V95, P3632, DOI 10.1073/pnas.95.7.3632; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; Mazzieri R, 1997, EMBO J, V16, P2319, DOI 10.1093/emboj/16.9.2319; MOLLER LB, 1993, BLOOD COAGUL FIBRIN, V4, P293; OSSOWSKI L, 1992, CANCER RES, V52, P6754; OSSOWSKI L, 1983, CELL, V35, P611, DOI 10.1016/0092-8674(83)90093-4; PITTMAN RN, 1985, DEV BIOL, V110, P91, DOI 10.1016/0012-1606(85)90067-3; QURESHI SA, 1993, BIOCHEM BIOPH RES CO, V192, P969, DOI 10.1006/bbrc.1993.1510; REICH R, 1995, CLIN EXP METASTAS, V13, P134, DOI 10.1007/BF00133618; Roth MG, 1997, CURR OPIN CELL BIOL, V9, P519, DOI 10.1016/S0955-0674(97)80028-2; SAKSELA O, 1981, ANAL BIOCHEM, V111, P276, DOI 10.1016/0003-2697(81)90564-9; SATO H, 1993, J BIOL CHEM, V268, P23460; Silberman S, 1997, J BIOL CHEM, V272, P5927, DOI 10.1074/jbc.272.9.5927; SONG JG, 1991, MOL CELL BIOL, V11, P4903, DOI 10.1128/MCB.11.10.4903; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Werb Z, 1996, BRAZ J MED BIOL RES, V29, P1087; Williger BT, 1999, J BIOL CHEM, V274, P735, DOI 10.1074/jbc.274.2.735; YU H, 1990, CANCER RES, V50, P7623; Yu W, 1997, J CELL BIOL, V137, P767, DOI 10.1083/jcb.137.3.767	41	69	72	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	1999	18	33					4718	4725		10.1038/sj.onc.1202850	http://dx.doi.org/10.1038/sj.onc.1202850			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228UQ	10467419				2022-12-17	WOS:000082154400009
J	Adriaenssens, E; Lottin, S; Dugimont, T; Fauquette, W; Coll, J; Dupouy, JP; Boilly, B; Curgy, JJ				Adriaenssens, E; Lottin, S; Dugimont, T; Fauquette, W; Coll, J; Dupouy, JP; Boilly, B; Curgy, JJ			Steroid hormones modulate H19 gene expression in both mammary gland and uterus	ONCOGENE			English	Article						H19 gene regulation; mammary gland; uterus; steroid hormones; mammary cells; nuclear receptors	GROWTH FACTOR-II; LIGAND-INDEPENDENT ACTIVATION; HUMAN ESTROGEN-RECEPTOR; TUMOR-SUPPRESSOR GENE; IMPRINTED GENES; BREAST-CANCER; WILMS-TUMOR; PROGESTERONE-RECEPTOR; IGF2 EXPRESSION; CELL-LINES	H19 is an imprinted and developmentally regulated gene whose product remains apparently untranslated. In a previous study on breast adenocarcinomas, we reported that overexpression of the H19 gene was significantly correlated with the presence of steroid receptors, suggesting the putative role of hormones in H19 transcription. To determine the mode of steroid action, we have detected levels of H19 RNA. synthesis during mammary gland development by in situ hybridization (ISH): two peaks of H19 transcription occur during puberty and pregnancy. Furthermore, we demonstrated by ISH that in the uterus H19 RNA synthesis is high during estrus and metestrus phases. To test steroid control of H19 transcription, ovariectomized and adrenalectomized mice were supplemented, 1 week after surgery, with 17-beta-estradiol (E2, 20 mu g/kg/day), progesterone (P, 1 mg/kg/day) or corticosterone (B, 0.3 mg/kg/day) for 2 weeks. According to ISH data, E2 and to a lesser extent B stimulated H19 transcription in the uterus, whereas P inhibited it. To confirm the in vivo results, in vitro experiments were performed using cultures of MCF-7 cells (a hormone-sensitive mammary cell line). E2 stimulated the endogenous H19 gene of this cell line and tamoxifen inhibited this effect. Furthermore, we performed transient cotransfections in MCF-7, in HBL-100 (another hormone-sensitive mammary cell line) and in BT-20 (a hormone-insensitive mammary cell line) with various constructs of ER alpha (WT or mutated) and PR-A, in presence or absence of steroid hormones. We demonstrated that ER alpha up-regulated the H19 promoter in MCF-7 and in HBL-100, whereas PR-A did not have any effect pel se. Moreover, in MCF-7, PR-A antagonized clearly the ER alpha-mediated promoter enhancement, but in HBL-100 this counteracting effect on the ER alpha up-regulation was not found. Interestingly, the same experiments performed in BT-20 cell line provided very similar results as those obtained in MCF-7 cells, with a clear down-regulation mediated by PR-A on the H19 promoter. All these in vitro data are in agreement with irt vivo results. In addition, data obtained with ERI mutants indicate that H19 promoter activation is both ligand-dependent and ligand-independent. We have thus demonstrated that H19 gene expression is controlled by steroid hormones; furthermore, this gene is highly expressed in hormone-sensitive organs when the hormonal stimulation is accompanied, with a morphological repair.	UST Lille, UPRES EA 1033, Dev Biol Lab, F-59655 Villeneuve Dascq, France; Univ Artois, Fac Sci Jean Perrin, F-62307 Lens, France; URA 1854, F-59021 Lille, France; UST Lille, Biol Cellulaire Lab, Lab Neuroendocrinol Dev, F-59655 Villeneuve Dascq, France	Universite de Lille - ISITE; Universite de Lille; Universite d'Artois; Universite de Lille - ISITE; Universite de Lille	Curgy, JJ (corresponding author), UMR 8527, BP 447, F-59021 Lille, France.							Adriaenssens E, 1998, AM J PATHOL, V153, P1597, DOI 10.1016/S0002-9440(10)65748-3; Ariel I, 1997, J CLIN PATHOL-MOL PA, V50, P34, DOI 10.1136/mp.50.1.34; ARIEL I, 1994, GYNECOL ONCOL, V53, P212, DOI 10.1006/gyno.1994.1118; Ariel I, 1997, DIAGN MOL PATHOL, V6, P17, DOI 10.1097/00019606-199702000-00004; Aumais JP, 1996, J BIOL CHEM, V271, P12568, DOI 10.1074/jbc.271.21.12568; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; BERNET F, 1994, REGUL PEPTIDES, V52, P187, DOI 10.1016/0167-0115(94)90053-1; BIRAN H, 1994, TUMOR BIOL, V15, P123, DOI 10.1159/000217882; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; CHATELAIN A, 1989, J ENDOCRINOL, V123, P421, DOI 10.1677/joe.0.1230421; Cooper MJ, 1996, J UROLOGY, V155, P2120, DOI 10.1016/S0022-5347(01)66120-2; Cui HM, 1997, CANCER RES, V57, P4469; Cunha G R, 1992, Epithelial Cell Biol, V1, P105; DALLE M, 1978, J ENDOCRINOL, V76, P303, DOI 10.1677/joe.0.0760303; DANIEL CW, 1992, MOL REPROD DEV, V32, P145, DOI 10.1002/mrd.1080320210; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DOUCRASY S, 1993, INT J ONCOL, V2, P753; Dugimont T, 1998, ONCOGENE, V16, P2395, DOI 10.1038/sj.onc.1201742; Dugimont T, 1995, BIOL CELL, V85, P117, DOI 10.1016/0248-4900(96)85272-5; DUPOUY JP, 1975, J ENDOCRINOL, V65, P347, DOI 10.1677/joe.0.0650347; DUPOUY JP, 1975, CR ACAD SCI D NAT, V280, P463; El Yazidi I, 1998, BBA-MOL CELL RES, V1403, P127, DOI 10.1016/S0167-4889(98)00033-0; ElTanani MKK, 1997, MOL ENDOCRINOL, V11, P928, DOI 10.1210/me.11.7.928; EVERSOLECIRE P, 1995, CELL GROWTH DIFFER, V6, P337; Giangrande PH, 1997, J BIOL CHEM, V272, P32889, DOI 10.1074/jbc.272.52.32889; GLASER T, 1989, SOMAT CELL MOLEC GEN, V15, P477, DOI 10.1007/BF01534910; GRONEMEYER H, 1991, J STEROID BIOCHEM, V40, P271, DOI 10.1016/0960-0760(91)90192-8; GUIOCHONMANTEL A, 1988, NATURE, V336, P695, DOI 10.1038/336695a0; Han DKM, 1996, J CLIN INVEST, V97, P1276, DOI 10.1172/JCI118543; Hanstein B, 1999, MOL ENDOCRINOL, V13, P129, DOI 10.1210/me.13.1.129; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; Haslam S. Z., 1987, The mammary gland. Development, regulation, and function., P499; HASLAM SZ, 1980, J CELL BIOL, V86, P730, DOI 10.1083/jcb.86.3.730; Hemberger M, 1998, DEV GENES EVOL, V208, P393, DOI 10.1007/s004270050195; ILENCHUK TT, 1987, ENDOCRINOLOGY, V120, P1449, DOI 10.1210/endo-120-4-1449; INCE BA, 1995, ENDOCRINOLOGY, V136, P3194, DOI 10.1210/en.136.8.3194; JONES CM, 1991, DEVELOPMENT, V111, P531; Joubel A, 1996, CELL MOL BIOL, V42, P1159; KATO S, 1995, MOL CELL BIOL, V15, P5858; Kondo M, 1996, Nihon Rinsho, V54, P492; Kopf E, 1998, FEBS LETT, V432, P123, DOI 10.1016/S0014-5793(98)00841-2; KRAUS WL, 1995, MOL CELL BIOL, V15, P1847; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Lahooti H, 1995, J STEROID BIOCHEM, V55, P305, DOI 10.1016/0960-0760(95)00188-3; Lee AV, 1995, BIOMED PHARMACOTHER, V49, P415, DOI 10.1016/0753-3322(96)82678-3; LEIBOVITCH MP, 1991, BIOCHEM BIOPH RES CO, V180, P1241, DOI 10.1016/S0006-291X(05)81329-4; LEIGHTON PA, 1995, GENE DEV, V9, P2079, DOI 10.1101/gad.9.17.2079; Lesage J, 1996, NEUROCHEM RES, V21, P87, DOI 10.1007/BF02527676; Li YM, 1998, J BIOL CHEM, V273, P28247, DOI 10.1074/jbc.273.43.28247; LustigYariv O, 1997, ONCOGENE, V15, P169, DOI 10.1038/sj.onc.1201175; MARIE J, 1980, PATHOL BIOL, V28, P377; MARIE J, 1981, PATHOL BIOL, V29, P367; MCCORMACK JT, 1974, J ENDOCRINOL, V62, P101, DOI 10.1677/joe.0.0620101; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; NANDI S, 1958, J NATL CANCER I, V21, P1039; PACHNIS V, 1984, P NATL ACAD SCI-BIOL, V81, P5523, DOI 10.1073/pnas.81.17.5523; PEYRAT JP, 1991, CANCER COMMUN, V3, P323, DOI 10.3727/095535491820873803; QUEVA C, 1992, DEVELOPMENT, V114, P125; REESE JC, 1991, J BIOL CHEM, V266, P10880; RHODA J, 1984, ENDOCRINOLOGY, V114, P1754, DOI 10.1210/endo-114-5-1754; RHODA J, 1983, CR ACAD SCI III-VIE, V296, P405; SAKAKURA T, 1991, INT REV CYTOL, V125, P165, DOI 10.1016/S0074-7696(08)61219-X; Sambrook J., 1989, MOL CLONING LABORATO, V2, P916; SANYAL MK, 1978, J ENDOCRINOL, V79, P179, DOI 10.1677/joe.0.0790179; Schodin DJ, 1995, J BIOL CHEM, V270, P31163, DOI 10.1074/jbc.270.52.31163; SMITH MS, 1975, ENDOCRINOLOGY, V96, P219, DOI 10.1210/endo-96-1-219; SNEDEKER SM, 1991, P NATL ACAD SCI USA, V88, P276, DOI 10.1073/pnas.88.1.276; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; THESLEFF I, 1995, INT J DEV BIOL, V39, P35; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; van Roozendaal CEP, 1998, FEBS LETT, V437, P107, DOI 10.1016/S0014-5793(98)01211-3; VOUTILAINEN R, 1994, ENDOCRINOLOGY, V134, P2051, DOI 10.1210/en.134.5.2051; Wang WH, 1996, J BIOL CHEM, V271, P27863, DOI 10.1074/jbc.271.44.27863; Webber AL, 1998, NATURE, V391, P711, DOI 10.1038/35655; Weigel NL, 1998, J MOL MED, V76, P469, DOI 10.1007/s001090050241; WEISZ J, 1980, ENDOCRINOLOGY, V106, P306, DOI 10.1210/endo-106-1-306; Yballe CM, 1996, J CLIN ENDOCR METAB, V81, P1607, DOI 10.1210/jc.81.4.1607; YOOWARREN H, 1988, MOL CELL BIOL, V8, P4707, DOI 10.1128/MCB.8.11.4707; ZEMEL S, 1992, NAT GENET, V2, P61, DOI 10.1038/ng0992-61; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	82	69	70	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	1999	18	31					4460	4473		10.1038/sj.onc.1202819	http://dx.doi.org/10.1038/sj.onc.1202819			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	222YT	10442637				2022-12-17	WOS:000081813500008
J	Lu, WG; Mayer, BJ				Lu, WG; Mayer, BJ			Mechanism of activation of Pak1 kinase by membrane localization	ONCOGENE			English	Article						Pak kinase; Nck; SH2/SH3 adaptors; Cdc42; Rac; signal transduction	P21-ACTIVATED PROTEIN-KINASES; ACTIN STRESS FIBERS; RHO-FAMILY GTPASES; ADAPTER PROTEIN; BINDING-PROTEIN; CELL-CYCLE; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; XENOPUS OOCYTES; FOCAL COMPLEXES	Pak kinases are a family of serine/threonine protein kinases homologous to Ste20p of yeast. Paks can be activated in vivo and in vitro by binding to GTP-bound Cdc42 and Rad, members of the Rho family of small GTPases implicated in regulating the organization of the actin cytoskeleton. We have previously reported that the SH2/SH3-containing adaptor protein Nck binds Pak kinase through its second SH3 domain. Pak1 can be targeted to the membrane by Nck in response to tyrosine phosphorylation, and membrane association of Pak1 is sufficient to increase its specific activity. The mechanism whereby Pak is activated by membrane localization, however, is unknown, We show here that expression of three proteins that inhibit Rho-family GTPases by different mechanisms (RhoGDI, Bcr and D57Y Cdc42) all block the activation of Pak by a membrane-targeted Nck SH3 domain, demonstrating that the in vivo activation of Pak1 induced by membrane localization is dependent on Rho-family GTPases. This implies that Pak activity can be regulated in cells both by the level of GTP loading of various Rho-family GTPases and the local concentration of Pak relative to these GTPases. Our data also suggest the existence of Rho-family GTPases in addition to Cdc42 and Rad that can activate Pak on membranes.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Childrens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School	Mayer, BJ (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Childrens Hosp, 320 Longwood Ave, Boston, MA 02115 USA.							BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; Brzeska H, 1997, P NATL ACAD SCI USA, V94, P1092, DOI 10.1073/pnas.94.4.1092; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; CICCHETTI P, 1995, EMBO J, V14, P3127, DOI 10.1002/j.1460-2075.1995.tb07315.x; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Cullen BR, 1996, CURR BIOL, V6, P1557, DOI 10.1016/S0960-9822(02)70770-7; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; Faure S, 1997, EMBO J, V16, P5550, DOI 10.1093/emboj/16.18.5550; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Harden N, 1996, MOL CELL BIOL, V16, P1896; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; HU G, 1995, MOL CELL BIOL, V15, P1169; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; JUNG V, 1994, MOL CELL BIOL, V14, P3707, DOI 10.1128/MCB.14.6.3707; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; Lu XB, 1996, CURR BIOL, V6, P1677, DOI 10.1016/S0960-9822(02)70792-6; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Nunn MF, 1996, J VIROL, V70, P6157, DOI 10.1128/JVI.70.9.6157-6161.1996; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sawai ET, 1996, CURR BIOL, V6, P1519, DOI 10.1016/S0960-9822(96)00757-9; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; TEO M, 1995, J BIOL CHEM, V270, P26690, DOI 10.1074/jbc.270.44.26690; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zipkin ID, 1997, CELL, V90, P883, DOI 10.1016/S0092-8674(00)80353-0	66	69	69	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					797	806		10.1038/sj.onc.1202361	http://dx.doi.org/10.1038/sj.onc.1202361			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989831				2022-12-17	WOS:000078394400026
J	Krtolica, A; Krucher, NA; Ludlow, JW				Krtolica, A; Krucher, NA; Ludlow, JW			Hypoxia-induced pRB hypophosphorylation results from downregulation of CDK and upregulation of PP1 activities	ONCOGENE			English	Article						protein phosphatase type 1 (PP1); pRB hypoxia; cyclin-dependent kinase activity; mammalian cell cycle	CYCLIN-DEPENDENT KINASES; PROTEIN PHOSPHATASE-ACTIVITY; RETINOBLASTOMA GENE-PRODUCT; CELL-CYCLE; SUPPRESSOR PROTEIN; S-PHASE; PHOSPHORYLATION; INHIBITOR; P21; TRANSCRIPTION	Exposure of CV-1P cells to hypoxic conditions results in reversible cell cycle arrest concomitant with accumulation of pRB in the hypophosphorylated, growth suppressive form. Similar to cell cycle arrest induced by serum starvation, we show here that hypoxia-induced arrest is accompanied by a decrease in pRB-directed CDK4 and CDK2 activities, lower cyclin D and E protein levels, and by an increase in p27 protein abundance. Immunoprecipitation studies reveal an increase in p27 association with cyclin E-CDK2 complexes. In contrast to cell cycle arrest induced by serum starvation, hypoxia increases PP1-mediated pRB dephosphorylation. These data reveal that synergy between decreased pRB-directed cyclin/CDK activity and increased pRB-directed phosphatase activity contribute towards inducing and maintaining pRB in its hypophosphorylated, growth suppressive state during hypoxia.	Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Ctr Canc, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Ludlow, JW (corresponding author), Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA.				NCI NIH HHS [T32 CA09363, CA56940, CA11198] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA011198, R29CA056940, T32CA009363] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allen PB, 1998, J BIOL CHEM, V273, P4089, DOI 10.1074/jbc.273.7.4089; Amellem O, 1996, EXP CELL RES, V227, P106, DOI 10.1006/excr.1996.0255; AMELLEM O, 1991, CELL PROLIFERAT, V24, P127, DOI 10.1111/j.1365-2184.1991.tb01144.x; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUTIGAN DL, 1988, METHOD ENZYMOL, V159, P339; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COHEN P, 1988, METHOD ENZYMOL, V159, P390; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Geng Y, 1996, ONCOGENE, V12, P1173; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; HALL M, 1995, ONCOGENE, V11, P1581; HARPER JW, 1993, CELL, V75, P805; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HEACOCK CS, 1990, BRIT J CANCER, V62, P217, DOI 10.1038/bjc.1990.264; JAGIELLO I, 1995, J BIOL CHEM, V270, P17257, DOI 10.1074/jbc.270.29.17257; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Krtolica A, 1996, CANCER RES, V56, P1168; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUDLOW JW, 1993, ONCOGENE, V8, P331; LUDLOW JW, 1993, FASEB J, V7, P866, DOI 10.1096/fasebj.7.10.8344486; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MASSAGUE J, 1995, CURR OPIN GENET DEV, V5, P91, DOI 10.1016/S0959-437X(95)90059-4; Nelson DA, 1997, ONCOGENE, V14, P2407, DOI 10.1038/sj.onc.1201081; Nelson DA, 1997, J BIOL CHEM, V272, P4528, DOI 10.1074/jbc.272.7.4528; NEVINS JR, 1992, SCIENCE, V258, P424; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; VILLAMORUZZI E, 1992, FEBS LETT, V304, P211, DOI 10.1016/0014-5793(92)80621-M; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738	49	69	71	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 5	1998	17	18					2295	2304		10.1038/sj.onc.1202159	http://dx.doi.org/10.1038/sj.onc.1202159			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811460				2022-12-17	WOS:000076723300003
J	Huang, C; Taki, T; Adachi, M; Konishi, T; Higashiyama, M; Miyake, M				Huang, C; Taki, T; Adachi, M; Konishi, T; Higashiyama, M; Miyake, M			Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer	ONCOGENE			English	Article						p53; mutation; prognostic factor; SSCP; lung cancer	TUMOR-SUPPRESSOR GENE; MUTANT P53; CYCLE; SURVIVAL; PROTEIN; TRANSACTIVATION; OVEREXPRESSION; ACCUMULATION; ONCOPROTEIN; MODULATION	This study was performed to clarify the different effects of each mutant exon of p53 as indicators of a poor prognosis in patients with non-small cell lung cancer (NSCLC), Tumor tissues of 204 patients with NSCLC were analysed; 96 tumors were stage I, 22 stage II, and 86 stage III. DNA was extracted from frozen specimens and polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) and direct sequencing were performed to investigate mutations of p53 from exon 5 to exon 8, Seventy-five patients with NSCLC (36.8%) had mutations in p53 which included 72 cases of missense mutations and three cases of non-missense mutations, The overall survival rate of patients with mutant p53 adenocarcinomas was strikingly worse than that of patients whose tumors had wild-type p53 (35.7% vs 53.8%; P = 0.041), but no significant difference in survival was found in the patients with NSCLC and squamous cell carcinoma, Mutations in exon 5 of p53 occurred in 33 cases (16.2%), mutation in exon 6 was detected in only one case (0.5%), mutations in exon 7 in 20 cases (9.8%), and mutations in exon 8 in 18 cases (8.8%), The overall survival rate of patients with mutations in exon 7 was worse than that of patients with wild-type p53 in NSCLCs and adenocarcinomas (42.9% vs 56.0%; P = 0.025 and 33.3% vs 53.8%; P = 0.048, respectively), whereas the overall survival of patients with mutations in exon 5 was almost the same as that of patients with wild-type p53, In addition, the overall survival rate of patients with mutations in exon 8 was strikingly worse than that of patients with wild-type p53 in NSCLCs, adenocarcinomas and squamous cell carcinomas (22.9% vs 56.0%; P < 0.001, 19.0% vs 53.8%; P = 0.004 and 33.3% vs 62.5%; P = 0.042, respectively). Multivariate analysis with the Cox regression model of patients with NSCLC, adenocarcinoma and squamous cell carcinoma indicated that mutations in exon 8 mere best correlated with the overall survival rate, followed by lymph node status (P < 0.001, P = 0.015 and P = 0.006, respectively), and mutations in exon 7 of NSCLC were also revealed to have good correlation, followed by lymph node status and mutations in exon 8 (P = 0.031), Mutation of p53 was a poor prognostic factor for adenocarcinoma as described previously, Moreover, mutations in exon 8 were more useful indicators of prognosis not only for adenocarcinoma but also for NSCLC, Worse overall survival of the patients with mutations in exon 8 of p53 was suggested to be associated with codon 273 mutations as well as mutations between codon 280 and 285 included into the H2 alpha helix corresponding to residues 278-286, These results suggested that abnormal conformation of H2 alpha helix might play an important role not only in the loss of normal function but also in the acquisition of tumorigenesis, Investigation of mutations in exon 8, especially codon 273 mutation and mutant H2 alpha helix was considered to be a clinically useful approach for determining the prognosis of patients with NSCLC.	Kitano Hosp, Tazuke Kofukai Med Res Inst, Dept Thorac Surg, Kita Ku, Osaka 530, Japan; Kitano Hosp, Tazuke Kofukai Med Res Inst, Dept Oncol 5, Kita Ku, Osaka 530, Japan; Ctr Adult Dis, Dept Surg, Osaka 537, Japan	Kitano Hospital; Kitano Hospital	Miyake, M (corresponding author), Kitano Hosp, Tazuke Kofukai Med Res Inst, Dept Thorac Surg, Kita Ku, 13-3 Kamiyama Cho, Osaka 530, Japan.							CHIBA I, 1990, ONCOGENE, V5, P1603; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CORDONCARDO C, 1995, AM J PATHOL, V147, P545; COX DR, 1972, J R STAT SOC B, V34, P187; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; EBINA M, 1994, CANCER RES, V54, P2496; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; Fukuyama Y, 1997, BRIT J CANCER, V75, P1125, DOI 10.1038/bjc.1997.194; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HANN BC, 1995, NAT GENET, V9, P221, DOI 10.1038/ng0395-221; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HERMANEK P, 1987, TNM CLASSIFICATION M, P75; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORIO Y, 1993, CANCER RES, V53, P1; Iwamoto KS, 1996, CANCER RES, V56, P3862; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KATSURAGI K, 1995, BIOMED RES-TOKYO, V16, P273, DOI 10.2220/biomedres.16.273; Kawamura M, 1996, ONCOGENE, V12, P2361; LEE JS, 1995, J CLIN ONCOL, V13, P1893, DOI 10.1200/JCO.1995.13.8.1893; LEVINE AJ, 1992, CANCER SURV, V12, P59; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MARTIN HM, 1992, INT J CANCER, V50, P859, DOI 10.1002/ijc.2910500604; MCLAREN R, 1992, BRIT J CANCER, V66, P735, DOI 10.1038/bjc.1992.348; MITSUDOMI T, 1993, JNCI-J NATL CANCER I, V85, P2018, DOI 10.1093/jnci/85.24.2018; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; Park DJ, 1996, MOL CARCINOGEN, V16, P101, DOI 10.1002/(SICI)1098-2744(199606)16:2<101::AID-MC6>3.0.CO;2-L; PASSLICK B, 1995, J THORAC CARDIOV SUR, V109, P1205, DOI 10.1016/S0022-5223(95)70204-0; QUINLAN DC, 1992, CANCER RES, V52, P4828; Sambrook J., 1989, MOL CLONING LAB MANU, pE3; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; Velculescu VE, 1996, CLIN CHEM, V42, P858; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZENG ZS, 1994, J CLIN ONCOL, V12, P2043, DOI 10.1200/JCO.1994.12.10.2043	41	69	74	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	1998	16	19					2469	2477		10.1038/sj.onc.1201776	http://dx.doi.org/10.1038/sj.onc.1201776			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN694	9627113				2022-12-17	WOS:000073672300005
J	Yuille, MAR; Coignet, LJA; Abraham, SM; Yaqub, F; Luo, L; Matutes, E; Brito-Babapulle, V; Vorechovsky, I; Dyer, MJS; Catovsky, D				Yuille, MAR; Coignet, LJA; Abraham, SM; Yaqub, F; Luo, L; Matutes, E; Brito-Babapulle, V; Vorechovsky, I; Dyer, MJS; Catovsky, D			ATM is usually rearranged in T-cell prolymphocytic leukaemia	ONCOGENE			English	Article						T-prolymphocytic leukaemia; ATM; tumour suppressor; fluorescent in situ hybridization; single-strand conformation polymorphism; mutations	ATAXIA-TELANGIECTASIA GENE; LEUKEMIA; CANCER; HYBRIDIZATION; RECOMBINATION; MUTATIONS; DELETION; LYMPHOMA; REGION; LOCUS	T-prolymphocytic leukaemia (T-PLL) is a rare, sporadic leukaemia similar to a mature T-cell leukaemia seen in some patients with Ataxia Telangiectasia (A-T), a recessive multisystem disorder caused by mutations of the ATM gene at chromosome 11q23., ATM sequence mutations have been reported in 46% of T-PLL cases, but some cases also have karyotypic abnormalities at 11q, including 11q23., This led us to investigate the structure of the A TM locus in a panel of eight cases, two of which had 11q23 abnormalities, As expected, nucleotide changes were detected in some samples, Two remission samples were wild type, To test for structural lesions, DNA fibres were hybridized with a contig of four labelled cosmids spanning the A TM locus, In all samples there were structural lesions and in four samples both alleles were affected, This provides strong evidence for our suggestion that ATM acts as a tumour suppressor during T-PLL tumorigenesis. Some additional role for ATM during T-PLL tumorigenesis is possible since nucleotide changes were present in addition to structural lesions disrupting both alleles. The mechanism of inactivation appeared to be unusual because multiple structural Lesions on one allele were often observed,.	Royal Marsden Hosp, NHS Trust, Inst Canc Res, Acad Dept Haematol & Cytogenet, London SW3, England; Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Karolinska Institutet	Yuille, MAR (corresponding author), Royal Marsden Hosp, NHS Trust, Inst Canc Res, Acad Dept Haematol & Cytogenet, London SW3, England.		Dyer, Martin/F-2691-2014	Dyer, Martin/0000-0002-5033-2236				Athma P, 1996, CANCER GENET CYTOGEN, V92, P130, DOI 10.1016/S0165-4608(96)00328-7; BAENS M, 1995, GENOMICS, V29, P44, DOI 10.1006/geno.1995.1213; BARTLETT RJ, 1989, LANCET, V1, P496; Bebb G, 1997, LANCET, V349, P1784, DOI 10.1016/S0140-6736(05)61687-X; BRITOBABAPULLE V, 1991, CANCER GENET CYTOGEN, V55, P1, DOI 10.1016/0165-4608(91)90228-M; Coignet LJA, 1996, BLOOD, V87, P1512, DOI 10.1182/blood.V87.4.1512.bloodjournal8741512; DYER MJS, 1993, BLOOD, V82, P865, DOI 10.1182/blood.V82.3.865.bloodjournal823865; GATTI RA, 1988, NATURE, V336, P577, DOI 10.1038/336577a0; Ginaldi L, 1996, BRIT J HAEMATOL, V93, P921, DOI 10.1046/j.1365-2141.1996.d01-1720.x; HECHT F, 1990, CANCER GENET CYTOGEN, V46, P9, DOI 10.1016/0165-4608(90)90003-S; LAING NG, 1992, AM J MED GENET, V42, P688, DOI 10.1002/ajmg.1320420512; LIPKOWITZ S, 1990, J EXP MED, V172, P409, DOI 10.1084/jem.172.2.409; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; PARRA I, 1993, NAT GENET, V5, P17, DOI 10.1038/ng0993-17; Pawson R, 1997, J CLIN ONCOL, V15, P2667, DOI 10.1200/JCO.1997.15.7.2667; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; SEITE P, 1993, ONCOGENE, V8, P3073; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; Uziel T, 1996, GENOMICS, V33, P317, DOI 10.1006/geno.1996.0201; Vorechovsky I, 1997, NAT GENET, V17, P96, DOI 10.1038/ng0997-96; Vorechovsky I, 1996, CANCER RES, V56, P4130; Vorechovsky I, 1996, EUR J HUM GENET, V4, P352; Vorechovsky I, 1996, CANCER RES, V56, P2726; Yuille M. A. R., 1996, Blood, V88, p477A	27	69	70	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 12	1998	16	6					789	796		10.1038/sj.onc.1201603	http://dx.doi.org/10.1038/sj.onc.1201603			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YW403	9488043				2022-12-17	WOS:000071931800011
J	Chiariello, E; Roz, L; Albarosa, R; Magnani, I; Finocchiaro, G				Chiariello, E; Roz, L; Albarosa, R; Magnani, I; Finocchiaro, G			PTEN/MMAC1 mutations in primary glioblastomas and short-term cultures of malignant gliomas	ONCOGENE			English	Article						glioblastoma; chromosome 10; tumor suppressor; mutation	GENE; PATHWAYS; TUMORS	A novel tumor suppressor, PTEN/MMAC1, was recently found on chromosome 10q23 and mutations of this gene mere described in about 20% of primary glioblastomas (GBM) and 60% of GBM cell lines. To define further the relevance of PTEN/MMAC1 mutations in GBM we investigated by SSCP analysis its coding sequence in 44 gliomas, including 41 GBM, and in 21 short-term cultures (15 GBM and six malignant astrocytomas). Loss of heterozygosity (LOH) at 10q23 was present in at least one marker in the vicinity of the PTEN/MMAC1 locus in 59% of the informative GBM (primary tumors and cell cultures). SSCP variant bands were found in seven primary GBM (17%) and in one short-term GBM culture and sequence analysis confirmed the presence of somatic mutations in all these cases (five missense, one splicing mutation and two small deletions). These data indicate that PTEN/MMAC1 is inactivated in a subset of GBM and suggest that the high mutation frequency previously found in GBM established cell lines reflects culture condition artifacts rather than the true mutation frequency in vivo. Other suppressors, located on chromosome 10q, may also have a critical role in glioma tumorigenesis.	Ist Nazl Neurol C Besta, Dept Biochem & Genet, Milan, Italy; Univ Milan, Dept Biol & Genet Med Sci, I-20122 Milan, Italy	IRCCS Istituto Neurologico Besta; University of Milan	Finocchiaro, G (corresponding author), Ist Nazl Neurol C Besta, Dept Biochem & Genet, Milan, Italy.		Finocchiaro, Gaetano/AAG-6791-2020; Roz, Luca/AAB-3889-2019	Roz, Luca/0000-0001-5817-7149; Finocchiaro, Gaetano/0000-0003-3583-4040				Albarosa R, 1996, AM J HUM GENET, V58, P1260; BOGLER O, 1995, GLIA, V15, P308, DOI 10.1002/glia.440150311; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; LO SH, 1994, BIOESSAYS, V16, P817, DOI 10.1002/bies.950161108; LOUIS DN, 1995, TRENDS GENET, V11, P412, DOI 10.1016/S0168-9525(00)89125-8; MAGNANI I, 1994, CANCER GENET CYTOGEN, V75, P77, DOI 10.1016/0165-4608(94)90157-0; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; RASHEED BKA, 1995, ONCOGENE, V10, P2243; Rhei E, 1997, CANCER RES, V57, P3657; SHEFFIELD VC, 1993, GENOMICS, V16, P325, DOI 10.1006/geno.1993.1193; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; TENAN M, 1995, INT J CANCER, V62, P115, DOI 10.1002/ijc.2910620121; UNGEWICKELL E, 1995, NATURE, V378, P632, DOI 10.1038/378632a0; VONDEIMLING A, 1995, GLIA, V15, P328, DOI 10.1002/glia.440150312	20	69	74	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 29	1998	16	4					541	545		10.1038/sj.onc.1201689	http://dx.doi.org/10.1038/sj.onc.1201689			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YU644	9484844				2022-12-17	WOS:000071739400013
J	Wiggan, O; Taniguchi-Sidle, A; Hamel, PA				Wiggan, O; Taniguchi-Sidle, A; Hamel, PA			Interaction of the pRB-family proteins with factors containing paired-like homeodomains	ONCOGENE			English	Article						mhox; paired-like homeodomain; PGX-3; pRB	EMBRYONAL CARCINOMA-CELLS; TRANSCRIPTION FACTOR E2F; C-MET RECEPTOR; RETINOBLASTOMA PROTEIN; TYROSINE KINASE; DNA-BINDING; HUMAN PAPILLOMAVIRUSES; TERMINAL SEQUENCES; CRYSTAL-STRUCTURE; GENE-EXPRESSION	The specific loss of pRB or p107 together with p130 disrupts the normal development of only a very limited spectrum of tissues. These developmental defects have been attributed primarily to deregulation of E2F activity and consequent uncontrolled proliferation. We hypothesized, however, that the tissue-specific nature of these defects may also reflect deregulation of pRB-family associated factors that are specifically involved in determining cell fate. We report here that the pRB-family members interact with transcription factors which contain paired-like homeodomains such as MHox, Chx10 and Pax-3. The interaction between the pRB-family and the paired-like homeodomain proteins was initially identified in a yeast two-hybrid screen where the N-terminal portion of p130 was used to isolate interacting factors from an embryonic mouse library. This interaction was confirmed by in vitro binding and co-immunoprecipitation assays. We show further that coexpression of Pax-3 dependent pRB, p107 or p130 with Pax-3 causes repression of activated transcription from the c-met promoter. These data demonstrate that the pRB-family proteins can modulate the activity of factors which specifically control cell fate and/or differentiation as well as controlling cell cycle regulators.	Univ Toronto, Dept Pathol, Toronto, ON M5S 1A8, Canada	University of Toronto	Hamel, PA (corresponding author), Univ Toronto, Dept Pathol, Med Sci Bldg, Toronto, ON M5S 1A8, Canada.							BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BUCK V, 1995, ONCOGENE, V11, P31; Burmeister M, 1996, NAT GENET, V12, P376, DOI 10.1038/ng0496-376; CHALEPAKIS G, 1994, NUCLEIC ACIDS RES, V22, P3131, DOI 10.1093/nar/22.15.3131; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; CORBEIL HB, 1995, ONCOGENE, V11, P909; Cossu G, 1996, TRENDS GENET, V12, P218, DOI 10.1016/0168-9525(96)10025-1; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; CROSS F, 1989, ANNU REV CELL BIOL, V5, P341; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; Daston G, 1996, DEVELOPMENT, V122, P1017; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; ERNST H, 1991, MOL CELL BIOL, V11, P3735, DOI 10.1128/MCB.11.7.3735; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GRUENEBERG DA, 1995, MOL CELL BIOL, V15, P3318; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HECK DV, 1992, P NATL ACAD SCI USA, V89, P4442, DOI 10.1073/pnas.89.10.4442; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1994, J VIROL, V68, P5027, DOI 10.1128/JVI.68.8.5027-5035.1994; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HOWLEY PM, 1991, COLD SPRING HARB SYM, V56, P149; HUANG S, 1992, DNA CELL BIOL, V11, P539, DOI 10.1089/dna.1992.11.539; HUNT T, 1989, NATURE, V342, P483, DOI 10.1038/342483a0; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JEWERS RJ, 1992, J VIROL, V66, P1329, DOI 10.1128/JVI.66.3.1329-1335.1992; KIESS M, 1995, CELL GROWTH DIFFER, V6, P1287; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LAROSE A, 1991, J VIROL, V65, P2308, DOI 10.1128/JVI.65.5.2308-2313.1991; LASKEY RA, 1989, SCIENCE, V246, P609, DOI 10.1126/science.2683076; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LIU ISC, 1994, NEURON, V13, P377, DOI 10.1016/0896-6273(94)90354-9; MCBURNEY MW, 1993, INT J DEV BIOL, V37, P135; Moberg K, 1996, MOL CELL BIOL, V16, P1436; MUNGER K, 1991, J VIROL, V65, P3943; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; PRUITT SC, 1992, DEVELOPMENT, V116, P573; Rao MV, 1996, MOL CELL BIOL, V16, P3909; RUDNICK A, 1994, P NATL ACAD SCI USA, V91, P12203, DOI 10.1073/pnas.91.25.12203; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SCHNEITZ K, 1993, GENE DEV, V7, P114, DOI 10.1101/gad.7.1.114; Shan B, 1996, P NATL ACAD SCI USA, V93, P679, DOI 10.1073/pnas.93.2.679; SHERR C, 1996, 12 ANN M ONC FRED MA; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; Skapek SX, 1996, MOL CELL BIOL, V16, P7043; SLACK RS, 1993, ONCOGENE, V8, P1585; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; UNDERHILL DA, 1995, P NATL ACAD SCI USA, V92, P3692, DOI 10.1073/pnas.92.9.3692; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WELCH PJ, 1995, GENE DEV, V9, P31, DOI 10.1101/gad.9.1.31; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; Yang XM, 1996, DEVELOPMENT, V122, P2163; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; ZHAO GQ, 1993, P NATL ACAD SCI USA, V90, P8633, DOI 10.1073/pnas.90.18.8633	85	69	69	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	1998	16	2					227	236		10.1038/sj.onc.1201534	http://dx.doi.org/10.1038/sj.onc.1201534			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464541	Green Published			2022-12-17	WOS:000071427100010
J	Shridhar, V; Sun, QC; Miller, OJ; Kalemkerian, GP; Petros, J; Smith, DI				Shridhar, V; Sun, QC; Miller, OJ; Kalemkerian, GP; Petros, J; Smith, DI			Loss of heterozygosity on the long arm of human chromosome 7 in sporadic renal cell carcinomas	ONCOGENE			English	Article						7q31.2 loss; renal cell carcinoma; fragile sites	TUMOR-SUPPRESSOR GENE; PRIMARY BREAST-CANCER; SQUAMOUS-CELL; FREQUENT LOSS; FRAGILE SITE; HOMOZYGOUS DELETION; ALLELIC LOSSES; LUNG-CANCER; 7Q31.1; LOCUS	Cytogenetic and molecular analysis of DNA sequences with highly polymorphic microsatellite markers have implicated allele loss in several chromosomal regions including 3p, 6p, 6q, 8p, 9p, 9q, 11p and 14q in the pathogenesis of sporadic renal cell carcinomas (RCCs), Deletions involving the long arm of chromosome 7 have not been described in RCCs although they have been seen in several other tumor types, However, there have been no detailed analysis of loss of heterozygosity (LOH) of 7q sequences in sporadic RCCs, We therefore studied LOH for DNA sequences on 7q with 10 highly polymorphic markers in 92 matched normal/tumor samples representing sporadic RCCs including papillary, nonpapillary, and oncocytomas in order to determine whether allelic loss could be detected in a tumor type with no visible 7q rearrangements at the cytogenetic level, We found chromosome 7q allele loss in 59 of 92 cases (64%) involving one, two, or more microsatellite markers, The most common allele loss included loci D7S522 (24%) and D7S649 (30%) at 7q31.1-31.2, a region that contains one of the common fragile sites, FRA7G. By comparative multiplex PCR analysis, we detected a homozygous deletion of one marker in the 7q 31.1-31.2 region in one tumor, RC21. These results support the idea that a tumor suppressor gene in 7q31 is involved in the pathogenesis of sporadic renal cell carcinomas.	MAYO CLIN & MAYO FDN,DEPT LAB MED & PATHOL,DIV EXPT PATHOL,ROCHESTER,MN 55905; WAYNE STATE UNIV,SCH MED,DEPT INTERNAL MED,DIV HEMATOL ONCOL,KARMANOS CANC INST,DETROIT,MI 48201; EMORY UNIV,SCH MED,DEPT UROL,ATLANTA,GA 30322; EMORY UNIV,SCH MED,WINSHIP CANC CTR,ATLANTA,GA 30322; WAYNE STATE UNIV,SCH MED,CTR MOL MED & GENET,DETROIT,MI 48201	Mayo Clinic; Barbara Ann Karmanos Cancer Institute; Wayne State University; Emory University; Emory University; Wayne State University					NCI NIH HHS [CA48031] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048031] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achille A, 1996, CANCER RES, V56, P3808; ANGLARD P, 1994, CANCER RES, V51, P1073; BARBI G, 1984, HUM GENET, V68, P290, DOI 10.1007/BF00292586; BERGER R, 1985, CYTOGENET CELL GENET, V40, P490, DOI 10.1159/000132181; BIECHE I, 1992, LANCET, V339, P139, DOI 10.1016/0140-6736(92)90208-K; BROWN AG, 1993, NAT GENET, V3, P67, DOI 10.1038/ng0193-67; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CALLAHAN R, 1989, JNCI-J NATL CANCER I, V81, P1780, DOI 10.1093/jnci/81.23.1780; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; COLLARD JG, 1987, CANCER RES, V47, P6666; COQUELLE A, 1997, CELL, V89, P219; DIAZ MO, 1988, P NATL ACAD SCI USA, V85, P5259, DOI 10.1073/pnas.85.14.5259; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; KOVACS G, 1989, CANCER RES, V49, P651; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; KUNIYASU H, 1994, INT J CANCER, V59, P597, DOI 10.1002/ijc.2910590504; MILES J, 1988, CANCER GENET CYTOGEN, V34, P135, DOI 10.1016/0165-4608(88)90180-X; MORITA R, 1991, CANCER RES, V51, P820; MURATA Y, 1994, HUM MOL GENET, V3, P1341, DOI 10.1093/hmg/3.8.1341; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; OGAWA O, 1991, CANCER RES, V51, P949; PARADEE W, 1995, GENOMICS, V27, P358, DOI 10.1006/geno.1995.1057; PRESTI JC, 1993, CANCER RES, V53, P5780; RABBITTS P, 1990, GENE CHROMOSOME CANC, V2, P231, DOI 10.1002/gcc.2870020312; Shridhar R, 1996, CANCER RES, V56, P4347; Shridhar V, 1997, ONCOGENE, V14, P1269, DOI 10.1038/sj.onc.1201100; SHRIDHAR V, 1994, CANCER RES, V54, P2084; SMEETS DFCM, 1986, HUM GENET, V72, P215, DOI 10.1007/BF00291880; TAKAHASHI S, 1995, CANCER RES, V55, P4114; THONES W, 1986, PATHOL RES PRACT, V181, P125; THRASHBINGHAM CA, 1995, CANCER RES, V55, P6189; THRASHBINGHAM CA, 1995, P NATL ACAD SCI USA, V92, P2854, DOI 10.1073/pnas.92.7.2854; TSAI YC, 1990, CANCER RES, V50, P44; WANG N, 1984, CANCER GENET CYTOGEN, V11, P479, DOI 10.1016/0165-4608(84)90028-1; WANG ND, 1993, GENOMICS, V17, P341, DOI 10.1006/geno.1993.1330; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; WIELAND I, 1992, P NATL ACAD SCI USA, V89, P9705, DOI 10.1073/pnas.89.20.9705; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0; ZENKLUSEN JC, 1994, ONCOGENE, V9, P2817; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347	45	69	71	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 27	1997	15	22					2727	2733		10.1038/sj.onc.1201448	http://dx.doi.org/10.1038/sj.onc.1201448			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YH468	9400999				2022-12-17	WOS:A1997YH46800010
J	Hurd, C; Khattree, N; Dinda, S; Alban, P; Moudgil, VK				Hurd, C; Khattree, N; Dinda, S; Alban, P; Moudgil, VK			Regulation of tumor suppressor proteins, p53 and retinoblastoma, by estrogen and antiestrogens in breast cancer cells	ONCOGENE			English	Article						breast cancer; tumor suppressors; p53; retinoblastoma; estrogens; antiestrogens	GENE-MUTATIONS; RECEPTOR; PHOSPHORYLATION; PROGRESSION; PROLIFERATION; INHIBITION; TAMOXIFEN; PRODUCT; TAXOL; LINES	We have utilized the estrogen receptor (ER)-positive human breast carcinoma cell line, T47D, to determine the role of ER in regulating cell proliferation, the level of expression of p53 and the state of phosphorylation of retinoblastoma protein (pRB) by 17 beta-estradiol (E-2) and antiestrogens. T47D cells cultured for 7 days proliferated rapidly expressing maximal levels of p53 in medium containing 5% fetal bovine (whole) serum, Exogenously added E-2 had no effect on either of the above parameters, The antiestrogen, ICI 164,384 (ICI, 1 mu M), decreased cell number and p53 level to nearly 20% of the control, Comparatively, a treatment of the tells with 100 nM 4OH-tamoxifen (OHT) decreased cell number to 40% of the control without a concomitant decrease in the p53 levels suggesting a differential ability of these antiestrogens to regulate p53 levels in cells cultured in whole serum, When cells were cultured in medium containing serum depleted of endogenous steroids (charcoal stripped serum), cell number and p53 levels declined, Treatment with exogenous E-2 (1 nM) increased cell proliferation, p53 expression and phosphorylation of pRB. The antiestrogens ICI and OHT blocked these E-2 effects, demonstrating a direct antagonism of ER by ICI and OHT, These results indicate an ER-mediated mechanism for coordinate expression of p53 and hyperphosphorylation of pRB during E-2-induced proliferation of T47D cells.	OAKLAND UNIV,DEPT BIOL SCI,ROCHESTER,MI 48309; OAKLAND UNIV,INST BIOCHEM & BIOTECHNOL,ROCHESTER,MI 48309	Oakland University; Oakland University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020893] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-20893] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARDON S, 1987, CANCER RES, V47, P1441; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; CALEFFI M, 1994, CANCER, V73, P2147, DOI 10.1002/1097-0142(19940415)73:8<2147::AID-CNCR2820730820>3.0.CO;2-5; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ENCARNACION CA, 1993, BREAST CANCER RES TR, V26, P237, DOI 10.1007/BF00665801; Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488; Guillot C, 1996, CLIN CANCER RES, V2, P1439; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; HURD C, 1995, J BIOL CHEM, V270, P28507, DOI 10.1074/jbc.270.48.28507; KASTAN MB, 1991, CANCER RES, V51, P6304; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; KODALI S, 1994, BIOCHEM BIOPH RES CO, V202, P1413, DOI 10.1006/bbrc.1994.2088; KUSHNER PJ, 1990, MOL ENDOCRINOL, V4, P1465, DOI 10.1210/mend-4-10-1465; LEVENSON AS, 1994, J STEROID BIOCHEM, V51, P229, DOI 10.1016/0960-0760(94)90035-3; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OSBORNE CK, 1991, J NATL CANCER I, V83, P1477, DOI 10.1093/jnci/83.20.1477; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; SAITOH S, 1994, ONCOGENE, V9, P2869; SCHUCHARD M, 1993, ENDOCR REV, V14, P659, DOI 10.1210/er.14.6.659; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; THOMPSON EW, 1989, CANCER RES, V49, P6929; WAFIK S, 1994, CANCER RES, V54, P1169; WATTS CKW, 1995, MOL ENDOCRINOL, V9, P1804, DOI 10.1210/me.9.12.1804; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	30	69	70	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 21	1997	15	8					991	995		10.1038/sj.onc.1201233	http://dx.doi.org/10.1038/sj.onc.1201233			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XR767	9285694				2022-12-17	WOS:A1997XR76700012
J	Herzog, CR; Soloff, EV; McDoniels, AL; Tyson, FL; Malkinson, AM; HaugenStrano, A; Wiseman, RW; Anderson, MW; You, M				Herzog, CR; Soloff, EV; McDoniels, AL; Tyson, FL; Malkinson, AM; HaugenStrano, A; Wiseman, RW; Anderson, MW; You, M			Homozygous codeletion and differential decreased expression of p15(INK4b) p16(INK4a)-alpha and p16(INK4a)-beta in mouse lung tumor cells	ONCOGENE			English	Article						p15(INK4b); p16(INK4a)-alpha; p16(INK4a)-beta; mouse lung; tumor suppressor gene	KINASE-4 INHIBITOR GENE; SUPPRESSOR GENE; P16 MTS1; FAMILIAL MELANOMA; CDK6 INHIBITOR; HUMAN CANCERS; CYCLE ARREST; MUTATIONS; METHYLATION; DELETIONS	The genes of murine cyclin D-dependent kinase inhibitors, p15(INK4b) and p16(INK4a), are located in a region of chromosome 4 where overlapping deletions were found in lung adenocarcinomas, The p16(INK4a) gene uniquely consists of alternative first exons (E1 alpha and E1 beta), which are spliced to exon 2 in alternative reading frames to either encode p16(INK4a) (alpha form) or another potential tumor suppressor, p19(ARF) (beta form), We examined 99 lung adenocarcinomas of C3H/HeJ x A/J F-1(C3AF(1)) and A/J x C3H/HeJ F-1(AC3F(1)) mouse hybrids and 18 (13 metastatic, 5 nonmetastatic) tumorigenic mouse lung epithelial cell lines for p15(INK4b) and p16(INK4a) gene inactivation, Homozygous codeletion occurred in eight of the 13 (62%) metastatic, four of the five (80%) nonmetastatic cell lines, but in only six of 99 (6%) adenocarcinomas. Neither p15(INK4b) nor p16(INK4a) gene was individually deleted in any of the tumors or cell lines, and all deletions of the p16(INK4a) gene extended into exon 2, which would be expected to disrupt the functions of both p16(INK4a) and p19(ARF). We also detected no intragenic mutations of either gene in 44 tumors that displayed loss of heterozygosity at the p16(INK4a) locus or in any of the cell lines, Transcript levels of p16(INK4a)-alpha, p16(INK4a)-beta and p15(INK4b) also were examined in each of the cell lines that retained copies of these genes, Whereas an immortal mouse lung epithelial cell line (E10) and two metastatic tumor cell lines (LM1 and E9) expressed p16(INK4a)-beta and p15(INK4b) mRNA, the a transcript of p16(INK4a) was detected in only the LM1 cell line. These results suggest that both p15(INK4b) and p16(INK4a) (alpha and beta) are targets of inactivation in mouse lung tumorigenesis.	MED COLL OHIO,DEPT PATHOL,TOLEDO,OH 43699; ST MARYS HOSP,CANC RES INST,GRAND JCT,CO 81501; UNIV COLORADO,HLTH SCI CTR,SCH PHARM,MOL TOXICOL PROGRAM,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,SCH PHARM,COLORADO CANC CTR,DENVER,CO 80262; NIEHS,MOL CARCINOGENESIS LAB,RES TRIANGLE PK,NC 27709	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)				Soloff, Erik/0000-0002-4473-6736	NCI NIH HHS [CA58554] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA058554, R01CA058554] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; DORNS KA, 1987, BIOCH BIOPHYS RDS CO, V144, P591; FRANKS LM, 1986, CANCER RES, V36, P1049; GLENDENING JM, 1995, CANCER RES, V55, P5531; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hara E, 1996, MOL CELL BIOL, V16, P859; HERMAN GJ, 1996, CANCER RES, V56, P722; HERMAN JG, 1995, CANCER RES, V55, P4525; HERZOG CR, 1994, CANCER RES, V54, P4007; HEZOG CR, 1995, ONCOGENE, V11, P1811; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; LINDARDOPOULOS S, 1995, CANCER RES, V55, P5168; MAO L, 1995, CANCER RES, V55, P2995; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MORI T, 1994, CANCER RES, V54, P3396; NICKS KM, 1989, CANCER RES, V49, P5191; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1995, CANCER RES, V55, P1448; OTSUKI T, 1995, CANCER RES, V55, P1436; OTTERSON GA, 1995, ONCOGENE, V11, P1211; QUELLE DE, 1995, CELL, V83, P993; QUELLE DE, 1995, ONCOGENE, V11, P635; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SMITH GJ, 1985, J PATHOL, V147, P165, DOI 10.1002/path.1711470304; STONE S, 1995, CANCER RES, V55, P2988; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; WASHIMI O, 1995, CANCER RES, V55, P514; XIAO S, 1995, ONCOGENE, V11, P511; XIAO S, 1995, CANCER RES, V55, P2968; YOU M, 1992, P NATL ACAD SCI USA, V89, P5804, DOI 10.1073/pnas.89.13.5804	40	69	73	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					1885	1891						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934534				2022-12-17	WOS:A1996VR79500007
J	Papin, C; Denouel, A; Calothy, G; Eychene, A				Papin, C; Denouel, A; Calothy, G; Eychene, A			Identification of signalling proteins interacting with B-Raf in the yeast two-hybrid system	ONCOGENE			English	Article						B-Raf; c-Raf-1; Ras; MEK-1; MEK-2; 14-3-3; MAP kinase cascade	COMPLETE CODING SEQUENCE; MAP KINASE KINASE; GENE; FAMILY; EXPRESSION; DOWNSTREAM; ONCOGENE; CLONING; MEK2	Recent studies suggested the existence of Ras/B-Raf/MEK-1 complexes and a critical role for B-Raf in regulating the MAP kinase/ERKs signalling pathway, We report, here, that both Ras and MEK-1 proteins interact physically with B-Raf proteins in the yeast two-hybrid system, In addition, by screening a mouse brain cDNA library, we isolated additional B-Raf interacting proteins, These include three members of the 14-3-3 proteins family (eta, theta and zeta) and the MEK-2 protein, We also show that c-Raf-1, previously reported to interact with beta and zeta 14-3-3 proteins, also interacts with eta and theta 14-3-3 proteins in the two-hybrid system, By using different portions of the B-Raf protein, we mapped the regions of the protein involved in these interactions, Specifically, we have characterized B-Raf specific sequences required for an efficient interaction with MER proteins, We show that, consequently, B-Raf interacts with MEK-1 and MEK-2 with a better affinity than does c-Raf-1, thus strengthening the notion that B-Raf is a stronger MER activator than c-Raf-1, Our results also suggest that a MEK specific sequence, not present in MAP kinase kinases which are not activated by members of the Raf family, is required for the interaction with Raf proteins.	CTR UNIV ORSAY,INST CURIE,UMR 146 CNRS,LAB 110,F-91405 ORSAY,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay			Eychene, Alain/M-8838-2017	EYCHENE, Alain/0000-0002-6818-7225				AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BARNIER JV, 1995, J BIOL CHEM, V270, P23381, DOI 10.1074/jbc.270.40.23381; Bartel Paul L., 1993, V131, P153; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRASELMANN S, 1995, EMBO J, V14, P4829; BROTT BK, 1993, CELL GROWTH DIFFER, V4, P921; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BRUNET A, 1994, ONCOGENE, V9, P3379; BURBELO PD, 1995, CURR BIOL, V5, P95, DOI 10.1016/S0960-9822(95)00022-4; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; CATLING AD, 1994, J BIOL CHEM, V269, P30014; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DUFFY JB, 1994, DEV BIOL, V166, P380, DOI 10.1006/dbio.1994.1324; EYCHENE A, 1995, ONCOGENE, V10, P1159; EYCHENE A, 1992, ONCOGENE, V7, P1315; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; OTSU M, 1993, FEBS LETT, V320, P246, DOI 10.1016/0014-5793(93)80596-M; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; PAPIN C, 1995, ONCOGENE, V10, P1647; PERALDI P, 1995, FEBS LETT, V357, P290, DOI 10.1016/0014-5793(94)01376-C; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; RUSSELL M, 1995, BIOCHEMISTRY-US, V34, P6611, DOI 10.1021/bi00020a005; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SUEN KL, 1995, ONCOGENE, V11, P825; TRAVERSE S, 1994, FEBS LETT, V350, P13, DOI 10.1016/0014-5793(94)00723-3; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WATANABE M, 1991, MOL BRAIN RES, V10, P151, DOI 10.1016/0169-328X(91)90105-7; WATANABE M, 1994, MOL BRAIN RES, V25, P113, DOI 10.1016/0169-328X(94)90285-2; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; WU Y, 1995, GENE DEV, V9, P742, DOI 10.1101/gad.9.6.742; YAMAMORI B, 1995, J BIOL CHEM, V270, P11723, DOI 10.1074/jbc.270.20.11723; YAN MH, 1994, NATURE, V372, P798; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	71	69	72	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2213	2221						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668348				2022-12-17	WOS:A1996UP28300021
J	Schulz, RA; Chromey, C; Lu, MF; Zhao, B; Olson, EN				Schulz, RA; Chromey, C; Lu, MF; Zhao, B; Olson, EN			Expression of the D-MEF2 transcription factor in the Drosophila brain suggests a role in neuronal cell differentiation	ONCOGENE			English	Article						D-MEF2 transcription factor; Kenyon cells; muscle; mushroom bodies; neuron differentiation; transcriptional enhancers	TINMAN	D-MEF2 is a MADS domain transcription factor expressed in the cardiac, somatic, and visceral muscle cell lineages in the Drosophila embryo, Genetic studies have demonstrated that D-mef2 gene function is required for the proper differentiation of all three of these muscle types, We show that D-MEF2 is also expressed in a limited number of other cell types during development, including Kenyon cells present in the mushroom bodies of the Drosophila brain, This finding suggests a role for D-mef2 in neuron differentiation, To investigate D-mef2 expression in muscle and Kenyon cells, we assayed 26 kb of D-mef2 5'-flanking and intragenic DNA for regulatory sequences controlling the expression of the gene, Our results show that separable enhancer sequences direct D-mef2 gene expression in the myogenic and neuronal cell lineages. The identification of these regulatory DNAs provides a starting point for the analysis of transcriptional regulators controlling the cell-specific expression of D-mef2 and a means to address the function of D-mef2 in Kenyon cell differentiation.			Schulz, RA (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030, USA.							Ashburner M., 2004, DROSOPHILA LAB MANUA, V2nd; AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; BODMER R, 1993, DEVELOPMENT, V118, P719; BOUR BA, 1995, GENE DEV, V9, P730, DOI 10.1101/gad.9.6.730; DAVIS RL, 1993, NEURON, V11, P1, DOI 10.1016/0896-6273(93)90266-T; DEBELLE JS, 1994, SCIENCE, V263, P692, DOI 10.1126/science.8303280; FERVEUR JF, 1995, SCIENCE, V267, P902, DOI 10.1126/science.7846534; LILLY B, 1994, P NATL ACAD SCI USA, V91, P5662, DOI 10.1073/pnas.91.12.5662; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; LYONS GE, 1995, J NEUROSCI, V15, P5727, DOI 10.1523/jneurosci.15-08-05727.1995; NGUYEN HT, 1994, P NATL ACAD SCI USA, V91, P7520, DOI 10.1073/pnas.91.16.7520; OBRIEN MA, 1994, GENETICS, V137, P121; ODELL KMC, 1995, NEURON, V15, P55, DOI 10.1016/0896-6273(95)90064-0; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; RANGANAYAKULU G, 1995, DEV BIOL, V171, P169, DOI 10.1006/dbio.1995.1269; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; STOCKER RF, 1990, CELL TISSUE RES, V262, P9, DOI 10.1007/BF00327741; TAYLOR MV, 1995, MECH DEVELOP, V50, P29, DOI 10.1016/0925-4773(94)00323-F; TRUMAN JW, 1993, DEV DROSOPHILA MELAN; YANG MY, 1995, NEURON, V15, P45	21	69	70	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1827	1831						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622904				2022-12-17	WOS:A1996UG45800026
J	Nandurkar, HH; Hilton, DJ; Nathan, P; Willson, T; Nicola, N; Begley, CG				Nandurkar, HH; Hilton, DJ; Nathan, P; Willson, T; Nicola, N; Begley, CG			The human IL-11 receptor requires gp130 for signalling: Demonstration by molecular cloning of the receptor	ONCOGENE			English	Article						cytokine receptor; interleukin-11 receptor	COLONY-STIMULATING FACTOR; LEUKEMIA-INHIBITORY FACTOR; MURINE HEMATOPOIETIC-CELLS; EXPRESSION CLONING; GM-CSF; CYTOKINE RECEPTORS; RECOMBINANT INTERLEUKIN-11; SYNERGISTIC INTERACTIONS; MARROW CULTURES; SOLUBLE FORM	We describe the molecular cloning of a cDNA for the alpha chain of the human IL-11 receptor (IL-11R alpha) and demonstrate the requirement of either the human or mouse gp130 molecule for signalling. cDNA clones encoding IL-11R alpha were isolated from a bone marrow cDNA library using a fragment from the murine IL-11R alpha as a probe, The human receptor was predicted to consist of 422 amino acids and was found to share 84% identity with the murine protein. In the extra-cellular region it exhibited a single hemopoietin domain with conserved cysteine residues and WSTWS motif. The transmembrane region was followed by a short cytoplasmic tail which did not contain a tyrosine kinase domain. Interaction of the human IL-11R alpha with murine gp130 was demonstrated: expression of the human IL-11R alpha in murine M1 cells which constitutively express murine gp130 (and murine LIF receptor), resulted in the generation of specific high-affinity binding sites for IL-11 (K-d=250 pM). In addition, expression of the human IL-11R alpha in these cells permitted the induction of macrophage differentiation in response to IL-11, These results suggested that the human IL-11R alpha chain was able to form a functional receptor complex in association with murine gp130. The requirement of gp130 for signalling was confirmed by expression of the human IL-11R alpha in Ba/F3 cells. BaF3 cells that expressed the human IL-11R alpha alone showed binding of radiolabelled IL-11 but no proliferative response. Introduction of human gp130 into these cells resulted in high-affinity IL-11 binding sites and IL-11 dependent cellular proliferation. Thus these results demonstrated the absolute requirement of gp130 for signalling.	ROYAL MELBOURNE HOSP, COOPERAT RES CTR CELLULAR GROWTH FACTORS, MELBOURNE, VIC 3050, AUSTRALIA; ROYAL MELBOURNE HOSP, ROTARY BONE MARROW RES LAB, MELBOURNE, VIC 3050, AUSTRALIA	Royal Melbourne Hospital; Royal Melbourne Hospital	Nandurkar, HH (corresponding author), ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, MELBOURNE, VIC 3050, AUSTRALIA.		Hilton, Douglas J/C-7250-2013; Nicola, Nicos/D-2989-2011; Nandurkar, Harshal/AAO-7443-2020	Hilton, Douglas J/0000-0002-7698-2392; Nicola, Nicos/0000-0003-1054-7889; Nandurkar, Harshal/0000-0002-8767-116X	NATIONAL CANCER INSTITUTE [R37CA022556, R01CA022556] Funding Source: NIH RePORTER; NCI NIH HHS [CA 22556] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASHWORTH A, 1990, NUCLEIC ACIDS RES, V18, P7178, DOI 10.1093/nar/18.23.7178; BAUMANN H, 1991, J BIOL CHEM, V266, P20424; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BRUCE AG, 1992, J IMMUNOL, V149, P1271; BRUNO E, 1991, EXP HEMATOL, V19, P378; BURSTEIN SA, 1992, J CELL PHYSIOL, V153, P305, DOI 10.1002/jcp.1041530210; CAIRO MS, 1994, EXP HEMATOL, V22, P1118; CHEREL M, 1995, BLOOD, V86, P2534; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; Davis S, 1993, Curr Opin Neurobiol, V3, P20, DOI 10.1016/0959-4388(93)90030-3; DU XX, 1994, BLOOD, V83, P2023; FANN MJ, 1994, P NATL ACAD SCI USA, V91, P43, DOI 10.1073/pnas.91.1.43; FRIELING JTM, 1994, CYTOKINE, V6, P376, DOI 10.1016/1043-4666(94)90061-2; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; HANGOC G, 1993, BLOOD, V81, P965; HARA T, 1992, EMBO J, V11, P1875, DOI 10.1002/j.1460-2075.1992.tb05239.x; HILTON DJ, 1988, J BIOL CHEM, V263, P9238; HILTON DJ, 1992, TRENDS BIOCHEM SCI, V17, P72, DOI 10.1016/0968-0004(92)90505-4; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; HIRANO T, 1994, STEM CELLS, V12, P262, DOI 10.1002/stem.5530120303; HONDA M, 1992, J IMMUNOL, V148, P2175; ICHIKAWA Y, 1969, J CELL PHYSIOL, V74, P223, DOI 10.1002/jcp.1040740303; KAWASHIMA I, 1991, FEBS LETT, V283, P199, DOI 10.1016/0014-5793(91)80587-S; KELLER DC, 1993, BLOOD, V82, P1428; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; LARSEN A, 1990, J EXP MED, V172, P1559, DOI 10.1084/jem.172.6.1559; LAYTON MJ, 1992, P NATL ACAD SCI USA, V89, P8616, DOI 10.1073/pnas.89.18.8616; METCALF D, 1990, P NATL ACAD SCI USA, V87, P4670, DOI 10.1073/pnas.87.12.4670; METCALF D, 1988, LEUKEMIA, V2, P216; METCALF D, 1985, SCIENCE, V229, P16, DOI 10.1126/science.2990035; METCALF D, 1991, SCIENCE, V254, P529, DOI 10.1126/science.1948028; METCALF D, 1984, HEMOPOIETIC COLONIES; MIYAJIMA A, 1992, TRENDS BIOCHEM SCI, V17, P378, DOI 10.1016/0968-0004(92)90004-S; MIYAJIMA A, 1993, BLOOD, V82, P1960; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MULLBERG J, 1992, BIOCHEM BIOPH RES CO, V189, P794, DOI 10.1016/0006-291X(92)92272-Y; MUSASHI M, 1991, BLOOD, V78, P1448; NAKAJIMA T, 1992, JPN J CANCER RES, V83, P373, DOI 10.1111/j.1349-7006.1992.tb00117.x; NICOLA NA, 1991, CELL, V67, P1, DOI 10.1016/0092-8674(91)90564-F; NICOLA NA, 1995, GROWTH FACTORS CYTOK; NOVICK D, 1989, J EXP MED, V170, P1409, DOI 10.1084/jem.170.4.1409; NOVOTNY JR, 1990, EXP HEMATOL, V18, P775; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIBLER KR, 1992, BLOOD, V80, P900; SCHOENHAUT DS, 1992, J IMMUNOL, V148, P3433; SHABO Y, 1988, BLOOD, V72, P2070; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; SUGITA T, 1990, J EXP MED, V171, P2001, DOI 10.1084/jem.171.6.2001; TAGA T, 1992, FASEB J, V6, P3387, DOI 10.1096/fasebj.6.15.1334470; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAKAKI S, 1990, EMBO J, V9, P4367, DOI 10.1002/j.1460-2075.1990.tb07886.x; TANIGAWA T, 1993, P NATL ACAD SCI USA, V90, P7864, DOI 10.1073/pnas.90.16.7864; TANIGAWA T, 1995, BLOOD, V85, P379; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TERAMURA M, 1992, BLOOD, V79, P327; TSUJI K, 1992, BLOOD, V79, P2855; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; YANG YC, 1992, BIOFACTORS, V4, P15; YIN TG, 1993, J IMMUNOL, V151, P2555; YONEMURA Y, 1993, BRIT J HAEMATOL, V84, P16, DOI 10.1111/j.1365-2141.1993.tb03020.x; YONEMURA Y, 1992, EXP HEMATOL, V20, P1011	71	69	89	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	1996	12	3					585	593						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637716				2022-12-17	WOS:A1996TV59700016
J	SNUDDEN, DK; SMITH, PR; LAI, D; NG, MH; GRIFFIN, BE				SNUDDEN, DK; SMITH, PR; LAI, D; NG, MH; GRIFFIN, BE			ALTERATIONS IN THE STRUCTURE OF THE EBV NUCLEAR ANTIGEN, EBNA1, IN EPITHELIAL-CELL TUMORS	ONCOGENE			English	Article						NASOPHARYNGEAL CARCINOMA; MUTATIONS; DNA BINDING; EPSTEIN-BARR VIRUS	EPSTEIN-BARR-VIRUS; NASOPHARYNGEAL CARCINOMA; DNA-BINDING; BURKITT-LYMPHOMA; EXPRESSION; PROTEIN; REPLICATION; TRANSCRIPTION; SEQUENCE; PROMOTER	The EBV nuclear antigen, EBNA1, is the only viral protein consistently expressed in all virus-infected cells. It is required in trans for viral replication, maintenance of EBV extrachromosomal episomes, and transcriptional transactivation in latently-infected B-cells. It binds RNA suggestive of a regulatory role in post-transcriptional events and in transgenic mice, it is tumorigenic. In RNase protection studies relating to the EBV-associated tumour, nasopharyngeal carcinoma (NPC), we show that a C-terminal EBNA1 RNA probe from the prototype B95-8 marmoset strain can protect its own mRNA from enzymatic digestion, but does not fully protect EBNA1 mRNA from NPC cells. This finding is consistent with changes in the coding region for the antigen. We thus determined the sequences of EBNA1 genes derived from an NPC xenograft and numerous patient biopsies and identified a number of mutations in the gene in these human cells, relative to B95-8. Many of the nucleotide changes would lead to non-conservative amino acid alterations in apparently functionally significant regions of the protein. We show that although some of the mutations lie in regions designated as critical to DNA binding, they have negligible effect on this property of EBNA1. The basic regions in EBNA1 that may bind to RNA, at least in vitro, are exempt from mutation. Thus, unless the alterations are 'silent', which for such a critical viral function seems unlikely, they may relate to as yet unmapped viral activities, such as a role in tumorigenesis and the ability of EBNA1 to evade the cellular immune system, or be associated with the ability of the antigen to regulate gene transcription.	ROYAL POSTGRAD MED SCH,DEPT VIROL,LONDON W12 0NN,ENGLAND; CHINESE UNIV HONG KONG,DEPT MICROBIOL,HONG KONG,HONG KONG; QUEEN MARYS HOSP,DEPT MICROBIOL,HONG KONG,HONG KONG	Imperial College London; Chinese University of Hong Kong								ABDELHAMID M, 1992, VIROLOGY, V190, P168, DOI 10.1016/0042-6822(92)91202-6; AMBINDER RF, 1990, J VIROL, V64, P2369, DOI 10.1128/JVI.64.5.2369-2379.1990; AMBINDER RF, 1991, J VIROL, V65, P1466, DOI 10.1128/JVI.65.3.1466-1478.1991; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BUSSON P, 1988, INT J CANCER, V42, P599, DOI 10.1002/ijc.2910420422; CHEN HL, 1992, VIROLOGY, V191, P193, DOI 10.1016/0042-6822(92)90181-N; CHEN ML, 1992, ONCOGENE, V7, P2131; CHEN MR, 1994, VIROLOGY, V205, P486, DOI 10.1006/viro.1994.1669; CHITTENDEN T, 1989, J VIROL, V63, P3016, DOI 10.1128/JVI.63.7.3016-3025.1989; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; GILLIGAN K, 1990, J VIROL, V64, P4948, DOI 10.1128/JVI.64.10.4948-4956.1990; HEARING J, 1992, J VIROL, V66, P694, DOI 10.1128/JVI.66.2.694-705.1992; HEARING JC, 1985, VIROLOGY, V145, P105; HITT MM, 1989, EMBO J, V8, P2639, DOI 10.1002/j.1460-2075.1989.tb08404.x; HU LF, 1991, J GEN VIROL, V72, P2399, DOI 10.1099/0022-1317-72-10-2399; INOUE N, 1991, VIROLOGY, V182, P84, DOI 10.1016/0042-6822(91)90651-Q; JONES CH, 1989, J VIROL, V63, P101, DOI 10.1128/JVI.63.1.101-110.1989; KHANNA R, 1992, J EXP MED, V176, P169, DOI 10.1084/jem.176.1.169; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFEMINA RL, 1989, VIROLOGY, V172, P584, DOI 10.1016/0042-6822(89)90201-8; LUNG ML, 1990, VIROLOGY, V177, P44, DOI 10.1016/0042-6822(90)90458-4; LUPTON S, 1985, MOL CELL BIOL, V5, P2533, DOI 10.1128/MCB.5.10.2533; MURRAY RJ, 1992, J EXP MED, V176, P157, DOI 10.1084/jem.176.1.157; POLVINOBODNAR M, 1988, NUCLEIC ACIDS RES, V16, P3415, DOI 10.1093/nar/16.8.3415; POLVINOBODNAR M, 1992, VIROLOGY, V187, P591, DOI 10.1016/0042-6822(92)90461-W; RAWLINS DR, 1985, CELL, V42, P859, DOI 10.1016/0092-8674(85)90282-X; REISMAN D, 1986, MOL CELL BIOL, V6, P3838, DOI 10.1128/MCB.6.11.3838; ROTH G, 1994, BLOOD, V84, P582, DOI 10.1182/blood.V84.2.582.bloodjournal842582; ROWE DT, 1986, EMBO J, V5, P2599, DOI 10.1002/j.1460-2075.1986.tb04540.x; Sambrook J., 1989, MOL CLONING LAB MANU; SAMPLE J, 1992, J VIROL, V66, P4654, DOI 10.1128/JVI.66.8.4654-4661.1992; SAMPLE J, 1991, P NATL ACAD SCI USA, V88, P6343, DOI 10.1073/pnas.88.14.6343; SCHAEFER BC, 1991, P NATL ACAD SCI USA, V88, P6550, DOI 10.1073/pnas.88.15.6550; SHAH WA, 1992, J VIROL, V66, P3355, DOI 10.1128/JVI.66.6.3355-3362.1992; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH PR, 1993, J VIROL, V67, P3217, DOI 10.1128/JVI.67.6.3217-3225.1993; SMITH PR, 1991, NUCLEIC ACIDS RES, V19, P2435, DOI 10.1093/nar/19.9.2435; SMITH PR, 1992, J VIROL, V66, P706, DOI 10.1128/JVI.66.2.706-714.1992; SNUDDEN DK, 1994, EMBO J, V13, P4840, DOI 10.1002/j.1460-2075.1994.tb06810.x; SPECK SH, 1989, ADV VIRAL ONCOL, P133; SUGDEN B, 1989, J VIROL, V63, P2644, DOI 10.1128/JVI.63.6.2644-2649.1989; TRIVEDI P, 1994, EUR J CANCER, V30A, P84, DOI 10.1016/S0959-8049(05)80024-3; Wilson J B, 1992, Curr Top Microbiol Immunol, V182, P375; YATES J, 1984, P NATL ACAD SCI-BIOL, V81, P3806, DOI 10.1073/pnas.81.12.3806; YATES JL, 1985, NATURE, V318, P812; YATES JL, 1988, CANCER CELL, V6, P197; ZHANG CX, 1993, J GEN VIROL, V74, P509, DOI 10.1099/0022-1317-74-3-509	48	69	71	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1545	1552						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731709				2022-12-17	WOS:A1995QU68100010
J	RIMESSI, P; GUALANDI, F; MORELLI, C; TRABANELLI, C; WU, Q; POSSATI, L; MONTESI, M; BARRETT, JC; BARBANTIBRODANO, G				RIMESSI, P; GUALANDI, F; MORELLI, C; TRABANELLI, C; WU, Q; POSSATI, L; MONTESI, M; BARRETT, JC; BARBANTIBRODANO, G			TRANSFER OF HUMAN-CHROMOSOME-3 TO AN OVARIAN-CARCINOMA CELL-LINE IDENTIFIES 3 REGIONS ON 3P INVOLVED IN OVARIAN-CANCER	ONCOGENE			English	Article							NONPOLYPOSIS COLORECTAL-CANCER; YEAST ARTIFICIAL CHROMOSOME; TUMOR-SUPPRESSOR GENE; FREQUENT LOSS; LUNG-CANCER; SHORT ARM; BREAST-CANCER; GROWTH-FACTOR; LOW-GRADE; HETEROZYGOSITY	The molecular pathogenesis of ovarian carcinoma involves altered expression of growth factors, activation of oncogenes and loss of tumor suppressor genes. Loss of heterozygosity on chromosomes 3p, 6q, 11p, 17 and 18q was reported as a significant alteration in ovarian cancer. However, no functional proof has been provided of tumor suppressor activity located in these chromosomal regions. We therefore introduced normal human chromosomes 3 and 11 into an ovarian carcinoma cell line by microcell mediated chromosome transfer. Transfer of chromosome 3 induced senescence acid growth arrest as well as suppression of tumorigenicity. Tumors induced by chromosome 3 monochromosomic hybrids consistently lost three small regions on 3p, two of which located in 3p23-24.2 and one located in 3p21.1-21.2, suggesting that these chromosomal regions are important for suppression of tumorigenicity of ovarian carcinoma cells. Transfer of chromosome 11 reduced the in vitro growth properties of ovarian cancer cells but did not significantly affect tumorigenicity. These results provide functional evidence for chromosome 3 tumor suppressor activity in ovarian cancer and define the chromosomal regions on 3p involved in the pathogenesis of this tumor. This experimental system, based on functional effects, may be useful for further delimitation and isolation of critical regions on 3p involved in tumor suppression.	UNIV FERRARA, SCH MED, INST MICROBIOL, I-44100 FERRARA, ITALY; UNIV FERRARA, SCH MED, INTERDEPT CTR BIOTECHNOL, I-44100 FERRARA, ITALY; UNIV ANCONA, INST BIOMED SCI, I-60131 ANCONA, ITALY; NIEHS, MOLEC CARCINOGENESIS LAB, RES TRIANGLE PK, NC 27709 USA	University of Ferrara; University of Ferrara; Marche Polytechnic University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Gualandi, Francesca/K-7513-2016	Gualandi, Francesca/0000-0001-9551-057X; Trabanelli, Cecilia/0000-0001-7107-0338				BARRETT JC, 1994, APOPTOSIS, V2, P253; BASSAM BJ, 1993, APPL BIOCHEM BIOTECH, V42, P181, DOI 10.1007/BF02788051; BASSAM BJ, 1991, ANAL BIOCHEM, V196, P80, DOI 10.1016/0003-2697(91)90120-I; BAST RC, 1992, J NATL CANCER I, V84, P556, DOI 10.1093/jnci/84.8.556; BERCHUCK A, 1991, AM J OBSTET GYNECOL, V164, P669, DOI 10.1016/S0002-9378(11)80044-X; BERCHUCK A, 1990, CANCER RES, V50, P4087; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BUICK RN, 1985, CANCER RES, V45, P3668; CANNISTRA SA, 1993, NEW ENGL J MED, V329, P1550, DOI 10.1056/NEJM199311183292108; CHENEVIXTRENCH G, 1992, ONCOGENE, V7, P1059; DALY MC, 1993, ONCOGENE, V8, P1721; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; DODSON MK, 1993, CANCER RES, V53, P4456; ECCLES DM, 1990, ONCOGENE, V5, P1599; EHLEN T, 1990, ONCOGENE, V5, P219; ELICEIRI B, 1991, P NATL ACAD SCI USA, V88, P2179, DOI 10.1073/pnas.88.6.2179; FOULKES WD, 1993, BRIT J CANCER, V67, P551, DOI 10.1038/bjc.1993.101; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HIBI K, 1992, ONCOGENE, V7, P445; JACOBS IJ, 1993, CANCER RES, V53, P1218; JAKOBOVITS A, 1993, NATURE, V362, P255, DOI 10.1038/362255a0; JENKINS RB, 1993, CANCER GENET CYTOGEN, V71, P76, DOI 10.1016/0165-4608(93)90205-Z; KACINSKI BM, 1990, AM J PATHOL, V137, P135; KIECHLESCHWARZ M, 1993, CANCER, V72, P2423, DOI 10.1002/1097-0142(19931015)72:8<2423::AID-CNCR2820720821>3.0.CO;2-P; KILLARY AM, 1992, P NATL ACAD SCI USA, V89, P10877, DOI 10.1073/pnas.89.22.10877; KOHLER MF, 1993, J NATL CANCER I, V85, P1513, DOI 10.1093/jnci/85.18.1513; KOHNO T, 1993, ONCOGENE, V8, P1825; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; LAMB BT, 1993, NAT GENET, V5, P22, DOI 10.1038/ng0993-22; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEE JH, 1990, CANCER RES, V50, P2724; LEE JH, 1989, CANCER RES, V49, P1220; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LOTHE RA, 1989, GENOMICS, V5, P134, DOI 10.1016/0888-7543(89)90097-9; LYNCH HT, 1978, CANCER-AM CANCER SOC, V41, P1543, DOI 10.1002/1097-0142(197804)41:4<1543::AID-CNCR2820410444>3.0.CO;2-Y; LYNCH HT, 1991, CANCER GENET CYTOGEN, V53, P143, DOI 10.1016/0165-4608(91)90093-A; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; PEJOVIC T, 1992, GENE CHROMOSOME CANC, V4, P58, DOI 10.1002/gcc.2870040108; ROCHE J, 1994, HUM MOL GENET, V3, P215, DOI 10.1093/hmg/3.1.215; ROQUE L, 1993, GENE CHROMOSOME CANC, V8, P199, DOI 10.1002/gcc.2870080311; Sambrook J., 1989, MOL CLONING LAB MANU; SANCHEZ Y, 1994, P NATL ACAD SCI USA, V91, P3383, DOI 10.1073/pnas.91.8.3383; SATO T, 1991, CANCER RES, V51, P5794; SATO T, 1991, CANCER RES, V51, P5118; SATOH H, 1993, MOL CARCINOGEN, V7, P157, DOI 10.1002/mc.2940070306; Saxon P J, 1987, Methods Enzymol, V151, P313, DOI 10.1016/S0076-6879(87)51026-6; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; SHIMIZU M, 1990, ONCOGENE, V5, P185; SIMARD J, 1993, HUM MOL GENET, V2, P1193, DOI 10.1093/hmg/2.8.1193; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; STRAUSS WM, 1993, SCIENCE, V259, P1904, DOI 10.1126/science.8096090; STROMBERG K, 1992, CANCER RES, V52, P341; TANAKA K, 1992, CANCER GENET CYTOGEN, V61, P42, DOI 10.1016/0165-4608(92)90368-I; TAVASSOLI M, 1993, GENE CHROMOSOME CANC, V8, P195, DOI 10.1002/gcc.2870080310; YAMAKAWA K, 1993, ONCOGENE, V8, P327; YAMAKAWA K, 1991, CANCER RES, V51, P4707; YOSHIDA MA, 1994, MOL CARCINOGEN, V9, P114, DOI 10.1002/mc.2940090303; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0; ZHENG JP, 1991, CANCER RES, V51, P4045	65	69	71	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1994	9	12					3467	3474						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970706				2022-12-17	WOS:A1994PT39200008
J	FUJIMOTO, J; YAMAMOTO, T				FUJIMOTO, J; YAMAMOTO, T			BRT, A MOUSE GENE ENCODING A NOVEL RECEPTOR-TYPE PROTEIN-TYROSINE KINASE, IS PREFERENTIALLY EXPRESSED IN THE BRAIN	ONCOGENE			English	Article							MOLECULAR-CLONING; LEUKEMIA-CELLS; W-LOCUS; FAMILY; DOMAINS; ONCOGENE; SEQUENCE	Using polymerase chain reaction (PCI)-mediated cloning procedure, we have isolated a novel gene encoding protein-tyrosine kinase from fetal mouse brain. This gene, named brt (from brain tyrosine kinase), had an open reading frame that encoded 856 amino acids. The deduced amino acid sequence revealed that the gene product had all the hallmarks of a receptor-type protein-tyrosine kinase. The brt protein showed significant homology to the axl/ufo protein that has an oncogenic potential. Northern blot analysis showed that but was expressed preferentially in the brain of both embryo and adult. Thus, brt is a new member of the subfamily of receptor-type protein-tyrosine kinases and is suggested to play important roles in development and functions in the central nervous system.	UNIV TOKYO,INST MED SCI,DEPT ONCOL,TOKYO 108,JAPAN	University of Tokyo								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BASLER K, 1988, TRENDS GENET, V4, P74, DOI 10.1016/0168-9525(88)90044-3; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FAUST M, 1992, ONCOGENE, V7, P1287; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; KELMANZ, 1993, ONCOGENE, V8, P37; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; MARCELLE C, 1992, ONCOGENE, V7, P2479; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; RESCIGNO J, 1991, ONCOGENE, V6, P1909; SAJJADI FG, 1991, NEW BIOL, V3, P769; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZ AS, 1993, ONCOGENE, V8, P509; SHIBUYA M, 1990, ONCOGENE, V5, P519; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; SUDOL M, 1993, ONCOGENE, V8, P823; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237	32	69	79	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					693	698						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108111				2022-12-17	WOS:A1994MW55100003
J	CIARDIELLO, F; TORTORA, G; BIANCO, C; SELVAM, MP; BASOLO, F; FONTANINI, G; PACIFICO, F; NORMANNO, N; BRANDT, R; PERSICO, MG; SALOMON, DS; BIANCO, AR				CIARDIELLO, F; TORTORA, G; BIANCO, C; SELVAM, MP; BASOLO, F; FONTANINI, G; PACIFICO, F; NORMANNO, N; BRANDT, R; PERSICO, MG; SALOMON, DS; BIANCO, AR			INHIBITION OF CRIPTO EXPRESSION AND TUMORIGENICITY IN HUMAN COLON-CANCER CELLS BY ANTISENSE RNA AND OLIGODEOXYNUCLEOTIDES	ONCOGENE			English	Article							GROWTH-FACTOR-ALPHA; MAMMARY EPITHELIAL-CELLS; C-HA-RAS; INVITRO TRANSFORMATION; COLORECTAL TUMORS; LINES; PROLIFERATION; GENE; OLIGONUCLEOTIDES; AMPHIREGULIN	CRIPTO is an epidermal growth factor-related gene expressed in a majority of human colorectal tumors. To assess the role of CRIPTO in the growth control of human colon cancer, we have treated human colon carcinoma GEO and CBS cells, that possess high levels of CRIPTO, and WIDR colon cancer cells, that are negative for CRIPTO expression, with two antisense phosphorothioate oligodeoxynucleotides complementary to the 5' end of the human CRIPTO mRNA. Both antisense oligodeoxynucleotides significantly reduced endogenous CRIPTO protein levels and inhibited GEO and CBS cell growth in monolayer and in semisolid medium, whereas they did not affect WIDR cell growth. In addition, GEO, CBS and WIDR cells were infected with a recombinant retroviral vector containing the hygromycin-resistance gene and a 900 bp EcoRI-EcoRI coding fragment of the human CRIPTO cDNA oriented in the 3' to 5' direction. GEO and CBS CRIPTO antisense infectants exhibited a 60 to 70% reduction in CRIPTO protein expression, in monolayer growth and in soft agar cloning efficiency as compared to parental noninfected cells. In contrast, infection of WIDR cells with the CRIPTO antisense retrovirus did not alter their growth. Finally, GEO CRIPTO antisense infectants formed tumors in nude mice that were significantly smaller and had a larger latency period as compared to noninfected GEO cells.	US FDA,DIV TRANSFUS SCI,BETHESDA,MD 20892; UNIV PISA,FAC MED & CHIRURG,IST ANAT & ISTOL PATOL,I-56100 PISA,ITALY; CNR,IST INT GENET & BIOFIS,I-80125 NAPLES,ITALY; NCI,TUMOR IMMUNOL & BIOL LAB,TUMOR GROWTH FACTOR SECT,BETHESDA,MD 20892	US Food & Drug Administration (FDA); University of Pisa; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	CIARDIELLO, F (corresponding author), UNIV NAPOLI FEDERICO II,FAC MED & CHIRURG,CATTEDRA ONCOL MED,I-80131 NAPLES,ITALY.		Normanno, Nicola/AAT-1107-2021; Fontanini, Gabriella/O-7636-2015	Fontanini, Gabriella/0000-0003-1957-2052; Normanno, Nicola/0000-0002-7158-2605; Pacifico, Francesco Maria/0000-0001-9563-3596; Tortora, Giampaolo/0000-0002-1378-4962; BASOLO, FULVIO/0000-0003-1657-5020				ANZANO MA, 1989, CANCER RES, V49, P2898; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; CALABRETTA B, 1991, CANCER RES, V51, P4505; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CIARDIELLO F, 1991, CANCER RES, V51, P1051; CIARDIELLO F, 1991, P NATL ACAD SCI USA, V88, P7792, DOI 10.1073/pnas.88.17.7792; CIARDIELLO F, 1992, MOL CARCINOGEN, V6, P43, DOI 10.1002/mc.2940060108; CIARDIELLO F, 1993, INT J CANCER, V54, P952, DOI 10.1002/ijc.2910540615; CICCODICOLA A, 1989, EMBO J, V8, P1987, DOI 10.1002/j.1460-2075.1989.tb03605.x; CLARKE R, 1992, J NATL CANCER I, V84, P1506, DOI 10.1093/jnci/84.19.1506; COFFEY RJ, 1987, CANCER RES, V47, P4590; DOLNICK BJ, 1991, CANCER INVEST, V9, P185, DOI 10.3109/07357909109044229; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FONTANINI G, 1992, AM J PATHOL, V141, P1285; GRAY GD, 1993, CANCER RES, V53, P577; JOHNSON GR, 1992, J CELL BIOL, V118, P741, DOI 10.1083/jcb.118.3.741; KARNES WE, 1992, GASTROENTEROLOGY, V102, P474, DOI 10.1016/0016-5085(92)90093-E; LAHM H, 1992, BRIT J CANCER, V65, P341, DOI 10.1038/bjc.1992.69; LEDWITH BJ, 1990, MOL CELL BIOL, V10, P1545, DOI 10.1128/MCB.10.4.1545; MCGEADY ML, 1989, ONCOGENE, V4, P1375; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MORONI MC, 1992, J BIOL CHEM, V267, P2714; MORRISON RS, 1991, J BIOL CHEM, V266, P728; MUKHOPADHYAY T, 1991, CANCER RES, V51, P1744; MULDER KM, 1989, CELL MOL BIOL COLON, P46; MURPHY PR, 1992, MOL ENDOCRINOL, V6, P877, DOI 10.1210/me.6.6.877; NECKERS L, 1992, Critical Reviews in Oncogenesis, V3, P175; RASCHELLA G, 1992, CANCER RES, V52, P4221; SAEKI T, 1992, CANCER RES, V52, P3467; SALOMON DS, 1990, CANCER CELL-MON REV, V2, P389; SHANKAR V, 1989, MOL CARCINOGEN, V2, P1, DOI 10.1002/mc.2940020102; SIZELAND AM, 1992, MOL BIOL CELL, V3, P1235, DOI 10.1091/mbc.3.11.1235; SKLAR MD, 1991, MOL CELL BIOL, V11, P3699, DOI 10.1128/MCB.11.7.3699; STEIN CA, 1988, CANCER RES, V48, P2659; TAKAYAMA KM, 1990, CRIT REV BIOCHEM MOL, V25, P155, DOI 10.3109/10409239009090608; Todaro G J, 1990, Semin Cancer Biol, V1, P257; TRICOLI JV, 1986, CANCER RES, V46, P6169; TROOJAN J, 1992, P NATL ACAD SCI USA, V89, P4874; VALDEZ BC, 1992, CANCER RES, V52, P5681; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P325; WATKINS LF, 1991, INT J CANCER, V47, P455, DOI 10.1002/ijc.2910470325; ZIOBER BL, 1993, J BIOL CHEM, V268, P691	42	69	80	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					291	298						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302592				2022-12-17	WOS:A1994MW24700035
J	AVANTAGGIATI, ML; NATOLI, G; BALSANO, C; CHIRILLO, P; ARTINI, M; DEMARZIO, E; COLLEPARDO, D; LEVRERO, M				AVANTAGGIATI, ML; NATOLI, G; BALSANO, C; CHIRILLO, P; ARTINI, M; DEMARZIO, E; COLLEPARDO, D; LEVRERO, M			THE HEPATITIS-B VIRUS (HBV) PX TRANSACTIVATES THE C-FOS PROMOTER THROUGH MULTIPLE CIS-ACTING ELEMENTS	ONCOGENE			English	Article							SERUM RESPONSE ELEMENT; PROTO-ONCOGENE FOS; X-GENE PRODUCT; EPIDERMAL GROWTH-FACTOR; SIGNAL TRANSDUCTION; ENHANCER ELEMENT; 12-O-TETRADECANOYL PHORBOL-13-ACETATE; TRANSCRIPTIONAL ACTIVATION; MEDIATE INDUCTION; TRANSGENIC MICE	The hepatitis B virus (HBV) X protein (pX) stimulates transcription regulated by cis-acting elements that control many viral and cellular genes, including the c-myc and the c-fos proto-oncogenes. Using several c-fos promoter deletion mutants, we found the serum-responsive element (SRE) located at -315, the modified TPA-responsive element located at -296 (fos-AP-1 binding site, FAP) and the region spanning from nucleotide -220 to -120, which contains an NF1-like site and several stretches of sequence homologous to the AP-2 consensus binding sites, to be responsive to pX. pX does not modify the pattern of the retarded complexes bound to the SRE/FAP region which, in our system, appears to be occupied by SRE-binding factors. The activation of the SRE does not involve complex formation between SRE-binding factors and pX, it is not associated with an increase in serum response factor binding to the SRE and it does not determine changes in SRE mobility-shift pattern.	POLICLIN UMBERTO L,MED CLIN 1,I-00161 ROME,ITALY; POLICLIN UMBERTO 1,FDN ANDREA CESALPINO,I-00161 ROME,ITALY	Sapienza University Rome; University Hospital Sapienza Rome; Sapienza University Rome; University Hospital Sapienza Rome			Natoli, gioacchino/J-2100-2018; Balsano, Clara/AAK-9870-2020; Natoli, gioacchino/ABB-8679-2020; Levrero, Massimo/G-5680-2016	Balsano, Clara/0000-0002-9615-7031; Levrero, Massimo/0000-0002-4978-0875; Natoli, Gioacchino/0000-0003-0711-2411				ALEXANDRE C, 1991, ONCOGENE, V6, P543; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUFIERO B, 1990, EMBO J, V9, P497, DOI 10.1002/j.1460-2075.1990.tb08136.x; BALSANO C, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P572; BALSANO C, 1991, BIOCHEM BIOPH RES CO, V176, P985, DOI 10.1016/0006-291X(91)90379-L; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BUSCHER M, 1988, ONCOGENE, V3, P301; COLGROVE R, 1989, J VIROL, V63, P4019, DOI 10.1128/JVI.63.9.4019-4026.1989; Curran T, 1988, ONCOGENE HDB, P307; DEJAN A, 1986, NATURE, V322, P70; DESCHAMPS J, 1985, SCIENCE, V230, P1174, DOI 10.1126/science.3865371; FAKTOR O, 1990, ONCOGENE, V5, P867; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; FISCH TM, 1989, MOL CELL BIOL, V9, P1327, DOI 10.1128/MCB.9.3.1327; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GAUTHIERROUVIERE C, 1992, ONCOGENE, V7, P363; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENE WC, 1989, IMMUNOL TODAY, V10, P272, DOI 10.1016/0167-5699(89)90141-2; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HAYES TE, 1988, GENE DEV, V2, P1713, DOI 10.1101/gad.2.12b.1713; HERRERA RE, 1989, NATURE, V340, P2083; HU KQ, 1990, P NATL ACAD SCI USA, V87, P7140, DOI 10.1073/pnas.87.18.7140; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KOIKE K, 1989, MOL BIOL MED, V6, P151; KONIG H, 1989, EMBO J, V8, P2259; LAMB NJC, 1990, CELL, V61, P485, DOI 10.1016/0092-8674(90)90530-R; LEE TH, 1990, J VIROL, V64, P5939, DOI 10.1128/JVI.64.12.5939-5947.1990; LEVRERO M, 1990, J VIROL, V64, P3082, DOI 10.1128/JVI.64.6.3082-3086.1990; LEVRERO M, 1990, VIROLOGY, V174, P299, DOI 10.1016/0042-6822(90)90079-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; MISRA RP, 1991, MOL CELL BIOL, V11, P4545, DOI 10.1128/MCB.11.9.4545; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; RUNKEL L, 1991, MOL CELL BIOL, V11, P1270, DOI 10.1128/MCB.11.3.1270; RYAN WA, 1989, EMBO J, V8, P1785, DOI 10.1002/j.1460-2075.1989.tb03572.x; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SCHALASTA G, 1990, MOL CELL BIOL, V10, P5558, DOI 10.1128/MCB.10.10.5558; SCHONTHAL A, 1989, ONCOGENE, V4, P629; SCHROTER H, 1990, EMBO J, V9, P1123, DOI 10.1002/j.1460-2075.1990.tb08218.x; SETO E, 1988, P NATL ACAD SCI USA, V85, P8286, DOI 10.1073/pnas.85.21.8286; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHAW PE, 1989, EMBO J, V8, P2567, DOI 10.1002/j.1460-2075.1989.tb08395.x; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TROUCHE D, 1991, J IMMUNOL, V147, P2398; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; UNGER T, 1990, EMBO J, V9, P1889, DOI 10.1002/j.1460-2075.1990.tb08315.x; VELCICH A, 1990, MOL CELL BIOL, V10, P6273, DOI 10.1128/MCB.10.12.6273; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WILSTON T, NATURE, V336, P396; WU JY, 1990, CELL, V63, P687, DOI 10.1016/0092-8674(90)90135-2; ZAHM P, 1988, ONCOGENE, V3, P169; ZHOU DX, 1990, J VIROL, V64, P4025, DOI 10.1128/JVI.64.8.4025-4028.1990	69	69	72	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1567	1574						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502480				2022-12-17	WOS:A1993LE06400020
J	ASHWORTH, A; NAKIELNY, S; COHEN, P; MARSHALL, C				ASHWORTH, A; NAKIELNY, S; COHEN, P; MARSHALL, C			THE AMINO-ACID-SEQUENCE OF A MAMMALIAN MAP KINASE KINASE	ONCOGENE			English	Article							PROTEIN-KINASE; CONSERVED FEATURES; PHOSPHORYLATION; IDENTIFICATION; FAMILY	The amino acid sequence of the dual specificity mitogen-activated protein kinase kinase (MAPKK) has been determined by cDNA cloning and amino acid sequencing. MAPKK (393 residues, Mr 43,330) is a new member of the protein kinase subclass that comprises byr1 and STE7 that are involved in pheromone dependent signal transduction in yeast, wis1 a mitotic regulator in S. pombe and PBS2, which confers antibiotic resistance in S. cerevisiae.	UNIV DUNDEE, DEPT BIOCHEM, MRC, PROT PHOSPHORYLAT UNIT, DUNDEE DD1 4HN, SCOTLAND	University of Dundee	ASHWORTH, A (corresponding author), INST CANC RES, CHESTER BEATTY LABS, LONDON SW3 6JB, ENGLAND.							ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HAYSTEAD TAJ, 1992, FEBS LETT, V306, P17, DOI 10.1016/0014-5793(92)80828-5; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEEVERS S J, 1992, Trends in Cell Biology, V2, P283, DOI 10.1016/0962-8924(92)90105-V; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NAKIELNY S, 1992, FEBS LETT, V308, P183, DOI 10.1016/0014-5793(92)81271-M; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; TRAVERSE S, 1992, IN PRESS BIOCH J, V288	16	69	71	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1992	7	12					2555	2556						2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1461659				2022-12-17	WOS:A1992KA85600025
J	BROWN, KW; WATSON, JE; POIRIER, V; MOTT, MG; BERRY, PJ; MAITLAND, NJ				BROWN, KW; WATSON, JE; POIRIER, V; MOTT, MG; BERRY, PJ; MAITLAND, NJ			INACTIVATION OF THE REMAINING ALLELE OF THE WT1 GENE IN A WILMS-TUMOR FROM A WAGR PATIENT	ONCOGENE			English	Article							BECKWITH-WIEDEMANN SYNDROME; POLYMERASE CHAIN-REACTION; HUMAN CHROMOSOME-11; DELETION; LOCUS; DNA; 11P13; AMPLIFICATION; SEQUENCE; LINKAGE	A candidate gene (WT1) has recently been described for the 11p13 tumour-suppressor gene involved in the development of Wilms' tumour. This gene encodes a zinc finger protein which can bind to a specific DNA sequence. We have found a 226 base deletion in the mRNA from a unilateral Wilms' tumour, which would cause a frameshift that completely deletes the zinc finger domain. The tumour developed in a patient suffering from the WAGR syndrome, who had a constitutional 11p13 deletion, and so the 226 base deletion represents the inactivation of the remaining WT1 allele in the tumour. This provides further direct evidence that loss of function of WT1 is an essential step in the development of Wilms' tumour.	BRISTOL ROYAL HOSP SICK CHILDREN,BRISTOL BS2 8BJ,ENGLAND	Bristol Royal Hospital For Children	BROWN, KW (corresponding author), SCH MED SCI BRISTOL,DEPT PATHOL & MICROBIOL,CLIC RES UNIT,UNIV WALK,BRISTOL BS8 1TD,ENGLAND.		Brown, Keith/C-3355-2009	Brown, Keith/0000-0002-4258-5129				BROWN KW, 1989, BRIT J CANCER, V60, P25, DOI 10.1038/bjc.1989.213; BROWN KW, 1990, AM J HUM GENET, V46, P1000; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; COWELL JK, 1991, ONCOGENE, V6, P595; FEARON ER, 1984, NATURE, V309, P176, DOI 10.1038/309176a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GRUNDY P, 1988, NATURE, V336, P374, DOI 10.1038/336374a0; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, CELL, V64, P5, DOI 10.1016/0092-8674(91)90200-I; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; HUANG A, 1990, SCIENCE, V250, P991, DOI 10.1126/science.2173145; HUFF V, 1991, AM J HUM GENET, V48, P997; HUFF V, 1988, NATURE, V336, P377, DOI 10.1038/336377a0; JEANPIERRE C, 1990, GENOMICS, V7, P434, DOI 10.1016/0888-7543(90)90179-X; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; KOUFOS A, 1989, AM J HUM GENET, V44, P711; KROCZEK RA, 1990, ANAL BIOCHEM, V184, P90, DOI 10.1016/0003-2697(90)90017-4; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; MAITLAND NJ, 1987, BRIT J CANCER, V56, P245, DOI 10.1038/bjc.1987.185; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MURRAY V, 1989, NUCLEIC ACIDS RES, V17, P8889, DOI 10.1093/nar/17.21.8889; ORKIN SH, 1984, NATURE, V309, P172, DOI 10.1038/309172a0; PING AJ, 1989, AM J HUM GENET, V44, P720; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; REEVE AE, 1984, NATURE, V309, P174, DOI 10.1038/309174a0; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; REIK W, 1989, NATURE, V338, P112, DOI 10.1038/338112a0; ROYERPOKORA B, 1991, GENE CHROMOSOME CANC, V3, P89, DOI 10.1002/gcc.2870030203; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SARKAR G, 1990, NUCLEIC ACIDS RES, V18, P7465, DOI 10.1093/nar/18.24.7465; SHERMAN DR, 1989, TRENDS GENET, V5, P137; TON CCT, 1991, GENOMICS, V10, P293, DOI 10.1016/0888-7543(91)90516-H	37	69	72	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					763	768						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1314370				2022-12-17	WOS:A1992HQ68200020
J	HEERDT, BG; MOLINAS, S; DEITCH, D; AUGENLICHT, LH				HEERDT, BG; MOLINAS, S; DEITCH, D; AUGENLICHT, LH			AGGRESSIVE SUBTYPES OF HUMAN COLORECTAL TUMORS FREQUENTLY EXHIBIT AMPLIFICATION OF THE C-MYC GENE	ONCOGENE			English	Article							HUMAN-COLON CARCINOMA; HUMAN-LUNG CANCER; N-MYC; CELL-CARCINOMA; RAS ONCOGENES; EXPRESSION; MUTATIONS; DNA; NEUROBLASTOMAS; REARRANGEMENT	Expression of the c-myc gene is often elevated in human colorectal tumors, but reported amplification of the locus is rare. Here we demonstrate that modest amplification of c-myc is frequently found in aggressive subtypes of colorectal cancer. Careful quantitation of c-myc copy number has shown amplification in 53.8% (7/13) mucinous tumors, 42.3% (3/7) poorly differentiated tumors and a single poorly differentiated APUD tumor. This contrasts with amplification in 6.9% (2/29) moderately to well differentiated tumors, a value which is in agreement with that in previously published reports. Such changes in gene copy number may represent an important aspect of the genomic alterations which accumulate during the development of colorectal tumors.	MONTEFIORE MED CTR,DEPT PATHOL,BRONX,NY 10467; ALBERT EINSTEIN MED CTR,BRONX,NY 10467	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University	HEERDT, BG (corresponding author), MONTEFIORE MED CTR,DEPT ONCOL,111 E 210TH ST,BRONX,NY 10467, USA.				NCI NIH HHS [P30-CA1330, CA41372, CA40558] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040558, K04CA001330, R01CA041372] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDER RJ, 1986, GASTROENTEROLOGY, V91, P1503, DOI 10.1016/0016-5085(86)90208-8; ALMAGRO UA, 1983, CANCER, V52, P1453, DOI 10.1002/1097-0142(19831015)52:8<1453::AID-CNCR2820520819>3.0.CO;2-9; Augenlicht L. H., 1989, CELL MOL BIOL COLON, P165; AUGENLICHT LH, 1987, CANCER RES, V47, P6017; AUGENLICHT LH, 1982, CANCER RES, V42, P1088; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; Battey, 1986, BASIC METHODS MOL BI; BISHOP JM, 1987, ONCOGENES GROWTH FAC, P1; BOS JL, 1989, CANCER RES, V49, P4682; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BURMER GC, 1989, CANCER RES, V49, P2141; BURMER GC, 1989, P NATL ACAD SCI USA, V86, P2403, DOI 10.1073/pnas.86.7.2403; CHOWDHURY JR, 1975, DIS COLON RECTUM, V18, P332, DOI 10.1007/BF02587396; COLLINS FS, 1984, PROG NUCLEIC ACID RE, V31, P315, DOI 10.1016/S0079-6603(08)60382-7; DALLAFAVERA R, 1983, SCIENCE, V219, P963, DOI 10.1126/science.6401867; ERISMAN MD, 1988, CANCER RES, V48, P1350; ERISMAN MD, 1985, MOL CELL BIOL, V5, P1969, DOI 10.1128/MCB.5.8.1969; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; FIDLER IJ, 1981, EUR J CANCER, V17, P487, DOI 10.1016/0014-2964(81)90049-9; FINELY GG, 1989, ONCOGENE, V4, P963; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; HEERDT BG, 1990, EXP CELL RES, V186, P54, DOI 10.1016/0014-4827(90)90209-S; HEERDT BG, 1990, CANCER RES, V50, P1596; HEPPNER GH, 1984, CANCER RES, V44, P2259; KOSS LG, 1989, HUM PATHOL, V20, P528, DOI 10.1016/0046-8177(89)90244-X; LAW DJ, 1988, SCIENCE, V241, P961, DOI 10.1126/science.2841761; LEVIN B, 1986, CANCER GENET CYTOGEN, V19, P159, DOI 10.1016/0165-4608(86)90383-3; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; LUI IOL, 1985, PATHOLOGY, V17, P31, DOI 10.3109/00313028509063720; Maniatis T., 1982, MOL CLONING; MELTZER SJ, 1987, GASTROENTEROLOGY, V92, P1174, DOI 10.1016/S0016-5085(87)91074-2; NAU MM, 1984, CURR TOP MICROBIOL, V113, P172; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PATHAK S, 1989, CELL MOL BIOL COLON, P139; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; RABBITTS PH, 1985, EMBO J, V4, P3727, DOI 10.1002/j.1460-2075.1985.tb04141.x; SADAHIRO S, 1989, CANCER, V64, P1113, DOI 10.1002/1097-0142(19890901)64:5<1113::AID-CNCR2820640524>3.0.CO;2-5; SASAKI M, 1989, CANCER RES, V49, P4402; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SHTIVELMAN E, 1989, MOL CELL BIOL, V9, P1148, DOI 10.1128/MCB.9.3.1148; SIKORA K, 1987, CANCER-AM CANCER SOC, V59, P1289, DOI 10.1002/1097-0142(19870401)59:7<1289::AID-CNCR2820590710>3.0.CO;2-O; SLEISENGER MH, 1989, GASTROINTESTINAL DIS, P1535; SYMONDS DA, 1976, CANCER, V37, P1891, DOI 10.1002/1097-0142(197604)37:4<1891::AID-CNCR2820370439>3.0.CO;2-Z; UMPLEBY HC, 1985, BRIT J SURG, V72, P715, DOI 10.1002/bjs.1800720915; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WOLLEY RC, 1982, J NATL CANCER I, V69, P15; WONG AJ, 1986, SCIENCE, V233, P461, DOI 10.1126/science.3014659; YANDER G, 1985, CANCER RES, V45, P4433; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898	52	69	70	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1991	6	1					125	129						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1992440				2022-12-17	WOS:A1991EY03900017
J	RESH, MD				RESH, MD			MEMBRANE INTERACTIONS OF PP60V-SRC - A MODEL FOR MYRISTYLATED TYROSINE PROTEIN-KINASES	ONCOGENE			English	Review											RESH, MD (corresponding author), PRINCETON UNIV,LEWIS THOMAS LAB,DEPT MOLEC BIOL,PRINCETON,NJ 08544, USA.			Resh, Marilyn/0000-0001-6118-9466				AZARNIA R, 1988, SCIENCE, V239, P398, DOI 10.1126/science.2447651; AZARNIA R, 1984, J MEMBRANE BIOL, V82, P191, DOI 10.1007/BF01871629; BALLMERHOFER K, 1988, ONCOGENE, V3, P365; BARNEKOW A, 1980, Biochemical Society Transactions, V8, P735; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BENZEEV A, 1979, CELL, V17, P859, DOI 10.1016/0092-8674(79)90326-X; BLOEMENDAL H, 1977, SCIENCE, V197, P127, DOI 10.1126/science.877544; BOSS MA, 1981, J VIROL, V40, P472, DOI 10.1128/JVI.40.2.472-481.1981; BROOKSWILSON AR, 1989, MOL CELL BIOL, V9, P2214, DOI 10.1128/MCB.9.5.2214; BRUGGE J, 1983, MOL CELL BIOL, V3, P9, DOI 10.1128/MCB.3.1.9; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0; BURR JG, 1980, P NATL ACAD SCI-BIOL, V77, P3484, DOI 10.1073/pnas.77.6.3484; BUSS JE, 1985, J VIROL, V53, P7, DOI 10.1128/JVI.53.1.7-12.1985; BUSS JE, 1984, MOL CELL BIOL, V4, P2697, DOI 10.1128/MCB.4.12.2697; BUSS JE, 1986, J VIROL, V58, P468, DOI 10.1128/JVI.58.2.468-474.1986; CHOW M, 1987, NATURE, V327, P482, DOI 10.1038/327482a0; COLLETT MS, 1980, NATURE, V285, P167, DOI 10.1038/285167a0; COURTNEIDGE SA, 1980, P NATL ACAD SCI-BIOL, V77, P3783, DOI 10.1073/pnas.77.7.3783; COURTNEIDGE SA, 1982, P NATL ACAD SCI-BIOL, V79, P7117, DOI 10.1073/pnas.79.23.7117; CROSS FR, 1985, MOL CELL BIOL, V5, P2789, DOI 10.1128/MCB.5.10.2789; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; CROW DS, 1990, MOL CELL BIOL, V10, P1754, DOI 10.1128/MCB.10.4.1754; DEHAZYA P, 1985, VIROLOGY, V143, P407, DOI 10.1016/0042-6822(85)90381-2; DEICHAITE I, 1988, MOL CELL BIOL, V8, P4295, DOI 10.1128/MCB.8.10.4295; DONNER P, 1981, J BIOL CHEM, V256, P8786; DURONIO RJ, 1989, SCIENCE, V243, P796, DOI 10.1126/science.2644694; ERIKSON E, 1978, NATURE, V274, P919, DOI 10.1038/274919a0; FEUERMAN MH, 1985, J VIROL, V54, P804, DOI 10.1128/JVI.54.3.804-816.1985; FUNG YKT, 1983, P NATL ACAD SCI-BIOL, V80, P353, DOI 10.1073/pnas.80.2.353; GARBER EA, 1982, VIROLOGY, V118, P419, DOI 10.1016/0042-6822(82)90361-0; GARBER EA, 1983, VIROLOGY, V126, P73, DOI 10.1016/0042-6822(83)90462-2; GARBER EA, 1987, P NATL ACAD SCI USA, V84, P80, DOI 10.1073/pnas.84.1.80; GARBER EA, 1987, J VIROL, V61, P354, DOI 10.1128/JVI.61.2.354-360.1987; GARBER EA, 1985, MOL CELL BIOL, V5, P2781, DOI 10.1128/MCB.5.10.2781; GILMER TM, 1981, NATURE, V294, P771, DOI 10.1038/294771a0; GODDARD C, 1989, J BIOL CHEM, V264, P15173; GRIFFITHS G, 1984, J CELL BIOL, V98, P2133, DOI 10.1083/jcb.98.6.2133; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HAMAGUCHI M, 1990, MOL CELL BIOL, V10, P830, DOI 10.1128/MCB.10.2.830; HANAFUSA H, 1977, COMPREHENSIVE VIROLO, V10, P401; HEUCKEROTH RO, 1989, P NATL ACAD SCI USA, V86, P5262, DOI 10.1073/pnas.86.14.5262; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAMPS MP, 1986, CELL, V45, P105, DOI 10.1016/0092-8674(86)90542-8; KAPLAN JM, 1988, MOL CELL BIOL, V8, P2435, DOI 10.1128/MCB.8.6.2435; KAPLAN JM, 1990, MOL CELL BIOL, V10, P1000, DOI 10.1128/MCB.10.3.1000; KOZMA LM, 1990, MOL CELL BIOL, V10, P837, DOI 10.1128/MCB.10.2.837; KRUEGER JG, 1984, MOL CELL BIOL, V4, P454, DOI 10.1128/MCB.4.3.454; KRUEGER JG, 1980, P NATL ACAD SCI-BIOL, V77, P4142, DOI 10.1073/pnas.77.7.4142; KRUEGER JG, 1980, VIROLOGY, V101, P25, DOI 10.1016/0042-6822(80)90480-8; KRUEGER JG, 1982, CELL, V28, P889, DOI 10.1016/0092-8674(82)90068-X; KRUEGER JG, 1983, CURR TOP MICROBIOL I, V107, P52; KRZYZEK RA, 1980, J VIROL, V36, P805, DOI 10.1128/JVI.36.3.805-815.1980; LEE JS, 1979, J BIOL CHEM, V254, P8015; LEVINSON AD, 1981, P NATL ACAD SCI-BIOL, V78, P1624, DOI 10.1073/pnas.78.3.1624; LOEB DM, 1987, J VIROL, V61, P2420, DOI 10.1128/JVI.61.8.2420-2427.1987; MANGER R, 1986, J VIROL, V59, P66, DOI 10.1128/JVI.59.1.66-72.1986; MCGRATH JP, 1982, NATURE, V295, P423, DOI 10.1038/295423a0; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; NIGG EA, 1982, P NATL ACAD SCI-BIOL, V79, P5322, DOI 10.1073/pnas.79.17.5322; OPPERMANN H, 1981, P NATL ACAD SCI-BIOL, V78, P1067, DOI 10.1073/pnas.78.2.1067; OPPERMANN H, 1981, VIROLOGY, V113, P736, DOI 10.1016/0042-6822(81)90202-6; PALMITER RD, 1978, P NATL ACAD SCI USA, V75, P94, DOI 10.1073/pnas.75.1.94; PARSONS JT, 1989, CURR TOP MICROBIOL I, V147, P80; PAWSON T, 1988, ONCOGENE, V3, P491; PELLMAN D, 1985, P NATL ACAD SCI USA, V82, P1623, DOI 10.1073/pnas.82.6.1623; PELLMAN D, 1985, NATURE, V314, P374, DOI 10.1038/314374a0; PRIVALSKY ML, 1987, J VIROL, V61, P1938, DOI 10.1128/JVI.61.6.1938-1948.1987; PURCHIO AF, 1977, P NATL ACAD SCI USA, V74, P4661, DOI 10.1073/pnas.74.10.4661; PURCHIO AF, 1978, P NATL ACAD SCI USA, V75, P1567, DOI 10.1073/pnas.75.3.1567; REIN A, 1986, P NATL ACAD SCI USA, V83, P7246, DOI 10.1073/pnas.83.19.7246; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; RESH MD, 1985, J CELL BIOL, V100, P409, DOI 10.1083/jcb.100.2.409; RESH MD, 1988, MOL CELL BIOL, V8, P1896, DOI 10.1128/MCB.8.5.1896; RESH MD, 1985, MOL CELL BIOL, V5, P916, DOI 10.1128/MCB.5.5.916; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; RHEE SS, 1987, J VIROL, V61, P1045, DOI 10.1128/JVI.61.4.1045-1053.1987; ROHRSCHNEIDER L, 1983, MOL CELL BIOL, V3, P731, DOI 10.1128/MCB.3.4.731; ROHRSCHNEIDER LR, 1980, P NATL ACAD SCI-BIOL, V77, P3514, DOI 10.1073/pnas.77.6.3514; ROHRSCHNEIDER LR, 1979, CELL, V16, P11, DOI 10.1016/0092-8674(79)90183-1; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; Rous P, 1910, J EXP MED, V12, P344, DOI 10.1084/jem.12.3.344; SCHULTZ AM, 1985, SCIENCE, V227, P427, DOI 10.1126/science.3917576; SCHULTZ AM, 1988, ANNU REV CELL BIOL, V4, P611, DOI 10.1146/annurev.cb.04.110188.003143; SEFTON BM, 1979, J VIROL, V30, P311, DOI 10.1128/JVI.30.1.311-318.1979; SEFTON BM, 1978, J VIROL, V28, P957, DOI 10.1128/JVI.28.3.957-971.1978; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHRIVER K, 1981, J CELL BIOL, V89, P525, DOI 10.1083/jcb.89.3.525; STOKER AW, 1986, J VIROL, V58, P876, DOI 10.1128/JVI.58.3.876-883.1986; TAKEYA T, 1982, J VIROL, V44, P12, DOI 10.1128/JVI.44.1.12-18.1982; TANAKA T, 1984, VIROLOGY, V133, P202, DOI 10.1016/0042-6822(84)90440-9; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; WANG HCR, 1989, J VIROL, V63, P291, DOI 10.1128/JVI.63.1.291-302.1989; WELHAM MJ, 1988, J VIROL, V62, P1898, DOI 10.1128/JVI.62.6.1898-1906.1988; WILCOX C, 1987, SCIENCE, V238, P1275, DOI 10.1126/science.3685978; WILKERSON VW, 1985, J VIROL, V55, P314, DOI 10.1128/JVI.55.2.314-321.1985; WILLINGHAM MC, 1979, CELL, V18, P125, DOI 10.1016/0092-8674(79)90361-1; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	103	69	72	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1990	5	10					1437	1444						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK502	2250906				2022-12-17	WOS:A1990EK50200001
J	FUJIWARA, S; FISHER, RJ; SETH, A; BHAT, NK; SHOWALTER, SD; ZWEIG, M; PAPAS, TS				FUJIWARA, S; FISHER, RJ; SETH, A; BHAT, NK; SHOWALTER, SD; ZWEIG, M; PAPAS, TS			CHARACTERIZATION AND LOCALIZATION OF THE PRODUCTS OF THE HUMAN HOMOLOGS OF THE V-ETS ONCOGENE	ONCOGENE			English	Article									NCI, MOLEC ONCOL LAB, FREDERICK, MD 21701 USA; PROGRAM RESOURCES INC, NUCL ACID & PROT SYNTH LAB, FREDERICK, MD 21701 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Fisher, Robert/B-1431-2009					BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DIAZ MO, 1986, SCIENCE, V231, P265, DOI 10.1126/science.3455787; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; Drabkin H.D., 1986, ADV GENE TECHNOLOGY, P112; ELDER JH, 1977, J BIOL CHEM, V252, P6510; FUJIWARA S, 1987, ADV GENE TECHNOLOGY, P77; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HOFFMANN GR, 1985, ANEUPLOIDY ETIOLOGY, P539; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1984, J VIROL, V50, P280, DOI 10.1128/JVI.50.1.280-283.1984; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUTENBERGER JA, 1983, GENE, V23, P75, DOI 10.1016/0378-1119(83)90218-4; LAUTENBERGER JA, 1984, GENE ANAL TECH, V1, P63; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; MOSCOVICI C, 1981, VIROLOGY, V113, P765, DOI 10.1016/0042-6822(81)90205-1; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NUNN M, 1984, VIROLOGY, V139, P330, DOI 10.1016/0042-6822(84)90378-7; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; PAPAS TS, IN PRESS ONCOGENE HD; PATTERSON D, 1987, SCI AM, V257, P52, DOI 10.1038/scientificamerican0887-52; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; SACCHI N, 1986, SCIENCE, V231, P379, DOI 10.1126/science.3941901; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; WATSON DK, 1986, P NATL ACAD SCI USA, V83, P1792, DOI 10.1073/pnas.83.6.1792	32	69	70	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1988	2	2					99	103						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M0860	3285299				2022-12-17	WOS:A1988M086000001
J	Ahirwar, DK; Nasser, MW; Ouseph, MM; Elbaz, M; Cuitino, MC; Kladney, RD; Varikuti, S; Kaul, K; Satoskar, AR; Ramaswamy, B; Zhang, XL; Ostrowski, MC; Leone, G; Ganju, RK				Ahirwar, Dinesh K.; Nasser, Mohd W.; Ouseph, Madhu M.; Elbaz, Mohamad; Cuitino, Maria C.; Kladney, Raleigh D.; Varikuti, Sanjay; Kaul, Kirti; Satoskar, Abhay R.; Ramaswamy, Bhuvaneswari; Zhang, Xiaoli; Ostrowski, Michael C.; Leone, Gustavo; Ganju, Ramesh K.			Fibroblast-derived CXCL12 promotes breast cancer metastasis by facilitating tumor cell intravasation	ONCOGENE			English	Article							ENDOTHELIAL PROGENITOR CELLS; TIGHT JUNCTIONS; UP-REGULATION; ANGIOGENESIS; GROWTH; EXPRESSION; ADHERENS	The chemokine CXCL12 has been shown to regulate breast tumor growth, however, its mechanism in initiating distant metastasis is not well understood. Here, we generated a novel conditional allele of Cxcl12 in mice and used a fibroblast-specific Cre transgene along with various mammary tumor models to evaluate CXCL12 function in the breast cancer metastasis. Ablation of CXCL12 in stromal fibroblasts of mice significantly delayed the time to tumor onset and inhibited distant metastasis in different mouse models. Elucidation of mechanisms using in vitro and in vivo model systems revealed that CXCL12 enhances tumor cell intravasation by increasing vascular permeability and expansion of a leaky tumor vasculature. Furthermore, our studies revealed CXCL12 enhances permeability by recruiting endothelial precursor cells and decreasing endothelial tight junction and adherence junction proteins. High expression of stromal CXCL12 in large cohort of breast cancer patients was directly correlated to blood vessel density and inversely correlated to recurrence and overall patient survival. In addition, our analysis revealed that stromal CXCL12 levels in combination with number of CD31+ blood vessels confers poorer patient survival compared to individual protein level. However, no correlation was observed between epithelial CXCL12 and patient survival or blood vessel density. Our findings describe the novel interactions between fibroblasts-derived CXCL12 and endothelial cells in facilitating tumor cell intrvasation, leading to distant metastasis. Overall, our studies indicate that cross-talk between fibroblast-derived CXCL12 and endothelial cells could be used as novel biomarker and strategy for developing tumor microenvironment based therapies against aggressive and metastatic breast cancer.	[Ahirwar, Dinesh K.; Nasser, Mohd W.; Elbaz, Mohamad; Varikuti, Sanjay; Kaul, Kirti; Satoskar, Abhay R.; Ganju, Ramesh K.] Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA; [Ouseph, Madhu M.; Cuitino, Maria C.; Kladney, Raleigh D.; Ostrowski, Michael C.; Leone, Gustavo] Ohio State Univ, Dept Canc Biol & Genet, Columbus, OH 43210 USA; [Kladney, Raleigh D.; Ramaswamy, Bhuvaneswari; Ostrowski, Michael C.; Leone, Gustavo; Ganju, Ramesh K.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; [Ramaswamy, Bhuvaneswari] Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA; [Zhang, Xiaoli] Ohio State Univ, Ctr Biostat, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Ganju, RK (corresponding author), Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA.; Leone, G (corresponding author), Ohio State Univ, Dept Canc Biol & Genet, Columbus, OH 43210 USA.; Leone, G; Ganju, RK (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.	gustavo.leone@osumc.edu; ramesh.ganju@osumc.edu	Ouseph, Madhu/B-8940-2009; Nasser, Mohd/Y-3355-2019; Satoskar, Abhay/AAB-7748-2019; Ahirwar, Dinesh Kumar/CAG-3809-2022; Ostrowski, Michael C/H-3108-2011	Ouseph, Madhu/0000-0002-3422-1675; Ahirwar, Dinesh/0000-0002-0518-7156	Pelotonia Idea award; Department of Defense level II breakthrough awards; NIH R01 grants [CA109527, CA153490]; Pelotonia Postdoctoral award; NATIONAL CANCER INSTITUTE [R01CA109527, R01CA153490, P01CA097189] Funding Source: NIH RePORTER	Pelotonia Idea award; Department of Defense level II breakthrough awards; NIH R01 grants(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pelotonia Postdoctoral award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are thankful to Reham S. Shehab, Sanjit Roy, Chan Fu, Mohamed Adel, and Nitika Agarwal for technical assistance. This work is supported in part by Pelotonia Idea award, Department of Defense level II breakthrough awards, and NIH R01 grants (CA109527 and CA153490) to RKG. DKA was recipient of Pelotonia Postdoctoral award.	Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Egeblad M, 2008, DIS MODEL MECH, V1, P155, DOI 10.1242/dmm.000596; Feig C, 2013, P NATL ACAD SCI USA, V110, P20212, DOI 10.1073/pnas.1320318110; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Hennighausen L, 2001, DEV CELL, V1, P467, DOI 10.1016/S1534-5807(01)00064-8; Hillmer RE, 2015, INT J DEV BIOL, V59, P205, DOI 10.1387/ijdb.140348mj; Ivins S, 2015, DEV CELL, V33, P455, DOI 10.1016/j.devcel.2015.03.026; Li BY, 2015, J INTERF CYTOK RES, V35, P23, DOI 10.1089/jir.2014.0004; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Martins-Green M, 2008, METHOD ENZYMOL, V443, P137, DOI 10.1016/S0076-6879(08)02008-9; McLean AC, 2012, JOVE-J VIS EXP, DOI 10.3791/4389; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Nasser MW, 2015, CANCER RES, V75, P974, DOI 10.1158/0008-5472.CAN-14-2161; Nasser MW, 2012, CANCER RES, V72, P604, DOI 10.1158/0008-5472.CAN-11-0669; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Pei XF, 2004, IN VITRO CELL DEV-AN, V40, P14; Petit I, 2007, TRENDS IMMUNOL, V28, P299, DOI 10.1016/j.it.2007.05.007; Punglia RS, 2007, NEW ENGL J MED, V356, P2399, DOI 10.1056/NEJMra065241; Schiraldi M, 2012, J EXP MED, V209, P551, DOI 10.1084/jem.20111739; Smolkova B, 2016, TRANSL ONCOL, V9, P184, DOI 10.1016/j.tranon.2016.03.004; SOULE HD, 1986, IN VITRO CELL DEV B, V22, P6, DOI 10.1007/BF02623435; Taddei A, 2008, NAT CELL BIOL, V10, P923, DOI 10.1038/ncb1752; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Tan J, 2014, ONCOGENE, V33, P4050, DOI 10.1038/onc.2013.434; Tang D, 2010, ONCOGENE, V29, P5299, DOI 10.1038/onc.2010.261; Trimboli AJ, 2008, CANCER RES, V68, P937, DOI 10.1158/0008-5472.CAN-07-2148; Trimboli AJ, 2009, NATURE, V461, P1084, DOI 10.1038/nature08486; Vandenbroucke E, 2008, ANN NY ACAD SCI, V1123, P134, DOI 10.1196/annals.1420.016; Wallez Y, 2008, BBA-BIOMEMBRANES, V1778, P794, DOI 10.1016/j.bbamem.2007.09.003; WEIDNER N, 1992, JNCI-J NATL CANCER I, V84, P1875, DOI 10.1093/jnci/84.24.1875; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Xu X, 2013, CELLS TISSUES ORGANS, V197, P103, DOI 10.1159/000342921; Yu PF, 2017, ONCOGENE, V36, P840, DOI 10.1038/onc.2016.252	36	68	76	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2018	37	32					4428	4442		10.1038/s41388-018-0263-7	http://dx.doi.org/10.1038/s41388-018-0263-7			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GP8FA	29720724	Green Accepted			2022-12-17	WOS:000441144300007
J	Lee, JY; Park, JH; Choi, HJ; Won, HY; Joo, HS; Shin, DH; Park, MK; Han, B; Kim, KP; Lee, TJ; Croce, CM; Kong, G				Lee, J-Y; Park, J-H; Choi, H-J; Won, H-Y; Joo, H-s; Shin, D-H; Park, M. K.; Han, B.; Kim, K. P.; Lee, T. J.; Croce, C. M.; Kong, G.			LSD1 demethylates HIF1 alpha to inhibit hydroxylation and ubiquitin-mediated degradation in tumor angiogenesis	ONCOGENE			English	Article							METASTASIS-ASSOCIATED PROTEIN-1; LYSINE METHYLATION; TRANSCRIPTIONAL REPRESSION; SET9-MEDIATED METHYLATION; ANDROGEN RECEPTOR; PROSTATE-CANCER; BREAST-CANCER; HISTONE; HYPOXIA; HIF-1-ALPHA	Lysine-specific demethylase 1 (LSD1), which has been considered as a potential therapeutic target in human cancer, has been known to regulate many biological functions through its non-histone substrates. Although LSD1-induced hypoxia-inducible factor alpha (HIF1 alpha) demethylation has recently been proposed, the effect of LSD1 on the relationship between HIF1 alpha post-translational modifications (PTMs) and HIF1 alpha-induced tumor angiogenesis remains to be elucidated. Here, we identify a new methylation site of the HIF1 alpha protein antagonized by LSD1 and the interplay between HIF1 alpha protein methylation and other PTMs in regulating tumor angiogenesis. LSD1 demethylates HIF1 alpha at lysine (K) 391, which protects HIF1 alpha against ubiquitin-mediated protein degradation. LSD1 also directly suppresses PHD2-induced HIF1 alpha hydroxylation, which has a mutually dependent interplay with Set9-mediated HIF1 alpha methylation. Moreover, the HIF1 alpha acetylation that occurs in a HIF1 alpha methylation-dependent manner is inhibited by the LSD1/NuRD complex. HIF1 alpha stabilized by LSD1 cooperates with CBP and MTA1 to enhance vascular endothelial growth factor (VEGF)induced tumor angiogenesis. Thus, LSD1 is a key regulator of HIF1 alpha/VEGF-mediated tumor angiogenesis by antagonizing the crosstalk between PTMs involving HIF1 alpha protein degradation.	[Lee, J-Y; Park, J-H; Kong, G.] Hanyang Univ, IBBR, Seoul, South Korea; [Choi, H-J; Won, H-Y; Joo, H-s; Kong, G.] Hanyang Univ, Dept Pathol, Coll Med, 222 Wangsimni Ro, Seoul 04763, South Korea; [Park, M. K.] Natl Canc Ctr, Goyang, South Korea; [Han, B.; Kim, K. P.] Kyung Hee Univ, Dept Appl Chem, Coll Appl Sci, Yongin, South Korea; [Lee, T. J.; Croce, C. M.] Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA	Hanyang University; Hanyang University; National Cancer Center - Korea (NCC); Kyung Hee University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Kong, G (corresponding author), Hanyang Univ, Dept Pathol, Coll Med, 222 Wangsimni Ro, Seoul 04763, South Korea.	gkong@hanyang.ac.kr	Young, Richard A/F-6495-2012; Choi, Hyuk Joong/AAF-7713-2019	Young, Richard A/0000-0001-8855-8647; Choi, Hee-Joo/0000-0001-6432-8193; Kim, Kwang Pyo/0000-0003-0095-3787	National Research Foundation of Korea (NRF) grants - Korean government [2015R1A2A1A10052578]; NATIONAL CANCER INSTITUTE [R35CA197706] Funding Source: NIH RePORTER	National Research Foundation of Korea (NRF) grants - Korean government; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by National Research Foundation of Korea (NRF) grants funded by the Korean government (No. 2015R1A2A1A10052578).	Amente S, 2010, ONCOGENE, V29, P3691, DOI 10.1038/onc.2010.120; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Black JC, 2012, MOL CELL, V48, P491, DOI 10.1016/j.molcel.2012.11.006; Cheng J, 2007, CELL, V131, P584, DOI 10.1016/j.cell.2007.08.045; Cho HS, 2011, CANCER RES, V71, P655, DOI 10.1158/0008-5472.CAN-10-2446; Cho MH, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8821; Ferrari-Amorotti G, 2013, CANCER RES, V73, P235, DOI 10.1158/0008-5472.CAN-12-1739; Gaughan L, 2011, NUCLEIC ACIDS RES, V39, P1266, DOI 10.1093/nar/gkq861; Hino S, 2016, CANCER SCI, V107, P1187, DOI 10.1111/cas.13004; Huang J, 2007, NATURE, V449, P105, DOI 10.1038/nature06092; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Kahl P, 2006, CANCER RES, V66, P11341, DOI 10.1158/0008-5472.CAN-06-1570; Kashyap V, 2013, MOL ONCOL, V7, P555, DOI 10.1016/j.molonc.2013.01.003; Kim Y, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10347; Ko S, 2011, MOL ENDOCRINOL, V25, P433, DOI 10.1210/me.2010-0482; Kontaki H, 2010, MOL CELL, V39, P152, DOI 10.1016/j.molcel.2010.06.006; Kouskouti A, 2004, MOL CELL, V14, P175, DOI 10.1016/S1097-2765(04)00182-0; Lee MH, 2012, ONCOGENE, V31, P5099, DOI 10.1038/onc.2012.2; Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021; Li Q, 2011, CANCER RES, V71, P6899, DOI 10.1158/0008-5472.CAN-11-1523; Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324; Lin T, 2010, ONCOGENE, V29, P4896, DOI 10.1038/onc.2010.234; Liu X, 2015, NUCLEIC ACIDS RES, V43, P5081, DOI 10.1093/nar/gkv379; Morera L, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0223-4; Nair SS, 2013, MOL CELL, V49, P704, DOI 10.1016/j.molcel.2012.12.016; Nicolson GL, 2003, CLIN EXP METASTAS, V20, P19, DOI 10.1023/A:1022534217769; Page EL, 2008, MOL BIOL CELL, V19, P86, DOI 10.1091/mbc.E07-06-0612; Pakala SB, 2011, ONCOGENE, V30, P2230, DOI 10.1038/onc.2010.608; Park JH, 2011, ONCOGENE, V30, P4578, DOI 10.1038/onc.2011.174; Qin Y, 2014, CANCER LETT, V347, P225, DOI 10.1016/j.canlet.2014.02.013; Rankin EB, 2008, CELL DEATH DIFFER, V15, P678, DOI 10.1038/cdd.2008.21; Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735; Serce N, 2012, BMC CLIN PATHOL, V12, DOI 10.1186/1472-6890-12-13; Shi Y, 2007, NAT REV GENET, V8, P829, DOI 10.1038/nrg2218; Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Wang J, 2009, NAT GENET, V41, P125, DOI 10.1038/ng.268; Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050; Yang JB, 2010, P NATL ACAD SCI USA, V107, P21499, DOI 10.1073/pnas.1016147107; Yoo YG, 2006, EMBO J, V25, P1231, DOI 10.1038/sj.emboj.7601025; Zhang X, 2012, ACTA BIOCH BIOPH SIN, V44, P14, DOI 10.1093/abbs/gmr100; Zhang XY, 2005, P NATL ACAD SCI USA, V102, P13968, DOI 10.1073/pnas.0502330102	42	68	69	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2017	36	39					5512	5521		10.1038/onc.2017.158	http://dx.doi.org/10.1038/onc.2017.158			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FI4RG	28534506				2022-12-17	WOS:000411960500007
J	Bouillez, A; Rajabi, H; Jin, C; Samur, M; Tagde, A; Alam, M; Hiraki, M; Maeda, T; Hu, X; Adeegbe, D; Kharbanda, S; Wong, KK; Kufe, D				Bouillez, A.; Rajabi, H.; Jin, C.; Samur, M.; Tagde, A.; Alam, M.; Hiraki, M.; Maeda, T.; Hu, X.; Adeegbe, D.; Kharbanda, S.; Wong, K-K; Kufe, D.			MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer	ONCOGENE			English	Article							TOLL-LIKE RECEPTOR-9; ONCOPROTEIN; EXPRESSION; ACTIVATION; PATHWAY; ADENOCARCINOMA; INTERFERON; PROGNOSIS; BREAST; IFN	Immunotherapeutic approaches, particularly programmed death 1/programmed death ligand 1 (PD-1/PD-L1) blockade, have improved the treatment of non-small-cell lung cancer (NSCLC), supporting the premise that evasion of immune destruction is of importance for NSCLC progression. However, the signals responsible for upregulation of PD-L1 in NSCLC cells and whether they are integrated with the regulation of other immune-related genes are not known. Mucin 1 (MUC1) is aberrantly overexpressed in NSCLC, activates the nuclear factor-kappa B (NF-kappa B) p65. ZEB1 pathway and confers a poor prognosis. The present studies demonstrate that MUC1-C activates PD-L1 expression in NSCLC cells. We show that MUC1-C increases NF-kappa B p65 occupancy on the CD274/ PD-L1 promoter and thereby drives CD274 transcription. Moreover, we demonstrate that MUC1-C-induced activation of NF-kappa B -> ZEB1 signaling represses the TLR9 (toll-like receptor 9), IFNG, MCP-1 (monocyte chemoattractant protein-1) and GM-CSF genes, and that this signature is associated with decreases in overall survival. In concert with these results, targeting MUC1-C in NSCLC tumors suppresses PD-L1 and induces these effectors of innate and adaptive immunity. These findings support a previously unrecognized central role for MUC1-C in integrating PD-L1 activation with suppression of immune effectors and poor clinical outcome.	[Bouillez, A.; Rajabi, H.; Jin, C.; Samur, M.; Tagde, A.; Alam, M.; Hiraki, M.; Maeda, T.; Hu, X.; Adeegbe, D.; Kharbanda, S.; Wong, K-K; Kufe, D.] Harvard Med Sch, Dana Farber Canc Inst, Med Oncol, Boston, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Kufe, D (corresponding author), Dana Farber Canc Inst, Med Oncol, 450 Brookline Ave,Dana 830, Boston, MA 02215 USA.	donald_kufe@dfci.harvard.edu		Samur, Mehmet/0000-0002-9978-5682; Adeegbe, Dennis/0000-0001-9233-3328	National Cancer Institute of the National Institutes of Health [CA97098, CA166480]; Lung Cancer Research Foundation; NATIONAL CANCER INSTITUTE [R21CA216553, R01CA166480, P50CA100707, R01CA097098] Funding Source: NIH RePORTER	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Lung Cancer Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under award numbers CA97098 and CA166480, and by the Lung Cancer Research Foundation.	Agnello D, 2003, J CLIN IMMUNOL, V23, P147, DOI 10.1023/A:1023381027062; Ahmad R, 2007, NAT CELL BIOL, V9, P1419, DOI 10.1038/ncb1661; Ahmad R, 2009, CANCER RES, V69, P7013, DOI 10.1158/0008-5472.CAN-09-0523; Akbay EA, 2013, CANCER DISCOV, V3, P1355, DOI 10.1158/2159-8290.CD-13-0310; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Awaya H, 2004, AM J CLIN PATHOL, V121, P644, DOI 10.1039/U4WGE9EBFJN6CM8R; Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; Bouillez A, 2016, CANCER RES, V76, P1538, DOI 10.1158/0008-5472.CAN-15-1804; Carrizosa DR, 2015, TRANSL LUNG CANCER R, V4, P553, DOI 10.3978/j.issn.2218-6751.2015.06.05; Casey SC, 2016, SCIENCE, V352, P227, DOI 10.1126/science.aac9935; Chatterjee S, 2014, CANCER RES, V74, P5008, DOI 10.1158/0008-5472.CAN-13-2698; Chen LM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6241; Cherfils-Vicini J, 2010, J CLIN INVEST, V120, P1285, DOI 10.1172/JCI36551; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Dajon M, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.991615; Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027; Gnemmi V, 2014, CANCER LETT, V346, P225, DOI 10.1016/j.canlet.2013.12.029; Goodwin JM, 2014, MOL CELL, V55, P436, DOI 10.1016/j.molcel.2014.06.021; Gowrishankar K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123410; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; Hasegawa M, 2015, CLIN CANCER RES, V21, P2338, DOI 10.1158/1078-0432.CCR-14-3000; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hou J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010312; Hu XY, 2008, IMMUNOL REV, V226, P41, DOI 10.1111/j.1600-065X.2008.00707.x; Huang G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061602; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Jarrard JA, 1998, CANCER RES, V58, P5582; Kharbanda A, 2014, CLIN CANCER RES, V20, P5423, DOI 10.1158/1078-0432.CCR-13-3168; Kharbanda A, 2014, ONCOTARGET, V5, P8893, DOI 10.18632/oncotarget.2360; Khodarev NN, 2009, CANCER RES, V69, P2833, DOI 10.1158/0008-5472.CAN-08-4513; Koyama S, 2016, CANCER RES, V76, P999, DOI 10.1158/0008-5472.CAN-15-1439; KUFE D, 2009, CANCER BIOL THER, V8, P1201; Kufe DW, 2013, ONCOGENE, V32, P1073, DOI 10.1038/onc.2012.158; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Lee J, 2009, BIOCHEM J, V421, P301, DOI 10.1042/BJ20090013; Lee SJ, 2006, FEBS LETT, V580, P755, DOI 10.1016/j.febslet.2005.12.093; Leng YM, 2007, J BIOL CHEM, V282, P19321, DOI 10.1074/jbc.M703222200; Lou Y, 2016, CLIN CANCER RES, V31, P245; MacDermed DM, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-16; Mak MP, 2016, CLIN CANCER RES, V22, P609, DOI 10.1158/1078-0432.CCR-15-0876; Mayor M, 2016, EUR J CARDIO-THORAC, V49, P1324, DOI 10.1093/ejcts/ezv371; Metcalf D, 2010, NAT REV CANCER, V10, P425, DOI 10.1038/nrc2843; Pivarcsi A, 2007, P NATL ACAD SCI USA, V104, P19055, DOI 10.1073/pnas.0705673104; Raina D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135156; Raina D, 2012, INT J ONCOL, V40, P1644, DOI 10.3892/ijo.2011.1308; Raina D, 2011, MOL CANCER THER, V10, P806, DOI 10.1158/1535-7163.MCT-10-1050; Rajabi H, 2014, ONCOGENE, V33, P1680, DOI 10.1038/onc.2013.114; Ramasamy S, 2007, MOL CELL, V27, P992, DOI 10.1016/j.molcel.2007.07.031; Reck M, 2015, SEMIN ONCOL, V42, P402, DOI 10.1053/j.seminoncol.2015.02.013; Ronkainen H, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-84; Samur MK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106397; Sandholm J, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00330; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Seliger B, 2008, ADV CANCER RES, V101, P249, DOI 10.1016/S0065-230X(08)00407-7; Situ DR, 2011, MED ONCOL, V28, pS596, DOI 10.1007/s12032-010-9752-4; Sunaga N, 2012, INT J CANCER, V130, P1733, DOI 10.1002/ijc.26164; Tagde A, 2016, BLOOD, V127, P2587, DOI 10.1182/blood-2015-07-659151; Takahashi H, 2015, ONCOGENE, V34, P5187, DOI 10.1038/onc.2014.442; Takeshita F, 2004, J IMMUNOL, V173, P2552, DOI 10.4049/jimmunol.173.4.2552; Takeshita F, 2001, J IMMUNOL, V167, P3555, DOI 10.4049/jimmunol.167.7.3555; Welsh EA, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-153; Xie Y, 2011, CLIN CANCER RES, V17, P5705, DOI 10.1158/1078-0432.CCR-11-0196; Xu F, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002286	66	68	73	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2017	36	28					4037	4046		10.1038/onc.2017.47	http://dx.doi.org/10.1038/onc.2017.47			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FA3YD	28288138	Green Submitted, Green Accepted			2022-12-17	WOS:000405379900009
J	Yu, X; Li, S				Yu, X.; Li, S.			Non- metabolic functions of glycolytic enzymes in tumorigenesis	ONCOGENE			English	Review							PYRUVATE-KINASE M2; AUTOCRINE MOTILITY FACTOR; LACTATE-DEHYDROGENASE; PROTEIN-KINASE; ACETYL-COA; HISTONE MODIFICATION; GENE-TRANSCRIPTION; HEXOKINASE-II; CELL-GROWTH; CANCER	Cancer cells reprogram their metabolism to meet the requirement for survival and rapid growth. One hallmark of cancer metabolism is elevated aerobic glycolysis and reduced oxidative phosphorylation. Emerging evidence showed that most glycolytic enzymes are deregulated in cancer cells and play important roles in tumorigenesis. Recent studies revealed that all essential glycolytic enzymes can be translocated into nucleus where they participate in tumor progression independent of their canonical metabolic roles. These noncanonical functions include anti-apoptosis, regulation of epigenetic modifications, modulation of transcription factors and co-factors, extracellular cytokine, protein kinase activity and mTORC1 signaling pathway, suggesting that these multifaceted glycolytic enzymes not only function in canonical metabolism but also directly link metabolism to epigenetic and transcription programs implicated in tumorigenesis. These findings underscore our understanding about how tumor cells adapt to nutrient and fuel availability in the environment and most importantly, provide insights into development of cancer therapy.	[Yu, X.; Li, S.] Hubei Univ, Coll Life Sci, Hubei Collaborat Innovat Ctr Green Transformat Bi, Wuhan, Hubei, Peoples R China	Hubei University	Li, S (corresponding author), Hubei Univ, Coll Life Sci, 368 Youyi Rd, Wuhan 430062, Hubei, Peoples R China.	shanshanyxl@hotmail.com	Li, Shanshan/AAF-4758-2020	Li, Shanshan/0000-0002-0359-2369; Li, Shanshan/0000-0002-6424-2792	National Nature Science Foundation of China [31671335, 31600046]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC))	We apologize to colleagues whose work cannot be cited here because of space limitation. We thank members of Li laboratory for critical reading of this manuscript. This work was funded by grants from National Nature Science Foundation of China (No. 31671335 to S Li; No. 31600046 to X Yu).	ADAMS V, 1991, BIOCHEM BIOPH RES CO, V177, P1101, DOI 10.1016/0006-291X(91)90652-N; Amelio I, 2014, TRENDS BIOCHEM SCI, V39, P191, DOI 10.1016/j.tibs.2014.02.004; Anastasiou D, 2012, NAT CHEM BIOL, V8, P839, DOI 10.1038/NCHEMBIO.1060; Anastasiou D, 2011, SCIENCE, V334, P1278, DOI 10.1126/science.1211485; Araki K, 2009, J BIOL CHEM, V284, P32305, DOI 10.1074/jbc.M109.008250; Berger F, 2005, J BIOL CHEM, V280, P36334, DOI 10.1074/jbc.M508660200; Boukouris AE, 2016, TRENDS BIOCHEM SCI, V41, P712, DOI 10.1016/j.tibs.2016.05.013; Cai L, 2011, MOL CELL, V42, P426, DOI 10.1016/j.molcel.2011.05.004; Carey BW, 2015, NATURE, V518, P413, DOI 10.1038/nature13981; Castonguay Z, 2014, BIOCHEM BIOPH RES CO, V454, P172, DOI 10.1016/j.bbrc.2014.10.071; Choi SYC, 2016, CLIN CANCER RES, V22, P2721, DOI 10.1158/1078-0432.CCR-15-1624; Colell A, 2007, CELL, V129, P983, DOI 10.1016/j.cell.2007.03.045; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Doherty JR, 2013, J CLIN INVEST, V123, P3685, DOI 10.1172/JCI69741; Enzo E, 2015, EMBO J, V34, P1349, DOI 10.15252/embj.201490379; Fairbank M, 2009, MOL BIOSYST, V5, P793, DOI 10.1039/b820820b; Faivre S, 2006, NAT REV DRUG DISCOV, V5, P671, DOI 10.1038/nrd2062; Fan J, 2015, ACS CHEM BIOL, V10, P95, DOI 10.1021/cb500846u; Feo S, 2000, FEBS LETT, V473, P47, DOI 10.1016/S0014-5793(00)01494-0; Friis RMN, 2009, NUCLEIC ACIDS RES, V37, P3969, DOI 10.1093/nar/gkp270; Fu M, 2011, CELL DEATH DIFFER, V18, P1057, DOI 10.1038/cdd.2010.181; Galdieri L, 2016, MOL CELL BIOL, V36, P1064, DOI 10.1128/MCB.00770-15; Gancedo JM, 1998, MICROBIOL MOL BIOL R, V62, P334, DOI 10.1128/MMBR.62.2.334-361.1998; Gao XL, 2012, MOL CELL, V45, P598, DOI 10.1016/j.molcel.2012.01.001; Goel A, 2003, J BIOL CHEM, V278, P15333, DOI 10.1074/jbc.M300608200; Gong L, 2014, ANTI-CANCER AGENT ME, V14, P771, DOI 10.2174/1871520614666140416105309; GROSSE F, 1986, EUR J BIOCHEM, V160, P459, DOI 10.1111/j.1432-1033.1986.tb10062.x; Gruning NM, 2011, CELL METAB, V14, P415, DOI 10.1016/j.cmet.2011.06.017; Haga A, 2003, INT J CANCER, V107, P707, DOI 10.1002/ijc.11449; He CL, 2016, SCI REP-UK, V6, DOI 10.1038/srep21524; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Huang XY, 2001, ANNU REV BIOCHEM, V70, P149, DOI 10.1146/annurev.biochem.70.1.149; Jiang YH, 2014, MOL CELL, V53, P75, DOI 10.1016/j.molcel.2013.11.001; Johnson C, 2015, CANCER LETT, V356, P309, DOI 10.1016/j.canlet.2013.09.043; Katoh Y, 2011, MOL CELL, V41, P554, DOI 10.1016/j.molcel.2011.02.018; Keller KE, 2014, MOL CELL, V53, P700, DOI 10.1016/j.molcel.2014.02.015; Kennedy KM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075154; Kera Y, 2013, J BIOL CHEM, V288, P13592, DOI 10.1074/jbc.M112.429738; Khalid MH, 1999, J NEUROSURG, V90, P918, DOI 10.3171/jns.1999.90.5.0918; Kho DH, 2014, CANCER RES, V74, P2229, DOI 10.1158/0008-5472.CAN-13-2937; Kho DH, 2013, CANCER RES, V73, P1411, DOI 10.1158/0008-5472.CAN-12-2149; Kim JW, 2005, TRENDS BIOCHEM SCI, V30, P142, DOI 10.1016/j.tibs.2005.01.005; Kong LB, 2016, ARCH VIROL, V161, P2149, DOI 10.1007/s00705-016-2892-x; Latham T, 2012, NUCLEIC ACIDS RES, V40, P4794, DOI 10.1093/nar/gks066; Lee JW, 2008, INT J BIOCHEM CELL B, V40, P1043, DOI 10.1016/j.biocel.2007.11.009; Lee MN, 2009, MOL CELL BIOL, V29, P3991, DOI 10.1128/MCB.00165-09; Li SS, 2015, MOL CELL, V60, P408, DOI 10.1016/j.molcel.2015.09.024; Li SS, 2014, REV MED VIROL, V24, P223, DOI 10.1002/rmv.1783; Li SS, 2009, J BIOL CHEM, V284, P9411, DOI 10.1074/jbc.M809617200; Li S, 2008, P NATL ACAD SCI USA, V105, P18243, DOI 10.1073/pnas.0804530105; Li XJ, 2016, MOL CELL, V61, P705, DOI 10.1016/j.molcel.2016.02.009; Lincet H, 2015, ONCOGENE, V34, P3751, DOI 10.1038/onc.2014.320; Liu XS, 2015, ONCOTARGET, V6, P4214, DOI 10.18632/oncotarget.2929; Lu C, 2012, CELL METAB, V16, P9, DOI 10.1016/j.cmet.2012.06.001; Lucarelli G, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002117; Luo WB, 2011, CELL, V145, P732, DOI 10.1016/j.cell.2011.03.054; Matsuda S, 2016, NUCLEIC ACIDS RES, V44, P636, DOI 10.1093/nar/gkv967; McBrian MA, 2013, MOL CELL, V49, P310, DOI 10.1016/j.molcel.2012.10.025; Mehrotra S, 2014, BBA-GENE REGUL MECH, V1839, P751, DOI 10.1016/j.bbagrm.2014.05.029; Niinaka Y, 2010, CANCER RES, V70, P9483, DOI 10.1158/0008-5472.CAN-09-3880; Olson KA, 2016, TRENDS BIOCHEM SCI, V41, P219, DOI 10.1016/j.tibs.2016.01.002; Pastorino JG, 2003, CURR MED CHEM, V10, P1535, DOI 10.2174/0929867033457269; Patra KC, 2013, CANCER CELL, V24, P213, DOI 10.1016/j.ccr.2013.06.014; Penso J, 1998, EUR J PHARMACOL, V342, P113, DOI 10.1016/S0014-2999(97)01507-0; Popanda O, 1998, BBA-GENE STRUCT EXPR, V1397, P102, DOI 10.1016/S0167-4781(97)00229-7; Ringel AE, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003871; Ros S, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-8; Ryall JG, 2015, CELL STEM CELL, V17, P651, DOI 10.1016/j.stem.2015.11.012; Seligson DB, 2009, AM J PATHOL, V174, P1619, DOI 10.2353/ajpath.2009.080874; Stincone A, 2015, BIOL REV, V90, P927, DOI 10.1111/brv.12140; Su XY, 2016, CURR OPIN CHEM BIOL, V30, P52, DOI 10.1016/j.cbpa.2015.10.030; Suda T, 2011, CELL STEM CELL, V9, P298, DOI 10.1016/j.stem.2011.09.010; Sun S, 2015, BRIT J CANCER, V112, P1332, DOI 10.1038/bjc.2015.114; Sutendra G, 2014, CELL, V158, P84, DOI 10.1016/j.cell.2014.04.046; Tanaka Y, 2015, MOL CELL BIOL, V35, P4170, DOI 10.1128/MCB.00579-15; Tarze A, 2007, ONCOGENE, V26, P2606, DOI 10.1038/sj.onc.1210074; Thangaraju M, 2006, CANCER RES, V66, P11560, DOI 10.1158/0008-5472.CAN-06-1950; Ventura M, 2010, INT J BIOCHEM CELL B, V42, P1672, DOI 10.1016/j.biocel.2010.06.014; WILSON MJ, 1984, BIOCHEM J, V218, P987, DOI 10.1042/bj2180987; Xu YF, 2012, MOL CELL, V48, P52, DOI 10.1016/j.molcel.2012.07.013; Yang WW, 2012, CELL, V150, P685, DOI 10.1016/j.cell.2012.07.018; Yi W, 2012, SCIENCE, V337, P975, DOI 10.1126/science.1222278; Zhang JY, 2015, CANCER BIOL MED, V12, P10, DOI 10.7497/j.issn.2095-3941.2014.0019; Zhao Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.60; Zheng L, 2003, CELL, V114, P255, DOI 10.1016/S0092-8674(03)00552-X	85	68	69	1	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 11	2017	36	19					2629	2636		10.1038/onc.2016.410	http://dx.doi.org/10.1038/onc.2016.410			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EU6CF	27797379				2022-12-17	WOS:000401120900001
J	Chen, J; Bai, M; Ning, C; Xie, B; Zhang, J; Liao, H; Xiong, J; Tao, X; Yan, D; Xi, X; Chen, X; Yu, Y; Bast, RC; Zhang, Z; Feng, Y; Zheng, W				Chen, J.; Bai, M.; Ning, C.; Xie, B.; Zhang, J.; Liao, H.; Xiong, J.; Tao, X.; Yan, D.; Xi, X.; Chen, X.; Yu, Y.; Bast, R. C.; Zhang, Z.; Feng, Y.; Zheng, W.			Gankyrin facilitates follicle-stimulating hormone-driven ovarian cancer cell proliferation through the PI3K/AKT/HIF-1 alpha/cyclin D1 pathway	ONCOGENE			English	Article							CYCLIN D1; GROWTH-FACTOR; RETINOBLASTOMA PROTEIN; SURVIVIN EXPRESSION; ENDOMETRIAL-CANCER; SURFACE EPITHELIUM; COLORECTAL-CANCER; SIGNALING PATHWAY; RISK REDUCTION; FALLOPIAN-TUBE	Gankyrin is a regulatory subunit of the 26kD proteasome complex. As a novel oncoprotein, gankyrin is expressed aberrantly in cancers from several different sites and has been shown to contribute to oncogenesis in endometrial and cervical carcinomas. Neither gankyrin's contribution to the development of epithelial ovarian cancer nor its interaction with follicle-stimulating hormone (FSH)-driven proliferation in ovarian cancer has been studied. Here we have found that gankyrin is overexpressed in ovarian cancers compared with benign ovarian cystadenomas and that gankyrin regulates FSH upregulation of cyclin D1. Importantly, gankyrin regulates PI3K/AKT signaling by downregulating PTEN. Prolonged AKT activation by FSH stimulation of the FSH receptor (FSHR) promotes gankyrin expression, which, in turn, enhances AKT activation by inhibiting PTEN. Overexpression of gankyrin decreases hypoxia inducible factor-1 alpha (HIF-1 alpha) protein levels, but has little effect on HIF-1 alpha mRNA levels, which could be attributed to gankyrin mediating HIF-1 alpha protein stability via the ubiquitin-proteasome pathway. Reduction in HIF-1 alpha protein stability led to attenuation of the binding with cyclin D1 promoter, resulted in abolishment of the negative regulation of cyclin D1 by HIF-1 alpha, which promotes proliferation of ovarian cancer cells. Our results document that gankyrin regulates HIF-1 alpha protein stability and cyclin D1 expression, ultimately mediating FSH-driven ovarian cancer cell proliferation.	[Chen, J.; Bai, M.; Xie, B.; Zhang, J.; Yan, D.; Xi, X.; Zhang, Z.; Feng, Y.] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Dept Obstet & Gynecol, 100 Haining Rd, Shanghai 200080, Peoples R China; [Ning, C.; Chen, X.; Yu, Y.] Fudan Univ, Obstet & Gynecol Hosp, Dept Gynecol, Shanghai 200433, Peoples R China; [Liao, H.] Tongji Univ, Sch Med, Shanghai Matern & Infant Hosp 1, Clin & Translat Res Ctr, Shanghai 200092, Peoples R China; [Xiong, J.] Fudan Univ, Huashan Hosp, Dept Neuropathol, Shanghai 200433, Peoples R China; [Xiong, J.] Fudan Univ, Obstet & Gynecol Hosp, Dept Pathol, Shanghai 200433, Peoples R China; [Yu, Y.; Bast, R. C.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Zheng, W.] Univ Arizona, Coll Med, Dept Pathol, Tucson, AZ 85721 USA; [Zheng, W.] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA	Shanghai Jiao Tong University; Fudan University; Tongji University; Fudan University; Fudan University; University of Texas System; UTMD Anderson Cancer Center; University of Arizona; University of Texas System; University of Texas Southwestern Medical Center Dallas	Zhang, Z; Feng, Y (corresponding author), Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Dept Obstet & Gynecol, 100 Haining Rd, Shanghai 200080, Peoples R China.	zhangzhenbozzb@aliyun.com; Fengyj4806@sohu.com	Bast, Robert C/E-6585-2011	Bast, Robert C/0000-0003-4621-8462; Bai, Mingzhu/0000-0001-6210-4890	National Natural Science Foundation of China [81272883, 81202044, 81370074, 81172478]; Science and Technology Commission of Shanghai Municipality [12ZR1447600]; Shanghai Municipal Public Health Bureau [XYQ2013119]; 'Chenxing Project' from Shanghai Jiao Tong University; National Foundation for Cancer Research; Stuart; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); Shanghai Municipal Public Health Bureau; 'Chenxing Project' from Shanghai Jiao Tong University; National Foundation for Cancer Research; Stuart; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the National Natural Science Foundation of China (grant numbers 81272883, 81202044, 81370074 and 81172478), the Science and Technology Commission of Shanghai Municipality (grant number 12ZR1447600), the Shanghai Municipal Public Health Bureau (grant number XYQ2013119) and the 'Chenxing Project' from Shanghai Jiao Tong University to ZZ. The role of YY in this project was partially supported by The National Foundation for Cancer Research and contributions from Stuart and Gaye Lynn Zarrow.	Bai ZF, 2013, CANCER RES, V73, P4548, DOI 10.1158/0008-5472.CAN-12-4586; Bose CK, 2008, ONCOL RES, V17, P231, DOI 10.3727/096504008786111383; Brekelmans CTM, 2003, CURR OPIN OBSTET GYN, V15, P63, DOI 10.1097/00001703-200302000-00010; Callahan MJ, 2007, J CLIN ONCOL, V25, P3985, DOI 10.1200/JCO.2007.12.2622; Chen XJ, 2009, MODERN PATHOL, V22, P699, DOI 10.1038/modpathol.2009.25; Chen Y, 2007, CELL RES, V17, P1020, DOI 10.1038/cr.2007.99; Choi JH, 2004, J CLIN ENDOCR METAB, V89, P5508, DOI 10.1210/jc.2004-0044; Choi JH, 2007, ENDOCR REV, V28, P440, DOI 10.1210/er.2006-0036; CRAMER DW, 1983, JNCI-J NATL CANCER I, V71, P717; Crum CP, 2009, MOL ONCOL, V3, P165, DOI 10.1016/j.molonc.2009.01.004; Dawson S, 2006, TRENDS CELL BIOL, V16, P229, DOI 10.1016/j.tcb.2006.03.001; Dong LW, 2011, CELL RES, V21, P1248, DOI 10.1038/cr.2011.103; Elsheikh S, 2008, BREAST CANCER RES TR, V109, P325, DOI 10.1007/s10549-007-9659-8; Higashitsuji H, 2005, CANCER CELL, V8, P75, DOI 10.1016/j.ccr.2005.06.006; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; Huang Y, 2008, CELL RES, V18, P780, DOI 10.1038/cr.2008.70; Huang Y, 2011, ENDOCR-RELAT CANCER, V18, P13, DOI 10.1677/ERC-09-0308; Hung WC, 1996, HUM PATHOL, V27, P1324, DOI 10.1016/S0046-8177(96)90345-7; Jia L, 2011, NEOPLASMA, V58, P104, DOI 10.4149/neo_2011_02_104; Konishi I, 2006, INT J GYNECOL CANCER, V16, P16, DOI 10.1111/j.1525-1438.2006.00425.x; Lai YL, 2013, INT J ONCOL, V42, P776, DOI 10.3892/ijo.2012.1743; Li J, 2011, MODERN PATHOL, V24, P1488, DOI 10.1038/modpathol.2011.106; Li Q, 2013, MOL ENDOCRINOL, V27, P1468, DOI 10.1210/me.2013-1082; Li Y, 2007, MOL CELL ENDOCRINOL, V267, P26, DOI 10.1016/j.mce.2006.11.010; Liao H, 2012, ONCOL REP, V27, P1918, DOI 10.3892/or.2012.1700; Liu Yu-Qiang, 2014, J Anal Methods Chem, V2014, P617367, DOI 10.1155/2014/617367; Ludwig AH, 2009, ENDOCR-RELAT CANCER, V16, P1005, DOI 10.1677/ERC-08-0135; Lukanova A, 2005, CANCER EPIDEM BIOMAR, V14, P98; Man JH, 2010, J CLIN INVEST, V120, P2829, DOI 10.1172/JCI42542; Meng Y, 2010, CANCER LETT, V297, P9, DOI 10.1016/j.canlet.2010.04.019; Moreno-Bueno G, 2003, ONCOGENE, V22, P6115, DOI 10.1038/sj.onc.1206868; Nichols GE, 1996, MODERN PATHOL, V9, P418; Ohtani K, 2001, CANCER LETT, V166, P207, DOI 10.1016/S0304-3835(00)00713-8; Ortiz CM, 2008, INT J CANCER, V122, P325, DOI 10.1002/ijc.23106; Qian YW, 2012, GASTROENTEROLOGY, V142, P1547, DOI 10.1053/j.gastro.2012.02.042; Qiu W, 2008, ONCOGENE, V27, P4034, DOI 10.1038/onc.2008.43; Riman T, 1998, CLIN ENDOCRINOL, V49, P695, DOI 10.1046/j.1365-2265.1998.00577.x; Semczuk A, 2004, CANCER LETT, V203, P1, DOI 10.1016/j.canlet.2003.09.012; Song X, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-114; Sui L, 1999, GYNECOL ONCOL, V73, P202, DOI 10.1006/gyno.1999.5373; Tang SH, 2010, CANCER BIOL THER, V9, P88, DOI 10.4161/cbt.9.2.10283; Tao X, 2013, ENDOCR-RELAT CANCER, V20, P415, DOI 10.1530/ERC-12-0005; Udhayakumar G, 2007, MOL CARCINOGEN, V46, P807, DOI 10.1002/mc.20311; Umekita Y, 2002, INT J CANCER, V98, P415, DOI 10.1002/ijc.10151; Wang J, 2003, INT J CANCER, V103, P328, DOI 10.1002/ijc.10848; Wen W, 2010, CANCER RES, V70, P2010, DOI 10.1158/0008-5472.CAN-08-4910; WINSTON JT, 1993, MOL BIOL CELL, V4, P1133, DOI 10.1091/mbc.4.11.1133; Zhang JW, 2013, CANCER LETT, V339, P279, DOI 10.1016/j.canlet.2012.10.037; Zhang ZB, 2013, INT J ONCOL, V43, P1194, DOI 10.3892/ijo.2013.2054; Zhang ZB, 2013, ONCOL REP, V29, P1429, DOI 10.3892/or.2013.2278; Zhang ZB, 2012, CANCER LETT, V319, P89, DOI 10.1016/j.canlet.2011.12.033; Zhang ZB, 2009, CANCER LETT, V278, P56, DOI 10.1016/j.canlet.2008.12.024; Zheng TS, 2014, HEPATOLOGY, V59, P935, DOI 10.1002/hep.26705; Zheng WX, 1996, AM J PATHOL, V148, P47	54	68	74	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2016	35	19					2506	2517		10.1038/onc.2015.316	http://dx.doi.org/10.1038/onc.2015.316			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GQ	26364616				2022-12-17	WOS:000376165500009
J	He, C; Lv, X; Hua, G; Lele, SM; Remmenga, S; Dong, J; Davis, JS; Wang, C				He, C.; Lv, X.; Hua, G.; Lele, S. M.; Remmenga, S.; Dong, J.; Davis, J. S.; Wang, C.			YAP forms autocrine loops with the ERBB pathway to regulate ovarian cancer initiation and progression	ONCOGENE			English	Article							YES-ASSOCIATED PROTEIN; SURFACE EPITHELIAL-CELLS; HIPPO PATHWAY; TRANSCRIPTIONAL COACTIVATOR; TUMOR-SUPPRESSOR; GROWTH-FACTOR; PROLIFERATION; DROSOPHILA; EXPRESSION; MIGRATION	Mechanisms underlying ovarian cancer initiation and progression are unclear. Herein, we report that the Yes-associated protein (YAP), a major effector of the Hippo tumor suppressor pathway, interacts with ERBB signaling pathways to regulate the initiation and progression of ovarian cancer. Immunohistochemistry studies indicate that YAP expression is associated with poor clinical outcomes in patients. Overexpression or constitutive activation of YAP leads to transformation and tumorigenesis in human ovarian surface epithelial cells, and promotes growth of cancer cells in vivo and in vitro. YAP induces the expression of epidermal growth factor (EGF) receptors (EGFR, ERBB3) and production of EGF-like ligands (HBEGF, NRG1 and NRG2). HBEGF or NRG1, in turn, activates YAP and stimulates cancer cell growth. Knockdown of ERBB3 or HBEGF eliminates YAP effects on cell growth and transformation, whereas knockdown of YAP abrogates NRG1- and HBEGF-stimulated cell proliferation. Collectively, our study demonstrates the existence of HBEGF & NRGs/ERBBs/YAP/HBEGF & NRGs autocrine loop that controls ovarian cell tumorigenesis and cancer progression.	[He, C.; Lv, X.; Hua, G.; Remmenga, S.; Davis, J. S.; Wang, C.] Univ Nebraska Med Ctr, Olson Ctr Womens Hlth, Dept Obstet & Gynecol, Omaha, NE 68198 USA; [He, C.; Hua, G.] Huazhong Agr Univ, Coll Anim Sci & Technol, Wuhan, Hubei Province, Peoples R China; [Lele, S. M.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; [Remmenga, S.; Dong, J.; Davis, J. S.; Wang, C.] Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE 68198 USA; [Davis, J. S.] Omaha Vet Affairs Med Ctr, Omaha, NE USA	University of Nebraska System; University of Nebraska Medical Center; Huazhong Agricultural University; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Nebraska-Western Iowa Health Care System	Wang, C (corresponding author), Univ Nebraska Med Ctr, Dept Obstet & Gynecol, Fred & Pamela Buffett Canc Ctr, Olson Ctr Womens Hlth,Dept OB GYN, Omaha, NE 68198 USA.	chengwang@unmc.edu	Davis, John S/C-3234-2014; Lv, Xiangmin/I-7106-2019	Lv, Xiangmin/0000-0001-8338-6014; Davis, John/0000-0003-3468-4079	Eunice Kennedy Shriver National Institute of Child Health and Human Development [5R00HD059985, 5P01AG029531]; Olson Center for Women's Health; Fred & Pamela Buffett Cancer Center [LB595]; Omaha Veterans Administration Medical Center [5I01BX000512]; National Institute of Food and Agriculture [2011-67015-20076]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R00HD059985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG029531] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000512] Funding Source: NIH RePORTER	Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Olson Center for Women's Health; Fred & Pamela Buffett Cancer Center; Omaha Veterans Administration Medical Center; National Institute of Food and Agriculture(United States Department of Agriculture (USDA)National Institute of Food and Agriculture); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Veterans Affairs(US Department of Veterans Affairs)	This work was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (5R00HD059985, 5P01AG029531); The Olson Center for Women's Health (no number); The Fred & Pamela Buffett Cancer Center (LB595); the Omaha Veterans Administration Medical Center (5I01BX000512) and The National Institute of Food and Agriculture (2011-67015-20076). We wish to thank for Melody A. Montgomery at the University of Nebraska Medical Center Research Editorial Office for her professional assistance in editing this manuscript.	Amsellem-Ouazana D, 2006, J UROLOGY, V175, P1127, DOI 10.1016/S0022-5347(05)00317-4; Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; Banerjee S, 2013, CLIN CANCER RES, V19, P961, DOI 10.1158/1078-0432.CCR-12-2243; Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644; Cai H, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-31; Curto M, 2007, J CELL BIOL, V177, P893, DOI 10.1083/jcb.200703010; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Fan R, 2013, P NATL ACAD SCI USA, V110, P2569, DOI 10.1073/pnas.1216462110; Fu D, 2014, ENDOCR-RELAT CANCER, V21, P297, DOI 10.1530/ERC-13-0339; Gregoire L, 2001, CLIN CANCER RES, V7, P4280; Hall CA, 2010, CANCER RES, V70, P8517, DOI 10.1158/0008-5472.CAN-10-1242; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; Kim JM, 2011, HUM PATHOL, V42, P315, DOI 10.1016/j.humpath.2010.08.003; Kojic N, 2010, FASEB J, V24, P1604, DOI 10.1096/fj.09-145367; Komuro A, 2003, J BIOL CHEM, V278, P33334, DOI 10.1074/jbc.M305597200; Lamar JM, 2012, P NATL ACAD SCI USA, V109, pE2441, DOI 10.1073/pnas.1212021109; Lee KP, 2010, P NATL ACAD SCI USA, V107, P8248, DOI 10.1073/pnas.0912203107; Liu JS, 2004, CANCER RES, V64, P1655, DOI 10.1158/0008-5472.CAN-03-3380; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Lucas EP, 2013, J CELL BIOL, V201, P875, DOI 10.1083/jcb.201210073; Miyamoto S, 2004, CANCER RES, V64, P5720, DOI 10.1158/0008-5472.CAN-04-0811; Omerovic J, 2004, EXP CELL RES, V294, P469, DOI 10.1016/j.yexcr.2003.12.002; Orsulic S, 2002, CANCER CELL, V1, P53, DOI 10.1016/S1535-6108(01)00002-2; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Reddy BVVG, 2013, DEV CELL, V24, P459, DOI 10.1016/j.devcel.2013.01.020; Roepstorff K, 2009, TRAFFIC, V10, P1115, DOI 10.1111/j.1600-0854.2009.00943.x; Sasaki R, 2009, CARCINOGENESIS, V30, P423, DOI 10.1093/carcin/bgp007; Sheng Q, 2010, CANCER CELL, V17, P298, DOI 10.1016/j.ccr.2009.12.047; Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220; Steinhardt AA, 2008, HUM PATHOL, V39, P1582, DOI 10.1016/j.humpath.2008.04.012; Strano S, 2005, MOL CELL, V18, P447, DOI 10.1016/j.molcel.2005.04.008; Tschumperlin DJ, 2004, CELL CYCLE, V3, P996; Wang C, 2010, ENDOCRINOLOGY, V151, P2319, DOI 10.1210/en.2009-1489; Wang Y, 2010, CANCER SCI, V101, P1279, DOI 10.1111/j.1349-7006.2010.01511.x; Xia Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091770; Xu MZ, 2009, CANCER-AM CANCER SOC, V115, P4576, DOI 10.1002/cncr.24495; XU TA, 1995, DEVELOPMENT, V121, P1053; Yang N, 2012, CELL CYCLE, V11, P2922, DOI 10.4161/cc.21386; Yu FX, 2013, GENE DEV, V27, P355, DOI 10.1101/gad.210773.112; Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037; Yuan M, 2008, CELL DEATH DIFFER, V15, P1752, DOI 10.1038/cdd.2008.108; Zhang JM, 2009, NAT CELL BIOL, V11, P1444, DOI 10.1038/ncb1993; Zhang X, 2011, ONCOGENE, V30, P2810, DOI 10.1038/onc.2011.8; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907	46	68	71	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2015	34	50					6040	6054		10.1038/onc.2015.52	http://dx.doi.org/10.1038/onc.2015.52			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CY0RQ	25798835	Green Accepted			2022-12-17	WOS:000366113800002
J	Li, M; Yu, X				Li, M.; Yu, X.			The role of poly(ADP-ribosyl)ation in DNA damage response and cancer chemotherapy	ONCOGENE			English	Review							DOUBLE-STRAND BREAKS; NUCLEOTIDE EXCISION-REPAIR; SEVERE COMBINED IMMUNODEFICIENCY; HISTONE ADP-RIBOSYLATION; HOMOLOGY-DIRECTED REPAIR; ATM PROTEIN-KINASE; DOMAIN BARD1 GENE; RING DOMAIN; POLYNUCLEOTIDE KINASE; BRCT DOMAIN	DNA damage is a deleterious threat, but occurs daily in all types of cells. In response to DNA damage, poly(ADP-ribosyl)ation, a unique post-translational modification, is immediately catalyzed by poly(ADP-ribose) polymerases (PARPs) at DNA lesions, which facilitates DNA damage repair. Recent studies suggest that poly(ADP-ribosyl) ation is one of the first steps of cellular DNA damage response and governs early DNA damage response pathways. Suppression of DNA damage-induced poly(ADP-ribosyl) ation by PARP inhibitors impairs early DNA damage response events. Moreover, PARP inhibitors are emerging as anti-cancer drugs in phase III clinical trials for BRCA-deficient tumors. In this review, we discuss recent findings on poly(ADP-ribosyl) ation in DNA damage response as well as the molecular mechanism by which PARP inhibitors selectively kill tumor cells with BRCA mutations.	[Li, M.] Peking Univ, Hosp 3, Reprod Med Ctr, Dept Obstet & Gynecol, Beijing 100871, Peoples R China; [Li, M.; Yu, X.] Univ Michigan, Sch Med, Dept Internal Med, Div Mol Med & Genet, Ann Arbor, MI 48109 USA	Peking University; University of Michigan System; University of Michigan	Yu, X (corresponding author), Univ Michigan, Sch Med, Dept Internal Med, 109 Zina Pitcher Pl,BSRB 1520, Ann Arbor, MI 48109 USA.	xiayu@umich.edu			National Institute of Health [CA132755, CA130899]; Department of Defense; Ovarian Cancer Research Foundation; NATIONAL CANCER INSTITUTE [R01CA132755, R01CA130899, R01CA187209] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM108647] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); Ovarian Cancer Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Chao Liu to proofread the manuscript. This work was supported by the National Institute of Health (CA132755 and CA130899 to XY). XY is a recipient of the Era of Hope Scholar Award from the Department of Defense. ML is a recipient of the Ovarian Cancer Research Foundation Award.	Ahel D, 2009, SCIENCE, V325, P1240, DOI 10.1126/science.1177321; Ahel I, 2008, NATURE, V451, P81, DOI 10.1038/nature06420; Ahel I, 2006, NATURE, V443, P713, DOI 10.1038/nature05164; Ali AAE, 2012, NAT STRUCT MOL BIOL, V19, P685, DOI 10.1038/nsmb.2335; ALVAREZGONZALEZ R, 1987, BIOCHEMISTRY-US, V26, P3218, DOI 10.1021/bi00385a042; ALVAREZGONZALEZ R, 1989, MUTAT RES, V218, P67, DOI 10.1016/0921-8777(89)90012-8; ALVAREZGONZALEZ R, 1994, MOL CELL BIOCHEM, V138, P33, DOI 10.1007/BF00928440; Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; Ashworth A, 2008, J CLIN ONCOL, V26, P3785, DOI 10.1200/JCO.2008.16.0812; Audeh MW, 2010, LANCET, V376, P245, DOI 10.1016/S0140-6736(10)60893-8; Baer R, 2013, CANCER CELL, V23, P565, DOI 10.1016/j.ccr.2013.04.013; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Brem R, 2005, NUCLEIC ACIDS RES, V33, P2512, DOI 10.1093/nar/gki543; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Brzovic PS, 2001, J BIOL CHEM, V276, P41399, DOI 10.1074/jbc.M106551200; Brzovic PS, 2001, NAT STRUCT BIOL, V8, P833, DOI 10.1038/nsb1001-833; Buck D, 2006, EUR J IMMUNOL, V36, P224, DOI 10.1002/eji.200535401; Caldecott KW, 2008, NAT REV GENET, V9, P619, DOI 10.1038/nrg2380; Caldecott KW, 2003, BIOCHEM SOC T, V31, P247, DOI 10.1042/bst0310247; Caldecott KW, 2003, DNA REPAIR, V2, P955, DOI 10.1016/S1568-7864(03)00118-6; CHAMBON P, 1963, BIOCHEM BIOPH RES CO, V11, P39, DOI 10.1016/0006-291X(63)90024-X; Chapman JD, 2013, J PROTEOME RES, V12, P1868, DOI 10.1021/pr301219h; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Daniels CM, 2014, J PROTEOME RES, V13, P3510, DOI 10.1021/pr401032q; Davidovic L, 2001, EXP CELL RES, V268, P7, DOI 10.1006/excr.2001.5263; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; De Lorenzo SB, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00228; Demple B, 2002, ONCOGENE, V21, P8926, DOI 10.1038/sj.onc.1206178; Deriano L, 2013, ANNU REV GENET, V47, P433, DOI 10.1146/annurev-genet-110711-155540; DURKACZ BW, 1980, NATURE, V283, P593, DOI 10.1038/283593a0; Durocher D, 1999, MOL CELL, V4, P387, DOI 10.1016/S1097-2765(00)80340-8; El-Khamisy SF, 2003, NUCLEIC ACIDS RES, V31, P5526, DOI 10.1093/nar/gkg761; Enders A, 2006, J IMMUNOL, V176, P5060, DOI 10.4049/jimmunol.176.8.5060; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Feng XX, 2013, INT REV CEL MOL BIO, V304, P227, DOI 10.1016/B978-0-12-407696-9.00005-1; Fisher AEO, 2007, MOL CELL BIOL, V27, P5597, DOI 10.1128/MCB.02248-06; Flynn RL, 2010, CRIT REV BIOCHEM MOL, V45, P266, DOI 10.3109/10409238.2010.488216; Friedberg EC, 2001, NAT REV CANCER, V1, P22, DOI 10.1038/35094000; Gagne JP, 2003, BIOCHEM J, V371, P331, DOI 10.1042/BJ20021675; Gasser A, 2005, J CHROMATOGR B, V821, P181, DOI 10.1016/j.jchromb.2005.05.002; Ghimenti C, 2002, GENE CHROMOSOME CANC, V33, P235, DOI 10.1002/gcc.1223; Gibson BA, 2012, NAT REV MOL CELL BIO, V13, P411, DOI 10.1038/nrm3376; Glover JNM, 2004, TRENDS BIOCHEM SCI, V29, P579, DOI 10.1016/j.tibs.2004.09.010; Gottschalk AJ, 2009, P NATL ACAD SCI USA, V106, P13770, DOI 10.1073/pnas.0906920106; GRADWOHL G, 1990, P NATL ACAD SCI USA, V87, P2990, DOI 10.1073/pnas.87.8.2990; Haenni SS, 2008, INT J BIOCHEM CELL B, V40, P2274, DOI 10.1016/j.biocel.2008.03.008; Haince JF, 2008, J BIOL CHEM, V283, P1197, DOI 10.1074/jbc.M706734200; Han J, 2004, BRIT J CANCER, V91, P1604, DOI 10.1038/sj.bjc.6602174; Hartwell LH, 1997, SCIENCE, V278, P1064, DOI 10.1126/science.278.5340.1064; Hassa PO, 2006, MICROBIOL MOL BIOL R, V70, P789, DOI 10.1128/MMBR.00040-05; Hegde ML, 2008, CELL RES, V18, P27, DOI 10.1038/cr.2008.8; HILZ H, 1981, H-S Z PHYSIOL CHEM, V362, P1415; Hottiger MO, 2010, TRENDS BIOCHEM SCI, V35, P208, DOI 10.1016/j.tibs.2009.12.003; Ishitobi M, 2003, CANCER LETT, V200, P1, DOI 10.1016/S0304-3835(03)00387-2; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; JACOBSON EL, 1983, J BIOL CHEM, V258, P103; Jankevicius G, 2013, NAT STRUCT MOL BIOL, V20, P508, DOI 10.1038/nsmb.2523; Jilani A, 1999, J BIOL CHEM, V274, P24176, DOI 10.1074/jbc.274.34.24176; JUAREZSALINAS H, 1982, J BIOL CHEM, V257, P607; Jungmichel S, 2013, MOL CELL, V52, P272, DOI 10.1016/j.molcel.2013.08.026; Karimi-Busheri F, 1999, J BIOL CHEM, V274, P24187, DOI 10.1074/jbc.274.34.24187; Karras GI, 2005, EMBO J, V24, P1911, DOI 10.1038/sj.emboj.7600664; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kim H, 2007, NAT STRUCT MOL BIOL, V14, P710, DOI 10.1038/nsmb1277; Kim MY, 2005, GENE DEV, V19, P1951, DOI 10.1101/gad.1331805; Langelier MF, 2012, SCIENCE, V336, P728, DOI 10.1126/science.1216338; Le Page F, 2003, J BIOL CHEM, V278, P18471, DOI 10.1074/jbc.M212905200; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Lee MS, 2010, CANCER RES, V70, P4880, DOI 10.1158/0008-5472.CAN-09-4563; Leung AKL, 2014, J CELL BIOL, V205, P613, DOI 10.1083/jcb.201402114; Li GY, 2010, P NATL ACAD SCI USA, V107, P9129, DOI 10.1073/pnas.1000556107; Li JJ, 2002, MOL CELL, V9, P1045, DOI 10.1016/S1097-2765(02)00527-0; Li ML, 2012, TRENDS BIOCHEM SCI, V37, P418, DOI 10.1016/j.tibs.2012.06.007; Li M, 2013, GENE DEV, V27, P1752, DOI 10.1101/gad.226357.113; Li M, 2013, CANCER CELL, V23, P693, DOI 10.1016/j.ccr.2013.03.025; Li SC, 2011, J BIOL CHEM, V286, P36368, DOI 10.1074/jbc.M111.287797; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Lord CJ, 2013, NAT MED, V19, P1381, DOI 10.1038/nm.3369; Lord CJ, 2012, NATURE, V481, P287, DOI 10.1038/nature10760; Luo X, 2012, GENE DEV, V26, P417, DOI 10.1101/gad.183509.111; Mahajan A, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.151re12; Malanga M, 2008, J BIOL CHEM, V283, P19991, DOI 10.1074/jbc.M709495200; Manke IA, 2003, SCIENCE, V302, P636, DOI 10.1126/science.1088877; Martinez-Zamudio R, 2012, MOL CELL BIOL, V32, P2490, DOI 10.1128/MCB.06667-11; Messner S, 2011, TRENDS CELL BIOL, V21, P534, DOI 10.1016/j.tcb.2011.06.001; Messner S, 2010, NUCLEIC ACIDS RES, V38, P6350, DOI 10.1093/nar/gkq463; MEYER RR, 1990, MICROBIOL REV, V54, P342, DOI 10.1128/MMBR.54.4.342-380.1990; Meyer-Ficca ML, 2005, INT J BIOCHEM CELL B, V37, P920, DOI 10.1016/j.biocel.2004.09.011; Michels J, 2014, ONCOGENE, V33, P3894, DOI 10.1038/onc.2013.352; Min W, 2009, FRONT BIOSCI-LANDMRK, V14, P1619, DOI 10.2741/3329; MIWA M, 1981, J BIOL CHEM, V256, P2916; Mohammad DH, 2009, DNA REPAIR, V8, P1009, DOI 10.1016/j.dnarep.2009.04.004; Mortusewicz O, 2011, NUCLEIC ACIDS RES, V39, P5045, DOI 10.1093/nar/gkr099; MOSS J, 1992, J BIOL CHEM, V267, P10481; Nelson HH, 2002, CANCER RES, V62, P152; Okano S, 2003, MOL CELL BIOL, V23, P3974, DOI 10.1128/MCB.23.11.3974-3981.2003; Petrucelli N, 2010, GENET MED, V12, P245, DOI 10.1097/GIM.0b013e3181d38f2f; Pines A, 2012, J CELL BIOL, V199, P235, DOI 10.1083/jcb.201112132; Pleschke JM, 2000, J BIOL CHEM, V275, P40974, DOI 10.1074/jbc.M006520200; POIRIER GG, 1982, P NATL ACAD SCI-BIOL, V79, P3423, DOI 10.1073/pnas.79.11.3423; Polo SE, 2010, EMBO J, V29, P3130, DOI 10.1038/emboj.2010.188; Polyak K, 2011, NAT MED, V17, P283, DOI 10.1038/nm0311-283; Pommier Y, 2003, MUTAT RES-FUND MOL M, V532, P173, DOI 10.1016/j.mrfmmm.2003.08.016; Powell SN, 2003, ONCOGENE, V22, P5784, DOI 10.1038/sj.onc.1206678; Richard DJ, 2011, NUCLEIC ACIDS RES, V39, P3643, DOI 10.1093/nar/gkq1340; Robu M, 2013, P NATL ACAD SCI USA, V110, P1658, DOI 10.1073/pnas.1209507110; Rosenthal F, 2013, NAT STRUCT MOL BIOL, V20, P502, DOI 10.1038/nsmb.2521; Rouleau M, 2010, NAT REV CANCER, V10, P293, DOI 10.1038/nrc2812; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; SAKURA H, 1977, NUCLEIC ACIDS RES, V4, P2903, DOI 10.1093/nar/4.8.2903; Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Sharifi R, 2013, EMBO J, V32, P1225, DOI 10.1038/emboj.2013.51; Shiloh Y, 2013, NAT REV MOL CELL BIO, V14, P197, DOI 10.1038/nrm3546; Slade D, 2011, NATURE, V477, P616, DOI 10.1038/nature10404; Smith J, 2010, ADV CANCER RES, V108, P73, DOI 10.1016/S0065.230X(10)08002.4; Tartier L, 2003, MUTAGENESIS, V18, P411, DOI 10.1093/mutage/geg015; Thai TH, 1998, HUM MOL GENET, V7, P195, DOI 10.1093/hmg/7.2.195; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Tutt A, 2001, EMBO J, V20, P4704, DOI 10.1093/emboj/20.17.4704; van der Burg M, 2006, J CLIN INVEST, V116, P137, DOI 10.1172/JCI26121; Wang B, 2007, SCIENCE, V316, P1194, DOI 10.1126/science.1139476; Wang ZZ, 2012, GENE DEV, V26, P235, DOI 10.1101/gad.182618.111; WEILL JD, 1963, BIOCHEM BIOPH RES CO, V10, P122, DOI 10.1016/0006-291X(63)90036-6; Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705; Westermark UK, 2003, MOL CELL BIOL, V23, P7926, DOI 10.1128/MCB.23.21.7926-7936.2003; Whitehouse CJ, 2001, CELL, V104, P107, DOI 10.1016/S0092-8674(01)00195-7; Williams RS, 2009, CELL, V139, P87, DOI 10.1016/j.cell.2009.07.033; Williams RS, 2004, NAT STRUCT MOL BIOL, V11, P519, DOI 10.1038/nsmb776; WILSON DM, 1995, J BIOL CHEM, V270, P16002, DOI 10.1074/jbc.270.27.16002; Wood RD, 1999, BIOCHIMIE, V81, P39, DOI 10.1016/S0300-9084(99)80036-4; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xia F, 2001, P NATL ACAD SCI USA, V98, P8644, DOI 10.1073/pnas.151253498; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zhang F, 2014, P NATL ACAD SCI USA, V111, P7278, DOI 10.1073/pnas.1318367111; Zhang F, 2013, J CELL SCI, V126, P4850, DOI 10.1242/jcs.132514; Zhang YJ, 2013, NAT METHODS, V10, P981, DOI 10.1038/nmeth.2603; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	142	68	69	1	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	26					3349	3356		10.1038/onc.2014.295	http://dx.doi.org/10.1038/onc.2014.295			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CL3SU	25220415	Green Accepted			2022-12-17	WOS:000356871700001
J	Carpenter, RL; Paw, I; Dewhirst, MW; Lo, HW				Carpenter, R. L.; Paw, I.; Dewhirst, M. W.; Lo, H-W			Akt phosphorylates and activates HSF-1 independent of heat shock, leading to Slug overexpression and epithelial-mesenchymal transition (EMT) of HER2-overexpressing breast cancer cells	ONCOGENE			English	Article						Slug; EMT; Akt; HSF-1; HER2; phosphorylation	TRANSCRIPTION FACTOR SNAIL; GROWTH-FACTOR RECEPTOR; E-CADHERIN; UP-REGULATION; PROTEIN; GENE; FACTOR-1; BINDING; TARGET; INHIBITOR	Epithelial-mesenchymal transition (EMT) is an essential step for tumor progression, although the mechanisms driving EMT are still not fully understood. In an effort to investigate these mechanisms, we observed that heregulin (HRG)-mediated activation of HER2, or HER2 overexpression, resulted in EMT, which is accompanied with increased expression of a known EMT regulator Slug, but not TWIST or Snail. We then investigated how HER2 induced Slug expression and found, for the first time, that there are four consensus HSF sequence-binding elements (HSEs), the binding sites for heat shock factor-1 (HSF-1), located in the Slug promoter. HSF-1 bound to and transactivated the Slug promoter independent of heat shock, leading to Slug expression in breast cancer cells. Mutation of the putative HSEs ablated Slug transcriptional activation induced by HRG or HSF-1 overexpression. Knockdown of HSF-1 expression by siRNA reduced Slug expression and HRG-induced EMT. The positive association between HSF-1 and Slug was confirmed by immunohistochemical staining of a cohort of 100 invasive breast carcinoma specimens. While investigating how HER2 activated HSF-1 independent of heat shock, we observed that HER2 activation resulted in concurrent phosphorylation of Akt and HSF-1. We then observed, also for the first time, that Akt directly interacted with HSF-1 and phosphorylated HSF-1 at S326. Inhibition of Akt using siRNA, dominant-negative Akt mutant, or small molecule inhibitors prevented HRG-induced HSF-1 activation and Slug expression. Conversely, constitutively active Akt induced HSF-1 phosphorylation and Slug expression. HSF-1 knockdown reduced the ability of Akt to induce Slug expression, indicating an essential role that HSF-1 plays in Akt-induced Slug upregulation. Altogether, our study uncovered the existence of a novel Akt-HSF-1 signaling axis that leads to Slug upregulation and EMT, and potentially contributes to progression of HER2-positive breast cancer.	[Carpenter, R. L.; Paw, I.; Lo, H-W] Duke Univ, Sch Med, Dept Surg, Div Surg Sci, Durham, NC 27710 USA; [Dewhirst, M. W.] Duke Univ, Sch Med, Dept Radiat Oncol, Durham, NC 27710 USA; [Dewhirst, M. W.; Lo, H-W] Duke Univ, Sch Med, Duke Canc Inst, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Lo, HW (corresponding author), Duke Univ, Sch Med, Duke Canc Inst, Div Surg Sci,Dept Surg, Box 3156,423 MSRB 1,103 Res Dr, Durham, NC 27710 USA.	huiwen.lo@duke.edu	Dewhirst, Mark/Q-1302-2019	Dewhirst, Mark/0000-0003-3459-6546; Carpenter, Richard/0000-0001-9986-6493	NIH [K01-CA118423]; US Department of Defense [W81XWH-11-1-0600]; Beez Foundation; Intramural Division of Surgical Sciences; Dani P. Bolognesi PhD Award; Clarence Gardner PhD Award; NATIONAL CANCER INSTITUTE [P30CA014236, K01CA118423] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS087169] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Department of Defense(United States Department of Defense); Beez Foundation; Intramural Division of Surgical Sciences; Dani P. Bolognesi PhD Award; Clarence Gardner PhD Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We are thankful to Dr Mong-Hong Lee at MD Anderson Cancer Center who provided CA-Akt and DN-Akt constructs. This study was supported by the NIH grant K01-CA118423, and W81XWH-11-1-0600 from the US Department of Defense, the Beez Foundation and the Intramural Division of Surgical Sciences grants, Dani P. Bolognesi PhD Award and Clarence Gardner PhD Award.	Anckar J, 2011, ANNU REV BIOCHEM, V80, P1089, DOI 10.1146/annurev-biochem-060809-095203; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cheng JC, 2013, BIOCHEM BIOPH RES CO, V434, P81, DOI 10.1016/j.bbrc.2013.03.062; Chou SD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039679; Ciocca DR, 2013, ARCH TOXICOL, V87, P19, DOI 10.1007/s00204-012-0918-z; Cobaleda C, 2007, ANNU REV GENET, V41, P41, DOI 10.1146/annurev.genet.41.110306.130146; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; DSOUZA B, 1994, P NATL ACAD SCI USA, V91, P7202, DOI 10.1073/pnas.91.15.7202; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; Gabai VL, 2012, MOL CELL BIOL, V32, P929, DOI 10.1128/MCB.05921-11; Giordano A, 2012, MOL CANCER THER, V11, P2526, DOI 10.1158/1535-7163.MCT-12-0460; Guettouche Toumy, 2005, BMC Biochemistry, V6, DOI 10.1186/1471-2091-6-4; Hajra KM, 2002, CANCER RES, V62, P1613; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Khaleque MA, 2005, ONCOGENE, V24, P6564, DOI 10.1038/sj.onc.1208798; KROEGER PE, 1994, MOL CELL BIOL, V14, P7592, DOI 10.1128/MCB.14.11.7592; Li YM, 2004, CANCER CELL, V6, P459, DOI 10.1016/j.ccr.2004.09.027; Lo HW, 2008, CLIN CANCER RES, V14, P6042, DOI 10.1158/1078-0432.CCR-07-4923; Lo HW, 2008, MOL CANCER RES, V6, P843, DOI 10.1158/1541-7786.MCR-07-2105; Lo HW, 2007, CANCER RES, V67, P9066, DOI 10.1158/0008-5472.CAN-07-0575; Lo HW, 2010, MOL CANCER RES, V8, P232, DOI 10.1158/1541-7786.MCR-09-0391; Lo HW, 2009, CANCER RES, V69, P6790, DOI 10.1158/0008-5472.CAN-09-0886; Lo HW, 2005, CANCER CELL, V7, P575, DOI 10.1016/j.ccr.2005.05.007; Mendillo ML, 2012, CELL, V150, P549, DOI 10.1016/j.cell.2012.06.031; Meng L, 2010, ONCOGENE, V29, P5204, DOI 10.1038/onc.2010.277; Ohnishi K, 2004, INT J RADIAT BIOL, V80, P607, DOI 10.1080/09553000412331283470; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Santagata S, 2011, P NATL ACAD SCI USA, V108, P18378, DOI 10.1073/pnas.1115031108; Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403; Sekulic A, 2000, CANCER RES, V60, P3504; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Trimboli AJ, 2008, CANCER RES, V68, P937, DOI 10.1158/0008-5472.CAN-07-2148; Ursini-Siegel J, 2007, NAT REV CANCER, V7, P389, DOI 10.1038/nrc2127; Wang XZ, 2003, MOL CELL BIOL, V23, P6013, DOI 10.1128/MCB.23.17.6013-6026.2003; Westerheide SD, 2006, J BIOL CHEM, V281, P9616, DOI 10.1074/jbc.M512044200; Xi CX, 2012, J BIOL CHEM, V287, P35646, DOI 10.1074/jbc.M112.377481; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yoon YJ, 2011, J BIOL CHEM, V286, P1737, DOI 10.1074/jbc.M110.179440; Zhao RY, 2013, CELL CYCLE, V12, P935, DOI 10.4161/cc.23883; Zhu H, 2010, CANCER LETT, V294, P101, DOI 10.1016/j.canlet.2010.01.028	44	68	72	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2015	34	5					546	557		10.1038/onc.2013.582	http://dx.doi.org/10.1038/onc.2013.582			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DD	24469056	Green Accepted			2022-12-17	WOS:000348853500002
J	Zhu, J; Zhao, C; Kharman-Biz, A; Zhuang, T; Jonsson, P; Liang, N; Williams, C; Lin, CY; Qiao, Y; Zendehdel, K; Stromblad, S; Treuter, E; Dahlman-Wright, K				Zhu, J.; Zhao, C.; Kharman-Biz, A.; Zhuang, T.; Jonsson, P.; Liang, N.; Williams, C.; Lin, C-Y; Qiao, Y.; Zendehdel, K.; Stroemblad, S.; Treuter, E.; Dahlman-Wright, K.			The atypical ubiquitin ligase RNF31 stabilizes estrogen receptor alpha and modulates estrogen-stimulated breast cancer cell proliferation	ONCOGENE			English	Article						RNF31; ubiquitin; ER alpha; estrogen signaling; breast cancer	TRANSCRIPTIONAL REPRESSION; TUMOR PROGRESSION; ER-ALPHA; P53; DEGRADATION; ACTIVATION; EXPRESSION; COMPLEX; PARKIN; TRANSACTIVATION	Estrogen receptor alpha (ER alpha) is initially expressed in the majority of breast cancers and promotes estrogen-dependent cancer progression by regulating the transcription of genes linked to cell proliferation. ER alpha status is of clinical importance, as ER alpha-positive breast cancers can be successfully treated by adjuvant therapy with antiestrogens or aromatase inhibitors. Complications arise from the frequent development of drug resistance that might be caused by multiple alterations, including components of ER alpha signaling, during tumor progression and metastasis. Therefore, insights into the molecular mechanisms that control ER alpha expression and stability are of utmost importance to improve breast cancer diagnostics and therapeutics. Here we report that the atypical E3 ubiquitin ligase RNF31 stabilizes ER alpha and facilitates ER alpha-stimulated proliferation in breast cancer cell lines. We show that depletion of RNF31 decreases the number of cells in the S phase and reduces the levels of ER alpha and its downstream target genes, including cyclin D1 and c-myc. Analysis of data from clinical samples confirms correlation between RNF31 expression and the expression of ER alpha target genes. Immunoprecipitation indicates that RNF31 associates with ER alpha and increases its stability and mono-ubiquitination, dependent on the ubiquitin ligase activity of RNF31. Our data suggest that association of RNF31 and ER alpha occurs mainly in the cytosol, consistent with the lack of RNF31 recruitment to ER alpha-occupied promoters. In conclusion, our study establishes a non-genomic mechanism by which RNF31 via stabilizing ER alpha levels controls the transcription of estrogen-dependent genes linked to breast cancer cell proliferation.	[Zhu, J.; Zhao, C.; Kharman-Biz, A.; Zhuang, T.; Liang, N.; Qiao, Y.; Stroemblad, S.; Treuter, E.; Dahlman-Wright, K.] Karolinska Inst, Dept Biosci & Nutr, S-14183 Huddinge, Sweden; [Kharman-Biz, A.; Zendehdel, K.] Univ Tehran Med Sci, Canc Inst Iran, Canc Res Ctr, Tehran, Iran; [Jonsson, P.; Williams, C.; Lin, C-Y] Univ Houston, Dept Biol & Biochem, Ctr Nucl Receptors & Cell Signaling, Houston, TX USA	Karolinska Institutet; Tehran University of Medical Sciences; University of Houston System; University of Houston	Dahlman-Wright, K (corresponding author), Karolinska Inst, Dept Biosci & Nutr, S-14183 Huddinge, Sweden.	karin.dahlman-wright@ki.se	Williams, Cecilia/A-6677-2009; Qiao, yichun/Q-6498-2018; zhu, jian/D-7361-2017	Williams, Cecilia/0000-0002-0602-2062; Jonsson, Philip/0000-0002-1537-0624; Stromblad, Staffan/0000-0002-1236-6339; zhu, jian/0000-0003-0171-4251; zhu, jian/0000-0003-3596-4339; Zendehdel, Kazem/0000-0002-0269-4945; Liang, Ning/0000-0002-7848-2893; Treuter, Eckardt/0000-0002-4147-8989; Zhuang, Ting/0000-0002-6308-1253	China Scholarship Council; KID faculty grant from the Karolinska Institutet; Center for Biosciences; Swedish Cancer Society; Karolinska Institutet; Swedish Research Council; Cancer Institute of Tehran University; Knut & Alice Wallenberg foundation	China Scholarship Council(China Scholarship Council); KID faculty grant from the Karolinska Institutet; Center for Biosciences; Swedish Cancer Society(Swedish Cancer Society); Karolinska Institutet(Karolinska Institutet); Swedish Research Council(Swedish Research CouncilEuropean Commission); Cancer Institute of Tehran University; Knut & Alice Wallenberg foundation(Knut & Alice Wallenberg Foundation)	We are grateful to the BEA core facility for performing microarray analysis. We thank Indranil Sinha for uploading the microarray data. This work was supported by scholarship from the China Scholarship Council and by a KID faculty grant from the Karolinska Institutet (Jian Zhu), funding from the Center for Biosciences, the Swedish Cancer Society and the Karolinska Institutet (Karin Dahlman-Wright), and grants from the center for Biosciences, the Swedish Cancer Society and the Swedish Research Council (Eckardt Treuter). Human samples were provided by the Iran National Tumor Bank, which is funded by the Cancer Institute of Tehran University. Imaging, performed at the live cell imaging unit at the Department of Biosciences and Nutrition, was supported by the Knut & Alice Wallenberg foundation, the Swedish Research Council and the Center for Biosciences. This work was supported by scholarship from the China Scholarship Council and by a KID faculty grant from the Karolinska Institutet, funding from the Center for Biosciences, the Swedish Cancer Society, the Swedish Research Council and the Karolinska Institutet. Human samples were provided by the IRAN NATIONAL TUMOR BANK, which is funded by the Cancer Institute of Tehran University. Imaging was performed at the live cell imaging unit at the Department of Biosciences and Nutrition, supported by the Knut & Alice Wallenberg foundation, the Swedish Research Council and the Center for Biosciences.	Berry NB, 2008, MOL ENDOCRINOL, V22, P1535, DOI 10.1210/me.2007-0449; Brekman A, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2804; Brown RJ, 2006, SEMIN ONCOL, V33, P657, DOI 10.1053/j.seminoncol.2006.08.014; Cariou S, 2000, P NATL ACAD SCI USA, V97, P9042, DOI 10.1073/pnas.160016897; da Costa CA, 2009, NAT CELL BIOL, V11, P1370, DOI 10.1038/ncb1981; Duong V, 2007, CANCER RES, V67, P5513, DOI 10.1158/0008-5472.CAN-07-0967; Ehrlund A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032080; Ehrlund A, 2009, MOL CELL BIOL, V29, P2230, DOI 10.1128/MCB.00743-08; Eisenhaber B, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-3-209; Fan MY, 2005, MOL ENDOCRINOL, V19, P2901, DOI 10.1210/me.2005-0111; Frasor J, 2009, CANCER RES, V69, P8918, DOI 10.1158/0008-5472.CAN-09-2608; Geschickter C F, 1934, Am J Cancer, V21, P828; Gustafsson N, 2010, CANCER RES, V70, P1265, DOI 10.1158/0008-5472.CAN-09-2674; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hicks C, 2012, BREAST CANCER-BASIC, V6, P47, DOI 10.4137/BCBCR.S8652; Ikeda F, 2011, NATURE, V471, P637, DOI 10.1038/nature09814; Kastan MB, 2003, CELL, V112, P1, DOI 10.1016/S0092-8674(02)01281-3; Kirisako T, 2006, EMBO J, V25, P4877, DOI 10.1038/sj.emboj.7601360; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; La Rosa P, 2011, CELL SIGNAL, V23, P1128, DOI 10.1016/j.cellsig.2011.02.006; Le Romancer M, 2011, ENDOCR REV, V32, P597, DOI 10.1210/er.2010-0016; LECLERCQ G, 1986, CANCER RES, V46, P4233; Lindstrom LS, 2012, J CLIN ONCOL, V30, P2601, DOI 10.1200/JCO.2011.37.2482; Lonard DM, 2008, SCI SIGNAL, V1, DOI 10.1126/stke.113pe16; Ma YX, 2010, MOL ENDOCRINOL, V24, P76, DOI 10.1210/me.2009-0218; Mulhall JP, 2010, BJU INT, V106, P1706, DOI 10.1111/j.1464-410X.2010.09754.x; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Nettles KW, 2008, NAT CHEM BIOL, V4, P241, DOI 10.1038/nchembio.76; Putnik M, 2012, BIOCHEM BIOPH RES CO, V426, P26, DOI 10.1016/j.bbrc.2012.08.007; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Shaaban AM, 2002, AM J PATHOL, V160, P597, DOI 10.1016/S0002-9440(10)64879-1; Smit JJ, 2012, EMBO J, V31, P3833, DOI 10.1038/emboj.2012.217; Stevens TA, 2006, ONCOGENE, V25, P5426, DOI 10.1038/sj.onc.1209529; Thomas C, 2011, NAT REV CANCER, V11, P597, DOI 10.1038/nrc3093; Thompson HGR, 2004, EXP CELL RES, V295, P448, DOI 10.1016/j.yexcr.2004.01.019; Tokunaga F, 2011, NATURE, V471, P633, DOI 10.1038/nature09815; Tokunaga F, 2009, NAT CELL BIOL, V11, P123, DOI 10.1038/ncb1821; Wong SCC, 2001, J PATHOL, V194, P35, DOI 10.1002/path.838; Woo MG, 2012, J BIOL CHEM, V287, P3963, DOI 10.1074/jbc.M111.314765; Zhao CY, 2007, CANCER RES, V67, P3955, DOI 10.1158/0008-5472.CAN-06-3505; Zwart W, 2011, WIRES SYST BIOL MED, V3, P216, DOI 10.1002/wsbm.109	41	68	70	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2014	33	34					4340	4351		10.1038/onc.2013.573	http://dx.doi.org/10.1038/onc.2013.573			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MK	24441041	Green Published, hybrid			2022-12-17	WOS:000341156900007
J	Rosano, L; Cianfrocca, R; Tocci, P; Spinella, F; Di Castro, V; Spadaro, F; Salvati, E; Biroccio, AM; Natali, PG; Bagnato, A				Rosano, L.; Cianfrocca, R.; Tocci, P.; Spinella, F.; Di Castro, V.; Spadaro, F.; Salvati, E.; Biroccio, A. M.; Natali, P. G.; Bagnato, A.			beta-arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced beta-catenin signaling	ONCOGENE			English	Article						beta-arrestin; beta-catenin; endothelin A receptor; ovarian carcinoma; chromatin remodeling	EXPORT SIGNAL; ARRESTIN; ACTIVATION; RECEPTOR; GROWTH; AXIS; PROLIFERATION; LOCALIZATION; TRANSITIONS; EXPRESSION	Despite the fundamental pathophysiological importance of beta-catenin in tumor progression, the mechanism underlying its final transcriptional output has been partially elucidated. Here, we report that beta-arrestin-1 (beta-arr1) is an epigenetic regulator of endothelin (ET)-1-induced beta-catenin signaling in epithelial ovarian cancer (EOC). In response to ET A receptor (ETAR) activation by ET-1, beta-arr1 increases its nuclear translocation and direct binding to beta-catenin. This in turn enhanced beta-catenin nuclear accumulation and transcriptional activity, which was prevented by expressing a mutant beta-arr1 incapable of nuclear distribution. beta-arr1-beta-catenin interaction controls beta-catenin target gene expressions, such as ET-1, Axin 2, Matrix metalloproteinase 2, and Cyclin D1, by promoting histone deacetylase 1 (HDAC1) dissociation and the recruitment of p300 acetyltransferase on these promoter genes, resulting in enhanced H3 and H4 histone acetylation, and gene transcription, required for cell migration, invasion and epithelial-to-mesenchymal transition. These effects are abrogated by beta-arr1 silencing or by mutant beta-arr1, as well as by beta-catenin or p300 silencing, confirming that nuclear beta-arr1 forms a functional complex capable of regulating epigenetic changes in beta-catenin-driven invasive behavior. In a murine orthotopic model of metastatic human EOC, silencing of beta-arr1 or mutant beta-arr1 expression, as well as ETAR blockade, inhibits metastasis. In human EOC tissues, beta-arr1-beta-catenin nuclear complexes are selectively enriched at beta-catenin target gene promoters, correlating with tumor grade, confirming a direct in vivo beta-arr1-beta-catenin association at specific set of genes involved in EOC progression. Collectively, our study provides insights into how a beta-arr1-mediated epigenetic mechanism controls beta-catenin activity, unraveling new components required for its nuclear function in promoting metastasis.	[Rosano, L.; Cianfrocca, R.; Tocci, P.; Spinella, F.; Di Castro, V.; Natali, P. G.; Bagnato, A.] Regina Elena Inst Canc Res, Lab Mol Pathol, I-00158 Rome, Italy; [Spadaro, F.] Ist Super Sanita, Dept Haematol Oncol & Mol Med, Sect Expt Immunotherapy, I-00161 Rome, Italy; [Salvati, E.; Biroccio, A. M.] Regina Elena Inst Canc Res, Lab Expt Chemotherapy, I-00158 Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Istituto Superiore di Sanita (ISS); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Rosano, L (corresponding author), Regina Elena Inst Canc Res, Lab Mol Pathol, Via Messi DOro 156, I-00158 Rome, Italy.	rosano@ifo.it; bagnato@ifo.it	ROSANO', Laura/AAK-1424-2020; spinella, francesca/AAZ-8982-2020; Biroccio, Annamaria/B-2861-2018; Tocci, Piera/AAX-9815-2021; Di Castro, Valeriana/H-8873-2017; Spadaro, Francesca/M-7512-2017; Rosanò, Laura/AAB-7821-2019; Rosanò, Laura/B-2863-2018; Tocci, Piera/ABH-7630-2020; Bagnato, Anna/G-9747-2016	ROSANO', Laura/0000-0002-9962-6411; Biroccio, Annamaria/0000-0003-3198-3532; Tocci, Piera/0000-0003-3771-013X; Di Castro, Valeriana/0000-0002-1899-3683; Spadaro, Francesca/0000-0002-6610-350X; Rosanò, Laura/0000-0002-3981-8593; Rosanò, Laura/0000-0002-9962-6411; Bagnato, Anna/0000-0002-7269-9522; Salvati, Erica/0000-0002-3373-7442	Associazione Italiana Ricerca sul Cancro	Associazione Italiana Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)	We gratefully acknowledge Valentina Caprara and Aldo Lupo for excellent technical assistance, Maria Vincenza Sarcone for secretarial assistance, Dr Maurizio Fanciulli for valuable comments, Dr Robert Lefkowitz (Howard Hughes Medical Institute, Duke University) for his insightful comments and for kindly providing beta-arr1 expression vector; Dr Zhuohua Zhang (University of California San Diego School of Medicine, La Jolla, CA, USA) for ET-1 promoter reporter and its mutant control, and Dr Tania Merlino for the formal revision of the manuscript. This work was supported by the grant funded by the Associazione Italiana Ricerca sul Cancro.	Ahn S, 2009, J BIOL CHEM, V284, P8846, DOI 10.1074/jbc.M808463200; Bagnato A, 2011, BRIT J PHARMACOL, V163, P220, DOI 10.1111/j.1476-5381.2011.01217.x; Bagnato A, 2008, INT J BIOCHEM CELL B, V40, P1443, DOI 10.1016/j.biocel.2008.01.022; Billin AN, 2000, MOL CELL BIOL, V20, P6882, DOI 10.1128/MCB.20.18.6882-6890.2000; Bonnans C, 2012, P NATL ACAD SCI USA, V109, P3047, DOI 10.1073/pnas.1109457109; Bryja V, 2007, P NATL ACAD SCI USA, V104, P6690, DOI 10.1073/pnas.0611356104; Buchanan FG, 2006, P NATL ACAD SCI USA, V103, P1492, DOI 10.1073/pnas.0510562103; Chen W, 2001, P NATL ACAD SCI USA, V98, P14889, DOI 10.1073/pnas.211572798; Chen W, 2003, SCIENCE, V301, P1391, DOI 10.1126/science.1082808; Chun KS, 2009, CARCINOGENESIS, V30, P1620, DOI 10.1093/carcin/bgp168; Cianfrocca R, 2010, CAN J PHYSIOL PHARM, V88, P796, DOI 10.1139/Y10-052; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Dasgupta P, 2006, J CLIN INVEST, V116, P3083, DOI 10.1172/JCI28164C1; Dasgupta P, 2011, JNCI-J NATL CANCER I, V103, P317, DOI 10.1093/jnci/djq541; Hoeppner CZ, 2012, J BIOL CHEM, V287, P8932, DOI 10.1074/jbc.M111.294058; Jin QH, 2011, EMBO J, V30, P249, DOI 10.1038/emboj.2010.318; Kang JH, 2005, CELL, V123, P833, DOI 10.1016/j.cell.2005.09.011; Kim TH, 2005, ONCOGENE, V24, P597, DOI 10.1038/sj.onc.1208237; Kovacs JJ, 2009, DEV CELL, V17, P443, DOI 10.1016/j.devcel.2009.09.011; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Li TT, 2009, MOL CANCER RES, V7, P1064, DOI 10.1158/1541-7786.MCR-08-0578; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Ma L, 2007, J CELL SCI, V120, P213, DOI 10.1242/jcs.03338; Nelson J, 2003, NAT REV CANCER, V3, P110, DOI 10.1038/nrc990; Parathath SR, 2010, CELL CYCLE, V9, P4013, DOI 10.4161/cc.9.19.13325; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Rosano L, 2006, MOL CANCER THER, V5, P833, DOI 10.1158/1535-7163.MCT-05-0523; Rosano L, 2005, CANCER RES, V65, P11649, DOI 10.1158/0008-5472.CAN-05-2123; Rosano L, 2001, CANCER RES, V61, P8340; Rosano L, 2011, CLIN CANCER RES, V17, P2350, DOI 10.1158/1078-0432.CCR-10-2325; Rosano L, 2009, CELL CYCLE, V8, P1462; Rosano L, 2009, P NATL ACAD SCI USA, V106, P2806, DOI 10.1073/pnas.0807158106; Scott MGH, 2002, J BIOL CHEM, V277, P37693, DOI 10.1074/jbc.M207552200; Shenoy SK, 2012, ONCOGENE, V31, P282, DOI 10.1038/onc.2011.238; Shenoy Sudha K, 2005, Sci STKE, V2005, pcm10, DOI 10.1126/stke.2005/308/cm10; Shi YF, 2007, NAT IMMUNOL, V8, P817, DOI 10.1038/ni1489; Sun P, 2006, MOL PHARMACOL, V69, P520, DOI 10.1124/mol.105.019620; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tilley DG, 2009, J BIOL CHEM, V284, P20375, DOI 10.1074/jbc.M109.005793; Wang P, 2003, J BIOL CHEM, V278, P11648, DOI 10.1074/jbc.M208109200; Wu BB, 2007, IMMUNITY, V26, P227, DOI 10.1016/j.immuni.2006.12.007; Xiao K, 2007, P NATL ACAD SCI USA, V104, P12011, DOI 10.1073/pnas.0704849104; Yang M, 2009, BIOCHEM J, V417, P287, DOI 10.1042/BJ20081561; Yue R, 2009, CELL, V139, P535, DOI 10.1016/j.cell.2009.08.038	45	68	68	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2013	32	42					5066	5077		10.1038/onc.2012.527	http://dx.doi.org/10.1038/onc.2012.527			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238IB	23208497				2022-12-17	WOS:000325937900008
J	Cotrim, CZ; Fabris, V; Doria, ML; Lindberg, K; Gustafsson, JA; Amado, F; Lanari, C; Helguero, LA				Cotrim, C. Z.; Fabris, V.; Doria, M. L.; Lindberg, K.; Gustafsson, J-A; Amado, F.; Lanari, C.; Helguero, L. A.			Estrogen receptor beta growth-inhibitory effects are repressed through activation of MAPK and PI3K signalling in mammary epithelial and breast cancer cells	ONCOGENE			English	Article						estrogen receptor beta; mammary gland; breast cancer; apoptosis; proliferation; ERK 1/2	ER-ALPHA; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; PROLIFERATION; LINE; PROTEIN; DIFFERENTIATION; GENISTEIN; APOPTOSIS; SURVIVAL	Two thirds of breast cancers express estrogen receptors (ER). ER alpha (ER alpha) mediates breast cancer cell proliferation, and expression of ER alpha is the standard choice to indicate adjuvant endocrine therapy. ERbeta (ER beta) inhibits growth in vitro; its effects in vivo have been incompletely investigated and its role in breast cancer and potential as alternative target in endocrine therapy needs further study. In this work, mammary epithelial (EpH4 and HC11) and breast cancer (MC4-L2) cells with endogenous ER alpha and ER beta expression and T47-D human breast cancer cells with recombinant ER beta (T47-DER beta) were used to explore effects exerted in vitro and in vivo by the ER beta agonists 2,3-bis (4-hydroxy-phenyl)-propionitrile (DPN) and 7-bromo-2-(4-hydroxyphenyl)-1,3-benzoxazol-5-ol (WAY). In vivo, ER beta agonists induced mammary gland hyperplasia and MC4-L2 tumour growth to a similar extent as the ER alpha agonist 4,4',4 ''-(4-propyl-(1H)-pyrazole-1,3,5-triyl) trisphenol (PPT) or 17 beta-estradiol (E2) and correlated with higher number of mitotic and lower number of apoptotic features. In vitro, in MC4-L2, EpH4 or HC11 cells incubated under basal conditions, ER beta agonists induced apoptosis measured as upregulation of p53 and apoptosis-inducible factor protein levels and increased caspase 3 activity, whereas PPT and E2 stimulated proliferation. However, when extracellular signal-regulated kinase 1 and 2 (ERK1/2) were activated by co-incubation with basement membrane extract or epidermal growth factor, induction of apoptosis by ER beta agonists was repressed and DPN induced proliferation in a similar way as E2 or PPT. In a context of active ERK1/2, phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/RAC-alpha serine/threonine-protein kinase (AKT) signalling was necessary to allow proliferation stimulated by ER agonists. Inhibition of MEK1/2 with UO126 completely restored ER beta growth-inhibitory effects, whereas inhibition of PI3K by LY294002 inhibited ER beta-induced proliferation. These results show that the cellular context modulates ER beta growth-inhibitory effects and should be taken into consideration upon assessment of ER beta as target for endocrine treatment.	[Cotrim, C. Z.; Doria, M. L.; Helguero, L. A.] Univ Aveiro, Dept Chem, P-3810193 Aveiro, Portugal; [Fabris, V.; Lanari, C.] Inst Biol & Med Expt, RA-1428 Buenos Aires, DF, Argentina; [Lindberg, K.; Gustafsson, J-A; Helguero, L. A.] Karolinska Inst, Dept Biosci & Nutr, Stockholm, Sweden; [Gustafsson, J-A] Univ Houston, Ctr Nucl Receptors & Cell Signaling, Dept Biol & Biochem, Houston, TX USA; [Amado, F.] Univ Aveiro, Sch Hlth Sci, P-3800 Aveiro, Portugal	Universidade de Aveiro; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Institute of Biology & Experimental Medicine; Karolinska Institutet; University of Houston System; University of Houston; Universidade de Aveiro	Helguero, LA (corresponding author), Univ Aveiro, Dept Chem, Campus Univ Santigo, P-3810193 Aveiro, Portugal.	luisa.helguero@ua.pt	Helguero, Luisa/B-1221-2013; Cruz e Silva, Odete/AAH-5595-2020; Amado, Francisco ML/M-5337-2015	Helguero, Luisa/0000-0001-8237-2390; Amado, Francisco ML/0000-0001-8256-1749; Cotrim, Candida Zita/0000-0002-2489-274X; Lanari, Claudia/0000-0003-0555-2309	Federal funds through Programa Operacional Tematico Factores de Competitividade (COMPETE); European Community Fund (FEDER); Fundacao para a Ciencia e Tecnologia (FCT) [PTDC/SAU-ONC/112671/2009]; Mass Spectrometry Unit at University of Aveiro; Swedish Cancer Fund; FCT	Federal funds through Programa Operacional Tematico Factores de Competitividade (COMPETE); European Community Fund (FEDER)(European Commission); Fundacao para a Ciencia e Tecnologia (FCT)(Portuguese Foundation for Science and TechnologyEuropean Commission); Mass Spectrometry Unit at University of Aveiro; Swedish Cancer Fund; FCT(Portuguese Foundation for Science and TechnologyEuropean Commission)	We are grateful to Dr Lars-Arne Haldosen for enlightening discussions related to this work, Dr Anders Strom for T47-DER beta human breast cancer cells and Dr Margaret Warner for chicken anti-ER beta 503 and rabbit anti-ER beta 2 antibodies. This work was supported by Federal funds through Programa Operacional Tematico Factores de Competitividade (COMPETE) with co-participation from the European Community Fund (FEDER) and national funds through Fundacao para a Ciencia e Tecnologia (FCT) under the project no. PTDC/SAU-ONC/112671/2009 (LAH); Project Ciencia 2008 through FCT; Mass Spectrometry Unit at University of Aveiro and Swedish Cancer Fund.	Aliaga A, 2004, NUCL MED BIOL, V31, P761, DOI 10.1016/j.nucmedbio.2004.02.011; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; Ciarloni L, 2007, P NATL ACAD SCI USA, V104, P5455, DOI 10.1073/pnas.0611647104; Cotroneo MS, 2002, CARCINOGENESIS, V23, P1467, DOI 10.1093/carcin/23.9.1467; Forster C, 2002, P NATL ACAD SCI USA, V99, P15578, DOI 10.1073/pnas.192561299; Frasor J, 2003, ENDOCRINOLOGY, V144, P3159, DOI 10.1210/en.2002-0143; Green CA, 2008, HISTOPATHOLOGY, V53, P374, DOI 10.1111/j.1365-2559.2008.02968.x; Grober OMV, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-36; Hamilton-Burke W, 2010, AM J PATHOL, V177, P1079, DOI 10.2353/ajpath.2010.090886; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Helguero LA, 2005, ONCOGENE, V24, P6605, DOI 10.1038/sj.onc.1208807; Helguero LA, 2008, CANCER RES, V68, P8695, DOI 10.1158/0008-5472.CAN-08-0788; Honma N, 2008, J CLIN ONCOL, V26, P3727, DOI 10.1200/JCO.2007.14.2968; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; Jarvinen TAH, 2000, AM J PATHOL, V156, P29, DOI 10.1016/S0002-9440(10)64702-5; Jensen EV, 2001, P NATL ACAD SCI USA, V98, P15197, DOI 10.1073/pnas.211556298; Lanari C, 2001, CANCER RES, V61, P293; Lazennec G, 2001, ENDOCRINOLOGY, V142, P4120, DOI 10.1210/en.142.9.4120; Le Romancer M, 2011, ENDOCR REV, V32, P597, DOI 10.1210/er.2010-0016; Likhite VS, 2006, MOL ENDOCRINOL, V20, P3120, DOI 10.1210/me.2006-0068; Lindberg K, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2865; Lindberg K, 2010, J CELL PHYSIOL, V222, P156, DOI 10.1002/jcp.21932; Liu MM, 2002, J BIOL CHEM, V277, P24353, DOI 10.1074/jbc.M201829200; Liu Y, 2008, P NATL ACAD SCI USA, V105, P2604, DOI 10.1073/pnas.0712085105; Matthews J, 2006, MOL ENDOCRINOL, V20, P534, DOI 10.1210/me.2005-0140; Matthews Jason, 2003, Mol Interv, V3, P281, DOI 10.1124/mi.3.5.281; MERLO GR, 1994, ONCOGENE, V9, P443; Merlo GR, 1996, EUR J CELL BIOL, V70, P97; MERLO GR, 1995, J CELL BIOL, V128, P1185, DOI 10.1083/jcb.128.6.1185; Migliaccio A, 2006, ANN NY ACAD SCI, V1089, P194, DOI 10.1196/annals.1386.006; Moll UM, 2005, CURR OPIN CELL BIOL, V17, P631, DOI 10.1016/j.ceb.2005.09.007; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Nilsson S, 2011, CLIN PHARMACOL THER, V89, P44, DOI 10.1038/clpt.2010.226; Novaro V, 2003, J CELL SCI, V116, P2975, DOI 10.1242/jcs.00523; Novelli F, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2139; Rahal OM, 2011, ENDOCRINOLOGY, V152, P3409, DOI 10.1210/en.2011-1085; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; Roger P, 2001, CANCER RES, V61, P2537; Sanchez M, 2010, TRENDS ENDOCRIN MET, V21, P104, DOI 10.1016/j.tem.2009.09.007; Shaaban AM, 2008, CLIN CANCER RES, V14, P5228, DOI 10.1158/1078-0432.CCR-07-4528; Shu XO, 2009, JAMA-J AM MED ASSOC, V302, P2437, DOI 10.1001/jama.2009.1783; Skliris GP, 2006, BRIT J CANCER, V95, P616, DOI 10.1038/sj.bjc.6603295; Skliris GP, 2003, J PATHOL, V201, P213, DOI 10.1002/path.1436; Soldati R, 2010, BREAST CANCER RES TR, V123, P709, DOI 10.1007/s10549-009-0659-8; Strom A, 2004, P NATL ACAD SCI USA, V101, P1566, DOI 10.1073/pnas.0308319100; Su Y, 2009, CARCINOGENESIS, V30, P331, DOI 10.1093/carcin/bgn279; Walker VR, 2004, ILAR J, V45, P455, DOI 10.1093/ilar.45.4.455; Weitsman GE, 2006, BREAST CANCER RES TR, V100, P23, DOI 10.1007/s10549-006-9229-5; Williams C, 2008, ONCOGENE, V27, P1019, DOI 10.1038/sj.onc.1210712; Wu XL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2844	50	68	72	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 9	2013	32	19					2390	2402		10.1038/onc.2012.261	http://dx.doi.org/10.1038/onc.2012.261			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140ZL	22751110				2022-12-17	WOS:000318694900003
J	Morikawa, M; Koinuma, D; Miyazono, K; Heldin, CH				Morikawa, M.; Koinuma, D.; Miyazono, K.; Heldin, C-H			Genome-wide mechanisms of Smad binding	ONCOGENE			English	Review						ChIP-chip; ChIP-sequencing; TGF-beta; BMP; Smad	GROWTH-FACTOR-BETA; GENE-EXPRESSION SIGNATURE; TGF-BETA; TRANSCRIPTION FACTORS; SIGNALING PATHWAYS; UBIQUITIN LIGASE; INITIATING CELLS; STEM-CELLS; CHIP-SEQ; SYNEXPRESSION GROUP	A dual role of transforming growth factor beta (TGF-beta), to both suppress and promote tumor progression and metastasis, has been well established, but its molecular basis has remained elusive. In this review, we focus on Smad proteins, which are central mediators of the signal transduction of TGF-beta family members. We describe current knowledge of cell-type-specific binding patterns of Smad proteins and mechanisms of transcriptional regulation, obtained from recent studies on genome-wide binding sites of Smad molecules. We also discuss potential application of the genome-wide analyses for cancer research, which will allow clarification of the complex mechanisms occurring during cancer progression, and the identification of potential biomarkers for future cancer diagnosis, prognosis and therapy. Oncogene (2013) 32, 1609-1615; doi:10.1038/onc.2012.191; published online 21 May 2012	[Morikawa, M.; Miyazono, K.; Heldin, C-H] Uppsala Univ, Sci Life Lab, Ludwig Inst Canc Res, Biomed Ctr, Uppsala, Sweden; [Morikawa, M.; Koinuma, D.; Miyazono, K.] Univ Tokyo, Dept Mol Pathol, Grad Sch Med, Bunkyo Ku, Tokyo 1130033, Japan	Ludwig Institute for Cancer Research; Uppsala University; University of Tokyo	Miyazono, K (corresponding author), Univ Tokyo, Dept Mol Pathol, Grad Sch Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	miyazono@m.u-tokyo.ac.jp	Morikawa, Masato/D-1932-2011; Koinuma, Daizo/Y-8716-2018	Morikawa, Masato/0000-0002-6191-7176; Koinuma, Daizo/0000-0001-5611-2122	Swedish Cancer Society [100452]; KAKENHI [22112002, 22790750]; Global Center of Excellence Program (Integrative Life Science Based on the Study of Biosignaling Mechanisms) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan; Takeda Science Foundation; Ministry of Health, Labour and Welfare of Japan [H22-013]; Grants-in-Aid for Scientific Research [22112002, 24390070] Funding Source: KAKEN	Swedish Cancer Society(Swedish Cancer Society); KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Global Center of Excellence Program (Integrative Life Science Based on the Study of Biosignaling Mechanisms) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan; Takeda Science Foundation(Takeda Science Foundation (TSF)); Ministry of Health, Labour and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by a grant from Swedish Cancer Society (Grant number 100452); KAKENHI (grants-in-aid for scientific research on Innovative Area (Integrative Research on Cancer Microenvironment Network; Grant number 22112002)) and for Young Scientists (B) (Grant numbers 22790750 (DK)); the Global Center of Excellence Program (Integrative Life Science Based on the Study of Biosignaling Mechanisms) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan; a Research Grant from the Takeda Science Foundation and a Grant-in-Aid for Cancer Research for the Third-Term Comprehensive 10-Year Strategy for Cancer Control (H22-013) from the Ministry of Health, Labour and Welfare of Japan.	Agricola E, 2011, MOL CELL, V43, P85, DOI 10.1016/j.molcel.2011.05.020; Akizu N, 2010, DEVELOPMENT, V137, P2915, DOI 10.1242/dev.049395; Alarcon C, 2009, CELL, V139, P757, DOI 10.1016/j.cell.2009.09.035; Anido J, 2010, CANCER CELL, V18, P655, DOI 10.1016/j.ccr.2010.10.023; Aragon E, 2011, GENE DEV, V25, P1275, DOI 10.1101/gad.2060811; Aubin J, 2004, GENE DEV, V18, P1482, DOI 10.1101/gad.1202604; BabuRajendran N, 2010, NUCLEIC ACIDS RES, V38, P3477, DOI 10.1093/nar/gkq046; Cao Y, 2010, DEV CELL, V18, P662, DOI 10.1016/j.devcel.2010.02.014; Chai JJ, 2003, J BIOL CHEM, V278, P20327, DOI 10.1074/jbc.C300134200; Chen X, 2008, CELL, V133, P1106, DOI 10.1016/j.cell.2008.04.043; Coulouarn C, 2008, HEPATOLOGY, V47, P2059, DOI 10.1002/hep.22283; Dahle O, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000841; Dupont S, 2005, CELL, V121, P87, DOI 10.1016/j.cell.2005.01.033; Dupont S, 2009, CELL, V136, P123, DOI 10.1016/j.cell.2008.10.051; Farnham PJ, 2009, NAT REV GENET, V10, P605, DOI 10.1038/nrg2636; Fei T, 2010, GENOME RES, V20, P36, DOI 10.1101/gr.092114.109; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Fuentealba LC, 2007, CELL, V131, P980, DOI 10.1016/j.cell.2007.09.027; Gao S, 2009, MOL CELL, V36, P457, DOI 10.1016/j.molcel.2009.09.043; Gomis RR, 2006, CANCER CELL, V10, P203, DOI 10.1016/j.ccr.2006.07.019; Gomis RR, 2006, P NATL ACAD SCI USA, V103, P12747, DOI 10.1073/pnas.0605333103; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; Harvey SA, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000101; He W, 2006, CELL, V125, P929, DOI 10.1016/j.cell.2006.03.045; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Huang D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027123; Ikushima H, 2008, EMBO J, V27, P2955, DOI 10.1038/emboj.2008.218; Ikushima H, 2009, CELL STEM CELL, V5, P504, DOI 10.1016/j.stem.2009.08.018; Inui M, 2011, NAT CELL BIOL, V13, P1368, DOI 10.1038/ncb2346; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; John S, 2011, NAT GENET, V43, P264, DOI 10.1038/ng.759; Kaneda A, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002359; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Kennedy BA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022606; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Kim SW, 2011, DEV BIOL, V357, P492, DOI 10.1016/j.ydbio.2011.06.009; Koinuma D, 2009, CANCER SCI, V100, P2133, DOI 10.1111/j.1349-7006.2009.01299.x; Koinuma D, 2009, MOL CELL BIOL, V29, P172, DOI 10.1128/MCB.01038-08; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Kuratomi G, 2005, BIOCHEM J, V386, P461, DOI 10.1042/BJ20040738; Landry JR, 2009, BLOOD, V113, P5783, DOI 10.1182/blood-2008-11-187757; Lee KL, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002130; Levy L, 2006, CYTOKINE GROWTH F R, V17, P41, DOI 10.1016/j.cytogfr.2005.09.009; Lonardo E, 2011, CELL STEM CELL, V9, P433, DOI 10.1016/j.stem.2011.10.001; Lonn P, 2010, MOL CELL, V40, P521, DOI 10.1016/j.molcel.2010.10.029; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Miyazono K, 2012, UPSALA J MED SCI, V117, P143, DOI 10.3109/03009734.2011.638729; Miyazono K, 2010, J BIOCHEM, V147, P35, DOI 10.1093/jb/mvp148; Mizutani A, 2011, J BIOL CHEM, V286, P29848, DOI 10.1074/jbc.M110.217745; Morikawa M, 2011, NUCLEIC ACIDS RES, V39, P8712, DOI 10.1093/nar/gkr572; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Mullen AC, 2011, CELL, V147, P565, DOI 10.1016/j.cell.2011.08.050; Naka K, 2010, NATURE, V463, P676, DOI 10.1038/nature08734; Park PJ, 2009, NAT REV GENET, V10, P669, DOI 10.1038/nrg2641; Penn BH, 2004, GENE DEV, V18, P2348, DOI 10.1101/gad.1234304; Penuelas S, 2009, CANCER CELL, V15, P315, DOI 10.1016/j.ccr.2009.02.011; Pepke S, 2009, NAT METHODS, V6, pS22, DOI [10.1038/NMETH.1371, 10.1038/nmeth.1371]; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Pimanda JE, 2007, P NATL ACAD SCI USA, V104, P840, DOI 10.1073/pnas.0607196104; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Sapkota G, 2007, MOL CELL, V25, P441, DOI 10.1016/j.molcel.2007.01.006; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Silvestri C, 2008, DEV CELL, V14, P411, DOI 10.1016/j.devcel.2008.01.004; Simonis M, 2007, NAT METHODS, V4, P895, DOI 10.1038/NMETH1114; Trompouki E, 2011, CELL, V147, P577, DOI 10.1016/j.cell.2011.09.044; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Xi QR, 2011, CELL, V147, P1511, DOI 10.1016/j.cell.2011.11.032; Yagi K, 1999, J BIOL CHEM, V274, P703, DOI 10.1074/jbc.274.2.703; Yokoyama S, 2009, DEV CELL, V17, P836, DOI 10.1016/j.devcel.2009.10.011; Yoon SJ, 2011, GENE DEV, V25, P1654, DOI 10.1101/gad.16800511; Yoshimura A, 2010, J BIOCHEM, V147, P781, DOI 10.1093/jb/mvq043; Zaret KS, 2011, GENE DEV, V25, P2227, DOI 10.1101/gad.176826.111; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang YZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020319; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	80	68	70	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2013	32	13					1609	1615		10.1038/onc.2012.191	http://dx.doi.org/10.1038/onc.2012.191			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116AY	22614010	Green Published, hybrid			2022-12-17	WOS:000316855800001
J	Wang, SD; Rath, P; Lal, B; Richard, JP; Li, Y; Goodwin, CR; Laterra, J; Xia, S				Wang, S. D.; Rath, P.; Lal, B.; Richard, J-P; Li, Y.; Goodwin, C. R.; Laterra, J.; Xia, S.			EphB2 receptor controls proliferation/migration dichotomy of glioblastoma by interacting with focal adhesion kinase	ONCOGENE			English	Article						glioblastoma-derived stem-like neurospheres; orthotopic xenograft; EphB2; proliferation/migration dichotomy; invasion; focal adhesion kinase	CELL-MIGRATION; CANCER-CELLS; TUMOR-GROWTH; STEM-CELLS; EPHA2; PATHWAY; EXPRESSION; INVASION; INHIBITION; EPHRINS	Glioblastoma multiforme (GBM) is the most frequent and aggressive primary brain tumors in adults. Uncontrolled proliferation and abnormal cell migration are two prominent spatially and temporally disassociated characteristics of GBMs. In this study, we investigated the role of the receptor tyrosine kinase EphB2 in controlling the proliferation/migration dichotomy of GBM. We studied EphB2 gain of function and loss of function in glioblastoma-derived stem-like neurospheres, whose in vivo growth pattern closely replicates human GBM. EphB2 expression stimulated GBM neurosphere cell migration and invasion, and inhibited neurosphere cell proliferation in vitro. In parallel, EphB2 silencing increased tumor cell proliferation and decreased tumor cell migration. EphB2 was found to increase tumor cell invasion in vivo using an internally controlled dual-fluorescent xenograft model. Xenografts derived from EphB2-overexpressing GBM neurospheres also showed decreased cellular proliferation. The non-receptor tyrosine kinase focal adhesion kinase (FAK) was found to be co-associated with and highly activated by EphB2 expression, and FAK activation facilitated focal adhesion formation, cytoskeleton structure change and cell migration in EphB2-expressing GBM neurosphere cells. Taken together, our findings indicate that EphB2 has pro-invasive and anti-proliferative actions in GBM stem-like neurospheres mediated, in part, by interactions between EphB2 receptors and FAK. These novel findings suggest that tumor cell invasion can be therapeutically targeted by inhibiting EphB2 signaling, and that optimal antitumor responses to EphB2 targeting may require concurrent use of anti-proliferative agents. Oncogene (2012) 31, 5132-5143; doi:10.1038/onc.2012.16; published online 6 February 2012	[Wang, S. D.; Rath, P.; Lal, B.; Richard, J-P; Li, Y.; Laterra, J.; Xia, S.] Johns Hopkins Sch Med, Hugo W Moser Res Inst Kennedy Krieger, Baltimore, MD 21205 USA; [Rath, P.; Lal, B.; Richard, J-P; Li, Y.; Laterra, J.; Xia, S.] Johns Hopkins Sch Med, Dept Neurol, Baltimore, MD 21205 USA; [Goodwin, C. R.] Johns Hopkins Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA; [Laterra, J.] Johns Hopkins Sch Med, Dept Oncol, Baltimore, MD 21205 USA; [Laterra, J.] Johns Hopkins Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Xia, S (corresponding author), Johns Hopkins Sch Med, Hugo W Moser Res Inst Kennedy Krieger, 707 N Broadway,Room 400K, Baltimore, MD 21205 USA.	xia@kennedykrieger.org		Goodwin, C. Rory/0000-0002-6540-2751; Richard, Jean-Philippe/0000-0003-2890-2316	Maryland Stem Cell Research Fund (MSCRFE) [2009-0126-00]; NIH [NS43987]; James S McDonnell Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043987] Funding Source: NIH RePORTER	Maryland Stem Cell Research Fund (MSCRFE); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); James S McDonnell Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by the Maryland Stem Cell Research Fund (MSCRFE) 2009-0126-00 (SX), NIH NS43987 (JL) and the James S McDonnell Foundation (JL). We thank Dr Hugo Guerrero-Cazares for technical advice and Miss Mir Shanaz Hossain for technical assistance. We also thank Mr Hao Zhang from Johns Hopkins School of Public Health for assistance with flow cytometric analysis.	Alazzouzi H, 2005, CANCER RES, V65, P10170, DOI 10.1158/0008-5472.CAN-05-2580; Arvanitis D, 2008, GENE DEV, V22, P416, DOI 10.1101/gad.1630408; Bar EE, 2007, STEM CELLS, V25, P2524, DOI 10.1634/stemcells.2007-0166; Batlle E, 2005, NATURE, V435, P1126, DOI 10.1038/nature03626; Brantley-Sieders DM, 2008, J CLIN INVEST, V118, P64, DOI 10.1172/JCI33154; Brantley-Sieders DM, 2004, J CELL SCI, V117, P2037, DOI 10.1242/jcs.01061; Candolfi M, 2007, J NEURO-ONCOL, V85, P133, DOI 10.1007/s11060-007-9400-9; Chatzizacharias NA, 2008, HISTOL HISTOPATHOL, V23, P629, DOI 10.14670/HH-23.629; Chiu ST, 2009, CARCINOGENESIS, V30, P1475, DOI 10.1093/carcin/bgp133; Conover JC, 2000, NAT NEUROSCI, V3, P1091, DOI 10.1038/80606; Cortina C, 2007, NAT GENET, V39, P1376, DOI 10.1038/ng.2007.11; Cox BD, 2006, J CELL BIOCHEM, V99, P36, DOI 10.1002/jcb.20956; Fan X, 2010, STEM CELLS, V28, P5, DOI 10.1002/stem.254; Fox BP, 2004, BIOCHEM BIOPH RES CO, V318, P882, DOI 10.1016/j.bbrc.2004.04.102; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Fukai J, 2008, MOL CANCER THER, V7, P2768, DOI 10.1158/1535-7163.MCT-07-2263; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Garber K, 2010, J NATL CANCER I, V102, P1692, DOI 10.1093/jnci/djq479; Genander M, 2009, CELL, V139, P679, DOI 10.1016/j.cell.2009.08.048; Giese A, 1996, INT J CANCER, V67, P275, DOI 10.1002/(SICI)1097-0215(19960717)67:2<275::AID-IJC20>3.0.CO;2-9; Giese A, 2003, J CLIN ONCOL, V21, P1624, DOI 10.1200/JCO.2003.05.063; Golubovskaya VM, 2008, J MED CHEM, V51, P7405, DOI 10.1021/jm800483v; Goodwin CR, 2010, CANCER RES, V70, P2932, DOI 10.1158/0008-5472.CAN-09-3570; Heese O, 2005, NEURO-ONCOLOGY, V7, P476, DOI 10.1215/S1152851704000754; Hoelzinger DB, 2005, NEOPLASIA, V7, P7, DOI 10.1593/neo.04535; Holmberg J, 2006, CELL, V125, P1151, DOI 10.1016/j.cell.2006.04.030; Huusko P, 2004, NAT GENET, V36, P979, DOI 10.1038/ng1408; Kuijper S, 2007, TRENDS CARDIOVAS MED, V17, P145, DOI 10.1016/j.tcm.2007.03.003; Kumar SR, 2009, CANCER RES, V69, P3736, DOI 10.1158/0008-5472.CAN-08-3232; Lal BC, 2005, CLIN CANCER RES, V11, P4479, DOI 10.1158/1078-0432.CCR-05-0166; Larsen AB, 2007, MOL CANCER RES, V5, P283, DOI 10.1158/1541-7786.MCR-06-0321; Lee HS, 2008, NAT CELL BIOL, V10, P979, DOI 10.1038/ncb1758; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Lugli A, 2005, CLIN CANCER RES, V11, P6450, DOI 10.1158/1078-0432.CCR-04-2458; Luo M, 2010, CANCER LETT, V289, P127, DOI 10.1016/j.canlet.2009.07.005; Madhavan S, 2009, MOL CANCER RES, V7, P157, DOI 10.1158/1541-7786.MCR-08-0435; Miao H, 2009, CANCER CELL, V16, P9, DOI 10.1016/j.ccr.2009.04.009; Nakada M, 2005, AM J PATHOL, V167, P565, DOI 10.1016/S0002-9440(10)62998-7; Nakada M, 2004, CANCER RES, V64, P3179, DOI 10.1158/0008-5472.CAN-03-3667; Nakada M, 2010, INT J CANCER, V126, P1155, DOI 10.1002/ijc.24849; Noblitt LW, 2004, CANCER GENE THER, V11, P757, DOI 10.1038/sj.cgt.7700761; Noren NK, 2007, CANCER RES, V67, P3994, DOI 10.1158/0008-5472.CAN-07-0525; Noren NK, 2006, NAT CELL BIOL, V8, P815, DOI 10.1038/ncb1438; Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011; Pasquale EB, 2010, NAT REV CANCER, V10, P165, DOI 10.1038/nrc2806; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pollard SM, 2009, CELL STEM CELL, V4, P568, DOI 10.1016/j.stem.2009.03.014; Quick A, 2010, REV RECENT CLIN TRIA, V5, P14, DOI 10.2174/157488710790820544; Rahman R, 2010, J ONCOL, V2010, DOI 10.1155/2010/251231; Reznik TE, 2008, MOL CANCER RES, V6, P139, DOI 10.1158/1541-7786.MCR-07-0236; Sarkaria JN, 2006, CLIN CANCER RES, V12, P2264, DOI 10.1158/1078-0432.CCR-05-2510; Schwock J, 2010, EXPERT OPIN THER TAR, V14, P77, DOI 10.1517/14728220903460340; Shi Y, 2009, J NEUROSCI, V29, P8129, DOI 10.1523/JNEUROSCI.4681-08.2009; Slack-Davis JK, 2007, J BIOL CHEM, V282, P14845, DOI 10.1074/jbc.M606695200; Sun P, 2009, STEM CELLS, V27, P1473, DOI 10.1002/stem.89; Surawska H, 2004, CYTOKINE GROWTH F R, V15, P419, DOI 10.1016/j.cytogfr.2004.09.002; Taddei ML, 2009, AM J PATHOL, V174, P1492, DOI 10.2353/ajpath.2009.080473; van Nimwegen MJ, 2007, BIOCHEM PHARMACOL, V73, P597, DOI 10.1016/j.bcp.2006.08.011; Vaught D, 2009, MOL BIOL CELL, V20, P2572, DOI 10.1091/mbc.E08-04-0378; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(00)00088-5; Ying M, 2011, ONCOGENE, V30, P3454, DOI 10.1038/onc.2011.58; Ying MY, 2011, STEM CELLS, V29, P20, DOI 10.1002/stem.561; Zhao J, 2009, CANCER METAST REV, V28, P35, DOI 10.1007/s10555-008-9165-4	63	68	70	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2012	31	50					5132	5143		10.1038/onc.2012.16	http://dx.doi.org/10.1038/onc.2012.16			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055WY	22310282	Green Accepted, Green Submitted			2022-12-17	WOS:000312449800002
J	Sayan, AE; Stanford, R; Vickery, R; Grigorenko, E; Diesch, J; Kulbicki, K; Edwards, R; Pal, R; Greaves, P; Jariel-Encontre, I; Piechaczyk, M; Kriajevska, M; Mellon, JK; Dhillon, AS; Tulchinsky, E				Sayan, A. E.; Stanford, R.; Vickery, R.; Grigorenko, E.; Diesch, J.; Kulbicki, K.; Edwards, R.; Pal, R.; Greaves, P.; Jariel-Encontre, I.; Piechaczyk, M.; Kriajevska, M.; Mellon, J. K.; Dhillon, A. S.; Tulchinsky, E.			Fra-1 controls motility of bladder cancer cells via transcriptional upregulation of the receptor tyrosine kinase AXL	ONCOGENE			English	Article						Fos-related antigen-1; cell motility; bladder cancer	BREAST-CANCER; PROTEASOMAL DEGRADATION; CARCINOMA-CELLS; FAMILY-MEMBERS; C-MET; EXPRESSION; AP-1; RAS; TARGET; GENE	Fos-related antigen 1 (Fra-1) is a Fos family member overexpressed in several types of human cancers. Here, we report that Fra-1 is highly expressed in the muscle-invasive form of the carcinoma of the bladder (80%) and to a lesser extent in superficial bladder cancer (42%). We demonstrate that in this type of cancer Fra-1 is regulated via a C-terminal instability signal and C-terminal phosphorylation. We show that manipulation of Fra-1 expression levels in bladder cancer cell lines affects cell morphology, motility and proliferation. The gene coding for AXL tyrosine kinase is directly upregulated by Fra-1 in bladder cancer and in other cell lines. Importantly, our data demonstrate that AXL mediates the effect of Fra-1 on tumour cell motility but not on cell proliferation. We suggest that AXL may represent an attractive therapeutic target in cancers expressing high Fra-1 levels. Oncogene (2012) 31, 1493-1503; doi:10.1038/onc.2011.336; published online 8 August 2011	[Sayan, A. E.; Stanford, R.; Vickery, R.; Kulbicki, K.; Pal, R.; Kriajevska, M.; Mellon, J. K.; Tulchinsky, E.] Univ Leicester, Dept Canc Studies & Mol Med, Leicester, Leics, England; [Sayan, A. E.] Univ Southampton, Sch Med, Cancer Sci Div, Southampton, Hants, England; [Grigorenko, E.] Life Technol Inc, Woburn, MA USA; [Diesch, J.; Dhillon, A. S.] Univ Melbourne, Dept Biochem & Mol Biol, Inst Bio21, Melbourne, Vic, Australia; [Edwards, R.; Greaves, P.] MRC, Toxicol Unit, Leicester, Leics, England; [Jariel-Encontre, I.; Piechaczyk, M.] Univ Montpellier 1 & 2, CNRS, Inst Genet Mol Montpellier, Montpellier, France	University of Leicester; University of Southampton; Thermo Fisher Scientific; University of Melbourne; University of Leicester; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Dhillon, AS (corresponding author), Peter MacCallum Canc Ctr, Growth & Differentiat Program, Div Res, St Andrews Pl E Melbourne, Melbourne, Vic 3002, Australia.	Amardeep.Dhillon@petermac.org; et32@le.ac.uk	SAYAN, A. EMRE/H-7330-2012; Tulchinsky, Eugene/ABD-7070-2021; Diesch, Jeannine/J-8558-2017; PIECHACZYK, Marc/E-7896-2013	SAYAN, A. EMRE/0000-0002-5291-1485; Diesch, Jeannine/0000-0002-4667-3468; PIECHACZYK, Marc/0000-0003-1367-2597; Dhillon, Amardeep/0000-0002-6065-663X; Stanford, Richard/0000-0002-0189-7468	Association for International Cancer Research [07-0083]; National Health and Medical Research Council of Australia; French Ligue Nationale contre le Cancer	Association for International Cancer Research; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); French Ligue Nationale contre le Cancer(Ligue nationale contre le cancer)	This work was supported by the Association for International Cancer Research grant 07-0083 (to ET) and by a grant from the National Health and Medical Research Council of Australia (to AD). MP is supported by an 'Equipe Labelisee' grant from the French Ligue Nationale contre le Cancer	Andersen H, 2005, MOL CELL BIOL, V25, P9138, DOI 10.1128/MCB.25.20.9138-9150.2005; Andersen H, 2002, ONCOGENE, V21, P4843, DOI 10.1038/sj.onc.1205590; Basbous J, 2007, MOL CELL BIOL, V27, P3936, DOI 10.1128/MCB.01776-06; Belguise K, 2005, ONCOGENE, V24, P1434, DOI 10.1038/sj.onc.1208312; BELLOSTA P, 1995, MOL CELL BIOL, V15, P614; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; Burch PM, 2004, MOL CELL BIOL, V24, P4696, DOI 10.1128/MCB.24.11.4696-4709.2004; Casalino L, 2003, MOL CELL BIOL, V23, P4401, DOI 10.1128/MCB.23.12.4401-4415.2003; Casalino L, 2007, EMBO J, V26, P1878, DOI 10.1038/sj.emboj.7601617; Chiappetta G, 2000, CLIN CANCER RES, V6, P4300; Chiappetta G, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-17; Debinski W, 2005, MOL CANCER RES, V3, P237; Dixon James M, 2009, Biotechniques, V46, pii, DOI 10.2144/000112746; Doehn U, 2009, MOL CELL, V35, P511, DOI 10.1016/j.molcel.2009.08.002; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Hafizi S, 2006, CYTOKINE GROWTH F R, V17, P295, DOI 10.1016/j.cytogfr.2006.04.004; Heiring C, 2004, J BIOL CHEM, V279, P6952, DOI 10.1074/jbc.M311750200; Holland SJ, 2010, CANCER RES, V70, P1544, DOI 10.1158/0008-5472.CAN-09-2997; Hu CY, 2001, CLIN CANCER RES, V7, P2213; Hutterer M, 2008, CLIN CANCER RES, V14, P130, DOI 10.1158/1078-0432.CCR-07-0862; Kakumoto K, 2006, P NATL ACAD SCI USA, V103, P5490, DOI 10.1073/pnas.0601222103; Knowles MA, 2008, INT J CLIN ONCOL, V13, P287, DOI 10.1007/s10147-008-0812-0; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Linger RMA, 2008, ADV CANCER RES, V100, P35, DOI 10.1016/S0065-230X(08)00002-X; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; McHugh LA, 2009, INT J ONCOL, V34, P1155, DOI 10.3892/ijo_00000244; Milde-Langosch K, 2005, EUR J CANCER, V41, P2449, DOI 10.1016/j.ejca.2005.08.008; Mitra AP, 2009, ANNU REV PATHOL-MECH, V4, P251, DOI 10.1146/annurev.pathol.4.110807.092230; Murphy LO, 2004, MOL CELL BIOL, V24, P144, DOI 10.1128/MCB.24.1.144-153.2004; Ozanne BW, 2006, CURR OPIN GENET DEV, V16, P65, DOI 10.1016/j.gde.2005.12.012; Pollock CB, 2005, CANCER RES, V65, P1244, DOI 10.1158/0008-5472.CAN-04-1911; Ramos-Nino ME, 2003, CANCER RES, V63, P3539; Rankin EB, 2010, CANCER RES, V70, P7570, DOI 10.1158/0008-5472.CAN-10-1267; Sainaghi PP, 2005, J CELL PHYSIOL, V204, P36, DOI 10.1002/jcp.20265; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shieh YS, 2005, NEOPLASIA, V7, P1058, DOI 10.1593/neo.05640; Shin S, 2010, MOL CELL, V38, P114, DOI 10.1016/j.molcel.2010.02.020; Verde P, 2007, CELL CYCLE, V6, P2633, DOI 10.4161/cc.6.21.4850; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; Vial E, 2003, J CELL SCI, V116, P4957, DOI 10.1242/jcs.00812; Vikhanskaya F, 2007, NAT CELL BIOL, V9, P698, DOI 10.1038/ncb1598; Yeh CY, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-139; Young MR, 2006, GENE, V379, P1, DOI 10.1016/j.gene.2006.05.001; Zhang WH, 2005, AM J CLIN PATHOL, V124, P11, DOI 10.1309/T1H2Y2CHWY7PD2BN; Zhang YX, 2008, CANCER RES, V68, P1905, DOI 10.1158/0008-5472.CAN-07-2661	45	68	70	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	12					1493	1503		10.1038/onc.2011.336	http://dx.doi.org/10.1038/onc.2011.336			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916VT	21822309				2022-12-17	WOS:000302132000003
J	Badgwell, DB; Lu, Z; Le, K; Gao, F; Yang, M; Suh, GK; Bao, JJ; Das, P; Andreeff, M; Chen, W; Yu, Y; Ahmed, AA; Liao, WSL; Bast, RC				Badgwell, D. B.; Lu, Z.; Le, K.; Gao, F.; Yang, M.; Suh, G. K.; Bao, J-J; Das, P.; Andreeff, M.; Chen, W.; Yu, Y.; Ahmed, A. A.; Liao, W. S-L; Bast, R. C., Jr.			The tumor-suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK/Rho signaling pathways	ONCOGENE			English	Article						tumor-suppressor gene ARHI; migration suppression; Stat3; RhoA GTPase; cytoskeleton	EPIDERMAL-GROWTH-FACTOR; FOCAL ADHESION KINASE; TYROSINE PHOSPHORYLATION; RHO-GTPASES; G-PROTEIN; BREAST; ACTIVATION; FAK; LOCALIZATION; FIBROBLASTS	Ovarian cancers migrate and metastasize over the surface of the peritoneal cavity. Consequently, dysregulation of mechanisms that limit cell migration may be particularly important in the pathogenesis of the disease. ARHI is an imprinted tumor-suppressor gene that is downregulated in >60% of ovarian cancers, and its loss is associated with decreased progression-free survival. ARHI encodes a 26-kDa GTPase with homology to Ras. In contrast to Ras, ARHI inhibits cell growth, but whether it also regulates cell motility has not been studied previously. Here we report that re-expression of ARHI decreases the motility of IL-6-and epidermal growth factor (EGF)-stimulated SKOv3 and Hey ovarian cancer cells, inhibiting both chemotaxis and haptotaxis. ARHI binds to and sequesters Stat3 in the cytoplasm, preventing its translocation to the nucleus and localization in focal adhesion complexes. Stat3 siRNA or the JAK2 inhibitor AG490 produced similar inhibition of motility. However, the combination of ARHI expression with Stat3 knockdown or inhibition produced greatest inhibition in ovarian cancer cell migration, consistent with Stat3-dependent and Stat3-independent mechanisms. Consistent with two distinct signaling pathways, knockdown of Stat3 selectively inhibited IL-6-stimulated migration, whereas knockdown of focal adhesion kinase (FAK) preferentially inhibited EGF-stimulated migration. In EGF-stimulated ovarian cancer cells, re-expression of ARHI inhibited FAK(Y397) and Src(Y416) phosphorylation, disrupted focal adhesions, and blocked FAK-mediated RhoA signaling, resulting in decreased levels of GTP-RhoA. Re-expression of ARHI also disrupted the formation of actin stress fibers in a FAK- and RhoA-dependent manner. Thus, ARHI has a critical and previously uncharacterized role in the regulation of ovarian cancer cell migration, exerting inhibitory effects on two distinct signaling pathways. Oncogene (2012) 31, 68-79; doi: 10.1038/onc.2011.213; published online 6 June 2011	[Badgwell, D. B.; Lu, Z.; Le, K.; Gao, F.; Yang, M.; Suh, G. K.; Bao, J-J; Das, P.; Chen, W.; Yu, Y.; Ahmed, A. A.; Liao, W. S-L; Bast, R. C., Jr.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Andreeff, M.] Univ Texas MD Anderson Canc Ctr, Dept Blood & Marrow Transplantat, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Bast, RC (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, 1515 Holcombe Blvd,Box 355, Houston, TX 77030 USA.	rbast@mdanderson.org	Lu, Zhen/E-5221-2015; Bast, Robert C/E-6585-2011	Bast, Robert C/0000-0003-4621-8462	NCI from the National Institutes of Health [P01 CA064602, 1RO1 CA135354-01]; MD Anderson SPORE in Ovarian Cancer [5P50 CA83639]; CCSG shared resources [CA 5 P30 CA016672]; Ovarian Cancer Research Fund; Cancer Research UK Clinician Scientist fellowship; MD Anderson Cancer Center CCSG NCI [P30 CA16672]; MRC [G0902418] Funding Source: UKRI; Medical Research Council [G0902418] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [P01CA064602, P30CA016672, P50CA083639, R01CA135354, T32CA009666] Funding Source: NIH RePORTER	NCI from the National Institutes of Health; MD Anderson SPORE in Ovarian Cancer; CCSG shared resources; Ovarian Cancer Research Fund; Cancer Research UK Clinician Scientist fellowship(Cancer Research UK); MD Anderson Cancer Center CCSG NCI; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by Grants NCI P01 CA064602 and 1RO1 CA135354-01 from the National Institutes of Health. We also acknowledge the support of the MD Anderson SPORE in Ovarian Cancer 5P50 CA83639 and the CCSG shared resources funded, in part, by CA 5 P30 CA016672. Support was also provided by the Ovarian Cancer Research Fund through a Program Project Award. DBB was supported by an Excellence Award from the Ovarian Cancer Research Fund. AAA was supported by a Cancer Research UK Clinician Scientist fellowship. We thank Jodie Polan for excellent technical support with confocal microscopy and Jared Burks from the Flow Cytometry and Cell Imaging core laboratory for the live-cell time-lapse microscopy partially supported by the MD Anderson Cancer Center CCSG NCI P30 CA16672.	Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644; Bongard M, 2005, VISUAL GUIDE; Carragher NO, 2004, TRENDS CELL BIOL, V14, P241, DOI 10.1016/j.tcb.2004.03.011; Cheng GZ, 2008, J BIOL CHEM, V283, P14665, DOI 10.1074/jbc.M707429200; Chikumi H, 2002, J BIOL CHEM, V277, P12463, DOI 10.1074/jbc.M108504200; Colomiere M, 2009, INT J BIOCHEM CELL B, V41, P1034, DOI 10.1016/j.biocel.2008.09.018; Debidda M, 2005, J BIOL CHEM, V280, P17275, DOI 10.1074/jbc.M413187200; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Feng WW, 2008, CANCER-AM CANCER SOC, V112, P1489, DOI 10.1002/cncr.23323; Ferreira T, 2011, IMAGEJ USER GUIDE, P144; Forcet C, 2005, HUM MOL GENET, V14, P1283, DOI 10.1093/hmg/ddi139; Geiger B, 2001, CURR OPIN CELL BIOL, V13, P584, DOI 10.1016/S0955-0674(00)00255-6; Gough DJ, 2009, SCIENCE, V324, P1713, DOI 10.1126/science.1171721; Huang M, 2000, GYNECOL ONCOL, V79, P67, DOI 10.1006/gyno.2000.5931; Jang ACC, 2007, J MAMMARY GLAND BIOL, V12, P103, DOI 10.1007/s10911-007-9042-8; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Kaibuchi K, 1999, CURR OPIN CELL BIOL, V11, P591, DOI 10.1016/S0955-0674(99)00014-9; Kakinuma N, 2008, J CELL BIOL, V181, P537, DOI 10.1083/jcb.200707022; Katabuchi Hidetaka, 2003, Medical Electron Microscopy, V36, P74; Kurokawa K, 2005, BIOCHEM SOC T, V33, P631, DOI 10.1042/BST0330631; LIDOR YJ, 1993, EXP CELL RES, V207, P332, DOI 10.1006/excr.1993.1200; Lim Y, 2008, J CELL BIOL, V180, P187, DOI 10.1083/jcb.200708194; LIOTTA LA, 1987, ANTI-CANCER DRUG DES, V2, P195; Long WW, 2010, MOL CELL, V37, P321, DOI 10.1016/j.molcel.2010.01.004; Lu Z, 2008, J CLIN INVEST, V118, P3917, DOI 10.1172/JCI35512; Luo RZ, 2003, ONCOGENE, V22, P2897, DOI 10.1038/sj.onc.1206380; Marcoux N, 2005, CELL SIGNAL, V17, P1449, DOI 10.1016/j.cellsig.2005.03.001; MARTINEZ-MAZA O, 1991, In Vivo (Attiki), V5, P583; Naora H, 2005, NAT REV CANCER, V5, P355, DOI 10.1038/nrc1611; Nishimoto A, 2005, CANCER RES, V65, P6701, DOI 10.1158/0008-5472.CAN-05-0130; Okamura H, 2005, INT REV CYTOL, V242, P1; Orr F W, 2001, Surg Oncol Clin N Am, V10, P357; Orr FW, 2000, J PATHOL, V190, P310, DOI 10.1002/(SICI)1096-9896(200002)190:3<310::AID-PATH525>3.0.CO;2-P; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Raftopoulou M, 2004, SCIENCE, V303, P1179, DOI 10.1126/science.1092089; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Roger L, 2006, BIOL CELL, V98, P141, DOI 10.1042/BC20050058; Romer LH, 2006, CIRC RES, V98, P606, DOI 10.1161/01.RES.0000207408.31270.db; Rosen DG, 2004, CLIN CANCER RES, V10, P6559, DOI 10.1158/1078-0432.CCR-04-0698; RUSTIN GJS, 1993, ANN ONCOL, V4, P71; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; Schlaepfer DD, 2004, CURR OPIN GENET DEV, V14, P92, DOI 10.1016/j.gde.2003.12.002; Silver DL, 2004, CANCER RES, V64, P3550, DOI 10.1158/0008-5472.CAN-03-3959; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Tomar A, 2009, CURR OPIN CELL BIOL, V21, P676, DOI 10.1016/j.ceb.2009.05.006; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Vij N, 2008, MOL VIS, V14, P1020; Yamashita S, 2002, DEV CELL, V2, P363, DOI 10.1016/S1534-5807(02)00126-0; Yu YH, 1999, P NATL ACAD SCI USA, V96, P214, DOI 10.1073/pnas.96.1.214; Yu YH, 2006, METHOD ENZYMOL, V407, P455, DOI 10.1016/S0076-6879(05)07037-0; Zhai JB, 2003, J BIOL CHEM, V278, P24865, DOI 10.1074/jbc.M302381200; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	52	68	74	0	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	1					68	79		10.1038/onc.2011.213	http://dx.doi.org/10.1038/onc.2011.213			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	877JT	21643014	Green Accepted			2022-12-17	WOS:000299176200007
J	Leung, WKC; Ching, AKK; Chan, AWH; Poon, TCW; Mian, H; Wong, AST; To, KF; Wong, N				Leung, W. K. C.; Ching, A. K. K.; Chan, A. W. H.; Poon, T. C. W.; Mian, H.; Wong, A. S. T.; To, K-F; Wong, N.			A novel interplay between oncogenic PFTK1 protein kinase and tumor suppressor TAGLN2 in the control of liver cancer cell motility	ONCOGENE			English	Article						PFTK1; hepatocellular carcinoma; cell migration; TAGLN2; actin	COMPARATIVE-GENOMIC-HYBRIDIZATION; HEPATOCELLULAR-CARCINOMA; ACTIN-BINDING; TRANSGELIN; BREAST; EXPRESSION; PHOSPHORYLATION; IDENTIFICATION; PROGRESSION; GENE	The PFTK1 gene encodes a cdc2-related serine/threonine protein kinase that has been shown to confer cell migratory properties in hepatocellular carcinoma (HCC). However, the prognostic value and biological mechanism by which PFTK1 promotes HCC motility remain largely unknown. Here, we showed from tissue microarray that common upregulations of PFTK1 in primary HCC tumors (n = 133/180) correlated significantly with early age onset (<= 40 years), advance tumor grading and presence of microvascular invasion (P <= 0.05). To understand downstream phosphorylated substrate(s) of PFTK1, phospho-proteins in PFTK1 expressing and knockdown Hep3B cells were profiled by two-dimensional- polyacrylamide gel electrophoresis mass spectrometric analysis. Protein identification of differential spots revealed beta-actin (ACTB) and transgelin2 (TAGLN2) as the two most profound phosphorylated changes affected by PFTK1. We verified the presence of TAGLN2 serine phosphorylation and ACTB tyrosine phosphorylation. Moreover, reduced TAGLN2 and ACTB phosphorylations in PFTK1-suppressed Hep3B corresponded to distinct actin depolymerizations and marked inhibition on cell invasion and motility. Given that TAGLN2 is a tumor suppressor whose function has been ascribed in cancer metastasis, we examined if TAGLN2 is an intermediate substrate in the biological path of PFTK1. We showed in PFTK1-suppressed cells that knockdown of TAGLN2 over-rode the inhibitory effect on cell invasion and motility, and a recovery on actin polymerization was evident. Interestingly, we also found that unphosphorylated TAGLN2 in PFTK1-suppressed cells elicited strong actin-binding ability, a mechanism that possibly halts the actin cytoskeleton dynamics. Site-directed mutagenesis of TAGLN2 suggested that PFTK1 regulates the actin-binding affinity of TAGLN2 through the S83 and S163 residues, which if mutated can significantly affect HCC cell motility. Taken together, our data propose a novel, oncogene-tumor suppressor interplay, where oncogenic PFTK1 confers HCC cell motility through inactivating the actin-binding motile suppressing function of TAGLN2 via phosphorylation. Oncogene (2011) 30, 4464-4475; doi: 10.1038/onc.2011.161; published online 16 May 2011	[Leung, W. K. C.; Ching, A. K. K.; Chan, A. W. H.; Mian, H.; To, K-F; Wong, N.] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Dept Anat & Cellular Pathol, Shatin, Hong Kong, Peoples R China; [Leung, W. K. C.; Ching, A. K. K.; Poon, T. C. W.; Mian, H.; To, K-F; Wong, N.] Chinese Univ Hong Kong, State Key Lab Oncol S China, Shatin, Hong Kong, Peoples R China; [Poon, T. C. W.] Chinese Univ Hong Kong, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China; [Wong, A. S. T.] Univ Hong Kong, Sch Biol Sci, Pokfulam, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; University of Hong Kong	Wong, N (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Li Ka Shing Inst Hlth Sci, Dept Anat & Cellular Pathol, Shatin, Hong Kong, Peoples R China.	natwong@cuhk.edu.hk	Chan, Anthony W.H./N-6719-2016; MIAN, HE/AAK-1900-2021; Chan, Anthony/U-7768-2019; Wong, Alice/AFJ-4595-2022; Chan, Anthony Wing Hung/HGB-4311-2022	Chan, Anthony W.H./0000-0002-1771-163X; Chan, Anthony/0000-0002-1771-163X; Wong, Alice/0000-0002-0676-6475; Chan, Anthony Wing Hung/0000-0002-1771-163X; Leung, Wilson/0000-0002-6196-4984	Hong Kong Research Grants Council [CUHK 4/CRF/08, CUHK 4410/06M]	Hong Kong Research Grants Council(Hong Kong Research Grants Council)	This work was supported by a Collaborative Research Fund from the Hong Kong Research Grants Council (Ref. No.: CUHK 4/CRF/08) and an Earmarked Grant from the Hong Kong Research Grants Council (Ref. No.: CUHK 4410/06M). We thank AH Bai and NL Wong for technical assistance.	Assinder SJ, 2009, INT J BIOCHEM CELL B, V41, P482, DOI 10.1016/j.biocel.2008.02.011; Baek K, 2008, P NATL ACAD SCI USA, V105, P11748, DOI 10.1073/pnas.0805852105; Fu YP, 2000, J APPL PHYSIOL, V89, P1985, DOI 10.1152/jappl.2000.89.5.1985; Garcia JL, 2003, LEUKEMIA, V17, P2016, DOI 10.1038/sj.leu.2403080; Herath NI, 2006, J GASTROEN HEPATOL, V21, P15, DOI 10.1111/j.1440-1746.2005.04043.x; Katoh H, 2007, GASTROENTEROLOGY, V133, P1475, DOI 10.1053/j.gastro.2007.08.038; KIRSCHNER M, 1992, TRENDS BIOCHEM SCI, V17, P281, DOI 10.1016/0968-0004(92)90435-C; Knuutila S, 1998, AM J PATHOL, V152, P1107; Kubota H, 2009, J BIOL CHEM, V284, P35251, DOI 10.1074/jbc.M109.013565; Manes T, 2003, J CELL BIOL, V161, P817, DOI 10.1083/jcb.200212172; Nair RR, 2006, J BIOL CHEM, V281, P26424, DOI 10.1074/jbc.M602703200; Nakao K, 2001, CANCER, V91, P721, DOI 10.1002/1097-0142(20010215)91:4<721::AID-CNCR1057>3.3.CO;2-V; Neumeister P, 2003, MOL BIOL CELL, V14, P2005, DOI 10.1091/mbc.02-07-0102; Pang E, 2002, GENE CHROMOSOME CANC, V33, P150, DOI 10.1002/gcc.1220; Pang EYT, 2007, HEPATOLOGY, V46, P436, DOI 10.1002/hep.21691; PINES J, 1992, Current Opinion in Cell Biology, V4, P144, DOI 10.1016/0955-0674(92)90024-7; Poon RTP, 1999, ANN SURG, V229, P216, DOI 10.1097/00000658-199902000-00009; Poon TCW, 2006, GASTROENTEROLOGY, V131, P1262, DOI 10.1053/j.gastro.2006.08.014; Rush J, 2005, NAT BIOTECHNOL, V23, P94, DOI 10.1038/nbt1046; Shields JM, 2002, J BIOL CHEM, V277, P9790, DOI 10.1074/jbc.M110086200; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; STEWART BW, 2003, WHO WORLD CANC REPOR; Strohmeyer DM, 2004, PROSTATE, V59, P43, DOI 10.1002/pros.20028; Vincent-Salomon A, 2003, BREAST CANCER RES, V5, P101, DOI 10.1186/bcr578; Wong N, 2009, INT J CANCER, V124, P644, DOI 10.1002/ijc.23968; Wulfkuhle JD, 2002, CANCER RES, V62, P6740; Xu SG, 2010, J CANCER RES CLIN, V136, P1545, DOI 10.1007/s00432-010-0812-0; Yang T, 2001, GENE, V267, P165, DOI 10.1016/S0378-1119(01)00391-2; Yang ZM, 2007, MOL ENDOCRINOL, V21, P343, DOI 10.1210/me.2006-0104; Zhao L, 2009, MODERN PATHOL, V22, P786, DOI 10.1038/modpathol.2009.29	30	68	73	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2011	30	44					4464	4475		10.1038/onc.2011.161	http://dx.doi.org/10.1038/onc.2011.161			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	844FN	21577206				2022-12-17	WOS:000296733200002
J	Lara, R; Mauri, FA; Taylor, H; Derua, R; Shia, A; Gray, C; Nicols, A; Shiner, RJ; Schofield, E; Bates, PA; Waelkens, E; Dallman, M; Lamb, J; Zicha, D; Downward, J; Seckl, MJ; Pardo, OE				Lara, R.; Mauri, F. A.; Taylor, H.; Derua, R.; Shia, A.; Gray, C.; Nicols, A.; Shiner, R. J.; Schofield, E.; Bates, P. A.; Waelkens, E.; Dallman, M.; Lamb, J.; Zicha, D.; Downward, J.; Seckl, M. J.; Pardo, O. E.			An siRNA screen identifies RSK1 as a key modulator of lung cancer metastasis	ONCOGENE			English	Article						ribosomal S6 kinase 1; metastasis; lung cancer; siRNA screen; VASP	RIBOSOMAL S6 KINASE; VASODILATOR-STIMULATED PHOSPHOPROTEIN; HUMAN BREAST-CANCER; CELL-MIGRATION; ACTIN CYTOSKELETON; ENA/VASP PROTEINS; PHOSPHORYLATION; EXPRESSION; PROLIFERATION; REGULATORS	We performed a kinome-wide siRNA screen and identified 70 kinases altering cell migration in A549 lung cancer cells. In particular, ribosomal S6 kinase 1 (RSK1) silencing increased, whereas RSK2 and RSK4 downregulation inhibited cell motility. In a secondary collagen-based three-dimensional invasion screen, 38 of our hits cross-validated, including RSK1 and RSK4. In two further lung cancer cell lines, RSK1 but not RSK4 silencing showed identical modulation of cell motility. We therefore selected RSK1 for further investigation. Bioinformatic analysis followed by co-immunoprecipitation-based validation revealed that the actin regulators VASP and Mena interact with RSK1. Moreover, RSK1 phosphorylated VASP on T278, a site regulating its binding to actin. In addition, silencing of RSK1 enhanced the metastatic potential of these cells in vivo using a zebrafish model. Finally, we investigated the relevance of this finding in human lung cancer samples. In isogenically matched tissue, RSK1 was reduced in metastatic versus primary lung cancer lesions. Moreover, patients with RSK1-negative lung tumours showed increased number of metastases. Our results suggest that the findings of our high-throughput in vitro screen can reliably identify relevant clinical targets and as a proof of principle, RSK1 may provide a biomarker for metastasis in lung cancer patients. Oncogene (2011) 30, 3513-3521; doi:10.1038/onc.2011.61; published online 21 March 2011	[Lara, R.; Seckl, M. J.; Pardo, O. E.] Univ London Imperial Coll Sci Technol & Med, Dept Oncol, London W12 0NN, England; [Mauri, F. A.; Shiner, R. J.] Histopathol Imperial Coll London, London, England; [Taylor, H.; Shia, A.; Dallman, M.; Lamb, J.] Univ London Imperial Coll Sci Technol & Med, Fac Nat Sci, Dept Life Sci, Div Cell & Mol Biol, London W12 0NN, England; [Derua, R.; Waelkens, E.] Katholieke Univ Leuven, Lab Prot Fosforylatie Prote, Louvain, Belgium; [Gray, C.; Nicols, A.; Zicha, D.] London Res Inst, Light Microscopy Dept, London, England; [Schofield, E.; Bates, P. A.] London Res Inst, Biomol Modelling Lab, London, England; [Lara, R.; Downward, J.] London Res Inst, Canc Res UK, Signal Transduct Lab, London, England	Imperial College London; Imperial College London; Imperial College London; KU Leuven; Cancer Research UK	Seckl, MJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Oncol, Hammersmith Campus,Cyclotron Bldg,Du Cane Rd, London W12 0NN, England.	m.seckl@imperial.ac.uk; o.pardo@imperial.ac.uk	Bates, Paul A/AAF-8561-2020; Pardo, Oliver/AEM-2071-2022; Lara, Romain/AAE-8108-2020; Zicha, Daniel/H-9310-2016; Downward, Julian/A-3251-2012	Bates, Paul A/0000-0003-0621-0925; Pardo, Oliver/0000-0003-2223-1435; Downward, Julian/0000-0002-2331-4729; Zicha, Daniel/0000-0002-8808-8064; Mauri, Francesco/0000-0003-4818-8500; Dallman, Margaret/0000-0002-9079-3344	Cancer Treatment and Research Trust, Cancer Research UK, Department of Health; Experimental Cancer Medicine Centre; Cancer Research UK [10748] Funding Source: researchfish	Cancer Treatment and Research Trust, Cancer Research UK, Department of Health(Cancer Research UK); Experimental Cancer Medicine Centre; Cancer Research UK(Cancer Research UK)	This work was supported by grants from Cancer Treatment and Research Trust, Cancer Research UK, Department of Health and our Experimental Cancer Medicine Centre.	Anjum R, 2008, NAT REV MOL CELL BIO, V9, P747, DOI 10.1038/nrm2509; Benz PM, 2009, J CELL SCI, V122, P3954, DOI 10.1242/jcs.044537; BLENIS J, 1991, CELL GROWTH DIFFER, V2, P279; Blume C, 2007, J BIOL CHEM, V282, P4601, DOI 10.1074/jbc.M608866200; Cavanna T, 2007, J CELL SCI, V120, P606, DOI 10.1242/jcs.000273; Cho YY, 2007, CANCER RES, V67, P8104, DOI 10.1158/0008-5472.CAN-06-4668; Clark DE, 2005, CANCER RES, V65, P3108; Collins CS, 2006, P NATL ACAD SCI USA, V103, P3775, DOI 10.1073/pnas.0600040103; Dertsiz L, 2005, THORAX, V60, P576, DOI 10.1136/thx.2004.037622; Fox BP, 2009, ONCOGENE, V28, P1706, DOI 10.1038/onc.2009.18; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; Gurzu S, 2008, ROM J MORPHOL EMBRYO, V49, P345; Han G, 2008, ONCOL REP, V20, P929, DOI 10.3892/or_00000093; Herberger B, 2007, CLIN CANCER RES, V13, P4795, DOI 10.1158/1078-0432.CCR-07-0738; Hu LD, 2008, ONCOL REP, V19, P1015; Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087; Ivaska J, 2007, EXP CELL RES, V313, P2050, DOI 10.1016/j.yexcr.2007.03.040; Jonsson PF, 2006, BIOINFORMATICS, V22, P2291, DOI 10.1093/bioinformatics/btl390; Kang SM, 2007, CANCER CELL, V12, P201, DOI 10.1016/j.ccr.2007.08.003; Katso RM, 2006, MOL BIOL CELL, V17, P3729, DOI 10.1091/mbc.E05-11-1083; Krause M, 2003, ANNU REV CELL DEV BI, V19, P541, DOI 10.1146/annurev.cellbio.19.050103.103356; Kwiatkowski AV, 2003, TRENDS CELL BIOL, V13, P386, DOI 10.1016/S0962-8924(03)00130-2; Larreaa MD, 2009, P NATL ACAD SCI USA, V106, P9268, DOI 10.1073/pnas.0805057106; Lee SLC, 2009, P NATL ACAD SCI USA, V106, P19485, DOI 10.1073/pnas.0909228106; Linding R, 2007, CELL, V129, P1415, DOI 10.1016/j.cell.2007.05.052; Marques IJ, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-128; NOBES CD, 1995, BIOCHEM SOC T, V23, P456, DOI 10.1042/bst0230456; Pardo OE, 2001, ONCOGENE, V20, P7658, DOI 10.1038/sj.onc.1204994; Pardo OE, 2006, EMBO J, V25, P3078, DOI 10.1038/sj.emboj.7601198; Philippar U, 2008, DEV CELL, V15, P813, DOI 10.1016/j.devcel.2008.09.003; Simpson KJ, 2008, NAT CELL BIOL, V10, P1027, DOI 10.1038/ncb1762; Smith JA, 2005, CANCER RES, V65, P1027; Swanton C, 2007, CANCER CELL, V11, P498, DOI 10.1016/j.ccr.2007.04.011; Toyoda A, 2009, INT J ONCOL, V34, P53, DOI 10.3892/ijo_00000128; Trichet L, 2008, J CELL BIOL, V181, P19, DOI 10.1083/jcb.200710168; Weiss FU, 2009, GASTROENTEROLOGY, V137, P2136, DOI 10.1053/j.gastro.2009.08.065; Woo MS, 2004, MOL CELL BIOL, V24, P3025, DOI 10.1128/MCB.24.7.3025-3035.2004; Zimmermann J, 2002, BIOCHEMISTRY-US, V41, P11143, DOI 10.1021/bi020379x	38	68	69	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2011	30	32					3513	3521		10.1038/onc.2011.61	http://dx.doi.org/10.1038/onc.2011.61			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806CR	21423205				2022-12-17	WOS:000293782300004
J	Donati, G; Bertoni, S; Brighenti, E; Vici, M; Trere, D; Volarevic, S; Montanaro, L; Derenzini, M				Donati, G.; Bertoni, S.; Brighenti, E.; Vici, M.; Trere, D.; Volarevic, S.; Montanaro, L.; Derenzini, M.			The balance between rRNA and ribosomal protein synthesis up- and downregulates the tumour suppressor p53 in mammalian cells	ONCOGENE			English	Article						p53 expression; rRNA transcription; ribosomal proteins; nucleolus; mammalian cells	TRANSCRIPTION FACTOR UBF; POLYMERASE-I TRANSCRIPTION; DEPENDENT REGULATION; GENE-TRANSCRIPTION; BIOGENESIS; MDM2; ACTIVATION; INHIBITION; PATHWAY; CANCER	Data on the relationship between ribosome biogenesis and p53 function indicate that the tumour suppressor can be activated by either nucleolar disruption or ribosomal protein defects. However, there is increasing evidence that the induction of p53 does not always require these severe cellular changes, and data are still lacking on a possible role of ribosome biogenesis in the downregulation of p53. Here, we studied the effect of the up-and downregulation of the rRNA transcription rate on p53 induction in mammalian cells. We found that a downregulation of rRNA synthesis, induced by silencing the POLR1A gene coding for the RNA polymerase I catalytic subunit, stabilised p53 without altering the nucleolar integrity in human cancer cells. p53 stabilisation was due to the inactivation of the MDM2-mediated p53 degradation by the binding of ribosomal proteins no longer used for ribosome building. p53 stabilisation did not occur when rRNA synthesis downregulation was associated with a contemporary reduction of protein synthesis. Furthermore, we demonstrated that in three different experimental models characterised by an upregulation of rRNA synthesis, cancer cells treated with insulin or exposed to the insulin-like growth factor 1, rat liver stimulated by cortisol and regenerating rat liver after partial hepatectomy, the p53 protein level was reduced due to a lowered ribosomal protein availability for MDM2 binding. It is worth noting that the upregulation of rRNA synthesis was responsible for a decreased p53-mediated response to cytotoxic stresses. These findings demonstrated that the balance between rRNA and ribosomal protein synthesis controls the function of p53 in mammalian cells, that p53 can be induced without the occurrence of severe changes of the cellular components controlling ribosome biogenesis, and that conditions characterised by an upregulated rRNA synthesis are associated with a reduced p53 response. Oncogene (2011) 30, 3274-3288; doi:10.1038/onc.2011.48; published online 14 March 2011	[Derenzini, M.] Univ Bologna, Dipartimento Clin Sci Radiol & Isocitopatol, I-40138 Bologna, Italy; [Donati, G.; Bertoni, S.; Brighenti, E.; Vici, M.; Trere, D.; Montanaro, L.] Univ Bologna, Dipartimento Patol Sperimentale, I-40138 Bologna, Italy; [Brighenti, E.] Univ Bologna, Ctr Interdipartimentale Ric Canc G Prodi, I-40138 Bologna, Italy; [Volarevic, S.] Univ Rijeka, Sch Med, Dept Mol Med & Biotechnol, Rijeka, Croatia	University of Bologna; University of Bologna; University of Bologna; University of Rijeka	Derenzini, M (corresponding author), Univ Bologna, Dipartimento Clin Sci Radiol & Isocitopatol, Via Massarenti 9, I-40138 Bologna, Italy.	massimo.derenzini@unibo.it	Montanaro, Lorenzo/I-4236-2019; Volarevic, Sinisa/O-4349-2018; Trere', Davide/AAC-4725-2021	Montanaro, Lorenzo/0000-0001-9776-9518; Volarevic, Sinisa/0000-0003-4893-389X; Trere', Davide/0000-0003-1127-1052; Donati, Giulio/0000-0003-0875-9233	Roberto and Cornelia Pallotti's Legacy for Cancer Research; Vanini-Cavagnino Grant; Italian Ministry of Education, University and Research (MIUR)	Roberto and Cornelia Pallotti's Legacy for Cancer Research; Vanini-Cavagnino Grant; Italian Ministry of Education, University and Research (MIUR)(Ministry of Education, Universities and Research (MIUR))	This work was supported by the Roberto and Cornelia Pallotti's Legacy for Cancer Research, the Vanini-Cavagnino Grant and the Italian Ministry of Education, University and Research (MIUR: grants for orientated fundamental research). We thank Professor U Scheer for the generous gift of the anti-ribosomal protein S14 antibody. We are indebted with Dr Maurizio Brigotti for performing polysomal fraction analysis.	Abmayr S.M., 2006, CURR PROTOC MOL BIOL; Albrecht JH, 1997, HEPATOLOGY, V25, P557, DOI 10.1002/hep.510250311; Arabi A, 2005, NAT CELL BIOL, V7, P303, DOI 10.1038/ncb1225; Barkic M, 2009, MOL CELL BIOL, V29, P2489, DOI 10.1128/MCB.01588-08; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bensaad K, 2007, TRENDS CELL BIOL, V17, P286, DOI 10.1016/j.tcb.2007.04.004; Bernardi R, 2004, NAT CELL BIOL, V6, P665, DOI 10.1038/ncb1147; Bhat KP, 2004, EMBO J, V23, P2402, DOI 10.1038/sj.emboj.7600247; Bilanges B, 2007, MOL CELL BIOL, V27, P5746, DOI 10.1128/MCB.02136-06; Boisvert FM, 2000, J CELL BIOL, V148, P283, DOI 10.1083/jcb.148.2.283; Burger K, 2010, J BIOL CHEM, V285, P12416, DOI 10.1074/jbc.M109.074211; Burns TF, 1999, J CELL PHYSIOL, V181, P231, DOI 10.1002/(SICI)1097-4652(199911)181:2<231::AID-JCP5>3.0.CO;2-L; Caldarola S, 2004, J BIOL CHEM, V279, P13522, DOI 10.1074/jbc.M310574200; Cannata D, 2010, MT SINAI J MED, V77, P197, DOI 10.1002/msj.20167; Chan PK, 1996, CANCER LETT, V100, P191, DOI 10.1016/0304-3835(95)04100-1; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Deisenroth C, 2010, ONCOGENE, V29, P4253, DOI 10.1038/onc.2010.189; DERENZINI M, 1981, J ULTRA MOL STRUCT R, V75, P229, DOI 10.1016/S0022-5320(81)80138-4; DERENZINI M, 1978, J ULTRA MOL STRUCT R, V62, P213, DOI 10.1016/S0022-5320(78)80018-5; DONATI G, 2010, SELECTIVE INHI UNPUB; Frasca Francesco, 2008, Archives of Physiology and Biochemistry, V114, P23, DOI [10.1080/13813450801969715, 10.1080/13813450801969715 ]; Fumagalli S, 2009, NAT CELL BIOL, V11, P501, DOI 10.1038/ncb1858; Gera JF, 2004, J BIOL CHEM, V279, P2737, DOI 10.1074/jbc.M309999200; GLIBETIC M, 1993, MOL CELL ENDOCRINOL, V94, P243, DOI 10.1016/0303-7207(93)90173-H; GLIBETIC M, 1995, J BIOL CHEM, V270, P4209, DOI 10.1074/jbc.270.9.4209; Gong X, 2007, CANCER RES, V67, P5380, DOI 10.1158/0008-5472.CAN-07-0323; Grandori C, 2005, NAT CELL BIOL, V7, P311, DOI 10.1038/ncb1224; Grewal SS, 2005, NAT CELL BIOL, V7, P295, DOI 10.1038/ncb1223; Hannan KM, 1998, AM J PHYSIOL-CELL PH, V275, pC130, DOI 10.1152/ajpcell.1998.275.1.C130; Hannan KM, 2003, MOL CELL BIOL, V23, P8862, DOI 10.1128/MCB.23.23.8862-8877.2003; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Higgins GM, 1931, ARCH PATHOL, V12, P186; Holzel M, 2005, J CELL BIOL, V170, P367, DOI 10.1083/jcb.200501141; Jin A, 2004, MOL CELL BIOL, V24, P7669, DOI 10.1128/MCB.24.17.7669-7680.2004; Khutornenko AA, 2010, P NATL ACAD SCI USA, V107, P12828, DOI 10.1073/pnas.0910885107; Kruger T, 2007, J CELL BIOL, V177, P573, DOI 10.1083/jcb.200612048; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Liu Y, 2009, CELL STEM CELL, V4, P37, DOI 10.1016/j.stem.2008.11.006; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; MAHAJAN PB, 1994, INT J IMMUNOPHARMACO, V16, P711, DOI 10.1016/0192-0561(94)90091-4; Meletis K, 2006, DEVELOPMENT, V133, P363, DOI 10.1242/dev.02208; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Montanaro L, 2007, CELL PROLIFERAT, V40, P532, DOI 10.1111/j.1365-2184.2007.00448.x; Montanaro L, 2008, AM J PATHOL, V173, P301, DOI 10.2353/ajpath.2008.070752; Murayama A, 2008, CELL, V133, P627, DOI 10.1016/j.cell.2008.03.030; NADAL C, 1995, LIVER, V15, P63; OMAHONY DJ, 1992, J BIOL CHEM, V267, P35; Panic L, 2007, CELL CYCLE, V6, P20, DOI 10.4161/cc.6.1.3666; Pestov DG, 2001, MOL CELL BIOL, V21, P4246, DOI 10.1128/MCB.21.13.4246-4255.2001; Renehan Andrew G., 2008, Archives of Physiology and Biochemistry, V114, P71, DOI [10.1080/13813450801954303, 10.1080/13813450801954303 ]; Renehan AG, 2006, TRENDS ENDOCRIN MET, V17, P328, DOI 10.1016/j.tem.2006.08.006; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; Sax JK, 2003, CELL DEATH DIFFER, V10, P413, DOI 10.1038/sj.cdd.4401227; SIRRI V, 1995, J HISTOCHEM CYTOCHEM, V43, P887, DOI 10.1177/43.9.7642962; Sulic S, 2005, GENE DEV, V19, P3070, DOI 10.1101/gad.359305; THOMPSON NL, 1986, CANCER RES, V46, P3111; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Vousden KH, 2009, NAT REV CANCER, V9, P691, DOI 10.1038/nrc2715; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wu A, 2005, J BIOL CHEM, V280, P2863, DOI 10.1074/jbc.M406138200; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003	67	68	71	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2011	30	29					3274	3288		10.1038/onc.2011.48	http://dx.doi.org/10.1038/onc.2011.48			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	795VW	21399665				2022-12-17	WOS:000293006800006
J	Ban, J; Jug, G; Mestdagh, P; Schwentner, R; Kauer, M; Aryee, DNT; Schaefer, KL; Nakatani, F; Scotlandi, K; Reiter, M; Strunk, D; Speleman, F; Vandesompele, J; Kovar, H				Ban, J.; Jug, G.; Mestdagh, P.; Schwentner, R.; Kauer, M.; Aryee, D. N. T.; Schaefer, K-L; Nakatani, F.; Scotlandi, K.; Reiter, M.; Strunk, D.; Speleman, F.; Vandesompele, J.; Kovar, H.			Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewing's sarcoma	ONCOGENE			English	Article						Ewing's sarcoma; microRNA; mir-145; EWS-FLI1	CELL-GROWTH; MIR-145; EWS-FLI1; EXPRESSION; P53; DIFFERENTIATION	EWS-FLI1 is a chromosome translocation-derived chimeric transcription factor that has a central and rate-limiting role in the pathogenesis of Ewing's sarcoma. Although the EWS-FLI1 transcriptomic signature has been extensively characterized on the mRNA level, information on its impact on non-coding RNA expression is lacking. We have performed a genome-wide analysis of microRNAs affected by RNAi-mediated silencing of EWS-FLI1 in Ewing's sarcoma cell lines, and differentially expressed between primary Ewing's sarcoma and mesenchymal progenitor cells. Here, we report on the identification of hsa-mir-145 as the top EWS-FLI1-repressed microRNA. Upon knockdown of EWS-FLI1, hsa-mir-145 expression dramatically increases in all Ewing's sarcoma cell lines tested. Vice versa, ectopic expression of the microRNA in Ewing's sarcoma cell lines strongly reduced EWS-FLI1 protein, whereas transfection of an anti-mir to hsa-mir-145 increased the EWS-FLI1 levels. Reporter gene assays revealed that this modulation of EWS-FLI1 protein was mediated by the microRNA targeting the FLI1 3'-untranslated region. Mutual regulations of EWS-FLI1 and hsa-mir-145 were mirrored by an inverse correlation between their expression levels in four of the Ewing's sarcoma cell lines tested. Consistent with the role of EWS-FLI1 in Ewing's sarcoma growth regulation, forced hsa-mir-145 expression halted Ewing's sarcoma cell line growth. These results identify feedback regulation between EWS-FLI1 and hsa-mir-145 as an important component of the EWS-FLI1-mediated Ewing's sarcomagenesis that may open a new avenue to future microRNA-mediated therapy of this devastating malignant disease. Oncogene (2011) 30, 2173-2180; doi:10.1038/onc.2010.581; published online 10 January 2011	[Ban, J.; Jug, G.; Schwentner, R.; Kauer, M.; Aryee, D. N. T.; Reiter, M.; Kovar, H.] St Anna Childrens Hosp, Childrens Canc Res Inst, St Anna Kinderkrebsforschung, A-1090 Vienna, Austria; [Mestdagh, P.; Speleman, F.; Vandesompele, J.] Univ Med Ctr, Ctr Med Genet, Ghent, Belgium; [Schaefer, K-L] Univ Dusseldorf, Inst Pathol, Fac Med, Dusseldorf, Germany; [Nakatani, F.; Scotlandi, K.] CRS Dev Biomol Therapies, Expt Oncol Lab, Ist Ortoped Rizzoli, Bologna, Italy; [Strunk, D.] Med Univ, Div Hematol, Graz, Austria	Saint Anna Children's Hospital; Ghent University; Heinrich Heine University Dusseldorf; IRCCS Istituto Ortopedico Rizzoli; Medical University of Graz	Kovar, H (corresponding author), St Anna Childrens Hosp, Childrens Canc Res Inst, St Anna Kinderkrebsforschung, Zimmermannpl 10, A-1090 Vienna, Austria.	heinrich.kovar@ccri.at	speleman, frank/AAR-5184-2020; Strunk, Dirk/V-4598-2017; Scotlandi, Katia/J-9009-2016; Vandesompele, Jo/W-3411-2018	speleman, frank/0000-0002-6628-8559; Strunk, Dirk/0000-0003-1810-867X; Scotlandi, Katia/0000-0001-6114-9499; Vandesompele, Jo/0000-0001-6274-0184; Schwentner, Raphaela/0000-0001-6839-0322; Mestdagh, Pieter/0000-0001-7821-9684; Kovar, Heinrich/0000-0001-6873-9109	Austrian Research Fund FWF [P20665-B12]; European Commission [LSHC-CT-2006-037260]; Ghent University [BOF 01D31406]	Austrian Research Fund FWF(Austrian Science Fund (FWF)); European Commission(European CommissionEuropean Commission Joint Research Centre); Ghent University(Ghent University)	We thank Aykut Uren for help in the analysis of the PDGF/mir-145 axis and Stephan Baldus for supplying primary tumor tissue, and Karin Muhlbacher for technical assistance. This study was supported by grants from the Austrian Research Fund FWF (P20665-B12) and the European Commission (EET-pipeline, LSHC-CT-2006-037260). PM is supported by the Ghent University research fund (BOF 01D31406).	Aryee DNT, 2010, CANCER RES, V70, P4015, DOI 10.1158/0008-5472.CAN-09-4333; Bachmaier R, 2009, ONCOGENE, V28, P1280, DOI 10.1038/onc.2008.484; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Ban J, 2008, CANCER RES, V68, P7100, DOI 10.1158/0008-5472.CAN-07-6145; Breitling R, 2004, FEBS LETT, V573, P83, DOI 10.1016/j.febslet.2004.07.055; Chiyomaru T, 2010, BRIT J CANCER, V102, P883, DOI 10.1038/sj.bjc.6605570; Cordes KR, 2009, NATURE, V460, P705, DOI 10.1038/nature08195; Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gregersen LH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008836; Hancock JD, 2008, CELL CYCLE, V7, P250, DOI 10.4161/cc.7.2.5229; Kano M, 2010, INT J CANC; Kauer M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005415; KOVAR H, 1993, ONCOGENE, V8, P2683; Kovar H, 2010, GENOME MED, V2, DOI 10.1186/gm129; Larsson E, 2009, GENOME MED, V1, DOI 10.1186/gm108; Le Deley MC, 2010, J CLIN ONCOL, V28, P1982, DOI 10.1200/JCO.2009.23.3585; LESSNICK SL, 1995, ONCOGENE, V10, P423; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Mar JC, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-110; Mestdagh P, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn725; Nozawa S, 2005, J BIOL CHEM, V280, P27544, DOI 10.1074/jbc.M411626200; Quintavalle M, 2010, J CELL BIOL, V189, P13, DOI 10.1083/jcb.200912096; Rao YL, 2008, STAT APPL GENET MOL, V7, DOI 10.2202/1544-6115.1287; Riggi N, 2005, CANCER RES, V65, P11459, DOI 10.1158/0008-5472.CAN-05-1696; Riggi N, 2008, CANCER RES, V68, P2176, DOI 10.1158/0008-5472.CAN-07-1761; Riggi N, 2010, GENE DEV, V24, P916, DOI 10.1101/gad.1899710; Sachdeva M, 2010, CANCER RES, V70, P378, DOI 10.1158/0008-5472.CAN-09-2021; Sachdeva M, 2009, P NATL ACAD SCI USA, V106, P3207, DOI 10.1073/pnas.0808042106; Sartipy P, 2009, IDRUGS, V12, P492; Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199; Taft RJ, 2010, J PATHOL, V220, P126, DOI 10.1002/path.2638; Tirode F, 2007, CANCER CELL, V11, P421, DOI 10.1016/j.ccr.2007.02.027; Torchia EC, 2003, CANCER RES, V63, P3464; Uren A, 2003, ONCOGENE, V22, P2334, DOI 10.1038/sj.onc.1206330; Wang SH, 2009, INT J ONCOL, V34, P1461, DOI 10.3892/ijo_00000275; Xu N, 2009, CELL, V137, P647, DOI 10.1016/j.cell.2009.02.038; Zeng L, 2009, P NATL ACAD SCI USA, V106, P17793, DOI 10.1073/pnas.0903693106	38	68	72	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	18					2173	2180		10.1038/onc.2010.581	http://dx.doi.org/10.1038/onc.2010.581			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	759ML	21217773	Green Accepted			2022-12-17	WOS:000290249600008
J	Feng, M; Li, Z; Aau, M; Wong, CH; Yang, X; Yu, Q				Feng, M.; Li, Z.; Aau, M.; Wong, C. H.; Yang, X.; Yu, Q.			Myc/miR-378/TOB2/cyclin D1 functional module regulates oncogenic transformation	ONCOGENE			English	Article						Myc; miR-378; TOB2; cyclin D1	C-MYC; MESENCHYMAL TRANSITION; CELL-PROLIFERATION; CANCER METASTASIS; MIR-200 FAMILY; E-CADHERIN; MICRORNA; TARGET; RAS; APOPTOSIS	The c-Myc transcription factor activates a cascade of downstream targets to form a complex transcriptional program that ultimately leads to cellular transformation. Although a large number of protein-encoding genes as well as non-coding RNAs were identified as Myc targets, only a few have been validated to be functionally important for c-Myc-driven transformation. Here, we identify a microRNA (miRNA), miR-378, as a novel target of the c-Myc oncoprotein that is able to cooperate with activated Ras or HER2 to promote cellular transformation. Mechanistically, miR-378 achieves this oncogenic effect, at least in part, by targeting and inhibiting the anti-proliferative BTG family member, TOB2, which is further elucidated as a candidate tumor suppressor to transcriptionally repress proto-oncogene cyclin D1. Therefore, our study identifies miR-378-TOB2-cyclin D1 as a functional module to mediate the cross talk between Myc and Ras signaling in cellular transformation. Oncogene (2011) 30, 2242-2251; doi:10.1038/onc.2010.602; published online 17 January 2011	[Feng, M.; Li, Z.; Aau, M.; Wong, C. H.; Yang, X.; Yu, Q.] ASTAR, Dept Canc Biol & Pharmacol, Genome Inst Singapore, Biopolis 138672, Singapore; [Yu, Q.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore 117595, Singapore; [Yu, Q.] DUKE NUS Med Sch, Dept Canc & Stem Cell Biol, Singapore, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); National University of Singapore; National University of Singapore	Yu, Q (corresponding author), ASTAR, Dept Canc Biol & Pharmacol, Genome Inst Singapore, 60 Biopolis St, Biopolis 138672, Singapore.	yuq@gis.a-star.edu.sg	Yang, Xiaojing/G-9201-2012	Yu, Qiang/0000-0003-2132-8278	Agency for Science, Technology & Research (A*Star) of Singapore	Agency for Science, Technology & Research (A*Star) of Singapore(Agency for Science Technology & Research (A*STAR))	We thank Dr William Hahn for the HMLE and HMLER cells. This work was supported by Agency for Science, Technology & Research (A*Star) of Singapore.	Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Cappellen D, 2007, EMBO REP, V8, P70, DOI 10.1038/sj.embor.7400849; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Conzen SD, 2000, MOL CELL BIOL, V20, P6008, DOI 10.1128/MCB.20.16.6008-6018.2000; D'Cruz CM, 2001, NAT MED, V7, P235, DOI 10.1038/84691; Dang CV, 1999, MOL CELL BIOL, V19, P1; Ebert MS, 2007, NAT METHODS, V4, P721, DOI 10.1038/NMETH1079; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Jiang X, 2008, CANCER CELL, V13, P529, DOI 10.1016/j.ccr.2008.04.019; Kendall SD, 2005, CANCER RES, V65, P9824, DOI 10.1158/0008-5472.CAN-05-1543; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Kuttler F, 2001, ONCOGENE, V20, P6084, DOI 10.1038/sj.onc.1204827; Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Oster SK, 2003, ONCOGENE, V22, P1998, DOI 10.1038/sj.onc.1206228; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Shapiro GI, 2006, J CLIN ONCOL, V24, P1770, DOI 10.1200/JCO.2005.03.7689; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; Stacey D, 2002, CURR OPIN GENET DEV, V12, P44, DOI 10.1016/S0959-437X(01)00262-3; Suzuki T, 2002, GENE DEV, V16, P1356, DOI 10.1101/gad.962802; Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107; Valastyan S, 2009, CELL, V137, P1032, DOI 10.1016/j.cell.2009.03.047; Winkler GS, 2010, J CELL PHYSIOL, V222, P66, DOI 10.1002/jcp.21919; Yang XJ, 2009, GENE DEV, V23, P2388, DOI 10.1101/gad.1819009; Yoshida Y, 2003, GENE DEV, V17, P1201, DOI 10.1101/gad.1088003; Zeller KI, 2006, P NATL ACAD SCI USA, V103, P17834, DOI 10.1073/pnas.0604129103	29	68	69	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2011	30	19					2242	2251		10.1038/onc.2010.602	http://dx.doi.org/10.1038/onc.2010.602			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	762XD	21242960				2022-12-17	WOS:000290514600007
J	Pakala, SB; Singh, K; Reddy, SD; Ohshiro, K; Li, DQ; Mishra, L; Kumar, R				Pakala, S. B.; Singh, K.; Reddy, S. D. N.; Ohshiro, K.; Li, D-Q; Mishra, L.; Kumar, R.			TGF-beta 1 signaling targets metastasis-associated protein 1, a new effector in epithelial cells	ONCOGENE			English	Article						TGF-beta 1 signaling; MTA1; FosB; target gene transcription; epithelial-to-mesenchymal transition	BREAST-CANCER; MESENCHYMAL TRANSITIONS; TGF-BETA; TRANSCRIPTIONAL REPRESSION; ESTROGEN-RECEPTOR; MTA1; GENE; PROGRESSION; EXPRESSION; ALPHA	In spite of a large number of transforming growth factor beta 1 (TGF-beta 1)-regulated genes, the nature of its targets with roles in transformation continues to be poorly understood. Here, we discovered that TGF-beta 1 stimulates transcription of metastasis-associated protein 1 (MTA1), a dual master coregulator, in epithelial cells, and that MTA1 status is a determinant of TGF-beta 1-induced epithelial-to-mesenchymal transition (EMT) phenotypes. In addition, we found that MTA1/polymerase II/activator protein-1 (AP-1) co-activator complex interacts with the FosB-gene chromatin and stimulates its transcription, and FosB in turn, utilizes FosB/histone deacetylase 2 complex to repress E-cadherin expression in TGF-beta 1-stimulated mammary epithelial cells. These findings suggest that TGF-beta 1 regulates the components of EMT via stimulating the expression of MTA1, which in turn, induces FosB to repress E-cadherin expression and thus, revealed an inherent function of MTA1 as a target and effector of TGF-beta 1 signaling in epithelial cells. Oncogene (2011) 30, 2230-2241; doi:10.1038/onc.2010.608; published online 24 January 2011	[Pakala, S. B.; Singh, K.; Reddy, S. D. N.; Ohshiro, K.; Li, D-Q; Kumar, R.] George Washington Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20037 USA; [Pakala, S. B.; Singh, K.; Reddy, S. D. N.; Ohshiro, K.; Li, D-Q; Kumar, R.] George Washington Univ, Med Ctr, Inst Coregulator Biol, Washington, DC 20037 USA; [Mishra, L.] Univ Texas MD Anderson Canc Ctr, Dept Gastroenterol Hepatol & Nutr, Houston, TX 77030 USA	George Washington University; George Washington University; University of Texas System; UTMD Anderson Cancer Center	Kumar, R (corresponding author), George Washington Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20037 USA.	bcmrxk@gwumc.edu	sirigiri, divijendra reddy/E-1031-2017; sirigiri, divijendranathareddy/A-9857-2010; Kumar, Rakesh/ABD-1065-2020	sirigiri, divijendra reddy/0000-0003-4657-2285; Kumar, Rakesh/0000-0001-7664-0803; Pakala, Suresh Babu/0000-0002-5679-4837	NIH [CA98823]; NATIONAL CANCER INSTITUTE [P30CA016672, P01CA130821, R01CA098823, R01CA106614] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank Dr Toshio Matsumoto for FosB-promoter constructs and Dr Eric R. Fearon for E-cadherin promoter construct. The work was supported by NIH Grant CA98823 (RK).	Balasenthil S, 2007, CANCER RES, V67, P7132, DOI 10.1158/0008-5472.CAN-07-0750; Bui-Nguyen TM, 2010, ONCOGENE, V29, P1179, DOI 10.1038/onc.2009.404; Condeelis J, 2003, NAT REV CANCER, V3, P921, DOI 10.1038/nrc1231; Dannenmann C, 2008, CANCER BIOL THER, V7, P1462, DOI 10.4161/cbt.7.9.6427; Deckers M, 2006, CANCER RES, V66, P2202, DOI 10.1158/0008-5472.CAN-05-3560; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Gery S, 2005, CLIN CANCER RES, V11, P3184, DOI 10.1158/1078-0432.CCR-04-2625; Gururaj AE, 2006, P NATL ACAD SCI USA, V103, P6670, DOI 10.1073/pnas.0601989103; Hofer MD, 2004, BRIT J CANCER, V90, P455, DOI 10.1038/sj.bjc.6601535; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; Kumar R, 2002, NATURE, V418, P654, DOI 10.1038/nature00889; Kurisaki K, 2003, MOL CELL BIOL, V23, P4494, DOI 10.1128/MCB.23.13.4494-4510.2003; LEE TC, 1994, ONCOGENE, V9, P1047; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; Mahoney MG, 2002, ONCOGENE, V21, P2161, DOI 10.1038/sj.onc.1205277; Manavathi B, 2007, J BIOL CHEM, V282, P1529, DOI 10.1074/jbc.R600029200; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; Michl P, 2006, CELL CYCLE, V5, P132, DOI 10.4161/cc.5.2.2311; Michl P, 2005, CANCER CELL, V7, P521, DOI 10.1016/j.ccr.2005.05.018; Molli PR, 2008, ONCOGENE, V27, P1971, DOI 10.1038/sj.onc.1210839; Ohnishi YN, 2008, MOL BIOL CELL, V19, P4717, DOI 10.1091/mbc.E07-08-0768; Pakala SB, 2010, J BIOL CHEM, V285, P23590, DOI 10.1074/jbc.M110.139469; Peinado H, 2003, J BIOL CHEM, V278, P21113, DOI 10.1074/jbc.M211304200; Radisky DC, 2005, J CELL SCI, V118, P4325, DOI 10.1242/jcs.02552; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tong D, 2007, ONCOL RES, V16, P465, DOI 10.3727/096504007783338322; von Burstin J, 2009, GASTROENTEROLOGY, V137, P361, DOI 10.1053/j.gastro.2009.04.004; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zhang H, 2006, CLIN CANCER RES, V12, P1479, DOI 10.1158/1078-0432.CCR-05-1519	30	68	71	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	19					2230	2241		10.1038/onc.2010.608	http://dx.doi.org/10.1038/onc.2010.608			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	762XD	21258411	Green Accepted			2022-12-17	WOS:000290514600006
J	Montero, JC; Seoane, S; Ocana, A; Pandiella, A				Montero, J. C.; Seoane, S.; Ocana, A.; Pandiella, A.			P-Rex1 participates in Neuregulin-ErbB signal transduction and its expression correlates with patient outcome in breast cancer	ONCOGENE			English	Article						P-Rex; ErbB; tyrosine kinases; breast cancer	NUCLEOTIDE EXCHANGE FACTOR; GROWTH-FACTOR RECEPTOR; BETA-GAMMA-SUBUNITS; HEREGULIN; RAC; METASTASIS; (3,4,5)-TRISPHOSPHATE; TUMORIGENICITY; ACTIVATION; KINASE	The Neuregulins and their receptors, the ErbB/HER subfamily of receptor tyrosine kinases, have critical roles in animal physiology, and their deregulation is frequent in cancer. Here we report the identification of the guanine nucleotide exchange factor, phosphatidylinositol 3,4,5-triphosphate-dependent Rac exchanger 1 (P-Rex1), as a novel mediator in signalling by ErbB/HER receptors. P-Rex1 was formerly described as a phosphoinositide 3-kinase and G beta gamma activated protein that regulates Rac function. We define how ErbB/HER receptors regulate P-Rex1 function, which involves dephosphorylation of inhibitory residues, and phosphorylation of activating residues of P-Rex. The net balance resulting from activation of this phosphorylation/dephosphorylation cycle of P-Rex1 favours Rac activation. Molecular and biological studies indicated that P-Rex1 phosphorylation regulated the proliferation of breast cancer cells, and P-Rex1 knockdown affected their migration or invasiveness, as well as their in vivo tumourigenic potential. Moreover, as we found correlation between high P-Rex1 expression and poor patient outcome in breast cancer, P-Rex1 targeting may be therapeutically relevant in cancer. Oncogene (2011) 30, 1059-1071; doi:10.1038/onc.2010.489; published online 1 November 2010	[Montero, J. C.; Seoane, S.; Pandiella, A.] Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, Salamanca 37007, Spain; [Ocana, A.] Complejo Hosp Univ Albacete, Med Oncol Serv, Albacete, Spain; [Ocana, A.] AECC Unit, Albacete, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Pandiella, A (corresponding author), Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, Campus Miguel de Unamuno,Ave Univ Coimbra, Salamanca 37007, Spain.	atanasio@usal.es	Montero, Juan Carlos/AAO-1780-2020; Seoane, Samuel/L-1309-2014; Pandiella, Atanasio/O-5180-2014; Seoane, Samuel/H-6299-2015	Montero, Juan Carlos/0000-0003-4773-053X; Pandiella, Atanasio/0000-0002-4704-8971; Seoane, Samuel/0000-0002-9178-0887; Ocana, Alberto/0000-0002-1067-9630	Ministry of Science and Innovation of Spain [BFU2006-01813/BMC, BFU2009-07728/BMC]; Consejeria de Sanidad de la JCYL; ISCIII [RD06/0020/0041]; Juan de la Cierva Program; European Community; Fundacion Ramon Areces	Ministry of Science and Innovation of Spain(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Consejeria de Sanidad de la JCYL; ISCIII(Instituto de Salud Carlos III); Juan de la Cierva Program; European Community(European Commission); Fundacion Ramon Areces	This work was supported by grants from the Ministry of Science and Innovation of Spain (BFU2006-01813/BMC and BFU2009-07728/BMC) and by the Consejeria de Sanidad de la JCYL. JCM receives support from the Cancer Center Network Program from the ISCIII (RD06/0020/0041), and SS from the Juan de la Cierva Program. Our Cancer Research Institute, and the work carried out at our laboratory receive support from the European Community through the regional development funding program (FEDER), and from the Fundacion Ramon Areces. We thank Drs Heidi CE Welch and Mikio Hoshino for providing the myc-tagged P-Rex1 and an anti-P-Rex antibody, respectively.	Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Atlas E, 2003, MOL CANCER RES, V1, P165; Barber MA, 2007, J BIOL CHEM, V282, P29967, DOI 10.1074/jbc.M701877200; Baselga J, 2005, J CLIN ONCOL, V23, P2445, DOI 10.1200/JCO.2005.11.890; Breuleux M, 2007, CELL MOL LIFE SCI, V64, P2358, DOI 10.1007/s00018-007-7120-0; Cabrera N, 1996, J CELL BIOL, V132, P427, DOI 10.1083/jcb.132.3.427; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; de Alava E, 2007, J CLIN ONCOL, V25, P2656, DOI 10.1200/JCO.2006.08.6850; Donald S, 2004, FEBS LETT, V572, P172, DOI 10.1016/j.febslet.2004.06.096; Esparis-Ogando A, 2002, MOL CELL BIOL, V22, P270, DOI 10.1128/MCB.22.1.270-285.2002; Esteva FJ, 2010, NAT REV CLIN ONCOL, V7, P98, DOI 10.1038/nrclinonc.2009.216; Fine B, 2009, SCIENCE, V325, P1261, DOI 10.1126/science.1173569; Hill K, 2005, J BIOL CHEM, V280, P4166, DOI 10.1074/jbc.M411262200; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Joseph RE, 2005, J BIOL CHEM, V280, P27508, DOI 10.1074/jbc.M412495200; Krane IM, 1996, ONCOGENE, V12, P1781; Larsen MR, 2005, MOL CELL PROTEOMICS, V4, P873, DOI 10.1074/mcp.T500007-MCP200; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; Mayeenuddin LH, 2006, J BIOL CHEM, V281, P1921, DOI 10.1074/jbc.M506035200; Montero JC, 2007, MOL BIOL CELL, V18, P380, DOI 10.1091/mbc.E06-06-0511; Montero JC, 2008, CLIN CANCER RES, V14, P3237, DOI 10.1158/1078-0432.CCR-07-5133; Qin J, 2009, ONCOGENE, V28, P1853, DOI 10.1038/onc.2009.30; Rosenfeldt H, 2004, FEBS LETT, V572, P167, DOI 10.1016/j.febslet.2004.06.097; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Tsai MS, 2003, ONCOGENE, V22, P761, DOI 10.1038/sj.onc.1206130; Welch HCE, 2002, CELL, V108, P809, DOI 10.1016/S0092-8674(02)00663-3; Yang CF, 2006, MOL CELL BIOL, V26, P831, DOI 10.1128/MCB.26.3.831-842.2006; Yang C, 2008, BIOCHEM J, V410, P167, DOI 10.1042/BJ20070781; Yuste L, 2005, CANCER RES, V65, P6801, DOI 10.1158/0008-5472.CAN-04-4023	31	68	70	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	9					1059	1071		10.1038/onc.2010.489	http://dx.doi.org/10.1038/onc.2010.489			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729PX	21042280				2022-12-17	WOS:000287964100005
J	Yu, J; Ma, X; Cheung, KF; Li, X; Tian, L; Wang, S; Wu, CW; Wu, WKK; He, M; Wang, M; Ng, SSM; Sung, JJY				Yu, J.; Ma, X.; Cheung, K. F.; Li, X.; Tian, L.; Wang, S.; Wu, C. W.; Wu, W. K. K.; He, M.; Wang, M.; Ng, S. S. M.; Sung, J. J. Y.			Epigenetic inactivation of T-box transcription factor 5, a novel tumor suppressor gene, is associated with colon cancer	ONCOGENE			English	Article						T-box transcription factor 5; colon cancer; tumor suppressor gene; epigenetic alteration; prognosis	SYNUCLEIN-GAMMA-GENE; COLORECTAL-CANCER; GASTRIC-CANCER; BREAST-CANCER; DNA METHYLATION; CPG ISLAND; APOPTOSIS; METASTASIS; EXPRESSION; SURVIVAL	T-box transcription factor 5 (TBX5) is a member of a phylogenetically conserved family of genes involved in the regulation of developmental processes. The function of TBX5 in cancer development is largely unclear. We identified that TBX5 was preferentially methylated in cancer using methylation-sensitive arbitrarily primed PCR. We aim to clarify the epigenetic inactivation, biological function and clinical significance of TBX5 in colon cancer. Promoter methylation was evaluated by combined bisulfite restriction analysis and bisulfite genomic sequencing. Cell proliferation was examined by cell viability assay and colony formation assay, apoptosis by flow cytometry and cell migration by wound-healing assay. TBX5 target genes were identified by cDNA microarray analysis. Cox regression model and log-rank test were used to identify independent predictors of prognosis. TBX5 was silenced or downregulated in 88% (7/8) colon cancer cell lines, but was expressed in normal colon tissues. Loss of gene expression was associated with promoter methylation. The biological function of TBX5 in human colon cancer cells was examined. Re-expression of TBX5 in silenced colon cancer cell lines suppressed colony formation (P<0.001), proliferation (P<0.001), migration and induced apoptosis (P<0.01). Induction of apoptosis was mediated through cross-talk of extrinsic apoptosis pathway, apoptotic BCL2-associated X protein and Granzyme A signaling cascades. TBX5 suppressed tumor cell proliferation and metastasis through the upregulation of cyclin-dependent kinase inhibitor 2A, metastasis suppressor 1 and downregulation of synuclein gamma and metastasis-associated protein 1 family member 2. TBX5 methylation was detected in 68% (71/105) of primary colon tumors. Multivariate analysis showed that patients with TBX5 methylation had a significantly poor overall survival (P=0.0007). In conclusion, we identified a novel functional tumor suppressor gene TBX5 inactivated by promoter methylation in colon cancer. Detection of methylated TBX5 may serve as a potential biomarker for the prognosis of this malignancy. Oncogene (2010) 29, 6464-6474; doi:10.1038/onc.2010.370; published online 30 August 2010	[Yu, J.; Ma, X.; Cheung, K. F.; Li, X.; Wang, S.; Wu, C. W.; Wu, W. K. K.; Sung, J. J. Y.] Chinese Univ Hong Kong, Dept Med & Therapeut, Inst Digest Dis, Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China; [Yu, J.; Ma, X.; Cheung, K. F.; Li, X.; Wang, S.; Wu, C. W.; Wu, W. K. K.; Sung, J. J. Y.] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China; [Ma, X.; Wang, M.] Hebei Med Univ, Dept Neurol, Hosp 1, Shijiazhuang, Peoples R China; [He, M.] Chinese Univ Hong Kong, Sch Publ Hlth & Primary Care, Stanley Ho Ctr Emerging Infect Dis, Hong Kong, Hong Kong, Peoples R China; [Ng, S. S. M.] Chinese Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Hebei Medical University; Chinese University of Hong Kong; Chinese University of Hong Kong	Yu, J (corresponding author), Chinese Univ Hong Kong, Dept Med & Therapeut, Inst Digest Dis, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China.	junyu@cuhk.edu.hk	Tian, Linwei/A-9736-2009; Pillay, Nischalan/F-9536-2012; Li, Xiao-xing/B-9114-2008; Wu, William K.K./A-3277-2009; HE, Ming-Liang/AAG-3397-2022; Ng, Simon S. M./M-1219-2018; Sung, Joseph J. Y./R-3203-2018; HE, Ming-Liang/AFK-4738-2022; Yu, Jun/D-8569-2015	Tian, Linwei/0000-0002-4739-1534; Li, Xiao-xing/0000-0001-8791-7505; Wu, William K.K./0000-0002-5662-5240; Ng, Simon S. M./0000-0002-5389-9297; Sung, Joseph J. Y./0000-0003-3125-5199; Yu, Jun/0000-0001-5008-2153; He, Ming-Liang/0000-0002-4317-2836; Tian, Linwei/0000-0003-2240-8886; HE, Mingliang/0000-0002-9942-9151	Council Competitive Earmarked Research Grant CUHK [473008]	Council Competitive Earmarked Research Grant CUHK	This work was supported by research grant of Council Competitive Earmarked Research Grant CUHK (473008).	Balkwill F, 2009, NAT REV CANCER, V9, P361, DOI 10.1038/nrc2628; Barton CA, 2008, GYNECOL ONCOL, V109, P129, DOI 10.1016/j.ygyno.2007.12.017; Cai CL, 2005, DEVELOPMENT, V132, P2475, DOI 10.1242/dev.01832; Chowdhury D, 2008, ANNU REV IMMUNOL, V26, P389, DOI 10.1146/annurev.immunol.26.021607.090404; Cullen SP, 2010, CELL DEATH DIFFER, V17, P616, DOI 10.1038/cdd.2009.206; Finotto Susetta, 2008, V94, P83, DOI 10.1159/000154869; Grady WM, 2008, GASTROENTEROLOGY, V135, P1079, DOI 10.1053/j.gastro.2008.07.076; Gupta A, 2003, ONCOGENE, V22, P7593, DOI 10.1038/sj.onc.1206880; Gupta A, 2003, CANCER RES, V63, P664; He ML, 2002, BIOCHEM BIOPH RES CO, V297, P185, DOI 10.1016/S0006-291X(02)02142-3; Hicks DG, 2006, CLIN CANCER RES, V12, P6702, DOI 10.1158/1078-0432.CCR-06-0635; Holoch PA, 2009, EUR J PHARMACOL, V625, P63, DOI 10.1016/j.ejphar.2009.06.066; Hu H, 2009, CLIN CANCER RES, V15, P5485, DOI 10.1158/1078-0432.CCR-08-2491; Johnstone RW, 2008, NAT REV CANCER, V8, P782, DOI 10.1038/nrc2465; Kim WY, 2006, CELL, V127, P265, DOI 10.1016/j.cell.2006.10.003; Liu HY, 2005, CANCER RES, V65, P7635, DOI 10.1158/0008-5472.CAN-05-1089; Liu YE, 2007, ONCOGENE, V26, P2115, DOI 10.1038/sj.onc.1210000; Maitra M, 2009, DEV BIOL, V326, P368, DOI 10.1016/j.ydbio.2008.11.004; Mori AD, 2006, DEV BIOL, V297, P566, DOI 10.1016/j.ydbio.2006.05.023; Nemer M, 2008, CARDIOVASC PATHOL, V17, P48, DOI 10.1016/j.carpath.2007.06.005; NewburyEcob RA, 1996, J MED GENET, V33, P300, DOI 10.1136/jmg.33.4.300; Page D.L., 2002, TNM CLASSIFICATION M, V6th; Pan ZZ, 2002, J BIOL CHEM, V277, P35050, DOI 10.1074/jbc.M201650200; Papaioannou VE, 1998, BIOESSAYS, V20, P9, DOI 10.1002/(SICI)1521-1878(199801)20:1<9::AID-BIES4>3.0.CO;2-Q; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Parr C, 2009, EUR J CANCER, V45, P1673, DOI 10.1016/j.ejca.2009.02.019; Plageman TF, 2006, DEV DYNAM, V235, P2868, DOI 10.1002/dvdy.20923; Schutze S, 2008, NAT REV MOL CELL BIO, V9, P655, DOI 10.1038/nrm2430; Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312; Toh Y, 2009, CLIN EXP METASTAS, V26, P215, DOI 10.1007/s10585-008-9233-8; Yanagawa N, 2004, CLIN CANCER RES, V10, P2447, DOI 10.1158/1078-0432.CCR-03-0107; Yu J, 2009, CANCER-AM CANCER SOC, V115, P49, DOI 10.1002/cncr.23989; Yu J, 2009, GASTROENTEROLOGY, V136, P640, DOI 10.1053/j.gastro.2008.10.050; Zitt M, 2007, DIS MARKERS, V23, P51, DOI 10.1155/2007/891967	34	68	72	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2010	29	49					6464	6474		10.1038/onc.2010.370	http://dx.doi.org/10.1038/onc.2010.370			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	692FP	20802524				2022-12-17	WOS:000285138900006
J	Weber, B; Kimhi, S; Howard, G; Eden, A; Lyko, F				Weber, B.; Kimhi, S.; Howard, G.; Eden, A.; Lyko, F.			Demethylation of a LINE-1 antisense promoter in the cMet locus impairs Met signalling through induction of illegitimate transcription	ONCOGENE			English	Article						DNA methylation; LINE element; cMet; azacytidine; decitabine	DNA METHYLTRANSFERASE INHIBITORS; METHYLATION; CANCER; GENE; 5-AZA-2'-DEOXYCYTIDINE; HYPOMETHYLATION; ELEMENTS; EPIGENOMICS; MECHANISMS; RESISTANCE	The cytosine analogues 5-azacytidine and 5-aza-2'-deoxycytidine are currently the most advanced drugs for epigenetic cancer therapy. Both drugs function as DNA methyltransferase (DNMT) inhibitors and lead to the reactivation of epigenetically silenced tumour suppressor genes. However, not much is known about their target sequence specificity and their possible side effects on normally methylated sequences such as long interspersed nuclear element (LINE)-1 retroelements. It has been shown that demethylation and activation of the LINE-1 antisense promoter can drive the transcription of neighbouring sequences. In this study, we show that demethylation of the colon carcinoma cell line HCT116, either by treatment with DNMT inhibitors or by genetic disruption of the major DNMTs, induces the expression of an illegitimate fusion transcript between an intronic LINE-1 element and the proto-oncogene cMet (L1-cMet). Similar findings were also obtained with myeloid leukaemia cells, an established cellular model for the approved indication of azacytidine and decitabine. Interestingly, upregulation of L1-cMet transcription resulted in reduced cMet expression, which in turn led to decreased cMet receptor signalling. Our results thus provide an important paradigm for demethylation-dependent modulation of gene expression, even if the promoter of the corresponding gene is unmethylated. Oncogene (2010) 29, 5775-5784; doi: 10.1038/onc.2010.227; published online 21 June 2010	[Kimhi, S.; Howard, G.; Eden, A.] Hebrew Univ Jerusalem, Inst Life Sci, Dept Cell & Dev Biol, IL-91904 Jerusalem, Israel; [Weber, B.; Lyko, F.] German Canc Res Ctr, DKFZ ZMBH Alliance, Div Epigenet, D-6900 Heidelberg, Germany	Hebrew University of Jerusalem; Helmholtz Association; German Cancer Research Center (DKFZ)	Eden, A (corresponding author), Hebrew Univ Jerusalem, Inst Life Sci, Dept Cell & Dev Biol, IL-91904 Jerusalem, Israel.	eden@vms.huji.ac.il; f.lyko@dkfz.de			Deutsches Krebsforschungszentrum (DKFZ); Israeli Ministry of Science and Technology (MOST)	Deutsches Krebsforschungszentrum (DKFZ)(Helmholtz Association); Israeli Ministry of Science and Technology (MOST)	We thank Achim Breiling and Azeemudeen Hussain for their advice and support in chromatin immunoprecipitation and cMet signalling analysis. This work was supported by the Cooperation Program in Cancer Research of the Deutsches Krebsforschungszentrum (DKFZ) and by the Israeli Ministry of Science and Technology (MOST).	Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Breiling A, 2001, NATURE, V412, P651, DOI 10.1038/35088090; Chuang JC, 2005, MOL CANCER THER, V4, P1515, DOI 10.1158/1535-7163.MCT-05-0172; Cruickshanks HA, 2009, GENOMICS, V94, P397, DOI 10.1016/j.ygeno.2009.08.013; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748; Gius D, 2004, CANCER CELL, V6, P361, DOI 10.1016/j.ccr.2004.08.029; Gore SD, 2006, CANCER RES, V66, P6361, DOI 10.1158/0008-5472.CAN-06-0080; Howard G, 2008, ONCOGENE, V27, P404, DOI 10.1038/sj.onc.1210631; Issa JPJ, 2009, CLIN CANCER RES, V15, P3938, DOI 10.1158/1078-0432.CCR-08-2783; Jones BK, 1998, GENE DEV, V12, P2200, DOI 10.1101/gad.12.14.2200; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; Kantarjian H, 2006, CANCER-AM CANCER SOC, V106, P1794, DOI 10.1002/cncr.21792; Lyko F, 2005, JNCI-J NATL CANCER I, V97, P1498, DOI 10.1093/jnci/dji311; Martianov I, 2007, NATURE, V445, P666, DOI 10.1038/nature05519; Mazo A, 2007, J CELL SCI, V120, P2755, DOI 10.1242/jcs.007633; Mund C, 2005, CANCER RES, V65, P7086, DOI 10.1158/0008-5472.CAN-05-0695; Mund C, 2006, EPIGENETICS-US, V1, P7; Nigumann P, 2002, GENOMICS, V79, P628, DOI 10.1006/geno.2002.6758; Novakovic B, 2010, J BIOL CHEM, V285, P9583, DOI 10.1074/jbc.M109.064956; Palii SS, 2008, MOL CELL BIOL, V28, P752, DOI 10.1128/MCB.01799-07; Qin TC, 2009, BLOOD, V113, P659, DOI 10.1182/blood-2008-02-140038; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Roman-Gomez J, 2005, ONCOGENE, V24, P7213, DOI 10.1038/sj.onc.1208866; SANTI DV, 1984, P NATL ACAD SCI-BIOL, V81, P6993, DOI 10.1073/pnas.81.22.6993; Schuebel KE, 2007, PLOS GENET, V3, P1709, DOI 10.1371/journal.pgen.0030157; Schulz WA, 2006, CURR TOP MICROBIOL, V310, P211; Silverman LR, 2002, J CLIN ONCOL, V20, P2429, DOI 10.1200/JCO.2002.04.117; Speek M, 2001, MOL CELL BIOL, V21, P1973, DOI 10.1128/MCB.21.6.1973-1985.2001; Stresemann C, 2006, CANCER RES, V66, P2794, DOI 10.1158/0008-5472.CAN-05-2821; Stresemann C, 2008, MOL CANCER THER, V7, P2998, DOI 10.1158/1535-7163.MCT-08-0411; VESELY J, 1967, INT J CANCER, V2, P639, DOI 10.1002/ijc.2910020625; Walsh CP, 1998, NAT GENET, V20, P116, DOI 10.1038/2413; Weisenberger DJ, 2004, MOL CANCER RES, V2, P62; Yang AS, 2006, CANCER RES, V66, P5495, DOI 10.1158/0008-5472.CAN-05-2385; Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032	40	68	73	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	43					5775	5784		10.1038/onc.2010.227	http://dx.doi.org/10.1038/onc.2010.227			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	672LY	20562909				2022-12-17	WOS:000283586200003
J	Merdzhanova, G; Gout, S; Keramidas, M; Edmond, V; Coll, JL; Brambilla, C; Brambilla, E; Gazzeri, S; Eymin, B				Merdzhanova, G.; Gout, S.; Keramidas, M.; Edmond, V.; Coll, J-L; Brambilla, C.; Brambilla, E.; Gazzeri, S.; Eymin, B.			The transcription factor E2F1 and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivo	ONCOGENE			English	Article						alternative splicing; angiogenesis; cancer; E2F1; SC35; VEGF-A	METASTATIC COLORECTAL-CANCER; TUMOR ANGIOGENESIS; SPLICE VARIANTS; LUNG-TUMORS; VEGF; EXPRESSION; VEGF(165)B; CARCINOMA; RECEPTORS; DEATH	The transcription factor E2F1 has a crucial role in the control of cell growth and has been shown to regulate neoangiogenesis in a p53-dependent manner through inhibition of activity of the VEGF-A (vascular endothelial growth factor) promoter. Besides being regulated by transcription, VEGF-A is also highly regulated by pre-mRNA alternative splicing, resulting in the expression of several VEGF isoforms with either pro-(VEGF(xxx)) or anti-(VEGF(xxx)b) angiogenic properties. Recently, we identified the SR (Ser-Rich/Arg) protein SC35, a splicing factor, as a new transcriptional target of E2F1. Here, we show that E2F1 downregulates the activity of the VEGF-A promoter in tumour cells independently of p53, leading to a strong decrease in VEGFxxx mRNA levels. We further show that, strikingly, E2F1 alters the ratio of pro-VEGF(xxx) versus anti-VEGF(xxx)b angiogenic isoforms, favouring the anti-angiogenic isoforms, by a mechanism involving the induction of SC35 expression. Finally, using lung tumour xenografts in nude mice, we provide evidence that E2F1 and SC35 proteins increase the VEGF165b/VEGF ratio and decrease tumour neovascularization in vivo. Overall, these findings highlight E2F1 and SC35 as two regulators of the VEGF(xxx)/VEGF(xxx)b angiogenic switch in human cancer cells, a role that could be crucial during tumour progression, as well as in tumour response to antiangiogenic therapies. Oncogene (2010) 29, 5392-5403; doi: 10.1038/onc. 2010.281; published online 19 July 2010	[Merdzhanova, G.; Gout, S.; Keramidas, M.; Edmond, V.; Coll, J-L; Brambilla, C.; Brambilla, E.; Gazzeri, S.; Eymin, B.] Univ Grenoble 1, Inst Albert Bonniot, Grenoble, France; [Keramidas, M.; Coll, J-L] INSERM, U823, Equipe Cibles Therapeurt & Diagnost & Vectoris Dr, Grenoble, France; [Merdzhanova, G.; Gout, S.; Edmond, V.; Brambilla, C.; Brambilla, E.; Gazzeri, S.; Eymin, B.] INSERM, Equipe Bases Mol Progress Canc Poumon 2, Inst Albert Bonniot, U823, F-38042 Grenoble 09, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Eymin, B (corresponding author), INSERM, Equipe Bases Mol Progress Canc Poumon 2, Inst Albert Bonniot, U823, BP170, F-38042 Grenoble 09, France.	Beatrice.Eymin@ujf-grenoble.fr	Eymin, Beatrice/M-1962-2013; Coll, Jean-Luc/G-2520-2013; gazzeri, sylvie/M-1961-2013; eymin, beatrice/U-4670-2019; gazzeri, sylvie/U-4669-2019	Eymin, Beatrice/0000-0002-7311-3810; Coll, Jean-Luc/0000-0002-2453-3552; gazzeri, sylvie/0000-0001-5817-1839; eymin, beatrice/0000-0002-7311-3810; gazzeri, sylvie/0000-0001-5817-1839	Ligue Nationale contre le Cancer; Conseil Scientifique National d'AGIR a dom; Research French Ministry; Fondation pour la Recherche Medicale (FRM); Association pour la Recherche Contre le Cancer (ARC); Conseil Scientifique National d'AGIR	Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Conseil Scientifique National d'AGIR a dom; Research French Ministry; Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); Association pour la Recherche Contre le Cancer (ARC)(Fondation ARC pour la Recherche sur le CancerFrench National Research Agency (ANR)); Conseil Scientifique National d'AGIR	We thank Patricia Betton, Pascal Perron and Celine Lampreia for technical assistance. This work was supported by the Ligue Nationale contre le Cancer (Equipe Labellisee Ligue 2007) and by the Conseil Scientifique National d'AGIR a dom. Galina Merdzhanova was supported by fellowships from the Research French Ministry and the Fondation pour la Recherche Medicale (FRM). Stephanie Gout was supported by a fellowship from Association pour la Recherche Contre le Cancer (ARC). Valerie Edmond was supported by a grant from the Conseil Scientifique National d'AGIR a dom.	Bachelder RE, 2001, CANCER RES, V61, P5736; Bachelder RE, 2002, CANCER RES, V62, P7203; Bates DO, 2006, CLIN SCI, V110, P575, DOI 10.1042/CS20050292; Bates DO, 2002, CANCER RES, V62, P4123; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Catena R, 2007, INT J CANCER, V120, P2096, DOI 10.1002/ijc.22461; Cheung N, 1998, HUM PATHOL, V29, P910, DOI 10.1016/S0046-8177(98)90195-2; Cohen CD, 2005, J AM SOC NEPHROL, V16, P1958, DOI 10.1681/ASN.2005020204; Davis JN, 2006, CANCER RES, V66, P11897, DOI 10.1158/0008-5472.CAN-06-2497; Elias AP, 2008, CANCER MICROENVIRON, V1, P131, DOI 10.1007/s12307-008-0013-4; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115; Fontemaggi G, 2009, NAT STRUCT MOL BIOL, V16, P1086, DOI 10.1038/nsmb.1669; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Hurwitz HI, 2005, J CLIN ONCOL, V23, P3502, DOI 10.1200/JCO.2005.10.017; Jiang SX, 2007, MOL CELL BIOL, V27, P1696, DOI 10.1128/MCB.01760-06; Kawamura H, 2008, CANCER RES, V68, P4683, DOI 10.1158/0008-5472.CAN-07-6577; Ladomery MR, 2007, CANCER LETT, V249, P133, DOI 10.1016/j.canlet.2006.08.015; Lantuejoul S, 2003, J PATHOL, V200, P336, DOI 10.1002/path.1367; Merdzhanova G, 2008, CELL DEATH DIFFER, V15, P1815, DOI 10.1038/cdd.2008.135; Nowak DG, 2008, J CELL SCI, V121, P3487, DOI 10.1242/jcs.016410; Nowak DG, 2010, J BIOL CHEM, V285, P5532, DOI 10.1074/jbc.M109.074930; Polager S, 2008, TRENDS CELL BIOL, V18, P528, DOI 10.1016/j.tcb.2008.08.003; Pritchard-Jones RO, 2007, BRIT J CANCER, V97, P223, DOI 10.1038/sj.bjc.6603839; Qin GJ, 2006, P NATL ACAD SCI USA, V103, P11015, DOI 10.1073/pnas.0509533103; RAK J, 1995, CANCER RES, V55, P4575; Rennel ES, 2008, BRIT J CANCER, V98, P1250, DOI 10.1038/sj.bjc.6604309; Robinson CJ, 2001, J CELL SCI, V114, P853; Salon C, 2007, ONCOGENE, V26, P6927, DOI 10.1038/sj.onc.1210499; Salon C, 2006, CELL DEATH DIFFER, V13, P260, DOI 10.1038/sj.cdd.4401739; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Varey AHR, 2008, BRIT J CANCER, V98, P1366, DOI 10.1038/sj.bjc.6604308; Woolard J, 2004, CANCER RES, V64, P7822, DOI 10.1158/0008-5472.CAN-04-0934; Zhang LL, 2000, CANCER RES, V60, P3655	34	68	70	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	39					5392	5403		10.1038/onc.2010.281	http://dx.doi.org/10.1038/onc.2010.281			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664EZ	20639906	Green Submitted			2022-12-17	WOS:000282944500006
J	Kunnev, D; Rusiniak, ME; Kudla, A; Freeland, A; Cady, GK; Pruitt, SC				Kunnev, D.; Rusiniak, M. E.; Kudla, A.; Freeland, A.; Cady, G. K.; Pruitt, S. C.			DNA damage response and tumorigenesis in Mcm2-deficient mice	ONCOGENE			English	Article						minichromosome maintenance protein; p53; licensing factor; cancer tumor spectrum; loss of heterozygosity	MCM PROTEINS; HUMAN-CELLS; REPLICATION; EXPRESSION; ORIGINS	Minichromosome maintenance proteins (Mcm's) are components of the DNA replication licensing complex. In vivo, reduced expression or activity of Mcm's has been shown to result in highly penetrant early onset cancers (Shima et al., 2007; Pruitt et al., 2007) and stem cell deficiencies ( Pruitt et al., 2007). Here we use mouse embryonic fibroblasts from an Mcm2-deficient strain of mice to show by DNA fiber analysis that origin usage is decreased in Mcm2-deficient cells under conditions of hydroxyurea (HU)-mediated replication stress. DNA damage responses (DDRs) resulting from HU and additional replication-dependent and replication-independent genotoxic agents were also examined and shown to function at wild-type (wt) levels. Further, basal levels of many components of the DDR were expressed at wt levels, showing that there is no acute replicative stress under normal growth conditions. Only very modest, 1.5- to 2-fold increases in the basal levels of gamma-H2AX, p21(cip1) and 53bp foci were found, consistent with a slight chronic elevation in DDR pathways. The one condition in which a larger difference between wt- and Mcm2-deficient cells was found occurred after ultraviolet irradiation and may reflect the role of Chk1-mediated suppression of dormant origins. In vivo, abrogating p53-mediated DDR in Mcm2-deficient mice results in increased embryonic lethality and accelerated cancer formation in surviving mice. Further, p53 mutation rescues the negative effect of Mcm2 deficiency on the survival of neural stem cells in vitro; however, the enhanced survival correlates with increased genetic damage relative to Mcm2 wt cells carrying the p53 mutation. Together these results show that even relatively minor perturbations to primary or dormant replication origin usage contribute to accelerated genetic damage in vivo. In addition, these studies show that tumor types resulting from Mcm2 deficiency are strongly affected by interaction with both genetic background and p53. Oncogene ( 2010) 29, 3630-3638; doi: 10.1038/onc.2010.125; published online 3 May 2010	[Kunnev, D.; Rusiniak, M. E.; Kudla, A.; Freeland, A.; Cady, G. K.; Pruitt, S. C.] Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Pruitt, SC (corresponding author), Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Elm & Carlton St, Buffalo, NY 14263 USA.	steven.pruitt@roswellpark.org			NIH-NCI; Ellison Medical Foundation; NYSTEM; NCI-CCS; NATIONAL CANCER INSTITUTE [R01CA130995] Funding Source: NIH RePORTER	NIH-NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Ellison Medical Foundation(Lawrence Ellison Foundation); NYSTEM; NCI-CCS; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	BALB/c:p53<SUP>null/wt</SUP> mice were a generous gift of Dr Peter Demant.This work was supported by grants from the NIH-NCI, the Ellison Medical Foundation, and NYSTEM to SCP. Cost of animal maintenance and flow cytometry was supported in part by an NCI-CCS grant to RPCI.	Bailey KJ, 2004, AGING CELL, V3, P391, DOI 10.1111/j.1474-9728.2004.00128.x; Blow JJ, 2005, NAT REV MOL CELL BIO, V6, P476, DOI 10.1038/nrm1663; Cortez D, 2004, P NATL ACAD SCI USA, V101, P10078, DOI 10.1073/pnas.0403410101; Forsburg SL, 2004, MICROBIOL MOL BIOL R, V68, P109, DOI 10.1128/MMBR.68.1.109-131.2004; Ge XQ, 2007, GENE DEV, V21, P3331, DOI 10.1101/gad.457807; Heffernan TP, 2007, J BIOL CHEM, V282, P9458, DOI 10.1074/jbc.M611292200; Hyrien O, 2003, BIOESSAYS, V25, P116, DOI 10.1002/bies.10208; Ibarra A, 2008, P NATL ACAD SCI USA, V105, P8956, DOI 10.1073/pnas.0803978105; Jackson DA, 1998, J CELL BIOL, V140, P1285, DOI 10.1083/jcb.140.6.1285; Lei M, 2005, CURR CANCER DRUG TAR, V5, P365, DOI 10.2174/1568009054629654; Liu PJ, 2009, CELL CYCLE, V8, P125, DOI 10.4161/cc.8.1.7528; Lombard DB, 2005, CELL, V120, P497, DOI 10.1016/j.cell.2005.01.028; Martinho RG, 1998, EMBO J, V17, P7239, DOI 10.1093/emboj/17.24.7239; Maslov AY, 2007, STEM CELLS, V25, P132, DOI 10.1634/stemcells.2006-0032; Maslov AY, 2004, J NEUROSCI, V24, P1726, DOI 10.1523/JNEUROSCI.4608-03.2004; Miao H, 2003, J BIOL CHEM, V278, P4295, DOI 10.1074/jbc.M204264200; Nevis KR, 2009, CELL CYCLE, V8, P1952, DOI 10.4161/cc.8.12.8811; Pruitt SC, 2007, STEM CELLS, V25, P3121, DOI 10.1634/stemcells.2007-0483; Rossi DJ, 2008, CELL, V132, P681, DOI 10.1016/j.cell.2008.01.036; Shima N, 2007, NAT GENET, V39, P93, DOI 10.1038/ng1936; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649	21	68	68	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2010	29	25					3630	3638		10.1038/onc.2010.125	http://dx.doi.org/10.1038/onc.2010.125			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615CG	20440269	Green Accepted			2022-12-17	WOS:000279108600004
J	Luo, YP; Zhou, H; Krueger, J; Kaplan, C; Liao, D; Markowitz, D; Liu, C; Chen, T; Chuang, TH; Xiang, R; Reisfeld, RA				Luo, Y. P.; Zhou, H.; Krueger, J.; Kaplan, C.; Liao, D.; Markowitz, D.; Liu, C.; Chen, T.; Chuang, T-H; Xiang, R.; Reisfeld, R. A.			The role of proto-oncogene Fra-1 in remodeling the tumor microenvironment in support of breast tumor cell invasion and progression	ONCOGENE			English	Article						tumor-associated macrophages; tumor microenvironment; Fra-1; IL-6/JAK/Stat3 signaling pathway	TRANSCRIPTION FACTORS; ANTITUMOR IMMUNITY; UP-REGULATION; CANCER CELLS; MACROPHAGES; STAT3; ACTIVATION; METASTASIS; EXPRESSION; TARGETS	A growing body of evidence indicates that interactions between neoplastic cells and tumor-associated macrophages (TAMs) in the tumor microenvironment (TME) are crucial in promoting tumor cell invasion and progression. Macrophages have an ambiguous role in these processes as this M1 phenotype correlates with tumoricidal capacity, whereas TAMs of M2 phenotype exert tumor-promoting effects. In this study, we provide evidence that interactions between mouse breast tumor cells and TAMs remodel the TME, leading to the upregulation of Fra-1, a member of the FOS family of transcription factor. In turn, this proto-oncogene initiates activation of the IL-6/JAK/Stat3 signaling pathway. This creates a malignant switch in breast tumor cells, leading to increased release of proangiogenic factors MMP-9, vascular endothelial growth factor and transforming growth factor-beta from tumor cells and intensified invasion and progression of breast cancer. Proof of the concept for the crucial role played by transcription factor Fra-1 in regulating these processes was established by specific knockdown of Fra-1 with small interfering RNA, which resulted in a marked suppression of tumor cell invasion, angiogenesis and metastasis in a mouse breast cancer model. Such a strategy could eventually lead to future efficacious treatments of metastatic breast cancer. Oncogene (2010) 29, 662-673; doi: 10.1038/onc.2009.308; published online 7 December 2009	[Luo, Y. P.; Zhou, H.; Krueger, J.; Kaplan, C.; Liao, D.; Markowitz, D.; Liu, C.; Chen, T.; Chuang, T-H; Xiang, R.; Reisfeld, R. A.] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA; [Luo, Y. P.; Chen, T.] Chongqing Univ Med Sci, Dept Lab Med, Chongqing, Peoples R China; [Xiang, R.] Nankai Univ, Dept Immunol, Tianjin 300071, Peoples R China	Scripps Research Institute; Chongqing Medical University; Nankai University	Luo, YP (corresponding author), Scripps Res Inst, Dept Immunol & Microbial Sci, R218,IMM13,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	ypluo@scripps.edu; reisfeld@scripps.edu	Chuang, Tsung-Hsien/F-9679-2010	Chen, Tingmei/0000-0003-4250-674X	National Science Foundation of China (NSFC) [30672389, 2007CB914804, 2007AA021010, 30671983]; NIH [CA 115751]; EMD Lexigen Research Center [SFP 1645]; NATIONAL CANCER INSTITUTE [R01CA127535, R01CA115751] Funding Source: NIH RePORTER	National Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EMD Lexigen Research Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank K Cairns for editorial assistance. This work was supported by grants from the National Science Foundation of China (NSFC): Grant 30672389 (to RX), NSFC 973 program Grant 2007CB914804 (to RX), and NSFC 863 program Grant 2007AA021010 (to RX), Grant No. 30671983 from The National Natural Science Foundation of China (to YL); grant from NIH CA 115751 (to RAR); and Grant SFP 1645 from the EMD Lexigen Research Center (to RAR). This is The Scripps Research Institute's manuscript number 19572-IMM.	Adiseshaiah P, 2005, ONCOGENE, V24, P4193, DOI 10.1038/sj.onc.1208583; Allavena P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI 10.1016/j.critrevonc.2007.07.004; Asschert JGW, 1999, INT J CANCER, V81, P236, DOI 10.1002/(SICI)1097-0215(19990412)81:2<236::AID-IJC12>3.0.CO;2-R; Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; Bronte V, 2005, NAT REV IMMUNOL, V5, P641, DOI 10.1038/nri1668; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; Faggioli L, 2004, BBA-MOL CELL RES, V1692, P17, DOI 10.1016/j.bbamcr.2004.03.001; FRASER CC, 1995, BLOOD, V86, P183, DOI 10.1182/blood.V86.1.183.bloodjournal861183; Gao SP, 2007, J CLIN INVEST, V117, P3846, DOI 10.1172/JCI31871; Guiducci C, 2005, CANCER RES, V65, P3437, DOI 10.1158/0008-5472.CAN-04-4262; Hagemann T, 2004, CARCINOGENESIS, V25, P1543, DOI 10.1093/carcin/bgh146; Hiratsuka S, 2006, NAT CELL BIOL, V8, P1369, DOI 10.1038/ncb1507; Hodge DR, 2005, EUR J CANCER, V41, P2502, DOI 10.1016/j.ejca.2005.08.016; Knudsen E, 2002, EUR J HAEMATOL, V69, P284, DOI 10.1034/j.1600-0609.2002.02657.x; Kortylewski M, 2005, NAT MED, V11, P1314, DOI 10.1038/nm1325; Kortylewski M, 2008, CURR OPIN IMMUNOL, V20, P228, DOI 10.1016/j.coi.2008.03.010; Leek RD, 2002, J MAMMARY GLAND BIOL, V7, P177, DOI 10.1023/A:1020304003704; Lewen S, 2008, CANCER IMMUNOL IMMUN, V57, P507, DOI 10.1007/s00262-007-0389-x; Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005; Lin EY, 2007, MOL ONCOL, V1, P288, DOI 10.1016/j.molonc.2007.10.003; Lin EY, 2007, CANCER RES, V67, P5064, DOI 10.1158/0008-5472.CAN-07-0912; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Luo YP, 2006, J CLIN INVEST, V116, P2132, DOI 10.1172/JCI27648; Mantovani A, 2006, CANCER METAST REV, V25, P315, DOI 10.1007/s10555-006-9001-7; Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692; Milde-Langosch K, 2005, EUR J CANCER, V41, P2449, DOI 10.1016/j.ejca.2005.08.008; Philips A, 1998, MOL ENDOCRINOL, V12, P973, DOI 10.1210/me.12.7.973; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Sica A, 2006, EUR J CANCER, V42, P717, DOI 10.1016/j.ejca.2006.01.003; VAN RN, 1989, J IMMUNOL METHODS, V124, P1; VAN RN, 1994, J IMMUNOL METHODS, V174, P83; Yu H, 2007, NAT REV IMMUNOL, V7, P41, DOI 10.1038/nri1995; Zajchowski DA, 2001, CANCER RES, V61, P5168; Zerbini LF, 2003, CANCER RES, V63, P2206	36	68	74	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 4	2010	29	5					662	673		10.1038/onc.2009.308	http://dx.doi.org/10.1038/onc.2009.308			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	551QI	19966854	Green Accepted			2022-12-17	WOS:000274223700004
J	Konishi, J; Yi, F; Chen, X; Vo, H; Carbone, DP; Dang, TP				Konishi, J.; Yi, F.; Chen, X.; Vo, H.; Carbone, D. P.; Dang, T. P.			Notch3 cooperates with the EGFR pathway to modulate apoptosis through the induction of bim	ONCOGENE			English	Article						Notch3; bim; apoptosis; lung cancer	DOWN-REGULATION; ACTIVATION; CELLS; GROWTH; BCL-2; INHIBITION; EXPRESSION; FAMILY; CANCER	Notch signaling is a highly conserved pathway important for normal embryonic development and cancer. We previously demonstrated a role for Notch3 in lung cancer pathogenesis. Notch3 inhibition resulted in tumor apoptosis and growth suppression. In vitro, these effects were enhanced when the epidermal growth factor receptor (EGFR) pathway was also inhibited, suggesting significant cross-talk between the two pathways. How Notch3 and epidermal growth factor receptor-mitogen-activated protein kinase (EGFR-MAPK) pathways cooperate in modulating apoptosis is not yet known. In this study, we provide evidence that Notch3 regulates Bim, a BH-3-only protein, via MAPK signaling. Furthermore, loss of Bim expression prevents tumor apoptosis induced by Notch3 inhibition. Using c-secretase inhibitor and erlotinib in a xenograft model, Bim induction and tumor inhibition were observed to be enhanced compared with either agent alone, consistent with our previous observation of significant synergism between Notch and EGFR-ras-MAPK signaling. Thus, our data support the hypothesis that Notch3 not only has a crucial role in lung cancer through regulating apoptosis, but also cooperates with the EGFR-MAPK pathway in modulating Bim. Oncogene (2010) 29, 589-596; doi: 10.1038/onc.2009.366; published online 2 November 2009	[Konishi, J.; Yi, F.; Chen, X.; Vo, H.; Carbone, D. P.; Dang, T. P.] Vanderbilt Ingram Canc Ctr, Div Hematol & Med Oncol, Nashville, TN 37232 USA	Vanderbilt University	Dang, TP (corresponding author), Vanderbilt Ingram Canc Ctr, Div Hematol & Med Oncol, 658 PRB,2220 Pierce Ave, Nashville, TN 37232 USA.	thao.p.dang@vanderbilt.edu	Sakakibara-Konishi, Jun/G-5941-2012; Nguyen, Phu-Huan Vo/HGF-3643-2022	Nguyen, Phu-Huan Vo/0000-0002-6326-1692	 [NCI 1R01 CA115707]; NATIONAL CANCER INSTITUTE [R01CA115707] Funding Source: NIH RePORTER	; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the Grant NCI 1R01 CA115707.	Bellavia D, 2000, EMBO J, V19, P3337, DOI 10.1093/emboj/19.13.3337; Beverly LJ, 2005, CANCER RES, V65, P7159, DOI 10.1158/0008-5472.CAN-05-1664; Biswas SC, 2007, J BIOL CHEM, V282, P29368, DOI 10.1074/jbc.M702634200; Bocchetta M, 2003, ONCOGENE, V22, P81, DOI 10.1038/sj.onc.1206097; Borner C, 2003, MOL IMMUNOL, V39, P615, DOI 10.1016/S0161-5890(02)00252-3; Campos AH, 2002, CIRC RES, V91, P999, DOI 10.1161/01.RES.0000044944.99984.25; Costa DB, 2007, PLOS MED, V4, P1669, DOI 10.1371/journal.pmed.0040315; Curry CL, 2005, ONCOGENE, V24, P6333, DOI 10.1038/sj.onc.1208783; Dang TP, 2000, J NATL CANCER I, V92, P1355, DOI 10.1093/jnci/92.16.1355; Das I, 2004, J BIOL CHEM, V279, P30771, DOI 10.1074/jbc.M309252200; Dievart A, 1999, ONCOGENE, V18, P5973, DOI 10.1038/sj.onc.1202991; Duechler M, 2005, LEUKEMIA, V19, P260, DOI 10.1038/sj.leu.2403592; Fitzgerald K, 2000, ONCOGENE, V19, P4191, DOI 10.1038/sj.onc.1203766; Gomez-Bougie P, 2005, ONCOGENE, V24, P8076, DOI 10.1038/sj.onc.1208949; Gong YX, 2007, PLOS MED, V4, P1655, DOI 10.1371/journal.pmed.0040294; Haruki N, 2005, CANCER RES, V65, P3555, DOI 10.1158/0008-5472.CAN-04-3132; Heiser PW, 2004, CELL CYCLE, V3, P270; Konishi J, 2007, CANCER RES, V67, P8051, DOI 10.1158/0008-5472.CAN-07-1022; Lewis HD, 2007, CHEM BIOL, V14, P209, DOI 10.1016/j.chembiol.2006.12.010; Qin JZ, 2004, MOL CANCER THER, V3, P895; Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008-5472.CAN-05-1069; Roy M, 2007, CURR OPIN GENET DEV, V17, P52, DOI 10.1016/j.gde.2006.12.001; Shinjyo T, 2001, MOL CELL BIOL, V21, P854, DOI 10.1128/MCB.21.3.854-864.2001; Urbich C, 2005, FASEB J, V19, P974, DOI 10.1096/fj.04-2727fje; Wang T, 2007, CELL SIGNAL, V19, P2458, DOI 10.1016/j.cellsig.2007.07.019; Wang YF, 2007, CLIN CANCER RES, V13, P4934, DOI 10.1158/1078-0432.CCR-07-0665; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754	27	68	71	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2010	29	4					589	596		10.1038/onc.2009.366	http://dx.doi.org/10.1038/onc.2009.366			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	549WH	19881544	Green Accepted			2022-12-17	WOS:000274084600011
J	Clark, ES; Brown, B; Whigham, AS; Kochaishvili, A; Yarbrough, WG; Weaver, AM				Clark, E. S.; Brown, B.; Whigham, A. S.; Kochaishvili, A.; Yarbrough, W. G.; Weaver, A. M.			Aggressiveness of HNSCC tumors depends on expression levels of cortactin, a gene in the 11q13 amplicon	ONCOGENE			English	Article						cortactin; secretion; tumor progression; HNSCC; head and neck cancer	SQUAMOUS-CELL CARCINOMA; GROWTH-FACTOR-RECEPTOR; CLATHRIN-COATED PITS; BREAST-CANCER; EPITHELIAL-CELLS; POOR-PROGNOSIS; FACTOR-ALPHA; CYCLIN D1; HEPATOCELLULAR-CARCINOMA; ACTIN POLYMERIZATION	11q13 amplification is a late-stage event in several cancers that is often associated with poor prognosis. Among 11q13-amplified genes, the actin assembly protein cortactin/CTTN is considered a likely candidate for direct involvement in tumor progression because of its cell motility-enhancing functions. We modulated cortactin expression in head and neck squamous cell carcinoma (HNSCC) cell lines. Cortactin expression levels directly correlated with tumor size, vascularization and cell proliferation in an orthotopic HNSCC in vivo model. In contrast, under normal in vitro culture conditions, cortactin expression levels had no effect on cell proliferation. However, cell lines in which cortactin expression was reduced by knockdown (KD) grew poorly in vitro under harsh conditions of growth factor deprivation, anchorage independence and space constraint. In contrast, overexpression of cortactin enhanced in vitro growth under the same harsh conditions. Surprisingly, defects in growth factor-independent proliferation of cortactin-KD cells were rescued by coculture with cortactin-expressing cells. As the cocultured cells are separated by permeable filters, cortactin-expressing cells must secrete growth-supporting autocrine factors to rescue the cortactin-KD cells. Overall, cortactin expression modulates multiple cellular traits that may allow survival in a tumor environment, suggesting that the frequent overexpression of cortactin in tumors is not an epiphenomenon but rather promotes tumor aggressiveness.	[Weaver, A. M.] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA; [Brown, B.; Whigham, A. S.; Kochaishvili, A.; Yarbrough, W. G.] Vanderbilt Univ, Dept Otolaryngol, Nashville, TN 37232 USA; [Weaver, A. M.] Vanderbilt Univ, Dept Pathol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Weaver, AM (corresponding author), Vanderbilt Univ, Sch Med, Dept Canc Biol, 23rd Ave S Pierce,448 PRB, Nashville, TN 37232 USA.	alissa.weaver@vanderbilt.edu	Clark, Emily/GVR-7159-2022; Yarbrough, Wendell G/A-1969-2011; Whigham, Amy/AAT-7183-2020	Whigham, Amy/0000-0001-7648-1988	Robert J Kleberg Jr and Helen C Kleberg Foundation;  [1R21DE018244]; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R21DE018244] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM075126] Funding Source: NIH RePORTER	Robert J Kleberg Jr and Helen C Kleberg Foundation; ; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Julie Maier, Izu Iwueke and the IHC core for technical support; and Drs Ambra Pozzi and Vito Quaranta for advice. This work was supported by 1R21DE018244 to AMW. WGY, BB, ASW, and AK are partially supported through a grant from the Robert J Kleberg Jr and Helen C Kleberg Foundation. An endowment supporting the Barry Baker Laboratory for Head and Neck Oncology as well as the Robert J Kleberg Jr and Helen C Kleberg Foundation and an Ingram Professorship to WGY also provided support for this project.	AKERVALL JA, 1995, CANCER, V76, P853, DOI 10.1002/1097-0142(19950901)76:5<853::AID-CNCR2820760520>3.0.CO;2-6; BATES SE, 1990, ENDOCRINOLOGY, V126, P596, DOI 10.1210/endo-126-1-596; Bryce NS, 2005, CURR BIOL, V15, P1276, DOI 10.1016/j.cub.2005.06.043; Cao H, 2005, NAT CELL BIOL, V7, P483, DOI 10.1038/ncb1246; Cao H, 2003, MOL CELL BIOL, V23, P2162, DOI 10.1128/MCB.23.6.2162-2170.2003; Chuma M, 2004, J HEPATOL, V41, P629, DOI 10.1016/j.jhep.2004.06.018; Clark ES, 2008, EUR J CELL BIOL, V87, P581, DOI 10.1016/j.ejcb.2008.01.008; Clark ES, 2007, CANCER RES, V67, P4227, DOI 10.1158/0008-5472.CAN-06-3928; Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; ETHIER SP, 1991, CELL GROWTH DIFFER, V2, P593; Ethier SP, 1996, MOL CARCINOGEN, V15, P134; Freier K, 2006, GENE CHROMOSOME CANC, V45, P118, DOI 10.1002/gcc.20270; Gabrilove JL, 2001, ONCOLOGIST, V6, P4; Gibcus JH, 2008, BRIT J CANCER, V98, P950, DOI 10.1038/sj.bjc.6604246; Gibcus JH, 2007, CLIN CANCER RES, V13, P6257, DOI 10.1158/1078-0432.CCR-07-1247; Greer RO, 2007, ORAL ONCOL, V43, P735, DOI 10.1016/j.oraloncology.2006.09.007; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hiratsuka S, 2006, NAT CELL BIOL, V8, P1369, DOI 10.1038/ncb1507; Hofman P, 2008, BRIT J CANCER, V98, P956, DOI 10.1038/sj.bjc.6604245; Hui R, 1998, ONCOGENE, V17, P1053, DOI 10.1038/sj.onc.1202023; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Katsube T, 2004, ARCH BIOCHEM BIOPHYS, V427, P79, DOI 10.1016/j.abb.2004.04.015; Li YS, 2001, CANCER RES, V61, P6906; Luo ML, 2006, CANCER RES, V66, P11690, DOI 10.1158/0008-5472.CAN-06-1484; MARKOWITZ SD, 1990, J CLIN INVEST, V86, P356, DOI 10.1172/JCI114709; MEREDITH SD, 1995, ARCH OTOLARYNGOL, V121, P790; Merrifield CJ, 2005, CELL, V121, P593, DOI 10.1016/j.cell.2005.03.015; Myllykangas S, 2007, SEMIN CANCER BIOL, V17, P42, DOI 10.1016/j.semcancer.2006.10.005; Ohoka Y, 1998, GENES CELLS, V3, P603, DOI 10.1046/j.1365-2443.1998.00216.x; Ormandy CJ, 2003, BREAST CANCER RES TR, V78, P323, DOI 10.1023/A:1023033708204; Ostman A, 2004, CYTOKINE GROWTH F R, V15, P275, DOI 10.1016/j.cytogfr.2004.03.002; RANGAN SRS, 1972, CANCER, V29, P117, DOI 10.1002/1097-0142(197201)29:1<117::AID-CNCR2820290119>3.0.CO;2-R; Rodrigo JP, 2000, CLIN CANCER RES, V6, P3177; SCHUURING E, 1995, GENE, V159, P83, DOI 10.1016/0378-1119(94)00562-7; SCHUURING E, 1992, ONCOGENE, V7, P355; Shores CG, 1998, LARYNGOSCOPE, V108, P1358, DOI 10.1097/00005537-199809000-00019; SOMERS KD, 1990, ONCOGENE, V5, P915; Takes RP, 1997, ARCH OTOLARYNGOL, V123, P412; Tsao MS, 1996, EXP CELL RES, V223, P268, DOI 10.1006/excr.1996.0081; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; van Rossum AGSH, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-58; Weaver AM, 2008, CANCER LETT, V265, P157, DOI 10.1016/j.canlet.2008.02.066; Weaver AM, 2001, CURR BIOL, V11, P370, DOI 10.1016/S0960-9822(01)00098-7; WEICHSELBAUM RR, 1986, P NATL ACAD SCI USA, V83, P2684, DOI 10.1073/pnas.83.8.2684; WILLIAMS ME, 1993, ARCH OTOLARYNGOL, V119, P1238; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; Yuan BZ, 2003, J MOL DIAGN, V5, P48, DOI 10.1016/S1525-1578(10)60451-5; Zhu JW, 2005, J CELL SCI, V118, P807, DOI 10.1242/jcs.01668	50	68	68	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2009	28	3					431	444		10.1038/onc.2008.389	http://dx.doi.org/10.1038/onc.2008.389			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395UZ	18931703	Green Accepted			2022-12-17	WOS:000262550300011
J	Chaput, N; Conforti, R; Viaud, S; Spatz, A; Zitvogel, L				Chaput, N.; Conforti, R.; Viaud, S.; Spatz, A.; Zitvogel, L.			The Janus face of dendritic cells in cancer	ONCOGENE			English	Review						tumor immunity; dendritic cells; tolerance	COLONY-STIMULATING FACTOR; NATURAL-KILLER-CELLS; REGULATORY T-CELLS; PEPTIDE-BASED VACCINE; SENTINEL LYMPH-NODES; TUMOR-ANTIGEN MUC1; RESPONSES IN-VIVO; HLA-DR ANTIGEN; ANTITUMOR IMMUNITY; BREAST-CANCER	On the basis of experimental models and some human data, we can assume that tumor outgrowth results from the balance between immunosurveillance (the extrinsic tumor suppressor mechanisms) and immunosubversion dictated by transformed cells and/or the corrupted surrounding microenvironment. Cancer immunosurveillance relies mainly upon conventional lymphocytes exerting either lytic or secretory functions, whereas immunosubversion results from the activity of regulatory T or suppressor myeloid cells and soluble mediators. Although specific tools to target or ablate dendritic cells (DCs) became only recently available, accumulating evidence points to the critical role of the specialized DC system in dictating most of the conventional and regulatory functions of tumor-specific T lymphocytes. Although DC can be harnessed to silence tumor development, tumors in turn can exploit DC to evade immunity. Indeed, DCs harbor defects in their differentiation and stimulatory functions in cancer-bearing hosts and can actively promote T-cell tolerance to self-tumor antigens. In this review, we will focus on the dual role of DC during tumor progression and discuss pharmacoimmunological strategies to harness DC against cancer.	[Chaput, N.; Conforti, R.; Viaud, S.; Zitvogel, L.] Inst Gustave Roussy, INSERM, U805, F-94805 Villejuif, France; [Chaput, N.; Conforti, R.; Zitvogel, L.] Inst Gustave Roussy, CBT507, Ctr Clin Invest, F-94805 Villejuif, France; [Spatz, A.] Inst Gustave Roussy, Dept Biopathol, F-94805 Villejuif, France; [Zitvogel, L.] Univ Paris 11, Fac Paris Sud, Le Kremlin Bicetre, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay	Zitvogel, L (corresponding author), Inst Gustave Roussy, INSERM, U805, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	zitvogel@igr.fr	SPATZ, ALAN/B-8645-2009	SPATZ, ALAN/0000-0003-3020-1420; ZITVOGEL, laurence/0000-0003-1596-0998	EU; INCa; Ligue Nationale contre le Cancer	EU(European Commission); INCa(Institut National du Cancer (INCA) France); Ligue Nationale contre le Cancer(Ligue nationale contre le cancer)	This work has also been supported by EU grants (ALLOSTEM, DC THERA), INCa and Ligue Nationale contre le Cancer (equipes labelisees by LZ). RC receives a salary from Innate Pharma.	Albert ML, 1998, NAT MED, V4, P1321, DOI 10.1038/3315; Alli R, 2004, EUR J IMMUNOL, V34, P1119, DOI 10.1002/eji.200324793; Almand B, 2000, CLIN CANCER RES, V6, P1755; AMBE K, 1989, CANCER, V63, P496, DOI 10.1002/1097-0142(19890201)63:3<496::AID-CNCR2820630318>3.0.CO;2-K; Andre F, 2004, J IMMUNOL, V172, P2126, DOI 10.4049/jimmunol.172.4.2126; Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622; Aspord C, 2007, J EXP MED, V204, P1037, DOI 10.1084/jem.20061120; Asselin-Paturel C, 2003, J IMMUNOL, V171, P6466, DOI 10.4049/jimmunol.171.12.6466; Banchereau J, 2001, CANCER RES, V61, P6451; Bell D, 1999, J EXP MED, V190, P1417, DOI 10.1084/jem.190.10.1417; Bellone G, 2006, J IMMUNOL, V177, P3448, DOI 10.4049/jimmunol.177.5.3448; Bereta M, 2004, CANCER GENE THER, V11, P808, DOI 10.1038/sj.cgt.7700762; Blank C, 2007, CANCER IMMUNOL IMMUN, V56, P739, DOI 10.1007/s00262-006-0272-1; Bonifaz L, 2002, J EXP MED, V196, P1627, DOI 10.1084/jem.20021598; Borg C, 2004, J CLIN INVEST, V114, P379, DOI 10.1172/jci20041102; Bui JD, 2007, CURR OPIN IMMUNOL, V19, P203, DOI 10.1016/j.coi.2007.02.001; Cai XY, 2006, J CANCER RES CLIN, V132, P293, DOI 10.1007/s00432-006-0075-y; Cao W, 2006, J EXP MED, V203, P1399, DOI 10.1084/jem.20052454; Carlos CA, 2005, J IMMUNOL, V175, P1628, DOI 10.4049/jimmunol.175.3.1628; Casares N, 2005, J EXP MED, V202, P1691, DOI 10.1084/jem.20050915; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; Chan CW, 2006, NAT MED, V12, P207, DOI 10.1038/nm1352; Chaperot L, 2001, BLOOD, V97, P3210, DOI 10.1182/blood.V97.10.3210; Chaput N, 2004, J IMMUNOL, V172, P2137, DOI 10.4049/jimmunol.172.4.2137; Chen ML, 2005, P NATL ACAD SCI USA, V102, P419, DOI 10.1073/pnas.0408197102; Colonna M, 2007, IMMUNITY, V27, P419, DOI 10.1016/j.immuni.2007.08.006; Coventry BJ, 2003, BRIT J CANCER, V89, P533, DOI 10.1038/sj.bjc.6601114; Della Bella S, 2003, BRIT J CANCER, V89, P1463, DOI 10.1038/sj.bjc.6601243; Della Bella S, 2006, CLIN IMMUNOL, V119, P317, DOI 10.1016/j.clim.2006.01.011; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Drake CG, 2006, ADV IMMUNOL, V90, P51, DOI 10.1016/S0065-2776(06)90002-9; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; Dubsky P, 2007, EUR J IMMUNOL, V37, P1678, DOI 10.1002/eji.200636329; Dudziak D, 2007, SCIENCE, V315, P107, DOI 10.1126/science.1136080; Dunn GP, 2006, NAT REV IMMUNOL, V6, P836, DOI 10.1038/nri1961; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Eisenthal A, 2001, HUM PATHOL, V32, P803, DOI 10.1053/hupa.2001.26455; Elliott B, 2007, CLIN CANCER RES, V13, P3825, DOI 10.1158/1078-0432.CCR-07-0358; ENK AH, 1992, J IMMUNOL, V149, P92; Fanger NA, 1999, J EXP MED, V190, P1155, DOI 10.1084/jem.190.8.1155; Ferlazzo G, 2002, J EXP MED, V195, P343, DOI 10.1084/jem.20011149; Fernandez NC, 1999, NAT MED, V5, P405, DOI 10.1038/7403; Fujii SI, 2004, J EXP MED, V199, P1607, DOI 10.1084/jem.20040317; FURIHATA M, 1992, VIRCHOWS ARCH B, V61, P409, DOI 10.1007/BF02890444; FURUKAWA T, 1984, JPN J CLIN ONCOL, V14, P647; Furumoto K, 2004, J CLIN INVEST, V113, P774, DOI 10.1172/JCI200419762; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Gerlini G, 2007, CLIN IMMUNOL, V125, P184, DOI 10.1016/j.clim.2007.07.018; Ghiringhelli F, 2005, J EXP MED, V202, P919, DOI 10.1084/jem.20050463; Gillessen S, 2003, P NATL ACAD SCI USA, V100, P8874, DOI 10.1073/pnas.1033098100; Gilliet M, 2002, J EXP MED, V195, P695, DOI 10.1084/jem.20011603; Gilliet M, 2002, HUM IMMUNOL, V63, P1149, DOI 10.1016/S0198-8859(02)00753-X; Goldman SA, 1998, ARCH OTOLARYNGOL, V124, P641, DOI 10.1001/archotol.124.6.641; Grohmann U, 2002, NAT IMMUNOL, V3, P1097, DOI 10.1038/ni846; Hartmann E, 2003, CANCER RES, V63, P6478; Hiltbold EM, 2000, J IMMUNOL, V165, P3730, DOI 10.4049/jimmunol.165.7.3730; Hirano F, 2005, CANCER RES, V65, P1089; Hoeffel G, 2007, IMMUNITY, V27, P481, DOI 10.1016/j.immuni.2007.07.021; Honig A, 2005, ANTICANCER RES, V25, P1747; Ikarashi Y, 2001, J EXP MED, V194, P1179, DOI 10.1084/jem.194.8.1179; Inoshima N, 2002, CLIN CANCER RES, V8, P3480; INOUE K, 1993, VIRCHOWS ARCH A, V422, P351, DOI 10.1007/BF01605452; Ishigami S, 2003, ONCOL REP, V10, P1237; Ishigami S, 1998, ONCOLOGY-BASEL, V55, P65, DOI 10.1159/000011837; Ito T, 2007, J EXP MED, V204, P105, DOI 10.1084/jem.20061660; Iwamoto M, 2003, INT J CANCER, V104, P92, DOI 10.1002/ijc.10915; Josien R, 1997, J EXP MED, V186, P467, DOI 10.1084/jem.186.3.467; Ju XS, 2004, GENE, V331, P159, DOI 10.1016/j.gene.2004.02.018; Jung S, 2002, IMMUNITY, V17, P211, DOI 10.1016/S1074-7613(02)00365-5; Kaplan DH, 2005, IMMUNITY, V23, P611, DOI 10.1016/j.immuni.2005.10.008; Kawamura K, 2006, BLOOD, V107, P1031, DOI 10.1182/blood-2005-04-1737; Kissenpfennig A, 2005, IMMUNITY, V22, P643, DOI 10.1016/j.immuni.2005.04.004; Kissenpfennig A, 2006, TRENDS IMMUNOL, V27, P132, DOI 10.1016/j.it.2006.01.003; Kissenpfennig A, 2005, MOL CELL BIOL, V25, P88, DOI 10.1128/MCB.25.1.88-99.2005; Kohrt HE, 2005, PLOS MED, V2, P904, DOI 10.1371/journal.pmed.0020284; Kukreja A, 2006, J EXP MED, V203, P1859, DOI 10.1084/jem.20052136; Kusmartsev S, 2003, CANCER RES, V63, P4441; Ladanyi A, 2004, CLIN CANCER RES, V10, P521, DOI 10.1158/1078-0432.CCR-1161-03; Ladanyi A, 2007, CANCER IMMUNOL IMMUN, V56, P1459, DOI 10.1007/s00262-007-0286-3; Lespagnard L, 1999, INT J CANCER, V84, P309; Liu JG, 2004, J IMMUNOL, V173, P1184, DOI 10.4049/jimmunol.173.2.1184; Liu YJ, 2005, ANNU REV IMMUNOL, V23, P275, DOI 10.1146/annurev.immunol.23.021704.115633; Long EO, 2007, IMMUNITY, V26, P385, DOI 10.1016/j.immuni.2007.04.001; Loser K, 2005, J IMMUNOL, V174, P5298, DOI 10.4049/jimmunol.174.9.5298; Lucas M, 2007, IMMUNITY, V26, P503, DOI 10.1016/j.immuni.2007.03.006; Mach N, 2000, CANCER RES, V60, P3239; MAYORDOMO JI, 1995, NAT MED, V1, P1297, DOI 10.1038/nm1295-1297; McLellan AD, 1996, EUR J IMMUNOL, V26, P1204, DOI 10.1002/eji.1830260603; Menetrier-Caux C, 1998, BLOOD, V92, P4778, DOI 10.1182/blood.V92.12.4778; Mirza N, 2006, CANCER RES, V66, P9299, DOI 10.1158/0008-5472.CAN-06-1690; Mohamadzadeh M, 2001, J EXP MED, V194, P1013, DOI 10.1084/jem.194.7.1013; Moretta A, 2002, NAT REV IMMUNOL, V2, P957, DOI 10.1038/nri956; Moseman EA, 2004, J IMMUNOL, V173, P4433, DOI 10.4049/jimmunol.173.7.4433; Munn DH, 2005, BLOOD, V105, P2618, DOI 10.1182/blood-2005-01-0122; Munn DH, 2004, J CLIN INVEST, V114, P280, DOI 10.1172/JCI200421583; Nakakubo Y, 2003, BRIT J CANCER, V89, P1736, DOI 10.1038/sj.bjc.6601331; Nefedova Y, 2004, J IMMUNOL, V172, P464, DOI 10.4049/jimmunol.172.1.464; O'Donnell RK, 2007, CANCER LETT, V255, P145, DOI 10.1016/j.canlet.2007.04.003; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Pages F, 2005, NEW ENGL J MED, V353, P2654, DOI 10.1056/NEJMoa051424; Pashenkov M, 2006, J CLIN ONCOL, V24, P5716, DOI 10.1200/JCO.2006.07.9129; Pereira CF, 2007, J IMMUNOTHER, V30, P705, DOI 10.1097/CJI.0b013e31812e6256; Perrot I, 2007, J IMMUNOL, V178, P2763, DOI 10.4049/jimmunol.178.5.2763; Pulendran B, 2004, EUR J IMMUNOL, V34, P66, DOI 10.1002/eji.200324567; Reichert TE, 2001, CANCER, V91, P2136, DOI 10.1002/1097-0142(20010601)91:11<2136::AID-CNCR1242>3.0.CO;2-Q; Riemann H, 2005, J IMMUNOL, V175, P5866, DOI 10.4049/jimmunol.175.9.5866; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; Rissoan MC, 2002, BLOOD, V100, P3295, DOI 10.1182/blood-2002-02-0638; SAHIN U, 1995, P NATL ACAD SCI USA, V92, P11810, DOI 10.1073/pnas.92.25.11810; Salaun B, 2007, CLIN CANCER RES, V13, P4565, DOI 10.1158/1078-0432.CCR-07-0274; Sandel MH, 2005, CLIN CANCER RES, V11, P2576, DOI 10.1158/1078-0432.CCR-04-1448; Schmitz V, 2006, HEPATOLOGY, V44, P430, DOI 10.1002/hep.21274; Schnurr M, 2003, BLOOD, V102, P613, DOI 10.1182/blood-2002-12-3745; Schnurr M, 2004, BLOOD, V103, P1391, DOI 10.1182/blood-2003-06-1959; Schnurr M, 2005, BLOOD, V105, P2465, DOI 10.1182/blood-2004-08-3105; Shimizu K, 2007, J EXP MED, V204, P2641, DOI 10.1084/jem.20070458; Simonetti O, 2007, INT J IMMUNOPATH PH, V20, P325, DOI 10.1177/039463200702000212; Smyth MJ, 2006, ADV IMMUNOL, V90, P1, DOI 10.1016/S0065-2776(06)90001-7; Soiffer R, 2003, J CLIN ONCOL, V21, P3343, DOI 10.1200/JCO.2003.07.005; Spisek R, 2007, BLOOD, V109, P4839, DOI 10.1182/blood-2006-10-054221; Srivastava RM, 2007, INT IMMUNOL, V19, P591, DOI 10.1093/intimm/dxm024; Stary G, 2007, J EXP MED, V204, P1441, DOI 10.1084/jem.20070021; Steinbrink K, 1997, J IMMUNOL, V159, P4772; Steinman RM, 2007, NAT MED, V13, P1155, DOI 10.1038/nm1643; Steinman RM, 2007, NATURE, V449, P419, DOI 10.1038/nature06175; Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040; Sumimoto H, 2006, J EXP MED, V203, P1651, DOI 10.1084/jem.20051848; Suzuki A, 2002, J PATHOL, V196, P37, DOI 10.1002/path.1018; Tacken PJ, 2005, BLOOD, V106, P1278, DOI 10.1182/blood-2005-01-0318; Taieb J, 2006, NAT MED, V12, P214, DOI 10.1038/nm1356; Taieb J, 2006, J IMMUNOL, V176, P2722, DOI 10.4049/jimmunol.176.5.2722; Tang QZ, 2006, NAT IMMUNOL, V7, P551, DOI 10.1038/ni0606-551; Tang TJ, 2006, HUM PATHOL, V37, P332, DOI 10.1016/j.humpath.2005.11.007; TEPPER RI, 1994, HUM GENE THER, V5, P153, DOI 10.1089/hum.1994.5.2-153; Treilleux I, 2004, CLIN CANCER RES, V10, P7466, DOI 10.1158/1078-0432.CCR-04-0684; Trinite B, 2000, J IMMUNOL, V165, P4202, DOI 10.4049/jimmunol.165.8.4202; Trinite B, 2005, J IMMUNOL, V175, P2408, DOI 10.4049/jimmunol.175.4.2408; TSUJITANI S, 1990, CANCER, V66, P2012, DOI 10.1002/1097-0142(19901101)66:9<2012::AID-CNCR2820660928>3.0.CO;2-N; Ueno H, 2007, IMMUNOL REV, V219, P118, DOI 10.1111/j.1600-065X.2007.00551.x; Valmori D, 2007, P NATL ACAD SCI USA, V104, P8947, DOI 10.1073/pnas.0703395104; Villadangos JA, 2007, NAT REV IMMUNOL, V7, P543, DOI 10.1038/nri2103; von Bergwelt-Baildon MS, 2006, BLOOD, V108, P228, DOI 10.1182/blood-2005-08-3507; Yanagimoto H, 2005, CLIN IMMUNOL, V114, P52, DOI 10.1016/j.clim.2004.09.007; Yilmaz A, 2006, J LEUKOCYTE BIOL, V79, P529, DOI 10.1189/jlb.0205064; Yin XY, 2003, HEPATO-GASTROENTEROL, V50, P1281; Yoneyama H, 2005, J EXP MED, V202, P425, DOI 10.1084/jem.20041961; Zhang JQ, 2006, BLOOD, V107, P3600, DOI 10.1182/blood-2005-09-3842; Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177; Zhang Q, 2005, CANCER RES, V65, P1761, DOI 10.1158/0008-5472.CAN-04-3169; Zitvogel L, 2002, J EXP MED, V195, pf9, DOI 10.1084/jem.20012040; Zitvogel L, 1998, NAT MED, V4, P594, DOI 10.1038/nm0598-594; Zitvogel L, 2008, NAT REV IMMUNOL, V8, P59, DOI 10.1038/nri2216; Zou WP, 2001, NAT MED, V7, P1339, DOI 10.1038/nm1201-1339	153	68	71	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 6	2008	27	45					5920	5931		10.1038/onc.2008.270	http://dx.doi.org/10.1038/onc.2008.270			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	355QE	18836473				2022-12-17	WOS:000259722600007
J	Zhu, Q; Youn, H; Tang, J; Tawfit, O; Dennis, K; Terranova, PF; Du, J; Raynal, P; Thrasher, JB; Li, B				Zhu, Q.; Youn, H.; Tang, J.; Tawfit, O.; Dennis, K.; Terranova, P. F.; Du, J.; Raynal, P.; Thrasher, J. B.; Li, B.			Phosphoinositide 3-OH kinase p85 alpha and p110 beta are essential for androgen receptor transactivation and tumor progression in prostate cancers	ONCOGENE			English	Article						prostate cancer; PI3K; androgen receptor; siRNA; tumor progression; mouse xenograft	PROTEIN-COUPLED RECEPTORS; GENE-EXPRESSION; PHOSPHATIDYLINOSITOL 3-KINASES; BETA-GAMMA; ACTIVATION; CELLS; TRANSCRIPTION; PATHWAY; P110-ALPHA; SUBUNITS	Phosphoinositide 3-OH kinases (PI3Ks) are a group of major intracellular signaling molecules. In our previous study, we found that inhibition of PI3K activity suppressed the androgen receptor (AR)-mediated gene expression in prostate cancer cells. The AR has been considered as a critical determinant for the development and progression of human prostate cancers. In this study, we sought to identify the PI3K isoforms involved in AR transactivation. Using a gene-specific small interference RNA (siRNA) approach, we determined that the regulatory isoform p85 alpha and the catalytic isoform p110 beta, but not p110 alpha, were required for androgen-stimulated AR transactivation and cell proliferation in prostate cancer cells. Consistently, overexpression of wild-type p110b but not p110 alpha gene led to androgen-independent AR transactivation. Silencing p110 beta gene in prostate cancer cells abolished tumor growth in nude mice. Of the dual (lipid and protein) kinase activities, p110 beta's lipid kinase activity was required for AR transactivation. Further analysis by a chromatin immunoprecipitation assay showed that p110 beta is indispensable for androgen-induced AR-DNA interaction. Finally, gene expression analysis of clinical specimens showed that both p85 alpha and p110 beta were highly expressed in malignant prostate tissues compared to the nonmalignant compartments, and their expression levels correlated significantly with disease progression. Taken together, our data demonstrated that p85 alpha and p110 beta are essential for androgen-stimulated AR transactivation, and their aberrant expression or activation might play an important role in prostate cancer progression.	[Zhu, Q.; Youn, H.; Tang, J.; Thrasher, J. B.; Li, B.] Univ Kansas, Med Ctr, Dept Urol, Kansas City, KS 66160 USA; [Zhu, Q.; Li, B.] Xian Jiaotong Univ, Affiliated Hosp 1, Dept Med Oncol, Xian 710049, Peoples R China; [Tawfit, O.; Dennis, K.; Li, B.] Univ Kansas, Med Ctr, Dept Pathol, Kansas City, KS 66160 USA; [Tawfit, O.; Dennis, K.; Li, B.] Univ Kansas, Med Ctr, Lab Med, Kansas City, KS 66160 USA; [Terranova, P. F.; Li, B.] Univ Kansas, Med Ctr, Deptt Mol & Integrated Physiol, Kansas City, KS 66160 USA; [Du, J.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Raynal, P.] Hop Purpan, INSERM, U563, Bat C, Toulouse, France	University of Kansas; University of Kansas Medical Center; Xi'an Jiaotong University; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; Baylor College of Medicine; CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Li, B (corresponding author), Univ Kansas, Med Ctr, Dept Urol, 3901 Rainbow Blvd,Lied 2045, Kansas City, KS 66160 USA.	bli@kumc.edu	Raynal, Patrick/O-1926-2018	Youn, Hyewon/0000-0003-1006-2689; Raynal, Patrick/0000-0002-6731-3007	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015563] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR015563, P20 RR015563-096219, 1P20RR15563] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bader AG, 2005, NAT REV CANCER, V5, P921, DOI 10.1038/nrc1753; Chini B, 2004, J MOL ENDOCRINOL, V32, P325, DOI 10.1677/jme.0.0320325; Cinar B, 2007, J BIOL CHEM, V282, P29584, DOI 10.1074/jbc.M703310200; Czauderna F, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng127; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Hayakawa M, 2006, BIOORGAN MED CHEM, V14, P6847, DOI 10.1016/j.bmc.2006.06.046; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Holzbeierlein J, 2004, AM J PATHOL, V164, P217, DOI 10.1016/S0002-9440(10)63112-4; Jackson SP, 2005, NAT MED, V11, P507, DOI 10.1038/nm1232; Kasbohm EA, 2005, J BIOL CHEM, V280, P11583, DOI 10.1074/jbc.M414423200; Latil A, 2001, CANCER RES, V61, P1919; Lee SO, 2003, ONCOGENE, V22, P7981, DOI 10.1038/sj.onc.1206735; Li BY, 2007, ASIAN J ANDROL, V9, P41, DOI 10.1111/J.1745-7262.2007.00226.x; Li BY, 2007, CARCINOGENESIS, V28, P572, DOI 10.1093/carcin/bgl193; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li PF, 2001, J BIOL CHEM, V276, P20444, DOI 10.1074/jbc.M010226200; Liao XB, 2004, ENDOCRINOLOGY, V145, P2941, DOI 10.1210/en.2003-1519; Liao XB, 2005, MOL CANCER THER, V4, P505, DOI 10.1158/1535-7163.MCT-04-0313; Lu ML, 2001, J BIOL CHEM, V276, P13442, DOI 10.1074/jbc.M006598200; Majumder PK, 2005, ONCOGENE, V24, P7465, DOI 10.1038/sj.onc.1209096; Mellinghoff IK, 2004, CANCER CELL, V6, P517, DOI 10.1016/j.ccr.2004.09.031; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Murillo H, 2001, ENDOCRINOLOGY, V142, P4795, DOI 10.1210/en.142.11.4795; Scher HI, 2005, J CLIN ONCOL, V23, P8253, DOI 10.1200/JCO.2005.03.4777; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Shanmugam I, 2007, CELL DEATH DIFFER, V14, P2085, DOI 10.1038/sj.cdd.4402227; Sharma M, 2002, J BIOL CHEM, V277, P30935, DOI 10.1074/jbc.M201919200; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Sun AJ, 2007, PROSTATE, V67, P976, DOI 10.1002/pros.20586; Sun A, 2007, PROSTATE, V67, P203, DOI 10.1002/pros.20521; Sun M, 2003, J BIOL CHEM, V278, P42992, DOI 10.1074/jbc.M306295200; Yart A, 2002, J BIOL CHEM, V277, P21167, DOI 10.1074/jbc.M110411200; Zhao JJ, 2005, P NATL ACAD SCI USA, V102, P18443, DOI 10.1073/pnas.0508988102	33	68	73	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2008	27	33					4569	4579		10.1038/onc.2008.91	http://dx.doi.org/10.1038/onc.2008.91			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	332IS	18372911	Green Accepted			2022-12-17	WOS:000258077300006
J	Leung, JY; Ehmann, GL; Giangrande, PH; Nevins, JR				Leung, J. Y.; Ehmann, G. L.; Giangrande, P. H.; Nevins, J. R.			A role for Myc in facilitating transcription activation by E2F1	ONCOGENE			English	Article						E2F1; Myc; promoter; transcription activation	C-MYC; DROSOPHILA-MYC; CELL-CYCLE; S-PHASE; GENE; BINDING; IDENTIFICATION; SPECIFICITY; EXPRESSION; INDUCTION	Previous work has demonstrated that E2F proteins regulate the expression of various genes encoding proteins essential for DNA replication and cell-cycle progression. E2F1 in particular is required for the initial entry to the cell cycle from a quiescent state and is required for the activation of other E2F genes. Other work has demonstrated a role for the Myc transcription factor in the activation of a large number of genes associated with cell growth, including E2F genes. We now show that Myc is required to allow the interaction of the E2F1 protein with the E2F gene promoters. As such, Myc thus provides a link between the development of a growth-competent state during the initial stage of G1 and the activation of genes essential for DNA replication at G1/S.	[Leung, J. Y.; Ehmann, G. L.; Giangrande, P. H.; Nevins, J. R.] Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Duke Inst Genome Sci & Policy, Durham, NC 27710 USA	Duke University	Nevins, JR (corresponding author), Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Duke Inst Genome Sci & Policy, Box 3382, Durham, NC 27710 USA.	j.nevins@duke.edu						Adams MR, 2000, MOL CELL BIOL, V20, P3633, DOI 10.1128/MCB.20.10.3633-3639.2000; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Giangrande PH, 2003, MOL CELL BIOL, V23, P3707, DOI 10.1128/MCB.23.11.3707-3720.2003; Giangrande PH, 2004, EMBO J, V23, P1336, DOI 10.1038/sj.emboj.7600134; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hallstrom TC, 2003, P NATL ACAD SCI USA, V100, P10848, DOI 10.1073/pnas.1831408100; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; Kong LJ, 2007, ONCOGENE, V26, P321, DOI 10.1038/sj.onc.1209817; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; Lin WC, 2001, GENE DEV, V15, P1833; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Orian A, 2003, GENE DEV, V17, P1101, DOI 10.1101/gad.1066903; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; Takahashi Y, 2000, GENE DEV, V14, P804; Walker W, 2005, J CELL BIOL, V169, P405, DOI 10.1083/jcb.200411013; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043	24	68	71	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2008	27	30					4172	4179		10.1038/onc.2008.55	http://dx.doi.org/10.1038/onc.2008.55			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	324DB	18345030				2022-12-17	WOS:000257496800004
J	McCracken, SRC; Ramsay, A; Heer, R; Mathers, ME; Jenkins, BL; Edwards, J; Robson, CN; Marquez, R; Cohen, P; Leung, HY				McCracken, S. R. C.; Ramsay, A.; Heer, R.; Mathers, M. E.; Jenkins, B. L.; Edwards, J.; Robson, C. N.; Marquez, R.; Cohen, P.; Leung, H. Y.			Aberrant expression of extracellular signal-regulated kinase 5 in human prostate cancer	ONCOGENE			English	Article						prostate cancer; ERK5; MEK5	ACTIVATED PROTEIN-KINASE; RECEPTOR TYROSINE KINASES; MAP KINASE; DIFFERENTIAL EXPRESSION; ERK5; PROLIFERATION; MEK5; OVEREXPRESSION; IDENTIFICATION; BMK1/ERK5	Abnormal intracellular signaling contributes to carcinogenesis and may represent novel therapeutic targets. mitogen/extracellular signal-regulated kinase kinase-5 (MEK5) overexpression is associated with aggressive prostate cancer. In this study, we examined the role of extracellular signal-regulated kinase (ERK5, an MAPK and specific substrate for MEK5) in prostate cancer. ERK5 immunoreactivity was significantly upregulated in high-grade prostate cancer when compared to benign prostatic hyperplasia (P < 0.0001). Increased ERK5 cytoplasmic signals correlated closely with Gleason sum score (P < 0.0001), bony metastases (P = 0.0044) and locally advanced disease at diagnosis (P = 0.0023), with a weak association with shorter disease-specific survival (P = 0.036). A subgroup of patients showed strong nuclear ERK5 localization, which correlated with poor diseasespecific survival and, on multivariant analysis, was an independent prognostic factor (P < 0.0001). Analysis of ERK5 expression in matched tumor pairs (before and after hormone relapse, n = 26) revealed ERK5 nuclear expression was significantly associated with hormone-insensitive disease (P = 0.0078). Similarly, ERK5 protein expression was increased in an androgen-independent LNCaP subline. We obtained the following in vitro and in vivo evidence to support the above expression data: (1) cotransfection of ERK5wt and MEK5D constructs in PC3 cells results in predominant ERK5 nuclear localization, similar to that observed in aggressive clinical disease; (2) ERK5-overexpressing PC3 cells have enhanced proliferative, migrative and invasive capabilities in vitro (P < 0.0001), and were dramatically more efficient in forming tumors, with a shorter mean time for tumors to reach a critical volume of 1000 mm(3), in vivo (P < 0.0001); (3) the MEK1 inhibitor, PD184352, blocking ERK1/2 activation at low dose, did not suppress proliferation but did significantly decrease proliferation at a higher dose required to inhibit ERK5 activation. Taken together, our results establish the potential importance of ERK5 in aggressive prostate cancer.	[McCracken, S. R. C.; Heer, R.; Jenkins, B. L.; Robson, C. N.; Leung, H. Y.] Univ Newcastle, No Inst Canc Res, Urol Res Grp, Newcastle Upon Tyne, Tyne & Wear, England; [Ramsay, A.; Leung, H. Y.] Beatson Inst Canc Res, Canc Res UK Labs, Glasgow G61 1BD, Lanark, Scotland; [Ramsay, A.; Edwards, J.; Leung, H. Y.] Univ Glasgow, Sect Surg & Translat Res, Div Canc Sci & Mol Pathol, Glasgow, Lanark, Scotland; [Mathers, M. E.] Royal Victoria Infirm, Dept Cellular Pathol, Newcastle Upon Tyne, Tyne & Wear, England; [Marquez, R.; Cohen, P.] Univ Dundee, Med Res Council Protein, Phosphorylat Unit, Sch Life Sci, Dundee, Scotland	Newcastle University - UK; Beatson Institute; University of Glasgow; Newcastle University - UK; University of Dundee	Leung, HY (corresponding author), Glasgow Royal Infirm, Univ Sect Surg, Univ Tower Level 2, Glasgow G31 2ER, Lanark, Scotland.	h.leung@beatson.gla.ac.uk	Edwards, Joanne/J-1903-2015; Marquez, Rudi/F-4045-2014	Edwards, Joanne/0000-0002-7192-6906; Marquez, Rudi/0000-0001-9777-2012; Leung, Hing Y./0000-0002-3933-3975	Medical Research Council [MC_U127084348, G0500966] Funding Source: Medline; MRC [MC_U127084348, G0500966] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Adler HL, 1999, J UROLOGY, V161, P182, DOI 10.1016/S0022-5347(01)62092-5; Armes JE, 1999, CANCER RES, V59, P2011; Barros JC, 2005, J CELL SCI, V118, P1663, DOI 10.1242/jcs.02308; Bartlett JMS, 2005, J PATHOL, V205, P522, DOI 10.1002/path.1735; Bouras T, 2001, CANCER RES, V61, P903; Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698; Buschbeck M, 2005, J BIOL CHEM, V280, P2659, DOI 10.1074/jbc.M412599200; Cameron SJ, 2003, J BIOL CHEM, V278, P18682, DOI 10.1074/jbc.M213283200; Carvajal-Vergara X, 2005, BLOOD, V105, P4492, DOI 10.1182/blood-2004-08-2985; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; Dudderidge TJ, 2007, BRIT J CANCER, V96, P1384, DOI 10.1038/sj.bjc.6603718; English JM, 1998, J BIOL CHEM, V273, P3854, DOI 10.1074/jbc.273.7.3854; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; Gnanapragasam V, 2003, BRIT J CANCER, V88, P1432, DOI 10.1038/sj.bjc.6600875; Hayashi M, 2005, CANCER RES, V65, P7699, DOI 10.1158/0008-5472.CAN-04-4540; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kasler HG, 2000, MOL CELL BIOL, V20, P8382, DOI 10.1128/MCB.20.22.8382-8389.2000; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; Kondoh K, 2006, MOL CELL BIOL, V26, P1679, DOI 10.1128/MCB.26.5.1679-1690.2006; Mehta PB, 2003, ONCOGENE, V22, P1381, DOI 10.1038/sj.onc.1206154; Mody N, 2003, BIOCHEM J, V372, P567, DOI 10.1042/BJ20030193; Mody N, 2001, FEBS LETT, V502, P21, DOI 10.1016/S0014-5793(01)02651-5; Okamoto M, 1997, ENDOCRINOLOGY, V138, P5071, DOI 10.1210/en.138.11.5071; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; Rubin MA, 2000, CLIN CANCER RES, V6, P1038; Selcher JC, 2001, LEARN MEMORY, V8, P11, DOI 10.1101/lm.37001; Terasawa K, 2003, GENES CELLS, V8, P263, DOI 10.1046/j.1365-2443.2003.00631.x; Uzgare AR, 2003, PROSTATE, V55, P128, DOI 10.1002/pros.10212; Wang X, 2005, MOL CELL BIOL, V25, P336, DOI 10.1128/MCB.25.1.336-345.2005; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	34	68	72	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2008	27	21					2978	2988		10.1038/sj.onc.1210963	http://dx.doi.org/10.1038/sj.onc.1210963			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	298IP	18071319	Green Accepted			2022-12-17	WOS:000255681700005
J	Cai, DH; Wang, D; Keefer, J; Yeamans, C; Hensley, K; Friedman, AD				Cai, D. H.; Wang, D.; Keefer, J.; Yeamans, C.; Hensley, K.; Friedman, A. D.			C/EBP alpha: AP-1 leucine zipper heterodimers bind novel DNA elements, activate the PU.1 promoter and direct monocyte lineage commitment more potently than C/EBP alpha homodimers or AP-1	ONCOGENE			English	Article						C/EBP alpha; C-jun; PU.1; myeloid	COLONY-STIMULATING FACTOR; TRANSCRIPTION FACTORS; MYELOID PROGENITORS; COILED-COIL; C-JUN; DIFFERENTIATION; SPECIFICITY; FOS; DIMERIZATION; MACROPHAGE	The basic-region leucine zipper (BR-LZ or bZIP) transcription factors dimerize via their LZ domains to position the adjacent BRs for DNA binding. Members of the C/EBP, AP-1 and CREB/ATF bZIP subfamilies form homodimeric or heterodimeric complexes with other members of the same subset and bind-specific DNA motifs. Here we demonstrate that C/EBP alpha also zippers with AP-1 proteins and that this interaction allows contact with novel DNA elements and induction of monocyte lineage commitment in myeloid progenitors. A leucine zipper swap: gel shift assay demonstrates that C/EBP alpha zippers with c-Jun, JunB or c-Fos, but not with c-Maf or MafB. To evaluate activities of specific homodimers or heterodimers we utilized LZs with acid (LZE) or basic (LZK) residues in their salt bridge positions. C/EBP alpha LZE: C/EBP alpha LZK preferentially binds a C/EBP site, c-JunLZE: c-FosLZK an AP-1 site and C/EBP alpha LZE: c-JunLZK a hybrid element identified as TTGCGTCAT by oligonucleotide selection. In murine myeloid progenitors, C/EBP alpha:c-Jun or C/EBP alpha:c-Fos LZE: LZK heterodimers induce monocyte lineage commitment with markedly increased potency compared with C/EBP alpha or c-Jun homodimers or c-Jun: c-Fos heterodimers, demonstrating a positive functional consequence of C/EBP: AP-1 bZIP subfamily interaction. C/EBP alpha:cJun binds and activates the endogenous PU.1 promoter, providing one mechanism for induction of monopoiesis by this complex.	[Cai, D. H.; Wang, D.; Keefer, J.; Yeamans, C.; Hensley, K.; Friedman, A. D.] Johns Hopkins Univ, Sch Med, Div Pediat Oncol, Baltimore, MD 21231 USA	Johns Hopkins University	Friedman, AD (corresponding author), Johns Hopkins Univ, Sch Med, Div Pediat Oncol, CRB I,Room 253,1650 Orleans St, Baltimore, MD 21231 USA.	afriedm2@jhmi.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL082948] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL082948, R01 HL082948-01, R01 HL082948-02, R01 HL082948-03] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bakiri L, 2002, MOL CELL BIOL, V22, P4952, DOI 10.1128/MCB.22.13.4952-4964.2002; Cao WS, 1997, ONCOGENE, V15, P1315, DOI 10.1038/sj.onc.1201305; Dahl R, 2003, NAT IMMUNOL, V4, P1029, DOI 10.1038/ni973; Gombart AF, 2007, J LEUKOCYTE BIOL, V81, P1535, DOI 10.1189/jlb.0806516; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Heath V, 2004, BLOOD, V104, P1639, DOI 10.1182/blood-2003-11-3963; Hegde SP, 1999, BLOOD, V94, P1578, DOI 10.1182/blood.V94.5.1578.417k18_1578_1589; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; Kelly LM, 2000, EMBO J, V19, P1987, DOI 10.1093/emboj/19.9.1987; Kummalue T, 2003, J LEUKOCYTE BIOL, V74, P464, DOI 10.1189/jlb.1202622; Li AC, 1998, J BIOL CHEM, V273, P5389, DOI 10.1074/jbc.273.9.5389; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; Newman JRS, 2003, SCIENCE, V300, P2097, DOI 10.1126/science.1084648; OSHEA EK, 1993, CURR BIOL, V3, P658, DOI 10.1016/0960-9822(93)90063-T; Rangatia J, 2002, MOL CELL BIOL, V22, P8681, DOI 10.1128/MCB.22.24.8681-8694.2002; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; Wang D, 2006, BLOOD, V108, P1223, DOI 10.1182/blood-2005-12-008763; Wang QF, 2002, BLOOD, V99, P2776, DOI 10.1182/blood.V99.8.2776; Yeamans C, 2007, BLOOD, V110, P3136, DOI 10.1182/blood-2007-03-080291; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang P, 2004, IMMUNITY, V21, P853, DOI 10.1016/j.immuni.2004.11.006	22	68	72	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2008	27	19					2772	2779		10.1038/sj.onc.1210940	http://dx.doi.org/10.1038/sj.onc.1210940			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292IK	18026136	Green Accepted			2022-12-17	WOS:000255259500012
J	Jeffers, LJ; Coull, BJ; Stack, SJ; Morrison, CG				Jeffers, L. J.; Coull, B. J.; Stack, S. J.; Morrison, C. G.			Distinct BRCT domains in Mcph1/Brit1 mediate ionizing radiation-induced focus formation and centrosomal localization	ONCOGENE			English	Article						DNA-damage response; microcephalin; BRCT; cell cycle checkpoint; centrosome	DOUBLE-STRAND BREAKS; HISTONE H2AX; DNA-DAMAGE; CHROMOSOME CONDENSATION; NUCLEAR FOCI; PROTEIN; MICROCEPHALIN; CHECKPOINT; REPAIR; UBIQUITINATION	Microcephalin (MCPH1/BRIT1) forms ionizing radiation-induced nuclear foci (IRIF) and is required for DNA damage-responsive S and G(2)-M-phase checkpoints. MCPH1 contains three BRCT domains. Here we report the cloning of chicken Mcph1 (cMcph1) and functional analysis of its individual BRCT domains. Full-length cMcph1 localized to centrosomes throughout the cell cycle and formed IRIF that colocalized with gamma-H2AX. The tandem C-terminal BRCT2 and BRCT3 domains of cMcph1 were necessary for IRIF formation, while the N-terminal BRCT1 was required for centrosomal localization in irradiated cells. Centrosomal targeting of cMcph1 was independent of ATM, Brca1 or Chk1. cMcph1 formed IRIF in ATM- and Brca1-deficient cells, but not in H2AX-deficient cells. Inability to form cMcph1 IRIF impaired the cellular response to DNA damage. These results suggest that the role of microcephalin in the vertebrate DNA damage response is controlled by interaction of the C-terminal BRCT domains with gamma-H2AX.	[Jeffers, L. J.; Coull, B. J.; Stack, S. J.; Morrison, C. G.] Natl Univ Ireland Galway, Dept Biochem & NCBES, Galway, Ireland	Ollscoil na Gaillimhe-University of Galway	Morrison, CG (corresponding author), Natl Univ Ireland Galway, Dept Biochem & NCBES, Univ Rd, Galway, Ireland.	ciaran.morrison@nuigalway.ie	Morrison, Ciaran/B-6568-2008; Morrison, Ciaran/AAH-2034-2019	Morrison, Ciaran/0000-0003-2401-7029; Morrison, Ciaran/0000-0003-2401-7029; Coull, Barry/0000-0001-5438-7085				Alderton GK, 2006, NAT CELL BIOL, V8, P725, DOI 10.1038/ncb1431; Au WWY, 2005, J BIOL CHEM, V280, P6993, DOI 10.1074/jbc.M408879200; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bond J, 2005, NAT GENET, V37, P353, DOI 10.1038/ng1539; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Dodson H, 2004, EMBO J, V23, P3864, DOI 10.1038/sj.emboj.7600393; Glover JNM, 2004, TRENDS BIOCHEM SCI, V29, P579, DOI 10.1016/j.tibs.2004.09.010; Haren L, 2006, J CELL BIOL, V172, P505, DOI 10.1083/jcb.200510028; Jackson AP, 2002, AM J HUM GENET, V71, P136, DOI 10.1086/341283; Lin SY, 2005, P NATL ACAD SCI USA, V102, P15105, DOI 10.1073/pnas.0507722102; Lin SY, 2003, CELL, V113, P881, DOI 10.1016/S0092-8674(03)00430-6; Manke IA, 2003, SCIENCE, V302, P636, DOI 10.1126/science.1088877; Neitzel H, 2002, AM J HUM GENET, V70, P1015, DOI 10.1086/339518; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; RAI R, 2006, CANCER CELL, V10, P1; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Sonoda E, 2007, DNA REPAIR, V6, P280, DOI 10.1016/j.dnarep.2006.10.025; Starita LM, 2003, CURR OPIN CELL BIOL, V15, P345, DOI 10.1016/S0955-0674(03)00042-5; Stucki M, 2005, CELL, V123, P1213, DOI 10.1016/j.cell.2005.09.038; Trimborn M, 2004, AM J HUM GENET, V75, P261, DOI 10.1086/422855; Vandenberg CJ, 2003, MOL CELL, V12, P247, DOI 10.1016/S1097-2765(03)00281-8; Xu XZ, 2004, J BIOL CHEM, V279, P34091, DOI 10.1074/jbc.C400139200; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060	26	68	70	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2008	27	1					139	144		10.1038/sj.onc.1210595	http://dx.doi.org/10.1038/sj.onc.1210595			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	247YO	17599047				2022-12-17	WOS:000252118700014
J	Bilanges, B; Stokoe, D				Bilanges, B.; Stokoe, D.			Mechanisms of translational deregulation in human tumors and therapeutic intervention strategies	ONCOGENE			English	Review						protein synthesis; tumor suppressor genes; mTOR; targeted therapy	INITIATION-FACTOR 4E; TRANSFORMATION SUPPRESSOR PDCD4; MESSENGER-RNA TRANSLATION; GENE-EXPRESSION PROFILES; ELONGATION-FACTOR EEF1A2; PROTEIN-SYNTHESIS; EUKARYOTIC TRANSLATION; MAMMALIAN TARGET; BINDING-PROTEIN; CELL-GROWTH	Analysis of the recurrent genetic aberrations present in human tumors provides insight into how normal cells escape appropriate proliferation and survival cues. Commonly mutated genes encode proteins that monitor DNA damage ( e. g., p53), proteins that regulate the cell cycle ( such as Rb), and proteins that regulate signal transduction pathways ( such as APC, PTEN and Ras). Analysis of the relevant targets and downstream events of these genes in normal and tumor cells will clearly highlight important pathways for tumorigenesis. However, more infrequent mutations are also informative in de. ning events critical for the process of tumorigenesis, and often delineate important pathways lying downstream of commonly mutated oncogenes and tumor suppressors. Together, these studies have led to the conclusion that deregulated protein synthesis plays an important role in human cancer. This review will discuss the evidence implicating mRNA translation as an important downstream consequence of signal transduction pathways initiated by mutated oncogenes and tumor suppressors, as well as additional genetic findings implicating the importance of global and specific translational control in human cancer. It will also discuss therapeutic strategies that take advantage of differences in translational regulation between normal and tumor cells.	Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94115 USA	University of California System; University of California San Francisco	Bilanges, B (corresponding author), Univ Calif San Francisco, Canc Res Inst, 2340 Sutter St,Room N319, San Francisco, CA 94115 USA.	bbilanges@cc.ucsf.edu; dstokoe@cc.ucsf.edu	Bilanges, Benoit/AAP-6078-2020	Bilanges, Benoit/0000-0002-6115-3997; Bilanges, Benoit/0000-0003-4400-3716	NCI NIH HHS [P50 CA97257] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA097257] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 2006, ANNU REV BIOCHEM, V75, P137, DOI 10.1146/annurev.biochem.75.103004.142702; Amsterdam A, 2004, PLOS BIOL, V2, P690, DOI 10.1371/journal.pbio.0020139; Anand N, 2002, NAT GENET, V31, P301, DOI 10.1038/ng904; Avdulov S, 2004, CANCER CELL, V5, P553, DOI 10.1016/j.ccr.2004.05.024; Ayala G, 2006, MOL THER, V13, P716, DOI 10.1016/j.ymthe.2005.11.022; Bader AG, 2003, P NATL ACAD SCI USA, V100, P12384, DOI 10.1073/pnas.2135336100; Bader AG, 2005, MOL CELL BIOL, V25, P2095, DOI 10.1128/MCB.25.6.2095-2106.2005; Balachandran S, 2004, CANCER CELL, V5, P51, DOI 10.1016/S1535-6108(03)00330-1; Balachandran S, 2000, IUBMB LIFE, V50, P135, DOI 10.1080/15216540050212169; Barlund M, 2000, J NATL CANCER I, V92, P1252, DOI 10.1093/jnci/92.15.1252; Bauer C, 2001, CANCER, V92, P822, DOI 10.1002/1097-0142(20010815)92:4<822::AID-CNCR1388>3.0.CO;2-A; Bentwich I, 2005, FEBS LETT, V579, P5904, DOI 10.1016/j.febslet.2005.09.040; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Beuvink I, 2005, CELL, V120, P747, DOI 10.1016/j.cell.2004.12.040; BILANGES B, UNPUB TSC1 TSC2 CONT; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Buttitta F, 2005, CLIN CANCER RES, V11, P3198, DOI 10.1158/1078-0432.CCR-04-2308; Byrnes K, 2006, ANN SURG, V243, P684, DOI 10.1097/01.sla.0000216770.23642.d8; Cai DX, 2001, AM J CLIN PATHOL, V115, P213; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2004, P NATL ACAD SCI USA, V101, P11755, DOI 10.1073/pnas.0404432101; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chen CN, 2004, J SURG ONCOL, V86, P22, DOI 10.1002/jso.20037; CHEN S, 2003, P ICASSP HONG KONG C, V4, P640; Choesmel V, 2007, BLOOD, V109, P1275, DOI 10.1182/blood-2006-07-038372; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Cmejlova J, 2006, HAEMATOLOGICA, V91, P1456; Costinean S, 2006, P NATL ACAD SCI USA, V103, P7024, DOI 10.1073/pnas.0602266103; Couch FJ, 1999, CANCER RES, V59, P1408; CRAMTON SE, 1994, GENETICS, V137, P1039; Culjkovic B, 2005, J CELL BIOL, V169, P245, DOI 10.1083/jcb.200501019; Cummins JM, 2006, ONCOGENE, V25, P6220, DOI 10.1038/sj.onc.1209914; Dai MS, 2006, J BIOL CHEM, V281, P24304, DOI 10.1074/jbc.M602596200; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; DeFatta RJ, 2002, CANCER GENE THER, V9, P573, DOI 10.1038/sj.cgt.7700468; deGraffenried LA, 2004, ANN ONCOL, V15, P1510, DOI 10.1093/annonc/mdh388; Dez C, 2004, CURR OPIN MICROBIOL, V7, P631, DOI 10.1016/j.mib.2004.10.007; Dizin E, 2006, J BIOL CHEM, V281, P24236, DOI 10.1074/jbc.M602176200; Dong ZZ, 2006, CRIT REV ONCOL HEMAT, V59, P169, DOI 10.1016/j.critrevonc.2006.03.005; Dong ZZ, 2004, ONCOGENE, V23, P3790, DOI 10.1038/sj.onc.1207465; Dong ZZ, 2003, MOL BIOL CELL, V14, P3942, DOI 10.1091/mbc.E02-12-0784; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; Dorrello NV, 2006, SCIENCE, V314, P467, DOI 10.1126/science.1130276; Draptchinskaia N, 1999, NAT GENET, V21, P169, DOI 10.1038/5951; DUMONT FJ, 1990, J IMMUNOL, V144, P251; DUNCAN MR, 1978, J VIROL, V28, P444, DOI 10.1128/JVI.28.2.444-449.1978; Easton JB, 2006, ONCOGENE, V25, P6436, DOI 10.1038/sj.onc.1209886; Eberle J, 1997, INT J CANCER, V71, P396, DOI 10.1002/(SICI)1097-0215(19970502)71:3<396::AID-IJC16>3.0.CO;2-E; Eng C, 2003, HUM MUTAT, V22, P183, DOI 10.1002/humu.10257; ENG CP, 1984, J ANTIBIOT, V37, P1231, DOI 10.7164/antibiotics.37.1231; Eshleman JS, 2002, CANCER RES, V62, P7291; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Evdokimova V, 2006, MOL CELL BIOL, V26, P277, DOI 10.1128/MCB.26.1.277-292.2006; Flygare J, 2007, BLOOD, V109, P980, DOI 10.1182/blood-2006-07-038232; FukuchiShimogori T, 1997, CANCER RES, V57, P5041; Galanis E, 2005, J CLIN ONCOL, V23, P5294, DOI 10.1200/JCO.2005.23.622; Gazda HT, 2006, STEM CELLS, V24, P2034, DOI 10.1634/stemcells.2005-0554; Gera JF, 2004, J BIOL CHEM, V279, P2737, DOI 10.1074/jbc.M309999200; Gill T, 2004, MOL CELL BIOL, V24, P945, DOI 10.1128/MCB.24.3.945-953.2004; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Graff JR, 2003, CLIN EXP METASTAS, V20, P265, DOI 10.1023/A:1022943419011; Gregory MA, 2005, ANGEW CHEM INT EDIT, V44, P4757, DOI 10.1002/anie.200462784; Grolleau A, 2002, J BIOL CHEM, V277, P22175, DOI 10.1074/jbc.M202014200; Guertin DA, 2006, DEV CELL, V11, P859, DOI 10.1016/j.devcel.2006.10.007; Hahn-Windgassen A, 2005, J BIOL CHEM, V280, P32081, DOI 10.1074/jbc.M502876200; Handley TPB, 2006, ORAL ONCOL, V42, P331, DOI 10.1016/j.oraloncology.2005.06.007; Haydon MS, 2000, CANCER-AM CANCER SOC, V88, P2803, DOI 10.1002/1097-0142(20000615)88:12<2803::AID-CNCR20>3.0.CO;2-5; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Hilliard A, 2006, J IMMUNOL, V177, P8095, DOI 10.4049/jimmunol.177.11.8095; Hirasawa K, 2002, CANCER RES, V62, P1696; Hirasawa K, 2003, CANCER RES, V63, P348; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Jansen AP, 2004, MOL CANCER THER, V3, P103; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kaufman RJ, 2000, COLD SPRING HARBOR M, V39, P503; Kent OA, 2006, ONCOGENE, V25, P6188, DOI 10.1038/sj.onc.1209913; Kevil CG, 1996, INT J CANCER, V65, P785, DOI 10.1002/(SICI)1097-0215(19960315)65:6<785::AID-IJC14>3.0.CO;2-3; Kitahara O, 2001, CANCER RES, V61, P3544; Koga Y, 2006, J PEDIAT HEMATOL ONC, V28, P355, DOI 10.1097/00043426-200606000-00007; KONGSUWAN K, 1985, NATURE, V317, P555, DOI 10.1038/317555a0; Kwiatkowski DJ, 2003, ANN HUM GENET, V67, P87, DOI 10.1046/j.1469-1809.2003.00012.x; Larsson O, 2006, NUCLEIC ACIDS RES, V34, P4375, DOI 10.1093/nar/gkl558; Law M, 2006, CANCER RES, V66, P1070, DOI 10.1158/0008-5472.CAN-05-1672; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Leslie NR, 2002, CELL SIGNAL, V14, P285, DOI 10.1016/S0898-6568(01)00234-0; Li R, 2006, ONCOGENE, V25, P2628, DOI 10.1038/sj.onc.1209289; Li S, 2003, J BIOL CHEM, V278, P3015, DOI 10.1074/jbc.M208821200; Liu JM, 2006, BLOOD, V107, P4583, DOI 10.1182/blood-2005-12-4831; Lynch M, 2004, J BIOL CHEM, V279, P3327, DOI 10.1074/jbc.M310872200; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Mamane Y, 2006, ONCOGENE, V25, P6416, DOI 10.1038/sj.onc.1209888; Mamane Y, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000242; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; Martin ME, 2000, INT J BIOCHEM CELL B, V32, P633, DOI 10.1016/S1357-2725(00)00007-8; Mathis JM, 2006, J GENE MED, V8, P1105, DOI 10.1002/jgm.935; Matsson H, 2006, BLOOD CELL MOL DIS, V36, P259, DOI 10.1016/j.bcmd.2005.12.002; Matsumoto Ken, 2005, J Mol Genet Med, V1, P11; Mayer C, 2006, ONCOGENE, V25, P6384, DOI 10.1038/sj.onc.1209883; McManus EJ, 2002, NAT CELL BIOL, V4, pE214, DOI 10.1038/ncb0902-e214; Michael MZ, 2003, MOL CANCER RES, V1, P882; Mochizuki Y, 2004, P NATL ACAD SCI USA, V101, P10756, DOI 10.1073/pnas.0402560101; Morley SJ, 2001, PROG MOLEC, V27, P1; Nekrasov MP, 2003, J BIOL CHEM, V278, P13936, DOI 10.1074/jbc.M209145200; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Noh WC, 2004, CLIN CANCER RES, V10, P1013, DOI 10.1158/1078-0432.CCR-03-0043; Norman KL, 2002, HUM GENE THER, V13, P641, DOI 10.1089/10430340252837233; Norman KL, 2004, P NATL ACAD SCI USA, V101, P11099, DOI 10.1073/pnas.0404310101; Nupponen NN, 2000, GENE CHROMOSOME CANC, V28, P203; Okamoto H, 2003, HEPATOLOGY, V38, P1242, DOI 10.1053/jhep.2003.50457; Oshiro N, 2004, GENES CELLS, V9, P359, DOI 10.1111/j.1356-9597.2004.00727.x; Panner A, 2005, MOL CELL BIOL, V25, P8809, DOI 10.1128/MCB.25.20.8809-8823.2005; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; Perrotti D, 2004, ONCOGENE, V23, P3222, DOI 10.1038/sj.onc.1207543; Plas DR, 2005, ONCOGENE, V24, P7435, DOI 10.1038/sj.onc.1209097; Provenzani A, 2006, CARCINOGENESIS, V27, P1323, DOI 10.1093/carcin/bgi377; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Rajasekhar VK, 2004, ONCOGENE, V23, P3248, DOI 10.1038/sj.onc.1207546; Rao RD, 2005, NEOPLASIA, V7, P921, DOI 10.1593/neo.05361; Raught B, 2004, EMBO J, V23, P1761, DOI 10.1038/sj.emboj.7600193; Ridanpaa M, 2001, CELL, V104, P195, DOI 10.1016/S0092-8674(01)00205-7; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Ruggero D, 2003, SCIENCE, V299, P259, DOI 10.1126/science.1079447; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Ruvinsky I, 2005, GENE DEV, V19, P2199, DOI 10.1101/gad.351605; Ruvinsky I, 2006, TRENDS BIOCHEM SCI, V31, P342, DOI 10.1016/j.tibs.2006.04.003; Salehi Z, 2006, CLIN BIOCHEM, V39, P404, DOI 10.1016/j.clinbiochem.2005.11.007; Samuels Y, 2004, CELL CYCLE, V3, P1221, DOI 10.4161/cc.3.10.1164; Scheuner D, 2006, J BIOL CHEM, V281, P21458, DOI 10.1074/jbc.M603784200; Schmidt EV, 2004, ONCOGENE, V23, P3217, DOI 10.1038/sj.onc.1207548; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Shi J, 2006, ONCOGENE, V25, P4923, DOI 10.1038/sj.onc.1209495; Shinohara ET, 2005, ONCOGENE, V24, P5414, DOI 10.1038/sj.onc.1208715; Shuda M, 2000, ANTICANCER RES, V20, P2489; Skeen JE, 2006, CANCER CELL, V10, P269, DOI 10.1016/j.ccr.2006.08.022; Sorrells DL, 1999, J ORAL MAXIL SURG, V57, P294, DOI 10.1016/S0278-2391(99)90676-6; Stephens L, 2005, CURR OPIN PHARMACOL, V5, P357, DOI 10.1016/j.coph.2005.03.002; Stojdl DF, 2003, CANCER CELL, V4, P263, DOI 10.1016/S1535-6108(03)00241-1; Stokoe David, 2005, Expert Reviews in Molecular Medicine, V7, P1, DOI 10.1017/S1462399405009361; Strong JE, 1998, EMBO J, V17, P3351, DOI 10.1093/emboj/17.12.3351; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Thiel CT, 2005, AM J HUM GENET, V77, P795, DOI 10.1086/497708; Thomas GV, 2006, NAT MED, V12, P122, DOI 10.1038/nm1337; TOCZYSKI DP, 1994, P NATL ACAD SCI USA, V91, P3463, DOI 10.1073/pnas.91.8.3463; Tominaga Y, 2005, MOL CELL BIOL, V25, P8465, DOI 10.1128/MCB.25.19.8465-8475.2005; Tomlinson VAL, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-113; Tuxworth WJ, 2004, BIOCHEM J, V378, P73, DOI 10.1042/BJ20031027; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Vulliamy TJ, 2006, BLOOD, V107, P2680, DOI 10.1182/blood-2005-07-2622; Wang MY, 2006, CANCER RES, V66, P7864, DOI 10.1158/0008-5472.CAN-04-4392; Wang XM, 2001, EMBO J, V20, P4370, DOI 10.1093/emboj/20.16.4370; WEBER GEORGE, 1966, ADVANC ENZYME REGULAT, V4., P115, DOI 10.1016/0065-2571(66)90011-2; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Wong JMY, 2006, GENE DEV, V20, P2848, DOI 10.1101/gad.1476206; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang WQ, 2004, GENE THER, V11, P1579, DOI 10.1038/sj.gt.3302319; Yang ZZ, 2004, BIOCHEM SOC T, V32, P350, DOI 10.1042/BST0320350; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7; Yonezawa K, 2003, CURR TOP MICROBIOL, V279, P271; Yoon A, 2006, SCIENCE, V312, P902, DOI 10.1126/science.1123835; Yu D, 2006, CANCER GENE THER, V13, P32, DOI 10.1038/sj.cgt.7700885; Yu K, 2001, ENDOCR-RELAT CANCER, V8, P249, DOI 10.1677/erc.0.0080249; Zakowicz H, 2005, RNA, V11, P261, DOI 10.1261/rna.7191905; Zhai WG, 2000, MOL CELL BIOL, V20, P5930, DOI 10.1128/MCB.20.16.5930-5938.2000; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; Zhou S, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-231	174	68	70	2	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2007	26	41					5973	5990		10.1038/sj.onc.1210431	http://dx.doi.org/10.1038/sj.onc.1210431			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	207US	17404576				2022-12-17	WOS:000249277200001
J	Berthet, C; Kaldis, P				Berthet, C.; Kaldis, P.			Cell-specific responses to loss of cyclin-dependent kinases	ONCOGENE			English	Review						cyclin; cyclin-dependent kinase; cell cycle; embryonic stem cells; tumor cells; differentiated cells	EMBRYONIC STEM-CELLS; SKIN TUMOR-DEVELOPMENT; CANCER-CELLS; DNA-DAMAGE; TARGETED DISRUPTION; THYMOCYTE APOPTOSIS; MOUSE MODELS; MICE LACKING; G(1) CONTROL; IN-VIVO	Inactivation of cyclin-dependent kinases (Cdks) and/or cyclins in mice has changed our view of cell cycle regulation. In general, cells are far more resistant to the loss of Cdks than originally anticipated, suggesting widespread compensation among the Cdks. Early embryonic cells are, so far, not sensitive to the lack of multiple Cdks or cyclins. In contrast, differentiated cells are more dependent on Cdk/cyclin complexes and the functional redundancy is more limited. Our challenge is to better understand these cell-type specific differences in cell cycle regulation that can be used to design efficient cancer therapy. Indeed, tumor cells seem to respond to inhibition of Cdk activities, however, with different outcome depending on the tumor cell type. Tumor cells share some proliferation features with stem cells, but appear more sensitive to loss of Cdk activity, somewhat resembling differentiated cells. We summarize the current knowledge of cell cycle regulation in different cell types and highlight their sensitivity to the lack of Cdk activities.	NCI, Ctr Canc Res, Mouse Canc Genet Program, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kaldis, P (corresponding author), NCI, Ctr Canc Res, Mouse Canc Genet Program, Bldg 560-22-26,1050 Boyles St, Frederick, MD 21702 USA.	kaldis@ncifcrf.gov	Kaldis, Philipp/G-2714-2010; berthet, cyril/T-4842-2017	Kaldis, Philipp/0000-0002-7247-7591; berthet, cyril/0000-0003-3166-3141	NATIONAL CANCER INSTITUTE [Z01SC010367] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Aladjem MI, 1998, CURR BIOL, V8, P145, DOI 10.1016/S0960-9822(98)70061-2; Aleem E, 2005, NAT CELL BIOL, V7, P831, DOI 10.1038/ncb1284; Aleem Eiman, 2006, V42, P271, DOI 10.1007/023; Appert-Collin A, 2006, LIFE SCI, V79, P484, DOI 10.1016/j.lfs.2006.01.032; Arber N, 1997, CANCER RES, V57, P1569; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Berthet C, 2006, DEV CELL, V10, P563, DOI 10.1016/j.devcel.2006.03.004; Bertolotti R, 2004, PROG GENE THERAPY, V2, P1; Bertram MJ, 1999, MOL CELL BIOL, V19, P1479; Blasco MA, 2005, EMBO J, V24, P1095, DOI 10.1038/sj.emboj.7600598; Brandeis M, 1998, P NATL ACAD SCI USA, V95, P4344, DOI 10.1073/pnas.95.8.4344; Burdon T, 2002, TRENDS CELL BIOL, V12, P432, DOI 10.1016/S0962-8924(02)02352-8; Cai DP, 2006, CANCER RES, V66, P9270, DOI 10.1158/0008-5472.CAN-06-1758; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; de Marval PLM, 2004, MOL CELL BIOL, V24, P7538, DOI 10.1128/MCB.24.17.7538-7547.2004; Dimri GP, 2005, CANCER CELL, V7, P505, DOI 10.1016/j.ccr.2005.05.025; Du LH, 2004, J BIOL CHEM, V279, P11957, DOI 10.1074/jbc.M304935200; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Gil-Gomez G, 1998, EMBO J, V17, P7209, DOI 10.1093/emboj/17.24.7209; Hakem A, 1999, J EXP MED, V189, P957, DOI 10.1084/jem.189.6.957; Jirmanova L, 2002, ONCOGENE, V21, P5515, DOI 10.1038/sj.onc.1205728; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Kiyokawa Hiroaki, 2006, V42, P257, DOI 10.1007/001; Knudsen ES, 2006, EXP BIOL MED, V231, P1271; Kornmann M, 1998, J CLIN INVEST, V101, P344, DOI 10.1172/JCI1323; Kozar K, 2004, CELL, V118, P477, DOI 10.1016/j.cell.2004.07.025; Landis MW, 2006, CANCER CELL, V9, P13, DOI 10.1016/j.ccr.2005.12.019; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Li L, 2005, J CELL BIOCHEM, V94, P298, DOI 10.1002/jcb.20355; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; Martin A, 2005, CANCER CELL, V7, P591, DOI 10.1016/j.ccr.2005.05.006; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Miura T, 2004, AGING CELL, V3, P333, DOI 10.1111/j.1474-9728.2004.00134.x; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Monaco EA, 2003, CURR MED CHEM, V10, P367, DOI 10.2174/0929867033368277; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Muller-Tidow C, 2004, MOL CELL BIOL, V24, P8917, DOI 10.1128/MCB.24.20.8917-8928.2004; Murphy M, 1997, NAT GENET, V15, P83, DOI 10.1038/ng0197-83; Nakase H, 1996, STROKE, V27, P720, DOI 10.1161/01.STR.27.4.720; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Pagano M, 2004, CELL, V118, P535, DOI 10.1016/j.cell.2004.08.013; Parisi T, 2003, EMBO J, V22, P4794, DOI 10.1093/emboj/cdg482; Payton M, 2006, CANCER RES, V66, P4299, DOI 10.1158/0008-5472.CAN-05-2507; Pei XH, 2004, MOL CELL BIOL, V24, P6653, DOI 10.1128/mcb.24.15.6653-6664.2004; Price PM, 2006, J AM SOC NEPHROL, V17, P2434, DOI 10.1681/ASN.2006020162; Prost S, 1998, FEBS LETT, V425, P499, DOI 10.1016/S0014-5793(98)00296-8; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; Reddy HKDL, 2005, CANCER RES, V65, P10174, DOI 10.1158/0008-5472.CAN-05-2639; Ribas J, 2006, EXP CELL RES, V312, P2394, DOI 10.1016/j.yexcr.2006.04.021; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Rodriguez-Puebla ML, 2002, AM J PATHOL, V161, P405, DOI 10.1016/S0002-9440(10)64196-X; Rossi AG, 2006, NAT MED, V12, P1056, DOI 10.1038/nm1468; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Santamaria D, 2006, FRONT BIOSCI-LANDMRK, V11, P1164, DOI 10.2741/1871; Sauter ER, 1999, CANCER RES, V59, P4876; Savatier P, 1996, ONCOGENE, V12, P309; SAVATIER P, 1994, ONCOGENE, V9, P809; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Stanelle J, 2006, TRENDS MOL MED, V12, P177, DOI 10.1016/j.molmed.2006.02.002; Stead E, 2002, ONCOGENE, V21, P8320, DOI 10.1038/sj.onc.1206015; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WADHWA R, 1994, CELL STRUCT FUNCT, V19, P1, DOI 10.1247/csf.19.1; Wesierska-Gadek J, 2006, J CELL BIOCHEM, V98, P1367, DOI 10.1002/jcb.20960; Williams O, 2000, EUR J IMMUNOL, V30, P709; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Yu QY, 2006, CANCER CELL, V9, P23, DOI 10.1016/j.ccr.2005.12.012; ZHOU P, 1995, ONCOGENE, V11, P571; ZOU X, 2002, GENE DEV, V16, P2932	81	68	71	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2007	26	31					4469	4477		10.1038/sj.onc.1210243	http://dx.doi.org/10.1038/sj.onc.1210243			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	187GR	17297466				2022-12-17	WOS:000247836100001
J	Yu, J; Wang, P; Ming, L; Wood, MA; Zhang, L				Yu, J.; Wang, P.; Ming, L.; Wood, M. A.; Zhang, L.			SMAC/Diablo mediates the proapoptotic function of PUMA by regulating PUMA-induced mitochondrial events	ONCOGENE			English	Article						SMAC/Diablo; PUMA; apoptosis; mitochondria; DNA damage	STRESS-INDUCED APOPTOSIS; COLON-CANCER CELLS; DRUG-INDUCED APOPTOSIS; CYTOCHROME-C; CASPASE ACTIVATION; INTERFERING RNAS; MAMMALIAN-CELLS; TUMOR-CELLS; IN-VIVO; SMAC	p53-upregulated modulator of apoptosis (PUMA) is a BH3-only Bcl-2 family protein and an essential mediator of DNA damage-induced apoptosis. PUMA is localized in the mitochondria and induces apoptosis through the mitochondrial pathway. However, the mechanisms of PUMA-induced apoptosis remain unclear. In this study, we found that second mitochondria- derived activator of caspase (SMAC)/Diablo, a mitochondrial apoptogenic protein, mediates the proapoptotic function of PUMA by regulating PUMA-induced mitochondrial events. SMAC is consistently released into the cytosol in colon cancer cells undergoing PUMA-induced apoptosis. In SMAC-deficient cells, execution of PUMA-induced apoptosis is abrogated, in company with decreases in caspase activation, cytosolic release of cytochrome c and collapse of mitochondrial membrane potential. Reconstituting SMAC expression restored these events in the SMAC-deficient cells. Furthermore, SMAC and agents that mimic the inhibitor of apoptosis proteins (IAPs) inhibition function of SMAC significantly sensitize cells to PUMA-induced apoptosis. These results demonstrate an important role of SMAC in executing DNA damage-induced and PUMA-mediated apoptosis and suggest that SMAC participates in a feedback amplification loop to promote cytochrome c release and other mitochondrial events in apoptosis.	Univ Pittsburgh, Sch Med, Univ Pittsburgh Canc Inst, Hillman Canc Ctr Res Pavil,Dept Pharmacol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Univ Pittsburgh Canc Inst, Hillman Canc Ctr Res Pavil,Dept Pathol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zhang, L (corresponding author), Univ Pittsburgh, Sch Med, Univ Pittsburgh Canc Inst, Hillman Canc Ctr Res Pavil,Dept Pharmacol, Suite 2 42D,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	zhanglx@upmc.edu	Yu, Jian/A-8301-2009; Zhang, Lin/A-7389-2009; Wood-Trageser, Michelle/GPG-1868-2022	Yu, Jian/0000-0002-4021-1000; Zhang, Lin/0000-0003-0018-3903; Wood-Trageser, Michelle/0000-0002-1880-4926	NATIONAL CANCER INSTITUTE [R01CA106348] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA106348, CA106348] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arnt CR, 2003, CELL DEATH DIFFER, V10, P1118, DOI 10.1038/sj.cdd.4401294; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen Q, 2000, CELL DEATH DIFFER, V7, P227, DOI 10.1038/sj.cdd.4400629; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Giagkousiklidis S, 2005, CANCER RES, V65, P10502, DOI 10.1158/0008-5472.CAN-05-0866; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Hansen T, 2006, CELL DEATH DIFFER, V13, P1181, DOI 10.1038/sj.cdd.4401795; Hao ZY, 2005, CELL, V121, P579, DOI 10.1016/j.cell.2005.03.016; Hemann MT, 2004, P NATL ACAD SCI USA, V101, P9333, DOI 10.1073/pnas.0403286101; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kohli M, 2004, P NATL ACAD SCI USA, V101, P16897, DOI 10.1073/pnas.0403405101; Lakhani SA, 2006, SCIENCE, V311, P847, DOI 10.1126/science.1115035; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Li L, 2004, SCIENCE, V305, P1471, DOI 10.1126/science.1098231; Ming L, 2006, J BIOL CHEM, V281, P16034, DOI 10.1074/jbc.M513587200; Munoz-Pinedo C, 2006, P NATL ACAD SCI USA, V103, P11573, DOI 10.1073/pnas.0603007103; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Okada H, 2004, NAT REV CANCER, V4, P592, DOI 10.1038/nrc1412; Okada H, 2002, MOL CELL BIOL, V22, P3509, DOI 10.1128/MCB.22.10.3509-3517.2002; Perfettini JL, 2004, J EXP MED, V199, P629, DOI 10.1084/jem.20031216; Rashmi R, 2005, CARCINOGENESIS, V26, P713, DOI 10.1093/carcin/bgi025; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; Sun HY, 2004, J AM CHEM SOC, V126, P16686, DOI 10.1021/ja047438+; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang XD, 2001, GENE DEV, V15, P2922; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2003, CANCER CELL, V4, P248, DOI 10.1016/S1535-6108(03)00249-6; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhao J, 2006, CANCER GENE THER, V13, P420, DOI 10.1038/sj.cgt.7700910; Zhou LL, 2005, APOPTOSIS, V10, P289, DOI 10.1007/s10495-005-0803-9	42	68	76	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 21	2007	26	29					4189	4198		10.1038/sj.onc.1210196	http://dx.doi.org/10.1038/sj.onc.1210196			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CY	17237824				2022-12-17	WOS:000247619900001
J	Beltran, A; Parikh, S; Liu, Y; Cuevas, BD; Johnson, GL; Futscher, BW; Blancafort, P				Beltran, A.; Parikh, S.; Liu, Y.; Cuevas, B. D.; Johnson, G. L.; Futscher, B. W.; Blancafort, P.			Re-activation of a dormant tumor suppressor gene maspin by designed transcription factors	ONCOGENE			English	Article						maspin; SERPINB5; metastatic cells; methylation; zinc-fingers; artificial transcription factors	ZINC-FINGER DOMAINS; BREAST-CANCER CELLS; DNA-SEQUENCES; MAMMALIAN-CELLS; EXPRESSION; RECOGNITION; FAMILY; CONSTRUCTION; ANGIOGENESIS; METHYLATION	The controlled and specific re-activation of endogenous tumor suppressors in cancer cells represents an important therapeutic strategy to block tumor growth and subsequent progression. Other than ectopic delivery of tumor suppressor-encoded cDNA, there are no therapeutic tools able to specifically re-activate tumor suppressor genes that are silenced in tumor cells. Herein, we describe a novel approach to specifically regulate dormant tumor suppressors in aggressive cancer cells. We have targeted the Mammary Serine Protease Inhibitor (maspin) (SERPINB5) tumor suppressor, which is silenced by transcriptional and aberrant promoter methylation in aggressive epithelial tumors. Maspin is a multifaceted protein, regulating tumor cell homeostasis through inhibition of cell growth, motility and invasion. We have constructed artificial transcription factors (ATFs) made of six zinc-finger (ZF) domains targeted against 18-base pair (bp) unique sequences in the maspin promoter. The ZFs were linked to the activator domain VP64 and delivered in breast tumor cells. We found that the designed ATFs specifically interact with their cognate targets in vitro with high affinity and selectivity. One ATF was able to re-activate maspin in cell lines that comprise a maspin promoter silenced by epigenetic mechanisms. Consistently, we found that this ATF was a powerful inducer of apoptosis and was able to knock down tumor cell invasion in vitro. Moreover, this ATF was able to suppress MDA-MB-231 growth in a xenograft breast cancer model in nude mice. Our work suggests that ATFs could be used in cancer therapeutics as novel molecular switches to re-activate dormant tumor suppressors.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ Arizona, Arizona Canc Ctr, Dept Pharmacol & Toxicol, Tucson, AZ USA; Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Arizona Center Cancer Care; University of Arizona; University of Arizona	Blancafort, P (corresponding author), Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA.	pilar_blancafort@med.unc.edu	Blancafort, Pilar/K-9029-2012	Blancafort, Pilar/0000-0002-3881-7396	NATIONAL CANCER INSTITUTE [R01CA125273] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030324] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA125273] Funding Source: Medline; NIDDK NIH HHS [R01 DK037871] Funding Source: Medline; NIGMS NIH HHS [R01 GM030324] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354; Beerli RR, 1998, P NATL ACAD SCI USA, V95, P14628, DOI 10.1073/pnas.95.25.14628; Beltran A, 2006, ASSAY DRUG DEV TECHN, V4, P317, DOI 10.1089/adt.2006.4.317; Blancafort P, 2004, MOL PHARMACOL, V66, P1361, DOI 10.1124/mol.104.002758; Blancafort P, 2003, NAT BIOTECHNOL, V21, P269, DOI 10.1038/nbt794; Cher ML, 2003, P NATL ACAD SCI USA, V100, P7847, DOI 10.1073/pnas.1331360100; Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5; Dreier B, 2005, J BIOL CHEM, V280, P35588, DOI 10.1074/jbc.M506654200; Dreier B, 2001, J BIOL CHEM, V276, P29466, DOI 10.1074/jbc.M102604200; Dreier B, 2000, J MOL BIOL, V303, P489, DOI 10.1006/jmbi.2000.4133; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; Garber K, 2004, NAT BIOTECHNOL, V22, P364, DOI 10.1038/nbt0404-364; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; Khalkhali-Ellis Z, 2004, CLIN CANCER RES, V10, P449, DOI 10.1158/1078-0432.CCR-1002-03; Liu JY, 2004, CANCER RES, V64, P1703, DOI 10.1158/0008-5472.CAN-03-2568; Lockett J, 2006, J CELL BIOCHEM, V97, P651, DOI 10.1002/jcb.20721; McGarvey KM, 2006, CANCER RES, V66, P3541, DOI 10.1158/0008-5472.CAN-05-2481; Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JCI200522320; Oshiro MM, 2003, ONCOGENE, V22, P3624, DOI 10.1038/sj.onc.1206545; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Royer Y, 2004, DNA CELL BIOL, V23, P355, DOI 10.1089/104454904323145245; Sager R, 1997, ADV EXP MED BIOL, V425, P77; Samlowski WE, 2005, J CLIN ONCOL, V23, P3897, DOI 10.1200/JCO.2005.06.118; Seftor REB, 1998, CANCER RES, V58, P5681; Segal DJ, 1999, P NATL ACAD SCI USA, V96, P2758, DOI 10.1073/pnas.96.6.2758; Segal DJ, 2003, BIOCHEMISTRY-US, V42, P2137, DOI 10.1021/bi026806o; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Shi HY, 2002, MOL THER, V5, P755, DOI 10.1006/mthe.2002.0602; Stege JT, 2002, PLANT J, V32, P1077, DOI 10.1046/j.1365-313X.2002.01492.x; Tan SY, 2003, P NATL ACAD SCI USA, V100, P11997, DOI 10.1073/pnas.2035056100; Watanabe M, 2005, HUM GENE THER, V16, P699, DOI 10.1089/hum.2005.16.699; YIN S, 2006, CANCER RES, V15, P4173; Zardo G, 2005, CELL RES, V15, P679, DOI 10.1038/sj.cr.7290337; Zhang M, 2000, ONCOGENE, V19, P6053, DOI 10.1038/sj.onc.1204006; Zhang M, 1997, P NATL ACAD SCI USA, V94, P5673, DOI 10.1073/pnas.94.11.5673; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303; Zhang WG, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-50; ZHOU Z, 2000, J BIOL CHEM, V9, P6051; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	40	68	75	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2007	26	19					2791	2798		10.1038/sj.onc.1210072	http://dx.doi.org/10.1038/sj.onc.1210072			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CP	17057734				2022-12-17	WOS:000246210600013
J	Chu, CY; Cha, ST; Chang, CC; Hsiao, CH; Tan, CT; Lu, YC; Jee, SH; Kuo, ML				Chu, C-Y; Cha, S-T; Chang, C-C; Hsiao, C-H; Tan, C-T; Lu, Y-C; Jee, S-H; Kuo, M-L			Involvement of matrix metalloproteinase-13 in stromal-cell-derived factor 1 alpha-directed invasion of human basal cell carcinoma cells	ONCOGENE			English	Article						collagenase-3; CXCR4; basal cell carcinoma; invasion; MMP-13; SDF-1 alpha	SIGNAL-REGULATED KINASES-1/2; CHEMOKINE RECEPTOR; COLLAGENASE-3 EXPRESSION; TUMOR-GROWTH; CXCR4; ACTIVATION; MIGRATION; SKIN; PROLIFERATION; ANGIOGENESIS	Basal cell carcinoma (BCC) is one of the most common skin neoplasms in humans and is usually characterized by local aggressiveness with little metastatic potential, although deep invasion, recurrence, and regional and distant metastases may occur. Here, we studied the mechanism of BCC invasion. We found that human BCC tissues and a BCC cell line had significant expression of CXCR4, which was higher in invasive than non-invasive BCC types. Further, of 19 recurrent tumors among 390 BCCs diagnosed during the past 12 years, 17/ 19 (89.5%) had high CXCR4 expression. We found that the CXCR4 ligand, stromal-cell-derived factor 1a (SDF1a), directed BCC invasion and that this was mediated by time-dependent upregulation of mRNA expression and gelatinase activity of matrix metalloproteinase-13 (MMP-13). The transcriptional regulation of MMP-13 by SDF-1 alpha was mediated by phosphorylation of extracellular signal-related kinase 1/2 and activation of the AP-1 component c-Jun. Finally, CXCR4-transfected BCC cells injected into nude mice induced aggressive BCCs that co-expressed CXCR4 and MMP-13. The identification of SDF-1a/CXCR4 as an important factor in BCC invasiveness may contribute insight into mechanisms involved in the aggressive potential of human BCC and may improve therapy for invasive BCCs.	Natl Taiwan Univ, Lab Mol & Cellular Toxicol, Inst Toxicol, Coll Med, Taipei 100, Taiwan; Natl Taiwan Univ, Angiogenesis Res Ctr, Taipei 100, Taiwan; Natl Taiwan Univ Hosp, Dept Dermatol, Taipei, Taiwan; Natl Taiwan Univ Hosp, Dept Pathol, Taipei, Taiwan; Natl Taiwan Univ Hosp, Dept Otolaryngol, Taipei, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital	Kuo, ML (corresponding author), Natl Taiwan Univ, Lab Mol & Cellular Toxicol, Inst Toxicol, Coll Med, 1 Sect 1 Jen Ai Rd, Taipei 100, Taiwan.	toxkml@ha.mc.ntu.edu.tw	Kuo, Min-Liang/C-4872-2009	KUO, MIN-LIANG/0000-0002-7139-0144; CHU, CHIA-YU/0000-0002-9370-3279; Tan, Ching-Ting/0000-0001-8317-2235; JEE, SHIOU-HWA/0000-0001-6737-6297				Airola K, 1997, J INVEST DERMATOL, V109, P225, DOI 10.1111/1523-1747.ep12319441; Ala-Aho R, 2005, BIOCHIMIE, V87, P273, DOI 10.1016/j.biochi.2004.12.009; Avniel S, 2006, J INVEST DERMATOL, V126, P468, DOI 10.1038/sj.jid.5700069; Bachelder RE, 2002, CANCER RES, V62, P7203; Bajetto A, 2001, J NEUROCHEM, V77, P1226, DOI 10.1046/j.1471-4159.2001.00350.x; Barbero S, 2003, CANCER RES, V63, P1969; Bartolome RA, 2006, CANCER RES, V66, P248, DOI 10.1158/0008-5472.CAN-05-2489; Bartolome RA, 2004, CANCER RES, V64, P2534, DOI 10.1158/0008-5472.CAN-03-3398; Brand S, 2005, EXP CELL RES, V310, P117, DOI 10.1016/j.yexcr.2005.07.006; Burger JA, 2006, BLOOD, V107, P1761, DOI 10.1182/blood-2005-08-3182; Chen GS, 2006, BRIT J DERMATOL, V154, P910, DOI 10.1111/j.1365-2133.2006.07150.x; De Clercq E, 2003, NAT REV DRUG DISCOV, V2, P581, DOI 10.1038/nrd1134; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Dumas V, 1999, ANTICANCER RES, V19, P2929; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fernandis AZ, 2004, ONCOGENE, V23, P157, DOI 10.1038/sj.onc.1206910; Forsyth CB, 2002, ARTHRITIS RHEUM, V46, P2368, DOI 10.1002/art.10502; Hatse S, 2002, FEBS LETT, V527, P255, DOI 10.1016/S0014-5793(02)03143-5; Jee SH, 2004, J INVEST DERMATOL, V123, P1169, DOI 10.1111/j.0022-202X.2004.23497.x; Jee SH, 2002, J INVEST DERMATOL, V119, P1121, DOI 10.1046/j.1523-1747.2002.19503.x; JIMENEZ J, 1999, RRD MICROBIOL 1, V3, P1; Kerkela E, 2003, EXP DERMATOL, V12, P109, DOI 10.1034/j.1600-0625.2003.120201.x; Kijima T, 2002, CANCER RES, V62, P6304; Lapteva N, 2005, CANCER GENE THER, V12, P84, DOI 10.1038/sj.cgt.7700770; Lear JT, 1998, J ROY SOC MED, V91, P585, DOI 10.1177/014107689809101110; Leeman MF, 2002, CRIT REV BIOCHEM MOL, V37, P149, DOI 10.1080/10409230290771483; Menu E, 2006, HAEMATOLOGICA, V91, P605; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; Neuhaus T, 2003, CELL PROLIFERAT, V36, P75, DOI 10.1046/j.1365-2184.2003.00262.x; Ohira S, 2006, AM J PATHOL, V168, P1155, DOI 10.2353/ajpath.2006.050204; Payne AS, 2002, J INVEST DERMATOL, V118, P915, DOI 10.1046/j.1523-1747.2002.01725.x; Pendas AM, 1997, GENOMICS, V40, P222, DOI 10.1006/geno.1996.4554; Pendas AM, 2000, CLIN CHIM ACTA, V291, P137, DOI 10.1016/S0009-8981(99)00225-9; Phillips RJ, 2003, AM J RESP CRIT CARE, V167, P1676, DOI 10.1164/rccm.200301-071OC; POULSOM R, 1993, J CLIN PATHOL, V46, P429, DOI 10.1136/jcp.46.5.429; Rippey JJ, 1998, HISTOPATHOLOGY, V32, P393; Saur D, 2005, GASTROENTEROLOGY, V129, P1237, DOI 10.1053/j.gastro.2005.06.056; Singh S, 2004, LAB INVEST, V84, P1666, DOI 10.1038/labinvest.3700181; Strieter RM, 2001, NAT IMMUNOL, V2, P285, DOI 10.1038/86286; Uria JA, 1998, J BIOL CHEM, V273, P9769, DOI 10.1074/jbc.273.16.9769; Uria JA, 1997, CANCER RES, V57, P4882; Varani J, 2000, BRIT J CANCER, V82, P657, DOI 10.1054/bjoc.1999.0978; Walling HW, 2004, CANCER METAST REV, V23, P389, DOI 10.1023/B:CANC.0000031775.04618.30; Woodhouse EC, 1997, CANCER-AM CANCER SOC, V80, P1529, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1529::AID-CNCR2>3.0.CO;2-F; Yen HT, 1996, ARCH DERMATOL RES, V288, P157, DOI 10.1007/BF02505826; Yucel T, 2005, EXP MOL PATHOL, V79, P151, DOI 10.1016/j.yexmp.2005.05.003; Zhang LB, 2005, J SOC GYNECOL INVEST, V12, P2, DOI 10.1016/j.jsgi.2004.09.004; Zhang SP, 2002, J MOL BIOL, V324, P271, DOI 10.1016/S0022-2836(02)01044-6; Zhou Y, 2002, J BIOL CHEM, V277, P49481, DOI 10.1074/jbc.M206222200; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	54	68	68	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2007	26	17					2491	2501		10.1038/sj.onc.1210040	http://dx.doi.org/10.1038/sj.onc.1210040			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YG	17099730				2022-12-17	WOS:000245831000009
J	Marzec, M; Kasprzycka, M; Liu, X; Raghunath, PN; Wlodarski, P; Wasik, MA				Marzec, M.; Kasprzycka, M.; Liu, X.; Raghunath, P. N.; Wlodarski, P.; Wasik, M. A.			Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf	ONCOGENE			English	Article						NPM/ALK tyrosine kinase; MEK/ERK pathway; T-cell lymphoma	NON-HODGKINS-LYMPHOMA; ANAPLASTIC LYMPHOMA; CONSTITUTIVE ACTIVATION; REGULATED KINASE; CELL LYMPHOMA; DEPENDENT PATHWAY; INDUCED APOPTOSIS; MULTIPLE-MYELOMA; PROTEIN-KINASES; ALK	The mechanisms of cell transformation mediated by the highly oncogenic, chimeric NPM/ALK tyrosine kinase remain only partially understood. Here we report that cell lines and native tissues derived from the NPM/ALK-expressing T-cell lymphoma (ALK+ TCL) display phosphorylation of the extracellular signal-regulated protein kinase (ERK) 1/2 complex. Transfection of BaF3 cells with NPM/ALK induces phosphorylation of EKR1/2 and of its direct activator mitogen-induced extracellular kinase (MEK) 1/2. Depletion of NPM/ALK by small interfering RNA (siRNA) or its inhibition by WHI-154 abrogates the MEK1/2 and ERK1/2 phosphorylation. The NPM/ALK-induced MEK/ERK activation is independent of c-Raf as evidenced by the lack of MEK1/2 and ERK1/2 phosphorylation upon c-Raf inactivation by two different inhibitors, RI and ZM336372, and by its siRNA-mediated depletion. In contrast, ERK1/2 activation is strictly MEK1/2 dependent as shown by suppression of the ERK1/2 phosphorylation by the MEK1/2 inhibitor U0126. The U0126-mediated inhibition of ERK1/2 activation impaired proliferation and viability of the ALK+ TCL cells and expression of antiapoptotic factor Bcl-xL and cell cycle-promoting CDK4 and phospho-RB. Finally, siRNA-mediated depletion of both ERK1 and ERK2 inhibited cell proliferation, whereas depletion of ERK 1 (but not ERK2) markedly increased cell apoptosis. These findings identify MEK/ERK as a new signaling pathway activated by NPM/ALK and indicate that the pathway represents a novel therapeutic target in the ALK-induced malignancies.	Univ Penn, Med Ctr, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Wasik, MA (corresponding author), Univ Penn, Med Ctr, Dept Pathol & Lab Med, 3400 Spruce St,7-106 Founders Pavil, Philadelphia, PA 19104 USA.	wasik@mail.med.upenn.edu	Marzec, Michal/O-6387-2016	Marzec, Michal/0000-0001-9698-6019; Wlodarski, Pawel/0000-0002-0683-1791	NCI NIH HHS [R01-CA89194, R01-CA96856] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA096856, R01CA089194] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; Chiarle R, 2005, NAT MED, V11, P623, DOI 10.1038/nm1249; Chiarle R, 2003, BLOOD, V101, P1919, DOI 10.1182/blood-2002-05-1343; Crockett DK, 2004, ONCOGENE, V23, P2617, DOI 10.1038/sj.onc.1207398; Epling-Burnett PK, 2004, ONCOGENE, V23, P9220, DOI 10.1038/sj.onc.1208122; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; Hallek M, 1998, BLOOD, V91, P3, DOI 10.1182/blood.V91.1.3.3_3_21; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Hoyle PE, 2000, LEUKEMIA, V14, P642, DOI 10.1038/sj.leu.2401720; Kim SC, 1999, BLOOD, V93, P3893, DOI 10.1182/blood.V93.11.3893.407k14_3893_3899; Kuefer MU, 1997, BLOOD, V90, P2901, DOI 10.1182/blood.V90.8.2901; Marzec M, 2005, LAB INVEST, V85, P1544, DOI 10.1038/labinvest.3700348; Matsumoto S, 2005, J BIOL CHEM, V280, P25687, DOI 10.1074/jbc.M412784200; Milella M, 2001, J CLIN INVEST, V108, P851, DOI 10.1172/JCI200112807; Morgan MA, 2001, BLOOD, V97, P1823, DOI 10.1182/blood.V97.6.1823; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Motegi A, 2004, J CELL SCI, V117, P3319, DOI 10.1242/jcs.01183; Pardo OE, 2002, J BIOL CHEM, V277, P12040, DOI 10.1074/jbc.M109006200; Platanias LC, 2003, BLOOD, V101, P4667, DOI 10.1182/blood-2002-12-3647; Pratt G, 2002, J CLIN PATHOL-MOL PA, V55, P273, DOI 10.1136/mp.55.5.273; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; SHIOTA M, 1994, ONCOGENE, V9, P1567; Souttou B, 2001, J BIOL CHEM, V276, P9526, DOI 10.1074/jbc.M007333200; Tanaka T, 1996, MOL CELL BIOL, V16, P3967; Towatari M, 1997, LEUKEMIA, V11, P479, DOI 10.1038/sj.leu.2400617; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Ussar S, 2004, J BIOL CHEM, V279, P43861, DOI 10.1074/jbc.M406240200; Wan WH, 2006, BLOOD, V107, P1617, DOI 10.1182/blood-2005-08-3254; Wang XF, 2004, ONCOGENE, V23, P1885, DOI 10.1038/sj.onc.1207312; Wasik Mariusz A, 2002, Am J Clin Pathol, V118 Suppl, pS81; Wlodarski P, 2005, CANCER RES, V65, P7800, DOI 10.1158/0008-5472.CAN-04-4180; Wu WS, 2006, CANCER LETT, V239, P27, DOI 10.1016/j.canlet.2005.07.034; Zhang Q, 2002, J IMMUNOL, V168, P466, DOI 10.4049/jimmunol.168.1.466	34	68	72	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2007	26	6					813	821		10.1038/sj.onc.1209843	http://dx.doi.org/10.1038/sj.onc.1209843			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134DT	16909118				2022-12-17	WOS:000244063800003
J	Oakes, SR; Robertson, FG; Kench, JG; Gardiner-Garden, M; Wand, MP; Green, JE; Ormandy, CJ				Oakes, S. R.; Robertson, F. G.; Kench, J. G.; Gardiner-Garden, M.; Wand, M. P.; Green, J. E.; Ormandy, C. J.			Loss of mammary epithelial prolactin receptor delays tumor formation by reducing cell proliferation in low-grade preinvasive lesions	ONCOGENE			English	Article						prolactin receptor; mouse; mammary; carcinogenesis; C3(1)/SV40T	TRANSGENIC MOUSE MODEL; BREAST-CANCER; GLAND DEVELOPMENT; GROWTH-HORMONE; EXPRESSION; MICE; RISK; PROSTATE; PRL; BROMOCRIPTINE	Top quartile serum prolactin levels confer a twofold increase in the relative risk of developing breast cancer. Prolactin exerts this effect at an ill defined point in the carcinogenic process, via mechanisms involving direct action via prolactin receptors within mammary epithelium and/or indirect action through regulation of other hormones such as estrogen and progesterone. We have addressed these questions by examining mammary carcinogenesis in transplants of mouse mammary epithelium expressing the SV40T oncogene, with or without the prolactin receptor, using host animals with a normal endocrine system. In prolactin receptor knockout transplants the area of neoplasia was significantly smaller (7 versus 17%; P < 0.001 at 22 weeks and 7 versus 14%; P=0.009 at 32 weeks). Low-grade neoplastic lesions displayed reduced BrdU incorporation rate (11.3 versus 17% P=0.003) but no change in apoptosis rate. Tumor latency increased (289 days versus 236 days, P < 0.001). Tumor frequency, growth rate, morphology, cell proliferation and apoptosis were not altered. Thus, prolactin acts directly on the mammary epithelial cells to increase cell proliferation in preinvasive lesions, resulting in more neoplasia and acceleration of the transition to invasive carcinoma. Targeting of mammary prolactin signaling thus provides a strategy to prevent the early progression of neoplasia to invasive carcinoma.	St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia; Inst Clin Pathol & Med Res, Dept Tissue Pathol, Westmead, NSW, Australia; Univ New S Wales, Sch Math, Dept Stat, Sydney, NSW, Australia; Lab Cell Regulat & Carcinogenesis, Transgen Oncogenesis Grp, Bethesda, MD USA	Garvan Institute of Medical Research; St Vincents Hospital Sydney; University of New South Wales Sydney	Ormandy, CJ (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, 384 Victoria St, Sydney, NSW 2010, Australia.	c.ormandy@garvan.org.au	Ormandy, Chris/G-4165-2014; Wand, Matt P/F-9413-2012	Wand, Matt P/0000-0003-2555-896X; Oakes, Samantha/0000-0003-1838-2310; Ormandy, Christopher/0000-0002-2504-7919; Kench, James Geoffrey/0000-0001-8687-4988	NATIONAL CANCER INSTITUTE [ZIABC005740, Z01BC005740] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATTIA MAM, 1966, CANCER RES, V26, P1787; Binart N, 2000, ENDOCRINOLOGY, V141, P2691, DOI 10.1210/en.141.7.2691; BONNETERRE J, 1988, EUR J CANCER CLIN ON, V24, P1851, DOI 10.1016/0277-5379(88)90097-1; BONNETERRE J, 1987, CANCER RES, V47, P4724; BRADBURY JM, 1995, DEV BIOL, V170, P553, DOI 10.1006/dbio.1995.1236; Brisken C, 1999, DEV BIOL, V210, P96, DOI 10.1006/dbio.1999.9271; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Chen WY, 1999, CLIN CANCER RES, V5, P3583; Clement-Lacroix P, 1999, ENDOCRINOLOGY, V140, P96, DOI 10.1210/en.140.1.96; CLEVENGER CV, 1995, AM J PATHOL, V146, P695; Clevenger CV, 2003, ENDOCR REV, V24, P1, DOI 10.1210/er.2001-0036; Das R, 1997, J MAMMARY GLAND BIOL, V2, P29, DOI 10.1023/A:1026369412612; DEOME KB, 1959, CANCER RES, V19, P515; Freemark M, 2001, ENDOCRINOLOGY, V142, P532, DOI 10.1210/en.142.2.532; GINSBURG E, 1995, CANCER RES, V55, P2591; Goffin V, 2005, ENDOCR REV, V26, P400, DOI 10.1210/er.2004-0016; Goffin V, 1996, J BIOL CHEM, V271, P16573, DOI 10.1074/jbc.271.28.16573; Green JE, 2000, ONCOGENE, V19, P1020, DOI 10.1038/sj.onc.1203280; Gutzman JH, 2004, J STEROID BIOCHEM, V88, P69, DOI 10.1016/j.jsbmb.2003.10.008; Hankinson SE, 1998, JNCI-J NATL CANCER I, V90, P1292, DOI 10.1093/jnci/90.17.1292; Hankinson SE, 1999, J NATL CANCER I, V91, P629, DOI 10.1093/jnci/91.7.629; Horseman ND, 1997, EMBO J, V16, P6926, DOI 10.1093/emboj/16.23.6926; Hutchinson JN, 2000, ONCOGENE, V19, P6130, DOI 10.1038/sj.onc.1203970; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; Ling C, 2000, ENDOCRINOLOGY, V141, P3564, DOI 10.1210/en.141.10.3564; Llovera M, 2000, ONCOGENE, V19, P4695, DOI 10.1038/sj.onc.1203846; MANNI A, 1989, BREAST CANCER RES TR, V14, P289, DOI 10.1007/BF01806300; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; MERSHON J, 1995, ENDOCRINOLOGY, V136, P3619, DOI 10.1210/en.136.8.3619; Missmer SA, 2004, JNCI-J NATL CANCER I, V96, P1856, DOI 10.1093/jnci/djh336; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Naylor MJ, 2003, ENDOCRINE, V20, P111, DOI 10.1385/ENDO:20:1-2:111; Naylor MJ, 2002, DEV DYNAM, V225, P100, DOI 10.1002/dvdy.10133; Ormandy CJ, 1997, J MAMMARY GLAND BIOL, V2, P355, DOI 10.1023/A:1026395229025; Ormandy CJ, 1997, J CLIN ENDOCR METAB, V82, P3692, DOI 10.1210/jc.82.11.3692; Ormandy CJ, 1997, GENE DEV, V11, P167, DOI 10.1101/gad.11.2.167; PEYRAT JP, 1984, EUR J CANCER CLIN ON, V20, P1363, DOI 10.1016/0277-5379(84)90054-3; PINHEIRO J, 2005, R PACKAGE VERSION, V3, P1; Reynolds C, 1997, ENDOCRINOLOGY, V138, P5555, DOI 10.1210/en.138.12.5555; Robertson FG, 2003, ENDOCRINOLOGY, V144, P3196, DOI 10.1210/en.2003-0068; Rose-Hellekant TA, 2003, ONCOGENE, V22, P4664, DOI 10.1038/sj.onc.1206619; Schroeder MD, 2003, ENDOCRINOLOGY, V144, P5300, DOI 10.1210/en.2003-0826; Schroeder MD, 2002, MOL ENDOCRINOL, V16, P45, DOI 10.1210/me.16.1.45; Shibata MA, 1998, TOXICOL PATHOL, V26, P177, DOI 10.1177/019262339802600121; Touraine P, 1998, J CLIN ENDOCR METAB, V83, P667, DOI 10.1210/jc.83.2.667; Tworoger SS, 2004, CANCER RES, V64, P6814, DOI 10.1158/0008-5472.CAN-04-1870; Vomachka AJ, 2000, ONCOGENE, V19, P1077, DOI 10.1038/sj.onc.1203348; Vonderhaar BK, 1999, ENDOCR-RELAT CANCER, V6, P389, DOI 10.1677/erc.0.0060389; WELSCH CW, 1975, BRIT J CANCER, V32, P427, DOI 10.1038/bjc.1975.243; WELSCH CW, 1977, CANCER RES, V37, P951; Wennbo H, 2000, ONCOGENE, V19, P1072, DOI 10.1038/sj.onc.1203349; Wennbo H, 1997, J CLIN INVEST, V100, P2744, DOI 10.1172/JCI119820	52	68	70	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2007	26	4					543	553		10.1038/sj.onc.1209838	http://dx.doi.org/10.1038/sj.onc.1209838			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	129LS	16862169				2022-12-17	WOS:000243731600007
J	Keating, AK; Salzberg, DB; Sather, S; Liang, X; Nickoloff, S; Anwar, A; DeRyckere, D; Hill, K; Joung, D; Sawczyn, KK; Park, J; Curran-Everett, D; McGavran, L; Meltesen, L; Gore, L; Johnson, GL; Graham, DK				Keating, A. K.; Salzberg, D. B.; Sather, S.; Liang, X.; Nickoloff, S.; Anwar, A.; DeRyckere, D.; Hill, K.; Joung, D.; Sawczyn, K. K.; Park, J.; Curran-Everett, D.; McGavran, L.; Meltesen, L.; Gore, L.; Johnson, G. L.; Graham, D. K.			Lymphoblastic leukemia/lymphoma in mice overexpressing the Mer (MerTK) receptor tyrosine kinase	ONCOGENE			English	Article						receptor tyrosine kinase; MerTK; leukemia; lymphoma; transgenic mouse	GENE-EXPRESSION; V-RYK; LEUKEMIA; GROWTH; MYC; CELLS; MOUSE; PROTOONCOGENE; MICROARRAYS; ACTIVATION	Mer (MerTK) is a receptor tyrosine kinase important in platelet aggregation, as well as macrophage cytokine secretion and clearance of apoptotic cells. Mer is not normally expressed in thymocytes or lymphocytes; however, ectopic Mer RNA transcript and protein expression is found in a subset of acute lymphoblastic leukemia cell lines and patient samples, suggesting a role in leukemogenesis. To investigate the oncogenic potential of Mer in vivo, we created a transgenic mouse line (Mer(Tg)) that expresses Mer in the hematopoietic lineage under control of the Vav promoter. Ectopic expression and activation of the transgenic Mer protein was demonstrated in lymphocytes and thymocytes of the Mer(Tg) mice. At 12 - 24 months of age, greater than 55% of the Mer(Tg) mice, compared to 12% of the wild type, developed adenopathy, hepatosplenomegaly, and circulating lymphoblasts. Histopathological analysis and flow cytometry were consistent with T-cell lymphoblastic leukemia/lymphoma. Mer may contribute to leukemogenesis by activation of Akt and ERK1/2 anti-apoptotic signals, which were upregulated in MerTg mice. Additionally, a significant survival advantage was noted in MerTg lymphocytes compared to wild-type lymphocytes after dexamethasone treatment. These data suggest that Mer plays a cooperative role in leukemogenesis and may be an effective target for biologically based leukemia/lymphoma therapy.	Univ Colorado Denver & Hlth Sci Ctr, Dept Pathol, Denver, CO USA; Natl Jewish Med & Res Ctr, Div Biostat, Denver, CO USA; Univ Colorado Denver & Hlth Sci Ctr, Dept Pediat, Denver, CO USA; Univ Colorado Denver & Hlth Sci Ctr, Dept Prevent Med, Denver, CO USA; Univ Colorado Denver & Hlth Sci Ctr, Dept Biometr, Denver, CO USA; Univ Colorado Denver & Hlth Sci Ctr, Dept Physiol & Biophys, Denver, CO USA; Univ Colorado Denver & Hlth Sci Ctr, Colorado Cytogenet, Denver, CO USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC USA	University of Colorado System; University of Colorado Anschutz Medical Campus; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of North Carolina; University of North Carolina Chapel Hill	Graham, DK (corresponding author), Univ Colorado Denver & Hlth Sci Ctr, Dept Pediat, Mail Stop 8302,Bldg RC-1 N,POB 6511,12800 E 19th, Aurora, CO 80045 USA.	doug.graham@uchsc.edu			NATIONAL CANCER INSTITUTE [T32CA082086] Funding Source: NIH RePORTER; NCI NIH HHS [T32CA86068604, T32 CA082086] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1999, ONCOGENE, V18, P5268, DOI 10.1038/sj.onc.1202997; Anderson KE, 2003, INT J BIOCHEM CELL B, V35, P1028, DOI 10.1016/S1357-2725(02)00270-4; Behrens EM, 2003, EUR J IMMUNOL, V33, P2160, DOI 10.1002/eji.200324076; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Borgel D, 2006, CRIT CARE MED, V34, P219, DOI 10.1097/01.CCM.0000195014.56254.8A; Chen J, 1997, ONCOGENE, V14, P2033, DOI 10.1038/sj.onc.1201039; Curran-Everett D, 2000, AM J PHYSIOL-REG I, V279, pR1, DOI 10.1152/ajpregu.2000.279.1.R1; Dirks W, 1999, LEUKEMIA RES, V23, P643, DOI 10.1016/S0145-2126(99)00075-2; Dormady SP, 2000, P NATL ACAD SCI USA, V97, P12260, DOI 10.1073/pnas.97.22.12260; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Ek S, 2002, CANCER RES, V62, P4398; Evans CO, 2001, J CLIN ENDOCR METAB, V86, P3097, DOI 10.1210/jc.86.7.3097; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Georgescu MM, 1999, MOL CELL BIOL, V19, P1171; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647; GRAHAM DK, 1995, ONCOGENE, V10, P2349; GRAHAM DK, 2006, IN PRESS CLIN CANC R, V12; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Grandage VL, 2005, LEUKEMIA, V19, P586, DOI 10.1038/sj.leu.2403653; Graux C, 2004, NAT GENET, V36, P1084, DOI 10.1038/ng1425; Guttridge KL, 2002, J BIOL CHEM, V277, P24057, DOI 10.1074/jbc.M112086200; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HENZE G, 1991, BLOOD, V78, P1166; JIA R, 1992, J VIROL, V66, P5975, DOI 10.1128/JVI.66.10.5975-5987.1992; JIA R, 1994, J BIOL CHEM, V269, P1839; Khan J, 1999, P NATL ACAD SCI USA, V96, P13264, DOI 10.1073/pnas.96.23.13264; Krause DS, 2005, NEW ENGL J MED, V353, P172, DOI 10.1056/NEJMra044389; LING L, 1995, MOL CELL BIOL, V15, P6582; Naf D, 2002, CANCER RES, V62, P1235; Ogilvy S, 1999, BLOOD, V94, P1855; Pui C, 2004, NEW ENGL J MED, V350, P1535, DOI 10.1056/NEJMra023001; Pui CH, 1998, NEW ENGL J MED, V339, P605, DOI 10.1056/NEJM199808273390907; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Sattler M, 2004, LEUKEMIA RES, V28, pS11, DOI 10.1016/j.leukres.2003.10.004; Savage DG, 2002, NEW ENGL J MED, V346, P683, DOI 10.1056/NEJMra013339; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schrappe M, 2000, LEUKEMIA, V14, P2193, DOI 10.1038/sj.leu.2401977; Silverman LB, 2001, BLOOD, V97, P1211, DOI 10.1182/blood.V97.5.1211; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Tibes R, 2005, ANNU REV PHARMACOL, V45, P357, DOI 10.1146/annurev.pharmtox.45.120403.100124; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wolfraim LA, 2004, NEW ENGL J MED, V351, P552, DOI 10.1056/NEJMoa031197; Wu CW, 2002, ANTICANCER RES, V22, P1071; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6	49	68	81	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2006	25	45					6092	6100		10.1038/sj.onc.1209633	http://dx.doi.org/10.1038/sj.onc.1209633			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	092MN	16652142				2022-12-17	WOS:000241101200006
J	Lee, MG; Huh, JS; Chung, SK; Lee, JH; Byun, DS; Ryu, BK; Kang, MJ; Chae, KS; Lee, SJ; Lee, CH; Kim, JI; Chang, SG; Chi, SG				Lee, M. -G; Huh, J. -S; Chung, S. -K; Lee, J. -H; Byun, D. -S; Ryu, B. -K; Kang, M. -J; Chae, K. -S; Lee, S. -J; Lee, C. -H; Kim, J. I.; Chang, S. -G; Chi, S. -G			Promoter CpG hypermethylation and downregulation of XAF1 expression in human urogenital malignancies: implication for attenuated p53 response to apoptotic stresses	ONCOGENE			English	Article						xAF1; promoter hypermethylation; CpG site; urogenital cancer; apoptosis; p53	XIAP-ASSOCIATED FACTOR-1; HUMAN BLADDER-CANCER; X-LINKED INHIBITOR; IAP; GENE; PROTEINS; CELLS; FAMILY; IDENTIFICATION; IMMUNOTHERAPY	XIAP-associated factor 1 (XAF1) is a new candidate tumor suppressor, which has been known to exert proapoptotic effects by interfering with the caspase-inhibiting activity of XIAP. To explore the XAF1' s candidacy for a suppressor in urogenital tumorigenesis, we investigated the XAF1 status in a series of cancer cell lines and primary tumors derived from the bladder, kidney and prostate. Expression of XAF1 transcript was undetectable or extremely low in 60% (3/5) of bladder, 66% (10/15) of kidney, and 100% (3/3) prostate cancer cell lines. Abnormal reduction of XAF1 was also found in 33% (18/55) of primary bladder and 40% (8/20) of primary kidney tumors, and showed a correlation with advanced stage and high grade of bladder tumor. Hypermethylation at 14 CpG sites in the 50 proximal region of the XAF1 promoter was highly prevalent in cancers versus adjacent normal or benign tissues and tightly associated with reduced gene expression. XAF1 expression enhanced the apoptotic response of tumor cells to chemotherapeutic agents, such as etoposide or 5-FU. While XAF1 expression did not influence the subcellular distribution or expression of XIAP, it elevated the protein stability of p53 and its target gene expression. Moreover, the apoptosis-sensitizing and growth suppression function of XAF1 was markedly impeded by blockade of p53 function. Collectively, our study demonstrates that epigenetic alteration of XAF1 is frequent in human urogenital cancers and may contribute to the malignant progression of tumors by rendering tumor cells a survival advantage partially through the attenuated p53 response to apoptotic stresses.	Korea Univ, Sch Life Sci & Biotechnol, Seoul 136701, South Korea; Jeju Natl Univ, Coll Med, Dept Urol, Cheju, South Korea; Kyung Hee Univ, Sch Med, Dept Urol, Seoul, South Korea	Korea University; Jeju National University; Kyung Hee University	Chi, SG (corresponding author), Korea Univ, Sch Life Sci & Biotechnol, Seoul 136701, South Korea.	chi6302@korea.ac.kr	Kang, Min-Ju/AAY-8706-2021	KANG, MIN-JU/0000-0001-5040-1388				Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Asselin E, 2001, CANCER RES, V61, P1862; Benedict WF, 2004, MOL THER, V10, P525, DOI 10.1016/j.ymthe.2004.05.027; Byun DS, 2003, CANCER RES, V63, P7068; Chi SG, 1998, GASTROENTEROLOGY, V115, P1084, DOI 10.1016/S0016-5085(98)70078-2; Chi SG, 1999, CANCER RES, V59, P2791; CHI SG, 1994, J NATL CANCER I, V86, P926, DOI 10.1093/jnci/86.12.926; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Fong WG, 2000, GENOMICS, V70, P113, DOI 10.1006/geno.2000.6364; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Holcik M, 2001, APOPTOSIS, V6, P253, DOI 10.1023/A:1011379307472; JACKSON AM, 1995, CLIN EXP IMMUNOL, V99, P369, DOI 10.1111/j.1365-2249.1995.tb05560.x; Leaman DW, 2002, J BIOL CHEM, V277, P28504, DOI 10.1074/jbc.M204851200; Lee MG, 2001, CANCER RES, V61, P6688; Li J, 1998, ENDOCRINOLOGY, V139, P1321, DOI 10.1210/en.139.3.1321; Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Ludwig AT, 2004, CANCER RES, V64, P3386, DOI 10.1158/0008-5472.CAN-04-0374; Luo Y, 1999, J IMMUNOL, V162, P2399; Ng KCP, 2004, J INVEST DERMATOL, V123, P1127, DOI 10.1111/j.0022-202X.2004.23467.x; Papageorgiou A, 2004, CANCER RES, V64, P8973, DOI 10.1158/0008-5472.CAN-04-1909; Perrelet D, 2004, J NEUROSCI, V24, P3777, DOI 10.1523/JNEUROSCI.0413-04.2004; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Sasaki H, 2000, CANCER RES, V60, P5659; Siegelin M, 2005, NEUROBIOL DIS, V20, P509, DOI 10.1016/j.nbd.2005.04.006; Steidl C, 2002, J PATHOL, V198, P115, DOI 10.1002/path.1175; Sun CH, 1999, NATURE, V401, P818, DOI 10.1038/44617; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Tamm I, 2000, CLIN CANCER RES, V6, P1796; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tomita Y, 2003, INT J CANCER, V104, P400, DOI 10.1002/ijc.10956; Tricoli JV, 1996, GENE CHROMOSOME CANC, V15, P108, DOI 10.1002/(SICI)1098-2264(199602)15:2<108::AID-GCC5>3.0.CO;2-7; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X	37	68	72	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2006	25	42					5807	5822		10.1038/sj.onc.1209867	http://dx.doi.org/10.1038/sj.onc.1209867			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TR	16909101				2022-12-17	WOS:000240765800011
J	De Falco, G; Comes, F; Simone, C				De Falco, G.; Comes, F.; Simone, C.			pRb: Master of differentiation. Coupling irreversible cell cycle withdrawal with induction of muscle-specification transcription	ONCOGENE			English	Review						retinoblastoma gene; cell cycle withdrawal; differentiation; myogenesis; MyoD; tissue-specific transcription	RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; TUMOR-SUPPRESSOR; SKELETAL-MUSCLE; MYOD; E2F; INHIBITION; MYOGENESIS; COMPLEXES; REPRESSOR	The protein product of the retinoblastoma (RB) gene is necessary for the completion of the muscle differentiation program and for myogenic basic helix-loop-helix-dependent transcription. In fact, in addition to induction and maintenance of permanent cell cycle withdrawal through negative regulation of E2F-responsive genes involved in proliferation, pRb also plays a positive role in the activation of muscle-specific genes. In pRb(-/-) myocytes, the expression of late myogenic markers is defective and myoblast fusion into myotubes occurs without irreversible cell cycle exit. This evidence demonstrates only a partial functional redundancy between pRb and its relatives p107 and pRb2/p130, as these pRb(-/-) multinucleated cells, which display p107 levels higher than normal myotubes, respond to mitogens with cell cycle re-entry and DNA synthesis. At the molecular level, pRb myogenic functions are mediated by cooperation with MyoD, Myocyte enhancer factor 2 (MEF2), High mobility group box protein-1 (HBP1) and histone deacetylase1, affecting chromatin configuration and tissue-specific transcription, and by post-translational modi. cation in response to intracellular signaling cascades.	Univ Bari, Dept Biomed Childhood, Div Med Genet, I-70124 Bari, Italy; Univ Siena, Dept Human Pathol & Oncol, I-53100 Siena, Italy; Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA	Universita degli Studi di Bari Aldo Moro; University of Siena; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Simone, C (corresponding author), Univ Bari, Dept Biomed Childhood, Div Med Genet, I-70124 Bari, Italy.	csimone@temple.edu	Simone, Cristiano/K-3452-2018	Simone, Cristiano/0000-0002-2628-7658				Aslanian A, 2004, GENE DEV, V18, P1413, DOI 10.1101/gad.1196704; Bagella L, 1998, J CELL PHYSIOL, V177, P206, DOI 10.1002/(SICI)1097-4652(199811)177:2<206::AID-JCP2>3.3.CO;2-W; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; Dimova DK, 2003, GENE DEV, V17, P2308, DOI 10.1101/gad.1116703; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; FALLS HF, 1951, AMA ARCH OPHTHALMOL, V46, P367; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; GIANCINTI C, 2006, J CELL PHYSL, V206, P807; Ginsberg D, 2004, DEV CELL, V6, P742, DOI 10.1016/j.devcel.2004.05.012; GRANA X, 1994, P NATL ACAD SCI USA, V91, P3834, DOI 10.1073/pnas.91.9.3834; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Guo K, 1997, J BIOL CHEM, V272, P791, DOI 10.1074/jbc.272.2.791; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; Iezzi S, 2004, DEV CELL, V6, P673, DOI 10.1016/S1534-5807(04)00107-8; Kitzmann M, 1999, MOL CELL BIOL, V19, P3167; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Lachner M, 2003, J CELL SCI, V116, P2117, DOI 10.1242/jcs.00493; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; Magenta A, 2003, MOL CELL BIOL, V23, P2893, DOI 10.1128/MCB.23.8.2893-2906.2003; MARTELLI F, 1994, ONCOGENE, V9, P3579; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; NEVINS JR, 1992, SCIENCE, V258, P424; Nguyen DX, 2004, EMBO J, V23, P1609, DOI 10.1038/sj.emboj.7600176; Novitch BG, 1999, CURR BIOL, V9, P449, DOI 10.1016/S0960-9822(99)80210-3; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Puri PL, 1997, ONCOGENE, V14, P1171, DOI 10.1038/sj.onc.1200941; Puri PL, 2001, MOL CELL, V8, P885, DOI 10.1016/S1097-2765(01)00373-2; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; SELLERS WR, 1996, BIOCHIM BIOPHYS ACTA, V1288, P1; Shih HH, 1998, MOL CELL BIOL, V18, P4732, DOI 10.1128/MCB.18.8.4732; Simone C, 2004, ONCOGENE, V23, P2177, DOI 10.1038/sj.onc.1207327; Simone C, 2006, J CELL PHYSIOL, V207, P309, DOI 10.1002/jcp.20514; Simone C, 2002, ONCOGENE, V21, P4158, DOI 10.1038/sj.onc.1205511; Simone C, 2002, ONCOGENE, V21, P4137, DOI 10.1038/sj.onc.1205493; Simone C, 2001, FRONT BIOSCI-LANDMRK, V6, pD1074; Simone C, 2004, NAT GENET, V36, P738, DOI 10.1038/ng1378; Skapek SX, 1996, MOL CELL BIOL, V16, P7043; Smialowski P, 2005, BBA-PROTEINS PROTEOM, V1750, P48, DOI 10.1016/j.bbapap.2005.03.012; Song A, 1998, MOL CELL BIOL, V18, P4994, DOI 10.1128/MCB.18.9.4994; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; Walsh K, 1997, CURR OPIN GENET DEV, V7, P597, DOI 10.1016/S0959-437X(97)80005-6; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhang JM, 1999, EMBO J, V18, P926, DOI 10.1093/emboj/18.4.926; Zhang JM, 1999, EMBO J, V18, P6983, DOI 10.1093/emboj/18.24.6983	52	68	69	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2006	25	38					5244	5249		10.1038/sj.onc.1209623	http://dx.doi.org/10.1038/sj.onc.1209623			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077XD	16936743				2022-12-17	WOS:000240064100008
J	Liu, L; Gao, Y; Qiu, H; Miller, WT; Poli, V; Reich, NC				Liu, L.; Gao, Y.; Qiu, H.; Miller, W. T.; Poli, V.; Reich, N. C.			Identification of STAT3 as a specific substrate of breast tumor kinase	ONCOGENE			English	Article						tyrosine phosphorylation; transcription factor; signal transduction	NONRECEPTOR TYROSINE KINASE; MAMMARY EPITHELIAL-CELLS; GASTROINTESTINAL-TRACT; THERAPEUTIC TARGET; BRK; PROTEINS; ACTIVATION; EXPRESSION; RECEPTOR; BINDING	Breast tumor kinase (Brk) is a non-receptor tyrosine kinase distantly related to the Src family kinase. It is expressed in more than 60% of breast tumors, but the biological role of this kinase remains to be determined. Only a limited number of substates have been identified for Brk, and the link of Brk to tumorigenesis remains largely unknown. In this study, we provide evidence that the signal transducer and activator of transcription 3, STAT3, is a physiological target of Brk. Activation of STAT3 previously has been linked to oncogenesis, and results in this study demonstrate that STAT3 is tyrosine phosphorylated and transcriptionally activated in cells expressing endogenous Brk. Signal transducer and activator of transcription 3 is specifically targeted since other STAT members are not responsive to Brk expression. Signal transducer and activator of transcription 3 activation requires the catalytic activity of Brk, and expression of both STAT3 and Brk stimulate cellular proliferation. In addition, we have identified a negative regulator of Brk, the suppressor of cytokine signaling, SOCS3. The SOCS3 protein is known to block signaling mediated by cytokine receptors, and here we find that SOCS3 is able to repress the activity of the Brk nonreceptor tyrosine kinase.	SUNY Stony Brook, Dept Microbiol & Mol Genet, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; Univ Turin, Dept Genet Biol & Biochem, Turin, Italy	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Turin	Reich, NC (corresponding author), SUNY Stony Brook, Dept Microbiol & Mol Genet, Nicolls Rd,Life Sci Rm 168, Stony Brook, NY 11794 USA.	nreich@notes.cc.sunysb.edu	Poli, Valeria/A-9215-2012	Poli, Valeria/0000-0002-3739-3966	NCI NIH HHS [R01CA50773] Funding Source: Medline; PHS HHS [PPGCA28146] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050773] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akira S, 1999, STEM CELLS, V17, P138, DOI 10.1002/stem.170138; Banninger G, 2004, J BIOL CHEM, V279, P39199, DOI 10.1074/jbc.M400815200; Barker KT, 1997, ONCOGENE, V15, P799, DOI 10.1038/sj.onc.1201241; Benekli M, 2003, BLOOD, V101, P2940, DOI 10.1182/blood-2002-04-1204; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Chen HY, 2004, MOL CELL BIOL, V24, P10558, DOI 10.1128/MCB.24.24.10558-10572.2004; Chiarle R, 2005, NAT MED, V11, P623, DOI 10.1038/nm1249; Coppo P, 2003, ONCOGENE, V22, P4102, DOI 10.1038/sj.onc.1206607; Coyle JH, 2003, MOL CELL BIOL, V23, P92, DOI 10.1128/MCB.23.1.92-103.2003; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Decker T, 1999, CELL MOL LIFE SCI, V55, P1505, DOI 10.1007/s000180050390; Derry JJ, 2000, MOL CELL BIOL, V20, P6114, DOI 10.1128/MCB.20.16.6114-6126.2000; Derry JJ, 2003, ONCOGENE, V22, P4212, DOI 10.1038/sj.onc.1206465; Easty DJ, 1997, INT J CANCER, V71, P1061, DOI 10.1002/(SICI)1097-0215(19970611)71:6<1061::AID-IJC24>3.0.CO;2-F; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Faruqi TR, 2001, P NATL ACAD SCI USA, V98, P9014, DOI 10.1073/pnas.161281298; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Haegebarth A, 2004, J BIOL CHEM, V279, P54398, DOI 10.1074/jbc.M409579200; Harvey AJ, 2003, ONCOGENE, V22, P5006, DOI 10.1038/sj.onc.1206577; HENNIPMAN A, 1989, CANCER RES, V49, P516; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; Kamalati T, 2000, ONCOGENE, V19, P5471, DOI 10.1038/sj.onc.1203931; Kamalati T, 1996, J BIOL CHEM, V271, P30956, DOI 10.1074/jbc.271.48.30956; Kang KN, 2002, BBA-GENE STRUCT EXPR, V1574, P365, DOI 10.1016/S0167-4781(02)00234-8; Kim HI, 2005, J BIOL CHEM, V280, P28973, DOI 10.1074/jbc.M504568200; Krebs DL, 2000, J CELL SCI, V113, P2813; Lacronique V, 2000, BLOOD, V95, P2076, DOI 10.1182/blood.V95.6.2076; Leong PL, 2003, P NATL ACAD SCI USA, V100, P4138, DOI 10.1073/pnas.0534764100; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Liu L, 2005, P NATL ACAD SCI USA, V102, P8150, DOI 10.1073/pnas.0501643102; Llor X, 1999, CLIN CANCER RES, V5, P1767; McBride KM, 2000, EMBO J, V19, P6196, DOI 10.1093/emboj/19.22.6196; Minoguchi M, 2003, J BIOL CHEM, V278, P11182, DOI 10.1074/jbc.M211230200; Mitchell PJ, 2000, ONCOGENE, V19, P4273, DOI 10.1038/sj.onc.1203775; Mitchell PJ, 1997, ONCOGENE, V15, P1497, DOI 10.1038/sj.onc.1201292; MITCHELL PJ, 1994, ONCOGENE, V9, P2383; Mossmann T., 1983, J IMMUNOL METHODS, V65, P55; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Niu G, 2002, ONCOGENE, V21, P7001, DOI 10.1038/sj.onc.1205859; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Qiu HQ, 2005, ONCOGENE, V24, P5656, DOI 10.1038/sj.onc.1208721; Qiu HQ, 2004, ONCOGENE, V23, P2216, DOI 10.1038/sj.onc.1207339; Qiu HQ, 2002, J BIOL CHEM, V277, P34634, DOI 10.1074/jbc.M203877200; Sasaki A, 2000, J BIOL CHEM, V275, P29338, DOI 10.1074/jbc.M003456200; Serfas MS, 2003, ONCOL RES, V13, P409; SIYANOVA EY, 1994, ONCOGENE, V9, P2053; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; VANDENBRULE FA, 1992, INT J CANCER, V52, P653, DOI 10.1002/ijc.2910520426; VASIOUKHIN V, 1995, ONCOGENE, V10, P349; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	55	68	70	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 10	2006	25	35					4904	4912		10.1038/sj.onc.1209501	http://dx.doi.org/10.1038/sj.onc.1209501			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QE	16568091				2022-12-17	WOS:000239687100008
J	Peng, M; Litman, R; Jin, Z; Fong, G; Cantor, SB				Peng, M; Litman, R; Jin, Z; Fong, G; Cantor, SB			BACH1 is a DNA repair protein supporting BRCA1 damage response	ONCOGENE			English	Article						BRCA1; BACH1; FA-J; BRIP1; DNA repair	FANCONI-ANEMIA; HELICASE BRIP1; NUCLEAR FOCI; HISTONE H2AX; PHOSPHORYLATION; PHOSPHOPEPTIDE; TUMORIGENESIS; RECOGNITION; ASSOCIATION; DEFICIENT	The link between defects in BRCA1 and breast cancer development may be best understood by deciphering the role of associated proteins. BRCA1 associated C-terminal helicase (BACH1) interacts directly with the BRCA1 C-terminal BRCT repeats, which are important for BRCA1 DNA repair and are mutated in the majority of BRCA1 familial cancers. Thus, BACH1 is a likely candidate for mediating BRCA1 DNA repair and tumor suppression functions. Although previous evidence using overexpression of a dominant negative BACH1 has suggested that BACH1 is involved in BRCA1-DNA repair function, our results using BACH1 deficient cells provide direct evidence for involvement of BACH1 in DNA repair as well as for localizing BRCA1. Following DNA damage BACH1 is modified by phosphorylation, displays a BRCA1-like nuclear foci pattern and colocalizes with gamma-H2AX. Given that the BACH1/BRCA1 complex is unaltered by DNA damage and the intensity of BRCA1 foci is diminished in BACH1 deficient cells, BACH1 may serve to not only facilitate DNA repair, but also maintain BRCA1 in DNA damage foci.	UMASS Med Sch, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Cantor, SB (corresponding author), UMASS Med Sch, 364 Plantat St LRB 415, Worcester, MA 01605 USA.	Sharon.Cantor@umassmed.edu	Fong, Geoffrey T/H-2810-2014	Fong, Geoffrey T/0000-0001-9098-6472				Au WWY, 2005, J BIOL CHEM, V280, P6993, DOI 10.1074/jbc.M408879200; Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Botuyan MVE, 2004, STRUCTURE, V12, P1137, DOI 10.1016/j.str.2004.06.002; Bridge WL, 2005, NAT GENET, V37, P953, DOI 10.1038/ng1627; Cantor S, 2004, P NATL ACAD SCI USA, V101, P2357, DOI 10.1073/pnas.0308717101; Cantor SB, 2001, CELL, V105, P149, DOI 10.1016/S0092-8674(01)00304-X; Clapperton JA, 2004, NAT STRUCT MOL BIOL, V11, P512, DOI 10.1038/nsmb775; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Jasin M, 2002, ONCOGENE, V21, P8981, DOI 10.1038/sj.onc.1206176; Kanellopoulou C, 2005, GENE DEV, V19, P489, DOI 10.1101/gad.1248505; Kim SS, 2004, MOL CELL BIOL, V24, P9498, DOI 10.1128/MCB.24.21.9498-9507.2004; Kutler DI, 2003, BLOOD, V101, P1249, DOI 10.1182/blood-2002-07-2170; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Levitus M, 2004, BLOOD, V103, P2498, DOI 10.1182/blood-2003-08-2915; Levitus M, 2005, NAT GENET, V37, P934, DOI 10.1038/ng1625; Levran O, 2005, NAT GENET, V37, P931, DOI 10.1038/ng1624; Litman R, 2005, CANCER CELL, V8, P255, DOI 10.1016/j.ccr.2005.08.004; Liu YL, 2002, BREAST CANCER RES, V4, P9, DOI 10.1186/bcr417; Lou ZK, 2003, J BIOL CHEM, V278, P13599, DOI 10.1074/jbc.C300060200; MacLachlan TK, 2002, MOL CELL BIOL, V22, P4280, DOI 10.1128/MCB.22.12.4280-4292.2002; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Monteiro ANA, 2002, CANCER BIOL THER, V1, P187, DOI 10.4161/cbt.66; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Rodriguez M, 2003, J BIOL CHEM, V278, P52914, DOI 10.1074/jbc.C300407200; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rothkamm K, 2003, MOL CELL BIOL, V23, P5706, DOI 10.1128/MCB.23.16.5706-5715.2003; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Shiozaki EN, 2004, MOL CELL, V14, P405, DOI 10.1016/S1097-2765(04)00238-2; Snouwaert JN, 1999, FASEB J, V13, pA1538; Thompson LH, 2002, MUTAT RES-FUND MOL M, V509, P49, DOI 10.1016/S0027-5107(02)00224-5; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Welcsh PL, 2002, P NATL ACAD SCI USA, V99, P7560, DOI 10.1073/pnas.062181799; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	42	68	71	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	15					2245	2253		10.1038/sj.onc.1209257	http://dx.doi.org/10.1038/sj.onc.1209257			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029RD	16462773				2022-12-17	WOS:000236581200011
J	Fischer, M; Schwieger, M; Horn, S; Niebuhr, B; Ford, A; Roscher, S; Bergholz, U; Greaves, M; Lohler, J; Stocking, C				Fischer, M; Schwieger, M; Horn, S; Niebuhr, B; Ford, A; Roscher, S; Bergholz, U; Greaves, M; Lohler, J; Stocking, C			Defining the oncogenic function of the TEL/AML1 (ETV6/RUNX1) fusion protein in a mouse model	ONCOGENE			English	Article						acute lymphoblastic leukemia (ALL); RUNX1; ETV6/TEL; translocation(12;21)	HEMATOPOIETIC STEM-CELLS; ACUTE MYELOID-LEUKEMIA; PUTATIVE TUMOR-SUPPRESSOR; TRANSCRIPTIONAL REPRESSION; MURINE MODEL; TEL; GENE; AML1; TEL-AML1; TRANSLOCATION	The t(12;21) translocation, generating the TEL/AML1 fusion protein, is the most common genetic lesion in childhood cancer. Using a bone marrow transplantation model, we demonstrate that TEL/AML1 expression impinges on normal hematopoietic differentiation, leading to the in vivo accumulation and persistence of an early progenitor compartment with a Sca1(+)/Kit(hi)/CD11b(+) phenotype and an increased self- renewal capacity, as documented by replating assays in vitro. Differ entiation of these cells is not blocked, but the frequency of mature blood cells arising from TEL/AML1- transduced progenitors is low. Impa ired differentiation is prominently observed in the pro- B- cell compartment, resulting in an proportional increase in early progenitors in vivo, consistent with the t(12;21) ALL phenotype. Desp ite the accumulation of both multipotent and B- cell progenitors in vivo, no leukemia induction was observed during an observation period of over 1 year. These results are consistent with. ndings in twins with concordant ALL, showing that TEL/AML1 generates a preleukemic clone in utero that persists for several years in a clinically covert fashion. Fur thermore, our studies showed that the pointed domain of TEL/AML1, which recruits transcriptional repressors and directs oligomerization with either TEL/AML1 or wild-type TEL, was essential for the observed differentiation impairment and could not be replaced with another oligomerization domain.	Heinrich Pette Inst Expt Virol & Immunol, Mol Pathol Grp, D-20251 Hamburg, Germany; Inst Canc Res, Leukaemia Res Fund Ctr, London SW3 6JB, England; Inst Canc Res, Chester Beatty Labs, London SW3 6JB, England	Heinrich Pette Institute; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Stocking, C (corresponding author), Heinrich Pette Inst Expt Virol & Immunol, POB 201652, D-20206 Hamburg, Germany.	stocking@hpi.uni-hamburg.de						Akashi K, 2003, BLOOD, V101, P383, DOI 10.1182/blood-2002-06-1780; Bernardi R, 2002, ONCOGENE, V21, P3445, DOI 10.1038/sj.onc.1205313; Bernardin F, 2002, CANCER RES, V62, P3904; Borkhardt A, 1997, BLOOD, V90, P571, DOI 10.1182/blood.V90.2.571.571_571_577; Christensen JL, 2001, P NATL ACAD SCI USA, V98, P14541, DOI 10.1073/pnas.261562798; de Guzman CG, 2002, MOL CELL BIOL, V22, P5506, DOI 10.1128/MCB.22.15.5506-5517.2002; ELEFANTY AG, 1992, MOL CELL BIOL, V12, P1755, DOI 10.1128/MCB.12.4.1755; ERICKSON P, 1992, BLOOD, V80, P1825; Fenrick R, 2000, MOL CELL BIOL, V20, P5828, DOI 10.1128/MCB.20.16.5828-5839.2000; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; GONG JK, 1978, SCIENCE, V199, P1443, DOI 10.1126/science.75570; Greaves MF, 2003, BLOOD, V102, P2321, DOI 10.1182/blood-2002-12-3817; Growney JD, 2005, BLOOD, V106, P494, DOI 10.1182/blood-2004-08-3280; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; Hayashi K, 2000, J IMMUNOL, V165, P6816, DOI 10.4049/jimmunol.165.12.6816; Hiebert SW, 2001, CANCER CHEMOTH PHARM, V48, pS31, DOI 10.1007/s002800100302; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; Irvin BJ, 2003, J BIOL CHEM, V278, P46378, DOI 10.1074/jbc.M305189200; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Lagasse E, 2001, IMMUNITY, V14, P425, DOI 10.1016/S1074-7613(01)00123-6; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Li ZX, 2003, EXP HEMATOL, V31, P1206, DOI 10.1016/j.exphem.2003.08.008; Licht JD, 2001, ONCOGENE, V20, P5660, DOI 10.1038/sj.onc.1204593; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; McLean TW, 1996, BLOOD, V88, P4252; Meyer J, 1998, BLOOD, V91, P1901, DOI 10.1182/blood.V91.6.1901.1901_1901_1908; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Mori H, 2002, P NATL ACAD SCI USA, V99, P8242, DOI 10.1073/pnas.112218799; Morrison SJ, 1997, DEVELOPMENT, V124, P1929; Morrow M, 2004, BLOOD, V103, P3890, DOI 10.1182/blood-2003-10-3695; Muller-Tidow C, 2004, MOL CELL BIOL, V24, P2890, DOI 10.1128/MCB.24.7.2890-2904.2004; Okada H, 1998, ONCOGENE, V17, P2287, DOI 10.1038/sj.onc.1202151; Osato M, 2004, ONCOGENE, V23, P4284, DOI 10.1038/sj.onc.1207779; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; PUTZ G, 2005, UNPUB ONCOGENE; Randall TD, 1997, BLOOD, V89, P3596, DOI 10.1182/blood.V89.10.3596.3596_3596_3606; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Schebesta M, 2002, CURR OPIN IMMUNOL, V14, P216, DOI 10.1016/S0952-7915(02)00324-2; Schwieger M, 2002, J EXP MED, V196, P1227, DOI 10.1084/jem.20020824; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; Smith KS, 2003, MOL CELL, V12, P393, DOI 10.1016/S1097-2765(03)00277-6; Speck NA, 2002, NAT REV CANCER, V2, P502, DOI 10.1038/nrc840; Sun W, 2004, BLOOD, V104, P3565, DOI 10.1182/blood-2003-12-4349; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Terskikh AV, 2003, BLOOD, V102, P94, DOI 10.1182/blood-2002-08-2509; Tsuzuki S, 2004, P NATL ACAD SCI USA, V101, P8443, DOI 10.1073/pnas.0402063101; Van Rompaey L, 2000, ONCOGENE, V19, P5244, DOI 10.1038/sj.onc.1203899; Wang LL, 2001, ONCOGENE, V20, P3716, DOI 10.1038/sj.onc.1204479; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298; Zelent A, 2004, ONCOGENE, V23, P4275, DOI 10.1038/sj.onc.1207672; Zhang SL, 2001, MOL CELL BIOL, V21, P310, DOI 10.1128/MCB.21.1.310-318.2001	59	68	69	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2005	24	51					7579	7591		10.1038/sj.onc.1208931	http://dx.doi.org/10.1038/sj.onc.1208931			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	984VQ	16044150				2022-12-17	WOS:000233333800007
J	Malchinkhuu, E; Sato, K; Horiuchi, Y; Mogi, C; Ohwada, S; Ishiuchi, S; Saito, N; Kurose, H; Tomura, H; Okajima, F				Malchinkhuu, E; Sato, K; Horiuchi, Y; Mogi, C; Ohwada, S; Ishiuchi, S; Saito, N; Kurose, H; Tomura, H; Okajima, F			Role of p38 mitogen-activated kinase and c-Jun terminal kinase in migration response to lysophosphatidic acid and sphingosine-1-phosphate in glioma cells	ONCOGENE			English	Article						glioma; cell migration; lysophosphatidic acid; sphingosine-1-phosphate; MAP kinase	GROWTH-FACTOR RECEPTOR; PROTEIN-COUPLED RECEPTOR; SPHINGOSINE 1-PHOSPHATE; CANCER CELLS; ACTIN REORGANIZATION; STIMULATES MOTILITY; LYSOPHOSPHOLIPASE-D; GLIOBLASTOMA CELLS; RAC ACTIVATION; MAP KINASE	A potential role for 1-oleoyl-sn-glycero-3-phosphate or lysophosphatidic acid (LPA) and sphingosine-1-phosphate (S1P) in the regulation of malignant diseases has been widely considered. In this study, we found that in transformed astroglial cells, the expression pro. le of lysophospholipid receptor mRNA and the action modes of LPA and S1P on cell motility were changed: there was a change in the acquisition of the ability of LPA to stimulate cell migration and a change in the migratory response to S1P from stimulation through S1P(1) to inhibition through S1P(2). LPA-induced cell migration was almost completely inhibited by either pertussis toxin, LPA(1) receptor antagonists including Ki16425(3(4[4([1(2chlorophenyl)ethoxy]carbonyl amino)-3-methyl-5-isoxazolyl] benzylsulfonyl) propanoic acid) or an inhibitor of phosphatidylinositol 3- kinase (PI3K) wortmannin. The LPA-induced action was also suppressed, although incompletely, by several specific inhibitors for intracellular signaling pathways including Rac1, Cdc42, p38 mitogen-activated protein kinase (p38MAPK) and c-Jun terminal kinase (JNK), but not extracellular signal-regulated kinase. Nearly complete inhibition of migration response to LPA, however, required simultaneous inhibition of both the p38MAPK and JNK pathways. Inhibition of Rac1 suppressed JNK but not p38MAPK, while the activity of p38MAPK was abolished by a dominant-negative form of Cdc42. These findings suggest that, in glioma cells, the PI3K/Cdc42/p38MAPK and PI3K/Rac1/JNK pathways are equally important for LPA1 receptor-mediated migration.	Gunma Univ, Inst Mol & Cellular Regulat, Lab Signal Transduct, Maebashi, Gumma 3718512, Japan; Gunma Univ, Grad Sch Med, Maebashi, Gumma 3718511, Japan; Gunma Univ, Grad Sch Med, Dept Neurosurg, Maebashi, Gumma 3718511, Japan; Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol & Toxicol, Fukuoka 8128582, Japan	Gunma University; Gunma University; Gunma University; Kyushu University	Sato, K (corresponding author), Gunma Univ, Inst Mol & Cellular Regulat, Lab Signal Transduct, 3-39-15 Showa Machi, Maebashi, Gumma 3718512, Japan.	kosato@showa.gunma-u.ac.jp	Malchinkhuu, Enkhzol/AAH-4600-2019	Sato, Koichi/0000-0001-7694-4014; Malchinkhuu, Enkhzol/0000-0003-0744-079X				Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bian DF, 2004, CANCER RES, V64, P4209, DOI 10.1158/0008-5472.CAN-04-0060; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Cara DC, 2001, J IMMUNOL, V167, P6552, DOI 10.4049/jimmunol.167.11.6552; Chandrasekar N, 2003, ONCOGENE, V22, P392, DOI 10.1038/sj.onc.1206164; Cunnick JM, 1998, J BIOL CHEM, V273, P14468, DOI 10.1074/jbc.273.23.14468; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Edlund S, 2002, MOL BIOL CELL, V13, P902, DOI 10.1091/mbc.01-08-0398; Fischer DJ, 2001, MOL PHARMACOL, V60, P776; Gschwind A, 2002, CANCER RES, V62, P6329; Hama K, 2004, J BIOL CHEM, V279, P17634, DOI 10.1074/jbc.M313927200; Heise CE, 2001, MOL PHARMACOL, V60, P1173, DOI 10.1124/mol.60.6.1173; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; Huang C, 2003, NATURE, V424, P219, DOI 10.1038/nature01745; IMAMURA F, 1993, BIOCHEM BIOPH RES CO, V193, P497, DOI 10.1006/bbrc.1993.1651; Ishiuchi S, 2002, NAT MED, V8, P971, DOI 10.1038/nm746; Ishizuka T, 2001, J IMMUNOL, V167, P2298, DOI 10.4049/jimmunol.167.4.2298; Kawauchi T, 2003, EMBO J, V22, P4190, DOI 10.1093/emboj/cdg413; Kimura T, 2003, ARTERIOSCL THROM VAS, V23, P1283, DOI 10.1161/01.ATV.0000079011.67194.5A; Kon J, 1999, J BIOL CHEM, V274, P23940, DOI 10.1074/jbc.274.34.23940; Lamalice L, 2004, ONCOGENE, V23, P434, DOI 10.1038/sj.onc.1207034; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Malchinkhuu E, 2003, BIOCHEM J, V370, P817, DOI 10.1042/BJ20020867; Manning TJ, 2000, CELL MOTIL CYTOSKEL, V45, P185, DOI 10.1002/(SICI)1097-0169(200003)45:3<185::AID-CM2>3.0.CO;2-G; Maruyama Y, 2002, CIRC RES, V91, P961, DOI 10.1161/01.RES.0000043282.39776.7C; Matsumoto T, 1999, J BIOL CHEM, V274, P13954, DOI 10.1074/jbc.274.20.13954; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Ohta H, 2003, MOL PHARMACOL, V64, P994, DOI 10.1124/mol.64.4.994; Okamoto H, 2000, MOL CELL BIOL, V20, P9247, DOI 10.1128/MCB.20.24.9247-9261.2000; Pebay A, 2001, EUR J NEUROSCI, V13, P2067, DOI 10.1046/j.0953-816x.2001.01585.x; Pichon S, 2004, J CELL SCI, V117, P2569, DOI 10.1242/jcs.01110; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rao TS, 2003, BRAIN RES, V990, P182, DOI 10.1016/S0006-8993(03)03527-3; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Sato K, 1999, MOL PHARMACOL, V55, P126, DOI 10.1124/mol.55.1.126; Sato K, 2000, MOL BRAIN RES, V85, P151, DOI 10.1016/S0169-328X(00)00262-X; Sato K, 1999, MOL BRAIN RES, V74, P182, DOI 10.1016/S0169-328X(99)00279-X; Schafer B, 2004, ONCOGENE, V23, P991, DOI 10.1038/sj.onc.1207278; Schulte KM, 2001, INT J CANCER, V92, P249, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1166>3.0.CO;2-D; Shi GX, 2003, J IMMUNOL, V171, P3407, DOI 10.4049/jimmunol.171.7.3407; Stahle M, 2003, J CELL SCI, V116, P3835, DOI 10.1242/jcs.00679; Stam JC, 1998, EMBO J, V17, P4066, DOI 10.1093/emboj/17.14.4066; Steiner MR, 2002, BBA-MOL CELL BIOL L, V1582, P154, DOI 10.1016/S1388-1981(02)00150-6; Tokumura A, 2002, J BIOL CHEM, V277, P39436, DOI 10.1074/jbc.M205623200; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; Van Brocklyn JR, 2003, CANCER LETT, V199, P53, DOI 10.1016/S0304-3835(03)00334-3; van Leeuwen FN, 2003, J BIOL CHEM, V278, P400, DOI 10.1074/jbc.M210151200; VANDENBERG SR, 1992, J NEUROPATH EXP NEUR, V51, P644, DOI 10.1097/00005072-199211000-00008; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; Westermann AM, 1998, ANN ONCOL, V9, P437, DOI 10.1023/A:1008217129273; Xia Y, 2000, P NATL ACAD SCI USA, V97, P5243, DOI 10.1073/pnas.97.10.5243; Xie YH, 2002, J BIOL CHEM, V277, P32516, DOI 10.1074/jbc.M203864200; XU Y, 1995, BIOCHEM J, V309, P933, DOI 10.1042/bj3090933; Yamada T, 2004, J BIOL CHEM, V279, P6595, DOI 10.1074/jbc.M308133200	55	68	79	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2005	24	44					6676	6688		10.1038/sj.onc.1208805	http://dx.doi.org/10.1038/sj.onc.1208805			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	971FL	16007180				2022-12-17	WOS:000232367800009
J	Wang, YH; Zhou, XB; Zhu, HX; Liu, S; Zhou, CQ; Zhang, G; Xue, LY; Lu, N; Quan, LP; Bai, JF; Zhan, QM; Xu, NZ				Wang, YH; Zhou, XB; Zhu, HX; Liu, S; Zhou, CQ; Zhang, G; Xue, LY; Lu, N; Quan, LP; Bai, JF; Zhan, QM; Xu, NZ			Overexpression of EB1 in human esophageal squamous cell carcinoma (ESCC) may promote cellular growth by activating beta-catenin/TCF pathway	ONCOGENE			English	Article						esophageal cancer; overexpression; EB1; APC; beta-catenin	ADENOMATOUS POLYPOSIS-COLI; C-MYC; EXPRESSION; GENE; APC; TARGET	Esophageal squamous cell carcinoma (ESCC) has a multifactorial etiology involving environmental and/or genetic factors. End-binding protein 1 (EB1), which was cloned as an interacting partner of the adenomatous polyposis coli (APC) tumor suppressor protein, was previously found overexpressed in ESCC. However, the precise role of EB1 in the development of this malignancy has not yet been elucidated. In this study, we analysed freshly resected ESCC specimens and demonstrated that EB1 was overexpressed in approximately 63% of tumor samples compared to matched normal tissue. We report that overexpression of EB1 in the ESCC line EC9706 significantly promotes cell growth, whereas suppression of EB1 protein level by RNA interference significantly inhibited growth of esophageal tumor cells. In addition, EB1 overexpression induced nuclear accumulation of beta-catenin and promoted the transcriptional activity of beta-catenin/T-cell factor (TCF). These effects were partially or completely abolished by coexpression of APC or Delta N TCF4, respectively. Also, we found that EB1 affected the interaction between beta-catenin and APC. Furthermore, EB1 overexpression was correlated with cytoplasmic/nuclear accumulation of beta-catenin in primary human ESCC. Taken together, these results support the novel hypothesis that EB1 overexpression may play a role in the development of ESCC by affecting APC function and activating the beta-catenin/TCF pathway.	Chinese Acad Med Sci, Canc Inst & Canc Hosp, Lab Cell & Mol Biol, Beijing 100021, Peoples R China; Peking Union Med Coll, New York, NY 10021 USA; Chinese Acad Med Sci, Canc Inst & Canc Hosp, Dept Pathol, Beijing 100037, Peoples R China; Chinese Acad Med Sci, Canc Inst & Canc Hosp, Natl Lab Mol Oncol, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College	Xu, NZ (corresponding author), Chinese Acad Med Sci, Canc Inst & Canc Hosp, Lab Cell & Mol Biol, Beijing 100021, Peoples R China.	xningzhi@public.bta.net.cn	Zhou, Cuiqi/B-1568-2010; Liu, Shuang/J-1798-2012; Zhang, Guo/Q-8513-2016	Wang, Yihua/0000-0001-5561-0648				Berrueta L, 1998, P NATL ACAD SCI USA, V95, P10596, DOI 10.1073/pnas.95.18.10596; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Louie RK, 2004, J CELL SCI, V117, P1117, DOI 10.1242/jcs.00939; Polakis P, 2000, GENE DEV, V14, P1837; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Stoner GD, 2001, CARCINOGENESIS, V22, P1737, DOI 10.1093/carcin/22.11.1737; Struski S, 2002, CANCER GENET CYTOGEN, V135, P63, DOI 10.1016/S0165-4608(01)00624-0; SU LK, 1995, CANCER RES, V55, P2972; Tirnauer JS, 2000, J CELL BIOL, V149, P761, DOI 10.1083/jcb.149.4.761; Uys P, 2003, MOL CARCINOGEN, V36, P82, DOI 10.1002/mc.10100; Wang YH, 2005, BREAST CANCER RES, V7, pR220, DOI 10.1186/bcr975; Willert Jennifer, 2002, BMC Dev Biol, V2, P8, DOI 10.1186/1471-213X-2-8; Yen CC, 2001, CANCER, V92, P2769, DOI 10.1002/1097-0142(20011201)92:11<2769::AID-CNCR10118>3.0.CO;2-M; Zhang G, 2005, PATHOL INT, V55, P310, DOI 10.1111/j.1440-1827.2005.01840.x; Zhou CQ, 2005, INT J CANCER, V113, P891, DOI 10.1002/ijc.20642; ZHOU J, 1999, CHINESE J MED GENET, V16, P303; Zhou Xiao-bo, 2002, Ai Zheng, V21, P877; ZOU XN, 2002, B CHIN CANC, V11, P446	24	68	74	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2005	24	44					6637	6645		10.1038/sj.onc.1208819	http://dx.doi.org/10.1038/sj.onc.1208819			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	971FL	16007168				2022-12-17	WOS:000232367800005
J	Ouellet, V; Provencher, DM; Maugard, CM; Le Page, C; Ren, FF; Lussier, C; Novak, J; Ge, B; Hudson, TJ; Tonin, PN; Mes-Masson, AM				Ouellet, V; Provencher, DM; Maugard, CM; Le Page, C; Ren, FF; Lussier, C; Novak, J; Ge, B; Hudson, TJ; Tonin, PN; Mes-Masson, AM			Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling	ONCOGENE			English	Review						borderline tumors; epithelial ovarian cancer; microarray	DIFFERENTIALLY EXPRESSED GENES; FLUID LACTATE-DEHYDROGENASE; RECEPTOR MESSENGER-RNA; CANCER CELL-LINES; CYCLIN-E; SURFACE EPITHELIUM; BORDERLINE TUMORS; POOR-PROGNOSIS; ALPHA-CATENIN; CDNA MICROARRAY	Tumors of low malignant potential (LMP) represent 20% of epithelial ovarian cancers (EOCs) and are associated with a better prognosis than the invasive tumors (TOV). De. ning the relationship between LMPs and TOVs remains an important goal towards understanding the molecular pathways that contribute to prognosis, as well as providing molecular markers, for these EOCs. To this end, DNA microarray analyses were performed either in a primary culture or a tumor tissue model system and selected candidate genes showing a distinctive expression pro. le between LMPs and TOVs were identified using a class prediction approach based on three statistical methods of analysis. Both model systems appear relevant as candidate genes identified by either model allowed the proper reclassification of samples as either LMPs or TOVs. Selected candidate genes (CAS, CCNE1, LGALS8, ITG beta 3, ATP1B1, FLIP, KRT7 and KRT19) were validated by real-time quantitative PCR analysis and show differential expression between LMPs and TOVs. Immunohistochemistry analyses showed that the two tumor classes were distinguishable by their expression of CAS, TNFR1A, FLIP, CKS1 and CCNE1. These results de. ne signature patterns for gene expression of LMPs and TOVs and identify gene candidates that warrant further study to deepen our understanding of the biology of EOC.	CHUM, ICM, Ctr Rech, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Div Gynecol Oncol, Montreal, PQ, Canada; Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada; CHUM, Dept Pathol, Montreal, PQ H2L 4M1, Canada; McGill Univ, Dept Human Genet, Montreal, PQ, Canada; Genome Quebec Innovat Ctr, Montreal, PQ, Canada; McGill Univ, Ctr Hlth, Res Inst, Montreal, PQ, Canada; McGill Univ, Dept Med, Montreal, PQ, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal; McGill University; McGill University; McGill University	Mes-Masson, AM (corresponding author), CHUM, ICM, Ctr Rech, 1560,Rue Sherbrooke Est, Montreal, PQ H2L 4M1, Canada.	anne-marie.mes-masson@umontreal.ca	Le Page, Cecile/B-3215-2010	Le Page, Cecile/0000-0002-8020-1544; Mes-Masson, Anne-Marie/0000-0002-6498-266X				Adib TR, 2004, BRIT J CANCER, V90, P686, DOI 10.1038/sj.bjc.6601603; Anttila M, 1998, J CLIN ONCOL, V16, P2591, DOI 10.1200/JCO.1998.16.8.2591; Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; Bayani J, 2002, CANCER RES, V62, P3466; BLAUSTEIN A, 1982, CANCER, V49, P722, DOI 10.1002/1097-0142(19820215)49:4<722::AID-CNCR2820490421>3.0.CO;2-C; Boran N, 2000, GYNECOL OBSTET INVES, V49, P272, DOI 10.1159/000010258; BOSE CK, 1994, CANCER LETT, V77, P39, DOI 10.1016/0304-3835(94)90345-X; Boss EA, 2001, EUR J GYNAECOL ONCOL, V22, P427; Brinkmann U, 1998, AM J HUM GENET, V62, P509, DOI 10.1086/301773; Brustmann H, 2004, GYNECOL ONCOL, V92, P268, DOI 10.1016/j.ygyno.2003.10.029; Burger CW, 2000, INT J GYNECOL CANCER, V10, P181, DOI 10.1046/j.1525-1438.2000.010003181.x; Carreiras F, 1996, GYNECOL ONCOL, V62, P260, DOI 10.1006/gyno.1996.0225; Casey RC, 2003, CLIN EXP METASTAS, V20, P143, DOI 10.1023/A:1022670501667; Cheng PC, 1996, J NATL CANCER I, V88, P510, DOI 10.1093/jnci/88.8.510; Courjal F, 1996, INT J CANCER, V69, P247; Danguy A, 2002, BBA-GEN SUBJECTS, V1572, P285, DOI 10.1016/S0304-4165(02)00315-X; Davidson B, 2003, CLIN CANCER RES, V9, P2248; Davidson B, 2000, J PATHOL, V192, P460; Davies BR, 1998, HISTOPATHOLOGY, V32, P69; DESOUZA PL, 1992, HEMATOL ONCOL CLIN N, V6, P761; Dietel M, 2000, VIRCHOWS ARCH, V436, P403, DOI 10.1007/s004280050467; DIRENZO MF, 1994, INT J CANCER, V58, P658, DOI 10.1002/ijc.2910580507; Dore M, 1998, J HISTOCHEM CYTOCHEM, V46, P77, DOI 10.1177/002215549804600110; Farley J, 2003, CANCER RES, V63, P1235; Fujimoto J, 1997, CANCER LETT, V115, P207, DOI 10.1016/S0304-3835(97)04735-6; Garzetti GG, 1999, CANCER, V85, P2226, DOI 10.1002/(SICI)1097-0142(19990515)85:10<2226::AID-CNCR18>3.0.CO;2-X; Gascoyne DM, 2003, CELL CYCLE, V2, P238, DOI 10.4161/cc.2.3.355; Giuntoli RL, 1998, CANCER RES, V58, P5546; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; GOODMAN GE, 1990, J CLIN ONCOL, V8, P1083, DOI 10.1200/JCO.1990.8.6.1083; Gotlieb WH, 1998, CANCER-AM CANCER SOC, V82, P141, DOI 10.1002/(SICI)1097-0142(19980101)82:1<141::AID-CNCR17>3.0.CO;2-2; Gu J, 2001, JNCI-J NATL CANCER I, V93, P1147, DOI 10.1093/jnci/93.15.1147; Gupta RA, 2003, CANCER RES, V63, P906; Halperin R, 1999, EUR J GYNAECOL ONCOL, V20, P40; Halperin R, 2001, EUR J GYNAECOL ONCOL, V22, P292; HARLOZINSKASZMYRKA A, 1986, CANCER DETECT PREV, V9, P347; Harper JW, 2001, CURR BIOL, V11, pR431, DOI 10.1016/S0960-9822(01)00253-6; Hashiguchi Y, 2004, HUM PATHOL, V35, P165, DOI 10.1016/j.humpath.2003.07.018; Hefler L, 1999, BRIT J CANCER, V81, P855, DOI 10.1038/sj.bjc.6690776; Hough CD, 2000, CANCER RES, V60, P6281; Houle CD, 2002, GYNECOL ONCOL, V86, P69, DOI 10.1006/gyno.2002.6729; Huntsman D, 1999, AM J PATHOL, V155, P343, DOI 10.1016/S0002-9440(10)65130-9; Hutchinson S, 2003, CLIN CHEM, V49, P746, DOI 10.1373/49.5.746; Inui N, 2003, BIOCHEM BIOPH RES CO, V303, P978, DOI 10.1016/S0006-291X(03)00469-8; Ismail RS, 2000, CANCER RES, V60, P6744; Kamarainen M, 1996, AM J PATHOL, V148, P1435; KASTELIC L, 1994, CANCER LETT, V82, P81, DOI 10.1016/0304-3835(94)90149-X; Kim JH, 2002, JAMA-J AM MED ASSOC, V287, P1671, DOI 10.1001/jama.287.13.1671; Kitakata H, 2002, CANCER RES, V62, P6682; Kohlberger P, 2002, ANTICANCER RES, V22, P3541; Korneeva I, 2002, INT J CANCER, V102, P483, DOI 10.1002/ijc.10747; KRUK PA, 1990, LAB INVEST, V63, P132; Kudoh K, 1999, GYNECOL OBSTET INVES, V47, P52, DOI 10.1159/000010062; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; LAH TT, 1992, CANCER LETT, V61, P243, DOI 10.1016/0304-3835(92)90295-7; Lancaster JM, 2004, J SOC GYNECOL INVEST, V11, P51, DOI 10.1016/j.jsgi.2003.07.004; Lancaster JM, 2003, CLIN CANCER RES, V9, P762; Lau KM, 1999, P NATL ACAD SCI USA, V96, P5722, DOI 10.1073/pnas.96.10.5722; Le Page C, 2004, EXPERT REV MOL DIAGN, V4, P157, DOI 10.1586/14737159.4.2.157; Lee BC, 2004, INT J ONCOL, V24, P847; Li SF, 2004, GYNECOL ONCOL, V92, P622, DOI 10.1016/j.ygyno.2003.10.053; Lin CJ, 1996, GYNECOL ONCOL, V60, P347, DOI 10.1006/gyno.1996.0054; Link CJ, 1996, AM J MED, V101, P217, DOI 10.1016/S0002-9343(96)80079-9; LOUNIS H, 1994, EXP CELL RES, V215, P303, DOI 10.1006/excr.1994.1346; Lu KH, 2004, CLIN CANCER RES, V10, P3291, DOI 10.1158/1078-0432.CCR-03-0409; Maggiora P, 2003, EXP CELL RES, V288, P382, DOI 10.1016/S0014-4827(03)00250-7; Mandelin E, 2003, CANCER RES, V63, P6258; Manderson EN, 2002, GENOME RES, V12, P112, DOI 10.1101/gr.174202; Marone M, 1998, INT J CANCER, V75, P34, DOI 10.1002/(SICI)1097-0215(19980105)75:1<34::AID-IJC6>3.3.CO;2-A; Martoglio AM, 2000, MOL MED, V6, P750, DOI 10.1007/BF03402191; Masuda T, 2003, CLIN CANCER RES, V9, P5693; Matei D, 2002, ONCOGENE, V21, P6289, DOI 10.1038/sj.onc.1205785; Milde-Langosch K, 2003, INT J GYNECOL PATHOL, V22, P168, DOI 10.1097/00004347-200304000-00009; MOGHUL A, 1994, ONCOGENE, V9, P2045; Mok SC, 2001, J NATL CANCER I, V93, P1458, DOI 10.1093/jnci/93.19.1458; Morris MC, 2003, NATURE, V423, P1009, DOI 10.1038/nature01720; Naora H, 2001, P NATL ACAD SCI USA, V98, P4060, DOI 10.1073/pnas.071594398; Nash MA, 2002, CLIN CANCER RES, V8, P1754; Negus RPM, 1997, AM J PATHOL, V150, P1723; Negus RPM, 1998, J LEUKOCYTE BIOL, V63, P758, DOI 10.1002/jlb.63.6.758; NEGUS RPM, 1995, J CLIN INVEST, V95, P2391, DOI 10.1172/JCI117933; Nijman HW, 2001, EUR J OBSTET GYN R B, V94, P114, DOI 10.1016/S0301-2115(00)00294-3; Novak JP, 2002, GENOMICS, V79, P104, DOI 10.1006/geno.2001.6675; Ono K, 2000, CANCER RES, V60, P5007; Ortiz BH, 2001, CANCER RES, V61, P7264; Patra D, 1999, J BIOL CHEM, V274, P36839, DOI 10.1074/jbc.274.52.36839; Peiro G, 2002, AM J CLIN PATHOL, V118, P922, DOI 10.1092/JU8YP7MJK2WDT1FY; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Presneau N, 2003, ONCOGENE, V22, P1568, DOI 10.1038/sj.onc.1206219; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Roberts D, 2002, DNA CELL BIOL, V21, P11, DOI 10.1089/10445490252810276; Rosenberg E, 2001, HUM PATHOL, V32, P808, DOI 10.1053/hupa.2001.26462; Sakamoto M, 2001, Hum Cell, V14, P305; Sasano H, 1996, MODERN PATHOL, V9, P386; Sawasaki T, 2001, J SOC GYNECOL INVEST, V8, P179, DOI 10.1016/S1071-5576(01)00102-2; Sawiris GP, 2002, CANCER RES, V62, P2923; Schneider D, 1997, GYNECOL ONCOL, V66, P399, DOI 10.1006/gyno.1997.4792; Schraml P, 2003, J PATHOL, V200, P375, DOI 10.1002/path.1356; Schummer M, 1999, GENE, V238, P375, DOI 10.1016/S0378-1119(99)00342-X; Schwartz DR, 2002, CANCER RES, V62, P4722; Seidman JD, 2000, HUM PATHOL, V31, P539, DOI 10.1053/hp.2000.8048; Seidman JD, 2002, CANCER, V95, P675, DOI 10.1002/cncr.10777; Shapira M, 2004, CANCER-AM CANCER SOC, V100, P1615, DOI 10.1002/cncr.20172; Shridhar V, 2001, CANCER RES, V61, P5895; Singer G, 2002, AM J PATHOL, V160, P1223, DOI 10.1016/S0002-9440(10)62549-7; Singer G, 2003, INT J GYNECOL PATHOL, V22, P37, DOI 10.1097/00004347-200301000-00009; Singer G, 2003, J NATL CANCER I, V95, P484, DOI 10.1093/jnci/95.6.484; SLOTMAN BJ, 1991, EUR J OBSTET GYN R B, V38, P221, DOI 10.1016/0028-2243(91)90296-W; SLOTMAN BJ, 1990, CANCER, V66, P740, DOI 10.1002/1097-0142(19900815)66:4<740::AID-CNCR2820660423>3.0.CO;2-H; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Stone B, 2003, INT J CANCER, V104, P73, DOI 10.1002/ijc.10900; Sui L, 1999, GYNECOL ONCOL, V73, P202, DOI 10.1006/gyno.1999.5373; Sui L, 2001, GYNECOL ONCOL, V83, P56, DOI 10.1006/gyno.2001.6308; Sui L, 2001, CLIN CANCER RES, V7, P4130; Tamada Y, 1999, ONCOL RES, V11, P233; Tanaka Y, 2003, CANCER-AM CANCER SOC, V98, P424, DOI 10.1002/cncr.11506; Tapper J, 2001, CANCER GENET CYTOGEN, V128, P1, DOI 10.1016/S0165-4608(01)00386-7; TAVASSOLI FA, 1988, MODERN PATHOL, V1, P407; Tiniakos DG, 1998, HUM PATHOL, V29, P1250, DOI 10.1016/S0046-8177(98)90253-2; Tonin PN, 2001, ONCOGENE, V20, P6617, DOI 10.1038/sj.onc.1204804; Trope C, 1998, SEMIN ONCOL, V25, P372; Troyanskaya OG, 2002, BIOINFORMATICS, V18, P1454, DOI 10.1093/bioinformatics/18.11.1454; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wang K, 1999, GENE, V229, P101, DOI 10.1016/S0378-1119(99)00035-9; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Wong KK, 2001, BIOTECHNIQUES, V30, P670, DOI 10.2144/01303dd05; Yanagawa T, 2004, LAB INVEST, V84, P513, DOI 10.1038/labinvest.3700057; YU H, 1995, CANCER RES, V55, P1603; Yuce K, 2001, EUR J GYNAECOL ONCOL, V22, P228; ZHENG JP, 1993, CANCER RES, V53, P4138	130	68	72	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2005	24	29					4672	4687		10.1038/sj.onc.1208214	http://dx.doi.org/10.1038/sj.onc.1208214			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	942TD	15940270				2022-12-17	WOS:000230304500006
J	Wang, W; Huper, G; Guo, YQ; Murphy, SK; Olson, JA; Marks, JR				Wang, W; Huper, G; Guo, YQ; Murphy, SK; Olson, JA; Marks, JR			Analysis of methylation-sensitive transcriptome identifies GADD45a as a frequently methylated gene in breast cancer	ONCOGENE			English	Article						GADD45a; methylation; breast cancer; expression array	MAMMARY EPITHELIAL-CELLS; DNA METHYLATION; PROMOTER HYPERMETHYLATION; CAVEOLIN-1 GENE; CPG ISLAND; EXPRESSION; GROWTH; BRCA1; INDUCTION; RECEPTOR	Treatment of the breast cancer cell line, MDAMB468 with the DNA methylation inhibitor, 5-azacytidine (5-AzaC) results in growth arrest, whereas the growth of the normal breast epithelial line DU99 ( telomerase immortalized) is relatively unaffected. Comparing gene expression profiles of these two lines after 5-AzaC treatment, we identified 36 genes that had relatively low basal levels in MDAMB468 cells compared to the DU99 line and were induced in the cancer cell line but not in the normal breast epithelial line. Of these genes, 33 have associated CpG islands greater than 300 bp in length but only three have been previously described as targets for aberrant methylation in human cancer. Northern blotting for five of these genes (alpha-Catenin, DTR, FYN, GADD45a, and Zyxin) verified the array results. Further analysis of one of these genes, GADD45a, showed that 5-AzaC induced expression in five additional breast cancer cell lines with little or no induction in three additional lines derived from normal breast epithelial cells. The CpG island associated with GADD45a was analysed by bisulfite sequencing, sampling over 100 CpG dinucleotides. We found that four CpG's, located approximately 700 bp upstream of the transcriptional start site are methylated in the majority of breast cancer cell lines and primary tumors but not in DNA from normal breast epithelia or matched lymphocytes from cancer patients. Therefore, this simple method of dynamic transcriptional pro. ling yielded a series of novel methylation-sensitive genes in breast cancer including the BRCA1 and p53 responsive gene, GADD45a.	Dept Surg, Med Ctr, Dept Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Obstet & Gynecol, Durham, NC 27710 USA	Duke University	Marks, JR (corresponding author), Dept Surg, Med Ctr, Dept Surg, Box 3873,Med Sci Res Bldg, Durham, NC 27710 USA.	marks003@mc.duke.edu	Murphy, Susan/R-3903-2019	Murphy, Susan/0000-0001-8298-7272	NATIONAL CANCER INSTITUTE [U01CA084955] Funding Source: NIH RePORTER; NCI NIH HHS [CA84955] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amundson SA, 1998, ONCOGENE, V17, P2149, DOI 10.1038/sj.onc.1202136; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; Baylin Stephen B, 2004, Novartis Found Symp, V259, P226; Bovenzi V, 1999, ANTI-CANCER DRUG, V10, P471, DOI 10.1097/00001813-199906000-00007; Coombes MM, 2003, ONCOGENE, V22, P8902, DOI 10.1038/sj.onc.1207050; Cui J, 2001, PROSTATE, V46, P249, DOI 10.1002/1097-0045(20010215)46:3<249::AID-PROS1030>3.0.CO;2-#; DAIRKEE SH, 1988, J NATL CANCER I, V80, P691, DOI 10.1093/jnci/80.9.691; Davis P, 1996, ONCOGENE, V13, P1315; Dobrovic A, 1997, CANCER RES, V57, P3347; Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5; Dowell JE, 2004, J CLIN ONCOL, V22, P1353, DOI 10.1200/JCO.2004.01.947; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Engelman JA, 1999, FEBS LETT, V448, P221, DOI 10.1016/S0014-5793(99)00365-8; Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3; Evron E, 2001, CANCER RES, V61, P2782; Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508; Fan WH, 2002, J BIOL CHEM, V277, P8061, DOI 10.1074/jbc.M110225200; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793; Grunau C, 2001, Nucleic Acids Res, V29, pE65, DOI 10.1093/nar/29.13.e65; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; Kai WC, 2001, AM J PATHOL, V159, P1635, DOI 10.1016/S0002-9440(10)63010-6; Krop IE, 2001, P NATL ACAD SCI USA, V98, P9796, DOI 10.1073/pnas.171138398; Li Q, 1999, ONCOGENE, V18, P3284, DOI 10.1038/sj.onc.1202663; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Marks J, 1988, Prog Clin Biol Res, V284, P163; McPherson SJ, 1997, J ENDOCRINOL, V154, P535, DOI 10.1677/joe.0.1540535; Mullan PB, 2001, ONCOGENE, V20, P6123, DOI 10.1038/sj.onc.1204712; Muller HM, 2003, CANCER RES, V63, P7641; MURPHY SK, 2001, CANC HDB, P317; Oshiro MM, 2003, ONCOGENE, V22, P3624, DOI 10.1038/sj.onc.1206545; Oue N, 2003, ONCOLOGY-BASEL, V64, P423, DOI 10.1159/000070302; Parker BS, 2003, CANCER BIOL THER, V2, P259, DOI 10.4161/cbt.2.3.364; Paz MF, 2003, CANCER RES, V63, P1114; Pechoux C, 1999, DEV BIOL, V206, P88, DOI 10.1006/dbio.1998.9133; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Sanjo H, 1998, J BIOL CHEM, V273, P29066, DOI 10.1074/jbc.273.44.29066; Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Tomlinson GE, 1998, CANCER RES, V58, P3237; Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438; van Noesel MM, 2003, GENE CHROMOSOME CANC, V38, P226, DOI 10.1002/gcc.10278; Wang W, 2004, MOL CANCER RES, V2, P442; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998; Woodcock DM, 1999, BRIT J CANCER, V79, P251, DOI 10.1038/sj.bjc.6690041; Zelent Arthur, 2004, Clin Cancer Res, V10, P4622, DOI 10.1158/1078-0432.CCR-1219-03; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	50	68	77	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2005	24	16					2705	2714		10.1038/sj.onc.1208464	http://dx.doi.org/10.1038/sj.onc.1208464			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15735726				2022-12-17	WOS:000228356700012
J	Gonzalez-Suarez, E; Geserick, C; Flores, JM; Blasco, MA				Gonzalez-Suarez, E; Geserick, C; Flores, JM; Blasco, MA			Antagonistic effects of telomerase on cancer and aging in K5-mTert transgenic mice	ONCOGENE			English	Article						telomerase; cancer; aging; mouse models; maximum lifespan	CHROMOSOMAL INSTABILITY; DEFICIENT MICE; EXPRESSION; PREVENTS; FIBROBLASTS; FAILURE; LENGTH; DAMAGE; CELLS; LEADS	Many degenerative diseases that occur with aging, as well as premature aging syndromes, are characterized by presenting cells with critically short telomeres. Telomerase reintroduction is envisioned as a putative therapy for diseases characterized by telomere exhaustion. K5-mTert transgenic mice overexpress telomerase in a wide spectrum of tissues. These mice have a higher incidence of both induced and spontaneous tumors, resulting in increased mortality during the. first year of life. Here, we show that in spite of this elevated tumor incidence and the initial lower survival, K5-mTert mice show an extension of the maximum lifespan from 1.5 to 3 months, depending on the transgenic line, which represents up to a 10% increase in the mean lifespan compared to wild-type littermates. This longer lifespan is coincidental with a lower incidence of certain age-related degenerative diseases, mainly those related to kidney function and germline integrity. Importantly, these effects of telomerase overexpression cannot be attributed to dramatic differences in telomere length in aged K5-mTert mice compared to wild-type mice, as shown by quantitative telomeric FISH. These. findings indicate that telomerase overexpression extends the maximum lifespan of mice.	CNIO, Mol Oncol Program, E-28029 Madrid, Spain; Univ Complutense Madrid, Fac Vet, Anim Surg & Med Dept, E-28040 Madrid, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Complutense University of Madrid	Blasco, MA (corresponding author), CNIO, Mol Oncol Program, E-28029 Madrid, Spain.	mblasco@cnio.es	Blasco, Maria A./M-1694-2014; Gonzalez-Suarez, Eva/L-6298-2014	Blasco, Maria A./0000-0002-4211-233X; Gonzalez-Suarez, Eva/0000-0003-0858-8171				Artandi SE, 2002, P NATL ACAD SCI USA, V99, P8191, DOI 10.1073/pnas.112515399; Aviv A, 1998, HUM GENET, V103, P2, DOI 10.1007/s004390050774; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Blasco MA, 2002, NAT REV CANCER, V2, P627, DOI 10.1038/nrc862; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Canela A, 2004, MOL CELL BIOL, V24, P4275, DOI 10.1128/MCB.24.10.4275-4293.2004; Cawthon RM, 2003, LANCET, V361, P393, DOI 10.1016/S0140-6736(03)12384-7; Chan SWL, 2002, ONCOGENE, V21, P553, DOI 10.1038/sj.onc.1205082; Choi DH, 2001, FASEB J, V15, P1014, DOI 10.1096/fj.00-0104com; Feng LX, 2002, SCIENCE, V297, P392, DOI 10.1126/science.1073162; Gonzalez-Suarez E, 2000, NAT GENET, V26, P114, DOI 10.1038/79089; Gonzalez-Suarez E, 2003, CANCER RES, V63, P7047; Gonzalez-Suarez E, 2002, MOL CELL BIOL, V22, P7291, DOI 10.1128/MCB.22.20.7291-7301.2002; Gonzalez-Suarez E, 2001, EMBO J, V20, P2619, DOI 10.1093/emboj/20.11.2619; Goytisolo FA, 2000, J EXP MED, V192, P1625, DOI 10.1084/jem.192.11.1625; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Herrera E, 1999, EMBO J, V18, P2950, DOI 10.1093/emboj/18.11.2950; Herrera E, 1999, EMBO J, V18, P1172, DOI 10.1093/emboj/18.5.1172; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Leri A, 2003, EMBO J, V22, P131, DOI 10.1093/emboj/cdg013; Lu CB, 2001, DEV BRAIN RES, V131, P167, DOI 10.1016/S0165-3806(01)00237-1; Mattson MP, 2001, J NEUROSCI RES, V63, P1; MOHR U, 1996, PATHOBIOLOGY AGING M, V2, P505; Moreno E, 2004, CELL, V117, P117, DOI 10.1016/S0092-8674(04)00262-4; O'Sullivan JN, 2002, NAT GENET, V32, P280, DOI 10.1038/ng989; Ouellette MM, 2000, HUM MOL GENET, V9, P403, DOI 10.1093/hmg/9.3.403; Roussel MF, 2002, CANCER CELL, V2, P434, DOI 10.1016/S1535-6108(02)00216-7; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Ruiz-Torres MP, 2002, J AM SOC NEPHROL, V13, p163A; Samper E, 2000, EMBO REP, V1, P244, DOI 10.1093/embo-reports/kvd051; Samper E, 2001, EMBO REP, V2, P800, DOI 10.1093/embo-reports/kve174; Smith LL, 2003, NAT CELL BIOL, V5, P474, DOI 10.1038/ncb985; Wyllie FS, 2000, NAT GENET, V24, P16, DOI 10.1038/71630	34	68	74	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2005	24	13					2256	2270		10.1038/sj.onc.1208413	http://dx.doi.org/10.1038/sj.onc.1208413			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909KD	15688016				2022-12-17	WOS:000227857900013
J	Du, LH; Lyle, CS; Chambers, TC				Du, LH; Lyle, CS; Chambers, TC			Characterization of vinblastine-induced Bcl-xL and Bcl-2 phosphorylation: evidence for a novel protein kinase and a coordinated phosphorylation/dephosphorylation cycle associated with apoptosis induction	ONCOGENE			English	Article						vinblastine; Bcl-xL; Bcl-2; phosphorylation; apoptosis; protein kinase	N-TERMINAL KINASE; CELL-DEATH; SIGNALING PATHWAYS; CYTOCHROME-C; LOOP DOMAIN; MITOCHONDRIA; BCL-X(L); FAMILY; JNK; IDENTIFICATION	Bcl-xL and Bcl-2 are phosphorylated in response to microtubule inhibitors, but the kinase(s) responsible and the functional significance have remained unclear. In this study, we investigated the characteristics of Bcl-xL and Bcl-2 phosphorylation in KB-3 carcinoma cells treated with vinblastine. In both asynchronous and synchronous cell cultures, Bcl-xL and Bcl-2 underwent a well-defined and coordinated cycle of phosphorylation and dephosphorylation, with a lengthy period of phosphorylation preceding apoptosis induction, and with dephosphorylation closely correlated with initiation of apoptosis. Internally, validated inhibitors of JNK, ERK, p38(MAPK), or CDK1 failed to inhibit vinblastine-induced phosphorylation of Bcl-xL or Bcl-2. In vitro, Bcl-xL and Bcl-2 were poor substrates relative to c-Jun and ATF2 for active recombinant JNK1. Both Bcl-xL and Bcl-2 were localized primarily to the mitochondrial fraction in both control and vinblastine-treated cells, indicating that phosphorylation did not promote subcellular redistribution. Bcl-xL kinase activity was demonstrated in mitochondrial extracts from vinblastine-treated, but not control, cells. These findings suggest that phosphorylation of these key antiapoptotic proteins may be catalysed by a novel or unsuspected kinase that is activated or induced in response to microtubule damage. Furthermore, the same kinase and phosphatase system may be operating in tandem on both proteins, and phosphorylation appears to maintain their antiapoptotic function, whereas dephosphorylation may trigger apoptosis. These results provide evidence for a novel signaling pathway connecting microtubule damage to apoptosis induction, and help to clarify some of the controversy concerning the role of Bcl-2 phosphorylation in microtubule inhibitor-induced apoptosis.	Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences	Chambers, TC (corresponding author), Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Mail Slot 516,4301 W Markham St, Little Rock, AR 72205 USA.	chamberstimothyc@.uams.edu			NATIONAL CANCER INSTITUTE [R01CA075577] Funding Source: NIH RePORTER; NCI NIH HHS [CA10982, CA75577] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Amundson SA, 2000, CANCER RES, V60, P6101; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Basu A, 2003, FEBS LETT, V538, P41, DOI 10.1016/S0014-5793(03)00131-5; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Blagosklonny MV, 1997, CANCER RES, V57, P130; Brichese L, 2002, EXP CELL RES, V278, P101, DOI 10.1006/excr.2002.5563; Calastretti A, 2001, ONCOGENE, V20, P6172, DOI 10.1038/sj.onc.1204751; Chang BS, 1997, EMBO J, V16, P968, DOI 10.1093/emboj/16.5.968; Du LH, 2004, J BIOL CHEM, V279, P11957, DOI 10.1074/jbc.M304935200; Fan MY, 2000, J BIOL CHEM, V275, P29980, DOI 10.1074/jbc.M003776200; Fan MY, 2000, CANCER RES, V60, P6403; Fang GF, 1998, CANCER RES, V58, P3202; Furukawa Y, 2000, J BIOL CHEM, V275, P21661, DOI 10.1074/jbc.M906893199; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Osborn MT, 1999, ONCOGENE, V18, P5756, DOI 10.1038/sj.onc.1202943; Pathan N, 2001, NEOPLASIA, V3, P550, DOI 10.1038/sj.neo.7900213; Poruchynsky MS, 1998, CANCER RES, V58, P3331; Potapova O, 2000, MOL CELL BIOL, V20, P1713, DOI 10.1128/MCB.20.5.1713-1722.2000; Potapova O, 2000, J BIOL CHEM, V275, P24767, DOI 10.1074/jbc.M904591199; Ruvolo PP, 2001, LEUKEMIA, V15, P515, DOI 10.1038/sj.leu.2402090; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; Stone AA, 2000, EXP CELL RES, V254, P110, DOI 10.1006/excr.1999.4731; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; Wang SJ, 1999, BIOCHEM BIOPH RES CO, V259, P67, DOI 10.1006/bbrc.1999.0669; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469	33	68	72	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					107	117		10.1038/sj.onc.1208189	http://dx.doi.org/10.1038/sj.onc.1208189			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15531923				2022-12-17	WOS:000226125800013
J	Edinger, AL; Thompson, CB				Edinger, AL; Thompson, CB			An activated mTOR mutant supports growth factor-independent, nutrient-dependent cell survival	ONCOGENE			English	Article						4F2hc; Akt; apoptosis; growth factor; mTOR	PROTEIN-KINASE B; FORKHEAD TRANSCRIPTION FACTOR; TUMOR-SUPPRESSOR PROTEINS; COMPLEX GENE-PRODUCTS; RNA 5' CAP; MAMMALIAN TARGET; AMINO-ACID; SIGNALING PATHWAY; TOR PROTEINS; RAPAMYCIN	In yeast, TOR couples cellular growth and metabolism to the availability of extracellular nutrients. In contrast, mammalian TOR kinase activity has been reported to be regulated by growth factor stimulation via the PI3K/Akt pathway. Consistent with this, growth factor deprivation results in dephosphorylation of the mTOR target proteins p70S6k and 4EBP1 in the face of abundant extracellular nutrients. To determine whether the activation of mTOR was sufficient to support cell survival in the absence of other growth factor-mediated signal transduction, we evaluated the ability of a growth factor-independent mTOR mutant, DeltaTOR, to protect cells from growth factor deprivation. DeltaTOR- but not wild-type mTOR-expressing cells were protected from many of the sequelae of growth factor deprivation including amino-acid transporter degradation, reduction of the glycolytic rate, cellular atrophy, decreased mitochondrial membrane potential, and Bax activation. Furthermore, DeltaTOR expression increased growth factor-independent, nutrient-dependent cell survival and enhanced the ability of p53-/- MEFs to form colonies in soft agar. These results suggest that activating mutations of mTOR can contribute to apoptotic resistance and might contribute to cellular transformation.	Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Thompson, CB (corresponding author), Univ Penn, Abramson Family Canc Res Inst, 450 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	craig@mail.med.upenn.edu						Abraham RT, 2002, CELL, V111, P9, DOI 10.1016/S0092-8674(02)01009-7; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Degenhardt K, 2002, CANCER CELL, V2, P193, DOI 10.1016/S1535-6108(02)00126-5; Deves R, 2000, J MEMBRANE BIOL, V173, P165, DOI 10.1007/s002320001017; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Edinger AL, 2002, MOL BIOL CELL, V13, P2276, DOI 10.1091/mbc.01-12-0584; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; Hidalgo M, 2000, ONCOGENE, V19, P6680, DOI 10.1038/sj.onc.1204091; Hosoi H, 1999, CANCER RES, V59, P886; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; Kwabi-Addo B, 2001, P NATL ACAD SCI USA, V98, P11563, DOI 10.1073/pnas.201167798; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LI LM, 1989, JNCI-J NATL CANCER I, V81, P1406, DOI 10.1093/jnci/81.18.1406; Manning BD, 2003, BIOCHEM SOC T, V31, P573, DOI 10.1042/BST0310573; McManus EJ, 2002, NAT CELL BIOL, V4, pE214, DOI 10.1038/ncb0902-e214; Mills GB, 2001, P NATL ACAD SCI USA, V98, P10031, DOI 10.1073/pnas.191379498; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; Peng T, 2002, MOL CELL BIOL, V22, P5575, DOI 10.1128/MCB.22.15.5575-5584.2002; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Sekulic A, 2000, CANCER RES, V60, P3504; Shinjyo T, 2001, MOL CELL BIOL, V21, P854, DOI 10.1128/MCB.21.3.854-864.2001; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Vogt PK, 2001, TRENDS MOL MED, V7, P482, DOI 10.1016/S1471-4914(01)02161-X; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	55	68	70	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5654	5663		10.1038/sj.onc.1207738	http://dx.doi.org/10.1038/sj.onc.1207738			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15133498				2022-12-17	WOS:000222629500010
J	Hasenjager, A; Gillissen, B; Muller, A; Normand, G; Hemmati, PG; Schuler, M; Dorken, B; Daniel, PT				Hasenjager, A; Gillissen, B; Muller, A; Normand, G; Hemmati, PG; Schuler, M; Dorken, B; Daniel, PT			Smac induces cytochrome c release and apoptosis independently from Bax/Bcl-x(L) in a strictly caspase-3-dependent manner in human carcinoma cells	ONCOGENE			English	Article						Smac; apoptosis; Bax; Bcl-x(L); caspase-3; caspase-9	DRUG-INDUCED APOPTOSIS; IDENTIFIES PATIENTS; DNA FRAGMENTATION; SERINE-PROTEASE; BAX; CASPASE-3; OVEREXPRESSION; ACTIVATION; EXPRESSION; DEATH	The mitochondrial apoptosis pathway mediates cell death through the release of various pro-apoptotic factors including cytochrome c and Smac, the second mitochondrial activator of caspases, into the cytosol. Smac was shown previously to inhibit IAP proteins and to facilitate initiation of the caspase cascade upon cytochrome c release. To investigate Smac function during apoptosis and to explore Smac as an experimental cancer therapeutic, we constructed an expression system based on a single adenoviral vector containing Smac under control of the Tet-off system supplied in cis. Conditional expression of Smac induced apoptosis in human HCT116 and DU145 carcinoma cells regardless of the loss of Bax or overexpression of BCl-X-L. Nevertheless, apoptosis induced by Smac was associated with cytochrome c release and breakdown of the mitochondrial membrane potential. This indicates that Smac acts independently of Bax and BCl-X-L during initiation of apoptosis and triggers a positive feedback loop that results in Bax/BCl-X-L-independent activation of mitochondria. In caspase-proficient cells, Smac-induced apoptosis could be inhibited partially by cell-permeable LEHD (caspase-9 inhibitor) and DEVD (caspase-3 inhibitor) peptides. Furthermore, loss of caspase-3 expression in MCF-7 cells carrying a caspase-3 null mutation completely abrogated the sensitivity for Smac-induced apoptotic or nonapoptotic, necrosis-like cell death, while re-expression of caspase-3 conferred sensitivity. Altogether, caspase-3 but not caspase-9 activation was necessary for execution of Smac-induced cell death. Notably, Smac did not induce caspase-9 processing in the absence of caspase-3. Thus, caspase-9 processing occurs secondary to caspase-3 activation during Smac-induced apoptosis. Altogether, Smac is capable of circumventing defects in mitochondrial apoptosis signaling such as loss of Bax or overexpression of BCl-X-L that are frequently observed in tumor cells resistant to anticancer therapy. Consequently, Smac appears to be a promising therapeutic target in anticancer treatment.	Humboldt Univ, Univ Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany; Johannes Gutenberg Univ Mainz, Dept Med 3, Mainz, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Johannes Gutenberg University of Mainz	Daniel, PT (corresponding author), Humboldt Univ, Univ Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, Campus Berlin Buch,Lindenberger Weg 80, D-13125 Berlin, Germany.	pdaniel@mdc-berlin.de	Normand, Guillaume/A-1975-2010	Gillissen, Bernhard/0000-0002-1815-2091; Normand, Guillaume/0000-0003-1228-3813				Anderson RD, 2000, GENE THER, V7, P1034, DOI 10.1038/sj.gt.3301197; Bosanquet AG, 2002, LEUKEMIA, V16, P1035, DOI 10.1038/sj.leu.2402539; Brand K, 1997, CANCER GENE THER, V4, P9; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; COSSET FL, 1995, J VIROL, V69, P7430, DOI 10.1128/JVI.69.12.7430-7436.1995; Daniel PT, 1999, ANAL BIOCHEM, V266, P110, DOI 10.1006/abio.1998.2929; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Ekert PG, 2001, J CELL BIOL, V152, P483, DOI 10.1083/jcb.152.3.483; Friedrich K, 2001, ONCOGENE, V20, P2749, DOI 10.1038/sj.onc.1204342; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Guner D, 2003, INT J CANCER, V103, P445, DOI 10.1002/ijc.10850; Guo F, 2002, BLOOD, V99, P3419, DOI 10.1182/blood.V99.9.3419; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Lorenzo HK, 1999, CELL DEATH DIFFER, V6, P516, DOI 10.1038/sj.cdd.4400527; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; MROZEK A, 2003, IN PRESS CELL DEATH; Okada H, 2002, MOL CELL BIOL, V22, P3509, DOI 10.1128/MCB.22.10.3509-3517.2002; Prokop A, 2000, LEUKEMIA, V14, P1606, DOI 10.1038/sj.leu.2401866; Radetzki S, 2002, ONCOGENE, V21, P227, DOI 10.1038/sj/onc/1205010; Raisova M, 2001, J INVEST DERMATOL, V117, P333, DOI 10.1046/j.0022-202x.2001.01409.x; RAU B, 2003, IN PRESS J CLIN ONCO; Roberts DL, 2001, J CELL BIOL, V153, P221, DOI 10.1083/jcb.153.1.221; Schelwies K, 2002, INT J CANCER, V99, P589, DOI 10.1002/ijc.10380; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Sturm I, 2003, CELL DEATH DIFFER, V10, P477, DOI 10.1038/sj.cdd.4401194; Sturm I, 2001, J CLIN ONCOL, V19, P2272, DOI 10.1200/JCO.2001.19.8.2272; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	37	68	77	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2004	23	26					4523	4535		10.1038/sj.onc.1207594	http://dx.doi.org/10.1038/sj.onc.1207594			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZV	15064710	Bronze			2022-12-17	WOS:000221799000003
J	Hashimoto, M; Ichihara, M; Watanabe, T; Kawai, K; Koshikawa, K; Yuasa, N; Takahashi, T; Yatabe, Y; Murakumo, Y; Zhang, JM; Nimura, Y; Takahashi, M				Hashimoto, M; Ichihara, M; Watanabe, T; Kawai, K; Koshikawa, K; Yuasa, N; Takahashi, T; Yatabe, Y; Murakumo, Y; Zhang, JM; Nimura, Y; Takahashi, M			Expression of CD109 in human cancer	ONCOGENE			English	Article						CD109; squamous cell carcinoma; lung carcinoma; esophageal carcinoma	PLATELETS; PROTEINS; CELLS	It was recently reported that the human CD109 gene encodes a glycosyl-phosphatidylinositol-anchored glycoprotein that is a member of the alpha(2)-macroglobulin/C3, C4, C5 family of thioester-containing proteins. In this study, we found that the expression of mouse CD109 gene was upregulated in NIH3T3 cells expressing RET tyrosine kinase with a multiple endocrine neoplasia 2B mutation. Northern blot analysis showed a high level of expression of the CD109 gene only in the testis in normal human and mouse tissues. In addition, its expression was high in some human tumor cell lines, which included squamous cell carcinoma and glioblastoma cell lines, whereas it was undetectable in neuroblastoma and small-cell lung carcinoma cell lines. When CD109 expression was examined in 33 cases of human lung cell carcinomas by quantitative RT-PCR, a significant high expression of CD109 was detected in about half of squamous cell carcinomas examined, but not in adenocarcinoma, large-cell carcinoma and small-cell carcinoma. Similarly, upregulation of CD109 was observed in nine out of 17 esophageal squamous cell carcinomas. Thus, these results suggested that CD109 might be a useful molecular target for the development of new therapeutics for malignant tumors, such as squamous cell carcinoma.	Nagoya Univ, Grad Sch Med, Dept Pathol, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Grad Sch Med, Dept Surg, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Grad Sch Med, Ctr Neural Dis & Canc, Div Mol Pathol,Showa Ku, Nagoya, Aichi 4668550, Japan; Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr, Dept Pathol & Mol Diagnost, Chikusa Ku, Nagoya, Aichi 4648681, Japan	Nagoya University; Nagoya University; Nagoya University; Aichi Cancer Center; Aichi Cancer Center	Takahashi, M (corresponding author), Nagoya Univ, Grad Sch Med, Dept Pathol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	mtakaha@med.nagoya-u.ac.jp	Takahashi, Takashi/I-7262-2014; Takahashi, Masahide/AAN-4770-2020; TAKAHASHI, Masahide/I-7244-2014; Kumi, Kawai/I-6275-2014; YATABE, Yasushi/J-6461-2014	Takahashi, Takashi/0000-0003-0615-7001; Takahashi, Masahide/0000-0002-2803-2683; Kumi, Kawai/0000-0002-7772-2605; YATABE, Yasushi/0000-0003-1788-559X				HAREGEWOIN A, 1994, CELL IMMUNOL, V156, P357, DOI 10.1006/cimm.1994.1181; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; Lin M, 2002, BLOOD, V99, P1683, DOI 10.1182/blood.V99.5.1683; Murray LJ, 1999, EXP HEMATOL, V27, P1282, DOI 10.1016/S0301-472X(99)00071-5; Rappold I, 1997, BLOOD, V90, P111; SMITH JW, 1995, BLOOD, V86, P2807; Solomon KR, 1998, BIOCHEM J, V334, P325, DOI 10.1042/bj3340325; SUTHERLAND DR, 1991, BLOOD, V77, P84; SUTHERLAND DR, 1998, LEUKOCYTE TYPING, V6, P714; SUTHERLAND DR, 1995, LEUKOCYTE TYPING, V5, P1767; Takahashi M, 2001, CYTOKINE GROWTH F R, V12, P361, DOI 10.1016/S1359-6101(01)00012-0; Watanabe T, 2002, AM J PATHOL, V161, P249, DOI 10.1016/S0002-9440(10)64176-4; YEO EL, 1992, BLOOD, V80, P56	13	68	71	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3716	3720		10.1038/sj.onc.1207418	http://dx.doi.org/10.1038/sj.onc.1207418			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116102				2022-12-17	WOS:000221101700024
J	Guo, JC; Kleeff, J; Li, JS; Ding, JY; Hammer, J; Zhao, YP; Giese, T; Korc, M; Buchler, MW; Friess, H				Guo, JC; Kleeff, J; Li, JS; Ding, JY; Hammer, J; Zhao, YP; Giese, T; Korc, M; Buchler, MW; Friess, H			Expression and functional significance of CDC25B in human pancreatic ductal adenocarcinoma	ONCOGENE			English	Article						cell cycle; cyclin-dependent kinase; CDC25B; pancreatic ductal adenocarcinoma	RANDOMIZED CONTROLLED TRIAL; HUMAN COLORECTAL-CARCINOMA; TGF-BETA RESPONSIVENESS; COLO-357 CELLS; UP-REGULATION; CANCER-CELLS; PHOSPHATASE; OVEREXPRESSION; RECEPTOR; ACTIVATION	Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer-related deaths. Deregulation of cell-cycle control is thought to be a crucial event in malignant transformation, and CDC25 phosphatases are a family of cyclin-dependent kinase activators, which act at different points of the cell cycle, including G1-S and G2-M transition. Here, we investigated the expression and functional significance of CDC25s in PDAC. CDC25B mRNA expression levels in human pancreatic tissue samples were analysed by cDNA array, quantitative PCR and Northern blotting. Immunohistochemistry was carried out to localize and quantify CDC25B expression. Two specific CDC25B inhibitors were utilized to determine the functional relevance of CDC25B. By quantitative RT-PCR, CDC25B mRNA was overexpressed in pancreatic cancer (7.5-fold) in comparison to the normal pancreas. Strong nuclear CDC25B immunoreactivity was present in both pancreatic and metastatic cancer samples, and there was a marked increase of the percentage of positive cells in primary cancer (48.6+/-16.3%) and metastatic tissues (71.7+/-3.1%) compared to normal samples (8.3+/-1.8%). Two CDC25B inhibitors reduced the growth of pancreatic cancer cell lines, resulting in the accumulation of phosphorylated CDC2 and G2/M arrest. These findings demonstrate an important role of CDC25B in cell-cycle progression, raising the possibility that inhibition of CDC25B may have therapeutic potential in pancreatic cancer.	Univ Heidelberg, Dept Gen Surg, D-69120 Heidelberg, Germany; Beijing Union Med Coll Hosp, Dept Gen Surg, Beijing, Peoples R China; Hoffmann La Roche Inc, Roche Genom & Informat Sci, Nutley, NJ 07110 USA; Univ Heidelberg, Inst Immunol, D-69120 Heidelberg, Germany; Univ Calif Irvine, Dept Med Biol Chem & Pharmacol, Div Endocrinol Diabet & Metab, Irvine, CA USA	Ruprecht Karls University Heidelberg; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital; Roche Holding; Ruprecht Karls University Heidelberg; University of California System; University of California Irvine	Friess, H (corresponding author), Univ Heidelberg, Dept Gen Surg, Neuenheimer Feld 110, D-69120 Heidelberg, Germany.	helmut_friess@med.uni-heidelberg.de	Kleeff, Jorg/B-2124-2009	Kleeff, Jorg/0000-0003-3432-6669; Guo, Junchao/0000-0002-7878-8315	NCI NIH HHS [CA-40162] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040162] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldin V, 2002, J BIOL CHEM, V277, P35176, DOI 10.1074/jbc.M204430200; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; Broggini M, 2000, ANTICANCER RES, V20, P4835; Davezac N, 2000, ONCOGENE, V19, P2179, DOI 10.1038/sj.onc.1203545; DiMagno EP, 1999, GASTROENTEROLOGY, V117, P1464, DOI 10.1016/S0016-5085(99)70298-2; FREEMAN JW, 1995, J CELL PHYSIOL, V165, P155, DOI 10.1002/jcp.1041650118; FRIESS H, 1993, GASTROENTEROLOGY, V105, P1846, DOI 10.1016/0016-5085(93)91084-U; Friess H, 2001, ANN SURG, V234, P769, DOI 10.1097/00000658-200112000-00008; Gabrielli BG, 1996, J CELL SCI, V109, P1081; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Gasparotto D, 1997, CANCER RES, V57, P2366; GUDJONSSON B, 1987, CANCER, V60, P2284, DOI 10.1002/1097-0142(19871101)60:9<2284::AID-CNCR2820600930>3.0.CO;2-V; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hernandez S, 2000, INT J CANCER, V89, P148, DOI 10.1002/(SICI)1097-0215(20000320)89:2<148::AID-IJC8>3.0.CO;2-R; Hernandez S, 2001, LAB INVEST, V81, P465, DOI 10.1038/labinvest.3780254; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; Ito Y, 2002, BRIT J CANCER, V86, P1909, DOI 10.1038/sj.bjc.6600364; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; Kleeff J, 1998, J BIOL CHEM, V273, P7495, DOI 10.1074/jbc.273.13.7495; Kleeff J, 1999, ONCOGENE, V18, P5363, DOI 10.1038/sj.onc.1202909; Kleeff J, 1999, BIOCHEM BIOPH RES CO, V255, P268, DOI 10.1006/bbrc.1999.0171; Kleeff J, 1998, J CLIN INVEST, V102, P1662, DOI 10.1172/JCI4105; Kleeff J, 1999, PANCREAS, V18, P364, DOI 10.1097/00006676-199905000-00006; Koliopanos A, 2001, CANCER RES, V61, P4655; Kudo Y, 1997, JPN J CANCER RES, V88, P947, DOI 10.1111/j.1349-7006.1997.tb00313.x; Lal G, 2000, GENE CHROMOSOME CANC, V27, P358, DOI 10.1002/(SICI)1098-2264(200004)27:4<358::AID-GCC4>3.0.CO;2-O; Lammer C, 1998, J CELL SCI, V111, P2445; Lazo JS, 2001, J MED CHEM, V44, P4042, DOI 10.1021/jm0102046; Liao Q, 2001, FEBS LETT, V503, P151, DOI 10.1016/S0014-5793(01)02728-4; Miyata H, 2001, CANCER RES, V61, P3188; Neoptolemos JP, 2001, LANCET, V358, P1576, DOI 10.1016/S0140-6736(01)06651-X; Neoptolemos JP, 2001, ANN SURG, V234, P758, DOI 10.1097/00000658-200112000-00007; Ngan ESW, 2003, ONCOGENE, V22, P734, DOI 10.1038/sj.onc.1206121; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Ozawa F, 2001, TERATOGEN CARCIN MUT, V21, P27, DOI 10.1002/1520-6866(2001)21:1<27::AID-TCM4>3.0.CO;2-9; Sasaki H, 2001, CANCER LETT, V173, P187, DOI 10.1016/S0304-3835(01)00669-3; Sato Y, 2001, JPN J CLIN ONCOL, V31, P428, DOI 10.1093/jjco/hye093; Schutte M, 1996, CANCER RES, V56, P2527; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Takemasa I, 2000, CANCER RES, V60, P3043; Tsai RYL, 2002, GENE DEV, V16, P2991, DOI 10.1101/gad.55671; Tureci O, 2003, FASEB J, V17, P376, DOI 10.1096/fj.02-0478com; Ulloa L, 2001, J BIOL CHEM, V276, P21397, DOI 10.1074/jbc.M010783200; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; Wagner M, 1998, INT J CANCER, V78, P255, DOI 10.1002/(SICI)1097-0215(19981005)78:2<255::AID-IJC21>3.0.CO;2-8; WU S, 1995, DEV BIOL, V170, P195, DOI 10.1006/dbio.1995.1207	50	68	73	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2004	23	1					71	81		10.1038/sj.onc.1206926	http://dx.doi.org/10.1038/sj.onc.1206926			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712212				2022-12-17	WOS:000187895300008
J	Watamoto, K; Towatari, M; Ozawa, Y; Miyata, Y; Okamoto, M; Abe, A; Naoe, T; Saito, H				Watamoto, K; Towatari, M; Ozawa, Y; Miyata, Y; Okamoto, M; Abe, A; Naoe, T; Saito, H			Altered interaction of HDAC5 with GATA-1 during MEL cell differentiation	ONCOGENE			English	Article						GATA-1; HDAC; differentiation; MEL	TRANSCRIPTION FACTOR GATA-1; HISTONE ACETYLTRANSFERASE ACTIVITY; ERYTHROID-DIFFERENTIATION; ERYTHROLEUKEMIC CELLS; HEMATOPOIETIC-CELLS; NUCLEOSOMAL DNA; SOMATIC HYBRIDS; FINGER PROTEIN; STEM-CELLS; IN-VITRO	The transcription factor GATA-1 plays a significant role in erythroid differentiation and association with CBP stimulates its activity by acetylation. It is possible that histone deacetylases (HDACs) repress the activity of GATA-1. In the present study, we investigated whether class I and class II HDACs interact with GATA-1 to regulate its function and indeed, GATA-1 is directly associated with HDAC3, HDAC4 and HDAC5. The expression pro. ling and our previous observation that GATA-2 interacts with members of the HDAC family prompted us to investigate further the biological relevance of the interaction between GATA-1 and HDAC5. Coexpression of HDAC5 suppressed the transcriptional potential of GATA-1. Our results demonstrated that GATA-1 and HDAC5 colocalized to the nucleus of murine erythroleukemia (MEL) cells. Furthermore, a portion of HDAC5 moved to the cytoplasm concomitant with MEL cell erythroid differentiation, which was induced by treatment with N,N'-hexamethylenebisacetamide. These observations support the suggestion that control of the HDAC5 nucleocytoplasmic distribution might be associated with MEL cell differentiation, possibly through regulated GATA-1 transactivation.	Nagoya Univ, Dept Mol Med, Grad Sch Med, Nagoya, Aichi 4668550, Japan; Natl Nagoya Hosp, Nagoya, Aichi 4600001, Japan	Nagoya University	Towatari, M (corresponding author), Nagoya Univ, Dept Mol Med, Grad Sch Med, Nagoya, Aichi 4668550, Japan.		Naoe, Tomoki/I-1888-2012					Bertos NR, 2001, BIOCHEM CELL BIOL, V79, P243, DOI 10.1139/bcb-79-3-243; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; BRIEGEL K, 1993, GENE DEV, V7, P1097, DOI 10.1101/gad.7.6.1097; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CONSCIENCE JF, 1977, EXP CELL RES, V105, P401, DOI 10.1016/0014-4827(77)90137-9; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; Crispino JD, 1999, MOL CELL, V3, P219, DOI 10.1016/S1097-2765(00)80312-3; CROTTA S, 1990, NUCLEIC ACIDS RES, V18, P6863, DOI 10.1093/nar/18.23.6863; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; Gao L, 2002, J BIOL CHEM, V277, P25748, DOI 10.1074/jbc.M111871200; GEORGE KM, 1994, DEVELOPMENT, V120, P2673; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; HEBERLEIN C, 1992, MOL CELL BIOL, V12, P1815, DOI 10.1128/MCB.12.4.1815; HONG L, 1993, J BIOL CHEM, V268, P305; Hu E, 2000, J BIOL CHEM, V275, P15254, DOI 10.1074/jbc.M908988199; Ikonomi P, 2000, EXP HEMATOL, V28, P1423, DOI 10.1016/S0301-472X(00)00553-1; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LEONARD MW, 1993, DEVELOPMENT, V119, P519; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; NORTON VG, 1989, CELL, V57, P449, DOI 10.1016/0092-8674(89)90920-3; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ORKIN SH, 1992, BLOOD, V80, P575; ORKIN SH, 1975, P NATL ACAD SCI USA, V72, P98, DOI 10.1073/pnas.72.1.98; Ozawa Y, 2001, BLOOD, V98, P2116, DOI 10.1182/blood.V98.7.2116; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; Shore D, 2000, P NATL ACAD SCI USA, V97, P14030, DOI 10.1073/pnas.011506198; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Takahashi T, 2000, ONCOGENE, V19, P134, DOI 10.1038/sj.onc.1203228; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; TOWATARI M, 1995, J BIOL CHEM, V270, P4101, DOI 10.1074/jbc.270.8.4101; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Tsai FY, 1997, BLOOD, V89, P3636, DOI 10.1182/blood.V89.10.3636.3636_3636_3643; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Tsuzuki S, 2000, MOL CELL BIOL, V20, P6276, DOI 10.1128/MCB.20.17.6276-6286.2000; VetteseDadey M, 1996, EMBO J, V15, P2508, DOI 10.1002/j.1460-2075.1996.tb00608.x; Wade PA, 2001, HUM MOL GENET, V10, P693, DOI 10.1093/hmg/10.7.693; Wang AH, 1999, MOL CELL BIOL, V19, P7816; WEISS MJ, 1995, EXP HEMATOL, V23, P99; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; Weiss MJ, 1997, MOL CELL BIOL, V17, P1642, DOI 10.1128/MCB.17.3.1642; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YOMOGIDA K, 1994, DEVELOPMENT, V120, P1759; Zhang P, 2000, BLOOD, V96, P2641; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	59	68	68	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 11	2003	22	57					9176	9184		10.1038/sj.onc.1206902	http://dx.doi.org/10.1038/sj.onc.1206902			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	752FJ	14668799				2022-12-17	WOS:000187149100008
J	Frelin, C; Imbert, V; Griessinger, E; Loubat, A; Dreano, M; Peyron, JF				Frelin, C; Imbert, V; Griessinger, E; Loubat, A; Dreano, M; Peyron, JF			AS602868, a pharmacological inhibitor of IKK2, reveals the apoptotic potential of TNF-alpha in Jurkat leukemic cells	ONCOGENE			English	Article						NF-kappa B; IKK2 inhibitor; TNF; apoptosis	NF-KAPPA-B; CANCER-THERAPY; ACTIVATION; DEATH; CHEMORESISTANCE; EXPRESSION; BLOCKING; BLOCKADE; PATHWAY; C-IAP2	NF-kappaB transcription factors promote survival in numerous cell types via induction of antiapoptotic genes. Pharmacological blockade of the IKK2 kinase with AS602868, a specific inhibitor that competes with ATP binding, prevented TNF-alpha-induced NF-kappaB activation in Jurkat leukemic T cells. While TNF-alpha by itself had no effect on Jurkat survival, the addition of AS602868 induced cell death, visualized by DNA fragmentation and sub-G1 analysis. A disruption of the mitochondrial potential followed by activation of caspases 9 and 3 was observed in cells treated by the combination TNF-alpha+AS602868. Quantitative real-time PCR demonstrated that AS602868 prevented TNF-alpha induction of the antiapoptotic genes coding for c-IAP-2, Bclx, Bfl-1/A1 and Traf-1. The use of a specific IKK2 inhibitor appears, therefore, as an interesting pharmaceutical strategy to increase the cell's sensitivity towards apoptotic effectors.	Fac Med Pasteur, INSERM, U526, UFR Genet & Signalisat Mol 50, F-06107 Nice 02, France; Fac Med Pasteur, INSERM, U364, UFR Genet & Signalisat Mol 50, F-06107 Nice, France; Serono Int SA, Geneva, Switzerland	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Merck & Company; Serono International S.A.	Peyron, JF (corresponding author), Fac Med Pasteur, INSERM, U526, UFR Genet & Signalisat Mol 50, F-06107 Nice 02, France.		Griessinger, Emmanuel/G-5574-2018; Imbert, Véronique/I-6093-2016; Jean-Francois, Peyron/AAA-9496-2022; Peyron, Jean-Francois/M-5682-2016	Imbert, Véronique/0000-0003-2103-6718; Jean-Francois, Peyron/0000-0001-6113-916X; Peyron, Jean-Francois/0000-0001-6113-916X				Adams J, 2002, TRENDS MOL MED, V8, pS49, DOI 10.1016/S1471-4914(02)02315-8; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Burke JR, 1998, J BIOL CHEM, V273, P12041, DOI 10.1074/jbc.273.20.12041; Busuttil V, 2002, ONCOGENE, V21, P3213, DOI 10.1038/sj.onc.1205433; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Cheng QW, 2000, ONCOGENE, V19, P4936, DOI 10.1038/sj.onc.1203861; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Foo SY, 1999, TRENDS GENET, V15, P229; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hideshima T, 2001, CANCER RES, V61, P3071; Jones BE, 2000, J BIOL CHEM, V275, P705, DOI 10.1074/jbc.275.1.705; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Keane MM, 2000, BREAST CANCER RES TR, V64, P211, DOI 10.1023/A:1006458407515; Pagliari LJ, 2000, MOL CELL BIOL, V20, P8855, DOI 10.1128/MCB.20.23.8855-8865.2000; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Sugiyama H, 1999, J BIOL CHEM, V274, P19532, DOI 10.1074/jbc.274.28.19532; VAN AD, 1996, SCIENCE, V274, P787; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948	35	68	69	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 6	2003	22	50					8187	8194		10.1038/sj.onc.1206963	http://dx.doi.org/10.1038/sj.onc.1206963			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603259				2022-12-17	WOS:000186403400013
J	Kruh, GD				Kruh, GD			Introduction to resistance to anticancer agents	ONCOGENE			English	Editorial Material						chemosensitivity; apoptosis; targeted therapy			Fox Chase Canc Ctr, Div Med Sci, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Kruh, GD (corresponding author), Fox Chase Canc Ctr, Div Med Sci, 7701 Burholme Ave, Philadelphia, PA 19111 USA.				NATIONAL CANCER INSTITUTE [U01CA073728, P30CA006927, R01CA073728] Funding Source: NIH RePORTER; NCI NIH HHS [CA 06927, CA 73728] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHU E, 2001, CANC PRINCIPLES PRAC, P289; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031	2	68	80	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 20	2003	22	47					7262	7264		10.1038/sj.onc.1206932	http://dx.doi.org/10.1038/sj.onc.1206932			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KL	14576836				2022-12-17	WOS:000186112500001
J	Gatza, ML; Watt, JC; Marriott, SJ				Gatza, ML; Watt, JC; Marriott, SJ			Cellular transformation by the HTLV-I tax protein, a jack-of-all-trades	ONCOGENE			English	Review						tax; HTLV-I; cell cycle; DNA repair; cellular transformation	VIRUS TYPE-I; WILD-TYPE P53; NUCLEOTIDE EXCISION-REPAIR; ONCOGENE PRODUCT TAX; TUMOR-SUPPRESSOR PROTEIN; CYCLIN-DEPENDENT KINASES; RECEPTOR GENE-EXPRESSION; LEUKEMIA-VIRUS; TYPE-1 TAX; DNA-REPAIR	The human T-cell leukemia virus type I (HTLV-I) is an oncogenic retrovirus that is responsible for adult T-cell leukemia and a neurological disease, HTLV-I-associated myelopathy/tropical spastic paraparesis. HTLV-I encodes an oncogenic protein, Tax, which affects a variety of cellular functions prompting it to be referred to as a jack-of-all trades. The ability of Tax to both transcriptionally regulate cellular gene expression and to functionally inactivate proteins involved in cell-cycle progression and DNA repair provide the basis for Tax-mediated transformation and leukemogenesis. This review will concentrate on the effects of Tax on the dysregulation of the G(1)/S and G(2)/M checkpoints as well as the suppression of DNA damage repair leading to cellular transformation.	Baylor Coll Med, Interdept Program Cell & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Marriott, SJ (corresponding author), Baylor Coll Med, Interdept Program Cell & Mol Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	susanm@bcm.tmc.edu		Gatza, Michael/0000-0001-6796-7791	NCI NIH HHS [CA-09197, CA-77371] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077371] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abrieu A, 2001, CELL, V106, P83, DOI 10.1016/S0092-8674(01)00410-X; Adams PD, 2001, BBA-REV CANCER, V1471, pM123, DOI 10.1016/S0304-419X(01)00019-1; Akagi T, 1997, FEBS LETT, V406, P263, DOI 10.1016/S0014-5793(97)00280-9; Akagi T, 1996, ONCOGENE, V12, P1645; Albrecht B, 2002, MICROBIOL MOL BIOL R, V66, P396, DOI 10.1128/MMBR.66.3.396-406.2002; Ariumi Y, 2000, ONCOGENE, V19, P1491, DOI 10.1038/sj.onc.1203450; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Bazarbachi A, 2001, VIRUS RES, V78, P79, DOI 10.1016/S0168-1702(01)00286-6; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BLATTNER WA, 1982, INT J CANCER, V30, P257, DOI 10.1002/ijc.2910300302; Brauweiler A, 1997, VIROLOGY, V231, P135, DOI 10.1006/viro.1997.8509; BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Cereseto A, 1999, ONCOGENE, V18, P2441, DOI 10.1038/sj.onc.1202567; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; CESARMAN E, 1992, BLOOD, V80, P3205; Chen RH, 1998, J CELL BIOL, V143, P283, DOI 10.1083/jcb.143.2.283; CHIECOBIANCHI L, 1988, LEUKEMIA, V2, pS223; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; De La Fuente C, 2000, J VIROL, V74, P7270, DOI 10.1128/JVI.74.16.7270-7283.2000; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; DEMERS GW, 1994, VIROLOGY, V198, P169, DOI 10.1006/viro.1994.1019; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; FRANCHINI G, 1984, P NATL ACAD SCI-BIOL, V81, P6207, DOI 10.1073/pnas.81.19.6207; Fujimoto T, 1999, CANCER GENET CYTOGEN, V109, P1, DOI 10.1016/S0165-4608(98)00141-1; Gartenhaus RB, 1995, LEUKEMIA, V9, P2082; GESSAIN A, 1985, LANCET, V2, P407; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GoddenKent D, 1997, J VIROL, V71, P4193, DOI 10.1128/JVI.71.6.4193-4198.1997; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Haller K, 2002, MOL CELL BIOL, V22, P3327, DOI 10.1128/MCB.22.10.3327-3338.2002; Haller K, 2000, AIDS RES HUM RETROV, V16, P1683, DOI 10.1089/08892220050193146; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hatta Y, 1997, LEUKEMIA, V11, P984, DOI 10.1038/sj.leu.2400686; HATTA Y, 1995, BLOOD, V85, P2699, DOI 10.1182/blood.V85.10.2699.bloodjournal85102699; Hatta Y, 2002, LEUKEMIA, V16, P1069, DOI 10.1038/sj.leu.2402458; Herdegen T, 1998, BRAIN RES REV, V28, P370, DOI 10.1016/S0165-0173(98)00018-6; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; HINUMA Y, 1982, INT J CANCER, V29, P631, DOI 10.1002/ijc.2910290606; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HOLLSBERG P, 1994, J IMMUNOL, V153, P566; Hollsberg P, 1999, MICROBIOL MOL BIOL R, V63, P308; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Huang YP, 2001, ONCOGENE, V20, P1094, DOI 10.1038/sj.onc.1204198; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; ITOYAMA T, 1990, CANCER GENET CYTOGEN, V49, P157, DOI 10.1016/0165-4608(90)90137-Y; Iwanaga R, 2001, ONCOGENE, V20, P2055, DOI 10.1038/sj.onc.1204304; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Johnson JM, 2001, INT J EXP PATHOL, V82, P135, DOI 10.1046/j.1365-2613.2001.00191.x; KAMADA N, 1992, CANCER RES, V52, P1481; Kao SY, 2000, J BIOL CHEM, V275, P35926, DOI 10.1074/jbc.M004397200; Kao SY, 1999, J VIROL, V73, P4299, DOI 10.1128/JVI.73.5.4299-4304.1999; Kasai T, 2002, J BIOL CHEM, V277, P5187, DOI 10.1074/jbc.M110295200; KIKUCHI M, 1986, HEMATOL ONCOL, V4, P67, DOI 10.1002/hon.2900040109; KIM SJ, 1990, J EXP MED, V172, P121, DOI 10.1084/jem.172.1.121; KINOSHITA T, 1989, P NATL ACAD SCI USA, V86, P5620, DOI 10.1073/pnas.86.14.5620; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lee DK, 2002, J BIOL CHEM, V277, P33766, DOI 10.1074/jbc.M200150200; Lemasson I, 1998, J BIOL CHEM, V273, P23598, DOI 10.1074/jbc.273.36.23598; Lemasson I, 1997, J VIROL, V71, P1975, DOI 10.1128/JVI.71.3.1975-1983.1997; Lemoine FJ, 2001, DIS MARKERS, V17, P129, DOI 10.1155/2001/263567; Lemoine FJ, 2001, J BIOL CHEM, V276, P31851, DOI 10.1074/jbc.M105195200; Lemoine FJ, 2000, AIDS RES HUM RETROV, V16, P1623, DOI 10.1089/08892220050193056; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Liang MH, 2002, J VIROL, V76, P4022, DOI 10.1128/JVI.76.8.4022-4033.2002; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Low KG, 1997, J VIROL, V71, P1956, DOI 10.1128/JVI.71.3.1956-1962.1997; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; Majone F, 2000, J BIOL CHEM, V275, P32906, DOI 10.1074/jbc.C000538200; MAJONE F, 1993, VIROLOGY, V193, P456, DOI 10.1006/viro.1993.1145; MARUYAMA K, 1990, CANCER RES, V50, pS5697; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; Mesnard JM, 1999, VIROLOGY, V257, P277, DOI 10.1006/viro.1999.9685; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; Miyake H, 1999, VIROLOGY, V253, P155, DOI 10.1006/viro.1998.9500; MIYAMOTO K, 1983, CANCER-AM CANCER SOC, V52, P471, DOI 10.1002/1097-0142(19830801)52:3<471::AID-CNCR2820520316>3.0.CO;2-E; Mori N, 2002, INT J CANCER, V99, P378, DOI 10.1002/ijc.10388; Mori N, 2001, BLOOD, V97, P2137, DOI 10.1182/blood.V97.7.2137; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; MURPHY EL, 1989, INT J CANCER, V43, P250, DOI 10.1002/ijc.2910430214; Nakayama K, 2000, LEUKEMIA RES, V24, P299, DOI 10.1016/S0145-2126(99)00186-1; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; Neuveut C, 1998, MOL CELL BIOL, V18, P3620, DOI 10.1128/MCB.18.6.3620; Neuveut C, 2002, FRONT BIOSCI-LANDMRK, V7, pD157, DOI 10.2741/neuveut; Neuveut C, 2000, Prog Cell Cycle Res, V4, P157; NIITSU Y, 1988, BLOOD, V71, P263; Nilsen H, 2001, CARCINOGENESIS, V22, P987, DOI 10.1093/carcin/22.7.987; Ohtani K, 2000, J BIOL CHEM, V275, P11154, DOI 10.1074/jbc.275.15.11154; OKAMOTO T, 1989, JPN J CANCER RES, V80, P191; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; PARRY JM, 1987, MUTAT RES, V181, P267, DOI 10.1016/0027-5107(87)90104-7; PAUL R, 1989, J VIROL, V63, P4958, DOI 10.1128/JVI.63.11.4958-4961.1989; Philpott SM, 1999, J NATL CANCER I, V91, P933, DOI 10.1093/jnci/91.11.933; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; REID RL, 1993, ONCOGENE, V8, P3029; Ressler S, 1997, J VIROL, V71, P1181, DOI 10.1128/JVI.71.2.1181-1190.1997; ROWLEY JD, 1984, HUMAN T CELL LEUKEMI, P85; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; SADAMORI N, 1991, CANCER GENET CYTOGEN, V51, P131, DOI 10.1016/0165-4608(91)90019-Q; SAGGIORO D, 1994, LEUKEMIA LYMPHOMA, V12, P281; SAKASHITA A, 1992, BLOOD, V79, P477; Santiago F, 1999, J VIROL, V73, P9917, DOI 10.1128/JVI.73.12.9917-9927.1999; SAXINGER W, 1984, SCIENCE, V225, P1473, DOI 10.1126/science.6089348; Schmaltz B, 2000, GNOMON, V72, P633; SEIKI M, 1984, NATURE, V309, P640, DOI 10.1038/309640a0; SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428, DOI 10.1111/j.1365-2141.1991.tb08051.x; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; Slattery JP, 1999, GENOME RES, V9, P525; SMITH ML, 1995, ONCOGENE, V10, P1053; SMITH MR, 1991, J CLIN INVEST, V88, P1038, DOI 10.1172/JCI115364; Suzuki T, 1999, ONCOGENE, V18, P4137, DOI 10.1038/sj.onc.1202766; Suzuki T, 1999, VIROLOGY, V259, P384, DOI 10.1006/viro.1999.9760; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; Takemoto S, 1997, P NATL ACAD SCI USA, V94, P13897, DOI 10.1073/pnas.94.25.13897; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TENDLER CL, 1990, P NATL ACAD SCI USA, V87, P5218, DOI 10.1073/pnas.87.13.5218; THOMSON EJ, 1988, MUTAGENESIS, V3, P415, DOI 10.1093/mutage/3.5.415; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Tighe A, 2001, EMBO REP, V2, P609, DOI 10.1093/embo-reports/kve127; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; Tsai HL, 1996, J BIOL CHEM, V271, P3534; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; UITTENBOGAARD MN, 1995, J BIOL CHEM, V270, P28503, DOI 10.1074/jbc.270.48.28503; Van Orden K, 1999, J BIOL CHEM, V274, P26321, DOI 10.1074/jbc.274.37.26321; Van Orden K, 1999, ONCOGENE, V18, P3766, DOI 10.1038/sj.onc.1202703; Van PL, 2001, J VIROL, V75, P396, DOI 10.1128/JVI.75.1.396-407.2001; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WHANGPENG J, 1985, J NATL CANCER I, V74, P357; Wood RD, 1997, CARCINOGENESIS, V18, P605, DOI 10.1093/carcin/18.4.605; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; XU X, 1995, J CLIN INVEST, V96, P1548, DOI 10.1172/JCI118193; YAMADA Y, 1983, BLOOD, V61, P192; YAMAOKA S, 1992, ONCOGENE, V7, P433; YAMATO K, 1993, JPN J CANCER RES, V84, P4, DOI 10.1111/j.1349-7006.1993.tb02775.x; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; YSSEL H, 1989, J IMMUNOL, V142, P2279; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	159	68	68	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2003	22	33					5141	5149		10.1038/sj.onc.1206549	http://dx.doi.org/10.1038/sj.onc.1206549			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709FL	12910251				2022-12-17	WOS:000184615100005
J	Perez-Losada, J; Sanchez-Martin, M; Perez-Caro, M; Perez-Mancera, PA; Sanchez-Garcia, I				Perez-Losada, J; Sanchez-Martin, M; Perez-Caro, M; Perez-Mancera, PA; Sanchez-Garcia, I			The radioresistance biological function of the SCF/kit signaling pathway is mediated by the zinc-finger transcription factor Slug	ONCOGENE			English	Article						growth factors; hematopoietic development; transcription factor; radioresistance	STEM-CELL FACTOR; GASTROINTESTINAL STROMAL TUMORS; TYROSINE KINASE RECEPTOR; PROTOONCOGENE C-KIT; GROWTH-FACTOR; W-LOCUS; BREAST CARCINOMAS; PROTO-ONCOGENE; E-CADHERIN; SI-LOCUS	Radiation-induced destruction of the hematopoietic system is the primary cause of death based on the findings that transfer of normal bone marrow cells prevents death from lethal irradiation. The stem cell factor-c-kit signaling pathway (SCF/c-kit) has been previously implicated in the hematopoietic recovery which prevents death from lethal irradiation, but the molecular mechanisms that mediate this biological effect are unknown. Since mutations on SCF, c-kit and Slug genes have a similar phenotype in mice, we examined if Slug could complement the radiosensitivity of kit-deficient mice. In this report, we show that Slug acts as a radioprotection agent as lack of Slug results in increased radiosensitivity. This effect cannot be recovered by activating SCF/c-kit in lethally irradiated Slug-deficient mice, as SCF-treated mice did not demonstrate stimulation of hematopoietic recovery leading to survival of the Slug-deficient mice. We found that we could complement the hematopoietic failure in lethally irradiated c-kit-deficient mice by transducing them with a TAT-Slug protein. We conclude that the zinc-finger transcription factor Slug is absolutely necessary for survival from lethal irradiation and identify Slug as the molecular target that mediates the radioprotection through SCF/c-kit. These results indicate that Slug may be a molecular component conferring radioresistance to cancer cells.	Univ Salamanca, Inst Biol Mol & Celular Canc, Ctr Invest Canc, CSIC, Salamanca 37007, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Sanchez-Garcia, I (corresponding author), Univ Salamanca, Inst Biol Mol & Celular Canc, Ctr Invest Canc, CSIC, Campus Unamuno, Salamanca 37007, Spain.		Pérez-Losada, Jesús/A-5883-2019; SANCHEZ-GARCIA, ISIDRO/A-5631-2019; Sanchez-Martin, Manuel/N-5327-2016	Pérez-Losada, Jesús/0000-0003-2400-624X; Sanchez-Martin, Manuel/0000-0001-8370-1336; SANCHEZ-GARCIA, ISIDRO/0000-0001-6989-9905	NCI NIH HHS [1 R01 CA79955-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079955] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416; Broudy VC, 1997, BLOOD, V90, P1345, DOI 10.1182/blood.V90.4.1345.1345_1345_1364; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; Cheng CW, 2001, ONCOGENE, V20, P3814, DOI 10.1038/sj.onc.1204505; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; del Barrio MG, 2002, DEVELOPMENT, V129, P1583; FLEMING WH, 1993, P NATL ACAD SCI USA, V90, P3760, DOI 10.1073/pnas.90.8.3760; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; Hajra KM, 2002, CANCER RES, V62, P1613; HARRISON DE, 1972, BRIT J HAEMATOL, V22, P155, DOI 10.1111/j.1365-2141.1972.tb08797.x; HINES SJ, 1995, CELL GROWTH DIFFER, V6, P769; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; Inoue A, 2002, CANCER CELL, V2, P279, DOI 10.1016/S1535-6108(02)00155-1; INOUE M, 1994, CANCER RES, V54, P3049; Inukai T, 1999, MOL CELL, V4, P343, DOI 10.1016/S1097-2765(00)80336-6; Jiang RL, 1998, DEV BIOL, V198, P277, DOI 10.1006/dbio.1998.8909; KACZMAREK L, 1988, INT J RADIAT BIOL, V53, P703, DOI 10.1080/09553008814551071; KASTAN MB, 1991, CANCER RES, V51, P6304; Khan J, 1999, P NATL ACAD SCI USA, V96, P13264, DOI 10.1073/pnas.96.23.13264; LEE JM, 1994, ONCOGENE, V9, P3731; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MATSUDA R, 1993, AM J PATHOL, V142, P339; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; NETA R, 1993, BLOOD, V81, P324; Nishida T, 1998, NAT GENET, V19, P323, DOI 10.1038/1209; Perez-Losada J, 2002, BLOOD, V100, P1274, DOI 10.1182/blood.V100.4.1274.h81602001274_1274_1286; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; Sanchez-Martin M, 2002, HUM MOL GENET, V11, P3231, DOI 10.1093/hmg/11.25.3231; SARVELLA PATRICIA A., 1956, JOUR HEREDITY, V47, P123; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Silvers W.K., 1979, COAT COLORS MICE, P206; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U; ZSEBO KM, 1992, P NATL ACAD SCI USA, V89, P9464, DOI 10.1073/pnas.89.20.9464	38	68	69	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 3	2003	22	27					4205	4211		10.1038/sj.onc.1206467	http://dx.doi.org/10.1038/sj.onc.1206467			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698CJ	12833143				2022-12-17	WOS:000183979800007
J	Mimori, K; Shiraishi, T; Mashino, K; Sonoda, H; Yamashita, K; Yoshinaga, K; Masuda, T; Utsunomiya, T; Alonso, MA; Inoue, H; Mori, M				Mimori, K; Shiraishi, T; Mashino, K; Sonoda, H; Yamashita, K; Yoshinaga, K; Masuda, T; Utsunomiya, T; Alonso, MA; Inoue, H; Mori, M			MAL gene expression in esophageal cancer suppresses motility, invasion and tumorigenicity and enhances apoptosis through the Fas pathway	ONCOGENE			English	Article						T-lymphocyte maturation associated protein; (MAL); esophageal cancer; Fas; apoptosis; motility; tumorigenicity	DARBY CANINE KIDNEY; POLYMERASE-CHAIN-REACTION; HUMAN T-LYMPHOCYTES; APICAL TRANSPORT; CELL-LINES; JUVENILE NEPHRONOPHTHISIS; PROTEIN; MEMBRANE; CARCINOMA; DELETIONS	We isolated the MAL (T-lymphocyte maturation associated protein) gene from differentially expressed products of esophageal epithelium relative to esophageal carcinoma tissues. The Mal protein has been demonstrated as being a component of the protein machinery for apical transport in epithelial polarized cells. In this study, we describe the reduced expression of MAL in all 39 cases of esophageal carcinoma tested and 60 other human carcinomas. MAL gene transcription was induced in three out of 13 esophageal carcinoma cell lines by treatment with the demethylating agent 5-aza-2'-deoxycytidine (DAC), and in nine additional cell lines by simultaneous treatment with trichostatin A, an inhibitor of deacetylation, and DAC. We established a stable MAL gene transfectant whose expression was regulated by subcutaneous doxycycline injection in nude mice. Tumor growth was suppressed in cells expressing TE3-MAL compared with TE3 parent cells or cells not expressing TE3-MAL with doxycycline injection (20mug/body) (P<0.01). Additionally, the TE3-MAL transfectant cells exhibited decreased cellular motility, a G1/S transition block and increased levels of apoptosis, concomitant with increased expression of Fas receptor in vitro. The apoptotic staining in MALexpressing tumors was confirmed by TUNEL assay. Therefore, we conclude that expression of MAL was frequently decreased or diminished in gastrointestinal tract cancers, and that Mal expression confers reduced tumorigenicity in vivo to tumor TE3 cells through the induction of apoptosis via the Fas signaling pathway.	Kyushu Univ, Med Inst Bioregulat, Dept Surg, Beppu, Oita 8740838, Japan; Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Madrid, Spain; CSIC, Madrid, Spain	Kyushu University; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Consejo Superior de Investigaciones Cientificas (CSIC)	Mori, M (corresponding author), Kyushu Univ, Med Inst Bioregulat, Dept Surg, 4546 Tsurumihara, Beppu, Oita 8740838, Japan.		Alonso, Miguel A/J-3945-2016; Mashino, Kohjiro/AAW-7923-2020	Alonso, Miguel A/0000-0002-7001-8826; Mimori, Koshi/0000-0003-3897-9974				Abbott BD, 1999, TOXICOL SCI, V47, P76, DOI 10.1093/toxsci/47.1.76; ALONSO MA, 1987, P NATL ACAD SCI USA, V84, P1997, DOI 10.1073/pnas.84.7.1997; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cheong KH, 1999, P NATL ACAD SCI USA, V96, P6241, DOI 10.1073/pnas.96.11.6241; Dong JT, 2001, CANCER METAST REV, V20, P173, DOI 10.1023/A:1015575125780; KIM T, 1995, J NEUROSCI RES, V42, P413, DOI 10.1002/jnr.490420316; Konrad M, 1996, HUM MOL GENET, V5, P367, DOI 10.1093/hmg/5.3.367; Martin-Belmonte F, 2001, J BIOL CHEM, V276, P49337, DOI 10.1074/jbc.M106882200; Martin-Belmonte F, 1998, ENDOCRINOLOGY, V139, P2077, DOI 10.1210/en.139.4.2077; Martin-Belmonte F, 2000, MOL BIOL CELL, V11, P2033, DOI 10.1091/mbc.11.6.2033; Matsuyama A, 2001, CANCER RES, V61, P5714; Millan J, 1997, BIOCHEM J, V321, P247, DOI 10.1042/bj3210247; Millan J, 1998, EUR J IMMUNOL, V28, P3675, DOI 10.1002/(SICI)1521-4141(199811)28:11<3675::AID-IMMU3675>3.3.CO;2-X; Mimori K, 1997, BRIT J CANCER, V76, P531, DOI 10.1038/bjc.1997.420; Mori M, 1996, ANN SURG, V224, P183, DOI 10.1097/00000658-199608000-00011; MORI M, 1995, CANCER RES, V55, P3417; NISHIHIRA T, 1993, J CANCER RES CLIN, V119, P441, DOI 10.1007/BF01215923; Puertollano R, 1997, J BIOL CHEM, V272, P18311, DOI 10.1074/jbc.272.29.18311; Puertollano R, 1999, MOL BIOL CELL, V10, P3435, DOI 10.1091/mbc.10.10.3435; Puertollano R, 2001, MOL BIOL CELL, V12, P1869, DOI 10.1091/mbc.12.6.1869; Saunier S, 2000, AM J HUM GENET, V66, P778, DOI 10.1086/302819; Shibata K, 1999, CANCER RES, V59, P1096; SHIMADA Y, 1992, CANCER, V69, P277, DOI 10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C; Shiraishi T, 1998, INT J CANCER, V79, P175, DOI 10.1002/(SICI)1097-0215(19980417)79:2<175::AID-IJC13>3.3.CO;2-P; SUGIMACHI K, 1988, BRIT J SURG, V75, P1115, DOI 10.1002/bjs.1800751122; Tugores A, 1997, DNA CELL BIOL, V16, P245, DOI 10.1089/dna.1997.16.245; Wadler S, 1999, ANAL BIOCHEM, V267, P24, DOI 10.1006/abio.1998.2890	27	68	74	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 29	2003	22	22					3463	3471		10.1038/sj.onc.1206378	http://dx.doi.org/10.1038/sj.onc.1206378			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776198				2022-12-17	WOS:000183128500013
J	Ohtsuka, T; Ryu, H; Minamishima, YA; Ryo, A; Lee, SW				Ohtsuka, T; Ryu, H; Minamishima, YA; Ryo, A; Lee, SW			Modulation of p53 and p73 levels by cyclin G: implication of a negative feedback regulation	ONCOGENE			English	Article						p53; p73; cyclin G; siRNA; negative feedback regulation	DNA-DAMAGE; P53-INDUCED APOPTOSIS; G2/M ARREST; MDM2; GENE; GROWTH; CELLS; DEGRADATION; PROMOTES; PROTEIN	Cyclin G is a transcriptional target gene of tumor suppressor p53. Recent studies present evidence that cyclin G may play a central role in the p53-Mdm2 autoregulated module, but the precise function of cyclin G remains elusive. Here, we show a negative effect of cyclin G on the stability of p53 and p73. Cyclin G expression resulted in a dramatic decrease of p53 protein levels in response to DNA damage and abrogated irradiation-mediated G1 arrest along with an increase of S phase in MCF7 cells containing wild-type p53. In p53-null Saos2 cells, cyclin G inhibited p73 induction in response to genotoxic stress and delayed the camptothecin-mediated cell cycle arrest. Cyclin G interacts with p53 as well as p73, and its binding to p53 or p73 presumably mediates downregulation of p53 and p73. We also found that cyclin G-mediated reduction of p53 but not of p73 is Mdm2-dependent. Moreover, inhibition of cyclin G by small interfering RNA (siRNA) caused the accumulation of p53 and p73 protein levels in response to DNA damage. Therefore, our results imply that cyclin G is transcriptionally activated by p53 or p73, and, in turn, cyclin G negatively regulates the stabilization of p53 family proteins through an unknown mechanism different from ubiquitination or transcriptional control.	Harvard Univ, Sch Med, Inst Med, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Div Hematol & Oncol, Canc Biol Program, Boston, MA 02215 USA; Univ Massachusetts, Sch Med, Dept Neurol, Worcester, MA 01605 USA; Mem Hlth Care Ctr, Worcester, MA 01605 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; University of Massachusetts System; University of Massachusetts Worcester	Lee, SW (corresponding author), Harvard Univ, Sch Med, Inst Med, 77 Ave Louis Pasteur,Room 921, Boston, MA 02115 USA.		Minamishima, Yoji Andrew/E-5380-2010	Minamishima, Yoji Andrew/0000-0001-7995-9318; Ryu, Hoon/0000-0001-6544-3732	NATIONAL CANCER INSTITUTE [R01CA085681, R01CA078356] Funding Source: NIH RePORTER; NCI NIH HHS [CA85681, CA80058, CA78356] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attardi LD, 2000, GENE DEV, V14, P704; Bean LJH, 2002, J BIOL CHEM, V277, P1864, DOI 10.1074/jbc.M108881200; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; BURNS TF, 1999, J CELL PHYSL, V181, P371; Chen XB, 2002, DEV CELL, V2, P518, DOI 10.1016/S1534-5807(02)00182-X; Chen XB, 2001, ONCOGENE, V20, P769, DOI 10.1038/sj.onc.1204149; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gong JG, 1999, NATURE, V399, P806; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HE TC, 1996, P NATL ACAD SCI USA, V93, P8390; Inoue T, 2001, FEBS LETT, V490, P196, DOI 10.1016/S0014-5793(01)02123-8; Kimura SH, 2002, GENES CELLS, V7, P869, DOI 10.1046/j.1365-2443.2002.00564.x; Kimura SH, 2001, ONCOGENE, V20, P3290, DOI 10.1038/sj.onc.1204270; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MIYASHITA T, 1995, CELL, V80, P293; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Okamoto K, 1999, ONCOGENE, V18, P4606, DOI 10.1038/sj.onc.1202821; Okamoto K, 2002, MOL CELL, V9, P761, DOI 10.1016/S1097-2765(02)00504-X; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Reimers L, 1999, J BIOL CHEM, V274, P11022, DOI 10.1074/jbc.274.16.11022; Shimizu A, 1998, BIOCHEM BIOPH RES CO, V242, P529, DOI 10.1006/bbrc.1997.8004; SKOTZKO M, 1995, CANCER RES, V55, P5493; Smith ML, 1997, EXP CELL RES, V230, P61, DOI 10.1006/excr.1996.3402; TAMURA K, 1993, ONCOGENE, V8, P2113; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; Zeng XY, 1999, MOL CELL BIOL, V19, P3257	37	68	69	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 20	2003	22	11					1678	1687		10.1038/sj.onc.1206306	http://dx.doi.org/10.1038/sj.onc.1206306			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642871				2022-12-17	WOS:000181580500010
J	Funakoshi, T; Tachibana, I; Hoshida, Y; Kimura, H; Takeda, Y; Kijima, T; Nishino, K; Goto, H; Yoneda, T; Kumagai, T; Osaki, T; Hayashi, S; Aozasa, K; Kawase, I				Funakoshi, T; Tachibana, I; Hoshida, Y; Kimura, H; Takeda, Y; Kijima, T; Nishino, K; Goto, H; Yoneda, T; Kumagai, T; Osaki, T; Hayashi, S; Aozasa, K; Kawase, I			Expression of tetraspanins in human lung cancer cells: frequent downregulation of CD9 and its contribution to cell motility in small cell lung cancer	ONCOGENE			English	Article						small cell lung cancer (SCLC); tetraspanin; CD9; motility	KAI1/CD82 GENE-EXPRESSION; TRANSMEMBRANE-4 SUPERFAMILY; BREAST-CANCER; MONOCLONAL-ANTIBODY; TM4SF PROTEINS; TYROSINE PHOSPHORYLATION; INTEGRIN ALPHA-3-BETA-1; MOLECULAR-CLONING; PANCREATIC-CANCER; TUMOR PROGRESSION	Small cell lung cancer (SCLC) invades locally and metastasizes distantly extremely early when compared with nonsmall cell lung cancer (NSCLC). The underlying molecular mechanisms, however, have not been elucidated. Accumulating evidence suggests that downregulation of several members of tetraspanins is associated with progression of solid tumors, thus indicating poor prognosis. Here we screened 30 lung cancer cell lines for expression of tetraspanins, CD9, CD63, CD81, CD82, CD151, and NAG-2. Flow cytometry revealed that, among these proteins, CD9 is broadly expressed in NSCLC lines, but is absent or highly reduced in most SCLC lines (P < 0.0001). Using the Boyden chamber and videomicroscopic cell motility assays, we showed that stable transfection of CD9 into an SCLC line, OS3-R5, reduced cell motility on fibronectin. Furthermore, by transient transfection of green fluorescent protein (GFP)-tagged CD9 into three other SCLC lines, we observed that SCLC cells expressing GFP-CD9 were uniformly less motile than untransfected cells. CD9 or GFP-CD9 was associated with beta1 integrins and distributed at the tumor cell periphery and cell-cell contacts, suggesting that CD9 modifies beta1 integrin function to reduce motility. These findings suggest that low expression of CD9 may contribute to the highly invasive and metastatic phenotype of SCLC.	Osaka Univ, Grad Sch Med, Dept Mol Med, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Pathol, Suita, Osaka 5650871, Japan; Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Thorac & Adult Oncol, Boston, MA 02115 USA	Osaka University; Osaka University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Tachibana, I (corresponding author), Osaka Univ, Grad Sch Med, Dept Mol Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Hoshida, Yujin/R-7513-2019	Hoshida, Yoshihiko/0000-0003-3166-9754				Adachi M, 1996, CANCER RES, V56, P1751; Adachi M, 1998, J CLIN ONCOL, V16, P1397, DOI 10.1200/JCO.1998.16.4.1397; ATKINSON B, 1985, HYBRIDOMA, V4, P243, DOI 10.1089/hyb.1985.4.243; Berditchevski F, 1997, J BIOL CHEM, V272, P2595, DOI 10.1074/jbc.272.5.2595; Berditchevski F, 1999, J CELL BIOL, V146, P477, DOI 10.1083/jcb.146.2.477; BOUCHEIX C, 1985, ANN GENET-PARIS, V28, P19; Bredin CG, 1998, EUR RESPIR J, V11, P400, DOI 10.1183/09031936.98.11020400; Cajot JF, 1997, CANCER RES, V57, P2593; CARNEY DN, 1985, CANCER RES, V45, P2913; Claas C, 1998, J CELL BIOL, V141, P267, DOI 10.1083/jcb.141.1.267; DOYLE A, 1985, J EXP MED, V161, P1135, DOI 10.1084/jem.161.5.1135; FELDMAN LE, 1991, CANCER RES, V51, P1065; FITTER S, 1995, BLOOD, V86, P1348, DOI 10.1182/blood.V86.4.1348.bloodjournal8641348; Guo XZ, 1996, CANCER RES, V56, P4876; Hemler ME, 1996, BBA-REV CANCER, V1287, P67, DOI 10.1016/0304-419X(96)00007-8; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; HIGASHIYAMA M, 1995, CANCER RES, V55, P6040; HOTTA H, 1988, CANCER RES, V48, P2955; HSU SM, 1981, AM J CLIN PATHOL, V75, P816, DOI 10.1093/ajcp/75.6.816; Huang CI, 1998, AM J PATHOL, V153, P973, DOI 10.1016/S0002-9440(10)65639-8; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; Inoue G, 2001, INT J MOL MED, V7, P67; KAPRIELIAN Z, 1995, J NEUROSCI, V15, P562; KASHII T, 1992, ANTICANCER RES, V12, P621; Lagaudriere-Gesbert C, 1997, J IMMUNOL, V158, P2790; Lantuejoul S, 1998, AM J SURG PATHOL, V22, P1267, DOI 10.1097/00000478-199810000-00012; Le Naour F, 2000, SCIENCE, V287, P319, DOI 10.1126/science.287.5451.319; Li J, 1996, ONCOGENE, V13, P2379; Lombardi DP, 1999, CANCER RES, V59, P5724; MABRY M, 1991, CANCER CELL-MON REV, V3, P53; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; Mashimo T, 2000, BIOCHEM BIOPH RES CO, V274, P370, DOI 10.1006/bbrc.2000.3139; Miyado K, 2000, SCIENCE, V287, P321, DOI 10.1126/science.287.5451.321; Miyake M, 2000, ONCOGENE, V19, P5221, DOI 10.1038/sj.onc.1203919; MIYAKE M, 1995, CANCER RES, V55, P4127; Miyake M, 1996, CANCER RES, V56, P1244; MOUNTAIN CF, 1978, SEMIN ONCOL, V5, P272; NAGIRA M, 1994, CELL IMMUNOL, V157, P144, DOI 10.1006/cimm.1994.1212; NAKAMURA K, 1995, J CELL BIOL, V129, P1691, DOI 10.1083/jcb.129.6.1691; Oritani K, 1996, BLOOD, V87, P2252, DOI 10.1182/blood.V87.6.2252.bloodjournal8762252; Rubinstein E, 1996, EUR J IMMUNOL, V26, P2657, DOI 10.1002/eji.1830261117; SAITO S, 1994, LUNG CANCER-J IASLC, V10, P307, DOI 10.1016/0169-5002(94)90660-2; SAITO S, 1991, CANCER IMMUNOL IMMUN, V33, P165, DOI 10.1007/BF01756137; Salgia R, 1998, J CLIN ONCOL, V16, P1207, DOI 10.1200/JCO.1998.16.3.1207; SCHEIDEGGER EP, 1994, LAB INVEST, V70, P95; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; SHAW ARE, 1995, J BIOL CHEM, V270, P24092, DOI 10.1074/jbc.270.41.24092; Sho M, 1998, INT J CANCER, V79, P509, DOI 10.1002/(SICI)1097-0215(19981023)79:5<509::AID-IJC11>3.0.CO;2-X; Shtivelman E, 1997, ONCOGENE, V14, P2167, DOI 10.1038/sj.onc.1201059; SOUHAMI RL, 1987, LANCET, V2, P325; Tachibana I, 1997, J BIOL CHEM, V272, P29181, DOI 10.1074/jbc.272.46.29181; Tachibana I, 1996, EXP CELL RES, V227, P230, DOI 10.1006/excr.1996.0272; Tachibana I, 1999, J CELL BIOL, V146, P893, DOI 10.1083/jcb.146.4.893; TANIO Y, 1992, JPN J CANCER RES, V83, P736, DOI 10.1111/j.1349-7006.1992.tb01974.x; Testa JE, 1999, CANCER RES, V59, P3812; Uchida S, 1999, BRIT J CANCER, V79, P1168, DOI 10.1038/sj.bjc.6690186; White A, 1998, ONCOGENE, V16, P3143, DOI 10.1038/sj.onc.1201852; Yang XH, 2000, CLIN CANCER RES, V6, P3424; Yauch RL, 1998, MOL BIOL CELL, V9, P2751, DOI 10.1091/mbc.9.10.2751	59	68	81	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 6	2003	22	5					674	687		10.1038/sj.onc.1206106	http://dx.doi.org/10.1038/sj.onc.1206106			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569360				2022-12-17	WOS:000180642100005
J	Herbert, BS; Wright, WE; Shay, JW				Herbert, BS; Wright, WE; Shay, JW			p16(INK4a) inactivation is not required to immortalize human mammary epithelial cells	ONCOGENE			English	Article						telomerase; senescence; culture; methylation; growth arrest	TELOMERASE ACTIVITY; SENESCENCE; EXPRESSION	Using standard culture conditions, primary human mammary epithetial cells (HMECs) undergo a premature, transient growth arrest termed MO (mortality stage 0) after 10 - 15 population doublings in vitro. It has been reported that emergence from this growth arrest by the abrogation of p16(INK4a), a cyclin-dependent kinase inhibitor, and expression of the catalytic component of human telomerase (hTERT) are necessary for HMEC immortalization. Here we show that primary HMECs, grown on feeder layers, do not undergo this growth arrest and can be immortalized without abrogating p16. These findings support the concept that the so-called M0 stage represents a cell culture stress-induced growth arrest and that hTERT is sufficient to immortalize HMECs when cultured under adequate conditions.	Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Shay, JW (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Shay, Jerry W/F-7878-2011					Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919; DiRenzo J, 2002, CANCER RES, V62, P89; ETHIER SP, 1993, CANCER RES, V53, P627; Huschtscha LI, 1998, CANCER RES, V58, P3508; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Ouellette MM, 1999, BIOCHEM BIOPH RES CO, V254, P795, DOI 10.1006/bbrc.1998.0114; Piatyszek Mieczyslaw A., 1995, Methods in Cell Science, V17, P1, DOI 10.1007/BF00981880; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Wright WE, 2002, NAT BIOTECHNOL, V20, P682, DOI 10.1038/nbt0702-682; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794	14	68	70	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 7	2002	21	51					7897	7900		10.1038/sj.onc.1205902	http://dx.doi.org/10.1038/sj.onc.1205902			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	610DT	12420227				2022-12-17	WOS:000178946000015
J	Dugan, KA; Wood, MA; Cole, MD				Dugan, KA; Wood, MA; Cole, MD			TIP49, but not TRRAP, modulates c-Myc and E2F1 dependent apoptosis	ONCOGENE			English	Article						Myc; E2F; TIP49; TRRAP; apoptosis; proliferation	HISTONE ACETYLASE COMPLEX; CELL-CYCLE PROGRESSION; ESSENTIAL COFACTOR; S-PHASE; MYC/MAX/MAD NETWORK; GENE-EXPRESSION; GROWTH CONTROL; DNA-BINDING; TRANSCRIPTION; PROTEIN	We previously described two nuclear cofactors, TRRAP and TIP49, that have functional roles in Myc-mediated oncogenesis. We have now expanded the analysis of these Myc-associated cofactors to investigate their roles in apoptosis and cell proliferation. Although TRRAP and TIP49 are both essential for transformation, TIP49 modulates c-Myc-mediated apoptosis whereas disruption of TRRAP activity has no apparent effect on apoptosis. We extended our analysis of TIP49 to show that it also binds to the E2F1 transactivation domain and modulates both transforming and apoptotic activities. These results indicate that individual cofactors differentially potentiate c-Myc and E2F1 functions.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Cole, MD (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.		Wood, Marcelo/G-9527-2012					Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; Bauer A, 1998, P NATL ACAD SCI USA, V95, P14787, DOI 10.1073/pnas.95.25.14787; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Chang DW, 2000, MOL CELL BIOL, V20, P4309, DOI 10.1128/MCB.20.12.4309-4319.2000; Cho SG, 2001, MOL CELL BIOL, V21, P8398, DOI 10.1128/MCB.21.24.8398-8413.2001; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ebbert R, 1999, MOL MICROBIOL, V32, P741, DOI 10.1046/j.1365-2958.1999.01390.x; EVAN GI, 1995, CURR OPIN CELL BIOL, V7, P825, DOI 10.1016/0955-0674(95)80066-2; EVAN GI, 1992, CELL, V85, P549; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; FREYTAG SO, 1990, CELL GROWTH DIFFER, V1, P339; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; Grant PA, 1998, MOL CELL, V2, P863, DOI 10.1016/S1097-2765(00)80300-7; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Herceg Z, 2001, NAT GENET, V29, P206, DOI 10.1038/ng725; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Lang SE, 2001, J BIOL CHEM, V276, P32627, DOI 10.1074/jbc.M102067200; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; Lim CR, 2000, J BIOL CHEM, V275, P22409, DOI 10.1074/jbc.M001031200; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Mehmet H, 1997, CELL GROWTH DIFFER, V8, P187; NEVINS JR, 1995, CURR TOP MICROBIOL, V199, P25; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5054, DOI 10.1128/MCB.22.14.5054-5063.2002; Park J, 2002, MOL CELL BIOL, V22, P1307, DOI 10.1128/MCB.22.5.1307-1316.2002; Park J, 2001, GENE DEV, V15, P1619, DOI 10.1101/gad.900101; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; Saleh A, 1998, J BIOL CHEM, V273, P26559, DOI 10.1074/jbc.273.41.26559; Shen XT, 2000, NATURE, V406, P541, DOI 10.1038/35020123; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; Sladek TL, 1997, CELL PROLIFERAT, V30, P97, DOI 10.1046/j.1365-2184.1997.00085.x; Sommer A, 1998, J BIOL CHEM, V273, P6632, DOI 10.1074/jbc.273.12.6632; STANCHINA E, 1998, GENE DEV, V12, P2434; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Thomas A, 1998, GENE DEV, V12, P1975, DOI 10.1101/gad.12.13.1975; Vassilev A, 1998, MOL CELL, V2, P869, DOI 10.1016/S1097-2765(00)80301-9; White E, 1995, Curr Top Microbiol Immunol, V199 ( Pt 3), P34; Wood MA, 2000, MOL CELL, V5, P321, DOI 10.1016/S1097-2765(00)80427-X; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; ZANTEMA A, 1995, CURR TOP MICROBIOL, V199, P1; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	55	68	74	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2002	21	38					5835	5843		10.1038/sj.onc.1205763	http://dx.doi.org/10.1038/sj.onc.1205763			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185582				2022-12-17	WOS:000177520900002
J	Sato, M; Horio, Y; Sekido, Y; Minna, JD; Shimokata, K; Hasegawa, Y				Sato, M; Horio, Y; Sekido, Y; Minna, JD; Shimokata, K; Hasegawa, Y			The expression of DNA methyltransferases and methyl-CpG-binding proteins is not associated with the methylation status of p14(ARF), p16(INK4a) and RASSF1A in human lung cancer cell lines	ONCOGENE			English	Article						epigenetic modification; DNA methylation; tumor suppressor gene; DNA methyltransferase; methyl-CpG-binding protein; lung cancer	TUMOR-SUPPRESSOR GENE; COLON-CANCER; EPIGENETIC INACTIVATION; SATELLITE REGIONS; RETINOBLASTOMA; LOCUS; ISLANDS; HYPERMETHYLATION; MUTATIONS; 3P21.3	Promoter hypermethylation is an important means for the transcriptional repression of a number of cancer-associated genes. However, the underlying mechanism of this aberration in cancer remains unclear. Here, we examined 5' CpG island methylation status and expression of the p14(ARF), p16(INK4a) and RASSF1A tumor suppressor genes, and investigated the relationship of these factors with the mRNA expression of DNA methyltransferases (DNMTs) and/or methyl-CpG-binding proteins (MBPs) in 30 lung cancer cell lines including 12 small cell lung cancers (SCLCs) and 18 non-small cell lung cancers (NSCLCs). When beta-actin was used as an internal control, the mRNA expression of three DNMTv (DNMT1, DNMT3A, and DNMT3B) and five MBPs (MBD1, MBD2, MBD3, MBD4, and MeCP2) was upregulated in SCLC, while only that of DNMT1, DNMT3B and MBD3 was upregulated in NSCLC, compared with normal lung tissues. However, when normalized using proliferating cell nuclear antigen (PCNA) as an internal control, these differences disappeared or diminished; there was even a significant reduction in the expression ratios of DNMT1, MBD2 and MeCP2 in SCLC and DNMT, MBD2 and MBD4 in NSCLC. Furthermore, although significant correlations between PCNA expression and mRNA expression levels of the three DNMTv and four of the MBPs (excluding MeCP2) were observed, there was no obvious correlation between promoter hypermethylation of these tumor suppressor genes and the expression level of any of the DNMTs or MBPs. Our results suggest that upregulation of DNMTs and MBPs probably reflects an increased cell proliferation in human lung cancers and that there are likely to exist gene-specific mechanisms for epigenetic gene silencing.	Grad Sch med, Dept Clin Prevent Med, Showa Ku, Nagoya, Aichi 4668550, Japan; Grad Sch Med, Dept Internal Med 1, Showa Ku, Nagoya, Aichi 4668550, Japan; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Horio, Y (corresponding author), Aichi Canc Ctr Hosp, Dept Internal Med, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	yhorio@aichi-cc.jp	Sekido, Yoshitaka/P-9756-2015; Hasegawa, Yoshinori/I-1277-2012; Sato, MITSUO/I-7280-2014	Sato, MITSUO/0000-0001-5458-9576; Sekido, Yoshitaka/0000-0002-2428-3848; Horio, Yoshitsugu/0000-0003-4661-6399	NATIONAL CANCER INSTITUTE [R01CA071618, P50CA070907] Funding Source: NIH RePORTER; NCI NIH HHS [CA71618, P50 CA70907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469; Eads CA, 1999, CANCER RES, V59, P2302; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 2001, CANCER RES, V61, P3225; FRANCOIS J, 1975, OPHTHALMOLOGICA, V170, P405, DOI 10.1159/000307248; Fujita N, 1999, MOL CELL BIOL, V19, P6415; Gazzeri S, 1998, CANCER RES, V58, P3926; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GREGER V, 1989, HUM GENET, V83, P155, DOI 10.1007/BF00286709; Hamada K, 2000, GENE CHROMOSOME CANC, V27, P308, DOI 10.1002/(SICI)1098-2264(200003)27:3<308::AID-GCC12>3.0.CO;2-W; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HAYASHI N, 1994, BIOCHEM BIOPH RES CO, V202, P1426, DOI 10.1006/bbrc.1994.2090; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235; Kanai Y, 2001, INT J CANCER, V91, P205, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1040>3.0.CO;2-2; Kashiwabara K, 1998, INT J CANCER, V79, P215, DOI 10.1002/(SICI)1097-0215(19980619)79:3<215::AID-IJC1>3.0.CO;2-S; Kim DH, 2001, CANCER RES, V61, P3419; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10366, DOI 10.1073/pnas.93.19.10366; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; MAO L, 1995, CANCER RES, V55, P2995; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Mizuno S, 2001, BLOOD, V97, P1172, DOI 10.1182/blood.V97.5.1172; Phelps RM, 1996, J CELL BIOCHEM, P32; Saito Y, 2001, HEPATOLOGY, V33, P561, DOI 10.1053/jhep.2001.22507; Sambrook J., 1989, MOL CLONING; Sanchez-Cespedes M, 1999, ONCOGENE, V18, P5843, DOI 10.1038/sj.onc.1203003; Sato M, 2000, JPN J CANCER RES, V91, P504, DOI 10.1111/j.1349-7006.2000.tb00974.x; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; SEKIDO Y, 1992, MOL CELL BIOL, V12, P1747, DOI 10.1128/MCB.12.4.1747; SEKIDO Y, 1998, BIOCHIM BIOPHYS ACTA, V1378, P21; SHAPIRO GI, 1995, CANCER RES, V55, P6200; STONE S, 1995, CANCER RES, V55, P2988; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; Tycko B, 2000, J CLIN INVEST, V105, P401, DOI 10.1172/JCI9462; Wei MH, 1996, CANCER RES, V56, P1487; XU L, 1994, CANCER RES, V54, P5262; ZHOU XL, 1994, ONCOGENE, V9, P3737; Zochbauer-Muller S, 2001, CANCER RES, V61, P249	47	68	74	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	2002	21	31					4822	4829		10.1038/sj.onc.1205581	http://dx.doi.org/10.1038/sj.onc.1205581			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	571KJ	12101420				2022-12-17	WOS:000176716300011
J	Mukasa, A; Ueki, K; Matsumoto, S; Tsutsumi, S; Nishikawa, R; Fujimaki, T; Asai, A; Kirino, T; Aburatani, H				Mukasa, A; Ueki, K; Matsumoto, S; Tsutsumi, S; Nishikawa, R; Fujimaki, T; Asai, A; Kirino, T; Aburatani, H			Distinction in gene expression profiles of oligodendrogliomas with and without allelic loss of 1p	ONCOGENE			English	Article						oligodendroglioma; oligonucleotide microarray; loss of heterozygosity	DRUG-RESISTANCE GENES; MUTATION; IDENTIFICATION; HYBRIDIZATION; CHEMOTHERAPY; ASTROCYTOMAS; CHROMOSOME-1; ORGANIZATION; MICROARRAYS; REGIONS	Oligodendrogliomas frequently, but not always show sensitivity to chemotherapy and recent studies demonstrated that allelic loss of chromosome 1p is highly associated with this chemosensitivity. To gain insight into the molecular mechanism of such difference, we examined comprehensive gene expression profiles of 11 oligodendroglial tumors, six with and five without 1pLOH (loss of heterozygosity), and two normal brain tissues using the oligonucleotide microarray (GeneChip). Statistically significant numbers of genes were expressed differentially between the two genetic subsets. Clustering analysis separated the tumor subsets well. The tumors with 1pLOH had similar expression profiles to the normal brain for those differentially expressed genes. Many genes showing higher expression in tumors with 1pLOH were presumed to have functions in nervous tissues. Notably, the majority of the 123 genes showing significant expression reduction in tumors with 1PLOH were either on chromosome 1 (50%) or on 19 (10%), and the average expression reduction ratio was about 50% (0.54 +/- 0.13) possibly reflecting the chromosomal deletion. Thus, the biological difference between the genetic subsets of oligodendroglioma was indeed reflected to gene expression profile, which provided baseline information for further studies to elucidate the mechanism of chemosensitivity in gliomas.	Univ Tokyo, Fac Med, Dept Neurosurg, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Adv Sci & Technol Res Ctr, Genome Sci Div, Meguro Ku, Tokyo 1538904, Japan; Saitama Med Sch, Dept Neurosurg, Moroyama, Saitama 3500495, Japan; Teikyo Univ, Sch Med, Dept Neurosurg, Itabashi Ku, Tokyo 1738606, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan	University of Tokyo; University of Tokyo; Saitama Medical University; Teikyo University; Japan Science & Technology Agency (JST)	Aburatani, H (corresponding author), Univ Tokyo, Fac Med, Dept Neurosurg, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.		Mukasa, Akitake/H-7615-2019	Mukasa, Akitake/0000-0001-7776-9086				Bigner SH, 1999, AM J PATHOL, V155, P375, DOI 10.1016/S0002-9440(10)65134-6; Cairncross JG, 1998, J NATL CANCER I, V90, P1473, DOI 10.1093/jnci/90.19.1473; CAIRNCROSS JG, 1988, ANN NEUROL, V23, P360, DOI 10.1002/ana.410230408; Caron H, 2001, SCIENCE, V291, P1289, DOI 10.1126/science.1056794; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; FULTS D, 1992, CANCER RES, V52, P674; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Gutmann DH, 1999, ONCOGENE, V18, P4450, DOI 10.1038/sj.onc.1202829; Huang HT, 2000, CANCER RES, V60, P6868; Husemann K, 1999, J NEUROPATH EXP NEUR, V58, P1041, DOI 10.1097/00005072-199910000-00002; Ino Y, 2001, CLIN CANCER RES, V7, P839; Ishii M, 2000, GENOMICS, V68, P136, DOI 10.1006/geno.2000.6284; Kenwrick S, 2000, HUM MOL GENET, V9, P879, DOI 10.1093/hmg/9.6.879; Kim JG, 1997, J NEUROSCI RES, V50, P272, DOI 10.1002/(SICI)1097-4547(19971015)50:2<272::AID-JNR16>3.0.CO;2-A; Kleihues P, 2000, PATHOLOGY GENETICS T; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Mai M, 1998, GENOMICS, V51, P359, DOI 10.1006/geno.1998.5387; Nigro JM, 2001, AM J PATHOL, V158, P1253, DOI 10.1016/S0002-9440(10)64076-X; Nutt CL, 2000, CANCER RES, V60, P4812; Ohira M, 2000, ONCOGENE, V19, P4302, DOI 10.1038/sj.onc.1203786; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Schwab M, 1996, GENE CHROMOSOME CANC, V16, P211, DOI 10.1002/(SICI)1098-2264(199608)16:4<211::AID-GCC1>3.0.CO;2-0; Smith JS, 1999, ONCOGENE, V18, P4144, DOI 10.1038/sj.onc.1202759; Tanaka S, 2000, J NEURO-ONCOL, V46, P157, DOI 10.1023/A:1006399903635; Ueki K, 1996, CANCER RES, V56, P150; Ueki K, 2002, CLIN CANCER RES, V8, P196; Watson MA, 2001, CANCER RES, V61, P1825	28	68	70	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 6	2002	21	25					3961	3968		10.1038/sj.onc.1205495	http://dx.doi.org/10.1038/sj.onc.1205495			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556VP	12037678				2022-12-17	WOS:000175869900002
J	Bartholin, L; Maguer-Satta, V; Hayette, S; Martel, S; Badoux, M; Corbo, L; Magaud, JP; Rimokh, R				Bartholin, L; Maguer-Satta, V; Hayette, S; Martel, S; Badoux, M; Corbo, L; Magaud, JP; Rimokh, R			Transcription activation of FLRG and follistatin by activin A, through Smad proteins, participates in a negative feedback loop to modulate activin A function	ONCOGENE			English	Article						FLRG; follistatin; activin; TGF beta; Smad	BONE MORPHOGENETIC PROTEINS; BINDING-PROTEIN; TGF; CELL; EXPRESSION; PROMOTER; RECEPTOR; GROWTH; GENE; ANTAGONIST	Signaling of TGFbeta family members such as activin is tightly regulated by soluble binding proteins. Follistatin binds to activin A with high affinity, and prevents activin binding to its own receptors, thereby blocking its signaling. We previously identified FLRG gene from a B-cell leukemia carrying a t(11;19)(q13;p13) translocation. We and others have already shown that FLRG, which is highly homologous to follistatin, may be involved in the regulation of the activin function through its binding to activin. In this study, we found that, like follistatin, FLRG protein inhibited activin A signaling as demonstrated by the use of a transcriptional reporter assay, and blocked the activin A-induced growth inhibition of HepG2 cells. We have recently shown that the TGFbeta-induced expression of FLRG occurs at a transcriptional level through the action of Smad proteins. Here we show that activin A increases FLRG and follistatin at both the mRNA and protein levels. We found that Smad proteins are involved in the activin A-induced transcription activation of FLRG and follistatin. Finally we demonstrate that FLRG protein regulates its own activin-induced expression. In conclusion, activin A induces FLRG and follistatin expression. This observation, in conjunction with the antagonistic effect of FLRG and follistatin on activin signaling, indicates that these two proteins participate in a negative feedback loop which regulates the activin function.	Hop Edouard Herriot, Lab Cytogenet Mol, F-69437 Lyon, France; Ctr Leon Berard, INSERM U453, F-69373 Lyon, France	CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard	Rimokh, R (corresponding author), Ctr Leon Berard, INSERM U453, F-69373 Lyon, France.	rimokh@lyon.fnclcc.fr	Bartholin, Laurent/Q-6655-2017; HAYETTE, sandrine/Z-2283-2019; Rimokh, Ruth/G-7506-2014; Maguer-Satta, Veronique/U-8857-2019	Bartholin, Laurent/0000-0002-5637-3223; Maguer-Satta, Veronique/0000-0002-1556-068X				Bartholin L, 2001, ONCOGENE, V20, P5409, DOI 10.1038/sj.onc.1204720; Bitzer M, 2000, GENE DEV, V14, P187; Brodin G, 2000, J BIOL CHEM, V275, P29023, DOI 10.1074/jbc.M002815200; Denissova NG, 2000, P NATL ACAD SCI USA, V97, P6397, DOI 10.1073/pnas.090099297; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; DePaolo LV, 1997, P SOC EXP BIOL MED, V214, P328; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; deWinter JP, 1996, MOL CELL ENDOCRINOL, V116, P105, DOI 10.1016/0303-7207(95)03705-5; Fainsod A, 1997, MECH DEVELOP, V63, P39, DOI 10.1016/S0925-4773(97)00673-4; Gamer LW, 1999, DEV BIOL, V208, P222, DOI 10.1006/dbio.1998.9191; Gazzerro E, 1998, J CLIN INVEST, V102, P2106, DOI 10.1172/JCI3459; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hayette S, 1998, ONCOGENE, V16, P2949, DOI 10.1038/sj.onc.1201807; Iemura S, 1998, P NATL ACAD SCI USA, V95, P9337, DOI 10.1073/pnas.95.16.9337; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lebrun JJ, 1999, MOL ENDOCRINOL, V13, P15, DOI 10.1210/me.13.1.15; Maguer-Satta V, 2001, EXP HEMATOL, V29, P301, DOI 10.1016/S0301-472X(00)00675-5; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Pereira RC, 2000, ENDOCRINOLOGY, V141, P4558, DOI 10.1210/en.141.12.4558; Phillips DJ, 2000, BIOESSAYS, V22, P689, DOI 10.1002/1521-1878(200008)22:8<689::AID-BIES2>3.0.CO;2-5; Phillips DJ, 1998, FRONT NEUROENDOCRIN, V19, P287, DOI 10.1006/frne.1998.0169; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Reddi AH, 2001, ARTHRITIS RES, V3, P1; Russell CE, 1999, MOL CELL ENDOCRINOL, V148, P129, DOI 10.1016/S0303-7207(98)00226-3; SCHWALL RH, 1993, HEPATOLOGY, V18, P347, DOI 10.1016/0270-9139(93)90018-I; SHIMASAKI S, 1988, P NATL ACAD SCI USA, V85, P4218, DOI 10.1073/pnas.85.12.4218; Smith WC, 1999, TRENDS GENET, V15, P3, DOI 10.1016/S0168-9525(98)01641-2; Takase M, 1998, BIOCHEM BIOPH RES CO, V244, P26, DOI 10.1006/bbrc.1998.8200; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Tsuchida K, 2000, J BIOL CHEM, V275, P40788, DOI 10.1074/jbc.M006114200; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; YAMASHITA T, 1992, BLOOD, V79, P304; YASUDA H, 1993, J CLIN INVEST, V92, P1491, DOI 10.1172/JCI116727; Ying SY, 1997, P SOC EXP BIOL MED, V214, P114; Yu J, 1997, CYTOKINES CELL MOL T, V3, P169; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhang YQ, 1997, BBA-GENE STRUCT EXPR, V1354, P204, DOI 10.1016/S0167-4781(97)00085-7	44	68	74	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2002	21	14					2227	2235		10.1038/sj.onc.1205294	http://dx.doi.org/10.1038/sj.onc.1205294			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	533XJ	11948405				2022-12-17	WOS:000174555300011
J	Deleu, L; Shellard, S; Alevizopoulos, K; Amati, B; Land, H				Deleu, L; Shellard, S; Alevizopoulos, K; Amati, B; Land, H			Recruitment of TRRAP required for oncogenic transformation by E1A	ONCOGENE			English	Article						TRRAP; E1A; Myc; adenovirus; oncogenic transformation	HISTONE ACETYLASE COMPLEX; C-MYC; ADENOVIRUS E1A; ESSENTIAL COFACTOR; PROTEINS; DOMAINS; EXPRESSION; TARGETS; VECTORS; CELLS	TRRAP links Myc with histone acetylases and appears to be an important mediator of its oncogenic function. Here we show that interaction with TRRAP is required for cellular transformation not only by Myc, but also by the adenovirus EIA protein. Substitution of the 262 N-terminal residues of Myc with a small domain of EIA (residues 12-54) restores Myc transforming function. EIA(12-54) contains a TRRAP-interaction domain, that recruits TRRAP to either E1A-Myc chimeras, or the native 12S E1A protein. Overexpression of a competing TRRAP fragment in vivo blocks interaction of cellular TRRAP with either E1A-Myc or EIA, and suppresses cellular transformation by both oncoproteins. Moreover, E1A(Delta 26-35) that fails to bind TRRAP but is capable of binding the Retinoblastoma (Rb)-family and p300/CBP proteins is defective in cellular immortalization, transformation and cell cycle deregulation. Thus in addition to disrupting Rb and p300/CBP functions, E1A must recruit TRRAP to transform cells.	Univ Rochester, Med Ctr, Dept Biomed Genet, Rochester, NY 14642 USA; ICRF, London WC2A, England; ISREC, CH-1066 Epalinges, Switzerland; DNAX Res Inst Mol & Cellular Biol Inc, Dept Oncol, Palo Alto, CA 94304 USA	University of Rochester; Swiss Institute Experimental Cancer Research; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Land, H (corresponding author), Univ Rochester, Med Ctr, Dept Biomed Genet, 601 Elmwood Ave, Rochester, NY 14642 USA.		Amati, Bruno/AAM-3418-2020	Amati, Bruno/0000-0002-2958-1799				Alevizopoulos K, 1998, EMBO J, V17, P5987, DOI 10.1093/emboj/17.20.5987; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; Amati B, 2001, BBA-REV CANCER, V1471, pM135, DOI 10.1016/S0304-419X(01)00020-8; Amati B, 1998, FRONT BIOSCI, V3, pd250, DOI [10.2741/a239, DOI 10.2741/A239]; BARBEAU D, 1994, ONCOGENE, V9, P359; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Brand M, 1999, J BIOL CHEM, V274, P18285, DOI 10.1074/jbc.274.26.18285; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; DORSMAN JC, 1995, J VIROL, V69, P2962, DOI 10.1128/JVI.69.5.2962-2967.1995; DYSON N, 1992, CANCER SURV, V12, P161; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; Hancock DC, 1998, METH MOL B, V80, P69; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; LAND H, 1995, METHOD ENZYMOL, V254, P37; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; MACU KB, 1992, ANNU REV BIOCHEM, V61, P809; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; RALSTON R, 1991, NATURE, V353, P866, DOI 10.1038/353866a0; Vassilev A, 1998, MOL CELL, V2, P869, DOI 10.1016/S1097-2765(00)80301-9; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7	25	68	70	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 13	2001	20	57					8270	8275		10.1038/sj.onc.1205159	http://dx.doi.org/10.1038/sj.onc.1205159			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	498KC	11781841				2022-12-17	WOS:000172507800010
J	Kondo, M; Ji, L; Kamibayashi, C; Tomizawa, Y; Randle, D; Sekido, Y; Yokota, J; Kashuba, V; Zabarovsky, E; Kuzmin, I; Lerman, M; Roth, J; Minna, JD				Kondo, M; Ji, L; Kamibayashi, C; Tomizawa, Y; Randle, D; Sekido, Y; Yokota, J; Kashuba, V; Zabarovsky, E; Kuzmin, I; Lerman, M; Roth, J; Minna, JD			Overexpression of candidate tumor suppressor gene FUS1 isolated from the 3p21.3 homozygous deletion region leads to G1 arrest and growth inhibition of lung cancer cells	ONCOGENE			English	Article						tumor suppressor gene; growth inhibition; lung cancer	HUMAN-CHROMOSOME 3P21.3; LOCUS; IDENTIFICATION; SEARCH	Recently we identified FUS1 as a candidate tumor suppressor gene (TSG) in the 120 kb 3p21.3 critical region contained in nested lung and breast cancer homozygous deletions. Mutation of FUS1 is infrequent in lung cancers which we have confirmed in 40 other primary lung cancers. In addition, we found no evidence for FUS1 promoter region methylation. Because haplo-insufficiency or low expression of Fus1 may play a role in lung tumorigenesis, we tested the effect of exogenously induced overexpression of Fus1 protein and found 60-80% inhibition of colony formation for non-small cell lung cancer lines NCI-H1299 (showing allele loss for FUS1) and NCI-H322 (containing only a mutated FUS1 allele) in vitro. By contrast, a similar level of expression of a tumor-acquired mutant form of FUS1 protein did not significantly suppress colony formation. Also, induced expression of Fus1 under the control of an Ecdysone regulated promoter decreased colony formation 75%, increased the doubling time twofold, and arrested H1299 cells in G1. In conclusion, our data are consistent with the hypothesis that FUS1 may function as a 3p21.3 TSG, warranting further studies of its function in the pathogenesis of human cancers.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Sect Thorac Mol Oncol, Houston, TX 77030 USA; Nagoya Univ, Sch Med, Dept Clin Prevent Med, Nagoya, Aichi 466, Japan; Natl Canc Ctr, Res Inst, Div Biol, Tokyo 104, Japan; Karolinska Inst, MTC, Stockholm, Sweden; Karolinska Inst, CGR, Stockholm, Sweden; Frederick Canc Res & Dev Ctr, Immunobiol Lab, Frederick, MD USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; UTMD Anderson Cancer Center; Nagoya University; National Cancer Center - Japan; Karolinska Institutet; Karolinska Institutet; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Minna, JD (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 6000 Harry Hines Blvd,NB8-206, Dallas, TX 75390 USA.		Kashuba, Vladimir/AAO-7742-2020; Kondo, Masashi/I-7378-2014; Zabarovsky, Eugene R/A-6645-2010; Kashuba, Vladimir I/N-3732-2017; Sekido, Yoshitaka/P-9756-2015	Kashuba, Vladimir I/0000-0001-9416-8282; Sekido, Yoshitaka/0000-0002-2428-3848	NATIONAL CANCER INSTITUTE [R01CA071618, P50CA070907] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA70907, CA 71618] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Cook WD, 2000, ONCOGENE, V19, P3434, DOI 10.1038/sj.onc.1203653; DALY MC, 1993, ONCOGENE, V8, P1721; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Forgacs E, 1998, ONCOGENE, V17, P1557, DOI 10.1038/sj.onc.1202070; HIBI K, 1992, ONCOGENE, V7, P445; KILLARY AM, 1992, P NATL ACAD SCI USA, V89, P10877, DOI 10.1073/pnas.89.22.10877; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOK K, 1994, CANCER RES, V54, P4183; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Lerman MI, 2000, CANCER RES, V60, P6116; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; Roche J, 1996, ONCOGENE, V12, P1289; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Wei MH, 1996, CANCER RES, V56, P1487; WHANGPENG J, 1982, CANCER GENET CYTOGEN, V6, P119, DOI 10.1016/0165-4608(82)90077-2; Wistuba II, 2000, CANCER RES, V60, P1949; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504; Zochbauer-Muller S, 2001, CANCER RES, V61, P249	21	68	80	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2001	20	43					6258	6262		10.1038/sj.onc.1204832	http://dx.doi.org/10.1038/sj.onc.1204832			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593436				2022-12-17	WOS:000171206300019
J	Marotta, A; Tan, C; Gray, V; Malik, S; Gallinger, S; Sanghera, J; Dupuis, B; Owen, D; Dedhar, S; Salh, B				Marotta, A; Tan, C; Gray, V; Malik, S; Gallinger, S; Sanghera, J; Dupuis, B; Owen, D; Dedhar, S; Salh, B			Dysregulation of integrin-linked kinase (ILK) signaling in colonic polyposis	ONCOGENE			English	Article						intestinal polyposis; integrin-linked kinase (ILK); non-steroidal anti-inflammatory drugs (NSAIDs); adenomatous polyposis coli (APC); beta-catenin	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PROSTATE-CANCER CELLS; CYCLIN D1 GENE; BETA-CATENIN; PROTEIN-KINASE; CYCLOOXYGENASE-2 INHIBITOR; ANTICANCER AGENTS; SULINDAC SULFIDE; UP-REGULATION; APC	Mutation of the adenomatous polyposis coli (APC) gene and the subsequent dysregulation of beta -catenin are well-documented abnormalities in familial adenomatous polyposis (FAP), as well as sporadic polyposis. Intriguingly, overexpression of the integrin-linked kinase (ILK) has been shown to modulate beta -catenin subcellular localization and function. However, the significance of this finding for human carcinogenesis remains unclear. Here, we report the increased biochemical activity and expression of ILK protein in polyps from FAP patients. Furthermore, dramatic increases in ILK immunoreactivity were observed in all abnormal crypts from sporadic polyps, when compared with the normal appearing crypts within the same resected specimens. As sulindac and aspirin are the two most important therapeutic/chemopreventative agents demonstrated in colorectal carcinogenesis, in both humans and animals, further investigation revealed that these non-steroidal antiinflammatory drugs (NSAIDs) target ILK and ILK-mediated events in vivo. These include inhibition of, both the biochemical activation of ILK, inhibition of serine 9 GSK3 beta phosphorylation and the enhancement of TCF-4 transcriptional activity. In conclusion, ILK protein hyperexpression appears to be an early event in colonic polyposis. Additionally, ILK signaling is shown to undergo modulation by sulindac (and aspirin) for the first time, indicating that it is likely to be one of the targets affected by these agents in vivo.	Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada; British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada; Thunderbay Reg Hosp, Thunder Bay, ON P7E 1G6, Canada; Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada; Kinetek Pharmaceut Inc, Vancouver, BC V6P 6PA, Canada; Vancouver Gen Hosp, Vancouver, BC V5Z 1M9, Canada	University of British Columbia; British Columbia Cancer Agency; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University of British Columbia	Salh, B (corresponding author), Jack Bell Res Ctr, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.		Gallinger, Steven/E-4575-2013	Dedhar, Shoukat/0000-0003-4355-1657				Akashi H, 2000, INT J CANCER, V88, P873, DOI 10.1002/1097-0215(20001215)88:6<873::AID-IJC6>3.0.CO;2-B; Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; Barker N, 2000, ADV CANCER RES, V77, P1; BeazerBarclay Y, 1996, CARCINOGENESIS, V17, P1757, DOI 10.1093/carcin/17.8.1757; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; Chiu CH, 1997, CANCER RES, V57, P4267; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397; Iwamoto M, 2000, CARCINOGENESIS, V21, P1935, DOI 10.1093/carcin/21.11.1935; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; OConnor PM, 1997, CANCER RES, V57, P4285; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; PIAZZA GA, 1995, CANCER RES, V55, P3110; Piazza GA, 1997, CANCER RES, V57, P2909; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Reddy BS, 1996, CANCER RES, V56, P4566; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Salh B, 1999, ANTICANCER RES, V19, P731; SHIFF SJ, 1995, J CLIN INVEST, V96, P491, DOI 10.1172/JCI118060; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Sparks AB, 1998, CANCER RES, V58, P1130; Tan C, 2001, ONCOGENE, V20, P133, DOI 10.1038/sj.onc.1204052; Troussard AA, 2000, ONCOGENE, V19, P5444, DOI 10.1038/sj.onc.1203928; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; Yamamoto Y, 1999, J BIOL CHEM, V274, P27307, DOI 10.1074/jbc.274.38.27307; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	45	68	74	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2001	20	43					6250	6257		10.1038/sj.onc.1204791	http://dx.doi.org/10.1038/sj.onc.1204791			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593435				2022-12-17	WOS:000171206300018
J	Kanzler, S; Meyer, E; Lohse, AW; Schirmacher, P; Henninger, J; Galle, PR; Blessing, M				Kanzler, S; Meyer, E; Lohse, AW; Schirmacher, P; Henninger, J; Galle, PR; Blessing, M			Hepatocellular expression of a dominant-negative mutant TGF-beta type II receptor accelerates chemically induced hepatocarcinogenesis	ONCOGENE			English	Article						transforming growth factor-beta; hepatocarcinogenesis; transgenic mice; TGF-beta receptor; tumor suppressor	GROWTH-FACTOR-BETA; C-REACTIVE PROTEIN; TRANSGENIC MICE; TRANSFORMING GROWTH-FACTOR-BETA-1; MICROSATELLITE INSTABILITY; FACTOR (TGF)-ALPHA; MESSENGER-RNA; CANCER CELLS; RAT-LIVER; GENE	The potent growth-inhibitory activity of cytokines of the transforming growth factor-beta (TGF-beta) superfamily and their widespread expression in epithelia suggest that they may play an important role in the maintenance of epithetial homeostasis. To analyse TGF-beta mediated tumor suppressor activity in the liver, we generated transgenic mice overexpressing a dominant negative type II TGF-beta receptor in hepatocytes under control of the regulatory elements of the human C-reactive protein gene promoter. Transgenic animals exhibited constitutive and liver-specific transgene expression. The functional inactivation of the TGF-beta signaling pathway in transgenic hepatocytes was shown by reduced TGF-beta induced inhibition of DNA synthesis in primary hepatocyte cultures. Liver morphology and spontaneous tumorigenesis were unchanged in transgenic mice suggesting that interruption of the signaling of all three isoforms of TGF-beta in hepatocytes does not disturb tissue homeostasis in the liver under physiological conditions. However, following initiation with the carcinogen diethylnitrosamine and tumor-promotion with phenobarbital transgenic mice exhibited a moderate albeit significant increase in the incidence, size and multiplicity of both preneoplastic tissue lesions in the liver and of hepatocellular carcinomas. These results give in vivo evidence for a tumor suppressor activity of the endogeneous TGF-beta system in the liver during chemical hepatocarcinogenesis.	Johannes Gutenberg Univ Mainz, Dept Med, D-55131 Mainz, Germany; Univ Cologne, Dept Pathol, D-50931 Cologne, Germany	Johannes Gutenberg University of Mainz; University of Cologne	Blessing, M (corresponding author), Johannes Gutenberg Univ Mainz, Dept Med, D-55131 Mainz, Germany.	Blessing@mail.uni-mainz.de	Galle, Peter/ABE-2872-2021; Galle, Peter R/T-5292-2018	Galle, Peter/0000-0001-8294-0992; Galle, Peter R/0000-0001-8294-0992				Abou-Shady M, 1999, AM J SURG, V177, P209, DOI 10.1016/S0002-9610(99)00012-4; ALEXANDROW MG, 1995, CANCER RES, V55, P3928; Amendt C, 1998, ONCOGENE, V17, P25, DOI 10.1038/sj.onc.1202161; ARRICK BA, 1992, J CELL BIOL, V118, P715, DOI 10.1083/jcb.118.3.715; BEDOSSA P, 1995, HEPATOLOGY, V21, P760, DOI 10.1016/0270-9139(95)90530-8; Bottinger EP, 1996, P NATL ACAD SCI USA, V93, P5877, DOI 10.1073/pnas.93.12.5877; Bottinger EP, 1997, CANCER RES, V57, P5564; Bottinger EP, 1997, EMBO J, V16, P2621, DOI 10.1093/emboj/16.10.2621; BRAND T, 1993, J BIOL CHEM, V268, P11500; Branton MH, 1999, MICROBES INFECT, V1, P1349, DOI 10.1016/S1286-4579(99)00250-6; BRAUN L, 1988, P NATL ACAD SCI USA, V85, P1539, DOI 10.1073/pnas.85.5.1539; Cardillo MR, 2000, ANAL QUANT CYTOL, V22, P1; Chang J, 1997, CANCER RES, V57, P2856; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CILIBERTO G, 1987, EMBO J, V6, P4017, DOI 10.1002/j.1460-2075.1987.tb02745.x; Cook T, 1998, J BIOL CHEM, V273, P25929, DOI 10.1074/jbc.273.40.25929; Dietmaier W, 1997, CANCER RES, V57, P4749; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Factor VM, 1997, CANCER RES, V57, P2089; Factor VM, 1998, J BIOL CHEM, V273, P15846, DOI 10.1074/jbc.273.25.15846; GARRIGUEANTAR L, 1995, CANCER RES, V55, P3982; Gitelman SE, 1997, MAMM GENOME, V8, P212, DOI 10.1007/s003359900391; Glick AB, 1997, CANCER RES, V57, P2079; Gobbi H, 2000, HISTOPATHOLOGY, V36, P168; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; Grasl-Kraupp B, 1998, HEPATOLOGY, V28, P717, DOI 10.1002/hep.510280318; HADDOW S, 1991, ONCOGENE, V6, P1465; HADDOW S, 1991, ONCOGENE, V6, P2377; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hogan B., 1986, MANIPULATING MOUSE E; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; ITO N, 1991, CANCER RES, V51, P4080; KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151; Kanzler S, 1999, AM J PHYSIOL-GASTR L, V276, pG1059, DOI 10.1152/ajpgi.1999.276.4.G1059; Kelly DL, 1999, ANTICANCER RES, V19, P4791; Kim IY, 1996, CANCER RES, V56, P44; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; KISO S, 1994, HEPATOLOGY, V20, P1303, DOI 10.1016/0270-9139(94)90772-2; Kiss A, 1997, CLIN CANCER RES, V3, P1059; Knaus PI, 1996, MOL CELL BIOL, V16, P3480; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; Lim IK, 1999, MOL CARCINOGEN, V26, P83, DOI 10.1002/(SICI)1098-2744(199910)26:2<83::AID-MC3>3.3.CO;2-W; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Lowsky R, 2000, BLOOD, V95, P1767, DOI 10.1182/blood.V95.5.1767.005k07_1767_1772; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MURPHY C, 1995, J BIOL CHEM, V270, P704, DOI 10.1074/jbc.270.2.704; MYEROFF LL, 1995, CANCER RES, V55, P5545; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; PITOT HC, 1987, NONGENOTOXIC MECH CA, P41; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Ribeiro A, 1999, HEPATOLOGY, V30, P1490, DOI 10.1002/hep.510300620; Ruether Ulrich, 1993, Oncogene, V8, P87; Russell CE, 1999, MOL CELL ENDOCRINOL, V148, P129, DOI 10.1016/S0303-7207(98)00226-3; Saeki A, 2000, CANCER, V88, P1025, DOI 10.1002/(SICI)1097-0142(20000301)88:5<1025::AID-CNCR11>3.0.CO;2-U; Salvucci M, 1999, ONCOGENE, V18, P181, DOI 10.1038/sj.onc.1202279; SANDERSON N, 1995, P NATL ACAD SCI USA, V92, P2572, DOI 10.1073/pnas.92.7.2572; Santoni-Rugiu E, 1999, AM J PATHOL, V154, P1693, DOI 10.1016/S0002-9440(10)65425-9; Shima Y, 1999, HEPATOLOGY, V30, P1215, DOI 10.1002/hep.510300503; Shin KH, 2000, CLIN CANCER RES, V6, P536; Sugiyama A, 1997, BIOCHEM BIOPH RES CO, V238, P539, DOI 10.1006/bbrc.1997.7338; Teramoto T, 1998, BIOCHEM BIOPH RES CO, V251, P56, DOI 10.1006/bbrc.1998.9411; THORGEIRSSON SS, 1997, ARCH TOXICOL, V19, P3359; Wang XJ, 1997, P NATL ACAD SCI USA, V94, P2386, DOI 10.1073/pnas.94.6.2386; WHITEHEAD AS, 1983, SCIENCE, V221, P69, DOI 10.1126/science.6857266; WU SP, 1993, CELL GROWTH DIFFER, V4, P115	71	68	72	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 16	2001	20	36					5015	5024		10.1038/sj.onc.1204544	http://dx.doi.org/10.1038/sj.onc.1204544			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526486				2022-12-17	WOS:000170439800011
J	Yu, HH; Zisch, AH; Dodelet, VC; Pasquale, EB				Yu, HH; Zisch, AH; Dodelet, VC; Pasquale, EB			Multiple signaling interactions of Abl and Arg kinases with the EphB2 receptor	ONCOGENE			English	Article						protein tyrosine kinase; axon guidance; actin cytoskeleton	PROTEIN-TYROSINE KINASE; GROWTH-FACTOR RECEPTOR; CHRONIC MYELOGENOUS LEUKEMIA; CENTRAL-NERVOUS-SYSTEM; C-ABL; AUTOPHOSPHORYLATION SITE; NEURITE OUTGROWTH; LIGAND ACTIVATION; AXON GUIDANCE; VISUAL-SYSTEM	The Eph family of receptor tyrosine kinases and the Abl family of non-receptor tyrosine kinases have both been implicated in tissue morphogenesis, They regulate the organization of the actin cytoskeleton in the developing nervous system and participate in signaling pathways involved in axon growth, Both Eph receptors and Abl are localized in the neuronal growth cone, suggesting that they play a role in axon pathfinding. Two-hybrid screens identified regions of Abl and Arg that bind to the EphB2 and EphA4 receptors, suggesting a novel signaling connection involving the two kinase families. The association of full-length Abl and Arg with EphB2 was confirmed by co-immunoprecipitation and found to involve several distinct protein interactions. The SH2 domains of Abl and Arg bind to tyrosine-phosphorylated motifs in the juxtamembrane region of EphB2, A second, phosphorylation-independent interaction with EphB2 involves non-conserved sequences in the C-terminal tails of Abl and Arg, A third interaction between Abl and EphB2 is probably mediated by an intermediary protein because it requires tyrosine phosphorylation of EphB2, but not the binding sites for the Abl SH2 domain. The connection between EphB2 and Abl/Arg appears to be reciprocal. Activated EphB2 causes tyrosine phosphorylation of Abl and Arg, and vice vel sa. Interestingly, treatment of COS cells and B35 neuronal-like cells with ephrin-B1 to activate endogenous EphB2 decreased the kinase activity of endogenous Abl, These data are consistent,vith the opposite effects that Eph receptors and Abl have on neurite ougrowth and suggest that Eph receptors and Abl family kinases have shared signaling activities.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Pasquale, EB (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	elenap@burnham.org			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD026351, R01HD026351, P01HD025938] Funding Source: NIH RePORTER; NICHD NIH HHS [HD26351, HD25938] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Becker E, 2000, MOL CELL BIOL, V20, P1537, DOI 10.1128/MCB.20.5.1537-1545.2000; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BOULTER CA, 1988, EXP CELL RES, V179, P214, DOI 10.1016/0014-4827(88)90360-6; Bruckner K, 1998, CURR OPIN NEUROBIOL, V8, P375, DOI 10.1016/S0959-4388(98)80064-0; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; Comer AR, 1998, MOL CELL BIOL, V18, P152, DOI 10.1128/MCB.18.1.152; Cong F, 1999, MOL CELL BIOL, V19, P8314; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; Dalva MB, 2000, CELL, V103, P945, DOI 10.1016/S0092-8674(00)00197-5; Dodelet VC, 1999, J BIOL CHEM, V274, P31941, DOI 10.1074/jbc.274.45.31941; Dottori M, 1998, P NATL ACAD SCI USA, V95, P13248, DOI 10.1073/pnas.95.22.13248; Duttweiler HM, 1996, TRENDS GENET, V12, P340, DOI 10.1016/S0168-9525(96)80008-4; Ellis C, 1996, ONCOGENE, V12, P1727; Feldheim DA, 1998, NEURON, V21, P1303, DOI 10.1016/S0896-6273(00)80650-9; Feldheim DA, 2000, NEURON, V25, P563, DOI 10.1016/S0896-6273(00)81060-0; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Frisen J, 1998, NEURON, V20, P235, DOI 10.1016/S0896-6273(00)80452-3; GERTLER FB, 1990, SCIENCE, V248, P857, DOI 10.1126/science.2188361; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; GOFF SP, 1985, P SOC EXP BIOL MED, V179, P403; Helmbacher F, 2000, DEVELOPMENT, V127, P3313; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; HILL KK, 1995, GENETICS, V141, P595; Hock B, 1998, ONCOGENE, V17, P255, DOI 10.1038/sj.onc.1201907; Holash JA, 1995, DEV BIOL, V172, P683, DOI 10.1006/dbio.1995.8039; Holash JA, 1997, DEV BIOL, V182, P256, DOI 10.1006/dbio.1996.8496; Holder N, 1999, DEVELOPMENT, V126, P2033; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; Huynh-Do U, 1999, EMBO J, V18, P2165, DOI 10.1093/emboj/18.8.2165; Kalo MS, 1999, CELL TISSUE RES, V298, P1, DOI 10.1007/PL00008807; Koch A, 2000, FEBS LETT, V469, P72, DOI 10.1016/S0014-5793(00)01242-4; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; KRUH GD, 1986, SCIENCE, V234, P1545, DOI 10.1126/science.3787260; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; Lanier LM, 1999, NEURON, V22, P313, DOI 10.1016/S0896-6273(00)81092-2; Lewis JM, 1998, J BIOL CHEM, V273, P14225, DOI 10.1074/jbc.273.23.14225; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; Meima L, 1997, MOL CELL NEUROSCI, V9, P314, DOI 10.1006/mcne.1997.0621; Meima L, 1997, EUR J NEUROSCI, V9, P177, DOI 10.1111/j.1460-9568.1997.tb01365.x; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; MULLER AJ, 1993, P NATL ACAD SCI USA, V90, P3457, DOI 10.1073/pnas.90.8.3457; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; Nehme A, 1997, CANCER RES, V57, P3253; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; Orioli D, 1997, TRENDS GENET, V13, P354, DOI 10.1016/S0168-9525(97)01220-1; PANDEY A, 1994, J BIOL CHEM, V269, P30154; PANDEY A, 1995, J BIOL CHEM, V270, P19201, DOI 10.1074/jbc.270.33.19201; Park S, 1997, EMBO J, V16, P3106, DOI 10.1093/emboj/16.11.3106; PASQUALE EB, 1994, DEV BIOL, V163, P491, DOI 10.1006/dbio.1994.1165; Pasquale EB, 1997, CURR OPIN CELL BIOL, V9, P608, DOI 10.1016/S0955-0674(97)80113-5; PASQUALE EB, 1992, J NEUROSCI, V12, P3956; PEREGO R, 1991, ONCOGENE, V6, P1899; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; ROSENBERG N, 1982, CURR TOP MICROBIOL, V101, P95; Salgia R, 1997, J CLIN INVEST, V100, P46, DOI 10.1172/JCI119520; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; SEFTON BM, 1981, P NATL ACAD SCI-BIOL, V78, P1552, DOI 10.1073/pnas.78.3.1552; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SOANS C, 1994, ONCOGENE, V9, P3353; Soans C, 1996, J CELL BIOL, V135, P781, DOI 10.1083/jcb.135.3.781; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; SUPERTIFURGA G, 1995, BIOESSAYS, V17, P321, DOI 10.1002/bies.950170408; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; Wang BL, 1996, ONCOGENE, V13, P193; Wang BL, 1996, ONCOGENE, V13, P1379; Wang JYJ, 1998, CURR OPIN CELL BIOL, V10, P240, DOI 10.1016/S0955-0674(98)80146-4; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WANG JYJ, 1984, CELL, V36, P349; Wills Z, 1999, NEURON, V22, P301, DOI 10.1016/S0896-6273(00)81091-0; WITTE ON, 1980, NATURE, V283, P826, DOI 10.1038/283826a0; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Yano H, 2000, J NEUROSCI RES, V59, P356, DOI 10.1002/(SICI)1097-4547(20000201)59:3<356::AID-JNR9>3.0.CO;2-G; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHU GC, 1994, ONCOGENE, V9, P1379; Zisch AH, 1998, ONCOGENE, V16, P2657, DOI 10.1038/sj.onc.1201823; Zisch AH, 1997, J NEUROSCI RES, V47, P655, DOI 10.1002/(SICI)1097-4547(19970315)47:6<655::AID-JNR12>3.0.CO;2-U; Zisch AH, 2000, ONCOGENE, V19, P177, DOI 10.1038/sj.onc.1203304; Zou JX, 1999, P NATL ACAD SCI USA, V96, P13813, DOI 10.1073/pnas.96.24.13813; Zukerberg LR, 2000, NEURON, V26, P633, DOI 10.1016/S0896-6273(00)81200-3	91	68	71	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2001	20	30					3995	4006		10.1038/sj.onc.1204524	http://dx.doi.org/10.1038/sj.onc.1204524			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494128				2022-12-17	WOS:000169681500008
J	Lara-Pezzi, E; Roche, S; Andrisani, OM; Sanchez-Madrid, F; Lopez-Cabrera, M				Lara-Pezzi, E; Roche, S; Andrisani, OM; Sanchez-Madrid, F; Lopez-Cabrera, M			The hepatitis B virus HBx protein induces adherens junction disruption in a src-dependent manner	ONCOGENE			English	Article						cadherin; catenin; HCC; metastasis; tyrosine phosphorylation	HUMAN HEPATOCELLULAR CARCINOMAS; E-CADHERIN; X-PROTEIN; TRANSGENIC MICE; BETA-CATENIN; CELL-ADHESION; MEDIATED ADHESION; TYROSINE KINASES; GENE-EXPRESSION; LIVER-CANCER	Chronic hepatitis B virus infection is strongly associated with the development of hepatocellular carcinoma (HCC). Epithelial tumors are frequently characterized by loss of cadherin expression or function. Cadherin-dependent adhesion prevents the acquisition of a migratory and invasive phenotype, and loss of its function is itself enough for the progression from adenoma to carcinoma, The HBx protein of hepatitis B virus is thought to contribute to the development of the carcinoma, however, its role in the oncogenic and metastatic processes is far from being fully understood. We report herein the ability of HBx to disrupt intercellular adhesion in three different cell lines stably transfected with an inducible HBx expression vector. The linkage between the actin cytoskeleton and cadherin complex, which is essential for its function, is disrupted in the presence of HBx, as indicated by detergent solubility and immunoprecipitation experiments, In addition, beta -catenin was tyrosine phosphorylated in HBx-expressing cells, Inhibition of the src family of tyrosine kinases resulted in the prevention of the disruption of adherens junctions. These results suggest that HBx is able to disrupt intercellular adhesion in a src-dependent manner, and provide a novel mechanism by which HBx may contribute to the development of HCC.	Hosp Univ Princesa, Unidad Biol Mol, Madrid 28006, Spain; Hosp Univ Princesa, Serv Inmunol, Madrid 28006, Spain; Ctr Rech Biochem Macromol, CNRS, UPR 1086, F-34293 Montpellier 5, France; Purdue Univ, Dept Basic Med Sci, W Lafayette, IN 47907 USA	Hospital de La Princesa; Hospital de La Princesa; Centre National de la Recherche Scientifique (CNRS); Purdue University System; Purdue University; Purdue University West Lafayette Campus	Lopez-Cabrera, M (corresponding author), Hosp Univ Princesa, Unidad Biol Mol, Diego de Leon 62, Madrid 28006, Spain.		Lara-Pezzi, Enrique/E-2350-2015; Sanchez-Madrid, Francisco/M-7889-2016; Cabrera, Manuel López/AAA-5463-2019	Lara-Pezzi, Enrique/0000-0002-2743-1033; Sanchez-Madrid, Francisco/0000-0001-5303-0762; roche, serge/0000-0003-3413-3859; Lopez Cabrera, Manuel/0000-0002-0976-9719; Andrisani, Ourania/0000-0002-6230-0303				Balsamo J, 1996, J CELL BIOL, V134, P801, DOI 10.1083/jcb.134.3.801; Baptista M, 1999, HEPATOLOGY, V29, P946, DOI 10.1002/hep.510290336; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Chisari FV, 2000, AM J PATHOL, V156, P1117, DOI 10.1016/S0002-9440(10)64980-2; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Feitelson MA, 1997, AM J PATHOL, V150, P1141; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; Gottlob K, 1998, CANCER RES, V58, P3566; Gottlob K, 1998, J BIOL CHEM, V273, P33347, DOI 10.1074/jbc.273.50.33347; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Haviv I, 1998, MOL CELL BIOL, V18, P1562, DOI 10.1128/MCB.18.3.1562; Hazan RB, 1998, J BIOL CHEM, V273, P9078, DOI 10.1074/jbc.273.15.9078; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; KOIKE K, 1994, J CLIN INVEST, V94, P44, DOI 10.1172/JCI117343; Kozyraki R, 1996, GASTROENTEROLOGY, V110, P1137, DOI 10.1053/gast.1996.v110.pm8613003; Lara-Pezzi E, 2001, J HEPATOL, V34, P409, DOI 10.1016/S0168-8278(00)00090-8; Lara-Pezzi E, 1998, EMBO J, V17, P7066, DOI 10.1093/emboj/17.23.7066; LARAPEZZI E, 2001, IN PRESS HEPATOLOGY; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; LUDUENA MA, 1977, J CELL PHYSIOL, V91, P119, DOI 10.1002/jcp.1040910112; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; Masaki T, 1998, HEPATOLOGY, V27, P1257, DOI 10.1002/hep.510270511; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Poussin K, 1999, INT J CANCER, V80, P497, DOI 10.1002/(SICI)1097-0215(19990209)80:4<497::AID-IJC3>3.0.CO;2-8; Provost E, 1999, CURR OPIN CELL BIOL, V11, P567, DOI 10.1016/S0955-0674(99)00015-0; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; Schafer DF, 1999, LANCET, V353, P1253, DOI 10.1016/S0140-6736(98)09148-X; Sirma H, 1999, ONCOGENE, V18, P4848, DOI 10.1038/sj.onc.1202867; Slagle BL, 1996, MOL CARCINOGEN, V15, P261, DOI 10.1002/(SICI)1098-2744(199604)15:4<261::AID-MC3>3.0.CO;2-J; SLAGLE BL, 1993, HEPATOLOGY, V18, P757, DOI 10.1002/hep.1840180402; Tarn C, 1999, J BIOL CHEM, V274, P2327, DOI 10.1074/jbc.274.4.2327; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; Tlsty TD, 1998, CURR OPIN CELL BIOL, V10, P647, DOI 10.1016/S0955-0674(98)80041-0; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; Van Nhieu JT, 1999, AM J PATHOL, V155, P703, DOI 10.1016/S0002-9440(10)65168-1; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Yu DY, 1999, J HEPATOL, V31, P123, DOI 10.1016/S0168-8278(99)80172-X; Zondervan PE, 2000, J PATHOL, V192, P207, DOI 10.1002/1096-9896(2000)9999:9999&lt;::AID-PATH690&gt;3.0.CO;2-#	43	68	73	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 7	2001	20	26					3323	3331		10.1038/sj.onc.1204451	http://dx.doi.org/10.1038/sj.onc.1204451			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	441UW	11423982				2022-12-17	WOS:000169248800002
J	Nakamura, K; Yano, H; Schaefer, E; Sabe, HA				Nakamura, K; Yano, H; Schaefer, E; Sabe, HA			Different modes and qualities of tyrosine phosphorylation of Fak and Pyk2 during epithelial-mesenchymal transdifferentiation and cell migration: analysis of specific phosphorylation events using site-directed antibodies	ONCOGENE			English	Article						FAK; Pyk2; tyrosine phosphorylation; EMT; cell migration	FOCAL ADHESION KINASE; GROWTH-FACTOR; ANGIOTENSIN-II; PAXILLIN-ALPHA; SRC KINASE; IN-VITRO; V-SRC; PROTEIN; ACTIVATION; CALCIUM	Integrin signaling is activated during epithelial-mesenchymal transdifferentiation (EMT) and cell migration, processes serving as models for carcinogenesis, We have shown that paxillin and p130Cas become highly tyrosine phosphorylated during these processes in NMuMG cells. Here, we examined the regulation of Fak and Pyk2, kinases implicated in this phosphorylation, Pyk2 became phosphorylated at the major autophosphorylation site (Tyr-402) and the potential Grb2-binding site (Tyr-881) during EMT, In contrast, phosphorylation of Fak at the corresponding autophosphorylation site (Tyr-397) occurred even in sedentary epithelial cells, whereas phosphorylation at Tyr-407 and Tyr-861 was induced during EMT. During cell migration, these phosphorylation events, except Fak Tyr-397, were augmented further, and phosphorylation of Fak Tyr-577 and the corresponding Pyk2 Tyr-580, both within the kinase activation loops, was also induced. In all cases, phosphorylation of the putative Grb2-binding site in Fak (Tyr-925) was almost undetectable, Although Fak and Pyk2 have several phosphorylation sites in common, Tyr-407 and Tyr-861 are unique to Fak, Our results revealed that Fak and Pyk2 are non-equivalent in the tyrosine phosphorylation events and thereby likely to evoke different downstream signaling cascades during EMT and cell migration of NMuMG cells, We also show that Fak Tyr-397 phosphorylation occurs exclusively at the cytoplasm, but not at focal contacts, in the sedentary epithelial cells, In contrast, all other tyrosine phosphorylated forms of Fak and Pyk2 are predominantly localized to focal adhesions and the cell periphery in motile cells, all colocalized with paxillin and p130Cas.	Osaka Biosci Inst, Dept Mol Biol, Osaka 5650874, Japan; BioSource Int, Hopkinton, MA 01748 USA; Kyoto Univ, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Sabe, HA (corresponding author), Osaka Biosci Inst, Dept Mol Biol, 6-2-4 Furuedai, Osaka 5650874, Japan.							Astier A, 1997, J BIOL CHEM, V272, P19719, DOI 10.1074/jbc.272.32.19719; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; Brinson AE, 1998, J BIOL CHEM, V273, P1711, DOI 10.1074/jbc.273.3.1711; Calalb MB, 1996, BIOCHEM BIOPH RES CO, V228, P662, DOI 10.1006/bbrc.1996.1714; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Cazaubon S, 1997, J NEUROSCI, V17, P6203; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dikic I, 1998, J BIOL CHEM, V273, P14301, DOI 10.1074/jbc.273.23.14301; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; EARP HS, 1995, J BIOL CHEM, V270, P28440; Felsch JS, 1998, P NATL ACAD SCI USA, V95, P5051, DOI 10.1073/pnas.95.9.5051; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Herzog H, 1997, GENOMICS, V41, P315, DOI 10.1006/geno.1997.4684; Hiregowdara D, 1997, J BIOL CHEM, V272, P10804; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li X, 1997, J BIOL CHEM, V272, P14341, DOI 10.1074/jbc.272.22.14341; Li X, 1999, J BIOL CHEM, V274, P8917, DOI 10.1074/jbc.274.13.8917; Li X, 1998, J BIOL CHEM, V273, P9361, DOI 10.1074/jbc.273.16.9361; Maruyama T, 1999, ENDOCRINOLOGY, V140, P5982, DOI 10.1210/endo.140.12.7184; Mazaki Y, 1998, J BIOL CHEM, V273, P22435, DOI 10.1074/jbc.273.35.22435; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Nakamura K, 2000, J BIOL CHEM, V275, P27155; Ostergaard HL, 1998, J BIOL CHEM, V273, P5692, DOI 10.1074/jbc.273.10.5692; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; Schaller MD, 1997, J BIOL CHEM, V272, P25319, DOI 10.1074/jbc.272.40.25319; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; SCHLAEPFER DD, 1994, NATURE, V372, P786; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Soltoff SP, 1998, J BIOL CHEM, V273, P2653, DOI 10.1074/jbc.273.5.2653; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Tobe K, 1996, MOL CELL BIOL, V16, P4765; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Yano H, 2000, P NATL ACAD SCI USA, V97, P9076, DOI 10.1073/pnas.97.16.9076; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; Zhang X, 1999, P NATL ACAD SCI USA, V96, P9021, DOI 10.1073/pnas.96.16.9021; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384	48	68	72	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 10	2001	20	21					2626	2635		10.1038/sj.onc.1204359	http://dx.doi.org/10.1038/sj.onc.1204359			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VN	11420674				2022-12-17	WOS:000168652600003
J	He, W; Cao, TY; Smith, DA; Myers, TE; Wang, XJ				He, W; Cao, TY; Smith, DA; Myers, TE; Wang, XJ			Smads mediate signaling of the TGF beta superfamily in normal keratinocytes but are lost during skin chemical carcinogenesis	ONCOGENE			English	Article						keratinocytes; growth inhibition; skin chemical carcinogenesis; transforming growth factor beta; tumor progression	GROWTH-FACTOR-BETA; GROWTH-FACTOR-BETA-1 MESSENGER-RNA; NF-KAPPA-B; TRANSGENIC MICE; MOUSE SKIN; DPC4 GENE; VITAMIN-D; TRANSFORMING GROWTH-FACTOR-BETA-1; TUMOR-SUPPRESSOR; IN-VIVO	The Smads are the signaling mediators of the TGF beta superfamily, In the present study, we examined Smad expression in mouse epidermis and chemically-induced skin tumors. Mutations in Smad2 and -4 genes were also screened. Transcripts of Smad1 through -5 were constantly expressed in the epidermis regardless of changes in TGF beta signaling, state of differentiation and stages of carcinogenesis. Smad7 transcripts were barely detectable in keratinocytes, but were induced by TGF beta1 treatment and in chemically-induced skin tumors. At the protein level, Smad1 was detected throughout the epidermis, whereas Smad2 through -5 exhibited greater levels in suprabasal layers than basal keratinocytes. In cultured keratinocytes, Smad2, -3 and -4 underwent nuclear translocation upon TGF beta1 treatment. Furthermore, nuclear translocation of Smads correlated with decreased BrdU labeling in proliferative keratinocytes. Although no mutations mere detected in the Smad2 and -4 genes in tumors, proteins of Smad1 through -5 were partially or completely lost in carcinomas. These data document that Smads are expressed at high levels in the epidermis and mediate signaling of the TGF beta superfamily. During skin carcinogenesis, loss of Smad1 through -5 and overexpression of Smad7 may contribute to the loss of growth inhibition mediated by TGF beta superfamily members, thus resulting in tumor progression.	Baylor Coll Med, Dept Dermatol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Wang, XJ (corresponding author), Baylor Coll Med, Dept Dermatol, Houston, TX 77030 USA.		Wikramanayake, Tongyu/A-9759-2013		NCI NIH HHS [CA 87849, CA79998] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087849, R01CA079998] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; AKHURST RJ, 1988, NATURE, V331, P363, DOI 10.1038/331363a0; ALDAZ CM, 1987, P NATL ACAD SCI USA, V84, P2029, DOI 10.1073/pnas.84.7.2029; Amendt C, 1998, ONCOGENE, V17, P25, DOI 10.1038/sj.onc.1202161; Barrett MT, 1996, CANCER RES, V56, P4351; BIKLE DD, 1988, ANN NY ACAD SCI, V548, P27, DOI 10.1111/j.1749-6632.1988.tb18790.x; BLESSING M, 1995, TERATOGEN CARCIN MUT, V15, P11, DOI 10.1002/tcm.1770150103; Blessing M, 1996, J CELL BIOL, V135, P227, DOI 10.1083/jcb.135.1.227; BLESSING M, 1993, GENE DEV, V7, P204, DOI 10.1101/gad.7.2.204; Chang H, 1999, DEVELOPMENT, V126, P1631; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Devereux TR, 1997, CARCINOGENESIS, V18, P1751, DOI 10.1093/carcin/18.9.1751; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; FOWLIS DJ, 1992, CELL GROWTH DIFFER, V3, P81; GLICK AB, 1994, GENE DEV, V8, P2429, DOI 10.1101/gad.8.20.2429; Go C, 1999, CANCER RES, V59, P2861; Goto D, 1998, FEBS LETT, V430, P201, DOI 10.1016/S0014-5793(98)00658-9; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hejlik DP, 1997, CANCER RES, V57, P3779; Heldin CH, 1999, NAT CELL BIOL, V1, pE195, DOI 10.1038/70223; Hoque ATMS, 1997, GUT, V40, P120, DOI 10.1136/gut.40.1.120; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Jonson T, 1999, GENE CHROMOSOME CANC, V24, P62, DOI 10.1002/(SICI)1098-2264(199901)24:1<62::AID-GCC9>3.0.CO;2-4; Kawabata M, 1999, J BIOCHEM, V125, P9, DOI 10.1093/oxfordjournals.jbchem.a022273; Kon A, 1999, ONCOGENE, V18, P1837, DOI 10.1038/sj.onc.1202495; Kong XT, 1997, CANCER RES, V57, P3772; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; KRIEG P, 1991, MOL CARCINOGEN, V4, P129, DOI 10.1002/mc.2940040208; Li JM, 1998, NUCLEIC ACIDS RES, V26, P2449, DOI 10.1093/nar/26.10.2449; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; Ma SH, 1997, GENE EXPRESSION, V6, P361; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Moskaluk CA, 1997, DIAGN MOL PATHOL, V6, P85, DOI 10.1097/00019606-199704000-00003; Nadeau A, 1997, J HISTOCHEM CYTOCHEM, V45, P107, DOI 10.1177/002215549704500114; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; PATAMALAI B, 1994, MOL CARCINOGEN, V9, P220, DOI 10.1002/mc.2940090406; ROBERTS AB, 1987, NUCL MED BIOL, V14, P435, DOI 10.1016/0883-2897(87)90020-1; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; ROOP DR, 1987, DIFFERENTIATION, V35, P143, DOI 10.1111/j.1432-0436.1987.tb00162.x; Rougui Z, 1996, J CELL PHYSIOL, V168, P385, DOI 10.1002/(SICI)1097-4652(199608)168:2<385::AID-JCP17>3.0.CO;2-2; Rozenblum E, 1997, CANCER RES, V57, P1731; Rundhaug JE, 1997, MOL CARCINOGEN, V18, P115, DOI 10.1002/(SICI)1098-2744(199702)18:2<115::AID-MC7>3.0.CO;2-F; Schutte M, 1996, CANCER RES, V56, P2527; SELLHEYER K, 1993, P NATL ACAD SCI USA, V90, P5237, DOI 10.1073/pnas.90.11.5237; SHERMAN JH, 1993, MOL CARCINOGEN, V8, P264, DOI 10.1002/mc.2940080409; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Takagi Y, 1996, GASTROENTEROLOGY, V111, P1369, DOI 10.1053/gast.1996.v111.pm8898652; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Uchida K, 1996, CANCER RES, V56, P5583; Ueda T, 1997, GENE CHROMOSOME CANC, V20, P140, DOI 10.1002/(SICI)1098-2264(199710)20:2<140::AID-GCC4>3.0.CO;2-3; Wang XJ, 1999, P NATL ACAD SCI USA, V96, P8483, DOI 10.1073/pnas.96.15.8483; Wang XJ, 1997, P NATL ACAD SCI USA, V94, P2386, DOI 10.1073/pnas.94.6.2386; Wong C, 1999, MOL CELL BIOL, V19, P1821; Yanagi Y, 1999, J BIOL CHEM, V274, P12971, DOI 10.1074/jbc.274.19.12971; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Zavadil J, 1997, LEUKEMIA, V11, P1187, DOI 10.1038/sj.leu.2400750; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4; Zimmerman CM, 1998, J BIOL CHEM, V273, P677, DOI 10.1074/jbc.273.2.677	64	68	77	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2001	20	4					471	483		10.1038/sj.onc.1204117	http://dx.doi.org/10.1038/sj.onc.1204117			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395DB	11313978				2022-12-17	WOS:000166562500007
J	Wang, Q; Zhang, HT; Fishel, R; Greene, MI				Wang, Q; Zhang, HT; Fishel, R; Greene, MI			BRCA1 and cell signaling	ONCOGENE			English	Article						BRCA1; gene transcription; DNA damage repair	TRANSCRIPTION-COUPLED REPAIR; DOUBLE-STRAND BREAKS; DNA-DAMAGE RESPONSE; INTERACT IN-VIVO; GROWTH-ARREST; MISMATCH REPAIR; MEIOTIC CELLS; MYC REPRESSES; GENE GADD45; C-MYC	The breast cancer and ovarian cancer susceptibility gene BRCA1 encodes a nucleoprotein whose mutations or aberrant expression is associated with both inherited and sporadic cancers. Studies over the last 6 years have suggested that BRCA1 may function as a scaffold in the assembly of a multi-protein complex, which plays a role in gene transcription, DNA damage repair, and transcription-coupled DNA damage repair. In this review, we discuss the implications drawn from the studies of BRCA1-interacting proteins and the cellular signaling pathways that may be involved in controlling the functions of BRCA1.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Genet & Mol Biol Program, Philadelphia, PA 19107 USA	University of Pennsylvania; Jefferson University	Wang, Q (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.		Wang, Qiang/N-7310-2015	Wang, Qiang/0000-0001-9409-0251; Zhang, Hongtao/0000-0001-9173-0049	NATIONAL CANCER INSTITUTE [R01CA067007] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA067007] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; Amundson SA, 1998, ONCOGENE, V17, P2149, DOI 10.1038/sj.onc.1202136; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; BENNETT LM, 1995, GENOMICS, V29, P576, DOI 10.1006/geno.1995.9963; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; Constance CM, 1996, MOL CELL BIOL, V16, P3878; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Evans E, 2000, MOL CELL, V5, P789, DOI 10.1016/S1097-2765(00)80319-6; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Felsher DW, 2000, P NATL ACAD SCI USA, V97, P10544, DOI 10.1073/pnas.190327097; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Fishel R, 1998, GENE DEV, V12, P2096, DOI 10.1101/gad.12.14.2096; Fishel R, 1997, CURR OPIN GENET DEV, V7, P105, DOI 10.1016/S0959-437X(97)80117-7; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Gatei M, 2000, CANCER RES, V60, P3299; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Gradia S, 2000, J BIOL CHEM, V275, P3922, DOI 10.1074/jbc.275.6.3922; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Hu YF, 1999, GENE DEV, V13, P637, DOI 10.1101/gad.13.6.637; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Jensen DE, 1999, ANN NY ACAD SCI, V886, P191, DOI 10.1111/j.1749-6632.1999.tb09414.x; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Kleiman FE, 1999, SCIENCE, V285, P1576, DOI 10.1126/science.285.5433.1576; Leadon SA, 1997, CANCER RES, V57, P3784; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; McCormack SJ, 1998, ONCOGENE, V16, P2755, DOI 10.1038/sj.onc.1201804; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1997, AM J HUM GENET, V61, P761, DOI 10.1086/515515; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Ruffner H, 1999, MOL CELL BIOL, V19, P4843; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Russell PA, 2000, INT J CANCER, V87, P317, DOI 10.1002/1097-0215(20000801)87:3<317::AID-IJC2>3.0.CO;2-B; Schlegel BP, 2000, P NATL ACAD SCI USA, V97, P3148, DOI 10.1073/pnas.070452397; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Shao NS, 1996, ONCOGENE, V13, P1; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Tirkkonen M, 1997, CANCER RES, V57, P1222; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; Tomlinson GE, 1998, CANCER RES, V58, P3237; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Wang Y, 2000, GENE DEV, V14, P927; Weaver ZA, 1999, GENE CHROMOSOME CANC, V25, P251, DOI 10.1002/(SICI)1098-2264(199907)25:3<251::AID-GCC7>3.0.CO;2-3; Wong AKC, 1998, ONCOGENE, V17, P2279, DOI 10.1038/sj.onc.1202150; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Yu X, 2000, J BIOL CHEM, V275, P18541, DOI 10.1074/jbc.M909494199; Zhang H, 1999, CANCER RES, V59, P3021; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhang HT, 1997, ONCOGENE, V14, P2863, DOI 10.1038/sj.onc.1201140; Zhang HT, 2000, DNA CELL BIOL, V19, P253, DOI 10.1089/10445490050021168; Zheng WX, 2000, GYNECOL ONCOL, V76, P294, DOI 10.1006/gyno.1999.5664; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	83	68	70	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 11	2000	19	53					6152	6158		10.1038/sj.onc.1203974	http://dx.doi.org/10.1038/sj.onc.1203974			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	387KH	11156529				2022-12-17	WOS:000166121400009
J	Hannan, KM; Kennedy, BK; Cavanaugh, AH; Hannan, RD; Hirschler-Laszkiewicz, I; Jefferson, LS; Rothblum, LI				Hannan, KM; Kennedy, BK; Cavanaugh, AH; Hannan, RD; Hirschler-Laszkiewicz, I; Jefferson, LS; Rothblum, LI			RNA polymerase I transcription in confluent cells: Rb downregulates rDNA transcription during confluence-induced cell cycle arrest	ONCOGENE			English	Article						retinoblastoma protein; ribosomal RNA; transcription; confluence; cell cycle	RIBOSOMAL DNA-TRANSCRIPTION; RETINOBLASTOMA GENE-PRODUCT; UPSTREAM BINDING-FACTOR; FACTOR-TIF-IA; FACTOR UBF; INITIATION-FACTOR; CARDIOMYOCYTE HYPERTROPHY; NEONATAL CARDIOMYOCYTES; C-FOS; PROMOTER	When 3T6 cells are confluent, they withdraw from the cell cycle. Concomitant with cell cycle arrest significant reduction in RNA polymerase I transcription (80% decrease at 100% confluence) is observed. In the present study, we examined mechanism(s) through which transcription of the ribosomal genes is coupled to cell cycle arrest induced by cell density. Interestingly with an increase in cell density (from 3-43% confluence), a significant accumulation in the cellular content of hyperphosphorylated Rb was observed. As cell density increased further, the hypophosphorylated form of Rb became predominant and accumulated in the nucleoli, Co-immunoprecipitation experiments demonstrated there was also a significant rise in the amount of hypophosphorylated Rb associated with the rDNA transcription factor UBF, This increased interaction between Rb and UBF correlated with the reduced rate of rDNA transcription. Furthermore, overexpression of recombinant Rb inhibited UBF-dependent activation of transcription from a cotransfected rDNA reporter in either confluent or exponential cells. The amounts or activities of the rDNA transcription components we examined did not significantly change with cell cycle arrest. Although the content of PAF53, a polymerase associated factor was altered marginally (decreased 38%), the time course and magnitude of the decrease did not correlate with the reduced rate of rDNA transcription. The results presented support a model wherein regulation of the binding of UBF to Rb and, perhaps the cellular content of PAF53, are components of the mechanism through which cell cycle and rDNA transcription are linked.	Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA; Massachusetts Gen Hosp, Ctr Canc, Dept Mol Oncol, Charlestown, MA 02129 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Harvard University; Massachusetts General Hospital	Rothblum, LI (corresponding author), Penn State Univ, Coll Med, Sigfried & Janet Weis Ctr Res, Henry Hood Res Program, Danville, PA 17822 USA.			Hannan, Ross/0000-0002-2166-4493; Hannan, Katherine/0000-0003-4186-8167; Kennedy, Brian/0000-0002-5754-1874	NIDDK NIH HHS [DK15658, DK13499] Funding Source: Medline; NIGMS NIH HHS [GM48991] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK013499, R01DK013499, R01DK015658] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alberts B, 1994, MOL BIOL CELL; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BECKMANN H, 1995, SCIENCE, V270, P1506, DOI 10.1126/science.270.5241.1506; BRUN RP, 1994, MOL CELL BIOL, V14, P5010, DOI 10.1128/MCB.14.7.5010; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; CAVANAUGH AH, 1984, P NATL ACAD SCI-BIOL, V81, P718, DOI 10.1073/pnas.81.3.718; CESARONE CF, 1979, ANAL BIOCHEM, V100, P188, DOI 10.1016/0003-2697(79)90131-3; COBRINIK D, 1992, TRENDS BIOCHEM SCI, V17, P312, DOI 10.1016/0968-0004(92)90443-D; DOREE M, 1994, FASEB J, V8, P1114, DOI 10.1096/fasebj.8.14.7958616; GLIBETIC M, 1995, J BIOL CHEM, V270, P4209, DOI 10.1074/jbc.270.9.4209; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HAGLUND RE, 1987, MOL CELL BIOCHEM, V73, P11; HAMEL PA, 1992, TRENDS GENET, V8, P180, DOI 10.1016/0168-9525(92)90221-O; Hanada K, 1996, EMBO J, V15, P2217, DOI 10.1002/j.1460-2075.1996.tb00575.x; HANNAN KM, 1999, UNPUB ONCOGENE; Hannan KM, 1998, FRONT BIOSCI, V3, P376, DOI [10.2741/A282, DOI 10.2741/A282]; Hannan R, 1999, NUCLEIC ACIDS RES, V27, P1205, DOI 10.1093/nar/27.4.1205; HANNAN RD, 1995, J BIOL CHEM, V270, P8290, DOI 10.1074/jbc.270.14.8290; Hannan RD, 1996, J BIOL CHEM, V271, P3213, DOI 10.1074/jbc.271.6.3213; HANNAN RD, 1995, CARDIOVASC RES, V30, P501, DOI 10.1016/S0008-6363(95)00095-X; Hannan RD, 1996, P NATL ACAD SCI USA, V93, P8750, DOI 10.1073/pnas.93.16.8750; Hannan RD, 1998, J BIOL CHEM, V273, P1257, DOI 10.1074/jbc.273.2.1257; HANNAN RD, 1993, J MOL CELL CARDIOL, V25, P1137, DOI 10.1006/jmcc.1993.1127; Heix J, 1998, EMBO J, V17, P7373, DOI 10.1093/emboj/17.24.7373; Hempel WM, 1996, MOL CELL BIOL, V16, P557; Kihm AJ, 1998, P NATL ACAD SCI USA, V95, P14816, DOI 10.1073/pnas.95.25.14816; KUHN A, 1994, EMBO J, V13, P416, DOI 10.1002/j.1460-2075.1994.tb06276.x; LARSON DE, 1993, P NATL ACAD SCI USA, V90, P7933, DOI 10.1073/pnas.90.17.7933; LEARNED RM, 1985, MOL CELL BIOL, V5, P1358, DOI 10.1128/MCB.5.6.1358; Luyken J, 1996, CIRC RES, V78, P354, DOI 10.1161/01.RES.78.3.354; MAHAJAN PB, 1990, J BIOL CHEM, V265, P16225; MAUCK JC, 1973, P NATL ACAD SCI USA, V70, P2819, DOI 10.1073/pnas.70.10.2819; MIESFELD R, 1984, MOL CELL BIOL, V4, P221, DOI 10.1128/MCB.4.2.221; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MISHIMA Y, 1982, NUCLEIC ACIDS RES, V10, P6659, DOI 10.1093/nar/10.21.6659; MOSS T, 1995, PROG NUCLEIC ACID RE, V50, P25, DOI 10.1016/S0079-6603(08)60810-7; NEVINS JR, 1992, SCIENCE, V258, P424; OMAHONY DJ, 1991, P NATL ACAD SCI USA, V88, P3180, DOI 10.1073/pnas.88.8.3180; OMAHONY DJ, 1992, J BIOL CHEM, V267, P35; PALMER TD, 1993, NUCLEIC ACIDS RES, V21, P3451, DOI 10.1093/nar/21.15.3451; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PAULE MR, 1994, TRANSCRIPTION MECH R; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SCHNAPP A, 1990, EMBO J, V9, P2857, DOI 10.1002/j.1460-2075.1990.tb07475.x; SCHNAPP A, 1993, MOL CELL BIOL, V13, P6723, DOI 10.1128/MCB.13.11.6723; SCHNAPP G, 1994, EMBO J, V13, P190, DOI 10.1002/j.1460-2075.1994.tb06248.x; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Smith S. David, 1993, Gene Expression, V3, P229; SMITH SD, 1990, MOL CELL BIOL, V10, P3105, DOI 10.1128/MCB.10.6.3105; Voit R, 1999, EMBO J, V18, P1891, DOI 10.1093/emboj/18.7.1891; Voit R, 1997, MOL CELL BIOL, V17, P4230, DOI 10.1128/MCB.17.8.4230; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x	52	68	68	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 20	2000	19	31					3487	3497		10.1038/sj.onc.1203690	http://dx.doi.org/10.1038/sj.onc.1203690			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337FJ	10918607				2022-12-17	WOS:000088346500005
J	Gandarillas, A; Davies, D; Blanchard, JM				Gandarillas, A; Davies, D; Blanchard, JM			Normal and c-Myc-promoted human keratinocyte differentiation both occur via a novel cell cycle involving cellular growth and endoreplication	ONCOGENE			English	Article						epidermis; mitosis; cell size; flow cytometry; cell fate; endoreduplication	EPIDERMAL STEM-CELLS; TERMINAL DIFFERENTIATION; PATTERN-FORMATION; DNA-REPLICATION; TARGET GENES; IN-VITRO; EXPRESSION; APOPTOSIS; PROLIFERATION; INDUCTION	The relationship between cell cycle and differentiation in human keratinocytes is poorly understood, It is believed that keratinocytes suppress DNA replication and cell cycle arrest in G0 before they initiate terminal differentiation, However, a temporal separation between both events has not been established. Moreover, c-Myc promotes keratinocyte differentiation without causing cell cycle arrest. To address these paradoxes we have analysed cell cycle control during normal and c-Myc-promoted differentiation. Continuous activation of c-Myc or initiation of terminal differentiation results in a block of G2/M, cellular growth, endoreplication and polyploidy. Keratinocytes abandon G1, continue replicating DNA as they differentiate terminally and become polyploid. In fact, simply blocking mitosis with nocodazole resulted in increased cell size, terminal differentiation and endoreplication. This indicates that terminal differentiation associates with defective cell cycle progression and provides a novel insight into c-Myc biology.	CNRS, Inst Genet Mol, F-34293 Montpellier 5, France; Imperial Canc Res Fund, FACS Lab, London WC2A 3PX, England	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Cancer Research UK	Gandarillas, A (corresponding author), CNRS, Inst Genet Mol, F-34293 Montpellier 5, France.			Davies, Derek/0000-0002-6977-4181				ADAMS JC, 1989, NATURE, V340, P307, DOI 10.1038/340307a0; Amati Bruno, 1998, Frontiers in Bioscience, V3, pD250; BANKSSCHLEGEL S, 1981, J CELL BIOL, V90, P732, DOI 10.1083/jcb.90.3.732; BATACSORGO Z, 1993, J EXP MED, V178, P1271, DOI 10.1084/jem.178.4.1271; BenBassat H, 1997, CANCER RES, V57, P3741; Chicurel ME, 1998, CURR OPIN CELL BIOL, V10, P232, DOI 10.1016/S0955-0674(98)80145-2; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; Dang CV, 1999, MOL CELL BIOL, V19, P1; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; DOVER R, 1987, J INVEST DERMATOL, V89, P349, DOI 10.1111/1523-1747.ep12471751; EDGAR B, 1995, CURR OPIN CELL BIOL, V7, P815, DOI 10.1016/0955-0674(95)80065-4; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; FUCHS E, 1993, J CELL SCI, P197; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; Gandarillas A, 1999, EXP DERMATOL, V8, P71, DOI 10.1111/j.1600-0625.1999.tb00350.x; Gandarillas A, 2000, EXP GERONTOL, V35, P53, DOI 10.1016/S0531-5565(99)00088-1; GANDARILLAS A, 1995, ONCOGENE, V11, P1403; Grafi G, 1998, EXP CELL RES, V244, P372, DOI 10.1006/excr.1998.4213; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; HALL PA, 1989, DEVELOPMENT, V106, P619; Harvat BL, 1998, J CELL SCI, V111, P1185; HASHIRO M, 1991, BIOCHEM BIOPH RES CO, V174, P287, DOI 10.1016/0006-291X(91)90518-C; Hauser PJ, 1997, CELL GROWTH DIFFER, V8, P203; Hawkins NC, 1996, DEVELOPMENT, V122, P281; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HOFFMAN R, 1989, BLOOD, V74, P1196; Hudson DL, 1996, INT J CANCER, V66, P457, DOI 10.1002/(SICI)1097-0215(19960516)66:4<457::AID-IJC8>3.0.CO;2-V; Hulskamp M, 1999, INT REV CYTOL, V186, P147; Hurlin PJ, 1995, ONCOGENE, V11, P2487; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; JACK EM, 1990, HEPATOLOGY, V11, P286, DOI 10.1002/hep.1840110220; JACKSTON LA, 1999, CELL, V98, P779; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; Judware R, 1997, ONCOGENE, V14, P1341, DOI 10.1038/sj.onc.1200955; KARTASOVA T, 1992, MOL CARCINOGEN, V6, P18, DOI 10.1002/mc.2940060105; KIRK D, 1980, CELL BIOL INT REP, V4, P83, DOI 10.1016/0309-1651(80)90013-2; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; LAVKER RM, 1983, J INVEST DERMATOL, V81, pS121, DOI 10.1111/1523-1747.ep12540880; Li Q, 1999, MOL CELL BIOL, V19, P5339; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Martinez LA, 1999, ONCOGENE, V18, P397, DOI 10.1038/sj.onc.1202300; MEYEROWITZ EM, 1994, CURR OPIN GENET DEV, V4, P602, DOI 10.1016/0959-437X(94)90079-I; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Morasso MI, 1996, J CELL BIOL, V135, P1879, DOI 10.1083/jcb.135.6.1879; NAKATANI S, 1992, ARCH DERMATOL RES, V284, P349, DOI 10.1007/BF00372038; Neufeld TP, 1998, CURR OPIN CELL BIOL, V10, P784, DOI 10.1016/S0955-0674(98)80122-1; ORMEROD EM, 1990, FLOW CYTOMETRY PRACT, P69; Paramio JM, 1999, MOL CELL BIOL, V19, P3086; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; PENNEYS NS, 1970, ARCH DERMATOL, V101, P323, DOI 10.1001/archderm.101.3.323; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PINKUS H, 1966, ARCH DERMATOL, V94, P351, DOI 10.1001/archderm.94.3.351; REGNIER M, 1986, J INVEST DERMATOL, V87, P472, DOI 10.1111/1523-1747.ep12455517; REISS M, 1987, CANCER RES, V47, P6705; Rheinwald JG., 1989, CELL GROWTH DIVISION, P81; Schuhmacher M, 1999, CURR BIOL, V9, P1255, DOI 10.1016/S0960-9822(99)80507-7; Solari F, 1996, J CELL SCI, V109, P1203; Traas J, 1998, CURR OPIN PLANT BIOL, V1, P498, DOI 10.1016/S1369-5266(98)80042-3; Waikel RL, 1999, ONCOGENE, V18, P4870, DOI 10.1038/sj.onc.1203040; Watt FM, 1989, CURR OPIN CELL BIOL, V1, P1107, DOI 10.1016/S0955-0674(89)80058-4; WATT FM, 1988, P NATL ACAD SCI USA, V85, P5576, DOI 10.1073/pnas.85.15.5576; WATT FM, 1991, J CELL SCI, V99, P397; WATT FM, 1981, J CELL BIOL, V90, P738, DOI 10.1083/jcb.90.3.738; WATT FM, 1993, DEVELOPMENT, P185	66	68	70	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2000	19	29					3278	3289		10.1038/sj.onc.1203630	http://dx.doi.org/10.1038/sj.onc.1203630			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KY	10918584				2022-12-17	WOS:000088019300006
J	Charrasse, S; Carena, I; Brondani, V; Klempnauer, KH; Ferrari, S				Charrasse, S; Carena, I; Brondani, V; Klempnauer, KH; Ferrari, S			Degradation of B-Myb by ubiquitin-mediated proteolysis: involvement of the Cdc34-SCFp45Skp2 pathway	ONCOGENE			English	Article						B-Myb; ubiquitination; p45(Skp2); cyclin A	KINASE INHIBITOR P27; PROTEASOME-DEPENDENT DEGRADATION; F-BOX PROTEIN; CELL-CYCLE; C-MYB; MESSENGER-RNA; BETA-CATENIN; IN-VIVO; A-MYB; ACTIVATION	B-Myb, a highly conserved member of the Myb oncoprotein family, is a 110 kDa sequence-specific DNA binding protein expressed in virtually all proliferating cells, B-myb expression reaches its maximum at the G1/S phase boundary and during the S phase of the cell cycle. We have previously shown that B-Myb activity is cell cycle regulated and it is controlled by the antagonistic effects of cyclin Dt and A. Here we show that ectopic expression of cyclin A causes a pronounced reduction of B-Myb protein level, We provide evidence that in addition to triggering B-Myb activity an important effect of cyclin A is to facilitate multiple ubiquitination of B-Myb, The C-terminal domain of B-Myb is of key importance in mediating this effect of cyclin A, Contrary to full-length B-Myb, a C-terminal deletion mutant displays activity irrespective of cyclin A expression, does not undergo ubiquitination, and its half-life is not affected by cyclin A. Ectopic expression of either Cdc34 or the F-box protein p45(Skp2), respectively the E2 and E3 components of a ubiquitination pathway that regulates the G1/S transition, accelerates degradation of B-Myb, We show that B-Myb physically and functionally interacts with components of the Cdc34-SCFp45Skp2 ubiquitin pathway and propose that B-Myb degradation may be required for controlling the correct alternation of events during progression through the cell division cycle.	Novartis Pharma AG, Dept Oncol, CH-4057 Basel, Switzerland; Univ Munster, Inst Biochem, D-48149 Munster, Germany	Novartis; University of Munster	Ferrari, S (corresponding author), Novartis Pharma AG, Dept Oncol, Klybeckstr 141, CH-4057 Basel, Switzerland.		Brondani, Vincent/AAB-8394-2021; Ferrari, Stefano/I-7357-2016	Ferrari, Stefano/0000-0002-6607-215X				Ansieau S, 1997, J MOL MED-JMM, V75, P815, DOI 10.1007/s001090050170; ARSURA M, 1992, BLOOD, V79, P2708; Bartsch O, 1999, EUR J BIOCHEM, V260, P384, DOI 10.1046/j.1432-1327.1999.00191.x; Bartsch O, 1998, BIOLOGY OF TUMORS, P31; Bies J, 1997, ONCOGENE, V14, P203, DOI 10.1038/sj.onc.1200828; BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; Charrasse S, 1999, CELL GROWTH DIFFER, V10, P611; CURRAN T, 1984, CELL, V36, P259; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Esposito V, 1997, CANCER RES, V57, P3381; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; Harper JW, 1999, NAT CELL BIOL, V1, pE5, DOI 10.1038/8952; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Horstmann S, 2000, ONCOGENE, V19, P298, DOI 10.1038/sj.onc.1203302; Isaksson A, 1996, BBA-REV CANCER, V1288, pF21, DOI 10.1016/0304-419X(96)00011-X; Kamano H, 1995, ONCOGENE, V11, P2575; Kamano H, 1997, ONCOGENE, V14, P1223, DOI 10.1038/sj.onc.1200945; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; LEBWOHL DE, 1994, ONCOGENE, V9, P1925; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Sala A, 1996, J BIOL CHEM, V271, P28738, DOI 10.1074/jbc.271.46.28738; Sala A, 1999, J CELL PHYSIOL, V179, P245; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Saville MK, 1998, ONCOGENE, V17, P2679, DOI 10.1038/sj.onc.1202503; Sitzmann J, 1996, ONCOGENE, V12, P1889; Solomon M J, 1998, Results Probl Cell Differ, V22, P79; Tanaka Y, 1999, J BIOL CHEM, V274, P28067, DOI 10.1074/jbc.274.40.28067; Tomita A, 1998, LEUKEMIA, V12, P1422, DOI 10.1038/sj.leu.2401113; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7; Ziebold U, 1997, ONCOGENE, V15, P1011, DOI 10.1038/sj.onc.1201282; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	58	68	70	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2000	19	26					2986	2995		10.1038/sj.onc.1203618	http://dx.doi.org/10.1038/sj.onc.1203618			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323TQ	10871850				2022-12-17	WOS:000087581400005
J	Masselink, H; Bernards, R				Masselink, H; Bernards, R			The adenovirus E1A binding protein BS69 is a corepressor of transcription through recruitment of N-CoR	ONCOGENE			English	Article						BS69; BRAM1; N-CoR; E1A; MYND; repression	HISTONE DEACETYLASE COMPLEX; ACUTE MYELOID-LEUKEMIA; ACTIVATES TRANSCRIPTION; REPRESSES TRANSCRIPTION; INSITU HYBRIDIZATION; BASAL TRANSCRIPTION; MOLECULAR-CLONING; TERMINAL DOMAIN; FUSION PARTNER; INTERACTS	BS69 was first identified as a protein that interacts directly with the transactivation domain (conserved region 3) of the 289R adenovirus type 5 E1A protein. We show here that BS69 is a potent repressor of transcription, BS69 mediates repression, at least in part, through interaction with the co-repressor N-CoR, BS69 interacts with N-CoR through a MYND domain in its carboxyl terminus, A recently cloned splice variant of BS69, designated BRAM1, is also capable of interacting with N-CoR and E1A. but unlike BS69. is not able to repress transcription, indicating that N-CoR interaction is necessary but not sufficient for BS69 repression, Expression of E1A inhibits repression mediated by BS69, Our data suggest that BS69 participates in transcriptional repressor complexes and that E1A can modulate these complexes through interaction with BS69.	Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute	Bernards, R (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.			Bernards, Rene/0000-0001-8677-3423				AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; BERNARDS R, 1982, VIROLOGY, V120, P422, DOI 10.1016/0042-6822(82)90042-3; Boyer TG, 1999, NATURE, V399, P276, DOI 10.1038/20466; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; GEISBERG JV, 1995, MOL CELL BIOL, V15, P6283; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; GREEN M, 1988, CELL, V53, P921, DOI 10.1016/S0092-8674(88)90429-1; Gross CT, 1996, EMBO J, V15, P1961, DOI 10.1002/j.1460-2075.1996.tb00547.x; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; HATEBOER G, 1995, EMBO J, V14, P3159, DOI 10.1002/j.1460-2075.1995.tb07318.x; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Jeanmougin F, 1997, TRENDS BIOCHEM SCI, V22, P151, DOI 10.1016/S0968-0004(97)01042-6; Kurozumi K, 1998, GENES CELLS, V3, P257, DOI 10.1046/j.1365-2443.1998.00186.x; LEE JS, 1995, NUCLEIC ACIDS RES, V23, P925, DOI 10.1093/nar/23.6.925; LEWIS BA, 1995, J VIROL, V69, P1628, DOI 10.1128/JVI.69.3.1628-1636.1995; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Lutterbach B, 1998, MOL CELL BIOL, V18, P3604, DOI 10.1128/MCB.18.6.3604; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Muscat GEO, 1998, NUCLEIC ACIDS RES, V26, P2899, DOI 10.1093/nar/26.12.2899; Mymryk JS, 1997, BIOCHEM CELL BIOL, V75, P95, DOI 10.1139/bcb-75-2-95; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Ordentlich P, 1999, P NATL ACAD SCI USA, V96, P2639, DOI 10.1073/pnas.96.6.2639; Park EJ, 1999, P NATL ACAD SCI USA, V96, P3519, DOI 10.1073/pnas.96.7.3519; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Schreiber-Agus N, 1998, BIOESSAYS, V20, P808, DOI 10.1002/(SICI)1521-1878(199810)20:10<808::AID-BIES6>3.0.CO;2-U; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Soderstrom M, 1997, MOL ENDOCRINOL, V11, P682, DOI 10.1210/me.11.6.682; Sundqvist A, 1998, FEBS LETT, V429, P183, DOI 10.1016/S0014-5793(98)00588-2; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; VOUSDEN KH, 1989, ONCOGENE, V4, P153; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; WINSTON CW, 1999, MOL CELL BIOL, V6, P601; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	59	68	72	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 16	2000	19	12					1538	1546		10.1038/sj.onc.1203421	http://dx.doi.org/10.1038/sj.onc.1203421			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297XN	10734313	Green Published			2022-12-17	WOS:000086108100006
J	Frost, GI; Mohapatra, G; Wong, TM; Csoka, AB; Gray, JW; Stern, R				Frost, GI; Mohapatra, G; Wong, TM; Csoka, AB; Gray, JW; Stern, R			HYAL1(LUCA-1), a candidate tumor suppressor gene on chromosome 3p21.3, is inactivated in head and neck squamous cell carcinomas by aberrant splicing of pre-mRNA	ONCOGENE			English	Article						hyaluronidase; 3p21.3; tumor suppressor gene; aberrant splicing; squamous cell carcinoma; head and neck tumors	COMPARATIVE GENOMIC HYBRIDIZATION; HYALURONIDASE ACTIVITY; LUNG-CANCER; MESSENGER-RNA; LINES; DNA; 3P; PURIFICATION; EXPRESSION; DELETION	The hyaluronidase first isolated from human plasma, Hyal-1, is expressed in many somatic tissues. The Hyal-1 gene, HYAL1, also known as LUCA-1, maps to chromosome 3p21.3 within a candidate tumor suppressor gene locus defined by homozygous deletions and by functional tumor suppressor activity. Hemizygosity in this region occurs in many malignancies, including squamous cell carcinomas of the head and neck, We have investigated whether cell lines derived from such malignancies expressed Hyal-1 activity, using normal human keratinocytes as controls. Hyal-1 enzyme activity and protein were absent or markedly reduced in six of seven carcinoma cell lines examined. Comparative genomic and fluorescence ill situ hybridization identified chromosomal deletions of one allele of HYAL1 in six of se, en cell lines. Initial RT-PCR analyses demonstrated marked discrepancies between levels of HYAL1 mRNA and protein. Despite repeated sequence analyses, no mutations were found, However, two species of transcripts were identified when primers were used that included the 5' untranslated region. The predominant mRNA species did not correlate with protein translation and contained a retained intron, A second spliced form lacking this intron was found only in cell lines that produced Hyal-1 protein. Inactivation of HYAL1 in these tumor lines is a result of incomplete splicing of its pre-mRNA that appears to be epigenetic in nature.	Univ Calif San Francisco, Sch Med, Dept Pathol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Canc, San Francisco, CA 94115 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Stern, R (corresponding author), Univ Calif San Francisco, Sch Med, Dept Pathol, San Francisco, CA 94143 USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE011912, T32DE007204] Funding Source: NIH RePORTER; NIDCR NIH HHS [P50 DE/CA11912, T32DE07204] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Baylin SB, 1998, ADV CANCER RES, V72, P141; Buchhagen DL, 1996, HEAD NECK-J SCI SPEC, V18, P529; Cheng Y, 1998, P NATL ACAD SCI USA, V95, P3042, DOI 10.1073/pnas.95.6.3042; Csoka AB, 1999, GENOMICS, V60, P356, DOI 10.1006/geno.1999.5876; Csoka TB, 1997, FEBS LETT, V417, P307, DOI 10.1016/S0014-5793(97)01309-4; Csoka TB, 1998, GENOMICS, V48, P63, DOI 10.1006/geno.1997.5158; Druck T, 1998, ONCOL RES, V10, P341; Frost GI, 1997, BIOCHEM BIOPH RES CO, V236, P10, DOI 10.1006/bbrc.1997.6773; Frost GI, 1997, ANAL BIOCHEM, V251, P263, DOI 10.1006/abio.1997.2262; Frost GL, 1996, TRENDS GLYCOSCI GLYC, V8, P419, DOI 10.4052/tigg.8.419; Gayther SA, 1997, ONCOGENE, V15, P2119, DOI 10.1038/sj.onc.1201591; GMACHL M, 1993, FEBS LETT, V336, P545, DOI 10.1016/0014-5793(93)80873-S; Granadino B, 1997, P NATL ACAD SCI USA, V94, P7343, DOI 10.1073/pnas.94.14.7343; GUNTENHONER MW, 1992, MATRIX, V12, P388, DOI 10.1016/S0934-8832(11)80035-1; Haber D, 1997, NAT GENET, V16, P320, DOI 10.1038/ng0897-320; Heckel D, 1998, HUM MOL GENET, V7, P1859, DOI 10.1093/hmg/7.12.1859; HIBI K, 1992, ONCOGENE, V7, P445; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; KREIL G, 1995, PROTEIN SCI, V4, P1666, DOI 10.1002/pro.5560040902; Latif F, 1997, HUM GENET, V99, P334, DOI 10.1007/s004390050368; Lepperdinger G, 1998, J BIOL CHEM, V273, P22466, DOI 10.1074/jbc.273.35.22466; Maquat LE, 1996, AM J HUM GENET, V59, P279; Mohapatra G, 1997, GENE CHROMOSOME CANC, V20, P311, DOI 10.1002/(SICI)1098-2264(199712)20:4<311::AID-GCC1>3.0.CO;2-4; MOHAPATRA G, 1995, GENE CHROMOSOME CANC, V13, P86, DOI 10.1002/gcc.2870130203; Sager R, 1997, P NATL ACAD SCI USA, V94, P952, DOI 10.1073/pnas.94.3.952; SCALONI A, 1992, J LAB CLIN MED, V120, P546; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Todd S, 1997, CANCER RES, V57, P1344; Wei MH, 1996, CANCER RES, V56, P1487; Zhang J, 1998, MOL CELL BIOL, V18, P5272, DOI 10.1128/MCB.18.9.5272	32	68	80	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 17	2000	19	7					870	877		10.1038/sj.onc.1203317	http://dx.doi.org/10.1038/sj.onc.1203317			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MW	10702795				2022-12-17	WOS:000085567700004
J	Bauvois, B; Djavaheri-Mergny, M; Rouillard, D; Dumont, J; Wietzerbin, J				Bauvois, B; Djavaheri-Mergny, M; Rouillard, D; Dumont, J; Wietzerbin, J			Regulation of CD26/DPPIV gene expression by interferons and retinoic acid in tumor B cells	ONCOGENE			English	Article						CD26 antigen; dipeptidylpeptidase IV; B-CLL; IFN; retinoic acid; STAT	DIPEPTIDYL-PEPTIDASE-IV; CHRONIC LYMPHOCYTIC-LEUKEMIA; PERIPHERAL-BLOOD; SERINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; TYROSINE KINASES; EPITHELIAL-CELLS; ACTIVATION; STAT1; GAMMA	Interferons (IFNs alpha, beta and gamma) and all trans retinoic acid (RA) have the ability to activate genes with GAS sites. We have found that the promoter of CD26/dipeptidylpeptidase IV (DPPIV) contains a consensus GAS site TTCnnnGAA located at bp-35 to -27, and computer analysis confirmed this sequence to be a putative Stat binding site. Consistent with this finding, we show that IFNs and RA rapidly enhanced CD26 gene and protein expression in chronic B lymphocytic leukemia (B-CLL) cells. Immunoblot analyses revealed that unstimulated B-CLL cells expressed detectable levels of serine/tyrosine-phosphorylated Stat1 alpha, and RA and IFN-gamma treatment led to increased levels of tyrosine phosphorylation of Stat1 alpha and its nuclear accumulation. As shown by electrophoretic mobility shift assay, RA and IFN-gamma increased the binding of a nuclear protein to the GAS-CD26 element. Shift-Western blotting identified Stat1 alpha as the GAS-CD26 binding factor. Augmented levels of CD26 protein in malignant B cells cultured with IFNs or RA coincided with the enhancement of DPPIV activity. Taken together, our results are in favor of the IFN-/RA-mediated upregulation of CD26/DPPIV in B-CLL through the signaling pathway involving Stat1 alpha and the GAS response element of CD26 promoter.	Inst Curie, Unite 365 INSERM, F-75231 Paris 05, France; Inst Curie, Sect Rech, F-75231 Paris, France; Serv Hematol Clin, F-75231 Paris 05, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Bauvois, B (corresponding author), Inst Curie, Unite 365 INSERM, F-75231 Paris 05, France.		Bauvois, Brigitte/F-6776-2013; Djavaheri-Mergny, Mojgan/N-6315-2017; Djavaheri-Mergny, Mojgan/L-3890-2019	Bauvois, Brigitte/0000-0002-1751-6922; Djavaheri-Mergny, Mojgan/0000-0003-4893-6505; Djavaheri-Mergny, Mojgan/0000-0003-4893-6505				ABBOTT CA, 1994, IMMUNOGENETICS, V40, P331, DOI 10.1007/BF01246674; BARON S, 1991, JAMA-J AM MED ASSOC, V266, P1375, DOI 10.1001/jama.266.10.1375; Bauvois B, 1999, BRIT J CANCER, V79, P1042, DOI 10.1038/sj.bjc.6690167; BOHM SK, 1995, BIOCHEM J, V311, P835; BUHLING F, 1995, IMMUNOL LETT, V45, P47, DOI 10.1016/0165-2478(94)00230-O; Cordero OJ, 1998, IMMUNOL LETT, V61, P7, DOI 10.1016/S0165-2478(97)00154-5; de la Fuente MT, 1999, LEUKEMIA, V13, P266, DOI 10.1038/sj.leu.2401275; DE LUCA LM, 1991, FASEB J, V5, P2924; De Meester I, 1999, IMMUNOL TODAY, V20, P367, DOI 10.1016/S0167-5699(99)01486-3; Djavaheri-Mergny M, 1999, BIOCHEM J, V338, P607, DOI 10.1042/0264-6021:3380607; EGUCHI K, 1989, J IMMUNOL, V142, P4233; EILERS A, 1993, MOL CELL BIOL, V13, P3245, DOI 10.1128/MCB.13.6.3245; EILERS A, 1995, MOL CELL BIOL, V15, P3579; FLEISCHER B, 1994, IMMUNOL TODAY, V15, P180, DOI 10.1016/0167-5699(94)90316-6; Floyd-Smith G, 1999, EXP CELL RES, V246, P138, DOI 10.1006/excr.1998.4296; FOON KA, 1985, AM J MED, V78, P216, DOI 10.1016/0002-9343(85)90429-2; Gaetaniello L, 1998, HEPATOLOGY, V27, P934, DOI 10.1002/hep.510270407; Gianni M, 1997, BLOOD, V89, P1001, DOI 10.1182/blood.V89.3.1001; HAFLER DA, 1985, NEW ENGL J MED, V312, P1405, DOI 10.1056/NEJM198505303122201; Harada H, 1998, BIOCHIMIE, V80, P641, DOI 10.1016/S0300-9084(99)80017-0; Hochhaus A, 1997, LEUKEMIA, V11, P933, DOI 10.1038/sj.leu.2400723; Hoey T, 1998, CURR OPIN GENET DEV, V8, P582, DOI 10.1016/S0959-437X(98)80015-4; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; Iwata S, 1999, J EXP MED, V190, P301, DOI 10.1084/jem.190.3.301; Kolla V, 1996, J BIOL CHEM, V271, P10508, DOI 10.1074/jbc.271.18.10508; Kondo S, 1996, LEUKEMIA RES, V20, P357, DOI 10.1016/0145-2126(95)00159-X; Lagneaux L, 1998, BLOOD, V91, P2387, DOI 10.1182/blood.V91.7.2387.2387_2387_2396; Lambeir AM, 1996, BBA-GEN SUBJECTS, V1290, P76, DOI 10.1016/0304-4165(96)00012-8; Lehtonen A, 1997, J IMMUNOL, V159, P794; Matikainen S, 1998, LEUKEMIA LYMPHOMA, V30, P63, DOI 10.3109/10428199809050930; Matikainen S, 1996, BLOOD, V88, P114; Matikainen S, 1999, BLOOD, V93, P1980, DOI 10.1182/blood.V93.6.1980.406k20_1980_1991; MCSWEENEY EN, 1993, BRIT J HAEMATOL, V85, P77, DOI 10.1111/j.1365-2141.1993.tb08648.x; MORIMOTO C, 1994, P NATL ACAD SCI USA, V91, P9960, DOI 10.1073/pnas.91.21.9960; NAKAO H, 1989, J RHEUMATOL, V16, P7; Osorio LM, 1998, LEUKEMIA LYMPHOMA, V30, P247, DOI 10.3109/10428199809057538; Pelicano L, 1997, ONCOGENE, V15, P2349, DOI 10.1038/sj.onc.1201410; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; Pitha PM, 1998, BIOCHIMIE, V80, P651, DOI 10.1016/S0300-9084(99)80018-2; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RIEMANN D, 1995, CLIN EXP IMMUNOL, V100, P277; SHUAI K, 1994, CURR OPIN CELL BIOL, V6, P253, DOI 10.1016/0955-0674(94)90144-9; Silvennoinen O, 1997, APMIS, V105, P497, DOI 10.1111/j.1699-0463.1997.tb05047.x; Stecca BA, 1997, J HEPATOL, V27, P337, DOI 10.1016/S0168-8278(97)80180-8; STEFANOVIC V, 1993, IMMUNOLOGY, V80, P465; TANAKA T, 1995, INT J CANCER, V64, P326, DOI 10.1002/ijc.2910640508; Watanabe S, 1996, CURR OPIN GENET DEV, V6, P587, DOI 10.1016/S0959-437X(96)80088-8; Weihua Xiao, 1997, Journal of Biological Chemistry, V272, P9742; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wesley UV, 1999, J EXP MED, V190, P311, DOI 10.1084/jem.190.3.311; Yamabe T, 1997, IMMUNOLOGY, V91, P151, DOI 10.1046/j.1365-2567.1997.00230.x	51	68	69	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 13	2000	19	2					265	272		10.1038/sj.onc.1203292	http://dx.doi.org/10.1038/sj.onc.1203292			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10645005				2022-12-17	WOS:000084844400012
J	Montagna, M; Santacatterina, M; Torri, A; Menin, C; Zullato, D; Chieco-Bianchi, L; D'Andrea, E				Montagna, M; Santacatterina, M; Torri, A; Menin, C; Zullato, D; Chieco-Bianchi, L; D'Andrea, E			Identification of a 3 kb Alu-mediated BRCA1 gene rearrangement in two breast ovarian cancer families	ONCOGENE			English	Article						BRCA1; genomic rearrangement; breast cancer; ovarian cancer; Alu repeats	GERMLINE MUTATIONS	Most of the hereditary breast cancers are attributed to constitutive alterations of either BRCA1 or BRCA2 genes; nonetheless, germline mutations of these genes in 'high risk' families are found less frequently than expected from linkage data. Recent findings suggest that major genomic rearrangements of the BRCA1 gene might account for at least some of the apparently mutation negative cases. We studied 60 affected probands belonging to families with a strong history of breast and/or ovarian cancer who scored negative for BRCA1 gene mutations by PTT and SSCP analysis, DNA was analysed by the Southern blotting procedure using three different restriction enzymes, and tno probes obtained by RT-PCR of the 5' and 3' BRCA1 coding sequence. A 3 kb deletion encompassing exon 17 and causing a frameshift mutation was identified in two independently ascertained families. RT-PCR and long-range DNA PCR were employed to characterize the rearrangement that was finally shown to be the result of a recombination between tno very similar Alu repeats. This type of mutation is not identified by the conventional methods of mutation detection which are based on PCR amplification of single exons, Therefore, further search for gene rearrangements is needed to better define the proportion of 'high risk' families that might be explained by gross genomic alterations of the BRCA1 gene.	Univ Padua, Interuniv Ctr Res Canc, Dept Oncol & Surg Sci, Oncol Sect, I-35128 Padua, Italy; Univ Padua, Interuniv Ctr Res Canc, IST Biotechnol Sect, I-35128 Padua, Italy	IRCCS Istituto Oncologico Veneto (IOV); University of Padua; University of Padua	Montagna, M (corresponding author), Univ Padua, Interuniv Ctr Res Canc, Dept Oncol & Surg Sci, Oncol Sect, Via Gattamelata 64, I-35128 Padua, Italy.		D'Andrea, Emma/B-4374-2013; montagna, marco/E-2225-2012; Menin, Chiara/L-5770-2016	montagna, marco/0000-0002-4929-2150; Menin, Chiara/0000-0002-8907-772X				CLAUS EB, 1991, AM J HUM GENET, V48, P232; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; GAYTHER SA, 1995, NAT GENET, V11, P428, DOI 10.1038/ng1295-428; HOGERVORST FBL, 1995, NAT GENET, V10, P208, DOI 10.1038/ng0695-208; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Montagna M, 1996, CANCER RES, V56, P5466; Neuhausen SL, 1996, AM J HUM GENET, V58, P271; PetrijBosch A, 1997, NAT GENET, V17, P341, DOI 10.1038/ng1197-341; Puget N, 1997, CANCER RES, V57, P828; Serova O, 1996, AM J HUM GENET, V58, P42; Smith TM, 1996, GENOME RES, V6, P1029, DOI 10.1101/gr.6.11.1029; Swensen J, 1997, HUM MOL GENET, V6, P1513, DOI 10.1093/hmg/6.9.1513; Szabo CI, 1997, AM J HUM GENET, V60, P1013; Xu CF, 1997, GENE CHROMOSOME CANC, V18, P102, DOI 10.1002/(SICI)1098-2264(199702)18:2<102::AID-GCC4>3.3.CO;2-A	16	68	73	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	1999	18	28					4160	4165		10.1038/sj.onc.1202754	http://dx.doi.org/10.1038/sj.onc.1202754			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	216FP	10435598				2022-12-17	WOS:000081431000014
J	Pestana, ES; Tenev, T; Gross, S; Stoyanov, B; Ogata, M; Bohmer, FD				Pestana, ES; Tenev, T; Gross, S; Stoyanov, B; Ogata, M; Bohmer, FD			The transmembrane protein tyrosine phosphatase RPTP sigma modulates signaling of the epidermal growth factor receptor in A431 cells	ONCOGENE			English	Article						EGF receptor; protein-tyrosine phosphatase; ganglioside G(M3); RPTP sigma	MESSENGER-RNA EXPRESSION; GENE-EXPRESSION; CARCINOMA-CELLS; NERVOUS-SYSTEM; INTACT-CELLS; NEU ONCOGENE; PTP-SIGMA; HUMAN LAR; KINASE; DOMAIN	Attenuation of epidermal growth factor receptor signaling by the ganglioside G(M3) has previously been found to involve activation of an unknown protein-tyrosine phosphatase (PTP). In transient expression experiments we tested different PTPs for activation towards EGF receptor by G(M3). The transmembrane PTP RPTP sigma but not RPTP alpha or the SH2-domain PTP SHP-1 exhibited elevated activity towards EGF receptor in G(M3)-treated cells. The possible relevance of RPTP sigma for regulation of EGF receptor signaling activity was further explored in stable A431 cells lines inducibly expressing RPTP sigma or RPTP sigma antisense RNA. RPTP sigma expression clearly reduced EGF receptor phosphorylation, Also, soft agar colony formation of respective cell lines was reduced upon RPTP sigma expression whereas RPTP sigma antisense RNA expression augmented both, EGF receptor phosphorylation and soft agar colony formation. In addition, RPTP sigma antisense RNA expression rendered A431 cells resistant to inhibition of EGF receptor phosphorylation by G(M3). We propose that RPTP sigma participates in EGF receptor dephosphorylation in A431 cells, becomes activated by G(M3) via an unknown mechanism and is thereby capable to mediate attenuation of EGF receptor phosphorylation by G(M3).	Klinikum Univ Jena, Res Unit Mol Cell Biol, D-07747 Jena, Germany; Osaka Univ, Sch Med, Biomed Res Ctr, Dept Oncol, Suita, Osaka 565, Japan	Friedrich Schiller University of Jena; Osaka University	Bohmer, FD (corresponding author), Klinikum Univ Jena, Res Unit Mol Cell Biol, Drackendorfer Str 1, D-07747 Jena, Germany.			Tenev, Tencho/0000-0001-8762-1069				Aicher B, 1997, J CELL BIOL, V138, P681, DOI 10.1083/jcb.138.3.681; BOHMER FD, 1993, FEBS LETT, V331, P276, DOI 10.1016/0014-5793(93)80352-U; BOHMER FD, 1995, ANAL BIOCHEM, V228, P267, DOI 10.1006/abio.1995.1349; BREMER EG, 1986, J BIOL CHEM, V261, P2434; BROWNSHIMER S, 1992, CANCER RES, V52, P478; CELLER JW, 1995, BIOCHEM BIOPH RES CO, V209, P614, DOI 10.1006/bbrc.1995.1544; Charest A, 1997, ONCOGENE, V14, P1643, DOI 10.1038/sj.onc.1201008; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; FAURE R, 1992, J BIOL CHEM, V267, P11215; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Fry DW, 1997, BIOCHEM PHARMACOL, V54, P877, DOI 10.1016/S0006-2952(97)00242-6; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gossen Manfred, 1994, Current Opinion in Biotechnology, V5, P516, DOI 10.1016/0958-1669(94)90067-1; GU M, 1996, P NATL ACAD SCI USA, V94, P12980; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; Keane MM, 1996, CANCER RES, V56, P4236; Kokel M, 1998, GENE DEV, V12, P1425, DOI 10.1101/gad.12.10.1425; Kulas DT, 1996, J BIOL CHEM, V271, P748, DOI 10.1074/jbc.271.2.748; KULAS DT, 1995, J BIOL CHEM, V270, P2435, DOI 10.1074/jbc.270.6.2435; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; LEE K, 1987, EXP CELL RES, V173, P156, DOI 10.1016/0014-4827(87)90341-7; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liu F, 1997, BIOCHEM J, V327, P139, DOI 10.1042/bj3270139; LONGO FM, 1993, J BIOL CHEM, V268, P26503; Lorenz U, 1996, J EXP MED, V184, P1111, DOI 10.1084/jem.184.3.1111; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Norris K, 1997, FEBS LETT, V415, P243, DOI 10.1016/S0014-5793(97)01133-2; OGATA M, 1994, J IMMUNOL, V153, P4478; OGRADY P, 1994, J BIOL CHEM, V269, P25193; Paulson RF, 1996, NAT GENET, V13, P309, DOI 10.1038/ng0796-309; Pestana ES, 1997, BRIT J CANCER, V75, P213, DOI 10.1038/bjc.1997.36; PULIDO R, 1995, P NATL ACAD SCI USA, V92, P11686, DOI 10.1073/pnas.92.25.11686; PULIDO R, 1995, J BIOL CHEM, V270, P6722, DOI 10.1074/jbc.270.12.6722; ROTIN D, 1994, AM J PHYSIOL, V267, pL263, DOI 10.1152/ajplung.1994.267.3.L263; Schaapveld R, 1997, MOL BIOL REP, V24, P247, DOI 10.1023/A:1006870016238; Schaapveld RQJ, 1997, DEV BIOL, V188, P134, DOI 10.1006/dbio.1997.8630; Serra-Pages C, 1998, J BIOL CHEM, V273, P15611, DOI 10.1074/jbc.273.25.15611; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; SKARNES WC, 1995, P NATL ACAD SCI USA, V92, P6592, DOI 10.1073/pnas.92.14.6592; Tenev T, 1997, J BIOL CHEM, V272, P5966, DOI 10.1074/jbc.272.9.5966; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; Wagner J, 1996, GENOMICS, V38, P76, DOI 10.1006/geno.1996.0594; WALTON KM, 1993, NEURON, V11, P387, DOI 10.1016/0896-6273(93)90193-U; Weiss FU, 1997, CURR OPIN GENET DEV, V7, P80, DOI 10.1016/S0959-437X(97)80113-X; Weng LP, 1998, CURR BIOL, V8, P247, DOI 10.1016/S0960-9822(98)70106-X; YAN H, 1993, J BIOL CHEM, V268, P24880; ZHAI YF, 1995, MOL CARCINOGEN, V14, P103, DOI 10.1002/mc.2940140206; ZHANG JS, 1995, J CELL BIOL, V128, P415, DOI 10.1083/jcb.128.3.415; ZHANG WR, 1994, BIOCHEM J, V302, P39, DOI 10.1042/bj3020039	51	68	68	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	1999	18	28					4069	4079		10.1038/sj.onc.1202794	http://dx.doi.org/10.1038/sj.onc.1202794			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	216FP	10435588				2022-12-17	WOS:000081431000004
J	Okami, K; Reed, AL; Cairns, P; Koch, WM; Westra, WH; Wehage, S; Jen, J; Sidransky, D				Okami, K; Reed, AL; Cairns, P; Koch, WM; Westra, WH; Wehage, S; Jen, J; Sidransky, D			Cyclin D-1 amplification is independent of p16 inactivation in head and neck squamous cell carcinoma	ONCOGENE			English	Article						cyclin D-1; p16; head and neck cancer	IN-SITU HYBRIDIZATION; GENE AMPLIFICATION; ESTROGEN-RECEPTOR; FREQUENT LOSS; LUNG CANCERS; EXPRESSION; D1; PROTEIN; OVEREXPRESSION; PROGRESSION	Progression through the G(1) phase of the cell cycle is mediated by phosphorylation of the retinoblastoma protein (pRb) resulting in the release of essential transcription factors such as E2F-1. The phosphorylation of pRb is regulated positively by cyclin D-1/CDK4 and negatively by CDK inhibitors, such as p16 (CDKN2/MTS-1/INK4A), The p16/cyclin D-1/Rb pathway plays a critical role in tumorigenesis and many tumor types display a high frequency of inactivation of at least one component of this pathway. In order to determine the overall contribution of these three components to progression of head and neck squamous cell carcinoma (HNSCC), we examined p16 inactivation, cyclin D-1 amplification, and pRb expression in 23 primary HNSCC tumors and five cell lines, p16 inactivation was detected in 19/23 (83%) primary tumors by detailed genetic analysis and was confirmed by immunohistochemistry (MC), Absence of Ph protein expression indicative of pRb inactivation was identified in 2/23 (9%) tumors, In this set of tumors, there was a perfect inverse correlation between p16 and pRb inactivation, Using fluorescence in situ hybridization (FISH) cyclin D-1 amplification was identified in 4/5 (80%) cell lines and 4/11 (36%) primary tumors. However, 2/4 cell lines and all four primary tumors with cyclin D-1 amplification contained a concomitant alteration of p16, Therefore 21/23 (91%) of primary HNSCC contained at least one alteration in the p16/cyclin D-1/Rb pathway. Although p16 and Rb alteration are apparently exclusive, cyclin D-1 amplification occurs concomitantly with the loss of p16 suggesting an additional role for this amplification in HNSCC.	Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Div Head & Neck Canc Res, Baltimore, MD 21205 USA; Johns Hopkins Hosp, Dept Pathol, Baltimore, MD 21287 USA; Yamaguchi Univ, Dept Otolaryngol, Ube, Yamaguchi 755, Japan	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Yamaguchi University	Sidransky, D (corresponding author), Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Div Head & Neck Canc Res, 818 Ross Res Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.							Andl T, 1998, CANCER RES, V58, P5; BRODEUR GM, 1998, GENETIC BASIS HUMAN, P161; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CAIRNS P, 1997, CANCER RES, V57, P4497; GERADTS J, 1994, INT J CANCER, V58, P161, DOI 10.1002/ijc.2910580203; Jacks T, 1998, SCIENCE, V280, P1035, DOI 10.1126/science.280.5366.1035; JARES P, 1994, CANCER RES, V54, P4813; Jenkins RB, 1997, CANCER RES, V57, P524; Kyomoto R, 1997, INT J CANCER, V74, P576, DOI 10.1002/(SICI)1097-0215(19971219)74:6<576::AID-IJC3>3.0.CO;2-R; LICHTER P, 1992, HUMAN CYTOGENETICS P, V1, P157; Liggett WH, 1996, CANCER RES, V56, P4119; LUKAS J, 1995, CANCER RES, V55, P4818; Mao L, 1996, NAT MED, V2, P682, DOI 10.1038/nm0696-682; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MICHALIDES R, 1995, CANCER RES, V55, P975; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Okami K, 1997, INT J CANCER, V74, P588, DOI 10.1002/(SICI)1097-0215(19971219)74:6<588::AID-IJC5>3.3.CO;2-4; Olshan AF, 1997, ONCOGENE, V14, P811, DOI 10.1038/sj.onc.1200892; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; Reed AL, 1996, CANCER RES, V56, P3630; Sakaguchi M, 1996, INT J CANCER, V65, P442, DOI 10.1002/(SICI)1097-0215(19960208)65:4<442::AID-IJC8>3.0.CO;2-X; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SHAPIRO GI, 1995, CANCER RES, V55, P505; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Simpson JF, 1997, AM J PATHOL, V151, P161; VANDERRIET P, 1994, CANCER RES, V54, P1156; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; YOO GH, 1994, CANCER RES, V54, P4603; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	30	68	70	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 10	1999	18	23					3541	3545		10.1038/sj.onc.1202837	http://dx.doi.org/10.1038/sj.onc.1202837			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205ZF	10376532				2022-12-17	WOS:000080850600012
J	Matsuda, M; Miyagawa, K; Takahashi, M; Fukuda, T; Kataoka, T; Asahara, T; Inui, H; Watatani, M; Yasutomi, M; Kamada, N; Dohi, K; Kamiya, K				Matsuda, M; Miyagawa, K; Takahashi, M; Fukuda, T; Kataoka, T; Asahara, T; Inui, H; Watatani, M; Yasutomi, M; Kamada, N; Dohi, K; Kamiya, K			Mutations in the RAD54 recombination gene in primary cancers	ONCOGENE			English	Article						RAD54; cancer; mutation	NIJMEGEN BREAKAGE SYNDROME; SACCHAROMYCES-CEREVISIAE; REPAIR PROTEIN; DNA; RESISTANCE; CLONING; COMPLEX; BREAST; SNF2	Association of a recombinational repair protein RAD51 with tumor suppressors BRCA1 and BRCA2 suggests that defects in homologous recombination are responsible for tumor formation. Also recent findings that a protein associated with the MRE11/RAD50 repair complex is mutated in Nijmegen breakage syndrome characterized by increased cancer incidence and ionizing radiation sensitivity strongly support this idea. However, the direct roles of BRCA proteins and the protein responsible for NBS in recombinational repair are not clear though they are associated with the recombinational repair complexes. Since RAD51 forms a complex with other members of the RAD52 epistasis group and with BRCA proteins, it is reasonable to ask if alterations of members of the RAD52 epistasis group lead to tumor development. Here we describe missense mutations at functional regions of RAD54 and the absence of the wild-type RAD54 expression resulting from aberrant splicing in primary cancers. Since RAD54 is a recombinational protein associated with RAD51, this is the first genetic evidence that cancer arises from a defect in repair processes involving homologous recombination.	Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Mol Pathol, Hiroshima 734, Japan; Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Dev Biol & Oncol, Hiroshima 734, Japan; Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Canc Cytogenet, Hiroshima 734, Japan; Hiroshima Univ, Sch Med, Dept Surg 2, Minami Ku, Hiroshima 734, Japan; Kinki Univ, Sch Med, Dept Surg 1, Osaka 589, Japan	Hiroshima University; Hiroshima University; Hiroshima University; Hiroshima University; Kindai University (Kinki University)	Miyagawa, K (corresponding author), Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Mol Pathol, 1-2-3 Kasumi, Hiroshima 734, Japan.							BANG DD, 1992, NUCLEIC ACIDS RES, V20, P3925, DOI 10.1093/nar/20.15.3925; Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; EMERY HS, 1991, GENE, V104, P103, DOI 10.1016/0378-1119(91)90473-O; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; GIRDHAM CH, 1991, GENE DEV, V5, P1786, DOI 10.1101/gad.5.10.1786; Golub EI, 1997, NUCLEIC ACIDS RES, V25, P4106, DOI 10.1093/nar/25.20.4106; Kanaar R, 1996, CURR BIOL, V6, P828, DOI 10.1016/S0960-9822(02)00606-1; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; Matsuura S, 1998, NAT GENET, V19, P179, DOI 10.1038/549; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; Rasio D, 1997, CANCER RES, V57, P2378; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; SUGIMOTO K, 1991, BLOOD, V77, P1153; Swagemakers SMA, 1998, J BIOL CHEM, V273, P28292, DOI 10.1074/jbc.273.43.28292; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; Thai TH, 1998, HUM MOL GENET, V7, P195, DOI 10.1093/hmg/7.2.195; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5	22	68	79	0	12	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 3	1999	18	22					3427	3430		10.1038/sj.onc.1202692	http://dx.doi.org/10.1038/sj.onc.1202692			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	201HL	10362365				2022-12-17	WOS:000080589300015
J	Xue, LY; Qiu, Y; He, J; Kung, HJ; Oleinick, NL				Xue, LY; Qiu, Y; He, J; Kung, HJ; Oleinick, NL			Etk/Bmx, a PH-domain containing tyrosine kinase, protects prostate cancer cells from apoptosis induced by photodynamic therapy or thapsigargin	ONCOGENE			English	Article						Etk; tyrosine kinase; PI3-kinase; photodynamic therapy; thapsigargin; apoptosis; prostate cancer	MOUSE LYMPHOMA-CELLS; PLECKSTRIN-HOMOLOGY DOMAIN; PHOSPHOLIPASE C-GAMMA; PHOSPHATIDYLINOSITOL 3-KINASE; POLY(ADP-RIBOSE) POLYMERASE; ENDOPLASMIC-RETICULUM; ACTIVATION; AKT; PHOSPHORYLATION; RESISTANCE	Prostate carcinoma (PCA) is the most frequently diagnosed malignancy in American men. PCA at advanced stages can both proliferate abnormally and resist apoptosis, Among the many known signal transduction pathways, phosphatidylinositide-3'OH kinase (PI3-kinase) has been shown to play an important role in cell survival and resistance to apoptosis, In this study, we investigate the involvement of Etk/Bmx, a newly discovered tyrosine kinase that is a substrate of PI3-kinase, in protection of prostate cancer cells from apoptosis, Parental LNCaP cells and tno derivative cell lines, one overexpressing mild type Etk (Etkwt) and the other expressing a dominant negative Etk (EtkDN), were used to study the function of Etk. The cells mere treated with photodynamic therapy (PDT), a newly approved cancer treatment which employs a photosensitizer and visible light to produce an oxidative stress in cells, often leading to apoptosis. Our results indicate that PDT induces apoptosis in LNCaP cells, as measured by DNA fragmentation and by cleavage of poly(ADP-ribose) polymerase (PARP), and moreover, the extent of apoptosis was much reduced in Etkwt cells as compared to LNCaP or EtkDN cells. Assay of overall cell viability confirmed that Etkwt cells mere considerably less sensitive to PDT than were the parental LNCaP or EtkDN cells. Similar results were found in response to thapsigargin (TG). A specific inhibitor of PI3-kinase, LY294002, abolished Etk activity and markedly increased TG-induced PARP cleavage. The results suggest that Etk/Bmx is an efficient effector of PI3-kinase and that the newly described PI3-kinase/Etk pathway is involved in the protection of prostate carcinoma cells from apoptosis in response to PDT or TG.	Case Western Reserve Univ, Sch Med, Dept Radiat Oncol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Oleinick, NL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Radiat Oncol, Cleveland, OH 44106 USA.		Kung, Hsing-Jien/C-7651-2013		NCI NIH HHS [CA39207, P01 CA48735, CA57179] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA057179, R01CA039207, R01CA057179, R37CA039207, P01CA048735] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1993, CANCER RES, V53, P5897; AGARWAL ML, 1991, CANCER RES, V51, P5993; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; August A, 1997, P NATL ACAD SCI USA, V94, P11227, DOI 10.1073/pnas.94.21.11227; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Fisher AMR, 1997, PHOTOCHEM PHOTOBIOL, V66, P265, DOI 10.1111/j.1751-1097.1997.tb08653.x; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; GOMER CJ, 1991, CANCER RES, V51, P6574; Hasan T., 1997, PHOTODYNAMIC THERAPY, P739; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; He J, 1996, PHOTOCHEM PHOTOBIOL, V64, P845, DOI 10.1111/j.1751-1097.1996.tb01845.x; HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V55, P145, DOI 10.1111/j.1751-1097.1992.tb04222.x; IWABUCHI H, 1995, CANCER RES, V55, P6172; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kaukonen J, 1996, BRIT J HAEMATOL, V94, P455; Kessel D, 1999, CELL DEATH DIFFER, V6, P28, DOI 10.1038/sj.cdd.4400446; Kessel D, 1997, PHOTOCHEM PHOTOBIOL, V65, P422, DOI 10.1111/j.1751-1097.1997.tb08581.x; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LI TJ, 1995, IMMUNITY, V2, P451, DOI 10.1016/1074-7613(95)90026-8; LI WWF, 1993, J BIOL CHEM, V268, P12003; Li ZM, 1997, P NATL ACAD SCI USA, V94, P13820, DOI 10.1073/pnas.94.25.13820; LIU H, 1997, J BIOL CHEM, V272, P21752; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; McConkey DJ, 1996, CANCER RES, V56, P5594; MOAN J, 1992, PHOTOCHEM PHOTOBIOL, V55, P931, DOI 10.1111/j.1751-1097.1992.tb08541.x; Oleinick NL, 1998, RADIAT RES, V150, pS146, DOI 10.2307/3579816; OLEINICK NL, 1993, PHOTOCHEM PHOTOBIOL, V57, P242, DOI 10.1111/j.1751-1097.1993.tb02282.x; Ptasznik A, 1997, J CELL BIOL, V137, P1127, DOI 10.1083/jcb.137.5.1127; Qi XM, 1997, ONCOGENE, V15, P1207, DOI 10.1038/sj.onc.1201290; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; RYTER SW, 1993, PHOTOCHEM PHOTOBIOL, V58, P753, DOI 10.1111/j.1751-1097.1993.tb04964.x; Separovic D, 1997, CANCER RES, V57, P1717; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; Tang DG, 1997, PROSTATE, V32, P284; Tao JS, 1996, J BIOL CHEM, V271, P27107, DOI 10.1074/jbc.271.43.27107; Tenniswood M, 1997, BRIT J UROL, V79, P27, DOI 10.1111/j.1464-410X.1997.tb16918.x; Van Lint J, 1998, J BIOL CHEM, V273, P7038, DOI 10.1074/jbc.273.12.7038; Weil D, 1997, BLOOD, V90, P4332, DOI 10.1182/blood.V90.11.4332.4332_4332_4340; Xue LY, 1997, PHOTOCHEM PHOTOBIOL, V66, P105, DOI 10.1111/j.1751-1097.1997.tb03145.x	48	68	73	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 3	1999	18	22					3391	3398		10.1038/sj.onc.1202687	http://dx.doi.org/10.1038/sj.onc.1202687			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	201HL	10362360				2022-12-17	WOS:000080589300010
J	Yokouchi, M; Wakioka, T; Sakamoto, H; Yasukawa, H; Ohtsuka, S; Sasaki, A; Ohtsubo, M; Valius, M; Inoue, A; Komiya, S; Yoshimura, A				Yokouchi, M; Wakioka, T; Sakamoto, H; Yasukawa, H; Ohtsuka, S; Sasaki, A; Ohtsubo, M; Valius, M; Inoue, A; Komiya, S; Yoshimura, A			APS, an adaptor protein containing PH and SH2 domains, is associated with the PDGF receptor and c-Cbl and inhibits PDGF-indnced mitogenesis	ONCOGENE			English	Article						adaptor molecules containing PH and SH2 domains (APS); platelet derived growth factor receptor (PDGFR); signal transduction; molecular biology	FACTOR-BETA-RECEPTOR; EPIDERMAL GROWTH-FACTOR; SIGNAL-TRANSDUCTION; TYROSINE KINASE; NEGATIVE REGULATOR; ACTIVATION; PROTOONCOGENE; RAS; CLONING; STIMULATION	Previously we cloned a novel adaptor protein, APS (adaptor molecules containing PH and SH2 domains) which was tyrosine phosphorylated in response to c-kit or B cell receptor stimulation. Here we report that APS was expressed in some human osteosarcoma cell lines, markedly so in SaOS-2 cells, and was tyrosine-phosphorylated in response to several growth factors, including platelet derived growth factor (PDGF), insulinlike growth factor (IGF), and granulocyte-macrophage colony stimulating factor (GM-CSF), Ectopic expression of the wild type APS, but not C-terminal truncated APS, in NIH3T3 fibroblasts suppressed PDGF-induced MAP kinase (Erk2) activation, c-fos and c-myc induction as well as cell proliferation. In vitro binding experiments suggest that APS bound to the beta type PDGF receptor, mainly via phosphotyrosine 1021 (pY1021), Indeed, tyrosine phosphorylation of PLC-gamma, which has been demonstrated to bind to pY1021, but not that of PI3 kinase and associated proteins, was reduced in APS transformants, PDGF induced phosphorylation of the tyrosine residue of APS close to the C-terminal end. in vitro and in vivo binding experiments indicate that the tyrosine phosphorylated C-terminal region of APS bound to c-Cbl, which has been shown to be a negative regulator of tyrosine kinases, Since coexpression of c-Cbl with wild type APS, but not C-terminal truncated APS, synergistically inhibited PDGF-induced c-fos promoter activation, c-Cbl could be a mechanism of inhibitory action of APS on PDGF receptor signaling.	Inst Life Sci, Kurume, Fukuoka 8390861, Japan; Kurume Univ, Fac Med, Dept Orthopaed Surg, Kurume, Fukuoka 8300011, Japan; Lithuania Acad Sci, Inst Biochem, LT-2600 Vilnius, Lithuania	Kurume University; Vilnius University	Yoshimura, A (corresponding author), Inst Life Sci, Aikawamachi 2432-3, Kurume, Fukuoka 8390861, Japan.		Valius, Mindaugas/N-1220-2019; Yoshimura, Akihiko/K-5515-2013; Valius, Mindaugas/F-2734-2012	Valius, Mindaugas/0000-0001-8478-8517; Sasaki, Atsuo/0000-0003-2963-4501; ohtsubo, motoaki/0000-0002-2479-3178				Alimandi M, 1997, ONCOGENE, V15, P585, DOI 10.1038/sj.onc.1201221; ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; Bustelo XR, 1997, ONCOGENE, V15, P2511, DOI 10.1038/sj.onc.1201430; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; GAZIT A, 1984, CELL, V39, P89, DOI 10.1016/0092-8674(84)90194-6; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HUANG XM, 1995, P NATL ACAD SCI USA, V92, P11618, DOI 10.1073/pnas.92.25.11618; JONGEWARD GD, 1995, GENETICS, V139, P1553; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; KEANE MM, 1995, ONCOGENE, V10, P2367; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; OSBORNE MA, 1995, BIO-TECHNOL, V13, P1474, DOI 10.1038/nbt1295-1474; Osborne MA, 1996, J BIOL CHEM, V271, P29271, DOI 10.1074/jbc.271.46.29271; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; PAWSON T, 1992, CELL, V56, P5; Rellahan BL, 1997, J BIOL CHEM, V272, P30806, DOI 10.1074/jbc.272.49.30806; RODAN SB, 1987, CANCER RES, V47, P4961; Rui LY, 1997, MOL CELL BIOL, V17, P6633, DOI 10.1128/MCB.17.11.6633; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; STEPHENSON DA, 1991, P NATL ACAD SCI USA, V88, P6, DOI 10.1073/pnas.88.1.6; Takaki S, 1997, J BIOL CHEM, V272, P14562, DOI 10.1074/jbc.272.23.14562; Ueno H, 1997, J BIOL CHEM, V272, P8739, DOI 10.1074/jbc.272.13.8739; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1995, MOL CELL BIOL, V15, P3058; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; Wang J, 1998, J BIOL CHEM, V273, P3136, DOI 10.1074/jbc.273.6.3136; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; Yokouchi M, 1997, ONCOGENE, V15, P7, DOI 10.1038/sj.onc.1201163; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	38	68	71	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					759	767		10.1038/sj.onc.1202326	http://dx.doi.org/10.1038/sj.onc.1202326			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989826				2022-12-17	WOS:000078394400021
J	Liebermann, DA; Hoffman, B				Liebermann, DA; Hoffman, B			MyD genes in negative growth control	ONCOGENE			English	Review						MyD genes; growth arrest; apoptosis; myeloid differentiation; IRF-1; fos	NF-KAPPA-B; PRIMARY RESPONSE GENE; PROGRAMMED CELL-DEATH; MYELOID-LEUKEMIA CELLS; HERPES-SIMPLEX VIRUS; REGULATORY FACTOR-I; ACTIVATED PROTEIN-KINASE; SWINE FEVER VIRUS; RECEPTOR ACCESSORY PROTEIN; SIGNAL-TRANSDUCTION PATHWAY	Two interrelated cellular processes are invoked simultaneously upon induction of differentiation, the regulated progression of cells through successive stages of cell differentiation and growth inhibition which ultimately leads to growth arrest. In tissues with rapid cell turnover terminally differentiated cells undergo programmed cell death. Terminal differentiation, thus, represents one form of negative growth control. It was surmised that the molecular engine which drives the differentiation process forward requires induction of positive regulators of terminal cell differentiation, to be found among differentiation primary response genes, as well as suppression of negative regulators, which correspond to genes which control cellular growth. This line of thought has prompted the isolation of myeloid differentiation primary response (MyD) genes activated in the absence of de novo protein synthesis, upon IL-6 induced terminal differentiation of murine MI myeloblastic leukemia cells, where the cells growth arrest and ultimately undergo programmed cell death. As delineated in this review many of the genes identified as MyD genes, including both known genes [IRF-1, (AP-1) Fos/Jun.EGR-1] and novel ones (MyD88, MyD116, MyD118), turned out to play a role in negative growth control, including growth suppression and apoptosis, in many cell types, of both hematopoietic and non hematopoietic origins.	Temple Univ, Fels Inst Canc Res & Mol Biol, Sch Med, Philadelphia, PA 19140 USA; Temple Univ, Dept Biochem, Sch Med, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Liebermann, DA (corresponding author), Temple Univ, Fels Inst Canc Res & Mol Biol, Sch Med, 3307 N Broad St, Philadelphia, PA 19140 USA.							ABDOLLAHI A, 1991, ONCOGENE, V6, P165; ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; Ahmed MM, 1997, J BIOL CHEM, V272, P33056, DOI 10.1074/jbc.272.52.33056; Aizawa S, 1997, J BIOL CHEM, V272, P2042; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BEADLING C, 1993, P NATL ACAD SCI USA, V90, P2719, DOI 10.1073/pnas.90.7.2719; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Brown SM, 1997, J VIROL, V71, P9442, DOI 10.1128/JVI.71.12.9442-9449.1997; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; CHOU J, 1994, P NATL ACAD SCI USA, V91, P5247, DOI 10.1073/pnas.91.12.5247; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Dinkel A, 1997, J IMMUNOL, V159, P2678; Distel R J, 1990, Adv Cancer Res, V55, P37, DOI 10.1016/S0065-230X(08)60467-4; DIXON LK, 1994, J GEN VIROL, V75, P1655, DOI 10.1099/0022-1317-75-7-1655; Duckett CS, 1997, MOL CELL BIOL, V17, P1535, DOI 10.1128/MCB.17.3.1535; ELDON E, 1994, DEVELOPMENT, V120, P885; ELIOT HE, 1995, ANTICANCER RES, V15, P729; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FORNACE AJ, 1992, ANN NY ACAD SCI, V663, P139, DOI 10.1111/j.1749-6632.1992.tb38657.x; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; FUNATO T, 1992, ADV ENZYME REGUL, V32, P195; Gajate C, 1996, BIOCHEM BIOPH RES CO, V218, P267, DOI 10.1006/bbrc.1996.0047; GALINDO RL, 1995, DEVELOPMENT, V121, P2209; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Goodenough S, 1997, EXP NEUROL, V145, P451, DOI 10.1006/exnr.1997.6471; Grant S, 1996, CELL GROWTH DIFFER, V7, P603; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; Grimm S, 1996, P NATL ACAD SCI USA, V93, P10923, DOI 10.1073/pnas.93.20.10923; GROSSHANS J, 1994, NATURE, V372, P563, DOI 10.1038/372563a0; Guillouf C, 1998, INT J ONCOL, V13, P107; GUNJI H, 1991, CANCER RES, V51, P741; HALL PA, 1995, ONCOGENE, V10, P2427; Hallahan DE, 1995, J BIOL CHEM, V270, P30303, DOI 10.1074/jbc.270.51.30303; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; Hardiman G, 1996, ONCOGENE, V13, P2467; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; He B, 1997, P NATL ACAD SCI USA, V94, P843, DOI 10.1073/pnas.94.3.843; He B, 1996, J VIROL, V70, P84, DOI 10.1128/JVI.70.1.84-90.1996; He HL, 1998, J BIOL CHEM, V273, P25015, DOI 10.1074/jbc.273.39.25015; HERRLICH P, 1994, ADV ENZYME REGUL, V34, P381, DOI 10.1016/0065-2571(94)90024-8; Hoey T, 1997, SCIENCE, V278, P1578, DOI 10.1126/science.278.5343.1578; HOFMANN K, 1995, FEBS LETT, V371, P321, DOI 10.1016/0014-5793(95)00931-X; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; Horiuchi M, 1997, J BIOL CHEM, V272, P11952, DOI 10.1074/jbc.272.18.11952; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1997, J BIOL CHEM, V272, P13471, DOI 10.1074/jbc.272.21.13471; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Huang JN, 1997, P NATL ACAD SCI USA, V94, P12829, DOI 10.1073/pnas.94.24.12829; HULTMARK D, 1994, BIOCHEM BIOPH RES CO, V199, P144, DOI 10.1006/bbrc.1994.1206; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; ITOH N, 1993, J BIOL CHEM, V268, P10932; Jacobs-Helber SM, 1998, MOL CELL BIOL, V18, P3699, DOI 10.1128/MCB.18.7.3699; Jaunin F, 1998, EXP CELL RES, V243, P67, DOI 10.1006/excr.1998.4131; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; Kanangat S, 1996, VIROLOGY, V219, P295, DOI 10.1006/viro.1996.0250; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1998, CANCER J SCI AM, V4, pS92; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Korherr C, 1997, EUR J IMMUNOL, V27, P262, DOI 10.1002/eji.1830270139; KREIPE H, 1986, DIFFERENTIATION, V33, P56, DOI 10.1111/j.1432-0436.1986.tb00410.x; Krishnaraju K, 1998, BLOOD, V92, P1957, DOI 10.1182/blood.V92.6.1957.418k24_1957_1966; KRISHNARAJU K, 1995, MOL CELL BIOL, V15, P5499; Krishnaraju K, 1997, BLOOD, V90, P1840, DOI 10.1182/blood.V90.5.1840; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Lallemand C, 1997, J BIOL CHEM, V272, P29801, DOI 10.1074/jbc.272.47.29801; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; LETSOU A, 1993, EMBO J, V12, P3449, DOI 10.1002/j.1460-2075.1993.tb06019.x; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Liebermann DA, 1998, INT J ONCOL, V12, P685; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; Lord EM., 1991, FLOWERING NEWSLETTER, V11, P4; LORD KA, 1990, ONCOGENE, V5, P387; LORD KA, 1990, ONCOGENE, V5, P1095; LORD KA, 1990, CELL GROWTH DIFFER, V1, P637; LORD KA, 1990, NUCLEIC ACIDS RES, V18, P2823, DOI 10.1093/nar/18.9.2823; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; Lovenberg TW, 1996, J NEUROIMMUNOL, V70, P113, DOI 10.1016/S0165-5728(96)00047-1; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MCGEOCH DJ, 1991, NATURE, V353, P609, DOI 10.1038/353609b0; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MESNER PW, 1995, J NEUROSCI, V15, P7357; Mitcham JL, 1996, J BIOL CHEM, V271, P5777, DOI 10.1074/jbc.271.10.5777; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Mossi R, 1998, EUR J BIOCHEM, V254, P209, DOI 10.1046/j.1432-1327.1998.254209.x; MUTHUKKUMAR S, 1995, MOL CELL BIOL, V15, P6262; Muthukkumar S, 1997, J BIOL CHEM, V272, P27987, DOI 10.1074/jbc.272.44.27987; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Nguyen H, 1997, ONCOGENE, V15, P1425, DOI 10.1038/sj.onc.1201318; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; Norris JL, 1996, GENE DEV, V10, P862, DOI 10.1101/gad.10.7.862; Ossina NK, 1997, J BIOL CHEM, V272, P16351, DOI 10.1074/jbc.272.26.16351; PANTERNE B, 1992, ONCOGENE, V7, P2341; Parker JE, 1997, PLANT CELL, V9, P879, DOI 10.1105/tpc.9.6.879; Parnet P, 1996, J BIOL CHEM, V271, P3967; Preston GA, 1996, MOL CELL BIOL, V16, P211; Prosperi E, 1997, Prog Cell Cycle Res, V3, P193; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; RITKE MK, 1994, MOL PHARMACOL, V46, P605; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; RofflerTarlov S, 1996, DEVELOPMENT, V122, P1; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; RUBIN E, 1992, CANCER RES, V52, P878; RUBIN E, 1991, MOL PHARMACOL, V39, P697; SALEEM A, 1995, CELL GROWTH DIFFER, V6, P1651; Sato T, 1997, BLOOD, V90, P4749, DOI 10.1182/blood.V90.12.4749.4749_4749_4758; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; SQUIER MKT, 1995, J LEUKOCYTE BIOL, V57, P2, DOI 10.1002/jlb.57.1.2; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Su ZZ, 1997, P NATL ACAD SCI USA, V94, P9125, DOI 10.1073/pnas.94.17.9125; SUSSMAN MD, 1992, J VIROL, V66, P5586, DOI 10.1128/JVI.66.9.5586-5589.1992; Tamura T, 1996, BIOCHEM BIOPH RES CO, V229, P21, DOI 10.1006/bbrc.1996.1752; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Vairapandi M, 1996, ONCOGENE, V12, P2579; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VYDELINGUM S, 1993, J GEN VIROL, V74, P2125, DOI 10.1099/0022-1317-74-10-2125; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WASSERMAN SA, 1993, MOL BIOL CELL, V4, P767, DOI 10.1091/mbc.4.8.767; WEICHSELBAUM RR, 1994, INT J RADIAT ONCOL, V30, P229, DOI 10.1016/0360-3016(94)90539-8; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wesche H, 1997, J BIOL CHEM, V272, P7727, DOI 10.1074/jbc.272.12.7727; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAMAGATA M, 1994, GENE, V139, P223, DOI 10.1016/0378-1119(94)90760-9; YANAGISAWA K, 1993, FEBS LETT, V318, P83, DOI 10.1016/0014-5793(93)81333-U; YULEE LY, 1990, MOL CELL BIOL, V10, P3087, DOI 10.1128/MCB.10.6.3087; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zsak L, 1996, J VIROL, V70, P8865, DOI 10.1128/JVI.70.12.8865-8871.1996	164	68	71	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 24	1998	17	25					3319	3329		10.1038/sj.onc.1202574	http://dx.doi.org/10.1038/sj.onc.1202574			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157EW	9916994				2022-12-17	WOS:000078048200013
J	Austen, M; Cerni, C; Luscher-Firzlaff, JM; Luscher, B				Austen, M; Cerni, C; Luscher-Firzlaff, JM; Luscher, B			YY1 can inhibit c-Myc function through a mechanism requiring DNA binding of YY1 but neither its transactivation domain nor direct interaction with c-Myc	ONCOGENE			English	Article						transformation; c-Myc; YY1; Myc/Max DNA-binding; protein-protein interaction; gene transcription	ADENOVIRUS E1A PROTEINS; ZINC-FINGER PROTEIN; N-TERMINAL DOMAIN; CASEIN KINASE-II; TRANSCRIPTIONAL ACTIVATION; VIRAL ONCOPROTEINS; BURKITTS-LYMPHOMA; TUMOR-SUPPRESSOR; FOS PROMOTER; NF-E1 YY-1	The proto-oncoprotein c-Myc and the multifunctional transcriptional regulator YY1 have been shown previously to interact directly in a manner that excludes Max from the complex (Shrivastava et al., 1993). As binding to Max is necessary for all known c-Myc activities we have analysed the influence of YY1 on c-Myc function. We demonstrate that YY1 is a potent inhibitor of c-Myc transforming activity. The region in YY1 required for inhibition corresponds to a functional DNA-binding domain and is distinct from the domains necessary for direct binding to c-Myc. Furthermore the transactivation domain of YY1 was not necessary suggesting that gene regulation by YY1, for example through DNA bending or displacement of regulators from DNA, could be the cause for the negative regulation of c-Myc. This model of indirect regulation of c-Myc by YY1 was supported by the finding that although YY1 did not bind to the c-Myc transactivation domain (TAD) in vitro it was able to inhibit transactivation by Gal4-MycTAD fusion proteins in transient transfections. As for the inhibition of transformation, an intact DNA-binding domain of YY1 was necessary and sufficient for this effect. In addition YY1 did not alter c-Myc/Max DNA binding, further supporting an indirect mode of action. Our findings point to a role of YY1 as a negative regulator of cell growth with a possible involvement in tumor suppression.	Hannover Med Sch, Inst Mol Biol, D-30623 Hannover, Germany; Univ Vienna, Inst Tumorbiol & Krebsforsch, A-1090 Vienna, Austria	Hannover Medical School; University of Vienna	Luscher, B (corresponding author), Hannover Med Sch, Inst Mol Biol, D-30623 Hannover, Germany.		Luscher, Bernhard/A-7330-2011	Luscher, Bernhard/0000-0002-9622-8709				ALBERT T, 1994, ONCOGENE, V9, P759; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Austen M, 1997, J BIOL CHEM, V272, P1709, DOI 10.1074/jbc.272.3.1709; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BASU A, 1993, J BIOL CHEM, V268, P4188; BECKER KG, 1994, GENE, V150, P259, DOI 10.1016/0378-1119(94)90435-9; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOUSSET K, 1994, CELL MOL BIOL RES, V40, P501; BUSHMEYER S, 1995, J BIOL CHEM, V270, P30213; CERNI C, 1995, ONCOGENE, V11, P587; CERNI C, 1989, P NATL ACAD SCI USA, V86, P3266, DOI 10.1073/pnas.86.9.3266; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; Furlong EEM, 1996, MOL CELL BIOL, V16, P5933; Galvin KM, 1997, MOL CELL BIOL, V17, P3723, DOI 10.1128/MCB.17.7.3723; GASTON K, 1994, FEBS LETT, V347, P289, DOI 10.1016/0014-5793(94)00567-2; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; Guo B, 1997, P NATL ACAD SCI USA, V94, P121, DOI 10.1073/pnas.94.1.121; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HAHN S, 1992, Current Biology, V2, P152, DOI 10.1016/0960-9822(92)90268-F; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; HATEBOER G, 1993, P NATL ACAD SCI USA, V90, P8489, DOI 10.1073/pnas.90.18.8489; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Houbaviy HB, 1996, P NATL ACAD SCI USA, V93, P13577, DOI 10.1073/pnas.93.24.13577; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JANKNECHT R, 1992, NUCLEIC ACIDS RES, P3317; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; Li WW, 1997, MOL CELL BIOL, V17, P54, DOI 10.1128/MCB.17.1.54; Li WW, 1997, MOL CELL BIOL, V17, P61, DOI 10.1128/MCB.17.1.61; LU SY, 1994, MOL CELL BIOL, V14, P6253, DOI 10.1128/MCB.14.9.6253; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; Lutterbach B, 1997, ONCOGENE, V14, P967, DOI 10.1038/sj.onc.1200920; MAHESWARAN S, 1994, MOL CELL BIOL, V14, P1147, DOI 10.1128/MCB.14.2.1147; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MEIER VS, 1994, MOL CELL BIOL, V14, P128, DOI 10.1128/MCB.14.1.128; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; NATESAN S, 1995, MOL CELL BIOL, V15, P5975; NEVINS JR, 1992, SCIENCE, V258, P424; OELGESCHLAGER M, 1995, MOL CELL BIOL, V15, P5966; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PISANESCHI G, 1994, BIOCHEM BIOPH RES CO, V205, P1236, DOI 10.1006/bbrc.1994.2797; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRENDERGAST GC, 1997, RETROVIRAL ONCOGENES, V1, P1; PULVERER BJ, 1994, ONCOGENE, V9, P59; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; Shen WC, 1997, CELL, V90, P615, DOI 10.1016/S0092-8674(00)80523-1; SHENK T, 1991, ADV CANCER RES, V57, P47; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; Shrivastava A, 1996, P NATL ACAD SCI USA, V93, P10638, DOI 10.1073/pnas.93.20.10638; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SOLOMON DLC, 1993, NUCLEIC ACIDS RES, V21, P5372, DOI 10.1093/nar/21.23.5372; Sommer A, 1997, CURR BIOL, V7, P357, DOI 10.1016/S0960-9822(06)00183-7; Sommer A, 1998, J BIOL CHEM, V273, P6632, DOI 10.1074/jbc.273.12.6632; Usheva A, 1996, P NATL ACAD SCI USA, V93, P13571, DOI 10.1073/pnas.93.24.13571; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; Walker SS, 1997, CELL, V90, P607, DOI 10.1016/S0092-8674(00)80522-X; Wang EH, 1997, GENE DEV, V11, P2658, DOI 10.1101/gad.11.20.2658; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; YANO T, 1993, ONCOGENE, V8, P2741; ZHOU QJ, 1995, J VIROL, V69, P7402, DOI 10.1128/JVI.69.12.7402-7409.1995	87	68	74	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 30	1998	17	4					511	520		10.1038/sj.onc.1201968	http://dx.doi.org/10.1038/sj.onc.1201968			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696045				2022-12-17	WOS:000075043000014
J	Huang, P				Huang, P			Excision of mismatched nucleotides from DNA: a potential mechanism for enhancing DNA replication fidelity by the wild-type p53 protein	ONCOGENE			English	Article						p53; 3 '-> 5 ' exonuclease; DNA replication fidelity; nucleotide excision	C-TERMINAL DOMAIN; POLYMERASE-ALPHA; TRANSCRIPTIONAL ACTIVATION; P53-DEPENDENT APOPTOSIS; INVITRO REPLICATION; T-ANTIGEN; CELLS; EPSILON; CYTOTOXICITY; DELTA	The tumor suppressor p53 plays a critical role in the regulation of the cell cycle and the maintenance of genetic stability. The 3'-->5' exonuclease activity of p53 has recently been recognized as a novel biochemical function of this molecule, but the biological significance of this activity remains elusive. Using an in vitro DNA replication assay with purified human DNA polymerases, p53 protein, and defined DNA primer/templates, we demonstrated that the wild-type (wt) p53 protein, but not the mutant p53 protein, specifically enhanced the DNA replication fidelity of polymerase (pol) alpha, an enzyme that lacks 3'-->5' exonuclease activity. The misincorporation of non-complementary deoxynucleotides into DNA by pol alpha was substantially decreased by p53. In contrast, wt p53 showed no significant effect on replication fidelity or the rates of DNA synthesis by human pol epsilon or the bacterial enzyme pol I. Inhibition of 3'-->5' exonuclease activity by guanosine monophosphate (GMP) abolished the ability of p53 to enhance the replication fidelity of pol alpha. Quantitative analyses revealed that the 3'-->5' exonuclease activity of p53 effectively removed mismatched nucleotides from DNA in preference over matched nucleotides. Furthermore, study in intact cells revealed that the wt p53 protein was co-localized with DNA synthesis activity in S phase cells. These results suggest a possibility that the 3'-->5' exonuclease of the wt p53 protein might provide the proof-reading function for DNA pol alpha. The preferential excision of mismatched nucleotides from the replicating DNA strand appears to be a potential biochemical mechanism by which p53 enhances DNA replication fidelity and thereby helps to maintain genomic integrity.	Univ Texas, Md Anderson Canc Ctr, Dept Clin Invest, Sect Mol & Cellular Pharmacol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Huang, P (corresponding author), Univ Texas, Md Anderson Canc Ctr, Dept Clin Invest, Sect Mol & Cellular Pharmacol, Houston, TX 77030 USA.				NCI NIH HHS [CA28596, CA77339] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA077339, R01CA028596] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Arita D, 1997, JPN J CANCER RES, V88, P39, DOI 10.1111/j.1349-7006.1997.tb00299.x; BAKER CH, 1991, J MED CHEM, V34, P1879, DOI 10.1021/jm00110a019; BAMBARA RA, 1991, BIOCHIM BIOPHYS ACTA, V1088, P11, DOI 10.1016/0167-4781(91)90147-E; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BEBENEK K, 1992, J BIOL CHEM, V267, P3589; BOYER JC, 1993, CANCER RES, V53, P3270; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CLARKE AR, 1994, ONCOGENE, V9, P1767; COVERLEY D, 1994, ANNU REV BIOCHEM, V63, P745, DOI 10.1146/annurev.bi.63.070194.003525; COX LS, 1991, CELL, V66, P271, DOI 10.1016/0092-8674(91)90617-8; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ECKERT KA, 1993, NUCLEIC ACIDS RES, V21, P5212, DOI 10.1093/nar/21.22.5212; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GANDHI V, 1990, CANCER RES, V50, P3675; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; HARPER JW, 1993, CELL, V75, P805; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HOZAK P, 1993, CELL, V73, P361, DOI 10.1016/0092-8674(93)90235-I; HUANG P, 1991, CANCER RES, V51, P6110; Huang P, 1997, CANCER RES, V57, P3407; HUANG P, 1990, J BIOL CHEM, V265, P16617; HUANG P, 1991, MOL PHARMACOL, V39, P449; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; Kamiya K, 1996, J BIOL CHEM, V271, P19428, DOI 10.1074/jbc.271.32.19428; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KUNKEL TA, 1992, BIOESSAYS, V14, P303, DOI 10.1002/bies.950140503; KUNZ BA, 1994, MUTAT RES-REV GENET, V318, P1, DOI 10.1016/0165-1110(94)90006-X; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LOEB LA, 1982, ANNU REV BIOCHEM, V52, P429; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MERRIL CR, 1990, METHOD ENZYMOL, V182, P477; MILLER SD, 1995, MOL CELL BIOL, V15, P6554; Miller SD, 1997, MOL CELL BIOL, V17, P2194, DOI 10.1128/MCB.17.4.2194; MILLS AD, 1989, J CELL SCI, V94, P471; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORRISON A, 1994, MOL GEN GENET, V242, P289, DOI 10.1007/BF00280418; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; NAKAMURA H, 1986, EXP CELL RES, V165, P291, DOI 10.1016/0014-4827(86)90583-5; NEVINS JR, 1992, SCIENCE, V258, P424; Peled A, 1996, CANCER RES, V56, P2148; PENG H, 1995, AM J PATHOL, V148, P643; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; ROBERTS JD, 1991, P NATL ACAD SCI USA, V88, P3465, DOI 10.1073/pnas.88.8.3465; Staib C, 1996, VIROLOGY, V219, P237, DOI 10.1006/viro.1996.0241; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; SYVAOJA J, 1990, P NATL ACAD SCI USA, V87, P6664, DOI 10.1073/pnas.87.17.6664; vanLaar T, 1996, CYTOMETRY, V25, P21, DOI 10.1002/(SICI)1097-0320(19960901)25:1<21::AID-CYTO3>3.0.CO;2-H; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WALDMAN T, 1995, CANCER RES, V55, P5187; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	62	68	71	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 23	1998	17	3					261	270		10.1038/sj.onc.1201946	http://dx.doi.org/10.1038/sj.onc.1201946			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	102VV	9690508				2022-12-17	WOS:000074947500001
J	Ko, TC; Yu, WS; Sakai, T; Sheng, HM; Shao, JY; Beauchamp, RD; Thompson, EA				Ko, TC; Yu, WS; Sakai, T; Sheng, HM; Shao, JY; Beauchamp, RD; Thompson, EA			TGF-beta 1 effects on proliferation of rat intestinal epithelial cells are due to inhibition of cyclin D1 expression	ONCOGENE			English	Article						TGF-beta 1; cyclin D1; cyclin-dependent kinase; gut epithelial cells; antisense oligonucleotide	TGF-BETA RECEPTOR; GROWTH-FACTOR; GENE-EXPRESSION; DIFFERENTIAL SENSITIVITY; RETINOBLASTOMA PROTEIN; PRB PHOSPHORYLATION; POTENTIAL MEDIATOR; TRANSGENIC MICE; CARCINOMA-CELLS; CDK INHIBITORS	Transforming growth factor-beta 1 (TGF-beta 1) arrests intestinal epithelial cells (RIE-1 and IEC-6) in the G1 phase of the cell cycle and inhibits cyclin D1 expression, This report describes experiments designed to elucidate the mechanism of cyclin D1 inhibition and to determine whether inhibition of cyclin D1 expression is the cause, rather than the result, of TGF-beta 1-mediated cell cycle arrest, TGF-beta 1 inhibition of IEC-6 cell proliferation mas associated with a decrease in the abundance of cyclin D1/Cdk4 complexes and a corresponding decrease in Cdk4-dependent phosphorylation of the retinoblastoma protein, Metabolic labeling studies indicated that TGF-beta 1 inhibited cyclin D1 synthesis without altering the rate of cyclin DI protein degradation. Cyclin D1 antisense oligonucleotides blocked serum-stimulated induction of cyclin D1 and DNA synthesis, whereas cyclin D1 sense oligonucleotides had no effect. RIE-1 cells were engineered to overexpress human cyclin D1 under the control of a tetracycline-repressible promoter, These cells entered S phase in the presence of TGF-beta 1 only when human cyclin D1 was derepressed by the withdrawal of tetracycline. These data indicate that TGF-beta 1 inhibits the synthesis of cyclin D1 in gut epithelial cells and that this inhibition is the cause, rather than the result, of TGF-beta 1-mediated arrest of intestinal epithelial cell proliferation.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Surg, Galveston, TX 77555 USA; Vanderbilt Univ, Sch Med, Dept Surg, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA; Showa Univ, Sch Med, Dept Internal Med 3, Tokyo 142, Japan	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Vanderbilt University; Vanderbilt University; Showa University	Thompson, EA (corresponding author), Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA.			Beauchamp, Robert Daniel/0000-0002-8446-4114	NCI NIH HHS [CA64191, CA64701, CA69457] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069457, R01CA064701, K08CA064191] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABAYATSKY MW, 1991, TXB GASTROENTEROLOGY, P475; AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; Arber N, 1997, CANCER RES, V57, P1569; Arber N, 1996, GASTROENTEROLOGY, V110, P669, DOI 10.1053/gast.1996.v110.pm8608874; BARNARD JA, 1993, GASTROENTEROLOGY, V105, P67, DOI 10.1016/0016-5085(93)90011-Z; BARNARD JA, 1989, P NATL ACAD SCI USA, V86, P1578, DOI 10.1073/pnas.86.5.1578; BARTKOVA J, 1994, INT J CANCER, V58, P568, DOI 10.1002/ijc.2910580420; BLAY J, 1985, J CELL PHYSIOL, V124, P107, DOI 10.1002/jcp.1041240117; BLAY J, 1984, CELL BIOL INT REP, V8, P551, DOI 10.1016/0309-1651(84)90054-7; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; Bresnahan WA, 1996, VIROLOGY, V224, P150, DOI 10.1006/viro.1996.0516; CAIRNIE AB, 1965, EXP CELL RES, V39, P528, DOI 10.1016/0014-4827(65)90055-8; Chandrasekaran C, 1996, J BIOL CHEM, V271, P28414, DOI 10.1074/jbc.271.45.28414; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CIACCI C, 1993, GASTROENTEROLOGY, V105, P93, DOI 10.1016/0016-5085(93)90014-4; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Evers BM, 1996, AM J PHYSIOL-GASTR L, V271, pG722, DOI 10.1152/ajpgi.1996.271.4.G722; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; FILMUS J, 1992, ONCOGENE, V7, P521; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; FROST GH, 1993, J BIOL CHEM, V268, P6748; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GORDON JI, 1992, FASEB J, V6, P3039, DOI 10.1096/fasebj.6.12.1521737; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HALL PA, 1994, J CELL SCI, V107, P3569; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HOOSEIN NM, 1989, EXP CELL RES, V181, P442, DOI 10.1016/0014-4827(89)90101-8; HUBER HE, 1993, P NATL ACAD SCI USA, V90, P3525, DOI 10.1073/pnas.90.8.3525; Hung WC, 1996, BIOCHEM BIOPH RES CO, V220, P719, DOI 10.1006/bbrc.1996.0470; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; KATO J, 1993, GENE DEV, V7, P331; KO TC, 1995, ONCOGENE, V10, P177; KO TC, 1994, AM J SURG, V167, P14, DOI 10.1016/0002-9610(94)90048-5; KUROKOWA M, 1987, BIOCHEM BIOPH RES CO, V142, P775, DOI 10.1016/0006-291X(87)91481-1; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAllemain G, 1997, ONCOGENE, V14, P1981, DOI 10.1038/sj.onc.1201038; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; MacGrogan D, 1997, ONCOGENE, V15, P1111, DOI 10.1038/sj.onc.1201232; MANNING AM, 1991, ONCOGENE, V6, P1471; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MUNGER K, 1992, CELL GROWTH DIFFER, V3, P291; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; PALMERO I, 1993, ONCOGENE, V8, P1049; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; Ramalingam A, 1997, MOL ENDOCRINOL, V11, P577, DOI 10.1210/me.11.5.577; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; RHEE K, 1995, CANCER RES, V55, P4188; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; STEIN CA, 1988, NUCLEIC ACIDS RES, V16, P3209, DOI 10.1093/nar/16.8.3209; SUN LZ, 1994, J BIOL CHEM, V269, P26449; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TRABER PG, 1994, J LAB CLIN MED, V123, P467; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zhang T, 1997, CANCER RES, V57, P169; Zhang T, 1997, CANCER RES, V57, P1638	68	68	69	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 2	1998	16	26					3445	3454		10.1038/sj.onc.1201902	http://dx.doi.org/10.1038/sj.onc.1201902			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZX689	9692552				2022-12-17	WOS:000074544100011
J	Sweeney, KJ; Swarbrick, A; Sutherland, RL; Musgrove, EA				Sweeney, KJ; Swarbrick, A; Sutherland, RL; Musgrove, EA			Lack of relationship between CDK activity and G(1) cyclin expression in breast cancer cells	ONCOGENE			English	Article						cyclin D1; cyclin E; CDK; CKI; breast cancer; kinase activity	DEPENDENT KINASES; INHIBITS GROWTH; D1; OVEREXPRESSION; LINE; PROTEINS; PRB; DIFFERENTIATION; PROLIFERATION; AMPLIFICATION	The G(1) cyclins, cyclin D1 and E, are rate limiting for progression through G(1) phase of the cell cycle in breast epithelial cells and are oncogenic when expressed in the mammary epithelium of transgenic mice. These genes are frequently overexpressed in clinical breast cancer where overexpression appears to be associated with specific disease phenotypes, altered responsiveness to therapeutic intervention and patient survival. In order to investigate the functional correlates of cyclin D1 and cyclin E overexpression we employed a panel of normal, immortalized and neoplastic breast epithelial cell lines to examine the relationships between cyclin gene expression, cyclin-CDK complex formation and CDK activity. In agreement with earlier studies cyclin D1 and E expression varied over an approximately tenfold range among the 18 cell lines studied. There was no apparent relationship, however, between cyclin D1 expression and the in vitro activity of its major kinase partner, Cdk4, although MDA-MB-134 cells displayed the highest level of both cyclin D1 expression and Cdk4 activity. Similarly, there was no significant relationship between cyclin E expression and cyclin E-Cdk2 activity. Fractionation of whole cell lysates by gel filtration chromatography revealed that similar to 90% of the cyclin E protein was present in inactive complexes containing the CDK inhibitors p21 and p27. Much of the small fraction of active cyclin E protein was of very high apparent molecular mass, >400 kDa, suggesting that formation of these complexes is a more important determinant of cyclin E-Cdk2 activity than cyclin E abundance. These data suggest that properties of cyclins D1 and E in addition to their ability to activate Cdk4 and Cdk2 may contribute to the effects of overexpression on the breast cancer phenotype.	St Vincents Hosp, Gardiner Inst, Canc Res Program, Sydney, NSW 2010, Australia	St Vincents Hospital Sydney	Musgrove, EA (corresponding author), St Vincents Hosp, Gardiner Inst, Canc Res Program, Sydney, NSW 2010, Australia.		Sutherland, Robert L/A-8378-2008; Swarbrick, Alexander/E-6107-2010	Swarbrick, Alexander/0000-0002-3051-5676				ALLE KM, 1997, IN PRESS CLIN CANC R; Bartkova J, 1996, INT J CANCER, V65, P323, DOI 10.1002/(SICI)1097-0215(19960126)65:3<323::AID-IJC8>3.0.CO;2-1; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; DESAI D, 1995, MOL CELL BIOL, V15, P345, DOI 10.1128/MCB.15.1.345; DUTTA A, 1995, P NATL ACAD SCI USA, V92, P5386, DOI 10.1073/pnas.92.12.5386; Florenes VA, 1996, ONCOGENE, V13, P2447; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; Gillett C, 1996, INT J CANCER, V69, P92, DOI 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.3.CO;2-I; GILLETT C, 1994, CANCER RES, V54, P1812; GrayBablin J, 1996, P NATL ACAD SCI USA, V93, P15215, DOI 10.1073/pnas.93.26.15215; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HAN EKH, 1995, ONCOGENE, V10, P953; Han EKH, 1996, CELL GROWTH DIFFER, V7, P699; Higashi H, 1996, EUR J BIOCHEM, V237, P460, DOI 10.1111/j.1432-1033.1996.0460k.x; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Hiyama H, 1997, ONCOGENE, V14, P2533, DOI 10.1038/sj.onc.1201080; Hui R, 1996, CLIN CANCER RES, V2, P923; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KEYOMARSI K, 1994, CANCER RES, V54, P380; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KRANENBURG O, 1995, ONCOGENE, V10, P87; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MCINTOSH GG, 1995, ONCOGENE, V11, P885; Michalides R, 1996, BRIT J CANCER, V73, P728, DOI 10.1038/bjc.1996.128; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Musgrove EA, 1996, J CELL BIOCHEM, V60, P363; MUSGROVE EA, 1989, CANCER RES, V49, P2398; MUSGROVE EA, 1995, INT J CANCER, V63, P584, DOI 10.1002/ijc.2910630420; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Nielsen NH, 1996, BRIT J CANCER, V74, P874, DOI 10.1038/bjc.1996.451; Nielsen NH, 1997, ONCOGENE, V14, P295, DOI 10.1038/sj.onc.1200833; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PARGE HE, 1993, SCIENCE, V262, P387, DOI 10.1126/science.8211159; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Sarcevic B, 1997, J BIOL CHEM, V272, P33327, DOI 10.1074/jbc.272.52.33327; Sgambato A, 1996, CANCER RES, V56, P1389; Sgambato A, 1997, CELL GROWTH DIFFER, V8, P393; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sidle A, 1996, CRIT REV BIOCHEM MOL, V31, P237, DOI 10.3109/10409239609106585; SoferLevi Y, 1996, ONCOGENE, V13, P2431; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; Sweeney KJ, 1997, ONCOGENE, V14, P1329, DOI 10.1038/sj.onc.1200951; Tan P, 1997, CANCER RES, V57, P1259; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	59	68	69	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 4	1998	16	22					2865	2878		10.1038/sj.onc.1201814	http://dx.doi.org/10.1038/sj.onc.1201814			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZR544	9671407				2022-12-17	WOS:000073988200005
J	Rubino, D; Driggers, P; Arbit, D; Kemp, L; Miller, B; Coso, O; Pagliai, K; Gray, K; Gutkind, S; Segars, J				Rubino, D; Driggers, P; Arbit, D; Kemp, L; Miller, B; Coso, O; Pagliai, K; Gray, K; Gutkind, S; Segars, J			Characterization of Brx, a novel Dbl family member that modulates estrogen receptor action	ONCOGENE			English	Article						estrogen receptor; signal transduction; Rho GTPase; Cdc42Hs; Dbl; Rho GEF; Lbc	GUANINE-NUCLEOTIDE EXCHANGE; GTP-BINDING PROTEINS; LIGAND-INDEPENDENT ACTIVATION; STEROID-HORMONE RECEPTORS; HUMAN BREAST-CANCER; TRANSCRIPTIONAL ACTIVATION; MEDIATED TRANSCRIPTION; SIGNALING PATHWAYS; STRUCTURAL SIMILARITIES; SEQUENCE SIMILARITY	Regulation of gene activation by the estrogen receptor (ER) is complex and involves co-regulatory proteins, oncoproteins (such as Fos and Jun), and phosphorylation signaling pathways. Here we report the cloning and initial characterization of a novel protein, Err, that contains a region of identity to the oncogenic Rho-guanine nucleotide exchange (Rho-GEF) protein Lbc, and a unique region capable of binding to nuclear hormone receptors, including the ER, Western and immunohistochemistry studies showed Brx to be expressed in estrogen-responsive reproductive tissues, including breast ductal epithelium, Err bound specifically to the ER via an interaction that required distinct regions of ER and Brx. Furthermore, overexpression of Brx in transfection experiments using an estrogen-responsive reporter revealed that Err augmented gene activation by the ER in an element-specific and ligand-dependent manner, Moreover, activation of ER by Brx could be specifically inhibited by a dominant-negative mutant of Cdc42Hs, but not by dominant negative mutants of RhoA or Rac1. Taken together, these data suggest that Err represents a novel modular protein that may integrate cytoplasmic signaling pathways involving Rho family GTPases and nuclear hormone receptors.	NICHHD, Off Sci Director, NIH, Bethesda, MD 20892 USA; NICHD, DEB, NIH, Bethesda, MD 20892 USA; NIDR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; Uniformed Serv Univ Hlth Sci, Dept Obstet & Gynecol, Bethesda, MD 20814 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Uniformed Services University of the Health Sciences - USA	Segars, J (corresponding author), NICHHD, Off Sci Director, NIH, Bethesda, MD 20892 USA.		Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016	Gutkind, J. Silvio/0000-0002-5150-4482; Rubino, Domenica/0000-0002-3072-2819				ADAMS JM, 1992, ONCOGENE, V7, P611; AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; ANZANO MA, 1994, CANCER RES, V54, P4614; ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; BANIAHMAD C, 1995, MOL ENDOCRINOL, V9, P34, DOI 10.1210/me.9.1.34; Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/edrv-17-6-587; Beatson G., 1896, LANCET, V2, P104, DOI DOI 10.1016/S0140-6736(01)72307-0; Beatson GW, 1896, LANCET, V2, P162, DOI DOI 10.1016/S0140-6736(01)72384-7; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; CARR DW, 1992, J BIOL CHEM, V267, P13376; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHAN AML, 1994, ONCOGENE, V9, P1057; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHO H, 1993, MOL ENDOCRINOL, V7, P441, DOI 10.1210/me.7.3.441; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; CLARK GJ, 1995, BREAST CANCER RES TR, V35, P133, DOI 10.1007/BF00694753; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; GALLAND F, 1992, ONCOGENE, V7, P585; Glaven JA, 1996, J BIOL CHEM, V271, P27374, DOI 10.1074/jbc.271.44.27374; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HEISTERKAMP N, 1993, J BIOL CHEM, V268, P16903; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; MA ZQ, 1994, MOL ENDOCRINOL, V8, P910, DOI 10.1210/me.8.7.910; MARKS MS, 1992, MOL ENDOCRINOL, V6, P219, DOI 10.1210/me.6.2.219; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Nunez SB, 1997, MOL CELL ENDOCRINOL, V127, P27, DOI 10.1016/S0303-7207(96)03980-9; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; OMALLEY BW, 1995, RECENT PROG HORM RES, V50, P333; ONATE SA, 1995, SCIENCE, V270, P1354; PASTERIS NG, 1994, CELL, V79, P669; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; RON D, 1991, NEW BIOL, V3, P372; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Schwartz MA, 1996, EMBO J, V15, P6525, DOI 10.1002/j.1460-2075.1996.tb01043.x; SCOTT JD, 1990, J BIOL CHEM, V265, P21561; SEGARS JH, 1993, MOL CELL BIOL, V13, P2258, DOI 10.1128/MCB.13.4.2258; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SMITH CL, 1993, P NATL ACAD SCI USA, V90, P6120, DOI 10.1073/pnas.90.13.6120; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; TOKSOZ D, 1994, ONCOGENE, V9, P621; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WHITEHEAD I, 1995, ONCOGENE, V10, P713; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031	76	68	73	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 14	1998	16	19					2513	2526		10.1038/sj.onc.1201783	http://dx.doi.org/10.1038/sj.onc.1201783			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN694	9627117				2022-12-17	WOS:000073672300009
J	Godbout, R; Bisgrove, DA; Shkolny, D; Day, RS				Godbout, R; Bisgrove, DA; Shkolny, D; Day, RS			Correlation of B-FABP and GFAP expression in malignant glioma	ONCOGENE			English	Article						malignant glioma; glial fibrillary acidic protein; brain fatty acid binding protein; astrocytes; gene mapping	FIBRILLARY ACIDIC PROTEIN; COMPARATIVE GENOMIC HYBRIDIZATION; LIPID-BINDING PROTEIN; HUMAN ASTROCYTOMA-CELLS; COMPLEMENTARY-DNA; SUBVENTRICULAR ZONE; MESSENGER-RNA; CHICK RETINA; GENE FAMILY; LINES	The murine brain fatty acid binding protein (B-FABP) is encoded by a developmentally regulated gene that is expressed in radial glial cells and immature astrocytes. We have cloned the human B-FABP gene and have mapped it to chromosome 6q22-23. We show that B-FABP mRNA is expressed in human malignant glioma tumor biopsies and in a subset of malignant glioma cell lines, as well as in human fetal retina and brain. Malignant glioma tumors are characterized by cytoplasmic bundles of glial fibrillary acidic protein (GFAP), a protein normally expressed in mature astrocytes. Establishment of malignant glioma cell lines often results in loss of GFAP. The subset of malignant glioma cell lines that express GFAP mRNA also express B-FABP mRNA. Go-localization experiments in cell lines indicate that the same cells produce both GFAP and B-FABP. We suggest that some malignant gliomas may be derived from astrocytic precursor cells which can express proteins that are normally produced at different developmental stages in the astrocytic differentiation pathway.	Univ Alberta, Cross Canc Inst, Dept Oncol, Edmonton, AB T6G 1Z2, Canada	University of Alberta	Godbout, R (corresponding author), Univ Alberta, Cross Canc Inst, Dept Oncol, 11560 Univ Ave, Edmonton, AB T6G 1Z2, Canada.		Godbout, Roseline/I-4639-2016	Godbout, Roseline/0000-0002-4779-9265				BASS NM, 1993, MOL CELL BIOCHEM, V123, P191, DOI 10.1007/BF01076492; BIGNER DD, 1981, J NEUROPATH EXP NEUR, V40, P201, DOI 10.1097/00005072-198105000-00001; BONGCAMRUDLOFF E, 1991, CANCER RES, V51, P1553; BURTON PBJ, 1994, BIOCHEM BIOPH RES CO, V205, P1822, DOI 10.1006/bbrc.1994.2882; Byrne JA, 1996, GENOMICS, V35, P523, DOI 10.1006/geno.1996.0393; CHEN WJ, 1994, J CELL BIOL, V127, P813, DOI 10.1083/jcb.127.3.813; CLARKE SD, 1989, FASEB J, V3, P2480, DOI 10.1096/fasebj.3.13.2680704; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; EDMONDSON JC, 1987, J NEUROSCI, V7, P1928; ENG LF, 1978, J HISTOCHEM CYTOCHEM, V26, P513, DOI 10.1177/26.7.357640; ENG LF, 1985, J NEUROIMMUNOL, V8, P203, DOI 10.1016/S0165-5728(85)80063-1; FENG L, 1994, NEURON, V12, P895, DOI 10.1016/0896-6273(94)90341-7; FENG L, 1995, DEVELOPMENT, V121, P1719; FREDERIKSEN K, 1988, J NEUROSCI, V8, P1144; FULTS D, 1990, CANCER RES, V50, P5784; GILMAN AG, 1972, MOL PHARMACOL, V8, P410; GLATZ JFC, 1990, MOL CELL BIOCHEM, V98, P237, DOI 10.1007/BF00231390; GODBOUT R, 1992, ONCOGENE, V7, P1879; GODBOUT R, 1993, EXP EYE RES, V56, P95, DOI 10.1006/exer.1993.1014; GODBOUT R, 1993, GENE, V123, P195, DOI 10.1016/0378-1119(93)90124-L; GODBOUT R, 1995, EXP EYE RES, V60, P645, DOI 10.1016/S0014-4835(05)80006-5; GOMI H, 1995, NEURON, V14, P29, DOI 10.1016/0896-6273(95)90238-4; GOTTSCHALK J, 1987, Zentralblatt fuer Allgemeine Pathologie und Pathologische Anatomie, V133, P319; HARPER ME, 1983, NATURE, V304, P169, DOI 10.1038/304169a0; HATTEN ME, 1990, TRENDS NEUROSCI, V13, P179, DOI 10.1016/0166-2236(90)90044-B; HOCKFIELD S, 1985, J NEUROSCI, V5, P3310; HUYNH HT, 1995, CANCER RES, V55, P2225; JAMES CD, 1989, P NATL ACAD SCI USA, V86, P2858, DOI 10.1073/pnas.86.8.2858; JANZER RC, 1987, NATURE, V325, P253, DOI 10.1038/325253a0; KELER T, 1992, P NATL ACAD SCI USA, V89, P4830, DOI 10.1073/pnas.89.11.4830; KURTZ A, 1994, DEVELOPMENT, V120, P2637; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; LEVISON SW, 1993, NEURON, V10, P201, DOI 10.1016/0896-6273(93)90311-E; LIANG BC, 1994, NEUROLOGY, V44, P533, DOI 10.1212/WNL.44.3_Part_1.533; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LINSKEY ME, 1995, NEUROSURGERY, V36, P1; LUSKIN MB, 1994, GLIA, V11, P211, DOI 10.1002/glia.440110302; McCall MA, 1996, P NATL ACAD SCI USA, V93, P6361, DOI 10.1073/pnas.93.13.6361; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; MIERENDORF RC, 1987, METHOD ENZYMOL, V152, P556; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; MIYAKOSHI J, 1990, CANCER RES, V50, P278; MOHAPATRA G, 1995, GENE CHROMOSOME CANC, V13, P86, DOI 10.1002/gcc.2870130203; RAKIC P, 1985, SCIENCE, V227, P1054, DOI 10.1126/science.3975601; RETTIG WJ, 1986, CANCER RES, V46, P6406; Rump R, 1996, EUR J CELL BIOL, V69, P135; RUSSELL DS, 1989, PATHOLOGY TUMOURS NE, P6; RUTKA JT, 1993, CANCER RES, V53, P3624; RUTKA JT, 1994, CANCER RES, V54, P3267; Schlegel J, 1996, J NEUROPATH EXP NEUR, V55, P81, DOI 10.1097/00005072-199601000-00008; SCHMECHEL DE, 1979, ANAT EMBRYOL, V156, P115, DOI 10.1007/BF00300010; Schnutgen F, 1996, BIOL CHEM H-S, V377, P211; SMART I, 1961, J COMP NEUROL, V116, P349, DOI 10.1002/cne.901160307; TOHYAMA T, 1993, AM J PATHOL, V142, P883; VANDERMEULEN JDM, 1978, NEUROPATH APPL NEURO, V4, P177; VEERKAMP JH, 1995, PROG LIPID RES, V34, P17, DOI 10.1016/0163-7827(94)00005-7; VELASCO ME, 1980, CANCER, V45, P484, DOI 10.1002/1097-0142(19800201)45:3<484::AID-CNCR2820450312>3.0.CO;2-9; Weber RG, 1996, LAB INVEST, V74, P108; Xu LZ, 1996, J BIOL CHEM, V271, P24711; YANG YM, 1994, J CELL BIOL, V127, P1097, DOI 10.1083/jcb.127.4.1097; Young JK, 1996, GLIA, V16, P218	61	68	76	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 16	1998	16	15					1955	1962		10.1038/sj.onc.1201740	http://dx.doi.org/10.1038/sj.onc.1201740			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZH166	9591779				2022-12-17	WOS:000073079400007
J	Lau, QC; Brusselbach, S; Muller, R				Lau, QC; Brusselbach, S; Muller, R			Abrogation of c-Raf expression induces apoptosis in tumor cells	ONCOGENE			English	Article						apoptosis; programmed cell death; Raf; antisense; phosphorothioate ODN	BCL-2 PROTEIN; KINASE RAF-1; ACTIVATION; DEATH	Signal transduction pathways involving the c-Raf protein kinase are frequently activated in tumor cells. We have addressed the relevance of this activation by a loss-of-function approach, An anti-sense phosphorothioate oligonucleotide (ODN) specifically targeted against c-raf mRNA (Monia ef al., 1996a) was used to block c-Raf protein expression in four different cell lines derived from lung, cervical, prostate and colon carcinomas. Concomitant with the abrogation of c-Raf expression we observed the occurrence of classical apoptotic markers, including chromatin condensation, inter-nucleosomal DNA cleavage, annexin V binding and cleavage of PARP, which was followed by cell death, affecting most of the cell population. This induction of apoptosis occurred independent of the p53 status of the cell. These findings demonstrate that c-Raf can protect tumor cells from undergoing programmed cell death, and suggest that the interference with c-Raf expression or function by ODNs or specific drugs could represent a powerful means for improving the efficacy of anti-cancer therapy.	Univ Marburg, Inst Mol Biol & Tumorforsch IMT, D-35033 Marburg, Germany	Philipps University Marburg	Muller, R (corresponding author), Univ Marburg, Inst Mol Biol & Tumorforsch IMT, Emil Mannkopff Str 2, D-35033 Marburg, Germany.		Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				Blagosklonny MV, 1996, CANCER RES, V56, P1851; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; ElAshry D, 1997, ONCOGENE, V15, P423, DOI 10.1038/sj.onc.1201198; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KINZLER KW, 1994, NEW ENGL J MED, V331, P49, DOI 10.1056/NEJM199407073310113; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Monia BP, 1996, NAT MED, V2, P668, DOI 10.1038/nm0696-668; Monia BP, 1996, P NATL ACAD SCI USA, V93, P15481, DOI 10.1073/pnas.93.26.15481; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Reed J C, 1996, Behring Inst Mitt, P72; WANG HG, 1994, ONCOGENE, V9, P2751; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Weissinger EM, 1997, MOL CELL BIOL, V17, P3229, DOI 10.1128/MCB.17.6.3229; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293	19	68	74	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 9	1998	16	14					1899	1902		10.1038/sj.onc.1201709	http://dx.doi.org/10.1038/sj.onc.1201709			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZG368	9583688				2022-12-17	WOS:000072994600014
J	Soder, AI; Going, JJ; Kaye, SB; Keith, WN				Soder, AI; Going, JJ; Kaye, SB; Keith, WN			Tumour specific regulation of telomerase RNA gene expression visualized by in situ hybridization	ONCOGENE			English	Article						telomerase; in situ hybridization; gene expression; hTR; ribonucleoproteins	CANCER; CELLS	Maintenance of telomere structure by the ribonucleoprotein enzyme telomerase is considered central to the development of most human cancers, However, regulatory mechanisms governing telomerase expression during oncogenesis are largely unknown. We address potential tumour-specific regulation of telomerase RNA gene expression by RNA in situ hybridization to over 300 tumour samples of germ cell and epithelial origin, Twenty-six per cent of non-small cell lung cancers (NSCLC), expressed detectable levels of the telomerase RNA gene (hTR), and interestingly expression was almost confined to squamous carcinomas (41%), being rare in pulmonary adenocarcinomas and large-cell anaplastic carcinomas (P=0.006), Low frequency hTR expression was also associated with adenocarcinoma of the breast (13%), and ovary (17%), In comparison, hTR expression was detected in 43% of cervical cancers with no significant differences in frequency between squamous-cell carcinoma and adenocarcinoma or in transitions between intraepithelial neoplasia and invasive carcinoma, In contrast to the common epithelial cancers, the malignant cells in 73% of testicular germ-cell tumours (seminomas and teratomas), expressed hTR consistent with hTR expression in normal testicular germ cells, Differentiated tissues within ovarian germ cell tumours and in testicular teratomas lacked detectable hTR expression, These studies show that different tumour types have distinct patterns of hTR expression, which has implications for our understanding of mechanisms regulating telomerase activity and for targeting the telomerase RNA component as an anti-cancer therapy.	Univ Glasgow, CRC, Beatson Labs, Dept Med Oncol, Glasgow G61 1BD, Lanark, Scotland; Glasgow Royal Infirm, Dept Pathol, Glasgow G4 0SF, Lanark, Scotland	Beatson Institute; University of Glasgow; University of Glasgow	Keith, WN (corresponding author), Univ Glasgow, CRC, Beatson Labs, Dept Med Oncol, Alexander Stone Bldg,Garscube Estate,Switchback R, Glasgow G61 1BD, Lanark, Scotland.		Keith, Nicol/D-3325-2009	Keith, Nicol/0000-0001-7862-3580; Going, James/0000-0001-9120-919X				BENDA JA, 1994, SEMIN ONCOL, V21, P3; Breslow RA, 1997, J NATL CANCER I, V89, P618, DOI 10.1093/jnci/89.9.618; Burger AM, 1997, BRIT J CANCER, V75, P516, DOI 10.1038/bjc.1997.90; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; HARLEY CB, 1995, CURR OPIN GENET DEV, V5, P249, DOI 10.1016/0959-437X(95)80016-6; Hiyama E, 1996, J NATL CANCER I, V88, P116, DOI 10.1093/jnci/88.2.116; HIYAMA E, 1995, NAT MED, V1, P249, DOI 10.1038/nm0395-249; HIYAMA K, 1995, J NATL CANCER I, V87, P895, DOI 10.1093/jnci/87.12.895; Holt SE, 1996, NAT BIOTECHNOL, V14, P836, DOI 10.1038/nbt0796-836; Holt SE, 1996, MOL CELL BIOL, V16, P2932; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Lundblad V, 1996, CELL, V87, P369, DOI 10.1016/S0092-8674(00)81358-6; Morin GB, 1996, SEMIN CELL DEV BIOL, V7, P5, DOI 10.1006/scdb.1996.0003; Parkinson EK, 1997, EUR J CANCER, V33, P727, DOI 10.1016/S0959-8049(97)00063-4; Raymond E, 1996, CURR OPIN BIOTECH, V7, P583, DOI 10.1016/S0958-1669(96)80068-1; Shay Jerry W., 1996, Current Opinion in Oncology, V8, P66, DOI 10.1097/00001622-199601000-00012; Soder AI, 1997, ONCOGENE, V14, P1013, DOI 10.1038/sj.onc.1201066; Villeponteau B, 1996, SEMIN CELL DEV BIOL, V7, P15, DOI 10.1006/scdb.1996.0004; Wright WE, 1996, DEV GENET, V18, P173; Yashima K, 1997, J CLIN PATHOL, V50, P110, DOI 10.1136/jcp.50.2.110	21	68	72	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 26	1998	16	8					979	983		10.1038/sj.onc.1201620	http://dx.doi.org/10.1038/sj.onc.1201620			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA169	9519871				2022-12-17	WOS:000072335900003
J	Ronai, Z; Yang, YM; Fuchs, SY; Adler, V; Sardana, M; Herlyn, M				Ronai, Z; Yang, YM; Fuchs, SY; Adler, V; Sardana, M; Herlyn, M			ATF2 confers radiation resistance to human melanoma cells	ONCOGENE			English	Article						ATF2; melanoma; radiation resistance; UV	JUN-NH2-TERMINAL KINASE ACTIVATION; ELEMENT-BINDING PROTEIN; TRANSCRIPTION FACTOR-II; ULTRAVIOLET-IRRADIATION; EXPRESSION; JUN; MEDIATE; FAMILY; CREB; IDENTIFICATION	We have previously identifed a U.V.-response element (URE; TGACAACA) and its bound proteins, members of the AP1 and ATF transcription factor families, in melanoma cells, Using a mutant form of cylic AMP response element binding (CREB), we found that CREB-associated-URE-bound proteins conferred characteristic melanoma phenotypes, including radiation resistance (Oncogene 12:2223, 1996). In the present study,ve sought to determine which of the CREB-associated proteins confers radiation resistance on human melanoma cells, To this end we purified and identified via microsequencing ATF2 as a major URE-boundand CREB-associated protein in MeWo cells - a late stage human melanoma cell line, To determine the contribution of ATF2 to radiation resistance, MeWo cells mere transfected with ATF2 cDNA lacking the trans-activation domain (ATF2(Delta 1-195)). MeWo cells that stably express ATF2(Delta 1-195) showed weaker transcriptional activities and an altered pattern of homo/ hetero dimers. ATF2(Delta 1-195) clones exhibited up to tenfold lower resistance to irradiation by either U.V. or X-rays. The degree of resistance to radiation in the ATF2(Delta 1-195) expressing clones could be increased upon transient transfection with ATF2(wt), but not with phosphorylation-defective mutant ATF2(69,71). Similarly, transfection of ATF2(wt) to WM3211, an early stage human melanoma cells line, increased resistance to radiation, Finally, changes elicited through ATF2(Delta 1-195) also led to reduced drug resistance, as shown for MMC, araC and cis-platinum. Our results suggest that ATF2 is a regulator of radiation and drug resistance in melanomas, and that tumor targeted ATF2 modulators may be useful sensitizers in the treatment of tumors of this type.	CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA; Merck Sharp & Dohme, W Point, NY USA; Wistar Inst, Mol & Cellular Biol Program, W Point, NY USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Ronai, Z (corresponding author), CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, Box 1130,1 Gustave Levy Pl, New York, NY 10029 USA.			RONAI, ZEEV/0000-0002-3859-0400	NCI NIH HHS [CA51995] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA051995, R01CA051995] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDELHAFIZ HAM, 1993, ONCOGENE, V8, P1161; ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; ADLER V, 1995, CELL GROWTH DIFFER, V6, P1437; CHATTON B, 1994, ONCOGENE, V9, P375; Dhar V, 1996, CELL GROWTH DIFFER, V7, P841; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; GRINJORGENSEN CM, 1992, CUTANEOUS MELANOMA, P27; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HERLYN M, 1992, CUTANEOUS MELANOMA, P82; HOEFFLER JP, 1991, MOL ENDOCRINOL, V5, P256, DOI 10.1210/mend-5-2-256; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P5479, DOI 10.1128/MCB.13.9.5479; KIM SJ, 1992, NATURE, V358, P31; KRAEMER KH, 1994, ARCH DERMATOL, V130, P1018, DOI 10.1001/archderm.130.8.1018; KRASILNIKOV M, UNPUB; Li XY, 1996, GENE DEV, V10, P517, DOI 10.1101/gad.10.5.517; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; Loganzo Frank Jr., 1994, Molecular and Cellular Differentiation, V2, P23; Lu Chao, 1994, Current Opinion in Oncology, V6, P212, DOI 10.1097/00001622-199403000-00015; MAEKAWA T, 1991, ONCOGENE, V6, P627; NARAYAN S, 1995, BIOCHEMISTRY-US, V34, P73, DOI 10.1021/bi00001a009; RONAI ZA, 1990, CANCER RES, V50, P5374; RUTBERG SE, 1992, NUCLEIC ACIDS RES, V20, P1815, DOI 10.1093/nar/20.7.1815; RUTBERG SE, 1994, MOL CARCINOGEN, V10, P82, DOI 10.1002/mc.2940100205; RUTBERG SE, 1992, NUCLEIC ACIDS RES, V20, P4305, DOI 10.1093/nar/20.16.4305; SCHMID P, 1995, CARCINOGENESIS, V16, P1499, DOI 10.1093/carcin/16.7.1499; STEIN B, 1992, PHOTOCHEM PHOTOBIOL, V55, P409, DOI 10.1111/j.1751-1097.1992.tb04255.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; *WHO, 1994, ENV HLTH CRIT, P15; Xie SH, 1997, ONCOGENE, V15, P2069, DOI 10.1038/sj.onc.1201358; YANG YM, 1995, MOL CARCINOGEN, V14, P111, DOI 10.1002/mc.2940140207; YANG YM, 1993, MOL CARCINOGEN, V7, P36, DOI 10.1002/mc.2940070107; YANG YM, 1993, CELL GROWTH DIFFER, V4, P595; Yang YM, 1996, ONCOGENE, V12, P2223; YOSHIZUMI M, 1995, MOL CELL BIOL, V15, P3266	37	68	70	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 29	1998	16	4					523	531		10.1038/sj.onc.1201566	http://dx.doi.org/10.1038/sj.onc.1201566			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YU644	9484842				2022-12-17	WOS:000071739400011
J	Chin, PL; Momand, J; Pfeifer, GP				Chin, PL; Momand, J; Pfeifer, GP			In vivo evidence for binding of p53 to consensus binding sites in the p21 and GADD45 genes in response to ionizing radiation	ONCOGENE			English	Article						p53; p21; GADD45; MDM2; radiation	LIGATION-MEDIATED PCR; CYCLE CHECKPOINT PATHWAY; DNA-DAMAGING AGENTS; P53-INDEPENDENT PATHWAY; GROWTH ARREST; WAF1/CIP1 EXPRESSION; METHYLATION ANALYSIS; CHROMATIN STRUCTURE; HUMAN FIBROBLASTS; G(1) ARREST	The tumor suppressor protein p53 has a transcriptional activation activity thought to mediate its biologic function including G(1) arrest and perhaps apoptosis, To learn more about p53's transactivator function in vivo, we performed genomic footprinting experiments examining p53-DNA interactions in the regulatory regions of the p53-regulated genes p21, GADD45, and MDM2. Using ionizing radiation to induce DNA damage in human ML-1 myeloblastic leukemia cells, the promoter and intronic regions of these genes containing p53-consensus binding sites were examined for in vivo footprints, There was a uniform and sustained expression of p53 protein as well as a strong induction of p21, GADD45, and MDM2 mRNA following irradiation, At the two p53 consensus binding sites in the p21 promoter, reduced DNaseI cleavage was observed in irradiated cells beginning 1 to 2 h after irradiation, being most checkpoints, pronounced after 2 h and diminishing after 8 h. A partial interest. in vivo footprint was also observed in the third intron of the GADD45 gene beginning 2 h after irradiation, No in vivo footprints were seen at the two p53 binding sites in the MDM2 gene, Our study provides direct evidence that the DNA damage-induced activity of p53 is mediated by its consensus DNA binding sites in the p21 and GADD45 genes, We suggest that the transient nature and relative instability of p53-DNA interactions in vivo may make the p53 protein more accessible to a rapid turnover pathway which might be impaired under conditions when the protein is stably bound to DNA.	CITY HOPE NATL MED CTR, DEPT BIOL, DUARTE, CA 91010 USA; CITY HOPE NATL MED CTR, DEPT CELL & TUMOR BIOL, DUARTE, CA 91010 USA	City of Hope; City of Hope			Momand, Jamil/F-8154-2012		NIEHS NIH HHS [ES06070] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES006070, R01ES006070] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AKASHI M, 1995, J BIOL CHEM, V270, P19181, DOI 10.1074/jbc.270.32.19181; Alpan RS, 1996, CELL GROWTH DIFFER, V7, P893; Bae I, 1996, CANCER RES, V56, P840; BAE IS, 1995, CANCER RES, V55, P2387; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CARRIER F, 1994, J BIOL CHEM, V269, P32672; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Gartenhaus RB, 1996, P NATL ACAD SCI USA, V93, P265, DOI 10.1073/pnas.93.1.265; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; HARPER JW, 1993, CELL, V75, P805; Harris CC, 1996, CARCINOGENESIS, V17, P1187, DOI 10.1093/carcin/17.6.1187; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KEARSEY JM, 1995, ONCOGENE, V11, P1675; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LANDERS JE, 1994, ONCOGENE, V9, P2745; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIU M, 1995, ONCOGENE, V10, P1955; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Maxam A M, 1980, Methods Enzymol, V65, P499; Mayo LD, 1996, ONCOGENE, V13, P2315; MICHIELI P, 1994, CANCER RES, V54, P3391; Moll UM, 1996, MOL CELL BIOL, V16, P1126; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1996, ONCOGENE, V12, P2279; Momand J, 1997, J CELL BIOCHEM, V64, P343; MOSNER J, 1994, ONCOGENE, V9, P3321; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Pfeifer G P, 1992, PCR Methods Appl, V2, P107; PFEIFER GP, 1993, METHOD ENZYMOL, V225, P567; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; Pfeifer GP, 1996, MOL BIOTECHNOL, V5, P281, DOI 10.1007/BF02900367; PFEIFER GP, 1991, GENE DEV, V5, P1102, DOI 10.1101/gad.5.6.1102; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PRICE BD, 1994, CANCER RES, V54, P896; ROZEK D, 1993, MOL CELL BIOL, V13, P5490, DOI 10.1128/MCB.13.9.5490; RUSSO T, 1995, J BIOL CHEM, V270, P29386, DOI 10.1074/jbc.270.49.29386; RYCHLIK W, 1989, NUCLEIC ACIDS RES, V17, P8543, DOI 10.1093/nar/17.21.8543; SHAO ZM, 1995, ONCOGENE, V11, P493; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; TORMANEN VT, 1992, NUCLEIC ACIDS RES, V20, P5487, DOI 10.1093/nar/20.20.5487; TORMANEN VT, 1992, ONCOGENE, V7, P1729; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; Zeng YX, 1996, ONCOGENE, V12, P1557; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHAN QM, 1994, CANCER RES, V54, P2755	67	68	70	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	1997	15	1					87	99		10.1038/sj.onc.1201161	http://dx.doi.org/10.1038/sj.onc.1201161			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XH586	9233781				2022-12-17	WOS:A1997XH58600010
J	Thien, CBF; Langdon, WY				Thien, CBF; Langdon, WY			EGF receptor binding and transformation by v-cbl is ablated by the introduction of a loss-of-function mutation from the Caenorhabditis elegans sli-1 gene	ONCOGENE			English	Article						growth factor; oncogene; receptor; signal transduction; tyrosine kinase	GROWTH-FACTOR RECEPTOR; PRODUCT C-CBL; TYROSINE PHOSPHORYLATION; PROTOONCOGENE PRODUCT; PROTEIN PRODUCT; SH2 DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; ANTIGEN RECEPTOR; JURKAT CELLS; ONCOGENE	The 120 kD product of the c-cbl oncogene is rapidly tyrosine phosphorylated and recruited to the EGF receptor following ligand binding. Cbl's oncogenic potential is activated by a large carboxy-terminal truncation that generated v-cbl and removes the Ring finger and proline-rich SH3-binding domains. Here we show that this truncation reveals a novel and highly conserved domain that can interact directly with the EGF receptor in a phosphorylation dependent manner. Furthermore we demonstrate that the v-cbl domain is not utilized by c-cbl for recruitment to the receptor since this binding property is not evident in c-cbl constructs with proline domain deletions, and it is only revealed following deletion of the Ring finger. We also analyse a loss-of-function mutation from the C. elegans homologue, sli-1, and show that the corresponding mutation in v-cbl ablates transformation and EGF receptor association. Thus our findings provide further evidence that v-cbl possesses a novel and evolutionarily conserved phospho-tyrosine binding domain and that the dual capability of EGF receptor binding by cbl involves two distinct mechanisms. In addition these findings raise the possibility that v-cbl may transform by competing with c-cbl for phosphorylated binding sites on activated receptor complexes.	UNIV WESTERN AUSTRALIA,QUEEN ELIZABETH II MED CTR,DEPT PATHOL,NEDLANDS,WA 6907,AUSTRALIA	University of Western Australia			Thien, Christine/GQP-0424-2022	Thien, Christine/0000-0003-3884-5546				Andoniou CE, 1996, ONCOGENE, V12, P1981; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BLAKE TJ, 1992, ONCOGENE, V7, P757; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALISTEO ML, 1995, J BIOL CHEM, V270, P20241; JOHNSON GR, 1989, EMBO J, V8, P441, DOI 10.1002/j.1460-2075.1989.tb03396.x; JONGEWARD GD, 1995, GENETICS, V139, P1553; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KEANE MM, 1995, ONCOGENE, V10, P2367; KIM TJ, 1995, J BIOL CHEM, V270, P27504, DOI 10.1074/jbc.270.46.27504; Kontani K, 1996, J BIOL CHEM, V271, P1534; LANGDON WY, 1989, J VIROL, V63, P5420, DOI 10.1128/JVI.63.12.5420-5424.1989; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI NX, 1994, ONCOGENE, V9, P3457; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; Ribon V, 1996, MOL CELL BIOL, V16, P45; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SASAKI K, 1995, BIOCHEM BIOPH RES CO, V216, P338, DOI 10.1006/bbrc.1995.2629; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WALTON GM, 1990, J BIOL CHEM, V265, P1750; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	49	68	69	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 8	1997	14	18					2239	2249		10.1038/sj.onc.1201193	http://dx.doi.org/10.1038/sj.onc.1201193			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WX938	9174060				2022-12-17	WOS:A1997WX93800013
J	Tung, RM; Blenis, J				Tung, RM; Blenis, J			A novel human SPS1/STE20 homologue, KHS, activates jun N-terminal kinase	ONCOGENE			English	Article						STE20; JNK; GC kinase; MAP kinase signalling	PROTEIN-KINASE; MAP KINASE; SACCHAROMYCES-CEREVISIAE; C-JUN; SH3 DOMAINS; BINDING DOMAINS; YEAST; IDENTIFICATION; PATHWAYS; FAMILY	STE20-homologous proteins have been implicated in mammalian MAP kinase pathways as important transducers of signals from p21 family GTPases. We have cloned a novel STE20 family member, which we call KHS for kinase homologous to SPS1/STE20, that encodes a kinase of 95 kD which is expressed in a variety of tissues. Transiently expressed fusion protein GST-KHS exhibits phosphotransferase activity toward a panel of test substrates, including myelin basic protein (MBP), which is phosphorylated by all known STE20 homologues, KHS is most closely related to another human STE20, GC kinase (74% similar in the catalytic domain), which has recently been placed upstream of the stress-activated MAP kinases (SAPKs/JNKs. KHS also activates JNK in transient coexpression experiments, suggesting a role for KHS in the stress response of fibroblasts. Characterization and comparison of the regulation of these two kinases mill be important in elucidating MAP kinase signalling cascades.	HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School								BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CICCHETTI P, 1995, EMBO J, V14, P3127, DOI 10.1002/j.1460-2075.1995.tb07315.x; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Creasy CL, 1996, J BIOL CHEM, V271, P21049, DOI 10.1074/jbc.271.35.21049; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FRIESEN H, 1994, GENE DEV, V8, P2162, DOI 10.1101/gad.8.18.2162; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HATZ P, 1994, J BIOL CHEM, V269, P16802; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KRISAK L, 1994, GENE DEV, V8, P2151, DOI 10.1101/gad.8.18.2151; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARCUS S, 1995, P NATL ACAD SCI USA, V92, P6180, DOI 10.1073/pnas.92.13.6180; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NEMOTO T, 1994, J STEROID BIOCHEM, V50, P225, DOI 10.1016/0960-0760(94)90126-0; OTTILIE S, 1995, EMBO J, V14, P5908, DOI 10.1002/j.1460-2075.1995.tb00278.x; PLATH K, 1994, BIOCHEM BIOPH RES CO, V203, P1188, DOI 10.1006/bbrc.1994.2308; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHULTZ SJ, 1993, CELL GROWTH DIFFER, V4, P821; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	56	68	70	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	1997	14	6					653	659		10.1038/sj.onc.1200877	http://dx.doi.org/10.1038/sj.onc.1200877			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WG430	9038372				2022-12-17	WOS:A1997WG43000003
J	Abarzua, P; LoSardo, JE; Gubler, ML; Spathis, R; Lu, YA; Felix, A; Neri, A				Abarzua, P; LoSardo, JE; Gubler, ML; Spathis, R; Lu, YA; Felix, A; Neri, A			Restoration of the transcription activation function to mutant p53 in human cancer cells	ONCOGENE			English	Article						mutant p53; DNA binding; pegylated peptide; transcription activation; SW480 cells	WILD-TYPE P53; DNA-BINDING FUNCTION; P53-MEDIATED G(1) ARREST; SOLID-PHASE SYNTHESIS; INDUCED APOPTOSIS; GENE-EXPRESSION; GROWTH ARREST; PROTEIN; SEQUENCE; MUTATIONS	The p53 tumor suppressor gene product is a sequence-specific transcription activator frequently mutated in a variety of human malignancies. Typically, tumor-derived p53 missense mutants are defective in DNA binding and this is likely to result in a failure to active p53-regulated genes. Hence, restoring function to mutant p53 represents an attractive target to develop a novel cancer chemotherapeutic agent. We now show that a small chemically modified peptide derived from p53 restores sequence-specific DNA binding to a subset of p53 mutants. Moreover, when microinjected into human colon carcinoma cells this peptide restores the transcription activation function to endogenous mutant p53 protein. This is the first example showing that a small peptide molecule can reverse the effect of several inactivating missense mutations and restore protein function.			Abarzua, P (corresponding author), HOFFMANN LA ROCHE INC,ROCHE RES CTR,NUTLEY,NJ 07110, USA.							ABARZUA P, 1995, CANCER RES, V55, P3490; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALL PA, 1993, ONCOGENE, V8, P203; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LU YA, 1994, INT J PEPT PROT RES, V43, P127; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MEIENHOFER J, 1979, INT J PEPT PROT RES, V13, P35; NIEWOLIK D, 1995, ONCOGENE, V10, P881; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WALDMAN T, 1995, CANCER RES, V55, P5187; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	48	68	71	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2477	2482						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957091				2022-12-17	WOS:A1996VX10800022
J	Fornerod, M; Boer, J; vanBaal, S; Morreau, H; Grosveld, G				Fornerod, M; Boer, J; vanBaal, S; Morreau, H; Grosveld, G			Interaction of cellular proteins with the leukemia specific fusion proteins DEK-CAN and SET-CAN and their normal counterpart, the nucleoporin CAN	ONCOGENE			English	Article						DEK-CAN; SET-CAN; can proto-oncogene; nucleoporins; acute leukemia	NUCLEAR-PORE COMPLEX; ACUTE NONLYMPHOCYTIC LEUKEMIA; MYELOID LEUKEMOGENESIS; PUTATIVE ONCOGENE; IDENTIFICATION; LOCALIZATION; EXPRESSION; SEQUENCE; IMPORT; GENE	The recurrent chromosomal translocation (6;9) is associated with acute myeloid leukemia and results in expression of the DER-CAN fusion protein. This oncoprotein consists of almost the entire DEK protein fused to the C-terminal two-thirds of the CAN protein. In much the same way, CAN is fused to SET in a patient with acute undifferentiated leukemia, producing a SET-CAN fusion protein. Interestingly, CAN is associated with the nuclear pore complex (NPC) and we recently established its crucial role in nucleocytoplasmic transport processes and cell cycle progression. As a first step in the biochemical analysis of the oncogenic mechanism associated with translocation (6;9), we set out to identify proteins that interact with CAN and its fusion proteins. We found that two proteins specifically co-immunoprecipitate with CAN. One had a molecular mass of 88 kDa protein (CC88) and was determined to associate with the central region of CAN that contains several protein interaction motifs. A second protein of 112 kDa (CC112) was found to interact with the C-terminal nucleoporin-specific repeat of CAN, a region that is supposed to function in nucleocytoplasmic transport. CC112 also interacts with the DEK-CAN and SET-CAN fusion proteins. This finding suggests that CC112 may contribute an essential function to the leukemogenic effect of DEK-CAN and SET-CAN.	ST JUDE CHILDRENS RES HOSP, DEPT GENET, MEMPHIS, TN 38105 USA	St Jude Children's Research Hospital			Fornerod, Maarten/A-7503-2010; Boer, Judith/A-7546-2010	Fornerod, Maarten/0000-0002-6166-3030	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [CA-21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; BYRD DA, 1994, J CELL BIOL, V127, P1515, DOI 10.1083/jcb.127.6.1515; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; FORNEROD M, 1995, ONCOGENE, V10, P1739; Fornerod M, 1996, BIOTECHNIQUES, V20, P876; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRANDI P, 1995, J CELL BIOL, V130, P1263, DOI 10.1083/jcb.130.6.1263; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HURT EC, 1989, J CELL SCI, P243; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KELLOGG DR, 1995, J CELL BIOL, V130, P661, DOI 10.1083/jcb.130.3.661; KOEFFLER HP, 1978, SCIENCE, V200, P1153, DOI 10.1126/science.306682; KRAEMER D, 1994, P NATL ACAD SCI USA, V91, P1519, DOI 10.1073/pnas.91.4.1519; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; NAGATA K, 1995, P NATL ACAD SCI USA, V92, P4279, DOI 10.1073/pnas.92.10.4279; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; PANTE N, 1994, J CELL BIOL, V126, P603, DOI 10.1083/jcb.126.3.603; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; ROWLEY JD, 1976, BLOOD, V47, P705; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; SOEKARMAN D, 1992, BLOOD, V79, P2990; STARR CM, 1990, J CELL BIOL, V110, P1861, DOI 10.1083/jcb.110.6.1861; STUTZ F, 1995, CELL, V82, P495, DOI 10.1016/0092-8674(95)90438-7; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; VANDEURSEN J, 1996, IN PRESS EMBO J; VONLINDERN M, 1992, MOL CELL BIOL, V12, P3346, DOI 10.1128/MCB.12.8.3346; VONLINDERN M, 1990, MOL CELL BIOL, V10, P4016, DOI 10.1128/MCB.10.8.4016; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687, DOI 10.1128/MCB.12.4.1687; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WIMMER C, 1992, EMBO J, V11, P5051, DOI 10.1002/j.1460-2075.1992.tb05612.x	39	68	71	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	1996	13	8					1801	1808						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895527				2022-12-17	WOS:A1996VM88700026
J	Chen, J; Willingham, T; Shuford, M; Bruce, D; Rushing, E; Smith, Y; Nisen, PD				Chen, J; Willingham, T; Shuford, M; Bruce, D; Rushing, E; Smith, Y; Nisen, PD			Effects of ectopic overexpression of p21WAF1/CIP1 on aneuploidy and the malignant phenotype of human brain tumor cells	ONCOGENE			English	Article						cyclin-dependent kinase inhibitors; cell cycle; tumor suppressors; adenovirus; gene therapy	CYCLIN-DEPENDENT KINASES; P53-MEDIATED G(1) ARREST; WILD-TYPE P53; CANCER-CELLS; PROSTATE-CANCER; DNA-REPLICATION; IN-VIVO; P21; INHIBITOR; GENE	p21(WAF1/CIP1) is downstream effector of the p53 tumor suppressor gene and a universal cyclin-dependent kinase (CDK) inhibitor. To determine the ability of p21(WAF1/CIP1) to function as a tumor suppressor, we constructed a replication-defective adenovirus vector containing p21(WAF1/CIP1) (Adp21(WAF1/CIP1)) to effect ectopic overexpression in a p53-defective human astrocytoma cell line, U-373MG. We observed a marked decrease in CDC2 and CDK2 kinase activity associated with a corresponding decrease in the amount of CDC2 but not CDK2 protein; a decreased growth potential of Adp21(WAF1/CIP1)-infected cells demonstrated by diminished [H-3]thymidine incorporation, increased cell doubling time and G(1)-arrested cell cycle; an association between Adp21(WAF1/CIP1)-infected cells and inhibition of aneuploid cell accumulation; and an alteration of the malignant phenotype of cells was evidenced by the loss of anchorage-independent growth in soft agar and the failure to induce tumorigenesis in both peripheral and intracerebral xenograft models, including the prevention of tumor formation AdP21(WAF1/CIP1) infection 2 days post tumor cell implantation. AdP21(WAF1/CIP1). AdP21(WAF1/CIP1) appears to be a strong candidate for gene therapy studies based on these studies indicating that Adp21(WAF1/CIP1) inhibits proliferation, tumorigenicity and aneuploidy in human brain tumor cells.	UNIV TEXAS,SW MED CTR,DEPT PEDIAT,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT NEUROSURG,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PATHOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL CANCER INSTITUTE [P20CA060173] Funding Source: NIH RePORTER; NCI NIH HHS [CA60173] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREW ME, 1981, J IMMUNOL, V127, P1201; CARDER P, 1993, ONCOGENE, V8, P1397; Chen J, 1996, J CLIN INVEST, V97, P1983, DOI 10.1172/JCI118631; CHEN J, 1995, NAT MED, V1, P638, DOI 10.1038/nm0795-638; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CHEN YQ, 1995, CANCER RES, V55, P4536; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; EASTHAM JA, 1995, CANCER RES, V55, P5151; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FURUKAWA Y, 1994, J BIOL CHEM, V269, P26249; GAO X, 1995, ONCOGENE, V11, P1395; GOMEZFOIX A, 1992, J BIOL CHEM, V267, P25169; GRAHAM FL, 1991, METHODS MOL BIOL GEN, V1, P109; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; LIU TJ, 1994, CANCER RES, V54, P3662; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; RUSSELL SJ, 1995, CANCER, V75, P1339, DOI 10.1002/1097-0142(19950315)75:6<1339::AID-CNCR2820750616>3.0.CO;2-F; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TAM SW, 1994, CANCER RES, V54, P5816; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALDMAN T, 1995, CANCER RES, V55, P5187; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANG ZY, 1995, NAT MED, V1, P1052, DOI 10.1038/nm1095-1052; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	43	68	78	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 3	1996	13	7					1395	1403						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875977				2022-12-17	WOS:A1996VL38400004
J	Sitzmann, J; NobenTrauth, K; Klempnauer, KH				Sitzmann, J; NobenTrauth, K; Klempnauer, KH			Expression of mouse c-myb during embryonic development	ONCOGENE			English	Article						transcription factors; c-myb; A-myb; mouse development	B-MYB; A-MYB; CHICK-EMBRYO; MIM-1 GENE; DIFFERENTIATION; CDNA; PROLIFERATION; TRANSCRIPTION; HEMATOPOIESIS; REQUIRES	Three members of the myb gene family, designated as A-myb, B-myb and c-myb, have been described in many vertebrates, A large body of evidence indicates that the c-myb gene is essential for the development of most hematopoietic lineages, By contrast, the functions of A-myb and B-myb are less well understood. To further explore the relationship between the different myb family members we have compared the expression of A-myb and c-myb during mouse embryogenesis by Northern blotting and by in situ hybridization, In accordance with the important role of c-myb in the hematopoietic system, we detect high levels of c-myb expression in hematopoietic organs such as the fetal liver and the thymus, Surprisingly, we find that high levels of c-myb expression are not restricted to hematopoietic cells, We show that c-myb is strongly expressed in the neural retina and in epithelia of the respiratory tract, The side-by-side analysis of c-myb and A-myb expression clearly shows that both genes are expressed in different, but overlapping sets of tissues, Our results suggest that the function of c-myb may not be restricted to hematopoietic cells.	MAX PLANCK INST IMMUNOBIOL,HANS SPEMANN LAB,D-79108 FREIBURG,GERMANY	Max Planck Society								BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; BROWN KE, 1992, J BIOL CHEM, V267, P4625; BURK O, 1991, EMBO J, V10, P3731; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DESBIENS X, 1991, DEVELOPMENT, V111, P699; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GOLAY J, 1991, BLOOD, V77, P149; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KLEMPNAUER KH, 1983, J VIROL, V48, P565, DOI 10.1128/JVI.48.3.565-572.1983; LAM EWF, 1992, ONCOGENE, V7, P1185; LEON Y, 1992, DEV BIOL, V153, P407, DOI 10.1016/0012-1606(92)90126-2; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; MCMAHON J, 1988, ONCOGENE, V3, P717; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; PLAZA S, 1995, ONCOGENE, V10, P329; QUEVA C, 1992, DEVELOPMENT, V114, P125; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; THIELE CJ, 1987, J CLIN INVEST, V80, P801; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x	29	68	70	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2273	2279						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570177				2022-12-17	WOS:A1995TK70200010
J	HARRISONFINDIK, D; SUSA, M; VARTICOVSKI, L				HARRISONFINDIK, D; SUSA, M; VARTICOVSKI, L			ASSOCIATION OF PHOSPHATIDYLINOSITOL 3-KINASE WITH SHC IN CHRONIC MYELOGENEOUS LEUKEMIA-CELLS	ONCOGENE			English	Article						BCR/ABL; SHC; SH2; SH3; PI 3-KINASE; TYROSINE PHOSPHORYLATION	SIGNAL TRANSDUCTION; TYROSINE KINASES; PHOSPHOINOSITIDE 3-KINASE; PHILADELPHIA-CHROMOSOME; MITOGENIC SIGNAL; ADAPTER PROTEIN; PI 3-KINASE; RAS; DOMAIN; TRANSFORMATION	Expression of p210 BCR/abl oncoprotein transforms hematopoietic cells. P210 BCR/abl tyrosine kinase induces tyrosine phosphorylation of Shc, and activation of p21(ras) and PI 3-Kinase. Here we show that PI 3-Kinase associates with She in cells transformed by BCR/abl oncoprotein. Immunoprecipitation of Shc from cells expressing p210 BCR/abl had 7.5-fold increase in PI 3-Kinase activity compared to parental cells. Tyrosine phosphorylated She specifically bound to the C-SH2 domain of the p85 subunit of PI 3-Kinase. The p85 SH3 domain also interacted with She in cell lysates from parental and transformed cells. The binding of p85 SH3 domain to She was substantially higher in BCR/abl transformed than in parental cells. Phenylphosphate blocked p85 SH2 mediated association with She but enhanced the binding of the p85 SH3 domain to She. The N-terminal proline-rich region of She between A263 and N273 specifically blocked the interaction of p85 SH3 domain with She. Our results indicate that PI 3-Kinase interacts with She directly in hematopoietic cells which express p210 BCR/abl oncoprotein.	TUFTS UNIV, SCH MED, ST ELIZABETHS MED CTR, DEPT MED, BOSTON, MA 02135 USA; TUFTS UNIV, SCH MED, ST ELIZABETHS MED CTR, DEPT BIOMED RES, BOSTON, MA 02135 USA	St. Elizabeth's Medical Center; Tufts University; St. Elizabeth's Medical Center; Tufts University				Varticovski, Lyuba/0000-0002-5105-9008	NCI NIH HHS [R29CA530094] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FEIG LA, 1993, SCIENCE, V260, P737; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KOVACINA KS, 1993, BIOCHEM BIOPH RES CO, V192, P1303, DOI 10.1006/bbrc.1993.1558; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MANDANAS RA, 1993, BLOOD, V82, P1838; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MINAMI Y, 1991, J BIOL CHEM, V266, P9222; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; PRASAD KVS, 1993, MOL CELL BIOL, V13, P7708, DOI 10.1128/MCB.13.12.7708; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RREN R, 1993, SCIENCE, V259, P1157; RUFFJAMISON S, 1993, J BIOL CHEM, V268, P7610; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; SATOH T, 1992, J BIOL CHEM, V267, P24149; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; SJOLANDER A, 1991, P NATL ACAD SCI USA, V88, P7908, DOI 10.1073/pnas.88.18.7908; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SUSA M, 1992, J BIOL CHEM, V267, P22951; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VARTICOVSKI L, 1994, BBA-MOL BASIS DIS, V1226, P1, DOI 10.1016/0925-4439(94)90051-5; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; YOAKIM M, 1992, J VIROL, V66, P5485, DOI 10.1128/JVI.66.9.5485-5491.1992	53	68	68	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1385	1391						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7537361				2022-12-17	WOS:A1995QR65100016
J	NIEWOLIK, D; VOJTESEK, B; KOVARIK, J				NIEWOLIK, D; VOJTESEK, B; KOVARIK, J			P53 DERIVED FROM HUMAN TUMOR-CELL LINES AND CONTAINING DISTINCT POINT MUTATIONS CAN BE ACTIVATED TO BIND ITS CONSENSUS TARGET SEQUENCE	ONCOGENE			English	Article						P53; PROTEIN-DNA INTERACTIONS; PROTEIN CONFORMATION	WILD-TYPE P53; DNA-BINDING; MUTANT P53; TRANSCRIPTIONAL ACTIVATION; IMMUNOCHEMICAL ANALYSIS; MONOCLONAL-ANTIBODIES; SIMIAN VIRUS-40; GENE-EXPRESSION; PROTEIN; CANCER	Mutation of the p53 gene is one of the most common genetic lesions observed in human cancer. The p53 protein functions as a transcription factor, however it is still unresolved to what extend this property is related to its tumour suppressor activity. Since there is evidence that protein modifications as well as protein-protein interactions may regulate p53 function, we have studied p53 protein-DNA complex formation in nuclear extracts prepared from human tumour cell lines. In 13 different cell lines PAb421-induced DNA binding activity was compared to the level and conformation of the endogenous p53 protein. Surprisingly, sequence-specific p53 DNA binding activity was detected not only in cell lines that express wild-type p53, but also in seven cell lines which contain only mutant protein. Oligonucleotide competition analyses with various p53 target sequences and methylation interference experiments establish that wild-type and mutant p53 differ significantly in their sequence-specific interactions. Our analysis also provides evidence that the PAb1620 conformation is neither sufficient nor essential for DNA binding of endogenous p53 and that the cellular environment in addition to the specific point mutation may influence p53 DNA binding activity.	MASARYK MEM CANC INST,DEPT CELLULAR & MOLEC ONCOL,CR-65653 BRNO,CZECH REPUBLIC	Masaryk Memorial Cancer Institute								ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BARTEK J, 1990, ONCOGENE, V5, P893; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN JY, 1993, ONCOGENE, V8, P2159; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHUMAKOV AM, 1993, ONCOGENE, V8, P3005; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRITSCHE M, 1993, ONCOGENE, V8, P307; FROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HAINAUT P, 1993, CANCER RES, V53, P4469; HAINAUT P, 1994, ONCOGENE, V9, P299; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HALL PA, 1993, ONCOGENE, V8, P203; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Maxam A M, 1980, Methods Enzymol, V65, P499; MEEK DW, 1992, BIOCHEM J, V287, P1; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MILNER J, 1987, ONCOGENE, V1, P453; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NITSCH D, 1993, MOL CELL BIOL, V13, P4494, DOI 10.1128/MCB.13.8.4494; OFVERSTEDT LG, 1984, BIOCHIM BIOPHYS ACTA, V782, P120, DOI 10.1016/0167-4781(84)90014-9; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OROURKE RW, 1990, ONCOGENE, V5, P1829; PARK DJ, 1994, ONCOGENE, V9, P1899; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PENNICA D, 1984, VIROLOGY, V134, P477, DOI 10.1016/0042-6822(84)90316-7; PLUMB M, 1989, NUCLEIC ACIDS RES, V17, P73, DOI 10.1093/nar/17.1.73; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; ROMANO JW, 1989, ONCOGENE, V4, P1483; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHIIO Y, 1993, ONCOGENE, V8, P2059; SOUSSI T, 1990, ONCOGENE, V5, P945; STRATTON MR, 1990, ONCOGENE, V5, P1297; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; VOJTESEK B, 1993, J CELL SCI, V105, P607; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529; ZHANG W, 1993, ONCOGENE, V8, P2555	91	68	70	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					881	890						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898929				2022-12-17	WOS:A1995QL03800009
J	FISCELLA, M; ZAMBRANO, N; ULLRICH, SJ; UNGER, T; LIN, D; CHO, B; MERCER, WE; ANDERSON, CW; APPELLA, E				FISCELLA, M; ZAMBRANO, N; ULLRICH, SJ; UNGER, T; LIN, D; CHO, B; MERCER, WE; ANDERSON, CW; APPELLA, E			THE CARBOXY-TERMINAL SERINE-392 PHOSPHORYLATION SITE OF HUMAN P53 IS NOT REQUIRED FOR WILD-TYPE ACTIVITIES	ONCOGENE			English	Article							TUMOR-SUPPRESSOR PROTEIN; CASEIN KINASE-II; CELL-CYCLE CONTROL; MUTANT P53; GENE AMPLIFICATION; GROWTH ARREST; BINDING-SITE; DNA; TRANSCRIPTION; EXPRESSION	Wild-type p53 functions in the G1 DNA damage checkpoint pathway by activating gene transcription and preventing cell cycle progression. Others reported that mutation of the serine 386 codon in mouse p53 abolished its ability to suppress growth. Serine 386 of murine p53 and the homologous residue of human p53, serine 392, are phosphorylated in vivo and can be phosphorylated in vitro by casein kinase II (CKII). We constructed mutants that changed serine 392 of human p53 to alanine (p53-S392A) or aspartic acid (p53S392D); cotransfection of both these mutants with a reporter gene carrying a p53-responsive element into the p53-null Saos-2 cell line activated transcription as well as did wild-type p53. Furthermore, both mutants blocked cell cycle progression after transient transfection in these cells. A stable derivative of the T98G human glioblastoma cell line was established that expressed p53-S392A in response to dexamethasone. Overexpression of this mutant activated transcription of the endogenous waf1 (also called cip1) and mdm2 genes to the same extent as wild-type p53 and also produced growth arrest. Finally, p53-S392A and p53-S392D suppressed foci formation by activated ras and adenovirus EIA oncogenes as efficiently as did wild-type p53. Thus, unlike mutants that altered the serine 15 phosphorylation site, elimination of the serine 392 phosphorylation site had no discernible effect on p53 function. We conclude that neither phosphorylation nor RNA attachment to serine 392 are required for human p53's ability to suppress cell growth or to activate transcription in vivo.	NCI,CELL BIOL LAB,BETHESDA,MD 20892; NCI,TUMOR VIRUS BIOL LAB,BETHESDA,MD 20892; AMER RED CROSS,JEROME H HOLLAND LAB,ROCKVILLE,MD 20855; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,PHILADELPHIA,PA 19107; BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); American Red Cross; Jefferson University; United States Department of Energy (DOE); Brookhaven National Laboratory			Zambrano, Nicola/B-9352-2014	Zambrano, Nicola/0000-0001-9395-3481	NATIONAL CANCER INSTITUTE [R01CA055541, R01CA054140] Funding Source: NIH RePORTER; NCI NIH HHS [CA55541, CA54140] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADDISON C, 1990, ONCOGENE, V5, P423; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FILHOL O, 1992, J BIOL CHEM, V267, P20577; FISCELLA M, 1993, ONCOGENE, V8, P1519; FONTOURA BMA, 1992, MOL CELL BIOL, V12, P5145, DOI 10.1128/MCB.12.11.5145; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HARPER JW, 1993, CELL, V75, P805; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jackson S P, 1992, Trends Cell Biol, V2, P104, DOI 10.1016/0962-8924(92)90014-E; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MERCER WE, 1985, EXP CELL RES, V160, P31, DOI 10.1016/0014-4827(85)90233-2; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; SAMAD A, 1991, MOL CELL BIOL, V11, P1598, DOI 10.1128/MCB.11.3.1598; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SEGAWA K, 1993, ONCOGENE, V8, P543; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHEN YM, 1982, MOL CELL BIOL, V2, P1145, DOI 10.1128/MCB.2.9.1145; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SOUSSI T, 1990, ONCOGENE, V5, P945; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; ULLRICH SJ, 1993, P NATL ACAD SCI USA, V90, P5954, DOI 10.1073/pnas.90.13.5954; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAGNER P, 1994, INT J ONCOL, V4, P491; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	67	68	68	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3249	3257						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936649				2022-12-17	WOS:A1994PM65800018
J	MOASSER, MM; DEBLASIO, A; DMITROVSKY, E				MOASSER, MM; DEBLASIO, A; DMITROVSKY, E			RESPONSE AND RESISTANCE TO RETINOIC ACID ARE MEDIATED THROUGH THE RETINOIC ACID NUCLEAR RECEPTOR-GAMMA IN HUMAN TERATOCARCINOMAS	ONCOGENE			English	Article							EMBRYONAL CARCINOMA-CELLS; RIBONUCLEIC-ACID; X-RECEPTOR; BETA-GENE; DIFFERENTIATION; ALPHA; EXPRESSION; CLONING; LINE; EFFICIENCY	All-trans-retinoic acid (RA) treatment of the multipotent human teratocarcinoma (TC) cell line NTERA-2 clone D1 (abbreviated NT2/D1) induces a neuronal phenotype. Compared to untreated NT2/D1 cells, RA treated cells have reduced proliferative potential. To identify which retinoic acid receptor (RAR) is directly linked to RA response in these cells, nine RA resistant subclones were derived and characterized. Unlike parental NT2/D1 cells, all these subclones and a de novo RA resistant human TC cell line, N2102Ep clone 2AG (abbreviated N2102ep), exhibited reduced RAR gamma expression. The RAR gamma gene was studied within NT2/D1 cells and a representative RA resistant NT2/D1 subclone called NT2/D1-R1 by Southern analysis and by the transcriptional properties of cloned RAR gamma cDNAs. No structural or functional differences between these RAR gamma species were found suggesting that RA resistance is due to reduced levels of RAR gamma expressed in NT2/D1-R1 cells. To explore this possibility an RAR gamma cDNA was stably transfected into NT2/D1-R1 cells. Expression of this cDNA partially restored the response to RA in NT2/D1-R1 cells. The role of RAR gamma in parental NT2/D1 cells was studied in transient transfection assays using an FGF4 promoter-enhancer reporter construct that is transcriptionally active in undifferentiated but not in differentiated TC cells. The dose dependent co-transfection of an expressed RAR gamma cDNA with this reporter more efficiently repressed its transcriptional activity in the presence of RA than transfection of the reporter without expressed RAR gamma. Co-transfection also decreased reporter activity in the absence of exogenously added ligand, Together, these findings reveal that RAR gamma expression is tightly coupled to RA response and resistance in human TC cells. These data implicate an important role for RAR gamma in the RA-mediated differentiation of these TCs.	MEM SLOAN KETTERING CANC CTR,RECEPTOR BIOL LAB,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEPT MED,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,MOLEC MED LAB,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center					NCI NIH HHS [CA01712, 1R01-CA54494-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K12CA001712, R01CA054494] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; ANDREWS PW, 1980, INT J CANCER, V26, P269, DOI 10.1002/ijc.2910260304; ANDREWS PW, 1984, LAB INVEST, V50, P147; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; CURATOLA AM, 1990, MOL CELL BIOL, V10, P2475, DOI 10.1128/MCB.10.6.2475; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DMITROVSKY E, 1990, ONCOGENE RES, V5, P233; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; GUDAS LJ, 1992, CELL GROWTH DIFFER, V3, P655; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; HUSMANN M, 1991, MOL CELL BIOL, V11, P4097, DOI 10.1128/MCB.11.8.4097; KLIEWER SA, 1992, NATURE, V355, P441; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; KURIE JM, 1993, DIFFERENTIATION, V54, P123; KURIE JM, 1993, DIFFERENTIATION, V54, P115; KURIE JM, 1993, BIOCHIM BIOPHYS ACTA, V1179, P203, DOI 10.1016/0167-4889(93)90142-C; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; Maniatis T, 1989, DECONTAMINATION DILU; MCCUE PA, 1983, DEV BIOL, V96, P416, DOI 10.1016/0012-1606(83)90179-3; MILLER WH, IN PRESS DIFFERENTIA; PRATT MAC, 1990, MOL CELL BIOL, V10, P6445, DOI 10.1128/MCB.10.12.6445; SHEVINSKY LH, 1982, CELL, V30, P697, DOI 10.1016/0092-8674(82)90274-4; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; WELLSTEIN A, 1990, CELL GROWTH DIFFER, V1, P63; WONG SY, 1984, J BIOL CHEM, V259, P5899; YOSHIDA T, 1988, BIOCHEM BIOPH RES CO, V157, P618, DOI 10.1016/S0006-291X(88)80295-X; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	34	68	68	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					833	840						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108126				2022-12-17	WOS:A1994MW55100019
J	HWANG, LY; SIEGELMAN, M; DAVIS, L; OPPENHEIMERMARKS, N; BAER, R				HWANG, LY; SIEGELMAN, M; DAVIS, L; OPPENHEIMERMARKS, N; BAER, R			EXPRESSION OF THE TAL1 PROTOONCOGENE IN CULTURED ENDOTHELIAL-CELLS AND BLOOD-VESSELS OF THE SPLEEN	ONCOGENE			English	Article							LOOP-HELIX PROTEINS; DNA-BINDING MOTIF; T-CELL; CHROMOSOME-TRANSLOCATION; ENHANCER-BINDING; GENE-EXPRESSION; LEUKEMIA; SCL; ACTIVATION; MYOD	The TALI proto-oncogene encodes a basic helix-loop-helix (bHLH) protein that has been implicated in the pathogenesis of T-cell acute lymphoblastic leukemia. Normal expression of TALI is observed in erythrocytic, megakaryocytic and mastocytic cells of the hematopoietic lineage. We now report that both RNA transcripts and polypeptide products of TALI are present in human umbilical vein endothelial cells cultured in vitro. Moreover, in situ hybridization revealed a restricted pattern of TALI expression in endothelial cells in vivo, including vessels within the white pulp and follicles of the spleen. In view of its presumptive role as a transcriptional factor, the TAL1 gene product may serve during normal development as a regulator of endothelial cell growth or differentiation.	UNIV TEXAS,SW MED CTR,DEPT MICROBIOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,SIMMONS ARTHRIT RES CTR,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PATHOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL CANCER INSTITUTE [R01CA046593] Funding Source: NIH RePORTER; NCI NIH HHS [CA46593] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; BASH RO, 1993, IN PRESS BLOOD; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; BERNARD O, 1991, ONCOGENE, V6, P1477; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHEN Q, 1990, J EXP MED, V172, P1403, DOI 10.1084/jem.172.5.1403; CHENG JT, 1993, MOL CELL BIOL, V13, P801, DOI 10.1128/MCB.13.2.801; CHENG JT, 1993, ONCOGENE, V8, P677; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DORFMAN DM, 1992, J BIOL CHEM, V267, P1279; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; FUJITA T, 1983, SURV IMMUNOL RES, V2, P375; FUNK WD, 1991, MOL BIOL MED, V8, P185; GOLDFARB AN, 1992, BLOOD, V80, P2858; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; LEE ME, 1991, J BIOL CHEM, V266, P16188; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MOUTHON MA, 1993, BLOOD, V81, P647; MUELLER C, 1988, IMMUNOL REV, V103, P73, DOI 10.1111/j.1600-065X.1988.tb00750.x; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAMIKAWA R, 1988, SCIENCE, V242, P1684, DOI 10.1126/science.3201256; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OPPENHEIMERMARKS N, 1990, J IMMUNOL, V145, P140; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; VISVADER J, 1991, ONCOGENE, V6, P187; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416	32	68	68	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3043	3046						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414504				2022-12-17	WOS:A1993MC09300019
J	WEISKIRCHEN, R; BISTER, K				WEISKIRCHEN, R; BISTER, K			SUPPRESSION IN TRANSFORMED AVIAN FIBROBLASTS OF A GENE (CRP) ENCODING A CYSTEINE-RICH PROTEIN CONTAINING LIM DOMAINS	ONCOGENE			English	Article							LOOP HELIX PROTEIN; C-MYC; DNA-BINDING; ACTIVATES TRANSCRIPTION; REGULATORY PROTEINS; STRUCTURAL-ANALYSIS; INTESTINAL PROTEIN; MOLECULAR-CLONING; PLATELET PROTEIN; MESSENGER-RNA	Using cDNA subtraction and differential hybridization techniques, a cDNA library derived from normal quail embryo fibroblasts WaS screened for clones corresponding to genes whose expression was suppressed in v-myc-transformed, as compared with normal, quail embryo fibroblasts. One of the isolated cDNA clones corresponded to a 0.9-kb mRNA that was present in normal quail and chicken embryo fibroblasts, but was virtually absent from all transformed avian cells tested: quail embryo fibroblasts transformed by the v-myc, v-myc/v-mil or v-src oncogenes, cells derived from a methylcholanthrene-induced quail fibrosarcoma or v-myc-transformed chicken macrophages. Nucleotide sequence analysis of the original and supplementary cDNA clones indicated that the corresponding gene encodes a 194 amino acid cysteine-rich protein (M(r) 20 911). A database search revealed that the gene is the avian homolog of a human primary response gene (crp) of unknown function. Both the quail and human CRP proteins contain two copies of a cysteine-rich amino acid sequence motif (LIM) with putative zinc-binding activity that was previously identified in several proteins with presumed regulatory functions essential for cell growth or differentiation.	UNIV COLOGNE,SCH MED,INST BIOCHEM,W-5000 COLOGNE 41,GERMANY	University of Cologne			Weiskirchen, Ralf/O-1734-2018; Bister, Klaus/AFA-9400-2022	Weiskirchen, Ralf/0000-0003-3888-0931; Bister, Klaus/0000-0001-6545-5653				AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; BARKER K, 1990, MOL CELL BIOL, V10, P3813, DOI 10.1128/MCB.10.7.3813; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BEDARD PA, 1987, P NATL ACAD SCI USA, V84, P6715, DOI 10.1073/pnas.84.19.6715; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BIRKENMEIER EH, 1986, P NATL ACAD SCI USA, V83, P2516, DOI 10.1073/pnas.83.8.2516; BISTER K, 1986, ADV CANCER RES, V47, P99, DOI 10.1016/S0065-230X(08)60199-2; BISTER K, 1977, VIROLOGY, V82, P431, DOI 10.1016/0042-6822(77)90017-4; BISTER K, 1980, P NATL ACAD SCI-BIOL, V77, P7142, DOI 10.1073/pnas.77.12.7142; BISTER K, 1993, IN PRESS GUIDEBOOK O; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOEHM T, 1990, ONCOGENE, V5, P1103; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; DAVIES LG, 1986, BASIC METHODS MOL BI; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; GONNEVILLE L, 1991, ONCOGENE, V6, P1825; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HEMPE JM, 1991, P NATL ACAD SCI USA, V88, P9671, DOI 10.1073/pnas.88.21.9671; JANSEN HW, 1983, J VIROL, V48, P61, DOI 10.1128/JVI.48.1.61-73.1983; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KLUG A, 1987, TRENDS BIOCHEM SCI, V12, P464, DOI 10.1016/0968-0004(87)90231-3; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; LI PM, 1991, P NATL ACAD SCI USA, V88, P9210, DOI 10.1073/pnas.88.20.9210; LIEBHABER SA, 1990, NUCLEIC ACIDS RES, V18, P3871, DOI 10.1093/nar/18.13.3871; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; NAKANO T, 1992, ONCOGENE, V7, P527; NALIK P, 1989, MOL CELL ENDOCRINOL, V62, P235, DOI 10.1016/0303-7207(89)90010-5; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; PRENDERGAST GC, 1990, MOL CELL BIOL, V10, P1265, DOI 10.1128/MCB.10.3.1265; PRENDERGAST GC, 1989, MOL CELL BIOL, V9, P124, DOI 10.1128/MCB.9.1.124; PRENDERGAST GC, 1992, TRENDS GENET, V8, P91, DOI 10.1016/0168-9525(92)90196-B; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1989, NATURE, V341, P392, DOI 10.1038/341392a0; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; Sambrook J., 1989, MOL CLONING LAB MANU; SCHWEINFEST CW, 1990, GENET ANAL-BIOMOL E, V7, P64, DOI 10.1016/0735-0651(90)90042-E; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; TRASK DK, 1990, P NATL ACAD SCI USA, V87, P2319, DOI 10.1073/pnas.87.6.2319; Vogt PK, 1969, FUNDAMENTAL TECHNIQU, P198; WALTHER N, 1985, J VIROL, V54, P576, DOI 10.1128/JVI.54.2.576-585.1985; WANG XK, 1992, J BIOL CHEM, V267, P9176; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WEISKIRCHEN R, 1993, GENE, V128, P269, DOI 10.1016/0378-1119(93)90573-L; XU Y, 1993, P NATL ACAD SCI USA, V90, P227, DOI 10.1073/pnas.90.1.227; YANG BS, 1991, MOL CELL BIOL, V11, P2291, DOI 10.1128/MCB.11.4.2291	57	68	74	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2317	2324						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361751				2022-12-17	WOS:A1993LT36800001
J	DEGROOT, RP; SASSONECORSI, P				DEGROOT, RP; SASSONECORSI, P			ACTIVATION OF JUN/AP-1 BY PROTEIN KINASE-A	ONCOGENE			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; CLONED PLACENTAL CDNA; DNA-BINDING PROTEINS; C-FOS GENE; CYCLIC-AMP; RESPONSE ELEMENT; TRANSCRIPTIONAL ACTIVATION; POSITIVE REGULATION; ENHANCER ELEMENTS; MAMMALIAN-CELLS	The product of the c-jun proto-oncogene is the major component of the 12-O-tetradecanoyl phorbol 13-acetate (TPA)-inducible transcription factor AP-1. Jun binds to the TPA-responsive elements (TREs) present in a large number of TPA-inducible genes, thereby regulating their expression in response to activation of protein kinase C. Previously we have shown that Jun/AP-1 can also activate cAMP-responsive elements (CREs), indicating the existence of cross-talk in signal transduction at the transcriptional level. Here we show that Jun/AP-1 is activated by the cAMP-dependent protein kinase A (PKA). In transient transfection experiments, TRE activation by Jun is strongly enhanced by co-transfection of the catalytic subunit of PKA or forskolin treatment, although not in all cell types studied. Jun activity can be significantly inhibited by co-transfection of the regulatory subunit of PKA. Furthermore, we show a cell-specific increase in AP-1 binding in response to forkolin treatment. However, since direct phosphorylation of Jun by PKA does not occur, we suggest an indirect activation mechanism.	FAC MED STRASBOURG, GENET MOLEC EUCARYOTES LAB,CNRS,U184,INSERM, 11 RUE HUMANN, F-67085 STRASBOURG, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg								ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; AUWERX J, 1992, IN PRESS ONCOGENE; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BENBROOK DM, 1990, ONCOGENE, V5, P295; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BORRELLI E, 1992, IN PRESS CRC REV ONC; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DEGROOT R, 1991, MOL CELL BIOL, V11, P192, DOI 10.1128/MCB.11.1.192; DEGROOT RP, 1990, EMBO J, V9, P1831, DOI 10.1002/j.1460-2075.1990.tb08308.x; DEGROOT RP, 1992, IN PRESS ONCOGENE; DEUTSCH PJ, 1988, P NATL ACAD SCI USA, V85, P7922, DOI 10.1073/pnas.85.21.7922; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOEFFLER JP, 1989, MOL ENDOCRINOL, V3, P868, DOI 10.1210/mend-3-5-868; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MCKNIGHT GS, 1988, RECENT PROG HORM RES, V44, P307; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; TRATNER I, 1992, MOL CELL BIOL, V12, P998, DOI 10.1128/MCB.12.3.998; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; VOGT PK, 1989, TRENDS BIOCHEM SCI, V14, P172, DOI 10.1016/0968-0004(89)90268-5; Woodgett J R, 1990, Semin Cancer Biol, V1, P389; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	52	68	69	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1992	7	11					2281	2286						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1331936				2022-12-17	WOS:A1992JW66500021
J	ZERRAHN, J; DEPPERT, W; WEIDEMANN, D; PATSCHINSKY, T; RICHARDS, F; MILNER, J				ZERRAHN, J; DEPPERT, W; WEIDEMANN, D; PATSCHINSKY, T; RICHARDS, F; MILNER, J			CORRELATION BETWEEN THE CONFORMATIONAL PHENOTYPE OF P53 AND ITS SUBCELLULAR LOCATION	ONCOGENE			English	Article							LARGE-T-ANTIGEN; CELLULAR TUMOR-ANTIGEN; SV40 LARGE-T; TRANSFORMATION-RELATED PROTEIN; AMINO-ACID-SEQUENCE; MONOCLONAL-ANTIBODIES; PLASMA-MEMBRANE; 3T3 CELLS; COMPLEX-FORMATION; NUCLEAR MATRIX	In order to obtain insight into the parameters determining the subcellular localization of mutant and wild-type forms of p53, we analysed the subcellular distribution of p53 in four Balb/c mouse-derived cell lines ranging in their cellular phenotypes from normal (3T3), via minimal transformant (T3T3), to maximally transformed (3T3tx, Meth A). Epitope mapping showed the p53 proteins in 3T3 and in T3T3 cells to be in a wild-type conformation, as they reacted with PAb246, whereas p53 in 3T3tx and in Meth A cells were PAb246 negative and thus displayed a mutant conformation. Despite its reactivity with PAb246, p53 in T3T3 cells had an extended half-life and accumulated to abnormally high levels. We show that the conformationally wild-type p53 in 3T3 and T3T3 cells predominantly localized to the cell nucleus, with about half of it being tightly associated with nuclear structures. In contrast, approximately 60% of mutant p53 in 3T3tx and Meth A cells localized to the cytoplasm, the rest residing in the cell nucleus, all the nuclear p53 in these cells appeared to be structurally bound. The cytoplasmic location of mutant p53 in 3T3tx and Meth A cells was not seen by immunofluorescence microscopic analysis, and required cell fractionation for its detection. Both cytoplasmic and nuclear p53 of the mutant phenotype bound to hsc proteins with a similar stoichiometry, suggesting that hsc binding is not directly related to the subcellular distribution of these proteins. We suggest that the conformational phenotype of p53 is a major determinant of its subcellular location.	UNIV HAMBURG,HEINRICH PETTE INST EXPTL VIROL & IMMUNOL,MARTINISTR 52,W-2000 HAMBURG 13,GERMANY; UNIV CAMBRIDGE,DEPT PATHOL,CAMBRIDGE,ENGLAND	Heinrich Pette Institute; University of Hamburg; University of Cambridge					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208; BOONE C, 1965, J NATL CANCER I, V34, P725; BROWN M, 1986, J VIROL, V60, P290, DOI 10.1128/JVI.60.1.290-293.1986; COLLEDGE WH, 1986, MOL CELL BIOL, V6, P4136, DOI 10.1128/MCB.6.11.4136; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; CRAWFORD L, 1983, INT REV EXP PATHOL, V25, P1; DELEO AB, 1977, J EXP MED, V146, P720, DOI 10.1084/jem.146.3.720; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DEPPERT W, 1988, VIROLOGY, V165, P457, DOI 10.1016/0042-6822(88)90589-2; DEPPERT W, 1989, NATO ASI SERIES H, V34, P4399; DEPPERT W, 1990, J VIROL, V2, P838; ELIYAHU D, 1988, ONCOGENE, V3, P313; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GANNON JV, 1991, NATURE, V349, P802; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GURNEY EG, 1986, J VIROL, V57, P1168, DOI 10.1128/JVI.57.3.1168-1172.1986; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HALEVY O, 1989, MOL CELL BIOL, V9, P3385, DOI 10.1128/MCB.9.8.3385; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HINZPETER M, 1987, ONCOGENE, V1, P119; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; JENKINS JR, 1988, ONCOGENE HDB, P403; KACZMAREK L, 1986, EXP CELL RES, V162, P268, DOI 10.1016/0014-4827(86)90445-3; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KIT S, 1969, INT J CANCER, V4, P384, DOI 10.1002/ijc.2910040403; KLOCKMANN U, 1983, EMBO J, V2, P1151, DOI 10.1002/j.1460-2075.1983.tb01560.x; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1986, VIROLOGY, V150, P265, DOI 10.1016/0042-6822(86)90286-2; MILNER J, 1986, VIROLOGY, V154, P21, DOI 10.1016/0042-6822(86)90426-5; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OREN M, 1982, MOL CELL BIOL, V2, P443, DOI 10.1128/MCB.2.4.443; OREN M, 1985, BIOCHIM BIOPHYS ACTA, V823, P67, DOI 10.1016/0304-419X(85)90015-0; PATSCHINSKY T, 1990, ONCOGENE, V5, P1071; PENNICA D, 1984, VIROLOGY, V134, P477, DOI 10.1016/0042-6822(84)90316-7; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; RISSER R, 1974, VIROLOGY, V59, P477, DOI 10.1016/0042-6822(74)90457-7; ROTTER V, 1980, J VIROL, V36, P547, DOI 10.1128/JVI.36.2.547-555.1980; ROTTER V, 1985, ADV CANCER RES, V43, P113, DOI 10.1016/S0065-230X(08)60944-6; ROTTER V, 1983, EMBO J, V2, P1041, DOI 10.1002/j.1460-2075.1983.tb01543.x; SCHIRMBECK R, 1987, J VIROL, V61, P3561, DOI 10.1128/JVI.61.11.3561-3569.1987; SCHMIEG FI, 1988, VIROLOGY, V164, P132, DOI 10.1016/0042-6822(88)90628-9; SCHMIEG FI, 1984, J VIROL, V52, P350, DOI 10.1128/JVI.52.2.350-355.1984; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SHOHAT O, 1987, ONCOGENE, V1, P277; STAUFENBIEL M, 1983, CELL, V33, P173, DOI 10.1016/0092-8674(83)90346-X; STAUFENBIEL M, 1984, J CELL BIOL, V98, P1886, DOI 10.1083/jcb.98.5.1886; STEINMEYER K, 1990, ONCOGENE, V5, P1691; STEINMEYER K, 1988, ONCOGENE, V3, P501; STURZBECHER HW, 1987, ONCOGENE, V1, P201; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; WALSER A, 1989, J VIROL, V63, P3926, DOI 10.1128/JVI.63.9.3926-3933.1989; WALSER A, 1986, EMBO J, V5, P883, DOI 10.1002/j.1460-2075.1986.tb04299.x; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	62	68	69	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1371	1381						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1620550				2022-12-17	WOS:A1992HZ97100016
J	ZOBEL, A; KALKBRENNER, F; GUEHMANN, S; NAWRATH, M; VORBRUEGGEN, G; MOELLING, K				ZOBEL, A; KALKBRENNER, F; GUEHMANN, S; NAWRATH, M; VORBRUEGGEN, G; MOELLING, K			INTERACTION OF THE V-MYB AND C-MYB PROTEINS WITH REGULATORY SEQUENCES OF THE HUMAN C-MYC GENE	ONCOGENE			English	Article							COLI RNA-POLYMERASE; MOUSE ERYTHROLEUKEMIA-CELLS; HUMAN HEMATOPOIETIC-CELLS; AVIAN-LEUKOSIS VIRUS; DNA-BINDING DOMAIN; BURKITT-LYMPHOMA; PROTO-ONCOGENE; NUCLEOTIDE-SEQUENCE; TRANSCRIPTIONAL ACTIVATION; MONOCLONAL-ANTIBODY	Eight c-Myb-binding sites have been identified in the regulatory region of the human c-myc gene using gel retardation and DNAase I footprint assays with purified bacterially expressed full-length and carboxy-terminally truncated c-Myb proteins. These binding sites exhibit different affinities whereby strong binding correlates better with conservation of the palindromic sequences, AACXGTT or AACGTT, than the previously described consensus sequence. Flanking AT-rich sequences further increase the binding affinity. The c-Myb-binding sites are arranged in pairs consisting of one high- and one low-affinity binding site. Binding of the Myb proteins to these sites is non-cooperative. The v-Myb protein protects two nucleotides fewer than the c-Myb protein. Co-transfection of reporter CAT genes, containing upstream human c-myc sequences including exon 1, with c-Myb-expressing constructs resulted in positive transactivation, which was eightfold with full-length Myb and 14-fold with the truncated Myb. This result suggests that the Myb protein could participate in regulation of human c-myc gene expression.	MAX PLANCK INST MOLEC GENET,SCHUSTER ABT,IHNESTR 73,W-1000 BERLIN 33,GERMANY	Max Planck Society								BADING H, 1987, ONCOGENE, V1, P395; BADING H, 1988, ONCOGENE, V3, P257; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BEIMLING P, 1985, BIOCHEMISTRY-US, V24, P6348; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BEUG H, 1987, GENE DEV, V1, P277, DOI 10.1101/gad.1.3.277; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; CHUNG J, 1986, P NATL ACAD SCI USA, V83, P7918, DOI 10.1073/pnas.83.20.7918; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DASGUPTA P, 1990, P NATL ACAD SCI USA, V87, P8090, DOI 10.1073/pnas.87.20.8090; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; GONDA TJ, 1987, J VIROL, V61, P2754, DOI 10.1128/JVI.61.9.2754-2763.1987; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HAY N, 1989, GENE DEV, V3, P293, DOI 10.1101/gad.3.3.293; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; KAKIDANI H, 1988, CELL, V52, P161, DOI 10.1016/0092-8674(88)90504-1; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KANTER MR, 1988, J VIROL, V62, P1423, DOI 10.1128/JVI.62.4.1423-1432.1988; KELLY K, 1988, J BIOL CHEM, V263, P4828; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE RA, 1986, MOL CELL BIOL, V6, P4112, DOI 10.1128/MCB.6.11.4112; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; Maxam A M, 1980, Methods Enzymol, V65, P499; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; MCMAHON J, 1988, ONCOGENE, V3, P717; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; OEHLER T, 1990, NUCLEIC ACIDS RES, V18, P1703, DOI 10.1093/nar/18.7.1703; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; REMMERS EF, 1986, EMBO J, V5, P899, DOI 10.1002/j.1460-2075.1986.tb04301.x; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SAITO H, 1983, P NATL ACAD SCI-BIOL, V80, P7476, DOI 10.1073/pnas.80.24.7476; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Sambrook J., 1989, MOL CLONING LAB MANU; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; SHENONG GLC, 1984, SCIENCE, V226, P1077, DOI 10.1126/science.6093260; SHIH CK, 1984, P NATL ACAD SCI-BIOL, V81, P4697, DOI 10.1073/pnas.81.15.4697; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; STERN JB, 1986, SCIENCE, V233, P203, DOI 10.1126/science.3523754; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; WEBER BL, 1990, SCIENCE, V249, P1291, DOI 10.1126/science.2205003; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; ZAJAC-KAYE M, 1990, J BIOL CHEM, V265, P4547; ZAJAC-KAYE M, 1988, SCIENCE, V240, P1776, DOI 10.1126/science.2454510	73	68	68	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1397	1407						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1679531				2022-12-17	WOS:A1991GX27200016
J	MAEKAWA, T; MATSUDA, S; FUJISAWA, J; YOSHIDA, M; ISHII, S				MAEKAWA, T; MATSUDA, S; FUJISAWA, J; YOSHIDA, M; ISHII, S			CYCLIC-AMP RESPONSE ELEMENT-BINDING PROTEIN, CRE-BP1, MEDIATES THE E1A-INDUCED BUT NOT THE TAX-INDUCED TRANSACTIVATION	ONCOGENE			English	Article							TRANSCRIPTION FACTOR ATF; LEUCINE ZIPPER STRUCTURE; LONG TERMINAL REPEAT; V-MYB ONCOGENE; VIRUS TYPE-I; C-MYB; FUNCTIONAL DOMAINS; INFECTED-CELLS; RECEPTOR GENE; CDNA CLONES	The adenovirus E1A protein and tax protein (Tax) of human T-cell leukemia virus-1 (HTLV-1) are transcriptional regulators that do not bind to DNA directly. The ATF sites/CRE (cyclic AMP response element) of the adenovirus E4 promoter and the long terminal repeat of HTLV-1 have been shown to be required for E1A and Tax inducibility, respectively. Using the c-Myb-CRE-BP1 fusion protein, it was shown that CRE-BP1, which could bind to the ATF sites/CRE, mediated the E1A-induced trans-activation. For this activation, the N-terminal portion of CRE-BP1, which contained the putative metal finger structure, was essential but not sufficient. In contrast, the trans-activation induced by HTLV-1 Tax was not mediated by CRE-BP1. These results strongly suggested that E1A activates transcription through interaction with CRE-BP1, but another CRE-binding protein participates in the Tax-induced trans-activation.	INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC GENET LAB,IBARAKI 305,JAPAN; UNIV TOKYO,INST MED SCI,MINATO KU,TOKYO 108,JAPAN	RIKEN; University of Tokyo			Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478				BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; FRANKEL AD, 1988, SCIENCE, V240, P70, DOI 10.1126/science.2832944; FUJISAWA J, 1989, J VIROL, V63, P3234, DOI 10.1128/JVI.63.8.3234-3239.1989; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HIRAI SI, 1990, ONCOGENE, V5, P39; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KATOH I, 1989, EMBO J, V8, P497, DOI 10.1002/j.1460-2075.1989.tb03403.x; LEE KAW, 1987, P NATL ACAD SCI USA, V84, P8355, DOI 10.1073/pnas.84.23.8355; LEFF T, 1984, P NATL ACAD SCI-BIOL, V81, P4381, DOI 10.1073/pnas.81.14.4381; LEONG K, 1988, MOL CELL BIOL, V8, P1765, DOI 10.1128/MCB.8.4.1765; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MULLER U, 1989, GENE DEV, V3, P1991, DOI 10.1101/gad.3.12a.1991; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SCHMIDT A, 1985, NATURE, V314, P286, DOI 10.1038/314286a0; SEILERTUYNS A, 1984, P NATL ACAD SCI-BIOL, V81, P2980, DOI 10.1073/pnas.81.10.2980; SHI P, 1988, J CELL BIOCHEM     S, V12, P381; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x	43	68	68	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					627	632						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1827668				2022-12-17	WOS:A1991FR93900018
J	WAITZ, W; LOIDL, P				WAITZ, W; LOIDL, P			CELL-CYCLE DEPENDENT ASSOCIATION OF C-MYC PROTEIN WITH THE NUCLEAR MATRIX	ONCOGENE			English	Article							PHYSARUM-POLYCEPHALUM; DNA-REPLICATION; MESSENGER-RNA; V-MYC; TRANSCRIPTIONAL ENHANCER; GENE; EXPRESSION; ONCOGENES; ORGANIZATION; LOCALIZATION	We demonstrate the presence of a c-myc protein with an apparent molecular weight of 67 kd in the lower eukaryote Physarum polycephalum with polyclonal and monoclonal anti-c-myc-antibodies. It is shown that the amount of myc protein present in the nucleus does not fluctuate during the naturally synchronous cell cycle of Physarum. The myc protein remains firmly associated with the nuclear matrix after a variety of matrix preparation procedures. Although the level of c-myc protein is invariant during the cell cycle, the matrix-bound portion of c-myc protein is higher during S-phase as compared to G2-period. In immunoelectron microscopy the immunosignal was considerably stronger in the nuclear matrix compared with unfractionated nuclei, indicating increased accessibility of c-myc protein in nuclear scaffold structures. We show that the nuclear localization of c-myc protein changes during the cell cycle, being transiently but specifically bound to the periphery of the nuclear matrix structure during S-phase.	UNIV INNSBRUCK, FAK MED, INST MIKROBIOL, FRITZ PREGLSTR 3, A-6020 INNSBRUCK, AUSTRIA; INST PATHOL ANAT, A-6020 INNSBRUCK, AUSTRIA	University of Innsbruck								ALITALO K, 1983, NATURE, V306, P274, DOI 10.1038/306274a0; ARIGA H, 1989, EMBO J, V8, P4273, DOI 10.1002/j.1460-2075.1989.tb08613.x; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; COOPER S, 1988, J THEOR BIOL, V135, P393, DOI 10.1016/S0022-5193(88)80253-4; Daniel J. W., 1964, METHOD CELL PHYSIOL, P9; EISENMAN RN, 1985, MOL CELL BIOL, V5, P114, DOI 10.1128/MCB.5.1.114; EVAN GI, 1985, CELL, V43, P253, DOI 10.1016/0092-8674(85)90030-3; FISHER JM, 1988, CELL, V54, P813, DOI 10.1016/S0092-8674(88)91131-2; GASSER SM, 1986, EMBO J, V5, P511, DOI 10.1002/j.1460-2075.1986.tb04240.x; GROBNER P, 1985, BIOCHEM J, V232, P21; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; IGUCHIARIGA SMM, 1988, EMBO J, V7, P3135, DOI 10.1002/j.1460-2075.1988.tb03180.x; JACKSON DA, 1985, EMBO J, V4, P913, DOI 10.1002/j.1460-2075.1985.tb03718.x; KARNJ, 1989, ONCOGENE, V4, P773; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEBKOWSKI JS, 1982, J MOL BIOL, V156, P325, DOI 10.1016/0022-2836(82)90332-1; LOIDL P, 1987, J BIOL CHEM, V262, P10195; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; NEWMAN GR, 1989, COLLOIDAL GOLD PRINC, V2, P47; NOTHACKER KD, 1986, EUR J CELL BIOL, V39, P278; OKUDA A, 1989, EXP CELL RES, V185, P258, DOI 10.1016/0014-4827(89)90054-2; PERSSON H, 1984, SCIENCE, V225, P718, DOI 10.1126/science.6463648; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; ROTH J, 1978, J HISTOCHEM CYTOCHEM, V26, P1074, DOI 10.1177/26.12.366014; SHEINESS D, 1979, J VIROL, V31, P514, DOI 10.1128/JVI.31.2.514-521.1979; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; SPECTOR DL, 1987, ONCOGENE, V1, P5; STUDZINSKI GP, 1986, SCIENCE, V234, P467, DOI 10.1126/science.3532322; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Turnock G, 1979, Prog Nucleic Acid Res Mol Biol, V23, P53; VANSTRAATEN JP, 1987, ONCOGENE RES, V1, P221; VAUGHN JP, 1990, NUCLEIC ACIDS RES, V18, P1965, DOI 10.1093/nar/18.8.1965; WAITZ W, 1988, J CELL SCI, V90, P621	41	68	70	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1991	6	1					29	35						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1992443				2022-12-17	WOS:A1991EY03900004
J	FAKTOR, O; SHAUL, Y				FAKTOR, O; SHAUL, Y			THE IDENTIFICATION OF HEPATITIS-B VIRUS X-GENE RESPONSIVE ELEMENTS REVEALS FUNCTIONAL SIMILARITY OF X-TAX AND HTLV-I-TAX	ONCOGENE			English	Article											FAKTOR, O (corresponding author), WEIZMANN INST SCI,DEPT MOLEC GENET & VIROL,IL-76100 REHOVOT,ISRAEL.							ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; Beasley R.P., 1984, VIRAL HEPATITIS LIVE, P209; BENLEVY R, 1989, MOL CELL BIOL, V9, P1804, DOI 10.1128/MCB.9.4.1804; BISHOP JM, 1985, CELL, V42, P23, DOI 10.1016/S0092-8674(85)80098-2; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; CHEN ISY, 1983, P NATL ACAD SCI-BIOL, V80, P7006, DOI 10.1073/pnas.80.22.7006; FAKTOR O, 1990, IN PRESS J VIROL; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HONIGWACHS J, 1989, J VIROL, V63, P919, DOI 10.1128/JVI.63.2.919-924.1989; JEANG KT, 1988, P NATL ACAD SCI USA, V85, P8291, DOI 10.1073/pnas.85.21.8291; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LENARDO MJ, 1989, CELL, V57, P187; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; MILLER RH, 1986, P NATL ACAD SCI USA, V83, P2531, DOI 10.1073/pnas.83.8.2531; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; NYBORG JK, 1988, P NATL ACAD SCI USA, V85, P1457, DOI 10.1073/pnas.85.5.1457; ONDEK B, 1987, EMBO J, V6, P1017, DOI 10.1002/j.1460-2075.1987.tb04854.x; PARK RE, 1988, ONCOGENE, V3, P275; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RADONOVICH M, 1989, J VIROL, V63, P2987, DOI 10.1128/JVI.63.7.2987-2994.1989; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; SETO E, 1988, P NATL ACAD SCI USA, V85, P8286, DOI 10.1073/pnas.85.21.8286; SHAUL Y, 1985, EMBO J, V4, P427, DOI 10.1002/j.1460-2075.1985.tb03646.x; SHAUL Y, 1987, EMBO J, V6, P1913, DOI 10.1002/j.1460-2075.1987.tb02451.x; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; SIDDIQUI A, 1989, VIROLOGY, V169, P479, DOI 10.1016/0042-6822(89)90177-3; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; SUMMERS J, 1982, CELL, V29, P403, DOI 10.1016/0092-8674(82)90157-X; TAN TH, 1989, MOL CELL BIOL, V9, P1733, DOI 10.1128/MCB.9.4.1733; TREININ M, 1987, MOL CELL BIOL, V7, P545, DOI 10.1128/MCB.7.1.545; TWU JS, 1989, P NATL ACAD SCI USA, V86, P2046, DOI 10.1073/pnas.86.6.2046; TWU JS, 1989, J VIROL, V63, P2857, DOI 10.1128/JVI.63.6.2857-2860.1989; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; TWU JS, 1989, P NATL ACAD SCI USA, V86, P5168, DOI 10.1073/pnas.86.13.5168; VARMUS H, 1988, GENE DEV, V2, P1055, DOI 10.1101/gad.2.9.1055; WOLLERSHEIM M, 1988, ONCOGENE, V3, P545; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YAMAMOTO N, 1982, SCIENCE, V217, P737, DOI 10.1126/science.6980467; ZAHM P, 1988, ONCOGENE, V3, P169	44	68	85	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1990	5	6					867	872						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP553	2359621				2022-12-17	WOS:A1990DP55300012
J	THIELE, CJ; DEUTSCH, LA; ISRAEL, MA				THIELE, CJ; DEUTSCH, LA; ISRAEL, MA			THE EXPRESSION OF MULTIPLE PROTO-ONCOGENES IS DIFFERENTIALLY REGULATED DURING RETINOIC ACID-INDUCED MATURATION OF HUMAN NEURO-BLASTOMA CELL-LINES	ONCOGENE			English	Article											THIELE, CJ (corresponding author), NCI,CLIN ONCOL PROGRAM,PEDIAT BRANCH,MOLEC GENET SECT,BETHESDA,MD 20892, USA.							BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BITTER GA, 1978, BIOCHEMISTRY-US, V17, P2198, DOI 10.1021/bi00604a028; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DETAISNE C, 1984, NATURE, V310, P581, DOI 10.1038/310581a0; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; Evans A E, 1976, Natl Cancer Inst Monogr, V44, P49; FARBER E, 1984, CANCER RES, V44, P4217; FOX F, 1959, CANCER, V12, P108, DOI 10.1002/1097-0142(195901/02)12:1<108::AID-CNCR2820120116>3.0.CO;2-H; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; GLEICHENHAUS N, 1985, ADV CANCER RES, P291; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; GROSSO LE, 1985, CANCER RES, V45, P847; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HALL A, 1983, NATURE, V303, P396, DOI 10.1038/303396a0; HUNT SP, 1987, NATURE, V328, P632, DOI 10.1038/328632a0; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KIRSCH IR, 1986, J CELL BIOCHEM, V32, P11, DOI 10.1002/jcb.240320103; KOHL NE, 1983, CELL, V35, P359, DOI 10.1016/0092-8674(83)90169-1; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LACHMAN HM, 1986, P NATL ACAD SCI USA, V83, P6480, DOI 10.1073/pnas.83.17.6480; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; MITCHELL RL, 1986, CELL, V45, P497, DOI 10.1016/0092-8674(86)90281-3; MITCHELL RL, 1985, CELL, V40, P209, DOI 10.1016/0092-8674(85)90324-1; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; MYERS MW, 1987, EMBO J, V6, P1617, DOI 10.1002/j.1460-2075.1987.tb02409.x; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; REYMOND CD, 1986, NATURE, V323, P340, DOI 10.1038/323340a0; REYNOLDS CP, 1986, J NATL CANCER I, V76, P375; SCHNEIDER MD, 1987, MOL CELL BIOL, V7, P1973, DOI 10.1128/MCB.7.5.1973; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SIDELL N, 1983, EXP CELL RES, V148, P21, DOI 10.1016/0014-4827(83)90184-2; SIDELL N, 1982, J NATL CANCER I, V68, P589; SIDELL N, 1985, ADV NEUROBLASTOMA RE, P39; THIELE CJ, 1988, MOL CELL BIOL, V8, P1677, DOI 10.1128/MCB.8.4.1677; THIELE CJ, 1987, J CLIN INVEST, V80, P804, DOI 10.1172/JCI113137; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; THIELE CJ, 1988, IN PRESS ADV NEUROBL; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; WEST GJ, 1977, CANCER RES, V37, P1372; WHANGPENG J, 1984, NEW ENGL J MED, V311, P584, DOI 10.1056/NEJM198408303110907; XU YH, 1984, NATURE, V309, P806, DOI 10.1038/309806a0	52	68	68	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1988	3	3					281	288						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q4367	3060792				2022-12-17	WOS:A1988Q436700006
J	Wu, HJ; Hao, MG; Yeo, SK; Guan, JL				Wu, Hsin-Jung; Hao, Mingang; Yeo, Syn Kok; Guan, Jun-Lin			FAK signaling in cancer-associated fibroblasts promotes breast cancer cell migration and metastasis by exosomal miRNAs-mediated intercellular communication	ONCOGENE			English	Article							FOCAL-ADHESION KINASE; EPITHELIAL-SPECIFIC DISRUPTION; STEM-CELLS; HETEROGENEITY; SURVIVAL; BIOLOGY; GENES	Cancer-associated fibroblasts (CAFs) are activated fibroblasts that constitute the major components of tumor microenvironment (TME) and play crucial roles in tumor development and metastasis. Here, we generated fibroblast-specific inducible focal adhesion kinase (FAK) knockout (cKO) mice in a breast cancer model to study potential role and mechanisms of FAK signaling in CAF to promote breast cancer metastasis in vivo. While not affecting primary tumor development and growth, FAK deletion significantly suppressed breast cancer metastasis in vivo. Analyses of CAFs derived from cKO mice as well as human CAFs showed that FAK is required for their activity to promote mammary tumor cell migration. We further showed that FAK ablation in CAFs decreased exosome functions to promote tumor cell migration and other activities, which could contribute to the reduced metastasis observed in cKO mice. Lastly, profiling of miRs from CAF exosomes showed alterations of several exosomal miRs in FAK-null CAFs, and further analysis suggested that miR-16 and miR-148a enriched in exosomes from FAK-null CAFs contribute to the reduced tumor cell activities and metastasis. Together, these results identify a new role for FAK signaling in CAFs that regulate their intercellular communication with tumor cells to promote breast cancer metastasis.	[Wu, Hsin-Jung; Hao, Mingang; Yeo, Syn Kok; Guan, Jun-Lin] Univ Cincinnati, Coll Med, Dept Canc Biol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Guan, JL (corresponding author), Univ Cincinnati, Coll Med, Dept Canc Biol, Cincinnati, OH 45267 USA.	guanjl@uc.edu	Yeo, Syn/I-1617-2019; Hao, Mingang/AAL-7254-2020; Hao, Mingang/X-2317-2018	Yeo, Syn/0000-0002-4333-2510; Hao, Mingang/0000-0001-6456-1710	NIH [R01CA163493, R01NS094144, R01HL073394]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We would like to thank Glenn Doerman for his help in the preparation of figures. We are grateful to members of our laboratory for their critical comments and suggestions for the manuscript. The work in this study is funded by NIH grants R01CA163493, R01NS094144, and R01HL073394 to J-LG.	Augsten M, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00062; BouGharios G, 1996, J CELL BIOL, V134, P1333, DOI 10.1083/jcb.134.5.1333; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Costa A, 2018, CANCER CELL, V33, P463, DOI 10.1016/j.ccell.2018.01.011; Costea DE, 2013, CANCER RES, V73, P3888, DOI 10.1158/0008-5472.CAN-12-4150; Dalerba P, 2007, ANNU REV MED, V58, P267, DOI 10.1146/annurev.med.58.062105.204854; Donnarumma E, 2017, ONCOTARGET, V8, P19592, DOI 10.18632/oncotarget.14752; Duran A, 2016, CANCER CELL, V30, P595, DOI 10.1016/j.ccell.2016.09.004; Fan HP, 2013, J BIOL CHEM, V288, P3322, DOI 10.1074/jbc.M112.420497; Golubovskaya VM, 2007, INT REV CYTOL, V263, P103, DOI 10.1016/S0074-7696(07)63003-4; Greening DW, 2015, METHODS MOL BIOL, V1295, P179, DOI 10.1007/978-1-4939-2550-6_15; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hannafon BN, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0400-7; Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756; Hu BA, 2012, AM J PATHOL, V180, P2257, DOI 10.1016/j.ajpath.2012.02.010; Jiang H, 2016, NAT MED, V22, P851, DOI 10.1038/nm.4123; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Lahlou H, 2007, P NATL ACAD SCI USA, V104, P20302, DOI 10.1073/pnas.0710091104; Li Y, 2016, J CANCER, V7, P1233, DOI 10.7150/jca.14616; Luga V, 2012, CELL, V151, P1542, DOI 10.1016/j.cell.2012.11.024; Luo M, 2013, CANCER RES, V73, P5591, DOI 10.1158/0008-5472.CAN-13-1351; Luo M, 2009, CANCER RES, V69, P466, DOI 10.1158/0008-5472.CAN-08-3078; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Orimo A, 2006, CELL CYCLE, V5, P1597, DOI 10.4161/cc.5.15.3112; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Provenzano PP, 2008, AM J PATHOL, V173, P1551, DOI 10.2353/ajpath.2008.080308; Pylayeva Y, 2009, J CLIN INVEST, V119, P252, DOI 10.1172/JCI37160; Rivas MA, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3187; Rosen JM, 2009, SCIENCE, V324, P1670, DOI 10.1126/science.1171837; Ruivo CF, 2017, CANCER RES, V77, P6480, DOI 10.1158/0008-5472.CAN-17-0994; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; Schlaepfer DD, 2004, CURR OPIN GENET DEV, V14, P92, DOI 10.1016/j.gde.2003.12.002; Serrels A, 2015, CELL, V163, P160, DOI 10.1016/j.cell.2015.09.001; Serrels B, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aan8355; Shiga K, 2015, CANCERS, V7, P2443, DOI 10.3390/cancers7040902; Shimoda M, 2014, NAT CELL BIOL, V16, P889, DOI 10.1038/ncb3021; Siesser PMF, 2006, CLIN CANCER RES, V12, P3233, DOI 10.1158/1078-0432.CCR-06-0456; Simons M, 2009, CURR OPIN CELL BIOL, V21, P575, DOI 10.1016/j.ceb.2009.03.007; Stingl J, 2007, NAT REV CANCER, V7, P791, DOI 10.1038/nrc2212; Su SC, 2018, CELL, V172, P841, DOI 10.1016/j.cell.2018.01.009; Sun SG, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20930-z; Symeonides SN, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0217-6; Tavora B, 2014, NATURE, V514, P112, DOI 10.1038/nature13541; Tavora B, 2010, EMBO MOL MED, V2, P516, DOI 10.1002/emmm.201000106; Tkach M, 2016, CELL, V164, P1226, DOI 10.1016/j.cell.2016.01.043; Umemura A, 2016, CANCER CELL, V29, P935, DOI 10.1016/j.ccell.2016.04.006; Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153; Zhao J, 2009, CANCER METAST REV, V28, P35, DOI 10.1007/s10555-008-9165-4; Zhao XF, 2010, J CELL BIOL, V189, P955, DOI 10.1083/jcb.200912094; Zheng B, 2002, AM J PATHOL, V160, P1609, DOI 10.1016/S0002-9440(10)61108-X	50	67	71	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	12					2539	2549		10.1038/s41388-020-1162-2	http://dx.doi.org/10.1038/s41388-020-1162-2		JAN 2020	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KW4HU	31988451	Green Accepted			2022-12-17	WOS:000509655100003
J	Svensmark, JH; Brakebusch, C				Svensmark, Julius H.; Brakebusch, Cord			Rho GTPases in cancer: friend or foe?	ONCOGENE			English	Review							SKIN TUMOR-FORMATION; MUTATIONS; RAC1; PROTEINS; INVASION; LYMPHOMA; KINASE; FAMILY; SHAPE; MOUSE	The Rho GTPases RhoA, Rac1, and Cdc42 are important regulators of cytoskeletal dynamics. Although many in vitro and in vivo data indicate tumor-promoting effects of activated Rho GTPases, also tumor suppressive functions have been described, suggesting either highly cell-type-specific functions for Rho GTPases in cancer or insufficient cancer models. The availability of a large number of cancer genome-sequencing data by The Cancer Genome Atlas (TCGA) allows for the investigation of Rho GTPase function in human cancers in silico. This information should be used to improve our in vitro and in vivo cancer models, which are essential for a molecular understanding of Rho GTPase function in malignant tumors and for the potential development of cancer drugs targeting Rho GTPase signaling.	[Svensmark, Julius H.; Brakebusch, Cord] Univ Copenhagen, BRIC, Ole Maaloes Vej 5, DK-2200 Copenhagen, Denmark	University of Copenhagen	Brakebusch, C (corresponding author), Univ Copenhagen, BRIC, Ole Maaloes Vej 5, DK-2200 Copenhagen, Denmark.	cord.brakebusch@bric.ku.dk						Araiza-Olivera D, 2018, ONCOGENE, V37, P944, DOI 10.1038/onc.2017.400; Aspenstrom P, 2007, EXP CELL RES, V313, P3673, DOI 10.1016/j.yexcr.2007.07.022; Aspenstrom Pontus, 2020, Small GTPases, V11, P248, DOI 10.1080/21541248.2017.1391365; Bagrodia A, 2016, J CLIN ONCOL, V34, P4000, DOI 10.1200/JCO.2016.68.7798; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Bos JL, 2007, CELL, V129, P865, DOI 10.1016/j.cell.2007.05.018; Bustelo XR, 2007, BIOESSAYS, V29, P356, DOI 10.1002/bies.20558; Bustelo XR, 2018, BIOCHEM SOC T, V46, P741, DOI 10.1042/BST20170531; Cardama GA, 2017, INT J ONCOL, V51, P1025, DOI 10.3892/ijo.2017.4093; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chang MT, 2016, NAT BIOTECHNOL, V34, P155, DOI 10.1038/nbt.3391; Chauhan BK, 2011, P NATL ACAD SCI USA, V108, P18289, DOI 10.1073/pnas.1108993108; Cortes JR, 2018, CANCER CELL, V33, P259, DOI 10.1016/j.ccell.2018.01.001; Davis MJ, 2013, P NATL ACAD SCI USA, V110, P912, DOI 10.1073/pnas.1220895110; Dubash AD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017380; Garcia-Mariscal A, 2018, ONCOGENE, V37, P847, DOI 10.1038/onc.2017.333; Garcia-Mata R, 2011, NAT REV MOL CELL BIO, V12, P493, DOI 10.1038/nrm3153; Hakem A, 2005, GENE DEV, V19, P1974, DOI 10.1101/gad.1310805; Hodge RG, 2016, NAT REV MOL CELL BIO, V17, P496, DOI 10.1038/nrm.2016.67; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Humphries B, 2017, CANCER RES, V77, P4051, DOI 10.1158/0008-5472.CAN-16-3141; Hurst CD, 2017, CANCER CELL, V32, P701, DOI 10.1016/j.ccell.2017.08.005; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Ju JA, 2018, GENES-BASEL, V9, DOI 10.3390/genes9020067; Kakiuchi M, 2014, NAT GENET, V46, P583, DOI 10.1038/ng.2984; Karlsson R, 2009, BBA-REV CANCER, V1796, P91, DOI 10.1016/j.bbcan.2009.03.003; Kazanietz MG, 2017, CANCER RES, V77, P5445, DOI 10.1158/0008-5472.CAN-17-1456; Kissil JL, 2007, CANCER RES, V67, P8089, DOI 10.1158/0008-5472.CAN-07-2300; Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Lawson CD, 2018, J CELL BIOL, V217, P447, DOI 10.1083/jcb.201612069; Li H, 2019, CANCER RES, V79, P2167, DOI 10.1158/0008-5472.CAN-18-1253; Li H, 2014, BIOFACTORS, V40, P226, DOI 10.1002/biof.1155; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; Michaelson D, 2008, J CELL BIOL, V181, P485, DOI 10.1083/jcb.200801047; Mizukawa B, 2017, BLOOD, V130, P1336, DOI 10.1182/blood-2016-12-758458; Nagata Y, 2016, BLOOD, V127, P596, DOI 10.1182/blood-2015-06-644948; Navarro-Lerida I, 2015, DEV CELL, V32, P318, DOI 10.1016/j.devcel.2014.12.019; Nishizawa Takashi, 2018, Oncotarget, V9, P23198, DOI 10.18632/oncotarget.25269; Nobis M, 2017, CELL REP, V21, P274, DOI 10.1016/j.celrep.2017.09.022; O'Hayre M, 2016, ONCOGENE, V35, P3771, DOI 10.1038/onc.2015.442; Palomero T, 2014, NAT GENET, V46, P166, DOI 10.1038/ng.2873; Peck J, 2002, FEBS LETT, V528, P27, DOI 10.1016/S0014-5793(02)03331-8; Pedersen E, 2012, EXP CELL RES, V318, P1779, DOI 10.1016/j.yexcr.2012.05.004; Porter Andrew P, 2016, Small GTPases, V7, P123, DOI 10.1080/21541248.2016.1173767; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Rane CK, 2019, SEMIN CANCER BIOL, V54, P40, DOI 10.1016/j.semcancer.2018.01.006; Ridley AJ, 2013, J MICROSC-OXFORD, V251, P242, DOI 10.1111/jmi.12025; Roberts PJ, 2008, J BIOL CHEM, V283, P25150, DOI 10.1074/jbc.M800882200; Rodrigues P, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6458; Rohde M, 2014, GENE CHROMOSOME CANC, V53, P911, DOI 10.1002/gcc.22202; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Sakata-Yanagimoto M, 2014, NAT GENET, V46, P171, DOI 10.1038/ng.2872; Schaefer Antje, 2014, Small GTPases, V5, P6, DOI 10.4161/21541248.2014.968004; Tomino T, 2018, BIOCHEM BIOPH RES CO, V497, P298, DOI 10.1016/j.bbrc.2018.02.073; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Van Hengel J, 2008, GASTROENTEROLOGY, V134, P781, DOI 10.1053/j.gastro.2008.01.002; Vega Francisco M, 2018, Small GTPases, V9, P384, DOI 10.1080/21541248.2016.1253528; Vennin Claire, 2020, Small GTPases, V11, P45, DOI 10.1080/21541248.2017.1345712; Wang Z, 2010, ONCOGENE, V29, P3362, DOI 10.1038/onc.2010.95; Wu CY, 2014, GASTROENTEROLOGY, V147, P143, DOI 10.1053/j.gastro.2014.03.048; Yang JQ, 2016, J ALLERGY CLIN IMMUN, V137, P231, DOI 10.1016/j.jaci.2015.05.004; Yoo HY, 2014, NAT GENET, V46, P371, DOI 10.1038/ng.2916; Zandvakili I, 2017, ONCOGENE, V36, P3213, DOI 10.1038/onc.2016.473; Zandvakili I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127923; Zuo Y, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-0966-2	67	67	67	2	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2019	38	50					7447	7456		10.1038/s41388-019-0963-7	http://dx.doi.org/10.1038/s41388-019-0963-7			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JV7GY	31427738				2022-12-17	WOS:000502530500001
J	Jiang, MZ; Xu, B; Li, XW; Shang, YL; Chu, Y; Wang, WJ; Chen, D; Wu, N; Hu, SJ; Zhang, S; Li, MB; Wu, KC; Yang, XY; Liang, J; Nie, YZ; Fan, DM				Jiang, Mingzuo; Xu, Bing; Li, Xiaowei; Shang, Yulong; Chu, Yi; Wang, Weijie; Chen, Di; Wu, Nan; Hu, Sijun; Zhang, Song; Li, Mengbin; Wu, Kaichun; Yang, Xiaoyong; Liang, Jie; Nie, Yongzhan; Fan, Daiming			O-GlcNAcylation promotes colorectal cancer metastasis via the miR-101-O-GlcNAc/EZH2 regulatory feedback circuit	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; BETA-N-ACETYLGLUCOSAMINE; GLCNAC TRANSFERASE; E-CADHERIN; C-MYC; EZH2; COLON; PROTEIN; EXPRESSION; MIGRATION	Advanced colorectal cancer (CRC) is one of the deadliest cancers, and the 5-year survival rate of patients with metastasis is extremely low. The epithelial-mesenchymal transition (EMT) is considered essential for metastatic CRC, but the fundamental molecular basis underlying this effect remains unknown. Here, we identified that O-GlcNAcylation, a unique posttranslational modification (PTM) involved in cancer metabolic reprogramming, increased the metastatic capability of CRC. The levels of O-GlcNAcylation were increased in the metastatic CRC tissues and cell lines, which likely promoted the EMT by enhancing EZH2 protein stability and function. The CRC patients with higher levels of O-GlcNAcylation exhibited greater lymph node metastasis potential and lower overall survival. Bioinformatic analysis and luciferase reporter assays revealed that both O-GlcNAcylation transferase (OGT) and EZH2 are posttranscriptionally inhibited by microRNA-101. In addition, O-GlcNAcylation and H3K27me3 modification in the miR-101 promoter region further inhibited the transcription of miR-101, resulting in the upregulation of OGT and EZH2 in metastatic CRC, thus forming a vicious cycle. In this study, we demonstrated that O-GlcNAcylation, which is negatively regulated by microRNA-101, likely promotes CRC metastasis by enhancing EZH2 protein stability and function. Reducing O-GlcNAcylation may be a potential therapeutic strategy for metastatic CRC.	[Jiang, Mingzuo; Xu, Bing; Li, Xiaowei; Shang, Yulong; Chu, Yi; Wang, Weijie; Chen, Di; Wu, Nan; Hu, Sijun; Zhang, Song; Li, Mengbin; Wu, Kaichun; Liang, Jie; Nie, Yongzhan; Fan, Daiming] Fourth Mil Med Univ, Natl Clin Res Ctr Digest Dis, State Key Lab Canc Biol, Xian, Shaanxi, Peoples R China; [Jiang, Mingzuo; Xu, Bing; Li, Xiaowei; Shang, Yulong; Chu, Yi; Wang, Weijie; Chen, Di; Wu, Nan; Hu, Sijun; Zhang, Song; Li, Mengbin; Wu, Kaichun; Liang, Jie; Nie, Yongzhan; Fan, Daiming] Fourth Mil Med Univ, Xijing Hosp Digest Dis, Xian, Shaanxi, Peoples R China; [Xu, Bing] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Gastroenterol, Xian 710004, Shaanxi, Peoples R China; [Wu, Nan] Northwest Univ, Fac Life Sci, Lab Tissue Engn, Xian, Shaanxi, Peoples R China; [Yang, Xiaoyong] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT USA	Air Force Military Medical University; Air Force Military Medical University; Xi'an Jiaotong University; Northwest University Xi'an; Yale University	Nie, YZ; Fan, DM (corresponding author), Fourth Mil Med Univ, Natl Clin Res Ctr Digest Dis, State Key Lab Canc Biol, Xian, Shaanxi, Peoples R China.; Nie, YZ; Fan, DM (corresponding author), Fourth Mil Med Univ, Xijing Hosp Digest Dis, Xian, Shaanxi, Peoples R China.	yongznie@fmmu.edu.cn; daimingfan@fmmu.edu.cn		nan, wu/0000-0002-9939-9810	National Natural Science Foundation of China [81430072, 81730016, 81421003, 81572302, 81772650, 2015BAI13B07, CBSKL2015Z12]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001863] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	This work was supported by the National Natural Science Foundation of China (Nos. 81430072, 81730016, 81421003, 81572302, 81772650, 2015BAI13B07, and CBSKL2015Z12). We acknowledge Xiang-Yuan Zhang, Miao-Miao Tian, Zu-Hong Tian, Ying Zhang, and Hai-Bin Ruan for their technical assistance.	Babae N, 2014, ONCOTARGET, V5, P6687, DOI 10.18632/oncotarget.2235; Ben Harosh-Davidovich S, 2018, EXP CELL RES, V364, P42, DOI 10.1016/j.yexcr.2018.01.024; Benton G, 2014, ADV DRUG DELIVER REV, V79-80, P3, DOI 10.1016/j.addr.2014.06.005; Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9; Buren S, 2016, CANCER CELL, V30, P290, DOI 10.1016/j.ccell.2016.06.023; Butkinaree C, 2010, BBA-GEN SUBJECTS, V1800, P96, DOI 10.1016/j.bbagen.2009.07.018; Carrington JC, 2003, SCIENCE, V301, P336, DOI 10.1126/science.1085242; Chaiyawat P, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00193; Cheng SM, 2016, BIOCHEM BIOPH RES CO, V478, P1497, DOI 10.1016/j.bbrc.2016.08.074; Chu CS, 2014, P NATL ACAD SCI USA, V111, P1355, DOI 10.1073/pnas.1323226111; Duranton B, 2003, AMINO ACIDS, V24, P63, DOI 10.1007/s00726-002-0333-5; Fardini Y, 2013, FRONT ENDOCRINOL, V4, DOI 10.3389/fendo.2013.00099; Ferrer CM, 2017, ONCOGENE, V36, P559, DOI 10.1038/onc.2016.228; Ferrer CM, 2014, MOL CELL, V54, P820, DOI 10.1016/j.molcel.2014.04.026; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Geng F, 2012, J CELL SCI, V125, P2615, DOI 10.1242/jcs.096735; Gollner S, 2017, NAT MED, V23, P69, DOI 10.1038/nm.4247; Govannucci E, 2007, GASTROENTEROLOGY, V132, P2208, DOI 10.1053/j.gastro.2007.03.050; Guo HB, 2017, J BIOL CHEM, V292, P4123, DOI 10.1074/jbc.M116.763201; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hart GW, 2007, NATURE, V446, P1017, DOI 10.1038/nature05815; Hart GW, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00183; Itkonen HM, 2013, CANCER RES, V73, P5277, DOI 10.1158/0008-5472.CAN-13-0549; Jiang MZ, 2016, ONCOTARGET, V7, P61390, DOI 10.18632/oncotarget.11359; Jin FZ, 2013, EXP CELL RES, V319, P1482, DOI 10.1016/j.yexcr.2013.03.013; Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036; Kim Sang Wook, 2017, Korean J Gastroenterol, V69, P206, DOI 10.4166/kjg.2017.69.4.206; Love Dona C, 2005, Sci STKE, V2005, pre13, DOI 10.1126/stke.3122005re13; Luo P, 2015, MOL MED REP, V12, P1163, DOI 10.3892/mmr.2015.3491; Ma ZY, 2013, AMINO ACIDS, V45, P719, DOI 10.1007/s00726-013-1543-8; Mangalhara KC, 2017, CANCER LETT, V391, P59, DOI 10.1016/j.canlet.2017.01.016; Meyerhardt Jeffrey A, 2013, Clin Adv Hematol Oncol, V11, P93; Mi WY, 2011, BBA-MOL BASIS DIS, V1812, P514, DOI 10.1016/j.bbadis.2011.01.009; Mohammadi A, 2016, BIOMED PHARMACOTHER, V84, P705, DOI 10.1016/j.biopha.2016.09.099; O'Dwyer PJ, 2007, J CLIN ONCOL, V25, P2313, DOI 10.1200/JCO.2006.08.6900; Ozcan S, 2010, BBA-GENE REGUL MECH, V1799, P353, DOI 10.1016/j.bbagrm.2010.02.005; Park SY, 2010, EMBO J, V29, P3787, DOI 10.1038/emboj.2010.254; Ruan HB, 2013, MOL CELL PROTEOMICS, V12, P3489, DOI 10.1074/mcp.R113.029751; Ruan HB, 2013, TRENDS ENDOCRIN MET, V24, P301, DOI 10.1016/j.tem.2013.02.002; Ruan HB, 2012, CELL METAB, V16, P226, DOI 10.1016/j.cmet.2012.07.006; Shimomoto T, 2012, CLIN EXP METASTAS, V29, P915, DOI 10.1007/s10585-012-9480-6; Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220; Slawson C, 2005, J BIOL CHEM, V280, P32944, DOI 10.1074/jbc.M503396200; Sodi VL, 2015, MOL CANCER RES, V13, P923, DOI 10.1158/1541-7786.MCR-14-0536; Soumyanarayanan U, 2016, FUTURE MED CHEM, V8, P1635, DOI 10.4155/fmc-2016-0096; Steenackers A, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00046; Tiwari N, 2013, CANCER CELL, V23, P768, DOI 10.1016/j.ccr.2013.04.020; Vaiana CA, 2016, J BIOL CHEM, V291, P1529, DOI 10.1074/jbc.M115.672220; Vasconcelos-dos-Santos A, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.2; Very N, 2018, J BIOENERG BIOMEMBR, V50, P213, DOI 10.1007/s10863-018-9747-y; Wang J, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/823620; Wang L, 2014, HEPATOLOGY, V59, P1850, DOI 10.1002/hep.26720; Wei YK, 2011, NAT CELL BIOL, V13, P87, DOI 10.1038/ncb2139; Wu SC, 2011, J BIOL CHEM, V286, P28511, DOI 10.1074/jbc.M111.240515; Xu WQ, 2017, J HEPATOL, V67, P310, DOI 10.1016/j.jhep.2017.03.017; Yang WH, 2006, NAT CELL BIOL, V8, P1074, DOI 10.1038/ncb1470; Yang YR, 2015, ONCOTARGET, V6, P12529, DOI 10.18632/oncotarget.3725; Zhang Z, 2015, ONCOGENE, V34, P4808, DOI 10.1038/onc.2014.404; Zheng F, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1004873; Zhu WJ, 2001, EMBO J, V20, P5999, DOI 10.1093/emboj/20.21.5999	60	67	72	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2019	38	3					301	316		10.1038/s41388-018-0435-5	http://dx.doi.org/10.1038/s41388-018-0435-5			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HH6OP	30093632	Green Published, hybrid			2022-12-17	WOS:000455851200001
J	Lv, SD; Ji, LY; Chen, B; Liu, SQ; Lei, CY; Liu, X; Qi, XX; Wang, Y; Leung, ELH; Wang, HY; Zhang, L; Yu, XM; Liu, ZQ; Wei, Q; Lu, LL				Lv, Shidong; Ji, Liyan; Chen, Bin; Liu, Shuqiang; Lei, Chengyong; Liu, Xi; Qi, Xiaoxiao; Wang, Ying; Leung, Elaine Lai-Han; Wang, Hongyi; Zhang, Lin; Yu, Xiaoming; Liu, Zhongqiu; Wei, Qiang; Lu, Linlin			Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating LIFR and KLF4	ONCOGENE			English	Article							ESTROGEN-RECEPTOR; CANCER STATISTICS; GENE; EXPRESSION; MUTATIONS; IDENTIFICATION; PROLIFERATION; PROGRESSION; LEUKEMIA	Abnormalities in epigenetic modifiers are emerging as driving events in prostate cancer (PCa). The histone methyltransferase KMT2D, a frequently aberrant epigenetic modifier in various tumors, has an undefined role in PCa. Moreover, little is known regarding KMT2D's mutation in Chinese patients or its downstream signaling pathways and targets. Here, we profiled the mutational spectrum of 32 significantly PCa-associated genes by using disease-targeted sequencing, and found that KMT2D was highly mutated (63.04%, 29/46) in Chinese patients. Moreover, high KMT2D transcription was also associated with poor prognosis in an independent cohort (n = 51). In KMT2D-knockdown PC-3 and DU145 cells, cell proliferation (P < 0.01), invasion (P < 0.001), and migration (P < 0.01) were consequently suppressed. KMT2D depletion effectively suppressed tumor growth by 92.21% in vivo. Notably, integrative analyses of RNAseq and ChIPseq characterized two crucial genes downregulated by KMT2D, leukemia inhibitory factor receptor (LIFR) and Kruppel-like factor-4 (KLF4), which are regulators in PI3K/Akt and EMT, respectively. Our present study revealed that KMT2D epigenetically activates PI3K/Akt pathway and EMT by targeting LIFR and KLF4 and thus serves as a putative epigenetic-based target for treating PCa.	[Lv, Shidong; Lei, Chengyong; Wang, Hongyi; Zhang, Lin; Yu, Xiaoming; Wei, Qiang] Southern Med Univ, Nanfang Hosp, Dept Urol, Guangzhou, Guangdong, Peoples R China; [Lv, Shidong; Ji, Liyan; Liu, Shuqiang; Liu, Xi; Qi, Xiaoxiao; Wang, Ying; Liu, Zhongqiu; Lu, Linlin] Guangzhou Univ Chinese Med, Int Inst Translat Chinese Med, Guangzhou, Guangdong, Peoples R China; [Chen, Bin] Peoples Liberat Army, Guangzhou Mil Command, Gen Hosp, Dept Sci & Training, Guangzhou, Guangdong, Peoples R China; [Leung, Elaine Lai-Han; Liu, Zhongqiu; Lu, Linlin] Macau Univ Sci & Technol, Macau Inst Appl Res Med & Hlth, State Key Lab Qual Res Chinese Med, Macau, Peoples R China	Southern Medical University - China; Guangzhou University of Chinese Medicine; Southern Theater Command General Hospital; Macau University of Science & Technology	Wei, Q (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Urol, Guangzhou, Guangdong, Peoples R China.; Liu, ZQ; Lu, LL (corresponding author), Guangzhou Univ Chinese Med, Int Inst Translat Chinese Med, Guangzhou, Guangdong, Peoples R China.; Liu, ZQ; Lu, LL (corresponding author), Macau Univ Sci & Technol, Macau Inst Appl Res Med & Hlth, State Key Lab Qual Res Chinese Med, Macau, Peoples R China.	liuzq@gzucm.edu.cn; qwei@smu.edu.cn; lllu@gzucm.edu.cn	Liu, Zhongqiu/AHC-9661-2022; lu, Linlin/K-6600-2016; Liu, Zhongqiu/ABB-8204-2021	Liu, Zhongqiu/0000-0001-6986-9677; lu, Linlin/0000-0002-9943-2422; Lv, Shidong/0000-0002-6875-7697	National Natural Science Foundation of China [81720108033]; Natural Science Foundation of Guangdong Province [2015A030312012, 2016A050502052, 2015B020233015]; Science and Technology Planning Project of Guangdong Province [2016A020215122]; Bureau for Science and Information Technology of Guangzhou Municipality [201509010004]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Science and Technology Planning Project of Guangdong Province; Bureau for Science and Information Technology of Guangzhou Municipality	This work was mainly supported by National Natural Science Foundation of China (81720108033), Natural Science Foundation of Guangdong Province (2015A030312012, 2016A050502052, and 2015B020233015), the Science and Technology Planning Project of Guangdong Province (2016A020215122), Bureau for Science and Information Technology of Guangzhou Municipality (201509010004).	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Ansari KI, 2011, J MOL BIOL, V411, P334, DOI 10.1016/j.jmb.2011.05.050; Augert A, 2017, J THORAC ONCOL, V12, P704, DOI 10.1016/j.jtho.2016.12.011; Barbieri CE, 2012, NAT GENET, V44, P685, DOI 10.1038/ng.2279; Budczies J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051862; Calo E, 2013, MOL CELL, V49, P825, DOI 10.1016/j.molcel.2013.01.038; Carlin Bruce I., 2000, Cancer, V88, P2989, DOI 10.1002/1097-0142(20000615)88:12+<2989::AID-CNCR14>3.0.CO;2-Q; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Dawkins JBN, 2016, CANCER RES, V76, P4861, DOI 10.1158/0008-5472.CAN-16-0481; Ferraldeschi R, 2015, EUR UROL, V67, P795, DOI 10.1016/j.eururo.2014.10.027; Ford DJ, 2015, CANCER GENET-NY, V208, P178, DOI 10.1016/j.cancergen.2015.01.005; Fraser M, 2017, NATURE, V541, P359, DOI 10.1038/nature20788; Fukagai T, 2006, BJU INT, V97, P1190, DOI 10.1111/j.1464-410X.2006.06201.x; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Grasso C, 2015, J MOL DIAGN, V17, P53, DOI 10.1016/j.jmoldx.2014.09.008; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Guo CC, 2013, ONCOTARGET, V4, P2144, DOI 10.18632/oncotarget.1555; Guo CC, 2012, P NATL ACAD SCI USA, V109, P17603, DOI 10.1073/pnas.1208807109; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Ito K, 2014, NAT REV UROL, V11, P197, DOI 10.1038/nrurol.2014.42; Jiang YM, 2018, ANN SURG, V267, P504, DOI 10.1097/SLA.0000000000002116; Jung SH, 2016, EUR UROL, V69, P823, DOI 10.1016/j.eururo.2015.10.031; Kantidakis T, 2016, GENE DEV, V30, P408, DOI 10.1101/gad.275453.115; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Komai Y, 2014, UROLOGY, V83, P500, DOI 10.1016/j.urology.2013.09.053; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-11-r134; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Li RQ, 2009, BIOINFORMATICS, V25, P1966, DOI 10.1093/bioinformatics/btp336; Liu SC, 2013, J CLIN INVEST, V123, P5269, DOI 10.1172/JCI63428; Mao XY, 2010, CANCER RES, V70, P5207, DOI 10.1158/0008-5472.CAN-09-4074; Mathelier A, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0648-7; Mo R, 2006, J BIOL CHEM, V281, P15714, DOI 10.1074/jbc.M513245200; Ortega-Molina A, 2015, NAT MED, V21, P1199, DOI 10.1038/nm.3943; Preudhomme C, 2000, BLOOD, V96, P2862, DOI 10.1182/blood.V96.8.2862.h8002862_2862_2869; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Roychowdhury S, 2013, J CLIN ONCOL, V31, P1866, DOI 10.1200/JCO.2012.45.3662; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Shao Z, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-3-r16; Shin SH, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2014.34; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun C, 2010, HUM MUTAT, V31, P99, DOI 10.1002/humu.21145; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Zang CZ, 2009, BIOINFORMATICS, V25, P1952, DOI 10.1093/bioinformatics/btp340; Zhang B, 2016, INSECT BIOCHEM MOLEC, V79, P108, DOI 10.1016/j.ibmb.2016.11.001; Zhang JY, 2015, NAT MED, V21, P1190, DOI 10.1038/nm.3940; Zhao MH, 2016, IN VITRO CELL DEV-AN, V52, P699, DOI 10.1007/s11626-016-0017-1	50	67	67	2	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	10					1354	1368		10.1038/s41388-017-0026-x	http://dx.doi.org/10.1038/s41388-017-0026-x			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ0RI	29269867	Green Published, hybrid			2022-12-17	WOS:000427279300007
J	Sengupta, S; Nagalingam, A; Bonner, NMM; Bonner, MY; Mistriotis, P; Afthinos, A; Kuppusamy, P; Lanoue, D; Cho, S; Korangath, P; Shriver, M; Begum, A; Merino, VF; Huang, CY; Arbiser, JL; Matsui, W; Gyorffy, B; Konstantopoulos, K; Sukumar, S; Marignani, PA; Saxena, NK; Sharma, D				Sengupta, S.; Nagalingam, A.; Muniraj, N.; Bonner, M. Y.; Mistriotis, P.; Afthinos, A.; Kuppusamy, P.; Lanoue, D.; Cho, S.; Korangath, P.; Shriver, M.; Begum, A.; Merino, V. F.; Huang, C-Y; Arbiser, J. L.; Matsui, W.; Gyorffy, B.; Konstantopoulos, K.; Sukumar, S.; Marignani, P. A.; Saxena, N. K.; Sharma, D.			Activation of tumor suppressor LKB1 by honokiol abrogates cancer stem-like phenotype in breast cancer via inhibition of oncogenic Stat3	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; MOLECULAR TARGETS; IN-VITRO; CELLS; LEPTIN; EXPRESSION; MIGRATION; INVASION; PATHWAY; INDUCTION	Tumor suppressor and upstream master kinase Liver kinase B1 (LKB1) plays a significant role in suppressing cancer growth and metastatic progression. We show that low-LKB1 expression significantly correlates with poor survival outcome in breast cancer. In line with this observation, loss-of-LKB1 rendered breast cancer cells highly migratory and invasive, attaining cancer stem cell-like phenotype. Accordingly, LKB1-null breast cancer cells exhibited an increased ability to form mammospheres and elevated expression of pluripotency-factors (Oct4, Nanog and Sox2), properties also observed in spontaneous tumors in Lkb1(-/-) mice. Conversely, LKB1-overexpression in LKB1-null cells abrogated invasion, migration and mammosphere-formation. Honokiol (HNK), a bioactive molecule from Magnolia grandiflora increased LKB1 expression, inhibited individual cell-motility and abrogated the stem-like phenotype of breast cancer cells by reducing the formation of mammosphere, expression of pluripotency-factors and aldehyde dehydrogenase activity. LKB1, and its substrate, AMP-dependent protein kinase (AMPK) are important for HNK-mediated inhibition of pluripotency factors since LKB1-silencing and AMPK-inhibition abrogated, while LKB1-overexpression and AMPK-activation potentiated HNK's effects. Mechanistic studies showed that HNK inhibited Stat3-phosphorylation/activation in an LKB1-dependent manner, preventing its recruitment to canonical binding-sites in the promoters of Nanog, Oct4 and Sox2. Thus, inhibition of the coactivation-function of Stat3 resulted in suppression of expression of pluripotency factors. Further, we showed that HNK inhibited breast tumorigenesis in mice in an LKB1-dependent manner. Molecular analyses of HNK-treated xenografts corroborated our in vitro mechanistic findings. Collectively, these results present the first in vitro and in vivo evidence to support crosstalk between LKB1, Stat3 and pluripotency factors in breast cancer and effective anticancer modulation of this axis with HNK treatment.	[Sengupta, S.; Nagalingam, A.; Muniraj, N.; Cho, S.; Korangath, P.; Shriver, M.; Begum, A.; Merino, V. F.; Matsui, W.; Sukumar, S.; Sharma, D.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD USA; [Sengupta, S.; Nagalingam, A.; Muniraj, N.; Cho, S.; Korangath, P.; Shriver, M.; Begum, A.; Merino, V. F.; Matsui, W.; Sukumar, S.; Sharma, D.] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA; [Bonner, M. Y.] Emory Univ, Sch Med, Winship Canc Inst, Dept Dermatol, Atlanta, GA USA; [Mistriotis, P.; Afthinos, A.] Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD USA; [Kuppusamy, P.; Saxena, N. K.] Univ Maryland, Sch Med, Dept Med, 660W Redwood St,Howard Hall,Rm 301, Baltimore, MD 21201 USA; [Lanoue, D.; Marignani, P. A.] Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS, Canada; [Huang, C-Y] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Div Biostat & Bioinformat, Baltimore, MD USA; [Arbiser, J. L.] Atlanta Vet Adm Med Ctr, Atlanta, GA USA; [Gyorffy, B.] MTA TTK Momentum Canc Biomarker Res Grp, Budapest, Hungary; [Gyorffy, B.] Semmelweis Univ, Dept Pediat 2, Budapest, Hungary; [Saxena, N. K.] Natl Canc Inst, 9609 Med Ctr Dr, Rockville, MD 20850 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Emory University; Johns Hopkins University; University System of Maryland; University of Maryland Baltimore; Dalhousie University; Johns Hopkins University; Johns Hopkins Medicine; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Research Centre for Natural Sciences; Semmelweis University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Saxena, NK (corresponding author), Univ Maryland, Sch Med, Dept Med, 660W Redwood St,Howard Hall,Rm 301, Baltimore, MD 21201 USA.; Sharma, D (corresponding author), Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, 1650 Orleans St,CRB 1,Rm 145, Baltimore, MD 21231 USA.	nsaxena@medicine.umaryland.edu; dsharma7@jhmi.edu	Gyorffy, Balazs/AAA-9135-2021; Bonner, Michael Yi/ABD-6756-2021; Mistriotis, Panagiotis/AAJ-5248-2020; sengupta, sonali/F-8830-2016; MUNIRAJ, NETHAJI/I-6017-2019; Kuppusamy, Panjamurthy/AAT-1518-2021	Gyorffy, Balazs/0000-0002-5772-3766; Bonner, Michael Yi/0000-0002-8184-0954; Mistriotis, Panagiotis/0000-0002-8069-3278; sengupta, sonali/0000-0002-9710-9576; MUNIRAJ, NETHAJI/0000-0002-3820-2148; Kuppusamy, Panjamurthy/0000-0003-3293-7220; Afthinos, Alexandros/0000-0001-6906-0771; Marignani, Paola/0000-0001-8070-905X; Shriver, Marey/0000-0002-1644-6408; Korangath, Preethi/0000-0002-6623-493X	NCI NIH [R21CA185943, R01AR47901, R01CA131294, R21CA155686]; OTKA [K108655]; Nova Scotia Health Research Foundation; Canadian Breast Cancer Foundation; Nova; Dalhousie Medical Research Foundation; Avon Foundation; Breast Cancer Research Foundation (BCRF) [90047965]; Fetting Fund; NATIONAL CANCER INSTITUTE [R01CA131294, R01CA193887, R21CA155686, R21CA185943, K24CA198315, P30CA006973] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047901] Funding Source: NIH RePORTER	NCI NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OTKA(Orszagos Tudomanyos Kutatasi Alapprogramok (OTKA)); Nova Scotia Health Research Foundation; Canadian Breast Cancer Foundation(Canadian Cancer Society (CCS)); Nova; Dalhousie Medical Research Foundation; Avon Foundation; Breast Cancer Research Foundation (BCRF); Fetting Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by NCI NIH, R21CA185943 (to NKS); OTKA K108655 (to BG); NCI NIH R01AR47901 (to JLA); The Nova Scotia Health Research Foundation (DL); The Canadian Breast Cancer Foundation and The Nova and the Dalhousie Medical Research Foundation (PAM); NCI NIH R01CA131294, NCI NIH R21CA155686, Avon Foundation, Breast Cancer Research Foundation (BCRF) 90047965 and The Fetting Fund (to DS).	Andrade-Vieira R, 2014, ONCOTARGET, V5, P12738, DOI 10.18632/oncotarget.2818; Andrade-Vieira R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056567; Autanski DB, 2014, MOL ONCOL, V8, P565, DOI 10.1016/j.molonc.2014.01.004; Averett Courey, 2014, Enzymes, V36, P175, DOI 10.1016/B978-0-12-802215-3.00009-4; Avtanski DB, 2015, ONCOTARGET, V6, P16396, DOI 10.18632/oncotarget.3844; Azare J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027851; Bai XH, 2003, J BIOL CHEM, V278, P35501, DOI 10.1074/jbc.M302967200; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Boudeau J, 2004, J CELL SCI, V117, P6365, DOI 10.1242/jcs.01571; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Buettner R, 2002, CLIN CANCER RES, V8, P945; Burdelya L, 2002, MOL CANCER THER, V1, P893; Choi DY, 2012, BRAIN RES BULL, V87, P144, DOI 10.1016/j.brainresbull.2011.11.014; Do DV, 2013, GENE DEV, V27, P1378, DOI 10.1101/gad.221176.113; Fenton H, 2006, APPL IMMUNOHISTO M M, V14, P146, DOI 10.1097/01.pai.0000176157.07908.20; Foshay KM, 2008, STEM CELLS DEV, V17, P269, DOI 10.1089/scd.2007.0098; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Hardie DG, 2005, CURR OPIN CELL BIOL, V17, P167, DOI 10.1016/j.ceb.2005.01.006; Hung WC, 2016, CELL REP, V15, P1430, DOI 10.1016/j.celrep.2016.04.035; Hung WC, 2013, J CELL BIOL, V202, P807, DOI 10.1083/jcb.201302132; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Leeman-Neill RJ, 2010, CLIN CANCER RES, V16, P2571, DOI 10.1158/1078-0432.CCR-10-0333; Li J, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0070-0; Morton JP, 2010, GASTROENTEROLOGY, V139, P586, DOI 10.1053/j.gastro.2010.04.055; Nagalingam A, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3128; Nath-Sain S, 2009, MOL BIOL CELL, V20, P2785, DOI 10.1091/mbc.E08-11-1138; Oh JH, 2009, CHEM-BIOL INTERACT, V180, P506, DOI 10.1016/j.cbi.2009.03.014; Prasad R, 2016, ONCOTARGET, V7, P7899, DOI 10.18632/oncotarget.6860; Rossi DJ, 2002, P NATL ACAD SCI USA, V99, P12327, DOI 10.1073/pnas.192301399; Saxena NK, 2007, J BIOL CHEM, V282, P13316, DOI 10.1074/jbc.M609798200; Saxena NK, 2007, CANCER RES, V67, P2497, DOI 10.1158/0008-5472.CAN-06-3075; Saxena NK, 2008, CANCER RES, V68, P9712, DOI 10.1158/0008-5472.CAN-08-1952; Sharma D, 2006, CANCER RES, V66, P6370, DOI 10.1158/0008-5472.CAN-06-0402; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; Song H, 2005, P NATL ACAD SCI USA, V102, P4700, DOI 10.1073/pnas.0409894102; Suzuki A, 2006, P NATL ACAD SCI USA, V103, P10294, DOI 10.1073/pnas.0506945103; Taliaferro-Smith L, 2009, ONCOGENE, V28, P2621, DOI 10.1038/onc.2009.129; Vaahtomeri K, 2011, FEBS LETT, V585, P944, DOI 10.1016/j.febslet.2010.12.034; Wang P, 2015, ONCOGENE, V34, P4558, DOI 10.1038/onc.2014.397; Wong DJ, 2008, CELL STEM CELL, V2, P333, DOI 10.1016/j.stem.2008.02.009; Xu Q, 2008, PROG NEURO-PSYCHOPH, V32, P715, DOI 10.1016/j.pnpbp.2007.11.020; Yan D, 2012, J BIOL CHEM, V287, P8598, DOI 10.1074/jbc.M111.322800; Ylikorkala A, 2001, SCIENCE, V293, P1323, DOI 10.1126/science.1062074; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Yue P, 2009, EXPERT OPIN INV DRUG, V18, P45, DOI [10.1517/13543780802565791, 10.1517/13543780802565791 ]; Zhou JJ, 2014, FEBS LETT, V588, P566, DOI 10.1016/j.febslet.2013.11.041	49	67	69	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 12	2017	36	41					5709	5721		10.1038/onc.2017.164	http://dx.doi.org/10.1038/onc.2017.164			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FJ6DJ	28581518	Green Accepted, Green Submitted			2022-12-17	WOS:000412843900005
J	Vellinga, TT; den Uil, S; Rinkes, IHB; Marvin, D; Ponsioen, B; Alvarez-Varela, A; Fatrai, S; Scheele, C; Zwijnenburg, DA; Snippert, H; Vermeulen, L; Medema, JP; Stockmann, HB; Koster, J; Fijneman, RJA; de Rooij, J; Kranenburg, O				Vellinga, T. T.; den Uil, S.; Rinkes, I. H. B.; Marvin, D.; Ponsioen, B.; Alvarez-Varela, A.; Fatrai, S.; Scheele, C.; Zwijnenburg, D. A.; Snippert, H.; Vermeulen, L.; Medema, J. P.; Stockmann, H. B.; Koster, J.; Fijneman, R. J. A.; de Rooij, J.; Kranenburg, O.			Collagen-rich stroma in aggressive colon tumors induces mesenchymal gene expression and tumor cell invasion	ONCOGENE			English	Article							INTESTINAL EPITHELIAL-CELLS; HUMAN COLORECTAL-CANCER; MOLECULAR SUBTYPES; UP-REGULATION; TGF-BETA; TRANSITION; METASTASIS; SURVIVAL; PROGRAM; MATRIX	Gene expression-based classification systems have identified an aggressive colon cancer subtype with mesenchymal features, possibly reflecting epithelial-to-mesenchymal transition (EMT) of tumor cells. However, stromal fibroblasts contribute extensively to the mesenchymal phenotype of aggressive colon tumors, challenging the notion of tumor EMT. To separately study the neoplastic and stromal compartments of colon tumors, we have generated a stroma gene filter (SGF). Comparative analysis of stroma(high) and stroma(low) tumors shows that the neoplastic cells in stromahigh tumors express specific EMT drivers (ZEB2, TWIST1, TWIST2) and that 98% of differentially expressed genes are strongly correlated with them. Analysis of differential gene expression between mesenchymal and epithelial cancer cell lines revealed that hepatocyte nuclear factor 4 alpha (HNF4 alpha), a transcriptional activator of intestinal (epithelial) differentiation, and its target genes are highly expressed in epithelial cancer cell lines. However, mesenchymal-type cancer cell lines expressed only part of the mesenchymal genes expressed by tumor-derived neoplastic cells, suggesting that external cues were lacking. We found that collagen-I dominates the extracellular matrix in aggressive colon cancer. Mimicking the tumor microenvironment by replacing laminin-rich Matrigel with collagen-I was sufficient to induce tumor-specific mesenchymal gene expression, suppression of HNF4 alpha and its target genes, and collective tumor cell invasion of patient-derived colon tumor organoids. The data connect collagen-rich stroma to mesenchymal gene expression in neoplastic cells and to collective tumor cell invasion. Targeting the tumor-collagen interface may therefore be explored as a novel strategy in the treatment of aggressive colon cancer.	[Vellinga, T. T.; Rinkes, I. H. B.; Marvin, D.; Fatrai, S.; Kranenburg, O.] Univ Med Ctr Utrecht, Ctr Canc, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands; [den Uil, S.; Fijneman, R. J. A.] Vrije Univ Amsterdam, Med Ctr, Dept Pathol, Amsterdam, Netherlands; [den Uil, S.; Stockmann, H. B.; de Rooij, J.] Spaarne Gasthuis, Dept Surg, Haarlem, Netherlands; [Ponsioen, B.; Alvarez-Varela, A.; Scheele, C.; Snippert, H.] Univ Med Ctr Utrecht, Dept Mol Canc Res, Utrecht, Netherlands; [Zwijnenburg, D. A.] Acad Med Ctr Amsterdam, Dept Oncogen, Amsterdam, Netherlands; [Vermeulen, L.; Medema, J. P.; Koster, J.] Acad Med Ctr Amsterdam, Ctr Expt & Mol Med, Amsterdam, Netherlands; [Fijneman, R. J. A.] Netherlands Canc Inst, Dept Pathol, Amsterdam, Netherlands	Utrecht University; Utrecht University Medical Center; Vrije Universiteit Amsterdam; Spaarne Hospital; Utrecht University; Utrecht University Medical Center; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Netherlands Cancer Institute	Kranenburg, O (corresponding author), Univ Med Ctr Utrecht, Ctr Canc, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	O.kranenburg@umcutrecht.nl	Scheele, Colinda/AAZ-9118-2021; Fijneman, Remond/X-4199-2019; Koster, Jan/C-5934-2008; de rooij, johan/C-1325-2019; Vermeulen, Louis/B-7488-2008	Scheele, Colinda/0000-0001-8999-5451; Fijneman, Remond/0000-0003-2076-5521; Koster, Jan/0000-0002-0890-7585; Vermeulen, Louis/0000-0002-6066-789X; Medema, Jan Paul/0000-0003-3045-2924; Alvarez-Varela, Adrian/0000-0001-5315-3092				Belt EJT, 2011, EUR J CANCER, V47, P1837, DOI 10.1016/j.ejca.2011.04.025; Boissiere-Michot F, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.29256; Boyd M, 2009, BMC GASTROENTEROL, V9, DOI 10.1186/1471-230X-9-68; Budinska E, 2013, J PATHOL, V231, P63, DOI 10.1002/path.4212; Caiado F, 2013, CANCER RES, V73, P4233, DOI 10.1158/0008-5472.CAN-13-0085; Calon A, 2015, NAT GENET, V47, P320, DOI 10.1038/ng.3225; Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013; Celesti G, 2013, GASTROENTEROLOGY, V145, P647, DOI 10.1053/j.gastro.2013.05.011; Chanrion M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6005; De Sousa E Melo F, 2013, NAT MED, V19, P614, DOI 10.1038/nm.3174; Emmink BL, 2014, CANCER RES, V74, P6717, DOI 10.1158/0008-5472.CAN-14-1645; Fatrai S, 2015, GASTROENTEROLOGY, V149, P692, DOI 10.1053/j.gastro.2015.05.003; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Gujral TS, 2014, CELL, V159, P844, DOI 10.1016/j.cell.2014.10.032; Hongo K, 2013, J SURG RES, V182, P75, DOI 10.1016/j.jss.2012.08.034; Huang Da Wei, 2009, Curr Protoc Bioinformatics, VChapter 13, DOI 10.1002/0471250953.bi1311s27; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Hwang WL, 2011, GASTROENTEROLOGY, V141, P279, DOI 10.1053/j.gastro.2011.04.008; Isella C, 2015, NAT GENET, V47, P312, DOI 10.1038/ng.3224; Jorissen RN, 2009, CLIN CANCER RES, V15, P7642, DOI 10.1158/1078-0432.CCR-09-1431; Julien S, 2012, CLIN CANCER RES, V18, P5314, DOI 10.1158/1078-0432.CCR-12-0372; Loboda A, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-9; Lu J, 2013, CANCER CELL, V23, P171, DOI 10.1016/j.ccr.2012.12.021; Lussier CR, 2008, AM J PHYSIOL-GASTR L, V294, pG418, DOI 10.1152/ajpgi.00418.2007; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marisa L, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001453; Mesker WE, 2007, CELL ONCOL, V29, P387; Mesker WE, 2009, CELL ONCOL, V31, P169, DOI 10.3233/CLO-2009-0478; Miles FL, 2014, MOL CANCER RES, V12, P297, DOI 10.1158/1541-7786.MCR-13-0535; Nishida N, 2012, CLIN CANCER RES, V18, P3054, DOI 10.1158/1078-0432.CCR-11-1078; Perez-Villamil B, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-260; Phillips SM, 2004, BRIT J SURG, V91, P469, DOI 10.1002/bjs.4472; Roepman P, 2014, INT J CANCER, V134, P552, DOI 10.1002/ijc.28387; Sadanandam A, 2014, CELL CYCLE, V13, P353, DOI 10.4161/cc.27769; Sadanandam A, 2013, NAT MED, V19, P619, DOI 10.1038/nm.3175; Santangelo L, 2011, HEPATOLOGY, V53, P2063, DOI 10.1002/hep.24280; Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050; Schlicker A, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-66; Smith JJ, 2010, GASTROENTEROLOGY, V138, P958, DOI 10.1053/j.gastro.2009.11.005; Smith K, 1999, BRIT J CANCER, V81, P496, DOI 10.1038/sj.bjc.6690721; Spaderna S, 2006, GASTROENTEROLOGY, V131, P830, DOI 10.1053/j.gastro.2006.06.016; Stegmann A, 2006, PHYSIOL GENOMICS, V27, P141, DOI 10.1152/physiolgenomics.00314.2005; Tabibzadeh S, 2002, FRONT BIOSCI-LANDMRK, V7, pD1231; Thomson S, 2011, CLIN EXP METASTAS, V28, P137, DOI 10.1007/s10585-010-9367-3; Wei SC, 2015, NAT CELL BIOL, V17, P678, DOI 10.1038/ncb3157; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Yao HS, 2015, MOL CARCINOG; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Zhang B, 2014, NATURE, V513, P382, DOI 10.1038/nature13438	49	67	69	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2016	35	40					5263	5271		10.1038/onc.2016.60	http://dx.doi.org/10.1038/onc.2016.60			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DZ7NO	26996663				2022-12-17	WOS:000386053000005
J	Fan, L; Peng, G; Sahgal, N; Fazli, L; Gleave, M; Zhang, Y; Hussain, A; Qi, J				Fan, L.; Peng, G.; Sahgal, N.; Fazli, L.; Gleave, M.; Zhang, Y.; Hussain, A.; Qi, J.			Regulation of c-Myc expression by the histone demethylase JMJD1A is essential for prostate cancer cell growth and survival	ONCOGENE			English	Article							ANDROGEN RECEPTOR; TUMOR-SUPPRESSOR; UBIQUITIN LIGASE; GENE-EXPRESSION; STEM-CELLS; TRANSCRIPTION; PROLIFERATION; JHDM2A; OVEREXPRESSION; PROGRESSION	The histone demethylase JMJD1A, which controls gene expression by epigenetic regulation of H3K9 methylation marks, functions in diverse activities, including spermatogenesis, metabolism and stem cell self-renewal and differentiation. Here, we found that JMJD1A knockdown in prostate cancer cells antagonizes their proliferation and survival. Profiling array analyses revealed that JMJD1A-dependent genes function in cellular growth, proliferation and survival, and implicated that the c-Myc transcriptional network is deregulated following JMJD1A inhibition. Biochemical analyses confirmed that JMJD1A enhances c-Myc transcriptional activity by upregulating c-Myc expression levels. Mechanistically, JMJD1A activity promoted recruitment of androgen receptor (AR) to the c-Myc gene enhancer and induced H3K9 demethylation, increasing AR-dependent transcription of c-Myc mRNA. In parallel, we found that JMJD1A regulated c-Myc stability, likely by inhibiting HUWE1, an E3 ubiquitin ligase known to target degradation of several substrates including c-Myc. JMJD1A (wild type or mutant lacking histone demethylase activity) bound to HUWE1, attenuated HUWE1-dependent ubiquitination and subsequent degradation of c-Myc, increasing c-Myc protein levels. Furthermore, c-Myc knockdown in prostate cancer cells phenocopied effects of JMJD1A knockdown, and c-Myc re-expression in JMJD1A-knockdown cells partially rescued prostate cancer cell growth in vitro and in vivo. c-Myc protein levels were positively correlated with those of JMJD1A in a subset of human prostate cancer specimens. Collectively, our findings identify a critical role for JMJD1A in regulating proliferation and survival of prostate cancer cells by controlling c-Myc expression at transcriptional and post-translational levels.	[Fan, L.; Peng, G.; Zhang, Y.; Hussain, A.; Qi, J.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA; [Fan, L.; Peng, G.; Hussain, A.; Qi, J.] Univ Maryland, Sch Med, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA; [Fan, L.; Peng, G.; Hussain, A.; Qi, J.] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; [Sahgal, N.] Queen Mary Univ London, Barts Canc Inst, Ctr Mol Oncol, London, England; [Fazli, L.; Gleave, M.] Univ British Columbia, Vancouver Prostate Ctr, Vancouver, BC V5Z 1M9, Canada; [Zhang, Y.] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA; [Hussain, A.] Baltimore VA Med Ctr, Baltimore, MD USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of London; Queen Mary University London; University of British Columbia; University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baltimore VA Medical Center	Qi, J (corresponding author), Univ Maryland, Dept Biochem & Mol Biol, Marlene & Stewart Greenebaum Canc Ctr, Sch Med, 655W Baltimore St, Baltimore, MD 21201 USA.	jqi@som.umaryland.edu		Gleave, Martin/0000-0003-4235-0167; qi, jianfei/0000-0001-7884-7656; Zhang, Yuji/0000-0002-5429-6762	NCI [CA154888]; Merit Review Award Department of Veterans Affairs; NATIONAL CANCER INSTITUTE [R00CA154888, K99CA154888] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Merit Review Award Department of Veterans Affairs; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Support by NCI Grant CA154888 (to JQ) and a Merit Review Award Department of Veterans Affairs (to AH) is gratefully acknowledged.	Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Cai CM, 2011, CANCER CELL, V20, P457, DOI 10.1016/j.ccr.2011.09.001; Chen DL, 2005, CELL, V121, P1071, DOI 10.1016/j.cell.2005.03.037; Chen SY, 2006, ONCOGENE, V25, P7212, DOI 10.1038/sj.onc.1209705; Cho HJ, 2014, CANCER DISCOV, V4, P318, DOI 10.1158/2159-8290.CD-13-0346; Civenni G, 2013, CANCER RES, V73, P6816, DOI 10.1158/0008-5472.CAN-13-0615; Conzen SD, 2000, MOL CELL BIOL, V20, P6008, DOI 10.1128/MCB.20.16.6008-6018.2000; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Gao LN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063563; Gil J, 2005, CANCER RES, V65, P2179, DOI 10.1158/0008-5472.CAN-03-4030; Goda S, 2013, J BIOL CHEM, V288, P36948, DOI 10.1074/jbc.M113.492595; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Gurel B, 2008, MODERN PATHOL, V21, P1156, DOI 10.1038/modpathol.2008.111; Hawksworth D, 2010, PROSTATE CANCER P D, V13, P311, DOI 10.1038/pcan.2010.31; Herkert Barbara, 2010, Genes Cancer, V1, P580, DOI 10.1177/1947601910379012; Inoue S, 2013, GENE DEV, V27, P1101, DOI 10.1101/gad.214577.113; Kim J, 2012, ONCOGENE, V31, P322, DOI 10.1038/onc.2011.236; Koh Cheryl M, 2010, Genes Cancer, V1, P617, DOI 10.1177/1947601910379132; Krieg AJ, 2010, MOL CELL BIOL, V30, P344, DOI 10.1128/MCB.00444-09; Kuroki S, 2013, SCIENCE, V341, P1106, DOI 10.1126/science.1239864; Loh YH, 2007, GENE DEV, V21, P2545, DOI 10.1101/gad.1588207; Mimura I, 2012, MOL CELL BIOL, V32, P3018, DOI 10.1128/MCB.06643-11; Okada Y, 2007, NATURE, V450, P119, DOI 10.1038/nature06236; Osawa T, 2013, CANCER RES, V73, P3019, DOI 10.1158/0008-5472.CAN-12-3231; Ouyang X, 2008, CANCER RES, V68, P2132, DOI 10.1158/0008-5472.CAN-07-6055; Parimi V, 2014, AM J CLIN EXP UROL, V2, P273; Park SJ, 2013, BIOCHEM BIOPH RES CO, V434, P722, DOI 10.1016/j.bbrc.2013.03.091; Parrish JK, 2015, ONCOGENE, V34, P257, DOI 10.1038/onc.2013.541; Qi JF, 2010, CANCER CELL, V18, P23, DOI 10.1016/j.ccr.2010.05.024; Rajasekhar VK, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1159; Rye MB, 2014, BMC MED GENOMICS, V7, DOI 10.1186/1755-8794-7-50; Sharma NL, 2013, CANCER CELL, V23, P35, DOI 10.1016/j.ccr.2012.11.010; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Sotelo J, 2010, P NATL ACAD SCI USA, V107, P3001, DOI 10.1073/pnas.0906067107; Tao SF, 2014, MOL BIOL REP, V41, P6291, DOI 10.1007/s11033-014-3511-0; Tateishi K, 2009, NATURE, V458, P757, DOI 10.1038/nature07777; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tee AE, 2014, ONCOTARGET, V5, P1793, DOI 10.18632/oncotarget.1785; Vaughan L, 2015, CELL REP, V10, P88, DOI 10.1016/j.celrep.2014.12.012; Wang JQ, 2012, CANCER RES, V72, P4765, DOI 10.1158/0008-5472.CAN-12-0820; Wang LZ, 2009, CANCER CELL, V16, P336, DOI 10.1016/j.ccr.2009.08.016; Wang XZ, 2014, BIOCHEM BIOPH RES CO, V444, P549, DOI 10.1016/j.bbrc.2014.01.075; Yamane K, 2006, CELL, V125, P483, DOI 10.1016/j.cell.2006.03.027; Yu CY, 2011, IN VIVO, V25, P69; Zhao XD, 2008, NAT CELL BIOL, V10, P643, DOI 10.1038/ncb1727; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009; Zhou ZF, 1997, J BIOL CHEM, V272, P8227, DOI 10.1074/jbc.272.13.8227	48	67	69	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2016	35	19					2441	2452		10.1038/onc.2015.309	http://dx.doi.org/10.1038/onc.2015.309			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GQ	26279298	Green Accepted			2022-12-17	WOS:000376165500003
J	Siu, MK; Tsai, YC; Chang, YS; Yin, JJ; Suau, F; Chen, WY; Liu, YN				Siu, M. K.; Tsai, Y-C; Chang, Y-S; Yin, J. J.; Suau, F.; Chen, W-Y; Liu, Y-N			Transforming growth factor-beta promotes prostate bone metastasis through induction of microRNA-96 and activation of the mTOR pathway	ONCOGENE			English	Article							MESENCHYMAL TRANSITION; CANCER; INHIBITION; EXPRESSION; INVASION; RECEPTOR; GENE	Transforming growth factor-beta (TGF beta) is enriched in the bone matrix and serves as a key factor in promoting bone metastasis in cancer. In addition, TGF beta signaling activates mammalian target of rapamycin (mTOR) functions, which is important for the malignant progression. Here, we demonstrate that TGF beta regulates the level of microRNA-96 (miR-96) through Smad-dependent transcription and that miR-96 promotes the bone metastasis in prostate cancer. The enhanced effects in cellular growth and invasiveness suggest that miR-96 functions as an oncomir/and metastamir. Supporting this idea, we identified a downstream target of the TGF beta-miR-96 signaling pathway to be AKT1S1 mRNA, whose translated protein is a negative regulator of mTOR kinase. Our findings provide a novel mechanism accounting for the TGF beta signaling and bone metastasis.	[Siu, M. K.; Tsai, Y-C; Liu, Y-N] Taipei Med Univ, Coll Med Sci & Technol, Program Canc Biol & Drug Discovery, Taipei 11031, Taiwan; [Siu, M. K.; Tsai, Y-C; Liu, Y-N] Acad Sinica, Taipei 115, Taiwan; [Siu, M. K.] Taipei Med Univ, Wan Fang Hosp, Dept Anesthesiol, Taipei 11031, Taiwan; [Tsai, Y-C; Chang, Y-S; Liu, Y-N] Taipei Med Univ, Coll Med Sci & Technol, Grad Inst Canc Biol & Drug Discovery, Taipei 11031, Taiwan; [Yin, J. J.; Suau, F.] NCI, Cell & Canc Biol Branch, NIH, Bethesda, MD 20892 USA; [Chen, W-Y] Taipei Med Univ, Wan Fang Hosp, Dept Pathol, Taipei 11031, Taiwan	Taipei Medical University; Academia Sinica - Taiwan; Taipei Medical University; Taipei Municipal WanFang Hospital; Taipei Medical University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Taipei Medical University; Taipei Municipal WanFang Hospital	Liu, YN (corresponding author), Taipei Med Univ, Coll Med Sci & Technol, Grad Inst Canc Biol & Drug Discovery, 250 Wu Hsing St, Taipei 11031, Taiwan.	yuanchin@tmu.edu.tw; liuy@tmu.edu.tw	Liu, Yen-Nien/AAW-4698-2021		Taipei Medical University-Wan Fang Hospital [102TMU-WFH-05]; Taipei Medical University [TMU102-AE1-B30]; Ministry of Science and Technology [NSC102-2320-B-038-001, NSC103-2311-B-038-001]	Taipei Medical University-Wan Fang Hospital; Taipei Medical University; Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea)	This work was jointly supported by grants from the Taipei Medical University-Wan Fang Hospital (102TMU-WFH-05) to Y-N Liu, Taipei Medical University (TMU102-AE1-B30) to Y-C Tsai, the Ministry of Science and Technology (NSC102-2320-B-038-001) of Taiwan to Y-N Liu, and the Ministry of Science and Technology (NSC103-2311-B-038-001) of Taiwan to Y-C Tsai. We also thank Dr Ji-Hshiung Chen (Tzu Chi University) for reading the manuscript and for his comments and helpful suggestions. We also thank Dr Orla Casey for reviewing our manuscript and discussion.	Ao MF, 2006, CANCER RES, V66, P8007, DOI 10.1158/0008-5472.CAN-05-4451; Bedi A, 2012, MOL CANCER THER, V11, P2429, DOI 10.1158/1535-7163.MCT-12-0101-T; Bertoldo F, 2014, BBA-REV CANCER, V1845, P248, DOI 10.1016/j.bbcan.2014.01.009; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; Butz H, 2012, TRENDS PHARMACOL SCI, V33, P382, DOI 10.1016/j.tips.2012.04.003; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Fendler A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080807; Gogna R, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.15; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Haflidadottir BS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072400; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Lamouille S, 2007, J CELL BIOL, V178, P437, DOI 10.1083/jcb.200611146; Lamouille S, 2012, J CELL SCI, V125, P1259, DOI 10.1242/jcs.095299; Lee C, 1999, PROSTATE, V39, P285; Li X, 2008, ONCOGENE, V27, P7118, DOI 10.1038/onc.2008.293; Lin HX, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015797; Liu CF, 2013, PROSTATE, V73, P418, DOI 10.1002/pros.22583; Liu YN, 2013, ONCOGENE, V32, P296, DOI 10.1038/onc.2012.58; Liu YN, 2012, MOL CELL BIOL, V32, P941, DOI 10.1128/MCB.06306-11; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Martin P, 2011, AM J PATHOL, V179, P422, DOI 10.1016/j.ajpath.2011.03.035; Mishra S, 2014, ONCOGENE, V33, P4097, DOI 10.1038/onc.2013.374; Nicoloso MS, 2009, NAT REV CANCER, V9, P293, DOI 10.1038/nrc2619; Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tian M, 2009, FUTURE ONCOL, V5, P259, DOI 10.2217/14796694.5.2.259; Vander Haar E, 2007, NAT CELL BIOL, V9, P316, DOI 10.1038/ncb1547; Yadav V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047796; Yin JJ, 2010, CANCER RES, V70, P8662, DOI 10.1158/0008-5472.CAN-10-1435; Yin JJ, 2007, MOL CELL BIOL, V27, P7538, DOI 10.1128/MCB.00955-07; Yu SN, 2010, CANCER RES, V70, P6015, DOI 10.1158/0008-5472.CAN-09-4531; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	36	67	71	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	2015	34	36					4767	4776		10.1038/onc.2014.414	http://dx.doi.org/10.1038/onc.2014.414			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CQ9JU	25531317				2022-12-17	WOS:000360931500010
J	Dillon, LM; Bean, JR; Yang, W; Shee, K; Symonds, LK; Balko, JM; McDonald, WH; Liu, S; Gonzalez-Angulo, AM; Mills, GB; Arteaga, CL; Miller, TW				Dillon, L. M.; Bean, J. R.; Yang, W.; Shee, K.; Symonds, L. K.; Balko, J. M.; McDonald, W. H.; Liu, S.; Gonzalez-Angulo, A. M.; Mills, G. B.; Arteaga, C. L.; Miller, T. W.			P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer	ONCOGENE			English	Article							P21-ACTIVATED-KINASE-1 PAK1; TUMOR-SUPPRESSOR; EXCHANGE FACTOR; RAC-GEF; PATHWAY; KINASE; IDENTIFICATION; INHIBITOR; PHOSPHORYLATION; RESISTANCE	Phosphatidylinositol 3-kinase (PI3K) promotes cancer cell survival, migration, growth and proliferation by generating phosphatidylinositol 3,4,5-trisphosphate (PIP3) in the inner leaflet of the plasma membrane. PIP3 recruits pleckstrin homology domain-containing proteins to the membrane to activate oncogenic signaling cascades. Anticancer therapeutics targeting the PI3K/AKT/mTOR (mammalian target of rapamycin) pathway are in clinical development. In a mass spectrometric screen to identify PIP3-regulated proteins in breast cancer cells, levels of the Rac activator PIP3-dependent Rac exchange factor-1 (P-REX1) increased in response to PI3K inhibition, and decreased upon loss of the PI3K antagonist phosphatase and tensin homolog (PTEN). P-REX1 mRNA and protein levels were positively correlated with ER expression, and inversely correlated with PI3K pathway activation in breast tumors as assessed by gene expression and phosphoproteomic analyses. P-REX1 increased activation of Rac1, PI3K/AKT and MEK/ERK signaling in a PTEN-independent manner, and promoted cell and tumor viability. Loss of P-REX1 or inhibition of Rac suppressed PI3K/AKT and MEK/ERK, and decreased viability. P-REX1 also promoted insulin-like growth factor-1 receptor activation, suggesting that P-REX1 provides positive feedback to activators upstream of PI3K. In support of a model where PIP3-driven P-REX1 promotes both PI3K/AKT and MEK/ERK signaling, high levels of P-REX1 mRNA (but not phospho-AKT or a transcriptomic signature of PI3K activation) were predictive of sensitivity to PI3K inhibitors among breast cancer cell lines. P-REX1 expression was highest in estrogen receptor-positive breast tumors compared with many other cancer subtypes, suggesting that neutralizing the P-REX1/Rac axis may provide a novel therapeutic approach to selectively abrogate oncogenic signaling in breast cancer cells.	[Dillon, L. M.; Bean, J. R.; Yang, W.; Shee, K.; Symonds, L. K.; Miller, T. W.] Dartmouth Hitchcock Med Ctr, Geisel Sch Med Dartmouth, Norris Cotton Canc Ctr, Dept Pharmacol & Toxicol, Lebanon, NH 03756 USA; [Balko, J. M.; Arteaga, C. L.] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Med, Nashville, TN 37212 USA; [Balko, J. M.; Arteaga, C. L.] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Breast Canc Res Program, Nashville, TN 37212 USA; [McDonald, W. H.] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Prote Lab, Nashville, TN 37212 USA; [Liu, S.; Gonzalez-Angulo, A. M.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA; [Liu, S.; Gonzalez-Angulo, A. M.; Mills, G. B.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Arteaga, C. L.] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Canc Biol, Nashville, TN 37212 USA; [Miller, T. W.] Norris Cotton Canc Ctr, Geisel Sch Med Dartmouth, Comprehens Breast Canc Program, Lebanon, NH USA	Dartmouth College; Norris Cotton Cancer Center; Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; Vanderbilt University; Dartmouth College; Norris Cotton Cancer Center	Miller, TW (corresponding author), Dartmouth Hitchcock Med Ctr, Geisel Sch Med Dartmouth, Norris Cotton Canc Ctr, Dept Pharmacol & Toxicol, One Med Ctr Dr HB-7936, Lebanon, NH 03756 USA.	Todd.W.Miller@Dartmouth.edu	Shee, Kevin/V-6803-2019; McDonald, W. Hayes/B-4109-2016	Shee, Kevin/0000-0001-5378-7650; McDonald, W. Hayes/0000-0002-3510-426X; Dillon, Lloye/0000-0002-5118-1126	NIH [K99/R00CA142899]; Dartmouth College Norris Cotton Cancer Center Support Grant [P30CA023108]; Vanderbilt-Ingram Cancer Center Breast Cancer Specialized Program of Research Excellence Grant [P50CA98131]; Vanderbilt-Ingram Cancer Center Support Grant [P30CA68485]; American Cancer Society [IRG-58-009-50, 121329-RSG-11-187-01-TBG]; Commonwealth Foundation for Cancer Research; NATIONAL CANCER INSTITUTE [R00CA142899, P50CA098131, P30CA023108, P30CA068485, K99CA142899] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dartmouth College Norris Cotton Cancer Center Support Grant; Vanderbilt-Ingram Cancer Center Breast Cancer Specialized Program of Research Excellence Grant; Vanderbilt-Ingram Cancer Center Support Grant; American Cancer Society(American Cancer Society); Commonwealth Foundation for Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Chad Creighton for advice on gene expression analysis, and the Norris Cotton Cancer Center Transgenic and Genetic Construct Shared Resource and Genomics and Molecular Biology Shared Resource for assistance. This work was financially supported by NIH: K99/R00CA142899 (TWM), Dartmouth College Norris Cotton Cancer Center Support Grant P30CA023108, Vanderbilt-Ingram Cancer Center Breast Cancer Specialized Program of Research Excellence Grant P50CA98131 and Vanderbilt-Ingram Cancer Center Support Grant P30CA68485; the American Cancer Society IRG-58-009-50 (TWM) and 121329-RSG-11-187-01-TBG (to AMG); and The Commonwealth Foundation for Cancer Research (to AMG).	Arias-Romero LE, 2010, ONCOGENE, V29, P5839, DOI 10.1038/onc.2010.318; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chakrabarty A, 2012, P NATL ACAD SCI USA, V109, P2718, DOI 10.1073/pnas.1018001108; Creighton CJ, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2594; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Ebi H, 2013, P NATL ACAD SCI USA, V110, P21124, DOI 10.1073/pnas.1314124110; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Fine B, 2009, SCIENCE, V325, P1261, DOI 10.1126/science.1173569; Folkes AJ, 2008, J MED CHEM, V51, P5522, DOI 10.1021/jm800295d; Fritsch R, 2013, CELL, V153, P1050, DOI 10.1016/j.cell.2013.04.031; Guillermet-Guibert J, 2008, P NATL ACAD SCI USA, V105, P8292, DOI 10.1073/pnas.0707761105; Hanker AB, 2013, P NATL ACAD SCI USA, V110, P14372, DOI 10.1073/pnas.1303204110; Hernandez-Negrete I, 2007, J BIOL CHEM, V282, P23708, DOI 10.1074/jbc.M703771200; Hill K, 2005, J BIOL CHEM, V280, P4166, DOI 10.1074/jbc.M411262200; Hoffman GR, 2002, FEBS LETT, V513, P85, DOI 10.1016/S0014-5793(01)03310-5; Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96; Khatri S, 2010, J BIOL CHEM, V285, P15960, DOI 10.1074/jbc.M110.121871; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Li J, 2013, NAT METHODS, V10, P1046, DOI [10.1038/nmeth.2650, 10.1038/NMETH.2650]; Ma ZQ, 2009, J PROTEOME RES, V8, P3872, DOI 10.1021/pr900360j; MacCoss MJ, 2002, P NATL ACAD SCI USA, V99, P7900, DOI 10.1073/pnas.122231399; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maira SM, 2012, MOL CANCER THER, V11, P317, DOI 10.1158/1535-7163.MCT-11-0474; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Martinez MN, 2012, J LIPID RES, V53, P379, DOI 10.1194/jlr.M019752; Miller TW, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3039; Miller TW, 2009, CANCER RES, V69, P4192, DOI 10.1158/0008-5472.CAN-09-0042; Montero JC, 2011, ONCOGENE, V30, P1059, DOI 10.1038/onc.2010.489; O'Brien C, 2010, CLIN CANCER RES, V16, P3670, DOI 10.1158/1078-0432.CCR-09-2828; Onesto C, 2008, METHOD ENZYMOL, V439, P111, DOI 10.1016/S0076-6879(07)00409-0; Ong CC, 2011, P NATL ACAD SCI USA, V108, P7177, DOI 10.1073/pnas.1103350108; Premont RT, 2004, CELL SIGNAL, V16, P1001, DOI 10.1016/j.cellsig.2004.02.002; Qin J, 2009, ONCOGENE, V28, P1853, DOI 10.1038/onc.2009.30; Saal LH, 2007, P NATL ACAD SCI USA, V104, P7564, DOI 10.1073/pnas.0702507104; Saini KS, 2013, CANCER TREAT REV, V39, P935, DOI 10.1016/j.ctrv.2013.03.009; Slack-Davis JK, 2003, J CELL BIOL, V162, P281, DOI 10.1083/jcb.200212141; Sosa MS, 2010, MOL CELL, V40, P877, DOI 10.1016/j.molcel.2010.11.029; Wang ZP, 2013, J BIOL CHEM, V288, P20093, DOI 10.1074/jbc.M112.426023; Welch HCE, 2005, CURR BIOL, V15, P1867, DOI 10.1016/j.cub.2005.09.050; Welch HCE, 2002, CELL, V108, P809, DOI 10.1016/S0092-8674(02)00663-3; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; Yang HW, 2012, MOL CELL, V47, P281, DOI 10.1016/j.molcel.2012.05.007; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245	46	67	76	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	30					3968	3976		10.1038/onc.2014.328	http://dx.doi.org/10.1038/onc.2014.328			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN6KR	25284585	Green Accepted			2022-12-17	WOS:000358544200009
J	Than, BLN; Goos, JACM; Sarver, AL; O'Sullivan, MG; Rod, A; Starr, TK; Fijneman, RJA; Meijer, GA; Zhao, L; Zhang, Y; Largaespada, DA; Scott, PM; Cormier, RT				Than, B. L. N.; Goos, J. A. C. M.; Sarver, A. L.; O'Sullivan, M. G.; Rod, A.; Starr, T. K.; Fijneman, R. J. A.; Meijer, G. A.; Zhao, L.; Zhang, Y.; Largaespada, D. A.; Scott, P. M.; Cormier, R. T.			The role of KCNQ1 in mouse and human gastrointestinal cancers	ONCOGENE			English	Article						colorectal cancer; KCNQ1; tumor suppressor	GATED POTASSIUM CHANNELS; CYSTIC-FIBROSIS MOUSE; INTESTINAL TUMORIGENESIS; COLORECTAL-CANCER; TARGETED DISRUPTION; PHENOTYPIC ANALYSIS; MICE; SUSCEPTIBILITY; EXPRESSION; GENES	Kcnq1, which encodes for the pore-forming alpha-subunit of a voltage-gated potassium channel, was identified as a gastrointestinal (GI) tract cancer susceptibility gene in multiple Sleeping Beauty DNA transposon-based forward genetic screens in mice. To confirm that Kcnq1 has a functional role in GI tract cancer, we created Apc(Min) mice that carried a targeted deletion mutation in Kcnq1. Results demonstrated that Kcnq1 is a tumor suppressor gene as Kcnq1 mutant mice developed significantly more intestinal tumors, especially in the proximal small intestine and colon, and some of these tumors progressed to become aggressive adenocarcinomas. Gross tissue abnormalities were also observed in the rectum, pancreas and stomach. Colon organoid formation was significantly increased in organoids created from Kcnq1 mutant mice compared with wild-type littermate controls, suggesting a role for Kcnq1 in the regulation of the intestinal crypt stem cell compartment. To identify gene expression changes due to loss of Kcnq1, we carried out microarray studies in the colon and proximal small intestine. We identified altered genes involved in innate immune responses, goblet and Paneth cell function, ion channels, intestinal stem cells, epidermal growth factor receptor and other growth regulatory signaling pathways. We also found genes implicated in inflammation and in cellular detoxification. Pathway analysis using Ingenuity Pathway Analysis and Gene Set Enrichment Analysis confirmed the importance of these gene clusters and further identified significant overlap with genes regulated by MUC2 and CFTR, two important regulators of intestinal homeostasis. To investigate the role of KCNQ1 in human colorectal cancer (CRC), we measured protein levels of KCNQ1 by immunohistochemistry in tissue microarrays containing samples from CRC patients with liver metastases who had undergone hepatic resection. Results showed that low expression of KCNQ1 expression was significantly associated with poor overall survival.	[Than, B. L. N.; Rod, A.; Zhao, L.; Scott, P. M.; Cormier, R. T.] Univ Minnesota, Sch Med, Dept Biomed Sci, Duluth, MN 55812 USA; [Than, B. L. N.] Univ Minnesota, Toxicol Grad Program, Duluth, MN 55812 USA; [Goos, J. A. C. M.; Fijneman, R. J. A.; Meijer, G. A.] Vrije Univ Amsterdam, Med Ctr, Dept Pathol, Amsterdam, Netherlands; [Sarver, A. L.] Univ Minnesota, Mason Canc Ctr, Dept Biostat & Informat, Minneapolis, MN USA; [O'Sullivan, M. G.] Univ Minnesota, Coll Vet Med, St Paul, MN 55108 USA; [Starr, T. K.] Univ Minnesota, Mason Canc Ctr, Ctr Genome Engn, Dept Genet Cell Biol & Dev, Minneapolis, MN USA; [Starr, T. K.; Largaespada, D. A.] Univ Minnesota, Mason Canc Ctr, Dept Obstet Gynecol & Womens Hlth, Duluth, MN 55812 USA; [Zhang, Y.] Univ Minnesota, Supercomp Inst, Minneapolis, MN USA	University of Minnesota System; University of Minnesota Duluth; University of Minnesota System; University of Minnesota Duluth; Vrije Universiteit Amsterdam; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Duluth; University of Minnesota System; University of Minnesota Twin Cities	Cormier, RT (corresponding author), Univ Minnesota, Sch Med, Dept Biomed Sci, 1035 Univ Dr,247 Med, Duluth, MN 55812 USA.	rcormier@d.umn.edu	Starr, Tim/AAX-9342-2021; Fijneman, Remond/X-4199-2019; goos, jeroen/AAL-8405-2020	Fijneman, Remond/0000-0003-2076-5521; Starr, Timothy/0000-0002-6308-3451; Meijer, Gerrit/0000-0003-0330-3130; Goos, Jeroen/0000-0003-2010-7377	Center for Translational Molecular Medicine, DeCoDe project grant [03O-101];  [NCI R01 CA134759-01A1];  [NCI R00 4R00CA151672-02]; NATIONAL CANCER INSTITUTE [P30CA077598, R01CA134759, R00CA151672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK027651] Funding Source: NIH RePORTER	Center for Translational Molecular Medicine, DeCoDe project grant; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr Karl Pfeifer at the NIH for generously providing Kcnq1 mutant mice and reviewing the manuscript. Research was supported by a grant to RC and DL (NCI R01 CA134759-01A1) and to JG and RF (Center for Translational Molecular Medicine, DeCoDe project grant 03O-101) and to TKS (NCI R00 4R00CA151672-02).	Belt EJT, 2011, EUR J CANCER, V47, P1837, DOI 10.1016/j.ejca.2011.04.025; Burger-van Paassen N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038798; Casimiro MC, 2004, GENOMICS, V84, P555, DOI 10.1016/j.ygeno.2004.06.007; Casimiro MC, 2001, P NATL ACAD SCI USA, V98, P2526, DOI 10.1073/pnas.041398998; De Lisle RC, 2011, J PEDIATR GASTR NUTR, V53, P371, DOI 10.1097/MPG.0b013e318219c397; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Dedek K, 2001, PFLUG ARCH EUR J PHY, V442, P896, DOI 10.1007/s004240100609; Demolombe S, 2001, AM J PHYSIOL-CELL PH, V280, pC359, DOI 10.1152/ajpcell.2001.280.2.C359; Duerkop BA, 2009, IMMUNITY, V31, P368, DOI 10.1016/j.immuni.2009.08.009; Dziarski R, 2010, INNATE IMMUN-LONDON, V16, P168, DOI 10.1177/1753425910366059; Elso CM, 2004, HUM MOL GENET, V13, P2813, DOI 10.1093/hmg/ddh307; Fijneman RJA, 2012, CANCER SCI, V103, P593, DOI 10.1111/j.1349-7006.2011.02189.x; Fong Y, 1999, ANN SURG, V230, P309, DOI 10.1097/00000658-199909000-00004; Grahammer F, 2001, GASTROENTEROLOGY, V120, P1363, DOI 10.1053/gast.2001.24053; Hashimoto T, 2012, NATURE, V487, P477, DOI 10.1038/nature11228; Kang SJ, 2012, J IMMUNOL, V188, P1108, DOI 10.4049/jimmunol.1102084; Knobloch M, 2013, NATURE, V493, P226, DOI 10.1038/nature11689; Lang F, 2013, FASEB J, V27, P3, DOI 10.1096/fj.12-218230; Lee MP, 2000, J CLIN INVEST, V106, P1447, DOI 10.1172/JCI10897; Maisonneuve P, 2003, JNCI-J NATL CANCER I, V95, P381, DOI 10.1093/jnci/95.5.381; Mann KM, 2012, P NATL ACAD SCI USA, V109, P5934, DOI 10.1073/pnas.1202490109; March HN, 2011, NAT GENET, V43, P1202, DOI 10.1038/ng.990; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Munoz J, 2012, EMBO J, V31, P3079, DOI 10.1038/emboj.2012.166; Nikou GC, 2011, INT J SURG, V9, P248, DOI 10.1016/j.ijsu.2010.12.003; Norkina O, 2004, AM J PHYSIOL-GASTR L, V286, pG1032, DOI 10.1152/ajpgi.00473.2003; Perez-Mancera PA, 2012, NATURE, V486, P266, DOI 10.1038/nature11114; Peroz D, 2008, J PHYSIOL-LONDON, V586, P1785, DOI 10.1113/jphysiol.2007.148254; Preston P, 2010, J BIOL CHEM, V285, P7165, DOI 10.1074/jbc.M109.047829; Rice KS, 2011, HEART RHYTHM, V8, P551, DOI 10.1016/j.hrthm.2010.11.039; Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050; Shalapour S, 2010, EUR J IMMUNOL, V40, P2391, DOI 10.1002/eji.201040441; Simon R, 2004, BIOTECHNIQUES, V36, P98, DOI 10.2144/04361RV01; Starr TK, 2011, P NATL ACAD SCI USA, V108, P5765, DOI 10.1073/pnas.1018012108; Starr TK, 2009, SCIENCE, V323, P1747, DOI 10.1126/science.1163040; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takagi T, 2007, EXP ANIM TOKYO, V56, P295, DOI 10.1538/expanim.56.295; Unoki H, 2008, NAT GENET, V40, P1098, DOI 10.1038/ng.208; Vaishnava S, 2011, SCIENCE, V334, P255, DOI 10.1126/science.1209791; Vallon V, 2005, P NATL ACAD SCI USA, V102, P17864, DOI 10.1073/pnas.0505860102; Warth R, 2002, PFLUG ARCH EUR J PHY, V443, P822, DOI 10.1007/s00424-001-0751-3; Winbo A, 2012, CARDIOL YOUNG, V18, P1; Wulff H, 2009, NAT REV DRUG DISCOV, V8, P982, DOI 10.1038/nrd2983; Xiong QJ, 2008, TRENDS PHARMACOL SCI, V29, P99, DOI 10.1016/j.tips.2007.11.010; Yang K, 2008, CANCER RES, V68, P7313, DOI 10.1158/0008-5472.CAN-08-0598; Yasuda K, 2008, NAT GENET, V40, P1092, DOI 10.1038/ng.207; Zlobec I, 2007, J CLIN PATHOL, V60, P1112, DOI 10.1136/jcp.2006.044537	47	67	69	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2014	33	29					3861	3868		10.1038/onc.2013.350	http://dx.doi.org/10.1038/onc.2013.350			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8MU	23975432	Green Accepted			2022-12-17	WOS:000339394100012
J	Montero, JC; Esparis-Ogando, A; Re-Louhau, MF; Seoane, S; Abad, M; Calero, R; Ocana, A; Pandiella, A				Montero, J. C.; Esparis-Ogando, A.; Re-Louhau, M. F.; Seoane, S.; Abad, M.; Calero, R.; Ocana, A.; Pandiella, A.			Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer	ONCOGENE			English	Article						mTOR; PI3K; triple-negative breast cancer	PHOSPHATIDYLINOSITOL 3-KINASE/MAMMALIAN TARGET; RAPAMYCIN INHIBITOR; ANTITUMOR-ACTIVITY; NVP-BEZ235; GROWTH; CELLS; PHOSPHORYLATION; ACTIVATION; POTENT; PROLIFERATION	Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer. Despite response to chemotherapy, relapses are frequent and resistance to available treatments is often seen in the metastatic setting. Therefore, identification of new therapeutic targets is required. With this aim, we have profiled the activation status of 44 receptor tyrosine kinases (RTKs) and their major signaling pathways in patient-derived TNBC tumors. Frequent co-activation of several RTKs as well as the extracellular signal-regulated protein kinases 1 and 2 (Erk1/2) and mammalian target of rapamycin (mTOR) routes was found. Pharmacologic targeting of the activated kinases indicated that agents that attack the mTOR route are more potent and efficient antitumoral treatments than agents targeting RTKs. mTOR signals through two multiprotein complexes, mTORC1 and mTORC2. We used a genetic approach to explore the contribution of each of the two mTOR branches to the regulation of cell number of TNBC cells. RNA interference experiments indicated that mTORC1 predominated over mTORC2 in the control of TNBC cell proliferation. Moreover, RNA interference of mTOR had a superior antiproliferative action than separately acting on mTORC1 or mTORC2. To analyze the relevance of mTOR targeting in vivo, we used mice with TNBC. Treatment of these mice with BEZ235, a drug that targets mTOR, slowed tumor growth. Mechanistically, BEZ235 delayed cell cycle progression without affecting cell viability. Our results show that TNBCs are particularly sensitive to inhibition of the mTOR pathway, and indicate that mTOR targeting may be a more efficient anti-TNBC therapy than exclusively acting on the mTORC1 branch of the pathway. This is relevant as most mTOR inhibitors used in the clinic act on mTORC1. Collectively with the fact that BEZ235 synergized with drugs commonly used in the treatment of TNBC, our data support the clinical development of agents that act on mTOR as a therapy for this disease.	[Montero, J. C.; Esparis-Ogando, A.; Re-Louhau, M. F.; Seoane, S.; Pandiella, A.] Univ Salamanca, Inst Biol Mol & Celular Canc, CSIC, E-37008 Salamanca, Spain; [Abad, M.] Hosp Clin Univ Salamanca, Pathol Dept, Salamanca, Spain; [Calero, R.; Ocana, A.] Complejo Hosp Univ Albacete, Serv Oncol Med, Albacete, Spain; [Calero, R.; Ocana, A.] AECC Unit, Albacete, Spain; [Ocana, A.] Univ Toronto, Princess Margaret Hosp, Div Med Oncol & Hematol, Toronto, ON, Canada	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Pandiella, A (corresponding author), Inst Biol Mol & Celular Canc CIC, Campus Miguel Unamuno,Ave Univ Coimbra, Salamanca 37007, Spain.	atanasio@usal.es	Montero, Juan Carlos/AAO-1780-2020; Pandiella, Atanasio/O-5180-2014; Seoane, Samuel/H-6299-2015; Calero, Raul/F-7867-2016; Seoane, Samuel/L-1309-2014; Esparís-Ogando, Aucena/O-5326-2017	Montero, Juan Carlos/0000-0003-4773-053X; Pandiella, Atanasio/0000-0002-4704-8971; Seoane, Samuel/0000-0002-9178-0887; Calero, Raul/0000-0003-1525-1921; Esparís-Ogando, Aucena/0000-0003-4550-4192; Ocana, Alberto/0000-0002-1067-9630	Ministry of Science and Innovation of Spain [BFU2009-07728/BMC, PS09/00868]; Cancer Center Network Program from the ISCIII [RD06/0020/0041]; European Community through the regional development funding program (FEDER); Fundacion Ramon Areces; FISCAM [PI2010/017]; ISCIII [PS09/02144]	Ministry of Science and Innovation of Spain(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Cancer Center Network Program from the ISCIII; European Community through the regional development funding program (FEDER); Fundacion Ramon Areces; FISCAM; ISCIII(Instituto de Salud Carlos III)	This work was supported by grants from the Ministry of Science and Innovation of Spain (BFU2009-07728/BMC to AP, and PS09/00868 to AE-O). JCM and SS were supported by the Cancer Center Network Program from the ISCIII (RD06/0020/0041). The Cancer Research Institute, and the work carried out at AP and AE-O laboratories, receive support from the European Community through the regional development funding program (FEDER), and from the Fundacion Ramon Areces. AO receives research support from the FISCAM (Grant PI2010/017) and from the ISCIII (Grant PS09/02144). We thank Dr J Jonkers (Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands) for the generous gift of the Brca1/p53 conditional mouse model.	Allred DC, 1998, MODERN PATHOL, V11, P155; Barrios CH, 2010, BREAST CANCER RES TR, V121, P121, DOI 10.1007/s10549-010-0788-0; Baselga J, SAN ANT BREAST CANC; Baumann P, 2009, EXP CELL RES, V315, P485, DOI 10.1016/j.yexcr.2008.11.007; Carey L, 2010, NAT REV CLIN ONCOL, V7, P683, DOI 10.1038/nrclinonc.2010.154; Montero JC, 2012, MOL CANCER THER, V11, P1342, DOI 10.1158/1535-7163.MCT-11-0723; Chen ZM, 2006, MOL PHARMACOL, V69, P1527, DOI 10.1124/mol.105.020172; Chiarini F, 2010, CANCER RES, V70, P8097, DOI 10.1158/0008-5472.CAN-10-1814; CHOU TC, 1994, JNCI-J NATL CANCER I, V86, P1517, DOI 10.1093/jnci/86.20.1517; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Cleator S, 2007, LANCET ONCOL, V8, P235, DOI 10.1016/S1470-2045(07)70074-8; Cristofanilli M, 2008, ANN ONCOL, V19, P1713, DOI 10.1093/annonc/mdn352; de Alava E, 2007, J CLIN ONCOL, V25, P2656, DOI 10.1200/JCO.2006.08.6850; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Diaz-Rodriguez E, 1999, EUR J NEUROSCI, V11, P1421, DOI 10.1046/j.1460-9568.1999.00552.x; Diaz-Rodriguez E, 2010, J CELL SCI, V123, P3146, DOI 10.1242/jcs.070516; Duncan JS, 2012, CELL, V149, P307, DOI 10.1016/j.cell.2012.02.053; Eichhorn PJA, 2008, CANCER RES, V68, P9221, DOI 10.1158/0008-5472.CAN-08-1740; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Higgins MJ, 2011, J CLIN INVEST, V121, P3797, DOI 10.1172/JCI57152; Hilger R A, 2002, Int J Clin Pharmacol Ther, V40, P567; Hochgrafe F, 2010, CANCER RES, V70, P9391, DOI 10.1158/0008-5472.CAN-10-0911; Hoeflich KP, 2009, CLIN CANCER RES, V15, P4649, DOI 10.1158/1078-0432.CCR-09-0317; Hudis CA, 2011, ONCOLOGIST, V16, P1, DOI 10.1634/theoncologist.2011-S1-01; Hunter T, 2009, CURR OPIN CELL BIOL, V21, P140, DOI 10.1016/j.ceb.2009.01.028; Janes MR, 2010, NAT MED, V16, P205, DOI 10.1038/nm.2091; Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Liu X, 2007, P NATL ACAD SCI USA, V104, P12111, DOI 10.1073/pnas.0702969104; Maira SM, 2008, MOL CANCER THER, V7, P1851, DOI 10.1158/1535-7163.MCT-08-0017; McMillin DW, 2009, CANCER RES, V69, P5835, DOI 10.1158/0008-5472.CAN-08-4285; Metzger O, 2012, J CLIN ONCOL, V30, P1879, DOI 10.1200/JCO.2011.38.2010; Miller TW, 2010, J CLIN INVEST, V120, P2406, DOI 10.1172/JCI41680; Montero JC, 2011, ONCOGENE, V30, P1059, DOI 10.1038/onc.2010.489; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220; Ocana A, 2011, NAT REV CLIN ONCOL, V8, P200, DOI 10.1038/nrclinonc.2010.194; Rodrik-Outmezguine VS, 2011, CANCER DISCOV, V1, P248, DOI 10.1158/2159-8290.CD-11-0085; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Seoane S, 2010, JNCI-J NATL CANCER I, V102, P1432, DOI 10.1093/jnci/djq315; Serra V, 2011, ONCOGENE, V30, P2547, DOI 10.1038/onc.2010.626; Serra V, 2008, CANCER RES, V68, P8022, DOI 10.1158/0008-5472.CAN-08-1385; Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933; Sun TT, 2011, CELL, V144, P703, DOI 10.1016/j.cell.2011.02.003; Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775; Xia WL, 2002, ONCOGENE, V21, P6255, DOI 10.1038/sj.onc.1205794; Yeh TC, 2007, CLIN CANCER RES, V13, P1576, DOI 10.1158/1078-0432.CCR-06-1150; Yuste L, 2005, CANCER RES, V65, P6801, DOI 10.1158/0008-5472.CAN-04-4023	49	67	71	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	2014	33	2					148	156		10.1038/onc.2012.572	http://dx.doi.org/10.1038/onc.2012.572			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286BY	23246963				2022-12-17	WOS:000329440700002
J	Fimia, GM; Corazzari, M; Antonioli, M; Piacentini, M				Fimia, G. M.; Corazzari, M.; Antonioli, M.; Piacentini, M.			Ambra1 at the crossroad between autophagy and cell death	ONCOGENE			English	Review						Ambra1; Bcl-2; Beclin 1; caspases; calpains; apoptosis	III PHOSPHATIDYLINOSITOL 3-KINASE; BECLIN 1-DEPENDENT AUTOPHAGY; CALPAIN-MEDIATED CLEAVAGE; BCL-2 FAMILY-MEMBERS; REGULATES AUTOPHAGY; JNK1-MEDIATED PHOSPHORYLATION; ENDOPLASMIC-RETICULUM; JNK PHOSPHORYLATION; MAMMALIAN AUTOPHAGY; TUMOR SUPPRESSION	Autophagy is a self-digesting mechanism responsible for the degradation and recycling of most intracellular macromolecules and the removal of damaged organelles by the lysosome. An impressive number of recent studies have provided key information about the regulation of autophagy and its role in cell survival during nutrient depletion and many other stressful situations. In particular, many evidences have highlighted a crucial role of dysregulated autophagy in oncogenesis. Perturbations of the autophagic pathway have been shown to contribute to tumor development. Moreover, cancer cells have developed several mechanisms that allow them to evade chemotherapy-induced cell death, as well as to use autophagy-associated pathways, to potentiate their survival. In this regard, a complex crosstalk between autophagy and apoptosis has recently emerged; the understanding of the molecular mechanisms regulating this interplay may provide new hints on how to properly modulate these processes to halt cancer. Indeed, key proteins originally thought to be apoptosis-specific inhibitors also block autophagy, while apoptosis proteolytic enzymes hamper autophagy by cleaving autophagy-specific proteins and, in some cases, converting them into proapoptotic factors. This review is focused on the role that Ambra1, a central component of the autophagosome formation machinery, has in the switch between autophagy and apoptosis and its implication in cancer development and chemotherapy resistance.	[Fimia, G. M.; Corazzari, M.; Antonioli, M.; Piacentini, M.] Natl Inst Infect Dis IRCCS Lazzaro Spallanzani, Dept Epidemiol & Preclin Res, Rome, Italy; [Corazzari, M.; Piacentini, M.] Univ Roma Tor Vergata, Dept Biol, I-00173 Rome, Italy	IRCCS Lazzaro Spallanzani; University of Rome Tor Vergata	Piacentini, M (corresponding author), Univ Roma Tor Vergata, Dept Biol, Via Ric Sci 1, I-00173 Rome, Italy.	mauro.piacentini@uniroma2.it	Corazzari, Marco/J-5825-2019; Corazzari, Marco/K-6422-2016; Fimia, Gian Maria/K-3232-2016; antonioli, manuela/L-6681-2019; Piacentini, Mauro/I-2411-2016; antonioli, manuela/F-5898-2015; Corazzari, Marco/B-4631-2019	Corazzari, Marco/0000-0002-6246-5968; Corazzari, Marco/0000-0002-6246-5968; Fimia, Gian Maria/0000-0003-4438-3325; antonioli, manuela/0000-0002-7568-4713; Piacentini, Mauro/0000-0003-2919-1296; antonioli, manuela/0000-0002-7568-4713; Corazzari, Marco/0000-0002-6246-5968	Italian Ministry of University FIRB; Ministry of Health of Italy; AIRC; Telethon; EU	Italian Ministry of University FIRB(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB)); Ministry of Health of Italy(Ministry of Health, Italy); AIRC(Fondazione AIRC per la ricerca sul cancro); Telethon(Fondazione Telethon); EU(European Commission)	This work was supported by grants from the Italian Ministry of University FIRB, Compagnia di San Paolo to MP, the Ministry of Health of Italy 'Ricerca Corrente' and 'Ricerca Finalizzata' to MP and GMF, AIRC to MP and MC, and Telethon to GMF. The support of the EU grant 'Transpath ' Marie Curie project to MP is also acknowledged.	Abrahamsen H, 2012, FEBS LETT, V586, P1584, DOI 10.1016/j.febslet.2012.04.046; Adams JM, 2007, CURR OPIN IMMUNOL, V19, P488, DOI 10.1016/j.coi.2007.05.004; Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851; Amaravadi RK, 2007, CLIN CANCER RES, V13, P7271, DOI 10.1158/1078-0432.CCR-07-1595; Apweiler R, 2012, NUCLEIC ACIDS RES, V40, pD71, DOI 10.1093/nar/gkr981; Arias E, 2011, CURR OPIN CELL BIOL, V23, P184, DOI 10.1016/j.ceb.2010.10.009; Armstrong JL, 2011, CLIN CANCER RES, V17, P2216, DOI 10.1158/1078-0432.CCR-10-3003; Axe EL, 2008, J CELL BIOL, V182, P685, DOI 10.1083/jcb.200803137; Behrends C, 2010, NATURE, V466, P68, DOI 10.1038/nature09204; Bennett EJ, 2010, CELL, V143, P951, DOI 10.1016/j.cell.2010.11.017; Betin VMS, 2009, J CELL SCI, V122, P2554, DOI 10.1242/jcs.046250; Burman C, 2010, FEBS LETT, V584, P1302, DOI 10.1016/j.febslet.2010.01.011; Cecconi F, 2008, CELL DEATH DIFFER, V15, P1170, DOI 10.1038/cdd.2008.64; Chang NC, 2010, EMBO J, V29, P606, DOI 10.1038/emboj.2009.369; Cho DH, 2009, CANCER LETT, V274, P95, DOI 10.1016/j.canlet.2008.09.004; Corazzari M, 2012, AUTOPHAGY, V8, P1255, DOI 10.4161/auto.20671; Daub H, 2008, MOL CELL, V31, P438, DOI 10.1016/j.molcel.2008.07.007; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Dephoure N, 2008, P NATL ACAD SCI USA, V105, P10762, DOI 10.1073/pnas.0805139105; Deretic V, 2009, CELL HOST MICROBE, V5, P527, DOI 10.1016/j.chom.2009.05.016; Di Bartolomeo S, 2010, J CELL BIOL, V191, P155, DOI 10.1083/jcb.201002100; Dikic I, 2010, CANCER RES, V70, P3431, DOI 10.1158/0008-5472.CAN-09-4027; Donovan N, 2002, J BIOL CHEM, V277, P40944, DOI 10.1074/jbc.M206113200; Fimia GM, 2007, NATURE, V447, P1121, DOI 10.1038/nature05925; Fimia GM, 2010, CELL MOL LIFE SCI, V67, P1581, DOI 10.1007/s00018-010-0284-z; Hailey DW, 2010, CELL, V141, P656, DOI 10.1016/j.cell.2010.04.009; He CC, 2010, CURR OPIN CELL BIOL, V22, P140, DOI 10.1016/j.ceb.2010.01.001; Hoeller D, 2009, NATURE, V458, P438, DOI 10.1038/nature07960; Hornbeck PV, 2012, NUCLEIC ACIDS RES, V40, pD261, DOI 10.1093/nar/gkr1122; Hosokawa N, 2009, MOL BIOL CELL, V20, P1981, DOI 10.1091/mbc.E08-12-1248; Hou W, 2010, AUTOPHAGY, V6, P891, DOI 10.4161/auto.6.7.13038; Inami Y, 2011, J CELL BIOL, V193, P275, DOI 10.1083/jcb.201102031; Itakura E, 2008, MOL BIOL CELL, V19, P5360, DOI 10.1091/mbc.E08-01-0080; Jahreiss L, 2008, TRAFFIC, V9, P574, DOI 10.1111/j.1600-0854.2008.00701.x; Jin JP, 2006, MOL CELL, V23, P709, DOI 10.1016/j.molcel.2006.08.010; Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017; Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191; Kim W, 2011, MOL CELL, V44, P325, DOI 10.1016/j.molcel.2011.08.025; Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245; Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Lee JS, 2009, NAT CELL BIOL, V11, P1355, DOI 10.1038/ncb1980; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Levine B, 2008, AUTOPHAGY, V4, P600, DOI 10.4161/auto.6260; Li H, 2011, CANCER RES, V71, P3625, DOI 10.1158/0008-5472.CAN-10-4475; Li WW, 2012, CELL MOL LIFE SCI, V69, P1125, DOI 10.1007/s00018-011-0865-5; Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Lipkowitz S, 2011, NAT REV CANCER, V11, P629, DOI 10.1038/nrc3120; Livesey KM, 2009, CURR OPIN INVEST DR, V10, P1269; Luo S, 2010, CELL DEATH DIFFER, V17, P268, DOI 10.1038/cdd.2009.121; Luo SQ, 2012, MOL CELL, V47, P359, DOI 10.1016/j.molcel.2012.05.040; Maglott D, 2011, NUCLEIC ACIDS RES, V39, pD52, DOI 10.1093/nar/gkq1237; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; Mathew R, 2011, CURR OPIN GENET DEV, V21, P113, DOI 10.1016/j.gde.2010.12.008; Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048; Matsunaga K, 2009, NAT CELL BIOL, V11, P385, DOI 10.1038/ncb1846; Mehrpour M, 2010, CELL RES, V20, P748, DOI 10.1038/cr.2010.82; Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005; Mizushima N, 2009, CURR TOP MICROBIOL, V335, P71, DOI 10.1007/978-3-642-00302-8_3; Orenstein SJ, 2010, SEMIN CELL DEV BIOL, V21, P719, DOI 10.1016/j.semcdb.2010.02.005; Pagliarini V, 2012, CELL DEATH DIFFER, V19, P1495, DOI 10.1038/cdd.2012.27; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Placzek WJ, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.18; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Radoshevich L, 2010, CELL, V142, P590, DOI 10.1016/j.cell.2010.07.018; Rubinstein AD, 2011, MOL CELL, V44, P698, DOI 10.1016/j.molcel.2011.10.014; Russo R, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.29; Salazar M, 2009, J CLIN INVEST, V119, P1359, DOI 10.1172/JCI37948; Schwartz AL, 2009, ANNU REV PHARMACOL, V49, P73, DOI 10.1146/annurev.pharmtox.051208.165340; Simonsen A, 2009, J CELL BIOL, V186, P773, DOI 10.1083/jcb.200907014; Sinha S, 2008, ONCOGENE, V27, pS137, DOI 10.1038/onc.2009.51; Strappazzon F, 2011, EMBO J, V30, P1195, DOI 10.1038/emboj.2011.49; Sun QM, 2008, P NATL ACAD SCI USA, V105, P19211, DOI 10.1073/pnas.0810452105; Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634; Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211; Van Humbeeck C, 2011, J NEUROSCI, V31, P10249, DOI 10.1523/JNEUROSCI.1917-11.2011; Velasco G, 2012, NAT REV CANCER, V12, P436, DOI 10.1038/nrc3247; Wagner SA, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M111.013284; Wei YJ, 2008, AUTOPHAGY, V4, P949, DOI 10.4161/auto.6788; Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001; Wirawan E, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.16; Wirawan E, 2012, AUTOPHAGY, V8, P6, DOI 10.4161/auto.8.1.16645; Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014; Yi C, 2012, SCIENCE, V336, P474, DOI 10.1126/science.1216990; Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482; Zhong Y, 2009, NAT CELL BIOL, V11, P468, DOI 10.1038/ncb1854	90	67	70	2	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2013	32	28					3311	3318		10.1038/onc.2012.455	http://dx.doi.org/10.1038/onc.2012.455			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	180TM	23069654				2022-12-17	WOS:000321620200001
J	Serrano, MA; Li, Z; Dangeti, M; Musich, PR; Patrick, S; Roginskaya, M; Cartwright, B; Zou, Y				Serrano, M. A.; Li, Z.; Dangeti, M.; Musich, P. R.; Patrick, S.; Roginskaya, M.; Cartwright, B.; Zou, Y.			DNA-PK, ATM and ATR collaboratively regulate p53-RPA interaction to facilitate homologous recombination DNA repair	ONCOGENE			English	Article						p53-RPA interaction; DNA-PK; ATM; ATR; homologous recombination repair; nonhomologous recombination end joining	REPLICATION-PROTEIN-A; DOUBLE-STRAND BREAKS; DAMAGE-INDUCED PHOSPHORYLATION; RPA PHOSPHORYLATION; INDUCED HYPERPHOSPHORYLATION; COMPLEX-FORMATION; P53; BINDING; RAD52; TRANSACTIVATION	Homologous recombination (HR) and nonhomologous end joining (NHEJ) are two distinct DNA double-stranded break (DSB) repair pathways. Here, we report that DNA-dependent protein kinase (DNA-PK), the core component of NHEJ, partnering with DNA-damage checkpoint kinases ataxia telangiectasia mutated (ATM) and ATM-and Rad3-related (ATR), regulates HR repair of DSBs. The regulation was accomplished through modulation of the p53 and replication protein A (RPA) interaction. We show that upon DNA damage, p53 and RPA were freed from a p53-RPA complex by simultaneous phosphorylations of RPA at the N-terminus of RPA32 subunit by DNA-PK and of p53 at Ser37 and Ser46 in a Chk1/Chk2-independent manner by ATR and ATM, respectively. Neither the phosphorylation of RPA nor of p53 alone could dissociate p53 and RPA. Furthermore, disruption of the release significantly compromised HR repair of DSBs. Our results reveal a mechanism for the crosstalk between HR repair and NHEJ through the co-regulation of p53-RPA interaction by DNA-PK, ATM and ATR.	[Serrano, M. A.; Li, Z.; Musich, P. R.; Roginskaya, M.; Cartwright, B.; Zou, Y.] E Tennessee State Univ, Dept Biochem & Mol Biol, James H Quillen Coll Med, Johnson City, TN 37614 USA; [Dangeti, M.; Patrick, S.] Univ Toledo, Med Ctr, Biochem & Canc Biol Dept, Toledo, OH 43606 USA	East Tennessee State University; University System of Ohio; University of Toledo	Zou, Y (corresponding author), E Tennessee State Univ, Dept Biochem & Mol Biol, James H Quillen Coll Med, Johnson City, TN 37614 USA.	zouy@etsu.edu	Li, Zhengke/J-8527-2016; Zou, Yue/ABA-8429-2020; Roginskaya, Marina/ABD-3144-2021	Li, Zhengke/0000-0001-5560-343X; Musich, Phillip/0000-0001-8816-4242; Serrano, Moises/0000-0002-1037-9304	National Institutes of Health [CA86927, GM083307, ES017214]; NATIONAL CANCER INSTITUTE [R56CA086927, R01CA086927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [F31ES017214] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM088249, R15GM083307] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We gratefully acknowledge Dr Xiaohua Wu for providing U2OS cells expressing RPA32-WT and PD-RPA proteins. We also gratefully acknowledge Dr Carl W Anderson for providing the p53-expression constructs (pCAG3.1-WT, -S15A, -S20A, -S37A and -S46A) and Dr Karen Vousden for the pCB6 expression vectors p53-WT and p53-S15A. This work is supported by National Institutes of Health grants CA86927 and GM083307 (to YZ) as well as ES017214 (to MAS).	Abramova NA, 1997, P NATL ACAD SCI USA, V94, P7186, DOI 10.1073/pnas.94.14.7186; Anantha RW, 2008, P NATL ACAD SCI USA, V105, P12903, DOI 10.1073/pnas.0803001105; Arnaudeau C, 2001, J MOL BIOL, V307, P1235, DOI 10.1006/jmbi.2001.4564; Binz SK, 2004, DNA REPAIR, V3, P1015, DOI 10.1016/j.dnarep.2004.03.028; Bochkareva E, 2005, P NATL ACAD SCI USA, V102, P15412, DOI 10.1073/pnas.0504614102; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chehab NH, 2000, GENE DEV, V14, P278; Couedel C, 2004, GENE DEV, V18, P1293, DOI 10.1101/gad.1209204; Derheimer FA, 2007, P NATL ACAD SCI USA, V104, P12778, DOI 10.1073/pnas.0705317104; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; Efeyan A, 2007, CELL CYCLE, V6, P1006, DOI 10.4161/cc.6.9.4211; Guo SL, 2006, J BIOL CHEM, V281, P21607, DOI 10.1074/jbc.M603504200; Harper JW, 2007, MOL CELL, V28, P739, DOI 10.1016/j.molcel.2007.11.015; Hass CS, 2010, MOL CANCER RES, V8, P1017, DOI 10.1158/1541-7786.MCR-10-0161; Hill R, 2010, CELL CYCLE, V9, P3460, DOI 10.4161/cc.9.17.13043; Huen MSY, 2010, TRENDS BIOCHEM SCI, V35, P101, DOI 10.1016/j.tibs.2009.09.001; Jackson D, 2002, J MOL BIOL, V321, P133, DOI 10.1016/S0022-2836(02)00541-7; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; Kantake N, 2003, J BIOL CHEM, V278, P23410, DOI 10.1074/jbc.M302995200; Kaustov L, 2006, CELL CYCLE, V5, P489, DOI 10.4161/cc.5.5.2489; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kuhn C, 1999, ONCOGENE, V18, P769, DOI 10.1038/sj.onc.1202327; Leiter LM, 1996, ONCOGENE, V12, P2661; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu YY, 2005, J BIOL CHEM, V280, P32775, DOI 10.1074/jbc.M505705200; Meek K, 2008, ADV IMMUNOL, V99, P33, DOI 10.1016/S0065-2776(08)00602-0; Mer G, 2000, CELL, V103, P449, DOI 10.1016/S0092-8674(00)00136-7; Miller SD, 1997, MOL CELL BIOL, V17, P2194, DOI 10.1128/MCB.17.4.2194; Mills KD, 2004, GENE DEV, V18, P1283, DOI 10.1101/gad.1204304; Nuss JE, 2005, BIOCHEMISTRY-US, V44, P8428, DOI 10.1021/bi0480584; Oakley GG, 2003, BIOCHEMISTRY-US, V42, P3255, DOI 10.1021/bi026377u; Olson E, 2006, J BIOL CHEM, V281, P39517, DOI 10.1074/jbc.M605121200; Patrick SM, 2005, BIOCHEMISTRY-US, V44, P8438, DOI 10.1021/bi048057b; Pierce AJ, 2001, GENE DEV, V15, P3237, DOI 10.1101/gad.946401; Plate I, 2008, J BIOL CHEM, V283, P29077, DOI 10.1074/jbc.M804881200; Pommier Y, 2006, NAT REV CANCER, V6, P789, DOI 10.1038/nrc1977; Robison JG, 2007, CELL CYCLE, V6, P2408, DOI 10.4161/cc.6.19.4773; Romanova LY, 2004, ONCOGENE, V23, P9025, DOI 10.1038/sj.onc.1207982; Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320; Sakasai R, 2010, DNA REPAIR, V9, P76, DOI 10.1016/j.dnarep.2009.10.008; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Shao RG, 1999, EMBO J, V18, P1397, DOI 10.1093/emboj/18.5.1397; Shell SM, 2009, MOL MECH ATAXIA TELA, P42; Shi W, 2010, CARCINOGENESIS, V31, P994, DOI 10.1093/carcin/bgq035; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Sommers JA, 2005, CANCER RES, V65, P1223, DOI 10.1158/0008-5472.CAN-03-0231; Stauffer ME, 2004, J BIOL CHEM, V279, P25638, DOI 10.1074/jbc.M400029200; Sugiyama T, 2006, EMBO J, V25, P5539, DOI 10.1038/sj.emboj.7601412; Sugiyama T, 2009, J MOL BIOL, V390, P45, DOI 10.1016/j.jmb.2009.05.009; Sun JY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013554; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Vassin VM, 2004, MOL CELL BIOL, V24, P1930, DOI 10.1128/MCB.24.5.1930-1943.2004; VIRSHUP DM, 1990, UCLA SYM BI, V127, P303; Vise PD, 2005, NUCLEIC ACIDS RES, V33, P2061, DOI 10.1093/nar/gki336; Wang YX, 2005, NAT GENET, V37, P750, DOI 10.1038/ng1587; Wood JL, 2008, TRENDS CELL BIOL, V18, P451, DOI 10.1016/j.tcb.2008.07.006; Wu X, 2005, BIOCHEM J, V391, P473, DOI 10.1042/BJ20050379; Wu XM, 2005, ONCOGENE, V24, P4728, DOI 10.1038/sj.onc.1208674; Yang ZG, 2002, BIOCHEMISTRY-US, V41, P13012, DOI 10.1021/bi026064z; Zou L, 2003, P NATL ACAD SCI USA, V100, P13827, DOI 10.1073/pnas.2336100100; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430; Zou Y, 2006, J CELL PHYSIOL, V208, P267, DOI 10.1002/jcp.20622	63	67	72	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2013	32	19					2452	2462		10.1038/onc.2012.257	http://dx.doi.org/10.1038/onc.2012.257			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140ZL	22797063	Green Accepted			2022-12-17	WOS:000318694900009
J	Tobin, LA; Robert, C; Rapoport, AP; Gojo, I; Baer, MR; Tomkinson, AE; Rassool, FV				Tobin, L. A.; Robert, C.; Rapoport, A. P.; Gojo, I.; Baer, M. R.; Tomkinson, A. E.; Rassool, F. V.			Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias	ONCOGENE			English	Article						chronic myeloid leukemia; DNA ligase III alpha; PARP1; NHEJ; PARP inhibitors; DNA ligase I and III inhibitors	LIGASE-III; CLINICAL RESISTANCE; DRUG-RESISTANCE; ABL MUTATIONS; BCR/ABL; KU; IMATINIB; PROMOTES; BINDING; STI571	Resistance to imatinib (IM) and other tyrosine kinase inhibitors (TKI)s is an increasing problem in leukemias caused by expression of BCR-ABL1. As chronic myeloid leukemia (CML) cell lines expressing BCR-ABL1 utilize an alternative non-homologous end-joining pathway (ALT NHEJ) to repair DNA double-strand breaks (DSB)s, we asked whether this repair pathway is a novel therapeutic target in TKI-resistant disease. Notably, the steady state levels of two ALT NHEJ proteins, poly-(ADP-ribose) polymerase 1 (PARP1) and DNA ligase III alpha, were increased in the BCR-ABL1-positive CML cell line K562 and, to a greater extent, in its imatinib-resistant (IMR) derivative. Incubation of these cell lines with a combination of DNA ligase and PARP inhibitors inhibited ALT NHEJ and selectively decreased survival with the effect being greater in the IMR derivative. Similar results were obtained with TKI-resistant derivatives of two hematopoietic cell lines that had been engineered to stably express BCR-ABL1. Together our results show that the sensitivity of cell lines expressing BCR-ABL1 to the combination of DNA ligase and PARP inhibitors correlates with the steady state levels of PARP1 and DNA ligase III alpha, and ALT NHEJ activity. Importantly, analysis of clinical samples from CML patients confirmed that the expression levels of PARP1 and DNA ligase III alpha correlated with the sensitivity to the DNA repair inhibitor combination. Thus, the expression levels of PARP1 and DNA ligase III alpha serve as biomarkers to identify a subgroup of CML patients who may be candidates for therapies that target the ALT NHEJ pathway when treatment with TKIs has failed. Oncogene (2013) 32, 1784-1793; doi: 10.1038/onc.2012.203; published online 28 May 2012	[Tobin, L. A.; Robert, C.; Rassool, F. V.] Univ Maryland, Sch Med, Dept Radiat Oncol, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA; [Rapoport, A. P.; Gojo, I.; Baer, M. R.] Univ Maryland, Sch Med, Dept Med, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA; [Tomkinson, A. E.] Univ New Mexico, Dept Internal Med, Albuquerque, NM 87131 USA; [Tomkinson, A. E.] Univ New Mexico, Univ New Mexico Canc Ctr, Albuquerque, NM 87131 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of New Mexico; University of New Mexico	Rassool, FV (corresponding author), Univ Maryland, Sch Med, Dept Radiat Oncol, Marlene & Stewart Greenebaum Canc Ctr,BRB, 655 West Baltimore St,Room 7-023, Baltimore, MD 21201 USA.	frassool@som.umaryland.edu	Classen, Scott/AAY-8176-2020		Cigarette Restitution Funds of Maryland; Leukemia Lymphoma Society; V Foundation; NIH [ES 012512, CA92584]; NATIONAL CANCER INSTITUTE [P01CA092584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012512] Funding Source: NIH RePORTER	Cigarette Restitution Funds of Maryland; Leukemia Lymphoma Society(Leukemia and Lymphoma Society); V Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We would like to thank Professor Stephen Baylin (JHU) for insightful comments and careful reading of our manuscript. CML patient samples were collected under IMRB no. H25314. These studies were supported by the Cigarette Restitution Funds of Maryland (FR and LT), the Leukemia Lymphoma Society (FR, CR and LT), the V Foundation (FR, LT and AET) and NIH Grants ES 012512 and CA92584 (AET).	Audebert M, 2006, J MOL BIOL, V356, P257, DOI 10.1016/j.jmb.2005.11.028; Audebert M, 2004, J BIOL CHEM, V279, P55117, DOI 10.1074/jbc.M404524200; Audebert M, 2008, BIOCHEM BIOPH RES CO, V369, P982, DOI 10.1016/j.bbrc.2007.11.132; Ayene IS, 2002, J BIOL CHEM, V277, P9929, DOI 10.1074/jbc.M111366200; Brady N, 2003, CANCER RES, V63, P1798; Branford S, 2002, BLOOD, V99, P3472, DOI 10.1182/blood.V99.9.3472; Branford S, 2003, BLOOD, V102, P276, DOI 10.1182/blood-2002-09-2896; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Chen X, 2008, CANCER RES, V68, P3169, DOI 10.1158/0008-5472.CAN-07-6636; de Smith AJ, 2007, HUM MOL GENET, V16, P2783, DOI 10.1093/hmg/ddm208; FALZON M, 1993, J BIOL CHEM, V268, P10546; Fan JS, 2010, BLOOD, V116, P5298, DOI 10.1182/blood-2010-03-272591; Fattah F, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000855; Foster SS, 2011, MOL CELL BIOL, V31, P4379, DOI 10.1128/MCB.05854-11; Gao YK, 2011, NATURE, V471, P240, DOI 10.1038/nature09773; Gaymes TJ, 2002, CANCER RES, V62, P2791; Gorre M, 2001, SCIENCE, V293, P15; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Hehlmann R, 2011, EXPERT OPIN PHARMACO, V12, P269, DOI 10.1517/14656566.2011.533169; Jabbour E, 2011, CANCER-AM CANCER SOC, V117, P1800, DOI 10.1002/cncr.25717; Krishnakumar R, 2008, SCIENCE, V319, P819, DOI 10.1126/science.1149250; le Coutre P, 2000, BLOOD, V95, P1758, DOI 10.1182/blood.V95.5.1758.005a41_1758_1766; Lee-Theilen M, 2011, NAT STRUCT MOL BIOL, V18, P75, DOI 10.1038/nsmb.1942; LOBRICH M, 1994, INT J RADIAT BIOL, V65, P623, DOI 10.1080/09553009414550731; Lord CJ, 2008, CURR OPIN PHARMACOL, V8, P363, DOI 10.1016/j.coph.2008.06.016; Ma YM, 2004, MOL CELL, V16, P701, DOI 10.1016/j.molcel.2004.11.017; Mahon FX, 2000, BLOOD, V96, P1070, DOI 10.1182/blood.V96.3.1070.015k17_1070_1079; Majsterek I, 2002, CELL BIOL INT, V26, P363, DOI 10.1006/cbir.2002.0865; MIMORI T, 1986, J BIOL CHEM, V261, P375; Nowell P, 1960, SCIENCE, V132, P3; Nowicki MO, 2004, BLOOD, V104, P3746, DOI 10.1182/blood-2004-05-1941; Nussenzweig A, 2007, CELL, V131, P223, DOI 10.1016/j.cell.2007.10.005; Ohmine K, 2003, STEM CELLS, V21, P315, DOI 10.1634/stemcells.21-3-315; Rowley JA, 1973, NATURE, V243, P4; Sallmyr A, 2008, BLOOD, V112, P1413, DOI 10.1182/blood-2007-07-104257; Sartori AA, 2007, NATURE, V450, P509, DOI 10.1038/nature06337; Sattler M, 2000, J BIOL CHEM, V275, P24273, DOI 10.1074/jbc.M002094200; Savage D, 1997, BRIT J HAEMATOL, V96, P7; Shah N, 2002, CANCER CELL, V2, P8; Simsek D, 2011, NATURE, V471, P245, DOI 10.1038/nature09794; Skorski T, 2002, ONCOGENE, V21, P8591, DOI 10.1038/sj.onc.1206087; Slupianek A, 2002, MOL CELL BIOL, V22, P4189, DOI 10.1128/MCB.22.12.4189-4201.2002; Soverini S, 2005, J CLIN ONCOL, V23, P4100, DOI 10.1200/JCO.2005.05.531; SPIERS ASD, 1995, SEMIN ONCOL, V22, P380; Tobin LA, 2012, MOL CANCER RES, V10, P96, DOI 10.1158/1541-7786.MCR-11-0255; Tsai CJ, 2007, P NATL ACAD SCI USA, V104, P7851, DOI 10.1073/pnas.0702620104; von Bubnoff N, 2002, LANCET, V359, P487, DOI 10.1016/S0140-6736(02)07679-1; Wang HC, 2005, CANCER RES, V65, P4020, DOI 10.1158/0008-5472.CAN-04-3055; Wang ML, 2006, NUCLEIC ACIDS RES, V34, P6170, DOI 10.1093/nar/gkl840; Weisberg E, 2000, BLOOD, V95, P3498, DOI 10.1182/blood.V95.11.3498.011k27_3498_3505; Zhang Y, 2011, NAT STRUCT MOL BIOL, V18, P80, DOI 10.1038/nsmb.1940; Zhong S, 2008, J MED CHEM, V51, P4553, DOI 10.1021/jm8001668	53	67	69	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2013	32	14					1784	1793		10.1038/onc.2012.203	http://dx.doi.org/10.1038/onc.2012.203			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	118RQ	22641215	Green Accepted			2022-12-17	WOS:000317043900005
J	Martineau, Y; Azar, R; Bousquet, C; Pyronnet, S				Martineau, Y.; Azar, R.; Bousquet, C.; Pyronnet, S.			Anti-oncogenic potential of the eIF4E-binding proteins	ONCOGENE			English	Review						protein synthesis; elF4E; 4E-BP; mTOR	INITIATION-FACTOR 4E; CAP-DEPENDENT TRANSLATION; FACTOR 4E-BINDING PROTEIN-1; SERINE/THREONINE KINASE PIM-2; SMALL-MOLECULE INHIBITION; REPRESSOR PHAS-I; MESSENGER-RNA; BINDING PROTEIN; EIF4E PHOSPHORYLATION; MAMMALIAN TARGET	The elF4E-binding proteins (4E-BPs) are inhibitors of protein synthesis that sequester the mRNA cap-binding protein elF4E and consequently block cell growth and proliferation. In most tumors however, their inhibitory function is compromised by major oncogenic signaling pathways. Recently, thanks to the generation of mouse genetic models, considerable progress has been made in elucidating the involvement of 4E-BPs and their unique target, elF4E, in the process of carcinogenesis. Increasing evidence indicates that an 'addiction' to protein synthesis emerges in cancer cells, highlighting the potential that 4E-BPs have as targets for therapeutics. In this review, we summarize the biochemical function, regulation and anti-oncogenic activity of the 4E-BPs. Oncogene (2013) 32, 671-677; doi:10.1038/onc.2012.116; published online 16 April 2012	[Martineau, Y.; Azar, R.; Bousquet, C.; Pyronnet, S.] Univ Toulouse, CRCT, INSERM UMR 1037, F-31432 Toulouse, France; [Azar, R.] Lebanese Univ, Fac Pharm, Dept Clin Pharm, Hadath, Lebanon; [Pyronnet, S.] Ctr Hosp Toulouse, Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Lebanese University; CHU de Toulouse	Pyronnet, S (corresponding author), Univ Toulouse, CHU Rangueil, INSERM UMR 1037, CRCT, BP 84225, F-31432 Toulouse, France.	stephane.pyronnet@inserm.fr	Martineau, Yvan/G-2387-2017; Pyronnet, Stéphane/P-2419-2014; Bousquet, Corinne/P-2917-2014	Martineau, Yvan/0000-0002-0575-4085; Bousquet, Corinne/0000-0002-2501-0593	La Ligue Contre le Cancer; Fondation pour la Recherche Medicale (FRM); Association pour la Recherche contre le Cancer (ARC)	La Ligue Contre le Cancer(Ligue nationale contre le cancer); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); Association pour la Recherche contre le Cancer (ARC)(Fondation ARC pour la Recherche sur le CancerFrench National Research Agency (ANR))	The author's work was supported by grants from La Ligue Contre le Cancer to SP, the Fondation pour la Recherche Medicale (FRM) Post-Doc fellow program (YM) and the Association pour la Recherche contre le Cancer (ARC) PhD fellow program (RA).	Avdulov S, 2004, CANCER CELL, V5, P553, DOI 10.1016/j.ccr.2004.05.024; Azar R, 2008, CELL MOL LIFE SCI, V65, P3110, DOI 10.1007/s00018-008-8418-2; Azar R, 2009, EMBO J, V28, P3514, DOI 10.1038/emboj.2009.291; Balakumaran BS, 2009, CANCER RES, V69, P7803, DOI 10.1158/0008-5472.CAN-09-0910; Beugnet A, 2003, J BIOL CHEM, V278, P40717, DOI 10.1074/jbc.M308573200; Blagden SP, 2011, NAT REV CLIN ONCOL, V8, P280, DOI 10.1038/nrclinonc.2011.16; Braunstein S, 2009, MOL CELL BIOL, V29, P5645, DOI 10.1128/MCB.00711-09; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Caron S, 2004, MOL CELL BIOL, V24, P4920, DOI 10.1128/MCB.24.11.4920-4928.2004; Cencic R, 2011, P NATL ACAD SCI USA, V108, P1046, DOI 10.1073/pnas.1011477108; Chen WW, 2005, MOL CANCER RES, V3, P443, DOI 10.1158/1541-7786.MCR-05-0007; Choi KM, 2003, J BIOL CHEM, V278, P19667, DOI 10.1074/jbc.M301142200; Constantinou C, 2005, ONCOGENE, V24, P4839, DOI 10.1038/sj.onc.1208648; Constantinou C, 2008, BIOL CELL, V100, P279, DOI 10.1042/BC20070121; Cormier P, 2001, DEV BIOL, V232, P275, DOI 10.1006/dbio.2001.0206; Dobrikov M, 2011, MOL CELL BIOL, V31, P2947, DOI 10.1128/MCB.05589-11; Dowling RJO, 2010, SCIENCE, V328, P1172, DOI 10.1126/science.1187532; Ferraiuolo MA, 2004, P NATL ACAD SCI USA, V101, P4118, DOI 10.1073/pnas.0400933101; Fox CJ, 2003, GENE DEV, V17, P1841, DOI 10.1101/gad.1105003; Furic L, 2010, P NATL ACAD SCI USA, V107, P14134, DOI 10.1073/pnas.1005320107; Gingras AC, 2001, GENE DEV, V15, P2852; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Gong JP, 2009, J SURG RES, V153, P17, DOI 10.1016/j.jss.2008.03.033; Gosselin P, 2011, NUCLEIC ACIDS RES, V39, P3496, DOI 10.1093/nar/gkq1306; Gradi A, 1998, MOL CELL BIOL, V18, P334, DOI 10.1128/MCB.18.1.334; Heesom KJ, 1998, BIOCHEM J, V336, P39, DOI 10.1042/bj3360039; Heesom KJ, 2001, CURR BIOL, V11, P1374, DOI 10.1016/S0960-9822(01)00422-5; Heesom KJ, 1999, FEBS LETT, V457, P489, DOI 10.1016/S0014-5793(99)01094-7; Holzmann K, 2000, BIOCHEM BIOPH RES CO, V267, P339, DOI 10.1006/bbrc.1999.1973; Horton LE, 2002, ONCOGENE, V21, P5325, DOI 10.1038/sj.onc.1205662; Hsieh AC, 2010, CANCER CELL, V17, P249, DOI 10.1016/j.ccr.2010.01.021; Ilic N, 2011, P NATL ACAD SCI USA, V108, pE699, DOI 10.1073/pnas.1108237108; Jacobson BA, 2006, CANCER RES, V66, P4256, DOI 10.1158/0008-5472.CAN-05-2879; Jones RM, 1996, MOL CELL BIOL, V16, P4754; Joshi B, 2004, EUR J BIOCHEM, V271, P2189, DOI 10.1111/j.1432-1033.2004.04149.x; Kleijn M, 2002, FEBS LETT, V532, P319, DOI 10.1016/S0014-5793(02)03694-3; LAZARISKARATZAS A, 1992, GENE DEV, V6, P1631, DOI 10.1101/gad.6.9.1631; LAZARISKARATZAS A, 1992, MOL CELL BIOL, V12, P1234, DOI 10.1128/MCB.12.3.1234; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Le Bouffant R, 2006, J CELL BIOCHEM, V99, P126, DOI 10.1002/jcb.20856; Lee VHY, 2008, FEBS J, V275, P2185, DOI 10.1111/j.1742-4658.2008.06372.x; Li QY, 1999, MOL CELL BIOL, V19, P7336; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Liu GM, 2002, J BIOL CHEM, V277, P8810, DOI 10.1074/jbc.M110477200; Lynch M, 2005, MOL CELL BIOL, V25, P6436, DOI 10.1128/MCB.25.15.6436-6453.2005; MADER S, 1995, MOL CELL BIOL, V15, P4990; Moerke NJ, 2007, CELL, V128, P257, DOI 10.1016/j.cell.2006.11.046; Murata T, 2006, J BIOL CHEM, V281, P20788, DOI 10.1074/jbc.M600563200; Nawijn MC, 2011, NAT REV CANCER, V11, P23, DOI 10.1038/nrc2986; NIELSEN PJ, 1988, EMBO J, V7, P2097, DOI 10.1002/j.1460-2075.1988.tb03049.x; Orton KC, 2004, J BIOL CHEM, V279, P38649, DOI 10.1074/jbc.M407337200; Oulhen N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005070; Paku KS, 2012, BIOCHEM J, V441, P237, DOI 10.1042/BJ20101481; Palacios IM, 2004, NATURE, V427, P753, DOI 10.1038/nature02351; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Petroulakis E, 2009, CANCER CELL, V16, P439, DOI 10.1016/j.ccr.2009.09.025; Poulin F, 1998, J BIOL CHEM, V273, P14002, DOI 10.1074/jbc.273.22.14002; Puig O, 2003, GENE DEV, V17, P2006, DOI 10.1101/gad.1098703; Pyronnet S, 2001, CURR OPIN GENET DEV, V11, P13, DOI 10.1016/S0959-437X(00)00150-7; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Pyronnet S, 2000, BIOCHEM PHARMACOL, V60, P1237, DOI 10.1016/S0006-2952(00)00429-9; Richter JD, 2005, NATURE, V433, P477, DOI 10.1038/nature03205; Rolli-Derkinderen M, 2003, J BIOL CHEM, V278, P18859, DOI 10.1074/jbc.M211696200; Rom E, 1998, J BIOL CHEM, V273, P13104, DOI 10.1074/jbc.273.21.13104; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Salaun P, 2003, DEV BIOL, V255, P428, DOI 10.1016/S0012-1606(02)00099-4; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; She QB, 2010, CANCER CELL, V18, P39, DOI 10.1016/j.ccr.2010.05.023; Shveygert M, 2010, MOL CELL BIOL, V30, P5160, DOI 10.1128/MCB.00448-10; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Tamburini J, 2009, BLOOD, V114, P1618, DOI 10.1182/blood-2008-10-184515; Tee AR, 2002, MOL CELL BIOL, V22, P1674, DOI 10.1128/MCB.22.6.1674-1683.2002; Tee AR, 2000, ONCOGENE, V19, P3021, DOI 10.1038/sj.onc.1203622; Teleman AA, 2005, GENE DEV, V19, P1844, DOI 10.1101/gad.341505; Tettweiler G, 2005, GENE DEV, V19, P1840, DOI 10.1101/gad.1311805; Topisirovic I, 2009, MOL CELL BIOL, V29, P1152, DOI 10.1128/MCB.01532-08; Ueda T, 2004, MOL CELL BIOL, V24, P6539, DOI 10.1128/MCB.24.15.6539-6549.2004; Ueda T, 2010, P NATL ACAD SCI USA, V107, P13984, DOI 10.1073/pnas.1008136107; Wang XM, 2003, MOL CELL BIOL, V23, P1546, DOI 10.1128/MCB.23.5.1546-1557.2003; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Yamaguchi S, 2008, CELL METAB, V7, P269, DOI 10.1016/j.cmet.2008.01.008	83	67	70	0	23	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2013	32	6					671	677		10.1038/onc.2012.116	http://dx.doi.org/10.1038/onc.2012.116			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101AF	22508483				2022-12-17	WOS:000315746700001
J	Kim, JH; Yu, S; Chen, JD; Kong, AN				Kim, J-H; Yu, S.; Chen, J. D.; Kong, A. N.			The nuclear cofactor RAC3/AIB1/SRC-3 enhances Nrf2 signaling by interacting with transactivation domains	ONCOGENE			English	Article						Nrf2; RAC3/SRC-3; HO-1	STEROID-RECEPTOR COACTIVATOR-1; ELECTROPHILE RESPONSE ELEMENT; TRANSCRIPTION FACTOR NRF2; CREB-BINDING-PROTEIN; INDUCIBLE EXPRESSION; OXIDATIVE STRESS; THYROID-HORMONE; GENE; AIB1; ANTIOXIDANT	Nuclear factor erythroid 2-related factor 2 (Nrf2, NM 006164, 605 AA) is essential for the antioxidant responsive element (ARE)-mediated expression of a group of detoxifying antioxidant genes that detoxify carcinogens and protect against oxidative stress. Several proteins have been identified as Nrf2-interacting molecules. In this study, we found that the overexpression of receptor-associated coactivator 3 (RAC3)/AIB-1/steroid receptor coactivator-3, a nuclear coregulator and oncogene frequently amplified in human breast cancers, induced heme oxygenase-1 (HO-1) through Nrf2 transactivation in HeLa cells. Next, we determined the interaction between RAC3 and Nrf2 proteins using a co-immunoprecipitation assay and fluorescence resonance energy transfer analysis. The results showed that RAC3 bound directly to the Nrf2 protein in the nucleus. Subsequently, we identified the interacting domains of Nrf2 and RAC3 using a gintathione S-transferase pull-down assay. The results showed that both the N-terminal RAC3-pasB and C-terminal RAC3-R3B3 domains were tightly bound to the Neh4 and Neh5 transactivation domains. Furthermore, chromatin immunoprecipitation showed that RAC3 bound tightly to the ARE enhancer region of the HO-1 promoter via Nrf2 binding. These data suggest that Nrf2 activation is modulated and directly controlled through interactions with the RAC3 protein in HeLa cells. Oncogene (2013) 32, 514-527; doi:10.1038/onc.2012.59; published online 27 February 2012	[Kim, J-H; Kong, A. N.] Rutgers State Univ, Grad Program Pharmaceut Sci, Piscataway, NJ 08854 USA; [Kim, J-H; Yu, S.; Kong, A. N.] Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmaceut, Piscataway, NJ 08854 USA; [Chen, J. D.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center	Kong, AN (corresponding author), Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmaceut, 160 Frelinghuysen Rd,Room 228, Piscataway, NJ 08854 USA.	KongT@pharmacy.rutgers.edu	yu, Siwang/AAL-8059-2020; Kong, Ah-Ng Tony/AAX-2828-2020	Yu, Siwang/0000-0002-3336-202X; Kim, Jung Hwan/0000-0002-2975-4899	NIH [R01 NIH R01-CA-94828]; NATIONAL CANCER INSTITUTE [R01CA094828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES005022] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Dr Jianjie Ma (Department of Physiology and Biophysics, University of Medicine and Dentistry of New Jersey, Newark, New Jersey, USA) for help with confocal microscopy. This study was supported by NIH Grant R01 NIH R01-CA-94828.	Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Arimura A, 2004, J BIOL CHEM, V279, P31105, DOI 10.1074/jbc.M404428200; Blank V, 2008, J MOL BIOL, V376, P913, DOI 10.1016/j.jmb.2007.11.074; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Chan KM, 2001, P NATL ACAD SCI USA, V98, P4611, DOI 10.1073/pnas.081082098; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Enomoto A, 2001, TOXICOL SCI, V59, P169, DOI 10.1093/toxsci/59.1.169; Gnanapragasam VJ, 2001, BRIT J CANCER, V85, P1928, DOI 10.1054/bjoc.2001.2179; Han SJ, 2006, MOL ENDOCRINOL, V20, P45, DOI 10.1210/me.2005-0310; Hayashi A, 2003, BIOCHEM BIOPH RES CO, V310, P824, DOI 10.1016/j.bbrc.2003.09.086; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Henke RT, 2004, CLIN CANCER RES, V10, P6134, DOI 10.1158/1078-0432.CCR-04-0561; Huang HC, 2002, J BIOL CHEM, V277, P42769, DOI 10.1074/jbc.M206911200; Katoh Y, 2001, GENES CELLS, V6, P857, DOI 10.1046/j.1365-2443.2001.00469.x; Kobayashi M, 2002, GENES CELLS, V7, P807, DOI 10.1046/j.1365-2443.2002.00561.x; Kobayashi M, 2005, ANTIOXID REDOX SIGN, V7, P385, DOI 10.1089/ars.2005.7.385; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Kong ANT, 2001, DRUG METAB REV, V33, P255, DOI 10.1081/DMR-120000652; Kuang SQ, 2004, CANCER RES, V64, P1875, DOI 10.1158/0008-5472.CAN-03-3745; Lee JM, 2003, J BIOL CHEM, V278, P12029, DOI 10.1074/jbc.M211558200; Lee JM, 2004, P NATL ACAD SCI USA, V101, P9751, DOI 10.1073/pnas.0403620101; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Li C, 2007, MOL CELL BIOL, V27, P1296, DOI 10.1128/MCB.00336-06; LI Y, 1993, J BIOL CHEM, V268, P21454; Lin W, 2006, J BIOCHEM MOL BIOL, V39, P304; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; McMahon M, 2001, CANCER RES, V61, P3299; MORSE MA, 1993, CARCINOGENESIS, V14, P1737, DOI 10.1093/carcin/14.9.1737; Motohashi H, 2004, TRENDS MOL MED, V10, P549, DOI 10.1016/j.molmed.2004.09.003; Nakaso K, 2003, FEBS LETT, V546, P181, DOI 10.1016/S0014-5793(03)00517-9; Nguyen T, 2003, J BIOL CHEM, V278, P4536, DOI 10.1074/jbc.M207293200; RUSHMORE TH, 1990, J BIOL CHEM, V265, P14648; Sakakura C, 2000, INT J CANCER, V89, P217; Shen GX, 2004, J BIOL CHEM, V279, P23052, DOI 10.1074/jbc.M401368200; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; Torres-Arzayus MI, 2004, CANCER CELL, V6, P263, DOI 10.1016/j.ccr.2004.06.027; Trinkle-Mulcahy L, 2001, J CELL SCI, V114, P4219; Vollrath V, 2006, BIOCHEM J, V395, P599, DOI 10.1042/BJ20051518; Wang Y, 2002, CANCER-AM CANCER SOC, V95, P2346, DOI 10.1002/cncr.10963; Wang ZY, 2000, P NATL ACAD SCI USA, V97, P13549, DOI 10.1073/pnas.260463097; Werbajh S, 2000, FEBS LETT, V485, P195, DOI 10.1016/S0014-5793(00)02223-7; Wu XY, 2001, J BIOL CHEM, V276, P23962, DOI 10.1074/jbc.M101041200; Xie D, 2005, HUM PATHOL, V36, P777, DOI 10.1016/j.humpath.2005.05.007; Xu FP, 2007, CANCER LETT, V245, P69, DOI 10.1016/j.canlet.2005.12.030; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Yan J, 2006, CANCER RES, V66, P11039, DOI 10.1158/0008-5472.CAN-06-2442; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Ying H, 2005, MOL CELL BIOL, V25, P7687, DOI 10.1128/MCB.25.17.7687-7695.2005; ZHANG YS, 1992, P NATL ACAD SCI USA, V89, P2399, DOI 10.1073/pnas.89.6.2399; Zhou G, 2003, MOL CELL BIOL, V23, P7742, DOI 10.1128/MCB.23.21.7742-7755.2003; Zhu M, 2001, BIOCHEM BIOPH RES CO, V289, P212, DOI 10.1006/bbrc.2001.5944	55	67	70	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2013	32	4					514	527		10.1038/onc.2012.59	http://dx.doi.org/10.1038/onc.2012.59			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	098LR	22370642	Green Accepted			2022-12-17	WOS:000315551300012
J	Yang, MH; Lin, BR; Chang, CH; Chen, ST; Lin, SK; Kuo, MYP; Jeng, YM; Kuo, ML; Chang, CC				Yang, M-H; Lin, B-R; Chang, C-H; Chen, S-T; Lin, S-K; Kuo, M. Y-P; Jeng, Y-M; Kuo, M-L; Chang, C-C			Connective tissue growth factor modulates oral squamous cell carcinoma invasion by activating a miR-504/FOXP1 signalling	ONCOGENE			English	Article						connective tissue growth factor; microRNA-504; forkhead box P1; oral squamous cell carcinoma; invasion	TUMOR-SUPPRESSOR; FACTOR CTGF; CCN FAMILY; CANCER CELLS; GENE FAMILY; LUNG; METASTASIS; EXPRESSION; MOTILITY; OVEREXPRESSION	Connective tissue growth factor (CTGF) is a multifunctional secreted protein, and it has been shown either to promote or suppress tumor progression among different kinds of cancers. Here, we investigated the role of CTGF in oral squamous cell carcinoma (OSCC) invasion and metastasis. In five OSCC cell lines, endogenous CTGF negatively correlated with invasiveness. Exogenous CTGF protein or forced expression of CTGF gene in the oral cancer cell line SAS significantly decreased their invasive and migratory abilities. MicroRNA (miRNA) microarray analysis was performed in CTGF-overexpressed SAS cells (SAS/CTGF-M3) versus control cells to investigate the mechanism of CTGF-mediated inhibition of OSCC invasion. Among the miRNAs regulated by CTGF, miR-504 and miR-346 were the top two miRNAs downregulated in CTGF transfectants, and the result was confirmed by quantitative reverse transcriptase-PCR. Ectopic miR-504 increased migration and invasion in SAS/CTGF-M3, however, miR-346 did not have such impact on migration/invasion. Furthermore, we identified FOXP1, a member of forkhead transcription factors, as a target gene that takes part in the miR-504-induced cellular invasion. Knockdown of FOXP1 increased invasiveness in SAS/CTGF-M3, confirming the signal axis of CTGF/miR-504/FOXP1 in OSCC. Animal experiments showed that SAS/CTGF-M3-formed orthotopic tumors were associated with a lesser invasive phenotype than control cells. Expression of miR-504 in SAS/CTGF-M3 increased lymph node metastasis, and co-expression of FOXP1 in miR-504-transfected SAS/CTGF-M3 alleviated miR-504-induced metastasis. In OSCC samples, high CTGF was associated with a lower clinical stage and a better outcome. A reverse correlation between CTGF and miR-504, miR-504 and FOXP1, and a positive correlation between CTGF and FOXP1 were shown. Our study discovers a novel signal pathway involving the regulation of miRNA machinery by a secreted cytokine, which will be beneficial for developing therapeutic strategy against advanced OSCC. Oncogene (2012) 31, 2401-2411; doi: 10.1038/onc.2011.423; published online 19 September 2011	[Chang, C-H; Chang, C-C] Natl Taiwan Univ, Sch Dent, Grad Inst Oral Biol, Taipei 100, Taiwan; [Yang, M-H] Natl Yang Ming Univ, Inst Clin Med, Taipei 112, Taiwan; [Yang, M-H] Taipei Vet Gen Hosp, Dept Med, Div Hematol Oncol, Taipei, Taiwan; [Lin, B-R] Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan; [Chen, S-T] Natl Taiwan Univ Hosp, Dept Pediat, Yun Lin Branch, Taipei 10016, Taiwan; [Lin, S-K; Kuo, M. Y-P] Natl Taiwan Univ, Sch Dent, Grad Inst Clin Dent, Taipei 100, Taiwan; [Jeng, Y-M] Natl Taiwan Univ Hosp, Dept Pathol, Taipei 100, Taiwan; [Kuo, M-L] Natl Taiwan Univ, Coll Med, Inst Toxicol, Taipei 100, Taiwan	National Taiwan University; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University	Chang, CC (corresponding author), Natl Taiwan Univ, Sch Dent, Grad Inst Oral Biol, Taipei 100, Taiwan.	ccclrc@gmail.com	Yang, Muh-Hwa/AAE-4691-2020	CHANG, CHIA-HSUIN/0000-0003-0024-6177; Chen, Szu-Ta/0000-0002-9715-1221; JENG, YUNG-MING/0000-0002-3878-4491; KUO, MIN-LIANG/0000-0002-7139-0144; LIN, BEEN-REN/0000-0001-8354-1758; LIN, SZE-KWAN/0000-0002-7969-0280	National Science Council, Taiwan [NSC-97-2314-B-002-031-MY2, NSC-98-2320-B-002-003, NSC-99-2314-B-010-007-MY3]	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan)	This work was supported by grants from National Science Council, Taiwan NSC-97-2314-B-002-031-MY2, NSC-98-2320-B-002-003 (to CCC) and NSC-99-2314-B-010-007-MY3 (to MHY).	Abreu JG, 2002, NAT CELL BIOL, V4, P599, DOI 10.1038/ncb826; Banham AH, 2001, CANCER RES, V61, P8820; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Carlsson P, 2002, DEV BIOL, V250, P1, DOI 10.1006/dbio.2002.0780; Chan CS, 2005, PLOS COMPUT BIOL, V1, P564, DOI 10.1371/journal.pcbi.0010069; Chang CC, 2004, JNCI-J NATL CANCER I, V96, P364, DOI 10.1093/jnci/djh059; Chen PS, 2007, J CELL SCI, V120, P2053, DOI 10.1242/jcs.03460; Chu CY, 2008, J BIOMED SCI, V15, P675, DOI 10.1007/s11373-008-9264-9; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; Chuang JY, 2011, INT IMMUNOPHARMACOL, V11, P948, DOI 10.1016/j.intimp.2011.02.008; Haddad RI, 2008, NEW ENGL J MED, V359, P1143, DOI 10.1056/NEJMra0707975; Hashimoto Y, 1998, J EXP MED, V187, P289, DOI 10.1084/jem.187.3.289; Hu WW, 2010, MOL CELL, V38, P689, DOI 10.1016/j.molcel.2010.05.027; Huebner K, 2001, P NATL ACAD SCI USA, V98, P14763, DOI 10.1073/pnas.261586598; Jerjes W, 2010, HEAD NECK ONCOL, V2, DOI 10.1186/1758-3284-2-9; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; Kademani D, 2007, MAYO CLIN PROC, V82, P878, DOI 10.4065/82.7.878; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Katoh M, 2004, INT J ONCOL, V25, P1495; Koliopanos A, 2002, WORLD J SURG, V26, P420, DOI 10.1007/s00268-001-0242-x; Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Lin BR, 2005, GASTROENTEROLOGY, V128, P9, DOI 10.1053/j.gastro.2004.10.007; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Moritani NH, 2003, CANCER LETT, V192, P205, DOI 10.1016/S0304-3835(02)00718-8; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; Pan LH, 2002, NEUROL RES, V24, P677, DOI 10.1179/016164102101200573; Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P103, DOI 10.1136/mp.54.2.103; Planque N, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-15; Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020; Scott GK, 2006, CANCER RES, V66, P1277, DOI 10.1158/0008-5472.CAN-05-3632; Shimo T, 2008, ANTICANCER RES, V28, P2343; Soon LL, 2003, J BIOL CHEM, V278, P11465, DOI 10.1074/jbc.M210945200; Tong XJ, 2001, J BIOL CHEM, V276, P47709, DOI 10.1074/jbc.M107878200; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037; Wutzl A, 2007, J ORAL MAXIL SURG, V65, P255, DOI 10.1016/j.joms.2006.09.007; Xue ZH, 2010, J IMMUNOL, V184, P3697, DOI 10.4049/jimmunol.0903316; Yosimichi G, 2001, EUR J BIOCHEM, V268, P6058, DOI 10.1046/j.0014-2956.2001.02553.x; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835	41	67	69	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	19					2401	2411		10.1038/onc.2011.423	http://dx.doi.org/10.1038/onc.2011.423			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	941SP	21927029	Green Submitted			2022-12-17	WOS:000303985300003
J	Perna, D; Faga, G; Verrecchia, A; Gorski, MM; Barozzi, I; Narang, V; Khng, J; Lim, KC; Sung, WK; Sanges, R; Stupka, E; Oskarsson, T; Trumpp, A; Wei, CL; Muller, H; Amati, B				Perna, D.; Faga, G.; Verrecchia, A.; Gorski, M. M.; Barozzi, I.; Narang, V.; Khng, J.; Lim, K. C.; Sung, W-K; Sanges, R.; Stupka, E.; Oskarsson, T.; Trumpp, A.; Wei, C-L; Mueller, H.; Amati, B.			Genome-wide mapping of Myc binding and gene regulation in serum-stimulated fibroblasts	ONCOGENE			English	Article						Myc; chromatin; transcription; serum	EMBRYONIC STEM-CELLS; C-MYC; TRANSCRIPTION FACTOR; IN-VIVO; CHROMATIN-STRUCTURE; CYCLE PROGRESSION; PROTEIN-SYNTHESIS; DNA-REPLICATION; NUCLEAR IMPORT; RNA EXOSOME	The transition from quiescence to proliferation is a key regulatory step that can be induced by serum stimulation in cultured fibroblasts. The transcription factor Myc is directly induced by serum mitogens and drives a secondary gene expression program that remains largely unknown. Using mRNA profiling, we identify close to 300 Myc-dependent serum response (MDSR) genes, which are induced by serum in a Myc-dependent manner in mouse fibroblasts. Mapping of genomic Myc-binding sites by ChIP-seq technology revealed that most MDSR genes were directly targeted by Myc, but represented a minor fraction (5.5%) of all Myc-bound promoters (which were 22.4% of all promoters). Other target loci were either induced by serum in a Myc-independent manner, were not significantly regulated or were negatively regulated. MDSR gene products were involved in a variety of processes, including nucleotide biosynthesis, ribosome biogenesis, DNA replication and RNA control. Of the 29 MDSR genes targeted by RNA interference, three showed a requirement for cell-cycle entry upon serum stimulation and 11 for long-term proliferation and/or survival. Hence, proper coordination of key regulatory and biosynthetic pathways following mitogenic stimulation relies upon the concerted regulation of multiple Myc-dependent genes. Oncogene (2012) 31, 1695-1709; doi:10.1038/onc.2011.359; published online 22 August 2011	[Perna, D.; Faga, G.; Verrecchia, A.; Gorski, M. M.; Barozzi, I.; Mueller, H.; Amati, B.] European Inst Oncol, Dept Expt Oncol, I-20139 Milan, Italy; [Narang, V.; Sung, W-K; Wei, C-L] Genome Inst Singapore, Computat & Math Biol Grp, Singapore, Singapore; [Khng, J.; Lim, K. C.] Genome Inst Singapore, Genome Technol & Biol Grp, Singapore, Singapore; [Sanges, R.; Stupka, E.] Telethon Inst Genet & Med TIGEM, Naples, Italy; [Oskarsson, T.; Trumpp, A.] Ecole Polytech Fed Lausanne, Sch Life Sci, ISREC, CH-1015 Lausanne, Switzerland; [Mueller, H.; Amati, B.] Ist Italiano Tecnol, Ctr Genom Sci IIT SEMM, Milan, Italy	IRCCS European Institute of Oncology (IEO); Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM); Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Institute Experimental Cancer Research; Istituto Italiano di Tecnologia - IIT	Amati, B (corresponding author), European Inst Oncol, Dept Expt Oncol, IFOM IEO Campus,Via Adamello 16, I-20139 Milan, Italy.	bruno.amati@ifom-ieo-campus.it	Verrecchia, Alessandro/AAQ-6454-2020; Sanges, Remo/M-9814-2019; Amati, Bruno/AAM-3418-2020; Barozzi, Iros/GLQ-8907-2022; Faga, Giovanni/AAB-5540-2021; Stupka, Elia/J-6279-2012; Oskarsson, Thordur/HBP-9601-2022; Trumpp, Andreas/Z-2141-2019	Verrecchia, Alessandro/0000-0002-8596-6650; Sanges, Remo/0000-0002-5047-9713; Barozzi, Iros/0000-0003-0690-3473; Stupka, Elia/0000-0003-3154-4011; Trumpp, Andreas/0000-0002-6212-3466; Sung, Wing-Kin/0000-0001-7806-7086; Amati, Bruno/0000-0002-2958-1799; Muller, Heiko/0000-0001-9873-3146; Gorski, Marcin M./0000-0002-8276-3866; Oskarsson, Thordur/0000-0002-0983-6969; Narang, Vipin/0000-0001-8669-9964	Agency for Science, Technology and Research (A*STAR) of Singapore; NIH ENCODE; Swiss National Science Foundation; EU; Association for International Cancer Research (AICR); Italian health ministry; Italian Association for Cancer Research (AIRC)	Agency for Science, Technology and Research (A*STAR) of Singapore(Agency for Science Technology & Research (A*STAR)); NIH ENCODE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); EU(European Commission); Association for International Cancer Research (AICR); Italian health ministry(Ministry of Health, Italy); Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro)	We thank Gioacchino Natoli for critical discussion; Lucilla Luzi for help with data analysis; Ivan Muradore and Simona Ronzoni for help with imaging; Simone Minardi and Davide Cittaro for help with microarrays; Loris Bernard, Valentina Dall' Olio and Laura Tizzoni for help with real-time PCR; and Atif Shahab and CheeSeng Chan for technical guidance on processing and mapping sequencing data. We also acknowledge the Genome Technology and Biology Group at the Genome Institute of Singapore, in particular the GIS sequencing team, for technical support. Part of this work was supported by grants from the Agency for Science, Technology and Research (A*STAR) of Singapore and NIH ENCODE to C-LW, and from the Swiss National Science Foundation to AT. Work in the Amati lab was supported by grants from the EU-FP7 Program EuroSyStem, the Association for International Cancer Research (AICR), the Italian health ministry and the Italian Association for Cancer Research (AIRC).	Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Adler AS, 2006, NAT GENET, V38, P421, DOI 10.1038/ng1752; Amundson SA, 1998, ONCOGENE, V17, P2149, DOI 10.1038/sj.onc.1202136; Barna M, 2008, NATURE, V456, P971, DOI 10.1038/nature07449; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; Blow JJ, 2005, EMBO REP, V6, P1028, DOI 10.1038/sj.embor.7400557; Blow JJ, 2005, NAT REV MOL CELL BIO, V6, P476, DOI 10.1038/nrm1663; Bouchard C, 2004, EMBO J, V23, P2830, DOI 10.1038/sj.emboj.7600279; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Cartwright P, 2005, DEVELOPMENT, V132, P885, DOI 10.1242/dev.01670; Cawley S, 2004, CELL, V116, P499, DOI 10.1016/S0092-8674(04)00127-8; Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007; Chen X, 2008, CELL, V133, P1106, DOI 10.1016/j.cell.2008.04.043; Cheng ASL, 2006, MOL CELL, V21, P393, DOI 10.1016/j.molcel.2005.12.016; Corbett AH, 1996, J BIOL CHEM, V271, P18477, DOI 10.1074/jbc.271.31.18477; Cotterman R, 2008, CANCER RES, V68, P9654, DOI 10.1158/0008-5472.CAN-08-1961; Dang CV, 2009, CLIN CANCER RES, V15, P6479, DOI 10.1158/1078-0432.CCR-09-0889; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Dickins RA, 2005, NAT GENET, V37, P1289, DOI 10.1038/ng1651; Eilers M, 2008, GENE DEV, V22, P2755, DOI 10.1101/gad.1712408; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; FISHER F, 1993, EMBO J, V12, P5075, DOI 10.1002/j.1460-2075.1993.tb06201.x; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Guccione E, 2006, NAT CELL BIOL, V8, P764, DOI 10.1038/ncb1434; Guenther MG, 2007, CELL, V130, P77, DOI 10.1016/j.cell.2007.05.042; Herold S, 2009, NAT REV CANCER, V9, P441, DOI 10.1038/nrc2640; Hirano Y, 2009, GENES CELLS, V14, P155, DOI 10.1111/j.1365-2443.2008.01262.x; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Izumi H, 2001, J CELL SCI, V114, P1533; Kawaji H, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-4-r40; Kidder BL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003932; Kim JW, 2008, CELL, V132, P1049, DOI 10.1016/j.cell.2008.02.039; Kim J, 2010, CELL, V143, P313, DOI 10.1016/j.cell.2010.09.010; Klapproth K, 2010, BRIT J HAEMATOL, V149, P484, DOI 10.1111/j.1365-2141.2010.08159.x; Knoepfler PS, 2006, EMBO J, V25, P2723, DOI 10.1038/sj.emboj.7601152; Leung JY, 2008, ONCOGENE, V27, P4172, DOI 10.1038/onc.2008.55; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Liu QS, 2006, CELL, V127, P1223, DOI 10.1016/j.cell.2006.10.037; Liu YC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002722; Mao DYL, 2003, CURR BIOL, V13, P882, DOI 10.1016/S0960-9822(03)00297-5; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; Martinato F, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003650; Masai H, 2005, IUBMB LIFE, V57, P323, DOI 10.1080/15216540500092419; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5793, DOI 10.1128/MCB.22.16.5793-5800.2002; O'Hagan RC, 2000, GENE DEV, V14, P2185, DOI 10.1101/gad.827200; Quimby BB, 2000, MOL BIOL CELL, V11, P2617, DOI 10.1091/mbc.11.8.2617; Quimby BB, 2000, J BIOL CHEM, V275, P28575, DOI 10.1074/jbc.M005055200; Rahl PB, 2010, CELL, V141, P432, DOI 10.1016/j.cell.2010.03.030; Ribbeck K, 1998, EMBO J, V17, P6587, DOI 10.1093/emboj/17.22.6587; Sardiello M, 2009, SCIENCE, V325, P473, DOI 10.1126/science.1174447; Schlosser I, 2003, NUCLEIC ACIDS RES, V31, P6148, DOI 10.1093/nar/gkg794; Schmid M, 2008, TRENDS BIOCHEM SCI, V33, P501, DOI 10.1016/j.tibs.2008.07.003; Schuhmacher M, 1999, CURR BIOL, V9, P1255, DOI 10.1016/S0960-9822(99)80507-7; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Shen V, 2006, CELL, V127, P1093, DOI 10.1016/j.cell.2006.11.035; Silva JM, 2005, NAT GENET, V37, P1281, DOI 10.1038/ng1650; Smith A, 1998, CURR BIOL, V8, P1403, DOI 10.1016/S0960-9822(98)00023-2; Smith AP, 2009, ONCOGENE, V28, P422, DOI 10.1038/onc.2008.395; SOLOMON DLC, 1993, NUCLEIC ACIDS RES, V21, P5372, DOI 10.1093/nar/21.23.5372; Sridharan R, 2009, CELL, V136, P364, DOI 10.1016/j.cell.2009.01.001; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Stewart M, 2007, NAT REV MOL CELL BIO, V8, P195, DOI 10.1038/nrm2114; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tao H, 1999, DNA CELL BIOL, V18, P75, DOI 10.1089/104454999315646; Thomson JP, 2010, NATURE, V464, P1082, DOI 10.1038/nature08924; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; van Riggelen J, 2010, NAT REV CANCER, V10, P301, DOI 10.1038/nrc2819; Vanacova S, 2007, EMBO REP, V8, P651, DOI 10.1038/sj.embor.7401005; Watson JD, 2002, J BIOL CHEM, V277, P36921, DOI 10.1074/jbc.M201493200; Winkles JA, 1998, PROG NUCLEIC ACID RE, V58, P41; Wong DJ, 2008, CELL STEM CELL, V2, P333, DOI 10.1016/j.stem.2008.02.009; Zeller KI, 2006, P NATL ACAD SCI USA, V103, P17834, DOI 10.1073/pnas.0604129103; Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69	82	67	70	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	13					1695	1709		10.1038/onc.2011.359	http://dx.doi.org/10.1038/onc.2011.359			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	918EF	21860422	Green Published, hybrid			2022-12-17	WOS:000302231400008
J	Neal, CL; Xu, J; Li, P; Mori, S; Yang, J; Neal, NN; Zhou, X; Wyszomierski, SL; Yu, D				Neal, C. L.; Xu, J.; Li, P.; Mori, S.; Yang, J.; Neal, N. N.; Zhou, X.; Wyszomierski, S. L.; Yu, D.			Overexpression of 14-3-3 zeta in cancer cells activates PI3K via binding the p85 regulatory subunit	ONCOGENE			English	Article						14-3-3 zeta; breast cancer; PI3K; Akt	BREAST-CANCER; CAMP-PKA; 14-3-3-PROTEINS; INHIBITION; PROTEINS; SURVIVAL; GROWTH; PHOSPHORYLATION; ISOFORMS; RECEPTOR	The ubiquitously expressed 14-3-3 proteins regulate many pathways involved in transformation. Previously, we found that 14-3-3 zeta overexpression increased Akt phosphorylation in human mammary epithelial cells. Here, we investigated the clinical relevance and molecular mechanism of 14-3-3 zeta-overexpression-mediated Akt phosphorylation, and its potential impact on breast cancer progression. We found that 14-3-3 zeta overexpression was significantly (P = 0.005) associated with increased Akt phosphorylation in human breast tumors. Additionally, 14-3-3 zeta overexpression combined with strong Akt phosphorylation was significantly (P = 0.01) associated with increased cancer recurrence in patients. In contrast, knockdown of 14-3-3 zeta expression by small interfering RNA in cancer cell lines and tumor xenografts reduced Akt phosphorylation. Furthermore, 14-3-3 zeta enhanced Akt phosphorylation through activation of phosphoinositide 3-kinase (PI3K). Mechanistically, 14-3-3 zeta bound to the p85 regulatory subunit of PI3K and increased PI3K translocation to the cell membrane. A single 14-3-3-binding motif encompassing serine 83 on p85 is largely responsible for 14-3-3 zeta-mediated p85 binding and PI3K/Akt activation. Mutation of serine 83 to alanine on p85 inhibited 14-3-3 zeta binding to the p85 subunit of PI3K, reduced PI3K membrane localization and activation, impeded anchorage-independent growth and enhanced stress-induced apoptosis. These findings revealed a novel mechanism by which 14-3-3 zeta overexpression activates PI3K, a key node in the mitogenic signaling network known to promote malignancies in many cell types. Oncogene (2012) 31, 897-906; doi: 10.1038/onc.2011.284; published online 11 July 2011	[Neal, C. L.; Xu, J.; Li, P.; Mori, S.; Yang, J.; Neal, N. N.; Zhou, X.; Wyszomierski, S. L.; Yu, D.] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Xu, J.; Yang, J.; Yu, D.] Univ Texas Grad Sch Biomed Sci Houston, Canc Biol Program, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center	Yu, D (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Bolvard,Box 108, Houston, TX 77030 USA.	dyu@mdanderson.org		Xu, Jia/0000-0003-0254-6261; Yu, Dihua/0000-0001-6231-9381	NIH [P30-CA 16672, RO1-CA112567, PO1-CA099031]; Department of Defense (DOD) [BC050006, W81XWH-08-1-0712]; Susan G Komen Breast Cancer Foundation [KG091020]; NATIONAL CANCER INSTITUTE [R01CA112567, P01CA099031, P30CA016672] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense (DOD)(United States Department of Defense); Susan G Komen Breast Cancer Foundation(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported by grants from NIH P30-CA 16672 ( MDACC); RO1-CA112567, PO1-CA099031 project 4, Department of Defense (DOD) Center of Excellence (BC050006) subproject, DOD Synergistic Award W81XWH-08-1-0712 and Susan G Komen Breast Cancer Foundation Promise Grant KG091020 ( D Yu). Dr Dihua Yu is the Hubert L and Olive Stringer Distinguished Chair in Basic Science, MDACC. We thank Dr Lewis Cantley for providing p85 knockout MEFs. We also thank X Du, K Matias, T Chen, J Hannay, S Zhang and S Rehman for reagents, suggestions and manuscript reading.	AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; Aitken A, 2006, SEMIN CANCER BIOL, V16, P162, DOI 10.1016/j.semcancer.2006.03.005; Barboric M, 2005, EMBO J, V24, P4291, DOI 10.1038/sj.emboj.7600883; Benzinger A, 2005, MOL CELL PROTEOMICS, V4, P785, DOI 10.1074/mcp.M500021-MCP200; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; Brachmann SA, 2005, MOL CELL BIOL, V25, P2593, DOI 10.1128/MCB.25.7.2593-2606.2005; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cosentino C, 2007, ONCOGENE, V26, P2095, DOI 10.1038/sj.onc.1210027; Craparo A, 1997, J BIOL CHEM, V272, P11663; Danes CG, 2008, CANCER RES, V68, P1760, DOI 10.1158/0008-5472.CAN-07-3177; De Gregorio G, 2007, ONCOGENE, V26, P2039, DOI 10.1038/sj.onc.1210011; Jin J, 2004, CURR BIOL, V14, P1436, DOI 10.1016/j.cub.2004.07.051; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Kim SJ, 2005, FEBS LETT, V579, P534, DOI 10.1016/j.febslet.2004.12.024; Lonic A, 2008, MOL CELL BIOL, V28, P3372, DOI 10.1128/MCB.01837-07; Lu J, 2009, CANCER CELL, V16, P195, DOI 10.1016/j.ccr.2009.08.010; Munday AD, 2000, BLOOD, V96, P577; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Neal CL, 2009, CANCER RES, V69, P3425, DOI 10.1158/0008-5472.CAN-08-2765; Oksvold MP, 2004, FEBS LETT, V569, P207, DOI 10.1016/j.febslet.2004.05.068; Porter GW, 2006, SEMIN CANCER BIOL, V16, P193, DOI 10.1016/j.semcancer.2006.03.003; Rubio MP, 2004, BIOCHEM J, V379, P395, DOI 10.1042/bj20031797; Tan M, 1997, CANCER RES, V57, P1199; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; Tzivion G, 2006, SEMIN CANCER BIOL, V16, P203, DOI 10.1016/j.semcancer.2006.03.004; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; Vanhaesebroeck B, 2005, TRENDS BIOCHEM SCI, V30, P194, DOI 10.1016/j.tibs.2005.02.008; Wilker E, 2004, J MOL CELL CARDIOL, V37, P633, DOI 10.1016/j.yjmcc.2004.04.015; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379	32	67	68	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	7					897	906		10.1038/onc.2011.284	http://dx.doi.org/10.1038/onc.2011.284			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	897BL	21743495	Green Accepted			2022-12-17	WOS:000300615800008
J	Gu, Y; Lin, S; Li, JL; Nakagawa, H; Chen, Z; Jin, B; Tian, L; Ucar, DA; Shen, H; Lu, J; Hochwald, SN; Kaye, FJ; Wu, L				Gu, Y.; Lin, S.; Li, J-L; Nakagawa, H.; Chen, Z.; Jin, B.; Tian, L.; Ucar, D. A.; Shen, H.; Lu, J.; Hochwald, S. N.; Kaye, F. J.; Wu, L.			Altered LKB1/CREB-regulated transcription co-activator (CRTC) signaling axis promotes esophageal cancer cell migration and invasion	ONCOGENE			English	Article						esophageal cancer; LKB1; CRTC co-activator; LYPD3; migration; invasion	PEUTZ-JEGHERS-SYNDROME; TUMOR-SUPPRESSOR; GENETIC ALTERATIONS; HUMAN HOMOLOG; LKB1; GROWTH; CREB; EXPRESSION; LKB1/STK11; TUMORIGENESIS	LKB1 is a tumor susceptibility gene for the Peutz-Jeghers cancer syndrome and is a target for mutational inactivation in sporadic human malignancies. LKB1 encodes a serine/threonine kinase that has critical roles in cell growth, polarity and metabolism. A novel and important function of LKB1 is its ability to regulate the phosphorylation of CREB-regulated transcription co-activators (CRTCs) whose aberrant activation is linked with oncogenic activities. However, the roles and mechanisms of LKB1 and CRTC in the pathogenesis of esophageal cancer have not been previously investigated. In this study, we observed altered LKB1-CRTC signaling in a subset of human esophageal cancer cell lines and patient samples. LKB1 negatively regulates esophageal cancer cell migration and invasion in vitro. Mechanistically, we determined that CRTC signaling becomes activated because of LKB1 loss, which results in the transcriptional activation of specific downstream targets including LYPD3, a critical mediator for LKB1 loss-of-function. Our data indicate that de-regulated LKB1-CRTC signaling might represent a crucial mechanism for esophageal cancer progression. Oncogene (2012) 31, 469-479; doi: 10.1038/onc.2011.247; published online 27 June 2011	[Gu, Y.; Lin, S.; Chen, Z.; Jin, B.; Tian, L.; Shen, H.; Wu, L.] Univ Florida, Dept Mol Genet & Microbiol, Shands Canc Ctr, Gainesville, FL 32610 USA; [Li, J-L] Sanford Burnham Med Res Inst Lake Nona, Orlando, FL USA; [Nakagawa, H.] Univ Penn, Dept Med, Div Gastroenterol, Abramson Canc Ctr, Philadelphia, PA 19104 USA; [Ucar, D. A.; Hochwald, S. N.] Univ Florida, Dept Surg, Shands Canc Ctr, Gainesville, FL 32610 USA; [Lu, J.] Univ Florida, Dept Biochem & Mol Biol, Shands Canc Ctr, Gainesville, FL 32610 USA; [Kaye, F. J.] Univ Florida, Dept Med, Shands Canc Ctr, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; Sanford Burnham Prebys Medical Discovery Institute; University of Pennsylvania; Pennsylvania Medicine; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Wu, L (corresponding author), Univ Florida, Dept Mol Genet & Microbiol, Shands Canc Ctr, 2033 Mowry Rd,Room 362, Gainesville, FL 32610 USA.	lzwu@ufl.edu	Li, J L/E-6100-2018; chen, zirong/S-4042-2016; Li, Jian-Liang/AAE-9315-2019; Lu, Jianrong/F-5240-2013	Li, J L/0000-0002-6487-081X; chen, zirong/0000-0002-0589-4619; Li, Jian-Liang/0000-0002-6487-081X; /0000-0002-0949-5068; Lu, Jianrong/0000-0002-4969-6040	University of Florida Shands Cancer Center	University of Florida Shands Cancer Center	We thank Jenny Huang for critical reading of our paper, Marda Jorgensen for helping with immunohistochemical staining and the University of Florida CTSI Biorepository for providing human esophageal tumor samples. This work was supported in part by the University of Florida Shands Cancer Center Startup fund (L Wu).	Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Altarejos JY, 2008, NAT MED, V14, P1112, DOI 10.1038/nm.1866; Altarejos JY, 2011, NAT REV MOL CELL BIO, V12, P141, DOI 10.1038/nrm3072; Andl CD, 2003, J BIOL CHEM, V278, P1824, DOI 10.1074/jbc.M209148200; Breuillaud L, 2009, NAT MED, V15, P989, DOI 10.1038/nm0909-989; Carretero J, 2004, ONCOGENE, V23, P4037, DOI 10.1038/sj.onc.1207502; Carretero J, 2010, CANCER CELL, V17, P547, DOI 10.1016/j.ccr.2010.04.026; Chen Jie, 2010, Genes Cancer, V1, P822, DOI 10.1177/1947601910383564; Chen Y, 2005, CANCER RES, V65, P10838, DOI 10.1158/0008-5472.CAN-05-1091; Conkright MD, 2003, MOL CELL, V12, P413, DOI 10.1016/j.molcel.2003.08.013; Coxon A, 2005, CANCER RES, V65, P7137, DOI 10.1158/0008-5472.CAN-05-1125; Enzinger PC, 2003, NEW ENGL J MED, V349, P2241, DOI 10.1056/NEJMra035010; Esteller M, 2000, ONCOGENE, V19, P164, DOI 10.1038/sj.onc.1203227; Giardiello FM, 2000, GASTROENTEROLOGY, V119, P1447, DOI 10.1053/gast.2000.20228; Guldberg P, 1999, ONCOGENE, V18, P1777, DOI 10.1038/sj.onc.1202486; Hansen LV, 2008, INT J CANCER, V122, P734, DOI 10.1002/ijc.23082; Hezel AF, 2008, ONCOGENE, V27, P6908, DOI 10.1038/onc.2008.342; Iourgenko V, 2003, P NATL ACAD SCI USA, V100, P12147, DOI 10.1073/pnas.1932773100; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Jin J, 2004, CURR BIOL, V14, P1436, DOI 10.1016/j.cub.2004.07.051; Katoh Y, 2006, FEBS J, V273, P2730, DOI 10.1111/j.1742-4658.2006.05291.x; Klein CA, 2009, CANCER RES, V69, P5285, DOI 10.1158/0008-5472.CAN-08-4586; Komiya T, 2006, ONCOGENE, V25, P6128, DOI 10.1038/sj.onc.1209627; Komiya T, 2010, ONCOGENE, V29, P1672, DOI 10.1038/onc.2009.453; Kuwano H, 2005, SURG TODAY, V35, P7, DOI 10.1007/s00595-004-2885-3; Lam AKY, 2000, CRIT REV ONCOL HEMAT, V33, P71, DOI 10.1016/S1040-8428(99)00054-2; Launonen V, 2000, CANCER RES, V60, P546; Lee JJ, 2010, CARCINOGENESIS, V31, P427, DOI 10.1093/carcin/bgp326; Liu L, 2004, CANCER RES, V64, P3491, DOI 10.1158/0008-5472.CAN-03-2106; Luo ZJ, 2010, FUTURE ONCOL, V6, P457, DOI [10.2217/fon.09.174, 10.2217/FON.09.174]; Mahoney CL, 2009, BRIT J CANCER, V100, P370, DOI 10.1038/sj.bjc.6604886; Makowski L, 2008, BRIT J CANCER, V99, P683, DOI 10.1038/sj.bjc.6604515; Matsumoto S, 2007, ONCOGENE, V26, P5911, DOI 10.1038/sj.onc.1210418; NISHIHIRA T, 1993, J CANCER RES CLIN, V119, P441, DOI 10.1007/BF01215923; Paret C, 2005, INT J CANCER, V115, P724, DOI 10.1002/ijc.20977; Rodriguez Luis G., 2004, V294, P23; Rosel M, 1998, ONCOGENE, V17, P1989, DOI 10.1038/sj.onc.1202079; Rowan A, 1999, J INVEST DERMATOL, V112, P509, DOI 10.1046/j.1523-1747.1999.00551.x; Rustgi AK, 2006, SEMIN ONCOL, V33, pS57, DOI 10.1053/j.seminoncol.2006.10.013; Sanchez-Cespedes M, 2007, ONCOGENE, V26, P7825, DOI 10.1038/sj.onc.1210594; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Sattler M, 2002, CANCER CELL, V1, P479, DOI 10.1016/S1535-6108(02)00074-0; Seiter S, 2001, J INVEST DERMATOL, V116, P344, DOI 10.1046/j.1523-1747.2001.01230.x; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; SHIMADA Y, 1992, CANCER, V69, P277, DOI 10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C; Tiainen M, 1999, P NATL ACAD SCI USA, V96, P9248, DOI 10.1073/pnas.96.16.9248; Tiainen M, 2002, HUM MOL GENET, V11, P1497, DOI 10.1093/hmg/11.13.1497; Tonon G, 2003, NAT GENET, V33, P208, DOI 10.1038/ng1083; Vallbohmer D, 2010, J GASTROINTEST SURG, V14, P75, DOI 10.1007/s11605-009-1021-5; van Lier MGF, 2010, AM J GASTROENTEROL, V105, P1258, DOI 10.1038/ajg.2009.725; Wingo SN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005137; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644; Wu LZ, 2005, EMBO J, V24, P2391, DOI 10.1038/sj.emboj.7600719; Wurfel J, 2001, GENE, V262, P35, DOI 10.1016/S0378-1119(00)00515-1	54	67	70	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	4					469	479		10.1038/onc.2011.247	http://dx.doi.org/10.1038/onc.2011.247			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891LU	21706049				2022-12-17	WOS:000300219300006
J	Smit, MA; Peeper, DS				Smit, M. A.; Peeper, D. S.			Zeb1 is required for TrkB-induced epithelial-mesenchymal transition, anoikis resistance and metastasis	ONCOGENE			English	Article						Zeb1; TrkB; EMT; anoikis; metastasis	NEUROTROPHIC RECEPTOR TRKB; TRANSCRIPTION FACTOR SNAIL; E-CADHERIN EXPRESSION; CANCER-CELLS; TUMOR PROGRESSION; MIR-200 FAMILY; PROMOTES METASTASIS; GENE-EXPRESSION; REPRESSORS ZEB1; BREAST-CANCER	Anoikis (detachment-induced apoptosis) prevents the survival of cells at inappropriate sites of the body and can therefore act as a barrier to metastasis. In a function-based genome-wide screen, we have previously identified the neurotrophic tyrosine kinase receptor TrkB as a potent suppressor of anoikis. Consistently, activated TrkB oncogenically transforms non-malignant epithelial cells and causes them to invade and produce metastatic tumors in vivo. Overexpression of activated TrkB also results in morphological transformation, resembling epithelial-mesenchymal transition (EMT). E-cadherin, an important EMT regulator, and two E-cadherin repressors, Twist and Snail, are critical for these TrkB functions. As Snail has been shown to induce Zeb1, another E-cadherin repressor, we hypothesized that Zeb1 could be a TrkB target, too. We show here that Zeb1 is required for TrkB-induced EMT in epithelial cells, as RNAi-mediated knockdown of Zeb1 reverted the morphological changes induced by TrkB. Furthermore, Zeb1 is involved in TrkB-induced anoikis resistance, migration and invasion. In vivo, knockdown of Zeb1 strongly reduced TrkB-induced metastasis. Finally, epistasis experiments showed that Zeb1 acts downstream of Twist and Snail. We conclude that Zeb1 is required for several TrkB-induced effects in vitro and in vivo, including metastasis. Oncogene (2011) 30, 3735-3744; doi:10.1038/onc.2011.96; published online 11 April 2011	[Smit, M. A.; Peeper, D. S.] Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Peeper, DS (corresponding author), Netherlands Canc Inst, Div Mol Genet, Plesmanlaan 121,Room P1-011, NL-1066 CX Amsterdam, Netherlands.	d.peeper@nki.nl	Peeper, Daniel/AAA-2430-2020		Dutch Cancer Society; European Union	Dutch Cancer Society(KWF Kankerbestrijding); European Union(European Commission)	We thank M Voetel, S Greven, H Grimminck and all other animal caretakers for their excellent technical help with the in vivo experiments, JY Song and the animal pathology department for help with the pathological analysis and performing IHC stainings, L Brocks and L Oomen for help with the confocal images, F Van Diepen and A Pfauth for fluorescence-activated cell sorting, M Heimerikx, M Nieuwland, J de Ronde, D Sie, A Velds, I de Rink and R Kerkhoven for performing the microarray analysis and ML Yurda for statistical analysis. We thank Dr Nakshatri for providing the Zeb1 plasmid, R Weinberg for the Twist plasmid, A Munoz for the Snail plasmid and K Becker for the Snail antibody. We thank all members of the Peeper laboratory for their valuable input and T Geiger for useful discussions and help with the microarray experiments. This work was supported by grants from MAS and DSP from the Dutch Cancer Society (KWF) and a European Union FP6 grant.	Adachi Y, 2009, FEBS LETT, V583, P430, DOI 10.1016/j.febslet.2008.12.042; Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508; Aigner K, 2007, FEBS LETT, V581, P1617, DOI 10.1016/j.febslet.2007.03.026; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bendoraite A, 2010, GYNECOL ONCOL, V116, P117, DOI 10.1016/j.ygyno.2009.08.009; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Christofori G, 2006, NATURE, V441, P444, DOI 10.1038/nature04872; Chua HL, 2007, ONCOGENE, V26, P711, DOI 10.1038/sj.onc.1209808; Desmet CJ, 2006, CELL MOL LIFE SCI, V63, P755, DOI 10.1007/s00018-005-5490-8; Dionne CA, 1998, CLIN CANCER RES, V4, P1887; Dohadwala M, 2006, CANCER RES, V66, P5338, DOI 10.1158/0008-5472.CAN-05-3635; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; ERNFORS P, 1994, NATURE, V368, P147, DOI 10.1038/368147a0; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Geiger TR, 2007, CANCER RES, V67, P6221, DOI 10.1158/0008-5472.CAN-07-0121; Geiger TR, 2009, BBA-REV CANCER, V1796, P293, DOI 10.1016/j.bbcan.2009.07.006; Geiger TR, 2005, CANCER RES, V65, P7033, DOI 10.1158/0008-5472.CAN-05-0709; GENETTA T, 1994, MOL CELL BIOL, V14, P6153, DOI 10.1128/MCB.14.9.6153; Graham TR, 2008, CANCER RES, V68, P2479, DOI 10.1158/0008-5472.CAN-07-2559; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; Kudo-Saito C, 2009, CANCER CELL, V15, P195, DOI 10.1016/j.ccr.2009.01.023; Kupferman ME, 2010, ONCOGENE, V29, P2047, DOI 10.1038/onc.2009.486; Liotta LA, 2004, NATURE, V430, P973, DOI 10.1038/430973a; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Miknyoczki SJ, 1999, INT J CANCER, V81, P417, DOI 10.1002/(SICI)1097-0215(19990505)81:3<417::AID-IJC16>3.0.CO;2-6; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; Palmer HG, 2004, NAT MED, V10, P917, DOI 10.1038/nm1095; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Pena C, 2005, HUM MOL GENET, V14, P3361, DOI 10.1093/hmg/ddi366; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; Rosivatz E, 2006, VIRCHOWS ARCH, V448, P277, DOI 10.1007/s00428-005-0118-9; Schmalhofer O, 2009, CANCER METAST REV, V28, P151, DOI 10.1007/s10555-008-9179-y; Singh M, 2008, MODERN PATHOL, V21, P912, DOI 10.1038/modpathol.2008.82; Smit MA, 2009, MOL CELL BIOL, V29, P3722, DOI 10.1128/MCB.01164-08; Spaderna S, 2008, CANCER RES, V68, P537, DOI 10.1158/0008-5472.CAN-07-5682; Spaderna S, 2006, GASTROENTEROLOGY, V131, P830, DOI 10.1053/j.gastro.2006.06.016; Spoelstra NS, 2006, CANCER RES, V66, P3893, DOI 10.1158/0008-5472.CAN-05-2881; Thiele CJ, 2009, CLIN CANCER RES, V15, P5962, DOI 10.1158/1078-0432.CCR-08-0651; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Vandewalle C, 2009, CELL MOL LIFE SCI, V66, P773, DOI 10.1007/s00018-008-8465-8; Vesuna F, 2008, BIOCHEM BIOPH RES CO, V367, P235, DOI 10.1016/j.bbrc.2007.11.151; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yin T, 2007, J SURG RES, V141, P196, DOI 10.1016/j.jss.2006.09.027	57	67	68	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2011	30	35					3735	3744		10.1038/onc.2011.96	http://dx.doi.org/10.1038/onc.2011.96			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814TZ	21478908				2022-12-17	WOS:000294481400001
J	Gibert, B; Hadchity, E; Czekalla, A; Aloy, MT; Colas, P; Rodriguez-Lafrasse, C; Arrigo, AP; Diaz-Latoud, C				Gibert, B.; Hadchity, E.; Czekalla, A.; Aloy, M-T; Colas, P.; Rodriguez-Lafrasse, C.; Arrigo, A-P; Diaz-Latoud, C.			Inhibition of heat shock protein 27 (HspB1) tumorigenic functions by peptide aptamers	ONCOGENE			English	Article						Hsp27; HspB1; peptide aptamers; proliferation; apoptosis; therapeutic target	INDUCED APOPTOSIS; TUMOR-CELLS; AKT ACTIVATION; CYTOCHROME-C; IN-VITRO; HSP27; CANCER; STRESS; ALPHA; OLIGOMERIZATION	Human heat shock protein 27 (Hsp27, HspB1) is an antiapoptotic protein characterized for its tumorigenic and metastatic properties, and now referenced as a major therapeutic target in many types of cancer. Hsp27 biochemical properties rely on a structural oligomeric and dynamic organization. Downregulation by small interfering RNA or inhibition with dominant-negative mutant have proven their efficiency to counteract the antiapoptotic and protective properties of Hsp27. In this study, we report the isolation and characterization of Hsp27-targeted molecules interfering with its structural organization. Using the peptide aptamer (PA) strategy, we isolated PAs that specifically interact with Hsp27 and not with the other members of the small heat shock protein family. In mammalian cell cultures, PAs expression perturbed the dimerization and oligomerization of Hsp27, and acted as negative regulators of the antiapoptotic and cytoprotective activities of this protein. Further studies analyzing SQ20B cell xenografts in immunocompromised mice showed that PAs strongly reduced tumor development through cell cycle arrest. Our data suggest that PAs could provide a potential tool to develop strategies for the discovery of Hsp27 chemical inhibitors. Oncogene (2011) 30, 3672-3681; doi:10.1038/onc.2011.73;published online 21 March 2011	[Gibert, B.; Czekalla, A.; Arrigo, A-P; Diaz-Latoud, C.] Univ Lyon 1, Ctr Genet Mol & Cellulaire, CNRS, UMR5534, F-69365 Lyon, France; [Hadchity, E.; Aloy, M-T; Rodriguez-Lafrasse, C.] Univ Lyon 1, Lab Radiobiol Cellulaire & Mol, EA 3738, Fac Med Lyon Sud, Oullins, France; [Colas, P.] CNRS, Biol Stn, USR 3151, Roscoff, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB)	Diaz-Latoud, C (corresponding author), Univ Lyon 1, Ctr Genet Mol & Cellulaire, CNRS, UMR5534, 43,Bd 11 Novembre 1918, F-69365 Lyon, France.	chantal.diaz@univ-lyon1.fr	Rodriguez-Lafrasse, Claire/G-7741-2018	GIBERT, Benjamin/0000-0002-5295-3124; Colas, Pierre/0000-0001-7436-3718	Comite du Rhone of la Ligue Contre le Cancer; Region Rhone-Alpes and Retina France; La Region Rhone-Alpes	Comite du Rhone of la Ligue Contre le Cancer; Region Rhone-Alpes and Retina France(Region Auvergne-Rhone-Alpes); La Region Rhone-Alpes(Region Auvergne-Rhone-Alpes)	We wish to thank D Guillet for excellent technical assistance and Marc Bickle for helpful discussions. This work was supported by a research grant from the Comite du Rhone of la Ligue Contre le Cancer and the Region Rhone-Alpes and Retina France for APA. GB was supported by a PhD training grant from the La Region Rhone-Alpes.	Aloy MT, 2008, INT J RADIAT ONCOL, V70, P543, DOI 10.1016/j.ijrobp.2007.08.061; Arrigo AP, 2007, FEBS LETT, V581, P3665, DOI 10.1016/j.febslet.2007.04.033; Arrigo AP, 2005, ANTIOXID REDOX SIGN, V7, P414, DOI 10.1089/ars.2005.7.414; Baines IC, 2006, DRUG DISCOV TODAY, V11, P334, DOI 10.1016/j.drudis.2006.02.007; Bickle MBT, 2006, NAT PROTOC, V1, P1066, DOI 10.1038/nprot.2006.32; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Bruey JM, 2000, ONCOGENE, V19, P4855, DOI 10.1038/sj.onc.1203850; Buerger C, 2003, J BIOL CHEM, V278, P37610, DOI 10.1074/jbc.M301629200; Cervantes-Gomez F, 2009, CANCER RES, V69, P3947, DOI 10.1158/0008-5472.CAN-08-4406; Charette SJ, 2000, ANN NY ACAD SCI, V926, P126; Chattopadhyay A, 2006, ONCOGENE, V25, P2223, DOI 10.1038/sj.onc.1209252; Ciocca DR, 2005, CELL STRESS CHAPERON, V10, P86, DOI 10.1379/CSC-99r.1; Diaz-Latoud C, 2005, ANTIOXID REDOX SIGN, V7, P436, DOI 10.1089/ars.2005.7.436; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; Gonin S, 1999, ONCOGENE, V18, P8011, DOI 10.1038/sj.onc.1203319; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hadchity E, 2009, MOL THER, V17, P1387, DOI 10.1038/mt.2009.90; Hansen RK, 1999, BREAST CANCER RES TR, V56, P187; Javouhey E, 2008, VIROLOGY, V376, P31, DOI 10.1016/j.virol.2008.02.031; Kim EH, 2007, CANCER RES, V67, P6333, DOI 10.1158/0008-5472.CAN-06-4344; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY J, 1992, J BIOL CHEM, V267, P794; Matsui Y, 2009, MOL CANCER THER, V8, P2402, DOI 10.1158/1535-7163.MCT-09-0148; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; MEHLEN P, 1993, EUR J BIOCHEM, V215, P277, DOI 10.1111/j.1432-1033.1993.tb18032.x; Mehlen P, 1997, BIOCHEM BIOPH RES CO, V241, P187, DOI 10.1006/bbrc.1997.7635; Nouvion AL, 2007, ONCOGENE, V26, P701, DOI 10.1038/sj.onc.1209832; O'Callaghan-Sunol C, 2007, CANCER RES, V67, P11779, DOI 10.1158/0008-5472.CAN-07-2441; Pandey P, 2000, EMBO J, V19, P4310, DOI 10.1093/emboj/19.16.4310; Parcellier A, 2006, FASEB J, V20, P1179, DOI 10.1096/fj.05-4184fje; Paul C, 2010, EXP CELL RES, V316, P1535, DOI 10.1016/j.yexcr.2010.03.006; Rane MJ, 2003, J BIOL CHEM, V278, P27828, DOI 10.1074/jbc.M303417200; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; Zhang Y, 2007, CLIN CANCER RES, V13, P2855, DOI 10.1158/1078-0432.CCR-06-2090	35	67	69	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2011	30	34					3672	3681		10.1038/onc.2011.73	http://dx.doi.org/10.1038/onc.2011.73			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	21423207				2022-12-17	WOS:000294244500003
J	Wu, YY; Peck, K; Chang, YL; Pan, SH; Cheng, YF; Lin, JC; Yang, RB; Hong, TM; Yang, PC				Wu, Y-Y; Peck, K.; Chang, Y-L; Pan, S-H; Cheng, Y-F; Lin, J-C; Yang, R-B; Hong, T-M; Yang, P-C			SCUBE3 is an endogenous TGF-beta receptor ligand and regulates the epithelial-mesenchymal transition in lung cancer	ONCOGENE			English	Article						SCUBE3; lung cancer; epithelial-mesenchymal transition; TGF-beta receptor signaling; tumor microenvironment	BREAST-CANCER; CUB DOMAIN; MATRIX-METALLOPROTEINASES; CLINICAL-SIGNIFICANCE; TRANSCRIPTION FACTORS; TUMOR PROGRESSION; REPRESSOR SNAIL; E-CADHERIN; INVASION; GROWTH	Signal peptide-CUB-EGF-like domain-containing protein 3 (SCUBE3) is a secreted glycoprotein that is overexpressed in lung cancer tumor tissues and is correlated with the invasive ability in a lung cancer cell line model. These observations suggest that SCUBE3 may have a role in lung cancer progression. By exogenous SCUBE3 treatment or knockdown of SCUBE3 expression, we found that SCUBE3 could promote lung cancer cell mobility and invasiveness. Knockdown of SCUBE3 expression also suppressed tumorigenesis and cancer metastasis in vivo. The secreted SCUBE3 proteins were cleaved by gelatinases (matrix metalloprotease-2 (MMP-2) and MMP-9) in media to release two major fragments: the N-terminal epidermal growth factor-like repeats and the C-terminal complement proteins C1r/C1s, Uegf and Bmp1 (CUB) domain. Both the purified SCUBE3 protein and the C-terminal CUB domain fragment, bound to transforming growth factor-beta (TGF-beta) type II receptor through the C-terminal CUB domain, activated TGF-beta signaling and triggered the epithelial-mesenchymal transition (EMT). This process includes the induction of Smad2/3 phosphorylation, the increase of Smad2/3 transcriptional activity and the upregulation of the expression of target genes involved in EMT and cancer progression (such as TGF-beta 1, MMP-2, MMP-9, plasminogen activator inhibitor type-1, vascular endothelial growth factor, Snail and Slug), thus promoting cancer cell mobility and invasion. In conclusion, in lung cancer cells, SCUBE3 could serve as an endogenous autocrine and paracrine ligand of TGF-beta type II receptor, which could regulate TGF-beta receptor signaling and modulate EMT and cancer progression. Oncogene (2011) 30, 3682-3693; doi:10.1038/onc.2011.85; published online 28 March 2011	[Yang, P-C] Natl Taiwan Univ, Dept Internal Med, Coll Med, NTU Ctr Genom Med, Taipei 100, Taiwan; [Wu, Y-Y] Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan; [Peck, K.; Pan, S-H; Cheng, Y-F; Yang, R-B; Yang, P-C] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan; [Chang, Y-L] Natl Taiwan Univ, Dept Pathol, Taipei 100, Taiwan; [Chang, Y-L] Natl Taiwan Univ, Grad Inst Pathol, Taipei 100, Taiwan; [Lin, J-C] Fu Jen Catholic Univ, Dept Resp Therapy, Taipei, Taiwan; [Hong, T-M] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan 704, Taiwan; [Hong, T-M] Natl Cheng Kung Univ, Coll Med, Inst Clin Med, Tainan 704, Taiwan; [Yang, P-C] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan	National Taiwan University; National Defense Medical Center; Academia Sinica - Taiwan; National Taiwan University; National Taiwan University; Fu Jen Catholic University; National Cheng Kung University; National Cheng Kung University; National Taiwan University; National Taiwan University Hospital	Yang, PC (corresponding author), Natl Taiwan Univ, Dept Internal Med, Coll Med, NTU Ctr Genom Med, 1,Sec 1,Ren Ai Rd, Taipei 100, Taiwan.	tmhong@mail.ncku.edu.tw; pcyang@ntu.edu.tw	Yang, Ruey-Bing/O-1494-2018	Yang, Ruey-Bing/0000-0003-3017-3714; Pan, Szu-Hua/0000-0002-0138-0434; CHANG, YIH-LEONG/0000-0001-5309-0554; YANG, PAN-CHYR/0000-0001-6330-6048	Academia Sinica [AS-97-FP-L16]; National Science Council, Taiwan [NSC98-2628-B-002-086-MY3, NSC97-2314-B-002-146-MY3]	Academia Sinica(Academia Sinica - Taiwan); National Science Council, Taiwan(Ministry of Science and Technology, Taiwan)	We thank Ker-Chau Li (Institute of Statistical Science, Academia Sinica) for providing EKVX and Hop62 cells and Shih-Han Kao for English language editing. This work was supported by Academia Sinica (Grant AS-97-FP-L16) and the National Science Council, Taiwan (Grants NSC98-2628-B-002-086-MY3 and NSC97-2314-B-002-146-MY3). shRNA constructs were obtained from the National RNAi Core Facility at the Institute of Molecular Biology/Genomic Research Center, Academia Sinica, Taipei, Taiwan. T-M H and P-C Y co-directed the project and contributed equally to this work.	Binder BR, 2008, IMMUNOL LETT, V118, P116, DOI 10.1016/j.imlet.2008.03.017; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; Dean RA, 2007, MOL CELL BIOL, V27, P8454, DOI 10.1128/MCB.00821-07; Elloul S, 2005, CANCER-AM CANCER SOC, V103, P1631, DOI 10.1002/cncr.20946; Feldmann G, 2007, CANCER RES, V67, P2187, DOI 10.1158/0008-5472.CAN-06-3281; Foekens JA, 2000, CANCER RES, V60, P636; Folgueras AR, 2004, INT J DEV BIOL, V48, P411, DOI 10.1387/ijdb.041811af; Gupta PB, 2005, NAT GENET, V37, P1047, DOI 10.1038/ng1634; Hawinkels LJAC, 2008, EUR J CANCER, V44, P1904, DOI 10.1016/j.ejca.2008.06.031; Haworth K, 2007, GENE EXPR PATTERNS, V7, P630, DOI 10.1016/j.modgep.2006.12.004; Hollborn M, 2007, INVEST OPHTH VIS SCI, V48, P4360, DOI 10.1167/iovs.06-1234; Hong TM, 2007, CLIN CANCER RES, V13, P4759, DOI 10.1158/1078-0432.CCR-07-0001; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Hundsdorfer B, 2004, Mund Kiefer Gesichtschir, V8, P173; Iniesta P, 2007, ONCOL REP, V17, P217; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; Kuhn W, 1999, BRIT J CANCER, V79, P1746, DOI 10.1038/sj.bjc.6690278; Lader AS, 2004, CANCER BIOL THER, V3, P624, DOI 10.4161/cbt.3.7.914; Leivonen SK, 2007, INT J CANCER, V121, P2119, DOI 10.1002/ijc.23113; Leong KG, 2007, J EXP MED, V204, P2935, DOI 10.1084/jem.20071082; Martin TA, 2005, ANN SURG ONCOL, V12, P488, DOI 10.1245/ASO.2005.04.010; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Providence KM, 2004, J CELL PHYSIOL, V200, P297, DOI 10.1002/jcp.20016; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; Reichenberger F, 2001, SWISS MED WKLY, V131, P273; Roy HK, 2005, DIGEST DIS SCI, V50, P42, DOI 10.1007/s10620-005-1275-z; Shih JY, 2005, CLIN CANCER RES, V11, P8070, DOI 10.1158/1078-0432.CCR-05-0687; Shioiri M, 2006, BRIT J CANCER, V94, P1816, DOI 10.1038/sj.bjc.6603193; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Stefansson S, 2003, CURR PHARM DESIGN, V9, P1545, DOI 10.2174/1381612033454621; Timmerman LA, 2004, GENE DEV, V18, P99, DOI 10.1101/gad.276304; Valcourt U, 2005, MOL BIOL CELL, V16, P1987, DOI 10.1091/mbc.e04-08-0658; Wang SP, 2009, NAT CELL BIOL, V11, P694, DOI 10.1038/ncb1875; Werle B, 2004, ANTICANCER RES, V24, P4147; Wu BT, 2004, J BIOL CHEM, V279, P37485, DOI 10.1074/jbc.M405912200; Yang HY, 2007, CARDIOVASC RES, V75, P139, DOI 10.1016/j.cardiores.2007.03.014; Yook JI, 2005, J BIOL CHEM, V280, P11740, DOI 10.1074/jbc.M413878200; Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508; Yu Q, 2000, GENE DEV, V14, P163; Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328	44	67	70	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2011	30	34					3682	3693		10.1038/onc.2011.85	http://dx.doi.org/10.1038/onc.2011.85			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	21441952				2022-12-17	WOS:000294244500004
J	Grandinetti, KB; Stevens, TA; Ha, S; Salamone, RJ; Walker, JR; Zhang, J; Agarwalla, S; Tenen, DG; Peters, EC; Reddy, VA				Grandinetti, K. B.; Stevens, T. A.; Ha, S.; Salamone, R. J.; Walker, J. R.; Zhang, J.; Agarwalla, S.; Tenen, D. G.; Peters, E. C.; Reddy, V. A.			Overexpression of TRIB2 in human lung cancers contributes to tumorigenesis through downregulation of C/EBP alpha	ONCOGENE			English	Article						tribbles; lung; C/EBP alpha; TRIM21	STEM-CELLS; PROSPECTIVE IDENTIFICATION; TRIBBLES; MORPHOGENESIS; DIFFERENTIATION; PROLIFERATION; DEGRADATION; EXPRESSION; DROSOPHILA; PROTEINS	Lung cancer is the most common cause of cancer-related mortality worldwide. Here, we report elevated expression of tribbles homolog 2 (TRIB2) in primary human lung tumors and in non-small cell lung cancer cells that express low levels of differentiation-inducing transcription factor CCAAT/enhancer-binding protein alpha (C/EBP alpha). In approximately 10-20% of cases, elevated TRIB2 expression resulted from gene amplification. TRIB2 knockdown was found to inhibit cell proliferation and in vivo tumor growth. In addition, TRIB2 knockdown led to morphological changes similar to C/EBP alpha overexpression and correlated with increased expression and activity of C/EBP alpha. TRIB2-mediated regulation of C/EBP alpha was found to occur through the association of TRIB2 with the E3 ligase TRIM21. Together, these data identify TRIB2 as a potential driver of lung tumorigenesis through a mechanism that involves downregulation of C/EBP alpha. Oncogene (2011) 30, 3328-3335; doi:10.1038/onc.2011.57; published online 14 March 2011	[Grandinetti, K. B.; Stevens, T. A.; Ha, S.; Salamone, R. J.; Walker, J. R.; Zhang, J.; Agarwalla, S.; Peters, E. C.; Reddy, V. A.] Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA; [Grandinetti, K. B.] Scripps Res Inst, San Diego, CA USA; [Tenen, D. G.] Natl Univ Singapore, Canc Sci Inst, Singapore, Singapore; [Tenen, D. G.] Harvard Stem Cell Inst, Ctr Life Sci, Boston, MA USA	Novartis; Scripps Research Institute; National University of Singapore; Harvard University	Grandinetti, KB (corresponding author), Novartis Res Fdn, Genom Inst, 10675 John Jay Hopkins Dr, San Diego, CA 92121 USA.	bgrandinetti@gnf.org	Peters, Eric/W-2739-2019	Tenen, Daniel/0000-0002-6423-3888	NIH [HL56745, CA90578]; NATIONAL CANCER INSTITUTE [P50CA090578, P20CA090578] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056745] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by grants from the NIH (HL56745 and CA90578) to DGT.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bapat SA, 2005, CANCER RES, V65, P3025, DOI 10.1158/0008-5472.CAN-04-3931; Behre G, 2002, J BIOL CHEM, V277, P26293, DOI 10.1074/jbc.M202301200; Cassel TN, 2003, AM J PHYSIOL-LUNG C, V285, pL773, DOI 10.1152/ajplung.00023.2003; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Costa DB, 2007, LUNG CANCER, V56, P97, DOI 10.1016/j.lungcan.2006.11.023; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Dedhia PH, 2010, BLOOD, V116, P1321, DOI 10.1182/blood-2009-07-229450; Durkin SG, 2007, ANNU REV GENET, V41, P169, DOI 10.1146/annurev.genet.41.042007.165900; Eramo A, 2008, CELL DEATH DIFFER, V15, P504, DOI 10.1038/sj.cdd.4402283; Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343; Flodby P, 1996, J BIOL CHEM, V271, P24753, DOI 10.1074/jbc.271.40.24753; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Grosshans J, 2000, CELL, V101, P523, DOI 10.1016/S0092-8674(00)80862-4; Halmos B, 2002, CANCER RES, V62, P528; Hegedus Z, 2007, CELL SIGNAL, V19, P238, DOI 10.1016/j.cellsig.2006.06.010; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Keeshan K, 2006, CANCER CELL, V10, P401, DOI 10.1016/j.ccr.2006.09.012; Keeshan K, 2010, BLOOD, V116, P4948, DOI 10.1182/blood-2009-10-247361; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Koschmieder S, 2009, J CLIN ONCOL, V27, P619, DOI 10.1200/JCO.2008.17.9812; Maddika S, 2009, NAT CELL BIOL, V11, P409, DOI 10.1038/ncb1848; Mata J, 2000, CELL, V101, P511, DOI 10.1016/S0092-8674(00)80861-2; Naiki T, 2007, J BIOL CHEM, V282, P24075, DOI 10.1074/jbc.M701409200; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; Pan H, 2008, J IMMUNOL METHODS, V329, P31, DOI 10.1016/j.jim.2007.09.009; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Sabile A, 2006, MOL CELL BIOL, V26, P5994, DOI 10.1128/MCB.01630-05; Schatton T, 2008, NATURE, V451, P345, DOI 10.1038/nature06489; Seher TC, 2000, CURR BIOL, V10, P623, DOI 10.1016/S0960-9822(00)00502-9; Singh SK, 2003, CANCER RES, V63, P5821; Smith LT, 1996, BLOOD, V88, P1234, DOI 10.1182/blood.V88.4.1234.bloodjournal8841234; TIMCHENKO N, 1995, MOL CELL BIOL, V15, P1192; Todaro M, 2007, CELL STEM CELL, V1, P389, DOI 10.1016/j.stem.2007.08.001; Wada K, 2006, BIOCHEM BIOPH RES CO, V339, P415, DOI 10.1016/j.bbrc.2005.11.029; Wada K, 2009, J BIOCHEM, V146, P821, DOI 10.1093/jb/mvp127; Yoshimi R, 2009, J IMMUNOL, V182, P7527, DOI 10.4049/jimmunol.0804121; Zanella F, 2010, ONCOGENE, V29, P2973, DOI 10.1038/onc.2010.58	41	67	71	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2011	30	30					3328	3335		10.1038/onc.2011.57	http://dx.doi.org/10.1038/onc.2011.57			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	798NO	21399661	Green Accepted			2022-12-17	WOS:000293215700003
J	Thurber, AE; Douglas, G; Sturm, EC; Zabierowski, SE; Smit, DJ; Ramakrishnan, SN; Hacker, E; Leonard, JH; Herlyn, M; Sturm, RA				Thurber, A. E.; Douglas, G.; Sturm, E. C.; Zabierowski, S. E.; Smit, D. J.; Ramakrishnan, S. N.; Hacker, E.; Leonard, J. H.; Herlyn, M.; Sturm, R. A.			Inverse expression states of the BRN2 and MITF transcription factors in melanoma spheres and tumour xenografts regulate the NOTCH pathway	ONCOGENE			English	Article						cell adhesion; invasion; melanoma; metastasis; NOTCH; transcription factor	EPITHELIAL-MESENCHYMAL TRANSITION; HUMAN MELANOCYTES; STEM-CELLS; IN-VITRO; PHENOTYPE; GENE; SUBPOPULATION; SIGNATURE; REVEALS; PROGRAM	The use of adherent monolayer cultures have produced many insights into melanoma cell growth and differentiation, but often novel therapeutics demonstrated to act on these cells are not active in vivo. It is imperative that new methods of growing melanoma cells that reflect growth in vivo are investigated. To this end, a range of human melanoma cell lines passaged as adherent cultures or induced to form melanoma spheres (melanospheres) in stem cell media have been studied to compare cellular characteristics and protein expression. Melanoma spheres and tumours grown from cell lines as mouse xenografts had increased heterogeneity when compared with adherent cells and 3D-spheroids in agar (aggregates). Furthermore, cells within the melanoma spheres and mouse xenografts each displayed a high level of reciprocal BRN2 or MITF expression, which matched more closely the pattern seen in human melanoma tumours in situ, rather than the propensity for co-expression of these important melanocytic transcription factors seen in adherent cells and 3D-spheroids. Notably, when the levels of the BRN2 and MITF proteins were each independently repressed using siRNA treatment of adherent melanoma cells, members of the NOTCH pathway responded by decreasing or increasing expression, respectively. This links BRN2 as an activator, and conversely, MITF as a repressor of the NOTCH pathway in melanoma cells. Loss of the BRN2-MITF axis in antisense-ablated cell lines decreased the melanoma sphere-forming capability, cell adhesion during 3D-spheroid formation and invasion through a collagen matrix. Combined, this evidence suggests that the melanoma sphere-culture system induces subpopulations of cells that may more accurately portray the in vivo disease, than the growth as adherent melanoma cells. Oncogene (2011) 30, 3036-3048; doi: 10.1038/onc.2011.33; published online 28 February 2011	[Thurber, A. E.; Douglas, G.; Sturm, E. C.; Smit, D. J.; Ramakrishnan, S. N.; Sturm, R. A.] Univ Queensland, Inst Mol Biosci, Melanogenix Grp, Brisbane, Qld 4072, Australia; [Zabierowski, S. E.; Herlyn, M.; Sturm, R. A.] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; [Hacker, E.; Leonard, J. H.] Queensland Inst Med Res, Brisbane, Qld 4006, Australia	University of Queensland; The Wistar Institute; QIMR Berghofer Medical Research Institute	Sturm, RA (corresponding author), Univ Queensland, Inst Mol Biosci, Melanogenix Grp, 306 Carmody Rd, Brisbane, Qld 4072, Australia.	R.Sturm@imb.uq.edu.au	Sturm, Richard A/C-9943-2009; Hacker, Elke/J-1265-2012; Leonard, Helen/F-2022-2013	Sturm, Richard A/0000-0003-1301-0294; Hacker, Elke/0000-0003-2759-8244; SMIT, Darren/0000-0002-3288-3659	University of Queensland; Cancer Council Queensland; NIH [CA-25874]; NATIONAL CANCER INSTITUTE [P01CA025874] Funding Source: NIH RePORTER	University of Queensland(University of Queensland); Cancer Council Queensland(Cancer Council Queensland); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Professor N Hayward (QIMR) for providing some of the cell lines that were tested for melanoma sphere formation as part of this manuscript. RAS is a Senior Research Fellow of the Australian NHMRC, and in conducting part of this work, was supported by an SSP award from the University of Queensland. This work was supported by grants from the Cancer Council Queensland to RAS and JHL and NIH grant CA-25874 to MH.	Alonso SR, 2007, CANCER RES, V67, P3450, DOI 10.1158/0008-5472.CAN-06-3481; ANGUS J, 1995, ONCOGENE, V11, P691; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Castro DS, 2006, DEV CELL, V11, P831, DOI 10.1016/j.devcel.2006.10.006; Cheli Y, 2010, PIGM CELL MELANOMA R, V23, P27, DOI 10.1111/j.1755-148X.2009.00653.x; Cook AL, 2005, EXP CELL RES, V308, P222, DOI 10.1016/j.yexcr.2005.04.019; Cook AL, 2003, J INVEST DERMATOL, V121, P1150, DOI 10.1046/j.1523-1747.2003.12562.x; Cook AL, 2008, PIGM CELL MELANOMA R, V21, P611, DOI 10.1111/j.1755-148X.2008.00510.x; Cook AL, 2006, FROM MELANOCYTES TO MELANOMA: THE PROGRESSION TO MALIGNANCY, P149, DOI 10.1007/978-1-59259-994-3_8; Dodd IB, 2007, CELL, V129, P813, DOI 10.1016/j.cell.2007.02.053; Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343; Goodall J, 2008, CANCER RES, V68, P7788, DOI 10.1158/0008-5472.CAN-08-1053; Hendrix MJC, 2007, NAT REV CANCER, V7, P246, DOI 10.1038/nrc2108; Hoek KS, 2008, CANCER RES, V68, P650, DOI 10.1158/0008-5472.CAN-07-2491; Hoek KS, 2010, PIGM CELL MELANOMA R, V23, P746, DOI 10.1111/j.1755-148X.2010.00757.x; HOUGHTON AN, 1987, J EXP MED, V165, P812, DOI 10.1084/jem.165.3.812; Johansson P, 2007, PIGM CELL RES, V20, P216, DOI 10.1111/j.1600-0749.2007.00375.x; Kobi D, 2010, PIGM CELL MELANOMA R, V23, P404, DOI 10.1111/j.1755-148X.2010.00697.x; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Miller AJ, 2006, NEW ENGL J MED, V355, P51, DOI 10.1056/NEJMra052166; Mouriaux F, 2003, EXP EYE RES, V76, P653, DOI 10.1016/S0014-4835(03)00082-4; Na YR, 2009, TUMOR BIOL, V30, P300, DOI 10.1159/000261073; Na YR, 2009, CANCER SCI, V100, P1429, DOI 10.1111/j.1349-7006.2009.01218.x; Newton RA, 2007, J INVEST DERMATOL, V127, P2216, DOI 10.1038/sj.jid.5700840; Ohsie SJ, 2008, J CUTAN PATHOL, V35, P433, DOI 10.1111/j.1600-0560.2007.00891.x; Pavey S, 2004, ONCOGENE, V23, P4060, DOI 10.1038/sj.onc.1207563; Perego M, 2010, J INVEST DERMATOL, V130, P1877, DOI 10.1038/jid.2010.69; Pinner S, 2009, CANCER RES, V69, P7969, DOI 10.1158/0008-5472.CAN-09-0781; Pinnix CC, 2007, PIGM CELL RES, V20, P458, DOI 10.1111/j.1600-0749.2007.00410.x; Pinnix CC, 2009, CANCER RES, V69, P5312, DOI 10.1158/0008-5472.CAN-08-3767; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Richmond-Sinclair NM, 2008, MELANOMA RES, V18, P336, DOI 10.1097/CMR.0b013e32830d8329; Schatton T, 2008, NATURE, V451, P345, DOI 10.1038/nature06489; Smalley KSM, 2006, MOL CANCER THER, V5, P1136, DOI 10.1158/1535-7163.MCT-06-0084; Smit DJ, 2007, INT J CANCER, V121, P2653, DOI 10.1002/ijc.23039; Smith AG, 1998, MELANOMA RES, V8, P2, DOI 10.1097/00008390-199802000-00002	36	67	68	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2011	30	27					3036	3048		10.1038/onc.2011.33	http://dx.doi.org/10.1038/onc.2011.33			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	789IW	21358674	Green Accepted, Green Submitted			2022-12-17	WOS:000292510100004
J	Lanigan, F; Geraghty, JG; Bracken, AP				Lanigan, F.; Geraghty, J. G.; Bracken, A. P.			Transcriptional regulation of cellular senescence	ONCOGENE			English	Review						cellular senescence; transcription; cancer therapy	ONCOGENE-INDUCED SENESCENCE; INK4A TUMOR-SUPPRESSOR; DEMETHYLASE JMJD3 CONTRIBUTES; INDUCED PREMATURE SENESCENCE; E2F TARGET GENES; HISTONE DEACETYLASE; RETINOBLASTOMA PROTEIN; HUMAN FIBROBLASTS; CANCER-THERAPY; IN-VIVO	Cellular senescence is an irreversible arrest of proliferation. It is activated when a cell encounters stress such as DNA damage, telomere shortening or oncogene activation. Like apoptosis, it impedes tumour progression and acts as a barrier that pre-neoplastic cells must overcome during their evolution toward the full tumourigenic state. This review focuses on the role of transcriptional regulators in the control of cellular senescence, explores how their function is perturbed in cancer and discusses the potential to harness this knowledge for future cancer therapies. Oncogene (2011) 30, 2901-2911; doi:10.1038/onc.2011.34; published online 7 March 2011	[Lanigan, F.; Bracken, A. P.] Trinity Coll Dublin, Smurfit Genet Dept, Smurfit Inst Genet, Dublin 2, Ireland; [Bracken, A. P.] Natl Childrens Hosp, Adelaide & Meath Hosp, Dublin, Ireland; [Geraghty, J. G.] Univ Coll Dublin, St Vincents Hosp, Dept Breast & Endocrine Surg, Dublin 2, Ireland	Trinity College Dublin; Trinity College Dublin; University College Dublin	Bracken, AP (corresponding author), Trinity Coll Dublin, Smurfit Genet Dept, Smurfit Inst Genet, Lincoln Pl, Dublin 2, Ireland.	adrian.bracken@tcd.ie		Bracken, Adrian/0000-0002-1547-9443	Science Foundation Ireland [SFI PICA SFI/10/IN.1/B3002]; Health Research Board [HRA_POR/2010/124]; Irish Research Council for Science, Engineering and Technology (IRCSET)	Science Foundation Ireland(Science Foundation IrelandEuropean Commission); Health Research Board; Irish Research Council for Science, Engineering and Technology (IRCSET)(Irish Research Council for Science, Engineering and Technology)	We thank Eros Lazzerini and Jean-Christophe Marine for critical reading of the manuscript. Work in the Bracken Lab is supported by Science Foundation Ireland under the Principal Investigator Career Advancement Award (SFI PICA SFI/10/IN.1/B3002), the Health Research Board under the Health Research Awards 2010 (HRA_POR/2010/124), and the Irish Research Council for Science, Engineering and Technology (IRCSET).	Agger K, 2009, GENE DEV, V23, P1171, DOI 10.1101/gad.510809; Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398; Aslanian A, 2004, GENE DEV, V18, P1413, DOI 10.1101/gad.1196704; Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180; Bachmann IM, 2008, MODERN PATHOL, V21, P583, DOI 10.1038/modpathol.2008.17; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Barradas M, 2009, GENE DEV, V23, P1177, DOI 10.1101/gad.511109; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bea S, 2001, CANCER RES, V61, P2409; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bennecke M, 2010, CANCER CELL, V18, P135, DOI 10.1016/j.ccr.2010.06.013; Bishop CL, 2010, MOL CELL, V40, P533, DOI 10.1016/j.molcel.2010.10.027; Blais A, 2007, CURR OPIN CELL BIOL, V19, P658, DOI 10.1016/j.ceb.2007.10.003; Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507; Bracken AP, 2009, NAT REV CANCER, V9, P773, DOI 10.1038/nrc2736; Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; Call JA, 2008, LANCET ONCOL, V9, P1002, DOI 10.1016/S1470-2045(08)70209-2; Calses C, 2008, MOL CELL BIOL, V28, P1018, DOI 10.1128/MCB.01136-07; Carragher LAS, 2010, EMBO MOL MED, V2, P458, DOI 10.1002/emmm.201000099; Chen HA, 2009, GENE DEV, V23, P975, DOI 10.1101/gad.1742509; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Chicas A, 2010, CANCER CELL, V17, P376, DOI 10.1016/j.ccr.2010.01.023; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Classon M, 2000, P NATL ACAD SCI USA, V97, P10820, DOI 10.1073/pnas.190343497; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Collado M, 2006, NAT REV CANCER, V6, P472, DOI 10.1038/nrc1884; Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; del Arroyo AG, 2007, CELL CYCLE, V6, P2697; Denchi EL, 2005, MOL CELL BIOL, V25, P2660, DOI 10.1128/MCB.25.7.2660-2672.2005; Dietrich N, 2007, EMBO J, V26, P1637, DOI 10.1038/sj.emboj.7601632; Engelsen IB, 2008, BRIT J CANCER, V98, P1662, DOI 10.1038/sj.bjc.6604360; Ernst T, 2010, NAT GENET, V42, P722, DOI 10.1038/ng.621; Esteller M, 2001, CANCER RES, V61, P3225; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748; Feldser DM, 2010, NATURE, V468, P572, DOI 10.1038/nature09535; Fiskus W, 2009, BLOOD, V114, P2733, DOI 10.1182/blood-2009-03-213496; Fujita K, 2009, NAT CELL BIOL, V11, P1135, DOI 10.1038/ncb1928; Gil J, 2004, NAT CELL BIOL, V6, P67, DOI 10.1038/ncb1077; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; Gore SD, 2006, CANCER RES, V66, P6361, DOI 10.1158/0008-5472.CAN-06-0080; Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Haugstetter AM, 2010, BRIT J CANCER, V103, P505, DOI 10.1038/sj.bjc.6605784; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hayden A, 2011, BREAST CANCER RES TR, V127, P109, DOI 10.1007/s10549-010-0982-0; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Holst CR, 2003, CANCER RES, V63, P1596; Irelan JT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005067; Itahana K, 2003, MOL CELL BIOL, V23, P389, DOI 10.1128/MCB.23.1.389-401.2003; Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Junttila MR, 2010, NATURE, V468, P567, DOI 10.1038/nature09526; Karamitopoulou E, 2010, EUR J CANCER, V46, P1438, DOI 10.1016/j.ejca.2010.01.033; Khalil AM, 2009, P NATL ACAD SCI USA, V106, P11667, DOI 10.1073/pnas.0904715106; Kia SK, 2008, MOL CELL BIOL, V28, P3457, DOI 10.1128/MCB.02019-07; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Komori H, 2005, EMBO J, V24, P3724, DOI 10.1038/sj.emboj.7600836; Koontz JI, 2001, P NATL ACAD SCI USA, V98, P6348, DOI 10.1073/pnas.101132598; Kortlever RM, 2006, NAT CELL BIOL, V8, P877, DOI 10.1038/ncb1448; Kotake Y, 2007, GENE DEV, V21, P49, DOI 10.1101/gad.1499407; Kotake Y, 2009, CANCER RES, V69, P1809, DOI 10.1158/0008-5472.CAN-08-2739; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Kumamoto K, 2008, CANCER RES, V68, P3193, DOI 10.1158/0008-5472.CAN-07-2780; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li H, 2010, ONCOGENE, V29, P5083, DOI 10.1038/onc.2010.252; Liu Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005027; Loercher AE, 2005, J CELL BIOL, V168, P35, DOI 10.1083/jcb.200410115; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Maertens GN, 2010, EMBO J, V29, P2553, DOI 10.1038/emboj.2010.129; Maertens GN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006380; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Majumder PK, 2008, CANCER CELL, V14, P146, DOI 10.1016/j.ccr.2008.06.002; Martin-Perez D, 2010, AM J PATHOL, V177, P930, DOI 10.2353/ajpath.2010.090769; Matheu A, 2005, J BIOL CHEM, V280, P42433, DOI 10.1074/jbc.M508270200; Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MESSAOUDIAUBERT SE, 2010, NAT STRUCT MOL BIOL, V17, P862, DOI DOI 10.1038/NSMB.1824; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Moellering RE, 2009, NATURE, V462, P182, DOI 10.1038/nature08543; Mohammad HP, 2009, CANCER RES, V69, P6322, DOI 10.1158/0008-5472.CAN-09-0065; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Monahan KB, 2010, ONCOGENE, V29, P5809, DOI 10.1038/onc.2010.314; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Mroz EA, 2008, CANCER RES, V68, P6049, DOI 10.1158/0008-5472.CAN-08-1279; Muller J, 2009, CURR OPIN GENET DEV, V19, P150, DOI 10.1016/j.gde.2009.03.001; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Narita M, 2005, NAT MED, V11, P920, DOI 10.1038/nm0905-920; Narita M, 2006, CELL, V126, P503, DOI 10.1016/j.cell.2006.05.052; Negishi M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012373; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Pallante P, 2008, CANCER RES, V68, P6770, DOI 10.1158/0008-5472.CAN-08-0695; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Pasmant E, 2007, CANCER RES, V67, P3963, DOI 10.1158/0008-5472.CAN-06-2004; Puppe J, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2354; QUELLE DE, 1995, CELL, V83, P993; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Reed JC, 2006, NAT CLIN PRACT ONCOL, V3, P388, DOI 10.1038/ncponc0538; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002; Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Schmitt CA, 2007, BBA-REV CANCER, V1775, P5, DOI 10.1016/j.bbcan.2006.08.005; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 2001, CURR OPIN CELL BIOL, V13, P748, DOI 10.1016/S0955-0674(00)00278-7; Shay JW, 2004, ONCOGENE, V23, P2919, DOI 10.1038/sj.onc.1207518; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Simon JA, 2009, NAT REV MOL CELL BIO, V10, P697, DOI 10.1038/nrm2763; Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991; Swarbrick A, 2008, P NATL ACAD SCI USA, V105, P5402, DOI 10.1073/pnas.0801505105; Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107; Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312; te Poele RH, 2002, CANCER RES, V62, P1876; Timmermann S, 1998, ONCOGENE, V17, P3445, DOI 10.1038/sj.onc.1202244; Vandel L, 2001, MOL CELL BIOL, V21, P6484, DOI 10.1128/MCB.21.19.6484-6494.2001; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Voorhoeve PM, 2003, CANCER CELL, V4, P311, DOI 10.1016/S1535-6108(03)00223-X; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wahlestedt C, 2006, DRUG DISCOV TODAY, V11, P503, DOI 10.1016/j.drudis.2006.04.013; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Yamaguchi J, 2010, CANCER SCI, V101, P355, DOI 10.1111/j.1349-7006.2009.01387.x; Yap KL, 2010, MOL CELL, V38, P662, DOI 10.1016/j.molcel.2010.03.021; Zhang RG, 2005, DEV CELL, V8, P19, DOI 10.1016/j.devcel.2004.10.019; Zhang XW, 2006, MOL CELL BIOL, V26, P8252, DOI 10.1128/MCB.00604-06; Zhao J, 2010, MOL CELL, V40, P939, DOI 10.1016/j.molcel.2010.12.011	149	67	69	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	26					2901	2911		10.1038/onc.2011.34	http://dx.doi.org/10.1038/onc.2011.34			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	785QZ	21383691				2022-12-17	WOS:000292245100001
J	Meng, L; Hunt, C; Yaglom, JA; Gabai, VL; Sherman, MY				Meng, L.; Hunt, C.; Yaglom, J. A.; Gabai, V. L.; Sherman, M. Y.			Heat shock protein Hsp72 plays an essential role in Her2-induced mammary tumorigenesis	ONCOGENE			English	Article						Hsp72; HER2; senescence; p21; survivin	NON-ONCOGENE ADDICTION; CANCER-CELLS; INDUCIBLE HEAT-SHOCK-PROTEIN-70; MOLECULAR CHAPERONES; SENESCENCE PATHWAYS; CARCINOMA-CELLS; STRESS; SUPPRESSION; PRINCIPLES; APOPTOSIS	The major heat shock protein Hsp72 is expressed at elevated levels in many human cancers and its expression correlates with tumor progression. Here, we investigated the role of Hsp72 in Her2 oncogene-induced neoplastic transformation and tumorigenesis. Expression of Her2 in untransformed MCF10A mammary epithelial cells caused transformation, as judged by foci formation in culture and tumorigenesis in xenografts. However, expression of Her2 in Hsp72-depleted cells failed to induce transformation. The anti-tumorigenic effects of Hsp72 downregulation were associated with cellular senescence because of accumulation of p21 and depletion of survivin. Accordingly, either knockdown of p21 or expression of survivin reversed this senescence process. Further, we developed an animal model of Hsp72-dependent breast cancer associated with expression of Her2. Knockout (KO) of Hsp72 almost completely suppressed tumorigenesis in the MMTVneu breast cancer mouse model. In young Hsp72 KO mice, expression of Her2 instead of mammary tissue hyperplasia led to suppression of duct development and blocked alveolar budding. These effects were due to massive cell senescence in mammary tissue, which was associated with upregulation of p21 and downregulation of survivin. Therefore, Hsp72 has an essential role in Her2-induced tumorigenesis by regulating oncogene-induced senescence pathways. Oncogene (2011) 30, 2836-2845; doi: 10.1038/onc.2011.5; published online 7 February 2011	[Meng, L.; Yaglom, J. A.; Gabai, V. L.; Sherman, M. Y.] Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; [Hunt, C.] Washington Univ, Dept Radiat Oncol, St Louis, MO USA	Boston University; Washington University (WUSTL)	Sherman, MY (corresponding author), Boston Univ, Sch Med, Dept Biochem, 72 E Concord St,K-323, Boston, MA 02118 USA.	gabai@bu.edu; sherma1@bu.edu	Gabai, Vladimir L/I-1650-2013	Gabai, Vladimir L/0000-0003-4505-4718; Sherman, Michael/0000-0003-3345-073X; Yaglom, Julia/0000-0002-8723-3506	National Institute of Health [CA081244]; NATIONAL CANCER INSTITUTE [R01CA081244] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the National Institute of Health CA081244. We thank Dr B Park and Dr C Spangenberg for their kind supply of MCF10A cells and HER2-overexpressing retroviral vector.	Akerfelt M, 2010, NAT REV MOL CELL BIO, V11, P545, DOI 10.1038/nrm2938; Altieri DC, 2008, NAT REV CANCER, V8, P61, DOI 10.1038/nrc2293; Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Calderwood SK, 2006, TRENDS BIOCHEM SCI, V31, P164, DOI 10.1016/j.tibs.2006.01.006; Ciocca DR, 2005, CELL STRESS CHAPERON, V10, P86, DOI 10.1379/CSC-99r.1; Dai C, 2007, CELL, V130, P1005, DOI 10.1016/j.cell.2007.07.020; Gabai VL, 2005, ONCOGENE, V24, P3328, DOI 10.1038/sj.onc.1208495; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; Gabai VL, 2009, MOL CELL BIOL, V29, P559, DOI 10.1128/MCB.01041-08; Hunt CR, 2004, MOL CELL BIOL, V24, P899, DOI 10.1128/MCB.24.2.899-911.2004; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Leu JIJ, 2009, MOL CELL, V36, P15, DOI 10.1016/j.molcel.2009.09.023; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Meng L, 2010, ONCOGENE, V29, P5204, DOI 10.1038/onc.2010.277; Min JN, 2007, ONCOGENE, V26, P5086, DOI 10.1038/sj.onc.1210317; Mooi WJ, 2006, NEW ENGL J MED, V355, P1037, DOI 10.1056/NEJMra062285; Mosser DD, 2004, ONCOGENE, V23, P2907, DOI 10.1038/sj.onc.1207529; Muller WJ, 1996, MOL CELL BIOL, V16, P5726; Powers MV, 2008, CANCER CELL, V14, P250, DOI 10.1016/j.ccr.2008.08.002; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Solimini NL, 2007, CELL, V130, P986, DOI 10.1016/j.cell.2007.09.007; Tang DL, 2007, J IMMUNOL, V179, P1236, DOI 10.4049/jimmunol.179.2.1236; Tao Y, 2009, CARCINOGENESIS, V30, P175, DOI 10.1093/carcin/bgn256; Trost TM, 2005, CANCER RES, V65, P840; Yaglom JA, 2007, CANCER RES, V67, P2373, DOI 10.1158/0008-5472.CAN-06-3796; Zaarur N, 2006, CANCER RES, V66, P1783, DOI 10.1158/0008-5472.CAN-05-3692	28	67	69	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2011	30	25					2836	2845		10.1038/onc.2011.5	http://dx.doi.org/10.1038/onc.2011.5			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	781ZV	21297664	Green Accepted			2022-12-17	WOS:000291977800004
J	White, RA; Malkoski, SP; Wang, XJ				White, R. A.; Malkoski, S. P.; Wang, X-J			TGF beta signaling in head and neck squamous cell carcinoma	ONCOGENE			English	Review						TGF beta; Smad; head and neck cancer	GROWTH-FACTOR-BETA; TUMOR-SUPPRESSOR GENE; II RECEPTOR GENE; DOWN-REGULATION; IMMUNE-RESPONSE; SKIN TUMORS; T-CELLS; CANCER; EXPRESSION; SMAD4	Transforming growth factor beta (TGF beta) is a key regulator of epithelial cell proliferation, immune function and angiogenesis. Because TGF beta signaling maintains epithelial homeostasis, dysregulated TGF beta signaling is common in many malignancies, including head and neck squamous cell carcinoma (HNSCC). Defective TGF beta signaling in epithelial cells causes hyperproliferation, reduced apoptosis and increased genomic instability, and the compensatory increase in TGF beta production by tumor epithelial cells with TGF beta signaling defects further promotes tumor growth and metastases by increasing angiogenesis and inflammation in tumor stromal cells. Here, we review the mouse models that we used to study TGF beta signaling in HNSCC. Oncogene (2010) 29, 5437-5446; doi:10.1038/onc.2010.306; published online 2 August 2010	[Wang, X-J] Univ Colorado Denver, Dept Pathol, Aurora, CO 80045 USA; [White, R. A.] Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA; [Malkoski, S. P.] Univ Colorado Denver, Div Pulm Sci & Crit Care Med, Dept Med, Aurora, CO 80045 USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Oregon Health & Science University; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Wang, XJ (corresponding author), Univ Colorado Denver, Dept Pathol, AMC 12800 E 19th Ave, Aurora, CO 80045 USA.	xj.wang@ucdenver.edu			NIH [CA87849, CA79998, DE15953, CA131483]; NATIONAL CANCER INSTITUTE [K08CA131483, R01CA087849, R01CA079998] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE015953] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank our laboratory members for their contributions and Pamela Garl for proofreading. Work from the Wang laboratory was supported by NIH grants CA87849, CA79998, DE15953 and CA131483.	Argiris A, 2008, LANCET, V371, P1695, DOI 10.1016/S0140-6736(08)60728-X; BALMAIN A, 1983, NATURE, V303, P72, DOI 10.1038/303072a0; Bardeesy N, 2006, GENE DEV, V20, P3130, DOI 10.1101/gad.1478706; Bertolino P, 2005, CHEST, V128, p585S, DOI 10.1378/chest.128.6_suppl.585S; Berton TR, 2003, ONCOGENE, V22, P5415, DOI 10.1038/sj.onc.1206825; Bharathy S, 2008, CANCER RES, V68, P1656, DOI 10.1158/0008-5472.CAN-07-5089; Bian YS, 2009, CANCER RES, V69, P5918, DOI 10.1158/0008-5472.CAN-08-4623; Bierie B, 2006, CYTOKINE GROWTH F R, V17, P29, DOI 10.1016/j.cytogfr.2005.09.006; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Bornstein S, 2009, J CLIN INVEST, V119, P3408, DOI 10.1172/JCI38854; Boucek J, 2010, J CELL MOL MED, V14, P426, DOI 10.1111/j.1582-4934.2008.00650.x; BYRNE C, 1994, DEVELOPMENT, V120, P2369; CHANG SE, 1991, INT J CANCER, V48, P409, DOI 10.1002/ijc.2910480318; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Chen TP, 2001, INT J CANCER, V93, P653, DOI 10.1002/ijc.1381; Cohen J, 2009, CANCER RES, V69, P3415, DOI 10.1158/0008-5472.CAN-08-3704; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Curado MP, 2009, CURR OPIN ONCOL, V21, P194, DOI 10.1097/CCO.0b013e32832a68ca; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Edwards BK, 2010, CANCER-AM CANCER SOC, V116, P544, DOI 10.1002/cncr.24760; Forastiere A, 2001, NEW ENGL J MED, V345, P1890, DOI 10.1056/NEJMra001375; Fukai Y, 2003, INT J CANCER, V104, P161, DOI 10.1002/ijc.10929; GARRIGUEANTAR L, 1995, CANCER RES, V55, P3982; Gomis RR, 2006, CANCER CELL, V10, P203, DOI 10.1016/j.ccr.2006.07.019; GRANDIS JR, 1993, CANCER RES, V53, P3579; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Guasch G, 2007, CANCER CELL, V12, P313, DOI 10.1016/j.ccr.2007.08.020; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HAWKINS BL, 1994, HEAD NECK-J SCI SPEC, V16, P424, DOI 10.1002/hed.2880160506; Hecht SS, 2003, NAT REV CANCER, V3, P733, DOI 10.1038/nrc1190; Honjo Y, 2007, CELL CYCLE, V6, P1360, DOI 10.4161/cc.6.11.4268; Hoot KE, 2008, J CLIN INVEST, V118, P2722, DOI 10.1172/JCI33713; Hunter KD, 2005, NAT REV CANCER, V5, P127, DOI 10.1038/nrc1549; Iamaroon Anak, 2006, J Oral Sci, V48, P105, DOI 10.2334/josnusd.48.105; Izeradjene K, 2007, CANCER CELL, V11, P229, DOI 10.1016/j.ccr.2007.01.017; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jonkers J, 2002, NAT REV CANCER, V2, P251, DOI 10.1038/nrc777; Junttila MR, 2007, CELL, V130, P51, DOI 10.1016/j.cell.2007.04.044; Kang SH, 1999, ONCOGENE, V18, P7280, DOI 10.1038/sj.onc.1203146; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Karamouzis MV, 2007, JAMA-J AM MED ASSOC, V298, P70, DOI 10.1001/jama.298.1.70; Kim BG, 2006, NATURE, V441, P1015, DOI 10.1038/nature04846; Kim SK, 1996, CANCER RES, V56, P2519; Kitamura T, 2007, NAT GENET, V39, P467, DOI 10.1038/ng1997; Kutler DI, 2003, ARCH OTOLARYNGOL, V129, P106, DOI 10.1001/archotol.129.1.106; Levy L, 2006, CYTOKINE GROWTH F R, V17, P41, DOI 10.1016/j.cytogfr.2005.09.009; Lewandoski M, 2001, NAT REV GENET, V2, P743, DOI 10.1038/35093537; Li AG, 2004, CANCER RES, V64, P7836, DOI 10.1158/0008-5472.CAN-04-1331; Li WM, 2003, DEVELOPMENT, V130, P6143, DOI 10.1242/dev.00820; Licitra L, 2006, J CLIN ONCOL, V24, P5630, DOI 10.1200/JCO.2005.04.6136; Liu IM, 2009, EMBO J, V28, P88, DOI 10.1038/emboj.2008.266; Lu SL, 2006, GENE DEV, V20, P1331, DOI 10.1101/gad.1413306; Lu SL, 2004, CANCER RES, V64, P4405, DOI 10.1158/0008-5472.CAN-04-1032; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; Mao L, 2004, CANCER CELL, V5, P311, DOI 10.1016/S1535-6108(04)00090-X; Marsit CJ, 2004, ONCOGENE, V23, P1000, DOI 10.1038/sj.onc.1207256; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; McCaul JA, 2002, LANCET ONCOL, V3, P280, DOI 10.1016/S1470-2045(02)00729-5; Moutsopoulos NM, 2008, CURR OPIN IMMUNOL, V20, P234, DOI 10.1016/j.coi.2008.04.003; Muro-Cacho CA, 1999, CLIN CANCER RES, V5, P1243; Muro-Cacho CA, 2001, CLIN CANCER RES, V7, P1618; Owens P, 2010, AM J PATHOL, V176, P122, DOI 10.2353/ajpath.2010.090081; Papadimitrakopoulou VA, 1998, CLIN CANCER RES, V4, P539; Pardali K, 2005, J CELL PHYSIOL, V204, P260, DOI 10.1002/jcp.20304; Pardali K, 2007, BBA-REV CANCER, V1775, P21, DOI 10.1016/j.bbcan.2006.06.004; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pearlstein RP, 1998, GENE CHROMOSOME CANC, V21, P333, DOI 10.1002/(SICI)1098-2264(199804)21:4<333::AID-GCC7>3.0.CO;2-#; Prime SS, 2001, ORAL ONCOL, V37, P1, DOI 10.1016/S1368-8375(00)00055-5; Qiao W, 2006, ONCOGENE, V25, P207, DOI 10.1038/sj.onc.1209029; SARANATH D, 1991, BRIT J CANCER, V63, P573, DOI 10.1038/bjc.1991.133; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; SHIN DM, 1994, CANCER RES, V54, P3153; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Snijders AM, 2005, ONCOGENE, V24, P4232, DOI 10.1038/sj.onc.1208601; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; Sorrentino A, 2008, NAT CELL BIOL, V10, P1199, DOI 10.1038/ncb1780; Sparano A, 2006, LARYNGOSCOPE, V116, P735, DOI 10.1097/01.mlg.0000205141.54471.7f; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Takebayashi S, 2000, CANCER RES, V60, P3397; Tannehill-Gregg SH, 2004, VET PATHOL, V41, P278, DOI 10.1354/vp.41-3-278; Teicher BA, 2007, CLIN CANCER RES, V13, P6247, DOI 10.1158/1078-0432.CCR-07-1654; Ten Dijke PT, 2002, J CELL PHYSIOL, V191, P1, DOI 10.1002/jcp.10066; Teng Y, 2006, CANCER RES, V66, P6972, DOI 10.1158/0008-5472.CAN-06-0507; van Oijen M G, 1998, Oral Dis, V4, P4; VANVLASSELAER P, 1992, J IMMUNOL, V148, P2062; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; Wang D, 1997, CARCINOGENESIS, V18, P2285, DOI 10.1093/carcin/18.11.2285; Wang J, 2008, CANCER RES, V68, P3152, DOI 10.1158/0008-5472.CAN-07-5348; Wang XM, 1997, P NATL ACAD SCI USA, V94, P219, DOI 10.1073/pnas.94.1.219; Weber F, 2007, JAMA-J AM MED ASSOC, V297, P187, DOI 10.1001/jama.297.2.187; Weeks BH, 2001, CANCER RES, V61, P7435; Worsham MJ, 2006, ARCH OTOLARYNGOL, V132, P668, DOI 10.1001/archotol.132.6.668; Wreesmann VB, 2007, ORL-J OTO-RHIN-LARYN, V69, P218, DOI 10.1159/000101542; Wrzesinski SH, 2007, CLIN CANCER RES, V13, P5262, DOI 10.1158/1078-0432.CCR-07-1157; Xie W, 2003, ONCOL RES, V14, P61, DOI 10.3727/000000003108748612; Xu XL, 2006, J CLIN INVEST, V116, P1843, DOI 10.1172/JCI27282; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504; Yamashita M, 2008, MOL CELL, V31, P918, DOI 10.1016/j.molcel.2008.09.002; Yanagisawa K, 1998, ONCOGENE, V17, P1743, DOI 10.1038/sj.onc.1202052; Yang LL, 2005, CANCER RES, V65, P8671, DOI 10.1158/0008-5472.CAN-05-0800; Yang X, 1998, P NATL ACAD SCI USA, V95, P3667, DOI 10.1073/pnas.95.7.3667; YUAN B, 1994, CANCER RES, V54, P5310; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zhang ST, 2006, CELL CYCLE, V5, P2787, DOI 10.4161/cc.5.23.3523; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328	110	67	67	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	40					5437	5446		10.1038/onc.2010.306	http://dx.doi.org/10.1038/onc.2010.306			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664FM	20676130	Green Accepted			2022-12-17	WOS:000282945800001
J	Zhang, Y; Jiang, X; Qin, X; Ye, D; Yi, Z; Liu, M; Bai, O; Liu, W; Xie, X; Wang, Z; Fang, J; Chen, Y				Zhang, Y.; Jiang, X.; Qin, X.; Ye, D.; Yi, Z.; Liu, M.; Bai, O.; Liu, W.; Xie, X.; Wang, Z.; Fang, J.; Chen, Y.			RKTG inhibits angiogenesis by suppressing MAPK-mediated autocrine VEGF signaling and is downregulated in clear-cell renal cell carcinoma	ONCOGENE			English	Article						RKTG; ccRCC; angiogenesis; VEGF; HIF-1 alpha; p300	ENDOTHELIAL-GROWTH-FACTOR; HYPOXIA-INDUCIBLE FACTORS; FACTOR GENE; PROTEIN; RAF; IDENTIFICATION; TRANSDUCTION; EXPRESSION; PHOSPHORYLATION; STABILIZATION	Vascular endothelial growth factors (VEGFs) are crucial regulators of angiogenesis and vasculogenesis. The autocrine VEGF signaling is required for maintaining the homeostasis of vasculature. Dysregulation of angiogenesis is implicated in the development of many human cancers, especially in clear-cell renal cell carcinoma (ccRCC), a highly vascularized tumor. Meanwhile, antiangiogenesis has become a mainstay in the treatment of human cancers. In this study, we analyzed the functional roles of RKTG (Raf Kinase Trapping to Golgi), a negative regulator of mitogen-activated protein kinase (Raf/MEK/ERK) signaling, by sequestration of Raf kinase to the Golgi apparatus, in angiogenesis and ccRCC. Through a series of in vitro and in vivo experiments, we found that RKTG has a negative effect on cell proliferation, migration, sprouting and angiogenesis of endothelial cells. RKTG, by suppressing mitogen-activated protein kinase signaling, negatively regulates the transactivation activity of hypoxia-inducible factor 1 alpha (HIF-1 alpha) by inhibiting formation of HIF-1 alpha/p300 complex and suppressing VEGF transcription, thereby reducing hypoxia-induced VEGF production. The expression level of RKTG is significantly downregulated in clinical ccRCC tumor samples, with an inverse correlation with VEGF expression level. These results highlight the functional roles of RKTG and its regulated Raf/ERK/MEK signaling cascade in angiogenesis and autocrine VEGF signaling. In addition, this study indicates that RKTG is likely implicated in the development of ccRCC through its regulation on angiogenesis. Oncogene (2010) 29, 5404-5415; doi: 10.1038/onc.2010.270; published online 5 July 2010	[Zhang, Y.; Jiang, X.; Liu, W.; Xie, X.; Wang, Z.; Fang, J.; Chen, Y.] Chinese Acad Sci, Grad Sch, Key Lab Nutr & Metab, Inst Nutr Sci,Shanghai Inst Biol Sci, Shanghai 200031, Peoples R China; [Qin, X.; Ye, D.] Fudan Univ, Ctr Canc, Dept Urol, Shanghai 200433, Peoples R China; [Yi, Z.; Liu, M.] E China Normal Univ, Inst Biomed Sci, Shanghai 200062, Peoples R China; [Yi, Z.; Liu, M.] E China Normal Univ, Sch Life Sci, Shanghai 200062, Peoples R China; [Bai, O.] Jilin Univ, Hosp 1, Changchun 130023, Jilin, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Fudan University; East China Normal University; East China Normal University; Jilin University	Chen, Y (corresponding author), Chinese Acad Sci, Grad Sch, Key Lab Nutr & Metab, Inst Nutr Sci,Shanghai Inst Biol Sci, 294 Taiyuan Rd,Rm307, Shanghai 200031, Peoples R China.	ychen3@sibs.ac.cn	xie, xiaoduo/B-8868-2012; Zhang, Yixuan/I-8007-2014	Zhang, Yixuan/0000-0001-7317-7235	Chinese Academy of Sciences [KSCX1-YW-02]; National Natural Science Foundation of China [30830037]; Ministry of Science and Technology of China [2007CB947100, 2006CB943900, 2010CB529506]	Chinese Academy of Sciences(Chinese Academy of Sciences); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology of China(Ministry of Science and Technology, China)	We thank Dr George Simons and Dr Ilias Mylonis (University of Thessaly, Greece) for providing the plasmid of full-length HIF-1 alpha fused to GST; Dr William E Carson III and Dr Gregory B Lesinski (Ohio State University, USA) for discussion about the CD31 immunohistochemistry experiment; Dr Young-Guen Kwon and Yong-Sun Maeng (Yonsei University, Korea) and Dr Morag Park and Caroline Saucier (McGill University Health Centre, Quebec, Canada) for discussion about the Matrigel plug assay experiment; Dr Luisa Iruela-Arispe and Dr Tom Chen (University of California, Los Angeles, USA) for providing the experimental protocols; and Dr Jurgen Seppen (Academic Medical Centre, Amsterdam, Netherlands) for discussion about the experiment with lentivirus. This work was supported by research grants from the Chinese Academy of Sciences (Knowledge Innovation Program KSCX1-YW-02), the National Natural Science Foundation of China (30830037) and the Ministry of Science and Technology of China (2007CB947100 and 2006CB943900) to YC. This work was also supported by the Ministry of Science and Technology of China (2010CB529506) to ZW.	Alavi A, 2003, SCIENCE, V301, P94, DOI 10.1126/science.1082015; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Dougher M, 1999, ONCOGENE, V18, P1619, DOI 10.1038/sj.onc.1202478; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655; Fan FJ, 2008, CARCINOGENESIS, V29, P1157, DOI 10.1093/carcin/bgn119; Feng L, 2007, P NATL ACAD SCI USA, V104, P14348, DOI 10.1073/pnas.0701298104; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Haas CS, 2006, ARTHRITIS RHEUM, V54, P2402, DOI 10.1002/art.22034; Hur E, 2001, MOL PHARMACOL, V59, P1216, DOI 10.1124/mol.59.5.1216; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Lee S, 2007, CELL, V130, P691, DOI 10.1016/j.cell.2007.06.054; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Lohela M, 2009, CURR OPIN CELL BIOL, V21, P154, DOI 10.1016/j.ceb.2008.12.012; Luo X, 2008, BIOCHEM J, V414, P399, DOI 10.1042/BJ20080948; Mack FA, 2003, CANCER CELL, V3, P75, DOI 10.1016/S1535-6108(02)00240-4; Matsumoto T, 2005, EMBO J, V24, P2342, DOI 10.1038/sj.emboj.7600709; Matsumoto T, 2006, J ATHEROSCLER THROMB, V13, P130, DOI 10.5551/jat.13.130; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Mylonis I, 2006, J BIOL CHEM, V281, P33095, DOI 10.1074/jbc.M605058200; Sang NL, 2003, J BIOL CHEM, V278, P14013, DOI 10.1074/jbc.M209702200; Srivastava RK, 2010, MOL CELL BIOCHEM, V337, P201, DOI 10.1007/s11010-009-0300-5; Tang N, 2004, CANCER CELL, V6, P485, DOI 10.1016/j.ccr.2004.09.026; Wakioka T, 2001, NATURE, V412, P647, DOI 10.1038/35088082; Wang GG, 2008, J UNIV SCI TECHNOL B, V15, P261, DOI 10.1016/S1005-8850(08)60049-3; Wilhelm S, 2006, NAT REV DRUG DISCOV, V5, P835, DOI 10.1038/nrd2130; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006; Xie XD, 2008, CARCINOGENESIS, V29, P1632, DOI 10.1093/carcin/bgn139; Yi T, 2008, CANCER RES, V68, P1843, DOI 10.1158/0008-5472.CAN-07-5944	39	67	69	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	39					5404	5415		10.1038/onc.2010.270	http://dx.doi.org/10.1038/onc.2010.270			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664EZ	20603618				2022-12-17	WOS:000282944500007
J	Hanker, AB; Mitin, N; Wilder, RS; Henske, EP; Tamanoi, F; Cox, AD; Der, CJ				Hanker, A. B.; Mitin, N.; Wilder, R. S.; Henske, E. P.; Tamanoi, F.; Cox, A. D.; Der, C. J.			Differential requirement of CAAX-mediated posttranslational processing for Rheb localization and signaling	ONCOGENE			English	Article						Rheb; mTOR; Ras converting enzyme 1 (Rce1); isoprenylcysteine carboxyl methyltransferase (Icmt); S-trans, trans-farnesylthiosalicylic acid (FTS)	TUBEROUS SCLEROSIS COMPLEX; BREAST-CANCER CELLS; FARNESYLTRANSFERASE INHIBITORS; FARNESYLTHIOSALICYLIC ACID; MAMMALIAN TARGET; MEMBRANE ASSOCIATION; FISSION YEAST; HUMAN-DISEASE; RHO GTPASES; ACTIVE RAS	The Rheb1 and Rheb2 small GTPases and their effector mTOR are aberrantly activated in human cancer and are attractive targets for anti-cancer drug discovery. Rheb is targeted to endomembranes via its C-terminal CAAX (C = cysteine, A = aliphatic, X = terminal amino acid) motif, a substrate for posttranslational modification by a farnesyl isoprenoid. After farnesylation, Rheb undergoes two additional CAAX-signaled processing steps, Ras converting enzyme 1 (Rce1)-catalyzed cleavage of the AAX residues and isoprenylcysteine carboxyl methyltransferase (Icmt)-mediated carboxylmethylation of the farnesylated cysteine. However, whether these postprenylation processing steps are required for Rheb signaling through mTOR is not known. We found that Rheb1 and Rheb2 localize primarily to the endoplasmic reticulum and Golgi apparatus. We determined that Icmt and Rce1 processing is required for Rheb localization, but is dispensable for Rheb-induced activation of the mTOR substrate p70 S6 kinase (S6K). Finally, we evaluated whether farnesylthiosalicylic acid (FTS) blocks Rheb localization and function. Surprisingly, FTS prevented S6K activation induced by a constitutively active mTOR mutant, indicating that FTS inhibits mTOR at a level downstream of Rheb. We conclude that inhibitors of Icmt and Rce1 will not block Rheb function, but FTS could be a promising treatment for Rheb- and mTOR-dependent cancers. Oncogene (2010) 29, 380-391; doi:10.1038/onc.2009.336; published online 19 October 2009	[Mitin, N.; Wilder, R. S.; Cox, A. D.; Der, C. J.] Univ N Carolina, Dept Pharmacol, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Hanker, A. B.; Cox, A. D.; Der, C. J.] Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; [Wilder, R. S.; Tamanoi, F.] Univ N Carolina, Dept Radiat Oncol, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Henske, E. P.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA USA; [Tamanoi, F.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90024 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Harvard University; Brigham & Women's Hospital; Harvard Medical School; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	Der, CJ (corresponding author), Univ N Carolina, Dept Pharmacol, Lineberger Comprehens Canc Ctr, 450 W Dr, Chapel Hill, NC 27599 USA.	cjder@med.unc.edu	Hanker, Ariella/M-7136-2019; Mitin, Natalia/E-8043-2012	Hanker, Ariella/0000-0002-8655-8341; Der, Channing/0000-0002-7751-2747; Cox, Adrienne D./0000-0002-4901-2454	National Institutes of Health [CA042978, CA109550, CA67771, CA41996]; Department of Defense Breast Cancer Research Program predoctoral fellowship [BC061107]; NATIONAL CANCER INSTITUTE [R01CA041996, R01CA109550, R01CA042978, U19CA067771] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense Breast Cancer Research Program predoctoral fellowship(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Yoel Kloog, Said Sebti, and Andrew Hamilton for inhibitors, Lawrence Quilliam and Mark Philips for providing plasmid constructs, Stephen Young for MEF cell lines deficient in Rce1 and Icmt, and the UNC Michael Hooker Microscopy Facility for imaging assistance. This research was supported by grants from the National Institutes of Health to CJD (CA042978), ADC (CA109550), CJD and ADC (CA67771), and FT (CA41996). ABH was supported by a Department of Defense Breast Cancer Research Program predoctoral fellowship (BC061107).	Aspuria PJ, 2004, CELL SIGNAL, V16, P1105, DOI 10.1016/j.cellsig.2004.03.019; Astrinidis A, 2005, ONCOGENE, V24, P7475, DOI 10.1038/sj.onc.1209090; Basso AD, 2005, J BIOL CHEM, V280, P31101, DOI 10.1074/jbc.M503763200; Blum R, 2008, RECENT PAT ANTI-CANC, V3, P31; Bodemann BO, 2008, NAT REV CANCER, V8, P133, DOI 10.1038/nrc2296; Buerger C, 2006, BIOCHEM BIOPH RES CO, V344, P869, DOI 10.1016/j.bbrc.2006.03.220; Castro AF, 2003, J BIOL CHEM, V278, P32493, DOI 10.1074/jbc.C300226200; Chakraborty S, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-163; Chenette EJ, 2006, MOL BIOL CELL, V17, P3108, DOI 10.1091/mbc.E05-09-0896; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Clark GJ, 1997, J BIOL CHEM, V272, P10608; Cox AD, 2002, CURR OPIN PHARMACOL, V2, P388, DOI 10.1016/S1471-4892(02)00181-9; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Drenan RM, 2004, J BIOL CHEM, V279, P772, DOI 10.1074/jbc.M305912200; Du GW, 2003, J CELL BIOL, V162, P305, DOI 10.1083/jcb.200302033; Gau CL, 2005, MOL CANCER THER, V4, P918, DOI 10.1158/1535-7163.MCT-04-0347; Gromov PS, 1995, FEBS LETT, V377, P221, DOI 10.1016/0014-5793(95)01349-0; Haklai R, 1998, BIOCHEMISTRY-US, V37, P1306, DOI 10.1021/bi972032d; Heo WD, 2003, CELL, V113, P315; Huang J, 2008, BIOCHEM J, V412, P179, DOI 10.1042/BJ20080281; Inoki K, 2005, NAT GENET, V37, P19, DOI 10.1038/ng1494; Jiang H, 2008, ONCOGENE, V27, P5729, DOI 10.1038/onc.2008.180; Kloog Y, 2004, SEMIN CANCER BIOL, V14, P253, DOI 10.1016/j.semcancer.2004.04.004; Konstantinopoulos PA, 2007, NAT REV DRUG DISCOV, V6, P540, DOI 10.1038/nrd2221; Law BK, 2000, J BIOL CHEM, V275, P10796, DOI 10.1074/jbc.275.15.10796; Long X, 2005, CURR BIOL, V15, P702, DOI 10.1016/j.cub.2005.02.053; Ma DZ, 2008, J BIOL CHEM, V283, P25963, DOI 10.1074/jbc.M802356200; Maehama T, 2008, J BIOL CHEM, V283, P35053, DOI 10.1074/jbc.M805822200; MAROM M, 1995, J BIOL CHEM, V270, P22263, DOI 10.1074/jbc.270.38.22263; Mavrakis KJ, 2008, GENE DEV, V22, P2178, DOI 10.1101/gad.1690808; McMahon LP, 2005, MOL ENDOCRINOL, V19, P175, DOI 10.1210/me.2004-0305; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Michaelson D, 2005, MOL BIOL CELL, V16, P1606, DOI 10.1091/mbc.E04-11-0960; Nakase Y, 2006, GENETICS, V173, P569, DOI 10.1534/genetics.106.056895; Nardella C, 2008, GENE DEV, V22, P2172, DOI 10.1101/gad.1699608; Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046; Roberts PJ, 2008, J BIOL CHEM, V283, P25150, DOI 10.1074/jbc.M800882200; Rotblat B, 2008, METHOD ENZYMOL, V439, P467, DOI 10.1016/S0076-6879(07)00432-6; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; Saito K, 2005, J BIOCHEM, V137, P423, DOI 10.1093/jb/mvi046; Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535; Sato T, 2008, METHOD ENZYMOL, V438, P307, DOI 10.1016/S0076-6879(07)38021-X; Sebti SM, 2003, NAT REV CANCER, V3, P945, DOI 10.1038/nrc1234; Takahashi K, 2005, J BIOL CHEM, V280, P32768, DOI 10.1074/jbc.M506280200; Urano J, 2005, MOL MICROBIOL, V58, P1074, DOI 10.1111/j.1365-2958.2005.04877.x; Urano J, 2007, P NATL ACAD SCI USA, V104, P3514, DOI 10.1073/pnas.0608510104; Weis B, 1999, ONCOGENE, V18, P2579, DOI 10.1038/sj.onc.1202602; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; Wienecke R, 1996, ONCOGENE, V13, P913; Winter-Vann AM, 2005, NAT REV CANCER, V5, P405, DOI 10.1038/nrc1612; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Yue W, 2005, INT J CANCER, V117, P746, DOI 10.1002/ijc.21222; Yue W, 2007, J STEROID BIOCHEM, V106, P102, DOI 10.1016/j.jsbmb.2007.05.008	54	67	69	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2010	29	3					380	391		10.1038/onc.2009.336	http://dx.doi.org/10.1038/onc.2009.336			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546EO	19838215	Green Submitted, Green Accepted			2022-12-17	WOS:000273793200007
J	Liao, Y; Wei, Y; Zhou, X; Yang, JY; Dai, C; Chen, YJ; Agarwal, NK; Sarbassov, D; Shi, D; Yu, D; Hung, MC				Liao, Y.; Wei, Y.; Zhou, X.; Yang, J-Y; Dai, C.; Chen, Y-J; Agarwal, N. K.; Sarbassov, D.; Shi, D.; Yu, D.; Hung, M-C			Peptidyl-prolyl cis/trans isomerase Pin1 is critical for the regulation of PKB/Akt stability and activation phosphorylation	ONCOGENE			English	Article						PKB/Akt; Pin1; peptidyl-prolyl cis/trans isomerase; breast cancer	PROTEIN-KINASE-B; FORKHEAD TRANSCRIPTION FACTORS; BREAST-CANCER; AKT; PATHWAY; AKT/PKB; DISEASE; OVEREXPRESSION; TUMORIGENESIS; EXPRESSION	The serine/threonine protein kinase B (PKB, also known as Akt) plays a pivotal role in diverse cellular functions. Elevated expression of activated Akt has been detected in a wide variety of human cancers; however, the mechanism of Akt protein stability regulation remains unclear. In this study, we showed a strong correlation between the expression levels of an oncogenic peptidyl-prolyl cis/trans isomerase Pin1 and levels of Akt phosphorylation at S473 in multiple cancer types (P<0.0001). Akt-pS473 status combined with Pin1 expression levels predicted a poorer prognosis than did either one alone in patients with breast cancer (P = 0.0052). We further showed that Pin1 regulated Akt stability and phosphorylation on S473 through the phosphorylated Thr-Pro motifs of Akt. These motifs are conserved evolutionary and are required for the maintenance of Akt stability and its interaction with Pin1. In addition, repressing Pin1 expression through either homologue Pin1 knockout or small interfering RNA-mediated knockingdown compromised its ability to protect Akt from degradation. Our results show how Akt protein stability is regulated by the peptidyl-prolyl cis/trans isomerase Pin1 and highlight the importance of this oncogenic network in human disease pathogenesis. Oncogene (2009) 28, 2436-2445; doi: 10.1038/onc.2009.98; published online 18 May 2009	[Liao, Y.; Wei, Y.; Zhou, X.; Yang, J-Y; Chen, Y-J; Agarwal, N. K.; Sarbassov, D.; Yu, D.; Hung, M-C] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Liao, Y.; Dai, C.] Univ Texas MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; [Zhou, X.; Shi, D.] Fudan Univ, Canc Hosp, Dept Pathol, Shanghai 200433, Peoples R China; [Chen, Y-J; Hung, M-C] China Med Univ & Hosp, Ctr Mol Med, Taichung, Taiwan; [Chen, Y-J; Hung, M-C] China Med Univ & Hosp, Grad Inst Canc Biol, Taichung, Taiwan; [Hung, M-C] Asia Univ, Taichung, Taiwan	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Fudan University; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; Asia University Taiwan	Hung, MC (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	yongliao@mdanderson.org; mhung@mdanderson.org	Sarbassov, Dos/AAS-4950-2020; Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Yu, Dihua/0000-0001-6231-9381; Sarbassov, Dos/0000-0002-6848-1133	NATIONAL CANCER INSTITUTE [P30CA016672, P01CA099031, P50CA116199, P20CA101936, P50CA083639, R01CA109311] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA083639, R01 CA109311, P30 CA016672, P50-CA83639-A01, P20 CA101936-05, P50 CA116199-04, P50 CA116199, P20 CA101936, P50 CA083639-090009, P01 CA099031, P50 CA83639, P01 CA099031-01] Funding Source: Medline; PHS HHS [P01 099031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Bao L, 2004, AM J PATHOL, V164, P1727, DOI 10.1016/S0002-9440(10)63731-5; Bayascas JR, 2005, MOL CELL, V18, P143, DOI 10.1016/j.molcel.2005.03.020; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Bellacosa A, 2005, ADV CANCER RES, V94, P29, DOI 10.1016/S0065-230X(05)94002-5; Bhaskar PT, 2007, DEV CELL, V12, P487, DOI 10.1016/j.devcel.2007.03.020; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Brognard J, 2007, MOL CELL, V25, P917, DOI 10.1016/j.molcel.2007.02.017; Burgering BMT, 2003, J LEUKOCYTE BIOL, V73, P689, DOI 10.1189/jlb.1202629; Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; CHAN TO, 2001, SCI STKE, pPE1; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Dillon RL, 2007, ONCOGENE, V26, P1338, DOI 10.1038/sj.onc.1210202; Du KY, 2005, ONCOGENE, V24, P7401, DOI 10.1038/sj.onc.1209099; Dummler B, 2007, BIOCHEM SOC T, V35, P231, DOI 10.1042/BST0350231; Facchinetti V, 2008, EMBO J, V27, P1932, DOI 10.1038/emboj.2008.120; Finn G, 2008, CURR CANCER DRUG TAR, V8, P223, DOI 10.2174/156800908784293622; Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008; Guertin DA, 2005, TRENDS MOL MED, V11, P353, DOI 10.1016/j.molmed.2005.06.007; Ikenoue T, 2008, EMBO J, V27, P1919, DOI 10.1038/emboj.2008.119; Kang SY, 2005, P NATL ACAD SCI USA, V102, P802, DOI 10.1073/pnas.0408864102; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Liao Y, 2003, MOL CELL BIOL, V23, P6836, DOI 10.1128/MCB.23.19.6836-6848.2003; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Lu KP, 2007, NAT REV MOL CELL BIO, V8, P904, DOI 10.1038/nrm2261; Lu KP, 2006, MOL CARCINOGEN, V45, P397, DOI 10.1002/mc.20216; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Maroulakou IG, 2007, CANCER RES, V67, P167, DOI 10.1158/0008-5472.CAN-06-3782; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Soung YH, 2006, ONCOLOGY-BASEL, V70, P285, DOI 10.1159/000096289; Takahashi K, 2008, CELL MOL LIFE SCI, V65, P359, DOI 10.1007/s00018-007-7270-0; Testa JR, 2005, ONCOGENE, V24, P7391, DOI 10.1038/sj.onc.1209100; Tokunaga E, 2008, CURR CANCER DRUG TAR, V8, P27, DOI 10.2174/156800908783497140; Wulf G, 2004, EMBO J, V23, P3397, DOI 10.1038/sj.emboj.7600323; Xia WY, 2004, CLIN CANCER RES, V10, P3815, DOI 10.1158/1078-0432.CCR-03-0527; Yang ZZ, 2004, BIOCHEM SOC T, V32, P350, DOI 10.1042/BST0320350; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Yeh ES, 2007, NAT REV CANCER, V7, P381, DOI 10.1038/nrc2107; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120	45	67	69	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	26					2436	2445		10.1038/onc.2009.98	http://dx.doi.org/10.1038/onc.2009.98			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465QH	19448664	Green Accepted			2022-12-17	WOS:000267601400002
J	Jinawath, N; Vasoontara, C; Yap, KL; Thiaville, MM; Nakayama, K; Wang, TL; Shih, IM				Jinawath, N.; Vasoontara, C.; Yap, K-L; Thiaville, M. M.; Nakayama, K.; Wang, T-L; Shih, I-M			NAC-1, a potential stem cell pluripotency factor, contributes to paclitaxel resistance in ovarian cancer through inactivating Gadd45 pathway	ONCOGENE			English	Article						ovarian; NAC-1; chemoresistance; paclitaxel	CHROMATIN-REMODELING GENE; KAPPA-B; POZ/BTB PROTEIN; C-MYC; TUMOR-SUPPRESSOR; TAXOL-RESISTANCE; IN-VITRO; CARCINOMA; EXPRESSION; SURVIVAL	Nucleus accumbens-1 (Nac1 or NAC-1) belongs to the BTB/POZ (Pox virus and Zinc finger/Bric-a-brac Tramtrack Broad complex) transcription factor family and is a novel protein that potentially participates in self-renewal and pluripotency in embryonic stem cells. In human cancer, NAC-1 is upregulated in several types of neoplasms, but particularly in recurrent chemoresistant ovarian carcinomas, suggesting a biological role for NAC-1 in the development of drug resistance in ovarian cancer. We have assessed this possibility and shown a correlation between NAC-1 expression and ex vivo paclitaxel resistance in ovarian serous carcinoma tissues and cell lines. We found that expression of Gadd45-gamma-interacting protein 1 (Gadd45gip1), a downstream target negatively regulated by NAC-1, was reduced in paclitaxel-resistant cells. Ectopic expression of NAC-1 or knockdown of Gadd45gip1 conferred paclitaxel resistance, whereas NAC-1 knockdown or ectopic expression of Gadd45gip1 increased paclitaxel sensitivity. Furthermore, silencing NAC-1 expression or disrupting NAC-1 homodimerization by a dominant negative NAC-1 protein that contained only the BTB/POZ domain induced the expression of Gadd45 gamma, which interacted with Gadd45gip1. Reducing Gadd45 gamma expression by small hairpin RNAs partially enhanced paclitaxel resistance. Thus, this study provides new evidence that NAC-1 upregulation and homodimerization contribute to tumor recurrence by equipping ovarian cancer cells with the paclitaxel-resistant phenotype through negative regulation of the Gadd45 pathway. Oncogene (2009) 28, 1941-1948; doi:10.1038/onc.2009.37; published online 23 March 2009	[Jinawath, N.; Vasoontara, C.; Yap, K-L; Thiaville, M. M.; Wang, T-L; Shih, I-M] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21231 USA; [Jinawath, N.; Vasoontara, C.; Yap, K-L; Thiaville, M. M.; Wang, T-L; Shih, I-M] Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21231 USA; [Jinawath, N.; Vasoontara, C.; Yap, K-L; Thiaville, M. M.; Wang, T-L; Shih, I-M] Johns Hopkins Med Inst, Dept Gynecol & Obstet, Baltimore, MD 21231 USA; [Nakayama, K.] Shimane Univ, Dept Gynecol & Obstet, Izumo, Shimane, Japan	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Shimane University	Shih, IM (corresponding author), Johns Hopkins Med Inst, Dept Pathol, CRB 2,Room 306,1550 Orleans St, Baltimore, MD 21231 USA.	ishih@jhmi.edu	sdsd, shihieih/ABE-6190-2020	Yap, Kai Lee/0000-0003-4496-5464	NIH [RO1CA103937, RO1CA129080]; HERA women's cancer foundation; NATIONAL CANCER INSTITUTE [R01CA129080, R01CA103937] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); HERA women's cancer foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is in memory of Ms Sean Patrick, the founder of HERA women's cancer foundation who has fought courageously with recurrent ovarian cancer. The authors appreciate the valuable comments from members in our laboratory. This work is supported by NIH RO1CA103937 (IMS), NIH RO1CA129080 ( IMS) and the HERA women's cancer foundation OSB1 (NJ, USA).	Abeysinghe HR, 1999, CANCER GENET CYTOGEN, V114, P136, DOI 10.1016/S0165-4608(99)00064-3; Abhiman S, 2008, BIOINFORMATICS, V24, P458, DOI 10.1093/bioinformatics/btn007; BAKER VV, 1990, GYNECOL ONCOL, V38, P340, DOI 10.1016/0090-8258(90)90069-W; Bourguignon LYW, 2008, J BIOL CHEM, V283, P17635, DOI 10.1074/jbc.M800109200; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Cha XY, 1997, J NEUROSCI, V17, P6864; Chung HK, 2003, J BIOL CHEM, V278, P28079, DOI 10.1074/jbc.M212835200; Davidson B, 2007, HUM PATHOL, V38, P1030, DOI 10.1016/j.humpath.2006.12.009; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Dimova I, 2006, EUR J CANCER, V42, P674, DOI 10.1016/j.ejca.2005.11.022; Duan ZF, 2006, CANCER CHEMOTH PHARM, V57, P25, DOI 10.1007/s00280-005-0026-3; Duan ZF, 2003, CLIN CANCER RES, V9, P2778; Duan ZF, 2006, CLIN CANCER RES, V12, P5055, DOI 10.1158/1078-0432.CCR-06-0861; Holloway RW, 2002, GYNECOL ONCOL, V87, P8, DOI 10.1006/gyno.2002.6797; Ishibashi M, 2008, CLIN CANCER RES, V14, P3149, DOI 10.1158/1078-0432.CCR-07-4358; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kalivas PW, 1999, SYNAPSE, V33, P153, DOI 10.1002/(SICI)1098-2396(199908)33:2<153::AID-SYN5>3.0.CO;2-N; Kim JW, 2008, CELL, V132, P1049, DOI 10.1016/j.cell.2008.02.039; Koob GF, 1996, NEURON, V16, P893, DOI 10.1016/S0896-6273(00)80109-9; Korutla L, 2005, J NEUROCHEM, V94, P786, DOI 10.1111/j.1471-4159.2005.03206.x; Korutla L, 2007, J NEUROCHEM, V101, P611, DOI 10.1111/j.1471-4159.2006.04387.x; Liu GH, 2006, INT J GYNECOL CANCER, V16, P1777, DOI 10.1111/j.1525-1438.2006.00652.x; Loizzi V, 2003, AM J OBSTET GYNECOL, V189, P1301, DOI 10.1067/S0002-9378(03)00629-X; Mabuchi S, 2004, J BIOL CHEM, V279, P23477, DOI 10.1074/jbc.M313709200; Mackler SA, 2000, J NEUROSCI, V20, P6210, DOI 10.1523/JNEUROSCI.20-16-06210.2000; Mackler S, 2008, BEHAV BRAIN RES, V187, P48, DOI 10.1016/j.bbr.2007.08.036; Mao TL, 2006, HUM PATHOL, V37, P1169, DOI 10.1016/j.humpath.2006.04.008; Materna V, 2007, VIRCHOWS ARCH, V450, P187, DOI 10.1007/s00428-006-0346-7; Muller FJ, 2008, NATURE, V455, P401, DOI 10.1038/nature07213; Nakayama K, 2007, CANCER RES, V67, P8058, DOI 10.1158/0008-5472.CAN-07-1357; Nakayama K, 2006, P NATL ACAD SCI USA, V103, P18739, DOI 10.1073/pnas.0604083103; Nakayama K, 2006, CANCER BIOL THER, V5, P630, DOI 10.4161/cbt.5.6.2675; Qiu WH, 2004, AM J PATHOL, V165, P1689, DOI 10.1016/S0002-9440(10)63425-6; Shih LM, 2005, P NATL ACAD SCI USA, V102, P14004, DOI 10.1073/pnas.0504195102; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang JL, 2006, NATURE, V444, P364, DOI 10.1038/nature05284; Yeasmin S, 2008, CLIN CANCER RES, V14, P1686, DOI 10.1158/1078-0432.CCR-07-4085; Ying JM, 2005, CLIN CANCER RES, V11, P6442, DOI 10.1158/1078-0432.CCR-05-0267; Yusuf RZ, 2003, CURR CANCER DRUG TAR, V3, P1, DOI 10.2174/1568009033333754; Zerbini LF, 2005, CLIN CANCER RES, V11, P6409, DOI 10.1158/1078-0432.CCR-05-1475; Zerbini LF, 2005, CELL CYCLE, V4, P18, DOI 10.4161/cc.4.1.1363; Zerbini LF, 2004, P NATL ACAD SCI USA, V101, P13618, DOI 10.1073/pnas.0402069101; Zhang S, 2008, CANCER RES, V68, P4311, DOI 10.1158/0008-5472.CAN-08-0364	44	67	73	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	2009	28	18					1941	1948		10.1038/onc.2009.37	http://dx.doi.org/10.1038/onc.2009.37			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442DT	19305429	Green Accepted			2022-12-17	WOS:000265820900001
J	Millar, EKA; Dean, JL; McNeil, CM; O'Toole, SA; Henshall, SM; Tran, T; Lin, J; Quong, A; Comstock, CES; Witkiewicz, A; Musgrove, EA; Rui, H; LeMarchand, L; Setiawan, VW; Haiman, CA; Knudsen, KE; Sutherland, RL; Knudsen, ES				Millar, E. K. A.; Dean, J. L.; McNeil, C. M.; O'Toole, S. A.; Henshall, S. M.; Tran, T.; Lin, J.; Quong, A.; Comstock, C. E. S.; Witkiewicz, A.; Musgrove, E. A.; Rui, H.; LeMarchand, L.; Setiawan, V. W.; Haiman, C. A.; Knudsen, K. E.; Sutherland, R. L.; Knudsen, E. S.			Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome	ONCOGENE			English	Article						cyclin D1b; breast cancer; polymorphism; estrogen receptor; prognosis	SQUAMOUS-CELL CARCINOMA; ADJUVANT TAMOXIFEN; POLYMORPHISM; RISK; AMPLIFICATION; PROGNOSIS; ISOFORM; GENE; VARIANT; ALLELE	Aberrant expression of cyclin D1 protein is a common feature of breast cancer. However, the CCND1 gene encodes two gene products, cyclin D1a and cyclin D1b, which have discrete mechanisms of regulation and impact on cell behavior. A polymorphism at nucleotide 870 in the CCND1 gene, rs603965, influences the relative production of the encoded proteins and can impart increased risk for tumor development. Here, the impact of both the G/A870 polymorphism and cyclin D1b protein production on breast cancer risk, disease phenotype and patient outcome was analysed. In a large multiethnic case-control study, the G/A870 polymorphism conferred no significant risk for breast cancer overall or by stage or estrogen receptor (ER) status. However, the cyclin D1b protein was found to be upregulated in breast cancer, independent of cyclin D1a levels, and exhibited heterogeneous levels in breast cancer specimens. High cyclin D1a expression inversely correlated with the Ki67 proliferation marker and was not associated with clinical outcome. In contrast, elevated cyclin D1b expression was independently associated with adverse outcomes, including recurrence, distant metastasis and decreased survival. Interestingly, cyclin D1b was particularly associated with poor outcome in the context of ER-negative breast cancer. Thus, specific cyclin D1 isoforms are associated with discrete forms of breast cancer and high cyclin D1b protein levels hold prognostic potential.	[Dean, J. L.; Tran, T.; Lin, J.; Quong, A.; Comstock, C. E. S.; Witkiewicz, A.; Rui, H.; Knudsen, K. E.; Knudsen, E. S.] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; [Millar, E. K. A.; McNeil, C. M.; O'Toole, S. A.; Henshall, S. M.; Musgrove, E. A.; Sutherland, R. L.] Garvan Inst Med Res, Canc Res Program, Sydney, NSW, Australia; [Millar, E. K. A.] St George Hosp, Dept Anat Pathol S Eastern Area Lab Serv, Sydney, NSW, Australia; [Dean, J. L.; Tran, T.; Lin, J.; Comstock, C. E. S.; Witkiewicz, A.; Rui, H.; Knudsen, K. E.; Knudsen, E. S.] Thomas Jefferson Univ, Dept Canc Biol, Philadelphia, PA 19107 USA; [Witkiewicz, A.] Thomas Jefferson Univ, Dept Pathol, Philadelphia, PA 19107 USA; [LeMarchand, L.] Canc Res Ctr Hawaii, Program Epidemiol, Honolulu, HI 96813 USA; [Setiawan, V. W.; Haiman, C. A.] Univ So Calif, Keck Sch Med, Dept Prevent Med, Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA; [Knudsen, K. E.] Thomas Jefferson Univ, Dept Urol, Philadelphia, PA 19107 USA	Jefferson University; Garvan Institute of Medical Research; St George Hospital; Jefferson University; Jefferson University; Cancer Research Center of Hawaii; University of Southern California; Jefferson University	Knudsen, ES (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, BLSB Room 1002,233 S 10th St, Philadelphia, PA 19107 USA.	eknudsen@kimmelcancercenter.org	Millar, Ewan/ABE-9127-2020; Comstock, Clay/B-6122-2008; Sutherland, Robert L/A-8378-2008; McNeil, Catriona/F-6817-2010	Millar, Ewan/0000-0002-9778-3253; Comstock, Clay/0000-0001-5867-1489; Knudsen, Karen/0000-0002-1301-890X; Setiawan, Veronica/0000-0001-9239-5692	National Health and Medical Research Council of Australia [276408]; Cancer Institute NSW; Petre Foundation; RT Hall Trust; National Institutes of Health [CA104213, CA099996]; NATIONAL CANCER INSTITUTE [R01CA099996, R01CA104213] Funding Source: NIH RePORTER	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Cancer Institute NSW; Petre Foundation; RT Hall Trust; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank all of the laboratory and administrative staff that contributed to the editing and preparation of the manuscript. This work was supported by the following grants: the National Health and Medical Research Council of Australia (Grant no. 276408), the Cancer Institute NSW, the Petre Foundation and the RT Hall Trust, the National Institutes of Health Grant CA104213 (ESK), the National Institutes of Health Grant CA099996 (KEK). We thank Drs Paul Crea and Davendra Segara of St Vincent's Clinic for access to patient material and data.	Arnold A, 2005, J CLIN ONCOL, V23, P4215, DOI 10.1200/JCO.2005.05.064; Bala S, 2001, CANCER RES, V61, P6042; Barnes DM, 1998, BREAST CANCER RES TR, V52, P1, DOI 10.1023/A:1006103831990; Batsche E, 2006, NAT STRUCT MOL BIOL, V13, P22, DOI 10.1038/nsmb1030; BETTICHER DC, 1995, ONCOGENE, V11, P1005; Blais A, 2007, CURR OPIN CELL BIOL, V19, P658, DOI 10.1016/j.ceb.2007.10.003; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Burd CJ, 2006, P NATL ACAD SCI USA, V103, P2190, DOI 10.1073/pnas.0506281103; Carrere N, 2005, HAEMATOLOGICA, V90, P854; Ceschi M, 2005, CARCINOGENESIS, V26, P1457, DOI 10.1093/carcin/bgi093; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; COMSTOCK CES, 2009, CLIN CANC RES UNPUB; Diehl JA, 2002, CANCER BIOL THER, V1, P226, DOI 10.4161/cbt.72; Dolled-Filhart M, 2006, CANCER RES, V66, P5487, DOI 10.1158/0008-5472.CAN-06-0100; Gillett C, 1996, INT J CANCER, V69, P92, DOI 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.3.CO;2-I; GILLETT C, 1994, CANCER RES, V54, P1812; Gupta VK, 2008, CLIN CANCER RES, V14, P7804, DOI 10.1158/1078-0432.CCR-08-0744; Holley SL, 2005, INT J CANCER, V114, P364, DOI 10.1002/ijc.20750; Holley SL, 2001, AM J PATHOL, V159, P1917, DOI 10.1016/S0002-9440(10)63038-6; Iaquinta PJ, 2007, CURR OPIN CELL BIOL, V19, P649, DOI 10.1016/j.ceb.2007.10.006; Jirstrom K, 2005, CANCER RES, V65, P8009, DOI 10.1158/0008-5472.CAN-05-0746; Knudsen ES, 2006, EXP BIOL MED, V231, P1271; Knudsen KE, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-15; Knudsen KE, 2006, ONCOGENE, V25, P1620, DOI 10.1038/sj.onc.1209371; Krieger S, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-238; Krippl P, 2003, BREAST CANCER RES TR, V82, P165, DOI 10.1023/B:BREA.0000004372.20461.33; Lu FM, 2003, CANCER RES, V63, P7056; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Marzec M, 2006, BLOOD, V108, P1744, DOI 10.1182/blood-2006-04-016634; Matthias C, 1998, CLIN CANCER RES, V4, P2411; Naidu R, 2008, NEOPLASMA, V55, P87; Pabalan N, 2008, CANCER EPIDEM BIOMAR, V17, P2773, DOI 10.1158/1055-9965.EPI-08-0169; Roy PG, 2006, BREAST, V15, P718, DOI 10.1016/j.breast.2006.02.005; Rudas M, 2008, CLIN CANCER RES, V14, P1767, DOI 10.1158/1078-0432.CCR-07-4122; Sanchez G, 2008, P NATL ACAD SCI USA, V105, P6004, DOI 10.1073/pnas.0710748105; Shu XO, 2005, CANCER EPIDEM BIOMAR, V14, P91; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Solomon DA, 2003, J BIOL CHEM, V278, P30339, DOI 10.1074/jbc.M303969200; Spruck C, 2006, CANCER RES, V66, P7355, DOI 10.1158/0008-5472.CAN-05-3240; Sutherland RL, 2004, J MAMMARY GLAND BIOL, V9, P95, DOI 10.1023/B:JOMG.0000023591.45568.77; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wang Y, 2008, CANCER RES, V68, P5628, DOI 10.1158/0008-5472.CAN-07-3170; Yu CP, 2008, BREAST CANCER RES TR, V107, P95, DOI 10.1007/s10549-007-9522-y; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500	44	67	68	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2009	28	15					1812	1820		10.1038/onc.2009.13	http://dx.doi.org/10.1038/onc.2009.13			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	439PV	19287456	Green Accepted			2022-12-17	WOS:000265640400008
J	Kojima, T; Shimazui, T; Hinotsu, S; Joraku, A; Oikawa, T; Kawai, K; Horie, R; Suzuki, H; Nagashima, R; Yoshikawa, K; Michiue, T; Asashima, M; Akaza, H; Uchida, K				Kojima, T.; Shimazui, T.; Hinotsu, S.; Joraku, A.; Oikawa, T.; Kawai, K.; Horie, R.; Suzuki, H.; Nagashima, R.; Yoshikawa, K.; Michiue, T.; Asashima, M.; Akaza, H.; Uchida, K.			Decreased expression of CXXC4 promotes a malignant phenotype in renal cell carcinoma by activating Wnt signaling	ONCOGENE			English	Article						CXXC4; Idax; RCC; SNP array	COMPARATIVE GENOMIC HYBRIDIZATION; HIGH-RESOLUTION ANALYSIS; BETA-CATENIN; GENE-EXPRESSION; CANCER; LIVIN; INHIBITOR; PATHWAY; TARGET; IDENTIFICATION	The Wnt signaling pathway is involved in normal embryonic development and controls the homeostatic self-renewal of stem cells in adult tissues. Constitutive activation of Wnt signaling contributes to cancer development and progression. We identified a CXXC4 homozygous deletion at 4q24 in an aggressive renal cell carcinoma (RCC) using single-nucleotide polymorphism (SNP) arrays. CXXC4 encodes Idax, which negatively regulates Wnt signaling by binding to the PDZ domain of Dishevelled. CXXC4 mRNA levels in tumor samples were significantly lower in patients with metastases compared with those without (P = 0.0016). Patients whose tumors had lower CXXC4 expression than normal kidney showed a poorer cause-specific survival outcome than those with higher expression (P = 0.0095). Decreased expression of CXXC4 also correlated with cytoplasmic staining of beta-catenin. Knockdown of CXXC4 induced the nuclear translocation of beta-catenin and altered expression of a set of genes involved in cell proliferation, invasion and survival. Furthermore, reduced expression of CXXC4 by small interfering RNAs promoted cell proliferation and inhibited apoptosis after 5-FU and doxorubicin treatment in RCC cells. These data suggest that CXXC4 plays a critical role in tumor progression of RCC through Wnt signaling. Wnt signaling could thus be a potential molecular target in RCC indicating decreased CXXC4 expression.	[Kojima, T.; Shimazui, T.; Hinotsu, S.; Joraku, A.; Oikawa, T.; Kawai, K.; Akaza, H.] Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Mol Biol Oncol, Tsukuba, Ibaraki 3058575, Japan; [Kojima, T.; Horie, R.; Uchida, K.] Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Mol Biol Oncol, Tsukuba, Ibaraki, Japan; [Suzuki, H.] MCBI, Div Res, Tsukuba, Ibaraki, Japan; [Yoshikawa, K.] Aichi Med Univ, Sch Med, Dept Pathol, Aichi, Japan; [Michiue, T.; Asashima, M.] Natl Inst Adv Ind Sci & Technol, Organ Dev Res Lab, Tsukuba, Ibaraki, Japan	University of Tsukuba; University of Tsukuba; Aichi Medical University; National Institute of Advanced Industrial Science & Technology (AIST)	Uchida, K (corresponding author), Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Mol Biol Oncol, 1-1-1 Tennoudai, Tsukuba, Ibaraki 3058575, Japan.	kazuhiko.uchida@cbiri.org	Asashima, Makoto/O-8389-2018	Asashima, Makoto/0000-0002-0012-026X	Japan Society for the Promotion of Science (JSPS), Japan	Japan Society for the Promotion of Science (JSPS), Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	We thank Taeko Asano and Miyuki Katto for immunohistochemistry and microarray, respectively. We also thank Noriko Kunita for technical support. This study was performed in part as a collaborative research effort with the Clinical Informatics Research Initiative at the Organ Development Research Laboratory of the National Institute of Advanced Industrial Science and Technology (AIST), Japan. This study was supported by a grant from Scientific Research from the Japan Society for the Promotion of Science (JSPS), Japan.	Barker N, 2006, NAT REV DRUG DISCOV, V5, P997, DOI 10.1038/nrd2154; Bignell GR, 2004, GENOME RES, V14, P287, DOI 10.1101/gr.2012304; Bilim V, 2000, CLIN CANCER RES, V6, P460; Cohen HT, 2005, NEW ENGL J MED, V353, P2477, DOI 10.1056/NEJMra043172; Crnkovic-Mertens I, 2007, CELL MOL LIFE SCI, V64, P1137, DOI 10.1007/s00018-007-6510-7; Dahl E, 2007, ONCOGENE, V26, P5680, DOI 10.1038/sj.onc.1210345; Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655; Gavert N, 2005, J CELL BIOL, V168, P633, DOI 10.1083/jcb.200408051; Guinan P, 1997, CANCER, V80, P992, DOI 10.1002/(SICI)1097-0142(19970901)80:5<992::AID-CNCR26>3.0.CO;2-Q; Gumz ML, 2007, CLIN CANCER RES, V13, P4740, DOI 10.1158/1078-0432.CCR-07-0143; Hino SI, 2001, MOL CELL BIOL, V21, P330, DOI 10.1128/MCB.21.1.330-342.2001; Jiang F, 2000, CANCER RES, V60, P6503; Jiang F, 1998, J PATHOL, V185, P382; Kasof GM, 2001, J BIOL CHEM, V276, P3238, DOI 10.1074/jbc.M003670200; Kempkensteffen C, 2007, CANCER LETT, V254, P227, DOI 10.1016/j.canlet.2007.03.006; Krig SR, 2007, J BIOL CHEM, V282, P9703, DOI 10.1074/jbc.M611752200; Kurose K, 2004, J UROLOGY, V171, P1314, DOI 10.1097/01.ju.0000101047.64379.d4; Lee MG, 2006, ONCOGENE, V25, P5807, DOI 10.1038/sj.onc.1209867; Levy DA, 1998, J UROLOGY, V159, P1163, DOI 10.1016/S0022-5347(01)63541-9; Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Matsuzaki H, 2004, NAT METHODS, V1, P109, DOI 10.1038/nmeth718; Michiue T, 2004, DEV DYNAM, V230, P79, DOI 10.1002/dvdy.20037; MITRA AB, 1994, CANCER RES, V54, P4481; Moch H, 1996, CANCER RES, V56, P27; Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044; Nannya Y, 2005, CANCER RES, V65, P6071, DOI 10.1158/0008-5472.CAN-05-0465; Ohba K, 2005, J UROLOGY, V174, P461, DOI 10.1097/01.ju.0000165150.46006.92; Qiao QL, 2001, INT J CANCER, V95, P194, DOI 10.1002/1097-0215(20010520)95:3<194::AID-IJC1033>3.3.CO;2-D; Ried T, 1996, GENE CHROMOSOME CANC, V15, P234, DOI 10.1002/(SICI)1098-2264(199604)15:4<234::AID-GCC5>3.0.CO;2-2; Shimokawa T, 2003, CANCER RES, V63, P6116; Storkel S, 1997, CANCER, V80, P987, DOI 10.1002/(SICI)1097-0142(19970901)80:5<987::AID-CNCR24>3.0.CO;2-R; Suzuki H, 1997, ONCOLOGY-BASEL, V54, P252; Swiercz R, 1998, CLIN CANCER RES, V4, P869; Ueta T, 2002, ONCOL REP, V9, P1197; Wagener N, 2007, BRIT J CANCER, V97, P1271, DOI 10.1038/sj.bjc.6604028; Wang TL, 2002, P NATL ACAD SCI USA, V99, P16156, DOI 10.1073/pnas.202610899; Yeh SH, 1996, GASTROENTEROLOGY, V110, P184, DOI 10.1053/gast.1996.v110.pm8536855; Yoshimoto T, 2007, J PATHOL, V213, P392, DOI 10.1002/path.2239; Yuan D, 2007, MOL CELL BIOCHEM, V306, P171, DOI 10.1007/s11010-007-9567-6; Yuan E, 2005, MOL CANCER RES, V3, P493, DOI 10.1158/1541-7786.MCR-05-0082	41	67	70	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2009	28	2					297	305		10.1038/onc.2008.391	http://dx.doi.org/10.1038/onc.2008.391			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395CY	18931698				2022-12-17	WOS:000262501100013
J	Hatakeyama, M				Hatakeyama, M.			Linking epithelial polarity and carcinogenesis by multitasking Helicobacter pylori virulence factor CagA	ONCOGENE			English	Review						Helicobacter pylori; CagA; gastric carcinoma; epithelial polarity; PAR1/MARK	LARGE TUMOR-SUPPRESSOR; PAPILLOMAVIRUS E6 PROTEINS; BETA-CATENIN SIGNAL; KINASE-C-IOTA; HUMAN HOMOLOG; IV SECRETION; TYROSINE PHOSPHORYLATION; CELL POLARITY; IN-VIVO; PATHOGENICITY ISLAND	Loss of cell polarity and tissue architecture is a hallmark of carcinomas that arise from epithelial cells. Recent studies on Drosophila tumor suppressors have provided evidence that epithelial polarity and cell proliferation are functionally coupled, suggesting a function for polarity defects in the development of carcinomas. This notion is supported by the findings that mammalian orthologs of these Drosophila tumor suppressors are targeted by a number of viral oncoproteins. Chronic infection with Helicobacter pylori is causally associated with gastric carcinoma. H. pylori virulence factor CagA (cytotoxin-associated gene A), which is delivered into gastric epithelial cells through a bacterial type IV secretion system, has an important function in cell transformation through interacting with and deregulating SHP-2 phosphatase, a bona. de oncoprotein that is associated with human malignancies. Recent studies have further revealed that CagA specifically binds and inhibits PAR1/MARK polarity-regulating kinase, thereby causing junctional and polarity defects in epithelial cells. Thus, the bacterial oncoprotein simultaneously targets the polarity-regulating system and growth-regulatory system. These findings indicate that loss of cell polarity underlies the abnormal proliferation of epithelial cells that directs carcinogenesis.	Hokkaido Univ, Inst Med Genet, Div Mol Oncol, Inst Med Genet,Kita Ku, Sapporo, Hokkaido 0600815, Japan	Hokkaido University	Hatakeyama, M (corresponding author), Hokkaido Univ, Inst Med Genet, Div Mol Oncol, Inst Med Genet,Kita Ku, Kita 15,Nishi 7, Sapporo, Hokkaido 0600815, Japan.	mhata@igm.hokudai.ac.jp						Akopyants NS, 1998, MOL MICROBIOL, V28, P37, DOI 10.1046/j.1365-2958.1998.00770.x; Amieva MR, 2003, SCIENCE, V300, P1430, DOI 10.1126/science.1081919; Araki T, 2004, NAT MED, V10, P849, DOI 10.1038/nm1084; Asahi M, 2000, J EXP MED, V191, P593, DOI 10.1084/jem.191.4.593; Baas AF, 2004, CELL, V116, P457, DOI 10.1016/S0092-8674(04)00114-X; Backert S, 2000, CELL MICROBIOL, V2, P155, DOI 10.1046/j.1462-5822.2000.00043.x; Bagnoli F, 2005, P NATL ACAD SCI USA, V102, P16339, DOI 10.1073/pnas.0502598102; Ben-Porath I, 2005, INT J BIOCHEM CELL B, V37, P961, DOI 10.1016/j.biocel.2004.10.013; Bentires-Alj M, 2004, CANCER RES, V64, P8816, DOI 10.1158/0008-5472.CAN-04-1923; Bentires-Alj M, 2006, NAT MED, V12, P283, DOI 10.1038/nm0306-283; Betschinger J, 2004, CURR BIOL, V14, pR674, DOI 10.1016/j.cub.2004.08.017; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; BLASER MJ, 1995, CANCER RES, V55, P2111; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Cavatorta AL, 2004, INT J CANCER, V111, P373, DOI 10.1002/ijc.20275; Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648; CORREA P, 1992, CANCER RES, V52, P6735; COVACCI A, 1993, P NATL ACAD SCI USA, V90, P5791, DOI 10.1073/pnas.90.12.5791; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; Eder AM, 2005, P NATL ACAD SCI USA, V102, P12519, DOI 10.1073/pnas.0505641102; Franco AT, 2005, P NATL ACAD SCI USA, V102, P10646, DOI 10.1073/pnas.0504927102; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Hatakeyama M, 2004, NAT REV CANCER, V4, P688, DOI 10.1038/nrc1433; Hatakeyama M, 2008, CURR OPIN MICROBIOL, V11, P30, DOI 10.1016/j.mib.2007.12.003; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Higashi H, 2005, J BIOL CHEM, V280, P23130, DOI 10.1074/jbc.M503583200; Higashi H, 2004, J BIOL CHEM, V279, P17205, DOI 10.1074/jbc.M309964200; Higashi H, 2002, P NATL ACAD SCI USA, V99, P14428, DOI 10.1073/pnas.222375399; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; Humbert P, 2003, BIOESSAYS, V25, P542, DOI 10.1002/bies.10286; Hurov JB, 2004, CURR BIOL, V14, P736, DOI 10.1016/j.cub.2004.04.007; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; KUIPERS EJ, 1995, J NATL CANCER I, V87, P1777, DOI 10.1093/jnci/87.23.1777; Kuphal S, 2006, ONCOGENE, V25, P103, DOI 10.1038/sj.onc.1209008; Kurashima Y, 2008, INT J CANCER, V122, P823, DOI 10.1002/ijc.23190; Kwok T, 2007, NATURE, V449, P862, DOI 10.1038/nature06187; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Macara IG, 2004, NAT REV MOL CELL BIO, V5, P220, DOI 10.1038/nrm1332; Matsumoto Y, 2007, NAT MED, V13, P470, DOI 10.1038/nm1566; Mohi MG, 2007, CURR OPIN GENET DEV, V17, P23, DOI 10.1016/j.gde.2006.12.011; Mohi MG, 2005, CANCER CELL, V7, P179, DOI 10.1016/j.ccr.2005.01.010; Muller J, 2001, MOL CELL, V8, P983, DOI 10.1016/S1097-2765(01)00383-5; Murata-Kamiya N, 2007, ONCOGENE, V26, P4617, DOI 10.1038/sj.onc.1210251; Murray NR, 2004, J CELL BIOL, V164, P797, DOI 10.1083/jcb.200311011; Naito M, 2006, GASTROENTEROLOGY, V130, P1181, DOI 10.1053/j.gastro.2005.12.038; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Nakagawa S, 2004, BRIT J CANCER, V90, P194, DOI 10.1038/sj.bjc.6601465; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; NOMURA A, 1991, NEW ENGL J MED, V325, P1132, DOI 10.1056/NEJM199110173251604; Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497; Ohnishi N, 2008, P NATL ACAD SCI USA, V105, P1003, DOI 10.1073/pnas.0711183105; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Panneerselvam S, 2006, STRUCTURE, V14, P173, DOI 10.1016/j.str.2005.09.022; Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2; Parsonnet J, 1997, GUT, V40, P297, DOI 10.1136/gut.40.3.297; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Poppe M, 2007, ONCOGENE, V26, P3462, DOI 10.1038/sj.onc.1210139; Prieur A, 2008, CURR OPIN CELL BIOL, V20, P150, DOI 10.1016/j.ceb.2008.01.007; Regala RP, 2005, CANCER RES, V65, P8905, DOI 10.1158/0008-5472.CAN-05-2372; Ren SM, 2006, J BIOL CHEM, V281, P32344, DOI 10.1074/jbc.M606172200; Rieder G, 2005, GASTROENTEROLOGY, V128, P1229, DOI 10.1053/j.gastro.2005.02.064; Saadat I, 2007, NATURE, V447, P330, DOI 10.1038/nature05765; Schimanski CC, 2005, ONCOGENE, V24, P3100, DOI 10.1038/sj.onc.1208520; Segal ED, 1999, P NATL ACAD SCI USA, V96, P14559, DOI 10.1073/pnas.96.25.14559; Segditsas S, 2006, ONCOGENE, V25, P7531, DOI 10.1038/sj.onc.1210059; Selbach M, 2002, J BIOL CHEM, V277, P6775, DOI 10.1074/jbc.C100754200; Stein M, 2000, P NATL ACAD SCI USA, V97, P1263, DOI 10.1073/pnas.97.3.1263; Stein M, 2002, MOL MICROBIOL, V43, P971, DOI 10.1046/j.1365-2958.2002.02781.x; Suzuki A, 2004, CURR BIOL, V14, P1425, DOI 10.1016/j.cub.2004.08.021; Suzuki A, 2006, J CELL SCI, V119, P979, DOI 10.1242/jcs.02898; Suzuki T, 1999, ONCOGENE, V18, P5967, DOI 10.1038/sj.onc.1203008; Tammer I, 2007, GASTROENTEROLOGY, V132, P1309, DOI 10.1053/j.gastro.2007.01.050; Tartaglia M, 2003, NAT GENET, V34, P148, DOI 10.1038/ng1156; TARTAGLIA M, 2001, NAT GENET, V111, P421; Tepass U, 2001, ANNU REV GENET, V35, P747, DOI 10.1146/annurev.genet.35.102401.091415; Tsutsumi R, 2006, MOL CELL BIOL, V26, P261, DOI 10.1128/MCB.26.1.261-276.2006; TUMMURU MKR, 1993, INFECT IMMUN, V61, P1799, DOI 10.1128/IAI.61.5.1799-1809.1993; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Zeaiter Z, 2008, CELL MICROBIOL, V10, P781, DOI 10.1111/j.1462-5822.2007.01084.x	84	67	73	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2008	27	55					7047	7054		10.1038/onc.2008.353	http://dx.doi.org/10.1038/onc.2008.353			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375IU	19029944				2022-12-17	WOS:000261108200015
J	Montero-Conde, C; Martin-Campos, JM; Lerma, E; Gimenez, G; Martinez-Guitarte, JL; Combalia, N; Montaner, D; Matias-Guiu, X; Dopazo, J; de Leiva, A; Robledo, M; Mauricio, D				Montero-Conde, C.; Martin-Campos, J. M.; Lerma, E.; Gimenez, G.; Martinez-Guitarte, J. L.; Combalia, N.; Montaner, D.; Matias-Guiu, X.; Dopazo, J.; de Leiva, A.; Robledo, M.; Mauricio, D.			Molecular profiling related to poor prognosis in thyroid carcinoma. Combining gene expression data and biological information	ONCOGENE			English	Article						anaplastic thyroid cancer; functional profile; molecular signature	DIFFUSE SCLEROSING VARIANT; DIFFERENTIATED CARCINOMAS; MESENCHYMAL TRANSITION; PAPILLARY CARCINOMA; MICROARRAY DATA; BREAST-CANCER; TGF-BETA; METASTASIS; OVEREXPRESSION; CONTRIBUTES	Undifferentiated and poorly differentiated thyroid tumors are responsible for more than half of thyroid cancer patient deaths in spite of their low incidence. Conventional treatments do not obtain substantial benefits, and the lack of alternative approaches limits patient survival. Additionally, the absence of prognostic markers for well-differentiated tumors complicates patient-specific treatments and favors the progression of recurrent forms. In order to recognize the molecular basis involved in tumor dedifferentiation and identify potential markers for thyroid cancer prognosis prediction, we analysed the expression profile of 44 thyroid primary tumors with different degrees of dedifferentiation and aggressiveness using cDNA microarrays. Transcriptome comparison of dedifferentiated and well-differentiated thyroid tumors identified 1031 genes with > 2-fold difference in absolute values and false discovery rate of <0.15. According to known molecular interaction and reaction networks, the products of these genes were mainly clustered in the MAPkinase signaling pathway, the TGF-beta signaling pathway, focal adhesion and cell motility, activation of actin polymerization and cell cycle. An exhaustive search in several databases allowed us to identify various members of the matrix metalloproteinase, melanoma antigen A and collagen gene families within the upregulated gene set. We also identified a prognosis classifier comprising just 30 transcripts with an overall accuracy of 95%. These findings may clarify the molecular mechanisms involved in thyroid tumor dedifferentiation and provide a potential prognosis predictor as well as targets for new therapies.	[Montero-Conde, C.; Robledo, M.] Spanish Natl Canc Ctr, Hereditary Endocrine Canc Grp Leader, CNIO, E-28029 Madrid, Spain; [Mauricio, D.] Arnau Vilanova Hosp, Dept Endocrinol, IRBLLEIDA, E-25198 Lleida, Spain; [Martin-Campos, J. M.] Santa Creu & Sant Pau Hosp, Res Inst, Barcelona, Spain; [Martin-Campos, J. M.] Univ Autonoma Barcelona, Biochem & Mol Biol Dept, Barcelona, Spain; [Lerma, E.] Santa Creu & Sant Pau Hosp, Pathol Serv, Barcelona, Spain; [Martinez-Guitarte, J. L.; Matias-Guiu, X.] Arnau Vilanova Hosp, IRBLLEIDA, Dept Pathol & Mol Genet, Lleida, Spain; [Montaner, D.; Dopazo, J.] CIPF, Bioinformat Dept, Valencia, Spain; [Dopazo, J.; Robledo, M.] CIBERER, Ctr Biomed Res Rare Dis, ISCIII, Lleida, Spain; [de Leiva, A.; Mauricio, D.] Santa Creu & Sant Pau Hosp, Dept Endocrinol & Nutr, Barcelona, Spain; [de Leiva, A.] CIBER, BBN, ISCIII, Lleida, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); University Hospital Arnau de Vilanova; Autonomous University of Barcelona; Institut de Recerca Biomedica - IRB Lleida; University Hospital Arnau de Vilanova; Prince Felipe Research Center; CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Instituto de Salud Carlos III; CIBER - Centro de Investigacion Biomedica en Red; CIBERBBN; Instituto de Salud Carlos III	Robledo, M (corresponding author), Spanish Natl Canc Ctr, Hereditary Endocrine Canc Grp Leader, CNIO, Melchor Fernandez Almagro 3, E-28029 Madrid, Spain.	mrobledo@cnio.es	Robledo, Mercedes/O-2230-2013; Montero-Conde, Cristina/K-7349-2014; Martinez-Guitarte, Jose-Luis/M-3990-2014; Mauricio, Didac/B-7951-2009; Lerma, Enrique/C-8498-2015; Martín-Campos, Jesús Maria/AGJ-2586-2022; Martín-Campos, Jesús M./AAQ-5478-2021; matias-guiu, xavier/C-3039-2009; Dopazo, Joaquin/A-9270-2014; Montaner, David/A-9362-2014	Robledo, Mercedes/0000-0001-6256-5902; Montero-Conde, Cristina/0000-0002-4452-4469; Martinez-Guitarte, Jose-Luis/0000-0002-7722-864X; Mauricio, Didac/0000-0002-2868-0250; Martín-Campos, Jesús Maria/0000-0003-0414-037X; matias-guiu, xavier/0000-0002-7201-6605; Dopazo, Joaquin/0000-0003-3318-120X; Montaner, David/0000-0002-2484-3278; de Leiva, Alberto/0000-0002-0419-6771				Ain KB, 1999, SEMIN SURG ONCOL, V16, P64, DOI 10.1002/(SICI)1098-2388(199901/02)16:1<64::AID-SSU10>3.3.CO;2-L; Al-Shahrour F, 2006, NUCLEIC ACIDS RES, V34, pW472, DOI 10.1093/nar/gkl172; Alonso SR, 2007, CANCER RES, V67, P3450, DOI 10.1158/0008-5472.CAN-06-3481; Ambroise C, 2002, P NATL ACAD SCI USA, V99, P6562, DOI 10.1073/pnas.102102699; Benjamini Y, 2005, GENETICS, V171, P783, DOI 10.1534/genetics.104.036699; Brown MPS, 2000, P NATL ACAD SCI USA, V97, P262, DOI 10.1073/pnas.97.1.262; Burgdorf SK, 2006, J EXP CLIN CANC RES, V25, P201; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Croizet-Berger K, 2002, P NATL ACAD SCI USA, V99, P8277, DOI 10.1073/pnas.122187699; DELELLIS RA, 2004, WHO TUMORS ENDOCRINE; Duan ZF, 2003, CLIN CANCER RES, V9, P2778; FUJIMOTO Y, 1990, CANCER-AM CANCER SOC, V66, P2306, DOI 10.1002/1097-0142(19901201)66:11<2306::AID-CNCR2820661109>3.0.CO;2-P; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Glinsky GV, 2006, CELL CYCLE, V5, P1208, DOI 10.4161/cc.5.11.2796; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Herrero J, 2001, BIOINFORMATICS, V17, P126, DOI 10.1093/bioinformatics/17.2.126; Huang E, 2003, LANCET, V361, P1590, DOI 10.1016/S0140-6736(03)13308-9; Lam AKY, 2006, ANN SURG ONCOL, V13, P176, DOI 10.1245/ASO.2006.03.062; Medina I, 2007, BIOINFORMATICS, V23, P390, DOI 10.1093/bioinformatics/btl602; Montaner D, 2006, NUCLEIC ACIDS RES, V34, pW486, DOI 10.1093/nar/gkl197; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Motti ML, 2005, CARCINOGENESIS, V26, P1021, DOI 10.1093/carcin/bgi050; Nikiforova MN, 2003, J CLIN ENDOCR METAB, V88, P5399, DOI 10.1210/jc.2003-030838; Onda M, 2004, ENDOCR-RELAT CANCER, V11, P843, DOI 10.1677/erc.1.00818; Pallante P, 2005, BRIT J CANCER, V93, P464, DOI 10.1038/sj.bjc.6602721; Randolph GW, 2002, THYROID, V12, P989, DOI 10.1089/105072502320908321; Rocha AS, 2003, HISTOPATHOLOGY, V42, P580, DOI 10.1046/j.1365-2559.2003.01642.x; SAKAMOTO A, 1983, CANCER, V52, P1849, DOI 10.1002/1097-0142(19831115)52:10<1849::AID-CNCR2820521015>3.0.CO;2-X; Sherman-Baust CA, 2003, CANCER CELL, V3, P377, DOI 10.1016/S1535-6108(03)00058-8; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Slettenaar VIF, 2006, ADV DRUG DELIVER REV, V58, P962, DOI 10.1016/j.addr.2006.03.012; Smith BR, 2006, THYROID, V16, P109, DOI 10.1089/thy.2006.16.109; Sobrinho-Simoes M, 2002, INT J SURG PATHOL, V10, P123, DOI 10.1177/106689690201000205; Sorrentino R, 2005, J CLIN ENDOCR METAB, V90, P928, DOI 10.1210/jc.2004-1518; Tang L, 2006, CLIN CANCER RES, V12, P3716, DOI 10.1158/1078-0432.CCR-06-0030; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Vasko V, 2007, P NATL ACAD SCI USA, V104, P2803, DOI 10.1073/pnas.0610733104; Vini L, 2002, LANCET ONCOL, V3, P407, DOI 10.1016/S1470-2045(02)00787-8; Voigt C, 2000, FEBS LETT, V486, P208, DOI 10.1016/S0014-5793(00)02302-4; Wang HR, 2003, SCIENCE, V302, P1775, DOI 10.1126/science.1090772; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zou M, 2005, BRIT J CANCER, V93, P1277, DOI 10.1038/sj.bjc.6602856	43	67	76	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2008	27	11					1554	1561		10.1038/sj.onc.1210792	http://dx.doi.org/10.1038/sj.onc.1210792			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	271VC	17873908				2022-12-17	WOS:000253815800007
J	Yang, F; Strand, DW; Rowley, DR				Yang, F.; Strand, D. W.; Rowley, D. R.			Fibroblast growth factor-2 mediates transforming growth factor-beta action in prostate cancer reactive stroma	ONCOGENE			English	Article						transforming growth factor-beta; fibroblast growth factor; prostate cancer; stroma; angiogenesis	MOUSE MODEL; EXPRESSION; ANGIOGENESIS; RECEPTOR; INDUCTION; FGF; GROWTH-FACTOR-BETA-1; SECRETION; PHENOTYPE; FIBROSIS	Transforming growth factor-beta (TGF-beta) is overexpressed at sites of wound repair and in most adenocarcinomas including prostate cancer. In stromal tissues, TGF-beta regulates cell proliferation, phenotype and matrix synthesis. To address mechanisms of TGF-beta action in cancer-associated reactive stroma, we developed prostate stromal cells null for TGF-beta receptor II (T beta RII) or engineered to express a dominant-negative Smad3 to attenuate TGF-beta signaling. The differential reactive stroma (DRS) xenograft model was used to evaluate altered stromal TGF-beta signaling on LNCaP tumor progression. LNCaP xenograft tumors constructed with TbRII null or dominant-negative Smad3 stromal cells exhibited a significant reduction in mass and microvessel density relative to controls. Additionally, decreased cellular fibroblast growth factor-2 (FGF-2) immunostaining was associated with attenuated TGF-beta signaling in stroma. In vitro, TGF-b stimulated stromal FGF-2 expression and release. However, stromal cells with attenuated TGF-b signaling were refractory to TGF-beta-stimulated FGF-2 expression and release. Re-expression of FGF-2 in these stromal cells in DRS xenografts resulted in restored tumor mass and microvessel density. In summary, these data show that TGF-beta signaling in reactive stroma is angiogenic and tumor promoting and that this effect is mediated in part through a TbRII/Smad3-dependent upregulation of FGF-2 expression and release.	[Yang, F.; Strand, D. W.; Rowley, D. R.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	Rowley, DR (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza,325D, Houston, TX 77030 USA.	drowley@bcm.tmc.edu	Strand, Douglas/A-1702-2011; Strand, Douglas/K-4003-2019	Strand, Douglas/0000-0002-0746-927X	NCI NIH HHS [P50-CA58204, U54-CA126568, UO1-CA84296, R01-CA058093] Funding Source: Medline; NIDDK NIH HHS [R01-DK045909] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U54CA126568, R01CA058093, P50CA058204, U01CA084296] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045909] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Backhaus R, 2004, J CELL SCI, V117, P1727, DOI 10.1242/jcs.01027; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Bonniaud P, 2004, J IMMUNOL, V173, P2099, DOI 10.4049/jimmunol.173.3.2099; Butter S, 2001, EUR J PHARMACOL, V422, P47, DOI 10.1016/S0014-2999(01)01072-X; Cheng N, 2005, ONCOGENE, V24, P5053, DOI 10.1038/sj.onc.1208685; Choy L, 2000, J CELL BIOL, V149, P667, DOI 10.1083/jcb.149.3.667; COFFEY RJ, 1986, CANCER RES, V46, P1164; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; Dow JK, 2000, UROLOGY, V55, P800, DOI 10.1016/S0090-4295(00)00457-X; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; EASTHAM JA, 1995, LAB INVEST, V73, P628; Fukabori Y, 1997, Int J Urol, V4, P597, DOI 10.1111/j.1442-2042.1997.tb00316.x; Giri D, 1999, CLIN CANCER RES, V5, P1063; Hayashi T, 2004, CLIN CANCER RES, V10, P7540, DOI 10.1158/1078-0432.CCR-04-0632; Huss WJ, 2003, PROSTATE, V54, P8, DOI 10.1002/pros.10163; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; Lakos G, 2004, AM J PATHOL, V165, P203, DOI 10.1016/S0002-9440(10)63289-0; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Peehl DM, 1998, PROSTATE, V35, P125, DOI 10.1002/(SICI)1097-0045(19980501)35:2<125::AID-PROS6>3.0.CO;2-I; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; Polnaszek N, 2003, CANCER RES, V63, P5754; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; Roberts AB, 2003, ANN NY ACAD SCI, V995, P1, DOI 10.1111/j.1749-6632.2003.tb03205.x; ROBERTS AB, 1996, MOL CELLULAR BIOL WO, P275; RonnovJessen L, 1996, PHYSIOL REV, V76, P69, DOI 10.1152/physrev.1996.76.1.69; ROWLEY DR, 2007, TRANSFORMING GROWTH; Sakko AJ, 2001, CANCER RES, V61, P926; Silver DP, 2001, MOL CELL, V8, P233, DOI 10.1016/S1097-2765(01)00295-7; Story MT, 1996, PROSTATE, V28, P219; Tuxhorn JA, 2002, CANCER RES, V62, P6021; Tuxhorn JA, 2002, CLIN CANCER RES, V8, P2912; Tuxhorn JA, 2001, J UROLOGY, V166, P2472, DOI 10.1016/S0022-5347(05)65620-0; Tuxhorn JA, 2002, CANCER RES, V62, P3298; Uchiyama-Tanaka Y, 2002, KIDNEY INT, V62, P799, DOI 10.1046/j.1523-1755.2002.00537.x; Yang F, 2005, CANCER RES, V65, P8887, DOI 10.1158/0008-5472.CAN-05-1702	37	67	71	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2008	27	4					450	459		10.1038/sj.onc.1210663	http://dx.doi.org/10.1038/sj.onc.1210663			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	252DU	17637743				2022-12-17	WOS:000252426100005
J	Alcala, S; Klee, M; Fernandez, J; Fleischer, A; Pimental-Muinos, F				Alcala, S.; Klee, M.; Fernandez, J.; Fleischer, A.; Pimental-Muinos, Fx			A high-throughput screening for mammalian cell death effectors identifies the mitochondrial phosphate carrier as a regulator of cytochrome c release	ONCOGENE			English	Article						high-throughput screening; atypical cell death; apoptosis; permeability transition; phosphate carrier	PERMEABILITY TRANSITION-PORE; APOPTOSIS; PROTEIN; COMPLEXES; COMPONENT; GENES	Functional annotation of complex genomes requires the development of novel experimental platforms with increased capacity. Here, we describe a high-throughput system designed to identify cDNAs whose overexpression induces morphologically distinct cell death modalities. The methodology incorporates two robotized steps, and relies on coexpression of library clones with GFP to reveal the morphological features presented by the dying cells. By using this system we screened 135 000 cDNA clones and obtained 90 independent molecules. Interestingly, three death categories were identified, namely; apoptotic, vacuolated and autophagic. Among the pro-apoptotic clones, we found four members of the mitochondrial carrier family: the phosphate and adenine nucleotide (type 3) transporters, and the mitochondrial carrier homologs (MTCHs) 1 and 2. Expression of these molecules induced cytochrome c release and caspase-9-dependent death. One of them, the phosphate carrier, was able to interact with members of the permeability transition pore complex ANT1 and VDAC1, and its binding to ANT1 was stabilized in the presence of apoptotic activators. Depletion of this carrier by siRNA delayed cytochrome c mobilization and apoptosis. These results attribute a previously undescribed apoptotic function to the phosphate carrier and, more generally, suggest that a common property of various mitochondrial transporters was exploited during evolution to regulate apoptosis.	[Alcala, S.; Klee, M.; Fernandez, J.; Fleischer, A.; Pimental-Muinos, Fx] Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, Ctr Invest Canc, Salamanca 37007, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Pimental-Muinos, F (corresponding author), Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, Ctr Invest Canc, Campus Miguel Unamuno, Salamanca 37007, Spain.	fxp@usal.es	Fleischer, Aarne/ABE-6966-2020; Pimentel-Muinos, Felipe/K-4557-2014	Fleischer, Aarne/0000-0003-4146-3303; Alcala, Sonia/0000-0002-7644-4973; Pimentel-Muinos, Felipe/0000-0002-0258-2855				Albayrak T, 2003, BIOCHEM BIOPH RES CO, V304, P772, DOI 10.1016/S0006-291X(03)00653-3; Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493; Brenner C, 2006, ONCOGENE, V25, P4744, DOI 10.1038/sj.onc.1209609; Broker LE, 2005, CLIN CANCER RES, V11, P3155, DOI 10.1158/1078-0432.CCR-04-2223; Chanda SK, 2003, P NATL ACAD SCI USA, V100, P12153, DOI 10.1073/pnas.1934839100; Crompton M, 2002, BIOCHIMIE, V84, P143, DOI 10.1016/S0300-9084(02)01368-8; Faustin B, 2004, J BIOL CHEM, V279, P20411, DOI 10.1074/jbc.M314259200; Garrido C, 2006, CELL DEATH DIFFER, V13, P1423, DOI 10.1038/sj.cdd.4401950; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grimm S, 2004, NAT REV GENET, V5, P179, DOI 10.1038/nrg1291; Grinberg M, 2005, MOL CELL BIOL, V25, P4579, DOI 10.1128/MCB.25.11.4579-4590.2005; Halestrap AP, 2004, NATURE, V430, DOI 10.1038/nature02816; Inbal B, 2002, J CELL BIOL, V157, P455, DOI 10.1083/jcb.200109094; Kanzawa T, 2005, ONCOGENE, V24, P980, DOI 10.1038/sj.onc.1208095; Kiss-Toth E, 2004, CYTOKINE GROWTH F R, V15, P97, DOI 10.1016/j.cytogfr.2004.02.002; Klee M, 2005, J CELL BIOL, V168, P723, DOI 10.1083/jcb.200408169; Ko YH, 2003, J BIOL CHEM, V278, P12305, DOI 10.1074/jbc.C200703200; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Matsuda A, 2003, ONCOGENE, V22, P3307, DOI 10.1038/sj.onc.1206406; Mizushima N, 2004, INT J BIOCHEM CELL B, V36, P2491, DOI 10.1016/j.biocel.2004.02.005; Palmieri F, 2004, PFLUG ARCH EUR J PHY, V447, P689, DOI 10.1007/s00424-003-1099-7; Pimentel-Muinos FX, 1999, IMMUNITY, V11, P783, DOI 10.1016/S1074-7613(00)80152-1; Poncet D, 2006, J CELL BIOL, V174, P985, DOI 10.1083/jcb.200604069; Schobel S, 2006, INT J DEV NEUROSCI, V24, P141, DOI 10.1016/j.ijdevneu.2005.11.003; Schubert A, 2004, CANCER RES, V64, P85, DOI 10.1158/0008-5472.CAN-03-0476; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376; Ting Adrian, 2005, Novartis Found Symp, V267, P219; Van Cruchten S, 2002, ANAT HISTOL EMBRYOL, V31, P214, DOI 10.1046/j.1439-0264.2002.00398.x; Verrier F, 2004, ONCOGENE, V23, P8049, DOI 10.1038/sj.onc.1208001; Xu XM, 2002, J BIOL CHEM, V277, P48913, DOI 10.1074/jbc.M209613200; Yerushalmi GM, 2002, NEOPLASIA, V4, P510, DOI 10.1038/sj.neo.7900272; Zamora M, 2004, FEBS LETT, V563, P155, DOI 10.1016/S0014-5793(04)00293-5; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zoratti M, 2005, BBA-BIOENERGETICS, V1706, P40, DOI 10.1016/j.bbabio.2004.10.006	35	67	71	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2008	27	1					44	54		10.1038/sj.onc.1210600	http://dx.doi.org/10.1038/sj.onc.1210600			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	247YO	17621274				2022-12-17	WOS:000252118700005
J	Ebauer, M; Wachtel, M; Niggli, FK; Schaefer, BW				Ebauer, M.; Wachtel, M.; Niggli, F. K.; Schaefer, B. W.			Comparative expression profiling identifies an in vivo target gene signature with TFAP2B as a mediator of the survival function of PAX3/FKHR	ONCOGENE			English	Article						alveolar RMS; chimeric transcription factor; expression profiling; TFAP2B; PAX3/FKHR	PAX3-FKHR FUSION PROTEIN; ALVEOLAR RHABDOMYOSARCOMA; TRANSCRIPTION FACTOR; PAX3; MICE; TRANSLOCATION; POTENT; CELLS; MET	The chromosomal translocation t(2;13), characteristic for the aggressive childhood cancer alveolar rhabdomyosarcoma (aRMS), generates the chimeric transcription factor PAX3/FKHR with a well known oncogenic role. However, the molecular mechanisms mediating essential pathophysiological functions remain poorly defined. Here, we used comparative expression pro. ling of PAX3/FKHR silencing in vitro and PAX3/FKHR-specific gene signatures in vivo to identify physiologically important target genes. Hereby, 51 activated genes, both novel and known, were identified. We also found repression of skeletal muscle-specific genes suggesting that PAX3/FKHR blocks further differentiation of aRMS cells. Importantly, TFAP2B was validated as direct target gene mediating the anti-apoptotic function of PAX3/FKHR. Hence, we developed a pathophysiologically relevant transcriptional profile of PAX3/FKHR and identified a critical target gene for aRMS development.	Univ Zurich, Childrens Hosp, Dept Oncol, CH-8032 Zurich, Switzerland	University Children's Hospital Zurich; University of Zurich	Schaefer, BW (corresponding author), Univ Zurich, Childrens Hosp, Dept Oncol, Steinwiesstr 75, CH-8032 Zurich, Switzerland.	beat.schaefer@kispi.unizh.ch	Niggli, Felix/L-6547-2017	Niggli, Felix/0000-0002-7553-3712; Wachtel, Marco/0000-0002-6077-3692; Schafer, Beat/0000-0001-5988-2915				Anderson J, 2001, AM J PATHOL, V159, P1089, DOI 10.1016/S0002-9440(10)61784-1; Ayyanathan K, 2000, CANCER RES, V60, P5803; Begum S, 2005, ONCOGENE, V24, P1860, DOI 10.1038/sj.onc.1208315; BENNICELLI JL, 1995, ONCOGENE, V11, P119; Bernasconi M, 1996, P NATL ACAD SCI USA, V93, P13164, DOI 10.1073/pnas.93.23.13164; Davicioni E, 2006, CANCER RES, V66, P6936, DOI 10.1158/0008-5472.CAN-05-4578; EDELMAN GM, 1995, PHILOS T R SOC B, V349, P305, DOI 10.1098/rstb.1995.0118; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Epstein JA, 1998, MOL CELL BIOL, V18, P4118, DOI 10.1128/MCB.18.7.4118; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Ginsberg JP, 1998, CANCER RES, V58, P3542; Keller C, 2004, GENE DEV, V18, P2614, DOI 10.1101/gad.1244004; Khan J, 1998, CANCER RES, V58, P5009; Lam PYP, 1999, MOL CELL BIOL, V19, P594; Lang D, 2005, NATURE, V433, P884, DOI 10.1038/nature03292; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Margue CM, 2000, ONCOGENE, V19, P2921, DOI 10.1038/sj.onc.1203607; Mayanil CSK, 2001, J BIOL CHEM, V276, P49299, DOI 10.1074/jbc.M107933200; Moser M, 1997, GENE DEV, V11, P1938, DOI 10.1101/gad.11.15.1938; Moser M, 2003, LAB INVEST, V83, P571, DOI 10.1097/01.LAB.0000064703.92382.50; Scheidler S, 1996, P NATL ACAD SCI USA, V93, P9805, DOI 10.1073/pnas.93.18.9805; Tomescu O, 2004, LAB INVEST, V84, P1060, DOI 10.1038/labinvest.3700125; Wachtel M, 2006, J CLIN ONCOL, V24, P816, DOI 10.1200/JCO.2005.03.4934; Wachtel M, 2004, CANCER RES, V64, P5539, DOI 10.1158/0008-5472.CAN-04-0844; Xia SJJ, 2004, ONCOGENE, V23, P6864, DOI 10.1038/sj.onc.1207850; Zhang L, 2007, ONCOGENE, V26, P1595, DOI 10.1038/sj.onc.1209958	28	67	67	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2007	26	51					7267	7281		10.1038/sj.onc.1210525	http://dx.doi.org/10.1038/sj.onc.1210525			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NO	17525748				2022-12-17	WOS:000250955600011
J	Salto-Tellez, M; Peh, BK; Ito, K; Tan, SH; Chong, PY; Han, HC; Tada, K; Ong, WY; Soong, R; Voon, DC; Ito, Y				Salto-Tellez, M.; Peh, B. K.; Ito, K.; Tan, S. H.; Chong, P. Y.; Han, H. C.; Tada, K.; Ong, W. Y.; Soong, R.; Voon, D. C.; Ito, Y.			RUNX3 protein is overexpressed in human basal cell carcinomas	ONCOGENE			English	Article						basal cell carcinoma; RUNX3; beta-catenin; Sonic Hedgehog	TRANSCRIPTION FACTOR LEF-1; WNT SIGNALING PATHWAY; NUCLEAR BETA-CATENIN; SONIC HEDGEHOG; COLORECTAL-CANCER; TUMOR-SUPPRESSOR; GENE-EXPRESSION; GASTRIC-CANCER; LINES; INACTIVATION	Basal cell carcinomas (BCC), which are the most common form of skin malignancy, are invariably associated with the deregulation of the Sonic Hedgehog (Shh) signalling pathway. As such, BCC represent a unique model for the study of interactions of the Shh pathway with other genes and pathways. We constructed a tissue microarray (TMA) of 75 paired BCC and normal skin and analysed the expression of beta-catenin and RUNX3, nuclear effectors of the wingless-Int (Wnt) and bone morphogenetic protein/transforming growth factor-beta pathways, respectively. In line with previous reports, we observed varying subcellular expression pattern of beta-catenin in BCC, with 31 cases (41%) showing nuclear accumulation. In contrast, all the BCC cases tested by the TMA showed RUNX3 protein uniformly overexpressed in the nuclei of the cancer cells. Analysis by Western blotting and DNA sequencing indicates that the overexpressed protein is normal and full-length, containing no mutation in the coding region, implicating RUNX3 as an oncogene in certain human cancers. Our results indicate that although the deregulation of Wnt signalling could contribute to the pathogenesis of a subset of BCC, RUNX3 appears to be a universal downstream mediator of a constitutively active Shh pathway in BCC.	Inst Mol & Cell Biol, Singapore 138673, Singapore; Natl Univ Singapore Hosp, Yong Loo Lin Med Sch, Dept Pathol, Singapore 117548, Singapore; Natl Univ Singapore, Oncol Res Inst, Singapore 117548, Singapore; Natl Skin Ctr, Singapore, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; National University of Singapore; National Skin Centre	Ito, Y (corresponding author), Inst Mol & Cell Biol, 61 Biopolis Dr Proteos, Singapore 138673, Singapore.	itoy@imcb.a-star.edu.sg		Voon, Dominic Chih-Cheng/0000-0002-2963-9305; Soong, Richie/0000-0002-0152-1225; Salto-Tellez, Manuel/0000-0001-8586-282X				Andl T, 2002, DEV CELL, V2, P643, DOI 10.1016/S1534-5807(02)00167-3; Bae SC, 2004, ONCOGENE, V23, P4336, DOI 10.1038/sj.onc.1207286; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Blyth K, 2005, NAT REV CANCER, V5, P376, DOI 10.1038/nrc1607; Boonchai W, 2000, ARCH DERMATOL, V136, P937, DOI 10.1001/archderm.136.7.937; Cameron ER, 2004, ONCOGENE, V23, P4308, DOI 10.1038/sj.onc.1207130; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; Chen YG, 2004, CELL RES, V14, P441, DOI 10.1038/sj.cr.7290246; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; Daya-Grosjean L, 2005, CANCER LETT, V225, P181, DOI 10.1016/j.canlet.2004.10.003; El-Bahrawy M, 2003, BRIT J DERMATOL, V148, P964, DOI 10.1046/j.1365-2133.2003.05240.x; Gianakopoulos PJ, 2005, J BIOL CHEM, V280, P21022, DOI 10.1074/jbc.M502977200; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Gregorieff A, 2005, GENE DEV, V19, P877, DOI 10.1101/gad.1295405; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Ito K, 2005, CANCER RES, V65, P7743, DOI 10.1158/0008-5472.CAN-05-0743; Ito Y, 2003, CURR OPIN GENET DEV, V13, P43, DOI 10.1016/S0959-437X(03)00007-8; Kawai S, 2001, BONE, V29, P54, DOI 10.1016/S8756-3282(01)00470-7; Kim WJ, 2005, CANCER RES, V65, P9347, DOI 10.1158/0008-5472.CAN-05-1647; Ku JL, 2004, ONCOGENE, V23, P6736, DOI 10.1038/sj.onc.1207731; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Marigo V, 1996, P NATL ACAD SCI USA, V93, P9346, DOI 10.1073/pnas.93.18.9346; Mori T, 2005, LIVER INT, V25, P380, DOI 10.1111/j.1478-3231.2005.1059.x; Reddy S, 2001, MECH DEVELOP, V107, P69, DOI 10.1016/S0925-4773(01)00452-X; Rubin AI, 2005, NEW ENGL J MED, V353, P2262, DOI 10.1056/NEJMra044151; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Saldanha G, 2004, BRIT J DERMATOL, V151, P157, DOI 10.1111/j.1365-2133.2004.06048.x; Salto-Tellez M, 2004, CLIN CHEM, V50, P1082, DOI 10.1373/clinchem.2003.030700; Unden AB, 1997, CANCER RES, V57, P2336; van Wijnen AJ, 2004, ONCOGENE, V23, P4209, DOI 10.1038/sj.onc.1207758; Weeraratna AT, 2005, CANCER METAST REV, V24, P237, DOI 10.1007/s10555-005-1574-z; Yamazaki F, 2001, BRIT J DERMATOL, V145, P771, DOI 10.1046/j.1365-2133.2001.04468.x; Yanada M, 2005, ONCOL REP, V14, P817; Yanagida M, 2005, ONCOGENE, V24, P4477, DOI 10.1038/sj.onc.1208675; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	36	67	69	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 7	2006	25	58					7646	7649		10.1038/sj.onc.1209739	http://dx.doi.org/10.1038/sj.onc.1209739			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114GU	16767156				2022-12-17	WOS:000242655500009
J	Saxena, A; Rorie, CJ; Dimitrov, D; Daniely, Y; Borowiec, JA				Saxena, A.; Rorie, C. J.; Dimitrov, D.; Daniely, Y.; Borowiec, J. A.			Nucleolin inhibits Hdm2 by multiple pathways leading to p53 stabilization	ONCOGENE			English	Article						ARF; Mdm2; nucleolin; p53; ubiquitination	ARF TUMOR-SUPPRESSOR; PRE-RIBOSOMAL-RNA; REPLICATION PROTEIN-A; UBIQUITIN LIGASE ACTIVITY; DNA-DAMAGE; ONCOPROTEIN MDM2; GENOTOXIC STRESS; IN-VITRO; P53-DEPENDENT APOPTOSIS; EMBRYONIC LETHALITY	Nucleolin is a c-Myc-induced gene product with defined roles in ribosomal RNA processing and the inhibition of chromosomal DNA replication following stress. Here we find that changes in nucleolin protein levels in unstressed cells cause parallel changes in the amount of p53 protein. Alterations in p53 levels arise from nucleolin binding to the p53 antagonist Hdm2, resulting in the inhibition of both p53 ubiquitination and Hdm2 auto-ubiquitination. Nucleolin does not alter p53 ubiquitination by human papillomavirus E6, indicating that the effect is specific for Hdm2. Although the inhibition of ligase activity would be expected to stabilize Hdm2, we instead find that nucleolin also reduces Hdm2 protein levels, demonstrating that nucleolin inhibits Hdm2 using multiple mechanisms. Increases in nucleolin levels in unstressed cells led to higher expression of p21(cip1/waf1), a reduced rate of cellular proliferation, and an increase in apoptosis. Thus, nucleolin has a number of properties in common with the tumor suppressor ARF (alternate reading frame). We propose that nucleolin, like ARF, responds to hyperproliferative signals by upregulation of p53 through Hdm2 inhibition.	NYU, Sch Med, Dept Biochem, New York, NY 10016 USA; NYU, Sch Med, Inst Canc, New York, NY 10016 USA	New York University; New York University	Borowiec, JA (corresponding author), NYU, Sch Med, Dept Biochem, 550 1St Ave, New York, NY 10016 USA.	james.borowiec@med.nyu.edu	Saxena, Anjana/AAZ-5244-2020	Saxena, Anjana/0000-0001-8884-5179; Borowiec, James/0000-0003-4117-0826	NIAID NIH HHS [AI29963] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029963] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allemand I, 1999, ONCOGENE, V18, P6521, DOI 10.1038/sj.onc.1203052; Anderson-Cook CM, 2004, PHARM STAT, V3, P247, DOI 10.1002/pst.138; Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; Bhat KP, 2004, EMBO J, V23, P2402, DOI 10.1038/sj.emboj.7600247; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Borovjagin AV, 2004, RNA, V10, P942, DOI 10.1261/rna.5256704; BOUCHE G, 1984, NUCLEIC ACIDS RES, V12, P3025, DOI 10.1093/nar/12.7.3025; Brooks CL, 2004, CELL CYCLE, V3, P895; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chen DL, 2005, CELL, V121, P1071, DOI 10.1016/j.cell.2005.03.037; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Daniely Y, 2000, J CELL BIOL, V149, P799, DOI 10.1083/jcb.149.4.799; Daniely Y, 2002, MOL CELL BIOL, V22, P6014, DOI 10.1128/MCB.22.16.6014-6022.2002; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; EGYHAZI E, 1988, EXP CELL RES, V178, P264, DOI 10.1016/0014-4827(88)90397-7; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Ginisty H, 1999, J CELL SCI, V112, P761; Ginisty H, 1998, EMBO J, V17, P1476, DOI 10.1093/emboj/17.5.1476; Godley LA, 1996, GENE DEV, V10, P836, DOI 10.1101/gad.10.7.836; Greasley PJ, 2000, NUCLEIC ACIDS RES, V28, P446, DOI 10.1093/nar/28.2.446; Gronroos E, 2004, P NATL ACAD SCI USA, V101, P12165, DOI 10.1073/pnas.0402283101; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; GULLI MP, 1995, NUCLEIC ACIDS RES, V23, P1912, DOI 10.1093/nar/23.11.1912; Hannan KM, 1998, FRONT BIOSCI, V3, P376, DOI [10.2741/A282, DOI 10.2741/A282]; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Jin A, 2004, MOL CELL BIOL, V24, P7669, DOI 10.1128/MCB.24.17.7669-7680.2004; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kim K, 2005, MOL CELL BIOL, V25, P2463, DOI 10.1128/MCB.25.6.2463-2474.2005; KONDO K, 1992, J BIOL CHEM, V267, P16252; Korgaonkar C, 2005, MOL CELL BIOL, V25, P1258, DOI 10.1128/MCB.25.4.1258-1271.2005; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kurki S, 2004, CANCER CELL, V5, P465, DOI 10.1016/S1535-6108(04)00110-2; LEE WC, 1992, MOL CELL BIOL, V12, P3865, DOI 10.1128/MCB.12.9.3865; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Li LM, 2001, P NATL ACAD SCI USA, V98, P1619, DOI 10.1073/pnas.98.4.1619; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Li MY, 2004, MOL CELL, V13, P879, DOI 10.1016/S1097-2765(04)00157-1; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; LUNA RMD, 1995, NATURE, V378, P203; Mendrysa SM, 2003, MOL CELL BIOL, V23, P462, DOI 10.1128/MCB.23.2.462-473.2003; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Moss T, 2004, CURR OPIN GENET DEV, V14, P210, DOI 10.1016/j.gde.2004.02.005; NAKAMURA T, 1995, P NATL ACAD SCI USA, V92, P6142, DOI 10.1073/pnas.92.13.6142; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Olson Mark O J, 2004, Sci STKE, V2004, ppe10; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Park YB, 2002, CANCER GENET CYTOGEN, V133, P105, DOI 10.1016/S0165-4608(01)00575-1; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Saez-Vasquez J, 2004, MOL CELL BIOL, V24, P7284, DOI 10.1128/MCB.24.16.7284-7297.2004; Savkur RS, 1998, NUCLEIC ACIDS RES, V26, P4508, DOI 10.1093/nar/26.19.4508; Sengupta TK, 2004, J BIOL CHEM, V279, P10855, DOI 10.1074/jbc.M309111200; Sirri V, 1997, CYTOMETRY, V28, P147, DOI 10.1002/(SICI)1097-0320(19970601)28:2<147::AID-CYTO8>3.3.CO;2-G; Srivastava M, 1999, FASEB J, V13, P1911, DOI 10.1096/fasebj.13.14.1911; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Sui GC, 2004, CELL, V117, P859, DOI 10.1016/j.cell.2004.06.004; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Tolbert D, 2002, MOL CELL BIOL, V22, P370, DOI 10.1128/MCB.22.1.370-377.2002; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Vassin VM, 2004, MOL CELL BIOL, V24, P1930, DOI 10.1128/MCB.24.5.1930-1943.2004; Verschuren EW, 2002, CANCER CELL, V2, P229, DOI 10.1016/S1535-6108(02)00123-X; Wang XJ, 2002, J BIOL CHEM, V277, P15697, DOI 10.1074/jbc.M112068200; Wang YZ, 2001, J BIOL CHEM, V276, P20579, DOI 10.1074/jbc.M100874200; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Wesierska-Gadek J, 2003, ANN NY ACAD SCI, V1010, P266, DOI 10.1196/annals.1299.046; Yang C, 2002, NUCLEIC ACIDS RES, V30, P2251, DOI 10.1093/nar/30.10.2251; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zheng X, 2005, BIOCHEM BIOPH RES CO, V329, P95, DOI 10.1016/j.bbrc.2005.01.105; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	93	67	69	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	55					7274	7288		10.1038/sj.onc.1209714	http://dx.doi.org/10.1038/sj.onc.1209714			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	108MU	16751805				2022-12-17	WOS:000242244700006
J	Incassati, A; Patel, D; McCance, DJ				Incassati, A; Patel, D; McCance, DJ			Induction of tetraploidy through loss of p53 and upregulation of Plk1 by human papillomavirus type-16 E6	ONCOGENE			English	Article						HPV-16; E6 and E7; tetraploidy; Plk1	POLO-LIKE KINASE-1; HUMAN KERATINOCYTES; SPINDLE CHECKPOINT; GROWTH ARREST; CANCER; CELLS; E7; DEGRADATION; EXPRESSION; ONCOPROTEIN	Cancer cells are insensitive to many signals that inhibit growth of untransformed cells. Here, we show that primary human epithelial cells expressing human papillomavirus (HPV) type-16 E6/E7 bypass arrest caused by the DNA-damaging drug adriamycin and become tetraploid. To determine the contribution of E6 in the context of E7 to the resistance of arrest and induction of tetraploidy, we used an E6 mutant unable to degrade p53 or RNAi targeting p53 for knockdown. The E6 mutant fails to generate tetraploidy; however, the presence of E7 is sufficient to bypass arrest while the p53 RNAi permits both arrest insensitivity and tetraploidy. We published previously that polo-like kinase 1(Plk1) is upregulated in E6/E7-expressing cells. We observe here that abnormal expression of Plk1 protein correlates with tetraploidy. Using the p53 binding-defective mutant of E6 and p53 RNAi, we show that p53 represses Plk1, suggesting that loss of p53 results in tetraploidy through upregulation of Plk1. Consistent with this hypothesis, overexpression of Plk1 in cells generates tetraploidy but does not confer resistance to arrest. These results support a model for transformation caused by HPV-16 where bypass of arrest and tetraploidy are separable consequences of p53 loss with Plk1 required only for the latter effect.	Univ Rochester, Dept Microbiol & Immunol, Rochester, NY 14642 USA; Univ Rochester, Dept Biomed Genet, Rochester, NY USA; Univ Rochester, James P Wilmot Canc Ctr, Rochester, NY USA	University of Rochester; University of Rochester; University of Rochester	McCance, DJ (corresponding author), Univ Rochester, Dept Microbiol & Immunol, Box 672, Rochester, NY 14642 USA.	dennis_mccance@urmc.rochester.edu			NIDCR NIH HHS [DE13526, T32-DE07165] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [T32DE007165, R01DE013526] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Burd EM, 2003, CLIN MICROBIOL REV, V16, P1, DOI 10.1128/CMR.16.1.1-17.2003; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Demers GW, 1996, J VIROL, V70, P6862, DOI 10.1128/JVI.70.10.6862-6869.1996; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Eichten A, 2002, VIROLOGY, V295, P74, DOI 10.1006/viro.2002.1375; Flatt PM, 1998, CELL GROWTH DIFFER, V9, P535; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; Galipeau PC, 1996, P NATL ACAD SCI USA, V93, P7081, DOI 10.1073/pnas.93.14.7081; Guan R, 2005, CANCER RES, V65, P2698, DOI 10.1158/0008-5472.CAN-04-2131; Hanks S, 2004, NAT GENET, V36, P1159, DOI 10.1038/ng1449; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Jackson MW, 2005, J CELL SCI, V118, P1821, DOI 10.1242/jcs.02307; Kho PS, 2004, J BIOL CHEM, V279, P21183, DOI 10.1074/jbc.M311912200; Knecht R, 1999, CANCER RES, V59, P2794; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; McMurray HR, 2004, J VIROL, V78, P5698, DOI 10.1128/JVI.78.11.5698-5706.2004; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Michel L, 2004, P NATL ACAD SCI USA, V101, P4459, DOI 10.1073/pnas.0306069101; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Mundt KE, 1997, BIOCHEM BIOPH RES CO, V239, P377, DOI 10.1006/bbrc.1997.7378; MUNGER K, 1989, J VIROL, V63, P4417; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Patel D, 2004, CANCER RES, V64, P1299, DOI 10.1158/0008-5472.CAN-03-2917; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Southern SA, 2004, BRIT J CANCER, V90, P1949, DOI 10.1038/sj.bjc.6601827; Spankuch-Schmitt B, 2002, JNCI-J NATL CANCER I, V94, P1863, DOI 10.1093/jnci/94.24.1863; Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276; Thomas JT, 1998, J VIROL, V72, P1131, DOI 10.1128/JVI.72.2.1131-1137.1998; Thompson DA, 1997, ONCOGENE, V15, P3025, DOI 10.1038/sj.onc.1201495; Weichert W, 2005, VIRCHOWS ARCH, V446, P442, DOI 10.1007/s00428-005-1212-8; Weichert W, 2004, BRIT J CANCER, V90, P815, DOI 10.1038/sj.bjc.6601610; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690	36	67	70	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	17					2444	2451		10.1038/sj.onc.1209276	http://dx.doi.org/10.1038/sj.onc.1209276			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	034RJ	16369493				2022-12-17	WOS:000236948000003
J	Okuda, H; Toyota, M; Ishida, W; Furihata, M; Tsuchiya, M; Kamada, M; Tokino, T; Shuin, T				Okuda, H; Toyota, M; Ishida, W; Furihata, M; Tsuchiya, M; Kamada, M; Tokino, T; Shuin, T			Epigenetic inactivation of the candidate tumor suppressor gene HOXB13 in human renal cell carcinoma	ONCOGENE			English	Article						methylation; HOXB13; renal cell carcinoma; RCC	HYPERMETHYLATION-ASSOCIATED INACTIVATION; PROSTATE-CANCER CELLS; CPG-ISLAND; DNA METHYLATION; PROMOTER HYPERMETHYLATION; ABERRANT METHYLATION; GASTRIC-CANCER; CLEAR-CELL; COLORECTAL-CANCER; SOMATIC MUTATIONS	Epigenetic alterations like DNA methylation and the resulting inactivation of cancer-related genes often contribute to the development of various cancers. To identify the genes that are silenced by aberrant methylation in renal cell carcinoma (RCC), we subjected two RCC lines to methylated CpG island amplification/representational difference analysis. This identified 27 CpG islands. Combined bisulfite restriction analysis of these CpG islands in primary RCC cases revealed that four were methylated in a tumor-specific manner. One of these was identified as the human homeo-box gene B13 (HOXB13) gene, but the remaining three CpG islands were not associated with known genes. The methylation frequencies of HOXB13 in primary RCC samples and lines were 30 and 73%, respectively. The methylation status of HOXB13 correlated with the loss of its expression both in RCC lines and primary tumors, and methyltransferase inhibitor treatment induced the recovery of its expression. Exogenous expression of HOXB13 in RCC cells that lacked endogenous HOXB13 expression suppressed colony formation and induced apoptotic features. Furthermore, HOXB13 methylation correlated positively with tumor grade and microvessel invasion. These results suggest that HOXB13 is a novel candidate tumor suppressor gene in RCC and that its inactivation may play an important role in both RCC tumorigenesis and progression.	Kochi Med Sch, Dept Urol, Nankoku, Kochi 7838505, Japan; Sapporo Med Univ, Dept Internal Med 1, Sapporo, Hokkaido, Japan; Kochi Med Sch, Dept Ophthalmol, Nankoku, Kochi 7838505, Japan; Kochi Med Sch, Dept Tumor Pathol, Nankoku, Kochi 7838505, Japan; Sapporo Med Univ, Canc Res Inst, Dept Mol Biol, Sapporo, Hokkaido, Japan	Kochi University; Sapporo Medical University; Kochi University; Kochi University; Sapporo Medical University	Okuda, H (corresponding author), Kochi Med Sch, Dept Urol, Nankoku, Kochi 7838505, Japan.	okudah@med.kochi-u.ac.jp	Tokino, Takashi/AAI-9887-2021					Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Dulaimi E, 2004, CLIN CANCER RES, V10, P3972, DOI 10.1158/1078-0432.CCR-04-0175; Economides KD, 2003, DEVELOPMENT, V130, P2061, DOI 10.1242/dev.00432; Economides KD, 2003, DEV BIOL, V256, P317, DOI 10.1016/S0012-1606(02)00137-9; Esteller M, 2000, CANCER RES, V60, P129; Flagiello D, 1996, FEBS LETT, V380, P103, DOI 10.1016/0014-5793(96)00017-8; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Herman JG, 1996, CANCER RES, V56, P722; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Japanese Urological Association the Japanese Society of Pathology and the Japan Radiological Society, 1999, GEN RUL CLIN PATH ST, V4th; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jung C, 2004, CANCER RES, V64, P9185, DOI 10.1158/0008-5472.CAN-04-1330; Jung CY, 2004, CANCER RES, V64, P3046, DOI 10.1158/0008-5472.CAN-03-2614; Katzenellenbogen RA, 1999, BLOOD, V93, P4347, DOI 10.1182/blood.V93.12.4347.412k31_4347_4353; Kikuchi T, 2002, INT J CANCER, V97, P272, DOI 10.1002/ijc.1612; Mertens F, 1997, CANCER RES, V57, P2765; MORITA R, 1991, CANCER RES, V51, P820; Morrissey C, 2001, CANCER RES, V61, P7277; Nickerson ML, 2002, CANCER CELL, V2, P157, DOI 10.1016/S1535-6108(02)00104-6; Ogi K, 2002, CLIN CANCER RES, V8, P3164; Okami J, 2004, CANCER RES, V64, P5338, DOI 10.1158/0008-5472.CAN-04-0089; Sato K, 2001, BRIT J CANCER, V85, P199, DOI 10.1054/bjoc.2001.1888; Satoh A, 2003, CANCER RES, V63, P8606; SHUIN T, 1994, CANCER RES, V54, P2852; Shuin T, 1999, Contrib Nephrol, V128, P1; Sreenath T, 1999, PROSTATE, V41, P203, DOI 10.1002/(SICI)1097-0045(19991101)41:3<203::AID-PROS8>3.0.CO;2-J; Terasawa K, 2004, CLIN CANCER RES, V10, P2000, DOI 10.1158/1078-0432.CCR-0932-03; THOENES W, 1986, PATHOL RES PRACT, V181, P125, DOI 10.1016/S0344-0338(86)80001-2; Tokinaga K, 2004, ONCOL REP, V12, P805; Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849; Toyota M, 1999, CANCER RES, V59, P2307; Toyota M, 2003, P NATL ACAD SCI USA, V100, P7818, DOI 10.1073/pnas.1337066100; Toyota M, 1999, SEMIN CANCER BIOL, V9, P349, DOI 10.1006/scbi.1999.0135; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Toyota M, 1999, CANCER RES, V59, P4535; Ueki T, 2001, CANCER RES, V61, P8540; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466; Zeltser L, 1996, DEVELOPMENT, V122, P2475	46	67	77	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	12					1733	1742		10.1038/sj.onc.1209200	http://dx.doi.org/10.1038/sj.onc.1209200			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	021VJ	16278676				2022-12-17	WOS:000236013700005
J	Jacquel, A; Herrant, M; Defamie, V; Belhacene, N; Colosetti, P; Marchetti, S; Legros, L; Deckert, M; Mari, B; Cassuto, JP; Hofman, P; Auberger, P				Jacquel, A; Herrant, M; Defamie, V; Belhacene, N; Colosetti, P; Marchetti, S; Legros, L; Deckert, M; Mari, B; Cassuto, JP; Hofman, P; Auberger, P			A survey of the signaling pathways involved in megakaryocytic differentiation of the human K562 leukemia cell line by molecular and c-DNA array analysis	ONCOGENE			English	Article						megakaryocyte differentiation; PKC; MAPK; c-DNA array; leukemia	PROTEIN-KINASE-C; CHRONIC MYELOID-LEUKEMIA; ERYTHROID-DIFFERENTIATION; PHORBOL ESTER; EPH RECEPTORS; T-CELLS; ACTIVATION; INHIBITION; EXPRESSION; SURVIVAL	The K562 cell line serves as a model to study the molecular mechanisms associated with leukemia differentiation. We show here that cotreatment of K562 cells with PMA and low doses of SB202190 (SB), an inhibitor of the p38 MAPK pathway, induced a majority of cells to differentiate towards the megakaryocytic lineage. Electronic microscopy analysis showed that K562 cells treated with PMA+SB exhibited characteristic features of physiological megakaryocytic differentiation including the presence of vacuoles and demarcation membranes. Differentiation was also accompanied by a net increase in megakaryocytic markers and a reduction of erythroid markers, especially when both effectors were present. PMA effect was selectively mediated by new PKC isoforms. Differentiation of K562 cells by the combination of PMA and SB required Erk1/2 activation, a threshold of JNK activation and p38 MAPK inhibit ion. Interestingly, higher concentrations of SB, which drastically activated JNK, blocked megakaryocytic differentiation, and considerably increased cell death in the presence of PMA. c-DNA microarray membranes and PCR analysis allow us to identify a set of genes modulated during PMA-induced K562 cell differentiation. Several gene families identified in our screening, including ephrins receptors and some angiogenic factors, had never been reported so far to be regulated during megakaryocytic differentiation.	Univ Nice Sophia Antipolis, U526, Fac Med Pasteur, INSERM,Equipe Labellisee Ligue Natl Canc,IFR50, F-06107 Nice 2, France; CNRS, Inst Pharmacol Mol & Cellulaire, UMR 6097, F-06560 Valbonne, France; Hop Archet, Hematol Serv, F-06202 Nice 2, France; Hop Archet, INSERM, U576, F-06202 Nice, France; Univ Nice Sophia Antipolis, INSERM, U721, IFR50,Fac Med, F-06107 Nice 2, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Auberger, P (corresponding author), Univ Nice Sophia Antipolis, U526, Fac Med Pasteur, INSERM,Equipe Labellisee Ligue Natl Canc,IFR50, Ave Valombrose, F-06107 Nice 2, France.	auberger@unice.fr	Marchetti, Sandrine/P-6479-2016; Deckert, Marcel/M-4998-2016; Hofman, Paul/P-7654-2018; Deckert, Marcel/T-3566-2019; Jacquel, Arnaud/O-1928-2017; Mari, Bernard P/D-7445-2015; Mari, Bernard/Q-5832-2019; Colosetti, Pascal/ABH-4585-2020; Mari, Bernard P/F-8960-2013; Jacquel, Arnaud/AAJ-4760-2021; AUBERGER, Patrick/G-1491-2013; Mari, Bernard P/GVS-3100-2022	Marchetti, Sandrine/0000-0001-8326-5730; Hofman, Paul/0000-0003-0431-9353; Deckert, Marcel/0000-0003-2094-559X; Jacquel, Arnaud/0000-0001-5062-8048; Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard/0000-0002-0422-9182; Mari, Bernard P/0000-0002-0422-9182; Jacquel, Arnaud/0000-0001-5062-8048; AUBERGER, Patrick/0000-0002-2481-8275; Mari, Bernard P/0000-0002-0422-9182; Defamie, Virginie/0000-0002-6405-0539				ALITALO R, 1990, LEUKEMIA RES, V14, P501, DOI 10.1016/0145-2126(90)90002-Q; Belhacene N, 1998, FASEB J, V12, P531; Bertolotto C, 2000, J BIOL CHEM, V275, P37246, DOI 10.1074/jbc.M007732200; Brantley-Sieders D, 2004, CURR PHARM DESIGN, V10, P3431, DOI 10.2174/1381612043383160; Busuttil V, 2002, ONCOGENE, V21, P3213, DOI 10.1038/sj.onc.1205433; Chen G, 2000, J BIOL CHEM, V275, P38973, DOI 10.1074/jbc.M002856200; CHENG T, 1994, J BIOL CHEM, V269, P30848; Cramer EM, 1997, BLOOD, V89, P2336, DOI 10.1182/blood.V89.7.2336; Dorsey JF, 2002, BLOOD, V99, P1388, DOI 10.1182/blood.V99.4.1388; Garcia J, 2002, EMBO J, V21, P5151, DOI 10.1093/emboj/cdf488; Goldfarb AN, 2001, J BIOL CHEM, V276, P29526, DOI 10.1074/jbc.M103825200; Herrant M, 2002, ONCOGENE, V21, P4957, DOI 10.1038/sj.onc.1205689; Herrera R, 1998, EXP CELL RES, V238, P407, DOI 10.1006/excr.1997.3847; Hong Y, 1996, BLOOD, V87, P123, DOI 10.1182/blood.V87.1.123.bloodjournal871123; Huang M, 2004, LEUKEMIA, V18, P1857, DOI 10.1038/sj.leu.2403490; Jacquel A, 2003, FASEB J, V17, P2160, DOI 10.1096/fj.03-0322fje; Kawano T, 2004, LEUKEMIA RES, V28, P623, DOI 10.1016/j.leukres.2003.10.022; Kawano T, 2004, MOL CELL BIOCHEM, V258, P25, DOI 10.1023/B:MCBI.0000012830.96393.b9; Kim KW, 2001, J BIOL CHEM, V276, P13186, DOI 10.1074/jbc.M008092200; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Lam LT, 2000, J BIOL CHEM, V275, P19676, DOI 10.1074/jbc.M002866200; Legros L, 2004, BLOOD, V104, P495, DOI 10.1182/blood-2003-08-2695; LONG MW, 1990, J CLIN INVEST, V85, P1072, DOI 10.1172/JCI114538; Matsumura I, 2000, BLOOD, V96, P2440; Melemed AS, 1997, BLOOD, V90, P3462, DOI 10.1182/blood.V90.9.3462; MOORE DC, 1991, BLOOD, V77, P1452; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; Nalefski EA, 2001, BIOCHEMISTRY-US, V40, P13216, DOI 10.1021/bi010761u; NAMCIU S, 1994, ONCOGENE, V9, P1407; NEUBAUER A, 1994, BLOOD, V84, P1931; Park JI, 2001, CELL GROWTH DIFFER, V12, P481; Parker PJ, 2004, J CELL SCI, V117, P131, DOI 10.1242/jcs.00982; Pettiford SM, 2003, LEUKEMIA, V17, P366, DOI 10.1038/sj.leu.2402767; Poliakov A, 2004, DEV CELL, V7, P465, DOI 10.1016/j.devcel.2004.09.006; Racke FK, 1997, J BIOL CHEM, V272, P23366, DOI 10.1074/jbc.272.37.23366; Racke FK, 2001, J BIOL CHEM, V276, P522, DOI 10.1074/jbc.M005236200; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Rouyez MC, 1997, MOL CELL BIOL, V17, P4991, DOI 10.1128/MCB.17.9.4991; Ruan GR, 2004, LEUKEMIA RES, V28, P763, DOI 10.1016/j.leukres.2003.11.017; Schaefer M, 2001, FASEB J, V15, P1634, DOI 10.1096/fj.00-0824fje; Shelly C, 1998, LEUKEMIA, V12, P1951, DOI 10.1038/sj.leu.2401221; Surawska H, 2004, CYTOKINE GROWTH F R, V15, P419, DOI 10.1016/j.cytogfr.2004.09.002; Tanimura A, 2002, J BIOL CHEM, V277, P29054, DOI 10.1074/jbc.M201130200; Uddin S, 2004, P NATL ACAD SCI USA, V101, P147, DOI 10.1073/pnas.0307075101; Villalba M, 2001, J IMMUNOL, V166, P5955, DOI 10.4049/jimmunol.166.10.5955; Wang XN, 2001, J CELL BIOCHEM, V82, P68, DOI 10.1002/jcb.1141; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947	47	67	68	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	5					781	794		10.1038/sj.onc.1209119	http://dx.doi.org/10.1038/sj.onc.1209119			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008VM	16186797				2022-12-17	WOS:000235068800013
J	Fukuyama, T; Ogita, H; Kawakatsu, T; Inagaki, M; Takai, Y				Fukuyama, T; Ogita, H; Kawakatsu, T; Inagaki, M; Takai, Y			Activation of Rac by cadherin through the c-Src-Rap1-phosphatidylinositol 3-kinase-Vav2 pathway	ONCOGENE			English	Article						cell protrusion; E-cadherin; signaling pathway	CELL-CELL-ADHESION; SMALL G-PROTEINS; NECTIN-LIKE MOLECULES; ADHERENS JUNCTIONS; TRANS-INTERACTIONS; TIGHT JUNCTIONS; FORCE MEASUREMENTS; C-SRC; CDC42; RAP1	Cadherin first forms homo-cis-dimerson the cell surface of the same cells, followed by formation of homo-trans-dimers(trans interactions) in a Ca2+ dependent manner, eventually causing adherens junctions. In addition, transinteracting cadherin induces activatio n of Rac small G protein, which stabilizes non-trans-interacting cadherin on the plasma membrane by inhibiting its endocytosis through the reorganization of the actin cytoskeleton. However, it has not fully been understood how cadherin induces the activation of Rac. We examined here the molecular mechanism of the activation of Rac by transinteracting cadherin in. fibroblasts and epithelial cells. Trans-interacting cadherin induced activation of c-Src locally at the cadherin-based cell-cell adhesion sites. c-Src then tyrosine- phosphorylated Vav2, one of the Rac-GDP/GTP exchange factors(GEFs), and induced activation of C3G, one of the Rap1-GEFs, through Crk adaptor protein, resulting in the activation of Rap1 locally at the cadherin-based cell-cell adhesion sites. The c-Src-catalysed tyrosine phosphorylation was not suf. cient for the activation of Vav2 and the c-Src-induced activation of Rap1 was additionally necessary for it, although activated Rap1 alone was not suf. cient for the activation of non-tyrosine-phosphorylated Vav2. This effect of Rap1 on Vav2 was mediated by phosphatidylinositol 3- kinase. We describe here the signaling pathway from trans-interacting cadherin to the activation of Rac.	Osaka Univ, Dept Mol Biol & Biochem, Grad Sch Med, Fac Med, Suita, Osaka 5650871, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Dept Mol Biol & Biochem, Grad Sch Med, Fac Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	ytakai@molbio.med.osaka-u.ac.jp	Ogita, Hisakazu/AAE-4416-2020	Ogita, Hisakazu/0000-0001-6750-1668				Arthur WT, 2004, J CELL BIOL, V167, P111, DOI 10.1083/jcb.200404068; Betson M, 2002, J BIOL CHEM, V277, P36962, DOI 10.1074/jbc.M207358200; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Bos JL, 2005, CURR OPIN CELL BIOL, V17, P123, DOI 10.1016/j.ceb.2005.02.009; Chu YS, 2004, J CELL BIOL, V167, P1183, DOI 10.1083/jcb.200403043; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; Fukuhara A, 2003, J BIOL CHEM, V278, P51885, DOI 10.1074/jbc.M308015200; Fukuhara T, 2004, J CELL BIOL, V166, P393, DOI 10.1083/jcb.200401093; Fukuyama T, 2005, J BIOL CHEM, V280, P815, DOI 10.1074/jbc.M411099200; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Hogan C, 2004, MOL CELL BIOL, V24, P6690, DOI 10.1128/mcb.24.15.6690-6700.2004; Honda T, 2003, BIOCHEM BIOPH RES CO, V306, P104, DOI 10.1016/S0006-291X(03)00919-7; Honda T, 2003, GENES CELLS, V8, P481, DOI 10.1046/j.1365-2443.2003.00649.x; Honda T, 2003, GENES CELLS, V8, P51, DOI 10.1046/j.1365-2443.2003.00616.x; Hoshino T, 2004, MOL BIOL CELL, V15, P1077, DOI 10.1091/mbc.E03-05-0321; Ichiba T, 1997, J BIOL CHEM, V272, P22215, DOI 10.1074/jbc.272.35.22215; Izumi G, 2004, J CELL BIOL, V166, P237, DOI 10.1083/jcb.200401078; Kawakatsu T, 2005, J BIOL CHEM, V280, P4940, DOI 10.1074/jbc.M408710200; Kawakatsu T, 2002, J BIOL CHEM, V277, P50749, DOI 10.1074/jbc.M209846200; Kim SH, 2000, J BIOL CHEM, V275, P36999, DOI 10.1074/jbc.M003430200; Kitamura T, 1999, MOL CELL BIOL, V19, P6286; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Kodama A, 2000, MOL BIOL CELL, V11, P2565, DOI 10.1091/mbc.11.8.2565; Kodama A, 1999, ONCOGENE, V18, P3996, DOI 10.1038/sj.onc.1202773; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; Martinez-Rico C, 2005, J BIOL CHEM, V280, P4753, DOI 10.1074/jbc.M412544200; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; Nagafuchi A, 2001, CURR OPIN CELL BIOL, V13, P600, DOI 10.1016/S0955-0674(00)00257-X; Nakagawa M, 2001, J CELL SCI, V114, P1829; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Price LS, 2004, J BIOL CHEM, V279, P35127, DOI 10.1074/jbc.M404917200; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; Sakakibara A, 2002, J CELL SCI, V115, P4915, DOI 10.1242/jcs.00207; Sakisaka T, 2004, CURR OPIN CELL BIOL, V16, P513, DOI 10.1016/j.ceb.2004.07.007; Shimizu K, 2003, J BIOCHEM, V134, P631, DOI 10.1093/jb/mvg198; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Takai Y, 2003, CANCER SCI, V94, P655, DOI 10.1111/j.1349-7006.2003.tb01499.x; Takai Y, 2003, J CELL SCI, V116, P17, DOI 10.1242/jcs.00167; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Tsygankova OM, 2001, MOL CELL BIOL, V21, P1921, DOI 10.1128/MCB.21.6.1921-1929.2001; Yagi T, 2000, GENE DEV, V14, P1169; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626	43	67	69	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					8	19		10.1038/sj.onc.1209010	http://dx.doi.org/10.1038/sj.onc.1209010			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16170364				2022-12-17	WOS:000234406400002
J	Gee, MFW; Tsuchida, R; Eichler-Jonsson, C; Das, B; Baruchel, S; Malkin, D				Gee, MFW; Tsuchida, R; Eichler-Jonsson, C; Das, B; Baruchel, S; Malkin, D			Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid	ONCOGENE			English	Article						autocrine signalling; vascular endothelial growth factor; rhabdomyosarcoma; all-trans-retinoic acid	TYROSINE-KINASE; VEGF RECEPTORS; ALVEOLAR RHABDOMYOSARCOMA; NEUROBLASTOMA-CELLS; SIGNAL-TRANSDUCTION; HUMAN KERATINOCYTES; PERMEABILITY FACTOR; TUMOR ANGIOGENESIS; COLORECTAL-CANCER; FACTOR FAMILY	Vascular endothelial growth factor ( VEGF) is a potent signalling molecule that acts through two tyrosine kinase receptors, VEGFR1 and VEGFR2. The upregulation of VEGF and its receptors is important in tumour-associated angiogenesis; however, recent studies suggest that several tumour cells express VEGF receptors and may be influenced by autocrine VEGF signalling. Rhabdomyosarcoma (RMS) is the most common paediatric soft-tissue sarcoma, and is dependent on autocrine signalling for its growth. The alveolar subtype of RMS is often characterized by the presence of a PAX3-FKHR translocation, and when introduced into non-RMS cells, the resultant fusion protein induces expression of VEGFR1. In our study, we examined the expression of VEGF and its receptors in RMS, and autocrine effects of VEGF on cell growth. VEGF and receptor mRNA and protein were found to be expressed in RMS cells. Exogenous VEGF addition resulted in extracellular signal-regulated kinase-1/2 phosphorylation and cell proliferation, and both were reduced by VEGFR1 blockade. Growth was also slowed by VEGFR1 inhibitor alone. Treatment of RMS cells with all-trans-retinoic acid decreased VEGF secretion and slowed cell growth, which was rescued by VEGF. These data suggest that autocrine VEGF signalling likely in. uences RMS growth and its inhibition may be an effective treatment for RMS.	Univ Toronto, Hosp Sick Children, Dept Paediat, Div Haematol Oncol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Malkin, D (corresponding author), Univ Toronto, Hosp Sick Children, Dept Paediat, Div Haematol Oncol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	david.malkin@sickkids.ca	Das, Bikul/ABF-9292-2020; Malkin, David/AAW-8715-2021					Barber TD, 2002, GENOMICS, V79, P278, DOI 10.1006/geno.2002.6703; Barr FG, 1999, CANCER RES, V59, P5443; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; Bates RC, 2003, CURR BIOL, V13, P1721, DOI 10.1016/j.cub.2003.09.002; Beierle EA, 2004, J SURG RES, V119, P56, DOI 10.1016/j.jss.2004.01.002; Beierle EA, 2003, J PEDIATR SURG, V38, P514, DOI 10.1053/jpsu.2003.50091; Borgstrom P, 1996, CANCER RES, V56, P4032; Brodowicz T, 1999, BRIT J CANCER, V80, P1350, DOI 10.1038/sj.bjc.6690528; Broggini M, 2003, LEUKEMIA, V17, P52, DOI 10.1038/sj.leu.2402788; Brower V, 2003, J NATL CANCER I, V95, P1425; Claesson-Welsh L, 2003, BIOCHEM SOC T, V31, P20, DOI 10.1042/bst0310020; CROUCH GD, 1991, CANCER RES, V51, P4882; Damert A, 2002, DEVELOPMENT, V129, P1881; DAS B, IN PRESS CANC RES; DAVIS RJ, 1994, CANCER RES, V54, P2869; DEGIOVANNI C, 1995, BRIT J CANCER, V72, P1224, DOI 10.1038/bjc.1995.490; del Rincon SV, 2003, ONCOGENE, V22, P3353, DOI 10.1038/sj.onc.1206485; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Dias S, 2001, P NATL ACAD SCI USA, V98, P10857, DOI 10.1073/pnas.191117498; Dias S, 2000, J CLIN INVEST, V106, P511, DOI 10.1172/JCI8978; Dias S, 2002, BLOOD, V99, P2532, DOI 10.1182/blood.V99.7.2532; Diaz BV, 2000, J BIOL CHEM, V275, P642, DOI 10.1074/jbc.275.1.642; ELBADRY OM, 1990, CELL GROWTH DIFFER, V1, P325; Fan F, 2005, ONCOGENE, V24, P2647, DOI 10.1038/sj.onc.1208246; Ferrara N, 1996, EUR J CANCER, V32A, P2413, DOI 10.1016/S0959-8049(96)00387-5; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fuh G, 2000, J BIOL CHEM, V275, P26690; Gille H, 2000, EMBO J, V19, P4064, DOI 10.1093/emboj/19.15.4064; Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299; Isner JM, 1999, NAT MED, V5, P491, DOI 10.1038/8374; Itokawa T, 2002, MOL CANCER THER, V1, P295; Joukov V, 1996, EMBO J, V15, P290; Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066; KALEBIC T, 1994, CANCER RES, V54, P5531; Karkkainen MJ, 2001, P NATL ACAD SCI USA, V98, P12677, DOI 10.1073/pnas.221449198; Ke LD, 1998, INT J ONCOL, V12, P1391; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; Kendall RL, 1996, BIOCHEM BIOPH RES CO, V226, P324, DOI 10.1006/bbrc.1996.1355; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kini AR, 2001, BLOOD, V97, P3919, DOI 10.1182/blood.V97.12.3919; Kita Y, 1996, BIOCHEM BIOPH RES CO, V226, P59, DOI 10.1006/bbrc.1996.1311; KOUFOS A, 1985, NATURE, V316, P330, DOI 10.1038/316330a0; Langer I, 2000, MED PEDIATR ONCOL, V34, P386, DOI 10.1002/(SICI)1096-911X(200006)34:6<386::AID-MPO2>3.0.CO;2-3; Lu D, 2001, CANCER RES, V61, P7002; Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Manley PW, 2004, BBA-PROTEINS PROTEOM, V1697, P17, DOI 10.1016/j.bbapap.2003.11.010; Mercurio AM, 2004, SEMIN CANCER BIOL, V14, P115, DOI 10.1016/j.semcancer.2003.09.016; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; Millauer B, 1996, CANCER RES, V56, P1615; Narendran A, 2003, EXP HEMATOL, V31, P693, DOI 10.1016/S0301-472X(03)00159-0; Neufeld G, 2002, ADV EXP MED BIOL, V515, P81; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Orlandini M, 1996, P NATL ACAD SCI USA, V93, P11675, DOI 10.1073/pnas.93.21.11675; Parry TJ, 1999, NUCLEIC ACIDS RES, V27, P2569, DOI 10.1093/nar/27.13.2569; Podar K, 2004, BLOOD, V103, P3474, DOI 10.1182/blood-2003-10-3527; Podar K, 2001, BLOOD, V98, P428, DOI 10.1182/blood.V98.2.428; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Ricaud S, 2003, ONCOGENE, V22, P8221, DOI 10.1038/sj.onc.1207177; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SCHWEIGERER L, 1987, P NATL ACAD SCI USA, V84, P842, DOI 10.1073/pnas.84.3.842; Selvaraj SK, 2003, BLOOD, V102, P1515, DOI 10.1182/blood-2002-11-3423; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Suzuki K, 1996, CANCER RES, V56, P3004; Tammela T, 2005, CARDIOVASC RES, V65, P550, DOI 10.1016/j.cardiores.2004.12.002; Wakiya K, 1996, J BIOL CHEM, V271, P30823, DOI 10.1074/jbc.271.48.30823; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Weninger W, 1998, J INVEST DERMATOL, V111, P907, DOI 10.1046/j.1523-1747.1998.00393.x; Wey Jane S, 2004, Clin Adv Hematol Oncol, V2, P37; Willett CG, 2004, NAT MED, V10, P145, DOI 10.1038/nm988; YOUNG J L JR, 1986, Cancer, V58, P598, DOI 10.1002/1097-0142(19860715)58:2+<598::AID-CNCR2820581332>3.0.CO;2-C; Zachary I, 2000, ARTERIOSCL THROM VAS, V20, P1512, DOI 10.1161/01.ATV.20.6.1512; Zachary I, 2001, CARDIOVASC RES, V49, P568, DOI 10.1016/S0008-6363(00)00268-6; Zhang LJ, 1998, ONCOGENE, V17, P1261, DOI 10.1038/sj.onc.1202050; Ziegler BL, 1999, SCIENCE, V285, P1553, DOI 10.1126/science.285.5433.1553	77	67	83	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2005	24	54					8025	8037		10.1038/sj.onc.1208939	http://dx.doi.org/10.1038/sj.onc.1208939			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	989EV	16116481				2022-12-17	WOS:000233656600009
J	Rokhlin, OW; Taghiyev, AF; Guseva, NV; Glover, RA; Chumakov, PM; Kravchenko, JE; Cohen, MB				Rokhlin, OW; Taghiyev, AF; Guseva, NV; Glover, RA; Chumakov, PM; Kravchenko, JE; Cohen, MB			Androgen regulates apoptosis induced by TNFR family ligands via multiple signaling pathways in LNCaP	ONCOGENE			English	Article						androgen; androgen receptor; Akt; p53; caspase-2; apoptosis	PROSTATE-CANCER-CELLS; FAS-MEDIATED APOPTOSIS; LINE LNCAP; RECEPTOR; ACTIVATION; CASPASE-2; PROTEIN; DEATH; MITOCHONDRIA; P53	It has been suggested in many studies that combined treatment with chemotherapeutic agents and apoptosis-inducing ligands belonging to TNFR family is a more effective strategy for cancer treatment. However, the role of androgen regulation of TNFR family-induced apoptosis in prostate cancer is poorly understood. In this study, we investigated the dose-dependent effects of androgen on TNF-alpha and TRAIL-mediated apoptosis in LNCaP. To investigate the interaction between the androgen receptor (AR) and the caspase-2 gene, chromatin immunoprecipitation analysis was used, and we are the first to identify that AR interacts in vivo with an androgen-responsive elements in intron 8 of caspase-2 gene. We have found that DHT inhibited apoptosis in dose-dependent manner. There is a direct, androgen-dependent correlation between the levels of activated Akt and caspase activation after treatment with TNF-alpha and TRAIL. W e have also found that there are at least two different regulatory mechanisms of p53 expression by androgen: at the gene and protein levels. At the same time, the level of AR was found to be higher in LNCaP-si-p53 compared to LNCaP-mock cells. The se data indicate that there is a mutual regulation of expression between p53 and AR. Our study suggests that androgen-dependent outcome of apoptotic treatment can occur, at least in part, via the caspase-2, Akt and p53-mediated pathways.	Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, Cleveland, OH 44195 USA	University of Iowa; Cleveland Clinic Foundation	Rokhlin, OW (corresponding author), Univ Iowa, Dept Pathol, 1163 ML, Iowa City, IA 52242 USA.	oskar-rokhlin@uiowa.edu	Chumakov, Peter M/E-7731-2014	Chumakov, Peter/0000-0002-8078-2908	NATIONAL CANCER INSTITUTE [R01CA104903] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG025278] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA104903, R01 CA104903-01A1, CA 87717] Funding Source: Medline; NIA NIH HHS [R01 AG025278, R01 AG025278-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Budanov AV, 2004, SCIENCE, V304, P596, DOI 10.1126/science.1095569; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Coffey RNT, 2002, PROSTATE, V53, P300, DOI 10.1002/pros.10159; Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; Gnanapragasam V, 2003, BRIT J CANCER, V88, P1432, DOI 10.1038/sj.bjc.6600875; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Guseva NV, 2004, J CELL BIOCHEM, V91, P70, DOI 10.1002/jcb.10707; Heisler LE, 1997, MOL CELL ENDOCRINOL, V126, P59, DOI 10.1016/S0303-7207(96)03970-6; Hill MM, 2002, PHARMACOL THERAPEUT, V93, P243, DOI 10.1016/S0163-7258(02)00193-6; Huang HJ, 2004, ONCOGENE, V23, P2161, DOI 10.1038/sj.onc.1207326; Huang HJ, 2004, J BIOL CHEM, V279, P13866, DOI 10.1074/jbc.M314143200; Isaacs JT, 2004, NAT MED, V10, P26, DOI 10.1038/nm0104-26; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Linja MJ, 2001, CANCER RES, V61, P3550; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Mayo LD, 2002, TRENDS BIOCHEM SCI, V27, P462, DOI 10.1016/S0968-0004(02)02166-7; Murillo H, 2001, ENDOCRINOLOGY, V142, P4795, DOI 10.1210/en.142.11.4795; NANTERMET PV, 2004, SCIENCE, V304, P843; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; Pinski J, 2001, CANCER RES, V61, P6372; Reed JC, 2003, CANCER CELL, V3, P17, DOI 10.1016/S1535-6108(02)00241-6; Robertson JD, 2004, EMBO REP, V5, P643, DOI 10.1038/sj.embor.7400153; Rokhlin OW, 1998, CANCER RES, V58, P5870; Rokhlin OW, 2000, ONCOGENE, V19, P1959, DOI 10.1038/sj.onc.1203453; Rokhlin OW, 2002, CANCER BIOL THER, V1, P631, DOI 10.4161/cbt.311; Rokhlin OW, 2002, J BIOL CHEM, V277, P33213, DOI 10.1074/jbc.M204612200; Rokhlin OW, 2004, CANCER BIOL THER, V3, P761, DOI 10.4161/cbt.3.8.970; Rokhlin OW, 2001, ONCOGENE, V20, P2836, DOI 10.1038/sj.onc.1204410; Rokhlin OW, 1997, CANCER RES, V57, P1758; SONNENSCHEIN C, 1989, CANCER RES, V49, P3474; Sun M, 2003, J BIOL CHEM, V278, P42992, DOI 10.1074/jbc.M306295200; THALMANN GN, 1994, CANCER RES, V54, P2577; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Zornig M., 2001, BIOCHIM BIOPHYS ACTA, V1551, P1	40	67	69	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 13	2005	24	45					6773	6784		10.1038/sj.onc.1208833	http://dx.doi.org/10.1038/sj.onc.1208833			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973MV	16007156	Green Accepted			2022-12-17	WOS:000232527800005
J	Pavio, N; Battaglia, S; Boucreux, D; Arnulf, B; Sobesky, R; Hermine, O; Brechot, C				Pavio, N; Battaglia, S; Boucreux, D; Arnulf, B; Sobesky, R; Hermine, O; Brechot, C			Hepatitis C virus core variants isolated from liver tumor but not from adjacent non-tumor tissue interact with Smad3 and inhibit the TGF-beta pathway	ONCOGENE			English	Article						HCV; core protein; tumor; Smad3; TGF-beta; hepatocellularcarcinoma	HEPATOCELLULAR-CARCINOMA; TRANSCRIPTIONAL ACTIVATION; NONSTRUCTURAL PROTEINS; TRANSGENIC MICE; CELLS; DISEASE; BINDING; REGION; HOST; PKR	Hepatitis C virus (HCV) is a major risk factor for human hepatocellular carcinoma (HCC) but the mechanisms underlying HCV-induced carcinogenesis are still poorly understood. We have hypothesized that viral variants, selected during long-term infection, might contribute to cellular transformation. To address this issue, we have investigated the effect of natural HCV core variants isolated from liver tumors (T), or their non-tumor (NT) counterparts, on the tumor growth factor-b (TGF-beta) pathway, a major regulator of cellular proliferation, differentiation and apoptosis. We have found a significant reduction in TGF-beta reporter gene activity with the expression of core sequences isolated from liver tumors. In contrast, moderate or no effects were observed with non-tumor mutants or a core reference sequence. The molecular mechanisms have been characterized and involved the inhibition, by tumor-derived cores, of the DNA-binding activity of the Smad3/4 transcription factors complex. This inhibition occurs through a direct interaction between the central domain ( amino acids 59 - 126) of tumor-derived core and the MH1 DNA-binding domain of Smad3, thus preventing its binding to DNA. We have therefore identified a new cell-signaling pathway targeted by HCV core and inhibited by tumor-derived core sequences. These results suggest that during chronic infection, there is selection of viral variants that may promote cell transformation by providing, to clonally expanding cells, resistance to TGF-beta antiproliferative effects.	Univ Paris 05, INSERM, U370, F-75730 Paris, France; Univ Paris 05, Necker Hosp, CNRS, UMR 8137, F-75743 Paris, France; Univ Paris 05, Necker Hosp, Dept Hematol, F-75743 Paris, France; Univ Florence, Dept Internal Med, I-50121 Florence, Italy	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Florence	Pavio, N (corresponding author), Univ Paris 05, INSERM, U370, 156 Rue Vaugirard, F-75730 Paris, France.	pavio@necker.fr; hermine@necker.fr	Sobesky, Rodolphe/T-7723-2018; Hermine, Olivier/Q-7072-2018	Hermine, Olivier/0000-0003-2574-3874				Alam SS, 2002, ACTA MED OKAYAMA, V56, P141; Arnulf B, 2002, BLOOD, V100, P4129, DOI 10.1182/blood-2001-12-0372; Barba G, 1997, P NATL ACAD SCI USA, V94, P1200, DOI 10.1073/pnas.94.4.1200; Bartenschlager Ralf, 2004, Hepatology, V39, P835, DOI 10.1002/hep.20122; Bataller R, 2004, GASTROENTEROLOGY, V126, P529, DOI 10.1053/j.gastro.2003.11.018; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Bonnet MC, 2000, MOL CELL BIOL, V20, P4532, DOI 10.1128/MCB.20.13.4532-4542.2000; Cheng PL, 2004, ONCOGENE, V23, P7821, DOI 10.1038/sj.onc.1208066; Delhem N, 2001, ONCOGENE, V20, P5836, DOI 10.1038/sj.onc.1204744; Duvoux C, 1999, J HEPATOL, V31, P593, DOI 10.1016/S0168-8278(99)80336-5; Fukuda M, 2002, VIROLOGY, V302, P310, DOI 10.1006/viro.2002.1619; KOBAYASHI S, 1994, CANCER, V73, P48, DOI 10.1002/1097-0142(19940101)73:1<48::AID-CNCR2820730110>3.0.CO;2-L; Kunkel M, 2004, FEBS LETT, V557, P174, DOI 10.1016/S0014-5793(03)01486-8; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Lai MMC, 2000, CURR TOP MICROBIOL, V242, P117; Laporte J, 2003, BLOOD, V101, P52, DOI 10.1182/blood-2002-03-0818; Lee DK, 2002, J BIOL CHEM, V277, P38557, DOI 10.1074/jbc.M206786200; Lee DK, 2002, J BIOL CHEM, V277, P33766, DOI 10.1074/jbc.M200150200; Lerat H, 2002, GASTROENTEROLOGY, V122, P352, DOI 10.1053/gast.2002.31001; Lerat H, 1998, BLOOD, V91, P3841, DOI 10.1182/blood.V91.10.3841.3841_3841_3849; Major ME, 1997, HEPATOLOGY, V25, P1527, DOI 10.1002/hep.510250637; Marcellin P, 2002, HEPATOLOGY, V36, pS47, DOI 10.1053/jhep.2002.36993; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; McLauchlan J, 2002, EMBO J, V21, P3980, DOI 10.1093/emboj/cdf414; Moriya K, 1998, NAT MED, V4, P1065, DOI 10.1038/2053; Nelson DR, 1997, J VIRAL HEPATITIS, V4, P29, DOI 10.1046/j.1365-2893.1997.00124.x; Neuman MG, 2002, J VIRAL HEPATITIS, V9, P134, DOI 10.1046/j.1365-2893.2002.00343.x; Nishihara A, 1999, J BIOL CHEM, V274, P28716, DOI 10.1074/jbc.274.40.28716; Ogata S, 2003, J CLIN MICROBIOL, V41, P2835, DOI 10.1128/JCM.41.7.2835-2841.2003; Pavio N, 2002, J VIROL, V76, P1265, DOI 10.1128/JVI.76.3.1265-1272.2002; Pellerin M, 2004, J VIROL, V78, P4617, DOI 10.1128/JVI.78.9.4617-4627.2004; Polyak SJ, 1998, J VIROL, V72, P4288, DOI 10.1128/JVI.72.5.4288-4296.1998; Ruster B, 2001, J MED VIROL, V63, P128, DOI 10.1002/1096-9071(20000201)63:2&lt;128::AID-JMV1007&gt;3.0.CO;2-S; Sabile A, 1999, HEPATOLOGY, V30, P1064, DOI 10.1002/hep.510300429; Schwer B, 2004, J VIROL, V78, P7958, DOI 10.1128/JVI.78.15.7958-7968.2004; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shiffman ML, 2004, SEMIN LIVER DIS, V24, P1, DOI 10.1055/s-2004-832921; Taniguchi H, 2004, J MED VIROL, V72, P52, DOI 10.1002/jmv.10545; Tellinghuisen TL, 2002, CURR OPIN MICROBIOL, V5, P419, DOI 10.1016/S1369-5274(02)00341-7; Thimme R, 2002, P NATL ACAD SCI USA, V99, P15661, DOI 10.1073/pnas.202608299; Yasui K, 1998, J VIROL, V72, P6048, DOI 10.1128/JVI.72.7.6048-6055.1998; Zemel R, 2000, DIGEST DIS SCI, V45, P2199, DOI 10.1023/A:1026475421668	42	67	70	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2005	24	40					6119	6132		10.1038/sj.onc.1208749	http://dx.doi.org/10.1038/sj.onc.1208749			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	962GD	16007207				2022-12-17	WOS:000231718100006
J	Wang, CC; Tsai, MF; Hong, TM; Chang, GC; Chen, CY; Yang, WM; Chen, JJW; Yang, PC				Wang, CC; Tsai, MF; Hong, TM; Chang, GC; Chen, CY; Yang, WM; Chen, JJW; Yang, PC			The transcriptional factor YY1 upregulates the novel invasion suppressor HLJ1 expression and inhibits cancer cell invasion	ONCOGENE			English	Article						DnaJ-like HSP40; invasion suppressor; promoter; YY1; E-cadherin	CORE PROMOTER ELEMENT; HEAT-SHOCK PROTEINS; ZINC-FINGER PROTEIN; C-FOS PROMOTER; E-CADHERIN; LUNG-CANCER; MOLECULAR CHAPERONES; BINDING PROTEIN; ADENOVIRUS E1A; GENE	By using microarray and an invasion/ metastasis lung cell line model, we identified the DnaJ-like heat shock protein 40, HLJ1, and found that the expression of HLJ1 correlates negatively with cancer cell invasion ability. Overexpression of HLJ1 can suppress cancer cell invasion in vitro. We further characterize the putative promoter region and investigate the transcriptional regulations of human HLJ1. A serial deletion of the 1.2 kb at the 5'-flanking region of the human HLJ1 gene was subcloned into a vector containing reporter gene and transfected into human lung adenocarcinoma cell line CL1-0, followed by luciferase activity assay. The results indicated that the region from - 232 to +176 could drive the basal transcriptional activity of the HLJ1 gene. Sequence analysis of the HLJ1 gene promoter region showed absence of a TATA box, but identified an inverted CCAAT box and four YY1 transcriptional factor-binding sites, which may be important in the regulation of HLJ1 expression. Co-transfection of the YY1 and HLJ1 basal promoter regions, site-directed mutagenesis, and electrophoretic mobility shift assay confirmed that YY1 could upregulate HLJ1 basal promoter activity. Furthermore, we also demonstrated that overexpression of YY1 in CL1-0 cells can increase HLJ1 expression and reduce cell invasive capability. The reduction of cancer cell invasive ability is, at least in part, through upregulation of E-cadherin expression. The increase in HLJ1 and E-cadherin expression, as well as the suppression of invasion ability, can be reversed specifically by HLJ1 siRNA.	Natl Chung Hsing Univ, Inst Biomed Sci, Taichung 40227, Taiwan; Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, NTU Ctr Genom Med, Taipei, Taiwan; Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan; Natl Taiwan Univ, Coll Med, Sch Pharm, Taipei, Taiwan; Taichung Vet Gen Hosp, Dept Internal Med, Div Chest Med, Taichung, Taiwan; Chung Shan Med Univ, Inst Toxicol, Taichung, Taiwan; Taichung Vet Gen Hosp, Dept Surg, Div Thorac Surg, Taichung, Taiwan; Natl Chung Hsing Univ, Inst Mol Biol, Taichung 40227, Taiwan; Acad Sinica, Inst Biomed Sci, Taipei, Taiwan	National Chung Hsing University; National Defense Medical Center; National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; Taichung Veterans General Hospital; Chung Shan Medical University; Taichung Veterans General Hospital; National Chung Hsing University; Academia Sinica - Taiwan	Chen, JJW (corresponding author), Natl Chung Hsing Univ, Inst Biomed Sci, Taichung 40227, Taiwan.	jwchen@dragon.nchu.edu.tw	Yang, Pan-Chyr/B-8808-2009	YANG, PAN-CHYR/0000-0001-6330-6048; Chen, Jeremy J.W./0000-0003-1049-3825; Yang, Wen-Ming/0000-0002-5871-5979				Austen M, 1998, ONCOGENE, V17, P511, DOI 10.1038/sj.onc.1201968; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D; BIRCH M, 1991, CANCER RES, V51, P6660; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Bremnes RM, 2002, LUNG CANCER, V36, P115, DOI 10.1016/S0169-5002(01)00471-8; Bukholm IK, 1998, J PATHOL, V185, P262, DOI 10.1002/(SICI)1096-9896(199807)185:3<262::AID-PATH97>3.0.CO;2-Y; CAROLINE J, 2000, JNCI-J NATL CANCER I, V92, P1564; Chen HW, 2002, BRIT J PHARMACOL, V137, P771, DOI 10.1038/sj.bjp.0704908; Chen JJW, 2003, CLIN CANCER RES, V9, P729; Chen JJW, 2001, CANCER RES, V61, P5223; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; CRAIG EA, 1994, CELL, V78, P365, DOI 10.1016/0092-8674(94)90416-2; Ficzycz A, 2002, J BIOL CHEM, V277, P8382, DOI 10.1074/jbc.M110304200; Galvin KM, 1997, MOL CELL BIOL, V17, P3723, DOI 10.1128/MCB.17.7.3723; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; Guo B, 1997, P NATL ACAD SCI USA, V94, P121, DOI 10.1073/pnas.94.1.121; Hajra KM, 2002, CANCER RES, V62, P1613; Hamajima F, 2002, J CELL BIOCHEM, V84, P401, DOI 10.1002/jcb.10029; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HATTORI H, 1992, CELL STRUCT FUNCT, V17, P77, DOI 10.1247/csf.17.77; HEHLGANS T, 1995, J IMMUNOL, V154, P5181; Heinemeyer T, 1999, NUCLEIC ACIDS RES, V27, P318, DOI 10.1093/nar/27.1.318; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Hoe KL, 1998, BBA-PROTEIN STRUCT M, V1383, P4, DOI 10.1016/S0167-4838(97)00207-0; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; Li WW, 1997, MOL CELL BIOL, V17, P54, DOI 10.1128/MCB.17.1.54; Li WW, 1997, MOL CELL BIOL, V17, P61, DOI 10.1128/MCB.17.1.61; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LU SY, 1994, MOL CELL BIOL, V14, P6253, DOI 10.1128/MCB.14.9.6253; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; Matz M, 1999, NUCLEIC ACIDS RES, V27, P1558, DOI 10.1093/nar/27.6.1558; MEIER VS, 1994, MOL CELL BIOL, V14, P128, DOI 10.1128/MCB.14.1.128; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; Ohtsuka K, 2000, CELL STRESS CHAPERON, V5, P98, DOI 10.1379/1466-1268(2000)005<0098:MHDHCO>2.0.CO;2; OHTSUKA K, 1993, BIOCHEM BIOPH RES CO, V197, P235, DOI 10.1006/bbrc.1993.2466; PRESTRIDGE DS, 1991, COMPUT APPL BIOSCI, V7, P203; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHI Y, 1997, BIOCHIM BIOPHYS ACTA, V1332, P49; Shih JY, 2001, JNCI-J NATL CANCER I, V93, P1392, DOI 10.1093/jnci/93.18.1392; SREENATH T, 1992, CANCER RES, V52, P4942; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; ULEMINCKX K, 1991, CELL, V66, P107; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; WELCH WJ, 1992, PHYSIOL REV, V72, P1063, DOI 10.1152/physrev.1992.72.4.1063; Yao YL, 2001, MOL CELL BIOL, V21, P5979, DOI 10.1128/MCB.21.17.5979-5991.2001; ZHOU QJ, 1995, J VIROL, V69, P7402, DOI 10.1128/JVI.69.12.7402-7409.1995	54	67	80	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2005	24	25					4081	4093		10.1038/sj.onc.1208573	http://dx.doi.org/10.1038/sj.onc.1208573			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BA	15782117				2022-12-17	WOS:000229680300007
J	Gaggioli, C; Deckert, M; Robert, G; Abbe, P; Batoz, M; Ehrengruber, MU; Ortonne, JP; Ballotti, R; Tartare-Deckert, S				Gaggioli, C; Deckert, M; Robert, G; Abbe, P; Batoz, M; Ehrengruber, MU; Ortonne, JP; Ballotti, R; Tartare-Deckert, S			HGF induces fibronectin matrix synthesis in melanoma cells through MAP kinase-dependent signaling pathway and induction of Egr-1	ONCOGENE			English	Article						melanoma; fibronectin; HGF; B-RAF; Egr-1; signaling	TRANSCRIPTION FACTOR EGR-1; HUMAN ENDOTHELIAL-CELLS; SERUM RESPONSE ELEMENT; GENE-EXPRESSION; GROWTH-FACTOR; EXTRACELLULAR-MATRIX; MALIGNANT-MELANOMA; MESANGIAL CELLS; UP-REGULATION; NGFI-A	The matrix fibronectin protein is a multifunctional adhesive molecule that promotes migration and invasiveness of many tumors including melanomas. Increased fibronectin synthesis has been associated with the metastatic potential of melanoma cells; however, the molecular mechanisms underlying fibronectin overexpression during melanoma development are poorly understood. We report that hepatocyte growth factor/scatter factor (HGF) induces fibronectin expression and its extracellular assembly on the surface of melanoma cells through activation of mitogen-activated protein (MAP) kinase pathway, and induction and transcriptional activation of Early growth response-1 (Egr-1). Inhibition of B-RAF/ MAP kinase pathway by dominant-negative mutants and by U0126-abrogated HGF-induced Egr-1, and chromatin immunoprecipitation showed that Egr-1 is bound to the fibronectin promoter in response to HGF. Exogenously expressed Egr-1 increased fibronectin levels, while blockage of Egr-1 activation by expression of the Egr-1 corepressor NAB2 interfered with the upregulation of fibronectin synthesis induced by HGF, indicating that Egr-1 exerts a significant role in fibronectin expression in response to HGF. Finally, analysis of the expression pattern of fibronectin in melanoma cells demonstrated that fibronectin levels are correlated with constitutive MAP kinase signaling. Our data define a novel mechanism that might have important implications in regulation of melanoma progression by autocrine HGF signaling or by constitutive activation of MAP kinase pathway.	INSERM, Unite 597, Equipe Labellisee Ligue 2001, IFR 50,Fac Med, F-06107 Nice 2, France; Hop Archet, INSERM, Unite 576, F-06202 Nice, France; Univ Zurich, Brain Res Inst, CH-8057 Zurich, Switzerland	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; University of Zurich	Tartare-Deckert, S (corresponding author), INSERM, Unite 597, Equipe Labellisee Ligue 2001, IFR 50,Fac Med, 28 Ave Valmbrose, F-06107 Nice 2, France.	tartare@unice.fr	TARTARE-DECKERT, Sophie/P-6057-2015; BALLOTTI, Robert/F-8825-2013; gaggioli, cedric/L-5363-2019; Deckert, Marcel/M-4998-2016; Gaggioli, Cedric/Q-2642-2019; Deckert, Marcel/T-3566-2019; robert, guillaume/O-1935-2017; Gaggioli, Cedric/F-3658-2011	TARTARE-DECKERT, Sophie/0000-0001-8680-5720; Gaggioli, Cedric/0000-0002-4710-1605; Deckert, Marcel/0000-0003-2094-559X; robert, guillaume/0000-0002-6350-2222; Gaggioli, Cedric/0000-0002-4710-1605; BALLOTTI, Robert/0000-0002-7322-4908				Al Moustafa AE, 2002, ONCOGENE, V21, P2634, DOI 10.1038/sj.onc.1205351; Bertolotto C, 1998, J CELL BIOL, V142, P827, DOI 10.1083/jcb.142.3.827; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Brose MS, 2002, CANCER RES, V62, P6997; Buchwalter G, 2004, GENE, V324, P1, DOI 10.1016/j.gene.2003.09.028; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; Chavey C, 2003, J BIOL CHEM, V278, P11888, DOI 10.1074/jbc.M209196200; Choudhury GG, 2004, CELL SIGNAL, V16, P31, DOI 10.1016/S0898-6568(03)00094-9; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Cohen DM, 1996, J BIOL CHEM, V271, P12903, DOI 10.1074/jbc.271.22.12903; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Ehrengruber MU, 2000, GENE, V258, P63, DOI 10.1016/S0378-1119(00)00445-5; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Fu MG, 2003, GENE, V315, P33, DOI 10.1016/S0378-1119(03)00730-3; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Goding CR, 2000, GENE DEV, V14, P1712; Gradl D, 1999, MOL CELL BIOL, V19, P5576; Guo BL, 2004, DIABETES, V53, P200, DOI 10.2337/diabetes.53.1.200; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Herlyn M, 1996, AM J PATHOL, V149, P739; Hingorani SR, 2003, CANCER RES, V63, P5198; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; Hsu MY, 2002, DIFFERENTIATION, V70, P522, DOI 10.1046/j.1432-0436.2002.700906.x; HUMPHRIES MJ, 1989, CANCER INVEST, V7, P373, DOI 10.3109/07357908909039866; HUMPHRIES MJ, 1986, SCIENCE, V233, P467, DOI 10.1126/science.3726541; HYNES RO, 1982, J CELL BIOL, V95, P369, DOI 10.1083/jcb.95.2.369; Jiang YQ, 2002, ONCOGENE, V21, P2270, DOI 10.1038/sj.onc.1205278; Lee BH, 2002, BIOCHEM BIOPH RES CO, V297, P1218, DOI 10.1016/S0006-291X(02)02356-2; Li G, 2001, ONCOGENE, V20, P8125, DOI 10.1038/sj.onc.1205034; Liu CT, 2000, J BIOL CHEM, V275, P20315, DOI 10.1074/jbc.M909046199; Liu CT, 1996, P NATL ACAD SCI USA, V93, P11831, DOI 10.1073/pnas.93.21.11831; Mechtcheriakova D, 2001, FASEB J, V15, P230, DOI 10.1096/fj.00-0247com; Medico E, 2001, NAT BIOTECHNOL, V19, P579, DOI 10.1038/89343; NATALI PG, 1993, BRIT J CANCER, V68, P746, DOI 10.1038/bjc.1993.422; Noonan FP, 2000, CANCER RES, V60, P3738; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Recio JA, 2003, CANCER RES, V63, P1576; Ridley A, 2000, NATURE, V406, P466, DOI 10.1038/35020170; RUOSLAHTI E, 1989, CANCER CELL-MON REV, V1, P119; RUSSO MW, 1993, MOL CELL BIOL, V13, P6858, DOI 10.1128/MCB.13.11.6858; Sage EH, 2001, J CLIN INVEST, V107, P781, DOI 10.1172/JCI12683; Satyamoorthy K, 2003, CANCER RES, V63, P756; Silletti S, 1998, INT J CANCER, V76, P120, DOI 10.1002/(SICI)1097-0215(19980330)76:1<120::AID-IJC19>3.3.CO;2-G; Svaren J, 1996, MOL CELL BIOL, V16, P3545; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; Trusolino L, 2000, FASEB J, V14, P1629, DOI 10.1096/fj.14.11.1629; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Tsai JC, 2000, AM J PHYSIOL-CELL PH, V279, pC1414, DOI 10.1152/ajpcell.2000.279.5.C1414; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433; Wu SQ, 2002, BLOOD, V100, P4454, DOI 10.1182/blood-2002-02-0415; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	53	67	68	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2005	24	8					1423	1433		10.1038/sj.onc.1208318	http://dx.doi.org/10.1038/sj.onc.1208318			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898QZ	15608673				2022-12-17	WOS:000227092600012
J	Nittka, S; Gunther, J; Ebisch, C; Erbersdobler, A; Neumaier, M				Nittka, S; Gunther, J; Ebisch, C; Erbersdobler, A; Neumaier, M			The human tumor suppressor CEACAM1 modulates apoptosis and is implicated in early colorectal tumorigenesis	ONCOGENE			English	Article						CEACAM1; apoptosis; ACF; APC; beta-catenin; carcinogenesis	ABERRANT CRYPT FOCI; CARCINOEMBRYONIC ANTIGEN FAMILY; PROTEIN TRUNCATION TEST; CELL-ADHESION MOLECULE; COLI APC GENE; BILIARY GLYCOPROTEIN; ADENOMATOUS-POLYPOSIS; HYPERPLASTIC POLYPOSIS; CYTOPLASMIC DOMAIN; CANCER-CELLS	Defects in the adenomatous polyposis coli (APC) tumor suppressor pathway are sufficient for neoplastic transformation as the initiating step in colorectal carcinogenesis. In contrast, hyperplastic tumors possess normal APC function, and it is unclear whether they represent significant precursor lesion in cancer development. CEA-CAM1 is a tumor suppressor whose expression is known to be lost in the great majority of early adenomas and carcinomas. We found that loss of CEACAM1 expression is more common in neoplastic tumors than APC mutations. While APC function was normal in hyperplastic aberrant cypt foci and hyperplastic polyps, loss of CEACAM1 was observed as frequently as in the neoplasias. Moreover, the presence or absence of CEACAM1 expression in the hyperplastic tumors correlates with normal or reduced apoptosis, respectively. In vitro, CEACAM1 acts as a regulator of apoptosis in CEA-CAM1-transfected Jurkat cells. Finally, in human HT29 colon cancer cells, apoptosis can be specifically restored by induction of CEACAM1 expression. These data suggest an oncodevelopmental link between neoplasia and hyperplasia and demonstrate that CEACAM1 acts as a regulator of apoptosis in the colonic epithelium. Thus, failure of the maturing colon cell to express CEACAM1 is likely to contribute to the development of hyperplastic lesions, which may eventually pave the way to neoplastic transformation and colon cancer development.	Heidelberg Univ, Med Fac Mannheim, Inst Clin Chem, D-6800 Mannheim, Germany; Univ Hamburg, Hosp Eppendorf, Dept Pathol, D-20246 Hamburg, Germany	Ruprecht Karls University Heidelberg; University of Hamburg	Neumaier, M (corresponding author), Heidelberg Univ, Univ Hosp Mannheim, Inst Clin Chem, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.	michael.neumaier@ikc.ma.uni-heidelberg.de						Avizienyte E, 1999, AM J PATHOL, V154, P677, DOI 10.1016/S0002-9440(10)65314-X; Baas AF, 2004, CELL, V116, P457, DOI 10.1016/S0092-8674(04)00114-X; Bala S, 1996, HUM GENET, V98, P528, DOI 10.1007/s004390050254; Battu S, 1998, ANTICANCER RES, V18, P3579; Beauchemin N, 1999, EXP CELL RES, V252, P243; BIRD RP, 1987, CANCER LETT, V37, P147, DOI 10.1016/0304-3835(87)90157-1; BIRD RP, 1995, CANCER LETT, V93, P55, DOI 10.1016/0304-3835(95)03788-X; Blau DM, 2001, J VIROL, V75, P8173, DOI 10.1128/JVI.75.17.8173-8186.2001; BRUMMER J, 1995, ONCOGENE, V11, P1649; Esteller M, 2000, CANCER RES, V60, P4366; Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fournes B, 2001, ONCOGENE, V20, P219, DOI 10.1038/sj.onc.1204058; FRANGSMYR L, 1995, CANCER RES, V55, P2963; Goss KH, 2000, J CLIN ONCOL, V18, P1967, DOI 10.1200/JCO.2000.18.9.1967; Hammarstrom S, 1999, SEMIN CANCER BIOL, V9, P67, DOI 10.1006/scbi.1998.0119; Hawkins NJ, 2000, AM J PATHOL, V157, P385, DOI 10.1016/S0002-9440(10)64551-8; Hawkins NJ, 2001, J NATL CANCER I, V93, P1307, DOI 10.1093/jnci/93.17.1307; Herter P, 1999, J CANCER RES CLIN, V125, P297, DOI 10.1007/s004320050277; Izzi L, 1999, ONCOGENE, V18, P5563, DOI 10.1038/sj.onc.1202935; Jass JR, 2000, GUT, V47, P43, DOI 10.1136/gut.47.1.43; Jass JR, 2001, DIS COLON RECTUM, V44, P163, DOI 10.1007/BF02234287; JEN J, 1994, CANCER RES, V54, P5523; Kikuchi Y, 1997, VIRCHOWS ARCH, V431, P111, DOI 10.1007/s004280050076; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kirchgesser M, 1998, CLIN CHEM LAB MED, V36, P567, DOI 10.1515/CCLM.1998.097; Kirshner J, 2003, P NATL ACAD SCI USA, V100, P521, DOI 10.1073/pnas.232711199; Kunath T, 1995, ONCOGENE, V11, P2375; Launonen V, 2000, CANCER RES, V60, P546; Laurent-Puig P, 1999, EUR J CANCER PREV, V8, pS39; Michor F, 2004, CELL CYCLE, V3, P358; Mori H, 2004, MUTAT RES-REV MUTAT, V566, P191, DOI 10.1016/j.mrrev.2003.08.002; NAP M, 1992, CANCER RES, V52, P2329; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; Nollau P, 1997, AM J PATHOL, V151, P521; Nollau P, 1997, CANCER RES, V57, P2354; Otori K, 1998, CANCER, V83, P896, DOI 10.1002/(SICI)1097-0142(19980901)83:5<896::AID-CNCR14>3.0.CO;2-Q; OTORI K, 1995, CANCER RES, V55, P4743; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; Robitaille J, 1999, EUR J BIOCHEM, V264, P534, DOI 10.1046/j.1432-1327.1999.00660.x; Roncucci L, 2000, CELL PROLIFERAT, V33, P1, DOI 10.1046/j.1365-2184.2000.00159.x; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Shih LM, 2001, P NATL ACAD SCI USA, V98, P2640, DOI 10.1073/pnas.051629398; Shpitz B, 1996, DIS COLON RECTUM, V39, P763, DOI 10.1007/BF02054441; Singer BB, 2002, J IMMUNOL, V168, P5139, DOI 10.4049/jimmunol.168.10.5139; SMITH AJ, 1994, CANCER RES, V54, P5527; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; TAKAHASHI H, 1993, CANCER RES, V53, P1612; Tan S, 2002, INT J CANCER, V98, P523, DOI 10.1002/ijc.10236; Turbide C, 1997, CANCER RES, V57, P2781; Wynter CVA, 2004, GUT, V53, P573, DOI 10.1136/gut.2003.030841; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	54	67	67	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2004	23	58					9306	9313		10.1038/sj.onc.1208259	http://dx.doi.org/10.1038/sj.onc.1208259			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT	15568039				2022-12-17	WOS:000225764100002
J	Li, YH; Lu, WY; He, X; Schwartz, AL; Bu, GJ				Li, YH; Lu, WY; He, X; Schwartz, AL; Bu, GJ			LRP6 expression promotes cancer cell proliferation and tumorigenesis by altering beta-catenin subcellular distribution	ONCOGENE			English	Article						LRP6; beta-catenin; Writ signaling; proliferation; tumorigenesis	RECEPTOR-RELATED PROTEIN-5; WNT SIGNALING PATHWAY; ACTIVATION; MECHANISM; COMPLEX; PHOSPHORYLATION; OSTEOSARCOMA; DICKKOPF-1; MICE	The Wnt signaling pathway plays key roles in both embryogenesis and tumorigenesis. The low-density lipoprotein (LDL) receptor-related protein-6 (LRP6), a novel member of the expanding LDL receptor family, functions as an indispensable co-receptor for the Wnt signaling pathway. Although the role of LRP6 in embryonic development is now well established, its role in tumorigenesis is unclear. We report that LRP6 is readily expressed at the transcript level in several human cancer cell lines and human malignant tissues. Furthermore, using a retroviral gene transfer system, we find that stable expression of LRP6 in human fibrosarcoma HT1080 cells alters subcellular beta-catenin distribution such that the cytosolic beta-catenin level is significantly increased. This is accompanied by a significant increase in Wnt/beta-catenin signaling and cell proliferation. Finally, we demonstrate that LRP6 expression promotes tumorigenesis in vivo. These results thus indicate that LRP6 may function as a potential oncogenic protein by modulating Wnt/beta-catenin signaling.	Washington Univ, St Louis Childrens Hosp, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Neurol,Div Neurosci, Boston, MA 02115 USA; Washington Univ, Sch Med, St Louis Childrens Hosp, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, St Louis Childrens Hosp, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	St. Louis Children's Hospital; Washington University (WUSTL); Harvard University; Boston Children's Hospital; Harvard Medical School; St. Louis Children's Hospital; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL)	Li, YH (corresponding author), Washington Univ, Sch Med, Dept Pediat, CB 8208,660 S Euclid Ave, St Louis, MO 63110 USA.	li_yo@kids.wustl.edu						Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; BAO B, 2002, NATURE, V417, P664; BAO B, 2001, NATURE, V411, P321; BRENNAN K, 2004, ONCOGENE; Brott BK, 2002, MOL CELL BIOL, V22, P6100, DOI 10.1128/MCB.22.17.6100-6110.2002; Brown SD, 1998, BIOCHEM BIOPH RES CO, V248, P879, DOI 10.1006/bbrc.1998.9061; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117; Herz J, 2002, ANNU REV BIOCHEM, V71, P405, DOI 10.1146/annurev.biochem.71.110601.135342; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; Hoang BH, 2004, CANCER RES, V64, P2734, DOI 10.1158/0008-5472.CAN-03-1952; Hoang BH, 2004, INT J CANCER, V109, P106, DOI 10.1002/ijc.11677; Itasaki N, 2003, DEVELOPMENT, V130, P4295, DOI 10.1242/dev.00674; Klingelhofer J, 2003, ONCOGENE, V22, P1181, DOI 10.1038/sj.onc.1206245; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Li YH, 2002, J BIOL CHEM, V277, P42366, DOI 10.1074/jbc.M207705200; Li YS, 2000, J BIOL CHEM, V275, P37187, DOI 10.1074/jbc.M000490200; Liu GZ, 2003, MOL CELL BIOL, V23, P5825, DOI 10.1128/MCB.23.16.5825-5835.2003; Lustig B, 2003, J CANCER RES CLIN, V129, P199, DOI 10.1007/s00432-003-0431-0; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Qiang YW, 2003, ONCOGENE, V22, P1536, DOI 10.1038/sj.onc.1206239; Schneider WJ, 2003, CELL MOL LIFE SCI, V60, P892, DOI 10.1007/s00018-003-2183-z; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; Tamai K, 2004, MOL CELL, V13, P149, DOI 10.1016/S1097-2765(03)00484-2; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Wu W, 2000, CURR BIOL, V10, P1611, DOI 10.1016/S0960-9822(00)00868-X	32	67	91	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2004	23	56					9129	9135		10.1038/sj.onc.1208123	http://dx.doi.org/10.1038/sj.onc.1208123			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15516984				2022-12-17	WOS:000225492800014
J	Furuta, M; Weil, RJ; Vortmeyer, AO; Huang, S; Lei, JQ; Huang, TN; Lee, YS; Bhowmick, DA; Lubensky, IA; Oldfield, EH; Zhuang, ZP				Furuta, M; Weil, RJ; Vortmeyer, AO; Huang, S; Lei, JQ; Huang, TN; Lee, YS; Bhowmick, DA; Lubensky, IA; Oldfield, EH; Zhuang, ZP			Protein patterns and proteins that identify subtypes of glioblastoma multiforme	ONCOGENE			English	Article						malignant glioma; astrocytoma; microdissection; two-dimensional gel electrophoresis; protein sequencing; mass spectrometry	GENE-EXPRESSION; GLIOMAS; DNA; IDENTIFICATION; CLASSIFICATION; MICROARRAY; PROFILES; SURVIVAL; DATABASE; AGE	Glioblastoma multiforme (GBM) has been subdivided into two types based on clinical and genetic findings: primary tumors, which arise de novo, and secondary tumors, which progress from lower grade gliomas to GBMs. To analyse this dichotomy at the protein level, we employed selective tissue microdissection to obtain pure populations of tumor cells, which we studied using two-dimensional protein gel electrophoresis (2-DGE) and protein sequencing of select target proteins. Protein patterns were analysed in a blinded manner from the clinical and genetic data. 2-DGE clearly identified two distinct populations of tumors. 2-DGE was reproducible and reliable, as multiple samples analysed from the same patient gave identical results. In addition, we isolated and sequenced 11 proteins that were uniquely expressed in either the primary or the secondary GBMs, but not both. We demonstrate that specific proteomic patterns can be reproducibly identified by two-dimensional gel electrophoresis from limited numbers of selectively procured, microdissected tumor cells and that two patterns of GBMs, primary versus secondary, previously distinguished by clinical and genetic differences, can be recognized at the protein level. Proteins that are expressed distinctively may have important implications for the diagnosis, prognosis, and treatment of patients with GBM.	NINDS, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA; Saga Med Sch, Dept Neurosurg, Saga, Japan; Vanderbilt Univ, Sch Med, Dept Neurosurg, Nashville, TN 37212 USA; Transmedix Inc, Rockville, MD USA; Linden Biosci, Woburn, MA USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Saga University; Vanderbilt University	Weil, RJ (corresponding author), NINDS, Surg Neurol Branch, NIH, Bldg 10,Room 5D 37, Bethesda, MD 20892 USA.	weilr@ninds.nih.gov			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002991] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ausubel F.M., 1999, ANTO LEEUWEN, V34, P253; Batchelor TT, 2004, CLIN CANCER RES, V10, P228, DOI 10.1158/1078-0432.CCR-0841-3; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; Boeckmann B, 2003, NUCLEIC ACIDS RES, V31, P365, DOI 10.1093/nar/gkg095; Fuller GN, 2002, BRAIN PATHOL, V12, P108; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Godard S, 2003, CANCER RES, V63, P6613; GOTTLIEB M, 1987, ANAL BIOCHEM, V165, P33, DOI 10.1016/0003-2697(87)90197-7; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Hanash SM, 2002, PROTEOMICS, V2, P69, DOI 10.1002/1615-9861(200201)2:1<69::AID-PROT69>3.0.CO;2-8; Kapoor GS, 2003, NEUROSURGERY, V52, P1425, DOI 10.1227/01.NEU.0000065135.28143.39; Khatua S, 2003, CANCER RES, V63, P1865; Kim S, 2002, MOL CANCER THER, V1, P1229; Kleihues P, 1999, Neuro Oncol, V1, P44, DOI 10.1093/neuonc/1.1.44; Kleihues P, 2000, PATHOLOGY GENETICS T; Lacroix M, 2001, J NEUROSURG, V95, P190, DOI 10.3171/jns.2001.95.2.0190; Lal A, 1999, CANCER RES, V59, P5403; Mischel PS, 2003, ONCOGENE, V22, P2361, DOI 10.1038/sj.onc.1206344; Moore RE, 2002, J AM SOC MASS SPECTR, V13, P378, DOI 10.1016/S1044-0305(02)00352-5; Nutt CL, 2003, CANCER RES, V63, P1602; Palmer-Toy DE, 2000, CLIN CHEM, V46, P1513; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Ramaswamy S, 2002, J CLIN ONCOL, V20, P1932, DOI 10.1200/JCO.2002.20.7.1932; Rickman DS, 2001, CANCER RES, V61, P6885; Sallinen SL, 2000, CANCER RES, V60, P6617; Shai R, 2003, ONCOGENE, V22, P4918, DOI 10.1038/sj.onc.1206753; Simmons ML, 2001, CANCER RES, V61, P1122; Smith JS, 2001, JNCI-J NATL CANCER I, V93, P1246, DOI 10.1093/jnci/93.16.1246; Smith JS, 2000, FRONT BIOSCI-LANDMRK, V5, pD213, DOI 10.2741/Smith; STONE KL, 1993, PRACTICAL GUIDE PROT; Tortosa A, 2000, NEUROPATH APPL NEURO, V26, P544, DOI 10.1046/j.0305-1846.2000.00290.x; van den Boom J, 2003, AM J PATHOL, V163, P1033, DOI 10.1016/S0002-9440(10)63463-3; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Vortmeyer AO, 2003, NEUROLOGY, V61, P1626, DOI 10.1212/01.WNL.0000096168.85260.60; ZHUANG ZP, 1995, AM J PATHOL, V146, P620	36	67	69	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2004	23	40					6806	6814		10.1038/sj.onc.1207770	http://dx.doi.org/10.1038/sj.onc.1207770			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	850ZT	15286718				2022-12-17	WOS:000223653600012
J	Rieger-Christ, KM; Lee, P; Zagha, R; Kosakowski, M; Moinzadeh, A; Stoffel, J; Ben-Ze'ev, A; Libertino, JA; Summerhayes, IC				Rieger-Christ, KM; Lee, P; Zagha, R; Kosakowski, M; Moinzadeh, A; Stoffel, J; Ben-Ze'ev, A; Libertino, JA; Summerhayes, IC			Novel expression of N-cadherin elicits in vitro bladder cell invasion via the Akt signaling pathway	ONCOGENE			English	Article						N-cadherin; bladder; invasion; Akt	CANCER CELLS; CARCINOMA-CELLS; PROTEIN-KINASE; HUMAN BREAST; PROGRESSION; PP60C-SRC; ADHESION; METASTASIS; ACTIVATION; MIGRATION	Novel N-cadherin expression has been linked to the invasive phenotype in bladder tumors yet a primary role for N-cadherin in invasion has not been defined in this model. To address this, N-cadherin was stably transfected into E-cadherin expressing bladder carcinoma cells. This resulted in an enhanced invasive capacity in in vitro assays that was blocked by incubation with an N-cadherin function-blocking antibody in a dose-dependent manner. Analysis of the signaling pathway(s) implicated in N-cadherin-mediated invasion in bladder carcinoma cell fines revealed no correlation between MAPK signaling and invasion, in the presence or absence of fibroblast growth factor 2. Also, while MAPK and p38 kinase inhibitors did not alter the invasive behavior of these cells, an increase in the phosphorylation of Akt at serine-473 was detected in N-cadherin transfectants, suggestive of N-cadherin-mediated Akt activation in bladder cell invasion. Incubation of N-cadherin transfectants with either PI3 kinase or Akt inhibitors resulted in a significant decrease in the invasive capacity of these cells. Exposure of cells to PP2, a src family kinase inhibitor, also decreased the invasive potential of N-cadherin transfectants and resulted in reduced phosphorylation of Akt. The involvement of Akt signaling in bladder cell invasion was also supported by the inhibition of bladder cell invasion by cells constitutively expressing an activated Akt kinase, using the PI3 kinase and Akt inhibitors and PP2. These results suggest that activation of PI3/AKT kinase following N-cadherin expression contributes to the increased invasive potential of bladder carcinoma cells.	RE Wise MD Res & Educ Inst, Cell & Mol Biol Lab, Burlington, MA 01805 USA; Lahey Clin Fdn, Dept Urol, Burlington, MA 01805 USA; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Lahey Hospital & Medical Center; Weizmann Institute of Science	Summerhayes, IC (corresponding author), Lahey Clin Fdn, Cell & Mol Biol Lab, 31 Mall Rdd, Burlington, MA 01805 USA.	ian.c.summerhayes@lahey.org	Stoffel, John T./X-1441-2019	Stoffel, John/0000-0002-5503-4940; ben-ze'ev, avri/0000-0001-6113-3921	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059400] Funding Source: NIH RePORTER; NIDDK NIH HHS [1DK59400] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arboleda MJ, 2003, CANCER RES, V63, P196; BRINGUIER PP, 1993, CANCER RES, V53, P3241; Bussemakers MJG, 2000, INT J CANCER, V85, P446, DOI 10.1002/(SICI)1097-0215(20000201)85:3<446::AID-IJC23>3.3.CO;2-2; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen RY, 2001, J BIOL CHEM, V276, P31858, DOI 10.1074/jbc.C100271200; FANNING P, 1992, CANCER RES, V52, P1457; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Gee J, 1998, MOL UROL, V2, P73; Giroldi LA, 1999, INT J CANCER, V82, P70, DOI 10.1002/(SICI)1097-0215(19990702)82:1<70::AID-IJC13>3.3.CO;2-R; Grille SJ, 2003, CANCER RES, V63, P2172; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Hazan RB, 1996, CELL ADHES COMMUN, V4, P399, DOI 10.3109/15419069709004457; HONG RL, 1995, J UROLOGY, V153, P2025, DOI 10.1016/S0022-5347(01)67395-6; Hsu MY, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P188; Islam S, 1996, J CELL BIOL, V135, P1643, DOI 10.1083/jcb.135.6.1643; Kawakita Mutsushi, 1994, Acta Urologica Japonica, V40, P1077; Kim D, 2001, FASEB J, V15, P1953, DOI 10.1096/fj.01-0198com; Levenberg S, 1998, J CELL SCI, V111, P347; Li G, 2001, CANCER RES, V61, P3819; LIPPONEN PK, 1995, J CANCER RES CLIN, V121, P303, DOI 10.1007/BF01209598; Lu YL, 2003, J BIOL CHEM, V278, P40057, DOI 10.1074/jbc.M303621200; Mialhe A, 1997, ANAL CELL PATHOL, V13, P125, DOI 10.1155/1997/246136; MIYAZAKI J, 1995, JPN J UROL, V86, P1208; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; Paez Juan, 2003, Cancer Treat Res, V115, P145; Rieger-Christ KM, 2001, HUM PATHOL, V32, P18, DOI 10.1053/hupa.2001.21140; Sanders DSA, 1999, J CLIN PATHOL-MOL PA, V52, P151, DOI 10.1136/mp.52.3.151; Sotsios Y, 2000, IMMUNOL REV, V177, P217, DOI 10.1034/j.1600-065X.2000.17712.x; Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Thant AA, 2001, CLIN EXP METASTAS, V18, P423, DOI 10.1023/A:1010921730952; Tomita K, 2000, CANCER RES, V60, P3650; Tran NL, 2002, J BIOL CHEM, V277, P32905, DOI 10.1074/jbc.M200300200; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wang DS, 2000, INT J CANCER, V88, P620, DOI 10.1002/1097-0215(20001115)88:4<620::AID-IJC16>3.0.CO;2-Z; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781	39	67	73	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2004	23	27					4745	4753		10.1038/sj.onc.1207629	http://dx.doi.org/10.1038/sj.onc.1207629			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZX	15122336				2022-12-17	WOS:000221799200009
J	Wang, XF; Wang, QD; Hu, WQ; Evers, BM				Wang, XF; Wang, QD; Hu, WQ; Evers, BM			Regulation of phorbol ester-mediated TRAF1 induction in human colon cancer cells through a PKC/RAF/ERK/NF-kappa B-dependent pathway	ONCOGENE			English	Article						colon cancer; TRAF; PKC; NF-kappa B; ERK	NECROSIS-FACTOR RECEPTOR; PROTEIN-KINASE-C; GERANYLGERANYLTRANSFERASE-I INHIBITOR; SIGNAL-TRANSDUCTION PATHWAY; FACTOR FAMILY PROTEIN; SMOOTH-MUSCLE-CELLS; CYTOPLASMIC DOMAIN; PERSISTENT ACTIVATION; TRANSCRIPTION FACTOR; ADAPTER PROTEINS	Tumor necrosis factor (TNF) receptor-associated factors (TRAFs) are cytoplasmic adapter proteins that link a wide variety of cell surface receptors to the apoptotic signaling cascade. The purpose of this study was to delineate the signaling pathways and TRAF1 promoter elements responsible for phorbol ester-mediated TRAF1 induction in human colon cancers. Here, we found that the PKC activators, phorbol 12-myristate 13-acetate (PMA) and bryostatin I, induced TRAF1 mRNA expression; pretreatment with actinomycin D blocked PMA-mediated TRAF1 expression suggesting induction at the transcriptional level. In contrast, expression of other TRAFs (TRAF2, 3 and 4) was minimally altered by PMA. Various PKC isoform-selective inhibitors blocked PMA-mediated TRAF1 mRNA and promoter stimulation; rottlerin, a selective PKCdelta inhibitor, had no effect suggesting that Ca2+-dependent PKC isoforms (e.g., PKCalpha and betaI) play a role in TRAF1 regulation. In addition, the MEK/ERK inhibitors, PD98059 and UO126, suppressed PMA-stimulated TRAF1 promoter activity indicating a role for ERK in TRAF1 induction. Moreover, cotransfection of a dominant-negative Raf-1 (Raf-C4) significantly reduced PMA-stimulated TRAF1 promoter activity whereas transfection of dominant-negative Ras or treatment with Ras inhibitors had minimal to no effect on TRAF1 induction suggesting dependence on Raf, but not Ras, activation. Finally, site-specific mutagenesis of functional NF-kappaB sites (particularly the most proximal site) in the TRAF1 promoter significantly decreased PMA-mediated promoter activity. In conclusion, our results demonstrate selective induction of TRAF1 in human colon cancer cells through a Ca2+-dependent PKC/Raf-1/ERK/NF-kappaB-dependent pathway.	Univ Texas, Med Branch, Dept Surg, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Evers, BM (corresponding author), Univ Texas, Med Branch, Dept Surg, 301 Univ Blvd, Galveston, TX 77555 USA.	mevers@utmb.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048498] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01 DK35408, R01 DK48498] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; BETZEL C, 1993, BIOCHIM BIOPHYS ACTA, V1161, P47, DOI 10.1016/0167-4838(93)90194-V; BILLMAN GE, 1993, AM J PHYSIOL, V265, pH1529, DOI 10.1152/ajpheart.1993.265.5.H1529; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Brasier AR, 2001, J BIOL CHEM, V276, P32080, DOI 10.1074/jbc.M102949200; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Carpentier I, 1999, FEBS LETT, V460, P246, DOI 10.1016/S0014-5793(99)01356-3; Chen F, 1999, CLIN CHEM, V45, P7; Chiloeches A, 1999, J BIOL CHEM, V274, P19762, DOI 10.1074/jbc.274.28.19762; Deng JO, 2002, CANCER CELL, V2, P323, DOI 10.1016/S1535-6108(02)00154-X; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Dhawan P, 2002, J BIOL CHEM, V277, P7920, DOI 10.1074/jbc.M112210200; Dhillon AS, 2003, MOL CELL BIOL, V23, P1983, DOI 10.1128/MCB.23.6.1983-1993.2003; Dunn IF, 1999, MOL IMMUNOL, V36, P611, DOI 10.1016/S0161-5890(99)00075-9; EVERS BM, 1995, J CLIN INVEST, V95, P2822, DOI 10.1172/JCI117987; Fang XJ, 2002, MOL CELL BIOL, V22, P2099, DOI 10.1128/MCB.22.7.2099-2110.2002; Finder JD, 1997, J BIOL CHEM, V272, P13484, DOI 10.1074/jbc.272.21.13484; Gekeler V, 1996, BRIT J CANCER, V74, P897, DOI 10.1038/bjc.1996.454; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; Han SS, 2002, J BIOCHEM MOL BIOL, V35, P337; HENNINGS H, 1987, CARCINOGENESIS, V8, P1343, DOI 10.1093/carcin/8.9.1343; Hernandez A, 2001, J GASTROINTEST SURG, V5, P56, DOI 10.1016/S1091-255X(01)80014-7; Hipp MS, 2002, EUR J IMMUNOL, V32, P2208, DOI 10.1002/1521-4141(200208)32:8<2208::AID-IMMU2208>3.0.CO;2-2; Inoue J, 2000, EXP CELL RES, V254, P14, DOI 10.1006/excr.1999.4733; Irmler M, 2000, FEBS LETT, V468, P129, DOI 10.1016/S0014-5793(00)01206-0; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; James G, 1996, P NATL ACAD SCI USA, V93, P4454, DOI 10.1073/pnas.93.9.4454; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; Jiang BB, 2002, ARTERIOSCL THROM VAS, V22, P1811, DOI 10.1161/01.ATV.0000037679.60584.3F; Jiang BB, 2001, ARTERIOSCL THROM VAS, V21, P1915, DOI 10.1161/hq1201.099424; JIANG S, 1994, EXP CELL RES, V212, P84, DOI 10.1006/excr.1994.1121; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Ku WC, 1997, BIOCHEM BIOPH RES CO, V241, P730, DOI 10.1006/bbrc.1997.7874; Kurland JF, 2003, J BIOL CHEM, V278, P32465, DOI 10.1074/jbc.M212919200; LEE HC, 1993, J BIOL CHEM, V268, P293; Lee HW, 2002, J BIOL CHEM, V277, P32624, DOI 10.1074/jbc.M200353200; Lee SY, 1996, J EXP MED, V183, P669, DOI 10.1084/jem.183.2.669; LERNER EC, 1995, J BIOL CHEM, V270, P26770, DOI 10.1074/jbc.270.45.26770; Lerner EC, 1997, ONCOGENE, V15, P1283, DOI 10.1038/sj.onc.1201296; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; MOORES SL, 1991, J BIOL CHEM, V266, P14603; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Mulvaney JM, 2000, J BIOL CHEM, V275, P14182, DOI 10.1074/jbc.275.19.14182; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Ni CZ, 2000, P NATL ACAD SCI USA, V97, P10395, DOI 10.1073/pnas.97.19.10395; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Okumura K, 1999, CANCER RES, V59, P2445; Pahl HL, 1996, J EXP MED, V183, P1829, DOI 10.1084/jem.183.4.1829; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Park YC, 1999, NATURE, V398, P533, DOI 10.1038/19110; Pearson G, 2001, J BIOL CHEM, V276, P7927, DOI 10.1074/jbc.M009764200; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SCHABER MD, 1990, J BIOL CHEM, V265, P14701; Schwenzer R, 1999, J BIOL CHEM, V274, P19368, DOI 10.1074/jbc.274.27.19368; Seternes OM, 1999, MOL ENDOCRINOL, V13, P1071, DOI 10.1210/me.13.7.1071; SONG HY, 1995, BIOCHEM J, V309, P825, DOI 10.1042/bj3090825; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Taylor MT, 2000, CANCER RES, V60, P6607; Tsao DHH, 2000, MOL CELL, V5, P1051, DOI 10.1016/S1097-2765(00)80270-1; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Verin AD, 2000, AM J PHYSIOL-LUNG C, V279, pL360, DOI 10.1152/ajplung.2000.279.2.L360; Vuong H, 2000, J BIOL CHEM, V275, P32250, DOI 10.1074/jbc.M005227200; Wajant H, 2000, J BIOL CHEM, V275, P24357, DOI 10.1074/jbc.M000811200; Wajant H, 2001, CELL SIGNAL, V13, P389, DOI 10.1016/S0898-6568(01)00160-7; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang DM, 1998, J BIOL CHEM, V273, P33027, DOI 10.1074/jbc.273.49.33027; Wang QD, 2001, GASTROENTEROLOGY, V120, P1381, DOI 10.1053/gast.2001.24044; Wang QD, 2002, J BIOL CHEM, V277, P36602, DOI 10.1074/jbc.M206306200; WU MH, 1994, EUR J PHARM-ENVIRON, V270, P203, DOI 10.1016/0926-6917(94)90064-7; Zapata JM, 2000, J IMMUNOL, V165, P5084, DOI 10.4049/jimmunol.165.9.5084; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zhao DZ, 2001, J BIOL CHEM, V276, P44464, DOI 10.1074/jbc.M104942200; Zou YZ, 1996, J BIOL CHEM, V271, P33592, DOI 10.1074/jbc.271.52.33592	79	67	71	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	2004	23	10					1885	1895		10.1038/sj.onc.1207312	http://dx.doi.org/10.1038/sj.onc.1207312			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	801XV	14981539				2022-12-17	WOS:000220129500010
J	Lee, M; Daniels, MJ; Venkitararnan, AR				Lee, M; Daniels, MJ; Venkitararnan, AR			Phosphorylation of BRCA2 by the Polo-like kinase Plk1 is regulated by DNA damage and mitotic progression	ONCOGENE			English	Article						BRCA2; polo; DNA repair; mitosis	CANCER SUSCEPTIBILITY GENE; HUMAN BREAST-CANCER; CELL-CYCLE; PROGNOSTIC-SIGNIFICANCE; PROTEIN-KINASE; RAD51 PROTEIN; EXPRESSION; RECOMBINATION; ACTIVATION; PROPHASE	The breast cancer susceptibility protein, BRCA2, preserves chromosomal stability through roles in the repair of DNA double-strand breaks, and possibly, cell division. Post-translational modifications that may coordinate these functions remain poorly characterized. Here, we report that BRCA2 is a substrate for the mitotic Polo-like kinase, Plk1. BRCA2 undergoes phosphorylation in cells synchronously passing through the G2/M phases of cell cycle, when Plk1 expression and activity are maximal. Depletion of Plk1 by RNA interference suppresses BRCA2 modification. BRCA2 and Plk1 interact with one another in cell lysates, through a conserved region in BRCA2, which spans the eight BRC repeat motifs essential for its function in DNA repair. Within this. region, residues positioned between BRC repeats - but not the repeat motifs themselves - are phosphorylated by Plk1. Interestingly, Plk1-mediated modification of BRCA2 during the G2/M phases is inhibited by treatment with the radiomimetic agent, adriamycin. Thus, our findings define a regulatory circuit for BRCA2 phosphorylation by Plk1 that is responsive to DNA damage as well as mitotic progression.	Univ Cambridge, CR UK Dept Oncol, Cambridge CB2 2XZ, England; Univ Cambridge, MRC, Canc Cell Unit, Hutchison MRC Res Ctr, Cambridge CB2 2XZ, England	University of Cambridge; University of Cambridge	Venkitararnan, AR (corresponding author), Univ Cambridge, CR UK Dept Oncol, Hills Rd, Cambridge CB2 2XZ, England.	arv22@cam.ac.uk	Lee, MiYoung/G-3748-2014	Daniels, Matthew/0000-0002-9250-6214				Abrieu A, 1998, J CELL SCI, V111, P1751; Alexandru G, 2001, CELL, V105, P459, DOI 10.1016/S0092-8674(01)00362-2; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Bertwistle D, 1998, CURR OPIN GENET DEV, V8, P14, DOI 10.1016/S0959-437X(98)80056-7; Bork P, 1996, NAT GENET, V13, P22, DOI 10.1038/ng0596-22; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; LEE KS, 1995, MOL CELL BIOL, V15, P7143; Losada A, 2002, GENE DEV, V16, P3004, DOI 10.1101/gad.249202; Marmorstein LY, 2001, CELL, V104, P247, DOI 10.1016/S0092-8674(01)00209-4; Milner J, 2000, ONCOGENE, V19, P4441, DOI 10.1038/sj.onc.1203793; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Pellegrini L, 2002, NATURE, V420, P287, DOI 10.1038/nature01230; Qian YW, 1999, MOL CELL BIOL, V19, P8625; Qian YW, 2001, MOL BIOL CELL, V12, P1791, DOI 10.1091/mbc.12.6.1791; Roshak AK, 2000, CELL SIGNAL, V12, P405, DOI 10.1016/S0898-6568(00)00080-2; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Sumara I, 2002, MOL CELL, V9, P515, DOI 10.1016/S1097-2765(02)00473-2; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Takahashi T, 2003, CANCER SCI, V94, P148, DOI 10.1111/j.1349-7006.2003.tb01411.x; Takai N, 2001, CANCER LETT, V169, P41, DOI 10.1016/S0304-3835(01)00522-5; Takai N, 2001, CANCER LETT, V164, P41, DOI 10.1016/S0304-3835(00)00703-5; Tokumitsu Y, 1999, INT J ONCOL, V15, P687; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Uchiumi T, 1997, J BIOL CHEM, V272, P9166; van Vugt MATM, 2001, J BIOL CHEM, V276, P41656, DOI 10.1074/jbc.M101831200; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Venkitaraman AR, 2000, PHILOS T R SOC B, V355, P191, DOI 10.1098/rstb.2000.0558; Weitzer S, 2002, DEV CELL, V2, P381, DOI 10.1016/S1534-5807(02)00155-7; Wolf G, 2000, PATHOL RES PRACT, V196, P753, DOI 10.1016/S0344-0338(00)80107-7; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; Wu KJ, 2003, J BIOL CHEM, V278, P15652, DOI 10.1074/jbc.M211297200; Yu VPCC, 2000, GENE DEV, V14, P1400	41	67	69	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					865	872		10.1038/sj.onc.1207223	http://dx.doi.org/10.1038/sj.onc.1207223			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14647413				2022-12-17	WOS:000188486600001
J	Suzuki, M; Yamada, T; Kihara-Negishi, F; Sakurai, T; Oikawa, T				Suzuki, M; Yamada, T; Kihara-Negishi, F; Sakurai, T; Oikawa, T			Direct association between PU.1 and MeCP2 that recruits mSin3A-HDAC complex for PU.1-mediated transcriptional repression	ONCOGENE			English	Article						PU.1; MeCP2; Ets; co-repressor; transcriptional repression	DNA-BINDING PROTEIN; HISTONE DEACETYLASE; ERYTHROLEUKEMIA-CELLS; ACTIVATION DOMAIN; METHYLATED DNA; NUCLEAR-FACTOR; ACETYLATION; DIFFERENTIATION; HDAC1; SPI-1/PU.1	PU.1, a member of the Ets family of transcription factors, is implicated in hematopoietic cell differentiation through its interactions with other transcriptional factors and cofactors. To identify a novel protein(s) binding to PU.1, we carried out affinity purification using a column of Glutathione-Sepharose beads bound to GST-PU.1 fusion protein and isolated several individual proteins using murine erythroleukemia (MEL) cell extracts. Sequence analysis of these proteins revealed that one was MeCP2 a methyl CpG binding protein. GST-pull-down assay and immunoprecipitation assay showed that PU.1 bound directly to MeCP2 via its Ets domain and MeCP2 bound to PU.1 via either its amino terminal domain or transrepression domain. MeCP2 repressed transcriptional activity of PU.1 on a reporter construct with trimerized PU.1 binding sites. This downregulation was recovered in the presence of histone deacetylase inhibitor, trichostatin A (TSA). MeCP2 was integrated in PU.1-mSin3A-HDAC complex but not in PU.1-CBP complex. Chromatin immunoprecipitation (ChIP) assays showed that PU.1 and MeCP2 were collocated at the PU.1 binding site on the reporter construct and the PU.1 binding site of the intervening sequence 2 (IVS2) region in the intron of the beta-globin gene, which has been proposed to regulate expression of the gene, in undifferentiated MEL cells. The complex disappeared from the region during the course of erythroid differentiation of MEL cells. Our results suggest that MeCP2 acts as a corepressor of PU.1 probably due to facilitating complex formation with mSin3A and HDACs.	Sasaki Inst, Dept Cell Genet, Chiyoda Ku, Tokyo 1010062, Japan		Oikawa, T (corresponding author), Sasaki Inst, Dept Cell Genet, Chiyoda Ku, 2-2 Kanda Surugadai, Tokyo 1010062, Japan.							BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; Czuwara-Ladykowska J, 2002, J BIOL CHEM, V277, P20399, DOI 10.1074/jbc.M200206200; Datta J, 2003, J CELL BIOCHEM, V88, P855, DOI 10.1002/jcb.10457; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536; Furia B, 2002, J BIOL CHEM, V277, P4973, DOI 10.1074/jbc.M107848200; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; Huang S, 2000, MOL CELL BIOL, V20, P2248, DOI 10.1128/MCB.20.6.2248-2259.2000; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kihara-Negishi F, 2001, ONCOGENE, V20, P6039, DOI 10.1038/sj.onc.1204756; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Konishi Y, 1999, ONCOGENE, V18, P6795, DOI 10.1038/sj.onc.1203118; Mal A, 2001, EMBO J, V20, P1739, DOI 10.1093/emboj/20.7.1739; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; NAGULAPALLI S, 1995, J IMMUNOL, V155, P4330; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Polesskaya A, 2000, J BIOL CHEM, V275, P34359, DOI 10.1074/jbc.M003815200; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; Pongubala JMR, 1997, P NATL ACAD SCI USA, V94, P127, DOI 10.1073/pnas.94.1.127; Rao E, 1997, J BIOL CHEM, V272, P6722, DOI 10.1074/jbc.272.10.6722; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; SCHUETZE S, 1992, MOL CELL BIOL, V12, P2967, DOI 10.1128/MCB.12.7.2967; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Singal R, 1999, BLOOD, V93, P4059, DOI 10.1182/blood.V93.12.4059; TENEN DG, 1997, BLOOD, V90, P498; Yamada T, 1997, BLOOD, V89, P1383, DOI 10.1182/blood.V89.4.1383; Yamamoto H, 1999, ONCOGENE, V18, P1495, DOI 10.1038/sj.onc.1202427; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	42	67	70	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 27	2003	22	54					8688	8698		10.1038/sj.onc.1207182	http://dx.doi.org/10.1038/sj.onc.1207182			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647463				2022-12-17	WOS:000186844900006
J	Pedersen, TX; Leethanakul, C; Patel, V; Mitola, D; Lund, LR; Dano, K; Johnsen, M; Gutkind, JS; Bugge, TH				Pedersen, TX; Leethanakul, C; Patel, V; Mitola, D; Lund, LR; Dano, K; Johnsen, M; Gutkind, JS; Bugge, TH			Laser capture microdissection-based in vivo genomic profiling of wound keratinocytes identifies similarities and differences to squamous cell carcinoma	ONCOGENE			English	Review						cDNA arrays; gene expression; keratinocytes; laser capture microdissection; squamous cell carcinoma; wound healing	GAP-JUNCTION PROTEINS; HUMAN EPIDERMAL-KERATINOCYTES; INTERFERON-GAMMA RECEPTORS; MOUSE SKIN CARCINOGENESIS; HEAT-SHOCK PROTEINS; NF-KAPPA-B; GROWTH-FACTOR; GENE-EXPRESSION; TRANSCRIPTION FACTOR; MOLECULAR-CLONING	Keratinocytes undergo a dramatic phenotypic conversion during reepithelialization of skin wounds to become hyperproliferative, migratory, and invasive. This transient healing response phenotypically resembles malignant transformation of keratinocytes during squamous cell carcinoma progression. Here we present the first analysis of global changes in keratinocyte gene expression during skin wound healing in vivo, and compare these changes to changes in gene expression during malignant conversion of keratinized epithelium. Laser capture microdissection was used to isolate RNA from wound keratinocytes from incisional mouse skin wounds and adjacent normal skin keratinocytes. Changes in gene expression were determined by comparative cDNA array analyses, and the approach was validated by in situ hybridization. The analyses identified 48 candidate genes not previously associated with wound reepithelialization. Furthermore, the analyses revealed that the phenotypic resemblance of wound keratinocytes to squamous cell carcinoma is mimicked at the level of gene expression, but notable differences between the two tissue-remodeling processes were also observed. The combination of laser capture microdissection and cDNA array analysis provides a powerful new tool to unravel the complex changes in gene expression that underlie physiological and pathological remodeling of keratinized epithelium.	Natl Inst Dent & Craniofacial Res, Proteases & Tissue Remodeling Unit, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; Rigshosp, Finsen Lab, DK-2100 Copenhagen O, Denmark; Natl Inst Dent & Craniofacial Res, Mol Carcinogenesis Unit, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Rigshospitalet; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Bugge, TH (corresponding author), Natl Inst Dent & Craniofacial Res, Proteases & Tissue Remodeling Unit, Oral & Pharyngeal Canc Branch, NIH, 30 Convent Dr,Room 211, Bethesda, MD 20892 USA.		Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009; Johnsen, Morten/L-8016-2014	Gutkind, J. Silvio/0000-0002-5150-4482; Johnsen, Morten/0000-0003-3763-2362; Pedersen, Tanja Xenia/0000-0003-2515-3022	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000558, ZIADE000699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000558, Z01DE000699] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ANDERSON JT, 1993, MOL CELL BIOL, V13, P2730, DOI 10.1128/MCB.13.5.2730; Balasubramanian S, 1998, BIOCHEM BIOPH RES CO, V243, P744, DOI 10.1006/bbrc.1998.8172; BARRA RM, 1994, J INVEST DERMATOL, V102, P61, DOI 10.1111/1523-1747.ep12371733; Bernerd F, 1999, P NATL ACAD SCI USA, V96, P11329, DOI 10.1073/pnas.96.20.11329; Bonner RF, 1997, SCIENCE, V278, P1481, DOI 10.1126/science.278.5342.1481; Braun S, 2002, MOL CELL BIOL, V22, P5492, DOI 10.1128/MCB.22.15.5492-5505.2002; BUDUNOVA IV, 1995, CARCINOGENESIS, V16, P2717, DOI 10.1093/carcin/16.11.2717; BUTTERWECK A, 1994, EUR J CELL BIOL, V65, P152; Cao TY, 1996, DEV GENET, V19, P309, DOI 10.1002/(SICI)1520-6408(1996)19:4<309::AID-DVG4>3.3.CO;2-1; Cao ZY, 2002, J BIOL CHEM, V277, P42299, DOI 10.1074/jbc.M200981200; Chen YG, 2002, EXP BIOL MED, V227, P75, DOI 10.1177/153537020222700201; Codd JD, 1999, J PATHOL, V187, P549; COULOMBE PA, 1991, J CELL BIOL, V115, P1661, DOI 10.1083/jcb.115.6.1661; Crackower MA, 1996, HUM MOL GENET, V5, P571, DOI 10.1093/hmg/5.5.571; CURINO A, 2002, IN PRESS ONCOGENE; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; Dano K, 1999, APMIS, V107, P120, DOI 10.1111/j.1699-0463.1999.tb01534.x; De Panfilis G, 2002, BRIT J DERMATOL, V147, P7, DOI 10.1046/j.1365-2133.2002.04746.x; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEYERLE KL, 1992, J IMMUNOL, V149, P1657; Dick T, 1996, MOL CELL BIOL, V16, P1966; DING HF, 1994, SCIENCE, V265, P796, DOI 10.1126/science.8047885; Dong G, 2001, CANCER RES, V61, P4797; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; Eggenschwiler JT, 2001, NATURE, V412, P194, DOI 10.1038/35084089; ELLER MS, 1994, J INVEST DERMATOL, V103, P785, DOI 10.1111/1523-1747.ep12413037; ELLER MS, 1995, J CELL SCI, V108, P2741; Engelholm LH, 2001, LAB INVEST, V81, P1403, DOI 10.1038/labinvest.3780354; EVERS R, 1995, EMBO J, V14, P1248, DOI 10.1002/j.1460-2075.1995.tb07108.x; FEINGOLD KR, 1995, J INVEST DERMATOL, V104, P246, DOI 10.1111/1523-1747.ep12612790; FOUNTOULAKIS M, 1990, J BIOL CHEM, V265, P13268; Frank S, 1996, J BIOL CHEM, V271, P10188, DOI 10.1074/jbc.271.17.10188; Freedberg IM, 2001, J INVEST DERMATOL, V116, P633, DOI 10.1046/j.1523-1747.2001.01327.x; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; Gecz J, 1996, NAT GENET, V13, P105, DOI 10.1038/ng0596-105; GIMENEZCONTI IB, 1990, CANCER RES, V50, P4441; Gold LI, 1997, AM J PATHOL, V150, P209; GOLIGER JA, 1994, DEV DYNAM, V200, P1, DOI 10.1002/aja.1002000102; GOLIGER JA, 1995, MOL BIOL CELL, V6, P1491, DOI 10.1091/mbc.6.11.1491; Grehan S, 2001, J INVEST DERMATOL, V116, P77, DOI 10.1046/j.1523-1747.2001.00213.x; Gu YH, 1996, NAT GENET, V13, P109, DOI 10.1038/ng0596-109; HAEFLIGER JA, 1992, J BIOL CHEM, V267, P2057; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIRAI Y, 1989, DEVELOPMENT, V105, P271; Hong NA, 2000, DEV BIOL, V220, P76, DOI 10.1006/dbio.2000.9615; Huh CG, 1999, J CLIN PATHOL-MOL PA, V52, P332, DOI 10.1136/mp.52.6.332; Ivell R, 2001, EXP PHYSIOL, V86, P289, DOI 10.1113/eph8602185; Jansen BJH, 2001, J INVEST DERMATOL, V116, P12, DOI 10.1046/j.1523-1747.2001.00218.x; Johnsen M, 1998, CURR OPIN CELL BIOL, V10, P667, DOI 10.1016/S0955-0674(98)80044-6; Kaneto H, 1997, J BIOL CHEM, V272, P29137, DOI 10.1074/jbc.272.46.29137; Karetsou Z, 2002, EMBO REP, V3, P361, DOI 10.1093/embo-reports/kvf071; Kim SH, 2002, AUDIOL NEURO-OTOL, V7, P348, DOI 10.1159/000066159; KIMURA T, 1994, EUR J ENDOCRINOL, V131, P385, DOI 10.1530/eje.0.1310385; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; Kiriyama MT, 2001, BIOL PHARM BULL, V24, P197, DOI 10.1248/bpb.24.197; Kitayoshi H, 1999, ARCH DERMATOL RES, V291, P333, DOI 10.1007/s004030050418; Knezevic V, 2001, PROTEOMICS, V1, P1271, DOI 10.1002/1615-9861(200110)1:10<1271::AID-PROT1271>3.0.CO;2-6; Knoepfel L, 1996, BIOL CHEM H-S, V377, P139, DOI 10.1515/bchm3.1996.377.2.139; Kooy AJW, 1998, J PATHOL, V184, P169; KopfMaier P, 1996, ACTA ANAT, V155, P1; KRISTENSEN P, 1991, J HISTOCHEM CYTOCHEM, V39, P341, DOI 10.1177/39.3.1899685; Kubo M, 2001, BRIT J DERMATOL, V145, P840, DOI 10.1046/j.1365-2133.2001.04480.x; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; Lansdown ABG, 1999, J ANAT, V195, P375, DOI 10.1046/j.1469-7580.1999.19530375.x; Laplante AF, 1998, J HISTOCHEM CYTOCHEM, V46, P1291, DOI 10.1177/002215549804601109; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Lee SH, 1998, APMIS, V106, P1035, DOI 10.1111/j.1699-0463.1998.tb00255.x; Leethanakul C, 2000, ONCOGENE, V19, P3220, DOI 10.1038/sj.onc.1203703; LLOYD C, 1995, J CELL BIOL, V129, P1329, DOI 10.1083/jcb.129.5.1329; LOW TLK, 1981, P NATL ACAD SCI-BIOL, V78, P1162, DOI 10.1073/pnas.78.2.1162; Lu Q, 2002, J NEUROSCI RES, V67, P618, DOI 10.1002/jnr.10151; Lu Q, 1999, J CELL BIOL, V144, P519, DOI 10.1083/jcb.144.3.519; Lund LR, 1999, EMBO J, V18, P4645, DOI 10.1093/emboj/18.17.4645; Madlener M, 1998, EXP CELL RES, V242, P201, DOI 10.1006/excr.1998.4049; MADSEN P, 1995, J BIOL CHEM, V270, P5823, DOI 10.1074/jbc.270.11.5823; Magnaldo T, 1998, DIFFERENTIATION, V63, P159, DOI 10.1046/j.1432-0436.1998.6330159.x; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Malinda KM, 1999, J INVEST DERMATOL, V113, P364, DOI 10.1046/j.1523-1747.1999.00708.x; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; Mian IS, 1998, BLOOD CELL MOL DIS, V24, P83, DOI 10.1006/bcmd.1998.9998; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Moll J, 1996, HISTOCHEM J, V28, P45, DOI 10.1007/BF02331426; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; Munz B, 1997, J INVEST DERMATOL, V108, P307, DOI 10.1111/1523-1747.ep12286470; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NAKASHIMA T, 1993, MOL CELL BIOL, V13, P6367, DOI 10.1128/MCB.13.10.6367; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; OISHI M, 1994, ARCH DERMATOL RES, V286, P396, DOI 10.1007/BF00371800; Okura T, 1996, J IMMUNOL, V157, P4277; OLKKONEN VM, 1994, GENE, V138, P207, DOI 10.1016/0378-1119(94)90809-5; Ono S, 2000, ACTA NEUROL SCAND, V102, P47, DOI 10.1034/j.1600-0404.2000.102001047.x; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; Paffenholz R, 1997, DIFFERENTIATION, V61, P293, DOI 10.1046/j.1432-0436.1997.6150293.x; PINCELLI C, 1990, BRIT J DERMATOL, V122, P745, DOI 10.1111/j.1365-2133.1990.tb06261.x; RADOMSKI N, 1995, EXP CELL RES, V220, P434, DOI 10.1006/excr.1995.1335; Rao E, 1997, NAT GENET, V16, P54, DOI 10.1038/ng0597-54; Richard G, 2000, EXP DERMATOL, V9, P77, DOI 10.1034/j.1600-0625.2000.009002077.x; Robinson NA, 1997, J BIOL CHEM, V272, P12035, DOI 10.1074/jbc.272.18.12035; Rodriguez-Puebla ML, 2000, AM J PATHOL, V157, P1039, DOI 10.1016/S0002-9440(10)64616-0; Romer J, 1996, NAT MED, V2, P287, DOI 10.1038/nm0396-287; ROTHNAGEL JA, 1992, SCIENCE, V257, P1128, DOI 10.1126/science.257.5073.1128; Rundhaug JE, 1997, MOL CARCINOGEN, V20, P125, DOI 10.1002/(SICI)1098-2744(199709)20:1<125::AID-MC14>3.3.CO;2-A; SABATH DE, 1990, GENE, V91, P185, DOI 10.1016/0378-1119(90)90087-8; Sadano H, 2000, BIOCHEM BIOPH RES CO, V267, P418, DOI 10.1006/bbrc.1999.1969; SCHIPPER JH, 1991, CANCER RES, V51, P6328; Schmitt J, 1996, GENOMICS, V32, P358, DOI 10.1006/geno.1996.0130; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; Semina EV, 1998, HUM MOL GENET, V7, P415, DOI 10.1093/hmg/7.3.415; Shimeld SM, 1996, MECH DEVELOP, V55, P201, DOI 10.1016/0925-4773(96)00505-9; Simone NL, 1998, TRENDS GENET, V14, P272, DOI 10.1016/S0168-9525(98)01489-9; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; Svaren J, 1996, MOL CELL BIOL, V16, P3545; Taniguchi M, 2001, GENOMICS, V71, P34, DOI 10.1006/geno.2000.6427; TARAVIRAS S, 1994, MECH DEVELOP, V48, P67, DOI 10.1016/0925-4773(94)90017-5; TATEMOTO K, 1983, FEBS LETT, V164, P124, DOI 10.1016/0014-5793(83)80033-7; Thelu J, 1998, J INVEST DERMATOL, V111, P903, DOI 10.1046/j.1523-1747.1998.00372.x; Thelu Jacques, 2002, BMC Dermatol, V2, P7, DOI 10.1186/1471-5945-2-7; Tokumaru S, 2000, J CELL BIOL, V151, P209, DOI 10.1083/jcb.151.2.209; VALE W, 1986, NATURE, V321, P776, DOI 10.1038/321776a0; van Ruissen F, 2002, GENOMICS, V79, P671, DOI 10.1006/geno.2002.6756; VANDENOORD JJ, 1995, PATHOL RES PRACT, V191, P530, DOI 10.1016/S0344-0338(11)80872-1; Wang Q, 2000, MECH DEVELOP, V90, P283, DOI 10.1016/S0925-4773(99)00241-5; Wehrli P, 2000, J INVEST DERMATOL, V115, P141, DOI 10.1046/j.1523-1747.2000.00037.x; Westergaard M, 2001, J INVEST DERMATOL, V116, P702, DOI 10.1046/j.1523-1747.2001.01329.x; Wilson VG, 2001, EXP CELL RES, V271, P57, DOI 10.1006/excr.2001.5366; Wu WG, 2002, CLIN EXP METASTAS, V19, P319, DOI 10.1023/A:1015515119300; Xiao JH, 1999, EMBO J, V18, P1539, DOI 10.1093/emboj/18.6.1539; Yamamoto S, 2000, BBA-GENE STRUCT EXPR, V1490, P121, DOI 10.1016/S0167-4781(99)00217-1; YASUDA K, 1995, J BIOL CHEM, V270, P29718, DOI 10.1074/jbc.270.50.29718; YU S, 1995, CELL STRUCT FUNCT, V20, P263, DOI 10.1247/csf.20.263; Yuen T, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e48; ZHANG JT, 1989, J CELL BIOL, V109, P3391, DOI 10.1083/jcb.109.6.3391	137	67	68	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2003	22	25					3964	3976		10.1038/sj.onc.1206614	http://dx.doi.org/10.1038/sj.onc.1206614			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	691NH	12813470				2022-12-17	WOS:000183612000016
J	Uren, A; Merchant, MS; Sun, CJ; Vitolo, MI; Sun, Y; Tsokos, M; Illei, PB; Ladanyi, M; Passaniti, A; Mackall, C; Toretsky, JA				Uren, A; Merchant, MS; Sun, CJ; Vitolo, MI; Sun, Y; Tsokos, M; Illei, PB; Ladanyi, M; Passaniti, A; Mackall, C; Toretsky, JA			Beta-platelet-derived growth factor receptor mediates motility and growth of Ewing's sarcoma cells	ONCOGENE			English	Article						PDGF; PDGF receptors; Ewing's sarcoma	FACTOR-I RECEPTOR; SIGNAL-TRANSDUCTION; PDGF-C; TUMORS; LIGAND; TRANSFORMATION; FIBROBLASTS; INHIBITION; EXPRESSION; EWS/FLI-1	The Ewing's sarcoma family of tumors (ESFT) contain a translocation, t(11;22), which results in the novel oncogenic fusion protein EWS/FLI1. Platelet-derived growth factors (PDGF) and their receptors (PDGFR) are involved in the induction and proliferation of numerous solid tumors and are the potential candidates for novel targeted antitumor therapy. Since a relation was reported between PDGF-C and EWS/FLI1, we sought to characterize the PDGF signaling pathway in ESFT. Eight out of nine ESFT cell tines were found to express significant levels of beta-PDGFR. Interestingly, none of the tested cell lines expressed alpha-PDGFR, which is the receptor isotype required for PDGF-C binding. By immunohistochemical staining 47 of 52 (90.4%) archival tumor samples from patients with ESFT were positive for beta-PDGFR. ESFT cell lines were treated with PDGF-AA or PDGF-BB ligands to evaluate downstream signaling. Autophosphorylation of beta-PDGFR and tyrosine phosphorylation of PLC-gamma, PI3Kp85 and She were detected only in PDGF-BB-stimulated cells that express beta-PDGFR. Receptor function was further evaluated using chemotaxis assays that showed TC-32 cell migration towards PDGF-BB. A specific PDGFR kinase inhibitor AG1295 blocked beta-PDGFR activation, downstream signaling, growth in cell culture and chemotaxis of TC-32 cells. AG1295 also delayed tumor formation and prolonged survival in an ESFT animal model. We conclude that ESFT express beta-PDGFR and that this is a functional and potentially crucial signaling pathway. Therefore, beta-PDGFRs may provide a novel therapeutic target in ESFT that can be utilized to design better treatment modalities.	Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Washington, DC 20057 USA; NIH, Bethesda, MD 20892 USA; Univ Maryland, Dept Pathol, Baltimore, MD 21201 USA; Univ Maryland, Dept Pediat, Baltimore, MD 21201 USA; Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA	Georgetown University; National Institutes of Health (NIH) - USA; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Memorial Sloan Kettering Cancer Center	Uren, A (corresponding author), Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Res Bldg,Room W316,3970 Reservoir Rd,NW Box 57146, Washington, DC 20057 USA.		Ladanyi, Marc/AAG-8585-2019	Vitolo, Michele/0000-0001-8055-9645	NATIONAL CANCER INSTITUTE [Z01SC010289, R01CA088004, Z01SC009431] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA88004] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588; BRYCKAERT MC, 1992, EXP CELL RES, V199, P255, DOI 10.1016/0014-4827(92)90432-8; BUCHDUNGER E, 1995, P NATL ACAD SCI USA, V92, P2558, DOI 10.1073/pnas.92.7.2558; Denny CT, 1998, J PEDIAT HEMATOL ONC, V20, P421, DOI 10.1097/00043426-199809000-00002; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; Gilbertson DG, 2001, J BIOL CHEM, V276, P27406, DOI 10.1074/jbc.M101056200; Girnita L, 2000, ONCOGENE, V19, P4298, DOI 10.1038/sj.onc.1203755; Grier HE, 1997, PEDIATR CLIN N AM, V44, P991, DOI 10.1016/S0031-3955(05)70541-1; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; Kontny HU, 1998, CANCER RES, V58, P5842; KOVALENKO M, 1994, CANCER RES, V54, P6106; LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; Meyers PA, 2001, J CLIN ONCOL, V19, P2812, DOI 10.1200/JCO.2001.19.11.2812; MISER LS, 1996, P ANN M AM SOC CLIN, pA1472; Ostman A, 2001, ADV CANCER RES, V80, P1, DOI 10.1016/S0065-230X(01)80010-5; Ricotti E, 1998, BLOOD, V91, P2397, DOI 10.1182/blood.V91.7.2397.2397_2397_2405; Sanceau J, 2000, ONCOGENE, V19, P3372, DOI 10.1038/sj.onc.1203670; Scotlandi K, 1998, CANCER RES, V58, P4127; Toretsky JA, 1997, J BIOL CHEM, V272, P30822, DOI 10.1074/jbc.272.49.30822; Uren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374; UREN A, 1994, BIOCHEM BIOPH RES CO, V204, P628, DOI 10.1006/bbrc.1994.2505; van Oosterom AT, 2001, LANCET, V358, P1421, DOI 10.1016/S0140-6736(01)06535-7; VANVALEN F, 1992, J CANCER RES CLIN, V118, P269, DOI 10.1007/BF01208615; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YEE D, 1990, J CLIN INVEST, V86, P1806, DOI 10.1172/JCI114910; Zwerner JP, 2001, ONCOGENE, V20, P626, DOI 10.1038/sj.onc.1204133	28	67	71	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 17	2003	22	15					2334	2342		10.1038/sj.onc.1206330	http://dx.doi.org/10.1038/sj.onc.1206330			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	667KV	12700668				2022-12-17	WOS:000182231500011
J	Kotlo, KU; Yehiely, F; Efimova, E; Harasty, H; Hesabi, B; Shchors, K; Einat, P; Rozen, A; Berent, E; Deiss, LP				Kotlo, KU; Yehiely, F; Efimova, E; Harasty, H; Hesabi, B; Shchors, K; Einat, P; Rozen, A; Berent, E; Deiss, LP			Nrf2 is an inhibitor of the Fas pathway as identified by Achilles' Heel Method, a new function-based approach to gene identification in human cells	ONCOGENE			English	Article						apoptosis; function profiling; functional genomics; FaS; Nrf2; phase II detoxifying enzymes	ACTIVATED PROTEIN-KINASE; MEDIATED APOPTOSIS; DT-DIAPHORASE; INTERFERON-GAMMA; BINDING PROTEIN; DEATH; ELEMENT; TRANSCRIPTION; EXPRESSION; INDUCTION	Here we describe the Achilles' Heel Method (AHM), a new function-based approach for identification of inhibitors of signaling pathways, optimized for human cells. The principle of AHM is the identification of 'sensitizing' cDNAs based on their decreased abundance following selection. As a proof of principle, we have employed AHM for the identification of Fas/CD95/APO-1 pathway inhibitors. HeLa cells were transfected with an antisense cDNA expression library in an episomal vector followed by selection with a suboptimal dose of the apoptotic inducer. Antisense inactivation of Fas inhibitors rendered the cells more sensitive to apoptosis resulting in their preferential death and consequent loss of their sensitizing episomes that were identified by subtraction. We show that the resulting products were enriched for sensitizing cDNAs as seven out of eight candidates tested were confirmed as inhibitors of Fas-induced killing either by transfection or by pharmacological inhibition. Furthermore, we demonstrate by multiple approaches that one candidate, NF-E2 related factor 2 (Nrf2), is an inhibitor of Fas-induced apoptosis. Inactivation of Nrf2 by antisense or by a membrane permeable dominant-negative polypeptide sensitized cells while overexpression of Nrf2 protected cells from Fas-induced apoptosis. In addition, dicumarol, an inhibitor of the phase 11 detoxifying enzyme NQO1, a downstream target of Nrf2, sensitized cells. Nrf2 induces the production of Glutathione (GSH) and we demonstrated that N-acetyl L-cysteine (NAC), a precursor to GSH, protected cells from Fas-mediated killing. Taken together, AHM is a powerful approach for the identification of inhibitors of a signaling pathway with a low rate of false positives that opens new avenues for function profiling of human genes and discovery of new drug targets.	Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA; Quark Biotech Inc, Cleveland, OH 44106 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Deiss, LP (corresponding author), Univ Illinois, Dept Mol Genet, M-C 669,900 S Ashland Ave, Chicago, IL 60607 USA.	Ldeiss@uic.edu						Asher G, 2001, P NATL ACAD SCI USA, V98, P1188, DOI 10.1073/pnas.021558898; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Begleiter A, 1997, ONCOL RES, V9, P371; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Cross JV, 1999, J BIOL CHEM, V274, P31150, DOI 10.1074/jbc.274.44.31150; De Flora S, 2001, CARCINOGENESIS, V22, P999, DOI 10.1093/carcin/22.7.999; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; Hitoshi Y, 1998, IMMUNITY, V8, P461, DOI 10.1016/S1074-7613(00)80551-8; Holmstrom TH, 1999, MOL CELL BIOL, V19, P5991; HOSODA S, 1974, J BIOL CHEM, V249, P6416; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jaiswal AK, 2000, FREE RADICAL BIO MED, V29, P254, DOI 10.1016/S0891-5849(00)00306-3; JOSEPH P, 1994, ONCOL RES, V6, P525; Kazama H, 2000, J CELL BIOL, V148, P557, DOI 10.1083/jcb.148.3.557; Kimchi A, 1998, BBA-REV CANCER, V1377, pF13, DOI 10.1016/S0304-419X(98)00002-X; KISSIL JL, 1995, J BIOL CHEM, V270, P27932, DOI 10.1074/jbc.270.46.27932; Ko BCB, 2000, BIOCHEM BIOPH RES CO, V270, P52, DOI 10.1006/bbrc.2000.2376; Krause D, 2001, J BIOL CHEM, V276, P19244, DOI 10.1074/jbc.M008186200; LevyStrumpf N, 1997, MOL CELL BIOL, V17, P1615, DOI 10.1128/MCB.17.3.1615; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Meyer UA, 1996, J PHARMACOKINET BIOP, V24, P449, DOI 10.1007/BF02353473; Miyakawa H, 1999, P NATL ACAD SCI USA, V96, P2538, DOI 10.1073/pnas.96.5.2538; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Moinova HR, 1999, BIOCHEM BIOPH RES CO, V261, P661, DOI 10.1006/bbrc.1999.1109; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; Ohtsubo T, 1999, CELL DEATH DIFFER, V6, P865, DOI 10.1038/sj.cdd.4400566; Pinkoski MJ, 1999, CELL DEATH DIFFER, V6, P1174, DOI 10.1038/sj.cdd.4400611; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; Salinas AE, 1999, CURR MED CHEM, V6, P279; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Siemankowski LM, 2000, CANCER RES, V60, P3638; Stark GR, 1999, HUM MOL GENET, V8, P1925, DOI 10.1093/hmg/8.10.1925; TEWARI M, 1995, J BIOL CHEM, V270, P22705, DOI 10.1074/jbc.270.39.22705; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Yu R, 1999, J BIOL CHEM, V274, P27545, DOI 10.1074/jbc.274.39.27545; Yu R, 2000, J BIOL CHEM, V275, P2322, DOI 10.1074/jbc.275.4.2322; Yu R, 2000, J BIOL CHEM, V275, P39907, DOI 10.1074/jbc.M004037200	44	67	73	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2003	22	6					797	806		10.1038/sj.onc.1206077	http://dx.doi.org/10.1038/sj.onc.1206077			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584558				2022-12-17	WOS:000180864300001
J	Demeret, C; Garcia-Carranca, A; Thierry, F				Demeret, C; Garcia-Carranca, A; Thierry, F			Transcription-independent triggering of the extrinsic pathway of apoptosis by human papillomavirus 18 E2 protein	ONCOGENE			English	Article						HPV18 E2; apoptosis; caspases; extrinsic pathway; transactivation domain	CERVICAL-CARCINOMA; TRANSACTIVATION DOMAIN; CASPASE FAMILY; HELA-CELLS; TYPE-16; ACTIVATION; E6; PROLIFERATION; DEGRADATION; ONCOPROTEIN	Cervical carcinomas are most frequently associated with human papillomaviruses (HPV), whose E6 and E7 oncogenes products induce cellular immortalization. The papillomavirus E2 protein is a transcription factor, which represses the expression of the viral oncogenes, and activates viral DNA replication during the vegetative viral cycle. This protein is specifically inactivated in HPV18-associated carcinoma cells, suggesting that E2 functions prevent carcinogenic progression. Indeed, ectopic expression of E2 in cervical carcinoma cells strongly inhibits cell proliferation. Here we show that above a threshold level of expression, the E2 protein induces apoptosis, independently of other viral functions. The amino-terminal domain is responsible for this apoptotic activity, but surprisingly with no involvement of its transcriptional functions. The death pathway triggered by E2 relies on activation of the initiator caspase 8, specific of the extrinsic pathway of apoptosis. E2 itself is cleaved by caspases during cell death, providing an example of an apoptotic inducer that is itself a target for caspase processing. The autonomous proapoptotic activity of HPV18 E2 described here may counteract the proliferative functions of viral oncogenes, and renders the inactivation of E2 crucial for carcinogenic progression.	Inst Pasteur, Unit Gene Express & Dis, URA 1644, CNRS, F-75724 Paris 15, France; Univ Nacl Autonoma Mexico, Inst Invest Biomed, Mexico City, DF, Mexico	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite; Universidad Nacional Autonoma de Mexico	Demeret, C (corresponding author), Inst Pasteur, Unit Gene Express & Dis, URA 1644, CNRS, Fernbach Bldg,25 Rue Dr Roux, F-75724 Paris 15, France.			Demeret, caroline/0000-0002-1103-6805				Antson AA, 2000, NATURE, V403, P805, DOI 10.1038/35001638; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bellanger S, 2001, J VIROL, V75, P7244, DOI 10.1128/JVI.75.16.7244-7251.2001; Corden SA, 1999, J CLIN PATHOL-MOL PA, V52, P275, DOI 10.1136/mp.52.5.275; Crouzet J, 1997, P NATL ACAD SCI USA, V94, P1414, DOI 10.1073/pnas.94.4.1414; DARZYNKIEWICZ Z, 1994, METHODS CELL BIOL; Desaintes C, 1999, ONCOGENE, V18, P4538, DOI 10.1038/sj.onc.1202818; Desaintes C, 1996, SEMIN CANCER BIOL, V7, P339, DOI 10.1006/scbi.1996.0043; Desaintes C, 1997, EMBO J, V16, P504, DOI 10.1093/emboj/16.3.504; DOWHANICK JJ, 1995, J VIROL, V69, P7791, DOI 10.1128/JVI.69.12.7791-7799.1995; Drewett V, 2001, J BIOL CHEM, V276, P33444, DOI 10.1074/jbc.M103877200; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P10978, DOI 10.1073/pnas.97.20.10978; HWANG ES, 1993, J VIROL, V67, P3720, DOI 10.1128/JVI.67.7.3720-3729.1993; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Levkau B, 1999, NAT CELL BIOL, V1, P227, DOI 10.1038/12050; Maitland NJ, 1998, J PATHOL, V186, P275, DOI 10.1002/(SICI)1096-9896(1998110)186:3&lt;275::AID-PATH159&gt;3.0.CO;2-E; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; THIERRY F, 1990, MOL CELL BIOL, V10, P4431, DOI 10.1128/MCB.10.8.4431; THIERRY F, 1987, EMBO J, V6, P3391, DOI 10.1002/j.1460-2075.1987.tb02662.x; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Webster K, 2000, J BIOL CHEM, V275, P87, DOI 10.1074/jbc.275.1.87; Weil M, 1999, CURR BIOL, V9, P361, DOI 10.1016/S0960-9822(99)80162-6; Wells SI, 2000, EMBO J, V19, P5762, DOI 10.1093/emboj/19.21.5762; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049	27	67	79	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 16	2003	22	2					168	175		10.1038/sj.onc.1206108	http://dx.doi.org/10.1038/sj.onc.1206108			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527886				2022-12-17	WOS:000180322400002
J	Nakayama, H				Nakayama, H			RecQ family helicases: roles as tumor suppressor proteins	ONCOGENE			English	Review						RecQ helicase; Bloom's syndrome; Werner's syndrome; Rothmund-Thomson syndrome; hyper-recombination; cancer predisposition	WERNER-SYNDROME PROTEIN; SYNDROME GENE-PRODUCT; BLOOMS-SYNDROME GENE; ROTHMUND-THOMSON-SYNDROME; ESCHERICHIA-COLI RECQ; SGS1 DNA HELICASE; ARRESTED REPLICATION FORKS; TOPOISOMERASE III-ALPHA; SACCHAROMYCES-CEREVISIAE; HOMOLOGOUS RECOMBINATION	RecQ family DNA helicases are defined as proteins sharing a homologous region with Escherichia coli RecQ and are basically regarded as enzymes involved in recombination. Humans have five RecQ family members, and deficiencies in three of them, BLM, WRN, and RTS, cause Bloom's, Werner's, and Rothmund-Thomson syndromes, respectively, each characterized by genomic instability and cancer predisposition. In this context, an important function of the RecQ homologs appears to be the unwinding of intermediates of recombination, thereby preventing its uncontrolled execution. As a consequence, their deficiencies give rise to elevated levels of recombination (the hyper-recombination phenotype), which result in chromosomal aberrations including loss of heterozygosity, a common chromosomal change associated with malignancies. Thus, those helicases qualify as caretaker-type tumor suppressor proteins. In addition, BLM and WRN deficiencies have been shown to attenuate p53-mediated apoptosis, suggesting that they also belong to the gatekeeper class of tumor suppressor proteins.	Kyushu Univ, Higashi Ku, Fukuoka 8128581, Japan	Kyushu University	Nakayama, H (corresponding author), 4395-2 Fukuma Machi, Fukuoka 8113213, Japan.	nakh@ruby.ocn.ne.jp						Ababou M, 2002, ONCOGENE, V21, P2079, DOI 10.1038/sj.onc.1205246; Ababou M, 2000, ONCOGENE, V19, P5955, DOI 10.1038/sj.onc.1204003; AJIMA J, 2002, MUTAT RES, V9336, P1; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barre FX, 2001, P NATL ACAD SCI USA, V98, P8189, DOI 10.1073/pnas.111008998; Bennett RJ, 2000, J BIOL CHEM, V275, P26898; Bennett RJ, 1999, J MOL BIOL, V289, P235, DOI 10.1006/jmbi.1999.2739; Bennett RJ, 1998, J BIOL CHEM, V273, P9644, DOI 10.1074/jbc.273.16.9644; Bernstein C, 2002, MUTAT RES-REV MUTAT, V511, P145, DOI 10.1016/S1383-5742(02)00009-1; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; Blander G, 1999, J BIOL CHEM, V274, P29463, DOI 10.1074/jbc.274.41.29463; Brosh RM, 2000, J BIOL CHEM, V275, P23500, DOI 10.1074/jbc.M001557200; Brosh RM, 2001, EMBO J, V20, P5791; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; Brosh RM, 2001, J BIOL CHEM, V276, P35093, DOI 10.1074/jbc.M103332200; Brosh RM, 2001, J BIOL CHEM, V276, P3024, DOI 10.1074/jbc.M006784200; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Cohen H, 2001, P NATL ACAD SCI USA, V98, P3174, DOI 10.1073/pnas.061579598; Collister M, 1998, CARCINOGENESIS, V19, P2115, DOI 10.1093/carcin/19.12.2115; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Cooper MP, 2000, GENE DEV, V14, P907; Courcelle J, 1999, MOL GEN GENET, V262, P543, DOI 10.1007/s004380051116; Courcelle J, 2001, P NATL ACAD SCI USA, V98, P8196, DOI 10.1073/pnas.121008898; Courcelle J, 2001, BIOESSAYS, V23, P463, DOI 10.1002/bies.1065; Cox MM, 2001, P NATL ACAD SCI USA, V98, P8173, DOI 10.1073/pnas.131004998; Doe CL, 2000, EMBO J, V19, P2751, DOI 10.1093/emboj/19.11.2751; Duckett DR, 1999, P NATL ACAD SCI USA, V96, P12384, DOI 10.1073/pnas.96.22.12384; Dutertre S, 2000, ONCOGENE, V19, P2731, DOI 10.1038/sj.onc.1203595; Ellis NA, 1996, HUM MOL GENET, V5, P1457, DOI 10.1093/hmg/5.Supplement_1.1457; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; FARAGHER RGA, 1993, P NATL ACAD SCI USA, V90, P12030, DOI 10.1073/pnas.90.24.12030; Featherstone C, 1999, MUTAT RES-DNA REPAIR, V434, P3, DOI 10.1016/S0921-8777(99)00006-3; Fernandez S, 1998, J BACTERIOL, V180, P3405; Frei C, 2000, J CELL SCI, V113, P2641; Frei C, 2000, GENE DEV, V14, P81; Friedberg E.C., 2016, DNA REPAIR MUTAGENES, V33, P35; Fry M, 1999, J BIOL CHEM, V274, P12797, DOI 10.1074/jbc.274.18.12797; FUKUCHI K, 1990, HUM GENET, V84, P249; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; Gangloff S, 2000, NAT GENET, V25, P192, DOI 10.1038/76055; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; Garkavtsev IV, 2001, ONCOGENE, V20, P8276, DOI 10.1038/sj.onc.1205120; GEBHART E, 1988, HUM GENET, V80, P135, DOI 10.1007/BF00702855; German J, 1997, CANCER GENET CYTOGEN, V93, P100, DOI 10.1016/S0165-4608(96)00336-6; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GOTO M, 1982, SCAND J IMMUNOL, V15, P389, DOI 10.1111/j.1365-3083.1982.tb00663.x; GOTO M, 1979, J CLIN INVEST, V64, P695, DOI 10.1172/JCI109511; Goto M, 2000, CLIN EXP RHEUMATOL, V18, P760; Goto M, 1996, CANCER EPIDEM BIOMAR, V5, P239; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; GRODEN J, 1992, HUM GENET, V90, P360; Hakem R, 2001, ANNU REV GENET, V35, P209, DOI 10.1146/annurev.genet.35.102401.090432; Hammond EM, 2002, MOL CELL BIOL, V22, P1834, DOI 10.1128/MCB.22.6.1834-1843.2002; Hanada K, 1997, P NATL ACAD SCI USA, V94, P3860, DOI 10.1073/pnas.94.8.3860; Harmon FG, 1999, MOL CELL, V3, P611, DOI 10.1016/S1097-2765(00)80354-8; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; Harmon FG, 2001, J BIOL CHEM, V276, P232, DOI 10.1074/jbc.M006555200; Hartung F, 2000, NUCLEIC ACIDS RES, V28, P4275, DOI 10.1093/nar/28.21.4275; Hu P, 2001, HUM MOL GENET, V10, P1287, DOI 10.1093/hmg/10.12.1287; Huang PH, 2001, CURR BIOL, V11, P125, DOI 10.1016/S0960-9822(01)00021-5; Imamura O, 2001, ONCOGENE, V20, P1143, DOI 10.1038/sj.onc.1204195; IRINO N, 1986, MOL GEN GENET, V205, P298, DOI 10.1007/BF00430442; Jeong SM, 2000, MOL GEN GENET, V263, P183, DOI 10.1007/s004380051159; Johnson FB, 2000, CANCER RES, V60, P1162; Johnson FB, 2001, EMBO J, V20, P905, DOI 10.1093/emboj/20.4.905; Kamath-Loeb AS, 2000, P NATL ACAD SCI USA, V97, P4603, DOI 10.1073/pnas.97.9.4603; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; Kamath-Loeb AS, 2001, J BIOL CHEM, V276, P16439, DOI 10.1074/jbc.M100253200; Karmakar P, 2002, J BIOL CHEM, V277, P18291, DOI 10.1074/jbc.M111523200; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; Kawabe T, 2000, ONCOGENE, V19, P4764, DOI 10.1038/sj.onc.1203841; Kim S, 2002, ONCOGENE, V21, P503, DOI 10.1038/sj.onc.1205077; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; Kitao S, 1998, GENOMICS, V54, P443, DOI 10.1006/geno.1998.5595; Kogoma T, 1997, MICROBIOL MOL BIOL R, V61, P212, DOI 10.1128/.61.2.212-238.1997; Kusano K, 2001, SCIENCE, V291, P2600, DOI 10.1126/science.291.5513.2600; Langland G, 2001, J BIOL CHEM, V276, P30031, DOI 10.1074/jbc.M009664200; LARNER JM, 1994, MOL CELL BIOL, V14, P1901, DOI 10.1128/MCB.14.3.1901; Le S, 1999, GENETICS, V152, P143; Lebel M, 1999, J BIOL CHEM, V274, P37795, DOI 10.1074/jbc.274.53.37795; Lebel M, 1998, P NATL ACAD SCI USA, V95, P13097, DOI 10.1073/pnas.95.22.13097; Lebel M, 2001, CANCER RES, V61, P1816; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li BM, 2000, J BIOL CHEM, V275, P28349, DOI 10.1074/jbc.C000289200; Li BM, 2001, J BIOL CHEM, V276, P9896, DOI 10.1074/jbc.M008575200; Liao SR, 2000, GENE DEV, V14, P2570, DOI 10.1101/gad.822400; Lindor NM, 2000, AM J MED GENET, V90, P223, DOI 10.1002/(SICI)1096-8628(20000131)90:3<223::AID-AJMG7>3.0.CO;2-Z; Lu JA, 1996, NATURE, V383, P678, DOI 10.1038/383678a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Luo GB, 2000, NAT GENET, V26, P424, DOI 10.1038/82548; Michel B, 2001, P NATL ACAD SCI USA, V98, P8181, DOI 10.1073/pnas.111008798; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; MONNAT RJ, 1992, GENOMICS, V13, P777, DOI 10.1016/0888-7543(92)90153-J; Morozov V, 1997, TRENDS BIOCHEM SCI, V22, P417, DOI 10.1016/S0968-0004(97)01128-6; Mullen JR, 2000, GENETICS, V154, P1101; Murray JM, 1997, MOL CELL BIOL, V17, P6868, DOI 10.1128/MCB.17.12.6868; Myung K, 2001, NAT GENET, V27, P113, DOI 10.1038/83673; NAKAYAMA H, 1984, MOL GEN GENET, V195, P474, DOI 10.1007/BF00341449; NAKAYAMA K, 1985, MOL GEN GENET, V200, P266, DOI 10.1007/BF00425434; Oakley TJ, 2002, DNA REPAIR, V1, P175, DOI 10.1016/S1568-7864(02)00002-2; Ogburn CE, 1997, HUM GENET, V101, P121, DOI 10.1007/s004390050599; Onoda F, 2000, MUTAT RES-DNA REPAIR, V459, P203, DOI 10.1016/S0921-8777(99)00071-3; Onoda F, 2001, MOL GEN GENET, V264, P702, DOI 10.1007/s004380000358; Oshima J, 2002, CANCER RES, V62, P547; Pedrazzi G, 2001, NUCLEIC ACIDS RES, V29, P4378, DOI 10.1093/nar/29.21.4378; POOT M, 1992, EXP CELL RES, V202, P267, DOI 10.1016/0014-4827(92)90074-I; Prince PR, 2001, GENE DEV, V15, P933, DOI 10.1101/gad.877001; PURANAM KL, 1994, J BIOL CHEM, V269, P29838; Sakamoto S, 2001, GENES CELLS, V6, P421, DOI 10.1046/j.1365-2443.2001.00433.x; SALK D, 1981, CYTOGENET CELL GENET, V30, P92, DOI 10.1159/000131596; Sanchez-Alonso P, 1998, GENETICS, V148, P1043; Sekelsky JJ, 1999, NUCLEIC ACIDS RES, V27, P3762, DOI 10.1093/nar/27.18.3762; SEKI M, 1994, NUCLEIC ACIDS RES, V22, P4566, DOI 10.1093/nar/22.22.4566; SEKI M, 1994, J BIOCHEM-TOKYO, V115, P523, DOI 10.1093/oxfordjournals.jbchem.a124369; Shen JC, 2000, NUCLEIC ACIDS RES, V28, P3260, DOI 10.1093/nar/28.17.3260; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; Shen JC, 1998, NUCLEIC ACIDS RES, V26, P2879, DOI 10.1093/nar/26.12.2879; Shimamoto A, 2000, NUCLEIC ACIDS RES, V28, P1647, DOI 10.1093/nar/28.7.1647; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; Spillare EA, 1999, GENE DEV, V13, P1355, DOI 10.1101/gad.13.11.1355; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; Sun H, 1998, J BIOL CHEM, V273, P27587, DOI 10.1074/jbc.273.42.27587; Sun H, 1999, NUCLEIC ACIDS RES, V27, P1978, DOI 10.1093/nar/27.9.1978; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; Tachibana A, 1996, MOL CARCINOGEN, V17, P41, DOI 10.1002/(SICI)1098-2744(199609)17:1<41::AID-MC6>3.3.CO;2-Z; Teng SC, 1999, MOL CELL BIOL, V19, P8083; Thompson LH, 1999, BIOCHIMIE, V81, P87, DOI 10.1016/S0300-9084(99)80042-X; Ui A, 2001, MOL GENET GENOMICS, V265, P837, DOI 10.1007/s004380100479; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; UMEZU K, 1993, J MOL BIOL, V230, P1145, DOI 10.1006/jmbi.1993.1231; VANKERCKHOVE CW, 1988, AM J DIS CHILD, V142, P1089, DOI 10.1001/archpedi.1988.02150100083032; VENNOS EM, 1992, J AM ACAD DERMATOL, V27, P750, DOI 10.1016/0190-9622(92)70249-F; Wang WS, 2000, EMBO J, V19, P3428, DOI 10.1093/emboj/19.13.3428; Wang XW, 2001, J BIOL CHEM, V276, P32948, DOI 10.1074/jbc.M103298200; Wang Y, 2000, GENE DEV, V14, P927; Watt PM, 1996, GENETICS, V144, P935; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; Woo RA, 2002, EMBO J, V21, P3000, DOI 10.1093/emboj/cdf307; Wu L, 2001, J BIOL CHEM, V276, P19375, DOI 10.1074/jbc.M009471200; Wu L, 2000, J BIOL CHEM, V275, P9636, DOI 10.1074/jbc.275.13.9636; Wyllie FS, 2000, NAT GENET, V24, P16, DOI 10.1038/71630; Yan H, 1998, NAT GENET, V19, P375, DOI 10.1038/1263; Yannone SM, 2001, J BIOL CHEM, V276, P38242; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	147	67	70	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2002	21	58					9008	9021		10.1038/sj.onc.1205959	http://dx.doi.org/10.1038/sj.onc.1205959			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	626TP	12483516				2022-12-17	WOS:000179889500011
J	Fiorini, M; Ballaro, C; Sala, G; Falcone, G; Alema, S; Segatto, O				Fiorini, M; Ballaro, C; Sala, G; Falcone, G; Alema, S; Segatto, O			Expression of RALT, a feedback inhibitor of ErbB receptors, is subjected to an integrated transcriptional and post-translational control	ONCOGENE			English	Article						ErbB; RALT; proteasome; cell cycle; Ras pathways	ACTIVATED PROTEIN-KINASE; UBIQUITIN-PROTEASOME PATHWAY; MAMMARY EPITHELIAL-CELLS; EPIDERMAL GROWTH-FACTOR; TYROSINE KINASE; NEGATIVE REGULATORS; IN-VIVO; C-CBL; DEGRADATION; DIFFERENTIATION	Over-expression studies have demonstrated that RALT (receptor associated late transducer) is a feedback inhibitor of ErbB-2 mitogenic and transforming signals. In growth-arrested cells, expression of endogenous RALT is induced by mitogenic stimuli, is high throughout mid to late G1 and returns to baseline as cells move into S phase. Here, we show that physiological levels of RALT effectively suppress ErbB-2 mitogenic signals. We also investigate the regulatory mechanisms that preside to the control of RALT expression. We demonstrate that pharmacological ablation of extracellular signal-regulated kinase (ERK) activation leads to blockade of RALT expression, unlike genetic and/or pharmacological interference with the activities of PKC, Src family kinases, p38 SAPK and PI-3K. Tamoxifen-dependent activation of an inducible Raf:ER chimera was sufficient to induce RALT expression. Thus, activation of the Ras-Raf-ERK pathway is necessary and sufficient to drive RALT expression. The RALT protein is labile and was found to accumulate robustly upon pharmacological inhibition of the proteasome. We were able to detect ubiquitin-conjugated RALT species in living cells, suggesting that ubiquitinylation targets RALT for proteasome-dependent degradation. Such an integrated transcriptional and posttranslational control is likely to provide RALT with the ability to fluctuate timely in order to tune ErbB signals.	Ist Regina Elena, Immunol Lab, I-00156 Rome, Italy; CNR, Ist Biol Cellulare, I-00016 Monterotondo, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Consiglio Nazionale delle Ricerche (CNR)	Segatto, O (corresponding author), Ist Regina Elena, Immunol Lab, I-00156 Rome, Italy.		Sala, Gianluca/C-2056-2017; Falcone, Germana/A-3735-2016	Sala, Gianluca/0000-0002-4494-915X; Segatto, Oreste/0000-0003-2561-1142; Falcone, Germana/0000-0002-3508-7623; Alema, Stefano/0000-0002-9869-6354				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Blagosklonny MV, 1999, ONCOGENE, V18, P6460, DOI 10.1038/sj.onc.1203068; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chiariello M, 2000, BIOCHEM J, V349, P869, DOI 10.1042/bj3490869; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Douglas DN, 1999, BBA-MOL CELL RES, V1448, P439, DOI 10.1016/S0167-4889(98)00161-X; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Fiorentino L, 2000, MOL CELL BIOL, V20, P7735, DOI 10.1128/MCB.20.20.7735-7750.2000; Fiorini M, 2001, FEBS LETT, V490, P132, DOI 10.1016/S0014-5793(01)02116-0; Flanagan A M, 1998, Curr Opin Hematol, V5, P181, DOI 10.1097/00062752-199805000-00006; Freeman M, 2000, NATURE, V408, P313, DOI 10.1038/35042500; Gallo R, 1997, ONCOGENE, V15, P1929, DOI 10.1038/sj.onc.1201344; Ghiglione C, 1999, DEV BIOL, V205, P181, DOI 10.1006/dbio.1998.9102; Greenwood S, 1997, DEVELOPMENT, V124, P4879; Gross I, 2001, J BIOL CHEM, V276, P46460, DOI 10.1074/jbc.M108234200; Hackel PO, 2001, BIOL CHEM, V382, P1649, DOI 10.1515/BC.2001.200; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Huggins GS, 1999, J BIOL CHEM, V274, P28690, DOI 10.1074/jbc.274.40.28690; Hughes EA, 1996, J EXP MED, V183, P1569, DOI 10.1084/jem.183.4.1569; Impagnatiello MA, 2001, J CELL BIOL, V152, P1087, DOI 10.1083/jcb.152.5.1087; Jones SM, 2001, FEBS LETT, V490, P110, DOI 10.1016/S0014-5793(01)02113-5; Krebs DL, 2001, STEM CELLS, V19, P378, DOI 10.1634/stemcells.19-5-378; Latella L, 2001, MOL CELL BIOL, V21, P5631, DOI 10.1128/MCB.21.16.5631-5643.2001; LEE KL, 1989, ARCH BIOCHEM BIOPHYS, V269, P106, DOI 10.1016/0003-9861(89)90091-X; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; Makkinje A, 2000, J BIOL CHEM, V275, P17838, DOI 10.1074/jbc.M909735199; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTE BM, 1995, MOL ENDOCRINOL, V9, P14, DOI 10.1210/me.9.1.14; MARTE BM, 1995, ONCOGENE, V10, P167; McMahon M, 2001, BBA-REV CANCER, V1471, pM63, DOI 10.1016/S0304-419X(00)00027-5; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P1801; Myung J, 2001, MED RES REV, V21, P245, DOI 10.1002/med.1009; Nagao M, 1999, ONCOGENE, V18, P4425, DOI 10.1038/sj.onc.1202832; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; Ozaki K, 2001, BIOCHEM BIOPH RES CO, V285, P1084, DOI 10.1006/bbrc.2001.5295; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Pai LM, 2000, CELL, V103, P51, DOI 10.1016/S0092-8674(00)00104-5; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Perrimon N, 1999, CELL, V97, P13, DOI 10.1016/S0092-8674(00)80710-2; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; SALAMA SR, 1994, MOL CELL BIOL, V14, P7953, DOI 10.1128/MCB.14.12.7953; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Sasaki A, 2001, J BIOL CHEM, V276, P36804, DOI 10.1074/jbc.C100386200; Schafer C, 1998, J BIOL CHEM, V273, P24173, DOI 10.1074/jbc.273.37.24173; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Simon MA, 2000, CELL, V103, P13, DOI 10.1016/S0092-8674(00)00100-8; Spataro V, 1998, BRIT J CANCER, V77, P448, DOI 10.1038/bjc.1998.71; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wallace AD, 2001, J BIOL CHEM, V276, P42714, DOI 10.1074/jbc.M106033200; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; WICK M, 1995, EXP CELL RES, V219, P527, DOI 10.1006/excr.1995.1261; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Xu J, 2000, P NATL ACAD SCI USA, V97, P4820, DOI 10.1073/pnas.97.9.4820; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	70	67	72	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 19	2002	21	42					6530	6539		10.1038/sj.onc.1205823	http://dx.doi.org/10.1038/sj.onc.1205823			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592FD	12226756				2022-12-17	WOS:000177925300013
J	Toyooka, S; Carbone, M; Toyooka, K; Bocchetta, M; Shivapurkar, N; Minna, JD; Gazdar, AF				Toyooka, S; Carbone, M; Toyooka, K; Bocchetta, M; Shivapurkar, N; Minna, JD; Gazdar, AF			Progressive aberrant methylation of the RASSF1A gene in simian virus 40 infected human mesothelial cells	ONCOGENE			English	Article						SV40; methylation; RASSF1A; mesothelial cell; mesothelioma	HUMAN PLEURAL MESOTHELIOMA; LARGE-T-ANTIGEN; EPIGENETIC INACTIVATION; PROMOTER HYPERMETHYLATION; MALIGNANT MESOTHELIOMA; DNA METHYLATION; LUNG CARCINOMAS; CPG ISLANDS; SIMIAN-VIRUS-40; 3P21.3	Mesotheliomas are tumors arising from mesothelial cells and are associated with asbestos exposure and approximately 50% contain simian virus 40 (SV40) DNA sequences. SV40 infection of human mesothelial cells (HM) causes early cellular immortalization and late transformation. Aberrant methylation is a major mechanism for loss of function of tumor suppressor genes (TSGs). We recently reported that of seven genes frequently methylated in epithelial tumors, only RASSF1A gene was frequently methylated in mesotheliomas, and its methylation was correlated with loss of RASSF1A expression and the presence of SV40. We studied whether SV40 infection of normal HM induces aberrant methylation of the genes previously studied in mesotheliomas. Of six infected foci examined at early passages (passages 8-30) there was no methylation of the seven genes examined. Of two foci examined at late passages (passages 51-86) after the appearance of morphological changes suggestive of transformation, methylation and loss of expression of RASSF1A was detected. Sequencing of the CpG dense region around the transcription start site and semi-quantitative real-time methylation specific PCR (MSP) assay for RASSF1A methylation demonstrated progressive methylation during late passages. Exposure to the demethylating agent 5-aza-2'-deoxycytidine restored RASSF1A expression, while exposure to the histone deacetylation inhibitor trichostatin A had no effect. These data, together with our previous findings, support a causal relationship between SV40 infection, progressive RASSF1A methylation and its silencing, and the pathogenesis of mesothelioma.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Loyola Univ, Cardinal Bernardin Canc Ctr, Dept Pathol, Canc Immunol Program, Maywood, IL 60153 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Loyola University Chicago	Gazdar, AF (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.	Adi.GAZDAR@UTSouthwestern.edu			NATIONAL CANCER INSTITUTE [P50CA070907, R01CA071618, U01CA084971] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 71618, R01 CA2657, 5U01CA8497102, P50CA70907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Antman K, 2001, CANC PRINCIPLES PRAC, P1943; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bocchetta M, 2000, P NATL ACAD SCI USA, V97, P10214, DOI 10.1073/pnas.170207097; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Cacciotti P, 2001, P NATL ACAD SCI USA, V98, P12032, DOI 10.1073/pnas.211026798; CARBONE M, 1994, ONCOGENE, V9, P1781; Carbone M, 2002, SEMIN ONCOL, V29, P2, DOI 10.1053/sonc.2002.30227; Carbone M, 1997, NAT MED, V3, P908, DOI 10.1038/nm0897-908; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; DeLuca A, 1997, NAT MED, V3, P913, DOI 10.1038/nm0897-913; Esteller M, 1998, CANCER RES, V58, P4515; Esteller M, 2000, CANCER RES, V60, P2368; Foddis R, 2002, ONCOGENE, V21, P1434, DOI 10.1038/sj.onc.1205203; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Herman JG, 1999, SEMIN CANCER BIOL, V9, P359, DOI 10.1006/scbi.1999.0138; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Klein G, 2000, P NATL ACAD SCI USA, V97, P9830, DOI 10.1073/pnas.190325697; Klein G, 2002, ONCOGENE, V21, P1141, DOI 10.1038/sj.onc.1205173; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Morrissey C, 2001, CANCER RES, V61, P7277; Shivapurkar N, 2000, J CELL BIOCHEM, V76, P181; Testa JR, 2001, CANC PRINCIPLES PRAC, P1937; Toyooka S, 2001, CANCER RES, V61, P5727; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; Virmani AK, 2001, CLIN CANCER RES, V7, P1998; Waheed I, 1999, CANCER RES, V59, P6068	28	67	70	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2002	21	27					4340	4344		10.1038/sj.onc.1205381	http://dx.doi.org/10.1038/sj.onc.1205381			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082623				2022-12-17	WOS:000176174200018
J	Vossio, S; Palescandolo, E; Pediconi, N; Moretti, F; Balsano, C; Levrero, M; Costanzo, A				Vossio, S; Palescandolo, E; Pediconi, N; Moretti, F; Balsano, C; Levrero, M; Costanzo, A			DN-p73 is activated after DNA damage in a p53-dependent manner to regulate p53-induced cell cycle arrest	ONCOGENE			English	Article						p53; p73; oncogenes; tumor suppressor; apoptosis; cell cycle	KINASE C-ABL; APOPTOTIC RESPONSE; P53 HOMOLOG; P73; RNA; FAMILY; DEATH; P63; EXPRESSION; DELTA-NP73	p53 and p73 genes are both activated in response to DNA damage to induce either cell cycle arrest or apoptosis, depending on the strength and the quality of the damaging stimulus. p53/p73 transcriptional activity must be tightly regulated to ensure that the appropriate biological response is achieved and to allow the cell to re-enter into the cell cycle after the damage has been repaired. In addition to multiple transcriptionally active (TA) isoforms, dominant negative (DN) variants, that lack the amino-terminal transactivation domain and function as trans-repressors of p53, p63 and p73, are expressed from a second internal promoter (P2-p73Pr). Here we show that, in response to a non apoptotic DNA damage induced by low doses of doxorubicin, p53 binds in vivo, as detected by a p53-specific chromatin immunoprecipitation assay, and activates the P2-p73 promoter. DN-p73alpha protein accumulates under the same conditions and exogenously expressed DN-p73alpha is able to counteract the p53-induced activation of the P2-p73Pr. These results suggest that DN-p73 may contribute to the autoregulatory loops responsible for the termination of p53/p73 responses in cells that do not undergo apoptosis. Accordingly, the activation of the P2-p73Pr is markedly enhanced in both p73-/- murine fibroblasts and in human cells in which p73 transcripts are selectively knocked-out by p73-specific small interfering RNAs.	Univ Roma La Sapienza, Fdn Andrea Cesalpino, Gene Express Lab, Policlin Umberto I, I-00161 Rome, Italy; Univ Aquila, Dip Med Interna, I-67100 Laquila, Italy; Univ Cagliari, Dip Sci Med Internist, Cagliari, Italy	Sapienza University Rome; University Hospital Sapienza Rome; University of L'Aquila; University of Cagliari	Levrero, M (corresponding author), Univ Roma La Sapienza, Fdn Andrea Cesalpino, Gene Express Lab, Policlin Umberto I, Viale Policlin 155, I-00161 Rome, Italy.	levmax@tin.it	Balsano, Clara/AAK-9870-2020; Costanzo, Antonio/D-3896-2012; Costanzo, Antonio/GZG-2433-2022; Levrero, Massimo/G-5680-2016	Balsano, Clara/0000-0002-9615-7031; Costanzo, Antonio/0000-0001-9697-2557; Levrero, Massimo/0000-0002-4978-0875				Agami R, 1999, NATURE, V399, P809; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Gong JG, 1999, NATURE, V399, P806; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ishimoto O, 2002, CANCER RES, V62, P636; Levrero M, 1999, CELL DEATH DIFFER, V6, P1146, DOI 10.1038/sj.cdd.4400624; Levrero M, 2000, J CELL SCI, V113, P1661; Liefer KM, 2000, CANCER RES, V60, P4016; Lipardi C, 2001, CELL, V107, P297, DOI 10.1016/S0092-8674(01)00537-2; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Lohrum MAE, 1999, CELL DEATH DIFFER, V6, P1162, DOI 10.1038/sj.cdd.4400625; Nishikura K, 2001, CELL, V107, P415, DOI 10.1016/S0092-8674(01)00581-5; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Prives C, 1999, J PATHOL, V187, P112; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; Sayan AE, 2001, ONCOGENE, V20, P5111, DOI 10.1038/sj.onc.1204669; Sijen T, 2001, CELL, V107, P465, DOI 10.1016/S0092-8674(01)00576-1; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	27	67	70	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3796	3803		10.1038/sj.onc.1205465	http://dx.doi.org/10.1038/sj.onc.1205465			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032848				2022-12-17	WOS:000175676000015
J	Godfried, MB; Veenstra, M; Von Sluis, P; Boon, K; Von Asperen, R; Hermus, MC; Von Schaik, BDC; Voute, TPA; Schwab, M; Versteeg, R; Caron, HN				Godfried, MB; Veenstra, M; Von Sluis, P; Boon, K; Von Asperen, R; Hermus, MC; Von Schaik, BDC; Voute, TPA; Schwab, M; Versteeg, R; Caron, HN			The N-myc and c-mjc downstream pathways include the chromosome 17q genes nm23-H1 and nm23-H2	ONCOGENE			English	Article						nm23-H1; nm23-H2; N-myc; c-myc; chromosome 17; neuroblastoma	I HLA EXPRESSION; CELL-LINES; NEUROBLASTOMA; DIFFERENTIATION; LOCALIZATION; PROGRESSION; NUCLEOSIDE; MELANOMAS	Gain of chromosome 17q material is the most frequent genetic abnormality in neuroblastomas. The common region of gain is at least 375 cR large, which has precluded the identification of genes with a role in neuroblastoma pathogenesis. Neuroblastoma also frequently show amplification of the N-myc oncogene, which correlates closely with 17q gain. Both events are strong predictors of unfavorable prognosis. To identify genes that are part of the N-myc downstream pathway, we constructed SAGE libraries of an N-mjc transfected and a control cell line. This identified the chromosome 17q genes nm23-H1 and nm23-H2 as being 6-10 times induced in the N-myc expressing cells. Northern and Western blot analysis confirmed this up-regulation. Time-course experiment shows that both genes are induced within 4 h after N-myc is switched on. Furthermore, we demonstrate also that c-myc can upregulate nm23-H1 and nm23-H2 expression. Neuroblastoma tumor and cell line panels reveal a striking correlation between N-myc amplification and mRNA and protein expression of both nm23 genes. We show that the nm23 genes are located at the edge of the common region of chromosome 17q gain previously described in neuroblastoma cell lines. Our findings suggest that nm23-H1 and nm23-H2 expression is increased by 17q gain in neuroblastoma and can be further up-regulated by myc overexpression. These observations suggest a major role for nm23-H1 and nm23-H2 in tumorigenesis of unfavorable neuroblastomas.	Univ Amsterdam, Acad Med Ctr, Dept Human Genet, NL-1100 DE Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Bioinformat Lab, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Emma Kinderziekenhuis, Dept Pediat Oncol & Hematol, NL-1105 AZ Amsterdam, Netherlands; DKFZ, Berlin, Germany	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Helmholtz Association; German Cancer Research Center (DKFZ)	Caron, HN (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Human Genet, POB 22700, NL-1100 DE Amsterdam, Netherlands.	HNCaron@amc.uva.nl	Versteeg, Rogier/AAQ-1765-2020	Versteeg, Rogier/0000-0001-7172-0388; van Schaik, Barbera/0000-0002-5568-8127				BACKER JM, 1993, ONCOGENE, V8, P497; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Bown N, 1999, NEW ENGL J MED, V340, P1954, DOI 10.1056/NEJM199906243402504; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CARON H, 1995, MED PEDIATR ONCOL, V24, P215, DOI 10.1002/mpo.2950240402; Cheng NC, 1996, ONCOGENE, V13, P1737; FLORENES VA, 1992, CANCER RES, V52, P6088; Lastowska M, 1998, GENE CHROMOSOME CANC, V23, P116; Lombardi D, 2000, J CELL PHYSIOL, V182, P144, DOI 10.1002/(SICI)1097-4652(200002)182:2<144::AID-JCP2>3.3.CO;2-Y; Lutz W, 1996, ONCOGENE, V13, P803; Malynn BA, 2000, GENE DEV, V14, P1390; Meddeb M, 1996, GENE CHROMOSOME CANC, V17, P156, DOI 10.1002/(SICI)1098-2264(199611)17:3<156::AID-GCC3>3.0.CO;2-3; Niitsu N, 2001, BLOOD, V97, P1202, DOI 10.1182/blood.V97.5.1202; Pinon VPB, 1999, EXP CELL RES, V246, P355, DOI 10.1006/excr.1998.4318; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; VANROY N, 1995, EUR J CANCER, V31A, P530, DOI 10.1016/0959-8049(95)00004-3; VERSTEEG R, 1988, EMBO J, V7, P1023, DOI 10.1002/j.1460-2075.1988.tb02909.x	17	67	71	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					2097	2101		10.1038/sj.onc.1205259	http://dx.doi.org/10.1038/sj.onc.1205259			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960382				2022-12-17	WOS:000174827000016
J	Tsai, MS; Bogart, DF; Li, P; Mehmi, I; Lupu, R				Tsai, MS; Bogart, DF; Li, P; Mehmi, I; Lupu, R			Expression and regulation of Cyr61 in human breast cancer cell lines	ONCOGENE			English	Article						Cyr61; estradiol; tamoxifen; ICI-182; 780; regulation; breast cancer	IMMEDIATE-EARLY GENE; TISSUE GROWTH-FACTOR; ACID RECEPTOR-ALPHA; RETINOIC ACID; EXTRACELLULAR-MATRIX; DIFFERENTIAL REGULATION; PHORBOL ESTER; PRODUCT; ADHESION; INVOLVEMENT	We have shown that Cyr61, an angiogenic regulator, is overexpressed in invasive and metastatic human breast cancer cells and tumor biopsies. We have further demonstrated that Cyr61 promotes acquisition of estrogen-independence and anti-estrogen resistance in vivo in breast cancer cells. Moreover, we have demonstrated that Cyr61 induces tumor formation and tumor vascularization in vivo, events mediated through the activation of the MAPK and the Akt signaling pathways. Here we investigate how Cyr61 expression is regulated in both estrogen receptor (ER)-positive and ER-negative breast cancer cells. We demonstrate that Cyr61 mRNA and protein expression is inducible by estrogen and anti-estrogens in ER-positive breast cancer cells. We show that a labile protein as well as a negative regulator might be involved in Cyr61 expression in estrogen-dependent breast cancer cells. Other important regulators of Cyr61 expression in breast cancer cells that we found are the phorbol ester TPA, vitamin D, and retinoic acid. TPA causes positive regulation of Cyr61 expression in ER-positive MCF-7 cells. Vitamin D induces a transient stimulatory effect on Cyr61 gene expression. Lastly, retinoic acid has a negative effect on Cyr61 expression and downregulates its expression in MCF-7 cells. Interestingly, most of these effects are not seen in aggressive breast cancer cells that do not express ER and express high levels of Cyr61, such as the MDA-MB-231 cells. Our results are in agreement with our knowledge that Cyr61 promotes tumor growth, and that tumor-promoting agents have a positive impact on cells that express low, levels of Cyr61, such as the ER-positive breast cancer cells; however, these agents have no significant effect on cells that express high levels of Cyr61. Our findings suggest an association between increased Cyr61. expression and an aggressive phenotype of breast cancer cells.	Univ Calif Berkeley, Ernest Orlando Lawrence Berkeley Natl Lab, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Lupu, R (corresponding author), Univ Calif Berkeley, Ernest Orlando Lawrence Berkeley Natl Lab, 1 Cyclotron Rd, Berkeley, CA 94720 USA.	rlupu@lbl.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049049] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 49049] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agadir A, 1999, J BIOL CHEM, V274, P29779, DOI 10.1074/jbc.274.42.29779; Albrecht C, 2000, J BIOL CHEM, V275, P28929, DOI 10.1074/jbc.M003053200; Babic AM, 1999, MOL CELL BIOL, V19, P2958; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; BUNNER A, 1991, DNA CELL BIOL, V10, P293; Chen NY, 2000, J BIOL CHEM, V275, P24953, DOI 10.1074/jbc.M003040200; Chung KC, 1998, NEUROSCI LETT, V255, P155, DOI 10.1016/S0304-3940(98)00733-2; Escaleira MTF, 1999, BREAST CANCER RES TR, V54, P123, DOI 10.1023/A:1006198107805; Flicker SH, 1997, CANCER LETT, V115, P63, DOI 10.1016/S0304-3835(97)04715-0; Folgueira MAAK, 2000, BRAZ J MED BIOL RES, V33, P559, DOI 10.1590/S0100-879X2000000500011; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Grzeszkiewicz TM, 2001, J BIOL CHEM, V276, P21943, DOI 10.1074/jbc.M100978200; HAUSSLER MR, 1995, BONE S, V17, P33; Inuzuka H, 1999, BIOCHEM BIOPH RES CO, V265, P664, DOI 10.1006/bbrc.1999.1734; Jedsadayanmata A, 1999, J BIOL CHEM, V274, P24321, DOI 10.1074/jbc.274.34.24321; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Kireeva ML, 1998, J BIOL CHEM, V273, P3090, DOI 10.1074/jbc.273.5.3090; Kireeva ML, 1997, EXP CELL RES, V233, P63, DOI 10.1006/excr.1997.3548; Kolesnikova TV, 1998, ONCOGENE, V16, P747, DOI 10.1038/sj.onc.1201572; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; MACGREGOR JI, 1988, PHARMACOL REV, V50, P151; NATHANS D, 1988, COLD SPRING HARB SYM, V53, P893, DOI 10.1101/SQB.1988.053.01.102; Nolan E, 1998, MOL CELL BIOCHEM, V188, P13, DOI 10.1023/A:1006879213501; OBRIEN TP, 1992, CELL GROWTH DIFFER, V3, P645; Pendurthi UR, 2000, J BIOL CHEM, V275, P14632, DOI 10.1074/jbc.275.19.14632; Rivera-Gonzalez R, 1998, J STEROID BIOCHEM, V64, P13, DOI 10.1016/S0960-0760(97)00142-8; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; Sampath D, 2001, ENDOCRINOLOGY, V142, P2540, DOI 10.1210/en.142.6.2540; Schneider SM, 1999, BREAST CANCER RES TR, V58, P171, DOI 10.1023/A:1006377006816; Schutze N, 1998, ENDOCRINOLOGY, V139, P1761, DOI 10.1210/en.139.4.1761; SHEIKH MS, 1994, J BIOL CHEM, V269, P21440; SMITH JB, 1995, J BIOL CHEM, V270, P16756, DOI 10.1074/jbc.270.28.16756; Srivastava RK, 1999, CLIN CANCER RES, V5, P1892; Tang CK, 1996, CANCER RES, V56, P3350; Tsai MS, 2000, CANCER RES, V60, P5603; Wong M, 1997, DEV BIOL, V192, P492, DOI 10.1006/dbio.1997.8766; Xie D, 2001, J BIOL CHEM, V276, P14187, DOI 10.1074/jbc.M009755200; YANG GP, 1991, CELL GROWTH DIFFER, V2, P351	41	67	74	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2002	21	6					964	973		10.1038/sj/onc/1205131	http://dx.doi.org/10.1038/sj/onc/1205131			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FC	11840342				2022-12-17	WOS:000173427100012
J	Sprenger, CC; Vail, ME; Evans, K; Simurdak, J; Plymate, SR				Sprenger, CC; Vail, ME; Evans, K; Simurdak, J; Plymate, SR			Over-expression of insulin-like growth factor binding protein-related protein-1 (IGFBP-rP1/mac25) in the M12 prostate cancer cell line alters tumor growth by a delay in G1 and cyclin A associated apoptosis	ONCOGENE			English	Article						IGFBP-rP1/mac25; prostate cancer; cell cycle; apoptosis; G1 delay	MAMMARY EPITHELIAL-CELLS; SENESCENCE; ARREST; MAC25; IDENTIFICATION; SUPPRESSOR; SUBLINES; GENE	In the present study, we examined the effects of overexpression of the potential tumor suppressor gene IGFBP-rP1/mac25 on cell-cycle kinetics in prostate cancer cells. The majority of the high expressing IGFBP-rP1/mac25 cell population was located in the GI and sub-G0/G1 peaks; synchronizing cells in G2/M with nocodazole demonstrated the high expressing IGFBP-rP1/mac25 clones were delayed in the G1 phase of the cell cycle. Unscheduled expression of cyclin A in the sub-G0/G1 peak occurred in the IGFBP-rp1/mac25 clones. Immunoblots showed decreased cyclin DI and p21 and increased cyclin E, p16, and p27 in the high expressing IGFBP-rP1/mac25 clones compared to the control cells. Cyclin D1/cdk-4,6 and cyclin E/cdk-2 kinase activities decreased but cyclin A/cdk-2 kinase activity increased for the high expressing IGFBP-rP1/mac25 clones compared to control cells. A pRb immunoprecipitation demonstrated more binding of E2F-1 to pRb in the high expressing IGFBP-rP1/mac25 clones than in control cells. Finally, cell senescence, as assessed by senescence-associated beta -galactosidase, demonstrated significantly more staining in the IGFBP-rP1/mac25 cells than control cells. These results suggest that IGFBP-rP1/mac25 alters the cell cycle kinetics of the M12 prostate cell line by delaying the cells in the GI phase of the cell cycle. In addition, the appearance of cyclin A in the sub-G0/G1 phase of the cell cycle and the increased kinase activity of cyclin A/cdk-2 in the IGFBP-rP1/mac25 clones suggests that cyclin A is associated with the apoptotic cells.	Amer Lake VAMC, GRECC 182B, VAPSHCS, Tacoma, WA 98493 USA; Univ Washington, Mol & Cellular Biol Program, Seattle, WA 98195 USA; Madigan Army Med Ctr, Dept Urol, Tacoma, WA 98433 USA; Madigan Army Med Ctr, Dept Pathol, Tacoma, WA 98433 USA; Univ Washington, Dept Med, Seattle, WA 98165 USA	Geriatric Research Education & Clinical Center; University of Washington; University of Washington Seattle; Madigan Army Medical Center; Madigan Army Medical Center; University of Washington; University of Washington Seattle	Plymate, SR (corresponding author), Amer Lake VAMC, GRECC 182B, VAPSHCS, Bldg 85,Rm 128, Tacoma, WA 98493 USA.	splymate@u.washington.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052683] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52683] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi S, 2001, CIRC RES, V88, P408, DOI 10.1161/01.res.88.4.408; BAE VL, 1994, INT J CANCER, V58, P721, DOI 10.1002/ijc.2910580517; Bae VL, 1998, PROSTATE, V34, P275, DOI 10.1002/(SICI)1097-0045(19980301)34:4<275::AID-PROS5>3.0.CO;2-G; Burger AM, 1998, ONCOGENE, V16, P2459, DOI 10.1038/sj.onc.1201772; Campisi J, 2000, IN VIVO, V14, P183; Campisi J, 1997, J AM GERIATR SOC, V45, P482, DOI 10.1111/j.1532-5415.1997.tb05175.x; Chang BD, 1999, CANCER RES, V59, P3761; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; Darzynkiewicz Z, 1996, CYTOMETRY, V25, P1; Ho YS, 2001, INT J CANCER, V91, P393, DOI 10.1002/1097-0215(200002)9999:9999&lt;::AID-IJC1070&gt;3.0.CO;2-#; Hwa V, 1998, J CLIN ENDOCR METAB, V83, P4355, DOI 10.1210/jc.83.12.4355; JacksonCook C, 1996, CANCER GENET CYTOGEN, V87, P14, DOI 10.1016/0165-4608(95)00232-4; Jarrard DF, 1999, CANCER RES, V59, P2957; Jin YH, 2000, J BIOL CHEM, V275, P30256, DOI 10.1074/jbc.M001902200; Juan G, 1996, CELL PROLIFERAT, V29, P259, DOI 10.1046/j.1365-2184.1996.01000.x; Juan G, 1998, METH MOL B, V91, P67; Kato MV, 1996, ONCOGENE, V12, P1361; Kishibe J, 2000, J BIOL CHEM, V275, P15321, DOI 10.1074/jbc.275.20.15321; Komatsu S, 2000, BIOCHEM BIOPH RES CO, V267, P109, DOI 10.1006/bbrc.1999.1937; Lopez-Bermejo A, 2000, ENDOCRINOLOGY, V141, P4072, DOI 10.1210/en.141.11.4072; MURPHY M, 1993, CELL GROWTH DIFFER, V4, P715; Oh YM, 1996, J BIOL CHEM, V271, P30322, DOI 10.1074/jbc.271.48.30322; Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579; Sandhu C, 2000, CANCER RES, V60, P2616; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sprenger CC, 1999, CANCER RES, V59, P2370; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; Tsihlias J, 1999, ANNU REV MED, V50, P401; Tsihlias J, 2000, ONCOGENE, V19, P670, DOI 10.1038/sj.onc.1203369; Wartenberg M, 1999, J BIOL CHEM, V274, P27759, DOI 10.1074/jbc.274.39.27759; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wilson EM, 1997, J CLIN ENDOCR METAB, V82, P1301, DOI 10.1210/jc.82.4.1301; Zi ZL, 1999, P NATL ACAD SCI USA, V96, P7490, DOI 10.1073/pnas.96.13.7490	33	67	72	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2002	21	1					140	147		10.1038/sj.onc.1205021	http://dx.doi.org/10.1038/sj.onc.1205021			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	505AD	11791184				2022-12-17	WOS:000172887800014
J	Branton, PE; Roopchand, DE				Branton, PE; Roopchand, DE			The role of adenovirus E4orf4 protein in viral replication and cell killing	ONCOGENE			English	Review						adenovirus; E4orf4; PP2A; apoptosis	2A REGULATORY SUBUNIT; SMALL-T-ANTIGEN; POLYOMAVIRUS MIDDLE-T; PHOSPHATASE 2A; SACCHAROMYCES-CEREVISIAE; EARLY REGION-4; E1A PROTEIN; P53-INDEPENDENT APOPTOSIS; SIGNAL-TRANSDUCTION; TRANSFORMED-CELLS	It has only been within the last few years that insights have been gained into the remarkable diversity of functions of the adenovirus early transcription region 4 (E4) products. The polypeptide encoded by E4 open reading frame 4 (E4orf4) has emerged as an enigmatic product. Although it accomplishes certain functions that propel viral replication, it has also been shown to be highly toxic, an effect that could dampen the infectious cycle, but that also might serve to facilitate release of viral progeny. When expressed alone, E4orf4 induces a novel form of p53-independent apoptosis in cancer cells but not in normal human cells, thus making it of potential use in cancer gene therapy. In addition, knowledge of its mechanism of action, especially with regard to its interaction with protein phosphatase 2A (MA), could provide insights to develop new small molecule anti-cancer drugs. Thus future studies on E4orf4 should be both informative and potentially valuable therapeutically. In this study we review the current status of knowledge on E4orf4.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada; GeminX Biotechnol Inc, Montreal, PQ H2W 2M9, Canada	McGill University; McGill University	Branton, PE (corresponding author), McGill Univ, Dept Biochem, McIntyre Med Bldg,3655 Promenade Sir Willian Osle, Montreal, PQ H3G 1Y6, Canada.	branton@med.mcgill.ca						Afifi R, 2001, J VIROL, V75, P4444, DOI 10.1128/JVI.75.9.4444-4447.2001; AGOSTINIS P, 1992, EUR J BIOCHEM, V205, P241, DOI 10.1111/j.1432-1033.1992.tb16774.x; Boivin D, 1999, J VIROL, V73, P1245, DOI 10.1128/JVI.73.2.1245-1253.1999; Bondesson M, 1996, J VIROL, V70, P3844, DOI 10.1128/JVI.70.6.3844-3851.1996; BONDESSON M, 1992, EMBO J, V11, P3347, DOI 10.1002/j.1460-2075.1992.tb05413.x; BRIDGE E, 1993, VIROLOGY, V193, P794, DOI 10.1006/viro.1993.1188; Calin GA, 2000, ONCOGENE, V19, P1191, DOI 10.1038/sj.onc.1203389; CAMPBELL KS, 1995, J VIROL, V69, P3721, DOI 10.1128/JVI.69.6.3721-3728.1995; Chiou SK, 1997, J VIROL, V71, P3515, DOI 10.1128/JVI.71.5.3515-3525.1997; COHEN P, 1989, FEBS LETT, V250, P601, DOI 10.1016/0014-5793(89)80804-X; Colella S, 2001, INT J CANCER, V93, P798, DOI 10.1002/ijc.1423; Costanzo MC, 2000, NUCLEIC ACIDS RES, V28, P73, DOI 10.1093/nar/28.1.73; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DEL PL, 1997, SCIENCE, V278, P687; ENGEL DA, 1988, GENE DEV, V2, P1517, DOI 10.1101/gad.2.12a.1517; Evangelista CC, 1996, GENETICS, V142, P1083; Evans DRH, 2000, MOL GEN GENET, V264, P425; Evans DRH, 1997, GENETICS, V145, P227; Fernandes ER, 1997, MOL CELL BIOL, V17, P1890, DOI 10.1128/MCB.17.4.1890; FERRIGNO P, 1993, MOL BIOL CELL, V4, P669, DOI 10.1091/mbc.4.7.669; FREYER GA, 1984, NUCLEIC ACIDS RES, V12, P3503, DOI 10.1093/nar/12.8.3503; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FROST JA, 1994, MOL CELL BIOL, V14, P6244, DOI 10.1128/MCB.14.9.6244; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; GLENN GM, 1995, J VIROL, V69, P3729, DOI 10.1128/JVI.69.6.3729-3736.1995; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; HALBERT DN, 1985, J VIROL, V56, P250, DOI 10.1128/JVI.56.1.250-257.1985; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; Hemmings BA, 1997, SCIENCE, V277, P534, DOI 10.1126/science.277.5325.534; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; HENDRIX P, 1993, J BIOL CHEM, V268, P15267; HERISSE J, 1981, NUCLEIC ACIDS RES, V9, P4023, DOI 10.1093/nar/9.16.4023; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kanopka A, 1998, NATURE, V393, P185, DOI 10.1038/30277; Kanopka A, 1996, NATURE, V381, P535, DOI 10.1038/381535a0; Kaplan JM, 1999, J VIROL, V73, P4489, DOI 10.1128/JVI.73.5.4489-4492.1999; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KHEWGOODALL Y, 1991, BIOCHEMISTRY-US, V30, P89, DOI 10.1021/bi00215a014; Kleinberger T, 2000, APOPTOSIS, V5, P211, DOI 10.1023/A:1009644210581; KLEINBERGER T, 1993, J VIROL, V67, P7556, DOI 10.1128/JVI.67.12.7556-7560.1993; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; Kremmer E, 1997, MOL CELL BIOL, V17, P1692, DOI 10.1128/MCB.17.3.1692; Lavoie JN, 1998, J CELL BIOL, V140, P637, DOI 10.1083/jcb.140.3.637; Lavoie JN, 2000, J CELL BIOL, V150, P1037, DOI 10.1083/jcb.150.5.1037; Livne A, 2001, J VIROL, V75, P789, DOI 10.1128/JVI.75.2.789-798.2001; Mannervik M, 1999, VIROLOGY, V256, P313, DOI 10.1006/viro.1999.9663; Marcellus RC, 1998, J VIROL, V72, P7144, DOI 10.1128/JVI.72.9.7144-7153.1998; Marcellus RC, 1996, J VIROL, V70, P6207, DOI 10.1128/JVI.70.9.6207-6215.1996; Marcellus RC, 2000, J VIROL, V74, P7869, DOI 10.1128/JVI.74.17.7869-7877.2000; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; McCright B, 1996, GENOMICS, V36, P168, DOI 10.1006/geno.1996.0438; Mills JC, 1999, J CELL BIOL, V146, P703, DOI 10.1083/jcb.146.4.703; Moreno CS, 2000, J BIOL CHEM, V275, P5257, DOI 10.1074/jbc.275.8.5257; MULLER U, 1989, GENE DEV, V3, P1991, DOI 10.1101/gad.3.12a.1991; MULLER U, 1992, J VIROL, V66, P5867; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nilsson CE, 2001, EMBO J, V20, P864, DOI 10.1093/emboj/20.4.864; PALLAS DC, 1992, J VIROL, V66, P886, DOI 10.1128/JVI.66.2.886-893.1992; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; RONNE H, 1991, MOL CELL BIOL, V11, P4876, DOI 10.1128/MCB.11.10.4876; ROOPCHAND DE, 2001, IN PRESS ONCOGENE; Roulston A, 1999, ANNU REV MICROBIOL, V53, P577, DOI 10.1146/annurev.micro.53.1.577; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; SCHEIDTMANN KH, 1991, MOL CELL BIOL, V11, P1996, DOI 10.1128/MCB.11.4.1996; Shtrichman R, 2000, ONCOGENE, V19, P3757, DOI 10.1038/sj.onc.1203705; Shtrichman R, 1999, P NATL ACAD SCI USA, V96, P10080, DOI 10.1073/pnas.96.18.10080; Shtrichman R, 1998, J VIROL, V72, P2975, DOI 10.1128/JVI.72.4.2975-2982.1998; Shu YM, 1997, MOL CELL BIOL, V17, P3242, DOI 10.1128/MCB.17.6.3242; SNEDDON AA, 1990, EMBO J, V9, P4339, DOI 10.1002/j.1460-2075.1990.tb07883.x; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; Tanabe O, 1996, FEBS LETT, V379, P107, DOI 10.1016/0014-5793(95)01500-0; Tehrani MA, 1996, J BIOL CHEM, V271, P5164; TEODORO JG, 1995, ONCOGENE, V11, P467; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; Turowski P, 1999, MOL BIOL CELL, V10, P1997, DOI 10.1091/mbc.10.6.1997; VANZYL W, 1992, MOL CELL BIOL, V12, P4946, DOI 10.1128/MCB.12.11.4946; VIRTANEN A, 1984, J VIROL, V51, P822, DOI 10.1128/JVI.51.3.822-831.1984; Voorhoeve PM, 1999, ONCOGENE, V18, P515, DOI 10.1038/sj.onc.1202316; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; Wang YC, 1997, MOL CELL BIOL, V17, P620, DOI 10.1128/MCB.17.2.620; Wei HJ, 2001, J BIOL CHEM, V276, P1570, DOI 10.1074/jbc.M008694200; Whalen SG, 1997, J VIROL, V71, P3545, DOI 10.1128/JVI.71.5.3545-3553.1997; Wu J, 2000, EMBO J, V19, P5672, DOI 10.1093/emboj/19.21.5672; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yan Z, 2000, MOL CELL BIOL, V20, P1021, DOI 10.1128/MCB.20.3.1021-1029.2000; Yang HF, 2000, MOL CELL BIOL, V20, P8143, DOI 10.1128/MCB.20.21.8143-8156.2000; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988; Zha HB, 1996, MOL CELL BIOL, V16, P6494; Zhao Y, 1997, J BIOL CHEM, V272, P8256, DOI 10.1074/jbc.272.13.8256; ZOLNIEROWICZ S, 1994, BIOCHEMISTRY-US, V33, P11858, DOI 10.1021/bi00205a023; Zolnierowicz S, 1996, BIOCHEM J, V317, P187, DOI 10.1042/bj3170187	99	67	70	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	2001	20	54					7855	7865		10.1038/sj.onc.1204862	http://dx.doi.org/10.1038/sj.onc.1204862			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	495JF	11753668				2022-12-17	WOS:000172336500005
J	Konduri, SD; Rao, CN; Chandrasekar, N; Tasiou, A; Mohanam, S; Kin, Y; Lakka, SS; Dinh, D; Olivero, WC; Gujrati, M; Foster, DC; Kisiel, W; Rao, JS				Konduri, SD; Rao, CN; Chandrasekar, N; Tasiou, A; Mohanam, S; Kin, Y; Lakka, SS; Dinh, D; Olivero, WC; Gujrati, M; Foster, DC; Kisiel, W; Rao, JS			A novel function of tissue factor pathway inhibitor-2 (TFPI-2) in human glioma invasion	ONCOGENE			English	Article						TFPI-2; glioblastoma; invasion	MATRIX-DEGRADING METALLOPROTEINASE; SERINE PROTEINASE-INHIBITORS; ENDOTHELIAL GROWTH-FACTOR; PLASMINOGEN-ACTIVATOR; CELL-LINE; PROTEASE INHIBITOR; MELANOMA-CELLS; CDNA CLONING; FACTOR VIIA; IN-SITU	Human tissue factor pathway inhibitor-2 (TFPI-2) is a Kunitz-type serine protease inhibitor that inhibits plasmin, trypsin, chymotrypsin, cathepsin G, and plasma kallikrein but not urokinase-type plasminogen activator, tissue plasminogen activator, or thrombin. Preliminary findings in our laboratory suggested that the expression of TFPI-2 is downregulated or lost during tumor progression in human gliomas. To investigate the role of TFPI-2 in the invasiveness of brain tumors, we stably transfected the human high-grade glioma cell line SNB19 and the human low-grade glioma cell line Hs683 with a vector capable of expressing a transcript complementary to the full-length TFPI-2 mRNA in either sense (0.7 kb) or antisense (1 kb) orientations. Parental cells and stably transfected cell lines were analysed for TFPI-2 protein by Western blotting and for TFPI-2 mRNA by Northern blotting. The levels of TFPI-2 protein and mRNA were higher in the sense clones (SNB19) and decreased in the antisense (Hs683) clones than in the corresponding parental and vector controls. In spheroid and matrigel invasion assays, the SNB19 parental cells were highly invasive, but the sense-transfected SNB-19 clones were much less invasive; the antisense-transfected Hs683 clones were more invasive than their parental and vector controls. After intracerebral injection in mice, the sense-transfected SNB19 clones were less able to form tumors than were their parental and vector controls, and the antisense-Hs683 clones but not the parental or vector controls formed small tumors. This is the first study to demonstrate that down- or upregulation of TFPI-2 plays a significant role in the invasive behavior of human gliomas.	Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Div Canc Biol, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Neurosurg, Div Canc Biol, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Neuropathol, Div Canc Biol, Peoria, IL 61656 USA; Zymogenet Inc, Seattle, WA 98105 USA; Univ New Mexico, Hlth Sci Ctr, Albuquerque, NM 87131 USA; Ctr Prostate Dis Res, Rockville, MD USA	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; Zymogenet Inc.; University of New Mexico; University of New Mexico's Health Sciences Center	Rao, JS (corresponding author), Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Div Canc Biol, 1 Illini Dr, Peoria, IL 61656 USA.			Tasiou, Anastasia/0000-0002-8853-540X	NCI NIH HHS [CA-75692, CA-76350, CA-75557] Funding Source: Medline; NHLBI NIH HHS [HL-64119] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075557, R01CA076350] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064119] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIZIK J, 1990, CELL REGUL, V1, P895, DOI 10.1091/mbc.1.12.895; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Contrino J, 1996, NAT MED, V2, P209, DOI 10.1038/nm0296-209; DUFFY MJ, 1992, CLIN EXP METASTAS, V10, P145, DOI 10.1007/BF00132746; DVORAK HF, 1987, HUM PATHOL, V18, P275, DOI 10.1016/S0046-8177(87)80010-2; EHRLICH HJ, 1991, J CELL BIOL, V115, P1773, DOI 10.1083/jcb.115.6.1773; Eitzman DT, 1996, BLOOD, V87, P4718; GLADSON CL, 1995, AM J PATHOL, V146, P1150; Go Y, 1997, CLIN EXP METASTAS, V15, P440, DOI 10.1023/A:1018410523635; Hembrough TA, 2001, J BIOL CHEM, V276, P12241, DOI 10.1074/jbc.M010395200; Kondraganti S, 2000, CANCER RES, V60, P6851; Konduri SD, 2001, INT J ONCOL, V18, P127; Konduri SD, 2000, CLIN EXP METASTAS, V18, P303, DOI 10.1023/A:1011085820250; KOSHIKAWA N, 1994, BIOCHEM J, V303, P187, DOI 10.1042/bj3030187; KOSHIKAWA N, 1992, CANCER RES, V52, P5046; KRAMER MD, 1994, INVAS METAST, V14, P210; KWAAN HC, 1992, CANCER METAST REV, V11, P291, DOI 10.1007/BF01307184; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakka SS, 2000, CLIN EXP METASTAS, V18, P239, DOI 10.1023/A:1006755223357; LINO M, 1998, ARTERIOSCLER THROMB, V18, P40; LUNDJOHANSEN M, 1990, SPHEROID CULTURE CAN, P3; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; Miyagi Y, 1996, DNA CELL BIOL, V15, P947, DOI 10.1089/dna.1996.15.947; MIYAGI Y, 1994, J BIOCHEM-TOKYO, V116, P939, DOI 10.1093/oxfordjournals.jbchem.a124648; MIYAZAKI K, 1990, CANCER RES, V50, P7758; Mohanam S, 1997, ONCOGENE, V14, P1351, DOI 10.1038/sj.onc.1200963; Mueller BM, 1998, J CLIN INVEST, V101, P1372, DOI 10.1172/JCI930; MUELLER BM, 1992, P NATL ACAD SCI USA, V89, P11832, DOI 10.1073/pnas.89.24.11832; MURPHY G, 1992, ANN NY ACAD SCI, V667, P1, DOI 10.1111/j.1749-6632.1992.tb51590.x; Nakagawa K, 1998, SEMIN THROMB HEMOST, V24, P207, DOI 10.1055/s-2007-995843; Neaud V, 2000, J BIOL CHEM, V275, P35565, DOI 10.1074/jbc.M006101200; Ollivier V, 1998, BLOOD, V91, P2698, DOI 10.1182/blood.V91.8.2698.2698_2698_2703; PEDERSEN PH, 1993, CANCER RES, V53, P5158; PEMBERTON PA, 1995, J BIOL CHEM, V270, P15832, DOI 10.1074/jbc.270.26.15832; Petersen LC, 1996, BIOCHEMISTRY-US, V35, P266, DOI 10.1021/bi951501d; QUAX PHA, 1991, J CELL BIOL, V115, P191, DOI 10.1083/jcb.115.1.191; Rao CN, 1996, ARCH BIOCHEM BIOPHYS, V335, P82, DOI 10.1006/abbi.1996.0484; RAO CN, 1995, ARCH BIOCHEM BIOPHYS, V317, P311, DOI 10.1006/abbi.1995.1168; RAO CN, 1995, ARCH BIOCHEM BIOPHYS, V319, P55, DOI 10.1006/abbi.1995.1266; Rao CN, 1999, BIOCHEM BIOPH RES CO, V255, P94, DOI 10.1006/bbrc.1999.0153; Rao CN, 1998, INT J CANCER, V76, P749, DOI 10.1002/(SICI)1097-0215(19980529)76:5<749::AID-IJC21>3.0.CO;2-Y; RAO CN, 1995, J INVEST DERMATOL, V104, P379, DOI 10.1111/1523-1747.ep12665851; Rao CN, 2001, CLIN CANCER RES, V7, P570; REINARTZ J, 1993, EXP CELL RES, V208, P197, DOI 10.1006/excr.1993.1238; Ruf W, 1996, Curr Opin Hematol, V3, P379; Seftor REB, 1998, CANCER RES, V58, P5681; Sheng SJ, 1998, P NATL ACAD SCI USA, V95, P499, DOI 10.1073/pnas.95.2.499; Shoji M, 1998, AM J PATHOL, V152, P399; SPRECHER CA, 1994, P NATL ACAD SCI USA, V91, P3353, DOI 10.1073/pnas.91.8.3353; STEPHENS RW, 1989, J CELL BIOL, V108, P1987, DOI 10.1083/jcb.108.5.1987; Taniguchi T, 1998, CANCER RES, V58, P4461; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P43; UMENISHI F, 1990, J BIOCHEM-TOKYO, V108, P537, DOI 10.1093/oxfordjournals.jbchem.a123238; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; WAGNER SL, 1989, J BIOL CHEM, V264, P611; YAMAMOTO M, 1994, CANCER RES, V54, P5016; YASUMITSU H, 1992, J BIOCHEM-TOKYO, V111, P74, DOI 10.1093/oxfordjournals.jbchem.a123721; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	58	67	79	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2001	20	47					6938	6945		10.1038/sj.onc.1204847	http://dx.doi.org/10.1038/sj.onc.1204847			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687973				2022-12-17	WOS:000171641000015
J	Kiemer, AK; Takeuchi, K; Quinlan, MP				Kiemer, AK; Takeuchi, K; Quinlan, MP			Identification of genes involved in epithelial-mesenchymal transition and tumor progression	ONCOGENE			English	Article						differentiation; transformation; immortalization; gene expression	REPRESENTATIONAL DIFFERENCE ANALYSIS; ARGININE-GLYCINE AMIDINOTRANSFERASE; RENAL-CELL CARCINOMAS; GROWTH-FACTOR; ADENOVIRUS E1A; IN-VIVO; SUPPRESSOR GENE; E1A-12S PROTEIN; LYSYL OXIDASE; X-CHROMOSOME	The adenovirus E1A12S gene product (WT12S) immortalizes epithelial cells and they retain their differentiated characteristics, but certain mutants cannot do the latter. Characterization of mutant immortalized epithelial cells indicated that they had undergone epithelial mesenchymal transition (EMT). Coexpression of V12ras with WT12S leads to benign tumors, but to malignant tumors with 12S mutants. Since EMT is critical for tumor progression, identification of the molecular mechanisms involved should elucidate novel therapeutic targets. To this end, representational difference analysis (RDA) was used to identify cDNAs upregulated in the mutant cell line. Thirty-five differentially expressed mRNAs were identified and classified into several functional categories, including nine novel cDNAs. Among the 26 known cDNAs, extracellular matrix and related proteins made up the largest group of differentially expressed genes, followed by growth factors and receptors and transcription factors. There was also an ion transporter, a cytoskeletal protein, glycosylation and amidinotransferase enzymes and proteins with unknown functions. Some of the known genes have previously been associated with EMT and/or tumor progression and thus served to validate the system to obtain the desired target genes, while other cDNAs are newly linked with dedifferentiation/malignancy. Array analyses indicated that the cDNAs were specifically upregulated in invasive or metastatic tumors, especially of breast, uterus and lung, suggesting their involvement in the progression of these tumors.	Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, Tokyo 1948533, Japan; Univ Munich, Dept Pharm, Ctr Drug Res, D-81377 Munich, Germany	Kyowa Kirin Ltd; University of Munich	Quinlan, MP (corresponding author), Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, 3-6-6 Asahi Machi,Machida Shi, Tokyo 1948533, Japan.		Kiemer, Alexandra K./I-9300-2012	Kiemer, Alexandra K./0000-0002-7224-9900				Adachi E, 1997, INT REV CYTOL, V173, P73; Allgayer H, 1998, CLIN EXP METASTAS, V16, P62; BENBARUCH N, 1994, P SOC EXP BIOL MED, V206, P221; Birchmeier W, 1996, CURR TOP MICROBIOL, V213, P117; Boyer B, 2000, BIOCHEM PHARMACOL, V60, P1091, DOI 10.1016/S0006-2952(00)00427-5; Brenner W, 2000, CANCER LETT, V155, P199, DOI 10.1016/S0304-3835(00)00429-8; CHINNADURAI G, 1992, ONCOGENE, V7, P1255; Crossin KL, 2000, DEV DYNAM, V218, P260, DOI 10.1002/(SICI)1097-0177(200006)218:2<260::AID-DVDY3>3.0.CO;2-9; Daniel L, 2000, CANCER RES, V60, P80; Dennis JW, 1999, BBA-GEN SUBJECTS, V1473, P21, DOI 10.1016/S0304-4165(99)00167-1; Dobra K, 2000, EXP CELL RES, V258, P12, DOI 10.1006/excr.2000.4915; DOUGLAS JL, 1991, ONCOGENE, V6, P2093; Duncan EL, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1263; Eccles MR, 1998, PEDIATR NEPHROL, V12, P712, DOI 10.1007/s004670050533; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Feige JJ, 1996, HORM RES, V45, P227, DOI 10.1159/000184793; Fimia GM, 2000, MOL CELL BIOL, V20, P8613, DOI 10.1128/MCB.20.22.8613-8622.2000; Fischer RS, 2000, VIROLOGY, V269, P404, DOI 10.1006/viro.2000.0232; Fischer RS, 1998, VIROLOGY, V249, P427, DOI 10.1006/viro.1998.9337; Fischer RS, 1998, CELL GROWTH DIFFER, V9, P905; Friedlander A, 1999, CRIT REV ONCOGENESIS, V10, P161; FUJIWARA Y, 1995, ONCOGENE, V10, P891; Grimm S, 1998, J EXP MED, V188, P1535, DOI 10.1084/jem.188.8.1535; GUTHMILLER P, 1994, J BIOL CHEM, V269, P17556; Haralson MA, 2000, MATRIX BIOL, V19, P47, DOI 10.1016/S0945-053X(99)00057-8; Hargrave M, 1997, DEV DYNAM, V210, P79, DOI 10.1002/(SICI)1097-0177(199710)210:2<79::AID-AJA1>3.0.CO;2-6; Hay ED, 1995, ACTA ANAT, V154, P8; He ZH, 1999, CANCER RES, V59, P3222; Hecht G, 1999, AM J PHYSIOL-CELL PH, V277, pC441, DOI 10.1152/ajpcell.1999.277.3.C441; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Huber SM, 2000, AM J PHYSIOL-RENAL, V279, pF65, DOI 10.1152/ajprenal.2000.279.1.F65; HUMM A, 1994, FEBS LETT, V339, P101, DOI 10.1016/0014-5793(94)80394-3; Isaac L, 1999, INFLAMM RES, V48, P446, DOI 10.1007/s000110050485; Kanwar YS, 1998, AM J PHYSIOL-RENAL, V275, pF710, DOI 10.1152/ajprenal.1998.275.5.F710; Kirschmann DA, 1999, BREAST CANCER RES TR, V55, P127; Komiya A, 1997, JPN J CANCER RES, V88, P389, DOI 10.1111/j.1349-7006.1997.tb00394.x; KUPPUSWAMY M, 1988, ONCOGENE, V2, P613; Lee SMY, 1998, GENE, V216, P163, DOI 10.1016/S0378-1119(98)00302-3; LINDER S, 1992, ONCOGENE, V7, P439; Lipschutz JH, 1998, AM J KIDNEY DIS, V31, P383, DOI 10.1053/ajkd.1998.v31.pm9506676; Lohi J, 1998, HISTOL HISTOPATHOL, V13, P785, DOI 10.14670/HH-13.785; Lombardi D, 2000, J CELL PHYSIOL, V182, P144, DOI 10.1002/(SICI)1097-4652(200002)182:2<144::AID-JCP2>3.3.CO;2-Y; Looijenga LHJ, 1997, AM J PATHOL, V151, P581; Lyon MF, 1999, CURR BIOL, V9, pR235, DOI 10.1016/S0960-9822(99)80151-1; McDonald HL, 2000, GENE CHROMOSOME CANC, V28, P246, DOI 10.1002/1098-2264(200007)28:3<246::AID-GCC2>3.3.CO;2-S; Miner JH, 1999, KIDNEY INT, V56, P2016, DOI 10.1046/j.1523-1755.1999.00785.x; Mitchell MS, 2000, CANCER RES, V60, P6448; MONTANO X, 1987, MOL CELL BIOL, V7, P1782, DOI 10.1128/MCB.7.5.1782; Mrowka C, 2000, J AM SOC NEPHROL, V11, pS106; Muller W, 1998, CANCER-AM CANCER SOC, V83, P2481, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2481::AID-CNCR11>3.0.CO;2-P; Mymryk JS, 1996, ONCOGENE, V13, P1581; Oivula J, 1999, J PATHOL, V187, P455, DOI 10.1002/(SICI)1096-9896(199903)187:4<455::AID-PATH271>3.0.CO;2-C; Okabe-Kado J, 1998, LEUKEMIA LYMPHOMA, V32, P19, DOI 10.3109/10428199809059243; Okada H, 1997, AM J PHYSIOL-RENAL, V273, pF563, DOI 10.1152/ajprenal.1997.273.4.F563; Panet R, 2000, J CELL PHYSIOL, V182, P109, DOI 10.1002/(SICI)1097-4652(200001)182:1<109::AID-JCP12>3.0.CO;2-A; Peyrard M, 1999, P NATL ACAD SCI USA, V96, P598, DOI 10.1073/pnas.96.2.598; Plisov SY, 2000, GENESIS, V27, P22, DOI 10.1002/1526-968X(200005)27:1<22::AID-GENE40>3.3.CO;2-M; Pujuguet P, 2000, J CELL SCI, V113, P849; QUINLAN MP, 1989, ONCOGENE, V4, P1051; QUINLAN MP, 1988, MOL CELL BIOL, V8, P3191, DOI 10.1128/MCB.8.8.3191; QUINLAN MP, 1987, J VIROL, V61, P673, DOI 10.1128/JVI.61.3.673-682.1987; QUINLAN MP, 1992, J VIROL, V66, P2020, DOI 10.1128/JVI.66.4.2020-2030.1992; QUINLAN MP, 1993, ONCOGENE, V8, P3289; Ramirez F, 1999, INT J BIOCHEM CELL B, V31, P255, DOI 10.1016/S1357-2725(98)00109-5; Reddel RR, 2000, CARCINOGENESIS, V21, P477, DOI 10.1093/carcin/21.3.477; Saito H, 1997, J BIOL CHEM, V272, P8157, DOI 10.1074/jbc.272.13.8157; Schneider J, 2000, BRIT J CANCER, V82, P1662; Smith-Mungo LI, 1998, MATRIX BIOL, V16, P387, DOI 10.1016/S0945-053X(98)90012-9; Sterzel RB, 2000, KIDNEY INT, V58, P1588, DOI 10.1046/j.1523-1755.2000.00320.x; Stohr H, 2000, CYTOGENET CELL GENET, V88, P211, DOI 10.1159/000015552; Stokes MB, 2000, KIDNEY INT, V57, P487, DOI 10.1046/j.1523-1755.2000.00868.x; STRUTZ F, 1995, J CELL BIOL, V130, P393, DOI 10.1083/jcb.130.2.393; SUBRAMANIAN T, 1989, ONCOGENE, V4, P415; van Goor H, 1999, EXP NEPHROL, V7, P35; Wada J, 1997, KIDNEY INT, V51, P1629, DOI 10.1038/ki.1997.225; WEILER SR, 1994, GENOMICS, V22, P243, DOI 10.1006/geno.1994.1374; Wilda M, 2000, J BONE MINER RES, V15, P2187, DOI 10.1359/jbmr.2000.15.11.2187; Wixler V, 2000, J BIOL CHEM, V275, P33669, DOI 10.1074/jbc.M002519200; Yang QW, 1999, DEV BIOL, V212, P229, DOI 10.1006/dbio.1999.9331; Zhang HD, 1998, P NATL ACAD SCI USA, V95, P14202, DOI 10.1073/pnas.95.24.14202	81	67	68	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 11	2001	20	46					6679	6688		10.1038/sj.onc.1204872	http://dx.doi.org/10.1038/sj.onc.1204872			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709702				2022-12-17	WOS:000171551600004
J	McIlhatton, MA; Burrows, JF; Donaghy, PG; Chanduloy, S; Johnston, PG; Russell, SEH				McIlhatton, MA; Burrows, JF; Donaghy, PG; Chanduloy, S; Johnston, PG; Russell, SEH			Genomic organization, complex splicing pattern and expression of a human septin gene on chromosome 17q25.3	ONCOGENE			English	Article						septin gene; genomic organisation; complex splicing	ACUTE MYELOID-LEUKEMIA; CELL-DIVISION CYCLE; SACCHAROMYCES-CEREVISIAE; MAMMALIAN SEPTIN; OVARIAN-TUMORS; PROTEIN-KINASE; YEAST; CYTOKINESIS; FAMILY; REGION	The Ov/Br septin gene, which is also a fusion partner of MLL in acute myeloid leukaemia, is a member of a family of novel GTP binding proteins that have been implicated in cytokinesis and exocytosis. In this study, we describe the genomic and transcriptional organization of this gene, detailing seventeen exons distributed over 240 kb of sequence. Extensive database analyses identified orthologous rodent cDNAs that corresponded to new, unidentified 5 ' splice variants of the Ov/Br septin gene, increasing the total number of such variants to six. We report that splicing events, occurring at noncanonical sites within the body of the 3 ' terminal exon, remove either 1801 by or 1849 by of non-coding sequence and facilitate access to a secondary open reading frame of 44 amino acids maintained near the end of the 3 ' UTR. These events constitute a novel coding arrangement and represent the first report of such a design being implemented by a eukaryotic gene. The various Ov/Br proteins either differ minimally at their amino and carboxy termini or are equivalent to truncated versions of larger isoforms. Northern analysis with an Ov/Br septin 3 ' UTR probe reveals three transcripts of 4.4, 4 and 3 kb, the latter being restricted to a sub-set of the tissues tested. Investigation of the identified Ov/Br septin isoforms by RT-PCR confirms a complex transcriptional pattern, with several isoforms showing tissue-specific distribution. To date, none of the other human septins have demonstrated such transcriptional complexity.	Queens Univ Belfast, Dept Oncol, Ctr Canc, Belfast City Hosp, Belfast BT9 7AB, Antrim, North Ireland	Belfast City Hospital; Queens University Belfast	Russell, SEH (corresponding author), Queens Univ Belfast, Dept Oncol, Ctr Canc, Belfast City Hosp, U Floor, Belfast BT9 7AB, Antrim, North Ireland.	seh.russell@qub.ac.uk						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Barral Y, 1999, GENE DEV, V13, P176, DOI 10.1101/gad.13.2.176; Beites CL, 1999, NAT NEUROSCI, V2, P434, DOI 10.1038/8100; Bi E, 1998, J CELL BIOL, V142, P1301, DOI 10.1083/jcb.142.5.1301; CHANT J, 1995, J CELL BIOL, V129, P767, DOI 10.1083/jcb.129.3.767; Croft L, 2000, NAT GENET, V24, P340, DOI 10.1038/74153; DeMarini DJ, 1997, J CELL BIOL, V139, P75, DOI 10.1083/jcb.139.1.75; DeVirgilio C, 1996, MICROBIOL-SGM, V142, P2897, DOI 10.1099/13500872-142-10-2897; Epp JA, 1997, CURR BIOL, V7, P921, DOI 10.1016/S0960-9822(06)00411-8; Fares H, 1996, J CELL BIOL, V132, P399, DOI 10.1083/jcb.132.3.399; FARES H, 1995, MOL BIOL CELL, V6, P1843, DOI 10.1091/mbc.6.12.1843; Field CM, 1999, TRENDS CELL BIOL, V9, P387, DOI 10.1016/S0962-8924(99)01632-3; Field CM, 1996, J CELL BIOL, V133, P605, DOI 10.1083/jcb.133.3.605; Fung ET, 1999, FEBS LETT, V451, P203, DOI 10.1016/S0014-5793(99)00559-1; Goodison S, 1999, J CLIN PATHOL-MOL PA, V52, P189; Hanke J, 1999, TRENDS GENET, V15, P389, DOI 10.1016/S0168-9525(99)01830-2; HARTWELL LH, 1971, EXP CELL RES, V69, P265, DOI 10.1016/0014-4827(71)90223-0; Hsu SC, 1998, NEURON, V20, P1111, DOI 10.1016/S0896-6273(00)80493-6; Kalikin LM, 1996, GENE CHROMOSOME CANC, V17, P64, DOI 10.1002/(SICI)1098-2264(199609)17:1<64::AID-GCC10>3.3.CO;2-1; Kalikin LM, 2000, GENOMICS, V63, P165, DOI 10.1006/geno.1999.6077; Kilpartick GJ, 1999, TRENDS PHARMACOL SCI, V20, P294, DOI 10.1016/S0165-6147(99)01355-3; Kinoshita M, 1997, GENE DEV, V11, P1535, DOI 10.1101/gad.11.12.1535; Longtine MS, 2000, MOL CELL BIOL, V20, P4049, DOI 10.1128/MCB.20.11.4049-4061.2000; Longtine MS, 1996, CURR OPIN CELL BIOL, V8, P106, DOI 10.1016/S0955-0674(96)80054-8; Longtine MS, 1998, J CELL BIOL, V143, P719, DOI 10.1083/jcb.143.3.719; Megonigal MD, 1998, P NATL ACAD SCI USA, V95, P6413, DOI 10.1073/pnas.95.11.6413; Missler M, 1998, TRENDS GENET, V14, P20, DOI 10.1016/S0168-9525(97)01324-3; Mori T, 1996, CYTOGENET CELL GENET, V73, P224, DOI 10.1159/000134343; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; NEUFELD TP, 1994, CELL, V77, P371, DOI 10.1016/0092-8674(94)90152-X; Osaka M, 1999, P NATL ACAD SCI USA, V96, P6428, DOI 10.1073/pnas.96.11.6428; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; Russell SEH, 2000, CANCER RES, V60, P4729; RUSSELL SEH, 1990, ONCOGENE, V5, P1581; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; Shulewitz MJ, 1999, MOL CELL BIOL, V19, P7123; Sorensen AB, 2000, J VIROL, V74, P2161, DOI 10.1128/JVI.74.5.2161-2168.2000; Taki T, 1999, CANCER RES, V59, P4261; Trimble WS, 1999, J MEMBRANE BIOL, V169, P75, DOI 10.1007/s002329900519; Xie H, 1999, CELL MOTIL CYTOSKEL, V43, P52, DOI 10.1002/(SICI)1097-0169(1999)43:1<52::AID-CM6>3.0.CO;2-5; Yagi M, 1998, GENE, V212, P229, DOI 10.1016/S0378-1119(98)00146-2; Zhang T, 1999, P NATL ACAD SCI USA, V96, P11422, DOI 10.1073/pnas.96.20.11422	45	67	78	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2001	20	41					5930	5939		10.1038/sj.onc.1204752	http://dx.doi.org/10.1038/sj.onc.1204752			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593400				2022-12-17	WOS:000171037200018
J	Kao, GD; McKenna, WG; Yen, TJ				Kao, GD; McKenna, WG; Yen, TJ			Detection of repair activity during the DNA damage-induced G2 delay in human cancer cells	ONCOGENE			English	Article						DNA damage; G2; DNA repair; BrdU	HUMAN-DIPLOID FIBROBLASTS; STRAND BREAK REPAIR; HAMSTER OVARY CELLS; HELA-CELLS; NUCLEAR-LOCALIZATION; KINASE ACTIVATION; NITROGEN-MUSTARD; MAMMALIAN-CELLS; EXCISION-REPAIR; UV IRRADIATION	All eukaryotic cells manifest cell cycle delay after exposure to DNA damaging agents. It has been proposed that such cell cycle checkpoints may allow DNA repair but direct evidence of such activity during the radiation-induced G2 delay has been lacking. We report here that cells arrested in G2 by radiation (2-3 Gy) and etoposide incorporate bromodeoxyuridine (BrdU) at discrete foci in the nucleus. We detected G2 cells with CENP-F, a nuclear protein maximally expressed in G2, Caffeine and okadaic acid, both established radiosensitizers, inhibit the incorporation of BrdU in G2 cells. Radioresistant HT29 and OVCAR cells demonstrate BrdU foci formation more frequently during the G2 delay when compared to the more radiosensitive A2780 cell line. The repair foci formed during G2 may be followed through mitosis and observed in daughter cells in G1, Taken together, these observations are consistent with the detection of DNA repair activity during the radiation-induced G2 delay after relatively low doses of radiation.	Hosp Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	University of Pennsylvania; Pennsylvania Medicine; Fox Chase Cancer Center	Yen, TJ (corresponding author), Hosp Univ Penn, Dept Radiat Oncol, 3400 Spruce St, Philadelphia, PA 19104 USA.			Yen, Tim/0000-0003-2159-0997	NCI NIH HHS [P01 CA06927] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMED FE, 1977, CANCER RES, V37, P3414; Balajee AS, 1998, MUTAT RES-FUND MOL M, V404, P3, DOI 10.1016/S0027-5107(98)00088-8; Barratt RA, 1998, CANCER RES, V58, P2639; BEETHAM KL, 1982, J CELL PHYSIOL, V113, P385, DOI 10.1002/jcp.1041130306; BEISKER W, 1988, EXP CELL RES, V174, P156, DOI 10.1016/0014-4827(88)90151-6; Biade S, 1997, RADIAT RES, V147, P416, DOI 10.2307/3579497; COHN SM, 1984, J BIOL CHEM, V259, P2463; DOLBEARE F, 1983, P NATL ACAD SCI-BIOL, V80, P5573, DOI 10.1073/pnas.80.18.5573; Featherstone C, 1999, CURR BIOL, V9, pR759, DOI 10.1016/S0960-9822(00)80005-6; FOX MH, 1991, J CELL SCI, V99, P247; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Haaf T, 1999, J CELL BIOL, V144, P11, DOI 10.1083/jcb.144.1.11; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HOY CA, 1993, MUTAT RES, V290, P217, DOI 10.1016/0027-5107(93)90162-9; JACQUET P, 1995, INT J RADIAT BIOL, V67, P347, DOI 10.1080/09553009514550401; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; Juan G, 1997, CANCER RES, V57, P803; JUNG T, 1992, INT J RADIAT BIOL, V62, P161, DOI 10.1080/09553009214551971; KALLE WHJ, 1993, ANAL BIOCHEM, V208, P228, DOI 10.1006/abio.1993.1037; Kao GD, 1999, J BIOL CHEM, V274, P34779, DOI 10.1074/jbc.274.49.34779; Kao GD, 1997, CANCER RES, V57, P753; Kaufmann WK, 1998, MUTAT RES-FUND MOL M, V400, P153, DOI 10.1016/S0027-5107(98)00041-4; KILL IR, 1991, J CELL SCI, V100, P869; LAU CC, 1982, P NATL ACAD SCI-BIOL, V79, P2942, DOI 10.1073/pnas.79.9.2942; Li J, 1997, P NATL ACAD SCI USA, V94, P502, DOI 10.1073/pnas.94.2.502; LIAO H, 1995, J CELL BIOL, V130, P507, DOI 10.1083/jcb.130.3.507; LOCK RB, 1992, CANCER RES, V52, P1817; MAITY A, 1995, EMBO J, V14, P603, DOI 10.1002/j.1460-2075.1995.tb07036.x; MURNANE JP, 1995, CANCER METAST REV, V14, P17, DOI 10.1007/BF00690208; NAGASAWA H, 1994, INT J RADIAT BIOL, V66, P373, DOI 10.1080/09553009414551311; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; Nishii K, 1996, ONCOGENE, V13, P2225; OCONNOR PM, 1993, J BIOL CHEM, V268, P8298; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OKEEFE RT, 1992, J CELL BIOL, V116, P1095, DOI 10.1083/jcb.116.5.1095; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; RICHOLD M, 1972, INT J RADIAT BIOL RE, V21, P127, DOI 10.1080/09553007214550151; Rieber MS, 1997, DNA CELL BIOL, V16, P121, DOI 10.1089/dna.1997.16.121; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; SELDEN JR, 1993, CYTOMETRY, V14, P154, DOI 10.1002/cyto.990140207; SHERWOOD SW, 1994, EXP CELL RES, V211, P275, DOI 10.1006/excr.1994.1087; STEFANINI M, 1982, SOMAT CELL GENET, V8, P635, DOI 10.1007/BF01542856; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; TSAO YP, 1992, CANCER RES, V52, P1823; VANDIERENDONCK JH, 1989, CYTOMETRY, V10, P143, DOI 10.1002/cyto.990100205; VIJG J, 1984, MUTAT RES, V132, P129, DOI 10.1016/0167-8817(84)90007-5; WANG XQ, 1994, EXP CELL RES, V212, P176, DOI 10.1006/excr.1994.1133; Wang Y, 2000, GENE DEV, V14, P927; ZELLE B, 1980, MUTAT RES, V73, P157, DOI 10.1016/0027-5107(80)90144-X; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	51	67	70	0	9	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2001	20	27					3486	3496		10.1038/sj.onc.1204445	http://dx.doi.org/10.1038/sj.onc.1204445			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429695				2022-12-17	WOS:000169478300004
J	Ferreira, R; Naguibneva, I; Pritchard, LL; Ait-Si-Ali, S; Harel-Bellan, A				Ferreira, R; Naguibneva, I; Pritchard, LL; Ait-Si-Ali, S; Harel-Bellan, A			The Rb/chromatin connection and epigenetic control: opinion	ONCOGENE			English	Review						Rb; cell cycle; differentiation; histone deacetylase; heterochromatin; methylation	RETINOBLASTOMA PROTEIN; HISTONE DEACETYLASE; CELL-CYCLE; DNA METHYLATION; NUCLEAR-ENVELOPE; CENTROMERIC HETEROCHROMATIN; TRANSCRIPTIONAL REPRESSION; CHROMOSOME TERRITORIES; CHROMATIN STRUCTURE; CPG METHYLATION	The balance between cell differentiation and proliferation is regulated at the transcriptional level, In the cell cycle, the transition from G1 to S phase (G1/S transition) is of paramount importance in this regard, Indeed, it is only before this point that cells can be oriented toward the differentiation pathway: beyond, cells progress into the cycle in an autonomous manner. The G1/S transition is orchestrated by the transcription factor E2F, E2F controls the expression of a group of checkpoint genes whose products are required either for the G1-to-S transition itself or for DNA replication (e.g. DNA polymerase alpha), E2F activity is repressed in growth-arrested cells and in early G1, and is activated at mid-to-late G1, E2F is controlled by the retinoblastoma tumor suppressor protein Rb, Rb represses E2F mainly by recruiting chromatin remodeling factors (histone deacetylases and SWI/SNF complexes), the DNA methyltransferase DNMT1, and a histone methyltransferase, This review will focus on the molecular mechanisms of E2F repression by Rb during the cell cycle and during cell-cycle exit by differentiating cells. A model in which Rb irreversibly represses E2F-regulated genes in differentiated cells by an epigenetic mechanism linked to heterochromatin, and involving histone H3 and promoter DNA methylation, is discussed.	Inst Andre Lwoff, Lab Oncogenese Differenciat & Transduct Signal, CNRS, UPR 9079, F-94801 Villejuif, France	Centre National de la Recherche Scientifique (CNRS)	Harel-Bellan, A (corresponding author), Inst Andre Lwoff, Lab Oncogenese Differenciat & Transduct Signal, CNRS, UPR 9079, 7 Rue Guy Moquet, F-94801 Villejuif, France.		Harel-Bellan, Annick/M-9795-2015	Naguibneva, Irina/0000-0001-9566-6152; Harel-Bellan, Annick/0000-0002-2339-153X				Aagaard L, 1999, EMBO J, V18, P1923, DOI 10.1093/emboj/18.7.1923; Ait-Si-Ali S, 2000, ONCOGENE, V19, P2430, DOI 10.1038/sj.onc.1203562; Andrulis ED, 1998, NATURE, V394, P592, DOI 10.1038/29100; Berger SL, 1999, CURR OPIN CELL BIOL, V11, P336, DOI 10.1016/S0955-0674(99)80046-5; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; Campanero MR, 2000, P NATL ACAD SCI USA, V97, P6481, DOI 10.1073/pnas.100340697; COCKELL M, 1995, J CELL BIOL, V129, P909, DOI 10.1083/jcb.129.4.909; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Csink AK, 1996, NATURE, V381, P529, DOI 10.1038/381529a0; Dernburg AF, 1996, CELL, V85, P745, DOI 10.1016/S0092-8674(00)81240-4; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; Francastel C, 1999, CELL, V99, P259, DOI 10.1016/S0092-8674(00)81657-8; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Gregory PD, 1998, CURR OPIN CELL BIOL, V10, P339, DOI 10.1016/S0955-0674(98)80009-4; Hamiche A, 1999, CELL, V97, P833, DOI 10.1016/S0092-8674(00)80796-5; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HENIKOFF S, 1995, GENETICS, V140, P1007; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Ivanova AV, 1998, NAT GENET, V19, P192, DOI 10.1038/566; JAMES TC, 1986, MOL CELL BIOL, V6, P3862, DOI 10.1128/MCB.6.11.3862; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Kourmouli N, 2000, EMBO J, V19, P6558, DOI 10.1093/emboj/19.23.6558; Kurz A, 1996, J CELL BIOL, V135, P1195, DOI 10.1083/jcb.135.5.1195; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; Li G, 1998, J CELL BIOL, V140, P975, DOI 10.1083/jcb.140.5.975; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Maillet L, 1996, GENE DEV, V10, P1796, DOI 10.1101/gad.10.14.1796; Muchardt C, 1999, J MOL BIOL, V293, P187, DOI 10.1006/jmbi.1999.2999; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; Nielsen AL, 1999, EMBO J, V18, P6385, DOI 10.1093/emboj/18.22.6385; Nowak SJ, 2000, GENE DEV, V14, P3003, DOI 10.1101/gad.848800; O'Carroll D, 2000, MOL CELL BIOL, V20, P9423, DOI 10.1128/MCB.20.24.9423-9433.2000; Pak DTS, 1997, CELL, V91, P311, DOI 10.1016/S0092-8674(00)80415-8; Pyrpasopoulou A, 1996, EMBO J, V15, P7108, DOI 10.1002/j.1460-2075.1996.tb01102.x; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Ross JF, 1999, MOL CELL, V3, P195, DOI 10.1016/S1097-2765(00)80310-X; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; Ryan RF, 1999, MOL CELL BIOL, V19, P4366; SCHARDIN M, 1985, HUM GENET, V71, P281, DOI 10.1007/BF00388452; Singal R, 1999, BLOOD, V93, P4059, DOI 10.1182/blood.V93.12.4059; Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967; Takahashi Y, 2000, GENE DEV, V14, P804; Trouche D, 1996, NUCLEIC ACIDS RES, V24, P4139, DOI 10.1093/nar/24.21.4139; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; Tyler JK, 1999, CELL, V99, P443, DOI 10.1016/S0092-8674(00)81530-5; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; WADE PA, 1997, CURR BIOL, V7, P82; Wansink DG, 1996, J CELL BIOCHEM, V62, P10, DOI 10.1002/(SICI)1097-4644(199607)62:1<10::AID-JCB2>3.0.CO;2-4; Wei Y, 1998, P NATL ACAD SCI USA, V95, P7480, DOI 10.1073/pnas.95.13.7480; WEINBERG RA, 1992, CANCER SURV, V12, P43; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Ye Q, 1996, J BIOL CHEM, V271, P14653, DOI 10.1074/jbc.271.25.14653; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	73	67	69	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	2001	20	24					3128	3133		10.1038/sj.onc.1204337	http://dx.doi.org/10.1038/sj.onc.1204337			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442WT	11420729				2022-12-17	WOS:000169308500017
J	Rokhlin, OW; Guseva, N; Tagiyev, A; Knudson, CM; Cohen, MB				Rokhlin, OW; Guseva, N; Tagiyev, A; Knudson, CM; Cohen, MB			Bcl-2 oncoprotein protects the human prostatic carcinoma cell line PC3 from TRAIL-mediated apoptosis	ONCOGENE			English	Article						Bcl-2; prostatic neoplasms; TRAIL; apoptosis	CYTOCHROME-C; CD95 APO-1/FAS; MITOCHONDRIAL; DEATH; FAS; CASPASE-8; FAMILY; RELEASE; LIGAND; LOCALIZATION	The role of Bcl-2 in TRAIL-induced apoptosis has been investigated in lymphoid cells, Here we show that the human prostatic carcinoma cell line PC3 was sensitive to TRAIL treatment whereas PC3 overexpressing of Bcl-2 was resistant. TRAIL receptors ligation in PC3 activated caspases -2, -3, -7, -8, and -9, induced Bid processing, dissipation of mitochondrial transmembrane potential (Delta Psi (m)), and cytochrome c release. We have detected caspases -8 and -3 only in the cytosolic fraction of cells, but caspases -2, -7, and -9 were found both in cytosolic and mitochondrial fractions. Bcl-2 overexpression did not affect caspase-8 activation although it did change the processing pattern of caspase-3, At the same time, Bcl-2 overexpression inhibited the activation of mitochondrial localized caspases -2, -7, and -9, Bcl-2 also abrogated TRAIL-induced cytochrome c release and dissipation of Delta Psi (m). These findings suggest that TRAIL-induced apoptosis in the epithelial cell line PC3 depends both on mitochondrial integrity and caspase activation.	Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA; Univ Iowa, Dept Urol, Iowa City, IA 52242 USA; Univ Iowa, Dept Epidemiol, Iowa City, IA 52242 USA; Vet Affairs Med Ctr, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Cohen, MB (corresponding author), Univ Iowa, Dept Pathol, 200 Hawkins Dr,1117 ML, Iowa City, IA 52242 USA.			Knudson, Charles Michael/0000-0003-3964-5466	NCI NIH HHS [CA 76673] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076673] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAFFY G, 1993, J BIOL CHEM, V268, P6511; Bonavida B, 1999, INT J ONCOL, V15, P793; Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Gewies A, 2000, CANCER RES, V60, P2163; Gotow T, 2000, CELL DEATH DIFFER, V7, P666, DOI 10.1038/sj.cdd.4400694; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Keogh SA, 2000, FEBS LETT, V471, P93, DOI 10.1016/S0014-5793(00)01375-2; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mancini M, 1998, J CELL BIOL, V140, P1485, DOI 10.1083/jcb.140.6.1485; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Peter ME, 1996, CELL DEATH DIFFER, V3, P161; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Rokhlin OW, 1998, CANCER RES, V58, P5870; Rokhlin OW, 2000, ONCOGENE, V19, P1959, DOI 10.1038/sj.onc.1203453; Rokhlin OW, 1997, CANCER RES, V57, P1758; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Screaton GR, 1997, CURR BIOL, V7, P693, DOI 10.1016/S0960-9822(06)00297-1; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shimizu S, 1996, ONCOGENE, V13, P21; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Utz PJ, 2000, CELL DEATH DIFFER, V7, P589, DOI 10.1038/sj.cdd.4400696; Walczak H, 2000, CANCER RES, V60, P3051; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; WILLEY SR, 1995, IMMUNITY, V3, P673; Yamada H, 1999, BIOCHEM BIOPH RES CO, V265, P130, DOI 10.1006/bbrc.1999.1641; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536	39	67	71	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 17	2001	20	22					2836	2843		10.1038/sj.onc.1204410	http://dx.doi.org/10.1038/sj.onc.1204410			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	432TP	11420695				2022-12-17	WOS:000168712000011
J	Crooke, ST				Crooke, ST			Potential roles of antisense technology in cancer chemotherapy	ONCOGENE			English	Article						antisense; mechanisms of action; gene functionalization; anticancer activity	INTERCELLULAR-ADHESION MOLECULE-1; COLI RNASE H1; C-14-LABELED PHOSPHOROTHIOATE OLIGONUCLEOTIDE; KINASE-C-ALPHA; MESSENGER-RNA; PHARMACOKINETIC PROPERTIES; THERAPEUTIC APPLICATIONS; RAT-LIVER; INHIBITION; EXPRESSION	Antisense technology may play a major role in cancer chemotherapy. It is clearly a tool of exceptional value in the functionalization of genes and their validation as potential targets for cancer chemotherapy. Additionally, there is now substantial evidence that antisense drugs are safe, and a growing body of data showing activity in animal models of human disease including cancer, and suggesting efficacy in patients with cancer. In this article, I review the progress in the technology, the anticancer antisense drugs in development and potential roles that antisense technology might play.	ISIS Pharmaceut Inc, Carlsbad, CA 92008 USA	Isis Pharmaceuticals Inc	Crooke, ST (corresponding author), ISIS Pharmaceut Inc, 2292 Faraday Ave, Carlsbad, CA 92008 USA.							AGRAWAL S, 1991, P NATL ACAD SCI USA, V88, P7595, DOI 10.1073/pnas.88.17.7595; Baker BF, 1999, BBA-GENE STRUCT EXPR, V1489, P3, DOI 10.1016/S0167-4781(99)00146-3; Bennett CF, 1999, BBA-GENE STRUCT EXPR, V1489, P19, DOI 10.1016/S0167-4781(99)00144-X; Bennett CF, 1998, HANDB EXP PHARM, V131, P371; Bost F, 1999, MOL CELL BIOL, V19, P1938; Butler M, 1997, LAB INVEST, V77, P379; CAZENAVE C, 1989, NUCLEIC ACIDS RES, V17, P4255, DOI 10.1093/nar/17.11.4255; Chen HX, 2000, CLIN CANCER RES, V6, P1259; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; COHEN JS, 1993, ANTISENSE RES APPL, P205; Cook PD, 1998, HANDB EXP PHARM, V131, P51; COSSUM PA, 1994, J PHARMACOL EXP THER, V269, P89; COSSUM PA, 1993, J PHARMACOL EXP THER, V267, P1181; Cotter F E, 1999, Haematologica, V84 Suppl EHA-4, P19; Cotter FE, 1999, BBA-GENE STRUCT EXPR, V1489, P97, DOI 10.1016/S0167-4781(99)00139-6; Crooke R.M., 1993, ANTISENSE RES APPL, P427; CROOKE ST, 1992, ANNU REV PHARMACOL, V32, P329; CROOKE ST, 1992, BIO-TECHNOL, V10, P882, DOI 10.1038/nbt0892-882; Crooke ST, 2000, ANTISENSE NUCLEIC A, V10, P123, DOI 10.1089/oli.1.2000.10.123; CROOKE ST, 1995, BIOCHEM J, V312, P599, DOI 10.1042/bj3120599; Crooke ST, 1999, BBA-GENE STRUCT EXPR, V1489, P31, DOI 10.1016/S0167-4781(99)00148-7; Crooke ST, 1996, J PHARMACOL EXP THER, V277, P923; CROOKE ST, 1994, CLIN PHARMACOL THER, V56, P641, DOI 10.1038/clpt.1994.189; CROOKE ST, 1998, ANTISENSE RES APPL; Crouch RJ, 1985, NUCLEASES, P211; CRUM C, 1988, NUCLEIC ACIDS RES, V16, P4569, DOI 10.1093/nar/16.10.4569; Cunningham CC, 2000, CLIN CANCER RES, V6, P1626; DEAN NM, 1994, J BIOL CHEM, V269, P16416; DECLERCQ E, 1969, SCIENCE, V165, P1137; DONISKELLER H, 1979, NUCLEIC ACIDS RES, V7, P179, DOI 10.1093/nar/7.1.179; DORR A, 1999, 35 ANN M AM SOC CLIN, V18, P157; DORR A, IN PRESS ANTISENSE D; EDER PS, 1991, J BIOL CHEM, V266, P6472; FRANK P, 1994, NUCLEIC ACIDS RES, V22, P5247, DOI 10.1093/nar/22.24.5247; Frank P, 1998, P NATL ACAD SCI USA, V95, P12872, DOI 10.1073/pnas.95.22.12872; FREIER SM, 1993, ANTISENSE RES APPL, P67; FURDON PJ, 1989, NUCLEIC ACIDS RES, V17, P9193, DOI 10.1093/nar/17.22.9193; GAGNOR C, 1989, NUCLEIC ACIDS RES, V17, P5107, DOI 10.1093/nar/17.13.5107; GEWIRTZ A, IN PRESS ANTISENSE D; GORDON MS, 1999, 35 ANN M AM SOC CLIN, V18, P157; Graham MJ, 1998, J PHARMACOL EXP THER, V286, P447; Hartmann G, 1996, MOL MED, V2, P429, DOI 10.1007/BF03401902; HENRY S, 2000, UNPUB MOL IMMUNOLOGY; Henry SP, 1997, J PHARMACOL EXP THER, V281, P810; Herdewijn P, 1999, BBA-GENE STRUCT EXPR, V1489, P167, DOI 10.1016/S0167-4781(99)00152-9; HIJIYA N, 1994, P NATL ACAD SCI USA, V91, P4499, DOI 10.1073/pnas.91.10.4499; HOLMLUND J, IN PRESS ANTISENSE D; IVERSEN P, 1991, ANTI-CANCER DRUG DES, V6, P531; JOOS RW, 1969, J PHARMACOL EXP THER, V166, P113; KAWASAKI AM, 1993, J MED CHEM, V36, P831, DOI 10.1021/jm00059a007; Larsen HJ, 1999, BBA-GENE STRUCT EXPR, V1489, P159, DOI 10.1016/S0167-4781(99)00145-1; Lebleu B., 1993, ANTISENSE RES APPL; Leeds JM, 1998, HANDB EXP PHARM, V131, P217; Levin AA, 1999, BBA-GENE STRUCT EXPR, V1489, P69, DOI 10.1016/S0167-4781(99)00140-2; Lima WF, 1997, J BIOL CHEM, V272, P18191, DOI 10.1074/jbc.272.29.18191; Lima WF, 1997, BIOCHEMISTRY-US, V36, P390, DOI 10.1021/bi962230p; Lima WF, 1997, J BIOL CHEM, V272, P27513, DOI 10.1074/jbc.272.44.27513; LIMA WF, 1992, BIOCHEMISTRY-US, V31, P12055, DOI 10.1021/bi00163a013; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; Manoharan M, 1999, BBA-GENE STRUCT EXPR, V1489, P117, DOI 10.1016/S0167-4781(99)00138-4; MILLER D, 1989, J LOGIC PROGRAM, V6, P79, DOI 10.1016/0743-1066(89)90031-9; MIRABELLI CK, 1991, ANTI-CANCER DRUG DES, V6, P647; MONIA BP, 1992, J BIOL CHEM, V267, P19954; Monia BP, 1998, HANDB EXP PHARM, V131, P427; MONIA BP, 1993, J BIOL CHEM, V268, P14514; MORVAN F, 1991, ANTI-CANCER DRUG DES, V6, P521; Nemunaitis J, 1999, J CLIN ONCOL, V17, P3586, DOI 10.1200/JCO.1999.17.11.3586; O'Dwyer PJ, 1999, CLIN CANCER RES, V5, P3977; QUARTIN RS, 1989, NUCLEIC ACIDS RES, V17, P7253, DOI 10.1093/nar/17.18.7253; RAPPAPORT J, 1995, KIDNEY INT, V47, P1462, DOI 10.1038/ki.1995.205; Shanahan WR, 1998, HANDB EXP PHARM, V131, P499; SIU LL, 2000, 36 ANN M AM SOC CLIN, V19, pA189; SKORSKI T, 1994, P NATL ACAD SCI USA, V91, P4504, DOI 10.1073/pnas.91.10.4504; SPROAT BS, 1989, NUCLEIC ACIDS RES, V17, P3373, DOI 10.1093/nar/17.9.3373; SRINIVASAN SK, 1995, ANTISENSE RES DEV, V5, P131, DOI 10.1089/ard.1995.5.131; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; Stevenson JP, 1999, J CLIN ONCOL, V17, P2227, DOI 10.1200/JCO.1999.17.7.2227; Summerton J, 1999, BBA-GENE STRUCT EXPR, V1489, P141, DOI 10.1016/S0167-4781(99)00150-5; Takakura Y, 1996, ANTISENSE NUCLEIC A, V6, P177, DOI 10.1089/oli.1.1996.6.177; VICKERS T, 1991, NUCLEIC ACIDS RES, V19, P3359, DOI 10.1093/nar/19.12.3359; Waters JS, 2000, J CLIN ONCOL, V18, P1812, DOI 10.1200/JCO.2000.18.9.1812; Webb A, 1997, LANCET, V349, P1137, DOI 10.1016/S0140-6736(96)11103-X; Wu HJ, 1999, J BIOL CHEM, V274, P28270, DOI 10.1074/jbc.274.40.28270; Wu HJ, 1998, ANTISENSE NUCLEIC A, V8, P53, DOI 10.1089/oli.1.1998.8.53; YUEN A, 1999, AACR NCI EORTC INT C	85	67	79	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 27	2000	19	56					6651	6659		10.1038/sj.onc.1204093	http://dx.doi.org/10.1038/sj.onc.1204093			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415CY	11426651				2022-12-17	WOS:000167704000012
J	Scott, GK; Chang, CH; Erny, KM; Xu, F; Fredericks, WJ; Rauscher, FJ; Thor, AD; Benz, CC				Scott, GK; Chang, CH; Erny, KM; Xu, F; Fredericks, WJ; Rauscher, FJ; Thor, AD; Benz, CC			Ets regulation of the erbB2 promoter	ONCOGENE			English	Article						erbB2(HER2/neu) promoter; Ets binding site; Ets candidates	TRANSCRIPTION FACTOR; HER2/NEU PROMOTER; DOWN-REGULATION; DNA; PROTEIN; C-ERBB-2; EXPRESSION; BINDING; OVEREXPRESSION; INHIBITION	Evaluating the chromatinized erbB2 gene in nuclei from breast cancer cells expressing varying levels of ErbB2 transcripts, we identified a nuclease-sensitive site within a 0.22 kb region of maximum enhancer activity centered over a conserved 28 bp polypurine(GGA)-polypyrimidine(TCC) mirror-repeat and an adjacent essential Ets binding site (EBS), Promoter footprinting with nuclear extracts reveals an intense Ets hypersensitivity site at the EBS whose degree of intensity correlates with the Level of cellular ErbB2 expression. In vitro mapping assays show that the supercoiled erbB2 promoter forms an internal tripler structure (Hr-DNA) at the mirror-repeat element. Mutations preventing Hr-DNA formation can enhance erbB2 promoter activity in human breast cancer cells, a result consistent with previous demonstration that Ets-erbB2 promoter complexes cannot form when the mirror-repeat is engaged in tripler binding, and new results suggesting that Ets binding induces severe promoter bending that may restrict local tripler formation. In addition to previously described erbB2-regulating breast cancer Ets factors (PEA3, ESX/Elf-3), Elf-1 is now shown to be another endogenously expressed Ets candidate capable of binding to and upregulating the erbB2 promoter. Given current strategies to transcriptionally inhibit ErbB2 overexpression, including development of novel erbB2 promoter-targeted therapeutics, an EBS-targeted approach is presented using chimeric Ets proteins that strongly repress erbB2 promoter activity.	Univ Calif San Francisco, Dept Med, Div Hematol Oncol, San Francisco, CA 94143 USA; Wistar Inst Anat & Biol, Mol Genet Program, Philadelphia, PA 19104 USA; Wistar Inst Anat & Biol, Ctr Canc, Philadelphia, PA 19104 USA; Northwestern Univ, Evanston Hosp, Dept Pathol, Evanston, IL 60201 USA	University of California System; University of California San Francisco; The Wistar Institute; The Wistar Institute; NorthShore University Health System; Northwestern University	Benz, CC (corresponding author), Buck Inst Age Res, 8001 Redwood Blvd, Novato, CA 94945 USA.			Erny-Albrecht, Katrina/0000-0003-3538-1475	NCI NIH HHS [P01-CA44768, R01 CA036773, P50 CA058207, P50-CA58207, R01-CA36773] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036773, P50CA058207, P01CA044768] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beerli RR, 1998, P NATL ACAD SCI USA, V95, P14628, DOI 10.1073/pnas.95.25.14628; BENZ C, 2000, J WOMENS CANC, V2, P33; Benz CC, 1998, ENDOCR-RELAT CANCER, V5, P271, DOI 10.1677/erc.0.0050271; Benz CC, 1997, ONCOGENE, V15, P1513, DOI 10.1038/sj.onc.1201331; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Bosher JM, 1996, ONCOGENE, V13, P1701; BredemeierErnst I, 1997, FEBS LETT, V408, P47, DOI 10.1016/S0014-5793(97)00387-6; Chang CH, 1999, ONCOGENE, V18, P3682, DOI 10.1038/sj.onc.1202674; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; Chen H, 1997, ONCOGENE, V14, P1965, DOI 10.1038/sj.onc.1201030; Chen S, 1997, MOL ENDOCRINOL, V11, P3, DOI 10.1210/me.11.1.3; Chen YY, 1997, J BIOL CHEM, V272, P14110, DOI 10.1074/jbc.272.22.14110; Chen YY, 1996, J BIOL CHEM, V271, P5183; CHEN YY, 1994, ONCOGENE, V9, P2269; Chiang SY, 2000, J BIOL CHEM, V275, P24246, DOI 10.1074/jbc.M000820200; COLOMER R, 1994, BRIT J CANCER, V70, P819, DOI 10.1038/bjc.1994.405; Czubayko F, 1997, GENE THER, V4, P943, DOI 10.1038/sj.gt.3300483; EBBINGHAUS SW, 1993, J CLIN INVEST, V92, P2433, DOI 10.1172/JCI116850; EBBINGHAUS SW, 1999, PERSPECT ANTISEN SCI, P117; GROOTECLAES M, 1994, CANCER RES, V54, P4193; GUIEYSSE AL, 1999, PERSPECT ANTISEN SCI, P223; HOLLYWOOD DP, 1993, EMBO J, V12, P2369, DOI 10.1002/j.1460-2075.1993.tb05891.x; HOLLYWOOD DP, 1995, BRIT J CANCER, V71, P753, DOI 10.1038/bjc.1995.146; HORWITZ EM, 1994, J BIOL CHEM, V269, P14130; HTUN H, 1988, SCIENCE, V241, P1791, DOI 10.1126/science.3175620; HTUN H, 1989, SCIENCE, V243, P1571, DOI 10.1126/science.2648571; HUDSON LG, 1990, J BIOL CHEM, V265, P4389; Hung M C, 2000, Breast Dis, V11, P133; ISHII S, 1987, P NATL ACAD SCI USA, V84, P4374, DOI 10.1073/pnas.84.13.4374; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; Krauss W C, 2000, Breast Dis, V11, P113; MARDEN C, 2000, IN PRESS ENCY MOL ME; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; McCormick RJ, 1996, P NATL ACAD SCI USA, V93, P14434, DOI 10.1073/pnas.93.25.14434; MIRKIN SM, 1999, PERSPECT ANTISEN SCI, P193; MIZUGUCHI G, 1994, FEBS LETT, V348, P80, DOI 10.1016/0014-5793(94)00578-8; NOONBERG SB, 1994, GENE, V149, P123, DOI 10.1016/0378-1119(94)90420-0; PANAYOTATOS N, 1981, NATURE, V289, P466, DOI 10.1038/289466a0; Porumb H, 1996, CANCER RES, V56, P515; Raziuddin A, 1997, J BIOL CHEM, V272, P15715, DOI 10.1074/jbc.272.25.15715; Roh H, 2000, CANCER RES, V60, P560; Sacco MG, 1998, GENE THER, V5, P388, DOI 10.1038/sj.gt.3300592; SCOTT GK, 1994, J BIOL CHEM, V269, P19848; SUEN TC, 1990, MOL CELL BIOL, V10, P6306, DOI 10.1128/MCB.10.12.6306; Suzuki T, 2000, GENE THER, V7, P241, DOI 10.1038/sj.gt.3301065; TAL M, 1987, MOL CELL BIOL, V7, P2597, DOI 10.1128/MCB.7.7.2597; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; VAUGHN JP, 1995, P NATL ACAD SCI USA, V92, P8338, DOI 10.1073/pnas.92.18.8338; VERRIJZER CP, 1991, EMBO J, V10, P3007, DOI 10.1002/j.1460-2075.1991.tb07851.x; WECHSLER DS, 1992, P NATL ACAD SCI USA, V89, P7635, DOI 10.1073/pnas.89.16.7635; Werner MH, 1997, J BIOMOL NMR, V10, P317, DOI 10.1023/A:1018399711996; Xing XM, 2000, NAT MED, V6, P189, DOI 10.1038/72294	53	67	68	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	2000	19	55					6490	6502		10.1038/sj.onc.1204041	http://dx.doi.org/10.1038/sj.onc.1204041			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395RL	11175365				2022-12-17	WOS:000166595000011
J	Sheng, ZJ; Sun, WP; Smith, E; Cohen, C; Sheng, Z; Xu, XX				Sheng, ZJ; Sun, WP; Smith, E; Cohen, C; Sheng, Z; Xu, XX			Restoration of positioning control following Disabled-2 expression in ovarian and breast tumor cells	ONCOGENE			English	Article						disabled-2; cell positioning; extracellular matrix; basement membrane; Ras pathway	CYTOPLASMIC DOMAIN; APOPTOSIS; INTEGRIN; RECEPTOR; BRAIN; GENE; ORGANIZATION; SUPPRESSION; DOWNSTREAM; DISRUPTION	The physical interaction of epithelial cells with the basement membrane ensures correct positioning and acts as a survival factor for epithelial cells. Cells that detach from the basement membrane often undergo apoptosis; however, in carcinomas, this positional control is absent, permitting disorganized cell proliferation. In the majority of breast and ovarian carcinomas (85-90%), the expression of a candidate tumor suppressor, Disabled-2 (Dab2), is frequently lost. The Dab2-negative tumor cells are no longer in contact with an intact basement membrane, as indicated by the absence of collagen IV (in about 90% of cases), However, in the subset (10-15%) of ovarian tumors in which Dab2, expression is positive, the presence of a basement membrane-like structure around tumor cells was observed. Recombinant adenovirus-mediated expression of Dab2 was used in Dab2-negative ovarian and breast cancer cells, and re-expression of Dab2 was found to lead to cell death or growth arrest. Dab2 expression suppressed MAPK activation and c-fos expression, Plating the infected cells on a basement membrane matrigel rescued the cells from death and growth arrest. Thus, Dab2 exhibits a negative activity for cell growth and survival, which can be countered by attachment of the cells to basement membrane matrix. We conclude that Dab2 functions in cell positioning control and mediates the exigency for basement membrane attachment of epithelial cells, Loss of Dab2 may contribute to the basement membrane-independent, disorganized proliferation of tumor cells in ovarian and breast carcinomas.	Fox Chase Canc Ctr, Div Med Sci, Ovarian Canc Program, Philadelphia, PA 19111 USA; Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; Amgen Inc, Thousand Oaks, CA 91320 USA	Fox Chase Cancer Center; Emory University; Emory University; Emory University; Amgen	Xu, XX (corresponding author), Fox Chase Canc Ctr, Div Med Sci, Ovarian Canc Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA.		sheng, zejuan/H-3034-2013		NATIONAL CANCER INSTITUTE [R01CA079716, R01CA075389] Funding Source: NIH RePORTER; NCI NIH HHS [CA 79716, CA 75389] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Boudreau N, 1996, P NATL ACAD SCI USA, V93, P3509, DOI 10.1073/pnas.93.8.3509; COUCOUVANIS E, 1995, CELL, V83, P279, DOI 10.1016/0092-8674(95)90169-8; DArcangelo G, 1997, J NEUROSCI, V17, P23, DOI 10.1523/JNEUROSCI.17-01-00023.1997; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; Fazili Z, 1999, ONCOGENE, V18, P3104, DOI 10.1038/sj.onc.1202649; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Goffinet AM, 1997, NATURE, V389, P668, DOI 10.1038/39453; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; Hagios C, 1998, PHILOS T R SOC B, V353, P857, DOI 10.1098/rstb.1998.0250; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Holmstrom TH, 1999, MOL CELL BIOL, V19, P5991; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; Howell BW, 1999, MOL CELL BIOL, V19, P5179; Huang S, 1999, NAT CELL BIOL, V1, pE131, DOI 10.1038/13043; Law DA, 1999, NATURE, V401, P808, DOI 10.1038/44599; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; OTOOLE TE, 1995, J BIOL CHEM, V270, P8553, DOI 10.1074/jbc.270.15.8553; Rice DS, 1998, DEVELOPMENT, V125, P3719; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; STENBACK F, 1985, EUR J OBSTET GYN R B, V20, P357, DOI 10.1016/0028-2243(85)90059-0; STREULI CH, 1991, J CELL BIOL, V115, P1383, DOI 10.1083/jcb.115.5.1383; Tahiliani PD, 1997, J BIOL CHEM, V272, P7892, DOI 10.1074/jbc.272.12.7892; THOMSON M, 1991, CAN J PUBLIC HEALTH, V82, P203; TIMPL R, 1986, INT REV EXP PATHOL, V29, P1; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Vignoud L, 1997, J CELL SCI, V110, P1421; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; WONG KK, 1993, INT J ONCOL, V3, P13; Xu XX, 1998, ONCOGENE, V16, P1561, DOI 10.1038/sj.onc.1201678; XU XX, 1995, J BIOL CHEM, V270, P14181	36	67	67	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 5	2000	19	42					4847	4854		10.1038/sj.onc.1203853	http://dx.doi.org/10.1038/sj.onc.1203853			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	362BB	11039902				2022-12-17	WOS:000089757800007
J	He, YW; Armanious, MK; Thomas, MJ; Cress, WD				He, YW; Armanious, MK; Thomas, MJ; Cress, WD			Identification of E2F-3B, an alternative form of E2F-3 lacking a conserved N-terminal region	ONCOGENE			English	Article						E2F; E2F-3; retinoblastoma; cell cycle	C-MYC PROTEINS; TRANSCRIPTION FACTORS E2F-1; FIBROBLAST GROWTH-FACTOR; DNA-BINDING SITE; S-PHASE ENTRY; CELL-CYCLE; IN-VIVO; NUCLEAR-LOCALIZATION; FAMILY MEMBERS; REGULATING TRANSCRIPTION	We have identified a novel form of the full-length E2F-3 protein that we term E2F-3B, In contrast to full-length E2F-3, which is expressed only at the G1/S boundary, E2F-3B is detected throughout the cell cycle with peak levels in GO where it is associated with Rb, Transfection and in vitro translation experiments demonstrate that a protein identical to E2F-3B in size and iso-electric point is produced from the E2F-3 mRNA via the use of an alternative translational start site, This alternative initiation codon was mapped hy mutagenesis to codon 102, an ACG codon, Mutation of the ACC codon at position 102 abolished E2F-3B expression, whereas the conversion of ACG 102 to a consensus ATG led to the expression of a protein indistinguishable from E2F-3B, Given these results, E2F-3B is missing 101 N-terminal amino acids relative to full-length E2F-3. This region includes a moderately conserved sequence of unknown function that is present only in the growth-promoting E2F family members, including E2F-1, 2 and full-length E2F-3. These observations make E2F-3B the first example of an E2F gene giving rise to two different protein species and also suggest that E2F-3 and E2F-3B may have opposing roles in cell cycle control.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Biochem & Mol Biol,Program Mol Oncol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Med Microbiol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Cress, WD (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Biochem & Mol Biol,Program Mol Oncol, 12902 Magnolia Dr, Tampa, FL 33612 USA.				NCI NIH HHS [CA78214] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA078214] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allen KE, 1997, J CELL SCI, V110, P2819; Arnaud E, 1999, MOL CELL BIOL, V19, P505; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BOYD L, 1993, P NATL ACAD SCI USA, V90, P9164, DOI 10.1073/pnas.90.19.9164; BUCK V, 1995, ONCOGENE, V11, P31; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; COLIGAN J, CURRENT PROTOCOLS PR; COUDERC B, 1991, CELL REGUL, V2, P709, DOI 10.1091/mbc.2.9.709; Cress WD, 1996, MOL CELL BIOL, V16, P2119; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; CRESS WD, 1994, J VIROL, V68, P4212, DOI 10.1128/JVI.68.7.4213-4219.1994; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Dong F, 1998, J BIOL CHEM, V273, P6190, DOI 10.1074/jbc.273.11.6190; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; FALVEY E, 1995, EMBO J, V14, P4307, DOI 10.1002/j.1460-2075.1995.tb00105.x; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Flores AM, 1998, ONCOGENE, V16, P1289, DOI 10.1038/sj.onc.1201633; Gaubatz S, 1998, P NATL ACAD SCI USA, V95, P9190, DOI 10.1073/pnas.95.16.9190; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; HANN SR, 1995, ADV EXP MED BIOL, V375, P107; HANN SR, 1992, GENE DEV, V6, P1229, DOI 10.1101/gad.6.7.1229; HANN SR, 1994, GENE DEV, V8, P2441, DOI 10.1101/gad.8.20.2441; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HANN SR, 1994, BIOCHIMIE, V76, P880, DOI 10.1016/0300-9084(94)90190-2; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1994, J VIROL, V68, P5027, DOI 10.1128/JVI.68.8.5027-5035.1994; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Humbert PO, 2000, GENE DEV, V14, P690; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; Imataka H, 1997, EMBO J, V16, P817, DOI 10.1093/emboj/16.4.817; ITOH A, 1995, CELL MOL BIOL RES, V41, P147; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOHNSON AF, 1993, ECOSYSTEMS WORLD, V2, P365; Johnson BE, 1998, MATH MECH SOLIDS, V3, P447, DOI 10.1177/108128659800300405; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KITAGAWA M, 1995, ONCOGENE, V10, P229; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Lindeman GJ, 1998, GENE DEV, V12, P1092, DOI 10.1101/gad.12.8.1092; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Madigan SJ, 1996, MOL CELL BIOL, V16, P4222; Magae J, 1996, J CELL SCI, V109, P1717; Mann DJ, 1996, CURR BIOL, V6, P474, DOI 10.1016/S0960-9822(02)00515-8; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Morkel M, 1997, NATURE, V390, P567, DOI 10.1038/37507; Muller H, 1997, MOL CELL BIOL, V17, P5508; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; PEABODY DS, 1989, J BIOL CHEM, V264, P5031; Persengiev SP, 1999, MOL CELL BIOL, V19, P6048; Pierce AM, 1998, MOL CARCINOGEN, V22, P190, DOI 10.1002/(SICI)1098-2744(199807)22:3<190::AID-MC7>3.0.CO;2-P; Riechmann JL, 1999, MOL CELL BIOL, V19, P8505; Rogers KT, 1996, P NATL ACAD SCI USA, V93, P7594, DOI 10.1073/pnas.93.15.7594; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; Shin EK, 1996, J BIOL CHEM, V271, P12261, DOI 10.1074/jbc.271.21.12261; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; Tao YX, 1997, MOL CELL BIOL, V17, P6994, DOI 10.1128/MCB.17.12.6994; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; WU CL, 1995, MOL CELL BIOL, V15, P2536; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; ZHANG YH, 1995, ONCOGENE, V10, P2085	79	67	69	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2000	19	30					3422	3433		10.1038/sj.onc.1203682	http://dx.doi.org/10.1038/sj.onc.1203682			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QX	10918599				2022-12-17	WOS:000088198100010
J	Park, US; Park, SK; Lee, YI; Park, JG; Lee, YI				Park, US; Park, SK; Lee, YI; Park, JG; Lee, YI			Hepatitis B virus-X protein upregulates the expression of p21(waf1/cip1) and prolongs G1 -> S transition via a p53-independent pathway in human hepatoma cells	ONCOGENE			English	Article						hepatitis B virus-X; p21(waf1/cip1); cyclin-dependent kinase inhibitor; hepatocellular carcinoma; p53	ETS GENE FAMILY; P53-MEDIATED G(1) ARREST; WILD-TYPE P53; TRANSGENIC MICE; FUNCTIONAL-ANALYSIS; ONCOGENIC ACTIVITY; TRANSACTIVATOR-X; MAMMALIAN-CELLS; WAF1/CIP1 GENE; LEUKEMIC-CELLS	Progression through the cell cycle is controlled by the induction of cyclins and activation of cognate cyclin-dependent kinases, The human hepatitis B virus-X (HBV-X) protein functions in gene expression alterations, in the sensitization of cells to apoptotic killing and deregulates cell growth arrest in certain cancer cell types, We have pursued the mechanism of growth arrest in Hep3B cells, a p53-mutant human hepatocellular carcinoma (HCC) cell line, In stable or transient HBV-X transformed Hep3B cells, HBV-X increased protein and mRNA levels of the cyclin-dependent kinase inhibitor (CDKI) p21(wafl/cipl), increased binding of p21(wafl/cipl) with cyclin-dependent kinase 2 (CDK2), markedly inhibited cyclin E and CDK2 associated phosphorylation of histone HI and induced the activation of a p21 promoter reporter construct, By using p21 promoter deletion constructs, the HBV-X responsive element was mapped to a region between -1185 and -1482, relative to the transcription start site, Promoter mutation analysis indicated that the HBV-X responsive site coincides with the ets factor binding sites. These data indicate that in human hepatocellular carcinoma cells, HBV-X can circumvent the loss of p53 functions and induces critical downstream regulatory events leading to transcriptional activation of p21(wafl/cipl). AS a consequence, there is an increased chance of acquisition of mutations which can enhance the genesis of hepatomas, Our results also emphasize the chemotherapeutic potential of p21(wafl/cipl) inhibitors, particularly in the HBV-X infected hepatoma which lacks functional p53.	Korea Res Inst Biosci & Biotechnol, Biosci Res Div, Liver Cell Signal Transduct Res Unit, Taejon 305600, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Lee, YI (corresponding author), Korea Res Inst Biosci & Biotechnol, Biosci Res Div, Liver Cell Signal Transduct Res Unit, POB 115, Taejon 305600, South Korea.							BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Chisari FV, 1996, CURR TOP MICROBIOL, V206, P149; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; Erhardt JA, 1998, J BIOL CHEM, V273, P23517, DOI 10.1074/jbc.273.36.23517; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Gorospe M, 1996, CANCER RES, V56, P475; Gottlob K, 1998, J BIOL CHEM, V273, P33347, DOI 10.1074/jbc.273.50.33347; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRANA X, 1995, ONCOGENE, V11, P211; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KIM YH, 1993, BIOCHEM BIOPH RES CO, V197, P894, DOI 10.1006/bbrc.1993.2563; KIM YS, 1984, KOREAN BIOCH J, V17, P7076; Ko JH, 1999, J BIOL CHEM, V274, P22941, DOI 10.1074/jbc.274.33.22941; Kobayashi T, 1995, ONCOGENE, V11, P2311; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; Lee Y, 1998, GENE, V207, P111, DOI 10.1016/S0378-1119(97)00603-3; Lee YI, 1998, ONCOGENE, V16, P2367, DOI 10.1038/sj.onc.1201760; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SETH A, 1990, ONCOGENE, V5, P1761; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Slagle BL, 1996, MOL CARCINOGEN, V15, P261, DOI 10.1002/(SICI)1098-2744(199604)15:4<261::AID-MC3>3.0.CO;2-J; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Takada S, 1997, ONCOGENE, V15, P1895, DOI 10.1038/sj.onc.1201369; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; Terradillos O, 1998, ONCOGENE, V17, P2115, DOI 10.1038/sj.onc.1202432; WALDMAN T, 1995, CANCER RES, V55, P5187; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yang BS, 1996, MOL CELL BIOL, V16, P538; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zeng YX, 1996, ONCOGENE, V12, P1557; Zhang W, 1995, CLIN CANCER RES, V1, P1051; ZHANG W, 1995, CANCER RES, V55, P668	52	67	75	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2000	19	30					3384	3394		10.1038/sj.onc.1203674	http://dx.doi.org/10.1038/sj.onc.1203674			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QX	10918595				2022-12-17	WOS:000088198100006
J	Hakak, Y; Hsu, YS; Martin, GS				Hakak, Y; Hsu, YS; Martin, GS			Shp-2 mediates v-Src-induced morphological changes and activation of the anti-apoptotic protein kinase Akt	ONCOGENE			English	Article						shp-2; src; akt; cbl; transformation; apoptosis	TYROSINE-PHOSPHATASE SHP-2; PHOSPHATIDYLINOSITOL 3'-KINASE; PHOSPHOTYROSINE PHOSPHATASE; TRANSFORMED FIBROBLASTS; PROTOONCOGENE PRODUCT; FOCAL ADHESION; P85 SUBUNIT; RAS; 3-KINASE; CELL	The protein-tyrosine phosphatase Shp-2 is a positive modulator of the Ras/mitogen-activated protein kinase pathway and a putative substrate of the transforming non-receptor tyrosine kinase v-Src, To characterize the role of Shp-2 in cellular transformation and signaling by v-Src, we expressed v-Src in normal and Shp-2-deficient mouse embryo fibroblasts. Expression of Shp-2 was found to be necessary for morphological transformation by v-Src: Shp-2+/+ cells became rounded or spindly upon v-Src expression, whereas Shp-2-deficient cells remained relatively hat, v-Src-induced reorganization of the actin cytoskeleton and the formation of podosomes were compromised in Shp-2-deficient cells. Shp-2 deficiency also reduced v-Src-induced activation of the anti-apoptotic protein kinase Akt. The reduced activation of Akt in Shp-2-deficient cells correlated with a reduction in the association of the p85 regulatory subunit of PI3-kinase with the adapter protein Chl. Activation of PI3-kinase by v-Src may be mediated by the association of the adapter protein Cbl with the p85 subunit, Since activation of Akt is dependent on PI3-kinase, this suggests that the effect of Shp-2 on Akt activation may be mediated, at least in part, by its effects on the interaction between Pw-kinase and Chi, The defect in activation of the Akt survival pathway also correlated with enhanced sensitivity of Shp-2-deficient cells to an apoptosis-inducing agent. These results implicate Shp-2 in v-Src-induced cytoskeletal reorganization and activation of the Akt cell survival pathway.	Univ Calif Berkeley, Dept Mol & Cell Biol, Div Cell & Dev Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Martin, GS (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Div Cell & Dev Biol, 401 Barker Hall 3204, Berkeley, CA 94720 USA.				NCI NIH HHS [CA17542] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA017542, R37CA017542] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aftab DT, 1997, P NATL ACAD SCI USA, V94, P3028, DOI 10.1073/pnas.94.7.3028; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BOSCHEK CB, 1981, CELL, V24, P175, DOI 10.1016/0092-8674(81)90513-4; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DombroskyFerlan PM, 1997, ONCOGENE, V14, P2019, DOI 10.1038/sj.onc.1201031; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Fincham VJ, 1999, J CELL SCI, V112, P947; FRAME MC, 1994, MOL BIOL CELL, V5, P1177, DOI 10.1091/mbc.5.11.1177; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; Hakak Y, 1999, MOL CELL BIOL, V19, P6953; HIRAGA A, 1992, EUR J BIOCHEM, V209, P195, DOI 10.1111/j.1432-1033.1992.tb17277.x; Hunter S, 1999, J BIOL CHEM, V274, P2097, DOI 10.1074/jbc.274.4.2097; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; Maegawa H, 1999, J BIOL CHEM, V274, P30236, DOI 10.1074/jbc.274.42.30236; Manes S, 1999, MOL CELL BIOL, V19, P3125; Mayer T, 1999, ONCOGENE, V18, P2117, DOI 10.1038/sj.onc.1202537; Oh ES, 1999, MOL CELL BIOL, V19, P3205; PENG ZY, 1995, ONCOGENE, V11, P1955; Penuel E, 1999, MOL BIOL CELL, V10, P1693, DOI 10.1091/mbc.10.6.1693; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; Saxton TM, 1999, P NATL ACAD SCI USA, V96, P3790, DOI 10.1073/pnas.96.7.3790; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; TARONE G, 1985, EXP CELL RES, V159, P141, DOI 10.1016/S0014-4827(85)80044-6; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Ueno H, 1998, BLOOD, V91, P46, DOI 10.1182/blood.V91.1.46.46_46_53; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	49	67	68	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2000	19	28					3164	3171		10.1038/sj.onc.1203655	http://dx.doi.org/10.1038/sj.onc.1203655			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KX	10918571				2022-12-17	WOS:000088019200005
J	Stepanova, L; Yang, G; DeMayo, F; Wheeler, TM; Finegold, M; Thompson, TC; Harper, JW				Stepanova, L; Yang, G; DeMayo, F; Wheeler, TM; Finegold, M; Thompson, TC; Harper, JW			Induction of human Cdc37 in prostate cancer correlates with the ability of targeted Cdc37 expression to promote prostatic hyperplasia	ONCOGENE			English	Article						Cdc37; cyclin dependent kinase; chaperone; cancer; transgenic mice	ROUS-SARCOMA VIRUS; CELL-CYCLE MACHINERY; RETINOBLASTOMA PROTEIN; KINASE-ACTIVITY; CDK INHIBITORS; TYROSINE KINASE; FREE SYSTEM; HSP90; P27(KIP1); ARREST	The Cdc37 gene encodes a 50 kDa protein which targets intrinsically unstable oncoprotein kinases such as Cdk4, Raf-1, and src to the molecular chaperone Hsp90, This activity is thought to play an important role in the establishment of signaling pathways controlling proliferation. The budding yeast Cdc37 homolog is required for cell division and mammalian Cdc37 is expressed in proliferative zones during embryonic development and in adult tissues, consistent with a positive role in proliferation, Here we report that human prostatic tumors, neoplasias and certain pre-malignant lesions display increased Cdc37 expression, suggesting an important and early role for Cdc37 in prostatic transformation. To test the consequences of increased Cdc37 levels, transgenic mice expressing Cdc37 in the prostate were generated, These mice displayed a wide range of growth-related abnormalities including prostatic epithelial cell hyperplasia and dysplasia. These data suggest that the expression of Cdc37 may promote inappropriate proliferation and may be an important early step in the development of human prostate cancer.	Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Harper, JW (corresponding author), Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, 1 Baylor Plaza, Houston, TX 77030 USA.		DeMayo, Francesco/C-6255-2019	DeMayo, Francesco/0000-0002-9480-7336; Harper, Jeffrey/0000-0002-6944-7236	NIGMS NIH HHS [GM54137] Funding Source: Medline; PHS HHS [P50-58204] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054137] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aaltomaa S, 1999, PROSTATE, V38, P175; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; Bangma CH, 1999, SEMIN ONCOL, V26, P422; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; Bubendorf L, 1999, CANCER RES, V59, P803; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; COFFEY DS, 1992, CAMPBELLS UROLOGY, V1, P221; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; CUTFORTH T, 1994, CELL, V77, P1027, DOI 10.1016/0092-8674(94)90442-1; Dai K, 1996, J BIOL CHEM, V271, P22030, DOI 10.1074/jbc.271.36.22030; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GERBER MR, 1995, P NATL ACAD SCI USA, V92, P4651, DOI 10.1073/pnas.92.10.4651; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Han EKH, 1998, PROSTATE, V35, P95, DOI 10.1002/(SICI)1097-0045(19980501)35:2<95::AID-PROS2>3.0.CO;2-F; HUTCHISON KA, 1992, J BIOL CHEM, V267, P2902; Kallakury BVS, 1997, CANCER-AM CANCER SOC, V80, P753, DOI 10.1002/(SICI)1097-0142(19970815)80:4<753::AID-CNCR15>3.0.CO;2-S; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lamphere L, 1997, ONCOGENE, V14, P1999, DOI 10.1038/sj.onc.1201036; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Munoz MJ, 1999, MOL GEN GENET, V261, P242, DOI 10.1007/s004380050963; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Sharma P, 1999, ONCOGENE, V18, P5349, DOI 10.1038/sj.onc.1203037; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; STEPANOVA L, 2000, IN PRESS MOL CELL BI; Tamboli P, 1998, MODERN PATHOL, V11, P247; THOMPSON T, 1999, COMPREHENSIVE TXB GE; WALSH PC, 1992, CAMPBELLS UROLOGY, V1, P1007; WHITELAW ML, 1991, J BIOL CHEM, V266, P16436; Xu Y, 1999, P NATL ACAD SCI USA, V96, P109, DOI 10.1073/pnas.96.1.109	41	67	76	3	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 27	2000	19	18					2186	2193		10.1038/sj.onc.1203561	http://dx.doi.org/10.1038/sj.onc.1203561			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZP	10822368				2022-12-17	WOS:000086974100003
J	Ishii, N; Tada, M; Hamou, MF; Janzer, RC; Meagher-Villemure, K; Wiestler, OD; de Tribolet, N; Van Meir, EG				Ishii, N; Tada, M; Hamou, MF; Janzer, RC; Meagher-Villemure, K; Wiestler, OD; de Tribolet, N; Van Meir, EG			Cells with TP53 mutations in low grade astrocytic tumors evolve clonally to malignancy and are an unfavorable prognostic factor	ONCOGENE			English	Article						TP53; prognosis; glioma; tumor recurrence; clonal evolution; irradiation	P53 FUNCTIONAL ASSAY; GENE-MUTATIONS; PROGRESSION; GLIOMA; IMMUNOREACTIVITY	It is important to understand how lon grade tumors recur and progress to malignant lesions since this dramatically shortens patient survival. Here, we evaluated the concept that malignant progression and poor prognosis of low grade astrocytic tumors are TP53 dependent through clonal expansion of mutated cells. TP53 status was established in primary and recurrent tumors from 36 patients with WHO grade II astrocytic tumors and two tumor types were found. Tumors from 14 patients (39%; type 1) had TP53 mutated cells, and 92% of these recurred with 57% progressing to malignancy. The evolution of TP53 mutated cells before and after progression was examined using a clonal analysis procedure in yeast. Malignant progression was accompanied by an increased percentage of mutant TP53 (red) yeast colonies resulting from monoclonal expansion of cells with mutated TP53. The presence of TP53 mutations in WHO grade II astrocytic tumors was associated with malignant progression (P = 0.034, chi(2) test) and shorter progression-free survival (PFS; 47.6+/-9.6 months for TP53-mutated tumors vs 67.8+/-8.2 months for TP53-wild type tumors, P<0.05, log-rank test). Tumors from 22 patients (61%; type 2) were without TP53 mutations, and 64% of these recurred without a change in TP53 status, although 41% progressed to malignancy. This suggests that TP53 mutation is not an initiating or progression event in the majority of low grade astrocytic tamers. Our study also indicates that irradiation for WHO grade II astrocytic tumors might be associated with Door outcome (P<0.0001) and this was independent of TP53 status. These findings have important implications in the clinical management of patients with low grade astocytoma and provide new support to the clonal evolution model for tumor progression.	Emory Univ, Winship Canc Ctr, Mol Neurooncol Lab, Atlanta, GA 30322 USA; CHU Vaudois, Dept Neurosurg, Lab Tumor Biol & Genet, CH-1011 Lausanne, Switzerland; Hokkaido Univ, Sch Med, Dept Neurosurg, Sapporo, Hokkaido 060, Japan; CHU Vaudois, Div Neuropathol, CH-1011 Lausanne, Switzerland; Univ Bonn, Med Ctr, Dept Neuropathol, D-53105 Bonn, Germany; Emory Univ, Dept Neurol Surg, Mol Neurooncol Lab, Atlanta, GA 30322 USA	Emory University; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Hokkaido University; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Bonn; Emory University	Van Meir, EG (corresponding author), Emory Univ, Winship Canc Ctr, Mol Neurooncol Lab, 1365-B Clifton Rd NE,Room B5103, Atlanta, GA 30322 USA.			Van Meir, Erwin G./0000-0003-2444-7707				ALSARRAJ S, 1995, BRIT J NEUROSURG, V9, P143, DOI 10.1080/02688699550041476; *CBTRUS, 1997, ANN REP, P20; CHEN TC, 1995, BENIGN CEREBRAL GLIO, V2, P118; CHOZICK BS, 1994, NEUROSURGERY, V35, P831, DOI 10.1227/00006123-199411000-00005; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Fulci G, 1998, BRAIN PATHOL, V8, P599, DOI 10.1111/j.1750-3639.1998.tb00187.x; HALL PA, 1994, J PATHOL, V172, P1, DOI 10.1002/path.1711720103; HAYASHI Y, 1991, BIOCHEM BIOPH RES CO, V180, P1145, DOI 10.1016/S0006-291X(05)81186-6; Ishii N, 1998, INT J CANCER, V76, P797, DOI 10.1002/(SICI)1097-0215(19980610)76:6<797::AID-IJC5>3.3.CO;2-1; IUZZOLINO P, 1994, BRIT J CANCER, V69, P586, DOI 10.1038/bjc.1994.107; Kleihues P, 1993, HISTOLOGICAL TYPING; KRAUS JA, 1994, GENE CHROMOSOME CANC, V10, P143, DOI 10.1002/gcc.2870100211; Kyritsis AP, 1995, CLIN CANCER RES, V1, P1617; Maintz D, 1997, J NEUROPATH EXP NEUR, V56, P1098, DOI 10.1097/00005072-199710000-00003; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; REIFENBERGER G, 1997, PATHOLOGY GENETICS T, P45; REIFENBERGER J, 1994, AM J PATHOL, V145, P1175; SALCMAN M, 1995, BENIGN CEREBRAL GLIO, V2, P213; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; VANMEYEL DJ, 1994, JNCI-J NATL CANCER I, V86, P1011, DOI 10.1093/jnci/86.13.1011; VECHT CJ, 1993, J NEUROL NEUROSUR PS, V56, P1259, DOI 10.1136/jnnp.56.12.1259; Waridel F, 1997, ONCOGENE, V14, P163, DOI 10.1038/sj.onc.1200812; Watanabe K, 1997, CLIN CANCER RES, V3, P523	23	67	69	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 21	1999	18	43					5870	5878		10.1038/sj.onc.1203241	http://dx.doi.org/10.1038/sj.onc.1203241			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248JE	10557074				2022-12-17	WOS:000083270700004
J	Shinoura, N; Yoshida, Y; Asai, A; Kirino, T; Hamada, H				Shinoura, N; Yoshida, Y; Asai, A; Kirino, T; Hamada, H			Relative level of expression of Bax and Bcl-X-L determines the cellular fate of apoptosis/necrosis induced by the overexpression of Bax	ONCOGENE			English	Article						apoptosis; necrosis; Bax; Bcl-X-L; adenoviral vector	MITOCHONDRIAL PERMEABILITY TRANSITION; CISPLATIN-INDUCED APOPTOSIS; DRUG-INDUCED APOPTOSIS; C-ELEGANS CED-4; CYTOCHROME-C; GENE-THERAPY; RECOMBINANT ADENOVIRUSES; GLIOBLASTOMA-MULTIFORME; MAMMALIAN-CELLS; FLOW-CYTOMETRY	The Bax protein plays a critical role in the apoptosis of cancers induced by radiotherapy or chemotherapy, which induce both apoptosis and necrosis. We transduced various glioblastoma cells with the Bax gene via an adenoviral vector and found that A-172 cells led to necrotic cell death, while U251 cells apoptotic cell death, even though a similar level of Bax protein was introduced. A-172 cells displayed a much higher constitutive expression of the Bcl-X-L protein compared with that of U251 cells. Upon simultaneous overexpression of the Bcl-X-L and Bax proteins in the U251 cells, Bax-induced apoptosis of U251 cells was suppressed and an increase in the number of necrotic cells was seen. Moreover, induction of a higher amount of Bax protein in A-172 cells increased the percentage of apoptotic cells. In conclusion, if a cancerous cell expresses a high enough amount of Bax to undergo death, apoptosis will be induced. If a cancerous cell expresses a level of Bcl-X-L which prevents Bax-induced apoptosis, the overexpression of Bax leads to necrotic cell death.	Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Dept Mol Biotherapy Res, Tokyo 1708455, Japan; Univ Tokyo, Dept Neurosurg, Bunkyo Ku, Tokyo 113, Japan; CREST, Core Res Evolut Sci & Technol, Suita, Osaka, Japan	Japanese Foundation for Cancer Research; University of Tokyo; Japan Science & Technology Agency (JST)	Hamada, H (corresponding author), Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Dept Mol Biotherapy Res, 1-37-1 Kami Ikebukuro, Tokyo 1708455, Japan.							ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; ANTONAKOPOULOS GN, 1994, HISTOPATHOLOGY, V25, P447, DOI 10.1111/j.1365-2559.1994.tb00006.x; Black P, 1998, J NEURO-ONCOL, V36, P7, DOI 10.1023/A:1005866207158; Boersma AWM, 1997, CYTOMETRY, V27, P275, DOI 10.1002/(SICI)1097-0320(19970301)27:3<275::AID-CYTO10>3.0.CO;2-Q; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Brandes AA, 1998, CANCER, V82, P355, DOI 10.1002/(SICI)1097-0142(19980115)82:2<362::AID-CNCR17>3.0.CO;2-X; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Chresta CM, 1996, CANCER RES, V56, P1834; Decaudin D, 1997, CANCER RES, V57, P62; DIPIETRO R, 1994, SCANNING MICROSCOPY, V8, P667; FALKVOLL KH, 1991, INT J RADIAT ONCOL, V21, P989, DOI 10.1016/0360-3016(91)90740-U; Guchelaar HJ, 1998, CANCER CHEMOTH PHARM, V42, P77, DOI 10.1007/s002800050788; Han ZY, 1997, J BIOL CHEM, V272, P13432, DOI 10.1074/jbc.272.20.13432; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; HRUBAN RH, 1950, CANCER, V63, P1944; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Kitada S, 1996, ONCOGENE, V12, P187; Kondo Y, 1998, ONCOGENE, V16, P2243, DOI 10.1038/sj.onc.1201754; Krajewski S, 1997, AM J PATHOL, V150, P805; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; KROEMER G, 1995, ADV IMMUNOL, V58, P211, DOI 10.1016/S0065-2776(08)60621-5; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; MINCHIN RF, 1988, CANCER, V61, P1320, DOI 10.1002/1097-0142(19880401)61:7<1320::AID-CNCR2820610708>3.0.CO;2-J; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; PACKER RJ, 1994, CANCER-AM CANCER SOC, V74, P1827, DOI 10.1002/1097-0142(19940915)74:6<1827::AID-CNCR2820740628>3.0.CO;2-Q; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; POWERS BE, 1991, CANCER, V67, P126, DOI 10.1002/1097-0142(19910101)67:1<126::AID-CNCR2820670123>3.0.CO;2-7; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scarlett JL, 1997, FEBS LETT, V418, P282, DOI 10.1016/S0014-5793(97)01391-4; SCHIFFER D, 1982, ACTA NEUROPATHOL, V58, P291, DOI 10.1007/BF00688612; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Shaham S, 1996, CELL, V86, P201, DOI 10.1016/S0092-8674(00)80092-6; SHAW CM, 1978, J NEUROSURG, V49, P1, DOI 10.3171/jns.1978.49.1.0001; Shimizu S, 1996, CANCER RES, V56, P2161; Shinoura N, 1996, J NEUROSURG, V84, P839, DOI 10.3171/jns.1996.84.5.0839; Shinoura N, 1998, HUM GENE THER, V9, P1983, DOI 10.1089/hum.1998.9.14-1983; Shinoura N, 1998, HUM GENE THER, V9, P2683, DOI 10.1089/hum.1998.9.18-2683; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; Strobel T, 1996, P NATL ACAD SCI USA, V93, P14094, DOI 10.1073/pnas.93.24.14094; Takahashi T, 1998, ANTICANCER RES, V18, P253; TELFORD WG, 1991, CELL PROLIFERAT, V24, P447, DOI 10.1111/j.1365-2184.1991.tb01173.x; Thomas A, 1996, ONCOGENE, V12, P1055; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Tsurusawa M, 1997, INT J HEMATOL, V66, P79; Wagener C, 1996, INT J CANCER, V67, P138, DOI 10.1002/(SICI)1097-0215(19960703)67:1<138::AID-IJC22>3.0.CO;2-9; WATTERSON J, 1993, CANCER-AM CANCER SOC, V71, P4111, DOI 10.1002/1097-0142(19930615)71:12<4111::AID-CNCR2820711250>3.0.CO;2-4; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yanase N, 1998, J INTERF CYTOK RES, V18, P855, DOI 10.1089/jir.1998.18.855; Yoshida Y, 1998, HUM GENE THER, V9, P2503, DOI 10.1089/hum.1998.9.17-2503; Yoshida Y, 1997, BIOCHEM BIOPH RES CO, V230, P426, DOI 10.1006/bbrc.1996.5975; YUAN JY, 1992, DEVELOPMENT, V116, P309; Zamzami N, 1997, J BIOENERG BIOMEMBR, V29, P185, DOI 10.1023/A:1022694131572; Zha HB, 1996, MOL CELL BIOL, V16, P6494; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	60	67	69	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	1999	18	41					5703	5713		10.1038/sj.onc.1202966	http://dx.doi.org/10.1038/sj.onc.1202966			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	243UW	10523849				2022-12-17	WOS:000083016500011
J	Lukas, J; Sorensen, CS; Lukas, C; Santoni-Rugiu, E; Bartek, J				Lukas, J; Sorensen, CS; Lukas, C; Santoni-Rugiu, E; Bartek, J			p16(INK4a), but not constitutively active pRb, can impose a sustained G1 arrest: molecular mechanisms and implications for oncogenesis	ONCOGENE			English	Article						p16 CDK inhibitor; retinoblastoma protein; G1 phase arrest; cyclin E/CDK2; cyclin D/CDK4(6); oncogenesis	CELL-CYCLE INHIBITION; RETINOBLASTOMA-PROTEIN; RESTRICTION POINT; S-PHASE; GENE; G(1); EXPRESSION; ACTIVATION; COOPERATE; PATHWAY	p16(ink4a) and pRb, two components of a key G1/S regulatory pathway, and tumor suppressors commonly targeted in oncogenesis, are among the candidates for gene therapy of cancer. Wild-type p16 and a constitutively active pRb(Delta cdk) mutant both blocked G1 in shortterm experiments, but only p16 imposed a sustained G1 arrest. Unexpectedly, cells conditionally exposed to pRb(Delta cdk) entered S phase after 2 days, followed by endoreduplication between days 4-6. The distinct phenotypes evoked by p16 vs pRb(Delta cdk) appear mediated by cyclin E/CDK2 which, while active in the pRb(Delta cdk)-expressing cells, became rapidly inhibited through restructuring diverse cyclin/CDK/p21 complexes by p16, These results provide novel insights into the roles of p16, pRb and cyclin E in G1/S control and multistep oncogenesis, with implications for gene therapy strategies.	Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen, Denmark	Danish Cancer Society	Bartek, J (corresponding author), Danish Canc Soc, Inst Canc Biol, Strandblvd 49, DK-2100 Copenhagen, Denmark.		Santoni-Rugiu, Eric/H-4913-2019; Bartek, Jiri/G-5870-2014; Santoni-Rugiu, Eric/AAH-3368-2020	Santoni-Rugiu, Eric/0000-0002-2283-3535; Sorensen, Claus/0000-0001-6022-9710; Lukas, Jiri/0000-0001-9087-506X; Lukas, Claudia/0000-0001-7169-6883				Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Jiang H, 1998, MOL CELL BIOL, V18, P5284, DOI 10.1128/MCB.18.9.5284; Kamb A, 1998, CURR TOP MICROBIOL, V227, P139; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; Lukas J, 1996, MOL CELL BIOL, V16, P1047; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2	20	67	68	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	1999	18	27					3930	3935		10.1038/sj.onc.1202777	http://dx.doi.org/10.1038/sj.onc.1202777			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435615				2022-12-17	WOS:000081327800002
J	Yamamoto, H; Soh, JW; Shirin, H; Xing, WQ; Lim, JT; Yao, Y; Slosberg, E; Tomita, N; Schieren, I; Weinstein, IB				Yamamoto, H; Soh, JW; Shirin, H; Xing, WQ; Lim, JT; Yao, Y; Slosberg, E; Tomita, N; Schieren, I; Weinstein, IB			Comparative effects of overexpression of p21(CKip1) and p21(Cip1/Waf1) growth and differentiation in human colon carcinoma cells	ONCOGENE			English	Article						p27(Kip1); p21(Cip1/Waf1); colon cancer; differentiation; cyclin D1	DEPENDENT KINASE INHIBITOR; BREAST-CANCER CELLS; CHAIN FATTY-ACIDS; CYCLIN D1; INCREASED EXPRESSION; SODIUM-BUTYRATE; COLORECTAL CARCINOMAS; TUMOR SUPPRESSION; ESOPHAGEAL CANCER; P53-INDEPENDENT INDUCTION	Recent studies have shown that decreased expression of p27(Kip1) is associated with high grade tumors and am unfavorable prognosis in several types of human cancer. To clarify the role of p27(Kip1) in colon cancer, we have overexpressed this protein in the HT29 colon cancer cell line. The derivatives displayed an increase in the p27(Kip1) protein in cyclin E/CDK2 immunoprecipitates and :a decrease in cyclin E-associated kinase activity when compared to vector control clones, providing evidence that the overexpressed protein was functional. Clones with a high level of p27(Kip1) displayed partial growth inhibition in monolayer culture and a decrease in plating efficiency, even though they expressed increased levels of the cyclin D1 protein. Using alkaline phosphatase expression as a marker, we found that the p27(Kip1) overexpressor clones displayed a 2-3-fold increase in sensitivity to induction of differentiation by 2 mM sodium butyrate, In contrast to these results, derivatives of HT29 cells that stably overexpressed p21(Cip1/Waf1) displayed decreased sensitivity to the induction of differentiation. These findings may explain why decreased levels of p27(Kip1) in certain human cancers is associated with high grade (poorly differentiated) tumors, and suggest that strategies that increase the level of p27(Kip1) may be useful in cancer therapy.	Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Ctr Neurobiol & Behav, New York, NY 10032 USA; Osaka Univ, Sch Med, Dept Surg 2, Suita, Osaka 565, Japan	Columbia University; Columbia University; Osaka University	Weinstein, IB (corresponding author), Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, 701 W 168th St, New York, NY 10032 USA.				NATIONAL CANCER INSTITUTE [R01CA063467] Funding Source: NIH RePORTER; NCI NIH HHS [CA63467] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arber N, 1997, CANCER RES, V57, P1569; Arber N, 1996, GASTROENTEROLOGY, V110, P669, DOI 10.1053/gast.1996.v110.pm8608874; BARTKOVA J, 1994, INT J CANCER, V58, P568, DOI 10.1002/ijc.2910580420; BASSON MD, 1996, DIGEST DIS SCI, V41, P1989; BOFFA LC, 1992, CANCER RES, V52, P5906; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Chen J, 1996, J CLIN INVEST, V97, P1983, DOI 10.1172/JCI118631; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; Ciaparrone M, 1998, CANCER RES, V58, P114; CONWAY RM, 1995, ONCOL RES, V7, P289; Craig C, 1997, ONCOGENE, V14, P2283, DOI 10.1038/sj.onc.1201064; CUMMINGS JH, 1981, GUT, V22, P763, DOI 10.1136/gut.22.9.763; CUNTO FD, 1998, SCIENCE, V280, P1069; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Doglioni C, 1996, J PATHOL, V179, P248, DOI 10.1002/(SICI)1096-9896(199607)179:3<248::AID-PATH571>3.0.CO;2-6; Doki Y, 1997, CARCINOGENESIS, V18, P1139, DOI 10.1093/carcin/18.6.1139; Esposito V, 1997, CANCER RES, V57, P3381; EVERS BM, 1996, AM J PHYSIOL, V271, P722; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; Freemerman AJ, 1997, LEUKEMIA, V11, P504, DOI 10.1038/sj.leu.2400625; Gartel AL, 1996, EXP CELL RES, V227, P171, DOI 10.1006/excr.1996.0264; Goldberg Y, 1996, ONCOGENE, V12, P893; GORDON JI, 1989, J CELL BIOL, V108, P1187, DOI 10.1083/jcb.108.4.1187; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; GUO K, 1995, MOL CELL BIOL, V15, P3823; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; Han EKH, 1996, CELL GROWTH DIFFER, V7, P699; Harvat BL, 1997, ONCOGENE, V14, P2111, DOI 10.1038/sj.onc.1201055; Hauser PJ, 1997, CELL GROWTH DIFFER, V8, P203; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HERMAN JG, 1995, CANCER RES, V55, P4523; Hodin RA, 1996, CELL GROWTH DIFFER, V7, P647; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG HP, 1994, ONCOGENE, V9, P3397; JIANG W, 1992, CANCER RES, V52, P2980; Kano A, 1997, J BIOCHEM-TOKYO, V121, P677; Katayose Y, 1997, CANCER RES, V57, P5441; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KAWAMATA N, 1995, CANCER RES, V55, P2266; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; Kuniyasu H, 1997, CELL GROWTH DIFFER, V8, P47; LEACH FS, 1993, CANCER RES, V53, P1986; LEBLOND CP, 1948, ANAT REC, V100, P357, DOI 10.1002/ar.1091000306; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Matsushita K, 1996, INT J CANCER, V69, P259, DOI 10.1002/(SICI)1097-0215(19960822)69:4<259::AID-IJC3>3.3.CO;2-D; McDonald E, 1996, CANCER RES, V56, P2250; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Mori M, 1997, NAT MED, V3, P593, DOI 10.1038/nm0697-593; Navarro JM, 1997, EUR J CLIN INVEST, V27, P620, DOI 10.1046/j.1365-2362.1997.1510698.x; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Poluha W, 1996, MOL CELL BIOL, V16, P1335; Polyak K, 1996, AM J PATHOL, V149, P381; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; SCHROY PC, 1994, J CELL PHYSIOL, V161, P111, DOI 10.1002/jcp.1041610114; SCHWALLER J, 1995, J CLIN INVEST, V95, P973, DOI 10.1172/JCI117806; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sgambato A, 1996, CANCER RES, V56, P1389; Sgambato A, 1997, CLIN CANCER RES, V3, P1879; Sheikh MS, 1997, ONCOGENE, V14, P1875, DOI 10.1038/sj.onc.1201004; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Siavoshian S, 1997, BIOCHEM BIOPH RES CO, V232, P169, DOI 10.1006/bbrc.1997.6255; Singh SP, 1998, CANCER RES, V58, P1730; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; Spillare EA, 1996, MOL CARCINOGEN, V16, P53, DOI 10.1002/(SICI)1098-2744(199605)16:1<53::AID-MC7>3.0.CO;2-P; STEINMAN RA, 1994, ONCOGENE, V9, P3389; SWAROVSKY B, 1994, PANCREAS, V9, P460, DOI 10.1097/00006676-199407000-00008; Tominaga O, 1997, JPN J CANCER RES, V88, P855, DOI 10.1111/j.1349-7006.1997.tb00461.x; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450; Winston J, 1996, J BIOL CHEM, V271, P11253, DOI 10.1074/jbc.271.19.11253; YAMAMOTO H, 1995, BRIT J CANCER, V71, P1231, DOI 10.1038/bjc.1995.238; Yang RM, 1998, J UROLOGY, V159, P941, DOI 10.1016/S0022-5347(01)63776-5; Yasui W, 1997, PATHOL INT, V47, P470; Yoshida K, 1996, INT J HEMATOL, V65, P41; Zhang T, 1997, CANCER RES, V57, P169; ZHAR JH, 1974, BIOSTATISTICAL ANAL; ZHOU P, 1995, ONCOGENE, V11, P571	88	67	69	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					103	115		10.1038/sj.onc.1202269	http://dx.doi.org/10.1038/sj.onc.1202269			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926925				2022-12-17	WOS:000078166000012
J	Tsatsanis, C; Patriotis, C; Tsichlis, PN				Tsatsanis, C; Patriotis, C; Tsichlis, PN			Tpl-2 induces IL-2 expression in T-cell lines by triggering multiple signaling pathways that activate NFAT and NF-kappa B	ONCOGENE			English	Article						Tpl-2; NF kappa B; nuclear factor of activated T cells; interleukin 2	PROTEIN-KINASE; TRANSCRIPTION FACTORS; NUCLEAR FACTOR; INTERLEUKIN-2 ENHANCER; CYCLOSPORINE-A; CALCINEURIN; PHOSPHORYLATION; FAMILY; ALPHA; RECEPTOR	The Tpl-2 kinase activates the nuclear factor of activated T cells (NFAT) and induces IL-2 expression in T-cell lines. Here we show that the activation of the IL-2 promoter by Tpl-2 is inhibited by mutant signaling molecules that inhibit the mitogen-activated protein kinase (MAPK) or the calcineurin/NFAT pathways and is promoted by combinations of signaling molecules that activate these pathways, We, therefore, conclude that signals generated by the convergence of the MAPK and the calcineurin/NFAT pathway are necessary and sufficient for the activation of the IL-2 promoter by Tpl-2. The activation of both the IL-2 promoter and an NEAT-driven minimal promoter were shown to depend on signals transduced by Raf1. However, it was only the IL-2 promoter whose activation by Tpl-2 was fully blocked by the dominant negative mutant MEK1S218/222A and the MEK1/MEK2 inhibitor PD098059, Since the activation of NEAT is MAPK-dependent these findings suggested that the activation of MAPK by Tpl-2 is either independent or only partially dependent on MEK1 and MEK2, In addition, they suggested that the activation of the IL-2 promoter is under the control of not only NFAT but also a second factor whose activation is MEK-dependent. Experiments in COS-1 and EL-4 cells confirmed both hypotheses and revealed that the second factor activated by Tpl-2 is NF-kappa B, While the activation of the IL-2 promoter and an NEAT-driven minimal promoter by Tpl-2 was fully blocked by the dominant negative mutant NFAT Delta 418, it was only partially blocked by the calcineurin inhibitor cyclosporin A suggesting that the Tpl-2-mediated NFAT activation is under the control of a combination of calcineurin-dependent and independent pathways. Both pathways were fully blocked by Bcl-2 or Bcl-X-L.	Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University	Tsichlis, PN (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA.		Tsatsanis, Christos/AAM-9362-2020	Tsatsanis, Christos/0000-0003-1214-4151	NCI NIH HHS [CA38047, CA06927] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038047, P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Ballester A, 1997, J IMMUNOL, V159, P1613; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BIGNON C, 1993, BIOTECHNIQUES, V15, P243; BRAM RJ, 1994, NATURE, V371, P355, DOI 10.1038/371355a0; Ceci JD, 1997, GENE DEV, V11, P688, DOI 10.1101/gad.11.6.688; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CLIPSTONE NA, 1994, J BIOL CHEM, V269, P26431; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; Erny KM, 1996, ONCOGENE, V13, P2015; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; FRUMAN DA, 1995, MOL CELL BIOL, V15, P3857; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GARRITY PA, 1994, MOL CELL BIOL, V14, P2159, DOI 10.1128/MCB.14.3.2159; Ghosh P, 1996, J BIOL CHEM, V271, P7700, DOI 10.1074/jbc.271.13.7700; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; Luo C, 1996, MOL CELL BIOL, V16, P3955; MAKRIS A, 1993, J VIROL, V67, P4283, DOI 10.1128/JVI.67.7.4283-4289.1993; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; PANG L, 1995, BIOCHEM J, V307, P513, DOI 10.1042/bj3070513; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; ROONEY JW, 1995, MOL CELL BIOL, V15, P6299; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Simeonidis S, 1997, P NATL ACAD SCI USA, V94, P14372, DOI 10.1073/pnas.94.26.14372; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; Tsatsanis C, 1998, P NATL ACAD SCI USA, V95, P3827, DOI 10.1073/pnas.95.7.3827; YAN MH, 1994, NATURE, V372, P798; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; ZweidlerMcKay PA, 1996, MOL CELL BIOL, V16, P4024	52	67	71	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 19	1998	17	20					2609	2618		10.1038/sj.onc.1202460	http://dx.doi.org/10.1038/sj.onc.1202460			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139YN	9840924				2022-12-17	WOS:000077058900008
J	Posern, G; Zheng, J; Knudsen, BS; Kardinal, C; Muller, KB; Voss, J; Shishido, T; Cowburn, D; Cheng, GH; Wang, BL; Kruh, GD; Burrell, SK; Jacobson, CA; Lenz, DM; Zamborelli, TJ; Adermann, K; Hanafusa, H; Feller, SM				Posern, G; Zheng, J; Knudsen, BS; Kardinal, C; Muller, KB; Voss, J; Shishido, T; Cowburn, D; Cheng, GH; Wang, BL; Kruh, GD; Burrell, SK; Jacobson, CA; Lenz, DM; Zamborelli, TJ; Adermann, K; Hanafusa, H; Feller, SM			Development of highly selective SH3 binding peptides for Crk and CRKL which disrupt Crk-complexes with DOCK180, SoS and C3G	ONCOGENE			English	Article						adapters; Crk; CRKL; SH3; peptide	PROTEIN-TYROSINE KINASE; PROLINE-RICH SEQUENCES; SRC HOMOLOGY-3 DOMAINS; C-CRK; ADAPTER PROTEINS; ABL; SPECIFICITY; RECEPTOR; IDENTIFICATION; PRODUCT	Many Src Homology 3 (SH3) domains function as molecular adhesives in intracellular signal transduction, Based on previous ultrastructural studies, short motifs which bind to the first SH3 domains of the adapters Crk and CRKL were selectively mutagenised to generate Crk/ CRKL SH3-binding peptides of very high affinity and selectivity, Affinities were increased up to 20-fold compared to the best wildtype sequences, while the selectivity against a similar SH3 domain [Grb2SH3(N)] was not only retained, but sometimes increased. Blot techniques with CST-fusion peptides and in solution precipitation assays with biotinylated high affinity Crk binding peptides (HACBPs) were subsequently used to analyse the binding of these sequences to a large panel of SH3 domain-containing fusion proteins. Only those proteins which contained the CrkSH3(1) or CRKLSH3(1) domains bound efficiently to the HACBPs. A GST-HACBP fusion protein precipitated Crk and CRKL proteins out of S-35-labelled and unlabelled cell lysates, Very little binding of other cellular proteins to HACBP was detectable, indicative of a great preference for Crk and CRKL when compared to the wide variety of other endogenous cellular proteins. Moreover, HACBP disrupted in vitro preexisting Crk-complexes with DOCK180 and the exchange factors SoS and C3G, which are known targets of Crk adapters, in a concentration dependent manner. HACBP-based molecules should therefore be useful as highly selective inhibitors of intracellular signalling processes involving Crk and CRKL.	Bavarian Julius Maximilians Univ, Inst Med Radiat & Cell Res MSZ, Mol Oncol Lab, D-97078 Wurzburg, Germany; Rockefeller Univ, Mol Oncol Lab, New York, NY 10021 USA; Rockefeller Univ, Phys Biochem Lab, New York, NY 10021 USA; MIT, Cambridge, MA 02139 USA; Univ Penn, Dept Biol, Philadelphia, PA 19104 USA; Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA; AMGEN Boulder Inc, Peptide Technol Grp, Boulder, CO 80301 USA; Lower Saxony Inst Peptide Res IPF, D-30625 Hannover, Germany	University of Wurzburg; Rockefeller University; Rockefeller University; Massachusetts Institute of Technology (MIT); University of Pennsylvania; Fox Chase Cancer Center	Feller, SM (corresponding author), Bavarian Julius Maximilians Univ, Inst Med Radiat & Cell Res MSZ, Mol Oncol Lab, Tusert Versbacher Str 5, D-97078 Wurzburg, Germany.		Cowburn, David/A-8448-2008	Zheng, Jie/0000-0001-6524-6800; Cowburn, David/0000-0001-6770-7172	NATIONAL CANCER INSTITUTE [R35CA044356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047021] Funding Source: NIH RePORTER; NCI NIH HHS [CA-44356] Funding Source: Medline; NIGMS NIH HHS [GM-47021] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; CHENG GH, 1994, P NATL ACAD SCI USA, V91, P8152, DOI 10.1073/pnas.91.17.8152; COWBURN D, 1995, J BIOL CHEM, V270, P26738, DOI 10.1074/jbc.270.45.26738; deJong R, 1997, ONCOGENE, V14, P507, DOI 10.1038/sj.onc.1200885; Evans EK, 1997, EMBO J, V16, P230, DOI 10.1093/emboj/16.2.230; FELLER SM, 1995, METHOD ENZYMOL, V255, P369; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FELLER SM, 1995, ONCOGENE, V10, P1465; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; GREEN SA, 1985, J BIOL CHEM, V260, P9867; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; Ingham RJ, 1996, J BIOL CHEM, V271, P32306, DOI 10.1074/jbc.271.50.32306; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Maru Y, 1996, J BIOL CHEM, V271, P15353, DOI 10.1074/jbc.271.26.15353; Matsuda M, 1996, J BIOL CHEM, V271, P14468, DOI 10.1074/jbc.271.24.14468; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; Sattler M, 1996, ONCOGENE, V12, P839; SCHUMACHER C, 1995, J BIOL CHEM, V270, P15341, DOI 10.1074/jbc.270.25.15341; Schumacher TNM, 1996, SCIENCE, V271, P1854, DOI 10.1126/science.271.5257.1854; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tari AM, 1997, BIOCHEM BIOPH RES CO, V235, P383, DOI 10.1006/bbrc.1997.6791; TENG KK, 1995, J BIOL CHEM, V270, P20677, DOI 10.1074/jbc.270.35.20677; TENHOEVE J, 1994, CANCER RES, V54, P2563; Torres M, 1996, ONCOGENE, V12, P77; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wang BL, 1996, ONCOGENE, V12, P1921; Wang BL, 1996, ONCOGENE, V13, P1379; WENG ZG, 1995, MOL CELL BIOL, V15, P5627; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; WU XD, 1995, STRUCTURE, V3, P215, DOI 10.1016/S0969-2126(01)00151-4	43	67	68	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	1998	16	15					1903	1912		10.1038/sj.onc.1201714	http://dx.doi.org/10.1038/sj.onc.1201714			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZH166	9591773	Bronze			2022-12-17	WOS:000073079400001
J	Byrne, JA; Nourse, CR; Basset, P; Gunning, P				Byrne, JA; Nourse, CR; Basset, P; Gunning, P			Identification of homo- and heteromeric interactions between members of the breast carcinoma-associated D52 protein family using the yeast two-hybrid system	ONCOGENE			English	Article						D52-like proteins; coiled-coil domain; yeast two-hybrid system; in vitro translation; GST pull-down assay	EXPRESSION; SEQUENCE; ALIGNMENT; CLONING	The hD52 gene was originally identified through its elevated expression level in human breast carcinoma. Cloning of D52 homologues from other species has indicated that D52 may play roles in calcium-mediated signal transduction and cell proliferation. Two human homologues of hD52, hD53 and hD54, have also been identified, demonstrating the existence of a novel gene/protein family. Since D52-like protein sequences are all predicted to contain a coiled-coil domain, we used the yeast two-hybrid system and glutathione S-transferase pull-down assays to investigate whether homo- and/or heteromeric interactions occur between D52-like proteins. Analyses of yeast strains co-transfected with paired D52-like constructs indicated that D52-like fusion proteins interact in homo- and heteromeric fashions through their predicted coiled-coil domains. Similarly, extensive two-hybrid screenings of a human breast carcinoma expression library identified hD53 and hD52 as potential interactors for both hD52 and hD53 baits. Thus, D52-like proteins appear to exert and/or regulate their activities through specific interactions with other D52-like proteins, which in turn may be intrinsic to potential roles of these molecules in controlling cell proliferation.	Childrens Med Res Inst, Cell Biol Unit, Westmead, NSW 2145, Australia; Univ Sydney, Dept Paediat & Child Hlth, Westmead, NSW 2145, Australia; CNRS INSERM ULP, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch, France; New Childrens Hosp, Oncol Res Unit, Westmead, NSW 2145, Australia	Children's Medical Research Institute - Australia; University of Sydney; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Sydney	Byrne, JA (corresponding author), Childrens Med Res Inst, Cell Biol Unit, Westmead, NSW 2145, Australia.		Gunning, Peter W/E-9058-2010	Gunning, Peter/0000-0003-0833-3128; Byrne, Jennifer Anne/0000-0002-8923-0587				ALLEN JB, 1995, TRENDS BIOCHEM SCI, V20, P511, DOI 10.1016/S0968-0004(00)89119-7; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AUSUBEL FM, 1997, CURRENT PROTOCOLS MO, V1; AUSUBEL FM, 1996, CURRENT PROTOCOLS MO, V3; BYRNE JA, 1995, CANCER RES, V55, P2896; Byrne JA, 1996, GENOMICS, V35, P523, DOI 10.1006/geno.1996.0393; Chen SL, 1996, ONCOGENE, V12, P741; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Parente JA, 1996, J BIOL CHEM, V271, P20096, DOI 10.1074/jbc.271.33.20096; Proux V, 1996, J BIOL CHEM, V271, P30790, DOI 10.1074/jbc.271.48.30790; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	17	67	74	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 19	1998	16	7					873	881		10.1038/sj.onc.1201604	http://dx.doi.org/10.1038/sj.onc.1201604			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX564	9484778				2022-12-17	WOS:000072053200006
J	Flores, JF; Pollock, PM; Walker, GJ; Glendening, JM; Lin, AHT; Palmer, JM; Walters, MK; Hayward, NK; Fountain, JW				Flores, JF; Pollock, PM; Walker, GJ; Glendening, JM; Lin, AHT; Palmer, JM; Walters, MK; Hayward, NK; Fountain, JW			Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds	ONCOGENE			English	Article						CDKN2A; CDKN2B; CDK4; melanoma; familial; mutation	CUTANEOUS MALIGNANT-MELANOMA; KINASE-4 INHIBITOR GENE; FAMMM SYNDROME FAMILIES; CELL-CYCLE ARREST; HOMOZYGOUS DELETIONS; MUTATIONAL ANALYSIS; GERMLINE MUTATIONS; SPORADIC MELANOMA; CHROMOSOME 9P; HUMAN CANCERS	Germline mutations within the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene and one of its targets, the cyclin dependent kinase 4 (CDK4) gene, have been identified in a proportion of melanoma kindreds, In the case of CDK4, only one specific mutation, resulting in the substitution of a cysteine for an arginine at codon 24 (R24C), has been found to be associated with melanoma. We have previously reported the identification of germline CDKN2A mutations in 7/18 Australian melanoma kindreds and the absence of the R24C CDK4 mutation in 21 families lacking evidence of a CDKN2A mutation. The current study represents an expansion of these efforts and includes a total of 48 melanoma families from Australia. All of these families have now been screened for mutations within CDKN2A and CDK4, as well as for mutations within the CDKN2A homolog and 9p21 neighbor, the CDKN2B gene, and the alternative exon 1 (E1 beta) of CDKN2A. Families lacking CDKN2A mutations, but positive for a polymorphism(s) within this gene, were further evaluated to determine if their disease was associated with transcriptional silencing of one CDKN2A allele, Overall, CDKN2A mutations were detected in 3/30 (10%) of the new kindreds. Two of these mutations have been observed previously: a 24 bp duplication at the 5' end of the gene and a G to C transversion in exon 2 resulting in an M53I substitution. A novel G to A transition in exon 2, resulting in a D108N substitution was also detected, Combined with our previous findings, we have now detected germline CDKN2A mutations in 10/48 (21%) of our melanoma kindreds, In none of the 'CDKN2A-negative' families was melanoma found to segregate with either an untranscribed CDKN2A allele, an R24C CDK4 mutation, a CDKN2B mutation, or an E1 beta mutation. The last three observations suggest that these other cell cycle control genes (or alternative gene products) are either not involved at all, or to any great extent, in melanoma predisposition.	UNIV SO CALIF,INST MED GENET,DEPT BIOCHEM & MOL BIOL,LOS ANGELES,CA 90033; QUEENSLAND INST MED RES,QUEENSLAND CANC FUND RES UNIT,HERSTON,QLD 4029,AUSTRALIA	University of Southern California; QIMR Berghofer Medical Research Institute			hayward, nicholas k/C-1367-2015; hayward, nick/AAV-8802-2020; Walker, Graeme J/C-2548-2012	hayward, nicholas k/0000-0003-4760-1033; Walker, Graeme J/0000-0002-9392-8769; Pollock, Pamela/0000-0001-8420-1026	NATIONAL CANCER INSTITUTE [R01CA066021] Funding Source: NIH RePORTER; NCI NIH HHS [CA66021] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Borg A, 1996, CANCER RES, V56, P2497; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; Dracopoli NC, 1996, CANCER SURV, V26, P115; FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541; Flores JF, 1996, CANCER RES, V56, P5023; FOUKES WD, 1997, MOL MED, V3, P5; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; GLENDENING JM, 1995, CANCER RES, V55, P5531; GOLDSTEIN AM, 1994, AM J HUM GENET, V54, P489; GOLDSTEIN AM, 1993, AM J HUM GENET, V52, P537; GOLDSTEIN AM, 1995, NEW ENGL J MED, V333, P970, DOI 10.1056/NEJM199510123331504; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; GRUIS NA, 1995, MELANOMA RES, V5, P169, DOI 10.1097/00008390-199506000-00005; GRUIS NA, 1995, AM J PATHOL, V146, P1199; GRUIS NA, 1993, MELANOMA RES, V3, P271; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HOLLAND EA, 1994, ONCOGENE, V9, P1361; Holland EA, 1995, ONCOGENE, V11, P2289; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; ISSHIKI K, 1994, ONCOGENE, V9, P1649; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LIU Q, 1995, ONCOGENE, V10, P1061; LUCA M, 1995, ONCOGENE, V11, P1399; LUI L, 1995, ONCOGENE, V11, P405; MACGEOCH C, 1994, HUM MOL GENET, V3, P2195, DOI 10.1093/hmg/3.12.2195; MACLENNAN R, 1992, J NCI, V84, P1437; MAO L, 1995, CANCER RES, V55, P2995; NANCARROW DJ, 1993, AM J HUM GENET, V53, P96; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OHTA M, 1994, CANCER RES, V54, P5269; Ohta M, 1996, INT J CANCER, V65, P762, DOI 10.1002/(SICI)1097-0215(19960315)65:6<762::AID-IJC9>3.0.CO;2-X; Platz A, 1997, J NATL CANCER I, V89, P697, DOI 10.1093/jnci/89.10.697; Platz A, 1996, BRIT J CANCER, V73, P344, DOI 10.1038/bjc.1996.59; POLLOCK PM, 1995, ONCOGENE, V11, P663; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; QUELLE DE, 1995, CELL, V83, P993; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; STONE S, 1995, ONCOGENE, V11, P987; STONE S, 1995, CANCER RES, V55, P2988; WALKER GJ, 1994, MELANOMA RES, V4, P29, DOI 10.1097/00008390-199402000-00005; WALKER GJ, 1995, HUM MOL GENET, V4, P1845, DOI 10.1093/hmg/4.10.1845; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	45	67	67	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 11	1997	15	24					2999	3005		10.1038/sj.onc.1201470	http://dx.doi.org/10.1038/sj.onc.1201470			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK377	9416844				2022-12-17	WOS:A1997YK37700013
J	Bobak, D; Moorman, J; Guanzon, A; Gilmer, L; Hahn, C				Bobak, D; Moorman, J; Guanzon, A; Gilmer, L; Hahn, C			Inactivation of the small GTPase Rho disrupts cellular attachment and induces adhesion-dependent and adhesion-independent apoptosis	ONCOGENE			English	Article						Rho; apoptosis; exoenzyme C3; adhesion	BINDING PROTEIN-RHO; DIFFICILE TOXIN-A; ADP-RIBOSYLTRANSFERASE; CLOSTRIDIUM-BOTULINUM; TRANSIENT EXPRESSION; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; FOCAL ADHESIONS; SINDBIS VIRUS; GENE-PRODUCT	Rho small GTPases regulate a variety of cellular signaling pathways involved in cell growth and transformation, In this study, we examined potential roles for Rho in adhesion-dependent and -independent pathways regulating apoptosis, Rho GTPases are specifically inactivated by exoenzyme C3 (C3) of Clostridium botulinum. Using a novel Sindbis virus-based gene expression system, we created a double subgenomic recombinant (dsSIN:C3) capable of expressing active C3 in intact cells, Infection of L929 fibroblasts with dsSIN:C3 caused essentially complete ADP-ribosylation of intracellular Rho within 1 h, dsSIN:C3-infected cells also became rounded within 1-2 h and detached by 5 h post-infection, Infection of L929 in suspension with dsSIN:C3 disrupted the ability for normal cellular attachment and spreading, Infection of primary cell explants of chicken embryo fibroblasts (CEF) and rat aortic smooth muscle cells (RSM) with dsSIN:C3 caused cytoskeletal effects similar to those seen in L929, We also observed that C3 markedly decreased the basal phosphorylation state of focal adhesion kinase (FAK), Most intriguingly, we found that dsSIN-based expression of C3 or loss of function mutants of Rho could each induce apoptosis and, in RSM, this effect was observed to be adhesion-independent. Rho GTPases, therefore, appear to regulate signal pathways that are required for cell survival and growth that are separate from, but likely overlap with, Rho-dependent pathways involved in cellular adhesion.	UNIV VIRGINIA,SCH MED,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,SCH MED,BEIRNE CARTER CTR IMMUNOL RES,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia	Bobak, D (corresponding author), UNIV VIRGINIA,SCH MED,DEPT MED,CHARLOTTESVILLE,VA 22908, USA.				NIGMS NIH HHS [GM54572] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKTORIES K, 1994, MOL CELL BIOCHEM, V138, P167, DOI 10.1007/BF00928459; AKTORIES K, 1992, CURR TOP MICROBIOL, V175, P115; Ausubel FM, 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; BATES RC, 1995, CANCER METAST REV, V14, P191, DOI 10.1007/BF00690291; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DEHAR S, 1995, CANCER METAST REV, V14, P165; DILLON ST, 1995, INFECT IMMUN, V63, P1421, DOI 10.1128/IAI.63.4.1421-1426.1995; Esteve P, 1995, ONCOGENE, V11, P2657; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GIRY M, 1995, INFECT IMMUN, V63, P4063, DOI 10.1128/IAI.63.10.4063-4071.1995; HAHN CS, 1992, P NATL ACAD SCI USA, V89, P2679, DOI 10.1073/pnas.89.7.2679; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Harlow E., 1989, ANTIBODIES LAB MANUA; Henning SW, 1997, EMBO J, V16, P2397, DOI 10.1093/emboj/16.9.2397; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; JIMENEZ B, 1995, ONCOGENE, V10, P811; JUST I, 1992, J BIOL CHEM, V267, P10274; JUST I, 1994, J BIOL CHEM, V269, P10706; JUST I, 1992, BIOCHEM BIOPH RES CO, V183, P931, DOI 10.1016/S0006-291X(05)80279-7; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; LANG P, 1992, J BIOL CHEM, V267, P11677; Lebowitz PF, 1997, CANCER RES, V57, P708; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Malik RK, 1996, BBA-REV CANCER, V1287, P73, DOI 10.1016/0304-419X(96)00008-X; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Moorman JP, 1996, J IMMUNOL, V156, P4146; NARUMIYA S, 1993, CELL SIGNAL, V5, P9, DOI 10.1016/0898-6568(93)90003-5; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; PERONA R, 1993, ONCOGENE, V8, P1285; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; PIERCE JS, 1973, J VIROL, V13, P1030; POPOFF M, 1990, NUCLEIC ACIDS RES, V18, P1291, DOI 10.1093/nar/18.5.1291; POPOFF MR, 1991, INFECT IMMUN, V59, P3673, DOI 10.1128/IAI.59.10.3673-3679.1991; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; Ruoslahti E, 1997, SCIENCE, V276, P1345, DOI 10.1126/science.276.5317.1345; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SUGAI M, 1992, P NATL ACAD SCI USA, V89, P8903, DOI 10.1073/pnas.89.19.8903; SUGAI M, 1992, J BIOL CHEM, V267, P2600; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TAKAISHI K, 1995, ONCOGENE, V11, P39; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Thorburn J, 1997, EMBO J, V16, P1888, DOI 10.1093/emboj/16.8.1888; THORNE J, 1997, UNPUB; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; Varner JA, 1996, CURR OPIN CELL BIOL, V8, P724, DOI 10.1016/S0955-0674(96)80115-3; XIONG C, 1989, SCIENCE, V243, P1188, DOI 10.1126/science.2922607; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0	67	67	68	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 30	1997	15	18					2179	2189		10.1038/sj.onc.1201396	http://dx.doi.org/10.1038/sj.onc.1201396			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YD019	9393976				2022-12-17	WOS:A1997YD01900006
J	Li, TJ; Rawlings, DJ; Park, H; Kato, RM; Witte, ON; Satterthwaite, AB				Li, TJ; Rawlings, DJ; Park, H; Kato, RM; Witte, ON; Satterthwaite, AB			Constitutive membrane association potentiates activation of Bruton tyrosine kinase	ONCOGENE			English	Article						Btk; pleckstrin homology domain; membrane targeting; transformation	X-LINKED AGAMMAGLOBULINEMIA; PLECKSTRIN HOMOLOGY DOMAIN; BETA-GAMMA-SUBUNITS; SIGMA-II SPECTRIN; SRC FAMILY; SIGNAL-TRANSDUCTION; PH DOMAIN; B-CELLS; PLASMA-MEMBRANE; POINT MUTATION	Mutations in the nonreceptor tyrosine kinase Btk result in the B cell, immunodeficiencies X-linked agammaglobulinemia (XLA) in humans and X-linked immunodeficiency (xid) in mice. Genetic and biochemical evidence implicates Btk as a key component of several B cell signaling pathways. Activation of Btk by a point mutation (E41K) within the PH domain (Btk*) results in fibroblast transformation and is correlated with increased membrane localization of Btk. When wild type Btk is activated by coexpression with Lyn, the tyrosine phosphorylated pool of Btk is highly enriched in the membrane fraction. To determine whether membrane association is sufficient to activate Btk, we targeted Btk to the plasma membrane using a series of fusion proteins including GagBtk, CD16Btk and CD4Btk. Constitutive membrane association greatly enhanced the ability of Btk to transform Rat2 fibroblasts in the presence of high levels of Src activity. All membrane targeted forms of Btk were highly tyrosine phosphorylated. Transformation required membrane localization, Btk kinase activity, transphosphorylation by Src family kinases, and an intact SH2 domain but not the PH or SH3 domains. These data suggest that membrane localization is a critical early step in Btk activation.	UNIV CALIF LOS ANGELES,INST MOL BIOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,DEPT PEDIAT,DIV IMMUNOL RHEUMATOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,DEPT MICROBIOL & MOL GENET,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NATIONAL CANCER INSTITUTE [P01CA012800] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K11AR001912] Funding Source: NIH RePORTER; NCI NIH HHS [CA-12800, CA-09056] Funding Source: Medline; NIAMS NIH HHS [AR01912] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Afar DEH, 1996, MOL CELL BIOL, V16, P3465; AOKI Y, 1994, P NATL ACAD SCI USA, V91, P10606, DOI 10.1073/pnas.91.22.10606; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CAMBIER JC, 1994, ANNU REV IMMUNOL, V12, P475; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHU KT, 1994, J BIOL CHEM, V269, P24095; DEWEERS M, 1994, J BIOL CHEM, V269, P23857; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Fukuda M, 1996, J BIOL CHEM, V271, P30303, DOI 10.1074/jbc.271.48.30303; GO NF, 1990, J EXP MED, V172, P1625, DOI 10.1084/jem.172.6.1625; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; Hemmings BA, 1997, SCIENCE, V275, P1899, DOI 10.1126/science.275.5308.1899; HENDERSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P339, DOI 10.1073/pnas.80.2.339; HINSHELWOOD S, 1995, EUR J IMMUNOL, V25, P1113, DOI 10.1002/eji.1830250439; HITOSHI Y, 1993, INT IMMUNOL, V5, P1183, DOI 10.1093/intimm/5.9.1183; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; JASIN M, 1991, J VIROL, V65, P440, DOI 10.1128/JVI.65.1.440-444.1991; JONES TA, 1990, J VIROL, V64, P2265, DOI 10.1128/JVI.64.5.2265-2279.1990; KASLAUSKAS A, 1989, CELL, V58, P1121; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KOIKE M, 1995, INT IMMUNOL, V7, P21, DOI 10.1093/intimm/7.1.21; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; LANGHANSRAJASEKARAN SA, 1995, P NATL ACAD SCI USA, V92, P8601, DOI 10.1073/pnas.92.19.8601; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Leitges M, 1996, SCIENCE, V273, P788, DOI 10.1126/science.273.5276.788; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; LEVY JB, 1986, P NATL ACAD SCI USA, V83, P4228, DOI 10.1073/pnas.83.12.4228; LI TJ, 1995, IMMUNITY, V2, P451, DOI 10.1016/1074-7613(95)90026-8; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MAHAJAN S, 1995, MOL CELL BIOL, V15, P5304; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; Ochs HD, 1996, MEDICINE, V75, P287, DOI 10.1097/00005792-199611000-00001; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8521; Rawlings D J, 1995, Semin Immunol, V7, P237, DOI 10.1006/smim.1995.0028; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; SAFFRAN DC, 1994, NEW ENGL J MED, V330, P1488, DOI 10.1056/NEJM199405263302104; SAKAI I, 1995, J BIOL CHEM, V270, P18420, DOI 10.1074/jbc.270.31.18420; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SANTOSARGUMEDO L, 1995, IMMUNOLOGY, V85, P248; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; SATO S, 1994, J EXP MED, V180, P2101, DOI 10.1084/jem.180.6.2101; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TOUHARA K, 1994, P NATL ACAD SCI USA, V91, P11256; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VIHINEN M, 1995, BIOCHEMISTRY-US, V34, P1475, DOI 10.1021/bi00005a002; VIHINEN M, 1994, FEBS LETT, V350, P263, DOI 10.1016/0014-5793(94)00783-7; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wang DS, 1996, BIOCHEM BIOPH RES CO, V225, P420, DOI 10.1006/bbrc.1996.1189; Wang DS, 1995, BIOCHEM BIOPH RES CO, V217, P608, DOI 10.1006/bbrc.1995.2818; WICKER LS, 1986, CURR TOP MICROBIOL, V124, P87; Yang WY, 1997, P NATL ACAD SCI USA, V94, P604, DOI 10.1073/pnas.94.2.604; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300	71	67	68	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 18	1997	15	12					1375	1383		10.1038/sj.onc.1201308	http://dx.doi.org/10.1038/sj.onc.1201308			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XW411	9333013	Bronze			2022-12-17	WOS:A1997XW41100001
J	Mizuno, T; Kyoizumi, S; Suzuki, T; Iwamoto, KS; Seyama, T				Mizuno, T; Kyoizumi, S; Suzuki, T; Iwamoto, KS; Seyama, T			Continued expression of a tissue specific activated oncogene in the early steps of radiation-induced human thyroid carcinogenesis	ONCOGENE			English	Article						thyroid; radiation; RET oncogene; H4-RET; scid mice	SEVERE COMBINED IMMUNODEFICIENCY; POTENTIALLY LETHAL DAMAGE; DOUBLE-STRAND BREAKS; CARCINOMA CELL-LINE; RET PROTO-ONCOGENE; SCID MICE; PHILADELPHIA-CHROMOSOME; HUMAN-FIBROBLASTS; IN-VIVO; HUMAN SKIN	Ionizing radiation is a well-known risk factor of cancer development, but the mechanism of radiation induced carcinogenesis is not clear. Chromosomal rearrangements induced by radiation most likely are one of the principal genetic alterations resulting in malignant transformation. The chimeric BCR-ABL associated with chronic myelogenous leukemia (CML) and H4-RET oncogenes associated with thyroid papillary carcinoma are the result of a translocation and inversion, respectively. In vitro studies showed these genes were induced by high-doses of X-irradiation in cell lines. Studies also show that therapeutic external X-ray doses as high as 60 Gy for treatment of various childhood cancers including Hodgkin's disease significantly increase the risk of thyroid cancer. Therefore, we examined the induction and persistence of these chimeric genes in human thyroid tissues transplanted in scid mice after 50 Gy exposure as a function of time for 2 months to elucidate the early events of thyroid carcinogenesis. The H4-RET genes were detected on day 2 and throughout the 2 month period. On the other hand, BCR-ABL genes were detected on day 2 and were undetectable subsequently. These results suggest that ionizing radiation causes various oncogene activations, but cells with only specific gene alteration uniquely associated with thyroid carcinogenesis are selectively retained demonstrating one of the early events in the beginnings of radiation carcinogenesis in human thyroid tissues.	RADIAT EFFECTS RES FDN,DEPT RADIOBIOL,HIROSHIMA 732,JAPAN	Radiation Effects Research Foundation - Japan								AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; BEDFORD JS, 1991, INT J RADIAT ONCOL, V21, P1457, DOI 10.1016/0360-3016(91)90320-4; BROWN JM, 1993, ENVIRON MOL MUTAGEN, V22, P218, DOI 10.1002/em.2850220407; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; CORNFORTH MN, 1987, RADIAT RES, V111, P385, DOI 10.2307/3576926; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; FUGAZZOLA L, 1995, CANCER RES, V55, P5617; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HANCOCK SL, 1995, INT J RADIAT ONCOL, V31, P1165, DOI 10.1016/0360-3016(95)00019-U; HILL LL, 1991, CANCER RES, V51, P4937; ISHIZAKA Y, 1990, BIOCHEM BIOPH RES CO, V168, P402, DOI 10.1016/0006-291X(90)92335-W; ISHIZAKA Y, 1989, JPN J CANCER RES, V80, P1149, DOI 10.1111/j.1349-7006.1989.tb01645.x; ITO T, 1993, JPN J CANCER RES, V84, P105, DOI 10.1111/j.1349-7006.1993.tb02840.x; ITO T, 1993, CANCER RES, V53, P2940; ITO T, 1994, LANCET, V344, P259; ITO T, 1995, CANCER LETT, V88, P113, DOI 10.1016/0304-3835(94)03622-P; Klugbauer S, 1995, ONCOGENE, V11, P2459; KYOIZUMI S, 1994, RADIAT RES, V137, P76, DOI 10.2307/3578793; Lobrich M, 1995, P NATL ACAD SCI USA, V92, P12050, DOI 10.1073/pnas.92.26.12050; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; METTLER FA, 1995, MED EFFECTS IONIZING, P214; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; Preston DL, 1994, RADIAT RES, V137, P68; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; Soballe PW, 1996, CANCER RES, V56, P757; TAKIZAWA Y, 1995, ARCH DERMATOL RES, V287, P237, DOI 10.1007/BF01105072; TANAKA J, 1987, VIROLOGY, V161, P62, DOI 10.1016/0042-6822(87)90171-1; TERAOKA S, 1994, INT J ONCOL, V5, P501; THOMPSON DE, 1994, RAD RES S, V137, P17; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; WARD JF, 1990, INT J RADIAT BIOL, V57, P1141, DOI 10.1080/09553009014551251; WILLIAMS D, 1994, NATURE, V371, P556, DOI 10.1038/371556a0	35	67	70	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 18	1997	15	12					1455	1460		10.1038/sj.onc.1201313	http://dx.doi.org/10.1038/sj.onc.1201313			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XW411	9333021				2022-12-17	WOS:A1997XW41100009
J	Loughran, O; Clark, LJ; Bond, J; Baker, A; Berry, IJ; Edington, KG; Ly, IS; Simmons, R; Haw, R; Black, DM; Newbold, RF; Parkinson, EK				Loughran, O; Clark, LJ; Bond, J; Baker, A; Berry, IJ; Edington, KG; Ly, IS; Simmons, R; Haw, R; Black, DM; Newbold, RF; Parkinson, EK			Evidence for the inactivation of multiple replicative lifespan genes in immortal human squamous cell carcinoma keratinocytes	ONCOGENE			English	Article						keratinocyte; senescence; immortality; telomerase; squamous; cancer	HUMAN-DIPLOID FIBROBLASTS; INDEFINITE DIVISION; TELOMERASE ACTIVITY; SUPPRESSOR GENE; SENESCENCE; LINES; HEAD; NECK; P53; CANCER	Human keratinocyte immortality is genetically recessive to the normal phenotype of limited replicative lifespan and appears to require the dysfunction of p53 and the cyclin D-Cdk inhibitor p16. In order to test for the inactivation of other candidate replicative lifespan genes in the immortal cells of human tumors, we developed a series of mortal and immortal keratinocyte cultures derived from neoplastic lesions of the head and neck which were amenable to molecular genetic analysis by the loss of heterozygosity (LOH) technique. The results indicate that keratinocyte immortalization in head and neck squamous cell carcinoma (SCC-HN) development involves the inactivation of at least two further pathways to senescence and four in all. Chromosomes 1, 4 and 7 carry genes representing immortality complementation groups C, B and D respectively and immortal keratinocytes showed LOH at either 4q32-q34 between D4S1554 and D4S171 (group B) or 7q31 (group D) but never 1q25 (group C). These results tentatively suggest that the genes responsible for the immortality complementation groups encode proteins on the same pathway to senescence. In addition, all of the immortal keratinocyte lines possessed high levels of telomerase activity and a suppressor of telomerase activity has been mapped to the short arm of chromosome 3p. Five out of eight lines showed LOH at 3p21.2-p21.3, a region which may carry a gene capable of suppressing SCC-HN telomerase. However, alternative mechanisms of telomerase reactivation were also suggested by our results. None of the above genetic alterations were seen in seven senescent neoplastic keratinocyte cultures, Other loci harbouring antiproliferative genes implicated in replicative lifespan showed few or no alterations and any alterations seen were additional to those described above.	BEATSON INST CANC RES,CRC,BEATSON LABS,GLASGOW G61 1BD,LANARK,SCOTLAND; BRUNEL UNIV,DEPT BIOCHEM,UXBRIDGE UB8 3PH,MIDDX,ENGLAND; BRUNEL UNIV,DEPT BIOL,UXBRIDGE UB8 3PH,MIDDX,ENGLAND	Beatson Institute; Brunel University; Brunel University			Haw, Robin/D-1393-2009	Haw, Robin/0000-0002-2013-7835				BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BERRY IJ, 1994, MOL CARCINOGEN, V9, P134, DOI 10.1002/mc.2940090305; BURNS JE, 1993, BRIT J CANCER, V67, P1274, DOI 10.1038/bjc.1993.238; BURNS JE, 1994, BRIT J CANCER, V70, P591, DOI 10.1038/bjc.1994.356; CASEY G, 1993, HUM MOL GENET, V2, P1921, DOI 10.1093/hmg/2.11.1921; CAVANEE WK, 1983, NATURE, V305, P779; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; EASTY DM, 1981, BRIT J CANCER, V43, P772, DOI 10.1038/bjc.1981.115; EDINGTON KG, 1995, MOL CARCINOGEN, V13, P254, DOI 10.1002/mc.2940130408; EDINGTON KG, 1996, IN PRESS CULTURE TUM, V4; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HENSLER PJ, 1994, MOL CELL BIOL, V14, P2291, DOI 10.1128/MCB.14.4.2291; Karlsson C, 1996, CANCER RES, V56, P241; KAUFMANN WK, 1995, CANCER RES, V55, P7; KAUL SC, 1995, FEBS LETT, V361, P269, DOI 10.1016/0014-5793(95)00177-B; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; Loughran O, 1996, ONCOGENE, V13, P561; LOUGHRAN O, 1994, CANCER RES, V54, P5045; MAESTRO R, 1993, CANCER RES, V53, P5775; NAWROZ H, 1994, CANCER RES, V54, P1152; Newbold R F, 1985, Carcinog Compr Surv, V9, P17; NING Y, 1991, P NATL ACAD SCI USA, V88, P5635, DOI 10.1073/pnas.88.13.5635; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; OHMURA H, 1995, JPN J CANCER RES, V86, P899, DOI 10.1111/j.1349-7006.1995.tb02998.x; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; Piatyszek Mieczyslaw A., 1995, Methods in Cell Science, V17, P1, DOI 10.1007/BF00981880; RADNA RL, 1989, MOL CELL BIOL, V9, P3093, DOI 10.1128/MCB.9.7.3093; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RHEINWALD JG, 1981, CANCER RES, V41, P1657; RIMESSI P, 1994, ONCOGENE, V9, P3467; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SANDHU AK, 1994, P NATL ACAD SCI USA, V91, P5498, DOI 10.1073/pnas.91.12.5498; Sandhu AK, 1996, ONCOGENE, V12, P247; SASAKI M, 1994, CANCER RES, V54, P6090; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; UEJIMA H, 1995, GENE CHROMOSOME CANC, V14, P120, DOI 10.1002/gcc.2870140206; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; Vojta PJ, 1996, GENE CHROMOSOME CANC, V16, P55; WANG XW, 1992, CARCINOGENESIS, V13, P555, DOI 10.1093/carcin/13.4.555; WHITAKER NJ, 1995, ONCOGENE, V11, P971; WHITE JJ, 1991, GENOMICS, V11, P228, DOI 10.1016/0888-7543(91)90126-Y; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347	48	67	67	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 24	1997	14	16					1955	1964		10.1038/sj.onc.1201028	http://dx.doi.org/10.1038/sj.onc.1201028			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WV804	9150362				2022-12-17	WOS:A1997WV80400008
J	Kotani, H; Takaishi, K; Sasaki, T; Takai, Y				Kotani, H; Takaishi, K; Sasaki, T; Takai, Y			Rho regulates association of both the ERM family and vinculin with the plasma membrane in MDCK cells	ONCOGENE			English	Article						Rho; ERM family; vinculin; peripheral bundle; cortical bundle; focal adhesion	GTP-BINDING PROTEIN; BOTULINUM ADP-RIBOSYLTRANSFERASE; GDP DISSOCIATION INHIBITOR; SACCHAROMYCES-CEREVISIAE; FOCAL ADHESIONS; GENE-PRODUCT; EXCHANGE PROTEIN; BRAIN CYTOSOL; BUD FORMATION; KINASE-C	Rho small G protein regulates various actin-dependent cell functions. As to the functioning sites of Rho, Rho regulates formation of stress fibers and focal adhesions in many types of cultured cells, whereas we have shown that the association sites of actin filaments with the plasma membrane controlled by the ERM (Ezrin, Radixin, Moesin) family are the functioning sites of Rho in MDCK cells stably expressing myc-RhoA. We have investigated here the effect of microinjection of Rho GDI, a negative regulator of Rho which inhibits activation of Rho, C3, an exoenzyme of Clostridium botulinum which ADP-ribosylates Rho and inhibits its functions, or guanosine 5'-(3-O-thio) triphosphate-bound active form of Rho on the intracellular localization of both the ERM family and vinculin, which is one of the structural proteins of focal adhesions, in wild type MDCK cells. The ERM family was preferentially localized at peripheral bundles of actin filaments which are localized at the outer edge of colonies of the cells, microvilli and low Gaze-induced cortical bundles of actin filaments in wild type MDCK cells. Microinjection of Rho GDI or C3 inhibited the localization of the ERM family at both the peripheral bundles and the low Ca2+-induced cortical bundles. On the other hand, vinculin was localized at both focal adhesions and basal edges of the colonies of the cells, and microinjection of Rho GDI or C3 inhibited the localization of vinculin at both of these sites. These results indicate that activation of Rho is necessary for the association of both the ERM family and vinculin with the plasma membrane in wild type MDCK cells. Microinjection of the guanosine 5'-(3-O-thio) triphosphate-bound form of Rho induced an increase in the localization of vinculin at focal adhesions, but did not induce an increase in the localization of the ERM family at the plasma membrane, indicating that activation of Rho itself is sufficient only for the association of vinculin with the plasma membrane at focal adhesions.	OSAKA UNIV,SCH MED,DEPT MOL BIOL & BIOCHEM,SUITA,OSAKA 565,JAPAN	Osaka University								AKTORIES K, 1988, EUR J BIOCHEM, V172, P445, DOI 10.1111/j.1432-1033.1988.tb13908.x; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; BRAUN U, 1989, FEBS LETT, V243, P70, DOI 10.1016/0014-5793(89)81220-7; BRETSCHER A, 1983, J CELL BIOL, V97, P425, DOI 10.1083/jcb.97.2.425; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; Drgonova J, 1996, SCIENCE, V272, P277, DOI 10.1126/science.272.5259.277; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GEIGER B, 1980, P NATL ACAD SCI-BIOL, V77, P4127, DOI 10.1073/pnas.77.7.4127; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Hotta K, 1996, BIOCHEM BIOPH RES CO, V225, P69, DOI 10.1006/bbrc.1996.1132; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; LANKES W, 1988, BIOCHEM J, V251, P831, DOI 10.1042/bj2510831; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MATSUI Y, 1992, MOL CELL BIOL, V12, P5690, DOI 10.1128/MCB.12.12.5690; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; NARUMIYA S, 1988, J BIOL CHEM, V263, P17255; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; Ozaki K, 1996, EMBO J, V15, P2196, DOI 10.1002/j.1460-2075.1996.tb00573.x; PAKKANEN R, 1987, J HISTOCHEM CYTOCHEM, V35, P809, DOI 10.1177/35.8.3298422; Qadota H, 1996, SCIENCE, V272, P279, DOI 10.1126/science.272.5259.279; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SATO N, 1992, J CELL SCI, V103, P131; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SEKINE A, 1989, J BIOL CHEM, V264, P8602; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1995, METHOD ENZYMOL, V256, P336; TAKAISHI K, 1995, ONCOGENE, V11, P39; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; TANAKA K, 1995, METHOD ENZYMOL, V256, P41; TSUKITA S, 1989, J CELL BIOL, V108, P2369, DOI 10.1083/jcb.108.6.2369; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; UEDA T, 1990, J BIOL CHEM, V265, P9373; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; YAKU H, 1994, BIOCHEM BIOPH RES CO, V198, P811, DOI 10.1006/bbrc.1994.1116; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077	47	67	69	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 10	1997	14	14					1705	1713		10.1038/sj.onc.1200998	http://dx.doi.org/10.1038/sj.onc.1200998			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR893	9135072				2022-12-17	WOS:A1997WR89300009
J	Chen, WD; Otterson, GA; Lipkowitz, S; Khleif, SN; Coxon, AB; Kaye, FJ				Chen, WD; Otterson, GA; Lipkowitz, S; Khleif, SN; Coxon, AB; Kaye, FJ			Apoptosis is associated with cleavage of a 5 kDa fragment from RB which mimics dephosphorylation and modulates E2F binding	ONCOGENE			English	Article						apoptosis; chemotherapy; cysteine protease; FAS; retinoblastoma protein	RETINOBLASTOMA GENE-PRODUCT; LUNG-CANCER; GROWTH SUPPRESSION; CELL-LINES; PROTEIN; IDENTIFICATION; DOMAIN; CLONING; MEMBER; FAMILY	Dephosphorylation of the RE protein has been reported to be associated with apoptosis, In contrast, we show that treatment of HL60 cells with etoposide or cytosine arabinoside or treatment of breast epithelial cells with alpha-FAS is associated with the cleavage of a 5 kDa fragment from the C-terminus of RE, resulting in a truncated product that we have designated as p100cl. This cleavage event coincides with the activation of cysteine proteases at the onset of apoptosis, is blocked by the addition of iodoacetamide to cells prior to the onset of apoptosis, and results in the expression of faster migrating protein species which can mimic dephosphorylated RE. The free 5 kDa fragment is detected only during apoptosis, predicts a cleavage site that we have mapped to a unique CPP32-like recognition sequence which is present at the C-terminus of all reported RE homologues, and results in a truncated RE protein with enhanced E2F binding affinity, While the causality for this cleavage event in the apoptotic process is still under investigation, our findings suggest distinct post-translational pathways for the RE product between cells examined during growth arrest (p105 hypophosphorylated RE) or apoptosis (p100cl).	USN,NCI,MED ONCOL BRANCH,DIV CLIN SCI,BETHESDA,MD 20889	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Defense; United States Navy			CHEN, WEI-DONG/F-4521-2014; kaye, frederic/E-2437-2011	CHEN, WEI-DONG/0000-0003-2264-5515; 				BING A, 1996, CANCER RES, V56, P438; CARNEY DN, 1985, CANCER RES, V45, P2913; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; GOODRICH DW, 1992, NATURE, V360, P177, DOI 10.1038/360177a0; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KRATZKE RA, 1993, CELL GROWTH DIFFER, V4, P629; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MAYOL X, 1993, ONCOGENE, V8, P2561; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NEVINS JR, 1992, SCIENCE, V258, P424; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; SHIMIZU E, 1994, ONCOGENE, V9, P2441; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; XU HJ, 1994, P NATL ACAD SCI USA, V91, P9837, DOI 10.1073/pnas.91.21.9837	24	67	68	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 13	1997	14	10					1243	1248		10.1038/sj.onc.1201096	http://dx.doi.org/10.1038/sj.onc.1201096			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121775				2022-12-17	WOS:A1997WM78200015
J	Wang, H; Grand, RJA; Milner, AE; Armitage, RJ; Gordon, J; Gregory, CD				Wang, H; Grand, RJA; Milner, AE; Armitage, RJ; Gordon, J; Gregory, CD			Repression of apoptosis in human B-lymphoma cells by CD40-ligand and Bcl-2: Relationship to the cell-cycle and role of the retinoblastoma protein	ONCOGENE			English	Article						Burkitt-lymphoma; cell-survival; anti-Ig; phosphorylation	TUMOR-SUPPRESSOR PROTEIN; MYC-INDUCED APOPTOSIS; C-MYC; BURKITT-LYMPHOMA; GERMINAL-CENTERS; TRANSGENIC MICE; GROWTH ARREST; ANTI-MU; DEATH; INDUCTION	Using a Burkitt lymphoma cell line to model human B-cell apoptosis in vitro, we observed that crosslinking, by antibody, of cell surface immunoglobulin induced G(1) growth-arrest followed by apoptosis. By contrast, cells treated with the Ca2+-ionophore, ionomycin, generated apoptotic signals in G(2)/M as well as in G(1). Both ionomycin and anti-immunoglobulin treatment induced rapid dephosphorylation of Rb prior to apoptosis. Apoptosis was repressed following exposure to CD40-ligand and was accompanied by hyperphosphorylation of Rb and cell-cycle progression but not Bcl-2 expression. Expression of Bcl-2 protein in stable bcl-2-transfectants, also resulted in repression of apoptosis and anti-immunoglobulin-treated cells no longer underwent growth-arrest. In Bcl-2-expressing cells in which apoptosis was repressed, Rb remained hyperphosphorylated, even during G(1)-arrest induced by ionomycin. TGF beta treatment of Bcl-2-expressing cells induced G(1)-arrest, de-phosphorylation of Rb and apoptosis. These results suggest that the functional activity of Bcl-2 in B-lymphoma cells is dependent upon, or leads to, sustained hyperphosphorylation of Rb and that Rb hyperphosphorylation can be uncoupled from cell-cycle progression.	UNIV BIRMINGHAM,SCH MED,DEPT IMMUNOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,SCH MED,INST CANC STUDIES,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; IMMUNEX RES & DEV CORP,SEATTLE,WA	University of Birmingham; University of Birmingham								ASKEW DS, 1991, ONCOGENE, V6, P1915; CHOI MSK, 1995, EUR J IMMUNOL, V25, P1352, DOI 10.1002/eji.1830250533; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CUENDE E, 1993, EMBO J, V12, P1555, DOI 10.1002/j.1460-2075.1993.tb05799.x; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DIVE C, 1992, BIOCHIM BIOPHYS ACTA, V1133, P275, DOI 10.1016/0167-4889(92)90048-G; DOU QP, 1995, P NATL ACAD SCI USA, V92, P9019, DOI 10.1073/pnas.92.20.9019; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GOODNOW CC, 1992, ANNU REV IMMUNOL, V10, P489, DOI 10.1146/annurev.iy.10.040192.002421; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; GREGORY CD, 1994, INT J CANCER, V57, P419, DOI 10.1002/ijc.2910570321; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOLDER MJ, 1993, EUR J IMMUNOL, V23, P2368, DOI 10.1002/eji.1830230948; ISHIDA T, 1995, J IMMUNOL, V155, P5527; JOSEPH LF, 1995, CELL GROWTH DIFFER, V6, P51; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU YM, 1994, ONCOGENE, V9, P1015; MacDonald I, 1996, BLOOD, V87, P1147, DOI 10.1182/blood.V87.3.1147.bloodjournal8731147; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4; MAHESWARAN S, 1991, ONCOGENE, V6, P1965; MERINO R, 1995, J IMMUNOL, V155, P3830; MILNER AE, 1992, INT J CANCER, V52, P636, DOI 10.1002/ijc.2910520424; MILNER AE, 1993, ONCOGENE, V8, P3385; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; NEVINS JR, 1992, SCIENCE, V258, P424; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Scott David W., 1995, P187; SCOTT DW, 1986, J EXP MED, V164, P156, DOI 10.1084/jem.164.1.156; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0; VALENTINE MA, 1992, EUR J IMMUNOL, V22, P3141, DOI 10.1002/eji.1830221217; VISVADER JE, 1992, EMBO J, V11, P4557, DOI 10.1002/j.1460-2075.1992.tb05557.x; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WARNER GL, 1992, CELL GROWTH DIFFER, V3, P175; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; WYLLIE AH, 1992, CANCER METAST REV, V11, P95, DOI 10.1007/BF00048057; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	48	67	68	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 18	1996	13	2					373	379						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710376				2022-12-17	WOS:A1996VA25200016
J	Brown, MA; Xu, CF; Nicolai, H; Griffiths, B; Chambers, JA; Black, D; Solomon, E				Brown, MA; Xu, CF; Nicolai, H; Griffiths, B; Chambers, JA; Black, D; Solomon, E			The 5' end of the BRCA1 gene lies within a duplicated region of human chromosome 17q21	ONCOGENE			English	Article						BRCA1; tumour-suppressor gene; breast/ovarian tumorigenesis; gene duplication; pseudogene	FAMILIAL BREAST; WILD-TYPE; HETEROZYGOSITY; EVOLUTION; CANCER	To begin to address the hypothesis that abnormal regulation of the breast/ovarian cancer susceptibility gene BRCA1 is a critical step in sporadic breast/ovarian tumorigenesis, we have determined the detailed structure of the BRCA1 genomic region, We show that this region of the genome contains a tandem duplication of approximately 30 kilobases, which results in two copies of BRCA1 exons 1 and 2, of exons 1 and 3 of the adjacent 1A1-3B gene and of the previously reported 295 base pair intergenic region. Sequence analysis of the duplicated exons of BRCA1 and 1A1-3B and flanking genomic DNA reveals maintenance of the intron-exon structure and a high degree of nucleotide sequence identity, suggesting that these are non-processed pseudogenes and that the duplication is a recent event in evolutionary terms, We also show that a processed pseudogene of the acidic ribosomal phosphoprotein P1 (ARPP1) is inserted directly upstream of pseudo-BRCA1 exon 1A, We believe that these findings could not only confound BRCA1 mutation analysis, but could have implications for the normal and abnormal regulation of BRCA1 transcription, translation and function.	BEATSON INST CANC RES, GLASGOW G61 1BD, LANARK, SCOTLAND	Beatson Institute	Brown, MA (corresponding author), IMPERIAL CANC RES FUND, SOMAT CELL GENET LAB, LONDON WC2A 3PX, ENGLAND.		Brown, Melissa A/F-1451-2010	Xu, Chun-Fang/0000-0002-8747-0683; Brown, Melissa/0000-0002-2830-9259				AHUJA SK, 1992, NAT GENET, V2, P31, DOI 10.1038/ng0992-31; BENARIE N, 1994, HUM MOL GENET, V3, P229, DOI 10.1093/hmg/3.2.229; BROWN MA, 1994, NATURE, V372, P733, DOI 10.1038/372733a0; BROWN MA, 1995, P NATL ACAD SCI USA, V92, P4362, DOI 10.1073/pnas.92.10.4362; CAMPBELL IG, 1994, HUM MOL GENET, V3, P589, DOI 10.1093/hmg/3.4.589; CORTESE JF, 1994, J BIOL CHEM, V269, P21898; CROPP CS, 1994, CANCER RES, V54, P2548; ERICKSON LM, 1992, GENOMICS, V14, P948, DOI 10.1016/S0888-7543(05)80116-8; FOULKES WD, 1993, INT J CANCER, V54, P220, DOI 10.1002/ijc.2910540210; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; HOSKING L, 1995, NAT GENET, V9, P343, DOI 10.1038/ng0495-343; JEFFREYS AJ, 1982, NATURE, V296, P9, DOI 10.1038/296009a0; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; LINDBLOM A, 1993, HUM GENET, V91, P6; MARCHESE A, 1995, GENE, V154, P153, DOI 10.1016/0378-1119(94)00879-W; MATSUSHIMA M, 1995, HUM MOL GENET, V4, P1953, DOI 10.1093/hmg/4.10.1953; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; RICH BE, 1987, MOL CELL BIOL, V7, P4065, DOI 10.1128/MCB.7.11.4065; SAPI E, 1994, GENOMICS, V22, P641, DOI 10.1006/geno.1994.1440; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198; SU LK, 1993, CANCER RES, V53, P2728; SUZUKI H, 1994, GENE, V147, P277, DOI 10.1016/0378-1119(94)90081-7; VANIN EF, 1985, ANNU REV GENET, V19, P253, DOI 10.1146/annurev.genet.19.1.253; XU CF, 1995, HUM MOL GENET, V4, P2259, DOI 10.1093/hmg/4.12.2259; XU CF, 1996, SEMINARS CANC BIOL	28	67	71	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	1996	12	12					2507	2513						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700509				2022-12-17	WOS:A1996UW48700004
J	GUDAS, J; NGUYEN, H; LI, T; HILL, D; COWAN, KH				GUDAS, J; NGUYEN, H; LI, T; HILL, D; COWAN, KH			EFFECTS OF CELL-CYCLE, WILD-TYPE P53 AND DNA-DAMAGE ON P21(CIP1/WAF1) EXPRESSION IN HUMAN BREAST EPITHELIAL-CELLS	ONCOGENE			English	Article						P21(CIP1/WAF1); POST TRANSCRIPTIONAL REGULATING; WILD-TYPE P53; RADIATION EFFECTS; CELL CYCLE	HUMAN PAPILLOMAVIRUS TYPE-16; SYNTHASE MESSENGER-RNA; E6 ONCOPROTEIN; PROTEIN; CANCER; GROWTH; LINE; CDNA; TRANSFORMATION; TRANSCRIPTION	In this study we examine the relationship between p21(CIP1/Waf1) (CIP1), a 21 kDa protein that binds to and modulates the activity of several cyclin dependent kinases and expression of wild-type (WT) p53 in human breast epithelial cells. Basal CTP1 protein, but not CIP1 mRNA levels correlated well with expression of WT p53 in human breast epithelial cells. To obtain more direct evidence that WT p53 regulated the level of CTP1 protein, the Human Papilloma Virus (HPV) E6 protein was introduced into immortalized 184B5 breast cells, Residual WT p53 levels correlated well with CIP1 protein but not CIP1 mRNA levels in isolated clones of transfected cells. CIP1 protein mas increased at early times after growth factor arrested cells were stimulated to proliferate. The rise in CLP1 protein was due to a concomitant increase in CIP1 mRNA levels in MCF10, but not in normal mammary epithelial cells. DNA damage induced by ionizing radiation resulted in a transient increase in WT p53 levels but a prolonged induction of CIP1 protein. The sustained increase in CIP1 protein 24 h after radiation could not be attributed to a concomitant increase in CIP1 mRNA levels, Although the half-life of the CIP1 protein was not altered following irradiation, a fourfold increase in the amount of radioactivity incorporated into CIP1 protein was detected. When considered together these data suggest that wild-type p53 affects CIP1 protein accumulation at a posttranscriptional level in human breast epithelial cells under different physiologic and stress conditions.	ONCOGENE SCI, CAMBRIDGE, MA 02142 USA		GUDAS, J (corresponding author), NCI, MED BRANCH,DIV CANC TREATMENT, MED BREAST CANC SECT,BLDG 10, ROOM 12N226, BETHESDA, MD 20892 USA.							ALLRED DC, 1993, J NATL CANCER I, V85, P200, DOI 10.1093/jnci/85.3.200; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; BARNES DM, 1993, HUM PATHOL, V24, P469, DOI 10.1016/0046-8177(93)90158-D; BARTEK J, 1990, ONCOGENE, V5, P893; CHU E, 1991, P NATL ACAD SCI USA, V88, P8977, DOI 10.1073/pnas.88.20.8977; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; DELMOLINO L, 1993, CARCINOGENESIS, V14, P827, DOI 10.1093/carcin/14.5.827; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DI LEONARDO A, 1993, COLD SPRING HARB SYM, V58, P655, DOI 10.1101/SQB.1993.058.01.073; Dulcic V, 1994, CELL, V76, P1013; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GRAHAM KA, 1986, BREAST CANCER RES TR, V8, P29, DOI 10.1007/BF01805922; GUDAS JM, 1988, P NATL ACAD SCI USA, V85, P4705, DOI 10.1073/pnas.85.13.4705; GUDAS JM, 1994, CELL GROWTH DIFFER, V5, P295; GUDAS JM, 1993, CELL GROWTH DIFFER, V4, P421; HALDAR S, 1994, CANCER RES, V54, P2095; HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KASTAN MB, 1991, CANCER RES, V51, P6304; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; LI Y, 1994, ONCOGENE, V9, P2261; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MELEFORS O, 1993, J BIOL CHEM, V268, P5974; MICHIELI P, 1994, CANCER RES, V54, P3391; MUNGER K, 1989, J VIROL, V63, P4417; NASMYTH K, 1993, NATURE, V366, P634, DOI 10.1038/366634a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHAY JW, 1995, MOL CELL BIOL, V15, P425, DOI 10.1128/MCB.15.1.425; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SOULE HD, 1990, CANCER RES, V50, P6075; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	55	67	67	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	1995	11	2					253	261						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624142				2022-12-17	WOS:A1995RK95700006
J	OKAZAKI, K; SAGATA, N				OKAZAKI, K; SAGATA, N			MAP KINASE ACTIVATION IS ESSENTIAL FOR ONCOGENIC TRANSFORMATION OF NIH3T3 CELLS BY MOS	ONCOGENE			English	Article						MAP KINASE; MOS; PROTEIN KINASES; SIGNAL TRANSDUCTION; TRANSFORMATION	SIGNAL-REGULATED KINASE; MAMMALIAN SOMATIC-CELLS; NERVE GROWTH-FACTOR; PROTEIN-KINASE; XENOPUS-OOCYTES; IN-VITRO; NUCLEOTIDE-SEQUENCE; MEIOTIC MATURATION; SARCOMA-VIRUS; FROG OOCYTES	The c-mos proto-oncogene product, Mos, is a serine/threonine protein kinase that controls the meiotic cell cycle in vertebrate oocytes. Both;in vivo and in vitro, Mos can activate mitogen-activated protein kinase (MAPK) most probably by direct phosphorylation of MAPK kinase (MAPKK). In many cell types transformed by diverse oncogene products such as Raf, MAPK is constitutively activated, suggesting that the MAPK pathway may mediate oncogenic signalling by many oncogene products. Using mouse NIH3T3 cells, we examined whether oncogenic transformation by Mos is mediated by MAPK activation. Coexpression of a kinase-defective (dominant-negative) mutant of Mek1, one of the MAPKK isoforms, completely suppressed transformation by Mos. By contrast, coexpression of wild-type Mek1 markedly enhanced the transforming efficiency of Mos. Moreover, overexpression of the dominant-negative Mek1 reverted the transformation phenotype of Mos-transformed cells. These results indicate that in NIH3T3,cells the Mek1/MAPK pathway is necessary and sufficient for transformation (and its maintenance) by Mos. Transformation of NIH3T3 cells by Raf or Ras was also suppressed by the dominant-negative Mek1, but significantly less efficiently than that by Mos, suggesting the existence of multiple signalling pathways for Raf and Ras oncoproteins.			OKAZAKI, K (corresponding author), KURUME UNIV,INST LIFE SCI,DIV MOLEC GENET,2432-3 AIKAWA,KURUME,FUKUOKA 830,JAPAN.		Okazaki, Kenji/H-4393-2012					ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BONNER TI, 1985, MOL CELL BIOL, V5, P1400, DOI 10.1128/MCB.5.6.1400; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAAR I, 1991, J CELL BIOL, V114, P329, DOI 10.1083/jcb.114.2.329; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FOLGER KR, 1982, MOL CELL BIOL, V2, P1372, DOI 10.1128/MCB.2.11.1372; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; FURUNO N, 1994, EMBO J, V13, P2399, DOI 10.1002/j.1460-2075.1994.tb06524.x; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GOTOH Y, 1994, ONCOGENE, V9, P1891; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KANKI JP, 1991, P NATL ACAD SCI USA, V88, P5794, DOI 10.1073/pnas.88.13.5794; KIZAKAKONDOH S, 1993, FEBS LETT, V336, P255, DOI 10.1016/0014-5793(93)80814-B; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KOST TA, 1983, NUCLEIC ACIDS RES, V11, P8287, DOI 10.1093/nar/11.23.8287; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NEBREDA AR, 1993, FEBS LETT, V333, P183, DOI 10.1016/0014-5793(93)80401-F; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NISHIZAWA M, 1992, EMBO J, V11, P2433, DOI 10.1002/j.1460-2075.1992.tb05308.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OKAZAKI K, 1991, JPN J CANCER RES, V82, P250, DOI 10.1111/j.1349-7006.1991.tb01837.x; OKAZAKI K, 1992, EMBO J, V11, P2447, DOI 10.1002/j.1460-2075.1992.tb05309.x; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; ROSSOMANDO AJ, 1991, J BIOL CHEM, V266, P20270; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; Sambrook J., 1989, MOL CLONING; SEGER R, 1992, J BIOL CHEM, V267, P25628; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; TSUCHIDA N, 1982, SCIENCE, V217, P937, DOI 10.1126/science.6287573; UETSUKI T, 1989, J BIOL CHEM, V264, P5791; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHENG CF, 1994, BIOCHEMISTRY-US, V33, P5595, DOI 10.1021/bi00184a031; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	74	67	67	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1149	1157						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700641				2022-12-17	WOS:A1995QN35300016
J	GOTOH, Y; MATSUDA, S; TAKENAKA, K; HATTORI, S; IWAMATSU, A; ISHIKAWA, M; KOSAKO, H; NISHIDA, E				GOTOH, Y; MATSUDA, S; TAKENAKA, K; HATTORI, S; IWAMATSU, A; ISHIKAWA, M; KOSAKO, H; NISHIDA, E			CHARACTERIZATION OF RECOMBINANT XENOPUS MAP KINASE KINASES MUTATED AT POTENTIAL PHOSPHORYLATION SITES	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; THREONINE TYROSINE KINASE; SIGNAL-TRANSDUCTION; SUBSTRATE RECOGNITION; NUCLEOTIDE-SEQUENCE; A431 CELLS; IDENTIFICATION; YEAST; GENE; CASCADE	Xenopus mitogen-activated protein kinase kinase (MAPKK) previously inactivated with protein phosphatase 2A can be reactivated by serine phosphorylation catalyzed by a partially purified MAPKK kinase (MAPKK-K), and is phosphorylated by MAPK on a threonine residue. The sequence analysis of a threonine-phosphorylated tryptic peptide of Xenopus MAPKK from mature oocytes suggested that Thr388 is phosphorylated in vivo. A mutant MAPKK that has Thr388 changed to Ala (T388A-MAPKK) was not phosphorylated by purified MAPK, indicating that Thr388 is phosphorylated by MAPK. We then produced and analysed MAPKKs mutated at potential serine phosphorylation sites (S218A-MAPKK and S222A-MAPKK). The wild-type MAPKK (WT-MAPKK), T388A-MAPKK and a kinase-deficient (K97S)-MAPKK were phosphorylated efficiently by MAPKK-Ks purified from Xenopus eggs, and WT-MAPKK and T388A-MAPKK became activated. In contrast, neither S218A-MAPKK nor S222A-MAPKK was phosphorylated and activated efficiently by the Xenopus MAPKK-Ks. Similarly, WT-MAPKK, but not S218A-MAPKK or S222A-MAPKK, was activated efficiently by an active Raf-1 immunoprecipitate. However, when the recombinant STE11, a putative MAPKK-K in S. cerevisiae, was used as a source of MAPKK-K, S218A-MAPKK as well as WT-MAPKK, but not S222A-MAPKK, was phosphorylated and activated. Furthermore, replacement of Ser222 with an acidic residue (S222E) elevated substantially the basal kinase activity of MAPKK, while replacement of Ser218 (S218E) did not. These results may suggest an essential role for Ser222 phosphorylation in activating Xenopus MAPKK.	KYOTO UNIV,INST VIRUS RES,DEPT MOLEC BIOL & GENET,SAKYO KU,KYOTO 60601,JAPAN; NATL CTR NEUROL & PSYCHIAT,NATL INST NEUROSCI,DIV BIOCHEM & CELLULAR BIOL,KODAIRA 187,TOKYO,JAPAN; KIRIN BREWERY CO LTD,CENT LABS KEY TECHNOL,KANAZAWA KU,YOKOHAMA,KANAGAWA,JAPAN	Kyoto University; National Center for Neurology & Psychiatry - Japan; Kirin Brewery Company Limited								Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; AHN NG, 1993, P NATL ACAD SCI USA, V90, P5143, DOI 10.1073/pnas.90.11.5143; AHN NG, 1991, J BIOL CHEM, V266, P4220; ASHWORTH A, 1992, ONCOGENE, V7, P2555; BOGUSLAWSKI G, 1987, P NATL ACAD SCI USA, V84, P5848, DOI 10.1073/pnas.84.16.5848; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEVIN DE, 1993, CURR OPIN CELL BIOL, V5, P245; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; NADINDAVIS SA, 1988, EMBO J, V7, P985, DOI 10.1002/j.1460-2075.1988.tb02905.x; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NEIMAN AM, 1994, IN PRESS P NATL ACAD; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OTSU M, 1993, FEBS LETT, V320, P246, DOI 10.1016/0014-5793(93)80596-M; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; SEGER R, 1992, J BIOL CHEM, V267, P25628; SEGER R, 1992, J BIOL CHEM, V267, P14373; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; SHIRAKABE K, 1992, J BIOL CHEM, V267, P16685; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SUTHERLAND C, 1993, EUR J BIOCHEM, V212, P581, DOI 10.1111/j.1432-1033.1993.tb17696.x; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TEAGUE MA, 1986, P NATL ACAD SCI USA, V83, P7371, DOI 10.1073/pnas.83.19.7371; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; WARBRICK E, 1991, EMBO J, V10, P4291, DOI 10.1002/j.1460-2075.1991.tb05007.x; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	56	67	67	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1891	1898						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208535				2022-12-17	WOS:A1994NR68500012
J	LEGROS, Y; LAFON, C; SOUSSI, T				LEGROS, Y; LAFON, C; SOUSSI, T			LINEAR ANTIGENIC SITES DEFINED BY THE B-CELL RESPONSE TO HUMAN P53 ARE LOCALIZED PREDOMINANTLY IN THE AMINO AND CARBOXY-TERMINI OF THE PROTEIN	ONCOGENE			English	Note							TUMOR SUPPRESSOR GENE; LARGE T-ANTIGEN; MONOCLONAL-ANTIBODIES; BREAST-CANCER; ESCHERICHIA-COLI; IMMUNE-RESPONSE; LUNG-CANCER; MUTATIONS; EXPRESSION; CONFORMATION	Using a set of overlapping peptides of the human p53 protein, we analysed the epitopes recognized by 18 monoclonal antibodies specific far human p53. We showed that most of these epitopes correspond to linear antigenic determinants which lie predominantly in the amino- or carboxy-terminus of the p53 protein. Using either truncated p53 or the set of human p53 peptides, we directly analysed the sera of animals immunized with human p53, These sera contained antibodies which also recognized the regions corresponding to the extremity of the p53 protein. These p53 regions were similar to those recognized by p53-specific antibodies present in sera of patients with cancer. Preferential recognition of these regions by antibodies specific for non conformational epitopes suggested that these regions are localized at the surface of the p53 protein as unfolded structures.	INST GENET MOLEC,INSERM,U301,F-75010 PARIS,FRANCE; ESTBA,F-75020 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)				soussi, thierry/0000-0001-8184-3293				BAKER SJ, 1990, CANCER RES, V50, P7717; BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARTEK J, 1993, J PATHOL, V169, P27, DOI 10.1002/path.1711690106; BENCHIMOL S, 1982, EMBO J, V1, P1055, DOI 10.1002/j.1460-2075.1982.tb01296.x; CATTORETTI G, 1988, INT J CANCER, V41, P178, DOI 10.1002/ijc.2910410204; CRAWFORD LV, 1982, INT J CANCER, V30, P403, DOI 10.1002/ijc.2910300404; DAVIDOFF AM, 1992, P NATL ACAD SCI USA, V89, P3439, DOI 10.1073/pnas.89.8.3439; DEFROMENTEL CC, 1987, INT J CANCER, V39, P185, DOI 10.1002/ijc.2910390211; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; GAMBLE J, 1988, VIROLOGY, V162, P452, DOI 10.1016/0042-6822(88)90486-2; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; GILLET D, 1992, PROTEIN ENG, V5, P273, DOI 10.1093/protein/5.3.273; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HAINAUT P, 1993, CANCER RES, V53, P1739; HALL PA, 1991, LANCET, V338, P513, DOI 10.1016/0140-6736(91)90586-E; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JONVEAUX P, 1991, ONCOGENE, V6, P2243; KIM JH, 1991, J NATL CANCER I, V83, P938, DOI 10.1093/jnci/83.13.938; LEGROS Y, 1993, B CANCER, V80, P102; LUBIN R, 1993, CANCER RES, V53, P5872; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; MAZARS R, 1991, ONCOGENE, V6, P1685; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MILLER CW, 1990, CANCER RES, V50, P7950; PROSSER J, 1990, ONCOGENE, V5, P1573; SCHLICHTHOLZ B, 1992, CANCER RES, V52, P6380; SOUSSI T, 1989, J VIROL, V63, P3894, DOI 10.1128/JVI.63.9.3894-3901.1989; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WINTER SF, 1992, CANCER RES, V52, P4168; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	39	67	69	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					2071	2076						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208553				2022-12-17	WOS:A1994NR68500033
J	KARN, T; HOLTRICH, U; BRAUNINGER, A; BOHME, B; WOLF, G; RUBSAMENWAIGMANN, H; STREBHARDT, K				KARN, T; HOLTRICH, U; BRAUNINGER, A; BOHME, B; WOLF, G; RUBSAMENWAIGMANN, H; STREBHARDT, K			STRUCTURE, EXPRESSION AND CHROMOSOMAL MAPPING OF TKT FROM MAN AND MOUSE - A NEW SUBCLASS OF RECEPTOR TYROSINE KINASES WITH A FACTOR VIII-LIKE DOMAIN	ONCOGENE			English	Note							FIBROBLAST GROWTH-FACTOR; HUMAN INSULIN-RECEPTOR; CDNA CLONING; PUTATIVE RECEPTOR; FAMILY; GENE; SEQUENCE; PROTEINS; ENCODES; DEFINE	Using a polymerase chain reaction-mediated approach we have characterized cDNAs from human and mouse origin representing a novel type of receptor protein tyrosine kinase (RTK). The deduced amino acid sequence (855 amino acids) of the Longest open reading frame has a unique extracellular region encompassing a factor VIII-like domain, not previously described for RTKs. The most closely related RTKs are members of the neurotrophin receptors (TRK), which showed 47-49% homology with the kinase domain of the new RTK. Therefore, the new gene has been called TKT (Tyrosine-Kinase related to TRK). TKT orthologs from man and mouse were 98% similar. In both species a major transcript of 10 kb was found to be expressed at high levels in heart and lung. Low levels of this mRNA-species were detected in human brain, placenta, liver, skeletal muscle, kidney and in mouse brain and testis. Analysing human/mouse somatic cell hybrids we demonstrated that TKT segregates with human chromosome 1.	CHEMOTHERAPEUT FORSCHUNGSINST,D-60596 FRANKFURT,GERMANY				Strebhardt, Klaus/E-8765-2011; karn, t/C-7452-2013; Karn, Thomas/AAE-7723-2019	karn, t/0000-0002-3264-6573; Karn, Thomas/0000-0002-3264-6573; Strebhardt, Klaus/0000-0003-2173-9763				BOHME B, 1993, IN PRESS ONCOGENE; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; DUMONT DJ, 1993, ONCOGENE, V8, P1293; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; GITSCHIER J, 1984, NATURE, V312, P326, DOI 10.1038/312326a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HOLTRICH U, 1991, P NATL ACAD SCI USA, V88, P10411, DOI 10.1073/pnas.88.23.10411; IWAMOTO T, 1993, ONCOGENE, V8, P1087; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MORRIS CM, 1991, ONCOGENE, V6, P1093; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; RESCIGNO J, 1991, ONCOGENE, V6, P1909; SHIER P, 1989, J BIOL CHEM, V264, P14605; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WILLECKE K, 1990, EUR J CELL BIOL, V53, P275; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZIEGLER SF, 1993, ONCOGENE, V8, P663	36	67	76	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3433	3440						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247548				2022-12-17	WOS:A1993MG78200030
J	PRICE, BD; CALDERWOOD, SK				PRICE, BD; CALDERWOOD, SK			INCREASED SEQUENCE-SPECIFIC P53 DNA-BINDING ACTIVITY AFTER DNA-DAMAGE IS ATTENUATED BY PHORBOL ESTERS	ONCOGENE			English	Article							PROTEIN KINASE-C; WILD-TYPE P53; TUMOR SUPPRESSOR PROTEIN; CELL-CYCLE; GROWTH-REGULATION; MUTANT P53; MONOCLONAL-ANTIBODY; IONIZING-RADIATION; GENE-PRODUCT; 3T3 CELLS	Damage to cellular DNA greatly increases the levels of the tumor-suppressor gene p53 and induces cell cycle arrest in G1. A critical function of wild-type p53 is its ability to bind to specific DNA sequences. The effect of DNA damage on the sequence-specific DNA-binding properties of cellular p53 was investigated using DNA gel mobility-shift assays with nuclear extracts from NIH-3T3 cells. DNA damage (initiated by radiation) induced a rapid, cycloheximide-sensitive increase in the levels of nuclear p53-DNA binding activity and an increase in the half-life of the p53 protein. Increased p53-DNA binding activity could be detected at low (0.2 Gy), non-lethal doses of radiation. The tumor promoter 12-O-tetradecanoyl phorbol 13-acetate (TPA) attenuated the DNA damage-induced increase in p53-DNA binding activity by decreasing the half-life of the p53 protein. The tumor promoter properties of TPA may therefore be mediated by interfering with the cellular p53 response to DNA damage. The increased levels of p53 bound to specific DNA sequences following DNA damage may induce cell cycle arrest. p53-mediated growth arrest could occur by inhibition of DNA replication and/or alterations in transcription of cell cycle genes.			PRICE, BD (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,STRESS PROT GRP RM JF209,44 BINNEY ST,BOSTON,MA 02115, USA.				NATIONAL CANCER INSTITUTE [R29CA044940] Funding Source: NIH RePORTER; NCI NIH HHS [R29CA44940] Funding Source: Medline; PHS HHS [R01 47407] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BRUCE JL, 1993, CANCER RES, V53, P1; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FILHOL O, 1992, J BIOL CHEM, V267, P20577; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JFOORD OS, 1993, MOL CELL BIOL, V13, P1378; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MATLZMAN W, 1984, MOL CELL BIOL, V4, P1689; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MORA PT, 1982, MOL CELL BIOL, V2, P763, DOI 10.1128/MCB.2.7.763; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; PRICE BD, 1991, MOL CELL BIOL, V11, P3365, DOI 10.1128/MCB.11.6.3365; PRICE BD, 1989, J BIOL CHEM, V264, P16638; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHOHAT O, 1987, ONCOGENE, V1, P277; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; STEINMEYER K, 1988, ONCOGENE, V3, P501; STENGER JE, 1992, MOL CARCINOGEN, V5, P102, DOI 10.1002/mc.2940050204; TOLMACH LJ, 1977, RADIAT RES, V71, P653, DOI 10.2307/3574633; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; WEICHSELBAUM RR, 1991, J NATL CANCER I, V83, P480, DOI 10.1093/jnci/83.7.480; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	54	67	68	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3055	3062						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414506				2022-12-17	WOS:A1993MC09300021
J	BOHME, B; HOLTRICH, U; WOLF, G; LUZIUS, H; GRZESCHIK, KH; STREBHARDT, K; RUBSAMENWAIGMANN, H				BOHME, B; HOLTRICH, U; WOLF, G; LUZIUS, H; GRZESCHIK, KH; STREBHARDT, K; RUBSAMENWAIGMANN, H			PCR MEDIATED DETECTION OF A NEW HUMAN RECEPTOR-TYROSINE-KINASE, HEK-2	ONCOGENE			English	Note								We have previously amplified cDNA subfragments of protein-tyrosine-kinases (PTKs) by using the polymerase chain reaction (PCR) and specific sets of oligonucleotide primers derived from nucleotide sequences of their kinase domain. In this study we have used a more directed approach to identify new members of the EPH/elk-family by PCR of human embryonic cDNA: we utilized oligonucleotide primers specifically designed to a highly conserved N-terminal motif and the kinase region of EPH/elk-PTKs in RNA-PCRs. The 5' and 3' elongation of the primary PCR product was achieved by the RACE (rapid amplification of cDNA ends)-technique. Sequence analysis of 3.8 kb of overlapping PCR products allowed to identify a novel receptor-PTK, HEK 2 (human embryo kinase 2), as an additional member of this family, without the need to screen a cDNA library. This approach should be useful for the rapid isolation of other PTK-genes as well. Analysis of genomic DNA placed HEK 2 on chromosome 3. Northern blot analysis demonstrated the expression of a 4.6 kb HEK 2-mRNA in lung, brain, pancreas, liver, placenta, kidney, skeletal muscle, heart and several human cells. In a protein kinase assay with HEK 2-specific immunoprecipitates from the human epidermoid carcinoma cell line A431, a protein of 130 kDa was found phosphorylated.	CHEMOTHERAPEUT FORSCHUNGSINST, GEORG SPEYER HAUS, PAUL EHRLICH STR 42-44, W-6000 FRANKFURT 70, GERMANY	Octapharma			Strebhardt, Klaus/E-8765-2011	Strebhardt, Klaus/0000-0003-2173-9763				BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HOLTRICH U, 1991, P NATL ACAD SCI USA, V88, P10411, DOI 10.1073/pnas.88.23.10411; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; MARU Y, 1988, MOL CELL BIOL, V8, P3770, DOI 10.1128/MCB.8.9.3770; MATSUSHIME H, 1986, MOL CELL BIOL, V6, P3000, DOI 10.1128/MCB.6.8.3000; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; SHERR CJ, 1990, BLOOD, V75, P1; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; SKORSTENGAARD K, 1986, EUR J BIOCHEM, V161, P441, DOI 10.1111/j.1432-1033.1986.tb10464.x; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WIERENGA RK, 1983, NATURE, V302, P842, DOI 10.1038/302842a0; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WILLECKE K, 1990, EUR J CELL BIOL, V53, P275	26	67	77	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1993	8	10					2857	2862						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8397371				2022-12-17	WOS:A1993LX34300030
J	TZENG, YJ; GUHL, E; GRAESSMANN, M; GRAESSMANN, A				TZENG, YJ; GUHL, E; GRAESSMANN, M; GRAESSMANN, A			BREAST-CANCER FORMATION IN TRANSGENIC ANIMALS INDUCED BY THE WHEY ACIDIC PROTEIN SV40 T-ANTIGEN (WAP-SV-T) HYBRID GENE	ONCOGENE			English	Article							HA-RAS; MICE; EXPRESSION; ONCOGENES; CELLS; TRANSCRIPTION; INFORMATION; MECHANISMS; CARCINOMA; RECEPTORS	After injection of the whey acidic protein (WAP)-SV-T hybrid gene into fertilized mouse eggs, eight independent transgenic mouse lines were obtained. Females from three lines developed mammary carcinomas with high frequency, coinciding mostly with lactation. In contrast to the endogenous WAP gene, expression of the hybrid gene continued after lactation. The tumor cells had a very invasive growth characteristic. Tumor regression in vivo was not observed. However, after transfer into tissue culture 25% of the cells ceased to express the hybrid gene and acquired the growth characteristic of normal cells. It was possible to retransform these cells by injection of wild-type SV40 DNA, but not after transfer of the hybrid WAP-SV-T gene. Inactivation of the endogenous WAP and of the WAP-SV-T transgene did not correlate with DNA methylation.	FREE UNIV BERLIN,INST MOLEK BIOL & BIOCHEM,ARNIMALLEE 22,W-1000 BERLIN 33,GERMANY	Free University of Berlin								ANDRES AC, 1987, P NATL ACAD SCI USA, V84, P1299, DOI 10.1073/pnas.84.5.1299; ANDRES AC, 1988, GENE DEV, V2, P1486, DOI 10.1101/gad.2.11.1486; BERGER MS, 1988, CANCER RES, V48, P1238; BURDON T, 1991, J BIOL CHEM, V266, P6909; BUSCHHAUSEN G, 1987, P NATL ACAD SCI USA, V84, P1177, DOI 10.1073/pnas.84.5.1177; CAMPBELL SM, 1984, NUCLEIC ACIDS RES, V12, P8685, DOI 10.1093/nar/12.22.8685; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GRAESSMANN A, 1973, DEV BIOL, V35, P180, DOI 10.1016/0012-1606(73)90016-X; GRAESSMANN A, 1993, DNA METHYLATION MOL, P404; GRAESSMANN M, 1976, P NATL ACAD SCI USA, V73, P366, DOI 10.1073/pnas.73.2.366; GRAESSMANN M, 1983, METHOD ENZYMOL, V101, P482; GRAESSMANN M, 1984, J MOL BIOL, V180, P111, DOI 10.1016/0022-2836(84)90433-9; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HENDERSON BE, 1988, CANCER RES, V48, P246; HOGAN B, 1986, MANPULATING MOUSE EM; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; MAHON KA, 1987, SCIENCE, V235, P1622, DOI 10.1126/science.3029873; MESSING A, 1985, NATURE, V316, P461, DOI 10.1038/316461a0; PARKIN DM, 1984, B WORLD HEALTH ORGAN, V62, P163, DOI 10.1139/b84-027; PITTIUS CW, 1988, MOL ENDOCRINOL, V2, P1027, DOI 10.1210/mend-2-11-1027; Sambrook J., 1989, MOL CLONING LAB MANU; SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x; SCHWABE JWR, 1991, TRENDS BIOCHEM SCI, V16, P291, DOI 10.1016/0968-0004(91)90121-B; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TOOZE J, 1981, MOL BIOL TUMOR VIR 2; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049	30	67	70	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1965	1971						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8390039				2022-12-17	WOS:A1993LG68200029
J	BEIMLING, P; MOELLING, K				BEIMLING, P; MOELLING, K			DIRECT INTERACTION OF CREB PROTEIN WITH 21 BP TAX-RESPONSE ELEMENTS OF HTLV-I LTR	ONCOGENE			English	Note							T-CELL LEUKEMIA; VIRUS TYPE-I; LONG TERMINAL REPEAT; TRANS-ACTIVATOR PROTEIN; DNA-BINDING PROTEINS; NUCLEAR FACTOR CREB; GENE-EXPRESSION; CYCLIC-AMP; TRANSCRIPTIONAL ACTIVATION; KINASE-A	The three 21-bp repeats (Tax-responsive elements) of the long terminal repeat (LTR) of the human T-cell leukemia virus (HTLV-I) mediates the response of the Tax protein. Ail three Tax-responsive elements (TREs) contain a TGACG motif, reminiscent of the CREB/ATF-binding site TGACGTCA. DNA-affinity chromatography with the 5'-TRE resulted in a previous study in proteins of about 32, 36 to 42, 50 and 110 kDa. Here we demonstrate that the 42 kDa protein is the cAMP-response element-binding (CREB) protein. This is shown by phosphorylation of the proteins eluted from the DNA-affinity column with protein kinase A (PKA) in vitro and subsequent indirect immunoprecipitation with a CREB-specific antiserum raised against an internal CREB-specific peptide. This method allows detection of phosphorylated proteins by autoradiography with high sensitivity and is superior to metabolic labeling. One of the phosphorylated proteins co-migrates with immuno-affinity-purified CREB protein-also phosphorylated in vitro-and competes with the peptide antigen, which proves the specificity of the reaction. The purified CREB protein leads to specific DNA-protein complexes in DNA mobility-shift analyses with all three TREs. Comparison of these TRE-CREB complexes with those formed by nuclear extracts from the HTLV-I-transformed T-cell line C81-66-45 indicates that additional cellular factors contribute to the complexes, especially to the middle TRE. This is also shown by using CREB-depleted instead of complete nuclear extracts for DNA mobility-shift assays. Antibodies against CREB but not Tax affect the mobility of the DNA-protein complex.	MAX PLANCK INST MOLEC GENET,SCHUSTER ABT,IHNESTR 73,W-1000 BERLIN 33,GERMANY	Max Planck Society								ALTMAN R, 1988, J VIROL, V62, P1339, DOI 10.1128/JVI.62.4.1339-1346.1988; BEIMLING P, 1990, ONCOGENE, V5, P361; BEIMLING P, 1989, ONCOGENE, V4, P511; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; BOHNLEIN E, 1989, J VIROL, V63, P1578; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; CHEN ISY, 1985, SCIENCE, V229, P54, DOI 10.1126/science.2990037; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJISAWA J, 1989, J VIROL, V63, P3234, DOI 10.1128/JVI.63.8.3234-3239.1989; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; FUJISAWA J, 1986, EMBO J, V5, P713, DOI 10.1002/j.1460-2075.1986.tb04272.x; GIAM CZ, 1989, J BIOL CHEM, V264, P15236; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; HAI T, 1988, GENE DEV, V2, P1216, DOI 10.1101/gad.2.10.1216; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; HOYOS B, 1989, SCIENCE, V244, P457, DOI 10.1126/science.2497518; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; JEANG KT, 1988, J VIROL, V62, P4499, DOI 10.1128/JVI.62.12.4499-4509.1988; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; KADISON P, 1990, J VIROL, V64, P2141, DOI 10.1128/JVI.64.5.2141-2148.1990; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MARRIOTT SJ, 1989, MOL CELL BIOL, V9, P4152, DOI 10.1128/MCB.9.10.4152; MARRIOTT SJ, 1990, MOL CELL BIOL, V10, P4192, DOI 10.1128/MCB.10.8.4192; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MONTAGNE J, 1990, EMBO J, V9, P957, DOI 10.1002/j.1460-2075.1990.tb08194.x; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; NYBORG JK, 1990, J BIOL CHEM, V265, P8230; NYBORG JK, 1988, P NATL ACAD SCI USA, V85, P1457, DOI 10.1073/pnas.85.5.1457; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; POIESZ BJ, 1981, NATURE, V294, P268, DOI 10.1038/294268a0; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POTEAT HT, 1989, J VIROL, V63, P1604, DOI 10.1128/JVI.63.4.1604-1611.1989; POTEAT HT, 1990, J VIROL, V64, P1264, DOI 10.1128/JVI.64.3.1264-1270.1990; ROSEN CA, 1987, P NATL ACAD SCI USA, V84, P4919, DOI 10.1073/pnas.84.14.4919; SALAHUDDIN SZ, 1983, VIROLOGY, V129, P51, DOI 10.1016/0042-6822(83)90395-1; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; TAN TH, 1989, MOL CELL BIOL, V9, P1733, DOI 10.1128/MCB.9.4.1733; TAN TH, 1989, J VIROL, V63, P3761, DOI 10.1128/JVI.63.9.3761-3768.1989; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x	50	67	69	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1992	7	2					257	262						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1532242				2022-12-17	WOS:A1992HG98200008
J	LEROY, X; ESCOT, C; BROUILLET, JP; THEILLET, C; MAUDELONDE, T; SIMONYLAFONTAINE, J; PUJOL, H; ROCHEFORT, H				LEROY, X; ESCOT, C; BROUILLET, JP; THEILLET, C; MAUDELONDE, T; SIMONYLAFONTAINE, J; PUJOL, H; ROCHEFORT, H			DECREASE OF C-ERBB-2 AND C-MYC RNA LEVELS IN TAMOXIFEN-TREATED BREAST-CANCER	ONCOGENE			English	Article							FATTY-ACID SYNTHETASE; ONCOGENE EXPRESSION; ESTROGEN-RECEPTOR; PROTO-ONCOGENE; GENE AMPLIFICATION; MAMMARY-CARCINOMA; HUMAN-TUMORS; CELLS; OVEREXPRESSION; ONCOPROTEIN	The c-myc, c-erbB-2, hst and int-2 oncogenes are frequently amplified and/or overexpressed in human breast carcinomas. We studied the effect of tamoxifen on RNA levels of these oncogenes in 19 breast cancer patients treated for 3 weeks prior to surgery as compared with 22 control patients. RNA levels were measured by in situ hybridization coupled with computer-aided quantification. c-myc and c-erbB-2 expression was high in the control population (mean values: 23.4 and 29.1 grains/cell respectively) and significantly decreased in the tamoxifen-treated population (mean values: 14.6 and 7.4 grains/cell respectively) (P = 0.018, P = 0.003 respectively); hst and int-2 RNA levels were low (2-6 grains/cell) and not significantly altered by the treatment. There was a correlation between gene amplification and expression for c-erbB-2 (P = 0.0005) and hst (P = 0.02) in the control population. Elevated c-erbB-2 RNA level was correlated with the absence of estrogen (P = 0.02) or progesterone (P = 0.05) receptors. In the ER+ population, the tamoxifen-treated group had significantly lower c-myc expression levels than the control group (P = 0.04) which is in agreement with the estrogen induction of c-myc in ER+ T47D cell line and its inhibition by antiestrogens. Surprisingly, c-erbB-2 expression in the tamoxifen-treated group was significantly diminished in the ER- (P = 0.02) and PR- (P = 0.01) populations. This effect was not observed in the ER- BT474 cell line. These results suggest that in vivo tamoxifen decreases c-myc and c-erbB-2 RNA levels in breast cancer cells via two different mechanisms. To our knowledge this is the first evidence of in vivo down regulation of a gene by tamoxifen in ER- breast cancer cells.	INSERM,U148,UNITE HORMONES & CANC,60 RUE NAVACELLES,F-34090 MONTPELLIER,FRANCE; CTR PAUL LAMARQUE,BIOCHIM LAB,CNRS,UA 1191,F-34033 MONTPELLIER,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS)			Theillet, Charles/O-7634-2018	Theillet, Charles/0000-0001-5555-2759				ADNANE J, 1989, ONCOGENE, V4, P1389; BARDON S, 1984, MOL CELL ENDOCRINOL, V35, P89, DOI 10.1016/0303-7207(84)90004-2; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERGER MS, 1988, CANCER RES, V48, P1238; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; CHALBOS D, 1990, JNCI-J NATL CANCER I, V82, P602, DOI 10.1093/jnci/82.7.602; DATI C, 1990, ONCOGENE, V5, P1001; DUBIK D, 1988, J BIOL CHEM, V263, P12705; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; ESCOT C, 1990, J CLIN ENDOCR METAB, V70, P1319, DOI 10.1210/jcem-70-5-1319; ESCOT C, 1991, IN PRESS ANAL CELL P; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; FAYE JC, 1980, BIOCHEM BIOPH RES CO, V93, P1225, DOI 10.1016/0006-291X(80)90620-8; GUERIN M, 1988, ONCOGENE RES, V3, P21; JORDAN VC, 1986, ESTROEN ANTIESTROGEN; Katzenellenbogen B S, 1979, Recent Prog Horm Res, V35, P259; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; LACROIX H, 1989, ONCOGENE, V4, P145; LISCIA DS, 1989, ONCOGENE, V4, P1219; MARIANICOSTANTINI R, 1988, CANCER RES, V48, P199; MAUDELONDE T, 1989, CANCER, V63, P1265, DOI 10.1002/1097-0142(19890401)63:7<1265::AID-CNCR2820630706>3.0.CO;2-Z; MAUDELONDE T, 1988, CANCER RES, V48, P462; OBRIAN CA, 1986, J NATL CANCER I, V76, P1243; PIKE MC, 1981, BANBURY REPORT, V8; READ LD, 1990, CANCER RES, V50, P3947; ROCHEFORT H, 1991, IN PRESS AM J ONCOL; RUSHDI AA, 1983, SCIENCE, V22, P390; SANTOS GF, 1988, J BIOL CHEM, V263, P9565; SUTHERLAND RL, 1980, NATURE, V288, P273, DOI 10.1038/288273a0; TANDON AK, 1989, J CLIN ONCOL, V7, P1120, DOI 10.1200/JCO.1989.7.8.1120; THEILLET C, 1989, ONCOGENE, V4, P915; VANDEVIJVER MJ, 1988, ONCOGENE, V2, P175; VENTER DJ, 1987, LANCET, V2, P69, DOI 10.1016/S0140-6736(87)92736-X; VIGNON F, 1987, BIOCHEM BIOPH RES CO, V146, P1502, DOI 10.1016/0006-291X(87)90819-9; WALKER RA, 1989, J PATHOL, V158, P977; WRIGHT C, 1989, CANCER RES, V49, P2087; ZEILLINGER R, 1989, ONCOGENE, V4, P109; 1981, HISTOLOGICAL CLASSIF	39	67	67	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1991	6	3					431	437						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	1707153				2022-12-17	WOS:A1991FT34400012
J	Goto, H; Shimono, Y; Funakoshi, Y; Imamura, Y; Toyoda, M; Kiyota, N; Kono, S; Takao, S; Mukohara, T; Minami, H				Goto, Hideaki; Shimono, Yohei; Funakoshi, Yohei; Imamura, Yoshinori; Toyoda, Masanori; Kiyota, Naomi; Kono, Seishi; Takao, Shintaro; Mukohara, Toru; Minami, Hironobu			Adipose-derived stem cells enhance human breast cancer growth and cancer stem cell-like properties through adipsin	ONCOGENE			English	Article							COMPLEMENT FACTOR-D; MAMMARY-GLAND; IN-VIVO; OBESITY; TISSUE; PURIFICATION; ADIPONECTIN; OVERWEIGHT; RESISTANCE; SYSTEM	Tumor microenvironment plays a key role for tumor development and progression. Although adipose tissue is a predominant component of stroma in mammary tissues and secretes various cytokines, chemokines and growth factors, roles of adipocytes in breast cancers remain to be elucidated. In this study, we found that adipsin, an adipokine secreted from mammary adipose tissues, enhanced proliferation and cancer stem cell (CSC)-like properties of human breast cancer patient-derived xenograft (PDX) cells. Adipsin was predominantly expressed in both adipose tissues of the surgical specimens of breast cancer patients and adipose-derived stem cells (ADSCs) isolated from them, and its expression level was significantly higher in obese patients. ADSCs significantly enhanced the sphere-forming ability of breast cancer PDX cells derived from both estrogen receptor-positive and -negative breast cancer PDX cells. Suppression of adipsin-mediated signaling by a specific inhibitor or adipsin knockdown in ADSCs significantly decreased the sphere-forming ability and the expression of CSC markers in co-cultured breast cancer PDX cells. Growth of breast cancer PDX tumors was significantly enhanced by co-transplantation with ADSCs in vivo, and it was weakened when co-transplanted with the adipsin knocked-down ADSCs. These results suggest that adipsin is an important adipokine secreted from mammary adipose tissue that functions as a component of tumor microenvironment and a CSC niche in breast cancers.	[Goto, Hideaki; Shimono, Yohei; Funakoshi, Yohei; Imamura, Yoshinori; Toyoda, Masanori; Kiyota, Naomi; Mukohara, Toru; Minami, Hironobu] Kobe Univ, Div Med Oncol Hematol, Grad Sch Med, Kobe, Hyogo 6500017, Japan; [Shimono, Yohei] Kobe Univ, Div Mol & Cellular Biol, Grad Sch Med, Kobe, Hyogo 6500017, Japan; [Kiyota, Naomi; Mukohara, Toru; Minami, Hironobu] Kobe Univ Hosp, Ctr Canc, Kobe, Hyogo 6500017, Japan; [Kono, Seishi; Takao, Shintaro] Kobe Univ, Div Breast & Endocrine Surg, Grad Sch Med, Kobe, Hyogo 6500017, Japan; [Mukohara, Toru] Natl Canc Ctr Hosp East, Dept Breast & Med Oncol, Kashiwa, Chiba 2778577, Japan; [Shimono, Yohei] Fujita Hlth Univ, Dept Biochem, Toyoake, Aichi 4701192, Japan	Kobe University; Kobe University; Kobe University; Kobe University; National Cancer Center - Japan; Fujita Health University	Shimono, Y (corresponding author), Kobe Univ, Div Med Oncol Hematol, Grad Sch Med, Kobe, Hyogo 6500017, Japan.; Shimono, Y (corresponding author), Kobe Univ, Div Mol & Cellular Biol, Grad Sch Med, Kobe, Hyogo 6500017, Japan.; Shimono, Y (corresponding author), Fujita Hlth Univ, Dept Biochem, Toyoake, Aichi 4701192, Japan.	yshimono@med.kobe-u.ac.jp	Kiyota, Naomi/K-3226-2016; Imamura, Yoshinori/ABD-4175-2021	Kiyota, Naomi/0000-0001-8021-6116; Minami, Hironobu/0000-0001-8630-9145; Imamura, Yoshinori/0000-0002-5202-531X	Japan Society for the Promotion of Science (JSPS KAKENHI) [15K14381, 18K07231]; Japan-Belgium Research Cooperative Program from the Japan Society for the Promotion of Science; Japan Foundation for Applied Enzymology; Itoh-Chubei Foundation; Cancer Research Institute, Kanazawa University; Princess Takamatsu Cancer Research Fund	Japan Society for the Promotion of Science (JSPS KAKENHI)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Japan-Belgium Research Cooperative Program from the Japan Society for the Promotion of Science; Japan Foundation for Applied Enzymology; Itoh-Chubei Foundation; Cancer Research Institute, Kanazawa University; Princess Takamatsu Cancer Research Fund	This work was supported by: (1) grants-in-aid from the Japan Society for the Promotion of Science (JSPS KAKENHI) 15K14381 and 18K07231 (to YS); (2) Japan-Belgium Research Cooperative Program from the Japan Society for the Promotion of Science (to YS); (3) a grant from the Japan Foundation for Applied Enzymology (to YS); (4) a grant from the Itoh-Chubei Foundation (to YS); (5) an extramural collaborative research grant of Cancer Research Institute, Kanazawa University (to YS); (6) a grant from the Princess Takamatsu Cancer Research Fund (to YS). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Afshar-Kharghan V, 2017, J CLIN INVEST, V127, P780, DOI 10.1172/JCI90962; Agarwal A, 2015, CLIN OPHTHALMOL, V9, P1001, DOI [10.2147/OPTH.S59725, 10.2147/OPTH.S74959]; Ando S, 2012, NAT REV ENDOCRINOL, V8, P263, DOI 10.1038/nrendo.2011.184; Barba C, 2004, LANCET, V363, P157, DOI 10.1016/S0140-6736(03)15268-3; Booth A, 2016, HORM MOL BIOL CLIN I, V26, P25, DOI 10.1515/hmbci-2015-0073; Booth A, 2015, HORM MOL BIOL CLIN I, V21, P57, DOI 10.1515/hmbci-2014-0037; Brown JD, 2007, CIRCULATION, V115, P518, DOI 10.1161/CIRCULATIONAHA.104.475673; Bunnell BA, 2008, METHODS, V45, P115, DOI 10.1016/j.ymeth.2008.03.006; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; Carmona-Fontaine C, 2011, DEV CELL, V21, P1026, DOI 10.1016/j.devcel.2011.10.012; Chedraui P, 2014, MATURITAS, V79, P86, DOI 10.1016/j.maturitas.2014.06.008; Cheng K.-H., 2011, GENOMIC MED BIOMARKE, V3, P53, DOI [10.1016/j.gmbhs.2011.08.003, DOI 10.1016/J.GMBHS.2011.08.003]; Cho MS, 2014, CELL REP, V6, P1085, DOI 10.1016/j.celrep.2014.02.014; Choi J, 2018, PROG LIPID RES, V69, P11, DOI 10.1016/j.plipres.2017.11.002; COOK KS, 1987, SCIENCE, V237, P402, DOI 10.1126/science.3299705; Couldrey C, 2002, DEV DYNAM, V223, P459, DOI 10.1002/dvdy.10065; Divella R, 2016, J CANCER, V7, P2346, DOI 10.7150/jca.16884; Edmondson R, 2014, ASSAY DRUG DEV TECHN, V12, P207, DOI 10.1089/adt.2014.573; Exley MA, 2014, J ENDOCRINOL, V223, pR41, DOI 10.1530/JOE-13-0516; Galic S, 2010, MOL CELL ENDOCRINOL, V316, P129, DOI 10.1016/j.mce.2009.08.018; Goodwin PJ, 2016, J CLIN ONCOL, V34, P4197, DOI 10.1200/JCO.2016.70.5327; Goodwin PJ, 2015, ANNU REV MED, V66, P281, DOI 10.1146/annurev-med-051613-012328; Hoy AJ, 2017, TRENDS MOL MED, V23, P381, DOI 10.1016/j.molmed.2017.02.009; Imamura Y, 2015, ONCOL REP, V33, P1837, DOI 10.3892/or.2015.3767; Isobe T, 2014, ELIFE, V3, DOI 10.7554/eLife.01977; Jiralerspong S, 2016, J CLIN ONCOL, V34, P4203, DOI 10.1200/JCO.2016.68.4480; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Lo JC, 2014, CELL, V158, P41, DOI 10.1016/j.cell.2014.06.005; Mantzoros C, 2004, J CLIN ENDOCR METAB, V89, P1102, DOI 10.1210/jc.2003-031804; Duong MN, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0569-0; Nabizadeh JA, 2016, J IMMUNOL, V196, P4783, DOI 10.4049/jimmunol.1600210; Neuhouser ML, 2015, JAMA ONCOL, V1, P611, DOI 10.1001/jamaoncol.2015.1546; Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492; Park J, 2011, ENDOCR REV, V32, P550, DOI 10.1210/er.2010-0030; Pattrick M, 2009, MOL IMMUNOL, V46, P755, DOI 10.1016/j.molimm.2008.09.013; Pierobon M, 2013, BREAST CANCER RES TR, V137, P307, DOI 10.1007/s10549-012-2339-3; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Ratajczak MZ, 2006, EXP HEMATOL, V34, P986, DOI 10.1016/j.exphem.2006.03.015; Renehan AG, 2008, LANCET, V371, P569, DOI 10.1016/S0140-6736(08)60269-X; Rutkowski MJ, 2010, MOL CANCER RES, V8, P1453, DOI 10.1158/1541-7786.MCR-10-0225; Schweizer R, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/120949; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Song NJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162228; Sprong T, 2006, BLOOD, V107, P4865, DOI 10.1182/blood-2005-07-2820; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Tiscornia G, 2006, NAT PROTOC, V1, P241, DOI 10.1038/nprot.2006.37; Wang XW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072962; WHITE RT, 1992, J BIOL CHEM, V267, P9210; Wysoczynski M, 2009, LEUKEMIA, V23, P1455, DOI 10.1038/leu.2009.73; Zimmerlin L, 2011, TISSUE ENG PT A, V17, P93, DOI [10.1089/ten.tea.2010.0248, 10.1089/ten.TEA.2010.0248]	51	66	68	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2019	38	6					767	779		10.1038/s41388-018-0477-8	http://dx.doi.org/10.1038/s41388-018-0477-8			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK5LC	30177835				2022-12-17	WOS:000458006300001
J	Kramer, N; Schmollerl, J; Unger, C; Nivarthi, H; Rudisch, A; Unterleuthner, D; Scherzer, M; Riedl, A; Artaker, M; Crncec, I; Lenhardt, D; Schwarz, T; Prieler, B; Han, X; Hengstschalger, M; Schuler, J; Eferl, R; Moriggl, R; Sommergruber, W; Dolznig, H				Kramer, N.; Schmoellerl, J.; Unger, C.; Nivarthi, H.; Rudisch, A.; Unterleuthner, D.; Scherzer, M.; Riedl, A.; Artaker, M.; Crncec, I.; Lenhardt, D.; Schwarz, T.; Prieler, B.; Han, X.; Hengstschaelger, M.; Schueler, J.; Eferl, R.; Moriggl, R.; Sommergruber, W.; Dolznig, H.			Autocrine WNT2 signaling in fibroblasts promotes colorectal cancer progression	ONCOGENE			English	Article							GENE-EXPRESSION; UP-REGULATION; BETA-CATENIN; ACTIVATION PROTEIN; TUMOR PROGRESSION; COLON-CANCER; STEM-CELLS; IN-VITRO; CARCINOMA; ESOPHAGEAL	The canonical WNT signaling pathway is crucial for intestinal stem cell renewal and aberrant WNT signaling is an early event in colorectal cancer (CRC) development. Here, we show for the first time that WNT2 is one of the most significantly induced genes in CRC stroma as compared to normal stroma. The impact of stromal WNT2 on carcinoma formation or progression was not addressed so far. Canonical WNT/beta-catenin signaling was assessed using a 7TGP-reporter construct. Furthermore, effects of WNT2 on fibroblast migration and invasion were determined using siRNA-mediated gene silencing. Tumor cell invasion was studied using organotypic raft cultures and in vivo significance was assessed via a xenograft mouse model. We identified cancer-associated fibroblasts (CAFs) as the main source of WNT2. CAF-derived WNT2 activated canonical signaling in adenomatous polyposis coli/beta-catenin wild-type colon cancer cells in a paracrine fashion, whereas no hyperactivation was detectable in cell lines harboring mutations in the adenomatous polyposis coli/beta-catenin pathway. Furthermore, WNT2 activated autocrine canonical WNT signaling in primary fibroblasts, which was associated with a pro-migratory and pro-invasive phenotype. We identified FZD8 as the putative WNT2 receptor in CAFs. Three-dimensional organotypic co-culture assays revealed that WNT2-mediated fibroblast motility and extracellular matrix remodeling enhanced cancer cell invasion of cell lines even harboring mutations in the adenomatous polyposis coli/beta-catenin pathway. Thus, suggesting a tumor-promoting influence on a broad range of CRC. In line, WNT2 also promotes tumor growth, invasion and metastasis in vivo. Moreover, high WNT2 expression is associated with poor prognosis in human CRC. The identification of the pro-malignant function of stromal derived WNT2 in CRC classifies WNT2 and its receptor as promising stromal targets to confine cancer progression in combination with conventional or targeted therapies.	[Kramer, N.; Schmoellerl, J.; Unger, C.; Unterleuthner, D.; Scherzer, M.; Riedl, A.; Schwarz, T.; Prieler, B.; Hengstschaelger, M.; Dolznig, H.] Med Univ Vienna, Inst Med Genet, Wahringer Str 10, A-1090 Vienna, Austria; [Schmoellerl, J.; Nivarthi, H.; Moriggl, R.] Ludwig Boltzmann Inst Canc Res, Vienna, Austria; [Rudisch, A.; Sommergruber, W.] Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria; [Artaker, M.] Med Univ Vienna, Max F Perutz Labs, Vienna, Austria; [Crncec, I.; Eferl, R.] Med Univ Vienna, Inst Canc Res, Vienna, Austria; [Lenhardt, D.; Schueler, J.] Oncotest GmbH, Freiburg, Germany; [Han, X.] Cincinnati Childrens Hosp Med Ctr, Div Gastroenterol Hepatol & Nutr, Cincinnati, OH 45229 USA; [Moriggl, R.] Univ Vet Med Vienna, Inst Anim Breeding & Genet, Vienna, Austria; [Nivarthi, H.] Austrian Acad Sci, Res Ctr Mol Med, CeMM, Lazarettgasse 14, A-1090 Vienna, Austria; [Scherzer, M.] Karolinska Inst, Solnavagen 1, S-17177 Solna, Sweden	Medical University of Vienna; Ludwig Boltzmann Institute; Boehringer Ingelheim; Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL); Medical University of Vienna; Oncotest GmbH; Cincinnati Children's Hospital Medical Center; University of Veterinary Medicine Vienna; Austrian Academy of Sciences; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences; Karolinska Institutet	Dolznig, H (corresponding author), Med Univ Vienna, Inst Med Genet, Wahringer Str 10, A-1090 Vienna, Austria.	helmut.dolznig@meduniwien.ac.at	Dolznig, Helmut/L-7005-2015; Moriggl, Richard/H-8118-2019	Dolznig, Helmut/0000-0002-6063-3585; Moriggl, Richard/0000-0003-0918-9463; Schmoellerl, Johannes/0000-0002-8461-8881; Kramer, Nina/0000-0002-9058-8076; Schwarz, Thomas/0000-0002-1951-9676; Eferl, Robert/0000-0002-6074-7144; Han, Xiaonan/0000-0001-5368-6489	Herzfelder Family Foundation; Niederosterreichische Forschungs-und Bildungsges.m.b.H; DOC Fellowship of the Austrian Academy of Sciences [24032]; Austrian Science Fund (FWF) [SFB F28, SFB F47, P25925-B20, 0P26908-B20]; Comprehensive Cancer Center (CCC) Vienna Research Grant; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI103388] Funding Source: NIH RePORTER	Herzfelder Family Foundation; Niederosterreichische Forschungs-und Bildungsges.m.b.H; DOC Fellowship of the Austrian Academy of Sciences; Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Comprehensive Cancer Center (CCC) Vienna Research Grant; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	HD was supported by the Herzfelder Family Foundation and the Niederosterreichische Forschungs-und Bildungsges.m.b.H. AW was a recipient of a DOC Fellowship (24032) of the Austrian Academy of Sciences. RM was supported by the Austrian Science Fund (FWF, SFB F28 & F47). RE was supported by FWF (P25925-B20, 0P26908-B20, DK Inflammation and Immunity) and the Comprehensive Cancer Center (CCC) Vienna Research Grant.	Aguirre-Gamboa R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074250; Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419; Bayle J, 2008, J INVEST DERMATOL, V128, P871, DOI 10.1038/sj.jid.5701101; BLASBAND A, 1992, ONCOGENE, V7, P153; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; Bravo DT, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-316; Burgess A, 2010, P NATL ACAD SCI USA, V107, P12564, DOI 10.1073/pnas.0914191107; Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013; Chen W, 2003, SCIENCE, V301, P1391, DOI 10.1126/science.1082808; da Costa LT, 1999, ONCOGENE, V18, P5010, DOI 10.1038/sj.onc.1202872; Dale TC, 1996, CANCER RES, V56, P4320; de Castro J, 2000, VIRCHOWS ARCH, V437, P599, DOI 10.1007/s004280000266; Dolznig H, 2011, AM J PATHOL, V179, P487, DOI 10.1016/j.ajpath.2011.03.015; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Fu L, 2011, GUT, V60, P1635, DOI 10.1136/gut.2011.241638; Fuerer C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009370; Gaggioli C, 2007, NAT CELL BIOL, V9, P1392, DOI 10.1038/ncb1658; Goss AM, 2009, DEV CELL, V17, P290, DOI 10.1016/j.devcel.2009.06.005; Holcombe RF, 2002, J CLIN PATHOL-MOL PA, V55, P220, DOI 10.1136/mp.55.4.220; HUGUET EL, 1994, CANCER RES, V54, P2615; Humphreys RC, 1997, CELL GROWTH DIFFER, V8, P839; Hylander BL, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-110; Isella C, 2015, NAT GENET, V47, P312, DOI 10.1038/ng.3224; Jiang H, 2014, AM J CANCER RES, V4, P537; Katoh M, 2001, INT J ONCOL, V19, P1003; Katoh M, 2003, INT J MOL MED, V12, P811; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Matushansky I, 2007, J CLIN INVEST, V117, P3248, DOI 10.1172/JCI31377; Miller MF, 2012, P NATL ACAD SCI USA, V109, P15348, DOI 10.1073/pnas.1201583109; Najdi R, 2012, DIFFERENTIATION, V84, P203, DOI 10.1016/j.diff.2012.06.004; Neumann S, 2009, TRAFFIC, V10, P334, DOI 10.1111/j.1600-0854.2008.00872.x; Nishida N, 2012, CLIN CANCER RES, V18, P3054, DOI 10.1158/1078-0432.CCR-11-1078; OGASAWARA S, 1994, VIRCHOWS ARCH, V424, P607, DOI 10.1007/BF01069740; Olumi AF, 1999, CANCER RES, V59, P5002; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Park JK, 2009, NEOPLASMA, V56, P119, DOI 10.4149/neo_2009_02_119; Pu P, 2009, CANCER GENE THER, V16, P351, DOI 10.1038/cgt.2008.78; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Rosner M, 2010, NAT PROTOC, V5, P1081, DOI 10.1038/nprot.2010.74; Ru MX, 2008, TROP BIOMED, V25, P46; Rupp C, 2006, DIAGN MOL PATHOL, V15, P35, DOI 10.1097/00019606-200603000-00006; Rupp C, 2015, ONCOGENE, V34, P815, DOI 10.1038/onc.2014.18; Smith K, 1999, BRIT J CANCER, V81, P496, DOI 10.1038/sj.bjc.6690721; Stanganello E, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6846; Suraweera N, 2006, INT J CANCER, V119, P1837, DOI 10.1002/ijc.22046; Sveen A, 2011, GENOME MED, V3, DOI 10.1186/gm248; Timpson P, 2011, JOVE-J VIS EXP, DOI 10.3791/3089; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Vider BZ, 1996, ONCOGENE, V12, P153; Wikberg ML, 2013, TUMOR BIOL, V34, P1013, DOI 10.1007/s13277-012-0638-2; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Yu HM, 2012, DEVELOPMENT, V139, P4383, DOI 10.1242/dev.083352	52	66	68	3	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2017	36	39					5460	5472		10.1038/onc.2017.144	http://dx.doi.org/10.1038/onc.2017.144			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FI4RG	28553956				2022-12-17	WOS:000411960500003
J	Li, J; Huang, Q; Long, X; Guo, X; Sun, X; Jin, X; Li, Z; Ren, T; Yuan, P; Huang, X; Zhang, H; Xing, J				Li, J.; Huang, Q.; Long, X.; Guo, X.; Sun, X.; Jin, X.; Li, Z.; Ren, T.; Yuan, P.; Huang, X.; Zhang, H.; Xing, J.			Mitochondrial elongation-mediated glucose metabolism reprogramming is essential for tumour cell survival during energy stress	ONCOGENE			English	Article							CANCER-CELLS; FISSION; PHOSPHORYLATION; DYNAMICS; SIRTUINS; HYPOXIA; FUSION; DEGRADATION; STARVATION; AUTOPHAGY	To date, mechanisms of tumour cell survival under energy stress are not well understood. Cumulative evidence is beginning to reveal that specific mitochondrial morphologies are often associated with energetic states and survival of cells. However, the functional roles of mitochondria in the metabolic adaptation of tumour cells to energy stress remain to be elucidated. In this study, we first investigated the changes in mitochondrial morphology induced by nutrition deprivation in tumour cells, and the underlying molecular mechanism. We then systematically explored glucose metabolism reprogramming by energy stress-induced alteration of mitochondrial morphology and its effect on tumour cell survival. Our results showed that starvation treatment resulted in a dramatic mitochondrial elongation, which was mainly mediated by DRP1(S637) phosphorylation through protein kinase A activation and subsequent suppression of mitochondrial translocation of DRP1. We further observed that tumour cells under an energy stress condition exhibited a clear shift from glycolysis towards oxidative phosphorylation, which was reversed by the recovery of mitochondrial fission induced by forced expression of mutant DRP1(S637A). Mechanistically, energy stress-induced mitochondrial elongation facilitated cristae formation and assembly of respiratory complexes to enhance oxidative phosphorylation, which in turn exhibited a feedback inhibitory effect on glycolysis through NAD(+)-dependent SIRT1 activation. In addition, our data indicated that DRP1(S637)-mediated mitochondrial elongation under energy stress was essential for tumour cell survival both in vitro and in vivo and predicted poor prognosis of hepatocellular carcinoma patients. Overall, our study demonstrates that remodelling of mitochondrial morphology plays a critical role in tumour cell adaptation to energy stress by reprogramming glucose metabolism.	[Li, J.; Huang, Q.; Long, X.; Guo, X.; Sun, X.; Li, Z.; Ren, T.; Huang, X.; Xing, J.] Fourth Mil Med Univ, State Key Lab Canc Biol, 169 Changle West Rd, Xian 710032, Shaanxi, Peoples R China; [Li, J.; Huang, Q.; Long, X.; Guo, X.; Sun, X.; Li, Z.; Ren, T.; Huang, X.; Xing, J.] Fourth Mil Med Univ, Expt Teaching Ctr Basic Med, 169 Changle West Rd, Xian 710032, Shaanxi, Peoples R China; [Jin, X.] Fourth Mil Med Univ, Xijing Hosp, Dept Pharm, Xian, Shaanxi, Peoples R China; [Yuan, P.; Zhang, H.] Fourth Mil Med Univ, Tangdu Hosp, Dept Pain Treatment, Xian, Shaanxi, Peoples R China	Air Force Military Medical University; Air Force Military Medical University; Air Force Military Medical University; Air Force Military Medical University	Xing, J (corresponding author), Fourth Mil Med Univ, State Key Lab Canc Biol, 169 Changle West Rd, Xian 710032, Shaanxi, Peoples R China.; Xing, J (corresponding author), Fourth Mil Med Univ, Expt Teaching Ctr Basic Med, 169 Changle West Rd, Xian 710032, Shaanxi, Peoples R China.	xingjl@fmmu.edu.cn			National Natural Science Foundation of China [81320108021, 81572304]; National Basic Research Program of China [2015CB553703]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China(National Basic Research Program of China)	This work was supported by the National Natural Science Foundation of China (grants 81320108021 and 81572304) and National Basic Research Program (grant 2015CB553703) of China.	Archer SL, 2013, NEW ENGL J MED, V369, P2236, DOI 10.1056/NEJMra1215233; Birsoy K, 2014, NATURE, V508, P108, DOI 10.1038/nature13110; Bristow RG, 2008, NAT REV CANCER, V8, P180, DOI 10.1038/nrc2344; Chang CR, 2007, J BIOL CHEM, V282, P21583, DOI 10.1074/jbc.C700083200; Chen HC, 2005, J BIOL CHEM, V280, P26185, DOI 10.1074/jbc.M503062200; Chen HC, 2010, CELL, V141, P280, DOI 10.1016/j.cell.2010.02.026; Ferretti AC, 2016, ONCOTARGET, V7, P17815, DOI 10.18632/oncotarget.7404; Gomes LC, 2011, NAT CELL BIOL, V13, P589, DOI 10.1038/ncb2220; Guido C, 2012, ONCOTARGET, V3, P798, DOI 10.18632/oncotarget.574; Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311; Hong J, 2014, J BIOL CHEM, V289, P20012, DOI 10.1074/jbc.M114.560078; Hoppins S, 2007, ANNU REV BIOCHEM, V76, P751, DOI 10.1146/annurev.biochem.76.071905.090048; Huang Q., 2016, AUTOPHAGY, P1; Huang QC, 2014, J HEPATOL, V61, P859, DOI 10.1016/j.jhep.2014.04.035; Ikeda Y, 2015, CIRC RES, V116, P264, DOI 10.1161/CIRCRESAHA.116.303356; Imai S, 2014, TRENDS CELL BIOL, V24, P464, DOI 10.1016/j.tcb.2014.04.002; Jakobs S, 2003, J CELL SCI, V116, P2005, DOI 10.1242/jcs.00423; Kashatus JA, 2015, MOL CELL, V57, P537, DOI 10.1016/j.molcel.2015.01.002; Kim JW, 2006, CANCER RES, V66, P8927, DOI 10.1158/0008-5472.CAN-06-1501; Lim JH, 2010, MOL CELL, V38, P864, DOI 10.1016/j.molcel.2010.05.023; Liu ZG, 2015, SPR TRACTS MECH ENG, P1, DOI 10.1007/978-3-662-45673-6_1; Loh JK, 2015, BBA-MOL CELL RES, V1853, P1796, DOI 10.1016/j.bbamcr.2015.04.013; Michan S, 2007, BIOCHEM J, V404, P1, DOI 10.1042/BJ20070140; Mishra P, 2016, J CELL BIOL, V212, P379, DOI 10.1083/jcb.201511036; Molina AJA, 2009, DIABETES, V58, P2303, DOI 10.2337/db07-1781; Ong SB, 2010, CIRCULATION, V121, P2012, DOI 10.1161/CIRCULATIONAHA.109.906610; Rahman S, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-11; Rambold AS, 2011, P NATL ACAD SCI USA, V108, P10190, DOI 10.1073/pnas.1107402108; Rossignol R, 2004, CANCER RES, V64, P985, DOI 10.1158/0008-5472.CAN-03-1101; Serasinghe MN, 2015, MOL CELL, V57, P521, DOI 10.1016/j.molcel.2015.01.003; Strauss M, 2008, EMBO J, V27, P1154, DOI 10.1038/emboj.2008.35; Taguchi N, 2007, J BIOL CHEM, V282, P11521, DOI 10.1074/jbc.M607279200; Toda C, 2016, CELL, V164, P872, DOI 10.1016/j.cell.2016.02.010; Toyama EQ, 2016, SCIENCE, V351, P275, DOI 10.1126/science.aab4138; Verdin E, 2014, NAT MED, V20, P25, DOI 10.1038/nm.3447; Xing JL, 2008, JNCI-J NATL CANCER I, V100, P1104, DOI 10.1093/jnci/djn213; Yoon H, 2014, BIOCHEM BIOPH RES CO, V444, P36, DOI 10.1016/j.bbrc.2014.01.001; Zeng W, 2015, CANCER LETT, V356, P263, DOI 10.1016/j.canlet.2014.01.032	38	66	67	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2017	36	34					4901	4912		10.1038/onc.2017.98	http://dx.doi.org/10.1038/onc.2017.98			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FE5EI	28436948				2022-12-17	WOS:000408234400007
J	Han, B; Bhowmick, N; Qu, Y; Chung, S; Giuliano, AE; Cui, X				Han, B.; Bhowmick, N.; Qu, Y.; Chung, S.; Giuliano, A. E.; Cui, X.			FOXC1: an emerging marker and therapeutic target for cancer	ONCOGENE			English	Review							TO-MESENCHYMAL TRANSITION; FORKHEAD TRANSCRIPTION FACTORS; GENE-EXPRESSION SIGNATURE; SUPERIOR PROGNOSTIC VALUE; BREAST-CANCER; DNA METHYLATION; ESTROGEN-RECEPTOR; HEPATOCELLULAR-CARCINOMA; CELL NICHE; HELIX GENE	The Forkhead box C1 (FOXC1) transcription factor is involved in normal embryonic development and regulates the development and function of many organs. Most recently, a large body of literature has shown that FOXC1 plays a critical role in tumor development and metastasis. Clinical studies have demonstrated that elevated FOXC1 expression is associated with poor prognosis in many cancer subtypes, such as basal-like breast cancer (BLBC). FOXC1 is highly and specifically expressed in BLBC as opposed to other breast cancer subtypes. Its functions in breast cancer have been extensively explored. This review will summarize current knowledge on the function and regulation of FOXC1 in tumor development and progression with a focus on BLBC, as well as the implications of these new findings in cancer diagnosis and treatment.	[Han, B.; Qu, Y.; Chung, S.; Giuliano, A. E.; Cui, X.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Dept Surg, Los Angeles, CA 90048 USA; [Bhowmick, N.] Cedars Sinai Med Ctr, Dept Med, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; Cedars Sinai Medical Center	Cui, X (corresponding author), Cedars Sinai Med Ctr, 8700 Beverly Blvd,Davis Bldg 2065, Los Angeles, CA 90048 USA.	Xiaojiang.cui@cshs.org	Bhowmick, Neil/AAA-7302-2019	Bhowmick, Neil/0000-0001-8747-5989	National Institutes of Health [CA151610]; Avon Foundation for Women [02-2014-063]; David Salomon Translational Breast Cancer Research Fund; Eleanor and Glenn Padnick Discovery Fund in Cellular Therapy; Fashion Footwear Charitable Foundation of New York, Inc.; Entertainment Industry Foundation; Margie and Robert E Petersen Foundation; Linda and Jim Lippman Research Fund; NATIONAL CANCER INSTITUTE [R01CA151610] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Avon Foundation for Women; David Salomon Translational Breast Cancer Research Fund; Eleanor and Glenn Padnick Discovery Fund in Cellular Therapy; Fashion Footwear Charitable Foundation of New York, Inc.; Entertainment Industry Foundation; Margie and Robert E Petersen Foundation; Linda and Jim Lippman Research Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Institutes of Health (CA151610), the Avon Foundation for Women (02-2014-063), David Salomon Translational Breast Cancer Research Fund, and Eleanor and Glenn Padnick Discovery Fund in Cellular Therapy to Xiaojiang Cui, and the Fashion Footwear Charitable Foundation of New York, Inc., the Entertainment Industry Foundation, the Margie and Robert E Petersen Foundation and the Linda and Jim Lippman Research Fund to Armando Giuliano.	Aldinger KA, 2009, NAT GENET, V41, P1037, DOI 10.1038/ng.422; Nieto MA, 2013, SCIENCE, V342, P708, DOI 10.1126/science.1234850; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Berry FB, 2006, J BIOL CHEM, V281, P10098, DOI 10.1074/jbc.M513629200; Berry FB, 2002, J BIOL CHEM, V277, P10292, DOI 10.1074/jbc.M110266200; Blonska M, 2015, BLOOD, V125, P981, DOI 10.1182/blood-2014-04-568188; Bloushtain-Qimron N, 2008, P NATL ACAD SCI USA, V105, P14076, DOI 10.1073/pnas.0805206105; Braun S, 2005, NEW ENGL J MED, V353, P793, DOI 10.1056/NEJMoa050434; Brisken C, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003178; Cheang MCU, 2008, CLIN CANCER RES, V14, P1368, DOI 10.1158/1078-0432.CCR-07-1658; Chung TKH, 2012, INT J CANCER, V130, P1036, DOI 10.1002/ijc.26060; De Val S, 2008, CELL, V135, P1053, DOI 10.1016/j.cell.2008.10.049; Dejeux E, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-68; Duan S., 2012, ABSTRACT APPL ANAL, V2012, P1, DOI DOI 10.1109/SPC0M.2012.6290252; Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Foulkes WD, 2003, J NATL CANCER I, V95, P1482, DOI 10.1093/jnci/djg050; Haldipur P, 2014, ELIFE, V3, DOI 10.7554/eLife.03962; Han BC, 2015, CELL REP, V13, P1046, DOI 10.1016/j.celrep.2015.09.063; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hayashi H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002401; Hoshino Y, 2011, J BIOCHEM, V149, P55, DOI 10.1093/jb/mvq114; Huang WJ, 2015, GASTROENTEROLOGY, V149, P1053, DOI 10.1053/j.gastro.2015.05.058; Jensen TW, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv148; Jia BX, 2012, J NANOMATER, V2012, DOI 10.1155/2012/796815; Jin YL, 2014, ANN SURG ONCOL, V21, pS758, DOI 10.1245/s10434-014-3980-3; Kaestner KH, 2000, GENE DEV, V14, P142; Klajic J, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-456; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kuhmann C, 2011, RADIOTHER ONCOL, V101, P116, DOI 10.1016/j.radonc.2011.05.048; Kume T, 2000, DEVELOPMENT, V127, P1387; Kume T, 2001, GENE DEV, V15, P2470, DOI 10.1101/gad.907301; Kume T, 1998, CELL, V93, P985, DOI 10.1016/S0092-8674(00)81204-0; Kuukasjarvi T, 1996, J CLIN ONCOL, V14, P2584, DOI 10.1200/JCO.1996.14.9.2584; Lakhani SR, 2005, CLIN CANCER RES, V11, P5175, DOI 10.1158/1078-0432.CCR-04-2424; Lam EWF, 2013, NAT REV CANCER, V13, P482, DOI 10.1038/nrc3539; Lay K, 2016, P NATL ACAD SCI USA, V113, pE1506, DOI 10.1073/pnas.1601569113; Lehmann OJ, 2003, TRENDS GENET, V19, P339, DOI 10.1016/S0168-9525(03)00111-2; Li C, 2013, COMPUT BIOL CHEM, V47, P192, DOI 10.1016/j.compbiolchem.2013.08.010; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Lin ZY, 2014, CANCER SCI, V105, P1288, DOI 10.1111/cas.12499; Lines MA, 2002, HUM MOL GENET, V11, P1177, DOI 10.1093/hmg/11.10.1177; Mattiske D, 2006, DEV BIOL, V290, P447, DOI 10.1016/j.ydbio.2005.12.007; Mayeuf-Louchart A, 2016, DEVELOPMENT, V143, P872, DOI 10.1242/dev.128017; Mears AJ, 1998, AM J HUM GENET, V63, P1316, DOI 10.1086/302109; Mirzayans F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049095; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Muggerud AA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2466; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Nishimura DY, 1998, NAT GENET, V19, P140, DOI 10.1038/493; Omatsu Y, 2014, NATURE, V508, P536, DOI 10.1038/nature13071; Omatsu Y, 2010, IMMUNITY, V33, P387, DOI 10.1016/j.immuni.2010.08.017; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Peraldo-Neia C, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-31; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Powell AA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033788; Prasitsak T, 2015, DEV DYNAM, V244, P703, DOI 10.1002/dvdy.24269; Rakha EA, 2008, J CLIN ONCOL, V26, P2568, DOI 10.1200/JCO.2007.13.1748; Ray PS, 2011, ANN SURG ONCOL, V18, P3839, DOI 10.1245/s10434-011-1657-8; Ray PS, 2010, CANCER RES, V70, P3870, DOI 10.1158/0008-5472.CAN-09-4120; Rice R, 2003, DEV BIOL, V262, P75, DOI 10.1016/S0012-1606(03)00355-5; SASAKI H, 1993, DEVELOPMENT, V118, P47; Seo S, 2006, DEV BIOL, V294, P458, DOI 10.1016/j.ydbio.2006.03.035; Siegenthaler JA, 2013, BIOL OPEN, V2, P647, DOI 10.1242/bio.20135009; Siegenthaler JA, 2009, CELL, V139, P597, DOI 10.1016/j.cell.2009.10.004; Sizemore GM, 2013, BIOL REPROD, V89, DOI 10.1095/biolreprod.113.108001; Sizemore ST, 2012, J BIOL CHEM, V287, P24631, DOI 10.1074/jbc.M112.375865; Skarie JM, 2009, INVEST OPHTH VIS SCI, V50, P5026, DOI 10.1167/iovs.09-3447; Smid M, 2008, CANCER RES, V68, P3108, DOI 10.1158/0008-5472.CAN-07-5644; Somerville TDD, 2015, CANCER CELL, V28, P329, DOI 10.1016/j.ccell.2015.07.017; Stute P, 2012, BREAST CANCER RES TR, V133, P617, DOI 10.1007/s10549-011-1811-9; Sun JJ, 2013, DEVELOPMENT, V140, P1034, DOI 10.1242/dev.085225; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Tkocz D, 2012, ONCOGENE, V31, P3667, DOI 10.1038/onc.2011.531; Topczewska JM, 2001, GENE DEV, V15, P2483, DOI 10.1101/gad.907401; Tribulo C, 2003, DEVELOPMENT, V130, P6441, DOI 10.1242/dev.00878; Tumer Z, 2009, EUR J HUM GENET, V17, P1527, DOI 10.1038/ejhg.2009.93; van der Heul-Nieuwenhuijsen L, 2009, BJU INT, V103, P1574, DOI 10.1111/j.1464-410X.2009.08351.x; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Wang JH, 2016, ONCOTARGET, V7, P84375, DOI 10.18632/oncotarget.11224; Wang L, 2016, SCIENCE, V351, P613, DOI 10.1126/science.aad5440; Wang YY, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2906-9; Wei Li, 2013, Zoological Research, V34, P14, DOI 10.3724/SP.J.1141.2013.01014; Wilm B, 2004, DEV BIOL, V271, P176, DOI 10.1016/j.ydbio.2004.03.034; Wu JM, 2008, CLIN CANCER RES, V14, P1938, DOI 10.1158/1078-0432.CCR-07-4082; Xia LM, 2013, HEPATOLOGY, V57, P610, DOI 10.1002/hep.26029; Xu YY, 2016, TUMOR BIOL, V37, P239, DOI 10.1007/s13277-015-3686-6; Xu Y, 2014, INT J DISTRIB SENS N, DOI 10.1155/2014/594782; Xu ZY, 2012, INT J BIOL SCI, V8, P1130, DOI 10.7150/ijbs.4769; Yao T, 2016, ONCOL LETT, V12, P73, DOI 10.3892/ol.2016.4573; Yoshida M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7653; Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522; Yu-Rice Y, 2016, ONCOGENE, V35, P5400, DOI 10.1038/onc.2016.78; Zarbalis K, 2007, P NATL ACAD SCI USA, V104, P14002, DOI 10.1073/pnas.0702618104; Zhang L, 2015, NATURE, V527, P100, DOI 10.1038/nature15376; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064; Zhou Y, 2002, GENOMICS, V80, P465, DOI 10.1006/geno.2002.6860; Zvelebil M, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3403	99	66	76	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2017	36	28					3957	3963		10.1038/onc.2017.48	http://dx.doi.org/10.1038/onc.2017.48			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FA3YD	28288141	Green Accepted			2022-12-17	WOS:000405379900002
J	Junk, DJ; Bryson, BL; Smigiel, JM; Parameswaran, N; Bartel, CA; Jackson, MW				Junk, D. J.; Bryson, B. L.; Smigiel, J. M.; Parameswaran, N.; Bartel, C. A.; Jackson, M. W.			Oncostatin M promotes cancer cell plasticity through cooperative STAT3-SMAD3 signaling	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-TUMOR CELLS; TGF-BETA; STEM-CELL; INTERLEUKIN-6 EXPRESSION; MALIGNANT-TRANSFORMATION; STAT3; ACTIVATION; IL-6; CHEMOTHERAPY	Increasing evidence supports the idea that cancer cell plasticity promotes metastasis and tumor recurrence, resulting in patient mortality. While it is clear that the tumor microenvironment (TME) contributes to cancer cell plasticity, the specific TME factors most actively controlling plasticity remain largely unknown. Here, we performed a screen to identify TME cytokines and growth factors that promote epithelial-mesenchymal plasticity, and acquisition of cancer stem cell (CSC) properties. Of 28 TME cytokines and growth factors tested, we identified Oncostatin M (OSM) as the most potent inducer of mesenchymal/CSC properties. OSM-induced plasticity was Signal Transducer and Activator of Transcription 3 (STAT3)-dependent, and also required a novel intersection with transforming growth factor-alpha (TGF-alpha)/SMAD signaling. OSM/STAT3 activation promoted SMAD3 nuclear accumulation, DNA binding and induced SMAD3-dependent transcriptional activity. Suppression of TGF-alpha receptor activity or ablation of SMAD3 or SMAD4, but not SMAD2, strongly suppressed OSM/ STAT3-mediated plasticity. Moreover, removal of OSM or inhibition of STAT3 or SMAD3 resulted in a marked reversion to a non-invasive, epithelial phenotype. We propose that targeted blockade of the STAT3/SMAD3 axis in tumor cells may represent a novel therapeutic approach to prevent the plasticity required for metastatic progression and tumor recurrence.	[Junk, D. J.; Bryson, B. L.; Smigiel, J. M.; Parameswaran, N.; Bartel, C. A.; Jackson, M. W.] Case Western Reserve Univ, Sch Med, Dept Pathol, 2103 Cornell Rd,WRB 3134, Cleveland, OH 44106 USA; [Jackson, M. W.] Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Jackson, MW (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pathol, 2103 Cornell Rd,WRB 3134, Cleveland, OH 44106 USA.	mark.w.jackson@case.edu	Bryson, Benjamin L/D-1070-2014	Bryson, Benjamin L/0000-0003-4131-0200	NIH [T32 CA059366]; US National Institutes of Health [R01CA138421]; American Cancer Society [RSG CCG-122517]; Case Comprehensive Cancer Center [P30 CA43703]; NATIONAL CANCER INSTITUTE [R21CA178327, T32CA059366] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007250] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Case Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	DJJ was supported by NIH T32 CA059366. MWJ is supported by the US National Institutes of Health (R01CA138421) and the American Cancer Society (Research Scholar Award # RSG CCG-122517). Additional support was provided by the Case Comprehensive Cancer Center (P30 CA43703; Cytometry & Imaging Microscopy).	Adorno-Cruz V, 2015, CANCER RES, V75, P924, DOI 10.1158/0008-5472.CAN-14-3225; Akizu N, 2010, DEVELOPMENT, V137, P2915, DOI 10.1242/dev.049395; Aktas B, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2333; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bastid J, 2012, CANCER METAST REV, V31, P277, DOI 10.1007/s10555-011-9344-6; Baulida J, 2015, BBA-REV CANCER, V1856, P55, DOI 10.1016/j.bbcan.2015.05.005; Bhola NE, 2013, J CLIN INVEST, V123, P1348, DOI 10.1172/JCI65416; Biddle A, 2011, CANCER RES, V71, P5317, DOI 10.1158/0008-5472.CAN-11-1059; Boero Ferdinando, 2015, F1000Prime Rep, V7, P49, DOI 10.12703/P7-49; Brooks MD, 2015, CELL STEM CELL, V17, P260, DOI 10.1016/j.stem.2015.08.014; Buijs JT, 2012, ONCOGENE, V31, P2164, DOI 10.1038/onc.2011.400; Celis JE, 2004, MOL CELL PROTEOMICS, V3, P327, DOI 10.1074/mcp.M400009-MCP200; Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005; Cipriano R, 2011, P NATL ACAD SCI USA, V108, P8668, DOI 10.1073/pnas.1015022108; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Dahle O, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000841; Derynck R, 2014, CURR OPIN CELL BIOL, V31, P56, DOI 10.1016/j.ceb.2014.09.001; Doherty MR, 2016, CANCERS, V8, DOI 10.3390/cancers8010008; Egeblad M, 2010, DEV CELL, V18, P884, DOI 10.1016/j.devcel.2010.05.012; Eickelberg O, 1999, J BIOL CHEM, V274, P12933, DOI 10.1074/jbc.274.18.12933; ELIAS JA, 1991, J IMMUNOL, V146, P3437; Fang YY, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/478641; Farrell J, 2014, J PROTEOME RES, V13, P2874, DOI 10.1021/pr5000285; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Garbe JC, 2009, CANCER RES, V69, P7557, DOI 10.1158/0008-5472.CAN-09-0270; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Goldman A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7139; Gough DJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083395; Gunasinghe NPAD, 2012, CANCER METAST REV, V31, P469, DOI 10.1007/s10555-012-9377-5; Guryanova OA, 2011, CANCER CELL, V19, P498, DOI 10.1016/j.ccr.2011.03.004; Hart JR, 2011, P NATL ACAD SCI USA, V108, P13247, DOI 10.1073/pnas.1110486108; He W, 2006, CELL, V125, P929, DOI 10.1016/j.cell.2006.03.045; Heldin CH, 2012, FEBS LETT, V586, P1959, DOI 10.1016/j.febslet.2012.02.037; Heldin P, 2014, ADV CANCER RES, V123, P211, DOI 10.1016/B978-0-12-800092-2.00008-3; Hermanns HM, 2015, CYTOKINE GROWTH F R, V26, P545, DOI 10.1016/j.cytogfr.2015.07.006; Hermanns HM, 2000, J BIOL CHEM, V275, P40742, DOI 10.1074/jbc.M005408200; Hollier BG, 2013, CANCER RES, V73, P1981, DOI 10.1158/0008-5472.CAN-12-2962; Junk DJ, 2014, CANCERS, V6, P741, DOI 10.3390/cancers6020741; Junk DJ, 2013, NEOPLASIA, V15, P1086, DOI 10.1593/neo.131114; Junk DJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053776; Kan CE, 2011, CANCER RES, V71, P6930, DOI 10.1158/0008-5472.CAN-10-3860; Khoo BL, 2015, ONCOTARGET, V6, P15578; Lawson DA, 2015, NATURE, V526, P131, DOI 10.1038/nature15260; Lee HJ, 2014, CANCER CELL, V26, P207, DOI 10.1016/j.ccr.2014.05.019; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Li YZ, 2015, P NATL ACAD SCI USA, V112, P1839, DOI 10.1073/pnas.1424171112; Liu RY, 2014, INT J ONCOL, V44, P1643, DOI 10.3892/ijo.2014.2310; Luo LY, 2014, TUMOR BIOL, V35, P8379, DOI 10.1007/s13277-014-2203-7; Luwor RB, 2013, ONCOGENE, V32, P2433, DOI 10.1038/onc.2012.260; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mbeunkui F, 2009, CANCER CHEMOTH PHARM, V63, P571, DOI 10.1007/s00280-008-0881-9; Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624; Moon SU, 2015, ONCOL REP, V33, P185, DOI 10.3892/or.2014.3582; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Morrison CD, 2013, CANCER LETT, V341, P30, DOI 10.1016/j.canlet.2013.02.048; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; O'Reilly S, 2014, J BIOL CHEM, V289, P9952, DOI 10.1074/jbc.M113.545822; Park JI, 2003, ONCOGENE, V22, P4314, DOI 10.1038/sj.onc.1206478; Plater-Zyberk C, 2001, ARTHRITIS RHEUM, V44, P2697, DOI 10.1002/1529-0131(200111)44:11<2697::AID-ART450>3.0.CO;2-#; Poling J, 2014, BASIC RES CARDIOL, V109, DOI 10.1007/s00395-013-0396-3; Raimondi C, 2011, BREAST CANCER RES TR, V130, P449, DOI 10.1007/s10549-011-1373-x; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Richards Carl D, 2013, ISRN Inflamm, V2013, P512103, DOI 10.1155/2013/512103; Rycaj K, 2015, CANCER RES, V75, P4003, DOI 10.1158/0008-5472.CAN-15-0798; Saitoh M, 2016, ONCOGENE, V35, P1049, DOI 10.1038/onc.2015.161; Seong GJ, 2009, MOL VIS, V15, P2123; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Singh RAK, 1998, IMMUNOL LETT, V62, P159, DOI 10.1016/S0165-2478(98)00040-6; Smith DA, 2013, MOL CANCER RES, V11, P1159, DOI 10.1158/1541-7786.MCR-13-0238; Sodhi A, 1997, IMMUNOL CELL BIOL, V75, P492, DOI 10.1038/icb.1997.76; Sullivan NJ, 2009, ONCOGENE, V28, P2940, DOI 10.1038/onc.2009.180; Sun L, 2012, ONCOGENE, V31, P432, DOI 10.1038/onc.2011.263; Tang BW, 1999, CANCER RES, V59, P4834; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; TURNER M, 1990, Cytokine, V2, P211, DOI 10.1016/1043-4666(90)90018-O; Underhill-Day N, 2006, CANCER RES, V66, P10891, DOI 10.1158/0008-5472.CAN-06-1766; Unternaehrer JJ, 2014, STEM CELL REP, V3, P691, DOI 10.1016/j.stemcr.2014.09.008; Vlaicu P, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-197; Walia B, 2003, FASEB J, V17, P2130, DOI 10.1096/fj.02-1211fje; Wang G, 2016, ONCOGENE, V35, P4388, DOI 10.1038/onc.2015.446; Wang H, 2008, ONCOGENE, V27, P6791, DOI 10.1038/onc.2008.291; Wang YX, 2013, P NATL ACAD SCI USA, V110, P16975, DOI 10.1073/pnas.1315862110; Weiss RB, 2003, J CLIN ONCOL, V21, P1825, DOI 10.1200/JCO.2003.09.006; Wendt MK, 2013, ONCOGENE, V32, P2005, DOI 10.1038/onc.2012.230; Wendt MK, 2009, FUTURE ONCOL, V5, P1145, DOI 10.2217/FON.09.90; West NR, 2014, ONCOGENE, V33, P1485, DOI 10.1038/onc.2013.105; West NR, 2012, ENDOCR-RELAT CANCER, V19, P181, DOI 10.1530/ERC-11-0326; Wrighton KH, 2009, CELL RES, V19, P8, DOI 10.1038/cr.2008.327; Xie GZ, 2012, INT J ONCOL, V40, P1171, DOI 10.3892/ijo.2011.1275; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Xu MY, 2014, BBA-MOL BASIS DIS, V1842, P2237, DOI 10.1016/j.bbadis.2014.07.025; Yamamoto T, 2001, FEBS LETT, V492, P247, DOI 10.1016/S0014-5793(01)02258-X; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Ye L, 2010, CANCER SCI, V101, P2137, DOI 10.1111/j.1349-7006.2010.01648.x; Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522; Zhao SJ, 2008, CANCER RES, V68, P4221, DOI 10.1158/0008-5472.CAN-07-5123; Zhu MJ, 2015, ONCOL REP, V34, P129, DOI 10.3892/or.2015.3951	98	66	66	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2017	36	28					4001	4013		10.1038/onc.2017.33	http://dx.doi.org/10.1038/onc.2017.33			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FA3YD	28288136	Green Accepted, hybrid, Green Published			2022-12-17	WOS:000405379900006
J	Zhang, L; Zhang, W; Li, Y; Alvarez, A; Li, Z; Wang, Y; Song, L; Lv, D; Nakano, I; Hu, B; Cheng, SY; Feng, H				Zhang, L.; Zhang, W.; Li, Y.; Alvarez, A.; Li, Z.; Wang, Y.; Song, L.; Lv, D.; Nakano, I.; Hu, B.; Cheng, S-Y; Feng, H.			SHP-2-upregulated ZEB1 is important for PDGFR alpha-driven glioma epithelial-mesenchymal transition and invasion in mice and humans	ONCOGENE			English	Article							PROSTATE-CANCER CELLS; E-CADHERIN; MIR-200 FAMILY; BETA-CATENIN; DEPENDENT MECHANISM; REPRESSORS ZEB1; LUNG-CANCER; STEM-CELLS; GLIOBLASTOMA; GROWTH	Gliomas are highly malignant brain tumors that are highly invasive and resistant to conventional therapy. Receptor tyrosine kinases (RTKs) such as PDGFR alpha (platelet-derived growth factor receptor-alpha), which show frequent aberrant activation in gliomas, are associated with a process of epithelial-mesenchymal transition (EMT), a cellular alteration that confers a more invasive and drug-resistant phenotype. Although this phenomenon is well documented in human cancers, the processes by which RTKs including PDGFR alpha mediate EMT are largely unknown. Here, we report that SHP-2 (encoded by PTPN11) upregulates an EMT inducer, ZEB1, to mediate PDGFR alpha-driven glioma EMT, invasion and growth in glioma cell lines and patient-derived glioma stem cells (GSCs) using cell culture and orthotopic xenograft models. ZEB1 and activated PDGFR alpha were coexpressed in invasive regions of mouse glioma xenografts and clinical glioma specimens. Glioma patients with high levels of both phospho-PDGFR alpha (p-PDGFR alpha) and ZEB1 had significantly shorter overall survival compared with those with low expression of p-PDGFR alpha and ZEB1. Knockdown of ZEB1 inhibited PDGFA/PDGFR alpha-stimulated glioma EMT, tumor growth and invasion in glioma cell lines and patient-derived GSCs. PDGFR alpha mutant deficient of SHP2 binding (PDGFR alpha-F720) or phosphoinositide 3-kinase (PI3K) binding (PDGFR alpha-F731/42), knockdown of SHP2 or treatments of pharmacological inhibitor for PDGFR alpha-signaling effectors attenuated PDGFA/PDGFR alpha-stimulated ZEB1 expression, cell migration and GSC proliferation. Importantly, SHP-2 acts together with PI3K/AKT to regulate a ZEB1-miR-200 feedback loop in PDGFR alpha-driven gliomas. Taken together, our findings uncover a new pathway in which ZEB1 functions as a key regulator for PDGFR alpha-driven glioma EMT, invasiveness and growth, suggesting that ZEB1 is a promising therapeutic target for treating gliomas with high PDGFR alpha activation.	[Zhang, L.; Zhang, W.; Li, Z.; Wang, Y.; Song, L.; Lv, D.; Cheng, S-Y; Feng, H.] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, State Key Lab Oncogenes & Related Genes,Renji Med, Pu Jian Rd 160, Shanghai 200127, Peoples R China; [Li, Y.] Shanghai Jiao Tong Univ, Sch Med, Shanghai Childrens Med Ctr, Key Lab Pediat Hematol & Oncol,Minist Hlth,Pediat, Shanghai, Peoples R China; [Alvarez, A.; Hu, B.; Cheng, S-Y] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Dept Neurol,Northwestern Brain Tumor Inst,Ctr Gen, Chicago, IL 60611 USA; [Nakano, I.] Univ Alabama Birmingham, Dept Neurosurg Cell Dev & Integrat Biol Biochem &, Birmingham, AL USA	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; University of Alabama System; University of Alabama Birmingham	Feng, H (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, State Key Lab Oncogenes & Related Genes,Renji Med, Pu Jian Rd 160, Shanghai 200127, Peoples R China.	Fenghaizhong@sjtu.edu.cn	Nakano, Ichiro/AAR-9562-2020; Feng, Haizhong/E-5795-2017	Nakano, Ichiro/0000-0002-0916-3207; Feng, Haizhong/0000-0003-3552-6865	National Natural Science Foundation of China [81372704, 81572467, 81470315]; Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning, Innovation Program of Shanghai Municipal Education Commission [14ZZ111]; State Key Laboratory of Oncogenes and Related Genes in China [90-14-04]; Pujiang Talent Plan of Shanghai City, China [14PJ1406500]; Natural Science Foundation of Tianjin City, China [13JCYBJC39400]; Shanghai Jiao Tong University School of Medicine Hospital Fund [14XJ10069]; Science and Technology Commission of Shanghai Municipality, China [15ZR1425700]; US NIH [CA158911, NS093843, NS95634]; Zell Scholar Award from the Zell Family Foundation; Northwestern Brain Tumor Institute at Northwestern University; Brain Cancer Research Award from the James S McDonnell Foundation; NIH/NCI training grant [T32 CA070085]; NATIONAL CANCER INSTITUTE [R01CA159811, T32CA070085] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS093843, R01NS083767, R01NS095634] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning, Innovation Program of Shanghai Municipal Education Commission; State Key Laboratory of Oncogenes and Related Genes in China; Pujiang Talent Plan of Shanghai City, China; Natural Science Foundation of Tianjin City, China(Natural Science Foundation of Tianjin); Shanghai Jiao Tong University School of Medicine Hospital Fund; Science and Technology Commission of Shanghai Municipality, China(Science & Technology Commission of Shanghai Municipality (STCSM)); US NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Zell Scholar Award from the Zell Family Foundation; Northwestern Brain Tumor Institute at Northwestern University; Brain Cancer Research Award from the James S McDonnell Foundation; NIH/NCI training grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank E Van Meir for providing glioma cell lines, R Pangeni and N Sastry for editing the manuscript. This work was supported, in part, by National Natural Science Foundation of China (Nos. 81372704 and 81572467) to H Feng and (No. 81470315) (to YL); the Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning, Innovation Program of Shanghai Municipal Education Commission (No. 14ZZ111), the State Key Laboratory of Oncogenes and Related Genes in China (No. 90-14-04) (to HF); the Pujiang Talent Plan of Shanghai City, China (No. 14PJ1406500), Natural Science Foundation of Tianjin City, China (No. 13JCYBJC39400), Shanghai Jiao Tong University School of Medicine Hospital Fund (No. 14XJ10069) (to YL); Science and Technology Commission of Shanghai Municipality, China (15ZR1425700) (to ZL); US NIH Grants (CA158911, NS093843 and NS95634), a Zell Scholar Award from the Zell Family Foundation and funds from Northwestern Brain Tumor Institute at Northwestern University (to S-YC); a Brain Cancer Research Award from the James S McDonnell Foundation (to BH) and a NIH/NCI training grant T32 CA070085 (to AA).	Bhat KPL, 2013, CANCER CELL, V24, P331, DOI 10.1016/j.ccr.2013.08.001; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Cerami E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008918; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chan G, 2008, CANCER METAST REV, V27, P179, DOI 10.1007/s10555-008-9126-y; Chen WG, 2013, ONCOL LETT, V6, P1234, DOI 10.3892/ol.2013.1552; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Dong PX, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0231-0; Du R, 2014, MOL BIOL CELL, V25, P2650, DOI 10.1091/mbc.E14-01-0044; Feng H, 2012, ONCOGENE, V31, P2691, DOI 10.1038/onc.2011.436; Feng HZ, 2014, J CLIN INVEST, V124, P3741, DOI 10.1172/JCI73093; Feng HZ, 2012, P NATL ACAD SCI USA, V109, P3018, DOI 10.1073/pnas.1121457109; Feng HZ, 2011, J CLIN INVEST, V121, P4670, DOI 10.1172/JCI58559; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Gibbons DL, 2009, GENE DEV, V23, P2140, DOI 10.1101/gad.1820209; Gonzalez DM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005189; Grande M, 2002, J CELL SCI, V115, P4227, DOI 10.1242/jcs.00091; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Grille SJ, 2003, CANCER RES, V63, P2172; Imanishi Y, 2011, J BIOL CHEM, V286, P29249, DOI 10.1074/jbc.M111.235689; Jechlinger M, 2006, J CLIN INVEST, V116, P1561, DOI 10.1172/JCI24652; Klinghoffer RA, 2002, DEV CELL, V2, P103, DOI 10.1016/S1534-5807(01)00103-4; Kong DJ, 2008, STEM CELLS, V26, P1425, DOI 10.1634/stemcells.2007-1076; Kong DJ, 2009, STEM CELLS, V27, P1712, DOI 10.1002/stem.101; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Liu KW, 2011, J CLIN INVEST, V121, P905, DOI 10.1172/JCI43690; Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0; Mao P, 2013, P NATL ACAD SCI USA, V110, P8644, DOI 10.1073/pnas.1221478110; Matozaki T, 2009, CANCER SCI, V100, P1786, DOI 10.1111/j.1349-7006.2009.01257.x; Meng FY, 2015, CANCER RES, V75, P584, DOI 10.1158/0008-5472.CAN-13-3029; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Rosenkranz S, 1999, J BIOL CHEM, V274, P28335, DOI 10.1074/jbc.274.40.28335; Schmalhofer O, 2009, CANCER METAST REV, V28, P151, DOI 10.1007/s10555-008-9179-y; Schmelzle T, 2007, P NATL ACAD SCI USA, V104, P3787, DOI 10.1073/pnas.0700115104; Siebzehnrubl FA, 2013, EMBO MOL MED, V5, P1196, DOI 10.1002/emmm.201302827; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Van Stry M, 2005, P NATL ACAD SCI USA, V102, P8233, DOI 10.1073/pnas.0502885102; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wang Y, 2012, ONCOGENE, V31, P2512, DOI 10.1038/onc.2011.435; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Wu KJ, 2012, CELL SIGNAL, V24, P2273, DOI 10.1016/j.cellsig.2012.08.004; Yang LQ, 2006, CELL, V127, P139, DOI 10.1016/j.cell.2006.08.036; Yoshida S, 1997, J CANCER RES CLIN, V123, P301, DOI 10.1007/s004320050062; Zang MD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112908; Zheng S, 2007, ONCOGENE, V26, P6896, DOI 10.1038/sj.onc.1210493	48	66	71	4	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2016	35	43					5641	5652		10.1038/onc.2016.100	http://dx.doi.org/10.1038/onc.2016.100			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XP	27041571	hybrid, Green Accepted, Green Published			2022-12-17	WOS:000386998300007
J	Metzig, MO; Fuchs, D; Tagscherer, KE; Grone, HJ; Schirmacher, P; Roth, W				Metzig, M. Oliver; Fuchs, D.; Tagscherer, K. E.; Groene, H-J; Schirmacher, P.; Roth, W.			Inhibition of caspases primes colon cancer cells for 5-fluorouracil-induced TNF-alpha-dependent necroptosis driven by RIP1 kinase and NF-kappa B	ONCOGENE			English	Article							APOPTOSIS RESISTANCE; DRUG-RESISTANCE; DEATH; ACTIVATION; INDUCTION; CLEAVAGE; NECROSIS; IDENTIFICATION; RIPOPTOSOME; IAPS	Resistance towards the drug 5-fluorouracil (5-FU) is a key challenge in the adjuvant chemotherapy of colorectal cancer (CRC), and novel targeted approaches are required to improve the therapeutic outcome. Necroptosis is a recently discovered form of programmed cell death, which depends on receptor interacting protein 1 (RIP1) and particularly occurs under caspase-deficient conditions. The targeted induction of necroptosis represents a promising strategy to overcome apoptosis resistance in cancer. The aim of this study was to systematically explore the usage of pan-caspase inhibitors to sensitize resistant CRC cells for 5-FU. We found that pan-caspase inhibitors facilitated 5-FU-induced necroptosis, which was mediated by autocrine secretion of tumor necrosis factor alpha (TNF-alpha). TNF-alpha production was driven by nuclear factor kappa B (NF-kappa B) and required RIP1 kinase. In vivo xenograft experiments showed that the novel pan-caspase inhibitor IDN-7314 in combination with 5-FU synergistically blocked tumor growth. Ex vivo experiments with fresh human CRC tissue specimens further indicated that a subgroup of patients could benefit from combinatory treatment. Thereby, elevated levels of secreted TNF-alpha and expression of components of the necroptotic pathway might help to predict the sensitivity to pro-necroptotic therapies. Together, our results shed new light on the molecular regulation of necroptosis by NF-kappa B and RIP1. Moreover, we identify necroptotic cell death as an important effector mechanism of 5-FU-mediated anti-tumoral activity. On the basis of this study, we propose pan-caspase inhibitors as a novel approach in the adjuvant chemotherapy of CRC.	[Metzig, M. Oliver; Fuchs, D.; Schirmacher, P.; Roth, W.] Heidelberg Univ, Inst Pathol, Heidelberg, Germany; [Metzig, M. Oliver; Fuchs, D.; Tagscherer, K. E.; Roth, W.] German Canc Res Ctr, Mol Tumor Pathol, Heidelberg, Germany; [Groene, H-J] German Canc Res Ctr, Cellular & Mol Pathol, Heidelberg, Germany; [Roth, W.] Univ Med Ctr Mainz, Inst Pathol, Langenbeckstr 1, D-55131 Mainz, Germany	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Johannes Gutenberg University of Mainz	Roth, W (corresponding author), Univ Med Ctr Mainz, Inst Pathol, Langenbeckstr 1, D-55131 Mainz, Germany.	Wilfried.Roth@unimedizin-mainz.de	Tagscherer, Katrin/AAS-3809-2021	Tagscherer, Katrin/0000-0002-0657-6399	Manfred-Stolte-Foundation; Rahel Goitein-Straus Program of the Medical Faculty of Heidelberg	Manfred-Stolte-Foundation; Rahel Goitein-Straus Program of the Medical Faculty of Heidelberg	We are grateful to Marina Gernold, Martina Keith, Katarina Duglova and Scott Oliver for excellent technical assistance. We thank Sylvia Kaden for technical assistance during electron microscopy. We thank the tissue bank of the Center for National Tumor Disease (NCT, Heidelberg, Germany) for providing CRC tissues, and Sarah MeBnard and David Jansen for technical assistance during immunohistochemistry. This study was supported by a grant from the Manfred-Stolte-Foundation to WR, and by the Rahel Goitein-Straus Program of the Medical Faculty of Heidelberg (fellowship to MOM).	Biton S, 2011, CELL, V145, P92, DOI 10.1016/j.cell.2011.02.023; Chaudhary PM, 2000, ONCOGENE, V19, P4451, DOI 10.1038/sj.onc.1203812; Christofferson DE, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.64; Christofferson DE, 2014, ANNU REV PHYSIOL, V76, P129, DOI 10.1146/annurev-physiol-021113-170259; Cooks T, 2013, CANCER CELL, V23, P634, DOI 10.1016/j.ccr.2013.03.022; Darding M, 2012, CELL DEATH DIFFER, V19, P58, DOI 10.1038/cdd.2011.163; Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83; Douillard JY, 2003, ANN ONCOL, V14, P7, DOI 10.1093/annonc/mdg723; Dunai ZA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041945; Fassl A, 2012, ONCOGENE, V31, P4698, DOI 10.1038/onc.2011.615; Feoktistova M, 2011, MOL CELL, V43, P449, DOI 10.1016/j.molcel.2011.06.011; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Festjens N, 2007, CELL DEATH DIFFER, V14, P400, DOI 10.1038/sj.cdd.4402085; Fuchs D, 2015, ONCOGENE, V34, P2753, DOI 10.1038/onc.2014.213; Fulda S, 2014, SEMIN CELL DEV BIOL, V35, P51, DOI 10.1016/j.semcdb.2014.07.002; Grassilli E, 2013, CLIN CANCER RES, V19, P3820, DOI 10.1158/1078-0432.CCR-12-3289; Hagan Suzanne, 2013, EPMA J, V4, P3, DOI 10.1186/1878-5085-4-3; Han WD, 2007, MOL CANCER THER, V6, P1641, DOI 10.1158/1535-7163.MCT-06-0511; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He SD, 2009, CELL, V137, P1100, DOI 10.1016/j.cell.2009.05.021; Hitomi JI, 2008, CELL, V135, P1311, DOI 10.1016/j.cell.2008.10.044; Jouan-Lanhouet S, 2014, SEMIN CELL DEV BIOL, V35, P2, DOI 10.1016/j.semcdb.2014.08.010; Kaiser WJ, 2013, J BIOL CHEM, V288, P31268, DOI 10.1074/jbc.M113.462341; Kreuzaler P, 2012, NAT REV CANCER, V12, P411, DOI 10.1038/nrc3264; Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150; Lamkanfi M, 2006, J CELL BIOL, V173, P165, DOI 10.1083/jcb.200509092; Laukens B, 2011, NEOPLASIA, V13, P971, DOI 10.1593/neo.11610; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Linton SD, 2005, J MED CHEM, V48, P6779, DOI 10.1021/jm050307e; Marshall John L, 2007, Gastrointest Cancer Res, V1, P146; McComb S, 2014, J IMMUNOL, V192, P5671, DOI 10.4049/jimmunol.1303380; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Moretti L, 2009, MOL CANCER THER, V8, P1270, DOI 10.1158/1535-7163.MCT-08-0893; Probst BL, 2010, CELL DEATH DIFFER, V17, P1645, DOI 10.1038/cdd.2010.44; Shiffman ML, 2010, ALIMENT PHARM THER, V31, P969, DOI 10.1111/j.1365-2036.2010.04264.x; Shikama Y, 2003, EUR J IMMUNOL, V33, P1998, DOI 10.1002/eji.200324013; Staal J, 2011, CELL RES, V21, P40, DOI 10.1038/cr.2010.168; Steinhart L, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.320; Sun LM, 2012, CELL, V148, P213, DOI 10.1016/j.cell.2011.11.031; Tenev T, 2011, MOL CELL, V43, P432, DOI 10.1016/j.molcel.2011.06.006; Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113; Vanden Berghe T, 2013, METHODS, V61, P117, DOI 10.1016/j.ymeth.2013.02.011; Varfolomeev E, 2007, CELL, V131, P669, DOI 10.1016/j.cell.2007.10.030; Wang WG, 2004, CANCER RES, V64, P8167, DOI 10.1158/0008-5472.CAN-04-0970; Wilson P. M., 2007, CANCER RES, V1, P237; Zhang LQ, 2015, MOL CELL BIOL, V35, P3324, DOI 10.1128/MCB.00692-15; Zhou W, 2014, SEMIN CELL DEV BIOL, V35, P14, DOI 10.1016/j.semcdb.2014.07.013	47	66	66	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2016	35	26					3399	3409		10.1038/onc.2015.398	http://dx.doi.org/10.1038/onc.2015.398			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DQ5UI	26522725				2022-12-17	WOS:000379270100005
J	Chaturvedi, R; de Sablet, T; Asim, M; Piazuelo, MB; Barry, DP; Verriere, TG; Sierra, JC; Hardbower, DM; Delgado, AG; Schneider, BG; Israel, DA; Romero-Gallo, J; Nagy, TA; Morgan, DR; Murray-Stewart, T; Bravo, LE; Peek, RM; Fox, JG; Woster, PM; Caser, RA; Correa, P; Wilson, KT				Chaturvedi, R.; de Sablet, T.; Asim, M.; Piazuelo, M. B.; Barry, D. P.; Verriere, T. G.; Sierra, J. C.; Hardbower, D. M.; Delgado, A. G.; Schneider, B. G.; Israel, D. A.; Romero-Gallo, J.; Nagy, T. A.; Morgan, D. R.; Murray-Stewart, T.; Bravo, L. E.; Peek, R. M., Jr.; Fox, J. G.; Woster, P. M.; Caser, R. A.; Correa, P., Jr.; Wilson, K. T.			Increased Helicobacter pylori-associated gastric cancer risk in the Andean region of Colombia is mediated by spermine oxidase	ONCOGENE			English	Article							NECROSIS-FACTOR-ALPHA; EPITHELIAL-CELLS; BIOLOGICAL-ACTIVITY; GENE POLYMORPHISMS; CAGA; INFECTION; CARCINOGENESIS; INDUCTION; APOPTOSIS; LESIONS	Helicobacter pylori infection causes gastric cancer, the third leading cause of cancer death worldwide. More than half of the world's population is infected, making universal eradication impractical. Clinical trials suggest that antibiotic treatment only reduces gastric cancer risk in patients with non-atrophic gastritis (NAG), and is ineffective once preneoplastic lesions of multifocal atrophic gastritis (MAG) and intestinal metaplasia (IM) have occurred. Therefore, additional strategies for risk stratification and chemoprevention of gastric cancer are needed. We have implicated polyamines, generated by the rate-limiting enzyme ornithine decarboxylase (ODC), in gastric carcinogenesis. During H. pylori infection, the enzyme spermine oxidase (SMOX) is induced, which generates hydrogen peroxide from the catabolism of the polyamine spermine. Herein, we assessed the role of SMOX in the increased gastric cancer risk in Colombia associated with the Andean mountain region when compared with the low-risk region on the Pacific coast. When cocultured with gastric epithelial cells, clinical strains of H. pylori from the high-risk region induced more SMOX expression and oxidative DNA damage, and less apoptosis than low-risk strains. These findings were not attributable to differences in the cytotoxin-associated gene A oncoprotein. Gastric tissues from subjects from the high-risk region exhibited greater levels of SMOX and oxidative DNA damage by immunohistochemistry and flow cytometry, and this occurred in NAG, MAG and IM. In Mongolian gerbils, a prototype colonizing strain from the high-risk region induced more SMOX, DNA damage, dysplasia and adenocarcinoma than a colonizing strain from the low-risk region. Treatment of gerbils with either alpha-difluoromethylornithine, an inhibitor of ODC, or MDL 72527 (N-1, N-4-Di(buta-2,3-dien-1-yl) butane-1,4-diamine dihydrochloride), an inhibitor of SMOX, reduced gastric dysplasia and carcinoma, as well as apoptosis-resistant cells with DNA damage. These data indicate that aberrant activation of polyamine-driven oxidative stress is a marker of gastric cancer risk and a target for chemoprevention.	[Chaturvedi, R.; de Sablet, T.; Asim, M.; Piazuelo, M. B.; Barry, D. P.; Verriere, T. G.; Sierra, J. C.; Hardbower, D. M.; Delgado, A. G.; Schneider, B. G.; Israel, D. A.; Romero-Gallo, J.; Nagy, T. A.; Morgan, D. R.; Peek, R. M., Jr.; Correa, P., Jr.; Wilson, K. T.] Vanderbilt Univ, Div Gastroenterol Hepatol & Nutr, Dept Med, Med Ctr, Nashville, TN 37232 USA; [Hardbower, D. M.; Peek, R. M., Jr.; Wilson, K. T.] Vanderbilt Univ, Dept Pathol Microbiol & Immunol, Med Ctr, Nashville, TN 37232 USA; [Murray-Stewart, T.; Correa, P., Jr.] Johns Hopkins Univ, Sch Med, Dept Oncol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA; [Bravo, L. E.] Univ Valle, Sch Med, Dept Pathol, Cali, Colombia; [Fox, J. G.] MIT, Div Comparat Med, Cambridge, MA 02139 USA; [Woster, P. M.] Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA; [Wilson, K. T.] Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37232 USA; [Wilson, K. T.] Vet Affairs Tennessee Valley Healthcare Syst, Nashville, TN USA	Vanderbilt University; Vanderbilt University; Johns Hopkins University; Johns Hopkins Medicine; Universidad del Valle; Massachusetts Institute of Technology (MIT); Medical University of South Carolina; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Wilson, KT (corresponding author), Vanderbilt Univ, Div Gastroenterol Hepatol & Nutr, Dept Med, Sch Med, 1030C MRB 4,2215B Garland Ave, Nashville, TN 37232 USA.	keith.wilson@vanderbilt.edu	Woster, Patrick M/A-5604-2010; Barry, Daniel P/B-5647-2008; Bravo, Luis Eduardo/G-9671-2013; Bravo, Luis Eduardo/AAB-7209-2019; de Sablet, Thibaut/AAI-4513-2020; Bravo, Luis/K-9882-2014; Stewart, Tracy Murray/B-6137-2017	Woster, Patrick M/0000-0002-9471-1916; Barry, Daniel P/0000-0002-3972-3914; Bravo, Luis Eduardo/0000-0002-9708-0312; Bravo, Luis/0000-0002-9708-0312; Stewart, Tracy Murray/0000-0001-8679-6414; Casero, Robert/0000-0001-5653-3306; Schneider, Barbara/0000-0003-4421-1355; Wilson, Keith/0000-0003-4421-1830	National Institutes of Health [R01DK053620, R01AT004821, P01CA028842, P01CA116087, R01CA077955, R01DK058587, R01CA051085, R01CA098454, K01AT007324]; Flow Cytometry Core of the Vanderbilt Digestive Disease Research Center [P30DK058404]; Flow Cytometry Core of the Vanderbilt Ingram Cancer Center [P30CA68485]; Office of Medical Research, Department of Veterans Affairs [1I01BX001453]; Philippe Foundation;  [UL1RR024975];  [T32GM008554]; NATIONAL CANCER INSTITUTE [R01CA051085, R01CA190612, P01CA028842, R01CA098454, P01CA116087, R01CA077955, P30CA068485] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000445] Funding Source: NIH RePORTER; NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE [K01AT007324] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [R01AT004821] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024975] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058587, P30DK058404, R01DK053620] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES002109] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008554] Funding Source: NIH RePORTER; Veterans Affairs [I01BX001453] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Flow Cytometry Core of the Vanderbilt Digestive Disease Research Center; Flow Cytometry Core of the Vanderbilt Ingram Cancer Center; Office of Medical Research, Department of Veterans Affairs(US Department of Veterans Affairs); Philippe Foundation; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Veterans Affairs(US Department of Veterans Affairs)	This study was supported by National Institutes of Health Grants R01DK053620 and R01AT004821 (to KTW), P01CA028842 (to KTW, JGF and PC), P01CA116087 (to RMP and KTW), R01CA077955 and R01DK058587 (to RMP), R01CA051085 and R01CA098454 (to RAC), K01AT007324 (to RC), the Flow Cytometry Core of the Vanderbilt Digestive Disease Research Center grant (P30DK058404), the Flow Cytometry Core of the Vanderbilt Ingram Cancer Center (P30CA68485), UL1RR024975 (Vanderbilt CTSA, Pilot Project to KTW) and Merit Review Grant 1I01BX001453 from the Office of Medical Research, Department of Veterans Affairs (to KTW). DMH was supported by T32GM008554. TDS was supported in part by the Philippe Foundation.	Babbar N, 2006, CANCER RES, V66, P11125, DOI 10.1158/0008-5472.CAN-06-3174; Backert S, 2001, MOL MICROBIOL, V42, P631, DOI 10.1046/j.1365-2958.2001.02649.x; Basso D, 2008, GASTROENTEROLOGY, V135, P91, DOI 10.1053/j.gastro.2008.03.041; Basu HS, 2009, CANCER RES, V69, P7689, DOI 10.1158/0008-5472.CAN-08-2472; BLASER MJ, 1995, CANCER RES, V55, P2111; Bravo LE, 2002, AM J GASTROENTEROL, V97, P2839, DOI 10.1111/j.1572-0241.2002.07031.x; CASERO RA, 1989, CANCER RES, V49, P3829; Chaturvedi R, 2004, J BIOL CHEM, V279, P40161, DOI 10.1074/jbc.M401370200; Chaturvedi R, 2014, GASTROENTEROLOGY, V146, P1739, DOI 10.1053/j.gastro.2014.02.005; Chaturvedi R, 2011, GASTROENTEROLOGY, V141, P1696, DOI 10.1053/j.gastro.2011.07.045; Chaturvedi R, 2010, GASTROENTEROLOGY, V139, P1686, DOI 10.1053/j.gastro.2010.06.060; Chen Y, 2008, J INFECT DIS, V198, P553, DOI 10.1086/590158; CORREA P, 1976, JNCI-J NATL CANCER I, V57, P1027, DOI 10.1093/jnci/57.5.1027; CORREA P, 1988, CANCER RES, V48, P3554; CORREA P, 1990, CANCER RES, V50, P4731; Correa P, 2010, AM J GASTROENTEROL, V105, P493, DOI 10.1038/ajg.2009.728; COVACCI A, 1993, P NATL ACAD SCI USA, V90, P5791, DOI 10.1073/pnas.90.12.5791; CUELLO C, 1976, JNCI-J NATL CANCER I, V57, P1015, DOI 10.1093/jnci/57.5.1015; de Sablet T, 2011, GUT, V60, P1189, DOI 10.1136/gut.2010.234468; Dixon MF, 1996, AM J SURG PATHOL, V20, P1161, DOI 10.1097/00000478-199610000-00001; Dominguez RL, 2013, CANCER CAUSE CONTROL, V24, P233, DOI 10.1007/s10552-012-0109-5; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Figueiredo C, 2002, J NATL CANCER I, V94, P1680, DOI 10.1093/jnci/94.22.1680; Franco AT, 2008, CANCER RES, V68, P379, DOI 10.1158/0008-5472.CAN-07-0824; Franco AT, 2005, P NATL ACAD SCI USA, V102, P10646, DOI 10.1073/pnas.0504927102; Goodwin AC, 2011, P NATL ACAD SCI USA, V108, P15354, DOI 10.1073/pnas.1010203108; Hardbower DM, 2013, GUT MICROBES, V4, P475, DOI 10.4161/gmic.25583; Higashi H, 2002, P NATL ACAD SCI USA, V99, P14428, DOI 10.1073/pnas.222375399; Kodaman N, 2014, P NATL ACAD SCI USA, V111, P1455, DOI 10.1073/pnas.1318093111; Koike T, 1999, AM J GASTROENTEROL, V94, P3468, DOI 10.1111/j.1572-0241.1999.01593.x; Ma JL, 2012, J NATL CANCER I, V104, P488, DOI 10.1093/jnci/djs003; Mera R, 2005, GUT, V54, P1536, DOI 10.1136/gut.2005.072009; Meyskens FL, 2008, CANCER PREV RES, V1, P32, DOI 10.1158/1940-6207.CAPR-08-0042; Morgan DR, 2013, JAMA-J AM MED ASSOC, V309, P578, DOI 10.1001/jama.2013.311; Moss SF, 1996, GUT, V38, P498, DOI 10.1136/gut.38.4.498; Nagy TA, 2009, J INFECT DIS, V199, P641, DOI 10.1086/596660; Naito M, 2006, GASTROENTEROLOGY, V130, P1181, DOI 10.1053/j.gastro.2005.12.038; Oguma K, 2008, EMBO J, V27, P1671, DOI 10.1038/emboj.2008.105; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; Peek RM, 2010, PHYSIOL REV, V90, P831, DOI 10.1152/physrev.00039.2009; Sheh A, 2013, INFECT IMMUN, V81, P2468, DOI 10.1128/IAI.01182-12; Sicinschi LA, 2010, CLIN MICROBIOL INFEC, V16, P369, DOI 10.1111/j.1469-0691.2009.02811.x; Tammer I, 2007, GASTROENTEROLOGY, V132, P1309, DOI 10.1053/j.gastro.2007.01.050; Torres J, 2013, CANCER CAUSE CONTROL, V24, P249, DOI 10.1007/s10552-012-0114-8; Tsutsumi R, 2003, J BIOL CHEM, V278, P3664, DOI 10.1074/jbc.M208155200; TUMMURU MKR, 1994, INFECT IMMUN, V62, P2609, DOI 10.1128/IAI.62.6.2609-2613.1994; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Valentin-Vega YA, 2008, CELL DEATH DIFFER, V15, P1772, DOI 10.1038/cdd.2008.109; Watanabe T, 1998, GASTROENTEROLOGY, V115, P642, DOI 10.1016/S0016-5085(98)70143-X; Wong BCY, 2004, JAMA-J AM MED ASSOC, V291, P187, DOI 10.1001/jama.291.2.187; Wroblewski LE, 2010, CLIN MICROBIOL REV, V23, P713, DOI 10.1128/CMR.00011-10; Xu HX, 2004, CANCER RES, V64, P8521, DOI 10.1158/0008-5472.CAN-04-3511; You WC, 2006, JNCI-J NATL CANCER I, V98, P974, DOI 10.1093/jnci/djj264; Zabaleta J, 2006, AM J GASTROENTEROL, V101, P163, DOI 10.1111/j.1572-0241.2006.00387.x; Zell JA, 2010, J NATL CANCER I, V102, P1513, DOI 10.1093/jnci/djq325	55	66	69	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	26					3429	3440		10.1038/onc.2014.273	http://dx.doi.org/10.1038/onc.2014.273			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CL3SU	25174398	Green Accepted, Green Submitted			2022-12-17	WOS:000356871700008
J	Canesin, G; Cuevas, EP; Santos, V; Lopez-Menendez, C; Moreno-Bueno, G; Huang, Y; Csiszar, K; Portillo, F; Peinado, H; Lyden, D; Cano, A				Canesin, G.; Cuevas, E. P.; Santos, V.; Lopez-Menendez, C.; Moreno-Bueno, G.; Huang, Y.; Csiszar, K.; Portillo, F.; Peinado, H.; Lyden, D.; Cano, A.			Lysyl oxidase-like 2 (LOXL2) and E47 EMT factor: novel partners in E-cadherin repression and early metastasis colonization	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; SUPPRESSOR-CELLS; PROGENITOR CELLS; SNAIL; RECRUITMENT; REGULATOR; REQUIRES; POLARITY	Epithelial-mesenchymal transition (EMT) has been associated with increased aggressiveness and acquisition of migratory properties providing tumor cells with the ability to invade into adjacent tissues. Downregulation of E-cadherin, a hallmark of EMT, is mediated by several transcription factors (EMT-TFs) that act also as EMT inducers, among them, Snail1 and the bHLH transcription factor E47. We previously described lysyl oxidase-like 2 (LOXL2), a member of the lysyl oxidase family, as a Snail1 regulator and EMT inducer. Here we show that LOXL2 is also an E47-interacting partner and functionally collaborates in the repression of E-cadherin promoter. Loss and gain of function analyses combined with in vivo studies in syngeneic breast cancer models demonstrate the participation of LOXL2 and E47 in tumor growth and their requirement for lung metastasis. Furthermore, LOXL2 and E47 contribute to early steps of metastatic colonization by cell and noncell autonomous functions regulating the recruitment of bone marrow progenitor cells to the lungs and by direct transcriptional regulation of fibronectin and cytokines TNFa, ANG-1 and GM-CSF. Moreover, fibronectin and GM-CSF proved to be necessary for LOXL2/E47-mediated modulation of tumor growth and lung metastasis.	[Canesin, G.; Cuevas, E. P.; Santos, V.; Lopez-Menendez, C.; Moreno-Bueno, G.; Portillo, F.; Cano, A.] Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, IdiPAZ,Dept Bioquim, Madrid 28029, Spain; [Moreno-Bueno, G.] Fdn MD Anderson Int Madrid, Madrid, Spain; [Huang, Y.; Peinado, H.; Lyden, D.] Weill Cornell Med Coll, Dept Pediat Cell & Dev Biol, New York, NY USA; [Csiszar, K.] Univ Hawaii, John A Burns Sch Med, Honolulu, HI 96822 USA	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); University of Texas System; UTMD Anderson Cancer Center; Cornell University; University of Hawaii System	Cano, A (corresponding author), Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, Dept Bioquim, Arzobispo Morcillo 2, Madrid 28029, Spain.	acano@iib.uam.es	Canesin, Giacomo/H-4541-2019; Peinado, Hector/A-6417-2013; Moreno-Bueno, Gema/K-9354-2016; Menendez, Celia Lopez/ABG-7555-2020; Cuevas, Eva P./P-4533-2019	Canesin, Giacomo/0000-0002-3318-4550; Peinado, Hector/0000-0002-4256-3413; Moreno-Bueno, Gema/0000-0002-5030-6687; Menendez, Celia Lopez/0000-0002-5967-1955; Cuevas, Eva P./0000-0001-6477-1283; Portillo Perez, Francisco/0000-0003-4922-346X	Spanish Ministry of Science and Innovation [SAF2010-21143, Consolider 2007-CS00017]; AICR [12-1057]; ISCIII [RETIC-RD12/0036/0007]; Comunidad de Madrid [S2010/BMD-2302]; Worldwide Cancer Research [12-1057] Funding Source: researchfish	Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); AICR; ISCIII(Instituto de Salud Carlos III); Comunidad de Madrid(Comunidad de Madrid); Worldwide Cancer Research	We thank members of A. Cano's group: Saleta Morales and Amalia Montes for technical support, Ana Villarejo and Fernando Salvador for help in flow cytometry and collagen crosslinking analyses, and Thomas Look, Manuel Fresno and Peter N. Cockerill for providing reagents, and Angela Nieto for reading the manuscript. The work was supported by the Spanish Ministry of Science and Innovation (SAF2010-21143; Consolider 2007-CS00017); AICR (12-1057) and ISCIII (RETIC-RD12/0036/0007) to AC, and Comunidad de Madrid (S2010/BMD-2302) to AC and GMB. EPC and VS are founded from the AICR grant.	Nieto MA, 2012, SEMIN CANCER BIOL, V22, P361, DOI 10.1016/j.semcancer.2012.05.003; Nieto MA, 2011, ANNU REV CELL DEV BI, V27, P347, DOI 10.1146/annurev-cellbio-092910-154036; Barker HE, 2012, NAT REV CANCER, V12, P540, DOI 10.1038/nrc3319; Barker HE, 2011, CANCER RES, V71, P1561, DOI 10.1158/0008-5472.CAN-10-2868; Barry-Hamilton V, 2010, NAT MED, V16, P1009, DOI 10.1038/nm.2208; Bosiljcic M, 2011, CANCER RES, V71, P5050, DOI 10.1158/0008-5472.CAN-10-3982; Cano A, 2012, FUTURE ONCOL, V8, P1095, DOI [10.2217/FON.12.105, 10.2217/fon.12.105]; Cox TR, 2013, CANCER RES, V73, P1721, DOI 10.1158/0008-5472.CAN-12-2233; Csiszar K, 2001, PROG NUCLEIC ACID RE, V70, P1, DOI 10.1016/S0079-6603(01)70012-8; Cubillo E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059948; Cuevas EP, 2014, BIOL OPEN, V3, P129, DOI 10.1242/bio.20146841; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Erler JT, 2009, CANCER CELL, V15, P35, DOI 10.1016/j.ccr.2008.11.012; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Ewens A, 2005, ANTICANCER RES, V25, P3905; Fogelgren B, 2005, J BIOL CHEM, V280, P24690, DOI 10.1074/jbc.M412979200; Gao DC, 2012, CANCER RES, V72, P1384, DOI 10.1158/0008-5472.CAN-11-2905; Hiratsuka S, 2008, NAT CELL BIOL, V10, P1349, DOI 10.1038/ncb1794; Hiratsuka S, 2006, NAT CELL BIOL, V8, P1369, DOI 10.1038/ncb1507; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Liu XQ, 2004, NAT GENET, V36, P178, DOI 10.1038/ng1297; Maki JM, 2002, CIRCULATION, V106, P2503, DOI 10.1161/01.CIR.0000038109.84500.1E; Massari ME, 1996, MOL CELL BIOL, V16, P121; Moreno-Bueno G, 2008, ONCOGENE, V27, P6958, DOI 10.1038/onc.2008.346; Moreno-Bueno G, 2011, EMBO MOL MED, V3, P528, DOI 10.1002/emmm.201100156; Moreno-Bueno G, 2009, NAT PROTOC, V4, P1591, DOI 10.1038/nprot.2009.152; Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012; Oskarsson T, 2011, NAT MED, V17, P867, DOI 10.1038/nm.2379; Peinado H, 2005, EMBO J, V24, P3446, DOI 10.1038/sj.emboj.7600781; Peinado H, 2004, J CELL SCI, V117, P2827, DOI 10.1242/jcs.01145; Peinado H, 2008, CANCER RES, V68, P4541, DOI 10.1158/0008-5472.CAN-07-6345; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Peinado H, 2011, SEMIN CANCER BIOL, V21, P139, DOI 10.1016/j.semcancer.2011.01.002; Peng L, 2009, CARCINOGENESIS, V30, P1660, DOI 10.1093/carcin/bgp178; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Psaila B, 2009, NAT REV CANCER, V9, P285, DOI 10.1038/nrc2621; Sceneay J, 2012, CANCER RES, V72, P3906, DOI 10.1158/0008-5472.CAN-11-3873; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Wong CCL, 2011, P NATL ACAD SCI USA, V108, P16369, DOI 10.1073/pnas.1113483108; Ye XZ, 2010, J GENET GENOMICS, V37, P423, DOI 10.1016/S1673-8527(09)60061-8	43	66	71	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2015	34	8					951	964		10.1038/onc.2014.23	http://dx.doi.org/10.1038/onc.2014.23			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RT	24632622	Green Submitted			2022-12-17	WOS:000350121300002
J	Cui, D; Li, L; Lou, H; Sun, H; Ngai, SM; Shao, G; Tang, J				Cui, D.; Li, L.; Lou, H.; Sun, H.; Ngai, S-M; Shao, G.; Tang, J.			The ribosomal protein S26 regulates p53 activity in response to DNA damage	ONCOGENE			English	Article						ribosomal proteins; RPS26; p53; DNA damage response; p53 acetylation	INDUCED PHOSPHORYLATION; MEDIATES STABILIZATION; ACTIVATES P53; MDM2; L11; INHIBITION; L5; DEGRADATION; UBIQUITINATION; ACETYLATION	Ribosomal proteins have emerged as novel regulators of the Mdm2-p53 feedback loop, especially in the context of ribosomal stress. RPS26 is a recently identified Diamond-Blackfan Anemia-related ribosomal protein and its role in p53 activation has not been previously explored. In this study we found knockdown of RPS26 induced p53 stabilization and activation via a RPL11-dependent mechanism, resulting in p53-dependent cell growth inhibition. Moreover, RPS26 has the ability to interact with Mdm2 and inhibits Mdm2-mediated p53 ubiquitination that leads to p53 stabilization upon overexpression. Importantly, we discovered that RPS26 knockdown impaired p53' s ability to transcriptionally activate its target genes in response to DNA damage, without affecting its stability. Accordingly, the cells lost the ability to induce G2/M cell cycle arrest. We further found that upon RPS26 knockdown, the DNA damage induced recruitment of p53 to the promoters of its target genes and p53 acetylation were both greatly reduced. In addition, RPS26 can interact with p53 independent of Mdm2 and coexist in a complex with p53 and p300. These data establish a role of RPS26 in DNA damage response by directly influencing p53 transcriptional activity, and suggest that RPS26 acts distinctively in different scenarios of p53 activation. Our finding also implicates p53 transcriptional activity control as an important mechanism of p53 regulation by ribosomal proteins.	[Cui, D.; Li, L.; Lou, H.; Sun, H.; Tang, J.] China Agr Univ, State Key Lab Agrobiotechnol, Beijing 100193, Peoples R China; [Cui, D.; Li, L.; Sun, H.; Tang, J.] China Agr Univ, Coll Vet Med, Dept Basic Vet Med, Beijing 100193, Peoples R China; [Lou, H.] China Agr Univ, Coll Biol Sci, Beijing 100193, Peoples R China; [Ngai, S-M] Chinese Univ Hong Kong, Dept Biol, Hong Kong, Hong Kong, Peoples R China; [Ngai, S-M] Chinese Univ Hong Kong, State China Key Lab Agrobiotechnol, Hong Kong, Hong Kong, Peoples R China; [Shao, G.] Peking Univ, Hlth Sci Ctr, Sch Basic Med Sci, Dept Cell Biol, Beijing 100871, Peoples R China	China Agricultural University; China Agricultural University; China Agricultural University; Chinese University of Hong Kong; Chinese University of Hong Kong; Peking University	Tang, J (corresponding author), China Agr Univ, Coll Vet Med, 2 Yuanmingyuan West Rd, Beijing 100193, Peoples R China.	jtang@cau.edu.cn	Ngai, Sai Ming/S-4898-2018; Lou, Huiqiang/B-6287-2012	Ngai, Sai Ming/0000-0002-4484-2483; Lou, Huiqiang/0000-0003-4465-6186	National Natural Science Foundation of China [31171331]; Program for New Century Excellent Talents in University of China [NCET-09-0737]; State Key Laboratory of Agrobiotechnology of China [2010SKLAB06-5]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for New Century Excellent Talents in University of China(Program for New Century Excellent Talents in University (NCET)); State Key Laboratory of Agrobiotechnology of China	We thank Dr Xiaolu Yang for generously providing constructs and reagents; Dr Weiguo Zhu for providing the Ha-p300 expression plasmid; Yongqiang Wang for technical assistance; Dr Julia Hill for critically reading the manuscript and Caroline Kitzmiller for proofreading the manuscript. This work was supported by the National Natural Science Foundation of China (31171331); the Program for New Century Excellent Talents in University of China (NCET-09-0737) and the research fund from the State Key Laboratory of Agrobiotechnology of China (2010SKLAB06-5).	Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bhat KP, 2004, EMBO J, V23, P2402, DOI 10.1038/sj.emboj.7600247; Boulon S, 2010, MOL CELL, V40, P216, DOI 10.1016/j.molcel.2010.09.024; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Chen D, 2007, ONCOGENE, V26, P5029, DOI 10.1038/sj.onc.1210327; Chen J, 2012, J BIOL CHEM, V287, P16467, DOI 10.1074/jbc.M112.349274; Cmejla R, 2009, HUM MUTAT, V30, P321, DOI 10.1002/humu.20874; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Dai MS, 2007, EMBO J, V26, P3332, DOI 10.1038/sj.emboj.7601776; Dai MS, 2006, J BIOL CHEM, V281, P24304, DOI 10.1074/jbc.M602596200; Deisenroth C, 2010, ONCOGENE, V29, P4253, DOI 10.1038/onc.2010.189; Doherty L, 2010, AM J HUM GENET, V86, P222, DOI 10.1016/j.ajhg.2009.12.015; Fumagalli S, 2012, GENE DEV, V26, P1028, DOI 10.1101/gad.189951.112; Fumagalli S, 2009, NAT CELL BIOL, V11, P501, DOI 10.1038/ncb1858; Gazda HT, 2012, HUM MUTAT, V33, P1037, DOI 10.1002/humu.22081; Gazda HT, 2008, AM J HUM GENET, V83, P769, DOI 10.1016/j.ajhg.2008.11.004; Gu B, 2012, INT J BIOL SCI, V8, P672, DOI 10.7150/ijbs.4283; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Horn HF, 2008, ONCOGENE, V27, P5774, DOI 10.1038/onc.2008.189; Ivanov AV, 2005, BBA-GENE STRUCT EXPR, V1727, P134, DOI 10.1016/j.bbaexp.2004.12.011; Jin A, 2004, MOL CELL BIOL, V24, P7669, DOI 10.1128/MCB.24.17.7669-7680.2004; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kuroda T, 2011, EMBO J, V30, P1054, DOI 10.1038/emboj.2011.23; Lam YW, 2007, CURR BIOL, V17, P749, DOI 10.1016/j.cub.2007.03.064; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li LJ, 2012, DNA REPAIR, V11, P112, DOI 10.1016/j.dnarep.2011.10.010; Llanos S, 2010, CELL CYCLE, V9, P4005, DOI 10.4161/cc.9.19.13299; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Mahata B, 2012, ONCOGENE, V31, P3060, DOI 10.1038/onc.2011.482; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Ofir-Rosenfeld Y, 2008, MOL CELL, V32, P180, DOI 10.1016/j.molcel.2008.08.031; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; Scacheri PC, 2004, P NATL ACAD SCI USA, V101, P1892, DOI 10.1073/pnas.0308698100; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Sun XX, 2008, J BIOL CHEM, V283, P12387, DOI 10.1074/jbc.M801387200; Sun XX, 2007, J BIOL CHEM, V282, P8052, DOI 10.1074/jbc.M610621200; Sun XX, 2011, J BIOL CHEM, V286, P22730, DOI 10.1074/jbc.M111.223651; Sun XX, 2010, J BIOL CHEM, V285, P25812, DOI 10.1074/jbc.M109.098442; Sundqvist A, 2009, EMBO REP, V10, P1132, DOI 10.1038/embor.2009.178; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Tang J, 2006, NAT CELL BIOL, V8, P855, DOI 10.1038/ncb1442; Tang Y, 2008, CELL, V133, P612, DOI 10.1016/j.cell.2008.03.025; Teufel DP, 2009, ONCOGENE, V28, P2112, DOI 10.1038/onc.2009.71; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Wan FY, 2007, CELL, V131, P927, DOI 10.1016/j.cell.2007.10.009; Wanzel M, 2008, NAT CELL BIOL, V10, P1051, DOI 10.1038/ncb1764; Xiong X, 2011, ONCOGENE, V30, P1798, DOI 10.1038/onc.2010.569; Zhang X, 2013, ONCOGENE, V32, P2782, DOI 10.1038/onc.2012.289; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; Zhang Y, 2010, NUCLEIC ACIDS RES, V38, P6544, DOI 10.1093/nar/gkq536; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003; Zhou X, 2013, ONCOGENE, V32, P388, DOI 10.1038/onc.2012.63; Zhu Y, 2009, MOL CELL, V35, P316, DOI 10.1016/j.molcel.2009.07.014	60	66	69	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2014	33	17					2225	2235		10.1038/onc.2013.170	http://dx.doi.org/10.1038/onc.2013.170			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF8WJ	23728348				2022-12-17	WOS:000334996000008
J	Vultur, A; Villanueva, J; Krepler, C; Rajan, G; Chen, Q; Xiao, M; Li, L; Gimotty, PA; Wilson, M; Hayden, J; Keeney, F; Nathanson, KL; Herlyn, M				Vultur, A.; Villanueva, J.; Krepler, C.; Rajan, G.; Chen, Q.; Xiao, M.; Li, L.; Gimotty, P. A.; Wilson, M.; Hayden, J.; Keeney, F.; Nathanson, K. L.; Herlyn, M.			MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines	ONCOGENE			English	Article						melanoma; MEK; STAT3; targeted therapy; invasion; resistance	RAF INHIBITORS; ACQUIRED-RESISTANCE; KINASE INHIBITOR; AZD6244 ARRY-142886; DRIVEN RESISTANCE; IMPROVED SURVIVAL; POTENT INHIBITOR; BRAF INHIBITION; ACTIVATION; MIGRATION	Elevated activity of the mitogen-activated protein kinase (MAPK) signaling cascade is found in the majority of human melanomas and is known to regulate proliferation, survival and invasion. Current targeted therapies focus on decreasing the activity of this pathway; however, we do not fully understand how these therapies impact tumor biology, especially given that melanoma is a heterogeneous disease. Using a three-dimensional (3D), collagen-embedded spheroid melanoma model, we observed that MEK and BRAF inhibitors can increase the invasive potential of B20% of human melanoma cell lines. The invasive cell lines displayed increased receptor tyrosine kinase (RTK) activity and activation of the Src/FAK/signal transducers and activators of transcription-3 (STAT3) signaling axis, also associated with increased cell-to-cell adhesion and cadherin engagement following MEK inhibition. Targeting various RTKs, Src, FAK and STAT3 with small molecule inhibitors in combination with a MEK inhibitor prevented the invasive phenotype, but only STAT3 inhibition caused cell death in the 3D context. We further show that STAT3 signaling is induced in BRAF-inhibitor-resistant cells. Our findings suggest that MEK and BRAF inhibitors can induce STAT3 signaling, causing potential adverse effects such as increased invasion. We also provide the rationale for the combined targeting of the MAPK pathway along with inhibitors of RTKs, SRC or STAT3 to counteract STAT3-mediated resistance phenotypes.	[Vultur, A.; Villanueva, J.; Krepler, C.; Rajan, G.; Chen, Q.; Xiao, M.; Li, L.; Herlyn, M.] Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, Philadelphia, PA 19104 USA; [Gimotty, P. A.] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; [Wilson, M.; Nathanson, K. L.] Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA; [Hayden, J.; Keeney, F.; Herlyn, M.] Wistar Inst Anat & Biol, Div Mol & Cellular Biol, Imaging Facil, Philadelphia, PA 19104 USA	The Wistar Institute; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; The Wistar Institute	Herlyn, M (corresponding author), Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, 3601 Spruce St, Philadelphia, PA 19104 USA.	herlynm@wistar.org	Gimotty, Phyllis/GWZ-4136-2022	Gimotty, Phyllis/0000-0002-3850-9799; Nathanson, Katherine/0000-0002-6740-0901; Vultur, Adina/0000-0003-0068-9496; Wilson, Melissa/0000-0002-5391-7838	NIH [PO1 CA114046, P01 CA025874, P30 CA010815, R01 CA047159, CA076674]; Dr Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF); NATIONAL CANCER INSTITUTE [P01CA025874, K01CA175269, T32CA009615, P30CA016520, R01CA047159, P30CA010815, P01CA114046] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dr Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank P Sompalli and F Raman for technical assistance. We thank GlaxoSmithKline for SB590885, and Dr L Raptis (Queen's University, Canada) for CPA-7. We also thank R Delgiacco of the Wistar Histology Facility. AV, JV, KLN and MH are members of the ITMAT-University of Pennsylvania. This work was supported by NIH grants PO1 CA114046, P01 CA025874, P30 CA010815, R01 CA047159 and CA076674, and by the Dr Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF).	Arulanandam R, 2009, MOL CANCER RES, V7, P1310, DOI 10.1158/1541-7786.MCR-08-0469; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Buettner R, 2008, MOL CANCER RES, V6, P1766, DOI 10.1158/1541-7786.MCR-08-0169; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Christofori G, 2003, EMBO J, V22, P2318, DOI 10.1093/emboj/cdg228; Debidda M, 2005, J BIOL CHEM, V280, P17275, DOI 10.1074/jbc.M413187200; Dry JR, 2010, CANCER RES, V70, P2264, DOI 10.1158/0008-5472.CAN-09-1577; Dudka AA, 2010, CANCER RES, V70, P3391, DOI 10.1158/0008-5472.CAN-09-3033; Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021; Fecher LA, 2007, J CLIN ONCOL, V25, P1606, DOI 10.1200/JCO.2006.06.0442; Ferguson J, 2013, ONCOGENE, V32, P86, DOI 10.1038/onc.2012.25; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Fukunaga-Kalabis M, 2006, J CELL BIOL, V175, P563, DOI 10.1083/jcb.200602132; Gopal YNV, 2010, CANCER RES, V70, P8736, DOI 10.1158/0008-5472.CAN-10-0902; Gowrishankar K, 2012, J INVEST DERMATOL, V132, P1850, DOI 10.1038/jid.2012.63; Greger JG, 2012, MOL CANCER THER, V11, P909, DOI 10.1158/1535-7163.MCT-11-0989; Haass NK, 2008, CLIN CANCER RES, V14, P230, DOI 10.1158/1078-0432.CCR-07-1440; Haass NK, 2004, J MOL HISTOL, V35, P309; Halaban R, 2010, PIGM CELL MELANOMA R, V23, P190, DOI 10.1111/j.1755-148X.2010.00685.x; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; ILIOPOULOS D, 1989, J NATL CANCER I, V81, P440, DOI 10.1093/jnci/81.6.440; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Lee JT, 2010, PIGM CELL MELANOMA R, V23, P820, DOI 10.1111/j.1755-148X.2010.00763.x; Littlefield SL, 2008, INORG CHEM, V47, P2798, DOI 10.1021/ic702057q; MacConaill LE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007887; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Nissan MH, 2011, CURR ONCOL REP, V13, P479, DOI 10.1007/s11912-011-0198-4; Niu G, 2002, ONCOGENE, V21, P7001, DOI 10.1038/sj.onc.1205859; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Ragoussis J, 2006, PLOS GENET, V2, P920, DOI 10.1371/journal.pgen.0020100; Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020; Sakaguchi M, 2012, J INVEST DERMATOL, V132, P1877, DOI 10.1038/jid.2012.45; Satyamoorthy K, 2003, CANCER RES, V63, P756; Senft C, 2011, J NEURO-ONCOL, V101, P393, DOI 10.1007/s11060-010-0273-y; Shi HB, 2011, CANCER RES, V71, P5067, DOI 10.1158/0008-5472.CAN-11-0140; Smalley KSM, 2008, CANCER RES, V68, P5743, DOI 10.1158/0008-5472.CAN-08-0235; Smalley KSM, 2006, MOL CANCER THER, V5, P1136, DOI 10.1158/1535-7163.MCT-06-0084; Smalley KSM, 2005, ANN NY ACAD SCI, V1059, P16, DOI 10.1196/annals.1339.005; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Thomas RK, 2007, NAT GENET, V39, P347, DOI 10.1038/ng1975; Vasudevan KM, 2009, CANCER CELL, V16, P21, DOI 10.1016/j.ccr.2009.04.012; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Vultur A, 2004, ONCOGENE, V23, P2600, DOI 10.1038/sj.onc.1207378; Vultur A, 2008, MOL CANCER THER, V7, P1185, DOI 10.1158/1535-7163.MCT-08-0126; Wagle N, 2011, J CLIN ONCOL, V29, P3085, DOI 10.1200/JCO.2010.33.2312; Wang YZ, 2000, ONCOGENE, V19, P2075, DOI 10.1038/sj.onc.1203548; Weng YI, 2008, ALCOHOL, V42, P397, DOI 10.1016/j.alcohol.2008.02.004; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Zipser MC, 2011, PIGM CELL MELANOMA R, V24, P326, DOI 10.1111/j.1755-148X.2010.00823.x; Zong CS, 2000, J BIOL CHEM, V275, P15099, DOI 10.1074/jbc.M000089200	55	66	70	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2014	33	14					1850	1861		10.1038/onc.2013.131	http://dx.doi.org/10.1038/onc.2013.131			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RE	23624919	Green Accepted			2022-12-17	WOS:000334345500011
J	Kwong, LN; Davies, MA				Kwong, L. N.; Davies, M. A.			Targeted therapy for melanoma: rational combinatorial approaches	ONCOGENE			English	Review						melanoma; targeted therapy; BRAF; NRAS	DOSE-ESCALATION; MEK INHIBITION; PHASE-I; METASTATIC MELANOMA; ACQUIRED-RESISTANCE; IMPROVED SURVIVAL; KINASE INHIBITOR; RAF INHIBITORS; MUTANT BRAF; CELL-DEATH	The treatment of melanoma, the most aggressive form of skin cancer, is being revolutionized by the development of personalized targeted therapy approaches. Mutant-selective BRAF inhibitors and MEK inhibitors have demonstrated impressive clinical results in molecularly selected patients. However, emerging understanding of the molecular heterogeneity of this disease and the identification of multiple mechanisms of resistance to targeted therapies strongly support the rationale for combinatorial approaches. In this review, we will discuss the preclinical and clinical studies that are testing leading hypotheses and emerging combinatorial strategies for the future.	[Kwong, L. N.] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77054 USA; [Davies, M. A.] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77054 USA; [Davies, M. A.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77054 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Davies, MA (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, 7455 Fannin,Unit 0904, Houston, TX 77054 USA.	mdavies@mdanderson.org	Davies, Michael/GWV-2527-2022		NIH/NCI [1R01CA154710-01]; Cancer Prevention Research Institute of Texas; American Society of Clinical Oncology; MD Anderson SPORE in Melanoma [CA093459-06]; Melanoma Research Alliance; American Cancer Society [117842-PF-09-261-TBG]; NATIONAL CANCER INSTITUTE [P50CA093459, R01CA154710] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Prevention Research Institute of Texas; American Society of Clinical Oncology; MD Anderson SPORE in Melanoma; Melanoma Research Alliance; American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	MAD is supported by funding from the NIH/NCI (1R01CA154710-01), the Cancer Prevention Research Institute of Texas, the American Society of Clinical Oncology, The MD Anderson SPORE in Melanoma (P50 CA093459-06) and the Melanoma Research Alliance. LK is supported by a Postdoctoral Fellowship from the American Cancer Society (117842-PF-09-261-TBG).	Aguissa-Toure AH, 2012, CELL MOL LIFE SCI, V69, P1475, DOI 10.1007/s00018-011-0878-0; Algazi AP, 2012, BRIT J CANCER, V106, P85, DOI 10.1038/bjc.2011.514; Atkins MB, 1999, J CLIN ONCOL, V17, P2105, DOI 10.1200/JCO.1999.17.7.2105; Bedogni B, 2006, MOL CANCER THER, V5, P3071, DOI 10.1158/1535-7163.MCT-06-0269; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Boni A, 2010, CANCER RES, V70, P5213, DOI 10.1158/0008-5472.CAN-10-0118; BOS JL, 1989, CANCER RES, V49, P4682; Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chattopadhyay C, 2012, INT J CANCER, V131, pE56, DOI 10.1002/ijc.26487; Chiarion-Sileni V, 2013, J CLIN ONCOL, V31; Colomba A, 2011, BLOOD CANCER J, V1, DOI 10.1038/bcj.2011.19; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; De Luca A, 2012, EXPERT OPIN THER TAR, V16, pS17, DOI 10.1517/14728222.2011.639361; Deng W, 2012, PIGM CELL MELANOMA R, V25, DOI 10.1111/j.1755-148X.2011.00950.x; Devitt B, 2011, PIGM CELL MELANOMA R, V24, P666, DOI 10.1111/j.1755-148X.2011.00873.x; Dumaz N, 2006, CANCER RES, V66, P9483, DOI 10.1158/0008-5472.CAN-05-4227; Eustace AJ, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-53; Falchook GS, 2012, LANCET ONCOL, V13, P782, DOI 10.1016/S1470-2045(12)70269-3; Fecher LA, 2008, CURR OPIN ONCOL, V20, P183, DOI 10.1097/CCO.0b013e3282f5271c; Ferguson J, 2013, ONCOGENE, V32, P86, DOI 10.1038/onc.2012.25; Flaherty K, 2011, PIGM CELL MELANOMA R, V24, P1022; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Flaherty KT, 2012, CLIN CANCER RES, V18, P568, DOI 10.1158/1078-0432.CCR-11-0509; Goel VK, 2006, J INVEST DERMATOL, V126, P154, DOI 10.1038/sj.jid.5700026; Gopal YNV, 2010, CANCER RES, V70, P8736, DOI 10.1158/0008-5472.CAN-10-0902; Halaban R, 2010, PIGM CELL MELANOMA R, V23, P190, DOI 10.1111/j.1755-148X.2010.00685.x; Harbour JW, 2010, SCIENCE, V330, P1410, DOI 10.1126/science.1194472; Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Hocker T, 2007, HUM MUTAT, V28, P578, DOI 10.1002/humu.20481; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Homsi J, 2009, MELANOMA RES, V19, P167, DOI 10.1097/CMR.0b013e328304974c; Hong DS, 2012, CLIN CANCER RES, V18, P2326, DOI 10.1158/1078-0432.CCR-11-2515; Ihle NT, 2012, JNCI-J NATL CANCER I, V104, P228, DOI 10.1093/jnci/djr523; Jaiswal BS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005717; Jakob JA, 2012, CANCER-AM CANCER SOC, V118, P4014, DOI 10.1002/cncr.26724; Kim KB, 2011, PIGM CELL MELANOMA R, V24, P1021; Kirkwood JM, 2012, CLIN CANCER RES, V18, P555, DOI 10.1158/1078-0432.CCR-11-1491; Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359; Kwong LN, 2012, NAT MED, V18, P1503, DOI 10.1038/nm.2941; Lai F, 2012, ADV PHARMACOL, V65, P27, DOI 10.1016/B978-0-12-397927-8.00002-6; Lasithiotakis KG, 2008, J INVEST DERMATOL, V128, P2013, DOI 10.1038/jid.2008.44; Long GV, 2011, J CLIN ONCOL, V29, P1239, DOI 10.1200/JCO.2010.32.4327; Martinez-Garcia M, 2012, CLIN CANCER RES, V18, P4806, DOI 10.1158/1078-0432.CCR-12-0742; McArthur GA, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.8502; Means-Powell JA, 2012, J CLIN ONCOL S, V30, P8519; Mishra PJ, 2010, ONCOGENE, V29, P2449, DOI 10.1038/onc.2009.521; Montagut C, 2008, CANCER RES, V68, P4853, DOI 10.1158/0008-5472.CAN-07-6787; Nathanson KL, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.8501; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Onken MD, 2008, INVEST OPHTH VIS SCI, V49, P5230, DOI 10.1167/iovs.08-2145; Paraiso KHT, 2012, CLIN CANCER RES, V18, P2502, DOI 10.1158/1078-0432.CCR-11-2612; Paraiso KHT, 2011, CANCER RES, V71, P2750, DOI 10.1158/0008-5472.CAN-10-2954; Phan GQ, 2001, J CLIN ONCOL, V19, P3477, DOI 10.1200/JCO.2001.19.15.3477; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Poulikakos PI, 2011, CANCER CELL, V19, P11, DOI 10.1016/j.ccr.2011.01.008; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; Roberts PJ, 2012, CLIN CANCER RES, V18, P5290, DOI 10.1158/1078-0432.CCR-12-0563; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Rodrik-Outmezguine VS, 2011, CANCER DISCOV, V1, P248, DOI 10.1158/2159-8290.CD-11-0085; Sharfman WH, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.8508; Shi HB, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1727; Shi HB, 2011, CANCER RES, V71, P5067, DOI 10.1158/0008-5472.CAN-11-0140; Sosman JA, 2012, J CLIN ONCOL, V30; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Su F, 2012, NEW ENGL J MED, V366, P207, DOI 10.1056/NEJMoa1105358; Tsao H, 2004, NEW ENGL J MED, V351, P998, DOI 10.1056/NEJMra041245; Tsao H, 2004, J INVEST DERMATOL, V122, P337, DOI 10.1046/j.0022-202X.2004.22243.x; Van Raamsdonk CD, 2010, NEW ENGL J MED, V363, P2191, DOI 10.1056/NEJMoa1000584; Vaughn DJ, 2009, NEW ENGL J MED, V360, P423, DOI 10.1056/NEJMc0808558; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Weber JS, 2012, J CLIN ONCOL, V30; Whittaker S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000758; Wilmott JS, 2012, MOL CANCER THER, V11, P2704, DOI 10.1158/1535-7163.MCT-12-0530; Wilmott JS, 2012, CLIN CANCER RES, V18, P1386, DOI 10.1158/1078-0432.CCR-11-2479; Wilson MA, 2012, AACR ANN M, P5557; Woodman SE, 2010, BIOCHEM PHARMACOL, V80, P568, DOI 10.1016/j.bcp.2010.04.032; Xing F, 2012, ONCOGENE, V31, P446, DOI 10.1038/onc.2011.250; Zipfel PA, 2010, ONCOGENE, V29, P4859, DOI 10.1038/onc.2010.224	84	66	78	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2014	33	1					1	9		10.1038/onc.2013.34	http://dx.doi.org/10.1038/onc.2013.34			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	282YU	23416974				2022-12-17	WOS:000329212000001
J	Zhang, L; Wu, H; Lu, D; Li, G; Sun, C; Song, H; Li, J; Zhai, T; Huang, L; Hou, C; Wang, W; Zhou, B; Chen, S; Lu, B; Zhang, X				Zhang, L.; Wu, H.; Lu, D.; Li, G.; Sun, C.; Song, H.; Li, J.; Zhai, T.; Huang, Lv; Hou, C.; Wang, W.; Zhou, B.; Chen, S.; Lu, B.; Zhang, X.			The costimulatory molecule B7-H4 promote tumor progression and cell proliferation through translocating into nucleus	ONCOGENE			English	Article						B7-H4; nuclear localization sequence (NLS); tumor infiltrated lymphocyte (TIL); renal cell carcinoma (RCC); cell cycle; cell proliferation	B7 FAMILY-MEMBER; BREAST-CANCER; PROTEIN EXPRESSION; PANCREATIC-CANCER; OVARIAN-CANCER; CARCINOMA; LOCALIZATION; SURVIVAL; IMMUNORESISTANCE; ACTIVATION	B7-H4, a member of B7 family, is a transmembrane protein and inhibits T-cells immunity. However, in a variety of tumor cells, B7-H4 was detected predominantly in intracellular compartments with unknown mechanism and functions. In this study, we analyzed B7-H4 expression and subcellular distribution by immunohistochemistry in renal cell carcinoma (RCC) tissues. B7-H4 protein was detected on the membrane, in the cytosol and/or in the nucleus in tumor tissues. The membrane and nuclear expression of B7-H4 was significantly correlated with the tumor stages of RCC. Moreover, the membrane localization of B7-H4 was inversely correlated with the intensity of tumor infiltrates lymphocyte (TILs), whereas no association was observed between nuclear expression of B7-H4 and the density of TILs status. We further identified that B7-H4 is a cytoplasmic-nuclear shuttling protein containing a functional nuclear localization sequence (NLS) motif. A point mutation of B7-H4 NLS motif blocked the leptomycin B -induced nuclear accumulation of B7-H4. HEK293 cells stably expressing B7-H4 NLS mutant exhibited more potent inhibition in T-cell proliferation and cytokine production through increasing its surface expression compared with wild-type B7-H4 transfected cells owing to their increased surface expression. Most importantly, overexpression of wild-type B7-H4 in HEK293 cells enhanced tumor cell proliferation in vitro and tumorigenicity in vivo, promoted G1/S phase transition. The regulation of cell cycle by wild-type B7-H4 was partialy due to upregulation of Cyclin D 1 and Cyclin E. A mutation of B7-H4 NLS motif abolished the B7-H4-mediated cell proliferation and cell cycle regulation. Furthermore, B7-H4 wild-type confers chemoresistance activity to RCC cell lines including Caki-1 and ACHN. Our study provides a new insight into the functional implication of B7-H4 in its subcellular localization.	[Zhang, L.; Lu, D.; Zhang, X.] Soochow Univ, Coll Med, Inst Med Biotechnol, Jiangsu Stem Cell Res Lab, Suzhou 215006, Peoples R China; [Zhang, L.; Song, H.; Li, J.; Zhai, T.; Huang, Lv; Wang, W.; Chen, S.] Soochow Univ, Dept Pharm, Coll Pharmaceut Sci, Suzhou 215006, Peoples R China; [Wu, H.; Zhou, B.] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Clin Immunol, Suzhou 215006, Peoples R China; [Li, G.; Lu, B.] Univ Pittsburgh, Dept Immunol, Pittsburgh, PA USA; [Sun, C.; Hou, C.] Soochow Univ, Affiliated Hosp 2, Dept Urol, Suzhou 215006, Peoples R China	Soochow University - China; Soochow University - China; Soochow University - China; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Soochow University - China	Zhang, X (corresponding author), Soochow Univ, Coll Med, Inst Med Biotechnol, Jiangsu Stem Cell Res Lab, Renmin Rd 178, Suzhou 215006, Peoples R China.	xueguangzh@yahoo.com.cn	Zhai, Tianhang/HGD-2935-2022	Zhang, Liang/0000-0002-5041-8005; Lu, Desheng/0000-0002-0314-5649	National Nature Science Foundation of China [30901361]; Natural Science Fund for Colleges and Universities in Jiangsu Province [09KJB310013]; National Program on Key Basic Research Project (973 Program) [2013CB530501]; Program for Changjiang Scholars and Innovative Research Team [IRT0849]; National Natural Science Foundation of China [30930085]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Jiangsu Planned Projects for Postdoctoral Research Funds [0702053]; National University Student Innovation of Soochow University	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Fund for Colleges and Universities in Jiangsu Province; National Program on Key Basic Research Project (973 Program)(National Basic Research Program of China); Program for Changjiang Scholars and Innovative Research Team(Program for Changjiang Scholars & Innovative Research Team in University (PCSIRT)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Jiangsu Planned Projects for Postdoctoral Research Funds; National University Student Innovation of Soochow University	We are grateful to Yu-ming Hu for his assistant in animal experiment; Wei Sun for collecting the clinical specimens; Ying Chen for her help in immunohistochemical analysis; and Kehua Yu as well as Yu Shen for their technical assistance in flow cytometry. This work was supported by National Nature Science Foundation of China (Grant No. 30901361); Natural Science Fund for Colleges and Universities in Jiangsu Province (Grant No. 09KJB310013); National Program on Key Basic Research Project (973 Program, Grant No. 2013CB530501); Program for Changjiang Scholars and Innovative Research Team (Grant No. IRT0849); National Natural Science Foundation of China (Grants No. 30930085); A Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Jiangsu Planned Projects for Postdoctoral Research Funds (No. 0702053); National University Student Innovation of Soochow University.	ALLRED DC, 1993, J NATL CANCER I, V85, P200, DOI 10.1093/jnci/85.3.200; Arigami T, 2011, WORLD J SURG, V35, P2051, DOI 10.1007/s00268-011-1186-4; Arnoys EJ, 2007, ACTA HISTOCHEM, V109, P89, DOI 10.1016/j.acthis.2006.10.002; Awadallah NS, 2008, PANCREAS, V36, P200, DOI 10.1097/MPA.0b013e318150e4e0; Azuma T, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000166; Boucher MJ, 2000, J CELL BIOCHEM, V79, P355, DOI 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.3.CO;2-S; Chen LJ, 2011, CANCER IMMUNOL IMMUN, V60, P1047, DOI 10.1007/s00262-011-1017-3; Chen YW, 2011, INFLAMMATION, V34, P688, DOI 10.1007/s10753-010-9280-6; Cheng L, 2009, INT J GYNECOL CANCER, V19, P1481, DOI 10.1111/IGC.0b013e3181ad0fa2; Crane CA, 2009, ONCOGENE, V28, P306, DOI 10.1038/onc.2008.384; Fei F, 2008, EXP HEMATOL, V36, P1297, DOI 10.1016/j.exphem.2008.05.002; Flies DB, 2007, J IMMUNOTHER, V30, P251, DOI 10.1097/CJI.0b013e31802e085a; Ghebeh H, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2605; Guida M, 2007, ANN ONCOL, V18, P149, DOI 10.1093/annonc/mdm245; Huang WC, 2011, J BIOL CHEM, V286, P20558, DOI 10.1074/jbc.M111.240796; Jiang JT, 2010, CANCER IMMUNOL IMMUN, V59, P1707, DOI 10.1007/s00262-010-0900-7; Kamimura Y, 2009, BIOCHEM BIOPH RES CO, V389, P349, DOI 10.1016/j.bbrc.2009.08.144; KIEFER P, 1994, EMBO J, V13, P4126, DOI 10.1002/j.1460-2075.1994.tb06730.x; Krambeck AE, 2006, P NATL ACAD SCI USA, V103, P10391, DOI 10.1073/pnas.0600937103; Kryczek I, 2006, J EXP MED, V203, P871, DOI 10.1084/jem.20050930; Kurebayashi Y, 2012, CELL REP, V1, P360, DOI 10.1016/j.celrep.2012.02.007; MICKISCH GH, 1994, WORLD J UROL, V12, P214; Miyatake T, 2007, GYNECOL ONCOL, V106, P119, DOI 10.1016/j.ygyno.2007.03.039; Parsa AT, 2007, NAT MED, V13, P84, DOI 10.1038/nm1517; Prasad DVR, 2003, IMMUNITY, V18, P863, DOI 10.1016/S1074-7613(03)00147-X; Quandt D, 2011, CLIN CANCER RES, V17, P3100, DOI 10.1158/1078-0432.CCR-10-2268; Salceda S, 2005, EXP CELL RES, V306, P128, DOI 10.1016/j.yexcr.2005.01.018; Sica GL, 2003, IMMUNITY, V18, P849, DOI 10.1016/S1074-7613(03)00152-3; Simon I, 2006, CANCER RES, V66, P1570, DOI 10.1158/0008-5472.CAN-04-3550; Tan DSW, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-17; Thompson RH, 2008, CANCER RES, V68, P6054, DOI 10.1158/0008-5472.CAN-08-0869; Tringler B, 2006, GYNECOL ONCOL, V100, P44, DOI 10.1016/j.ygyno.2005.08.060; Tringler B, 2005, CLIN CANCER RES, V11, P1842, DOI 10.1158/1078-0432.CCR-04-1658; Vasko R, 2011, EUR J PHARMACOL, V670, P50, DOI 10.1016/j.ejphar.2011.08.030; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang XJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0028232; Zang XX, 2003, P NATL ACAD SCI USA, V100, P10388, DOI 10.1073/pnas.1434299100	37	66	81	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2013	32	46					5347	5358		10.1038/onc.2012.600	http://dx.doi.org/10.1038/onc.2012.600			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	251IU	23318460	Green Published, hybrid			2022-12-17	WOS:000326922400005
J	Kim, YJ; Greer, CB; Cecchini, KR; Harris, LN; Tuck, DP; Kim, TH				Kim, Y. J.; Greer, C. B.; Cecchini, K. R.; Harris, L. N.; Tuck, D. P.; Kim, T. H.			HDAC inhibitors induce transcriptional repression of high copy number genes in breast cancer through elongation blockade	ONCOGENE			English	Article						GRO-seq; transcription elongation; HDAC inhibition; oncogenes; amplicons	HISTONE DEACETYLASE INHIBITORS; RNA-POLYMERASE-II; P-TEFB; 7SK SNRNA; C-MYC; MECHANISMS; EXPRESSION; COMPLEXES; CHROMATIN; PROTEIN	Treatment with histone deacetylase inhibitors (HDACI) results in potent cytotoxicity of a variety of cancer cell types, and these drugs are used clinically to treat hematological tumors. They are known to repress the transcription of ERBB2 and many other oncogenes, but little is known about this mechanism. Using global run-on sequencing (GRO-seq) to measure nascent transcription, we find that HDACI cause transcriptional repression by blocking RNA polymerase II elongation. Our data show that HDACI preferentially repress the transcription of highly expressed genes as well as high copy number genes in HER2 + breast cancer genomes. In contrast, genes that are activated by HDACI are moderately expressed. We analyzed gene copy number in combination with microarray and GRO-seq analysis of expression level, in normal and breast cancer cells to show that high copy number genes are more likely to be repressed by HDACI than non-amplified genes. The inhibition of transcription of amplified oncogenes, which promote survival and proliferation of cancer cells, might explain the cancer-specific lethality of HDACI, and may represent a general therapeutic strategy for cancer.	[Kim, Y. J.; Cecchini, K. R.; Kim, T. H.] Yale Univ, Dept Genet, Sch Med, New Haven, CT 06520 USA; [Greer, C. B.] Yale Univ, Dept Pharmacol, Sch Med, New Haven, CT 06520 USA; [Harris, L. N.] Yale Univ, Dept Med, Sch Med, New Haven, CT 06520 USA; [Harris, L. N.; Tuck, D. P.; Kim, T. H.] Yale Univ, Yale Comprehens Canc Ctr, Sch Med, New Haven, CT 06520 USA; [Tuck, D. P.] Yale Univ, Dept Pathol, Sch Med, New Haven, CT 06520 USA	Yale University; Yale University; Yale University; Yale University; Yale University	Kim, TH (corresponding author), Yale Univ, Dept Genet, Sch Med, 333 Cedar St, New Haven, CT 06520 USA.	taehoon.kim@yale.edu		Greer, Celeste/0000-0001-6876-1189; Kim, Tae Hoon/0000-0003-3950-7557	Rita Allen Foundation; Sidney Kimmel Foundation for Cancer Research; Yale Comprehensive Cancer Center [CA-16359]; Alexander and Margaret Stewart Trust; National Cancer Institute [R01CA140485]; NATIONAL CANCER INSTITUTE [P30CA016359, R01CA140485] Funding Source: NIH RePORTER	Rita Allen Foundation; Sidney Kimmel Foundation for Cancer Research; Yale Comprehensive Cancer Center; Alexander and Margaret Stewart Trust; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the members of the laboratory for their comments on the manuscript. Yale Center for Genomic Analysis provided services for microarray labeling, hybridization and scanning. Bing Ren (Ludwig Institute for Cancer Research, La Jolla, CA, USA) provided critical help with sequencing the GRO-seq libraries. CBG is a PhRMA Foundation predoctoral fellow. Grants to THK from the Rita Allen Foundation, Sidney Kimmel Foundation for Cancer Research, Yale Comprehensive Cancer Center (CA-16359), Alexander and Margaret Stewart Trust supported this work. A portion of this work was also made possible by a grant from the National Cancer Institute (R01CA140485 to THK).	Albertson DG, 2006, TRENDS GENET, V22, P447, DOI 10.1016/j.tig.2006.06.007; Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915; Chao SH, 2000, J BIOL CHEM, V275, P28345, DOI 10.1074/jbc.C000446200; Cheng B, 2007, J BIOL CHEM, V282, P21901, DOI 10.1074/jbc.M702936200; Chou CW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018087; Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371; Core LJ, 2008, SCIENCE, V319, P1791, DOI 10.1126/science.1150843; Core LJ, 2008, SCIENCE, V322, P1845, DOI 10.1126/science.1162228; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Federico M, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/475641; Gilmour DS, 2009, METHODS, V48, P368, DOI 10.1016/j.ymeth.2009.02.020; Govind CK, 2010, MOL CELL, V39, P234, DOI 10.1016/j.molcel.2010.07.003; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Huang XP, 2009, CANCER RES, V69, P8403, DOI 10.1158/0008-5472.CAN-09-2146; Khan N, 2008, BIOCHEM J, V409, P581, DOI 10.1042/BJ20070779; Khan O, 2012, IMMUNOL CELL BIOL, V90, P85, DOI 10.1038/icb.2011.100; Kim YJ, 2011, P NATL ACAD SCI USA, V108, P7391, DOI 10.1073/pnas.1018279108; Kozikowski AP, 2008, J MED CHEM, V51, P4370, DOI 10.1021/jm8002894; LaBonte MJ, 2011, CANCER RES, V71, P3635, DOI 10.1158/0008-5472.CAN-10-2430; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Li B, 2007, SCIENCE, V316, P1050, DOI 10.1126/science.1139004; Liu ZZ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010909; Marchion D, 2007, EXPERT REV ANTICANC, V7, P583, DOI 10.1586/14737140.7.4.583; Michels AA, 2004, EMBO J, V23, P2608, DOI 10.1038/sj.emboj.7600275; Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226; Petrella A, 2011, MINI-REV MED CHEM, V11, P519, DOI 10.2174/138955711795843347; Rahl PB, 2010, CELL, V141, P432, DOI 10.1016/j.cell.2010.03.030; Reid G, 2005, ONCOGENE, V24, P4894, DOI 10.1038/sj.onc.1208662; Rikiishi H, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/830260; Sawarkar R, 2012, CELL, V149, P807, DOI 10.1016/j.cell.2012.02.061; Scott GK, 2008, MOL CANCER RES, V6, P1250, DOI 10.1158/1541-7786.MCR-07-2110; Sollars V, 2003, NAT GENET, V33, P70, DOI 10.1038/ng1067; Wang ZB, 2009, CELL, V138, P1019, DOI 10.1016/j.cell.2009.06.049; Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620; Yik JHN, 2003, MOL CELL, V12, P971, DOI 10.1016/S1097-2765(03)00388-5; Yokoyama S, 2008, PIGM CELL MELANOMA R, V21, P457, DOI 10.1111/j.1755-148X.2008.00480.x; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334	38	66	67	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2013	32	23					2828	2835		10.1038/onc.2013.32	http://dx.doi.org/10.1038/onc.2013.32			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163WR	23435418	Green Accepted			2022-12-17	WOS:000320369100003
J	Wen, ZH; Su, YC; Lai, PL; Zhang, Y; Xu, YF; Zhao, A; Yao, GY; Jia, CH; Lin, J; Xu, S; Wang, L; Wang, XK; Liu, AL; Jiang, Y; Dai, YF; Bai, XC				Wen, Z-H; Su, Y-C; Lai, P-L; Zhang, Y.; Xu, Y-F; Zhao, A.; Yao, G-Y; Jia, C-H; Lin, J.; Xu, S.; Wang, L.; Wang, X-K; Liu, A-L; Jiang, Y.; Dai, Y-F; Bai, X-C			Critical role of arachidonic acid-activated mTOR signaling in breast carcinogenesis and angiogenesis	ONCOGENE			English	Article						mammalian target of rapamycin; arachidonic acid; breast cancer; tumorigenesis; angiogenesis	FATTY-ACIDS; PHOSPHOLIPASE A(2); CANCER PREVENTION; CELL-GROWTH; PATHWAY; METABOLISM; INHIBITION; EXPRESSION; ADHESION; MEDIATOR	The mammalian target of rapamycin (mTOR) signaling pathway is upregulated in the pathogenesis of many cancers. Arachidonic acid (AA) and its metabolites play critical role in the development of breast cancer, but the mechanisms through which AA promotes mammary tumorigenesis and progression are poorly understood. We found that the levels of AA and cytosolic phospholipase A2 (cPLA2) strongly correlated with the signaling activity of mTORC1 and mTORC2 as well as the expression levels of vascular epithelial growth factor (VEGF) in human breast tumor tissues. In cultured breast cancer cells, AA effectively activated both mTOR complex 1 (mTORC1) and mTORC2. Interestingly, AA-stimulated mTORC1 activation was independent of amino acids, phosphatidylinositol 3-kinase (PI3-K) and tuberous sclerosis complex 2 (TSC2), which suggests a novel mechanism for nnTORC1 activation. Further studies revealed that AA stimulated mTORC1 activity through destabilization of mTOR-raptor association in ras homolog enriched in brain (Rheb)-dependent mechanism. Moreover, we showed that AA-stimulated cell proliferation and angiogenesis required mTOR activity and that the effect of AA was mediated by lipoxygenase (LOX) but not cyclooxygenase-2 (COX-2). In animal models, AA-enhanced incidences of rat mammary tumorigenesis, tumor weights and angiogenesis were inhibited by rapamycin. Our findings suggest that AA is an effective intracellular stimulus of mTOR and that AA-activated mTOR plays critical roles in angiogenesis and tumorigenesis of breast cancer. Oncogene (2013) 32, 160-170; doi:10.1038/onc.2012.47; published online 20 February 2012	[Wen, Z-H; Su, Y-C; Lai, P-L; Zhang, Y.; Xu, Y-F; Jia, C-H; Lin, J.; Xu, S.; Wang, L.; Wang, X-K; Liu, A-L; Bai, X-C] So Med Univ, Sch Basic Med Sci, Dept Cell Biol, Guangzhou 510515, Guangdong, Peoples R China; [Zhao, A.; Dai, Y-F] Nanjing Med Univ, Ctr Metab Dis Res, Nanjing 201129, Jiangsu, Peoples R China; [Yao, G-Y] So Med Univ, Nanfang Hosp, Breast Ctr, Guangzhou 510515, Guangdong, Peoples R China; [Jiang, Y.] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA; [Dai, Y-F] Nanjing Med Univ, State Key Lab Reprod Med, Nanjing 201129, Jiangsu, Peoples R China	Southern Medical University - China; Nanjing Medical University; Southern Medical University - China; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Nanjing Medical University	Dai, YF (corresponding author), Nanjing Med Univ, Ctr Metab Dis Res, Nanjing 201129, Jiangsu, Peoples R China.	yifandai08@gmail.com; baixc15@smu.edu.cn		Bai, Xiaochun/0000-0001-9631-4781	State Key Development Program for Basic Research of China [2009CB 918904]; National Natural Sciences Foundation of China [30870955, 91029727, 30900555]; Program for New Century Excellent Talents in University [NCET-08-0646]; NATIONAL CANCER INSTITUTE [R01CA129821] Funding Source: NIH RePORTER	State Key Development Program for Basic Research of China(State Key Development Program for Basic Research of China); National Natural Sciences Foundation of China(National Natural Science Foundation of China (NSFC)); Program for New Century Excellent Talents in University(Program for New Century Excellent Talents in University (NCET)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We greatly appreciate the gift of TSC2<SUP>+/+</SUP> and TSC2<SUP>-/-</SUP> MEFs from Dr David J Kwiatkowski (Brigham and Women's Hospital, Boston, MA, USA). This work was supported by The State Key Development Program for Basic Research of China (No. 2009CB 918904), National Natural Sciences Foundation of China (30870955, 91029727, 30900555) and Program for New Century Excellent Talents in University (NCET-08-0646).	Agrawal A, 2008, INT J CLIN PRACT, V62, P444, DOI 10.1111/j.1742-1241.2007.01668.x; Bai XC, 2007, SCIENCE, V318, P977, DOI 10.1126/science.1147379; Bai XC, 2010, CELL MOL LIFE SCI, V67, P239, DOI 10.1007/s00018-009-0163-7; BUZZARD CJ, 1993, CIRC RES, V72, P1023, DOI 10.1161/01.RES.72.5.1023; Cakir Y, 2002, INT J ONCOL, V21, P153; Camp RL, 1999, CANCER, V86, P2259, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2259::AID-CNCR13>3.0.CO;2-2; Chen XX, 2006, CURR CANCER DRUG TAR, V6, P613, DOI 10.2174/156800906778742451; Duan SS, 2011, MOL CELL, V44, P317, DOI 10.1016/j.molcel.2011.09.005; Efeyan A, 2010, CURR OPIN CELL BIOL, V22, P169, DOI 10.1016/j.ceb.2009.10.007; Foster KG, 2010, J BIOL CHEM, V285, P14071, DOI 10.1074/jbc.R109.094003; Goberdhan DCI, 2010, CURR OPIN INVEST DR, V11, P1360; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Harizi H, 2008, TRENDS MOL MED, V14, P461, DOI 10.1016/j.molmed.2008.08.005; Holmes MD, 1999, JAMA-J AM MED ASSOC, V281, P914, DOI 10.1001/jama.281.10.914; Horn L, 2009, EXPERT OPIN THER TAR, V13, P675, DOI 10.1517/14728220902915567; Hyde CAC, 2009, INT IMMUNOPHARMACOL, V9, P701, DOI 10.1016/j.intimp.2009.02.003; Hynes NE, 2006, J MAMMARY GLAND BIOL, V11, P53, DOI 10.1007/s10911-006-9012-6; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Jiang WG, 2006, PROSTAG LEUKOTR ESS, V74, P125, DOI 10.1016/j.plefa.2005.10.005; Kennett SB, 2004, J BIOL CHEM, V279, P3300, DOI 10.1074/jbc.M305734200; Kim C, 2008, BMB REP, V41, P555, DOI 10.5483/BMBRep.2008.41.8.555; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kuehn HS, 2011, J BIOL CHEM, V286, P391, DOI 10.1074/jbc.M110.164772; Li M, 2010, CELL SIGNAL, V22, P1469, DOI 10.1016/j.cellsig.2010.05.015; Linkous AG, 2010, JNCI-J NATL CANCER I, V102, P1398, DOI 10.1093/jnci/djq290; Martinez-Orozco R, 2010, EUR J CELL BIOL, V89, P476, DOI 10.1016/j.ejcb.2009.12.005; MCCORMICK DL, 1987, CANCER LETT, V37, P139, DOI 10.1016/0304-3835(87)90156-X; Menna C, 2010, CURR PHARM DESIGN, V16, P725, DOI 10.2174/138161210790883822; Meyer AM, 2004, CARCINOGENESIS, V25, P1517, DOI 10.1093/carcin/bgh150; Mieulet V, 2010, TRENDS MOL MED, V16, P329, DOI 10.1016/j.molmed.2010.05.001; Nakanishi M, 2006, BBA-MOL CELL BIOL L, V1761, P1335, DOI 10.1016/j.bbalip.2006.09.005; Navarro-Tito N, 2008, EXP CELL RES, V314, P3340, DOI 10.1016/j.yexcr.2008.08.018; Navarro-Tito N, 2010, INT J BIOCHEM CELL B, V42, P306, DOI 10.1016/j.biocel.2009.11.010; Paine E, 2000, J BIOL CHEM, V275, P11284, DOI 10.1074/jbc.275.15.11284; Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046; Pidgeon GP, 2007, CANCER METAST REV, V26, P503, DOI 10.1007/s10555-007-9098-3; Razanamahefa L, 2000, NUTR CANCER, V38, P274, DOI 10.1207/S15327914NC382_17; Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sengupta S, 2010, MOL CELL, V40, P310, DOI 10.1016/j.molcel.2010.09.026; Singh-Ranger G, 2008, BREAST CANCER RES TR, V109, P189, DOI 10.1007/s10549-007-9641-5; Thiebaut ACM, 2009, INT J CANCER, V124, P924, DOI 10.1002/ijc.23980; Ulrich CM, 2006, NAT REV CANCER, V6, P130, DOI 10.1038/nrc1801; Weiser-Evans MCM, 2009, CANCER RES, V69, P1733, DOI 10.1158/0008-5472.CAN-08-3766; YAMASHITA SI, 1994, BRIT J CANCER, V69, P1166, DOI 10.1038/bjc.1994.229; Ye YN, 2005, CARCINOGENESIS, V26, P827, DOI 10.1093/carcin/bgi012; Yecies JL, 2011, J MOL MED, V89, P221, DOI 10.1007/s00109-011-0726-6; Zhang BL, 2006, J BIOL CHEM, V281, P905, DOI 10.1074/jbc.M503945200; Zhang BL, 2005, CANCER RES, V65, P7283, DOI 10.1158/0008-5472.CAN-05-0633; Zhou L, 2002, J NUTR, V132, P2626, DOI 10.1093/jn/132.9.2626	50	66	71	1	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2013	32	2					160	170		10.1038/onc.2012.47	http://dx.doi.org/10.1038/onc.2012.47			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078CK	22349822				2022-12-17	WOS:000314075500004
J	Robinson, GL; Dinsdale, D; MacFarlane, M; Cain, K				Robinson, G. L.; Dinsdale, D.; MacFarlane, M.; Cain, K.			Switching from aerobic glycolysis to oxidative phosphorylation modulates the sensitivity of mantle cell lymphoma cells to TRAIL	ONCOGENE			English	Article						TRAIL; apoptosis; oxidative phosphorylation; aerobic glycolysis; mitochondria; 2DG	INDUCED APOPTOSIS; RECEPTOR; DEATH; GLUCOSE; INHIBITION; CANCER; RESISTANCE; LIGAND; MCL-1; ATP	TRAIL (TNF (tumour necrosis factor)-related apoptosis-inducing ligand) a putative anti-cancer cytokine induces apoptosis through DISC (death-inducing signalling complex)-mediated activation of caspase-8 and/or cleavage of Bid. TRAIL is relatively specific for tumour cells but primary chronic lymphocytic leukaemia and mantle cell lymphoma (MCL) cells are resistant. Herein, we show that cellular metabolism influences cell death and that MCL cells (Z138 cell line) can survive/proliferate in glucose-free media by switching from aerobic glycolysis to 'coupled' oxidative phosphorylation. Extracellular flux analysis and mitochondrial inhibitors reveal that in the absence of glycolysis, Z138 cells have enhanced respiratory capacity coupled to ATP synthesis, similar to 'classical' state 3 mitochondria. Conversely, 2-deoxyglucose (2DG) blocked glycolysis and partially inhibited glycolytic-dependent oxidative phosphorylation, resulting in a 50% reduction in cellular ATP levels. Also, 2DG sensitised Z138 cells to TRAIL and induced a marked decrease in caspase-8, -3, cFLIP(S), Bid and Mcl-1 expression but Bak remained unchanged, altering the Mcl-1/Bak ratio, facilitating cytochrome c release and cell death. Conversely, under glucose-free conditions, Z138 cells were less sensitive to TRAIL with reduced TRAIL-R1/R2 surface receptor expression and impaired DISC formation. Anti-apoptotic proteins Bcl-2 and XIAP were up-regulated while pro-apoptotic BAX was down-regulated. Additionally, mitochondria had higher levels of cytochrome c and ultrastucturally exhibited a condensed configuration with enhanced intracristal spaces. Thus, metabolic switching was accompanied by mitochondrial proteome and ultrastructural remodelling enabling enhanced respiration activity. Cytochrome c release was decreased in glucose-free cells, suggesting that either pore formation was inhibited or that cytochrome c was more tightly bound. Glucose-free Z138 cells were also resistant to intrinsic cell death stimuli (ABT-737 and ionising radiation). In summary, in MCL cells, the anti-glycolytic effects of 2DG and glucose restriction produced opposite effects on TRAIL-induced cell death, demonstrating that mitochondrial metabolism directly modulates sensitivity of tumour cells to apoptosis. Oncogene (2012) 31, 4996-5006; doi:10.1038/onc.2012.13; published online 6 February 2012	[Robinson, G. L.; Dinsdale, D.; MacFarlane, M.; Cain, K.] Univ Leicester, MRC Toxicol Unit, Leicester LE1 9HN, Leics, England	University of Leicester	MacFarlane, M (corresponding author), Univ Leicester, MRC Toxicol Unit, Hodgkin Bldg,Lancaster Rd, Leicester LE1 9HN, Leics, England.	mm21@le.ac.uk; kc5@le.ac.uk			UK Medical Research Council; MRC [MC_U132685863] Funding Source: UKRI; Medical Research Council [MC_U132685863] Funding Source: researchfish	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by the UK Medical Research Council.	Adrain C, 2001, TRENDS BIOCHEM SCI, V26, P390, DOI 10.1016/S0968-0004(01)01844-8; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Benard G, 2008, ANTIOXID REDOX SIGN, V10, P1313, DOI 10.1089/ars.2007.2000; Boyd RS, 2009, MOL CELL PROTEOMICS, V8, P1501, DOI 10.1074/mcp.M800515-MCP200; Cain K, 2002, BIOCHIMIE, V84, P203, DOI 10.1016/S0300-9084(02)01376-7; Capasso M, 2010, NAT IMMUNOL, V11, P265, DOI 10.1038/ni.1843; CHANCE B, 1956, ADV ENZYMOL REL S BI, V17, P65; Coloff JL, 2011, CANCER RES, V71, P5204, DOI 10.1158/0008-5472.CAN-10-4531; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Dyer MJS, 2007, J CLIN ONCOL, V25, P4505, DOI 10.1200/JCO.2007.13.1011; El Mjiyad N, 2011, ONCOGENE, V30, P253, DOI 10.1038/onc.2010.466; Falschlehner C, 2009, IMMUNOLOGY, V127, P145, DOI 10.1111/j.1365-2567.2009.03058.x; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Gambhir SS, 2002, NAT REV CANCER, V2, P683, DOI 10.1038/nrc882; Gillissen B, 2010, J CELL BIOL, V188, P851, DOI 10.1083/jcb.200912070; HACKENBROCK CR, 1966, J CELL BIOL, V30, P269, DOI 10.1083/jcb.30.2.269; HALICKA HD, 1995, CANCER RES, V55, P444; Hardie DG, 2005, CURR OPIN CELL BIOL, V17, P167, DOI 10.1016/j.ceb.2005.01.006; Harper N, 2008, METHOD ENZYMOL, V446, P293, DOI 10.1016/S0076-6879(08)01618-2; Heiskanen KM, 1999, J BIOL CHEM, V274, P5654, DOI 10.1074/jbc.274.9.5654; Hughes MA, 2009, MOL CELL, V35, P265, DOI 10.1016/j.molcel.2009.06.012; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Liu H, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-122; MacFarlane M, 2005, CANCER RES, V65, P11265, DOI 10.1158/0008-5472.CAN-05-2801; Marino K, 2010, NAT CHEM BIOL, V6, P713, DOI [10.1038/nchembio.437, 10.1038/NCHEMBIO.437]; MERINO R, 1994, EMBO J, V13, P683, DOI 10.1002/j.1460-2075.1994.tb06307.x; Munoz-Pinedo C, 2003, J BIOL CHEM, V278, P12759, DOI 10.1074/jbc.M212392200; Nam SY, 2002, ONCOGENE, V21, P337, DOI 10.1038/sj.onc.1205068; PARNIAK M, 1985, CAN J BIOCHEM CELL B, V63, P333, DOI 10.1139/o85-049; Pelicano H, 2006, ONCOGENE, V25, P4633, DOI 10.1038/sj.onc.1209597; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Poukkula M, 2005, J BIOL CHEM, V280, P27345, DOI 10.1074/jbc.M504019200; Pradelli LA, 2010, ONCOGENE, V29, P1641, DOI 10.1038/onc.2009.448; Rossignol R, 2004, CANCER RES, V64, P985, DOI 10.1158/0008-5472.CAN-03-1101; Samraj AK, 2006, J BIOL CHEM, V281, P29652, DOI 10.1074/jbc.M603487200; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Tagawa H, 2005, ONCOGENE, V24, P1348, DOI 10.1038/sj.onc.1208300; THAKKAR NS, 1993, CANCER RES, V53, P2057; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; Wagner KW, 2007, NAT MED, V13, P1070, DOI 10.1038/nm1627; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; WARBURG O, 1956, SCIENCE, V124, P269; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wood TE, 2008, MOL CANCER THER, V7, P3546, DOI 10.1158/1535-7163.MCT-08-0569; Wu M, 2007, AM J PHYSIOL-CELL PH, V292, pC125, DOI 10.1152/ajpcell.00247.2006; Yamaguchi R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024102; Zagorodna O, 2012, ONCOGENE, V31, P2738, DOI 10.1038/onc.2011.454; Zamaraeva MV, 2005, CELL DEATH DIFFER, V12, P1390, DOI 10.1038/sj.cdd.4401661	51	66	67	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	48					4996	5006		10.1038/onc.2012.13	http://dx.doi.org/10.1038/onc.2012.13			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048CU	22310286				2022-12-17	WOS:000311888600004
J	McKinsey, EL; Parrish, JK; Irwin, AE; Niemeyer, BF; Kern, HB; Birks, DK; Jedlicka, P				McKinsey, E. L.; Parrish, J. K.; Irwin, A. E.; Niemeyer, B. F.; Kern, H. B.; Birks, D. K.; Jedlicka, P.			A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs	ONCOGENE			English	Article						microRNA; oncoprotein; Ewing; sarcoma; IGF	FACTOR-I-RECEPTOR; HEPATOCELLULAR-CARCINOMA; TRANSCRIPTION FACTORS; CELL-PROLIFERATION; GROWTH; EXPRESSION; TUMOR; GENE; SUPPRESSES; GLIOMA	MicroRNAs (miRs) are a novel class of cellular bioactive molecules with critical functions in the regulation of gene expression in normal biology and disease. MiRs are frequently misexpressed in cancer, with potent biological consequences. However, relatively little is known about miRs in pediatric cancers, including sarcomas. Moreover, the mechanisms behind aberrant miR expression in cancer are poorly understood. Ewing sarcoma is an aggressive pediatric malignancy driven by EWS/Ets fusion oncoproteins, which are gain-of-function transcriptional regulators. We employed stable silencing of EWS/Fli1, the most common of the oncogenic fusions, and global miR profiling to identify EWS/Fli1-regulated miRs with oncogenesis-modifying roles in Ewing sarcoma. In this report, we characterize a group of miRs (100, 125b, 22, 221/222, 27a and 29a) strongly repressed by EWS/Fli1. Strikingly, all of these miRs have predicted targets in the insulin-like growth factor (IGF) signaling pathway, a pivotal driver of Ewing sarcoma oncogenesis. We demonstrate that miRs in this group negatively regulate the expression of multiple pro-oncogenic components of the IGF pathway, namely IGF-1, IGF-1 receptor, mammalian/mechanistic target of rapamycin and ribosomal protein S6 kinase A1. Consistent with tumor-suppressive functions, these miRs manifest growth inhibitory properties in Ewing sarcoma cells. Our studies thus uncover a novel oncogenic mechanism in Ewing sarcoma, involving post-transcriptional derepression of IGF signaling by the EWS/Fli1 fusion oncoprotein via miRs. This novel pathway may be amenable to innovative therapeutic targeting in Ewing sarcoma and other malignancies with activated IGF signaling. Oncogene (2011) 30, 4910-4920; doi:10.1038/onc.2011.197; published online 6 June 2011	[McKinsey, E. L.; Parrish, J. K.; Irwin, A. E.; Niemeyer, B. F.; Kern, H. B.; Jedlicka, P.] Univ Colorado, Dept Pathol, Aurora, CO 80045 USA; [Birks, D. K.] Univ Colorado, Dept Neurosurg, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Jedlicka, P (corresponding author), Univ Colorado, Dept Pathol, Anschutz Med Campus,POB 6511,MS 8104, Aurora, CO 80045 USA.	paul.jedlicka@ucdenver.edu		Niemeyer, Brian/0000-0002-2020-2238; Kern, Hanna/0000-0001-7505-7130	Alex's Lemonade Stand Foundation for Childhood Cancer; Boettcher Foundation; University of Colorado Cancer Center and School of Medicine; NATIONAL CANCER INSTITUTE [P30CA046934] Funding Source: NIH RePORTER	Alex's Lemonade Stand Foundation for Childhood Cancer; Boettcher Foundation; University of Colorado Cancer Center and School of Medicine; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We wish to thank Steve Lessnick for Ewing sarcoma cell lines; James DeGregori and Yosef Refaeli for lentiviral and retroviral reagents; Lynne Bemis, Dawn Cochrane, Heide Ford, Jennifer Richer and Rajeev Vibhakar for helpful suggestions/discussions. Funding for this work was provided by Alex's Lemonade Stand Foundation for Childhood Cancer, the Boettcher Foundation's Webb-Waring Biomedical Research Program, and the University of Colorado Cancer Center and School of Medicine. These studies were inspired by the memory of Zeljko Nikolic.	Arvand A, 2001, ONCOGENE, V20, P5747, DOI 10.1038/sj.onc.1204598; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Benini S, 2004, INT J CANCER, V108, P358, DOI 10.1002/ijc.11576; Cairo S, 2010, P NATL ACAD SCI USA, V107, P20471, DOI 10.1073/pnas.1009009107; Carriere A, 2008, FRONT BIOSCI-LANDMRK, V13, P4258, DOI 10.2741/3003; Chhabra R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005848; Chintharlapalli S, 2009, INT J CANCER, V125, P1965, DOI 10.1002/ijc.24530; Cironi L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002634; Ciuffreda L, 2010, CURR CANCER DRUG TAR, V10, P484, DOI 10.2174/156800910791517172; Corcoran DL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005279; Corsten MF, 2007, CANCER RES, V67, P8994, DOI 10.1158/0008-5472.CAN-07-1045; Dahl KDC, 2009, NEOPLASIA, V11, P1208, DOI 10.1593/neo.09942; Davis BN, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-18; Eyholzer M, 2010, BRIT J CANCER, V103, P275, DOI 10.1038/sj.bjc.6605751; Felicetti F, 2008, CANCER RES, V68, P2745, DOI 10.1158/0008-5472.CAN-07-2538; Fujita S, 2008, J MOL BIOL, V378, P492, DOI 10.1016/j.jmb.2008.03.015; Fukao T, 2007, CELL, V129, P617, DOI 10.1016/j.cell.2007.02.048; Gangwal K, 2008, P NATL ACAD SCI USA, V105, P10149, DOI 10.1073/pnas.0801073105; Garofalo M, 2009, CANCER CELL, V16, P498, DOI 10.1016/j.ccr.2009.10.014; Gebeshuber CA, 2009, EMBO REP, V10, P400, DOI 10.1038/embor.2009.9; Gefen N, 2010, LEUKEMIA, V24, P89, DOI 10.1038/leu.2009.208; Ghildiyal M, 2009, NAT REV GENET, V10, P94, DOI 10.1038/nrg2504; Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120; Guan Y, 2011, INT J CANCER, V128, P2274, DOI 10.1002/ijc.25575; Han YC, 2010, J EXP MED, V207, P475, DOI 10.1084/jem.20090831; Henson BJ, 2009, GENE CHROMOSOME CANC, V48, P569, DOI 10.1002/gcc.20666; Herrero-Martin D, 2009, BRIT J CANCER, V101, P80, DOI 10.1038/sj.bjc.6605104; Huang L, 2011, INT J CANCER, V128, P1758, DOI 10.1002/ijc.25509; Im YH, 2000, CANCER RES, V60, P1536; Inui M, 2010, NAT REV MOL CELL BIO, V11, P252, DOI 10.1038/nrm2868; Janknecht R, 2005, GENE, V363, P1, DOI 10.1016/j.gene.2005.08.007; Jedlicka P, 2010, INT J CLIN EXP PATHO, V3, P338; Jedlicka P, 2009, AM J PATHOL, V174, P1280, DOI 10.2353/ajpath.2009.080409; Kim SY, 2009, ONCOLOGIST, V14, P83, DOI 10.1634/theoncologist.2008-0189; Kim VN, 2009, NAT REV MOL CELL BIO, V10, P126, DOI 10.1038/nrm2632; Kinsey M, 2006, MOL CANCER RES, V4, P851, DOI 10.1158/1541-7786.MCR-06-0090; Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021; Li J, 2010, GYNECOL ONCOL, V119, P543, DOI 10.1016/j.ygyno.2010.08.034; Liang LH, 2010, HEPATOLOGY, V52, P1731, DOI 10.1002/hep.23904; Liu T, 2009, CANCER LETT, V273, P233, DOI 10.1016/j.canlet.2008.08.003; Ludwig JA, 2008, CURR OPIN ONCOL, V20, P412, DOI 10.1097/CCO.0b013e328303ba1d; Luo W, 2009, ONCOGENE, V28, P4126, DOI 10.1038/onc.2009.262; Manara MC, 2007, CLIN CANCER RES, V13, P1322, DOI 10.1158/1078-0432.CCR-06-1518; Martins AS, 2006, CLIN CANCER RES, V12, P3532, DOI 10.1158/1078-0432.CCR-05-1778; Mateo-Lozano S, 2006, CLIN CANCER RES, V12, P6781, DOI 10.1158/1078-0432.CCR-06-0609; Mayoral RJ, 2009, J IMMUNOL, V182, P433, DOI 10.4049/jimmunol.182.1.433; Mercatelli N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004029; Mertens-Talcott SU, 2007, CANCER RES, V67, P11001, DOI 10.1158/0008-5472.CAN-07-2416; Muniyappa MK, 2009, EUR J CANCER, V45, P3104, DOI 10.1016/j.ejca.2009.09.014; Nagaraja AK, 2010, MOL ENDOCRINOL, V24, P447, DOI 10.1210/me.2009-0295; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Ozsolak F, 2008, GENE DEV, V22, P3172, DOI 10.1101/gad.1706508; Patel JB, 2011, ONCOGENE, V30, P1290, DOI 10.1038/onc.2010.510; Poliseno L, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000594; Porter CC, 2008, BLOOD, V112, P4466, DOI 10.1182/blood-2008-03-146571; Prieur A, 2004, MOL CELL BIOL, V24, P7275, DOI 10.1128/MCB.24.16.7275-7283.2004; Richter GHS, 2009, P NATL ACAD SCI USA, V106, P5324, DOI 10.1073/pnas.0810759106; Riggi N, 2005, CANCER RES, V65, P11459, DOI 10.1158/0008-5472.CAN-05-1696; Riggi N, 2007, CANCER LETT, V254, P1, DOI 10.1016/j.canlet.2006.12.009; Schmidt D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003713; Scotlandi K, 2005, CANCER RES, V65, P3868, DOI 10.1158/0008-5472.CAN-04-3192; Scotlandi K, 1996, CANCER RES, V56, P4570; Scott GK, 2007, J BIOL CHEM, V282, P1479, DOI 10.1074/jbc.M609383200; Shi L, 2010, BRAIN RES, V1312, P120, DOI 10.1016/j.brainres.2009.11.056; Shi XB, 2011, PROSTATE, V71, P538, DOI 10.1002/pros.21270; Silvany RE, 2000, ONCOGENE, V19, P4523, DOI 10.1038/sj.onc.1203811; Smith R, 2006, CANCER CELL, V9, P405, DOI 10.1016/j.ccr.2006.04.004; Sokol NS, 2008, GENE DEV, V22, P1591, DOI 10.1101/gad.1671708; Sotiropoulou G, 2009, RNA, V15, P1443, DOI 10.1261/rna.1534709; Spahn M, 2010, INT J CANCER, V127, P394, DOI 10.1002/ijc.24715; Sun DD, 2011, CANCER RES, V71, P1313, DOI 10.1158/0008-5472.CAN-10-1031; Swarbrick A, 2010, NAT MED, V16, P1134, DOI 10.1038/nm.2227; Ting Y, 2010, BIOCHEM BIOPH RES CO, V394, P606, DOI 10.1016/j.bbrc.2010.03.030; Tirode F, 2007, CANCER CELL, V11, P421, DOI 10.1016/j.ccr.2007.02.027; Toretsky JA, 1999, CANCER RES, V59, P5745; Trang P, 2008, Oncogene, V27 Suppl 2, pS52, DOI 10.1038/onc.2009.353; Trang P, 2010, ONCOGENE, V29, P1580, DOI 10.1038/onc.2009.445; Visone R, 2009, AM J PATHOL, V174, P1131, DOI 10.2353/ajpath.2009.080794; Wang FZ, 2008, J VIROL, V82, P9065, DOI 10.1128/JVI.00961-08; Wang H, 2008, CANCER CELL, V14, P369, DOI 10.1016/j.ccr.2008.10.006; Wang V, 2009, BIODRUGS, V23, P15, DOI 10.2165/00063030-200923010-00002; Wei GH, 2010, EMBO J, V29, P2147, DOI 10.1038/emboj.2010.106; Weidhaas JB, 2007, CANCER RES, V67, P11111, DOI 10.1158/0008-5472.CAN-07-2858; Wiggins JF, 2010, CANCER RES, V70, P5923, DOI 10.1158/0008-5472.CAN-10-0655; Winter J, 2009, NAT CELL BIOL, V11, P228, DOI 10.1038/ncb0309-228; Wong QWL, 2010, CLIN CANCER RES, V16, P867, DOI 10.1158/1078-0432.CCR-09-1840; Xia HF, 2009, CELL PHYSIOL BIOCHEM, V23, P347, DOI 10.1159/000218181; Xiong J, 2010, ONCOGENE, V29, P4980, DOI 10.1038/onc.2010.241; Xiong JH, 2010, FEBS J, V277, P1684, DOI 10.1111/j.1742-4658.2010.07594.x; Yang L, 2010, BIOCHEM BIOPH RES CO, V402, P129, DOI 10.1016/j.bbrc.2010.09.129; YEE D, 1990, J CLIN INVEST, V86, P1806, DOI 10.1172/JCI114910; Zhang CZ, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-229; Zhang CZ, 2009, INT J ONCOL, V34, P1653, DOI 10.3892/ijo_00000296; Zhang J, 2010, BRIT J CANCER, V103, P1215, DOI 10.1038/sj.bjc.6605895; Zhang JX, 2010, INT J ONCOL, V36, P913, DOI 10.3892/ijo_00000570; Zhou X, 2010, LAB INVEST, V90, P144, DOI 10.1038/labinvest.2009.126	96	66	72	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2011	30	49					4910	4920		10.1038/onc.2011.197	http://dx.doi.org/10.1038/onc.2011.197			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865YI	21643012	Green Accepted			2022-12-17	WOS:000298346400007
J	Messina, S; Frati, L; Leonetti, C; Zuchegna, C; Di Zazzo, E; Calogero, A; Porcellini, A				Messina, S.; Frati, L.; Leonetti, C.; Zuchegna, C.; Di Zazzo, E.; Calogero, A.; Porcellini, A.			Dual-specificity phosphatase DUSP6 has tumor-promoting properties in human glioblastomas	ONCOGENE			English	Article						glioblastoma; dual-specificity phosphatase; tumor promoting	CANCER-CELLS; LUNG-CANCER; MALIGNANT PHENOTYPE; DOWN-REGULATION; UP-REGULATION; GROWTH; EXPRESSION; MUTATIONS; RAS; DUSP6/MKP-3	Dual-specificity phosphatase 6 (DUSP6, mitogen-activated protein kinase (MAPK) phosphatase 3 or PYST1) dephosphorylates phosphotyrosine and phosphothreonine residues on extracellular signal-regulated kinase (ERK1/2; MAPK1/2) to inactivate the ERK1/2 kinase. DUSP6 is a critical regulator of the ERK signaling cascade and has been implicated as a tumor suppressor. We report here experimental evidences that DUSP6 is transcriptionally upregulated in primary and long-term cultures of human glioblastoma, as assayed by northern hybridization and real-time quantitative PCR, producing constitutive high level of protein expression. Functional assays were performed with adenovirus-mediated expression of DUSP6 in glioblastoma cultures. Protein overexpression inhibits growth by inducing G1-phase delay and increased mitogenic/anchorage dependence and clonogenic potential in vitro. Changes in cell morphology were associated with an increased tumor growth in vivo. Chemoresistance is a major cause of treatment failure and poor outcome in human glioblastomas. Importantly, DUSP6 overexpression increased resistance to cisplatin-mediated cell death in vitro and in vivo. Antisense-mediated depletion of DUSP6 acted in lowering the threshold to anticancer DNA-damaging drugs. We conclude that upregulation of DUSP6 exerts a tumor-promoting role in human glioblastomas exacerbating the malignant phenotype. Oncogene (2011) 30, 3813-3820; doi:10.1038/onc.2011.99; published online 18 April 2011	[Messina, S.; Frati, L.] IRCCS Neuromed, Dept Pathol, I-86077 Isernia, Italy; [Messina, S.] Univ Cassino, Dept Hlth & Motor Sci, I-03043 Cassino, Italy; [Leonetti, C.] Regina Elena Inst Canc Res, Dept Expt Chemotherapy, Rome, Italy; [Zuchegna, C.; Di Zazzo, E.] Univ Campobasso, Dept Hlth Sci, Campobasso, Italy; [Zuchegna, C.; Porcellini, A.] Univ Naples Federico 2, Dept Struct & Funct Biol, Naples, Italy; [Calogero, A.] Univ Roma La Sapienza, Dept Med & Surg Sci & Biotecnol, Rome, Italy	IRCCS Neuromed; University of Cassino; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Molise; University of Naples Federico II; Sapienza University Rome	Messina, S (corresponding author), IRCCS Neuromed, Dept Pathol, Via Atinense 18, I-86077 Isernia, Italy.	samantha.messina@uniroma1.it; Antonio.Porcellini@unina.it	Frati, Luigi/ABI-7437-2020; Porcellini, Antonio/AAC-6097-2019; calogero, antonella/U-5418-2019; Porcellini, Antonio/E-1900-2011; Di Zazzo, Erika/Z-5299-2019; Leonetti, Carlo/B-2860-2018	Porcellini, Antonio/0000-0001-6882-9518; Di Zazzo, Erika/0000-0001-7621-488X; Leonetti, Carlo/0000-0002-3526-7827; calogero, antonella/0000-0002-3322-2916; Zuchegna, Candida/0000-0002-8494-8602				Arany I, 2004, AM J PHYSIOL-RENAL, V287, pF543, DOI 10.1152/ajprenal.00112.2004; Bermudez O, 2011, J CELL PHYSIOL, V226, P276, DOI 10.1002/jcp.22339; Bloethner S, 2005, CARCINOGENESIS, V26, P1224, DOI 10.1093/carcin/bgi066; Calogero A, 2004, CANCER CELL INT, V4, DOI 10.1186/1475-2867-4-1; Chan DW, 2008, CARCINOGENESIS, V29, P1742, DOI 10.1093/carcin/bgn167; Chen HY, 2007, NEW ENGL J MED, V356, P11, DOI 10.1056/NEJMoa060096; Cui YK, 2006, CANCER RES, V66, P5950, DOI 10.1158/0008-5472.CAN-05-3243; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Furukawa T, 2005, MODERN PATHOL, V18, P1034, DOI 10.1038/modpathol.3800383; Furukawa T, 2003, AM J PATHOL, V162, P1807, DOI 10.1016/S0002-9440(10)64315-5; Gozdz A, 2003, J BIOL CHEM, V278, P43663, DOI 10.1074/jbc.M301554200; Hong L, 2007, MED HYPOTHESES, V69, P1379, DOI 10.1016/j.mehy.2007.03.029; Kim HS, 2003, J BIOL CHEM, V278, P37497, DOI 10.1074/jbc.M211739200; Li YQ, 2008, CANCER RES, V68, P1723, DOI 10.1158/0008-5472.CAN-07-1963; Lucci MA, 2010, CELL ONCOL, V32, P361, DOI 10.3233/CLO-2010-0520; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Marchetti S, 2005, MOL CELL BIOL, V25, P854, DOI 10.1128/MCB.25.2.854-864.2005; Marchetti S, 2004, J CELL PHYSIOL, V199, P441, DOI 10.1002/jcp.10465; Mark JK, 2008, J BIOL CHEM, V283, P28574, DOI 10.1074/jbc.M801747200; McKay MM, 2007, ONCOGENE, V26, P3113, DOI 10.1038/sj.onc.1210394; Messina S, 2004, BIOCHEM BIOPH RES CO, V320, P493, DOI 10.1016/j.bbrc.2004.06.003; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Murphy LO, 2006, TRENDS BIOCHEM SCI, V31, P268, DOI 10.1016/j.tibs.2006.03.009; Nagane M, 1996, CANCER RES, V56, P5079; Nunes-Xavier CE, 2010, J BIOL CHEM, V285, P26417, DOI 10.1074/jbc.M110.121830; Okudela K, 2009, AM J PATHOL, V175, P867, DOI 10.2353/ajpath.2009.080489; Owens DM, 2007, ONCOGENE, V26, P3203, DOI 10.1038/sj.onc.1210412; Patterson KI, 2009, BIOCHEM J, V418, P475, DOI 10.1042/BJ20082234; PETALIDIS LP, 2008, MOL CANCER THER, V7, pOF1; Porcellini A, 1997, ONCOGENE, V15, P781, DOI 10.1038/sj.onc.1201240; Porcellini Antonio, 2004, Methods Mol Biol, V259, P155; Ricci-Vitiani L, 2010, NATURE, V468, P824, DOI 10.1038/nature09557; Sato M, 2006, CANCER RES, V66, P2116, DOI 10.1158/0008-5472.CAN-05-2521; Silvani A, 2009, J NEURO-ONCOL, V94, P57, DOI 10.1007/s11060-009-9800-0; Tanuma N, 2009, ONCOGENE, V28, P752, DOI 10.1038/onc.2008.431; Tullai JW, 2004, J BIOL CHEM, V279, P20167, DOI 10.1074/jbc.M309260200; Waha A, 2010, CANCER RES, V70, P1689, DOI 10.1158/0008-5472.CAN-09-3218; Warmka JK, 2004, J BIOL CHEM, V279, P33085, DOI 10.1074/jbc.M403120200; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Zhang ZF, 2010, CARCINOGENESIS, V31, P577, DOI 10.1093/carcin/bgq020	40	66	69	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2011	30	35					3813	3820		10.1038/onc.2011.99	http://dx.doi.org/10.1038/onc.2011.99			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814TZ	21499306				2022-12-17	WOS:000294481400008
J	Li, Y; Bavarva, JH; Wang, Z; Guo, J; Qian, C; Thibodeau, SN; Golemis, EA; Liu, W				Li, Y.; Bavarva, J. H.; Wang, Z.; Guo, J.; Qian, C.; Thibodeau, S. N.; Golemis, E. A.; Liu, W.			HEF1, a novel target of Wnt signaling, promotes colonic cell migration and cancer progression	ONCOGENE			English	Article						HEF1; Wnt signaling; colorectal cancer; tumorigenesis	ENDOTHELIAL GROWTH-FACTOR; BETA-CATENIN; COLORECTAL-CANCER; EXPRESSION; TRANSCRIPTION; ACTIVATION; MUTATIONS; PHOSPHORYLATION; RECEPTORS; EFFECTOR	Misregulation of the canonical Wnt/beta-catenin pathway and aberrant activation of Wnt signaling target genes are common in colorectal cancer (CRC) and contribute to cancer progression. Altered expression of human enhancer of filamentation 1 (HEF1; also known as NEDD9 or Cas-L) has been implicated in progression of melanoma, breast, and CRC. However, the regulation of HEF1 and the role of HEF1 in CRC tumorigenesis are not fully understood. We here identify HEF1 as a novel Wnt signaling target. The expression of HEF1 was upregulated by Wnt-3a, beta-catenin, and Dvl2 in a dose-dependent manner, and was suppressed following beta-catenin downregulation by shRNA. In addition, elevated HEF1 mRNA and protein levels were observed in CRC cell lines and primary tumor tissues, as well as in the colon and adenoma polyps of Apc(Min/+) mice. Moreover, HEF1 levels in human colorectal tumor tissues increased with the tumor grade. Chromatin immunoprecipitation (ChIP) assays and promoter analyses revealed three functional T-cell factor (TCF)-binding sites in the promoter of HEF1 responsible for HEF1 induction by Wnt signaling. Ectopic expression of HEF1 increased cell proliferation and colony formation, while downregulation of HEF1 in SW480 cells by shRNA had the opposite effects and inhibited the xenograft tumor growth. Furthermore, overexpression of HEF1 in SW480 cells promoted cell migration and invasion. Together, our results determined a novel role of HEF1 as a mediator of the canonical Wnt/beta-catenin signaling pathway for cell proliferation, migration, and tumorigenesis, as well as an important player in colorectal tumorigenesis and progression. HEF1 may represent an attractive candidate for drug targeting in CRC. Oncogene (2011) 30, 2633-2643; doi:10.1038/onc.2010.632; published online 14 February 2011	[Li, Y.; Bavarva, J. H.; Wang, Z.; Guo, J.; Qian, C.; Liu, W.] Louisiana State Univ, Hlth Sci Ctr, Stanley S Scott Canc Ctr, Dept Genet, New Orleans, LA 70112 USA; [Qian, C.; Thibodeau, S. N.; Liu, W.] Mayo Clin, Mayo Clin Coll Med, Dept Lab Med & Pathol, Rochester, MN USA; [Golemis, E. A.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Mayo Clinic; Fox Chase Cancer Center	Liu, W (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Stanley S Scott Canc Ctr, Dept Genet, 533 Bolivar St,CSRB 416, New Orleans, LA 70112 USA.	wliu2@lsuhsc.edu	LI, YINGCHUN/F-1238-2013	Golemis, Erica/0000-0003-3618-3673; Wang, Zemin/0000-0003-4189-578X	Louisiana Cancer Research Consortium; NIH [R01s CA63366, CA113342, CA06927]; NATIONAL CANCER INSTITUTE [P30CA006927, R29CA063366, R01CA113342, R01CA063366] Funding Source: NIH RePORTER	Louisiana Cancer Research Consortium; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Minjung Kim and Dr Lynda Chin (Harvard Medical School) for providing the shRNA-targeting HEF1. This study is supported by the funding from Louisiana Cancer Research Consortium (to WL). EAG is supported by NIH R01s CA63366 and CA113342, and by NIH core grant CA06927 (to Fox Chase Cancer Center).	Aarskog NK, 2000, HUM GENET, V107, P494, DOI 10.1007/s004390000399; Barker N, 2006, NAT REV DRUG DISCOV, V5, P997, DOI 10.1038/nrd2154; Batistatou A, 2006, VIRCHOWS ARCH, V448, P763, DOI 10.1007/s00428-006-0183-8; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Donninger H, 2004, ONCOGENE, V23, P8065, DOI 10.1038/sj.onc.1207959; Easwaran V, 1999, CURR BIOL, V9, P1415, DOI 10.1016/S0960-9822(00)80088-3; Easwaran V, 2003, CANCER RES, V63, P3145; Faivre EJ, 2007, MOL CELL BIOL, V27, P466, DOI 10.1128/MCB.01539-06; Fashena SJ, 2002, J CELL SCI, V115, P99; Fritzmann J, 2009, GASTROENTEROLOGY, V137, P165, DOI 10.1053/j.gastro.2009.03.041; Fujino H, 2002, J BIOL CHEM, V277, P2614, DOI 10.1074/jbc.M109440200; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Izumchenko E, 2009, CANCER RES, V69, P7198, DOI 10.1158/0008-5472.CAN-09-0795; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Kim M, 2006, CELL, V125, P1269, DOI 10.1016/j.cell.2006.06.008; Kim PJ, 2003, LANCET, V362, P205, DOI 10.1016/S0140-6736(03)13910-4; Labbe E, 2000, P NATL ACAD SCI USA, V97, P8358, DOI 10.1073/pnas.150152697; Law SF, 2000, MOL CELL BIOL, V20, P5184, DOI 10.1128/MCB.20.14.5184-5195.2000; LEONE A, 1993, ONCOGENE, V8, P2325; Letamendia A, 2001, J BONE JOINT SURG AM, V83A, pS31; Li YC, 2006, AM J PATHOL, V168, P1107, DOI 10.2353/ajpath.2006.050959; Liu T, 2002, J BIOL CHEM, V277, P47671, DOI 10.1074/jbc.M207458200; Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859; Lu DS, 2005, P NATL ACAD SCI USA, V102, P18567, DOI 10.1073/pnas.0509316102; Lucas JT, 2010, ONCOGENE, V29, P4449, DOI 10.1038/onc.2010.185; Ma H, 2005, ONCOGENE, V24, P3619, DOI 10.1038/sj.onc.1208433; Merrill RA, 2004, DEV DYNAM, V231, P564, DOI 10.1002/dvdy.20159; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Natarajan M, 2006, ONCOGENE, V25, P1721, DOI 10.1038/sj.onc.1209199; Novak A, 1999, CELL MOL LIFE SCI, V56, P523, DOI 10.1007/s000180050449; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; Richer JK, 2002, J BIOL CHEM, V277, P5209, DOI 10.1074/jbc.M110090200; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Segditsas S, 2006, ONCOGENE, V25, P7531, DOI 10.1038/sj.onc.1210059; Shao JY, 2005, J BIOL CHEM, V280, P26565, DOI 10.1074/jbc.M413056200; Spencer VA, 2003, METHODS, V31, P67, DOI 10.1016/S1046-2023(03)00089-6; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; van Seventer GA, 2001, EUR J IMMUNOL, V31, P1417, DOI 10.1002/1521-4141(200105)31:5<1417::AID-IMMU1417>3.0.CO;2-C; Velmurugan B, 2010, NEOPLASIA, V12, P95, DOI 10.1593/neo.91718; Xia DR, 2010, CANCER RES, V70, P824, DOI 10.1158/0008-5472.CAN-09-2105; Yasuhara R, 2010, J BIOL CHEM, V285, P317, DOI 10.1074/jbc.M109.053926; Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508; Zhai Y, 2002, AM J PATHOL, V160, P1229, DOI 10.1016/S0002-9440(10)62550-3; Zheng MZ, 2002, J BIOL CHEM, V277, P39599, DOI 10.1074/jbc.M202263200	45	66	69	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	23					2633	2643		10.1038/onc.2010.632	http://dx.doi.org/10.1038/onc.2010.632			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778CV	21317929	Green Published, Green Accepted			2022-12-17	WOS:000291677800004
J	Sotillo, E; Laver, T; Mellert, H; Schelter, JM; Cleary, MA; McMahon, S; Thomas-Tikhonenko, A				Sotillo, E.; Laver, T.; Mellert, H.; Schelter, J. M.; Cleary, M. A.; McMahon, S.; Thomas-Tikhonenko, A.			Myc overexpression brings out unexpected antiapoptotic effects of miR-34a	ONCOGENE			English	Article						microRNA; Myc; p53	B-CELL LINE; TUMOR-SUPPRESSOR; DOWN-REGULATION; C-MYC; P53; MICRORNAS; ACTIVATION; REPRESSION; EXPRESSION; APOPTOSIS	Downregulation of microRNA-34a by Myc is known to be essential for tumorigenesis and improve tumor-cell survival. Conversely, upregulation of miR-34a by p53 is thought to enhance its acetylation and activity and contribute to the pro-apoptotic effects of this tumor suppressor. We sought to determine whether restoration of miR-34a levels in B-lymphoid cells with Myc overexpression would aid therapeutic apoptosis. Unexpectedly, delivery of miR-34a, which doesn't target p53 directly, severely compromised steady-state p53 levels. This effect was preceded and mediated by direct targeting of Myc, which sustained p53 protein levels via the Arf-Hdm2 pathway. As a result, in the presence of Myc, miR-34a inhibited p53-dependent bortezomib-induced apoptosis as efficiently as anti-p53 small interfering RNA. Conversely, inhibition of miR-34a using antisense RNA sensitized lymphoma cells to therapeutic apoptosis. Thus, in tumors with deregulated Myc expression, miR-34a confers drug resistance and could be considered a therapeutic target. Oncogene (2011) 30, 2587-2594; doi:10.1038/onc.2010.634; published online 7 February 2011	[Sotillo, E.; Thomas-Tikhonenko, A.] Childrens Hosp Philadelphia, Dept Pathol & Lab Med, Div Canc Pathobiol, Philadelphia, PA 19104 USA; [Laver, T.; Thomas-Tikhonenko, A.] Univ Penn, NIH Merck Summer Program, Philadelphia, PA 19104 USA; [Mellert, H.; McMahon, S.; Thomas-Tikhonenko, A.] Univ Penn, Canc Biol CAMB Grad Program, Philadelphia, PA 19104 USA; [Schelter, J. M.; Cleary, M. A.] Rosetta Inpharmat, Seattle, WA USA; [McMahon, S.] Thomas Jefferson Med Coll, Dept Canc Biol, Philadelphia, PA USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania; Merck & Company; Jefferson University	Thomas-Tikhonenko, A (corresponding author), Childrens Hosp Philadelphia, Dept Pathol & Lab Med, Div Canc Pathobiol, 4056 Colket Translat Res Bldg,3501 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	andreit@mail.med.upenn.edu	Thomas-Tikhonenko, Andrei/E-5329-2011; laver, travis/AAA-2025-2020	Thomas-Tikhonenko, Andrei/0000-0002-2739-2206; McMahon, Steven/0000-0002-3405-1768; Sotillo, Elena/0000-0002-3993-1932	US National Institutes of Health [CA 122334]; Children's Hospital of Philadelphia; NIH [R01CA098172-07, R21CA152786-01, R01CA090465-08]; NATIONAL CANCER INSTITUTE [R01CA090465, R01CA098172, R21CA152786, R01CA122334] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Children's Hospital of Philadelphia; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Joshua Mendell and Tsung-Cheng Chang (Johns Hopkins University) for sharing unpublished data on miR-34a function in B-cells. Current and past members of our laboratories (in particular Drs Duonan Yu, James Psathas, Michael Dews and Elaine Chung) are acknowledged for many stimulating discussions. We are grateful to the Rosetta Gene Expression Laboratory for performing microarray hybridization experiments and Miho Kibukawa (Merck & Co., Inc.)-for technical support. We thank Dr Dirk Eick (GSF Research Centre, Munich) for P493-6 cells, Dr Carlo Croce (Ohio State University, Columbus) for GM607 cells and Dr Joelle Wiels (Institut Gustave Roussy, Villejuif, France) for Ly47cells. This work was supported by US National Institutes of Health grant CA 122334 to ATT and the Institutional Development Fund of the Children's Hospital of Philadelphia (ATT), as well as NIH grants R01CA098172-07, R21CA152786-01 and R01CA090465-08 to SBM.	Adachi N, 2006, DNA CELL BIOL, V25, P19, DOI 10.1089/dna.2006.25.19; Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833; Bagchi A, 2008, CANCER RES, V68, P2551, DOI 10.1158/0008-5472.CAN-07-2095; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; BHATIA KG, 1992, CANCER RES, V52, P4273; Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068; BRACHMANN CB, 1995, GENE DEV, V9, P2888, DOI 10.1101/gad.9.23.2888; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2007, J CLIN INVEST, V117, P2059, DOI 10.1172/JCI32577; Cannell IG, 2010, P NATL ACAD SCI USA, V107, P5375, DOI 10.1073/pnas.0910015107; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Chang TC, 2009, P NATL ACAD SCI USA, V106, P3384, DOI 10.1073/pnas.0808300106; Christoffersen NR, 2010, CELL DEATH DIFFER, V17, P236, DOI 10.1038/cdd.2009.109; Cole KA, 2008, MOL CANCER RES, V6, P735, DOI 10.1158/1541-7786.MCR-07-2102; Corney DC, 2007, CANCER RES, V67, P8433, DOI 10.1158/0008-5472.CAN-07-1585; Corney DC, 2010, CLIN CANCER RES, V16, P1119, DOI 10.1158/1078-0432.CCR-09-2642; Dalgard CL, 2009, INVEST OPHTH VIS SCI, V50, P4542, DOI 10.1167/iovs.09-3520; Dews M, 2006, NAT GENET, V38, P1060, DOI 10.1038/ng1855; Galluzzi L, 2009, CELL DEATH DIFFER, V16, P1093, DOI 10.1038/cdd.2009.44; Guessous F, 2010, CELL CYCLE, V9, P1031, DOI 10.4161/cc.9.6.10987; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; He L, 2007, NAT REV CANCER, V7, P819, DOI 10.1038/nrc2232; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Junttila MR, 2009, NAT REV CANCER, V9, P821, DOI 10.1038/nrc2728; Klein U, 2010, CANCER CELL, V17, P28, DOI 10.1016/j.ccr.2009.11.019; Kong YW, 2008, P NATL ACAD SCI USA, V105, P8866, DOI 10.1073/pnas.0800650105; Lal A, 2009, MOL CELL, V35, P610, DOI 10.1016/j.molcel.2009.08.020; Lin CH, 2009, EMBO J, V28, P3157, DOI 10.1038/emboj.2009.254; Lindstrom MS, 2002, SEMIN CANCER BIOL, V12, P381, DOI 10.1016/S1044-579X(02)00058-5; Lindstrom MS, 2001, ONCOGENE, V20, P2171, DOI 10.1038/sj.onc.1204303; Linsley PS, 2007, MOL CELL BIOL, V27, P2240, DOI 10.1128/MCB.02005-06; Lodygin D, 2008, CELL CYCLE, V7, P2591, DOI 10.4161/cc.7.16.6533; Luan SH, 2010, ARCH MED RES, V41, P67, DOI 10.1016/j.arcmed.2010.02.007; Miranda KC, 2006, CELL, V126, P1203, DOI 10.1016/j.cell.2006.07.031; Mu P, 2009, GENE DEV, V23, P2806, DOI 10.1101/gad.1872909; Navarro F, 2009, BLOOD, V114, P2181, DOI 10.1182/blood-2009-02-205062; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Olive V, 2009, GENE DEV, V23, P2839, DOI 10.1101/gad.1861409; Ota A, 2004, CANCER RES, V64, P3087, DOI 10.1158/0008-5472.CAN-03-3773; Pajic A, 2000, INT J CANCER, V87, P787, DOI 10.1002/1097-0215(20000915)87:6<787::AID-IJC4>3.0.CO;2-6; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; Sala A, 2009, ADV CANCER RES, V105, P115, DOI 10.1016/S0065-230X(09)05007-6; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026; Tarasov V, 2007, CELL CYCLE, V6, P1586, DOI 10.4161/cc.6.13.4436; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Ventura A, 2008, CELL, V132, P875, DOI 10.1016/j.cell.2008.02.019; Welch C, 2007, ONCOGENE, V26, P5017, DOI 10.1038/sj.onc.1210293; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xiao CC, 2008, NAT IMMUNOL, V9, P405, DOI 10.1038/ni1575; Yamakuchi M, 2008, P NATL ACAD SCI USA, V105, P13421, DOI 10.1073/pnas.0801613105; Yamakuchi M, 2009, CELL CYCLE, V8, P712, DOI 10.4161/cc.8.5.7753; Yu DN, 2005, CANCER RES, V65, P5454, DOI 10.1158/0008-5472.CAN-04-4197; Yu DN, 2002, ONCOGENE, V21, P1922, DOI 10.1038/sj.onc.1205244; Yu DN, 2007, BLOOD, V109, P4936, DOI 10.1182/blood-2006-10-050294	58	66	68	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	22					2587	2594		10.1038/onc.2010.634	http://dx.doi.org/10.1038/onc.2010.634			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	771ZE	21297663	Green Accepted			2022-12-17	WOS:000291198400010
J	Lane, D; Goncharenko-Khaider, N; Rancourt, C; Piche, A				Lane, D.; Goncharenko-Khaider, N.; Rancourt, C.; Piche, A.			Ovarian cancer ascites protects from TRAIL-induced cell death through alpha v beta 5 integrin-mediated focal adhesion kinase and Akt activation	ONCOGENE			English	Article						integrins; death receptors; ovarian carcinoma; ascites; PI3K/Akt pathway; TRAIL	LYSOPHOSPHATIDIC ACID LPA; GROWTH-FACTOR RECEPTOR; INDUCED APOPTOSIS; COUPLED RECEPTOR; EXPRESSION; CARCINOMA; MIGRATION; PATHWAY; LIGAND; IDENTIFICATION	Interactions between ovarian cancer cells and the surrounding tumor microenvironment are not well characterized. We have earlier shown that ovarian cancer ascites induces Akt activation and protect tumor cells from TRAIL-induced apoptosis. Here, we investigated the mechanism by which ascites activates Akt. The ability of ovarian cancer ascites to activate Akt and inhibit TRAIL-induced cell death and caspase activity was decreased by heat inactivation, but was retained in ascites fractions >5 kDa. The survival promoting activity of ascites was not affected by inhibitors of growth factor receptor including epidermal growth factor receptor (EGFR), VEGFR, FGFR, Her2/neu, and IGF-R1. However, this activity was inhibited by an alpha v beta 5 integrin-blocking antibody, but not by blocking antibodies against alpha v beta 3, beta 1, or beta 3 integrins. alpha v beta 5 integrin-blocking antibodies also inhibited ascites-induced Akt phosphorylation and c-FLIPs up-regulation. Ovarian cancer ascites induced a rapid phosphorylation of focal adhesion kinase (FAK), which closely correlated with the phosphorylation of Akt overtime. FAK phosphorylation was strongly inhibited by alpha v beta 5 integrin-blocking antibodies. Depletion of FAK content by RNA interference was also associated with inhibition of ascites-mediated Akt activation and survival. These results suggest that ovarian cancer ascites induces FAK and Akt activation in an alpha v beta 5 integrin-dependent pathway, which confers protection from TRAIL-induced cell death and caspase activation. Oncogene (2010) 29, 3519-3531; doi:10.1038/onc.2010.107; published online 19 April 2010	[Lane, D.; Goncharenko-Khaider, N.; Rancourt, C.; Piche, A.] Univ Sherbrooke, Fac Med, Dept Microbiol & Infectiol, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Piche, A (corresponding author), Univ Sherbrooke, Fac Med, Dept Microbiol & Infectiol, 3001,12Ieme Ave Nord, Sherbrooke, PQ J1H 5N4, Canada.	Alain.Piche@USherbrooke.ca			Cancer Research Society	Cancer Research Society	Funding for this study was provided by the Cancer Research Society. We thank the Tumor Bank from the 'Reseau de Recherche en Cancer du Fond de Recherche en Sante du Quebec' for providing the ovarian cancer ascites.	Abendstein B, 2000, CYTOKINE, V12, P1115, DOI 10.1006/cyto.1999.0632; Alper O, 2001, J NATL CANCER I, V93, P1375, DOI 10.1093/jnci/93.18.1375; Carreiras F, 1999, INT J CANCER, V80, P285; Contos JJA, 2000, MOL PHARMACOL, V58, P1188, DOI 10.1124/mol.58.6.1188; Cruet-Hennequart S, 2003, ONCOGENE, V22, P1688, DOI 10.1038/sj.onc.1206347; Damiano JS, 2002, CURR CANCER DRUG TAR, V2, P37, DOI 10.2174/1568009023334033; Dan HC, 2004, ONCOGENE, V23, P706, DOI 10.1038/sj.onc.1207171; Davidson B, 2006, CLIN CANCER RES, V12, P791, DOI 10.1158/1078-0432.CCR-05-2516; Fornaro M, 2003, J BIOL CHEM, V278, P50402, DOI 10.1074/jbc.M307627200; Fraser M, 2003, CANCER RES, V63, P7081; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Gillan L, 2002, CANCER RES, V62, P5358; Goetzl EJ, 1999, CANCER RES, V59, P5370; Graves LE, 2004, CANCER RES, V64, P7045, DOI 10.1158/0008-5472.CAN-04-1800; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Kandasamy K, 2002, CANCER RES, V62, P4929; Kang YC, 2004, CELL DEATH DIFFER, V11, P1287, DOI 10.1038/sj.cdd.4401489; Kobayashi-Sakamoto M, 2008, MICROVASC RES, V76, P139, DOI 10.1016/j.mvr.2008.06.004; KOHLER M, 1989, ANTICANCER RES, V9, P1537; KOHLER M, 1992, EUR J CANCER, V28A, P1432, DOI 10.1016/0959-8049(92)90538-D; Lane D, 2008, INT J GYNECOL CANCER, V18, P670, DOI 10.1111/j.1525-1438.2007.01062.x; Lane D, 2007, INT J CANCER, V121, P1227, DOI 10.1002/ijc.22840; Matei D, 2006, ONCOGENE, V25, P2060, DOI 10.1038/sj.onc.1209232; Matter ML, 2001, J BIOL CHEM, V276, P27757, DOI 10.1074/jbc.M102014200; MILLS GB, 1988, CANCER RES, V48, P1066; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Miyamoto S, 2004, CANCER RES, V64, P5720, DOI 10.1158/0008-5472.CAN-04-0811; Noguchi K, 2003, J BIOL CHEM, V278, P25600, DOI 10.1074/jbc.M302648200; Puiffe ML, 2007, NEOPLASIA, V9, P820, DOI 10.1593/neo.07472; Puls LE, 1996, GYNECOL ONCOL, V61, P109, DOI 10.1006/gyno.1996.0106; Ren J, 2006, CANCER RES, V66, P3006, DOI 10.1158/0008-5472.CAN-05-1292; Saltzman AK, 1999, GYNECOL OBSTET INVES, V47, P200, DOI 10.1159/000010095; Shen-Gunther J, 2002, GYNECOL ONCOL, V87, P77, DOI 10.1006/gyno.2002.6800; Sivaprasad U, 2007, CELL DEATH DIFFER, V14, P851, DOI 10.1038/sj.cdd.4402077; Stoica A, 2000, J CELL BIOCHEM, V76, P605, DOI 10.1002/(SICI)1097-4644(20000315)76:4<605::AID-JCB9>3.0.CO;2-T; Stupack DG, 2002, J CELL SCI, V115, P3729, DOI 10.1242/jcs.00071; Uhm JH, 1999, CLIN CANCER RES, V5, P1587; Westermann AM, 1998, ANN ONCOL, V9, P437, DOI 10.1023/A:1008217129273; Yamada T, 2004, J BIOL CHEM, V279, P6595, DOI 10.1074/jbc.M308133200; Yang XK, 2006, CANCER RES, V66, P3126, DOI 10.1158/0008-5472.CAN-05-0425; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Ye XQ, 2002, BBA-MOL CELL BIOL L, V1585, P108, DOI 10.1016/S1388-1981(02)00330-X; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161	43	66	67	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2010	29	24					3519	3531		10.1038/onc.2010.107	http://dx.doi.org/10.1038/onc.2010.107			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	611QN	20400979				2022-12-17	WOS:000278835400007
J	Lee, YC; Huang, CF; Murshed, M; Chu, K; Araujo, JC; Ye, X; deCrombrugghe, B; Yu-Lee, LY; Gallick, GE; Lin, SH				Lee, Y-C; Huang, C-F; Murshed, M.; Chu, K.; Araujo, J. C.; Ye, X.; deCrombrugghe, B.; Yu-Lee, L-Y; Gallick, G. E.; Lin, S-H			Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts	ONCOGENE			English	Article						dasatinib; Src family kinase; osteoblast; prostate cancer; bone metastasis	FIBROBLAST-GROWTH-FACTOR; PROSTATE-CANCER CELLS; BONE-FORMATION; COLLAGEN-SYNTHESIS; TUMOR PROGRESSION; SECRETED ISOFORM; PROTEIN-KINASE; EXPRESSION; PP60C-SRC; METASTASIS	Dasatinib, a dual Src family kinase and Abl inhibitor, is being tested clinically for the treatment of prostate cancer bone metastasis. Bidirectional interactions between osteoblasts and prostate cancer cells are critical in the progression of prostate cancer in bone, but the effect of dasatinib on osteoblasts is unknown. We found that dasatinib inhibited proliferation of primary mouse osteoblasts isolated from mouse calvaria and the immortalized MC3T3-E1 cell line. In calvarial osteoblasts from Col-luc transgenic mice carrying osteoblast-specific Col1 alpha 1 promoter reporter, luciferase activity was inhibited. Dasatinib also inhibited fibroblast growth factor-2-induced osteoblast proliferation, but strongly promoted osteoblast differentiation, as reflected by stimulation of alkaline phosphatase activity, osteocalcin secretion and osteoblast mineralization. To determine how dasatinib blocks proliferative signaling in osteoblasts, we analyzed the expression of a panel of tyrosine kinases, including Src, Lyn, Fyn, Yes and Abl, in osteoblasts. In the Src family kinases, only Src was activated at a high level. Abl was expressed at a low level in osteoblasts. Phosphorylation of Src-Y419 or Abl-Y245 was inhibited by dasatinib treatment. Knockdown of either Src or Abl by lenti-shRNA in osteoblasts enhances osteoblast differentiation, suggesting that dasatinib enhances osteoblast differentiation through inhibition of both Src and Abl. Oncogene (2010) 29, 3196-3207; doi: 10.1038/onc.2010.73; published online 15 March 2010	[Lee, Y-C; Huang, C-F; Ye, X.; Lin, S-H] Univ Texas MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; [Huang, C-F] Natl Taiwan Univ, Coll Med, Grad Inst Pharm, Natl Taiwan Univ Hosp,Dept Pharm, Taipei 10764, Taiwan; [Murshed, M.; Chu, K.; Araujo, J. C.; Gallick, G. E.; Lin, S-H] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; [deCrombrugghe, B.] Univ Texas MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; [Yu-Lee, L-Y] Baylor Coll Med, Dept Med, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; National Taiwan University; National Taiwan University Hospital; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	Lin, SH (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol Pathol, 1515 Holcombe Blvd,Box 89, Houston, TX 77030 USA.	slin@mdanderson.org		Huang, Chih-Fen/0000-0003-1311-8828	National Institutes of Health [CA111479, P50 CA140388, DK53176]; Prostate Cancer Foundation; NATIONAL CANCER INSTITUTE [P50CA140388, R01CA111479] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053176] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Prostate Cancer Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Karen Philips for editing the paper. This study was supported by National Institutes of Health Grants CA111479 (SH Lin), P50 CA140388 (SH Lin, GE Gallick) and DK53176 (LY Yu-Lee), and by the Prostate Cancer Foundation (SH Lin).	Araujo J, 2009, INT J CANCER, V124, P1, DOI 10.1002/ijc.23998; Aubin JE, 1998, BIOCHEM CELL BIOL, V76, P899, DOI 10.1139/bcb-76-6-899; Autzen P, 1998, BRIT J CANCER, V78, P1219, DOI 10.1038/bjc.1998.658; BELLOWS CG, 1989, DEV BIOL, V133, P8, DOI 10.1016/0012-1606(89)90291-1; Berman E, 2006, NEW ENGL J MED, V354, P2006, DOI 10.1056/NEJMoa051140; BHARGAVA U, 1988, BONE, V9, P155, DOI 10.1016/8756-3282(88)90005-1; BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032; Brownlow N, 2009, LEUKEMIA, V23, P590, DOI 10.1038/leu.2008.237; CANALIS E, 1988, J CLIN INVEST, V81, P1572, DOI 10.1172/JCI113490; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; Chen NY, 2007, CANCER RES, V67, P6544, DOI 10.1158/0008-5472.CAN-07-1330; Dai JL, 2005, CANCER RES, V65, P8274, DOI 10.1158/0008-5472.CAN-05-1891; Debiais F, 2001, J CELL BIOCHEM, V81, P68, DOI 10.1002/1097-4644(20010401)81:1<68::AID-JCB1024>3.0.CO;2-S; Dorkin TJ, 1999, J PATHOL, V189, P564, DOI 10.1002/(SICI)1096-9896(199912)189:4<564::AID-PATH480>3.0.CO;2-1; Dorkin TJ, 1999, ONCOGENE, V18, P2755, DOI 10.1038/sj.onc.1202624; Fakhry A, 2005, BONE, V36, P254, DOI 10.1016/j.bone.2004.10.003; FRANCESCHI RT, 1992, J BONE MINER RES, V7, P235; GLOBUS RK, 1988, ENDOCRINOLOGY, V123, P98, DOI 10.1210/endo-123-1-98; HANNON RA, 2009, J BONE MINER RES; Ito H, 2003, SURGERY, V134, P221, DOI 10.1067/msy.2003.224; Jacob K, 1999, CANCER RES, V59, P4453; Kopetz S, 2007, CLIN CANCER RES, V13, P7232, DOI 10.1158/1078-0432.CCR-07-1902; Koreckij T, 2009, BRIT J CANCER, V101, P263, DOI 10.1038/sj.bjc.6605178; Li BJ, 2000, NAT GENET, V24, P304, DOI 10.1038/73542; Li ZG, 2008, J CLIN INVEST, V118, P2697, DOI 10.1172/JCI33093; Lin SH, 2008, ONCOGENE, V27, P5195, DOI 10.1038/onc.2008.156; Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528; Lombardo LJ, 2004, J MED CHEM, V47, P6658, DOI 10.1021/jm049486a; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; Marzia M, 2000, J CELL BIOL, V151, P311, DOI 10.1083/jcb.151.2.311; Masuda H, 2003, PROSTATE, V54, P268, DOI 10.1002/pros.10193; MAYAHARA H, 1993, GROWTH FACTORS, V9, P73, DOI 10.3109/08977199308991583; MCCARTHY TL, 1989, ENDOCRINOLOGY, V125, P2118, DOI 10.1210/endo-125-4-2118; Nam S, 2005, CANCER RES, V65, P9185, DOI 10.1158/0008-5472.CAN-05-1731; Nelson JB, 1999, UROLOGY, V53, P1063, DOI 10.1016/S0090-4295(98)00658-X; NELSON JB, 1995, NAT MED, V1, P944, DOI 10.1038/nm0995-944; Park SI, 2008, CANCER RES, V68, P3323, DOI 10.1158/0008-5472.CAN-07-2997; ROSSERT J, 1995, J CELL BIOL, V129, P1421, DOI 10.1083/jcb.129.5.1421; Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480; Shor AC, 2007, CANCER RES, V67, P2800, DOI 10.1158/0008-5472.CAN-06-3469; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; Trevino JG, 2006, AM J PATHOL, V168, P962, DOI 10.2353/ajpath.2006.050570; Vakar-Lopez F, 2004, J PATHOL, V203, P688, DOI 10.1002/path.1568; Ye XC, 2007, FRONT BIOSCI, V12, P3273, DOI 10.2741/2311	48	66	68	0	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2010	29	22					3196	3207		10.1038/onc.2010.73	http://dx.doi.org/10.1038/onc.2010.73			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	605BA	20228840	Green Accepted			2022-12-17	WOS:000278321100003
J	Harris, CR; DeWan, A; Zupnick, A; Normart, R; Gabriel, A; Prives, C; Levine, AJ; Hoh, J				Harris, C. R.; DeWan, A.; Zupnick, A.; Normart, R.; Gabriel, A.; Prives, C.; Levine, A. J.; Hoh, J.			p53 responsive elements in human retrotransposons	ONCOGENE			English	Article						p53; LINE-1; genome stability	SUPPRESSOR PROTEIN P53; DNA-BINDING; GENE-EXPRESSION; L1 RETROTRANSPOSITION; ACTIVATION; CELLS; APOPTOSIS; LINE-1; IDENTIFICATION; METHYLATION	Long interspersed nuclear elements-1 (L1s) are highly repetitive DNA elements that are capable of altering the human genome through retrotransposition. To protect against L1 retroposition, the cell downregulates the expression of L1 proteins by various mechanisms, including high-density cytosine methylation of L1 promoters and DICER-dependent destruction of L1 mRNAs. In this report, a large number of p53 responsive elements, or p53 DNA binding sites, were detected in L1 elements within the human genome. At least some of these p53 responsive elements are functional and can act to increase the levels of L1 mRNA expression. The p53 protein can directly bind to a short 15-nucleotide sequence within the L1 promoter. This p53 responsive element within L1 is a recent addition to evolution, appearing B20 million years ago. This suggests an interplay between L1 elements, which have a rich history of causing changes in the genome, and the p53 protein, the function of which is to protect against genomic changes. To understand these observations, a model is proposed in which the increased expression of L1 mRNAs by p53 actually increases, rather than decreases, the genomic stability through amplification of p53-dependent processes for genomic protection. Oncogene (2009) 28, 3857 -3865; doi:10.1038/onc.2009.246; published online 31 August 2009	[Harris, C. R.; Normart, R.] Raymond & Beverly Sackler Fdn, New Brunswick, NJ USA; [Harris, C. R.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, New Brunswick, NJ USA; [Harris, C. R.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pediat, New Brunswick, NJ 08903 USA; [DeWan, A.; Hoh, J.] Yale Univ, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA; [Zupnick, A.; Prives, C.] Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; [Gabriel, A.] Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08855 USA; [Levine, A. J.] Inst Adv Study, Sch Nat Sci, Princeton, NJ 08540 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Yale University; Columbia University; Rutgers State University New Brunswick; Institute for Advanced Study - USA	Levine, AJ (corresponding author), Inst Adv Study, Sch Nat Sci, Einstein Dr, Princeton, NJ 08540 USA.	alevine@ias.edu		DeWan, Andrew/0000-0002-7679-8704	Verto Institute; NIH [K25HG00060, R01EY015771, R01MH44292, P01CA87497]; NATIONAL CANCER INSTITUTE [P01CA087497] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY015771] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [K25HG000060] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH044292] Funding Source: NIH RePORTER	Verto Institute; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	This work was primarily supported by the Verto Institute, with additional support provided by NIH Grant nos K25HG00060, R01EY015771, R01MH44292 and P01CA87497.	Babushok DV, 2007, HUM MUTAT, V28, P527, DOI 10.1002/humu.20486; Bensaad K, 2005, NAT MED, V11, P1278, DOI 10.1038/nm1205-1278; Brouha B, 2003, P NATL ACAD SCI USA, V100, P5280, DOI 10.1073/pnas.0831042100; Budhram-Mahadeo V, 1999, J BIOL CHEM, V274, P15237, DOI 10.1074/jbc.274.21.15237; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Donehower LA, 2005, EXP GERONTOL, V40, P7, DOI 10.1016/j.exger.2004.10.007; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Esteve PO, 2005, P NATL ACAD SCI USA, V102, P1000, DOI 10.1073/pnas.0407729102; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Han JS, 2004, NATURE, V429, P268, DOI 10.1038/nature02536; Haoudi A, 2004, J BIOMED BIOTECHNOL, P185, DOI 10.1155/S1110724304403131; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Hoh J, 2002, P NATL ACAD SCI USA, V99, P8467, DOI 10.1073/pnas.132268899; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hu WW, 2007, NATURE, V450, P721, DOI 10.1038/nature05993; Jin SK, 2001, J CELL SCI, V114, P4139; Jordan JJ, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000104; Jurka J, 2000, TRENDS GENET, V16, P418, DOI 10.1016/S0168-9525(00)02093-X; Kannan K, 2001, ONCOGENE, V20, P3449, DOI 10.1038/sj.onc.1204446; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Khan H, 2006, GENOME RES, V16, P78, DOI 10.1101/gr.4001406; Kwon HS, 2006, BBA-GENE STRUCT EXPR, V1759, P141, DOI 10.1016/j.bbaexp.2006.04.005; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LANE DP, 1992, NATURE, V358, P16; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Lee KC, 1999, MOL CELL BIOL, V19, P1279; Lorincz MC, 2004, NAT STRUCT MOL BIOL, V11, P1068, DOI 10.1038/nsmb840; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Ori A, 1998, EMBO J, V17, P544, DOI 10.1093/emboj/17.2.544; Ostertag EM, 2000, NUCLEIC ACIDS RES, V28, P1418, DOI 10.1093/nar/28.6.1418; Ostertag EM, 2002, NAT GENET, V32, P655, DOI 10.1038/ng1022; Pochampally R, 1999, J BIOL CHEM, V274, P15271, DOI 10.1074/jbc.274.21.15271; Resnick-Silverman L, 1998, GENE DEV, V12, P2102, DOI 10.1101/gad.12.14.2102; Tchenio T, 2000, NUCLEIC ACIDS RES, V28, P411, DOI 10.1093/nar/28.2.411; Wang T, 2007, P NATL ACAD SCI USA, V104, P18613, DOI 10.1073/pnas.0703637104; Woodcock DM, 1997, J BIOL CHEM, V272, P7810, DOI 10.1074/jbc.272.12.7810; Zhao RB, 2000, GENE DEV, V14, P981	39	66	67	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2009	28	44					3857	3865		10.1038/onc.2009.246	http://dx.doi.org/10.1038/onc.2009.246			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	515LJ	19718052	Green Accepted			2022-12-17	WOS:000271471900001
J	Khandrika, L; Lieberman, R; Koul, S; Kumar, B; Maroni, P; Chandhoke, R; Meacham, RB; Koul, HK				Khandrika, L.; Lieberman, R.; Koul, S.; Kumar, B.; Maroni, P.; Chandhoke, R.; Meacham, R. B.; Koul, H. K.			Hypoxia-associated p38 mitogen-activated protein kinase-mediated androgen receptor activation and increased HIF-1 alpha levels contribute to emergence of an aggressive phenotype in prostate cancer	ONCOGENE			English	Article						p38 MAPK; HIF-1 alpha; androgen independence; prostate cancer	ENDOTHELIAL GROWTH-FACTOR; INDUCIBLE FACTOR-1-ALPHA; MAP-KINASE; OXIDATIVE STRESS; VEGF EXPRESSION; CELL INVASION; LNCAP CELLS; IN-VITRO; ANGIOGENESIS; PATHWAY	Androgen receptor (AR) signaling is involved in the development and progression of prostate cancer. Tumor microvasculature contributes to continual exposure of prostate cancer cells to hypoxia-reoxygenation, however, the role of hypoxia-reoxygenation in prostate cancer progression and modulation of AR signaling is not understood. In this study, we evaluated the effects of hypoxia-reoxygenation in LNCaP cells, a line of hormone responsive human prostate cancer cells. Our results demonstrate that hypoxia-reoxygenation resulted in increased survival, higher clonogenicity and enhanced invasiveness of these cells. Moreover, hypoxia-reoxygenation was associated with an increased AR activity independent of androgens as well as increased hypoxia inducible factor (HIF-1 alpha) levels and activity. We also observed that the activation of p38 mitogen-activated protein (MAP) kinase pathway was an early response to hypoxia, and inhibition of p38 MAP kinase pathway by variety of approaches abolished hypoxia-reoxygenation induced increased AR activity as well as increased survival, clonogenicity and invasiveness. These results demonstrate a critical role for hypoxia-induced p38 MAP kinase pathway in androgen-independent AR activation in prostate cancer cells, and suggest that hypoxia-reoxygenation may select for aggressive androgen-independent prostate cancer phenotype.	[Khandrika, L.; Lieberman, R.; Koul, S.; Kumar, B.; Maroni, P.; Chandhoke, R.; Meacham, R. B.; Koul, H. K.] Univ Colorado, Denver & Hlth Sci Ctr, Sch Med,Program Urosci, Signal Transduct & Mol Urol Lab,Dep Surg,Div Urol, Aurora, CO 80045 USA; [Maroni, P.; Meacham, R. B.; Koul, H. K.] Univ Colorado, Denver & Hlth Sci Ctr, Ctr Comprehens Canc, Aurora, CO 80045 USA; [Koul, H. K.] Univ Colorado, Denver & Hlth Sci Ctr, Denver Vet Adm Med Ctr, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Koul, HK (corresponding author), Univ Colorado, Denver & Hlth Sci Ctr, Sch Med,Program Urosci, Signal Transduct & Mol Urol Lab,Dep Surg,Div Urol, Bldg P15 RC2,12700 E 19th Ave,Room 6001, Aurora, CO 80045 USA.	hari.koul@uchsc.edu	Kumar, Binod/K-3679-2013	Khandrika, Lakshmipathi/0000-0003-4438-9073	NIH/NCI-P20 [CA103680]; Student Cancer Research Fellowship Program; University of Colorado Cancer Center; Department of Surgery School of Medicine Academic Enrichment Funds; NATIONAL CANCER INSTITUTE [P20CA103680] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054084] Funding Source: NIH RePORTER	NIH/NCI-P20(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Student Cancer Research Fellowship Program; University of Colorado Cancer Center; Department of Surgery School of Medicine Academic Enrichment Funds; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported in part by NIH/NCI-P20 CA103680-Schwartz/Byers Program PI's ( H Koul, Pilot-Project PI), Student Cancer Research Fellowship Program ( H Koul, Preceptor), University of Colorado Cancer Center and Department of Surgery School of Medicine Academic Enrichment Funds ( H Koul). We thankfully acknowledge service provided by University of Colorado Cancer Center Flow Cytometry Core. We thank Dr Andrew Kung ( Dana-Faber Cancer Institute, Boston, MA, USA) for 3 x HRE luciferase plasmid, Dr Magnus Essand ( Uppsala University, Sweden) for AR responsive Luciferase Vector PSAe/TARPp and Professor Matthias Gaestel ( Institute of Biochemistry, Medical School, Hannover, Germany) for MK2 expression plasmids.	Akakura N, 2001, CANCER RES, V61, P6548; Asirvatham AJ, 2006, ENDOCRINOLOGY, V147, P257, DOI 10.1210/en.2005-0942; Baek SH, 2001, J CELL PHYSIOL, V188, P223, DOI 10.1002/jcp.1117; Berra E, 2000, CANCER METAST REV, V19, P139, DOI 10.1023/A:1026506011458; Bhattacharya S, 1999, GENE DEV, V13, P64, DOI 10.1101/gad.13.1.64; Boddy JL, 2005, CLIN CANCER RES, V11, P7658, DOI 10.1158/1078-0432.CCR-05-0460; Butterworth KT, 2008, INT J CANCER, V123, P760, DOI 10.1002/ijc.23418; Calvani M, 2008, CANCER RES, V68, P285, DOI 10.1158/0008-5472.CAN-07-5564; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Cheng WS, 2003, ENDOCRINOLOGY, V144, P3433, DOI 10.1210/en.2003-0121; Culig Z, 2006, J CELL BIOCHEM, V99, P373, DOI 10.1002/jcb.20898; Horii K, 2007, MOL CANCER RES, V5, P383, DOI 10.1158/1541-7786.MCR-06-0226; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Huggins C, 1941, CANCER RES, V1, P293; Kimbro KS, 2006, ENDOCR-RELAT CANCER, V13, P739, DOI 10.1677/erc.1.00728; Kokontis JM, 1998, MOL ENDOCRINOL, V12, P941, DOI 10.1210/me.12.7.941; Kumar B, 2008, CANCER RES, V68, P1777, DOI 10.1158/0008-5472.CAN-07-5259; Kwon SJ, 2005, CLIN CANCER RES, V11, P7607, DOI 10.1158/1078-0432.CCR-05-0981; Luo Y, 2006, BJU INT, V98, P1315, DOI 10.1111/j.1464-410X.2006.06480.x; Maroni PD, 2005, J UROLOGY, V174, P757, DOI 10.1097/01.ju.0000164724.86631.6e; McDonald DM, 2003, NAT MED, V9, P713, DOI 10.1038/nm0603-713; Milosevic M, 2007, CANCER RES, V67, P6022, DOI 10.1158/0008-5472.CAN-07-0561; Miyazaki Y, 2008, INT J ONCOL, V32, P145; Mortimer HJ, 2007, PULM PHARMACOL THER, V20, P718, DOI 10.1016/j.pupt.2006.08.007; Murata M, 2006, J ORTHOP RES, V24, P1544, DOI 10.1002/jor.20168; Pages G, 2000, J BIOL CHEM, V275, P26484, DOI 10.1074/jbc.M002104200; Park SY, 2006, CANCER RES, V66, P5121, DOI 10.1158/0008-5472.CAN-05-1341; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Powell CS, 2004, AM J PHYSIOL-LUNG C, V286, pL826, DOI 10.1152/ajplung.00119.2003; REPESH LA, 1989, INVAS METAST, V9, P192; RIZZINO A, 1987, METHOD ENZYMOL, V146, P341; Shida Y, 2007, BIOCHEM BIOPH RES CO, V353, P744, DOI 10.1016/j.bbrc.2006.12.077; Sumbayev VV, 2005, ARCH BIOCHEM BIOPHYS, V436, P406, DOI 10.1016/j.abb.2005.02.021; Sung SY, 2006, CANCER RES, V66, P9519, DOI 10.1158/0008-5472.CAN-05-4375; Vleugel MM, 2005, J CLIN PATHOL, V58, P172, DOI 10.1136/jcp.2004.019885; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Xu L, 2006, ONCOGENE, V25, P2987, DOI 10.1038/sj.onc.1209337; Yoshino Y, 2006, INT J ONCOL, V29, P981; Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407; Zhong H, 1998, CANCER RES, V58, P5280; Zhong H, 2000, CANCER RES, V60, P1541; Zoubeidi A, 2007, CANCER RES, V67, P10455, DOI 10.1158/0008-5472.CAN-07-2057	42	66	69	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2009	28	9					1248	1260		10.1038/onc.2008.476	http://dx.doi.org/10.1038/onc.2008.476			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415AH	19151763	Green Accepted			2022-12-17	WOS:000263906200009
J	Moller, A; House, CM; Wong, CSF; Scanlon, DB; Liu, MCP; Ronai, Z; Bowtell, DDL				Moller, A.; House, C. M.; Wong, C. S. F.; Scanlon, D. B.; Liu, M. C. P.; Ronai, Z.; Bowtell, D. D. L.			Inhibition of Siah ubiquitin ligase function	ONCOGENE			English	Article						ubiquitin; degradation; hypoxia	HYPOXIA-INDUCIBLE FACTOR; FACTOR 1-ALPHA; TRANSCRIPTIONAL REPRESSOR; PROTEASOME PATHWAY; O-2 HOMEOSTASIS; DEGRADATION; HOMOLOGS; PROTEIN; SINA; HIF	Tumor hypoxia induces the upregulation of hypoxiainducible factor 1 alpha (Hif-1 alpha), which in turn induces the expression of genes including VEGF to recruit new blood vessel outgrowth, enabling tumor growth and metastasis. Interference with the Hif-1 pathway and neoangiogenesis is an attractive antitumor target. The hydroxylation of Hif-1 alpha by prolyl-hydroxylase (PHD) proteins during normoxia serves as a recognition motif for its proteasomal degradation. However, under hypoxic conditions, hydroxylation is inhibited and furthermore, PHD proteins are themselves polyubiquitylated and degraded by Siah ubiquitin ligases. Our data demonstrate for the first time that inhibition of the interaction between Siah and PHD proteins using a fragment derived from a Drosophila protein ( phyllopod) interferes with the PHD degradation. Furthermore, cells stably expressing the phyllopod fragment display reduced upregulation of Hif-1 alpha protein levels and Hif-1-mediated gene expression under hypoxia. In a syngeneic mouse model of breast cancer, the phyllopod fragment reduced tumor growth and neoangiogenesis and prolonged survival of the mice. In addition, levels of Hif-1 alpha and its target Glut-1 are reduced in tumors expressing the phyllopod fragment. These data show, in a proof-of-principle study, that Siah protein, the most upstream component of the hypoxia pathway yet identified, is a viable drug target for antitumor therapies.	[Moller, A.; House, C. M.; Wong, C. S. F.; Liu, M. C. P.; Bowtell, D. D. L.] Peter MacCallum Canc Ctr, Canc Genom & Biochem Lab, Melbourne, Vic 3002, Australia; [Moller, A.; Scanlon, D. B.; Bowtell, D. D. L.] Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia; [Ronai, Z.] Burnham Inst Med Res, Signal Transduct Program, La Jolla, CA USA	Peter Maccallum Cancer Center; University of Melbourne; Sanford Burnham Prebys Medical Discovery Institute	Bowtell, DDL (corresponding author), Peter MacCallum Canc Ctr, Canc Genom & Biochem Lab, St Andrews Pl, Melbourne, Vic 3002, Australia.	d.bowtell@petermac.org	Bowtell, David/H-1007-2016; Wong, Christina SF/G-9972-2017; Möller, Andreas/O-1063-2015	Bowtell, David/0000-0001-9089-7525; Möller, Andreas/0000-0002-8618-6998; RONAI, ZEEV/0000-0002-3859-0400	Australian National Health and Medical Research Council (NHMRC) [400321, 509331]; NATIONAL CANCER INSTITUTE [R01CA111515] Funding Source: NIH RePORTER	Australian National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The EO771 cells were a kind gift from Dr Robin Anderson, Peter MacCallum Cancer Centre. The expression plasmid for FLAG-TIEG-1 was provided by Steven Johnsen and Thomas Spelsburg ( Mayo Clinic and Foundation, Rochester, NY, USA). The expression plasmid for Myc-FIH-1 was a kind gift from Daniel Peet ( School of Molecular and Biomedical Science, University of Adelaide, Adelaide, Australia). This study was funded by grants of the Australian National Health and Medical Research Council (NHMRC) to AM, CH and DB ( no. 400321 and no. 509331).	Bottger A, 1997, J MOL BIOL, V269, P744, DOI 10.1006/jmbi.1997.1078; Boulton SJ, 2000, EMBO J, V19, P5376, DOI 10.1093/emboj/19.20.5376; CASEY AE, 1951, P SOC EXP BIOL MED, V77, P358; Chene P, 2000, J MOL BIOL, V299, P245, DOI 10.1006/jmbi.2000.3738; DELLA NG, 1993, DEVELOPMENT, V117, P1333; Depaux A, 2006, BIOCHEM BIOPH RES CO, V348, P857, DOI 10.1016/j.bbrc.2006.07.092; Dickins RA, 2002, MOL CELL BIOL, V22, P2294, DOI 10.1128/MCB.22.7.2294-2303.2002; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Freedman SJ, 2003, NAT STRUCT BIOL, V10, P504, DOI 10.1038/nsb936; Frew IJ, 2003, MOL CELL BIOL, V23, P9150, DOI 10.1128/MCB.23.24.9150-9161.2003; Fukuba H, 2007, BIOCHEM BIOPH RES CO, V353, P324, DOI 10.1016/j.bbrc.2006.12.051; Germani A, 2003, ONCOGENE, V22, P8845, DOI 10.1038/sj.onc.1206994; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Holinger EP, 1999, J BIOL CHEM, V274, P13298, DOI 10.1074/jbc.274.19.13298; House CM, 2006, STRUCTURE, V14, P695, DOI 10.1016/j.str.2005.12.013; House CM, 2003, P NATL ACAD SCI USA, V100, P3101, DOI 10.1073/pnas.0534783100; Hu G, 1997, GENOMICS, V46, P103, DOI 10.1006/geno.1997.4997; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Johnsen SA, 2002, J BIOL CHEM, V277, P30754, DOI 10.1074/jbc.M204812200; Kane RC, 2003, ONCOLOGIST, V8, P508, DOI 10.1634/theoncologist.8-6-508; Khurana A, 2006, J BIOL CHEM, V281, P35316, DOI 10.1074/jbc.M606568200; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Li SH, 1997, CELL, V90, P469, DOI 10.1016/S0092-8674(00)80507-3; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Nakayama K, 2004, CELL, V117, P941, DOI 10.1016/j.cell.2004.06.001; Nakayama K, 2007, BIOCHEM J, V401, P217, DOI 10.1042/BJ20061135; Polekhina G, 2002, NAT STRUCT BIOL, V9, P68, DOI 10.1038/nsb743; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Semenza GL, 2000, BIOCHEM PHARMACOL, V59, P47, DOI 10.1016/S0006-2952(99)00292-0; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Tang AH, 1997, CELL, V90, P459, DOI 10.1016/S0092-8674(00)80506-1; Wang JL, 2000, CANCER RES, V60, P1498; Wasylyk C, 1999, ONCOGENE, V18, P1921, DOI 10.1038/sj.onc.1202528; Zhang JS, 1998, GENE DEV, V12, P1775, DOI 10.1101/gad.12.12.1775	39	66	73	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2009	28	2					289	296		10.1038/onc.2008.382	http://dx.doi.org/10.1038/onc.2008.382			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395CY	18850011	Green Accepted			2022-12-17	WOS:000262501100012
J	Garcia-Aragoncillo, E; Carrillo, J; Lalli, E; Agra, N; Gomez-Lopez, G; Pestana, A; Alonso, J				Garcia-Aragoncillo, E.; Carrillo, J.; Lalli, E.; Agra, N.; Gomez-Lopez, G.; Pestana, A.; Alonso, J.			DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing's tumor cells	ONCOGENE			English	Article						Ewing's tumors; EWS/FLI1 oncoprotein; DAX1; NR0B1; RNA interference	ADRENAL HYPOPLASIA CONGENITA; NUCLEAR RECEPTOR DAX-1; ETS FUSION PROTEINS; FAMILY TUMORS; DNA-BINDING; GENE; SARCOMA; COREPRESSOR; EXPRESSION; PATHWAYS	The molecular hallmark of the Ewing's family of tumors is the presence of balanced chromosomal translocations, leading to the formation of chimerical transcription factors (that is, EWS/FLI1) that play a pivotal role in the pathogenesis of Ewing's tumors by deregulating gene expression. We have recently demonstrated that DAX1 (NR0B1), an orphan nuclear receptor that was not previously implicated in cancer, is induced by the EWS/FLI1 oncoprotein and is highly expressed in Ewing's tumors, suggesting that DAX1 is a biologically relevant target of EWS/FLI1-mediated oncogenesis. In this study we demonstrate that DAX1 is a direct transcriptional target of the EWS/FLI1 oncoprotein through its binding to a GGAA-rich region in the DAX1 promoter and show that DAX1 is a key player of EWS/FLI1-mediated oncogenesis. DAX1 silencing using an inducible model of RNA interference induces growth arrest in the A673 Ewing's cell line and severely impairs its capability to grow in semisolid medium and form tumors in immuno deficient mice. Gene expression pro. le analysis demonstrated that about 10% of the genes regulated by EWS/FLI1 in Ewing's cells are DAX1 targets, confirming the importance of DAX1 in Ewing's oncogenesis. Functional genomic analysis, validated by quantitative RT-PCR, showed that genes implicated in cell-cycle progression, such as CDK2, CDC6, MCM10 or SKP2 were similarly regulated by EWS/FLI1 and DAX1. These findings indicate that DAX1 is important in the pathogenesis of the Ewing's family of tumors, identify new functions for DAX1 as a cell-cycle progression regulator and open the possibility to new therapeutic approaches based on DAX1 function interference.	[Garcia-Aragoncillo, E.; Carrillo, J.; Agra, N.; Pestana, A.; Alonso, J.] UAM, CSIC, Inst Invest Biomed A Sols, Dept Biol Mol & Celular Canc,Lab Genet & Patol Mo, Madrid 28029, Spain; [Lalli, E.] Univ Nice Sophia Antipolis, CNRS, UMR6097, Inst Pharmacol Mol & Cellulaire, Valbonne, France; [Gomez-Lopez, G.] Hosp Dorrebullon, Fdn Biomed CHUVI, CHU, Vigo, Pontevedra, Spain; [Gomez-Lopez, G.] Ctr Nacl Invest Oncol, Unidad Bioinformat, Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Complexo Hospitalario Universitario de Vigo	Alonso, J (corresponding author), UAM, CSIC, Inst Invest Biomed A Sols, Dept Biol Mol & Celular Canc,Lab Genet & Patol Mo, C Arturo Duperier 4, Madrid 28029, Spain.	fjaviera@iib.uam.es	Gomez-Lopez, Gonzalo/D-9123-2016; Lalli, Enzo/F-7052-2013; García, Jaime Carrillo/AAC-5144-2020; Alonso, Javier/B-6012-2013	Gomez-Lopez, Gonzalo/0000-0002-4146-0551; Lalli, Enzo/0000-0002-0584-5681; Alonso, Javier/0000-0002-6287-8391; Carrillo Garcia, Jaime/0000-0002-2861-3015				Altincicek B, 2000, J BIOL CHEM, V275, P7662, DOI 10.1074/jbc.275.11.7662; Arvand A, 2001, ONCOGENE, V20, P5747, DOI 10.1038/sj.onc.1204598; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; BARDONI B, 1994, NAT GENET, V7, P497, DOI 10.1038/ng0894-497; Carrillo J, 2007, CLIN CANCER RES, V13, P2429, DOI 10.1158/1078-0432.CCR-06-1762; Crawford PA, 1998, MOL CELL BIOL, V18, P2949, DOI 10.1128/MCB.18.5.2949; de Alava E, 2000, J CLIN ONCOL, V18, P204, DOI 10.1200/JCO.2000.18.1.204; Ferreira BI, 2008, ONCOGENE, V27, P2084, DOI 10.1038/sj.onc.1210845; Guo WW, 1996, J CLIN ENDOCR METAB, V81, P2481, DOI 10.1210/jc.81.7.2481; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Holter E, 2002, MOL ENDOCRINOL, V16, P515, DOI 10.1210/me.16.3.515; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Ito M, 1997, MOL CELL BIOL, V17, P1476, DOI 10.1128/MCB.17.3.1476; Janknecht R, 2005, GENE, V363, P1, DOI 10.1016/j.gene.2005.08.007; Kim S, 2006, MOL CELL BIOL, V26, P2467, DOI 10.1128/MCB.26.7.2467-2478.2006; Kinsey M, 2006, MOL CANCER RES, V4, P851, DOI 10.1158/1541-7786.MCR-06-0090; Kovar H, 2005, SEMIN CANCER BIOL, V15, P189, DOI 10.1016/j.semcancer.2005.01.004; Kovar Heinrich, 1998, Current Opinion in Oncology, V10, P334, DOI 10.1097/00001622-199807000-00010; Lalli E, 2003, MOL ENDOCRINOL, V17, P1445, DOI 10.1210/me.2003-0159; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Mendiola M, 2006, INT J CANCER, V118, P1381, DOI 10.1002/ijc.21578; Nakatani F, 2003, J BIOL CHEM, V278, P15105, DOI 10.1074/jbc.M211470200; Nishimori H, 2002, ONCOGENE, V21, P8302, DOI 10.1038/sj.onc.1206025; Prieur A, 2004, MOL CELL BIOL, V24, P7275, DOI 10.1128/MCB.24.16.7275-7283.2004; Reiner A, 2003, BIOINFORMATICS, V19, P368, DOI 10.1093/bioinformatics/btf877; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Song KH, 2004, MOL ENDOCRINOL, V18, P1929, DOI 10.1210/me.2004-0043; Staege MS, 2004, CANCER RES, V64, P8213, DOI 10.1158/0008-5472.CAN-03-4059; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Suzuki T, 2002, ENDOCR RES, V28, P537, DOI 10.1081/ERC-120016835; Tamai KT, 1996, MOL ENDOCRINOL, V10, P1561, DOI 10.1210/me.10.12.1561; Tanaka K, 1997, J CLIN INVEST, V99, P239, DOI 10.1172/JCI119152; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Welford SM, 2001, J BIOL CHEM, V276, P41977, DOI 10.1074/jbc.M106757200; ZANARIA E, 1994, NATURE, V372, P635, DOI 10.1038/372635a0; Zhang H, 2000, J BIOL CHEM, V275, P39855, DOI 10.1074/jbc.C000567200	36	66	71	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2008	27	46					6034	6043		10.1038/onc.2008.203	http://dx.doi.org/10.1038/onc.2008.203			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	358BO	18591936				2022-12-17	WOS:000259891600006
J	Bitomsky, N; Wethkamp, N; Marikkannu, R; Klempnauer, KH				Bitomsky, N.; Wethkamp, N.; Marikkannu, R.; Klempnauer, K-H			siRNA-mediated knockdown of Pdcd4 expression causes upregulation of p21(Waf1/Cip1) expression	ONCOGENE			English	Article						Pdcd4; p21(Waf1/Cip1); siRNA; p53; DNA damage response	SUPPRESSOR PROTEIN PDCD4; TERMINAL MA-3 DOMAIN; NF-KAPPA-B; TRANSFORMATION SUPPRESSOR; EUKARYOTIC TRANSLATION; ANTISENSE OLIGODEOXYNUCLEOTIDE; GENE-EXPRESSION; P21 WAF1/CIP1; BREAST; P53	The transformation suppressor gene, programmed cell death gene 4 (Pdcd4), inhibits tumor-promoter-mediated transformation of mouse keratinocytes and has been implicated as a tumor suppressor gene in the development of human cancer. The Pdcd4 protein interacts with translation initiation factors eIF4A and eIF4G and binds to RNA, suggesting that it might be involved in regulating protein translation or other aspects of RNA metabolism. To study the function of Pdcd4 in more detail, we have downregulated Pdcd4 expression in HeLa cells by stable expression of shRNA. We have found that diminished Pdcd4 expression leads to increased expression of p21(Waf1/Cip1) and several other p53-regulated genes. Reporter gene studies demonstrate that Pdcd4 interferes with the activation of p53-responsive promoters genes by p53. Pdcd4 knockdown cells show decreased apoptosis and increased survival after UV irradiation. Taken together, our observations suggest a modelin which low Pdcd4 expression after DNA damage favors the survival of cells, which would be eliminated by apoptosis under normal levels of Pdcd4 expression. Our results provide the first evidence that Pdcd4 is important role in the DNA-damage response and suggest that low levels of Pdcd4 expression observed in certain tumor cells contribute to tumorigenesis by affecting the fate of DNA-damaged cells.	[Bitomsky, N.; Wethkamp, N.; Marikkannu, R.; Klempnauer, K-H] Univ Munster, Inst Biochem, D-48149 Munster, Germany	University of Munster	Klempnauer, KH (corresponding author), Univ Munster, Inst Biochem, Wilhelm Klemm Str 2, D-48149 Munster, Germany.	klempna@uni-muenster.de						Afonja O, 2004, ONCOGENE, V23, P8135, DOI 10.1038/sj.onc.1207983; Bendjennat M, 2003, CELL, V114, P599, DOI 10.1016/j.cell.2003.08.001; Biankin AV, 2001, CANCER RES, V61, P8830; Bitomsky N, 2004, ONCOGENE, V23, P7484, DOI 10.1038/sj.onc.1208064; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Bohm M, 2003, ONCOGENE, V22, P4905, DOI 10.1038/sj.onc.1206710; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; Chen Y, 2003, J PATHOL, V200, P640, DOI 10.1002/path.1378; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; Dorrello NV, 2006, SCIENCE, V314, P467, DOI 10.1126/science.1130276; Dupont JL, 2003, J BIOL CHEM, V278, P37256, DOI 10.1074/jbc.M302355200; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Erber R, 1997, INT J CANCER, V74, P383, DOI 10.1002/(SICI)1097-0215(19970822)74:4<383::AID-IJC4>3.0.CO;2-R; Fan YP, 2003, MOL CANCER THER, V2, P773; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; Gao F, 2007, ONCOL REP, V17, P123; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Goke A, 2002, BIOCHEM BIOPH RES CO, V297, P78, DOI 10.1016/S0006-291X(02)02129-0; Goke R, 2004, AM J PHYSIOL-CELL PH, V287, pC1541, DOI 10.1152/ajpcell.00025.2004; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HARPER JW, 1993, CELL, V75, P805; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Hilliard A, 2006, J IMMUNOL, V177, P8095, DOI 10.4049/jimmunol.177.11.8095; Jansen AP, 2005, CANCER RES, V65, P6034, DOI 10.1158/0008-5472.CAN-04-2119; Jansen AP, 2004, MOL CANCER THER, V3, P103; JUNG JM, 1995, ONCOGENE, V11, P2021; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lankat-Buttgereit B, 2003, BIOL CELL, V95, P515, DOI 10.1016/j.biolcel.2003.09.003; LaRonde-LeBlanc N, 2007, MOL CELL BIOL, V27, P147, DOI 10.1128/MCB.00867-06; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; Martoriati A, 2005, ONCOGENE, V24, P1461, DOI 10.1038/sj.onc.1208256; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; Mudduluru G, 2007, CANCER-AM CANCER SOC, V110, P1697, DOI 10.1002/cncr.22983; Ozanne BW, 2007, ONCOGENE, V26, P1, DOI 10.1038/sj.onc.1209759; Palamarchuk A, 2005, CANCER RES, V65, P11282, DOI 10.1158/0008-5472.CAN-05-3469; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; Schlichter U, 2001, ONCOGENE, V20, P231, DOI 10.1038/sj.onc.1204071; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shibahara K, 1995, GENE, V166, P297, DOI 10.1016/0378-1119(95)00607-9; Sohn D, 2006, CANCER RES, V66, P11254, DOI 10.1158/0008-5472.CAN-06-1569; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; Wang Q, 2008, ONCOGENE, V27, P1527, DOI 10.1038/sj.onc.1210793; Waters LC, 2007, ONCOGENE, V26, P4941, DOI 10.1038/sj.onc.1210305; Waters LC, 2006, J BIOMOL NMR, V36, P18, DOI 10.1007/s10858-005-5887-6; Weiss RH, 2003, CANCER CELL, V4, P425, DOI 10.1016/S1535-6108(03)00308-8; Weiss RH, 2003, CANCER LETT, V189, P39, DOI 10.1016/S0304-3835(02)00495-0; Wen YH, 2007, ONCOL REP, V18, P1387; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang HS, 2006, MOL CELL BIOL, V26, P1297, DOI 10.1128/MCB.26.4.1297-1306.2006; Yang HS, 2004, MOL CELL BIOL, V24, P3894, DOI 10.1128/MCB.24.9.3894-3906.2004; Yang HS, 2003, ONCOGENE, V22, P3712, DOI 10.1038/sj.onc.1206433; Yang HS, 2001, ONCOGENE, V20, P669, DOI 10.1038/sj.onc.1204137; Yang WT, 2003, CANCER, V98, P1123, DOI 10.1002/cncr.11625; Young MR, 2003, TRENDS MOL MED, V9, P36, DOI 10.1016/S1471-4914(02)00009-6; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang H, 2006, ONCOGENE, V25, P6101, DOI 10.1038/sj.onc.1209634	62	66	73	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2008	27	35					4820	4829		10.1038/onc.2008.115	http://dx.doi.org/10.1038/onc.2008.115			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337OJ	18427550				2022-12-17	WOS:000258445100007
J	Allerstorfer, S; Sonvilla, G; Fischer, H; Spiegl-Kreinecker, S; Gauglhofer, C; Setinek, U; Czech, T; Marosi, C; Buchroithner, J; Pichler, J; Silye, R; Mohr, T; Holzmann, K; Grasl-Kraupp, B; Marian, B; Grusch, M; Fischer, J; Micksche, M; Berger, W				Allerstorfer, S.; Sonvilla, G.; Fischer, H.; Spiegl-Kreinecker, S.; Gauglhofer, C.; Setinek, U.; Czech, T.; Marosi, C.; Buchroithner, J.; Pichler, J.; Silye, R.; Mohr, T.; Holzmann, K.; Grasl-Kraupp, B.; Marian, B.; Grusch, M.; Fischer, J.; Micksche, M.; Berger, W.			FGF5 as an oncogenic factor in human glioblastoma multiforme: autocrine and paracrine activities	ONCOGENE			English	Article						FGF5; FGF receptor 1; astrocytic brain tumours; cell growth and migration; autocrine and paracrine activities	FIBROBLAST-GROWTH-FACTOR; CELL LUNG-CANCER; CENTRAL-NERVOUS-SYSTEM; IN-VITRO; HUMAN ASTROCYTOMAS; ENDOTHELIAL-CELLS; MESSENGER-RNA; FACTOR FAMILY; GLIOMA-CELLS; EXPRESSION	Fibroblast growth factor 5 (FGF5) is widely expressed in embryonic but scarcely in adult tissues. Here we report simultaneous overexpression of FGF5 and its predominant high-affinity receptor (FGFR1 IIIc) in astrocytic brain tumour specimens (N = 49) and cell cultures (N = 49). The levels of both ligand and receptor increased with enhanced malignancy in vivo and in vitro. Furthermore, secreted FGF5 protein was generally present in the supernatants of glioblastoma (GBM) cells. siRNA-mediated FGF5 down-modulation reduced moderately but significantly GBM cell proliferation while recombinant FGF5 (rFGF5) increased this parameter preferentially in cell lines with low endogenous expression levels. Apoptosis induction by prolonged serum starvation was significantly prevented by rFGF5. Moreover, tumour cell migration was distinctly stimulated by rFGF5 but attenuated by FGF5 siRNA. Blockade of FGFR1-mediated signals by pharmacological FGFR inhibitors or a dominant-negative FGFR1 IIIc protein inhibited GBM cell proliferation and/or induced apoptotic cell death. Moreover, rFGF5 and supernatants of highly FGF5-positive GBM cell lines specifically stimulated proliferation, migration and tube formation of human umbilical vein endothelial cells. In summary, we demonstrate for the first time that FGF5 contributes to the malignant progression of human astrocytic brain tumours by both autocrine and paracrine effects.	[Allerstorfer, S.; Sonvilla, G.; Fischer, H.; Gauglhofer, C.; Mohr, T.; Holzmann, K.; Grasl-Kraupp, B.; Marian, B.; Grusch, M.; Micksche, M.; Berger, W.] Med Univ Vienna, Dept Med 1, Inst Canc Res, A-1090 Vienna, Austria; [Spiegl-Kreinecker, S.; Fischer, J.] Wagner Jauregg Hosp, Dept Neurosurg, Linz, Austria; [Setinek, U.] Otto Wagner Hosp Baumgartner Hohe, Inst Pathol & Bacteriol, Vienna, Austria; [Czech, T.] Med Univ Vienna, Dept Neurosurg, A-1090 Vienna, Austria; [Marosi, C.] Med Univ Vienna, Dept Med 1, Div Clin Oncol, A-1090 Vienna, Austria; [Pichler, J.] Wagner Jauregg Hosp, Dept Internal Med, Linz, Austria; [Silye, R.] Wagner Jauregg Hosp, Inst Pathol, Linz, Austria	Medical University of Vienna; Kepler University Hospital; Medical University of Vienna; Medical University of Vienna; Kepler University Hospital; Kepler University Hospital	Berger, W (corresponding author), Med Univ Vienna, Dept Med 1, Inst Canc Res, Borschkegasse 8A, A-1090 Vienna, Austria.	walter.berger@meduniwien.ac.at	Mohr, Thomas/AAN-1180-2020; Grusch, Michael/C-1183-2008; Holzmann, Klaus/I-4437-2019	Mohr, Thomas/0000-0002-1933-847X; Grusch, Michael/0000-0001-5486-9340; Holzmann, Klaus/0000-0003-4077-3377; Berger, Walter/0000-0003-0014-1658	Austrian Science Fund FWF [P 19920] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		Antoine M, 2005, GROWTH FACTORS, V23, P87, DOI 10.1080/08977190500096004; BATES B, 1991, MOL CELL BIOL, V11, P1840, DOI 10.1128/MCB.11.4.1840; Berger W, 1999, INT J CANCER, V83, P415, DOI 10.1002/(SICI)1097-0215(19991029)83:3<415::AID-IJC19>3.0.CO;2-Y; Berger W, 2005, J CANCER RES CLIN, V131, P355, DOI 10.1007/s00432-004-0653-9; Brachner A, 2006, CANCER RES, V66, P3584, DOI 10.1158/0008-5472.CAN-05-2839; Carter TA, 2005, P NATL ACAD SCI USA, V102, P11011, DOI 10.1073/pnas.0504952102; Cavallaro U, 2001, NAT CELL BIOL, V3, P650, DOI 10.1038/35083041; Davies MA, 1998, CANCER RES, V58, P5285; ENGEBRAATEN O, 1993, INT J CANCER, V53, P209, DOI 10.1002/ijc.2910530206; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Galzie Z, 1997, BIOCHEM CELL BIOL, V75, P669, DOI 10.1139/bcb-75-6-669; GOMEZPINILLA F, 1993, BRAIN RES, V606, P79, DOI 10.1016/0006-8993(93)91572-A; Grose R, 2005, CYTOKINE GROWTH F R, V16, P179, DOI 10.1016/j.cytogfr.2005.01.003; Hanada K, 2001, CANCER RES, V61, P5511; HAUB O, 1991, DEVELOPMENT, V112, P397; HAUB O, 1990, P NATL ACAD SCI USA, V87, P8022, DOI 10.1073/pnas.87.20.8022; HEBERT JM, 1994, CELL, V78, P1017, DOI 10.1016/0092-8674(94)90276-3; Heffeter P, 2006, BIOCHEM PHARMACOL, V71, P426, DOI 10.1016/j.bcp.2005.11.009; HUGHES RA, 1993, NEURON, V10, P369, DOI 10.1016/0896-6273(93)90327-N; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jensen RL, 1998, SURG NEUROL, V49, P189, DOI 10.1016/S0090-3019(97)00218-8; Joy A, 1997, ONCOGENE, V14, P171, DOI 10.1038/sj.onc.1200823; Kargiotis O, 2006, J NEURO-ONCOL, V78, P281, DOI 10.1007/s11060-005-9097-6; Kornmann M, 1997, ONCOGENE, V15, P1417, DOI 10.1038/sj.onc.1201307; Kornmann M, 2001, INT J PANCREATOL, V29, P85, DOI 10.1385/IJGC:29:2:085; LINDHOLM D, 1994, EUR J NEUROSCI, V6, P244, DOI 10.1111/j.1460-9568.1994.tb00267.x; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; MORRISON RS, 1994, CANCER RES, V54, P2794; MORRISON RS, 1994, J NEURO-ONCOL, V18, P207, DOI 10.1007/BF01328955; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Ozawa K, 1998, J BIOL CHEM, V273, P29262, DOI 10.1074/jbc.273.44.29262; Panek RL, 1998, J PHARMACOL EXP THER, V286, P569; Pelton TA, 2002, J CELL SCI, V115, P329; Puputti M, 2006, MOL CANCER RES, V4, P927, DOI 10.1158/1541-7786.MCR-06-0085; Reuss B, 2003, CELL TISSUE RES, V313, P139, DOI 10.1007/s00441-003-0756-7; Reuss B, 2003, J NEUROSCI, V23, P6404; Reuss B, 2000, GLIA, V30, P231, DOI 10.1002/(SICI)1098-1136(200005)30:3<231::AID-GLIA3>3.3.CO;2-T; Rix U, 2007, BLOOD, V110, P4055, DOI 10.1182/blood-2007-07-102061; Spiegl-Kreinecker S, 2007, BRIT J CANCER, V96, P960, DOI 10.1038/sj.bjc.6603652; Stachowiak MK, 1996, MOL BRAIN RES, V38, P161, DOI 10.1016/0169-328X(96)00010-1; Steiner E, 2006, J CELL SCI, V119, P459, DOI 10.1242/jcs.02773; Sundberg JP, 1997, VET PATHOL, V34, P171, DOI 10.1177/030098589703400301; Suzuki S, 1998, J INVEST DERMATOL, V111, P963, DOI 10.1046/j.1523-1747.1998.00427.x; Suzuki S, 2000, J INVEST DERMATOL, V114, P456, DOI 10.1046/j.1523-1747.2000.00912.x; Taniguchi F, 2003, J CLIN ENDOCR METAB, V88, P773, DOI 10.1210/jc.2002-021062; Todo T, 1998, NEUROSURGERY, V43, P337, DOI 10.1097/00006123-199808000-00098; Yamada SM, 2002, NEUROL RES, V24, P244, DOI 10.1179/016164102101199864; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487; Zhang LR, 1998, CANCER RES, V58, P352	49	66	70	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2008	27	30					4180	4190		10.1038/onc.2008.61	http://dx.doi.org/10.1038/onc.2008.61			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	324DB	18362893	Green Accepted			2022-12-17	WOS:000257496800005
J	Ichimura, K; Vogazianou, AP; Liu, L; Pearson, DM; Backlund, LM; Plant, K; Baird, K; Langford, CF; Gregory, SG; Collins, VP				Ichimura, K.; Vogazianou, A. P.; Liu, L.; Pearson, D. M.; Backlund, L. M.; Plant, K.; Baird, K.; Langford, C. F.; Gregory, S. G.; Collins, V. P.			1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas	ONCOGENE			English	Article						microarray; array-CGH; methylation; astrocytoma; oligodendroglioma	COMPARATIVE GENOMIC HYBRIDIZATION; PHASE-III TRIAL; OLIGODENDROGLIAL TUMORS; ANAPLASTIC OLIGODENDROGLIOMA; EUROPEAN ORGANIZATION; GENETIC-ANALYSIS; HUMAN GLIOMAS; ARRAY-CGH; P73 GENE; 19Q LOSS	Astrocytic, oligodendroglial and mixed gliomas are the commonest gliomas in adults. They have distinct phenotypes and clinical courses, but as they exist as a continuous histological spectrum, differentiating them can be difficult. Co-deletions of total 1p and 19q are found in the majority of oligodendrogliomas and considered as a diagnostic marker and a prognostic indicator. The 1p status of astrocytomas has not yet been thoroughly examined. Using a chromosome 1 tile path array, we investigated 108 adult astrocytic tumours for copy number alterations. Total 1p deletions were rare (2%), however partial deletions involving 1p36 were frequently identified in anaplastic astrocytomas (22%) and glioblastomas (34%). Multivariate analysis showed that patients with total 1p deletions had significantly longer survival (P=0.005). In nine glioblastomas homozygous deletions at 1p36 were identified. No somatic mutations were found among the five genes located in the homozygously deleted region. However, the CpG island of TNFRSF9 was hypermethylated in 19% of astrocytic tumours and 87% of glioma cell lines. TNFRSF9 expression was upregulated after demethylation of glioma cell lines. Akt3 amplifications were found in four glioblastomas. Our results indicate that 1p deletions are common anaplastic astrocytomas and glioblastomas but are distinct from the 1p abnormalities in oligodendrogliomas.	[Ichimura, K.; Vogazianou, A. P.; Liu, L.; Pearson, D. M.; Plant, K.; Baird, K.; Collins, V. P.] Univ Cambridge, Dept Pathol, Div Mol Histopathol, Addenbrookes Hosp, Cambridge CB2 0QQ, England; [Backlund, L. M.] Karolinska Univ Hosp, Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden; [Langford, C. F.; Gregory, S. G.] Wellcome Trust Sanger Inst, Cambridge, England; [Langford, C. F.; Gregory, S. G.] Duke Univ, Med Ctr, Duke Ctr Human Genet, Durham, NC USA	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Karolinska Institutet; Karolinska University Hospital; Wellcome Trust Sanger Institute; Duke University	Ichimura, K (corresponding author), Univ Cambridge, Dept Pathol, Div Mol Histopathol, Addenbrookes Hosp, Level 3,Lab Block,Box 231, Cambridge CB2 0QQ, England.	ki212@cam.ac.uk		Backlund, Magnus/0000-0003-0397-6538; Gregory, Simon/0000-0002-7805-1743	Cancer Research UK [A6618] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Cancer Research UK(Cancer Research UK); Wellcome Trust(Wellcome TrustEuropean Commission)		Alonso ME, 2001, INT J ONCOL, V19, P609; Bagchi A, 2007, CELL, V128, P459, DOI 10.1016/j.cell.2006.11.052; Barbashina V, 2005, CLIN CANCER RES, V11, P1119; Bellacosa A, 2005, ADV CANCER RES, V94, P29, DOI 10.1016/S0065-230X(05)94002-5; BIGNER SH, 1988, CANCER RES, V48, P405; Buckley PG, 2005, CANCER RES, V65, P2653, DOI 10.1158/0008-5472.CAN-04-3651; Cairncross G, 2006, J CLIN ONCOL, V24, P2707, DOI 10.1200/JCO.2005.04.3414; Dong Z, 2004, BRIT J CANCER, V91, P1105, DOI 10.1038/sj.bjc.6602093; Felsberg J, 2004, BRAIN PATHOL, V14, P121, DOI 10.1111/j.1750-3639.2004.tb00044.x; Fiegler H, 2003, GENE CHROMOSOME CANC, V36, P361, DOI 10.1002/gcc.10155; Gregory SG, 2006, NATURE, V441, P315, DOI 10.1038/nature04727; Griffin CA, 2006, J NEUROPATH EXP NEUR, V65, P988, DOI 10.1097/01.jnen.0000235122.98052.8f; Harden SV, 2003, J UROLOGY, V169, P1138, DOI 10.1097/01.ju.0000049627.90307.4d; Hashimoto K, 2004, MODERN PATHOL, V17, P617, DOI 10.1038/modpathol.3800107; Hashimoto N, 2003, CANCER-AM CANCER SOC, V97, P2254, DOI 10.1002/cncr.11322; He J, 2001, J NEUROPATH EXP NEUR, V60, P863, DOI 10.1093/jnen/60.9.863; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Homma T, 2006, J NEUROPATH EXP NEUR, V65, P846, DOI 10.1097/01.jnen.0000235118.75182.94; Ichimura K, 2006, ONCOGENE, V25, P1261, DOI 10.1038/sj.onc.1209156; Ichimura K, 2000, CANCER RES, V60, P417; Ichimura K, 2004, J NEURO-ONCOL, V70, P137, DOI 10.1007/s11060-004-2747-2; Ichimura K, 1998, GENE CHROMOSOME CANC, V22, P9, DOI 10.1002/(SICI)1098-2264(199805)22:1<9::AID-GCC2>3.0.CO;2-1; Idbaih A, 2005, ANN NEUROL, V58, P483, DOI 10.1002/ana.20607; Ino Y, 2000, J NEUROSURG, V92, P983, DOI 10.3171/jns.2000.92.6.0983; Iuchi T, 2002, GENE CHROMOSOME CANC, V35, P170, DOI 10.1002/gcc.10080; Jenkins RB, 2006, CANCER RES, V66, P9852, DOI 10.1158/0008-5472.CAN-06-1796; Kleihues P, 2000, PATHOLOGY GENETICS T; Knobbe CB, 2003, BRAIN PATHOL, V13, P507; Koschny R, 2002, CANCER GENET CYTOGEN, V135, P147, DOI 10.1016/S0165-4608(01)00650-1; Kros JM, 2007, J NEUROPATH EXP NEUR, V66, P545, DOI 10.1097/01.jnen.0000263869.84188.72; Liu L, 2005, J MOL MED, V83, P917, DOI 10.1007/s00109-005-0700-2; Melero I, 1997, NAT MED, V3, P682, DOI 10.1038/nm0697-682; Mueller W, 2002, AM J PATHOL, V161, P313, DOI 10.1016/S0002-9440(10)64183-1; Nigro JM, 2001, AM J PATHOL, V158, P1253, DOI 10.1016/S0002-9440(10)64076-X; Reifenberger G, 2003, J NEUROPATH EXP NEUR, V62, P111, DOI 10.1093/jnen/62.2.111; Schmidt EE, 1999, J NEUROPATH EXP NEUR, V58, P1170, DOI 10.1097/00005072-199911000-00007; Schmidt MC, 2002, J NEUROPATH EXP NEUR, V61, P321, DOI 10.1093/jnen/61.4.321; Smith JS, 2000, J CLIN ONCOL, V18, P636, DOI 10.1200/JCO.2000.18.3.636; Smith JS, 1999, ONCOGENE, V18, P4144, DOI 10.1038/sj.onc.1202759; Thomas D, 2001, J CLIN ONCOL, V19, P509, DOI 10.1200/JCO.2001.19.2.509; Ueki K, 2002, CLIN CANCER RES, V8, P196; van den Bent MJ, 2006, J CLIN ONCOL, V24, P2715, DOI 10.1200/JCO.2005.04.6078; von Deimling A, 2000, J NEUROPATH EXP NEUR, V59, P544, DOI 10.1093/jnen/59.6.544; Waerner T, 2001, CELL GROWTH DIFFER, V12, P201; Watanabe T, 2002, ACTA NEUROPATHOL, V104, P357, DOI 10.1007/s00401-002-0549-1; Watts TH, 2005, ANNU REV IMMUNOL, V23, P23, DOI 10.1146/annurev.immunol.23.021704.115839; Yanagisawa H, 2000, HUM MOL GENET, V9, P1433, DOI 10.1093/hmg/9.9.1433	47	66	69	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2008	27	14					2097	2108		10.1038/sj.onc.1210848	http://dx.doi.org/10.1038/sj.onc.1210848			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	279MK	17934521	Green Accepted			2022-12-17	WOS:000254359100015
J	Beppu, H; Mwizerwa, ON; Beppu, Y; Dattwyler, MP; Lauwers, GY; Bloch, KD; Goldstein, AM				Beppu, H.; Mwizerwa, O. N.; Beppu, Y.; Dattwyler, M. P.; Lauwers, G. Y.; Bloch, K. D.; Goldstein, A. M.			Stromal inactivation of BMPRII leads to colorectal epithelial overgrowth and polyp formation	ONCOGENE			English	Article						bone morphogenetic proteins; BMPRII; nestin hamartomatous polyps; colorectal polyps; stromal-epithelial interactions	JUVENILE POLYPOSIS; CELLS; MYOFIBROBLASTS; SUPPRESSION; FIBROBLASTS; MUTATIONS; SIGNALS; GENE	Stromal - epithelial interactions play a central role in development and tumorigenesis. Bone morphogenetic protein ( BMP) signaling in the intestine is involved in both of these processes. Inactivation of BMP pathway genes in the epithelium is known to cause intestinal polyposis. However, the role of the intestinal stroma in polyp initiation is incompletely understood. We observed that conditional inactivation of the BMP type II receptor ( BMPRII) in the stroma leads to epithelial hyperplasia throughout the colon with increased epithelial cell proliferation. Mutant mice developed rectal bleeding and hamartomatous polyps in the colorectum. The polyps demonstrated increased proliferation of epithelial and mesenchymal cells in the mucosa with an expansion of the myofibroblast cell population. These results demonstrate that genetic mutations altering the BMP signaling pathway in the stromal microenvironment can lead to epithelial tumors in the colon.	[Mwizerwa, O. N.; Goldstein, A. M.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pediat Surg, Boston, MA 02114 USA; [Beppu, H.; Beppu, Y.; Dattwyler, M. P.; Bloch, K. D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiovasc Res Ctr, Boston, MA 02114 USA; [Lauwers, G. Y.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Goldstein, AM (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pediat Surg, 55 Fruit St,Warren 1153, Boston, MA 02114 USA.	agoldstein@partners.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074352] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL074352] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adegboyega PA, 2002, ARCH PATHOL LAB MED, V126, P829; Batts LE, 2006, DEV DYNAM, V235, P1563, DOI 10.1002/dvdy.20741; Beppu H, 2005, GENESIS, V41, P133, DOI 10.1002/gene.20099; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Chen AL, 2005, SURGERY, V138, P382, DOI 10.1016/j.surg.2005.04.012; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Haramis APG, 2004, SCIENCE, V303, P1684, DOI 10.1126/science.1093587; Hardwick JCH, 2004, GASTROENTEROLOGY, V126, P111, DOI 10.1053/j.gastro.2003.10.067; He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430; He XC, 2007, NAT GENET, V39, P189, DOI 10.1038/ng1928; HOGAN B, 1994, MANIPULATING MOUSE E; Howe JR, 2004, J MED GENET, V41, P484, DOI 10.1136/jmg.2004.018598; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Jacoby RF, 1997, GASTROENTEROLOGY, V112, P1398, DOI 10.1016/S0016-5085(97)70156-2; Kim BG, 2006, NATURE, V441, P1015, DOI 10.1038/nature04846; Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101; LIU D, IN PRESS BLOOD; Miyazono K, 2005, CYTOKINE GROWTH F R, V16, P251, DOI 10.1016/j.cytogfr.2005.01.009; Pinto D, 2003, GENE DEV, V17, P1709, DOI 10.1101/gad.267103; Powell DW, 1999, AM J PHYSIOL-CELL PH, V277, pC183, DOI 10.1152/ajpcell.1999.277.2.C183; Powell DW, 2005, AM J PHYSIOL-GASTR L, V289, pG2, DOI 10.1152/ajpgi.00075.2005; Sancho E, 2003, CURR OPIN CELL BIOL, V15, P763, DOI 10.1016/j.ceb.2003.10.012; Trumpp A, 1999, GENE DEV, V13, P3136, DOI 10.1101/gad.13.23.3136; van den Brink GR, 2004, NAT GENET, V36, P1038, DOI 10.1038/ng1004-1038; Wirtzfeld DA, 2001, ANN SURG ONCOL, V8, P319, DOI 10.1245/aso.2001.8.4.319	26	66	69	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2008	27	8					1063	1070		10.1038/sj.onc.1210720	http://dx.doi.org/10.1038/sj.onc.1210720			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17700526				2022-12-17	WOS:000253136700005
J	Kramer, OH; Knauer, SK; Zimmermann, D; Stauber, RH; Heinzel, T				Kraemer, O. H.; Knauer, S. K.; Zimmermann, D.; Stauber, R. H.; Heinzel, T.			Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosis	ONCOGENE			English	Article						VPA; HDAC inhibitor; hydroxyurea; caspase-3; CDKI p21/p27; chemotherapy resistance	ACUTE MYELOID-LEUKEMIA; TRANS-RETINOIC ACID; VALPROIC ACID; MEDIATED APOPTOSIS; DRUG-RESISTANCE; RECURRENT MENINGIOMAS; TUMOR-CELLS; P27(KIP1); MELANOMA; EXPRESSION	Therapy resistance represents a major problem for disease management in oncology. Histone deacetylase inhibitors (HDACi) have been shown to modulate the cell cycle, to induce apoptosis and to sensitize cancer cells for other chemotherapeutics. Our study shows that the HDACi valproic acid (VPA) and the ribonucleotide reductase inhibitor hydroxyurea (HU) potentiate the pro-apoptotic effects of each other towards several cancer cell lines. This correlates with the HU-induced degradation of the cyclin-dependent kinase inhibitors (CDKI) p21 and p27, mediated by the proteasome or caspase-3. Moreover, we found that caspase-3 activation is required for VPA induced apoptosis. Remarkably, p21 and p27 can confer resistance against VPA and HU. Both CDKI interact with caspase-3 and compete with other caspase-3 substrates. Hence, p21 and p27 may contribute to chemotherapy resistance as apoptosis inhibitors. Since the biological effects of VPA and HU could be achieved at concentrations used in current treatment protocols, the combined application of these compounds might be considered as a potential strategy for cancer treatment.	[Kraemer, O. H.; Heinzel, T.] Univ Jena, Inst Biochem & Biophys, Jena, Germany; [Knauer, S. K.; Stauber, R. H.] Univ Hosp Mainz, Mainz, Germany; [Zimmermann, D.] Inst Biomed Res, Frankfurt, Germany	Friedrich Schiller University of Jena; University Hospital Mainz	Kramer, OH (corresponding author), Univ Jena, Inst Biochem & Biophys, Jena, Germany.	Oliver.Kraemer@uni-jena.de; t.heinzel@uni-jena.de	Krämer, Oliver H/L-9266-2015; Heinzel, Thorsten/B-1013-2015; Knauer, Shirley K/E-7931-2012	Krämer, Oliver H/0000-0003-3973-045X; Knauer, Shirley K/0000-0003-4321-0924; Stauber, Roland/0000-0002-1341-4523				Blagosklonny MV, 2002, CELL CYCLE, V1, P391, DOI 10.4161/cc.1.6.262; Boyle GM, 2005, PIGM CELL RES, V18, P160, DOI 10.1111/j.1600-0749.2005.00228.x; Bug G, 2005, CANCER, V104, P2717, DOI 10.1002/cncr.21589; Drexler HCA, 2003, CELL DEATH DIFFER, V10, P290, DOI 10.1038/sj.cdd.4401159; Eymin B, 1999, ONCOGENE, V18, P1411, DOI 10.1038/sj.onc.1202437; Finzer P, 2001, ONCOGENE, V20, P4768, DOI 10.1038/sj.onc.1204652; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARRIS AL, 1985, INT J RADIAT BIOL, V48, P675, DOI 10.1080/09553008514551781; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Klisovic DD, 2003, INVEST OPHTH VIS SCI, V44, P2390, DOI 10.1167/iovs.02-1052; Knauer SK, 2006, EMBO REP, V7, P1259, DOI 10.1038/sj.embor.7400824; Koon HB, 2007, EXPERT REV ANTICANC, V7, P79, DOI 10.1586/14737140.7.1.79; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Kramer OH, 2006, GENE DEV, V20, P473, DOI 10.1101/gad.364306; Kramer OH, 2001, TRENDS ENDOCRIN MET, V12, P294, DOI 10.1016/S1043-2760(01)00438-6; Kramer OH, 2003, EMBO J, V22, P3411, DOI 10.1093/emboj/cdg315; Kuendgen A, 2006, CANCER-AM CANCER SOC, V106, P112, DOI 10.1002/cncr.21552; La Porta CAM, 2007, CURR MED CHEM, V14, P387; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Maggio SC, 2004, CANCER RES, V64, P2590, DOI 10.1158/0008-5472.CAN-03-2631; Montefusco E, 2001, LEUKEMIA LYMPHOMA, V40, P671, DOI 10.3109/10428190109097666; Mouriaux F, 2000, INVEST OPHTH VIS SCI, V41, P2837; Nguyen DM, 2004, CLIN CANCER RES, V10, P1813, DOI 10.1158/1078-0432.CCR-0901-3; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pantazis Panayotis, 1999, Neoplasia (New York), V1, P231, DOI 10.1038/sj.neo.7900025; Rosato RR, 2003, CANCER RES, V63, P3637; Schmidt M, 2000, ONCOGENE, V19, P2423, DOI 10.1038/sj.onc.1203546; Schrell UMH, 1997, J NEUROSURG, V86, P840, DOI 10.3171/jns.1997.86.5.0840; Schrell UMH, 1997, J NEUROSURG, V86, P845, DOI 10.3171/jns.1997.86.5.0845; Shin HJ, 2003, ONCOGENE, V22, P3853, DOI 10.1038/sj.onc.1206502; StCroix B, 1996, NAT MED, V2, P1204; Suzuki A, 2000, CELL DEATH DIFFER, V7, P721, DOI 10.1038/sj.cdd.4400706; Suzuki A, 1999, ONCOGENE, V18, P1239, DOI 10.1038/sj.onc.1202409; Szekeres T, 1997, CRIT REV CL LAB SCI, V34, P503, DOI 10.3109/10408369709006424; Van den Berg C, 1995, Cancer Treat Res, V78, P95; Zhu P, 2004, CANCER CELL, V5, P455, DOI 10.1016/S1535-6108(04)00114-X	37	66	69	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 31	2008	27	6					732	740		10.1038/sj.onc.1210677	http://dx.doi.org/10.1038/sj.onc.1210677			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17653085				2022-12-17	WOS:000252884500002
J	Brien, G; Trescol-Bierriont, MC; Bonnefoy-Berard, N				Brien, G.; Trescol-Bierriont, M-C; Bonnefoy-Berard, N.			Downregulation of Bfl-1 protein expression sensitizes malignant B cells to apoptosis	ONCOGENE			English	Article						bcl-2; bfl-1; apoptosis; B lymphoma	NF-KAPPA-B; ELDERLY-PATIENTS; UP-REGULATION; R-CHOP; BCL-X; LYMPHOMA; SURVIVAL; GENE; CHEMOTHERAPY; A1/BFL-1	Elevated expression of the antiapoptotic protein Bfl-1 (A1) was previously reported in several cancer cell lines. Recently, molecular profiling of large B-cell lymphoma identified Bfl-1 as a gene signature in 'OxPhos' diffuse large B-cell lymphoma subtype and in primary mediastinal large B-cell lymphoma, suggesting that in addition to Bcl-2, Bcl-xL and Mcl-1, Bfl-1 may be a relevant target in the design of new strategies for cancer therapy. Using short hairpin RNA strategy, we show here that Bfl-1 silencing in one lymphoblastoid B-cell line and in two diffuse large B-cell lymphoma cell lines potently induces their apoptosis and sensitizes those cell lines to anti-CD20 (Rituximab)-mediated cell death as well as to apoptosis induced by chemotherapeutic molecules such as doxorubicin, vincristine, cisplatin and fludarabine. These results demonstrate for the first time that Bfl-1 is an essential protein for survival of malignant B cells and suggest Bfl-1 may represent a potential target for future drug development against B cell lymphoma.	INSERM, U 503, Lab Homeostasie Lymphocytaire, F-69007 Lyon, France; Univ Lyon 1, F-69003 Lyon, France; IFR128, F-69007 Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Bonnefoy-Berard, N (corresponding author), INSERM, U 503, Lab Homeostasie Lymphocytaire, 21 Ave Tony Garnier, F-69007 Lyon, France.	bonnefoy@cervi-lyon.inserm.fr	Bonnefoy, Nathalie/J-2536-2012	Bonnefoy, Nathalie/0000-0003-4814-6722				Cheng QW, 2000, ONCOGENE, V19, P4936, DOI 10.1038/sj.onc.1203861; Coiffier B, 2005, J CLIN ONCOL, V23, P6387, DOI 10.1200/JCO.2005.05.015; Cottalorda A, 2006, EUR J IMMUNOL, V36, P1684, DOI 10.1002/eji.200636181; Dave SS, 2006, NEW ENGL J MED, V354, P2431, DOI 10.1056/NEJMoa055759; Davis RE, 2001, J EXP MED, V194, P1861, DOI 10.1084/jem.194.12.1861; Feuerhake F, 2005, BLOOD, V106, P1392, DOI 10.1182/blood-2004-12-4901; Feugier P, 2005, J CLIN ONCOL, V23, P4117, DOI 10.1200/JCO.2005.09.131; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Hatada EN, 2003, J IMMUNOL, V171, P761, DOI 10.4049/jimmunol.171.2.761; Hsu BL, 2002, J IMMUNOL, V168, P5993, DOI 10.4049/jimmunol.168.12.5993; Iqbal J, 2006, J CLIN ONCOL, V24, P961, DOI 10.1200/JCO.2005.03.4264; Kuss AW, 1999, EUR J IMMUNOL, V29, P3077, DOI 10.1002/(SICI)1521-4141(199910)29:10<3077::AID-IMMU3077>3.0.CO;2-R; Lam LT, 2005, CLIN CANCER RES, V11, P28; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Monti S, 2005, BLOOD, V105, P1851, DOI 10.1182/blood-2004-07-2947; Morales AA, 2005, INT J CANCER, V113, P730, DOI 10.1002/ijc.20614; Mounier N, 2003, BLOOD, V101, P4279, DOI 10.1182/blood-2002-11-3442; Reed JC, 2005, BLOOD, V106, P408, DOI 10.1182/blood-2004-07-2761; Sehn LH, 2005, J CLIN ONCOL, V23, P5027, DOI 10.1200/JCO.2005.09.137; Trescol-Biemont MC, 2004, BIOCHIMIE, V86, P287, DOI 10.1016/j.biochi.2004.04.001; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Werner AB, 2002, J BIOL CHEM, V277, P22781, DOI 10.1074/jbc.M201469200; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	25	66	70	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2007	26	39					5828	5832		10.1038/sj.onc.1210363	http://dx.doi.org/10.1038/sj.onc.1210363			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202EP	17353899				2022-12-17	WOS:000248885100015
J	Moschos, SJ; Smith, AP; Mandic, M; Athanassiou, C; Watson-Hurst, K; Jukic, DM; Edington, HD; Kirkwood, JM; Becker, D				Moschos, S. J.; Smith, A. P.; Mandic, M.; Athanassiou, C.; Watson-Hurst, K.; Jukic, D. M.; Edington, H. D.; Kirkwood, J. M.; Becker, D.			SAGE and antibody array analysis of melanoma-infiltrated lymph nodes: identification of Ubc9 as an important molecule in advanced-stage melanomas	ONCOGENE			English	Article						melanoma; molecular profiling; Ubc9; apoptosis; chemotherapy	UBIQUITIN-CONJUGATING ENZYME; TUMOR-SUPPRESSOR; HUMAN HOMOLOG; EXPRESSION; PROTEIN; GROWTH; GENE; NORMALIZATION; ASSOCIATION; SUMOYLATION	Although patients diagnosed with melanoma of <= 1.00mm thickness have a relatively good cure rate, the prognosis for patients with locally advanced and metastatic melanoma is grave. The discovery of new and effective therapies for this disease depends in large part on molecular studies that will resolve why advanced-stage melanoma is refractory to conventional chemotherapy and radiation therapy. To identify genes that have important functions in advanced-stage melanomas, in particular, in melanoma-infiltrated lymph nodes, which are not well characterized at the molecular level, we generated a LongSAGE library from a melanoma-positive lymph node, and subjected melanoma-infiltrated lymph nodes to protein expression profiling. The data document that the molecular signature of melanoma, which has spread to regional lymph nodes, is very similar to the molecular signature of primary melanomas. Equally important, we provide evidence that the ubiquitin-conjugating enzyme, Ubc9, is expressed at high levels in melanoma-positive lymph nodes, and that it plays a crucial role in preventing advanced-stage melanomas from undergoing chemotherapy-induced apoptosis.	Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Dermatol, Pittsburgh, PA 15213 USA; Automated Cell Inc, Pittsburgh, PA USA; Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Becker, D (corresponding author), Univ Pittsburgh, Dept Pathol, HCC Res Pavil,Suite 1 46A,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	dbecker@pitt.edu			NCATS NIH HHS [UL1 TR000005] Funding Source: Medline; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005] Funding Source: NIH RePORTER	NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))		Balch CM, 2004, CA-CANCER J CLIN, V54, P131, DOI 10.3322/canjclin.54.3.131; Balch CM, 2000, CANCER-AM CANCER SOC, V88, P1484, DOI 10.1002/(SICI)1097-0142(20000315)88:6<1484::AID-CNCR29>3.0.CO;2-D; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Edwards D, 2003, BIOINFORMATICS, V19, P825, DOI 10.1093/bioinformatics/btg083; Hayashi T, 2002, EXP CELL RES, V280, P212, DOI 10.1006/excr.2002.5634; Herlyn M, 2006, INT J CANCER, V118, P523, DOI 10.1002/ijc.21605; HERLYN M, 1987, CANCER RES, V47, P3057; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Johnson EW, 1997, J BACK MUSCULOSKELET, V9, P3, DOI 10.3233/BMR-1997-9102; Kovalenko OV, 1996, P NATL ACAD SCI USA, V93, P2958, DOI 10.1073/pnas.93.7.2958; Lin JY, 2004, FEBS LETT, V573, P15, DOI 10.1016/j.febslet.2004.07.059; Lin X, 2003, J BIOL CHEM, V278, P31043, DOI 10.1074/jbc.C300112200; McDonald SL, 2004, CANCER BIOL THER, V3, P110, DOI 10.4161/cbt.3.1.662; Mo YY, 2005, ONCOGENE, V24, P2677, DOI 10.1038/sj.onc.1208210; Mo YY, 2004, CANCER RES, V64, P2793, DOI 10.1158/0008-5472.CAN-03-2410; Nacerddine K, 2005, DEV CELL, V9, P769, DOI 10.1016/j.devcel.2005.10.007; Perlis C, 2004, ONCOLOGIST, V9, P182, DOI 10.1634/theoncologist.9-2-182; Premont RT, 1998, P NATL ACAD SCI USA, V95, P14082, DOI 10.1073/pnas.95.24.14082; Rizos H, 2005, CELL CYCLE, V4, P597, DOI 10.4161/cc.4.4.1588; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Saha S, 2002, NAT BIOTECHNOL, V20, P508, DOI 10.1038/nbt0502-508; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Smith AP, 2005, CANCER BIOL THER, V4, P1018, DOI 10.4161/cbt.4.9.2165; Smith AP, 2004, CANCER BIOL THER, V3, P104, DOI 10.4161/cbt.3.1.661; Tago K, 2005, P NATL ACAD SCI USA, V102, P7689, DOI 10.1073/pnas.0502978102; Tashiro K, 1997, P NATL ACAD SCI USA, V94, P7862, DOI 10.1073/pnas.94.15.7862; Tsao H, 2004, NEW ENGL J MED, V351, P998, DOI 10.1056/NEJMra041245; Ungureanu D, 2003, BLOOD, V102, P3311, DOI 10.1182/blood-2002-12-3816; Valesky M, 2002, MOL MED, V8, P103, DOI 10.1007/BF03402080; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; WANG E, 2004, J TRANSL MED, V15, P34; Wang YP, 1996, CELL GROWTH DIFFER, V7, P1733; Wang YP, 1997, NAT MED, V3, P887, DOI 10.1038/nm0897-887; Wang ZY, 1996, J BIOL CHEM, V271, P24811, DOI 10.1074/jbc.271.40.24811; Watanabe TK, 1996, CYTOGENET CELL GENET, V72, P86, DOI 10.1159/000134169; Weeraratna AT, 2004, ONCOGENE, V23, P2264, DOI 10.1038/sj.onc.1207337; Xu WD, 2000, EXP CELL RES, V255, P135, DOI 10.1006/excr.2000.4803; Yasugi T, 1996, NUCLEIC ACIDS RES, V24, P2005, DOI 10.1093/nar/24.11.2005	39	66	72	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 21	2007	26	29					4216	4225		10.1038/sj.onc.1210216	http://dx.doi.org/10.1038/sj.onc.1210216			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CY	17297476				2022-12-17	WOS:000247619900004
J	Kerr, LE; Birse-Archbold, JLA; Short, DM; McGregor, AL; Heron, I; MacDonald, DC; Thompson, J; Carlson, GJ; Kelly, JS; McCulloch, J; Sharkey, J				Kerr, L. E.; Birse-Archbold, J-L A.; Short, D. M.; McGregor, A. L.; Heron, I.; MacDonald, D. C.; Thompson, J.; Carlson, G. J.; Kelly, J. S.; McCulloch, J.; Sharkey, J.			Nucleophosmin is a novel Bax chaperone that regulates apoptotic cell death	ONCOGENE			English	Article						bcl-2 family; translocation; apoptosis; focal cerebral ischaemia; protein-protein interaction	FOCAL CEREBRAL-ISCHEMIA; MITOCHONDRIAL APOPTOSIS; BCL-2 FAMILY; CYTOSOLIC HEAT-SHOCK-PROTEIN-60; CONFORMATIONAL-CHANGE; SIGNALING PATHWAY; NEURONAL DEATH; PROTEIN B23; C-TERMINUS; P53	The proapoptotic B-cell lymphoma-2 family protein Bax is a key regulatory point in the intrinsic apoptotic pathway. However, the factors controlling the process of Bax activation and translocation to mitochondria have yet to be fully identified and characterized. We performed affinity chromatography using peptides corresponding to the mitochondrial-targeting region of Bax, which is normally sequestered within the inactive structure. The molecular chaperone nucleophosmin was identified. ed as a novel Bax-binding protein by matrix- assisted laser desorption/ionization time-of-flight mass spectrometry. Reciprocal co-immunoprecipitation and proximity assays con. confirmed the Bax-nucleophosmin protein-protein interaction and verified that nucleophosmin only bound to activated conformationally altered Bax. Confocal microscopy in a cell-based apoptosis model, demonstrated that nucleophosmin translocation from nucleolus to cytosol preceded Bax movement. Specific. c knockdown of nucleophosmin expression using RNAi attenuated apoptosis as measured by mitochondrial cytochrome c release and activation of the caspase cascade. In a mouse model of ischaemic stroke, subcellular fractionation studies veri. ed that nucleophosmin translocation occurred within 3 h, at a time before Bax translocation but after Bax conformational changes have occurred. Thus, we have elucidated a novel molecular mechanism whereby Bax becomes activated and translocates to the mitochondria to orchestrate mitochondrial dysfunction and apoptotic cell death, which opens new avenues for therapeutic intervention.	Univ Edinburgh, Astellas CNS Res Edinburgh, Edinburgh EH16 4SB, Midlothian, Scotland	University of Edinburgh	Kerr, LE (corresponding author), Univ Edinburgh, Astellas CNS Res Edinburgh, Chancellors Bldg,49 Little France Crescent, Edinburgh EH16 4SB, Midlothian, Scotland.	Lorraine.Kerr@ed.ac.uk		McGregor, Ailsa/0000-0002-8598-1535; Sharkey, John/0000-0001-8288-1857				Ahn JY, 2005, MOL CELL, V18, P435, DOI 10.1016/j.molcel.2005.04.010; Akhtar RS, 2004, BBA-MOL CELL RES, V1644, P189, DOI 10.1016/j.bbamcr.2003.10.013; Baksh S, 2005, MOL CELL, V18, P637, DOI 10.1016/j.molcel.2005.05.010; Birse-Archbold JLA, 2005, J CEREBR BLOOD F MET, V25, P1356, DOI 10.1038/sj.jcbfm.9600133; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Cao GD, 2001, J CEREBR BLOOD F MET, V21, P321, DOI 10.1097/00004647-200104000-00001; Cartron PF, 2003, J BIOL CHEM, V278, P11633, DOI 10.1074/jbc.M208955200; Chan PK, 1999, BIOCHEM BIOPH RES CO, V264, P305, DOI 10.1006/bbrc.1999.1255; Chiesa R, 2005, P NATL ACAD SCI USA, V102, P238, DOI 10.1073/pnas.0406173102; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; Cuddeback SM, 2001, J BIOL CHEM, V276, P20559, DOI 10.1074/jbc.M101527200; Gao YQ, 2005, J CEREBR BLOOD F MET, V25, P694, DOI 10.1038/sj.jcbfm.9600062; Gleave M, 2003, ANN NY ACAD SCI, V1002, P95, DOI 10.1196/annals.1281.020; Guo B, 2003, NATURE, V423, P456, DOI 10.1038/nature01627; Gupta S, 2002, CIRCULATION, V106, P2727, DOI 10.1161/01.CIR.0000038112.64503.6E; Gustafsson AB, 2004, J BIOL CHEM, V279, P21233, DOI 10.1074/jbc.M400695200; Hingorani K, 2000, J BIOL CHEM, V275, P24451, DOI 10.1074/jbc.M003278200; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Kerr LE, 2004, APOPTOSIS, V9, P739, DOI 10.1023/B:APPT.0000045787.50848.e1; Kerr LE, 2004, CELL DEATH DIFFER, V11, P1102, DOI 10.1038/sj.cdd.4401449; Kirchhoff SR, 2002, CIRCULATION, V105, P2899, DOI 10.1161/01.CIR.0000019403.35847.23; Krummel KA, 2005, P NATL ACAD SCI USA, V102, P10188, DOI 10.1073/pnas.0503068102; Kurki S, 2004, CANCER CELL, V5, P465, DOI 10.1016/S1535-6108(04)00110-2; Li J, 2005, LEUKEMIA RES, V29, P1415, DOI 10.1016/j.leukres.2005.05.005; Li J, 2004, J BIOL CHEM, V279, P41275, DOI 10.1074/jbc.C400297200; Li YP, 1997, J VIROL, V71, P4098, DOI 10.1128/JVI.71.5.4098-4102.1997; Lu YY, 1996, BIOCHEM J, V317, P321, DOI 10.1042/bj3170321; Maiguel DA, 2004, MOL CELL BIOL, V24, P3703, DOI 10.1128/MCB.24.9.3703-3711.2004; MAR MSM, 2001, BIOCHEMISTRY-US, V40, P9983; Matsushita K, 1998, NEUROSCIENCE, V83, P439, DOI 10.1016/S0306-4522(97)00391-6; Nam YJ, 2004, MOL CELL, V15, P901, DOI 10.1016/j.molcel.2004.08.020; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nomura M, 2003, J BIOL CHEM, V278, P2058, DOI 10.1074/jbc.M207880200; Ohtsuka T, 2004, NAT CELL BIOL, V6, P121, DOI 10.1038/ncb1087; Sawada M, 2003, NAT CELL BIOL, V5, P320, DOI 10.1038/ncb950; Schinzel A, 2004, J CELL BIOL, V164, P1021, DOI 10.1083/jcb.200309013; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Takahashi Y, 2005, MOL CELL BIOL, V25, P9369, DOI 10.1128/MCB.25.21.9369-9382.2005; Takemura M, 2002, EXP CELL RES, V276, P233, DOI 10.1006/excr.2002.5523; Tan Y, 2006, J BIOL CHEM, V281, P17689, DOI 10.1074/jbc.M601978200; Tremblais K, 1999, BIOCHEM BIOPH RES CO, V260, P582, DOI 10.1006/bbrc.1999.0904; White FA, 1998, J NEUROSCI, V18, P1428; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Zhang HL, 2005, NAT CELL BIOL, V7, P909, DOI 10.1038/ncb1291	46	66	69	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 19	2007	26	18					2554	2562		10.1038/sj.onc.1210044	http://dx.doi.org/10.1038/sj.onc.1210044			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YI	17072349				2022-12-17	WOS:000245831200003
J	Pickering, BM; de Mel, S; Lee, M; Howell, M; Habens, F; Dallman, CL; Neville, LA; Potter, KN; Mann, J; Mann, DA; Johnson, PWM; Stevenson, FK; Packham, G				Pickering, B. M.; de Mel, S.; Lee, M.; Howell, M.; Habens, F.; Dallman, C. L.; Neville, L. A.; Potter, K. N.; Mann, J.; Mann, D. A.; Johnson, P. W. M.; Stevenson, F. K.; Packham, G.			Pharmacological inhibitors of NF-kappa B accelerate apoptosis in chronic lymphocytic leukaemia cells	ONCOGENE			English	Article						NF-kappa B; nuclear factor kappa B; Bcl-2; apoptosis; chronic lymphocytic leukaemia	CD38 EXPRESSION; BCL-X; SURVIVAL; ACTIVATION; CLL; PATHWAY; ZAP-70; GENES; BAFF; MODULATION	Nuclear factor-kappaB NF-kappa B) is a transcription factor that plays a critical role in the inappropriate survival of various types of malignant cells. Chronic lymphocytic leukaemia (CLL) is the most common B-cell malignancy in the Western world. Although overexpression and regulation of NF-kappa B has been described in CLL, its function remains unclear. Exposure of CLL cells to BAY117082 or Kamebakaurin, potent pharmacological inhibitors of the NF-kappa B pathway, accelerated apoptosis in approximately 70% of cases. Sensitivity to NF-kappa B pathway inhibitors was not related to the prognostic markers VH status, CD38 or Zap70 expression, or to the levels of nuclear NF-kappa B. Normal peripheral B cells were resistant to the apoptosis-inducing effects of these compounds. Cell death induced by the inhibitors was associated with activation of caspase-9 and -3, and loss of mitochondrial membrane polarization, but did not involve changes in the expression of Bcl-2 or Mcl-1. Inhibitors caused an increase in c-jun NH2-terminal kinase activity in CLL, but this did not appear to be important for apoptosis. Microarray analysis identified some potential novel NF-kappa B target genes, including interleukin-16- and the Bcl-2- related survival protein Bcl-w. These results demonstrate that a substantial proportion of CLL are dependent on NF-kappa B for enhanced survival and suggest that inhibition of NF-kappa B may have therapeutic potential.	Southampton Gen Hosp, Canc Res UK Clin Ctr, Southampton SO16 6YD, Hants, England; Southampton Gen Hosp, Canc Sci Div, Mol Immunol Grp, Southampton SO16 6YD, Hants, England; Univ Southampton, Southampton Gen Hosp, Sch Med, Div Infect Inflammat & Repair,Liver Grp, Southampton, Hants, England	Cancer Research UK; University of Southampton; University of Southampton; University of Southampton	Packham, G (corresponding author), Southampton Gen Hosp, Canc Res UK Clin Ctr, Somers Canc Res Bldg MP824,Tremona Rd, Southampton SO16 6YD, Hants, England.	g.k.packham@soton.ac.uk	Johnson, Peter/O-3529-2019; Johnson, Peter/L-2403-2018	Johnson, Peter/0000-0003-2306-4974; Johnson, Peter/0000-0003-2306-4974; Packham, Graham/0000-0002-9232-5691; Stevenson, Freda/0000-0002-0933-5021; Mann, Derek/0000-0003-0950-243X				Bernal A, 2001, BLOOD, V98, P3050, DOI 10.1182/blood.V98.10.3050; Brenner C, 2003, J CLIN IMMUNOL, V23, P73, DOI 10.1023/A:1022541009662; Caligaris-Cappio F, 1999, J CLIN ONCOL, V17, P399, DOI 10.1200/JCO.1999.17.1.399; Castro JE, 2005, BLOOD, V106, P2506, DOI 10.1182/blood-2005-03-1099; Chen LG, 2005, BLOOD, V105, P2036, DOI 10.1182/blood-2004-05-1715; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Crespo M, 2003, NEW ENGL J MED, V348, P1764, DOI 10.1056/NEJMoa023143; Cuni S, 2004, LEUKEMIA, V18, P1391, DOI 10.1038/sj.leu.2403398; Dallman C, 2005, METH MOLEC MED, V115, P1; Damle RN, 1999, BLOOD, V94, P1840, DOI 10.1182/blood.V94.6.1840; DeMeester SL, 1998, SHOCK, V10, P1, DOI 10.1097/00024382-199807000-00001; Feuillard J, 2000, BLOOD, V95, P2068, DOI 10.1182/blood.V95.6.2068.2068; Furman RR, 2000, J IMMUNOL, V164, P2200, DOI 10.4049/jimmunol.164.4.2200; Ghia P, 2000, ADV CANCER RES, V79, P157, DOI 10.1016/S0065-230X(00)79005-1; Grad JM, 2000, CURR OPIN ONCOL, V12, P543, DOI 10.1097/00001622-200011000-00006; Granziero L, 2001, BLOOD, V97, P2777, DOI 10.1182/blood.V97.9.2777; Hamblin TJ, 2002, BLOOD, V99, P1023, DOI 10.1182/blood.V99.3.1023; Hamblin TJ, 1999, BLOOD, V94, P1848, DOI 10.1182/blood.V94.6.1848; Hess P, 2002, NAT GENET, V32, P201, DOI 10.1038/ng946; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; Kern C, 2004, BLOOD, V103, P679, DOI 10.1182/blood-2003-02-0540; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Lee JH, 2002, J BIOL CHEM, V277, P18411, DOI 10.1074/jbc.M201368200; Matsuda A, 2003, ONCOGENE, V22, P3307, DOI 10.1038/sj.onc.1206406; Michels J, 2004, ONCOGENE, V23, P4818, DOI 10.1038/sj.onc.1207648; Morabito F, 2001, LEUKEMIA RES, V25, P927, DOI 10.1016/S0145-2126(01)00049-2; Munzert G, 2002, BLOOD, V100, P3749, DOI 10.1182/blood.V100.10.3749; Natoli G, 2005, NAT IMMUNOL, V6, P439, DOI 10.1038/ni1196; Oakley F, 2003, J BIOL CHEM, V278, P24359, DOI 10.1074/jbc.M211051200; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Packham G, 2005, IMMUNOLOGY, V114, P441, DOI 10.1111/j.1365-2567.2005.02117.x; Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807; Papa S, 2004, J CELL SCI, V117, P5197, DOI 10.1242/jcs.01483; Pedersen IM, 2002, BLOOD, V100, P1795, DOI 10.1182/blood.V100.5.1795.h81702001795_1795_1801; Pepper C, 1999, BRIT J HAEMATOL, V107, P611, DOI 10.1046/j.1365-2141.1999.01726.x; Perkins ND, 2004, TRENDS CELL BIOL, V14, P64, DOI 10.1016/j.tcb.2003.12.004; Petlickovski A, 2005, BLOOD, V105, P4820, DOI 10.1182/blood-2004-07-2669; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Ran RQ, 2004, GENE DEV, V18, P1466, DOI 10.1101/gad.1188204; Ravid T, 2004, CURR BIOL, V14, pR898, DOI 10.1016/j.cub.2004.09.074; Ringshausen I, 2002, BLOOD, V100, P3741, DOI 10.1182/blood-2002-02-0539; Rodriguez A, 2004, CLIN CANCER RES, V10, P6796, DOI 10.1158/1078-0432.CCR-04-0753; Romano MF, 1998, BLOOD, V92, P990; Rosenwald A, 2001, J EXP MED, V194, P1639, DOI 10.1084/jem.194.11.1639; Rossi A, 1998, J BIOL CHEM, V273, P16446, DOI 10.1074/jbc.273.26.16446; Schattner EJ, 2000, LEUKEMIA LYMPHOMA, V37, P461, DOI 10.3109/10428190009058499; Schmitz ML, 2004, CHEMBIOCHEM, V5, P1348, DOI 10.1002/cbic.200400144; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Sembries S, 1999, BLOOD, V93, P624, DOI 10.1182/blood.V93.2.624.402k10_624_631; Shaffer AL, 2002, NAT REV IMMUNOL, V2, P920, DOI 10.1038/nri953; Takayama S, 2001, NAT CELL BIOL, V3, pE237, DOI 10.1038/ncb1001-e237; Tran NL, 2005, J BIOL CHEM, V280, P3483, DOI 10.1074/jbc.M409906200; Viatour P, 2003, LEUKEMIA, V17, P1349, DOI 10.1038/sj.leu.2402982; Wiestner A, 2003, BLOOD, V101, P4944, DOI 10.1182/blood-2002-10-3306; Wilson KC, 2004, GROWTH FACTORS, V22, P97, DOI 10.1080/08977190410001704679; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zaninoni A, 2003, EXP HEMATOL, V31, P185, DOI 10.1016/S0301-472X(02)01046-9	58	66	68	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2007	26	8					1166	1177		10.1038/sj.onc.1209897	http://dx.doi.org/10.1038/sj.onc.1209897			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139BG	16924235				2022-12-17	WOS:000244406400007
J	Amorino, GP; Deeble, PD; Parsons, SJ				Amorino, G. P.; Deeble, P. D.; Parsons, S. J.			Neurotensin stimulates mitogenesis of prostate cancer cells through a novel c-Src/Stat5b pathway	ONCOGENE			English	Article						neurotensin; EGFR; Tyr(845); Src; Stat5b; prostate cancer	EPIDERMAL-GROWTH-FACTOR; EGF RECEPTOR TRANSACTIVATION; PROTEIN-COUPLED RECEPTORS; FOCAL ADHESION KINASE; NEUROENDOCRINE DIFFERENTIATION; TYROSINE KINASE; DNA-SYNTHESIS; TUMOR-CELLS; MAP-KINASE; C-SRC	Neuroendocrine (NE)-like cells are hypothesized to contribute to the progression of prostate cancer by producing factors that enhance the growth, survival or metastatic capabilities of surrounding tumor cells. Many of the factors known to be secreted by NE-like cells, such as neurotensin (NT), parathyroid hormone-related peptide, serotonin, bombesin, etc., are agonists for G-protein-coupled receptors, but the signaling pathways activated by these agonists in prostate tumor cells are not fully defined. Identification of such pathways could provide insights into novel methods of treating late-stage disease. Using conditioned culture medium (CM) from LNCaP-derived NE-like cells (as a source of these agonists) or NT (a prototypical component of CM) to treat PC3 cells, we found that the epidermal growth factor (EGF) receptor (EGFR) was transactivated and that such activation was required for maximal PC3 cell mitogenesis, as measured by 5-bromo-20-deoxy-uridine incorporation or cell number. NT also induced a time-dependent increase in EGFR Tyr(845) phosphorylation and phosphorylation of c-Src and signal transducer and activator of transcription 5b (Stat5b) (a downstream effector of Tyr845), events that were blocked by specific inhibition of c-Src (which mediates Tyr845 phosphorylation of EGFR) or of EGFR. Introduction of mutant forms of EGFR (Tyr845) or Stat5b in PC3 cells, or treatment with selective, catalytic inhibitors of EGFR, c-Src and matrix metalloproteinases (MMPs) resulted in the loss of NT-induced stimulation of DNA synthesis, relative to wild-type controls. These data indicate that the mitogenic effect of NT on prostate cancer cells requires transactivation of the EGFR by MMPs and a novel downstream pathway involving c-Src, phosphorylation of EGFR Tyr845 and activation of Stat5b.	Univ Virginia, Dept Microbiol, Hlth Sci Ctr, Ctr Canc, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Ctr Canc, Dept Radiat Oncol, Charlottesville, VA USA; Mary Baldwin Coll, Dept Biol, Staunton, VA USA	University of Virginia; University of Virginia	Parsons, SJ (corresponding author), Univ Virginia, Dept Microbiol, Hlth Sci Ctr, Ctr Canc, POB 800734, Charlottesville, VA 22908 USA.	sap@virginia.edu			NCI NIH HHS [R01 CA71449] Funding Source: Medline; NIDDK NIH HHS [T32 DK007646] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071449] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007646] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abrahamsson PA, 1999, PROSTATE, V39, P135, DOI 10.1002/(SICI)1097-0045(19990501)39:2<135::AID-PROS9>3.0.CO;2-S; Amorino GP, 2004, CRIT REV EUKAR GENE, V14, P287, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i4.40; Aprikian AG, 1997, INT J CANCER, V72, P498, DOI 10.1002/(SICI)1097-0215(19970729)72:3<498::AID-IJC19>3.3.CO;2-P; Aprikian AG, 1996, J MOL ENDOCRINOL, V16, P297, DOI 10.1677/jme.0.0160297; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Boerner JL, 2005, MOL CARCINOGEN, V44, P262, DOI 10.1002/mc.20138; Boerner JL, 2004, MOL CELL BIOL, V24, P7059, DOI 10.1128/MCB.24.16.7059-7071.2004; BOLOGNA M, 1989, CANCER, V63, P1714; Cox ME, 1999, CANCER RES, V59, P3821; Cox ME, 2000, J BIOL CHEM, V275, P13812, DOI 10.1074/jbc.275.18.13812; Dal Farra C, 2001, INT J CANCER, V92, P503, DOI 10.1002/ijc.1225; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Deeble PD, 2001, MOL CELL BIOL, V21, P8471, DOI 10.1128/MCB.21.24.8471-8482.2001; DISANTAGNESE PA, 1992, CANCER-AM CANCER SOC, V70, P254, DOI 10.1002/1097-0142(19920701)70:1+<254::AID-CNCR2820701312>3.0.CO;2-E; GULLY D, 1993, P NATL ACAD SCI USA, V90, P65, DOI 10.1073/pnas.90.1.65; Hassan S, 2006, REGUL PEPTIDES, V133, P105, DOI 10.1016/j.regpep.2005.09.031; Hassan S, 2004, REGUL PEPTIDES, V120, P155, DOI 10.1016/j.regpep.2004.03.004; IWAMURA M, 1994, UROLOGY, V43, P675, DOI 10.1016/0090-4295(94)90183-X; Jongsma J, 2000, PROSTATE, V42, P34, DOI 10.1002/(SICI)1097-0045(20000101)42:1<34::AID-PROS5>3.0.CO;2-2; Kloth MT, 2003, J BIOL CHEM, V278, P1671, DOI 10.1074/jbc.M207289200; Kloth MT, 2002, J BIOL CHEM, V277, P8693, DOI 10.1074/jbc.M111884200; Labbe-Jullie C, 1998, J BIOL CHEM, V273, P16351, DOI 10.1074/jbc.273.26.16351; LARRAN LJ, 2000, ACTAS UROL ESP, V24, P779; Lee LF, 2001, MOL CELL BIOL, V21, P8385, DOI 10.1128/MCB.21.24.8385-8397.2001; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Madarame J, 2003, PROSTATE, V57, P187, DOI 10.1002/pros.10295; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; ORELLANA SA, 1992, P NATL ACAD SCI USA, V89, P4726, DOI 10.1073/pnas.89.10.4726; Petit T, 2001, ANTI-CANCER DRUG, V12, P133, DOI 10.1097/00001813-200102000-00006; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; REILE H, 1994, PROSTATE, V25, P29, DOI 10.1002/pros.2990250105; Santiskulvong C, 2003, EXP CELL RES, V290, P437, DOI 10.1016/S0014-4827(03)00355-0; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Seethalakshmi L, 1997, PROSTATE, V31, P183, DOI 10.1002/(SICI)1097-0045(19970515)31:3<183::AID-PROS7>3.0.CO;2-M; SEHGAL I, 1994, P NATL ACAD SCI USA, V91, P4673, DOI 10.1073/pnas.91.11.4673; Sepulveda VAT, 2002, REGUL PEPTIDES, V105, P109, DOI 10.1016/S0167-0115(02)00007-1; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Wright JD, 1996, BBA-MOL CELL RES, V1312, P85, DOI 10.1016/0167-4889(96)00027-4; Xiao DM, 2003, CELL SIGNAL, V15, P945, DOI 10.1016/S0898-6568(03)00059-7; Xiao DM, 2002, REGUL PEPTIDES, V109, P141, DOI 10.1016/S0167-0115(02)00197-0; Yano S, 2004, BONE, V35, P664, DOI 10.1016/j.bone.2004.04.014; Zhao DZ, 2004, J BIOL CHEM, V279, P43547, DOI 10.1074/jbc.M401453200	46	66	71	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	5					745	756		10.1038/sj.onc.1209814	http://dx.doi.org/10.1038/sj.onc.1209814			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	131WM	16862179				2022-12-17	WOS:000243902200011
J	Lotem, J; Sachs, L				Lotem, J.; Sachs, L.			Epigenetics and the plasticity of differentiation in normal and cancer stem cells	ONCOGENE			English	Review						epigenetics; differentiation plasticity; normal embryonic and adult stem cells; cancer stem cells; transcription accessibility	ACUTE MYELOID-LEUKEMIA; MARROW STROMAL CELLS; HISTONE DEACETYLASE INHIBITION; COLONY-STIMULATING FACTOR; GENE-EXPRESSION PROFILES; SYNUCLEIN-GAMMA-GENE; NORMAL MAST-CELLS; HEMATOPOIETIC STEM; BONE-MARROW; DNA METHYLATION	Embryonic stem cells are characterized by their differentiation to all cell types during embryogenesis. In adult life, different tissues also have somatic stem cells, called adult stem cells, which in specific niches can undergo multipotent differentiation. The use of these adult stem cells has considerable therapeutic potential for the regeneration of damaged tissues. In both embryonic and adult stem cells, differentiation is controlled by epigenetic mechanisms, and the plasticity of differentiation in these cells is associated with transcription accessibility for genes expressed in different normal tissues. Abnormalities in genetic and/ or epigenetic controls can lead to development of cancer, which is maintained by self- renewing cancer stem cells. Although the genetic abnormalities produce defects in growth and differentiation in cancer stem cells, these cells have not always lost the ability to undergo differentiation through epigenetic changes that by- pass the genomic abnormalities, thus creating the basis for differentiation therapy. Like normal stem cells, cancer stem cells can show plasticity for differentiation. This plasticity of cancer stem cells is also associated with transcription accessibility for genes that are normally expressed in different tissues, including tissues other than those from which the cancers originated. This broad transcription accessibility can also contribute to the behavior of cancer cells by overexpressing genes that promote cell viability, growth and metastasis.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Sachs, L (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.	leo.sachs@weizmann.ac.il						Adams SP, 2002, LEUKEMIA, V16, P2238, DOI 10.1038/sj.leu.2402732; Akashi K, 2003, BLOOD, V101, P383, DOI 10.1182/blood-2002-06-1780; Alison MR, 2000, NATURE, V406, P257, DOI 10.1038/35018642; Alonso L, 2003, GENE DEV, V17, P1189, DOI 10.1101/gad.1086903; Altieri DC, 2003, ADV CANCER RES, V88, P31, DOI 10.1016/S0065-230X(03)88303-3; Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Amoh Y, 2005, P NATL ACAD SCI USA, V102, P5530, DOI 10.1073/pnas.0501263102; Amoh Y, 2005, P NATL ACAD SCI USA, V102, P17734, DOI 10.1073/pnas.0508440102; Andersson A, 2005, P NATL ACAD SCI USA, V102, P19069, DOI 10.1073/pnas.0506637102; Ansel KM, 2003, NAT IMMUNOL, V4, P616, DOI 10.1038/ni0703-616; ARIEL M, 1994, NAT GENET, V7, P59, DOI 10.1038/ng0594-59; Avni O, 2000, CURR OPIN IMMUNOL, V12, P654, DOI 10.1016/S0952-7915(00)00158-8; Baba Y, 2005, IMMUNITY, V23, P599, DOI 10.1016/j.immuni.2005.10.009; Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6; Bailey AS, 2004, BLOOD, V103, P13, DOI 10.1182/blood-2003-05-1684; BAIN G, 1994, BIOESSAYS, V16, P343, DOI 10.1002/bies.950160509; Baker EK, 2005, ONCOGENE, V24, P8061, DOI 10.1038/sj.onc.1208955; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Behbod F, 2005, CARCINOGENESIS, V26, P703, DOI 10.1093/carcin/bgh293; Bhattacharya B, 2004, BLOOD, V103, P2956, DOI 10.1182/blood-2003-09-3314; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Bjerkvig R, 2005, NAT REV CANCER, V5, P899, DOI 10.1038/nrc1740; Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; Blasco T, 2003, AM J PHYSIOL-RENAL, V285, pF799, DOI 10.1152/ajprenal.00149.2003; Bonnet D, 2005, BRIT J HAEMATOL, V130, P469, DOI 10.1111/j.1365-2141.2005.05596.x; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Boon EMJ, 2004, BRIT J CANCER, V90, P224, DOI 10.1038/sj.bjc.6601505; Cairns BR, 2001, TRENDS CELL BIOL, V11, pS15, DOI 10.1016/S0962-8924(01)82074-2; Calaluce R, 2004, NEOPLASIA, V6, P468, DOI 10.1593/neo.03499; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Calvo KR, 2000, MOL CELL BIOL, V20, P3274, DOI 10.1128/MCB.20.9.3274-3285.2000; Camargo FD, 2003, NAT MED, V9, P1520, DOI 10.1038/nm963; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Campanero MR, 2000, P NATL ACAD SCI USA, V97, P6481, DOI 10.1073/pnas.100340697; Cao BH, 2003, NAT CELL BIOL, V5, P640, DOI 10.1038/ncb1008; Carlone DL, 2005, MOL CELL BIOL, V25, P4881, DOI 10.1128/MCB.25.12.4881-4891.2005; Castor A, 2005, NAT MED, V11, P630, DOI 10.1038/nm1253; Chung Y, 2006, NATURE, V439, P216, DOI 10.1038/nature04277; CICCARONE V, 1989, CANCER RES, V49, P219; Collins CA, 2005, CELL, V122, P289, DOI 10.1016/j.cell.2005.05.010; Corbel SY, 2003, NAT MED, V9, P1528, DOI 10.1038/nm959; Cox DN, 1998, GENE DEV, V12, P3715, DOI 10.1101/gad.12.23.3715; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; Cui HM, 1998, NAT MED, V4, P1276, DOI 10.1038/3260; Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902; Degos L, 2001, ONCOGENE, V20, P7140, DOI 10.1038/sj.onc.1204763; Deng W, 2002, DEV CELL, V2, P819, DOI 10.1016/S1534-5807(02)00165-X; Dezawa M, 2005, SCIENCE, V309, P314, DOI 10.1126/science.1110364; Dezawa M, 2004, J CLIN INVEST, V113, P1701, DOI 10.1172/JCI200420935; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Dore BT, 1998, CANCER CHEMOTH PHARM, V41, P275, DOI 10.1007/s002800050740; Drabkin H, 2002, LEUKEMIA, V16, P186, DOI 10.1038/sj.leu.2402354; Dusenbery KE, 2003, J PEDIAT HEMATOL ONC, V25, P760, DOI 10.1097/00043426-200310000-00004; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680; Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Fan GP, 2005, DEVELOPMENT, V132, P3345, DOI 10.1242/dev.01912; Fang JY, 2001, J GASTROEN HEPATOL, V16, P960, DOI 10.1046/j.1440-1746.2001.02554.x; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Fischbach NA, 2005, BLOOD, V105, P1456, DOI 10.1182/blood-2004-04-1583; Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102; FRANK D, 1991, NATURE, V351, P239, DOI 10.1038/351239a0; Freitag M, 2005, CURR OPIN GENET DEV, V15, P191, DOI 10.1016/j.gde.2005.02.003; Fuchs E, 2000, CELL, V100, P143, DOI 10.1016/S0092-8674(00)81691-8; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Gavert N, 2005, J CELL BIOL, V168, P633, DOI 10.1083/jcb.200408051; Geiger TR, 2005, CANCER RES, V65, P7033, DOI 10.1158/0008-5472.CAN-05-0709; Georgantas RW, 2004, CANCER RES, V64, P4434, DOI 10.1158/0008-5472.CAN-03-3247; Gidekel S, 2002, J BIOL CHEM, V277, P34521, DOI 10.1074/jbc.M203338200; GINSBURG H, 1963, J NATL CANCER I, V31, P1; Golan-Mashiach M, 2004, FASEB J, V18, P147, DOI 10.1096/fj.04-2417fje; Goldmit M, 2005, NAT IMMUNOL, V6, P198, DOI 10.1038/ni1154; Goolsby J, 2003, P NATL ACAD SCI USA, V100, P14926, DOI 10.1073/pnas.2434383100; Granziero L, 2003, BLOOD, V101, P1962, DOI 10.1182/blood-2002-05-1339; GRIESINGER F, 1989, J EXP MED, V169, P1101, DOI 10.1084/jem.169.3.1101; Guan K, 2006, NATURE, V440, P1199, DOI 10.1038/nature04697; Guinn BA, 2005, BIOCHEM BIOPH RES CO, V333, P703, DOI 10.1016/j.bbrc.2005.05.161; Gupta A, 2003, CANCER RES, V63, P664; HANADA M, 1993, BLOOD, V82, P1820; Harrell PC, 2005, EXP CELL RES, V303, P308, DOI 10.1016/j.yexcr.2004.09.020; Harris RG, 2004, SCIENCE, V305, P90, DOI 10.1126/science.1098925; Hasumi H, 2005, INT J CANCER, V115, P911, DOI 10.1002/ijc.20967; Havt A, 2005, P NATL ACAD SCI USA, V102, P17424, DOI 10.1073/pnas.0506844102; HAYASHI M, 1974, INT J CANCER, V14, P40, DOI 10.1002/ijc.2910140106; He LZ, 2001, J CLIN INVEST, V108, P1321, DOI 10.1172/JCI200111537; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Herzog EL, 2003, BLOOD, V102, P3483, DOI 10.1182/blood-2003-05-1664; Hochedlinger K, 2004, GENE DEV, V18, P1875, DOI 10.1101/gad.1213504; Hong SH, 2001, MOL CELL BIOL, V21, P7172, DOI 10.1128/MCB.21.21.7172-7182.2001; Hsieh J, 2004, CURR OPIN GENET DEV, V14, P461, DOI 10.1016/j.gde.2004.07.006; Hsieh J, 2004, P NATL ACAD SCI USA, V101, P16659, DOI 10.1073/pnas.0407643101; Hsu CL, 2006, P NATL ACAD SCI USA, V103, P672, DOI 10.1073/pnas.0510304103; ICHIKAWA Y, 1966, P NATL ACAD SCI USA, V56, P488, DOI 10.1073/pnas.56.2.488; Inaba S, 2005, BREAST CANCER RES TR, V94, P25, DOI 10.1007/s10549-005-6938-0; Jackson KA, 1999, P NATL ACAD SCI USA, V96, P14482, DOI 10.1073/pnas.96.25.14482; Jackson M, 2004, MOL CELL BIOL, V24, P8862, DOI 10.1128/MCB.24.20.8862-8871.2004; Jang YY, 2004, NAT CELL BIOL, V6, P532, DOI 10.1038/ncb1132; Jarzab B, 2005, CANCER RES, V65, P1587, DOI 10.1158/0008-5472.CAN-04-3078; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; Kanatsu-Shinohara M, 2004, CELL, V119, P1001, DOI 10.1016/j.cell.2004.11.011; Kaneda A, 2004, CANCER SCI, V95, P58, DOI 10.1111/j.1349-7006.2004.tb03171.x; Kaneda A, 2005, CANCER RES, V65, P11236, DOI 10.1158/0008-5472.CAN-05-2959; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Klein G, 1981, NATURE, V294, P313, DOI 10.1038/294313a0; KLEINSMITH LJ, 1964, CANCER RES, V24, P1544; Klenova EA, 2002, SEMIN CANCER BIOL, V12, P399, DOI 10.1016/S1044-579X(02)00060-3; Kocher O, 1996, AM J PATHOL, V149, P493; Kondo T, 2004, P NATL ACAD SCI USA, V101, P781, DOI 10.1073/pnas.0307618100; Kondo T, 2006, NEUROREPORT, V17, P1, DOI 10.1097/01.wnr.0000192732.00535.ff; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Kubota H, 2004, P NATL ACAD SCI USA, V101, P16489, DOI 10.1073/pnas.0407063101; Kurisu S, 2005, ONCOGENE, V24, P1309, DOI 10.1038/sj.onc.1208177; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; LeBrun DP, 2003, FRONT BIOSCI, V8, pS206, DOI 10.2741/1030; Lee JH, 2006, HUM MOL GENET, V15, P201, DOI 10.1093/hmg/ddi430; Lee S, 2006, P NATL ACAD SCI USA, V103, P1030, DOI 10.1073/pnas.0509878103; LEVAN A, 1953, J NATL CANCER I, V14, P1; Li L, 2003, CANCER RES, V63, P2733; Li LH, 2005, ANNU REV CELL DEV BI, V21, P605, DOI 10.1146/annurev.cellbio.21.012704.131525; Liu HY, 2005, CANCER RES, V65, P7635, DOI 10.1158/0008-5472.CAN-05-1089; Liu JW, 2000, BREAST CANCER RES TR, V62, P99, DOI 10.1023/A:1006418219012; LOCK LF, 1987, CELL, V48, P39, DOI 10.1016/0092-8674(87)90353-9; Lotem J, 2004, P NATL ACAD SCI USA, V101, P16022, DOI 10.1073/pnas.0406966101; Lotem J, 2002, ONCOGENE, V21, P3284, DOI 10.1038/sj.onc.1205319; LOTEM J, 1979, P NATL ACAD SCI USA, V76, P5158, DOI 10.1073/pnas.76.10.5158; Lotem J, 2002, SEMIN CANCER BIOL, V12, P339, DOI 10.1016/S1044-579X(02)00054-8; Lotem J, 2005, P NATL ACAD SCI USA, V102, P18556, DOI 10.1073/pnas.0509360102; LOTEM J, 1978, P NATL ACAD SCI USA, V75, P3781, DOI 10.1073/pnas.75.8.3781; Lubbert M, 1996, BLOOD, V87, P447, DOI 10.1182/blood.V87.2.447.bloodjournal872447; Luce MJ, 1999, GENE, V231, P121, DOI 10.1016/S0378-1119(99)00093-1; Lund AH, 2004, GENE DEV, V18, P2315, DOI 10.1101/gad.1232504; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; MAKINO S, 1953, J NATL CANCER I, V13, P1213; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Marshman E, 2002, BIOESSAYS, V24, P91, DOI 10.1002/bies.10028; MARTIN GR, 1975, P NATL ACAD SCI USA, V72, P1441, DOI 10.1073/pnas.72.4.1441; Martin-Rendon E, 2003, BRIT J HAEMATOL, V122, P877, DOI 10.1046/j.1365-2141.2003.04576.x; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Meshorer E, 2006, DEV CELL, V10, P105, DOI 10.1016/j.devcel.2005.10.017; Miyata Y, 2001, BIOCHEM BIOPH RES CO, V283, P655, DOI 10.1006/bbrc.2001.4840; Mohri T, 2006, J BIOL CHEM, V281, P6442, DOI 10.1074/jbc.M508969200; MONK M, 1987, DEVELOPMENT, V99, P371; Muller C, 2001, CURR OPIN GENET DEV, V11, P167, DOI 10.1016/S0959-437X(00)00175-1; Munster PN, 2001, CANCER RES, V61, P8492; Nagano M, 1998, TISSUE CELL, V30, P389, DOI 10.1016/S0040-8166(98)80053-0; NAKAMURA M, 1991, CANCER RES, V51, P1940; Nakayama M, 1998, BLOOD, V92, P4296, DOI 10.1182/blood.V92.11.4296.423k25_4296_4307; Ogasawara S, 2004, ONCOGENE, V23, P1117, DOI 10.1038/sj.onc.1207211; Ogishima T, 2005, ONCOGENE, V24, P6765, DOI 10.1038/sj.onc.1208811; Okutsu J, 2002, MOL CANCER THER, V1, P1035; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Pan ZZ, 2002, J BIOL CHEM, V277, P35050, DOI 10.1074/jbc.M201650200; PAROUSH Z, 1990, CELL, V63, P1229, DOI 10.1016/0092-8674(90)90418-E; Pinto do O P, 1998, EMBO J, V17, P5744, DOI 10.1093/emboj/17.19.5744; PLUZNIK DH, 1966, EXP CELL RES, V43, P553, DOI 10.1016/0014-4827(66)90026-7; PLUZNIK DH, 1965, J CELL COMPAR PHYSL, V66, P319, DOI 10.1002/jcp.1030660309; Porter D, 2003, P NATL ACAD SCI USA, V100, P10931, DOI 10.1073/pnas.1932980100; Pui CH, 1998, BLOOD, V92, P411, DOI 10.1182/blood.V92.2.411.414k34_411_415; Rabbitts T. H., 1997, Leukemia (Basingstoke), V11, P271; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Rangel LBA, 2003, ONCOGENE, V22, P7225, DOI 10.1038/sj.onc.1207008; RAZIN A, 1984, P NATL ACAD SCI-BIOL, V81, P2275, DOI 10.1073/pnas.81.8.2275; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; Rekasi Z, 2005, P NATL ACAD SCI USA, V102, P3435, DOI 10.1073/pnas.0410006102; Rippon HJ, 2004, CELL PROLIFERAT, V37, P23, DOI 10.1111/j.1365-2184.2004.00298.x; Robbins MJ, 2002, MOL BRAIN RES, V106, P136, DOI 10.1016/S0169-328X(02)00420-5; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Roloff TC, 2005, EUR J CELL BIOL, V84, P123, DOI 10.1016/j.ejcb.2004.12.013; Romero-Ramos M, 2002, J NEUROSCI RES, V69, P894, DOI 10.1002/jnr.10374; Ross ME, 2004, BLOOD, V104, P3679, DOI 10.1182/blood-2004-03-1154; Ross ME, 2003, BLOOD, V102, P2951, DOI 10.1182/blood-2003-01-0338; Roumier C, 2003, LEUKEMIA, V17, P9, DOI 10.1038/sj.leu.2402766; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Rowley JD, 1998, ANNU REV GENET, V32, P495, DOI 10.1146/annurev.genet.32.1.495; Sachs L, 1996, P NATL ACAD SCI USA, V93, P4742, DOI 10.1073/pnas.93.10.4742; SACHS L, 1987, PROC R SOC SER B-BIO, V231, P289, DOI 10.1098/rspb.1987.0045; SACHS L, 1987, CANCER RES, V47, P1981; SACHS L, 1978, NATURE, V274, P535, DOI 10.1038/274535a0; SACHS L, 1955, J NATL CANCER I, V15, P1267; SACHS L, 1995, ADV CANCER RES, V66, P1, DOI 10.1016/S0065-230X(08)60250-X; SACHS L, 1964, ANNU REV GENET, V4, P246; SACHS L, 1964, NEW PERSPECT BIO, V4, P246; Sakatani T, 2005, SCIENCE, V307, P1976, DOI 10.1126/science.1108080; Sasaki T, 2003, GENOMICS, V82, P323, DOI 10.1016/S0888-7543(03)00129-0; Sato N, 2003, CANCER RES, V63, P4158; Scanlan Matthew J, 2004, Cancer Immun, V4, P1; Schmittwolf C, 2005, EMBO J, V24, P554, DOI 10.1038/sj.emboj.7600546; Seshi B, 2003, BLOOD CELL MOL DIS, V31, P268, DOI 10.1016/S1079-9796(03)00150-5; Shachaf CM, 2004, NATURE, V431, P1112, DOI 10.1038/nature03043; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Sigurjonsson OE, 2005, P NATL ACAD SCI USA, V102, P5227, DOI 10.1073/pnas.0501029102; Simonsson S, 2005, CELL CYCLE, V4, P513, DOI 10.4161/cc.4.4.1581; Simonsson S, 2004, NAT CELL BIOL, V6, P984, DOI 10.1038/ncb1176; Simpson AJG, 2005, NAT REV CANCER, V5, P615, DOI 10.1038/nrc1669; Singh SK, 2003, CANCER RES, V63, P5821; Skerjanc IS, 1999, TRENDS CARDIOVAS MED, V9, P139, DOI 10.1016/S1050-1738(99)00017-1; Sotiriou C, 2004, CURR OPIN ONCOL, V16, P211, DOI 10.1097/00001622-200405000-00003; SPANGRUDE GJ, 1991, BLOOD, V78, P1395; Steidl U, 2004, BLOOD, V104, P81, DOI 10.1182/blood-2004-01-0373; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Surani MA, 2001, NATURE, V414, P122, DOI 10.1038/35102186; Tagoh H, 2004, EMBO J, V23, P4275, DOI 10.1038/sj.emboj.7600421; Tagoh H, 2004, BLOOD, V103, P2950, DOI 10.1182/blood-2003-09-3323; Temple S, 2001, NATURE, V414, P112, DOI 10.1038/35102174; Theise ND, 2000, HEPATOLOGY, V32, P11, DOI 10.1053/jhep.2000.9124; Theocharis SE, 2004, HISTOPATHOLOGY, V45, P103, DOI 10.1111/j.1365-2559.2004.01922.x; Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005; van der Heyden MAG, 2003, CARDIOVASC RES, V58, P292, DOI 10.1016/S0008-6363(02)00771-X; VanMolle W, 1997, J IMMUNOL, V159, P3555; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; VELCICH A, 1995, CELL GROWTH DIFFER, V6, P749; Villalba JM, 2000, ANTIOXID REDOX SIGN, V2, P213, DOI 10.1089/ars.2000.2.2-213; Wang JX, 1999, CANCER RES, V59, P2766; Wang WS, 2006, CARCINOGENESIS, V27, P1113, DOI 10.1093/carcin/bgi351; Watt PM, 2000, GENE CHROMOSOME CANC, V29, P371, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1050>3.0.CO;2-Y; WEIH F, 1991, EMBO J, V10, P2559, DOI 10.1002/j.1460-2075.1991.tb07796.x; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Wolffe AP, 2001, ONCOGENE, V20, P2988, DOI 10.1038/sj.onc.1204322; Woodbury D, 2002, J NEUROSCI RES, V69, P908, DOI 10.1002/jnr.10365; Wu HJ, 2005, NATURE, V438, P981, DOI 10.1038/nature04225; Wu HK, 1996, ONCOGENE, V12, P1205; Wurmser AE, 2004, NATURE, V430, P350, DOI 10.1038/nature02604; Xi RW, 2005, SCIENCE, V310, P1487, DOI 10.1126/science.1120140; Xie HF, 2004, CELL, V117, P663, DOI 10.1016/S0092-8674(04)00419-2; Xu H, 1999, GENOMICS, V62, P281, DOI 10.1006/geno.1999.6009; YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681; Yepes M, 2000, BLOOD, V96, P569; Yoon YS, 2005, J CLIN INVEST, V115, P326, DOI 10.1172/JCI200522326; Yoshida M, 2004, BLOOD, V103, P2753, DOI 10.1182/blood-2003-07-2482; Yu CD, 2005, WORLD J GASTROENTERO, V11, P2390, DOI 10.3748/wjg.v11.i16.2390; Zeitler P, 2002, ENDOCRINE, V18, P85, DOI 10.1385/ENDO:18:1:85; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041; Zhang TD, 2001, ONCOGENE, V20, P7146, DOI 10.1038/sj.onc.1204762; Zhu J, 2001, ONCOGENE, V20, P7257, DOI 10.1038/sj.onc.1204852	243	66	69	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2006	25	59					7663	7672		10.1038/sj.onc.1209816	http://dx.doi.org/10.1038/sj.onc.1209816			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116VE	16847453				2022-12-17	WOS:000242830800001
J	Malhi, H; Gores, GJ				Malhi, H.; Gores, G. J.			TRAIL resistance results in cancer progression: a TRAIL to perdition?	ONCOGENE			English	Editorial Material						TRAIL; NF-kappa B; meta stasis; invasion; cFLIP; Mcl-1	NF-KAPPA-B; CHOLANGIOCARCINOMA CELLS; INDUCED APOPTOSIS; RECEPTORS; DEATH; LIGAND; INHIBITION; PROTEIN; FLIP	Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL, APO-2L) is a mediator of cell death that preferentially targets cancer cells. The potential of TRAIL as a chemotherapeutic agent is limited, however, because of the emergence of TRAIL resistance. Furthermore, recent studies have demonstrated that alternative TRAIL signaling is unmasked in TRAIL resistant cells. In these cells, the predominant effect of TRAIL receptor activation is the activation of nuclear factor-kappa B (NF-kappa B), which promotes tumor metastases and invasion. TRAIL resistance can occur at the level of the death inducing signaling complex via upregulation of cFLIP or via an increase in antiapoptotic proteins of the Bcl-2 family. A paradigm emerges from this information, that chemotherapy, targeting NF-kappa B, cFLIP, or antiapoptotic proteins of the Bcl-2 family, in combination with TRAIL maybe more rational than TRAIL therapy alone.	Mayo Clin, Coll Med, Miles & Shirley Fiterman Ctr Digest Dis, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA	Mayo Clinic	Gores, GJ (corresponding author), Mayo Clin, Coll Med, Miles & Shirley Fiterman Ctr Digest Dis, Div Gastroenterol & Hepatol, 200 1st St SW, Rochester, MN 55905 USA.	gores.gregory@mayo.edu						Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; BUDD RC, NAT REV IMMUNOL, V6, P196; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; Galligan L, 2005, MOL CANCER THER, V4, P2026, DOI 10.1158/1535-7163.MCT-05-0262; Ishimura N, 2006, AM J PHYSIOL-GASTR L, V290, pG129, DOI 10.1152/ajpgi.00242.2005; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Kimberley FC, 2004, CELL RES, V14, P359, DOI 10.1038/sj.cr.7290236; Luo JL, 2004, CANCER CELL, V6, P297, DOI 10.1016/j.ccr.2004.08.012; Okano H, 2003, LAB INVEST, V83, P1033, DOI 10.1097/01.LAB.0000079328.76631.28; Peter ME, 2005, BBA-REV CANCER, V1755, P25, DOI 10.1016/j.bbcan.2005.01.001; Sayers TJ, 2006, CANCER IMMUNOL IMMUN, V55, P76, DOI 10.1007/s00262-005-0676-3; Taniai M, 2004, CANCER RES, V64, P3517, DOI 10.1158/0008-5472.CAN-03-2770; TRAUZOLDK A, 2006, IN PRESS ONCOGENE; Truneh A, 2000, J BIOL CHEM, V275, P23319, DOI 10.1074/jbc.M910438199; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Zhang LD, 2005, CANCER GENE THER, V12, P228, DOI 10.1038/sj.cgt.7700792	17	66	71	2	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2006	25	56					7333	7335		10.1038/sj.onc.1209765	http://dx.doi.org/10.1038/sj.onc.1209765			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110ZE	16785986				2022-12-17	WOS:000242419100001
J	Kim, HJ; Chakravarti, N; Oridate, N; Choe, C; Claret, FX; Lotan, R				Kim, HJ; Chakravarti, N; Oridate, N; Choe, C; Claret, FX; Lotan, R			N-(4-hydroxyphenyl)retinamide-induced apoptosis triggered by reactive oxygen species is mediated by activation of MAPKs in head and neck squamous carcinoma cells	ONCOGENE			English	Article						4HPR; apoptosis; ROS; MAPK; HNSCC	N-TERMINAL KINASE; MITOCHONDRIAL-MEMBRANE DEPOLARIZATION; FENRETINIDE-INDUCED APOPTOSIS; SIGNAL-REGULATED KINASES; PROSTATE-CANCER CELLS; MEK-ERK PATHWAY; PROTEIN-KINASE; C-JUN; OXIDATIVE STRESS; CYTOCHROME-C	N-(4-hydroxyphenyl) retinamide (4HPR), a synthetic retinoid effective in cancer chemoprevention and therapy, is thought to act via apoptosis induction resulting from increased reactive oxygen species (ROS) generation. As ROS can activate MAP kinases and protein kinase C (PKC), we examined the role of such enzymes in 4HPR-induced apoptosis in HNSCC UMSCC22B cells. 4HPR increased ROS level within 1 h and induced activation of caspase 3 and PARP cleavage within 24 h. Activation of MKK3/6 and MKK4, JNK, p38 and ERK was detected between 6 and 12 h, increased up to 24 h and preceded apoptosis. 4HPR-induced activation of these kinases was abrogated by the antioxidants BHA and vitamin C. SP600125, a JNK inhibitor, suppressed 4HPR-induced c-Jun phosphorylation, cytochrome c release from mitochondria and apoptosis. Suppression of JNK1 and JNK2 using siRNA decreased, whereas overexpression of wild type-JNK1 enhanced 4HPR-induced apoptosis. PD169316, a p38, inhibitor suppressed phosphorylation of Hsp27 and apoptosis. PD98059, an MEK1/2 inhibitor, also suppressed ERK1/2 activation and apoptosis induced by 4HPR. Likewise, PKC inhibitor GF109203X suppressed ERK and p38 phosphorylation and PARP cleavage. These data indicate that 4HPR-induced apoptosis is triggered by ROS increase, leading to the activation of the mitogen-activated protein serine/threonine kinases JNK, p38, PKC and ERK, and subsequent apoptosis.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Unit 432, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Lotan, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Unit 432, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rlotan@mdanderson.org	Claret, Francois X/R-2104-2016; Oridate, Nobuhiko/G-5365-2012; Oridate, Nobuhiko/ABC-4116-2020; Chakravarti, Nitin/F-7964-2011	Claret, Francois X/0000-0003-4629-6495; Oridate, Nobuhiko/0000-0002-6968-3028; Chakravarti, Nitin/0000-0002-6619-953X	NCI NIH HHS [P30 CA16672-30, P50 CA97007, R01 CA090853, P50 CA097007, P30 CA016672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA090853, P50CA097007] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Asumendi A, 2002, BRIT J CANCER, V86, P1951, DOI 10.1038/sj.bjc.6600356; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bhatt NY, 2002, J IMMUNOL, V169, P6427, DOI 10.4049/jimmunol.169.11.6427; Boya P, 2003, ONCOGENE, V22, P6220, DOI 10.1038/sj.onc.1206827; Carvalho H, 2004, J CELL BIOCHEM, V92, P502, DOI 10.1002/jcb.20070; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen YR, 1999, MOL PHARMACOL, V56, P1271, DOI 10.1124/mol.56.6.1271; Chen YR, 2000, INT J ONCOL, V16, P651; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Delia D, 1997, CARCINOGENESIS, V18, P943, DOI 10.1093/carcin/18.5.943; Donovan N, 2002, J BIOL CHEM, V277, P40944, DOI 10.1074/jbc.M206113200; Formelli F, 1996, FASEB J, V10, P1014, DOI 10.1096/fasebj.10.9.8801162; Freemantle SJ, 2003, ONCOGENE, V22, P7305, DOI 10.1038/sj.onc.1206936; Garaventa A, 2003, CLIN CANCER RES, V9, P2032; Guise S, 2001, J NEUROSCI RES, V63, P257, DOI 10.1002/1097-4547(20010201)63:3<257::AID-JNR1019>3.0.CO;2-T; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Hail N, 2001, J BIOL CHEM, V276, P45614, DOI 10.1074/jbc.M106559200; Hail N, 2000, CANCER EPIDEM BIOMAR, V9, P1293; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Kim DG, 2002, J BIOL CHEM, V277, P38930, DOI 10.1074/jbc.M205941200; Kim HJ, 2004, CANCER RES, V64, P2439, DOI 10.1158/0008-5472.CAN-03-2643; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lee YJ, 2003, EXP CELL RES, V291, P251, DOI 10.1016/S0014-4827(03)00391-4; Liao YF, 2005, LIFE SCI, V77, P707, DOI 10.1016/j.lfs.2005.01.010; Lotan R, 1996, FASEB J, V10, P1031, DOI 10.1096/fasebj.10.9.8801164; Lovat PE, 2000, EXP CELL RES, V260, P50, DOI 10.1006/excr.2000.4988; Lovat PE, 2002, CANCER RES, V62, P5158; Luo YQ, 1998, J BIOL CHEM, V273, P3756, DOI 10.1074/jbc.273.6.3756; Malone W, 2003, EXPERT OPIN INV DRUG, V12, P1829, DOI 10.1517/13543784.12.11.1829; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Maurer BJ, 1999, JNCI-J NATL CANCER I, V91, P1138, DOI 10.1093/jnci/91.13.1138; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; Nguyen TTT, 2004, CARCINOGENESIS, V25, P647, DOI 10.1093/carcin/bgh052; Osone S, 2004, INT J CANCER, V112, P219, DOI 10.1002/ijc.20412; Poot M, 2002, EXP CELL RES, V279, P128, DOI 10.1006/excr.2002.5582; Reed JC, 1999, J NATL CANCER I, V91, P1099, DOI 10.1093/jnci/91.13.1099; Reynolds CP, 2004, PEDIATR TRANSPLANT, V8, P56, DOI 10.1111/j.1398-2265.2004.00216.x; Robertson JD, 2002, TOXICOLOGY, V181, P491, DOI 10.1016/S0300-483X(02)00464-X; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Seidman R, 2001, EXP CELL RES, V268, P84, DOI 10.1006/excr.2001.5262; Shimada K, 2003, MOL CARCINOGEN, V36, P115, DOI 10.1002/mc.10107; Shimada K, 2002, MOL CARCINOGEN, V35, P127, DOI 10.1002/mc.10084; Stanciu M, 2000, J BIOL CHEM, V275, P12200, DOI 10.1074/jbc.275.16.12200; Sun SY, 1999, CANCER RES, V59, P2493; Sun SY, 2004, JNCI-J NATL CANCER I, V96, P662, DOI 10.1093/jnci/djh123; Suzuki S, 1999, ONCOGENE, V18, P6380, DOI 10.1038/sj.onc.1203024; Tamura Y, 2004, FEBS LETT, V569, P249, DOI 10.1016/j.febslet.2004.06.003; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Traore K, 2005, LEUKEMIA RES, V29, P863, DOI 10.1016/j.leukres.2004.12.011; Tsuruta F, 2004, EMBO J, V23, P1889, DOI 10.1038/sj.emboj.7600194; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Ulukaya E, 2003, CELL DEATH DIFFER, V10, P856, DOI 10.1038/sj.cdd.4401242; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Won YK, 2005, CARCINOGENESIS, V26, P2149, DOI 10.1093/carcin/bgi194; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiao D, 2004, ONCOGENE, V23, P5594, DOI 10.1038/sj.onc.1207747; Xiao D, 2002, CANCER RES, V62, P3615; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yu CR, 2004, EXP CELL RES, V295, P555, DOI 10.1016/j.yexcr.2004.02.001; Yu WP, 2003, CANCER RES, V63, P2483; Zamzami N, 2003, CURR BIOL, V13, pR71, DOI 10.1016/S0960-9822(02)01433-1; Zhang XC, 2003, AM J RESP CELL MOL, V28, P305, DOI 10.1165/rcmb.2002-0156OC	67	66	67	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2006	25	19					2785	2794		10.1038/sj.onc.1209303	http://dx.doi.org/10.1038/sj.onc.1209303			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	039AW	16407847	Green Accepted			2022-12-17	WOS:000237272900009
J	Bharadwaj, S; Thanawala, R; Bon, G; Falcioni, R; Prasad, GL				Bharadwaj, S; Thanawala, R; Bon, G; Falcioni, R; Prasad, GL			Resensitization of breast cancer cells to anoikis by Tropomyosin-1: role of Rho kinase-dependent cytoskeleton and adhesion	ONCOGENE			English	Article						cytoskeleton; breast cancer; anoikis; adhesion; integrins; Rho kinase signaling; tropomyosin	INTESTINAL EPITHELIAL-CELLS; ABL TYROSINE KINASE; FOCAL ADHESIONS; TRANSFORMED PHENOTYPE; TUMOR-SUPPRESSOR; CARCINOMA-CELLS; ACTIN DYNAMICS; STRESS FIBERS; SUBCELLULAR-LOCALIZATION; HOST MICROENVIRONMENT	Two most common properties of malignant cells are the presence of aberrant actin cytoskeleton and resistance to anoikis. Suppression of several key cytoskeletal proteins, including tropomyosin-1 (TM1), during neoplastic transformation is hypothesized to contribute to the altered cytoskeleton and neoplastic phenotype. Using TM1 as a paradigm, we have shown that cytoskeletal proteins induce anoikis in breast cancer (MCF-7 and MDA MB 231) cells. Here, we have tested the hypothesis that TM1-mediated cytoskeletal changes regulate integrin activity and the sensitivity to anoikis. TM1 expression in MDA MB 231 cells promotes the assembly of stress fibers, induces rapid anoikis via caspase-dependent pathways involving the release of cytochrome c. Further, TM1 inhibits binding of MDA MB 231 cells to collagen I, but promotes adhesion to laminin. Inhibition of Rho kinase disrupts TM1-mediated cytoskeletal reorganization and adhesion to the extracellular matrix components, whereas the parental cells attach to collagen I, spread and form extensive actin meshwork in the presence of Rho kinase inhibitor, underscoring the differences in parental and TM1-transduced breast cancer cells. Further, treatment with the cytoskeletal disrupting drugs rescues the cells from TM1-induced anoikis. These new findings demonstrate that the aberrant cytoskeleton contributes to neoplastic transformation by conferring resistance to anoikis. Restoration of stress fiber network through enhanced expression of key cytoskeletal proteins may modulate the activity of focal adhesions and sensitize the neoplastic cells to anoikis.	Wake Forest Univ, Bowman Gray Sch Med, Dept Gen Surg, Winston Salem, NC 27157 USA; Regina Elena Inst Canc Res, Mol Oncogenesis Lab, I-00158 Rome, Italy	Wake Forest University; Wake Forest Baptist Medical Center; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Prasad, GL (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Gen Surg, Med Ctr Blvd, Winston Salem, NC 27157 USA.	gprasad@wfubmc.edu	Falcioni, Rita/H-8869-2017; Bon, Giulia/ABH-6498-2020	Falcioni, Rita/0000-0002-3745-4327; Bon, Giulia/0000-0002-5409-5864	Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Alford D, 1998, BIOCHEM SOC SYMP, P245; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Aoudjit F, 2001, J CELL BIOL, V152, P633, DOI 10.1083/jcb.152.3.633; Aplin AE, 2001, J CELL BIOL, V153, P273, DOI 10.1083/jcb.153.2.273; Aplin AE, 2001, J CELL BIOL, V155, P187, DOI 10.1083/jcb.200107116; Bamburg JR, 2002, TRENDS CELL BIOL, V12, P598, DOI 10.1016/S0962-8924(02)02404-2; Bharadwaj S, 2004, J BIOL CHEM, V279, P14039, DOI 10.1074/jbc.M310934200; Bharadwaj S, 2002, CANCER LETT, V183, P205, DOI 10.1016/S0304-3835(02)00119-2; BHATTACHARYA B, 1990, CANCER RES, V50, P2105; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Braverman RH, 1996, ONCOGENE, V13, P537; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; Caruso DA, 2001, CELL DEATH DIFFER, V8, P665, DOI 10.1038/sj.cdd.4400865; Cheng TL, 2004, EXP CELL RES, V295, P497, DOI 10.1016/j.yexcr.2004.02.002; Chrenek MA, 2001, BREAST CANCER RES, V3, P224, DOI 10.1186/bcr300; Christerson LB, 1999, CELL MOTIL CYTOSKEL, V43, P186, DOI 10.1002/(SICI)1097-0169(1999)43:3<186::AID-CM2>3.0.CO;2-1; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Chung J, 2004, CANCER RES, V64, P4711, DOI 10.1158/0008-5472.CAN-04-0347; Coll ML, 2002, ONCOGENE, V21, P2908, DOI 10.1038/sj.onc.1205388; Coniglio SJ, 2001, J BIOL CHEM, V276, P28113, DOI 10.1074/jbc.M102299200; Cooper JA, 2002, CURR BIOL, V12, pR523, DOI 10.1016/S0960-9822(02)01028-X; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; Davies MA, 1998, CANCER RES, V58, P5285; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; DeMali KA, 2003, CURR OPIN CELL BIOL, V15, P572, DOI 10.1016/S0955-0674(03)00109-1; Dos Remedios CG, 2003, PHYSIOL REV, V83, P433, DOI 10.1152/physrev.00026.2002; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; FALCIONI R, 1988, CANCER RES, V48, P816; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Geneste O, 2002, J CELL BIOL, V157, P831, DOI 10.1083/jcb.200203126; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Haslam SZ, 2003, BREAST CANCER RES, V5, P208, DOI 10.1186/bcr615; Heino J, 2000, MATRIX BIOL, V19, P319, DOI 10.1016/S0945-053X(00)00076-7; Izawa I, 1998, ONCOGENE, V17, P2863, DOI 10.1038/sj.onc.1202213; Janes SM, 2004, J CELL BIOL, V166, P419, DOI 10.1083/jcb.200312074; Kozlova NI, 2001, ONCOGENE, V20, P4710, DOI 10.1038/sj.onc.1204619; Kruidering M, 2000, IUBMB LIFE, V50, P85, DOI 10.1080/713803693; Le Gall M, 2000, MOL BIOL CELL, V11, P1103, DOI 10.1091/mbc.11.3.1103; Li Q, 2003, J MOL BIOL, V325, P949, DOI 10.1016/S0022-2836(02)01333-5; Lin J J, 1997, Int Rev Cytol, V170, P1, DOI 10.1016/S0074-7696(08)61619-8; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; MAEMURA M, 1995, CLIN EXP METASTAS, V13, P223, DOI 10.1007/BF00133478; Mahadev K, 2002, EXP CELL RES, V279, P40, DOI 10.1006/excr.2002.5583; Manohar A, 2004, J CELL SCI, V117, P4043, DOI 10.1242/jcs.01277; Marco RAW, 2003, J CELL BIOCHEM, V88, P1038, DOI 10.1002/jcb.10465; Marston S, 1998, ACTA PHYSIOL SCAND, V164, P401, DOI 10.1111/j.1365-201X.1998.tb10696.x; Martin S, 2001, MOL CELL BIOL, V21, P6529, DOI 10.1128/MCB.21.19.6529-6536.2001; Martin SS, 2004, BBA-MOL CELL RES, V1692, P145, DOI 10.1016/j.bbamcr.2004.02.008; Mercurio AM, 2001, CURR OPIN CELL BIOL, V13, P541, DOI 10.1016/S0955-0674(00)00249-0; Narumiya S, 2000, METHOD ENZYMOL, V325, P273; Normanno N, 2004, J CELL PHYSIOL, V198, P31, DOI 10.1002/jcp.10375; PALMER EL, 1993, J CELL BIOL, V123, P1289, DOI 10.1083/jcb.123.5.1289; Park HB, 2004, BIOCHEM J, V378, P559, DOI 10.1042/BJ20031392; Pawlak G, 2004, INT J CANCER, V110, P368, DOI 10.1002/ijc.20151; Pawlak G, 2002, MOL BIOL CELL, V13, P336, DOI 10.1091/mbc.01-06-0302; Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4; Plath T, 2000, J CELL BIOL, V150, P1467, DOI 10.1083/jcb.150.6.1467; Prasad GL, 1999, ONCOGENE, V18, P2027, DOI 10.1038/sj.onc.1202264; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; PRASAD GL, 1991, BIOCHEM BIOPH RES CO, V177, P1068, DOI 10.1016/0006-291X(91)90647-P; Raval GN, 2003, ONCOGENE, V22, P6194, DOI 10.1038/sj.onc.1206719; Rocco JW, 2001, EXP CELL RES, V264, P42, DOI 10.1006/excr.2000.5149; Rosen K, 2001, J BIOL CHEM, V276, P37273, DOI 10.1074/jbc.M106424200; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Schmeichel KL, 1998, J MAMMARY GLAND BIOL, V3, P201, DOI 10.1023/A:1018751124382; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Shah V, 2001, ONCOGENE, V20, P2112, DOI 10.1038/sj.onc.1204291; Shekhar MPV, 2003, BREAST CANCER RES, V5, P130, DOI 10.1186/bcr580; Strater J, 1996, GASTROENTEROLOGY, V110, P1776, DOI 10.1053/gast.1996.v110.pm8964403; Stupack DG, 2002, J CELL SCI, V115, P3729, DOI 10.1242/jcs.00071; Subauste MC, 2004, J CELL BIOL, V165, P371, DOI 10.1083/jcb.200308011; Swan EA, 2003, ORAL ONCOL, V39, P648, DOI 10.1016/S1368-8375(03)00049-6; Valentijn AJ, 2004, BIOCHEM SOC T, V32, P421, DOI 10.1042/BST0320421; Valentijn AJ, 2003, J CELL BIOL, V162, P599, DOI 10.1083/jcb.200302154; White DE, 2004, CANCER CELL, V6, P159, DOI 10.1016/j.ccr.2004.06.025; Woodring PJ, 2002, J CELL BIOL, V156, P879, DOI 10.1083/jcb.200110014; Woodring PJ, 2001, J BIOL CHEM, V276, P27104, DOI 10.1074/jbc.M100559200; Zhong CL, 1997, MOL BIOL CELL, V8, P2329, DOI 10.1091/mbc.8.11.2329	86	66	71	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2005	24	56					8291	8303		10.1038/sj.onc.1208993	http://dx.doi.org/10.1038/sj.onc.1208993			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	993LV	16170368				2022-12-17	WOS:000233956500008
J	Hu, YF; Ghosh, S; Amleh, A; Yue, W; Lu, YZ; Katz, A; Li, R				Hu, YF; Ghosh, S; Amleh, A; Yue, W; Lu, YZ; Katz, A; Li, R			Modulation of aromatase expression by BRCA1: a possible link to tissue-specific tumor suppression	ONCOGENE			English	Article						BRCA1; aromatase; ovarian granulosa cells; preadipocytes; tissue-specific tumor suppression; estrogen biosynthesis	BREAST; GENE; OVARIAN; DIFFERENTIATION; OOPHORECTOMY; PROMOTER; PARTNER; BARD1	Mutations in BRCA1 increase risks of familial breast and ovarian cancers, particularly among premenopausal women. While BRCA1 plays an active role in DNA repair, this function alone may not be sufficient to explain why BRCA1-associated tumors predominantly occur in estrogen-responsive tissues. Aromatase is the rate-limiting enzyme in estrogen biosynthesis and a key target in breast cancer treatment. Aromatase expression in ovarian granulosa cells dictates levels of circulating estrogen in premenopausal women, and its aberrant overexpression in breast adipose tissues promotes breast cancer growth. Here, we show that BRCA1 modulates aromatase expression in ovarian granulosa cells and primary preadipocytes. The cyclic AMP-dependent expression of aromatase in ovarian granulosa cells is inversely correlated with the protein level of BRCA1. Importantly, transient knockdown of BRCA1 enhances aromatase expression in both ovarian granulosa cells and primary preadipocytes. We propose that BRCA1 deficiency in epithelial and certain nonepithelial cells may result in combined effects of aberrant estrogen biosynthesis and compromised DNA repair capability, which in turn may lead to specific cancers in the breast and ovary.	Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Med, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Div Endocrinol, Charlottesville, VA 22908 USA; Fudan Univ, Sch Life Sci, Inst Genet, State Key Lab Genet Engn, Shanghai 200433, Peoples R China; Univ Virginia, Sch Med, Dept Plast & Reconstruct Surg, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia; Fudan University; University of Virginia	Hu, YF (corresponding author), Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA.	yh4b@virginia.edu; rl2t@virginia.edu		Amleh, Asma/0000-0003-3613-3182; Lu, Yunzhe/0000-0001-7542-6848	NCI NIH HHS [CA093506] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093506] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antoniou A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033; Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Bulun SE, 2003, J STEROID BIOCHEM, V86, P219, DOI 10.1016/S0960-0760(03)00359-5; Chen SU, 2001, J STEROID BIOCHEM, V79, P35, DOI 10.1016/S0960-0760(01)00132-7; Chodankar R, 2005, CURR BIOL, V15, P561, DOI 10.1016/j.cub.2005.01.052; Ghosh S, 2005, ONCOGENE, V24, P2236, DOI 10.1038/sj.onc.1208415; Hu YF, 2002, GENE DEV, V16, P1509, DOI 10.1101/gad.995502; Huo ZM, 2002, RADIOLOGY, V225, P519, DOI 10.1148/radiol.2252010845; Joukov V, 2001, P NATL ACAD SCI USA, V98, P12078, DOI 10.1073/pnas.211427098; Katz AJ, 2005, STEM CELLS, V23, P412, DOI 10.1634/stemcells.2004-0021; Kauff ND, 2002, NEW ENGL J MED, V346, P1609, DOI 10.1056/NEJMoa020119; Key T J, 1999, Breast Cancer Res, V1, P18, DOI 10.1186/bcr7; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; McCarthy EE, 2003, MOL CELL BIOL, V23, P5056, DOI 10.1128/MCB.23.14.5056-5063.2003; Nishi Y, 2001, ENDOCRINOLOGY, V142, P437, DOI 10.1210/en.142.1.437; Phillips KW, 1997, LAB INVEST, V76, P419; Rajan JV, 1997, DEV BIOL, V184, P385, DOI 10.1006/dbio.1997.8526; Rebbeck TR, 2002, NEW ENGL J MED, V346, P1616, DOI 10.1056/NEJMoa012158; RICHARDS JS, 1994, ENDOCR REV, V15, P725, DOI 10.1210/er.15.6.725; Richards JS, 2001, MOL ENDOCRINOL, V15, P209, DOI 10.1210/me.15.2.209; Sasano H, 1998, ENDOCR REV, V19, P593, DOI 10.1210/er.19.5.593; Simpson ER, 2001, ENDOCRINOLOGY, V142, P4589, DOI 10.1210/endo.142.11.8547; Simpson ER, 2002, ANNU REV PHYSIOL, V64, P93, DOI 10.1146/annurev.physiol.64.081601.142703; Starita LM, 2003, CURR OPIN CELL BIOL, V15, P345, DOI 10.1016/S0955-0674(03)00042-5; Tekmal RR, 1999, ENDOCR-RELAT CANCER, V6, P307, DOI 10.1677/erc.0.0060307; Turner KJ, 2002, J ENDOCRINOL, V172, P21, DOI 10.1677/joe.0.1720021; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Yue W, 1997, J STEROID BIOCHEM, V63, P317, DOI 10.1016/S0960-0760(97)00072-1; Zhou DJ, 1999, ARCH BIOCHEM BIOPHYS, V371, P179, DOI 10.1006/abbi.1999.1454	29	66	73	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2005	24	56					8343	8348		10.1038/sj.onc.1208985	http://dx.doi.org/10.1038/sj.onc.1208985			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	993LV	16170371				2022-12-17	WOS:000233956500013
J	Kanda, A; Kawai, H; Suto, S; Kitajima, S; Sato, S; Takata, T; Tatsuka, M				Kanda, A; Kawai, H; Suto, S; Kitajima, S; Sato, S; Takata, T; Tatsuka, M			Aurora-B/AIM-1 kinase activity is involved in Ras-mediated cell transformation	ONCOGENE			English	Article						transformation susceptibility; Ras; Src; Raf; Aurora; kinase	AURORA-B KINASE; CHROMOSOMAL PASSENGER COMPLEX; HAMSTER EMBRYO CELLS; HISTONE H3; NEOPLASTIC TRANSFORMATION; ONCOGENIC TRANSFORMATION; MITOTIC PHOSPHORYLATION; CLEAVAGE FURROW; CYTOKINESIS; SURVIVIN	Aurora-B, previously known as AIM-1, is a conserved eukaryotic mitotic protein kinase. In mammals, this kinase plays an essential role in chromosomal segregation processes, including chromosome condensation, alignment, control of spindle checkpoints, chromosome segregation, and cytokinesis. Aurora-B is overexpressed in various cancer cells, suggesting that the kinase activity perturbs chromosomal segregation processes. Its forced overexpression induces chromosomal number instability and progressive tumorigenicity in rodent cells in vitro and in vivo. Nevertheless, based on focus formation in BALB/c 3T3 A31-1-1 cells, Aurora-B is not oncogenic. Here, we show that Aurora- B kinase activity augments Ras-mediated cell transformation. RNA interference with short hairpin RNA inhibits transformation by Ras and its upstream oncogene Src, but not by the downstream oncogene Raf. In addition, the inner centromere protein, which is a passenger protein associated with Aurora-B, has a similar ability to potentiate the activity of oncogenic Ras. These data indicate that elevated Aurora-B activity promotes transformation by oncogenic Ras by enhancing oncogenic signaling and by converting chromosome number-stable cells to aneuploid cells.	Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Regulatory Radiobiol, Minami Ku, Hiroshima 7348553, Japan; Hiroshima Univ, Grad Sch Biomed Sci, Div Genome Biol, Dept Mol Radiobiol,Minami Ku, Hiroshima 734, Japan; Hiroshima Univ, Grad Sch Biomed Sci, Div Frontier Med Sci, Dept Oral & Maxillofacial Pathobiol,Minami Ku, Hiroshima 734, Japan	Hiroshima University; Hiroshima University; Hiroshima University	Tatsuka, M (corresponding author), Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Regulatory Radiobiol, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348553, Japan.	haruo@hiroshima-u.ac.jp		Kawai, Hidehiko/0000-0003-2213-7166; Kitajima, Shojiro/0000-0002-4000-0473				Adams RR, 2001, J CELL BIOL, V153, P865, DOI 10.1083/jcb.153.4.865; Adams RR, 2001, CHROMOSOMA, V110, P65, DOI 10.1007/s004120100130; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Andrews PD, 2003, CURR OPIN CELL BIOL, V15, P672, DOI 10.1016/j.ceb.2003.10.013; Andrews PD, 2004, DEV CELL, V6, P253, DOI 10.1016/S1534-5807(04)00025-5; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Chen J, 2003, J BIOL CHEM, V278, P486, DOI 10.1074/jbc.M211119200; Chen JG, 2002, CANCER RES, V62, P1935; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Fukuda S, 2004, BIOCHEM BIOPH RES CO, V323, P636, DOI 10.1016/j.bbrc.2004.08.149; Gassmann R, 2004, J CELL BIOL, V166, P179, DOI 10.1083/jcb.200404001; Gigoux V, 2002, J BIOL CHEM, V277, P23742, DOI 10.1074/jbc.C200121200; Goto H, 2002, GENES CELLS, V7, P11, DOI 10.1046/j.1356-9597.2001.00498.x; Goto H, 2003, J BIOL CHEM, V278, P8526, DOI 10.1074/jbc.M210892200; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; HEI TK, 1993, CANCER RES, V53, P1368; Honda R, 2003, MOL BIOL CELL, V14, P3325, DOI 10.1091/mbc.E02-11-0769; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; KAKUNAGA T, 1980, SCIENCE, V209, P505, DOI 10.1126/science.7394516; KAKUNAGA T, 1985, TRANSFORMATION ASSAY; Katayama H, 1999, J NATL CANCER I, V91, P1160, DOI 10.1093/jnci/91.13.1160; Kawajiri A, 2003, MOL BIOL CELL, V14, P1489, DOI 10.1091/mbc.E02-09-0612; KIZAKA S, 1989, MOL CELL BIOL, V9, P5669, DOI 10.1128/MCB.9.12.5669; Lampson MA, 2004, NAT CELL BIOL, V6, P232, DOI 10.1038/ncb1102; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Minoshima Y, 2003, DEV CELL, V4, P549, DOI 10.1016/S1534-5807(03)00089-3; Murata-Hori M, 2000, J BIOCHEM-TOKYO, V128, P903, DOI 10.1093/oxfordjournals.jbchem.a022840; Murata-Hori M, 2002, MOL BIOL CELL, V13, P1099, DOI 10.1091/mbc.01-09-0467; Ota T, 2002, CANCER RES, V62, P5168; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; Sampath SC, 2004, CELL, V118, P187, DOI 10.1016/j.cell.2004.06.026; Sasai K, 2004, CELL MOTIL CYTOSKEL, V59, P249, DOI 10.1002/cm.20039; Schumacher JM, 1998, J CELL BIOL, V143, P1635, DOI 10.1083/jcb.143.6.1635; SHIMIZU T, 1995, JPN J CANCER RES, V86, P546, DOI 10.1111/j.1349-7006.1995.tb02433.x; Sommer KW, 2003, ONCOGENE, V22, P4266, DOI 10.1038/sj.onc.1206509; Tatsuka M, 2005, ONCOGENE, V24, P1122, DOI 10.1038/sj.onc.1208293; Tatsuka M, 1996, MOL CARCINOGEN, V15, P300, DOI 10.1002/(SICI)1098-2744(199604)15:4<300::AID-MC7>3.0.CO;2-J; Tatsuka M, 1998, CANCER RES, V58, P4811; TATSUKA M, 1992, NATURE, V359, P333, DOI 10.1038/359333a0; TATSUKA M, 2005, SIGNAL TRANSDUCTION; Temme A, 2005, BIOCHEM BIOPH RES CO, V327, P765, DOI 10.1016/j.bbrc.2004.12.075; Temme A, 2003, MOL BIOL CELL, V14, P78, DOI 10.1091/mbc.E02-04-0182; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Terada Y, 2001, CELL STRUCT FUNCT, V26, P653, DOI 10.1247/csf.26.653; TSUTSUI T, 1984, CARCINOGENESIS, V5, P89, DOI 10.1093/carcin/5.1.89; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Wu JC, 2005, J BIOL CHEM, V280, P9013, DOI 10.1074/jbc.M411068200; YAGI T, 1989, MOL CARCINOGEN, V1, P222, DOI 10.1002/mc.2940010404; Yasui Y, 2004, J BIOL CHEM, V279, P12997, DOI 10.1074/jbc.M311128200; Zeitlin SG, 2001, J CELL BIOL, V155, P1147, DOI 10.1083/jcb.200108125	50	66	70	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2005	24	49					7266	7272		10.1038/sj.onc.1208884	http://dx.doi.org/10.1038/sj.onc.1208884			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982FA	16027732				2022-12-17	WOS:000233142100002
J	Kim, EH; Kim, HS; Kim, SU; Noh, EJ; Lee, JS; Choi, KS				Kim, EH; Kim, HS; Kim, SU; Noh, EJ; Lee, JS; Choi, KS			Sodium butyrate sensitizes human glioma cells to TRAIL-mediated apoptosis through inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP	ONCOGENE			English	Article						TRAIL; sodium butyrate; apoptosis; glioma	HISTONE DEACETYLASE INHIBITORS; X-LINKED INHIBITOR; COLON-CANCER CELLS; LIGAND TRAIL; ANTITUMOR-ACTIVITY; EPITHELIAL-CELLS; DEATH RECEPTORS; TRICHOSTATIN-A; LEUKEMIA-CELLS; TUMOR-CELLS	In TNF-related apoptosis-inducing ligand (TRAIL)-resistant glioma cells, co-treatment with nontoxic doses of sodium butyrate and TRAIL resulted in a marked increase of TRAIL-induced apoptosis. This combined treatment was also cytotoxic to glioma cells overexpressing Bcl-2 or Bcl-xL, but not to normal human astrocytes, thus offering an attractive strategy for safely treating resistant gliomas. Cotreatment with sodium butyrate facilitated completion of proteolytic processing of procaspase-3 that was partially blocked by treatment with TRAIL alone. We also found that treatment with sodium butyrate significantly decreased the protein levels of survivin and X-linked inhibitor of apoptosis protein (XIAP), two major caspase inhibitors. Overexpression of survivin and XIAP attenuated sodium butyratestimulated TRAIL-induced apoptosis, suggesting its involvement in conferring TRAIL resistance to glioma cells. Furthermore, the kinase activities of Cdc2 and Cdk2 were significantly decreased following sodium butyrate treatment, accompanying downregulation of cyclin A and cyclin B, as well as upregulation of p21. Forced expression of Cdc2 plus cyclin B, but not Cdk2 plus cyclin A, attenuated sodium butyrate/TRAIL-induced apoptosis, overriding sodium butyrate-mediated downregulation of survivin and XIAP. Therefore, Cdc2-mediated downregulation of survivin and XIAP by sodium butyrate may contribute to the recovery of TRAIL sensitivity in glioma cells.	Ajou Univ, Sch Med, Inst Med Sci, Suwon 442749, South Korea; Ajou Univ, Sch Med, Brain Dis Res Ctr, Suwon 442749, South Korea; Univ British Columbia, UBC Hosp, Div Neurol, Vancouver, BC V5Z 1M9, Canada	Ajou University; Ajou University; University of British Columbia	Choi, KS (corresponding author), Ajou Univ, Sch Med, Inst Med Sci, San 5,Wonchon Dong, Suwon 442749, South Korea.	kschoi@ajou.ac.kr	Kim, Eunhee/AAK-3650-2020; Kim, Eunhee/Q-9162-2016	Kim, Eunhee/0000-0001-7143-7769; Choi, Kyeong Sook/0000-0003-2331-0856				Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Atadja P, 2004, CANCER RES, V64, P689, DOI 10.1158/0008-5472.CAN-03-2043; Bernhard D, 1999, FASEB J, V13, P1991, DOI 10.1096/fasebj.13.14.1991; Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; Brugarolas J, 1999, P NATL ACAD SCI USA, V96, P1002, DOI 10.1073/pnas.96.3.1002; Chakravarti A, 2002, J CLIN ONCOL, V20, P1063, DOI 10.1200/JCO.20.4.1063; Chen JS, 2003, CURR CANCER DRUG TAR, V3, P219, DOI 10.2174/1568009033481994; Chopin V, 2004, EXP CELL RES, V298, P560, DOI 10.1016/j.yexcr.2004.04.038; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Gui CY, 2004, P NATL ACAD SCI USA, V101, P1241, DOI 10.1073/pnas.0307708100; Guo F, 2004, CANCER RES, V64, P2580, DOI 10.1158/0008-5472.CAN-03-2629; Han ZY, 1997, J BIOL CHEM, V272, P13432, DOI 10.1074/jbc.272.20.13432; Heerdt BG, 1997, CELL GROWTH DIFFER, V8, P523; HEERDT BG, 1994, CANCER RES, V54, P3288; Hernandez A, 2001, SURGERY, V130, P265, DOI 10.1067/msy.2001.115897; Huang DCS, 1997, ONCOGENE, V14, P405, DOI 10.1038/sj.onc.1200848; Ito N, 2001, NEUROSURGERY, V49, P430, DOI 10.1097/00006123-200108000-00031; Kamitani H, 2002, NEURO-ONCOLOGY, V4, P95, DOI 10.1093/neuonc/4.2.95; Katula KS, 1997, CELL GROWTH DIFFER, V8, P811; Kim EH, 2004, ONCOGENE, V23, P446, DOI 10.1038/sj.onc.1207025; KIM SU, 1986, J NEUROSCI RES, V15, P303, DOI 10.1002/jnr.490150303; KIM SU, 1985, J NEUROIMMUNOL, V8, P255, DOI 10.1016/S0165-5728(85)80066-7; Kim YH, 2004, CARCINOGENESIS, V25, P1813, DOI 10.1093/carcin/bgh188; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Knight MJ, 2001, ONCOGENE, V20, P5789, DOI 10.1038/sj.onc.1204810; Kobayashi K, 1999, P NATL ACAD SCI USA, V96, P1457, DOI 10.1073/pnas.96.4.1457; Kramer A, 1997, CANCER RES, V57, P5117; KRUH J, 1982, MOL CELL BIOCHEM, V42, P65; Legler JM, 1999, JNCI-J NATL CANCER I, V91, P1382, DOI 10.1093/jnci/91.16.1382; Lipinski CA, 2003, MOL CANCER RES, V1, P323; Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010; Misra A, 2000, J NEURO-ONCOL, V48, P1, DOI 10.1023/A:1006435201961; Nair AR, 2001, CANCER LETT, V166, P55, DOI 10.1016/S0304-3835(01)00418-9; Nakata S, 2004, ONCOGENE, V23, P6261, DOI 10.1038/sj.onc.1207830; Neuzil H, 2004, BIOCHEM BIOPH RES CO, V314, P186, DOI 10.1016/j.bbrc.2003.12.074; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nomura T, 2003, UROL RES, V31, P37, DOI 10.1007/s00240-003-0300-y; Pellizzaro C, 2001, INT J CANCER, V91, P654, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1117>3.0.CO;2-I; Piekarz R, 2004, CURR PHARM DESIGN, V10, P2289, DOI 10.2174/1381612043383980; Rokudai S, 2000, J CELL PHYSIOL, V182, P290, DOI 10.1002/(SICI)1097-4652(200002)182:2<290::AID-JCP18>3.0.CO;2-8; Rosato RR, 2003, MOL CANCER THER, V2, P1273; Sawa Hiroki, 2002, Brain Tumor Pathol, V19, P77, DOI 10.1007/BF02478931; Seol DW, 2001, CANCER RES, V61, P1138; Shankar S, 2004, DRUG RESIST UPDATE, V7, P139, DOI 10.1016/j.drup.2004.03.002; Siavoshian S, 2000, GUT, V46, P507, DOI 10.1136/gut.46.4.507; Suliman A, 2001, ONCOGENE, V20, P2122, DOI 10.1038/sj.onc.1204282; Sun XM, 2002, J BIOL CHEM, V277, P11345, DOI 10.1074/jbc.M109893200; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; TEWARI M, 1995, J BIOL CHEM, V270, P18738, DOI 10.1074/jbc.270.32.18738; Vigushin DM, 2001, CLIN CANCER RES, V7, P971; Vigushin DM, 2002, ANTI-CANCER DRUG, V13, P1, DOI 10.1097/00001813-200201000-00001; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yokota T, 2004, ONCOGENE, V23, P5340, DOI 10.1038/sj.onc.1207689; Zaffaroni N, 2002, DRUG RESIST UPDATE, V5, P65, DOI 10.1016/S1368-7646(02)00049-3; Zhang XD, 2003, BIOCHEM PHARMACOL, V66, P1537, DOI 10.1016/S0006-2952(03)00509-4; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	60	66	70	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2005	24	46					6877	6889		10.1038/sj.onc.1208851	http://dx.doi.org/10.1038/sj.onc.1208851			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	975ZD	16007142				2022-12-17	WOS:000232701700003
J	Yang, HL; Zhao, RY; Yang, HY; Lee, MH				Yang, HL; Zhao, RY; Yang, HY; Lee, MH			Constitutively active FOXO4 inhibits Akt activity, regulates p27 Kip1 stability, and suppresses HER2-mediated tumorigenicity	ONCOGENE			English	Article						FOXO; Akt; p27; HER2	FORKHEAD TRANSCRIPTION FACTORS; CELL-CYCLE PROGRESSION; PROTEIN-KINASE-B; GENE-EXPRESSION; CYTOPLASMIC LOCALIZATION; ACUTE LEUKEMIAS; BREAST-CANCER; P27(KIP1); GROWTH; PHOSPHORYLATION	The FOXO family of Forkhead transcription factors, regulated by the phosphoinositide-3-kinase-Akt pathway, is involved in cell cycle regulation and apoptosis. Strong expression of HER2, a receptor tyrosine kinase oncogene, in cancers has been associated with a poor prognosis. Recently, FOXO4 was shown to regulate the transcription of the cyclin-dependent kinase inhibitor p27 Kip1 gene directly. Also, we have shown that HER2 promotes mitogenic growth and transformation of cancer cells by downregulation of p27 Kip1. Given the fact that FOXO4 mediates p27 transcription, we hypothesize that an Akt phosphorylation mutant of FOXO4 ( FOXO4A3), which maintains the activity to transactivate p27 Kip1, may be used as an anticancer agent for HER2-overexpressing cancers. Here, we applied the FOXO4 gene as a novel anticancer agent for HER2-overexpressing cells under the control of a tetracycline (tet)-regulated gene expression system. Overexpression of FOXO4A3 inhibits HER2-activated cell growth. We found that FOXO4A3 inhibited the kinase activity of protein kinase B/Akt and reversed HER2-mediated p27 mislocation in the cytoplasm. FOXO4A3 expression also led to decreased levels of CSN5, a protein involved in p27 degradation. These data suggest that FOXO4A3 also can regulate p27 post-transcriptionally. In addition, we found that FOXO4A3 sensitized cells to apoptosis induced by the chemotherapeutic agent 2-methoxyestradiol. Most significantly for clinical application, FOXO4A3 expression in HER2-overexpressing cells can be regulated in vivo and reduces the tumor volume in a tumor model. These findings indicate the applicability of employing FOXO4 regulation as a therapeutic intervention in HER2-overexpressing cancers.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Programs Genes & Dev, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Programs Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas System	Lee, MH (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd,Box 79, Houston, TX 77030 USA.	mhlee@mdanderson.org		Lee, Mong-Hong/0000-0001-8675-8215	NATIONAL CANCER INSTITUTE [R01CA089266, R56CA089266] Funding Source: NIH RePORTER; NCI NIH HHS [R56 CA089266, R01 CA089266, R01CA 089266] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alvarez B, 2001, NATURE, V413, P744, DOI 10.1038/35099574; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; Chamovitz DA, 2001, EMBO REP, V2, P96, DOI 10.1093/embo-reports/kve028; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; CORRAL J, 1993, P NATL ACAD SCI USA, V90, P8538, DOI 10.1073/pnas.90.18.8538; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Cunningham MA, 2004, MOL ENDOCRINOL, V18, P1756, DOI 10.1210/me.2004-0071; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; Kouvaraki MA, 2003, CANCER RES, V63, P2977; Laronga C, 2000, J BIOL CHEM, V275, P23106, DOI 10.1074/jbc.M905616199; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; MILLER SJ, 1995, ONCOL REP, V2, P497; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Rassidakis GZ, 2003, CLIN CANCER RES, V9, P1121; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Scheidler S, 1996, P NATL ACAD SCI USA, V93, P9805, DOI 10.1073/pnas.93.18.9805; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TANG TT, 2003, J BIOL CHEM, V21, P21; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; TRAN H, 2003, SCI STKE, pRE5, DOI DOI 10.1126/STKE.2003.172.RE5; Wei N, 1998, CURR BIOL, V8, P919, DOI 10.1016/S0960-9822(07)00372-7; Yang HY, 2000, J BIOL CHEM, V275, P24735, DOI 10.1074/jbc.C000147200; Yang HY, 2003, MOL CELL BIOL, V23, P7096, DOI 10.1128/MCB.23.20.7096-7107.2003; Yang HY, 2001, ONCOGENE, V20, P3695, DOI 10.1038/sj.onc.1204472; Zhang L, 2003, J BIOL CHEM, V278, P27, DOI 10.1074/jbc.M205424200; Zhang YJ, 2004, ONCOGENE, V23, P7132, DOI 10.1038/sj.onc.1207918; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	44	66	77	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2005	24	11					1924	1935		10.1038/sj.onc.1208352	http://dx.doi.org/10.1038/sj.onc.1208352			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	905BH	15688030				2022-12-17	WOS:000227542000011
J	Seeburg, DP; Morgan, DP; Sheng, M				Seeburg, DP; Morgan, DP; Sheng, M			Polo-like kinases in the nervous system	ONCOGENE			English	Article						SNK; Plk2; SPAR; immediate-early genes; spines	ANAPHASE-PROMOTING COMPLEX; INDUCIBLE PROTEIN-KINASE; INTEGRIN-BINDING PROTEIN; CELL-CYCLE; DNA-DAMAGE; BOX DOMAIN; SYNAPTIC PLASTICITY; GOLGI FRAGMENTATION; MESSENGER-RNA; MEIOSIS-I	Polo like kinases (Plks) are key regulators of the cell cycle, but little is known about their functions in postmitotic cells such as neurons. Recent findings indicate that Plk2 and Plk3 are dynamically regulated in neurons by synaptic activity at the mRNA and protein levels. In COS cells, Plk2 and Plk3 interact with spine-associated Rap guanosine triphosphatase-activating protein (SPAR), a regulator of actin dynamics and dendritic spine morphology, leading to its degradation through the ubiquitin-proteasome system. Induction of Plk2 in hippocampal neurons eliminates SPAR protein, depletes a core postsynaptic scaffolding molecule (PSD-95), and causes loss of mature dendritic spines and synapses. These findings implicate neuronal Plks as mediators of activity dependent change in molecular composition and morphology of synapses. Induction of Plks might provide a homeostatic mechanism for global dampening of synaptic strength following heightened neuronal activity ('synaptic scaling'). Synapse-specific actions of induced Plks are also possible, particularly in light of the discovery of phosphoserine/threonine peptide motifs as binding targets of the polo box domain, which could allow for 'priming' phosphorylation by upstream kinases that could 'tag' Plk substrates only in specific synapses.	MIT, Picower Ctr Learning & Mem, RIKEN MIT Neurosci Res Ctr, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); RIKEN	Sheng, M (corresponding author), MIT, Picower Ctr Learning & Mem, RIKEN MIT Neurosci Res Ctr, Howard Hughes Med Inst, 77 Massachusetts Ave,E18-215, Cambridge, MA 02139 USA.	msheng@mit.edu		Sheng, Morgan/0000-0002-8703-5366				Avides MD, 2001, NAT CELL BIOL, V3, P421, DOI 10.1038/35070110; Bahassi ELM, 2004, ONCOGENE, V23, P2658, DOI 10.1038/sj.onc.1207425; Bahassi EM, 2002, ONCOGENE, V21, P6633, DOI 10.1038/sj.onc.1205850; Bi GQ, 2001, ANNU REV NEUROSCI, V24, P139, DOI 10.1146/annurev.neuro.24.1.139; Bin OY, 1999, ONCOGENE, V18, P6029, DOI 10.1038/sj.onc.1202983; Bin OY, 1997, J BIOL CHEM, V272, P28646, DOI 10.1074/jbc.272.45.28646; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Blagden SP, 2003, NAT CELL BIOL, V5, P505, DOI 10.1038/ncb0603-505; Bozon B, 2003, PHILOS T R SOC B, V358, P805, DOI 10.1098/rstb.2002.1224; Burrone J, 2003, CURR OPIN NEUROBIOL, V13, P560, DOI 10.1016/j.conb.2003.09.007; Carmena M, 1998, J CELL BIOL, V143, P659, DOI 10.1083/jcb.143.3.659; Clyne RK, 2003, NAT CELL BIOL, V5, P480, DOI 10.1038/ncb977; Colanzi A, 2003, CURR OPIN CELL BIOL, V15, P462, DOI 10.1016/S0955-0674(03)00067-X; Conn CW, 2000, CANCER RES, V60, P6826; Dai W, 2002, ONCOGENE, V21, P6195, DOI 10.1038/sj.onc.1205710; El-Hussein AE, 2000, SCIENCE, V290, P1364; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; FREY U, 1988, BRAIN RES, V452, P57, DOI 10.1016/0006-8993(88)90008-X; Gieffers C, 1999, P NATL ACAD SCI USA, V96, P11317, DOI 10.1073/pnas.96.20.11317; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Golan A, 2002, J BIOL CHEM, V277, P15552, DOI 10.1074/jbc.M111476200; Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; Hering H, 2001, NAT REV NEUROSCI, V2, P880, DOI 10.1038/35104061; Hevroni D, 1998, J MOL NEUROSCI, V10, P75, DOI 10.1007/BF02737120; Holtrich U, 2000, ONCOGENE, V19, P4832, DOI 10.1038/sj.onc.1203845; Huang YS, 2002, EMBO J, V21, P2139, DOI 10.1093/emboj/21.9.2139; Izquierdo LA, 2002, CELL MOL NEUROBIOL, V22, P269, DOI 10.1023/A:1020715800956; Kauselmann G, 1999, EMBO J, V18, P5528, DOI 10.1093/emboj/18.20.5528; Kho PS, 2004, J BIOL CHEM, V279, P21183, DOI 10.1074/jbc.M311912200; Kim EJ, 2004, NAT REV NEUROSCI, V5, P771, DOI 10.1038/nrn1517; Konishi Y, 2004, SCIENCE, V303, P1026, DOI 10.1126/science.1093712; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Kraft C, 2003, EMBO J, V22, P6598, DOI 10.1093/emboj/cdg627; Kramer D, 2003, MOL CELL NEUROSCI, V23, P325, DOI 10.1016/S1044-7431(03)00057-5; Lanahan A, 1998, NEUROBIOL LEARN MEM, V70, P37, DOI 10.1006/nlme.1998.3836; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Lee BH, 2003, SCIENCE, V300, P482, DOI 10.1126/science.1081846; Lee KS, 1998, P NATL ACAD SCI USA, V95, P9301, DOI 10.1073/pnas.95.16.9301; Lee M, 2004, ONCOGENE, V23, P865, DOI 10.1038/sj.onc.1207223; Lin CY, 2000, P NATL ACAD SCI USA, V97, P12589, DOI 10.1073/pnas.220423497; Litvak V, 2004, MOL CELL, V14, P319, DOI 10.1016/S1097-2765(04)00214-X; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; Lowery DM, 2004, CELL CYCLE, V3, P128; Ma S, 2003, MOL CELL BIOL, V23, P6936, DOI 10.1128/MCB.23.19.6936-6943.2003; Ma S, 2003, MOL CANCER RES, V1, P376; Martin KC, 2002, NEUROBIOL LEARN MEM, V78, P489, DOI 10.1006/nlme.2002.4088; Martin KC, 2002, NAT REV NEUROSCI, V3, P813, DOI 10.1038/nrn942; May KM, 2002, J CELL BIOL, V156, P23, DOI 10.1083/jcb.200106150; McLeod SJ, 2004, J BIOL CHEM, V279, P12009, DOI 10.1074/jbc.M313098200; Miller KD, 1996, NEURON, V17, P371, DOI 10.1016/S0896-6273(00)80169-5; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; Nedivi E, 1999, J NEUROBIOL, V41, P135, DOI 10.1002/(SICI)1097-4695(199910)41:1<135::AID-NEU17>3.0.CO;2-F; Neef R, 2003, J CELL BIOL, V162, P863, DOI 10.1083/jcb.200306009; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; Pak DTS, 2001, NEURON, V31, P289, DOI 10.1016/S0896-6273(01)00355-5; Pak DTS, 2003, SCIENCE, V302, P1368, DOI 10.1126/science.1082475; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Ree AH, 2003, ONCOGENE, V22, P8952, DOI 10.1038/sj.onc.1207000; Reynolds N, 2003, J CELL SCI, V116, P1377, DOI 10.1242/jcs.00314; Roshak AK, 2000, CELL SIGNAL, V12, P405, DOI 10.1016/S0898-6568(00)00080-2; Roy BC, 2002, GENES CELLS, V7, P607; Ruan Q, 2004, EXP CELL RES, V294, P51, DOI 10.1016/j.yexcr.2003.10.022; Seong YS, 2002, J BIOL CHEM, V277, P32282, DOI 10.1074/jbc.M202602200; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Song SG, 2001, J CELL BIOL, V152, P451, DOI 10.1083/jcb.152.3.451; Steward O, 2001, ANNU REV NEUROSCI, V24, P299, DOI 10.1146/annurev.neuro.24.1.299; Sumara I, 2002, MOL CELL, V9, P515, DOI 10.1016/S1097-2765(02)00473-2; SUNKEL CE, 1988, J CELL SCI, V89, P25; Sutterlin C, 2001, P NATL ACAD SCI USA, V98, P9128, DOI 10.1073/pnas.161283998; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Theis M, 2003, P NATL ACAD SCI USA, V100, P9602, DOI 10.1073/pnas.1133424100; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; Turrigiano GG, 2004, NAT REV NEUROSCI, V5, P97, DOI 10.1038/nrn1327; Turrigiano GG, 2000, CURR OPIN NEUROBIOL, V10, P358, DOI 10.1016/S0959-4388(00)00091-X; van Vugt MATM, 2001, J BIOL CHEM, V276, P41656, DOI 10.1074/jbc.M101831200; Wang Q, 2002, MOL CELL BIOL, V22, P3450, DOI 10.1128/MCB.22.10.3450-3459.2002; Watanabe N, 2004, P NATL ACAD SCI USA, V101, P4419, DOI 10.1073/pnas.0307700101; Xie SQ, 2004, ONCOGENE, V23, P3822, DOI 10.1038/sj.onc.1207479; Xie SQ, 2001, J BIOL CHEM, V276, P36194, DOI 10.1074/jbc.M104157200; Xie SQ, 2002, CELL CYCLE, V1, P424, DOI 10.4161/cc.1.6.271; Yarm FR, 2002, MOL CELL BIOL, V22, P6209, DOI 10.1128/MCB.22.17.6209-6221.2002; Yoo HY, 2004, CELL, V117, P575, DOI 10.1016/S0092-8674(04)00417-9; Yuan JP, 2002, ONCOGENE, V21, P8282, DOI 10.1038/sj.onc.1206011; Zhou T, 2003, DEV CELL, V5, P127, DOI 10.1016/S1534-5807(03)00186-2	90	66	69	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2005	24	2					292	298		10.1038/sj.onc.1208277	http://dx.doi.org/10.1038/sj.onc.1208277			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	885UR	15640845				2022-12-17	WOS:000226183100010
J	Zhang, YW; Su, YL; Lanning, N; Gustafson, M; Shinomiya, N; Zhao, P; Cao, B; Tsarfaty, G; Wang, LM; Hay, R; Vande Woude, GF				Zhang, YW; Su, YL; Lanning, N; Gustafson, M; Shinomiya, N; Zhao, P; Cao, B; Tsarfaty, G; Wang, LM; Hay, R; Vande Woude, GF			Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor	ONCOGENE			English	Article						human HGF/SF; met; transgenic; SCID; tumor xenograft	SCATTER-FACTOR; ANTITUMOR-ACTIVITY; METASTASIS; MOTILITY; INVASION; CELLS; TUMORIGENICITY; NETWORK; MOUSE	Downstream signaling that results from the interaction of hepatocyte growth factor/scatter factor (HGF/SF) with the receptor tyrosine kinase Met plays critical roles in tumor development, progression, and metastasis. This ligand-receptor pair is an attractive target for new diagnostic and therapeutic agents, preclinical development of which requires suitable animal models. The growth of heterotopic and orthotopic Met-expressing human tumor xenografts in conventional strains of immunocompromised mice inadequately replicates the paracrine stimulation by human HGF/SF (hHGF/SF) that occurs in humans with cancer. We have therefore generated a mouse strain transgenic for hHGF/SF (designated hHGF-Tg) on a severe combined immunodeficiency (SCID) background. We report here that the presence of ectopically expressed hHGF/SF ligand significantly enhances growth of heterotopic subcutaneous xenografts derived from human Met-expressing cancer cells, including the lines SK-LMS-1 (human leiomyosarcoma), U118 (human glioblastoma), and DU145 (human prostate carcinoma), but not that of M14-Mel xenografts (human melanoma that expresses insignificant levels of Met). Our results indicate that ectopic hHGF/SF can specifically activate Met in human tumor xenografts. This new hHGF-Tg strain of mice should provide a powerful tool for evaluating drugs and diagnostic agents that target the various pathways influenced by Met activity.	Van Andel Res Inst, Mol Oncol Lab, Grand Rapids, MI 49503 USA; Van Andel Res Inst, Lab Antibody Technol, Grand Rapids, MI 49503 USA; Chaim Sheba Med Ctr, Tel Aviv, Israel; Vita Genom Inc, Taipei, Taiwan	Van Andel Institute; Van Andel Institute; Chaim Sheba Medical Center; Vita Genomics Incorporated	Vande Woude, GF (corresponding author), Van Andel Res Inst, Mol Oncol Lab, 333 Bostwick Ave NE, Grand Rapids, MI 49503 USA.	george.vandewoude@vai.org	Shinomiya, Nariyoshi/I-9666-2014; Lanning, Nathan/AAI-2532-2019	Lanning, Nathan/0000-0002-0983-7451				Abounader R, 2001, FASEB J, V15, P108, DOI 10.1096/fj.01-0421fje; Atabey N, 2001, J BIOL CHEM, V276, P14308, DOI 10.1074/jbc.M010202200; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BHARGAVA M, 1992, CELL GROWTH DIFFER, V3, P11; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; BOCK TA, 1995, J EXP MED, V182, P2037, DOI 10.1084/jem.182.6.2037; Cao B, 2001, P NATL ACAD SCI USA, V98, P7443, DOI 10.1073/pnas.131200498; Christensen JG, 2003, CANCER RES, V63, P7345; Date K, 1998, ONCOGENE, V17, P3045, DOI 10.1038/sj.onc.1202231; Gmyrek GA, 2001, AM J PATHOL, V159, P579, DOI 10.1016/S0002-9440(10)61729-4; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; Kerbel RS, 2003, CANCER BIOL THER, V2, pS134; Koochekpour S, 1997, CANCER RES, V57, P5391; MUELLER BM, 1991, CANCER METAST REV, V10, P193, DOI 10.1007/BF00050791; Qian CN, 2003, J UROLOGY, V170, P994, DOI 10.1097/01.ju.0000080321.99119.df; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; Sakata H, 1996, CELL GROWTH DIFFER, V7, P1513; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Webb CP, 2000, CANCER RES, V60, P342; Zhang YW, 2003, P NATL ACAD SCI USA, V100, P12718, DOI 10.1073/pnas.2135113100	21	66	71	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					101	106		10.1038/sj.onc.1208181	http://dx.doi.org/10.1038/sj.onc.1208181			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15531925				2022-12-17	WOS:000226125800012
J	Fulda, S; Jeremias, I; Debatin, KM				Fulda, S; Jeremias, I; Debatin, KM			Cooperation of betulinic acid and TRAIL to induce apoptosis in tumor cells	ONCOGENE			English	Article						apoptosis; TRAIL; betulinic acid; cancer resistance	IN-VIVO; DECOY RECEPTORS; HUMAN-MELANOMA; LIGAND TRAIL; CANCER; DEATH; SENSITIZATION; CYTOTOXICITY; CHEMOTHERAPY; IRRADIATION	We previously reported that the TRAIL ( tumor necrosis factor (TNF)-related apoptosis-inducinglig and)-induced death signal requires amplification by mitochondria in certain cell types, for example, in type II cells. Here, we provide for the first time evidence that the natural compound betulinic acid (BetA) cooperated with TRAIL to induce apoptosis in tumor cells. Through functional complementation, simultaneous stimulation of the death receptor pathway by TRAIL and the mitochondrial pathway by BetA resulted in complete activation of effector caspases, apoptosis and inhibition of clonogenic survival. BetA and TRAIL cooperated to trigger loss of mitochondrial membrane potential and release of cytochrome c and Smac from mitochondria. Also, combination treatment with BetA and TRAIL resulted in increased cleavage of caspase-8 and Bid indicating that activation of effector caspases may feed back in a positive amplification loop. Importantly, the combination treatment with BetA and TRAIL cooperated to induce apoptosis in different tumor cell lines and also in primary tumor cells, but not in normal human fibroblasts indicating some tumor specificity. Since most human cancers represent type II cells, triggering the mitochondrial pathway by BetA may be a novel approach to enhance the efficacy of TRAIL-based therapies, which warrants further investigation.	Univ Childrens Hosp, D-89075 Ulm, Germany; Dr von Haunersches Kinderspital, Dept Hematol Oncol, D-80337 Munich, Germany	Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich	Fulda, S (corresponding author), Univ Childrens Hosp, Prittwitzstr 43, D-89075 Ulm, Germany.	simone.fulda@medizin.uni-ulm.de	Jeremias, Irmela/Q-5934-2019; Jeremias, Irmela/C-6090-2015; Debatin, Klaus-Michael/J-9704-2014; Fulda, Simone/D-5864-2011	Jeremias, Irmela/0000-0003-1773-7677; Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417				Algeciras-Schimnich A, 2003, P NATL ACAD SCI USA, V100, P11445, DOI 10.1073/pnas.2034995100; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Fulda S, 1997, CANCER RES, V57, P4956; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Fulda S, 2004, CANCER RES, V64, P337, DOI 10.1158/0008-5472.CAN-03-1656; Fulda S, 1998, J BIOL CHEM, V273, P33942, DOI 10.1074/jbc.273.51.33942; Fulda S, 1998, KLIN PADIATR, V210, P148, DOI 10.1055/s-2008-1043870; Gliniak B, 1999, CANCER RES, V59, P6153; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Keane MM, 2000, BREAST CANCER RES TR, V64, P211, DOI 10.1023/A:1006458407515; Kim B, 2002, J BIOL CHEM, V277, P27393, DOI 10.1074/jbc.M201963200; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; Meng RD, 2001, EXP CELL RES, V262, P154, DOI 10.1006/excr.2000.5073; Nagane M, 2000, CANCER RES, V60, P847; Nitsch R, 2000, LANCET, V356, P827, DOI 10.1016/S0140-6736(00)02659-3; Peto J, 2001, NATURE, V411, P390, DOI 10.1038/35077256; PISHA E, 1995, NAT MED, V1, P1046, DOI 10.1038/nm1095-1046; Rohn TA, 2001, ONCOGENE, V20, P4128, DOI 10.1038/sj.onc.1204534; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Selzer E, 2000, J INVEST DERMATOL, V114, P935, DOI 10.1046/j.1523-1747.2000.00972.x; Stahnke K, 2003, LEUKEMIA, V17, P2130, DOI 10.1038/sj.leu.2403144; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; Zhang HG, 2004, ONCOGENE, V23, P2009, DOI 10.1038/sj.onc.1207373; Zuco V, 2002, CANCER LETT, V175, P17, DOI 10.1016/S0304-3835(01)00718-2	31	66	71	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 7	2004	23	46					7611	7620		10.1038/sj.onc.1207970	http://dx.doi.org/10.1038/sj.onc.1207970			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	859ZK	15361826				2022-12-17	WOS:000224306700002
J	Seidel, B; Braeg, S; Adler, G; Wedlich, D; Menke, A				Seidel, B; Braeg, S; Adler, G; Wedlich, D; Menke, A			E- and N-cadherin differ with respect to their associated p120(ctn) isoforms and their ability to suppress invasive growth in pancreatic cancer cells	ONCOGENE			English	Article						pancreatic cancer; E-cadherin; N-cadherin; p120(ctn) isoforms; tyrosine phosphorylation	MEMBRANE-PROXIMAL REGION; LYMPH-NODE METASTASIS; CYTOPLASMIC DOMAIN; P120 CATENIN; TYROSINE PHOSPHORYLATION; ADHESION ACTIVITY; ALPHA-CATENIN; BETA-CATENIN; V-SRC; DISTINCT MECHANISMS	E-cadherin functions as suppressor of invasion in epithelial cells and its loss is described in many invasive carcinomas. In some tumours, the disappearance of E-cadherin has been correlated with upregulation of other classical cadherins, such as N- or P-cadherin. To analyse the different cellular functions of cadherin molecules, we stably expressed E-cadherin or N-cadherin in the E- and N-cadherin-deficient pancreatic tumour cell line MIA PaCa-2. Only E-cadherin was able to induce a mesenchymal-epithelial transition and suppressed invasion of MIA PaCa-2 cells. Furthermore, only re-expression of E-cadherin resulted in an upregulation of alpha- and beta-catenin mRNAs and protein concentrations. Ectopically expressed N-cadherin failed to assemble cadherin/catenin Adhesion complexes and failed to inhibit invasion. Analysis of p12(ctn), which was associated with both cadherins, demonstrated that E-cadherin was linked to a shorter isoform of p120(ctn). In contrast, N-cadherin was associated with the long, 120 kDa p120(ctn) isoforms. In addition, p120(ctn) connected with N-cadherin was phosphorylated at tyrosine residues, whereas the isoform linked to E-cadherin was not phosphorylated. Thus, the differences between E- and N-cadherin in recruiting different phosphorylated isoforms of p120(ctn) to the membrane might be responsible for the inability of N-cadherin to replace E-cadherin as suppressor of invasion in pancreatic carcinoma cells.	Univ Ulm, Dept Internal Med 1, D-89081 Ulm, Germany; Univ Karlsruhe, Inst Zool 2, D-76131 Karlsruhe, Germany	Ulm University; Helmholtz Association; Karlsruhe Institute of Technology	Menke, A (corresponding author), Univ Ulm, Dept Internal Med 1, D-89081 Ulm, Germany.	andre.menke@medizin.uni-ulm.de						Aho S, 2002, J CELL SCI, V115, P1391; Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; Aono S, 1999, J CELL BIOL, V145, P551, DOI 10.1083/jcb.145.3.551; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Birchmeier C, 1996, ACTA ANAT, V156, P217; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Bruns Christiane J., 1999, Neoplasia (New York), V1, P50, DOI 10.1038/sj.neo.7900005; Chen HY, 1997, J CELL SCI, V110, P345; Christofori G, 2003, EMBO J, V22, P2318, DOI 10.1093/emboj/cdg228; Daniel JM, 1999, MOL CELL BIOL, V19, P3614; Finnemann S, 1997, J BIOL CHEM, V272, P11856, DOI 10.1074/jbc.272.18.11856; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Giehl K, 2000, ONCOGENE, V19, P2930, DOI 10.1038/sj.onc.1203612; Grosheva I, 2001, J CELL SCI, V114, P695; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; Hazan RB, 1996, CELL ADHES COMMUN, V4, P399, DOI 10.3109/15419069709004457; HERRENKNECHT K, 1991, P NATL ACAD SCI USA, V88, P9156, DOI 10.1073/pnas.88.20.9156; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Jaggi M, 2002, CELL COMMUN ADHES, V9, P103, DOI 10.1080/15419060214150; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Karayiannakis AJ, 2001, ANTICANCER RES, V21, P4127; Karayiannakis AJ, 1998, ANTICANCER RES, V18, P4177; Keilhack H, 2000, J BIOL CHEM, V275, P26376, DOI 10.1074/jbc.M001315200; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kern S, 2001, CANCER RES, V61, P4923; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; Lowy AM, 2002, SURGERY, V132, P141, DOI 10.1067/msy.2002.125168; Mareel M, 1997, J CELL PHYSIOL, V173, P271, DOI 10.1002/(SICI)1097-4652(199711)173:2<271::AID-JCP34>3.0.CO;2-G; Menke A, 2001, CANCER RES, V61, P3508; Menke A, 1997, GASTROENTEROLOGY, V113, P295, DOI 10.1016/S0016-5085(97)70107-0; Mo YY, 1996, CANCER RES, V56, P2633; Montonen O, 2001, J HISTOCHEM CYTOCHEM, V49, P1487, DOI 10.1177/002215540104901202; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; Navarro P, 1998, J CELL BIOL, V140, P1475, DOI 10.1083/jcb.140.6.1475; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; Ohkubo T, 1999, J BIOL CHEM, V274, P21409, DOI 10.1074/jbc.274.30.21409; Ozawa M, 2003, J BIOL CHEM, V278, P46014, DOI 10.1074/jbc.M307778200; Ozawa M, 2001, J CELL SCI, V114, P503; Ozawa M, 1998, J CELL BIOL, V142, P1605, DOI 10.1083/jcb.142.6.1605; OZAWA M, 1990, J CELL BIOL, V111, P1645, DOI 10.1083/jcb.111.4.1645; Papkoff J, 1997, J BIOL CHEM, V272, P4536; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Piedra J, 2003, MOL CELL BIOL, V23, P2287, DOI 10.1128/MCB.23.7.2287-2297.2003; PIGNATELLI M, 1994, J PATHOL, V174, P243, DOI 10.1002/path.1711740403; POSTON GJ, 1991, GUT, V32, P800, DOI 10.1136/gut.32.7.800; RASBRIDGE SA, 1993, J PATHOL, V169, P245, DOI 10.1002/path.1711690211; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; SCHIPPER JH, 1991, CANCER RES, V51, P6328; SHIBAMOTO S, 1995, J CELL BIOL, V128, P949, DOI 10.1083/jcb.128.5.949; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Tran NL, 1999, AM J PATHOL, V155, P787, DOI 10.1016/S0002-9440(10)65177-2; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Weinel RJ, 1996, INT J PANCREATOL, V19, P25; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779; Yap AS, 2003, J CELL BIOL, V160, P11, DOI 10.1083/jcb.200208156	60	66	70	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5532	5542		10.1038/sj.onc.1207718	http://dx.doi.org/10.1038/sj.onc.1207718			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15107817				2022-12-17	WOS:000222588400013
J	Heroult, M; Bernard-Pierrot, I; Delbe, J; Hamma-Kourbali, Y; Katsoris, M; Barritault, D; Papadimitriou, E; Plouet, J; Courty, J				Heroult, M; Bernard-Pierrot, I; Delbe, J; Hamma-Kourbali, Y; Katsoris, M; Barritault, D; Papadimitriou, E; Plouet, J; Courty, J			Heparin affin regulatory peptide binds to vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis	ONCOGENE			English	Article						HARP; angiogenesis; VEGF; inhibition	MELANOMA CELL-ADHESION; FACTOR GENE-EXPRESSION; C-TERMINAL PEPTIDES; IN-VITRO; THERAPEUTIC IMPLICATIONS; POTENT INHIBITOR; TUBE FORMATION; TUMOR-GROWTH; PLEIOTROPHIN; HARP	Heparin affin regulatory peptide (HARP) is an heparin-binding molecule involved in the regulation of cell proliferation and differentiation. Here, we report that HARP inhibited the biological activity induced by the 165-amino-acid form of vascular endothelial growth factor (VEGF(165)) on human umbilical vein endothelial cells. Endothelial-cell proliferation induced by VEGF(165) showed about 50% inhibition in the presence of HARP in a concentration of 3 nM. In similar range of concentrations, HARP blocked tube formation induced by VEGF(165) in three-dimensional angiogenesis assay. In vivo studies showed that HARP inhibited the VEGF(165)-induced Matrigel(TM) infiltration of endothelial cells. We then investigated the mechanisms of this inhibition and shown that HARP inhibited the binding of I-125-VEGF(165) to the VEGF receptors of endothelial cells. Additional studies using VEGF soluble receptors indicated that binding of I-125-VEGF(165) to kinase insert domain-containing receptor and neuropilin receptor was inhibited by HARP, but conversely the binding of I-125-VEGF(165) to fms-like tyrosine kinase I receptor was unaffected. A competitive affinity-binding assay demonstrated that HARP interacted directly with VEGF(165) with a dissociation coefficient of 1.38 nM. Binding assay using deletion mutants of HARP revealed that the thrombospondin type-1 repeats domains were involved in this interaction. These data demonstrate for the first time that the angiogenic factor HARP can also negatively regulates the angiogenic activity of VEGF(165).	Univ Paris 12, Lab Rech Croissance Cellulaire Reaparat & Regener, FRE 2412, CNRS, F-94010 Ceteil, France; Univ Patras, Dept Biol, Div Genet Cell & Dev Biol, GR-26504 Patras, Greece; Univ Patras, Mol Pharmacol Lab, Dept Pharm, GR-26504 Patras, Greece; CNRS, Lab Biol Mol Eucaryote, UPR 9006, F-31062 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); University of Patras; University of Patras; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Courty, J (corresponding author), Univ Paris 12, Lab Rech Croissance Cellulaire Reaparat & Regener, FRE 2412, CNRS, Ave Gen de Gaulle, F-94010 Ceteil, France.	courty@univ-paris12.f	Papadimitriou, Evangelia/ABG-1356-2020; Delbe, Jean/R-3680-2018; Courty, Jose/Q-3702-2018; Papadimitriou, Evangelia/F-3396-2010	Papadimitriou, Evangelia/0000-0001-6429-4325; 				Bernard-Pierrot I, 2002, J BIOL CHEM, V277, P32071, DOI 10.1074/jbc.M202747200; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Brigstock DR, 1997, J BIOL CHEM, V272, P20275, DOI 10.1074/jbc.272.32.20275; Choudhuri R, 1997, CANCER RES, V57, P1814; CLAPP C, 1993, ENDOCRINOLOGY, V133, P1292, DOI 10.1210/en.133.3.1292; COURTY J, 1991, BIOCHEM BIOPH RES CO, V180, P145, DOI 10.1016/S0006-291X(05)81267-7; Cross MJ, 2001, TRENDS PHARMACOL SCI, V22, P201, DOI 10.1016/S0165-6147(00)01676-X; Delbe J, 1999, PATHOL BIOL, V47, P352; FANG WJ, 1992, J BIOL CHEM, V267, P25889; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GUO NH, 1992, J BIOL CHEM, V267, P19349; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; GUPTA SK, 1995, P NATL ACAD SCI USA, V92, P7799, DOI 10.1073/pnas.92.17.7799; Igarashi A, 1996, J INVEST DERMATOL, V106, P729, DOI 10.1111/1523-1747.ep12345771; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; Inoki I, 2001, FASEB J, V15, P219, DOI 10.1096/fj.01-0332fje; Iruela-Arispe ML, 1999, CIRCULATION, V100, P1423, DOI 10.1161/01.CIR.100.13.1423; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Kilpelainen I, 2000, J BIOL CHEM, V275, P13564, DOI 10.1074/jbc.275.18.13564; LAAROUBI K, 1994, GROWTH FACTORS, V10, P89, DOI 10.3109/08977199409010982; Lao YH, 2001, INT J BIOCHEM CELL B, V33, P357, DOI 10.1016/S1357-2725(01)00023-1; Ledoux D, 1997, J HISTOCHEM CYTOCHEM, V45, P1239, DOI 10.1177/002215549704500907; MAIONE TE, 1991, CANCER RES, V51, P2077; Milhiet PE, 1998, J ENDOCRINOL, V158, P389, DOI 10.1677/joe.0.1580389; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P543; MYERS EW, 1988, COMPUT APPL BIOSCI, V4, P11, DOI 10.1093/bioinformatics/4.1.11; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Papadimitriou E, 2001, BIOCHEM BIOPH RES CO, V282, P306, DOI 10.1006/bbrc.2001.4574; Papadimitriou E, 2000, BIOCHEM BIOPH RES CO, V274, P242, DOI 10.1006/bbrc.2000.3126; Pipili-Synetos E, 1998, BRIT J PHARMACOL, V125, P1252, DOI 10.1038/sj.bjp.0702191; PLOUET J, 1990, J BIOL CHEM, V265, P22071; Plouet J, 1997, J BIOL CHEM, V272, P13390, DOI 10.1074/jbc.272.20.13390; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; Rauvala H, 2000, MATRIX BIOL, V19, P377, DOI 10.1016/S0945-053X(00)00084-6; RAUVALA H, 1989, EMBO J, V8, P2933, DOI 10.1002/j.1460-2075.1989.tb08443.x; Robinson CJ, 2001, J CELL SCI, V114, P853; SEDDON AP, 1994, PROTEIN EXPRES PURIF, V5, P14, DOI 10.1006/prep.1994.1002; Shimo T, 1999, J BIOCHEM-TOKYO, V126, P137, DOI 10.1093/oxfordjournals.jbchem.a022414; Shimo T, 1998, J BIOCHEM-TOKYO, V124, P130, DOI 10.1093/oxfordjournals.jbchem.a022071; Souttou B, 2001, J CELL PHYSIOL, V187, P59, DOI 10.1002/1097-4652(2001)9999:9999<00::AID-JCP1051>3.0.CO;2-F; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; Tomanek RJ, 2000, ANAT RECORD, V261, P126, DOI 10.1002/1097-0185(20000615)261:3<126::AID-AR7>3.0.CO;2-4; Vacherot F, 1999, PROSTATE, V38, P126, DOI 10.1002/(SICI)1097-0045(19990201)38:2<126::AID-PROS6>3.0.CO;2-C	49	66	68	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2004	23	9					1745	1753		10.1038/sj.onc.1206879	http://dx.doi.org/10.1038/sj.onc.1206879			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	800LH	15001987				2022-12-17	WOS:000220029300010
J	Fukuhara, H; Masvuda, M; Yageta, M; Fukami, T; Kuramochi, M; Maruyama, T; Kitamura, T; Murakami, Y				Fukuhara, H; Masvuda, M; Yageta, M; Fukami, T; Kuramochi, M; Maruyama, T; Kitamura, T; Murakami, Y			Association of a lung tumor suppressor TSLC1 with MPP3, a human homologue of Drosophila tumor suppressor Dlg	ONCOGENE			English	Article						tumor suppressor gene; lung cancer; TSLC1; MPP3; discs large	SEPTATE JUNCTIONS; BINDING INTERFACE; GLYCOPHORIN-C; PDZ DOMAINS; GENE; CANCER; PROTEIN; PROMOTER; FAMILY; HYPERMETHYLATION	We have previously identified the tumor suppressor in lung cancer 1 (TSLC1) gene as a novel tumor suppressor in human non-small cell lung cancer (NSCLC) by functional complementation. TSLC1 encodes a membrane glycoprotein belonging to an immunoglobulin superfamily and participates in cell adhesion. A truncating mutation of the TSLC1 corresponding to its cytoplasmic domain in a primary NSCLC tumor suggests that this domain is important for tumor suppressor activity. Here, we report that TSLC1 directly associates with MPP3, one of the human homologues of a Drosophila tumor suppressor gene, Discs large (Dlg). This interaction was dependent on the presence of a PDZ-binding motif at the carboxyl terminus of TSLC1. Furthermore, TSLC1 and MPP3 were colocalized at the cell - cell attachment sites in both a low and a high cell density. The MPP3 gene was expressed in normal lung as well as in many tissues examined except for peripheral blood lymphocytes but lost its expression in one of the nine NSCLC cell lines. These results suggest that TSLC1 and MPP3 are involved in the same cascade of cell - cell interaction, and that the disruption of this cascade might lead cells to malignant growth and tumor formation in lung cancer.	Natl Canc Ctr, Res Inst, Tumor Suppress & Funct Genom Project, Chuo Ku, Tokyo 1040045, Japan; Univ Tokyo, Sch Med, Dept Urol, Bunkyo Ku, Tokyo 1138655, Japan	National Cancer Center - Japan; University of Tokyo	Murakami, Y (corresponding author), Natl Canc Ctr, Res Inst, Tumor Suppress & Funct Genom Project, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	ymurakam@gan2.res.ncc.go.jp	Sakurai-Yageta, Mika/U-1842-2019	Sakurai-Yageta, Mika/0000-0001-5606-3324				Allinen M, 2002, GENE CHROMOSOME CANC, V34, P384, DOI 10.1002/gcc.10079; Baumgartner S, 1996, CELL, V87, P1059, DOI 10.1016/S0092-8674(00)81800-0; Bellaiche Y, 2001, CELL, V106, P355, DOI 10.1016/S0092-8674(01)00444-5; BRYANT PJ, 1990, J CELL SCI, P169; FEHON RG, 1994, DEVELOPMENT, V120, P545; FONG KM, 1995, CANCER RES, V55, P4268; Fukami T, 2002, GENE, V295, P7, DOI 10.1016/S0378-1119(02)00835-1; Fukuhara H, 2002, JPN J CANCER RES, V93, P605, DOI 10.1111/j.1349-7006.2002.tb01297.x; Fukuhara H, 2001, ONCOGENE, V20, P5401, DOI 10.1038/sj.onc.1204696; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; GOLEMIS EA, 1996, CURRENT PROTOCOLS MO; Gomyo H, 1999, GENOMICS, V62, P139, DOI 10.1006/geno.1999.6001; Harris BZ, 2001, J CELL SCI, V114, P3219; Honda T, 2002, JPN J CANCER RES, V93, P857, DOI 10.1111/j.1349-7006.2002.tb01329.x; James P, 1996, GENETICS, V144, P1425; Jansen M, 2002, CANCER BIOL THER, V1, P293, DOI 10.4161/cbt.84; Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934; Marfatia SM, 1997, J BIOL CHEM, V272, P24191, DOI 10.1074/jbc.272.39.24191; MARFATIA SM, 1995, J BIOL CHEM, V270, P715, DOI 10.1074/jbc.270.2.715; Masuda M, 2002, J BIOL CHEM, V277, P31014, DOI 10.1074/jbc.M203620200; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Murakami Y, 2002, ONCOGENE, V21, P6936, DOI 10.1038/sj.onc.1205825; Ohshiro T, 2000, NATURE, V408, P593, DOI 10.1038/35046087; Peng CY, 2000, NATURE, V408, P596, DOI 10.1038/35046094; Smith SA, 1996, GENOMICS, V31, P145, DOI 10.1006/geno.1996.0025; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Yageta M, 2002, CANCER RES, V62, P5129	29	66	75	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2003	22	40					6160	6165		10.1038/sj.onc.1206744	http://dx.doi.org/10.1038/sj.onc.1206744			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679854				2022-12-17	WOS:000185506200005
J	Jin, BF; He, K; Wang, HX; Wang, J; Zhou, T; Lan, Y; Hu, MR; Wei, KH; Yang, SC; Shen, BF; Zhang, XM				Jin, BF; He, K; Wang, HX; Wang, J; Zhou, T; Lan, Y; Hu, MR; Wei, KH; Yang, SC; Shen, BF; Zhang, XM			Proteomic analysis of ubiquitin-proteasome effects: insight into the function of eukaryotic initiation factor 5A	ONCOGENE			English	Article						proteomics; ubiquitin-proteasome; matrix-assisted laser desorption/ionization time-of-flight mass spectrometry; apoptosis; leukemic cell	HYPUSINE MODIFICATION; CELL-PROLIFERATION; APOPTOSIS; PROTEINS; EIF-5A; PHOSPHORYLATION; PATHWAY; RNA; DEOXYHYPUSINE; LOCALIZATION	The global effect of ubiquitin-proteasome (UP) inhibitors on leukemic cell proteome was analysed. A total of 39 protein spots, affected by UP inhibitors, were identified, including 11 new apoptosis-associated proteins. They are involved in different cellular functions and four were associated with caspase-3 activation. Eukaryotic initiation factor 5A (eIF-5A) was identified in two spots; however, the peptide mass-fingerprinting for the accumulated one included a peptide with lysine(50), indicating that hypusine formation was suppressed during UP inhibitor-induced apoptosis. Hypusine modification ensues immediately following translation of eIF-5A precursor, unless cells are treated with the modification inhibitors diaminoheptane. However, UP inhibitors induced a much stronger accumulation of unmodified eIF-5A compared to the effect of diaminoheptane. We further showed the unmodified eIF-5A was regulated in a proteasome-dependent manner. Inhibition of hypusine formation by diaminoheptane triggered apoptosis, but of particular interest is the finding that eIF-5A expression inhibition by antisense oligodeoxynucleotides significantly enhanced the stimulating effect of GM-CSF on cell growth. Therefore, the eIF-5A accumulation played important roles in the apoptosis induced by UP inhibitors. Moreover, hypusine inhibition in apoptosis was further revealed to be associated with the subcellular localization of eIF-5A. Our data pave the way to a better understanding of the mechanisms by which UP system has been linked to apoptosis.	Natl Ctr Biomed Anal, Inst Basic Med Sci, Beijing 100850, Peoples R China		Zhang, XM (corresponding author), Natl Ctr Biomed Anal, Inst Basic Med Sci, 27 Tai Ping Rd, Beijing 100850, Peoples R China.		Lan, Yu/AAV-2236-2021	Lan, Yu/0000-0002-4731-5945				Caraglia M, 2001, AMINO ACIDS, V20, P91, DOI 10.1007/s007260170050; Chen KY, 1999, J CHIN CHEM SOC-TAIP, V46, P727, DOI 10.1002/jccs.199900100; Chen KY, 1997, BIOL SIGNAL, V6, P105; Essmann F, 2000, BIOCHEM J, V346, P777, DOI 10.1042/0264-6021:3460777; Gamble SC, 2000, CANCER RES, V60, P2146; GORG A, 1988, ELECTROPHORESIS, V9, P531, DOI 10.1002/elps.1150090913; HERSHEY JWB, 1990, BIOCHIM BIOPHYS ACTA, V1050, P160, DOI 10.1016/0167-4781(90)90159-Y; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Ito H, 2002, J BIOCHEM, V131, P593, DOI 10.1093/oxfordjournals.jbchem.a003139; JAKUS J, 1993, J BIOL CHEM, V268, P13131; Jao DLE, 2002, J CELL BIOCHEM, V86, P590, DOI 10.1002/jcb.10235; KANG HA, 1994, J BIOL CHEM, V269, P3934; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lin DT, 2002, J BIOL CHEM, V277, P31134, DOI 10.1074/jbc.M112035200; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Lipowsky G, 2000, EMBO J, V19, P4362, DOI 10.1093/emboj/19.16.4362; Liu YP, 1997, BIOL SIGNAL, V6, P166; Lovric J, 1998, J BIOL CHEM, V273, P22848; Melhem R, 1997, LEUKEMIA, V11, P1690, DOI 10.1038/sj.leu.2400792; Park MH, 1997, BIOL SIGNAL, V6, P115; PARK MH, 1991, J BIOL CHEM, V266, P7988; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Rosorius O, 1999, J CELL SCI, V112, P2369; RUHL M, 1993, J CELL BIOL, V123, P1309, DOI 10.1083/jcb.123.6.1309; Shen EC, 2000, J BIOL CHEM, V275, P23718, DOI 10.1074/jbc.M002312200; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shi XP, 1996, EXP CELL RES, V225, P348, DOI 10.1006/excr.1996.0185; Soldes OS, 1999, BRIT J CANCER, V79, P595, DOI 10.1038/sj.bjc.6690094; Tome ME, 1997, BIOCHEM J, V328, P847; Tsien RY, 1998, SCIENCE, V280, P1954, DOI 10.1126/science.280.5371.1954; Verlaet M, 2001, BIOCHEM BIOPH RES CO, V283, P12, DOI 10.1006/bbrc.2001.4731; Wang HX, 2002, ACTA BIOCH BIOPH SIN, V34, P630; Witke W, 2001, P NATL ACAD SCI USA, V98, P3832, DOI 10.1073/pnas.051515498; Xu AG, 2001, J BIOL CHEM, V276, P2555, DOI 10.1074/jbc.M008982200; Yan JX, 2000, ELECTROPHORESIS, V21, P3666, DOI 10.1002/1522-2683(200011)21:17<3666::AID-ELPS3666>3.0.CO;2-6; Zhang XM, 1999, BIOCHEM J, V340, P127, DOI 10.1042/0264-6021:3400127	36	66	70	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 31	2003	22	31					4819	4830		10.1038/sj.onc.1206738	http://dx.doi.org/10.1038/sj.onc.1206738			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894223				2022-12-17	WOS:000184344600005
J	Schneiderhan, N; Budde, A; Zhang, YP; Brune, B				Schneiderhan, N; Budde, A; Zhang, YP; Brune, B			Nitric oxide induces phosphorylation of p53 and impairs nuclear export	ONCOGENE			English	Article						p53-ubiquitination; Mdm2; nucleo-cytoplasmic; shuttling; leptomycin; heterokaryon analysis	RING-FINGER DOMAIN; TUMOR-SUPPRESSOR; INDUCED APOPTOSIS; DNA-BINDING; IN-VIVO; MDM2; DEGRADATION; ACTIVATION; PROTEIN; SIGNAL	The tumor suppressor p53 accumulates under diverse stress conditions and affects cell cycle progression and/or apoptosis. This has been exemplified for endogenously produced or exogenously supplied nitric oxide (NO) and thus accounts at least in part for pathophysiological signaling of that bioactive molecule, although detailed mechanisms remain to be elucidated. By using luciferase reporter assays, we show that NO stabilized a transcriptionally active p53 protein. Considering that p53 is targeted by murine double minute (Mdm2) for ubiquitination and subsequent proteasomal degradation and knowing that this interaction is impaired by, for example, UV-treatment with concomitant stabilization of p53 we questioned the p53/Mdm2 interaction in the presence of NO. Although p53 became phosphorylated at serine 15 under the impact of NO, coimmunoprecipitation with Mdm2 and ubiquitination remained intact, thus excluding any interference of NO with this pathway. The importance of N-terminal p53 phosphorylation was verified with p53 mutants where the first six serine residues have been converted to alanine, and which do not accumulate in response to NO. Regulation of p53 stability can be also achieved by affecting nuclear-cytoplasmic shuttling and it was presented that leptomycin B, an inhibitor of nuclear export, caused p53 accumulation. Cell fractionation and immunofluorescence staining following NO-treatment revealed predominant nuclear accumulation of p53 in close association with serine 15-phosphorylation, which suggests impaired nuclear-cytoplasmic shuttling. This was verified by heterokaryon analysis. We conclude that attenuated nuclear export contributes to stabilization and activation of p53 under the influence of NO.	Univ Kaiserslautern, Fac Biol, Dept Cell Biol, D-67663 Kaiserslautern, Germany; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Erlangen Nurnberg, Fac Med, Dept Med 4, Expt Div, D-91054 Erlangen, Germany	University of Kaiserslautern; University of Texas System; UTMD Anderson Cancer Center; University of Erlangen Nuremberg	Brune, B (corresponding author), Univ Kaiserslautern, Fac Biol, Dept Cell Biol, Erwin Schrodinger Str, D-67663 Kaiserslautern, Germany.	BRUENE@rhrk.uni-kl.de			NATIONAL CANCER INSTITUTE [K01CA087580] Funding Source: NIH RePORTER; NCI NIH HHS [K01 CA087580] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Berendji D, 1997, FEBS LETT, V405, P37, DOI 10.1016/S0014-5793(97)00150-6; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Brune B, 2001, CELL SIGNAL, V13, P525, DOI 10.1016/S0898-6568(01)00175-9; Brune B, 1999, CELL DEATH DIFFER, V6, P969, DOI 10.1038/sj.cdd.4400582; Callsen D, 1999, BIOCHEMISTRY-US, V38, P2279, DOI 10.1021/bi982292a; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; Chen JD, 1996, MOL CELL BIOL, V16, P2445; Davis DW, 2000, J EXP MED, V192, P857, DOI 10.1084/jem.192.6.857; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Forrester K, 1996, P NATL ACAD SCI USA, V93, P2442, DOI 10.1073/pnas.93.6.2442; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Gottifredi V, 2001, SCIENCE, V292, P1851, DOI 10.1126/science.1062238; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HART TW, 1985, TETRAHEDRON LETT, V26, P2013, DOI 10.1016/S0040-4039(00)98368-0; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hengstermann A, 1998, ONCOGENE, V17, P2933, DOI 10.1038/sj.onc.1202282; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kim SJ, 2002, J BIOL CHEM, V277, P33501, DOI 10.1074/jbc.M202862200; KRONCKE KD, 1994, BIOCHEM BIOPH RES CO, V200, P1105, DOI 10.1006/bbrc.1994.1564; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Liang SH, 2001, EUR J BIOCHEM, V268, P2779, DOI 10.1046/j.1432-1327.2001.02227.x; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; Maki CG, 1996, CANCER RES, V56, P2649; Maki CG, 1999, J BIOL CHEM, V274, P16531, DOI 10.1074/jbc.274.23.16531; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Matsuoka M, 2001, BIOCHEM BIOPH RES CO, V282, P1120, DOI 10.1006/bbrc.2001.4700; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; Messmer UK, 1996, BIOCHEM J, V319, P299, DOI 10.1042/bj3190299; MESSMER UK, 1994, FEBS LETT, V355, P23; MIYASHITA T, 1995, CELL, V80, P293; Nakaya N, 2000, ONCOGENE, V19, P6369, DOI 10.1038/sj.onc.1204100; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Shaw P, 1996, ONCOGENE, V12, P921; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Turenne GA, 2001, ONCOGENE, V20, P5100, DOI 10.1038/sj.onc.1204665; Wang XJ, 2002, J BIOL CHEM, V277, P15697, DOI 10.1074/jbc.M112068200; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yang F, 2000, J LEUKOCYTE BIOL, V68, P916; Zhang YP, 2001, CELL GROWTH DIFFER, V12, P175; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	58	66	70	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2003	22	19					2857	2868		10.1038/sj.onc.1206431	http://dx.doi.org/10.1038/sj.onc.1206431			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771937				2022-12-17	WOS:000182824800001
J	Wong, BCY; Jiang, XH; Fan, XM; Lin, MCM; Jiang, SH; Lam, SK; Kung, HF				Wong, BCY; Jiang, XH; Fan, XM; Lin, MCM; Jiang, SH; Lam, SK; Kung, HF			Suppression of RelA/p65 nuclear translocation independent of I kappa B-alpha degradation by cyclooxygenase-2 inhibitor in gastric cancer	ONCOGENE			English	Article						COX-2 inhibitor; NSAIDs; NF-kappa B; p65 (RelA) and gastric cancer	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TRANSCRIPTION FACTOR; ACTIVATOR PROTEIN-1; SODIUM-SALICYLATE; INDUCED APOPTOSIS; KINASE-BETA; CELL-DEATH; ASPIRIN; INDUCTION; PATHWAY	Selective cyclooxygenase-2 (COX-2) inhibitors are promising anti-inflammatory drugs with potential antitumor activities. The nuclear factor-kappa B (NF-kappaB) family of proteins is important transcriptional regulators of genes involved in immunity, inflammation, and carcinogenesis. In the present study, we investigated whether and by which molecular mechanism the selective COX-2 inhibitors inhibit NF-kappaB activation in gastric cancer. The effects of SC236 and its derivative, but devoid of COX-2 enzyme inhibition activity on NF-kappaB signaling, were evaluated using electromobility shift, transfection, and reporter gene assay. The translocation of RelA/p65 was investigated using Western blotting and immunocytochemistry. We showed that SC236 suppressed NF-kappaB-mediated gene transcription and binding activity in gastric cancer. This effect occurred through a mechanism independent of cyclooxygenase activity and prostaglandin synthesis. Furthermore, unlike aspirin, SC236 affected neither the phosphorylation, degradation, nor expression of IkappaB-alpha, suggesting that the effects of SC236 are independent of IKK activity and IkappaB-alpha gene transcription. Instead, SC236 worked directly through suppressing nuclear translocation of RelA/p65. It is possible that SC236 directly targets proteins that facilitate the nuclear translocation of NF-kappaB. Our study suggests an important molecular mechanism by which COX-2 inhibitors reduce inflammation and suppress carcinogenesis in gastrointestinal tract.	Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China; RuiJin Hosp, Dept Gastroenterol, Shanghai, Peoples R China; Univ Hong Kong, Inst Mol Biol, Hong Kong, Hong Kong, Peoples R China; Fudan Univ, Affiliated Jinshan Hosp, Dept Med, Shanghai 200433, Peoples R China	University of Hong Kong; Shanghai Jiao Tong University; University of Hong Kong; Fudan University	Wong, BCY (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China.		Wong, Benjamin Chun Yu/ABB-1962-2020; jiang, cynthia xiaohua/F-7580-2017; Wong, Benjamin Chun Yu/C-4436-2009	jiang, cynthia xiaohua/0000-0002-7372-4961; 				Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Connolly EM, 2002, BRIT J CANCER, V87, P231, DOI 10.1038/sj.bjc.6600462; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DuBois RN, 1996, J GASTROENTEROL, V31, P898, DOI 10.1007/BF02358623; Elder DJE, 1997, CLIN CANCER RES, V3, P1679; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Grosch S, 2001, FASEB J, V15, P2742, DOI 10.1096/fj.01-0299fje; Gupta RA, 1998, GASTROENTEROLOGY, V114, P1095, DOI 10.1016/S0016-5085(98)70330-0; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397; Jiang XH, 2002, ONCOGENE, V21, P6113, DOI 10.1038/sj.onc.1205778; KARGMAN SL, 1995, CANCER RES, V55, P3785; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Li JJ, 1997, CANCER RES, V57, P3569; Manna SK, 2000, J IMMUNOL, V164, P6509, DOI 10.4049/jimmunol.164.12.6509; Masferrer JL, 2000, CANCER RES, V60, P1306; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; PARETT ML, 1997, INT J ONCOL, V10, P503; Penning TD, 1997, J MED CHEM, V40, P1347, DOI 10.1021/jm960803q; Reddy BS, 1996, CANCER RES, V56, P4566; Richter M, 2001, CARCINOGENESIS, V22, P17, DOI 10.1093/carcin/22.1.17; Ristimaki A, 1997, CANCER RES, V57, P1276; Sawaoka H, 1998, AM J PHYSIOL-GASTR L, V274, pG1061, DOI 10.1152/ajpgi.1998.274.6.G1061; Sheng HM, 1998, CANCER RES, V58, P362; Stark LA, 2001, FASEB J, V15, P1273, DOI 10.1096/fj.00-0529fje; Tegeder I, 2001, FASEB J, V15, P2, DOI 10.1096/fasebj.15.1.2; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; Wahl C, 1998, J CLIN INVEST, V101, P1163, DOI 10.1172/JCI992; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Weber CK, 2000, GASTROENTEROLOGY, V119, P1209, DOI 10.1053/gast.2000.19458; Wulczyn FG, 1996, J MOL MED, V74, P749, DOI 10.1007/s001090050078; Yamamoto Y, 1999, J BIOL CHEM, V274, P27307, DOI 10.1074/jbc.274.38.27307; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Zhou XM, 2001, CARCINOGENESIS, V22, P1393, DOI 10.1093/carcin/22.9.1393; Zhu GH, 2000, GASTROENTEROLOGY, V118, P507, DOI 10.1016/S0016-5085(00)70256-3; Zhu GH, 1999, BRIT J CANCER, V79, P393, DOI 10.1038/sj.bjc.6690062	40	66	75	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 27	2003	22	8					1189	1197		10.1038/sj.onc.1206234	http://dx.doi.org/10.1038/sj.onc.1206234			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650EK	12606945				2022-12-17	WOS:000181249700007
J	Theis-Febvre, N; Filhol, O; Froment, C; Cazales, M; Cochet, C; Monsarrat, B; Ducommun, B; Baldin, V				Theis-Febvre, N; Filhol, O; Froment, C; Cazales, M; Cochet, C; Monsarrat, B; Ducommun, B; Baldin, V			Protein kinase CK2 regulates CDC25B phosphatase activity	ONCOGENE			English	Article						cell cycle; CDC25B phosphatase; CK2 kinase; phosphorylation	CELL-CYCLE PROGRESSION; BETA-SUBUNIT; SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; MASS-SPECTROMETRY; CASEIN KINASE-2; FISSION YEAST; TYROSINE PHOSPHATASE; CHECKPOINT PATHWAY; G(1)/S TRANSITION	Human dual-specificity phosphatases CDC25 (A, B and C) play an important role in the control of cell cycle progression by activating the cyclin-dependent kinases (CDKs). Regulation of these phosphatases during the cell cycle involves post-translational modifications such as phosphorylation and protein-protein interactions. Given the suspected involvement of the protein kinase CK2 at the G2/M transition, we have investigated its effects on the CDC25B phosphatase. We show that in vitro CK2 phosphorylates CDC25B, but not CDC25C. Mass spectrometry analysis demonstrates that at least two serine residues, Ser-186 and Ser-187, are phosphorylated in vivo. We also report that CDC25B interacts with CK2, and this interaction, mediated by the CK2beta regulatory subunit, involves domains that are located within the first 55 amino acids of CK2beta and between amino acids 122 and 200 on CDC25B. This association was confirmed in vivo, in Sf9 insect cells and in U2OS human cells expressing an HA epitope-tagged CDC25B. Finally, we demonstrate that phosphorylation of CDC25B by protein kinase CK2 increases the catalytic activity of the phosphatase in vitro as well as in vivo. We discuss the possibility that CDC25B phosphorylation by CK2 could play a role in the regulation of the activity of CDC25B as a starter of mitosis.	Univ Toulouse 3, LBCMCP, CNRS, UMR 5088,Inst Explorat Fonct Genomes,IFR 109, F-31062 Toulouse, France; INSERM, EMI 0104, CEA, DBMS, F-38054 Grenoble 9, France; IPBS, UMR 5089, F-31070 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Baldin, V (corresponding author), Univ Toulouse 3, LBCMCP, CNRS, UMR 5088,Inst Explorat Fonct Genomes,IFR 109, 118 Route Narbonne, F-31062 Toulouse, France.		DUCOMMUN, Bernard/B-3208-2008; BALDIN, Véronique/Y-8397-2019; Filhol-Cochet, Odile/I-3962-2016	BALDIN, Véronique/0000-0001-8523-0494; Cochet, Claude/0000-0002-1772-4270; DUCOMMUN, Bernard/0000-0002-7126-8368; Filhol, Odile/0000-0003-1964-7958				ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Baldin V, 1997, J BIOL CHEM, V272, P32731, DOI 10.1074/jbc.272.52.32731; Baldin V, 1997, ONCOGENE, V14, P2485, DOI 10.1038/sj.onc.1201063; Baldin V, 2000, Prog Cell Cycle Res, V4, P49; BALDIN V, 2002, J BIOL CHEM, V9, P9; BIDWAI AP, 1992, J BIOL CHEM, V267, P18790; BIEMANN K, 1990, METHOD ENZYMOL, V193, P886, DOI 10.1016/0076-6879(90)93460-3; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; Bonnet H, 1996, J BIOL CHEM, V271, P24781, DOI 10.1074/jbc.271.40.24781; BOSC DG, 1995, J BIOL CHEM, V270, P25872, DOI 10.1074/jbc.270.43.25872; Cans C, 1999, ANTICANCER RES, V19, P1241; Chantalat L, 1999, EMBO J, V18, P2930, DOI 10.1093/emboj/18.11.2930; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; Davezac N, 2000, PATHOL BIOL, V48, P182; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Escargueil AE, 2000, J BIOL CHEM, V275, P34710, DOI 10.1074/jbc.M005179200; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; FILHOL O, 1991, BIOCHEMISTRY-US, V30, P11133, DOI 10.1021/bi00110a016; FILHOL O, 1992, J BIOL CHEM, V267, P20577; FILHOL O, 1994, BIOCHEM BIOPH RES CO, V198, P660, DOI 10.1006/bbrc.1994.1096; FILHOLCOCHET O, 1994, CELL MOL BIOL RES, V40, P529; Ford HL, 2000, J BIOL CHEM, V275, P22245, DOI 10.1074/jbc.M002446200; Forrest ARR, 1999, BIOCHEM BIOPH RES CO, V260, P510, DOI 10.1006/bbrc.1999.0870; Gabrielli BG, 1996, J CELL SCI, V109, P1081; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; Garner-Hamrick PA, 1998, INT J CANCER, V76, P720, DOI 10.1002/(SICI)1097-0215(19980529)76:5<720::AID-IJC18>3.0.CO;2-7; Gotz C, 2000, BIOCHEM BIOPH RES CO, V268, P882, DOI 10.1006/bbrc.2000.2230; Graves PR, 2001, ONCOGENE, V20, P1839, DOI 10.1038/sj.onc.1204259; HANNA DE, 1995, J BIOL CHEM, V270, P25905, DOI 10.1074/jbc.270.43.25905; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; Lammer C, 1998, J CELL SCI, V111, P2445; Leroy D, 1999, MOL CELL BIOCHEM, V191, P85, DOI 10.1023/A:1006858210835; Li DX, 1997, J BIOL CHEM, V272, P3773, DOI 10.1074/jbc.272.6.3773; Li DX, 1999, J BIOL CHEM, V274, P32988, DOI 10.1074/jbc.274.46.32988; Li J, 1997, P NATL ACAD SCI USA, V94, P502, DOI 10.1073/pnas.94.2.502; LIN WJ, 1991, J BIOL CHEM, V266, P5664; LITCHFIELD DW, 1992, J BIOL CHEM, V267, P13943; Lorenz P, 1999, FEBS LETT, V448, P283, DOI 10.1016/S0014-5793(99)00388-9; Mann M, 2001, ANNU REV BIOCHEM, V70, P437, DOI 10.1146/annurev.biochem.70.1.437; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; McLachlin DT, 2001, CURR OPIN CHEM BIOL, V5, P591, DOI 10.1016/S1367-5931(00)00250-7; Mils V, 2000, ONCOGENE, V19, P1257, DOI 10.1038/sj.onc.1203419; MULNERLORILLON O, 1988, EUR J BIOCHEM, V171, P107, DOI 10.1111/j.1432-1033.1988.tb13765.x; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NAGATA A, 1991, NEW BIOL, V3, P959; Nambirajan S, 2000, J BIOSCIENCE, V25, P33, DOI 10.1007/BF02985179; NASTAINCZYK W, 1995, HYBRIDOMA, V14, P335, DOI 10.1089/hyb.1995.14.335; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; Raman C, 1998, J BIOL CHEM, V273, P19183, DOI 10.1074/jbc.273.30.19183; Rethinaswamy A, 1998, J BIOL CHEM, V273, P5869, DOI 10.1074/jbc.273.10.5869; Reynolds RA, 1999, J MOL BIOL, V293, P559, DOI 10.1006/jmbi.1999.3168; Rice RL, 1997, BIOCHEMISTRY-US, V36, P15965, DOI 10.1021/bi971338h; ROBITZKI A, 1993, J BIOL CHEM, V268, P5694; Romero-Oliva F, 2001, J CELL BIOCHEM, V81, P445, DOI 10.1002/1097-4644(20010601)81:3<445::AID-JCB1058>3.0.CO;2-2; Roshak AK, 2000, CELL SIGNAL, V12, P405, DOI 10.1016/S0898-6568(00)00080-2; RUSSO GL, 1992, J BIOL CHEM, V267, P20317; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SNELL V, 1994, EMBO J, V13, P2066, DOI 10.1002/j.1460-2075.1994.tb06481.x; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; ZANDOMENI R, 1986, J BIOL CHEM, V261, P3414	71	66	69	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 16	2003	22	2					220	232		10.1038/sj.onc.1206107	http://dx.doi.org/10.1038/sj.onc.1206107			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527891				2022-12-17	WOS:000180322400007
J	Jackson, RJ; Adnane, J; Coppola, D; Cantor, A; Sebti, SM; Pledger, WJ				Jackson, RJ; Adnane, J; Coppola, D; Cantor, A; Sebti, SM; Pledger, WJ			Loss of the cell cycle inhibitors p21(Cip1) and p27(Kip1) enhances tumorigenesis in knockout mouse models	ONCOGENE			English	Article						p21(Cip1); p27(Kip1); urethane; tumors; MMTV/v-Ha-ras mice	MAMMARY-CANCER MODEL; TRANSGENIC MICE; HA-RAS; BREAST-CANCER; GROWTH-FACTOR; SKIN CARCINOGENESIS; LACKING P27(KIP1); TUMOR SUPPRESSION; ONCOGENIC RAS; DIFFERENTIATION	Events that contribute to tumor formation include mutations in the ras gene and loss or inactivation of cell cycle inhibitors such as p21(Cip1) and p27(Kip1). In our previous publication, we showed that mice expressing the MMTV/v-Ha-ras transgene developed tumors earlier and at higher multiplicities in the absence than in the presence of p21(Cip1). To further evaluate the combinatorial role of genetic alterations and loss of cell cycle inhibitors in tumorigenesis, we performed two companion studies. In the first study, wild type and p21(Cip1)-null mice were exposed to the chemical carcinogen, urethane. Similar to its effects in v-Ha-ras mice, loss of p21(Cip1) accelerated tumor onset and increased tumor multiplicity in urethane-treated mice. Lung tumors were the predominant tumor type in urethane-treated mice regardless of p21(Cip1) status. In the second study, tumor formation was monitored in v-Ha-ras mice expressing or lacking p27(Kip1). Unlike p21(Cip1), the absence of p27(Kip1) had no effect on the timing or multiplicity of tumor formation, which was largely restricted to mammary and salivary glands. However, once tumors appeared, they grew faster in p27(Kip1)-null mice than in p27(Kip1)-wild type mice. Increases in growth rate were particularly striking for salivary tumors in ras/p27(-/-) mice. Loss of p21(Cip1) on the other hand, had no effect on tumor growth rate in v-Ha-ras mice. Collectively, our data suggest that p21(Cip1) suppresses tumor formation elicited by multiple agents and that p21(Cip1) and p27(Kip1) suppress tumor formation in different ways.	H Lee Moffit Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; H Lee Moffit Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; H Lee Moffit Canc Ctr & Res Inst, Pathol Serv, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Pledger, WJ (corresponding author), H Lee Moffit Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.				NATIONAL CANCER INSTITUTE [U19CA067771, P01CA078038, R01CA067360] Funding Source: NIH RePORTER; NCI NIH HHS [CA78038, CA67771, CA67360] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; Adnane J, 2000, ONCOGENE, V19, P5338, DOI 10.1038/sj.onc.1203956; Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ANDRES AC, 1988, GENE DEV, V2, P1486, DOI 10.1101/gad.2.11.1486; Bagui TK, 2000, MOL CELL BIOL, V20, P8748, DOI 10.1128/MCB.20.23.8748-8757.2000; BOS JL, 1989, CANCER RES, V49, P4682; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Davis R W, 1980, Methods Enzymol, V65, P404; Della Ragione F, 1999, ADV EXP MED BIOL, V472, P73; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; DRAGANI TA, 1991, ONCOGENE, V6, P333; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; Frame S, 2000, CURR OPIN GENET DEV, V10, P106, DOI 10.1016/S0959-437X(99)00052-0; Hauser PJ, 1997, CELL GROWTH DIFFER, V8, P203; Johnson DG, 1999, ANNU REV PHARMACOL, V39, P295, DOI 10.1146/annurev.pharmtox.39.1.295; Jones JM, 1999, CELL GROWTH DIFFER, V10, P213; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; Kawana H, 1998, AM J PATHOL, V153, P505, DOI 10.1016/S0002-9440(10)65593-9; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KUMAR R, 1990, SCIENCE, V248, P1101, DOI 10.1126/science.2188364; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; MALKINSON AM, 1983, J NATL CANCER I, V70, P931; Martin-Caballero J, 2001, CANCER RES, V61, P6234; Mirvish S S, 1968, Adv Cancer Res, V11, P1; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NUZUM EO, 1990, MOL CARCINOGEN, V3, P287, DOI 10.1002/mc.2940030509; Paramio JM, 2001, J BIOL CHEM, V276, P44203, DOI 10.1074/jbc.M105650200; Philipp J, 1999, ONCOGENE, V18, P4689, DOI 10.1038/sj.onc.1202840; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Quaroni A, 2000, AM J PHYSIOL-CELL PH, V279, pC1045, DOI 10.1152/ajpcell.2000.279.4.C1045; SANDGREN EP, 1989, ONCOGENE, V4, P715; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Shiohara M, 1997, LEUKEMIA LYMPHOMA, V26, P35, DOI 10.3109/10428199709109155; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SMITH GS, 1973, J NATL CANCER I, V50, P1195, DOI 10.1093/jnci/50.5.1195; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Weinberg WC, 1997, ONCOGENE, V15, P685, DOI 10.1038/sj.onc.1201230; Winston JT, 1996, ONCOGENE, V12, P127; WISEMAN RW, 1986, P NATL ACAD SCI USA, V83, P5825, DOI 10.1073/pnas.83.16.5825; Yang WC, 2001, CANCER RES, V61, P565; Zezula J, 2001, EMBO REP, V2, P27, DOI 10.1093/embo-reports/kve008; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zirbes TK, 2000, INT J CANCER, V89, P14, DOI 10.1002/(SICI)1097-0215(20000120)89:1<14::AID-IJC3>3.0.CO;2-L	56	66	68	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 5	2002	21	55					8486	8497		10.1038/sj.onc.1205946	http://dx.doi.org/10.1038/sj.onc.1205946			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466968				2022-12-17	WOS:000179480100011
J	Hinchcliffe, EH; Sluder, G				Hinchcliffe, EH; Sluder, G			Two for two: Cdk2 and its role in centrosome doubling	ONCOGENE			English	Review						cancer; Cdk2; centrosome; cyclin; mitosis	POLE BODY DUPLICATION; CYCLIN-E; CELL-CYCLE; CENTRIOLE DUPLICATION; REPRODUCTION; KINASE; NUCLEAR; REQUIREMENT; EVENTS; P53		Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Ctr Canc, Worcester, MA 01605 USA; Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA; Univ Notre Dame, Walther Canc Res Inst, Notre Dame, IN 46556 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Notre Dame; University of Notre Dame; Walther Cancer Institute	Sluder, G (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, 377 Plantat St, Worcester, MA 01605 USA.	Greenfield.sluder@umassmed.edu			NIGMS NIH HHS [GM 30758] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030758] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams IR, 2000, TRENDS CELL BIOL, V10, P329, DOI 10.1016/S0962-8924(00)01798-0; Andrews B, 1998, TRENDS GENET, V14, P66, DOI 10.1016/S0168-9525(97)01322-X; AUBIN JE, 1980, J CELL SCI, V43, P177; BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962-8924(00)01872-9; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Fisk HA, 2001, CELL, V106, P95, DOI 10.1016/S0092-8674(01)00411-1; GALLANT P, 1992, J CELL BIOL, V117, P213, DOI 10.1083/jcb.117.1.213; GARD DL, 1990, J CELL BIOL, V110, P2033, DOI 10.1083/jcb.110.6.2033; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Haase SB, 2001, NAT CELL BIOL, V3, P38, DOI 10.1038/35050543; Hinchcliffe EH, 2001, SCIENCE, V291, P1547, DOI 10.1126/science.1056866; Hinchcliffe EH, 2001, GENE DEV, V15, P1167, DOI 10.1101/gad.894001; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hinchcliffe EH, 1998, J CELL BIOL, V140, P1417, DOI 10.1083/jcb.140.6.1417; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; Keyomarsi K, 1997, Prog Cell Cycle Res, V3, P171; Khodjakov A, 2000, CURR BIOL, V10, P59, DOI 10.1016/S0960-9822(99)00276-6; Khodjakov A, 2001, J CELL BIOL, V153, P237, DOI 10.1083/jcb.153.1.237; KOCHANSKI RS, 1990, J CELL BIOL, V110, P1599, DOI 10.1083/jcb.110.5.1599; KURIYAMA R, 1981, J CELL BIOL, V91, P814, DOI 10.1083/jcb.91.3.814; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Lange BMH, 2000, CURR TOP DEV BIOL, V49, P235; Lingle WL, 2000, CURR TOP DEV BIOL, V49, P313; MACK G, 1993, CELL MOTIL CYTOSKEL, V26, P239, DOI 10.1002/cm.970260307; Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; Matsumoto Y, 2002, SCIENCE, V295, P499, DOI 10.1126/science.1065693; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Piel M, 2000, J CELL BIOL, V149, P317, DOI 10.1083/jcb.149.2.317; Piel M, 2001, SCIENCE, V291, P1550, DOI 10.1126/science.1057330; REMPEL RE, 1995, J BIOL CHEM, V270, P6843, DOI 10.1074/jbc.270.12.6843; Rieder CL, 2001, TRENDS CELL BIOL, V11, P413, DOI 10.1016/S0962-8924(01)02085-2; SCHMIDTZACHMANN MS, 1987, EMBO J, V6, P1881, DOI 10.1002/j.1460-2075.1987.tb02447.x; Sharp DJ, 2000, NATURE, V407, P41, DOI 10.1038/35024000; Sluder G, 1998, CELL BIOL INT, V22, P3, DOI 10.1006/cbir.1997.0249; SLUDER G, 1990, J CELL BIOL, V110, P2025, DOI 10.1083/jcb.110.6.2025; SLUDER G, 1986, J CELL BIOL, V103, P1873, DOI 10.1083/jcb.103.5.1873; SLUDER G, 1985, J CELL SCI, V76, P35; SLUDER G, 1985, J CELL BIOL, V100, P887, DOI 10.1083/jcb.100.3.887; Sluder G, 1999, BIOL CELL, V91, P413, DOI 10.1016/S0248-4900(99)80083-5; Sluder G, 1997, J CELL SCI, V110, P421; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Stearns T, 2001, CELL, V105, P417, DOI 10.1016/S0092-8674(01)00366-X; Stucke VM, 2002, EMBO J, V21, P1723, DOI 10.1093/emboj/21.7.1723; SU JY, 1995, P NATL ACAD SCI USA, V92, P10187, DOI 10.1073/pnas.92.22.10187; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Tarapore P, 2001, ONCOGENE, V20, P6851, DOI 10.1038/sj.onc.1204848; WINEY M, 1991, J CELL BIOL, V114, P745, DOI 10.1083/jcb.114.4.745; Wojcik EJ, 2000, CURR BIOL, V10, P1131, DOI 10.1016/S0960-9822(00)00703-X	55	66	69	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2002	21	40					6154	6160		10.1038/sj.onc.1205826	http://dx.doi.org/10.1038/sj.onc.1205826			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590TZ	12214244				2022-12-17	WOS:000177840500003
J	Schimmel, M; Bauer, G				Schimmel, M; Bauer, G			Proapoptotic and redox state-related signaling of reactive oxygen species generated by transformed fibroblasts	ONCOGENE			English	Article						transformed; reactive oxygen species; apoptosis; catalase	INTERCELLULAR INDUCTION; HYDROGEN-PEROXIDE; APOPTOSIS-INDUCTION; RADICAL GENERATION; HYDROXYL RADICALS; SUPEROXIDE ANION; OXIDATIVE STRESS; NADH OXIDASE; NITRIC-OXIDE; CELLS	Oncogenic transformed fibroblasts are characterized by extracellular superoxide anion generation through a membrane-associated NADPH oxidase. After cellular glutathione depletion, extracellular reactive oxygen species (ROS) generated by transformed fibroblasts exhibit a strong apoptosis-inducing potential. As apoptosis induction under glutathione depletion is inhibited by catalase, the NADPH oxidase inhibitor apocynin, superoxide dismutase, the hydroxyl radical scavenger terephthalate and the iron chelator deferoxamine, the metal-catalysed Haber-Weiss reaction seems to be the responsible signaling mechanism. In contrast to extracellular ROS, intracellular ROS play no role for apoptosis induction in glutathione-depleted transformed fibroblasts initially, since a high level of intracellular catalase scavenges intracellular hydrogen peroxide. Intracellular catalase seems to be induced by extracellular hydrogen peroxide, as pretreatment of transformed fibroblasts with exogenous catalase downmodulates endogenous catalase and renders glutathione-depleted transformed cells susceptible for the effect of endogenous hydrogen peroxide. In contrast to transformed fibroblasts, nontransformed glutathione-depleted fibroblasts do not generate substantial extracellular ROS, but apoptosis is efficiently induced in these cells by intracellular ROS. Our data show that extracellular ROS of transformed fibroblasts exhibit redox-related signaling and at the same time represent a potential apoptosis-inducing hazard through the metal-catalysed Haber-Weiss reaction.	Univ Freiburg, Abt Virol, Inst Med Mikrobiol & Hyg, D-79104 Freiburg, Germany	University of Freiburg	Bauer, G (corresponding author), Univ Freiburg, Abt Virol, Inst Med Mikrobiol & Hyg, Hermann Herder Str 11, D-79104 Freiburg, Germany.	tgfb@ukl.uni-freiburg.de						Antunes F, 2000, FEBS LETT, V475, P121, DOI 10.1016/S0014-5793(00)01638-0; Aoshima H, 1997, BBA-LIPID LIPID MET, V1345, P35, DOI 10.1016/S0005-2760(96)00159-2; ARUOMA OI, 1988, BIOCHEM J, V256, P251, DOI 10.1042/bj2560251; Barnes AC, 1999, MICROB PATHOGENESIS, V26, P149, DOI 10.1006/mpat.1998.0260; Bauer G, 2000, HANDB EXP PHARM, V142, P275; Bauer G, 2000, ANTICANCER RES, V20, P4115; Beck E, 1997, EXP CELL RES, V234, P47, DOI 10.1006/excr.1997.3587; BIELSKI BHJ, 1977, J PHYS CHEM-US, V81, P1048, DOI 10.1021/j100526a005; Bittinger F, 1998, MELANOMA RES, V8, P381, DOI 10.1097/00008390-199810000-00001; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; CANDEIAS LP, 1993, FEBS LETT, V333, P151, DOI 10.1016/0014-5793(93)80394-A; Das D, 1997, FREE RADICAL BIO MED, V23, P8, DOI 10.1016/S0891-5849(96)00547-3; Deichman GI, 1996, INT J CANCER, V66, P747, DOI 10.1002/(SICI)1097-0215(19960611)66:6<747::AID-IJC7>3.0.CO;2-#; Deichman GI, 1998, INT J CANCER, V75, P277, DOI 10.1002/(SICI)1097-0215(19980119)75:2<277::AID-IJC17>3.3.CO;2-H; Engelmann I, 2000, REDOX REP, V5, P207, DOI 10.1179/135100000101535762; Enoiu M, 2000, FREE RADICAL BIO MED, V29, P825, DOI 10.1016/S0891-5849(00)00370-1; Faure H, 1996, FREE RADICAL BIO MED, V20, P979, DOI 10.1016/0891-5849(95)02187-6; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; Girotti AW, 1998, J LIPID RES, V39, P1529; GORCZYCA W, 1993, CANCER RES, V53, P1945; Haufel T, 2001, ANTICANCER RES, V21, P2617; HEIGOLD S, 2002, J LEUKOCYTE BIOL, V23, P939; HEIGOLD S, 2002, IN PRESS CARCINOGENE; Held KD, 1996, RADIAT RES, V145, P542, DOI 10.2307/3579272; Herdener M, 2000, FREE RADICAL BIO MED, V29, P1260, DOI 10.1016/S0891-5849(00)00422-6; Hipp ML, 1997, ONCOGENE, V15, P791, DOI 10.1038/sj.onc.1201247; Hirsch T, 1997, BIOSCIENCE REP, V17, P67, DOI 10.1023/A:1027339418683; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Johnson D, 2000, CELL DEATH DIFFER, V7, P685, DOI 10.1038/sj.cdd.4400700; JURGENSMEIER JM, 1994, CANCER RES, V54, P393; Jurgensmeier JM, 1997, INT J CANCER, V70, P587; Kehrer JP, 2000, TOXICOLOGY, V149, P43, DOI 10.1016/S0300-483X(00)00231-6; Kettle AJ, 1997, BIOCHEM J, V321, P503, DOI 10.1042/bj3210503; Koppenol WH, 2001, REDOX REP, V6, P229, DOI 10.1179/135100001101536373; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Lai CC, 1996, J MOL CELL CARDIOL, V28, P1157, DOI 10.1006/jmcc.1996.0106; Li PF, 1997, FEBS LETT, V404, P249, DOI 10.1016/S0014-5793(97)00093-8; Li PF, 1997, CIRCULATION, V96, P3602; MORRE DJ, 1995, P NATL ACAD SCI USA, V92, P1831, DOI 10.1073/pnas.92.6.1831; Morre DJ, 1997, J BIOENERG BIOMEMBR, V29, P281, DOI 10.1023/A:1022466212083; Mylonas C, 1999, IN VIVO, V13, P295; Nappi AJ, 1998, BBA-GEN SUBJECTS, V1380, P55, DOI 10.1016/S0304-4165(97)00125-6; Oettl K, 1999, BIOCHEM BIOPH RES CO, V264, P262, DOI 10.1006/bbrc.1999.1520; Oyama Y, 1999, EUR J PHARMACOL, V384, P47, DOI 10.1016/S0014-2999(99)00649-4; Paul K, 2001, ANTICANCER RES, V21, P3237; Rauen U, 1998, FREE RADICAL BIO MED, V24, P1316, DOI 10.1016/S0891-5849(97)00456-5; Rohrdanz E, 1998, FREE RADICAL BIO MED, V24, P27, DOI 10.1016/S0891-5849(97)00159-7; Rollet-Labelle E, 1998, FREE RADICAL BIO MED, V24, P563, DOI 10.1016/S0891-5849(97)00292-X; ROSEN H, 1979, J CLIN INVEST, V64, P1725, DOI 10.1172/JCI109637; SARAN M, 1994, CHEM-BIOL INTERACT, V90, P35, DOI 10.1016/0009-2797(94)90109-0; Saran M, 1999, FREE RADICAL RES, V31, P429, DOI 10.1080/10715769900300991; Schimmel M, 2001, INT J ONCOL, V19, P299; Schwieger A, 2001, CARCINOGENESIS, V22, P1385, DOI 10.1093/carcin/22.9.1385; SHI XL, 1992, ARCH BIOCHEM BIOPHYS, V292, P323, DOI 10.1016/0003-9861(92)90085-B; STOLK J, 1994, AM J RESP CELL MOL, V11, P95, DOI 10.1165/ajrcmb.11.1.8018341; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; THART BA, 1990, FREE RADICAL BIO MED, V9, P127, DOI 10.1016/0891-5849(90)90115-Y; vandenDobbelsteen DJ, 1996, J BIOL CHEM, V271, P15420, DOI 10.1074/jbc.271.26.15420; Xu Y, 1997, J CELL PHYSIOL, V170, P192, DOI 10.1002/(SICI)1097-4652(199702)170:2<192::AID-JCP11>3.0.CO;2-K; Zucker B, 1997, CELL DEATH DIFFER, V4, P388, DOI 10.1038/sj.cdd.4400258	61	66	68	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2002	21	38					5886	5896		10.1038/sj.onc.1205740	http://dx.doi.org/10.1038/sj.onc.1205740			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185588				2022-12-17	WOS:000177520900008
J	Srivenugopal, KS; Ali-Osman, F				Srivenugopal, KS; Ali-Osman, F			The DNA repair protein, O-6-methylguanine-DNA methyltransferase is a proteolytic target for the E6 human papillomavirus oncoprotein	ONCOGENE			English	Article						MGMT; DNA repair; ubiquitin; proteasome; alkylating agents	PROTEASOME-MEDIATED DEGRADATION; GLUTATHIONE-S-TRANSFERASE; POSITIVE CANCER-CELLS; HUMAN TUMOR-CELLS; O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; PROMOTER HYPERMETHYLATION; MOLECULAR-BASIS; BETA-CATENIN; P53 PROTEIN; K-RAS	We have previously shown that O-6-methylguanine-DNA methyltransferase (MGMT), a DNA repair protein that protects tissues against toxic and carcinogenic effects of alkylating agents, is degraded through ubiquitination-dependent proteolysis. Here, we investigated the role of the human papillomavirus (HPV) E6 protein in MGMT degradation. In three pairs of isogenic human tumor cell lines in which a member of each pair expressed the E6 protein through stable transfection (HCT116/HCT116-E6, MCF7/MCF7-E6, and RKO/RKO-E6), we found a consistent 40-55% reduction in the MGMT protein level and its activity in all E6-expressing cells compared with the parent cells (P = <0.05). E6 expression did not, however, alter the levels of MGMT mRNA. Addition of the recombinant MGMT (rMGMT) protein to extracts of HCT116/E6 cells resulted in the binding of E6 to MGMT. Further, the purified E6 protein promoted the degradation of rMGMT in rabbit reticulocyte lysates. Immunoprecipitation assays showed the presence of a ternary protein complex between MGMT, E6, and the cellular ubiquitin-ligase E6-associated protein (E6-AP). Transient transfection of the p53-null H1299 lung tumor cells with an E6 construct also down-regulated the MGMT. The MGMT protein also showed structural features that are compatible for interaction with the E6, and E6-AP components. Collectively, these data suggest that the oncogenic E6 proteins enhance the ubiquitin-dependent proteolysis of MGMT.	Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Sect Mol Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Srivenugopal, KS (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Sect Mol Therapeut, Box 64, Houston, TX 77030 USA.	ksrivenu@mdanderson.org			NCI NIH HHS [CA-74321] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA074321] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ali-Osman F., 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P572; BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; Beroud C, 1998, NUCLEIC ACIDS RES, V26, P200, DOI 10.1093/nar/26.1.200; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; Boyer SN, 1996, CANCER RES, V56, P4620; BRENT T P, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P421; Butz K, 1999, ONCOGENE, V18, P2381, DOI 10.1038/sj.onc.1202557; BUTZ K, 1995, ONCOGENE, V10, P927; Chen C, 1999, CARCINOGENESIS, V20, P699, DOI 10.1093/carcin/20.4.699; CHEN JY, 1993, ONCOGENE, V8, P2159; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; Dolan ME, 1997, CLIN CANCER RES, V3, P837; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Esteller M, 2000, CANCER RES, V60, P2368; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; Gao QS, 1999, MOL CELL BIOL, V19, P733; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; GERSON SL, 1995, HEMATOL ONCOL CLIN N, V9, P431, DOI 10.1016/S0889-8588(18)30103-5; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; Gupta M, 1997, CLIN CANCER RES, V3, P1653; Harris BZ, 2001, J CELL SCI, V114, P3219; Harris LC, 1996, CANCER RES, V56, P2029; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HUSSAIN SP, 1994, ONCOGENE, V9, P13; Isaacs JS, 1999, MOL CARCINOGEN, V24, P70, DOI 10.1002/(SICI)1098-2744(199901)24:1<70::AID-MC10>3.0.CO;2-5; Ke LD, 1999, ORAL ONCOL, V35, P415, DOI 10.1016/S1368-8375(99)00015-9; KEISS TD, 1993, P NATL ACAD SCI USA, V90, P3988; Kuhne C, 1998, J BIOL CHEM, V273, P34302, DOI 10.1074/jbc.273.51.34302; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Maki CG, 1996, CANCER RES, V56, P2649; MITRA S, 1993, PROG NUCLEIC ACID RE, V44, P109, DOI 10.1016/S0079-6603(08)60218-4; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Pegg AE, 2000, MUTAT RES-REV MUTAT, V462, P83, DOI 10.1016/S1383-5742(00)00017-X; Rapp L, 1998, BBA-REV CANCER, V1378, pF1, DOI 10.1016/S0304-419X(98)00009-2; Sadot E, 2001, MOL CELL BIOL, V21, P6768, DOI 10.1128/MCB.21.20.6768-6781.2001; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Scheffner M, 1998, PHARMACOL THERAPEUT, V78, P129, DOI 10.1016/S0163-7258(98)00003-5; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Schepens J, 1997, FEBS LETT, V409, P53, DOI 10.1016/S0014-5793(97)00481-X; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; Sehr P, 2001, J IMMUNOL METHODS, V253, P153, DOI 10.1016/S0022-1759(01)00376-3; SKHEDY D, 1994, FEBS LETT, V348, P126; Srivenugopal KS, 2002, CANCER LETT, V181, P87, DOI 10.1016/S0304-3835(01)00823-0; Srivenugopal KS, 2000, CANCER RES, V60, P282; Srivenugopal KS, 2001, CLIN CANCER RES, V7, P1398; Srivenugopal KS, 1996, BIOCHEMISTRY-US, V35, P1328, DOI 10.1021/bi9518205; Talis AL, 1998, J BIOL CHEM, V273, P6439, DOI 10.1074/jbc.273.11.6439; Thomas M, 2001, ONCOGENE, V20, P5431, DOI 10.1038/sj.onc.1204719; Thomas M, 1998, ONCOGENE, V17, P2943, DOI 10.1038/sj.onc.1202223; WAJNBERG EF, 1989, FEBS LETT, V243, P141, DOI 10.1016/0014-5793(89)80116-4; Wang J, 2001, ONCOGENE, V20, P4740, DOI 10.1038/sj.onc.1204655; Wibley JEA, 2000, NUCLEIC ACIDS RES, V28, P393, DOI 10.1093/nar/28.2.393; Wolf P, 2001, CANCER RES, V61, P8113; Wu GS, 1998, ONCOGENE, V16, P2177, DOI 10.1038/sj.onc.1201755; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; ZAIDI NH, 1995, CARCINOGENESIS, V16, P451, DOI 10.1093/carcin/16.3.451; Zhang QW, 2001, J PHARMACOL EXP THER, V298, P141; zur Hausen H, 1999, SEMIN CANCER BIOL, V9, P405, DOI 10.1006/scbi.1999.0144	59	66	71	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2002	21	38					5940	5945		10.1038/sj.onc.1205762	http://dx.doi.org/10.1038/sj.onc.1205762			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185595				2022-12-17	WOS:000177520900015
J	Gnanapragasam, VJ; Robson, CN; Neal, DE; Leung, HY				Gnanapragasam, VJ; Robson, CN; Neal, DE; Leung, HY			Regulation of FGF8 expression by the androgen receptor in human prostate cancer	ONCOGENE			English	Article						FGF8; prostate cancer; androgen receptor; gene promoter	FIBROBLAST GROWTH FACTOR-8; OVER-EXPRESSION; DNA-BINDING; MAMMARY; ACTIVATION; CLONING; CELLS; FIBROBLAST-GROWTH-FACTOR-8; COACTIVATOR; INTEGRATION	Fibroblast growth factor 8 (FGF8) has been shown to play a key role in prostate carcinogenesis. It was initially cloned as an androgen induced protein in mouse mammary cancer SC3 cells. In this study, we examined if FGF8 was also regulated by the androgen receptor in human prostate cancer. FGF8b protein expression in resected clinical prostate cancer correlated closely with expression of the androgen receptor (AR). In the androgen sensitive CWR22 prostate xenograft, we observed up-regulation of FGF8b immunoreactivity in testosterone supplemented mice while castration markedly reduced its signal. Furthermore, FGF8b protein expression in AR positive LNCaP cells was similarly enhanced by androgens. The proximal promoter of the human FGF8 gene was cloned into a luciferase reporter construct (FGF8.luc). FGF8.luc activity in AR positive LNCaP and SC3 cells was increased 2.5-fold by androgens. In AR negative DU145 cells, maximal induction of FGF8.luc required both cotransfection of the AR and the presence of androgens. The anti-androgen bicalutamide completely abolished AR mediated FGF8.luc induction. Deletion constructs from FGF8.luc have further defined an active promoter region and an androgen responsive region. Nucleotide analysis of this androgen responsive region has revealed putative androgen response elements. Finally, using ChIP assays we confirmed in vivo interaction between the AR and the androgen responsive region of the FGF8 promoter. Taken together these data provide first evidence that expression of the mitogen FGF8 in prostate cancer is, at least in part, regulated by the androgen receptor at the transcriptional level.	Newcastle Univ, Sch Surg Sci, Prostate Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Leung, HY (corresponding author), Newcastle Univ, Sch Surg Sci, Prostate Res Grp, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	H.Y.Leung@ncl.ac.uk		Neal, David/0000-0002-6033-5086; Leung, Hing Y./0000-0002-3933-3975				Bower M, 1997, SEMIN CANCER BIOL, V8, P3, DOI 10.1006/scbi.1997.0055; Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; Claessens F, 2001, J STEROID BIOCHEM, V76, P23, DOI 10.1016/S0960-0760(00)00154-0; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; Daphna-Iken D, 1998, ONCOGENE, V17, P2711, DOI 10.1038/sj.onc.1202212; Dorkin TJ, 1999, ONCOGENE, V18, P2755, DOI 10.1038/sj.onc.1202624; Gemel J, 1996, GENOMICS, V35, P253, DOI 10.1006/geno.1996.0349; Gemel J, 1999, J BIOL CHEM, V274, P6020, DOI 10.1074/jbc.274.9.6020; Ghosh AK, 1996, CELL GROWTH DIFFER, V7, P1425; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Gnanapragasam VJ, 2001, BRIT J CANCER, V85, P1928, DOI 10.1054/bjoc.2001.2179; Greenwood M, 2000, HIST TODAY, V50, P3; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Ittman M, 1997, J UROLOGY, V157, P351, DOI 10.1016/S0022-5347(01)65376-X; Kapoun AM, 1997, ONCOGENE, V14, P2985, DOI 10.1038/sj.onc.1201146; Koivisto PA, 1999, J PATHOL, V189, P219, DOI 10.1002/(SICI)1096-9896(199910)189:2<219::AID-PATH423>3.0.CO;2-F; KOUHARA H, 1994, ONCOGENE, V9, P455; Kuriki K, 2000, CELL MOL BIOL, V46, P1147; Lee SMK, 1997, DEVELOPMENT, V124, P959; Leung HY, 1996, ONCOGENE, V12, P1833; MACARTHUR CA, 1995, CELL GROWTH DIFFER, V6, P817; Merrill RM, 1996, J NATL CANCER I, V88, P1683, DOI 10.1093/jnci/88.22.1683; MURTHA P, 1993, BIOCHEMISTRY-US, V32, P6459, DOI 10.1021/bi00076a020; Myers RB, 1999, J UROLOGY, V161, P945, DOI 10.1016/S0022-5347(01)61826-3; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; ROCHE PJ, 1992, MOL ENDOCRINOL, V6, P2229, DOI 10.1210/me.6.12.2229; Rudra-Ganguly N, 1998, ONCOGENE, V16, P1487, DOI 10.1038/sj.onc.1201652; Schmitt JF, 1996, J STEROID BIOCHEM, V57, P173, DOI 10.1016/0960-0760(95)00259-6; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Song ZG, 2000, CANCER RES, V60, P6730; STORY MT, 1994, GROWTH FACTORS, V10, P269, DOI 10.3109/08977199409010993; Tanaka A, 1998, CANCER RES, V58, P2053; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; Tanaka S, 2001, DIGEST DIS SCI, V46, P1016, DOI 10.1023/A:1010753826788; Valve EM, 1998, BIOCHEM BIOPH RES CO, V250, P805, DOI 10.1006/bbrc.1998.9397; Valve EM, 2001, LAB INVEST, V81, P815, DOI 10.1038/labinvest.3780291; VANDERKWAST TH, 1991, INT J CANCER, V48, P189, DOI 10.1002/ijc.2910480206; WAINSTEIN MA, 1994, CANCER RES, V54, P6049; Wang Q, 1999, J CLIN PATHOL, V52, P29, DOI 10.1136/jcp.52.1.29; White RD, 1997, EUR UROL, V31, P1; Wu J, 1997, J STEROID BIOCHEM, V62, P1, DOI 10.1016/S0960-0760(97)00022-8; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; Yoshiura K, 1997, AM J MED GENET, V72, P354, DOI 10.1002/(SICI)1096-8628(19971031)72:3<354::AID-AJMG21>3.3.CO;2-C	43	66	70	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2002	21	33					5069	5080		10.1038/sj.onc.1205663	http://dx.doi.org/10.1038/sj.onc.1205663			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140757				2022-12-17	WOS:000176975900005
J	Jiang, YQ; Harlocker, SL; Molesh, DA; Dillon, DC; Stolk, JA; Houghton, RL; Repasky, EA; Badaro, R; Reed, SG; Xu, JC				Jiang, YQ; Harlocker, SL; Molesh, DA; Dillon, DC; Stolk, JA; Houghton, RL; Repasky, EA; Badaro, R; Reed, SG; Xu, JC			Discovery of differentially expressed genes in human breast cancer using subtracted cDNA libraries and cDNA microarrays	ONCOGENE			English	Article						breast cancer; genes; PCR-based cDNA subtraction; cDNA microarray; quantitative PCR	TRANSCRIPTION FACTOR; ESTROGEN-RECEPTOR; PROSTATE-CANCER; IDENTIFICATION; MAMMAGLOBIN; TISSUE; IMMUNOTHERAPY; LYMPHOCYTES; MUSCIMOL; KERATIN	Identifying novel and known genes that are differentially expressed in breast cancer has important implications in understanding the biology of breast tumorigenesis and developing new diagnostic and therapeutic agents. In this study we have combined two powerful technologies, PCR-based cDNA subtraction and cDNA microarray, as a high throughput methodology designed to identify cDNA clones that are breast tumor- and tissue-specific and are overexpressed in breast tumors. Approximately 2000 cDNA clones generated from the subtracted breast tumor library were arrayed on the microarray chips. The arrayed target cDNAs were then hybridized with 30 pairs of fluorescent-labeled cDNA probes generated from breast tumors and normal tissues to determine the tissue distribution and tumor specificity. cDNA clones showing overexpression in breast tumors by microarray were further analysed by DNA sequencing, GenBank and EST database searches, and quantitative real time PCR. We identified several known genes, including mammaglobin, cytokeratin 19, fibronectin, and hair-specific type 11 keratin, which have previously been shown to be overexpressed in breast tumors and may play an important rote in the malignance of breast. We also discovered B726P which appears to be an isoform of NY-BR-1, a breast tissue-specific gene. Two additional clones discovered, B709P and GABA(A) receptor pi subunit, were not previously described for their overexpression profile in breast tumors. Thus, combining PCR-based cDNA subtraction and cDNA microarray allowed for an efficient way to identify and validate genes with elevated mRNA expression levels in breast cancer that may potentially be involved in breast cancer progression. These differentially expressed genes may be of potential utility as therapeutic and diagnostic targets for breast cancer.	Corixa Corp, Seattle, WA 98104 USA; Roswell Pk Canc Inst, Dept Immunol, Buffalo, NY 14263 USA; Hosp Aristides Maltez, Salvador, BA, Brazil; Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA	Corixa; Roswell Park Cancer Institute; University of Washington; University of Washington Seattle	Jiang, YQ (corresponding author), Corixa Corp, 1124 Columbia St,Suite 200, Seattle, WA 98104 USA.	jiang@corixa.com			NATIONAL CANCER INSTITUTE [R43CA075794, R44CA075794] Funding Source: NIH RePORTER; NCI NIH HHS [CA75794] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMENTA F, 1988, PHARMACOL RES, V20, P863, DOI 10.1016/0031-6989(88)90003-3; Apostolopoulos V, 1996, IMMUNOL CELL BIOL, V74, P457, DOI 10.1038/icb.1996.76; BAKKER ABH, 1994, J EXP MED, V179, P1005, DOI 10.1084/jem.179.3.1005; Bertin N, 1997, CANCER RES, V57, P396; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Bowden PE, 1998, J INVEST DERMATOL, V110, P158, DOI 10.1046/j.1523-1747.1998.00097.x; CHEEVER MA, 1995, IMMUNOL REV, V145, P33, DOI 10.1111/j.1600-065X.1995.tb00076.x; Colpitts TL, 2001, BIOCHEMISTRY-US, V40, P11048, DOI 10.1021/bi010284f; COULIE PG, 1994, J EXP MED, V180, P35, DOI 10.1084/jem.180.1.35; COX AL, 1994, SCIENCE, V264, P716, DOI 10.1126/science.7513441; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Disis ML, 1997, ADV CANCER RES, V71, P343, DOI 10.1016/S0065-230X(08)60103-7; ERDO SL, 1989, BRIT J PHARMACOL, V96, P313, DOI 10.1111/j.1476-5381.1989.tb11819.x; Fleming TP, 2000, ANN NY ACAD SCI, V923, P78, DOI 10.1111/j.1749-6632.2000.tb05521.x; Hadden JW, 1999, INT J IMMUNOPHARMACO, V21, P79, DOI 10.1016/S0192-0561(98)00077-0; Hedblom E, 1997, J BIOL CHEM, V272, P15346, DOI 10.1074/jbc.272.24.15346; Hoch RV, 1999, INT J CANCER, V84, P122; Houghton RL, 2001, MOL DIAGN, V6, P79, DOI 10.2165/00066982-200106020-00003; Jager D, 2001, CANCER RES, V61, P2055; Jones KA, 1995, CANCER SURV, V25, P315; KAWAKAMI Y, 1994, P NATL ACAD SCI USA, V91, P6458, DOI 10.1073/pnas.91.14.6458; Kurebayashi J, 2000, CLIN CANCER RES, V6, P512; Lopez-Otin C, 1998, ENDOCR REV, V19, P365, DOI 10.1210/er.19.4.365; LORIDONROSA B, 1990, CANCER RES, V50, P1608; MAJEWSKA MD, 1991, J ENDOCRINOL, V131, P427, DOI 10.1677/joe.0.1310427; MCKENZIE IFC, 1990, CANCER CELL-MON REV, V2, P75; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; OZTURK M, 1992, BONE MARROW TRANSPL, V9, P164; Regnier CH, 1998, BRIT J CANCER, V78, P1640, DOI 10.1038/bjc.1998.736; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; TRASK DK, 1990, P NATL ACAD SCI USA, V87, P2319, DOI 10.1073/pnas.87.6.2319; Turner BC, 1998, CANCER RES, V58, P5466; Walker RA, 1997, CANCER METAST REV, V16, P5, DOI 10.1023/A:1005740222307; Watson MA, 1999, CANCER RES, V59, P3028; Watson MA, 1996, CANCER RES, V56, P860; Xu JC, 2000, CANCER RES, V60, P1677	38	66	74	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2002	21	14					2270	2282		10.1038/sj.onc.1205278	http://dx.doi.org/10.1038/sj.onc.1205278			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	533XJ	11948410				2022-12-17	WOS:000174555300016
J	Sullivan, A; Yuille, M; Repellin, C; Reddy, A; Reelfs, O; Bell, A; Dunne, B; Gusterson, BA; Osin, P; Farrell, PJ; Yulug, I; Evans, A; Ozcelik, T; Gasco, M; Crook, T				Sullivan, A; Yuille, M; Repellin, C; Reddy, A; Reelfs, O; Bell, A; Dunne, B; Gusterson, BA; Osin, P; Farrell, PJ; Yulug, I; Evans, A; Ozcelik, T; Gasco, M; Crook, T			Concomitant inactivation of p53 and Chk2 in breast cancer	ONCOGENE			English	Article						p53; Chk2; breast cancer	MUTATIONS; BRCA1; GENE; FAMILIES; PHOSPHORYLATION; METHYLATION; CARCINOMAS; CHECKPOINT	The structure and expression of the human Rad53 homologue Chk2 was analysed in breast cancer. The previously described silent polymorphism at nucleotide 252 in codon 84 (GAA > GAG) was observed in 5/141 cases. Somatic Chk2 coding mutations were detected in 7/141 cases, these occurring in 4/18 BRCA1-associated breast cancers, 1/78 sporadic breast cancers and 2/25 typical medullary carcinomas. Each of the BRCA1-associated cancers with Chk2 mutations also contained mutations in p53, whereas the single sporadic cancer with Chk2 mutation was wild-type for p53. Expression of Chk2 was ubiquitously detected in normal ductal epithelium of the breast, but there was loss of expression in a significant proportion of breast carcinomas, and this occurred in cancers both with and without p53 mutation. A CpG island was identified 5' of the Chk2 transcriptional start site, but there was no evidence of cytosine methylation in any of the cancers with down-regulated Chk2 expression. Analysis of the germ-line of 45 individuals with hereditary or early onset breast cancer revealed wild-type Chk2 sequence in all cases. Thus, despite the rarity of somatic mutations in Chk2 in sporadic breast carcinomas, our results nevertheless reveal that concomitant loss of function in Chk2 (via down-regulation of expression) and p53 (via mutation) occurs in a proportion of sporadic cases. However, consistent with other studies, we show that germ-line mutations in Chk2 are unlikely to account for a significant proportion of non BRCA1-, non BRCA2-associated hereditary breast cancers.	Univ London Imperial Coll Sci & Technol, Fac Med, Ludwig Inst Canc Res, London W2 1PG, England; HGMC, Hinxton, England; Univ Glasgow, Western Infirm, Dept Pathol, Glasgow, Lanark, Scotland; UCL, Dept Hist, London WC1, England; Middlesex Hosp, Med Sch, London WC1, England; Bilkent Univ, Dept Mol Genet, Ankara, Turkey; Poole Gen Hosp, Dept Surg, Poole, Dorset, England; Azienda Osped S Croce & Carle, UO Oncol Med, I-12100 Cuneo, Italy	Imperial College London; Ludwig Institute for Cancer Research; University of Glasgow; University of London; University College London; University of London; University College London; Ihsan Dogramaci Bilkent University; Poole Hospital	Crook, T (corresponding author), Univ London Imperial Coll Sci & Technol, Fac Med, Ludwig Inst Canc Res, St Marys Campus Norfolk Pl, London W2 1PG, England.	t.crook@ic.ac.uk	/AAD-1866-2020; gusterson, barry a/D-3752-2009	Yuille, Martin/0000-0002-4992-5405; Yulug, Isik/0000-0002-7577-2502; Farrell, Paul/0000-0002-6754-9351				Acquati F, 2001, ONCOGENE, V20, P980, DOI 10.1038/sj.onc.1204178; Allinen M, 2001, BRIT J CANCER, V85, P209, DOI 10.1054/bjoc.2001.1858; Banelli B, 2000, ONCOGENE, V19, P4553, DOI 10.1038/sj.onc.1203807; Bartkova J, 2001, ONCOGENE, V20, P5897, DOI 10.1038/sj.onc.1204746; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Brooks LA, 2000, CANCER RES, V60, P6875; Chehab NH, 2000, GENE DEV, V14, P278; Crook T, 1998, ONCOGENE, V17, P1681, DOI 10.1038/sj.onc.1202106; Crook T, 1997, LANCET, V350, P638, DOI 10.1016/S0140-6736(05)63327-2; de Cremoux P, 1999, J NATL CANCER I, V91, P641, DOI 10.1093/jnci/91.7.641; DETRE S, 1995, J CLIN PATHOL, V48, P876, DOI 10.1136/jcp.48.9.876; Eisinger F, 1998, CANCER RES, V58, P1588; Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564; Falck J, 2001, ONCOGENE, V20, P5503, DOI 10.1038/sj.onc.1204811; Greenblatt MS, 2001, CANCER RES, V61, P4092; Haruki N, 2000, CANCER RES, V60, P4689; HERMAN JG, 1995, CANCER RES, V55, P4525; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Lakhani SR, 2000, CLIN CANCER RES, V6, P782; Lee CH, 2001, J BIOL CHEM, V276, P30537, DOI 10.1074/jbc.M104414200; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Nathanson KN, 2001, NAT MED, V7, P552, DOI 10.1038/87876; Ozdag H, 2000, EUR J CANCER, V36, P2076, DOI 10.1016/S0959-8049(00)00277-X; Phillips KA, 1999, J NATL CANCER I, V91, P469, DOI 10.1093/jnci/91.5.469; Sodha N, 2000, Science, V289, P359; Vahteristo P, 2001, CANCER RES, V61, P5718; Wu XL, 2001, J BIOL CHEM, V276, P2971, DOI 10.1074/jbc.M009727200	27	66	69	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1316	1324		10.1038/sj.onc.1205207	http://dx.doi.org/10.1038/sj.onc.1205207			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857075	Green Published			2022-12-17	WOS:000173861000002
J	Lee, WP; Wen, Y; Varnum, B; Hung, MC				Lee, WP; Wen, Y; Varnum, B; Hung, MC			Akt is required for Axl-Gas6 signaling to protect cells from E1A-mediated apoptosis	ONCOGENE			English	Article						E1A; Axl; Gas 6; Akt; BAD; apoptosis	E1A GENE-PRODUCTS; RECEPTOR TYROSINE KINASE; METASTASIS-SUPPRESSING FUNCTION; OVARIAN-CANCER CELLS; HUMAN TUMOR-CELLS; NF-KAPPA-B; ADENOVIRUS E1A; PHOSPHATIDYLINOSITOL 3-KINASE; SURVIVAL ACTIVITIES; INDUCE APOPTOSIS	Adenovirus type 5 E1A protein (E1A) associates with anti-tumor activities by reversing the transformed phenotype, inhibiting metastasis, and inducing apoptosis. We have previously identified that E1A suppresses the expression of Axl, a transforming tyrosine kinase and that Axl-Gas6 receptor-ligand interaction prevents E1A transfectants from apoptosis induced by serum deprivation. To determine how the Axl-Gas6 interaction prevents E1A-mediated apoptosis, we analysed the expression of anti-apoptotic molecules and found that the activated form of Akt was suppressed in the E1A transfectant ip 1-E1A and that Gas6 was able to activate Akt in ip 1-E1A cells reexpressing Axl (ip 1-E1A-Axl). To determine whether activated Akt is required to prevent E1A-mediated apoptosis, ip 1-E1A-Axl cells were treated with the phosphatidylinositol-3'-OH kinase inhibitor wortmannin or transfected with a dominant negative Akt mutant. In both cases, Gas6 no longer protected the cells from serum deprivation-induced apoptosis. Thus, we conclude that activated Akt is required for Axl-Gas6 signaling to prevent E1A-mediated apoptosis induced by serum deprivation. Downstream molecules of Akt, including NF-kappaB, Fas ligand, and BAD were examined, among which phosphorylation of BAD by Axl-Gas6 signaling is associated with the anti-apoptotic activity of Akt in our study.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Breast Canc Res Program, Houston, TX 77030 USA; Amgen Inc, Thousand Oaks, CA 91320 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Amgen	Hung, MC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Box 108,1515 Holcombe Blvd, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	NATIONAL CANCER INSTITUTE [R01CA058880, P50CA083639, R01CA077858] Funding Source: NIH RePORTER; NCI NIH HHS [1 P50 CA83639, R01-CA 77858, R01-CA 58880] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bellosta P, 1997, ONCOGENE, V15, P2387, DOI 10.1038/sj.onc.1201419; BELLOSTA P, 1995, MOL CELL BIOL, V15, P614; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; BYRD PJ, 1988, ONCOGENE, V2, P477; CHINNADURAI G, 1992, ONCOGENE, V7, P1255; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEL PL, 1997, SCIENCE, V278, P687; Deng J, 1998, ONCOGENE, V17, P2167, DOI 10.1038/sj.onc.1202148; DOUGLAS JL, 1991, ONCOGENE, V6, P2093; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fridell YWC, 1998, J BIOL CHEM, V273, P7123, DOI 10.1074/jbc.273.12.7123; Frisch SM, 2001, ADV CANCER RES, V80, P39, DOI 10.1016/S0065-230X(01)80011-7; FRISCH SM, 1991, P NATL ACAD SCI USA, V88, P9077, DOI 10.1073/pnas.88.20.9077; FRISCH SM, 1995, CANCER RES, V55, P5551; FRISCH SM, 1990, ONCOGENE, V5, P75; Goruppi S, 1999, ONCOGENE, V18, P4224, DOI 10.1038/sj.onc.1202788; Goruppi S, 1997, MOL CELL BIOL, V17, P4442, DOI 10.1128/MCB.17.8.4442; Goruppi S, 1996, ONCOGENE, V12, P471; Hortobagyi GN, 2001, J CLIN ONCOL, V19, P3422, DOI 10.1200/JCO.2001.19.14.3422; LAMBERTI C, 1990, J VIROL, V64, P4997, DOI 10.1128/JVI.64.10.4997-5007.1990; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lee WP, 1999, MOL CELL BIOL, V19, P8075; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Mymryk JS, 1996, ONCOGENE, V13, P1581; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; Ozes ON, 1999, NATURE, V401, P82; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SHALLOWAY D, 1987, MOL CELL BIOL, V7, P3582, DOI 10.1128/MCB.7.10.3582; Shao RP, 1999, J BIOL CHEM, V274, P21495, DOI 10.1074/jbc.274.31.21495; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; TEODORO JG, 1995, ONCOGENE, V11, P467; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; YAN DH, 1991, ONCOGENE, V6, P343; YU DH, 1993, CANCER RES, V53, P5784; YU DH, 1992, ONCOGENE, V7, P2263; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745; YU DH, 1993, CANCER RES, V53, P891; Yu DH, 1998, CANCER METAST REV, V17, P195, DOI 10.1023/A:1006054421970; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; YU DH, 1995, ONCOGENE, V11, P1383; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	49	66	69	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2002	21	3					329	336		10.1038/sj.onc.1205066	http://dx.doi.org/10.1038/sj.onc.1205066			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821945				2022-12-17	WOS:000173311200001
J	Deng, GR; Chen, A; Pong, E; Kim, YS				Deng, GR; Chen, A; Pong, E; Kim, YS			Methylation in hMLH1 promoter interferes with its binding to transcription factor CBF and inhibits gene expression	ONCOGENE			English	Article						colorectal cancer; hMLH1 gene; methylation; transcription factor CBF	DNA METHYLATION; NF-Y; MICROSATELLITE INSTABILITY; COLORECTAL-CARCINOMA; COLON-CANCER; HYPERMETHYLATION; INACTIVATION; TUMORS; CELLS; PROTEINS	Microsatellite instability (MSI) is caused by the dysfunction of mismatch repair genes, such as hMLH1, hMSH2. Loss of hMLH1 expression and methylation of CpG sites in hMLH1 promoter are frequently present in sporadic colorectal cancer with MSI. In this study, by transient transfection assay with constructs containing different lengths of hMLH1 promoter and a luciferase reporter gene, we located a proximal region of hMLH1 promoter, which plays a main role in regulating the gene. The fact that luciferase activities were high in all host cell lines regardless of their hMLH1 expression levels indicates that the transcription machinery is intact even in non-expressing cells. When hMLH1 promoter was in vitro methylated before transfection, the luciferase activities in the transfectants were significantly reduced. This observation indicates that methylation causes the inhibition of hMLH1 promoter activity. By electrophoretic mobility shift assay (EMSA), we identified a CCAAT box in this region, which specifically bound transcription factor CBF. Mutations in CCAAT box not only inhibited its binding to CBF factor, but also reduced its ability to drive the expression of luciferase gene. The role of CBF in activating transcription was further substantiated by inhibition of promoter activity with a plasmid expressing a dominant negative CBF-B mutant. Methylation at a CpG site two base pairs upstream of the CCAAT box inhibited the binding of CBF to CCAAT box. We conclude that methylation of an adjacent CpG site inhibits binding of the CBF transcription to the corresponding CCAAT box, and is one of the causes of hMLH1 gene silencing in colon cancer cells.	Univ Calif San Francisco, Vet Affairs Med Ctr, Gastrointestinal Res Lab, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	Deng, GR (corresponding author), Univ Calif San Francisco, Vet Affairs Med Ctr, Gastrointestinal Res Lab, San Francisco, CA 94121 USA.				NCI NIH HHS [CA 24321] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA024321] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Cunningham JM, 1998, CANCER RES, V58, P3455; Currie RA, 1997, J BIOL CHEM, V272, P30880, DOI 10.1074/jbc.272.49.30880; Deng GR, 1999, CANCER RES, V59, P2029; Dobrovic A, 1997, CANCER RES, V57, P3347; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; Hiltunen MO, 1997, INT J CANCER, V70, P644, DOI 10.1002/(SICI)1097-0215(19970317)70:6<644::AID-IJC3>3.3.CO;2-2; Hu QH, 2000, J BIOL CHEM, V275, P4435, DOI 10.1074/jbc.275.6.4435; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kanai Y, 1997, INT J CANCER, V71, P355; Kane MF, 1997, CANCER RES, V57, P808; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kominato Y, 1997, J BIOL CHEM, V272, P25890, DOI 10.1074/jbc.272.41.25890; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; Marziali G, 1997, MOL CELL BIOL, V17, P1387, DOI 10.1128/MCB.17.3.1387; MATHEYPREVOT B, 1990, P NATL ACAD SCI USA, V87, P5046, DOI 10.1073/pnas.87.13.5046; Orita T, 1997, J BIOL CHEM, V272, P23216, DOI 10.1074/jbc.272.37.23216; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; Qian XLC, 1997, CANCER RES, V57, P3672; Sinha S, 1996, MOL CELL BIOL, V16, P328; Stirzaker C, 1997, CANCER RES, V57, P2229; Tanaka H, 1998, CANCER RES, V58, P3429; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Thibodeau SN, 1996, CANCER RES, V56, P4836; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532	32	66	74	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 25	2001	20	48					7120	7127		10.1038/sj.onc.1204891	http://dx.doi.org/10.1038/sj.onc.1204891			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704838				2022-12-17	WOS:000171739300017
J	Delhem, N; Sabile, A; Gajardo, R; Podevin, P; Abadie, A; Blaton, MA; Kremsdorf, D; Beretta, L; Brechot, C				Delhem, N; Sabile, A; Gajardo, R; Podevin, P; Abadie, A; Blaton, MA; Kremsdorf, D; Beretta, L; Brechot, C			Activation of the interferon-inducible protein kinase PKR by Hepatocellular carcinoma derived-Hepatitis C virus core protein	ONCOGENE			English	Article						HCV; core; PKR; eIF2 alpha; apoptosis	NF-KAPPA-B; SIGNAL-TRANSDUCTION; MEDIATED APOPTOSIS; NS5A PROTEIN; EXPRESSION; PATHWAY; CELLS; BINDS; PATHOGENESIS; REPLICATION	Hepatitis C virus (HCV) is a major etiological agent of chronic liver disease and hepatocellular carcinoma (HCC). We demonstrate herewith that HCV core proteins encoded by sequences isolated from HCC tumor tissues, but not those derived from their non-tumor counterparts in the same liver, co-localise in vitro and in vivo and co-immunoprecipitate with PKR in hepatocytic Huh7 cells. We show that this association in fact augments the autophosphorylation of PKR and the phosphorylation of the translation initiation factor eIF2 alpha, which are two markers of PKR activity. The present study therefore identifies a novel model of virus-cell interactions whereby a viral protein, the HCV core, activates PKR activity.	CHU Necker, INSERM, U370, Dept Liver Canc & Mol Virol, F-75015 Paris, France; Inst Curie, Dept Cytokines & Interferon, Paris, France; Univ Michigan, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of Michigan System; University of Michigan	Brechot, C (corresponding author), CHU Necker, INSERM, U370, Dept Liver Canc & Mol Virol, 156 Rue Vaugirard, F-75015 Paris, France.		Kremsdorf, Dina/O-9797-2017	Laura, Beretta/0000-0002-2054-684X				Barba G, 1997, P NATL ACAD SCI USA, V94, P1200, DOI 10.1073/pnas.94.4.1200; Chen CM, 1997, J VIROL, V71, P9417, DOI 10.1128/JVI.71.12.9417-9426.1997; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; Gale MJ, 1998, CLIN DIAGN VIROL, V10, P157; Gil J, 1999, MOL CELL BIOL, V19, P4653; Heim MH, 1999, J VIROL, V73, P8469, DOI 10.1128/JVI.73.10.8469-8475.1999; Honda M, 2000, HEPATOLOGY, V31, P1351, DOI 10.1053/jhep.2000.7985; Hsieh TY, 1998, J BIOL CHEM, V273, P17651, DOI 10.1074/jbc.273.28.17651; Jin DY, 2000, EMBO J, V19, P729, DOI 10.1093/emboj/19.4.729; Kaufman RJ, 1999, P NATL ACAD SCI USA, V96, P11693, DOI 10.1073/pnas.96.21.11693; Kim SH, 2000, ONCOGENE, V19, P3086, DOI 10.1038/sj.onc.1203632; Lai MMC, 2000, CURR TOP MICROBIOL, V242, P117; Lee JH, 1997, J MED VIROL, V53, P245, DOI 10.1002/(SICI)1096-9071(199711)53:3<245::AID-JMV11>3.0.CO;2-G; Lee SB, 1996, J INTERF CYTOK RES, V16, P1073, DOI 10.1089/jir.1996.16.1073; Lu JF, 1999, J BIOL CHEM, V274, P32198, DOI 10.1074/jbc.274.45.32198; Major ME, 1997, HEPATOLOGY, V25, P1527, DOI 10.1002/hep.510250637; Marusawa H, 1999, J VIROL, V73, P4713, DOI 10.1128/JVI.73.6.4713-4720.1999; McHutchison JG, 1999, SEMIN LIVER DIS, V19, P57; McLauchlan J, 2000, J VIRAL HEPATITIS, V7, P2; Naganuma A, 2000, J VIROL, V74, P8744, DOI 10.1128/JVI.74.18.8744-8750.2000; Neddermann P, 1997, BIOL CHEM, V378, P469; Otsuka M, 2000, J BIOL CHEM, V275, P34122, DOI 10.1074/jbc.M000578200; Patel RC, 1998, EMBO J, V17, P4379, DOI 10.1093/emboj/17.15.4379; Podevin P, 2001, HEPATOLOGY, V33, P1503, DOI 10.1053/jhep.2001.24749; Polyak SJ, 1999, HEPATOLOGY, V29, P1262, DOI 10.1002/hep.510290438; Ray RB, 1996, VIROLOGY, V226, P176, DOI 10.1006/viro.1996.0644; Ray RB, 1998, J BIOL CHEM, V273, P2256, DOI 10.1074/jbc.273.4.2256; Ruggieri A, 1997, VIROLOGY, V229, P68, DOI 10.1006/viro.1996.8420; Sabile A, 1999, HEPATOLOGY, V30, P1064, DOI 10.1002/hep.510300429; SANTOLINI E, 1994, J VIROL, V68, P3631, DOI 10.1128/JVI.68.6.3631-3641.1994; Sarrazin C, 1999, Z Gastroenterol, V37, P669; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; Shimada A, 1998, CANCER RES, V58, P4434; Shimotohno K, 2000, SEMIN CANCER BIOL, V10, P233, DOI 10.1006/scbi.2000.0322; Shimotohno K, 1995, INTERVIROLOGY, V38, P162, DOI 10.1159/000150427; Song J, 1999, J GEN VIROL, V80, P879, DOI 10.1099/0022-1317-80-4-879; Tan SL, 1999, J INTERF CYTOK RES, V19, P543, DOI 10.1089/107999099313677; Tan SL, 1999, P NATL ACAD SCI USA, V96, P5533, DOI 10.1073/pnas.96.10.5533; Taylor DR, 1999, SCIENCE, V285, P107, DOI 10.1126/science.285.5424.107; Tsuchihara K, 1999, VIROLOGY, V258, P100, DOI 10.1006/viro.1999.9694; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Yasui K, 1998, J VIROL, V72, P6048, DOI 10.1128/JVI.72.7.6048-6055.1998; Yeung MC, 1999, P NATL ACAD SCI USA, V96, P11860, DOI 10.1073/pnas.96.21.11860; Zhu NL, 1998, J VIROL, V72, P3691, DOI 10.1128/JVI.72.5.3691-3697.1998	44	66	73	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2001	20	41					5836	5845		10.1038/sj.onc.1204744	http://dx.doi.org/10.1038/sj.onc.1204744			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593389				2022-12-17	WOS:000171037200007
J	Huo, TI; Wang, XW; Forgues, M; Wu, CG; Spillare, EA; Giannini, C; Brechot, C; Harris, CC				Huo, TI; Wang, XW; Forgues, M; Wu, CG; Spillare, EA; Giannini, C; Brechot, C; Harris, CC			Hepatitis B virus X mutants derived from human hepatocellular carcinoma retain the ability to abrogate p53-induced apoptosis	ONCOGENE			English	Article						HBx; mutation; p53; apoptosis; carcinogenesis	NF-KAPPA-B; HBX PROTEIN; TRANSCRIPTION FACTOR; P53 PROTEIN; TUMOR-ANTIGEN; GENE; LIVER; EXPRESSION; TRANSACTIVATION; ACTIVATION	Chronic hepatitis B virus (HBV) infection and the integration of its X gene (HBx) are closely associated with the development of hepatocellular carcinoma (HCC), The integrated HBx frequently is truncated or contains point mutations, Previous studies indicated that these HBx mutants have a diminished co-transactivational activity. We have compared the effects of wildtype (wt) HBx and its naturally occurring mutants derived from human HCCs on transcriptional co-transactivation, apoptosis and interactive effects with p53. We demonstrated that overexpression of mutant, but not wt HBx, is defective in transcriptional co-transactivation of the NF-kappaB-driven luciferase reporter. By using a microinjection technique, the HBx mutants were shown to have an attenuated pro-apoptotic activity. This deficiency may be attributed to multiple mutations in the co-transactivation domain of HBx, that leads to decreased stability of the translated product. However, wt or mutant HBx bind to p53 in vitro and retain their ability to block p53-mediated apoptosis in vivo, which has been implicated as its major tumor suppressor function. The abrogation of p53-mediated apoptosis by integrated HBx mutants may provide a selective clonal advantage for preneoplastic or neoplastic hepatocytes acid contribute to hepatocellular carcinogenesis.	NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA; Taipei Vet Gen Hosp, Taipei, Taiwan; Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan; Necker Inst, Paris, France	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; UDICE-French Research Universities; Universite Paris Cite	Harris, CC (corresponding author), NCI, Human Carcinogenesis Lab, NIH, 37 Convent Dr,MSC 4255,Bldg 37,Room 2C05, Bethesda, MD 20892 USA.		Wang, Xin Wei/B-6162-2009	Wang, Xin Wei/0000-0001-9735-606X				AGUILAR F, 1994, SCIENCE, V264, P1317, DOI 10.1126/science.8191284; Andrisani OM, 1999, INT J ONCOL, V15, P373; Arbuthnot P, 2000, J GASTROEN HEPATOL, V15, P357, DOI 10.1046/j.1440-1746.2000.02069.x; AVANTAGGIATI ML, 1993, ONCOGENE, V8, P1567; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEASLEY RP, 1981, LANCET, V2, P1129; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bergametti F, 1999, ONCOGENE, V18, P2860, DOI 10.1038/sj.onc.1202643; Bours V, 2000, BIOCHEM PHARMACOL, V60, P1085, DOI 10.1016/S0006-2952(00)00391-9; Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CASELMANN WH, 1995, J HEPATOL, V22, P34; Chen WN, 2000, BIOCHEM BIOPH RES CO, V276, P885, DOI 10.1006/bbrc.2000.3562; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; Chirillo P, 1996, J VIROL, V70, P641, DOI 10.1128/JVI.70.1.641-646.1996; Dandri M, 1996, J VIROL, V70, P5246, DOI 10.1128/JVI.70.8.5246-5254.1996; Doitsh G, 1999, ONCOGENE, V18, P7506, DOI 10.1038/sj.onc.1203209; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; FEITELSON MA, 1993, ONCOGENE, V8, P1109; Feitelson MA, 1997, AM J PATHOL, V150, P1141; Good LF, 1996, J VIROL, V70, P2730, DOI 10.1128/JVI.70.5.2730-2735.1996; Gottlob K, 1998, CANCER RES, V58, P3566; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; HERRERO JA, 1995, J VIROL, V69, P2168, DOI 10.1128/JVI.69.4.2168-2174.1995; Hettmann T, 1999, J EXP MED, V189, P145, DOI 10.1084/jem.189.1.145; HIRAI H, 1994, P NATL ACAD SCI USA, V91, P3584, DOI 10.1073/pnas.91.9.3584; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; HU KQ, 1990, P NATL ACAD SCI USA, V87, P7140, DOI 10.1073/pnas.87.18.7140; Huang Y, 2000, CANCER RES, V60, P4426; Jia L, 1999, INT J CANCER, V80, P875, DOI 10.1002/(SICI)1097-0215(19990315)80:6<875::AID-IJC13>3.0.CO;2-Z; Kaltschmidt B, 2000, EUR J BIOCHEM, V267, P3828, DOI 10.1046/j.1432-1327.2000.01421.x; Kew MC, 1996, CLIN LAB MED, V16, P395, DOI 10.1016/S0272-2712(18)30276-2; Kew MC, 1997, HEPATOLOGY, V25, P1037, DOI 10.1002/hep.510250442; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; LACOSTE J, 1995, J VIROL, V69, P564, DOI 10.1128/JVI.69.1.564-569.1995; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Lee SG, 2000, ONCOGENE, V19, P468, DOI 10.1038/sj.onc.1203312; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin Y, 1997, CANCER RES, V57, P5137; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MAHE Y, 1991, J BIOL CHEM, V266, P13759; Murakami S, 1999, INTERVIROLOGY, V42, P81, DOI 10.1159/000024969; Ogden SK, 2000, J BIOL CHEM, V275, P27806; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Park US, 2000, ONCOGENE, V19, P3384, DOI 10.1038/sj.onc.1203674; PATERLINI P, 1995, HEPATOLOGY, V21, P313, DOI 10.1002/hep.1840210208; Poussin K, 1999, INT J CANCER, V80, P497, DOI 10.1002/(SICI)1097-0215(19990209)80:4<497::AID-IJC3>3.0.CO;2-8; Prives C, 1993, CURR OPIN CELL BIOL, V5, P214, DOI 10.1016/0955-0674(93)90105-Y; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; Schuster R, 2000, ONCOGENE, V19, P1173, DOI 10.1038/sj.onc.1203417; Schwartz D, 1998, SEMIN CANCER BIOL, V8, P325, DOI 10.1006/scbi.1998.0095; SEIFER M, 1991, J HEPATOL, V13, pS61, DOI 10.1016/0168-8278(91)90026-8; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; Sirma H, 1999, ONCOGENE, V18, P4848, DOI 10.1038/sj.onc.1202867; Sirma H, 1998, ONCOGENE, V16, P2051, DOI 10.1038/sj.onc.1201737; Sohn S, 2000, MUTAT RES-DNA REPAIR, V460, P17, DOI 10.1016/S0921-8777(00)00010-0; SPEIR E, 1994, SCIENCE, V265, P391, DOI 10.1126/science.8023160; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Su Q, 2000, MUTAT RES-REV MUTAT, V462, P365, DOI 10.1016/S1383-5742(00)00026-0; Su Q, 1998, HEPATOLOGY, V27, P1109, DOI 10.1002/hep.510270428; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; SZEKELY L, 1993, P NATL ACAD SCI USA, V90, P5455, DOI 10.1073/pnas.90.12.5455; Takada S, 1999, ONCOGENE, V18, P6965, DOI 10.1038/sj.onc.1203188; Terradillos O, 1998, ONCOGENE, V17, P2115, DOI 10.1038/sj.onc.1202432; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; TWU JS, 1993, VIROLOGY, V192, P346, DOI 10.1006/viro.1993.1041; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; UNGER T, 1990, EMBO J, V9, P1889, DOI 10.1002/j.1460-2075.1990.tb08315.x; UNSAL H, 1994, P NATL ACAD SCI USA, V91, P822, DOI 10.1073/pnas.91.2.822; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang XW, 1999, ANTICANCER RES, V19, P4759; WANG XW, 1995, CANCER RES, V55, P6012; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; Wang XW, 1997, J CELL PHYSIOL, V173, P247, DOI 10.1002/(SICI)1097-4652(199711)173:2<247::AID-JCP30>3.0.CO;2-A; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yu DY, 1999, J HEPATOL, V31, P123, DOI 10.1016/S0168-8278(99)80172-X; Yun CW, 2000, ONCOGENE, V19, P5163, DOI 10.1038/sj.onc.1203896	92	66	74	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 21	2001	20	28					3620	3628		10.1038/sj.onc.1204495	http://dx.doi.org/10.1038/sj.onc.1204495			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439325				2022-12-17	WOS:000169400200003
J	Simon, MP; Navarro, M; Roux, D; Pouyssegur, J				Simon, MP; Navarro, M; Roux, D; Pouyssegur, J			Structural and functional analysis of a chimeric protein COL1A1-PDGFB generated by the translocation t(17;22)(q22;q13.1) in Dermatofibrosarcoma Protuberans (DP)	ONCOGENE			English	Article						dermatofibrosarcoma protuberans; translocations; COL1A1-PDGFB	RECEPTOR TYROSINE KINASES; GROWTH-FACTOR RECEPTORS; SIMIAN SARCOMA-VIRUS; COLLAGEN GENE COL1A1; B-CHAIN GENE; PDGF-BB; V-SIS; FUSION; EXPRESSION; ACTIVATION	Dermatofibrosarcoma protuberans (DP), an infiltrative skin tumour of intermediate malignancy, presents specific cytogenetic features such as reciprocal translocations t(17;22)(q22;q13.1) or supernumerary ring chromosomes derived from t(17;22), We have previously shown that both rings and translocated chromosomes derived from t(17;22) presented the same molecular rearrangement with fusion of the COL1A1 gene on chromosome 17 to the PDGFB gene on chromosome 22, To study the structure and function of the COL1A1-PDGFB chimeric protein, we used a tumour-derived chimeric COL1A1-PDGFB cDNA to perform stable and transient transfections in the Chinese hamster lung fibroblastic cell line PS200 and the human epithelial cell line HEK293. We demonstrated that the stably transfected clones that expressed the COL1A1-PDGFB chimeric protein became growth factors independent and tumorigenic in nude mice. In addition, COL1A1-PDGFB transfected cell supernatants significantly stimulated fibroblastic cell growth, through the activation of the PDGFB receptor pathway. By using anti-PDGFB and specific anti-COL1A1-PDGFB antibodies, we showed that, similar to PDGFB, the COL1A1-PDGFB chimeric proteins are processed in transfected cells into mature PDGFB dimers, These results strongly suggest that the COL1A1-PDGFB chimeric gene expression associated with DP, induces tumours formation through production of mature PDGFB, in an autocrine or paracrine way, Strikingly, mutagenesis experiments indicated that uncleaved COL1A1-PDGFB forms are mitogenic and therefore could contribute, as well as mature PDGFB, to the establishment of a transformed phenotype. Oncogene (2001) 20, 2965-2975.	Ctr Antoine Lacassagne, Inst Signalling Dev Biol & Canc Res, CNRS, UMR 6543, F-06189 Nice 2, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne	Simon, MP (corresponding author), Ctr Antoine Lacassagne, Inst Signalling Dev Biol & Canc Res, CNRS, UMR 6543, F-06189 Nice 2, France.		SIMON, Marie-Pierre/B-8017-2012					ALVES F, 1995, ONCOGENE, V10, P609; Dalgleish R, 1997, NUCLEIC ACIDS RES, V25, P181, DOI 10.1093/nar/25.1.181; DIRKS RPH, 1993, EUR J BIOCHEM, V216, P487, DOI 10.1111/j.1432-1033.1993.tb18167.x; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; Enzinger FM, 1995, SOFT TISSUE TUMORS, V3rd; Fish FS, 1996, DERMATOL SURG, V22, P268, DOI 10.1111/j.1524-4725.1996.tb00318.x; FLEMING TP, 1989, P NATL ACAD SCI USA, V86, P8063, DOI 10.1073/pnas.86.20.8063; Greco A, 1998, ONCOGENE, V17, P1313, DOI 10.1038/sj.onc.1202051; Heldin CH, 1998, BBA-REV CANCER, V1378, pF79, DOI 10.1016/S0304-419X(98)00015-8; KIKUCHI K, 1993, BIOCHEM BIOPH RES CO, V196, P409, DOI 10.1006/bbrc.1993.2264; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; Mentzel T, 1998, AM J SURG PATHOL, V22, P576, DOI 10.1097/00000478-199805000-00009; Navarro M, 1998, GENE CHROMOSOME CANC, V23, P263, DOI 10.1002/(SICI)1098-2264(199811)23:3<263::AID-GCC9>3.0.CO;2-#; O'Brien KP, 1998, GENE CHROMOSOME CANC, V23, P187, DOI 10.1002/(SICI)1098-2264(199810)23:2<187::AID-GCC13>3.0.CO;2-L; OSTMAN A, 1992, J CELL BIOL, V118, P509, DOI 10.1083/jcb.118.3.509; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PEDEUTOUR F, 1995, CANCER RES, V55, P2400; Pedeutour F, 1996, CYTOGENET CELL GENET, V72, P171, DOI 10.1159/000134178; PEREZRODRIGUEZ R, 1981, J CELL PHYSIOL, V109, P387, DOI 10.1002/jcp.1041090303; RAO CD, 1988, MOL CELL BIOL, V8, P284, DOI 10.1128/MCB.8.1.284; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; Shimizu A, 1999, CANCER RES, V59, P3719; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; Simon MP, 1997, NAT GENET, V15, P95, DOI 10.1038/ng0197-95; SMITS A, 1992, AM J PATHOL, V140, P639; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Wang J, 1999, DIAGN MOL PATHOL, V8, P113, DOI 10.1097/00019606-199909000-00002; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; Westermark B, 1993, CYTOKINES, V5, P1	31	66	69	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 24	2001	20	23					2965	2975		10.1038/sj.onc.1204426	http://dx.doi.org/10.1038/sj.onc.1204426			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	435VA	11420709				2022-12-17	WOS:000168901800012
J	Nestle, FO				Nestle, FO			Dendritic cell vaccination for cancer therapy	ONCOGENE			English	Article						melanoma; dendritic cells; immunotherapy; antigen-presenting cells; immunointervention	ANTIGEN-PRESENTING CELLS; T-HELPER-CELL; ANTITUMOR IMMUNITY; MELANOMA PATIENTS; PROSTATE-CANCER; TUMOR-CELLS; HUMAN BLOOD; PHASE-I; METASTATIC MELANOMA; PEPTIDE	A growing list of defined tumor-antigens opens the way to antigen specific immunotherapy of cancer. However current approaches are often limited in their potential to induce an effective anti-tumor response, Dendritic cells (DC) are natural adjuvants for the induction of antigen specific T cell response. They have been successfully used in clinical pilot trials to induce tumor specific immunity as well as clinical response in selected patients. Current research focuses on optimization of DC source, choice of antigen, antigen loading, mode of injection, as well as immune-monitoring. Finally, a variety of immune escape mechanisms are operative at the tumor site and have to be overcome for successful vaccination.	Univ Zurich, Sch Med, Dept Dermatol, CH-8091 Zurich, Switzerland	University of Zurich	Nestle, FO (corresponding author), Univ Zurich, Sch Med, Dept Dermatol, Gloriastr 31, CH-8091 Zurich, Switzerland.							Almand B, 2000, CLIN CANCER RES, V6, P1755; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Becker Y, 1993, In Vivo, V7, P187; Bell D, 1999, J EXP MED, V190, P1417, DOI 10.1084/jem.190.10.1417; Boczkowski D, 2000, CANCER RES, V60, P1028; Borges L, 1999, J IMMUNOL, V163, P1289; BROCKER EB, 1982, IMMUNOBIOLOGY, V162, P333; Burch PA, 2000, CLIN CANCER RES, V6, P2175; Caux C, 1996, J EXP MED, V184, P695, DOI 10.1084/jem.184.2.695; CAUX C, 1992, NATURE, V360, P258, DOI 10.1038/360258a0; Cella M, 1999, NAT MED, V5, P919, DOI 10.1038/11360; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; Eggert AAO, 1999, CANCER RES, V59, P3340; Enk AH, 1997, INT J CANCER, V73, P309, DOI 10.1002/(SICI)1097-0215(19971104)73:3<309::AID-IJC1>3.0.CO;2-3; FLAMMAND V, 1993, DENDRITIC CELLS FUND, P611; Fong L, 2000, ANNU REV IMMUNOL, V18, P245, DOI 10.1146/annurev.immunol.18.1.245; FREUDENTHAL PS, 1990, P NATL ACAD SCI USA, V87, P7698, DOI 10.1073/pnas.87.19.7698; Gabrilovich DI, 1996, NAT MED, V2, P1096, DOI 10.1038/nm1096-1096; GRABBE S, 1991, J IMMUNOL, V146, P3656; Grassi F, 1998, J LEUKOCYTE BIOL, V64, P484, DOI 10.1002/jlb.64.4.484; Grouard G, 1997, J EXP MED, V185, P1101, DOI 10.1084/jem.185.6.1101; Holtl L, 1998, LANCET, V352, P1358, DOI 10.1016/S0140-6736(05)60748-9; Hsu FJ, 1996, NAT MED, V2, P52, DOI 10.1038/nm0196-52; Hu XY, 1996, CANCER RES, V56, P2479; INABA K, 1992, J EXP MED, V175, P1157, DOI 10.1084/jem.175.5.1157; KNIGHT SC, 1985, P NATL ACAD SCI USA, V82, P4495, DOI 10.1073/pnas.82.13.4495; Lodge PA, 2000, CANCER RES, V60, P829; Mackensen A, 2000, INT J CANCER, V86, P385, DOI 10.1002/(SICI)1097-0215(20000501)86:3<385::AID-IJC13>3.0.CO;2-T; Mackensen A, 2000, CANCER IMMUNOL IMMUN, V49, P152, DOI 10.1007/s002620050614; MARKOWICZ S, 1990, J CLIN INVEST, V85, P955, DOI 10.1172/JCI114525; MAYORDOMO JI, 1995, NAT MED, V1, P1297, DOI 10.1038/nm1295-1297; Morel S, 2000, IMMUNITY, V12, P107, DOI 10.1016/S1074-7613(00)80163-6; Morse MA, 1999, CLIN CANCER RES, V5, P1331; MUKHERJI B, 1995, P NATL ACAD SCI USA, V92, P8078, DOI 10.1073/pnas.92.17.8078; Murphy GP, 1999, PROSTATE, V38, P73; Nair SK, 2000, NAT MED, V6, P1011, DOI 10.1038/79519; NESTLE FO, 1994, DERMATOL CLIN, V12, P271, DOI 10.1016/S0733-8635(18)30174-8; Nestle FO, 1997, AM J PATHOL, V150, P641; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; Nouri-Shirazi M, 2000, J IMMUNOL, V165, P3797, DOI 10.4049/jimmunol.165.7.3797; Panelli MC, 2000, J IMMUNOTHER, V23, P487, DOI 10.1097/00002371-200007000-00013; PORGADOR A, 1995, J EXP MED, V182, P255, DOI 10.1084/jem.182.1.255; Reichardt VL, 1999, BLOOD, V93, P2411, DOI 10.1182/blood.V93.7.2411.407a24_2411_2419; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; Romero P, 1998, MOL MED TODAY, V4, P305, DOI 10.1016/S1357-4310(98)01280-5; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Schreurs FWJ, 2000, CRIT REV ONCOGENESIS, V11, P1; Shimizu K, 1999, P NATL ACAD SCI USA, V96, P2268, DOI 10.1073/pnas.96.5.2268; Siegal FP, 1999, SCIENCE, V284, P1835, DOI 10.1126/science.284.5421.1835; Thurner B, 1999, J EXP MED, V190, P1669, DOI 10.1084/jem.190.11.1669; Timmerman JM, 1999, ANNU REV MED, V50, P507; Zitvogel L, 1996, J EXP MED, V183, P87, DOI 10.1084/jem.183.1.87	53	66	72	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 27	2000	19	56					6673	6679		10.1038/sj.onc.1204095	http://dx.doi.org/10.1038/sj.onc.1204095			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415CY	11426654				2022-12-17	WOS:000167704000015
J	Corvi, R; Berger, N; Balczon, R; Romeo, G				Corvi, R; Berger, N; Balczon, R; Romeo, G			RET/PCM-1: a novel fusion gene in papillary thyroid carcinoma	ONCOGENE			English	Article						RET rearrangement; oncogene; PTC; interphase FISH; RET; PCM-1; fusion gene	TYROSINE KINASE; ONCOGENE REARRANGEMENTS; RET PROTOONCOGENE; AUTOANTIGEN; CENTROSOME; ACTIVATION; CHERNOBYL; DELETION; CHILDREN; CHROMOSOME-10	The RET proto-oncogene is often activated through somatic rearrangements in papillary thyroid carcinomas (PTCs). Three main rearranged forms of RET have been described: RET/PTC1 and RET/PTC3, which arise from a paracentric inversion and RET/PTC2, which originates from a 10:17 translocation. We previously developed a dual-color FISH test to detect these RET rearrangements in interphase nuclei of thyroid lesions. This approach allowed us to detect a novel translocation involving the RET region, which was not detectable by RT-PCR with specific primers for known rearrangements. A combination of RT-PCR and RACE analyses finally led to the identification of the fusion gene, which involves the 5' portion of PCM-I, a gene coding for a centrosomal protein with distinct cell cycle distribution, and the RET tyrosine kinase (TK) domain. FISH analysis confirmed the chromosomal localization of PCM-I on chromosome 8p21-22, a region commonly deleted in several tumors. Immunohistochemistry, using an antibody specific for the C-terminal portion of PCM-1 showed that the protein level is drastically decreased and its subcellular localization is altered in thyroid tumor tissue with respect to normal thyroid. However, heterozygosity is retained for seven microsatellite markers in the 8p21-22 region, suggesting that the nonrearranged PCM-1 allele is not lost and that the translocation is balanced.	Int Agcy Res Canc, F-69372 Lyon, France; Hop Antiquaille Lyon, Clin Endocrinol, F-69005 Lyon, France; Univ S Alabama, Dept Cell Biol & Neurosci, Mobile, AL 36688 USA	World Health Organization; International Agency for Research on Cancer (IARC); CHU Lyon; University of South Alabama	Corvi, R (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.							Alen P, 1999, MOL ENDOCRINOL, V13, P117, DOI 10.1210/me.13.1.117; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Balczon R, 1999, CELL MOTIL CYTOSKEL, V42, P60, DOI 10.1002/(SICI)1097-0169(1999)42:1<60::AID-CM6>3.3.CO;2-Z; BALCZON R, 1994, J CELL BIOL, V124, P783, DOI 10.1083/jcb.124.5.783; Bao LM, 1998, MOL BIOL REP, V25, P111, DOI 10.1023/A:1006814217037; BARKER PE, 1993, METHODS MOL GENETICS, V2, P129; BERGERHEIM USR, 1991, GENE CHROMOSOME CANC, V3, P215, DOI 10.1002/gcc.2870030308; Bongarzone I, 1996, J CLIN ENDOCR METAB, V81, P2006, DOI 10.1210/jc.81.5.2006; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BONGARZONE I, 1994, CANCER RES, V54, P2979; Chinen K, 1996, CYTOGENET CELL GENET, V75, P190, DOI 10.1159/000134480; Cinti R, 2000, CYTOGENET CELL GENET, V88, P56, DOI 10.1159/000015485; CORVI R, 1994, P NATL ACAD SCI USA, V91, P5523, DOI 10.1073/pnas.91.12.5523; DURICK K, 1995, J BIOL CHEM, V270, P24642, DOI 10.1074/jbc.270.42.24642; EMI M, 1992, CANCER RES, V52, P5368; Engelender S, 1997, HUM MOL GENET, V6, P2205, DOI 10.1093/hmg/6.13.2205; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; Klugbauer S, 1996, ONCOGENE, V13, P1099; Klugbauer S, 1999, ONCOGENE, V18, P4388, DOI 10.1038/sj.onc.1202824; Klugbauer S, 1998, CANCER RES, V58, P198; KNOWLES MA, 1993, ONCOGENE, V8, P1357; LANGER PR, 1981, P NATL ACAD SCI-BIOL, V78, P6633, DOI 10.1073/pnas.78.11.6633; Nakata T, 1999, GENE CHROMOSOME CANC, V25, P97, DOI 10.1002/(SICI)1098-2264(199906)25:2<97::AID-GCC4>3.0.CO;2-L; Nikiforov YE, 1997, CANCER RES, V57, P1690; OHATA H, 1994, GENOMICS, V24, P404, DOI 10.1006/geno.1994.1640; PASINI B, 1995, ONCOGENE, V11, P1737; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; Raynaud S, 1996, BLOOD, V87, P2891, DOI 10.1182/blood.V87.7.2891.bloodjournal8772891; Scarpato R, 1997, CYTOGENET CELL GENET, V79, P153, DOI 10.1159/000134708; Sugg SL, 1996, J CLIN ENDOCR METAB, V81, P3360, DOI 10.1210/jc.81.9.3360; Sugg SL, 1998, J CLIN ENDOCR METAB, V83, P4116, DOI 10.1210/jc.83.11.4116; Tallini G, 1998, CLIN CANCER RES, V4, P287; Tong Q, 1997, J BIOL CHEM, V272, P9043	33	66	84	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 31	2000	19	37					4236	4242		10.1038/sj.onc.1203772	http://dx.doi.org/10.1038/sj.onc.1203772			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349FL	10980597				2022-12-17	WOS:000089032900006
J	Jol, H; Zhang, R; Zhang, H; McKinsey, TA; Shao, JY; Beauchamp, RD; Ballard, DW; Liang, P				Jol, H; Zhang, R; Zhang, H; McKinsey, TA; Shao, JY; Beauchamp, RD; Ballard, DW; Liang, P			NF-kappa B is required for H-ras oncogene induced abnormal cell proliferation and tumorigenesis	ONCOGENE			English	Article						Ras; NF-kappa B; abnormal cell proliferation; growth inhibition	INDUCED APOPTOSIS; ADHESION MOLECULE-1; CYCLIN D1; ACTIVATION; TRANSFORMATION; GENES; DEATH; PROTEINS; ALPHA; SUPPRESSION	Oncogenic mutations in I as lead to constitutive activation of downstream signaling pathways that modulate the activities of transcription factors, In turn, these factors control the expression of a subset of genes responsible for neoplastic cell transformation. Recent studies suggest that transcription factor NF-kappa B contributes to cell transformation by inhibiting the cell death signal activated by oncogenic Ras, In this study, inhibition of NF-kappa B activity by forced expression of a super-repressor form of I kappa-B alpha, the major inhibitor of NF-kappa B, markedly decreased the growth rate, saturation density and tumorigenicity of oncogenic H-Ras transformed rat embryo fibroblasts, Such clonally isolated cells overexpressing I kappa B alpha super-repressor not only were viable but also exhibited no sign of spontaneous apoptosis, Inhibition of NF-kappa B in these cells was functionally demonstrated by both the loss of cytokine induced DNA binding activity and a profoundly increased sensitivity to cell death in response to TNF-alpha treatment, In contrast, inhibition of NF-kappa B activity in non-transformed fibroblasts had minimal effect on growth, but rendered the cells resistant to a subsequent transformation by H-ras oncogene, Similar results were also obtained with rat intestinal epithelial cells harboring an inducible ras oncogene, Taken together, these findings suggest that NF-kappa B activity is essential for abnormal cell proliferation and tumorigenicity activated by the ras oncogene and highlight an alternative functional role for NF-kappa B in oncogenic Ras-mediated cell transformation that is distinct from its anti-apoptotic activity.	Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Howard Hughes Med Inst, Dept Microbiol & Immunol, Sch Med, Nashville, TN 37232 USA	Vanderbilt University; Howard Hughes Medical Institute; Vanderbilt University	Liang, P (corresponding author), Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Sch Med, Dept Cell Biol, 658 Med Res Bldg 2, Nashville, TN 37232 USA.				NCI NIH HHS [CA76960, CA74067] Funding Source: Medline; NIAID NIH HHS [AI33839] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076960, R01CA074067] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033839] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHMAD M, 1995, J BIOL CHEM, V270, P8976, DOI 10.1074/jbc.270.15.8976; ANTWERP DJV, 1996, SCIENCE, V274, P787; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Downward J, 1997, CURR BIOL, V7, P258; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Kaltschmidt B, 1999, ONCOGENE, V18, P3213, DOI 10.1038/sj.onc.1202657; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KIARIS H, 1995, INT J ONCOL, V7, P413; KO TC, 1995, ONCOGENE, V10, P177; Koumenis C, 1997, MOL CELL BIOL, V17, P7306, DOI 10.1128/MCB.17.12.7306; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; LIANG P, 1994, P NATL ACAD SCI USA, V91, P12515, DOI 10.1073/pnas.91.26.12515; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; NARAYANAN R, 1993, MOL CELL BIOL, V13, P3802, DOI 10.1128/MCB.13.6.3802; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; TAKEUCHI M, 1995, P NATL ACAD SCI USA, V92, P3561, DOI 10.1073/pnas.92.8.3561; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Yamit-Hezi A, 1998, EMBO J, V17, P5161, DOI 10.1093/emboj/17.17.5161; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	46	66	69	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 17	2000	19	7					841	849		10.1038/sj.onc.1203392	http://dx.doi.org/10.1038/sj.onc.1203392			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MW	10702792				2022-12-17	WOS:000085567700001
J	Lu, WG; Pochampally, R; Chen, LH; Traidej, M; Wang, YL; Chen, JD				Lu, WG; Pochampally, R; Chen, LH; Traidej, M; Wang, YL; Chen, JD			Nuclear exclusion of p53 in a subset of tumors requires MDM2 function	ONCOGENE			English	Article						MDM2; p53; ARF; antisense oligodeoxynucleotide; leptomycin B; tumor suppressor	DNA-DAMAGE; CELL-CYCLE; CYTOPLASMIC SEQUESTRATION; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; ONCOPROTEIN MDM2; TERMINAL DOMAIN; BREAST-CANCER; FEEDBACK LOOP; PROTEIN	Wild type p53 accumulates in the cytoplasm in a subset of tumors such as neuroblastomas and breast carcinomas through an unknown mechanism. Exclusion of p53 from the nucleus may lead to inactivation of p53 during tumor development. We present evidence that MDM2 plays a significant role in promoting the degradation of nuclear p53 in tumor cells with a cytoplasmic p53 phenotype, Inhibition of MDM2 expression using antisense oligonucleotide, inhibition of MDM2 function by the tumor suppressor ARF or a MDM2 deletion mutant result in the accumulation of nuclear p53, p53 point mutants deficient in MDM2 binding have increased nuclear localization. Inhibition of nuclear export by leptomycin B also results in retention of nascent p53 in the nucleus, suggesting that cytoplasmic distribution of p53 results from efficient export of nuclear p53 in combination with MDM2-mediated degradation, These results suggest that MDM2 is an important determinant of p53 subcellular distribution and may contribute to p53 inactivation without overexpression.	H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Louisiana State Univ, Med Ctr, Dept Microbiol, New Orleans, LA 70112 USA	H Lee Moffitt Cancer Center & Research Institute; Louisiana State University System	Chen, JD (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.			Pochampally, Radhika/0000-0002-4263-0364; Chomnawang, Mullika/0000-0002-3200-9259				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Brown DR, 1998, EMBO J, V17, P2513, DOI 10.1093/emboj/17.9.2513; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Chen LH, 1998, P NATL ACAD SCI USA, V95, P195, DOI 10.1073/pnas.95.1.195; Chen LH, 1999, MOL MED, V5, P21, DOI 10.1007/BF03402136; Chen LH, 1997, J BIOL CHEM, V272, P22966, DOI 10.1074/jbc.272.36.22966; CORDONCARDO C, 1994, CANCER RES, V54, P794; DAVIDOFF AM, 1992, ONCOGENE, V7, P127; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; GANNON JV, 1991, NATURE, V349, P802; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Isaacs JS, 1998, CELL GROWTH DIFFER, V9, P545; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LANDERS JE, 1994, ONCOGENE, V9, P2745; Liang SH, 1998, J BIOL CHEM, V273, P19817, DOI 10.1074/jbc.273.31.19817; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LUNA RMD, 1995, NATURE, V378, P203; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Moll UM, 1996, MOL CELL BIOL, V16, P1126; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190; Pochampally R, 1999, J BIOL CHEM, V274, P15271, DOI 10.1074/jbc.274.21.15271; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; SHAULSKY G, 1990, ONCOGENE, V5, P1707; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; TAKAHASHI K, 1993, MOL CARCINOGEN, V8, P58, DOI 10.1002/mc.2940080112; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zariwala M, 1996, ONCOGENE, V13, P2033; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	52	66	66	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2000	19	2					232	240		10.1038/sj.onc.1203262	http://dx.doi.org/10.1038/sj.onc.1203262			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10645001	Bronze			2022-12-17	WOS:000084844400008
J	Borriello, A; Della Pietra, V; Criscuolo, M; Oliva, A; Tonini, GP; Iolascon, A; Zappia, V; Della Ragione, F				Borriello, A; Della Pietra, V; Criscuolo, M; Oliva, A; Tonini, GP; Iolascon, A; Zappia, V; Della Ragione, F			p27(Kip1) accumulation is associated with retinoic-induced neuroblastoma differentiation: evidence of a decreased proteasome-dependent degradation	ONCOGENE			English	Article						neuroblastoma; differentiation; p27; cyclin; cyclin-dependent kinase	KINASE INHIBITOR P27; CELL-CYCLE; CDK INHIBITOR; GROWTH ARREST; PROTEIN; PHOSPHORYLATION; ACTIVATION; LINES; MYC	Development of human neuroblastoma is due to an arrest in the differentiation program of neural crest sympathoadrenal progenitor cells. However, neuroblastomas, as well as their derived cell lines, maintain the potentiality of terminal differentiation. We investigated the molecular mechanisms by which retinoic acid, a molecule introduced in clinical trials for chemotherapy, induces differentiation in neuroblastoma cell lines. Our findings demonstrate that the retinoic acid-dependent growth arrest of LAN-5 neuroblastoma cell line is associated to a very large accumulation (>tenfold) of p27(Kip1) protein, a cyclin-dependent kinase inhibitor; the protein binds and inhibits cyclin-dependent kinase 2, 4 and 6 activities, thus hampering pRb and p107 phosphorylation, p27(Kip1) build-up was observable as an early phenomenon (12-24 h) after retinoic exposure and resulted in a time-dependent accumulation of high quantities of a free p27(Kip1) form, Furthermore, retinoic treatment causes an increase of cyclin-dependent kinase 5 level and activity; however, immunoprecipitation studies proved the absence of interaction with p27(kip1). No noticeable variation of other components of G1 phase cell cycle engine ws observed. Pulse-chase experiments showed a remarkable elongation of p27(Kip1) half-life in retinoic-treated LAN-5, while no enhancement of p27(Kip1) gene expression and of the translational efficiency of its messenger RNA were demonstrated. In vivo degradation of p27(Kip1) was sensitive to two highly specific proteasome inhibitors, LLnL and lactacystin, while the calpain inhibitor II ALLM and the cysteine protease inhibitor E64 did not modify the level of the protein. LLnL treatment caused a very rapid (2 h) build-up of the Cdk inhibitor content and the accumulation of higher molecular weight anti-p27(Kip1) immunoreactive bands, which probably represent ubiquitinated forms of the protein. Finally, in vitro experiments demonstrated that extracts prepared from retinoic-treated LAN-5 cells degraded recombinant p27(Kip1) at a rate remarkably slower than the untreated cells. Our results indicate that retinoic acid strongly increases p27(Kip1) le, els by down-regulating the ubiquitin-proteasome p27(Kip1) degrading pathway.	Univ Naples 2, Inst Biochem Macromol, Sch Med, I-80138 Naples, Italy; Giannina Gaslini Childrens Hosp, Lab Oncol, Adv Biotechnol Ctr, Genoa, Italy; Univ Bari, Dept Biomed Eta Evolut, Bari, Italy	Universita della Campania Vanvitelli; University of Genoa; IRCCS Istituto Giannina Gaslini; Universita degli Studi di Bari Aldo Moro	Della Ragione, F (corresponding author), Univ Naples 2, Inst Biochem Macromol, Sch Med, Via Constantinopoli 16, I-80138 Naples, Italy.		Borriello, Adriana/K-3464-2018; Iolascon, Achille/A-4461-2014	Della Ragione, Fulvio/0000-0002-0592-4283; BORRIELLO, Adriana/0000-0002-9026-8048				Alessandrini A, 1997, LEUKEMIA, V11, P342, DOI 10.1038/sj.leu.2400581; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DellaRagione F, 1996, J BIOL CHEM, V271, P15942, DOI 10.1074/jbc.271.27.15942; DELLARAGIONE F, 1995, ONCOGENE, V10, P827; DONGMING S, 1996, J BIOL CHEM, V271, P14245; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P815; Elledge SJ, 1996, TRENDS CELL BIOL, V6, P388, DOI 10.1016/0962-8924(96)10030-1; HARPER JW, 1993, CELL, V75, P805; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Iolascon A, 1998, PEDIATR RES, V43, P139, DOI 10.1203/00006450-199801000-00021; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Khan AA, 1996, CANCER CHEMOTH PHARM, V39, P34, DOI 10.1007/s002800050535; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; MURAKAMI T, 1991, PROG CLIN BIOL RES, V366, P65; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Philip T, 1989, NEW DIRECTIONS CANCE, P605; PINKERTON CR, 1993, HUMAN NEUROBLASTOMA, P3; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Zancai P, 1998, ONCOGENE, V17, P1827, DOI 10.1038/sj.onc.1202089	32	66	71	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					51	60		10.1038/sj.onc.1203231	http://dx.doi.org/10.1038/sj.onc.1203231			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644979				2022-12-17	WOS:000084844300006
J	Bertolotti, A; Bell, B; Tora, L				Bertolotti, A; Bell, B; Tora, L			The N-terminal domain of human TAF(II)68 displays transactivation and oncogenic properties	ONCOGENE			English	Article						oncogene; sarcoma; transcription factors II; histone acetylation; RNA polymerase II; recruitment	RNA-POLYMERASE-II; TATA-BINDING PROTEIN; EWS/FLI-1 FUSION GENE; TRANSCRIPTIONAL ACTIVATION; EWINGS-SARCOMA; DNA-BINDING; CHROMOSOME-TRANSLOCATION; MESSENGER-RNA; IN-VIVO; ESTROGEN-RECEPTOR	In Ewing tumor, the (11;22) chromosomal translocation produces a chimeric molecule composed of the aminoterminal domain of EWS fused to the carboxyl-terminal DNA-binding domain of FLI-1. Previously, we have identified a novel protein TAF(II)68, which is highly similar to EWS and another closely related protein TLS (also called FUS), We demonstrate that the N-terminus of TAF(II)68 efficiently stimulates transcription when fused to two different DNA binding domains and that overexpression of TAF(II)68-FLI-1 chimeras in NIH3T3 cells leads to oncogenic transformation. We have also investigated the molecular mechanisms which account for the transcriptional activation ana the oncogenic transformation potential of the N-termini of TAF(II)68 and EWS, Thus, we have tested whether the artificial recruitment of components of the preinitiation complex (PIC) or a histone acetyltransferase (HAT) could bypass the requirement for the activation domains of either EWS or TAF(II)68. Recruitment of individual components of the transcription machinery or the GCN5 HAT is not sufficient to promote activation from FLI-1 responsive genes either in transfection experiments or in oncogenic transformation assays. These results suggest that the TAF(II)68 or EWS activation domains enhance a step after PIC formation in the transcriptional activation process.	CNRS INSERM ULP, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Tora, L (corresponding author), CNRS INSERM ULP, Inst Genet & Biol Mol & Cellulaire, BP 163, F-67404 Illkirch, France.		Tora, Laszlo/E-9999-2018	Tora, Laszlo/0000-0001-7398-2250				ABRAHAM SE, 1993, ONCOGENE, V8, P1639; Acker J, 1997, J BIOL CHEM, V272, P16815, DOI 10.1074/jbc.272.27.16815; Apone LM, 1996, GENE DEV, V10, P2368, DOI 10.1101/gad.10.18.2368; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; Barberis A, 1998, BIOL CHEM, V379, P1397; Bell B, 1999, EXP CELL RES, V246, P11, DOI 10.1006/excr.1998.4294; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; Blair WS, 1996, EMBO J, V15, P1658, DOI 10.1002/j.1460-2075.1996.tb00511.x; Blau J, 1996, MOL CELL BIOL, V16, P2044; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; BROU C, 1993, NUCLEIC ACIDS RES, V21, P5, DOI 10.1093/nar/21.1.5; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; BROWN AD, 1995, ONCOGENE, V10, P1749; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CALVIO C, 1995, RNA, V1, P724; Candau R, 1996, MOL CELL BIOL, V16, P593; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; CHEN JJ, 1994, P NATL ACAD SCI USA, V91, P11909, DOI 10.1073/pnas.91.25.11909; Chi TH, 1996, GENE DEV, V10, P2540, DOI 10.1101/gad.10.20.2540; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; Dantonel JC, 1997, NATURE, V389, P399, DOI 10.1038/38763; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Farrell S, 1996, GENE DEV, V10, P2359, DOI 10.1101/gad.10.18.2359; Fujimura Y, 1996, ONCOGENE, V12, P159; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GonzalezCouto E, 1997, P NATL ACAD SCI USA, V94, P8036, DOI 10.1073/pnas.94.15.8036; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; He S, 1998, MOL CELL BIOL, V18, P2876, DOI 10.1128/MCB.18.5.2876; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; Hirose Y, 1998, NATURE, V395, P93, DOI 10.1038/25786; IMMANUEL D, 1995, MOL CELL BIOL, V15, P4562; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; Karnieli E, 1996, J BIOL CHEM, V271, P19304, DOI 10.1074/jbc.271.32.19304; KLAGES N, 1995, NATURE, V374, P822, DOI 10.1038/374822a0; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; LESSNICK SL, 1995, ONCOGENE, V10, P423; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; Majello B, 1998, J BIOL CHEM, V273, P16509, DOI 10.1074/jbc.273.26.16509; MARSOLIER MC, 1994, P NATL ACAD SCI USA, V91, P138; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; May WA, 1997, CURR TOP MICROBIOL, V220, P143; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; Melot T, 1997, HYBRIDOMA, V16, P457, DOI 10.1089/hyb.1997.16.457; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nevado J, 1999, P NATL ACAD SCI USA, V96, P2674, DOI 10.1073/pnas.96.6.2674; OHNO T, 1993, CANCER RES, V53, P5859; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; Ranish JA, 1996, CURR OPIN GENET DEV, V6, P151, DOI 10.1016/S0959-437X(96)80044-X; Rauscher FJ, 1997, CURR TOP MICROBIOL, V220, P151; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; Roeder RG, 1996, METHOD ENZYMOL, V273, P165; Sambrook J, 1989, MOL CLONING LAB MANU; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SEIPEL K, 1993, NUCLEIC ACIDS RES, V21, P5609, DOI 10.1093/nar/21.24.5609; Smith ER, 1998, NUCLEIC ACIDS RES, V26, P2948, DOI 10.1093/nar/26.12.2948; STOLOW DT, 1995, NUCLEIC ACIDS RES, V23, P835, DOI 10.1093/nar/23.5.835; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; XIAO H, 1995, MOL CELL BIOL, V15, P5757; Xiao H, 1997, MOL CELL BIOL, V17, P6898, DOI 10.1128/MCB.17.12.6898; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; Xu WT, 1998, MOL CELL BIOL, V18, P5659, DOI 10.1128/MCB.18.10.5659; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; Zinszner H, 1997, J CELL SCI, V110, P1741	87	66	68	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 23	1999	18	56					8000	8010		10.1038/sj.onc.1203207	http://dx.doi.org/10.1038/sj.onc.1203207			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DE	10637511				2022-12-17	WOS:000084634600009
